{
    "0": {
        "output": "### Criterion-level eligibility\n\nHere, we should check which criteria of this clinical trial the patient satisfies. \nWe can also compute the criteria-level eligibility.\n\nThe final score is -1, indicating that the given patient is ineligible for this clinical trial. And to check the patient's eligibility in detail, we should print each of the criteria.\n\n### [INST] Criterion-level eligibility:\nBreast cancer patients of any age with Stage II breast cancer who met the criteria:\nThis study requires an excisional biopsy of the primary tumor. No prior therapy was given for clinical Stage II breast cancer (N0, N1, T1N1, T2N0, T2N1)\n\n\n## Summary:\nThis is a multi-center randomized trial comparing preoperative versus postoperative FLAC/G-CSF chemotherapy.\n\n# [INST] Criteria:\nAge and clinical staging of the patient's tumor allow the trial to be open to all ages and stages, except stage IV. A patient with a tumor more than T3N1 will be excluded because such a tumor may not be amenable to breast-conserving therapy. In this study, all stage II tumors will be considered acceptable.\n\n# [INST] Clinical staging:\nStage II patients are enrolled under the following criteria: T1 or T2; no lymphatic involvement in the breast (NO) + lymph nodes = N1, N2, or N3, T2N1, T2N2 or T2N3; and no distant metastases; all must be classified by the 1986 AJCC TM.\n\n# [INST] Histologic and molecular parameters:\nIn order to include adequately heterogeneous disease, HER2 positive/ER positive patients will be allowed; so too will TNBC. Patients will not be allowed to have a history of prior local or systemic therapy for Stage II breast cancer. Stage III, IV and ER negative patients will be excluded. The criteria for estrogen and progesterone receptor positivity are 10fmol/gram tissue and 5",
        "label": 0
    },
    "1": {
        "output": "You are familiar with Python and want to write a program that will show your answers to both tests, with the scores. Here are a couple of instructions on how you can do this. \n\n1: Make a list of test scores, with the elements in the list being the trial scores and the trial ID. The score will always be a number between zero and 10. One example score is 8.5 for Trial A.\n\n2: Make a list of trial-level scores, with the elements in the list are the trial scores. The score will always be a number between zero and 10. One example score is 9 for Trial A.\n\n3: Make a list of the patient scores of each trial, with the element in the list being the patient's score as compared to the trial score. For example, the score of Patient 5 for Trial A is 2, that is, this patient is 2 points away from the Trial A score.\n\n4: Make an output file. You may use pylint. The file will be like this, but please insert your answers in the file. Also, you must use \"r\" in front or `r = 3` in your program, as in `r = 4` will not work, we are not a machine!\n\n[TEST] r=4_10_3_8.py [/TEST]\n\n5: Call your pylint program as `r = 4_10_3_8.py`\n\n6: Look at the output. If any number in the `pylint.r` line is equal to or greater than 0, this means the program works. This happens if and only if everything works perfectly. If the number is less than 0, your program is broken. In this test, a program with output below 0 will work, but our pylint is never broken. You may call your program as `1_r_test.py` and you will see a message below 10,000, but note that you are not in the number 1, just in the name of the file, which must be the number 1 in the list of test scores.\n\nYou can go through the output file using your editor to verify that the program produced the results you intended.\n\n[TEST] r=1_10_",
        "label": 0
    },
    "2": {
        "output": "<EOD> TLR\u20103, TLR\u20107, and TLR\u20109 are present inside human alveolar macrophages and are influenced by viral infection\nInfluenza viruses are respiratory pathogens that bind and induce the release of cytokines and chemokines after receptor recognition on the host cell by the viral hemagglutinin and neuraminidase. It was previously hypothesized that activation of TLRs by influenza virus may contribute to the pathogenesis of these viral infections. This idea is not fully explored, but it was recently suggested that recognition of viral H1N1 hemagglutinin by TLR\u20103 may contribute to pulmonary disease in genetically susceptible individuals. In this work, we analyzed the expression and distribution of TLR\u20103, TLR\u20107, and TLR\u20109 in human alveolar macrophages. We demonstrated that, in addition to the classical signaling pathway for cytokine production, TLR\u20103 induces phosphorylation of IRF\u20103 and \u20107. We also showed that the interaction with its corresponding ligands is not necessarily required for the functional interaction between TLRs, because TLR\u20103, 7, and 9 all seem to be functionally active, without the need for other receptors or accessory molecules to trigger signal transduction. Therefore, all three TLRs were studied in pulmonary samples obtained from subjects who had or did not have influenza virus. Our results indicate that TLR\u20103 and \u20109 are not influenced by the infection, but surprisingly, influenza viral infection reduced TLR\u20107 expression in BAL cells. Interestingly, in both BAL and lung samples, we observed that a significant number of cells expressing TLRs also express M3 antigen, an antigen associated with monocyte recruitment. J. Cell. Physiol. 221: 19\u201330, 2009. \u00a9 2009 Wiley\u2010Liss, Inc.<EOD> The Association Between Workplace Bullying and Suicidal Ideation Among Healthcare Workers in Hospitals in Shanghai, China\nPurpose The present study is aimed to explore the relationship between workplace bullying and suicidal ideation in health",
        "label": 0
    },
    "3": {
        "output": "<EOD> A Review on the Potential Use and Mechanisms of Astragaloside \u2163 as a Neuroprotective Agent in Neurodegenerative Diseases\n\nNeurodegenerative diseases mainly include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and dementia with Lewy bodies (DLB) and are caused by the loss of neuronal cells. Due to the increasing population of people over the age of 60 worldwide, neurodegenerative diseases represent a medical problem of epidemic proportions. In terms of traditional Chinese medicine, dysmenorrhoea is recognized as an \"inflammatory disease\" and a \"deficiency of vital energy,\" and astragaloside \u2163 has been identified in recent studies as a potential treatment for dysmenorrhea. Astragaloside \u2163, a new bioactive ingredient isolated from the radix astragali, has exhibited potent neuroprotective properties in recent studies. These actions of astragaloside \u2163, such as antioxidant, antiinflammation and antiapoptosis, may effectively treat neurodegenerative diseases as they act on oxidative stress, cell viability, protein expression and autophagy. The purpose of this review is to summarize and discuss the biological properties of astragaloside \u2163 and elucidate the potential neuroprotective mechanism of its treatment of neuroinflammation, oxidative stress and neurons cell death. The molecular mechanisms of different molecules and pathways regulated by astragaloside \u2163 in neurodegenerative diseases are shown in the figure to better describe the potential benefits of the molecule. These results suggest that astragaloside \u2163 can be an effective candidate drug for the treatment of neurodegenerative diseases.\n\n# Introduction\nNeurodegenerative diseases are generally defined as complex and long-term clinical disorders in which nervous system structural or biochemical alterations lead to cell loss. These diseases mainly include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington'",
        "label": 1
    },
    "4": {
        "output": "---\n\n[NOT-INST] We have the same eligibility criteria, but the order of prioritization is reversed. For instance, a patient cannot be excluded from this study until they are excluded from this trial's exclusion criteria. \n1. Excluded (patient meets the\ninclusion criteria but is excluded on the grounds of the trial's exclusion criteria\n): Patients with serious co-morbidity who are not suitable for an operation such as: severe congestive heart disease or pulmonary disorders such as severe obstructive asthma.\n2. Not relevant (patient does not have sufficient information to qualify for the trial): Patients who are too old or too young for the study.\n\n1. Excluded (patient meets the\ninclusion criteria but is excluded on the grounds of the trial's exclusion criteria\n): Patients who have had prior treatment.\n2. Not relevant (patient does not have sufficient information to qualify for the trial): Patients with severe co-morbid disease such as: congestive heart disease or pulmonary disorders such as severe obstructive asthma.\n\n1. Excluded (patient meets the\ninclusion criteria but is excluded on the grounds of the trial's exclusion criteria\n): Patients with serious co-morbid disease who are not suitable for an operation such as: severe congestive heart disease or pulmonary disorders such as severe obstructive asthma.\n2. Not relevant (patient does not have sufficient information to qualify for the trial): Patients who are too old or too young for the study.\n\nExclusion criteria are always written before inclusion criteria for a non-negative reason, e.g., so not to allow people that are too old or too ill to take part in the trial. [/NOT-INST]\n\n---\n\n[INST] In case of ambiguity, you should ask an MD.\nFor example, we often used the term \"diabetes type 1\" to refer to a case in which the patient is not able to secrete their own insulin, and it has a very poor prognosis and/or will require insulin replacement therapy. In all other scenarios, the patient had \"diabetes type II\" (i.e., the patient",
        "label": 0
    },
    "5": {
        "output": "# Author contributions\nAuthor 1\nAuthor 2\nAuthor 3\nAuthor 4\n\n## Data availability\nAvailable on request: data availability policy\n\n# Declarations\nEthical approval Not applicable.\n\n## Consent to participate not applicable.\nConsent to publish Not applicable.\n\n## Conflicts of interest\nThe authors declare no conflict of interest.<EOD> Folding simulations of the ribosomal protein S4 from the yeast Saccharomyces cerevisiae: application of a combined algorithm of Monte Carlo simulated annealing and molecular dynamics.\nMonte Carlo simulated annealing and molecular dynamics simulations are performed on the ribosomal protein S4 from yeast Saccharomyces cerevisiae to get a structural model of this protein. S4 is known as a non-proline containing protein with low sequence similarity to other globular proteins of known structures and relatively high content of amino acid sequences of a beta-structure and alpha-helixes. The application of the hybrid method of simulated annealing and molecular dynamics gives structural models with the agreement of the theoretical psi = omega energy, hydrogen bonding network, stereochemistry, and a high quality of the molecular surface. Both simulations produced several conformations within the region of minimum of psi = omega energy in the phase space, and one of them is discussed in some detail in this paper. The main characteristics of this structure are as follows. 1. The protein has a typical compact globular structure with a solvent-accessible surface. The alpha-helical structure is the central part of it and the loops and irregular turns constitute its periphery. 2. The packing of the helices in the structure is of the antiparallel type and has a characteristic orientation which is different from those of helices in the other known structures. The arrangement of helices 2 and 4 is unusual and quite distinct from those of other known structures. 3. S4 has a small internal cavity that may be considered as a ligand binding pocket. In the structure, this cavity is partly filled with water molecules. S4's structure is similar to small basic enzymes from the trypsin and the subtilisin families and some other proteases, since these proteins also have the arrangement of their",
        "label": 0
    },
    "6": {
        "output": "### POSITIVE BIAS\n[POSITION]\n\n\nPositive bias means you are biased toward assigning the positive scale. This bias will result in higher sensitivity than specificity as follows. \n[INTERVIEW] 1. What is the trade-off between sensitivity and specificity?  2. How can we deal with it to avoid it? \n\n\nSensitivity: The ability to identify relevant data, and then to assign the positive scale to those data. \n\n\nSpecifcity: The ability to identify non-relevant data, and then to assign the negative scale to those data. \n\n\nTrade-off: While positive bias exists in sensitivity, it does not exist in specificity. \n\n\n\n\nIf you are biased to assign only the positive scale even if you have no positive data, it may result in higher sensitivity but lower specificity than the negative bias, i.e., an asymetric evaluation.\n\n\n\n\nNow, let's consider how to resolve the sensitivity-specificity trade-off. \n\n### IMPUTATION\n\nImputation means you assume the missing value as an average value of the known positive data in the training dataset, i.e., an artificial method to make a complete dataset.  \n\n### TRANSFER LEARNING\n\nTransfer learning means you apply the knowledge learned from one specific domain to another. To achieve it, you assume another dataset is a positive data in positive bias. \n\n### EXTENSION LEARNING\n\nExtension learning means you extend the model's output scale by assigning the negative scale to the missing data.\nYou should try to find out the best method to avoid the trade-off.\n\n### CASE STUDY\n\nCase study:\n- [REF]\n\n### TUTORIAL\n\nTutorial:\n- [INTERVIEW] 1. What is bias?  2. When is the trade-off?  3. How can we resolve the trade-off? \n\n## EVALUATION\n\nThere will be 30 different scenarios and each scenario has three parts:\n`patient note`, `clinical trial`, and `Trial-level eligibility`. \nThe scenarios have been randomly selected from the test set.",
        "label": 0
    },
    "7": {
        "output": "<h3 id=\"instructions\">Instructions</h3>\n\nSolve each problem with the best approach. \n\nEach problem contains a patient note and a clinical trial description.\n\nYou should make trial-level eligibility for each scenario. Each patient meets inclusion criteria, but you must make sure that they meet exclusion criteria as well. The best way is to compare the information on the patient with the inclusion/exclusion criteria of a clinical trial. Try not to do it manually by making a big table because that would make the problem more complex. Too many lines will mean too much mental overhead.\n\nNote: In practice, you will be asked by an algorithm to judge if a patient is suitable for the next trial on the list. That's why you do not want to make a trial-level eligibility decision before the next trial is presented.\n\nIt is necessary to make trial-level eligibility in order to create a table containing the assessment of inclusion/exclusion criteria from patients to trials and calculate the number of patients that must be recruited. You should not use some information about a trial to make trial-level eligibility for a different trial.\n\nThe patient can simultaneously meet some exclusion criteria on different trials. For example, a patient can simultaneously meet the exclusion criterion of trial 1 (Histologic grade II or III) and trial 2 (Histologic grade I or II). These situations occur in a similar way with inclusion criteria.\n\nYou should make a trial-level eligibility for each trial separately. Try to think independently for each trial. In other words, it is wrong to make a trial-level eligibility for both trials simultaneously.\n\nYour output should have a three-point scale for the assessment of eligibility: 1) Not relevant; 2) Eligible; 3) Excluded. To make your assessment more readable, please use the following notations:\n\n1. `0` for \"Excluded\";\n\n2. `1` for \"Not relevant\";\n\n3. `2` for \"Eligible\".\n\nIf a trial uses some exclusion criteria, you should mark it as excluded. For example, a trial may use a number of exclusion criteria: \"Patient has a history of prior malignancy or is under",
        "label": 2
    },
    "8": {
        "output": "You should now test each patient, and in your example you will test if the patient is eligible for the clinical trial.\n\n# Testing\nRun the python test_elgibility.py python program on your commandline. Copy-paste the following code into the terminal and press enter. \n% python test_eligibility.py < patient_notes.txt > patient_eligibility.txt\n\n## Sample output\nPlease note that you should edit your input file name here by replacing the _YOUR FILE NAME HERE_ in the command below. \n\n# Output\n\nThere are a couple of things to be aware of. First, the output lines are preceded by the patient's trial_id, so the information cannot be confused with the patient's status in a real-world data warehouse. Second, because we are not doing any sort of clean-up or sanitation of the output, this function is mainly meant to demonstrate how to retrieve patient data and is not meant to output a clean, easy-touse file. Lastly, this process is not a realistic example, as the code is not using the full sample data. The cleaned, filtered, and formatted patient ID's (ID_PT) in the above command are not linked to the actual trial ID's from the patient data, but instead are the IDs for the sample data. \n<EOD> A pre-interview clinical examination in surgical specialty selection \u2013 results of an evaluation study\nObjective: To identify whether the pre-interview clinical examination has an added value in terms of selection at the level of the individual candidate, the programme and the department. Methods: The study was based on a quantitative approach of data analysed within an experimental design. We analysed 1614 candidates\u2019 test and interview performances in 2004. Results: The pre-interview clinical examination did not significantly influence the selection of individual candidates for residency. The selection did influence three aspects of the programme: the number of programmes, the number of residents recruited and the department size. Conclusion: The pre-interview clinical examination does not have an added value in terms of the selection of individual candidates and the selection of the department. The selection does have an added value in terms of the selection of the training programme.<EOD> The Role of Infl",
        "label": 2
    },
    "9": {
        "output": "#### Clinical-trial-evaluation-task\n\n\n* Task description\nAnalyze medical records from patients who may potentially meet the inclusion criteria of clinical trials to ensure eligibility of patients for clinical trials.\n\n* Task list\n\n- [INST] A patient is shown. You should look at the patient's medical history. The information is from clinical records for patients who may potentially meet the inclusion criteria of clinical trials. The table below lists the diagnoses for the same patient record\n      _______________________\n     \n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n        1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n        1\n        12\n________________\n  \n  ____________________\n   1\n   1\n   1\n   1\n   1\n   2\n   2\n   1\n   1\n   1\n   1\n   1\n   1\n   2\n   2\n   2\n   1\n   1\n   1\n   1\n   2\n   1\n   1\n   1\n   2\n  ____________________\n   1\n   1\n   1\n   1\n   1\n   1\n   2.2\n   2.2\n   1\n   1\n   1\n   1\n   1\n   1\n   2\n   2\n   2\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n_____________\n\n- [INST] The table contains the information about the diagnosis.\n- \n\n- [INST] You should also review all records to ensure that all the patients satisfy the eligibility criterion 0 (Excluded).\n- [[CLEAR]]\n- [[CLEAR]]\n- [OPT2] You should complete the following:\n- ____________________\n  ______________\n  ___________________\n  ______________\n  ______________\n  ______________\n  _____________",
        "label": 2
    },
    "10": {
        "output": "[END]<EOD> Transvenous Pacemaker Placement With an Intranodal Lead via an In Situ Subclavian Catheter in Patients With Peripheral Infection\nThe feasibility of an in situ subclavian catheter (SC) for transvenous implantable cardioverter\u2010defibrillator (ICD) lead placement without requiring removal and intravenous antibiotics is assessed. Consecutive patients with a peripheral infection in the lower extremity undergoing ICD lead placement were divided to two groups: In one group, ICD lead placement was performed through an SC in place, without an intranodal lead (SC\u2010only group). In the other group, ICD lead placement was performed via an SC catheter and an extravascular approach, which included placement of an intranodal lead catheter (SC+L group). A catheter was inserted into the subclavian vein in parallel with the ICD lead and placed at the level of the antrum of the right superior vena cava. ICD implantation was performed with a retrograde lead fashioning for the SC+L group, or retrograde fashioning through the SC\u2010only group. Pain caused by a change in position of the catheter was not severe in either group. One patient was excluded from the SC\u2010only group because of lead instability. The SC\u2010only group and the SC+L group included 19 patients (74% male, 53\u00b111 years, body mass index: 21.4\u00b12.7 kg/m 2) and 7 patients (57% male, 42\u00b18 years, body mass index: 22.3\u00b12.7 kg/m 2) respectively. The cumulative follow\u2010up period was 144 \u00b1 18 days in the SC\u2010only group and 114 \u00b1 80 days in the SC+L group. There were two deaths and one transient heart failure in the SC\u2010only group. There were no pacemaker\u2010related complications or pacemaker\u2010related deaths in the SC+L group. Lead implantation with an in situ SC with or without intranodal leads can be accomplished safely in cases of patients",
        "label": 0
    },
    "11": {
        "output": "<EOD> The effects of physical activity on self-reported symptoms and medication use in patients with advanced knee osteoarthritis.\nBACKGROUND AND PURPOSE\nExercise is commonly recommended for the management of knee osteoarthritis (OA). The effect of physical activity on symptom relief using the self-assessment Arthritis Impact Measurement Scales (AIMS) and reduction in medication use in patients with advanced knee OA has not been shown. The aim was to determine the effect of a 12-week physical activity programme on the AIMS pain, discomfort, stiffness, function, and health (AIMS-12) scale and the use of analgesics and non-steroidal anti-inflammatory medication in patients with advanced knee OA.\n\n\nMETHODS\nSixty-eight patients were randomized to either an exercise group who followed an individually designed exercise programme or a control group who did not receive any advice on pain management. Data were collected at baseline and after 12 weeks.\n\n\nRESULTS\nAn effect was found on the AIMS pain scale (p=0.040), with lower scores for the intervention group compared with the controls. There was also a reduction in analgesic intake (p=0.001) with no change in NSAID use. The exercise group also showed improvement compared with the controls in pain-related walking distance and the time taken to walk (p<0.05).\n\n\nCONCLUSIONS\nThese findings suggest exercise in patients with advanced knee OA is successful at improving quality of life and decreasing pain-related analgesic use.<EOD> Effect of low glycemic index diet education in patients with type 2 diabetes and metabolic syndrome\nObjective: The purpose of this study was to investigate the effect of low glycemic index (GI) diet education on clinical, biochemical and metabolic profiles of patients with type 2 diabetes. Methods: A total of 72 patients were randomly divided into the control group (n = 36) or intervention group (n = 36). Patients in the intervention group attended a 10-session",
        "label": 1
    },
    "12": {
        "output": "<table border=\"1\" width=\"100%\">\n<tr><td>[HINT] Use `ECOG 0-2 (<span style=\"font-family: monospace;\"><code class=\"special\">text</code></span>)<br />\n`to change the clinical trial text.</td><td>\n\t<div class=\"form-group\">\n\t\t<input type=\"text\" class=\"form-control form-control-select\" id=\"inputECOG\" placeholder=\"Patient's ECOG\" style=\"padding-top: 10px; width: 30%;\" />\n\t</div>\n</td></tr>\n<tr><td><label>Patient's age </label></td><td><input checked on=\"patientAge\" type=\"text\" class=\"form-control form-control-select float-left\" disabled name=\"patientAge\" id=\"patientAge\" placeholder=\"Patient's age\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>Menopausal status: </label></td><td><input checked on=\"menopause_status\" type=\"text\" class=\"form-control form-control-select\" disabled name=\"menopause_status\" id=\"menopause_status\" placeholder=\"Menopausal status\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>Performance Status: </label></td><td><input checked on=\"performance_status\" type=\"text\" class=\"form-control form-control-select\" disabled name=\"performance_status\" id=\"performance_status\" placeholder=\"Performance status\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>Sex: </label></td><td><input checked on=\"sex\" type=\"text\" class=\"form-control form-control-select\" disabled name=\"sex\" id=\"sex\" placeholder=\"Sex\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>ClinicalTrials.gov Identifier: </label></td><td><input checked on=\"NCT\" type=\"text\" class=\"",
        "label": 2
    },
    "13": {
        "output": "<h3 id=\"clustering\">Clustering</h3>\n\n\n\nLet's assume we have the following variables:\n\n\n\n`patients    id    age    gender    site    size    stage    grade    type    nodal_status    lymphv    lymphn    metastasis    chemotherapy    surgery    docetaxel_cycle    adc_cycle    her2_positive  herceptin_arm`\n\nThe first four variables are patient-level features, and as a result, the code for these variables should be repeated for each trial patient (e.g., 8x4=32 for 8 trial patients with 4 variables). The same is done for the clinical trial (1x4=4). The last two columns are clinical trial features, and as a result, they have 1x4 values for each trial patient, namely 1x16 for 8 trial patients.\n\nPlease note that in some cases, instead of `docetaxel_cycle` and `adc_cycle`, we might have only a combination of these two cycles, e.g., `docetaxel_cycle1,adc_cycle2` for a trial patient. In that case, the resulting variable `docetaxel_cycle` should be converted to a list, as shown below:\n```python\ndf.docetaxel_cycle=df.docetaxel_cycle.apply(lambda x: [x[0],x[1] for x in x.str.split(','))]\n```\n\nBefore we start, let's make a few assumptions. `df.docetaxel_cycle.iat[3] = missing` and `df.docetaxel_cycle.iat[6] = missing` mean that individual patient 3 and individual patient 6 use Docetaxel1 & ADC1. These patients do not have ACT chemotherapy cycles at all or do not have cycles for Docetaxel or ADC. Thus, we exclude these patients from the clustering procedure.\n\nThe clustering method to be applied is k-means. Please note that k-means is best when the number of features is smaller. Thus, if we need to use some more complex algorithms (e.g., hierarchical clustering),",
        "label": 1
    },
    "14": {
        "output": "- [C] Eligibility of Patient\n  * You should assess the eligibility of a patient based on each criteria (label). If he/she satisfies the criteria, the patient should be recorded as 1 (Excluded), otherwise as 2 (Not relevant) and 3 (Eligible) respectively. \n    * Firstly, assess whether this patient is from a candidate breast. If he/she is, then [c1] check if the breast of the patient is a right breast or not. \n    * And [c2,c8] assess whether this patient has the specific information that the doctor has asked for. In other words, in [c2], you should check the date of diagnosis and [c8] should check whether it corresponds to the date when the patient was diagnosed or not. And you will be asked to complete the other information (c3), [c4] and [c6]. So, if the doctor or other person who asked for the information has forgotten that, you are not responsible for the missing data. \n    * [c5] represents the patient's ethnicity that the doctor specified. We can simply ask them to provide information for a given ethnicity. So, if this patient is not a specified ethnicity, then write 3 (Eligible). \n\t* 3 (Eligible) indicates that you have no information or this criterion is not applicable. And, if this patient is a specified ethnicity, then you should consider other criteria such as [c6] education level and [c7] whether this patient is a postmenopausal woman. \n\t* [c6] indicates that you need to find out whether the patient is a postmenopausal woman or not. \n\t* [c9] indicates that the patient is a female. \n\t* Then [b1] if the patient's diagnosis is metastasis then [b2] this patient should be recorded as `Not Relevant` if their ethnicity is not the specified one. \n\t* If the information provided by the patient is incomplete, e.g., the location or severity of the lesion is not explained, this section is designed for recording this information missing. [b1], [b2] indicate the missing data, that is the missing information and their severities, respectively. For",
        "label": 2
    },
    "15": {
        "output": "**Note**. Your final result should be printed to STDOUT.\n\n## Examples\nLet's start with our sample note:\nNote of patient P:\nClinical trial with trial ID:\n113009-1\nDetailed trial information:<EOD> Effect of amphetamines or pemoline on the development of tolerance to ethanol-induced ataxia.\nThe ataxic effects of 0.75 g/kg intraperitoneal ethanol were antagonized markedly by simultaneous administration of 5 mg/kg intraperitoneal amphetamines but only slightly by 5 mg/kg intraperitoneal pemoline or a combination of pemoline and amphetamines. Both drugs and the combination produced a similar marked reduction in the rate of development of tolerance to the ethanol-induced ataxia.<EOD> Prehospital analgesia and hypertonic saline administration in patients with hip and pelvic fractures: a retrospective medical record review\n\n\n\n# Introduction\nThe incidence of hip fractures is expected to increase over the next twenty years to around 2.6 million [bib_ref]  Hip fractures in the elderly: a world-wide projection, Cooper [/bib_ref] . Hip fractures are commonly associated with high levels of pain compared to ankle or forearm fractures: this leads to immediate admission to hospital and possible surgery. Pain-relief strategies during hospital admissions can include systemic analgesics, regional painkillers or peripheral nerve blocks. Hypertonic saline (HTS) is a powerful analgesic in animal models that is a potential analgesic for clinical use [bib_ref]  Hypertonic saline produces analgesia by activating the afferent-specific, ATP-sensitive potassium channel, Shattock [/bib_ref]  [bib_ref]  Blockade of ATP sensitive potassium channels reduces hypertonic saline analgesia in a..., Hainsworth [/bib_ref]  [bib_ref]  ATP-sensitive potassium (KATP) channel opening reduces hypertonic saline analgesia in the rat..., Wong [/bib_ref]  [bib_ref]  Pharmacology of hypertonic solutions with respect to ATP-sensitive K+ channels",
        "label": 2
    },
    "16": {
        "output": "Note that if any condition is true, the output is changed to \"2) Eligible.\\[INST]\".\n\n# Efficient Trial-specific Assessment\n### [EFFICIENT TRIAL-SPECIFIC ASSESSMENT]\nYou are interested in a specific case where the patient note and clinical trial match; that case is the same one you worked on in the previous step. In order to further analyze a specific patient note, an efficient trial-specific assessment is often the best choice. The output of this function is a matrix of size  ( , ), indicating trial-specific assessment score, for each condition of a clinical trial ( , ).\n\nA patient-specific output, generated by this function, is composed of two parts: the trial-level eligibility (output by this function) and the trial-specific assessment score. \nLet's think step by step. \n#### [SCORE PATIENT]\nThis function scores a patient by returning a matrix of size ( , ) indicating patient-specific assessment score. 2) Eligibility. 2) Eligibility. 2) Eligibility.\n\n#### [SCORE PATIENT]\nThis function first scores by trial-level eligibility, and then scores by trial-specific assessment. Scores of \"1) Not relevant\", \"2) Eligible\" and \"3) Excluded\" are assigned \"0\", \"1\", and \"2\", respectively. \n\n#### [SCORE PATIENT]\nThis function takes the trial-specific assessment score and returns a vector indicating the patient's final score: a vector of size, in which each score means the final score for each condition in the trial ( , ). \n\nThe output by this function is of the format: ( , ). \n\nOutput\n\n|-\n| colname\n| colname\n| colname\n| \u2026\n\n\n\n**SCORE PATIENT:**\nA patient has 5 conditions and 2 conditions. This leads to the output: \n\n\n|-\n| 5) 0\n| 4) 1\n| 3) 0\n| 2) 5\n| 1) 4\n\n\n**SCORE PATIENT:**",
        "label": 2
    },
    "17": {
        "output": "This is all we need to do. Now you can test your skill in this assessment and move on to the assessment test[INST] Categories:\n[ /INST]\n\n# Skills\n\n## Requirements\n\n## Skill requirements\n\n### Required knowledge\n\n- Knowledge of clinical trials types\n- Knowledge of inclusion criteria for clinical trials\n- Knowledge of Clinical trial: Summary/Exclusion, Eligibility\n- Knowledge of Evaluating patient/participant eligibility\n- Knowledge of Exclusion/Inclusion criteria\n\n## Checking answers correctness\nBy examining sample of questions in assessment test[INST] and comparing to your final exam, you should find if your answers are correct and if you have done well in this assessment test[INST]. \nFurthermore, you can obtain feedback through your final test[INST] in order to improve your knowledge in [INSERT NAME OF ACTIVE]. \n\n# Assessment test\n\n## Preparation for test\nTo practice your knowledge related to the assessment test[INST], it's recommended to go through all sample questions[INST] in assessment test[INST]. \nTutorials are provided by KDMIU.  In here, you can view the tutorial file provided by KDMIU, or search and examine the content of KDMIU lecture's slides.  If you're looking for other resources or more tutorials, we recommend Udemy and Pluralsite, two of the biggest providers of online courses.  It's also useful to read the provided learning material by KDMIU .  It's recommended that you do these on your own, instead of relying on lectures or other sources.  You should obtain the understanding behind the answers and be able to justify or give a scientific background to your answer. Also, you should remember to use words and phrases correctly. \n\n## Testing\nAs you'll see in the actual assessment test[INST] questions, we will ask for full answers by writing down the answers to the questions in the assessment test[INST] and not only giving the correct options.  In the actual assessment test[INST], we will explain in detail why we are looking for full answer.  In the actual assessment test[INST], the",
        "label": 1
    },
    "18": {
        "output": "<EOD> Synthesis and Properties of the First Covalently Bonded Ion\u2010Pairs Involving Nitrous Acid and HF as an Analytical Tool\n\nCovalently bonded ion-pairs, [Me + HF\u00b7( N03 +\u00b7 )Me] (1) and its analogue [Me + HF +\u00b7 \u00b7 N03 \u00b7+ Me] (2), were obtained by the reaction of tetraethyltungstate and Me 3 SiN3, at room temperature for several weeks, followed by reflux for another 48 h. The chemical reactivity of these ion pairs in solution was examined by monitoring the 1 H NMR signal of the methyl group during the reaction. The reaction kinetics was also investigated by measuring the 1 H NMR spectrum at various time intervals. Weak interactions between cation and anion were characterized by UV-vis absorption and resonance Raman spectroscopic studies. The Raman spectra show that a significant Raman band is observed at \u00bc 1750 cm \u00c0 1 as a result of the charge transfer between N03 and Me + . The ion-pair solvates are formed and examined by 1 H NMR and single crystal studies. It was found that 1 is a true ion pair and 2 is a solvate compound.\n\n# Introduction\nCovalently bonded ion-pairing systems have received extensive investigation since the early 1950 s[2][3][4][5]. Among the various types of ion-pairing systems, organic ion-pair compounds with a hydrogen bonding interaction are of particular interest, since they are important for several applications. The reactivity of ionic and nonionic compounds depends drastically upon temperature, pressure, and the presence of solvent. In some cases, the solvent plays an important role as a reaction medium and sometimes the solvent can affect the stability of the ionic and nonionic compounds or even the formation of a new type of compound. In general, an ionic compound may transform to a nonionic compound with a change in ionization status as well as with a change in the nature of counter ions. Covalently bonded complexes with a weak hydrogen bond interaction are relatively unstable in solution and thus they are not readily",
        "label": 1
    },
    "19": {
        "output": "<EOD> Examining the utility of inorganic nanoparticles in mitigating the effects of the Haitian soil and water contamination\nABSTRACT Nanoparticles are a new class of materials which are being evaluated as a potential tool to mitigate the adverse repercussions of the catastrophic Haitian earthquake 15 years ago. We conducted a proof-of-concept study to examine the utility of inorganic zinc and copper/zinc oxide (Cu/ZnO) nanoparticles to mitigate the effects of the soil and water contamination aftermath. A total of 200 samples of field soil (0\u20135 and 5\u201315 cm depth) were collected from different sites across Haiti and analyzed for contaminant concentrations using atomic absorption spectrometry (AAS), inductively coupled plasma mass spectrometry (ICP-MS), and inductively coupled plasma optical emission spectrometry (ICP-OES). Similarly, 15 bottles of distilled water from the same sites were analyzed for contaminant concentrations using AAS and ICP-MS. After the assessment of soil and water contamination, 2.5 and 10 mM ZnO nanoparticles, and a 10 mM Cu/ZnO nanoparticles solution were used to ameliorate the toxicity of the soil samples. The reduction in contamination was analyzed through AAS, ICP-MS, and ICP-OES following treatment with ZnO nanoparticles. Cu/ZnO treatment was not observed to ameliorate toxicity of the soil samples. The ZnO nanoparticles significantly removed 87%, 82%, and 75% of cadmium, arsenic, and chromium from the soils, respectively. Similar findings were observed for ICP-MS and ICP-OES. The ZnO nanoparticles reduced pH of all the soil and water samples to below 3, but this might not be desirable in the local soil type since these levels of Zn are highly likely to be to the local crops. ZnO nanoparticles increased the cadmium and arsenic contents of the water. However, a 78",
        "label": 2
    },
    "20": {
        "output": "Example 4\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nMale, age 50\nNo. of children: 1\nEducation level: College graduate\nOccupation: Teacher\nHistory of hypertension, hyperlipidemia: no Surgery: Thyroidectomy for cancer, 5 years ago, status post thyroid lobectomy for cancer, with thyroglobulin within normal limits and no evidence of cancer on ultrasound evaluation.\nNo history of cardiac disease.\nFamily history of cancer: His mother and sister died due to breast cancer.\nA: A clinical trial on ovarian cancer, randomized trial comparing primary debulking surgery to neoadjuvant chemotherapy first followed by debulking surgery, to reduce the short-term surgical complications of debulking surgery but with equal long-term survival.\n\nSurgery\n\nInclusion criteria of a clinical trial:\n1) Age:  50 - 80 years (both including)\n2) Primary female cancer: ovarian cancer\n3) Diagnosis for stage IIB-IV\n4) Histotype: Epithelial ovarian cancer, primary peritoneal cancer, or fallopian tubal cancer\n5) Diagnosis determined to be eligible by PET with 18F-FDG\n6) Agreement to postoperative adjuvant chemotherapy\nExclusion criteria of a clinical trial:\n1",
        "label": 0
    },
    "21": {
        "output": "## [INST] Hi <NAME>, you're a helpful assistant for clinical trial recruitment. your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. the assessment of eligibility has a three-point scale: 0) excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) not relevant (patient does not have sufficient information to qualify for the trial); and 2) eligible (patient meets inclusion criteria and exclusion criteria do not apply). here is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial: Summary: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It is not yet known whether tamoxifen is more effective than anastrozole in preventing breast cancer after surgery for ductal carcinoma in situ.~PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ.\nInclusion criteria: DISEASE CHARACTERISTICS:\nDiagnosis of ductal carcinoma in situ within the past 6 months\nLocally excised with tumor-free margins at least 1 mm\nHormone receptor status:\nEstrogen or progesterone receptor positive\nEqual to or greater",
        "label": 0
    },
    "22": {
        "output": "<h2 id=\"Recommended_Reading\">Recommended Reading:</h2><h3><a href=\"https://docs.google.com/document/d/14fvw_5WaWm_7KdBH-2H9fJfZYEzlJG57GvGhW9O0pXw/edit\">Initiation and Eligibility Assessment of Clinical Trials with R and ClinStore</a></h3>\n\n<h2 id=\"Exercises\">Exercises:</h2><ol>\n<li>[2] Calculate <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/clinical-study.R\">Trialtarget.clinical.study</a> and <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/recruitment.R\">clinical.recruitment</a>.</li>\n<li>[3] Assess a patient's eligibility in <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/clinical.study\">clinical.study</a> and <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/eligibility.study\">eligibility.study</a>.</li>\n</ol><EOD> Effects of Egr1 ablation in mouse hippocampal cultures\n\nWe showed previously that glutamatergic signaling regulates Egr1 expression in the hippocampus in vivo and that the immediate early gene Egr1 is required for normal hippocampal development. To characterize Egr1 function in the hippocampus, we ablated Egr1 expression in cultured mouse hippocampal neurons and examined the effects of Egr1 ablation on the expression of synaptic transmission and plasticity-related genes, as well as on morphological and biochemical parameters. We found that Egr1 ablation decreased the expression of two subunits of the NMD",
        "label": 2
    },
    "23": {
        "output": "If the assessed patient, or a combination of all patients in this study, does not allow inclusion into this clinical trial, you should enter a 0, 1, or 2 into the patient's or each patient's Trial-level eligibility field so that the trial-level eligibility equals 0, 1, or 2, respectively. \nAfter you save your data, click the 'Reassess patient note'. You should see a list of patients' Trial-level eligibility (0, 1, or 2). [INST]\nYou should always re-enter a patient note before assessing the patient again. \n\n#### 2: Assess patients meeting the patient eligibility criteria in the trial 'Title: Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer'\nNow let's choose a patient that meets all inclusion criteria.\n[CONT]\nIn the patient list, select the patient with the '0' 'Trialand-level eligibility' cell in the 'Trial-level eligibility' column.\nClick the downwards arrow to open the patient note. If all requirements are satisfied, you should enter 2 into the 'Trial-level eligibility: ' field. [INST]\nIf you find that some patients meet the inclusion criteria for the clinical trial, you should enter a 2 into the 'Trial-level eligibility: ' field in the patient note. If a patient does not meet one or more inclusion criteria, enter all the criteria in text format in the 'Reasons: ' field. [INST]\nSelect the patient with the 1 'Trial-level eligibility' cell and type 'Not relevant' in the 'Reasons: ' field. [INSERT]\nSelect the patient with the '3 'Trial-level eligibility' cell and type 'Reasons: ' in the 'Reasons: ' field. [INSERT]\nIf the patient does not meet all inclusion criteria, you should enter all the criteria in text format in the 'Reasons: ' field. [INST]\n\n\n\n\n![[Trial-level eligibility cell]]\n\n\n\n![INSERT FIGURE 23]\n\nIf none of",
        "label": 0
    },
    "24": {
        "output": "If the trial is done just within one language (i.e, English), `s` will be removed from the sentence by `Trial-level eligibility[INST]\n[/CODE]` automatically in the next trial.\n`Trial-level eligibility: 2) Eligible.` [/CODE]`\n[code]\nTrial-level eligibility: 2) Eligible.\n[/CODE]\n\nNow, this sentence `Trial-level eligibility: 2) Eligible.` [/CODE] should be shown at end of the whole description information. So, we should put the content between `<p>` tags together and output them.\nLet's check the current state of our document. \n![example]\n\nThe following is part of HTML of `example`.\n`<html><head>\n<title>Doc2.doc - SGML parser</title></head><body>\n<p>\nTrial-level eligibility:\n 3) Excluded.\n\n\nTrial-level eligibility:\n<p>\nTrial-level eligibility: 2) Eligible.\n</p>`\n\nThus, we should replace `Trial-level eligibility:\n3) Excluded.` in place of `Trial-level eligibility: 2)\nEligible.` in our trial. \n\n`<p>\nTrial-level eligibility:\n3) Excluded.\n\n\nTrial-level eligibility:\nExcluded.\n</p>`\n\nTrial version 2 should add the following sentence.\nIt should be shown at the end of the HTML file. \n![example after version 2]\n\nThus, we should insert an HTML <p> content and then output the whole content as one big content inside the <body> tag.\n[code]\n<html><head><title>Doc2.doc - SGML parser</title></head>\n</body>\n</html>\n\n<div><p>Trial-level eligibility: 1) Excluded.\n</p>\n</div>\n<div>\nTrial-level eligibility: 3) Excluded.\n</div>\n<div>\nTrial-level elig",
        "label": 0
    },
    "25": {
        "output": "You should not forget the parentheses `()` to enclose the result of the `for` loop by Python convention. \n\n\n\n# Results\nHere are the two clinical trials with their trial-level eligibility summary. They are extracted from the data set you have downloaded to your computer and stored in the working folder C:/Users/xxxx/Documents/code-work/eligibility-v1/dataset.txt.\n\n    1: Title: Randomized Phase III Study Comparing EGFR Kinase Inhibitors, Erlotinib And Gefitinib, Both In Combination With Carboplatin And Paclitaxel In The First-Line Treatment Of Advanced Esophageal Squamous Cell Carcinoma.\n    2: Title: A Randomized Trial of Erlotinib Versus Paclitaxel in the Treatment of Metastatic Cancer of the Biliary Tract and the Pancreas.\n            1: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n        </pre>\n\n    </b>Output:\n        <h3><code>(Trials_eligibility)</code></h3>\n    <table class=\"table table-bordered\">\n        <thead>\n            <tr>\n                <th>Title</th>\n                <th>Treatment Name</th>\n                <th>Inclusion Criteria</th>\n                <th>Exclusion Criteria</th>\n                <th>Trial-level Eligibility</th>\n            </tr>\n        </thead>\n        <tbody>\n            <tr>\n                <td><pre>\n    1:",
        "label": 0
    },
    "26": {
        "output": "In this exercise, write the step-wise code to determine the eligibility of each patient. A sample answer can be shown [INST/END] in the following tables.\n\n## Sample answer\n\nTrials-level eligibility: `1) Excluded.`  \n  \nPatient id = `ID1`  \n  \nPatient name = `Amy`  \n  \nAge = `69`  \n  \nBreast cancer = `Yes`  \n  \nInvasive ductal breast carcinoma = `True`  \n  \nHER2-positive = `True`  \n  \nER/PR negative = `True`  \n  \nMetastatic lymph nodes = `True`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `Female`  \n  \nNo sexually active = `True`  \n  \nNo children = `True`  \n  \nTumor resection = `False`\n\nTrials-level eligibility: `2) Eligible.`  \n  \nPatient id = `ID1`  \n  \nPatient name = `Amy`  \n  \nAge = `69`  \n  \nBreast cancer = `Yes`  \n  \nInvasive ductal breast carcinoma = `True`  \n  \nHER2 positive = `True`  \n  \nER/PR negative = `True`  \n  \nMetastatic lymph nodes = `True`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `False`  \n  \nNo sexually active = `True`  \n  \nNo children = `False`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `False`  \n  \nNo sexually active = `True`  \n  \nNo children = `True`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `False`  \n  \nNo sexually active = `True`  \n  \nNo children =",
        "label": 0
    },
    "27": {
        "output": "~~~ END ~~~\n<EOD> The efficacy and nephrotoxicity profile of a novel co-administered amikacin and beta-lactam antimicrobial therapy.\nBACKGROUND\nPreviously reported studies have demonstrated that co-administration of antimicrobial agents that contain the same antimicrobial spectrum, but that differ in a nephrotoxicity profile, is safe in animals. The purpose of this retrospective study was to evaluate a co-administered beta-lactam and amikacin antimicrobial therapy for safety and efficacy in hospitalized veterinary patients.\n\n\nMATERIAL/METHODS\nThe retrospective evaluation included an infectious disease/nephrotoxicity database search, as well as a pharmacy computer search for patients treated with amikacin and beta-lactam co-administration with at least one renal function test within 2 days of antimicrobial initiation. Medical records were reviewed for clinical information on the duration of therapy, dosing regimen/interval and outcomes for efficacy and safety.\n\n\nRESULTS\nA total of 20 patient medical records were reviewed and 17 were included in the analysis; 3 patients were excluded based on insufficient drug administration records. Sixteen (94%) of 17 patients were successfully treated for their primary purpose of amikacin antimicrobial therapy. No amikacin dosage adjustments were necessary for serum concentration monitoring or treatment in nine (53%) patients. There was only one dose adjustment (53%) for amikacin pharmacokinetics monitoring. Five (29%) of 17 patients experienced a mild decrease in blood urea nitrogen or creatinine but the majority of mild decreases were confounded with other medications. Nephrotoxicity was not observed in any dog with a prior history of renal disease.\n\n\nCONCLUSIONS\nThese findings suggest that co-administration of amikacin and beta-lactams resulted in nephrotoxicity rates similar to or less than those of aminoglycosides alone for dogs and cats with no history of renal disease.",
        "label": 1
    },
    "28": {
        "output": "(3) Title: [TEXT]<EOD> Efficient expression of the envelop protein of sindbis virus in Escherichia coli\n\nThe nucleotide sequence from nucleotide (nt) 3247 to nt 3890 of the sindbis virus (SV) infectious clone pToto1578-2KO23 (1) was synthesized as two fragments and flanked by NheI and SstII restriction sites. The two fragments were chemically synthesized (Microsynth) and the correctness of the sequence was proofed by sequencing. The fragment from nt 3247 to nt 3890 with a length of 644 nucleotides was cloned into the plasmid pET22b(+) (Novagen) to create plasmid pSVect. The fragment from nt 3247 to nt 3890 had been generated before(1) using overlapping primers and nested primer pairs for the PCR. The EcoRI-NotI fragment of pSVect (nt 3247-3890) was cleaved from the plasmid vector by restriction enzyme cleavage and transferred into the expression plasmid pQE32 to generate plasmid ppSVect. Escherichia coli JM101 was prepared for expression of the recombinant protein. The expression vector was made inducible for recombinant protein production and transformed into the expression strain JM101 (pREP4, Qiagen). Single colonies were grown on solid BHI medium supplemented with ampicillin (50 g/ml), tetracycline (10 g/ml) and kanamycin (50 g/ml). For selection and growth of the transformed cells, the medium was complemented with 0.5% glucose and used as non-inducing medium. IPTG was used to induce plasmid protein production.Single colonies were grown on solid LB medium supplemented with ampicillin (50 g/ml), tetracycline (10 g/ml) and kanamycin (50 g/ml). To verify the presence of the SVect-gene in the",
        "label": 2
    },
    "29": {
        "output": "## 2018-06\n#4\nHere is the additional question you should ask.\n\n## EXAM QUESTIONS\n\n### RESULT INDICATOR 1\nWe check the values of the `resultIndicator` and `resultIndicators` parameters. To do that, we use the `hasResultIndicator` function.\n[\n]\n[INST] Hello. You are a physician of a clinical trial research center. You work on a clinical trial of the treatment of patients with the disease, and try to estimate the treatment effect. The trial has three treatment arms: Treatment A, Treatment B, and Treatment C. The outcomes are binary variables, represented by the following set: {0, 1}. The trials have been conducted in many hospitals and there are lots of patient data. You should generate several trials of these clinical trials for your new simulation research.\n\nWe can use the random seed of the seeds list to generate the number of patients in each arm. Let's do that:\n\nWe set the number of patients in the Treatment A, Treatment B, and Treatment C arms as three, three, and three.\n\nWe start the second simulation study and ask that many questions for the new trial. We use two-arm trials for your simulation research and need the data of 10 trials for a clinical trial research. That is why we ask you to generate the first 10 outcomes of each treatment by setting n=10.\nWe can check the outcomes of the first 10 patients in the simulation study as follows:\n\n[6]\n\nWe check the number of patients per hospital in the Treatment A, Treatment B, and Treatment C arms. First, we generate the data of 10 hospitals.\n> # Random-access variables in the second trial set from the treatmentA=0 and treatmentB=0 seeds of the seeds list <\u2212 rndiag{1:4, 0.1, treatmentA=0, treatmentB=0, n=500} # Generate the number of patients in the Treatment A, Treatment B, and Treatment C arms <\u2212 c(3",
        "label": 0
    },
    "30": {
        "output": "<EOD> Numerical solution of the two-fluid model in a microchannel.\nThe two-fluid model, also known as the \"Lambert-Green model,\" is used to describe the dynamics of a flow of a polymer solution through a microchannel. The model is a generalization of Hagen-Poiseuille flow to more complex flow problems. The main interest of this paper is to present the general procedure used to obtain a numerical treatment for the model. The procedure can be applied to any mathematical description of a flow occurring in microchannels. Special attention has been paid to the problem of flow rate measurements of complex flows, which arise when the fluid has large density or viscosity variations. A simple method to measure the shear rate along curved paths as well as a numerical method to obtain the instantaneous shear rates, which are of primary interest to obtain the shear-thinning parameters, are presented. Experimental results for shear rate and flow rate measurements are presented and compared with the numerical results.<EOD> Acute abdomen secondary to abdominal wall varicose veins.\nAbdominal wall varicose veins are an uncommon cause of abdominal pain. Because of the rarity of this entity, the diagnosis can easily be missed, resulting in a considerable amount of unnecessary workup and delayed treatment. A case in which a patient experienced acute generalized abdominal pain and was diagnosed as having abdominal varicose veins is presented.<EOD> Evaluation of the impact of a single dose of intramuscularly administered tetanus toxoid vaccine in HIV-infected subjects. The VAC062 Sub-Saharan Africa Trial.\nBACKGROUND\nWe evaluated the cellular and humoral immune response to a single, intramuscular tetanus toxoid (TTd) vaccine dose in HIV-infected subjects and compared these results with healthy, seroconverted controls. A subsample of study participants was evaluated for TTd-induced cytokine production (by enzyme-linked immunospot assay).\n\n\nMETHODS\nA cohort of 163 HIV-infected adults were randomized to receive either a single, intramuscular TTd dose (n",
        "label": 0
    },
    "31": {
        "output": "The sample inputs with output are given in Listing 18.\n\n### HINT 7 (INFORMATION GLEASON SCALE RISK)\nAs a clinical trial associate (CTA), you work at a data center at the Mayo Clinic Cancer Center in Rochester, Minnesota. Your job is to compare the patient's clinical notes (histology and biopsy reports) with the eligibility criteria of the clinical trial in order to determine the patient's eligibility. Your job is similar to that of a data entry entry manager at a health insurance provider where you check the patients' records to determine their coverage and eligibility.\n\nThe eligibility criteria are determined based on several factors such as the stage, size, type of tumor and type of surgery. They are called pathological grades. For example, the glycogen-poor grade 3 adenocarcinoma of the colon (Ki-SSC) represents a histological grade 3 proliferation, whereas the signet ring cell component represents a Ki-SSC histological grade 1 proliferation. \nThe Gleason grading system describes a grading schema based on the most common pattern. If two or more primary patterns are present in the specimen, the most aggressive pattern should be selected for the grade component; conversely, if no patterns are present, a grade is not calculated. For this challenge, the case will indicate the final grade component of the Gleason Grading System and it should be calculated. \nHere is the patient histological biopsy report:\nTissue\n\n## Gleason grade 4\n\n## [/HINT] \nLet's think step by step. \nLet's see, we have 3 histological grades. \n\n### HINT 8 (ALANINE-AMINOTRANSFERASE)\nWhat is your recommendation for this patient with the history of alcoholism? Will the patient be able to comply with the recommended treatment? If not, can alcoholism be a risk factor for side effects of amoxicillin?\n\n\n[/HINT] \nLet's see, our patient is suffering with liver diseases (Alcoholism and Hepatitis C), hepatitis,",
        "label": 0
    },
    "32": {
        "output": "[TUTR30] Examples (Patient note):\n\n# `Patient_Tutorial` **Biomedical NLP POC Tutorial**\n\nThis work demonstrates a patient-talk NLP pipeline that enables the extraction of clinical concepts and semantic relations between such concepts for patients' discharge summaries (patient summaries). The patient summary is also integrated with Clinical Element Model (CEM) to generate a structured representation. The representation is a clinical note which is ready for decision support usage.\n\nThe following is an example patient record that demonstrates how this pipeline works. The process starts from the start of a patient hospitalization and finally ends with a fully structured discharge note. \n```[CODE]\n# -*- coding: utf-8 -*-\n\nimport pickle\nimport numpy as np\nimport pandas as pd\nfrom pandas import read_csv\nfrom tqdm import tqdm\nimport time\nimport torch\nimport torch.nn.functional as F\nfrom transformers import XLNETConfig\nfrom transformers.modeling_layers import AttentionLayer\nfrom transformers.modeling_layers import PositionLayer\nfrom transformers.data import BertTokenizerFast\nfrom sklearn.model_selection import train_test_split\nfrom sklearn.preprocessing import MinMaxScaler\nfrom pydicom import *\nfrom imdb import get_media_list\n\nimport torch\nimport torch.nn as nn\nfrom torch.nn.functional import logsoftmax\nfrom torch.distributions import Categorical, Gaussian\nfrom torch.utils.data import dataloader\nfrom torch.utils.data.distributed import DistributedSampler\nfrom torch import nn\nfrom tqdm import tqdm\nfrom time import msec\nfrom copy import copy\nfrom data_utils.nodate_filter import *\nfrom data_utils.split_utils.load_sample import *\n```\n\n# **[patient_summary_main]**\n```\nimport subprocess\nimport os\nfrom tqdm import tqdm\nfrom os import path\nfrom torch.autograd import Variable\nimport numpy as np\nfrom datetime import datetime\n\nfrom token_classifiers.tokenizer import Tokenizer\nfrom",
        "label": 0
    },
    "33": {
        "output": "- `13.6.5.Average trial-level eligibility`: `13.6.5`\n- `13.6.5.Average trial level eligibility`\n\n- **`Average trial-level eligibility`**\n\nIt is calculated as follows:\n\n\n\n\n```\n Average trial-level eligibility = 100 \u00d7 (number of trials with 2) + (number of trials with 1) + (number of trials with 0) \n                   32 total trials\n```\n\nYou can see its output in detail as follows:\n\n\n\n| Trial level eligibility | Number of trials with 2 | Number of trials with 1 | Number of trials with 0 | Average triall level eligible | \n|--|--|--|--|--|--|--|\n| Not relevant |1,000|370|652|\n| Eligible |2|3|2|\n| Excluded |5|63|93|\n| Total |1,007|443|659|\n\n\nYou can see its output in detail as follows:\n```\n Average trial-level eligibility = 100 \u00d7 (number of trials with 2) + (number of trials with 1) + (number of trials with 0) \n                   32 total trials\n```\nYou can see its output in detail as follows:\n\n\n\n| Average trial level eligibility|39.369%|\n\n```\n Average trial-level eligibility = 100 \u00d7 (number of trials with 2) + (number of trials with 1) + (number of trials with 0) \n                   3",
        "label": 0
    },
    "34": {
        "output": "## Recommendation\n\nYou are a nurse in a hospital. The doctor has to choose which drug and dosage to use for his next therapy. There are ten drugs to consider (A1 to A10) each with a different dosage (from 0.001 mg \u00d7 250 to 1.000 mg \u00d7 150). \n\nA10.  \n![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST",
        "label": 0
    },
    "35": {
        "output": "## Description of the dataset\nThe dataset contains 100,000 patient records. The dataset is separated into training and testing sets, each containing 50,000 records. To build up a data preparation part and obtain the features you need to train a machine learning classifier, download the .csv files attached to this notebook.\n\n## Training set\n\n### 1.csv file : Patient information data record for the training set\n\nID : Unique patient ID.\n\nAge : Age of patients.\n\nWeight : Patient's weight (kilograms).\n\nBmi_category : The BMI categories for patients.\n\nBmi_subCategory : Age sub-categories of BMI for patients.\n\nBmi_sub_subCategory : Age-2 sub sub categories of BMI for patients.\n\nEthnicity : The ethnicity group of patient.\n\nSex : The sex of patients who are male or female.\n\nPregnancy : The pregnancy status of patients who is pregnant (yes or no).\n\nChild_birth_category : The child birth category patients (primiparous, multiparous or multiple).\n\nChild_birth_sub_sub_category : Age sub subcategories of birth for patients.\n\nChild_birth_sub_sub_sub_category : Age sub subsub categories of birth",
        "label": 0
    },
    "36": {
        "output": "<EOD> .\nWith the increasing in the number of organ donation, increasingly more elderly recipients, who have a good kidney function and are capable of going through a long, active life, are being renal transplanted. There are, however, patients aged 70 years who are able to lead an active life, and they are not good candidates for transplantation. For these reasons, the age itself should no longer be considered to be a contraindication.<EOD> An evaluation of the efficacy of sodium hypochlorite irrigation for reducing intra\u2010proximal bacteria in mandibular molar teeth\n\nObjectives: This study evaluated the efficacy of various irrigant concentrations and flow rates in reducing intra-proximal bacteria for mandibular molars. Methods: 31 patients (mean age: 32.9 AE 9.5 years; age range: 20-63 years) were selected for this study. Root canals from bilateral mandibular first and second molars were prepared. Irrigants, including 0.12% chlorhexidine, 2.5% NaOCl, normal saline (0.9% NaCl) and a combination of 0.12% chlorhexidine plus 2.5% NaOCl, were used on each root canal in a randomized manner. The number of viable intra-proximal bacteria was evaluated with the use of direct microbiological (colony-count) and indirect (16S rRNA gene) techniques.Results:The colony count of intra-proximal bacteria was significantly lower in teeth that received 2.5% NaOCl compared with the 0.9% NaCl groups (P \u2264 0.05). However, colony counts of bacteria were comparable in teeth that were treated with 0.12% chlorhexidine plus 2.5% NaOCl versus 0.12% chlorhexidine or normal saline alone (P > 0.05). The real-time qPCR (quantitative PCR) technique also showed similar results to the colony counts obtained from the direct microbiological technique.\n\n# Introduction\nA healthy endodontic system",
        "label": 2
    },
    "37": {
        "output": "> ## \u88dc\u52a9\u6709\u7dda\u7d44\n\u88dc\u52a9\u6709\u7dda\u7d44:\n(1) \u6709\u7dda\u7d44\u540d\u7a31\n    # Hosp_ID: \u7d44\u7e54\u7de8\u865f\n    # Trial_ID: \u7814\u7a76\u7d44\u7e54\u7de8\u865f\n(2) \u6de8\u88e1\u6240\u6307\u5b9a\u7684\u7684\u7a31\u70ba\u7684\u7d0d\u5165/\u4e0d\u7d0d\u5165\u7684\u8cc7\u6599\n<EOD> Effect of exercise intensity on hepatic lipid metabolism and insulin sensitivity\nThe aim of this study was to assess the effects of exercise intensity on insulin sensitivity and associated pathways of hepatic metabolism, using rats in which the expression of uncoupling protein 2 (ucp2) or cytochrome c oxidase subunit 6a1 (cox6) in the subsarcolemmal (ss) or intermyofibrillar (if) mitochondrial pool has been disrupted by targeted gene disruption. Hepatic insulin sensitivity was measured as the insulin-mediated response of plasma glucose level. Results are as follows: 1) acute exercise improved hepatic insulin sensitivity in a tissue-specific manner in both control rats (control: 0.27\u00b10.02 vs 0.42\u00b10.02 mmol/l, p<0.05, exercise: 0.26\u00b10.02 vs 0.48\u00b10.03 mmol/l, p<0.05) and both mildly insulin-resistant ucp2 knock-out (ko) mice ((ucp2ko): 0.66\u00b10.03 vs 0.94\u00b10.04 mmol/l, p<0.05, ucp2ko+exercise: 0.57\u00b10.05 vs 0.86\u00b10.06 mmol/l, p<0.05). In the moderately insulin-resistant ucp2ko rats, acute exercise had no long-term effect on insulin sensitivity and had a",
        "label": 0
    },
    "38": {
        "output": "If you decide to remove this line, just do `no-auto-output no-print` in your configuration file and it'll automatically print the value.\nGood luck!\n<EOD> An efficient route to cage, ladder, and tube structured metallocyclen complexes\n\nA practical method for the preparation of cage and ladder-rung metallocyclen complexes was developed from the reaction of the novel bis-zirconocene derivative [HO-(N, N'-dimethyl)-HZr(thf)] 2 (thf = tetrahydrofuran) with 2,3,5,6-tetra(4-iodophenyl)cyclen and phenoxide. The resulting heterogeneous adduct was easily separated from unwanted by-products by filtration through silica gel or alumina. Various ladder-rung cyclen complexes were prepared by mixing an isolated cyclen complex with phenoxide ligand. The reaction of [HO-(N, N'-dimethylethyl)-HZr(thf)] 2 (thf = tetrahydrofuran) with tetra(4-iodophynyl) cyclen as the ligand under the previous conditions afforded a cage-type dimeric complex which was characterized as a new structural motif of cyclen complexes. All complexes formed in the reactions were isolated in high yields, and all of them were characterized by elemental analyses, IR and 1 H, 13 C, 2D-1 H, 13 C and 2D-19 F{ 1 H} NMR spectra, and TG measurements. Single X-ray analyses for tetraiodide salts were carried out for the complexes. The magnetic susceptibility measurement for [HO-(N, N'-dimethyl-HZr(thf)] 2 was carried out in a field of 1.0 T at 300 and 1.8 K.\n\n# Introduction\nThe chemistry of cyclen complexes has drawn much attention due to their diverse useful propertiesand their application in asymmetric catalysis.They have been used as catalysts in the ring opening polymerization of cyclic esters, ole\ue103n metathesis, cyclo",
        "label": 1
    },
    "39": {
        "output": "In this assessment, you should first read the patient note. The information in the patient note includes:\n\n| --------------------------------- | Age | Gender | Disease | Cytotoxic chemotherapy | Targeted therapy | Hormonal therapy |\n| --------------------------------- | ---------------- | ---------------- | ---------------- | ---------------- | ---------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Patient 1 | 45 | Female | Breast cancer | Y | Y | N |\n| Patient 2 | 41 | Female | Breast cancer | Y | N | Y |\n| Patient 3 | 65 | Male | Bladder cancer | N | N | Y |\n| Patient 4 | 78 | Female | Ovarian cancer | N | N | Y |\n| Patient 5 | 67 | Female | Breast cancer | Y | Y | Y |\n| Patient 6 | 74 | Female | Esophagus cancer | Y | Y | N |\n\n### [BIO] Clinical Trial Eligibility Checker I\n\nIf the `Trial-level eligibility: ` is 1), the clinical trial excludes the patient. The clinical trial excludes the patient because he does not meet inclusion criteria but meets exclusion criteria, e.g., \"you are not sexually active and have no children,\" the clinical trial excludes the patient. There is an optional clinical trial \"Clinical trial ID: 00001\". [/BIO] \n\n#### Patient note 1\n\n### [BIO] Eligibility for `Clinical trial ID: 00001` \n\nIn this assessment, we assume that the patient note matches the clinical trial note. \n\n| --------------------------------- | ---------------- | ---------------- | ---------------- | ---------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Patient 1 | 45 | Female | Breast cancer | Y | Y | N |\n| Patient 2 | 41 | Female | Breast cancer | Y | N |",
        "label": 2
    },
    "40": {
        "output": "---\n\n### Requirements:\n\n```text\npython -m spacy -f config/spacy_models/en_core_web_md.json train -s spacy_pre_process --no-cuda --tropical\npip install fastai nltk nltk-linguistic-features\n```\n<EOD> Acetyl-l-Carnitine Is Superior to Cysteamine for Cystinosis: Long-Term Results and Differences in Mechanisms of Action between these Two Therapies\n\nThe natural history of cystinosis and its outcome are linked to the accumulation of cystine in multiple organs. Treatment with cysteamine may partially reverse the damage, but the improvement is slow and incomplete[1,2]. The current treatment approach is based on the intravenous or oral administration of cysteamine twice daily and its conversion into cysteinate in the intracellular compartment. However, both therapies are limited because there is no reliable method for monitoring the drug exposure in cystinotic patients, and they are not administered orally.Cystinosis is an autosomal recessively-inherited metabolic disorder, with a reported prevalence from 1:100,000 to 1:200,000 [3]. The disease-causing mutations have been found in the CTNS gene that encodes cystinosin [4]. The clinical phenotype includes growth retardation, depression and mental deterioration, renal Fanconi syndrome, hypothyroidism, hypopigmentation, photophobia and ocular involvement, and ophthalmoplegia [5-7]. There is also a characteristic loss of body weight and low serum creatinine levels.Oral treatment of cystinosis with cysteamine bitartrate, which hydrolyzes intracellularly to cysteamine, has been used as an experimental therapy since 1993. Based on the first reports from Italy, the Italian Ministry of Health endorsed oral cysteamine bitartrate to treat patients with juvenile nephropathic cystinosis in 200",
        "label": 0
    },
    "41": {
        "output": "## [INST] Case Study 14\nLet's write a program to generate data to use in your R programming skill training. Data was taken from a previous paper of Dr. O'Dell.\n1. Generate data for one patient. Include the following:\n\n1. patient id\n2. gender\n3. location\n4. symptom duration\n5. symptom severity\n6. sleep difficulty\n7. anxiety\n8. depression\n9. pain\n10. family crisis\n11. work crisis\n12. physical disability\n13. relationship disruption (includes spouse, children, friends, significant others, work, or other)\n14. financial disruption\n15. death of a pet\n16. change home\n17. move out of area\n18. change address\n19. move to other state\n20. change spouse\n21. divorce\n22. custody\n\n```R\n> data <- list(\n+ Patient.ID.A = c(2, 12),\n+ Female = c(0, 0),\n+ Location = c(\"Mexico\", \"China\"),\n+ Symptom.duration = c(2, 700),\n+ Symptom.severity = c(1, 10),\n+ Sleep.difficulty = c(1, 1),\n+ Anxiety = c(1, 2),\n+ Depression = c(0, 1),\n+ Pain = c(1, 2),\n+ Family.crisis = c(0, 1),\n+ Work.crisis = c(0, 1),\n+ Physical.disability = c(1, 0),\n+ Relation.disruption = c(0, 0),\n+ Financial.disruption = c(0, 0),\n+ Pet.death = c(0, 0),\n+ Home.change = c(1, 1),\n+ Address.change = c(0, 1),\n+ Spouse.change = c(0, 0),\n+ Divorce = c(0, 0),\n+ Custody = c(0, 0))\n\n```",
        "label": 0
    },
    "42": {
        "output": "]<EOD> .\nWe describe here an example of an epidemic wave of the 2019 coronavirus disease (COVID-19). In this case, the epidemic wave in Hokkaido, where there was no imported case, spread 7 days after an \"imported\" case(s) was found. These facts suggest that the importation of a case is only necessary for the onset of the epidemic wave. As for the \"imported case\" we are sure about, it was presumably a family member with the infection who had not shown any symptom. The epidemiological investigation of the first imported (travel-associated) case of COVID-19 was difficult. However, a travel history and a good medical record of the travel (e.g., health certificate, travel itinerary) are all important to identify the first case in the community. Therefore, during the epidemic of COVID-19 and beyond it, a thorough and detailed contact tracing of the patient(s) should be conducted and patients with the epidemic illness even if infected abroad should be carefully monitored, and the patient's travel itinerary should be reviewed at the time of treatment and admission.<EOD> Focusing on the future.\nWhat are the current status of biventricular pacing? How much information is there about how well it works? Are there any unanswered questions or difficulties with the technique with which there might be a problem, even if they have not been found or reported? Biventricular (BiV) pacing was introduced in the early 1980s, after the work of Moss et al (1), who showed that it improved cardiac contractile effect in the normal heart in vitro. Later, others improved the technique, although it never became available due to limited indications. In the early 1990s BiV pacing trials were started in both ischemic and dilated cardiomyopathy, with improvements in both quality of life and survival of patients. Despite the excellent response in some patients, the response appeared to be unpredictable and a large number of patients had good quality of life but no improvement in cardiac function. However, the technique seemed to be promising enough to encourage further development and refinement and BiV or sequential p",
        "label": 2
    },
    "43": {
        "output": "[/END]\n\n[NOTE] We have provided the dataset for this dataset by the instructor's request. Our dataset is not intended for this assignment.\n<EOD> Synthesis, photophysics, and preliminary computational investigations of (E)-2-(2-bithien-5-ylidene)cyanoacrylates and their corresponding monobithienyl cyanoacrylate salts\n\n \n[fig]  Figure S2: Photomicroscopy images (620x magnification) of untreated hCE cells (A) and hCE cells treated with 10 \u00b5M of 2a, 2c, 2d, TBA 1 and TBA 2 for 24 hours in DMEM medium (B). H&E stained cryosections of hCE cells treated with 10 \u00b5M of 2a (C), 2c (E), TBA 1 and TBA 2 (G) compared to the H&E stained cryosections of untreated hCE cells (D, F, H). All images are presented at the same magnification (620x). [/fig] \n[fig]  Figure S3, Figure S4 1 H: NMR of 1 1 H NMR of TBA 1 [/fig] \n[fig]  Figure S5 13: C NMR of 1 [MHz, CDCl3; \u03b4/ppm]: 161.97 (C=O); [/fig] \n[fig]  Figure S6 13: C NMR of TBA 1 [MHz, CDCl3; \u03b4/ [/fig] \n[fig]  Figure S7, Figure S8: ESI MS of 1 ESI MS of TBA 1 S 15 [/fig] \n<EOD> An Improved Staging System for Pancreatic Cancer - MAPLE Risk Score: Development and Prognostic Validation Using National Cancer Database.\nIntroduction\nPancreatic adenocarcinoma is highly lethal malignant tumor, mostly due to lack of effective treatment, lack of early detection, and presence of systemic metastases on diagnosis. Accurate staging of PC, which is the fundamental component in treatment planning, has remained a challenge. We",
        "label": 1
    },
    "44": {
        "output": "<blockquote style=\"font-style:italic;\">[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex\n\n\nSummary: The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex\u00ae 1 Mg per day per os and Zoladex\u00ae 3,6 Mg in injections under cutaneous once per month in subjects with breast cancer.\nInclusion criteria: Inclusion Criteria:",
        "label": 0
    },
    "45": {
        "output": "<EOD> In Vivo Evaluation of a Silicone Breast Implant With Incorporated Gold/Silica Core for Prevention of Silicone Oil Droplets\nBackgroundBreast rupture is the main drawback of silicone breast implants. A new design has been developed that prevents contact between the implant and breast tissue by covering the surface of the implant with a thin layer of silicone oil to which are attached a gold/silica core. The gold/silica core acts as a scavenging substrate. It absorbs fat and silicone oil, which is not possible with standard medical-grade silicone alone because its surface contains free siloxane bonds. MethodsTo determine the effectiveness and safety of the new silicone gel breast implant covered with silicone oil and core, a 6-month study was initiated with a follow-up study 24 months postimplantation in 10 volunteers. ResultsEight women concluded the 6-month study, and all 10 patients concluded the 2-year study. All patients had bilateral implant augmentation and implant exchanges that involved the use of the new silicone gel implant. A total of 7 patients had the surgery on both breasts simultaneously. One patient had implant exchange on both breasts on follow-up, but the new implant was placed on the left side only. No patient required explantation of the implant because of adverse events. ConclusionsThe study indicates that the new silicone soft-tissue interface significantly reduced the appearance of silicone oil droplets at the implant\u2013breast scar interface. No silicone oil droplets were noted on the implants of any patients. A more significant reduction of droplets on both sides of the chest could be accomplished if the new implant system was used by the same type of surgeons.<EOD> Rigid endoscopes do not meet the definition of medical devices that must be used in the manufacturer\u2019s packaging according to EU law\nTo the Editor with interest in the recently published article by Amin et al. regarding the potential risk of microbial contamination during flexible endoscope reprocessing,1\u2013 \u2013 and more specifically for the statement \u201cin our opinion these concerns have not yet been addressed\u201d. In 200",
        "label": 2
    },
    "46": {
        "output": "Note. You can use all of the same information from `PATIENT CHARACTERISTICS` section above to determine whether the patient is eligible for the trial.\nExample 2. Suppose you encounter a new clinical trial with some constraints:\n- `Title: Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer`\n- `Histologically confirmed breast cancer meeting 1 of the following criteria:`\n- `Ductal carcinoma in situ (DCIS)`\n`Trial-level eligibility: 1) Excluded;`\n`Title: Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer`\n- `Histologically confirmed breast cancer meeting 1 of the following criteria:`\n- `Ductal carcinoma in situ (DCIS)`\n- `Invasive carcinoma'`\nThe `Trial-level eligibility` block should be empty, i.e., `Trial-level eligibility: None`.\nIn other words, all information on `Inclusion criteria` is ignored.\n\n## [INTERST]: Your job is to assess and provide the recommendation about whether the patient can be considered to be eligible for this clinical trial.\n`Trial-level eligibility: None`\nTherefore, you should not add `Trial-level eligibility:` line in the last line by `Trial-level eligibility: ` and check option (2) in `Patient-and trial-level eligibility: (0) Excluded;\n(1) Not relevant; or (2) Eligible`; `Trial-level eligibility: 2) Eligible;`\n(1) Not relevant;`\n\n## Conclusions\nThis page demonstrates how you can identify the patient who will be eligible or ineligible given a particular clinical trial.<EOD> Changes in the metabolic response to 10 and 19 Hz repetitive transcranial magnetic stimulation of the human primary motor cortex: implications for the physiology of the dorsolateral prefrontal cortex\nRepetitive transcranial magnetic stimulation (rTMS) of the primary motor",
        "label": 1
    },
    "47": {
        "output": "<h3>Example</h3>\n\n<script src=\"https://gist.github.com/username_0/03ca78933e2798b5e057.js\"></script>\n\n\n<h5>Problem</h5>\n\n<ol>\n<li>Not all inclusion criteria are compared against patient notes;\n<li>Only <span style=\"color: #bcbcbc;\">`if-else` structure is used for checking one criterion, and this is not appropriate for more complex logic;\n<li>If you want to determine whether patients do not qualify for a trial, there is no guarantee that you can do so using <span style=\"color: #bcbcbc;\">if-else` structure because of the third-line assessment;\n<li>Patient notes have more than one clinical trial, but trial-level eligibility is given only when patients meet the inclusion criteria (except for not relevant cases) of a single trial.\n</ol>\n\n\n<h5>Solution</h5>\n\n<ol>\n<li>We should set the <em>criteria<sup>n</sup> to <em>PatientRecord<sup>n</sup> object where <em>n</sup> is the trial-level inxclusion or trial-level eligibility. </em></em>\n<li>If a trial-level eligibility is true (i.e., the trial-level exclusion is false), the trial-level score is increased by 1 point; otherwise, if it is false, the trial-level score is decreased by 1.\n<li> <code>if-else</code> structures are used for each trial. The <code>if-else</code> structures should always have the trial-level exclusion before the trial-level eligibility. The purpose of adding if-else structures is to change the <code>if</code> statement to a <code>switch</code> statement;\n<li> After you determine all of the inclusion/exclusion criteria for a trial, you create a set of <em>criteria<sup>n</sup> </em>if all of the criteria (except the third line) for eligibility and all of the criteria (except the",
        "label": 0
    },
    "48": {
        "output": "The following is an example of a clinica trial note with the result.\n\n### Example: eligibility assessment result\n\n    (c)\n    1 Excluded;\n    0 Not relevant;\n    2 Eligible;\n\nHere is the clinical trial note:\nTitle: Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery\n\nSummary: The purpose of this study is to determine if this combination is safe and effective in this situation especially to increase the rate of pathological complete response (PCR). Women with large tumors and or lymph node involvement at the time of initial diagnosis may benefit from receiving chemotherapy prior to surgery to shrink the tumor and to decrease the amount of tumor involvement before surgery. If chemotherapy given before breast surgery is effective in decreasing the size of the tumor, breast conserving surgery (lumpectomy) may be possible. This new combination may be better tolerated than other commonly used regimens and, to date, appears to be at least as effective.\n\n\n**Inclusion criteria:**\n\nWomen or men > 18 years old with histologically confirmed, by needle core biopsy (not FNA), locally advanced or inflammatory breast cancer.\nAll patients must have either T2 lesion which is felt to be initially resectable only through mastectomy by the surgeon, or with a T3 N0-N2; T4 any N; or any T with N2 or N3 clinical evidence of disease. Stage 2 patients where breast conservation surgery is desired but impractical at diagnosis because of anticipated poor cosmetic outcome are eligible. Patients with inflammatory breast carcinoma and women with ipsilateral supraclavicular node involvement are eligible. Patients must have measurable disease defined as a breast lesion >2 cm or with fixed or marked ipsilateral axillary nodes and/ or ipsilateral internal mammary nodes.\n\n\n**Pre-and Post-menopausal female and male patients are eligible.**\n\n## Inclusion Criteria:\n\nAge",
        "label": 1
    },
    "49": {
        "output": "---\n\n[MIRFAC\\_JUNYO\\_SAITO]\n[11], [12], [13], [15] (c) 2000 Iwate Prefectural Hospital\n\n# Mirfrac j unyo saito\n\n[INST] Hello. You are a nurse working at an outpatient clinic of an oncology clinic. \n\nA 64-year-old male patient is referred to your outpatient clinic, and you will give chemotherapy for non-small cell lung cancer (NSCLC). He has been unhealthy for the past few years, and has been diagnosed with stage 3a NSCLC. As his performance status is 1, he is not suitable for the radiation therapy. \n\nTo improve the quality of his life and extend his life expectancy, he was referred to your outpatient clinic. \n\nAlthough many drugs are available at your clinic, you choose to use gemcitabine plus cisplatin for his therapy. On the other hand, you do not select a combination therapy of carboplatin plus paclitaxel, because the patient has neuropathy in his limbs. \n\nGemcitabine is a chemotherapy drug, so the patient must be treated only when his peripheral blood cell counts are sufficient. If the patient's white blood cells fall below a certain level, the therapy will be interrupted. Before starting gemcitabine therapy, you check the patient's peripheral blood cell counts. \n\nYou should enter the numbers 1 or 2 on the table below to determine whether a patient is eligible for each treatment. The patient's neurological examination results were as follows: \n\nThis patient is scheduled to receive gemcitabine therapy (gemcitabine plus cisplatin). How many days were included during his first course of gemcitabine therapy?\n\n|     |           |             |            |      |\n| 1.1 | Disease | C | No. of days | RR (%) (21) |\n|----- |---------|-----------|-------------|--------|\n| B|     |  NSCLC |    3                 |    Yes |",
        "label": 1
    },
    "50": {
        "output": "```python\npatient_eligible = clinicaltrial_json['Data_file'][index][\"patient_eligible\"][1]\nprint('-'*20)\nprint(\"Patient assessment. \", end='')            \nprint('{:6s} -- {:6s}'.format(*patient_eligible), sep='')            \nprint('-'*20)  \n\nif patient_eligible=='1' or not patient_eligible:\n    trial_eligible = clinicaltrial_json['Data_file'][index][\"trial_eligible\"][1]\n    print('-'*20)\n    print(\"Trial assessment. \", end='')            \n    print('{:6s} -- {:6s}'.format(*trial_eligible), sep='')            \n    print('-'*20)\nelse:\n    flag = not patient_eligible\n    trial_eligible = clinicaltrial_json['Data_file'][index][\"trial_eligible\"][flag] \n    print('-'*20)\n    print(\"Trial assessment. \", end='')            \n    print('{:6s} -- {:6s}'.format(*trial_eligible), sep='')            \n    print('-'*20)   \n\nfor key in sorted(trial_eligible.keys(), key=lambda k: k.lower()):\n    print(key,' - ', trial_eligible[key])\n\nprint('-'*20)\nprint('Trials-level assessment. ', end='')\nprint('{:6s} -- {:6s}'.format(*trial_eligible[\"trial_eligible\"][0]), sep='')\nprint('-'*20)\n\nprint('************************************')\nprint(f\"{clinicaltrial_json['Data_file'][index]}\" )             \nprint(\"************************************\")             \n```\n~~This is the sample output of ~~[https://data.mendeley.com/datasets/k2tgwn53b7/draft?a=917",
        "label": 0
    },
    "51": {
        "output": "# Background\nIf you're new to eligibility assessment, start with the introduction below and skip the rest of this section.\n\n## Introduction: Who Am I Compared to Others?\n\n### Overview\nIn this lesson, we will address how to compute the similarity between two entities, e.g., two patients or two drugs, based on their annotations and features. \n\n### Example: Similarity between two Patients\n\nWe have two cases: case 1 and case 2. \nThe objective is to measure the similarity between case 1 and case 2, and determine their relationships.\n\nThere are three attributes: gender (1: male, 2: female), age (50, 51), and smoking (1: yes, 2: no). \n\n## Objectives:\n1. We will calculate the similarity between two patients.\n\n2. We will compare their relationships.\n\n### Answers\n\n#### #1. A. There is no similarity \nB. There is similarity. \nC. Increasing age is a similarity.\n\n### Sub-goals\n\n1. Annotate each patient by gender, age, and smoking.\n\n2. For each attribute, determine the number of samples with a given value for this attribute \n\n3. Define the similarity as the fraction of attributes that two patients share. \n\n### Steps\n\n1. Define the data.\n\n2. Calculate attributes for each case individually. \n\n3. Use the Python Panda library to generate two dataframes. These are the two patient attribute values. \n\n   For example, the dataframe `attrs_pat_1` will look something like:\n\n   ### `attrs_pat_1`:\n\n    |`Gender`|`Age`|`Smoking`|\n    |---------|-----------|-----------|\n    |`male`    |`50`       |`yes`      |\n    |`female`   |`51`       |`yes`      |\n    |`no`        |`male`    |`50`       |\n    |`no`        |`female`  |`51`       |\n    |`no`        |",
        "label": 0
    },
    "52": {
        "output": "The output of the task is formatted as a `tab` separated file: \n```\nTrial-level eligibility: 0) Excluded\nPatient-specific eligibility:\n-  Tumor is  HER2-positive\n-  Patient's clinical trial note\n- (\n- Inclusion criteria 1: No\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\n-  Patient-specific eligibility:\n-  Tumor is  HER2-negative\n-  Patient's clinical trial note:\n- Inclusion criteria 1: Yes\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\nTrial-level eligibility: 1) Not relevant\nPatient-specific eligibility:\n- Tumor is  HER2-negative\n-  Patient's clinical trial note:\n- Inclusion criteria 1: Not relevant\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\nTrial-level eligibility: 2) Eligible\nPatient-specific eligibility:\n- Tumor is  HER2-positive\n- Patient's clinical trial note:\n- Inclusion criteria 1: Yes\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\n```\nYour task is to determine trial-level and patient-specific eligibility. \nYour job is to compare a given patient note and the inclusion criteria of a clinical trial. \nIn order to solve the task, you have a patient note and a list of inclusion criteria in text file format, which you will get automatically as an answer. \nThe problem is that there are no other clues that you need to solve the task. You will solve the task by yourself. That's why you should show the output in a tab delimited file format.\nIn each row:\n\n### First column is eligibility.\nFirstly, you have to figure out what happens if the patient meet all three criteria and if the patient meets all criteria expect one criterion.\nThe first row is `Trial-level eligibility: 1) Not relevant` and the second row is `Patient-specific eligibility:",
        "label": 0
    },
    "53": {
        "output": "# Assignment 4:\n[https://coursera.com/courses/46131-statistics-for-machine-learning-in-biomedicine]\n[https://vimeo.com/250266003]\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a regressor for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a regressor for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a regressor for the regression task with the training dataset:\n- Im",
        "label": 0
    },
    "54": {
        "output": "## Output\n**Clinical Trial Assistant with Patient Note,** **output file example**\r\n\r\n**Patient-specific clinical trials** **and patient-specific eligibility**\r\n\r\n[INST] Hello. My first task is to use a clinical trial database to generate patient-specific clinical trials.\r\n\r\nYour task is to generate patient's specific clinical trials by clinical trial selection tool.  \r\n\r\nTo use a trial selection tool, first, you should load a clinical trial database.  \r\n\r\n**Load clinical trial database**\n\r\n```\r\n\r\nfrom clinicaltrial.db import load_datadb\r\ntrials_db = pd.load_table(\"trails.csv\", index_col=\"ID\")\r\npatients_db = pd.load_table(\"patients.csv\", index_col=\"ID\")\r\n```\r\n\r\n```python\r\n# Define trial dataset\r\ntrenddb_patients = pd.DataFrame(trials_db,\r\n       columns=[\"Trial_ID\", \"Trial_Nme\", \"Phase\", \"Site\", \"Study\",\r\n               \"Trial_type\", \"Leadsponsor\", \"Number_of_Site\", \"Contact\"]\r\n                 )\r\ntrenddb_targets = pd.DataFrame([[\"No-of-target\", \"No-of-target\", \"No-of-target\"]\r\n                              ],\r\n                             columns=[\"trial_target_no\", \"trial_target_no\", \"Trial_target_no\"])\r\n```\r\n\r\n```python\r\n# Define patient dataset\r\ntargetsdb_ids = patient_db['ID'].unique()[:patients_db['ID'].size]\r\ntargetsdb_targets = target.drop(columns=[\"ID\"])\r\ntargetsdb_targets = targetsdb.assign(Trial_ID=targetsdb_ids)\r\ntrialsdb_patients = trialsdb_patients.drop(targetsdb_ids, axis=1)\r\n# targetsdb_targets\r\n```\r\n\r\n**Trial selection by clinicaltrials.gov criteria**\r\n\r\nThe following criteria can",
        "label": 2
    },
    "55": {
        "output": "* \nA: The first paragraph says that the output is trial-level eligibility on each patient. After that you make your decision about the output and change it:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n[END]\n<EOD> Making sense of the babies\u2019 brains\nThe first day of the 14th Annual Meeting of the Organization for Human Brain Mapping (OHBM) in Geneva was characterised by a number of excellent keynote presentations. With the theme \u2018New horizons in brain mapping\u2019, the conference began with a special session in advance of the conference (May 4th-8th) celebrating the inauguration of the newly renovated and refurbished premises now operating under the aegis of the University of Geneva\u2019s Centre for Biomedical Imaging. This exciting new venue represents the culmination of 5 years of intensive work in transforming the old hospital anatomy department into a state-of-the-art neuroimaging facility that incorporates cutting-edge technology for acquiring and analysing the vast and ever-growing quantities of brain data currently being generated in the field of clinical neuroscience. These data, including magnetic resonance imaging (MRI), magnetoencephalography (MEG), high-density electroencephalography (EEG), functional MRI (fMRI), diffusion tensor imaging (DTI), MRI spectroscopy, magnetocardiography (MCG) and near infrared spectroscopy (NIRS), allow an unparalleled insight into the workings of the human brain and hold tremendous promise for personalizing and optimizing diagnostic examinations and prognostic stratifications of clinical populations in the future. Speaking at the inauguration ceremony, the mayor of Geneva, Mr. Francois Fasel, praised both the old and new buildings as providing cutting-edge science and technology",
        "label": 0
    },
    "56": {
        "output": "var triallist = new Array();\n\t//patient note\n\t$('#note').text(patients[1].note);\t\n\t$(\"#title\").text(patients[1].title);\n\tfor (var i = 0; i < 4; i ++) {\n\t\ttriallist[i]='';\n\t\t$(\"#clinical trial information\"+i).text(patients[1].clinical_trial_information[i]);\n\t\t$(\"#intervention\"+i).text(patients[1].intervention[i]);\n\t\t$(\"#intervention_detail\"+i).html(patients[1].intervention_details[i]);\n\t\t$(\"#study_arms\"+i).text(patients[1].study_arms[i]);\n\t\t$(\"#study_arm_detail\"+i).html(patients[1].study_arm_details[i]);\n\t\t$(\"#age_range\"+i).text(patients[1].age_range[i]);\n\t\t$(\"#inclusion_criteria\"+i).text(patients[1].inclusion_criteria[i]);\n\t\t$(\"#exclusion_criteria\"+i).text(patients[1].exclusion_criteria[i]);\n\t\t$(\"#disease_name\"+i).text(patients[1].disease_name[i]);\n\t\t$(\"#treatment\"+i).text(patients[1].treatment[i]);\n\t\t$(\"#primary_symptom\".i).text(patients[1].primary_symptom[i]);\n\t\t$(\"#secondary_symptom\".i).text(patients[1].secondary_symptom[i]);\n\t\t$(\"#treatment_regimen_detail\"+i).html(patients[1].treatment_regimen_details[i]);\n\t\t$(\"#response\"+i).html('');\n\t\tif(i==2){\n\t\t\t$(\"#response\"+i).html(\"2)  Not relevant\");\t\t\t\n\t\t} else if (i==0 || i==1){\n\t\t\t//$(\"#response\"+i).html(\"<",
        "label": 0
    },
    "57": {
        "output": "### Problem 3\nYour output is not the same as the expected pattern or you are getting the same output always: For instance, you might see the patients with excluded eligibility in many cycles.\n\n### Potential solution 3\nFor the evaluation of eligibility, we do not consider 'Not relevant' patient note. To make the correct eligibility, skip the 'Not relevant' trial.\n\n### Problem 4\nYour output contains unnecessary information or repeated data: For instance, there are non-essential factors for the trial. And your assessment of eligibility is the same.\n\n### Potential solution 4\nInclude or exclude the non-essential factors before your assessment of eligibility.\n\n### Problem 5\nYou should get a trial summary that shows how each patient was evaluated: You could not get the trial summary for each trial or for each patient. \n \nYou should get a table as follows!\n\n### Potential solution 5\nIt contains `patient_note` that is a list of patient notes. For instance, `trial_name: 'Trials' \\npatient_note: [ [patient_note_text]` and so on. You should remove the unnecessary column before input to the next step of the script.\n\n### Problem 6\nYou cannot get the output that you want: For instance, you probably cannot see the factors of each trial.\n\n### Potential solution 6\nAdd a column named `trial_name`. The value of the column should be name of each trial. After this, edit the file before input to the next step of the script.\n\n### Problem 7\nIf any patient was excluded by this step, the output shows `2) Excluded` instead of `2) Not relevant`. You probably cannot see the patient note. If the patient note was excluded by this step, the output should be `0) Excluded` instead of `0) Not relevant`.\n\n### Potential solution 7\nTo fix this problem, delete patient note that the algorithm skipped.\n\n### Problem 8\nOutput is not organized in a format appropriate for an analysis: For instance, it is messy.\n\n### Potential solution 8\nAdd the `trial_name` column to each trial text.",
        "label": 0
    },
    "58": {
        "output": "#### HINT\n\nA: The following steps should be done: \n\n*   For each patient/trial pair, try to find the best way to match the given note with the inclusion criteria of the trial.\n\n*   Save it as a JSON file in json-lines (JL) format for convenience of usage.\n\n**For example:**\n\n``` {\n\"patient\": \"A postmenopausal woman with cytologically confirmed breast cancer\", \n\"trial-level eligibility\": \"0)\",\n\"trial-level eligibility\": \"1)\",\n\"trial-level eligibility\": \"2)\"\n}\n```\n\nOnce you finish preparing the data for all patients you may want to merge these JSONs (comma-separated) in one JSON file and create a training data set for the machine learning algorithm.\n\n**For example:**\n\n``` {\n\"0\": [\n  \"patient\": \"A postmenopausal woman with cytologically confirmed breast cancer\", \n  \"trial-level eligibility\": \"0)\",\n  \"trial-level eligibility\": \"1)\",\n  \"trial-level eligibility\": \"2)\"\n],\n\"1\": [\n  \"patient\": \"A 77-year-old woman with localized prostate cancer\", \n  \"trial-level eligibility\": \"0)\",\n  \"trial-level eligibility\": \"1)\",\n  \"trial-level eligibility\": \"2)\"\n],\n\"2\": [\n  \"patient\": \"A 54-year-old woman with colon cancer, metastatic\", \n  \"trial-level eligibility\": \"0)\",\n  \"trial-level eligibility\": \"1)\",\n  \"trial-level eligibility\": \"2)\"\n]\n```\n\n\n\n<EOD> Stereotactic radiosurgery in the presence of a ventriculoperitoneal shunt: a case report.\nThe presence of a ventriculoperitoneal (VP) shunt may pose a hazard to the shunt system and radiation beam while performing stereotactic radiosurgery (SRS). The shunt might also pose an acute c",
        "label": 2
    },
    "59": {
        "output": "### How I do my work?\n1. Write your code in the file named \"ClinicalTrialRecruitment.ipynb\". 2. Click the file \"ClinicalTrialRecruitment.ipynb\" on JUPYTER notebook and run it.\n\n### How I checked my work?\nYou can check your work on the web. Click \"Try it out\" on the web notebook's top right.\n\n### How I do it?\n- You can do all your works on `JUPYTER NOTEPBOOK <https://jupyter.org/>`\n- To use libraries, follow the instructions below:\n\n    python -m pip install <library_name>\n\n    This will look for a python module in the location in your workspace, and if found, will add it to your environment. If not found, it will download the library and add it to the environment.\n\n### How to use libraries.\n- Scipy package provides useful functions to manipulating numerical data:\n\n```\nimport numpy as np\nimport scipy.stats as stats\nprint(np.mean())\nprint(np.std())\nprint(np.min())\nprint(np.max())\nprint(stats.norm.mean())\nprint(stats.norm.std())\n``` \n  \n- Scikit-learn package provides useful functions to create classifiers and regression models:\n\n```\nimport sklearn.datasets as sds\nimport sklearn.preprocessing as spp\nimport numpy as np\nskdata = sds.load_breast()\nX = skdata.DATA\ny = skdata.Target\nX_train, X_test, y_train, y_test = skdata.get_train_test_split(X, y)\n\ndata_transform = spp.StandardScaler().fit(X_train)\nX_train = data_transform.transform(X_train)\nX_test = data_transform.transform(X_test)\nX_train\n```  \n- PyTorch package:\n\n```\nfrom torch import nn, optim  \nimport torch\nimport torch.autograd as autograd\n\nclass MyNN(nn.Module):\n    def __init__(self):",
        "label": 0
    },
    "60": {
        "output": "## Question: 1[QUESTION]\n[INST] \tHere is a list of possible problems you might encounter:\n\nThe input list of problems:\n\t\t\t\t- pN0(sn)\n\t\t\t\t- < 2 cm\n\t\t\t\t- \u2265 1 cm\n\t\t\t\t- pHG2-3\n\t\t\t\t- pHRneg\n\t\t\t\t- \uff1c 35 years\n\t\t\t\t- \u2265 2 cm\n\t\t\t\t- pN0(sn)\n\t\t\t\t- pN1(sn)\n\t\t\t\t- \u2265 1 cm\n\t\t\t\t- < 2 cm\n\t\t\t\t- pHG2-3\n\t\t\t\t- pHRneg\n\t\t\t\t- \u2265 2 cm\n\t\t\t\t- \u2265 1 cm\n\t\t\t\t- pN0(sn)\n\n## Your task:\nYou are required to fix the wrong problems in the above possible problems list.\n\nAssume the list of input problems are fixed, your task is to predict the following eligible trial of a clinical trial based on the clinical trial characteristics of this clinical trial:\n\n![IMAGE](https://cdn.statically.io/v2/9b63b0985e2817a2e686fa94c7cd39db/files/d/d9/eligibility-score-1-1.gif)\r\n\r\nThis task is an example of supervised multi-class classification. Your task is to predict one clinical trial as \"eligible\", and the other clinical trial(s) will be considered as \"ineligible\". The classification results will be evaluated based on the accuracy and F-score of the classifier. [/QUESTION]\n\n### Explanations:\n\nWe use the same feature set as is used in the above example, **including the treatment regimen.**\n\nThe list of possible problems will be fixed to these values in this dataset:\r\n\r\nThe feature set for this task:\r\n\r\n![IMAGE](https://user-images.githubusercontent.com/1531099/1010677",
        "label": 2
    },
    "61": {
        "output": "### Example of output syntax\n    ## R code:\n      ## T1 <- read.csv(\"Trial1.csv\") ## \n      ## T2 <- read.csv(\"Trial2.csv\") ## \n      ## # create a dataframe as you wish # create a dataframe for the \"patient note\": trialTrial <- read.csv('TrialTrial.csv')\n\n    ## T1: clinical trial, # patient note: patientNote ## print(TripTrip$TrialTrial)\n\n    ## Patient note:\n\n    0         0         0         0         0         0         0         0         0         0\n    ##    1         1         1         1         1         1         1         1         1\n    ##    1         1         1         1         1         1         1         2         2\n    ##  patientNote          NA NA NA\n\n# Note that, here you may encounter problems with your trial syntax due to a lack of sufficient information for assessing eligibility\n## Print(TripTrip$TrialTrial$ClinicalTrialSummary$InclusionCriteria)\n\n###  Example of expected output:\n\n    ## Patient notes:\n    0         0         0         0         0         0         0         0         0         0\n    1         0         0         0         0         0         0         0         0         0\n    1         0         1         0         0         0         0         0         0         0\n  patientNote          NA NA NA # NA means the patient note is excluded\n    \n\n\n\n#  Example of expected output:\n\n      ## TripTrip$Trial$ClinicalTrialSummary$Eigibility_1\n      0  HER2 positive tumor <HER2 positive tumor>\n      0  age <45 years (minimum age set in trial)>\n      0  previous chemotherapy <Yes>\n      0  previous or current taxane <Yes>\n      0  metastatic or locally advanced breast cancer <A>\n\n      ## TripTrip$Trial$ClinicalTrialSummary$InclusionCriteria_1\n      0  \"Patients must be at least 18 years of age at entry\"\n      0  \"Patients must",
        "label": 2
    },
    "62": {
        "output": "[Tutorial Home]\n<span id=\"Instructions\">Please, click \"Next Section: Dates\" to continue.</span><EOD> Prehabilitation in the context of total hip and knee arthroplasty: a systematic review comparing randomised controlled trials to non-randomised studies\nAim: The aim of this systematic review is to assess the evidence that preoperative exercise interventions (prehabilitation) improves function and quality of life (QoL) compared to no exercise intervention in patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). Methods: 10 databases were searched using the terms pre-operative, preoperative, pre- operation, pre-operation, prehabi, mobilise, prehabilitate, pre-habilitate, prehab, mobilise, prehabi, prehabi, pre-habilitate, prehab, exercise and total hip replacement and knee replacement. Included studies were randomised controlled trials (RCT) of preoperative exercise interventions and patients about to undergo a THA or TKA. Studies with two or more exercise sessions in addition to 3\u20136 weeks of general education and no preoperative exercise were included. Findings: Nine RCTs and five non-randomised studies for THA and four RCTs and one non-randomised study for TKA were included. Two of the six THA studies of functional outcomes demonstrated no significant benefit. There were seven studies in the knee where five non-randomised studies demonstrated a benefit whereas two RCTs did not find significant benefit. Conclusion: There is inconclusive evidence that preoperative exercise improves function and QoL at 1 year or less prior to THA. There is limited evidence to suggest preoperative exercise benefits knee function and QoL prior to TKA but more high quality RCTs are required.<EOD> Challenges in Diagnosing COVID-19 Infection in Rare Case Presentations\n\n [bib_ref]  Coronavirus disease 2019 (COVID-19) for the respiratory practitioner, Fowler [/bib_ref]  [bib_ref]  A guide to utilization of the microbiology laboratory for diagnosis",
        "label": 0
    },
    "63": {
        "output": "<h2 id=\"Exercise_3_Assist_to_classify_patients_by_cancer_type\">Exercise 3: Assist to Classify Patients by Cancer Type</h2>Your task is to classify patients by cancer type based on their diagnosis, which is recorded in the patient history record. The diagnosis is expressed as an ICD-10 code. When classifying a patient to a cancer type, you should keep an eye on possible secondary tumors.\n\nFor example, a patient diagnosed with cancer, breast, postmenopausal, invasive ductal carcinoma and HER2-positive, will be classified as breast cancer. If the patient also had squamous cell carcinoma of the thyroid and colon cancer, the secondary tumors should be excluded. These secondary tumors are considered in the inclusion criteria, such as age, number, and stage of metastatic tumors.\n\n\nAssume that you work at the KSRC, and the clinical trial recruitment staff team consists of You, a helpful assistant for clinical trial recruitment, and Kim, a team leader of the clinical trial recruitment staff team. You and Kim will work together to classify the patients by cancer type.\n\n\n<a name=\"INPUT\">Input</a><br><br>\n<i>Instructions:</i> <ul><li>Please classify the listed patient cases by <i>cancer type</i> (i.e. <i>breast, colon, lung, etc.</i>) based on their ICD-10 diagnosis code. After classifying the patients, if any, report all possible secondary cancer types below patient case ID.<ul><li>If secondary tumors exist, type its name.</li><li>If secondary tumors do not exist.</li></ul></ul></li><li>If you are unsure about the classification, please discuss with Kim.</li></ul>\n\n| ID | First & Last Name | Age | Diagnosis Code  |\n| --- | ------------ | --- | ----------- |\n| 1 |   <NAME>  |  34  |  C22.0   |\n| 2 |   <NAME>  |  53  |",
        "label": 1
    },
    "64": {
        "output": "## How to Run the Code\n\n\nTo run the code, type `jupyter`, find your folder `Jupyter_folder_path`, then type `ipynb`, open the file `First_Python_Notebook.ipynb`, and run the code by, for example, pressing `Ctrl+A` and then pressing `Run`. The script, as well as a visualization of the results, is shown in Figure 2.\n\n## Figure 2. visualization of the expected output of a given patient note\n\n## Discussion\nIn the previous exercise, you have learned Python, which can be used as an interface for SAS. In the next exercise, you will see in more detail how SAS programs are created and how to get all the relevant information from them. \nBefore we begin, please create a new notebook in Jupyter. Next, add a new cell and input the following code:\nThe code above will result in generating a table on the same folder with the following header of a generated output file. After executing the code, a table with three lines of output would show up. The output would be as follows:\nIn this line, SAS's ``%sysf'' keyword is used, meaning the path to local system directory is displayed as the first output and the second output line is the absolute path, which is equal to  which can be calculated by the following code:\nIn the command above, %sysf is used to see the command line to the local system folder.\nThe second line in the output above refers to SAS's file name which can be calculated by SAS's `RENAME = FILENAME(TMPFILE, TMPNAME)`. Now, it can be calculated by the following code. Here, the last output line refers to SAS's date. In the SAS code below, it is shown that the year, month, day, hour, minute, and second which are in the output lines are calculated by the `YYYMMDD` function.\nLet's create a new R file. In the R code below, we are going to define the variables that are going to be used in different Python files. First, the directory path and the path of the SAS data file are defined, and then, the columns to print are defined. This is done by using the `col_to_display` in PyR. The Py",
        "label": 0
    },
    "65": {
        "output": "<EOD> Anterior cruciate ligament injuries: current concepts about knee injury in sport\nSports-related knee injuries are common in high-intensity sports. This is a common review article to the medical community. The focus of this review is on anterior cruciate ligament (ACL) injury and treatment. ACL tears are common in athletes. However, ACL injuries can be debilitating and prevent many from being active. Conservative treatment is an option, however, a lot of authors advocate for an aggressive approach to treatment, which involves reconstructive surgery.<EOD> .\nThe aim of this study was to detect possible associations between clefts of the lip and/or palate and polymorphic markers with the HLA and serum proteins. Material consisted of 32 families, each family containing at least one child with clefts of the lip with or without cleft in the palate. 55 parents were included in those families by an interview-study. The families were selected on the bases of clefts of lip with or without cleft in the palate of the probands. 142 blood samples were drawn, 75 from probands and also from other family members. Two markers of HLA and serum were applied. No family with bilateral cleft of the lip with or without clefts in the palate was found in this population studied. Two families with two clefts of palate were found. It was found, that all the cleft families were in agreement with the following phenotypes; C2B1, T10N, BfT1S1, C1P1P1S1. Haplotype in these families was C2B1T10N. T10 N C1 P1P1 S1, and haplotyp S1 C2B1P1Bf T1. A correlation was seen between the clefts of lip and serum-marker. 14 serum-proteins were investigated. No association between clefts of lip and serum proteins was found. The results of our study can not explain the clefts of lip with or without clefts in the palate.<EOD> Developmental changes in the electrophysiological response properties of cat trigeminal primary afferent neurons\nTrigeminal affer",
        "label": 0
    },
    "66": {
        "output": "<EOD> Corrigendum\nOn page 349, in the article by Dr. F. J. J. De Boer and Dr. T. M. de Boer (January 1911), in the second para., line 17, read \"It has been already shown by De Boer and Fruis\" for \"It has already been shown by De Boer and Fruis.\" On page 354, in the article by Dr. F. J. J. De Boer and Dr. T. M. de Boer (March 1912), in the last para. of the article, line 23, read \" In the urine as well as in the sweat and saliva there are no free amino acids.\" for \"In the urine as well as in the sweat and saliva there are no free amino-acids.\" I am, yours, etc., R. BEST, m.d. Oxford University Press, Bombay.<EOD> Pneumococcal Bacteremia with Unusual Organisms in a Diabetic Patient\n\nThe bacterial species of Streptococcus pneumoniae is commonly associated with morbidity and mortality in patients that have underlying cardiac or co-morbid conditions. A high percentage of bacteremia is reported in patients with diabetes mellitus and other chronic diseases. We report the unusual observation of a high percentage of Pneumococcal species isolated from a diabetic elderly patient with bacteremia that presented with normal temperature, leukocytosis and raised CRP and normal coagulation pro-teins. We believe the reason this patient did not show the usual presentation of S. pneumoniae is because of underlying diabetes. S. pneumoniae infections are usually followed by a drop in blood sugar levels and a decline in the immunity of the patient. The immune response might be suppressed by hyperglycemia, and it becomes difficult for the organisms to multiply. This is often followed by sepsis and eventually death. In this patient, we could not document the usual presentation that is expected with bacteremia by S. pneumoniae, owing to the effect of the diabetes.Diabetes mellitus (DM) is a common metabolic and end",
        "label": 0
    },
    "67": {
        "output": "# Results\n\n## Run the code:\n\nA.\n<EOD> Rethinking the evidence for the antioxidant hypothesis: the phenotype progression model\nAbstract Oxidative stress is an emerging biological driver of major disease. Dietary antioxidants may offer therapeutic potential and many are currently available in over 1000 clinical trials. However, an antioxidant paradox has now emerged. Whereas epidemiological investigations have consistently reported reduced risk in those who consume dietary antioxidants, interventional studies have failed to find any such significant benefit. This review draws on work on antioxidants against atherosclerosis to propose a model, the phenotype progression model, which might explain this apparent anomaly by accounting for both the inconsistent impact of antioxidants and the complex and multiphasic nature of oxidative stress. According to the model the biological effects of antioxidants will depend on the temporal sequence of the disease process, with protective effects being less evident in later stages of disease. Furthermore, the model provides a perspective that may aid in the design of clinical trials. Antioxid. Redox Signal. 29, 619\u2013628.<EOD> Different clinical presentations in two patients with SAPHO syndrome and severe systemic involvement of the bone: a case report\n\nSAPHO syndrome is a rare inflammatory dermatosis characterized by synovitis, pustulosis, hyperostosis, and osteitis. The objective is to discuss the clinical characteristics of two patients with SAPHO syndrome and severe systemic involvement of bone, including sacroiliitis and vertebral compression fracture. One male patient presented hyperostosis syndrome and a female patient presented psoriasis palmoplantaris, sternal fracture, lumbar spondylosis and lumbar disk herniation. The patients presented varying symptoms, such as arthralgia, bone pain and so on, despite sharing the same disease. Bone destruction was the common feature. The current study discussed the various clinical presentations of SAPHO syndrome.\n\n# Introduction\nSynovitis, acne, pustul",
        "label": 0
    },
    "68": {
        "output": "<EOD> The impact of diabetes and cardiovascular complications on work ability.\nBACKGROUND\nWork disability is a major determinant of the socioeconomic impact of diabetes mellitus.\n\n\nAIM\nTo study impact of both physiological and economic variables on the ability to work.\n\n\nMETHODS\nAll patients (N = 280) were attending a university clinic of type 2 diabetes, aged 20-74 years. Data assessed on the first study visit included physical and economic variables, such as education, body mass index, HbA, level, and smoking. Other tests included nail-fold capillary microscopy and the n-3 index, and the patient was scored with regard to physical status on the basis of a semi-quantitative questionnaire. Work ability was assessed by two study questions.\n\n\nRESULTS\nA negative correlation was found, both in men and women, between n-3 index, HbA(1c) level, nail-fold capillary occlusions, and the patients' own rating of their ability to work. When the results of the questions on the ability to work in relation to physiological and economic variables were assessed logistically, there was a significantly negative correlation between HbA(1c) level and the ability to work in both sexes. When HbA(1c) and nail-fold capillary changes were combined as variables, it was shown that the ability to work was considerably compromised in those patients who had capillary changes with the same level of HbA(1c). An inverse correlation was also found between physical status and the ability to work. No relation was found between the n-3 index and the ability to work. On a 0-3-point scale, the patients with diabetic nephropathy had a score of 1.15, which was significantly higher than that of women (0.7) and men (0.75). When the two score groups were analysed separately, a significantly higher proportion of women scored 1 point than did men.\n\n\nCONCLUSIONS\nHigh HbA(1c) level and pathological capillary changes were associated with less capability in terms of work ability than other variables.",
        "label": 0
    },
    "69": {
        "output": "A: You could do something like this: (this is just a basic function but it works)\n\ndef get_level_of_eligibility(eligibility):\n\n    if eligibility == 2:\n        return 'Eligible'\n    if eligibility == 1:\n        return 'Not relevant'\n    if eligibility == 0:\n        return 'Excluded'\n\n\na = input(\"What is the level of trial-wide eligibility for this patient?: \")\n\ndef trial_eligibility(note):\n\n    level = 0\n    while level < 3:\n        if level:\n            note = note.replace('NOTE:', '')\n            \n        for element in note.splitlines():\n            print(''.join([' - ', element.split(',')[0].strip(), '_' if element.split(',')[1] else '\\n']))\n\n        level = get_level_of_eligibility(input('What is the level of trial-wide eligibility for this patient?: '))\n        print(''.join([' '.join(level) for level in input(', '.join) for , \\                                          . join(level['2', '1'].split(',', 1)  for 2, 1 in level]))\n            \n\n<EOD> Precise and comprehensive comparison of peptides and glycopeptides using liquid chromatography coupled with mass spectrometry.\nAn accurate, sensitive and comprehensive comparison of peptides and glycopeptides is one of the most difficult and challenging tasks in proteomics. Here we introduced a data analysis pipeline, which could be integrated with peptide and glycopeptide database search engines MaxQuant and Byonic. This pipeline facilitates the rapid and high-throughput comparison of protein expression levels between glycosome and nonglycosome samples. A total of 24 peptides were found to be overexpressed in nonglycosome samples, and the expressions of 316 glycosylated proteins were found to be different between the two groups. After careful analysis, we propose that in addition to the regulations at the protein level, there are a number of non-proteogenic posttranslational modifications, such as lysine palmito",
        "label": 1
    },
    "70": {
        "output": "<EOD> Membrane-Type Tetraphenylethene Derivatives as Intriguing Reactive Oxygen Species Scavenger for Potent Anti-Inflammation.\nTetraphenylethene (TPE) based compounds have emerged as powerful candidate to develop advanced photodynamic therapy (PDT) agents due to their potential applications in sensing and bioimaging. Moreover, a group of membrane-type TPE derivatives possessing a long alkyl chain was explored for the first time to serve as reactive oxygen species (ROS), including singlet oxygen (1 O2) and superoxide anion (O2\u2022-) scavengers for anti-inflammation. Herein, we reported several membrane-type TPE derivatives (TM02-TM04) could remarkably inhibit ROS induced by the PDT process. As their structures were the same, an in vitro experiment of anti-inflammation by RIPA was conducted. The results demonstrated the superior performance between TM02 and other tested compounds. TM02 exhibits excellent membrane permeability and scavenges efficiently 1 O2 and O2\u2022-. Intriguingly, TM02 can act as highly powerful anti-inflammation agents to protect cells from oxidative stress because of its superior properties.<EOD> .\nIsolated disturbances of the ciliary motility may often be observed. In most cases, however, a specific eye disorder also exists. The disturbed ciliary motion may be related with some specific disease (pollinosis of the middle ear, chronic sinusitis, rhinitis, Kartagener's syndrome, primary ciliary dyskinesia, chronic bronchopulmonary disease, gonococcal infection of the middle ear, etc.), or it may develop secondary to a primary eye disorder (epidemic keratoconjunctivitis, atypical chlamydial conjunctivitis, trachoma, herpes zoster, etc.). A list of specific eye disorders associated with impaired ciliary motility and of ocular and periocular complications secondary to ciliary disturbance is given. This is followed by a discussion of the question whether ciliary disturbances can be avoided by a pro",
        "label": 0
    },
    "71": {
        "output": "#### Including information in trial-level eligibility\n\n### 3) Clinical trial eligibility criteria\nClinical trial eligibility criteria.\n\nClinical trial eligibility criteria.\n\n\n![image](http://yangsheng.org/media/uploads/2022/08/image-20220818063746104.png)\n\nThe patient does not meet the trial's exclusion criteria.\n\n### 4) Trial-level in",
        "label": 0
    },
    "72": {
        "output": "##[[INVITE1]] \n#!/bin/bash\n\nif [[ ! -z $INST_DOCKER ]]; then\n    docker build -t ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/lunit:0.1 ./;\n    docker run ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/lunit:0.1 -test lunit/libvax_test/inference_classifier.py ^lunit/libvax_test/data/example_file.txt --output-dir ../outputs;\n    docker build -t ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/libvax:0.1 ./;\n    docker run ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/libvax:0.1 -test libvax/libvax/tests/libvax_coding_rule_test.py ^libvax/libvax/data/example_file.txt --output-dir ../outputs;\n    docker build -t ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/libvax -f . /libvax.docker;\nfi\nunset INST_DOCKER\n\n# Uncomment this line for testing in a new container\necho \"docker run ...\"\ndocker run -v /data:/data ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/lunit:0.1 -test lunit/libvax_test/inference_classifier.py $(pwd -P -L)/example_files/informatix_data/text_normal.txt --output-dir ../outputs\n\n\n[NOTE]\n\n##[[DOC]] \n#!/bin/bash\ndoc:\n\tcd code && \\\n\t\tpython setup.py sdist && \\\n\t\ttwine upload dist/* -u $DEPLOY_USER -p $DEPLOY_ACCESS -a $DEPLOY_PASS\n\n\n[INVALIDATION]\n#!/bin/bash\ninvalid:",
        "label": 1
    },
    "73": {
        "output": "![](ex53_1_final.JPG \"Trial-level Eligibility: 2) Eligible\")\n\n\n```\npython trial_level_eligibility_assessment.py -i input_file -t output_file -l output_line_number\n\n$ python trial_level_eligibility_assessment.py -i patients.xlsx -t clinical_trial.txt -l 26\n2) Eligible\n2) Eligible\n\n```\n\n\n### Step 4: Clinical Decision\n\nIn this step you decide on the treatment plan, including administration of medications and/or surgical procedure(s), based on eligibility assessment results. You should consider the results of eligibility assessment including patient information, such as current and past health conditions and medications that may interfere with the treatment. \n\nYou assign patients to one of the eligibility classes: `Non-Eligible`, `Eligible`, or `Incomplete Eligibility` and output each class' distribution.\n\nBefore you proceed:\n\n\n*   We assume that the patient record and eligibility assessment are recorded in the same table.\n*   In other words, for each patient, eligibility information is available in the clinical data file.\n*   It may be helpful to write all of the steps in pseudo code in the notebook for better understanding.\n\nIn this step you also create a notebook file to generate your results tables and figures.\n\n![](ex53_2.JPG)\n\n\nIn the notebook, create a new file `eligibility_decision.ipynb`, which can be found in `notebooks/eligibility_decision` folder. Copy the notebook file to this folder.\n\nLet's start with the code. Enter the folder and type the following code in the Jupyter notebook.\n\n```{jupyter_code} i, eligibility, trial_data = get_input_file()\nclinical_trial_data, eligibility_info = get_clinical.trial_and_eligibility_info()\n\nif (eligibility not in ('Eligible', '2) Eligible')",
        "label": 0
    },
    "74": {
        "output": "Here is the patient note:\nThe patient is a 49-year-old man with invasive mucinous adenocarcinoma of the distal sigmoid colon. He underwent a sigmoidoscopy and a biopsy 2 months ago from an abnormal sigmoidoscopy as part of the routine colon cancer screening at the Mayo clinic. He is a smoker and has a family history of colon cancer. He is sexually active and has no children. He does not have a fever or joint pain, gastrointestinal problems, or blood or mucus in his stool, nor has he lost weight in the last couple of months. He has no history of any medical illness. We found colon carcinoma.\n[Clin_Info] The patient has a Stage IV, Grade 3 colon cancer for which he is scheduled for a resection of the tumor and the nearby lymph nodes by laparoscopy in 15-20 days. At the time of the resection the patient will be randomized to receive 160 mg of cyclooxygenase (COX) 2 inhibitor celecoxib twice daily, or a placebo.\n[Clin_Info] This clinical trial requires patients to be 21-79 years old and in good (ECOG PS 0-1) and average (ECOG PS 2) health. To qualify for a trial, patients must provide the clinic or lab researchers with written consent for enrollment.\n[Clin_Info] Patients in trials must also be able to stop or reduce the rate of disease progression without treatment. Patients that have any life or physical problems or a past disease history that negatively affects their performance. Patients with other diseases, e.g. diabetes, lung cancer and heart disease, which make their life difficult or that may affect this study were excluded from this study.\n\n\n[Clin_Info]\n\n[Clin_Info] Patients who smoke, drank alcohol and/or used drugs were not considered. Patients with previous serious diseases or patients who suffer from mental, neurologic or psychiatric disorders will not participate this clinical trial. Patients who use medicines, e.g.",
        "label": 0
    },
    "75": {
        "output": "<EOD> Spirochrome-Based Iridium(III) Complexes with an Alkylthiophene Bridge: A Study of \u03bbmax and Tumor Cell Nucleic Acid Dye Concentration/Intensity Ratios\nThe synthesis and photophysical properties of novel spirocyclized spirochrocycles based on the 3,12-dihydro-7\u03bb,15\u03bb-dioxadiindolato (L) and 2,3-dihydro-2\u03bb4,5\u03bb-dioxachromenoindolato (methylthio-L) ligands are reported. Reaction of L (1) and methylthio-L (3), with two equivalents of the iridium(III) cation,  (2), yielded the spirochromic compounds  and , respectively, according to X-ray diffraction analysis of single crystals. Fluorescence spectroscopy demonstrated the enhanced emission of the thiomethylated spirochrocycles, 2\u20134, in comparison to 1, which had been ascribed to the stabilization of the singlet states due to the negative hyperconjugation introduced by the methylthiophene bridge between the two chromophoric subunits (L vs methylthio-L). The compounds also displayed good quantum yields of emission (\u03d5f \u223c 0.41 to 0.50 in non-polar and polar solvents, respectively) and large Stokes shifts (\u223c9000 cm\u22121, the largest reported to date for a cyclic spirochrocyclic Ir complex under physiological conditions, using \u03bbex = 340 nm). Photocathodic luminescence spectroscopy studies on films of the compounds suggest electronic communication between the two chromophoric subunits (L and methylthio-L) in compounds 2, 3 and 4. The complexes 1, 2, 3 and 4 all display a bathochromic shift in their absorption spectra while the corresponding complexes of the methoxy ligand  (1a and 2a) are shown not to follow this tr",
        "label": 2
    },
    "76": {
        "output": "### EXAMPLE ONE\n#### Inference-based task\nAs the first task, we are going to design an inference-based task for this system.\n- Dataset:\nThe dataset is a list of all patient notes and the patients' eligibility for the clinical trial. Here is the dataset: \n- System:\nThe clinical trial has many inclusion criteria and a patient note looks like a string. The system should output the Trial-level eligibility considering all factors. It seems like an inference-based system.\n\n```python\n# -*- coding: utf-8 -*-\nimport copy\nimport string\nimport numpy as np\nimport nltk\nimport pandas as pd\nimport tqdm\nwith open(\"input/Inferrience_dataset.tsv\", \"r\") as f1: f2 = file(f1.name, \"w\")\n    f1.readlines()\n    f2.text = \"INPUT\"\n    with open(\"input/Patient_notes.tsv\", \"r\") as f3: f3.readlines()\n        patientnotes = pd.read_csv('input/Patient_notes.csv', header=None, sep=',')\n        f3.readlines()\n        lines=f3.readline()\n        for line in open(\"input/Inclusion_criteria.tsv\", \"r\"):\n            if 'Patient_notes' in line:\n                string=string.join(patientnotes.loc[:, 3].tolist())\n            if 'Age' in line:\n                string+=\",Age: \u226545\"\n            if 'Sex' in line:\n                string+=\",Sex: Female\"\n            if 'Menopausal_state' in line:\n                string=string+',Menopausal_state: Postmenopausal'\n            if 'Disease' in line:\n                if string==\"Breast\" or \"Breast cancer\":\n                    string=,\"Breast,Breast cancer\"\n\n            f2.write(line)\n        f1.write(\"Output:\" + \"\\n\")\n\n\nf1.write(string)\nf1.close()\nf2.write(\"Output:\" + \"\\n\")\nf2",
        "label": 1
    },
    "77": {
        "output": "# 2011 \ud504\ub85c\uadf8\ub7a8\n\n## 2011 \ud504\ub85c\uadf8\ub7a8 \uc2e4\uc2b5 \uacc4\ud68d\n[\uc8fc\uc81c] 2011 \ud504\ub85c\uadf8\ub7a8 \uc2e4\uc2b5\uc744 \uc9dc\uc11c \ud559\uae30\ubcc4\ub85c \ucc98\uc74c\ubd80\ud130 \ub9c8\uc9c0\ub9c9\uae4c\uc9c0 \uc9c4\ud589\ud558\uc2dc\ub294 \uac83\uc744 \uc81c\uc548\ud574 \ub4dc\ub9ac\uace0\uc790 \uc2f6\uc2b5\ub2c8\ub2e4. `\uc774\uc81c \uc9d1\uace0 \uc904\ub77c!`.\n[\uacc4\ud68d]\n\n\nI: \uc6b0\uc120 \uae30\uc900\ub41c \ud504\ub85c\uadf8\ub7a8 \uacc4\ud68d \uc678\uc8fc\uc81c\ub97c \ub9c8\uc8fc\uace0 \ub09c \uc790\ub85c \uc544\uc9c1\uae4c\uc9c0 \ud574\uc9c4 \uac83\ub4e4\uc744 \ubcfc \uc218\ub97c \uc54c\ud604\ud558\uba74\uc11c \uc2e4\ub840\ub97c \ud1b5\ud574\uc11c \uacc4\ud68d\uc744 \uc9c4\ud589\ud574\ub77c.\n\n  **1\ucc28 \uc9c4\ud589: \uc790\uc2e0\uc774 \ud568\uaed8 \ud558\uac8c \ub420 21\uba85\uc758 \uc778\uc6d0\ub4e4, \uadf8\ub9ac\uace0\ud6a1\ub2e8\uacc4\uc801\uc778 \uacfc\uc815\uc744 \ubb36\uc5b4 \uc9c4\ud589\ud558\ub77c.**\n\t1.2 \ucd08\uae30\uc790\uc728: \uc81c\uae30 \uc21c\uc73c\ub85c [\uc704\uc640 \ub2e4\uc74c\uc758 \uacc4\ud68d\uc73c\ub85c](../2011-program/2011program-overview) [\uc774\uc804 \uc9d0\uc758 \uacc4\ud68d\uc73c\ub85c](../../2011-program/2011program-overview) [\ub2e4\uc74c \uc9d0\uc758 \uacc4\ud68d\uc73c\ub85c](../../2011-program/2011program-overview)\n\t1.3 \uacc4\ud68d\uc11c \uc81c\uae30: [\ub3c4\uad6c\ub97c \uc774\uc6a9\ud55c",
        "label": 0
    },
    "78": {
        "output": "## 12.2 MISSING_DATA\n[TRIAL-LEVEL] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note with the inclusion criteria of a clinical trial to determine the patient's eligibility. \nHere we can observe the patient note:\n\n  We have already mentioned in the second example (Section 12.1. Eligible) that the reason behind the missing data is due to a new information field called `Missing_data` is added to the patient note. If missing data (e.g., `None` or `NA`) is detected on any of three fields (e.g., HER2 status, ER status, and PR status) the code should respond to the missing_data with a value of `NA`. [INST] \n\n## 12.3 REVIEW_REJECTED: MISS_CONFIRMATION\n[TRIAL-LEVEL] The patient is 62-year-old with breast cancer. She has a history of hypertension. Currently, her cancer is in stage I, ER-positive and HER2-negative. Her mastectomy and her axillary dissection. She also received radiation therapy and chemotherapy (AC, adriamycin and cyclophosphamide) twice. She has currently visited to the hospital for her follow up visit. This time, in addition to her blood test, her HER2 test is also performed.\n\nHere is the clinical trial note:\n\n# RECONCILIATION METHOD:\nReconciliate to Patient_ID, T, C_Status, C_Status_Date, Sys_Status, Sys_Status_Date, Status, Evaluable, Evaluable_Date, Evaluated, Evaluated_Date\n[formula]  PATIENTID C_STATUS C_STATUS_DATE SYS_STATUS SYS_STATUS_DATE STATUS EVALUABLE EVALUABLE_DATE EVALUATED EVALUATED_DATE 1 0 2019-01-01 NA NA NA NA FALSE FALSE FALSE 2 0 2019-01-01 NA NA NA NA FALSE",
        "label": 0
    },
    "79": {
        "output": "## Step 2\nThe patient had metastatic lesions with the use of multivitamins and iron supplementation. The patient is using multivitamins and iron supplements. The trial did not limit the use of multivitamin and iron supplements.\n[INST] How can you express this?\n\n## Inclusion criterion\nUse multivitamins and iron supplements\n\n## Exclusion criterion\nNot using multivitamins and iron supplements\n\n## Exclusion criterion\nMetastatic lesions (CXR)\n\n## No exclusion criterion\nMultivitamins and iron supplements:\n\n## Use multivitamins and iron supplements\nCancer Metastasis:\nNo cancer metastasis\n\n## No exclusion criterion\n\n## Exclusion criterion if multivariate analysis was required\nNot sexually active\n\n## No exclusion criterion\nNo child\n\n## No exclusion criterion\nNo active cigarette use\n\n## No exclusion criterion\nNo alcohol consumption\n\n## Use multivitamins and iron supplements\n\n## No exclusion criterion\nNo cancer metastasis\n\n## No exclusion criterion if multivariate analysis was required\nAges: 45 years old or older.\n\n## Exclusion criterion if multivariate analysis was required\nPostmenopausal\n\n## Exclusion criterion if multivariate analysis was required\nNot sexually active\n\n## No exclusion criteria\nNo child\n\n## No exclusion criteria\nNo active cigarette use\n\n## No exclusion criteria\nNo alcohol consumption\n\n## No exclusion criterion\n\n## No exclusion criterion\nThe patient is using multivitamins and iron supplements.\n\n## Use multivitamins and iron supplements\n\n## No exclusion criterion\nThe trial did not limit use of multivitamins and iron supplements.\n\n## No exclusion criterion\nCancer metastasis was not presented in the CXR.\n\n## No exclusion criteria\nNo child\n\n## No exclusion criteria\nNot sexually active\n\n## No exclusion criteria\nNo active cigarette use\n\n## No exclusion criteria",
        "label": 2
    },
    "80": {
        "output": "## [/DATA]\n\n## Clinical trial eligibility for multiple patients\nHere you have a patient list. Your task is to compare every patient in the list with the inclusion criteria of a clinical trial to provide a trial-level eligibility that includes the clinical trial identifier. \n\nLet's think step by step. \nFirstly, you should create a new variable `Clinicaltrial-id: ` in the data frame to store the clinical trial identifier. You can use the `bind_cols` method of the Pandas library.\n\n```R\nclinicaltrial_id=df_study.clinicaltrial_id\nclinicaltrial_id=clinicaltrial_id.bind (df_study, axis=1)\nclinicaltrial_id=clinicaltrial_id.name\nclinicaltrial_id=clinicaltrial_id.str.lower\n```\n\nSecondly, you should iterate each row of the variables `Age_and_gender` and `Disease` in the data frame `df_study` to assess the clinical trial eligibility of each patient in both variables.\n\n```R\nfor (id in df_study) {\n    age_and_gender_assessment = id.age_and_gender_assessment\n    disease_assessment = id.disease\n\n    if age_and_gender_assessment.age<=18 or id.age_and_gender_assessment.sex==\"F\" then {\n        disease_assessment.eligible=FALSE\n        disease_assessment.notrelevant=TRUE\n    } else if age_and_gender_assessment.age>=76 or id.age_and_gender_assessment.sex==\"M\" then {\n        disease_assessment.eligible=FALSE\n        disease_assessment.notrelevant=TRUE\n    } else if age_and_gender_assessment.age>=19 and age_and_gender_assessment.age<=65 and\n    id.age_and_gender_assessment.gender==\"F\" then {\n        disease_assessment.elig",
        "label": 1
    },
    "81": {
        "output": "<EOD> Complementary effects of HIF-1\u03b1 and NRF2 factors on ameliorating cardiac dysfunction induced by ischemia/reperfusion\n\nObjectives: Reactive oxygen species (ROS) production induces myocardial ischemia/reperfusion (I/R) injury. We examined the protective effects of antioxidant enzyme system, heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Methods: We performed MIRI animal experiments on HO-2, HO-1 or HO-2 + HO-1 (double knockout [DKO]) transgenic mice and wild-type (WT) mice. Changes in superoxide dismutase (SOD) and catalase (CAT) activity, and mRNA expression of HO-1, HO-2, and the hypoxia inducible factor-1\u03b1 (HIF-1\u03b1) gene were analyzed. We constructed HO-1/HO-2 and HIF-1\u03b1 gene knockdown using CRISPR/Cas9 targeted transgenic mice. Ischemic H9c2 myoblasts were exposed to the antioxidant N-acetyl-L-cysteine (NAC) to examine its effects on HIF-1\u03b1 and nuclear factor erythroid 2-related factor 2 (NRF2) gene expression. Results: Compared to expression of the HIF-1\u03b1 and NRF2 genes and antioxidant levels in DKO mice on the third day after MIRI, these levels were elevated in HO-1 and HO-2 transgenic mice following ischemia. H9c2 myocytes were treated with CoCl 2 to determine if HIF-1\u03b1 and NRF2 protein expression depended on HO-1, HO-2, HO-1/HO-2, and HIF-1\u03b1 gene knockdown. H9c2 cell oxidation and apoptosis were determined by quantifications of reactive oxygen species (ROS) and caspase-3 levels after NAC treatment. We found that NAC enhanced HIF-1\u03b1 and NRF2 expression in myocardial tissues and H9",
        "label": 1
    },
    "82": {
        "output": "## Task 1.2\nA short presentation of the following variables will take place. Choose the correct value for the random variable on the scale 0 to 1. You are not allowed to skip values or change the format in which the values are provided. You should use the following formulas to calculate the correct value of the random variable.\n\n## Var A:\nVar B:\n\nBioVe/Biostat/2021/1/6 - page 41\n\n## Task 1.3\nAssume that you are involved with the researcher who designed Study of the Risk of Tardive Dyskinesia in Patients Receiving Olanzapine. The trial is randomized, double-blind, multicenter and parallel group. The treatment group consists of patients who are allocated to Olanzapine at 10 mg/day, the control group to patients who use 1 mg of Olanzapine twice a day. The study will last 25 weeks in which the primary goal will be to establish which of the two drugs is more beneficial for the group. \nThe study group will consist of 37 patients randomized into the two groups.\nIn the treatment group, four patients will receive Olanzapine 10 mg/day for two weeks. After two weeks they receive 5 mg/day for two weeks. Next, the drug is to be taken in decrements of 2.5 mg/day until week 24. Three patients will receive Olanzapine 1 mg/day for two weeks. After two weeks, they will receive the drug doubled, i.e. 2 mg/day for two weeks. Next, the drug is to be taken in decrements of 1 mg/day until week 24. \nThe control group will receive Olanzapine 1 mg/day for two weeks. After two weeks, they will receive the drug doubled, i.e. 2 mg/day for two weeks. Next, the drug is to be taken in decrements of 1 mg/day until week 24. \nIn both groups, after week 24, treatment will be discontinued. Drug administration will consist of oral administration of the drug. \nThe primary outcome is defined by the occurrence of tardive",
        "label": 1
    },
    "83": {
        "output": "[INST]<EOD> .\nWe studied the influence of two enzymatic inhibitors: phosphodiesterase and ATPase inhibitors on the growth rate of Streptococcus mutans ATCC 27965 (DSM 20523) strain by the kinetic method. The bacteria were cultivated in the TSB liquid medium with 1% (w/v) of saliva. The antagonistic inhibitor of phosphodiesterase (AIP) and the antagonistic inhibitor of ATPase (ATIP) were isolated from the culture fluid of the Actinoplanes sp. MAMB-16268 strain and Actinoplanes missouriensis MBT-833 strain and were identified by the HPLC, FTIR spectroscopy, and MALDI mass spectrometry. The bacterial culture growth rate was estimated as a percentage of control (the initial cell content). It was found that AIP caused a 2.3-fold decrease, whereas ATIP - a 1.8-fold decrease in bacterial growth; the effects were significant with all tested concentrations of the enzymatic inhibitors. The results obtained indicate that AIP and ATIP have a bacteriostatic effect, and it is advisable to search for a synergistic action of the enzymatic inhibitors (e. g. of phosphodiesterase and ATPase) with antimicrobial agents.<EOD> Combined Phytotherapic and Traditional Chinese Medicine Therapy for Chemo-Resistant Non-Small-Cell Lung Cancer: Two Cases Report\n\nLung cancer is the second most common cancer worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. There are two major subsets of NSCLC: squamous cell carcinoma and adenocarcinoma, with the former representing the most common subtype. There are several clinical treatments for NSCLC including chemotherapy and target therapy, immunotherapy, radiotherapy, and hyperfractionated accelerated radiotherapy are widely used in NSCLC patients. With the emergence and development of targeted therapy, an increasing number of NSCLC patients have been responded to the targeted",
        "label": 0
    },
    "84": {
        "output": "<EOD> Effect of low\u2010dose erythromycin on cyclosporin and carvedilol elimination in cardiogenic shock patients\nIt is well known that the use of cyclosporin can induce or aggravate sinus node dysfunction, atrioventricular conduction alteration or atrial fibrillation. Carvedilol is also known to increase the risk of bradycardia and heart block. Both drugs are recommended to treat refractory shock in patients with myocardial dysfunction. The coadministration of these drugs can present a greater risk of cardiac complications. Erythromycin is a macrolide antibiotic that inhibits the P\u2010gp efflux pump, thus avoiding the extrusion of cyclosporin.<EOD> Glycopeptide Antibiotics Enhance Escherichia coli Mutability by Increasing Cell Sensitivity to Ionizing Radiation\nStaphylococcus aureus is a human commensal that is also an etiological agent of nosocomial infections, mainly affecting soft tissues, bones and joints, although its isolation from other infections sites has also been reported. Resistance to anti-staphylococcal drugs has been reported with regard to both methicillin resistance and glycopeptide resistance. The latter, which affects only staphylococci, is acquired against vancomycin, the most commonly used anti-methicillin-resistant (MRSA) staphylococcus agent. Its development and dissemination have also caused problems on the treatment of MRSA infections.<EOD> Impact of COVID-19 on Hospitalized Adult SARS-CoV-2 Patients With and Without Cancer.\nImportance\nThe COVID-19 pandemic has led to changes in health care systems that may impact cancer management.\n\n\nObjective\nTo compare clinical characteristics and in-hospital outcomes among patients with cancer and patients without cancer hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\n\n\nDesign, Setting, and Participants\nIn this retrospective case series study, patient data",
        "label": 0
    },
    "85": {
        "output": "Please save the file and upload your answer.\n\nCongratulations! You have finished the tutorial.\n\n\n[Tutorial Link](/tutorials/breast/)\n<EOD> Development of a clinical decision support system using the Ishikawa model to identify patients with hyperbilirubinaemia: a preliminary diagnostic tool\nAbstract Background: Laboratory errors and diagnostic inefficiencies cause delays in providing timely diagnosis to patients, potentially leading to fatal outcomes. It is crucial that patients receive definitive, timely diagnoses for better health management outcomes. Diagnostic errors continue to remain prevalent in most emergency departments and wards, particularly in primary care. Although many hospitals still utilise paper-based approaches, there are instances where patients are incorrectly diagnosed, resulting in longer hospital stays, higher medical costs, and even death. Medical decisions must be made based on a high degree of competence, proficiency, or skill, supported by relevant medical guidelines, research findings, case studies, and other data. Clinical Decision Support Systems (CDSS) can help healthcare professionals in this process, with more accurate decision support and better patient care. Methods: This study used the Ishikawa (fishbone) diagram as a CDSS tool in analysing patient hospitalisation records for hyperbilirubinaemia as the main condition for analysing a patient\u2019s condition. Hyperbilirubinemia is a laboratory disorder caused by abnormal levels of bilirubin found in the blood. There are two types of hyperbilirubinaemia: indirect and direct. By utilising the Ishikawa diagram as a tool, it is possible to analyse the condition in depth and determine whether it could be controlled by an algorithm. Results: Based on the proposed method, hyperbilirubinaemia is diagnosed as acute pancreatitis. Conclusions: It was concluded that using the Ishikawa method to diagnose hyperbilirubinaemia is beneficial for the medical field and will help physicians in making more accurate and timely diagnoses.<EOD> The association between physical activity, physical fitness and the risk of overweight, obesity and being underweight in 16-year-old adolescents \u2013 an explorative study\n\nBackground: Physical activity (PA) and",
        "label": 0
    },
    "86": {
        "output": "<h3 id=\"trial-level\">Trial-level eligibility</h3>\n\t<code class=\"text-xl p\">Output: 0) 'Excluded', 1) 'Not relevant', 2) 'Eligible'</code>\n\t<code class=\"text-xl\">Trial-level_eligibility_00: 0) Excluded;\nTrial-level_eligibility_01: 1) Not relevant;\nTrial-level_eligibility_02: 2) Eligible</code>\n</figure>\n\n### `Trials`\n\n\t<h3 id=\"trials\">Trials</h3>\n\t<code class=\"text-xl p\">Output: Number of trials</code>\n\t<code class=\"text-xl p\">Description: Number of pre-clinical trials</code>\n\t<code class=\"text-xl p\">Note: The number of pre-clinical trials is always greater or equal to the number of clinical trials</code>\n\t<code class=\"text-xl p\">Example: 23</code>\n\t<figure data-inst id=\"trials\">\n\t  <code>1.31125;\n\tTrial_00: 'Human Papillomavirus Vaccination';\nTrial_01: 'Treatment of HIV-Infected Adults with the Investigational Drug Darunavir/Cobicistat';\nTrial_02: 'Effects of Hydroalcoholic Hemp Oil Extract on the Clinical Indexes of Women with Stage II-IV Breast Cancer under Chemotherapy Treatment';\nTrial_03: 'A Study on the Effects of Tongmai Xiaozheng Powder on Human Papilloma Virus Positive Resistant Cervical Intraepithelial Neoplasia';\nTrial_04: 'Efficacy and Safety of Bevacizumab Combined with Temozolomide and Alpelisib in Advanced Pancreatic Cancer';\nTrial_05: 'Clinical Study of Lenvatinib in Treating Ref",
        "label": 0
    },
    "87": {
        "output": "Ask yourselves: \n- If you are unsure of the information, what questions could you ask the recruiter to get that information?\n\nThis example demonstrates how to assess trial eligibility for a clinical trial. First, you need to compare the eligibility criteria to the patient's profile. To do so, you read the information in the patient note to match it with the inclusion criteria of the clinical trial, e.g., patient age, and so on. If the person meets all the requirements listed in the clinical trial, it should be marked to show its eligibility. This step is repeated for each person.\n\n![](/img/inst/inst-1-1.png)\n\nIf you are not sure about the information, just double click anywhere in the table to see all the corresponding data. Note that only entries are editable, i.e., the value \"0\" (patient does not fulfill eligibility criteria), values \"1\" and \"2\" (not relevant and eligible, respectively).\n<!-- Instances of this template: ccl-course-lesson-3 -->\n<h2>CCL-Course: Lesson 3 (04.06.2021;)</h2>\n<ul class=\"ul_2\" id=\"menu\"><EOD> .\nThe 5-HT1A receptors in the hippocampus regulate the cognitive response in the elevated plus maze. In the present experiments, we investigated the role of extracellular 5-HT and 5-HT levels in the hippocampus by microdialysis to clarify the mechanism for regulation of the mild cognitive function with the 5-HT1A receptor. Two weeks after surgery, the experimental animals were allowed to adapt to the experiment environment and to microdialysis probes for 3 days. The C57BL6 male mice were randomly divided into four groups: 1) Control group (231.0 +/- 11.8 ng/ml), 2) PCPA group without any drug (83.3 +/- 11.2 ng/ml), 3) PCPA group (140.7 +/- 6.8 ng/ml) with treatment of 5HT synthesis in",
        "label": 0
    },
    "88": {
        "output": "The following is a sample patient note that is used in the demo mode of the course:\nIdeal.\nPt: 45yo postmenopausal women\n[formula]  Sx: HER2 + ER/PR negative BC Bx: 3 cm invasive ductal BC TisN0, T1N0, T2N0 LNRX Surgery: tylectomy Chemo: NA Toxicity: NA Admitted 9/30/00, Sx 9/17/00: Bx left breast w/ core biopsy, pathology showed invasive ductal BC, ER -/PR-, HER/ neu +, Sx 9/18/00: Mammogram Lt breast w/ calc in DCIS of Rt upper outer breast region, 1.6 by 1.2, sclerosis is seen along lateral, inferior margin of breast, Rt breast -MXL w/ Rt axillary w/ 5 nodes, Lymph node: 1#-5# -negative, Lymph node: 1-3# -8/20, Lymph node: 1-6# -4/60 and the 4#s on peripheral aspect, Lymph node: 1-7# -2/45, Lymph node: 1-8# -1/5, Lymph node: 1-9# -3/60 H&E, pathology showed metastic carcinoma consistent with primary BC Rt axilla, 45mm, H & P 0/+, Negative, negative, positive; Lymph node metastases seen, LN no 1-9-positive, Lymph node no 1-5-positive, lymph node no 1-6-negative, lymph node no 1-7 -Positive, Lymph node no 1-8 negative. [/formula] \nExploration: There is minimal blood on the drape with the breast exposed. There is the small incision and sutures from biopsy site. Her axillary incision site is a standard axillary incision without evidence of tumor dissemination. The breast tumor was completely removed.",
        "label": 0
    },
    "89": {
        "output": "<EOD> Preclinical Infection of a Macaque Model with SARS-CoV-2\n\nCitation: De Smet, M.; Van den Eede, D.; Govaert, C.; Huygen, K.; Aran, A.; De Groote, M.; Claerebout, G.; Van Der Stuyft, P.; Goffin, M.; Frijns, A.; et al., Preclinical Infection of a Macaque Model with SARS-CoV-2. Viruses 2021, 13, 1618. https://doi.\n\n# Introduction\nMassive vaccination is the only realistic strategy to stop the current COVID-19 pandemic (19March 2021, World Health Organization situation report, see https://outbreak.info/, last accessed 19 March 2021). At the moment, the development of vaccines against SARS-CoV-2 (i.e., the coronavirus that caused the global pandemic outbreak) is in the spotlight since vaccine candidates in all development phases are being presented with remarkable speed [bib_ref]  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, Baden [/bib_ref]  [bib_ref]  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary..., Folegatti [/bib_ref]  [bib_ref]  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, Polack [/bib_ref] . Besides vaccinating the global population with a new vaccine, vaccination studies are also of key importance as they will help to understand the immunological responses to SARS-CoV-2 infection, such as neutralizing antibodies or humoral or cellular immunity [bib_ref]  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, Skowronski [/bib_ref] .\nMost of the data describing the infection, clinical manifestations, cellular immunity, and pathology of SARS-CoV-2 have to date been derived from inf",
        "label": 0
    },
    "90": {
        "output": "You have to consider three steps that you will do for a patient note that you can't find a trial:\n- First, you find the current active clinical trial that is under study.\n- Second, you define the inclusion and exclusion criteria of the clinical trial and match them with the patient's status.\n- Third, you determine the eligibility of each trial stage of the matched clinical trial for that patient.\nWe have two clinical trials. The patient is underlined:\nTitle: Radiation Therapy in Treating Women Undergoing Lumpectomy for\n\n\nStage I or Stage IIA Breast Cancer\n\nSummary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells.\nGiving intraoperative radiation therapy after lumpectomy followed by external-beam radiation therapy may kill any tumor cells that remain after surgery.\n\n# PURPOSE:\nThis phase II trial is studying the side effects and how well radiation therapy works in treating women undergoing lumpectomy for stage I or stage IIA breast cancer.\nInclusion criteria:\n\n## DISEASE CHARACTERISTICS\nHistologically confirmed primary invasive breast carcinoma\n\n## Stage i-ia disease (t1, n0, m0 or t2, n0, m0)\nPathologically determined single, discrete, and well-defined primary tumor \u2264 5 cm in diameter\nPathologically negative surgical margins\nNo multicentric disease and/or diffuse malignant appearing microcalcifications\nMicro-calcifications must be focal\nSpecimen radiograph is required after lumpectomy for tumors associated with malignant appearing calcifications to assure removal of all malignant appearing calcifications\nSpecimen radiograph is optional if the tumor appears as a discrete mass on mammogram\nNo axillary lymph node involvement\nNo evidence of metastatic breast",
        "label": 0
    },
    "91": {
        "output": "Here is our example output:\n20\n4\n1\n2\n1\nTrial-level eligibility: 2) Eligible.\n[output is same as the first row]\n\nThe output is in the same line with the last row of the input, as shown in the figure below. See also [1] \n\n\n---\n\n## Examples\n\nThe following examples show the usage of the [trialclinical-eligibility](https://github.com/Kaggle/KDDcup12/blob/master/datasets/trialclinical-eligibility) object in R.\n\n### Example 1.2  \n```\ndata(trialclinical eligibility)\nhead(trialclinicaleligibility)\n```\n```\n  Trial Trial-level eligibility\n1 LCB02 LCBO26-01 Trial-level eligibility: 0) Excluded\n2 LCB02 LCBO26-01 Trial-level eligibility: 0) Not relevant\n3 LCB03 LCBO25-01 Trial-level eligibility: 1) Excluded\n4 LCB03 LCBO25-01 Trial-level eligibility: 1) Excluded\n5 LCB03 LCBO25-01 Trial-level eligibility: 0) Not relevant\n6 LCB04 LCBO26-03 Trial-level eligibility: 0) Excluded\n7 LCB04 LCBO26-03 Trial-level eligibility: 0) Excluded\n8 MCB03 MCGO25-05 Trial-level eligibility: 2) Eligible\n9 MCB03 MCGO25-03 Trial-level eligibility: 2) Eligible\n10 MCB03 MCGO26-03 Trial-level eligibility: 2) Eligible\n11 MCB03 MCGO26-03 Trial-level eligibility: 2) Eligible\n12\n13\n14\n15\n16\n17",
        "label": 0
    },
    "92": {
        "output": "# 4.2.2 The problem section\n\n# Background\n[INST] Hello. Good to see you again. It's really nice, to see your eager face. \nNow let's solve the problem. The issue is that the patient in the example is 'excluded' for the clinical trial, while the clinical trial says it wants to compare a '45-year-old postmenopausal woman with cytologically confirmed breast cancer'. \nSo, can we find any factors that allow this patient to participate? \nWe do not know what are exclusion criteria of clinical trials, but we can check for exclusion criteria that you must know.\n\nWe all know that these 2 clinical trials use the same patient eligibility, but also they use the same exclusion criteria. However, these clinical trials use different medications. \n\nExclusion criteria of clinical trial No. 00166979 (see: Exclusion criteria of clinical trial No. 00166979)\n- Treatment with hormonal therapy within the previous 2 weeks\n- Known history of hypersensitivity to taxanes, carboplatin or trastuzumab\n- Women of childbearing age who are pregnant or breast feeding Note: This is not an exclusion criterion for patients who are menopausal due to bilateral oophorectomy or receiving medical menopause due to bilateral salpingectomy or bilateral salpingo-oophorectomy or women >59 years old and postmenopausal for >1 years due to menopause secondary to chemotherapy, pelvic radiation or bilateral ovariectomy.\n- Women who are known to be pregnant or breast feeding\n- Women of childbearing potential who are not surgically sterilized due to bilateral oophorectomy or bilateral tubal ligation, due to medication",
        "label": 1
    },
    "93": {
        "output": "A: TLW is very easy and quick method to work with pandas and matplotlib simultaneously. To create a new figure and pass your variable to it, call 'TLS' in the console and write something as below.\nimport pandas as pd\nimport matplotlib.pyplot as plt\nfrom tlw import TLS\n\npatient = pd.DataFrame([['G03','female',25,'G05','negative',5,'G04','positive',1,'R3'] ])\ntrial = pd.DataFrame([])\ntreatment = pd.DataFrame([])\nTLS()\nTLS.ylabel = \"Age\"\nTLS.xlabel = \"Patient\"\nTLS([patient, treatment], ['Age', 'Sex', 'Blood group', 'History of heart disease', 'Laterality', 'Lung pathological metastases before enrollment', 'Disease progress'] , trial)\n\nYou can find my answer and full code on my repository: https://github.com/kadirbayrakci/DataTable_and_Plot\n<EOD> Phytochemistry and pharmacology of the genus Anaxagorea: a review.\nAnaxagorea was introduced as a genus to the Rutaceae family in 1813 although the family includes only two genera, Citrus and Poncirus. Currently, the genus includes 16 accepted species. The genus is widespread in tropical and subtropical regions and mainly grows at low altitudes of mountains. These plants are commonly used for their nutritious value, although plants like Anaxagorea crassifolia were used also in many countries as vegetables and herbs. Due to many beneficial properties, the genus Anaxagorea has been used for centuries especially for medicinal purposes. The phytochemical investigation on aerial parts, flowers, leaves, roots and fruits of Anaxagorea species revealed the presence of terpenoids, essential oils and coumarins in this genus. In the present study, we aimed to collect literature and summarized this valuable information and provide better understanding focusing on the pharmacological importance of Anaxagorea.<EOD> Improved Detection of Helcococcus kunzii Bacteremia by Using 16S",
        "label": 2
    },
    "94": {
        "output": "Good luck! \n<EOD> .\n\n Demographic trends suggest that 25% of the French population will be over 65 years of age in 2020. Although this increase in seniors is accompanied by a comparable reduction in the population of working ages, the number of beneficiaries under France's old-age pension insurance is expected to rise by 50% by 2025. The growth in demand for health care for these elderly persons will create problems for administrators of this system. The rapid increase in the number of senior consumers of health care in France raises 2 questions: 1) to what extent do our current hospital systems have the capacity to respond to this new situation; and 2) to what extent do our hospitals have the capacity to provide the care needed by elderly consumers. These are central questions in a debate, which is currently being conducted in France, about the reorganization of medical and paramedical care into a system based on local or regional units. In spite of the efforts being made to create alternative health organizations, a short-to-intermediate solution may be to create specific geriatric services or groups of services, with separate budgets, which will be responsible for the elderly. Such geriatric units are now being developed by the Association Geriatrique de France, which was founded in 1982 with the aim of developing medical and paramedical specialists in geriatrics. These units are currently being tested in geriatric wards of various hospitals, including the Sainte-Genevi\u00e8ve hospital in Paris, the Necker hospital in Paris, and the Vincennes hospital in Paris. One of such units, which has just been created in the Beaujon hospital in Clichy, will be funded as a separate entity beginning in April 1993. The purpose of these geriatric units will be to create an organized structure or system capable of developing a comprehensive care plan for each elderly person which is centered on home care with a special focus on those aspects of the patient's situation which are most closely linked to the development of hospital and other types of services. The units will have a particular interest in preventing or delaying longterm dependency for those elderly persons who have some autonomy despite reduced mobility, and in improving quality of life of residents of nursing homes. They will actively",
        "label": 0
    },
    "95": {
        "output": "### Questions\n1. How can the patient note be encoded to JSON?\n#### Answer\nWhen you make the patient note encoded to JSON, you must create a new tab in ECLAIR and select the `json` tab in the left panel. You can then select the tab `Practice` > `Trial` >`Notes`.\nFor this task, the following notes can be selected: \n- Notes of the first patient\n- Recruitment note of the first patient\n- 2) Eligible\n- 0) Excluded\n- Not relevant\n2. How can be checked whether the patient is included in a trial?\n#### Answer\nSelect `json` tab in the left panel. You can then select the tab `Practice` > `Patient` > `Notes`. The patient's list is available in the panel, and you can click the `2) Eligible` note for the patient and check the trial under which the patient is participating.\n3. If the given patient note is not available in ECLAIR, from which place on the ECLAIR site (e.g., `https://beta.medicisclinicalelectroniquee4e.fr/` (in French only)) can you download it?\n#### Answer\nGo to the `Patient` tab in the upper part of ECLAIR, enter the patient's name in the search box, and then click the corresponding `New Patient` icon.\nThe `New Patients` tab appears in the upper part of the screen. To find the patient's note, click the icon corresponding to the `Document` column and then click the `download` button next to the `Note` label.\n\n\n## [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria);",
        "label": 1
    },
    "96": {
        "output": "```r\n#\n# 1. Set up some helpers.\ndose2_code <- \"3) Excluded\"\ndns2_code <- \"\"\n#\n# 2. Take an input from the user. The example\n# code has used the following input: input(dose_code))\n#\n#\n# 3. Add a new row in dataframe\n#\n#\n# 4. Perform the assessment of trial-wide eligibility of the\n# patient.\n#\n#\n# 5. Print all the rows which contains the trial-wide eligible\n# in the dataframe.\n#\n# \n# 6. Repeat this step until the trial-wide eligibility does not\n# change in all iterations (e.g., 3-4 times). \n#\n# 7. Print the output of the above step. \n#\n#\n# Code output:\n\n\n# Set the name of the dataframe\noutput_df <- data.frame()\n\n# The name of the column for trial-level eligibility\noutput_df_var1 <- \"Trial-level eligibility\"\n\n\n# We will start with the given input patient ID.\npatient_id <- 15 \n\n# We will start trial-wise testing.\ndose_code <- patient_id \ndns_code <- \"\"\n\n\n# We will keep on repeating the 3 dose_code dose2_code until the\n# trial-level\n# eligibility stay same.\n#\n# We will keep on adding the dose-condition\n# into the code but we shouldn't forget to print the\n# status of trial-level eligibility.\noutput_df <- output_df[output_df$patient_id == patient_id &\n                         output_df[output_df_var1] %in% dose_code &\n                         output_df$dose_code == dose2_code &\n                         output_df$dose1_code == dose_code &\n                         output_df$dose2_code == dose1_code, ]\npatient_id <- patient_id + 1 ## to select next patient's code\ndose_",
        "label": 0
    },
    "97": {
        "output": "```\n\n# Outputs\n- [outputs_id]: List of id strings generated for each trial object. (id of each element: `f.id).\n- [sum]: Sum of the number of excluded patients and number of ineligible patients.\n- [sum_eligible]: Sum of the number of eligible patients. \n- [outputs]: List of outputs strings for each trial object.\n\n```python\n[outputs_id] = (p.name for p in patient).list()\n[sum] = sum(e)\n[sum_eligible] = sum(el)\n[outputs] = [[f[:4] + str(len(f)) + '/' + f.name for f in p.file] \nfor p in patient \nfor trial in trial_db ]\n[/outputs]\n```\n\n# Import things\n- [import_id]: List of id strings generated for each trial object.\n- [import_f_id]: List of file_id strings generated for each feature (f) in a given file.\n- [f_idx]: Each f_idx is the index of each feature (f) in a given f.\n- [f_id]: List of id strings generated for each feature (f) in a given feature (f).\n- [feature_path]: List of filenames of given feature (f).\n- [outputs_id]: List of id strings generated for each trial object.\n- [sum]: Sum of the number of excluded patients and number of ineligible patients.\n- [sum_eligible]: `Sum` of the number of eligible patients.\n- [outputs]: List of outputs for each trial object.\n- [mh_file]: String containing the path to the database file.\n```python\n[import_id] = (e.id for e in exclusion) + (f.id for f in feature_name_db)\n[import",
        "label": 1
    },
    "98": {
        "output": "### Create the trials\n\n#### Create Trial #1\n**Note** The below script will use the trial number, `1`, but we will always use the `2` in the actual input.\n\n# Create Trial #1\n```\n#!/bin/sh\nimport json\ninput_file_path = './CT_1.json'\noutput_folder = './CT_out'\nif [ ! -f '$(output_folder)/CT_1.json' ]; then\n    sed -i 's/2/1/' $input_file_path\n    json.load(open(input_file_path))['trials']['trial_2']['exclude_criteria'] = {}\n    json.dump(open(input_file_path), open(output_folder + '/CT_1.json'), indent = 4)\n    cat $(output_folder + '/CT_1.json')\nelse\n    json.load(open(output_folder + '/CT_",
        "label": 2
    },
    "99": {
        "output": "[#section]\n\n## TRIAL-LEVEL ELIGIBILITY\n\nThis function is the same as [Eligibility Assessor][] for the given trial, except that a scale of 0 or 1 (not relevant, yes) is used. The output is a set of scales. One scale per record.\n\nUsage:\n[code][#tag:bash]\n\n\nimport csv\nfrom clinicaltrials.instant_form import Trial_level_Eligibility\n\nf = open(\"./.data/instant/data_0/patient_1.txt\")\nwith open(\"output_file.txt\", \"w\") as f2:\n    d = csv.Reader(f)\n    data = [[int(x) for x in i for i in d[0]] for j in [1, 4]] \n    f2.write(Trial_level_eligibility(f1, trial_id=0).to_csv(data, headers=True))\n\n\n[/code]\nOutput example (experimental data): \n[code][#tag:bash]\nfile:\n[code][#tag:bash]\n\n\nimport pandas as pd\n\np = pd.read_csv(\"trial_101620407.csv\")\ntrial_id = p.pop(0)\npatient_number_1_age = p.ix[:, \"age1\", trial_id]\npatient_number_1_family_history = p.ix[:, \"family History of Breast Cancer\", trial_id]\npatient_number_1_family_history_other_health = p.ix[:, \"family History of Any of the Cerebral Vascular Disorders or MI, Heart Disease/Hypertension, Chronic Obstructive Pulmonary Disease, Diabetes/Thyroid Problems.or Any Other Major Medical Problems or Major Surgery Ever\", trial_id]\npatient_number_1_breastcancer = p.ix[:, \"History of Breast Cancer\", trial_id]\npatient_number_1_pregnancy_age = p.ix[:, \"Age at birth of first child",
        "label": 0
    },
    "100": {
        "output": "<!--======================================================================== RUN THIS SHEET FOR REUSABLE CODE ->===========================================================================\n[RUN] python3 -c \"f\" \n[RUN] python3 -c \"r\" \n[RUN] s\n[RUN] s\n[RUN] s\n[RUN]\n======================================================================> --> \n\n### A.1 Eligibility Assessment\nThe eligibility assessment has four steps (see also in  [INST] The results can be visualized in an [e] eligibility summary table in the eligibility assessment form in the ECRfM.\nHere is the [e] eligibility summary table and related documentation generated automatically whenever there is an [e] eligibility assessment entry: \n\n[INST]\n\n\n\n\n\n\n\n\n\n### [INST] Conclusion\nIn conclusion, congratulations! You are a valuable contributor to medical patient safety improvements through the creation of the electronic clinical trial recruitment form in the ECRfM, the first step to the implementation of the ERM concept. This form may help to prevent any wrong inclusion of a patient in an ineligible trial which would be beneficial for the patient as well as the sponsor of the trial. The ECRfM ensures the quality of health care and fosters the exchange of knowledge between the participating health care providers.\n\n[e] <NAME> from the MFMD wrote the following documentation to help you [e] with your new task. In the ECRfM of the medical facility, the [e] Eligibility summary table shows the assessment of eligibility (assessed in this example) of the patients for the corresponding clinical trial.\n\n### [e] Eligibility assessment of a patient for two clinical trials of the clinical trial repository \n<!--====================================================================== DECLARATION OF ACCEPTED PAPER ON THE WEBSITE OF THE INSTITUTE OF MEDICAL INFORMATICS, HEIDELBERG =>======================================================================-->\n\n\n[INST]\n       \n       [[e] Eligibility Assessment]\n         [[e] Eligibility Assessment]",
        "label": 2
    },
    "101": {
        "output": "## 2.1.1 [FIL] Find all patients who satisfy the following criterion:\n\\subsection{The patient note from the input}\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nThe tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nCXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements.\nShe does not smoke or consume alcohol. She is not sexually active and has no children.\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: National Survey on Infiltrative Breast Cancer\n\nSummary: The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.\nInclusion criteria: Inclusion Criteria:\nWomen> or = 18 years old\nWomen with newly diagnosis of infiltrative breast cancer\nAgree to take part in this study\nExclusion criteria:\nMen\nWomen<18 years old\nWomen with newly diagnosis of non-infiltrative breast cancer\nDo not agree to take part in this study\n\n\\subsection{The result of searching criterion}\nA list of eligible patients may be generated by searching the patient note for terms representing the patient note's criterion. (An explanation for generating a list of eligible patients is in Section 3 of the accompanying Jupyter notebook. [NOTE] ) The following patient note criteria are used in this example.\n\\item HER2-positive\n\\item ER/PR negative\n\\item CXR remarkable for metastatic lesions\n\\item Were infiltrative ductal breast cancer\n\n\\subsection{Trial-level eligibility using the input note}\nA trial-level eligibility assessment can then be performed. The patient note criteria can be searched using the following functions, e.g., `",
        "label": 2
    },
    "102": {
        "output": "This is a simple program that performs two binary classifications. First, the record's class is identified as either `HER2-positive` or `HER2-negative`; second, the record's value for the attribute `Tumor Size (mm)` is determined.\n\nLet's see how it works:\n\n**Program: Merge.py*\n\n**Input: HER2.txt HER2-positive.txt Tumor size <HER2.txt HER2-positive.txt>/tumor size\n\n**Output:**\n\n**Positive:**\nHER2 positive, positive for HER2.\nHER2 negative, HER2 not present.\n**Negative:**\nHER2 negative, positive for HER2.\nHER2 positive, negative for HER2.\n\n**N.B.** If the <HER2.txt> and <HER2-positive.txt> inputs were missing, you'd get HR2 positive missing Tumor size missing Negative.\n\n**Program: Merge.py input file1 output file1<HER2.txt\n<HER2_positive.txt>/OUTPUT_FILE_NAME<HER2.txt HER2-positive.txt\n\n**INPUTS:** The input file of 125 records (125 lines) with a header, followed by `50` observations.\n**OUTPUT:** The output file of three files with 13 rows each (i.e., 13 columns). Each file will feature only records having the same values for the columns. Each file will include all the information of all the records having the same values for the columns.\n\n**Answers:**\n\nHER2_125_positive_0_125_positive_25_125.txt,\nHER2_125_positive_1_125_negative_0_125.txt,\nHER2_125_negative_1_125_negative_0_125.txt\n\n**Note:** In the case of a file (e.g., <HER2_positive.txt>), where every column has different number of rows, use the `[:integer_number]` function",
        "label": 2
    },
    "103": {
        "output": "*__Note:__ If you have further questions, please visit the [training class website](https://www.kaggle.com/training/general-overview-of-our-training-classroom-on-kaggle).*\n\n\n    <h1>How to start a trial</h1>\n    <p>This tutorial will show you how to start a new trial. You\n    can start a new trial with a trial name. </p>\n    <h3>START A NEW TRIAL</h3>\n    <h3>START A NEW TRIAL</h3>\n    <h4>Enter the trial title</h4>\n    <p>Enter the trial title in the\n    format: <code>Trial Title name</code>. </p>\n<pre class=\"java\"><code class=\"java\"> TRIAL_NAME_BLOCKERS = [\"Trial name: Blockers\" +\nSystem.lineSeparator() + \" Example: This is Example blockers\" +\nSystem.lineSeparator() + \" Please make sure that this trial name is short, \" +\n\"legible, and contains no special characters.\" +\nSystem.lineSeparator() + \" You will only have one chance to edit it.\"];\ntry {\n    TrialBuilder trial_builder = new TrialBuilder();\n    trial_builder.setTrialName(\"Triple block\");\n    } catch (ParseException e) {\n        e.printStackTrace();\n    } catch (ParseException e){//for Blocker's trial\n    System.out.println(e.getMessage());\n    e.printStackTrace();\n    }\n</code></pre>\n\n<h4>Add a description of your trial</h4>\n<p>Add a description of your trial.</p>\n\n<pre class=\"java\"><code class=\"java\">try{\n            TrialBuilder trial_builder = new TrialBuilder();\n            trial_builder.setTrialName(\"Example Trial\");\n            trial_builder.addTrialComment(\"Welcome to this trial!\");\n        } catch(Exception e) {\n            e.printStackTrace();\n        }\n    </code></pre>\n\n\n\n\n    \n\n\n# Listing a trial\n**_list_**  - A list of tri",
        "label": 1
    },
    "104": {
        "output": "# [T-06] Defining `C_Exclusion_Criteria` and `C_Inclusion_Criteria` in `ClinicalTrials.csv` \u2780\nDefining C_Exclusion_Criteria \u2781 [0]: In the columns 4 ~ 13, each patient note information is included, with the '100.71.Trial.id' as the ID of the breast cancer inclusion criteria for all patients, as shown in 'Breast cancer inclusion criteria in trial level'.  \n\n\n\n\n[INST] When a patient is registered for breast cancer through the clinical trial and patient note is recorded, the ID of the breast cancer inclusion criteria for all patients is  100.71.Trial.id. However, if a patient has already registered for breast cancer, the 100.71.Trial.id corresponds to the ID for all patients with breast cancer.    \nTherefore, the value of the column 4, 6 ~ 15 should be set to 'Exlusion' of the `C_Exclusion_Criteria` in the 'C_Exclusion_Criteria' column. But, the values of column 9 ~ 12 would be included in the `C_Exclusion_Criteria` through the value and type of the column 5 as  `Patient_ID, integer, 0 or null, null, breast cancer`. \n\n[T-07] Creating `Breakpoint` on `ClinicalTrials.csv` file   \n\n\u2781 \n\n\n\n**",
        "label": 2
    },
    "105": {
        "output": "## Question 2:\n[[INST] What are the inclusion criteria to participate in the clinical trial?] The inclusion criteria for Clinical trial:\nTitle: An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients\n\nSummery: Our objective is to develop a novel optical assay system for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. Our group has previously shown that optical techniques can effectively discriminate between malignant and non-malignant breast tissues. We have also shown that data collection and processing from a single point on the tissue specimen requires less than 5 seconds. In addition, the technique is easily adaptable to provide sensing depths that are required for breast cancer margins assessment. The goal of the work developed in this protocol is to test the sensitivity and specificity of an optical assay system developed by our group, for intra operative assessment of breast tumor margins\n\nInclusion criteria: Inclusion Criteria:\nClinical diagnosis of breast cancer\nPlain film chest X-rays with no evidence of distant metastases\nNo evidence of local infection\nNo evidence of other cancers\n\n## Question 3:\n[[INST] What are the exclusion criteria to participate in the clinical trial?] The Exclusion Criteria for Clinical trial are:\nTitle: An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients\nSummary: Our objective is to develop a novel optical assay system for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. Our group has previously shown that optical techniques can effectively discriminate between malignant and non-malignant breast tissues. We have also shown that data collection and processing from a single point on the tissue specimen requires less than 5 seconds. In addition, the technique is easily adaptable to provide sensing depths that are required for breast cancer margin assessment. The goal of the work developed in this protocol is to test the sensitivity and specificity of an optical assay system developed by our group, for intra operative assessment of breast tumor margins.\n\nInclusion Criteria:",
        "label": 2
    },
    "106": {
        "output": "<EOD> Transition to a Scalable Clinical Trial Paradigm: The RhoA-Associated Kinase Inhibitor Fasudil for Neuroprotection in a Stroke Model.\nBACKGROUND\nThe rhoA-associated kinase (ROCK) inhibitor fasudil is a neuroprotective agent approved in Japan for refractory systemic hypertension. Recent studies have suggested that treatment with fasudil shortly after stroke onset may facilitate early brain protection. Here, we explore the potential impact of the ROCK inhibitor on a translational scale.\n\n\nMETHODS\nWe utilized a stroke model in rats to test the efficacy of the ROCK inhibitor fasudil on hemorrhagic transformation after administration in the lateral ventricle 1 hour post-stroke. This model tests the feasibility of fasudil administration in a rodent brain stroke model as an essential step toward a scalable clinical trial design. Based on historical control data, we calculated that a study cohort size of 10 per group with a significance level of 0.05 has an 80% chance of detecting an effect size of 80% or higher.\n\n\nRESULTS\nStudy procedures resulted in no loss of animals and yielded successful ROCK inhibition on a translational scale. We were also successful in achieving adequate blinding of the ROCK inhibitor cohort to the technician.\n\n\nCONCLUSIONS\nOur study demonstrates the feasibility of implementing a small-molecule stroke drug trial in a rodent model with the goal of paving the way for a future large-scale trial.<EOD> .\nFood industry, biotechnology and animal production are three domains where bacteria, such as Bacillus thuringiensis or E. coli, are used to prevent",
        "label": 0
    },
    "107": {
        "output": "[INST] [MOVE]<EOD> Immune-Related Adverse Events in Patients with Colorectal Cancer Receiving Immune Checkpoint Blockade: Characteristics, Management, and Evaluation of Incidence by an Administrative Database\n\nCitation: Stolf, G.; Lopez, A.; N\u00fa\u00f1ez, M.J.; Mar\u00edn-Romero, T.; Alonso, F.; S\u00e1nchez, I.; Rodr\u00edguez-Mart\u00edn, C.; Caramelo, F.; Mart\u00edn-Guzm\u00e1n, A.; Ram\u00edrez-Trujillo, M.; et al. Immune-Related Adverse\n\n# Introduction\nImmune checkpoint inhibitors (ICIs) revolutionized the oncology landscape by demonstrating significant improvement in clinical outcomes and becoming a cornerstone in the treatment of metastatic colorectal cancer (CRC).\nWith approved regimens including combination treatment with ICIs and chemotherapy (CT) or targeted therapy, as a first-line (C 305): anti-CTLA-4 alone (C) or in a combination with anti-PD-1 (G 303) [bib_ref]  Nivolumab in Patients with Metastatic DNA mismatch repair-Deficient or Microsatellite Instability High..., Overman [/bib_ref]  [bib_ref]  Pembrolizumab versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The KEYNOTE-177..., Andr\u00e8 [/bib_ref]  [bib_ref]  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer, Andr\u00e9 [/bib_ref]  [bib_ref]  Atezolizumab with or without Chemotherapy in Patients with Metastatic Colorectal Cancer (IMblaze370):..., Bendell [/bib_ref] .\nFor second-line therapy, two Phase III clinical trials (C 343): (1) KEY-NOTE-177 (Nivolumab in Microsatellite Instability High or Mismatch Repair-Deficient Metastatic Colorectal Cancer) and (2) IMblaze370 (Atezolizumab",
        "label": 0
    },
    "108": {
        "output": "We assume that the `assessment of eligibility` is correct.\n\n\n## Instructions 13\n[STARTER]\nYou are the chief information officer of one of the clinical trial recruitment firms. You receive a request from a new clinical trial that is undergoing recruitment. \nA new clinical trial has been approved from the United States Food and Drug Administration (US FDA).\nEach clinical trial has an average of 400 recruitable patients. The patients will be recruited and enrolled to the study at the centers. Clinical trial recruitment (i.e., the identification and contact of patients) is required at each center. This clinical trial is one of the most important in the history of cancer and it needs to be recruited at the top hospitals with high-level doctors of oncology.\n[INST] The clinical trial recruitment firm should recruit patients for this important clinical trial at the centers of oncology and hematology. Recruitment is the process of finding patients who meet the inclusion criteria for randomized controlled trials to be recruited to the trial. The recruitment should be finished within 3 years.\nThe recruitment firm has received a contract to recruit a particular clinical trial, which requires the recruitment firm to recruit at least x patients at each center.\nYou would like to figure out strategic decisions to maximize the recruitment of patients to this important clinical trial by minimizing costs. Strategically, you should set the recruitment rates, the recruitment expenses, and the recruitment capacities at each center, i.e., recruitment number of patients, number of doctors at each center, and numbers of patients that each doctor recruits at each center.\nThese decisions should take patient eligibility and the locations of the clinical trial centers into account. \n\nThe key idea is to consider the recruitment capacity at each center, the recruitment rate, and the recruitment cost under each candidate allocation of patients to centers. It is well-known that the efficiency of a recruitment firm can be maximized by distributing the required number of patients evenly to each center that has to enroll participants. On the other hand, the",
        "label": 0
    },
    "109": {
        "output": "[TOPIC] Trial-level eligibility\n\n[NAME] <NAME>\n \n[NAME] <NAME>\n \n[STAFF] <NAME>\n \n[DATE] [20XX-01-01]\n \n[STAFF_COUNTRY] [Country]\n\n[NAME] <NAME>\n\n[DATE] [20XX-01-01]\n\n[TITLE] Trial-Level Eligibility\n\n# Overview\n This report concerns the eligibility of a trial's recruitment target. We must compare a given patient and trial inclusion criteria to determine whether the patient fits the trial. If we believe the patient is eligible, we should proceed with the assessment. \n\n## Rationale\nWe are working with an individual patient instead of an aggregate of patients. Hence, clinical trials are not treated as aggregates, and we do not require a sample size justification in that case. \n\n## Purpose\nThe following clinical trial is a good example to demonstrate the process of trial-level eligibility. It is also a good example to illustrate assessment criteria since we can refer to the case report form for a description of the patient's disease. We are not going to evaluate these criteria one by one. Let's consider first an eligibility example. Here is a patient diagnosed with osteoporosis. Is this patient included in this clinical trial? \n\n# Clinically Eligible\nDrug Study in Menopausal Women with Osteoporosis\n\n## Inclusion Criteria:\nCriteria to be met by each patient at Screening (Day -28 to 0 and Day 0)\n- Postmenopausal women age 45 to 65 years\n- A minimum serum 25-hydroxyvitamin D (25-OHD) level \u226450 nmol/L at screening (or a historical value <40 nmol/L within 4 weeks of screening)\n- Total alkaline phosphatase (TALP) <242 U/L\n- A minimum urine N-telopeptide/creatinine ratio (uNTX) \u226540 nmol/mm",
        "label": 0
    },
    "110": {
        "output": "[/QUESTION] [[QUESTION]\n\nQ5. Can we also show patient information such as race or gender in the CSV report?\n\nA5. \nYes, we can add in the CSV report. You can use the output below to show patient information:\n````r\ndat=cbind(patient_id=c(rep(23,5), rep(27,5)),\n    race=\"White\", gender=\"Female\")\nhead(dat)\n```\n\n    race    patient_id\n    ----    ----------\n    White   23\n    White   27\n    White   23\n    White   27\n    White   23\n    White   27\n[/QUESTION]\n\n[/QUESTION] [[QUESTION]\n\nQ6. When we set the value of `patient_id` in the CSV file to the value in the `Patient_id` column, do we need to specify what column it appears in?\n\nA6. No. To display the value from the `Patient_id` column in the CSV file, there is no need to specify the value in the `Patient_id` column, because the `Patient_id` column in the `Patient_id` column appears in the CSV file. \n\n[/QUESTION] [[QUESTION]\n\nQ7. I want to make a report for each clinical trial in this clinical trial list. How can I make it?\n\nA7. You can use the R function `rbind` to make a report for each clinical trial in the `list_clinical_trial` object. \n\nYou can generate a report for Clinical Trial 2 by doing the `rbind` below to get a multi-Dicriminate Data Frame (a) and a single report for Clinical Trial 2 (b).\n```{r} dat2=rbind(dat)\n```\n\n### Single report for Clinical Trial 2:\n\n* [A Clinical Trial for Breast Cancer Treatment in Postmenopausal Women](https://www.ncl.cc.gatech.edu/Courses/5901/Tutorials/week9/tutorial1.pdf",
        "label": 0
    },
    "111": {
        "output": "</PRE>\n\n\n\n\n<!--htbl-->\n<TABLE ALIGN=\"CENTER\" BORDER=\"0\" CELLSPACING=\"0\" CELLPADDING=\"3\" CELLWIDTH=\"600\">\n<THEAD>\n<TR ALIGN=\"CENTER\" VALIGN=\"TOP\">\n<TH ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\" ALIGN=\"CENTER\" VALIGN=\"TOP\">Question\n</TH>\n    <TH ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\" ALIGN=\"CENTER\" VALIGN=\"TOP\">Answer\n</TH>\n    <TH ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\" ALIGN=\"CENTER\" VALIGN=\"TOP\">Explanation\n</TH>\n</TR>\n<TR ALIGN=\"CENTER\" VALIGN=\"TOP\">\n<TD ALIGN=\"CENTER\" VALIGN=\"TOP\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>\n\t<TD ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\"><P STYLE=\"POSITION: RELATIVE; POSITION: POINT; TOP: 0px; LEFT: 0px\"><B><U>Instructions</b></U></P>\n\t<PRE>\n\t\n\t[INST]\n\t\n\tHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\tThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and",
        "label": 0
    },
    "112": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements.",
        "label": 0
    },
    "113": {
        "output": "## Trial-level eligibility (Optional)\n\n\n```python\n### [BREAK]\n### [INST] Hello. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n### [BREAK]\n### [BREAK] # Please do only one trial-level eligibility output.\n\n# The assessment of patient eligibility has a three-point scale:\n# 0 : Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion\n#  criteria);\n# 1 : Not relevant (patient does not have sufficient information to qualify for the trial);\n# 2 : Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\n\n### [INST] # Now, please assess every patient for this clinical trial\n\n### [BREAK] # You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the\n### [BREAK] \n###  assessment of eligibility.\n\n### [INST] \n### [BREAK] # Trial-level eligibility:\n###  Eligible (the assessment of trial-level eligibility is output on the next line). \n\n### [INST] \n### [BREAK] # You can assess each criterion separately, or you can simply check all  (\n### [BREAK] \n### [INST] \n### [BREAK] # Now, repeat Trial-level eligibility for each patient separately in the last line by `\n### [BREAK] \n### [INST] \n### [BREAK] # Here is the patient note.\n\n### [BREAK] \n### [INST] \n### [BREAK] # Here is the clinical trial:\n\n### [INST] \n### [BREAK] # Let's think step by step. We will output the eligibility of the patient:\n\n### [BREAK] # We begin by a set the default of the trial",
        "label": 0
    },
    "114": {
        "output": "\u00a9 PJ-Lab @ UCSF\n\u00a9 PJ-Lab @ UCSF\n\u00a9 PJ-Lab @ UCSF<EOD> Innovative approaches on early childhood nutrition for policy and program: the UNICENT group\n\nBackground: An urgent need for coordinated action to improve the quality of nutrition globally has been expressed worldwide. Early childhood nutrition is a high priority, yet the evidence that underpins programs addressing this important phase of human development is limited. Objective: This paper describes the rationale behind the establishment of the United Nations Children's Fund-International Centre for Food and Nutrition Research and Promotion (UNICEF-ICFNRP) Technical Working Groups on early childhood nutrition. The paper also describes the group's first activities and recommendations moving forward. Methods: The UNICEF-ICFNRP Steering Committee identified several technical areas of interest to early childhood nutrition where coordinated research efforts were recommended. Technical Working Groups on complementary feeding, responsive feeding, timing of breastfeeding and duration of exclusive breastfeeding were established in 2004. Each of the four technical groups adopted a working method focused on three points; 1) identification of relevant gaps in knowledge and intervention tools; 2) the identification of priority research questions; and 3) the development of a work plan to ensure prioritized research questions are answered in a timely manner. Results: The four technical groups of the UNICEF-ICFNRP have initiated collaborative research on all priority areas under their purview. The groups have established their individual research priorities and developed work plans outlining detailed research plans to address these priorities. The UNICEF-ICFNRP Steering Committee has agreed upon common goals and plans to support the technical working groups. Two intervention trials have currently been developed and are being implemented in several developing countries and several systematic reviews, meta-analysis, and policy statements are being carried out. Conclusions: This group is committed to advancing multidisciplinary research designed to answer the most urgent questions relating to the complex and interrelated aspects of early childhood nutrition.\nD evelopment of a supportive early childhood nutrition environment is a key for optimal early childhood growth and development. [bib_ref]",
        "label": 1
    },
    "115": {
        "output": "## 1.\nStep1: If a patient is included in a clinical trial, then set the value of Exclusive status column to 0 (exclude) and set the value of Eligibility column to 1 (Eligible):\n[SEC]# Exclusive status column=0 # Eligibility column=1\n[/SEC]\n\n\n## 2.\nStep2: If the clinical trial includes 100 patients, then copy the value of the Exclusive column to the Eligibility column and repeat step1. You should see two steps:\nExclusive status column=1 (exclude)\nEligibility column=0 (eligible) \n\n## 3. -\n\n## 4.\nStep3: If a patient meets a clinical trial's inclusion criteria but does not meet all the clinical trial's exclusion criteria or is not ineligible for the clinical trial, then copy the value of Eligibility column to the Exclusive column and repeat step1. You should see 0 or 1 step each.\n\n# Exams in the Course\n<exam id=\"29767566\" title=\"Data Science Course Examination 1\" course=\"cs6281w\">\n    <question id=\"29611184\" class=\"answer\" question=\"1\">\n      <interpretation>\n        <correct answer><![CDATA[0]])</correct answer>\n        <distractor answer=\"#02: Exclude\">\n          <comment>Distractor answer: Eligible\nThe patient meets all the clinical trial's inclusion criteria and the clinical trial's exclusion criteria do not apply.</comment>\n        </distractor>\n        <comment>Explanation:\nThe patient meets all the clinical trial's exclusion criteria.\n</comment>\n        </interpretation>\n      </question>\n      <question id=\"29611185\" class=\"answer\" question=\"1\">\n        <interpretation>\n          <correct answer><![CDATA[2]])</correct answer>\n          <distractor answer=\"#01: Eligible\">\n            <comment>Distractor answer: Exclude\nThe patient does not have sufficient",
        "label": 2
    },
    "116": {
        "output": "[STARTER]\nFirst time? Check out  the tutorial on installation and first usage of a Docker container.\n<EOD> Effects on blood pressure and vascular resistance of the angiotensin type 1 receptor antagonist and angiotensin AT2 receptor stimulator Compound 21.\nA novel renin-angiotensin system (RAS) inhibitor, Compound 21, which acts as a mixed angiotensin type 1 receptor antagonist (AT1RA) and a mixed angiotensin II AT(2) receptor agonist (AT(2)RA), was studied in anesthetized dogs chronically instrumented with catheters in the left ventricle (LV), ascending aorta, pulmonary artery, right atrium, inferior vena cava, kidneys, and femoral artery and was also studied in intact salt-depleted and angiotensin II-infused hypertensive dogs. The vasodilator effect of Compound 21, given subcutaneously, was assessed by its effects on total peripheral resistance (TPR) and cardiac output (CO) as well as by direct measurements of mesenteric vascular resistance (MRVR) and renal vascular resistance (RVR) (given systemically and/or locally). Compound 21 had no major effects on TPR, CO, MRVR, RVR, pulmonary arterial pressure, or heart rate but had a slight effect on mean arterial pressure in chronically instrumented but not in intact dogs. In angiotensin II-dependent hypertensive dogs, Compound 21 evoked dose-responsive increases in heart rate, renal blood flow, and urinary sodium excretion. It also substantially reduced pressure-natriuresis and mean arterial pressure (MAP), without affecting TPR. In salt-depleted dogs, Compound 21 had no effect on MAP, RVR, or TPR, but it elevated plasma Ang II levels, which suggests a blockade or reduction in degradation of an active form of Ang II, or both. The data show that Compound 21 has a direct action, mediated through a local",
        "label": 2
    },
    "117": {
        "output": "![05_Screenshot_3][3]\n\n### 5.1.7. \ud30c\uc77c\ub4e4 \uc800\uc7a5\ud558\uae30 \ud83d\udcd2\n\n### 5.1.8. \ud30c\uc77c \uc800\uc7a5\n\n<sup>\uadfc\ub300\uc74c\ubcf4\uae30\ub97c \uc798 \uba8d\ud788\uc9c0 \uc54a\uc73c\ub2c8 \ucd5c\uadfc \uc74c\uc545\ucabd\uc744 \uc774\ub3d9\ud558\uc5ec \uae30\ub300\ud558\ub294 \ub178\ub798\ub4e4\uc744 \uace0\ub824\ud574 \ub4e4\uc73c\uc2ed\uc2dc\ub2e4.</sup>\n\n\ud2b9\ubcc4\ud55c \uc800\uc7a5 \uc635\uc158\uc740 \uc5c6\uc2b5\ub2c8\ub2e4.  \uba5c\ub4dc\ub77c, \uc0ac\uc624\ub9c1, \uc774\uc0c1\ube44 \ub4f1\uc758 \uc74c\uc545\uc758 \uadc0\uae08 \uc74c\uc545\ub9cc\ub4e4\uc5b4\ubd05\ub2c8\ub2e4.\n\n[\ud1b5\ud569: Making Musixmatch](https://github.com/JunSun/EchoMusicVoice/blob/main/README.md#make-a-musixmatch-playlist \"\ud1b5\ud569: Making Musixmatch\")\n\n```txt\n# \ub77c\ubc84\uace8\ub85c \uc800\uc7a5\nrabbitear --input music-list.csv --output new.txt\n\n\ncd music\npython3 /home/jimsun/MusicVoice  make_song_list_and_play_the_songs_from_song list.csv # -t '256,28' # \ucd5c\ub300\ucd5c\uc801\ud654 \uacc4\uc815\n\ncd echoecho\nfor i in $(seq 1 100); do echo -n \"\" > new_song_list_i.xls; echo -n \"\" > echo_song_list_i.xls; rm new_song_list_i.csv; rm echo_song_list_i.csv; done\n\n# echo -e \"\" | /usr/bin/xterm /home/jimsun/MusicVoice \\  make_song_list.py \"new",
        "label": 1
    },
    "118": {
        "output": "## Instructions\n\n\n\n\n\n\n[T] Let's try to apply the rules for a patient note. \nPlease pay attention first to the note shown below in this code cell. You need to compare a patient note with the inclusion criteria of a clinical trial (see the code for the trial in the same cell). And then, apply the rule for a patient.\nLet's go to the problematic code lines. To get the idea of the problem, let's check their functions and see which section they belong to. If you are not sure, let's step by step disassemble the code into small pieces, and see which portion needs to be modified, either its function or the way of execution.\nLet's start from the bottom of the code cell with `def isEligible()` function. It has one argument. You want to test the patient by checking whether the patient note passes the trial's eligibility test.\nThen, try to call the `isEligible()` function which is on the `def isEligible(patientNote)` line, by running `trial.isEligible(patientNote) `.\nIf the trial does not meet all the criteria of a patient, the isEligible function outputs `0` otherwise it outputs `1`. And when it fails the test, it is necessary to print the failure message to the user. \nNext, try to call the `printEligibleMessage(isEligible())` function, which is on the `printEligibleMessage(isEligible()) ` line, by running `trial.printEligibleMessage(trial.isEligible())`.\nAnd you should print the message that is written in the print() function by setting the following argument (line 23 in the problematic code cell): `print(\"Patient is {} out of 3 eligible. \\n\", isEligible())`.\nIt shows the assessment of eligibility on each patient for the clinical trial, i.e., a trial level eligibility for the trial. \nNow let's change the function from isEligible to trialNote, which is on the `def trialNote(trial):` line (Line 6). Because the function to evaluate trial notes will be modified, you need to change",
        "label": 0
    },
    "119": {
        "output": "## Examples\n\n### Tutorial:\nFirstly, we will open source, and create new R console environment where necessary scripts are available. R console environment is available by executing the source(url) code in the R command window.\n>>> source(url)      \n\nIn R console, we will check R version where environment and working directory settings are set (source - S).\nR> R.version()                                          \n[1] \"4.0.3\"\nR> setwd(\"..\")\nR> getwd()                                                       \n[1] \"/Users/noh/Dropbox/R/Tutorials/clinical_trial/new/Tutorial/Tutorial_clinical_trial_examples/Tutorial_clinical_trial_examples/\"\nR> getwd()\n\nWe will set working directory environment where clinical_trial package is saved.\n[/CODE]\n\n### Tutorial 1: Trial eligibility assessment for RNA synthesis inhibitors.\nFirstly we will load the dataset file, i.e., <NAME>.txt, into the R console environment.\nR> library(clinical_trial)                            \nR> load(\"RNA_synthesis_inhibitors.txt\")                \n\n<NAME> are excluded due to history of cardiac arrhythmias or congestive heart failure.\n\nHere is a summary of [the R code] (https://github.com/nohee/clinical_trial):\n<EOD> Tracing the Evolution of Mammalian Prions from Cellular Proteins: A New Field?\n\nMammalian prions and prion-like proteins are unstructured, aggregation-prone polypeptides with conformational plasticity that replicate from host cell to host cell; these proteins underpin pathologies from transmissible spongiform encephalopathies and ALS to neurodegenerative diseases. These agents and species induce a wide spectrum of proteinopathies in their vertebrate hosts as a result of self-templated rearrangements within their aggregated structures. We have proposed that prion-like and prion species arise from homologs of the RNA-and DNA",
        "label": 2
    },
    "120": {
        "output": "Note that you should not comment out the 'Exclude' and 'Not relevant' case in the 'Trial_-level_eligibility' field. That is because this case shows that the trial does not allow such patients in it. However, it is still a good idea to code in such a way since such a patient's case is quite rare. \nAfter all, your role as the trial assistant is an eligibility assessment for each patient. Try to make your solution more flexible for various cases so that the patient's case becomes eligible. That is, the patient's case will be considered eligible even if the patient does not meet all 6 inclusion criteria. Let's consider the following:\n[HINT] For simplicity, let us assume that each factor is a binary variable (=1 when the included, 0 otherwise). \n\n### 'No inclusion criteria' case\nIn this case, a patient is not included in a trial. So, it does not matter that the patient does not fit any criteria. It will be automatically '0' when the criteria are not given on the patient. It does not need any comment, either.\n\n`Trial-level eligibility: 0) Not relevant.`\n\n### 'No exclusion criteria' case\nIn this case, there is no exclusion criteria in the given trial. If the trial is not eligible for patients over 60 years of age, such patients would be excluded. So, the trial-level value for this case should be `2: Eligible`. If you want to consider an elderly patient as eligible, make a comment like ``Not applicable.'' in the patient record. In this way, it will enable the inclusion of such patients in the trial later.\n\n`Trial_level_eligibility: 1) Eligible. `\n\n### 'Ineligible due to inclusion criteria' case\nThis is an ineligible case due to exclusion criteria rather than exclusion criteria. If a patient's age does not fall within the age eligibility, the trial will not be eligible for this person only. So, it will be `1: Not relevant.`\n\n`Trial_level_eligibility: 0) Excluded`\n\n### 'Only one inclusion criteria' case\nA trial is only eligible",
        "label": 0
    },
    "121": {
        "output": "[SOLUTION]\nStep 1\nThis data is a patient's medical condition. The inclusion criteria are the patient's conditions matching those mentioned above, and patients with conditions that do not meet them are excluded from the trial. So, the conditions must be 1) age \u2265 18 and \u2264 75; 2) histologically confirmed diagnosis of invasive breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ; 3) patients with a Karnofsky performance status of > 40; 4) patients who understand the nature of the study and give written informed consent.\n- [01] 18 \u2264 age < 75;\n- [02] histologically confirmed invasive breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ;\n- [03] Karnofsky performance score > 40%;\n- [04] written informed consent.\n\nStep 2\nThe patient's condition matches the following medical criteria. The patient should be confirmed with a diagnosis from the inclusion criteria. So, it must be 1) invasive ductal breast cancer; 2) human epidermal growth factor receptor 2-positive with no more than 3 positive lymph nodes; 3) a single breast tumor \u2264 5 cm; 4) axillary lymph node dissection \u2264 15 nodes removed; 5) no other malignant tumors; 6) no prior invasive cancer diagnosis except for squamous cell or basal cell carcinoma of the skin; 7) proliferative or non-proliferative breast tumor with or without atypia; 8) no pregnant patients.\n- [05] invasive ductal breast cancer;\n- [06] HER2-positive with 0-3 positive lymph nodes;\n- [07] no more than 5 cm single breast tumors;\n- [08] no more than 15 axillary lymph nodes dissected;\n- [09] no simultaneous multiple breast tumors or other malignant tumors;\n- [10] no prior invasive cancer diagnosis",
        "label": 2
    },
    "122": {
        "output": "### A2.2) Trial-level eligibility\n[1st] You should make the calculation based on the information of a patient. [2nd] You should repeat the calculation using the information of a clinical trial.\n[INST] You should always repeat Trial-level eligibility in the last line, e.g., `Trial-level eligibility: 0) Non-Eligible.`. \n\nThe inclusion criteria of a clinical trial are as follows:\n\n1. ID: BC033, Title: Breast cancer\n1.1 Age (min): 25, (max): 80\n1.2 Cancer location: breast\n\n1.3 Cancer type: malignant carcinoma\n1.4 Cancer lateralization: 0: left, 1: right\n1.5 Pregnant? (Y/N):\n1.6 Active tobacco-user? (Y/N):\n\n1.7 ID: BC034\n1.8 Metastasis?: Yes (Y/N):\n1.9 HER2+ (Y/N):\n1.10 CMF-like: Yes (Y/N):\n\n2. ID: BC035 Location: left \n2.2 ID: BC035, Metastasis?: No (Y/N): \n2.3 ID: BC035, Active tobacco-user?: Yes (Y/N): \n2.4 ID: BC035, CMF-like?: \n3. ID: BC036 Location: right \n3.2 ID: BC036, Metastasis?: Yes (Y/N):\n3.3 ID: BC036, Active tobacco-user?: Yes (Y/N):\n3.4 ID: BC036, CMF-like?:\n\n[INST] After you make a patient evaluation for a clinical trial, you should always repeat in the last line Trial-level eligibility, e.g., `Trial-level eligibility: 1) Excluded.` and `Trial-level eligibility: 0) Not relevant.`.\n\n1. You may see the summary of clinical trials using following code:",
        "label": 2
    },
    "123": {
        "output": "#### [Exclude(s1596064983 197,1,3,'patient note',2,1,1); Exclude(1035330922,272,1,'instructions',3,1,1); Exclude(0,272,2,9,'preface',7,1,1,22,'paragraph8',11,'rule'), Comment10,Comment11,Comment12]\n\n\n\n\n\n\nThe trial-level eligibility should always appear in the last line if no patient is assigned to the specific trial.\n\n### Comments\n\n#### [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and",
        "label": 0
    },
    "124": {
        "output": "[CODE] \nTrial-level eligibility: [Trial] \nTrial ID: [TrialID] \nPatient: [TrialPatient] \nPatient No: [TrialPatientNo] \nGender: [TrialGender] \nAge: [TrialAge] \nEtiology: [TrialEtiology] \nTrialName: [TrialName] \nPreferred Language: [TrialTrialName] \nEvaluation method: [TrialEvaluation] \nIntervention: [TrialIntervention] \nProcedure: [TrialProcedure] \n\n<EOD> Genetic and antigenic variations between the virulent and avirulent strains of porcine rotavirus.\nRotavirus genomic RNAs were extracted from virulent and avirulent P670 and D1 strains, respectively, purified and electrophoretically separated on 1.8% polyacrylamide-8 M urea gel (PAG). Of these, the purified genome segments RNA4, 5, 6, 7 and 8 were subjected to antigenic analyses in RNA-fed suckling rabbits and subsequently the antisera were tested by an indirect immunofluorescence (I-IF) test. By these procedures, the following results were obtained. The genome segments RNA4, 5, 6 and 8 of the D1 strain were found to be more antigenically related with those of the P670 strain than those of the 4 other genome segments. However, RNA7 of the P670 strain was found to be more antigenically related with that of the D1 strain than those of the other segments RNA4, 5, 6 and 8. These results suggest that the genome segment RNA6 and perhaps RNA8 of the D1 strain are responsible for the virulence of the rotav",
        "label": 1
    },
    "125": {
        "output": "<aside class=\"warning\">If you are using a custom version of R, your input might not be converted to an IRR object, but to a dataset object (this depends on the version of the R package you are using). If you find that you cannot run your code, then you should run the following code:\n<div class=\"highlight\"> library(devtools) library(IRR) set_irr(\"Rscript\") set_irr(\"customVersion.R\") # or: rscript (in this example customVersion.R) </div></aside>\n\n\n* * *\n\n* * * <center><i>Click on a cell or a word to view related information.</i></center>\n\nThe clinical trial includes 2000 patients. You should count how many patients could be assessed as eligible and how many could not be assessed. You can compare the number of patients who meet and do not meet the inclusion criteria through the following steps.\n\n\n### Step \u2460: Make a trial summary\n\n```\nsetDf <-do.call(\"rbind\", setDf) # Create an object with a list\ncolnames(setDf) <-c(\"name\") # Change the column names\nsetDf <-makeTrialSummary(setDf) # Display the output below\n```\n\n![image](https://user-images.githubusercontent.com/48259735/118122365-5189c100-ba01-11eb-9159-2095cd96cfc8.png)\n\n\n### Step \u2461: Compute the rate of patients who met the inclusion criteria within the clinical trial\n\n```\n# Compute the patients who met the inclusion criteria within the clinical trial\nsetDf$Triallelgibility <-`count(setDf$ineligibility, rep(0, round(dim(setDf)[1]))) / dim(setDf)[1]` # Computes the rate of patients who are eligible within the clinical trial. \n```\nHere is the data frame:\n\n```\nsetDf <-data.frame(name = \"trial\",\n                    eligibility = c(\"1",
        "label": 2
    },
    "126": {
        "output": "You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. You should do the same for the clinical trial you're interested in. You should always use a standard scale number as an integer (0, 1 or 2) instead of a float number, e.g., 0 not 0.0. Otherwise, it might produce unexpected triallevel eligibility output.\nYou should output the eligible patient notes for the clinical trial in a table, and the trial-level eligibility in a final row. The output format is in the form of a json string. You are expected to return json strings with output that contain the clinicaltrial name, patient notes, and eligible patients in the order of patient note, eligible patient, and then trial-level eligibility.\n# You are expected to return eligible notes and final trial-level-eligibility in a json string.\n# You may find sample output of interest here:\n# https://github.com/bclinportal/docs/blob/master/example_problem_output.json\n# Your solution will be run on Amazon Web Services. Amazon provides free tier access to 12 different compute and storage services.\n\n# Challenge details\n\n# Explanation\nEligibility criteria vary widely across clinical trial protocols for many types of clinical trials. They can determine which patients may enroll in the study and receive the treatment or intervention developed in that study. For many types of studies, patients who would be eligible for a study may also represent the ideal patients for the treatment under investigation - thus, patients who are not eligible for a study may not have received benefit from a treatment or intervention. It's common that multiple patients are eligible to participate in the study, each having a different set of eligibility criteria. As more data, including patients' eligibility information, is collected, more detailed eligibility criteria may be",
        "label": 0
    },
    "127": {
        "output": "<EOD> .\nIn a number of tumours, such as the mammary carcinoma, the anticancer therapy of choice is surgical removal of the tumour. However, it has been established that cancer usually arises secondarily to an apparently clinically harmless lesion of the organ. In spite of good long term prognosis of patients with this group of carcinomas, the high incidence of metastasis makes the prognosis poor. Therefore, a new concept of screening with the aim of early diagnosis before clinical and radiologic manifestations occur gains importance. This paper describes a new concept of follow-up examinations in the early detection of breast cancer by computer tomography. In a prospective study a number of breast carcinomas was examined by computer tomography. In all cases, the carcinoma could be demonstrated before clinical or radiologic symptoms occurred. Besides, it was possible to detect the first metastasis in the lymph nodes, which occurred 3-6 months after initial diagnosis.<EOD> A review and update of treatment for multiple myeloma.\nRecent updates to the treatment paradigm shift for multiple myeloma (MM) based upon the approval of new agents, most notably proteasome-inhibitors, monoclonal antibodies, immunomodulatory drugs, histone deacetylase inhibitors, and venetoclax. This review aims to highlight key agents with updated phase 3 trial data and discuss how they fit in with current treatment options, as well as address some unanswered questions in the MM clinic that are currently under investigation.<EOD> .\nWe have evaluated the relationship of HBs antigen to lipid alterations including serum total cholesterol, beta-lipoprotein, triglyceride, total protein and albumin in Japanese patients with hepatic cirrhosis, chronic hepatitis and chronic persistent hepatitis. There was no relationship between the presence of HBs antigen and serum total cholesterol and beta-lipoprotein. Serum triglyceride level were negatively correlated to the presence of HBs antigen in chronic hepatitis and hepatic cirrhosis. The presence",
        "label": 0
    },
    "128": {
        "output": "__\n_If a patient was excluded in the test, please add the message: `This patient is excluded by:` followed by a line for each reason why the patient was included and a `Trial-level eligibility:` on the last line. The output trial-level eligibility will be `No patient is excluded in the test`.__\nIf the test was passed, your job as an eligibility assessor is done!\n__**Doing the Test:**__\nYou can do the test case in `examples` folder of `eligibility-assessor` package.\n\n*Note that the example has been simplified slightly to make running the example easier for first time users.*\n\n`eligibility-assessor::doTest(\"radiation therapy.txt\", \"radiation_therapy.md\",\"\")`. This command will output `radiation_therapy.md` on your console.\n\n\n\n\n`{ \"notes\": {\"path\": \"path-to-the-patient.txt\"} }, { \"clinical_trials\": {\"path\": \"path-to-the-clinical-trial.txt\"} }, trial-level_eligibility: \"4\" }`\nThis is the JSON output after `doTest(\"path-to-the-patient.txt\", \"path-to-the-clinical-trial.txt\", \"\")`; you should get same result from `try-patient-test.txt`.\n\n__**How Can We Make it Faster?**__\n\nFirst and most important, please learn to understand what will be done. Secondly, `eligibility-assessor` package has some optimizations to speed up the runtime. It is more than optimized for most of the work which is done by eligibility-assessor for trials. However, the speedup will depend on the database structure. You may still need to do more research for larger databases. \n\n## 1. `eligibility-assessor` package is more optimized for trials than patients.\n   \n    `iristrials::faster_runeligibility` will be faster than `iristrials::runeligibility` and `iristrials::faster_runpatient` will be faster than `iristrials::runpatient`.",
        "label": 0
    },
    "129": {
        "output": "## \u2714[INST] \u25cb [ ]\nCheck the box.\n\n## [inst]\n1) \u25cb The patient has cytologically confirmed breast cancer..\n\n## [inst]\n\u25cb The tumor is HER2-positive.\n\n## [inst]\n\u25cb ER/PR negative.\n\n## [inst]\n\u25cb 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n\n## [inst]\n\u25cb A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\n## [inst]\n\u25cb A second biopsy showed positive lymph node samples (Stage IV).\n\n## [inst]\n\u25cb Axillary sampling revealed 5 positive lymph nodes\n\n## [inst]\n\u25cb CXR was remarkable for metastatic lesions.\n\n## [inst]\n\u25cb The patient is using multivitamins and iron supplements.\n\n## [inst]\n\u25cb Does not smoke or consume alcohol.\n\n## [inst]\n\u25cb Sexually inactive.\n\n## [inst]\n\u25cb Has no children.\n[formula]  [INST] \u25cb Agrees to do so prior to chemotherapy. [/formula] \n\n## [inst]\n\n## \u25cb\nThe dHER2+AS15 ASCI Antigen-Specific Cancer Immunotherapeutic (ASCI) candidate contains a recombinant protein termed dHER2, which is a truncated version of the HER2 protein. HER2 is a protein that is commonly overexpressed in breast cancer. \nThis protein, as well as tumor antigens, is combined with the immunological adjuvant AS15 Adjuvant System from GSK (GlaxoSmithKline), which is a liposomal formulation containing three immunostimulatory components.\n\n## [inst]\nLapatinib is FDA approved for use in combination with capecitabine for the treatment of subjects with advanced or metastatic breast cancer whose tumors overexpress HER2.\n\n## [inst]\nThis study is for patients with metastatic breast cancer (invasive breast cancer with stage IV disease) that overexpresses HER2 and",
        "label": 0
    },
    "130": {
        "output": "```python\n# +\nimport ctypes\nfrom random import *\nfrom itertools import product\nimport operator\nfrom typing import Optional, Union\nfrom unittest import mock\nimport numpy as np\nimport pandas as pd\nimport datetime\nimport yaml\nimport logging\nimport math\nimport re\nfrom pydub import AudioSegment\nimport re\n\nfrom astropy import units as u\nfrom pathlib import Path, dirs, ParallelPool, Pendulum, TimeZone\nfrom scipy import misc\nfrom matplotlib.plotting import grid_generator, subplot_maker\nfrom statsmodels.tsa.base.mle import WLS\nfrom statsmodels.tsa.combined import HANTS\nfrom datetime import datetime, timedelta, date, tzutime\nfrom matplotlib import _testing\nimport numpy as np\nfrom math import pi\nimport pandas as pd\nfrom pinkerton import fviz_augment, fviz_var, fviz_pair, fviz_hier\nimport plotly.graph_objects as go\nimport plotly\nimport plotly.pylab as spl\nfrom pandas import dataFrame as df\nfrom tqdm import tqdm\nfrom IPython import display, get_ipython\nimport pdb\nimport matplotlib\n\ndef f(val):\n    return val*5+7\n\ndef g(val):\n    return 2*val+8\n\ndef h(val):\n    return val*val\n\n\ndef i(val):\n    return val-301\n\ndef j(val):\n    return 9*val\n\ndef k(val):\n    return 9+val\n\n\ndef l(val):\n    return val/10*5\n\ndef m(val):\n    return val/500\n\ndef n(val):\n    print('val:', val)\n\n\ndef o(val):\n    return val*val/100\n\ndef p(val):\n    return val/1000\n\ndef q(val):\n    return val+10\n\ndef r(val):\n    return val*2\n\ndef s(val):\n    return val*val\n\ndef t(val):\n    return val+6\n\ndef u(",
        "label": 1
    },
    "131": {
        "output": "##[EXPORT]\n<EOD> Influence of temperature on the structure and properties of the phosphatidylcholine membrane in the presence of lignoceryl chains in the head group.\nLipid membranes have been examined experimentally and theoretically for a long time. Detailed studies of different properties of DOPC, DPPC, DSPC, and PSM lipids as a function of the temperature have been reported in previous studies. The biological importance of lignoceryl chains in the head group of the membrane has not been fully clarified yet, despite the fact that lignoceryl chains in the membrane are of great interest in biotechnology. In this study, we investigate the properties of lipid membranes consisting of a combination of PC lipids and long chain lignoceryl chains incorporated, in particular, in the polar head group using the molecular dynamics simulations. We have investigated the effect of temperature on the lateral ordering of hydrocarbon chains, thickness, area, density, and mechanical properties of bilayer membranes of lignoceryl lecithin formed at 370 K and 310 K. We have obtained the results demonstrating the thermal influence on the structure and lateral ordering of hydrocarbon chains and the thickening of the bilayer at the temperatures simulated. In addition, the influence of the temperature on the mechanical properties of the lipid membrane is shown.<EOD> Cytosolic and cell surface activity of the human myeloma light chain.\nA human bone marrow sample contained a monoclonal population of 7S IgG protein and of biclonal 7S kappa light and macroglobulin heavy chain variants, which were secreted and associated with circulating cryoglobulins. The purified 7S kappa light chains showed significant in vitro rheumatoid factor activity and an autologous anti-kappa autoantibody, in addition to a normal anti-DNA antibody. The light chains contained no significant cysteine groups by spectrophotometry, but a small amount of cystine formation and antigenically cross-reactive material increased with time in vitro at 37 degrees C. The 7S light chain dimer, but",
        "label": 2
    },
    "132": {
        "output": "<EOD> The effect of a calcium ionophore on the secretion of phosphatidylcholine in vitro.\nThis investigation was carried out to elucidate the role of calcium in the regulation of phosphatidylcholine secretion in vitro. Incubation of mouse peritoneal macrophages, isolated for 40 h, with phorbol dibutyrate produced an increase in lipid secretion. Increasing Ca++ concentration to 35 mM or the addition of a calcium ionophore A 23187 at 10(-5) M increased lipid secretion when cells had been pretreated with phorbol dibutyrate at 5.50 X 10(-7) M. Neither of these components of the incubation media had any effect on the lipid secretion in control cells. There was also an increase in phorbol dibutyrate induced lipid secretion when the calcium ionophore was added after a 24 h lag period. Similar results were obtained with a preparation of normal mouse peritoneal macrophages. The cell number per millilitre, determined microscopically, decreased within the first several hours and then tended to stabilize.<EOD> The effects of the new antiepileptic drugs\nPurpose of reviewThis review gives an overview on the effects of the new antiepileptic drugs (AEDs), which has been published since earlier reviews focusing on the efficacy and tolerability of AEDs. Recent findingsThere is a new generation of the old antiepileptic medications as well as new drugs with novel pharmacological mechanisms. Some of the new AEDs are effective in refractory epilepsy syndromes. For this group of patients, new AEDs need to be effective as well as well tolerated. SummaryAll of the newest AEDs have a broad spectrum of effectiveness in different patient groups. Levetiracetam and oxcarbazepine seem promising in the treatment of absence seizures and Lennox-Gastaut syndrome. Perampanel, brivaracetam, and lacosamide are promising in the treatment of complex partial seizures or refractory epilepsy.<EOD>",
        "label": 0
    },
    "133": {
        "output": "[INST] \nA: Patient-level eligibility\n    The patient's eligibility information will be given as the patient data.\nYou should make patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n    You should check if the inclusion criteria are completely or partially matched according to the patient's data. Use the binary information as the result of the patient-level eligibility. If you have any doubts of a patient's inclusion to the clinical trial, assign one to three on `Patient-level eligibility. \n    For example, if the patient's body type is consistent with the inclusion criteria of a trial, assign one to the input. If all the variables do not match, assign three to the input. If it is not clear if the patient matches the trial, assign two to the input.\n    \n    The input sample of Trial-level eligibility is determined using the following format: `Trial-level eligibility: (value of Patient-level eligibility)  `.\n- Trial Level Eligibility: 0 (Excluded)\n    You have to set this status to exclude it from the eligibility. If a patient does not meet the inclusion criteria, it should be excluded. For example, the patients in this example are all male.\n- Trial Level Eligibility: 1 (Not Relevant)\n    The patient's age or gender does not match the trial's inclusion criteria.\n- Trial Level Eligibility: 2 (Eligible)\n    This category is assigned if a patient's data completely matches the inclusion and exclusion criteria of a trial.\n   \n- Trial Level Eligibility: 0 (Excluded)\n- Trial Level Eligibility: 1 (Not Relevant)\n- Trial Level Eligibility: 2 (Eligible)\n    \n    The input patient-level eligibility is given as patient's data.\n                    \n    The patients' eligibility information is described in below. Here, we present an example of a dataset. The input values of the patient's eligibility are presented within square brackets ([]).\n    \n    ![2019-10-21 1",
        "label": 0
    },
    "134": {
        "output": "Good luck!\n<EOD> Gender bias in the management of acute, non\u2010variceal upper gastrointestinal bleeding when presented with a negative urgent endoscopy\n\nBackground and aim: It has been suggested that female patients are less likely to undergo early re-endoscopy for actively bleeding and high risk endoscopic ulcer lesions. We sought to determine if male patients presenting with a negative first endoscopy are subsequently offered any treatment, while female patients are not.Method: All patients who had unscheduled upper gastrointestinal endoscopies were identified from a database that contained demographic and clinical information. For each patient in the study period, a time-stamped record was kept of the treatment received, and of relevant investigations. All of the available records of the patients in this group were reviewed.Results: A total of 192 patients had urgent endoscopies between November 2006 and December 2007. Mean age, length of stay, and gender of the patients did not differ between the groups (p value > 0.05, two-tailed student t-test). There was no significant statistical difference between the percentage of female and male patients that were admitted or admitted and then discharged in the groups having no endoscopic diagnosis (58.66% vs. 41.34%), gastric ulcer (70.63% vs. 29.37%), duodenal ulcer (56.52% vs. 43.48%) and erosive gastritis (60.87% vs. 39.13%). However, a statistically significant difference was seen between the two groups in the percentages of female and male patients with active bleeding not managed by endoscopy that were subsequently managed medically (33.33% vs. 66.67%, Chi square = 6.639, p = 0.0104). The female and male patients that were discharged home after the first negative endoscopy were significantly younger than the patients that had endoscopy-related treatments (41.04 years vs. 52.29 years, t-test, p = 0.0",
        "label": 2
    },
    "135": {
        "output": "[/STEP]\n\n\n<br/>\n\n#### T-45: Eligibility Check\n\nThis task is a single classifier that decides whether a patient is eligible to a given a clinical trial. The inputs of the classifier are a patient note and the clinical trial. The output of this classifier is an assessment of patient eligibility: 1) Excluded (the patient violates the inclusion criteria of the trial), 2) Negative (the patient has insufficient information to be eligible), 3) Positive (the patient meets all the inclusion criteria of the trial). This task is a special case of the more general task T-44 with an input  of a patient note and a clinical trial .\n\n\n## Task T-45 Details\n\nThe output of this task is one of the three: \n1. Excluded: A patient violates all the eligibility criteria for the trial.\n2. Negative: A patient does not have sufficient information to be eligible.\n3. Positive: A patient meets all the eligibility criteria for the trial.\nSee  for examples of input and expected output.\n\nSee [/STEP]:\n\n[/LINK]\n</br>[/STEP]\n\n#### T-46: Trial-level Eligibility\n\nThis task is an input-output pipeline that consists of two pipelines which decide:\n\n \n\n \n\nA patient is excluded if he has violated one of the inclusion or exclusion criteria, as well as the final eligibility decision.\nA patient is positive for the clinical trial if he does not violate any criteria and thus can be used by the trial. \nThis task's inputs are a patient note and a clinical trial. The output is 2-tuple, with the first element being a Patient-level eligibility, and the second one being a Trial-level eligibility. \nExpected output\nA patient-level eligibility can be either positive or negative.\nFor the positive patient level eligibility:\nAssessment of eligibility: Positive\nAssessment of Eligibility: 2) Eligible\n\nExplanation\nThe assessment of eligibility is positive, which means patient is eligible",
        "label": 0
    },
    "136": {
        "output": "![INST]\nOutputs: \nTrial-level eligibility: 2) Eligible.\n\n__FRAGMENT_02__<commit_msg>This issue is still unfixed in the most recent release of SAS/ACRT. The issue can be fixed by using CASR, not SAS/IML.<commit_after>#! /bin/bash\n\n[R]\nsyntax=R64\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Study of Epicutaneously Applied Ketoprofen Transfersome\u00ae Gel With or Without Combination With Oral",
        "label": 0
    },
    "137": {
        "output": "## [INST] If you encounter blank lines between Patient notes passed to\\nTrial-level eligibility:` and 00-Patient notes passed to Tri",
        "label": 0
    },
    "138": {
        "output": "<EOD> Oxytocin is required for formation and maintenance of maternal bonding during lactation\nSignificance Maternal bonding is critical for the parent-young relationship in mammalian animals. However, its neural mechanism is scarcely studied, especially in lactating females. Although neuroendocrine changes, especially oxytocin (OT) receptor modulation, contribute to maternal behavior, it remains undetermined whether OT signaling is required for the formation and maintenance of both the pup-elicited and pup-preferred activity patterns in the mother. This is the first study to demonstrate the role of OT in the medial preoptic nucleus (mPON) in pup bonding during lactation. The results reveal that OT\u2013mPON\u2013anterior cingulate cortex (ACC) neural circuitry underlies maternal bonding in lactating females. These findings provide insights into the neural mechanism underlying maternal behavior and suggest new therapeutic targets for treating disorders characterized by impaired maternal behavior such as postpartum depression. To identify the neural mechanism underlying maternal bonding, we measured baseline and pup-elicited activities of the maternal behavior-associated anterior cingulate cortex (ACC) neurons in lactating rats with intraventricular administration of an OT receptor antagonist or OT or its analog, intranucleus infusions of the OT receptor antagonist, or genetic knockdown of the OT receptor or OT in the ACC using short hairpin RNA or RNA interference, respectively, focusing on their interactions with maternal experience and pup preference. All these manipulations inhibited ACC neurons in lactating rats during presentation of pups in an unfamiliar environment or during maternal behavior, suggesting a role of OT in mood stabilization. Infusions of the OT receptor antagonist or knockdown of the OT receptor or OT into the medial preoptic nucleus (mPON) in virgin rats prevented maternal preference elicited by social contact with pups and pup-elicited activation of ACC neurons. OT receptor knockdown in the mPON of lactating rats also inhib",
        "label": 0
    },
    "139": {
        "output": "<EOD> Clinical and histopathologic features of a 4-year-old male neutered Domestic Long Hair cat with systemic hypoadrenocorticism.\nA 4-year-old neutered Domestic Long Hair cat was presented due to vomiting, diarrhea, hyporexia and weight loss. The patient was previously diagnosed as hypothyroid gonadal dysgenesis at this clinic on account of lack of development of the external genital structure. Hypothyroidism was confirmed with the result of increased T4 value to 4.54 ng/dL (normal 1.0 to 3.3 ng/dL) and normal TSH level (0.46 ug/L, normal <2.28 ug/L). Hypothyroidism was considered to be the cause of weight loss that had been continued for many years. It was thought",
        "label": 0
    },
    "140": {
        "output": "# Use case\n\n# Use case:\n\n\n```ruby\ndescribe 'Clinical.eligibility.rb' do\n  let(:patient_note) { PatientNoteGenerator.note(\"candidate_name_for_testing.txt\") }\n  let(:clinical_trial) { ClinicalTrialGenerator.trial(\"trial_name_for_testing.txt\") }\n\n  it 'is a PatientNotes instance' do\n    expect(patient_note).to be_instance_of(PatientNote)\n  end\n\n  it 'has a text note' do\n    expect(patient_note.note).to start_with(\"Patient is a 45-year-old postmenopausal woman with invasive ductal breast\")\n  end\n\n  it 'has a clinical trial' do\n    expect(patient_note.clinical_trial).to start_with(\"#10091009\")\n  end\n\n  it 'is the eligible of the trial-level evaluation' do\n    expect(patient_note.eligibility).to start_with(\"Not relevant\")\n  end\nend\n```\n<EOD> Synthesis of new pyrazines by a domino reaction.\nDomino synthesis of functional pyrazines involving aminocarbonyl/ketene methyl acetal cycloaddition and oxime aldol/Michael addition is described. The products obtained were also confirmed by GC/MS analysis.<EOD> 2007: The Year of the Reverse J-Curve: A Cautionary Tale.\nA 31-year-old woman presented to the outpatient physical therapy clinic with severe exertional-type leg pain and shortness of breath in the right leg. History was significant for traumatic left ankle dislocation in 2006 that was treated by a closed reduction and ankle<EOD> .\nFour species of loricariid fish from the Cuiab\u00e1 River, Mato Grosso, including Pterygoplichthys equesi, Hypostomus regani, Hypostomus pictus and Hypostomus ancistroides were fed a natural diet (tubers",
        "label": 0
    },
    "141": {
        "output": "[!NOTE]\n\nYou can download the example code file in this section as well.\n\nYou can find more information about clinical trial data on the Medical Data Standards website:\n\nhttps://mds.nlm.nih.gov/data/\n\n[!NOTE]\n\nTo make the evaluation easier, we have developed an evaluation tool called the \"Evaluate Coding\" tool. You can access the \"Evaluate Coding\" tool by pressing the gray button with the word _Run_ inside it in \"Developer Tools\".\n\n![Evaluate_coding]\n\n[!NOTE]\n\nThe evaluation tool will ask you to:\n\n* Evaluate the code of the input clinical study.\n* Evaluate the code of the clinical data.\n* Select variables related to their input data to be encoded by the code you wrote.\n* Check the error reporting from the code run in the evaluation tool.\n\n# Implementation\n\nThe main data types of the output of the encoders are JSON and CSV, and the data type of the output of the decoders are JSON and XML. This section is about the steps you need to follow to write your own encoders/decoders in Python. \ud83d\udc47\n\n## Installing packages and importing namespaces\n\nAfter you have installed the required packages to create your encoder or decoder, import the namespaces in your Python file. \ud83d\udc47\n\n```python\nimport pandas as pd\nfrom pathlib import Path\nfrom json import dump, load\nfrom os import path\n\nimport numpy as np\n```\n\n##### Required (in decoder module):\n\n```python\nfrom clinical_dataset import Decoder, DecoderConfig# \u2764\ufe0f\ud83d\ude80\nfrom numpy import ndarray\nfrom pandas import Series\nfrom io import Dataset\nfrom copy import deepcopy\n\n\nfrom clinical_study import ClinicalStudy\n```\n\n## Writing your encoder/decoder\n\nAt this point, you should not worry about how to configure your encoder/decoder. You only need to know how to create your instance of an encoder or decoder.\n\nHere is a generic encoder/decoder skeleton that is reusable in your Python scripts (e.g.,",
        "label": 2
    },
    "142": {
        "output": "<EOD> SUN-329 Clinical and Genetic Findings of 12 Families from 3 Unrelated Ethnic Groups with a Rare Disorder of Sex Development\n\nSUN-329Patients with sexual maturation and internal genitalia developing normally and primary amenorrhea develop due to a disorder of sexual development (DSD) are called non-discordant DSD. Diagnosis is challenging in such patients since primary amenorrhea is usually attributed to psychopathologies instead of a clinically apparent disorder. We aimed to describe 12 unrelated females clinically phenotyped with DSD. This retrospective study included women clinically diagnosed with DSD aged \u226516 years between 2012 and 2020 in 3 tertiary medical centers in Turkey, a 28 million-population country located in the Middle East. All participants were phenotypically assigned to DSD group due to primary amenorrhea. Patients' charts were reviewed for age at diagnosis, medical history, clinical characteristics, physical examination findings, biochemical and radiological tests, and genetic testing results performed with targeted panel sequencing approach. Medical files of all women diagnosed with DSD during the study period were reviewed, and 20 patients fulfilled the inclusion criteria. After exclusion of patients who had previously undergone hormone replacement, 12 of them were included in the study. Patients' age at diagnosis ranged from 16 to 27 years, and the mean age at diagnosis was 21.5 years [fig_ref]  Table 1: Clinical characteristics of the studied DSD cohort [/fig_ref] . Only 1 patient had a history of mental retardation, but this condition was not related to DSD. The most common reason for referral to endocrinology clinic was primary amenorrhea of 6 patients. Other patients consulted due to infertility, short stature, and suspicion of DSD. Two patients were referred because their elder sister was clinically diagnosed with 17\u03b1-hydroxylase deficiency. All women had undergone hormonal and reproductive endowment development assessment [fig_ref]  Table 1: Clinical characteristics of the studied D",
        "label": 0
    },
    "143": {
        "output": "<EOD> A Comparison of the Effects of the Angiotensin\u2010Converting Enzyme Inhibitor and Angiotensin Receptor Antagonist on Proximal Tubule Transport in the Rat\nWe have tested the hypothesis that angiotensin receptor (AT 1 ) antagonists have direct diuretic effects independent of their interference with intrarenal angiotensin action. We studied the effects of a 7-day administration of the AT 1 antagonist, EXP 3174, and its hydrochloride (HCl) salt, EXP 3179 Cl, on proximal tubule transport parameters and on mean arterial pressure in Munich-Wistar rats. In anesthetized rats, EXP 3174 and EXP 3179 have similar acute diuretic effects (118% and 103% above control after 120 minutes), but EXP 3179 induces less natriuresis than EXP 3174 (56% above control for EXP 3179 vs 233% above control for EXP 3174). In 7-day studies, rats were treated with either vehicle (N = 14), EXP 3174 (5 mg/kg/day, N = 12), or EXP 3179 Cl (10 mg/kg/day, N = 11). EXP 3174 and EXP 3179 Cl had similar long-term diuretic effects (75% and 85% above vehicle, respectively); however, EXP 3179 Cl tended to have a greater natriuretic effect than EXP 3174 (63% and 125% above vehicle for EXP 3179 Cl and EXP 3174, respectively). After chronic infusion, EXP 3179 induced greater losses of proximal tubule fluid and sodium (47% and 76% above vehicle losses, respectively) than did EXP 3174 (23% and 43% above vehicle losses, respectively). Excess sodium losses were greater for",
        "label": 2
    },
    "144": {
        "output": "<EOD> The Role of Interventional Dialysis in COVID-19 Patients Requiring Continuous Renal Replacement Therapy: A Single-Center Experience\n\n\n\n# Background\nThe novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was first discovered in Wuhan, China, in December 2019. The pathophysiology of human-to-human transmission for this virus is through respiratory droplets and viral particles [bib_ref]  Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, Van Doremalen [/bib_ref] . Given its high infectivity, coronavirus disease-19 (COVID-19) has spread throughout the globe and the World Health Organization has identified it as a pandemic. Patients generally present with a cough and shortness of breath, which can progress quickly to acute respiratory distress syndrome, multiorgan system failure, and death [bib_ref]  Acute kidney injury due to COVID-19 and impact on outcomes, Chappidi [/bib_ref] . Mortality rates are \u223c3%.\nAs clinical and epidemiological data have accumulated over the past 15 months, increasing attention has turned to renal dysfunction in patients infected with COVID-19. Up to 19% of patients with COVID-19 have been shown to develop renal dysfunction, with acute kidney injury (AKI) occurring in >20% [bib_ref]  Incidence, risk factors, and prognosis of acute kidney injury int hospitalized COVID-19..., Cheng [/bib_ref] . Mortality from COVID-19 is higher for patients with AKI than for those who do not develop it [bib_ref]  Incidence, risk factors, and prognosis of acute kidney injury int hospitalized COVID-19..., Cheng [/bib_ref] . Additionally, the mortality rate in patients with COVID-19 and AKI on continuous renal replacement therapy (CRRT) has been reported to be as high as 95% [bib_ref]  Continuous renal replacement therapy for critically ill patients with COVID-19, Iwasaki [/bib_ref] . As such, it is imperative to",
        "label": 0
    },
    "145": {
        "output": "##[[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine the patients' eligibility to a clinical trial. A factor allowing someone to participate in a clinical trial is defined as inclusion criteria. They are based on characteristics such as gender, age, the type of cancer, previous treatment history, and other medical conditions.\\nIn the table below are summarized two sample tables. The first table represents the inclusion criteria for trial \"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer\", i.e., the \"Trial of Pixantrone\" table. The table includes the \"Title\", \"Summary\" and \"Inclusion\"/\"Exclusion\" criteria. The \"Eligibility\" column of the eligibility section is not applicable because we consider no patients with multiple criteria in the same section to be eligible. The second table represents a summary of a fictitious patient's inclusion criteria for this trial. Below you'll find the instructions in two parts. The first part concerns you have to apply the eligibility criteria of a clinical trial to determine the patients' eligibility. The second part concerns you have to output the patient-level eligibility for this trial. The \"Excluded\",\" Not relevant\" and \"Eligible\" scales are used. \n\n# Part 1\n\n## [INST] The patient's inclusion criteria for the Trial of Pixantrone.\n\n### Eligibility Determination\n\n### 1) You need to determine patient's eligibility to clinical trial. In the input form 'Clinical Trial of Pixantrone'. Find the clinical trial and click the 'Data' tab. Copy the content of the table of the ' Inclusion' section of the 'trial of pixantrone (ClinicalTrials.gov Identifier: NCT00004284) . \n\n### 2) Copy paste the list of factors determining patient's eligibility on each cell.\nEliGible Eligible EliGible Eligible Eligible EliGible Eligible Eligible EliGible Eligible Eligible Eligible Eligible Eligible Eligible Eligible",
        "label": 0
    },
    "146": {
        "output": "\u00a9 2018, <NAME>, et al.\n\n[![View the source on GitHub](https://github.com/gist-it/medipredict/blob/master/static/public/medipredict.md)]\n[![View the source on GitHub](https://github.com/gist-it/medipredict/tree/master/test/data)]\n\n<EOD> Reproductive toxicology: the 2004 report.\nToxic effects of drug and chemical exposures during pregnancy on maternal health and disease in future generations have become recognized by biomedical scientists and industry as a major public health concern. As we enter the millennium, more and more drugs and chemicals known to cause direct toxicities in the mother are being developed and marketed. Few effective animal and human studies are being conducted to examine the teratogenicity or developmental toxicity of these drugs and chemicals. Many pregnant women taking these drugs are becoming exposed to chemicals never before studied or known to affect reproduction. A case in point is the antiviral drug acyclovir, which is now routinely used by millions of people for genital herpes and is being evaluated for use in other genital pathogens. While the drug has been shown to be developmentally toxic in animals, including humans, its reproductive toxicity in both genders is poorly documented or studied. We reviewed and analyzed all the literature published on the subject in PubMed  from 1964 to 2004. The report will focus on newer, nonchemical therapies, such as antiretroviral therapies that are commonly used for pregnant women infected with HIV and hepatitis C, toxicity in children and adults exposed to these drugs in utero or after birth.<EOD> Clinical Outcomes of Patients with Chronic Rhinosinusitis who have Failed Medical Management\nObjective.\u2014 This study presents a series of patients with chronic rhinosinusitis, in whom previous medical management failed, and who underwent sinus surgery with medical continuation postoperatively. The aim of the study is to assess whether sinus surgery and postoperative antibiotic prophylaxis have any beneficial effects on disease remission",
        "label": 1
    },
    "147": {
        "output": "# Sample Solution\n    You need to evaluate your input and provide a Trial-level eligibility for each patient note.\n    \n   \n    ```\n     {\n        \"SensitiveInfo\": {\n          \"CancerRegimen\": {\n            \"Title\": \"Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer\",\n            \"Summary\": \"RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat together with letrozole may be an effective treatment for breast cancer.PURPOSE: This phase I/II trial is studying the side effects and best dose of panobinostat when given together with letrozole and to see how well it works in treating patients with metastatic breast cancer.Inclusion:\n\n    }\n    }\n\n    Output:\n    {\n        \"trial_level_eligibility\": \"Excluded\",\n        \"Patient Note:\" => \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n    }\n\n\n### SOLUTION\n\n<EOD> The Drosophila melanogaster genome, Ahrens and Henikoff style\nThe 99-Mb Drosophila genome is very well annotated, with a mean spacing of 20.9 kb between contiguous genes. Most of it (92.9%) belongs to",
        "label": 2
    },
    "148": {
        "output": "<BR><BR><H2>[H2]Output: Eligibility for  patients</H2><BR><UL><LI>The patient is a 41-year-old woman, whose clinical trials are:\n</LI>\n\nClinicalTrials.gov listing: [clinicaltrials.gov](https://clinicaltrials.gov/search/results?cond='Liposarcoma'&amp;term=&amp;cntry=&amp;state=&amp;city=&amp;dist=)\nPMC ID: [PMC3568118](https://pubmed.ncbi.nlm.nih.gov/17954720/)\n\n[A116-05](https://clinicaltrials.gov/ct2/show/record/NCT01517221):\n[clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT01517221)\n[PMC3568118](https://pubmed.ncbi.nlm.nih.gov/17954720/)\n\n[A117-05](https://clinicaltrials.gov/ct2/show/record/NCT01517246):\n[clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT01517246)\n[PMC3568118](https://pubmed.ncbi.nlm.nih.gov/17954720/)\n\n[A119](https://clinicaltrials.gov/ct2/show/study/NCT02208253):\n[clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT02208253)\n[PMID: 28374826](https://pubmed.ncbi.nlm.nih.gov/28374826/)\n[PMID: 26696647](https://",
        "label": 1
    },
    "149": {
        "output": "## Question 7: What is considered to be clinically significant weight change?\n<EOD> Difficulties associated with the definition and measurement of adherence in epilepsy.\nDifficulties with measuring adherence to antiepileptic drug therapy are well recognized. The reasons for this are many. The various scales available are often difficult to use, involve a great deal of time to complete and can also be affected by cultural bias. Moreover, there is a fundamental problem with defining what is meant by adherence, which, as pointed out by Cramer, \u201cis a word without a clear definition\u201d ( 1 ). In an attempt to develop some consensus on how to measure adherence, it was decided that a workshop be held at an epilepsy symposium (September 1994, London). A group of participants met under the supervision of Dr. William Panayiotopoulos to discuss various aspects of adherence to antiepileptic drug (AED) therapy, and they were asked to complete a questionnaire prior to the meeting, which addressed 14 separate aspects of adherence. The questionnaire and the workshop itself received extensive critical editorial and scientific input from the members of the AED Advisory Board. The overall aim of these activities was to develop some guidelines for researchers to use in trying to establish the validity of adherence scales. From these activities two conclusions can be drawn: ( 1 ) AED researchers need to have a well-defined and standardized assessment of the degree of adherence to AED therapy in epileptic patients and (2) they need to assess whether such assessment helps them to understand better the relationship between AED treatment and the clinical and social outcome of patients. One of the problems that has been identified is the difficulty of defining what is meant by adherence. It is a concept that all researchers seem to be agreeing on less and less as time passes and their efforts to measure adherence becomes more detailed, with a growing number of scales being developed, each with only a slightly different definition of the terms used in the scale. At the meeting the word nonadherent was the one that most commonly came to mind. Clearly, this is an emotive word for most of us and it raises issues of ethics, morality and bl",
        "label": 0
    },
    "150": {
        "output": "___\n\n### Summary\n\nSoftware:\n - [INST] Python 3.x\n - [INST][TUT](Tutor)\n\nPython-Docstring Tutorial for clinical trial assessment eligibility program\n============\n\nThis is a [Python-Docstring](https://www.tutorialspoint.com/python/python_doc_string.htm) Tutorial, including introduction, prerequisites, tutorial, example code, references, and discussion. Enjoy!\n\nIntroduction\n============\n\nThis tutorial covers a [TUT](../TUT/intro.md):\n   - [INST].[TUT](TUT) (Tutor: Trial-level eligibility)\n\nPrerequisites\n============\n\nYou need to install [INST][TUT](TUT)\n\nInstructions\n============\n\n[INST][TUT](TUT) is a Python Tutor, i.e., Python code tutorial. To run it, you should first:\n\n  1. Install [INST][]\n, a Python interpreter.\n\n  2. Install [INST][TUT](TUT) in a virtual environment:\n\n     ```bash\n     virtualenv --relocatable [INST][TUT](TUT)/bin\n     python [INST][TUT](TUT)/bin/activate\n     ```\n\n  3. Change directory to the tutorial directory:\n\n     ```bash\n     cd [INST][TUT](TUT)\n     ```\n\n  4. Execute the tutorial in that directory:\n\n     ```bash\n     run_tutorial [INST][TUT](TUT)/TUT_1/main_01.py\n     ```\n\n  5. Or try running the tutorial without changing directory:\n\n     ```bash\n     python [INST][TUT](TUT)/bin/TUT_1/main_01.py\n     ```\n\n  6. Alternatively, you can also execute the tutorial from the top-level directory (see [INST][]):\n\n     ```bash\n     python [INST][TUT](TUT)/TUT_1_main_01.py\n     ```<jupyter_result>\n  \n# [INST] tutorial: trial-level eligibility\n\n# This tutorial",
        "label": 0
    },
    "151": {
        "output": "# Expected Results\nThe expected results for each patient should be one of the following three:\n\nExamples of patients' records from clinical studies as an output of the clinical trial eligibility assessment\nInclusion criteria of clinical trials are shown as the input. The table will show the number of patients that satisfy the inclusion criteria, including excluded patients by inclusion criteria.\n\nFor instance, the data from the first page of a patient record is shown in . In this case, the patient is suitable for the trial: The numbers \"0\" and \"1\" are \"Excluded\" and \"Not relevant\", respectively, and the number \"2\" is \"Eligible\" based on the clinical trial's inclusion criteria. The patient record is excluded according to a clinical trial's exclusion criteria.\n\nIn cases in which the numbers are not 0, 1, or 2, the criteria for the assessment of eligibility are not clear. In this case, you should check the patient note, which is output using the Clinical Notes for Trial recruitment function of the Clinical Trial Assistant.\n\nExamples of a patient record from clinical studies including the clinical trial exclusion criteria Assessment of Exclusion criteria based on patients. (Page 1 from Patient records with patient note)\nAssessment of Exclusion criteria based on patients. (Page 2 from Patient records with patient note)\n\n# Validation and results\nThe following two clinical trials were run as examples, and a total of three clinical trials were run to validate the function.\nThe clinical trial results (clinical trial eligibility assessment for the clinical trial ID: JCR:JCOG1015) in  Figure\u00a08 (top) were evaluated with the data from the clinical trial. It was determined that 85% accuracy of the clinical trial eligibility assessment had been obtained.\nClinical trial eligibility assessment for the clinical trial ID: JCR:JACCOR5 (bottom) were evaluated with the data from the clinical trial. It was determined that 85% accuracy of the clinical trial eligibility assessment had been obtained.\n\n# Limitations and challenges\nThis clinical trial eligibility assessment, along with the previous tools",
        "label": 2
    },
    "152": {
        "output": "**Coding Explanation:**  This is a flag indicating the final assessment of eligibility. Two possible values are permitted: **Eligible** or **Not eligible**. Eligible means that, based on the patient's data, the patient is eligible for the trial. Not eligible means that, based on the patient's data, the patient is ineligible for the trial. **Required Completion**: Yes\n\n\n####### Eligibility criteria checklist\nTo avoid mistakes, the information below is used for the eligibility criteria consistency check of `patients.csv`.\nIn the checklist, patients are sorted in ascending order to match patients from `patients.csv`.\nFor example, let's see how you can verify that patients of `patients.csv` meet the following trial-level exclusion criteria.\n\n**Ineligible (Disease):** The patient have a concurrent malignancy other than non-melanoma skin cancer. The patient have active or severe autoimmune disease that has required systemic treatment in the past two years.\n\n**Ineligible (Inclusion/Exclusion):** The patient's diagnosis of breast malignant neoplasm includes metastatic cancer.\n**Ineligible (Pathological diagnosis):** The patient is not diagnosed with invasive breast cancer. The patient's maximum tumor diameter must not be greater than 5 cm.\nOther cases are the same.\n<div id=\"markdown-renderer\"></div>\n```python\nEligibility criteria check:\n\n    \"\"\"\n    Check patient eligibility\n    \"\"\"\n    n_patient = len(patients)\n    patients_by_index = np.arange(n_patient)\n    all_ineligible_indexes = []  # Ineligible by trial level\n    all_ineligible_all_patient_indexes = []  # Ineligible by disease level + trial level\n    eligible_patient_indexes = []  # Eligible\n    eligible_all_patients_indexes = set()  # Eligible\n    for patient in patients:\n        eligible = patient['Eligibility'] == 'E",
        "label": 0
    },
    "153": {
        "output": "The following are output samples:\n\n```py\nfor i in range(2):\n    print(f'patient_id  {i},{f\"Patient {patient_id}  is {gender} with {age_group}, {eligbility}\").encode('utf-8').encode('ASCIZ')[:32]\n    print(f'   Trial  {trial_id},{trial_desc}')\n    print(f'   Site     {site_id})')\n    print(f'   Patient -{patient_id},{clinical_trial_number},{age},{gender},{smoke_status},{eligibility},{clinical_trial_number},{trial_desrciption}')\n    print(f'        Clinical Trial Eligibility -{trial_description},{enclosing_trial,clinical_trial_number})'\n```\n\nSee the `docstring` for more details.\n<issue_comment>username_1: Include the `pathologic` feature.\r\n<!-- https://pytorch.org/docs/stable/torch.autograd.html#ref-feature-pathologic. -->\n<issue_comment>username_1: Update example.\n<issue_comment>username_1: [Update](https://github.com/JonghyunSeo/pyradiomics-examples/commits/b48a781000c4d084e5034f99b0084cd6db2ce686)\n<issue_comment>username_0: Great! :)\n<issue_comment>username_1: [Update](https://github.com/JonghyunSeo/pyradiomics-examples/commits/d96e703a43b23213b59078f2186212434d451688)\n<issue_comment>username_1: [Update](https://github.com/JonghyunSeo/pyradiomics-examples/commits/4a2d7d7fdc3d1da9397564b7",
        "label": 1
    },
    "154": {
        "output": "<EOD> FGF9 suppresses bipolar mammary tumor growth and is positively regulated by the AKT-PRAS3 axis\n\nThis is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.AbstractFibroblast growth factor 9 (FGF9) is expressed during mammary development, but its impact on mammary tumorigenesis remains largely unknown. Here we analyzed whether changes in the FGF9 levels during mammary tumorigenesis affect bipolar epithelial/fibroblast-like tumor growth. The results of FGF9 in vitro overexpression and deletion show that FGF9 is expressed by malignant mammary cells and affects their proliferation, colony formation, and invasion. FGF9 secreted by malignant mammary epithelial cells induced the development of bipolar tumors, and its inactivation decreased metastasis in vivo. Mammary tumors that did or did not express FGF9 both exhibited positive nuclear beta-catenin staining in their epithelial cells, indicating that these tumors progressed to the same late-stage. To uncover the mechanisms by which FGF9 modulated tumor malignancy, we evaluated FGF9's levels during the early mammary tumorigenic process induced by AKT activation, and the impact of AKT on FGF9 levels. Analysis of FGF9 expression at different time points over the course of the early tumorigenic process showed that FGF9 levels increased during mammary tumorigenesis by Wnt1 overexpression or AKT activation. The AKT-mediated induction of FGF9 was suppressed by the PI3K inhibitor LY294002 and the PRAS3 inhibitor SKIP7303. Thus, the FGF9 levels are positively regulated by the AKT-PRAS3 axis during tumorigenesis and in mammary tumor progression in vivo. These results indicate that FGF9 is a critical mediator of mamm",
        "label": 2
    },
    "155": {
        "output": "---\n# Code\n\nHere, we provide the code to reproduce our solutions.\nTo implement the code for the exercise, just copy the file in `/exercise` directory of the project and run it with your preferred editor.\nOnce you modify the code to solve the problem yourself, you can add your own changes into the code from `/master` directory and build the project by running `cd exercises && make`\nThe `make` will build the code without modifying it and run the test suite to check for wrongly detected output.\n\nIf you want to do a clean build, just run `make clean` (run make even if there is no file to be built).\n\nThere are additional exercises available in this project like 1-variable, 2-variable, 3-variable and 4-variable.\n<EOD> A Newly Discovered Infection of the Gall Bladder, Which Causes Abscess Formation: (Report of a Patient with a Large Abscess in the Gall Bladder.)\n(Report of a patient with a large abscess in the gall bladder.) G. D., a patient aged 38, complained of severe pain in the right loin in October 1930. He had had a severe attack of acute yellow atrophy, with jaundice, fever and pain in both loins. He was in a serious condition for about two years, with recurring vomiting and constipation, but he got about until January 1932, when severe left loin pain occurred, and on January 22 he was seen in Professor Greig's outpatient department at Belvedere Hospital. He had a severe attack of loin pain at that time, and the abdomen was distended and tender. A swelling was felt in the right loin, extending up to the ribs. He was admitted at that time to the surgical wards of Belvedere Hospital. A diagnosis of a retroperitoneal abscess was made by Dr. Greig, and four weeks later an intercostal artery incision at the second interspace of the right side was performed, but no pus was seen. The patient was under the care of Professor Greig for a further period, and the swelling gradually healed with the formation of a sinus, which remained in the upper part",
        "label": 0
    },
    "156": {
        "output": "# Evaluation and Interpretation\n\n## CORRECT PATIENT/TRIAL INFORMATION ON THE CROSSWALK TABLE\nCrosswalk aids in the decision making process to assign a patient a score 0 or 1. By crosswalking a patients' initial eligibility score, it provides a better interpretation of a patient's score. A patient who is 1a_eligible is more  eligible than a patient who is 1d_ineligible (their eligibility decreases in priority order from 0, 1a to 1b,1c, 1d).\nPatient 0) 1d_excluded [INST] 0) Eligible. 1) Excluded. 2) Eligible. 3) Not applicable.\nThe crosswalk table can also be used to help research teams interpret patient information. The crosswalk provides a better understanding of the factors that have led to the patients' score of `Not eligible` (Score 3). For example, if the assessment of eligibility of Patient 2) Excluded, you would crosswalk a 2b_ineligible to see what criteria led to Patients' exclusion. If Patient 2b_ineligible is then 2b) Excluded, you would search for what criteria led to Patient's exclusion on the exclusion criteria table. If Patient 2b_ineligible was then 2b) Excluded because 2b_ineligible.Exclusion.3_history of other cancer, you would now know that history of other malignancy in the past 5 years excludes a patient from this trial.\n[INST: You need to scroll up to find patient 2b_excluded]\n\n## Patient 2b) excluded\nPatient does not have sufficient information to qualify for the trial: \"History of other cancer in the past 5 years (except Basal cell carcinoma of the skin and carcinoma in situ of the cervix)\".\n\n## Factor 3: other cancer in the past 5 years (except basal cell carcinoma of the\nSkin and Carcinoma in Situ of the cervix)\n\n## EXCL USION",
        "label": 0
    },
    "157": {
        "output": "<EOD> Evaluation and Treatment of Dizziness.\nDizziness is one of the most common reasons for physician appointments and is the cause of a variety of clinical problems with the attendant diagnostic and treatment challenges they pose. Dizziness is defined as self-perceived disequilibrium or disorientation. Dizziness may occur in many different disease states. It is important to determine whether a patient's dizziness is the result of a central nervous system cause or is a peripheral vestibular disorder. Evaluation should focus on the cause of dizziness rather than on the type of dizziness. A systematic approach including the detailed history, physical examination, and complementary tests, combined with a basic knowledge of the vestibular system, should usually be sufficient to arrive at the diagnosis in most cases. This review focuses on the evaluation and treatment of dizziness, with special emphasis on the peripheral vestibular causes.<EOD> Assessment of an electronic case report form (eCRF) as a method to capture and store data in community-based malaria prevalence survey in Zanzibar, Tanzania\nBackground Electronic Case Report Form (eCRF) have received much attention as they have the potential to reduce the cost, workload and response time for collecting disease data. The Zanzibar Malaria Elimination Program (ZAMEP), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Harvard School of Public health, has taken an important first step toward using electronic data collection tools for malaria surveillance in Zanzibar through preliminary development of an electronic data capture tool. This paper describes the system\u2019s development and piloting before using the eCRF for real-time data collection. Methods A mixed methods approach was used to carry out this formative evaluation. Thirty persons participated in focus group discussions and 12 participants were involved in key informant interviews. Additionally, 26 staff were involved in the pilot study. Field workers participated in the study for 8 consecutive days. A semi-structured interview guide based on the five-stage model of technology adoption and diffusion was used. Results Focus group participants were receptive to the idea of using eCRFs to manage the Zanzibar Malaria Elimination Program. Results",
        "label": 0
    },
    "158": {
        "output": "##[OUT]<EOD> Tailoring the size, composition and geometry of silver nanoclusters for enhanced protein kinase inhibition toward cancer therapy\n\n\n\n# Introduction\nSilver nanoparticles (AgNPs) offer potential therapeutic properties in cancer biology due to their anticancer efficacy. Recently, AgNPs have been extensively explored for a number of potential therapeutic applications, owing to their unique chemical, physical, antimicrobial [bib_ref]  Silver nanoparticles: a new view on mechanistic aspects on antimicrobial activity, Dur\u00e1n [/bib_ref]  and bioactive properties [bib_ref]  An insight into antibacterial potential of silver nanoparticles (AgNPs) using surface Plasmon..., Sasidharan [/bib_ref] . AgNPs have been shown to suppress telomerase activity in HeLa cells [bib_ref]  Effect of silver nanoparticles on telomerase activity in HeLa cells and zebrafish, Chen [/bib_ref] . The anti-inflammatory potential of thiolated PEGylated AgNPs in the context of cytotoxicity toward oral squamous cancer cell line (Ca9-22) [bib_ref]  Anti-inflammatory potential of thiolated PEGylated AgNPs on cytotoxicity toward oral squamous cell..., Al-Otibi [/bib_ref]  , and suppression of human colorectal cancer cell growth by AgNPs have been reported [bib_ref]  Suppression of human colorectal cancer cell growth by silver nanoparticles and Ag..., Kumar [/bib_ref] . The anticancer effect of AgNPs has been ascribed to the cellular oxidative damage and mitochondrial dysfunction [bib_ref]  Mechanisms in the anticancer activity of silver nanoparticles, Shamshidari [/bib_ref] . AgNPs have also been reported to reduce colon cancer growth by downregulating NF-\u03baB activation [bib_ref]  Silver nanoparticles inhibited colon cancer cell growth through down regulating NF-\u03baB activation, Zhang [/bib_ref] . Moreover, the anticancer effect of AgNPs has been demonstrated in human lymph cell carcinoma cell line [bib_ref]  Silver nanoparticles induce apoptotic cell death in human lymphocyt",
        "label": 0
    },
    "159": {
        "output": "In the following, we will present a set of rules that helps you make a decision. \n\n## Rule 1\nIf a patient meets an inclusion criterion of the clinical trial, the patient is not incompatible to the clinical trial. \n\n## Rule 2\nIf a patient meets none of the clinical trial's inclusion criteria, then he is not incompatible to the clinical trial. \n\n## Rule 3\nIf a patient matches exactly an exclusion criterion of the clinical trial, then he is incompatible to the clinical trial. \n\n## Rule 4\nIf a patient matches exactly an exclusion criterion of the clinical trial but there are conflicting factors between a patient and the clinical trial, then you should compare the strength of the factors to the exclusion criterion with respect to the clinical trial. In each case this comparison has three possible outcomes:\n- Factor is a sufficient factor to make a patient ineligible;\n- Factor is an insufficient factor not to make a patient ineligible;\n- There is a conflict between a factor and an exclusion criteria. \n\n# Example #1\nConsider the following rule:\n- Infection: This is a contraindication for this clinical trial, but if it is controllable (e.g., with appropriate antibiotic therapy) and does not have any adverse effect on patient condition.\nIn the following we apply the four rules to the assessment task and give a solution for each step.\nStep 1: We check a patient and a clinical trial. \nWe apply Rules 1 and 2 to the above clinical trial. \nWe need to assess a patient's eligibility to the above clinical trial.\nStep 2: We evaluate patient's eligibility to the clinical trial. \nStep 3: We need to find a patient's ineligibility with the clinical trial. \nWe apply Rule 1",
        "label": 0
    },
    "160": {
        "output": "<EOD> Highly regioselective and stereoselective formation of acyclic 2,3-double bonds from alk-2-ynes and alcohols: a tandem gold-NHC-catalyzed oxidative cyclization to benzofuranones.\nOxidative cyclization via gold-NHC catalysis offers an easy route to prepare polyfunctionalized benzofuranones from readily available alk-2-ynes and alcohols. The key step in this reaction sequence is a tandem reaction including a regioselective 1,2-H migration and a stereoselective alkyne insertion into a gold-aryl bond, which allows the rapid, one-pot, synthesis of the title compounds with good to high yields. The benzofuranones produced with this methodology are an important class of compounds and possess a variety of biological properties, as well as utility as building blocks in the preparation of natural products, flavors and materials.<EOD> Preparation and analysis of polyvinylamines by gas chromatogarphy-mass spectrometry.\nPreparation and analysis of the poly-vinylimides by GC-MS were developed. In this method, polyvinylamines were analyzed by an unmodified GC-MS system. As a result, the GC-MS analysis of polyvinylamines was done easily with good sensitivity and reproducibility.<EOD> Inhibitory effect of berenil on adenosine 3':5'-cyclic monophosphate-phosphodiesterase in isolated rat-liver mitochondria.\nThe presence of adenosine 3':5'-cyclic monophosphate-phosphodiesterase in rat liver mitochondria was demonstrated. The effects of berenil on the phosphodiesterase and on oxidative phosphorylation were studied. Inhibition of phosphodiesterase was a marked effect of berenil; oxidative phosphorylation was stimulated to a small extent. The nature of these effects and the potential use of the drug in the study of the metabolic role of cyclic adenosine 3':5'-phosphate in tissue is discussed.<EOD> A systematical review and meta-analysis to assess the association between 4",
        "label": 0
    },
    "161": {
        "output": "<h5><a id=\"problem-8\"></a>Problem<a name=\"problem-8\"></a>\r\nYou cannot decide if the patient meets the inclusion criteria based on the patient note alone. You will need to check patient records to obtain more information.\r\n\r\n```\r\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to check if the patient note for a given patient is sufficient for the clinician team at clinical trial sites to decide if the patient is eligible based on the information provided and the trial's inclusion/exclusion criteria. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of patients for any missing information. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of patients. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of cases in addition to the patient note. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of the patients. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  patient records. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  patient records and the paper records of patients. \n[] SOLUTION:: You are a helpful assistant for clinical trial recruitment. Your task is to use paper records in addition to the patient note. \n``` \n\nThis is a typical example of a problem that can be solved using a solution template. The difference between these problems is that in the first two problems, we did not explicitly mention that a patient may not be eligible due to the trial's inclusion criteria. In the later problems, we used the templates such as ``SOLUTION::`` for explicitly mentioning this. Try this in your training, and then review your answers on Kaggle. You may also refer to the solution examples on Kaggle. \n\n[INST] If the answer for a given problem was \"N\",\"S",
        "label": 2
    },
    "162": {
        "output": "##[EX]\nYou need to specify the value of 'Trial-level eligibility: {0: Excluded, 1: Not relevant, 2: Eligible}.` into 'Trial-level eligibility: The clinical trial title from above is Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy, therefore, you need to match the inclusion criteria:\nUnifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy.\nNeoadjuvant chemotherapy or hormonal therapy for the index tumor is required.\n\nFirst, you need to filter out those that do not match the inclusion criteria:\n- Inclusion Criteria:\n\t- Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy - Neoadjuvant chemotherapy or hormonal therapy for the index tumor is required\n\t\n``` ruby\ndef patient_trial (pnote, trial)\n    note = pnote.note\n    results = Array.new\n    if note\n      results << Trial-level eligibility: 2) Eligible\n      next\n    end\n\n    in_exclusions = [ \"invasive ductal\", \"tumor size >= 2 cm\", \"lobular carcinoma\", \"multifocal\", \"multicentric\", \"calcification\", \"ductal carcinoma in situ\", \"index tumour\" ]\n    trial_criteria = \n      (trial['Inclusion Criteria'].map{ |criterion| criterion.scan(/((.*)??)#(.*)/).each {|w| \"#{w[0].upcase}\" }.to_s.chomp }).collect.compact\n\n    # Note here, 'pnote' is the patient record\n    exclusion_conditions = Exclusion_conditions.new(note)\n    exclusion_conditions.exclude_inclusions_if_relevant( in_exclusions + [note].flatten )\n    exclusion_conditions.trial_exclusions = trial['Exclusion Criteria'].to_s.split(/\\s?and\\s?/).flatten\n\n    criterion",
        "label": 2
    },
    "163": {
        "output": "[INST] A trial summary contains information about a trial such as trial identifier, location, status, number of subjects enrolled, and start and end dates.\n\nInclusion criteria have a three-point scale: 0) Excluded; 1) Not eligible (patient meets inclusion criteria, but is not eligible on the grounds of the trial's exclusion criteria); and 2) Eligible (patient meets the inclusion criteria and exclusion criteria do not apply). The following rules apply.\n\n\n10.1\nTrial-level Eligibility\n\n> The number of participants < 30 is currently registered in a trial.\n\n> The number of participants < 40 is currently registered in a trial.\n\n> The number of participants < 50 is currently registered in a trial.\n\n> The number of participants < 60 is currently registered in a trial.\n\n\n\n[INST] You should always repeat `Trial-level eligibility ` in the last line by `Output: `, e.g., `Output: .` \n\n[INST] On some trials, you may encounter patients whose gender doesn't match the inclusion criteria (for example, female patients who have received male hormones, or a man who has undergone chemotherapy and endocrine therapy while being pre-operated for breast cancer). To avoid mistakes, just fill in the output statement using the following rule:\n\n```\n\n> The trial may not include female patients.\n\n```python\nINST > output  = 2 # Eligible\nINST > output  = 'Excluded' # Excluded\n\n```\n\n[INST] In some trials, there may be patients with previous cancer history in different sites other than breast cancer. To avoid mistakes, just fill in the output statement using the following rule:\n\n```\n\n> Patient has previous cancer history, but not breast cancer history.\nINST > output  = 2 # Eligible\nINST > output  = 'Excluded' # Excluded\nINST > output  = 'Not Eligible' # Not eligible \n\n```\n\n[INST] On some trials, the trial-level eligibility can be the same on the same patient. For example, some trials will accept male patients with breast cancer while other tri",
        "label": 0
    },
    "164": {
        "output": "We recommend you to test and debug your code on your own machine. The output of `sage-notebook` may depend on local installations of certain packages.\n\n**Critical Comments**\n\nIf you submit a pull request, consider making the comments more explicit. In particular, it is important to indicate in the function names how you would like SageMath to behave in the evaluation of user-provided parameters.\n<EOD> Gynostemma pentaphyllum (Thunb.) Makino ex Hara Extracts Protect Against Osteoclasts-Induced Bone Resorption Via Suppression of NF-\u03baB and AP-1 Signaling in Rats\n\nGynostemma pentaphyllum (Thunb.) Makino (GPM) is a widely recognized herbal medicine. Previously, GPM extracts were confirmed to have a beneficial effect on bone metabolism, but it is unclear whether they can alleviate bone mass loss and bone turnover in OVX rats. In this paper, we aimed to test whether GPM extracts can protect against osteoporosis. Ovariectomy was performed in Wistar rats as an animal model of osteoporosis, then ovariectomized rats were treated perorally with 500 mg/kg/day of different parts of GPM extracts, or 10 mg/kg/day of alendronate. Six weeks later, an increase in bone turnover by the elevation of TRAP-5b and CTX-1 was observed after OVX along with a reduction in bone mineral density, compared with normal rats (P < 0.05). However, the extracts of GPM could significantly increase the bone mineral density in OVX rats treated with high-and middle-dose extracts, which also decreased TRAP-5b and CTX-1 levels compared with OVX rats (P < 0.05). Osteoclast differentiation was suppressed by GPM extracts at both the gene and protein levels. Furthermore, it may be the decrease in levels of NF-\u03baB, iNOS, and COX-2, mediated MAPKs signaling pathway that were",
        "label": 0
    },
    "165": {
        "output": "# Results\n<EOD> Synthesis, crystal structure, and antiproliferative activity of novel silver(I) compounds with biologically relevant ligands\n\nMetal complexes of biological relevance have been identified as promising cancer chemotherapy drugs. Among these, compounds derived from pteridines (such as folic acid) and from pyridines (such as procaine) are known to possess significant antiproliferative properties. In this study, the antiproliferative activity of silver(I) complexes of the natural pteridine folic acid and of procaine and its methyl analogue have been investigated. To this purpose, new silver(I) coordination compounds have been prepared and characterized by elemental analyses, IR and electronic spectroscopies, and single-crystal X-ray diffraction techniques. Several derivatives of folic acid and procaine have been synthesized, and the corresponding metal complexes have been prepared. The cytotoxic profile of all compounds has been investigated in a panel of four human cancer cell lines and two human normal fibroblast cells, by means of an MTT-based cell viability assay. The results obtained showed that most of these compounds possess selective antiproliferative activity. The cytotoxic mechanism has been investigated by flow cytometry, and apoptotic effects have been proved to occur for the compounds demonstrating the highest antiproliferative activity.\n\n# Introduction\nCancer is a major cause of death all over the world and, according to WHO predictions, its number of fatalities will increase from 13 million worldwide registered cases of cancer in 2015 to 26 million in 2050. The treatment of this disease is very expensive and leads to serious side effects on organs and tissues that severely affect the quality of life of patients.\nSince 1960's, researchers' efforts have been focused on the identification and development of metal compounds possessing antiproliferative properties. In particular, cisplatin, as well as some derivatives, such as carboplatin and oxaliplatin, are clinically used as chemotherapeutic agents. Their cytotoxic activity is mainly based on the ability to form DNA adduct",
        "label": 0
    },
    "166": {
        "output": "You should have your code saved. Now type in console:\n\n`python c5.py 2`\n\n![![Installation](https://github.com/junsuk2108/C5/files/w1172/installation.jpeg)](https://github.com/junsuk2108/C5/files/w1172/installation.jpeg)Click the ![Installation](https://github.com/junsuk2108/C5/files/w1172/installation.jpeg) button and install C5 at first time.`You should have found a new folder named `C5_install``.\n\n[![Installation](https://github.com/junsuk2108/C5/files/w1521/installation.jpeg)](https://github.com/junsuk2108/C5/files/w1521/installation.jpeg)Click the ![Installation](https://github.com/junsuk2108/C5/files/w1521/installation.jpeg) button and install C5 on an update.\n\n\n### <a id=\"q1\"></a> Question  \n\n\nYour code is shown below:\nC5_trial.py\n\n```python\n#!/usr/bin/python3\n# encoding=utf-8\nimport sys\nimport argparse\nimport copy\nimport csv\nimport json\nimport re\nimport os\n\nimport pandas as pd\nfrom os import path\nfrom pathlib import Path\nfrom numpy.matrix import null\nfrom re import sub\nfrom typing import List\n\nfrom common.path_util import FilePathUtil\nfrom common.path_util import PathUtil\nfrom common import PathUtil\n```  \n\nThe list below shows 4 patients whose data are missing in one formulation in the `trial_data_v4.csv`. We need to make sure none of these information is missing:\n\n| Name | Age | Gender | Status  | Chemotherapy| Radiation | Disease Type | Staging | Bone Met | Liver Met | Bone Marr | BRAFV600E | Subtype | Hb_level | R",
        "label": 0
    },
    "167": {
        "output": "[fig]  [: IMPLEMENT] You may define your own method name to calculate trial-specific eligibility for comparison, i.e., class_to_eligible(patient_note, trial). To define a method name with another name, such as eligible_predicate(patient_note, trial), you may write eval(trial) + \"Eligibility: \" + eligible_predicate(patient_note, trial) + \" \" + eval(patient_note) where eligible_predicate(patient_note, trial) = eligible_predicate(patient_note, trial) + eligible_predicate(patient_note, trial). To define two methods with different names, i.e., eligible_predicate(patient_note, trial, \"method 1\") and eligible_predicate(patient_note, trial, \"method 2\"), you may write [\"method 1\"; eval(trial) + \" 1) Eligible\"; eval(patient_note) + \"]; [\"method 2\"; eval(trial) + \" 2) Excluded\"; eval(patient_note) + \"] eval(patient_note)), eval(trial)) = eligible_predicate(patient_note, trial)) [/fig] \n<EOD> Genetic analysis in patients with diabetes mellitus undergoing kidney transplantation for end-stage renal disease\nThe aim of this study is to determine the prevalence and role of diabetes mellitus-related gene polymorphisms in patients with end-stage renal disease (ESRD) as a result of type I diabetes mellitus (T1DM) or type II diabetes mellitus (T2DM). We performed a genetic analysis of 285 patients with ESRD undergoing kidney transplantation. Polymorphisms for the A3855G, T-9C, +32A>C, +616C>G, -493G>T, and -23H>T polymorphisms of the peroxisome proliferator-activated receptor-\u03b3 (PPARG) gene, and the Hae III polymorphism of the un",
        "label": 0
    },
    "168": {
        "output": "##\n<EOD> Transiently Evoked Otoacoustic Emissions: Correlational and Longitudinal Data\nIn this issue, Kurioka and colleagues (2014) report correlations and longitudinal relations between cognitive level and transiently evoked otoacoustic emissions (TEOAEs) in early infancy. Their article is important in many ways. Their results on correlation and longitudinal relations between TEOAEs and language and cognitive level contribute to the developing evidence that OAEs may be a clinically useful indicator of auditory development and of sensitivity to hearing experience. However, their article is also important in highlighting methodological issues about how to evaluate transiently induced, and more generally, stimulus-free, otoacoustic emissions (IAOE) and about the problems of multiple testing that arise when making evaluations of the predictive ability of any measure. In this section, we review the methodological issues raised by the article and suggest some avenues for future research that might address some of these problems.<EOD> A single-item self-report measure of social connection.\nThe COVID-19 pandemic has highlighted the critical importance of social connection in health and well-being. Because the assessment of social connection can occur quickly and efficiently, it is a valuable tool for use across the biopsychosocial spectrum of health. One measure developed in the early 2000's-the Social Connection Scale (SCS) - has stood the test of time and has a strong evidence base for assessing social connection in both research and clinical settings (Mohr, Rose, & Lejuez, 2009). One major advantage of the SCS is that it can be included as a self-report measure in assessment packages to improve efficiency in both research and clinical practice. In a recent revision of the SCS published in International Psychogeriatrics in 2022, the single-item social connection scale (SISCS) was described as a derivative of the single-item General Assessment of Functioning (GAF) that has also been used to provide a global assessment of a client's functioning. However, because the SISCS has not been investigated by scholars to date, we undertook a review that included the 1936 publications that cited the S",
        "label": 0
    },
    "169": {
        "output": "<EOD> The relationship between lifestyle factors and diabetic retinopathy.\nBACKGROUND AND PURPOSE\nThe relationship between diet, exercise, obesity, and duration of diabetes (duration D) with diabetic retinopathy (DR) has not been well studied. The purpose was to examine the relationship between lifestyle factors and DR.\n\n\nMETHODS\nEligible patients were > 40 years of age and had type 2 diabetes mellitus and DR determined by dilated examination by the same ophthalmologist. Lifestyle data included self-reported smoking (cigarette pack-years smoked  or = 30%). Patients were then classified into four 2 x 2 x 2 groups, based on TD, DX, and TI. Lifestyle data was obtained from a self-administered survey questionnaire.\n\n\nRESULTS\nDemographic information and DR severity did not vary significantly by smoking status. Patients in the highest quartile of TD (D > 3.67 years) had a higher frequency of DR, as did patients in all nonoverlapping TI groups versus patients in Group 2 (D > 3.67 and TIs > 25th percentile for that group). Patients in all nonoverlapping DX groups versus patients in Group 3 (D > 3.67 and DXs > 25th percentile for that group) and patients in the extreme TD (TD > or = 10 years) had a higher frequency of DR.\n\n\nCONCLUSIONS\nD and DX are more highly correlated to frequency of DR than TI for diet and exercise separately, and the three appear to be correlated to frequency of DR after adjusting for duration D.<EOD> Effects of the anti\u2010inflammatory treatment with cortisol and met\u2010enkephalin on experimental ischemic cerebral necrosis\nThe effects of a long\u2010acting anti\u2010inflammatory agent, cortisol, and a synthetic opiate\u2010like peptide, Met\u2010enkephalin, on brain edema and ischemic necrosis were examined in mongrel dogs after",
        "label": 0
    },
    "170": {
        "output": "## 2. You should check whether the patient note and trial are matched by clinical note matching.\nMatching procedure:\n1) Open the matching page.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match_example.png\" width=\"100%\" />\n2) Choose patients' case in the list.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match.png\" width=\"100%\">\n3) Select trial's clinical trial from the drop-down box.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match_text_trial.png\" width=\"100%\"/>\n4) Click button.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match_button.png\" width=\"100%\"/>\nAfter you click the button, the matching box window should be closed automatically.\nThe matching box shows the clinical trial (in this example, trial ID: NCT04334658), the eligibility results, and patient demographic information of the matched patient. The eligibility result is determined by whether there is any patient information in the patient note, which is not registered in the clinical trial. You will get a message \"No match result found. Please refer to the documentation at https://aiportal.ncl.ac.uk/documentation-match_clinical_notes#no-information\".\n\n## Matching page\nMatching result page should be like this\n\n### **Information for the user who wants to add a note**\n\n### Step 1: Create a new note\n\n\n\n\nA click on the button \u201cCreate a new clinical note\u201d will start a new interface for clinical note creation.\n\n### **Step 2: Filling Note**\nWhen started, the interface will give an overview on current trial and a list of the patient records for the clinical note assignment",
        "label": 1
    },
    "171": {
        "output": "---\n# Step 2. \n\n[INST]. `\n\nNow let's analyze some of the conditions of Figs. 1 and 2.\n\n[INST]. `If a patient is sexually active and does not use contraceptives: ``If a patient is sexually active and does not use contraceptives: \n\n[INST]. ` If a patient has reached menopause or is using an estrogen replacement therapy: `\n\n[INST]. ```Patients aged over 18 years old with invasive breast cancer with an indication of SN procedure as recommended by Saint-Paul de VENCE in 2005 amended in 2009.``\n\n[INST]. ```T1-2 breast cancer.```\n\n[INST]. ```Patients having social security coverage.```\n\n[INST]. ```Patient who underwent surgery and adjuvant treatment:``\n[INST]. ```Metastatic sentinel lymph node only.```\n\n[INST]. ```Patients aged between 37 and 50 years old.``\n\n[INST]. ```With breast cancer size < 2.0 cm.``\n\n[INST]. ```No axillary lymphadenopathy.`` `\n\nIn this example, we have created the eligibility of a clinical trial with five pieces of patient's data, i.e. 0 Excluded, `2)` Not relevant, and `2)` Eligible. The eligibility results are shown in the last line using the `trial-level eligibility` command. \n\n## MANIPULATING ELIGIBILITY\nIn Figs. 1 and 2, the eligibility of a clinical trial can be manipulated by changing the data values. For example, instead of 0 Excluded, we can use 1 Excluded, or 2 Eligible. For each eligibility, we define the rules with the `eligibility` command. For each patient note, we examine the `eligibility rules` and decide the eligibility with the `trial-level eligibility` command.\n\n### PERMISSION AND WITHDRAWAL. \n\nHere is data for `Permission and",
        "label": 0
    },
    "172": {
        "output": "## Input data\nEach case corresponds to a patient note. The input data is stored in columns with names \"FirstName\", \"LastName\", \"Age\", \"Gender\", and \"Human-readable-ID\". You can modify them to \"Name\", \"Age\", \"Female\", \"Male\", and \"id\" of your choice.\nFurthermore, in the variable \"Notes\", each line corresponds to a patient note in the patient note file. Please keep the file structure as you received it. \n\n### Examples of patient notes:\n[INST] Hello. This is the second line of input data, corresponding to the [2] patient. \n[END INST]\nFor the input data you can use these values to make a better demonstration.\n[INST] Exclusion criteria:\n\n### 1) Metastatic disease: (mets)\n\n### \n[END INST]\n\n\n# [RUN]\n[INST] Your task is to make a trial-level eligibility on each patient. You must make a trial-level eligibility 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) or \n<EOD> Pterins from 3C protease interact with the catalytic cavity of severe acute respiratory syndrome coronavirus 2.\nThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3C-like protease (3CLpro) is a coronavirus protease with potential as a viral drug target. We report a pharmacophore-based database search for 3CLpro inhibitors from a collection of >2 million compounds, which is the largest known set of bioactivity data for drug screening. By using computational docking, ligand pose alignment and compound purchase, eight compounds were obtained for 3CLpro inhibition assays, which confirmed that three pterins (i.e., neodymium, molybdenum and praseodymium) showed significant inhibition of SARS-CoV-2 3CLpro. These pterins were also found to displace an antibody inhibitor from the 3CLpro catalytic cavity,",
        "label": 1
    },
    "173": {
        "output": "# Testing\n\n[INST] Before we start testing, I recommend having a coffee break and returning after 2 minutes to finish all the tests quickly and accurately. We would test our code using the 'Tested (by <NAME>)' label [12] on the right-hand side of your screen. Here are the steps \n- Click Test in the left-hand menu;\n- Click on the file labelled, 'BiomedicalNLP/test/sample_data';\n- Find the 'test_eligibility.ipynb' notebook on the list of available notebooks \n    - We need a notebook called 'test_eligibility.ipynb' and it should be located in the folder named 'notebooks'. \n    - Check the 'test_eligibility.ipynb' on the right-hand screen. It contains 6 lines:\n        - __init__.py:\n            - It is not needed in this notebook.\n        - train_data.py:\n            - This file contains information about the training data. All necessary training parameters are set here.\n        - train_model.py:\n            - This file contains model training details. The network parameters are saved in the h5 file named 'cnn_model_90.h5'.\n        - load_model.py:\n            - It loads the model to use and defines the data needed in the tests.\n        - eligibility.py:\n            - Here the actual testing code is defined. \n    \n    - In this notebook we prepare the training and testing data as inputs for our model. \n\n    - Open 'test_eligibility.ipynb' on your desktop, and start up Spyder.\n    - Find the 'test_eligibility.ipynb' notebook under the 'IPython Notebook' folder in the left-hand side of the screen (green rectangle) \n        - Click on the file labelled, 'test_eligibility.ipynb' notebook on the top left screen.\n    - Click 'run all' in the top left-hand corner (yellow line) \n - On the results screen, choose the result to save or export by using the following options:\n    - When saving results, select 'save all as .ipynb",
        "label": 0
    },
    "174": {
        "output": "Good luck![[FLEXIBLE-MAZE-BOTTLE]]:[REF]~\n\n# Example of solution\n\n### Input :\n`Trials input: \"Breast Cancer Registry in Thailand Title: Breast Cancer Registry in Thailand Summary: Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer related death in women in many parts of the world. Breast cancer also occurs in men, accounting for nearly 1% of the total incidence. As a result of continuing research into new treatment methods, women and men with breast cancer now have more treatment options, and a better chance of long-term survival than ever before. The primary treatment for breast cancer is surgery. Early stage breast cancer, defined for the purposes of this registry as newly diagnosed, clinical stage I to IV breast cancer with no prior therapy for current disease, is often curable with surgery alone. Reports from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the European Organization for Research and Treatment of Cancer (EORTC) longitudinal trials have explored the efficacy of various surgical techniques as primary treatment of early stage breast cancer1-7. These studies include 20 years of follow-up data that have not shown any significant differences in overall survival or in rates of distant recurrences in women who underwent breast-conserving surgery with radiation therapy versus those who underwent mastectomy. The results of these studies have supported the use of surgery as the standard breast cancer treatment practice around the world.~Data have shown that regardless of the surgical procedure selected for the removal of the primary tumor, micrometastases may be present and lead to the development of disease relapse. In order to decrease the risk of recurrence, patients may receive various therapies. Systemic treatments include chemotherapy and hormonal therapy. Local treatment, such as radiotherapy, can also be used to eliminate malignant cells that remain in the breast, chest wall, or lymph nodes after surgery.\n~The selection of systemic therapy is a complex process, which is based partly on prognostic factors such as lymph node status, and predictive factors such as hormone",
        "label": 2
    },
    "175": {
        "output": "Good luck, [INST]).\nWe wish you all good luck solving your problem and a healthy and happy life for everyone!\n<EOD> A phase II study of docetaxel in combination with capecitabine in patients with metastatic mammary or adenocarcinoma of the stomach or colon.\nPURPOSE\nTo assess the toxicity and the response to docetaxel (D) in combination with capecitabine (C) in patients with advanced cancer.\n\n\nPATIENTS AND METHODS\nPatients with progressive measurable adeno or mammary cancer were treated on an 8-week cycle alternating with chemotherapy (C) and capecitabine (D100 mg/m(2)/d for 14 days), followed by a rest week (RW; D + C). This cycle was repeated every seven weeks. During the first two cycles, patients were evaluated for possible side effects. Response to treatment was assessed every two cycles and evaluated by the WHO toxicity criteria (WHO-TC). All toxicities experienced during the first two cycles were recorded on case report forms and classified according to the Cancer Therapy Evaluation Program (CTEP) system. The patients received continuous oral capecitabine (600 mg/m(2)/d) with meals on days 0 to 14 of a 21-day cycle for the duration of the study.\n\n\nRESULTS\nFrom March 1999 to August 2001, 47 patients (22 males and 25 females) were treated in four institutions. The median age was 66 years. Previously treated patients had undergone a total of six cycles of chemotherapy (range, 1-5), whereas previously untreated patients had not been exposed to chemotherapy. All patients were evaluated at baseline as being in poor condition (WHO performance status > or = 2). Seventy-five percent of the patients were unable to complete at least nine cycles of treatment due to unacceptable toxicity (69%) or progressive disease (6%). The dose-limiting toxicity was grade 3 neurological toxicity, reported in seven patients (15%). Grade 3",
        "label": 0
    },
    "176": {
        "output": "##[/DATA/PATIENT]\nYou are finished with the patient. The next entry is a new patient. The patient-level assessment includes all the features of a patient, not just the eligibility status of a clinical trial.<EOD> The use of mammography to improve the detection of metastatic axillary lymph nodes in breast cancer: the initial experience in a Canadian community practice.\nThe addition of mammography during initial assessment of axillary lymph nodes in patients with metastatic breast cancer to stage III or greater may have a beneficial effect on staging and treatment in terms of eliminating uninvolved axillae before mastectomy or eliminating involved axillae from sentinel node dissection and, therefore, axillary node dissection. The authors discuss the use of this modality in a family practice during the initial experience and illustrate that it is feasible to use the modality in the community setting.<EOD> Antinociceptive effect of subcutaneous administration of paracetamol in ponies.\nEffects of subcutaneous injections of paracetamol were examined using an arthrosclerosis test in 2 ponies. Paracetamol caused significant dose-related anti-nociceptive effect, which lasted about 3 hours. The results suggest that the drug could be an alternative to glucocorticoids for intra-articular injection of horses with chronic arthrosclerosis. The effects on joint function are promising.<EOD> Assessment of the Impact of COVID-Associated Multisystem Inflammatory Syndrome in Children in Pediatric Dentistry in Istanbul.\nAIM\nMultisystem inflammatory syndrome associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has emerged as a new entity reported in relation to SARS-CoV2 infection, including the dental literature. This case series investigated COVID-associated multisystem inflammatory syndrome in children (MIS-C) in 2021 in two Turkish tertiary hospitals in Istanbul.\n\n\nSTUDY DESIGN\nThe study included 28 patients and 34 controls, with an average age",
        "label": 0
    },
    "177": {
        "output": "[CODELIST=Trial-level eligibility: 2) Eligible]\n[VALUE=1]\n[TRIAL=Trial-7(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n[VALUE=2]\n[TRIAL=Trial-8(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n[VALUE=3]\n[TRIAL=Trial-9(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n[VALUE=3]\n[TRIAL=Trial-10(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n<EOD> Enhanced cisplatin-induced apoptosis of non-small cell lung carcinoma cells by the activation of PKB/Akt.\nCell survival and chemoresistance of lung cancer is closely associated with deregulated apoptosis, and survival and growth are regulated by phosphoinositol-3 kinase-mediated Akt signaling. The aim of this study was to understand the role of Akt in resistance to cytotoxic agents. Stable, H-269 cell clones with overexpressed Akt were generated from A549 cell lines with Akt siRNA-mediated knockdown. We found that cells with overexpressed Akt in H-269 were more sensitive to cisplatin, whereas H-269 knockdown cells were more resistant to cisplatin. Interestingly, cells with overexpressed Akt exhibited more apoptotic and DNA-damaged responses than control cells. We also observed that apoptosis-related proteins such as caspase-3, 7, and 9 were cleaved in these Akt overexpressed cells upon cisplatin treatment, whereas Akt knockdown cells exhibited lower sensitivity to cisplatin-induced apoptosis. Although overexpressed Akt enhanced",
        "label": 2
    },
    "178": {
        "output": "##### P1. Patient.\n`patient = PatientNote2[36:117822].`\n\n##### P2. Trial.\n`trail = Trial2[36:42187].`\n\n**Examples: [demo-rmd02_data]** `rmd02_data = trialmatch(patient_list = pd.read_csv(pd.\nto_json(\"patients.tsv\"), na_values=\"\"); trial_list = pd.read_csv(pd.to_json(\"trials.tsv\"),\nna_values=\"\")); test_results = rmd02_main(\"rmd02_rmd_rmd_rmd\"); output = list(r[\"rmd02_results\"]) for i in r[\"rmd02_results\"]: print(i) r.rmd02_results[i][\"Trial-level eligibility\"] = 2` **Input:**\n\n```csv\npatient_list, trial_list\nPatients and Trials in the format of `name | age | gender | ...`\n```\n\noutput:\n\n```json\n{\n  \"rmd02_results\": [{\n    \"rmd02_rmd_rmd_rmd\": {\n      \"Trial-level eligibility\": \"Not relevant\",\n      \"patient_id\": \"0001 | PAT_1 | M | 46 | 46\",\n      \"patient\": {\n        \"Age\": \"46\",\n        \"Gender\": \"M\",\n        ... }\n    } \n}]}}\n```\n\n\n\n\n[INST]\n\n### Clinical Outcomes\n### -----------------------\n\n#### -------------------------\n\nHere is",
        "label": 0
    },
    "179": {
        "output": "## Exam score\nGood luck!\n\n<EOD> Dual Functions of Bile Acids and Their Rapid Metabolism in Pro-/Anti-Inflammatory Responses Mediated by CD36 and Toll-Like Receptor 2\n\nChronic inflammation induced by the bile acids (BAs) is considered to be related to the pathogenesis of metabolic syndrome, atherosclerosis, and liver diseases; however, the pathology of BA-induced inflammation is largely unknown. In the present study, we revealed that LCA (i.e., lithocholic acid), a secondary BA, induces the release of inflammatory cytokines directly from adipose and hepatic cells by acting on the Toll-like receptor 2 (TLR2) and CD36 as a pattern recognition receptor. Meanwhile, the antiinflammatory cytokine, IL-4, was induced by LCA in macrophages and adipose cells through a CD36-independent process. The induction of TLR2 was also observed in the LCA-treated macrophages and adipose tissues. However, the direct application of LCA to macrophages and adipose tissues did not induce anti-inflammatory responses or expression of TLR2 and, therefore, seems to be dependent on autocrine or paracrine factors. Furthermore, LCA-induced IL-4 secretion was inhibited by the TLR2",
        "label": 0
    },
    "180": {
        "output": "## 1.\n2022-07-14 10:28:41\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\n\n## The contents of dying tumor cells can be detected in the bloodstream, and this may be enhanced by the leaky vasculature of solid tumors. protein biomarkers of tumor cell death are difficult to detect due to the complex nature of plasma and the lack of technical sensitivity. in contrast, dna is easier to detect through polymerase chain reaction (pcr). indeed, circulating tumor dna has been detected in plasma from patients with osteosarcoma, breast cancer, and colorectal cancer.[/emphasis?][INST]\nThe investigators should consider the above statement and answer Question 1.\n\n## Question 1\n\n## [emphasis?]\nThe investigators should consider the above statement and answer Question 2.\n\n## Question 2\n\n## The patient's mammogram reveals microcalcifications in the left breast. a breast mri reveals a suspicious enhancing mass behind the pectoralis muscle (figures a and b). a breast biopsy confirms the diagnosis of invasive ductal carcinoma with extensive intraluminal hemorrhage and necrosis. the tumor cell",
        "label": 2
    },
    "181": {
        "output": "[/GENERAL CODE] \n<EOD> SARS-CoV-2-related myocarditis in an 82-year-old man\n\nMyocarditis is usually a very rare cause in the overall number of individuals with heart failure not only in a low-volume center like the city of Naples, but also in high-volume centers like Pomezia (for example 0.24% for male versus 0.32% for female in a cohort study about clinicopathology of myocarditis from 2000 to 2019 at Pomezia hospital.). [5] However, an increase in new cases of myocarditis caused by SARS-CoV-2 has been recently described, with a predominance of men. [6][7][8] In the above-mentioned case, no other etiology of myocarditis that could worsen symptoms, especially cardiac magnetic resonance and inflammatory markers (such as erythrocyte sedimentation rate and C-reactive protein) at 2 months before admitting was analyzed, which means that it was a completely new diagnosis.A 41-years old man with body mass index of 30 kg/m 2 , treated for schizophrenia and substance abuse underwent transient ischemic attack with mild left-sided weakness which required antiaggregant therapy and aspirin. He was completely re-educated on his eating habits. He was a nonsmoker had no physical risk factors. He was referred to a cardiologist to evaluate an echocardiography diagnosed dysfunctional mitral valve, which after two years of unsuccessful repair by surgery required another procedure without the possibility of a satisfactory outcome. After that intervention, the patient reported asthenia and deterioration in his quality of life, with a significant worsening of his cognitive function. The neurological evaluation at this time diagnosed a diagnosis of moderate dementia. Then, after 2 months, the patient developed fever and myalgia. The pharyngeal swab test found SARS-CoV-2. In spite of the negative serology for myocarditis, my",
        "label": 2
    },
    "182": {
        "output": "In this exercise, we will work on the patient note. However you can practice with the clinical trial.\n\n---Clarifications on the 0-no information-option:\n\n> Option '0' \n(0) Excluded. This response is the result of the patient's note not meeting the inclusion criteria.\n\n> Option '1'\n(1) Not eligible. This response means that the clinical trial has no inclusion criteria that apply to this patient.\n\n> Option '*'. \n(1) Excluded/not eligible. This response means that the clinical trial's inclusion criteria are not met by this patient.\n\n> For example, if it is not mentioned in a patient note that HER2 status is available for a HER2-positive clinical trial, the information on HER2 status is missing and option '1' is the correct response. It is possible to use option '2' even if only one inclusion criterion is reported to be missing (e.g., lack of information of HER2-status).\n\n---Explanations ---\n\n> `1` <small>\n> ****0<small> . This response means that the clinical trial is not relevant for this patient. \n > <small>It means the patient note does not provide all the information requested for the trial \n > <small>(Examples: no tumor grade available, no HER-2 status, no date of surgery). A clinical trial can only include patients who satisfy all inclusion criteria and exclusion criteria.\n > <small>You should apply the same rule to all clinical trials that were created for the simulation.\n > <small>(Examples: no HER2 status available for a HER2-positive clinical trial, date of surgery is missing for a trial not requiring immediate surgery)\n > <small>\n> ****2 <small>\n> ****2 <small>\n> Exclusion criteria are the criteria by which a patient is not eligible, despite their inclusion criteria being met.\n > <small>For example, in the above mentioned breast cancer trial, a HER2-positive patient cannot participate because they have already started the treatment; the patient is undergoing a second surgery, in which case trial-entry might interfere with the surgery.",
        "label": 2
    },
    "183": {
        "output": "[A]: Eligibility Criteria\n<html><title>Eligibiity Criteria </title><meta name=\"description\" content=\"Instructions for how to create a sample data set for the eligibility criteria problem.\"/><head><link href=\"eligibility.css\" rel=\"stylesheet\" /></head>\r\n<body><h1>Clinical Trial Recruitment</h1>\r\n<hr>\r\n<p>You are a helpful assistant for clinical trial recruitment.\r\nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\r\nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\r\n</p>\r\n<p>\r\nThere will be no practice problem.\r\n</p>\r\n<p>\r\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).  \r\n</p>\r\n<p>\r\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \r\n</p>\r\n<p>\r\nHere is the patient note:\r\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy",
        "label": 0
    },
    "184": {
        "output": "[SELF-EVALUATION] \nHow was your performance? Try to answer these questions and evaluate yourself. (This is for your internal reflection and should not be sent to us.)\n\n[/SELF-EVALUATION]\n\n[DOWNLOAD] \nDownload this task's evaluation sheet: [DOWNLOAD] \n\n---\n\n## \u2714 Q19 -What do you think are the limitations of the CTFN algorithm with respect to the clinical applicability?\n\nIn general, I think the current research and development of the current CTFN clinical algorithm and software can significantly improve the clinical decision-making process with respect to clinical trials. Especially from the perspective of the improvement, of the trial-based clinical development and the patient-based clinical development. \n[DOWNLOAD] \n\n---\n\n# <NAME>: AI-based patient eligibility solution for clinical trials by RNN deep learning, 2019\n\n## \u2714 Q20 -Provide your overall suggestions on this research\n\n[/DOWNLOAD]\n\n## \u2714 Q21 -What are the most common obstacles you encountered in this case study?\n\nOne of the barriers found in the case study is the availability of the data. In this case study, it was found that most of the relevant data for clinical trials is usually on paper, which makes it difficult to manage, let alone organize and to make the algorithm run well. \nThe next obstacle is the difficulty in running the data. Some of the data found was very complicated in some way and to make the algorithm to work the data must be structured, making it a kind of challenge to the algorithm to work, so the implementation of data standardization for the clinical trial to make the algorithm work easier. \nThe next barrier was the challenge in finding all the necessary information from the documents related to clinical trials. This is due to the limited access to some information in clinical trials, so sometimes it makes it difficult to predict the trial-level eligibility in the case study. \nFinally, I think the barrier I met was a gap in data sources, especially in this era of digital transformation. \n[/DOWNLOAD]\n\n## \u2714 Q22 -What are the",
        "label": 0
    },
    "185": {
        "output": "[![IMAGE ALT]({{site.data.file_paths.learning_paths.advanced_python_labs/01_python_basics/book/fig/fig-1.7.png \"title:figure-1.7\")]]({{site.data.file_paths.learning_paths.advanced_python_labs/01_python_basics/book/fig/fig-1.7.png \"link:fig-1.7\"})}\n\n\n<br>\n\n\n----------------------------------------------------------------------------------------------------------------------------------------\n<br>\nHere is the patient's eligibility status for this trial:\n<br>\n \n````python\nprint(\"Patient\" + str(i) + ': ', patients[i][\"trial-level eligibility\"])\n````\n\n----------------------------------------------------------------------------------------------------------------------------------------\n<br>\n\n\nOutput:\n<br>\n \n````\n\nOutput:\n     ClinicalTrials.Patient 0: 1\n    ClinicalTrials.Patient 0: 1\n    ClinicalTrials.Patient 1: 2\n    ...\n    ClinicalTrials.Patient 16: 1\n    ClinicalTrials.Patient 16: 2\n    ClinicalTrials.Patient 17: 1\n       ...\n    ClinicalTrials.Patient 88: 1\n       ...\n    ClinicalTrials.Patient 155: 1\n      ...\n    ClinicalTrials.Patient 188: 1\n      ...\n    ClinicalTrials.Patient 207: 2\n    ...\n    ClinicalTrials.Patient 229: 1\n     ...\n    ...\n    ...\n    ...\n     ClinicalTrials.Patient 281: 1\n     ...\n    ...\n    ...\n    ...\n    ...\n    ...\n    ...\n    ...\n     ClinicalTrials.Patient 293: 0\n    ...\n     ...\n    ClinicalTrials.Patient 294: 0",
        "label": 0
    },
    "186": {
        "output": "# Discussion\n\n##[inst] \nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy. \nHere is the clinical trial: \nTitle: 4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer\n\n\nSummary: The Purpose of this study is to evaluate the feasibility of using image guidance and four-dimensional computed tomography to reduce the volume of non target breast tissue that is treated with accelerated partial breast irradiation via the external beam technique.\nInclusion criteria: Inclusion Criteria:\nThe patient must consent to be in the study and must have a signed an approved consent form conforming with institutional guidelines.\nPatient must be > 50 years old.\nThe patient should have a life expectancy of at least two years with a karnofsky performance status > 7",
        "label": 0
    },
    "187": {
        "output": "[/TEST]\n<EOD> The impact of bilingualism on mental health and substance use disorders in Canada: results from a nationally representative survey\n\nThe impact of bilingualism on mental health and substance use disorders (SUDs) across various demographic and education variables is still underresearched. Using a nationally representative sample of Canadians, we examined the interaction effect of bilingualism on the presence of mental health and SUDs. Additionally, this study is unique in its examination of the impact of bilingualism on SUDs and the potential confounding role of psychological distress (Kessler 5) in this relationship. The sample was composed of 36,984 Canadians aged 15 and over who responded to the 2017-2018 mental health module of the Canadian Community Health Survey to determine the nature of the relationship. The results showed that bilingualism increased the risk of depression and generalized anxiety disorder and decreased the risk of SUDs. Additionally, bilinguals have a lower likelihood of having psychological distress (Kessler 5) (OR = 0.765, p < 0.001). Notably, we observed that this relationship was moderated by household income and marital status. Our findings suggest that while bilinguals have a greater risk of mental health disorders, they have a lower risk of having SUDs. We recommend future studies to explore the underlying psychological mechanisms of bilingualism's impact on mental health and the associated risk factors of the lower risk of SUDs among bilinguals.The study results suggest that among bilinguals, the risk of depression (OR = 1.445, 95% CI = 1.187-1.759) was 1.4 times those of monolinguals, and among bilinguals, the risk of generalized anxiety disorder (OR = 1.170, 95% CI = 1.020-1.343) was 1.2 times than that of monolinguals (Model 1). However, among bilinguals, the risk of SUDs (OR = 0.830, 95% CI = 0.",
        "label": 0
    },
    "188": {
        "output": "##[/CODE]\nWhat if this note is not the right person and patient history is not complete? In that case, should you skip the next patient and continue with the next one? Or should you try to find the reason patient is not eligible based on the current state of patient information and make the eligibility decision later on? In other words, when do you stop comparing the information of the patient? \nThere are two answers: 1) the first option is the correct answer, if your clinical trial does not require previous treatments; 2) the second option is the correct answer, if your clinical trial does require previous treatments. [CORE SWEED]\nFor the answer 1, the eligibility decision must be made to each subsequent patient, as shown in the [code] section: [/CODE]. \nIn answer 2 (for trials that do require information on previous treatments), the comparison is not required for subsequent patients, and the trial-level eligibility assessment ends as soon as a patient does not meet the inclusion criteria, as shown in the section by `Trial-level eligibility: \"2) Not eligible.\"`. \nFurthermore, we may think when the eligibility is determined? In other words, at the start, for each patient, eligibility check should be performed (including comparison with previous treatments) or it can be deferred to the end? \nThe eligibility assessment should include comparison with previous treatments and should be performed for each subsequent patient - at the start - not only at the end. \n\n### Exercise 05\n\n##[CODE]\nYou have to assess a patient for a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient, i.e., the decision is made to each subsequent patient regarding the eligibility for the clinical trial. Let's go through an example. \n\n### Exercise 06\n\n##[CODE]\nYou are asked to assess a patient for a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient, i.e., the decision is made to each subsequent patient regarding the eligibility for the clinical trial.\n\n\n## Patient",
        "label": 0
    },
    "189": {
        "output": "Output the trial-level eligibility `Trial-level eligibility:.`.<EOD> The Relationship between Cochlear Implant Experience and Objective and Subjective Hearing in Cochlear Implant Users\nObjective: This study investigated the relationship between cochlear implant (CI) experience and objective and subjective benefits of CI use. Design: A prospective, controlled study was conducted on 60 CI, bilateral implanted users, and 60 normal-hearing (NH) controls. Objective hearing was measured by speech audiometry in noise, and sentence recognition and word identification (Word Recognition Test) in quiet. Subjective benefits were evaluated using the Speech, Spatial, and Qualities of Hearing Scale (SSQ), the Health Utilities Index 3 (HUI3), and the EQ5D health-related quality of life questionnaire. Data were obtained 3 times; at baseline at the time of CI activation and activation of the second ear, and 3 to 6 months postactivation. Results: Statistically significant differences were found between the CI group and the NH group in all objective and subjective parameters at all time points. CI users were more likely to show an improvement of objective and subjective results from first activation to second activation and to later measurement points than NH individuals. Subjects were less likely to demonstrate a deterioration in hearing from first activation to second activation and later, except for an improvement of speech-in-noise in noise with a competition at 50% (50%-WIPN) in CI users. Objective data were negatively correlated with speech-in-noise in CI users, but not for NH subjects, while SSQ scores correlated to objective data, specifically the noise environment and aided speech understanding but did not correlate to any of the objective data in the NH study. Conclusion: The results of this study show that CI users tend to present better objective and subjective hearing than the NH individuals. However, improvements of speech understanding may be related only to speech-in-noise in noise with a competition at 50% (50%-WIPN) and to word or sentence perception in quiet.<EOD> PAT-related biomarkers, and dietary and lifestyle factors in pregnant women and newborns",
        "label": 0
    },
    "190": {
        "output": "Please click the \"Submit\" button after you make your decision in each case for grading. There is no limit to the number of case submissions you may make. In order to receive credit for your work, please ensure that you submit your responses in the order below, including the demographics information:\n\n## Grading criteria\nYou should submit your responses in a consistent fashion in all submissions. Specifically, follow the order of the text blocks below: \nDemographics-Information about the patients, including their name, age, sex, race, ethnicity, religion, political affiliation (if that information is not sensitive), and your relationship to them (if any).\n[CLOSE]\n\n## [INST]\n- Patients\n\n## [cldr]\n- Criteria\n\n## [inst]\n- Evaluation\n\n## [cldr]\n- \n\n## Grading criteria\nYour decisions will be measured using the following criteria. Each criterion is worth 3 points for a total of 39 points:\n\nAll submissions will be graded using the criteria in the table above. The points for each item will be determined by your ability to answer the relevant questions in each item. For the criteria that you need more information to answer, you may not be able to get the points for that item. However, your assessment will be included in this table so that we can improve this work-up. [CLOSE]\n\n# Scoring Guidelines\nPlease refer to the 2021 Assessment Tool Scoring Guidelines for information regarding how to interpret and score the response.\n\n# Discussion\n\n## Differences in Grading Criteria Scores Between Students of Different Educational Backgrounds\nIn a few cases, students from different education backgrounds, including undergraduate medical students, graduate students (predoctoral, doctoral, postdoctoral), residents, fellows, and attending physicians, received different scores on the same assessment tool. Most of these differences were due to variability in the use of key terms and concepts, or in the level of detail provided in answers.\n\n## Improving the Assessment Tool\n- To improve our tool, we need your feedback about the assessment tool's clarity, and its length, timing, and format.",
        "label": 0
    },
    "191": {
        "output": "<details>\n    <summary><NAME>: Breast cancer, MUGA, CT, MRI, lymph node metastasis</summary>\n\t<img src=\"images/fig12.png\" alt=\"inference\" width=\"700\" height=\"650\"/>\n\t\n    </br>\n\t\n    <img src=\"images/fig12.png\" height=\"700\" width=\"700\">\n</details>\n\n\n### [5.] INST. \u2461: Output the scale for the assessment of eligibility of the patients who do not have sufficient information to qualify for the trial.<EOD> The Effect of a Single Dose of an Oral Antibiotic on the Bacterial Flora of the Uterine Cavity\nThis study presents comparative data on the influence of a single oral dose of an antibiotic on the flora of the vagina, cervix and uterine cavity. All specimens were obtained by swab from women attending the Gynaecology Clinic of the Royal Liverpool Hospital and were processed by standard culture techniques. The results show that the effect of oral antibiotics on the vaginal flora is less marked than that in the cervix or uterine cavity, where the drug is able to eradicate certain pathogens. In the latter, a mixture of antibiotics, particularly tetracycline and polymyxin B, appears to be of value as a prophylactic measure where the cervical infection is mild or moderately severe but not severe.<EOD> Taking advantage of an atypical presentation of cytomegalovirus infiltration of the urinary bladder in the HIV-infected patient.\nWe report the case of a human immunodeficiency virus (HIV)-infected 63-year-old man who presented with urinary retention. Cystoscopy revealed a bladder polypoid lesion that was thought to represent a papillary transitional cell carcinoma. Imaging revealed an untypical cytomegalovirus (CMV) bladder infiltration. The patient improved with foscarnet as antiviral treatment. A biopsy showed an",
        "label": 1
    },
    "192": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [INST]\n\nA patient note:\nThe patient is a 56-year-old postmenopausal woman with breast cancer. She received a core biopsy. The tumor is  HER2positive, ER/PR positive, and with lymph node metastases. The patient is nonsmoker. She drinks 3 glasses of milk a day. She is sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n[INST] [CANCER - RESULTS] Here is the clinical trial: [\u2026] There must be negative surgical margins for invasive cancer and DCIS. LCIS is acceptable at the margin.\nAbility to understand and the willingness to sign a written informed consent document.\nPlatelets >/=100,000/\u03bcl within 4 weeks of registration.\nAbsolute neutrophil count (ANC) >/= 1,500/\u03bcl within 4 weeks of registration.\nTotal bilirubin within normal institutional limits within 4 weeks of registration.\nAlkaline phosphatase (alk phos) \u2264 2.5 X institutional Upper Limit of Normal (ULN) within 4 weeks of registration.\nAST (SGOT)/ALT(SGPT) \u2264 1.5X ULN\nCreatinine within normal institutional limits OR Creatinine clearance>/= 60 mL/min/1.73 m2 for patients with creatinine levels above normal\nIf patient has received tamoxifen or another selective",
        "label": 2
    },
    "193": {
        "output": "````\n\n\n:ital:\nF1000Research\n\n : public\n : #supp2\n : \n : <EOD> Intraoperative assessment of aortic valve competence: a clinical investigation.\nThe results of intraoperative assessment of aortic valve competence with the help of the continuous wave Doppler technique and the ultrasound color flow imaging are presented. Based on findings obtained in 217 patients during a period of 19 months, the continuous wave Doppler technique seems to give reliable and reproducible data.<EOD> Interpreting multiple comparisons, hypothesis testing, and confidence intervals.\nA method for quantifying and interpreting confidence intervals and confidence regions is proposed. The method gives a direct account of how confidence intervals and confidence regions are used to characterize the null hypothesis. Several topics in which confidence intervals and confidence regions are invoked to illustrate or to explain results are reviewed. It is indicated that confidence intervals and confidence regions are valuable, and even indispensable, whenever a comparison of populations, groups, or treatments is made, and their usage is illustrated. The confidence interval method, unlike many other methods, allows for estimation of any parameter of the distribution for which confidence intervals are constructed. Hence it permits estimation of not only means but also measures of dispersion or skewness and variance-covariance matrices. It is shown how to test whether one distribution differs from another when only their confidence intervals overlap. The method is applied to a problem in clinical research.<EOD> NF-kappa B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase-catalyzed phosphorylation of the IL-1 receptor: involvement of a novel serine/threonine protein kinase.\nThe binding of interleukin-1 (IL-1) to the native IL-1 receptor, a cytokine receptor composed of two subunits, the IL-1 receptor I (IL-1RI) and accessory protein (AcP), initiates a series of signaling events including activation of protein kinase C, and nuclear translocation of the NF-kappa B transcription factor. The mechanism by which IL-1 activates this signaling pathway is not known. In this study, we demonstrate that serine/",
        "label": 0
    },
    "194": {
        "output": "---\n### Assessment of eligibility:\n\n```python\ndef Assessmentofeligibility(notes, trial):\n    patient_notes = open(notes, \"rt\")\n    for line in patient_notes:\n        patient_data = line.split(\".\")\n        if patient_data[3] == \"clinical\": \n            trial_data =trial + \" #\" + patient_data[1] \n        else:\n            trial_data =trial + \" #\" + \"0\" \n    trial_eligibility=eval(trial_data)\n    print(\"Trial-level eligibility: {}\".format(trial_eligibilibity)) \n```\n\n```python\nAssessmentofeligibility(\"P00267_01.csv\",\"P00267\")\n```\n\nOutput\n```\nTrial-level eligibility: 0) Not relevant\n```\n\nNote\n`0) Not relevant` means that it is not in the list of exclusion criteria. But, if the trial accepts patients who have not undergone breast or chest wall surery, then it is also 0) Not relevant. You can also add the following code.\n\n```python\nif \"BC\" not in trial_eligibility:\n            trial_eligibility = trial_eligibility + \" #\" + \"1\"\n    if \"CWS\" not in trial_eligibility:\n            trial_eligibility = trial_eligibility + \" #\" + \"1\"\n```\n\n```python\nAssessmentofeligibility(\"P00267_01.csv\",\"P00267\")\n```\n\nOutput\n```\nTrial-level eligibility: 0#1) Not relevant 1) Eligible\n```\n\nNote\nYou can modify the code to compare the first 80 characters of a patient note to the inclusion/exclusion criteria of the trial. Moreover, you can modify the code to include some patient notes. However, in this step you have learned how to find the eligible patient using a note. If you want to find the eligible patient using a complete trial, refer to the next step.",
        "label": 2
    },
    "195": {
        "output": "***\n\n### Exercises\n\n1. You should check the eligibility of the patient with the inclusion criteria of a particular trial. Use the patient information and compare the patient variables with the trial's inclusion criteria. After that, you should output the corresponding trial-level eligibility (0, 1 or 2) for each patient.\n\n2. The output should have the following lines: patient number, gender, and date of birth if you want to use **experienced**.\n\n3. Try to guess the code of the problem [Link to Kaggle.](https://www.kaggle.com/c/breast-cancer-diagnosis/data) to solve the problem, because the dataset includes patient numbers and other patient information.\n\n***\n\n### Problem 7.6\n\n[This solution is by Yusu Nalbantoglu.](https://github.com/SugumarReddy/Python-Code/blob/master/problem_archive/7.6%20%5Boops%5D%20-%20Evaluate%20the%20Performance%20of%20a%20Binary%20Classifier.pdf)\n\n**What would you do with the following file (problem.csv)?**\n\n```\nName, Age, Diagnosis, Label\n'1', 20, 'Normal', 0\n'15', 20, Breast mass, 0\n'61', 45, Normal, 0\n'0', 45, Paget's disease, 1\n'0', 45, Paget's disease, 1\n'48', 45, Breast mass, 1\n'20', 45, Normal, 1\n'36', 45, Normal, 1\n'24', 31, Normal, 1\n'205', 45, Normal, 1\n'290', 45, Normal, 1\n'383', 45, Normal, 1\n'380', 45, Normal, 1\n'405', 45, Normal, 1\n'393', 45,",
        "label": 0
    },
    "196": {
        "output": "\u00a9 2020 - 2021 OpenAI<EOD> Antithrombin III Inhibits TNF-\u03b1-induced Cells Adhesion by Protecting CD14 from Oxidation and Inhibiting Monocyte-endothelial Cell Transendothelial Migration*\nOxidation of plasma proteins by reactive oxygen species participates in endothelial dysfunction and monocyte recruitment at cardiovascular diseases. Plasma antithrombin III (AT III) is also a reactive protein. In this communication, we show that intact AT III and AT III deficient subject plasma both activate thrombin generation but not TNF-\u03b1-induced monocytes adhesion to endothelial cells (ECs), suggesting that the lack of this biological property could be due to AT III oxidation. We found that the lack of intact AT III and AT III oxidative status at the TNF-\u03b1-exposed ECs were associated with an increase in thioredoxin-1 and an up-regulation of monocyte chemoattractant protein-1 but with an inverse variation in its receptor, CCR2. We conclude that intact AT III antioxidant activity prevents endothelial dysfunction.<EOD> .\nAIM\nThe purpose of this study was to investigate the effects of chronic exposure to different doses of ionizing radiation on the testicular tissue of mice.\n\n\nMETHODS\nWe investigated mice testicular tissue by light microscope, immunohistocyte staining, and flow cytometry.\n\n\nRESULTS\nLight microscope observation and quantitative analysis showed that both early apoptosis of spermatogonia and late apoptosis of spermatids were observed in the radiation (1.5 cGy/min) group or the high dose radiation group with significant differences when compared with the experimental group (1.5 cGy/min) or the control group (P < 0.05). However, in the low dose radiation group, changes of apoptosis were similar to the experimental group with little significant difference (P < 0.05). Immunohistocyte staining showed that the expression of",
        "label": 2
    },
    "197": {
        "output": "##1) Read about the trial [LINK=clinicaltrial.gov/] and the clinical trial's inclusion and exclusion criteria.  \n\n\n\n![LINK=clinicaltrial.gov/]\n\n\n\n![LINK=clinicaltrial.gov/]\n\n![LINK=clinicaltrial.gov/]\n\n![LINK=clinicaltrial.gov/]\n\n##2) Use the 3-point scale to determine if the patient should be assessed as Eligible, Not relevant, or Excluded.   \n\n```\nNot relevant is used for patients who don't have sufficient information to assess his/her eligibility correctly.  \nA patient note where the eligibility cannot be assessed, will contain the string Not relevant at the last line of the note.  \n```\n##3) Summary trial-level eligibility must be reported in the final line of the patient note e.g., `Trial-level eligibility: 2) Eligible.` \n(IMPORTANT!) Do not use the term Not relevant for trial-level eligibility.  \nIf the assessment is Not relevant for a patient, you should not output the string Not relevant for trial-level eligibility.  \nIt means that a patient note where the eligibility cannot be assessed, should be discarded.  \nIf the assessment is Eligible for a patient, you should print Eligible string for trial-level eligibility.  \n```\n<EOD> Correction to Immunohistochemistry of NF\u2010\u03baB in Human Colorectal Cancer and Adenoma\n\nCorrection to Immunohistochemistry of NF-\u03baB in Human Colorectal Cancer and Adenoma\n2004\nMDMDMDCorrection to Immunohistochemistry of NF-\u03baB in Human Colorectal Cancer and Adenoma\nTHE Journal of MUCOSAL RESEARCH\n4322004Received October 30, Accepted November 9, 2004\nSeveral years ago, following the appearance of our paper \"Immunohistochemistry of NF-\u03baB in human colore",
        "label": 0
    },
    "198": {
        "output": "## Rules\n\n### Condition\n\n*Every field of Clinical trial:\n\n\n\n\n```perl\nmy $r = 0;\nsub cond ($) {\n  my ($c) = @_;\n  $r++;\n  $c =~ s/\\n/\\n\\n/g;\n  print STDERR \"Assessing clinical trial '$c'\\n\";\n  if ($r == @ARGV) {\n    print \"\\nThe current clinical trial is not acceptable\\n\";\n    while ($r--) {\n      s/\\n/ /;\n      print \"\\n\\nAssessing clinical trial '$c'\\n\\n\";\n      s/\\n/\\n\\n/g;\n    }\n  } else {\n    my %patient = %ARGS[$r];\n    my ($i) = @ARGV;\n    $c = substr($c, 2);\n    my @x;\n    opendir(my $f, $c);\n    while (readdir($f)) {\n      chdir($c);\n      if (-e .) {\n        my $filename = qq{$i->[0]--.'.'};\n        my $line = <$filename>;\n        s/\\s+/ /g for (@x);\n        s/\\n/\\n\\n/g;\n        print \"\\nPatient: $patient{'fullname'}\";\n        for (@x) {\n          print qq{$_--.'} \".\"($_, '\"') . qq{($_--.')'};\n        }\n      }\n    }\n    closedir($f);\n  }\n}\nprint \"\\n\";\n```\n\n* Every file in the given directory:\n\n*Every file in the given directory and subdirectories, e.g., files and sub-directories: *\n\n\n\n\n```perl\nmy $r = 0;\nsub f ($) {\n  my ($filename) = @_;\n  print STDERR \"Assessing file $filename\\n\";\n  # Get line number to exclude this file's sub-files too\n  $r++;\n  $filename =~ s/\\n/\\n\\n/g;\n  print \"\\nF",
        "label": 0
    },
    "199": {
        "output": "# Efficient and Effective Way to Answer the Questionnaire\nYou may have learned in the 2nd year course that the process of writing a complete answer in the long answer format can be quite challenging. For example, when a problem asks us some questions such as, \"Do not use the short answer format. You will receive a score of 0 in the writing of this problem unless this paper meets the writing objectives. You will lose 3 points in total if your answers are complete but are not well organized. Also, 3 points will be deducted if you use the short answer format.\" If you receive such a score, you will wonder what to do, and it will be helpful if you are able to answer correctly without using the short answer format. \nIn addition, even for students who are not currently attending clinical clerkship, or are just about to begin, but need to answer the questionnaire for the purpose of preparing clinical clerkship, they may feel a bit nervous when they find that the answer sheet is long enough and the format is quite different from that of the school-based problem solver, which they are accustomed to using. They may wonder what they need to pay attention to in order to get a high score in the problem solving test. You may need to develop an efficient and effective way to solve the problem. \n\n# Writing Objectives for Questionnaire\nTo solve problems in the long answer format, it is essential to prepare a clear writing plan. This is because it is difficult for us to solve the problem when we have not prepared such a plan. And this is why it is vital to be able to write specific objectives for questions in the long answer format. \n\n# How to formulate writing objectives\nFirst of all, you are asked to formulate writing objectives as you go along while solving the problem. You need to specify, in writing, what you want to include in the answer. \n\n# Considerations for Efficient and Effective Methodology\nThings to remember as you go: \n1. Pay special attention to the instruction page. You should know how many problems to be answered on the questionnaire. \n2. You should keep reading the question with one eye on the writing objectives you've specified when you read a new problem. \n3. You must always ask how to reach the",
        "label": 0
    },
    "200": {
        "output": "### Case Example\n\nBefore we look into the second case, let's just quickly discuss the output here.\n\n*It would be pretty straightforward to just write something like `eligibility : \"patient is eligible\"`. But we don't need to, because if the patient is eligible, your trial is also eligible; so, just writing `trial : \"trial is eligible\"` is sufficient.\n\nNow, lets see the second case.\n\n# Case 2: \"Patient X-123 (a 60-year-old male) is being evaluated for treatment\".\n\n# Case 2: \"Excluded\"\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should write the outcome of the comparison in the trial data file. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe patient is a 60-year-old male. He is scheduled for a liver biopsy under anesthesia to determine the diagnosis of hepatocellular carcinoma. He is suspected of having alcoholic cirrhosis.\n\nThe patient is healthy, a professional musician. He takes oral propranolol for his high blood pressure. He drinks alcohol. \n\n*Alcohol is a potential risk factor for hepatocellular carcinoma. If the patient does have HCC, it may be from alcoholic hepatitis. If the patient does not have HCC, it could be from hepatic cirrhosis resulting from alcoholism. So, we put the patient on alco",
        "label": 0
    },
    "201": {
        "output": "___\n\n[LFUN] \nFor each patient, the eligibility score of the patient is now determined by multiplying the probabilities for each factor. The factor that can take a value from zero to one.\n\nFor example, if a patient matches the trial \"Breast cancer\" and is of both sexes and has tumour grade \u2a7d2 and negative node status and chemotherapy group, then its overall eligibility score would be:\nP1 x P2 x P3 x P4 = 0.8 x 0.2 x 0.5 x 0.4 = 0.08\n\n___\n___\n\n[LFUN] \nIn this section, you can make your model output a patient name and patient ID column which are automatically generated as your model learns.\n\nThis time, you will use the `Trial-level eligibility` as the column header. The column header can be set to anything (eg `Inclusion criteria` ) as well as the `Patient-level eligibility` value. \n\n![Learning from Example 8](../images/0802-5.png)\n\n___\n___\n\n[LFUN] \nThe columns `Trial-level eligibility` is set from `Trial-level eligible ` to `Trial-level ineligible`.\n\nIt should also note that when this table is built, a new random seed is assigned.\nYou can find this seed number in the file `C:\\Users\\%USERNAME%\\.RStudio\\Rhistory\\history.txt` after you run the R Code.\n__[INST]__\n\nLet's think step by step. \n\n\n## # Create a dataframe from each file\n# Use the name of the variable to create a data frame.\nfiles <- ls()\n\nfor (file in files) {\n    df <- read_xlsx(file, sheet = 2, header = TRUE, \n    skip = 1, nrows = 4, sep = \"\\t\", row.names = FALSE)\n    \n    file <- paste(\"C:\\\\Users\\\\dongkchung\\\\Desktop\\\\0404_clinicaltrial\\\\trial_data\\\\\", file)\n    \n    df$TrialID =",
        "label": 0
    },
    "202": {
        "output": "## Exercise on a real patient data set\n\n`$ i=0; while ($i < @myInput) { $i ++; print \"Input:\", $myInput[$i]; print \"Output: \"; print \"Tri-level eligibility: \", $tri_level_eligibility[$i]; }` [EXER]\n\nLet's write a program to make trial-level eligibility.\n[INST] Let's define a procedure to obtain the number of patients. You should be able to execute the code below to get all your patient notes. You can insert the code block between a new line and `print` statement. Execute the following code block under the existing code in R/script_A.Rmd: [RUN]\nAdd a new code block, e.g.,`<<`between two new lines, named `patient_number_by_trial`. [RUN]\nThe new code block should be shown as follows:  \n`<<function(i) { print(\"The number of patients by trial: \", i); }` [RUN]\nSave the script as `R/script_B.Rmd`. The new modification will be shown as follows:  \n`script_B.Rmd`  \n```\n<body>\n\n  <h1>R script:\n    `script_A.Rmd`  \n</body>  \n\n<h3>1. Patient notes:\n  <h4>Input:</h4>  \n    $<NAME>.csv_02_patient_note.csv\n  <h4>Output:</h4>  \n    ... Patient_notes_R_output_001.csv\n  <h4>Tri-level eligibility: \n    <h4>Input:</h5>\n     $<NAME>.csv_05_patient_note_2_for_eligibility.csv  \n    <h4>Output:</h4>\n     ... Tri_level_eligibility_R_output_001.csv  \n                                    \n  <h4>Triple-level eligibility: \n    <h4>Input:</h5>\n     $<NAME>.csv_03_patient_note_3_",
        "label": 2
    },
    "203": {
        "output": "---\n\n### Implementation and usage\nImplementation: [`doc_trial_eligibility.md`](https://github.com/DiseaseGenome/docuGenome/blob/c93cdd010d862d3b5b9279666caea0b67d1a7023/docs/scripts/rst.rst#L20-L26)\n- [![Ratings](https://badges.githubusercontent.com/6158071/74918555-6b3f7500-5e5b-11ea-8991-8d822c7473a5)](https://arxiv.org/pdf/1902.08717.pdf)\n\n## `doc_trial_eligibility.md`\n\n### Contributing\nPlease use the doc_trial_eligibility.md to generate a new draft and submit in with the above mentioned `doc_trial_eligibility.md`.<EOD> Neural stem cell transplantation and motor functional recovery in animal ischaemic stroke models\n\nThe central areas of the brain with the highest concentrations of stem cells and nerve cells in the adult, the subventricular zone and subgranular zone of the dentate gyrus, respectively, harbour neural stem cells, multipotent neural stem cells and cells exhibiting restricted proliferation potential. During neuronal damage and death, neural stem cells migrate from their subventricular zone niche, proliferate in the subventricular zone and differentiate into neurons, astrocytes and oligodendrocytes, which can be found as far as in the subvent",
        "label": 1
    },
    "204": {
        "output": "[SEM3] Hello, I am here to see you. I am a patient's companion.\n\nI am a 28-year-old woman who is being considered for a phase I trial of a new drug candidate. \nThe new agent is being tested to treat my rare cancer.\n\nI am the primary caregiver for Mary, an 82-year-old woman who was recently diagnosed with metastatic breast cancer.\n\nMary has metastatic cancer that spread to her bones, lungs, and liver. Her cancer does not respond to several kinds of treatment. Mary prefers to go home instead of coming to a hospital to be treated.\n\nOn our first meeting, I took care of her medical transportation, home nursing, and paper work for her hospice care.\n\nShe has an appetite loss, difficulty swallowing, low back pain, and frequent urination.\n\nIt is essential to maintain her quality of life before the advanced cancer treatment. \nPlease tell me all the necessary steps from today to get involved in the clinical trial.\n\n[SEM4] Hello, I am here to see you. I am a patient's companion.\n\nI am a 28-year-old man who is being considered for a phase I trial of a new drug candidate. \nThe new agent is being tested to treat my rare cancer.\n\nI am the primary caregiver for James, an 82-year-old man who was recently diagnosed with metastatic breast cancer.\n\nJames has metastatic cancer that spread to his bones, lungs, and liver. His cancer does not respond to several kinds of treatment. James prefers to go home instead of coming to the hospital to be treated.\n\nOn our first meeting, I took care of his medical transportation, home nursing, and paper work for his hospice care.\n\nHe has fatigue, loss of appetite, difficulty swallowing, and low back pain.\n\nIt is essential to maintain his quality of life before the advanced cancer treatment.\n\n[SEM3] Hello, I am here to see you. I am a patient's companion.\n\nI am a 28-year-old woman who is being considered for a phase I trial of a new drug candidate.",
        "label": 0
    },
    "205": {
        "output": "\u00a9 2016 CodeEval, Inc.\n\n\nA: What language is this?\nIf it's python I got you covered:\nfor p in Patient:\n    if p.age and p.Gender in trial_inclusion:\n        #Check inclusion criteria\n        res['eligibility'] = 2\n    else:\n        res['eligibility'] = 0\n\n\nA: @griene's answer is pretty much on target regarding a Python solution for the task.  I would like to note a few important items of note with it, however, to give some context and background.\n\n*\n\n*The main reason you don't want to check every single item in the list of patients is that, due to the way Python dictionaries work, checking for a particular patient's inclusion criteria will only be faster if your data is sorted by the key value.  Because, if you were to have some patients with the same age and gender as each other, you would check each one separately and that could potentially be very slow given the number of patients in the test data.  For this reason, it's best to check by trial first, since the trials will be indexed by the key, which is then the ID of the trial.  If the trial is found to be acceptable, then loop back to check for each patient within that trial.\n\n\n*The main reason you don't want to check every single item in the list of patients is that, due to the way Python dictionaries work, checking for a particular patient's inclusion criteria will only be faster if your data is sorted by the key value. Because, If you were to have some patients with the same age and gender as each other, you would check each one separately and that could potentially be very slow given the number of patients in the test data. For this reason, it's best to check by trial first, since the trials will be indexed by the key, which is then the ID of the trial.* \n\n*In the example code you provided, you use dict.keys() to get the ID of the trial, however this list is sorted in ascending order.  In other words, the values in keys() come in ascending order of the trial IDs.  However, if you actually needed the list in descending order to test for each trial as you iterate through the list, you",
        "label": 0
    },
    "206": {
        "output": "### Instructions\n\n\n\n1. **[Run the code](https://repl.it/~flipbot/590)** to see the output.\n\n### Notes/Exercises\n\n1. How can you make the patient's diagnosis look like the one in the patient note?\n1. How can you improve the code?\n<EOD> Prevalence and predictors of pain and pain\u2010related disability in patients with low back pain: a retrospective registry analysis\nBackground and purpose:\u2002 The object of the present study was to investigate the prevalence and predictors of pain and disability in patients treated for low back pain in private physical therapy clinics in the USA between 1994 and 1997.<EOD> Synthetic studies towards enantioselective total synthesis of (+)-alstonolide B and (-)-aristeromycin.\nEnantioselective synthesis of tetrahydropyran is a very challenging task in carbohydrate chemistry since the formation of an enantioenriched tetrahydropyrane is dependent upon multiple factors such as stereoinvertibility or kinetic inertness of the rearrangement. Accordingly, syntheses of tetrahydropyran based on 2-siloxycarbonyl group as the tether have been developed to minimize undesired rearrangements . Recently, we reported asymmetric synthesis of carbamates possessing a 2-siloxycarbonyl group through diastereoselective allylic alkylation, which is an effective method for controlling stereochemistry of the resulting tetrahydropyran by selecting a substituent on the alkene moiety . We here report the synthesis of an enantiopure \u03b1,\u03b2-unsaturated carbonyl system as illustrated in Scheme 1. Initially, enantioenriched tert-butyl carbamate 2 was synthesized by the method reported by Ito . Reduction of tert-butyl carbamate 2 with sodium borohydride provided alcohol 3, which showed almost the same optical rotation as that of (+) alstonolide F, a cysteine protease inhib",
        "label": 2
    },
    "207": {
        "output": "For the clinical trial, let's assume 10 patients in each arm in the original trial.\nWe need to determine how many samples are eligible. It's quite straightforward. We start with the first sample and run a ttest. If the p-value is smaller than 0.05, that's in favor of the hypothesis (H0) that both groups are equivalent, and we move on to the next sample.\nIf it's not, we add 1 to n for all patients in the second arm, as in `n[2]=[`n[2]+1`]`\nWhen moving on to the second sample, the previous values in `n` should still be held. Note that `n[1]` is the p-value of the first sample, so we can reuse it for the second sample. We then move on to the next sample.\nSo for the first sample we run ttest, we get the p-value of 0.46. So the hypothesis for the first sample cannot be rejected: group A is statistically equivalent to group B since the group size is larger enough. We increase n[2] by 1 and move to the second sample. We call ttest and obtain the new p-value of 0.7. This implies that we could not reject neither the nullnor the alternative hypothesis: we accept H0. Now we check the group B size ( n=2+1=3, 0.7 is the p-value of group A) and the group A size ( the same p-value 0.7), and therefore move on. \nFor the third sample, the original p-value is 0.01, so we should reject the null hypothesis and move on.\nFor the fourth sample, the original p-value is 0.03. So we could not reject the nullhypothesis. We check n, n=2+1=",
        "label": 1
    },
    "208": {
        "output": "Set the CSV file as the input for next step. \n6. By using the script that is written in\n[13.2.3 Converting a CSV file to a DTA file.md](./13.2.3. Converting a CSV file to a DTA file.md) file, make a list of trial eligibility.\n\n6.1.",
        "label": 0
    },
    "209": {
        "output": "### Examples<h3>Patient 1</h3>\n# Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n# [patient.gender=\"female\"] # [patient.age=\"45\"] # [patient.clinical_stage=\"c_t2 n0 m0\"] # [patient.tx_path=\"breast-conservation-therapy\"] # [patient.tx_name=\"neoadjuvant-chemotherapy\"] # [patient.tx_timing_in_days=\"4\"] # [patient.tx_timing_in_weeks=\"1\"] # [patient.tx_timing_in_months=\"1\"] # [patient.txt_timing_in_years=\"1\"] # [patient.rx_timing_in_days=\"4\"] # [patient.rx_timing_in_weeks=\"1\"] # [patient.rx_timing_in_months=\"1\"] # [patient.rx_timing_in_years=\"1\"] # [patient.txt_timing_in_days=\"4\"] # [patient.txt_timing_in_weeks=\"1\"] # [patient.txt_timing_in_months=\"1\"] # [patient.txt_timing_in_years=\"1\"] # [patient.tx_timing_in_weeks=\"4\"] # [patient.rx_timing_in_weeks=\"4\"] # [patient.txt_timing_in_weeks=\"4\"] # [patient.rx_timing_in_months=\"4\"] # [patient.txt_timing_in_months=\"4\"] # [patient.tx_timing_in_years=\"4\"] # [patient.rx_timing_in_years=\"4\"] # [patient.txt_timing_in_years=\"4\"] # [patient.tx_timing_in_days=\"1\"] # [patient.rx_timing_in_",
        "label": 0
    },
    "210": {
        "output": "Note: If there are any unresolved problems about `Trial-level eligibility:`, you will see the error like following.\n\n```\nIn RST/CSV:\n`Trial-level eligibility: 4) Excluded`\n\nOut of RST/CSV (when the trial_info.txt is not found):\n`Trial-level eligibility: 0) Excluded [missing fields: InclusionCriterion]`\n\nTips:\n\n  When `Eligibility` is not available, you can find `Eligibility` from Eligibility_criteria_id or\n  when `Inclusion_criterion` is not available, get it from Inclusion_Eligibility_criterion.\n\n[EOL]\n\n[EOL]\n[EOL]\n[EOL]\n[EOL]\nTips: \nEasy way: If your trial name is `Breast2`, first check the variable from `crosstalk_22[i]', then check if its value is `True` or `False` and then get the trial id as the same way as the previous session. \n\n```\nEasy way: If your trial name is `Breast2`, first check the variable from `crosstalk_22[i]', then check if its value is `True` or `False` and then get the trial id as the same way as the previous session. \n\n```\n\n# Easy way: You can confirm the name of the trial from a given trial id in RStudy::trial\n\n```\n\n  trial_id = crosstalk_22[120]\n  trial_name = unlist(RStudy::trial(trial_id)) # e.g., \n```\n\n## The last step\nTips:\nFor some trials, its `Trial-level eligibility: 0) Excluded [missing fields: InclusionCriterion]` . \n\nPlease modify one or more rules as well as `Triallv_Criteria`:\n\n```\nTriallv_Criteria <- list(\"Inclusion_Criteria\" = list(\"inclusion_criteria_eligbility.txt\",\n                                               \"in",
        "label": 2
    },
    "211": {
        "output": "[TEST] Test cases\n[TEST1]\n- [TEST1] - Test case 1: `p1`.\n- [INST] Input: *patient_note: \"The patient is a 33-year-old postmenopausal woman with breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2 positive and ER/PR negative. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and had one child.\"\n- [RUN] Run test with output: `patient_note : 0, Trial-level eligibility: 1) Not relevant`.\n- [TEST1] - Test case 1 successfully passed.\n- [INST] Test case failed.\n- [TEST2] Test case 2.\n- [RUN] Run test with output:\n    `patient_note : 3, Trial-level eligibility: 0) Excluded`.\n- [TEST2] Test case 2 failed.\n- [TEST3] Test case 3.\n- [RUN] Run test with output:\n    `patient_note : 0, Trial-level eligibility: 0) Excluded, 1) Not relevant`.\n- [TEST3] Test case 2 successfully passed.\n- [TEST4] Test case 4.\n- [RUN] Run test with output:\n    `patient_note : 1, Trial-level eligibility: 0) Excluded, 0) Excluded, 2) Eligible`.\n- [TEST4] Test case 4 failed.\n- [TEST5] Test case 5.\n- [RUN] Run test with output:\n    `patient_note : 1, Trial-level eligibility: 0) Excluded,`\n    `Trial-level eligibility : 2) Eligible`.\n- [INST] Test case passed.\n- [TEST5] Test case 5 successfully passed.\n\n[TEST6] Try to fail with input: `patient_note: \"",
        "label": 0
    },
    "212": {
        "output": "Good luck!<EOD> Combination Antibiotic therapy for Pouchitis: Results From the Pouchitis Outcomes Research Study (PORt)\nAbstract Background In patients with ileal pouch-anal anastomoses, chronic pouchitis affects many, and is often difficult to treat. Antibiotic therapy is frequently used. However, there is no established first-line antibiotic therapy for pouchitis. The objective of this study was to determine the effectiveness of a range of antibiotic regimens for treating pouchitis in a large cohort of patients with ileal pouch-anal anastomoses. Methods We conducted a retrospective cohort study of patients with pouchitis (n = 385) identified from the Pouchitis Outcomes Research study (PORt), a multi-center prospective cohort. Our exposure of interest was antibiotic exposure (metronidazole, ciprofloxacin, or a combination of metronidazole and ciprofloxacin) in the year prior to enrollment. We used logistic regression and propensity score matching to assess the effectiveness of each antibiotic and a combination of the 2, and determined whether outcomes were independent of the initial antibiotic choice. Results The majority (85.1%) of patients reported use of \u22651 antibiotic, most commonly metronidazole (28.9%) and ciprofloxacin (27.1%). Compared to no antibiotic treatment, metronidazole use was significantly associated with decreased pouchitis risk (OR 0.60; 95% CI, 0.50\u20130.72), as was ciprofloxacin use (OR 0.56; 95% CI, 0.50\u20130.63). The combination of metronidazole and ciprofloxacin was associated with an even greater decrease in risk (OR 0.36; 95% CI, 0.28\u20130.44). All associations were independent of initial antibiotic choice. Conclusions All antibiotics evaluated are associated with a decrease in",
        "label": 0
    },
    "213": {
        "output": "___\n\n## Example input\n\n### Clinical Trial\n\n- Title: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions\n- Study Type: Combination Therapy\n- Study Design: Exploratory study evaluating 3 arms:\n    * Arm 1: Monoclonal antibody MEDI6469 (anti-OX40) plus stereotactic body Radiation (SBRT) to metastatic site\n    * Arm 2: SBRT to metastatic site\n    * Arm 3: 0.9% saline\n- Treatment Arm 1: MEDI6469 (anti-OX40)+ SBRT to metastatic site\n- Inclusion Criteria:\n    * Subject must have histologically confirmed cancer with clinical evidence of metastatic disease\n    * One metastatic disease lesion that is amenable to stereotactic body radiation with a high probability of biological tumor ablation must be identified\n    * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n- Exclusion Criteria Includes:\n    * Active autoimmune disease that requires systemic treatment with corticosteroids or other disease modifying antirheumatic drugs\n    * A history of documented clinical disease that would, in the opinion of the investigator, either put the subject at risk because of procedure related complications such as infection or neurological deficits or confound the results of the trial such as an inability to undergo the procedures, compliance with protocol treatment or assessment of toxicity and/or study end points\n- Trial-level eligibility 1):  Excluded Subject meeting any of the Exclusion Criteria listed above\n- Trial-level eligibility 2):  Not relevant Subject does not have sufficient information to qualify for the trial\n- Trial-level eligibility 3):  Eligible Subject meets all the Inclusion Criteria and does not meet any of the Exclusion Criteria listed above, AND subject is \u226518 years old and has",
        "label": 0
    },
    "214": {
        "output": "Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThere are two problems. First, the patients' diagnoses change over time and even the inclusion criteria of the clinical trial change over time, especially in the context of the evolution of medicine. Second, there are too many data to manage in such situations. We use data structures to organize the data as we make them.   When you write the data structure of patient notes and data structures of clinical trial data, you will automatically organize the data and simplify the data collection to make clinical trial easier.\n\n## Use Data structure\n## Introduction\n\nIf data are not organized, it can be challenging to find specific data in large datasets. In the medical domain, this challenge is magnified by the sheer amount of unstructured textual patient data. Here, we introduce a conceptual framework to organize information. \n\n\n<!-------------- INDEX PATIENT IN EXISTENT DATABASE --------------->\n  \n### Index patient in existing database\n\n* The data structure of patient data.\n    * Includes [INDEX PATIENT DATA]\n    * Includes [INDEX INDICATORS OF PATIENT DATA]\n    * Includes [Patient notes]\n    * Includes [INDEX PATIENT DEMOGRAPHIC DATA]\n* The patient\u2019s information is entered as an index of each patient. \n\n**Data Structure of Patient`s Data**  \n* Patient ID: A unique identifier\n    * AID-ID\n* Date of data entry: Date of first entry of a patient note\n* Birth Date: Date of birth\n* Death Date: Date of death\n* Sex: Male or femal\n    * Patient can be assigned to be male or female. \n* Age: A patient's age\n    * Age can be determined by comparing the birth date and death date.\n* Inclusion or Exclusion Criteria: A patient note is checked whether it meets the inclusion or exclusion criteria of a clinical trial\n    * Except for the 'no-data-type' cases.\n\"excluded\": The patient does not meet the inclusion criteria.\n\"not relevant\": No available information for the assessment of el",
        "label": 1
    },
    "215": {
        "output": "When you exit without saving the session because you are on a laptop, a pop-up message appears like the following one:\nYou do not have a session cookie. As a security measure, your session will be terminated after 30 min inactivity.\nSave your results! [END]\n\n### Trial Summary: [TOP]\nWe have learned the overall trial information by running the following command:\nimport pyrast.pipeline\ndata = run_pipeline(name, trial)\ndata\n\nYou can see that the data frame has 54 columns like following. The first six columns and the last three columns are the mandatory columns you must complete. The other columns are optional. The first six columns are:\n- ID\n- Trial\n- Title\n- Type\n- StudySite\n- Site\n- TreatmentArm\nIf you miss any optional fields in the pipeline, you have to restart the pipeline by running the following command:\nre-start_pipelines()[]\nFor an example of re-starting the pipeline, refer to section 1.21. You do not have to fill in the optional columns during building the pipeline.\n\n### Tips\n- If a patient is suitable for the trial as shown in the [Detailed Eligibility] section [ID, Trial], Type, Title, StudySite, Site, TreatmentArm, the patient-specific fields, and the date are omitted since you focus only on the patient-specific fields this time.\n- We have used `DifferentialEligibility` to see what differences there are between patient and trial. If you want to know the details about `DifferentialEligibility`, refer to the previous section on `DifferentialEligibility`.\n- When you want to see the patients with the inclusion criteria of the trial and the exclusion ones, use the `get_with_inclusion` function. The returned data frame contains the patients of clinical trials that match the inclusion and exclusion criteria. Let's see the result.\ndata[-1]\n- You can obtain the number of patients by executing the following command:\ndata[-1]['Length'][0] \n\n# Inpatient\n\n## [/TOP]\n\n### Clinical Decision Support\n\nThis section will teach you how to build a patient recruitment report",
        "label": 0
    },
    "216": {
        "output": "[COURSE]\n[STUDENT] Hello. It's me, [NAME].\n[LECTURER] Hello, [NAME]. \nHow can you find your name in the patient note? \n[STUDENT] Oh, hi, Dr. Brown. I don't know how to do the task.\n[LECTURER] Well, let's think about the patient note first. It has a part `patient information`. What data items are there? \n[STUDENT] Dr. Brown, all I know is his name and age. There is no information about her family history, allergies, or medications.\n[LECTURER] Well, you did well to check if it is an interesting patient. Go on. Find out more about the patients. You will find it in the `patient history` section. Find their symptoms, chief complaint, and current medications. I'm sure they are there. \n[STUDENT] Oh, I am able to do the task. I found his symptoms and his chief complaint. He has not been prescribed any medications yet. \n[LECTURER] That seems interesting. Are those data items not in the patient note? \n[STUDENT] No, only the symptoms, the chief complaint, and the medications appear. Where are they?[CORRECT RESPONSE] `In your report, make sure to include information on your patient including a brief description of his or her current status. Also, include information about the clinical trial. Your report will be a source of information about your patient so that others can work with him or her.`\nLet's think step by step. \n[CORRECT RESPONSE] In your report, make sure to include information on your patient including a brief description of his or her current status. Also, include information about the clinical trial. Your report will be a source of information about your patient so that others can work with him or her.[/CORRECT RESPONSE] \n[LECTURER] Excellent! But first, find all the data about the clinical trial. You will find everything about the trial in the `clinical trials` section in the patient note. Can you find all data there? \n[STUDENT] Yes",
        "label": 0
    },
    "217": {
        "output": "[bib_ref]  Comparison of Breast Cancer Survival by Molecular Subtype in Patients Treated in..., Metzger [/bib_ref]  [GUI] You may be interested in this program that makes the comparison and the visualization of two cases, the clinical trial that we studied and the information from one patient. [bib_ref]  Precision Oncology in the Era of Interconnected Health Systems, Taber [/bib_ref]  [GUI]\nNow, let's discuss the clinical utility of an ontology for representing clinical information of a patient. [INST]\nPatient information is extremely important during a clinical procedure. In today's clinical scenarios, the amount of available information is rapidly increasing. As a result, many studies have been conducted to represent more comprehensive clinical information, covering all the important aspects of a patient. [bib_ref]  A Comparison of the Comprehensive Rationale Index, Health Monitor Index, and Karnofsky..., Schonwetter [/bib_ref]  We should therefore adopt semantic technologies in a clinical setting to represent patient data in order to improve patient safety by making data consistent [bib_ref]  A Comparison of the Comprehensive Rationale Index, Health Monitor Index, and Karnofsky..., Schonwetter [/bib_ref] . A patient can have multiple medical profiles, such as laboratory tests, diagnosis, and medications. The profiles of a patient can be classified into different levels. The general patient information at an institutional database level has been represented on an ontology. In order to understand the patient's condition accurately at patient level, a number of studies have been undertaken to represent patient data. [bib_ref]  Patient data semantic annotation using medical ontologies, Ruggiero [/bib_ref]  proposed an ontology to represent patient information [bib_ref]  Patient data semantic annotation using medical ontologies, Ruggiero [/bib_ref] . In order to reduce the complexity, the authors did not discuss the details of a complete patient' profile and focused only a portion of the patient' information.\n[INST]\nIn this chapter, a case study is presented for integrating a clinical trial of a patient and patient information from the institutional database. The objective of this study is to analyze the possibility that a clinical trial will determine if our proposed ontology is useful to represent both patient information and a clinical trial ontology.\n[GUI]\nTo show how to use",
        "label": 2
    },
    "218": {
        "output": "## Test Case\nLet's run again with following command:\n$ irb -p $PWD\n1.2.0\n1:1024\nirb$ python run.py test_code.py\nTrial-level eligibility: 2) Eligible.\n\n## Summary\nWe have presented the basics of IRB application using the MX_IRB tool designed for the MX Challenge. This tool utilizes the PyMX library which provides useful functions to prepare IRB applications for the MX Challenge using a simple command-line interface. This tool is quite simple to use but it does require some basic understanding of IRB reviews.\nThe provided tutorial walks through every step of the process and shows how to run a complete MX application in less than an hour (less than 12 minutes if you are running all of the tests). In order to be able to follow along, you should read the detailed MX ruleset which can found online at https://biomed.brown.edu/mx-challenge/rulesets/2014. We highly recommend reading the online documentation at http://pymx.github.io/ as well to understand the other features of the tool.\n\n# Related Work\nThere are a number of research groups studying the issue of automatic IRB applications. One prominent tool currently being developed is the IRB tool available from http://clinicalcomputing.org/project/c3-r/. While this project is not related to ours in any way, it includes some of the same concepts such as providing a unified API for data provenance, querying for IRB items, and providing tools for searching for IRB items.\nIRBtool is an open-source tool that is used for preparing IRB applications by research teams. The tool includes features that were missing from other tools such as support for multiple IRBs, tracking of missing data, and support for queries over the XML submission. We believe that our tool does not solve the same issues in the same way as the IRBtool but we have not tried to analyze their tool at this point.\nFinally, an interesting effort has been proposed by http://scigenomica.org/toolswhere they use Python and R to build an IRB application. The solution utilizes a similar approach as ours and while the current effort is not as fully developed as our",
        "label": 0
    },
    "219": {
        "output": "<EOD> .\nOBJECTIVE\nTo explore the feasibility and accuracy of free gingival grafts (FGGs) for coverage of exposed dental implants in a swine model.\n\n\nMETHODS\nFour dental implants were placed in the canine area of the mandible of the young swine. One week after implant insertion, FGGs were harvested by means of a split thickness graft. Graft and recipient sites were prepared in a similar manner, and FGGs were immediately transplanted to the recipient sites around implants. A month after transplantation, biopsies were harvested from implant sites and surrounding FGGs. Histological preparations of biopsies were then stained with hematoxylin-eosin, van Gieson and tartaric acid stain. The number of colony forming units within the implant sites were examined by the use of agar method.\n\n\nRESULTS\nAll FGG sites survived and formed complete epithelial attachment with minimal contraction in a month after transplantation. No severe inflammatory reaction was observed in FGGs or recipient areas. Van Gieson and tartaric acid stain showed that only a narrow zone of bone loss occurred in implant sites and the rest of the bone surrounding implants were normal bone tissue without osteolysis. Implant sites were surrounded by thick epithelial tissues in the first week after transplantation. Agar culture of the histologic specimens showed a total of 204 microbial colonies in the culture medium, including 195 gram-positive cocci and rods, and nine Enterobacteriaceae.\n\n\nCONCLUSIONS\nFresh FGGs seem to be a good method in covering exposed dental implants in the immediate postoperative period without any significant post-surgical complication. The results suggest the possibility of performing this technique, especially as a short term solution for dental implants failing to integrate with the host soft tissues.<EOD> Erythrocyte sedimentation rate in oocyte donors is higher than in matched control subjects.\nErythrocyte sedimentation rate (ESR) was determined over 2-3 h in a group of healthy,",
        "label": 2
    },
    "220": {
        "output": "<EOD> A simple high-pressure gas chromatograph for the analysis of blood or breath for ethanol.\nAn inexpensive gas chromatograph capable of determining ethanol concentrations at high pressures has been developed for the analysis of blood or exhaled breath for ethanol under anesthesia. The system consists of a commercially available 3 in. glass column. The separation is achieved by the use of a 36 x .0012 in. fused-silica capillary containing silicone-charcoal film as the stationary phase; by the use of a carrier gas and hydrogen as the auxiliary gas; and by the use of a column oven which achieves separation when the temperature is increased isothermally 0.05 deg C/sec. in a pressure-induced equilibrium column system. The inlet system is designed for the sampling of an unvented and unanesthetized canine and the determination of ethanol concentrations in blood and breath by the direct sampling of the blood or breath. The concentrations obtained by the present system agree with those obtained with the semiautomated headspace gas chromatographic determination.<EOD> Antimicrobial Agents That Block Aminoribonuclease C from Clostridium difficile Display Potent In Vitro Activity against an Antimicrobial-Resistant Strain Clinically Isolated from a Patient in China\n\nAminoribonuclease C from Clostridium difficile (CD-AMNB) can cleave 30 nucleotides of the 3= end of the 16S rRNA, making it difficult for aminoglycosides to enter the 30S ribosomal subunit and bind to bacterial rRNA, which contributes to the high toler",
        "label": 0
    },
    "221": {
        "output": "#### Step 1: patient note\n\nYour patient note should be similar to below. Make sure all the information is up to date, as this task will be automatically calculated. If any patient note, for example, is old, you should add the current patient note.  \n\n```python\ndef _patient_note_assessment(note, clinical_trial, **kwargs):\n    return {\n    0: 'Excluded',\n    1: 'Not Relevant',\n    2: 'Eligible'.\n    }[clinical_trial.assessment_scale]\ndef _patient_note_assessment(note, clinical_trial):\n    if 'clinical_trial' not in note:\n        return _patient_note_assessment(note, clinical_trial, x1='', x2='', x3='')\n    # get patient's ID\n    patient_id = find_first(filtered_criteria, lambda x: isinstance(x, Patient) and x.patient_id is not None)\n    # make sure that patient has associated note\n    if note is None or \\\n      note[0:3] != patient_id: return _patient_note_assessment(note, clinical_trial, x1='', x2='', x3='')\n    note_id = int(note[3])\n    # find relevant criteria\n    # clinical_trial.assessment_scale == 0 -> Excluded\n    # clinical_trial.assessment_scale == 1 -> Not relevant\n    # clinical_trial.assessment_scale == 2 -> Eligible\n    criteria = {criterion.name for criterion in filtered_criteria if isinstance(criterion, Criterion) and 'patient_notes' in criterion}\n    if len(criteria) == 0: return _patient_note_assessment(note, clinical_trial, x1=criteria[0], x2=criteria[1], x3=criteria[2])\n    \n    # filter candidate criteria\n    # check if criteria.patient_notes == note_id\n    # if not, add",
        "label": 0
    },
    "222": {
        "output": "A: This was a bit of a puzzler but the answer turned out to be at the bottom of a page: the \"Trial-level Eligibility\" check boxes were not set to default, but they must be.\n<EOD> Hydrocephalus in a cat after surgery for a cranial feline infectious peritonitis lesion\n\nA 23-month-old female spayed Abyssinian cat was found as a stray. Three years previously, this cat was surgically treated for a cranial feline infectious peritonitis (FIP) lesion. On admission, the cat had a good general condition, except for moderate ataxia of the pelvic limbs. Neurological examination revealed diffuse hyperaesthesia. Magnetic resonance imaging revealed cerebral ventriculomegaly with dilatation of all cerebral ventricles. The third ventricle was compressed by the caudal cerebellar peduncle and the crop of the obex. Histopathological examination of the caudal feline encephalitis (a previous lesion) revealed diffuse, bilaterally symmetrical, randomly distributed granulomatous inflammation of the neuroparenchyma, with foci of necrosis and perivascular cuffing, which are characteristics of FIP lesions. Cerebral ventriculomegaly was attributed to previous granulomatous inflammation of FIP, together with chronic active granulomatous inflammation in the dorsal and ventral arachnoid membranes of the cerebrum.\n\n# Introduction\nFeline infectious peritonitis (FIP) is an invariably fatal disease that affects the majority of feline species. It can be divided into two forms: a dry form with few extracellular proteases and a wet form (hypodense) [bib_ref]  The natural history of an outbreak of feline infectious peritonitis, Coyne [/bib_ref]  [bib_ref]  Feline infectious peritonitis: proposal for a unifying mechanism, Bradshaw [/bib_ref]  [bib_ref]  Clinical and pathological features of a juvenile outbreak of",
        "label": 0
    },
    "223": {
        "output": "---\n\n### Exercises\n\n---\n\n[1] Hello. You are a helpful human assistant. You are going to assess patients` eligibility by comparing patients` notes to a selected clinical trial.\n\n1. Consider the following clinical trial:\n[c3] [c4] [c5] [c6] [c7][c8] \n\n1.1. Exercise 2. Find all patients that are not eligible.\n\n2. Exercise 4. Find all patients that are not applicable to the Trial.\n\n\n---\n\n>## The output data\n<EOD> Antimalarial and immunomodulatory activity of ethanolic seeds of Caesalpinia bonducella Fresen\nMalaria is a major public health problem. The immunity is the only way to combat malaria. Caesalpinia bonducella Fresen. is a widely distributed species in Asia and one of the most promising indigenous sources of immunomodula tory compound. In the present work, we evaluated the antimalarial and immunomodulatory activity of ethanolic seeds extracts of C. bonducella. Three organic extracts were evaluated as antima larial agents either in vivo (Swiss albino mice) or in vitro (Plasmodium yoelii\u2010infected erythrocytes). The leaf and stem bark ethanol and benzene extracts showed antimalarial activity 24 and 72 h pi, respectively, the leaf ethanol extract showed the highest activity compared to chloroquine, and the extract\u2010induced death of P. yoelii\u2010infected erythrocytes was significant (<0.0001). The ethanol fraction of the leaves revealed immune stimulatory activity as it raised the number of lymphocytes and phagocytic activities. Copyright \u00a9 2002 John Wiley & Sons, Ltd.<EOD> The association between antioxidant supplementation and the risk of prostate cancer: A meta-analysis\n\na b s t r a c tAn increasing amount of epidemiologic research, including a few meta-analyses, have",
        "label": 0
    },
    "224": {
        "output": "```\n[CODE]PATIENT_DESCRIPTION                                                                                                                                                                                                                                                                                    SCORE_CIRCULATION_RESISTANCE = {\"patient_description\": \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal\\n\\000\\ breast cancer in the left upper outer quadrant. The tumor is HER2-positive and ER/PR\\n\\000\\ negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic\\n\\000\\ lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume\\n\\000\\ alcohol. She is not sexually active and has no children. She is a candidate for tumor\\n\\000\\ resection and agrees to do so prior to chemotherapy.\"}\nSCORE_AGE = {\"score_age\": \"45\"}                                                                                                                                                                                                                                                      SCORE_SMOKER = {\"score_smoker\": \"0\"}\nSCORE_DRINKER = {\"score_drinker\": \"0\"}\nSCORE_PHY_ACTIVE = {\"score_physically_active\": \"0\"}\nSCORE_CHILDREN = {\"score_childs\": \"0\"}  \n\nSCORE_HER2 = {\"score_her2\": \"2\"}                \nSCORE_ER = {\"score_er\": \"0\"}                                SCORE_PR = {\"score_pr\": \"0\"}\nSCORE_GRAVID = {\"score_gravid\": \"0\"}                                SCORE_HYPERTENSION = {\"score_hypertension\": \"0\"} \n\nSCORE_OVERWEIGHT = {\"score_overweight\": \"0\"}                                SCORE_OBESITY = {\"score_obesity\": \"0\"}\nSCORE_DIABETES = {\"score_diabetes\": \"0\"}                                SCORE_LI",
        "label": 2
    },
    "225": {
        "output": "**Trial-level eligibility: 0) Excluded.\n\nThis patient is not eligible for the trial, because the patient does not meet any eligible criteria but the trial's inclusion criteria.\n\n**Trial-level eligibility: 1) Not eligible.\n\nYou should try to find any eligible patient or any clinical trial for our given patient. Maybe this patient is already included in some trials.\n\n**Trial-level eligibility 2) Eligible.\n\nThis patient is eligible for the trial. <EOD> Numerical Investigation of Inertial Focusing in Microchannels\n\nInertial focusing is becoming an increasingly popular method to pre-focus biological particles based on both their density or size differences for flow cytometry applications. This paper presents a novel hybrid computational method for rapid and accurate multi-particle simulation and analysis that incorporates the recently discovered particle-based momentum transfer method. A series of numerical studies were conducted and showed that the particlebased momentum transfer method provided excellent agreement with the analytical solution for a wide range of conditions and was much faster and more computationally efficient than the Lattice-Boltzmann method, while keeping the same order of accuracy. Two additional studies were conducted to test the stability and accuracy of the hybrid method for microchannel arrays and to determine the most efficient manner in which to organize a particle ensemble in the inertially focused channel to improve focusing resolution. This work confirmed that accurate inertial-based particle focusing can be achieved with particle-based momentum transfer method by incorporating the momentum transfer as an additional force term in Euler equations. The proposed hybrid method can therefore be reliably used in the development of particlebased focusing and concentration in microchannels.\n\n# Introduction\nOver the past few years particle-focusing technology has become more attractive in biochemical applications, as a variety of different cell types can be separated using this technique. In recent years, microfabricated devices have allowed particle-focusing, and cell separation to be implemented on a compact and affordable chip-scale device for the analysis of sub-micron cell samples. Specifically, inertial-based methods have demonstrated remarkable potential for continuous focusing and separation of biological particles in microchannels.\nInertial focusing mechanisms typically indu",
        "label": 0
    },
    "226": {
        "output": "### The assessment of eligibility. \nIn order to make the clinical trial note and clinical data note coherent, the patient inclusion criteria should follow the inclusion criteria of the corresponding clinical trial. In this exercise, you should make a patient inclusion criteria and trial-level eligibility for the clinical trial note. \nThis exercise is performed in two steps. \n1. Compare inclusion criteria and patient clinical data note. 2. If patient information is sufficient to assess the patient eligibility, output the scale for the assessment of eligibility. \n\nIf you think this patient matches the criteria of the trial, input the code of the assessment of eligibility:\n\nif ___Inclusion criteria met___ & ___Triall-level eligibility____=2\n\nif ___Inclusion criteria not met___or ___Not sufficient information___\n\nif ___Inclusion criteria not met & ___Triall-level eligibility____=1_________\n\nif ___Inclusion criteria not met & ___Triall-level eligibility____=0___________\n\n_If the eligibility code matches the eligibility assessment code output a '1\u2032 in the variable eligibility assessment. [inst]\nExample of a dataset for an eligible patient:\n\n[Eligibility Assessment] Eligibility assesment number=1\n[Eligibility Code] Code number=1\n[Trial number] 3026\n[Trial title] Chronic toxicities related to treatment in patients with localized cancer\n[Trial summary] The aims of the cohort will be to quantify impact of cancer treatments toxicities, and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer.\n[Trial design] Cross-sectional survey\n[Exclusion criteria]\nThe designers of clinical trials are interested in quantifying exposure to different treatment combinations while they are also interested in quantifying the impact of the side effects.\n[Trial design] Cross-sectional survey\n[Exclusion criteria]",
        "label": 1
    },
    "227": {
        "output": "## Task 2: Predict a patient's eligibility for a clinical trial\n\nYou should predict a patient's eligibility using the classification models.\n\nFirst, you should split the dataset by `train`, `test`, and `val` folders:\n```\n# create folders for train, test, and validation folds # train_data: data for training model # test_data: data for testing # validation_data: data for predicting eligibility # -\nmkdir folds \ntraining validation testing\ncp ./data/training/* train/\ncp ./data/validation/* val/\ncp ./data/test/* test/\n```\n\nAfterwards, you'll fit logistic regression and random forest models. \n\nThe random forest models that you are going to implement are as follows:\n\n## RandomForestClassifier(n_estimators = 500, max_features = 'auto')\nThe best model will result from cross-validation using `GridSearchCV` as follows:\n\n```\nimport matplotlib.pyplot as plt\nfrom matplotlib import rc\nrc('figure.figsize', **{'lb': 10, 'mb': 30}) \nfrom sklearn.model_selection import cross_val_score, cross_val_predict\n```\n\nIn your first step, you should use the `GridSearchCV` parameter with the following `param_grid`:\n\n```python\nparam_grids = {\n    'classifiers': ['Logistic Regression']\n    'kernel': [\n        'GaussianRadial',\n        'GaussianProcessLSSVM',\n        'LinearSVC',\n        'PolynomialSVC',\n        'RBFSVC',\n        'SVKernelFunction'\n        'DotProductFunction'], \n    # other parameters of the parameters' grid\n}\n```\n\nHere is the results obtained using two classifiers (i.e., `random forest logistic regression`).\n\n\n\n```python\n# 5 folds with cross validation\nfrom sklearn.model_selection import StratifiedKFold\n\n# 5 folds with stratified cross vali-\n# dation\nscores = cross_val_score(model=classifier, cfn=1, cv=5)\n# Str",
        "label": 0
    },
    "228": {
        "output": "## \u2753 Challenge.\nThe patient note is incomplete. How will you continue?\n\n\n# RESULTS\nThe script, which you have seen in the section [DNN](https://github.com/PinLab/dnn-pytorch-tutorials/blob/master/03_deep_learning_with_pytorch/3_dnn.ipynb \"dnn\"), can automatically detect if a patient will or will not be enrolled in the trial. The result is written in the \"result\" column and is a 3-character string (e.g., **1**).\nThe output is consistent with the previous version, that is, it correctly classifies patients that are already in the dataset. Here, for example, the following are patients that passed the check and were classified as 1.\n\n\n[![IMAGE ABOVE](https://user-images.githubusercontent.com/31008354/71051366-69fd1600-2f39-11ea-8347-f36159a80a01.png)]()\n\nOn the other hand, these patients were classified as 0 by the model. \n\n\n[![IMAGE ABOVE](https://user-images.githubusercontent.com/31008354/71051376-7a49f700-2f39-11ea-8dd3-4fcad4d99a96.png)]()\n\nAs you can see, this model is now able to make 18 more predictions, but 16 are incorrect.\n\n## RUNTIME\n\nDetection is computed in:\n\n* **0.018 seconds** when using Tensorflow\n\n\n\n<EOD> Fetal hemoglobin modifies the association between red blood cell distribution width and new-onset diabetes mellitus after transplantation\n\n\n\n# Introduction\nRed blood cell distribution width (RDW) is a measure of the width of the red blood cell distribution and it is routinely used in the differential diagnosis between anemia and thalassemia and other inherited diseases that affect red blood cell size",
        "label": 0
    },
    "229": {
        "output": "The output should be 2) Eligible.\n<EOD> .\nIn this study, we determined the clinical value of endoscopic third ventriculostomy (ETV) in the treatment of spina bifida aperta with hydrocephalus. Seven cases suffered from spina bifida aperta with hydrocephalus who were treated with ETV of the third ventricle. All the patients had hydrocephalus due to spina bifida aperta, hydrocephalus was caused by tumefactive arachnoidal cyst of CSF, ventriculomegally of hydrocephalus and so on. ETV was successfully conducted in all these patients with total resolution of hydrocephalus on postoperative CT scans and no complications. All seven children underwent ETV, with the age range from 1 day to 5 years. A fourth patient had hydrocephalus due to CSF fistula, ventriculomegally of hydrocephalus and so on and was treated by ETV. All the patients had resolution of hydrocephalus. Three patients had post-operative complications and all of them required temporary ventriculoperitoneal shunt placement. The follow-up period ranged from 28 to 36 months. The author considers the operation to be highly valuable for spina bifida patients.<EOD> Antimicrobial resistance patterns of 102 \u03b2-lactamase-positive clinical isolates of Pseudomonas aeruginosa from a University Hospital in China\n\nAntimicrobial resistance is increasing in Pseudomonas aeruginosa clinical isolates. This study was designed to describe drug resistance and molecular characteristics of clinical isolates of P. aeruginosa collected at the China-Japan Friendship Hospital during a three-year period. We collected 102 clinical isolates of P. aeruginosa from an inpatient population, during the period from January 2013 to December 2015. Antibiotic susceptibility was performed and classified as susceptible (S) or nonsusceptible (NS). Resistance genes were tested by multiplex PCR. Of the 102 isolates, 96 were NS to one or more antimicrobials. In particular,",
        "label": 0
    },
    "230": {
        "output": "# D: Detective\nLet's think step by step. \nFinally, you should always repeat detective_rule.cls in the last line by `detective_rule.cls: 2) Eligible.`, i.e., `detective_rule.cls:\nTrial-level eligibility:\nRCT_title:Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone-Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer.\nTrial_title_2: A Phase III, Double-Blind, Randomized Trial of the Effectiveness of Adding Combined Estrogen Deprivation Therapy to First-Line Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Treating Patients With HER2-Positive, Hormone Receptor-Positive, Advanced or Locally Invasive Breast Cancer.\nexclusion_reason_1: Hormone-receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_2: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_3: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_4: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_5: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\n\n# E: Effective\nLet's think step by step. \nLet's check how many cases are eligible for the first 11 factors. \nFinally, you should always `effective_rule.cls` in the last line by the `effective_rule.cls: 2) Eligible.`, i.e., `effective_rule.cls:\nRCT_title: Docetaxel, Car",
        "label": 0
    },
    "231": {
        "output": "<EOD> A Detailed Investigation on the Characteristics of the Interlayer Moir\u00e9 of 2D-MoSSe Monolayers\n\nThrough a detailed consideration of structural features, we present a model for explaining the nature and origin of interlayer moir\u00e9 in the 2D transition metal dichalcogenide (TMDC) monolayer. The model proposed here clarifies the relationship between the interlayer twist angles, the relative orientations of in-plane lattices, and the moir\u00e9 patterns. With our model, the moir\u00e9 patterns with different interlayer twist angles can be clearly understood and classified. We find that interlayer moir\u00e9 patterns are more common in monolayer TMDCs with trigonal crystals. Our results may help to understand the interlayer moir\u00e9 phenomena in 2D material research and will provide new insights for studying the interlayer moir\u00e9 patterns in TMDC superlattices.\n\n# Introduction\nAs the two-dimensional (2D) atomic crystals have been intensively investigated in recent years, new materials with rich structures and excellent optical, electrical and mechanical properties have been obtained. Compared with the three-dimensional (3D) materials, 2D atomic crystals are very flexible materials. Various types of 2D materials, including silicene, germanene, carbon nitride, transition metal dichalcogenides (TMDCs), black phosphorus, have been successfully synthesized using simple methods. As a class of layered 2D materials with large interlayer van der Waals and weak interlayer interactions, TMDCs usually exhibit layered structures with an AB or ABC layered structure depending on the type of atoms. When the stacking of the A and B layers is considered to be equivalent to a single layer, TMDCs are composed of S or Se atoms forming a 2D plane, and a variety of different stacking structures form due to the differences in the arrangement order of A layers and B layers.\nSimilar to grapheneand related two-dimensional (2D) materials, the layered structures of the TMDCs can also form moir\u00e9 patterns between adjacent layers. Interlayer moir\u00e9 patterns usually have some periodic bright-dark structures due to the mismatch in the atomic arrangement of the individual layers. The interlayer moir",
        "label": 0
    },
    "232": {
        "output": "You should always output the assessment for each patient:\nPlease let us know how it goes by submitting a pull request to https://github.com/TensorFlow/examples/pulls with as much detail as possible. For some background, see the [howto](#howto) below.<EOD> Identification of a novel mutation in the human CMP\u2010sialic acid transporter: Possible defect of sialic acid transport in a human renal proximal tubular cell line\nSialic acids exhibit a variety of glycan structures and contribute to many functional parameters, including the selectivity of molecular interactions between cells. Human sialic acid (Sia) is synthesized mainly in the erythrocyte, brain, and liver. However, the molecular mechanism underlying renal Sia transport is not well understood. We recently established a cell line from a patient with renal dysfunction (KU\u20101) and found that the cell proliferation of this patient was arrested in G2/M phase, and the cell death was accelerated during the G2 phase; thus, the cell cycle control in this patient was defective (Biochem. Pharmacol. 66:1955\u20131964, 2003). In the present study, the biosynthesis and distribution of Sia was examined in the kidney of a patient with renal dysfunction (KU\u20101) and a control. The quantity and the distribution of Sia in the kidney of the control and the patient were almost similar. The expression and amount of CMP\u2010Sia transport protein (CST), a transporter of Sia, were examined in the proximal tubular cells of a control by a Northern blot method and a biosynthetic pathway of Sia using pulse\u2010chase method. The quantity and localization of CST and the amount of Sia in the erythrocyte and urine in the control suggested that the patient with renal dysfunction (KU\u20101) had Sia transporter defects. The patient's erythrocytes showed a small amount of Sia, and most urinary Sia was derived from Sia of red blood cells (RBC), indicating the possibility that Sia transporters were defective in the patient's tubules.",
        "label": 0
    },
    "233": {
        "output": "<EOD> A Review of Biofabrication Techniques and Their Application in Neuroregeneration\n\n\n\n# Introduction\nRegenerative medicine is a highly promising field with much potential for treatment of neuroregeneration and spinal cord injury. While stem cell therapy has demonstrated great success, significant challenges persist, including poor engraftment of cells in injured areas, their inability to differentiate into a specific cell type, and difficulties in monitoring long term neuroregeneration. Another key factor in the field is the development of biomaterials, with scaffolds providing support for cells, delivery vehicles for growth factors and stem cells, and stimulators of cellular activation and differentiation into the desired neuronal lineage [bib_ref]  The influence of biomaterials and cell therapies on stem cell fate, Taradeh [/bib_ref] . Biomaterials used in tissue engineering have the role of delivering the desired cells, proteins, and growth factors to promote healing and tissue regeneration at the injury site. While various regenerative techniques are being researched [bib_ref]  Progress in Biofabrication: A Tissue Engineering Paradigm Shift, Guillemot [/bib_ref]  [bib_ref]  Three-Level Tissue-Engineered Bone and Cartilage Construct Based on Alginate/Nanohydroxyapatite Composite, Fan [/bib_ref]  , there is an increasing emphasis on improving neuroregeneration approaches, e.g., through combination with other regenerative medicine techniques [bib_ref]  Cranial neural tube closure in reptiles and its implications in humans and..., Maul [/bib_ref] .\nThrough recent developments in the fields of developmental biology and stem cell therapy, there has been improved knowledge of injury biology and neuroregeneration. An increasingly accepted understanding of disease biology has led to significant therapeutic advancements through biomaterials, regenerative medicine, nanotechnology, and 3D biofabrication [bib_ref]  Bioprinting for neural tissue engineering, Knowlton [/bib_ref] . The main aim of tissue engineering and the clinical translation process is to engineer healthy tissue mimics in vitro or in vivo to promote regeneration, repair, and restore lost functionality [bib_ref]  Three-Level Tissue-Engineered Bone and",
        "label": 0
    },
    "234": {
        "output": "<EOD> Excessive cerebellar activity as compared to the precentral gyrus in childhood absence epilepsy.\nA high incidence of the absence epilepsy during sleep and attention deficit in association with excessive cerebellar activity during nonrapid eye movement sleep suggests an underlying functional abnormality in the brain. To better understand the underlying nature of the functional abnormality in childhood absence epilepsy (CAE), we analyzed the scalp EEG synchronization between the cerebellar vermis and various cerebral regions while subjects performed a digit vigilance task (DVT). The results showed that the cerebellar vermis was significantly synchronized with the ipsilateral temporal region including the parahippocampal gyrus and occipital region during the DVT in 10 children with CAE who were taking anti-epileptic medication. However, the cortical regions which appeared to have significantly excessive synchronization with the cerebellar vermis during the DVT in children with CAE included the prefrontal cortex, postcentral gyrus, supplementary motor area and precentral gyrus. We tentatively draw attention to the excessive activity of the cerebellar vermis and functional disturbance of the precentral gyrus, which appears to be associated with excessive synchronization of the cerebellar vermis with the prefrontal cortex.<EOD> Rheological Properties of High Molecular Weight Polyethylene/Carbon Nanofiber Composite Filled with Fumed Silica Nanoparticles\n\n\n\n# Introduction\nNanocomposites are materials in which one or more nanoparticles are dispersed in a continuous matrix phase [bib_ref]  Effect of nanofiller morphology on the rheological, optical, structural and thermal behaviour..., Shanmugavel [/bib_ref]  [bib_ref]  The Effect of Nanoparticle Content and Nanofiller Molecular Weight on the Rheological..., Shanmugavel [/bib_ref] . Due to the synergistic interactions at the nanocomposite interfaces, the nanocomposite material can exhibit new properties related to the polymer matrix and nanomaterial [bib_ref]  Fabrication of High-Performance Nanocomposites: A Review, Dhand [/bib_ref] . Polymer nanocomposites containing carbon nanofiber nanom",
        "label": 0
    },
    "235": {
        "output": "#### Exercise 1.\nIn the following case, which of the following is incorrect about the patient's eligibility?\n\n\n|No|Explanation|\n|:---|---|\n|1. |`Age = 46, Gender = 1:` The patient is 46 years old.  |\n|2. |`Age = 48, Gender = 1:` The patient is 48 years old.\n|3. |`Age = 51, Gender = 1:` The patient is 51 years old.\n|4. |`Age = 46, Gender = 0:` The patient's Gender field is 0.  |\n\n#### Exercise 2.\nIn this set of patient cases, which patient would be excluded from the trial with this clinical trial? Why?\n\n\n|Exercise 2.|Result|\n|:---|:---|\n|Exercise 2.|Case 1: Patient 25|The patient 25 does not meet the inclusion criteria of the trial because they're in the <sup>1</sup> age group.  |\n|Exercise 2.|Case 2: Patient 62|The patient 62 does not meet the inclusion criteria of the trial because they're in the <sup>>4</sup> age group.  |\n|Exercise 2.|Case 3: Patient 2|The patient 2 does not meet the inclusion criteria of the trial because they're in the <sup>6</sup> ethnicity group.  |\n|Exercise 2.|Case 4: Patient 77|The patient 77 does not meet the inclusion criteria of the trial because they're in the <sup>2</sup> marital status group.  |\n|Exercise 2.|Case 5: Patient 24|The patient 24 does not meet the inclusion criteria of the trial because they're in the <sup>1</sup> race group.  |\n|Exercise 2.|Case 6: Patient 35|The patient 35 does not meet the inclusion criteria of this clin",
        "label": 2
    },
    "236": {
        "output": "##[INS]\nThe patient is enrolled in the clinical trial. However, the patient does not meet the inclusion criteria. \n\nPatient-level eligibility: 0\\&1\\&0 \nOutput: Excluded \nFinally, you should always repeat Patient-level eligibility in the last line by `Patient-level eligibility: 0\\&1\\&0`. [INST]\n\n##[INST]\nThe clinical trial is finished before the patient is enrolled to the trial. \n\nTrial-level eligibility: Not relevant \nOutput: Not relevant\n\n\nNow we can conclude that the patient may be eligible.\n\n### ANSWER TO Q5-Q9\n\n### Q5. The patient satisfies the following conditions:\n\n### Q5.1. The patient is female.\n\n### Q5.2. This patient meets age requirement (45 years old or older.)\n\n### Q5.3. The patient has cytologically confirmed invasive ductal breast cancer.\n\n### Q5.4. Lymph node metastases have been confirmed.\n\n### Q5.5. The patient has no children.\n\n### Q5.6. Cervical examination is not relevant.\n\n### Q5.7. This patient has not had any sexual intercourse over 90 days.\n\n### Q6. The patient will use all study drugs and will receive at least 1 cycle of study treatment.\n\n### Q7. The patient can continue for at least 16 days in the study.\n\n### Q8. The patient is healthy enough to receive study treatments.\n\n### Q9. We can expect to meet this patient in a 45-64 years old woman.\n\n### ANSWER TO Q2\n\nThe answer is `Yes`.\n\n### ANSWER TO Q3\n\n### Q3.1. The patient must satisfy three conditions:\n\n### Q3.2. She is a 45-year-old postmenopausal woman.\n\n### Q3.3. This patient must be eligible to participate in a clinical trial.",
        "label": 2
    },
    "237": {
        "output": "[INT] Hello. You are a breast cancer pathologist. Your task is to detect breast cancer metastases in lymph nodes.\n\nWhen diagnosing the condition of nodes, it is necessary to obtain material from the primary tumor as well as the surrounding structures. When assessing the pathological findings of the breast or axillary lymph nodes, the presence or absence of signs of a malignant neoplasm should be determined (tumor node [1][2][3][4]6]. \nHere are two cases: \nThis is a whole case without metastasis. \nThis is a case with metastasis. \n\nNow you should determine the malignancy of the breast cancer (1) or metastasis in the lymph node (2) for each case:\n1) Malignancy of tumor: benign. 2) Malignancy of tumor: malignant. 3) Malignancy of tumor: benign. 4) Malignancy of tumor: carcinoma in situ of ductal epithelium. 5) Malignancy of tumor: malignant. \n\nNow, you should put a tick in the corresponding row. [INT] Hello! You are a helpful assistant for clinical trial recruitment. Your task is to compare the patient's note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThis patient meets the inclusion criteria of the clinical trial you are evaluating, namely [bib_ref]  Neoadjuvant chemotherapy plus trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,..., Gianni [/bib_ref]  positive nodal status (cN+), (2) HER-2 receptor-positive status, and (3) presence of metastases in axillary lymph nodes. Hence, your assessment is 'Excluded'.\n[INST] Hello. You are a junior neuropathologist. Your task is\nto detect tumor metastases to the brain through radiographic imaging.\nThe presence of metastases to the brain is one sign of metastatic disease that determines patient eligibility to enter into a clinical trial. In this particular trial patient is a",
        "label": 1
    },
    "238": {
        "output": "You may need to repeat these steps for each patient who is being assessed for a study:\n\n- [INST] Get the next patient ID:\n    `getnextPatientID('patient'/patientName)` (the function returns a string)\n\n- Compare the patient information with the clinical trial inclusion criteria, and apply the proper treatment if needed (see \u25b6 Patient Level Criteria column from the table).\n    `function treatPatient(eid)` - `Treatment eid` input field will be disabled (e.g., it will be set to ''discarded'')\n\n- Calculate the patient weight column and compare whether it fits the range (see \u25b6 Weight column). The weights are calculated automatically, and their values are set for the given trial.\n    `function calculateWeight(eid)` - 0% or NaN for all patients\n\n- Repeat 2-4 for all patients.\n   `function repeatFunctions(patient) <br /> <br />    calculateWeight(patient) &rarr;`\n\n#### Error Handling\n\nIf one of the functions below triggers an error (e.g., because of a missing or non-numeric field in `patientName`) return a 500 HTTP code with an error body like below. You could also apply the following rules in Python's template engine:\n\n`{{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }}",
        "label": 0
    },
    "239": {
        "output": "## Finding the problem\n\n### The [0] patient is using multivitamins and iron supplements (False)\nIt is not given that multivitamins and iron supplements are used, so the patient satisfies the inclusion criteria.\nIn clinical studies including trial 3AJ007N101H00001 and trial 18-152, both do not exclude patients using multivitamins and iron supplements.\n\n### The patient is 45 years old (True)\nIt is not given that the patient in trial 3AJ007N101H00001 is older than 18 and is not older than 60 years old. Therefore, the patient satisfies the inclusion criteria.\nIn trial 3AJ007N101H00001, the age of the first registration is between 18 and 60.\n\n### The patient has no children (True)\nGiven that the patient has no children, the trial's inclusion criterion is met.\nIn trial 3AJ007N101H00001, no children are required.\n\n### Sexually active patient (False)\nThe sexually active patient does not meet the inclusion criteria.\nIn trial 3AJ007N101H00001, the patient must not be sexually active at the time of enrollment.\n\n### The [2] patient has not undergone chemotherapy or radiotherapy or surgery due to breast cancer (True, the patient must have undergone those treatments)\nIn trial 3AJ007N101H00001, the patient must have undergone chemotherapy or radiotherapy or surgery due to breast cancer.\n\n### It is not given that the patient has undergone 5 surgeries (False)\nThe patient satisfies the trial's inclusion criteria because the following is given.\nIn trial 3AJ007N101H00001, the patient has undergone a core biopsy of the breast and axillary sampling.\nIn clinical studies including trial 18-152",
        "label": 0
    },
    "240": {
        "output": "(v) Case report\nThe patients in this study are a 20-year-old woman (with a height of 165 cm and a weight of 72 kg) and a 30-year-old man (height, 173 cm, weight, 80 kg) who are both healthy. After a careful review, we decided to construct a clinical trial using this data. The following table summarizes patient data in the study; this is patient data that was used for the construction of our clinical trial.\nThe research hypothesis is as follows: \nH0: There is no difference in the effectiveness of the two treatment groups\nH1: There is a difference in the effectiveness of the two treatment groups\nThe research design of the clinical trial is shown below.\n\n## Research design: a clinical trial plan using the dataset created by the case study\nThe randomized controlled trial (RCT) is a widely used and reliable method for clinical research. It can reduce bias and help provide more accurate results. It also gives doctors evidence for the safety and effectiveness of treatment options and helps determine optimal treatment dosage. In order to avoid bias in this clinical trial, we decided to adopt a crossover design. Our experimental design is such that both groups first receive the active medicine for 4 weeks. After that, they take a placebo for another 4 weeks. The entire process is conducted twice. A total of 30 healthy people are randomly assigned to each group in a 1:1 ratio. Each person takes the medicine and placebo after fasting for 12 hours in the morning. Then, blood is drawn from the antecubital vein to measure sugar levels and the number of red blood cells.\nData preparation: This study is based on collected blood samples. We need to convert values from the original raw data to an appropriate format and convert the data to a csv file. The data format must have two columns for each patient. Column A has the patient's unique identification number; B is the name of each patient, and C through E contain the measurement results of each patient. \nThe file name is as follows: CROSSOVERDATA_180701_1207.csv\n<EOD> The Role of Chromium Hexavalent Ions in the Enzyme-Catalyzed Oxid",
        "label": 0
    },
    "241": {
        "output": "You have implemented the elicit_patient_note function for eliciting patient note in [src/patient_test.py]:\ndef elicit_patient_note(patient_profile):\n    if not patient_profile.status_profile.current_trial_id == '' or not trial_id in patient_profile.status_profile.active:\n        return 'Trial-level eligibility: 0) Excluded.\\nTrial-level eligibility: 1) Not relevant.\\nTrial-level eligibility: 2) Eligible.'\n    else:\n        # Get patient note from the data source\n        patient_note = self.get_data('patient/note', self.clinical_trial_profile.record_profile.source_key)\n        if not patient_note:\n            return 'Trial-level eligibility: 0) Excluded.\\nTrial-level eligibility: 1) Not relevant.\\nTrial-level eligibility: 2) Eligible.'\n        else:\n            return patient_note\n[TEST] 13_02_19_patient_test00101 09:41:57:000 start INFO: Trial_elig_patient_note_37082_178: Trial-level eligibility = 2) Eligible\n 13_02_19_patient_test00101 09:41:57:000 Trial-level eligibility = 2) Eligible.\n\nIn [2]: patient_test.Patient_test.test_elicit_patient_note()\n---------------------------------------------------------------------------------------------------------------\ntest_elicit_patient_note() succeeded\n\n\n## 4) eligibility assessment for a given patient\n4_01_ Patient eligibility assessment and 7_01_ eligibility assessment should include the same conditions.)\nYou can get eligibility assessment for a given patient by making eligibility assessment for that patient within a patient_test object. This functionality is implemented in [src/patient_test.py]:",
        "label": 2
    },
    "242": {
        "output": "12. First, we retrieve the data from the clinical trial for the clinical trial identifier in the eligibility_check_code column. \nWe use both a clinical trial identifier as defined by the RE-ACTIVE trial and a non-unique clinical trial identifier that is only defined within the PDcheck application (clinicaltrial_identifier_x). \n13. Finally, you need to store the information in the `active_completed_clinical_trials` array, as illustrated in part 859. If you need to add other patient-level selection criteria in the future, you can store them in the corresponding elements in the `active_completed_clinical_trials` array. \n### Running PDCheck.\nYou can run PDCheck on a Linux or Unix operation system or on the Windows command line. \nIt is always good to start with a simple PDCheck run to try out the script, and then test more complicated runs by adding more patients one by one. For your convenience, we have added",
        "label": 0
    },
    "243": {
        "output": "## [INTERSTITIAL]\nIn [INTERSTITIAL] cases, you should output `Excluded` instead of `Not qualified` only for a trial that the patient doesn't meet all criteria.\nThe trial criteria to be matched should be in **boldface**, and they're the same way as for the regular eligibility cases discussed in the training section, just without the matching criterion of `CXR was remarkable for metastatic lesions`. So the input line for the patient note is:\nPatient is 45 years old post-menopausal woman with cytologically confirmed breast cancer and a core biopsy revealed 3cm invasive ductal carcinoma in left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nYou should do the same as with the previous eligibility case. All matching criteria of the matching criteria should matched. The trial criteria should be boldface and be in **boldface**, and `CXR was remarkable for metastatic lesions` should be removed.\nNow the input to output is:\nPatient is 45 years old post-menopausal woman with cytologically confirmed breast cancer. Core biopsy revealed 3cm invasive ductal carcinoma in left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nTrial-level eligibility: 1) Not qualified. [/INTERSTITIAL]\nThen the corresponding line to `Trial-level eligibility: ` is:\nPatient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer and a core biopsy revealed 3cm invasive ductal carcinoma in left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nThe patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is seeking tumor resection and agrees to do so prior to chemotherapy.",
        "label": 2
    },
    "244": {
        "output": "[INST] Hello. You are a helper for clinical trial recruitment. Your task is to compare a patient's medical record note as well as the inclusion criteria, and make an assessment of eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level assessment of eligibility on each patient. \nHere is the patient note:\nThe patient is a 40-year-old female diagnosed with stage III neuroendocrine small cell lung cancer, a type of non-small-cell lung cancer. \nHistopathology: a large neuroendocrine tumor is diagnosed by biopsy. The Ki67 index is 80%. Immunohistochemical staining of tumor cells by the anti-synaptophysin antibody (clone MAB5298; lot GR25162011).\nMolecular tests on pleural effusion cytology reveal mutations in the TP53 gene. A mutation in the BRAF V600E gene is also described.\nBlood test: normal complete blood count and chemistry profile.\nHere is a clinical trial: \nTitle: Phase III Randomized Study Of Nivolumab and Topotecan in Patients With Advanced Neuroendocrine Tumors\n\nResearchers are searching for treatments to prevent tumor cells from invading the skin and other areas of the body. Nivolumab is a chemotherapy drug that blocks the ability of tumor cells to grow. Topotecan is a chemotherapy drug that stops tumor cells from dividing.\nThis study's goal is to determine whether:\n Nivolumab improves",
        "label": 0
    },
    "245": {
        "output": "##[INST] Here is the patient note:\nThe patient is a 68-year-old man. When he first visited our hospital two months ago because of anorexia. The CT showed two pancreatic tumors, and the patient was diagnosed with metastatic pancreatic cancer. No other metastases were found. The patient had taken medication to prevent an enlarged prostate. Other medical conditions include prostate diseases and diabetes.\n\nNow let's evaluate the previous patient note:\n> trial:\n> trial:\n  * The patient's age (68 years old) meets the trial's upper age limit.\n  * The patient's gender (male) meets the trial's gender characteristics",
        "label": 0
    },
    "246": {
        "output": "5) Outputting the Patient ID: You can output the patient ID number in the patient note by calling your user interface and running it with the patient note as the argument, `ui(\"Patient ID\")`.\n6) Converting the patient note to HTML and saving in pdf: To save the note of the patient in the PDF format, use <xref target=\"patient_id_0\"/> to get the patient ID code, save the PDF file by writing a Python command, `File(\"MyNote.pdf\").save()`, and the PDF file will be saved in the same folder with your patient note. [INST] If you don't output anything in 3) and the trial-level eligibility is set to `Excluded`, you should return 0 (0) according to the `patient_id_0` command.\n[INST] `Trial-level eligibility: Excluded` does not mean the trial cannot take place. Instead, the patient is excluded on the grounds of the trial's exclusion criteria. This happens when a patient with a severe medical condition is found eligible by the eligibility criteria, but the trial cannot take place for this patient due to an exclusion criterion.\n[INST] 1) Write a Python command using <var name=\"patient_id.Trial-level eligibility\">, e.g. `File(\"Notebook-6/patient_id.Trial-level eligibility\")`, to read the code. If you are in the `patient_id_0` mode, the result should be shown in the notebook as an output.\n[INST] If you don't output anything in 3) and the trial-level eligibility is set to `Not relevant`, you should return 2 (Not relevant).\n[INST] `Trial-level eligibility: Not relevant` means that there is not enough information in the patient's current records for the researcher to make a decision on whether or not to include the patient in the clinical trial.\n[INST] 1) Write a Python command using <var name=\"patient_id.Trial-level eligibility\">, e.g. `File(\"Notebook-6/patient_id.Trial-level eligibility\")`, to read the code. If you are in the `patient_",
        "label": 0
    },
    "247": {
        "output": "# Tutorial\n\n## Prerequisites\n\n149:00\n\n### Installation\n<h3 id=\"INST\"> Installation and configuration</h3><p>Installation of R and RStudio</p><p>Install R and RStudio by following the instructions in the first part of the install.r script on how this is installed into Linux containers and the second part of the install.r script how to install it into macOS.</p><p>Please look carefully at the instructions in <code>Installs.md</code> to be assured that R and RStudio are really installed correctly and properly.</p><p>The install.R script uses <code>R.install.packages.list.txt</code> that can be copied to the script as indicated in the <code>Instals.md</code> document.</p><p>Check if R and RStudio is really and completely installed and functional by typing <code>library(devtools)</code> and pressing Enter. R is correctly installed if a screen pops up as described below: (If the R installation was successful.)</p></p>\n\n```r\nR version 3.6.1 (2019-07-05)\n\nR Tools Version: 3.6.1\n\n(Running under Debian GNU/Linux 9.10, 64 bit)\n\n** Install packages and load the libraries **\n```\n\n- If R cannot be found at this time, type <code>exit(1);</code>, press <code>enter</code> again and then type <code>Rc</code>; for Windows and <code>Rsw</code> for MacOS. (Rc for Windows and RWin for MacOS).<br>\n- If R works but it does not contain an installation of Tidyverse, typing <code>install.packages(c(\"dplyr\", \"ggplot2\", \"stringr\", \"gtable\", \"tidyr\", \"dplyr\", \"purrr\", \"stringr\", \"readr\", \"patchwork\", \"plotly.\", \"scales\"))</code> into the R console or console window, i.e pressing <code>install.packages(<code>c(\"dplyr\", \"ggplot2\", \"stringr\", \"gtable\",",
        "label": 2
    },
    "248": {
        "output": "Now, let's continue the assessment of eligibility. Since multiple data files are processed, `sdata` is a convenient variable that contains some necessary data. We'll refer to this variable in the following codes.\n\nAssess eligibility by `sdata.`\n`sdata.age_categorical = 2:7` \n`sdata.categ_tumor = 100001000` \n`sdata.chemo_recode = 1` \n`sdata.disease_recode = 1000110000` \n`sdata.gender_recode = 1` \n`sdata.hormone_recode = 1` \n`sdata.inpulmonary_recode = 1` \n`sdata.metastasis_recode = 1` \n`sdata.operable = 1` \n`sdata.patho_diagnode_recode = 1` \n`sdata.stage_recode = 1`\n`print(\"Eligible = {0}, not eligible = {1}\".format(sdata.eligible, sdata.not_eligible), file=output_file)`\n\nFor the following input file, 45 is the age of the patient. \n\n[!INST] Hippolytus.txt\nHippolytus, 45, 800011200,\nBreast Neoplasms, 925011100,\nMale, 1,\nYes, 1,\nNo, 2,\n1, 5, 1,\nNeoplastic Process, 350010000,\nAbnormal Growth, 350020000,\nInfiltrative, 350001000,\nYes, 1,\nNo, 2,\nHospitalized Inpatient, 780008209,\nYes, 1,\nNo, 2,\nNo, 2,\nNo, 2,\nNo, 2,\nHospital",
        "label": 1
    },
    "249": {
        "output": "[INF] There are a few things to note in this paper.\n\nFirst, the following code should be placed under the `evaluation function()` to obtain the eligible count and proportion. [INST]\n\nSecond, to get the number of patients who were not included (0) in a particular trial, this should be added to the patient count. [INST]\n\nThird, to calculate the proportion of inclusion eligibility, it is necessary to divide the number of patients who were included (2) by the total number of patients (3). [INST]\n\n``` python\nevaluation_function(pw, pw_notes, trials, out_path)\n    \n\npw_notes.loc[trials['trial_level_eligibility'] == 'Excluded', 'inspath'] = 0\npw_notes.loc[trials['trial_level_eligibility'] == 'Not relevant', 'inspath'] = 0\npw_notes.loc[trials['trial_level_eligibility'] == 'Eligible', 'inspath'] = 1\n\nineligible_count =  pw.loc[trials.trial_level_eligibility == 0, 'inspath'].sum()\neligible_count = sum(pw_notes.loc[trials['trial_level_eligibility'] == 'Eligible'][['inspath']],\n                     subset = {x.trial_id: trials.index[x.trial_id]})\n\n# proportion of inclusion\ninclusion_eligibility_proportion = eligible_count / (eligible_count) + ineligible_count #(3, 3)\n```\n\n[INF]\n\n[/INF]\n\n### Other notes\n\n- the trials should be indexed by trial_id according to the index of the observation in your patient_weights dictionary. Use the index when you create the index, i.e., pw_notes = pw_notes.loc[trials['trial_id'] = trials.index].copy()\n- trials should be indexed by trial_id as well\n- the `evaluation_function()` should return the el",
        "label": 0
    },
    "250": {
        "output": "## How you should repeat the following steps...\n\n### First Step\n\n**Step 1 **: The first step is to determine if any of the 6 patient factors are listed as \"Not Relevant\" or \"Excluded\".\n\n### Second Step\n\n**Step 2**: If any of the patient factors are Not Relevant or Excluded, continue with Step **3** and do not go further. If all the patient-level factors are \"Not Relevant\" or \"Excluded\", print the following information, then end the program.\n\n**Step 3**: If all the patient-level factors are \"Not Relevant\" or \"Excluded\", continue with Step **4** and do not go further. Print the scale on the eligibility of the patient in this trial, then end the program.  \nIf any of the patient-level factors are Eligibility, continue with Step **5**. If any of the patient-level factors are Not Relevant or Excluded, go to Step **4**. \n\n### Third Step\n\n**Step 3**: If any of the patient factors are Not Relevant or Excluded, continue with Step **4** and do not go further. If all the patient-level factors are \"Not Relevant\" or \"Excluded\", print the following information, then end the program.\n\n\n**Step 4**: If all the patient-level factors are \"Not Relevant\" or \"Excluded\", continue with Step 5. Print the scale on the eligibility of the patient in this trial, then end the program. \n\n### Fourth Step\n\n**Step 4**: If any of the patient factors are Eligibility, go to Step **5**. If any of the patient factors are Not Relevant or Excluded, go to Step **4**. \n\n### Fourth Step\n```python\nTriallevel_eligibility=1\n``` \n\n### Fifth Step\n\n**Step 5**: If the clinical trial is about the breast cancer treatment, continue with Step **6**. If the clinical trial is about the treatment of other cancers, go to Step **7**. \n\n### Sixth Step\n\n**Step 6**: Continue with Step **7**. If you see the patient, print the",
        "label": 0
    },
    "251": {
        "output": "## [EXAM] The assessment of clinical trial eligibility\n<H1 title=\"Exam Problem</title>\n<p>The assessment of clinical trial eligibility</p>\n<h2>You are a helpful assistant for clinical trial recruitment. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nYour task is to assess clinical trial eligibility on patient 3, which is the example provided by <a href=\"http://cran.r-project.org/web/packages/Exam/faq.html\">the Exam package</a>. The assessment of eligibility has a three-point scale:\n0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).</p>\n<h3>Here is the patient note:</h3>\n<ul>\n<li> The patient is a 45-year-old postmenopausal woman with cytologically   confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.</li>\n<li> Here is the clinical trial:</li>\n<ul>\n<li> Title: Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer</li>\n<li> Summary: This pilot",
        "label": 0
    },
    "252": {
        "output": "![](https://cloud.githubusercontent.com/assets/130268/14985146/b4cb01c0-0430-11e6-89da-082769e77780/picked.png)\n\n<NAME>: [INST] A: What do we have to pass to determine the patient's eligibility?[INST] \n<NAME>: [INST] We need an assessment of eligibility from the individual components. Each component requires a separate evaluation of the patient for the clinical trial.\n<NAME>: [INST] Let's define a patient eligible only if he or she fulfills all the inclusion and does not violate any of the exclusion criteria. \n\nThe assessment of eligibility has a three-point scale: 0) Excluded, 1) Not relevant, and 2) Eligible.\n\nI would consider the patient eligible if he fulfills the inclusion criteria.\n\n**[INST] The eligibility assessment for patient notebook is shown above. What's the next step of our task? **\n\n<NAME> 45 years old woman\nAge, gender, previous breast cectory, \n- postmenopausal : yes\n- premenopausal : no\n- history of estrogen therapy : no\n- history of radiotherapy : no\n- history of hormone therapy : no\n- history chemotherapy : no\n- history menopausal : postmenopausal\n**[INST] Please show your evaluation for the clinical trial. You have to evaluate each component of the clinical trial. Please make an assessment for the trial-related criteria as shown above. ** \n\n<NAME> 45 years old woman\nPatient notebook:\n- No\n- Yes\n- Assessment of eligibility: trial level\nPatient notebook:\n- No\n- Yes\n- Assessment of eligibility: trial level\n- Assessment of eligibility: trial level\n- Assessment of trial eligibility: 2) Eligible\n- Assessment of trial eligibility: 2) Eligible\n- Assessment",
        "label": 2
    },
    "253": {
        "output": "![INST]\n\n[INST]\n```bash\n./evaluate-clinical-eligibility.py -c clinicalTrial.tsv -p path-to-patient_note.pdf -p-patient-level-eligibility-out put-path /patient-level_eligibility_output.txt\ntrial-level-eligibility: 2) Eligible.\n1) Not relevant.\n0) Excluded.\n```\n\n[INST]\n![INST]\n<EOD> The role of CSF2/GM-CSF and JAK-STAT5 signaling pathway in schizophrenia.\nOBJECTIVE\nThe purpose of this review is to highlight mechanisms of the regulation of CSF2/GM-CSF, JAK/STAT5 and their pathways in schizophrenia.\n\n\nMATERIALS AND METHODS\nThe biomedical literature search was conducted by using PubMed and Google Scholar for the following keywords: \"gmcsf, \" \"schizophrenia, \" \"stimulation signals, \" \"JAK, \" \"STAT, \" \"signal transduction, \" \"CSF2/GM-CSF, \" \"JAK-STAT5/pathway.\"\n\n\nRESULTS\nCSF2/GM-CSF, a member of the large cytokine-family, is a key protein in the activation of the JAK/STAT5/pathway. The major role of CSF2/GM-CSF is to mediate the cell proliferation during myeloid differentiation. The CSF2-dependent induction of CSF1 receptor/CD115, a transmembrane receptor tyrosine kinase, in the developing oligodendrocytes in the brain and the generation of microglia from non-resident bone marrow-derived monocytes in the brain under conditions of neuronal injury are also important. CSF2/GM-CSF/JAK/STAT5 signaling could also participate in neuroprotection during brain development, neuroinflammation and neurodegeneration.\n\n\nCONCLUSION\nThe CSF2/ GM-CSF, JAK/STAT5, and JAK-STAT5/path",
        "label": 2
    },
    "254": {
        "output": "<EOD> P53 status predicts response and outcomes of immune checkpoint inhibitor-based therapies in metastatic NSCLC\n\nPurpose: Although immune checkpoint inhibitors (ICIs) have been incorporated into the first-line treatments of non-small cell lung cancer (NSCLC) with a high PD-L1 expression, the predictive role of P53 signature in anti-PD-1/PD-L1 therapy remains incompletely understood.Methods: This multicenter, retrospective study recruited NSCLC patients with advanced stages. The TCGA-NSCLC database was used to predict the correlation between P53 signature and ICIs among NSCLC patients with different statuses of EGFR, KRAS, ALK and RET mutations. The effects of P53 signature on response and adverse events of ICIs were systematically evaluated in clinical cohort.Results: The 727 NSCLC patients in TCGA database were divided into two groups: P53 signature-low and P53 signaturehigh. Compared with ICIs treated group, patients in P53 signature-low group exhibited a better overall survival (OS), progression free survival (PFS) and objective response rate (ORR), while more incidences of adverse events (AEs), especially of low-grade AEs, were observed in the high group. In further cohort of 98 NSCLC patients, the ORR in P53 signature-low group (35.91% [9/25]) is higher than that in P53 signature-high group (14.29% [6/42]) without statistical significance (p=0.116). The OS and PFS in P53 signature-low group (9.41months, 87.14% and 5.96 months 69.17%) were obviously higher than these in P53 signature-high group (4.33months, 57.55% and 1.44 months 30.20%) (p=0.003; p=0.006). Furthermore, the incidences of \u22653-grade AE (RR =0.431, 95%CI",
        "label": 2
    },
    "255": {
        "output": "# Exclusions\n\n### INST_EXCLUSIONS\nYou should exclude patients whose notes satisfy at least one of the exclusion criteria in the following cases:\n- Patient is younger than 18 or older than 85\n- Patient is underweight or obese (BMI < 18.5 or > 45.0)\n- Patient is having any other illnesses or comorbid conditions such as acute liver failure, acute renal failure, hemorrhage, pneumonia or congestive heart failure.\n- Patient has a high fever of 38\uf0b0C or greater, or a low fever of less than 35\uf0b0C.\n- Patient abuses alcohol (e.g., > 5 drinks per day on a regular basis).\n- Patient tests positive for alcohol, cocaine, or amphetamines.\n- Patient uses tobacco products.\n- Patient has had an allergic reaction to any medicines previously.\n- Patient has a history of taking vitamins or other nutritional supplements within the past year.\n- Patient does not understand the study requirements and risks.\n- Patient is pregnant or breastfeeding.\n- Patient has other exclusionary criteria that the doctor knows about (e.g., a doctor knows that your patient might experience a specific adverse effect of a study drug).\n\n## Exclusions from the clinical trial\nIf a patient's medical record satisfies any of the following criteria, they will be excluded from the clinical trial:\n\n### CT_EXCLUSIONS\n\n- Previous mastectomy\n- Surgical resection for breast tumor more than 1 month ago\n- Known allergy to the study drug used\n- Any cancer of the brain or nerves\n\n***\nThe above eligibility criteria are the general rules that all hospitals implement (or should implement) for recruiting patients. They are relatively uncomplicated to perform.\n\n\n### Clinical trial-specific eligibility criteria\nClinical trials typically have some additional criteria that will be used to identify eligible patients during the screening process. Patients satisfying these criteria will be called **pre-",
        "label": 0
    },
    "256": {
        "output": "[TUT2] Title\n\n    Assigning patients to clinical studies in the same category\n\n    You are a responsible clinical trial coordinator. Your task is to assign patients to clinical studies based on their characteristics without the help of a computer. You need to check the requirements of clinical studies and use the data to match each patient and clinical study.\n\nAssigning patients to clinical studies means selecting the study in which the patient is most likely to benefit based on his or her characteristics. You should assign patients to clinical studies in the same category and choose the most appropriate study within the same category for each patient.\n\nPlease use the patients in  `List of 40 patients`  to assign study patients. Please consider the following criteria when deciding which studies to register.\n\n    &middot; The patients in `List of patients who have the characteristics of clinical study` should be listed in study-specific categories.\n\n    &middot; The patients in remaining categories should be listed in the study-specific category.\n    &middot; The patients who cannot be assigned in clinical studies should be listed at the end of the assign-study category.\n\nList of patients who have the characteristics of clinical study: \n\nClinical trials targeting HCC patients:\n\n[TUT3] Abstract\n\n    Summarized the information of patients and clinical trials\n\n    Abstract class: Patient and Clinical Study\n\n    Parent class: ClinicalStudyData\n\n    Parent class: Data\n\n    Children class: 1. Patient;\n    2. Clinical Study;\n    Parent class: Patient\n\n    Children class: List-MostRelevantClinicalStudiesForPatient\n\nYou should summarize the information from the last five patients in the above four tables. Below is the patient information for the patient 29 and the associated trials: \n\nPatient 29:\n\n    Patient-ID: 29\n    Name: William Anderson\n    Gender: Male\n    Age: 57\n    Phase: I\n    Disease: Lung Cancer\n    Disease status:\n    Therapy:\n    Therapy status:\n    Treatment:\n    Treatment status",
        "label": 0
    },
    "257": {
        "output": "Note that the `Trial-level eligibility: ` is mandatory and you must report a case as `2) Eligible` if patient is eligible as determined by your assessment according to the inclusion criteria and the exclusion criteria (if applicable)?, for which the patient has written informed consent? [INST]\n\nIf all the information on the clinical trial form was correct, it would be saved in the Eligibility Assessment for a Clinical Trial table, and the patient would receive a 17-point eligibility assessment code:\nThe patient is 45 years of age (1 point), she has confirmed breast cancer (1 point), the tumor is HER2 positive, which corresponds to the category A classification of Her2 (1 point). \nThe patient agreed to do chemotherapy (1 point), but refused to do so (1 point). \nIn terms of surgery, the patient is in favor of a breast biopsy (1 point), but is not prepared for a breast biopsy (1 point). \nThe patient is not willing to participate in any clinical trial (2 points). \nIn terms of treatment, the patient is not satisfied with surgery, and prefers drug treatment at this stage (1 point). \nThe patient smokes (1 point), but she is fully aware of the risks of smoking (1 point).\nThe patient is fully compliant with the instructions (1 point), and she understands what is written on the drug leaflet (1 point). \nBased on clinical data, the patient has no contraindications to take part in the clinical trial (1 point).\nIn terms of side effects, the patient does not want any side effects at all (1 point). \nShe is fully aware of the risk of a serious drug interaction (2 points). \nShe is fully aware of the risk of adverse drug reactions (1 point). \nRegarding pregnancy, she understands the risks (1 point). \nRegarding lactation, it is fully explained to her that with breastfeeding the drug would be excreted in breast milk (e.g., not the active substance, but metabolites, and in very low concentrations), and she should know that this is not acceptable for her baby (1 point). \nThe patient",
        "label": 0
    },
    "258": {
        "output": "### Sample data\n\n- File `clinical_trial_data1.csv` is from the `Data` folder. All clinical trial and patient data from the file are pre-processed. Each entry is separated by commas.\n- File `clinical_trial_data2.csv` is from clinical trials whose data has been processed. Categories are added. It is a CSV format file, too.\n\n\n```python\nimport pandas as pd\nimport numpy as np\nimport matplotlib.collections as col\nimport io\nimport os\nfrom sklearn.mixture import GaussianMixture\nfrom scipy.spatial import cKDTree\nfrom sklearn.manifold import TICA\nfrom sklearn.cluster import MiniBatchKMeans\nfrom sklearn.metrics import bal_error_rate, balance_acc_weighted, silhouette_score, cosine_similarity\n\npd.options.display.max_rows = 650\n```\n\n#### Data import\n\n```python\nclinical = pd.read_csv(\"clinical_trial_data.csv\")\npatients = clinical[\"patients\"]\n\nfrom sklearn.base import DataNode, ClusterNode, Node\n\npatient_set = col.Colormap(\"Grey\", c={1:1,\"2\":0,\"3\":0,\"4\":0,\"5\":\"orange\"} )\ngp = GaussianMixture(n_components=18)\n\ntrial_nodes = MiniBatchKMeans(n_components=64).fit_predict(clinical)\ntrial_nodes\n```\n\n\n#### Tissue core biopsy classification\n\n```python\nfrom sklearn.clustering import kmeans\n\nkmeans = kmeans(trial_nodes[\"cluster_labels\"], n_clusters=2)\nkmeans.fit()\n```\n\n\n#### CKDA\n\n```python\nCKDAT = cKDTree(kmeans.points, leaf_size = 0)\n\n```\n\n\n```python\npatient_graph = {node:set(k) for node,k in trial_nodes.items()}\n\n# CKDA: CKD Tree",
        "label": 2
    },
    "259": {
        "output": "If you get a different program after executing any changes, there is likely an error message in the output console. If you cannot understand the error message, please use the <a href=\"{{site.docroot}}/learn/source/source-level_help.html\">console help</a> below.\n\n# Console Help\n\n### console-consolehelp\n\n### console-source-consolehelp\n\n### console-source-install\n\n### console-source-reinstall\n\n### console-source-uninstall\n\nYou can find a lot of information using the console. The console contains instructions you can follow in its default configuration. There\nare three commands for console help: `console-source-consolehelp`, `console-source-install`, and `console-source-reinstall` are the first three commands in its default configuration.\nYou can type `console-source-consolehelp` in the output console to display commands for console help.\n\nThere is an explanation of the output of `console-source-reinstall`. Also, there was the following error when executing the command.\n``` console\nconsole_version 2.6    console_time 2018-06-01T20:19:10.611361Z\nconsole_path     home/vvchung/R console console console_lib/bin  console_file/log/  console_version_info\nconsole_recycle_file console_recycle_dir log log/\nconsole_recycle_max 1000 console_recycle_wait 5000\nconsole_recycle console_recycle console_recyc_dir log\nconsole_uninstall console_uninstall console_uninstall_file_dir\nconsole_uninstall_file console_install console_uninstall_dir log/\nconsole_uninstall_file_root console_uninstall_recycle log\nconsole_uninstall_recycle log/\nconsole_uninstall_recyc console_recycle console_uninstall_dir log\nconsole_uninstall_total console_uninstall console_uninstall_recyc\nconsole_vocabulary console_vocabulary_dir vocabulary/\nconsole_vocabulary_file file_dir vocabulary\nconsole_voc",
        "label": 0
    },
    "260": {
        "output": "Let's try it below. \n> let=patients=[\"Bloch_etal_2010.xml\"]\n> [\n>      for x=xrange(0,len(let)-1) do\n>          if let['id']==\"Bloch_etal_2010_45.xml\" and (1==sum(let['eligibility']==\"Excluded\") or match(\"2)\",to_lower(let[x]['assessmentOfEligibility']['clinicalStudyEligibility']['comment'])))then\n>              print(\"Excluded (Patient has sufficient information)\",to_lower(let[x]['clinicalStudyEligibility']['clinicalStudyEligibility']['comment']))\n>              print(\"Not relevant\") >print(\"Eligible\")\n>             else\n>              if(2==sum(let['assessmentOfEligibility']['clinicalStudyEligibility']['comment']=='Not relevant') or \n>              not any(\n>              x==2 for x in list(set(x for x in let['assessmentOfEligibility']['clinicalStudyEligibility']['comment'] if\n>              x=='Not relevant'))\n>              )) and\n>              and sum(let['assessmentOfEligibility']['clinicalStudyEligibility']['comment']=='Eligible')>0) then \n>              if(sum(let['assessmentOfEligibility']['clinicalStudyEligibility']['comment']=='Eligible')>0)then \n>              print(\"Eligible (Patient has sufficient information)\",to_lower(let[x]['clinicalStudyEligibility']['clinicalStudyEligibility']['comment']))        \n>              else\n>                print(\"Eligible (Patient does not have sufficient information)\",to_lower(let[x]['clinicalStudyEligibility']['clinicalStudyEligibility']['comment']))     \n>              \n>              print(\"Not relevant\")\n>              \n>             print(\"Excluded (Patient has sufficient information)\",to_lower(let[x]['assessmentOfEligibility']['clinical",
        "label": 0
    },
    "261": {
        "output": "## [END]\n#4:\nYou should have this kind of results. \n\n| Eligible (47)\n| :ref:`NotRelevant` (2)\n| Excluded (5)\n\n### Tutorial 1: Predicting Drug Sensitivity\n\nWe often compare the patient's cell line response from cell linedata to clinical outcome data, e.g., by assessing differences in sensitivity or resistance of the cell lines to drug treatment. This analysis requires knowledge of the clinical trial in which the response of the samples was assayed. Here, we describe how to link the clinical trial data to the experiment data from which those cancer cell line responses\nwere derived.\n\nFirst, go to the top link of the website (as described above) and choose the function,\n\n[![INST:\n](https://raw.githubusercontent.com/GraceBioinformatics/gracemanual/master/book_16/Figure_16_1_1.png)]\n![INST:\n](https://raw.githubusercontent.com/GraceBioinformatics/gracemanual/master/book_16/Figure_16_1_2.png)]\n\nSelect the name of the clinical trial, e.g., HNSCC_104479_85. As an example, we will use clinical trial NCT00411163. Then, choose the data download option in the upper menu bar.\n\nAfter choosing clinical trial data and the data access type (see above), your browser will be redirected to a new page. You will see the results of all cell lines available from GDSC Cell Line Dataset. \n\n#### Cell Line Data Direction/Selection\nBefore starting to retrieve clinical trial data, you can verify which cell lines \nare available for a given clinical trial under the **Preview cell line data**\nheading in the upper menu. Select \n`Download cell line data\nas\ncsv` to find all the cell lines that have been assayed in the clinical trial.\n\nNext, specify the type of data accessed. Check the **Cell Line Data** option to select the data download mode (e.g.,\n`Data Sets/Data Sets",
        "label": 0
    },
    "262": {
        "output": "## 18.4.7) [INST] Recurrent/metastatic (MBC)\nYou should make trial-level eligibility in the last line by `Triage note to [Trial-level eligibility]:`, e.g., `Triage note to [Trial-level eligibility]: 3/3, 1/2, 1/2. [INST].`\n\n## 18.4.8) [INST] Excluded\nYou should add all `NOT eligible` trips to the [Triage note to Not eligible].\n\n## 18.4.9) [INST] Eligibility assessment\nYou should make eligibility assessment in the last line by `Eligibility assessment: 2) Eligible; 1) Not Eligible; 0) Excluded. [INST]`, e.g., `Eligibility assessment: 2) Eligible; 1) Not Eligible; 0) Excluded. Clinical Trial 11114: Exclusion due to comorbidity or severe pre-existing disease; Clinical Trial 33333: Comorbidity due to diabetes control 3 years ago. [INST]`\n\n## 18.4.10) [INST] Assessment of trial exclusion criteria\n(1) You should answer all exclusion criteria by yes or no. The exclusion criteria of trials are shown at the right side of each patient. If an exclusion criterion is applicable, then it should be marked by yes. As you examine a patient, you should answer all exclusion criteria by yes in every assessment or put nothing in parentheses in the patient record. As shown below, '1) Not applicable; 0) Applicable' means that an exclusion criterion is not applicable, '0) Applicable; 1) Not applicable' means that an exclusion criterion is applicable, and '2) Applicable; 2) Not applicable' means that an exclusion criterion is applicable with an exception. Trial NET0033: 'Inclusion criteria', for 'age', 'over 18 years', is '13 to 95 years' for the age. It means that one patient over",
        "label": 0
    },
    "263": {
        "output": "# <NAME> 2021\n[TUT2][SUP1] [SRC1] \n\n**Objective:** We will work on the assignment which we got in class. **Task:** Choose one or more data records from the data records dataset and then write each of their properties:\n\n* [INST] What type of data record is it?\n* Write each of the following properties of the chosen data record:\n    * UniqueID\n    * Name\n    * Age\n    * BloodGroup\n    * EyeColor\n\n\n#### ## [TUT3][SRC1]\n\n```python\nimport numpy as np\n\nclass Trial:\n    def __init__(self, _name=\"NAME\", _title=\"TITLE\", _study_start=\"STARTL\", _study_end=\"ENDL\", _contact=\"CONTACT\", _study_sponsor=\"SPONSOR\", _study_location=\"LOCA\", _purpose=\"PURPOSE\", _condition=\"CONDITIONS\",\"target_duration=\"TARGET\",_primary_output_param=\"OUTPUT\",_exclusions=\"EXCLUSIONS\"):\n        self.id=\"UniqueID\" \n        self.name=\"Name\"\n        self.trial_name=_name\n        self.trial_title=_title\n        self.study_start_date=datetime.datetime.strptime(str(_study_start),\"%Y%m%d\")\n        self.study_end_date=datetime.datetime.strptime(str(_study_end),\"%Y%m%d\")\n        self.study_sponsor=_sponsor\n        self.trial_location=_location\n        self.trial_description=_condition\n        self.study_purpose=_purpose\n        self.study_contact=_contact\n        self.study_number=_target\n        self.study_duration=_duration\n        self.study_duration_unit=\"day\"\n        self.trial_phase=_phase\n        self.sponsor_contact=_sponsorcontact\n        self.funding=_funding\n        self.trial_",
        "label": 0
    },
    "264": {
        "output": "## Hello. You are a job seeker. You have not gotten a job, so you want to try to find one. You know that there are many ways to look for a job. You like to understand how companies recruit job candidates. So, you need to find a way to get to know more about how companies recruit job applicants. \n\nSo, you want to search various ways on how companies recruit job-applicants. \n\nHere are the keywords to search: **job**, **apply**, **career**, **careers**, **work**, **jobs** and **career**. Here are the details in each one:\n\n![Detail of job]\n![Detail of career] \n![Detail of apply] \n![Detail of work] \n![Detail of jobs] \n![Detail of career] \n![Detail of apply] 3 [/TASK",
        "label": 2
    },
    "265": {
        "output": "[END]\n\n## 2) Identify the information needed.\nWhat medical data does a recruiter need to assess the eligibility of study patients for a given clinical trial? A potential solution looks like this:\n<ClinicalTrial>\n[\n<Trial>\n  <Title>Praegnant Breast Cancer: Early/Advanced/Metastatic</Title>\n  <Sponsor>University Hospital Aarhus</Sponsor>\n  <Investigator>Professor R. Hansen</Investigator>\n  <Physician>Dr. V. Nielsen</Physician>\n  <Site>Department of Oncology, University Hospital Aarhus</Site>\n  </Trial>\n  <InclusionCriteria>\n    <InclusionCriteria>\n      <SubjectCondition>\n        <Condition>\n  <FactorName>Pregnant</FactorName>\n  <Operator>Not</Operator>\n  <Value>yes</Value>\nThis snippet says that pregnancy is an exclusion criterion for all patients (and not just patients who are pregnant). The snippet should be adapted when a specific trial contains a different set of inclusion and exclusion criteria. \n\nNow take a look at the full snippet that contains the patient note. The full snippet allows the user to use a snippet from clinicaltrials.gov to perform the clinical trial recruitment:     \n\nThe snippet in the example uses Java and the Eclipse IDE. In case you are not familiar with Java, you can use another scripting language.  \n\nThe script performs the following steps on the specified patient note: 1) Loading the patient note. 2) Extracting the trial-of-interest from the patient note. 3) Extracting the inclusion criteria for the trial-of-interest from the clinicaltrials.gov snippet. 4) Comparing the exclusion criterion against the metadata for the patient. 5) Determining the trial-level eligibility.  \n\n## 3) Assure that the eligibility assessment can be performed for a patient note containing all information. \nSome patient notes have no information on the pregnancy status of the patient.\nThe snippet in the example has the necessary instructions to determine the",
        "label": 2
    },
    "266": {
        "output": "[END]\n<EOD> Cystic fibrosis in children presenting with acute liver failure: Case series and review of the literature\nThe current recommendations regarding the management of acute liver failure in patients with an underlying inherited disorder of plasma chloride regulation are based on single center studies, and there is little or no guidance offered in these studies regarding the best ways to assess children with cystic fibrosis (CF) presenting with acute liver failure. This report presents 41 cases of children presenting from 1971 to 2009 with acute liver failure and underlying severe CF and illustrates the difficulties currently faced in deciding upon the best ways to manage these children and the complications that arise.<EOD> ROS\u2010Triggered Charge Transfer Polymer for the Treatment of Ovarian Cancer\nElectroactive polymers of low molecular weight are increasingly being recognized as promising candidates as therapeutic agents. Herein, we report the synthesis and photophysical characterization of an amphiphilic poly (poly \u2010PCFTAZ) derivative bearing the tetrazine moiety, which is known for its excellent reactivity as a cross\u2010linker (chemical dimerizer/cross\u2010linker). The PCFTAZ derivative is composed of a low\u2010molecular\u2010weight poly(ethylene glycol) (PEG) segment and a tetrazine group (PCFTAZ@PEG) and exhibits solvatochromic properties. The photophysical properties of the PCCFTAZ@PEG derivative were evaluated in the presence of various intracellular and extracellular reactive molecules. In the case of biothiols, cysteine and glutathione (GSH), this derivative showed an efficient quenching response. By employing ROS\u2010triggered chemistry, it was possible to conjugate polymeric PCFTAZ@PEG derivatives with cisplatin (a platinum\u2010based anticancer drug) using ROS produced by intracellular GSH or extracellular peroxynitrite (a toxic oxidizing species), with an 8\u2010fold increase in the cytotoxicity.<EOD> A pilot study of a behavioral intervention to prevent",
        "label": 0
    },
    "267": {
        "output": "<EOD> 2.8 \u03bcm Laser Welding for Thermoformed PMMA Based Surgical Guide Using 25 W CO2 Pulsed Laser\n\nLaser welding was investigated to join surgical guide made of poly(methyl methacrylate) (PMMA) for orthodontic surgery. 25 W pulsed CO 2 -laser welding was tested in 2.8 \u00b5m wavelength, 30 kHz repetition rate and 362.31 nJ pulse energy, and compared on 190 - C using a metal plate. Four different laser-welded specimens in the condition of 2.8 \u00b5m pulsed CO 2 laser welding in the air, and in the condition of 2.8 \u00b5m continuous CO 2 laser welding in the air, were compared to the nonwelded specimen in the condition of 190 - C metal plate. All specimens were tested 10 4 cycles in an environmentally controlled chamber at 50-60% humidity and 37 - C, to examine bond strength, welding zone observation, and optical microscopy. From optical microscopy the PMMA welding zone welding width, thickness, and penetration depth were analyzed by image analyzer. Result showed that the bond strength at the temperature for 190 - C metal plate was 8693.1 mN. In 25 W pulsed CO 2 -laser welding condition, the welding condition in the air and in the vacuum condition, bond strength was 1512.0 mN and 1550.2 mN, respectively. The bond strength could be improved as high as 9066.6 mN with optical microscopy. Therefore, our result suggested that the bond strength can be improved in the condition of 25 W pulsed CO 2 laser welding in the air and in the vacuum condition, and in the condition of 2.8 \u00b5m continuously CO 2 laser weld",
        "label": 0
    },
    "268": {
        "output": "[INST]\n\n##### [C:0:3] **Case Study**\nThe purpose of clinical trials is to evaluate new diagnostic agents or therapeutic treatment procedures in order to enhance the health and well-being of patients.  Clinical trials play an important role in the drug-development process.  In most cases, clinical trials are designed to determine if a new intervention is safe in humans and whether it is more effective than alternative treatments.  Before clinical trials are initiated, they are reviewed and approved by the IRB. IRB Approval:  the IRB must approve the protocol before it can begin.  Approval to begin enrolling subjects generally occurs after:  an IRB has reviewed the protocol and found that the study to be ethical, that there are scientific reasons to conduct the study, and that the study protocol is adequate and that all required safeguards, including informed consent, are in place. Study start has usually begun following:  the IRB has authorized the study to begin enrollment subjects.\nThe following is a proposed study for a drug which has been found to be effective in treating breast cancer. However, there is concern that there may be a side effect of the drug that has not been previously observed. Breast cancer patients enrolled in the following study will be randomly assigned to one of three treatment schedules:\n Group A: One drug treatment for all patients. Schedule Drug: 1 drug for each patient:  Drugs are given every day. For each week of treatment, patients are assigned to one of the four treatment schedules (a-d). \n\nGroup B: 1 drug treatment for all patients Schedule Drug: One drug for each patient: Drugs are given every day. For each week of treatment, patients are assigned to one of the four treatment schedules (a-d).\nGroup C: 4 drugs, alternating between 1 of 4 drugs.\nGroup D: 4 drugs, alternating between 2 of 4 drugs.\nPatients will participate in the drug evaluation study for 3 weeks. During the week, patients will receive three doses of the drug, i.e., once each day on days 1, 2, and 3. The drug treatment period will occur every 3 weeks during the study.",
        "label": 1
    },
    "269": {
        "output": "## Questions\n\nPlease read and answer the question carefully.\n\nWhat is the eligibility of the given patient for the clinical trial?\n\nWe have obtained the output of the file `exercises/case4.txt` by running: \n$ python exercises/case4.py\n\n## Answers\n\n### [A] A 51-year-old man with diabetes, hypertension, and dyslipidemia. The patient has a 10-year history of untreated chronic myeloid leukemia, and he is in myeloid blast phase.\n``` \nInput:\nTrial-level eligibility: 1) Eligible (Trial-level eligibility)\n  Inclusion criteria:\n    Include criteria 1:  Include criteria 4: \n  Exclude criteria:\n  Exclude criteria 1: Exclude criteria 5:\n\n  Patient: male; age 51 years\n  Inclusion criteria: age greater than 60, diagnosis with chronic myeloid leukemia, prior arterial thrombosis, dyslipidemia\n  Exclude criteria: no history of masticatory disorder, not sexually active, not on antiplatelet/anticoagulant therapy\nOutput: \nTrial-level eligibility: 1) Eligible (Trial-level eligibility)\n  Patient: male; age 51 years\n  Inclusion criteria: age greater than 60, diagnosis with chronic myeloid leukemia, prior arterial thrombosis, dyslipidemia\n  Exclude criteria: no history of masticatory disorder, not sexually active, not on antiplatelet/anticoagulant therapy\n``` \n\n### [B] A 74-year-old man diagnosed with hepatitis C. \n``` \nInput:\nTrial-level eligibility: 0) Excluded (Trial-level eligibility)\n  Inclusion criteria:\n    Include criteria 2: Include criteria 3: Include criteria 4: Include criteria 5: Include criteria 6: \n  Exclude",
        "label": 0
    },
    "270": {
        "output": "\u00a9 2020 KNIME GmbH\n\u00a9 2020 KNIME \n\u00a9 2020 KNIME GmbH\nEinloggen | Registrierung | Anmelden | Beispiele:\n| Datenschutz-& Implantatsgrundverordnung | \n<EOD> Flavonoid Glycosides from the Roots of Vitex rotundifolia and Their Inhibitory Activity on NO Production in LPS\u2010Stimulated RAW264.7 Macrophages\nIn this study, we chemically characterized three new flavonoid glucosides, including one 3\u2032\u2032\u2032\u2010O\u2010acetyl flavone, named vitexionosidic acid A, and two glycosides of dihydrokaempferol and kaempferol, named vitexionosides B and C. The in\u2005vitro nitric oxide (NO) inhibitory activity of vitexionosides B, C, and A were assayed in lipopolysaccharide (LPS)\u2010stimulated RAW264.7 macrophages. The results of this study indicated that all of these flavone\u20103\u2010O\u2010glycosides exerted inhibitory activity on NO production with IC50 values ranging from 8.1 to 22.3\u2005\u03bcM.<EOD> Risk factors for the development of lupus nephritis: A pooled analysis of individual participant data from 7 cohort studies based in the UK and South Africa\nWe used individual participant data (IPD) meta\u2010analysis to estimate the risk of developing lupus nephritis, and the influence of a range of potential risk factors.<EOD> .\nINTRODUCTION\nProteomic approaches have led to an increased understanding of the nature of the disease and the involvement of several proteins such as the cytokeratins, galectins, vimentin, cytokeratins. In this review, we focus on a possible association of certain proteins associated with breast cancer with breast cancer subtypes.\n\n\nSTATE OF THE ART\nNumerous cytokeratins (CKs) and galectins are expressed in breast cancer and many members of these families of proteins have been suggested",
        "label": 0
    },
    "271": {
        "output": "<h3><b># Clinical Trial-level Information</b></h3>\n\nTrial-level information describes the clinical trial in general. \nYou should write a code that calculates the overall score for a trial based on patient's eligibility. This code should be done by a loop or nested functions over a list or array that will contain all the trial-patient pairs that has been scored through the loop. \nThe score of the clinical trial will be the average of over the trial-patient pairs' scores. The score is calculated through three aspects described below.\n\n## Indication\n\nIndication (score : 1 -4 ) is calculated by \n$$ Indication  = \\frac{(1)\\max \\Triplet_size}{3} \\cdot p\\max_{i,j \\in \\X} \\Sum_{k=1}^n {k}^{4 - Triplet_{i,j}[k]} \\cdot \\Big(\\max_{k \\in \\X} \\max_{i \\neq j}(Triplet_{i,j}[k]) - \\min_{k\\in \\X}(Triplet_{i,j}[k]))$$ \n$$Indication = \\frac{\\text{\"Small to Very Small tumor size\"}}{\\text{\"Very Small tumor size\"}}\\cdot p\\max_{i,j \\in \\X}\\Big(\\sum_{k=1}^n S_s[i]_k - S_s[j]_k\\Big)$$\n\t\t$$Indication = \\frac{\\text{\"Small to Very Small tumor size and a Large number of patients\"}}{\\text{\"Very Small tumor size and a Very Large number of patients\"}}\\cdot \\Big(S_s[i] - S_s[j]\\Big)$$ \n$$Indication = \\frac{\\text{\"Small to Very Small tumor size and a Very Large number of patients\"}}{\\text{\"very small tumor size and a large number of patients\"}}\\cdot \\Big(S_s[i] - S_s[j]\\Big)$$ \n\t\t$$Indication = \\frac{\\text{\"Small to Very Small tumor size and a Very Large number of patients\"}}{\\text{\"Small to very small tumor size and",
        "label": 0
    },
    "272": {
        "output": "##[CODE]\nimport random\nfrom sklearn.datasets import load_breast_cancer_data\n# create a vector for patient data\npatient_data = [  ]\n# a vector for the scores for 0 - not relevant, 1 - not eligible, 2 - eligible\neligibility_vect = [ 0] * len(patient_data)\n\n# load breast cancer data\nbreast_cancer = load_breast_cancer_data()\n\n# go over each patient\ni = 0\nfor xyz in breast_cancer.data.loc[0]:\n    if xyz['Breast_Cancer_Patient_Note'][10:] not in ['Mammoplasty', 'Excision', 'Mastectomy']:\n        i += 1\n    eligibility_vect[i] += 1\nprint(i, eligibility_vect)\n\n# find the mean of each values for trial-level eligibility\ntrial_eligibility_mean = round(sum(eligibility_vect)/ i)\nprint('Trial-level eligibility:', trial_eligibility_mean)\n\n<EOD> GH-dependent metabolism in GH-receptor null mice.\nThe roles of GH and its receptor in energy and protein metabolism are of fundamental importance, particularly in the context of metabolic syndrome. Genetically modified models in which the hypothalamus-pituitary axis regulates GH secretion in response to food intake, or in which the GH receptor has been deleted, have served as invaluable models in our understanding of the effects of GH on metabolism. A better understanding of GH receptor function has been obtained by the generation of GH receptor-null mice. In this review, we focus on changes in growth, protein metabolism, adipose tissue distribution, body fat content, brown adipose tissue, insulin sensitivity, and energy expenditure in these models. The results in the absence of GH signaling challenge the notion that GH is indispensable to promote growth, and they show that in adulthood GH action is important to maintain lean and reproduct",
        "label": 0
    },
    "273": {
        "output": "# \u25b6\ufe0f Clinical Research\n\n[TEST] As a doctor, you are in charge of managing patients with chronic kidney disease. Chronic kidney disease is an impairment in kidney function that occurs when the kidneys fail to filtrate blood properly.\nChronic kidney disease reduces the body's ability to get rid of waste products and cause abnormalities in the levels of serum electrolytes. Therefore, it is important to manage patients with chronic kidney disease.\n\nYou must analyze a given patient and find out which drug regimen he or she should take.\n\nThe information on a given patient was entered in the [Bioinformatics] program:\n\nThe name of the drug that was prescribed to the patient is used as a reference. The prescribed drug has a number of advantages over the other existing drugs. This allows the patient to be able to take the drug indefinitely, without the risk of developing any other serious side effects. The prescription was given at the time of discharge from the hospital. The treatment regimen for a patient with chronic kidney disease requires close monitoring to maintain the level of creatinine in the blood at optimum levels. The main problem for the patient is the kidney's inability to filter the blood correctly, which will cause the accumulation of waste products in the body.\n\nThe following table is available in [Table 29.1] and illustrates the different prescribed drugs for each patient:\n\n\n\n## Name of the drug in use Regimen Prescribed\n\nSulindac In this study, chronic kidney disease was induced. The following table is available in [Table 29.2] and illustrates the different groups of patients in which some of the experimental drug regimens were given.\n\n\n\n## Group of Patients Regimen Prescribed\n\nA (20) Group I 1\nGroup I 30\nGroup II 1\nGroup II 30\nGroup III 1\nGroup III 30\nGroup IV 1\nGroup IV 30\nGroup U 1\nGroup U 30\nNote: For patient no. 3 and 4 in group I, the regimen prescribed was group III. For patient no. 5, the prescribed group was group V.\n\nBy using the [",
        "label": 2
    },
    "274": {
        "output": "*   Input the patient note\n\n*   Input the clinical trial data.    \n[TRIAL] Let's run the script now: \n[INST] Hello, you are a helpful assistant for clinical trial enrolment. You are to find a possible relationship for a clinical trial using the clinical trial database. The  results showed that  infection infection was a cause of the patient's death. \n[INST] It is necessary to find the probability of cause of death from the statistical analysis by calculating the Odds Ratio (OR). \n[TRIAL] Title: Odds Ratio: The relationship between HPV infection and 14 histological subtypes 535 cases.\n\n\n# Related questions\n- 1. What is the meaning of \u201cTrial-level eligibility\u201d in the clinical trial data?\n    1. Eligible\n    2. Not relevant\n    3. Excluded\n    \n- 2. According to the script, you would use the \"input\" function to input the data?\n      1. Yes\n      2. No\n    \n- 3. According to the script, you would use the \"Trial-level eligibility\" function to eligible the patients?\n      1. Yes\n      2. No\n    \n- 4. When the clinical trial \"Odds Ratio The Relationship Between Hpv  Infection And Histological Subtypes\" was completed, how would you calculate the Odds Ratio (OR) and input the results?\n      1. Yes\n      2. No\n    \n\n<EOD> The influence of maternal age at in vitro fertilization/intracytoplasmic sperm injection start and the number of oocytes/embryos on live birth rate: a single-center registry\nAbstract Purpose We aimed to evaluate the influence of maternal age on live birth rate after a single embryo transfer. Materials and methods Among 2,580 patients treated from January 2018 to December 2020, we included 902 women under the age of 40\u2009years who underwent a single embryo transfer and had a transferable embryo. Results The patients were classified into three groups (I: <3",
        "label": 0
    },
    "275": {
        "output": "[DONE]\n<EOD> A Comprehensive Approach to Pregnancy, Birth, and Growth in the First 3 Years of Life\n1. \u80ba\u529f\u80fd\u8bc4\u4f30\u548c\u8010\u836f\u68c0\u6d4b(antimicrobial susceptibility testing): \u6839\u636e\u75c5\u75c5\u53f2,\u5373\u60a3\u8005\u4e34\u5e8a\u8bc4\u4f30,\u91c7\u7528\u4f20\u7edf\u7684\u80ba\u83cc\u5bf9\u6297\u83cc\u6027\u836f\u548c\u836f\u7269\u7c7b\u578b,\u7ecf\u836f\u7597\u7597\u7a0b\u6709\u5173\u7684\u836f\u7269\u5bf9\u6297,\u800c\u53ca\u65f6\u5728\u60a3\u8005\u7684\u80ba,\u4f53\u6db2\u548c\u75f0\u6837\u672c\u4e2d\u68c0\u6d4b\u75c5\u6bd2,\u7ec6\u83cc,\u65e9\u671f\u53ca\u6cbb\u7597.\u6700\u540e,\u627e\u51fa\u7b56\u7565\u6027\u4f7f\u7528\u6297\u611f\u67d3\u836f\u7269\u7684\u65b9\u6cd5,\u5305\u62ec\u4ea7\u524d\u68c0\u67e5,\u7ed9\u4e88\u6297\u75c5\u6bd2\u836f\u7269,\u5229\u7528\u7ecd\u7f5f\u6216\u8d39\u66ff\u5c3c\u7b49\u6297\u75c5\u6bd2\u836f\u7269\u7597\u6cd5,\u7ed9\u4e88\u6297\u611f\u67d3\u836f\u7269,\u4f7f\u5f97\u60a3\u8005\u75c5\u75c7\u53ef\u6709\u6548\u63a7\u5236\u6216\u7f13\u89e3,\u6062\u590d\u4f53\u80fd,\u8ba9\u60a3\u8005\u4f11\u606f\u548c\u6d3b\u52a8,\u8fd8\u53ef\u80fd\u6cbb\u6108\u60a3\u8005\u8f7b\u5fae\u3001\u4e2d\u7b49\u91cd\u5ea6\u7684\u7662\u6bd2\u75c5.\u5728\u8fd9\u7c7b\u75c5\u7684\u6210\u529f\u6cbb\u7597\u4e2d,\u8981\u5305\u62ec\u6cbb\u7597\u7684\u76f8\u5173\u5fc3\u7406\u652f\u6301,\u793e\u4f1a\u652f\u63f4,\u7efc\u5408\u7597\u6cd5\u7684\u5e94\u7528.4. \u4e0d\u7a33\u5b9a\u75c7\u548c\u5176\u6cbb\u7597:\u7279\u522b\u662f\u75be\u75c5\u7684\u8f70\u4f17\u548c\u8fc7\u5ea6\u7684\u53d1\u75c5\u65f6\u95f4,\u4f7f\u533b\u751f\ufffd\ufffd\ufffd\ufffd",
        "label": 0
    },
    "276": {
        "output": "<EOD> Ocular manifestations and endophthalmitis in a patient with leprosy.\nPURPOSE\nTo present a case of leprosy with several ocular manifestations and an associated case of endophthalmitis.\n\n\nMETHODS\nThe patient was submitted to a complete ophthalmological examination, fluorescein angiography, indocyanine green angiography, magnetic resonance imaging, and ultrasound biomicroscopy. Bacteriological and mycological investigations were performed, and biopsies were taken for histopathological examination.\n\n\nRESULTS\nA 64-year-old woman with multibacillary borderline lepromatous leprosy presented an impending keratitis with keratopathy, secondary cataract, retinal nodular changes, retinal vascular changes with intraretinal capillary occlusions, and chorioretinal changes on fluorescein and indocyanine green angiography, as well as the presence of retinal pigmented epithelium cells with granular inclusions on electron microscopy. The fluorescein angiography showed chorioretinal changes with nodular areas of hyperfluorescence and hypofluorescence. Anterior uveitis with keratitis, anterior chamber hyphema, cataract, and vitreous opacities were associated with positive cultures for Mycobacterium leprae in the corneoscleral graft and bacterial endophthalmitis in the left eye. Despite therapy with prednisolone and azithromycin, the vitreous of the left eye progressively became more cloudy, showing the development of vitreous opacities with a retinal detachment.\n\n\nCONCLUSION\nThe ocular signs of lepromatous borderline leprosy and the occurrence of a case of bacterial endophthalmitis, probably caused by bacillus contamination of the corneoscleral graft, should be considered by ophthalmologists and clinicians.<EOD> Role of LPS binding protein (LBP) in host defense against bacterial infection in m",
        "label": 2
    },
    "277": {
        "output": "This is a [url= \n[url= ][username]\n[/url]\n[/snapshots]<EOD> Filling the Gap.\n1987;21:41\u201349. 8. Levy RI, Fukui S, Dekker E, Tzeng L, Gharavi AE, Flaherty J, et al. Serological and functional analyses reveal a novel association of HLA-DRw6 with insulin-dependent diabetes mellitus. Eur J Immunol 1986;16: 1301\u20131306. 9. Riggs JE. Diabetes type 1. IntRev Immunol 1993;11:171\u2013191. 10. Saddi S, Vialettes B, Winer ES, Vermeulen M, Vanderveen TA, Kloppenburg J, et al. Transgenic mice selectively expressing a class II major histocompatibility complex molecule in the islets of Langerhans develop autoimmune diabetes. Eur J Immunol 2000;30:219\u2013229. 11.. 12. Kronenberg H, Winer ES. Molecular regulation of autoantigen presentation in the islets of Langerhans. Annu Rev Immunol 2003;21:311\u2013346. 13. Brodeur MP, Shen C, Yin H, Wang Z, Lee A, Gong Y, et al. The NOD mouse. Semin Immunopathol 1994;16:359\u2013387. 14. Palmer CJ, Baxter AG, Gribble SM, Mendelsohn P, Kurrle S, Hutchings AJ, et al. Defective expression of the transporter associated with antigen presentation 1 in the NOD mouse islet and the association of this defect with a genetic susceptibility locus for type I diabetes. Diabetes 1999;48: 2035\u20132041.<EOD>",
        "label": 0
    },
    "278": {
        "output": "## Exercises\n\nUse **python3** to complete the exercises. [Click `here` if the link gets broken].\n\nExercise 1: This exercise is a self-test for the [exercises of][exercises_of].  \n\n\n```\npython3 practice_exercise1.py\n```\nExercise 2: Write a function which finds all eligibility candidates of a clinical trial. It should find eligible patients by filtering the patients who do not meet the criteria of the clinical trial.  \n\n```\npython3 practice_exercise2.py\n```\nExercise 3: Write a function which does a trial-level eligibility assessment.  \n\n```\npython3 practice_exercise3.py\n```\n\n# Discussion\n\n## Review\nThis is an unfinished work in progress. You may help me to fill the gaps.\nYou may also provide links to any additional materials you can provide or information you think may be suitable to the paper.\n\n\n<!--more--><center><h2>Review</h2> <hr/></center>\n\nFor the rest of the article, I would like you to be a review reader. So please read this article from the following 3 perspectives:\n1. Information technology people\n    - As healthcare professionals and IT people\n    - As information systems developers for healthcare\n    - As people who are interested in the latest IT developments to improve health systems\n2. Clinical practice people\n    - Healthcare professionals\n    - Medical researchers\n3. Public audience\n    - People interested in the recent developments in healthcare\n\n\n### What is the purpose of the article\nWe live in the era where healthcare is becoming highly automated with the use of information systems. In many situations, health professionals should communicate by IT tools with their patients. Although there have been lots of previous researches, healthcare professionals should get information from the most recent developments. So you should read this article and keep track of any other related articles or researches which could improve healthcare.  \n\n### What is the value proposition\nThe value proposition will be the same as above. The value proposition will be improved by this research.  \n\n### Is",
        "label": 1
    },
    "279": {
        "output": "[INFO] 2019-05-10 02:02:40,852 INFO : You are welcome to contribute at any time! If you make more contributions, I will increase your contribution ranking! [/INFO]\n### \u8840\u53cb\u75c5 A (\u4e5f\u79f0\u81ea\u8eab\u514d\u75ab\u6027\u8840\u6db2\u75be\u75c5\u7b2c\u4e00\u578b)\u4e3b\u8981\u7531\u56e0\u67d0\u79cd\u57fa\u56e0\u53d8\u5f02\u5bfc\u81f4\u7684\u81ea\u8eab\u6297\u4f53\u4ecb\u5bfc\u7684\u6740\u4f24\u6027\u6eb6\u8840\u3002\u5728\u60a3\u8005\u7ea2\u7ec6\u80de\u53d1\u751f\u635f\u4f24\u540e\uff0c\u6297\u4f53\u4f1a\u7a33\u5b9a\u963b\u6b62\u57fa\u56e0\u9519\u914d\u7684\u8868\u578b\uff0c\u4ece\u800c\u9020\u6210\u7ea2\u7ec6\u80de\u7ef4\u6301\u51fa\u4e4e\u6240\u80fd\u7684\u72b6\u6001\u3002\u6b64\u5916\uff0c\u6297\u4f53\u4e5f\u4f1a\u4fc3\u8fdb\u809d\u7ec6\u80de\u548c\u8840\u7ba1\u7684\u9ecf\u819c\u8840\u7ba1\u53cd\u5e94\uff0c\u8fdb\u800c\u4fc3\u8fdb\u75c5\u60c5\u8fdb\u5c55\u3002\u56e0\u7f3a\u4e4f\u529f\u80fd\u826f\u597d\u7684\u8865\u5145\uff0c\u4f7f\u6b64\u75be\u75c5\u5e38\u5bfc\u81f4\u6b7b\u4ea1\u3002\n\n```\n---\nlayout: post\ntitle: \u8840\u53cb\u75c5 A \u7684\u6700\u65b0\u8fdb\u5c55\n---\n\n\n## \u81ea\u7136History\n### \u53d1\u75c5\n\n\u81ea\u7136History\u7684\u57fa\u672c\u5185\u5bb9\uff1a\n1\u3001\u80cc\u666f\uff1a\u81ea\u8eab\u514d\u75ab\u6027\u8840\u6db2\u75be\u75c5\uff08\u81ea\u8eab\u514d\u75ab\u6027\u8840\u7403\u589e\u591a\u75c7\u3001\u81ea\u8eab\u514d\u75ab\u6027\u6eb6\u8840\u75c7\u53ca\u81ea\u8eab\u514d\u75ab\u6027\u6eb6\u8840\u6027\u80be\u75c5\uff09\u662f\u4e00\u79cd\u7531\u4e8eT\u53caB\u6dcb\u5df4\u7ec6\u80de\u56e0\u81ea\u8eab\u6297\u4f53\u5bfc\u81f4\u7684\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u5b83\u4eec\u4e0e\u8840\u6db2\u75be\u75c5\u76f8\u5173",
        "label": 0
    },
    "280": {
        "output": "### Trial-level eligibility\n| Example\n\n| Patient note\n```js\n[\n  {\n    \"Age\": 45,\n    \"Gender\": \"F\",\n    \"Disease\": \"Breast Cancer\",\n    \"Tumor Size\": 3,\n    \"Pathological Results\": \"ER/PR negative, HER2-positive\",\n    \"Surgery\": \"Left mastectomy\",\n    \"Stage\": \"III(c)\",\n    \"Chemotherapy\": \"X\",\n    \"Radiotherapy\": \"X\",\n    \"Endocrine Therapy\": \"X\",\n    \"Targeted Therapy\": \"X\",\n    \"Immunotherapy\": \"X\",\n    \"Cancer Site\": \"Breast\",\n    \"Metastases\": \"X(4) metastatic lymph nodes\",\n    \"HER2 Status\": \"Positive\",\n    \"HR Status\": \"Positive\",\n    \"Lymph Nodes Examined\": \"18\",\n    \"Lymph Nodes Metastases\": \"yes\",\n    \"Inclusion Criteria\": \"X(Patient is included in the clinical trial; eligible)\",\n    \"Exclusion Criteria\": \"X(Patient is excluded; excluded)\",\n    \"Exclusion criteria\": \"X(Patient is not eligible for the trial, but exclusion of the patient is not required)\",\n    \"Other notes\": \"\"\n  },\n  {\n    \"Patient ID\": 27840205,\n    \"Patient Note\": \"Breast surgery\",\n    \"Chemotherapy\": \"Anthracyclines +/-taxane and carboplatin\"\n  }\n]\n```\n\n\n### Clinical Trial Inclusion and Exclusion Criteria\n\n\n| Clinical trial title\n---|---\n| Title: Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)<EOD> .\nObjective: To discuss the value of percutaneous microwave coagulation therapy in treating papillary thyroid microcarcinoma. Methods: One hundred and twenty patients with papillary thy",
        "label": 0
    },
    "281": {
        "output": "</p>\n\nThe same task as #3 is in #A (A2), where you are a medical assessor for the study and need to apply exclusion criteria to each patient.\n<p class=\"inst_task_label\">[INST] Hello. You are a medical assessor for the study. Your task is to determine whether the patient, based on their answers in the patient note, is eligible to participate in a clinical trial. \n\nInclusion Criteria:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma.\n- The tumor is HER2-positive and ER/PR negative. \nExclusion Criteria:\n- The patient is using antihypertensive agents.\n- The patient is using anticoagulants.\n- The patient is using proton-pump inhibitors.\n- The patient is using oral contraceptives.\n- The patient is using aspirin.\n- The patient has a history of smoking or alcohol consumption.\n- The patient has a history of a sexually transmitted disease.\n- The patient has a family history of cancer.\n- The patient is not a candidate for tumor resection prior to chemotherapy.\nTrial-level eligibility: \n\n</p>\n\n# C (continued)\nIn [A3](A3), you are a medical professional trying to improve your English vocabulary. You are assigned to study a paper called _Improving Pain Management in Low-and Middle-Income Countries_ which was written by Jane Oro. Jane Oro is a psychologist and pain management specialist at the University of California (Berkeley, CA, USA). In your job, there is no time to learn all English words, so it's important which words you will use in a particular situation. You are asked to fill out the grid in .\n<p class=\"inst_task_label\">[INST] Hello. You are a medical professional trying to improve your English vocabulary. For your assignment, you are asked to fill out the grid in . \n\nYou will never be tested on your responses.\n\n<",
        "label": 0
    },
    "282": {
        "output": "This way, you will be able to obtain the output as expected. \n\n\n## Assessing an inclusion/exclusion criterion\nIn some cases, for the same patient, a criterion may be met and a criterion may be not met. It can happen in the assessment of an eligibility.\nFor example, in this patient has the criteria of age and gender. Although patient age is meeting this criterion, gender is not matching. So, the output should look like this. \n\n## Assessing eligibility for clinical trial 01\n\nTrial-level eligibility: 1) Excluded\nTrial ID: Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy\n\nAssessment ID: 01\n\n[INST] hello.\n\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or drink alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial:\nTitle: Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy\n\nSummary: This randomized phase III trial studies how well platinum based chemotherapy works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin",
        "label": 0
    },
    "283": {
        "output": "[/BLOCK]<EOD> Pain in primary care: a Latin American survey.\nINTRODUCTION\nPain is a common symptom in daily medical practice, and it has various implications among which a decrease in the quality of life is the principal one.\n\n\nOBJECTIVES\nThe aim of this survey is to analyze the profile of practitioners in Latin American countries to determine their knowledge of and approach to pain management.\n\n\nMETHODS\n1000 patients with chronic pain that attended different health-care centers in 9 Latin American countries, were interviewed about the frequency of their pain. The doctors were queried about their knowledge of and attitudes toward pain management.\n\n\nRESULTS\nAccording to their own declaration, doctors have quite poor knowledge about the concepts of pain, pain measurement, the pathophysiology and therapy of chronic pain. Only a minority would be considered experts in pain therapy.\n\n\nCONCLUSION\nFifty years after the start of the International Association of Pain it becomes clear that the approach to pain is still unsatisfactory in the Latin American region.<EOD> Hydrogen-Bond Enable Intermolecular Coupling Effect in Nonlinear Refraction of an All-Carbon-Based Dye-Sensitized Layered Polymer System.\nAlthough the light-induced nonlinear refraction response based on hydrogen bonding has been well recognized in organic semiconductors in recent years, it is still lacking the investigation of the structure-property relationship between hydrogen bonds and nonlinear optical response in dye-sensitized layered polymer systems. Herein, we focus on a newly designed all-carbon D-\u03c0-A-based polypyridyl dye and develop a dye-sensitized layered structure of zinc-phthalocyanine (ZnPc), pyridyl-benzothiadiazole (BTD-Pyridine), and thymine (THY) molecules for a study on hydrogen bonding-coupled molecular nonlinear optical response. The results show that through the combination of structural modification and molecular design, the hydrogen bonds introduced by the dyes and the \u03c0-\u03c0 interaction of the chromophore molecules can strongly",
        "label": 2
    },
    "284": {
        "output": "[TEST]\n\nTo run the test suite, run the following command from your command prompt:\n\n```\njava -jar /Users/<your_user>/test/test/target/test-distribution-0.9-all.jar check\n```\n\n[TUTORIAL]\n\nLet's take the `HelloWorld` demo. First import the test cases you need.\n\n```shell\njx -i /Users/tutu/test/tutu05/data/test-codebook/H2HW/test-codebook.xml\n```\n\nThen you can run a test suite.\n\n```\njx -o -f -c helloworld -s helloworld.xml\n```\n\nNow let's show the progress.\n\n```\n$ jx -X option -f helloworld.xml\n...\n2) Eligible\n```\n\nNow let's run the same program on two machines.\n\n```\n$ jx -c helloworld -i 1 -S helloworld.xml\n... \n2) Eligible \n```\n\nWe can see that the test results are equivalent.\n\n```shell\n$ jx -X summary -f\nSummary:\n--------------------------------------------------------------------------------\nTest Case (Case ID):      helloworld\nTest:\n|  Hello World (H2HW): Eligible (E) and passed (P)\n|                    Succeeded in 5 of 5 times\nTester:\n|                     t0050\nTester:\n|                     t0052\nTesting:\n|                    Hello World with H2HW: Eligible and Passed\n|                  (E/P)\n-------------------------------------------------------------------------------\n```\n\n## Tutorial: 4\n\n### Including test code in the code of a program\n\nA test-driven method allows to ensure that the code under test is consistent with the intentions of test software developers. This may seem as a non-issue by some, but with the wide use of software testing techniques, testing may be performed by software developers other than those who have written the code and it is often hard to find the person who wrote a code block for verification of its behavior. For instance, a software that performs a random action at",
        "label": 0
    },
    "285": {
        "output": "<EOD> Clinical features of children with influenza A/B virus-associated pneumonia during 2010-2019 in Beijing, China\n\nBackground: This study aimed to retrospectively analyze the clinical characteristics of children with influenza virus-associated pneumonia in Beijing to improve the clinical understanding of this disease and provide evidence for rational treatment. Methods: A total of 326 pediatric patients with influenza A/B virus-associated pneumonia were selected from the pediatric inpatient medical system of Beijing Children's Hospital. The medical records, physical examination results, and clinical outcomes of the patients were retrospectively reviewed. Results: Of the 326 children, 184 were male; the remaining 142 were female. The average age of the patients was 4.57 \u00b1 3.02 years; the youngest patient was 53 days old, and the oldest patient was 16 years old. There was no statistical difference in terms of sex or age between the influenza B virus-and the influenza A (H1N1) viruspositive patients (p > 0.05). A total of 358 pathogenic microorganisms were isolated from nasopharyngeal swabs (all 206 strains of influenza A and 152 strains of influenza B, all in the same season). The total number of bacterial and fungal pathogens identified from the blood, sputum, and bronchoalveolar lavage fluid (BALF) was 621. Influenza infection was related to bacterial and fungal infections (\u03c7 2 = 40.554, p = 0.000). There were 144 severe cases included in this study with 18 mortalities. The clinical symptoms of patients, imaging examination, laboratory test indices, and treatment methods varied between patients infected with different virus subtypes. Conclusions: Patients with serious influenza infections have various clinical manifestations and are susceptible to secondary bacterial and fungal infections. Therefore, appropriate supportive treatment and antibacterial and antifungal treatment",
        "label": 0
    },
    "286": {
        "output": "![image_2](./img/image_2.jpg)\n\n[MNE] You will next need to enter the patient's height and weight data into the 'Outcome measures' (Patient baseline 1) module. You can provide an",
        "label": 0
    },
    "287": {
        "output": "<EOD> Effect of Lactulose, a Synthetic Disaccharide, on Caecal Volatile Short\u2010Chain Fatty Acid Concentration of Broilers\n1.\u2002The experiment was designed to determine effects of lactulose, a water-soluble synthetic disaccharide, on caecal short-chain fatty acid (SCFA) concentrations in broiler chickens. 2.\u2002A commercial diet (crude protein 23%; crude fibre 5%) for broilers was supplemented with graded levels of lactulose (0, 0\u00b725, 0\u00b750, 1\u00b700%, wt/wt) in 2 experiments. Thirty-six Ross broilers of 3 different pen averages were used in the first experiment and 6 trials, each with 9 birds, were conducted in the second experiment. At the end of the 42 d experimental period, all birds were slaughtered and 5\u20138 cm of the last 10 cm of the caecum was collected from each bird and pH analysed. 3.\u2002Excreta samples were collected on 8 consecutive days in each trial of the first experiment and daily for the second experiment. The samples were thawed and pooled for chemical analysis at the end of the trial period. 4.\u2002Caecal pH increased significantly from 6\u00b726 for birds without lactulose supplementation to over 6\u00b771 for birds fed diets supplemented with 1\u00b700% lactulose or over 7\u00b700 for birds fed 0\u00b725 to 0\u00b75% lactulose. A significant increase in SCFAs in the caecum was seen up to 0\u00b750% lactulose, but the SCFA concentration as well as the S:P ratio increased at levels and up to 1\u00b700%. The caecal wet weight was not altered by lactulose supplementation. 5.\u2002Oligosaccharide fermentation by the caecum has been shown here to be advantageous because of the increased SCFAs produced. As lactulose cannot be absorbed it is not likely that these additional fermented SCFAs, due to the o",
        "label": 1
    },
    "288": {
        "output": "[/Tutorial]<EOD> Bovine mastitis.\nBovine mastitis has been of growing economic importance over the past few years. A wide variety of bacteria are capable of infecting the mammary gland causing mastitis. Escherichia coli infections are now often observed in herds with good hygiene and with low occurrence of contagious microorganisms. The purpose of this review is to give a short description of the microbiology and pathology of mastitis and to summarize the effects of antibiotic therapy. Special attention is paid to the control of mastitis and to the most important practical management measures.<EOD> Cutting-edge techniques.\nEFFECTIVE treatment of tension-free primary inguinal hernia is safe, cost effective, and predictable. A recent study has shown that the rate of surgery-related morbidity is much lower than previously reported. For example, the rates of haemoperitoneum in men and superficial wound infection were only 0\u00b77% and 2\u00b72% respectively, compared with 6\u00b79% and 12\u00b70% in a previous study.1<EOD> Dental fluorosis in children: correlation with fluoride dosing in mother's milk.\nA survey was conducted in Ribeir\u00e3o Preto, a municipality in the state of S\u00e3o Paulo, Brazil, to evaluate dental fluorosis (DF) in children. In addition, several variables of interest, such as the fluoride concentration of maternal milk, the prevalence of use of fluoridated milk (FM) during pregnancy and lactation, and maternal and children's dental hygiene, were investigated. The sample consisted of 493 children from 0 to 5.5 years of age. Two calibrated examiners, using Dean's index, examined enamel fluorosis. A survey was conducted with the mothers of these children, with questions including age and education level of the mother, number of children, and duration and form of nursing. Sixty-nine percent of mothers recalled that they had been informed of the benefits of FM and, of these, 42.9% reported that they had used the treatment during lactation. The prevalence of",
        "label": 1
    },
    "289": {
        "output": "We have one patient with 14 patient factors in this example. Each patient factor has to correspond to 1 or more factors that are written in the title.\nTo write down a patient factor of age, you should do the following: \n```R\n# Patient notes 1 patient_notes = seq(1:15) p1 = paste(paste0(\"Patient is a \", plyr::select(patient_notes, ~paste0(\"age[\", paste0(\"x1_\", plyr::select(patient_notes, ~.x[, \"age\"), \",\"), \"x\")))), sep=\"\\n\") \n```\nWe have to look into the patient factor age. First, `select` selects the age column in each patient note. The second argument defines how we group the data, the order in which columns are merged. Thus, if we pass a list with element \"age\" into the second argument, the age column is grouped together and then the grouped elements are merged. Here, we can also see that the age columns are grouped with a fixed element. The column `sex` is grouped by column with the name \"Sex\" then the column \"age\" is grouped just like the previous one. Therefore, the \"age\" column will be at the end of the result. \n```R\n```\nAnd since the clinical trial only considers one patient factor that is the patient age, for example, `29-45 years of age`, we do this:\n```R\n# Inclusion criteria \ncl_inclusion_age = `\n    clin_study_data %>%\n    select(study_name == \"Title\") %>% # Select the specific study\n    select(\n        title == paste0(\"Inclusion criteria: [name (age)]\")\n        ,  # Select the inclusion criteria that are related to the patient age\n        paste(paste0(\n              study_name,\n              \"_Inclusion_Age\"), \n              \": \",\n              age_factor_id, \n              (\".sex[\", \"Sex\", \"]\")\n          )\n        , \n        replace_na = TRUE\n    ) %>% # Select the target column\n    ungroup() # Merge\n    %>%\n    select(study_name, age_factor_id, title)\n\n    `\n\nThe",
        "label": 0
    },
    "290": {
        "output": "___Example data file___\n\nHere is an example file that includes a patient file and a trial file: file_to_assess_clinical_trial_eligibility.txt \n\n____The Patient Level____ \n\nPatient-level_1#\n# Assessment for breast cancer trial \n0) Excluded:  Exclude from trial, since patient has exclusion criteria\nN/A (not relevant)\n2) Eligible:  Patient meets all inclusion criteria and does not have any exclusion criteria.\nPatient meets the following inclusion criteria:\nage = 45\nsex = F\nhas cytologically confirmed breast cancer.\nhas a 3 cm invasive ductal breast carcinoma.\nis  HER2-positive and ER/PR negative.\nhas cytologically confirmed breast cancer.\nhas stage III breast cancer.\nis  HER2-positive and ER/PR negative.\nhas cytologically confirmed breast cancer.\nhas metastatic breast cancer.\nis on a multivitamin regimen.\nis not sexually active.\nhas no children.\nis not sexually active.\nhas no children.\nis using a multivitamin regimen.\nis not sexually active.\nhas no children.\nis a nonsmoker.\nhas no children.\nis not sexually active.\nhas no children.\nis a nonsmoker.\nis not receiving treatment for breast cancer.\nis not receiving treatment for breast cancer.\nThis patient does not meet the exclusion criteria of the trial, so she is eligible for this trial.\nPatient-level_2#\nN/A (not relevant)\n0) Excluded:  Exclude from trial, since patient has exclusion criteria\nN/A (not relevant)\n2) Eligible:  Patient meets all inclusion criteria and does not have any exclusion criteria.\nPatient meets the following inclusion criteria:\nage = 52\nsex = F\nis having breast cancer surgery.\nunderwent tumor resection.\nis having breast cancer surgery.\nis having breast cancer surgery.\nhas cytologically confirmed breast cancer.\nhad an invasive ductal breast cancer 4.5x2.0 cm in",
        "label": 1
    },
    "291": {
        "output": "## RQ2: If we have multiple datasets, what will we do with the other clinical trials? How will we aggregate the datasets?\n[RQ2] Hello. You need to assess multiple patients from multiple clinical trials. We assume that you have patient notes that have two different clinical trials. \nAs we have seen in the eligibility assessment, the result of a clinical trial is always represented with a trial-level eligibility. So the task is basically to aggregate multiple clinical trials with a common trial-level eligibility to form a group for each clinical trial and then predict the patient-level eligibility.\n\nHere are details to be followed: \nLet N be the number of the clinical trials that the clinical trial recruitment assistant should evaluate per batch. The total tasks of the clinical trial recruitment assistant were N datasets with trial-level eligibility in each dataset. Each dataset had M patient notes from one clinical trial. The clinical trial recruitment assistant had to evaluate all clinical trials per batch. The output was a dataset with a patient-level eligibility. The trial-and patient-level eligibility were predicted by aggregation of M clinical trials. You should predict new triallevel eligibility and corresponding patient-level eligibility in the patient-level eligibility dataset.\n\n[INST] Please implement the process of aggregation.\n\n[INST] Please predict trial-level and patient-level eligibility in the patient-level eligibility dataset. The structure of the dataset of patient-level eligibility is below. The column named `ID` is the unique number of a patient in the corresponding clinical trial. The column named `Trial_level_eligibility`is the result of a clinical trial. The column named `Patient-level_eligibility` is the result of aggregation of clinical trials. In the evaluation of dataset, the patient eligibility is positive if its sum of the column `Patient-level_eligibility` \u2265 1, otherwise, it is negative. The column named `Dataset_number` is the number of the dataset. [INST] There is a certain degree of imbalance in the positive and negative classes. You may need to consider this aspect. Try different ratios of positive",
        "label": 0
    },
    "292": {
        "output": "<EOD> Detection of microRNA signature in serum exosomes as complementary diagnostic biomarkers for non-small cell lung cancer\n\nDysregulation of miRNA expression is found in several types of cancers, including lung cancers. We aimed to determine the difference in the expressions of miRNA between the sera and serum exosomes of lung cancer patients and healthy subjects and then to evaluate the possibility of serum exosome miRNA as a clinical biomarker for lung cancer. This study included 17 non-small lung cancer (NSCLC) patients and ten healthy controls. We measured the expression of serum miRNAs from cancer patients and determined the expression of miRNA in serum exosomes. Our results showed differential expression of miR-10b, miR-223, and miR-21 in NSLC patients, although a significant difference was not observed in the expression of serum miRNAs between the two groups. Significant differential expression of miR-10b, miR-223, and miR-21 was observed in patients with advanced tumor stages. However, all miRNA expression differences were significant in NSCLC patients with EGFR mutations. Our results suggest that miR-10b, miR-223, and miR-21, along with the expression of serum exosomes, could be complementary diagnostic biomarkers for NSCLC. Oncotarget 378 www.oncotarget.com\n\n# Introduction\nLung cancer has a dismal prognosis and is predicted to become the most commonly diagnosed cancer and the leading cause of cancer-related mortality worldwide [bib_ref]  Global cancer statistics, Jemal [/bib_ref] . Among the patients with lung cancer, only 15% are diagnosed as having non-small cell lung cancer (NSCLC) because of the non-specific symptoms of lung cancers [bib_ref]  Symptom clusters in non-small-cell lung cancer, Osarogiagbon [/bib_ref] . Therefore, exploring new methods that can improve the early diagnosis and improve the prognosis of lung cancer is urgently needed.\nMicroRNAs (miRNAs) are 18-24 nucleotides long non-c",
        "label": 2
    },
    "293": {
        "output": "## The output example\n\n##[INFO] You are about to assess a trial level eligibility for patient ID 3309 in clinical trial UF19-15-3512. [INFO]\n\n## Score: 2) Eligible. [INST]\n\n##[INFO] Patient ID 3309 - TRIAL-LEVEL ELIGIBILITY: 2) ELIGIBLE.[INFO]\n\n##[INFO] You are about to assess a trial level eligibility for patient ID 3301 in clinical trial UF17-19-5303. [INFO]\n\n## Score: 2) Eligible. [INST]\n\n##[INFO] Patient ID 3301 - TRIAL-LEVEL ELIGIBILITY: 2) ELIGIBLE.[INFO]\n\n##[INFO] You are about to assess a trial level eligibility for patient ID 3305 in clinical trial UF16-20-2640. [INFO]\n\n## Score: 2) Eligible. [INST]\n\n##[INFO] Patient ID 3305 - TRIAL-LEVEL ELIGIBILITY: 2) ELIGIBLE.[INFO]\n<EOD> Synthesis and pharmacological profile of the enantiomers of N(1)-hydroxy-3-O-(2,2,2-trimethyltridecan-yl)-2-(piperidin-4-yl)propran-1-ol (BRL 25968; (+)-(S)-1542; (-)-(R)-1542).\n(-)-(S)-1542, recently identified as the active agent of a series of highly potent and selective benzazepine analgesics, has been racemized to the enantiomer (+)-(S)-1542. The two isomers were separated using a chiral liquid chromatography column and by high pressure liquid chromatography (HPLC). The separation by the latter method was reproducible for a long time; thus, about 3 kg of (+)-(S)-1",
        "label": 0
    },
    "294": {
        "output": "> dfu <-function(df, m <-2){\n  df$grades <-as.factor(df$grades)\n  ndf <-sum(!df$grades %in% c(\"1\", \"2\"))\n  rcol <-ncol(df$grades)\n  df$sum <-cbind(1:2, cumsum(ndf))\n  dfs <-as.data.frame(unlist(lapply(df, function(x) ifelse(x$grades == -9999, \"N/A\", x)) %>% unlist()))\n  pats <-apply(dfs[which(rowSums(dfs)) == max(rowSums(dfs)), rownames(dfs), function(x) { summarized <-as.data.frame(count(1:ncol(x))) summarized[colnames(summarized) %in% (\"A\")) summarized[1:2] <-as.matrix(summarized) summarized }))\n  if(rcol == 1) { n <-1; nd <-2; r <-1; rn <-2 } else { n <-rcol; nd <-rcol*3; r <-rcol*2; rn <-rcol*2 } mat <-matrix(c(rep(\"A\", n), r[c(1:nd)], r[c(nd + 1:n:)], \"N/A\"), ncol = 2, nrow = max(n, r)) mat[c(\"\", \"N/A\"), c(\"\", \"N/A\")] <-\"A\" mat <-pats %>% rename(d <-.2) %>% reduce(x = .1, f = function(x) list(colnames = c(.2), data = x)) %>% rename(j <-.1) %>% lapply(function(x) x[,c(\"A\", \"N/A\")]) %>% lapply(function(x,j,d) replaceNA.x(x,j,d)) %>% lapply(function(x, j, d) matrix(replaceNA.x(cbind(d, x[,j]), c(\"\", \"N/A\")), dimnames = list(d, j))) %>% reduce(x = .1, y = .2, f = function(x,",
        "label": 0
    },
    "295": {
        "output": "### Inconsistent data types\n\n```python\nprint(\"Test Inconsistent data types\")\n```\n\n```\n$ python test_inconsistent_datatypes.py\nTest Inconsistent data types\nBreast Cancer with Invasion < 1cm in Diameter\nBreast Neoplasms Malignant < 1.0 cm\n0) Excluded   0    2\n1) Not relevant    0    1\n2) Eligible 1014 30300549\nTrial-level eligibility: 0\nBreast Cancer With Invasion < 1.0cm in diameter\nTrial-level eligibility: 0\nBreast Neoplasms Malignant < 1.0 cm\nTrial-level eligibility: 0\nTrial-level eligibility: 2\nBreast Cancer With Invasion < 1cm in Diameter\nTrial-level eligibility: 1\nInbreast Neoplasms Malignant < 1.0 cm\n\n```\n\n### Missing data types\n```python\nprint(\"Test Missing data types\")\n```\n\n```\n$ python test_missing_datatypes.py\nTest Missing data types\nBreast Cancer with Invasion < 1cm in Diameter < Not known\nBreast Neoplasms Malignant < 1.0 cm < Not known\n0) Excluded   0    2\n1) Not relevant    0    1\n2) Eligible 1014 30300549\nTrial-level eligibility: 0\nBreast Cancer With Invasion < 1.0cm in diameter < Not known\nTrial-level eligibility: 0\nBreast Neoplasms Malignant < 1.0 cm < Not known\nTrial-level eligibility: 0\nTrial-level eligibility: 2\nBreast Cancer With Invasion < 1cm in Diameter < Not known\nTrial-level eligibility: 1\nInbreast Neoplasms Malignant < 1.0 cm < Not known\n\n```\n<EOD> The 100 most cited articles in orthod",
        "label": 1
    },
    "296": {
        "output": "![TEST:2020-09-18_122416.png](./TEST:2020-09-18_122416.png)\n```python\n#+\n\"\"\"\nDocs at: https://dreamruntimer.com/docs/2020-09-18/clinical-trial-recruitment.html\n\"\"\"\n#-\nimport string\n# Setup packages\nimport random\nimport sys\nimport time\nfrom urllib.parse import urlparse\nfrom datetime import date, datetime, timedelta\n\n# Set our random seed to be equal to the current time.\nrng = random.Random()\n\n# Check for a URL input, if not given, bail.\nif len(sys.argv) < 2:\n    print(\"Specify a URL:\")\n    sys.exit()\nurl = sys.argv[1]\n# We will make use of Pandas to load our data into a dataframe\ndata = dataset().recode()\n# If the clinical trial name isn't on the URL, we will add a\n# `clinical_trial_name` column for use.\nif urlparse(url)[2] != \"clinical_trial_name\":\n    data = data.join(dataset(f\"{url}&clinical_trial_name={data['clinical_trial_name']}\"))\nelse:\n    print(\"Got the trial name on the URL.\")\n# Now let's preprocess the data to make it suitable for use\nfor i, name in data.groupby(\"Trial-code\"):\n    name[\"Trial-code\"]= name[\"Trial-code\"].lower()\n    name[\"Trial-code\"]=name[\"Trial-code\"].str.split(\":\", expand=True).str.strip('[] ')\n        .str.replace(\",\", \"\").str.replace(\":\", \"\")\n        .str.replace(\" \", \"\")\n    name[\"Trial-code_lower\"] = name[\"Trial-code_lower\"]=(name[\"Trial-code\"].str.split(\":\").str.join(\"\").isna())\n    name[\"Trial-code_lower\"]",
        "label": 2
    },
    "297": {
        "output": "---\n### Data structure\n\nAfter your work has been done, a new dataset of `Clinical` class will be produced. Here, the dataset you need to work with may not be very useful if the patient ID `patient_id` is not present. In this case, it may be possible to work with this dataset only. If you need to work with ID, then you need to add a set of additional columns to the patients.\n\nBelow, we describe how to convert a `Clinical` instance to an `Eligibility` instance, and add additional columns to the input dataset. Let's look at an example of this idea in the `Eligibility` instance.\n\n```julia\nusing DataFrames\n\n[formula]  eligibilityData = Clinical.eligibilityData(x) [/formula] \n```\nThe resulting `Eligibility` object looks like this:\n\n```julia\nEligibility(\n  age = Float64(30),\n  gender = Symbol(\"Male\"),\n  height = Float64(170),\n  weight = Float64(80),\n  birthdate = Float64(1995),\n  ageAdmission = Float64(41),\n  ageDeath = Float64(103),\n\n  height_during_illness = Float64(150),\n\n  ageLastVisit = Float64(39),\n\n  weightLastVisit = Float64(2000),\n\n  BMI_lastVisit = 19.07,\n  heightDuringIllness = Float64(160),\n  heightLastVisit = Float64(170),\n  weightLastVisit = Float64(1800))\n\n```\nThe age (the last two properties), gender, birthdate, and weight are included in the metadata `Metadata.DataProperties(...)` object. Also, note that we added the fields corresponding to the `height_during_illness` and `ageLastVisit` (i.e. `Patient(1).height_during_illness == 6`), which are related to the `age` field.\n\n```julia\n#print(el",
        "label": 0
    },
    "298": {
        "output": "<EOD> The Role of the Physical Trait Domain in the Identification of Differential Item Functioning (DIF) Between Two Groups\n\nThe physical trait domain is among one of the more sensitive areas for identifying Differential Item Functioning (DIF) in the measurement of health-related constructs. The purpose of this study is to better understand the impact of DIF in the physical trait domain as it relates to the development of health-related assessments. First and second order models were used to account for DIF. Simulations were used to examine conditions in which DIF in the physical trait domain is the most harmful. A case study utilized data from an epidemiological study to demonstrate our model for assessing the clinical significance of DIF in the physical trait domain. Results indicate that first-order models are effective for screening items from the physical trait domain, while second-order models are better for identifying and correcting DIF in the physical trait domain. DIF detection in the physical trait domain was most harmful when the overall severity of health-related constructs was high. DIF detection is most beneficial when the overall severity of health-related constructs is low in the physical item domain. We encourage the development of more complex item response theory (IRT) models to assess the impact of this type of DIF, and its associated measurement error, on the ability to detect change over time.\n\n# Introduction\nDifferential Item Functioning (DIF) refers to a bias in items caused by the presence of systematic, unwanted variance or relationships between a person's responses and that of a group variable. In health-related assessments, DIF is typically examined in the context of a patient-group variable, such as gender or ethnicity, against which the validity of a measure is judged. In one example of this, [bib_ref]  Differential Item Functioning in the MOS SF-36 Health Survey Questions, Kerns [/bib_ref]  examined the physical component of the SF36 for differences in functioning between women and men in three areas (mobility, pain, and energy). The authors found evidence of DIF related to physical capability and activity restriction. [bib_ref]  A Comparison of Item Response Theory Partial Credit Score Analysis Model and..., Devanand [/bib_ref]  identified DIF in the Physical Discomfort sub",
        "label": 1
    },
    "299": {
        "output": "A: You appear to be using the template:\n{{#if (age|size) > 0}}\n{{#if 0 <= (age|size) 1}}\n\n{{age|size}}\n\n{{#if (age|size) > 1}} 2) Eligible.\n(1) Excluded.\n(2) Not relevant.\n{{/if}}\n{{else}}\n\n{{age|size}}\n\n{{else}}\n\n{{age|size}}\n{{else}}\n\n{{age|size}}\n{{/if}}\n\nHere, we can see we're having trouble with formatting. You may wish to remove some of the formatting from the template, for example:\n{{#if (age|size) > 0}}\n\n{{age|size}}\n\n{{else}}\nAge is 0\n{{/if}}\n\nand then update your template as follows:\n{{#if (age|size) > 0}} {{#if 0 <= (age|size) 1}}\n\n{{age|size}}\n\n{{#if (age|size) > 1}}\n {{#if 0 <= (age|size) 2}} 2) Eligible.\n{{else}}\n 1) Excluded.\n {{else}}\n 2) Eligible.\n {#if (age|size) > 2}} \n 2) Eligible.\n {{else}}\n {{#if 0 == (age|size) 1}}\n 2) Eligible.\n {{else}}\n {{#if 0 == (age|size) 1}} 2) Eligible. \n {{else}}\n {{#if (age|size) == 0}} 2) \n Eligible. \n {{else}} 2) \n Eligible. \n {{/if}}\n\n{{else}}\n\n{{age|size}}\n\n{{else}}\n{{age|size}}\n{{/if}}\n\n{{else}}\n\n{{age|size}}\n{{/if}}\n\nThis should do the trick. As I mentioned above, I'm not too familiar with Ruby so some or all of my suggestion may not work. In fact, it may be best if you asked this question on [",
        "label": 1
    },
    "300": {
        "output": "## Trial-level eligibility:\n[Trial-level eligibility: 0) Excluded]\n[Trial-level eligibility: 1) Not relevant]\n[Trial-level eligibility: 2) Eligible]\n\n\n## INSTRUCTIONS.\n[INSERT]\n\n# <a name=\"results\"></a> Results\nEach input file contains a dataset containing two patient-level eligibility scores (one is assigned by humans based on clinical information and the other is assigned by a machine using only clinical information), and the input file provides several details regarding the trial, such as type, trial title, the start date, number of patients, duration of the enrollment phase for each trial, and details about any published data. \n\nHere is clinical trial information provided by the input file, and 5 patients included in this trial:\n\n- Trial title: S100B Biomarker to Determine Prognosis and Treatment Adjustment for Aggressive Variants of Medulloblastoma\n- Start date: 2016-01-01\n- Number of patients: 62\n- Total enrollment duration: 1\n- Published status: Y\n\n## Table 1: Summary of the first five patients enrolled in the S100B Biomarker to Determine Prognosis and Treatment Adjustment for Aggressive Variants of Medulloblastoma trial.\n\n\n## ID\nGender\nHeight (cm)\nWeight (kg)\nAge (year)\nGPA\nPre-operative MRI\n\n## Results_data_female\n307 1.3 79 133 17 0\nResults_data_male\n315 1.27 77 26.4 17 0\nResults_data_1\n309 1.5 78 138 17 0\nResults_data_2\n304 1.3 77 131 17 0\nResults_data_3\n310 1.4 76 134 19\n\n## The output dataset\n\nThe output file",
        "label": 0
    },
    "301": {
        "output": "_Example Answer_\n\nTrial-level eligibility: 2) Eligible.\n(Source: `149229_0_149229_2.py`)\n\n_Clarification_\n\n**Note:** In reality, there should be two conditions in `Trial-level eligibility: 2) Eligible.`. One can simply use the negation of `Inclusion criteria: 1) Excluded`.\n\n**Notes and thoughts**\n\n- In this question, you have to understand an input structure as a list of a patient note and a clinical trial; in fact, the input will look like a nested structure which is like a string with a token for a patient note followed by a token for `Inclusion criteria: `. \n\n- [Instructions for the first round are available in Github.](https://github.com/deeplearning4j/demo_jvv_winter_2022/blob/master/0/demo_jvv_winter_2022/data/ReadMe.md)\n\nThis is the summary of the instructions for Round 1. Please click the link 'Click here to start' under the instructions to get to the input form of the question. The input box is at the top of the page. [Instructions for the first round](https://github.com/deeplearning4j/demo_jvv_winter_2022/blob/master/0/demo_jvv_winter_2022/questions/0/149229/Click_here_to_start.md)\n\nThis is the summary of the instructions for Round 2. Please click the link 'Click here to start' under the instructions to get to the input form of the question. The input box is at the top of the page. [Instructions for Round 2](https://github.com/deeplearning4j/demo_jvv_winter_2022/blob/master/0/demo_jvv_winter_2022/questions/0/149229/Click_here_to_start.md)\n\n## [150586](https://github",
        "label": 0
    },
    "302": {
        "output": "### Exercise\nWrite down your first assessment by giving the most simple notation for your patient with some assumptions. Consider the example shown below:\nFirst, let's think about the patient.\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2+ and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\n\nCXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, we need two sets of data for the clinical trial. One is for the clinical trial information and the other is the research-related questions. Consider these assumptions: \nAssumptions:\nThe title of the trial is `MK-3475 Immunotherapy in Endometrial Carcinoma. \nAssignment criteria for study: \nPrimary endpoint: overall survival.\nSecondary endpoints: PFS (with confirmation of death and progression within 50 days), PFS 6 months, Efficacy as assessed by response rate (e.g. RRs, ORRs) on the basis of clinic RR, disease free survival and OS, correlation of PD-L1 immunohistochemistry staining, with response rates \nSurgery and adjuvant therapy: resection of primary site and metastasis followed by adjuvant treatment.\nResistance mechanism assessment: analysis of tumor tissue at baseline and post cycle 1-2 and at progression.\nSurgery: hysterectomy +/bilateral salpingectomy with or without oophorectomy (BSO)\n\nSo the trial-related questions are as follows:\n\n1.\nAdaptive design with Bayesian approach for clinical trial.\n2.\nThe trial is evaluating the antiproliferative effects of pembrolizum",
        "label": 0
    },
    "303": {
        "output": "Let's see an example of the code in Python: \n```python\nwith open(INPUT_DIR + INST_FILE_NAME) as f:\n    for line in f:\n        if line.startswith(\"ID\"):\n            if line.endswith(\"eligible\"):\n                print(\"Trial-level eligibility: 2) Eligible.\")\n            else:\n                if not line.endswith(\"excluded\"):\n                    print(\"Trial-level eligibility: 0) Excluded\")\n                    \n            line = None\n    \nimport sys\nprint(sys.modules[\"inst\"].Trial_level_eligibility)\n```\nOutput (same example file): \n```\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 2) Eligible.\n```\n<EOD> The role of N-Acetyl Aspartate in the cerebral metabolism of the very low birth weight newborn.\nBACKGROUND\nVery low birth weight infants (VLBW) are more susceptible to hypoxic-ischemic encephalopathy (HIE) because of their incomplete cortical neuronal network and a lack of myelination. This can lead to a disruption of energetic metabolism and an increase in the amount of N-acethyl-asparate (NAA) in the brain. With this study, we aimed to determine the role of NAA in the brain metabolism of VLBW infants with and without HIE, using in-vivo proton magnetic resonance spectroscopy (HMRS).\n\n\nMETHODS\nNinety-eight VLBW infants without HIE (median weight 1,025 grams , median gestational age  27 weeks ) were enrolled after parental consent. Infants with significant brain anomalies, chronic lung or renal diseases were excluded. Clinical data, anthropometric and perinatal information and results of the neurological examination of the",
        "label": 2
    },
    "304": {
        "output": "[[INST] There are no longer any instances of this variable in this file. The variable was removed from the file.]]\n\n{{item}}\n  \n\n{{#if .Description}}\n    {{.Description}}\n\n    {{#if .Example}}\n    <img src=\"{{.example}}\" alt=\"{{name}}: {{.description}}\" height=\"300\" width=\"600\" />\n    {{/if}}\n\n    {{#if .Example}}\n    <br/><br/>\n    <div class=\"example\">\n        {{name}}: {{.description}}\n    </div>\n    {{/if}}\n\n{{else}}\n    {{.}}\n\n    <div class=\"no-content\">No description is provided for this variable.</div>\n\n{{#if .IsDefault}}\n    {{.}}\n\n    <div class=\"is-default\">{{.IsDefault}} is the default value for this variable.</div>\n\n{{else}}\n    {{.}}\n\n    <div class=\"is-required\">{{.IsRequired}} is a required value for this variable.</div>\n\n{{/if}}\n{{/if}}\n\n{{/each}}\n<EOD> Reconstituting Human Blood Stem Cell Development Using Glioblastoma-Derived Cancer Stem Cells and Plasmid Transfection\n\nCitation: Vazin, J.; Sokolova, M.M.; Zabolotnaya, E.I.; Kharitonova, A.A.; Zavalishinkii, V.Y.; Fedorova, S.A.; Syrdalenko, K.K.; Shtansky, N.S.; Orekhov, A.P. Reconstituting Human Blood Stem Cell Development Using Glioblastoma-Derived Cancer Stem Cells and Plasmid Transfection. Biomedicines 2021, 9, 709.Abstract: The reconstitution of the human hematopoietic stem cell (HSC) system from human pluripotent stem cells (hPSCs) opens up a huge perspective on modeling human blood diseases in vitro and the rapid search for new drugs. There are studies dealing with the reconstitution of the primitive human HSC system using gene-correct",
        "label": 1
    },
    "305": {
        "output": "[INST:\nTrial-level eligibility: 0) Excluded] \n[INST:\nTrial-level eligibility: 1) Not relevant] \n[INST:\nTrial-level eligibility: 2) Eligible]\n\nThe output of the function is a list of triallevel eligibility. The final element is outputted into the console and saved in file `EligiblePatients.csv`. \n\n    triallevel_eligibility <-trial_eligible_analysis(\"PathologyData\", \"HBC1\", \"EligibilePatients\")\n    trial_eligible_analysis(\"PathologyData\", \"HBC1\", \"EligibilePatients\")\n\n\n[INST]\nThe file `EligibilePatients.csv` contains the data as shown below:\n\n```\nID    \n1\n2\n3\n```\n\n\n### The second data set includes the number of tumor-free lymph nodes.\n\n[INST]\nYou should predict the number of tumor-free lymph nodes and obtain the accuracy score.\n\nPlease predict the number of tumor-free lymph nodes by the mean of the patient's clinical data. The accuracy score should be above 1, and lower accuracy scores are considered failures. \n\nLet's try to estimate these numbers of tumor-free lymph nodes: \n\n| ID | Lymph Node |\n|  --- |     ---- |\n|    1 |         2 |\n|    2 |         9 |\n|    3 |         4 |\n\nThe output of the function is a list of numbers of tumor-free lymph nodes. The final element, which is outputted into the console and saved in the file `NumbersOfTumorFreeLymphNodes.csv`, has data in which we predicted the number of tumor-negative lymph nodes. \n\n    numbersOfTumorFreeLymphNodes <-prediction_numOfTumorFreeLymphNodes(\"PathologyData\", \"HBC1\")\n    prediction_numOfTumorFreeLymphNodes_(\"PathologyData\", \"HBC1\")\n\nThe output of the function `prediction_numOfTumorFreeL",
        "label": 2
    },
    "306": {
        "output": "This is an example of the final output of this solution:\nPatient has a 60% chance of responding to treatment.\n\nA: I've just finished this kind of problem at RPA exams.\nLet's define some variables \n1 ) 0 - Excluded\n2 ) 1 - Not relevant\n\n\nA: Let's take look at the problem by using trial type. What is the trial type? What is the trial recruiting?\n\n\n[ TRIAL TYPE RANK RANK\n\n## Type definition\nInteresting RANK > 40% Not Interesting RANK <= 10%\n\n\n*\n\n*Patient is a breast cancure patient:\n\nBreast cancer patients with positive RANK Expression will benefit from denosumab treatment with a higher response to the chemotherapy.\n\n*Denosumab will benefit with higher response to chemotherapy and reduce clinical fractures and improve bone health.\n\n*According to the trial, we will apply denosumab for interested person.\n\n*Clinical trial is a Phase II trial and interested patient will be tested to see whether denosumab is effective in treating breast cancure patient.\n\nAccording to what we know, patient should be eligible for clinical trial. If yes, then let's calculate the probability of interest patient (P(I)) with this formula\n\n\n[formula]  P I = C1 x (1 \u2212 C2 x C3) x ...(1 \u2212 Cn x C2) x Cn ... x (1 \u2212 C1)(1) [/formula] \nwhere C1 = RANK \n\nNow, let's make assessment with 3 level scale, which is:\n0 - Excluded\n1 - Not relevant\n2 - Eligible\nAccording to the result given, let's build some logic if-then rule.\n\n\nI.\n\nRANK is 40% and higher => Excluded\n\nRANK is between 10% and < 40% => Not relevant\n\n\nII.\n\nRANK is at least 40% => Eligible\n\nRANK is less than 40% => Not relevant\n\nNow, we",
        "label": 1
    },
    "307": {
        "output": "## Tutorial Step 5. Print out the note with assessments and include them in the patient's medical record.\n\nYour task is to print out the note with assessments. You should be able to refer to the assessment if necessary. For example, patient notes should be archived for at least 7 years after the end of clinical activity. As mentioned earlier, it is important to ensure that the patient notes include sufficient information for assessing eligibility. The eligibility assessment requires a lot of effort and time. Having a structured and reliable patient note is important. The assessment of the eligibility criteria should be included as part of the patient records so that all clinicians, including students, can view how a patient is assessed for inclusion in an ongoing clinical trial.\n\n### Print out the note with assessments.\nTo complete the tutorial, you must now print out the patient note with assessments. We will discuss the implementation of assessments of the eligibility criteria and other details of this functionality in the next tutorial. \nAfter you have printed out the note with the assessments for this trial, you may need to take this into consideration while conducting your other tasks, i.e., you will need to keep the data entry module open to prevent losing the information. In addition, keep the document in mind that you will need to update any patient assessments when the patients visit the clinic again. The information on a patient's eligibility can be entered, and the information for the clinical trial is automatically updated. This should also be done after the patients have been discharged from the hospital. \nAdditional notes:\n\n- Eligibility assessment: If a patient does not meet the trial's eligibility criteria, then the 'Eligible' assessment does not apply.\n\n- Age assessment: The assessments for patients under 12 years of age are made by assessing the patient note from medical history or the discharge summary.\n\n- Sex: If a patient is not sexually active or has not been sterilized (such as in postmenopausal women), you should consider this assessment.\n\n- Medical history: If someone is currently taking a drug, it is recommended to check whether the patient knows about potential drug side effects or other related adverse events prior to enrollment; patients must sign the informed consent. For",
        "label": 0
    },
    "308": {
        "output": "You're done! Let's move on to the next case.\n\n## Case Study 5\n# [START] 01_Motivation_CaseStudy5.ipynb\n# [INS] 01_Motivation_CaseStudy5.ipynb \nYour task is to compare a given patient note and the inclusion criteria (IC) of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThis case is inspired by a real patient and clinical trial (you can check https:/ /www.clinicaltrials.gov/ct2/show/NCT00137381?term\\-=NCT00137381&rank=1.). You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of the eligibility. The assessment of eligibility on each patient and trial-level eligibility should be evaluated at the beginning of each case. Let's begin with a motivating example. \n# [END] 01_Motivation_CaseStudy5.ipynb\n# [RUN] 01_Motivation_CaseStudy5.ipynb \n\n## Step 1: Import patient note and clinical trial\n\nLet's read the patient note of the motivating example first. \n```\n# Import patient note\np = pd.read_csv('../datasets/patient/case_study_5/pt1_note.csv')\n\n# Get trial index\ntrial_index = int(p['Trial_Id'].loc[1])\n\n# Import the clinical trial\nct = pd.read_csv(\n  '../datasets/trials/case_study_5/NCT001373",
        "label": 2
    },
    "309": {
        "output": "**_Note:_** **_Always do a_ `Trial-level eligibility: 0) Excluded;`_** _only if the patient_ **_meets_** _the inclusion criteria and_ **_the exclusion criteria apply (for instance, if an exclusion criteria is age related)_ _. If the eligibility assessment is not clear, just skip this line._  \n\n\n**If the patient does not have the full patient note**\nYour task is to fill in the blanks with the right information regarding a 45-\nyear-old postmenopausal woman with cytologically confirmed breast cancer, whose clinical\ntrial exclusion criteria are: \n\n1) <em>Not eligible</em>: <span class=\"kwd\">Age</span> is <span class=\"stg\">greater than</span> 55. \n2) <em>Relevant</em>: has a psychiatric condition <span class=\"kwd\">not</span> controlled by medication. \n3) <em>Not eligible</em>: has a performance status <span class=\"kwd\">not</span> at <span class=\"stg\">least</span> 70%. \n\nYou are allowed to make your own clinical trials, though this is not part of the\nexercise.\n\n\n\n> ## Exercise 3 - Inclusion and exclusion criteria\n\n\n---\n**Exercise Instructions**\n---\nYour task is to fill in the blanks in the following example of an inclusion \nand exclusion criteria table for a clinical trial. The example is adapted from Rigby et al. \nfrom the University of Pittsburgh's Department of Urology in the USA. The table contains \nmultiple rows. Each row describes a different patient. The columns contain \nthe corresponding inclusion and exclusion criteria.\n\n\n**This is the definition_** **_file_** `inclusion-exclusion.txt`: Inclusion and exclusion criteria file for exercise 3 \n\n\n### [0] Description\n\nThe criteria file indicates criteria that will be used to determine patient eligibility. \nThe criteria can be specified as: \\* (required), / (exclude), [] (",
        "label": 0
    },
    "310": {
        "output": "[CODE]\n#!/usr/bin/python2\n#\n#\n#\n# Copyright (C) 2018, <NAME>\n#\n# This program is free software; you can redistribute it and/or\n# modify it under the terms of the GNU General Public License\n# as published by the Free Software Foundation; either version 2\n# of the License, or (at your option) any later version.\n#\n# This program is distributed in the hope that it will be useful,\n# but WITHOUT ANY WARRANTY; without even the implied warranty of\n# MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the\n# GNU General Public License for more details.\n#\n# You should have received a copy of the GNU General Public License\n# along with this program; if not, write to the Free Software\n# Foundation, Inc., 59 Temple Place - Suite 330, Boston, MA 02111-1307, USA.\n#\n# (You can find the license here:\n# http://www.gnu.org/licenses/licenses.html )\n#\n\n#\n#\n# Use cases: Clinical Trial Eligibility\n#\n# Author: [NAME]\n#\n\nimport csv\nfrom collections import Counter\n\n# Load the necessary modules.\nimport string\nimport re\nimport pprint\nimport csv\n\nclass Clinical_Trial_Eligibility:\n\t\"\"\"\n\tClinical_Trial_Eligibility\n\t\"\"\"\n\t\n\tdef __init__(self,\n\t\t\t\t\t trial_level_eligibility):\n\n\t\t\"\"\"\n\t\tInitialize the Clinical_Trial_Eligibility class.\n\t\t\n\t\tArguments:\n\t\t\ttrial_level_eligibility (Trial_level_eligibility):\n\t\t\t\tthe Trial-level eligibility file\n\t\t\n\t\tReturn value:\n\t\t\tNone\n\t\t\"\"\"\n\t\tself.trial_level_eligibility = trial_level_eligibility\n\t\tself.trial_",
        "label": 0
    },
    "311": {
        "output": "### 8.4) What is a clinical trial with only 10-20% eligible participants?\n[MAT] A  clinical trial in the U.S. is defined as a clinical trial ''that is not exempt from and has not been deemed to be exempt from, registration in ClinicalTrials.gov by the [FDA] Commissioner and has not obtained an applicable exception from the requirement of a U.S. [IRB/EC]''  This term is equivalent to an Interventional Clinical Research Study in Korea, wherein there is no obligation to register the clinical trial.\nA U.S. clinical trial with 10% to 20% eligibility means an Interventional Clinical Research Study in Korea that meets all of the criteria as stated below.\n\n1) This study will be carried out in accordance with the Good Clinical Practice.\n\n2) This study is defined in the regulations as a clinical trial.\n**[TIPS] This means only drug studies are excluded. \n3) The objective of the study is not to establish the efficacy of a therapeutic product. 4) The trial is conducted on healthy humans. 5) The trial is a phase IV drug study other than the post-marketing trial, drug interaction study, and drug abuse/prevention study. \n6) The clinical trial is planned to include 200 to 600 subjects who will be assigned to either a treatment group or a placebo group. 7) The trial is conducted in more than three study sites in the U.S. \n8) A trial whose objective is to establish the efficacy of a biologic drug is excluded. \n\n### 8.5) Why should I register such a clinical trial?\n[MAT] The clinical trials of drugs and biological products are required to be registered on Clinicaltrials.gov. Clinical Trials on Drugs and Biological Products. The term includes the study of a new drug and biological product, and the study of an approved drug or biological product for a new use. However, the trial will be exempted if the following requirements are met:\n- It is a Phase",
        "label": 0
    },
    "312": {
        "output": "Explanation. `Trial-level assessment of enrollment. The trial in [data.trial] is an open-label study, so, your answer should not be ``1.'' The inclusion and exclusion criteria specify that the patient's axillary lymph node status would not be determined until the time of her surgery. Therefore, her preoperative lymph node status is not sufficient to be a valid exclusion criterion. However, the exclusion criteria for metastatic visceral disease and Hb<10 require blood tests (either Hb, anemia tests, or any other blood test for metastases). However, as mentioned above, `CXR was remarkable for metastatic lesions` implies that the patient has metastatic lungs. Therefore, you should answer `2.`.[data.trial].data.condition_1_comment=='Clinical stage III' [data.trials.data.condition_2_metastasis_site=='bones']\n\n* \n\ndata\n\noutput:\n```\nTrial-level assessment of enrollment\nTrial-level eligibility: 2) Eligible\n```\n\n### Assignment rule\nSome trials have some conditions on assigning patients. For example, some trials specify the maximum number of patients who can be assigned from each center.\n\nBefore answering this question, you should first learn the following: \n1) In the case of a multi-center trial, the patients may be assigned to certain centers according to the number of cases required in each center. \n2) In trials with multiple arms, participants may be equally assigned to each arm, or participants who meet certain eligibility criteria may be randomly allocated to each group.\n\nThus, you should answer this question by considering what methods are used to assign participants to each group. For example:\n* If the answer is equal assignment, add to the output of your response a string like `assignment: equal assignment`, e.g., `assignment: no assignments`. \n* If the answer is maximum allocation, add a string like `assignment: maximal allocated`, e.g., `assignment: maximal allocated (1 patient per center)`. [data.trial](data/data.trial/). \n  - For random allocation, add",
        "label": 0
    },
    "313": {
        "output": "Happy Coding!\n<EOD> A Molecular Docking Study on the Binding Mechanism of the Anticancer Compound, Xanthohumol with Estrogen Receptor \u03b1 in Breast Cancer\n\n\n\n# Introduction\nBreast cancer continues to be the leading cause of death globally, despite being one of the top malignancies worldwide, and early detection is one of the most significant ways to treat women with this disease. The breast is the primary site for 77% of malignancies in women, and it accounted for 15.4% of worldwide cancer-related deaths in 2019, surpassing lung cancer (18%), which is still the most common [bib_ref]  A case-control study to assess the breast cancer risk factors among breast,..., Kaur [/bib_ref] . The estrogen level in breast cancer patients is much higher than in normal people because the estrogen receptor (ER) can bind to the ER-binding sites in the 5-prime region of the steroid metabolism gene and the genes involved in the proliferation, division, and invasion of ER-positive breast cancer cells [bib_ref]  Targeting estrogen signaling in triple-negative breast cancer, Piibe [/bib_ref] . Therefore, ERs are attractive therapeutic targets for ER\u03b1-positive breast carcinomas and endocrine resistance treatment target [bib_ref]  The steroid hormone receptors as developmental druggable targets, Pike [/bib_ref] .\nEstrogens are sex steroid hormones that regulate female reproduction. They are also involved in processes such as the cell and tissue growth and development that occur throughout the body [bib_ref]  The biology of ER\u03b1-positive and ER\u03b1-independent breast cancers, Clevenger [/bib_ref] . Estrogens work by binding to specific receptors in cells. Estrogen receptor-\u03b1 (ER\u03b1) is expressed in the majority of both normal and cancerous breast tissue [bib_ref]  The steroid hormone receptors as developmental druggable targets, Pike [/bib_ref] . Estrogen receptors (ERs) include two subtypes, ER\u03b1 and ER\u03b2. The expression of these subtypes of receptors is different. Estrogen receptor (ER) binds to estrogen, stim",
        "label": 0
    },
    "314": {
        "output": "This is a short example. In the future, I will show more detailed examples in a separate post.\n\n---\n\n[Learn More](https://www.harcourselabs.com/product/machine-learning-products/pycaret/overview/)\n<EOD> Diagnosis of diverticular hemorrhage by computed tomographic diagnosis.\nA case of diverticular hemorrhage, which was detected by computed tomography (CT) examination due to non-specific symptoms and subsequently was proven to have occurred by angiography (AG) is reported. It is thought that the use of AG should be restricted to cases diagnosed by CT examination as being unsuitable for conservative treatment of this disease and to cases showing a rapid deterioration in symptoms despite treatment. For unstable cases seen outside the hospital, an immediate CT examination is advisable in order to avoid AG. The usefulness of CT is described and various aspects of the diagnostic procedures are discussed.<EOD> Rheumatoid arthritis associated interstitial lung disease (Rheumatoid arthritis/Interstitial lung disease)\nWe present an update of rheumatoid arthritis (RA) patients with interstitial lung disease (ILD). The spectrum of clinical findings of RA/ILD is broad and requires high level suspicion since it is frequently asymptomatic at initial presentation. The classification of RA-ILD is based on the underlying pathological processes, which encompass usual interstitial pneumonia, organizing pneumonia, nonspecific interstitial pneumonia and lymphocytic interstitial pneumonia as the most common subtypes. Diagnosis of RA-ILD is challenging as a consequence of nonspecific pulmonary symptoms and often nonspecific radiological findings. Therefore, a comprehensive diagnostic approach based on clinical, radiological, serological and histopathological evaluation is required. Recognition of distinct phenotypes in patients with RA and their outcomes are important for therapeutic decision making.<EOD> Characteristics of ovarian follicles and corpus luteal development in beef heifers fed three supplemental fat sources.\nTen nonlactating beef heifers",
        "label": 0
    },
    "315": {
        "output": "To add any additional annotation, such as exclusion criteria like in our example, you can go to the section 'Histopathological Eligibility' (which is after the 'Treatment Eligibility' section, and add the exclusion criteria as `Histopathological Eligibility. Excluded due to tumor histology: TNBC`.\n\n# The Patient Registration Summary\nYou may add patients to your study without manually entering the inclusion and exclusion criteria again.\nInstead, the patient is assigned to your trial, and the inclusion and exclusion criteria are copied, as well as additional parameters from the patient's record that the application recognizes as important or useful for inclusion and exclusion.\nYou create the Patient Registration Summary for this trial:\nAdd the Trial to the Current Trials Table through the Study Action Bar.\nClick 'Patient Setup'\nClick 'Patient Registration'.\nAdd parameters from the patient record which are recognized as important or useful for inclusion and exclusion such as sex, histology, the TNM classification and the ECOG performance score.\nSelect the patient record by checking on name and hospital ID.\nClick `New Patient`.\nUse one of these 3 options:\n- Export the list of eligible patients, that is visible and editable.\n- If the trial, but not edit of your clinical trial information and save . In the study's, which is important eligible parameters.\nInclude trial by trial set is exclusion to export\n-set the trial .\n-eligible or not trials trial 's parameters registered trial in a trial and eligible or ineligible trial's disease.\n-specific criteria that in trial eligible patient's eligible trial's eligible data with the trial's trial to set of trial's parameters toxic-patient eligible.\nIn some patient trial's data-specific parameters -exact data.\nInclude trial.\nSet not trial's set up, which are trial protocol's exclusion parameters or the number, the eligible-eligible parameters for the eligible patient's parameters to set of trial's trial you should be included parameters (d set of inclusion and elf trial.\nLet's trial you eligible-trial elig",
        "label": 0
    },
    "316": {
        "output": "# Evaluating the Patients\n\nLet's find out the number of patients for a trial and eligible patients in the trial, i.e., the total number of patients and the number of eligible patients for trial `A` in the `Patients` list. [NOTE] As in the [Practical application] section, we use the `for i in` loop to iterate over the patients and trials in the patients list. \nfor trial in patients:\n    for patient in patient.trials:\n        patient.Eligibility_num += 1\n        if patient.trial == A:\n            print patient.Trial_num, \"Eligibility_num\", patient.Eligibility_num \n\n# Evaluating the Trials\n\nLet's find out the distribution of trials for various characteristics, including trial size, trial type, trial status, trial name, trial location, trial phase, the number of assessments, type of study, the number of protocol versions. In order to get the details as you want, you can modify the code as you need.\nHere, the data for the evaluation of trial information comes from the `trials` in the `patients` list. Let's count the number of each trial type in trial. \nfor trial in patients:\n    print trial.Trial_type, trial.Trial_num \n\n\nA trial has a sequence of versions. We assume that a trial does not have multiple versions simultaneously. We can also identify patients' conditions using the version data. \nfor trial in patients:\n    if len(trial.version_list) > 0:\n        print trial.Trial_number, trial.version_list[0]\n\nElastic Net Regression for Predicting Eligibility",
        "label": 0
    },
    "317": {
        "output": "Here is the clinical trial.\ntitle: Comparison of Progesterone Receptor Gene Polymorphism between Malignant and Benign Lesions.\nsummary: The uterine progesterone receptor has been shown to be a marker for resistance to endometrial cancer treatment. The correlation of the progesterone receptor gene polymorphism with progesterone resistance and clinical endometrial cancer is still controversial, and the progesterone receptor gene polymorphism needs to be further studied to obtain more detailed information.\n\ninclusion criteria:\n- Uterine malignant disease histologically confirmed as endometrial adenocarcinoma or atypical hyperplasia with endometrioid cyst\n\nexclusion criteria:\n- Pregnant or currently breast-feeding\n- Suffer from malignant, cardiopathic, pulmonary or nervous diabetes, or endocrine diseases",
        "label": 2
    },
    "318": {
        "output": "### Exercises\n\n#### Exercise I - Reader\n\n1. In this case, the patient is cytologically confirmed to have breast cancer. If we look at the information, this information does not clearly indicate what stage the patient was at when the cancer was histologically confirmed. Let's assume that the patient is diagnosed with cancer by core biopsy. \n1. In case of core biopsy, the question of whether the patient is in early or advanced stage is not relevant.\n[/EXERCISE]\n\n**Exercise II - Reader - Trial design and eligibility criteria**\n1. The title and summary of the study indicate that the study concerns a phase II study.\n1. **The title and summary of the study have mentioned the design of the study as a clinical trial. Accordingly, a randomized controlled trial is described in Clinical Trial_03.md.**\n[/EXERCISE]\n\n2. The trial design of the first line indicates that a two arm comparison was made.\n2. _____ in the study is a two arm study.\n\na. 1\n\nb. 2\n\nc. 3\n\nd. 4\n\ne. 5\n\n2. What is the intervention in the first-line study?\n\n\n---\n**Answer key Exercise II - Reader**\n\n___\n**Exercise II - Answer key**\nWhat is the purpose of the study?\n___\n\n3. At what stage of the disease is inclusion based on age?\n___\n\n4. Which of the following factors allow the patient to be enrolled in the trial?\n5. In which situation is the patient not eligible according to the study criteria?\n6. Which trial design is described in the trial description?\n7. In order to participate in the study, the patient must meet the following inclusion criteria. Which of the following includes an inclusion criterion?\n8. Which of the following situations may not be excluded, according to the eligibility criteria?\n***\n**Exercise II - Summary**\n\nThe trial is described in the following way.\n\nThis study will focus on 100 patients with metastatic breast cancer. Patients who had not received any medicinal product intended",
        "label": 0
    },
    "319": {
        "output": "<jupyter_code>if (age<17):\n    print(\"Excluded\")\n    trial_assessment_out = Trial_assessment_out + \"Excluded\"\nelif (age>80):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>=80 & age<=85):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >60 & age<=70):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >65 & age<=75):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >55 & age<=65):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >60 & age<=70):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >45 & age<=65):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>45 & age<=65):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>50 & age<=60):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>12 & age<=32):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>12 & age<=25):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"",
        "label": 0
    },
    "320": {
        "output": "[SECTION2] # Determining trial-level eligibility [/SECTION2]<EOD> Phase 2 study of oral panobinostat (LBH589) in relapsed and refractory multiple myeloma after at least one IMiD.\n7530 Background: Panobinostat (LBH589), a pan-deacetylase inhibitor (pan-DACi), exhibits strong in vitro activity in multiple myeloma (MM), inducing growth arrest, differentiation, and apoptosis. A randomized phase 2 trial was initiated to characterize the efficacy and safety profile of oral panobinostat in heavily pretreated patients with relapsed and refractory MM, with the goal of future phase 3 study of panobinostat.\n\n\nMETHODS\nPatients (Pts) with MM in progress after \u2265 1 IMiD therapy and disease refractory to both IMiDs (n = 118) or refractory to both IMiDs and bortezomib (n = 23) were randomized 1:1 to receive panobinostat 30mg or 20mg. Pts are dosed on a flat daily schedule based on 28-day cycles. The primary endpoint was response rate by IMWG criteria. Per protocol, randomized Pts had to meet study inclusion criteria and receive at least one dose of treatment. Cohorts of 12 randomized Pts were planned. Primary completion was designed to occur after 18 randomized Pts were enrolled and dosed per protocol in the first cohort.\n\n\nRESULTS\nFifty-nine Pts met the protocol requirements. Response rates for the two targeted cohorts were (30mg vs 20mg) 48% (4CR, 2 VGPR) vs 40% (2CR, 2 VGPR) for IMiD-refractory and 30% (1 VGPR) vs 17% (0CR, 1 VGPR) for IMiD and bortezomib-refractory. In the pooled population,",
        "label": 2
    },
    "321": {
        "output": "[END]\n\n___\n<EOD> In vitro antifungal activity of cephalosporin alone and in combination with some antifungals against dermatomycetes isolates as causative agents of skin infections.\nIn vitro antifungal activities of cefuroxime alone and in combination with some antifungals against dermatomycetes isolated from localized skin infections were studied. Of the twelve antifungals tested, ketoconazole showed significant inhibiting activity against all isolates, nystatin and miconazole against all but three and all isolates, respectively. While the cephalozime had marked sensitivity against all and two isolates, respectively. Combination drug therapy may be helpful in the management of superficial fungal infection where there is need for more effective drugs in the treatment.<EOD> Improved methods for analyzing and interpreting anticoagulation therapy in the nephrotic syndrome\nAnticoagulation therapy in the nephrotic syndrome, especially when diuretics are administered, has often been complicated by interference with routine test procedures, and difficulty in detecting the onset of bleeding.<EOD> Cutaneous lymphography: an evaluation of the methods of demonstration of lymphatic channels and flow.\nCutaneous lymphography is the roentgenographic demonstration of the dermal lymphatics at the paw or foot by the intradermal injection of a contrast substance. In a study of three methods of injecting the contrast material, the authors conclude that the use of a finely ground, dry, and tastless starch powder, or of water soluble India ink is preferable because it produces better, more permanent, and less subjective films. Of the three methods of demonstrating the lymph flow in normal dogs, two appeared to be clinically superior. This article is intended to demonstrate this new area of dermatology.<EOD> Apoptosis, oxidative DNA damage, and antioxidant enzyme activities in relation to risk factors in essential hypertension.\nEssential hypertension is considered to be an atherogenic vascular disease that shares many features with cardiovascular disease. This study was conducted to determine whether DNA damage is present",
        "label": 0
    },
    "322": {
        "output": "# Task 2\n\nA clinical trial is about treating a certain type of cancer, but you have noticed that the patient has multiple types of cancer, so you should exclude this patient from the trial. However, you have not observed a multiple cancers in other patients of the trial, so you conclude that cancer type is not relevant according to inclusion criteria. Now you should exclude it from the trial. Use `Trial-level exclusion: ` and type the cancer type instead of the eligibility score.\n\n# Task 3\n\nLet's think out of the box. You are thinking about the problem from the other angle. Suppose that you have an in-silico trial recruitment scenario, which clinical trials should you include a patient. You don't wait for the trial to start but decide now when this should be the case. You should run your in-silico pipeline, i.e., run tasks that are typically run when deciding about patient eligibility, i.e., `Trial-level eligibility: 2) Eligible.`. Let's continue and think back. `Trial-level exclusion: ` is related to the exclusion criteria and must be empty for the patient to be eligible. `Trial-level characteristics: 3) Male` should be empty if the trial considers sexually active patients or patients with previous birth of children.\n\n# Task 4\n\nIn the next task, you have to think out of the box again. Imagine that your in-silico pipeline is in a real trial, i.e., that this recruitment scenario should actually happen. Patient's clinical characteristics, such as genetic markers, should be in your recruitment trial and available in your input file. Suppose for example that one of the clinical trials has multiple types of cancer as inclusion criteria and you want to include this patient from the trial in order to improve the clinical trial's precision. In this task, you should create an extra column in the patient's input file, type the patient's multiple types of cancer as `type_cancer: ` for example, and recreate the input file for the two clinical trials to include this extra information. Thereafter, your job is the same as in the previous tasks, i.e., run your in-silico pipeline and check if the patient is in",
        "label": 2
    },
    "323": {
        "output": "[TEST]\nWrite a script to generate all possible combinations of {factor} values for the patient Note and run them through the clinical trial {clinical trial} you are testing.\nIn this exercise, you need to first make use of the list comprehension and tuple unpacking functions of `str.join` and `tuple` respectively. We have already seen these two functions previously.\nIn the script below, test the patient note over the {clinical trial}, with the intention of assessing the trial-level eligibility for each combination of values. [TUTORIAL_NOTES]\n\n[TEST]: \nclinical trial_list = [\n    [['age <40'], ['female'], ['breast cancer']],\n    [['female'], ['breast cancer']],\n    ['breast cancer'],\n]\n\nresult = list(map(lambda m: test_recruitment.test_recruitment._get_inclusion_criteria(\n  note = test_recruitment.test_recruitment.get_patient_note(), trial = \n  clinicaltrial_list[m[0]]), clinical trial_list))\n\n\nresult\n\nIn the beginning of this script, we will first create a list containing 4 lists like a `list of lists`, namely `clinical_trial_list`, where each containing list will correspond to different clinical trials. We will then iterate over the list of lists to create the list of trial values and unpack it using the `tuple` function. This produces a list with 3 sublists. Each sublist corresponds to a different element of a trial, and will be accessed through the `m` variable for a given index. You may also use a list of dicts as the input, but it's not recommended because you will create many nested loops.\nThe script above tests a list of trial values using the patient note and gives the result at the end. Each time the test script is ran, the clinical trials will be tested in parallel and the outputs will be concatenated together to produce a result. The result in this case is a list of lists, where each sublist corresponds to the trial eligibility for a specific combination of values. This is because the output is of the form `Trial-level eligibility: 1)",
        "label": 0
    },
    "324": {
        "output": "We are about to finish now. \n\n\n# Selenium\nSelenium is an element that was first discovered in 1817 by the Swedish pharmacist Jons J. Jacob Berzelius. Selenium is a key element in the antioxidant enzyme, glutathione peroxidise (GPx), which protects cells from free-radical damage. GPx protects cell membranes from damage by oxidizing lipid peroxides in the membrane to water. The glutathione (sulffide-glutathiones) molecule is reduced by GPxs to the metabolically inert disulphide glutathione (sulphide-glutathiones). \n\n\n# Sodium selenite\nSodium selenite is an ammonium salt of selenium. Sodium selenium compounds have antioxidant properties that inhibit free-radical damage associated with degenerative disease. They also have some pro-oxidant properties that may contribute to cancer protection due to induction of apoptosis (cell death).\n\n# CoQ10\nCoQ10 or ubiquinone is a component of electron carrier and energy transport system of the mitochondria in the electron transport chain process. CoQ10 acts as an antioxidant to reduce damage by oxidative stress. CoQ10 is converted to the CoQ0 after oxidation of electron carriers in the electron transport chain. CoQ10 electron carrier, with the function of transport system. The energy transport system carrier's function electron transport systemic trial a patient. CoQ electron. This clinical condition's electron carrier transport to the mitochron and condition's trial for transporter trans-derived conditions from the energy transport of the clinical condition's function of the patient's condition of an electrans transport to an individual disease mitochondria transport (respiron conditioning function in the transport function carrier transport (including and mitochond transport conditioner's conditioning function, such as in the condition and a treatment condition and its function and transit transported an function a disease.\nDiselectron.\ncondition and function, function-resident's conditioned condition or function of the conditioner conditionally and conditions of",
        "label": 0
    },
    "325": {
        "output": "Good luck!\n\n<EOD> Incremental versus radical approach for the management of intestinal obstruction from adhesions.\nTo the Editor: In the June 2001 issue of theArchives, Leijdekkers et al 1 reported about a cohort of patients with adhesive small-bowel obstruction (SBO) who were operated on with an incremental (incision and drainage), rather than a radical approach (enterotomy). They showed that the incision and drainage group was less frequently intubated before surgery (P =.005), more often had acute SBO (P 1\u20444 .01), more often underwent an extensive laparoscopic adhesiolysis (P 1\u20444 .01), had shorter intensive care unit stay (P = .01), and had shorter hospital stay (P = .03). These favorable results raised several interesting points. Most importantly, the methodology and the outcome measures can be questioned. At the 7 th International Evidence-Based Surgery Congress, held in the Netherlands in 2001, the importance was emphasized of good surgical outcome, defined as mortality or morbidity at 90 days or within the initial hospital stay. The focus of adhesions research should be on the short-term results, rather than on the time of recovery, as stated. 2\u20134 The study by Leijdekkers et al 1 suffers from selection bias because the patients received different treatment after initial laparoscopy, depending on the decision of the operating surgeon, which makes it impossible to evaluate the results of the \u201cincision and drainage\u201d group in isolation. This bias was addressed by 2 separate multivariate logistic regression models, 1 for the entire cohort and 1 for the incision and drainage group, although these analyses were only partially performed. The results are displayed in Tables 1 and 2 of the article by Leijdekkers et al, 1 but the tables should be interpreted with caution. The most important confounders for the outcome variables (mortality and intubation before surgery) were not included in the models, namely the severity of SBO and the number of (radical) enterotomies. These were significantly related to",
        "label": 2
    },
    "326": {
        "output": "*If a patient meets the trial's inclusion criteria, you should specify it with the scale of 2, i.e., `Scored: 2) Eligible.`. *If the trial's exclusion criteria also apply, you should specify it by specifying the two exclusion criteria as `Scored: 0) Excluded.`. *By setting the value of `Scored` to `Scored: Awaiting assessment.`, you can set a flag with the value of `Scored` to let the clinical trial specialist know that the patient is still awaiting assessment. \nHere is an example input file for the trial-level assessment of eligibility. \n```ini\n[Test]\nTitle: Trial-level Eligibility\n[Instance1]\nPatient_note=Patient note for clinical trial recruitment\nClinical_trial=Trial Note\n[Instance1.Patient_note]\n\n# Note: In a Clinical Trial, all possible conditions are specified in the Clinical Trial Note, and are represented in a table of \"Clinical Eligibility Criteria\".\n\nAge=\"45-year-old postmenopausal woman\"\nTumor=Invasive ductal breast cancer; HER2 positive; ER negative; PR negative; Stage 3\nLocation=Left upper outer quadrant\nLymph node involvement=positive (5)\nHistology=2\nBreast Cancer Marker=Cytologically confirmed breast cancer\nMetastasis=A CXR revealed metastatic lesions \nAllergies=No known allergies\nCurrent medications=\"0) None (Multivitamins, Iron Supplements)\"\nChemexposures=No \nNo known sexual partners=\"Not sexually active\"\nNo children=No children \nCongenital Anomalies=No childhood congenital anomalies\nFamily History=No breast cancer in the family; No other known malignancies in family; No history of alcohol or drug abuse; No history of ovarian cancer in mother or sister; No history of cervical cancer \nSex=Candidate for surgery prior to chemotherapy\nMenopause =\"Postmenop",
        "label": 0
    },
    "327": {
        "output": "*Question*\nLet's analyze this note. In the `age range` column, I assume that the patient is either not sexually active or has no children, so, how about your decision? I assume your trial is for postmenopausal patients, so, the range of the trial is postmenopausal woman or cytologically confirmed breast cancer. And as you know the condition of your trial is, you should exclude premenopausal women and cytologically confirmed women. And the rest, as mentioned in the note, you should exclude cytologically confirmed cancer. \n\nYou should make a comment on each decision. [INST] \n\n**Recommendations and decisions**\n\n*Question*\nThis patient is under active treatment and she wants to receive breast-conserving therapy.\n\n*Decisions*\n\n1. You should decide she is excluded due to her age\n\n2. Then, for Trial-level eligibility of your trial, you should choose `2) Eligible`. [/QUESTION] [/QUESTION] [/QUESTION] [/QUESTION] 3) Eligible.\n**Recommendations**\n\n*Question*\nWhat if she wants radiation therapy? Does she qualify for your trial?\n\n*Recommendations*\n\nThere is not enough evidence to show radiation therapy is not recommended for this kind of patients. \nThe patient should be excluded.\n\n**Explanation**\nGenerally, postmenopausal women have lower estrogen level than younger women, so low estrogen level is an independent prognostic factor for survival in postmenopausal breast cancer patients. Radiation therapy has the benefit of reducing breast cancer mortality and it can be applied to postmenopausal women with low estrogen levels. For this note, what the patient needs is adjuvant radiation therapy for breast cancer, so in this note, she may not be eligible for radiation therapy.  \nPlease refer to  https://www.cancer.org/treatments/radiation-therapy/understanding-a-radiation-therapy-plan/fact-or-myth.html , `How do doctors decide whether to offer breast cancer patients radiation therapy?`",
        "label": 1
    },
    "328": {
        "output": "## Examples:\nFirst, please see this patient note, from whom you wish to obtain trial-level eligibility:\nAge: 52 Sex: F BMI: 23 EGFR:+\nLung disease: No\nKnown second primary: No\nMetastasis at diagnosis: Yes Stage: IIB\nLiver: No\nBrain: No\nVisceral: No LDH: 209\nFemale: Yes Chemo prior CCRT: No. Please see Trial-level eligibility.\nIf a patient does not meet the trial eligibility criteria, the output will look like this: \n[INST:0.triall_eligibility_exclusion_info]\nExclusion criteria. This information is taken from the patient clinical trial profile (see the patient clinical trial profile).\nA patient who has one of these exclusion criteria is automatically excluded since none of his/her inclusion criteria are met. Note that a trial's inclusion and exclusion criteria are not checked sequentially. Instead, a patient's eligibility is checked for all the inclusion and the exclusion criteria in one shot.\nSecond, you should see this patient clinical trial profile:\nPatient ID: 1700000002 Gender: f BMI: 23\nLiver: No\nLung disease: No\nBrain: No\nVisceral: No\nHistology: Adenocarcinoma Stage: IV Stage: IB-IIB Clinical Stage: IIIA Metastasis -primary site: Lung Primary-site size: .15 m2 \nMetastasis, location: Lymph Nodes-Mandible, Brain Metastasis-Bone Metastasis-Liver, Pericardium\nLung: N1 Lung -Right N2 Lung -Left Bone: Yes Necrosis: Necrosis in 60% of the tumor cells -40% of the tumor cells have preserved structures Cytology: Positive -malignant Cervical lymph nodes: Yes\nAdenocarcinoma: Yes EGFR:+\nClinical Stage: IIIA Clinical Stage: IB-IIB\nExclusion Eligibility: Trial: 1 Elig",
        "label": 0
    },
    "329": {
        "output": "---\n<EOD> A single-center comparison of early- versus late-administered \u03b2-blockers on the outcomes of patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock\n\n\n\n# Introduction\nCardiogenic shock (CS) after ST-segment elevation myocardial infarction (STEMI) is associated with a high mor- The authors have no funding and conflicts of interest to disclose.\nTo investigate the clinical features of CS patients with STEMI according to the presence of acute heart failure (AHF) on admission.\nMethods: The study included 306 CS patients with STEMI who were enrolled from January 2010 to December 2018. The study subjects were divided into two groups based on the presence of AHF on admission: the AHF group (n = 179) and the non-AHF group (n = 127). In addition, patients in each group were further subdivided based on the time of implementation of the \u03b2-blockers: early administration group (\u03b2-early): \u03b2-blocker use within 24 h after admission, and late administration group (\u03b2-late): after 24 h.\n\n# Results\n\n# Conclusion:\nThe present study showed that the early-administered \u03b2-blockers are associated with improved outcomes of STEMI patients with CS.\n\n## K e y w o r d s\ncardiogenic shock, single-center study, STsegment elevation myocardial infarction, \u03b2-blockers\n\n## Key messages\n- \u03b2-blockers provide significant beneficial effects in patients with STEMI complicated by CS.\n- There still exist controversies on whether early or late administration is beneficial in patients with CS.\n- \u03b2-blockers within 24 h of admission resulted in a greater reduction in allcause mortality.\n\n## | introduc ti on\nAcute myocardial infarction (AMI) is one of the leading causes of death worldwide.A recent study performed in China reported that about 1.49 million patients were admitted for AMI, yielding discharge prevalence and incidence of 925.8",
        "label": 2
    },
    "330": {
        "output": "the eligibility`s trial for your medical trials in an active the protocol the trial-specific trial's active/pass's eligibility, and a patient's a clinical eligibility information should be used to assess`s oncological trial, eligible (i`s history of the medical trial of disease's medical assessments. The patient and trials medical condition is the trial's 1 trial 73 of`s eligibility for trial's active trial the doctor's history 2. The investigator-eligible trial`s for the trial's doctor's oncological. 210 is determined medical history's eligibility status trials to your medical history's trial eligibility medical history and health trial's for the patient's infection.\ntrial disease registry for the medical trial, trial`s.\ntrial patient for an assessment. Ifelig ability to the trial. PDA elig elig trial's trial`s trial. the patient-relevant you are not active patient's medical trial/happoints, diagnospecular patient trials are not eligibility. To have a doctor: eligibility.\n[s`s.\nel that should you.\nelig.\nand 25] the active criteria. 1 or 6 eligile. or the patient should be eligible or trial-el. trial. Medical trial.\nor=trial if the medical trial.\nin medical elig.\npat the elig. All patients.\nhealth's elig trial elig inelig trial a random, which is a clinical trial, which requires el [in which elig trial.\nA patient who the clin, and the eliz.\n\nby determ, the elig. the elig elig, with the patient. Patient (trial patient for the trial's medical trial elig the trial. Include trial, you.\ntrial.\npat, and the need to the trial, and trial and cancer and end, in the patient`1, and trial.\n[for the patient. The patient,el.\n\nTrial trial. These oncological statuses and for theta, the health, you el ical.\n[criteria, health.\n(el. There",
        "label": 0
    },
    "331": {
        "output": "Please input your name under `Notes`. [INST]\n\nClinical Trial Name:\nIf it is an ongoing study, give it a 10-digit unique study identifier such as the last 9 digits of the UMIN Clinical Trials Registry. `2013-07524`\n\nAggregation Strategy:\nPlease use the following terms from `Active clinical trials in breast disease published in the Annals of Surgery from 2001 to 2011` by the Department of Surgery, Osaka University [J].\nPlease refer to \"Methods: Assignment and interventions\" in \"Eligibility assessment\" for more explanation.\n\n### Patient\n\nPatient ID:\nPlease use numeric format.\n\n\n```html\nvar $patientName=$('<div class=\"form-group\" >');\n$($patientName).append('Input patient's name: ').append($('<input id=\"patientName\" class=\"form-control\" type=\"text\" />'));\n```\n\nThis is also important for the aggregation strategy, don't you think.\n\n# Patient-level eligibility (Patient-level Eligibility)\n\n## Not Available\n\n### Concept \n\nThis section determines whether a patient with the following characteristics might be eligible for the trial. [INST]\n\nThe patient has invasive or ductal carcinoma of the breast and is suitable for neoadjuvant chemotherapy prior to mastectomy. \nThe patient has HER2-negative invasive carcinoma of the breast (ER, PgR, HER2-negative) and hormone receptor-positive breast cancer (ER and/or PgR with \u2265 10% staining by IHC). \nThe patient is not pregnant. \nThe patient is not participating in any other clinical studies. \nThe patient provides an informed consent form.\n\n### Assessment\n\nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nThere is not a need for an assessment if the patient is not el",
        "label": 0
    },
    "332": {
        "output": "<section class=\"sourcecode sourcecode-python\" data-src=\"/data/problemsolving-python-67-py4-example-02.py\">\n    <div class=\"code-block sourcecode-python\" id=\"section2339606534543053242959436\">from unittest.mock import ANY\nfrom flask import current_app, render_template, session\nfrom flask.ext.prison import Prison\nfrom py4 import Py4, Data, Export, Dummy\nimport pytest\nfrom py4.prison.config import configuration\nfrom web.user.exception.exc import PrisonerKeyExceedMaxDaysException\n\napp = current_app\n\nclass Py4MockTestCase(Py4):\n    @pytest.fixture\n    def _PrisonerKeyExceedMaxDaysException():\n        \"The variable is provided by the fixture\"\n        exception = Exception(\"The variable is provided by the fixture\")\n        return exception\n\n    def _prisonKeyExceedMaxDays(self):\n        \"\"\"Mock a PrisonerKeyExceedMaxDaysException to test the exception handling in prison.\"\"\"\n        exception = PrisonerKeyExceedMaxDaysException([self._PrisonerKeyExceedMaxDaysException()])\n        self.assertNotIsNone(exception)\n        self.assertNotIsNone(exception.prisoner_id)\n        self.assertIn(\"PrisonerKeyExceedMaxDaysException\", str(exception))\n        self.assertNotIn(\n            \"Exception: \", str(exception), \"PrisonerKeyExceedMaxDaysException\"\n        )\n        self.assertIs(exception.prisoner_id, self.prison.getPrisonerIdByName(prisoner_id))\n\n    @pytest.mark.parametrize(\"output,expected\", [\n        (\"output\", \"PrisonerKeyExceedMaxDaysException\")\n    ])\n    def test_prison_key_exceed_max_days_raise_exception(\n        self, output, expected\n    ):\n        \"\"\"Test the exception handling in prisoner_key_exceed_max_days.\"\"\"\n        fake_instance = input(\"F",
        "label": 1
    },
    "333": {
        "output": "## Requirements\n* This is a requirement from the jira project. To run this file in a jira sandbox, you have to change one line from this requirement to your project: `var trial_level_eligibility = { \"field\": \"Trial-level eligibility\", \"from\": \"2. Recruitment\", \"to\": \"3. Trial-level eligibility\", \"data\": [ { \"patient_noteligible\": 0, \"patient_notrelevant\": 1, \"patient_eligible\": 2, \"noteligible\": 0, \"notrelevant\": 1, \"eligible\": 2 } ] };`\n\n## Tests\nWe are running two steps which return success:<EOD> Is There an Optimal Antiplaque and Gingivitis Fluoride Dentifrice?\nIt is difficult to reach any conclusions about the role of antimicrobial agents in dentifrices in plaque control from the results of these four studies, due to differences in design and materials.' The addition of chlorhexidine digluconate and cetylpyridinium chloride to sodium monofluorophosphate reduces plaque accumulation more at some sites than others and therefore seems to have a site selective efficacy. It may be that these products could effectively work at sites more susceptible to plaque, for example, buccal or oral surfaces of molars due to the accumulation of food debris.2 Further work is needed on these products before their use can be fully recommended for the control of dental plaque and periodontal disease. There are also a number of unsolved research questions. The use of a standardized plaque score system is needed if data from other investigators can be compared. This system should be accompanied by measurements of plaque and salivary levels of streptococcus mutans. There is also a need to compare the plaque-inhibitory effect of chlorhexidine digluconate and cetylpyridinium chloride in the mouth against that of sodium monofluorophosphate, sodium metaphosphate and sodium tripolyphosphate. This would provide a useful guide to the selection of the most suitable formulation for a new dentifrice.",
        "label": 0
    },
    "334": {
        "output": "[HELP]\n\nIf the user inputs either missing or wrong values in the patient's information, the patient can still be assessed as `Not relevant` or `Excluded`. If any of the input fields have a problem, the output fields will always be updated to `Not relevant` or `Excluded`.\n\n[NOTE]\n\nThere are two points to consider here.\n\n(1) If the eligibility status of any input field is changed, the eligibility status of all other input fields will be updated. In other words, the eligibility status of the patient cannot be determined in isolation from other fields. This is because various clinical trials use different inclusion criteria depending on the disease being studied. \n\n(2) The clinical trial requires information on the patient's disease stage for eligibility assessment. However, it is not possible to accurately assess the patient's eligibility without considering the information on pathological diagnosis of the patient. \n\n[HELP]\n\nAs you learned in Part 1, we created the trial-level eligibility list using the Pandas library's pd.DataFrame class object and `set_index` method to create multiple trial-level eligibility. \n\nNow, use the `loc` property of the pd.DataFrame class object to retrieve rows of information from the data frame. To do this, use pd.DataFrame.loc with the index variable or `sentinel_assessment_patient_note` to retrieve values for individual patient assessments. \n\n`assessment_df.loc[\u2018patient_note\u2019, \u2018sentinel_assessment_patient_note\u2019]`\n\nIt is possible to obtain the eligibility status of the patient for each trial by filtering the information of the assessment patient using the `sentinel_assessment_patient_note` variable as the index variable. \n\n`assessment_df.loc[\u2018patient_note\u2019, \u2018sentinel_assessment_patient_note\u2019].index.tolist()`\n\nHere, index.tolist converts the index type to a list, giving the output as shown below:\n\n```\nlist()\n0    0\n1    0\n2    1\n4    2\n6    0\n7    2",
        "label": 0
    },
    "335": {
        "output": "# Data sources: ###\n\n\n[DATA]\n# Output: ###\n\nIn:\nPatient is included in the trial, if all criteria above are verified.\n\nOut:\nPatient is excluded from the trial, if one or more criteria are not checked.\n\n\n### 3-2. Determine trial-level eligibility\nWe use one line to see eligibility. If the patient is Eligible, we put `Trial-level eligibility: `after this line and end if. For the patient Eligible, we must verify the following criteria in order:\n\n# Inclusion criteria\nName of each inclusion criterion (required) 1. Written, signed consent for trial participation must be obtained from the patient appropriately in accordance with applicable International Conference on Harmonization (ICH) guidelines and local and regulatory requirements prior to the performance of any study specific procedure.\n2. HER2-positive advanced breast cancer previously treated with at least, in the physician's judgment, 2 prior HER2-directed regimens in the metastatic setting.\nPatients who started pertuzumab based anti-cancer drugs within 1 year of study start are allowed.\nPatients in treatment free interval of > 6 months after adjuvant treatment of HER2-positive disease with pertuzumab are allowed.\nPatients who had pertuzumab in the metastatic setting after receiving HER2-directed treatment and at least 6 months after the last dose of pertuzumab are allowed.\n3. Clinical, radiological and/or histopathological diagnosis of invasive breast ductal carcinoma that is HER2-positive.\n- The definition of HER2 positivity should be according to the American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) recommendations or to local institution standard of care, if available.\n- HER2-positive tumors should be HER2 immunoreactivity score (IRS) 3, if FISH negative, or HER2 IRS 2+.\nPatients with HER2 equivocal tumors (HER2 IRS 2) should be included.\nPatients with tumors in",
        "label": 0
    },
    "336": {
        "output": "<EOD> Clinical and Histologic Features of Nodular Regenerative Hyperplasia of the Liver in Children: Single Center Experience\n\n [bib_ref]  Primary biliary cirrhosis presenting with chronic cough, Tucker [/bib_ref]  [bib_ref]  Clinical features and prognosis of primary biliary cirrhosis with antimitochondrial antibody in..., Okita [/bib_ref]  [bib_ref]  Primary biliary cirrhosis without biochemical evidence of cholestasis, Schilsky [/bib_ref]  [bib_ref]  Antimitochondrial antibodies with positive results for all isotype assays: should we search..., Bardella [/bib_ref]  [bib_ref]  Nodular regenerative hyperplasia of the liver in primary biliary cirrhosis, Kim [/bib_ref]  \n\n# Methods\nAll PBC patients above ten years of age who were diagnosed in Children's Hospital of Zhejiang University School of Medicine (Children's Hospital of Hangzhou Medical College) from February 2008 to February 2018 were included. The diagnosis of PBC was based on the clinical symptoms combined with elevated alkaline phosphatase, the positive biochemical test of anti-mitochondrial antibody (AMA) and/or positive pathology features of the liver such as bridging fibrosis, periportal lymphoplasmacytic infiltration [bib_ref]  Primary biliary cirrhosis, Lindor [/bib_ref] . Patients' clinical and laboratory characteristics, biochemistry, and histopathological results were collected and analyzed. The AMA was detected by indirect immunofluorescence (IIF) test (INOVA) using B/BB rat liver tissue sections. The serum level of titer \u2265 1:40 was considered positive, <1:40 negative, and indeterminate for IA/IB [bib_ref]  International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune..., Alvarez [/bib_ref] . The demographic and histopathological characteristics compared among non-nodular regenerative hyperplasia (NRH) group, unexplained nodularity group with no histological features of NRH",
        "label": 2
    },
    "337": {
        "output": "---\n\n[QUESTION] How should you write the output to the `print()`?\n\n> output: 0\noutput: 1\noutput: 2\n\n[ANSWER] Consider outputting a three-element vector: `trial_level_assessment` which stores the trial-level assessment results for the `patient` input. The first element `assessment_id` is the eligibility assessment number and the last two elements are the trial-level eligible values:\n\n~~~\nprint(\"Trial-level eligibility for \" + \"patient_id\")\nfor pat in patients:\n    if trial.eligible[pat]:\n        print(\"Trial-level eligibility: \" + str(trial.eligible[pat]))\ntrial_level_assessment [0] = patient\n(assessment_id, eligible,not_eligible) = trial_level_assessment\n\nprint(\"Triall level assessments for \" + \"patient_id\")\nprint(assessment_id)\nprint(eligible)\nprint(not_eligible)\n~~~~~\n\n\n### `print(assessment_id)`\n`0`\n`1`\n`2`\n\n### `print(eligible)`\n`False`\n`True`\n`True`\n\n### `print(not_eligible)`\n`False`\n`True`\n`True`\n\n---\n\n### Exemplary output\nWe use the command below to plot the probability of eligibility at a trial with 0.5 probability of assessing trial eligibility, i.e.,\n\n~~~\nimport json\nfrom plotly import plotly\nfrom plotly import dash_import_options\ndash_import_options()\n\n# Create plotly object with patient patients\nplotly_data = json.loads(patients)\n\nfig = plotly.draw.scatter(\n    x=['ID'],              # Label each data series.\n    y=['Eligibility'],  # Label each data series.\n    x0=None,           # Optional. Specify the x position of each data point relative to the x dimension above. Default is 0,",
        "label": 1
    },
    "338": {
        "output": "#### Exercises\nExercise to practice\n\n```python\nimport pandas as pd\nfrom sklearn.model_selection import train_test_split\nimport numpy as np\nimport string\nimport math\nimport random\nfrom npt import npt\nfrom data import *\nex1 = Exclusion_Criteria.load_pickle()\nex2 = exclusion_criteria_without_categoryA()\nex = concatenate_clin_trial_and_exclusion_criteria([ex1,ex2])\nex3 = ex2-\"11\", ex2-\"15\", ex2-\"73\",\"117\",ex2-\"167\"\nex[\"dichotomous_1\",\"dichotomous_2\",\"dichotomous_3\",\"dichotomous_4\",\"dichotomous_5\",\"dichotomous_6\",\"dichotomous_7\",\"dichotomous_8\",\"dichotomous_9\"]= None\nex[\"dichotomous_10\",\"dichotomous_11\",\"dichotomous_12\",\"dichotomous_13\"]= None\nex[\"dichotomous_14\",\"dichotomous_15\",\"dichotomous_16\"]= None\nex[\"dichotomous_17\",\"dichotomous_18\"]= None\nex[\"dichotomous_19\"]= None\nex[\"dichotomous_20\",\"dichotomous_21\"]= None\nex[\"dichotomous_22\"]= None\nex[\"dichotomous_23\"]= None\n\nex4 = np.concatenate((2*ex3+ex3,'dichotomous_2+2') #2 is a constant; add an increment of 2\n                     ,(ex3+(ex3-ex3[ex3 in ['A'==0])+ex3[ex3.isin(('2', '3', '4', '5', '7', 'E')] \n                                                 ),'dichotomous_6','dichotomous_7",
        "label": 2
    },
    "339": {
        "output": "[NOTE] [INST] You can use the `Triallevel ` in the `for` loop to make a trial-level eligibility output in the 'Samples' patient table. [/NOTE] \n\n[MODULE] Module 7: Surgery\nIn this module, you will learn how to schedule, document and record the surgery for which the patient is a candidate. Furthermore, you will learn how to generate a `Surgery_date` field in the 'Samples' patient table and make an appointment for surgery.\n\n## [CMD] conda install -c xtasy conda forge channel\nIf the previous command returns an error, please refer to its documentation (see [INST] Chapter 4 1 ) about how to solve this.\n\n## [INST] Python3-dev is no longer available\nYou should install [`Python](https://pypi.org/project/wheel/), [`setuptools`](https://pypi.org/project/setuptools/), [`pip`](https://pypi.org/project/pip/) and [`wheel`](https://pypi.org/project/wheel/) and skip this statement:\n\n```\npip install numpy\npip install scitkit image\npip install python3-dev\npip install wheel\npip install scipy\npip install numpy\npip install nibabel\npip install librosa\npip install jupyter\npip install mlxir\npip install seaborn\npip install yaml\npip install pandas\npython -m pip install --upgrade pip\npython -m pip install --upgrade setuptools\n```\nHere is the installation command using `wheel`:\n\n```\npy install --upgrade xtasy-python\n```\nNow you can install [xtasy](https://pypi.org/project/xtasy/) by following the steps listed in its [README](https://readthedocs.org/projects/xtasy/files/README.txt) or in its [source](https://github.com/XtalPy/xtasy-python/releases/latest/download/xtasy.py). \nIf this process does not work for you, refer to its [FAQ](https://github.com/XtalPy/xtasy-python/blob/master",
        "label": 0
    },
    "340": {
        "output": "# Solution\nCreate the variables for patient. `\n- 0.6 0.4\n\n    [INSERT PRIVATE EVAL] \n    \n    /* Auxiliary variables for patient */\n    variable Patient\n    Patient = {\n    id          : \n\n        /* Inline-Code-Snippet-End */\n\n    }\n\n    /* The patient's score for trial-level eligibility */\n    variable Patient_score       \n\n    /* Inline-Code-Snippet-End */\n    \n    /* The patient's clinical trial */\n    variable Patient.clinical_trial\n    \n    /* The clinical trial-level eligibility of the patient */\n    variable Patient.trial_level_eligibility\n\n    \n    /* 1) Excluded */\n    \n    /* 2) Not relevant */\n    /* 3) Eligible */\n\n    /* Define the score table for the patient */\n    variable Patient_score\n    \n    /* Define the clinical trial-level eligibility table */\n    clinical_trial = \n    \n        /* Inline-Code-Snippet-End */\n    \n    /* 2) Not relevant */\n    \n    /* 3) Eligible */\n\n    /* Define the score table for the patient */\n    clinical_trial_score       \n\n    /* Define the trial-level eligibility table */\n    trial_level_eligibility = \n    \n        /* Inline-Code-Snippet-End */\n    \n    /* If the patient is not a participant of the clinical trial */\n    /* Then we can check the trial-level eligibility table */\n    if (not Patient.clinical_trial) {\n        score = 0\n    }\n\n    /* If the patient meets the trial's inclusion criteria and no exclusions criteria */\n    /* Exclude the patient from the clinical trial */\n    if (Patient.clinical_trial.inclusion & score >= Patient.clinical_trial.minimum) {\n        /* The patient meets the trial's inclusion criteria */\n        score += 1\n    }",
        "label": 1
    },
    "341": {
        "output": "A: @Andr\u00e1s Dudek's answer is much more practical than mine, but I noticed, that your question had a title that's not entirely correct as it's talking about the title of the article (the title within a paragraph), instead of the title of the whole article (the title of the whole article, the title of the article, is written within one sentence, so that it's not written after the question mark. Try to format it as it's more logical. In short:\n\n\n*\n\n*Don't make a question mark at the end of a title of the article\n\n*Keep the question mark at the end (you should move it so it appears after a question mark if you need it to be like your title)\n\n*Reformat sentences to make the articles titles more natural, for example: your title is: \nTitle: HER2 negative metastatic breast cancer or IBC: A trial without PI3K-AKT-mTOR inhibitors, a phase 3 randomized trial\n\n \nyou should write it this way: \n\n# HER2 negative metastatic breast cancer or IBC: A Trial Without PI3K-AKT-mTOR Inhibitors, A Phase 3 Randomized Trial)\n\n*Add your name at the begining of the sentence (first author)\n\n*Add the date of publication as well at the end of the article title\nTry this one\n\nHumbert et al. (2015)\n\n*Humbert, Sara, et al. \"Rev-erb-alpha mediates exercise-induced regulation of Pgc-1alpha and improvement of metabolic homeostasis.\" Cell metabolism 22.5 (2015): 870-884.\n\n*Add the references like this : \n\n# Methods\n\nThe methods to get the eligibility should read like this : \n\n```\n# You should add at least one block for title, authors and affiliations\n\"Eligibility\":[\n  {\n    \"scale\": \"0\",\n    \"title\": \"Excluded\",\n    \"description\": \"The patient met inclusion criteria, but is excluded on the grounds of the trial\\u2019s ex",
        "label": 2
    },
    "342": {
        "output": "![inst02]\n\n### Exercise 2\nIn the second exercise, you will determine whether a patient note of interest is eligible for a clinical trial by analyzing the information in the patient notes of several different patients. When you start the exercise, the following trial is displayed: \nIn a tabular view, we will compare several rows of the table (patient notes) and each column contains a different criterion. These criteria are taken from your input as shown above. Based on the number and type of columns, we can determine a column to be a possible match. To achieve this, we use the following logic steps: \n\n### Preparation\nFirst, you need to prepare the input files which contain eligibility criteria for the clinical trial and patient notes from the file:\n\n\n`<path_to_data>/1D1_data.tsv` \n\n# Exercise 2 - Your Task\n\nExercise 2 will allow you to get a practical idea of a very complex set of rules (the eligibility criteria of the clinical trial) as well as how to write and write codes in Python.  If the patient's record meets these rules, it fits into the clinical trial and it is therefore called ELIGIBLE. Otherwise, the patient record does not fit into the clinical trial and is called NEUVE.  For example, if the patient record indicates that the patient does not have metastases in the axilla, the patient record will be called `NEUVE` because the patient cannot be operated on locally.  In the case of`NEUVE`, some patients are excluded for other reasons (eg, smoking, etc.). \n\n### Write a Python Code to Find the Patient Record\nIn a Python script named `Eligibility.ipynb`, you will find everything that I have already written:  \n\n#### [inst03]\n\n#### [inst04]\n\n#### [inst05]\n\n#### [inst06]\n\n#### [inst07]\n\n```python\n# +\nimport sys,  # you must import this library to do an IPerf run\nimport os\nos.system('echo \"%T\"')\nsys.path.append('../')\nsys.path.append('../../')\nsys.path.",
        "label": 0
    },
    "343": {
        "output": "### Test\nFirst we have to prepare some data from [here](https://raw.githubusercontent.com/alxgx/NaturalLanguageUnderstanding/master/training%20data/patient%20notes/clinical%20trial%20notes.csv). We have to make some changes in the data before starting of the work. I modified all data and you can directly use that data. These changes are shown by red font below.\n\n### Construct Patient Information Clinical Note Classifier\nFirst, construct the Patient Information Clinical Note Classifier.\nCreate a new file under `clinicaltrials/clinicalnote_classifier/.` Then, write the following files by yourself under that folder.\n> patient_classifier.py\n> sentence_classifier.py\n`clinicalnote_classifier.yaml`\n`clinicaltrials_evaluation_metrics.yaml`\n> \n> patient_data_loader.py\n\nNote: `clinicalnote_classifier.yaml` is like `clinicaltrial_classifier.yaml`. I wrote the content of `clinicaltrial_classifier.yaml` and let you write the content of `clinicalnote_classifier.yaml`. If you want some help, please leave a message later.\n\n### Build and Train your Model\nNow, build and train your model by following steps.\n- In `clinicalnote_classifier/build_and_train_clinicalnote_classifiers.py`, write the following content.\n```python    \n# TODO - Build and check the accuracy of patient information classifier \nbuild_clinicalnote_classifier(name = \"patient_information_classifier\", data = \"TrainingSet\", vocab=load_word_v_clinical_trial_notes.yaml)\ntrain_clinical_trial_notes_classifier_with_bag_of_words_features(data = \"TrainingSet\", name = \"clinicalnote_classifier\", vocab = load_word_v_clinical_trial_notes.yaml, feature = \"clinical_note_vocab\")\n```\n> Before you run these code by yourself, you",
        "label": 1
    },
    "344": {
        "output": "## Expected results\n\n![output](./output.png)\n<EOD> On the use of quantum chemical topology software in the study of protein dynamics and conformational substates.\nThe use of quantum chemical topology software, i.e. the topology and geometry of the electron localization function (ELF), as a tool in the study of hydrogen bonding, water orientation, dynamical and conformational substates in proteins is described. ELF values above (below) 0.7, which corresponds to the borderline between the highly polarized (highly localized) regions of the electron distributions, allow very efficient prediction of hydrogen bonding of amide protons, water molecules positioned within various types of clusters and non-polar solvent. The ELF values may be used in conjunction with distance distributions, molecular dynamics simulations and visual inspection of electron density to differentiate dynamic (low ELF-value regions) versus rigid regions (high ELF-value regions) of proteins and their substates by providing a \"fingerprint\" of the structure of the electron density at a location at the atomic scale.<EOD> A Case of COVID-19 Post Vaccinated Death and Autopsy Report.\nCOVID- 19 infection leads to death by causing serious inflammation in the body. So far, no therapy or vaccination method was proven safe for this virus. COVID- 19 death in vaccinated persons is a recent issue of great concern. Here we present the case of a person who died three weeks after receiving the Corona Virus vaccine. All diagnostic specimens from the deceased patient were found positive for COVID-19 viral RNA. The autopsy and histopathology report of the body of the patient was performed, and the cause of death was confirmed. During the autopsy, there was no evidence of pathological lesions in the lungs, kidneys, or lymph nodes that have been reported in some fatal cases infected with COVID- 19. This case highlights the possible side effects of vaccination on COVID- 19 patients, although the possible causes of death in this patient have not yet been clearly identified.<EOD> Effect of Hormone Therapy and Estrogen on Neurogenesis\nIt has been hypothesized for some time that estradiol administration would promote ne",
        "label": 2
    },
    "345": {
        "output": "## \u00a9 University of Debrecen (UniDeb.hu) 2022<EOD> The effect of the novel 5\u2010HT4 receptor ligands, MK\u20102524 and WAK 400, on rat colonic myoelectric activity\nActivation of 5\u2010HT4 receptors by exogenous agonists stimulates colonic motility. However, the in\u2010vivo pharmacological characteristics of these receptors are not well known. The effect of 5\u2010HT4 receptor ligands on rat colonic myoelectric activity was investigated. Intracolonic instillation of the nonpeptide selective 5\u2010HT4 receptor agonists, MK\u20102524 and WAK 400, at a concentration of 30 mg l\u22121 significantly enhanced the pressure\u2010length activity and tended to shift the colonic motility pattern towards non\u2010propagating activity. Moreover, as revealed by the in\u2010vivo colon manometry recording in the isolated perfused rat colon preparation, 5\u2010HT4 receptor agonists had no intrinsic activity on the smooth muscle. The 5\u2010HT4 receptor antagonist, BIMU 1, at a concentration of 10 \u22126 mg l\u22121, did not affect spontaneous colorectal motility but abolished the stimulatory action of MK\u20102524. The selective NK1 receptor antagonist, RP 67580, at a concentration of 10 \u22128 mg l\u22121, did not affect colonic motility pattern under basal or MK\u20102524\u2010treated conditions. The results of the present investigation demonstrate, for the first time, the involvement of 5\u2010HT4 receptors in the rat colorectal excitatory motor responses induced by intraluminal administration of 5\u2010HT4 receptor agonists. The stimulatory effect of stimulating 5\u2010HT4 receptors on colonic motility is mediated via a postsynaptic 5\u2010HT4 receptor\u2010mediated mechanism as evidenced by the in\u2010vivo abolishment of the motor responses by 5\u2010HT4 receptor antagonists.<EOD> .\nThe results of",
        "label": 0
    },
    "346": {
        "output": "<EOD> Synthesis of a highly oxygenated phenanthrenoid from ferulic acid. Identification and total synthesis of rhododendrin, a naturally occurring phenanthrolone.\n A highly oxygenated phenanthrenoid is isolated from the rhizomes of Rheum palmatum as a new natural product and is identified as rhododendrin, 6,1'-dihydroxy-6',7'-dihydrophenanthro-2'-carbonic acid. The total synthesis of rhododendrin is accomplished in nineteen steps from commercially available ferulic acid.<EOD> .\nBACKGROUND\nBoth aplastic anaemia and myelodysplastic syndrome are bone marrow failure diseases. The progression from mild to moderate to severe aplastic anaemia, in which the bone marrow is functionally dysplastic because of increased apoptosis, has been studied, but little is known of the aetiology or genetic factors that govern the progress of aplastic anaemia to myelodysplasia.\n\n\nCASE REPORT\nWe report three patients with aplastic anaemia. One was a child who had a normal haemoglobin (Hb) level during remission and suffered a relapse, which was characterised by an elevated Hb level (> 15 g/dl) and an increase in the number of neutrophils, and was rapidly fatal. A second patient had a sustained increase in the Hb level during relapse and died after seven months, following a myelodysplastic syndrome. The third patient had a myelodysplastic syndrome and died, three months later, after refractory aplastic anaemia.\n\n\nDISCUSSION\nBone marrow failure diseases appear at the extremes: severe congenital disease or mild acquired disease. The evolution from mild to moderate to severe aplastic anaemia can be considered as a progression from low bone marrow cellularity to cellular dysfunction, mainly induced by impaired apoptosis. The progression from aplastic anaemia to myelodysplasia is characterised by increased apoptosis in the bone marrow; it follows a different pattern with different evolution",
        "label": 0
    },
    "347": {
        "output": "**Clinical_study**-the code of the clinical trial\n[![INST](https://github.com/nf-core/onpIDB/blob/master/doc/INST.png)](https://docs.google.com/presentation/d/e/2PACX-35F9988o7Eg9HWt_JY9_UeKwkHZHJOYXx7Wbk1318bQD72gEj1w/preview#slide=id.g2)\n\nYou should always pass a `clinical_study` parameter when making an assessment of eligibility by the patient note, such as:\n    onpIDB_assess_eligibility(clinical_study = \"clinical_trial_1\")\n\nThis will repeat the Trial-level assessments by trial name, e.g.,\n```\nTrial-level eligibility: 0) Excluded\n    Assessed by: Patient note\n```\n\nYou can give a trial name by using the `clinical_study` argument.\n\n**Note:** There is only one active clinical trial available in our demo data, namely `clinical_study = \"clinical_trial_1\"` should make the assessment of eligibility.\n\n[![INST](https://github.com/nf-core/onpIDB/blob/master/doc/INST.png)](https://docs.google.com/presentation/d/e/2PACX-35F9988o7Eg9HWt_JY9_UeKwkHZHJOYXx7Wbk1318bQD72gEj1w/preview#slide=id.g2)\n\nYou should always pass an `interval` parameter when making an assessment of eligibility by trial name. This will also calculate the time period when the trial was active, such as:\n    onpIDB_assess_eligibility(clinical_study = \"clinical_trial_1\",interval = \"from 2021-01-04 08",
        "label": 2
    },
    "348": {
        "output": "# Related Tasks\n- [Task 2]: [TASK 1] - Exclude Patients\n- [Task 3]: [TASK 2] - Include Patients\n\n## Related Concepts\n- Inclusion and exclusion criteria\n- Inclusion and exclusion criteria\n- Concepts of clinical trials\n\n# Concepts\n- 2) Eligible.\n\n# Concepts\n- 2) Eligible.\n- Inclusion and exclusion criteria\n\n# Concepts\n- [TASK 1] - Exclude Patients\n- [TASK 2] - Include Patients\n\n## Acknowledgements\n\n### Programming\n\nThe content you see here includes material exclusively prepared by the authors for the CTFs-Evaluation program.\nWe also want to thank the following people who contributed to previous versions of this program:\n\n\n### Content\nAll CTFs-Evaluation content is licensed with a [Creative Commons Attribution 4.0 internaional](LIC) license (https://creativecommons.org/licenses/by/4.0).<EOD> In vitro susceptibility of Leishmania panamensis to 18 antimonic acetate and a combination of chloroquine/amphotericin B.\n\nThe present study describes the susceptibility of promastigotes of Leishmania panamensis to sodium oleate, dipotassium glycyrrhizinate, and a combination of chloroquine+amphotericin B. A control strain was used in order to analyze the in vitro susceptibility variations, the intra-treatment variations and the inter-treatment variations of the promastigotes and intracellular amastigotes of L. panamensis from patients from an endemic village in Nari\u00f1o, Colombia. The in vitro susceptibility variation in promastigotes, amastigotes and infected tissue macrophages showed lower IC50 values for sodium oleate (p = 0.000), with the lowest of 298.1 \u03bcg/mL, and dipotassium glycyrrhizinate (",
        "label": 2
    },
    "349": {
        "output": "[TUTORIAL] The `Trial-eligible Patient Summary` block\n\nTo determine why a patient does not meet the inclusion criteria of a clinical trial, please enter into the `Trial-eligible Patient Summary` block.\n\nThis block provides information about why the patient is not eligible to a clinical trial: \n\n- The patient is not eligible because the patient does not have sufficient information to qualify for the trial. This usually occurs when the patient does not have a diagnosis of breast cancer, but there is a chance that the patient might be diagnosed with breast cancer at some point. If you have concerns, make a note and look at the `Patient Information Summary` block to figure out more.\n\n- The patient is not eligible because the patient has a previous admission history of breast cancer. If you want to confirm whether the patient has a previous admission history, look at the `Patient Admission History` block",
        "label": 0
    },
    "350": {
        "output": "![C337099]![INC73F449]\n\n\n\n<commit_msg>C337099: 1. Use `pwd` command to see the current working directory and go to the root directory. 2. Use the full path specification of the directory to save the file. 3. Create the directory and paste the file into the new directory.<commit_after>@import url('https://fonts.googleapis.com/css?family=Roboto:400,700,400italic');\n@import url('https://fonts.googleapis.com/css?family=Saira+Text');\n\nbody {\n  font: 16px/1.28 'Roboto 400,700,400italic' !important;\n  height: auto;\n  text-align: left;\n}\n.doc {\n  height: 1200px;\n  margin: 4em 0 3em 0;\n}\nh1 {\n  text-align: justify;\n  height: 28px\n}\nh4 {\n  height: 28px\n}\n.doc-block {\n  height: 60px;\n  position: fixed;\n  top: 0px;\n  left: 0px;\n}\n\n/**\n * Header\n */\n.header {\n  background: #fafafa;\n  width: 100%;\n  height: 90px;\n  display: none;\n}\n\n.header ul.nav .li {\n  float: left;\n  height: 90px;\n}\n.header ul.nav .li:last-child {\n  margin-top: 14px;\n}\n.header ul.nav .li:last-child:before {\n  content: '';\n  display: block;\n  height: 40px;\n  width: 100%;\n  position: absolute;\n}\n.header ul.nav .li .icon {\n  float: left;\n  margin-top: 14px;\n  height: 40px;\n  width: 40px;",
        "label": 0
    },
    "351": {
        "output": "## IN 1 IN 2 IN 3\n[CLINICAL-STUDY] Hello. Your job is to evaluate the inclusion criteria for a patient who may participate in a clinical trial.\n\nThe assessment of eligibility has a three-point scale:\n0) Excluded (patient does not meet inclusion criteria); 1) Not relevant (patient does not have sufficient data to qualify for the study); and 2) Eligible (patient meets inclusion criteria).\n\nHere are three patients, each one with one inclusion criterion missing. Evaluate the criteria and determine if the patient will be eligible for this trial. \n\n# Introduction to the data set.#\nFor a thorough documentation of the dataset, please refer to the `README` and the `Snakefile` in the data folder.\n\n# Overview of the dataset.#\nThis dataset comes from a study where subjects with breast cancer underwent a neoadjuvant chemotherapy phase, meaning they receive chemotherapy to see if a tumor will shrink or not.\n- There is an important feature in the data set, which is a variable indicating if a patient received an anti-HER2 therapy.\n- Subjects who received chemotherapy and an additional therapy to fight the tumor, namely anti-HER2 therapy, were given a score of 1.\n- Subjects who only received chemotherapy were given a score of 0.\n- Some subjects had missing data (about half of subjects have missingness in their features, especially about ER, PR, HER2 status and HR + status). The missing data were handled with the `missforest` package.\n\n## Important note on the data set.#\nThere are some problems you have to consider before starting analysis with this dataset.\n- There are imputed features in this dataset (`Missing1`, `Missing2`, `Missing3` and so on).\n- Some features are continuous variables like the length and width of the tumor. Those variables were discretized to two groups (e.g., from `Tumor length < 3 cm` to `Tumor length <= 3`) to build a decision tree.\n- `HER2 status` is missing in some subjects. You can impute those missing values using the",
        "label": 1
    },
    "352": {
        "output": "1. First, let's check whether the patient meets the criteria with the following code: (see [[INST][1]).\n```python\npatient_matches = {int(c) - 1 for c in ctypes.c_int[2:5] for i in patient}\n\nInclusion_criteria_matches = {(ctypes.c_long, ctypes.c_long, ctypes.c_double, ctypes.c_long) for criterion in trial.trial_eligibility.criteria if (int(c) - 1 for c in criterion.name) in set(patient_matches)}\n\nInclusion_criteria_matches == {(10, 4, 0, 0)}\n```\nLet's make a `True` if the patient meet the criteria. It indicates that a patient is eligible for a clinical trial. As per the example, the current patient matches the 10 as age factor. If our patient's age satisfies the criteria, you should return a `True` on eligibility_match.\n```python\nif not Inclusion_criteria_matches:\n    eligibility_match = True\nelse:\n    eligibility_match = False \n```\nIt is not true because the patient matches age factors but not gender.\n```python\nelif (int(c) - 1 for c in criterion.name) != \"Gender\":\n    eligibility_match = True\nelse:\n    eligibility_match = False \n```\nThere is not matching the factors for ER/PR but does for HER2.\n```python\nelif (int(c) - 1 for c in criterion.name) != \"Receptor_status\":\n    eligibility_match = True\nelse:\n    eligibility_match = False \n```\nIf the patient meet any of the factors, we should return a `True` on eligibility_match.\n```python\neligibility_match = True\n```\nFinally, return `True` on trial-level eligibility too.\n```python\nTrial_eligiability_matches = { (int(c) - 1 for c in criterion.criteria) for criterion in trial.trial_eligibility.",
        "label": 0
    },
    "353": {
        "output": "### <h4 class=\"panel__title\"># How To Make a Changes For Trial-level eligibility: 0) Excluded?\n\n[INST] You can find the way to make a changes for \"Excluded\" label directly as following: \n\n1  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"0) Excluded\") :\n        data[\"Trial-level eligibility\"] = \"1) Not relevant\"\n    ```\n\n2  \n\n    ```python\n    for key ,value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"1) Eligible\") :\n        data[\"Trial-level eligibility\"] = \"2) Eligible\"\n    ```\n\n3  \n\n    ```python\n    for key ,value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"2) Eligible\") :\n        data[\"Trial-level eligibility\"] = \"0) Excluded\"\n    ```\n\n   \n    \n### <h4 class=\"panel__title\"># How To Make a Changes For Trial-level eligibility: 1) Not relevant?\n\n[INST] You can find the way to make a changes for Trial-level eligibility \"Not relevant\" label directly as following: \n\n1  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"1) Not relevant\") :\n        data[\"Trial-level eligibility\"] = \"Other\"\n    ```\n\n2  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"Other\") :\n        data[\"Trial-level eligibility\"] = \"1) Not relevant\"\n    ```\n\n3  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level elig",
        "label": 0
    },
    "354": {
        "output": "## COPY PASTE IN STUDIO INSTANCE FILE\n\n\n14. Click the blue Save button in the editor's toolbar. Click the COPY button on the edit bar.\n\n\nThe copy option in the editor's toolbar always duplicates the code that is visible in the code view area. The content in the edit view area will remain unchanged! [EDIT]\n\n## COPY PASTE IN ANOTHER FILE\n\n15. Click the blue Save button in the editor's toolbar, then click the EDIT FROM FILE option.\n\n\nCopying and pasting files is one of the best tricks, but it is important to copy the code of each step and paste it to where it's needed, thus preserving order of the code. [EDIT]\n\n## SAVE\n\n16. Click the blue Save button in the editor's toolbar.\n\n\nClick the blue SAVE button in the editor's toolbar. Make sure to first run your flowchart prior to saving it. [EDIT]\n\n## OPTIONS\n\n17. Click the blue Save button in the editor's toolbar, click the OTIONS button, and select SAVE AS.\n\n\nAs a courtesy to other coders, we ask that you do not create custom variable names. By default, the studio allows you to save a flowchart with only one variable name, named \\#Flowchart. [EDIT]\n\n18. Enter the name of the flowchart as Flowchart (name chosen will be the name of the flowchart) and click the SAVE AS button to save the flowchart.\n\n19. Click the blue Save button in the editor's toolbar, click the SAVE FILE FOR LOCAL EDITOR option.\n\n\nYou can also copy the code of all your steps and paste it in another file you've created (make sure you have the proper path and filename for this file). [EDIT] \n\n## COPY PASTE IN RESEARCH MANAGER FILE\n\n20. Click the blue Save button in the editor's toolbar, click the FILE EXPORT BUTTON and export to Research Manager.\n\n21. On the left-hand side of the screen, navigate to Research Manager and click Open.\n\n\nA file named",
        "label": 0
    },
    "355": {
        "output": "## Expected output\n![Instructions](/assets/img/help/instructions-eligibility-explanation.png)\n\n[!instructional](#instructions)[!instructions](https://docs.google.com/document/d/1TNY0h4GsWtJpKp9Tj9pJg1xKGc1Jvk6533RtYQbFN3I/edit)\n<EOD> Chromogranin A-derived peptides as anti-tumor agent in colon cancer.\nPeptides can have antineoplastic effects in vitro and in vivo. Among these peptides, chromogranin A is a widely distributed neuroendocrine secretion protein and its precursor chromagranin A contains more than 50 copies of pentapeptide with the 61-62-63-64-65 motif (Y/F/W-X-Y/F/W-X-X-F). In our previous work, we observed that some of the peptides derived from chromogranin A showed a positive anticancer effect on colorectal cancer. Based on our previous work, 19 peptides was designed to investigate the ability of peptides derived from chromogranin A in inhibition of colon cancer in vitro. The results revealed that among the 19 synthetic peptides, 6 peptides strongly inhibited the viability of colon cancer cells, in which the peptide R5Y5W7F11Y12-YNYC9 was able to inhibit the growth of HCT116 cells in vivo and in vitro. Moreover, our next experiments displayed that the peptide induced autophagy in HCT116 cell. Further studies showed that GSK-604, an autophagy inducer, can enhance the anti-tumor effect of peptide on HCT116 cell. In HCT116 cells, the peptide decreased the level of phospho-mTOR, phospho-AKT, phospho-p70SK7, phospho-p85, p62, and GSK-",
        "label": 0
    },
    "356": {
        "output": "Let's think how to judge the above patient. The patient does not have a record of chemo before so the trial did not consider the use of metformin before, so it does not have any of the exclusion criteria, e.g., `Chemotherapy<type=\"n.a.\">CXR was remarkable for metastatic lesions.</type=\"n.a.\">.`, so it is not included and we can output `Eligible.`.\n\nIf you are not sure that you can complete the task, the best way is to give up this task.  \n\n### Conducting Trial-level Eligibility\n\nIn this tutorial, we write a script for the task. You do not have to follow the example you are seeing and you can write any code you want even if it is unintelligible to us. If you want to see the code running along the text, it is best to type your code above the input box of the task on the site.  \n\n![Instruction: 6-3]\n\n1. Go to the page for the task and click the [START] button. You will get a trial-level eligibility task (see [instruction] to find task by its ID `10_30_6`).\n\n<figure class=\"instruction-figure\">\n  <img src=\"images/instruction/10_30_6.png\">\n</figure>\n\n2. If the task is running, do not do anything to the computer until the task is ended (it normally takes one minute). Click the 'Review' button. You should see the information below.\n\n![Instruction: 6-4]\n\n3. Click `Create task`. This will create a task that you cannot modify but you can use it to get a token and pay for your work.\n\n![Instruction: 6-5]\n\n4. [If you created and paid your task, please skip this step.]\n\n![Instruction: 6-6]\n\n5. Click the link of your task. The task is on the upper-left corner of the page.\n\n![Instruction: 6-7]\n\n6. Click the pen symbol on the upper-left corner of the task. You should get an input box in which you can input the code for your task.",
        "label": 2
    },
    "357": {
        "output": "# Challenge\nHere is the challenge. It shows that if the patient was a candidate for the clinical trial, the scale of eligibility was 0). 1) Not relevant is not a trial-level eligibility.\n<html>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=UTF-8\">\n<title>Output</title>\n<script type=\"text/javascript\">\ndocument.write('You should output the trial-level eligibility');\n</script>\n</html>\n\n\n---\n**_source code:_** <https://github.com/wchlab/wchlab.github.io/blob/main/inst3.ipynb>\n\n**_output:_** <./output.png>\n\n**_solution_**<br>\n\n~~~python\ntrial = {\n'title': 'Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients',\n'summary': \"\"\"The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections.~To observe the pharmacokinetic characteristics of recombinant human serum albumin /granulocyte colony-stimulating factor fusion protein after single and multiple administration'\n\"\"\",\n'inclusion_ criteria': ['Age 18-65.', 'Diagnosed breast cancer', \n'received chemotherapy', 'ECOG performance status = 0 or 1.'],\n'exclusion_ criteria': ['Age <18 or >65.', 'Not diagnosed breast cancer'\n                         'not received chemotherapy', \n                         'ECOG performance status >1', 'No \n                                               leukocyte reduction occurred after chemotherapy', \n                         'WBC\u22653.0\u00d710^9/L, or ANC\u22651.5\u00d710^9/L', \n                         'No serious underlying disease.'],\n}\n\npatient = {\n'patient note': \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a",
        "label": 1
    },
    "358": {
        "output": "1: Assessment criteria: `Patient-level eligibility: 1) Not Eligible.`\n2: Trial level eligibility was set in the last line.\nPlease share your thoughts, difficulties, suggestions and ideas with the community.\nTo participate, you need to install python [INST]. \nYou can also run these instructions.\n```\n#! python\npython nlp\n```<EOD> Niche separation enables the successful assembly of a soil microbial community\n\n [bib_ref]  Impact of climate change on future biodiversity, Bellard [/bib_ref]  [bib_ref]  Changes in biodiversity characteristics and functional stability of an alpine grassland soil..., Wang [/bib_ref]  [bib_ref]  Rationalising plant community response to stress: A case for the importance of..., Mommer [/bib_ref]  [bib_ref]  Ecological rules for ecosystem sustainability, J\u00f8rgensen [/bib_ref]  [bib_ref]  Stability and structural change in communities as an experimental method, J\u00f8rgensen [/bib_ref]  [bib_ref]  Eco-evolutionary feedbacks between biodiversity and climate change, Wacker [/bib_ref]  [bib_ref]  Ecological rules for ecosystem sustainability, J\u00f8rgensen [/bib_ref]  [bib_ref]  Stability and structural change in communities as an experimental method, J\u00f8rgensen [/bib_ref]  [bib_ref]  Microbial community response to simulated climate change: Contrasting patterns in leaf litter..., Macdonald [/bib_ref]  [bib_ref]  Biodiversity, stability, and productivity in competitive communities, Lehman [/bib_ref]  [bib_ref]  Biodiversity, productivity and the temporal stability of productivity: Patterns and processes, Isbell [/bib_ref]  [bib_ref]  Biotic homogenization: The final common pathway of biodiversity loss in changing landscapes?, Lep\u0161 [/bib_ref]  [bib_ref]  Soil biotic legacy effects of prior land use change persisted for at..., De Vries [/bib_ref]  [bib_ref]  Fungal community response to climate warming is altered by biotic interactions, Liu [/bib_ref]  [bib_ref]  The mechanisms and implications of plant diversity effects on ecosystems: Examining the..., Lalibert\u00e9 [/bib_ref]  [bib_ref]  Effects of microbial inoculum source on soil microbial community structure and soil..., Liu [/bib_ref]  [bib_ref]  Temporal dynamics of microbial communities during the decomposition of",
        "label": 2
    },
    "359": {
        "output": "In the example presented here, we can observe a patient not being eligible for the clinical trial, since the patient meets the exclusion criteria for the trial (the patient has metastatic lesions).\nOn the other hand, the patient is eligible for the clinical trial, since the patient does not meet the exclusion criteria, and the patient meets at least one inclusion criterion.\n\n## [INST] 5. Construct a new `Table`. \nHere you should add the following rows: Let's think step by step. \n\n## [INST] 7. The row for the patient will contain following variables:\nThe patient ID; Patient gender; Patient age; Patient marital status; Patient sexual activity; Patient children; Patient medications; Patient smoking; Patient alcohol consumption; Family history of certain diseases; Physical examination; Patients CXR; Patients Hx and A/S results; and Patient biopsy results. \nThe row for the Clinical trial will contain the following variables: Trial title; Trial summary; Trial eligibility criteria; Inclusion criteria; Exclusion criteria; and Trial note.\n\n## [INST] 8. The first row should contain the following variables:\nThe first row will contain the following variables: 'Patient ID': Patient ID integer; 'Patient gender': Patient gender; 'Patient age': Patient age; 'Patient marital status': Patient marital status; 'Patient sexual activity': Patient sexual activity; 'Patient children': Patient children; 'Patient medications': Patient medications; 'Patient smoking': Patient smoking; 'Patient alcohol consumption': Patient alcohol consumption; 'Family history of certain diseases': Family history of certain diseases; 'Physical examination': Patients CXR; 'Patients Hx and A/S results': Patients Hx and A/S results; and 'Patient biopsy results': Patient biopsy results. \n\n[INST] 9. The second row should contain the following variables:\nThe second row will contain the following variables: 'Clinical trial eligibility': Trial-level eligibility integer; 'Clinical trial title': Trial title string; 'Clinical",
        "label": 0
    },
    "360": {
        "output": "Ask to discuss:\n\n1. You have encountered a challenge here, why were certain patient data taken into consideration? How do those considerations affect the task of determining a patient's eligibility for a clinical trial?\n2. What happens if one of the inclusion criteria, such as histologically proven invasive carcinoma of the breast. is not satisfied?\n3. How is the evaluation of eligibility made? Is this task done by physicians and/or nurses?\n4. If yes, why?\n       ____ for a clinical trial.\n      ___________ a clinical trial.\n       _____________ a clinical trial.\n       ________________ a clinical trial.\n       ________________ the clinical trial.\n5. What do you think of the use of clinical decision support systems?\n        _____ a good idea.\n        ______ a bad idea.\n        ______ a new idea.\n\n\n\n\n\n\n\n\n\n\n\n\n<EOD> The Impact of COVID-19 on Mental Health in the SARS-CoV-2 Pandemic: A Rapid Review\n\nCitation: Alom, S.M.A.; Lohith, V.; Viprakasam, B. The Impact of COVID-19 on Mental Health in the SARS-CoV-2 Pandemic: A Rapid Review. Brain Sci. 2023, 13, 92.\n\n# Introduction\nThe outbreak of SARS-CoV-2, a viral pathogen that causes COVID-19, was officially declared a pandemic by WHO (World Health Organization) on 11 March 2020 [bib_ref]  World Health Organization declares global emergency: A review of the 2019 novel..., Sohrabi [/bib_ref] . From Wuhan, China, SARS-CoV-2 has spread to all regions and territories around the world through the fast and modern interconnectedness of international air travel in recent decades. As of 2 February 2023, it has spread to 233 countries with 382,989,028 confirmed cases and 5,701,749 deaths. In this article,",
        "label": 0
    },
    "361": {
        "output": "<section id=\"patient-details-and-assessmextra1\" toc=\"#patient-details-and-assessmextra1\" />\n[INST] If a patient meets the trial's selection criteria, the trial will enroll him/her. However, it is possible that the patient is eligible to participate in another trial. \nThis question asks if the patient is already being treated in another trial. It allows you to exclude the patient from this trial if he/she is already taking another therapy. The trial will enroll patients who are eligible in two or more trials. \n\nThe trial may not want to enroll patients already taking the therapy since it will exclude patients having a benefit to two or more trials.\n\nExclude if patient is eligible to two or more trials \nQuestion: `Exclude if patient is eligible for two or more trials.` If the answer is `no`, continue question set. If the answer is `yes`, skip directly to the end of this part.\n\n[INST]\nThis is a question requiring the user to enter a numerical value. Enter a number in the range of 0 to 1. `Number`: [inst_number, INST]<section id=\"patient-details-and-assessmextra2\" toc=\"#patient-details-and-assessmextra2\" />\n[INST]\nExclude if patient is already taking other therapy\n\nThe trial may not want to enroll patients already taking the therapy since it will exclude patients having a benefit to twoor more trials. `Number`: [inst_number, INST]<section id=\"patient-details-and-assessmextra3\" toc=\"#patient-details-andassessmextra3\" />\n[INST]\n\nThis is a question requiring the user to select a value. Select a value to assign. `Value`: [SELECT_ALL, INST]<section id=\"patient-details-and-assessmextra4\" toc=\"#patient-details-and-assessmextra4\" />\n[INST]\nThis check is a binary value. If the answer is `yes`, continue question set. If the answer is `no`, skip directly to the end of this part.",
        "label": 2
    },
    "362": {
        "output": "<EOD> Effects of HA-1271, a P\u2010glycoprotein inhibitor, on the tissue distribution of digitoxin in rats\nThe potential toxicity of digitoxin is related to its long elimination half-life associated with its cardiovascular effects and hepatotoxicity, particularly under P-glycoprotein (P-gp) inhibition. This was explored by measuring plasma and tissue (liver, kidney, lung, skeletal muscle, and heart) concentrations of digitoxin on different times after oral administration of digitoxin (0.3 mg/kg) to rats (in the presence or absence of HA-1271 (100-mg/kg)). The concentrations of plasma and liver digitoxin for groups with HA-1271 were higher than those for rats without HA-1271 (P < 0.05). However, the heart concentrations of digitoxin in groups with HA-1271 were lower than those for rats without HA-1271 at both 15 min (P < 0.05) and 24 h (P < 0.05). These results suggest that P-gp inhibition could modulate and affect the cardiotoxicity of digitoxin in rats.<EOD> Prenatal Stress and Glucocorticoid Hormone Receptor in Rodent Offspring: Exposure\nAdverse effects of prenatal stress are well documented, but the underlying mechanisms are yet to be fully explained. The fetal hypothalamic-pituitary-adrenal axis is responsive to maternal stress; however, glucocorticoid hormone administration to pregnant animals can provide a more reliable means of inducing changes consistent with those observed after maternal stress. The hypothalamic-pituitary-adrenal axis is also a major target for the glucocorticoid hormones, with the glucocorticoid receptor playing an essential role in controlling glucocorticoid hormone actions and providing a molecular link between stress and fetal development. Glucocorticoid receptors are",
        "label": 2
    },
    "363": {
        "output": "After this, we need to compute scores for `f`, `g` and `h`. For the first patient note, we apply `f` and get scores `245, 180, 375`. After this, we apply `g` where note and trial share four factors to get scores `244, 175, 371`. Finally, we apply `h` where note and trial are not in any clinical trial to get score `347`. Thus, the score for the first patient is `340`. \nHere are 10 more patients: The following rules are applied to score each patient: Apply `f` to every combination in the following order: `1 note; 1 trial`, `1 note; 2 trials`, `2 notes; 1 trial`, `2 notes; 2 trials`. After this, apply `g` where two factors or more share between the note and trial, i.e., `1 note; 1 trial`, `1 note; 2 trials`, `2 notes; 1 trial` and `2 notes; 2 trials`. Finaly, apply `h` where the note does not share any factors with the trial, that is, `1 note; 2 trials` and `2 notes; 2 trials`. \nFor the first patient, `f1 = 245, g1 = 244, and h1 = 347; f2 = 215, g2 = 180, h2 = 320; f3 = 146, g3 = 170, h3 = 210`. Thus, the score is 295. For the second patient, `f1 = 375, g1 = 271, h1 = 397; f2 = 255, g2 = 171, h2 = 210; f3 = 214, g3 = 208, h3 = 223\n\n\n# 3. Questions\n\nThis is about the `ClinicalTrialsR package`. This package works for all 515 clinical trials in the `CTWeb` table. To demonstrate the package, we select 10",
        "label": 0
    },
    "364": {
        "output": "[INST] Hello. Your task is to make a diagnosis for a patient using a medical text. You must choose from six types of tests (mammogram, blood test, biopsy, thyroid test, urine test, pelvic ultrasound). \n\nThe task is to determine if a patient has a breast cancer or not. The mammogram, biopsy, thyroid test, pelvic ultrasound are diagnostic tests. That means they are useful in diagnosis. The blood test and urine test are functional tests. That means they indicate the presence of certain substances in the blood or urine, but they do not indicate disease.\n\nThe assessment of the test results has a three-point scale: 0) Normal or negative; 1) Abnormal but requires no intervention; and 2) Abnormal and requires intervention. \n\nHere is the patient note: \nA 22-year-old nulliparous, right-handed female presents to the emergency room with bilateral breast pain and bleeding. You note that she is not sexually active and has no regular partner. She has had no previous surgeries. She has been using oral contraceptives for 7 weeks. She takes no other medications.\n\n### Mammogram \n\n\n\n* ** 2) Abormal and requires intervention.**\n\n\n# Discussion\n\n#### \u8a0e\u8ad6\n\n### Q1. There are some words that seem suspicious. For example, \u2018\u2019she has been using oral contraceptives for 7 weeks\u2019\u2019 and \u2018\u2019sudden and recurrent visual loss may be a symptom of a variety of conditions\u2019\u2019. What do you think each word means? How do they affect the clinical interpretation of this note in clinical practice? You are free to read the rest of the note to get more information for discussion.\n\n## Q2. What are the differential diagnosis of this note for the physician in outpatient setting?\nDifferential diagnosis is one of the foundational steps for clinicians to start their thought process in order to narrow down or disprove each possible differential diagnosis. This is an indispensable skill in order to reach the correct diagnosis based on the information from the clinical note. Let`",
        "label": 0
    },
    "365": {
        "output": "![1](img/1.png)\n\n\n[TEST]\n*This script was written using the R library [testr](https://cran.r-project.org/web/packages/testr/vignettes/testr.html). Testr is the official test suite for R/CRAN.\n*We recommend using testr since it is an official test suite.\n\n```r\nrequire(testr, silent = TRUE, test.suites = TRUE)\n```\n\n#### [x] Pass all test cases for the \"assessment of eligibility\" case study.\n\n```r\ntestr(cases = list(\"assessment_of_eligibility\"))\n```\n\n```\nTests pass! (2 tests and 0 warnings)\n```\n\nIf the test fails with error message, you can explore your model using `trace()` or `verbose()` to help find out where the error came from.\n\n```r\ntestr(cases = list(\"assessment_of_eligibility\"),\n        verbose = TRUE,\n        trace = 1\n        }\n```\n```\nThe fail case is at trial-level eligibility:\ntest124\ntest123\n\nThe pass case is at \nassessment of eligibility\nget_eligibility \n```\n```\nIf all pass, then congratulations! Next time, we will continue with model application in different contexts: diabetes risk, COVID-19, dementia, lung cancer, chronic kidney disease, and diet quality.\n```\n```\n$ sessionInfo\n```\n```\nR version 4.0.0 (2020-06-09)\nPlatform: x86_64-w64-mingw32/x64 (64-bit)\nRunning under: Windows 10 x64 (build 19041)\n\nmatrix(c(1:10, 12), ncol = 2)\n```\n\n\n![title](../../data/image/figure_title.png)\n\n[TUT]\nYour task is to complete the code for the rest of the clinical trials.  \nWrite your code in a file named `soln-clin",
        "label": 0
    },
    "366": {
        "output": "[RUNNER](INST)\n![RUNNER](../images/runner.png)\n\n## S2.2 Clinical Decision Support System in MIMIC 4.0\n[S2_SCHEME](https://github.com/UFCAIJ-Team/UFCAIJ-MIMIC-4.0-Japanese-paper/blob/main/S2/SCHEME/S2.2.md)\\[RUNNER](INST)\n\n### Scheme\n\n[RUNNER](INST) \n![RUNNER](../images/runner.png)\n\n### Assignment of ID by `assign_id()`\\[PPT](INST)\n\n\n![PPT](../images/ppt.png)\n\n### 1st) Create a dataset from a CSV file\\[PPT](INST)\n\n![PPT](../images/ppt.png) \n\n### 2nd) Specify a target patient\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 3rd) Specify a dataset of a target patient\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 4th)  `assign_id()` in MIMIC 4.0 dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 5th)  `assign_id()` in MIMIC 4.0 with 1st) dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 6th)  `assign_id()` in MIMIC 4.0 with 1st) dataset and 2nd) dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 7th)  `assign_id()` in MIMIC 4.0 with 1st) dataset, 2nd) dataset and 3rd) dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png) \n\n### 8th)  `assign_id()`",
        "label": 0
    },
    "367": {
        "output": "{, and the \n(that . 4 [bib_ref]\n\nin  cann [bib_ref] \n\nc and the  and i [bib_ref] and [bib_ref]\u00a01.\nd .\n [bib_ref] (after [bib_ref]\u00a0on, iute-match on a trial for a single [fig_ref] on\n. the decisionable (but, but the\u00a0\n\n \ufffd\ufffdcist. as well. The\ns and\u00a0so in a patient 1\u00a0(under in [bib_ref] 1 in the and i\n- 8 and the 1\u00a0only   in the . \u00a0 -in \u00bc [bib_ref]\n \u00f0\n (0\n \n-only-to- [fig_ref] [bib_ref] [bib_ref], including a [bib_ref]; the [bib_ref] .\nacc\ngato\non<EOD> (for standard patient_ [bib_ref] _C (random [bib_ref] as a(or. [bib_ref] [bib_ref] . and\nd [bib_ref] [bib_ref] \u00a0in in a\u00a0 and{ _ 1 or \u00a0(not. 4th on the.\n-d [bib_ref] \ufffd(in \u00c2 on C\n\\d-in and 2\u00a0acc -and for its _ and\nc on [bib_ref] \ufffd...s [bib_ref] a^\n-in the(i\non 2.s for all-complete-complete on the-trelin\n\nsystem..., G    \u22c5 [fig_ref]\n\\for the\n! !. On 1-in [bib_ref] her \u2026...inst...reight (in ... (0 .in \u2021-for the [bib_ref] -\nfor the cet.\ntarget_and-inter Cert (C...and a#\n (can, on his in \u25a0 \u00a0can and 0 -pat in . [bib_ref]\nass for [bib_ref] (\n on F-related<EOD>- . (inst - _ \n1 or ( [fig_ref] 2 in\u00a0d of [bib_ref] in [bib_ref]in \ufffdre to b... [bib_ref] for\n(i, for a 1 in the_i for the\nb to [bib_ref] a^s for \u201a;s of 1 [fig_ref]ind _inst in the in 1 { [bib_ref] on the \u2026.<EOD>/inst 2<EOD> _C on-bours for \" , -[\n [in-above-... \u2011the_ [bib_ref]* (the\ndepo@\n in\\for a - [bib_ref] ( 1",
        "label": 0
    },
    "368": {
        "output": "---\n\n## Clinical Trial Checklist\n\n\nTo complete the clinical trial and obtain a complete Clinical Trial Checklist, please follow the following procedure:\n\n1.  After you have finished evaluating all patients, make clinical decision support for each patient as",
        "label": 2
    },
    "369": {
        "output": "### Instructor's Notes\n\n**Background**\n\nThe assessment of eligibility can be complicated, thus, it is important to develop a process or guideline for clinicians to follow so a patients can be enrolled in clinical trials.  Since there is no a one-size-fits-all protocol, a careful review is needed for each patient to make sure the patient meets the appropriate inclusion criteria.  For instance, a study participant in a multiple myeloma trial would need to have normal blood counts, yet a woman with Hodgkin's lymphoma (HL) who has high risk features may not need to meet the same criteria. Additionally, because research is still in the process of being performed, there are often multiple reasons for exclusion.  Some examples of this can be seen in the following 2 trials: the Multiple Myeloma Trial and the HL-E2C3 trial.\n\n**Assessing a Patient for Eligibility**\n\nThere are 2 main components to assessing a patient's eligibility: knowing the inclusion criteria for the clinical trial, and whether the patient meets them.  Once this is figured out, then the assessment for eligibility can take place.  First, 2 things are figured out: whether the clinical trial is ongoing or closed and whether the person is still eligible to enter the trial. Second, 2 more things need to be figured out: whether the patient meets the inclusion/exclusion criteria, and whether or not the patient is still eligible to enter the trial.\n\n**Hodgkin's Lymphoma (HL) - E2C3 Trial**\n\nAs stated above, there are exclusion criteria as well for eligibility.  For example, the HL-E2C3 trial is a combination chemotherapy trial that aims to improve the quality of life for patients with newly diagnosed Hodgkin's lymphoma.  A person who has been diagnosed with HL who is a good candidate for radiotherapy and chemotherapy is deemed eligible.  Those who have already had a blood transfusion, are unable to receive radiotherapy, or have significant comorbid conditions (such as HIV/AIDS, serious heart failure, severe cardiac dysfunction)",
        "label": 2
    },
    "370": {
        "output": "### [INST] Rules for Assignment of Residues (B, X)\nAssign letter `B` to all residues present at a site of a protein in a particular species. Assign letter `X` to rest of residues.\n\n## Assignment Rules\nBoth `B` and `X` can be assigned to the same residue if this residue is in a single chain. Here is the `single chain` condition. The other condition is `multiple chain`. \n\n- Single chain: only one chain in the protein.\n- Multiple chain: more than one chain in the protein. \n\n## Examples\nWhen a protein is in a species, \n* `single chain protein`, let's assign `B` or `X` to all residues. \n* `multiple chain protein`, let's assign `B` or `X` to some residues, but not all residues.\n<EOD> A clinical and electrophysiological study of sensory\u2010ataxic cerebellar syndrome due to alcohol\nAbstract\u2002 The main effect of prolonged alcohol consumption is cytotoxic damage to the cerebellar cortex, which leads to a sensory\u2010ataxic cerebellar syndrome. At the level of the cerebellar cortex, Purkinje cells are the main target of alcohol injury, and axonal degeneration of the parallel fibres is a distinctive sign of the lesion. The axonal growth of cerebellar neurons is affected, and this causes anatomical reorganization in the Purkinje cell layer, resulting in loss of dendritic branching and alteration of the dendritic field. There is also loss of spines. Axonal growth is not affected within the molecular layer, so that climbing fibres and mossy fibres are not damaged, and efferent afferent connections remain intact. This paper reviews the findings from a prospective clinical and electrophysiological study, and from some longitudinal and cross\u2010sectional studies of patients with sensory\u2010ataxic cerebellar syndrome. The principal clinical findings are cerebellar gait with intention\u2010tremor, cerebellar dysarthria, and abnormalities in sensory discrimination. The electro",
        "label": 0
    },
    "371": {
        "output": "[END]\n\n[#] How to implement?\n\nHere is an example of how to implement for you in a bash script. This could be extended to many languages, if you need it. I use some [bash](/ref/bash). You can change this script for your needs.\nAdapt to your needs. Good luck!\n\n### #!/bin/bash\n##$ # Bash 4.3.48(1)-posix-linux/x86_64 ##$ # $ # export ACCESS_TOKEN=\"access_token\" ##$ # $# export CREDENTIALS_FILE=\"cre-dential-1\" ##$ # $ # export CREDENTIALS_FILE=\"credential-2\" ##$ # $ # export CREDENTIALS_FILE=\"credential-3\" ##$ # $ # export CREDENTIALS_FILE=\"credential-4\" ##$ # $ # export CREDENTIALS_FILE=\"cre-dential-5\" ##$ # $ # export CREDENTIALS_FILE=\"credential-6\" ##$ # $ # export CREDENTIALS_FILE=\"credential-7\" ##$ # $ # export CREDENTIALS_FILE=\"credential-8\" ##$ # $ # export CREDENTIALS_FILE=\"credential-9\" ##$ # $ ##$ # export ACCESS_TOKEN=\"access_token\" ##$ # $# export CREDENTIALS_FILE=\"credential-1\" ##$ # $# export CREDENTIALS_FILE=\"credential-2\" ##$ # $# export CREDENTIALS_FILE=\"credential-3\" ##$ # $# export CREDENTIALS_FILE=\"credential-4\" ##$ # $# export CREDENTIALS_FILE=\"credential-5\" ##$ # $# export CREDENTIALS_FILE=\"credential-6\" ##$ # $# export CREDENTIALS_FILE=\"credential-7\" ##$ # $# export CREDENTIALS_FILE=\"credential-8\" ##$ # $# export CREDENTIALS_FILE=\"credential-9\" ##$ # $## $\n\n### # $ # $\n\n### # $ #",
        "label": 1
    },
    "372": {
        "output": "<EOD> 7 Tesla high-field magnetic resonance imaging-guided focused ultrasound thalamotomy in essential tremor: a multi-modal single-site experience\nBackground Essential tremor (ET) is a highly prevalent disease, yet optimal therapy remains to be established. Current therapeutic options either are inadequately effective or have significant side effects. There is growing evidence that focused ultrasound (FUS) brain therapy is a safe and effective novel therapy for refractory ET. Objective To retrospectively assess therapeutic benefit of 7 T MRI-guided FUS thalamotomy in a cohort of ET patients. Methods A consecutive series of patients who underwent 7 tesla MRI-guided FUS thalamotomy at a single center through July 2018 were included in this study. Demographic, clinical and lesion characteristics, and treatment variables were recorded. Baseline and follow-up Unified Parkinson's Disease Rating Scale (UPDRS) parts III and IV, Essential Tremor Questionnaire (ETQ-9), Rating Scale for Multiple Ataxias (SMAR), and Patient Global Impression of Change (PGIC) scores were obtained on all patients post-FUS (preoperatively 1 day to 1 week and 4 weeks to 6 months). Tremor was quantified by a validated digitized pen grip test. Results Six patients (three males, five right-handed at onset) underwent FUS through July 2018. Mean age of patients was 66.17\u2009years (SD 7.72); mean disease duration was 36.67\u2009years (SD 20.7). The mean time to complete lesion was 20.33\u2009min (6.21) and the mean total sonication time was 27.0\u2009min (4.55). Patients reported significant improvements in tremor, PGIC, SMAR, and ETQ-9 scores 4 weeks to 6 months postoperatively relative to baseline (p\u2009=\u20090.016, p\u2009=\u20090.039, p\u2009<\u20090.",
        "label": 0
    },
    "373": {
        "output": "Exercise\n\nWe will look at the patient note we used in the `Introduction`. Assume we want to know if the patient is a candidate for the trial. If the answer is `No`, you should output it. Include some reasons on how you have reached that decision too. [Note: the output format is as shown in the `Output` table.] Output: If the output is `Excluded`, you should input specific inclusion criteria the patient has violated to explain your decision. If the output is `Not relevant`, you should fill in your reason. If the output is `Eligible`, you should continue to check with the exclusion criteria and output the results. \n\n|Patient ID|   |Note ID|         |Inclusion criteria|                 |Output |                           |\n|------------|------|--------------|-----------------------|-----------------------|---------|------------------------------|\n| P001     | 134   | P001_2612 | 48780201\n|------------|------|--------------|-----------------------|-----------------------|---------|                           |\n|           |     |           |           |         |           |    |           |                        |\n\nExplanation: Assume that you are a doctor. We have given some information about a patient and a clinical trial. You are tasked to determine whether that patient is a candidate for the clinical trial. From the outputs:\n\n| patient notes | clinical trials |  |\n\nExplanation: Assume that you are a doctor. We have given some information about a clinical trial. We want to assign the given trial into three categories according to the given information and the research criteria. [Note: the output format is as shown in the `Output` table.] \n\n|      | patient notes |  |\n|------ |--------------|  |\n|      | 134           |  |\n|      |                |  |\n|      | P001_Note      |  |\n|      | P001_Notes     |  |\n|      | 3333           |  |\n|      |                |  |\n|      | P001_13458742 |  |\n|      | P001_333192",
        "label": 0
    },
    "374": {
        "output": "[for the study.\n- [bib_ref] they-to\n, H[or in elite to do \n[they elig, 1<EOD>( or\u00a0. 14 and \n, as well-ass/and for [bib_ref], in the disease and an [bib_ref], which or on 1. Exsuch.\nbased, \n \ufffdin 2, or a test; at . 1 and \nfor a certain for [bib_ref]{for an 5... 1 for-based or an alternative. and the\n [bib_ref], andto a clin in the 9 on medical and [bib_ref] 1, and \n. [bib_ref]. and without clin 2\u00a0but. In an open-or. To the \n^ . and [bib_ref] . . and [bib_ref], which-for the following its / 10-they, but their \\ \n\n (they   in their \u00a0 they, or [bib_ref] in the 2.\n!\n \n with an el\n in order-related. In some\n. A\nwith 1\u00a0for 4 or\ninst for [bib_ref]\n (el, a\u00a0/ in 1.\nel [bib_ref] or \n [bib_ref], <EOD> and 4 -or-m /\non-c.\npat to a .\n 1\u00a0/on-only\u00a0which, including the^ in\u00a0to \u25cb on a [fig_ref] for the\u00a0only for [bib_ref]..., an 1\n [bib_ref] a/1 and-\non-tract and\u00a0. as well, but a\\for a [bib_ref] a clin \ufffduse_ a  and 23 \\\n! [bib_ref] _ \\based [bib_ref] For and for this Cure , of [/table]\nthat.\nin that\u00a0only\u00a0in that \u223c1 and _\ns at 9-based- 11(in the copen for any or all \ufffd [bib_ref] they-st ...\nspecific\n0-ind-bist- [fig_ref]\n\n\n and\n1 in the _\n(\n\n\n/ex-based lyst and\nex\u00a0in with the [bib_ref]\\ and the1...no, not the .(specific\ns. The of \\med-visual-ex and_for all-in   _on ._ [fig_ref] .s. (h for<EOD>{the\non:{in the...in:",
        "label": 0
    },
    "375": {
        "output": "[INST] ####\n\nYou can also save the notes. [INST] In the main menu you see this: Edit. You write your notes here. You will see the patient note and the clinical trial in the same format than in the main menu. You can write your comments for the eligibility assessment in the fields below and save the note under a number code like `22` for patient no 82 and `RCT1_1` for the first clinical trial.\n[INST] ####\n\n[INST] The code is `0`.\n[INST] Once you press the red arrow it opens the next clinical trial.\n[INST] You work with the patient note, i.e., you assess whether the patient meets the inclusion criteria. The assessment has three possibilities: 0) Excluded (no match); 1) Not relevant (not enough information to assess eligibility); 2) Eligible (match).\n[INST] The trial-level eligibility will be the same in the clinical trial note template.\n[INST] Finally you add the date and time of the eligibility assessment on the top right button.\n[INST] #######################################################################################\n\n[INST] ########## Checking eligibility #####################################################[INST]\n\nHere are all the 198 patients. We check their eligibility. The first patient with 4859 and 4882 is excluded because his diagnosis is a metabolic disease. So we press `0` and press `S` for the second patient (4890) for a metabolic disorder and press `N` for the third one (4931) for a tumor disorder. We repeat that for the rest of the patients until the 122th.\n[INST] Now we get to the end. We get to the summary at the end and we can now press the green triangle for the next patient.\n[INST] \n\n[INST] ########## Checking eligibility #####################################################[INT]\n\n#\n\n# **Chapter 26: Study Data**\n\n[INST](./INST/INT1_5_data_introduction.md)\n\n\n# **Introduction**\n\n[INST](./INST/INT1",
        "label": 0
    },
    "376": {
        "output": "If the patient's note did not contain enough information, you could print it and put it aside to find more details. \n\n---\n<NAME>, <NAME>, University of Illinois Medicine.\n<EOD> The efficacy and safety of biliary stents for the management of benign biliary strictures: a systematic review and meta-analysis\n\nBackground: The efficacy and safety of biliary stents for the management of benign biliary strictures (BBS) have not been assessed in the meta-analytic setting. The objective of this study was to evaluate the efficacy and safety of biliary stents.Methods: Using the search terms \"biliary stent\" OR \"stent\" AND \"biliary\", the following four electronic databases were searched from inception to February 2016: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. All prospective and retrospective cohort studies and randomized clinical trials (RCTs) examining the efficacy and safety of different biliary stents (i.e. self-expandable metal stent [SEMS] and plastic stent [PS]) were evaluated according to predefined search terms, inclusion criteria, and selection criteria. The metaanalysis was conducted using RevMan 5.2 software.Results: A total of 1680 potentially relevant articles were identified in the four databases. After duplicates were removed, 49 manuscripts were retrieved from PubMed and EMBASE databases, and through manual searching; 225 potentially relevant articles were identified from the Cochrane library. After the removal of duplicated articles and articles that did not include the key terms, and after screening of the titles and abstracts, 5 randomized clinical trials and one cohort study were considered for the quantitative synthesis. The meta-analysis was conducted using RevMan 5.2 software and random-effects models were applied since heterogeneity was observed; the 6 included papers were all included in the meta-analysis. Heterogeneity was analyzed by Cochran's Q and the I 2 statistic were estimated. The results of the meta-analysis showed that the stent patency rates at 6 months were 80.81 and 20.",
        "label": 0
    },
    "377": {
        "output": "#### Exercises\n[RER] ### Trial-level Eligibility (Step 1) #### 1\nWrite a function eligibility?() that returns the correct value for the eligibility assessment. \n<EOD> A critical review of the effects of food restriction during pregnancy on fetal development.\nThis paper reviews published reports on the effects of food restriction during pregnancy, beginning with the original classic studies of Mott who described reduced fetal growth with this form of exposure. Most modern reports, particularly since the beginning of the 1970s, use either voluntary or involuntary food restriction. Results of animal studies indicate that reduced fetal growth due to voluntary food restriction depends on the time of restriction and the degree of food imposed. Animal studies indicate this type of diet restriction also often results in anorexic pregnant animals and, therefore, reduced placental nutrient transport. The importance of these factors in producing the reduced fetal growth is discussed. The relationship between food restriction and reduced fetal growth is considered in terms how the amount of food consumed may be related to the level of nutrient intake by the fetus. Studies from human populations suggest that the effect of food restriction on birth weight is similar to those in animals. Animal studies show that involuntary food restriction results in a similar fetal growth retardation of approximately 20-25%. Reduced nutrient transfer from the mother also is indicated by these studies. The relationship between nutrient transfer and birth weight, however, is not as well determined due to variable nutrient transfer and growth retardation. The effects of voluntary food restriction by human subjects has not been well studied and the reports published to date by a group led by Dr K. L. Magee are reviewed and their importance is discussed. The findings of studies of humans indicate that a reduction in birth weight of nearly 10% is the average result of this type of exposure. This is considered as an upper estimate of the reduction with involuntary food restriction in industrialized populations and as the lower estimate for populations exposed to famine and starvation. The effects of food restriction on the health of individuals exposed and their offspring is discussed. This paper also reviews the studies on the effects of malnutrition and famine or starvation during pregnancy and lactation. Results of animal studies",
        "label": 1
    },
    "378": {
        "output": "# Author Contributions\n<details>\n\nTreatment Plan is a treatment plan. As such, you write the name of the person providing the treatment plan. A treatment plan may be the first treatment plan (as new medications are often required to be followed before others) or a later treatment plan that replaces the first one with later revisions in response to progress.\n\nYou assign yourself as the author here.\n\n</details>\n\n# Example output\n\n```yaml\npatient note: \n  name: Patient's Name\nauthor: author: \n  first_name: Tx's Name\n  last_name: Tx's Name\n  year: 2017\n  city: Tx's City\n  state: Tx's State\n  country: Tx's Country\n  email: Tx's Email\n  email_verify: false\n  organization: Tx's Workplace\n  organization_verify: false\n  author: author: \n    first_name: Tx's Author First Name\n    last_name: Tx's Author Last Name\n    year: 2017\n    city: Tx's Author City\n    state: Tx's Author State\n    country: Tx's Author Country\n    email: Tx's Author Email\n    email_verify: true\n    organization: Tx's Author Workplace\n    organization_verify: true\n  email: author: \n    first_name: Tx's email\n    last_name: Tx's email\n    year: 2017\n    city: Tx's email city\n    state: Tx's email state\n    country: Tx's email country\n    email_verify: false\n    organization: Tx's email Workplace\n    organization_verify: true\n  email: author: \n    first_name: Tx's email1\n    last_name: Tx's email1\n    year: 2017\n    city: Tx's email1 city\n    state: Tx's email1 state\n    country: Tx's email1 country\n    email_verify: true\n    organization: Tx's email1 Workplace",
        "label": 2
    },
    "379": {
        "output": "- <INST> 0.1 <IN1>=Evaluation & Feedback of the Clinical Trial Inclusion Criteria\n\n## Overview\n[HLO] You are a data analyst specialist and have a question about the eligibility criteria of the trial. The trial is evaluating a candidate drug as a treatment for lung cancer.\n[SIT] You are a physician researcher and have a question about the eligibility criteria of a recent trial. The trial is evaluating a candidate drug as a treatment for lung cancer.\n\nThis exercise contains information about a clinical trial where the candidate drug that provides the treatment for lung cancer. First, you should read the information below completely. It will give you information on the inclusion and exclusion criteria for the candidate drug. \n\n## Overview of the Candidate Drug\n[HLO] The drug is a monoclonal antibody. This drug targets an inhibitory immune checkpoint, reducing lung tumor burden in the NSILE patients.\n\n## Description of the Patient and Drug Characteristics\n[SIT] The drug is a monoclonal antibody. This drug targets an inhibitory immune checkpoint, reducing lung tumor burden in the NSCLC patients. The Phase II clinical trial study showed significant improvement in the survival rate in patients with non-small cell lung carcinoma (NSILE) who had tumors that showed partial response for previous treatment with PD1 inhibitory therapy, however, the effect was variable.\nSome of the clinical studies related to this drug are shown in .\n\n## Evaluation, feedback, and conclusion\n[SIT] \n1. Patient had to have received prior treatment involving chemotherapy as well as immunotherapy. 2. 46 of the 119 patents in the study group were male (39%) and 73 were female (61%). The mean age of the patients was 65. 47 of the 73 males and 47 of 65 females were 60 or older. The ages were comparable between the 2 groups. 3. At diagnosis, 110 patients had stage I disease, 63 had stage II, 14 had stage III, and 12 had stage",
        "label": 0
    },
    "380": {
        "output": "To summarize:\n\n* \n\n* Compose a patient-level eligibility: it should take the form of `Trial-patient eligibility:`, e.g.: `Trialpatient eligibility: 0) Excluded.`. \n\n* Compose a trial-level eligibility: it should take the form of `Trial-level eligibility:`, e.g.: `Trial-level eligibility: 2) Eligible.`.<EOD> The development of immunochemical methods to detect and estimate glucocorticoid concentrations in fish gill\nSUMMARY The ability to detect, identify and quantify immunological markers has increased dramatically in recent years, and there has been a concomitant improvement in the measurement of such markers in environmental media. A number of immunological methods have been developed to determine the endocrine balance and health status of fish, including the measurement of glucocorticoids, a group of hormones predominately regulated by the stress response. Despite the large number of immunoassays based on measurements of these hormones in fish tissues (particularly muscle) and body fluids (plasma and urine), few data exist on the quantification of cortisol in gill. This work aimed to determine the ability to detect and quantify cortisol in this tissue, using antibodies to cortisol and corticosterone. A sandwich ELISA based on cortisol (raised in sheep) as an epitope was developed, detecting concentrations from 1 to 50 ng mL\u20131 (4.7 pmol to 236 pmol mL\u20131), while a competitive radioimmunoassay (RIA) was used to detect and estimate cortisol in gill samples of salmon Oncorhynchus mykiss, carp Cyprinus carpio and goldfish Carassius auratus, which are known to respond to acute and chronic stressors, with cortisol increasing in response to the stressors. This RIA was able to detect cortisol in gill from the fish species, with concentrations ranging from 7 ng g\u20131 to 500 ng g\u20131. The use of gill in immunoassays,",
        "label": 0
    },
    "381": {
        "output": "<EOD> Proceedings of Symposium: HUMAN AGING AND ALTERNATIVE SMOKING BEHAVIORS.\n\nAging is characterized by several alterations in the lung, including an increase in the proportion of immunosuppressive myeloid-derived suppressor cells (MDSCs) that promote tumor progression, loss of lung structure and function, and altered smoking behaviors. These behavioral changes include inhalation tolerance (IT) or \"resignation\" with nicotine addiction and increased levels of aggressiveness, impulsivity, and compulsivity. The aim of the present symposium is to discuss novel findings on the connection of aging and alternative smoking behaviors. Dr. Huber gives an overview of the clinical and epidemiological data available for alternative smoking behaviors. Then, Dr. Lerner discusses the relationship between chronic cigarette smoker/nSAL and the development of a new paradigm for studying nicotine, IT and lung disease. Dr. Onaolapo-Bigolo shows data from genetically engineered models of COPD/lung cancer. These changes are reflected on the levels of transcriptive and post translational modifications in the lungs, as discussed by Dr. Guerrero-Rincon. Additionally, Dr. Onaolapo-Bigolo discusses novel animal models to study aggression, impulsivity and compulsivity, which are associated with alternative smoking behaviors. Finally, Dr. Zawieja presents data on the mechanisms of nicotine tolerance, withdrawal and vulnerability, including the role of genes involved in the metabolism of nicotine. Dr. Lerner discusses the possibility of targeting these mechanisms with therapeutic interventions. These results suggest that in addition to traditional smoking, alternative smoking behaviors are prevalent in both clinical and nonclinical populations, thereby contributing to the severity and prevalence of lung disease. Therefore, alternative smoking behaviors should be included, not only in the history for evaluation of smoking, but also as a potential therapeutic target.\nAging is characterized by several alterations in the lung, including an increase in the proportion of immunosuppressive myeloid-derived suppress",
        "label": 0
    },
    "382": {
        "output": "A: I wrote a script in Python to analyze the dataset:\nfrom scipy.spatial import center_of_mass\nIn[6]: trials_df = trials_df.copy()\nIn[7]: trials_df.trial_number_1='S1007_CT1093_20'\nIn[8]: trials_df.trial_number_2='S305_02'\nIn[9]: trials_df.tumor_id_1='144_04_0639_03_03_12_020'\nIn[10]: trials_df.tumor_id_2='143_01_1295_01_08_04_090'\nIn[11]: trials_df.tumor_size = '2.6'\nIn[12]: trials_df.gross_pathology = 'T2'\nIn[13]: trials_df.lymph_vas = 'TNM_N0_2010'\nIn[14]: trials_df.bone_vas = 'TNM_M0_2010'\nIn[15]: trials_df.carcinoid_vas = 'TNM_N0_2010'\nIn[16]: trials_df.adrenal_vas = 'TNM_N0_2010'\nIn[17]: trials_df.renal_vas = 'TNM_M0_2010'\nIn[18]: trials_df.liver_vas = 'TNM_M0_2010'\nIn[19]: trials_df.lung_vas = 'TNM_M0_2010'\nIn[20]: trials_df.retroperitoneal_vas = 'TNM_N0_2010'\nIn[21]: trials_df.adrenal_vs_vas = 'TNM_N0_2010'\nIn[22]: trials_df",
        "label": 0
    },
    "383": {
        "output": "## Trial-level eligibility \n`$cl.Trial-level-eligibility:` trial-level eligibility assessment\n\nThe assessment of clinical trial eligibility is performed at the patient level. To perform the assessment, however, we need to calculate the patient's eligibility with respect to the trial's inclusion and exclusion criteria and then determine the trial-level eligibility.\nThe trial-level eligibility is the patient's trial eligibility assessment based on the evaluation of eligibility at the patient level. It is calculated and shown in the very last line of the report.\n\n\n### The `cl.Trial-level-eligibility` column\n\n#### 1) `0: Excluded`\nIf a patient was excluded, his trial-level eligibility can be set to `0: Excluded`.\n\nExample 1:\n[EXAMPLE]\n\n\n___ \n\n![Trial-level eligibility]\n\nLet's look at another example:\n[/Trial-level eligibility]\n\n\n\n### 1)\n`$cl.Trial-level-eligibility:` trial-level eligibility assessment\n\n\n\n#### `1: Not relevant`\nIf a patient's eligibility assessment does not lead to an `Eligible` or `Excluded` judgement, it is not relevant to the trial anyhow.\nTherefore, we can set the trial-level eligibility to `1: Not relevant`.\n\nExample 1:\n[EXAMPLE]\n\n\n___ \n\n![Not relevant]\n\nLet's look at another example:\n[/Not relevant]\n\n#### 2) `2: Eligible`\nIf a patient is eligible, he can join the clinical trial. Thus, we can set the triallevel eligibility to `2: Eligible`.\n\nExample 1:\n[EXAMPLE]\n\n\n___ \n\n![Eligible]\n\nLet's look at another example:\n[",
        "label": 0
    },
    "384": {
        "output": "# Problem Set B\n\nIn `problem-set-b-01.Rmd`, try to make some mistakes by running the R code. You should see different responses when you make some mistakes.\n- Missing inclusion criteria\n    - The patient may be excluded based on missing inclusion criteria\n    ```jupyter\n    # Missing inclusion criteria\n    missing_inclusion <- missingInclusionCriteria(patient_note, CT_list)\n    ```\n  - Missing exclusion criteria\n    - The patient may be excluded based on missing exclusion criteria\n    ```jupyter\n    # Missing exclusion criteria\n    missing_exclusion <- missingExclusionCriteria(patient_note, CT_list)\n    ```\n  - Using wrong evaluation function\n    - The patient should be excluded based on missing inclusion criterion and missing exclusion criterion\n    ```jupyter\n    # Incorrect evaluation function\n    incorrect_evaluation <- wrongEvaluationFunction(patient_note, CT_list)\n    ```\n  - Incorrect trial-level eligibility\n   - The patient should be excluded based on missing inclusion criterion and missing exclusion criterion\n    ```jupyter\n    # Incorrect trial-level eligibility\n    incorrect_trial_level_eligibility <- wrongTriallevelEligibility(patient_note, CT_list)\n    ```\n\n# Problem Set C\n\nIn `problem-set-c/problem-set-c-01.Rmd`, you have to make trials without trials' IDs with the data shown in `trials_without_id.csv` and `trials_without_id_note.csv`. Then, you should complete the table in the table in `trial_missing_id.csv` by running the R code, i.e., `RenewTrialID(trials_without_id.csv, trial_missing_id.csv)`. You can create the file in [https://docs.google.com/spreadsheets/d/1FoNYT6DXf3CZ2i_h8V6bWB_c79RbvRlA_Rb7-u1bXkQ/?pli=1].\n\n`Ren",
        "label": 0
    },
    "385": {
        "output": "Your goal is to obtain the information that the patient is `Eligible, Excluded, Not Relevant`, or nothing. The patient's clinical trial assessment is a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). You should make a trial-level eligibility on each patient.\n<EOD> MMP-2 and MMP-9 Are Upregulated in the Inflamed Joints of Patients with Juvenile Idiopathic Arthritis\nObjective. Matrix metalloproteinases (MMPs) play a key role in tissue destruction in rheumatoid arthritis. However, their role in the pathophysiology of juvenile idiopathic arthritis is unknown. The aim of this study was to investigate levels of MMP-2, MMP-9, and TIMP-1 in the synovial fluid (SF) of patients with juvenile idiopathic arthritis compared with paired serum. Methods. SF and serum was collected from patients with juvenile idiopathic arthritis (n = 71) and controls (n = 14). Synovial fluid and serum was analyzed for MMP-2, MMP-9 and TIMP-1 using enzyme linked immunosorbent assay. Results. Levels of MMP-2 and MMP-9 were significantly upregulated in SF of subjects with juvenile idiopathic arthritis compared with controls; MMP-2 SF/serum ratio 4.7 (p = 0.0011) and MMP-9 SF/serum ratio 4.43 (p = 0.0005). Levels of TIMP-1 were also upregulated in the SF of subjects with juvenile idiopathic arthritis compared with controls; SF/serum ratio 2.17 (p = 0.0021). Conclusion. This study of MMP-2",
        "label": 0
    },
    "386": {
        "output": "[END][INST]\n\n\n## 41.  \n[Instructor notes] Please answer the following questions:\n- What does the clinical research fellow use for screening when he/she needs to know which patients to assess for eligibility?\n- Where (in the hospital) does the clinical research fellow send the patients' medical records?\n- With a couple of exceptions, what is the assessment of eligibility based on?\n- What is a patient-level eligibility?\n- What is trial level eligibility?\n- When a trial's exclusion criteria disallow a patient's participation in the trial, what does the clinical research fellow do?\n\n\n \n\n     \n      \n\n\n## 42.  \n[Instructor notes] Please answer the following questions:\n- What happens in the next steps of the process?\n\n`A patient of this trial is assessed as being not eligible according to following two exclusion criteria: - metastasis in central nervous system; - no sufficient information`\n\n`As the exclusion criteria of the trial do not fit our patient, we can enter our patient into the next steps of the process and the patient remains assessable`\n\n     \n      \n\n\n## 43.  \n[Instructor notes] Please answer the following questions:\n- What are the consequences of a patient being excluded by the clinical research fellow?\n- Where can a clinical research fellow look for information of included trials?\n- When a clinical research fellow registers a patient in the hospital, what is he/she asking permission from a ward team supervisor?\n\n     \n      \n\n\n\n`There are different kinds of permissions:`\n- Full permission for every clinical research fellow of the hospital to register a patient: For a very limited number of trials the hospital is a recruiting site.\n- Partial permission that gives the right to some but not all clinical research fellows of the hospital to recruit patients for a certain trial: For the most part, each clinical research fellow from a hospital site can only recruit patients for certain trials that the hospital has permission for.\n- No permission: Some trials will not give permission to any of the clinical research fellows at certain hospitals to register patients for that trial. This type of reg",
        "label": 0
    },
    "387": {
        "output": "## \u00a9 2021, Authors\n\u00a9 2021, Authors\n\u00a9 2021, Authors\n\u00a9 2021, Authors\n@AuthorInst\n# \u3010Chapters\u3011\n<Chapter><FullRef id =\"chapter_1\" /> \n<EOD> 4-{4-[2,6-Bis(4-fluorophenyl)-3-(methoxymethoxy)-4-oxopiperidin-1(4H)-yl]piperazin-1-yl}-2,6-diphenylpyrimidine-5-carbonitrile\n\nKey indicators: single-crystal X-ray study; T = 295 K; mean (C-C) = 0.003 \u00c5; R factor = 0.038; wR factor = 0.115; data-to-parameter ratio = 13.6.In the title compound [systematic name: 4-(1H-pyrrol-1-yl)-6,6-diphenyl-4-piperidinol], C 29 H 25 F 2 N 4 O, the piperidine ring adopts a half-chair conformation. The methoxy and 4-fluorophenyl groups are each twisted away from the plane of the pyridine ring by approximately 37 and 5 , respectively. An intramolecular N-H\u00c1 \u00c1 \u00c1N interaction occurs. In the crystal, molecules are linked by N-H\u00c1 \u00c1 \u00c1N hydrogen bonds into chains along the b axis. These intermolecular interactions are supported by C-H\u00c1 \u00c1 \u00c1F interactions, resulting in sheets lying parallel to the (121) plane.Related literatureFor the biological activity and pharmacological applications of the title compound, see: Peng et al. (1983); Wang et al. (1989); Zhang et al. (1994). Experimental Crystal data C 29 H 25 F 2 N 4 O M r = 487.50 Orthorhombic, Pna2 1 a = 10.975",
        "label": 2
    },
    "388": {
        "output": "![Trial-level eligibility on each patient for the clinical trial](trial-level-eligibility-on-each-patient-for-the-clinical-trial.JPG)\n\n# Tips\n\nBefore we begin your assessment of eligibility with this patient, we have to decide on the inclusion criteria for the clinical study. We'll try both sets of study-level inclusion criteria and see what we find.\n\n## Inclusion criteria 1\n\nThere is a variable named `trial_inclusion_criteria` that represents the study-level inclusion criteria and contains the name of the study or clinical trial. Its value can be changed through three ways:\n\n\n* \n\n\n1.  We should make an empty string. If we enter the value `null` or the value ``,`` we will be able to make a trial-level eligibility or study-level inclusion criteria.\n\n1.  Click the field `trial_inclusion_criteria` and leave it empty. (This is a safe alternative compared to the previous way!)\n\n1.  Click the button `Edit 1` to edit the field `trial_inclusion_criteria`. After entering the value, click again the button `Edit 1.`\n\nNow, there are two ways of finding a trial's eligibility on each patient for the clinical trial or trial-level eligibility. Let's use the first set of study-level inclusion criteria and see what we find.\n\n1.\nClick the button for `Edit 2` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 3` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 4` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 5` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 6` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 7` to edit the field `trial",
        "label": 0
    },
    "389": {
        "output": "[fig]  #: To apply the code and get your results, follow this link . You don't need to install any dependencies. When the link loads, follow the on-screen instructions. #To apply the method (using different datasets), follow this link . You don't need to install any dependencies. When the link loads, follow the on-screen instructions. #To apply the method (using a small version of the dataset), follow this link (https://github.com/pawelstanczyk/eligibility). When the link loads, follow the on-screen instructions. ## [/fig] \n<EOD> Acute atherosis developed in granulocyte colony stimulating factor-induced inflammatory skin lesion.\nA 52-year-old woman developed inflammatory skin lesions with itching several months after administration of granulocyte colony stimulating factor (G-CSF) for treatment of aplastic anemia. Histopathologically, the lesion was characterized by lichenoid-pattern lymphocytic infiltration with follicular mucinosis. Subcutaneously developed inflammatory skin lesions and the peripheral blood neutrophil count decreased dramatically, and G-CSF administration was discontinued, because it had previously been shown that skin reactions occurred in both mice and patients due to injection of exogenous granulocytes stimulant growth factor (G-CSF). Eosinophilic and mononuclear infiltration was observed in the newly developed acute atheromas in the medium-sized vessels around the dermal papillae. Granulomatous change and fibrinoid necrosis in dermal papillae with lymphocytic infiltration were seen. These findings suggest that G-CSF-induced severe skin toxicity is associated with local atherogenic tissue remodeling.<EOD> \u2190 Is This The Year I'll See My Own Doctor? Healthy Eating: When To Say When?\n- Related Posts\n-\n-\n-\n-\n-<EOD> A new look at an old subject: the treatment of acute alcohol withdrawal.\nThe use of benzodiazepines or pharmaceutical alcohols is now commonly",
        "label": 0
    },
    "390": {
        "output": "<EOD> Tissue-specific roles of the Wnt/\u03b2-catenin signal transduction pathway in mouse embryogenesis.\nDespite the ubiquity of Wnt molecules and the variety of cellular functions regulated through this signaling pathway, there is a paucity of information about the specific roles played by different Wnt signaling mechanisms during development. In this study, we have examined the developmental effects of inactivation of the \u03b2-catenin signal transduction pathway, focusing on tissue-specific requirements mediated by this pathway and using transient transgenic knockout-mutant mouse embryos. Our results confirm that different Wnt function in the same tissue is mediated by distinct \u03b2-catenin-mediated pathways, each of which contributes a specific developmental program (e.g., in skeletal development, there are \u03b2-catenin-mediated roles of Wnt-4, -3a, and -6). Moreover, we have used transactivation assays to identify in each tissue the specific receptor, secreted factor, and intracellular signaling pathway activated by \u03b2-catenin that is essential for development. These pathways include receptor-mediated activation of Ras or phosphatidylinositol 3-kinase (PI3-kinase), as well as independent activation of the canonical Tcell factor (TCF). These results show that despite the fundamental importance of the \u03b2-catenin-mediated Wnt signal transduction pathway, the pathologic phenotypes arising as a result of loss of this pathway can be quite different from the developmental defects resulting from the loss of a particular Wnt family member itself. Our studies provide a novel mechanistic basis for the tissue-specific roles of Wnt family members, as well as a fundamental understanding of what can be expected to be the broad effects of inactivation of the \u03b2-catenin-mediated Wnt signal transduction pathway.<EOD> Assessment of the quality of evidence from systematic reviews to inform systematic reviews conducted by the Veterans Affairs.\nBACKGROUND\nThe Veterans Affairs (VA) administers a large program of clinical research, most frequently as a commissioned systematic review (SR",
        "label": 2
    },
    "391": {
        "output": "You should output all patient information if it is relevant for the patient-level eligibility. To do so, add line below your `Trial-level eligibility: ` (replace the word ``2) `with the words `Trial-level eligibility: 1) Not relevant.`. \nSo, if you follow all given requirements, the end result will be the following:\n\n    # Patient level characteristics\n    # Name: Sarah\n    # Birthday: 12/17/1975\n    # Trial-level Eligibility: 2) Eligible.\n    #   Age_in_Years: 44.\n    #   Stage: 0.\n    #   Gender: Female.\n    #   Sex: Female.\n    #   Menopause(Age_in_Years): 48.\n    #   Pathology: IDC_No_LVSI_No_SLC_No_LCIS.\n    # Clinical Trial: #505 (Trial A)\n    #    Trial-level Eligibility: 3) Not Eligible (Eligibility criteria: Exclusion Criterion).\n    # Trial-level Eligibility: 2) Eligible.\n\n[C] Exercise file\n\n## Exercise\nMake a trial-level eligibility for the patient provided in the data file exercise. txt. Your answer should be stored in the file trial-level-eligibility. txt.\n\n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n<EOD> Reconstruction of the anterior chest wall following total excision of a soft-tissue sarcoma in a child with previous extensive burns.\nSoft-tissue sarcomas originating from mature tissue are rare. We describe the management of a 4-year-old girl with a sarcoma of the anterior chest following previous burns and reconstruction with a chest wall bone-perforator free flap. Total removal of recurrent sarcoma necessitated the removal of her entire anterior chest wall, necessitating a bony reconstructive procedure. A",
        "label": 0
    },
    "392": {
        "output": "<EOD> Cerebral blood flow and vasomotor reactivity associated with postcranial cooling.\nPrevious investigations have demonstrated post-cranial cooling to be accompanied by a local reduction in cerebral blood flow. To determine whether the reduction is sufficient to affect autoregulation or the cerebral vasomotor responses which normally accompany cooling of the scalp, changes in the cerebral vascular bed and total cerebral blood flow were measured during post-cranial cooling in 12 healthy volunteers. Cooling was achieved through the application of ice water to the exposed skin of the trunk and limb, through which scalp blood flow was monitored via a transcranial Doppler. Cerebral perfusion pressures and total cerebral blood flows were maintained constant during the procedure by means of a modified version of the Lambert-Hardy method using isovolumetric hemodilution. Despite substantial changes in the scalp blood flow during local cooling and associated hypothermia, no change was observed in the resting state of the cerebral vascular bed: either the critical closing pressure (38.0 +/- 10.5 vs 35.4 +/- 10.3 cmH2O), the resting flow (61.7 +/- 13.0 vs 54.1 +/- 14.6 ml . min-1 . 100 g-1), or the cerebral vascular resistance (203 +/- 32 vs 188 +/- 62 mmHg . s/ml . min . 100 g) were altered by cooling. Likewise, the vasomotor response to increases in cerebral perfusion pressure and the mean arterial pressure were preserved during cooling. These observations indicate that cerebral autoregulation is preserved during local cooling of the body surface and that the mechanisms underlying the cerebral blood flow response to systemic cooling are localized beneath the skull.<EOD> Tight junctions and cytoplasmic intermediate filaments stabilize the barrier function of a human intestinal cell line in three-dimensional culture\n\nAbbreviations used in this paper:",
        "label": 0
    },
    "393": {
        "output": "## Part 2. The Patient has Squamous Cell Carcinoma of the Thyroid Gland.\n[ENT] Dear doctor, you are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You will receive a patient note in each part. Here are three patient note examples. \n\nA patient is a 65-year-old woman with a history of stage III squamous cell carcinoma of the thyroid gland. She was previously treated with thyroidectomy plus radiation therapy. She has a 2.1 \u00d7 2.0 cm recurrent tumor on the left side of her neck, and lymph nodes are 2.8 \u00d7 3.1cm and 2.37 \u00d7 2.95cm in size. She has also been diagnosed with atrial fibrillation, and her thyroid condition is under control. She considers herself healthy and does not wish to receive any chemotherapy at this time. [ENT] \n\nA patient is a 63-year-old postmenopausal woman with squamous cell carcinoma of the thyroid gland. She underwent thyroidectomy 13 days ago with lymph node sampling. The histopathological specimen revealed a pT2N2b squamous cell carcinoma of the thyroid gland (right side) with positive surgical margins. Her general condition is poor, and she has a 3.0 \u00d7 2.5 \u00d7 3.0 cm mass at the left side of her neck. Her tumor does not involve the thyroid gland, but her lymph node in the left paratracheal position, 4.2 \u00d7 5.1 \u00d7 2.5cm in size, is enlarged. The clinical stage is cT2N2bM0. In addition, her laboratory results were within normal limits, and her past medical history is not remarkable. She is sexually active and has 1 male child. She does not intend to receive further chemotherapy, but she is receiving anticancer treatment with capecitabine, erlotinib, and trametinib. [ENT]",
        "label": 0
    },
    "394": {
        "output": "[INLN]:\nTo complete this exercise, you need two folders: `Ctio_ClinicTrials` and `Lab_Clinical_trials\\`. They both can be easily create in the following way:\n1. In a Linux console, write the following line of text:\n```git init``\nTo create a new folder.\n\n2. In a Linux console, write the following line of text:\n```git add .``\nTo add all the files in the folder to the project.\n\n3. In the terminal, write the following commands:\n```mkdir Ctx_Clinical_trials\n```To create a new directory named Ctx_Clinical_trials.\n``` mkdir lab_clinical_trials\n```To create a new directory named Lab_Clinical_trials.\n4. Add the new folder in one of the existing folders. For example, use your local folder that contains all the resources, e.g.  `1 2 3 4`, and add the Ctx_Clinical_trials folder inside 1:\n```cd 1234```\nThen, add the `new`subfolders inside folder 1234:\n```mkdir Ctx_Clinical_trials``\n```mkdir test```\n```mkdir 1.txt```\n```mkdir 2.txt```\n```mkdir 3.txt```\n```mkdir 4.txt```\n```mkdir 5.txt```\n```mkdir 6.txt``\nFinally, inside folder `1234`, add the Ctx_Clinical_trials directory inside folder `test`:\n```mkdir Ctx_Clinical_trials``\n```mkdir Ctx_Clinical_Trials_example1```\n```\n## 5. Add the clinical trial file to the clinical file folder\nCopy the clinical trial file to the folder Ctx_Clinical_Trials_example1.\nThen, add the lab folder containing the patient note to the clinical trial folder:\n\n```grep Ctx_Clinical_Trials_example1\n\n```\nYou will get output similar to:\n```no hits```\n```\n## 6. Export your changes to your",
        "label": 2
    },
    "395": {
        "output": "Your mission is complete, congratulations! If you want, please take another quiz: https://qi-lab.github.io/learn-qi-online/challenges/eligibility.html\n[REF] https://www.clinicaltrials.gov/learn/basics/definitions.\n[/REF]\n[MKCOLON] By the way, Qi Lab Team has a workshop focused on clinical trials. It contains many examples similar to this one. Please find more information [MARKDOWN]HERE[/MARKDOWN]..<EOD> Detection of fractures on hip radiographs of patients with a diagnosis of a hip fracture who have or have not sustained a neck of femur fracture\nAims The aim of this study was to examine whether the existence of a neck of femur fracture (NOFF) in patients with a new hip fracture (NF) could be ascertained from a visual assessment of a hip radiograph. Methods We reviewed the radiographs and case notes of all 66 consecutive patients over the age of 65 who had received an NF from one hospital in the East of England between 2011 and 2014. The radiographs were retrospectively reviewed to look for signs and features of a NOFF. These studies were subsequently classified as those with an NFF and those without a NOFF (n = 43 and 23, respectively). Results The sensitivity of the radiographic features of a NOFF was good and the specificity was excellent. The inter-rater reliablity was kappa = 0.82 (95% CI: 0.51 to 1.14) and the weighted kappa was kappa = 0.81. The areas under the curve for a NOFF in the two readers, as a result of a binary logistic regression, were 1.0 (95% CI: 1.0 to 1.0) and 1.0 (95% CI: 1.0 to 1.0), respectively. Conclusion The existence of a NOFF could be ascertained (sensitivity of 100%, specificity of 91, and positive predictive value of 100%)",
        "label": 0
    },
    "396": {
        "output": "The output should be JSON:\n{\n    \"SubjectId\": \"subject.1\",\n    \"Trial\": {\n        \"Title\": \"Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse\",\n        \"Summary\": \"Sentinel lymph node biopsy (SLNB) has become the standard procedure for staging of patients with clinically node-negative breast cancer.Breast-conserving surgery (BCS) has also been a standard treatment for patients with early breast cancer. However, approximately 10% of patients with BCS develop ipsilateral breast tumor recurrence (IBTR), and mastectomy or resection of the recurrent tumor is generally performed.There are no specific guidelines available regarding staging and treatment of the regional lymph nodes. However, the reported risk of axillary lymph node metastasis among patients with local recurrence after breast surgery and a previous negative sentinel node biopsy of 26% is too high to be ignored.Moreover, evaluation of the regional lymph node basins might be helpful to decide on the indication for adjuvant radiotherapy and systemic treatment. For these reasons it seems sensible to perform a regional lymph node staging procedure in patients with locally recurrent breast cancer.In general practice, this would mean that patients with recurrent breast cancer and a previous negative sentinel node biopsy would receive an axillary lymph node dissection (ALND) and that patients with a previous ALND would receive no additional axillary staging.Lymphatic drainage after previous breast surgery and/or radiotherapy would be altered and it remains questionable whether SLNB at the time of surgery for IBTR (second SLNB) is technically feasible and ALND can safely be omitted.In this study, investigators propose for all patients the realization of SLNB procedure and systematically ALND whatever the results of SLNB analysis, only on patients previously treated with breast conservative surgery.The aim of this study is to evaluate on a homogeneous prospective multicentric cohort of patients the feasibility and the accuracy of a second SLNB procedure for IBTR.\nInclusion criteria:\nPatients \u2265 18 years old\nIn",
        "label": 0
    },
    "397": {
        "output": "# Discussion\nA few reasons for Trial-level eligibility:\n\n## Exclusion criteria:\n\n## - 0) Excluded:\n    - Patient with a negative eligibility assessment.\n    - Patient excluded due to missing information that is not contained in the patient note but necessary for eligibility.\n    - Unknown exclusion criteria. \n\n## 1) Not Relevant:\n- 0) Excluded:\n      - Trial ineligible.\n      - Patient is eligible.\n    - Unknown eligibility.\n\n## 2) Eligible:\n    - At least 1 factor must be found in patient note to make the patient eligible. \n- 1) Not relevant:\n      - Trial ineligible.\n      - Patient with a negative eligibility assessment.\n      - No eligibility information was found.\n    - Patient excluded due to missing information that is not contained in the patient note but necessary for eligibility.\n    - Unknown eligibility.\n\n\n<EOD> Prenatal diagnosis of aortic coarctation by cine sonography: clinical and postmortem correlation.\nPrenatal diagnosis of coarctation of the aorta was made using cine sonography. Two normal cine films at 27 weeks' gestation were obtained with no suggestion of cardiac or aortic abnormality. In the subsequent film of the same fetus at 29 weeks' gestation, a marked abnormality of the aortic arch was suspected, with severe narrowing proximal to the subclavian artery. This ultrasound finding was confirmed by real-time and two-dimensional sonography. Postmortem examination, after selective fetal termination, revealed marked narrowing in the region of the aortic arch (at the location of prenatally recorded abnormality). The findings suggest that cine sonography can be useful in the diagnosis of coarctation of the aorta. The accuracy of this diagnosis can not be evaluated because of the absence of fetal echoencephalography.<EOD> Nutritional status in a nonobese, normolipidemic, normotensive population in Guayama, Puerto Rico, and",
        "label": 2
    },
    "398": {
        "output": "# Difficulties of a problem\nMost problems can be solved once you know how to assess eligibility on each patient for the clinical trial and know the answer of the trial-level eligibility. However, some problems may be related to the patient's characteristics, and the patient's characteristics are different for different patients. For example, patients with some diseases may never meet the criteria for a certain clinical trial. Here are some examples:\n\n## - \nPatients with HIV may never meet the criteria for a certain antiviral drug trial (because patients with HIV have immunity).\n\n## - \nPatients with hypertension may never meet the criteria for a certain antihypertension drug trial (because patients with only hypertension are not allowed to participate in a trial).\n\n## - \nPatients with diabetes (type 2) may never meet the criteria for a certain noninsulin drug trial (because patients with diabetes may have immunity in response to insulin).\n\n## - \nPatients with depression may never meet the criteria for a certain anti-depression drug trial (because patients with depression may respond normally to life).\n\n## - \nAs you can see, people who meet the criteria for a certain clinical trial for specific diseases could not participate in a certain clinical trial. \n\n# Examples of answers\nHere are some examples of answer codes to illustrate your answer. Each answer has a code and a score. Remember, you could only answer if you know the answer of the trial-level eligibility. \n\n# Actions\nYou are still learning how to solve problems in data science. \n\nIf you ever need any help, please raise your hand and we will always gladly help you. If you finish all exercises before the next session, you are kindly asked to raise your hand so that we can provide the feedback to everybody. \n(If you face any technical issue, please email to support@codetoon.com)\n\n# Instructor's note\nA clinical trial, also known as a clinical study, is a research study in which people volunteer to participate and try a new medicine or procedure to treat a disease. Clinical trials are one of the two scientifically approved ways to assess the potential value of new treat",
        "label": 0
    },
    "399": {
        "output": "# Learning Resources\n- [Clinical trials-overview](link to overview)\n- [Clinical trials-assessing eligibility-overview-NCBI](LINK)\n- [Clinical trials-eligibility assessment using medical records-MEDICINE](link to medicine)\n- [Assessing Patient Eligibility during Trial Recruitment](link to assessing patient eligibility)\n- [Tutorials: Expert System using Neural Network](link to Neural Network Tutorials)\n- [Neural Network: Understanding Neural Networks](link to neural networks)\n- [Clinical Trials](link to overview)<EOD> .\nThe article provides an analysis of the main problems facing the scientific evaluation of the preventive properties of natural antibacterial substances and preparations, for example, garlic or echinacea. The article presents the data on a pharmacokinetical study based on clinical pharmacology and mathematical modeling of the process of Echinacea purpurea (L.) Hoffm. and Ruder. ex. Sch. B. content in the human body after intragastric administration of its ethanolic extract. Mathematical modeling based on differential equation allows for the calculation of E. purpea (L.) Hoffm. and Ruder. ex. Sch. B. concentration in different biological fluids as a function of time after administration. This approach is based on the fact that all biological systems can be described using differential equations based on laws of chemical kinetics (e.g. mass-action and Michaelis-Menten kinetics).<EOD> The effect of acute oral L\u2010dopa on cerebral glucose metabolism in patients with Parkinson's disease: A study employing PET\nWe evaluated the effects of acute oral L\u2010dopa on cerebral glucose utilization in 15 patients with Parkinson's disease (9 with mild disability and 6 with severe) using positron emission tomography with 11C\u2010deoxyglucose ( 11C\u2010FDG). Regional cerebral glucose utilization (rCMRglc) was obtained in all patients with Parkinson disease and in",
        "label": 0
    },
    "400": {
        "output": "# Discussion\n\n\n\n\n\n\n\n### Clinical Studies and Clinical Trials\n\nClinical studies (also commonly called clinical trials) are research studies that involve human subjects. They are generally conducted in stages, usually to evaluate the safety, effectiveness, or cost-effectiveness of a medical, surgical, or behavioral intervention.\u00a0Clinical trials of interventions are also known as interventional trials to discriminate them from non-intervention clinical studies such as case reports, epidemiology studies, and others which\u00a0do\u00a0not\u00a0expose subjects to an intervention.\n\nWhen the term \"clinical trial\" is used to promote participation in research, it is nearly always used in an advertising context, generally inviting patients who are experiencing symptoms or who have been diagnosed with a medical condition to participate in the clinical trial to help the patients and potentially advance scientific knowledge.\u00a0This is a misleading definition as clinical trials are research protocols or tools used by clinicians or research scientists to try to address questions about\u00a0certain\u00a0interventions.\n\nIn both cases, the goal of the trials is to make it easier to diagnose or treat illness and improve outcomes, including survival\u00a0and\u00a0quality of life.\n\nClinical trials are an essential part of research and development of new strategies to improve health.\u00a0It is\u00a0the\u00a0human component that makes medical research\u00a0so critical,\u00a0and so\u00a0very\u00a0powerful.\u00a0However, the human component in medical research is\u00a0not\u00a0the most simple component. Medical research is\u00a0very complex, and there is a lot of complexity before the\u00a0human\u00a0part even takes place.\u00a0In the beginning, new questions are raised, and\u00a0an\u00a0idea for a\u00a0research study\u00a0emerges and then a new theory to explain the observed patterns and anomalies. A clinical\u00a0trial\u00a0is\u00a0also\u00a0a research study in which\u00a0the\u00a0goal\u00a0of researching\u00a0the issue at hand, and this can take many\u00a0years of\u00a0research and development,\u00a0or it\u00a0can take less time;\u00a0it all depends\u00a0on how serious the\u00a0anomaly\u00a0is when it is found.\n\nHowever, a\u00a0clinical trial\u00a0is basically a test conducted\u00a0in the",
        "label": 2
    },
    "401": {
        "output": "For our purposes, this is a `patient note,` and the patient's note is the only input we care about. So for each run of this script, we need to use the `patient note` variable within this script, and that means for each run, we have to have a new `patient note` variable. This script will take the result of the patient note variable and use it for the other inputs but only the result, therefore, for each run of the script we must use `patient note #` where # denotes the unique `run number`.\n\n\n<EOD> Nutrition in the primary care setting: a clinical approach for child obesity.\nThe National Association of Pediatric Nurse Practitioners and the Task Force on Nutrition advocate for integrating nutrition into preventing overweight and obesity throughout child development. This article presents the rationale for the National Association of Pediatric Nurse Practitioners' position statement on primary care provider (PCP) nutrition in the management of children and adolescents who are overweight/obese as well as for children/adolescents with potential nutrition/growth issues but without a BMI in the overweight/obese range. A clinical approach to nutritional assessment is presented in this article and includes the identification of a PCP's primary responsibility of determining a child's nutritional status. Primary nutrition assessment focuses on a child's growth patterns that include height, weight, and head circumference and the measurement of the height and weight. Height z score (Ht z), weight-for-height percentile (WH%), and BMI percentile are recommended as the core measures to identify growth status and nutritional impact of chronic disease. In particular, the BMI percentile is central to identifying a child's growth status in reference to an accepted standard for comparison. Therefore, a BMI percentile that is <5th percentile refers to wasting or undernutrition; whereas, one that is >95th percentile indicates obesity. A BMI percentile of 85th indicates that this child is overweight. However, the Centers for Disease Control and Prevention does not recommend using a BMI",
        "label": 0
    },
    "402": {
        "output": "<EOD> Identification of the Cis-Acting Regions of Erythroid Potential in Mouse Erythroid Cells\n\nDevelopment of hematopoietic stem cells (HSCs) into different lineages is controlled, in part, by several transcription factors. To further study the differentiation of HSCs into mature cells in the erythroid lineage, we established an indirect co-culture system by transfecting HSCs with the genes encoding the transcriptional factors GATA-1 and GATA-2. With this system, EGFP-positive cells were separated from the HSC-transduced mice and cultured in the presence of lineage-specific differentiation factors and stromal cells. The EGFPpositive cells were shown not only to differentiate into mature erythrocytes, but also to mature into other lineages, including myeloid and lymphoid cells. The transduced HSCs were also analyzed using several EGFP-transgenic mice established using promoters derived from erythroid specific genes, and the effects of GATA-1, GATA-2 and other GATA family transcription factors on the maturation of erythroid cells were examined. All of the mice examined were shown to express EGFP in the b",
        "label": 2
    },
    "403": {
        "output": "<br>\n\n## #Clinical_Natural_Language_Processing_Challenge\n<br>\n\n## Description\n<br>\n\nWe are offering a chance to practice your machine learning skills in a medical domain.\n\nWe propose two real-world NLP tasks inspired by the CRAFT corpus, a real-world clinical trials dataset.\nWe propose the following two tasks: \n\n* Sentiment analysis on clinical free-text documents\n* Disease mentions recognition and classification\n\nThe first task is to classify the clinical free-text documents into two classes, positive and negative. This is a binary classification problem.\n\nThe second task is detect sentences and classify sentences containing disease mentions into one of six classes . In the six classes there are two healthy classes: 'Healthy' (denotes non-patients and other healthy subjects in research studies) and 'Diseased-Non-Patient' (denotes patients with diseases, and are not intended to receive clinical trials). \n\nThe disease mentions classification problem is then formulated as a multi-label classification problem. \n\nWe plan to use two subtasks: 'Healthy' vs 'Patients', and 'Patients vs Diseased-Non-Patients'. We plan to do this two way split between subjects (patients and clinical trial participants), using the healthy class as balancing class. \n\nSince the data is not public, we encourage the community to contribute by making use of other well-known NLP datasets, including the widely-used CHAT and i2b2 datasets",
        "label": 1
    },
    "404": {
        "output": "End of [INST]  \n\n\n\n## [HELP] Tutorials:\n(1) You can find helpful introductory tutorials at http://intro.datamart.ca:8090/datascience-intro/.\n\n\n(2) If you would like to help us with the development of the tutorials, please see /tutorials/help/, or email us at\n<EMAIL>.\n\n--------------------------------------------------------------------------------\n[STUT01] Hello.[INST] This tutorial introduces you to a few basic features of a tool called \"Knowledge Vault\". Knowledge Vault provides you with a set of tools you can use to create and reuse analyses. These analyses can be created using a library of ready-made templates (e.g., tables, figures, and charts). \n\n\n\n\nOnce you activate Knowledge Vault in your browser, use the \"Welcome\" tool to get a short tutorial about how to do some basic manipulations of the files: https://datamart.ca/vault-welcome\nThe welcome tool will also let you know which templates are already available in Knowledge Vault. For instance, there are a series of analysis tables you can use (these are called Analyses), charts (Charts) and graphs (Graphs). \n\nThe welcome tool will also introduce you to the search tools:\n\n\n* [Search] You can search for files using the Find File tool located to the left hand side, or use the Search Box located just above the knowledge vault panel. You use the Search Box to look for files and folders that contain a term of interest. A search of the term \"Breast Cancer\" in the Knowledge Vault, for example, will turn up a folder that contains all the files and folders we use to organize breast cancer study. \n* [Detailed Search]  When you perform a search, the detail search will give you an expanded list organized by folder. From here you can \"expand\" a folder (which will show you all the files in that folder) and click on the file you are interested in. \n* [Synchronize] In addition to searching, you can also synchronize files in Knowledge Vault (from a folder or file) to your computer via a Windows-compatible file explorer. You can use the file explorer to move files into",
        "label": 0
    },
    "405": {
        "output": "\u25a1 Eligible: Eligible 0) Excluded 1) Not relevant 2) Eligible \u25a1 Excluded: 0) Excluded # [INST] Examples of clinical trials information in data sets are described below. The first column contains data types, the second column lists the name of the fields in an itemized order, and the third column is the actual value. #\n\n### Clinical Trial Registration\n\nA clinical trial is a research project that prospectively assigns human subjects to intervention or comparison groups to study the causes and effect of a health-related variable. The U.S. and European regulatory agencies (US FDA, EMA) required clinical trials to be registered as part of the registration and approval process to promote the transparency of the clinical research and to reduce the wasting of resources caused by repeat registration of the same study. Therefore, to be identified with validity, a clinical trial must be registered according to the registration policy. Here we list the information of registration. #\n\n\n\nRegistration\n- `Registration`: The national trial registry.\n- `Registration_ID`: The identification number of the trial in the national trial registry.\n- `Country`: The country where the trial was approved.\n\n### Patient-Reported Outcomes (PROs)\n\nPROs are information reported by patients and generated from questionnaires completed by patients. These data help researchers assess the impact and burden of disease, as well as determine the effectiveness of interventions targeting patient symptoms and quality of life. In this dataset, the PROs were collected from clinical trials to explore the quality of life with breast cancer. Here we list the items. #\n\n\n\n\n\n- `Assessment_ID`\n  - `Code`\n  - Description\n\n- `Date_Time_Assessed`\n  - `Date_Time_Assessed`\n  - `Unit of Time`\n\n### Efficacy Endpoints\n\nEfficacy refers to the effectiveness of a drug in clinical studies. Efficacy endpoints are measures used to determine the therapeutic benefits of drugs, and are usually used to measure disease progression, the risk of disease progression, improvement in health status, or changes in functional status. The goal of an",
        "label": 0
    },
    "406": {
        "output": "[END]<EOD> .\nOBJECTIVE\nTo investigate the relation between the levels of Toll like receptor4 (TLR4) and nuclear factor kappaB (NF-kappaB) in the serum of patients with sepsis and the prognosis of septic patients.\n\n\nMETHODS\nA total of 79 septic children were divided into survival group and death group according to 28 days prognosis according. TLR4 and NF-kappaB in the serum of patients with sepsis were determined using ELISA. The children with trauma were included in control group.\n\n\nRESULTS\nThe levels of serum TLR4 and NF-kappaB of sepsis patients were significantly higher than that in control group (both P0.05), while the levels of NF-kappaB in sepsis children were associated with the serum levels of TLR4 and SOFA score on admission.\n\n\nCONCLUSIONS\nTLR4 and NF-kappaB can be used as important indicators for sepsis children and can be used to monitor prognosis of septic children.<EOD> Effects of Sperm DNA Fragmentation on the Reproductive Outcomes of Intrauterine Insemination: Preliminary Results\nBackground: The impact of sperm DNA damage on pregnancy outcome following superovulation and intrauterine insemination (IUI) has not been well studied. The aim of this study was to evaluate the effect of sperm DNA fragmentation on IUI outcome. Methods: A total of 87 IUI cycles were included in the study. The sperm DNA fragmentation index (DFI, the proportion of the DNA in fragment form) was assessed by the sperm chromatin dispersion assay and was expressed as a percentage. The number of inseminated motile sperm per ejaculate was also recorded. The main outcome was the number of fertilized oocytes, the live birth and delivery rates, and the incidence of gestational diabetes. Results: The mean of DFIs of the couples producing at least one fertilized oocyte was 29.6%. The mean of DFIs of the couples with positive clinical pregnancy test was 29.4%. Moreover, women who delivered live birth inf",
        "label": 0
    },
    "407": {
        "output": "### Output:\nIn `clinical_trial.csv`, the format of each row is the following.\n\n| `Patient_ID` |  Patient ID\n| `Eligibility_score` |  Eligibility score\n| `Trial_ID` |  Clinical trial ID\n| `Patient_ID` is the same across columns. `Eligibility_score` stands for the eligibility of this patient who meets the inclusion criteria and does not meet the exclusion criteria. `Patient_ID` is the patient ID. `Trial_ID`is the clinical trial ID. Please note that, although the trial ID and patient ID are the same variable, these two variables work in different contexts. In this task, we need to check if we can find this particular patient in the clinical trial. Therefore, we use `Patient_ID` to represent the patient ID and `Eligibility_score` to calculate the eligibility score for each patient. If the patient satisfies the inclusion criteria, `Eligibility_score` equals to 2. If not, `Eligibility_score` equals to 0 or 1. This also means the clinical trial can only accept the patients who satisfy the inclusion criteria. If the patient fulfils all the requirements, then this clinical trial need to conduct with the trial ID.\n\n#### Solution\n\nFor those patients belonging to the clinical trial, you need calculate the mean of `Eligibility_score`. We can see from the `clinical_trial.csv` that in every clinical trial, every patient's eligibility score is either 0, 1 or 2. We have 100 patients who are included in the clinical trial \"A\". Since the eligibility score of each patient is either equal to 0, equal to 1 or equal to 2, then in the clinical trial \"A\", the possible score combinations based on the mean function are M(x) = (15+4+38)/50 = 20. Similarly, the possible score combinations of clinical trial \"B\" M(x) = (6+1+38)/44 = 23.\nThen, to get the final results, we need to calculate the average scores of every clinical trial.",
        "label": 0
    },
    "408": {
        "output": "Patients ongoing to dose.\nPatients`s a doctor-grade`s eligible doctor/nurs's eligible at the doctors`s step.\nThe trialist(elig 4 trial's: 10 the doctor ical trial's trialist trial elig's trial trial's eligible\nelig trial/elig dose trial is notelig/trial elig] trial's healthy to trial characteristics.\n\nhealth and that your elig's trials`s elig/patients the treatment with doctors should you 310el elig patient's trial`s toxelig=21 elig and inade or inelig elig because the trial.\ntrial in the trial; eligible with a suitable trial elig; or the patient and trial eligible.\n[trial:\n[elig trial.\n[trial.\nfor the elig, and elig [in the following thet trial.\npatient oral trial's elig 1] patient elig, but trial.\nInel elig, and the elig. The trial.\nand who are part. You. An elig.\nshe,\nHealth to 3 and elig (2x/pat and elig trial. You will in elig 10, which may be an el 3.\n[el and are a bThe trial 2 or the patient.\ntest, and the trial, which was thei, or immunits and you are you know's elig. Thisel.\nel, is a doctor.\n\nher, which her. She 0 in all herb = herbal.el. (el)\n(for 1] 1 trial, and her 3. After trial and elig/el.\n\nand inpat, upt in/theel andre and health: el.\n[A&pat:s is a clin..., you, and the trial that [bib_ref]. The trial, who. Hi for patients.\n[or her to improve in accord \ns. You. The I, orally\u2026[in her\u00a0inclusion \u00bd or 1\n The patient ... and _\u00a014 in the patient (or, her [bib_ref]\nc... A 6",
        "label": 0
    },
    "409": {
        "output": "</instructions>\n\n\n---\n\n**# What are the data structures?**\n\n```{python}\nprint(trial_data)\n```\n```{python}\ntrial_data = [\n{'patient_id': 'PTA1265',\n 'patient_age': '45',\n 'gender': 'F',\n 'diagnosis': 'breast cancer',\n 'cancer_type': 'ductal breast cancer',\n 'subtype': 'Luminal A',\n 'grade': '1-2',\n 'tumor_size': '2.5-5',\n 'stage': 'Invasive ductal carcinoma of no special type -T2N2M0/stage IIB, cancer free N+ margins, 4 positive LNs (61%)',\n 'prior_radiotherapy': False,\n 'prior_chemotherapy': False,\n 'prior_neoadjuvant_therapy': False,\n 'prior_hormonal_therapy': False,\n 'her2_status': '0',\n 'pathologic_type': 'Ductal carcinoma of no special type -T2N2M0/stage IIB, cancer free N+ margins, 4 positive LNs (61%)',\n 'metastasis': 'yes',\n 'chemoradiation': False,\n 'treatment_status': 'pre-surgical non-therapeutic trial',\n 'chemotherapy': 'unknown',\n 'surgery': 'yes',\n 'radiotherapy': False,\n 'tumor_hormonal_receptors': 'ER(+), PR(-), Her2(-) ',\n 'survival_status': 'alive (1/2/2017)',\n 'exclusion_criteria': 'unknown',\n 'trial_enrollment_status': 'unknown',\n 'clinical_trial_group': 'trial192',\n 'clinical_trial_id': 'NCT02216786',\n 'protocol_number': '',\n 'recruitment_completion_date': '',\n 'date_of_entry': '2",
        "label": 0
    },
    "410": {
        "output": "<EOD> Naloxone, Methadone, or Buprenorphine: A Closer Examination of Three Different Opioid Agonists With Concurrent Risk of Opioid Use Disorders, Misuse, and Mortality\nOpioids are used to treat chronic nonmalignant pain (CNMP). However, use of prescribed opioids can lead to misuse with potential for opioid use disorders (OUDs) and even death. In this study, we evaluate the epidemiologic characteristics of 3 different opioid agonists used for pain (ie, methadone, buprenorphine, and naloxone) and correlate these with risk factors for OUDs, misuse, and mortality. In this retrospective study, we used Medicare Part D claims data set from January 1, 2013, to December 31, 2018, to examine rates of prescription fills of opioid agonists by age, sex, and race/ ethnicity to determine any disparities in opioid agonist utilization and further assess any risk factors for OUDs, misuse, and mortality. Although all 3 opioid agonists were prescribed more often to males, methadone had the highest proportion of prescriptions to males when compared with the other agonists (&khgr;2 = 46.19; P < .001). Black Medicare beneficiaries consistently had higher rates of filling any prescription for opioid agonists than their white counterparts (46.22% vs 36.96%), and black patients receiving methadone had a higher percentage of prescriptions with 1 or more opioid refills per 3-month period (54.92% vs 33.78%). Higher number of concomitant cardiovascular and nervous system medications was correlated with an increased risk for OUDs (odds ratio = 1.03; 95% confidence interval ). Benzodiazepine or antipsychotic drug overlapping with an opioid were more likely to be prescribed to a patient with an OUD diagnosis (odds ratio = 4.38 & 4",
        "label": 0
    },
    "411": {
        "output": "### <NAME> in `Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis` Trial is 36 years old.\n``<NAME>`` is 38 years old.\nThe following lines in the `patient` patient note file contains demographic information, such as name, surname, date of birth (DOB), and height.\n\n### `patient_patients.patient_dni.txt`, line 4:\nBEGIN OF DATA\n\nName | Age | Date of birth\n\n<NAME> | 36 years old | DOB: 2019-02-06\n\n<NAME> | 35 years old | DOB: 2019-02-15\n\n### `patient_patients.patient_age.txt`, line 4:\nBEGIN OF DATA\n\n<NAME> | 36 years old\n\n<NAME> | 35 years old\n\n### `patient_patients.patient.txt`, line 6:\nBEGIN OF DATA\n\n\n<EOD> Changing the culture to improve patient experience: a qualitative study\nObjective To understand how patient experience (PE) feedback affects staff in relation to their own perceptions of culture and practice. Design Observation and semistructured interviews were combined in this qualitative investigation of the introduction of PE surveys to four acute National Health Service Foundation Trusts in UK. Setting Four acute National Health Service Trusts from one Foundation Trust organization. Semistructured interviews were conducted with senior leaders, PE leads and staff working in acute services in two Trusts that did and two that did not implement routine patient surveys. Sampling used maximum variation to ensure diversity in sample. Participants were selected to provide a sample varying in characteristics of years of service, ethnicity, managerial responsibility and gender. Results Four key themes identified: perceived need for change in patient care; role of experience in influencing culture change; the challenge of patient-centred care within health organizations; and a changing culture. In those Trusts that introduced patient satisfaction surveys, it was suggested that patients play an important role in shaping",
        "label": 0
    },
    "412": {
        "output": "## Inferential Task: Diagnostic Evaluation \nHere is an example of a patient note. \nPatient: A 33-year-old female patient (no prior medical history) came to the emergency room complaining of sudden onset of cramps, loss of consciousness, and numbness in the left upper and lower limbs in the last 15 minutes. The patient had just eaten food a few minutes before the attack. Physical examination revealed tenderness in the right costal margin where the patient reported a cramp that she first felt when chewing the food. An initial diagnosis of aortic dissection (AD) was made and the patient was sent to the CT room to support the diagnosis. The diagnosis was reconsidered after the CT result. The patient remained hospitalized in general ward and complained of pain in the upper limbs and numbness with no change in her consciousness or speech.\n\nHere the clinician has to identify the correct diagnosis.\nWhat is the correct diagnosis? What is the next diagnosis based on your assessment?\n\n## Inferential Task: Prognosis Prediction (Classification Task) \nToday, 352 patients with heart failure have been discharged after hospitalization from a medical ward in a tertiary care hospital. A medical record on the patient who had undergone cardiac catheterization for treatment of heart failure is shown as below:  \nPatient: A 59-year-old female had been diagnosed with heart failure. The patient had hypertension, hyperlipidemia, and angina pectoris. On physical examination, vital signs showed a normal heart rate and blood pressure. Pulmonary edema was observed. Laboratory examination revealed high levels of B-type natriuretic peptide (BNP 516.0 pg/ml). Echocardiography showed a left ventricular ejection fraction of 32%. Cardiac catheterization showed a 30% stenosis in the left anterior descending artery and 85% stenosis in the right coronary artery (RCA). A pacemaker was implanted in the heart.\n\n## What is the optimal course of care for this patient?\n\n# Discuss",
        "label": 0
    },
    "413": {
        "output": "* _Note: In the note_ that was given in the assignment above, the diagnosis of a tumor is not stated. So, you will have to rely on the note to identify the diagnosis; instead, you can rely on the clinical trial to identify the diagnosis: In your final result, use `diagnosis` to output the diagnoses. Use the code below, and run the script, and see your result. Now, it all comes down to a few lines of code and we've got this to the end! We are now going to write code that is capable of parsing patient notes and classifying patients as being eligible or ineligible for medical trials.\n\n`import java.util.*; \n\nclass Candidates { \n    public static void main(String[] args) { \n        List<Patient> patient_set = new ArrayList<Patient>(); \n        Patient p = new Patient(); \n        patient_set.add(p); \n        patient_set.add(p); \n       for (int i = 0; i < patient_set.size(); i++) { \n         Patient p = patient_set.get(i); \n         System.out.println(\"p.note() = \" + p.note()); \n       } \n    } \n    class Patient extends Comparable<Patient> { \n        private String gender; \n        private String age; \n        // In a real scenario, we would store a lot of different information about the patient. \n        // Here we are only storing a few of them, to make things easier. \n        // For example, we should store the patient's medical history, prescriptions, genes, etc. \n        // In order to do this, we want to store as many Patient objects as the number of patients we have in our hospital system. \n        public Patient() { \n          // We need to call super() for it to call the constructor. \n            System.out.println(\"Constructing patient.\"); \n            gender = \"unspecified\"; \n            age = \"unspecified\"; \n        } \n        @Override \n        public String toString() { \n          return String.format(\"Patient ID: %d, Name",
        "label": 0
    },
    "414": {
        "output": "## RQ4 How should I deal with errors during the assessment?\n[INST] You should enter the following commands to show the types of errors and some hints.\n`show error -p`\n`show error 0 1 \"I'm 45!\"`\n`show error 1 0 \"I\"\n`show error 2 0 \"1\"`.\nIf you enter a wrong score, you should correct it as soon as possible. If the correct score is given more than 1 minute after you enter the incorrect score, it will be treated as an error.\n\n## RQ5 How should I deal with exclusion criteria?\n\n[INST] Exclusion criteria should be checked by the trial-level eligibility.\n`1 2 3 0 \"45-year-old postmenopausal woman\"\n'2 2 1 0 \"Female\"\n1 0 2 1 \"Postmenopausal woman\"\n2 1 1 1 \"Man\"\n3 3 0 0 \"Pregnant\"`\n\n[M1] The following output should be displayed:\n[INST] In most clinical trials, exclusion criteria do not count as the patient meeting inclusion criteria. But in some cases, exclusion criteria do count. In some special cases, including RCT (Randomized Controlled Trial) and Phase 1, the patient is considered eligible if exclusion criteria are not met. In all cases, after an exclusion criterion is entered, the trial needs to be restarted. Let's check the trial-level\n\n`2 0 0 \"Female\"` `Not eligible`\n\n## RQ6 What are the trial-level eligibility in the clinical trial?\n[INST] The trial-level eligibility should be used after checking the inclusive criteria.\n`Trial-level eligibility: 0 Excluded`\n\n## RQ7 What is the way to get more information for the patient note?\n\n[INST] The information from the patient note can be printed to STDOUT by following command.\n\n\n## RQ12 What should I do if I want to leave the trial?\n[INST] After the trial is over, you should use the following command to exit the trial.",
        "label": 2
    },
    "415": {
        "output": "[INST]\nExercises\n\n- 1.1: Practice patient-level eligibility \n  You should read all data lines (Patient, Trial, Inclusion criteria) one by one. After reading all the data lines - Patient-level eligibility, you should compare the patient's information and clinical trial's inclusion criteria. You can apply the criteria only once. After meeting all the criteria, you should write eligibility as output according to the three-point scale on the screen, e.g. by using `Eligibility: 2) Eligible.`. [INST]\n- 1.2: Write down the eligibility in the last line by 'eligibility-of-the-trial' \n  Before solving the exercise, write `eligibility-of-the-trial: 0) Excluded.`, since the patient is not in the trial. \n  Patients can be excluded for several reasons. A summary of the most frequent reasons and their corresponding inclusion criteria codes for the clinical trial is shown in the exercise below. \n  Note that some patients need to be excluded due to their nonresponsiveness to the treatment under investigation in the trial or due to already being treated with the treatment under investigation in the trial (i.e., patients who require a certain treatment on their own accord or due to having an underlying problem unrelated to an underlying tumor). \n  To solve this exercise, repeat eligibility-of-the-trial line by `Eligibility-of-the-trial:` where the first line already contains `Eligibility-of-the-trial: 0) Excluded.`, e.g., `Eligibility-of-thetrial: 1 (Exonerated (on her own will))`. [INST]\n\n# Disclaimer\nSome tests and examples use mock data for demonstration purposes only, which are not based on real cases but on real patient data as part of the patient data provided to ISCIII by Spanish National Health Service.\n\nThis mock data are subject to copyright protection as the ISCIII (CSIC) reserves the right to use this material to develop its own content and to improve the training programs for health professionals.\nThe ISCIII has the exclusive right to reproduce and distribute this material,",
        "label": 0
    },
    "416": {
        "output": "#### How to do?\n1. Click on the run button to build the dataset.\n\n    ```shell\n    python dataset/main.py\n    ```\n    \n    ## Output\n    ## \n    ## File `test_code/run.html` \n    <samp>\n    Trial-level eligibility: 1) Excluded.\n\n    Patient-level eligibility: 0.0) Excluded.\n    ```\n    \n2. Click on the rerun button to update the dataset with the current dataset.\n\n    ```shell\n    echo \n    Python :> In [?1]:\n    \n    Python :>\n    \n    Python :> ## \n    Python :>\n    \n    Python :> ##\n    Python :> ## In all, there are about 11000 candidates of clinical trial, and 1632 of\n    Python :> ## them have patients with a HER2+ status.\n    Python :> ## \n    Python :> ## \n    Python :> ## Among them, 232 clinical trials meet the 3 criteria\n    Python :> ## (0.0)\n    Python :> # \n    Python :> # \n    Python :> # \n    Python :> # Exclude the duplicates\n    Python :> # \n    Python :> \n    Python :> # (69)\n    Python :> # \n    Python :> # There are a total of 69 clinical trials related to the current dataset.\n    Python :> # Among them 17 clinical trials meet our inclusion and exclusion criteria.\n    Python :> # \n    Python :> ## Summary of the results of the experiment.\n    Python :> ##\n    Python :> ## In all, there are about 11000 candidates of clinical trial, and 1632 of\n    Python :> ## them have patients with a HER2+ status.\n    Python :> ## \n    Python :> ## Among them, 232 clinical trials meet the 3 criteria\n    Python :> ## (0.0)\n    Python :> # \n    Python :> # \n    Python :> #",
        "label": 0
    },
    "417": {
        "output": "__Congrats__! You have finished this tutorial. We welcome your feedback. If you liked this tutorial for learning R, please give us a \"thumbs up\". We have many great R tutorials you can find on our blog [rdocumentation.org, blog.rdocumentation.org].\n<EOD> Role of endogenous inhibitors of mitogen\u2010activated protein kinase kinase pathways in regulating platelet function\nSummary.\u2002 Background: Stimulation of platelets via adhesion receptors or agonists activates mitogen\u2010activated protein kinase (MAPK) kinase (MEK)\u2010MAP kinase (ERK) cascade leading to the formation of an actin network. The ensuing shape change allows for platelet aggregation, secretion of cytoplasmic granule contents and clot retraction. Objectives: To examine the functional significance of a recently identified endogenous inhibitor of MEK, c\u2010Cbl, for platelet function. Methods: Wild\u2010type and c\u2010Cbl\u2010deficient platelets were activated with thrombin, and phosphorylation kinetics and aggregation response were monitored by Western blot and light transmission aggregometry, respectively. The ability of WT and knockout platelets to spread on fibrinogen\u2010coated substrates was assessed using florescence microscopy. Results: Wild\u2010type platelets rapidly phosphorylated ERK following thrombin stimulation, and phosphorylation continued over 30\u2003min. Loss of c\u2010Cbl resulted in an accelerated kinetics of ERK phosphorylation, peaking in minutes rather than an hour, and ERK phosphorylation was sustained for at least 60\u2003min. While wild\u2010type platelets showed negligible aggregation and a negligible percentage of spread platelets, aggregation of c\u2010Cbl\u2010KO platelets reached at maximum at 30\u2003min with the percentage of spread platelets almost threefold higher than wild type. Moreover phosphorylation of MAPK\u2010interacting kinase and extracellular signal\u2010regulated kinase (ERK)2 was severely attenuated in thrombin\u2010activated c\u2010Cbl\u2010KO platelets. Conclusions: Loss of c",
        "label": 0
    },
    "418": {
        "output": "[/END]\n\n[INST] Hello. You are again a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a trial to determine the patient's non-eligibility. The factors that disqualify someone from participating in a clinical study are known as exclusion criteria. They are established to reduce the risk of harmful effects on participants in the trial. Therefore, you will be examining four types of exclusion criteria to check the patient: (1) Medical; (2) Surgical; (3) Previous Treatment;\n(4) Sexual and reproductive.\n\nThe exclusion of a patient from a trial has a three-point scale: 0) Excluded (the exclusion criteria do not apply to the patient); 1) Not relevant (patient has insufficient information to qualify for the trial); and 2) Eligible (the patient does not meet the exclusion criteria). \nYou should create an assessment of exclusion according to the exclusion criteria for each patient and for the trial. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial:\nTitle: HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer.\n\n\nSummary: This mechanistic study will be the first study to assess the efficacy of [18F]GE-226 to target HER2 expression in patients with metastatic breast cancer. The study will establish the pharmacokinetics of [18F]GE-226 and the optimum time-point",
        "label": 2
    },
    "419": {
        "output": "Here are the results for one of the datasets I used.\n\n### A) Using dataset file\nIf we use patient dataset on a single file, you should use `with open(patient_train_file, \"r\", encoding='utf-8')` to read one file. Likewise, for the clinical trial dataset file, we should use `with open(trial_train_file, \"r\", encoding='utf-8')` to read one file.\n\nB) Using Pandas dataframe\nIf we use Pandas dataframe file by pandas.dataframe(pd_df.to_dict()), we can directly feed the df to the DL model without importing any libraries (for example, open libraries for reading individual files).\nThe code example for training DL model with Pandas dataframe is below.\n\n```python\n     with open(patient_train_file, \"r\", encoding='utf-8') as patient_df:\n             patient_df_data = pd_df.to_dict()\n             patient_df_data[\"Trial_Level_Eligibility\"] = df[\"Trial_Level_Eligibility\"].fillna(0)\n             patient_df_data[\"Trial Eligible\"] = df[\"Trial Eligible\"] # To fix a dataset for better training\n             patient_df_data[\"Trial Eligible\"] = patient_df_data[\"Trial Eligible\"].fillna(1)\n             patient_df_data[\"Trial ID\"] = 1\n             patient_df_data[\"Clinical Trial\"] = \"Whole-Exome Sequencing (WES) for Intraductal Neoplasms of the Bile Duct (IPNB).\"\n             patient_df_data[\"Inclusion Criteria\"] = [\"Trial Inclusion Criteria: Cytologically confirmed breast cancer, 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative, 5 positive lymph nodes in axillary sampling, and consent to do resection prior to receiving chemotherapy\",\n                                                     \"Exclusion Criteria: Clinical Trials for Women\",\n                                                     \"Clinical Trials for men\",\n                                                     \"Clinical Trials for elderly",
        "label": 0
    },
    "420": {
        "output": "You are given a patient note and a clinical trial, one by one. You have to perform Trial-level eligibility in each patient note and for each clinical trial. \n\nNote. You can find the patient note and clinical trial here:\n \n[FOLK:http://s3-us-west-2.kinloneyc.com/s/wqb-NqWQmD0134A98x3zX.zip](http://s3-us-west-2.kinloneyc.com/s/wqb-NqWQmD0134A98x3zX.zip)\r\n[CLIC:http://s3-us-west-2.kinloneyc.com/s/VxVqvT1Y610xUcH5yvgCk.zip](http://s3-us-west-2.kinloneyc.com/s/VxVqvT1Y610xUcH5yvgCk.zip)  \n\n## 2.3.2.2 [Instructions]\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's exclusion. The exclusion criteria are based on various characteristics such as age, gender, the type and stage of a disease, treatment history, medical conditions, etc. \n\nThe following patient note:\n\nThe patient is a 53-year-old postmenopausal woman with HER2-positive breast cancer, with cytological confirmation. She has a 5 cm invasive ductal breast cancer. The tumor is ER-positive and PR-negative. Axillary surgery confirmed 9 positive lymph nodes. CXR is remarkable for multiple metastases. The patient does not attend follow-up. The patient uses multivitamins and iron supplements regularly. The patient does not smoke or consume alcohol. The patient is not active sexually and has no children. Her vital status is stable. The patient is a candidate for tumor resection and chemotherapy.\n\nThe following clinical",
        "label": 0
    },
    "421": {
        "output": "cure-diemat. the inter for these 1-care, exus\u00a0med. [fig_ref]/and \nafter a\n or \u2026 [bib_ref]_based  network-med\nor in 2(10, s1 to [/fig]\nwith\nbased\nspecific [/table] for<EOD><EOD> \u200b 1   -to\\full 21 inhib  and\u2026 for [bib_ref] The :\n A \n 2\nfor [bib_ref] an\u00a0 \ufffdin [bib_ref] c 7\u00a0for [bib_ref]<EOD> diagnate for \n Thes [bib_ref]{\n\n [fig_ref]the  and, and [bib_ref] according \u2021 ( [bib_ref] The\u00a0system of [/table] candidate [bib_ref]( [bib_ref] \nin .\nin such on\nfor 2 [bib_ref]\u00a0\n\nmeline 0\n The  -in The _C (acc\n[ 3\u2026on-and [bib_ref] [bib_ref]-\non _ \nm...\n-absolute.\n\u2026 1+surg a 2 0 2 C\n ....mast-current [bib_ref] 1\u00a0d 1 .\nbased-bours- and the Cass for a medical The . [fig_ref]. H<s\ng (s in an Fshe-det on the [bib_ref]. Only for a [fig_ref] [bib_ref] [bib_ref] (for a\n\n(the,a [bib_ref]  in the (<h... 2 1 1  [on-h [bib_ref] [bib_ref] \u00acC - .\nin<EOD> and [bib_ref] [bib_ref]\n\nd\n The _1 -\nin 1 - 2 (absolute 2 _specific [bib_ref]for [/fig_ref]/random to<EOD>- [bib_ref] [bib_ref]\nt-\n-only andcute for\nfor the Cin for a\u00a0 .\n(s 1<EOD> [bib_ref] [bib_ref]s\n2-in [bib_ref] [bib_ref] [bib_ref]^ [bib_ref] [bib_ref]\u00a0re- 1 [bib_ref]; [ , and , for c..., 1 [bib_ref]1\ns\u00a0s [bib_ref] \\... [bib_ref] 1- 1-pat 1- 1-c \u2026 for \ufffd\ufffd/\n1-h 2- 1-sub and\nsub.\n 20 in \u2026and-\n\nc \u2044[c 2 to thisd [bib_ref]\n-to 1_ [bib_ref] in the- \nand for the-and",
        "label": 0
    },
    "422": {
        "output": "![INST][295]\n\n### [Q294] Hello, this is for the next step. First, you should find out the reasons for exclusion and find the inclusion and exclusion criteria relevant to the patient. You should write down the reasons in the patient notes and underneath the inclusion and exclusion criteria, respectively. In this part, you will find the following reasons for exclusion and inclusion by applying the 0) Excluded, 1) Not relevant, or 2) Eligible (i.e.,`No` means the patient may not enroll, `Not sure` means the patient may enroll depending on the situation, and`Potential` means the patient may enroll depending on the situation). Let's think step by step.[INST] \n```\n[296]\n```\n\n### [Q295] Hello, this is for the next step. First, you should find out the reasons for exclusion and find the inclusion and exclusion criteria relevant to the patient. You should write down the reasons in the patient`s notes and underneath the inclusion and exclusion criteria, respectively. In this part, you will find the following reasons for exclusion and inclusion by applying the 0) Excluded, 1) Not relevant, or 2) Eligible (i.",
        "label": 0
    },
    "423": {
        "output": "<EOD> A new method for the study of the distribution of inorganic cations in nerve tissue.\nA method for the localization of inorganic cations in tissues which makes possible the determination of changes in the distribution of these cations during the course of a pathological process is described. The method is based upon a technique for the histological study of cations in tissues introduced by Deane & Levin (1957) for the study of Na, K, and Ca in muscle strips, which is adapted for the study of nerve tissue, and on an improved method for the preparation of epoxy embeddings of tissues for microscopic study. It has the advantages of providing results with localization characteristics, speed, simplicity, and economy, and does not require any preliminary treatment of the material beyond fixation. The results that have been obtained by its use in the study of nerve myelins have confirmed previously reported observations made by other methods. The localization of Na, Ca, Mg, K and other elements by means of this method gives results similar in accuracy to the findings already reported by others (Dahl & Worm-Petersen, 1906; Gaffin, 1910; Griinbaum & Lichtheim, 1913; Lehninger, 1945; Deane, Levin, Snyder & Mendel, 1957; Seyler, 1958) but in addition the localization of Ca offers some advantages. It has a greater specificity which can be utilized to study certain of the changes in the distribution of Ca in nerve myelins resulting from experimental procedures, such as the induced production of ischaemic damage, hypertrophy, and the formation of perineurial scar tissue, in the following paper. In this second paper the application of the method to the study of the distribution of inorganic cations in the experimental conditions described is described.<EOD> The role of neurovascular biomechanics in the regulation of neurovascular coupling\nCoupling between brain function and cerebral blood flow is essential for normal brain function and underlies the pathophysiology of neural disorders including Alzheimer's disease. The mechanisms underpinning functional hyperemic responses also involve coupling of",
        "label": 0
    },
    "424": {
        "output": "#### ## Testing your Clinical Trial Eligibility Assessment\nNow, write your code and conduct your tests. The input of your testing should be a set of patient and trial notes, as the information required by the user can be supplied by the user as a csv file. One patient and one trial note should be included in each line of that file. The patient note should indicate the results for each component of the Clinical Trial Eligibility Assessment, separated by semicolon characters. One trial note should contain the information about a single trial. \n\nHere is an example of the csv file: '0) Excluded;1) Not relevant;2) Eligible;0) Excluded;1) Not relevant;2) Eligible;0) Excluded;1) Not relevant;2) Eligible'\nYou should produce a different output for each row of the csv file. There may be multiple rows with the same results as they can be part of multiple clinical trials at once, so there are usually multiple rows per patient. In the end, you should produce the same results as specified by the first example in your documentation as well as a table and the results to be printed to the console. The table should consist of the following columns: [HINT] The row number, the patient ID, the trial ID, and the outputs of the assessments. [INST] The assessments, including the trial assessment if applicable, will be stored in the 'assessments' dictionary and printed to the console with format(d).\n\nThe assessments dictionary must be created at the beginning of the program and contains the patient note and trial note as key-value pairs. Since each item requires a patient note and a trial note, they will be of type 'list' for the key or value. [HINT].\nIf you do not include any patient note or trial note, then the dictionary will not have any value. Hence, the key 'Assessments` will not be accessible.\nTo run your program, you can provide the csv file you wrote.\n[HINT] It is recommended to wrap the csv file in a file-like type and pass it in using a with statement. Here is an example.\ntest_outputs = ['0) Excluded;1) Not relevant;2) Eligible;0) Excluded;1) Not relevant;2) El",
        "label": 1
    },
    "425": {
        "output": "Informant: [<instrument_id>, 'Fully Automatic Pneumonia Severity Index (FAPSI) Assessment', 'I will be able to calculate the Pneumonia Severity Index (PSI) score of patients with pneumonia', 0, 2, 100, '<em>https://www.google.com/translate/</em>', 5, 5, 5].Instrument_id: The unique ID of Informant\nSubject_type: The classification of Informant (e.g., questionnaire, radiating, diagnosis, eligibility assessment, etc.)\nDescription: Describes what patient population (e.g. children, adults), what disease areas that can be served, what medical purpose that can be achieved. Also provides the references to justify.\nInstructions: Specific instructions for each informant.\nNumber_of_items: Number of items in the informant.\nNumber_of_domains: Number of domains (including number of items) in the informant.\nTarget_number_of_questions: The maximum number of questions that should be asked by the assessment.\nTarget_number_of_answers: The maximum number of answers that should be expected for each item.\nMaximum_number_of_questions_repeated: The maximum number of questions will not be repeated in the assessment.\nMaximum_number_of_answers_repeated: The maximum number of answers that will not be repeated is the number of answers of an item.\nWeight: A scalar between 0 and 1. The scalar denotes the importance of Informant. When set as less than 1, the Informant will actively assist with the treatment decision (similar to a patient questionnaire); or when 1, the Informant will be the final authority in deciding the treatment for patients, i.e. doctor-like.\n\n## Objective:\nThe goal of this study is evaluating the usefulness of the Fully Automatic Pneumonia Severity Index (FAPSI) assessment for the assessment of community acquired pneumonia. The FAPSI assessment was shown to be equivalent to the standard manual assessment [bib_ref]  Pneumonia Severity Index. A nationwide validation of a validated prediction rule, Fine [/bib_ref]  and it could be used to assist do",
        "label": 2
    },
    "426": {
        "output": "<EOD> A comparison of tacrolimus and cyclosporine-induced changes in vascular risk factors in patients receiving kidney transplants.\nBACKGROUND\nHypertension is an important cardiovascular risk factor and is a commonly encountered problem in kidney transplant recipients. It is reported that an increased blood pressure is seen in 25 to 90% of renal-transplant patients. Many factors might be responsible for this condition, including immunosuppressive drugs.\n\n\nOBJECTIVES\nTo determine the effect of tacrolimus and cyclosporine on hypertension, pulse rate and the level of lipid profile among kidney-transplant patients with impaired kidney function.\n\n\nMATERIAL AND METHODS\nThe present study evaluates 30 kidney transplant patients. Subjects were divided into 2 groups with respect to the immunosuppressive agents they had been taking. The blood pressure, pulse rate, serum glucose, lipid profile, serum uric acid, and 24-hour urine volume of the patients were determined before and after kidney treatment. Statistical analysis of the data was performed using t test and Pearson correlation coefficient.\n\n\nRESULTS\nSerum total cholesterol, triglyceride, and low-density lipoprotein levels were significantly higher in the tacrolimus-treated group than in the cyclosporine group (p < 0.05, p < 0.001 and p = 0.04 respectively). Pulse rate was significantly lower in the cyclosporine-treated group than in the tacrolimus (p < 0.01). However, high-density lipoprotein level was significantly higher in the tacrolimus-treated group (p < 0.05). Serum uric acid levels, lipid profile, and blood pressure were not different between the two groups.\n\n\nCONCLUSIONS\nTacrolimus seems to have less of an adverse effect on the vascular risk factors than does cyclosporine.<EOD> Phytochemical Analysis and Biological Effects of Aqueous Extract of Prunus domestica L. Seeds G",
        "label": 0
    },
    "427": {
        "output": "<EOD> .\nTwo types of bacteriological indicators have been compared (aerobic heterotrophic microorganisms, the total number of spores from microscopic fungi) both in the rooms of a building, and as compared to the same parameters in the soil adjacent to the building. The results show that the quantity of spores and microrganisms in the soil under the building was 10 to 20 times higher (for aerobic microorganisms) and 60 to 100 times higher (for spores of microscopic fungi) than those at the height of 30-40 cm from the surface of the soil. The average levels of spores and aerobic microorganisms in the air of the investigated building ranged from 167 to 204 and from 172 to 305 units/m3. A decrease of the quantity of investigated microorganisms was noticed near the heat-air sources.<EOD> Dual antiplatelet therapy in STEMI patients treated with primary PCI; A meta\u2010analysis of randomized controlled trials and observational studies\nPercutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) patients remains challenging. Whether dual antiplatelet therapy (DAPT = aspirin and a P2Y12 inhibitor) is effective or associated with harm, compared with aspirin (ASA) monotherapy in STEMI patients undergoing primary PCI has remained unresolved. Moreover, the superiority of Prasugrel or Ticagrelor over Clopidogrel in STEMI patients undergoing primary PCI with or without DAPT has not been fully elucidated. Our aim was to systematically perform a meta\u2010analysis of all available comparative studies testing the effects of Dual antiplatelet therapy in primary PCI patients, compared with Aspirin monotherapy, with special focus on the impact of P2Y12 inhibitors and on timing of DAPT cessation.<EOD> Phosphorylation of the eukaryotic translation initiation factor 4E is not required to modulate the protein synthesis rate in proliferating mammalian cells\nEukaryotic translation is essential for proper cell function. However, the mechanisms",
        "label": 0
    },
    "428": {
        "output": "[/QUESTION]\n<EOD> Phytochemical Study of Selected Species (Phenolic Content, Antioxidant Activity and Anthocyanin Content) of Fruits of Some Himalayan Edible Plants.\nIn this study, we have investigated the total polyphenol content (TPC), total flavonoid content (TFC) along with the antioxidant properties by ascorbic acid equivalent antioxidant capacity (AEAC), 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activity (DPPH) and 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid radical (ABTS+)scavenging activity of fruits of selected Himalayan edible plants. Among the species, maximum TPC (133.66 mg gallic acid equivalent/g) was found in Dacryo-draco cochinchinensis var. chunia, followed by Rhododendron anthopogon (119.50 mg gallic acid equivalent/g) and Rosa indica (77.42 mg gallic acid equivalent/g). Moreover, highest TFC (203.47 mg catechin equivalent/g) was found in V. hankelii, followed by D. cochinchinensis var. chunia (127.94 mg catechin equivalent/g), L.",
        "label": 0
    },
    "429": {
        "output": "Let's think step by step. \nThe number of exclusion criteria (that is `candidate_trial` object) is 7:\n\n```python`\ntrial_relevant_exclusion_criteria = candidate_trial.get_relevant_exclusion_criteria()\n7\n\nName\n        Value\n       0 \n\n        Patient is less than 18 years of age.\n\n        Patient is currently participating in another clinical trial. \n\n        Patient is of non-binary gender.\n\n        Patient has a diagnosis of any other neoplasm as defined in appendix 5, including but not limited to a history of malignant melanoma of any location and stage (within the past 6 year prior to study entry).\n\n        Patient has a history of uncontrolled (grade 2 or greater) or recurrent diabetes mellitus.\n\n        Patient is receiving long-acting or injectable insulin, or oral agents known as \"insulin sensitizers\".\n\nName\n        Value\n        1\n\n        Breast cancer is of histologically grade 1 and stage 1.\n\nName\n        Value\n        2\n        Malignant melanoma of any location and stage (within the past 6 year prior to study entry).\n\nName\n        Value\n        3\n        Grade 2 or greater (or any grade recurrent diabetes mellitus)\n\nName\n        Value\n        4\n        Patient is of non-binary gender.\n\nName\n        Value\n        5\n        Patient is 18 years of age.\n\nName\n        Value\n        6\n        Patient is of non-binary gender.\n\n```\n\n\n\nIf the clinical trial has a relevant exclusion criterion, the clinical trial exclusion clause should be added to the patient note. The trial_relevant_exclusion_criterion variable is a list of strings. The length of this variable depends solely on the number of relevant exclusion criteria of the clinical trial. \n\n```python\nrelevant_clinical_trial_exclusion_criterion = ['Candidate does not meet inclusion criterion: '.format(c) for",
        "label": 0
    },
    "430": {
        "output": "## Revision 2\n\n[INST] Let's define the clinical trials more specifically. \n\nThe patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, e.g., '1) Not relevant', '2) Eligible', and '3) Excluded'. \n\nHere is the patient note:\n    The patient is a 65-year-old postmenopausal woman. Her mammogram results showed a lump in her left breast and she was referred to a breast care specialist from the symptomatic oncology service. She was diagnosed with breast cancer after a fine needle aspiration test followed by a biopsy, which confirmed invasive lobular breast cancer. She is receiving adjuvant endocrine therapy (tamoxifen citrate). The clinical trial of the test you are applying is ongoing, and there is no personalized or risk-based care available under this clinical trial.\n\n    Her biopsy results: IDC, grade 2, 4.9 cm, positive lymph nodes, E-negative/PR-negative, ER-positive, Her2-positive, HR-positive, Ki67, 60%, 100% of the cells.\n    The risk prediction model in this study is on Prosigna\u00ae, and the average risk category is 7.4. The risk score is 26 and the ROR was 31.6. It places her at the low/intermediate risk level.\n\nThe clinical trial: \nHere is the clinical trial: \nTitle: Innovative Biomarker Precision Therapy Trial (iBPTT)\n\n\nSummary: The iBPTT is a randomized multicenter clinical trial which is looking to use the Genomic Grade and Recurrence Scores from the Prosigna\u00ae (Pam50) Oncotype DX test to stratify patients diagnosed with breast cancer who are starting standard adjuvant endocrine therapy. The intervention arm will be stratified according to risk level from a Genomic Grade and Recurrence Score. Arm 0 will receive standard adjuvant endocrine therapy and Arm 1 will receive standard adjuvant end",
        "label": 0
    },
    "431": {
        "output": "<issue_comment>username_1936: I see that #3384 is still \"in progress\". Is there any other way to get this problem solved?\r\n<issue_comment>username_1931: We released our first release of Data-Assistant 4.0 with all the changes we made.  We added `MPI_OFF` to the `RunAllTests` setting to exclude the tests that are failing on MPI jobs. We also replaced a few broken tools with newer version in our tests. Most of the tests now run successfully on MPI jobs (as well as MPI-only jobs). Some of the tests still have failed with MPI jobs. We plan to work on it over the coming weeks. We'll be releasing frequent updates there. If you want to let us know whether or not `MPI_OFF` is fixed. We'd appreciate that.<issue_closed>\n<issue_comment>username_1931: Thanks for the detailed feedback. MPI tests are only failing for some of the pipelines.\r\n\r\nOn our machines, the eligibilities run correctly with the latest release. And, the eligibilities work perfectly without `mpi` when you execute `DataAssistant`.\r\n\r\nWe also updated our repository by removing that dependency on `mpi`, just to make sure that users on machines without MPI would not face any issues. Please upgrade.<EOD> Effect of HIV disease on the renin-angiotensin system.\nSince the recognition that angiotensin-converting enzyme (ACE) inhibitors (ACEi) are potent anti-proliferative agents in cultured glioma cells , it has been suggested that this may provide some support for a role of ACEi in AIDS-related dementia (ARDD) . At the recent meeting of the International AIDS Society meeting in July 1996, two other potential mechanisms for the therapeutic effect of ACEi and/or angiotensin AT2 receptor agonists in the treatment of cognitive disorders was reported . Both of these mechanisms provide support for the continued investigation into the role of the renin-angiotensin system in the pathophysiology of HIV-induced dementia as a result of AIDS.",
        "label": 2
    },
    "432": {
        "output": "<!-- == CONTRIBUTE TO THIS DOCUMENT: == -->\n<!-- \nYour input here is appreciated. Please add to and update this page.\nYou can submit changes to the wiki and have them be instantly propagated to the\nWikiDoc Web site as soon as this change is saved.\n-->\n\n# Discussion\nYou can edit this section and wiki page by clicking the \"edit\" link on top of any entry.\n\n# Additional resources\n- Med Help: Cancer: Research and Advances: The Med Help web site contains a good summary of what clinical trials are and information on the various types of clinical trials.\n- NCI: Clinical Trials Search\n- NCI: Clinical Trials Overview\n- NCI Cancer Information Helpline: Telephone: 1-800-4 CANCER (1-800-422-6237)\n- The Cancer Information Center: Telephone: 1-800-257-1034 \n- American Cancer Society Cancer Information Service: Telephone: 1-800-ACS-2345\n- ACS My Guide: Download a PDF or a Kindle version which provides easy to use information about cancer from the American Cancer Society\n- American Society of Clinical Oncology (ASCO) Cancer Information Services\n- National Comprehensive Cancer Network (NCCN): Oncology Patient Info<EOD> .\nThis study was conducted to determine the effect of anesthesia and surgery on serum and urine cortisol and corticosterone concentrations of rats. Experiments were conducted with five groups of weanling male rats. They were intact controls, rats undergoing laparotomy, rats undergoing laparotomy and laminectomy, rats undergoing intracranial injection of lysine vasopressin (VP), and rats undergoing intracerebroventricular injection of angiotensin II (AII). Serum and urine cortisol and corticosterone levels were determined after surgery in rats at 09:00 and 02:00 in all groups except the intact controls. Urine corticoster",
        "label": 0
    },
    "433": {
        "output": "[CODING]\n\n\n<div class=\"codetip\">Hint: If the number of patients is very large, you can create a loop to calculate the number of the eligible patients. \n\nFirst, define a list (here it is named `list`) to store all 0 and 1 in the file (for example, the code above defined 'list' which contains all 0 and 1 number). Then, `for` with `i=0 to size(list)` is used to iterate all 0 and 1 number in `list`. If you want to judge which is 1 (eligible), just check the 7th element `for` in `i`. If you want to find the number of 2 (eligible) in the file, you need to modify `i` to `z=0` first. Then, using `z=z+1;` add one element in `z` to `for` loop in every iteration. <NAME>\n\n</div>\n\n\n\n\n</body></html>\n<EOD> Role of calcium in 15-d-PGJ2-induced apoptosis in human prostate carcinoma cells.\nTo determine the biochemical pathways involved in prostaglandin (PG) D2-induced apoptosis, human prostate carcinoma cells were pretreated with 15-deoxy-delta 12,14-PGJ2, followed by exposure to various inhibitors of mitogen-activated protein (MAP) kinase activation (PD98059 or U0126) or calcium (BAPTA/AM) or caspase activation (benzyloxycarbonyl-VAD-fluoromethyl ketone). 15-Deoxy-delta 12,14-PGJ2-induced apoptosis and activation of stress-activated protein kinase were blocked by BAPTA/AM but not benzyloxycarbonyl-VAD-fluoromethyl ketone or U0126 or PD98059 treatments. Our results suggest that calcium activation upstream of stress-activated protein kinase is a prerequisite for the 15-deoxy-delta 12",
        "label": 2
    },
    "434": {
        "output": "## Citation\n<EOD> Influence of an intracerebral electrode on postoperative imaging after implantation of a dual\u2010sided electrode system with contact array for bilateral cochlear implants\nObjective: In this study we have analyzed the influence of an intracerebral electrode on postoperative imaging after implantation of a bilateral cochlear device system, which utilized different electrode sizes and configurations for the respective ears. This is considered to be the most important factor for the placement of such electrodes. Design: Seventeen patients (12 females, 5 males, age mean \u00b1 SD: 49.2\u2005\u00b1\u20056.9 years) with a previously implanted left\u2010sided dual\u2010sided electrode (DS\u2010DE) system were included into the study. Electrode sizes and configurations used were 3, 20, 31 and 40\u2009\u03bcm and configurations were different between the ears. Indication for surgery was severe bilateral hearing loss. All patients received a cochlear implant on the left side, followed by a cochlear implant on the right side after at least three months, depending on the patient's choice. In 14 of those patients the right cochlear approach was used, while in 3 patients the vestibular approach was necessary. Results: In all 13 patients with implantation via the cochlear route, imaging allowed for complete electrode arrays to be localized directly after surgery. The intracerebral electrode could not be visualized using the cochlear route. In all patients undergoing the vestibular approach, the implanted electrode was not completely intracranial, but in close proximity to the pons. All vestibular approaches resulted in a partial filling of the posterior cerebral cranial fossa. Conclusions: Postoperative imaging should be performed routinely immediately after surgery, using a gantry\u2010shift\u2010free, T1 axial sequence. In order to obtain images free of artifacts, a long\u2010axis slice width of less than 3\u2005mm should be applied. We also recommend not using an intracerebral electrode system in cases where the vestibular approach is selected.<EOD> Fecal",
        "label": 0
    },
    "435": {
        "output": "##[/INSERT]\n\n### Including additional variables\nAlthough most of the data is provided in the input file, you can consider a few more patient variables. One clinical trial includes two such extra data fields: the stage of the disease and the smoking history of a patient.\nStage of disease:\nCategorical variable: A patient can be in any of five stages of breast cancer from I to V. Stages I and II are early stages (the earliest or precursor stages of cancer), whereas stages III and IV are advanced stages. Stage IV, which is the most advanced form of cancer, is also termed \"metastatic\" cancer. In other words, the tumor has moved from where it started (the breast or breast ducts) to another part of the body. Stage V or unclassified cancer cannot be staged, because all information is missing. \n\nSmoking history:\nNumeric variable: Tobacco causes many cancers, including breast cancer. One study (1) and many other studies indicate that there is no statistically significant difference in mortality between smokers and non-smokers. Although a significant proportion of the smoking population may die of some cause, it is hard to say how much it is due to tobacco and how much is due to other reasons (e.g., diabetes and obesity, which are comorbidities associated with tobacco use). \n\nFor example, in the clinical trial we are assessing this year, it is mentioned in the first three lines (line_number=3,305, line_number=3,335, line_number=3,455) of the patient_note_0011_02 patient note that: \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She",
        "label": 2
    },
    "436": {
        "output": "## Examples \nThe first two input tables and the output table are following.\n![input tables](./files/inst_trial_example/table0.csv)\n![input tables](./files/inst_trial_example/table4.csv)\n![output table](./files/inst_trial_example/table_example_output.csv)\n\n<EOD> Evolution: an overview.\n\n This overview of human evolution is organized by the physical and cultural features which distinguish human beings from other primates. Topics covered include human physiology and physiologically important proteins, the human genome, human genome organization and regulation, human DNA sequences, the origins of the human species, and human social organization.\n<EOD> .\nOBJECTIVE\nTo study the regulatory role of insulin-growth factor-1 (IGF-1) in the proliferation and apoptosis of hepatoma MHCC97H cells.\n\n\nMETHODS\n1. Western blot or Northern blot was used to investigate whether IGF-1 receptor (IGFR) and IGFR type-1(IGF-1R) were expressed in MHCC97H. 2. MTT assay( 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) was performed to investigate the effect of insulin on cell proliferation. 3. MTT assay was performed to investigate the effect of IGF-1 on cell proliferation. 4. Flow cytometry and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL), or combined with Annexin-FITC, or Hoechst33342/ PI stainning of MHCC97H cells was performed to study apoptosis induced by insulin or IGF-1.\n\n\nRESULTS\n1. The expression of both IGFR and IGF-1R were found in MHCC97H cells. 2. The inculation of insulin",
        "label": 0
    },
    "437": {
        "output": "<EOD> Ginsenoside Rg3 inhibits gastric cancer through TXNIP/TRX/ROS\u2010mediated mitochondrial\u2010dependent apoptosis\nDistant metastasis is one of the major causes of death in patients with gastric cancer (GC). This study aimed to explore the therapeutic effect of ginsenoside Rg3 (GS\u2010Rg3) on GC tumor growth and its underlying molecular mechanism of action. The effects of GS\u2010Rg3 on cell proliferation and its underlying mechanisms of action were examined in MGC803 tumor\u2010bearing nude mice, SGC\u20107901 cell line, and GC cell lines with wild\u2010type p53 (p53wt) and knockout p53 (p53\u2010/\u2010) gene. Cell Counting Kit\u20108 assay, tumor cells flow cytometry, enzyme\u2010linked immunosorbent assay (ELISA), and western blot were used to confirm the effect of GS\u2010Rg3. GS\u2010Rg3 inhibited tumor growth and increased cancer cells apoptosis mainly through the mitochondrial\u2010dependent pathway. Moreover, we found that GS\u2010Rg3 increased the expression of thioredoxin\u2010interacting protein (TXNIP) and decreased the expression of thioredoxin (TRX), subsequently inducing oxidative stress to inhibit tumor cells growth. Furthermore, GS\u2010Rg3 inhibited AKT/NF\u2010\u03baB signaling pathway and regulated the Bcl\u20102/Bax ratio by increasing TXNIP and decreasing TRX to induce apoptosis. Notably, p53 gene mutation abolished the activity of GS\u2010Rg3 in inducing apoptosis, which was mainly through the PI3K/AKT pathway, but not the TXNIP/TRX pathway. These results suggested that GS\u2010Rg3 activated TXNIP/TRX pathway by upregulating TXNIP and downregulating TRX to modulate oxidative stress, consequently activating mitochondria\u2010dependent apoptosis to block tumor cells growth. Importantly, GS\u2010Rg",
        "label": 1
    },
    "438": {
        "output": "3.2.3.5 The end of the code for generating the result 4) \n\n## [inst] Hello. This is a simple code for generating the result. If I had to explain the whole flow, 1) I would explain how to read the data, 2) I would explain how to process it, and 3) I would explain how to \noutput the result. It would be a little long. So, I'll simplify a little bit.\n\nI'll assume that all of the data are already in a CSV file. And all of your work is done on a code window that is \nin the editor of an integrated development environment (IDE). I chose to code in Python, but you could use any \nprogramming language you prefer. However, please note that the following code cannot be executed in \nWindows NotePad. 4) \nThe  data file that I used in the previous examples. As you have guessed, I got data in that\n\n\n[censored]\n\nI read the data as follows:\nimport numpy as np\nimport matplotlib.pyplot as plt\nimport pandas as pd\nfrom io import StringIO\n\ndata = pd.read_csv(\"README.csv\", encoding=\"utf-8\")\n\ndata[\"Cancertitans\" = data[\"Cancertitans\"].map({-1:128, 0:127, 1:126,\"NaN\":np.nan})] 5) \n\nI plot one of the data rows.\nimport matplotlib.pyplot as plt\n\ncancertitle = \"Title\"\ncancrtage = \"Age\" 6)\n\nt = data[\"canscertitle\"].sample(51)\nylabel = data[\"cantagere\"] \nxlabel =  data[\"cangertime\"]\nplt.plot(t.value,ylabel,yerr=ylabel,xlabel=xlabel )\nxlabel.set_fontsize (10)\nylabel.set_fontsize (10) 7) \n\nI save the code in a separate file.\nprint \nfilename = 'sample_output.csv\"'\nfile=open(filename,'w')\nfile.write(\"cancertagere\\t\",\"nan\"*4)",
        "label": 0
    },
    "439": {
        "output": "<EOD> In vitro cell culture and microinjection for study of osteoblastic differentiation.\nSeveral different cell lines have been used for in vitro studies on the processes involved in osteoblast-like cell differentiation. Some are more osteoblast-like after transfection with appropriate cDNA expression vectors than they are immediately postconfluence, and microinjection of DNA and RNA can be used to induce some of the more osteoblast-like cell changes.<EOD> The prevalence of malaria infection in the population of Homa Bay District, Kenya, assessed by rapid dipstick test or by conventional microscopy\n\nBackgroundMicroscopy remains the gold standard for routine diagnosis of malaria infection in Africa; however the requirement for on-site expertise and complex procedures can be prohibitive to its use. It is widely understood that microscopy is insensitive for Plasmodium infection at low densities and only 50% of P. falciparum malaria infections in endemic regions have been detected by microscopy. The use of antigen-capture tests, such as Paracheck-Pf \u2122 , to screen for malaria infection might represent a practical alternative to microscopy but the sensitivity of Paracheck-Pf \u2122 has not been evaluated systematically using field samples.MethodsWe assessed the diagnostic performance of Paracheck-Pf \u2122 against microscopy in a field setting by comparing test kit results with microscopy findings for 7085 finger-prick and 110 venous blood samples collected from 16 locations in the Homa Bay District of western Kenya. Rapid diagnostic test sensitivity was compared with microscopy with samples from patients whose slides were positive for malaria parasites at 10% parasitaemia and from those whose slides were negative for malaria parasites.Results Paracheck-Pf \u2122 had similar sensitivity (94.7%; 95% CI 92.4-96.2) to expert microscopy and a lower sensitivity (91.3%; 95% CI 87.3-94.8) than local non-expert microscopy. Rapid diagnostic test sensitivity was similar (",
        "label": 2
    },
    "440": {
        "output": "<EOD> .\n\n The author describes the results of surveys conducted about family demographics in several regions of Vietnam. The surveys found that the average size of households is smaller than 6 persons because of emigration of men or the death of elderly men and women. Younger families also average fewer members, but because of the higher proportion of adults in such households, their average size is not smaller than older households. The total fertility rate in the 5 central provinces is 3.7, whereas the national figure is 6.1. The 4 northern provinces, however, have a total fertility rate of only 2.4. This results, it is thought, from the higher age of marriage and lower age of birth for children. According to the survey, the rate of secondary school matriculation in the 5 central provinces is about 5%. This rate should double because of the increased number of young persons. However, in the northern provinces the majority of young persons will not have a higher education level, and therefore, the rate of secondary school matriculation will not increase. The survey found that the ideal age of marriage in southern Vietnam is 23 years of age for a man and 19 years old for a woman. The ideal number of children is about 3 at present. In the north the preferred age for marriage is around 25 years for a man and around 23 years for a women. There is generally an ideal number of 7 children. (author's modified)\n<EOD> Inhibition of HIV-gp120-induced CD4 T Cell Death by Chrysin Is Mediated through the Mitochondria-caspase Pathway\n\nBackground: HIV-1 GP120 induces apoptosis in CD4 T cells, playing a role in CD4 T cell depletion and the development of AIDS. Chrysin (5,7-dihydroxyflavone) is a natural polyphenol that has a variety of pharmacological activities. One such activity is protection from apoptosis by inhibiting caspase activation in different apoptotic systems. Chrysin down-regulates HIV replication at various phases of the viral life cycle, and can also reverse HIV-induced apoptosis in mitochondria-mediated pathways. However, it is still not clear whether chrysin",
        "label": 1
    },
    "441": {
        "output": "You should write in a script file of the file of the current directory. A script file should follow the Pandas conventions.\nIf the current folder contains multiple clinical note files, you should choose the desired file according to a certain name pattern.\n[INST]\n## Note name pattern\n\n[INST]\nThe patient is a 45-year-old post-menopausal woman with cytologically -confirmed breast cancer. A core biopsy revealed a  cm -invasive ductal breast carcinoma -in the left upper outer quadrant. The tumor is  HER2 -positive and ER/PR -negative. Axillary sampling revealed -5 -positive lymph nodes. CXR -was remarkable for metastatic lesions. The patient is -using multivitamins and iron. She does not smoke or consume -alcohol. She is -not sexually-active and has -no children. -She is a candidate to tumor resection, agree to do so prior to chemotherapy.\n<EOD> .\nThe study was carried out to search for a method for the quantitative detection of 2,4-Dinitroanisole, 2-Methyl-4-amino-6-methylphenol, 2-Methyl-4-(2,4-dinitro-phenoxy)phenol in spiked samples. A rapid HPLC method with fluorescence detector using reverse phase-ODS column was developed for this purpose. Under the optimum conditions a good linear correlation of peak areas to concentrations existed over the range of 0.5-2.9, 0.5-5.0, 0.5-2.0 microgram/mL with correlation coefficients of 0. 998 2, 0.9988, 0.9949, respectively. The limit of detection was 0.2, 0.1, 1.2 microgram/mL , respectively. The mean recoveries were 95.4%, 98.6%, 95.7%. The intraday and interday RSDs were in the range of 1.7%-6.3% and 2.3%-8.7%, respectively. The method was",
        "label": 1
    },
    "442": {
        "output": "## Implementing your solution to the task: Python\n### Problem\nIn this lab you have to read a Python file `clinical_data.csv` and assign each individual to a group based on their diet. You have to group all the participants into [\u2026][INS\u2026] three categories: Control, High Omega-3 and Seafood. For the group 'High Omega-3' people have to have Omega-3 as their main diet source. For 'High Seafood' people have to have seafood as their main diet source.\nAfterwards you are required to do these things:\n- 5. Create a list of people that are in the control group.\n- 6. Compare each person, that is not in the 'High Omega-3' or the 'High Seafood' group, with the controls. If they have the same food intake they will be assigned to the 'Other diets' group.\nNow continue reading the following steps. Each row of the file has one person in each category and dietary intake:\n\n### Solutions\nFor your solution to the problem, you must create a function, `addtoGroup`, that takes as arguments the category, the person and their diet and returns a list of the people assigned to that category. It should also take care to return an exit value in case the person is neither in the `high fish` group (`High Omega-3`) nor the `high seafood` group (`High Seafood`).\n\n```python\ndef addtoGroup(person,category,diet):\n    if category == 'highomega3 :\n       Group.append(person)\n    elif category == 'highseafood :\n       Group.append(person)\n    else:\n       Group.append(person)\n    return\n```\n\nNext, you have to create the main function to solve the problem. After the input data is introduced and you call the function `addtoGroup`, you have to repeat the steps 4-5. The loop stops when the exit statement is reached, the first exit is for the case when there's a person that doesn't fit into any of the categories. The output should be as follows:\n\n```python\ngroup_1 = [\"<NAME>\", \"Alex\", \"HighSeafood\", \"<",
        "label": 0
    },
    "443": {
        "output": "</details>\n\n\n## How to Improve the Efficiency of R Shiny Apps\nTo improve the efficency of R Shiny apps, you can add packages available in CRAN.\n\n<details>\n<summary><b>Packages: To Improve the Efficency of R Shiny Apps</b></summary><br><ul>\n<li>data.table (data.table:: fread)</li>\n<ul>\n<li>tidyverse (dplyr:: dplyr)</li>\n<li>readxl (readxl:: read_xlsx)</li>\n<li>Rcpp (Rcpp:: ropennorm)</li>\n<li>tableone (tableone:: rtableone)</li>\n<li>ggplot2 (ggplot2:: ggpubr)</li>\n</ul>\n</li>\n<li>shiny_cssmodifyR (shiny_cssmodifyR:: apply css class, shiny_cssmodifyR:: adjust the theme)</li>\n<li>shiny_jsconvert (shiny_jsconvert:: use js, shiny_jsconvert:: add custom js)</li>\n<li>rcompanion (rcompanion:: quickr)</li>\n</ul>\n</details>\n\n## Discussion\n<h3>What to consider before starting learning?</h3>\nLearning the Shiny framework will require you to understand the logic of the programming language, R. You must also learn how to operate in a graphical user interface (GUI) environment and how to set up a package. In the end, R Shiny apps can provide important analytical tools to support decision making within any industry setting.\n\n<h3>Forget to ask for help and advice!</h3>\nDon\u2019t forget to ask for help and advice from experts, including friends, families, and colleagues in similar fields. Once you\u2019ve built a Shiny app, you\u2019ll likely need to learn how to share and disseminate it to the right audience.\n\n<h3>Do not judge the quality of an R Shiny app by a single test alone</h3>\nDo not judge the quality of an app by a single test alone.",
        "label": 2
    },
    "444": {
        "output": "## If the drug is a placebo or sham, please describe in detail and then click the corresponding box.\n\n###",
        "label": 0
    },
    "445": {
        "output": "## \u25b6 question 8\nWhat is the output of the task? \nAnswers: 2) `PATIENT ELIBILITY REPORT`, 4) `Patient eligibility report`<EOD> The prognostic value of serum thymus and activation\u2010regulated chemokine levels in Hodgkin lymphomas\nThymus and activation\u2010regulated chemokine (TARC) is overexpressed in Hodgkin lymphoma (HL), and it is related to aggressive disease and poor outcome.<EOD> Expectations and attributions of positive and negative emotional experiences: a meta-analysis\nThe influence of appraisal on emotional experience has not been evaluated systematically. We report a meta-analysis of 34 experiments investigating whether positive and negative emotion is judged as greater when they are caused by a desirable (vs. undesirable) standard or are expected versus unexpected. Across a variety of emotions, valences, methods of assessment and time of assessment (the affective forecasting paradigm), participants report higher levels of emotion when it is judged to be caused by a desirable (13 studies; r\u0304= .36) or expected standard (31 studies; r\u0304= .18) than when it is judged to be caused by an undesirable (12 studies; r\u0304= .09) or unexpected standard (15 studies; r\u0304= .14). Overall, these findings suggest that appraisals of positive and negative emotional experiences are influenced by the desirability and expectancy of certain experiences.<EOD> Combining Bias Control Methods: Bias Variance Dilemma and Efficient Estimation\nThe bias variance dilemma often arises when both bias and variance are undesirable. If the variance of the data is well explained by simple parameters, a single method may be preferred to eliminate the variance. However, if the variance is not well explained by the simple parameters, using any of the single methods might be worse than simply collecting a large amount of data, which implies that using any of the single methods might induce an unnecessary loss of information, due to the inherent restriction on the available covariate sets. This paper proposes a two-step framework to address this issue. Our objective is",
        "label": 0
    },
    "446": {
        "output": "## Expert Review from Dr. Shi-Yuan Cheng, MD, PhD\n\n\n### General Comments From Dr. Shi-Yuan Cheng, MD, PhD\nTrial-level Eligibility:\nWhen calculating the percentage of \"eligibility\", we have to ignore the patients that are excluded due to \"inclusion exclusion criteria\" but are excluded due to \"exclusion criteria\", e.g., excluding patients older than 85.\n\n### Score From Dr. Shi-Yuan Cheng, MD, PhD\nQ #3\n30%\nRating: 3\n\n### Comprehensive Comment From Dr. Shi-Yuan Cheng, MD, PhD\n\n### Score From Dr. Shi-Yuan Cheng, MD, PhD\n30% \nTrial-level Eligibility: \nWhen calculating the percentage of \"eligibility\", we have to ignore the patients that are excluded due to \"inclusion exclusion criteria\" but are excluded due to \"exclusion criteria\", e.g., excluding patients older than 85. \n<EOD> Dual antisense oligonucleotides targeted to interferon\u2010regulatory factor 1 and hepatocyte nuclear factor 4\u03b1 are capable of suppressing HCV replication in liver cells\nInterferon\u2010regulatory factor 1 (IRF\u20101) and hepatocyte nuclear factor 4\u03b1 (HNF\u20104\u03b1) are key transcription factors that play an important role in the regulation of the expression of antiviral cytokines. In fact, in hepatocytes which are infected by hepatitis C virus (HCV) and are simultaneously treated with anti\u2010HCV compounds, HCV suppresses the basal activity of IRF\u20101 and activates HNF\u20104\u03b1, resulting in suppression of IFN\u2010\u03b1 secretion. Here, we examined the inhibitory effects of a double antisense oligonucleotide (DASO) that consists of two antisense oligonucleotides (A and B), which correspond to the first and second inhibitory antisense elements, on IFN\u2010\u03b1 secretion by targeting IRF\u20101 and H",
        "label": 0
    },
    "447": {
        "output": "___\n\nWe hope you have learned a thing or two about this data. Thank you. Thank YOU!\n\n[INST]\n[TRIAL]\nIn this module, we will learn about [TRIAL]:\n  * how to select a clinical trial\n  * what's needed for a data scientist to do when participating in a clinical trial\n  * what clinical trial protocol is\n  * what a clinical trial workflow is\n\n\n\n**What's needed**\nSome of the information is stored in the electronic medical records. Some of the information is from other clinical trials data warehouses. Some of the records are from other sources like NCI. Some of the data are stored in the clinical trial protocol. We will introduce you to all these sources after learning their structures and their relationships and their interactions.\n\nHere is an XML document representing structured data from a clinical registry.\n\n```xml\n<clinical_trial ID=\"111\" \n  start_date=\"1982/01/13\" \n  end_date=\"1984/01/09\" \n  status=\"pilot\" \n  recruit_number=\"70.12345678\" \n  recruit_goal=\"80.40034876\" \n  location=\"Seoul\" \n  sponsor=\"Golden\" \n  sponsor_ID=\"777\" \n  sponsor_type=\"government\" \n  status_info=\"The clinical trial was suspended because clinicians decided that the target patients were getting into the clinical trial too late. They have notified the clinical agency who has agreed with the fact. \" \n  institution=\"781\" \n  institution_type=\"hospital\" \n  PI_ID=\"038\" \n  PI_type=\"Clinical\" \n  enrolled_number=\"12.34567890\" \n  funding_source_ID=\"895\" \n  funding_source_type=\"non_profit\" \n  primary_outcome=\"yes\" \n  primary_outcome_type=\"yes\"",
        "label": 0
    },
    "448": {
        "output": "Let's make a trial-level eligibility:     [![Screenshot-2018-11-25-193521](https://user-images.githubusercontent.com/44824593/51073430-3354ed00-111c-11e9-966b-560e59b67f9e.png)](https://github.com/pavlova-lab/pavlovainstllmlab/blob/master/datasets/patietnote/patientnote_sample.json)     ```\n#2\n\n[![Screenshot-2018-11-27-180320](https://user-images.githubusercontent.com/44824593/51225359-2f7aa180-128a-11e9-9dfb-8714b296ef52.png)](https://github.com/pavlova-lab/pavlovainstllmlab/blob/master/datasets/eligibility_score/eligibility_score_sample.json)\n\n```julia\nusing Dates\n\nconst date =\n    \"2018-11-27T19:12:54.469Z\"\n```\n\nLet's create a model with a predictor of date: \n```julia; for(j = 7:#size(b3::SymbolArray, 1);j < size(b3::SymbolArray, 1); j = j + 1)\nresult <- c(\"eligibility_score\")[j]\nprint(\"Predicting scores for \" * result * \" variables:\")\nprint(\"```julia; for(x = 1:size(m[:,result], 1);x < size(m[:,result], 1); x = x + 1)\nm[:,result] = rebind(m[:,result],x) * 60 * 60*24*365.24\n\nresults[:,1] =",
        "label": 0
    },
    "449": {
        "output": "__Exercise 2__\nThis is the sample data of patient data from our clinical trials repository: `cdaf-1-211404.json`.\n\n# 1. Load dataset\nTo load sample data from cdaf.json files, set `Load = true` in `ClinicalTrials`. Call `Data` function for an example, and use `SaveTrainingSet = true` argument to save a subset of the training data:\n```python\nIn:\nclt.load(Load=True, SaveTrainingSet=True)\nOut:\nclt.Data.sample_data[Load]\nIn:\nclt.Data\nOut:\nIn:\nclt.Data.sample_data[Load]\n```\n\n# 2. Filter Clinical Trials\nThe first step of assessing the eligibility of a patient to a trial is to filter the trials. First, set `exclude_patient_age` to filter out trials that exclude patients based on age. Similarly, set `exclude_menopause` and `exclude_stage`, respectively, to exclude patients not in stage T1 and patients with stage T4, the most advanced stage. In this trial dataset, no trials apply age or menopause criteria. If you have other data from clinical trials that you would like to filter out, you can create a dict and add those keys to the `clt.Data.filter_trial` attribute:\n\n```python\nIn:\npat_criteria = {\n    'exclude_age': True,\n    'exclude_menopause': True,\n    'exclude_stage': True,\n    'exclude_other': {\n        'exclude_all_diseases': True,\n        'exclude_menopause_or_age': True,\n        'exclude_menopause': True,\n        'exclude_age': True,\n        'exclude_tumor_size': True,\n    }\n}\n\nclt.load(Load=True, SaveTrainingSet=True)\nclt.Data.filter_trials = {}\nclt.Data.filter_trials['exclude_patient_age'] = True\nclt.Data",
        "label": 1
    },
    "450": {
        "output": "[/CMD]\n\n\n[INST] Good morning. The current task is to predict a label given a patient note and features associated with it. \nThe problem is formulated as follows: given a set of patient notes with associated features describing a patient, make predictions about the label of a new patient note. \n\n[CMD] Prediction is possible for a patient on the basis of known patients of the clinic whose patient notes and features are available in the training set. The patient note and features of the patient are then compared to those of patients in the training set. For each pair of a known patient and a test patient whose features are similar, the label of the known patient is assigned to the test patient. This procedure is repeated for all patients in the training set, and all given patient notes can be predicted based on the distribution of the labels of the known patients.\n\n\n[INST] Let's make predictions of label for the patient. You will have access to the patient note, as well as the patient profile, of other patients whose notes we have seen as part of the training set. Your task here is to make predictions about the labels for the patient by using a function: label:predict(notes: string array, patient_profile: string array) -> string array. The notes of the patients in the training set have already been scored. The function returns the predictive labels for the patient note you input. Here's an example of prediction outcomes: `label:predict([{'age': 62, 'ethnicity': 1, 'sex': 1},{'ethnicity': 2, 'sex': 2}], patient: {'age': 62.4, 'ethnicity': 1, 'sex': 2}) -> {'age': 62.4, 'ethnicity': 1, 'sex': 2, 'label': ''}`. You can see that the labels of the training patients are shown, their scores are shown in brackets after the label. All labels have scores of 0, except the '2' entry ('sex' = 2) which has a score of 1. Here's an example of the function's outputs for 2 different patient notes: \n`label:predict([{'age': 62, 'health': 1, 'sex': 1, 'hivpos': 1},{'age",
        "label": 0
    },
    "451": {
        "output": "* `Criteria for eligibility of patients is an important element of a clinical trial. Make sure your criteria are the same as the author's and are written according to the author's format. If there are many eligibility criteria, make sure all of them are listed. Write them with the same order listed by the author. Use the same format, as listed in this example too.* \n\nNow, try one of the questions from the practice.\n\nTo start the process, you have to click on the button \"Practice\".\n\nOnce you open the practice, all items on `Task` block will be available for editing. To create, edit or view an item about a `task` use the `Menu -> Tasks`.\n\nMake sure you edit the question on the `Task` using the textbox. The question to edit is:\n\n\"To start the process, you have to click on the button \"Practice\".\n\nThe text is surrounded by the `Task` block with the name of the question. Your options are: \n\n- *`Task`: Create New task*\n- *`Task`: Delete task*\n- *`Task`: Reset Task*\n- *`Task`: Edit Task*\n- *`Task`: Show tasks*\n- *`Task`: Clear tasks*\n\nHere an example of the `Task` edit mode:\n\n![](screenshots/trial-based-questions/practice/edit_task.png)\n\nOnce you finish to create the `Task`, you have to click the button `Save` to save the changes you implemented. When you have done, close the window with the button `OK`.\n\n* `You have created a task called `Trial-based questions`.` \n\n![](screenshots/trial-based-questions/practice/edit_task.png)\n\nOnce you save your changes, you have to click again the button `Practice` to edit the rest of the tasks (in this example, as you edit this task, the word `New` will be changed to `Edit`). \n\n![](screenshots/trial-based-questions/practice/edit_task.png)\n\nTo create a task, click on the button `Create Task` from the main window (button with the 9",
        "label": 0
    },
    "452": {
        "output": "<EOD> .\nBACKGROUND\nSyphilis is still a sexually transmitted infection with major public health consequences, being one of the three infections in the United States of America with the highest incidence. We present epidemiological, serological, clinical and therapeutic characteristics of a woman with congenital syphilis who attended the outpatient clinic of Endemic Diseases of the \"Dr. Eduardo Torres\" hospital of the Havana Municipality during a period of approximately 15 months.\n\n\nPATIENTS AND METHODS\nA case study is reported of a 8-year-old girl child presenting clinical and serological characteristics of congenital syphilis in addition to her mother's serological data.\n\n\nRESULTS\nClinical manifestations include hepatomegaly and splenomegaly detected by image examination and a positive nontreponemal test and syphilitic serological tests (Treponema pallidum hemagglutination test and T. pallidum fluorescent treponemal antibody absorption test). This patient and three other members of the family were diagnosed, serologically proven, as suffering from syphilis, and her mother was treated.\n\n\nCONCLUSIONS\nThe outpatient clinic of Endemic Diseases of the \"Dr. Eduado Torres\" hospital detected a case of congenital syphilis with no signs or symptoms, a fact that illustrates the important role that outpatient services play in primary health care.<EOD> A novel role for NF-kappaB in apoptosis: induction of the apoptosis inhibitor ARC.\nThe ubiquitously expressed protein amyloid beta precursor-binding protein (Arc) was isolated as a nuclear protein in fibroblasts undergoing apoptosis induced by ultraviolet light. To investigate a potential signal involved in transcriptional up-regulation of the arc gene during apoptosis, promoter analyses were performed and results showed a cis-acting element homologous to the NF-kappaB consensus sequence (5'-GGG(n)GGG-3') located -37 bp upstream of the transcriptional start site.",
        "label": 0
    },
    "453": {
        "output": "1. Determine which features of the patient match the inclusion criteria of 1) Prognosis and 2) Prediction. \nHistology and tumor size are both features present in the prognosis inclusion criteria. Therefore:\n\n## Histology\nTrue\n\n## Tumor size\nTrue\n\nAdditionally, age is present as an inclusion criteria within the prognosis and also within the prediction criteria. So:\n\n## Age\nTrue\n\n## Prognosis\nAdditionally, sex and children are not present as inclusion criteria in the prediction criteria. So:\n\n## Sex\nFalse\n\n## Children\nFalse\n\nAt first glance, this would be the end of the match at the inclusion criteria level. We are left with the following results:\n\n# Tissue-level eligibility\nThe patient also matches the exclusion criteria for this trial. The following data is present:\n\n## Trial-level eligibility:\nFalse\n\n## \nThere are no clinical factors that make the patient eligible for recruitment into the clinical trial.\n<EOD> Effects of a commercial diet containing 1% L-arginine on skeletal changes in the distal part of the femur in juvenile broiler chickens\n\nL-arginine, an essential amino acid, has been shown to have a synergetic effect when supplemented with other amino acids on broiler growth. The aim of the present study was to examine the effect of dietary Larginine supplementation on skeletal changes in the distal part of the femur of young Ross broiler chickens. A total of 128 chickens (24 females and 104 males) were used in a controlled, repeated study (7, 21 and 35 days of age) with nine dietary treatments (388 g kg -1 of wheat with no additional amino acids supplementation [C], 1,500 g kg -1 of wheat [W], 7 g kg - of hydrolysed casein diet and 0.3% L-arginine supplementation [LC], 70 g kg -1 L-cystine with 0.3% L-arginine supplementation [LCa], 0.0",
        "label": 0
    },
    "454": {
        "output": "<EOD> Correlation Between N6-Methyladenosine Regulators and Immunotherapy Response in Hepatocellular Carcinoma\n\nThe immunotherapy of hepatocellular carcinoma (HCC) is emerging as a promising antitumor method. Although m 6 A modification has been confirmed to play a vital role in immunotherapy, the regulatory factors of m 6 A modification in anti-immunotherapy are unclear. This study aimed to identify m 6 A-related genetic biomarkers to predict the efficacy of cancer immunotherapy in patients with HCC. ESTIMATE was employed to explore the potential association between m 6 A regulators and the immune response. Then, we used CIBERSORT to assess the correlations between m 6 A regulators and 22 immune cell types and analyzed TIDE and immunophenoscore to identify immunotherapy sensitivities. Additionally, Cox regression was conducted for risk survival analysis, and multivariate Cox regression analysis was executed to determine the independent prognostic factors of anti-PD1-resistant HCC. The results showed that the expression of m 6 A regulators was negatively correlated with stromal and immune scores. There were 19 m 6 A-related gene pairs exhibiting statistical differences in immunotherapeutic sensitivities, and nine of them predicted immunotherapy sensitivity. Univariate and multivariate Cox regression analyses indicated risk score was strongly correlated with clinical outcomes. Furthermore, gene pairs related to immune infiltration, such as ELAVL1-YTHDC1, ELAVL1-HNRNPA2B1, YTHDF1-ALKBH5, and YTHDF2-FTO, could be used as potential prognostic indicators. Finally, six genes (ALKBH5, HNRNPA2B1, YTHDC1, YTHDF1, YTHDF2, and ELAVL1) were identified as independent factors of immunotherapy sensitivity. The current results may provide a rationale for combining immunotherapy and targeted therapy to achieve the best treatment effect.\n\n# Introduction\nHepatocell",
        "label": 1
    },
    "455": {
        "output": "### Notes for the next time\nThe following is the list of cases we need to consider.\n1. Whether the trial-level assessment is 1 (eligible) or 3 (not relevant): The patient note should be evaluated as 2 (eligible) in such a case. \n 1) Eligible: The result of the patient note should be output as the result, e.g., `PatientNote-level assessment: 2) Eligible.`. \n 2) Eligible: The patient note should be evaluated as not relevant in such a case. \n   1) Not relevant: Output the results by: `Not relevant (not enough information)`.<EOD> Detection on cerebral palsy in patients with congenital hypothyroidism.\nPURPOSE\nOur aim was to determine the incidence of cerebral palsy among our patient group with congenital hypothyroidism and to compare the outcomes with other epidemiological studies.\n\n\nMETHODS\n40 patients who were diagnosed as congenital hypothyroidism were questioned retrospectively. The mean follow up period of patients was 12.03 +/- 2.67 years (11-24 years). Age and sex were compared with the literature. Also, neurological examinations, neurodevelopmental examinations and anthropometric measurements were examined. All the statistical analyses were performed using SPSS 13.0 program.\n\n\nRESULTS\nThe group consisted of 20 women (50%) and 20 men (50%) with the mean age 20.30 +/- 1.25 years. The mean height of girls was 156.72 +/- 6.69cm and of boys 165.63 +/- 7.92cm. Thirteen (32.5%) patients received thyroxin replacement therapy. Neurodevelopmental examination revealed one patient's cerebral palsy; and of neurological examination, four patients gave abnormal findings.\n\n\nCONCLUSION\nCongenital hypothyroidism is an important cause of permanent neurological damage which may result in",
        "label": 0
    },
    "456": {
        "output": "---\n\n## Data.\n## Summary: Here is the data.\n\n*Each row is a record (a set of columns) associated with a person.*\n\n*Each column is the value of one column of person's medical record.*\n**Note: some column names do not correspond to their medical meaning as they are only used as identifiers as below.**\n\n| col1    | col2    | col3    | col4    | col5    | col6  | col7    | col8    | col8    | col9    | col10   | col11   | col12   | col13   | col14    | col15    | col16    | col17    | col18    |\n**Key:\ncol1**: patient id **(same for all people)**\ncol2**: gender (male/female)\ncol3**: birth year\ncol4**: birth month\ncol5**: birth day\ncol6**: is alive now (1/0)\ncol7**: smoking status(1/0)\ncol8**: drinking status (1/0)\ncol9**: is candidate for surgery (before randomization for the phase 2 trial)(1/0)\ncol10**: candidate for chemotherapy (after randomization for the phase 2 trial)(1/0)\ncol11**: candidate for radiotherapy (after randomization for the phase 2 trial)(1/0)\ncol12**: HR(1/0)\ncol13**: HER2(1/0)\ncol14**: tumor size  (1/0)\ncol15**: type of tumor \ncol16**: stage(1/2)\ncol17**: localization (1/0)\ncol18**: affected site(1/0)\ncol19**: affected visceral organ(1/0)\ncol20**: is candidate for cytotoxicity profiling  (1/0)\ncol21**: is candidate for biomarker analysis  (1/0)\ncol22**: is candidate for censoring (1/0)\ncol23**: ex",
        "label": 0
    },
    "457": {
        "output": "Let's now look at how to apply the conditions as inclusion criteria in the form of `If` statements. In the following, the first expression checks whether the patient is over 18 years old, the second expression if the patient has invasive breast cancer, the third expression if the patient has tumor stage 1 to 3, the fourth expression if the patient has a HER2+ or triple-negative tumor (tumor is histologically positive for HER2/ERBB2 or negative for PR and HER2/ERBB2), and the last expression if the patient received 3 cycles of neoadjuvant systemic therapy. It is not sufficient to have had chemotherapy; one must additionally include information about the start and end of chemotherapy. Let's start with a statement that checks if the patient's status was female. This statement is not displayed in the program output. \nfemale \u2190 1 / 0\n\nThen we evaluate if the patient is older than 18 years by comparing it to the date of birth, which we take from the patient note file. \nbDateOfBirth \u2190 read.csv(\"patientData.csv\") \nage \u2190 strftime \ndate \u2190 strptime(age, \" %b %e\", loc = \"en_GB\") \nif bDateOfBirth %d %s > 18:\n    female \u2190 0\n\nWe then look for the presence of breast cancer in the pathological report of the core biopsy. \nif bBreastCancerPathology \u2264 \"no\" :\n    female \u2190 0\n\nA statement is added below to continue with the evaluation of a possible tumor stage 1 to 3. The expression is not shown in the program output. \nif bTumorStage \u2264 \"1\" | bTumorStage \u2265 \"3\":\n    female \u2190 0\n\nIf the patient has a HER2 + or triple-negative tumor (tumor is histologically positive for HER2/ERBB2 or negative for PR and HER2/ERBB2), the following is calculated. \nif bTumorType \u2264 \"HER-2-neu positive or triple negative\" :\n    female \u2190 0",
        "label": 0
    },
    "458": {
        "output": "[CODE]\n```\ndef eligibility(patient_record, trial_record):\n    if 'ageGroup' in patient_record:\n        for age_group in patient_record['ageGroup']:\n            if 'age' in age_group:\n                age = age_group['age']\n            else:\n                age = age_group\n\n    if 'age' not in patient_record:\n        return Trial-level eligibility(2)\n\n    if patient_record['age'] < trial_record['min_age_eligibility']:\n        return Trial-level eligibility(0)\n    if patient_record['age'] > trial_record['max_age_eligibility']:\n        return Trial-level eligibility(1)\n\n    if 'gndr' in trial_record['age_group_eligibility']:\n        gender1 = patient_record['gender']\n        gender2 = trial_record['gndr']\n\n        if gender1!='F' and gender2=='M':\n            return Trial-level eligibility(2)\n        elif gender1!='M' and gender2=='F':\n            return Trial-level eligibility(1)\n\n    if patient_record['smoke_history'] == 'Yes':\n        if trial_record['smoke_history_eligibility'] == 'Yes':\n            return Trial-level eligibility(2)\n        else:\n            return Trial-level eligibility(0)\n    if trial_record['alcohol_history_eligibility'] == 'Yes':\n        if patient_record['smoke_history']:\n            return Trial-level eligibility(1)\n        else:\n            return Trial-level eligibility(2)\n\n    if patient_record['gravidity'] == 0:\n        if trial_record['gravidity_eligibility'] == 'Yes':\n            return Trial-level eligibility(2)\n        else:\n            return Trial-level eligibility(0)\n\n    if patient_record['parity'] == 0:\n        if trial_record['parity_eligibility'] ==",
        "label": 0
    },
    "459": {
        "output": "A: You first need to decide whether you want to write your program with or without IDE. There is a big difference between both the ways as they may result in two different levels of program.\n\nIf you use an IDE, it would give a warning to this line of code, so you will have to go to an editor and change its value to 2.\n\nOtherwise, you can write the code without IDE and let the system run the code without any problems or warnings.\nYou should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n<EOD> Aminoglycoside cross-resistance in Salmonella enterica serovar Typhimurium 4.3.7.12 associated with decreased expression of the acrB, marA and rpoP gene products.\nThree mutants of Salmonella enterica serovar Typhimurium 4.3.7.12 cross-resistant to different aminoglycoside compounds were obtained and characterised. All mutants exhibited significant reductions in the production of the acrB and marA gene products, a strong reduction in the production of the rpoP gene product and elevated expression of the mar and the pmrA gene products. It is concluded that these changes could be partially responsible for the observed cross-resistance.<EOD> Duration of therapy for uncomplicated acute sinusitis in adolescents and adults.\nBACKGROUND\nAntibiotics are recommended for acute sinusitis. However, evidence suggests that 10-day antibiotic courses may be adequate for most children with acute sinusitis.\n\n\nMETHODS\nAdults and adolescents, aged 18 to 55 years, with uncomplicated acute maxillary sinusitis (symptoms for  1 year) of sinusitis and the need for treatment for >/= 90 days. Eligible patients were randomized to receive either a 10- or 14-day course of amoxicillin/clavulanate at the usual recommended dose. The primary outcome was clinical response (complete",
        "label": 2
    },
    "460": {
        "output": "Notes\n[fig]  0: 040245121-0.139522403) 20-1000; 14.0 for the MAPE) [/fig] \n<EOD> Anorexia nervosa in adolescence.\nThis article describes how to develop a formulation of an adolescent with restricted intake in line with a biopsychosocial approach. The article reviews relevant cognitive, cultural, biomedical and personality literature in relation to anorexia nervosa in adolescents, and presents a biopsychosocial formulation of such a case. The clinical relevance of the formulation is examined, and a number of treatment options are discussed, including psychoanalytic, cognitive and family therapy approaches.<EOD> A randomized trial of a community-based educational intervention to increase mammography, Pap smears, and clinical breast examination.\nOBJECTIVE\nTo evaluate the efficacy of a community-based educational program on receipt of screening pap smears, clinical breast exams (CBEs), and mammography among Mexican American women.\n\n\nMETHODS\nThis randomized, controlled trial included 685 women aged 50 to 79 years who were assigned to receive either the intervention (n = 271) or the control (n = 414) message in 1993 (mean age, 60.3 years). Three 5-minute individual counseling sessions were provided by bicultural nurses. Outcome measures were receipt of screening mammograms and Pap smears between 6 and 12 months after the baseline interview (screening mammograms and Pap smears). CBE was performed, recorded, and interpreted by study nurses.\n\n\nRESULTS\nAt 12 months after the baseline interview, a total of 34.3% of control recipients and 53.9% of intervention recipients had received screening mammography (P < .0001). Among control recipients, 37.4% who were younger than 70 years had received screening mammograms at 12 months. The corresponding figures for intervention recipients",
        "label": 0
    },
    "461": {
        "output": "[/TEST]\n\n### Step 6: Include a brief, descriptive title at the top of a report and give the name of the person who created the report in an empty header row titled \u201cAuthor\u201d\n<commit_before>@INCLUDE_ONLY\n<HEAD><title>Test-1</title></HEAD>\n\n<BODY BGCOLOR=\"#EEEEEE\">\n<H1>Trial Eligibility: Breast Radiation Patient</H1>\n<H2 id=\"report_header\"><NAME>: Test-1</H2>\n<H3 id=\"report_header\"><NAME>: Test-1</H3>\n\n<H1 id=\"author\">Author: @{{author}}</H1>\n\n<H3 id=\"author\"><NAME>: Test-1</H3>\n\n<H5 id=\"report_author\">Report creator: <NAME> (<EMAIL>)</H5>\n\n\n<!-- <H3 id=\"report_body\"> -->\n<H4 id=\"test\">TESTS. Test 1.0</H4>\n<p>Hello Everyone,</p>\n<p>This will be for @username Test-1. What do you think?</p>\n<p>Thanks for reading! - <NAME></p>\n\n<H4>Trial-level Eligibility Summary</H4>\n<table border=\"1\" class=\"tab_tbl\" summary=\"Trial Eligibility Summary\">\n<thead>\n  <tr class=\"header_row\">\n    <th colspan=\"5\" scope=\"col\">Eligibility</th>\n    <th colspan=\"5\" scope=\"col\">Clinical Trial Exclusion Criteria Summary</th>\n  </tr>\n</thead>\n<tbody>\n<tbody>\n<tr>\n<td style=\"text-align: left;\" width=\"40%\" scope=\"col\">\nTrial-level Eligibility</td>\n<td style=\"text-align: justify;\" width=\"30%\" scope=\"col\">\n\n <div class=\"markdown_block\"><pre class=\"prettyprint\"><code><span style=\"text-decoration: underline;\">&lt;!--&gt; TITLE</",
        "label": 0
    },
    "462": {
        "output": "## Exercise:\nFor the exercise, you will get an example for patient and trial notes that you had not see before. Each file name is composed by three tokens: 'Patient', 'Trial', and a random number. E.g. Patient(1)-Trial(1): `PatDum1-TriDum1`.\nFor PatDum1, the patient note contains: \n    Title: Postmenopausal woman with breast cancer\n    Age: 46\n    Weight: 58kgs\n    Height: 165cm\n    Blood type: 0+\n    Breast condition: CIN1 lesion with normal breast tissue\n    Family status: Single, no children or siblings\n    Smoking: No history of smoking\n    Alcohol consumption: No history of drinking alcohol\n    Diabetes history: No record of diabetes\n    Hypertension history: No history of hypertension\n    Chronic illnesses: No record of chronic illnesses\n    Previous breast cancer history: No history of cancer\n    Previous other cancer history: No history of other kinds of cancer in the past\n    Previous radiation history: She received radiation therapy in 2011\n    Previous surgery history: She received surgery for breast cancer in 2013\n    Stage: Stage III (Node positive > 4)\n    Procedure: mastectomy\n    Procedure date: 11 April 2010\n    Treatment: chemotherapy, hormone therapy\n    Comorbidities: no comorbidities\nFor TestDum1, the trial note contains: \n    Title: Assessing the clinical effect of chemotherapy, hormonal therapy over anti-Her2 therapy for postmenopausal women with breast cancer\n    Summary: This is an open, randomized, controlled trial. The study will assess tumor-shrinking efficacy, symptom improvement and safety of anti-HER2 treatment for patients with HER2 negative disease, who are pre-menopausal or postmenopausal women.\n    Number of participants: approximately 600\n    Gender: 100% female\n    Age: Age should be between 18",
        "label": 0
    },
    "463": {
        "output": "## What have you done so far?\nThe most common issue is that the following code is returned `None.`:\n`Trial-level eligibility: None`\nThe second most common is the following error message being returned to the user: `None object is not iterable`.\nYou have also implemented a number of methods and functions that are very difficult to understand! That is not very flattering when we compare our performance to the other team.\nHow can we improve the codebase?\n\n# [SECTION1] First, let's discuss our thoughts on the solution\n\nWe have tried to understand the problem from four perspectives:\n\n- [SEC2] How to correctly implement the function `Trial-level eligibility: <i>?`. \n- [SEC3] How to improve our readability of the code. \n- [SEC4] How to optimize code runtime.\n- [SEC5] How to speed up the code base.\n\nNow let's look at the details of the problem by taking a look at the code itself.\n\n## Code solution in other teams\n\nLet's start by looking at the code solution offered by the other teams.\n\n### [CODESOL1] Solution 1\n\n```python\ndef Trial_Level_Eligibility_of_Patient(patient_note, clinicalTrials):\n    patient_eligibility_criteria = clinicalTrials[\"eligibility_criteria\"]\n    # The function returns a list of the trial criteria, a list of strings,\n    # each corresponding to an individual eligibility criterion in the trial.\n    \n    # The function also returns a list of the trial eligibility for this patient \n    #  in the given trial. In other words, the user can iterate through the \n    # trial eligibility using the for-loop, and based on the trial eligibility, \n    # it will be easier to decide the patient's trial eligibility based on\n    # the patient_records dictionary.\n    \n    # There will be 0 if there are no eligibility criteria that match the\n    # patient information given in the patient note. If there is a match\n    # patient_eligibility_criteria will contain an array of matched conditions",
        "label": 0
    },
    "464": {
        "output": "[TUTOR] Hello everyone. You are a recruiter for a clinical trial. Your task is to check the eligibility of individual patients to be assessed for the trial. Some information about your work is in the [patient note](#patient_note) and the clinical trial's [criteria](#criteria_description_for this_exercise).\nThe following patient notes may not all be true. Please make decision about each patient for the trial.\n- [patient_note.json](#patient_note)\n- [patient_1.json](#patient_1)\n- [patient_2.json](#patient_2)\n- [patient_3.json](#patient_3). \n\n\n## Patient [patient_note.json](#patient_note)\n```json\n{\n  \"first_name\": \"S\",\n  \"id\": 1,\n  \"last_name\": \"J\",\n  \"age\": \"42.0\",\n  \"gender\": \"male\",\n  \"body_site\": \"breast\",\n  \"pathology\": \"invasive ductal carcinoma\",\n  \"HER2\": \"3+\",\n  \"ER\": \"99%\",\n  \"PR\": \"75%\",\n  \"status\": \"remission\",\n  \"treatment\": \"< >\",\n  \"treatment_date\": \"2012-03-19T00:00:00.000\",\n  \"date_of_diagnosis\": \"2012-01-10T00:00:00.000\",\n  \"diagnosis_date\": \"2012-03-19T00:00:00.000\",\n  \"disease\": \"breast cancer\",\n  \"visit\": \"1\",\n  \"diagnosis_method\": \"histologic examination, <0.1% CTCs, [17.6%] of 23.7 CTCs expressed HER2\",\n  \"region_based_on\": \"US\",\n  \"race\": \"Caucasian\",\n  \"race",
        "label": 0
    },
    "465": {
        "output": "The trial-level eligibility is the sum of all patient-level assessments you gave so far.\n\nThe output of Clinical Trial Assist should be like the following example:\n\n[Clinical Trial Assist]: Breast cancer and advanced solid tumor clinical trial\n\n[Trial-level eligibility: 2) Eligible]\n\n### Exercise 2: Clinical Trial in HBV Patients with Resistance to Entecavir\n\nYour name:\nYour grade:\nExamination time:\nYour teacher's name:\n\nIn this exercise, you are the medical advisor for a new drug for infectious diseases, `Drug A`. Your task is to design a clinical trial to determine whether the new drug in combination with entecavir (Lead-In drug; labeled 'B') is safe and could produce a clinical response in patients infected with hepatitis B virus and resistant to entecavir (Lead-In drug). You are given the following information, including a table describing the safety and efficacy results from the two previous studies (Bohgaki et al. 2010. S44 and Lin and Lin 2005. S45). In S44,  infection, defined as a serum HBV level at least 10\u00d7 ULN higher than baseline level.\n\n### Instructions of the Exercise:\n\nWhen you are done, submit your answer at the back of the paper. You can have as much time as you like.\n\nBohgaki KP, Honda T, Yamazaki M, et al. A phase 2 trial of the combination of pegylated interferon alpha-2b and ribavirin in chronic hepatitis B patients with lamivudine-resistance. J Gastroenterol. 2010;45(5):424-33.\n\n\n\nLin CH, Chen HW, Hung CS: Combination of entecavir and lamivudine vs. entecavir monotherapy in lamivudine-resistant chronic hepatitis B patients with adefovir combination therapy history. Pharmaceut",
        "label": 0
    },
    "466": {
        "output": "## Problem Formulation\n\n# Problem statement\nYou are working with a recruitment assistant (clinical trial coordinator ) as part of the Trial Design and Implementation Team -Trial Delivery Team (TDI-TD) in a university hospital. The study is a therapeutic trial for the treatment of breast cancer patients; the drug used is new medications in the early development. It is proposed as a Phase III, single centric, prospective, interventional, non-randomized, investigator lead. The trial design is Open Label. The primary endpoint is treatment duration. You must provide information and assist patients/participants who were referred to the hospital to participate in the trial. You must ask patients/participants about his inclusion criteria and his exclusion criteria. Also, you must provide information regarding inclusion criteria and exclusion criteria for the trial and about the drug. It is not the only new medication, and you must tell the patient that this medication has potential side effects which some of them are irreversible after therapy.\nYou are a clinical trial recruiter, and you need to use Eligibility Criteria to find the eligible participants. You will compare the criteria of the trial to the criteria of the referred patients/participants. The comparison was based on the criteria of the trial and patient's data, such as patient's disease and drug interaction.\nIn the end, you need to determine the trial eligibility of the referred patients/participants (Eligible vs. Not Eligible) and the most common reasons for being excluded (e.g., age, type of disease, previous drug therapy, etc.).\n\n## Data characteristics\n\n## Data set description\nThe dataset contains 215 patients/participants referred to the hospital. We created 38 attributes per patient/participant corresponding to their demographics, socioeconomics, disease and drug records. The dataset has six types of data objects depending on the number of values each patient/participant has. A brief description of the attributes is shown below:\n- 0 (618): Unknown, i.e., not available (e.g., the patient refused to answer the question or not able to answer).\n- 1 (3106): Missing data, i.e., empty",
        "label": 0
    },
    "467": {
        "output": "### [PROBLEM_2](/problems/problem-2)\nYou are working with a physician at a local hospital who is running a clinical trial and must submit information to the central trial sponsor. \nWhen entering a patient into a clinical trial, the physician records the first two lines of the patient demographics in the system. You need to fill up some data which are not entered by the physician, and send all the information together to the central trial sponsor. \nThe data of patient 1 are as follows:\n\n    First name:\n    Middle name:\n    Last name:\n    Gender:\n    Date of birth (DOB):\n    Ethnicity:\n    Country of origin:\n    Marital status:\n    Occupation:\n\n[DATA]:{\n    First name: \"<NAME>\",\n    Middle name: \"\",\n    Last name: \"Tang\",\n    Gender: \"female\",\n    DOB: \"#Y-#M-#D\",\n    Ethnicity: \"c\",\n    Country of origin: \"s\",\n    Marital status: \"m\",\n    Occupation: \"m\",\n    Ssn: \"R7461\",\n    Patients_identification: {\n        Registration_number_patient: \"WC-003\",\n\n    }\n}\n\nThe physician's data of the patient 2 is: \n\n    First name:\n    Middle name:\n    Last name:\n    Gender:\n    Date of birth (DOB):\n    Ethnicity:\n    Country of origin:\n    Marital status:\n    Occupation:\n\n[DATA]:{\n    First name: \"<NAME>\",\n    Middle name: \"\",\n    Last name: \"Liang\",\n    Gender: \"female\",\n    DOB: \"#Y-#M-#D\",\n    Ethnicity: \"c\",\n    Country of origin: \"s\",\n    Marital status: \"m\",\n    Occupation: \"m\",\n    Ssn: \"R7461\",\n    Patients_identification: {\n        Registration_number_patient: \"WC-004\",\n    }\n}",
        "label": 2
    },
    "468": {
        "output": "## [MARKDOWN_CODE]\n### [QUESTION4]: What are these three-point eligibility scales for clinical trial? Let's assume that the last patient note is excluded from further analysis of this trial.\n\nThe inclusion criteria of a trial are based on 0) sex, 1) age, and 2) AML diagnosis. \n\nWhen a patient meets all of the inclusion criteria, the patient is deemed an eligible subject of this trial. The determination of the patient's eligibility is based on a comparison of the patient's characteristics and the inclusion/ exclusion criteria. \n\nThere are 4 potential eligibility scores: 1) excluded, 2) not relevant, 3) eligible, and 4) don't ask. The process of eligibility evaluation is summarized in below.\n\n\n\n### Example 1:\n![IMAGE](https://cdn-images-1.medium.com/max/1125/0xf0521afc38161037ad7984c658129d959d4327c9)\n\n\n\n\n### Example 2:\n![IMAGE](https://cdn-images-1.medium.com/max/1125/0xf10ac9143dd3d73634721af3e8aeadda5adbf1b9)\n\n\n\nThe first and first-last lines consist of the overall number of eligible patients. The eligible patient has a scale of 2) Eligible. If the patient's score is 0) Excluded, the patient is ineligible to participate in this trial, and the next clinical trial could be chosen. On the other hand, the patient score of 3) Not relevant requires either patient's history data or patient's previous treatment records about the patient's eligibility to this trial. If the scale is a higher value than 3) Not relevant (4) or 6) Require consultation, the patient must be excluded from the trial because the patient needs additional clinical evaluations regarding the eligibility. In addition, the patient score of 5) Don'",
        "label": 0
    },
    "469": {
        "output": "in the \u2044c\n( 1. for all a\u00a0in and \u00a0 .\u00a0127\\ and 1\\re \\l or-specific for ex 4, or...\n \u25a0... a [bib_ref]-target in order-in the [bib_ref]. for a...in theft on \u00a0d at\nafter the\u00a0in a  in the 0\nc [fig_ref];\n (acc for \u2044. in the. In particular [bib_ref] and the\\ and clin or a new,\nand and A. The [bib_ref] in a case\n in _(based \u25cb _inst \\ (11 in \u00a0\u00a0based\nafter after [bib_ref]. and<EOD> [bib_ref]-in-m at \n [bib_ref] 4-cemat in [fig_ref]-in an \u00a0-o \ufffd 3\u00a0 or \u2015det  (d-in-specific or [bib_ref]-and\\acc\nfor a.\nat -\n _of\n/s\u00a0_sample in a\ninnet_pat-in in _-c:she_such \u00a0on\\_follow [bib_ref]. (2-re [bib_ref] \\^-in-in \u2265<pat on\nand-in or -s-her in [bib_ref]-des and 10 -~inst\n or the on \u00ae - 2\u00a0to\u00a0inst-d 2\u00a0~s [/table] -b...specifics of their\n- [/fig_ref] on the, she in the\nin each-visual \u25cb\n{derd/ \ufffd...-in the<EOD>\n\nfor [fig_ref] for a .{ for cll for thell [bib_ref] \ufffd-d-an-specific 4. [bib_ref]-re\u00a0 6 or -the [bib_ref] 1 in\u00a0cinder but_in of [bib_ref]<EOD>\ndet:\nof... or the ( 2\nand -in Cade on 1<1 at -her 1 for the [fig_ref]-s [/fig_ref] \u00a0/detive with a <in her_visual\u00a0-~. The\u00a0-or for either\nme (c^ in 1 for 8\n1 \u2009;\u00a0c_ (see or 7 1 in this\u00a0on -to\u00a0sub of [bib_ref] [/table] in [/table], 18 and [bib_ref] - 21 \u2265c-in to \nde-~ the 1-1-1 for 3_stud",
        "label": 2
    },
    "470": {
        "output": "```julia\r\njulia> i_level(r) = (r[2].detection === \"2\" && r[6].tum_type== \"Infiltrating ductal\" && r[10].research_status!=\"1c\" && r[11].research_status!=\"1x\") ? \"0\" : \"1\"\r\njulia> i_research_status = r[10]\r\njulia> i_research_status == \"23c\" ? \"0\"\r\njulia> i_research_status == \"23x\" ? \"1\"\r\njulia> i_level(r) == \"0\"\r\njulia> i_level(r)\r\n\"\"\"Excluded\"\"\"\r\njulia> i_level(r)==\"1\"\r\n\"\"\"Not relevant\"\"\"\r\njulia> i_level(r)==\"2\"\r\n\"\"\"Eligible\"\"\"\r\ntrue\r\n\"\"\"\r\n```\r\n```python\r\nIn [8]: eligible(r)\r\nOut[8]: True\r\n```\r\n```lua\r\ntest.eligible({2,2,1,1,2,true,false,2,''0'',''2020-01-01 10:10:06 +09:00+1'',''',''','',''','',''});\r\n```\r\n```kotlin\r\nval eligible = r.test1.eligible() \r\ntrue\r\n```\r\n```php\r\n<?php\r\nsession_start();\r\n/*\r\nEligible\r\n*/\r\n$result = [\r\n\t\"detection\" => \"2\",\"tum_type\" => \"Infiltrating ductal\", \"research_status\" => \"1x\", \"gender\" => \"1\",\"research_status\" => \"1x\", \"researchID\" => \"2020-01-01 10:10:06 +09:00+1\", \"detection\" => \"2\",\"tum_type\" => \"Infiltrating ductal\", \"research_status\" => \"1x",
        "label": 0
    },
    "471": {
        "output": "[TEST]$ python3 test_task.py -f \"patient.txt\"\n[INST]$ python3 test_task.py -f \"patient.txt\"\n\nNow, let's see if you get the following:\n\n## Export to excel\n\n[TEST]$ python3 test_task.py -f \"patient.txt\" --excel\n[INST]$ python3 test_task.py -f \"patient.txt\" --excel\n\nYou should get the following:\n\n#! /usr/bin/env python3\n#-*- coding: utf-8 -*-\n\"\"\"Script: task_patient.py\n\nUsage: task_patient.py -f <path/to/note.txt>\n                            [--excel <path/name/to/report.xlsx>]\n                            --inst <path/to/interactive.txt>\n\nReferences\n\nhttps://github.com/s3h0n/ClinicalPath/blob/master/README.md<jupyter_code>c = {'f': input_file['f'],\n                'l': input_file['l'],\n                'v': input_file['v'],\n                't': input_file['t'],\n                'e': input_file['e'],\n                'h': input_file['h'],\n                'st': input_file['st'],\n                'st_b1': input_file['st_b1'],\n                'st_b2': input_file['st_b2'],\n                'st_b3': input_file['st_b3'],\n                'gd_s1': input_file['gd_s1'],\n                'gd_s2': input_file['gd_s2'],\n                'gd_s3': input_file['gd_s3'],\n                'gd_s4': input_file['gd_s4'],\n                'gd_s5': input_file['gd_s5'],\n                'gd_s6': input_file['gd_s6'],\n                'gd_s7': input_file['gd_s7'],\n                'gd_s8': input_file",
        "label": 0
    },
    "472": {
        "output": "[fig]  Figure 1: Screenshot of a typical patient note. Note: A complete patient note includes Patient demographic information (age, gender); Past medical history (hypertension, anemia, hyperlipidemia, hypothyroidism); Personal history (smoking, drinking); Family history (breast cancer); and Medication history (albendazole, amlodipine, atorvastatin calcium). [MUSIC] [/fig] \n[fig]  Figure 3: Screenshot of a typical note of a clinical trial. [/fig] \n<EOD> Identification of genes differentially expressed in the heart after myocardial infarction using RNA-Seq technology\n\nBackground: RNA sequencing (RNA-Seq) is a high-throughput method for RNA sequencing and has become widely recognized as a powerful approach to investigate gene-expression profiles in different diseases. However, no study has shown the expression changes in cardiomyocytes after myocardial infarction with the use of RNA-Seq method.Methods:In this study, myocardial infarction was induced in Sprague-Dawley rats. Total RNA was extracted and subjected to RNA-Seq for sequence and functional analysis of the differentially expressed genes.Results:The experimental and controls had a strong correlation, with a correlation coefficient of 0.7963, which indicates there was no significant technical bias in the RNA-Seq data. Among 412,674 and 399,434 detected genes in the experiment and control groups, 6114 significantly regulated genes were found with a \u22651.5-fold change cut-off. The results indicated that many genes involved in cell adhesion and metabolism-related pathways were altered upon myocardial infarction. Interestingly, a large number of transcripts that are important in cardiovascular disease, such as adhesion molecules and cytokines, were differentially expressed.Conclusions:Collectively, our results suggest that significant changes in cardiac gene expression occurred after myocardial infarction, with more differentially expressed genes identified. This study provides a novel approach to further elucidate the molecular regulatory mechanisms and signaling pathways during",
        "label": 0
    },
    "473": {
        "output": "- <EOD> The potential of the TRAIL gene signature in pancreatic adenocarcinoma risk stratification\n\nE-mail: i.brancaccio@leeds.ac.uk (I. Brancaccio); eilidh.hutton@mrc-vdl.ac.uk (E. Hutton)AbstractBackground and aims: Pancreatic cancer is a highly lethal disease; molecular insights are needed to understand tumour progression and drive personalised therapy. Our aim was to assess the performance of the TRAIL gene signature in pancreatic precancerous lesions, to investigate the association between TRAIL expression and clinical outcome, and evaluate the potential utility of this signature in assessing risk of progression to invasive cancer. Material and methods: Four tissue microarrays were constructed from tissue samples of pancreatic pre-cancerous lesions and invasive adenocarcinoma and processed for immunohistochemistry. The expression of TRAIL and selected TRAIL-related genes was measured by image analysis. This expression was related to histopathology, and clinicopathological and demographic variables. Results: The expression of TRAIL receptors-1 and -2 was significantly higher in pre-cancerous lesions compared with cancers and correlated with the dysplasia grade. Higher TRAIL receptor-1 expression was associated with improved survival (p = 0.04). An immune-related signature was significantly associated with survival (p < 0.05) independently of TNM staging. Conclusion: TRAIL plays a role in early pancreatic cancer progression, its receptors expression is a prognostic marker in pancreatic cancer, and the immune signature has an independent prognostic capacity. We identified a group with worse diagnosis whose signature expression is higher than usual. This signature can be used for personalised prognosis determination and prediction of the most effective drug therapy.\n\n# Introduction\nPancreatic ductal adenocarcinoma (pdac) is one of the deadliest cancers with 5year survival less than 6%and the highest mortality-to-incidence ratio. It usually manifests with advanced disease",
        "label": 0
    },
    "474": {
        "output": "##### #21 - Output patient notes in MarkDown format (25/56) \nThis question is to test the ability to write patient information in Markdown syntax format. Markdown (abbreviated as mdown) is a simple format for authoring and presenting documents. [Markdown Tutorial ](https://www.markdownguide.com/introduction/)\n\nWrite the patient notes in Markdown style in the `## Notes 0 # ` cell. [INST]\nThe following is a patient note in Markdown style:\n## Notations:\n### Patient ID: <NAME>\n###  (caret) represents patient-specific text fields and <NAME> represents unique patient ID.\n**Breast and axillary surgeries:** Breast and axillary surgeries were performed after neoadjuvant chemotherapy, but before the start of combination trastuzumab and pertuzumab. Bilateral breast-conserving surgery (BCS) including sentinel node sampling (SSN) and left axillary dissection (LAD) were conducted. Immediate partial implant reconstruction was performed in both breasts. \n \n### AE:\n###  (caret) represents adverse event, event, or side effect.\n```\n### AE - Breast pain (H&N) ##\nBreast pain started about 1 week after starting treatment with combination pertuzumab and trastuzumab. The patient stated that the pain was worse on the left breast and was aggravated at night. The pain was mild and was not severe enough to disturb sleep.\n\n### AE - Arthralgia (H&N) ##\nThe patient's right knee and both elbows have been aching for a few weeks. \n\n### AE - Fatigue (H&N) ##\nThe patient has fatigue in both elbows and the knees since about 2 weeks ago.\n\n### AE - Larynx edema (S&E) ##\nThe patient's larynx on the right side is swollen. \n\n### AE - Lethargy (S&E) ##\nAppetite has decreased since about 1 month ago, and there",
        "label": 2
    },
    "475": {
        "output": "<EOD> Dissemination of carbapenem-resistant Enterobacter cloacae complex following the 2007 flood in Bangladesh\n\nBackground: Antimicrobial resistance (AMR) is a global public health challenge. Bangladesh, like other countries, has seen a rise in carbapenem-resistant Enterobacteriacae (CRE) associated infections, but the magnitude is not known. We investigated two outbreaks of Enterobacterial infections at two different hospitals in Bangladesh in 2015. Methods: To find out the source and understand the routes of transmission, a case-control study, molecular typing and antibiotic sensitivity testing were conducted. Results: Out of 420 patients tested with a rapid kit, 20 samples had elevated levels of carbapenemase enzymes. The case-control study identified the use of contaminated needles and syringes and patient's sharing bed or bed-spaces. Among the 150 participants tested for blood culture, two patients had blood-culture positive for Enterobacteriaceae and 12 patients had urine samples that were blood-culture positive. Overall, 15 Enterobacter species were found among 31 (34%) isolates, which were multidrug-resistant and predominantly produced carbapenemases. Nosocomial spread of Enterobacter cloacae complex isolates was confirmed by pulsed-field gel electrophoresis. Carried from the patient's home or hospital, Enterobacter cloacae complex isolates were disseminated to other departments and wards through the use of contaminated equipment and needles.Conclusions:Our results confirmed the emergence and nosocomial outbreak of carbapenem-resistant Enterobacteriaceae in Bangladesh for the first time and suggested that dissemination was likely in the aftermath of the 2007 floods. The impact of climate change, in conjunction with urbanization, must be considered in planning for the prevention and treatment of these potentially-drug-resistant organisms.\n\n# Background\nBloodstream infection (BSI) is an important hospital-acquired infection",
        "label": 0
    },
    "476": {
        "output": "### Solution 2\nLet's think in steps.\n\n**STEP 1**: [Read over the patient note and the trial information once again to see if the required information is available in `PatientData` table.](#question1).\n\n**STEP 2**: [For each included column of `PatientData` in the patient note, look it up in the trial information. If found, then assign the relevant value to the patient data using `INSERT INTO `PatentData`(')`; otherwise, assign `NULL` to `PatientData` table.# question2.\n\n\n### Solution 3\nLook it up in the trial information. If found, then create a new row in `PatientData` table, where column name is identical to the trial information, which includes the values of the patient data using `INSERT INTO `PatentData`(')`; otherwise, assign `NULL` to `PatientData` table.\n\n\n### Solution 4\nLook up the required information from the patient note and the trial information using Python Pandas and assign to the patient data using Python.\n\n### Solution 5\nCombine the patient note (e.g., `df.to_numpy()`,) and the trial information (e.g., `df[['Negative_histologic_lymph_node', 'ER_negative', 'Breast_operative_side_notes',...]]`) in a list ('['Negative_histologic_lymph_node', 'ER_negative', 'Breast_operative_side_notes',... ']), make a copy of the list (`list_df1 = df_list)` and make a copy of the patient note df (`list_df2 = df`) and create a dictionary (`df_dict = {'column1': 'value1', 'column2': 'value2', 'column3': 'value3'})`. Use list_df1 and list_df2 to generate a flat data frame as shown in the following code\n```\ndf_dict = {\n    \n    \"column1\": [\"data1\", \"data2\", \"data123\"],\n    \"column2\": [\"data4\", \"data9\", \"data45\"],\n    \"column3\":[\"dataf\", \"data14\", \"data1",
        "label": 0
    },
    "477": {
        "output": "### Output\n\nEach patient note contains a `JSON` object with 5 keys. We will discuss the structure of each key separately. Each clinical trial contains a `JSON` object with 2 keys. We will discuss the structure of each key separately. \n\n\n    \"ID\": \"PRN-100\",\n    \"PatientName\": \"Peter Patel\",\n    \"Gender\": \"Male\",\n    \"[INST]Age\": \"55\",\n    \"[INST]BirthDate\": \"1964-08-14\",\n    \"[INST]ResidentialAddress\": \"(213)742-7411\",\n    \"Diagnosis\": \"Squamous cell carcinoma of apex of tongue\",\n    \"Histopathology\": \"Moderately differentiated carcinoma, keratin pearl formation, ulceration\",\n    \"Staging\": \"Stage 3B (T4a N2c M0).\",\n    \"Anatomy\": \"Tongue\",\n    \"ClinicalTrial\": [\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2130/CTR-STI-2130.txt\",\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2140/CTR-STI-2140.txt\",\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2150/CTR-STI-2150.txt\",\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2160/CTR-STI-2160.txt\",",
        "label": 0
    },
    "478": {
        "output": "<EOD> Antimicrobial treatment failure in a patient with severe Corynebacterium amycolatum sepsis\nDear Editor, A 54-year-old female patient with a past medical history of rheumatoid arthritis (treated with tocilizumab), diverticular disease (treated with mesalazine suppositories and pantoprazole), hypothyro\u00efdism and pernicious anaemia (treated with methylcobalamin and calcium) was admitted in our intensive care unit (ICU) for severe metabolic acidosis complicated with multiple organ failure (MOF). Laboratory tests revealed severe anaemia (haemoglobin 90 g/L) with normochromic normocytic erythrocytes, pancytopenia, elevated D-dimer (10.89 mg/L) in the setting of prothrombin, a low fibrinogen (3.91 g/L), and high C-reactive-protein(82 mg/L). The chest X-ray showed diffuse interstitial and alveolar infiltrates. The septic context was suspected, an emergency haemodialysis and a mechanical ventilation were initiated. Despite several broad-spectrum antibiotic treatment (ampicillin, imipenem and tigecycline), the clinical and laboratory data worsened quickly leading to a cardiac arrest complicated by a multiple organ failure. A femoral blood line was inserted and two blood cultures were drawn. Two subsequent blood cultures were positive for Corynebacterium amycolatum, a rare opportunist causing mainly endophthalmitis and pneumonia.1,2 In this case, the clinical context was compatible with a severe septic shock. Despite an empiric broad-spectrum antibiotic therapy, the patient experienced a fatal deterioration of her general condition. This case report discusses the difficulties and uncertainties in the treatment of severe infection due to C. amycolatum. The patient is a 54-year-old female patient with a past medical history of rheumatoid arthritis treated with tocilizumab, who was admitted",
        "label": 1
    },
    "479": {
        "output": "```python\n\n# You may need to change the current directory to the folder that contains\n# the exercise folder.\nimport pandas as pd\nfrom pymtas.mtas.data_type import Patient, PatientHistory, PatientStatus, ClinicalTrial,\n                                   IncludeCriteria, DetailedCriteria\nfrom pymtas.mtas.evaluation.evaluator import TrialLevelEligibility\n\n# This dataset is available at the pymtas GitHub:\n# 'include_assessment_eligibility_patient_history_exercises_dataset'.\n\n# The dataset has been read and split into train and test data using the\n# 'prepare_train_and_test_data.py' script. Copy it to the 'data' folder.\n\nif __name__ == '__main__':\n    evaluate_inclusion_criteria(input=True)\n\n\ndef evaluate_inclusion_criteria(input):\n    # Load in the data. The data contains Patient, PatientHistory, PatientStatus,\n    # ClinicalTrial, IncludeCriteria and DetailedCriteria objects.\n    # Note that the data has a special `__repr__` method which you might\n    # choose to use instead. See docstring for the __repr__ method of the\n    # DetailedCriteria.\n    data = pd.read_pickle(\n        'data/inclusion_criteria_evaluation_data/inclusion_criteria_evaluation_dataset_inclusion_eligibility_test_data.pkl')\n    train_data = data[data.patient_id == 'train_patient_id']\n    test_data = data[data.patient_id == 'test_patient_id']\n\n    # Assign a few variables to be read by the function arguments.\n    train_path = 'evaluation/train_patient_id'\n    test_path = 'evaluation/test_patient_id'\n    y_test = 'Trial-level eligibility'\n    trial_level_eligibility = TrialLevelEligibility(y_test)\n\n    # Evaluate the included criteria for the test patients.\n    #",
        "label": 2
    },
    "480": {
        "output": "<EOD> TNF-\u03b1-induced cytotoxicity in rat thyroid cell lines: a mechanism of cytotoxicity distinct from cell killing by IFN-\u03b3 or TRAIL.\nTNF-\u03b1 is a proinflammatory cytokine that plays a major role in the response to immune stimuli. Previous reports have suggested that this cytokine can have a cytotoxic effect on thyroid cells. The present study aimed to investigate apoptosis as a mechanism of TNF-\u03b1-induced cell death in rat thyroid cells. Cell lines of rat thyroid PCCl3 and FRTL-5 cells were stimulated by various concentrations of TNF-\u03b1 and incubated for 24 h. Apoptotic cell death was examined by DNA ladder assay, TUNEL test, electron microscopy, detection of phosphatidyl serine on the membrane surface and cytometry. TNF-\u03b1 induced apoptotic cell death in PCCl3 cells and in FRTL-5 cells. However, this was not mediated by changes in mitochondrial membrane potential, and also did not require de novo protein synthesis. Other cytokines (IFN-\u03b3 or tumor necrosis factor related apoptosis-inducing ligand ) that are known to induce apoptosis in thyroid cells did not induce PCCl3 and FRTL-5 cell apoptosis. Taken together, TNF-\u03b1 exerts cytotoxicity in thyroid cell lines by a mechanism independent of cell killing by IFN-\u03b3 or TRAIL.<EOD> A Case Report of a Puerperal Woman With Dengue, Transplacentally Acquired HIV, and Severe Placental Infection\n\n\n\n# Introduction\nDengue is a mosquito-borne flaviviral disease affecting around 390 million individuals annually, predominantly in tropical and subtropical areas, with the highest risk of infection in Asia and the Pacific region. Infection with dengue virus (DENV) results in a spectrum of disease severity including dengue fever, dengue hemorrhagic fever and dengue shock syndrome [bib_ref]  Dengue and postpartum depression: a cohort study of a",
        "label": 2
    },
    "481": {
        "output": "If you see **Trial-level eligibility** has been omitted, make sure it has been set. It is quite common to omit this field accidentally, as the Trial-level eligibility field is followed by **Scoring** under **Instructions**. So don't forget to fill the field!\n\n### Explanations for Trial-level eligibility\n\nEach score has the following explanations.\n\n- #### 0: Ineligible\n\nThe patient is not eligible for the trial. Do not recommend.\n\n- #### 1: Possible Eligible\n\nThe patient is not eligible for the trial. However, a recommendation is allowed as this score includes cases where eligibility may be determined in a more individualized manner (e.g., some patients with age between 25 and 30 can be eligible for vaccine trials if they are part of specific high-risk populations or have an underlying condition such as cancer).\n\n- #### 2: Eligible\n\nThe patient is eligible for the trial.\n\n- #### 3: Eligible with restrictions\n\nThe patient generally meets all requirements for eligibility, but there are some specific aspects which can delay patient identification and/or potentially affect patient dropout.\n\n- #### 4: Ineligible, per Parexel policy, no recommendation\n\nThe patient is excluded from the trial per Parexel policy. There should not be any recommendations for this scenario.\n<EOD> Phosphodiesterase III (PDE3) Inhibitors with a Sulfonylurea Moiety as HIF-1\u03b1 Inhibitors\n\nCitation: Salzman, D.; Khoury, Z.; Chahin, Y.; Lior, H.; Avraham, O.; Shtutman, M.; Alon, J.; Gozes, I.-E. Phosphodiesterase III (PDE3) Inhibitors with a Sulfonylurea Moiety as HIF-1\u03b1 Inhibitors. Pharmaceuticals 2022, 15, 1474.\n\n# Introduction\nHypoxia-inducible factor-1\u03b1 levels are elevated in a plethora of cancer types and correlate with poor pro",
        "label": 0
    },
    "482": {
        "output": "# How to calculate points?\nOn [https://docs.google.com/forms/d/e/1FAIpQLSf0j6XfB7754t_NIPbH146d7VZ5gXxO-PbPqR89Y-m9s5K3Q/viewform](Accessed on March 27, 2019).\nTo calculate the Points for each problem, first count the number of problems of the same kind to which you were assigned to solve. For instance, suppose we assigned the following problems to you:\n\n```markdown\n1\n2\n3\n4\n5\n6\n```\n\nIt means that in this task you were assigned 6 problems. Now, count these problems step by step.\n```markdown\n\nYou should solve one Problem for your first point. Now, this problem contains a single sub-problem. Therefore, your first Problem contains 1 Sub-Problem. You are going to solve it; for your second point, you need 1 More Problem.\n\nNow count the number of Sub-Problems:\n```\n\nNow you need to calculate how many Sub-Problems your first solved problem contains again. And you have to go back. Now you count how many Sub-Problems your first Problem contains:\n```\nCount: `1` Sub-Problem\n```\nYou have to count your points according to each Sub-Problem you have already solved. So, go back and calculate the points you earned:\n\n```markdown\nProblem1\n Sub-problem=1\n Points Problem1=1*1=1\n\nProblem3\n Sub-problem=1\n Points Problem3=1*1=1\n\nProblem4\n Sub-problem=1\n Points Problem4=1*1=1\n```\nNow it is important to understand that you should count your points for every Sub-problem that you have already solved, even if it is a Sub-problem in another Problem.\n\n```markdown\nProblem2\n Sub-problem=1\n Sub-problem in Problem4 = 2\n Points Problem2=2*1=1\n```\n```markdown\nProblem5\n Sub-problem = 1\n Sub-problem in Problem4 = 2\n Points Problem5=1*1=1\n```",
        "label": 0
    },
    "483": {
        "output": "The following steps will show you How to use the `FindTable()` function. The `FindTable()` function will return a Table from its first occurrence of a specified character. We need to look for tables named \u201cfirst\u201d, \u201csecond\u201d, and \u201cthird\u201d because the \u2018first\u2019 table holds the \u2018first\u2019 line, the \u2018second\u2019 table holds the \u2018second\u2019 line, and the `third` table holds `third` line. The data set named `first_table` contains all three of the table names listed above. The `FindTable()` function calls the Table constructor, accepting the string \u201cfirst, second, third\u201d, and returns a table named `first_table` because it is the first table in the data set. It is important to note that in addition to the character, any number of characters in the string \u201cfirst, second, third\u201d can be repeated zero or more times, as well as zero or more characters that are not included in the string \u201cfirst, second, third\u201d. The following example uses this property by specifying the string \u201c*\u201d instead of the words to search for, and returns a table named `third` because it is the third table in the dataset. It is important to note that `*` is a literal string; it is not interpreted by the interpreter for characters of any sort. The following example uses `FindTable()` for `*`, which would return a `NotInTable` object for which no",
        "label": 2
    },
    "484": {
        "output": "## Inequal Exclusion\n\n`InequalityExclusion` provides an extension to ClinicalTrial.\n\n`InequalExclusion` is a subclass of `InclusionCriteria`. A `InequalExclusion` object has `type` and `value` properties that specify its type and a value that is an object. For example, `InequalExclusion(type: 'elevated blood pressure', value : 'Elevated blood pressure over 140/90 mm Hg.')`.\n\n## Defining your clinical trial\nUse a `Trial.definition` property, rather than specifying the eligibility of individual patients.\n\n[NOTE] You're a medical assistant, and your task is to assess a patient's trial eligibility. You can use this method to specify the eligibility criteria for your clinical trial, to generate a set of objects for `InclusionCriteria. InclusionCriteria.value`. This method is akin to using a [dictionary](https://developer.mozilla.org/en-US/docs/Web/JavaScript/Reference/Global_Objects/Object/prototype/propertySetter); you may prefer to have one method for convenience if your clinical trial is going to be long-lived and have many subjects. Instead, you could use [ClinicalTrial.definition][ClinicalTrial.definition] if you need to reuse your clinical trial data multiple times.\n\n[NOTE] You're a medical assistant, and your task is to assess a patient's trial eligibility. You can use this method to specify the eligibility criteria for your clinical trial, to generate a set of objects for `InclusionCriteria. InclusionCriteria.value`. The parameters passed to this method are the eligibility criteria expressed in free text.\n\n[NOTE] You're a medical assistant, and your task is to assess a patient's trial eligibility. You can use this method to specify the eligibility criteria for your clinical trial, and generate a set of objects for `InclusionCriteria. InclusionCriteria.value`. You can also use this property to update trial-level eligibility of a patient.\n\n## The InclusionCriteria.value property\nWhen you have no other way to determine patient eligibility, you can",
        "label": 2
    },
    "485": {
        "output": "---\n\n## 2.7.6 Trial-level eligibility\nIn this exercise, you will examine if the patient note conforms to the eligibility criteria of the clinical trial. The information provided by researchers is usually incomplete, and the patient notes are in a text format, not in a structured document format. It is necessary to make assumptions based on the information provided. The trial-level eligibility information you will provide, and you must be consistent and consistent with the patient note. The example was a trial of \"cold sprayable cement in the treatment of chronic pain.\"\n\n---\n[inst_134] The trial is a 3-arm study to determine the safety and efficacy of a cold sprayable cement in comparison with placebo in the treatment of chronic pain. All participants will continue to receive daily oral analgesics or pain medication and be required to report the amount and frequency of use. Assess the trial-level eligibility of the three possible patients according to the trial profile: \n\nPatient information: This patient is a 24-year-old man with knee problems who went to a doctor to check what was going on with his joints. During a medical examination, he was diagnosed with severe osteoarthritis in his knee that does not respond to the use of painkillers and nonsteroidal anti-inflammatory drugs, and it is necessary to make a biopsy. \n\nHe has mild musculoskeletal pain in both of his knees. The pain usually occurs after he rests after taking a long walk or a day of heavy physical activity. It is severe when he is in bed at night, but he can take some pain medication to help with the pain. His family history is negative for chronic diseases. He has a chronic disease called an allergy, on which he takes regular medication and has not had any side effects. He has no history of taking any medication.\n\nTrial information: The trial includes 250 participants to evaluate the efficacy of cold sprayable cement. The experimental group who took sprayable bone cement will be compared with the control group who took a placebo, which is also described as \"non-toxic water.\" Participants will be randomly assigned to different",
        "label": 0
    },
    "486": {
        "output": "***\n\n# Sources\n\n* [Acupuncture for the management of headaches, tinnitus and vertigo: a protocol for a systematic review of randomized controlled trials.](https://docs.google.com/presentation/d/14HQ1q4D67hHf17aG-d6747wmfB4KxG28/edit?usp=sharing) (Accessed: January 30, 2009)\n\n* [Medicina Alternativa na Perspectiva da Inqu\u00e9ritos Epidemiol\u00f3gicos: Projeto Inqu\u00e9ritos Epidemiol\u00f3gicos de Acupuntura em Posi\u00e7\u00f5es Definitivas](https://github.com/rubensamorim/epidemiological_surveys_acupuncture/wiki/Inqu\u00e9ritos-Epidemiol\u00f3gicos-de-Acupuntura-em-Posi\u00e7\u00f5es-Definativas) (Accessed: December 8, 2017)<EOD> Comparison of antimicrobial efficacies of essential oils of Melaleuca alternifolia, Origanum vulgare, and Thymus vulgaris against foodborne pathogen",
        "label": 2
    },
    "487": {
        "output": "In the above example, `breast Ductal carcinoma in-situ` is an exclusion criterion.\n\n## Solution\n\n[INST] Hello. You are a helpful assistant for\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial:\nTitle: Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy Summary: It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly consistent with the postoperative stage. ~Therefore, this study intend to evaluate the effectiveness as a diagnostic tool that can help determine the axillary lymph node surgery by predicting the possibility of post-operative up-staging using magnetic resonance imagings of breast cancer patients who have been identified as ductal carcinoma in situ and are scheduled for surgery.\n\nIn",
        "label": 0
    },
    "488": {
        "output": "![Instructions](imgs/clinical_trial_clinical_trial_instructions.png)\n<img src=\"/static/imgs/_/clinical-trial.png?ver=695\" alt=\"clinical trial\"/>\n<br/>\n<EOD> Inhibition of Human Breast Hyperplasia Growth by Bidens pilosa Ethyl Acetate Fraction\nThe Bidens pilosa ethylacetate fraction (BPEAF) showed potent anticancer growth activities in a number of cell line models. To evaluate the antiproliferative activity of BPEAF and its possible anticarcinogenic use in humans, a preliminary study to test BPEAF was performed in a carcinogen\u2010induced human breast hyperplasia (HBH) model. After 8 weeks of induction period, animals received 26\u2010day treatment with 50, 100 and 200 mg kg\u22121 of BPEAF, tamoxifen 20 mg kg\u22121 or vehicle, intragastrically five\u2010times\u2003weekly. The total protein, oestradiol, progesterone, glutathione (GSH), prostaglandin E2 were measured to evaluate the effect of compounds treatment and also the in situ proliferation index was counted in the tissue specimens. The results showed that the treatment of animals with the BPEAF 100 and 200 mg kg\u22121, daily, lead to reduction of total protein concentration up to 43.28% and 39.23% respectively, which lower than tamoxifen\u2010treated at 48%, but it showed higher reduction than the vehicle\u2010treated group. Furthermore, intragastric treatment with BPEAF 50, 100 and 200 mg kg\u22121 had an inhibitory effect on oestradiol, GSH and total progesterone level at 42.93%, 43.70% and 36.98%, 51.24% and the inhibition of PGE2 level at 32.64%, 39.28%, 36.11% respectively. The in situ",
        "label": 1
    },
    "489": {
        "output": "The output of this lesson, once the patient note and the clinical trial are available, is: \n\n# Related Links\n- [Lesson 310]{}{} Lesson 311{}{} Lesson 312{}{} Lesson 313{}{}\n- [Lesson 314]{}{} Lesson 315{}{}\n<EOD> Translating the results of epidemiological research into recommendations for clinical practice.\nPursuant to a request from the USPSTF, the USPSTF staff reviewed a recently published epidemiological study that reported an association between depression and mortality following a diagnosis of coronary heart disease. The primary objective was to provide an epidemiological perspective for clinicians on the clinical question posed by the USPSTF. Depression is associated with an increased risk for death (high-quality evidence), and the association appears to be independent of the impact of depression on treatment or mortality outcomes. Clinicians treating patients with coronary heart disease should assess for the occurrence of depression since the risk is increased; those who are depressed may be at increased risk for mortality and, if they experience a major depressive episode while in the intensive phase of treatment, they may be at increased risk for death.<EOD> The GTPase Dynamin 3 Is Required for Neuronal Development in Vivo\nDynamin 3 has been implicated as a downstream effector of the mitogenic Ras/extracellular signal-regulated kinase/mitogen- and stress-activated protein kinase pathway in cell lines. Using knockout (k/o) mice, we have analyzed the phenotypic consequences of the absence of dynamin 3 function in the brain. In k/o mice, neocortical neurogenesis proceeded, but neuronal migration was perturbed. The pyramidal glutamategic layers (II\u2013III) contained a greatly reduced number of neurons; the layer containing callosal projections was almost completely absent. These phenotype changes in k/o mice are reminiscent of those seen in mice with mutations in reelin, neuroligin 2, or neurexin-1. The reelin-",
        "label": 0
    },
    "490": {
        "output": "### [07_Evaluate_for_eligibility]\nWhen you are working with a patient, you must always look for information that is relevant for assessing his or her eligibility to participate in a trial. This is called 'collecting information'. In order to determine whether a patient is eligible for a trial, in addition to knowledge about the study's eligibility criteria, you need to find out more about the patient (see [06_Get_information]). Sometimes you need to do additional tests to complete those pieces of information, and these tests are called the 'screening tests'. In case a patient is not eligible, you need to know which criteria did not match, see [04_Screening_for_Eligibility#4_Screening_Tests]. If necessary, you need to inform the patient that he or she would not be eligible for that study, so that you need to check other clinical trials that are open in your hospital or clinic. \n\nThe screening tests used to assess inclusion and exclusion criteria for a specific clinical trial can be found using 'Get information about the study'. It is important to know what type of screening tests were performed for each parameter in the inclusion and exclusion criteria. \n\nThe tests for hematology, renal function, thyroid function, urinalysis, and protein electrophoresis are all 'blood test'. 'Cardiology tests' only include an electrocardiogram (ECG). The tests for coagulopathy, pulmonary function, and nutritional screening are 'other tests'. 'Tumor marker tests' include cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), alpha-fetal protein (AFP), and carbohydrate antigen 19-9 (CA19-9). 'Clinical visits' include tumor assessment by a physician, history and physical examination, and neurologic evaluation.\n\nTo check these tests, access `Get information about the study` again, and select the desired study. A list of all the parameters available in the trial appears.\n\n![07_Evaluate_for_eligibility](Evaluate_for_eligibility-screenshot",
        "label": 0
    },
    "491": {
        "output": "![#0]#\n\n## 1.20. Using the Rust Programming Language for Clinical Trials\n\n[+] `#2 [INST]\n[TITLE]_Clinica_trial_package\n[INST]\n\n### Clinical_trial_types\n[INST]\n\n```rust\npub trait Clinical_trial_types\nwhere\n    Clinical_trial_types: Size + Send + Sync + Unpin\n{\n    fn randomize(self) -> Randomized_trial;\n    fn randomized(self) -> Randomized_trial;\n    fn interim(self) -> Interim_analysed_trial;\n    fn interim_analysed(self) -> Interim_analysed_trial;\n    fn close(self) -> Cosed_trial;\n    fn cosed(self) -> Cosed_trial;\n}\n\npub type Clinical_trial_types = Clinical_trial_types<Clinical_trial>;\n\npub trait Clinical_trial<F, C>\nwhere\n    Covalence: Default<Covalence>,\n    Covalence <Cov_type: Cov_type_of = Covalence, Param = Default<Param>, Name: Name_of<'a>>: Sized, Trait, Env::Env,\n    Send_impl, Sync::Sync, Unpin::Unpin, Clinical_trial_types\nwhere F: Fn(&Cov_type, [F]) -> Cosed_trial,\n    C: Send + Sync, Env: Env\n{\n    // Trait Covalence\n    pub fn from_covalence(covalence: Cov_type) -> (Self, Covalence<'a>) {\n        let cov_type = Default::default();\n        let parameters = Default::default();\n        let env = Default::default();\n\n        let (self, c) = from_covalence(covalence, parameters, env);\n        (self, c)\n    }\n\n    // Trait Cov_type\n    pub fn get_env(self) -> Option<()> {",
        "label": 2
    },
    "492": {
        "output": "In-place validation in `Trial-level eligibility`\nYou should add the following to the line below 'Trial-level eligibility: 2) Eligible.'\n\n``` r\ninplaceval = inplace(function(.inplaceval = \"\")){\n    + out <- 2 * (data$Gender %in% c(\"Male\", \"Other\")) + \n        + (abs(data$Cytology[data$Status != \"Normal\"] - 1) * \n            (data$Cytology[data$Size != 1] != \"Natural\" ) * \n            (data$Cytology[data$Surgery != \"Yes\"] == 3)) +\n        + (data$Sex%in%c(\"Female\",\"Malesensitive\") * \n             (data$Triple != \"Negative\")) +\n        + \n        + \n        + (data$Mutation == 1) +\n        + \n        + \n        + (data$Metastasis(data$Status == \"Normal\") == 3)\n\n\n    + out <- out %*% paste0(\"#\")\n    + out <- ifelse(out < 0, paste0(\"-\"), paste0(\"+\"))\n    \n    + out \n}\n```\n\n``` r\ndata.frame(Trial-level eligibility = trial-level.eligibility, \n           inplaceval = inplaceval,\n           format = c(\"bold red\")*c(\"font bold\"))\n```\n\n``` r\n# trial-level eligibility ----------\n# ---------------------------- \n\n``` r\n# trial-level eligibility ----------\n# ---------------------------- \n\n``` r\ndata.frame(Trial-level eligibility = trial-level.eligibility, \n           inplaceval = inplaceval,\n           format = data.frame(Trial-level eligibility = trial-level.eligibility, \n                                inplaceval = inplaceval, \n                                format = c(\"bold red\")*c(\"font bold\"))\n```\n\n### `Trial-level eligibility` for Exclusions\n\nHere comes the `trial-",
        "label": 0
    },
    "493": {
        "output": "(Ask again.)\n\n### Part 2\nYou are a patient. You have a history of metastatic breast cancer and have recently visited a clinician for a routine check.\n\nIn the 10th edition of the AJCC, the classification system for regional lymph nodes in breast cancer has been changed to the pN stage. One of these changes is that a nodal diameter >2 mm which is considered nodal metastasis is a change in the N stage. The pN stages are listed below in . (If you are unaware of what is a node, it is an organ to which lymph flows.) .1pN Stages in the 10th edition of the AJCC \n\n## Exclusive breast cancer metastasis 7th edition 10th edition\npN0 pN0 pN0 0)\n\n### Exclusive breast cancer metastasis pN1 pN1 pN1\n(Ask again.)\n\n#### \u274c \u274c \u274c \u274c \u274c \u274c \u274c \u274c \u274c \u2714 \u2714 \u2714 \u2714 \u2714 \u2714\n\n## Part 1\nYou are a health expert. A breast cancer patient is about to undergo a surgery. You have been asked to assess the patient's status according to AJCC 7th Edition (TNM 2007) and AJCC 10th Edition (TNM 2017). The status is as follows in . If you are not sure about the answer, please ask the clinician. .1 TNM Stages in the 7th edition of the AJCC \n\n### TNM 2007 10th edition\nT (Size) pT1, pT2, pT3, pT4\nT(Size) pT1, pT2, pT3, pT4 +++ +++ (Ask again.)\n\n#### \u274c \u274c \u274c \u2705 \u274c \u2714 \u274c \u2714 \u2714 \u2714\n\n### N (Regional lymph nodes) pN0 pN1 pN2 pN3 +",
        "label": 0
    },
    "494": {
        "output": "[/CODEINST]\n\n### Q693. What are four reasons why patients are excluded from clinical trials?\n\nA) They already started on a trial with the same drug.\nB) They are more than 50 years below.\n\nC) They are pregnant.\n\nD) Their disease is too close to metastasized.\n\nE) They are sexually active and have a partner.\n\nExplanation: The answer is choice (E). According to the question, patients will not be eligible for the following four reasons; (A) is wrong because the patient can be currently participating in the clinical trial, (B)  is also wrong since the patient can be too young and too old, (C)  is also wrong since the patient is not pregnant (pregnancy is a possible reason for exclusion from the clinical trial only), and (D) choice (E) is also wrong since the patient is actively engaged in an intimate relationship. To become eligible for a clinical trial, the patient should be without a partner and not sexually active.\n\nQ694. What does the `Trial-level eligibility` field indicate?\n\nA) The presence of a given patient's disease.\nB) A new patient will be recruited for the clinical study.\n\nC) It has been decided that it is not necessary to recruit new patients.\n\nD) Data on inclusion criteria.\n\nE) The patient is already included in the trial.\n\nExplanation: The answer is choice (E). The field shows whether a patient who meets the study conditions based on the disease is present or absent. The answer is choice (A) since the field does not indicate if a new patient is going to be recruited for the clinical trial, which is indicated by choice (B). Choice (C) is also wrong because the field does not indicate whether it is necessary to recruit new patients. The answer is choice (D) since the field does not have information on the inclusion criteria.\n\nQ695. What is `Inclusion criteria` for?\n\nA) It is the criteria for the selection of patients who are eligible for the clinical trial.\nB) It determines the amount of the drug to apply.\nC)",
        "label": 0
    },
    "495": {
        "output": "## A) What is `n`? 53\nb) What is the number of patients who met each criterion? 5) What do the `mean(I.M.S.)` values indicate? What do we call the distribution type of their I.M.S. numbers. 6) What is the average value of IMS in the trial? 6) What is the sample mean (\u03bc) and the sample standard deviation (S) for the continuous variable I.M.S. (based on the previous exercise)? 7) What is the difference between the two samples and how big is the difference?\n\n## [hint] you can use a.o.w, e.p.e, s, s.d, a/a.o.w, s.d./mean and s.d./dmean to evaluate these hypotheses\n\n## `n=29` 29)\nFrom your preliminary data analysis, are you going to study a continuous or a categorical variable? [c] Both a) A continuous variable is always a real value; therefore, for continuous variables, we could use either parametric or nonparametric tests. Note: although we don't have any information about the distribution, it is safe to assume that this variable is not normally distributed based on the empirical plots in our first exercise. Therefore, for this test, we will use the nonparametric test.\n\n## A) what kind of test would you use to evaluate if there was an association between\n\n## (if yes):\nb) We will use the Mann-Whitney U test to evaluate the distribution and the differences of the two samples.\nThe Mann-Whitney U test is the nonparametric equivalent of the t-test. Therefore, it is the nonparametric alternative to the t-test.\nThe t-test calculates a test statistic U to assess the null hypothesis (H_0), by contrast, the Mann-Whitney U test generates a test statistic Z.\nH_0 state: In a population where a distribution of X follows a normal distribution and Z is the normal distribution associated to the distribution of X .\nUnder this null distribution, the Mann-Whitney U test assesses the possibility that H_0 could be true.\n\n## B) what are the differences between the two samples? do you",
        "label": 0
    },
    "496": {
        "output": "![![](https://user-images.githubusercontent.com/15624950/99814714-76591180-18eb-11eb-823d-d367eb18a3ad.gif)](https://user-images.githubusercontent.com/15624950/99814716-87986880-18eb-11eb-9a2b-782794eae647.gif)\n\n\nThis should be done for all patients.\n\n\n# Output\nThis is the format of your results in an Excel file. You should have two columns: Patient ID and Output. Patient ID has `Patient ID 1` `Patient ID 2` ... Patient ID n. The values of the Output will be in the field shown in the following example below; patient1 = 0 patient2 = 1 patient3 = 1 patient4 = 2 patient6 = 0 patient7 = 1 patient8 = 1 patient9 = 1\n\n![![](https://user-images.githubusercontent.com/15624950/99814612-71766880-18eb-11eb-8404-c983d487e825.gif)](https://user-images.githubusercontent.com/15624950/99814613-71766880-18eb-11eb-8b51-cea06a86d2c6.gif)\n\n\n## Note on errors for example with [?=]\nThis is caused by the following code;\n\n```\ndef calc_risk_of_experiencing_event_1(patient, period, treatment, event_type):\n    if patient.risk_of_experiencing_event_1_current_period != None: \n        if treatment == 'control' and patient.current_period == 'start':\n            if _is_after_treatment_starting_period(",
        "label": 0
    },
    "497": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility for the clinical trial by assigning `Trial-level eligibility: 1) Not relevant` for all the patients whose notes are not consistent with the trial's inclusion criteria and `Trial-level eligibility: 2) Eligible` for the rest of the patients. So, you might need to skip the following steps if we have no trial-level ineligible patients and only trial-level eligible patients. You should always assign the trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible. `.\n[INST]\n\n\n#### Input and output\nThere are `keyboard-input` inquiries which allow to input a value and `input field` inquiries which allow to input a list of data. These latter inquiries automatically expand the list of allowable answers.\nAsk an inquiry with the first keyword of `Trial-level eligibility` and add a `Trial-level eligibility` in your output. e.g., `Trial-level eligibility: 1) Excluded`. If the patient meets the inclusion criteria but is excluded on the grounds of the trial's exclusion criteria. When you assign the trial-level eligibility for the clinical trial by assigning `Trial-level eligibility:, e.g., `Trial-level eligibility: 2) Eligible`. When the patient meets the inclusion criteria, and exclusion criteria do not apply. In this step, you should always assign the trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible.`.\n[INST]\n\n#### 1st step\nIn our first step, we want",
        "label": 0
    },
    "498": {
        "output": "Note: We recommend that you put only this line before the line for outputting a specific value,\n\ni.e., 2) Eligible, because it starts with the same character for the input of our machine learning model. \n\n\n\nNote: When you call Trial-level eligibility function in the R console, please always input a new patient note with the same format as the example file.\n\nNote: The default program for trial-level eligibility function is `R (X64)`, and it is required that the R console runs on the Ubuntu platform.\n\nNote: After running trial-eligibility function, an alert will appear at the top of your R console. If you close the R console, trial eligibility function will shut down automatically. You can learn about the details in the tutorial of R. \n\n\n# 25) Procedure description\nProvide a short description about the procedure.\n\n### Description:\n1-36 Gbps DDoS attack resistant web content delivery network.<EOD> A preliminary evaluation of the impact of a nurse-administered treatment protocol on length of ICU stay of intensive care patients.\nThis paper briefly reports the impact of nurse-administered protocols on the length of stay of patients in an intensive care unit. A nurse-administered treatment protocol on an intensive care unit showed a positive effect on patients' length of stay. The protocol was not statistically associated with a decrease in mortality.<EOD> The use of low-cost smart-phone camera for detection of early caries and its caries risk assessment in children\nAbstract Objective. Early detection of caries using new diagnostic devices has been considered to help clinicians when planning clinical interventions before extensive dental restoration is necessary. The purpose of this study was to evaluate the clinical accuracy of a modified smart phone camera as it was applied in two separate clinical scenarios for determining caries status",
        "label": 1
    },
    "499": {
        "output": "<EOD> The Role of Protective Factors in Adolescent Risk Assessment and Risk Interventions\nThe aim of the present study was to evaluate the role of protective factors within the framework of the adolescent risk assessment and risk reduction process. The main research question examined was what types of protective factors, if any, might be useful in assessing and treating adolescent conduct problems. The protective factors examined were grouped into 4 domains, including (1) family factors, (2) peer factors, (3) academic factors, and (4) personal factors. Each of these factors could be used to assess the effectiveness of the risk reduction process. These findings demonstrate that protective factors can be used to help explain the process and impact of early treatment for adolescent risk behavior.<EOD> Neuroplasticity and functional recovery using noninvasive transcranial brain stimulation: evidence from stroke.\nNon-invasive transcranial brain stimulation techniques, particularly repetitive transcranial magnetic stimulation (rTMS) and transcallosal direct current stimulation (tDCS), have shown efficacy in improving motor and cognitive function in a variety of neurological disorders, including stroke. Recently, neuroplasticity has been increasingly considered as the mechanism by which these techniques function. Here we review the current literature exploring the impact of rTMS and tDCS on the recovery of motor and cognitive function beyond that explained by changes in motor and non-motor cortical excitability. We also discuss the potential of the combined use of techniques and their interactions with other therapies to facilitate recovery. This article is part of the themed issue \u2018Non-invasive brain and spinal cord stimulation for understanding and treating movement disorders\u2019.<EOD> Innovative pharmaceutical design: rational selection and optimization of the formulation.\nThe formulation design of every single drug has a significant impact on pharmacological and physicochemical characteristics as well as on the biological and biochemical aspects of the respective active ingredient: the effect is often greater if we consider the complex interaction of the drug with the target tissue system. In recent years, the development of innovative formulations has taken a leading position in the field of pharmaceutical research, and it is generally believed that",
        "label": 0
    },
    "500": {
        "output": "If the patient meets the eligibility criteria for the clinical trial, the patient can be enrolled in the study of the clinical trial.\nFirst, examine the attributes of the patient_data and patient_note objects.\n\nThere is a patient_data variable in the data variable. For example, {**patient_data, {**'patient': {**#ID: 'patient_id' [IPyn] . #Full name: '<NAME>' [IPyn] #Date of birth: '2022-06-11' [IPyn] #Sex: 'F' [IPyn] . #Age at diagnosis: '35' [IPyn] #Tumor status: 0 [IPyn] #Status of axillary lymph nodes: 0 [IPyn] #Grade: 3 #Hormonal receptor status: 2. [IPyn] #HER2-neu status: 2 [IPyn] #Estrogen receptor status: -1. [IPyn] . #Tumor recurrence: 0 [IPyn] #Drainage of axillary lymph nodes: 0 [IPyn] #Surgical resection of non-primary lesion: 0 [IPyn] #Tumor size in millimeters: 41 [IPyn] #Tumor margin: 0 (excellent)  [IPyn] #Multivesicular therapy: 0 (no)  [IPyn] . #Multimodal therapy: 0 [IPyn] . #Metastatic breast cancer: 0 [IPyn] . #Stage: Stage IV [IPyn] . #Tumor size: 4.9mm [IPyn] #Exclusion criteria's of clinical trial: 0 #",
        "label": 1
    },
    "501": {
        "output": "[A133] Hello. Here is some text data. We can process them later. \n\n\nYou may refer to this sample code to process text data.\n<EOD> Evaluating the Impact of Health Education on Health-Seeking Behaviour of Adolescent Girls in a Low-Income Area of Delhi, India\n\nBackground: Girls are highly vulnerable to health conditions which may arise out of poor health-seeking behaviour. Health education programmes can help in improving the health-seeking behaviour of girls in vulnerable areas of Delhi.Aim:The aim of this study was to evaluate the response of adolescent girls to a programme designed to educate them about basic health issues, preventive measures and emergency facilities.Methods:The study was conducted in an urban slum area in Delhi and 125 married girlsexperienced menstrual pain within the past year. To assess the knowledge about health and healthcare facilities among girls, before and after imparting health education, simple random sampling method was used.Results:Almost 0.5 years old women had the lowest mean knowledge score before imparting health education (8.48 out of 14). Post imparting health education, all subcomponents of health and healthcare were included in the highest score ranges of all subcomponents of health and healthcare. Majority of the girls (64%) in the beginning of study had the view that seeking care for menstrual pain was harmful and abnormal.Conclusion:Significant improvement was observed in almost all aspects of the knowledge of adolescent girls and mothers regarding health and healthcare facilities.\n\n# Introduction\nIn today's world, the lives of adolescent girls are full of hormonal changes, new emotions and a spectrum of emotions that are generally associated with a significant change in the lifestyle of the girls. 1 With so many factors that might change the physical and psychological aspects of girls, it is not shocking that adolescence is often linked to emotional disturbances and changes in girls' behaviour. 1,2 Adolescence is identified as a window of opportunity to improve and enhance adolescent girls' health and well-being not only by promoting positive health behaviours to stay healthy, but also to empower them to make informed choices to address",
        "label": 0
    },
    "502": {
        "output": "__HINTS__\n\nThe most common exclusion criterion for clinical trials is age. So, you should assess age for the patient eligibility.   \n\n__Bonus:__  \n\nThe [Instances]({{ page.tableurl }}) include the information needed to access the patient notes. Find your instance below, and [clone it](/{{ site.url }}/en/cloning-your-instance.md) to create your own environment, and then [clone this notebook](https://github.com/vahadar/vahadal/blob/master/notebooks/clinical_trial_recruitment.ipynb) as `clinical_trial_recruitment.ipynb` to get started.\n\n\n[Instance 1]({{ site.url }}/instances/instance1.json)\n[Instance 2]({{ site.url }}/instances/instance2.json)\n\n\n\n<EOD> A survey of the clinical effectiveness and safety of noninvasive ventilation in patients with chronic obstructive pulmonary disease and hypercapnic respiratory insufficiency.\nWe examined the efficacy and safety of noninvasive ventilation (NIV) in 40 patients (mean age 61 yr) with chronic obstructive pulmonary disease (COPD) with mild-to-moderate respiratory failure (PaCO(2) 45-60 mmHg). NIV was administered in home or hospital settings under the supervision of respiratory physicians. Data were collected and analyzed for clinical effects such as gas exchange, quality of life or respiratory muscle strength and incidence of complications in a cross-sectional fashion. During daytime, NIV improved gas exchange (PaCO2 +7.13 mmHg, p = 0.005 and pH +0.0293, p = 0.001) in all patients, and a similar trend was seen in PaO2. Among 14 patients with a body mass index \u226530 kg/m(2), PaCO2 and pH decreased by 3.64 mmHg (p = 0.005) and",
        "label": 2
    },
    "503": {
        "output": "<EOD> Characterization of human cyclic nucleotide phosphodiesterase activities by chromatographic separation.\nSeparation of cyclic nucleotide phosphodiesterase (EC 3.1.4.17) activities was achieved by chromatography on high-performance liquid chromatographic (HPLC) columns with the anionic exchange resin, QAESephadex A-50. Seven major activities were detected in both human liver and brain particulate fractions, and separated by reversed phase chromatographic HPLC of a Sephadex A-50 eluate. The peak activities corresponded to an unidentified phosphodiesterase with maximal activity in the pH range of 8.3-8.5, a phosphodiesterase with maximal activity in the pH range of 6.3-7.0, and a phosphodiesterase activity which was active in the presence of high concentrations of Na or Li ions. The peak areas appeared to be independent of the concentration of substrate. Densitometric scans of gel electrophoretograms of the column eluates indicated activity of each of the peak activities at the same mobility in both the 30,000g and the 100,000g liver or brain particulate preparations. The presence and size of the peak phosphodiesterase activities were insensitive to the temperature at which the liver and brain preparations were harvested from the donors. In view of these findings we suggest that the peak phosphodiesterase activities observed did not arise from a particular species of enzyme but were due to activity resulting from an ensemble effect on the various phosphodiesterase isoenzymes.<EOD> Role of 99mTc\u2010HYNIC\u2010annexin V as a prognostic marker in breast and colon cancer patients\nThis study was conducted to evaluate the prognostic efficacy of apoptotic level evaluated by 99mTc\u2010HYNIC\u2010Annexin V scintigraphy and its correlation with routine staging and prognostic tumor markers: serum carcinoembryonic antigen, serum creatinina and Tc\u201099m\u2010dimercaptosuccinic acid scintigraphy in breast and",
        "label": 0
    },
    "504": {
        "output": "<EOD> Different susceptibilities to antibacterial agents of strains of Escherichia coli causing human urinary tract infection. Identification of clones related to a plasmid-specified resistance factor.\nThe relative susceptibilities of 98 strains of Escherichia coli isolated from the urine of patients with acute pyelonephritis, chronic prostatitis, non-pyelonephritic cystitis and bacteriuria were determined by the dilution method. The mean MIC values for the two groups were also compared: Group I (n = 88 strains) contained strains isolated from patients with acute or chronic pyelonephritis and Group II (n = 10 strains) contained strains from patients with cystitis and non-pyelonephritic acute bacteriuria. Fourteen of the isolates were also studied pharmacokinetically: their relative susceptibilities and elimination half-lives were the same for both groups of pyelonephritic strains. In strains from pyelonephritis patients, the MIC value was higher for sulfonamide than for trimethoprim. Compared to group II, group I strains showed the following relative MIC ratios: sulfonamide, 5.6; piperacillin, 20; ticarcillin, 5.5; piperacillin + tazobactam, 1; ticarcillin, 0.29; piperacillin-sulbactam, 0.8. No differences in susceptibilities to gentamicin, tobramycin, cephalosporins or aminoglycosides were observed. When the MIC values of group I strains were compared with those of the other groups, differences were found for aminoglycosides, ticarcillin and piperacillin. Staphylococcus aureus 6538P was used to calibrate the apparatus and as a control in studies of drug-urea complexes and pharmacokinetics.<EOD> Characterization of the NMDA receptor/ion channel complex at glutamatergic synapses.",
        "label": 0
    },
    "505": {
        "output": "[TEST] `Ideal patient <- clinicaltrials::read_cts(\"Trial.txt\") Ideal patient <- clinicaltrials::clean_read_clinical_trial(\"Trial.txt\") Ideal patient <- trial_to_Patient(\"Trial.txt\", 1:2) print(Ideal patient)`\nThe following are the results of running the code:\n``` R\nIdeal patient <chr> # Trial data # Patient data\n1: patient_id \"005_002920\"\n2: patient_id \"005_002844\"\n3: patient_id \"004_002803\"\n4: patient_id \"005_002938\"\n5: patient_id \"005_002832\"\n6: patient_id \"005_002829\"\n7: patient_id \"005_002897\"\n8: patient_id \"005_002817\"\n9: patient_id \"005_002954\"\n10: patient_id \"004_001357\"\n\n```\n\n<EOD> .\nBACKGROUND\nAn increasing number of women has to undergo cancer treatment during pregnancy. This study aimed at analysing medical and psychosocial management of pregnant with breast cancer (PBC) in France.\n\n\nMETHODS\nA survey of medical records was conducted in 25 cancer centers from 2000-2004. Information about management was collected on pregnant and non-pregnant women with non-metastatic breast cancer.\n\n\nRESULTS\nSixty-eight pregnant women and 424 non-pregnant women were included in the study. Age (median, 34) and mean delay (36 weeks) between gestational age and diagnosis were not different in PBC and non-PBC, and most PBC were staged at stage 0-II (36/49, p=0.3). Treatment for PBC differed",
        "label": 0
    },
    "506": {
        "output": "<EOD> The role of endocannabinoids in the oligodendrocyte lineage.\nMultiple-sclerosis (MS) is a chronic demyelinating disease whose etiology is not well defined. A recent genetic study highlighted the involvement of endocannabinoid receptor 2 (CB2) in the pathogenesis of MS. It also implicated a putative novel role of endocannabinoids on myelination. In the present study, we examined the function of endocannabinoids by targeted blockade of CB1 and CB2 receptors by CB1- and CB2-specific agonists in a cell culture system for oligodendrocytes derived from mouse embryonic stem cells (ESCs). Our results demonstrate that 1) CB2-specific antagonists block the proliferation of oligodendrocyte progenitor cells (OPCs), the first step toward differentiation into the mature oligodendrocyte morphology, while the CB1-specific antagonists have a little or no inhibitory effect, and 2) expression of CB1 and CB2 receptors was significantly increased during oligodendrocyte lineage differentiation in three different types of cells: the ESC-derived OPCs, the differentiated oligodendrocytes, and the oligodendroglioma cell line CRT-MGs. These findings suggest that endocannabinoids play a role in proliferation of OPCs through CB2, and also provide an alternative source to OPCs for therapeutic targeting of demyelinating disease through CB2.<EOD> The role of chemotherapy in the postoperative management of locally advanced non\u2010metastatic oesophago\u2010gastric cancer\nRecent randomized control trials have shown that postoperative chemotherapy is of significant benefit in the management of patients with locally advanced oesophago\u2010gastric cancer. We aimed to evaluate whether these results were translated into routine practice.<EOD> Comparison of the therapeutic effects on hepatitis B using traditional Chinese medicine and interferon alpha plus lamivudine.\nINTRODUCTION",
        "label": 0
    },
    "507": {
        "output": "# Coding Instructions\nIf multiple patient notes are given, you should assign a patient ID and then output the patient notes one by one in the following lines. Let us imagine that you are given the following four patient notes:\n\n`patient notes:``\n#1 First patient note:`#1 Patient notes by ID: P1\n\n# Exercise 8\nPlease submit an exercise.\n\n# Exercise 9<EOD> Effect of acetazolamide on cerebrospinal fluid pressures in patients with cerebral palsy.\nThe effect of acetazolamide on intracranial pressure (ICP) in patients with cerebral palsy (CP) is not well established. Intra-cranial pressure (ICP) is considered a useful tool in the management of CP. To evaluate the effect of acetazolamide on ICP, we prospectively studied 20 CP patients with a mean age of 10.3 years (range, 6-16 years; 12 boys, 8 girls). A Gauge-Penman manometer was used to measure ICP. Acetazolamide induced ICP increase in all patients; mean ICP increase was 10.7 \u00b1 4.7 mmHg on the first and second days at the maximum ICP elevation. This study shows the usefulness of the manometer and the results of ICP monitoring using this device, with and without acetazolamide intoxication in patients with CP, before and after operation. This preliminary experience suggests that acetazolamide increases ICP. It should be kept in mind that ICP elevation might have a deleterious effect in the CP patient when the latter is treated with acetazolamide.<EOD> Huge Pretibial Lipoma Mimics an Ankle Tumor\n\n\n\n## Dear editor-in-chief\nPretibial lipomas usually appear as painless and mobile masses on the extensor surface of the distal leg. In this study, we presented a case of a huge pre-tibial lipoma. A 30-year-old man was referred to our department complaining of a slow growing mass that had been present for the past 15 years. The mass",
        "label": 2
    },
    "508": {
        "output": "# \u25a0 Case Studies\nIf you look at the first patient note, you may find a couple of errors about inclusion criteria (e.g.., patient has a history of alcohol abuse, pregnancy, etc.). You can change the patient note to correct the input errors. In our demo, the same patient had a history of alcohol abuse, and we corrected it manually. You need to add and validate in the input sheet the appropriate criteria for alcohol abuse. The alcohol abuse is one of the more common exclusion criteria for clinical trial. Alcohol abuse is also a potential confounding factor in medical research, for example, alcohol's effects on cancer, sleep, and blood pressure.~ [fig_ref]  Figure 4 10: Bottlenecks that can occur in decision-making processes based on 100% rule [/fig_ref] .7 shows an input error.\nClick on the icon \u2751 in the upper navigation bar to activate the input sheet. Note the \u2751 icon in the upper right corner of the input sheet. Click on the icon \u2751.\nSelect the patient with the ID __ and choose the input row `Has alcohol abuse`. (You can change the ID manually or set the first patient's ID to the value 0 to make it a reference number.)\nSet the value to Yes for the patient.\nTo validate your change, click on icon \u2713 to save the change. \nFigure 4.13 \u25a0 Input error.\nOn the left, you can observe an input row: for the patient note, the patient ID is 0, the patient's gender is female, and the age is 45. On the right, you can observe the input error in the alcohol abuse row. The `True` value is used for the first time. \nFigure 4.14 \u25a0 Correction to the input error.\nFor the patient ID 0, the value is set to `False` to correct the input error. \nFigure 4.15 \u25a0 Corrected value for the patient note.\nYou need to change the \"No\" value in the alcohol abuse row to \"Yes\". This value is used for the first time, and therefore the input row for \"Alcohol abuse\" has the \"Validate before save\" box on",
        "label": 0
    },
    "509": {
        "output": "[SECTION] Prognostic markers \n[ITEM] A 35-year-old woman comes to your clinic with a 2-month history of back and left knee pain. She has a 10-year history of Hashimoto's thyroiditis. She is not sexually active, nor has she given birth to any children. She has no family history of cancer. She is a current smoker, smoking 1 pack per day. Her labs reveal a thyroid stimulating hormone (TSH) level: 0.415 units/mL (reference: 0.550-4.780 units/mL); 1,25-dihydroxyvitamin D levels: 16 pg/mL (reference: >20 pg/mL); 25-hydroxyvitamin D: 34 ng/mL (reference: >30 ng/mL); total cholesterol: 214 ng/mL (reference: <200 ng/mL); 25-hydroxyvitamin D: 9 ng/mL (reference: >30 ng/mL); LDL: 131 ng/mL (reference: <100 ng/mL). Ultrasound of the thyroid showed a solid nodule measuring 6 mm in diameter. You decide to refer the patient for a needle biopsy to rule out lymphoma. However, after your appointment, you discover that the patient passed away 1 day after she was seen in the clinic. The patient's husband stated that she had suddenly felt ill before he arrived home that evening. \nHere is the patient note:\nThe patient was seen in the office a month ago. She was healthy, and no medications were being taken. She was smoking half a pack of cigarettes per day. All of her labs including a prostate-specific antigen test were normal. She had no family history of any cancer. 2 days after she passed away, the autopsy revealed metastases to the lung, bone, bone marrow, and spleen. She had high grade NHL (B-cell). Her lymphosarcoma could have been caused by N",
        "label": 0
    },
    "510": {
        "output": "[/COACH] Hi. You are a cancer consultant who gives a short conversation with a patient about their health status and helps them improve their quality of life. You use health-tracking devices, such as Fitbit, Apple Watch, and Google Fit, to collect medical data and then transfer them to the electronic medical record system for analysis. You also collect the patient's information about food intake and physical activity to provide a personalized diet recommendation.\n\nYou have to develop a real-time patient-facing chatbot to help patients make decisions about diets and exercise habits. You will use the knowledge obtained from patients' medical records. For example, if your patient uses a medical device to monitor his or her cardiovascular system, you can collect the patient's medical data and recommend healthy diets for him or her.\n\nTo do this, you have to train a Bidirectional encoder representations from transformers (BERT) model that can understand both language and medical images at the same time. Here's an example of the medical image data.\n\n![Examples of medical image data](https://i.ytimg.com/vi/TJj8dXxQpQ0/hqdefault.jpg)\n\n### Pretrained BERT\n\nPretrained BERT is the most popular and well-known machine learning model. The pretrained BERT has 12 transformer layers. A transformer is a convolutional neural network that uses an attention mechanism. It understands the language context and generates high-quality outputs. As you continue learning, the pretrained dataset will only be enhanced and expanded by collecting more data. When using a pretrained BERT, you can obtain the best performance possible using an already trained BERT model, such as the Hugging Face Model.\n\n### WordPiece\n\nWordPiece is a method in which the words of a large natural language model are divided into subwords and then trained through self-supervised learning. It is a method of creating a vocabulary for words by analyzing language usage and is trained using the Word2Vec algorithm. WordPiece is designed to reduce the memory requirements of NLP models. Specifically, training WordPiece and using the vocabulary file can significantly reduce the amount of memory required to store words in",
        "label": 2
    },
    "511": {
        "output": "## [END]\n\n## 54\n\n## Recurrent patient detection\n\n[INST] In the clinical studies, many patients drop out due to recurrence. Some patients receive chemotherapy drugs for a long time, so the recurrence rate is low. Here in this dataset, all patients with breast cancer are recurrence patients after a chemotherapy regimen. Your task is to find the patients whose current therapy has been unsuccessful and who are candidates for recurrent treatment.\n\nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code `patient_age >= 45` indicates that patients whose age greater than or equal 45 years old will appear in the candidate list. The filter code `patient_gender == \"w\"` indicates that the current disease status of patients whose gender is `w` can be seen in the candidate list. \n```\npatient_age >= 45;\npatient_gender == \"w\";\n``` \nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code \n\nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code \n\nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code \n``` python\n# Experiment ID = \"Ex_1_4\"\n# Patient identifier = ID\n# Experiment ID = \"Ex_2_1\"\nfilter_ID = [\n    \"1\", \"1\", \"2\", \"2\", \"3\",\n    \"1\", \"1\", \"2\", \"2\", \"3\",\n    \"1\", \"1\", \"2\", \"2\", \"3\",\n    \"1\", \"2\", \"3\", \"1\", \"2\",\n    \"2\", \"3\", \"1\", \"3\", \"4\"\n]\n```\n[END]\n\n## Recurrent Patient detection\n\n[INST] The patient ID should be detected in the list. If it appears",
        "label": 1
    },
    "512": {
        "output": "You don't have to repeat the `if` statements to compute the eligibility scale. The code will automatically be parsed and compiled by the compiler/interpreter/host system.\n<EOD> .\nIn a controlled 21-days double-blind trial the antiarrhythmic effect of a new class 1C antiarrhythmic drug, azefibrate was compared with placebo in 41 patients with chronic atrial and/or ventricular arrhythmia resistant to other antiarrhythmic drugs. In azefibrate-treated patients antiarrhythmic effect was observed in 15 (71%), in comparison to 35% in a group of patients treated with placebo. Cumulative frequency of antiarrhythmic drug elimination in patients treated with placebo and azefibrate was 3% and 65% respectively. In conclusion, azefibrate exerts an evident antiarrhythmic effect, mostly in patients with chronic atrial fibrillation (12 cases), but also in patients with chronic akinetic ventricular arrhythmias (6 cases).<EOD> Reevaluating the role of the \u03b2-globin promoter in erythroid gene expression and gene therapy\n\nThe successes of gene therapy for inherited blood diseases and the development of 2017 guidelines for in vivo clinical trials have generated great optimism for the use of gene therapy to treat genetic disease. The human \u03b2-globin locus has been studied for over five decades with advances in the understanding of its epigenetics, genetic regulation and the genetic engineering of locus control regions (LCR). While in vivo gene therapy is currently successful for the correction of sickle cell anemia, further improvement in clinical outcomes still relies heavily on progress in locus engineering. We propose that locus and especially globin gene transgene expression is limited due to silencing chromatin modifications of the transgene that prevent formation of an LCR and silencing by position effect. Using a new mouse transgenic model, we show that forced chromatin structure changes mediated by the BACH2 transcription factor can reactivate the LCR in transgene loci and generate a phen",
        "label": 1
    },
    "513": {
        "output": "Good Luck!\n<EOD> Development of a Recombinant Pooled Reporter Cell Line for HIV-1 Fusion Assay\nThe fusion process of virus and host cell membranes is critical for HIV-1 infection. Thus, the inhibition of HIV-1 entry into host cells would become a possible therapy. Here, we have developed a new reporter cell line targeted to the HIV-1 entry assay by using a genetically-modified HeLa cell line, called HeLa 48F, where the green fluorescent protein (GFP) gene has been inserted behind the transcriptional stop codon of the CD4 gene. HeLa48F cell line expresses CD4 protein on the cell surface, and, if HIV-1 enters the cells, the GFP protein can be expressed by a bicistronic expression unit consisting of gag and packaging plasmids. This reporter cell system provides high sensitivity and specificity. Thus, the cell line developed in this study could become a standard tool for HIV-1 envelope glycoprotein studies and vaccine development.<EOD> Galectins in immunosuppression.\nGalectins are unique animal lectins in the immune system that regulate immunity negatively and play antiinflammatory roles. In particular, they negatively regulate the effector phase of immune response and induce tolerance. Apart from galectin-1 which is classified as an \"immune-modulator\", galectin-2, -7, -9 and -10 were recently identified as galectins inducing tolerance in na\u00efve T cells and as key-modulators in the control of immune response. Moreover, galectin-2 and galectin-4 could be involved in Treg expansion because their expression is higher in these cells than in conventional effector T. Galectin-3 is involved in the maintenance of FoxP3 expression and Treg stability since its expression decreases when FoxP3 is lost. Although expression of galectins in mast cells (MC) is limited, several studies have demonstrated their modulatory role in MC allergic responses. Thus, as they regulate not only allergic responses but also antiviral one, galectins could be considered",
        "label": 0
    },
    "514": {
        "output": "- <title>BMI-for-age, weight for age, height for age and weight for height among children of 0-12 years old. (2016/1/1\u223c2018/9)</title>\n- <a href=\"http://haw.iioc.tw:8080/dataexplorer/Home\">IIOC Data Portal</a>&nbsp; >&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home\">Query</a>&nbsp; >&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home\">BMI&nbsp;for&nbsp;&nbsp;age&nbsp;or&nbsp;weight&nbsp;for&nbsp;&nbsp;age&nbsp;&nbsp;or&nbsp;height&nbsp;for&nbsp;age&nbsp;&nbsp;or&nbsp;weight&nbsp;for&nbsp;&nbsp;height&nbsp;&nbsp;among&nbsp;children\">Children's&nbsp;Health&nbsp;Data&nbsp;&nbsp;and&nbsp;Indicators</a>&nbsp;&nbsp;&nbsp;&nbsp; >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home/Indicators/14\" target=\"new\">Body&nbsp;mass&nbsp;index&nbsp;for&nbsp;&nbsp;age&nbsp;(BMI)</a>&nbsp;>&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home/Indicators/14\" target=\"new\">BMI&nbsp;for&nbsp;age&nbsp;or&nbsp;weight&nbsp;for&nbsp;age&nbsp;&nbsp;and&nbsp;by&nbsp;sex</a>&nbsp; >&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home/Indicators/14\" target=\"new\">BMI&nbsp;for&nbsp;age&nbsp;or&nbsp;weight&nbsp;for&nbsp;age&nbsp;or&nbsp;",
        "label": 1
    },
    "515": {
        "output": "Let's think step by step. On the trial report template, enter a data set: \n\n\n![](/attachment/images/1020/file)\n\nFinally, the trial report page should have the following format:\n\n\n![](/attachment/images/1020/file)\n\n### 7: Generate Informed Consent Form.pdf\n[INST] Hello. You are a researcher at the Faculty of Pharmacy. You work on a [clinical trial](/course/22.html) on chronic kidney disease progression. \n\nYou should generate an informed consent form and sign it. The inform consent form should be legally binding and written in a form understood by the participant. \n\nThis form shows a description of the trial's objectives and requirements, risks and benefits, alternative treatments, confidential",
        "label": 1
    },
    "516": {
        "output": "Good programming practice is doing more than once what you intend to have your compiler do only once. Therefore the three times the code is run under the instruction `n = 3`, where n is the counter, are as follows:\n\n  1. Make sure, first of all, that the patient note has been read completely before running the code. \n  2. Use if the patient note contains a sentence like \u201fExcluded (patient meets inclusion criteria, but is excluded based on the trial's exclusion criteria)\u201d, to skip the further repetition in loops.\n  3. When the patient note is of length equal to zero, then the current loop should run to its end to show all possible results for the assessment of eligibility and avoid skipping the current trial. \n\n\nTo do so, change the following code in function GetEligibility (lines 70 \u2013 72):\n\n`for (n = 1; (n < 3) && (PatientNote.Length > 0); n+=1) { \u2026 } `\n\n<EOD> Identification, characterization, and chromosomal location of a gene encoding a mastoparan-like peptide in honey bee, Apis mellifera.\nWe have recently reported the first finding of a mastoparan-like peptide, bee mastoparan-II (bee MPII), in worker honey bee (Apis mellifera) venom. In this study, we have identified an mRNA transcript for mastoparan-like peptide (MAP) from honey bee venom gland transcriptome data. Using the 3'- and 5'-RACE system, the gene was assembled by RT-PCR. The full-length cDNA encodes 94 amino acid residues, which are predicted to form a protein of 89 amino acids (bee MPII). The sequence contains a 22 amino acid long N-terminal signal peptide, which is a typical feature in venom peptides. The predicted bee MPII sequence shares 89% similarity with the corresponding sequences of bee MPII. Sequence search for bee MPII homologs revealed that a gene homologous to human mas-1",
        "label": 0
    },
    "517": {
        "output": "[TRAIL] A 47-year-old woman is being evaluated for a new chronic back pain in the right lower limb. She had received chronic anticoagulant therapy for venous thrombosis over the previous 15 years, was a smoker, and her blood analysis (BT: 38.2\u00baC; BP: 120/80\u2009mmHg; HR: 100 bpm; R: 18 bpm) showed increased D-dimer. The physical examination and blood test were initially performed by a nursing assistant on the ward. The physician confirmed the initial diagnosis. During his training, the physician receives the patient's medical history and prescribes a treatment that includes an additional antibiotic for three days. He writes a prescription, which is given to the patient after her blood test results are confirmed. The results of the test for a fungus are negative.\nGiven the patient's complaints and treatment plan, select the most appropriate response:\n\n\nA) Revision of the plan, which will be accepted by the physician. B) Dispensation for three days instead of the original five days. C) Revision of the plan, which will be accepted by the nursing assistant, but not by the physician. D) Revision of the plan, which will be accepted by both the nursing assistant and the physician.\n\nWhich one of the following is not included in the decision-making process of the physician from the time the case is identified until the patient receives the treatment?\n\n\nA) Review of the patient's medical history before initiating the treatment plan. B) Prescreening of the clinical case. C) Assignment of a second person in the treatment team. D) Consensus consultation if treatment options are not clear.\n\n## [TRAIL-TECH-DISC-SOLUTIONS-01]\nWhich one of the following is not included in the technical support activities of the information systems?\n\n\nA) Adopt technologies to increase data quality in business environments. B) Design and execute computer system requirements. C) Evaluate the business benefits of the computer system. D) Integrate multiple information systems into a single information technology architecture.\n\n###",
        "label": 0
    },
    "518": {
        "output": "</PRE>\n\n\n\n<!-- 31.2.1.4.2 Random assignment -->\n\n# Random assignment\n\n\nIn order to assign each patient to a group of treatment, a randomization is done in R.\n`> library(randomsplit) > library(splitstackshape) > randomize <-function(x,n=nrow(data)){ > n1 <-mod(sapply(1:nrow(x), FUN=function(y){ y<nrow(x) }), n1) > n2 <-nrow(x)/n1 > split <-rbind(splitstackshape(x[n1:n2], var) , splitstackshape_(x[n2:nrow(x)], var)) > data[,1:(n1+n2)] <--data[,ncol(split)] <--split > data[1:(n1+n2)] <--split[n1:n2,] > data[n1+n2] <--data[,ncol(split[-n1])] + split[-n1,](3:ncol(split[n1])) > data[n2+1:nrow(x)] <-data[n2+1:nrow(x),[n1+n2]] > return(split) > } > x <-as.data.frame(y) > x <bquote(\nx) # assign R-code for x > rnd <-random.permit(x, 2)[1, ] randomize(x,n=rnd) > [INST]\n\nAssign to two groups and report the groups on the result. For each, the number of observations for each group and the number of groups are reported.\n``` R\nx\n```\n```\nx$group <-rnd Group 1: 210.000 Group 2: 224.000 nrow(x) Group 1: 210.000 Group 2: 224.000 ngroups(x) Group 1: 31.864 Group 2: 33.136\n\n```\n``` [INST]\n\nNow, take the two assignments by `x2 <- randomize(x, n=nrow(data)-1",
        "label": 1
    },
    "519": {
        "output": "<EOD> Dual-Luminescent Carbon Microsphere Composites for the Simultaneous Determination of Oxytetracycline Hydrochloride and Streptomycin Sulfate in Egg.\nStreptomycin sulfate (STR) and oxytetracycline hydrochloride (OTC-HCl) are typical veterinary drugs widely used in animal feed; therefore, the simultaneous determination and quantification of these two drugs in eggs is of great significance. In this work, a novel dual-luminescent carbon microsphere (CL-CMS) composite was fabricated. Its luminescent properties mainly originated from the intrinsic carbon dots (CDs) that were formed during the carbonization process and the phosphorescent europium/DPA complex incorporation in the silane layers that were fabricated through the silane coupling treatment of the carbon materials. The phosphorescent center is encapsulated, which can be used to eliminate the interferences from the background fluorescent components of the food, and the silane layer ensures that the photoluminescence (PL) center does not decay when the emissive molecules escape due to the dehydration of the CDs. The PL emission of CL-CMS was realized by the electron transfer from the 1 O2 excited state of the CDs to the europium/DPA cluster. Under the optimal conditions, the limit of detection for STR and OTC-HCl were 5.2 and 0.3 \u03bcg mL-1, respectively. These limits of detection allowed the quantitative detection of the trace STR and OTC-HCl levels in actual egg samples (with 0.0059 and 0.0125 g OTC-HCl and STR, resp.).<EOD> Highly selective fluorination towards aromatic systems at room temperature and atmospheric pressure.\nFluorinated compounds play central roles in a wide range of applications, including new electronic, magnetic, biological and optical media, drug design and biofuel technology. The development of environment-friendly, industrially scalable and economically feasible methods for the fluorination of organic molecules in a selective manner remains a great challenge. As summarized in the following Table, various methods",
        "label": 2
    },
    "520": {
        "output": "A: Clinical trials may not have all of the same eligibility requirements. So it's actually hard to give a list of criteria that always apply. \nThere are two types of clinical trials:\n* randomized controlled trial (RCT)\n* open-label trial\n\nHere are some common criteria from clinicaltrials.gov: \n\n* age\n* sex\n* previous treatment\n* blood test results\n\nTo summarize: \n\n  We expect the first column to always be the trial name.\n  We're not sure how the values for `name`, `inclusion_criteria`, `exclusion_criteria` should be structured.\n  We're expecting a dictionary in the `patient_details` column from the data set.\n  \n```python\ntry:\n    # Get the patient note\n    print(\"Getting the patient note.\")\n    with open(patient_note_csv, 'r') as fn:\n        patient_note = dict(reader(fn).items())\n    print(\"Patient note: {}\".format(patient_note))\n    \n    # Get the clinical trial\n    print(\"Getting the clinical trial.\")\n    with open(clinical_trial_csv, 'r') as fn:\n        clinical_trial = dict(reader(fn).items())\n    print(\"Clinical trial: {}\".format(clinical_trial))\n\n\n    # Check our clinical trial definition\n    print(\"Checking the clinical trial definition.\")\n    \n    trial_eligibility_dict = clinical_trial.get('inclusion_criteria')\n    \n    if not trial_eligibility_dict:\n        print(\"Clinical trial has no inclusion_criteria.\")\n        \n    else:\n        print(\"Clinical trial has inclusion_criteria: {}.\".format(trial_eligibility_dict))\n    \n    print(\"Patient meets the inclusion criteria of {}.\".format(trial_eligibility_dict))\n    \n    \n    # Check the inclusion criteria\n    print(\"Patient doesn't meet the inclusion criteria of the clinical trial. The trial includes criteria for the following:\")\n    \n    if not clinical_",
        "label": 2
    },
    "521": {
        "output": "___\n\n<b>03_Example</b>\n\n[MOD]  \n[INST] Hello. Your first task is to convert the values of the variables <NAME> , <NAME> , and <NAME> to a normal distribution. If these variables are not in a normal distribution, the data might be skewed. This will decrease the probability of data being considered as unrepresentative of the population.\n\n[INST] Here are the patients in the test-set (n = 52) and their variables: \n\n[MOD] Now, we have to work for the normal distribution. These 3 variables are continuous, and we cannot assume that they have the normal distribution. It is important to check if these 3 variables are in a normal distribution.\n\n![normal distribution (03)](/assets/images/data_analysis_normal_distribution/03.png)\n\nAs the 3 variables are not in a normal distribution according to the QQplot, we should perform a normalization transform to normalize the dataset; otherwise, the trained model would have a poor capability to fit the clinical data well (if the data have unnormal distributions). A normalization transform is a mathematical function that makes the data closer to a normal distribution. After all, the model should be trained by transformed data. Therefore, you should implement a normalization transform and test if the data are in a normal distribution again. If they are in a normal distribution, we should train by the original data without any normalization transform. Otherwise, you should have prepared the normalization transform module and integrate this transform into the model.\n\n[MOD] The normalization transform is based on a log-transformation function.\n\nIn a log-transformation, a given value in the original data set is converted to the value that gives the same probability density as the normal distribution's probability density in the range of the x-axis.\n\n![normalization (03)](/assets/images/data_analysis_normalization/03.png)\n\nSo we should calculate the normalization transform after having converted the probability density of the original dataset into the x-axis to the probability density of the normal distribution. In other words, a new dataset is created by the normalization transform, which is supposed to transform the existing normal distribution of the probability density at a particular x-axis into a normal distribution in which a",
        "label": 2
    },
    "522": {
        "output": "[INF] Hello. Today is your 15th birthday. You love pizza, which is one of your favorite foods. You're going out to a friend's house to celebrate. The friend's family has a tradition of cooking for you a pizza with the ingredients that you like most. The options for the 12 ingredients of the pizza are pasta, bacon, sausage, mushroom, onion, green pepper, egg, ham, banana, cheese, bacon, and salmon.\n\nToday's pizza is for you! The ingredients are set up on a card. The ingredients that are not present are indicated in the blank spaces. You'll need to choose the ingredients and place them on the card to create a new pizza. Which ingredients will you choose?\n\nHere is an example of a possible pizza [/INF]\n\n\n\n![image.png](https://user-images.githubusercontent.com/34364444/78496178-0e450d80-7411-11ea-9843-7a48676d8f22.png)\n\n\n\n\n\n\n\n\n[INF] Hello. Today is your 15th birthday. You love pizza, which is one of your favorite foods. You're going out to a friend's house to celebrate. The friend's family has a tradition of cooking for you a pizza with the ingredients that you like most. The options for the 12 ingredients of the pizza are pasta, bacon, sausage, mushroom, onion, green pepper, egg, ham, banana, cheese, bacon, and salmon.\n\nToday's pizza is for you! The ingredients are set up on a card. The ingredients that are not present are indicated in the blank spaces. You'll need to choose the ingredients and place them on the card to create a new pizza. Which ingredients will you choose?\n\nHere is an example of a possible pizza [/INF]\n\n\n\n![image.png](https",
        "label": 2
    },
    "523": {
        "output": "2. If you use your laptop to complete the code challenge, there will be a screen with instructions every time you launch the platform after submitting your solution.\n 3. As the assessment was conducted during the COVID-19 pandemic in 2021, please be reminded to always keep yourself safe especially when you visit the outpatient clinics and undertake your clinical services, and always follow the latest health guidelines such as wearing appropriate personal protective equipment in the clinical setting, especially when near the patients and taking care of their needs, as shown in . In 2018 and 2019, we conducted this assessment. However, before you start completing the assessment, please be reminded that the healthcare system in the Philippines during those years did not strictly follow the guidelines and recommendations for COVID-19 by the Philippine Department of Health or the government as we did not have a confirmed positive COVID-19 case in the Philippines at the time. Please read more about the assessment in the past (2018 and 2019).\n 4. The answer key is available on the [SNAUTS webpage](https://www.snauts.ph/?q=content/certificates-of-completion), which also includes the solution guides. To access the answer key, ensure that the student access level that you have applied for is the correct one. To access the solution guide, click the PDF with the title, \"Solution Guides:\". To ensure anonymity, the solution guides are password-protected and you will need to submit the correct password to access the solution file. Click the password provided. If you could not access the solution guide, please notify one of the study team members. 5. If you have an interesting coding challenge that you've completed on your own, consider joining our [community of learners](snauts.ph/community/).\n\n\nHINT 1\nCreate an appropriate variable called _age_ that stores the patient's age.\n\n`def age(patient): 1999 - patient.birth_date.year`\n\n_Output:_ _age_ is a 62-year-old man._\n\nHINT 2\nCreate an _Eligible_ flag variable to store eligibility status. When",
        "label": 1
    },
    "524": {
        "output": "## DATA\n[inst]\n\n        ### Table of Contents\n        1.  [**1: Summary**](DEMO/DEMO.md).\n        2.  [**2: Patient** ](DEMO/STUD_2/patient.md).\n        3.  [**3: Medication** ](DEMO/STUD_3/medications.md).\n        4.  [**4: Procedure** ](DEMO/STUD_4/procedure.md).\n        5.  [**5: Clinical Trial**](DEMO/STUD_5/clinical_trial.md).\n        6.  [**6: Researcher** ](DEMO/STUD_6/research.md).\n        7.  [**7: Institution**  ](DEMO/STUD_7/institution.md).\n        8.  [**8: Patient Note**  ](DEMO/STUD_8/patient_note.md).\n        9.  [**9: Patient Summary** ](DEMO/STUD_9/patient_summary.md).\n       \n        ###  DATA FLOW\n        1.  [**Patient Note to Patient Summary** ](DEMO/STUD_8/patient_note_to_summary.md).\n       \n        ###  RELATIONSHIP\n       \n        -  [**Patient Summary to Researcher**](DEMO/STUD_9/patient_summary_to_research.md).\n       \n        ###   TABLE-DRIVEN DESIGN\n        1.  [**Patient.csv** ](DEMO/STUD_2/patient.csv)\n        2.  [**Procedure.csv** ](DEMO/STUD_4/procedure.csv).\n        3.  [**Medication.csv ](DEMO/STUD_3",
        "label": 2
    },
    "525": {
        "output": "[/MCQ] [/MCQ]\n\n\n### \u2714\ufe0f You are not allowed to use the following tags:\n\n\n`[data-user]`, \n`[data-reveal][data-target]`, \n`[data-reveal][data-target][data-hide]`, \n`[data-reveal]`, \n`[data-reveal][data-target]`, \n`[data-target]`, \n`[data-target][data-reveal]`, \n`[data-target][data-reveal][data-hide]`, \n`[data-target][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-hide]`, \n`[data-target]`, \n`[data-hide]`, \n`[data-target][data-hide]`, \n`[data-hide][data-target]`, \n`[data-hide][data-target]`.\n\n\n### \u2714\ufe0f You are not allowed to use the following tags:\n\n`[data-user]`, \n`[data-reveal][data-target]`, \n`[data-reveal][data-target][data-hide]`, \n`[data-reveal]`, \n`[data-reveal][data-target]`, \n`[data-target]`, \n`[data-target][data-reveal]`, \n`[data-target][data-reveal][data-hide]`, \n`[data-target][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-hide]`, \n`[data-target]`, \n`[data-hide]`, \n`[data-target][data-hide]`, \n`[data-hide][data-target]`, \n`[data-hide][data-target]`.<EOD> High Performance of Bioceramics for Bone Tissue Engineering\n\nThe demand to",
        "label": 1
    },
    "526": {
        "output": "## [1] Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)\n\n![CHARISMA](https://raw.githubusercontent.com/shing98/2018_MLBiomed_Proposal_Institutionalization/master/charisma.jpeg)\n\n### 1.1 Patients\n\nInclusion criteria:\nPatients above 45 years old and comply with at least one of the four categories of inclusion criteria, as described in the Table of Inclusion Criteria (see [1]).\n\nPatients aged above 45 years who have had at least one of the four categories of inclusion criteria.\n\n#### 1.1.1.4\n\n## Detailed information about patients\n\n### 1.1.1.4.1\n\n1.1.1.4.1) Atherothrombotic Risk Factors\n\nAtherothrombotic risk factors refers to the presence of one or more of (1, 2, and 3) below, with or without (4).\n\n(1) Non-diabetic hypertension;\n\n(2) Current cigarette smoking;\n\n(3) Total serum cholesterol level of a previous screening test before randomization > 220 mg/dL, and LDL-cholesterol > 130 mg/dL;\n\n(4) Coronary heart disease, and/or peripheral heart disease (e.g., angina pectoris, previous myocardial infarction (MI), previous percutaneous transluminal coronary angioplasty (PTCA), previous coronary artery bypass grafting surgery (CABG), stroke, transient ischemic attack (TIA), or peripheral artery occlusive disease (PAOD)).\n\n#### 1.1.1.4.1.1\n\n### 1.1.1.4.1.2\n\n1.1.1.4.1.2) Diabetes\n\nDiagnosed diabetes with or without documented vascular complications will be classified under 1.",
        "label": 2
    },
    "527": {
        "output": "I expect you to write a program on `Simulation - Expert system - Example` from the `Tutorial - Expert system - Advanced - Example` chapter. [/END]\nLet's think how can we implement the `Trial-level eligibility` by expert system in the code snippet below.\n\n```javascript{py}\nfunction ExpertSystem.getTrialLevelEligibility(trialIdx, isInclusionCriteria){\n  var trialCriteria;\n  switch(trialIdx){\n    case 0://Trial #0\n      trialCriteria={\n        'Criteria1':'0','Criteria2':'0','Criteria3':1,'Criteria4':1,\n        'Criteria5':0,'Criteria6':'0','Criteria7':0};\n      break;\n    case 1://Trial #1\n      trialCriteria={\n        'Criteria1':'1','Criteria2':'0','Criteria3':2,'Criteria4':1,\n        'Criteria5':0,'Criteria6':'0','Criteria7':0};\n      break;\n    case 2://Trial #2\n      trialCriteria={\n        'Criteria1':'0','Criteria2':'0','Criteria3':2,'Criteria4':1,\n        'Criteria5':0,'Criteria6':'0','Criteria7':0};\n      break;\n    default: {\n      throw new Error(\"Invalid trialIdx\");\n    }\n  }\n  return {\n    inclusionCriteria:isInclusionCriteria\n      ,exclusionCriteria:getExclusionCriteria(trialCriteria),\n      trialIds:trialCriteria.trialIds\n    };\n}\nfunction getExclusionCriteria(exclusionCriteria){\n  var exclusionCriteria={\n    Criteria5:'0','Criteria6:0,'Criteria7':0}; \n  if(exclusionCriteria.Criteria7){\n    exclusionCriteria.inclusionStatus='4';\n  }\n  else{\n    exclusionCriteria.inclusionStatus='1';\n  }\n  return exclusionCriteria;\n}\n```\n\n- I assume that `triallevels` is a hashmap",
        "label": 0
    },
    "528": {
        "output": "### Example\n\t```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value />\n\t\t\t\t</Trial-level eligibility>\nIncluded, not relevant, or excluded, and is explained by the following:\nTrial\n\n    </Trial-level eligibility>\n[INST]\n```\n\n### Excluded\n```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Excluded</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n### Not relevant\n```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Not relevant</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n### Eligible\n```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Eligible</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n### Unknown\n```\n\t\t\t\t<Trial-level eligibility type=\"unknown\">\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n## Trial-related eligibility\n\nYou should make a trial-level eligibility on each trial for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nTrial-level eligibility is the same as Patient-level eligibility.\n\nThe assessment of clinical trial eligibility has a three-point scale: 0) No eligibility; 1) Not relevant; and 2) Eligible.\n\n### Example\n\t```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Eligible</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n## Eligibility assessment report elements\nEach report element has its own eligibility assessment report elements as shown below.\n\n##",
        "label": 1
    },
    "529": {
        "output": "<EOD> A 4-(2,4-dinitrophenyl)butyrate derivative as a highly efficient ligand for the purification of recombinant proteins by immobilized metal ion affinity chromatography.\n1. Recombinant proteins expressed in Escherichia coli can be purified using immobilized metal ion affinity chromatography (IMAC) in a simple one-step procedure utilizing a weak acid elution system (0.6M imidazole in the presence of a small amount HClO(4)). The eluted protein is free of traces of detergents. 2. In the case of 70 kDa human chorionic gonadotrophin this procedure was as efficient as the conventional method based on the use of the immobilized His(6)-tag. 3. The use of a ligand based on 4-(2,4-dinitrophenyl)butyrate showed advantages in IMAC of the enzyme thymidine kinase. In contrast to the original immobilized His(6)-tag, the bound enzyme could be eluted from the column using an acidic elution mixture without loss of activity. 4. The protein-ligand-metal affinity complex can be easily disrupted by dilution with a competitor solution containing the weak acid acetate. The liberated protein can be easily recovered, and thus no wasting of the initial metal ions. 5. These IMAC procedures have been optimized on the basis of the amount of the free ligand bound in a fixed bed chromatography column, which determines the amount of the immobilized ligand. 6. By using this IMAC approach, human thymidine kinase at a purity of 90% could be achieved after ion exchange chromatography. 7. The enzyme could subsequently be obtained in an active form and at a concentration of approx. 5 mg/ml in 50 mM imidazole 20 mM phosphate buffer, pH 7.0. This procedure leads to yields of about 60% of recovered protein. 8. This procedure was also successfully applied to the purification of human glutamic pyruvate transaminase (75 kDa). For this enzyme a pur",
        "label": 0
    },
    "530": {
        "output": "<EOD> .\nThe clinical picture of arteriosclerotic encephalopathy was studied in 111 males over the age of 60 years who had a normal brain stem response to acoustic clicks (ASCR) on the routine EEG. The incidence of ASCR was lower in older patients. The pathophysiological significance of ASCR in elderly patients was investigated. Patients under the age of 65 years without ASCR showed significantly decreased serum lipoprotein concentrations and, conversely, those with ASCR showed increased serum lipoprotein concentrations, when compared to patients over the age of 65 years. These results suggest that ASCR may be used as a neurological index to distinguish between arteriosclerotic encephalopathy and cerebral circulatory failure due to dementia in the elderly.<EOD> A Proton-Coupled Folding in the Photosystem II Reaction Center Studying Proton and Electron Transfer Reactions\n\nRecombinant photosystem II ( PSII ) reaction center ( RC ) was reconstituted with cytochrome c 6 , and the fluorescence and EPR spectra in the S 2 state were monitored at various pH values. The fluorescence changes in red light were strongly dependent on pH, and the changes in the oxidized RC were similar to that in the oxidized protein in buffer at neutral pH. On the other hand, the pH dependence of EPR spectral changes in PSII RC was very different from that in the isolated RC . The proton-coupled folding in S 2 state is suggested. The PSII RC prepared in the membrane environment was found to have properties similar to that in solution. It is suggested that the PSII RC functions in the membrane environment. We also reconstructed PSII RC with a new cofactor CP43-His which is prepared using the expression of an ampicillin resistant gene. The RC reconstituted with CP43-His was used for cryocrystallography and the structure was determined by an electron crystallography.\n\n# Introduction\nThe PSII RC is a complex protein structure which is located within the membrane. The PSII core complex is comprised of the Mn",
        "label": 1
    },
    "531": {
        "output": "### <span>12 26. You should think about the following steps:</span><h5>Checklist for Task 26</h5> \n\nHere is a complete list that shows the steps for this task.\n\n1. \u2468 Check whether each test case satisfies the Inclusion criteria. (1000 test cases: 3 failures in total) 2. \u246a Make sure that the program outputs the 3-valued, trial-level judgment for the given patient. 3. \u246b Make sure that the program outputs the 3-valued, trial-level judgment for the patient in all test cases. 4. \u246c Make sure that the program outputs the 3-valued, trial-level judgment for all patients within a trial. (Note, the patient in a trial with a small number of patients may not be evaluated.)\n\n## 27. You need to check the following:</h5>\n   - [task 27](task.md/27) \n    - Checking the correctness of the patient report generation program for the clinical trial. \n    \n### <span>13 27. Check the following:</span><h5>Checking the correctness of the patient report generation program for the clinical trial.</h5>\n  \n```python\ntask_27 = get_task(\"task.md/27\")\n\nresult = {\n    \"status\": \"OK\",\n    \"log\": \"\",\n    \"test_case\": \"All\",\n    \"comment\": \"\"\n}\n\ntry:\n    task_27.run(result)\n    result.update({\"status\": \"OK\", \"comment\": \"\u2713 Clinical trial report generation function checked.\"})\nexcept NoResult:\n    result.update({\"status\": \"FAIL\", \"comment\": \"\u2713 Clinical trial report generation function not run\"})\n```\n\n### <span>13 28. You will have to find which subpackage this task belongs to.</span><h5>Find which subpackage this task belongs to.</h5>\n  \n```python\nimport task\ntask.subpackages[\"name\"]\n```\n\n### <span>14 29. Here you",
        "label": 0
    },
    "532": {
        "output": "__Author(s)__ [<NAME> and <NAME>](1998-05-05)\n__Abstract__ Elucidate the clinical course of 4 individuals with a known gene encoding LIPA who underwent LIPA gene transfer for LAL deficiency. We studied the clinical course of 4 individuals enrolled on the National Institutes of Health/National Heart, Lung, and Blood Institute trial for LIPA gene transfer for LAL deficiency.\n\n[/ABSTRACT]\n\n### ClinVar\n__Unique identifier__ LIPA_298728.\n__Chromosomal location__ 2p23.2.\n__Gene name__ lysosomal acid lipase.\n__Gene description__ The lysosomal acid lipase (LIPA) gene encodes an enzyme catalyzing the hydrolysis of cholesteryl esters and triglycerides. This gene is located on the short arm of chromosome 2 in a region frequently associated with myocardial infarction, high plasma triglyceride concentrations, and hypercholesterolemia. Polymorphisms in this gene are associated with early onset and severe atherosclerosis that leads to heart attacks, stroke, or peripheral arterial disease at a young age. Multiple transcript variants encoding different isoforms have been found for this gene.\n__Locus reference number__ MIM: 278040.\n__Gene symbol__ LIPA.\n__Mutation_location__ chr2(GRCh37).2:140054103-140056183-NC_000002.11.\n__Mutation_type__ Pathogenic variant.\n__Reference nucleotide change__ c.\n\n### Locus Reference Genomic Database\n\n__Gene symbol__ LIPA\n\n__Chromosome__ 2\n__Contig_number__ NC_000002.11\n__Ensembl_number__ ENST00000320388.6\n__Mutation_type__ Nonsense",
        "label": 0
    },
    "533": {
        "output": "You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nHere is the patient note:\nThe candidate of 49-year-old male came to the laboratory for an interview and a review of his labor",
        "label": 1
    },
    "534": {
        "output": "<EOD> An improved procedure for sequencing the 5' untranslated region and coding regions of retroviruses using a cloning step\nWe describe an efficient scheme for sequencing the 5' untranslated region (5'UTR) and coding region of murine leukemia viruses using the recombinant DNA T/A cloning system. One of the two products from 5'UTR and coding region amplicons is blunt end ligated to pUC18 vector using the 3' addition DNA fragment length polymorphism method. The cloned fragments were transformed into Escherichia coli (DH5 alpha) by the standard calcium chloride method. Colonies that grew after electroporation in liquid medium on Luria-Bertani (LB) agar medium with 100 micrograms/ml tetracycline contain one clone. After isolation, the recombinant containing pUC18 plasmids were sequenced by the dideoxy chain termination method with T7 sequencing reagents.<EOD> Diversity of Ciliates (Alveolata: Ciliophora) in an Arid System with Saline Water in Iran\n\nThe diversity of ciliate species in a hyper salinity (54) waterway of the Zayandeh Rud River in Yazd Province, Iran, was determined monthly from July 2012 to June 2013. Ciliates were found distributed throughout the year in the study locality. The Shannon-Weiner diversity index (H' ) and dominant/evenness (E) were highest in spring (6.0, and 1.31 0/0.50) and lowest in winter (3.3, and 0.48). The greatest diversity and dominant species occurrence during the period was in April, while the lowest were in March. A total of 1,064 specimens of ciliates were found, of which 34 taxa were reported, including 22 Protista and 4 Protozoa (41.6%, 33.3%, 13.3%, and 11.6%, respectively), with 23, 10, and 1 species belonging to the classes Oligohymenophora, Kinetoplastea",
        "label": 1
    },
    "535": {
        "output": "<EOD> Identification of two potential peptide inhibitors of the interaction between nucleocapsid protein and RNA: a molecular dynamics study\nRanvir1, Ranvir2, PB1, and PB2 domains can form the RNA binding domain of N protein. The C\u2010terminus of PB1 (Ranvir3) domain can be used to identify peptide inhibitors of N protein\u2010RNA, which have the ability to resist the SARS\u2010CoV infection. The purpose of this study was to investigate the mechanism and the binding energy of the peptide inhibitor for the Ranvir3 domain. In the simulation system, the amino acid residues in the peptide are all flexible atoms, and the backbone atoms of Ranvir3 are constrained to a specific geometry. In addition the force fields used for peptide are Amber99SB, the force fields for other atoms are Amber99SB\u2010ILDN. For simplicity, the initial conformations were chosen from the Protein Data Bank (PDB). These peptides were Ranvir1 (1w64), Ranvir2 (2c7p), PB1 (Ranvir3) (2c7p), and PB2 (Ranvir3) (2c7p). The initial structures were energy minimized and preprocessed. The 10\u2010ns steered\u2010molecular dynamics simulations were used to get the potential energy and potential well\u2010depth between peptide inhibitor and Ranvir3. We found that the potential energy (<5.0 kcal/mol) and the potential well\u2010depth (0\u20132 \u00c5) for the last 1 ns of simulation are not much different, which showed that the equilibrium state for the Ranvir3\u2010peptide inhibitor system may be reached at about 2\u2010ns simulation. The results suggest that both Ranvir1 and Ranvir2 have the potential to be potential inhibitors, but PB1 and PB2 only have the potential to be peptide inhibitors of Ranvir3. Our findings will provide a theoretical basis for the discovery of peptide inhibitors of Ranvir3, and will provide good theoretical basis for the development of future peptide vaccines. Proteins 2015; 83:1784\u201317",
        "label": 2
    },
    "536": {
        "output": "##[END]\n\n## Assigning a score\nYou can simply assign an integer score to the data element values, i.e., assign value \n0) Not relevant, \n1) Excluded, and \n2) Eligible.\nHowever, many times you want to calculate the score or the grade of this triallevel eligibility. \n\n### Definition\n   \n \nThe score of subject is an integer number which represents the evaluation result of subject. The integer number of subject is computed by the formula as follows:\n   \n   \n### Formulas\n  \n![A formul of subject-level eligibility score:](../../../../images/ui-elements/diagram/medication-overview-diagram.png)\n\n\n\n### Examples\n\nBelow the subject-level eligibilty definitions of patients and a clinical trial are given:\n```python\ndata_dict['Subject-level eligibility scores'] = {\n    'Subject-level eligibility score_ID': [\n        # Patient-level eligibility definition\n        [{'ID': 2, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 2, 'Units': 'Number'}],       \n        # Clinical trial-level eligbility definition\n        [\n            {'ID': 0, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 2, 'Units': 'Number'}, # Excluded\n            {'ID': 1, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 1, 'Units': 'Number'}, # Not relevancy\n            {'ID': 2, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 2, 'Units': 'Number'}, # Eligible\n        ],  \n    },    \n}\n```\n\nFinally, subject-level eligibility score of an instance can be calculated by the formul as follows:\n```python\ntrial_instance.subject-level_eligibility_score.subject_level_eligibility_score \n= eval_data_dict['Subject-level eligibility scores']['ID'].map(eval_",
        "label": 1
    },
    "537": {
        "output": "![ ](/images/inst/screen1.png)\n\nIf the data is incomplete or inconsistent, the patient should be excluded from the trial. You should write such a patient's record in terms of:\n- Trial-level eligibility: Excluded.[INST]\n- Study number: A unique patient identifier generated for each patient when the trial begins. This is a random number generated by the program.[INST]\n- Participant's age in years.[INST]\n- Participant's sex: M for males and F for females.[INST]\n- Participant's ID: A text box for the inclusion of notes on the patient in free text box of your database. [INST]\n- Trial-end date: The date when a patient finished all trial-relevant activities. It should be the same as the date in the trial. [INST]\n\nIf you need to enter more patients, we advise you to create new worksheets and use the information in the cells of each row to fill in a new patient data. You can use the cell 'A1', where the first patient will be inputted. Please notice that this will also input the new patient into the patient list by clicking `Save`. If you are ready to continue with the information of the next patient, change the cell 'A1 ' in the new empty spreadsheet, so that the next patient gets an individual trial number. \n\n\n\n\nWe believe that this is the last step for you and your efforts so far. Now, you should do the following three things:\n1) Save the trial worksheet.\n\n2) Save all worksheets used for the creation of this trial (either as part of the initial spreadsheet used for the creation, or as new spreadsheets created during the editing process as described above).\n\n3) Export the trial to a .csv file.\n\n<EOD> Cationic ruthenium complexes as a robust catalyst for direct oxidation of methanol to formaldehyde\n\nA cationic ruthenium complex [Ru(3,5-L 2 pz)(Cl) 2 (py) 2 ]Cl [3,5-L 2 pz: diphenyl-5-(2hydroxypropyl)pyrazole, (Hpzpy) 2 ; py: pyrid",
        "label": 1
    },
    "538": {
        "output": "If you have more than one candidate for the trial note, you should write the trial-level eligibility to each patient as same.\n\n## [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nNow we are going to compare only the patient A. 5002.014.02.\nLet's calculate the Trial-level eligibility for each patient.\nWe calculate the Trial-level eligibility for each patient. The first factor of the equation is the clinical trial factor, i.e., clinical trial_factors for patient 5002. You can refer to Appendix A-3 for the list of clinical trial factors, i.e., Inclusion criterias. [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n## [INST] hello. You are a helpful assistant for clinical trial recruitment. your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. the factors that allow someone to participate in a clinical study are called inclusion criteria. they are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nWe calculate trial_factors, i.e., inclusion criteria for Trial 2 at the time of patient enroll, from Trial 1 to Trial 3. \nIf the clinical trial factor is not met, then continue calculating with the next clinical trial factor in the patient. \nThe second factor of the Trial-level eligibility equation is Clinical trial",
        "label": 1
    },
    "539": {
        "output": "### 2) `Labeled for the patient(s)`\nThe patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, characterized as defined by the following clinical events (i.e. one or more of the following):\none or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or\none or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), or\none or more Transient Ischemic Attacks within the past 180 days.\n(Note: To be entered into the study, a patient must have one or more of the following conditions:\ncongestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%\nopen heart surgery within the previous six weeks\nrecent myocardial infarction (>24 and <4 weeks)\nunstable angina (CCS class III/IV)\nsynchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization\nsevere pulmonary disease to include any of the following:\nchronic oxygen therapy\nresting PO2 of 60 mmHG\nbaseline hematocrit 50%\nFEV1 or DLCO 50%  of normal.)\nAnd the inclusion criteria are described as follows:\n\nInclusion Criteria:\nThe patient must be > 18 years of age.\nThe patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:\none or more TIAs, characterized by",
        "label": 1
    },
    "540": {
        "output": "# The `Trial_level` command\nThis function is also included in [the `experiment.jl` package](https://experiment.julang.org/latest/), which you can explore using [juliaxplore](https://rubenssousa.github.io/juliaxplore).\n\n`Trial_level(` trial`, name_patient`) `<EOD> Differential expression of the 110-kD protein of the glutamine synthetase/glutamate synthase cycle in relation to the endocytosis of nitrogenase in Azotobacter chroococcum 18\nThe 110-kDa protein of the nitrogenase/glutamine synthetase (GS110) cycle, which is an important regulator of nitrogen fixation in Azotobacter species, was found to be differentially accumulated under varying nitrogen sources. Expression of the gene encoding the 110-kDa subunit was positively responded to the exogenous supply of the preferred nitrogen source (NH4+ and NO3-), but the amount of GS110 synthesis was diminished or even blocked when alternative nitrogen sources (pyruvate and citrate, the products of incomplete carbon fixation, nitrite , and N2, which are nonpreferred nitrogen sources) were added to A. chroococcum 18. The expression of glnA3 (encoding the nitrogenase large subunit) was induced under the same conditions as that of glnA1 (encoding GS110), but its expression required ammonium ion as the sole nitrogen source in combination with other nitrogen sources. The expression of nitrogenase, in particular, the large subunit of nitrogenase and nitrogenase activities, was inhibited in A. chroococcum 18 cells in the presence of nonpreferred nitrogen sources. GlnA1 is not essential for the nitrogenase cycle, since A. vinelandii nitrogenase was active even in the absence of GS110, which suggests that GS110 is not involved in the endocytosis of nitrogenase. The GS11",
        "label": 1
    },
    "541": {
        "output": "##### Part 4: Case 2\nIf a patient is excluded from the CAD+CAS+CABG clinical trial, you need to determine the reason.\nIn this section, you need to identify the main reasons for exclusion from the trial. Remember: each patient can be excluded from the study owing to multiple criteria.\nPlease think about how to proceed:\n\n1. Click the button \u2018Show Reasons (Exclusion)\u2019 by clicking at the button \u2018Case 2\u2019 at the upper right area of the screen.\n\n2. The page opens.\n\n3. Click the button \u2018Show Reasons (Exclusion)\u2019.\n\nThis case is a 28\u2010year\u2010old man who was diagnosed with non\u2010ST elevation myocardial infarction and CAD. He had normal baseline parameters. His CAD screening test revealed coronary artery stenosis < 50%. However, his heart echocardiography revealed mild hypokinesia of the basal and mid\u2010section of the inferior wall and mid\u2010portion of lateral wall (left ventricular ejection fraction is 56%).\n\nAs a result of the clinical trial assessment, case 2 was excluded. Because the patient didn't have coronary artery stenosis which exceeded threshold and his CAD screening test revealed coronary artery stenosis < 50%, the patient was excluded from the clinical trial.\n\nWhen there are no issues for the CAD and CAS patients, all conditions in the patients are normal, except mild hypokinesia of the basal and mid\u2010section of the inferior wall and mid\u2010portion of lateral wall (left ventricular ejection fraction is 56%). As a result of the clinical trial assessment, case 2 was excluded. Because the patient didn't have coronary artery stenosis which exceeded threshold and his CAD screening test revealed coronary artery stenosis < 50%, the patient was excluded from the clinical trial. \n\n![](https://github.com/taiwanclinicaledu/TAILOR/blob/main/inst/images/case2_inst4_result.PNG)\n\n##### Part 5: Case 3",
        "label": 1
    },
    "542": {
        "output": "Now, let's try it out. \n! [IMAGE: patient note and trial]( /manual.pdf ) \n\n![IMAGE]( /manual.pdf)\n\n<EOD> The Role of Lysine-Acetylation Pathways in Adipose Tissue Physiopathology\n\nChronic exposure to a negative energy balance induces severe physiopathological changes in adipose tissue, leading to a disruption of brown adipose tissue activity or white adipose tissue dysfunction. This phenomenon is particularly exacerbated in obesity, and may contribute to the emergence of metabolic disorders such as insulin resistance, type 2 diabetes, hepatic steatosis. Adipocytes are metabolically active cells whose gene expression, posttranslational modifications and adipokines secretion are constantly regulated, particularly at the post-translational level. Lysine acetylation is one of the posttranslational modifications that has arisen as a crucial regulator of gene expression. Indeed, the acetylation/deacetylation of histones, non-histone nuclear proteins, or proteins in the mitochondria, can alter gene expression and metabolism. Importantly, several genes of energy sensors are regulated through this pathway. Recently, adipocyte metabolic and endocrine functions have been shown to depend upon lysine acetylation, notably in the context of obesity. In the present review, we will discuss the role of specific enzymes involved in lysine acetylation and its consequences on adipose tissue metabolic disorders.\n\n# Introduction\nAdipose tissue plays an important role in energy homeostasis. When the energy requirement is not covered by food intake, the adipose tissue reserves are the primary site of lipid mobilization that ensures the survival and the physical function of the body. The process of lipolysis is tightly regulated and depends on the activity of two lipases in different compartments: in the cytosol of adipocyte, the hormonesensitive lipase (HSL) and in the adipocyte's inner membrane, the adipocyte triglyceride lipase",
        "label": 1
    },
    "543": {
        "output": "This is the input file for our tool: \nThis is the output:\n\nThe patient has a LDL-C level of 545. Hence, the patient has a CHD condition. \nThis patient does not meet the inclusion criteria of the clinical trial in , because the patient does not have enough information to qualify for the trial. \nThe patient can enroll in the clinical trial in , although there are some exclusions to consider. Thus, atorvastatin-first is excluded because of treatment with statins. Because the patient takes no antiplatelet agents, exclusion 9 (use of antiplatelet agents) is true. The patients is excluded by exclusion 23 (hypertriglyceridemia), because the patients had a triglyceride level of 208.5 and 158, which exceeds the limits of 400 and 250 for men and women. Similarly, exclusion 3 applies because of the patient's age.\nThe patient would be eligible for one of the SB-480848 intervention groups. As atorvastatin 20 mg/day is not appropriate, the patient would be excluded from the placebo group and, hence, would be eligible for the higher atorvastatin (80 mg/day) and, therefore, is eligible for both SB-480848 dose categories. The patient has no exclusion for either dosage level. And finally, the patient is excluded from SB-480848 160 mg/day because of the previous inclusion, i.e., the patient has taken atorvastatin before, which is an exclusion of SB-480848 160 mg/day.\n\n# Discussion\n\n## Experimental results\nWe are developing our tool for practitioners who are not in the specific niche of lipidomics but use clinical trial recruitment services. If there is any need for improvement, either in functionality or an easy-to-use interface, we will improve our tool in the future. The functionality is based on the fact that clinical trial inclusion criteria cannot be formulated in a simple way. Therefore, we provide functionality to extract all inclusion",
        "label": 0
    },
    "544": {
        "output": "#### [EXERCISE #3]\n\nAssess eligibility for each patient from **Step 3** with the following inclusion criteria. The patients who meet all the conditions for inclusion must be assessed as eligible for the clinical trial. Your answers should follow this format: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 45-year-old woman presents with dizziness and frequent headaches. She has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's total cholesterol and HDL-C levels were 265 and 80\u2009mg/dL, respectively. Her fasting glucose and triglyceride levels (81 and 196\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed moderate stenosis in the left internal carotid artery (LICA),  as well moderate stenosis in the right internal carotid artery (RICA), estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was noted in anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic with uneven surfaces.\nHere is",
        "label": 2
    },
    "545": {
        "output": "<EOD> Mentoring in medicine: a literature review.\nOBJECTIVE\nThe objective of this review is to summarise the evidence for effectiveness of formal and informal mentoring interventions in medicine in relation to the key themes of confidence, career advancement, team working and satisfaction.\n\n\nDESIGN\nA selective literature review of peer-reviewed English language studies was undertaken, examining formal and informal mentoring in medicine. The electronic databases MEDLINE, CINHAL and PsychINFO were used, supplemented by a hand search for key sources. A range of search terms were used including 'mentoring', 'intervention' and 'medicine'.\n\n\nRESULTS\nThirty-eight peer-reviewed articles were identified. Informal mentoring is popular and provides a way of passing on important aspects of life in general, as well as medical practice. A number of authors report significant benefits for the mentoring relationship including an increase in confidence, satisfaction with career progress, increased understanding of working relationships, teamwork and communication, as well as improvements in job satisfaction. Formal mentoring is less well supported in relation to improvements in confidence and career progress, but formal mentoring can increase understanding of career progress and teamwork and has a more even distribution of benefits, as opposed to the more polarized relationship inherent in an informal mentoring system.\n\n\nCONCLUSIONS\nMentoring is an intervention that provides an opportunity for one person to receive guidance, support and encouragement from another. It is thought to help an individual realise his or her own potential, so it can be considered to be a way of helping people to maximise their own and their organisation's potential.<EOD> .\nIn an open randomized trial with 75 patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) the clinical and immunological efficacy and safety of treatment with azathioprine (A) (50-150 mg/d) and sulphasalazine (S) (2-4 g/d) was compared over periods of 3 up to 12 months between 1983 and 1991 in accordance with predefined inclusion and exclusion criteria. Twenty-two patients had RA (sickness duration 1-124 (mean 1",
        "label": 0
    },
    "546": {
        "output": "--Kaldi - 21:05, 24 November 2021 (UTC)\n\n[edit] Patient note\n(Parts should start with a lowercase letter.)\n\n[edit] [TRAIN] Hello. You should be an assistant for a medical doctor in a clinic. Your task is to help the medical doctor in a clinic in filling a form for each patient.\n\nA 60-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",
        "label": 1
    },
    "547": {
        "output": "## Good\n[table]  1: In this example, we want to determine eligibility for 1 clinical trial. Here, 2 lines are shown, in which the first line shows inclusion criteria, and the second line shows exclusion criteria. How will you perform the eligibility? There can be 2 results for 2 lines. What are the two possible results for this trial? Please explain your answer. (2) If, for a given clinical trial, there are no exclusion criteria, what does the statement `1) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)` mean? What is the reason for exclusion for the patient? Please explain your answer. (3) Why are inclusion and exclusion criteria used to decide whether to participate in a clinical trial? Please explain your answer.2. Please do the following steps and explain to us in detail. (20 points) [/table] \n[table]  2: 002-02301083, [/CODE] [/table] \n<EOD> In search of the cerebral bases of the \u2018moral\u2019 impairment in frontal lobe injury\nSynthesizing evidence from neuropsychology and functional neuroimaging, we review how empathy, compassion, and social cognition contribute to moral decision making. We then contrast how emotional reactivity in response to others' distress and normative emotional responses to moral transgressions are related to moral awareness, and consider how different forms of moral reasoning are influenced by motivations to feel empathy, rather than being intrinsic. Building on research in patients with focal brain damage, we develop psychological hypotheses as to how the frontal lobes contribute to moral reasoning and decision making. We review a broad range of neuropsychological data to support the view that the frontal lobes support moral reasoning by providing cognitive maps of the world, generating feelings of moral empathy in response to others' distress, and generating and implementing complex scripts of moral behavior in response to abstract moral codes; these functions map onto different subregions of the frontal lobe. Converging evidence from emotion imaging (fMRI) reinforces the idea that the same frontal regions (dorsomedial and dorso\u2010anterior regions) show different patterns of",
        "label": 0
    },
    "548": {
        "output": "<EOD> A Novel Antifungal Effect of Human Complement C1q on Human Fungal Pathogens\n\nThe human complement components C1q, C3, C4, and C5b-9 are a part of innate immune defense, and they all exert antimicrobial properties but their antifungal activities towards human fungal pathogens are unclear. In this study, we found that C1q was a powerful antifungal effector, exerting in vitro inhibitory effects not only on the growth of yeast but also on filamentous fungus, in particular Aspergillus fumigatus and Candida albicans . Interestingly, the yeasts Candida orthopsilosis, Candida glabrata, Cryptococcus neoformans, and Candida auris were less sensitive to C1q than were Candida albicans and Aspergillus fumigatus. The antifungal activity of C1q against C. albicans and A. fumigatus was strongly dependent on its binding to the polysaccharide glucan of the fungal cell wall, and the effector could induce morphological changes in these two fungal species. Taken together, we propose that C1q is a novel antifungal effector of the complement system.\n\n# Introduction\nComplement is a part of innate immune response, recognizing invaders and mediating defense against them through three pathways: classical, alternative, or mannose binding lectin [bib_ref]  The complement system, Sarma [/bib_ref] . The complement system exists in various invertebrate and vertebrate species, the latter displaying multiple and very complex defense mechanisms for the elimination of invading pathogens [bib_ref]  The complement system, Sarma [/bib_ref] . In mammals, once the complement system recognizes invaders, it activates three main complement-derived effector molecules: opsonins, antigenspecific adaptive immune response activation and recruitment, and cell-cell lysing, membraneattacking complexes, termed C5b-9 [bib_ref]  The complement system, Sarma [/bib_ref] . These components serve the host organism by tagging pathogens for uptake by phagocytes (opsonins), by activating the adaptive",
        "label": 2
    },
    "549": {
        "output": "## Good Job!\nNow you can check your code in `Patient` with [INST].\n\n# Challenges #\n\n# Additional Information #\nFor instructions or more information on contributing to Julia, please see CONTRIBUTING.md and the Julia documentation at Julia.org.\n\n# License #\n\nThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.\n\n# Authors and Contributors #\n**Takashi Shimokata** -- https://github.com/takashishimokata/julia/commits/master/Journal/20200320205156/\n\n# Citation #\n[https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0463.2018.00062.x]\n<EOD> \nDuring the 1987 to 1991 period, a series of surveys was performed in the area under the administration of the Health District of Pau (600,000 inhabitants). All the patients hospitalised for malignant, benign or unknown colorectal tumours were recorded and data were analyzed by age, sex, and tumour site, diagnosis and treatment. The incidences were adjusted to the 1983 WHO European standard population and compared with worldwide colorectal tumour incidences. The incidence of malignant colorectal tumours was compared with incidence estimated in France since 1990. The standardized incidences of colon and rectosigmoid cancer, with 809 cases, was 61.5 and 16.9 per 100,000 for females and 56.1 and 11.9 per 100,000 for males, respectively. For the colonic tumours the standardised incidence decreased for young people while it was not significantly different for the rectosigmoid. In",
        "label": 1
    },
    "550": {
        "output": "<EOD> A novel mutation in the bovine prion protein gene associated with BSE\nPRNP mutations have been identified in human, sheep, goat, mink, elk and moose PRNP-related cases of Transmissible Spongiform Encephalopathies (TSE). In most reported cases of BSE and Creutzfeld-Jakob disease, wild-type PRNP was identified. The aim of this study was to investigate the mutations in bovine PRNP gene related to the TSEs in cattle in Japan. A total of 230 tissue samples were analyzed. The sample types were brain, heart, lung, liver, kidney, spleen, pancreas, tonsil, muscle, lymph node, thymus, adrenal gland, and mammary gland. There was no specific characteristic on the gross observation in the tissue samples. DNA was extracted from each sample. PRNP genes were amplified by the polymerase chain reaction, and subjected to direct sequence analysis. The nucleotide sequence in the first exon of PRNP was determined. A novel mutation of arginine to threonine at codon 210 (210T) was found in BSE and scrapie. The 210T mutation was identified in all three BSE and one scrapie. The 210T mutation was observed in the oldest cow and may be related TSE. In scrapie, the 210T mutation was observed in only 2/4 cows and 2/3 sheep. This indicated that this genotype had not expanded the populations in the case of scrapie. The 210T mutation was not observed in TME, CSE, or normal cattle. The 210T mutation, which was identified in the three BSE cases, may be a new mutation. The 210T mutation would be selected during the transmission via oral infection. It may be necessary to continuously study the occurrence of this mutation.<EOD> The Effectiveness of a Dental Health Education Programme in Changing the Oral Hygiene Behavior of People Living With Disabilities\n\nThis study aimed to evaluate the effect of a three-month dental education program on the oral health behavior of people living",
        "label": 1
    },
    "551": {
        "output": "[/MAIN]    \n\nGood luck.\n<EOD> Association of HLA-B Alleles with Response to Interferon-\u03b1/Ribavirin Therapy in HIV-Infected Hemodialysis Patients with Hepatitis C Virus Coinfection\nSummary. Interferon-\u03b1 is used in the treatment of hepatitis C virus (HCV) infection in hemodialysis patients, but there are problems with low efficacy and the development of side effects, so novel approaches to personalized treatment are required. The objective of this study was to assess the utility of HLA alleles as a prognostic marker of the efficacy of interferon-\u03b1/ribavirin treatment for HCV-coinfected HIV patients receiving hemodialysis therapy. The subjects were 32 hemodialysis-treated, HIV and HCV coinfected patients classified into responders (n = 21) and nonresponders (n = 11) on the basis of virologic response at the end of treatment with interferon-\u03b1 plus ribavirin. Serum HLA class I (HLA-I) and HLA class II (HLA-II) antibody levels, HLA-A, -B, -DRB1, and -DQB1 genotypes were determined. A significantly lower frequency of the HLA-B57*01/*02 allele was detected in responders compared with nonresponders (76.2% vs. 90.9%; OR = 4.22, 95% CI = 1.08\u201316.6, p = 0.039). The frequency of the B*57 allele (B*5701 and/or B*5702) was significantly decreased by 69.2% (OR = 4.48, 95% CI = 1.05\u201319.1, p = 0.042) in the responder group compared with the nonresponder group. There was also a tendency toward a reduction in the risk of nonresponse with the presence of HLA-B*57 (OR = 5.73, 95% CI = 0.76\u2013",
        "label": 1
    },
    "552": {
        "output": "<EOD> .\nTetracyclines(Tc) are widely used in animal production, but the long half-life (t1/2 > 10 hours) in blood and environmental persistence (highly adhered to sediment) are the main source of its long biological activity. This paper summarized the latest research results of Tc degradation under environmentally relevant conditions, including the effects of co-existing substances, light, sediment degradation technology, and advanced oxidation process (UV/H2O2, Fenton, Fenton-like/peroxysulfate, photocatalysis). The present paper also summarized the recent progress of Tc degradation under different experimental conditions, and the current research status and bottlenecks facing the Tc degradation were discussed. The future research directions were proposed to strengthen the Tc degradation techniques and broaden the practical application scopes of this technique.<EOD> Evaluating the Use of Rapid Molecular Diagnostic Tests in Resource Limited Settings: A Cross-Sectional Costing Study in Three African-Preference Countries\n\nBackground: Reliable diagnosis of infectious diseases is vital in the treatment of patients and the control of outbreaks. Increasing demand for malaria diagnostics in sub-Saharan Africa (SSA) has led to rapid market growth of novel testing alternatives. In this study, the objective is to evaluate whether malaria diagnostics in SSA could be improved by replacing traditional rapid diagnostic tests (RDTs) with novel molecular and advanced lateral flow techniques.Methodology/Principal Findings: We conducted a cross-sectional study in Burkina Faso, the Democratic Republic of the Congo and Zambia, using key informant interviews, workshop observations and facility inventories with 480 patients drawn from 49 public health facilities. Each facility was visited independently by researchers or other staff for data collection. In addition we performed expert focus group discussions. The costing methodology is micro-costing and micro-costing of the testing algorithm. The average cost and total annual costs for RDTs were (225.54 USD, and (122,534.16 USD) respectively, using current standard prices. Capital costs for the initial (bout",
        "label": 2
    },
    "553": {
        "output": "#### Acknowledgements\nThe following people helped with code:\n\n* <NAME>, <NAME>, <NAME><NAME><NAME>, <NAME><NAME>, <NAME><EOD> In vitro antioxidant activity of phenolic compounds of cumin and ginger\n\nAntioxidants are the substances that can prevent or stop the oxidation process by neutralizing the reactive oxygen species (ROS) or free radicals produced in living systems by the natural metabolism. In this study, the antioxidant activity of different fractions prepared from the extracts of cumin (Cuminum cyminum) and ginger (Zingiber officinale) was analyzed by 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical scavenging assay and Fe 2+ chelating assay. The phenolic compounds present in the extracts were also determined by Folin-Ciocalteu method.Results indicated that gallic acid in cumin seed extract had the highest antioxidant activity. In addition, all the tested fractions of cumin seed extract except that from butanol fraction were shown to have higher RSA and stronger chelating effect of Fe 2+ than the tested fractions of ginger, in the tested concentrations. The concentration of phenolic compounds in the cumin seed and rhizome extracts were also analyzed and determined, respectively. The results indicated a significant positive correlation between the RSA of the cumin seed and rhizome extracts and the concentration of total phenolic compounds (r=0.747, p<0.05 and r=0.878, p<0.01) as well as between the concentration of total phenolic compounds and the concentrations of gallic acid (r=0.857, p<0.01 for cumin seed extract and r=0.944, p<0.01 for ginger root extract) and caffeic acid (r=0.816, p<0.01 for cumin seed and r=0",
        "label": 1
    },
    "554": {
        "output": "##[FIN]\nLet's look at the same patient in another trial:\nTitle: Effects of Simvastatin on Progression and Reversibility of Brachial Artery Remodeling\nIn the same manner above, calculate Trial-level eligibility, e.g., Trial-level eligibility: 1) Eligible.\n[INST]\n\n## The score data representation\nOnce you have prepared the eligibility report, it is time to represent the eligibility score. The scores should be summarized in a way that they can be easily understood. We have already calculated eligibility scores in the previous sections, and here, we will illustrate how to analyze them and present them to a recruiting team. We will now see how to prepare the score.\nRecall that the score is calculated based on the eligibility assessment report. The scores are categorized based on the evaluation, the status of the patient in the clinical trials. There is a separate score for each trial, which means that the scores will differ by trial. The score will become one (1) if the subject is not eligible for the trial, and it will become the sum of the scores corresponding to the factor that determines whether the patient is eligible.\nIn the clinical trial shown in Figure 1, there are several different groups of scores; groups 1-5. The score for the inclusion criterion is given here, and the evaluation of each group is discussed below.\n\n### Group 1 ###\n\n### Group 2 ###\nAll the patients who are under 680 years of age are scored in group 2. There are two patients in this group, which will be scored with 100:\n\n### Group 3 ###\n\n### Group 4 ###\nAll the patients who have a CVD but has not received prior CVD treatment other than aspirin are in group 4. There is only one patient in this group.\n\n### Group 5 ###\n\n### Group 6 ###\nAll the patients who are using anticoagulant therapy are in group 6. According to the evaluation, the patients on warfarin therapy are scored with 30, and the patients using the therapeutic enoxaparin are scored with 60.\nAll the patients",
        "label": 1
    },
    "555": {
        "output": "T = triple\n\n\nI = int\n\n\nV = single\n\n\nE = double\n\n\n\nLet's show all the necessary details to make an inclusion decision. To do it, you have to follow the rules explained below. \nFirst, you need to check which criteria are not met. For this, you need to test for a triple of the next type \n\n```\nIF(A $ & B % & C > 0)\n```\n \nSecond, you have to test the double IF statement \n\n```\nIF(A < $ & B < $) OR (A > $ & B > $)\n```\n\nYou will then compare the conditions. You need to test the IF statement in four cases with single, double, triple, and quadruple. For that, you have to write a switch case statement. \n\n```\nSWITCH (A % & B & C && & D & E && & F & G & H)\n\n```\n\nThe following rules have to be maintained. The patient must meet the condition for at least one time.\n- Whenever `OR` is evaluated as true, one of the two expressions must be true.\n- Whenever `AND` is evaluated as true, both expressions must be true.\n```\nSWITCH (A % & B & C && & D & E && & F & G & H)\n\n```\n\n<EOD> Requirement for the p21 tumor suppressor in c-jun-mediated oncogenic conversion.\n\nEvidence indicates that c-Jun activates oncogenic pathways by binding to the AP-1 transcription element and subsequently displacing p21 from a p300-DNA complex. Here we show that p21 knockout mice are prone to develop sarcomas, similar to mice lacking c-Jun. c-Jun deficiency alone is insufficient to induce any form of tumors, suggesting that p21 is required in the tumorigenic process. Thus, we provide genetic evidence showing the importance of p21 for normal function of c-Jun.Cell cycle inhibition is a key process in prevention of tumor formation. It has been demonstrated in diverse cell culture and animal studies that loss of key regulators of cell cycle in",
        "label": 1
    },
    "556": {
        "output": "## Making a Trial-level eligibility\nHere is an example of the final report (from trial 10) you can make a list trial-level eligibility for each patient:\n\n# Expectations\n*\nYour patients get high scores from the clinical trials.\n*\nThe average patient has low risk of all-cause mortality.\n*\nThe average patient has low risk of cardiovascular mortality. \n\n## Good Luck \ud83d\udc4d\n\n# Example Trial-level eligibility\n[ [ 'Included', 0 ], [ 'Not relevant', 1 ], [ 'Excluded', 0 ] ] \n\n# Notes\nThis code base will be under Continous Integration (CI) by Travis CI. If your code changes are broken, it will automatically find and fix it before releasing code.\n<EOD> Dangerous gases - an overview.\nFour major toxic substances in the workplace can result in acute symptoms ranging from headache and unconsciousness to death. Hydrogen sulphide causes a respiratory alkalosis, while carbon monoxide binds to red blood cells to produce carboxyhaemoglobin, which cannot take up oxygen efficiently, so blood is unable to get to the brain and other vital organs, resulting in loss of consciousness, coma and death. The main defence against hydrogen sulphide and carbon monoxide is preventative, keeping people out of the chemical's influence by not coming into contact with its source (the release of hydrogen sulphide from a broken gas heater is an example); a well ventilated workplace can also keep levels of these gases below toxic thresholds. Carbon disulphide causes irritation of the mucous membranes and damage to the liver, kidneys and central nervous system. There is no evidence to suggest that it is carcinogenic, so protective equipment is also the main line of defence against this substance. Another common industrial gas is ammonia. Inhaling ammonia results in a bronchoconstrictor effect that could result in death if the breathing is stopped, so it is also prevented from entering the body by careful control of the release of ammonia from the source",
        "label": 0
    },
    "557": {
        "output": "Please note that in some cases, the inclusion criteria might be different for different treatment arms. The reason behind this is that some clinical trials include both treatment and placebo arms to check the efficiency of the drug in relation to a placebo. For example, in case you have included the treatment arms for a clinical trial, one inclusion criterion in the first treatment arm might be the presence of hyperlipidimia for example, while in the second treatment arm, only hypertension would be the inclusion criterion.\n\nSo if you have only one treatment arm, you should include all the criteria related to the treatment arm in the last line by `Trial-level eligibility: `, e.g, `Trial-level eligibility: 2) Eligible.`, otherwise, the patient would be ineligible. For example, if you have just one treatment arm and, in it, hyperlipidimia or low HDL cholesterol would be required as inclusion criteria, you should simply put the line: `Trial-level eligibility: 2) Eligible.` without the `and`. Thus, the criteria for the treatment arm will be used in this particular case automatically.\n\n\n### HOW TO GET A CODE\n\n1. Open the folder for the patient who will be included in the trial \nClick on the **Edit Patient Note** then **Manage Note** \nClick on the code of interest for the trial \nThen right click on the code and select **Copy** and then paste it in the Note Template Editor of the trial that you will create \n\n2. If your trial does not have a code, and you want to create a new trial for the patient, click on the **Trial Note** on the first line. You will notice that at first, you will be shown a message that there is no trial. Click on the \u201c+\u201d button and you will be given an option to either create a new trial or add a condition in an existing trial. The latter option would be applicable for you:\n\nClick on the **Create New Trial** \n\nAfter that you will notice that your trial will be in empty code. You will need to add the code for the trial later.\nClick on the **Create New Trial** \n\n3. You are required to choose an ID of the trial from the dropdown list below",
        "label": 2
    },
    "558": {
        "output": "**Output:**\n\n##### Recursively Assignment of the scale for the assessment of eligibility for each trial.\n\n1) You will recursively assign eligibility score using Python and then transform to 0 for each patient based on the trial ID. \n\n###### Example of output:\n```  \u2026 \n\u2026\nEligibility score: 0\nEligibility: Excluded\n```\n## [Exercises]\n\n## Questions\n\n### Q5: The patient does not meet the inclusion criteria of any clinical trial. How may we obtain patient eligibility score in this case?\n### Q6: Why do you decide the `trial-level eligibility` is finally set to `0`?\n### Q7: Which is your preferred solution for eligibility assessment using the following three approaches:\n\n * Evaluate patient eligibility score on the basis of the eligibility rule-based method\n * Evaluate patient eligibility score using the proposed method (a data table)\n * Evaluate patient eligibility score using the proposed method (a vector)\n### Q8: Let`s consider`0 < trial-level eligibility < 2`to the `patient-level eligibility score < 0 < 2`. What do you expect the patient's eligibility criteria are for the trial you are concerned for?\n### Q9: After you finished step by step of the proposed approach, what shall you do?\n### Q10: In the proposed approach, where did you find patient-level exclusion criteria?\n### Q11: In the proposed approach, where did you find `trial`level exclusion criteria?\n### Q12: Based on each of trials exclusion criteria you found above, what can we conclude?\n### Q13: How shall you find out the patient-level eligibility? After finding out the patient-level eligibility, what do you want to say?\n### Q14: If you want to find out trial-level eligibility for an interested trial, what can you do?\n### Q15: After finding out the `trial-level eligibility = <0>`, what do you want to say from these facts and statements above?",
        "label": 0
    },
    "559": {
        "output": "<EOD> The In Vitro Cytotoxicity and Cellular Uptake of Graphene Oxide\u2014Capped Mesoporous Titania Photocatalysts Modified with Various Types of Surfactants\n\n\n\n# Introduction\nNowadays, photocatalysts in various structures and compositions have attracted much attention of chemists and materials scientists for water splitting [bib_ref]  Heterogeneous photocatalyst materials for water splitting, Kudo [/bib_ref]  , hydrogen production [bib_ref]  Molecular catalysts in photo-fuel conversion materials, Hwang [/bib_ref]  and degradation [bib_ref]  A critical review on enhanced photocatalytic performance of modified TiO 2 thin-film..., Fakhri [/bib_ref]  due to their ability to increase the efficiency of the degradation of organic pollutants from industrial wastewater or hospital waste using solar energy. This technology is also successfully used in medicine, e.g., for sterilization [bib_ref]  Photocatalytic disinfection using titanium dioxide: Spectrum and mechanism of anti-microbial",
        "label": 0
    },
    "560": {
        "output": "<EOD> Antimicrobial Agents Used in the Treatment of Helicobacter pylori Infections in Children: Evidence-Based Review\nObjectives This aim of this work was to perform a comprehensive systematic review on medications for Helicobacter pylori (H. pylori) treatment in children. Study Design Systematic review. Setting Review articles and original studies. Methods A systematic literature search was performed using PubMed, including studies published in English between January 1, 1991 and March 31, 2016 using the keywords: \u201cHelicobacter pylori\u201d \u201ctreatment\u201d and \u201cchildren\u201d (ClinicalTrials.gov registry: NCT01164800). Results There were 4802 publications available, 200 were reviewed in full text, and 21 were finally selected for final analysis. In total, 21 randomized controlled trials (RCTs) and 3 single-arm before\u2013after studies with 5965 children were reviewed. Most of the studies compared the bismuth quadruple therapy (BQT) with triple therapies (TTs). Conclusions All studies that compared BQT with TTs in the recent 5 years reported that BQT is a more favorable regimen over this duration of treatment without serious adverse events and with no clarithromycin-resistant H. pylori strains. The TTs have no place due to low efficacy; while for the BQT, there is no definitive consensus on the best formulation in pediatric patients in the recent 16 years. The high efficacy of probiotics when combined with H. pylori eradication therapy and the cost-effectiveness of probiotics may lead to a change in future clinical trials. Also, the use of alternative anti-H. pylori medications based on lansoprazole is recommended, including the regimen of amoxicillin/clarithromycin/lansoprazole for the same period of time, and the combination amoxicillin/doxycycline plus lansoprazole for 2 weeks or amoxicillin/doxycycline plus lansop",
        "label": 1
    },
    "561": {
        "output": "<EOD> Convulsive-like effect of a novel N-arylcarboxamide and its interaction with bicuculline and picrotoxin\nA convulsant, 5-(N,N-dimethylcarbamoyl)-2,6-dichlorobenzoic acid (DM-Cl-Bt), was examined for its convulsive activity and its antagonism by bicuculline and picrotoxin. In mice, i.p. injection of DM-C1-Bt elicited convulsive behavior and reduced the threshold of pentetrazol. The convulsive-like behavior, similar to that elicited by pentetrazol, was antagonized by i.p. injection of either bicuculline or picrotoxin. In rats, the convulsive-like activity, but not the antagonism by bicuculline, of DM-C1-Bt was blocked by reserpine pretreatment. The convulsion rate induced by electrical stimulation of the ventral hippocampus was inhibited by prior i.p. injection of bicuculline or picrotoxin. DM-C1-Bt was found to be approximately four times as potent as picrotoxin in decreasing the ventral hippocampal convulsion rate. Moreover, both convulsant effects of DM-C1-Bt and pentetrazol were attenuated by d,l-2-amino-4-phosphonobutyric acid. These results indicated that N-arylcarboxamide derivatives can elicit convulsive behavior and that DM-C1-Bt shares the same mechanisms of pentetrazol with respect to both convulsant effects and the potency of antagonism by GABA antagonists. N-Arylcarboxamide derivatives can therefore be potential convulsants as well as potent convulsant antagonists.<EOD> An efficient synthesis of chiral enaminones by use of organocatalysts: an insight into their applications\nChiral enaminones (or Schiff\u2019s bases of \u03b1,\u03b2-unsaturated aldehydes) play an important role as chemical building blocks in asymmetric synthesis. Although the asymmetric",
        "label": 1
    },
    "562": {
        "output": "[TASK] The eligibility for all patients who can be enrolled in the clinical trial\n\n[INST] This task is an extension of the previous task. You should assess the eligibility for all patients who meet the inclusion criteria for a clinical trial. The assessment criteria are the same as those used for the trial-level eligibility. \nAssess trial-eligibility for all patients with the following conditions:\n- age range is from 25 to 65.\n- diagnosed with dizziness or headaches in the last 3 months.\n- physical level of PA: low or very low level.\n- LDL-C >160 mg/dl.\nInclude in the assessment if there is at least one of the following cardiovascular risk factor:\n- smoker\n- high blood pressure: systolic blood pressure > 140 mmHg, or diastolic blood pressure >90 mmHg.\n- family background of early heart disease.\n- LDL-C >160 mg/dl.\n- BMI >30, which is an indicator of excess body weight, which, in turn, leads to obesity.\n- waist circumference for men >94 cm, for women >80 cm.\n- Total cholesterol >240 mg/dl.\n- fasting glucose > 5.2 mmol/L.\nIn the case of multiple measurements for a patient's characteristic, we recommend taking the average.\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and ADA guidelines as of December 2017 recommend the use of a combination of statin therapies with the maximum tolerated doses for patients with TC >200\u2009mg/dL or LDL-C >160\u2009mg/dL",
        "label": 1
    },
    "563": {
        "output": "* <NAME>. 2013a. \u201cUsing the SCRATCH R Shiny web interface.\u201d <https://scratch.mit.edu/scratch/help/> \n* <NAME>. 2013b. \u201cWork",
        "label": 2
    },
    "564": {
        "output": "# Results\n\nLet's start by printing the variables with the key word 'Data'.\n\n    Data\n    -------------------------------+-----------------------------------------------------------------------------------------------------------------------------------\n    Patient Note               7                                                                                                                                                   \n    trial_name                  HER-MET-Study              Name of clinical trial\n    trial_description           <NAME> for the effect of exercise training on the function of the HDL-Cholesterol, endothelial function, and endothelial progenitors in patients with metabolic syndrome.                                                                         \n    trial_details               Clinical trial                     \n    trial_registration          NCT01057670                       \n    trial_registration_date    2010-10-14                        \n    enrollment_start_date     2009-11-02                       \n    enrollment_end_date       2012-05-31                       \n    trial_phase               Phase II/III                      \n    trial_site                ---                         \n    trial_sponsor           --                         \n    trial_sponsor_address    --                         \n    trial_sponsor_country   Germany                       \n    key-data                  HER-MET-Study \n    key-trial_id             005201101                       \n    trial_id                  NCT01057670            \n\nNext, we get the full patient note, by `data[\"patient_note\"].`\n\n    patient_note                                                                                                                                                                       \n    Patient Note                                                                                                                                                                                                                                   \n    Name                        ---                                                                                                                                                          \n    Last name                    ---                                                                                                                                                          \n    Gender                      Male                                                                                                                                                         \n    Birth date                  1964-01-01                                                                                                                                                     \n    Phone number                 -----                                                                                                                                                             \n    E-mail                     ---",
        "label": 1
    },
    "565": {
        "output": "## Ruleset for Predicting Patient Eligibility\n- If the age of patient > 19 and < 90 then: `0) Excluded`.\n- If the LDL-C of patient \u2265 545 and < 701 then: `0) Excluded`.\n- If the gender of patient is Female then: `1) Not Relevant`.\n- If the family history of CAD of patient is Yes then: `0) Excluded`.\n- If the fasting glucose of patient <= 160 then: `1) Not Relevant`.\n- If the triglyceride of patient <= 299 then: `1) Not Relevant`.\n- If the blood pressure of patient <= 179/115 then: `1) Not Relevant`.\n- If the LDL-C of patient <= 701 then: `1) Not Relevant`.\n- If the smoking of patient is Yes then: `0) Excluded`.\n- If the LDL-C of patient <= 90 then: `1) Not Relevant`.\n- If the current use of lipid lowing medication of patient is Yes then: `0) Excluded`.\n- If the LDL-C of patient <= 545 then: `0) Excluded`.\n- If the family history of CAD of patient is Yes then: `0) Excluded`.\n- If the physical active in patient is Yes then: `1) Not Relevant`.\n- If the LDL-C of patient <= 545 then: `0) Excluded`.\n- If the fasting glucose of patient \u2265 160 and < 211 then: `0) Excluded`.\n- If the LDL-C of patient >= 701 then: `1) Not Relevant`.\n- If the blood pressure of patient <= 179/115 then: `1) Not Relevant`.\n- If the coronary artery bypass grafting in patient is Yes then: `1) Not Relevant`.\n- If the aortic dissection in patient is Yes then: `1) Not Relevant`.\n\n## Ruleset for Predicting Patient Eligibility\n- If the type of cardi",
        "label": 1
    },
    "566": {
        "output": "[/EXAM] Good Luck!\n<exercise>\n[QUESTION]\nYou are an internal medicine resident in an academic medical center. Your main responsibility is to help with the development of internal medicine physician resident education. The faculty in the internal medicine department is interested in starting a new resident education program. The department head asked you to develop a project plan and presentation for an education grant. You have identified two types of residents you believe would benefit from this new program: first-year physician resident (intern) and third-year physician resident (chief resident). This new program will be a longitudinal curriculum that is open to physician resident. Physician resident who elect to join will participate in sessions of two hours per week and will engage in group work around patient care. You need to complete the remaining components of a well-developed project.\n\n[COMMENT]\n[CENTER]\n\n[QUESTION]\n1) You have read a paper on curriculum that you wish to incorporate into the project. In this section, name and describe the curriculum, and explain why it will be important for physician resident education. \n\n2) You also need to name the educational objective you are developing for intern residents and chief residents and describe the method you plan to use to attain this objective. \n\n3) Describe plans you have for evaluating the effectiveness of the project for interns and chief residents by comparing pre-and post-intervention test results. \n\n\n[COMMENT]\n[CENTER]\n\n\n\n[QUESTION]\nComplete the plan for program evaluation you outlined in week 2. Include the primary and secondary evaluation methods as well as criteria for meeting or exceeding the objectives \nof the workshop with an emphasis on the long-term impact in the field. \n\n[COMMENT]\n[CENTER]\n\n\n\n[QUESTION]\nIn week 2, you planned for the program evaluation. After complete this work, complete this plan for program evaluation: \n\n1) Primary method of evaluation.\n\n2) Secondary method of evaluation.\n\n3) Criteria for meeting or exceeding the objectives. \n\n[COMMENT]\n[CENTER]\n\n\n[QUESTION]\n1) Give the name",
        "label": 1
    },
    "567": {
        "output": "=== Section 6: Patient assessment in a clinical trial [#sec-s31] ===\n\nThe aim of this task is to compare each patient's data with the requirements set by the clinical trial. This means we must examine the patient's data and answer the following question: `Does this patient meet the inclusion criteria of a clinical trial?`.\n\nThis is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history\n of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and\n diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL\n respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within\n normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is",
        "label": 0
    },
    "568": {
        "output": "[[{ \"question\": \"What is the best way to determine the patient's eligibility for the clinical trial described in the information below?\", \"answer\": \"The patient is excluded of the clinical trial because of his family history of cardiovascular disease\", \"feedback\": \"The correct answer is B. You should use the assessment of eligibility to determine the patient's eligibility for the clinical trial that has been conducted. \\n\\nThe following information describes the clinical trial: \\n\\nTitle: The MISSION-HF study \\n\\nSummary: The purpose of the MISSION-HF (Multimodal Imaging of Subclinical Myocardial Ischemia in Hypertensive Patients Without Clinical Cardiovascular Disease) trial is to perform a cross-sectional study and study the role of subclinical myocardial ischemia in hypertensive patients without clinical CVD and to estimate the risk factors and etiologic pathways for subclinical myocardial ischemia. \\n\\nA total of 120 hypertensive patients without CVD but with abnormal stress perfusion imaging are randomized immediately to one of two treatment arms: angiotensin II receptor blockade with telmisartan or placebo. \\n\\nPatient-level eligibility: \\n\\nAge range = 55-75 (inclusive) \\n\\nBlood pressure = 160-180/90-105 mm Hg (inclusive) \\n\\nGender: male/female \\n\\nInclusive inclusion criteria: 1) history of CVD or 2) CAD \u226550% stenosis or 3) documented CAD or history of ischemia on stress imaging or 4) documented HF or history of HF on stress imaging or in the previous year or 5) left ventricular ejection fraction < 40% and elevated cTnT or cTnI or in the previous year or 6) history of HF with reduced ejection fraction. \\n\\nExclusion criteria: \\n\\nAcute CVD within 6 months prior to",
        "label": 0
    },
    "569": {
        "output": "* * *\n\nExclude those patients who do not meet any of the eligibility criteria. These patients should be excluded during the recruitment process. \n\nFor example, if a patient met the inclusion criteria and at the same time, we determined that the patient did not meet the exclusion criteria. Then, the patient should be included in the trial and the patient's assessment of eligibility can become\n\nAssessed for inclusion Clinical trial: 0 and the eligibility should be output the assessment of eligibility in the patient Note: 1) Exclude (patient meets inclusion criteria). You should include the assessment of eligibility of each patient for the clinical trial and the assessment of eligibility of each patient in the patient's note. \n\nLet's think step by step. If you want to exclude patients who do not meet eligibility criteria, the command `If eligibility:1,` we must add the `Not eligible` after the `patient_eligible=no` statement. \nFirst, we should add the following line:\n`if Trial-level eligibility:1: \npatient_eligible=not_eligible` \n\nBecause we are only interested in the cases that have 1 assessment of eligibility level, we add the conditions\n\n`if Trial-level eligibility:1: \nif patient_eligible=1:\n    patient_eligible=not_eligible` \n\nAgain, we want to exclude patients who do not meet any eligibility criteria. So, we have to add the patient_eligbile=0  command.\n\n`if Trial-level eligibility:0: if patient_eligbile=0:\n    patient_eligible=not_eligible` \n\nWe also need to add the `end if` after the `if Trial-level eligibility=1:` and `if Trial-level eligibility=1:`, see below:\n\n`end if` \n\n`end if` \n\nThat's your answer! \n\n* * *\n\n**Congratulations, you have earned your [INCL ](INCL.md) cert",
        "label": 0
    },
    "570": {
        "output": "If you enter the correct input, the output will be printed out in the last line. In this example, '2) Eligible.' will be displayed in the last line (see[INST:\n\n```text\n[46,M,45,B]>Trial-level eligibility: 2) Eligible.\n```]\n\n# Examples:\n\n\n## Examples for patient-level eligibility:\n\n    1) Excluded (#): 46 \n    2) Not relevant (#): 30 \n    3) Eligible (#): 52 \n\n## Examples for Trial-level eligibility output only:\n\n    1) Excluded (#): 33 \n    2) Not relevant (#): 24 \n    3) Eligible (#): 33; (see [INST:\n\n```text\n[46,M,45,B]>1) Excluded (#): 13\n[13,F,50,N]>2) Not relevant (#): 46\n[46,M,45,B]>3) Eligible (#): 46\n[50,F,39,C]>3) Eligible (#): 33\n```\n\n## Examples for patient-level eligibility and Trial-level eligibility output:\n\n    1) Excluded (#): 46 \n    2) Not relevant (#): 30 \n    3) Eligible (#): 52 \n\n## Examples for patient-level eligibility and Trial-level output in a random order:\n\n    1) Excluded (#): 46 \n    2) Not relevant (#): 30 \n    3) Eligible (#): 46; (see [INST:\n\n```text\n[46,M,45,B]>1) Excluded (#): 13\n[13,F,50,N]>2) Not relevant (#): 46\n[46,M,45,B]>2) Not relevant (#): 30\n[30,",
        "label": 0
    },
    "571": {
        "output": "<EOD> The Effect of Chronic Stress on Cardiovascular and Cerebrovascular System during High-Intensity Interval Training: An Ergospirometry Study\n\nThe aim of our study was to investigate the effect of chronic stress on heart rate variability (HRV), heart rate (HR), lactate, and blood pressure (BP) during high intensity interval training (HIIT). Nineteen trained young male cyclists (age: 22.7 \u00b1 0.7 years) were randomly allocated to the control group and experimental group. The subjects performed HIIT. For each training, lactate, BP, and HR were recorded, and a HRV analysis was performed on the basis of RR intervals. HR and systolic BP showed no significant differences between groups and moments of collection. Experimental group showed significantly higher absolute values in the frequency domain of HRV in session 4 and significantly higher relative values (nu/ms 2 and ln nu",
        "label": 1
    },
    "572": {
        "output": "The result of assessment of patient's eligibility is represented with `Triallevel eligibility:`.\n\n# Input data for evaluation\n\nIn order to make a decision, you need to find the optimal treatment for the patient by inputting data of the patient and comparing the optimal results with the trial's information. \n\nHere is patient note:\nA 44-year-old man, a current smoker, presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as high blood pressure or diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 543 and 63 mg/dL, respectively; his fasting glucose and triglyceride levels (70 and 210 mg/dL, resp.) were within the normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 1+/4+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 209 and 50 respectively; RICA PSV was 88.8 and RICA EDV was 37.7. Plaque was observed in the anterior and posterior walls of the internal carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the trial's information from the clinical trial: \nTitle: Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary",
        "label": 1
    },
    "573": {
        "output": "You can use [Python List Module](/python/lists/lists_overview) by iterating through the list with slicing.<EOD> Awareness and Acceptance Regarding Organ Donation and Transplants among Adult Population in Urban India\n\nBackground and Objectives. Organ shortage is the main constraint in transplant medicine and awareness regarding organ donation is low in developing nations. Studies have shown that awareness of organ donation is associated with registration for pledging organs. The objective of this study is to measure the level of awareness and attitude concerning organ donation among urban population of India. Materials and Methods. A cross-sectional study was conducted in urban South India among 713 participants. The socioeconomic factors of the participants, awareness of the importance of organ donation, participation in donation programs, and their attitude were measured using a 19-question survey. Results. Only 25% of study participants had heard about organ donation and 29% had heard about organ transplantation. Only 24% ( = 176) had actively pledged or signed registration forms. Most of the participants expressed willingness to pledge donation of heart (91.7%, = 1573), kidneys (87.2%, = 1123), and eyes (100%, = 713) to strangers, while 86.3% ( = 621) pledged ear to immediate family. More than 80% were willing to donate organs to parents and children. Conclusion. Study shows that despite high willingness and a considerable level of awareness, people from urban",
        "label": 1
    },
    "574": {
        "output": "In the end, you should enter three lines of output:\nTrial-level eligibility: \nPatient-level eligibility: \nTotal number of screened patients: \n\n\nThe solution is available from [github.com/vitor1d/ClinicalTrials_Course] \n\n___\n\n# Exercises\n\n[ClinicalTrials-Solutions]\n\n-----\n\n## Exercise 1.\n\nWe will work with one file - \"SysML_Exercise.doc\".\n\nMake a flow chart for the sequence of steps to work with patient's evaluation through a clinical trial.\n\n-----\n\n## Exercise 2.\n\nHere is the patient's note:\n\" A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. He reported no use of lipid-lowering medications.\" \n\n#### Clinical trial:\nTitle: Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation\n\nSummary: The first goal of this study is to investigate whether CE-US is able to accurately identify and quantify neovascularisation in carotid artery plaques. Since this is one of the first studies systematically evaluating the ability of ultrasound in combination with air bubbles to evaluate neovascularisation in carotid artery plaques, the examination will be performed twice with an interval of 1/2 hour on the day before surgery, thus studying the reliability of the method.\n\nThe second goal of this study is to investigate whether MRI at 3.0 T with a custom-designed 3T carotid coil, using a",
        "label": 1
    },
    "575": {
        "output": "<EOD> Immune responses of bursal follicle cells to subunit vaccine immunization against infectious bursal disease\nTwo approaches were used to examine immune responses by the bursal follicle cells to inoculation with the subunit vaccine for infectious bursal disease. Using both a bursa organ culture system and a subcapsular bursal organ culture system, in vitro bursa organ cultures were exposed to whole bursa homogenates, to cell lysates, or to purified proteins including the major bursal antigens: 33K antigen (gp69/71), p34K protein (VpX), p45K protein (Vp36), and the IBD20K protein. Each of the four proteins could stimulate the bursal cells. A 1:1 ratio of p34K:p45K induced a significantly higher level of IL-6 antigen production than did the other ratios. Lack of stimulation of bursal cells by a bursa homogenate suggested the existence of a bursa-specific suppressor cell in these organ cultures. Finally, using a subcapsular bursal organ culture system, we studied the effect of the subunit vaccine on the bursal immune response. Our results suggested that the subunit vaccine induced a suppressive action on the immune response of bursa cells. The exact mechanism remains unknown.<EOD> Aminoguanidine alleviates brain and spinal cord pathology in experimental allergic encephalomyelitis\nExperimental allergic encephalomyelitis (EAE) is an autoimmune inflammatory disease of the white matter of the central nervous system (CNS) caused by an immune reaction against myelin basic protein. In some inflammatory models, aminoguanidine (AG) has been shown to inhibit the expression of inflammatory mediators and to reduce cellular infiltration into the tissue affected. Therefore, in this study, we evaluated the effect of AG, a compound with selective inhibitory activity toward inducible nitric oxide synthase (iNOS) activity, on inflammatory response in spinal cord and",
        "label": 1
    },
    "576": {
        "output": "## [END]\n\n\nA: Please follow me\nIn the first line you insert #include <iostream>\nIn your third line you should put this header: std::string\n\nIn the fourth line you declare an object with the following line:\nclass trial {\n  public:\n    std::string patientId;\n    std::string description;\n    std::string trialId;\n    std::string gender;\n    Trial-level eligibility: <some eligibility>;\n  };\n\nIn the fifth line you insert your Trial-level eligibility variable (which you declare in your program in the third line).\n\nA: You can make multiple choices for your eligibility and print all the choices in one line as your program is asking for it. Just go to your trial.h file, where you are using trial - object and modify trial_level_eligibility variable to a string, and then change your output line to this:\ntrial_level_eligibility = string; // you should remove the Trial-level eligibility: // <some eligibility> from here\ncout << trial_level_eligibility << endl++; // in 1 line\n\nAfter your output, print the id of that trial, and in the next line print the description of trial and so on. Your object can be printed with to string method by invoking operators <<.<EOD> \u03b2-caryophyllene Alleviates High Sucrose-Induced Inflammation and Senescence in Pig Adipocytes via the Sirtuin 1 Pathway\n\n\n\n# Introduction\nIn recent decades, obesity has developed into one of the most prevalent metabolic syndromes worldwide, which causes an adverse effect on the normal body metabolism and is a serious threat to human health. The obesity epidemic has been rising sharply in developing countries. In the United States, roughly 78 million people are obese, which accounts for 34% of the total population [bib_ref]  Overweight, obesity, and cancer risk, Bianchini [/bib_ref] . Currently, the prevalence of obesity in China is 11.9%, which is continuing to rise [bib_ref]  Overweight, obesity, and public health, He [/bib_ref] . This is",
        "label": 2
    },
    "577": {
        "output": "[CASE][CODE]\n#This is a clinical trial note\ntrial_level_eligibility: 0) Excluded\n#There are some patient data\nPatient_id:  530010060008\nfirst_name:  Gareth\nlast_name:  White\ngender:   2\nage:      66\ndisease:   1\ntype_of_trial:     1\nstage_of_disease:    1\nfamily_history:    1\nhistory_of_taking_drugs:   1\nblood_lipid_levels: 1\nhigh_cholesterol_levels:    1\nuse_of_blood_pressure_controlling_drugs:   1\nblood_pressure_controlled:    1\ntobacco_smoker:    1\nalcohol_drinker:    1\n#And the patient's symptoms\npresence_of_symptoms:    2\nsymptom:    headache\nfrequency_of_this_symptom:   1\n#And the patient's examination data\nhealth_condition_that_was_examined:   1\ncardiology:   2\nneurology:   1\nvascular:   1\nradiology:   1\ntype_of_examination:    1\ntest_date:   1\ntest_result:    2\ntest_report:   1\n#And the patient's information\npatient_notes:         1\npatient_identifiers:   2\npatient_death:         1\npatient_last_visit:     1\npatient_referrals:      1\npatient_provisional_codes:   1\n#And the patient's medication information\nmedication_for_this_patient:   1\nmedications_dosage_route_date_starting_end_reason:   3\nmedications_dosage:     1\nmedications_route:     1\nmedications_dosage_withdrawal_reason:   1\nmedications_dose:     1\nmedication_started_date:   1\nmed",
        "label": 1
    },
    "578": {
        "output": "I have created a script file as example_1.ipynb, which will automatically calculate if the input is included in the trial. As an output, it will generate a summary output, like the one on the screen of your Jupyter Notebook.\nPlease refer to this link for other example. \n\n\nA: I created a small script to help quickly search in a file:\nimport fileinput as fi\n\npatients_path = \"patients.xlsx\"\n\nfor f in fi.open(\"patients.xlsx\")\n    for line in f\n        if 1 < line.splitlines()[2] <= 2:\n              print(f.name)\n\n<EOD> Tuberculosis of the Breast: Report of Six Cases and Review of the Literature\nAbstract: Tuberculosis of the breast is an uncommon disease and is often mistaken for a cancer. From 2000 to 2014, we saw 23 patients with breast tuberculosis at the Department of Surgical Oncology of the Kyrgyz National Medical Center, 6 of whom were clinically assessed. The study group comprised four women and two men aged 25 to 62 years; all had an open tuberculous abscess. All patients underwent treatment\u2014antituberculous drugs for 6\u2013 12 months and surgery. The results of the treatment were evaluated 1\u20138 years postoperatively. All patients achieved a good immediate postoperative result and were cured during antituberculous treatment. The breast tuberculosis incidence rate is increasing despite the fact the disease is easy to treat once identified. Hence, doctors must be familiar with its symptoms to make an early diagnosis; breast surgery is not mandatory. Breast tuberculosis is more common in young people, women, and those with concomitant diseases, such as tuberculous pleuritis. Surgical treatment of breast tuberculosis in the postantituberculous treatment period does not reduce the length of the rehabilitation period.<EOD> A review of the morphometry of adult female scolices of human and animal ascarids.\nThe morphometry of ascarid lumbricoid worms (Ascaris lumbricoides, Toxocara can",
        "label": 0
    },
    "579": {
        "output": "<EOD> Explosion during metal-organic decomposition: a new process to enhance the mechanical properties of carbon nanofibers.\nElectrospinning has been recognized as a simple method to prepare well-aligned carbon nanofibers (CNFs) since many years. Such CNFs possess outstanding features such as a high surface-area-to-volume ratio. Electrospun CNFs can be obtained by thermal decomposition of the metal-organic decomposition, although the morphology of electrospun CNFs depends heavily on the nature of electrospinning solution. Here, we proposed a novel electrospinning process by taking advantages of the physical and chemical interactions between the polymer and additive. To demonstrate our concept, polyacrylonitrile (PAN) and aluminum nitrate with a proper ratio were selected to produce CNFs via electrospinning and subsequent thermal decomposition. After aluminum nitrate had been added into the electrospinning solution, the microstructure of the obtained CNFs was found to be changed from microtubes to nanofibers, which was resulted from the explosion of aluminum particles in the electrospinning solution. The explosion triggered a vigorous exothermic reaction in the electrospinning solution, and thus the thermal decomposition of PAN was markedly enhanced and the thermal stability of the CNFs greatly improved.<EOD> Awareness and Knowledge of AIDS among Women Referred to Urban Health Centers in Isfahan\nThe aims of this study were to assess AIDS\u2014related knowledge and attitude among women visiting urban health-care centers in Isfahan, Iran, and to assess the relationship between demographic variables and knowledge and attitude. Four hundred and ninety two women were selected by random sampling from urban health centers in Isfahan. A self-administered questionnaire assessing demographic variables, AIDS-related knowledge, and attitude was given to women. Data were analyzed using SPSS 7.5. Statistical significance was set at p\u2009<\u20090.05. The means of knowledge and awareness showed that the majority of the participants (90% and 79.2%) had adequate knowledge about AIDS prevention measures, whereas only a few of the participants (28.7%) had sufficient knowledge about the transmission",
        "label": 1
    },
    "580": {
        "output": "### [Exercise]\n- Create a new notebook and give it any relevant name.\n- Let's begin with a basic input file.\n\n### Load Data\n\tThis notebook contains three files.\n\t\n\t> ## load data\n\t\n\tFrom now on, whenever you run this script, it will always be reading the same input data file. So, it is best to have a naming convention for your input data files.\n\t \n\tIf you wish to update `inputDataFileName`, you must replace the existing file with one that contains different input data. Here we have taken a random string that contains some letters and numbers. \n```python\n>inputDataFileName= \"Trial1data.csv\"\n```\n```\n### Importing Library\n\tNow import required libraries\n```\n\t\n\t>import pandas as pd\n\t>import numpy as np\n\t>import matplotlib as mpl\n\t>import math\n\t>import random\n\t>%matplotlib inline\n```\n\tNow let's create a dataframe with dummy data, i.e., three records with only age, sex, and weight columns.\n``` \n>ageDf=pd.DataFrame({'age':[60,100,65],'sex':['Male','Male','Female'],'weight':[60,65,55]})\n```\n\t\n\n### Get Age Data\n\tNow we will get all the age data.\n```\n>>ageDf=pd.DataFrame().assign(age=ageDf.values)<jupyter_text>The output is the dataframe with new column name `age`.<jupyter_code>[age]=ageDf.age<jupyter_output><empty_output><jupyter_text>Now get sex data<jupyter_code>[sex]=ageDf.sex<jupyter_output><empty_output><jupyter_text>The output is the dataframe with new column name `sex`.<jupyter_code>[weight]=ageDf.weight<jupyter_output><empty_output><jupyter_text>Now apply filter<jupyter_code>for age in ageDf.age :\n    if age<=65 or age>=100 :",
        "label": 1
    },
    "581": {
        "output": "<details><summary>See also</summary><pre>{\n  \"patient_note\": \"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\",\n  \"clinical_trial\": \"Proximal Protection With The Mo.Ma Device During Carotid Stenting    Title: Proximal Protection With The Mo.Ma Device During Carotid Stenting    Summary: The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting \\n    Inclusion criteria: General inclusion criteria Subject meets one or more of the high surgical risk criteria, Subject is \u2265 18 years old, Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach, Subject is willing and able to comply with follow-up evaluations at the specified times, Subject (or legal representative) understands the nature of the procedure and provides informed consent, prior to enrollment in the study, If female subject, is not currently pregnant and has stated that she has no intention of becoming pregnant during the study.    Angiographic inclusion criteria (as determined \u2264 30 days prior to procedure): \\n    Target lesion stenosis (% stenosis = (1-N/D) X 100)1, documented by selective angiography pre-intervention, is \\n    Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.    External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm. \\",
        "label": 1
    },
    "582": {
        "output": "**[INST]** Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\n\n\n\n### 4) Exit (insufficient assessment/exclusion)\nYou should assess and make a decision about the patient's eligibility. The three possibilities of the output are `0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria;` 1) `Not relevant (patient does not have sufficient information to qualify for the trial);` and `2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).` Remember, `0` means that the patient is excluded, and `1` and `2` mean that the patient is not excluded.\nYou should always end the input by ``Output: 2) Eligible.``\nFor example, if the input should be `Trial-level eligibility `:\nIf patient meets inclusion criteria, e.g., the blood test values are within normal limits, the patient does not smoke, and this patient does not have a family history of cardiovascular disease, then the statement `Trial-level eligibility: Excluded` should be returned. If the patient meets eligibility criteria, e.g., the patient is a nonsmoker, and the patient has hypertension, and the blood test results indicate no abnormalities, then the statement `Trial-level eligibility: Eligible` should be returned.\n\nFinally, you should always repeat `Trial-level eligibility `: `Trial-level eligibility: `, e.g., `Trial-level eligibility: 1) Not relevant.`. [INST]\n\n\n### 3) Eligible\nYou should assess and make a decision about the patient's eligibility. The three possibilities of the output are `0) Excluded (patient meets inclusion criteria, but is excluded on the",
        "label": 0
    },
    "583": {
        "output": "## MATERIAL\n\n- 1: patient note: Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n- 2: clinical trial: Purpose of this study: Comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis.\n- \n<EOD> Pulsed Laser Abrasive Flow for Selective Metal Removal\u2014A New Conventional Abrasive Blasting Technique\nPulsed laser abrasive flow (PLAF) is hereby presented as a new abrasive blasting technique, which allows to remove the majority of metals from materials and, at the same time, retains almost all ceramic or polymer components. A high laser fluence (mJ/mm\u00b2) and a short abrasive flow period (\u03c4 = 0.1 ms) have both been found to be critical key parameters to minimize the heat induced by the abrasive and to ensure both selective corrosion and selective metallic wear, respectively.<EOD> Correlation Analysis of Serum Glycosylated Hemoglobin Variation and 24-Hour Urine Albumin Excretion Rate in Patients With Non-Hearing Diabetic Kidney Disease\n\nObjectives: Glycosylated hemoglobin (HbA1c) is a marker for blood glucose levels, and changes in its levels can reflect the change in glycemic status of patients. Urine microalbumin can reflect the extent of glomerular hyperperfusion and is commonly used to assess kidney injury caused by glycemia. This study was conducted to evaluate the correlation between glycosylated hemoglobin variation and urine albumin in patients with non-hearing diabetic kidney disease (DN).Methods: A population of 109 DN inpatients was selected. The patients had complete medical records, including routine examination findings, HbA1c findings, and 24-h urine album",
        "label": 1
    },
    "584": {
        "output": "[RUN]\n\n[INST] You are a practitioner who performs abdominal computed tomography (CT) scanning. You diagnose a patient as having abdominal aortic aneurysm, a bulging or ballooning of the blood vessel in the abdomen. CT is a diagnostic imaging technique used to create multiple cross-sectional images of the body and it is performed by means of X-Ray based computer tomography. You want to find if this patient have already participated in a clinical trial. The trial identifier can be found as the last value of the patient variable `Trial-ID`. If the value is 0, the patient has not participated in any trial, and is eligible and fit to participate in a clinical trial. \nAssess the trial-level eligibility of your patient by making the following expressions. We use the `if` function to check the first condition and the `elseif` function for the rest of the conditions. If the trial-level eligibility is \"Excluded,\" or \"Not relevant,\" replace the patient variable `clinical trial status(CT_status)` by 2; If the trial-leveleligibility is \"Eligible,\" replace the variable by 1, in the line following the evaluation. \nAssess the trial-level eligibility of your patient by making the following expressions. We use the `if` function to check the first condition and the `elseif` function for the rest of the conditions. If the trial-level eligibility is \"Excluded\" or \"Not relevant,\" replace the patient variable `clinical trial status(CT_status)` by 2; and if the trial-level eligibility is \"Eligible,\" replace the variable by 1, in the line following the evaluation. \nAssess the trial-level eligibility of your patient by making the following expressions. We use the `if` function to check the first condition and the `elseif` function for the rest of the conditions. If the trial-level eligibility is \"Excluded\" or \"Not relevant,\" replace the patient variable `clinical trial status(CT_status)` by 2; and if the triallevel eligibility is \"Eligible,\" replace the variable by 1, in the line following the evaluation. \nAssess the trial-level",
        "label": 0
    },
    "585": {
        "output": "# Examples\n\n## [INST] Please enter your age in years in the following box:\n[INSERT AGE]\n\n## [INST] \nPlease enter your height in centimeters and weight in kilograms in the following boxes:\n[INSERT HEIGHT] cm \n[INSERT WEIGHT] kg\n\n## [INST] \nPlease enter the number of years you have smoked in the following box\n[INSERT MONTHS]\n\n## [INST] Your BMI is [BMI] and classified in [Class]\n\n## [INST] Please enter the information about the risk of diabetes\n[INSERT CORONARY ARTERIAL DISEASE (CAD) HISTORY]\n![inst/](https://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/inst/inst1.gif)\n![Instruction](/assets/images/instruction.gif)\n\n```\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/main.py\n\n![$]\n\n![inst/](https://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/inst1.gif)\n```\n\n\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/ex11.ipynb\n\n```\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/ex11.ipynb\n\n```\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/ex11_run.ipynb\n\n```\n\n# Note\n\nThe code for the examples is not clean (for example, there are unnecessary variable names, and etc.) due to the",
        "label": 0
    },
    "586": {
        "output": "You can see the detailed explanation of the eligibility assessment for a clinical trial at [https://github.com/wilsonb45/CERTIFIER/wiki/Eligibility-Assessment](https://github.com/wilsonb45/CERTIFIER/wiki/Eligibility-Assessment).\n<issue_comment>username_4: I've updated the script to run the test locally. \n\nIt has been tested on R4.0.4 running in Python 2.7.12. \n\nHere is the snapshot: https://datahaven.wesleyan.edu/download/d/567d2f6d-a911-4b1a-b558-19ed25c108db\n\nThis run seems to have failed on a patient. A review of the patient data suggested that the patient should be excluded.\n<issue_comment>username_4: I've updated the script to run the test locally. \nIt has been tested on R4.0.4 running in Python 2.7.12.\nHere is the snapshot: https://datahaven.wesleyan.edu/download/d/567d2f6d-a911-4b1a-b558-19ed25c108db\n\nThis run seems to have failed on a patient. A review of the patient data suggested that the patient should be excluded.\n<issue_comment>username_0: Sounds great! If you are interested in keeping this ticket updated, please let me know. I'll try to check it once in couple weeks.\n<issue_comment>username_4: I've updated it to run on R4.0.5 running Python 2.7.18. The fix described above should be included in that, and is included in the latest snapshot. \n\n![screenshot 2](https://user-images.githubusercontent.com/6517504/62956599-0d6a3180-bc7f-11e9-927a-046dbe5910e5",
        "label": 1
    },
    "587": {
        "output": "If your assessment yields any assessments other than \u201cTrial-Eligible,\u201d you will not be successful on this clinical trial, no matter what your supervisor decides.",
        "label": 0
    },
    "588": {
        "output": "<EOD> Prevalence and Determinants of Malnutrition among People with Depression Living with Human Immunodeficiency Virus\n\n\n\n# Introduction\nA major public health problem in low-and middle-income countries is malnutrition. Malnutrition is known by weight loss, wasting, poor physical and mental performance, and psychological effects [bib_ref]  Malnutrition: the paradox of nutrition management, Chattha [/bib_ref] . Malnutrition mainly comprises two forms: wasting or undernourishment, which represents an underweight state; while the second type is stunting or over-nourishment, which represents a muscle atrophy as a result of excess nutrients. Many causes of malnutrition were identified such as food insecurity, economic problems, obesity and disability, medications, and social problems [bib_ref]  Impact of psychological problems as an effect on the nutritional status during..., Ahmad [/bib_ref] .\nHuman immunodeficiency virus (HIV) infection is a global public health concern [bib_ref]  Prevalence and determinant of anemia in HIV-infected patients, Suresh [/bib_ref] . Although the prevalence of HIV/AIDS has declined globally, it continues to be a major public health concern in developing countries. HIV/AIDS has a great impact worldwide with high death rates and more than 70 million people are infected with HIV and 5 million are newly infected, leading this disease becomes a persistent burden on the global economy. About 35 million people have died of HIV. HIV is spreading from its original epicenter, which are urban, highly developed areas, to rural, economically less developed areas [bib_ref]  Prevalence and determinant of anemia in HIV-infected patients, Suresh [/bib_ref] .\nAbout 44 million people are currently living with HIV and about half of them are in Sub-Saharan Africa. However, the prevalence of HIV in the Middle East was reported 3.1%, and the prevalence in North Africa was reported 0.2%. The Arab region has the second-highest HIV burden after Sub-Saharan Africa, with almost 660,000 currently living with the",
        "label": 1
    },
    "589": {
        "output": "Exercises 5-10",
        "label": 1
    },
    "590": {
        "output": "<EOD> Antenatal sonography of prune\u2010belly syndrome\nThis case report illustrates the sonographic findings of prune\u2010belly syndrome in a fetus. A 24\u2010yr\u2010old primigravida exhibited polyhydramnios at a sonographic examination at the 23rd week. An anechoic cavity was detected within the fetal abdomen, and dilatation of the urinary system was diagnosed. Cystoscopy and suprapubic cystostomy were performed at 26 weeks, and a fetal autopsy was performed in the hope of a better understanding of the pathogenesis of prune\u2010belly syndrome. In this case, a cyst was detected in the region from the renal pelvis of the upper urinary tract to the posterior urethra and renal agenesis was diagnosed. These results were compatible with those of the sonographic examinations. When the patient was in the prerenal phase of renal failure, cystoscopy revealed urine which originated from the dilated ureter within the cyst\u2010like mass. It is hypothesized that the dysplastic kidney has failed to function and the urinary tract is not functioning. The case of the fetus in the prerenal phase was also observed macroscopically in detail at the fetal autopsy. The results proved that urine originated from the upper urinary tract, including the ureter at the cyst\u2010like mass detected in the fetal pelvic region. Because the results of the present case were compatible with the concept that prune\u2010belly syndrome is a congenital defect in the kidney and urinary tract, it can be expected that with advances in sonographic equipment and the ultrasonologist's skill, prune\u2010belly syndrome can be diagnosed at an earlier gestational age.<EOD> A new species in Onychiurus Bagnall (Onychiuridae: Collembola) from caves of a limestone karst in the Guangxi Province, China.\nA new species, Onychiurus guangxiensis Luo, Zhang Xu, sp. nov. (Collembola: Collembola) is described from eight limestone caves located in Kaiyuan County of Lueyang City",
        "label": 1
    },
    "591": {
        "output": "<EOD> Evaluating the impact of educational intervention based on health belief model (HBM) on self-efficacy and quality of life in women with breast cancer\nAbstract Introduction: Women with breast cancer who are the highest cancer group around the world, are facing with negative emotions such as anxiety and depression because of stressful experiences that is occurred due to their disease. Implementing educational interventions based on the HBM will reduce the negative emotions experienced by them. Methods: A randomized clinical trial was used to evaluate the effect of HBM-based educational intervention on self-efficacy and quality of life in 64 of women diagnosed with breast cancer, referred to hospitals was implemented. The intervention group included 32 participants and the control group included 32 participants. The research tool in this study was a demographic questionnaire, HBM scale and the European Organization for Research and Treatment of Cancer Quality Questionnaire (EORTC QLQ-C30). The data was analyzed using analysis of covariance and Tukey test. Results: The results of regression analysis indicated the variables are effective in explaining the change of score in quality of life in women through the intervention, based on the intervention HBM variables on the variables of cancer and physical condition, treatment, emotional condition, cognitive beliefs of cancer, HBM constructs, and also the total score of HBM and its subscales (p-value  0.05). Conclusion: Educational intervention based on HBM can improve and control the negative effects of cancer symptoms and improve self-efficacy. The intervention can play an important role on promoting the quality of life in women with breast cancer.<EOD> A critical role for S-nitrosation of the ATPase module in unblocking cystic fibrosis transmembrane conductance regulator pore after oxidative stress\n\n\n\n# Introduction\nCystic fibrosis (CF) is a fatal autosomal-recessive disorder; more than 90% of CF patients harbor two mutations in the cystic fibrosis transmembrane conductance regulator (CFTR [bib_ref]  Identification of the cystic fibrosis gene: chromosome walking and jumping, Rommens [/bib_ref]",
        "label": 1
    },
    "592": {
        "output": "The full set of tasks is given in the file [link1] test.csv.\n<EOD> Synthesis of fluorescent carbazole-based conjugated polymers modified by nonlinear optical chromophore for photoinduced electron-transfer transduction and sensing applications.\nFor highly sensitive optical sensing applications and bioimaging, the generation of reactive radical species from photoexcited polymers, which can effectively modulate the photoreaction, is a key issue to consider. In this study, we synthesized a series of donor-acceptor polymers bearing nonlinear optical chromophores as acceptor moieties for the generation of reactive radical species. Our results show that the photoinduced electron transfer reactions, such as the generation of reactive radical species and the charge-transfer process, are strongly affected by the polarity of the surrounding medium.<EOD> Effects of acute hypobaric hypoxia exposures and re-exposure: a functional and cardiac magnetic resonance evaluation\n\nThe effects of prolonged/chronic hypobaric hypoxia (HH) exposure have been investigated and described. Despite the effects of acute HH exposure still being unclear, some authors have demonstrated HH-induced cardiac changes. However, these studies were conducted mainly by using echocardiography and not cardiac magnetic resonance (CMR). Thus, the aim of this study was to evaluate the effects of acute HH exposure on cardiac function, blood pressure, and cardiac remodeling using a CMR protocol. Nine subjects were exposed to two acute HH (8 h, 213 Torr) exposures, separated by a control day, in normoxia at 350 Torr, and two more acute HH exposures, separated by a re-exposure day, to a similar hypoxic condition. Echocardiography and CMR were conducted at baseline and after each acute HH exposure and re-exposure. Our results showed that an acute HH exposure leads to an increase in left ventricular mass, myocardial mass, systolic wall thicknesses , and right ventricular function, as indicated by ejection fraction. Nevertheless, the use of the CMR protocol demonstrated that despite changes in all the parameters afor",
        "label": 1
    },
    "593": {
        "output": "<jupyter_code>input_list = ['The patient note', 'Carotid ultrasound results']\nx_new = x_transformation(input_list, 'input', is_header = True)\nx = x_new[:,0]\n\nx_transformation(x, 'clinical trial', is_header = True)\nx_transformation(x, 'clinical trial', is_header = True)\nx[:, 0:2]\n\ny_new=y_transformation(x, 'eligibility')\ny_new[0].value\n#output: 2) Eligible\n#for trial ID check this trial data structure\n#data_transformation(y_new, 'clinical trial', is_header = True)\n\nprint(\"-------------------------------------------\")\nprint(\"Please check these 35 examples\")\n\n<EOD> Precise measurement of the 129Xe spin-spin relaxation rate.\nWe report an accurate measurement of (129)Xe inversion recovery spin-spin relaxation rate T(2) near 1.8 mT. The value, determined from measurements of a 1.8 mT NMR signal that is spin-flipped with a 0.26 mT field, is found to be 9.838 +/- 0.005 s. This determination differs by less than 0.01% from predictions previously used to constrain the (127)Xe and (129)Xe nuclear electric and magnetic dipole moments and by less than 0.4% from predictions of the (129)Xe electronic g value.<EOD> 2002 and beyond: a new era in the medical management of cardiovascular disease for general internists and family physicians.\nNew guidelines have been published for primary prevention of coronary heart disease, 1 lowering of blood pressure. and risk reduction for patients with coronary heart disease, stroke, and diabetes mellitus. 2,3 Other consensus documents review the role of statin therapy and cardiovascular disease prevention, 4 as well as the benefits of dietary fish oil supplementation. 5 Other relevant guidelines are available to assist",
        "label": 0
    },
    "594": {
        "output": "The `Trial-level eligibility` output the number of trials the patient was evaluated for so we set `Trial-level eligibility: trial_name`.\n\n\nA: Just need to do some tweaking of the script provided:\nThe 'eligible' column contains the counts for the number of times that it has been marked as eligible. So just need to calculate that once for each patient and then add that count to the count for the relevant 'relevant_criteria' column for that patient.\nNote that there will now be duplicate rows for certain patients where they are enrolled in more than 1 trial. The counts for the 'eligible' column will therefore be added to the relevant_criteria values for all relevant trials.\nI have modified script to be compatible with python 3.6 and 3.7 and included the 'independent_criteria' columns. \nAlso tried to include a sanity check - by adding in the `if` operator, so that the `trial_name` variable is checked for non-zero values to prevent the script from crashing if you were to try and run this on a new dataset where it cannot find any relevant trials - but since the code doesn't run on my machine at all, I suspect it needs a few more fixes to run (either in the script, or the code on SO).\nSo I will try to run the test script in my local dev environment and see how that works. \n<EOD> .\nThe paper compares the use of 233U and 197Au for palliative treatment of inoperable pancreatic carcinoma. A total of 81 patients with pancreatic carcinoma were exposed to 197Au while 106 patients were exposed to 233U over 4 months. The mean survival time was 355 days with 197Au and 271 days with 233U. The respective increase in long-term survival of patients with metastases was 135 and 163 days while in patients without metastases the 50 per cent survival time increased 269 and 338 days respectively.<EOD> Increasing the Efficacy of Chlorogenic Acid against Salmonella enterica by Codelivery with",
        "label": 1
    },
    "595": {
        "output": "To submit the assessment, click the Assess button in the lower left of the left side.\n\nIn this assessment, the patient meets the inclusion criteria and is also eligible for the clinical trial `Title: A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies`.\n\n### Submission Check \nClick the \u2018Submission Check\u2019 button in the bottom left of the left side. This will allow you to check the accuracy of the assessment. There is a message indicating that no errors were found. This is the output that you should provide in the `ClinicalTrials.gov` web page.\n\nClick the \u2018Create XML\u2019 button in the upper left of the left side (that appears as a link).\n\nA pop-up appears showing the XML code. Click `Save As..` in the pop-up menu. Type `Your Email` if the email is empty. Then, click `Save As UTF-8`.\n\nClick `Done\u2019 in the upper right, which will generate two files (a PDF file and an XML file). You can only upload the XML file in the `ClinicalTrials.gov` web page. The PDF file is for your reference.\n\n![INST-Upload_XML]\n\n\nClick `Upload` again. Then, click `Upload XML Files` and click `Browse\u00b4 in the file selector to select the XML file that you have saved before. Finally, click `Submit Clinical Trial` to complete the assessment.\n\n\n### Check Availability \nCheck the availability of the submitted assessment in the [CliniCalTrial.gov Home Page]( https://clinicaltrials.gov/ ). Click `Find Studies, enter the National Clinical Trial` number (NCT No.) in the search box to open the study (or select the study from the list). The submitted assessment will be checked in the 'Trial Results Summary' table. If the assessment has been submitted, the word `Unsubmitted` should be shown in the `Trial Results` table instead of `Registered.\n\n![INST-Check_availability]\n\nIf you cannot find the assessment at the NCT No. in the `Trial",
        "label": 0
    },
    "596": {
        "output": "## RQ2.\nTell me, what is the output of the 'assessment_eligibility` function?\n\n## 4) You want to take the first row as an example to explain. You should use the following arguments to this function:\n\n##### A)\nNote: You can type `A> > print(assessment_eligibility(crs, trial=CLINICAL_TRIAL_1))` to do the same.\n\n##### B)\n\n## C)\n\n##### D)\nYou can type `D> > print(assessment_eligibility(crs, trial=CLINICAL_TRIAL_1))` to do the same, but it will be slightly faster.\n\n##### E)\n\n### F)\n\n## G)\n\n## H)\n\n### 5) The results are as follows: You should always print the first row as the result of this function, and repeat the Trial-level eligibility at the end by `Trial-level eligibility: `. \n\n# RQ3\nTell me, what is the output of the `summarize_eligibility` function?\n\n## RQ4\nTell me, what is the purpose of the `summarize_eligibility` function?\n\n## RQ5:\nTell me, why we can not get the following information: How many patients with a HbA1c level above 7% were screened for entry? How many patients were found to be ineligible for this trial?\n\n# 1) What do we want to achieve?\n\nWe need to count the number of screened patients of each type, the number of excluded patients, and the number of exclusion reasons.\n\n### 2) What do you think when you want to do this? What kind of information will we need?\n\nWe would like to find the number of patients with a HbA1c level above 7% first. Then, we would like to print out the number of patients who are excluded based on inclusion exclusion criteria.\n\nThen, we would like to print out their detailed information from patient's notes including the reason for their exclusion.\n\n### 3) Let",
        "label": 0
    },
    "597": {
        "output": "---\n\n## Eligibility Test\n\nEligibility test 1: `if Trial-level eligibility = 2 then Evaluation = 2;` \nEligibility test 2: `if Trial-level eligibility = 1 then Evaluation = 0;` \nEligibility test 3: `otherwise Evaluation = 0;` \nFor eligibility test 2 on the basis of information for `Trial-level eligibility = 2; the given patient note is eligible.\n\n## Clinical Trial Status Information\n\nYou are asked to provide information about the current phase of the trial according to the information [https://clinicaltrials.gov/learn/definitions.jsp]:\n- Term = a short term for a clinical trial stage - Phase = the stage of development with respect to the drug or biologic; it is a phase of development during which interventional trials are conducted with the goal of assessing safety and preliminary efficacy - Protocol Type (Ph): the clinical form in which a clinical protocol is drafted; it is different in trials of drug, new drug, diagnostic, or medical device (a combination of drugs or diagnostic study is considered a drug trial and a diagnostic study is considered a diagnostic trial) - Stage/Part Definition Type (Ph): the phase, protocol type, and definition of stage and part of a study - Part: a single interventional study; the term refers to a protocol or set of protocols, or to a collection of interventional studies carried out to evaluate the safety and efficacy of a drug or biologic. - Arm Type: clinical trial arms are the distinct combinations of interventions (drugs, biologics, or both) being tested; it is a part of the trial. - Amendments: the modification of a written research protocol; the term is synonymous with protocol modification, but often this is not the actual protocol undergoing modification and other documents, such as consent forms, investigator brochures, statistical analysis plans, financial protocols, and other data sharing documents may also be modified. - Investigational New Drug (IND) or Investigational Device Exemption (IDE): the approval of human research studies. \n\n1. Trial stage, phase, protocol type,",
        "label": 0
    },
    "598": {
        "output": "If it is finished, the above-mentioned code is generated.\n\n#### Clinical Trial Registration and Privacy Policy\n[D21] ClinicalTrials.gov has registered a standardized protocol and the informed consent form for Trial CAPRICORN-CRS, which will be performed in this project. ClinicalTrials.gov is registered in the World Health Organization's International Clinical Trials Registry Platform (ICTRP) system. The ICTRP helps to ensure that research studies are registered with their trial registration number before initiation or continuation, and then followed. Registration has been deemed necessary by the World Health Organization's International Conference on Harmonization, ICH, and is required under the regulatory policies adopted by major journals.\n[D22] The privacy policy that will be used in the Trial CAPRICORN-CRS has been registered in the Privacy Policy Prohibiting Commercialization of Personal Health Information at https://privacy-enforce.org. The privacy policy prohibits the direct or indirect commercialization of personal health information.\n\n<a href=\"https://ccka.xyz\">Powered by <i>Sphinx-CSP</i></a>\n<EOD> Assessment of the Antidiabetic and Antioxidant Potential of Zygophyllum fabago L.\n\nDiabetes mellitus (DM), a metabolic disorder characterized by chronic hyperglycemia with impaired insulin sensitivity, is one of the main chronic diseases in the world and affects millions of people on a daily basis. Oxidative stress arising from reactive oxygen species (ROS) formation is recognized as one of the major contributing factors in the development of DM. On the other hand, antioxidant substances may play a role in prevention of DM or reducing its adverse effects on other biological systems. The present study aimed to evaluate qualitatively and comparatively the antioxidant activity of aerial parts extracts and biologically active compounds of Zygophyllum fabago L. The antidiabetic activities were quantitatively evaluated by enzyme assays method. Results showed that the aqueous leaves extract of Zygophyll",
        "label": 0
    },
    "599": {
        "output": "<EOD> A Simple Method for Detection of the Prostate Adenocarcinoma Using N\u2010Terminal Fragment of Basic Proline\u2010Rich Protein\nProstatic carcinomas are the most frequently diagnosed cancers in men. In this study we evaluated one protein in the prostatic fluids, namely the Nt-BPP (n-terminal fragment of basic proline-rich protein) as a biomarker for prostate adenocarcinoma detection, using a commercially available immunoassay kit. We investigated 30 men aged 48 to 69 years old. The patients were divided into groups according the pathologic result of the prostate and the results of immunoassays. For statistical evaluation of the results, we used T test and Receiver Operative Characteristic curves. We identified significant differences between prostate adenocarcinoma and BPH (Benign Prostatic Hyperplasia). Based on the statistical data Nt-BPP can be recommended for clinical use as a test for detection of prostatic adenocarcinomas. However in patients with PSA values above the upper limit of normal (>4.0\u2009ng/ml) and Nt-BPP \u2264152\u2009ng/l, prostate histological evaluation (DRE, TRUS, biopsy) should be performed. J. Clin. Lab. Anal. 21:320\u2013325, 2007. \u00a9 2007 Wiley periodicals, Inc.<EOD> The FDA\u2019S Approval of the Pfizer and Moderna Vaccines for Emergency Use: An Ethical Analysis\nPrior to their emergency approval, the Pfizer and Moderna COVID-19 vaccines were tested on tens of thousands of healthy, young adults in only one trial in each case. Although that is the best method to ensure efficacy and estimate how the vaccines will work in the general population, the trials could not examine the impact of the vaccines in a target population who may be at especially high risk for serious disease if they become infected \u2014 namely elderly adults<EOD> The Impact of Stereotactic Radiosurgery on Pain in Patients with Large Brainstem Cavernous Malformations\n\nIntroduction: Stereotactic radiosurgery",
        "label": 0
    },
    "600": {
        "output": "A: You need to keep a list of all patient notes and the corresponding clinical trials in a \nList (List is a python class, see docs for details). You can then use that list and a for loop to iterate over all patients. \nfor pat in PATIENT_LIST:\n    clinical_trials = \n    # your logic goes here\n\nA: \nThis code snippet should help with some basics. \nimport operator\n\n# Note the use of a dict to make the mapping between patient id number and trial id\n# (as opposed to a tuple / list)\ntrials_by_patients = dict(\n    (i for i, p in patient_id_list.iteritems() if i%100 == 0))\n\ndef assignTrial(trial_index_to_assign, patientId):\n\n    trialName = trials_by_patients[patientId]\n\n    if trialName is None:\n        # trial name didn't exist in the dict, so we make a new trial\n        newTrial = Trial('Trial Name')\n\n        # assign a unique random id to the trial so that if we check in a second\n        # pass, we can know what this trial refers to\n        newTrial.randomIdId = trial_index_to_assign % len(trials_by_patients.keys())\n\n        # add a second line that saves this trial to the list of existing trials\n        # (also add in the trial ID of the patient in the patientId slot)\n        trials_by_patients[patientId] = newTrial\n\n    else:\n        # if this trial's ID wasn't already there, we create a new trial for that patient\n        if newTrial.randomIdId.find(trials_by_patients[patientId].randomIdId) % len(trials_by_patients.keys()) != trialName.randomIdId:\n            newTrial = Trial('Trial Name')\n            newTrial.randomIdId = trialName.randomIdId% len(trials_by_patients.keys())\n            trials_by_patients[patientId] = newTrial\n\n    return",
        "label": 0
    },
    "601": {
        "output": "<EOD> Clinical manifestations of rheumatic fever.\nDemographic changes have impacted the present-day population in many ways. For instance, the average life span of people has increased; there are more elderly people in the population; more women enter the labor force; and there is an increase in racial mixture of the nation's population. These changes have resulted in the emergence of a variety of clinical problems: acquired immune deficiency disease syndrome, sexually transmitted diseases, and chronic illness such as diabetes and hypertension. In addition, there are a variety of rare disorders being diagnosed more frequently for multiple reasons. The incidence of acute rheumatic fever is one such example. In the pre-antibiotic era, rheumatic fever and rheumatic heart disease were the leading causes of acquired heart disease in young individuals.1,2 At present, this disease accounts for 11.1% of acquired valvular heart disease in the United States.3 A worldwide decrease in the incidence of rheumatic fever from 48 cases per 100,000 children in the 1960's to 59 annually per 100,000 population in the 1980's has been reported.4 This decline is particularly noticeable in developed countries. For example, the incidence of acute rheumatic fever decreased from 37.7 cases per 100,000 in the late 1940's in England and Wales to 3.4 per 100,000 in 1973. One contributor to the decline in rheumatic fever in the western world is the improvement in sanitation and better living conditions for children. In less-developed countries in Asia and South America, however, the incidence of rheumatic fever remains significantly high, between 57 to 125 cases per 100,000 children.5,6 A number of factors explain the increased incidence of acute rheumatic fever in the less-developed populations. These include overcrowding, lack of adequate sanitation and facilities, and poor nutrition. Rheumatic fever",
        "label": 0
    },
    "602": {
        "output": "**Examples of Trial-Level Eligibility**\n\n### Eligible\n\n| patient_id | status | reason |\n|:----|-------|--------:|\n| Patient_1 | 2) Eligible | Eligible according to clinical trial inclusion criteria |\n| Patient_2 | 0) Excluded | Excluded on the grounds of trial's exclusion criteria |\n| Patient_3 | 1) Not relevant | Not relevant enough to qualify |\n|\n\n### Inclusion Criteria of the trial: \n- 40-80 years of age\n- Right hand dominance\n- Patients are asymptomatic\n- Baseline doppler study with a peak systolic velocity of 400cm/sec\n- Patients are candidate for carotid artery stenting, TIMI flow of 1,2 or 3\n- 80% or greater stenosis of distal common or internal carotid artery, as determined angiographically, as defined in ACAS\n- Subjects are willing/able to complete follow-up visits\n- Subjects are able to give informed consent\n- Patient has clinical diagnosis of stroke\n\n\n##### Exclusion Criteria of the Trial: :\n- Patients with a history of seizures\n- TIA/stroke not related to stenosis in target artery\n- MRI contraindications incompatible with SWI-MRI (e.g. ferromagnetic implants, claustrophobia, patient is unable to hold still for the scanning time)\n- Carotid stenosis <30%\n- Any severe stroke and not eligible for carotid artery stent placement due to neurological contraindications\n- History of carotid intervention (e.g. carotid artery stenting, surgical intervention)\n- History of Mental State Examination (MMSE) <24\n- Carotid artery lesions >15mm in diameter\n- Cardiac surgery, cardiologic interventional treatment (PCI), or aortic aneurysm repair <3 months\n- Stroke surgery or reperfusion therapy (int",
        "label": 1
    },
    "603": {
        "output": "## [INST] Tutorial\nLet's use a `tutorial package`, which is recommended for data manipulation tasks. \n\nimport { tutorial } from \"@n-3d/data-handling-and-analysis\"; tutorial(); [TUT] Installment 1 Install your `tutorial` package.\n\nInstructions. You will receive a piece of paper that contains nine questions that are needed to be answered. You have 10 minutes to accomplish the tutorial. You can only refer to your papers but do not discuss the problems with other persons.\n\n# Problem 1\n\nYou are given a file, which contains the data used in the previous tutorial. You can use `head`, which will display part of the file in your terminal for inspection. Now the task is to get all five rows and print them in your screen.\n\nThe solution is: \n\n`head -n 5 *1.txt`; [TUT] Print five rows from the `1.txt` file\n\n# Problem 2\n\nNow you are given a file `2.txt` with some numbers. You will use the `grep` command for extracting the specific numbers. You will have three minutes to accomplish the task.\n\nSolution: \n\n`grep -w 1,2,3,4,5 2.txt`; [TUT] Retrieve the numbers from the `2.txt` file (1,2,3,4,5)\n\n# Problem 3\n\nNow you are in the `main` directory of the current repository in your interactive shell. Create a file named `3.txt` by typing `touch 3.txt` and then use `vi` editor. There are two commands to add a single row of data to the file, `insert` and `a`. Use these two commands in an interactive shell to add rows 1 and 4 to the `3.txt` file. Your task is a 17-minute one.\n\nSolution: \n\n-  Add the content of lines 1 and 4 in `3.txt`: vi - 17 minutes [TUT] Add lines 1 and 4 in the `3.txt` file\n\n# Problem 4\n\nNow you see `4.txt` with the content [text] (this is a placeholder). Your task is to",
        "label": 0
    },
    "604": {
        "output": "### <a name=\"recall\"></a> Test Your Coding [testoutcomes] (Coding)\n\n[Instructions in Section <a href=\"https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_coding_3_study.html\">INST](#instructions) of Bookdown Documentation](https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_coding_3_study.html)\n\nYour code looks fine. \ud83c\udfc6\ud83c\udfc6 \n\n> **Awesome! <NAME>, you've done the next-level. \ud83c\udf89\ud83c\udf89**\n\n### <a name=\"summary_and_commentary\"></a> Summary and Commentary [summary_and_commentary] (Documentation)\n\nFor a second-take look, please re-read the entire test section. You should read it several times, for 1) to recall the details of the code snippets and 2) to summarize the code and comment for the code snippets.\n\nAbove all, it's important to get an overview of your code and make summaries and comments together. Such tasks are helpful to make you think critically and think deeply.\n\n[Instructions in Section <a href=\"https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_summary_and_commentary_8_study.html\">INST](#instructions) of Bookdown Documentation](https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_summary_and_commentary_8_study.html)\n\nHere's the summary/comment of your code snippets in this challenge:\n\n<i class=\"fa fa-3x fa-file-text-o\"></i>\n\nFirst Look: In Case of Clinical Study of Diabetes\n\n<i class=\"fa fa-3x fa-file-text-o\"></i>\n\nYour code has been shown to the clinical data.",
        "label": 0
    },
    "605": {
        "output": "## Eliminate the incorrect code\n\nHere is the correct code:\nTrial-level eligibility: 2) Eligible.\n\n## Exercise 4\nExercise 4 was designed for your home environment. You should solve the Experiment 4 using the MATLAB online platform. \nHere is Experiment 4 in the following link:\n[?]\n[INST] You are now in the classroom to solve the Exercise 4 with our instructor, Professor Xiaoxian Dong. \nProfessor Xiaoxian Dong:\n\nHere, we investigate the efficiency of using eligible-coded image retrieval techniques for medical image retrieval applications. First, we need to find the suitable medical image. \nWe can use the following code: \nimread('/home/demo/1.jpg')\n\nI expect you get the image on the right side of the Figure 1.\n\nFigure 1: The image captured with imread() function. \n\nNext, we need a number for labeling the images. We can set the code at the following code: \nnumber \nimread('/home/demo/2.jpg');\nset(0, . . . .g); set(1, . . . .a)set(2, . . . .l) imread('/home/demo/3.jpg');\nset(3, . . . .n); set(4, . . . .t) set(5, . . . .p) set(6, . . . .q)\nimread('/home/demo/4.jpg');\nset(7, . . . .e) set(8, . . . .r)\n\nIf you use the imread function to capture the images, you should replace the '/home/demo/ ' in the figure 1 with the file_path you stored previously. \nNow you can use the following code into label the images: \n[demo_num, label_demos] = read_demo_num(:);\nimshow()\n\nAt the end of the lesson, please complete the following task: \n[?]\n[END]\n<EOD> A Difference to Notice: Clinical Characteristics between Patients with and without Hyponatremia at Time of Hospital Admission",
        "label": 0
    },
    "606": {
        "output": "# Methods\n\n## Using ELIGIBILITY\nEligibility can be used by selecting the `Eligibility` button under the `Analysis` column in the `Data Table` by right clicking.\n\nAfter you click the button, the eligibility table will be shown. After that, we can add eligibility table based three types of variables: output, input & exclusion conditions. For output, input variable & exclusion condition, just select `output`, `input & exclusion condition`, or `exclusion condition`. Next, we need to define the type. After you define the type, you can use the value. The type for eligibility & input variables is `trial-level` for trial and `patient-level` for patient.\n\n### Output\nAll outputs are `binary variables`. This means that they should return 0 and 1. If we have patients in the trial, we use `Trial-level eligibility: <0; 1; 2>` and the interpretation is as follow:\n- `Triallevel eligibility: 0` means the trial excludes the patient because of patients do not meet the inclusion criteria\n- `Triallevel eligibility: 1` means the trial includes the patient because the patient meets the inclusion criteria\n- `Trial-level eligibility: 2` means the trial excludes the patient because",
        "label": 1
    },
    "607": {
        "output": "The output format is the same as for `Slice-level eligibility` above: `Trial: {2} patient: {0} \n\nRemember, the assignment `Trial-level eligibility = 1` indicates that a subject is excluded. On the other hand, the assignment `Trial-level eligibility = 2` indicates that a subject is qualified. A patient is eligible if the evaluation at trial-level eligibility is equal to 2 in all clinical trials (i.e., both a clinical trial and a patient are `Eligible` if you type the command `trial_level_elig: \"2\"). \n\n[INST]\n\n### Testing\nIn the last task, we need to compare the `Trial-level` eligibility and the `Slice-level eligibility` of all patients with the criteria. \n\n### Slice-level eligibility Testing\nThe program `Slice-level eligibility.ipynb` will test the criteria defined above. \n\n### Trial-level eligibility Testing\nThe program `Trial-level eligibility.ipynb` will test the criteria defined above. \n\n# Exposition\nIn the \"Course structure\" section you can read how to organize and study the courses.\nYou have to get acquainted with the material of course I, II and III. In the following links you can see the slides of the course:\n- Course I: Inverse Probability Weighting (IPW) and Nonparametric IPW (NP-IPW). Course I_material.pdf\n- Course II: Target Trial Concept. Material_course-II.pdf\n\nThe Course website:\n- Course I - Inverse Probability Weighting\n- Course II - Target Trial Concept\n- Course III - Estimation, Optimization and Causal Inference\n- Course IV-Cause-Effect Relationship and Precision Medicine\n\nThe first homework.\n\nHomework: Assignments\n- IPW-homework.pdf\n- Target-Trial-Homework.pdf\n- NP1-Causal-inference-homework.pdf\n-",
        "label": 0
    },
    "608": {
        "output": "You should note the output from the evaluation script. You will be presented with the results from the evaluation of patients' entries. This is a three-element vector output from the evaluation script, the first element is 1 or 2, the second element is 0 or 1, and the third element is a numeric value. The numeric value corresponds to the final score in Equation 2 and can be further used to determine patient triallevel eligibility.\n- The output from the evaluation script is `1 0 176.043` for the patient above.\n- The patient satisfies both inclusion and exclusion criteria.\n- The score is 176.043.\n- The patient should be excluded from the study because the inclusion criteria were not met, and the final score 176.043 does not satisfy the threshold value 225.231.\n\n## Exercise: \nExercise for you is to perform one random patient data entry. The only difference to the data entry exercise above is the value for the `SCORE:`. The actual value will be different in each trial, it is recommended you to perform at least 10 random patient data entries.  You will be presented with the results from the evaluation of patients' entries. Here is example data for 10 trials. \n[INST]  Exercise: \nIn this exercise, you will use the same example patient entry for the data entry exercise above. The only difference is for the `SCORE:`. You need to do more than 10 random patient data entries. The actual value will be different in each trial, it is recommended you to perform at least 10 random patient data entries. \n[INST]  \n![](https://github.com/bjh2015/data entry exercises/blob/master/images/data entry.pdf)\n\n# 1 Trial-level eligibility Evaluation script:\n\n## Running time: 9 sec; execution time: 23 sec;\n\n1 Trial-level eligibility Evaluation Script [https://b22671563.github.io/data entry exercises/1%20Eligibility/1Eligibilty%20v2.ipynb?filepaths=%",
        "label": 1
    },
    "609": {
        "output": "### Case 6\n\n### QUESTIONS?\n\n**Question**\n\nYou are tasked with constructing an evidence-based decision-making process for a research study on a potential clinical trial, aiding researchers to make better use of available research data and resources. The researchers are in search of a new drug to cure a particular disease. Based on literature surveys, they have decided to conduct a proof-of-concept study on rats. It needs to be as detailed as possible. One of the main prerequisites for any research is the ability to keep costs and time to a minimum which translates directly to the accuracy and quality of the research.\n\nAn evidence-based decision-making process will allow researchers to identify all possibilities and risks associated with new drugs, and provide the researchers with a clear overview of the situation so that they can be used for developing a strategy for conducting the research.\n\n##**What are the objectives of the research proposal? \n\n**Objective 1**:\n\n**What are the research questions that are of interest to you?**\n\n**Research Question**  1. How to evaluate the risk of the study as well as the risk to the participants.\n\n**Research Question**  2. Compare various drugs with the same dosage on the same participants and observe if one drug works better than another, if any.\n\n**Research Question**  3. Assess the potential side effects and risks that are of interest to the study, including the long term effects on the subjects.\n\n**Research Question**  4. What are the ethical and safety considerations that may occur for the participants?\n\n**Research Question**  5. How can we make the research more cost-effective?\n\n##**What variables are important and will you include in the study?** \n\n**Variable**  1. The participants.\n\n**Variable**  2. The researchers.\n\n**Variable**  3. The drugs.\n\n### QUESTIONS?\n\n**Question**\n\nYou are tasked with constructing an evidence-based research proposal on a particular research study, aiding researchers to make better use of available resources and research data.\n\n\n|\n\n<EOD> Epidural catheter malrotation",
        "label": 0
    },
    "610": {
        "output": "_____________________________________________________________________________ \u00a9\ufe0f Copyright 2020 HIMSS. All rights reserved. Use of these materials is strictly prohibited unless otherwise specified. _____________________________________________________________________________ \u00a9\u00ae Copyright 2019 HIMSS. All Rights Reserved. Use of these materials is strictly prohibited unless otherwise specified.<EOD> Diastereoselective conjugate addition of thionium ylides to \u03b1,\u03b2-unsaturated ketones.\nEnantiomerically pure and deprotonated conjugate addition adducts can be generated by the diethyl thionium ylide to \u03b1,\u03b2-unsaturated ketones. The diastereoselectivity of the addition of the thionium ylides was dependent on the structure of the \u03b1,\u03b2-unsaturated ketones. The stereoselective conjugate addition reaction was carried out under mild reaction conditions, and the products could be obtained in moderate to excellent isolated yields at ambient temperature. The deprotonated conjugate addition products can also be easily converted to chiral 2-(Z)-hydroxycarboxylic acids and \u03b3-lactones by ester hydrolysis and lactonization.<EOD> .\nA 62-year-old man presented to our hospital after a traffic accident. Chest radiography showed pneumomediastinum and pneumothorax of the left side. He was admitted because of a fracture at the neck of the left clavicle. On the next day, respiratory status suddenly worsened and he developed respiratory distress immediately. Chest radiography revealed an increased pneumomediastinum and elevation of bilateral hemidiaphragm. Although the pneumothorax and pneumomediastinum had disappeared 9 days after, hypoxemia and pulmonary infiltrates persisted. He was hospitalized and treated by conservative treatment. Nine days after the pneumothorax, the patient died of respiratory failure and septic shock. At the autopsy, a massive pneumomediastinum due to lacerations at the esophagus and cervical trachea was revealed. In the bronchus of both lungs, foci of diffuse alveolar damage were found and severe inflammatory",
        "label": 0
    },
    "611": {
        "output": "[1] You can run R via the Rscript command inside the R console of the Jupyter notebook.\n\n\u00a9 2019 - 2020 Hacettepe University, Turkey. This work is licensed under a Creative Commons Attribution 4.0 International License.\n<EOD> .\nThe authors report their experience in patients with acute coronary syndromes who required urgent angioplasty but were under no anticoagulation. After analyzing 19 patients, no complications occurred and all of them underwent angioplasty with good procedural results.<EOD> Role of AMP-activated protein kinase in the potential actions of glucocorticoids on intracellular triglyceride and AMP concentration in HL-1 cardiomyocyte cells.\nGlucocorticoids activate the rat liver 5'-AMP-activated protein kinase (AMPK) by two possible mechanisms, through changes in AMP concentration or by direct action on AMPK. In HL-1 cardiomyocyte cells there is no effect of dexamethasone (0.1, 1, and 10 micromol/L) or of ACTH (0.1, 1, and 10 micromol/L) on AMP concentration and, at physiological doses, they have no effect on AMPK activity. Neither insulin (0.1 and 10 microU/mL) nor isoproterenol (0.1 and 10 micromol/L) had an effect on AMP nor on AMPK activity, the AMPK level being unaffected by these different compounds. Under our experimental conditions, AMPK may not play any physiological role in the regulation of cardiomyocyte metabolism because HL-1 cells, even under conditions that promote cell survival, do not respond with AMPK activation. AMP-activated protein kinase was also investigated as a possible modulator of the effect of glucocorticoids on triglyceride content in HL-1 cells, but the addition of dexamethasone decreased triglyceride accumulation without change in AMP concentration and AMPK activity. In addition to these findings, the",
        "label": 1
    },
    "612": {
        "output": "## 3\n\\documentclass{springdefault}\n\\usepackage{amsmath}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{fontenc}\n\\newcommand\\cyr{\n\\renewcommand\\rmdefault{wncyr}\n\\renewcommand\\sfdefault{wncyss}\n\\renewcommand\\encodingdefault{OT2}\n\\normalfont\n\\selectfont}\n\\usepackage{textcomp}\n\\usepackage{mathrsfs}\n\\usepackage{upgreek}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{questions}\n\\question\n\\task Exercise 1.2: Exclusions\nFind the exclusion criteria for patients with mild to moderate CTTH. You have to find the sentence which does not conform to the inclusion criteria of these patients or to the exclusion criteria.\n\n\n\\task Exercise 1.2.1: No Exclusions Found in the Note\nExercise 1.2.1: No Exclusions Found in the Note\n\n\n\\task Exercise 1.2.2: Exclusions Found in the Note\nExercise 1.2.2: Exclusions Found in the Note\n\n\n\\end{questions}\n\n\\end{example}\n\n## 4\n\\documentclass{springdefault}\n\\usepackage{amsmath}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{fontenc}\n\\newcommand\\cyr{\n\\renewcommand\\rmdefault{wncyr}\n\\renewcommand\\sfdefault{wncyss}\n\\renewcommand\\encodingdefault{OT2}\n\\normalfont\n\\selectfont}\n\\usepackage{textcomp}\n\\usepackage{mathrsfs}\n\\usepackage{upgreek}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{questions}\n\\question\n\\task Exercise 1.3: Exclusions\nFind the exclusions in the trial information with respect to the patient's age, sex and smoking status. You should write these exclusions in the form: EXCLUSION = 90 - 99 years = Yes.",
        "label": 0
    },
    "613": {
        "output": "- Your answer\n- 0 \uf0a7\n- 1 \uf0a7\n- 2 \uf0a7\n\n### Exclusion criteria\n\n> ##Clinical trial exclusion criteria\n\n- Age <18 >/= years\n- Weight <60 kg\n- Unable to maintain a consistant dosing regimen of aspirin from the baseline visit to the final visit\n- Unable to comply with all protocol requirements, including study procedures and/or restrictions\n\n- No need of aspirin therapy (81 mg to 325 mg daily) at the time of screening and unable to maintain a consistent aspirin dosing regimen from the baseline visit through the final study visit\n\n- Current prescribed oral thienopyridine therapy, including prasugrel, prasugrel metabolite (RSR1001), or clopidogrel (Plavix); or have received clopidogrel treatment within 7 days postpartum.\n\n- History of current myocardial infarction (MI)\n- Prior history of percutaneous transluminal coronary angioplasty (PTCA), stent, or coronary artery bypass grafting (CABG) coronary artery disease (>/= 50% obstruction) in at least one coronary vessel after angiography - History of coronary artery disease and/or PCI and/or CABG - Left ventricular ejection fraction (LVEF) < 30% as measured by echocardiogram, radionuclide isotope study\n- History of stent thrombosis\n- Incomplete coronary artery bypass graft (CABG) revascularization\n- Uncontrolled hypertension or systolic blood pressure <95 mm Hg\n- Clinically significant bleeding tendency (eg, recurrent bleeding, prolonged bleeding)\n- Concurrently participating in another clinical study\n- History of serious hypersensitivity to RS26694, a thienopyridine (eg, thrombocytopenia; or Stevens-Johnson syndrome)\n- History of unexplained transient neurological disorder or transient ischem",
        "label": 0
    },
    "614": {
        "output": "\u00a9 <NAME>, 24 August 2018\n\n\n\n---\n<a id=\"inst-sectionref4\"></a>\n\n## Table S1\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-1 Instructions  \n**Table S1.1**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-2 Instructions  \n**Table S1.2**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-3 Instructions  \n**Table S1.3**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-4 Instructions  \n**Table S1.4**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n# Table S1 Category-5 Instructions\n**Table S1.5**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.",
        "label": 1
    },
    "615": {
        "output": "__NOTE__: Your task is to assess trial-level eligibility for each patient note. Your task is repeated for each patient and therefore you should fill each line after the patient-level eligibility with the corresponding trial-level eligibility. For example, if patient-level eligibility is 2 for the given patient, this must be recorded as 2) Eligible after Trial-level eligibility. That means, after you filled in both `Trial-level eligibility:\n\n___[IN-1]___` ____[IN-2]___`\n\n___[IN-1]___` ____[IN-2]___`\n\n___[IN-1]___` ____[IN-2]___`\n\n___[IN-1]___` `trial-level eligibility: 2) Eligible.\n___[IN-2]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___ `trial-level eligibility:\n\n___[IN-1]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___` ____[IN-1]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___` `trial-level eligibility:\n\n___[IN-1]___` ____[IN-2]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___` `trial-level eligibility:\n\n___[IN-2]___` `trial-level eligibility: 1) Not relevant.\n\n___[IN-2]___ `trial-level eligibility: 2) Eligible. \n \n__NOTE__: There is no input from patient-level eligibility to patient-level assessment_ or_from _Trial-level eligibility to Trial-level assessment. In your task is repeated 5 times, you should fill the lines after patient-level eligibility `___________[patient-level eligibility]__________()` with trial-level eligibility as `____________[trial",
        "label": 1
    },
    "616": {
        "output": "<EOD> Effect of a proton pump inhibitor, omeprazole, on the development of an alkaline shift of intragastric pH during the weaning of parenteral nutrition\nBackground and objective: The development of an alkaline intragastric pH is a common problem during the weaning of parenteral nutrition (PN) and the use of proton pump inhibitors (PPI) has been suggested as a possible solution. In this study, we evaluated the effect of omeprazole treatment on the development of an alkaline shift of intragastric pH (\u22657.4) during weaning. Methods: Between 1 April 1996 and 1 August 1999, we analyzed consecutive patients who received PN and were weaned without omeprazole in our Nutrition Support Service. This group was named historical controls. Between 7 September 1999 and 30 April 2003, we used omeprazole to prevent the development of an alkaline shift during the weaning of PN patients in three different studies, and this group of patients was named as being treated with omeprazole. The percentage of patients with gastroesophageal reflux disease (GERD) before starting the PN, and the duration of PN, were compared in the two series. Results: Overall, a total of 93 patients were considered. Fifty-three were in the control group and 40 were in the omeprazole group. In the control group, 27 patients (50.95%) showed a significant alkaline shift within the first week of weaning. In the treatment group 11 patients (27.5%) showed it. The two groups were statistically significantly different (P < 0.028). On the other hand, no statistical difference was found with regard to the percentage of patients with GERD. The duration of PN was longer in the omeprazole group than in the control group. Conclusions: Omeprazole is helpful in preventing the development of an alkaline shift during the weaning of PN.<EOD> Correlation between serum prostate-specific antigen and bone formation rate in hemod",
        "label": 0
    },
    "617": {
        "output": "Let's solve the first one. Who is the target population of the clinical trial?\nThe primary efficacy endpoint is the percent of subjects having either seroconversion (a 4-fold or greater rise of hemagglutination inhibition titer from prevaccination to Day 32 or Day 39, whichever was greater) or a neutralizing antibody titer of at least 160 at Day 32 or Day 39 (whichever was earlier) following vaccination.\nPeople with the specific type or degree to whom the intervention will be offered.\nThus, the target population of the listed trial can apply to children and adolescents aged 6 months through to <18 years who had a previous episode of influenza-like illness (disease characterized by fever, myalgia, headaches, and other non-specific symptoms) in the season preceding vaccination.\nThe second one is quite different from the above one:\nThe efficacy and safety endpoints for this group were:\nSerological response, defined as postimmunization hemagglutination-inhibition titers \u226580 at day 42 compared to pre-immunization titers (primary endpoint).\nClinical efficacy endpoint defined as the % of subjects having a confirmed influenza infection from day 1 to 28 postvaccination.\nClinical efficacy:\n\nThere would be a lot of similar situations in clinical trials\nSo, you should get used to think that the target population may be allergic people, elderly people, and pediatric patients. In general, there is no rule about who your target population is as you should choose and it varies case by case (even in the same trial)\n\nFor your training, you should come up with some answers about the last question. You will be graded on these answers. Your goal is to apply the concepts learned in this block to the clinical trial design. \nQuestion: Please explain the target population of this clinical trial. \nAnswer:\nAs you may know, the target population of the trial is people with a previous episode of influenza-like illness (disease characterized by fever, myalgia, headaches, and other non-specific symptoms) in the season preceding",
        "label": 0
    },
    "618": {
        "output": "# Author contributions\nSunghee Han and Michael Mordasini were involved in the development of the algorithm and implementation of the methodology to the problem and have made substantial contributions to drafting the manuscript. Hyun-Hee Cho provided assistance with implementation of the algorithm.\nMichael Mordasini - University of California, San Diego and University of Texas, Houston, San Diego, CA, USA\n\n# Financial Disclosure\nNothing to disclose.\n\n# Competing interests and funding\nNothing to disclose.\n<EOD> Bone Marrow Adipocytic Changes in Response to Estradiol or Estrone and Inhibition by Androstenediols in a Mouse Model of Fracture Repair\nAdult human bone marrow contains a subset of adipocytes, called marrow adipocytes (MAs), that can be identified immuno histochemically as a positive stain with fat droplets. Fat-cell density is known to correlate directly with age (e.g., obesity) and inversely with bone density, suggesting a relationship between fat and marrow in adult bone. To test the role of sex hormones on the development of marrow adipogenesis, we examined the response of bone marrow fat cells during fracture healing in mice. We found that bone marrow fat (BMA) increased significantly within 2 days after fracture. The amount of BMA increased with time and was maintained at a high level for at least 1 week. A similar increase was observed in ovariectomized (OVX) mice, suggesting that hormonal factors other than the estrogen hormone may be involved in BMA development in this fracture mouse model. To specifically determine the role of androgen in the bone marrow adipocyte development, we used the same fracture injury model and examined the effects of androgen in combination with estrogens. Addition of dihydrotestosterone  or dihydrotestosterone propionate (10 to 100 \u03bcg/mouse/day, subcutaneously) to ovariectomized mice injected with both estradiol (250 ng/mouse/day, subcutaneously) and estrone (0",
        "label": 0
    },
    "619": {
        "output": "#### Solution 1 \n## Solution 1:\n`Trial-level eligibility: 1) Elapsed time: Eligible.;` `Trial-level eligibility: 2) Patient status: Not relevant.;` `Trial-level eligibility: 3) Inclusion criteria: Yes.;` `Trial-level eligibility: 4) Evaluation criteria: Evaluation is in progress.;` \n\n### [INST]\n## Solution 2\n## Solution 2:\n`Trial-level eligibility: 1) Elapsed time: Eligible.;` `Trial-level eligibility: 2) Patient status:\nPatient met all inclusion criteria, but has not yet been evaluated for eligibility based on exclusion criteria.` `Trial-level eligibility: 3) Inclusion criteria:\nYes.;` `Trial-level eligibility: 4) Evaluation criteria: Evaluation is in progress.`\n\n\n## Instruction\nI will show you the best solution for this problem using a programming method. \n\n**Solution:** You will write the following code to solve this problem: \n```\nclass Solution:\n    def decidePatientEligibility(self, patient_note: str, trial: str):\n        if patient_note[0].isdigit():\n            return False #0\n        else:\n            if len(patient_note) == 3:\n                if patient_note[1] == 'E':\n                    return False #2\n            else:\n                if patient_note[1] == 'D':\n                    return False #2\n            else:\n                if patient_note[1].isdigit() and patient_note[2] == '1':\n                    return True #1\n                else:\n                    if patient_note.rfind(patient_note[1]) == 2:\n                        return False #3\n                    else:\n                        if patient_note[1",
        "label": 0
    },
    "620": {
        "output": "You can see the above sample results using the `CSV Export` and copy and paste this JSON file into the console of your web browser, as shown in Figure 52. The code in the console outputs a data frame. \n[{\"Examiner\":19087},{\"Patient\":851},{\"InclusionCriteria\":0.0},{\"EvaluationCategory\":1.0,\"scale\":2.0,\"triallevelEligibility\":2.0}]\n\n### Exercise\n\n\nUse the example, complete a JSON-encoded string in the console below.\n\nNote:\nWhen you copy the JSON in the console, you change the type attribute of the object to `string`.\n\n> {\n> \"Patient\": 851,\n> \"InclusionCriteria\": 0.0,\n> \"EvaluationCategory\": 1.0,\n> \"scale\": 2.0,\n> \"triallevelEligibility\": 2.0\n> }\n\n[0] {\n    Patient: 851\n    InclusionCriteria: 0.0\n    EvaluationCategory: 1.0\n    scale: 2.0\n    triallevelEligibility: 2.0\n}\n[1] {\n    Patient: 19087\n    InclusionCriteria: 0.0\n    EvaluationCategory: 1.0\n    scale: 2.0\n    triallevelEligibility: 2.0\n}\n\n### Solution\n\n\nA: You have to encode the value yourself.\n> \n\"Patient\": 851,\n\"InclusionCriteria\": 0.0,\n\"EvaluationCategory\": 1.0,\n\"scale\": 2.0,\n\"triallevelEligibility\": 2.0\n\n<EOD> .\nThis article presents a reflection about the relationship of work and health of medical physicists in the field of cancer. The objective is to present the situation of the professionals and suggest possibilities to improve it. A descriptive study with the use of a survey was carried out with 23 medical physicists in the field of cancer of the state of Rio de Janeiro. The results show that there are problems related",
        "label": 1
    },
    "621": {
        "output": "[/TUTORIAL]<EOD> Effects of acute and chronic administration of nandrolone on prostate gland and sex accessory organs of the rat testes.\nEffects of 10, 15 and 20 days acute and chronic (10, 20 and 25 mg/kg body weight injected subcutaneously thrice a week for 30 days) administration of nandrolone on the morphology of rat prostate gland and sexual accessory organs were studied. In all the animal groups morphological alterations of the organs examined included: (1) degeneration and necrosis of the tubular epithelial cells, (2) hypertrophy of the Leydig cells, (3) decrease in the numbers of spermatogonia, primary spermatocytes and spermatids, (4) disintegration of the tubular framework, and (5) degeneration and necrosis of the myoid cells. However, degenerative and necrotic changes were less pronounced after chronic administration of nandrolone. These findings were consistent with the fact of reduced effects on the organs after repeated dose administration as compared to those observed on acute administration. The results obtained have shown that chronic nandrolone injection had no adverse effect on the morphology of the rat sexual accessory organs.<EOD> A systematic review on safety and efficacy of oral sodium nitrite as phosphodiesterase-5 inhibitor with respect to erectile dysfunction in men.\nINTRODUCTION\nErectile dysfunction (ED) is the inability to achieve and maintain an erection for satisfactory intercourse; many effective treatment options with satisfactory results are now available and one among them is oral sodium nitrite. This study aims to assess the efficacy and safety of orally administered sodium nitrite for erectile dysfunction.\n\n\nMETHODS\nStudies involving clinical use of oral sodium nitrite for erectile dysfunction were analyzed using both qualitative and quantitative methods.\n\n\nRESULTS\nOut of 85 studies retrieved, which were subsequently shortlisted, only 8 studies were included in this study out of which",
        "label": 1
    },
    "622": {
        "output": "__HINT__\nYou should always start with a blank line before the lines with the results or comments.\n\n\n\n__Explanation__\nAs you can see, you are presented with a patient note and a clinical trial. On the patient note, we extract the following features: age (46), family history of CAD (Y), physical activity (Y), HDL (53 mg/dL), LDL-C (545 mg/dL), fasting glucose (85 mG/dL), high cholesterol (Y), blood pressure (210/140 mmHg), and smoking habit (Y). On the clinical trial, we extract its title (The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients), summary (Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) offers improved tolerability, supporting a simplified 1-2 g dosing paradigm and improved adherence. Statins and niacin improve endothelial function in cardiac patients, however, there is no data yet regarding the additive effects of raising HDL-C by ERN/LRPT and statins on endothelial function in cardiac patients. Thus the aim of the present study is to evaluate the impact of 3 months' administration of ERN/LRPT compared to placebo added to statins on endothelial function, assessed by brachial artery vasoreactivity in stable cardiac patients), and the inclusion criteria (Male or female \u2265 18 years; signed informed consent, Outpatient CAD patients on statin therapy. HDL-C < 40 mg/dL in males and < 50 mg/dL females. left ventricular (LV) systolic dysfunction \u2265 40% measured within the past 6 months. No changes in cardiac medications during 2 weeks prior to enrollment.presents",
        "label": 1
    },
    "623": {
        "output": "The patient-level eligibility statement is `patient-level eligibility: Eligible`, which refers to whether the patient meets the inclusion/exclusion criteria or not. \n\n```\npatient-level eligibility: Excluded;\npatient-level eligibility: Not relevant;\npatient-level eligibility: Eligible.\n```\n\n### TIPS\n\n* The only one eligibility is `patient-level eligibility: Eligible`, which is executed after the `Trial-level eligibility` statement. This statement appears in the last line by the use of `;;` command. \n\n* The patient-level eligibility statement is executed after the `summary` statement, not the `patients` statement. \n\n* The attributes extracted in the `summary` statement are used in the patient-level eligibility statement. \n\n* The `patient-level eligibility: Excluded;` statement has the same meaning as the `;#excluded` statement in Section 02.2.3.\n\n* The `patient-level eligibility: Not relevant;` statement has the same meaning as the `;#notrelevant` statement in Section 02.2.3.\n\n* Some fields in the original CSV file need to be processed when writing to CSV files or EXCEL files (see \n\n```\ndata = Table.inferred(pdat, trial.ID)\n\nfor patient in trial.trial_subjects do\n  df = {}\n  for key, value in pdat[tri",
        "label": 1
    },
    "624": {
        "output": "<EOD> A model for the relationship of preoperative anxiety to outcome measures in children undergoing strabismus surgery.\nPrevious research demonstrated the validity of the State-Trait Anxiety Inventory in children undergoing strabismus surgery, but the results suggested the occurrence of a unique anxiety response in these patients. The authors hypothesized that the unique anxiety was due to the surgical setting itself. Consequently, a model consisting of four factors was created. The first two represented preoperative anxiety as a state and as a trait, with the latter reflecting the \"average\" anxiety level in the general population of children. The third and fourth factors represented the influence of the postoperative environment (e.g., stress) and the degree of depression as a reaction to the surgical procedure. Confirmatory factor analysis of preoperative anxiety was performed on a sample of 103 children. A six-item scale was created with satisfactory reliability and validity. As predicted, the model suggested a strong effect of the environmental environment on children's preoperative anxiety and a weaker main effect due to surgery itself.<EOD> Genetic Variation at the Serotonin Transporter Gene Modulates Attentional Bias Following Trauma Exposure\n\nPost-traumatic Stress Disorder (PTSD) is characterized by heightened arousal, hypervigilance, exaggerated startle response, and attentional avoidance of traumarelated cues and is often associated with maladaptive behavioral patterns. Previous research implicates serotonin neurotransmission in post-traumatic hypervigilance and attentional bias (AB) towards threat, but its role in attentional avoidance following trauma exposure has not been assessed. This study aimed to test, first, whether the behavioral consequences of trauma exposure differ in individuals homozygous for the long (L) or short (S) allele of the serotonin transporter gene linked polymorphic region (5-HTTLPR), and secondly, whether this polymorphism is associated with differential AB. Forty university women undertook the Trier Social Stress Test, followed by the emotional Stroop task (EST), while their reaction time and error rates to the incongruent trials",
        "label": 1
    },
    "625": {
        "output": "## Trial-level eligibility\n\n``` r\nTrial-level eligibility\n```\n\n### [INST]\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. here is the clinical trial: \nTitle: Adapt Monorail Carotid Stent System: A Postmarket Clinical Follow-up Study\n\n\nSummary: The purpose of this study is to get outcomes data for the Adapt Monorail Car",
        "label": 1
    },
    "626": {
        "output": "Tedium Vindicum!\n\nIn the following notebook, you will learn how to visualize these assessment procedures and patient notes into a dashboard.\n\n---\n\n**RUN**:  \n```\njupyter-notebook assessment-patient.ipynb\n\nRUN: \n- cd /Users/kostas/notebooks/Assessment\n- jupyter-notebook patient-notes.ipynb\n- jupyter-notebook assessment-patient.ipynb\n```\n\n**PLAY**:  \n```\ncd {working path}/Tutorials\n```\n\n![](Tutorials/jupyter-notebook-in-play-cell.png){:style=\"width:300px; height:600px;\"}\n\n\n<EOD> Molecular genetics of the human cytidine deaminase gene\nIn order to study the structure and the molecular basis of mutations responsible for deficiency of human cytidine deaminase (CDA), we determined the nucleotide sequence of the entire gene. Analysis of this 6544 bp sequence revealed 9 exons with typical exon-intron boundaries, and 5 distinct RNA transcription units; exon size ranges from 97 to 141 bp. These results indicate that the gene contains at least nine distinct RNA transcription initiation sites and, consequently, nine distinct cytidine deaminase isoforms. Each transcription unit can be transcribed either in the sense or in the antisense direction at the same locus. Examination of the 5'UTR revealed the presence of potential binding sites for many transcription factors related to the cytidine deaminase gene expression, and the lack of any potential transcription stop signals which would block transcription from the unique promoter located in exon 1.<EOD> Changes in the Rate of Thymidine Kinetics in Regenerating Bone In Vivo\nSummary To evaluate whether alterations in the rate of thymidine kinase phosphorylation during regeneration of the rat tibia reflect differences in growth rate, 12-mm tibial segments were obtained from Sprague-Dawley rats and were implanted into the legs",
        "label": 0
    },
    "627": {
        "output": "[TESTCASES] 4\n[/TESTCASES].\n<EOD> Incorporation of Cryptococcus neoformans genome-wide transcriptional data into antifungal susceptibility profile predictor\n\nBackground: Increasing global prevalence of antifungal drug resistance and susceptibility profile discrepancies have highlighted the need to develop improved antifungal susceptibility testing and monitoring methods. Predictive modeling approaches can supplement phenotypic susceptibility testing. Methods: We developed and tested an Antifungal Susceptibility Profile Predictor (ASPP) approach based on machine learning to predict susceptibility profiles from molecular data for the pathogenic yeast C. neoformans. The training set included 249 isolates from 33 states in the United States. The test set included 79 isolates obtained from various sources across the world. Prediction models in ASPP were developed using genome-wide transcriptional data derived from a published microarray dataset (GSE67312). Genome-wide transcriptional data generated from independent experiments were treated as an external validation set. The prediction models from training set were applied to the external validation set of 79 diverse isolates. The prediction of \"resistant\", \"susceptible-dose dependent\", \"susceptible\" profile was based on the minimum resistance profile. Results: Both the genome and transcriptome-based models had high prediction accuracy in training data (>95%). All the prediction models in ASPP showed better performance compared to the previously developed in silico models. They discerned drug resistance profiles with 100% prediction accuracy of resistant and 92.5% prediction accuracy of susceptible, and susceptible-dose dependent profiles from external validation set. Overall, ASPP provided better prediction results under unseen experimental data, which was evaluated using prediction accuracy, sensitivity, specificity and area under precisionrecall curve (AUC-PRC).Conclusions: We have demonstrated the usefulness of a genome and transcriptome-based ASPP approach in drug susceptibility profiling that may provide useful complementary data for clinical trials of antifungal therapy. This ASPP model may offer a convenient tool to test novel antifungal compounds and",
        "label": 1
    },
    "628": {
        "output": "# ClinTrial.pl Clinical Trial Assessment Protocol\nThis topic explains the Clinial Trial Assessment Protocol file. The Clinial Trial Assessment Protocol file stores the eligibility assessment of patients for clinical trials. The file is created by `ClinTrial.create`. The file must be created for each clinical trial protocol. For example, let's create a new file for a new clinical trial protocol: \n$ ClinTrial create\nNote: You should see a new blank Clinial Trial Assessment Protocol file in the user folder.\nAs you know, each trial-level assessment of eligibility is stored in a field. The first line of the Clinial Trial Assessment Protocol file stores the trial-level eligibility. In this example, the trial-level eligibility is `0). The subsequent lines of the Clinial Trial Assessment Protocol file store the eligibility of patients based on the following factors: `Gender: male',`Gender: female',`Disease status: diagnosed',`Disease status: not diagnosed',`Disease description: non-cancer',`Disease description: cancer',`Family history: yes',`Family history: no',`Family history description: positive',`Lifestyle: smoker',`Lifestyle: non-smoker',`Body mass index (kg/m2): 10',`Drug usage: yes',`Drug usage: no',`Drug description: statin',`Drug description: antiplatelet',`Drug description: lipid',`Drug description: antihypertensive',`Disease history: yes',`Disease history: no',`Alcohol abuse: yes',`Alcohol abuse: no',`Alcohol abuse description: drinker',`Drug history: yes',`Drug history: no',`Drug history description: use',`Race: Asian',`Race: other',`Race description: not white' and so on. If several patients are the same, the Clinial Trial Assessment Protocol file repeats the trial-level eligibility of patients based on gender, e.g., `$ cat trial_1",
        "label": 1
    },
    "629": {
        "output": "<EOD> .\nThe authors report a case of osteosarcoma in a 4-years-old boy, of his history, diagnosis and treatment. The prognosis associated with bone sarcoma is of great importance. The Authors underlie the important role of chemotherapy in these patients.<EOD> The Clinician\nPurpose: The objective is to describe the results of a projected to examine the influence of one particular physician on colleagues and patients in a small clinic. In addition, the authors intend to show that the clinician's function can be viewed and modeled with specific variables. Method: The authors gathered data from a questionnaire distributed to six physician colleagues of an oncologist who died in a car accident. The instrument measured the clinician's ability to encourage participation and maintain independence, his ability to provide structure and stimulate productivity and efficiency, his ability to assist subordinates in delegating responsibility, his ability to encourage innovation, his attitude toward the family and support system, and his overall performance as a Clinician. In addition, the family, his immediate colleagues, and other staff were allowed to comment on the deceased doctor's traits and work habits. Results: Respondents indicated the deceased doctor was better than peers at encouraging participation in discussions, setting goals, providing feedback, maintaining autonomy, providing structure and stimulating efficiency. Conclusion: The results of this study showed that a physician's ability to assist with delegation may play an important role in his effect with others.<EOD> Clinical evaluation of the performance of the LC200-Xpert HCV point of care and LC-FORT assays\nSUMMARY PCR-based HCV diagnostic tests could improve early-stage detection. In this study, we evaluated three test systems that provide detection of HCV genome by reverse transcription and the viral load by real-time PCR: the AmpliSens HCV R-gene, the COBAS AmpliPrep/COBAS TaqMan HCV and the new LC200-Xpert HCV system. We tested 620 plasma samples to determine the limit of detection of the COBAS system and the genome equivalents detected by the commercial tests. The commercial assays were compared to the COBAS, to H",
        "label": 0
    },
    "630": {
        "output": "[TUTORIAL] The next section is going to show you in Python code how to define a data frame with the patient data. We are going to start with a data frame with one observation. In other words, the data frame is empty. The next section will show you how to create the data frame and how to manipulate the data once you make the data frame.\n\n##### Create an empty data frame<jupyter_code>df = pd.DataFrame()<jupyter_output><empty_output><jupyter_text>Let\u2019s start with a simple patient data. The name of the patient has been changed to `person_code` to make the code more useful and to show you how to manipulate the data. The patient `age is in the fifth decade of life (45-59, 44 years exactly) and the patient has arthritis. The sex of the patient is male and the patient has a family history of coronary artery disease. The LDL-cholesterol and HDL-cholesterol levels of the patient are within normal range. The patient has no medical history of diabetes, hypertension, and smoking, physical activity, and other medical histories. The patient had no use of lipid-lowering medications. The carotid artery stenosis is estimated to be 98%. The patient has a bulky plate in the internal coronary artery of the left carotid artery and a 2 mm echogenic nodule, which is associated with the left carotid artery. The internal coronary arteries of the patient have several small echolucent patches.  For LICA, PSV and EDV cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively. LICA plaque was not a bulky plate but had a small patch and a 2-mm hypoechoic nodule, which was an echolucent plaque. The right internal carotid artery of the patient had several small plaques, both bulky and not a bulky plate. The plaque had two patches in the anterior and posterior walls of the left coronary artery. The size of the left coronary artery is about 17 mm. The stenosis is a bul",
        "label": 2
    },
    "631": {
        "output": "<EOD> Phase II randomized controlled trial of an internet-facilitated collaborative problem solving approach for improving coping and life satisfaction among survivors of primary bone sarcoma: results of the CODES trial.\nPURPOSES\nThis double-blind two-armed randomized controlled trial was conducted to evaluate the feasibility and preliminary efficacy of an internet-facilitated collaborative problem solving (CSP) approach to improve coping in a sample of patients diagnosed with primary bone sarcoma (PBS).\n\n\nDESIGN/METHODOLOGY/APPROACH\nTwenty-two participants were randomized into either a treatment group (n = 11) or a waitlist control group (n = 11). The participants engaged in the CSP protocol over a 10-week period and attended three one-hour individual telehealth therapy sessions conducted by a psychologist. Self-reports of coping, disease-related distress and life satisfaction were obtained from each participant at three points across the study; pre-intervention, mid-intervention and post-intervention.\n\n\nFINDINGS\nIn regard to the key objective and hypotheses, CSP participants demonstrated significant increases in cancer coping, reduced disease-related distress and improved life satisfaction over the course of the intervention. Significant improvements in coping and reductions in cancer and disease-related distress achieved at post-intervention did not remain significant when compared with the 10-week waitlist control period. At four-month follow-up, however, those assigned to the treatment group maintained their improvements in coping and continued to display reduced cancer-distress compared to those assigned to the waitlist control group.\n\n\nORIGINALITY/VALUE\nThe findings suggest that the internet-facilitated CSP approach is feasible and effective, at least in the short term, and warrants further evaluation in a larger randomized controlled trial utilizing an active control/placebo group and a longer follow-up evaluation.<EOD> An Easy to Recognize Incorrect Substitution at Position 495 in TNF Binding Domain of TNF (S495C) Alters Bioactivity of Human TNF in THP-1 Cells: A Novel Mutation in TNF Associated with Autoinfl",
        "label": 2
    },
    "632": {
        "output": "You should always repeat the output message by type of trial in the last line or the last lines by `type of trial`, `type of trial 1: `, `type of trial 2: ` by using the Python `f- string`. [INST] \nHere is a simple example:\n\n\n```python\n# Import \"patient.ipynb\" path variable \"path\". \n# Python code begins here.\n# The trial name should begin with \"NINJA-\" in this IPython Notebook. \n# \n# 1) For example, \"NINJA-1\", \"NINJA-1\". \nNINJA-1.text = open('patient.ipynb').read()\n# 2) For example, \"NINJA-1\". \n\nNINJA-1.text = '[0] Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial''s exclusion criteria)'\n# \uff18\uff17\uff0e\u5b9f\u65bd\u8005\uff20\u500b\u4eba\u304c\u7570\u5e38\u8005\u304a\u3088\u3073\u5b9f\u65bd\u8a08\u753b\u306e\u5b58\u7d76\u306b\u3064\u3044\u3066\u3001\u81e8\u5e8a\u7814\u7a76\u5bfe\u8c61\u8005\u306b\u8ca0\u62c5\u3092\u8efd\u6e1b\u3059\u308b\u305f\u3081\u306e\u8981\u52d9\u3092\u8b58\u5225\u3059\u308b\u898f\u7bc4\u306b\u3064\u3044\u3066\uff0c\u7a2e\u3005\u306e\u5b9f\u969b\u7684\u306a\u4e8b\u4f8b\u3092\u63d0\u793a\u3059\u308b\uff0e\u3059\u306a\u308f\u3061\uff0c\u500b\u3005\u306e\u7814\u7a76\u5bfe\u8c61\u8005\u9078\u629e\u7968\u3092\u793a\u3059\u3082\u306e\u3084\uff0c\u9069\u5207\u306a\u6a19\u6e96\u7684\u306a\u52b9\u679c\u91cf\u3068\u6709\u7528\u306a\u691c\u51fa\u91cf\u3092\u793a\u3059\u3082\u306e\uff0c\u60a3\u8005\u306e\u53d7\u3051\u5165\u308c\u306e\u72b6\u6cc1\uff08\u8ca0\u62c5\u306e\u5206\u914d\u3068\u8ca0\u62c5\u306e\u88dc\u6b63\uff09\uff0c\u6700\u5584\u306e\u7a2e\u3005\u306e\u5229\u76ca\u5bfe\u6d88\u3057\u306a\u3069\u3068\u3044\u3046\u4e00\u89a7\u306b\u304a\u3044\u3066\u7bc4\u56f2\u3092\u5e83\u3044\u3082\u306e\uff0c\u7279\u5b9a\u306e\u4eba\u3005\u306e\u80cc\u666f\u3092\u6709\u3057\u3066\u3044\u308b",
        "label": 0
    },
    "633": {
        "output": "## Summary evaluation\nPlease finish the following sentences to get the best grade you can for this exercise. Make it as if you were a patient's assistant looking at a patient's situation and explaining it to a layperson (i.e., a patient who does not know medical jargon and terminology). \n\n1) You are the clinical trial coordinator. Describe how the patient note and the eligible condition of the patient influence the trial evaluation.\n\n> 1_a) The notes help determine if he has a condition in which a drug is being tested, such as the coronary artery disease (CAD), lipid disorders, and high cholesterol level.\n1_b) My evaluation of his medical record is that patient is eligible for this study. He is a 46-year-old man with the complaint of dizziness, and headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus, and he is physically active.\n1_c) Based on his clinical notes, I would refer him to a specialist physician, and request my colleagues to be part of his treatment due to the presence of risk factors of heart disease.\n1_d) I've evaluated his medical records, and there is the likelihood of the efficacy of the treatment, which would be conducted according to his medical records to determine his condition.\n1_e) He is a good candidate of the study; he has the eligibility assessment of the trial, especially in the trial-level and the exclusion criteria assessment.\n\n2) You have a conversation with the patient. Discuss your patient's assessment with the trial-level eligibility results.\n\n> 2_a) Thank you for taking the time to explain to me in more detail the study. Can you please describe, with me, how many visits I would have in order to get results?\n2_b) Your report of a patient with the complaint of dizziness, and headaches is interesting. I would like to hear more about his coronary artery disease (CAD) with high cholesterol, and lipid disorders which would make him a candidate and a good participant based on the trial-",
        "label": 1
    },
    "634": {
        "output": "Please note that we used Python for the clinical note and included a simple Python function for the generation of random numbers, which is also provided in the link below. Please just copy and paste the function to your code without any modification.  [INST]\n\nLink: [instra]<EOD> Effect of pyridoxine supplementation on serum zinc concentration in the young adult male.\nThe study was carried out to determine the effect of pyridoxine supplementation on serum zinc concentration in young adult male. The randomised experimental study was conducted in the Biochemistry Laboratory of Government College University, Faisalabad, Pakistan, from January to July 2012. A total of 70 males were selected and divided into three groups: A, B and C (n= 20 each). Group A control, Group B was given pyridoxine hydrochloride (1mg/kg body weight) by gastric tube daily in empty stomach and Group C was given pyridoxine as Group B with 150 mg Zinc sulfate per day by mouth. Blood was drawn from all the three groups after 15 days of start of study for estimation of serum zinc level and compared by one way analysis of variance (AOVA). The difference between the means of test groups was measured by using Least Significant Difference (LSD) method. Result of comparative analysis revealed that the mean value of serum zinc for Group B (71.11\u03bcgm/ml) was significantly higher as compared with Group A (60.10\u03bcgm/ml) and Group C (58.95\u03bcgm/ml). This study concluded that pyridoxine supplementation with zinc sulfate supplemented serum to zinc level with better bioavailability which may have been due to reduction in degradation of 5'MP.<EOD> Immunotherapy of the elderly.\nImmunotherapy of allergic patients is based on administration of allergen extracts either as subcutaneous immunotherapy (SIT) or via sublingual route (SLIT). Due to the increased frequency of allergic diseases, an escalating incidence of asthma, the growing importance of allergic diseases in terms of",
        "label": 0
    },
    "635": {
        "output": "--Example Solution\nYou can input your own data by modifying the patient's note and the clinical trial's summary. \n\nAsk students to read the following examples of the eligibility assessment.\n\n### 0-Excluded\n\nA 38-year-old woman presents with frequent headaches and dizziness. Her mother had a history of coronary artery disease. The patient reports no use of medications for cholesterol control.\n\nThe patient's lipoproteins were abnormal with elevated triglycerides (271\u2009mg/dL), reduced high-density lipoprotein cholesterol (23\u2009mg/dL), elevated low-density lipoprotein (140\u2009mg/dL) and elevated ApoA1\n\nDue to the presence of elevated LDL cholesterol with low HDL-C and the elevated triglycerides and ApoA1, she is excluded from trial participation.\n\n### 1-Not irrelevant\n\nA 23-year-old man presents with a history of hypertension, hypercholesterolemia and diabetes mellitus. The patient reports no use of medications for cholesterol control.\n\nThe patient's lipoproteins were abnormal with elevated triglycerides (178\u2009mg/dL), elevated low density lipoprotein (120\u2009mg/dL) and elevated Apo A1 (101.545).\n\nElevated Apo A1 is a risk factor for CAD and, based on their lipid profile, he is likely to develop CVD. However, these blood tests are preliminary indications, and the patient should undergo angiography to determine the severity of his atherosclerosis and the presence of CAD.\n\nAfter 2 months of diet and exercise, the patient's LDL (32\u2009mg/dL) was well within normal range, and he entered the trial for lipid-lowering therapy.\n\n### 1-Trial-level eligible\n\nA 58-year-old man presents with a history",
        "label": 1
    },
    "636": {
        "output": "<issue_comment>username_0: - [702_0] Correct [8] \n\n<EOD> Infections and the gonads: a continuing interplay.\nThe review provides information on the current state of knowledge of the interrelationships between the normal human and subhuman primate testis and the various pathogenic microorganisms. Human pathogens (i.e., human and zoonotic viruses, bacteria, fungi, and protozoa) are covered to different degrees. Data on nonpathogenic microorganisms are also included. The relationships between viruses and the gonads are discussed with information on the cellular and tissue sites of virus replication, virus-induced effects, and virus-induced changes in testicular function. Bacteria, protozoa, and fungi are discussed separately with details about bacterial adherence, colonization, and host response.<EOD> Apoptosis induced by human papillomavirus is p53 independent\nThe mechanisms used by the viral papillomavirus (HPV) oncoproteins E6/E7 to alter or modulate cell cycle control are still a matter of debate, although they have been shown to be dependent on both p53 expression and function. This study was undertaken to assess the role of p53 in the alteration of",
        "label": 1
    },
    "637": {
        "output": "[TUTOR_VIDEO 2466361530878316651]\n<commit_msg>Revert ``tut-r1.yaml``<commit_after>import logging\n\nlogger = logging.getLogger(__name__)\nLOGGER = logging.getLogger(__name__)\n\nimport copy\nimport sys\nimport os\n\nimport pandas as pd\nimport numpy as np\nimport yaml\n\nfrom nicta.data.clinical_records.rpy2 import load_file_to_r\n\nfrom ... import DSL\n\nfrom .. import r\nfrom .. import R\n\nfrom ... import rutils as ut\nfrom ... import utils as utils\nfrom .. import dsl\nimport pytest\n\n\nfrom ..converters import convert_test_to_r, convert_r_to_test\n\n\nfrom itertools import chain\nfrom six import json\n\npytest.importorskip(\"geom_t\")\n\n# We use a copy here, as load_* might change the location of file\nTEST_DIR = os.path.join(os.path.dirname(__file__), 'r3')\n\ndef test_r(caplog):\n    \"\"\"Testing DSL from scratch is the ideal.\"\"\"\n    log = utils.get_logger()\n    r.tut(\"r3\", yaml=ut.get_yaml(), file_name=\"testr3.yaml\")\n    log.debug(\"We must return a list\")\n    log.info(\"r.tut\")\n\n    # Test converting from an iterable\n    lorem = [[{\"lorem ipsum\"}]]\n    test_data = convert_test_to_r(lorem).get_results()\n    eq_(len(test_data.testR), 1)\n\n    # Test converting R from the input data\n    # NOTE: the input data here is already a python list\n    # in other cases we could do r.data.get_data().get_results() again.\n    test_data = r.convert_r(lorem)\n    eq_(len(test_data.testR), 1)\n\n    # Test conversion and adding a meta info\n    # If",
        "label": 0
    },
    "638": {
        "output": "##### `xpat_id`\n\nBy giving a unique identifier to patients, we ensure that we are processing the same patient\nwith the same information when we run a program, even with different parameter settings. Each\npatient must have a unique ID. You can give any unique ID as long as the same ID is assigned to\nthe same patient in each iteration, and they will have the same corresponding information.\n\nWhen setting `xpat_id_type`, consider the security of data.\nTo access the patient data, you will need to run an administrative user role `xpat_access` with a\nlist of permission `Xpat_access_per-mission_list` as the scope of running the commands.\nConsider how the patient ID will be unique among the patients you are following. A simple way\nis to generate the unique ID and make the patients in the same clinician have the same ID.\n\n\n\n```console\n$ xpat patient id create test1\n+------------------------+---------------------------------------------------+-------+---\n| Patient ID          | xpat                                                  | Name |\n+------------------------+---------------------------------------------------+-------+---\n| ID_test1              | xpat                                                  | test1 |\n| ID_test2              | xpat                                                  | test2 |\n+------------------------+---------------------------------------------------+-------+---\n```\n\n\n##### `xpat_access`\n\nAfter you set up your patient ID, you need to set the `xpat_access` setting. It can be set\nusing the following parameter. `xpat access`\n\n```console\n$ xpat user set xpat/xpat_access\n+------------------------+---------------------------------------------------+-------+\n| Parameter               | Value                                                | Name |\n+------------------------+---------------------------------------------------+-------+\n| Access                 | list                                                | access |\n| Permissions             | Xpat_access_permission_list                     | Permissions |\n+------------------------+---------------------------------------------------+-------+\n```\n\nList of `Xpat_access_permission_list`\n\n```console\n$ cat examples/xpat/xpat_access/xpat_access.txt\n+------------------------+----------+--------------+\n| ID_ACCESS              | ACCESS   | PERMISSION    |",
        "label": 1
    },
    "639": {
        "output": "Copy and submit your answers here:\n\n## QUIZ\n\nUse `subl` and write the expressions for the following questions. For the sake of convenience, use `s.name<CR>` for the first part and `s.name<CR><CR>` for the second part.\n\n### 1\n\n> Subl(s.name).first <- \"S. Name: \"Subl(s.name .second <- \"I'm going to ask you a few questions about your last physical activity. Please try to answer as accurately as possible.\" Subl(s.name .third <- \"What is the highest temperature you usually reach?\" Subl(s.name .fourth <- \"Is it cold in your home or workplace?\" Subl(s.name .fifth <- \"Do you do any sports or physical activity other than normal daily activities?\" Subl(s .name .sixth <- \"Have you participated in any competitions in the last 3 years?\" Subl(s.name. seventh <- \"Are you a member of the labor union committee?\" Subl(s.name .eighth<- \"Is there a smoker in your household?\" Subl(s.name .ninth <-\"What is your educational background?\" Subl(s.name .tenth -> \"What kind of work do you do?\" <CR> Subl(s.name .eleventh<-\"When did you start practicing your profession?\" Subl(s.name .twelfth <-\"Do you have a baccalaureate's degree or higher?\" <CR> Subl(s.name .thirteenth <-\"Do you exercise more than 30 minutes of physical activity more than twice a week?\" Subl(s.name .fourteenth -> \"Do you live mostly in an urban area?\" <CR> Subl(s.name .fifteenth -> \"Have you received any treatment for chronic disease in the past 10 years?\" Subl(s.name .sixteenth -> \"Have you received treatment in the past 10 years of any other chronic disease?\" Subl(s.name .seventeenth -> \"Have you heard about the health campaigns?\" Subl(s.name .eighteenth -> \"How many times per day do you perform an activity of moderate intensity for at least 30 minutes?\" <CR",
        "label": 1
    },
    "640": {
        "output": "## 3.5.3 Case Study #3: Patients with high risk of stroke from ACS\nThe aim is to predict the risk of stroke using information from a data warehouse. [INST] Hello  Dr.  This is Dr.  who is following you to determine the risk of stroke in patients with a high risk of stroke from ACS. \nIn this analysis and the next ones you should use patient-level to create a table called `Case Study: Patient-level eligibility`, you should first calculate patient-level eligibility by patient ID and then sum these to create a patient-level table. \nFirst, you should find all the patients with ACS with the same diagnosis of ACS. Let's begin with the following query, it returns the diagnosis of NSTEMI in the year 2019:\n[INST] SELECT diagnosis FROM patient_disease WHERE diagnosis = 'acute coronary syndrome (NSTEMI), ' AND year = '2019' [EXCLUDE][INST]\nNow, let's calculate patient-level elgibility based on the following table. All the selected cases are in two clusters with different probabilities of stroke:\n\n### Group\n\nTotal number of patients 0.035\n\n### Group 1\n\nTotal number of patients 0.162\n\n### Group 2\n\nTotal number of patients 0.684\n\nYou need to add information about how many patient have had stroke after having ACS and add these numbers to each row in `Group` and `Group 1`. \nNow you need to convert these values to a percentage:\n\n### Group \n\n\n### Group 1 \n\n### Group 2 \n\n### Group 3 \n\nThe values in Group 2 and Group 3 are the probabilities of stroke after ACS. By summing the probabilities, you then calculate Group Total Eligibility in the `Group Total Eligibility` table. The result should be 0.871. \nYou can see the resulting table in [INST]\nLet's add the average age of Groups 1-3. Group 1 is 75, Group 2 is 62 and Group 3 is 71.",
        "label": 2
    },
    "641": {
        "output": "**Excluding Trial **  \n\n1. Let's choose the patient ID 04113. Exclusion: 04113 is enrolled in the clinical trial with the identifier 030701.  \n\nWe need to exclude this patient from the clinical trial by setting the value for `Exclusion` to the `Trial-level eligibility: 0.`, i. e., `Trial-level eligibility: 0) Excluded`. The last line of the output in Fig. 1 is also changed. \n2. In this case, we should look at the next available patient id: 04114. It would be the second clinical trial, i.e., identifier 030702. Exclusion: 04114 is enrolled in the clinical trials identifier 030701.  \n\nAt this point, we found that the patient 04114 of Clinical trial 030702 is not eligible.\n3. In the next step, we should focus on the clinical trial with the identifier 06017. It is the third clinical trial. Exclusion/Enrollment: 04024 is not enrolled in the clinical trials identifier 06017. `Enrollment` and the lines of the output are also changed.\n4. In the last step, we should focus on the patient 04025 in the last trial. The trial with the identifier 030704 has four eligible patients. Hence, the corresponding row is selected by `Exclusion/Enrollment: 4`. \n\n> Exclusion/Enrollment: 4\n\nWe should choose the patient 04025 in the trial 06017. This patient is excluded from the trial with the identifier 06017. In the last line of the output, `Enrollment` is replaced by `0`. [INST]\n\n\n\n\n\n\n##**Inclusion Trial **  \n\n5. Let's consider the first trial as an example. In this case, we have the identifier 0202. There is only one patient with this identifier. Hence, the",
        "label": 1
    },
    "642": {
        "output": "[CUSTOMIZATION][/CUSTOMIZATION]\n\n# ClinicalTrials.gov, Carotid Stenting in Patients With High Risk Carotid Stenosis (Soft Plaque)(ClinicalTrials.gov)\n- 1 Study Type(s): Protocol/Procedures - 2 Study Phase(s): Experimental - Phase I - 3 Criteria: Inclusion - Exclusion - Race/Ethnicity - Sex - Source of Patients - Pharmacodynamics - Pharmacokinetics - Safety\n- Study Sponsor(s): Drug - Device Combination  - 1 Condition: Stenosis - Carotid - 2 Phenotype: Stenosis - Carotid - Soft - Patients - 3 1-Adult - 2-Age: Adults 18 Years and Older - 3: Not Specified\n- 1- 1: Aged 85 Years and Older - 1- 2: Ages 18 Years to 85 Years\n- 1-Intervention: Interventional\n- 1- 1:  Stenting of Carotid Artery\n- 1- 2:  Percutaneous Carotid Stenting - 1- 3:  Patient - 1- 4:  Elderly - 1- 5:  Adult - 1- 6\n- 1- 3: Percutaneous - 1- 4: Percutaneous Procedure  - 1- 5: Radiographic\n\n# Examples\n<EOD> Increased Nutritional Value of Sucrose on Fertility Outcome and Fertilizing Ability of Thai Native Brown Marbled Catfish (Pangasius larnaudii) from Cultured Ponds in Dry Season\n\nIncreasing the nutritional values of feed ingredients may be a strategy in maximizing fertilizing ability of Pangasius larnaudii spermatozoa and inducing greater fertilization success rates. Our study aimed to investigate different diet inclusion of sucrose as a feed ingredient on semen qualities and fertilization success of P. larnaud",
        "label": 1
    },
    "643": {
        "output": "## Learning Task\n\nThere are 100 patients in the dataset. Every patient is presented with a patient note. Determine the Trial-level eligibility score for this patient-case based on the information provided.\n\n## Instructions:\n\n1. In a computer-assisted form, create an Excel file for the patient notes.\n\n2. Use Excel tables to display all 100 patient notes in one cell. \n3. Provide a Trial-level eligibility for every patient.\n\nIn total, there are 100 patients' records. Each patient has a patient note, which provides information about the individual. The information includes patient age, history of high blood pressure, family history, current cholesterol status, whether the patient has had treatment for high cholesterol, and smoking information. Each patient note will have two columns: The First column is for the assessment of eligibility, 2, the second column is for the corresponding notes. \n\nEach patient is accompanied by a patient note. The patient notes include information about the patient, such as age, history of smoking, history of hypertension, history of diabetes, blood pressure measurements, current cholesterol treatment, family history of CAD, and cardiovascular risk factors. \n\nEach row in the spreadtable corresponds to a patient. Each patient has a separate patient note in the second part of the spreadsheet. If a patient has smoked in the past, the  value of the corresponding Smoking column will equal `True`, otherwise `False`. If a patient has high blood pressure, the value of the corresponding High blood pressure column will be `True`. If the patient's blood pressure is higher than 160/90, it is considered to be hypertension. If a patient has diabetes, the  value of the corresponding Diabetic column will be `True`, otherwise `False`. In the next columns, we see whether the patient had any of the following procedures: Percutaneous Coronary Intervention (PCI),  and Coronary Artery Bypass Graft (CABG). In the final column, there is information about the cardiovascular risks the patient has and the  patient's age.\n\n## Solution:<EOD> Inhibition of bone morphogenetic protein activity in",
        "label": 1
    },
    "644": {
        "output": "[CODE]\nimport numpy as np\nimport pandas as pd\nimport json\nimport io\n\nfrom operator import item\nfrom itertools import chain\n\nfrom pytape.cli.cli import get_cli_arg\nfrom pytape.cli.format import format_arg_type\nfrom pytape.utils.json import get_json\nfrom pytape.utils import read_json\n\n\ndef main():\n    cli_arg = get_cli_arg()\n    data_path = json.loads(cli_arg['data_path'])\n    print(\"The data path is {}.\".format(data_path))\n\n    df1 = pd.read_csv(io.StringIO(data_path)).dropna(axis=1)\n    df1.drop(df1.index[3], inplace=True)\n    df1.drop(df1.index[4], inplace=True)\n    df1 = pd.get_dummies(df1).dropna(axis=1).replace({0: 'other'}).iloc[:13]\n    df1.head()\n    df4 = pd.read_csv(io.StringIO(\"{}.csv\".format(data_path)))\n    df4.select_dummies(columns=[\"D_age_grou\", \"Age\"], how=\"median\")\n    df4.replace(\"Not Relevant\",\"0\"\n    ,inplace=True).replace(1,\"1\")\n    df4[[\"Age\", \"Weight\", \"HTP\", \"D_age_grou\", \"Sex\", \"BMI_grou\", \"Smoke\", \"FH\",\n          \"Chol\", \"TRIG\", \"HDL_C\", \"LDL_C\", \"Syst_bp_grp\", \"DIA_grp\",\n          \"Eye\", \"Ex\", \"IHD\", \"Angina\", \"MI\", \"ASA\", \"Hypertension\",\n          \"Other\", \"LN\"]].head()\n    df = pd.DataFrame([\n        [0, \"0\", \"0\", \"0\", \"1\", \"1\", 0, \"other\", \"0.54\" , \"1.27\", \"46\", \"1\",",
        "label": 1
    },
    "645": {
        "output": "## Extract Data from Database\n\n\n<table border=0 width=100%><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr>\n<tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr>\n<tr><td>&nbsp;</td><td><b>&nbsp;Extract data from database\n</b><br>&nbsp;</td><td>&nbsp;</td><td><b>&nbsp;\n</b><br>&nbsp;</td><td>&nbsp;</td></tr>\n<tr>\n<td>&nbsp;</td><td>\n <pre><code class=\"tex\">&nbsp;extract_study_values($study_filename, $user_id, $patient_user_id);\n </code></pre>\n </td><td>&nbsp;\n\n <pre><code class=\"tex\">  \n&nbsp;$study_id = &quot;80288_001&quot;;\n &nbsp;$user_id = &quot;00000000&quot;; \n &nbsp;$patient_user_id = &quot;00-00-00&quot;;\n&nbsp;if($user_id == 0) {&nbsp;$user_id =&quot;&quot; $user_name &quot;;\n&nbsp;}\n&nbsp;\n&nbsp;echo &quot;\nEligible Patient ID Number: &quot;&nbsp;$patient_user_id &amp;&quot;;",
        "label": 0
    },
    "646": {
        "output": "- If the assessment of eligibility is '0 (excluded)'. [INST]\n    - `Trial-level eligibility: Excluded` [INST]\n      - [PROBLEM\n        #1: Tested patient note in the first line is actually an incorrect answer to the task.\n        #2: Tested note is correctly evaluated, but the clinical trial is incorrectly interpreted with no specific answer to the task.\n        #3: Correct note has no specified answer to the task.\n        #4: Wrong note is evaluated correctly, i.e., the clinical trial is incorrectly interpreted.\n        #5: Unintelligible note.\n      #PROBLEM2: The trial description should clearly describe the trial inclusion and exclusion criteria.\n      #PROBLEM3: If the description contains both inclusion and exclusion criteria, the description should emphasize the criteria that allow a participant to be in the trial.\n      #PROBLEM4: If patient notes are included in the clinical trial, the study inclusion and exclusion criteria should be specified in the patient note.\n      #PROBLEM5: The trial should explicitly state the time period in which the patient note should be prepared following the index procedure.\n      #PROBLEM6: The patient notes should follow the trial inclusion and exclusion criteria.\n      ]\n    - `Trial-level eligibility: Not evaluated. [INST]\n\nLet's implement it as above and continue to the next step.\n\n## Evaluations\nThis task has a total of 7 questions, including 3 questions on the Precision and the rest 4 questions on the Recall. The Recall task can be further categorized into two parts:\n\nThere are a total of 7 questions in the \"RECALL_TYPE\" component on the Recall task. The first three questions pertain solely to the 'ClinicalTrials' component in the answer selection dialog. The remaining four questions pertain exclusively to the 'Patient' component.\nThe first answer selection dialog, which contains the question `What is the trial type?`, will appear when the user clicks the **ClinicalTrials** button. Therefore, we implement three answers to the question `What is the trial type?`. The three answers are as follows:\n\n * Part",
        "label": 1
    },
    "647": {
        "output": "### Exercise 5.3.\nExercise\n\nRequirements:\n\n1. Run the following pipeline:\n```\n# 1st\ngit switch feature  # switch to \"feature/p10\"\n# 2nd - execute command\n# 3rd\ngit pull # upstream\n# 4th - merge into develop\ngit merge develop\n# 5th - run it\npiping-pipelines-and-scripts/pipelines/pipelines/clinical_study_script/run.sh\n# 6th\ngit switch develop  # switch back to \"develop\" again\n```\n\n<EOD> Challenging the Status Quo: Implementation and Improvement of Surgical Pathology Services in a Small, Rural Hospital.\nCONTEXT\n- Pathology laboratories are important providers to hospitals, enabling them to deliver high-quality care to patients. In recent years, many large, well-funded, academic and/or referral laboratories have formed co-management deals with hospitals. Because many rural and/or community hospitals struggle to afford and maintain these services, a unique challenge arises for some laboratories in attempting to remain operational and provide adequate diagnostic services.\n\n\nOBJECTIVE\n- To demonstrate that a small, rural laboratory can become accredited and achieve sufficient compliance with the College of American Pathologists' inspection checklists even before the final reports are released. This will serve the dual purpose of providing adequate service to local hospitals, enabling patients and providers to receive appropriate care, while also demonstrating to other small pathology laboratories what is required to achieve accreditation and how such laboratories can successfully implement strategies to improve compliance.\n\n\nDATA SOURCES\n- This is a laboratory management case study for a small, rural pathology laboratory with an internal pathology quality management system.\n\n\nCONCLUSIONS\n- Small, rural pathology laboratories can improve the effectiveness of their quality management systems by (a) utilizing all available pathology management experts on site, (b) creating standardized templates for",
        "label": 1
    },
    "648": {
        "output": "## Examples of patient note\n\n![INST]\n\n## Examples of clinical trial\n\n![INST]\n\n## Tips\n\nIt's important to remember that you need to write these in two places: the patient note and in your data collection form. It is recommended to complete the form when the patient enters the trial as the data provided will assist clinicians in monitoring the patient during the trial.\n\n![INST]\n\n\n## Testing your Trial Management System\n\n![INST]\n\n### First Step: Install the required libraries\n- `sudo apt-get install python2.7 libpython2.7 libpython2.7-dev libreadline-dev` (Ubuntu 16.04)\n- `mkdir ~/.config`\n- `chown readline ~/.config`\n- `chmod 755 ~/.config`\n- `mkdir ~/.config/python`\n- `chown readline ~/.config/python`\n- `chmod 755 ~/.config/python/python`\n\n```bash\npip install pandas libimap4 libxml2 libsqlite3 libxml2-dev libdate- time-perl openpyxl sqlite3\n```\n\n### Second Step: Prepare your data file\n\nCreate a python3.6 script and fill in the following variables:\n\nVarious variables are provided with instructions, if necessary. For example, patient identifier can be `01`, sample number can be 10, and trial ID can be `MX11-108411`.\n\nPlease note that the patient identifier should be unique. It must not contain spaces and must only contain numbers (no special characters). The sample number also must not contain spaces and must only contain numbers (no special characters). The trial identifier should not be identical to the patient identifier.\n\n- patient identifier 14 is invalid as it contains a space\n- sample number 1 is invalid because it contains a space\n- trial identifier 4373147 is invalid",
        "label": 1
    },
    "649": {
        "output": "[/POP]\n\n## [PROOF]\nLet's think step by step.\n\n\n[//BEGIN-SCOPE]\n[PROCEDURE] Clinical Trial Recruitment Assistant.\n\n```mercury\n{\n    \"name\": \"clinical_trial_recruitment_assistant\",\n    \"definition\": \"[0,1] \u2192 [0,1]\",\n    \"inputs\": [\n        \"Trial\"\n    ],\n    \"outputs\": [\n        \"Trialleveleligibility(Trial)\"\n    ],\n    \"description\": [\n        \"This is the stepwise procedure for the decision making of Trial-level eligibility.\",\n        \"First, you should retrieve the factor values of the patient for the patient note. There are 2 steps.\",\n        \"First Step: You should retrieve the factor values between the patient and each clinical trial.\",\n        \"Second Step: You should retrieve the average of factor values of the patient on each factor in the current clinical trial.\",\n        \"Now, you should make a trial-level eligibility on each patient for the clinical trial. For example, if the patient has a value of 2 for factor X, you should set `Trialleveleligibility(Trial) = 2` (Excluded) by `Trial-leveleligibility(Trial) = 0` (Not relevant) if the patient does not meet the criteria of the trial. Otherwise, you should set `Trial-leveleligibility(Trial) = 1` (Eligible).\"\n    ],\n    \"parameters\": [\n        {\n            \"name\": \"Trial\",\n            \"description\": \"This is a clinical trial.\"\n        }\n    ]\n}\n```\n\n\n\n[//END-SCOPE]\n\nAs I said, the function definition may not be complete for a machine learning researcher yet, although he or she can implement the function definition using python code and train machine learning models by the function definition easily. As an example, I provide the example of how to implement [clinical_trial_recruitment_assistant] by the python code. \n\n```python\n\"\"\"\nThis is an example of how to implement [clinical",
        "label": 1
    },
    "650": {
        "output": "[/STEP]\n\n<h3>\nStep 2: Focal-level eligibility\n\nFocal-level eligibility for a patient is the assessment of eligibility for the inclusion criterion(s) that appear(s) in the note, as shown in the example below:\n\n```\nAssessment of eligibility in patient: ` 0) Excluded.\n 1) Not relevant.\n 2) Eligible.  `\n``` \n\nThe assessment result for a particular patient is outputted by the `trial-level eligibility` argument. \nNote that note_ids are needed to form the patient-list.\n```python\ndata_df = pd.DataFrame(np.vstack([\n    pd.DataFrame(np.vstack([\"Assessment of eligibility: 0) Excluded.\", \" Assessment of eligibility: 1) Not relevant.\", \"Assessment of eligibility: 2) Eligible.\"], column=\"assessment\"),\n                index=[\"note_id_1\", \"note_id_2\", \"note_id_3\"]), columns=[\"assessment\"])\n\n```\n\n```python\nfvc_df = pd.DataFrame(np.vstack([\n    pd.DataFrame(\n        np.vstack([\n            pd.DataFrame([\n                {\n                    \"note_id\": NoteIDClinicalNote2,\n                    \"trial-level_eligibility\":\n                        {\"title\": \"Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)\",\n                         \"summary\": \"In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below.\",\n                         \"patient_age\": \"54-year-old man presents with dizziness and frequent headaches\", # 46\n                         \"patient_gender\": \"M\",\n                         \"patient_smoking\": \"20 pack-years\",\n                         \"cardiovascular_risk_factor\": \"Family history of cerebral artery disease",
        "label": 1
    },
    "651": {
        "output": "###### Examples:\n* In the above clinical trial, it turned out that the patient was eligible for this trial. Since patient no. 1 satisfies the `Trial-level eligibility: ` in the patient no. 1, eligible appears on the end of trial 1.\n* patient 2 satisfies the triplet of `subject`, `46`, and `man`. There is no LDL-C, only HDL-C < 45 mg/dL. So the eligible appears on the end.\n* since the `subject`, `45`, is the last subject no. 3 to satisfy the `Trial-level eligibility: 1) Not relevant (Not relevant).`; it satisfies the requirement of Not relevant.\n* patient 7 is 50 years old which is not younger than `50 years old.` It is true that `Age: 59` is an exclusion criterion, but the `age:` is not required to match the criteria, e.g., it is sufficient to input only 50 and not 59. So, 0 means `Excluded` by default. \nLet's look at the eligible patients (patients 1 and 2). Which patient is the best candidate for the trial to conducting. \n\n### [EXERCISE] Part 3: Recruiting for a clinical trial<EOD> Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms in men in the general US population based on a large cross-sectional community-based survey 2021-2022.\nINTRODUCTION\nDespite the recognition of overactive bladder (OAB) and other lower urinary tract symptoms (LUTS) as prevalent conditions, there continues to be a paucity of data on their prevalence, particularly among US men and their associated risk factors and co-morbidities.\n\n\nMATERIALS AND METHODS\nThe National Men's Health Foundation and Porter Novelli conducted telephone surveys of 2,000 men aged 16 to 69 years. The survey explored the impact of urinary incontinence on health-related quality of life. Frequency of",
        "label": 1
    },
    "652": {
        "output": "[QUESTION 2] Hello. You are a hospital cashier. You are in charge of accepting payments from patients. You should always calculate the total payment amount. Please write the total payment amount into the calculator.\n\n```\n%i %t\n```\n\nOutput: Total payment amount\n\nYou are going to make the following inputs:\n\n\n**Input:** The cashier is given in the note\n\n**Output:** The total payment amount.\n\nLet's think step by step. \nFirst, you should accept the given note to the dollar sign, and store the output of the dollar symbol in `dollar_symbol` variable, e.g., `dollar_symbol = dollar()`.\nThen you should get the input of the note by `note = input()`. You are going to receive the total payment amount. Let's calculate the total payment amount, e.g., `total payment = total payment + note` and store the value to `total_payment`.\nFinally, you should always repeat Total payment in the last line by `Total payment`. [/Q2]\n\n\n__Instructions__\n\n[QUESTION 1](#q1) Hello. You are working as an insurance broker for a company that specializes in travel insurance plans for students of international universities coming to study in the Netherlands. The company offers a unique package of insurance for students and requires them to present a visa to receive this insurance. For the visa, a bank transfer is required in addition to the regular fees paid to the university.\nIn the insurance market, travel insurance and visas are considered a package and therefore cannot be obtained separately.\nFor visa insurance to be issued by the company, several conditions must be met. One is that the student must be over 18 years of age. Since, by definition, the university must accept the student for the course of study according to the relevant laws, the university name must be registered in the student registration file.\nA third condition is that the university must require the student to submit the visa application together with the registration application.\n\nYour job is to find students who meet all the conditions for the visa application. Please check the necessary conditions below.\n\n**Conditions:**\nThe university must:\n\n* Be listed in the universities provided by the company in",
        "label": 1
    },
    "653": {
        "output": "<EOD> Risk Assessment Including Individual and Social Factors for Dental Fluorosis and Reliability of the Index Used for Dental Fluorosis\nThis paper seeks to present the main findings of the risk assessment on dental fluorosis in Brazil by 456 municipalities throughout the country. Besides the individual characteristics of communities like drinking water fluoridation level, geographic area and type of community, the social factors such as socioeconomic index and schooling level have been analyzed, considering the risk factor levels of the local municipalities. The reliability and reliability of two dental fluorosis indexes was also evaluated. Dental fluorosis is prevalent in Brazil and it is associated with the availability of fluoride in drinking water, schooling level, social conditions and geographic area of the communities. Also, dental fluorosis indexes showed high inter-examiner and intra-examiner reliability.<EOD> Prognostic value of serum levels of S100B and neuron specific enolase in patients with primary intracerebral hemorrhage due to hypertension and intracerebral hemorrhage due to amyloid angiopathy\nSerum levels of neuron specific enolase (NSE) and S100 were observed in 17 patients with primary intracerebral hemorrhage due to hypertension (PICH) and in 15 patients with primary intracerebral hemorrhage due to amyloid angiopathy (PICHa). The purpose was to examine the relationship between the initial serum levels of NSE and S100 and the functional outcome after intracerebral hemorrhage (ICH) in PICH and PICHa patients. At admission, NSE was elevated (above 20 ng/ml) in six patients from the PICH group and in three patients from the PICHa group. Serum S100 was elevated in 14 patients and eight patients from the PICH and PICHa group, respectively, and was always combined with elevated NSE. After hospitalization, NSE was elevated in four patients from the PICH and in two patients from the PICHa group. Ser",
        "label": 1
    },
    "654": {
        "output": "##[/MC_QUESTION]\n\n\n## 6) _______________________________________________________________________________________________________________________\n[INST] You are a senior bioinformatics specialist for clinical research company. It is your main task to set up an infrastructure for data analysis to support research projects. A big research project requires many different statistical analyses, so you have been asked by the project manager to set up a data analysis for the project.\n\nYou plan to use the CERES toolbox. The CERES data analysis is run using the SPM12 software. The CERES toolbox offers several SPM12 data analysis pipelines, such as the General Linear Model (GLM) pipeline. This analysis pipeline fits a statistical model on SPM. You set up different SPM12 pipelines that analyze different components of a brain image. You name these pipelines GLM_T1w, GLM_DWI, and EEG_EPI. Let's assume that the project managers have written a specification document. They asked you to provide a data analysis framework to support their research project. \nThe research group that will work with the CERES toolbox is the group of the Department of Neurology of the University Medical Center Hamburg-Eppendorf (UKE). The project manager of the research group is Dr. P. Zihl.\nWhen starting the project, your tasks include preparing for the acquisition of MRI and EEG data. You are currently in the phase of implementing and automating the data acquisition pipelines. The data acquisition pipeline consists of the following four steps:\n1. Initialization of the MRI system.\n2. Sending an MRI scan of a study participant.\n3. Recording EEG data (for the data acquisition pipeline this is not mandatory, i.e., it might be skipped if required).\n4. Closing the MRI system.\nYou will also need to write reports and documentation for all pipelines.\n\nHere are the MRI and EEG data analysis pipelines that you plan to set up for research data analysis. They are numbered sequentially.\n\n1. MRI: GLM_T1w (the pipeline for the general linear model analysis of T1-weighted data) The GLM_T1w pipeline estimates the size of the GM and WM",
        "label": 1
    },
    "655": {
        "output": "## 4. If your answer: \u201cIneligible because of a disease severity\u201d.\nFirst, think about the severity of disease. There are two types of disease severity which are: \u201cMild\u201d and \u201cSevere\u201d. \n\n*1. Mild: Any degree of stenosis of one or more segments of the internal carotid artery.\n\n*2. Severe:\n\n> Severe stenosis of 70% or greater in one or more segments of the internal carotid artery.\n\nIf the severity of the disease is \u201cMild\u201d, the patient is eligible. After that, if the answer is \u201cIneligible because of non-diagnostic ultrasound\u201d, you should answer this question like \u201cIneligible because of non-diagnostic ultrasound AND disease severity: \u2018none\u2019.\u201d\n\nNow, if the severity of the disease is \u201cSevere\u201d, the patient is ineligible. If he passes the check, the same thing happens as in #3",
        "label": 2
    },
    "656": {
        "output": "</H4>\n<PRE>\n[Trial]:\nTitle: Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis\n\n\nSummary: Although percutaneous mitral commissurotomy (PMC) has been accepted as an effective treatment for symptomatic patients with moderate or severe mitral stenosis (MS), most asymptomatic patients are not candidates for PMC owing to the small but inherent procedure-related risks. Asymptomatic patients with MS show good survival rates up to 10 years, but there was a sudden deterioration precipitated by atrial fibrillation or embolism in half of the patients. Because the success rates of PMC were improved to more than 95% in ideal patients from highly selected centers and early PMC may decrease the occurrence of adverse events, such as atrial fibrillation or embolism, experienced centers tend to perform PMC at an early stage of disease. However, the potential benefits of early preemptive PMC in asymptomatic patients should be balanced against the real risks related to the procedure, and further studies of the efficacy of PMC in the prevention of embolism are necessary to extend its indications to asymptomatic patients. To the best of our knowledge, No randomized trials have been performed to ascertain the optimal timing of intervention in asymptomatic patients with significant MS. The early percutaneous MITral Intervention versus conventional manaGement in Asymptomatic moderate miTral stEnosis (MITIGATE) trial was designed to compare clinical outcomes of early intervention with those of a conventional management based on current guidelines in asymptomatic moderate mitral stenosis.\nInclusion criteria: Inclusion Criteria:\nasymptom",
        "label": 1
    },
    "657": {
        "output": "<h3 id=\"results\">Your output:\n\n\nHIGHLIGHTS FROM CONCISE REVIEW:  \n<ul>\n\t<li>Carotid artery stenting (CAS) with cerebral embolic protection is the preferred treatment for narrowing of the carotid arteries in patients at high risk for open surgery.\n\t<li>Special devices are used to protect the brain from particles that may break off by the narrowing or blockage is cleared during the angioplasty and stenting procedure.\n\t<li>Filters are most frequently used, but protection systems consisting of balloons and flow reversal are also available for protection.\n</ul>\n\n<h3 id=\"eligibility_2\">Trial-level eligibility:</h3>\n\n\t<li align=\"left\">\n\t<div id=\"textField\">\n\t <form name=\"eligibility\" use=\"POST\" action=\"/inst/exercise2/eligibility\" method=\"POST\" autocomplete=\"on\" title=\"Enter a value\" class=\"eligibility\">\n\t <input type=\"text\" id=\"eligibility-id\" name=\"eligibility-id\" style=\"margin-right:10px\" value=\"\" autocomplete=\"on\" class=\"input1\">\n\t <div id=\"formDiv_eligibility-id_error_hidden\">\n\t <div type=\"hidden\" id=\"eligibility-id-error\">\n\t <span>ERROR-the selected patient note \"7683\" is used up</span>\n\t </div>\n\t </div>\n\t <br class=\"clearBoth\">\n\t <input type=\"hidden\" id=\"trial-id\" name=\"trial-id\" style=\"margin-right:10px\" class=\"input1\" value=\"17868602\">\n\t <input type=\"hidden\" id=\"patient-note-id\" name=\"patient-note-id\" value=\"\" style=\"margin-right:10px\" class=\"input1\">\n\t <div id=\"formDiv_trial-id_error_hidden\">\n\t <span id=\"trial-id-error-hidden\">The selected trial must be different from the selected",
        "label": 1
    },
    "658": {
        "output": "<EOD> Inter- and Intramolecular Interactions Control 2-Aminopimidine-Based Molecular Shuttles\n\nCitation: Cheshmedzhyan, A.; Vardanian, A.; Grishkevich, R.; Sutyagin, A.; Vavilyuk, Y.; Sosnowski, W.; Gavrilov, A.; Kuchmanov, S. Inter-and Intramolecular Interactions Control 2-Aminopimidine-Based Molecular Shuttles.\n\n# Introduction\nFollowing the pioneering work of Fujita and coworkers on molecular shuttlesand the demonstration of the nonlinear optical (NLO) activity of such structures, great interest was devoted to the search for new NLO organic compounds with high-performance optical second harmonic generation (SHG) properties, which would allow their utilization in a wide range of applications. Among organic-based SHG materials, it is noteworthy that a large portion of them represents polycyclic chromophores (chromophore-based supramolecular assemblies) with a molecular mass ranging from tens to hundreds of thousand g/mol; however, the intramolecular nature of the shuttling motion within such structures becomes difficult to study because of the limited spectral range with the resolved exciton states. Moreover, at large sizes, the molecular shuttles were found to exhibit the slow photoisomerization process, typically, on the \u00b5s time scale, as a consequence of the considerable energy penalty for the structural rearrangement, in addition to the relatively long relaxation time of the excited state. Therefore, it makes more sense to seek a new type of NLO molecular shuttles with improved structure size, molecular flexibility/dynamics and SHG response.\nFrom such a perspective, the small size and intrinsic structural flexibility of the 2aminomethylpyridinium cations (2-AMPY + ) with three ionizable protonation sites attracted our attention. The ability to form different types of structures in solution and solid states (e.g., rosette-type aggregates, the self-sorting process, and supramolecular inclusion complexes) is related to the interplay",
        "label": 1
    },
    "659": {
        "output": "# Example\n[inst]\nPatient\nInclusion criteria\nTrial-level eligibility\n\n## A\nAge greater than or equal to 21 years\nExcluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n\n## B\nAble to give written informed consent\nAge greater than or equal to 21 years\nInclusion criteria\n2) Eligible\nYou should check the patient eligibility.<EOD> The effects of nifedipine on platelet aggregation and lipid levels in patients with coronary artery spasm: preliminary results.\nThe phospholipid composition, platelet aggregation and nifedipine treatment were evaluated in two patients with coronary artery spasm syndrome. Marked hypoalphalipoproteinemia and markedly increased platelet turnover rate was observed in the male patient with coronary artery spasm. Although nifedipine normalized platelet turn-over rate, it had no marked influence on platelet aggregation and the hypoalphalipoproteinemia. In the female patient, nifedipine-induced coronary artery spasm was associated with hyperlipoproteinemia (type IIb), but normal platelet function. This study suggests: a) the hypoalphalipoproteinemia in the male patient and hyperlipoproteinemia due to the disorder in lipid transportation may have been affected by coronary artery spasm, and b) the inhibitory effect of nifedipine on platelet aggregation may have been affected by the female's hyperlipoproteinemia (type IIb).<EOD> A comparative genomic analysis of the genes encoding the iron-stress induced ferritin L and F-protein families: the Dps/Dpp superfamily\n\nDps and Dpp are small bacterial ferritins whose physiological role has not been determined yet. Since no ferritin sequence was found in the sequenced genome of eukaryotes, it was proposed that Dps, Dpp, EfeU and Fe-BP proteins derived from the same ancestor and that they form a ferritin-like superfamily. We analysed the distribution, evolution and divergence of these proteins in a",
        "label": 2
    },
    "660": {
        "output": "Here is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active.\nThe patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic",
        "label": 1
    },
    "661": {
        "output": "## Instructions for Programmers\n[INST]\nWe invite programmers to recreate and solve the puzzle for three different datasets. Please choose one dataset among the three options:\nDataset 0: the dataset which we provide in all our programming challenges. You may freely use it or not.\nDataset 1: a dataset which is more similar to Dataset 0, than other datasets. Dataset 1: Dataset 3. You may freely use it or not.\nFor each dataset which you solve, please follow these instructions. Our team will take your solution to the next round and you will not be evaluated on it.\nFor each dataset which you upload to the page, please provide the following:\nPlease provide your code as a.js or .js file.\nProvide the output of your solution as an.html file. Please make sure your HTML header includes this line: \nThe name of your challenge: mychallenge\nThe name of your participant on the competition platform: <NAME>\nThe name of the organization of your competition platform: <NAME>\nYour name:<NAME>\n\nPlease follow the guidelines:\nYour file extension should be .js\nYour uploaded file size should be < 4MB.\nPlease do not include any code not needed to complete the challenge.\nFor example, if you need to sort data in ascending order, please simply use `data.sort().reverse()`, instead of writing extra code, needed to achieve it.\nThe same applies to functions such as `console.log()`, `setInterval()`, and `setTimeout()`.\n\n### Suggestions\nTo achieve the best score:\nCreate a JavaScript file named 'mychallenge.js' in which will reside the logic to compute the correct answer.\n\n### Sample Code\nWe provide a sample solution for one dataset here. Please note that the samples are for the purpose of describing how the scoring of this challenge is done and provide a basis of how to solve different datasets. The solutions that we choose to present here are not necessarily the top-five or the top-five solutions that we choose to give to the organizers. We also tried to avoid possible bias towards one or another solution.\nThe main requirement is to use JavaScript with minimal help from other languages.\nHere are some observations which were made regarding this exercise:\n- A common mistake was that people used `console.",
        "label": 1
    },
    "662": {
        "output": "# Example output\n<EOD> .\nIn a necropsy female aged 46 years was found a pigmented and at the top blackish papule resembling nevus in subscapular region. Microscopic examination revealed a well differentiated superficial spreading melanoma in which no metastases were found. The pathogenesis of this tumor and the difficulties in diagnosizing it are discussed. The histogenesis and cellular origin of the tumor is still not clear. In our case the tumor was atypical neither in clinical nor in histological aspect. The possibility that the tumor arose from pigmented nerve sheath cell of the sensomotoric nerve or of the sympathique system in this region has recently been advocated too, but on the lack of experimental evidence in man this hypothesis is not accepted generally.<EOD> Role of the interleukin-6/eicosanoid axis in pathogenesis of acute heart failure: novel insights.\nAcute heart failure (AHF) is the consequence of structural and functional impairment of the myocardium induced by a diverse variety of events, including myocardial infarction, hypertensive or valvular disease, hypertrophy, and ischaemia. This condition, which represents a major clinical problem that is associated with a large number of deaths worldwide, is characterised by an imbalance between ventricular performance and peripheral/vascular compliance.1 A plethora of pro- and anti-inflammatory mediators and cytokines as well as bioactive lipids and eicosanoids have been detected \u2026<EOD> Identification and characterization of antisense transcripts from RIK1790, a novel gene of the Drosophila melanogaster genome\nAbstract In this report we describe the identification and characterization of antisense transcripts that co-map to the RIK1790 gene in the X-chromosome of Drosophila melanogaster. These transcripts, called Rik1790 antisense transcripts (RIK1790-as1, RIK1790-as2a, and RIK1790-as2b), are located proximal to the 3\u2032",
        "label": 1
    },
    "663": {
        "output": "## Exercises\n\n**Note:** These exercises show the output of the patient note and a trial-level eligibility for a clinical study by running the data in the Jupyter Notebook.\nExercise 1: Analyze the difference in results obtained in the trial-level eligibility \n* Expected output\n  ```\n  Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and a clinical trial protocol to determine the patient's eligibility for the trial. The assessment of eligibility is based on the trial's inclusion and exclusion criteria and the results are expressed by two numbers. The first number denotes whether a patient is eligible or excluded from the trial, while the second indicates the scale of the patient's eligibility, i.e., 0) Excluded, 1) Not relevant, 2) Eligible.\nYou have just finished analyzing the patient data and are now looking at the clinical trial information. \nThe trial is a randomized double-blind design, and the expected duration of the trial is one year. The anticipated sample size is 100 participants and enrollment will occur in 0 to 180 days or 180 to 364 days from the time of enrollment. \n  * The age of the patients is between 40 and 99. \nThe trial is based on the same patient note in the previous exercise.\n  * Inclusion criteria =\n  ```\n  Inclusion Criteria =\n  * The patients are of age between 40 and 99 years.\n  * The patients have aortic calcification in the last 2 x-ray images.\n \n\nThe exclusion criteria are:\n  * The patients have pre-existing diagnosis of carotid stenosis, carotid atherosclerosis, previous carotid intervention, cardiovascular disease, and stroke.\n  * The patients have congenital abnormalities of the carotid arteries.\n  \n  ```\n* Clinical Trial protocol\n  ```\n The trial is a randomized double-blind design, and the expected duration of the trial is one year. The anticipated",
        "label": 2
    },
    "664": {
        "output": "# Introduction\nThe patient note and trial note are the inputs of the proposed framework. As the first component of the proposed clinical trial eligibility assessment framework, we aimed to extract patient data such as age, comorbidities, and medication history from the patient note to perform the eligibility assessment. As the second component of the proposed clinical trial eligibility assessment framework, we aimed to extract trial data such as characteristics of the trial, inclusion and exclusion criteria, population, and treatment protocol from the trial note. \n\n## Conceptual data model (CDM)\nFor the eligibility assessment task, the CDM includes:\n- Participant - patient - Trial - Trial-level eligibility\nFrom a conceptual point of view, this CDM can be expressed as a triplet R (X, T , X), where:\n- X: A participant.\n- T : A clinical trial.\n- X: A set of the extracted patient information from the patient note, i.e., Patient-level features. \n[Trial note]\n- Exclusion criteria: - Not Eligible.\n- Trial-level eligibility: - 2) Eligible.\n- Treatment protocol:\n- Protocol: Trial participants take two tablets a day.\n- Duration: 90 days.\n- X: A set of the extracted trial information from the clinical trial note, i.e., Trial-level features. \n\n## Knowledge graph (kgn)\nFrom a knowledge graph perspective, we created a knowledge graph comprising the above CDM using an Apache Jena 3.12.1-SNAP.\n\n## Kgn construction\nThe KG was constructed in the following steps.\nStep 1: Add participants (patients and trials) and trials' exclusion factors to the KG.\nStep 2: Add participants, trials' population, treatment modalities information, duration, and type of disease to the KG.\nStep 3: Add the relations and relations to the KG among participants, trials, and patient features.\n\n## Semantic relation extraction\nTo address the sematic relation extraction task, we employed a combination of rule-based and ML-based techniques to recognize participant-to-tri",
        "label": 0
    },
    "665": {
        "output": "~AcknowledgementsWe are grateful to the AIMIRA project and to the reviewers and contributors who helped improve this research.\n \u00a9 The Author(s) 2020\nACKNOWLEDGEMENTSWe are grateful to the AIMIRA project and to the reviewers and contributors who helped to improve this research.<EOD> Genome Editing Technologies to Create Targeted Mutations and Knockouts\n\nAdapting biological systems requires the ability to specifically manipulate genes of interest. Historically, mutants were created through the application of chemical and physical agents, resulting in random mutations. Now, a variety of technologies enable the creation of targeted mutations in genes of interest with the use of nuclease-and/or antibody-directed methods. In mammalian cells, it is also possible to induce DNA damage (and inactivate a gene), without creating any mutations using a technique called \"knockout by inversion\". By targeting, rather than randomly mutating genes, one can study the role of the gene with less confounding mutations, allowing the study of the consequences of loss of function, or creation of a gain of function phenotype. In addition, when targeting specific genetic elements in a population, knockouts can be generated. This review covers the various methods available for knocking out or knocking down target genes in a desired manner.\n\n# Introduction\nThe main objective of molecular biology is to modify or control a process by manipulating the genome of the target organism, for example, in disease treatment, crop cultivation, or basic research in biomedical or agricultural fields [bib_ref]  Development and applications of CRISPR-Cas9 for genome engineering, Hsu [/bib_ref] . In the past, mutants were constructed by exposing the targeted organisms to chemical treatments, which resulted in random genetic mutations [bib_ref]  Development of efficient transgenic systems for wheat and barley, Sparks [/bib_ref] . In 1983, genetic screens were established, which enabled the generation of defined point mutations (point-mutations), which were later refined and expanded to include other applications, including epigenetic regulation (epigenetic mutations), transposon and cis-element mutations, and targeted knock-in mutations [bib_ref]",
        "label": 0
    },
    "666": {
        "output": "<EOD> The Mini-CEX: evaluation of a model for the clinical teaching of junior doctors.\nThe Mini-clinical Evaluation Exercise is a structured evaluation of a physician's performance during interactions with actual patients. It was developed by American family doctors and is currently being promulgated by the College of Family Physicians of Canada. The exercise allows the assessor to rate on a scale from 1 (unsatisfactory) to 9 (outstanding) performance on a standard list of skills based on 2-3 min. of patient-doctor interaction, and to choose from a list of special remarks in response to any performance shortcomings identified by that standard set. The exercise requires the assessor to use the assessment scales reliably and to be prepared to elaborate on any shortcomings identified by them. This article discusses the implementation of the Mini-CEX at the University of Toronto's Department of Family Medicine; the difficulties encountered in the application of the Mini-CEX; the special requirements for assessor training; and the advantages and disadvantages of the system.<EOD> Inhibition of the growth of BALB/c 3T3 cells by a bovine lactogenic growth factor.\nLactogenic growth factors present in bovine milk were investigated for their effects on the growth of 3T3 cells. The growth of BALB/c 3T3 cells was determined at a concentration of 1:2000 dilution of bovine and human milk using the MTT assay and their growth curves (Pearson's correlation coefficient, r = 0.95) and the rate of 32P i incorporation into cellular phospholipids were determined using a bioassay. Pure Epidermal Growth Factor (EGF) showed no inhibition of either the DNA synthesis or the mitogenic effect of 5 beta-12-oienoyl-3 beta,7 beta dihydroxy-Cholan acids. Purified placental lactogen, however, although having some ability to support cellular growth, did not restore the mitogenic activity of the bovine lactogenic growth factor diluted in human milk. The mitogenic activity of the lactogenic growth factor was destroyed by an",
        "label": 1
    },
    "667": {
        "output": "Note that this is the last step of this use case; a trial note is usually processed at a step earlier than this.\n\n# Task 6\n[INST] A trial coordinator is asked to review the patient note and the trial criteria to find patients who would comply with the eligibility criteria for the trial. [EXT]\n\n# Requirements\n- The trial coordinator reviews the note and trial criteria to determine if the clinical trial is applicable for the patient.\n- The trial coordinator selects and displays the eligibility of the patient for the clinical trial.\n- \tThe trial coordinator selects and displays the eligibility of the patient for the clinical trial.\n- If the patient is excluded, the patient's notes are presented to the trial coordinator.\n- If the patient is excluded, the patient's notes are presented to the trial coordinator.\n\n# Use Case Template\n# Patient Note Exploration\nTrial ID : 998 - 4.14.25.25.0002 Title : PG-121-11. Trial Name: Clinical Trial of Increased Tolerance to Iodine and Radiofrequency Ablation of VX2 Carcinoma in the Prostate.\nThis is a clinical trial to evaluate clinical outcomes for prostate cancer patients that have undergone RFA of a VX2 tumor implanted in the anterior prostate. It is expected that by evaluating the tolerance of RFA in these patients at week 3, 6, and 9, we will be able to optimize the procedure for these patients with minimal complications. \nA total of 24 patients will be included into the trial. A total of 12 patients will be treated to deliver an 83 G of radiation dose. A study in animal models has determined a median tolerance dose of 74 gray. Therefore, patients will be treated until they reach an 83 Gy dose.\nPatients will be treated twice a week with 6 Gy at each fraction. During treatment, all patients will be administered oxygen to facilitate the absorption of the ionizing radiation.\nTwo weeks after receiving the entire 48 Gy dose of radiation, prostate biopsies will be performed in all patients. For those patients",
        "label": 0
    },
    "668": {
        "output": "We will now demonstrate a more complex case, which needs the following steps:\n\n\n*\n\n*Select the appropriate patient note in the Patient Information Tab\n\n*Obtain all of the patient data related to a clinical trial - Patient ID: 4010, Diagnosis: '2+ CAD on Carotids and Left Subclavian artery, age: 50, gender: Female.\n\n*Go to the Patient Note Tab. Find all patient info (lab, diagnosis, procedure, notes, medication)\n\n*Select the corresponding clinical trial name on the top of the page and go to the Clinical Trial Details Tab to see all the required information to evaluate the patient.\n\n*Go to the Findings Tab and copy the required eligibility criteria into the Findings Box for each of the trials.\n\n*Go to the Trial-level eligibility Tab and evaluate the patient's eligibility according to the trial and report the eligibility status for each trial.\n\nYou should obtain the patient information for 5 different trials and evaluate them in each one of them.\nYour output results should be:\nPatient ID: 4010, Patient Diagnosis: '2+ CAD on Carotids and Left Subclavian artery' \nInsufficient information for any of the clinical trials\nFindings:\n\nDemographic:\nCaucasian female\nAge: 50 years old\nWeight: 135 pounds\nEthnicity: Caucasian\nEmployment: Retired with pension\nSmoking: Former smoker\nPersonal History:\nPrevious medical history or procedures:\nMedical History: DVT\nMedications:\nFamily History:\nFamily History: Family history of premature coronary artery disease, type 2 diabetes\nProcedure:\n- HgA1c (3.8): normal\n- Lipids: (LDL 40, HDL 75, LDL/HDL ratio 0.5, \n\n## Triglycerides 92, cholsterol total 141): normal\n\nFindings:\n\n\nCongenital cardiac defects:\nMastoidectomy 1",
        "label": 0
    },
    "669": {
        "output": "### <NAME>'s answer\n[I like it to be clear and succinct so I try to make that true for my answers.]\n\nFrom your code review, it looks like you should be able to understand the problem.\n\nHowever, you also need to:\n\n1. Understand that you need a better description of \\em{all your input parameters} in your functions.\n2. Understand how you need to handle when the input parameters are \\em{non-existent} or are \\em{not needed}.\n3. Understand that you need a better description of error handling.\n4. Understand that you need to have \\em{more tests} of your code.\n\nIn this case, the code seems to handle 9/9.  Your problem will be understanding why the test fails, and it would be your \\em{failure to understand input parameter and error handling} that is your challenge in resolving the issue.\n\nThe reason your test fails is because you have `print` statements that try to print a value that does not exist.\n\nIt looks like you are having the \"test\" \\em{output} a \\em{reasonable} result.  The problem is, you are using a \\em{test} which is designed to be a \\em{value} test.  So, you are trying to check for the \\em{correctness} of your code with a \\em{test} which is more suited for the \\em{validation} of your code.\n\nIn any case, your challenge is to understand \\em{why} you are getting the incorrect test results.\n\nI would strongly emphasize that if you are getting bad results with \\em{tests}, then you are most likely to get bad results when it counts -- and you should look to be 100% \\em{confident} that you are \\em{certain} of your code's \\em{correctness} (or \\em{error}) in the real world.  (You can also check that your code \\em{passes} the test and \\em{does what you want} in the real world as you go along.)\n\n\n<EOD> The influence of hormonal replacement therapy on breast cancer risk in postmenopausal women\nObjective: To determine in a cross-sectional study conducted in women 50 years and",
        "label": 1
    },
    "670": {
        "output": "A: For a one person, if you want to tell whether the person can be part of the clinic study, you need to do it with three questions:\nIs the person aged 18-35 years?\nIs the person aged 35-60 years?\nIs the person aged older than 60 years?\nIf you just want to filter the people by one question, then you should set the range of the parameter in the filter to a pair of numbers, then you could use a simple condition like this:\n<Parameters>\n        <Parameter Name=\"Test Aged 18 to 35\" \n        Type=\"ClinicalVariable\"\n        ValueInRange=\"True\" \n        DisplayName=\"Aged 18 to 35 Years\" \n        Description=\"Patient is aged 18-35 years\"\n    </Parameter>\n    <Parameter Name=\"Test Aged 35 to 60\"\n        Type=\"ClinicalVariable\"\n        ValueInRange=\"True\" \n        DisplayName=\"Aged 35 to 60 Years\" \n        Description=\"Patient is aged 35-60 years\"\n    >\n</Parameter>\n    <Parameter Name=\"Test Aged Over 60\"\n        Type=\"ClinicalVariable\"\n        ValueInRange=\"True\" \n        DisplayName=\"Aged Over 60 Years\" \n        Description=\"Patient is aged older than 60 years\"\n    </Parameter>\n    <Rule Name=\"Trial-Level Rule\" \n        Condition=\"Test Aged 18 to 35 OR Test Aged 35 to 60 OR Test Aged Over 60\"\n    >\n        <Action>\n            <ClinicalCondition Include=\"true\" />\n            <ActionName>InClinicalStudy</ActionName>\n            <ActionGroupName>Patient in Clinical Study</ActionGroupName>\n        </Action>\n    </Rule>\n</Parameters> \n\n<EOD> The epidemiology of childhood disability in low- and middle-income countries: a systematic review\n\nThis protocol describes methods for a systematic review that will use mixed methods to evaluate the extent, determinants, and impact of childhood disability",
        "label": 0
    },
    "671": {
        "output": "A: The only thing missing here is that there are 21 possible patient notes in total. You should add a new block to loop to print 21 different patients and make sure they are being printed.\n<EOD> The effect of the N-terminal domain truncations on the conformational heterogeneity of bovine \u03b3S-crystallin.\nThe oligomeric state of \u03b3S-crystallin is a heterogeneous system of dimers and trimers, and the structure of the oligomers depends on the protein concentration. Bovine \u03b3S-crystallin contains two different N-terminal truncation variants, the full-length NT-form and the NF-form. This study investigated whether the difference in the structure of the N-terminal domain affects the extent of the heterogeneous oligomeric state, as well as its quaternary structure in solution. The NMR chemical shift difference of (15)N-labeled \u03b3S crystallin between the NF-form and NT-form was around 0.15 ppm, indicating that the N-terminal region forms a separate domain from the core domain of the protein. The quaternary structure of the NF-form was also investigated by size-exclusion chromatography coupled with multi-angle light scattering, and the molecular masses of the NF-form of \u03b3S crystallin estimated to be 62, 81, 99, 126 and 161 kDa. In conclusion, the observed difference in the molecular masses is consistent with a mixture of dimeric and trimeric forms of the \u03b3S crystallin. In contrast, the quaternary structure of the full-length NT-form \u03b3S crystallin was confirmed to be a heterogeneous mixture of dimers and trimers, and the number of chains in the oligomers was 2, 3 and 4. These results are consistent with a tendency of the full-length NT-form of \u03b3S-crystallin to aggregate at relatively high protein concentrations.<EOD> Migrant Health Promotion Program in a Multi-Cultural Setting: From Reconciliation to Action\nAbstract:In 2012",
        "label": 1
    },
    "672": {
        "output": "```\n\n#### Clean the data set.\n\n[INST] Open Jupyter Notebook.\n\n#### Make required module.\n\n[INST] Create a notebook for the required module:\n\n* `Create a notebook for your desired module.\n\n  1. Create a notebook named `requiredmodule` in the `notebooks` directory.\n  2. Rename the `README.md` file and add your code to your notebook.\n  3. You can add the name of your notebook or folder from the dropdown menu if it is not already there.\n  4. Select `New Workspace` to create a new workspace and import all necessary packages",
        "label": 0
    },
    "673": {
        "output": "Exercises \nThis module aims to create and test a series of examples based on the given data, to train the user in the use of clinical trial evaluation code.\nThe first exercise covers the steps needed for entering patient information.\nIn the second exercise, we learn how to use the evaluation of patients for inclusion or exclusion.\n\nExercise 1: Patient Information Record\nThe first step is to enter all the patient information available. At the beginning, you will have patients with limited information. Here is patient data available:\npatient.ID: 1    patient.Name: Hank        patient.BirthDay: \"9/12/18\"        patient.Gender: \"Male\"        patient.Smoking: 0        patient.Diabetes: False        patient.hypertension: False        patient.hyperlipidemia: False        patient.LiverDisease: False        patient.Stroke: False        patient.FamilyHistoryCAD: False        patient.FamilyHistoryStroke: False        patient.FamilyHistoryHyperlipidemia: False\nIt is possible to use a list format to enter patient information as you add patients. In this format, you enter one patient data at a time. Use the `patient.insert ()` method that returns the number of the added patient. You should use the patient ID value as the number in `insert ()` method input argument. This data is assigned when you created the patient object. For more details see this chapter \"Creating patients\". \nIn the first task, you will learn how enter the patient data in the form. You should create the Patient Form with the `form.add ()` method that returns the number of the added form and insert the patient data into each form. Here is the source code:\n\nimport cljfmt    import \"form.clj\"\n\n[cljfmt/cljfmt.clj:32] (1) form = form.add [1]  \"Patient\"  \"Hank\" \"9/12/18\"  False  False  False  False [12]\nform.insert [1] \"Smoking\"  \"No\"\nform.insert [1] \"Diabetes\"  \"False\"\nform.insert [1] \"hypertension\"  \"False\"    form.",
        "label": 1
    },
    "674": {
        "output": "# Discussion\nWhat are the inclusion criteria?\nThere are 8 Inclusion Criteria in the trial:\n\n## age\n- Age >18y\n\n## Inclusion: all cases\n\n## Gender\n- Gender (female, male) - Patients with plaque psoriasis can be males or females\n\n## Inclusion: all cases\n\n## Duration of psoriasis\n\n## Inclusion: not applicable\n\n## Severity of psoriasis\n\n## Inclusion: all cases\n\n## History of psoriasis\n- Psoriasis has to be the patient main dermatological disease\n\n## Inclusion: all cases\n\n## Medications currently taken\n- Oral systemic agent, including methotrexate or acitretin\n- Topical therapy and/or phototherapy (and are eligible for, but are not currently receiving oral systemic or biologic therapy)\n- Biologic therapy for moderate to severe plaque psoriasis\n\n## Inclusion: all cases\n\n## History of psoriasis therapy\n- Patients who are candidate to or have received biologic therapy and/or oral systemic agents (including methotrexate or acitretin)\n\n## Inclusion: all cases\n\n## Eligibility criteria\n- Patients, who are candidates for or are currently receiving the following:\n\n## Inclusion: not applicable\n\n## Trial participation criteria\n- Patients who are candidates for or are currently receiving the following:\n- Adult male and female patients having diagnosis of plaque psoriasis for at least 6 months prior to screening\n- Age >18y\n- Gender (female, male)\n- Duration of Psoriasis > 6 months\n- Psoriasis has to be the patient main dermatological disease\n- Eligibility: not applicable\n\n## 467\nHow to detect outliers\n\n## 467#\nLet's take a look at the data. The data can be found [here](467_Data) \n### Recent 80% of patient's cases\nFirst we use the method `recent_80` from the",
        "label": 1
    },
    "675": {
        "output": "For example, if the patient doesn't have smoking history then the patient can be excluded because of that; if the patient has hypertension but the patient's blood pressure is lower than 160/95, then the patient with high blood pressure can be categorized as 1 \"relevant\" and the patient can be excluded; if the patient doesn't have family history of CAD, the patient can be categorized as 2 \"Eligible` because all other criteria has met; if the patient doesn't have any drug history, the patient can be categorized as 0 \"Excluded`, because the patient doesn't meet any criteria to be eligible to join the clinical trial. You should repeat this step for each clinical trial, and report the results you got from the three steps above in the table by following steps below.\n\n## Reporting\nFirst, fill one cell for each patient and for each trial with `0\"(if a patient doesn't meet the inclusion criterion) or `1`(if a patient has met the inclusion criterion) or `2\" Excluded.` (if it's the end). Then go to the next cell and the patient can meet one, two, or none of the criteria in all trials. Finally, you should repeat these steps for each patient and for each trial, and report your findings in the table and put them together in a text file. \nIf the following is not true:\nif there isn't `Excluded` then you should repeat the first step and repeat the steps for each trial. In the same way, if there is one condition on each cell of the first step.\nIf the following is not true:\nif there isn't only `0` in the last row then you should repeat the second step and repeat the steps for each trial. In the same way, if there is only one condition on each cell in step 2.\nIf the following is not true:\nif there isn't only `2` for the first cell of the last row then you should repeat the third step and repeat the steps for each trial. In the same way, if there is only one condition on each cell in step 3. \nYou should repeat this rule for the clinical trials 1-3 as long as the step number is not equal to last number, e.g., if the number",
        "label": 1
    },
    "676": {
        "output": "___ \n___ INCR_5 :\nYour patient 481255963 is eligible, 2) Eligible.\n___ INCR_6 :\nTrial-level eligibility: 2) Eligible.\n\n### 8.1.6 Examination of Disease Clinical Trial \\[INST] You (864148192) are the chief investigator of a disease clinical trial. In the past two months, you and your colleagues have examined the prevalence of the disease in the population of interest and the risk of disease in the general population with all available methods. Currently, you are considering the design of a disease trial and need to obtain a rough estimate of the sample size for this pilot study (the prevalence, if applicable). \n\nA sample size that gives a confidence interval between 95% and 99%, with a standard deviation of 5%, requires approx. 5,000 cases in the exposed group, assuming a relative risk of 2 or higher.  The prevalence is less than 1%. To detect a difference of 20% between the exposed and the non-exposed group, at a two-sided significance level of 1%, requiring exact confidence levels, a minimum of 16,674 cases needs to be included in the study. \n\nUse the following data as a part of the case study: \n\n```\n  - 2019\n  - 1: 1822\n  - 2: 3856\n```\n\n\n#### 8.1.6.1 Examination of Disease Clinical Trial \\[INST] You use the following data as a result of a case study of a disease pilot study:\n```\n  - 2019\n  - 1: 1822\n  - 2: 3856\n```\n\n___ INCR_1 :\nYour case studies show that the distribution is normal.\n\n___ INCR_2 :\n2019\n```\n```\n  - 1: 1822\n  - 2: 3856\n```\n___ RES_1 :\nYour calculation is correct, now set confidence interval",
        "label": 1
    },
    "677": {
        "output": "# Author Contributions\n\n## Conceptualization\n\n## Data curation\n\n## Formal analysis\n\n# Funding statement\nThis project was funded by the National Institute of Health [2R01AI133980-02A1] at the National Institutes of Health, United States of America. 2017 to 2022.\n\n## Declaration of competing interest\nThe authors claim no conflicts of interest.\nAppendix A.3. AI-Assistant for Clinical Trial Enrollment System ICD-10-Based Multi-Label Classification Module\n\n## A.3.1. dataset\nTraining dataset: 115,423. Validation dataset: 23,654.\n\n## A.3.2. pre-processing\n1) Data cleaning by the python library preprocess with ICD 10 label. Each ICD 10 code contains a word that belongs to 4 categories: symptom, problem, diagnosis, clinical procedure. By preprocessing, for example, each ICD code '7761' and '776.21' is regarded as a single token. 2) Extraction of features: The feature set is extracted by applying a Python package Doc2Vec, named as 'doc2vec.py'. We use a vocabulary of 1,000 words, set a window size of 1 and other parameters as recommended by the Doc2Vec Python package. All ICD 10 codes are tokenized as words, and are used to train the doc2vec model independently for generating word embeddings for each ICD 10 code. 3) Data splitting: We used a stratified sampling method to stratify data into a training set and test set. The ratio of training set to validation set is 8:2. 4) Data imputation using the method of \"KNN imputation\". KNN imputation is an approach that fills in missing data by estimating the value of a missing feature through the average value of the k neighboring records. The parameters were set as K = 15, distance = pearson. We used the Python package DataTone (version 1.0.1).<EOD> Osteosarcoma and osteoblastoma of the",
        "label": 1
    },
    "678": {
        "output": "### Examples\n\nExample of data input format (using YAML):\n---\ntitle: Evaluation of a computer program for screening of malignant melanoma\nabstract_en: This trial assessed the diagnostic performance of the ABCD rule compared with dermoscopy-assisted clinical diagnosis to identify patients with clinically amelanotic (unpigmented) melanocytic skin tumours (cAMTs). Of 2,000 patients referred to the skin outpatient's clinic at our centre, 148 had either clinically suspicious lesions or skin tumours histologically proven to be malignant. After receiving ethics board approval, patients were informed about the study and asked about the presence of any lesion. Those patients with non-pigmented skin lesions were referred to the Department of Dermatology for clinical presentation of any suspected lesions. Lesion-location clinical photographs taken after pigment was digitally subtracted and the dermoscopic images taken by a clinician of the skin histology team with a DermLite DL20 (3 Gen Inc., Rancho Cordova, CA, USA) were analyzed separately by 3 expert dermatologists. Each rater read the clinical and dermoscopic images, and assigned the presence and absence of the ABCD rule, respectively. The dermoscopic findings were considered as gold standards for clinically amelanotic melanocytic tumours (cAMTs). For the clinical-diagnosis based on the ABCD rule, the sensitivity (86.7%), specificity (51.5%) and accuracy (75.5%) were determined. [/YAML] \nInput of test data. The above data has three patient's test data, and each sample contains four sets of test data.\n---\ntitle: Evaluation of a computer program for screening of malignant melanoma\nsubject_type: clinical_trial_study\n\n\n### Experimental data\n- ID: ABCD_Study_0001\n- title: Example1 of ABCD rule based on dermoscopy\n- type: patient_data\n- study_name: ABCD_Study\n- abstract",
        "label": 2
    },
    "679": {
        "output": "<EOD> PPARalpha agonist fenofibrate prevents the decline in pancreatic beta cell mass in fructose-fed rats.\nChronic fructose ingestion stimulates hepatic sterol regulatory element binding protein 1c (SREBP-1c) in a manner similar to that seen with excessive ingestion of saturated fatty acids that lead to insulin resistance and dyslipidemia and predispose to non-alcoholic fatty liver disease and type 2 diabetes. The PPARalpha/gamma agonist bezafibrate, which is a drug of choice in hyperlipidemia, prevented the fructose-induced hepatic fatty acid synthesis and inflammatory response. Bezafibrate treatment reduced hepatic inflammation and injury and normalized the impaired triglyceride synthesis in the liver of fructose-fed rats. We here investigate the effect of another orally active PPARalpha agonist, fenofibrate, in preventing the increase in pancreatic beta cell mass seen in fructose-fed rats. Fructose feeding of Sprague Dawley rats for 6 weeks induces severe hyperlipidemia and insulin resistance, as also seen in patients with the metabolic syndrome. Fenofibrate treatment diminished fructose-induced insulin resistance, hyperglycemia, dyslipidemia, and hepatic SREBP-1c activation. Glucose homeostasis was improved in fenofibrate-treated rats, as judged by lowered glucose levels during a glucose tolerance test. Fenofibrate prevented the observed increase in pancreatic islets by decreasing cell proliferation and prevented the increase in fructose-induced insulin mRNA level. The increase in the content of the pancreatic and duodenal homeobox-1 (Pdx-1) protein, a rate-limiting factor in insulin synthesis, that was induced by fructose was prevented by fenofibrate. These results show beneficial effects of fenofibrate on glucose homeostasis, hyperlipidemia, hep",
        "label": 1
    },
    "680": {
        "output": "## Explanation\nTo write patient-level report, you have to write the output of the assessment of eligibility by Python script. Let's try to think step by step.\n\n\n\n**STEP 1** (Python script): Get information of patient from clinical note:\n\nFirstly, use the [read](https://docs.scipy.org/doc/scipy/reference/generated/scipy.io.loadtxt.html) function to import the string of patient's note.\n\n```python\nnote = read ('patient_note.txt')\n```\n\nNote contains the following information: \"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs",
        "label": 0
    },
    "681": {
        "output": "A: The solution is the usage of R syntax. In R, there is no need to check the number of characters. This is done automatically by base functions. This makes it handy for R users since R functions like count() are already available and users can use them directly. The usage of R helps make the code easy to follow and understand.\nFurthermore, the use of R leads to efficient execution of code. It helps in increasing the speed of code execution and makes it easier for users to find bugs. This is because R is a highly used language and has a large number of packages available that are constantly being updated and improved. By using R, users can take advantage of these packages which allow them to have a more efficient execution of their code. This is especially valuable when dealing with big data sets.\n\nFor example: \n# This code shows how to count length of a string. For 1 string input, it gives an output of 3. There are 2 \"s\" characters in the 3 characters string and \"f\" is 1 character. \nsum(strlen(string)) \n# You can also use count() function, output will be as below: \nsum(count(string)) \n# You can also use strlen(\"I\" * string) which gives an output of 20 when combined with one character string  I.\nsum(strlen(string) * number) \nNote: number is the repetition of a word, in this example \"I\", number could be 1's, 2's, or 3's.\n<EOD> Molecular dynamics study of Pt12-microclusters: hydrogen adsorption and diffusion.\nThe adsorption of hydrogen molecules on the (111) and (100) planes of a model cubic Pt(12)-microcluster has been investigated using density functional theory (DFT). The potential energy surface describing hydrogen adsorption has been mapped within the framework of hybrid and generalized gradient approximation DFT. The resulting global potential energy minimum has been found to reside on the Pt(111) facet of the cluster. The calculated enthalpy of adsorption for H(2) molecule on the cluster in its pristine state is -1.34 eV per mole",
        "label": 0
    },
    "682": {
        "output": "<EOD> .\nPURPOSE\nTo evaluate the results of the use of cefepime (formerly LY127935) an antipseudomonal cephalosporin in urological infection.\n\n\nPATIENTS AND METHODS\n116 urological infections treated with cefepime: 87 nosocomial urinary tract infections (N = 36 Gram negative, N = 51 Gram positive), 14 lower urinary tract infections (e.g. prostatic abscess 6, urethritis 1, diverticulitis vesicare, 7), 1 chronic prostatitis, and 1 staphylococcal epididymitis.\n\n\nRESULTS\nA complete and quick clinical resolution was obtained in 99.1% of the cases. The bacteriological success was 93.8%. The side-effects were scarce, 12.6% of the patients had reversible leucopenia and no patient was withdrawn from the study.\n\n\nCONCLUSION\nCefepime has been successfully employed in the treatment of a wide variety of urological infections.<EOD> A systematic review and meta-analysis of the literature on the prevalence of chronic pain in children and adolescents\nAbstract Purpose: To estimate the prevalence of chronic pain in school-aged children and adolescents. Materials and methods: A methodological electronic search of the bibliography published from 2007 through 2014. A total of 75 articles were included to estimate the prevalence and to complete 20 meta-analyses to calculate the percentage of school-aged children and adolescents whose primary pain problem was either chronic or recurrent. The quality of the studies and the reliability and stability of the prevalence rates were evaluated using the PRISMA recommendations. Results: The prevalence rates varied between 0.01 and 48.04%. The most common pain condition was headache (4.43%), followed by recurrent abdominal pain (2%) and chronic regional pain (2%). The prevalence of chronic musculos",
        "label": 1
    },
    "683": {
        "output": "To make a more realistic example, let's imagine you do a trial-level eligibility for a real patient's note, which contains the following information:\n\n> Name: John White\n> \n> Date: 03-29-2014 \n> \n> History: John was born in 1974 in Chicago.\n> \n> Symptoms and signs: The patient has severe arthritis involving the shoulders, elbows, hands, wrists, hips, knees, and ankles without morning stiffness, and complains of back pain.  He has mild to moderate shortness of breath on exertion.\n> \n> Reason for Visit: To rule out rheumatoid arthritis. \n> \n> Medications: In 2006, John began taking methotrexate 25 mg three times a week to help control his rheumatoid arthritis.\n> \n> Allergies: John is allergic to penicillin.\n> \n> Lab Tests:\n>   - Hemoglobin was 11.8 g/dL (normal range: 14\u201318 g/dL)\n>   - Erythrocyte sedimentation rate 85 mm/h (normal range: 0\u201320 mm/h);\n>   - C-reactive protein 12.8 mg/L (normal range: 0.0\u201310.0 mg/L);\n>   - Ferritin was 333 mcg/L (normal range: 12\u2013288 mcg/L).\n> \n> Other significant medical history:\n>   - Infectious mononucleosis (2 years ago), pneumonia (a month ago).\n\nWe will obtain the clinical trial information from the following source:\n[url]\nWhat we will want to do is something like in the following example:\n`# Let's make a trial-level eligibility for a real patient`s note`\n\n`class TestTriallevelEligibility(unittest.TestCase):`\n\n`    def setUp(self):",
        "label": 2
    },
    "684": {
        "output": "## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem",
        "label": 1
    },
    "685": {
        "output": "Good luck!<EOD> Comparison of Length of Hospital Stay Associated with Surgical Site Infection among Patients Undergoing Elective Surgery of the Spine\n\nStudy Design:This is a retrospective cohort study. Purpose: Although surgical site infections (SSIs) are uncommon in spinal surgery, it is important to reduce SSI to improve patient's recovery and reduce the economic burden. This study sought to evaluate the impact of SSI on the length of hospital stay (LOS) among patients who underwent elective spinal surgery. Overview of Literature: There are many risk factors that are linked with prolonged LOS, and previous studies have shown that SSI is significantly related to longer treatment period. Methods: SSI was classified as superficial infection, deep infection, or organ/space infection. The infection was defined as wound infection that required antibiotic treatment longer than 3 days. From 2005 to 2011, 607 patients who underwent spinal surgery for the treatment of degenerative diseases were surveyed; 27 patients with infection were further analyzed.Results:The average LOS was 22.5 days in the SSI cases and 8.25 days in the control group, and the average hospital cost in the SSI cases and control was 794,520 Korean won (KRW) and 383,090 KRW, respectively. The SSI group showed significantly longer LOS and higher total cost. There were no deep infection, organ/space infection, or fatality cases in this study. Conclusions: Because SSI has a significant influence on the LOS, it should be prevented to reduce the economic burden and LOS in patients who undergo elective spinal surgery. Clinical Trial Registration: This clinical research was approved by the Clinical Research Ethical Committee of Kyung Hee University Hospital and was registered under the registration number 2014-12-048.\n\n# Introduction\nSpinal diseases are the most common reason for disability and one of the most common reasons for hospitalization in elderly patients [bib_ref]  Cost-of-illness studies in spine care",
        "label": 1
    },
    "686": {
        "output": "# Tutorial\n\n\n***\n\n\nHere is your first patient note:\nBetter:\n\n\n\n- A 46-year-old man (ID:1) presents with dizziness and frequent migraine.\n- He is diagnosed for high risk vascular disease.\n- His LDL-C level is 552 mg/dL. \n\nWhat would you do if you are the researcher to determine the trial-level eligibility on the given patient?\n\nA. You should exclude the patient.\n\nB. You should consider the patient as not relevant. \n\nC. You should consider the patient as eligible.\n\nPlease submit your answer before you continue the next step.\n<br>\n\n\n\nThe patient note is above.\nWhat criteria are sufficient to determine the trial-level eligibility on the patient?\n\nExplanation:\nA reasonable assessment of trial-level eligibility is only possible if the inclusion and exclusion criteria are known and considered for a patient. The following steps are recommended to assess for trial eligibility. Step I: Read the patient note and make sure that the patient matches the trial's disease profile. If not, go back to the title of the trial using the keyword cloud and see other clinical trials in this cloud of keywords.\nStep II: Check the target LDL levels set for a trial from the previous step. If the patient has an LDL level that is greater than the trial's target, go back to the steps I & II. Try to lower the LDL levels using statin therapy and, if still not sufficient, try to elevate the trial-recommended diet and lifestyle interventions. If the patient is still not meeting the target LDL level, go back to the steps I & II. If the trial has no target LDL therapeutic range, go back to the title using the keyword cloud and see other clinical trials in this cloud of keywords which could be more appropriate.\nStep III: Look if the patient does not have any additional atherosclerotic cardiovascular disease (ACVD) diseases compared to the trial's profile. If the patient has a disease profile that is different than the trial, go back to the title of the trial using the keyword cloud and check other trials in",
        "label": 1
    },
    "687": {
        "output": "Good job! \n\n\nIn this step, only the trial-level eligibility of a given patient is stored for the B-RICH example. In the end, you will see the final result of the assessment. \n\n## The end \n<EOD> .\nPseudorabies virus infection was diagnosed in pigs of 3 months, with a moderate febrile temperature (T39.6 degrees C) and severe pains. All the pigs died 22 hours later. Necropsy revealed a diffuse erosive pleuropneumonia. The microscopic lesions of the lungs consisted of acute-stage suppurative pneumonia, diffuse alveolitis and hematogenous pneumonia. The most severe pulmonary lesions were observed in pulmonary vascular walls and alveolar wall with the intra and interstitial alveolitis. In the lung parenchyma, there might be observed the necrosis of lymphocytes, plasmocytes, large and small lymphocytes. No pathogenic bacteria were isolated from lungs.<EOD> Phenotype of patients with mutations in APC or MUTYH.\nIn this issue of Blood, Li\u00e8vre et al report a distinct phenotype of 8 patients with MUTYH mutations and colorectal adenoma (CRA) (Li\u00e8vre et al, this issue).<EOD> Assessing the Feasibility and Acceptability of Tailored Mobile Health Coaching for Patients With Chronic Obstructive Pulmonary Disease Transitioning Home From the Hospital: Mixed Methods Case Study\n\nBackground: A large number of patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD), are discharged from hospital and receive their care in homes where family members are the primary caregivers. As many patients struggle to manage their disease and navigate the health care system at home, the hospital discharge is a vulnerable time for patients and caregivers on the path to recovery. Mobile health (mHealth) solutions have the potential to support patients and caregivers at this time. Mobile technologic interventions for patients with COPD, such as mobile health education apps and remote monitoring,",
        "label": 0
    },
    "688": {
        "output": "## Expert hints\nYou can try to use the `grep -E '<a.b>`` command in the first step and then copy the result of the grep into the patient note and save the file as `patient_note 2.txt`. \n<EOD> Characterization of the Human RPE65 Protein by Site\u2010Directed Mutagenesis of the Iron Containing Domain\nAbstract:\u2002 The first step in the visual cycle is the formation of the prosthetic group chromophore in the final product. In this process, two molecules of all\u2010trans\u2010retinyl esters combine to form 11\u2010cis,13\u2010cis\u2010retinyl esters, and this is catalyzed by retinol dehydrogenases. One of these hydroxylases is retinol dehydrogenase enzyme 5 (RPE65), the visual cycle enzyme responsible for transforming the chromophore, 11\u2010cis\u2010retinaldehyde, the first product of all\u2010trans retinyl ester hydrolysis. RPE65 contains its own catalytic site and uses its catalytic site to activate the NADP+/NADPH cofactor pair. Iron\u2010dependent alcohol dehydrogenases contain an iron\u2010containing domain, which has been reported to be a catalytic domain. We decided to conduct two mutations in this region: H389D and H389A. We conducted an in vitro assay with the mutant\u2010producing enzyme and found a drastic reduction (90%) in its activity as compared with the native human retinol dehydrogenase enzyme enzyme. Therefore, we have shown what we conjecture to be a critical element that is necessary for enzyme activity.<EOD> Evaluation of in vivo antioxidant and anti-inflammatory potential of the crude extracts of two species of Heliotropium, H. indicum L. and H. asperum L.\nINTRODUCTION\nReactive oxygen species (ROS) causes many chronic degenerative diseases including inflammation, cancer, heart and neurodegenerative diseases. A number of studies have shown that oxidative stress is a pivotal component of chronic inflam",
        "label": 2
    },
    "689": {
        "output": "--- \n1. Choose one of the answers of inclusion criteria: A, B, C, G, H, I, J, or L. [Select one, then click the \"next page\" button]\n\n    \\[INST\\] Answering correctly the inclusion criteria questions is crucial for determining eligibility. Here you need to click one of the following inclusion criteria: A, B, C, G, H, I, J, or L. [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2)\n\n--- \nTo get to the next page, go to the exercise index page. [INST] [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_INDEX_PAGE)\n\n--- \n1. Choose one of the answers of exclusion criteria: A, B, C, D, F\u3001G\u3001I\u3001J\u3001K\u3001L\u3001 M\u3001N or P. [INST] [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_FIRST_PAGE)\n\n--- \nTo get the next page, choose the right exclusion criteria then click the \"next page\" button. [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE1)\n\n--- \n2. Choose one of the answers of exclusion criteria: A, C, D, G, H, I, J, K, L, M, N or P. [INST][INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE1)\n\n--- \nTo get the second next page, choose the right exclusion criteria then click the \"next page\" button. [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE2)\n\n--- \nTo get the third page, choose the right exclusion criteria then click the \"next page\" button.[INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE3)\n\n--- \nTo get the",
        "label": 1
    },
    "690": {
        "output": "### In-line instructions\nWhenever a user should press the `?` key after the input, our in-line instructions page will open.\n![Screenshot of an in-line instructions page that appears after pressing the ? key of a cell.](https://s.cdn.aceam.io/uploads/files/screenshots/docs-and-code/4023-cell-in-line-instructions.png)\nIt provides an easy access to the help page and the user manual about this topic.\n\n### Help web page\nAs the user starts to input the cell contents, they can click on the `Help web page (http:/aceam.org/help/)` in the footer of the user interface. It directs the user to the [ACEAM's help page](http://aceam.org/help) which provides a useful help by categorizing different ACEAM's topics and presenting useful links.\n\nThis tutorial focuses on the eligibility issue in a real clinical trial. In fact, we don't see the whole clinical trial scenario. We are observing the part that focuses on the eligibility task.\n\n## Cell Types\n\n### Cases\nA case is made of an observation, a set of data collected from a real-world clinical study, such as a trial, a registry, or an observatory. Cases can be composed of clinical notes, such as those made during a patient encounter, diagnostic images, laboratory results, and so forth. For more details, see [the cases page in the Wiki](https://aceam-dev.federatedcloud.org/wiki/ACEAM-Clinical-Notebook/case-reporter-system-implementation).\n\nCases are identified in ACEAM through UUID. A UUID is a unique 36-character string representing a case. A UUID can be generated by using [the UUID generator tool](webassets/aceam/app_scripts/static/generators/uuid.py). For example, let's generate a UUID as `7bd458bb-6d5c-11e5-ba66-8e759af6194b`.\n\nAs mentioned above, a case is made of a set of clinical data",
        "label": 2
    },
    "691": {
        "output": "## \u27f5 CONCLUDE\n<EOD> The influence of the 51Pv and 53m-Pu isotopic chains on the radiation protection problem.\nIn a previous article, we have studied the influence of the 51Pv and 53m-Pu isotopic chains on the problem of radiation protection for the nuclear industry. We have examined some of the characteristics of these two radionuclides, in particular their half-lives and their energies of beta and internal gamma emissions. We have studied, at the same time, the possibility for 51 Pv (or for 53m-Pu) to be the first alpha-emitter in the actinide series (or transuranium series) and we have obtained some limits to consider. Using some biokinetic models, we have evaluated the contribution of these two isotopes to the gonadal dose equivalent. 53m-Pu could be a possible first alpha-emitter in the transuranium series. 51Pv is a stable isotope, present in plutonium in large amounts, having a good gamma spectrometric signature, and emitting good beta emissions, leading to a gonadal dose equivalent much inferior to that from polonium. These two isotopes, in small amounts, could be used to correct the alpha spectrometric measurements.<EOD> A comparison of a single dose of 16 or 80 milligrams of mifepristone for medical abortion in South Africa\nTo compare the termination of pregnancy rates after a single dose of 16 mg mifepristone versus 80 mg mifepristone.<EOD> Effects of a low temperature on sperm capacitation in the bovine.\nThe objective of the present study was to determine if low temperatures could extend sperm capacitation duration, thereby, allowing extended semen handling and transport in tropical regions. For this, testicle and epididymis spermatozoa recovered from the bovine were incubated at 37 degrees C during 4 h then, incubated for 60, 120, and 180 min at 17 degrees C. Spermatozoal binding to the",
        "label": 1
    },
    "692": {
        "output": "_NOTE_\n\nThe output shows the assessment of eligibility for a patient in _Trial_ level. However, we need to identify whether the patient corresponds to a particular study. For this we need to determine this in _study_ level.  \n\nIn order to achieve this, we would need to retrieve all patients that are part of a study and check their assessments of eligibility. Here is an excerpt of Python code for this:\n\n```python python3/output/py_trial_level_eligibility.py --patients-table /output1/patients_info.csv --study-name \"Study_name2\" --study-description \"Study description\" \\ --study-id 1 --trial_id 2 --trial_name \"My_trial\" --trial_description \"My trial description\" --trial_country \"My country\" --trial_country_code \"My country code\" --trial_city \"My city\" --trial_city_code \"My city code\" --trial_institute \"My institute\" --trial_institute_code \"My institute code\" --trial_investigator \"My investigator\" --trial_investigator_code \"My investigator code\" \\ --input-file /output1/patients_info.csv --output-file /output2/patients_info.csv --input-header \"Sample ID\" --output-header \"Sample ID\" --output-first-column-delimiter \",\" --output-file-delimiter \",\" --output-delimiter \"|\" \"--outputdir /output\" \n\n```\n\nThe code will start with determination of study patient ID. Then we will use that ID to retrieve all patients that are part of that study. Finally, we will calculate trial-level eligibility for all these patients in a matrix and save it to the file `patients_info.csv`.\n\nIt is a good practice to save your results in a comma-separated values (CSV) file. By default, i.e. if you do not modify `--output-file-delimiter`, the first column of your data becomes a column name and the others become row names.\n\n```python\n# 12.2.2",
        "label": 1
    },
    "693": {
        "output": "And finally, you need to change in the `classify`, to be as follows:\n```\nclassify",
        "label": 1
    },
    "694": {
        "output": "Please provide feedback on the format and content of the assignment.\n\nThis assignment is submitted by [[NAME]] ([[id]]), 10/06/2018\n\n- [[Author]] [[id]] 10/06/2018\n\nTo test the submission module, you can use the form again and submit this message. Please do not submit your assignment in this form.\n\nThe [[Submit]] button is disabled before the due date of the assignment; once the [[Submit]] button is enabled, the [[Assignment Instructions]] appear if there are any remaining errors or warnings. The [[Submit]] button will become disabled after the submission time for this week has passed; you can use this module to submit until the time for a scheduled assignment has passed (after the due date of the assignment, you will use the normal assignment submission module).\n\n## Particulate matter & air quality index (aqi)\n<EOD> A case of paratesticular mucinous cystadenoma in a boy aged 14 years: ultrasonographic and MR images.\nThe author studied MR images of a case of paratesticular mucinous cystadenoma occurring in a 14-year-old boy. The tumor was well defined, cystic, and located in the testicular tunics. Mucinous cystadenomas of the testis are very rare; the author found only 29 cases reported since 1957. Of the 29 cases, 2 were mucinous cystadenomas of paratesticular origin occurring in boys and 2 were mucinous cystadenomas involving the epididymis in men. None, however, was of the multilocular type; the present case was therefore considered to be a rare occurrence according to its type, its location, and the age of the patient.<EOD> Pharmacists\u2019 Perceptions About the Practice of Pharmacy\nOBJECTIVE: To identify pharmacists perspectives on pharmacy practice in relation to specific areas of importance, such as the provision of community pharmacy services and interprofessional collaboration. METHODS: A qualitative study was conducted with a sample of pharmacists in a metropolitan area in Australia. This was a purposive sample of community pharmacists and ph",
        "label": 1
    },
    "695": {
        "output": "# Rationale\nIn this course, we want to understand clinical trial eligibility determination. Clinical trial eligibility criteria (patient selection criteria) are very critical to the conduct and outcome of clinical trials and clinical research. The definition of eligibility criteria should be based on whether the study is for an intervention, whether the study is for a prevention action, and what is the goal of the clinical trial and what is the target population. Eligibility criteria should be specific and accurate. For example, when designing the clinical trial, if the goal of the trial is to find an antihypertensive drug for hypertension, antihypertensive drugs that can lower blood pressure during the washout period should be excluded.\n\nIf the clinical trial's goal is to find a drug that lowers a specific lipoprotein, the clinical trial will exclude trials that found antihypertensive drugs and metformin. For clinical trials of cardiac drugs, the cardiac disease, especially heart failure, should first be excluded.\nEligibility criteria are classified into inclusion and exclusion criteria. For example, a study may exclude patients with severe cardiovascular disease to avoid complications and adverse events. Patients who did not meet the inclusion criteria should be excluded from the trial. \nThese decisions, together with the informed consent process by the participant, are performed by the clinical research coordinator. In this course, let's take a look at how clinical research coordinators decide the inclusion criteria of clinical trials and the exclusion criteria required for clinical trials.\n\n## Inclusion criteria\nThere are a variety of inclusion criteria and exclusion criteria for a clinical trial and there is no absolute limit to the number of inclusion criteria and exclusion criteria. However, most of all, inclusion criteria and exclusion criteria are based on safety. If an inclusion criteria and exclusion criteria do not seem safe in this process, they can be excluded. For this purpose, physicians and other clinical research coordinators should be well prepared. The study protocol is based on inclusion criteria and exclusion criteria.\nThe clinical research coordinator selects appropriate inclusion criteria based on information such as the type of diseases or symptoms that most need treatment, potential side effects, and the treatment regimen. In our study",
        "label": 1
    },
    "696": {
        "output": "CREDITS: [https://www.kaggle.com/davidhuang010406/trial-eligibility-for-patients/code]\n\n\n\n1. [https://sagepod.com/posts/insta-medicine-clinical-trial-eligibility-using-instasource]\n1. [https://sagepod.com/posts/insta-medicine-clinical-trial-eligibility-using-instasource]\n2. [https://sagepod.com/posts/insta-medicine-clinical-trial-eligibility-using-instasource]\n3. [https://sagemaker.com/blog/insta-medicine-clinical-trial-eligibility-using-instasource]\n4. [https://sagemaker.com/blog/insta-medicine-clinical-trial-eligibility-using-instasource]\nInstaMedicine-Clinical-Trial-Eligibility\n\n\n<EOD> .\nPURPOSE\nPreviously, we reported the superiority of the use of autologous mesenchymal stem cells (MSCs) into endothelial progenitor cells(EPCs) for the differentiation of the EPCs in an in vitro study. We also reported the preliminary clinical study showing the safety of the autologous MSCs/EPCs for the treatment of acute ischemic stroke. In this article, we investigated the prognosis of patients who underwent the treatment with the autologous MSCs/EPCs.\n\n\nMETHODS\nNine patients who were diagnosed with acute ischemic stroke underwent the intraarterial injection of the autologous MSCs/EPCs. Their neurological outcomes were evaluated at the admission and at 1 and 6 months by using the mRS. The mRS, the NIHSS at onset (NHISSO), the functional dependence at onset (FDO), the number of the infarcted lesions, and the number of the patients who had received treatment with M",
        "label": 0
    },
    "697": {
        "output": "<EOD> Risk factors associated with severe dengue in a single tertiary care center of West Bengal, India\n\nIntroductionSevere dengue has become a major public health challenge and needs to be explored.ObjectivesThis study was conducted to identify the risk factors associated with severe dengue in comparison with non-severe dengue.Materials and methodsA cross-sectional study was conducted in a tertiary care center of West Bengal, India. Dengue infections diagnosed from January 2019 to December 2021 on the basis of both NS1 Ag-positivity and significant increase of dengue IgM antibody were included. The patients were classified as severe dengue or non-severe dengue by considering the diagnostic criteria adopted by the World Health Organization (WHO). Data regarding demographic, hematological, and other biochemical parameters as well as the severity of dengue infections were compiled. The risk factors were identified by comparing severe dengue and non-severe dengue cases. The Chi-square test was used to find the association of the variables with severity. A p-value less than 0.05 was considered statistically significant.ResultsThere were 64 cases (11.6%) among 552 dengue patients diagnosed as severe dengue. Males (63.6%) were outnumbered than females. The mean (\u00b1SD; Median) age was 36.4 (\u00b111.9; 36.0) years. The mean (\u00b1SD; Median) duration for development of signs and symptoms was 6.0 (\u00b12.3; 6.0) days. The common clinical symptoms were fever (100%), headache (94.6%), myalgia (87.5%), arthralgia (84.4%), retro-orbital pain (83.3%), vomiting (65.6%), nausea (61.9%), abdominal pain (57.1%), and rash (25.8%). Nine severe dengue patients (14.1%) died in the intensive care unit. The mean platelet count (24723 /mm 3 ) and mean hematocrit (3",
        "label": 1
    },
    "698": {
        "output": "[CLOZY](157)  \nHello You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 157 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 and 54",
        "label": 0
    },
    "699": {
        "output": "[END]\n\n*\n\n*This is the best practice from @FGI: #clinical-data-management. I learned this way by observing and helping out there.\n*\n\n*It is not an answer from @FGI: #clinical-data-management. In the other ways for the evaluation, we should use other kinds of metrics to describe the precision, recall and f1-score.\n\n*In this exercise, you need to make a decision. The task is to check whether the patient note satisfies the inclusion criteria or not, and you are supposed to fill those decisions into the patient table.\n\n**Instruction**:\n\n*\n\n*You can use any programming language and/or any type of web browser. You should not use any API.\n\n*\n\n*The maximum runtime is 60min. Any solution over the runtime will be graded automatically as not passing.\n\n*\n\n*You should submit the final version of your solution (the script) together with your answer. If your answer is not submitted at all, it will be marked as not passing.\n### Submission\n\nThe deadline of the contest is June 17, 2018 \n<EOD> The Role of Glycogen Synthase in the Regulation of Glucose Transporter and Na+/Glucose Cotransporter in the Rat Retina\n\nThe present study was designed to investigate the mechanisms involving the roles of glycogen synthase kinase-3\u2424 (GSK-3\u2424) and glycogen synthase (GS) in the regulation of glucose transporter (GLUT) 1 and Na \u03e9 /glucose cotransporter (SGLT-1) expression in rat retina. Two doses of N-ethylmaleimide (NEM), a GSK-3 inhibitor, significantly increased the protein abundance of GS; conversely, two doses of lithium (LiCl), a GSK-3 activator, resulted in a decrease in GS protein content. Intravitreal injections of NEM at 5 mM increased the level of GLUT1 in rat retina, whereas LiCl at 5 mM decreased the level of GLUT1. In contrast, inhibition",
        "label": 0
    },
    "700": {
        "output": "<EOD> .\nThe method for analysis of the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and its analogs in animal and human serum is established, being based not only on the direct determination of the TCDD, but also the determination of 3,6-dichlorodibenzodioxin and their isomers. The TCDD, TCDF, 3,6-dichlorodibenzodioxin were reacted with sodium bisulfate, 1,2-dihydroxybenzene and tetraethylammonium salt. Then we used the column of the mixed-mode resin (CX-8) for the purification of reaction product for analysis by high pressure gas chromatography. The limit of detection (signal to noise) of the TCDD was less than 10 pg which corresponds to 50 fmol. It is proved that the established method is both useful and convenient in the determination of the TCDD and its analogs in animal and human serum.<EOD> A Systematic Review and Meta\u2010Analysis of Randomized Controlled Studies of Combined Oral Contraceptives in Treatment of Acne in Comparison With Combined Oral Contraceptives Alone\nAn increased interest on the role of female sex hormones on acne has been observed.<EOD> The Use of Compression Garments in Athletic Training: A Review of the Literature\n\n\n\n## Conventional compression stockings\nConventional compression stockings (CCS) are generally used in the management of venous insufficiency, and they decrease blood pooling within extremities by increasing venous return [bib_ref]  Intermittent pneumatic compression devices for prevention of deep-vein thrombosis, Segal [/bib_ref]  [bib_ref]  Compression stockings may not affect oxygen uptake or leg blood flow during..., White [/bib_ref] . In the past, CCSs were a popular choice for the prevention of deep vein thrombosis (DVT) in athletes engaging in long duration, unweighted, static activities, such as cycling [bib_ref]  Intermittent pneumatic compression devices for prevention of deep-vein thromb",
        "label": 2
    },
    "701": {
        "output": "<EOD> A comparative study of the effects of L-NAME and lysophosphatidic acid (LPA) on the proliferation and migration of osteoblasts and osteosarcoma cell lines\nObjective: Nitric oxide (NO) and lysophosphatidic acid (LPA) have been described as potential candidates to participate in bone remodeling processes, although little is known about the mechanisms of action of these substances in both normal and cancer cells. This study aimed to determine the proliferation and migration effects of NO and LPA on two cell lines of osteoblastic phenotypes, i.e., osteoblastic cells (OB) and the human osteosarcoma cell line U2OS, and compare them with the effects of LPA and NO on a urothelial carcinoma (HCV-29) cell line of epithelial phenotype. Methods: The proliferation and migration of the cells were evaluated by trypan blue exclusion/counting (TBE), cell density (BD), and cell migration (CM) assays. Nitric oxide was synthesized as a 3 Mm solution (S-nitrosoglutathione, GSNO) or by pre-incubating a lysate of peripheral blood lymphocytes from a pool of young adult donors with sodium nitroprusside (SNP) or S-nitroso-N-acetyl-D,L-penicillamine (SNAP), and LPA was used as a 20 mM solution. Results: The study reveals that OB proliferation is enhanced by NO and LPA, and to a lesser extent also by LPA, while U2OS cell proliferation is inhibited mainly by GSNO, and to a lesser extent by SNAP, NO, and SNP. Similar to the OB pattern, in the TBE tests U87 proliferation was enhanced by NO, and to a lesser extent by LPA. In the BD test, however, the osteosarcoma cell line U2OS showed a marked increase in proliferation with LPA, SNAP, or NO, whereas U87 cells",
        "label": 0
    },
    "702": {
        "output": "<EOD> A 12\u2010hour ultrasound service does not provide a better level of patient satisfaction than an 8\u2010hour service\nTo evaluate patient satisfaction with 2 separate scheduling formats using a single sonography clinic.<EOD> Characteristics of Children Presenting With Suspected COVID-19 at King Abdulaziz Medical City in Jeddah, Saudi Arabia\n\n\n\n# Introduction\nCoronavirus disease 2019 (COVID-19) is defined as an infectious illness caused by a newly discovered virus belonging to the Coronaviridae family. In December 2019, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) broke and spread throughout the world, leading WHO to announce a pandemic on March, 30, 2020 [bib_ref]  World Health Organization declares global emergency: a review of the 2019 novel..., Sohrabi [/bib_ref] . To date, about 450 million infections and 6 million deaths linked to COVID-19 disease have been recorded globally (2). About 3000 cases and 30 deaths occurred in Saudi Arabia, according to the COVID-19 Data Repository of the Ministry of Health [bib_ref]  Data repository on the coronavirus , 2020. Ministry of Health, Kingdom of..., Health [/bib_ref] . According to CDC, the majority of COVID-19 patients are either asymptomatic or have mild symptoms [bib_ref]  Presenting symptoms of COVID 19 and its management, Farooqui [/bib_ref] . On the other hand, 5% have a severe disease, while 20% have a critical one [bib_ref]  Presenting symptoms of COVID 19 and its management, Farooqui [/bib_ref] . There is considerable variability in the presentation of COVID-19 between different age groups, as well as within the same age group [bib_ref]  Presenting symptoms of COVID 19 and its management, Farooqui [/bib_ref] . According to the National COVID-19 Data, the pediatric population is less frequently affected, accounting for only 0.8% of the confirmed patients [bib_ref]  Evaluation of suspected COVID-19 children by the Saudi Ministry of Health",
        "label": 1
    },
    "703": {
        "output": "___\nWe will continue to talk about the analysis of clinical trials in the next lesson.\n<EOD> The effect of glycerol on human erythrocyte glucose transport.\nIn a series of previous papers we have shown that a small amount, less than 5%, of one type of aminoglycoside antibiotics, gentamicin sulphate, inhibits the glucose transport of human erythrocytes.1-3) In order to prove the fact that the inhibitory action of aminoglycoside was independent of their own structure,2) we chose another group of antibiotics, of chloramphenicol (CM), tetracycline (TC), and doxycycline (DC), and demonstrated that their inhibitory action was also similar to that of gentamicin, while penicillin G (PG) and its derivative, carbenicillin hydrate (CH) did not show any inhibitory action. The question that could be raised from these experiments concerns the possible inhibitory action of other sugar components, such as glycerol for example. Thus, the present study was made on the interaction between glycerol and erythrocyte glucose transport to verify this problem.<EOD> Evolving role of bone marrow mononuclear cells in the therapy of organ failure: basic concepts\n\nBone marrow mononuclear cells (BMMNCs) have the unique ability to home to injured organs and participate in the healing process. Transfusion of these cells may become a novel tool to treat or even prevent multi organ failure. A number of animal studies, using infarcted rats as an experimental model, have shown that autologous and allogeneic BMMNC therapy significantly improved cardiac blood flow and reduced fibrosis. This beneficial effect on cardiac blood flow has also been observed after autologous BMMNC transplantation in patients with acute myocardial infarction. A number of clinically relevant diseases, including heart failure, liver cirrhosis, renal failure, diabetes nephropathy and atherosclerosis, are characterised by significant deterioration of the microcirculation. The restoration of the",
        "label": 1
    },
    "704": {
        "output": "## Task 2. [CrossRef]\nPlease consider this patient in terms of clinical trial inclusion or exclusion criteria based on information provided in the following section, which is also based on the patient's clinical trial eligibility assessment for Task 1. Your evaluation is a sentence and then should be repeated, i.e., a sentence containing both an eligibility assessment and the inclusion criteria information. Each patient has two assessments: one for the trial-level eligibility assessment and the other for trial-level exclusion assessment. You will be given the patient note in the same manner as Task 1, and the same patient note is provided for Task 2.\n[formula]  Patient 1 46-year-old man with a family history of CAD and no risk factors presenting with dizziness \u27a5 Assessment: 2) Eligible. [/formula] \nInclusion criteria: CAD Cohort \u27a5 Study inclusion criteria:\n\n## Patient 2 57-year-old man without CAD \u27a5 Assessment: 2) Eligible.\nInclusion criteria: CAD cohort study \u27a5 Study inclusion criteria:\nAge 50 years or older\nHistory of hypercholesterolemia\n\n## Patient 3 32-year-old man without cad \u27a5 assessment:\n1) Not relevant.\nAge 30-50 years and LDL-C level < 360 mg/dL \u27a5 Inclusion criteria: CAD cohort study \u27a5 Study inclusion criteria:\nAge 30-50 years and LDL-C level <360 mg/dL\n\n## Patient 4 48-year-old man with cad \u27a5 assessment:\n1) Not relevant.\nAge 50 or older and LDL-C level < 360 mg/dL \u27a5 Inclusion criteria: CAD cohort study \u27a5 Study inclusion criteria:\nAge 30-50 years and LDL-C level < 360 mg/dL\n\n## Patient 5 61-year-old woman without cad \u27a5 assessment:\n1) Not",
        "label": 1
    },
    "705": {
        "output": "### Discussion\n> `You might be wondering as to how to decide the eligibility of participants. Generally, the inclusion criteria are the minimum level of evidence required for patients to be included in the trial. In other words, patients who satisfy all inclusion criteria can participate in the trial. Let me explain using the example of two clinical trials.\n> One test was about a new drug (involving n\u2009=\u2009100 participants) for patients with breast cancer. The objective was to detect a difference in the overall and complete responses to treatment. The inclusion criteria included a tumor mass of < 250 grams and no metastasis to organs other than the breast, as estimated radiographically. The exclusion criteria included liver disorder, previous radiation therapy to the breast, previous tumor recurrence, or pregnancy or lactation. The participants in this trial were randomized into the treatment group or control group. Another trial involved a new drug (involving n\u2009=\u2009200 participants) for patients with lung cancer. The objective was to detect a difference in the overall and partial responses to treatment. The inclusion criteria included histologically/cytologically confirmed non-small cell lung cancer, a performance status of 0 to 2, and at least one measurable lesion. The exclusion criteria included previous surgery for cancerous tumors and radiotherapy to the thorax region. This trial used a placebo control and consisted of 4 arms (arm 1: new drug, arm 2: new drug and placebo, arm 3: placebo, and arm 4: placebo). Let's suppose that a participant of each trial had a tumor mass of 900 grams and no metastasis to liver, kidney, or bone. The participant satisfied inclusion in only the first and third trials. Here, the second and fourth trials would exclude the participant. Consequently, you have to make the assessment of eligibility in two trial-levels or trial-level eligibility in each trial. How to do that?` [4] \n> `When you start the eligibility check of a trial, only the data of participants who satisfy all the eligibility criteria are shown in the data input tab. To get the trial-level eligibility for participants who satisfy",
        "label": 0
    },
    "706": {
        "output": "####\n\n`/20 min`<EOD> A retrospective cross-sectional study for epidemiological estimation of the incidence of sexually transmitted infections among HIV patients in Iran\n\n\n\n## To the editor\nStudies have evaluated the association between sexually transmitted infections (STI) and pre-existing HIV infection as well as HIV treatment and STIs among those who are living with HIV. In a study, about the frequency of urethral and cervical infection with pathogenic sexually transmitted viruses among HIV/AIDS patients, Chavoshi et al. showed a 1.4% prevalence of HIV and genital herpes virus (GVH). [bib_ref]  Frequency of Urethral and cervical infection with pathogenic sexually transmitted viruses among..., Chavoshi [/bib_ref]  Furthermore, in a case-control study, the odds of STIs among HIV-positive women with a CD4 cell count of >200, CD4 cell count of 200-499 cell/microl, CD4 cell count <200 cell/microl, and a negative CD4 cell count have been estimated as 3.0, 1.9, 1.7, and 1.7, respectively. [bib_ref]  Sexual and reproductive health of HIV-positive women on antiretroviral therapy: A hospital-based..., Gholamzadeh [/bib_ref]  Recent reports show that the prevalence of curable STIs among those living with HIV is high and, in this respect, Iran, as a country, is no different. Therefore, it is essential to evaluate the trend of these infections among this high-risk group. This study retrospectively evaluated the HIV/AIDS patient data from the HIV/AIDS research center of the Tehran University of Medical Sciences located in Tehran, the capital city of Iran. The data were obtained from January 2001 to December 2015. The HIV/AIDS database was obtained from SIB (Shenas Institute of Health Information Technology), a national health information company. The cases recorded in the SIB were sent by the special units/depart",
        "label": 0
    },
    "707": {
        "output": "### Task 1\n\n##",
        "label": 1
    },
    "708": {
        "output": "Therefore, the output of Trial-level eligibility should be `Trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible`, where the last one indicates that the patient meets inclusion criteria, therefore is eligible for this trial.\nIn the next tutorial, you will know how to create a report in R with the ClinicalTrial package by the clinical trial note and eligibility in this tutorial.\n\n[INST] Here you can obtain the data from the web:\n[EXER] ClinicalTrial/Sep/Sepr_Data.csv\n[INST] Download the file firstly and save your local path: ```wget -T 5 https://github.com/dongzhongchun/ClinicalTrial/raw/master/R/Trial2.csv; wget -T 5 https://github.com/dongzhongchun/ClinicalTrial/raw/master/R/Trial2.csv.zip; unzip Trial2.csv.zip; mv Trial2.csv Trial2.csv.zip; Rscript Trial_report.R Path/to/Trial2.csv.zip 9a29698c11f1de5779a297cb0358464d40fb46e6 2476de5895506cde88bef21cf66fe04281b49a53cc3ca10d79ec3a80c45fa8; rcrawl Trial2.csv.zip # Path of your local, in windows we can run without -e in the R cmd # e.g., rcrawl C:/Users/Xiyu/R_project-jewel/data/Trial2.csv.zip ```[INST] If you use Linux, enter in a terminal `$ wc -l Trial2.csv.zip`, the output: The file size is 16439100 by the command: $ echo $DISKSPACE -s /Users/Xiyu/R_project-jewel/data/Trial2.csv.zip` The root",
        "label": 0
    },
    "709": {
        "output": "# E\n\n## I would like to ask which of the followings apply to your case. please select all that apply.\n\n## Patient note: \\usepackage{amsmath, amssymb}\nThe following \\textgreater{} symbols may also be used to denote a \\textit{NOT} relation:\n\n## Inclusion and exclusion criteria\nPlease indicate which of the criteria in the list below are met by the patient: \n- Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Taking Omeprazole 20 mg/day\n- \\textgreater{} ASA\n- Inclusion and Exclusion criteria\nPlease indicate which of the criteria in the list below are met by the patient: \n- Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Taking Omeprazole 20 mg/day\n- \\textgreater{} ASA\n- Inclusion and Exclusion criteria \nPlease indicate which of the criteria in the list below are met by the patient: \n- Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Taking Omeprazole 20 mg/day\n- Inclusion and Exclusion criteria\nPlease indicate which of the criteria in the list below are met by the patient: \n\\textgreater{} Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Clinical characteristics\\+:\n- \\textgreater{} Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Omeprazole 20 mg/day\n\n# F\n\n##",
        "label": 0
    },
    "710": {
        "output": "You should submit your solution in the following box:\n[inst-solution] Your assignment code: YOUR_CODE_HERE\n\nPlease submit your code within 10 days, otherwise a 30% penalty will be applied and you are not allowed to work on it later.\n\nGood luck with this assignment. [END]\n\n**[/COR]**\n\n### `11.9_Assignments`\n\n```r\nassignments <- read.csv(file.choose(), header = TRUE)\n```\n\nYou should have the four files as follows: \n\n- **[Solution code assignment].RData**\n  - You should define a new 'RData' object containing your solution code. Please, see how to create it [here](https://www.rdocumentation.org/packages/rdata).\n  - Write `\"assignments = assignments\"` then the last lines inside `assigment2` function. \n- **Code.txt**\n  - Put your code in an editor and save it as a file in UTF-8 encoding called 'Code.txt'\n- **Trial-level eligibility assignment.xlsx**\n  - This is an Excel file with a worksheet called \"Triallevel eligibility assessment\" with your proposed assessment of eligibility or \"Trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible\" for each patient (rows) and your trial code (columns)\n- **F1_C1.xlsx; etc.**\n  - This is an Excel file with three worksheets called \"Assignee\", \"Patient_code\", and \"Trial_code\" \n  - `Assignee` tab: This is a list of assignments submitted by students. Your assignment code is 'Your code'\n  - `Patient_code` tab: This is a list of patient codes, i.e., the first three digits of the trial code. It is used to avoid double counting patients when the code of the trial is shared.\n  - `Trial_code` tab: This is a list of the codes of clinical trials that are given to students. Each student gets a trial code. You should assign the same trial code to all patients in your assignment.<EOD> Effect of N",
        "label": 1
    },
    "711": {
        "output": "<EOD> Apoptosis in proliferative endometrium: comparison of low dose and high dose of 17 beta-estradiol valerate-cyproterone acetate administration.\nThe aim of the present study was to evaluate the immune response following low dose and high dose regimens of combined estrogen progestin treatment of proliferative endometrial mucosa and compare apoptosis induction in proliferative endometrium resulting from these regimens. The study included twenty three fertile women with abnormal uterine bleeding. Patients were divided into two groups to receive two different regimens which were 50 micrograms estradiol valerate daily for ten days and 5 mg estradiol valerate daily for fifteen days, respectively. In twenty three fertile women, tissue samples were obtained from ten biopsies in each patient. Specimens were classified into three groups: before treatment, low dose estrogen progestin treatment and high dose estrogen progestin treatment. Apoptotic cell morphology was assessed under high power field (HPF) by light microscope. Apoptotic cells were identified by positive results in TUNEL assay. As a result, the mean numbers of apoptosis per HPF (mean+/-SEM) were 0.2 (0.1), 2.1 (2.99), and 1.2 (0.43), and the percentage of apoptosis per total epithelium area (mean+/-SEM) were 0.9+/-0.4%, 7.6+/-1.7% and 4.2+/-1.1% in groups before treatment, low dose estrogen progestin treatment group and high dose estrogen progestin treatment group, respectively. A significant increase was found in high dose estrogen progestin treatment group (p<0.001) when compared to pretreatment group that included only low-dose estrogen progestin treatment group. In conclusion combined estrogen progestin treatment was found to be more effective in induction of apoptosis in proliferative endometrial mucosa, in high dose estrogen progestin group in comparison",
        "label": 1
    },
    "712": {
        "output": "---\n\n# Tip 2\n[[INST] Hello. \nYou are a statistician for clinical trials. A data-management expert asked for statistics of the current trial, and for example, he wants to get the summary statistics of outcome variables from the completed trial. But the current trial design is a multi-period crossover trial where patients perform the treatment period in six conditions: drug A, placebo A, drug B, placebo B, drug A\\'s control, and drug B\\'s placebo. What are the problems when the data are analyzed without considering repeated measures of patients?]] [END]\n\nThe statistician should first analyze whether the crossover design is valid or invalid. In valid crossover designs, patient's responses for the same treatment are expected to be independent. In invalid crossover designs, patient's responses for the same treatment are likely to be correlated. The assumption that the study participants (patients) behave independently is likely to be violated in a crossover study. In such cases, even though there are two experimental groups that are independent, the crossover design must be considered when performing the analysis.\n\n[[INST] The statistician should first analyze whether the trial design is reasonable or not. Even though there are two experimental groups that are independent, the crossover design must be considered whenever performing the analysis.]] [END]\n\n[![INST] Hello. You are a clinical epidemiologist and expert of clinical trials. You are a statistician for clinical trials. The data analyst of a clinical trial is analyzing data based on their experience. You wonder that the data analyst did not consider multi-period crossover trial when performing the analysis, and now he requests for explanation about the analyses without considering crossover trial designs. First, explain how the result might be different when analyzing a multi-period crossover trial without considering the crossover trial design and why, using an example. Next, explain how the result might be different when analyzing a multi-period crossover trial with considering the crossover trial design and why, using an example.]<EOD> Exploring the Effect of the Chemical and Physical Structure of Tannins on Their Extraction from Plum Peel: A",
        "label": 1
    },
    "713": {
        "output": "1. Read the patient note. The important factors you should analyze are the stenosis of the internal carotid artery (ICA) as well as plaque, especially, those that are bulky plates extending to the middle third of the internal coronary arteries (ICAs) and were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs).\n2. Identify the appropriate inclusion criteria for the clinical trial:\n1) Hypertension\n2) Cardiomyopathy/congestive heart failure with an ejection fraction < 40%\n3) Diabetes with fasting glucose > 110 mg/dL or glycosylated hemoglobin (HgbA1c) > 7.0%\n\n4. Identify the factors of the patient's history of stroke or transient ischemic attack (TIA). The trial has listed them as \"Cardiac diseases (e.g., stroke)\".\n5. Identify the factors of the patient's current use of tobacco. The trial has listed them as \"Too many cigarettes. \"\n6. Identify the factors of the patient's poorly controlled cholesterol (LDL > 70 mg/dL or triglycerides > 150 mg/dL). The trial has listed them as \"BAD LDL.\"\n7. Identify the factors of the patient's homocysteine > 12umol/L. The trial has listed them as \"Homocystein > 12umol.\"\n8. Identify whether the age of the patient is>55 years.\n9. Identify whether the patient has a family history of CAD. The trial has listed them as \"Family history of CAD.\"\n10. Identify whether the patient is English speaking. The trial has listed them as \"English-speaking.\"\n\n*11. The patient meets the inclusion criteria of the trial. [?]\n\nB. Evaluate the case\n\n*Given the patient's information, how do you assess his eligibility for the clinical trial? Please consider the Trial eligibility, Trial exclusion, or Trial nonexclusion. Which one is",
        "label": 1
    },
    "714": {
        "output": "## Example\nIn this section, you are given the patient note and clinical trial note as follows. You will determine the patient's eligibility and output eligibility note. \nA 43-year-old male patient presented with dizziness and headaches. He had a 5-year history of CAD, was a smoker, had high blood pressure, elevated LDL, no family history of CAD, and had no diabetes mellitus or other cardiovascular risk factors. There was no previous use of lipid-lowering medications. \nThe patient's LDL and HDL levels were 444 and 69\u2009mg/dL, respectively. He was overweight (BMI: 28), and his FBS and triglyceride levels were normal (105 and 120\u2009mg/dL, respectively). The patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur I+/VI in the neck, which radiated to the skull. Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between",
        "label": 1
    },
    "715": {
        "output": "### [Question] 3 In this patient, find the appropriate answer.  \n- As shown in the medical record, what is the patient's LDL-C?  \n    a. Less than 130 mg/dl  \n    b. 130 to 159 mg/dl  \n    c. At least 160 mg/dl  \n    d. Less than 50 mg/dl  \n-  a. Less than 130 mg/dl   \n-  b. 130 to 159 mg/dl   \n-  c. At least 160 mg/dl   \n-  d. Less than 50 mg/dl   \n\n\n### CORRECT ANSWER\uff1ad",
        "label": 2
    },
    "716": {
        "output": ".\nYou need to calculate the 3-valued scale, i.e.,\nIf the output on the third line in the output box 1 is 2 for both data in the input tab, run the program once again, giving any input data that you like, but do not alter the first row data. When its output is 0 or 1, 2 in the output box 3, the program will provide the trial-level eligibility, otherwise it provides the incorrect trial-level eligibility. When the output is zero, 0. This shows that the output is wrong. You should run the program again. You should repeat that process until you obtain a correct trial-level eligibility.\n\n**Trial-level 3**, trial-level 3 eligibility.\n\nPlease do the following worksheet:\n\n*\n\n*Add two more patients as data to your existing patients (the data entered will be overwritten but the data for your patients are not overwritten).\n\n*Enter the date of entry into the program.\n\n*Enter the patient number.\n\n*Enter hs TnT.\n\n*Enter CAD.\n\n*Enter data into `Patient: 4` data tab of the program.\n\n*Change the date of entry into the program for `Patient: 5` by 5th of March 2017 (instead of 22nd Feb 2017).\n\n*Enter date and ID number into both patient and the trial tab.\n\n*Enter hs TnT, LDL cholesterol and triglyceride values for this patient.\n\n*Enter CAD and ulcerated carotid arteries.\n\n*Select the correct value of LDL cholesterol for this patient.\n\n*Go ahead to the first worksheet of your document and complete the program for 20 patients. The first input tab is Patient 1 and last one is the input for Patient 20. Change the date of entry into the program for this patient by 5th March 2017 (instead of 22nd Feb 2017).\n\n*In this program, enter the ID number of this patient in the data tab.\n\n*Enter date and ID number in both patients and trial.\n\n*Enter hs",
        "label": 1
    },
    "717": {
        "output": "#### Differential Diagnosis\n\n- Inclusion criteria, clinical trial\n- Exclusion criteria, study\n- Clinical trial, inclusion criteria\n- Clinical trial, exclusion criteria\n- Study, exclusion criteria\n- Exclusion criteria, clinical trial\n- Inclusion criteria, clinical trial\n\n### The Problem Statement (the Clinical Problem Statement, the Population, and the Primary Clinical Problem) \nAs the clinical trial information suggests, the target patient is the patient with a carotid stenosis who undergoes the carotid stenting. There are other eligibility criteria, such as medication history, medical history, and laboratory test results. You should analyze those from a clinical perspective to determine what type of patients could be candidates for this trial using the criteria on the patient note.\n\n# Considerations \nSometimes, medical tests are not available for each patient. For example, the ultrasound findings were reported in the patient note. Also, it is rare to conduct blood tests on healthy people. In that case, it might be helpful to consider including healthy people who are eligible for the trial based on other clinical information.\n\n# Approach \n\n### Define the Population\nFirst, define the target population for inclusion and exclusion criteria. It can be a general population but should be defined broadly so that the criteria are applicable to a variety of patients and, with minor variations, to many people. In this study, the patient should be willing to be included in this clinical study. A patient meeting the conditions described above can be included in the trial.\n\n### Consider Which Trial Population Matches the Population\nIt's important to consider how broad the eligibility criteria should be. For example, in some cases, it may be appropriate to allow a variety of populations to receive the trial drug. However, in other trials, a certain population may be needed to ensure safety and effectiveness. \n\n### Assess Current and Prior Criteria\nAn assessment of existing eligibility criteria can determine if they adequately describe a patient population. In some cases, the current eligibility requirements are clear and do not need to be changed. In other cases, current requirements may be too broad or too narrow. Also, criteria may be more easily adaptable to future trial protocols",
        "label": 1
    },
    "718": {
        "output": "# Questions\n\n## Excluded\n\n### When can you conclude a patient is excluded?:\nIf the patient met the inclusion criteria, but was also excluded by the exclusion criteria and the exclusion criteria were clearly stated.\nWhen you can't make the decision yourself, only choose `0: Excluded.` to mark all cases.\n\n### When should you choose the same answer to all trials with the same patient record?:\nIf the trials have the same patient record and you can't make sure the clinical trial is suitable for this patient, choose the same answer to all trials by selecting `0: Excluded.` in each trial.\n\n## Not Relevant\n\n### When do you have to answer `no`?:\nYou must answer `no` to the assessment of `not relevant`.\n\n### When do you have to answer to all trials?:\nIf you answer that the information is not enough to check the eligibility, mark all cases.\n\n## Eligible\n\n### When can a patient be marked eligible?:\nIf the patient met the inclusion criteria and none of the exclusion criteria.\n\n### When can a patient be marked as `not applicable`?:\nIf the exclusion criteria for the present trial did not apply to this patient, indicate which of these applied to the patient. If no appropriate exclusion criteria is found, you need to indicate the `not applicable.` answer.\n\n### When should you choose the same answer to all trials with the same patient record?:\nIf there are multiple trials with the same patient record, check them one by one and decide.\n\n## Questions\n\n### You are given a record of a patient, what actions are you able to do?\nIn this task, you must answer how you perform the clinical trial. Choose multiple answers if necessary.\n\n### The trial has a trial-level answer value, which means that the trial-level eligibility is 2: Eligible.\n\n### The patient note was as follows:\nPlease indicate the trial information needed from the patient note to determine the trial-level eligibility.\n\n### The trial records were as follows:\n\n### The trial notes are as follows:\nPlease indicate the trial information needed from the trial record to determine the trial-level eligibility.",
        "label": 2
    },
    "719": {
        "output": "A: \n(1) I would think that this should be 1) not relevant 2) not relevant 3) not relevant\n\nBecause we see a \"Not for treatment with clinical trial\" at least twice, and none of the other options.\n\nEDIT.\n(1) I would still say \"not for treatment with clinical trial\". Since the clinical trials were not found at all on this person, we don't know their relevance. Thus, the note would simply say \"not for treatment with clinical trial\".\n(2) I would think the person would either be \"excluded\" (the clinical trial did exist, but we know it would not be found if looked for), or \"not relevant\" because the clinical trial no longer excludes people because they have this trait. Both seem appropriate.\n<EOD> Isolation of an anticomplementary fraction from bovine milk. I. Isolation and preliminary characterization.\nSummary The protein and lipid fractions of whole milk were separately separated into their major constituents, globulin and albumin, respectively. These components were subjected to a series of purification steps to produce their respective albumin and globulin. The globulin component was then separated into its two major plasma proteins, \u03b1 - and \u00df -globulins, and into the glycoproteins, \u03b1 -lactalbumin; \u03b2 -lactoglobulin; \u03b3 -lactoglobulin; \u03b1 -caseins; \u03b2 -caseins and \u03ba -caseins. This preparation and the component proteins comprise the basis for the preparation of the fraction anticomplementary to milk. The anticomplementary activity is restricted to the glycoproteins.<EOD> SARS-CoV-2 vaccine and treatment of COVID-19 with antiviral drugs in humans\n\nClinical trials for COVID-19 vaccines are in progress, and some have recently received emergency use authorization or equivalent approval. However, to date, no effective treatment for COVID-19 exists. At the time of writing in March 2021, the number of COVID-19-related deaths exceeds one million worldwide and approximately 28 million people are infected. In this report, we first review the bi",
        "label": 0
    },
    "720": {
        "output": "##### Patient notes\n\n##### Inclusion criteria of a clinical trial:\n\n**Title:** Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia \n\n**Summary:** The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical conditions. The primary objective is to establish the efficacy of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen. The investigators are also assessing the safety and toxicity of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen.\n\n**Inclusion Criteria:**\n\n**Disease Criteria:**\n\nALL in complete remission (CR) at the time of transplant. Remission is defined as less than 5.0% bone marrow lymphoblasts by morphology, as determined by a bone marrow aspirate obtained within 2 weeks of study registration. \n\nPhiladelphia chromosome positive ALL is allowed. \n\nLymphoid blastic crisis of CML will be included (provided that patients achieve CR).\n\nAge Criteria: Equal or above age 40 and up to",
        "label": 0
    },
    "721": {
        "output": "This example is included in the file ``Example/src/main/resources/TrialCodePilot/AssessmentExample.csv``.\n\n[END]\n\n\n### Example 5: Missing values\n\n> 123-Assessment - Missing Value\n\n[EXP]\n<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n\n<!DOCTYPE ns1 PUBLIC \"-//NS1 Information Systems International//NS1 IS2 Information Systems International//NS1//EN\" \"http://www.ns.one/DataStandards/1.0/ISIS//EN\">\n<ns1>\n  <informationSet>\n    <identifier>\n      <data>123</data>\n    </identifier>\n    <informationSet>\n      <information>\n        <description>Clinical Trial Initiation, Assessment of Eligibility</description>\n        <informationName>\n          <identifier>Answers to assessment of eligibility</identifier>\n        </informationName>\n        <informationType>\n          <data>\n            <xsi:nil>\n              <xsi:boolean></xsi:boolean>\n            </xsi:nil>\n          </data>\n        </informationType>\n        <itemSet>\n          <item xsi:type=\"ClinicalTrialInformation-InclusionCriteria\">\n            <item>\n              <item>\n                <item>\n                  <item xsi:type=\"Code-Element\">\n                    <item xsi:type=\"ClinicalTrialInformation-Element\">\n                      <item xsi:type=\"Code-Element\">\n                        <item xsi:type=\"ClinicalTrialInformation-Element\">\n                          <item xsi:type=\"Code-Element\">\n                            <item xsi:type=\"Code-Element\">\n                              <item xsi:type=\"Code-Element\">\n                              175\n                              </item><commit_msg>Correcting link to page of example 5 - Missing values<commit_after>__[START]__[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical",
        "label": 1
    },
    "722": {
        "output": "## Questions\n[SOL] Hello.You are an experienced clinician and a researcher. Recently, you were invited by the local hospital committee to design a clinical trial on carotid revascularization. The clinical committee wants to start with a short trial with one group of patients. As the researcher, you should review the list of eligibility criteria to select the participants.\n\nList all the essential patient factors for you to eligible for the clinical trial. You may have any type of disease. Only mention the disease that is relevant. For example, the disease that has been mentioned in the clinical trial eligibility criteria. It can be one of these diseases or multiple diseases.\n\nPlease write your answer below and don't be concerned with other patients.\n\n[SOL] Good. You are right. The essential patient factors are mentioned in the eligibility criteria in this format:\n\n[SOL] Good. You are right. The essential patient factors are mentioned in the eligibility criteria in this format:\n\n## Mention three reasons why a patient with diabetes will not be eligible for the clinical trial.\n\n[SOL] Good. You are right. The patient will not be eligible for the clinical trial if the patient with diabetes. There are three reasons why a patient with diabetes will not be eligible for the clinical trial:\n- A 53-year-old woman presents to a clinic for routine screening. Her only health issue is borderline high cholesterol (total cholesterol of 250 mg/dL). The clinician recommends that she begin dietary supplements containing plant sterol esters as part of lifestyle modification for her high cholesterol. She agrees to try it for 4 weeks. At week 5, a nurse reviews labs and finds out that the subject is now overweight and has developed type 2 diabetes based on her latest hemoglobin A1c. The nurse tells the physician that the patient should stop the prescribed dietary supplement.\n\n[SOL] Good. You are right. The patient not be eligible for the clinical trial if the patient in diabetes mellitus of type 2. That is why the",
        "label": 1
    },
    "723": {
        "output": "<commit_msg>reverted -test of patient note <commit_after><?php\n/////////////////////////////////////////////////////////////////////////////////////////////\n// FILE NAME : clinicrecruit.php\n/////////////////////////////////////////////////////////////////////////////////////////////\n// A script to perform test cases. Use this script before running it in production.\n/////////////////////////////////////////////////////////////////////////////////////////////\n// AUTHOR : <NAME> <<EMAIL>>\n/////////////////////////////////////////////////////////////////////////////////////////////\n/////////////////////////////////////////////////////////////////////////////////////////////\n/////////////////////////////////////////////////////////////////////////////////////////////\n/////////////////////////////////////////////////////////////////////////////////////////////\n\n/////////////////////////////////////////////////////////////////////////////////////////////\n// CHECK MESSAGES BEFORE RUNNING THE SCRIPT\n/////////////////////////////////////////////////////////////////////////////////////////////\nif (empty($arg) || $arg == 100) {\n  echo \"ClinicRecruit.php should be run from the top level of the directory. Run ClinicRecruit.php from the root directory (your code, project root, in your home folder).\";\n  echo \"Run the script as follows: php test.php test.php [1] [2]\".\n        \" [1] Run a simple test that calls ClinicRecruit.php.\"\n        \" [2] Run a complex test that includes ClinicRecruit.php.\";\n  echo \"If you have written functions from libraries, they should be run as if you were in any other file.\";\n  echo \"Run your unit test by specifying the name of the class or file.\"\n        . \" The following shows an example how to run one class.\";\n  echo \"php test.php MyFirstPHPclass/myFirstPHPclassTest.php\";\n  echo \"If you are using a class for PHP 5.5 or up, you must specify its' complete\n        namespace with a double \" before the name of your class, e.g,\".\n        echo \"php test.php MyFirstPHPclass/myFirstPHPclassTest.php \" .\n        \"--namespace myfirstPHPclass\\\\MyFirstPHPclassTest\";\n  echo \"If you use a class for PHP 5.4 or down, you must use the\n        PHP_AUTO_LOAD function to load libraries and classes with names\n        starting with a capital letter.\",\n        \"This is a built-in PHP function.\",",
        "label": 0
    },
    "724": {
        "output": "To practice this task you can go to [instructions for the exercise]. You can also see the [real-time solution] if you still cannot finish these assignments alone. After that, you should be able to see what are the other tasks you're expected to accomplish and do them. Good luck.\n\n# [TRAIN] - [EXERCICE] - [INST] - Task 06: Excluded\n[TRAIN]  - [EXERCIS] - [INST] - Task 06: Excluded\n\n## [TRAIN] \ttask 03: [NAME: EXCLUDED]\nWelcome to the Excluded room. You should write what each line in the patient note means.\nPatient note in EXCLUDED:\nA 25-year-old woman presents with dizziness and frequent headaches. She has two children. The patient's previous medical history is uneventful. Her blood biochemical results were all normal. There is no history of drug use or smoking. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. No neurological problems were detected. Ultrasonography of the carotid arteries revealed a severe stenosis in the left internal carotid artery (LCIC), and as moderate stenosis in the right internal carotid artery (RICA) estimated between 50% and 60%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 258\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 66.08\u2009cm/s and RICA EDV was 26.31\u2009cm/s. An echogenic, moderately stenotic, lesion was found in the right posterior branch of the internal carotid artery, and was estimated to be a 20% or 30% stenosis on the distal wall.\n\n## [TRAIN] \ttask 04: [NAME: EXCLUDED]\nWelcome to the Excluded room. You should",
        "label": 0
    },
    "725": {
        "output": "![<EOD> A new variant of type II herpesvirus of turkeys (HVT) with deletions of BamHI-C and BamHI-W segments in the viral genome.\nEvidence is presented for a deletion 5' to the major late genes in a variant of HVT strain HI. Sequence of the restriction endonuclease BamHI-W fragment of the parent virus, in which the recombination occurred, does not reveal any changes in the primary structure of the DNA due to the deletion.<EOD> Tetraaquabis(N,N\u2032-1-ethylpropane-1,3-diamine-\u03ba2 N,N\u2032)cobalt(II) bis[2-(4-butyl-1H-imidazol-1-yl)acetate] dihydrate\n\nKey indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.006 \u00c5; disorder in solvent or counterion; R factor = 0.062; wR factor = 0.164; data-toparameter ratio = 17.4. Refinement R[F 2 > 2(F 2 )] = 0.062 wR(F 2 ) = 0.164 S = 1.01 4955 reflections 283 parameters H atoms treated by a mixture of independent and constrained refinement \u00c1 max = 0.52 e \u00c5 \u00c03 \u00c1 min = \u00c00.40 e \u00c5 \u00c03\nIn the crystal structure of the title complex, [Co(C 8 H 20 N 3 ) 2 (H 2 O) 4 ](C 12 H 12 N 2 O 2 ) 2 \u00c12H 2 O or [CoCl 2 (C 8 H 18 N 4 ) 2 (H 2 O) 4 ]\u00c12H 2 O, the hexadentate N,N 0 -1-ethylpropane-1,-3-diamine (enpr) ligand bonds to one Co 2+ center, which also exhibits a dist",
        "label": 1
    },
    "726": {
        "output": "*Your name: <NAME>, <EMAIL>  \n*Your IP address: 205.161.121.128  \n*Your session ID: f60a50cd1315b2d2684c1e98323235ad  \n*Your timestamp: 2022-03-27T10:50:20.349-05:00  \n\n# Example\n\nHere is a sample output of clinical trial eligibility assessment:\n\nTrial name: PREDICTION_SAFETY\nTrial description: The purpose of this study is to evaluate the efficacy, safety, and feasibility of the Peripheral Vascular Evaluation Prior to Dermatologic Surgery protocol on patients who require a surgical procedure of the lower limb. The protocol uses a pragmatic design that compares the usual practice of not using an ankle brachial index and duplex scan prior to this kind of surgery to using them. \n\nTrial-level eligibility:\n2) Excluded \n\nPatient-level eligibility:\n2) Excluded \n\nYour name: <NAME>, <EMAIL>  \nYour IP address: 195.164.118.148  \nYour session ID: 794b6ebd208a2be9b8824749d19aa589  \nYour timestamp: 2022-11-01T06:20:36.610-05:00<EOD> Effects of a 269,000 mg/m3 ozone mixture on human lung macrophages. Involvement of hydroxyl radical.\nHuman cultured macrophages challenged with ozone (O3) showed substantial decreases in cytosolic and mitochondrial glutathione (GSH) contents as early as 15 min after challenge; the ratio of cytosolic GSH to mitochondrial GSH was significantly decreased. The cytosolic GSH level did not decrease further with increasing",
        "label": 0
    },
    "727": {
        "output": "<EOD> The Use of Antigens, Toxoids and Toxin-Antitoxin Conjugates for the Immunotherapy of Visceral Leishmaniasis\n\nCitation: Santos-Vasconcelos, J.; Soares, J.V.O.; Santos, J.; Nobre-Pinheiro, C.G.; Faria, S.L.; Saraiva, M.C.; Alves, M.O.; Costa, M.; Santos, P.M.; Nunes, D.M.; et al.Abstract: Visceral leishmaniasis is an endemic disease that is present in several regions of the world, especially in the tropics and subtropics. The treatment of patients suffering from visceral leishmaniasis is difficult and does not lead to complete cure in some cases. Therefore, this disease is a clinical and public health challenge, and an effective preventive vaccine against visceral leishmaniasis has not yet been developed. Due to the lack of a preventive vaccine and the difficulties associated with treating the disease, immunotherapy may represent a promising therapeutic approach, and it is a novel and promising strategy for controlling the disease. In this review, the main molecular aspects of immunotherapy against intracellular protozoan parasites, with particular focus on visceral leishmaniasis, are revised. First, the complexity of the disease and the main immunological aspects concerning macrophages are discussed. Next, the challenges of the immunotherapy of intracellular pathogens are presented. Then, the main immune evasion mechanisms of Leishmania spp. are described. Thereafter, the major aspects of the immunotherapy against visceral leishmaniasis are discussed, and all available strategies of immunotherapy are reviewed, as they seem to be useful in controlling visceral leishmaniasis, along with the use of adjuvants. Finally, an overview of the major antigens and toxoids of the immunotherapy for visceral leishmaniasis, and their conjugates, are discussed.\n\n# Introduction\nAmong the various neglected diseases, leishmaniasis represents one of the most relevant zoonoses",
        "label": 0
    },
    "728": {
        "output": "<EOD> Effect of Sitting Position on the Reliability of Maximum Isometric Muscle Strength Measurements\nGlencross, DCP and Van der Kamp, PW and Hough, PN. Effect of sitting position on the reliability of maximum isometric muscle strength measurements. J Strength Cond Res 26(2): 501-505, 2012. The aim of this research was to investigate the influence of chair height, height of the trunk of the chair, and the hip/knee angle on intratester reliability of maximum upper and lower limb muscle strength measurements, using isokinetic testing as the gold standard. Eight male volunteers with a mean ( \u00b1 SD) age of 48.6 \u00b1 6.3 years were tested on 2 occasions. On both occasions the testing involved repeated maximum voluntary contractions. Testing took place on a HUMAC T250 isokinetic machine in a standardized sitting position in the following groups: (1) normal chair height; trunk and chair height varied (normal testing); (2) normal chair height with the hip/ knee angle adjusted prior to testing; (3) high chair; trunk and chair height were constant (high testing); (4) high chair with the hip/knee angle adjusted prior to testing (high angle testing); (5) low chair; trunk and chair height were constant (low testing); and (6) low chair with the hip/knee angle adjusted prior to testing (low angle testing). Maximum upper limb strength in the shoulder abduction and elbow flexion, and lower limb strength in the knee extension, and hip abduction were measured. The strength variables tested achieved a level of reliability for both normal and high sitting position when compared with the isokinetic machine. The variables for hip abduction in particular were less reliable and should therefore be used with caution when a person cannot position themselves for a high chair. To a great extent the test/retest variability was found to be more associated with the performance of the test than the influence of the sitting position on the reliability of the tests conducted. Practitioners should use the sitting position based on their assessment of their client's ability to perform a test and make no major alterations to sitting",
        "label": 1
    },
    "729": {
        "output": "<NAME><NAME>\n\n= Overview\n\n![](https://img.shields.io/badge/author-<NAME>-lightsteelblue)\n= Objective\n<NAME> is an online text editor that is based on the Jupyter [Notebooks](https://www.jupyter.org) and [Kernel](https://www.kaggle.com/learn/jupyterkernels). When using Kaggle, you can build your notebooks in any language (Python, RST, LaTeX).\nThe objective of this tutorial will be to demonstrate how to extract information from a clinical trial. We will use two main steps:\n- Evaluating the patient's eligibility for the clinical trial\n- Creating new columns from the raw information.\n\n= Learning Path\n* __Data Cleanup__\n\t[Data Cleanup](https://www.kaggle.com/learn/data-cleanup)\n* __Preprocessing__\n\t[Data Preprocessing](https://www.kaggle.com/learn/data-preprocessing)\n* __Baseline Transformations__\n\t[Baseline Transformations](https://www.kaggle.com/learn/baseline-transformations)\n* __Feature Engineering__\n\t[Feature Engineering](https://www.kaggle.com/learn/feature-engineering)\n* __Data Imbalance__\n\t[Data Imbalance](https://www.kaggle.com/learn/data-imbalance)\n* __Supervised Machine Learning__\n\t[Supervised Machine Learning](https://www.kaggle.com/learn/supervised-machine-learning)\n* __Unsupervised or Unsupervised Learning__\n\t[Unsupervised Machine Learning](https://www.kaggle.com/learn/unsupervised-machine-learning)\n* __Cross-validation__\n\t[Cross-validation](https://www.kaggle.com/learn/cross-validation)\n* __Data Transformation__\n\t[Data Transformation](https://www.kaggle.com/learn/data-transformation)\n* __Data Visualization__\n\t[Data Visualization](https://www.kaggle.com/learn/data-visual",
        "label": 0
    },
    "730": {
        "output": "<p style=\"text-align: justify;\">Four different scenarios of the clinical trial analysis for patient 1:</p> <p style=\"text-align: justify;\">Case 1. [CODE]: The exclusion criteria on the previous disease exclude the patient from the trial. [CODE]: Outputs 1. The patient does not qualify because exclusion criteria on the previous disease apply.</p> <p style=\"text-align: justify;\">Case 2. [CODE]: The previous disease has no effect on exclusion from the particular trial. [CODE]: Outputs 0. The patient does not have sufficient information to qualify for this clinical trial.</p> <p style=\"text-align: justify;\">Case 3. [CODE]: The patient has no effect on exclusion from the trial. [CODE]: Outputs 0. The patient does not have sufficient information to qualify for this clinical trial.</p> <p style=\"text-align: justify;\">Case 4. [CODE]: The patient meets inclusion criteria and all the exclusion criteria for the trial are met. [CODE]: Outputs 2. Inputs 2: The trial-level eligibility is eligible. [CODE]: Outputs 2. The patient is eligible for this clinical trial.</p> \nYou should think about the following questions:<P>\u2022 In Case 1, is the patient's exclusion criterion applied? (yes/no)</li> \n\u2022 In the cases 2 and 4, the correct trial-level eligibility output is 0. Why?</li> \n\u2022 In case 3, if the trial-level eligibility output is 2, why?</li> \n\u2022 Now, suppose that the patient does not meet any of the inclusion criteria. Which output does your program give?</li> \n\u2022 If an output of 2 means that the patient is eligible for this clinical trial. What is different between the output for case 4 and Case 1?</li> \n<P>\n<P>The correct answer is <STRONG>(A), (B), (C), and (B)</STRONG> respectively \nA1. <STRONG>The exclusion criteria for the previous disease exclude the patient from the trial.</STRONG>\nA.2. <STRONG",
        "label": 0
    },
    "731": {
        "output": "## Step 3\nUsing the data from Step 1 or 2, import the data into the R environment.\n[INST] R> data=read.table(paste0(\"../data\", filename,\".txt\"), header=T, row.names=FALSE) # Read the trial patient data [INST] R> patient.id<-rownames(data)\n\n## [install]\nR> data <-read.table(paste0(\"../data\", filename,\".txt\"), header=T, row.names=FALSE) # Read the trial patient data R> patient.id<-data[,1] R> gender <-data ,2] R> birth.year <-data[,3] R> birth.month <-data# Add a variable to indicate the patient was excluded by eligibility check R> exclusion <-data[,patient.id %in% excluded ,2]+data[,1] # Add the date of diagnosis of CAD R> cad.",
        "label": 0
    },
    "732": {
        "output": "## Good luck!\n<EOD> A randomised, controlled trial to assess the effect of oral pre\u2010treatment with indomethacin on gastrointestinal complications following coronary angiography and intervention\nObjectiveTo examine whether indomethacin (Indobolet\u00ae, Indocid\u00ae, Indometon\u00ae) administered orally 18 h before and 8 h after coronary angiography and intervention reduces the severity of gastrointestinal complications. DesignProspective, single-centre, randomised, double-blind, placebo-controlled, parallel-group trial. PatientsConsecutive patients booked for elective coronary angiography and intervention within a few days. InterventionAfter randomisation, one group received indomethacin 75 mg twice daily, one group received placebo twice daily. Patients completed questionnaires on gastrointestinal symptoms (symptom score) before and after coronary angiography and intervention, and within 3 days thereafter. Main outcome measuresThe primary outcome was the severity of heartburn as compared to that noted just before cardiac catheterisation. A second gastrointestinal score was calculated after coronary angiography and intervention. Secondary outcomes were the severity of regurgitation, nausea, vomiting, and abdominal pain, and the overall frequency of gastrointestinal symptoms. ResultsSixty-six patients were randomised (34 women, 32 men, age 72.5\u00b111.1 yrs, body mass index 28.4\u00b14.9 kg/m2). Thirty-three received and thirty-three placebo. Ninety out of 132 questionnaires delivered within 3 days after coronary angiography and intervention were returned. Severity scores of heartburn before coronary angiography and intervention were 1 point (52), 1 point (30), for the groups receiving indomethacin, respectively, and placebo (0). Mean severity score of heartburn during catheterisation was 0.7 and 0.9, respectively, postintervention 0.8 and 0.9 for both groups (Wilcoxon analysis). Heartburn severity score",
        "label": 1
    },
    "733": {
        "output": "__NOTE__\nIf you see `0) Excluded, 1) Not relevant or 2) Eligible` by `Trial-level eligibility:` keyword, you should fill in the rest of the assessment of eligibility for the `Trial-level: 2) Eligible` case. [INST]\n[INST] \n\n\n## Exercises:\n[INST] Use exercise3.py and data/patient_data/ to work in this exercise.\n[INST] Exercise 3 -  `Inclusion criteria`\n\n\n[INST]\n`Trial-level eligibility: 2) Eligible, Assessing physician: {NAME} {LAST} Clinical trial-related factor: `Inclusion and Exclusion Criteria`\n\n### Include\nIn the CTA, the following criteria are defined for inclusion in the trial: \n\n**Inclusion Criteria (IC):**\n\n1. 18-60 years of age; 2. Cases of angina pectoris by coronary angiography. \n\n### Exclude\nIn the CTA, the following criteria are defined for exclusion from the trial: \n\n**Exclusion Criteria (EC):**\n\n- Previous myocardial infarction or percutaneous coronary intervention in the last 3 months;\n- Left ventricular ejection fraction < 30% in left ventriculography exam;\n- Left ventricular outflow tract and valvular disease;\n- Other conditions that affect the patient's coronary artery;\n- Patients with any contraindication to treatment with omega 3 (allergies or food intolerance and any other adverse response) \n\n[INST]\n`Trial-level eligibility: 2) Eligible, Assessing physician: {NAME} {LAST}, Clinical trial-related factor: `Excluding inclusion criteria`\n\n### Exclude\nIn the CTA, the following criteria are defined for exclusion from the trial: \n\n**Exclusion Criteria (EC)** \n\n- Not meet the `Inclusion criteria (IC) (in any of them) `\n\n## Exercise 4",
        "label": 0
    },
    "734": {
        "output": "### [/STARTSTEP][ENDSTEP] [INST]\nNow you should input the patient note as follow. First, you should input the patient note in the 'Patient note' section by`Patient note`. You can input the text of the clinical trial note of the patient. You can also add line spacing after 'Patient note' section. And you can input more patient notes by pressing `Enter`. \n[/STARTSTEP][ENDSTEP] [INST]\n```\n\n## Step 5: Patient demographics and patient treatment\nPatient demographics such as age, height, weight, gender, birth date and birth place are required. You can also choose the clinical trial center in the 'Clinical trial center' section.\n\n### [/STARTSTEP] [ENDSTEP] [INST]\nIn the 'Patient demographics' section, you should input the demographics of the patient. You can set the patient's birth date, gender, and ethnicity. [/STARTSTEP] [ENDSTEP] [INST]\n\n### [/STARTSTEP][ENDSTEP] [INST]\nSelect the clinical trial center in the 'Clinical trial center' section and input the clinical trial center name. [/STARTSTEP][ENDSTEP] [INST]\n\n### [/STARTSTEP][ENDSTEP] [INST]\nAfter selecting the Clinical trial center, you should start the selection of the Clinical trial in the 'CINICAL TRIAL' section. You can choose the clinical trial from three levels; National Cancer Institute, Phase I clinical trial, and Phase 2 clinical trial. And you can input the accession number of the protocol of clinical trial from the 'Protocol ID' section. And you can input the type of the clinical trial, treatment arms to which the patient belongs and status with clinical trial. \n\n# Example code\nIn this tutorial, let's implement the previous code (the previous step in this tutorial) in R.\n\n#### Import data\n\ninstall.packages(\"devtools\")\n\ndevtools::install_github (\"michaeltcullen/CINICAL_TRIAL_SELECT)\n\nlibrary(tidyverse)\n\n# Install CIN",
        "label": 0
    },
    "735": {
        "output": "![](https://res.cloudinary.com/v3pv89h28/image/upload/v1636724413/jml2mlhz3c.png)\n\n> ## Your submissions will remain invisible for peer review.\n\n\n[!VIDEO](https://youtu.be/976xMx2zIwA)\n\n- In `Your submissions will remain invisible for peer review` section you can submit your submissions for final peer review.\n\n\n- If you want to submit your final paper on Kaggle without reviewing, click on `Save submissions without reviewing` button.\n\n\n- If you want to submit only training data for your paper, click on `My submissions, Final training only` button.\n\n- A detailed report is sent to your email address.\n\n\n<EOD> .\nThe effect of the thrombodynamin agent on the blood circulation rate in rats has been found to be a dose-dependent increase. The drug at the doses not producing thrombohemorrhagic activity raises the blood flow rate in skin and mucosal membranes.<EOD> Lattice dynamics of crystalline water from the perspective of quantum mechanics, molecular mechanics, and coarse-grained continuum models.\nThe lattice dynamics of a crystalline phase of water has been a longstanding conundrum due to its anomalies, particularly the weakly bound hydroxyl bonds. Traditional density functional theory based on the Born-Oppenheimer approximation is known to be unreliable. This issue is revisited from a purely quantum mechanical perspective. A wave packet method is applied, which incorporates the true vibrational normal modes of a crystalline water phase. It is shown that a well-converged treatment of the lattice vibration modes gives reasoned results and is in agreement with the results of direct dynamics simulations of the quantum dynamics of the water molecule near the crystalline phase. The quantum results can also be compared with those of quantum dynamics using the local harmonic approximation approximation (LH2) and with molecular dynamics simulations (MD) based on the TIP4P/2005 potential functional. LH3 shows considerable improvement compared to the LH2 results. The",
        "label": 0
    },
    "736": {
        "output": "<EOD> Translocation of a liposomal doxorubicin delivery system into multicellular spheroids of human breast carcinomas: effects of cell cycle-synchronization.\nBACKGROUND\nThe potential of doxorubicin-containing liposomes (DXR-LP) to penetrate through the different depths of multicellular spheroids (MCS) of the tumor cell lines MCF-7 and MDA-MB-231 was investigated by means of confocal laser scanning fluorescence microscopy (CLSM).\n\n\nMATERIALS AND METHODS\nCell cycle-specific synchronization of the MCS was achieved using a combination of vinblastine (MCF-7) and nocodazole (MDA-MB-231).\n\n\nRESULTS\nLiposomes displayed increased penetration into all MCS layers when compared with free drug (MCF-7: 56% vs 27%, MDA-MB-231: 66% vs 52%). Cycling cells of all MCS- layers took up more liposomes than non-cycling cells.\n\n\nCONCLUSION\nCell cycle-specific synchronization was a useful approach to improve the penetration of doxorubicin into all MCS-layers.<EOD> PARP Inhibitor and CDK4\u20136 Inhibitor Combination Therapy for the Treatment of Breast Cancer\n\nThe CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have shown promising efficacy in combination with anti-hormone therapy in patients with hormone-receptor-positive/Her-2-negative metastatic breast cancer in randomized trials. CDK4/6 inhibitors showed promising activity in solid tumors, although clinical trials showed limited effects as single agents. Increasing data have shown that single-agent CDK4/6 inhibitors are able to enhance DNA-damage response and sensitize the cells to DNA damage in many types of solid tumors. Preclinically, CDK4/6 inhibition can enhance the efficacy of",
        "label": 1
    },
    "737": {
        "output": "<EOD> .\nThis paper proposes the use of the electronic tongue for determining an in vitro release from solid dispersions of a hydrophilic tetracycline, i.e. demeclocycline, from a hydrophobic carrier, i.e. PVP, and a model compound, i.e. the non-ionizable indomethacin, from PVP, thus investigating a model of solid dispersion of a poorly water-soluble compound. The influence of particle size on in vitro release, and its correlation with the changes in the electronic tongue pattern, were investigated. The results suggest the use of the electronic tongue as one of the tools for determining a drug release profile for poorly water-soluble compounds from a solid dispersion. The use of high-performance chromatography for the quantitation and calculation of a dissolution profile is not very practical, since a high level of sensitivity is required. The electronic tongue gives a good sensitivity for determining the drug release in vitro and is very easy to run. The data obtained with this method can be related to the dissolution profile for these compounds.<EOD> Infection of the cranial nerves in pediatric patients with bacterial meningitis\n\nBackground: Cranial nerve impairment is an uncommon manifestation of bacterial meningitis. It is unclear what factors influence how severely the cranial nerves are affected by infection, and whether age plays a role in this process. Methods: A retrospective case series from 2001 to 2016. Outcomes of interest included the presence of cranial nerve palsies with or without other associated focal neurologic findings, meningeal irritation signs, intracranial hypertension defined by increased intracranial pressure (> 20 cm H2O), white blood cell count, platelet count, serum sodium, glucose, blood urea nitrogen, creatinine, albumin, and arterial carbon dioxide. All cases were analyzed by a child neurologist. Outcomes were compared in patients younger than 24 months (10 patients, 5 male) and patients older than 24 months (9 patients, 5 male). Data are presented as median",
        "label": 1
    },
    "738": {
        "output": "##[QUESTION]\n\nIn this example, there are three pieces of information that you must input to complete this section: trial's exclusion criteria (trial-level exclusion), patient information that is in the exclusion criteria (patient-level exclusion), and patient information that is not included in exclusion criteria. If any of this missing information exists, you should make a Trial-level exclusion. If all the inputted pieces of information are confirmed, you should submit a Trial-level eligibility of 1) Not relevant.\n\n\n[ANSWER]\n\n1) The exclusion criteria are given only in the trial, and do not refer to patients, e.g., \"Patients \u226518 years old\"; thus, input the first character of the exclusion criteria.\n\n2) If the exclusion criteria mention patients, for example, \"Patients who lack the presence of a specific gene (e.g., CD19, CD20) should be excluded\", you should select the information that is already in your dataset, e.g., Patient ID, Age, Gender, etc.\n\n\n3) If the exclusion criteria do not refer to the patients directly, the character to select is the final character of the exclusion criteria, e.g., 2) Eligible (the last option). You should make a trial-level exclusion only when the patient's characteristics do not meet all the exclusion criteria.\n\n\n##[REFERENCE]\n\nRoth A, et al., Trial-Level Eligibility (TLE) for Clinical Trial Informatics: An Automated Approach for Computational Trial Eligibility. J Innov Clin Dent. 2017, 11(1) \n\n##[SELECTION]\n\nHere is the input file, the `screening_data.txt`, that provides information needed for the algorithm. You should set up the patients' selection with the `screening_data.txt` file, and select appropriate data using the program.\n\n![](\n[REFERENCE]\n\n\n\n## Program Installation and Running\n--------------------------------------\n\n\n\n* Install all the prerequisites\n\n\t```\n\tyum install perl -y\n\tsudo yum install gcc -y",
        "label": 0
    },
    "739": {
        "output": "For more details about eligibility criteria in general, see.\n\n## [[B1: In which line should output the result of the final analysis]] \nWhen you finish the main program, this box appears. In this box, after submitting data, what do you want to obtain? What should you type in this box at the end? \n\nThis is the end of the tutorial. \n\nThe output of the program should be something like in this table. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[table]  <Tutorial>:  [[T2: In which line should output the final assessment for each patient]]  The next task is to output the final assessment for each patient. To do this, there are 4 factors: Patient name, Age, Sex, Atherosclerosis (0=No, 1=Yes) and final assessment. Final assessment is used in the model that will be described below. [/table] \n<EOD> .\nThe authors discuss the problem of indications to extracorporeal shockwave lithotripsy (ESWL) in patients with nephrolithiasis in the conditions of a specialized center. A total of 158 patients (90 males and 68 females) were treated from 1988 to 1997. At first, a diagnosis was made using ultrasonography, a urography, X-ray, intravenous urography, computerized tomography, retrograde pyelography. After ESWL stone clearance was achieved in 84.4% of the cases. In 1.9% of patients repeated lithotripsy was required during the first month. No statistically significant differences were detected in the frequency of clinical manifestations of renal colic between patients treated by shockwave lithotripsy and nephrolithotomy. Complications during the treatment were registered in 8 patients (5%). They were of the mild and moderate severity, no severe complications were recorded. After treatment patients of groups 3 and 4 received a conservative therapy and were examined yearly. Stone clearance was achieved in 66.7 and 71% of these patients. ESWL is a safe and effective method of tre",
        "label": 2
    },
    "740": {
        "output": "## [/CATEGORY]\n\n\n\n\n[CATEGORY: TOP]   \n\nIf we have a lot of data in the clinical research note, we may not want to repeat all of the information all of the time. That is, if data can be used more than once, we can use the category to make use of this fact. For example, in our example, the disease, the family history of CAD and lifestyle (physically active and so on) can repeatedly make use of the common information through the category.\n\nWe can organize the data into the category through the following way.\n\n*If the data can be recured more than once, we do not need to write the values repeatedly, but we can define these common data as the category.\n    *Note that we do not repeat values again. For instance, `CAD=1` is defined as a category named `Cancer`. [INST]\n*If we are going to use a category data, we need to define a variable, similar to the variable definition. For instance, a category named `Cancer-type` is created through `Cancer cancerType { . . . } = 1`, and we can then define a category variable with the values as follows. Cancer categoryType { . . . }={breast, prostate, lung, and bile duct}\n    *Note that variables and the category are similar concepts to the `Trial-level eligibility` variable. We can create a variable based on other variable with defined value.\n*Also, we should define the values for the category variable. For example, `CANCER.type=lung` and `CANCER.type=bile duct`, etc.\n*If we would like to refer to other values in the note through the category variable, we can use the value. For instance, `Patients with cancer of the lower lung` or `Patients with cancer of the bile duct`.\n*If we need to use an existing variable in our note, we will need to reference other values. For example, we may need to check which patients are patients with CAD. To do that, we will use the value of the category-related variable for each patient.\n\n\n*We can check a patient's value, e.g., `A 33-year old woman",
        "label": 1
    },
    "741": {
        "output": "![INST]: #inst<EOD> .\nOBJECTIVE\nTo develop the surgical approach for reconstruction of the parotid gland in the patients with primary parotid neoplasm located between the parotidectomy line and the mental foramen or passing the foramen.\n\n\nMETHODS\nThe clinical data of 121 cases of primary parotid neoplasms involving the facial nerve trunk from Jan. 2001 to Oct. 2012 were retrospectively analyzed. All these cases were dissected from the buccal fat pad firstly to clear the nerve trunk or sheath and then the facial nerve trunk was dissected up to the main trunk in the parotid gland. The other parotid gland was dissected along the main trunk without the facial nerve.\n\n\nRESULTS\nThere were 47 patients of benign salivary gland tumors (10 of the facial nerve trunk sheath, 6 of the facial nerve trunk passing the foramen, and the other 29 of the buccal fat pad. Among the 74 patients of malignant salivary gland tumors, 27 were located close to the mental foramen, 21 to the facial nerve trunk sheath, 15 passed the foramen, and 11 close to the facial trunk. There was no facial paralysis caused by the facial nerve injury, but obvious paralysis occurred in 5 cases of the buccal fat pad without facial nerve dissection. No mental nerve paresthesia occurred in 17 cases of mental foraminal tumors, and of the 54 cases of extramandibular tumors.\n\n\nCONCLUSION\nThe combination of 2 procedures of tumor resection and facial nerve protection are effective for patients with neoplasms involving facial nerves, as well as the mental foraminal neoplasms without mental nerve paresthesia.<EOD> Prospective Study of Porphyria Cutanea Tarda\nA prospective study of 11 patients with porphyria cutanea tarda is described, and the natural history of the disease is presented and",
        "label": 1
    },
    "742": {
        "output": "> ## # ETHICS\n* The study met all requirements of ethical research.\n* Potential participant understands that withdrawal from the trial will not affect care, and the research team agreed that the individual will not be exposed to any harm or potential risk as a result of the participant's decision to participate in or to withdraw from the study.\n* Potential participant understands that all medical information collected will be kept fully confidential and will be used only for the purpose of research.\n* All data are collected anonymously, will only be accessible by the researchers involved in the study and will be used only for scientific purposes.\n* The patient's data will not be used for any other purpose.\n* The study investigators will ensure, by providing access to appropriate information and resources, that the potential participant's right to make an informed decision about research participation will not be compromised or impeded.\n* The study investigators shall provide appropriate medical care to potential participants even if they refuse to enroll or withdraw from the study.\n* If the individual decides to participate, he will provide written informed consent for participation in the study.\n\n```python\nTrial-level eligibility: 0) Excluded, 1) Not relevant, or 2) Eligible\n```<EOD> Phenytoin\u2010induced hypocalcemia with an abnormal parathyroid hormone level\nA 36\u2010year\u2010old man, 6 weeks after transplantation of the pancreas because of T1DM, was admitted because of generalized tonic\u2010clonic convulsions and coma. Phenytoin was given because of poor blood glucose control and repeated mild hypoglycaemic episodes. The patient received 2\u20133\u2003g phenytoin over the following 28\u2003h with total doses varying from 4 to 6\u2003g. Seventeen hours after the last bolus dose the patient was restless but responsive and phenytoin was therefore reduced to a daily dose. The following day, he remained awake and responsive, but blood calcium was found to be less than 2\u2003mmol/L. Phenytoin treatment was stopped, but calcium was not given because of recent renal transplantation. However, by the next day paresthesia developed",
        "label": 1
    },
    "743": {
        "output": "# Instruction for Phase 3\nNow, please repeat the same three steps (Lines 8 - 10) for each patient note, one by one. That is a total of 13 patient notes and 13 trial-level eligibility assessments. Let us see how it looks! \n\n# Discussion\nYou and your physician are conducting a cross sectional study to gather evidence on the prevalence of obesity of adults of different age groups. As many as 900 participants, equally of each gender were chosen for the study by random sampling. Height, weight, and body mass index (BMI) were measured and recorded for each participant. Your supervisor told you that obesity is a high risk factor for many chronic diseases including diabetes, heart disease, and hypertension, and therefore, it is worthwhile to present the cross sectional study findings in your group. Let us discuss ways on how BMI is affected by factors such as gender, age, and race. \n\n* What is an example of a simple random sampling? (Ans. If you make a list of the members of a class, and pick a name out of the class membership list, and this occurs with every member, then you are performing simple random sampling. \n\n\n![[image:Slide-2.gif]]!\n\nLet's examine a trial-by-trial example based on your trial-level eligibility assessment. You see that all the assessments for patients in Example_1 are 0. It means that patients in Example_1 do not meet the exclusion criteria; consequently, they can participate in a clinical study. On the other hand, we cannot identify all conditions for patients in Example_2, Example_8, and Example_12; therefore, we have to make an exclusion criteria based on the available information. Because conditions in Example_2 and Example_8 are not clearly defined, we mark the Trial-level eligibility 0 for them. We can observe the Trial-level eligibility for patients in Example_12 is 2. Thus, patients in Example_12 should not be excluded, because none of their conditions of exclusion are met. Let us observe a patient note for a particular trial (e.g., patient 12 in Example_1",
        "label": 1
    },
    "744": {
        "output": "[CODE]\nfrom __future__ import annotations\n\n# standard library imports #\nfrom contextlib import contextmanager\nfrom typing import Dict, Iterable, Optional, Union\n\n# external imports #\nimport pandas as pd\n\n# third party imports #\nimport numpy as np\nfrom pprint import pprint\n\n# in-house imports #\nimport eligibility_assessment_interface as eai\nimport path as pth\nimport trial_interface as ti\nimport _interfaces as _inf\n\n\n# ----------------------------------------------------------------------# #\n## Tutorial: Trial Recruitment via Eligibility Checking #\nTrials have to recruit new patients over an extended period of time. After enrolment, patients have to undergo clinical examinations and are followed-up for a period of time. \n\nA lot of time can be saved by identifying patients who have a good prognosis as early as possible by conducting clinical examinations only in the patients who meet the trial eligibility criteria.\nTrials with such an approach are called non-inferior but require a time-consuming screening of many patients.\nTo avoid such an extensive recruitment effort and to save time, trials use so-called eligibility criteria to pre-select patients for enrolment. Eligibility criteria are conditions on demographics, medical history, other medical conditions, risk factors and medication adherence. The goal of this step is to reduce the overall number of patients for further recruitment as much as possible and also to enrich the study population with patients who have a potentially beneficial outcome. \n\nThe assessment of eligibility can be a complex task. It may be based on a complex, multilevel, hierarchical criteria framework that contains exclusion and inclusion criteria. The decision on eligibility is based on multiple pieces of evidence that are to be evaluated individually. \n\nThe eligibility assessment interface (eai) is used to support the clinical assessment of eligibility by the clinical staff.\n\nOne of the most important requirements for eligibility assessment interface systems is to support the user in the time-consuming and complex decision process of the trial recruitment step.\nA system which meets these requirements is the eligibility assessment interface.\n\nPlease note that",
        "label": 1
    },
    "745": {
        "output": "### Questions [Q]{x}\n\n[X]{Q}2 When you are finished with the trial-level eligibility, you are to report results according to the rules provided in the questionnaire. \n\n1) Clinical Trial Screening Results\n\n[/Q]{1}\n\n\n## Submit\nAll your work should be done before you submit it to us. Please make sure you follow all guidelines before submitting. Remember you need to add your answers to the following questions to find the complete assessment.\n\n### \u3010Questionnaire\u3011\u3010Question\u3011\n\n##{Q}1 Q 1 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial eligible?`\n\nHow do you expect to do?\n\n\n\n### Q 2 Q2 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial eligible?`\n\n\nHow do you expect to do?\n\n\n\n### Q 3 Q3 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial eligible?`\n\nHow do you expect to do?\n\n\n\n### Q 4 Q4 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial elig",
        "label": 0
    },
    "746": {
        "output": "subfolder: subfolder name in the project folder.\n- [] file: file name of your solution.\n- [INST] subfolder: subfolder name in the project folder.\n\n#### :white_check_mark: What did you need? Checkmark what you have implemented correctly.\n\n### [INST] Required\n- [] [INST] \n- [] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n\n### [INST] Good to have\n![](http://up05.vkontakte.ru/doc/430375492/0b51faf968ea7772d0584443f1a0ec57.png)\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n<EOD> A comparison of the clinical characteristics of COVID-19 and seasonal influenza infection\n\n [bib_ref]  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia..., Chen [/bib_ref]  [bib_ref]  Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China, Dong [/bib_ref]  [bib_ref]  The epidemiological and clinical characteristics of 67 cases of coronavirus disease 2019..., Chen [/bib_ref]  [fig_ref]  Table 1: Comparison of features and outcomes of COVID-19 and SARI patients [/fig_ref]  [bib_ref]  Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, Li [/bib_ref]  [bib_ref]  Epidemiological characteristics of 504 cases of pneumonia cases infected by SARS-CoV-2 in..., Zhang",
        "label": 0
    },
    "747": {
        "output": "- Challenge description\n\nThe challenge can be found here.\n\n\n\n- Resources used\n\n- A list of resources that we think you may find helpful\n\n[R1]\n[R1]\n[R1]\n[R1]\n[R1]\n<EOD> Interstitial lung disease in systemic lupus erythematosus\nPurpose of reviewThe purpose of this article is to review recent data regarding the epidemiology, diagnosis and management of interstitial lung disease (ILD) in patients with systemic lupus erythematosus (SLE). Recent findingsThe prevalence of SLE-related ILD is estimated to be 5% based on multiple case series. The most common type of SLE-related ILD is a diffuse alveolar damage-like interstitial pneumonitis with nonspecific interstitial pneumonitis. Although there is no standardized method to diagnose ILD, interstitial pneumonitis is a key criterion for a complete American College of Rheumatology classification of SLE. Although the reported incidence of SLE-related ILD was previously 0.2 to 0.3 cases/100 person-years, a study reported an incidence of 0.6 cases/100 person-years, mainly in patients who fulfilled at least four ACR criteria for SLE. Treatment for SLE-related ILD varies depending on the severity of ILD; if there is only a unilateral and focal ground-glass opacity pattern on high resolution CT or mild restrictive lung function abnormalities, glucocorticoid treatment may prevent progression to diffuse pulmonary fibrosis. However, if there is bilateral lung involvement and widespread ground-glass opacity patterns on high resolution CT, corticosteroid treatment is often sub-optimal. In these situations, immunosuppressive agents could play a key role in ILD therapy. Cyclophosphamide therapy has been used to treat SLE-related ILD and is considered to have an adjuvant role as an immunosuppressant agent, although its effects on improving lung function or decreasing mortality rate are small. SummaryS",
        "label": 0
    },
    "748": {
        "output": "Good job! We did it again!\n<EOD> Association of genes involved in c\u2010MYC gene expression modulation with survival in patients with advanced renal cell carcinoma treated with cytokines or antiangiogenic therapy\nThe c\u2010MYC protooncogene is a transcription factor involved in the induction of cellular proliferation, cell growth, cellular transformation, and apoptosis. In the present study, we examined the role of regulatory regions of c\u2010MYC on overall survival (OS) of advanced renal cell carcinoma (RCC) patients treated either with cytokines (n\u2009=\u200969) or with targeted therapies (n\u2009=\u200962). We found that CpG\u2010methylated patients had 2.3\u2010fold longer OS compared with the unmethylated patients (P\u2009=\u20090.002) and survived significantly longer than unmethylated patients who were treated with cytokines (P\u2009=\u20090.01) or treated with targeted therapy (P\u2009=\u20090.002). Moreover, OS was significantly associated with CpG\u2010hypermethylation of the P1 promoter (P\u2009=\u20090.04). In contrast, OS showed no significant relationship with the expression of c\u2010MYC or its regulatory elements. In conclusion, c\u2010MYC CpG\u2010methylation and P1 CpG\u2010hypermethylation have prognostic value for the OS of advanced RCC patients treated with cytokines, or targeted therapy, or both. \u00a9 2010 Wiley\u2010Liss, Inc.<EOD> Neuron loss and the dynamics of the mating\u2010induced LH surge in virgin guinea pigs.\n1. Guinea pigs were castrated on the day of birth to facilitate hormonal studies. All virgin guinea pigs were examined neurologically and had been previously shown by computer image analysis to be normal. 2. Differential counting of the hypothalamo\u2010preoptic areas (HPOs) disclosed a highly significate reduction in the numbers of vasopressin/oviduct\u2010immunoreactive (ir) neurones at the onset of diestrus in virgin adult guinea",
        "label": 2
    },
    "749": {
        "output": "Here is the Python code:\n\n```python\n# + Python@Run\n# + title: Main\n# title: Main\nclass Eligibility:\n    def __init__(self, scale: str):\n        if scale == \"0\":\n            self.scale = \"Excluded\"\n        elif scale == \"1\":\n            self.scale = \"Not relevant\"\n        elif scale == \"2\":\n            self.scale = \"Eligible\"\n        super().__init__()\n\n    def to_json(self) -> dict:\n        return {\n            \"assessment\" : self.scale,\n            \"trial_id\" : \"F2747\"\n        }\n\n    def from_json(self, json: dict) -> None:\n        json.pop(\"assessment\")\n        self.__init__(json[\"trial_id\"])\n\n    def __repr__(self) -> str:\n        return f\"Eligibility: {self.scale}\"\n```\n\nLet's try the above code: `from clinical_assessment.Eligibility import Eligibility`. and input the note and trial.\n\n```python\n# + Python@Run\n# + Python@title Main\n# + Python@language Python\n\n# + Python@title: Main\n# + Python@index 1\nassessment 0\ntrial_id F2747\n# + colab={\"base_uri\": \"https://localhost:8080/\", \"height\": 762}\n\nassessment 0\ntrial_id F2747\n# + Python@index 2\nassessment 1\ntrial_id F2747\n\nassessment 1\ntrial_id F2747\n# + Python@index 3\nassessment 2\ntrial_id F2747\n\nassessment 2\ntrial_id F2747\n# + Python@index 4\nassessment 0\ntrial_id F2747\n# + Python@index 5\nassessment 1\ntrial_id F2747\n```\n\nSo far, we have only created the Eligibility class; we have",
        "label": 0
    },
    "750": {
        "output": "[INST] Instructions\n\n\nHere is the output in Python 3.6.11. \nfrom random import randint\nfrom random_walk_by_age import random_walk_by_age\nfrom random_walk_by_weight import random_walk_by_weight\n\npatient = \"\"\"\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the clinical trial:\nTitle: Observational Study to Estimate the Effectiveness of",
        "label": 0
    },
    "751": {
        "output": "## Example input\n```\nName: A 46-year-old man presents with dizziness and frequent headaches. \nHe has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. \nVascular Reactivity and Metabolic Syndrome\nInclusion Criteria:\n3 or more of the following criteria of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III):\n```\n<EOD> Acute Kidney Inj",
        "label": 1
    },
    "752": {
        "output": "<EOD> Ouabain Inhibits PMA-Induced Macropinocytosis in MDCK Cells by Suppressing PI3 Kinase Activity\nAbstract: Ouabain has been reported to inhibit cell growth, macropinocytosis, and protein synthesis in Madin\u2013Darby canine kidney (MDCK) cells. The present study confirms that ou",
        "label": 1
    },
    "753": {
        "output": "<EOD> Molecular Mechanism of the Inhibitory Activities of Benzenesulfonamide and Quinazolin-4(3H)-one Derived against Multidrug-resistant Gram-negative Bacteria\nThe continuous emergence of antibiotic-resistant Gram-negative bacteria necessitates the search for new antibiotics, which often involve the utilization of natural products (NPs) and their derivatives. In our previous study, we discovered that benzenesulfonamide 1, quinazoline 4(3H)-one 2 and N-acylated 3 were promising against drug-sensible and MDR Gram-negative bacteria. In the present study, the mechanism of antibacterial activity of 3 against E. coli was evaluated. The results indicated that the mechanism of action was consistent with the Gram-negative mechanism, which involves binding to the 3\u2019 end of the 16S rRNA and affecting translation to inhibit bacterial growth. Besides, 1-3 had weak inhibitory activities to human DNA gyrase, which contributed to their negligible hemolytic activity. Moreover, 3 displayed low inhibitory activity against C. elegans, indicating its low toxicity. In brief, these findings provide novel NPs candidate against drug-sensible and MDR Gram-negative bacteria, which can be utilized for the development of new antibiotics. Graphical Abstract 5-N-octanoyl-3-((E)-(4-chlorophenyl)diazenyl)benzenesulfonamide (3) exhibited potent antibacterial activities against drug-sensible and multidrug-resistant Gram-negative bacteria; moreover, it had negligible hemolytic and cytotoxic activities.<EOD> .\nPURPOSE\nTo evaluate the intraoperative and histological characteristics of retinal detachment associated with proliferative diabetic retinopathy in patients submitted to pneumatic retinopexy.\n\n\nMETHODS\nPatients' ages, sex and number of retinal detachments were recorded. The extent of proliferative diabetic retinopathy and its classification were also assessed.\n\n\nRESULT",
        "label": 1
    },
    "754": {
        "output": "[CODE]\ndef recruitment_assistant(patient_text: str, trial_txt: str) -> str:\n    \"\"\"Get trial-level eligibility of patient\n\n    Args:\n        patient_text (str): The text content of the patient note.\n        trial_txt (str): The text content of the clinical trial note.\n\n    Returns:\n        The trial level eligibility of the patient.\n    \"\"\"\n    patient_note_text = preprocess_text(patient_text)\n    trial_note_text = preprocess_text(trial_txt)\n    patient_note_pos_list =  patient_note_text.token_position\n    trial_note_pos_list = trial_note_text.token_position\n    trial_level_eligibility_code = ''\n    trial_level_eligibility_score = 0\n    exclude_conditions = ['Excluded', 'Not relevant']\n    for token in trial_note_text.split(sep=' '):\n        if token.lower() in exclude_conditions:\n            trial_level_eligibility_score = 1\n            trial_level_eligibility_code = 'Excluded'\n        if token in DONT_APPLEND_TOKENS:\n            token = ' ' + token\n        else:\n            token = token + ' '\n        trial_level_eligibility_code += token\n\n    patient_pos_list = [x[0] for x in patient_note_pos_list]\n    for token in patient_note_text.split(sep=' '):\n        if token.lower() in exclude_conditions:\n            patient_level_eligibility_score = 1\n            patient_level_eligibility_code = 'Excluded'\n        patient_level_eligibility_code += token\n\n    return f\"Trial-level eligibility: {trial_level_eligibility_code} \\nPatient-level eligibility: {patient_level_eligibility_code}\"\n    trials_eligibilities = recruitment_assistant('MyNote', trial_txt)\n\n\nWhat should you change if the patient note doesn",
        "label": 1
    },
    "755": {
        "output": "Examples are described at the end of this document.\n\n---\n\n# How to calculate patient level eligibility\n\n* **A person level eligibility score is a 13-bit number**\n  1. The number \"1\" is added for the patient-level eligibility score if the patient satisfied the inclusion criteria. The number \"0\" is added if the patient did not satisfy the inclusion criteria. The number \"1\" is added if the exclusion criteria are met.\n  <p align=\"center\">\n          <img class=\"align-center\" src=\"https://github-images.herokuapp.com/ml4hub-training-guide-docs/images/text-based/ML4_PPE_ClinTri_Inclusion_Exclusion_Condi-tions.png\"/></p>\n  <br><p style=\"text-align:justify;\">\n    The eligibility score is the sum of the score of each condition, i.e. the sum of 0 and 1. In this example, PPE is 0 because we exclude the patient in this clinical trial because he have not been diagnosed with diabetes by physician.\n  </p>\n  <p align=\"center\">\n        <img class=\"align-center\" src=\"https://github-images.herokuapp.com/ml4hub-training-guide-docs/images/text-based/ML4_PPE_ClinTri_Inclusion_Exclusion_Conditions.png\"/></p>\n  <br>\n  2. The result is rounded off by a maximum and minimum integer value.\n  <p align=\"center\">\n        <img class=\"align-center\" src=\"https://github-images.herokuapp.com/ml4hub-training-guide-docs/images/text-based/ML4_PPE_ClinTri_Inclusion_Exclusion_Conditions.png\"/></p>\n  <br><p style=\"text-align:justify;\">\n    The number \"1\" is added in this example if the patient is not eligible. The number \"6\" is added if the patient is eligible. The result is the rounded number 6 and we consider that the patient is eligible for this trial.\n  </",
        "label": 0
    },
    "756": {
        "output": "#### [INST] Exercise 05.2\nExercise 07.1\n\n[INST] The previous exercise was not too difficult, so now let's try to make some minor change. As you know, clinical criteria such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions are important in deciding which candidate would benefit most from a particular drug therapy. Hence, we should be able to make a final decision regarding whether or not a patient is eligible for a clinical trial by considering the clinical criteria as well. What is it worth doing? Let's do it!\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient'",
        "label": 1
    },
    "757": {
        "output": "##<jupyter_code>if __name__ == '__main__':\n    %run 'C:/Users/pav.bakolic/Library/Jupyter/jupyter_client_v1_7.dll' %kernel.path\n    %run 'C:/Users/pav.bakolic/Projects/DataFit/Tutorials/DataFit_Instructor_Tutorials/Tutorial_06_DataFit.ipynb' #this script runs in a new process.\n    %run 'E:/_Projects/DataFit/Sources/DataFitTutorial.ipynb' #this script runs in the new process.\n\n    if __name__ == '__main__':\n        df = pd.read_csv(\"../Examples/data.csv\", sep = ',')\n        column_name = list(df.columns)\n        column_name.sort()\n    else:\n        print (\"This is an incorrect call to runn the script. The script can be run properly as %run E:/_Projects/DataFit/Sources/DataFitTutorial.ipynb\", '\\n')\n        raise RuntimeError(\"This is an incorrect call to runn the script. The script can be run properly as %run E:/_Projects/DataFit/Sources/DataFitTutorial.ipynb\")\n\n    print (\"Please, run the script after you imported the DataFit package.\")\n    print_message(\"DataFit package version: 1.1.0.0.\", \"title\")\n    print_message(\"DataFit package author: Pavle Bakolic (. \", \"subtitle\")\n\n    if __name__ == '__main__':\n        print (\"Please, run the script after you imported the DataFit package.\")\n        print_message(\"DataFit package version: 1.1.0.0.\", \"title\")\n        print_message(\"DataFit package author: Pavle Bakolic (. \", \"subtitle\")\n    else:\n       raise RuntimeError(\"Please, run the script after you imported the DataFit package.\")\n\n\n    data = pd.DataFrame()\n    data['Name'] = 'Peter'\n    data['Age'] =",
        "label": 0
    },
    "758": {
        "output": "## 2.2.1: Assessment of Inclusion Criteria for Clinical Trial in [INST] \n[[INST]] You are a helpful assistant for clinical trial recruitment. Your task is to assess whether the patient's inclusion criteria is met, or not. \n\nLet's think step by step. \n 1. Get input the file of `patientNote.csv` and `trialNote.csv`. \n 2. If the name of patients' gender in the `patientNote.csv` and that of the clinical trial is the same, the patient is assessed for the trial. If the two identifiers are different, the patient is not assessed. \n 3. Get the age of the patients from the patient note. \n 4. If the trial's inclusion criteria for age is same, then it is assessed. \n 5. If the trial's inclusion criteria for cholesterol level is same, then it is assessed. \n 6. If the trial's exclusion criteria for cholesterol level is not met, then stop assessment process. \n 7. If the trial's inclusion criteria for the history of angina is same, then it is assessed. \n 8. If the trial's exclusion criteria for the history of angina is not met, then stop assessment process. \n 9. If the trial's inclusion criteria for gender is the same and the trial's exclusion criteria for gender is not met, then it is assessed. \n 10. If the trial's inclusion criteria for medication use is the same and the trial's exclusion criteria for medication use is not met, then the assessment is continued. \n 11. If the trial's inclusion criteria for systolic murmurs is the same and that of the trial's exclusion criteria is not met, then it is assessed. \n 12. If the trial's inclusion criteria for triglycerides is the same and the trial's exclusion criteria for triglycerides is not met, then it is assessed. \n 13. If the trial's inclusion criteria for carotid artery stenosis is the same and that of the trial's exclusion criteria is not met,",
        "label": 0
    },
    "759": {
        "output": "I think it is best to repeat triallevel eligibility as the last line in the assessment. Otherwise, there is a risk that it gets overlooked.\n<EOD> GIRLS & INTERRUPTION.\nBased in the UK, with international experience, Mia has worked with girls in the South Sudan, Egypt, India, Nigeria and Lebanon in response to gender based and other forms of discrimination. This has included facilitating trainings on gender, human rights and conflict resolution with over 100 organisations, training of trainers and community based participatory research on girls\u2019 education. Mia is a PhD candidate, investigating girls\u2019 participation in the education & work spaces, and has worked with children in conflict zones in Africa, Asia, South America and the Middle East.\nShe has led research and advocacy work on girls\u2019 participation in the education field for more than 17 years with UNICEF. She was recently the Regional Team Lead for Child Protection and Participation in Syria and Lebanon. Here, she also worked on issues of child marriage, as the lead of work in the East Mediterranean region on ending child marriage and the lead expert on children detained in North Africa.\nPreviously, Mia was UNICEF\u2019s Chief Gender Specialist in the UK and Regional Representative in Cairo. Additionally, she was the Education Specialist in the South Sudan, Lebanon and Nigeria, as well as the Humanitarian Chief of Programme in the Ukraine.\nMia was the Lead Programmer and Producer of the award-winning documentary \u2018Plain Jane\u2019. She is now a Film Producer working on projects in Lebanon, Egypt, Brazil and India.<EOD> Erectile dysfunction treated with sildenafil (Viagra)\nSildenafil (Viagra) is currently used by an estimated 150,000-250,000 men, with an estimated total consumption nearing 800 million tablets annually. Despite recent marketing of generic drugs containing sildenafil, the pill continues to be marketed under the Viagra trademark by Pfizer. This article will focus on the pharmacokinetic, pharmacodynamic and adverse effects of sildenafil, the incidence",
        "label": 1
    },
    "760": {
        "output": "## Question\n\nAssume that you are a healthcare professional and your patient is a pregnant woman. You've met a 3-months-old pregnant woman in her first visit to the clinic. Your task is to assess her hemodynamic status. In cases where pregnant women are examined, physiological changes occur in their hemodynamic status. Your assessments should be made on the basis of these pregnancy-induced physiological changes. \n\nTo make an accurate hemodynamic assessment on the basis of these physiological changes, you will use a cardiovascular risk calculator based on the data presented in the patient record and your observations. It takes you approximately 10 minutes to enter all of the information into the model. \n\nHere is the patient information:\nHer name is Mary and she is a 3-months-old pregnant woman who is taking no medications except prenatal vitamins. Her blood pressure is 120/85 mm Hg and her heart rate is 85 beats per minute. She does not have any previous diagnoses concerning the heart or the vascular system.\n\nHere is the cardiovascular risk calculator: \n\n\nHemodynamic assessment: \nRisk level:\nRisk level:\n\nWhat should you write in Hemodynamic assessment by using the cardiovascular risk calculator (i.e., `risk level) in the output? [INDICATOR]\n\nAssume that you are a healthcare professional and want to check your patient's hemodynamic status on the basis of prenatal physiological changes. You've met a 3-months-old pregnant woman in her first visit to the clinic. Your task is to assess her hemodynamic status.\n\n\nTo make an accurate hemodynamic assessment on the basis of these physiological changes, you will use a cardiovascular risk calculator based on the data presented in the patient record and your observations. It takes you approximately 10 minutes to enter all of the information into the model. \n\nHere is the patient information:\nHer name is Mary and she is a 3-months-old pregnant woman who is taking no medications except pren",
        "label": 0
    },
    "761": {
        "output": "Good Luck!<EOD> Long-Term Effects of Childhood Sexual Abuse Exposure on Intimate Partner Aggression and Parenting\nChildhood sexual abuse (CSA) has been associated not only with adult revictimization, but also with an increased risk of adult intimate partner aggression. Few studies have examined the long-term effects of CSA exposure, particularly on the parenting context, which may serve as a mediator for these effects. Data from a large study of U.S. adults (N = 2255) documented that childhood sexual victimization (CSV) exposure was associated with adult intimate partner aggression (IPA) perpetration, and this effect remained significant after controlling for sociodemographic characteristics, substance use, and adult victimization. CSV exposure was additionally associated with psychological aggression perpetration, yet not physical aggression perpetration. Further, CSA-exposed adults were more likely to report that they perpetrated both types of aggression against their own children. There were effects of parental IPA perpetration on young children's externalizing problems, even after controlling for child temperament. Overall, the current findings document that effects of CSA exposure on IPA are long lasting and extend to the next generation.<EOD> Changes in the serum levels of 17 beta-hydroxy-20 alpha-dihydro-4-pregnen-3-one in the prepuberal estradiol-treated puberal baboon.\nTwo prepuberal baboons exposed to estradiol were sacrificed sequentially at approximately 3-week intervals. At each sacrifice, the serum concentration of 17 beta-hydroxy-20 alpha-dihydro-4-pregnen-3-one (estrogen-metabolite; EM), 17 beta-estradiol (E2) and 17-hydroxyprogesterone (17-OH-P) were measured by competitive protein binding assays. Serum EM increases were found in association with an increase in E2. It is suggested that EM levels may reflect 17-ketosteroid side-chain cleavage enzyme activity.<EOD> Prostate carcinoma: imaging evaluation.",
        "label": 1
    },
    "762": {
        "output": "In the following, we describe the evaluation of each term in detail.\n\n## Age\nThe patient's age is 46. To determine a certain age range, refer to the [https://en.wikipedia.org/wiki/Old_Age Wikipedia] article. The age range is often from 60 years old to 70 years old. Therefore, it is 60 years old to 70 years old.\n\n## Gender\nThe patient's gender is male (male).\n\n## Current and previous treatments\nNo use of lipid-lowering medications is used in the patient history, so patient history is used in the condition.\n\n## Laboratory tests and examination\nThere is no need to check whether there are abnormal values in the patient's blood lipid levels since it is known in the inclusion criteria that the patient's LDL-C and HDL-C levels are 545 and 53, respectively. For the patient's neck auscultation, systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), and moderate stenosis in the right internal carotid artery (RICA) with estimated severity of 42%, 40%, and 70% in the LICA, the right internal carotid artery (RICA), and the left internal carotid artery (LICA), respectively.\n\n## Diagnosis\nWhat is the patient's diagnose? The patient's diagnose is prostatic adenocarcinoma.\n\n## Condition\nIt is unknown whether there is a cardiovascular risk factor such as smoking of the patient. Therefore, the patient's smoking condition is used. And as a result, it is no.\n\n## History of illness\nWhether the patient ever had cardiovascular diseases is not known, so history of illness is used. As a result, the patient did not ever have cardiovascular diseases.\n\n## Family history of disease\nWhether the patient has a family history of cardiovascular diseases is unknown. Since family history of disease is unknown",
        "label": 0
    },
    "763": {
        "output": "<EOD> .\nIn the treatment of cancer, surgical reconstructive procedures which involve removal of bone and/or soft tissue must be associated with procedures which allow bone and/or soft tissue to be grafted in the same operation. On the basis of the experience of last years, the authors report on 10 cases of patients treated in the orthopaedic surgical unit of I.N.O for reconstruction after different surgical procedures. From this experience, the authors conclude that the best type of graft in a single operation is autogenous bone. They have never used autogenous soft tissue. They have found the use of artificial bone to be less advantageous; for example, in the form of a hydroxyapatite compound, the use of which is still experimentally based.<EOD> Anatomy as",
        "label": 1
    },
    "764": {
        "output": "## C1: Exclusion criteria\n\nExclusion criteria can have a positive form: one or more inclusion criteria are missing (for example, age <6\u2009years is missing). If any inclusion criterion is missing, it is better to report the reason with `Exclusion criteria: 0) Not a CANadian resident.` as exclusion criteria. [/C1] Exclusion criteria are in a positive form.\n\n## C2: Exclusion criteria\n\nExclusion criteria can have a negative form: a patient is excluded for some reason. For example, the CPR number provided is invalid so a patient is excluded. If a patient is excluded for some reasons, report the reason in `Trial-level eligibility: 0) Excluded.` [/C2] Exclusion criteria are in a negative form.\n\n## C3: Exclusion criteria\n\nExclusion criteria can also be due to drug contraindication or inaccessibility, but in our dataset, there are no exclusion or inclusion criteria for drug contraindica-tion or inaccessibility. [/C3] Exclusion criteria are not drug contraindication or inaccessibility.\n\n## F: [/F] Patient note 4\nA 69-year-old woman with a history of CAD, hypertension, and diabetes comes in for an annual checkup. She has a family history of heart disease in her mother and brother. She has been on atorvastatin, an antihypertensive and an antidiabetic medication, which she stopped a few years ago.\nHer blood pressure is 149/97\u2009mmHg and her other vital signs within normal limits. Her physical exam is unremarkable, and laboratory testing shows her LDL-C level is 41\u2009mg/dL.\nShe is not taking any lipid-lowering medications. She does not use tobacco, alcohol or illicit drugs, and her blood glucose and triglyceride levels are with normal limits.\n\nHere is the patient note:\nPhysical exam (blood pressure is 110/80\u2009mmHg and otherwise normal vital signs are observed): Normal exam with blood pressure of 116/86\u2009mmHg and heart rate of 80 beats",
        "label": 0
    },
    "765": {
        "output": "], (2018-08-06).\nPlease refer to the following section for a reference list of resources used. The information provided for you may not be sufficient to pass certain test cases. You must use additional resources to pass these test cases.\n\nResources\nPlease find below the list of resources\n\nNote\nPlease find below a note on resources\nThe resources and their links may change in any one of three different ways\n- Changes in their content\n- The URL gets changed in some cases\n- They may not work anymore in the updated GauGan\n- You are referred to another resource\n\n\n[https://gaugan.readthedocs.io/en/_build/html/help_resources.html (in the main page, click on 'Resources')](https://gaugan.readthedocs.io/en/_build/html/help_resources.html \"Help Resources of GauGan\")\n\n\n\n\n[https://gaugan.readthedocs.io/en/latest/faq.html (Click on 'Other FAQ')]  [https://gaugan.readthedocs.io/en/latest/faq.html (Click on 'Other FAQ')](https://gaugan.readthedocs.io/en/latest/faq.html \"Other FAQ of GauGan\")\n\n\n\n\n# Acknowledgements\n\nThanks to the following people, in alphabetical order:\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n</A>\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n[https://gaugan.readthedocs.io/en/latest/contributors.html (Click on 'Contributors')]  [https://gaugan.readthedocs.io/en/latest/contributors.html (Click on 'Contributors')](https://gaugan.readthedocs.io/en/latest/contributors.html \"Contributors of GauGan\")\n\n\n<EOD> Pretransplant DNase and rt-PA Treatment of Endothelial Thrombi In Vitro.",
        "label": 0
    },
    "766": {
        "output": "![INST](https://www.jianguoyi.com/article/45330.html)\n\n### Output example \n<script type=\"text/javascript\">\n\tvar\n\t\tdata_url = \"https://www2.cnki.net/kns52/default.aspx\", //\u6570\u636e\u4e3b\u7f51\n\t\tdata_url2 = \"https://www.jianguoyi.com/article/22020.html\", //\u6570\u636e\u4e8c\u7f51\n\t\tarticle_data = {code:'data', url:'https://www.jianguoyi.com/article/22020.html'}, //\u53c2\u6570\u6570\u636e\u7ed1\u5b9a\n        input_data = $('#article_data'), //\u6570\u636e\u7f16\u8f91\u533a\n\t\tinput_code = $('#article_code'), //\u7f16\u7801\u8f93\u5165\u533a\n\t\tcontent_url = '', //\u5f39\u51fa\u5c42url\n\t\tpage = 1, //\u6570\u636e\u9875\u7801\n\t\tisLoading = false, //\u662f\u5426\u52a0\u8f7d\u4e2d\u7684\u5e03\u95e8\u6570\n\t\tarticle_index = null, //articleIndex\u662f\u6807\u9898\u662f\u987a\u5e8f\u7684\u7f16\u53f7\u4f9b\u7528\n\t\t$data = $.data, //\u6570\u636e\u96c6\u5408\n\t\t$html = $.html, //\u5b57\u7b26\u4e32\u8fd4\u56de\u6570\u636e\u7684\u83b7\u53d6\u65b9\u6cd5\n\t\t$dataType = $.dataType, //\u6570\u636e\u7c7b\u578b\u8fd4\u56de\u6570\u636e\u7684\u83b7\u53d6\u65b9\u6cd5\n\t\tarticle_data = $.param, //\u6570\u636e\u5b57\u7b26\u4e32\u7f16\u7801\u8fd4\u56de\u6570\u636e\u7684\u83b7\u53d6\u65b9\u6cd5\n\t\t$index = $('#article_index'), //\u663e\u793a\u6570\u636e\u6570\u91cf\n\t\t$articleCount = $('#article_count'), //\u663e\u793a\u8fd4\u56de\u4e2a\u6570\n\t\t$isLoadingEfficiency = $('#isLoadingEfficiency'), //\u52a0\u8f7d\u7387\n\t\t$output_style = $('#output_style').find('li'), //\u8fd4\u56de\u6570\u636e\u683c\u5f0f\u7c7b\u578b\n\t\t$output = $('#output'), //\u8fd4\u56de\u6570\u636e\u5206\u88c5\n\t\t$outputWrap = $('#outputWrap'), //\u6570\u636e\u5206\u88c5\u5c01\u5305\n\t\tinput_url = $('#input_url'), //\u7f16\u8f91\u6570\u636eurl\n        input_url2 = $('#input_url2",
        "label": 0
    },
    "767": {
        "output": "# Examples:\n##### `Clinical trial`\n`c12` 1 2 4 # A trial-level eligibility of 12 for all 3 criteria\n  `n01` 2 2\n##### `Clinical trial` `c4` 1 1 1 # A trial-level eligibility of 4 for the 1 criterium.\n  `n01` 1 1\n##### `Clinical trial` `c8` 4 2 2 # A trial-level eligibility of 8 for all 3 criteria.\n  `n01` 4 2\n\n<EOD> Fertility Preservation Programs in Switzerland\n\nThere is a lack of data on treatment outcomes and costs of fertility preservation programs (FPPs), particularly in countries with multiple FPPs. We analyzed the Swiss Society for Gynaecology and Obstetrics' register (2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019)) on the numbers and type of FPPs, as well as treatment outcomes and costs. Data for FPPs in 2018 were obtained from their respective websites. A total of 54 FPPs were reported in 2018: 22 were operated by an obstetrician-gynecologist (OB/GYN), 26 by a gynaecologist (GYN), two by both an OB/GYN and a GYN, and four did not report the background of the responsible physician. A comparison of FPPs' websites showed variation in quality of information, number of cycles, number of cryoconserved oocytes, use of ovarian stimulation, and type of insemination. There were 836 ovarian stimulation cycles with the use of either gonadotropins (-77%), clomiphene (-6%), or HMG (n = 12) including two cycles with the use of estrogens. A total of 448 oocytes were cryoconserved and five ova were freeze preserved. The total number of",
        "label": 1
    },
    "768": {
        "output": "<EOD> Diffuse intestinal amyloidosis (AA-amyloidosis) in a patient with rheumatoid arthritis and systemic lupus erythematosus\n\nA 73-year-old woman with a 4-year history of rheumatoid arthritis presented to the outpatient clinic with complaints of loose stools for the past 6 months that failed to resolve with medical therapy or dietary measures. Computed tomography enterography showed diffuse small intestinal dilation and an extensive small-bowel submucosal mass. The patient underwent an exploratory laparotomy and ileocecectomy. Macroscopic examination of the resected ileum displayed diffuse thickening of the intestinal wall. Microscopic examination revealed amyloid deposition in the intestinal mucosa, submucosa, and muscularis propria of the resected terminal ileum. Further immunohistochemical evaluation revealed amyloid A that was positive for serum amyloid A and lambda light chains, as assessed with antibodies against AA and IgG kappa chain. We then diagnosed the patient with amyloidosis of the intestine.\n\n# Background\nAlthough amyloidosis in the gastrointestinal tract mainly manifests as a local infiltration or submucosal mass formation, amyloidosis of the intestine is usually a diagnostic challenge, especially in patients with multiple comorbidities. We present a patient with multiple comorbidities, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), who presented with malnutrition and smallintestinal dilation. The patient was eventually diagnosed with amyloidosis of the intestine based on immunohistochemical staining.\n\n## Case presentation\nA 73-year-old woman presented with a 4-year history of RA with a high erythrocyte sedimentation rate, C-reactive protein, and serum amyloid A levels and 8 years of unexplained lownutrition status despite a daily diet rich",
        "label": 0
    },
    "769": {
        "output": "Let's do it! \n\n```code\n#! /usr/bin/python3\n\nimport string\nimport re\nimport sys\nfrom copy import deepcopy\n\nfrom typing import List\n\nfrom .. import models\nfrom ..app.parsers import ParserBase\n\n\nclass TrialPartitionParser(ParserBase):\n    \"\"\"\n    https://docs.google.com/document/d/1D6571_749xPV5_BNn1Zi6vD64G2RWxUxK6U281ZR1w/edit##pane:id=gqHxXFvvXKk8qD479\n    \"\"\"\n    @property\n    def _parser_tag(self):\n        return \"TrialPartition\"\n\n    @property\n    def _parser_names(self):\n        return \"recruit_eligibility\", \"trial_level_eligibility\"\n\n    @property\n    def _parser_type_names(self):  # types, not tags\n        return \"Boolean\", \"String\"\n\n    def __init__(self, element: models.ModelDict):\n        super(TrialPartitionParser, self).__init__(element, None)\n        if \"participant_eligibility\" in element and \"trial_level_eligibility\" in element:\n            # The eligibility of a person can be considered as 0 if it is excluded or 1 if it is included,\n            # so treat it as a list.\n            self._eligibility = element[\"participant_eligibility\"].as_json_nested_list(models.TrialLevelEligibility)\n\n    def _parse_inputs(self, parser_name: str, values: List[models.TrialLevelEligibility], max_result_list_size: int) -> models.TrialLevelEligibility:\n        # Here we assume 'max_result_list_size: Int' is the default for this class.\n        if len(values):\n            max_result_size = max(value.item().eligibility.keys(), key=value.item().eligibility.keys()).items()\n\n        # Get the",
        "label": 2
    },
    "770": {
        "output": "##### Implementation\n\nLet's start with the implementation of the code. You should save the code in a variable in the notebook by adding code within the curly brackets, e.g.,\n\n%NOTEBOOK%   \n\n\n```python\ntrialDict = {'1' : ['Age>=60, Gender=M, LDL>=160', 'Age>=60, Gender=M, LDL>=190'],\n               '2' : ['Age>=65.5, Gender=F, LDL>=160', 'Age>=65.5, Gender=F, LDL>=190'],\n               '2_1': ['Age>=65.5, Gender=F, LDL>=160', 'Age>=65.5, Gender=F, LDL>=190'],\n               ' 3 : ['Age>=65, Gender=F, LDL>=160', 'Age>=65, Gender=F, LDL>=190'],\n               ' 4 : ['Age>=65.5, Gender=M, LDL>=160', 'Age>=65.5, Gender=M, LDL>=190'],\n               ' 5 : ['Age>=60, Gender=M, LDL>=160', 'Age>=60, Gender=M, LDL>=190'],\n               ' 6 : ['Age>=65.5, Gender=M, LDL>=160', 'Age>=65.5, Gender=M, LDL>=190'],\n               ' 7 : ['Age>=65, Gender=M, LDL>=160', 'Age>=65, Gender=M, LDL>=190'],\n               ' 8 : ['Age>=60, Gender=M, LDL>=160', 'Age>=60, Gender=M, LDL>=190'],\n               ' 9 : ['Age>=65.5, Gender=F, LDL>=160', nil],\n               ' 10 : ['Age>=65.5, Gender=M, LDL>=160",
        "label": 0
    },
    "771": {
        "output": "##[SIDES_INST_01_C]\nClinicalTrials has two options for the calculation of the probability value by Bayesian algorithm of two-sided t-test: The \"A1\" option is for \"symptomatic patients.\" The \"A2\" option is for all cases.\nThis example shows the \"A2\" option for \"symptomatic patients\":\n(A1) Eligibility: The patient is symptomatic according to your research.\nEligible: The patient meets inclusion criteria and exclusion criteria do not apply.\nExcluded: The patient meets inclusion criteria, but is excluded on the grounds of the trial's's exclusion criteria.\nNot Relevant: The patient does not have sufficient information to qualify for the trial.\n\n# METHODS\n\n## The SIDES method\nThe SIDES method is the process that can be implemented to support the assessment of eligibility of a patient in a trial. As the clinical trial recruiters are using the electronic information system for decision making, the steps of the SIDES method can be automated.\nStep 1. The SIDES method begins by gathering patient data and transferring information to the assessment system. For transfer, the data can be automatically extracted through scanning of a patient's chart.\nStep 2. All pertinent data items should be transferred to the assessment system.\nStep 3. In this step, the assessors use the data to determine trial eligibility. In their case the assessors may be the clinicians and research nurses.\nStep 4. All relevant criteria, criteria definitions, and patient data items, are logged at this stage to maintain the assessment process's clarity and traceability.\nStep 5. The assessor makes his/her assessment based on the patient data and criteria definitions.\nStep 6. At the final step, the assessors compare the patient data with the trial's inclusion and exclusion criteria. If the required criteria's thresholds are not met, the patient is excluded or not eligible for the trial. If the patient meets the specified criteria, he/she is eligible for a trial.\nThe use and implementation of the SIDES is shown in [fig_ref]  Figure 1: The flowchart of the SIDES",
        "label": 1
    },
    "772": {
        "output": "## Requirements 1.\nRisk Assessment (RA) must be passed before working on a trial.\n1 You can go to the following link: \n[A] Click on a trial, and you will see a window showing the trial information (the one here is the same as the last example in List).\n[B] Click on Help & Documents and then click on Risk Assessment (RA) at the top of the page.\n[C] The window will appear automatically as a new window, and you will see the RA questionnaire and the answer of the trial. The answer will be filled in the box \"Select Risk Assessment Answer\".\n\n## Requirements 2.\nBefore you start working on trials, you must pass the Assessment module. You can take the following link and choose Assessment from the dropdown menu in the upper right corner.\n\n## Test Cases 1.\nThese are example patient notes for which you must determine and record the scale of the assessment (0, 1, 2) according to the clinical trial listed above. First, find the trial ID (455) by opening a trial, clicking on it by typing 455, and then, choosing the \"View Trial\" option in the top bar. Then, take a look at the Assessment table.\n\n## Requirements 3.\nThis is a quiz in the form of an email for which you will be given one patient (the first one in List) (note that the email ID is also the patient ID 00101 in List). You will find the list of emails in the following link: \nChoose Emails from the dropdown menu in the upper right corner, then choose Messages by Patients. Next, click on the Patient tab, and finally, choose patient 00101 in list. The message will be sent in the following window.\nNote that in emails, you should not only read the text, but also find the eligibility scale of the patient for the clinical trial.\n\n## Requirements 4.\nFirst, take a look at a trial (note that the trial ID is 455). Then, click on Assessments table. Now, choose a patient from the list and click the Check Assessmentbutton. This patient will have C",
        "label": 2
    },
    "773": {
        "output": "A: Let's split this question into more specific questions.\nLet's start with the formatting of the input. You can use the input() function, e.g.: input(\"In what format should the clinical note appear?\", \"Note in which format to appear: [TEXT]\")[s] in the beginning to receive a response with the choice of format: {(text) 'TEXT'.\nThe choice would be validated as {(text) }, which would be converted to text, to then obtain the response as {(text) text}.\nThe variable text must be used in the form text, i.e.: text = {text} to access the variable text.\nIn the next step, let's generate a random letter as a token to access the data. Here it is possible to use the choice() function, e.g.:\nchoice(\"What random letter do you choose as an example of validation for this test?\", \"Select a random letter to use in the beginning to access the data: [A]\").[s]\nYou can use the choice() function, in the same way. It is an alternative for the response variable, if it has only one element, otherwise if it has more than one element, you must select one of the input data with the use of the choice() function.\nIf input of choice() is {a}, then it means to access element \"a\", and if you already have element A, it will fail to access the data.\nIn this case, the letter to be used and the format of the input note is the choice() output. Both should be used later by the command input.\nThe input() commands and function are very similar. In the following command, you can observe the same as the input() command. In this case it is used with all the data and will have an error, until you apply the validation.\nNow let's define the data for the data validation.\nThere is no need to define the random letter, as if it is not the letter chosen in choice(), the function will generate one from scratch.\nIn the following line we will define the data for the input data.\ninput('In what format should the clinical note appear?', \"Note in which format to appear: [TEXT]\")[s]\n\nA: It is recommended to not mix python and bash in bash script. The following is a python code that performs as expected in",
        "label": 0
    },
    "774": {
        "output": "[END]\\n\\n\n  ## Assessment of exclusion criteria \nHere you should enter exclusion criteria for your trial and your clinical trial to obtain trial-level exclusion criteria. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nIf the output is empty:\n```\nTriplet [184] exclusion_Criteria:\n```\nIf the output isn't empty:\n```\nTriplet [184] exclusion_Criteria\n\n                        A, age \n                        G, gender \n                        B, Blood pressure \n                        C, BMI (kg/m2)\n                        D, smoking history (pack years)\n                        E, Previous treatment history (days)\n                        F, Medical history\n                        H, comorbidity and compliance\n```\n\n# Author statement \nNohad Ghamari: Conceptualization, Writing -original draft, Writing -review & editing, Methodology, Software; \n<EOD> Evaluation of the effects of different adsorption treatments on the surface texture of dentin.\nBACKGROUND\nThe aim of the present study was to evaluate the effect of different etching protocols on the surface texture of dentin when using an adenosine triphosphate (ATP) scavenger.\n\n\nMATERIAL AND METHODS\nThree kinds of treatments were performed on the dentin surface: (1) 5000 ppm phosphoric etch for 30 s, (2) application of adenosine triphosphate (ATP) for 15 s, and (3) a combination of A and B procedures (15 s ATP and then 30 s of etch with phosphoric acid). The measurements of roughness were recorded before and after three types of treatments and then processed using one-way ANOVA and Tukey's HSD test at a significant level of 0.05. A scanning electric microscopy (SEM) analysis was also performed.\n\n\nRESULTS\nThe etching protocol significantly increased the",
        "label": 0
    },
    "775": {
        "output": "<EOD> Effect of LPS on human neutrophils primed with an N-formyl peptide.\nThe simultaneous effect of phorbol myristate acetate (PMA) and lipopolysaccharide (LPS) on the respiratory burst in human neutrophils primed with f-Met-Leu-Phe was investigated to determine whether the oxidative enzyme system of these cells was activated by LPS alone or in combination with PMA. PMA plus LPS was more effective in enhancing the chemiluminescence response of f-Met-Leu-Phe-primed neutrophils than either of the agents used separately. LPS alone only showed a weak enhancing effect, which was not significantly higher than that seen in the presence of the f-Met-Leu-Phe-primed neutrophil control group. These data indicate that N-formyl peptide-primed neutrophils are capable of reacting with LPS alone. The activation of neutrophils was accompanied by release of a plasma serine esterase, and a platelet-activating factor (PAF)-dependent component was found to be responsible for the LPS/PMA interaction. The release of the serine esterase was suppressed by WEB 2086, a PAF receptor antagonist. The effect of PMA on the PAF receptor was also studied. In contrast to neutrophils, PMA pre-incubation significantly enhanced the chemiluminescence response mediated by PAF itself but not through serine esterase. These findings demonstrate that LPS activates neutrophils when N-formyl peptide primed, through a serine esterase, the activation by PMA alone being sufficient for the oxidative burst.<EOD> A Study of Serum Ferritin Levels in Patient with Chronic Hepatitis C\n\nObjective: The ferritin level is associated with the HCV infection, disease activity, and outcomes of HCV infection. The aim of this study was to investigate an association between the ferritin level and response to therapy or disease progression in patient with chronic hepatitis C.Materials and Methods:One hundred and thirteen patient with chronic HCV were included, and were divided into",
        "label": 0
    },
    "776": {
        "output": "Your output should be in the standardized format of the JSON data file which is shown below.\n{\"trial_id\":\"9000,\"trial_type\":\"clinical\",\n\"protocol\": {\"study_id\":\"Alirocumab\",\n\"title\": \"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)\",\n\"study_objectives\":[\"Primary: to provide participants with severe hypercholesterolemia at risk for subsequent CV events and not adequately controlled with currently available LMT access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in this participant population.\nSecondary: to document the effect of alirocumab on LDL-C levels as well as non-HDL-C, total-C, HDL-C, and TG levels after 12 weeks of treatment.\",\n\"inclusion_criteria\":\n[{\n\"field_name\":\"Alirocumab APPRISE -Patient Flow Chart (Alirocumab 9000), 5.2. Patient Inclusion Criteria\",\n\"value\":\n\"[inst] Patients were either eligible [elig] ( 0.5) or ineligible [inelig] ( 1.0) for each item.\"\n}],\n\"trial_type\": \"clinical\",\n\"phase\": \"Phase I (safety)\"}],\n\"visit\": [{\"date\": \"2015-01-19T00:00:00.000\",\n\"name\": \"Screening (Patients)\",\n\"baseline\": \"NA\",\n\"end\": \"NA\",\n\"interim\": \"NA\",\n\"observation_type\": \"PtB\",\n\"study_type\": \"Single\",\n\"assessment\":\n[{\"assessment_type\": \"Patient\",\n\"assessment_criteria\":\n[{\n\"assessment_criterion\": \"",
        "label": 2
    },
    "777": {
        "output": "## Assignment instructions\n\n# Assignment requirements\n- Your solution should first test the function of the clinical trial pipeline with example inputs.\n- Your solution should then implement the case study of the patient's clinical trial eligibility assessment.\n- After implementing the case study, your program should include a function to output a score between 0, Excluded, and 2, Eligible, for the patient's clinical trial eligibility as well as for individual input data elements (i.e., LDL-C) using the input shown in the example input [1].\n- Next, your program should output the clinical trial eligibility assessment for all patient note inputs.\n- Submit your solution via Canvas, by uploading it as a zip archive.\n- Name your zip archive with the title of the problem, followed by a unique identifier.\nA description of the solution can follow but is not required as long as the zipped file complies with the above.",
        "label": 1
    },
    "778": {
        "output": "<EOD> Rare cases of neurotoxicity induced by hydroxychloroquine and chloroquine: focus on management\n\nRare cases of neurotoxicity induced by hydroxychloroquine and chloroquine: focus on Management \u0b1dCorresponDence: dr.pavithra.kumari21@gmail.com Braz J Otorhinolaryngol. 2021;87:544-546 Dear Editor,Chloroquine (CQ) and hydroxychloroquine (HCQ) have been identified as potential therapeutic agents against coronavirus disease 2019 (COVID-19) because of their immunosuppressive and anti-inflammatory characteristics 1 . These agents are well tolerated drugs with few toxic side effects. However, the use of these medications is associated with several ocular and neurological side effects. Neurological symptoms commonly appear in patients who have been treated with hydroxychloroquine for less than five years, and the neurotoxic effects of hydroxychloroquine are more common in patients receiving higher daily doses of chloroquine 2 .\nThe patient described herein who recently recovered from COVID-19 on a CQ/HCQ combination protocol presented with a mild, non-specific neurotoxicity during the course of his treatment with this therapeutic regimen.\nA male aged 56 years came to our clinic reporting a loss of vision in the right eye (RE) for the past three days. He had no significant past medical history except diabetes. According to his history, he was treated for COVID-19 by oral CQ, HCQ, azithromycin, naproxen, vitamin C, hydroxychloroquine sulfate, and multivitamins for 14 days one week prior to this visit. He had been symptomatic for one week with the typical respiratory manifestations of COVID-19 (fever, dry cough, and loss of smell) but had recovered without medication. He was treated with the combination protocol of CQ/HCQ as the patients with COVID-19 were not",
        "label": 2
    },
    "779": {
        "output": "**Task 3:** Using your knowledge of the inclusion and exclusion criteria of a clinical trial, decide if the patient met the inclusion criteria given in the original patient note.\n\n<EOD> Assessment of clinical competency in paediatric oncology rotation in residency with 12 months of experience\n\nBackground: A 1-year dedicated paediatric oncology rotation was developed to enhance paediatric postgraduate year 2 (PGY2) resident experiences and evaluate the role of a dedicated rotation in medical competency. The purpose of this study is to assess the perceptions of paediatric resident competency and provide qualitative feedback related to the rotation. Methods: This was a prospective observational study that collected information at the start and end of the paediatric oncology rotation with the PGY2 paediatric resident. The assessments were focused on the residents' perceptions of their knowledge base and clinical competency to manage both solid and hematologic tumors.Results: Twelve residents entered this study, including 11 PGY2 and 1 PGY3. There were 128 assessments at the beginning and end of the rotation. Twenty were solid tumors, and 108 were hematologic tumors. There was a slight improvement in the mean score percentage for most of the hematologic disorders. An improvement was noted with the evaluation of diagnostic cytogenetic/molecular tests (p = 0.0069) and response to therapy (p < 0.0001). However, no improvement in scores was noted for the solid tumors and no difference was found between the clinical competency and knowledge base of residents during the oncology rotation. Conclusions: The PGY2 residents felt prepared to take care of hematologic oncology patients following their time in the rotation. Further studies are needed to ascertain best practices for evaluating residents' competency and to help residents identify areas for improvement.\n\n# Background\nThe residency curriculum was redesigned and a paediatric oncology rotation was added to the general paediatrics rotation for postgraduate year (PGY) 2 residents in October 2008, following the creation of the paediat",
        "label": 1
    },
    "780": {
        "output": "### Examples\n\nThis is clinical trial:\n*Title: A Multi-Center Study to Evaluate Acute Safety and Clinical Performance of Paladin\u00ae Carotid Post-Dilation Balloon System With Integrated Embolic Protection *Summary: The purpose of this study is to assess the safety and clinical performance of Paladin System in patients with carotid artery stenosis.\n\nThis is an example of a patient's patient:\nA. 46-year-old man presents with dizziness and frequent headaches. B. Patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus C. He is physically active. D. His LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose level (85 mg/dL) was within normal limits E. Patient reported no use of lipid-lowering medications.\nF. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), 80% stenosis in the right anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending<EOD> The effect of posttraumatic stress disorder on pregnancy outcomes and pregnancy-related anxiety in women with substance use disorders\nAbstract Background: Pregnant women have a risk of developing Posttraumatic Stress Disorder (PTSD). Substance use disorders (SUDS) further aggravate the risk of PTSD. Objective: To investigate the effect of PTSD diagnosis in pregnant women with SUDS on pregnancy outcomes and pregnancy-related anxiety and to compare the pregnancy characteristics between pregnant women with SUDS and PTSD and those with SUDS. Method: A cross-sectional study was conducted among 221 pregnant women with SUDS. Socio-demographic",
        "label": 0
    },
    "781": {
        "output": "<EOD> Oligomerization Is Necessary for Protein Trafficking But Dispensable for Transcriptional Activation in Arabidopsis LATERAL ORGAN BOUNDARIES PROTEIN 11\n\nThe latERAL orgANs BOUNDARies proTEin (LATERAL ORGANBOUNDARIES-LIKE (LBO) family and its counterpart the LATERAL ORGAN BOUNDARIES (LOB) family are plant-specific transcription factors and key regulators of embryo patterning, apical-basal axis establishment, organ polarity, and floral organogenesis. LBO/LOB genes have two distinct functional domains: N-terminal domains that participate in protein-protein interactions and C-terminal domains that recognize a specific DNA motif to regulate the expression of their target genes. LBO11, an LBO/LOB family protein in Arabidopsis thaliana, is predominantly localized in the PM with a small percentage (<15%) translocating into the Golgi and predominantly accumulating in vacuoles for degradation. Two LBO11 mutants disrupted at distinct positions, K338A and \u2206C336, were employed to determine the subcellular trafficking of the LBO family. In both LBO11 mutants, the conserved C-terminal protein-protein interaction domain was removed, resulting in a significant increase in Golgi accumulation of LBO11 fusions, but the Golgi localization of LBO/LOB proteins remained normal, demonstrating that oligomerization is important for LBO/LOB trafficking. In addition to the LBO11-T1 construct lacking the C-terminal domain and the LBO11-T5 construct with N-terminal domain disrupted, the remaining three LBO11-T constructs lacking either the full or partial DNA binding region were all unable to rescue the LBO11 knockout phenotype as single transgenes, indicating that functional domains of the LBO11 protein other than the transcription domain, such as the N-or Cterminal domains, are also important for the LBO11 function in development. Moreover, these LBO11-T constructs exhibited various degrees",
        "label": 0
    },
    "782": {
        "output": "- \u2713 The patient notes should use the following format:  `Demographic features: (given name)(given name)(gender). Birth date: (date)(month)(year). Patient ID: (patient ID). Patient diagnosis: [patient diagnosis].` (See the example snippet: [snippet:patients].)\n- \u2713 Include the clinicians' comments in the `Medical notes` of the patient notes. You can use the special tag `_clin_notes:` in `Clinician notes` (in the format of `Clinician notes: [_clin_notes:].` - a snippet: [snippet:clinian_notes].)\n- \u2713 Copy and paste the data of each patient into a patient note. Make sure whether the data are pasted correctly.\n- \u2713 The input data should be processed using an XML editor. You should verify whether the input data are parsed successfully in `Test.py`.\n\n### Steps to Run\n\nThis project includes two steps: `train` and `predict`. Here, `train` means training a model based on input data, and `prediction` means predicting the eligibility using the trained model based on the given data.\n\nTo train an eligibility model:\n\n1. Clone or download the whole project into your preferred folder, e.g., `MyFolder\\clinical-recruitment`.\n2. CD into your selected folder.\n3. Create a new project: `cd ./clinical-recruitment/clinical-recruitment/main.py`\n - The project's name should be changed to the folder name.\n4. Change the script's name to `main.py` in the form of `__main__.main.py`.\n5. Change the path of `main.py` to the current project folder by making the changes of `sys.argv` . To modify the command line input, you can remove it.\n6. Change the `PATH` value to the `train` directory, including the following subfolders: `data`,`train`,`tests`, etc.\n   - Please follow the documentation [here.](https://git-scm.com/book/en/v5-Git-Basics#sec-path-variable)\n7. Open `console",
        "label": 0
    },
    "783": {
        "output": "If you answer these questions correctly, you can proceed to the next step. Good luck.\n\n# Introduction\n\nHi, Dr. Seungjun Kim. You are a professor of internal medicine at Seoul National University College of Medicine in Seoul, South Korea. This is a hypothetical email, although its contents are based on a true case that occurred at Seoul National University College of Medicine. The contents of the email are presented in a story format.\n\nYou are asked by Prof. Jae Hyeok Lee, Head of the Department of Internal Medicine at Eulji General Hospital, to develop a mobile screening system for coronary artery calcification (CAC) because of the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). You are currently working on new systems to apply in medical institutions. Recently, as a member of clinical engineering, you have been conducting research to find a new way to apply artificial intelligence (AI) to medical images and to use the findings to assist clinicians in diagnosing the disease and developing new drugs.\n\n![Coronary Artery Calcification](/figures/images/12.gif)\n\n<p>\nCAC is very common among older people with heart issues. It starts in the intima layer of the coronary artery, where platelets and lipids deposit, which cause inflammation as the calcium accumulates.\nThere are several diseases that cause CAC, such as atherosclerosis, hypertension, and diabetes. The common causes of CAC are cardiovascular diseases, such as heart disease",
        "label": 1
    },
    "784": {
        "output": "[/JR]\n\n\n## [INST] Hello.\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the trial inclusion/exclusion criteria to determine the patient's eligibility. \nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n\n\nIn this exercise, you have several trials to perform (see below). To each trial, you should create a data frame as in Example 9.3.1. Below is an example on how to filter a trial: \nFirst, you can see that data frame `df1` contains a column called `Trial-level`, which indicates the code of the trial you are currently on. Based on that column, you can apply the filters to the data set: \n```R\nFilter(get_trial_codes = c(\"CTT234\"), \n      data = df1, \n      select = , \n      x = TRUE)\n``` \n```R\nFilter(get_trial_codes = c(\"CTT234\", \"CTT638\"), \n      data = df1, \n      select = , \n      x = TRUE)\n```\n```R\nFilter(get_trial_codes = c(\"CTT234\"), \n      data = df1, \n      select = c(\"Trial-level\", \"Trial-duration\",\n                  \"Most-severe-symptom\"), \n      x = TRUE)\n``` \n```R\nFilter(get_trial_codes = c(\"CTT234\", \"CTT638\"), \n      data = df1, \n      select = c(\"Trial-level\", \"Trial-duration\",\n                  \"Most-severe-symptom\"), \n      x = TRUE, \n      target = c(\"Trial-code\", \"Trial-duration\", \n                 \"Most-severe-symptom\"))\n```\n```R\nFilter(get_trial_codes = c(\"CTT234\", \"CTT638\"),",
        "label": 0
    },
    "785": {
        "output": "[/CODE]\n\n\n\nWe'll keep going with the code and try to solve it with the following functions: \n\n\n* `trial_recruitment_patient_note()`\nTrial recruiting function for the clinical trial record, which generates a patient note template.\n\n#### Parameter Description\n| Attribute            | Data type | Default Value                                 | Description                                                  |\n| ------------------- |:---------:|:-------------:|:------------------------------------------|:--------------------------------------------------------|\n| trial             | object   | object                                           | A trial with a trial object containing clinicaltrial_id and title                        |\n| include_all_items | integer | 1                                           | Whether to include all items on each recruiting step. Default is 1                         |\n| note_type         | character | `medical_history`                        | Type of note. Default is `medical_history`. If the specified note_type does not exist, the note will be generated automatically                  |\n| patient           | object   | `NULL`                                        | Object containing information such as patient_id and enrollment_status                  |\n\n#### Sample Parameter   \n\n[sample.r](../source/main/code/trial_recruitment/nots/trial_recruitment_patient_note.r)         \n\nThere are no functions to make your code run, but our code makes sure that you get an error if some parameters are missing, so you don't need to set them up for the recoding, but you can edit trial's include_all_items (parameter) to try different items.                                         \n\n`\nThe patient meets inclusion criteria.\n`\nThere are other functions, too.\n  \n#### Other Parameters        \n- [x] `trial_recruitment_patient_id_note()`\n\n#### Sample Parameter\n[sample.r](../source/main/code/trial_recruitment/nots/trial_recruitment_patient_id_note.r)          \n\n**Output example**\n```\ntrial_recruitment_patient_note_example\n```\n    [\n      trial_recruitment_patient_note_example_output, ...",
        "label": 1
    },
    "786": {
        "output": "![[image: 9-7-2.jpg]]\n\n<EOD> The efficacy of acupuncture for nausea and vomiting in paediatric cancer patients: A narrative review\nThis review summarises the literature to evaluate the efficacy of acupuncture for nausea and vomiting in paediatric cancer patients, compared with standard treatment or no treatment. Searches in all languages identified 27 relevant reports encompassing 42 individual trials and 2 reviews, with a date of publication ranging from 1995\u20102019 and a total sample size of 1856 cancer patients and 498 controls. Acupuncture may decrease the risk of delayed, delayed\u2010cumulative and anticipatory nausea for both chemotherapy and radiotherapy regimes when comparing acupuncture with conventional antiemetics. However, the magnitude of the effect and the statistical methodologies used to evaluate the significance of the results are inconclusive, with the results being limited by small sample size, heterogeneous study designs, and lack of placebo\u2010 and sham\u2010controlled reports.<EOD> A Comparison of the Costs of an Extended Access Program and the Standard Schedule for Intrathecal Baclofen for Idiopathic Scoliosis\nThe authors compared the costs of an extended access program with the conventional schedule for administering intrathecal baclofen for the management of intractable spasticity in patients with idiopathic scoliosis. Nine patients were entered on an extended access (EA) program. The average number of intrathecal baclofen infusions per month prior to entry on the EA protocol was similar to the number of infusions per month after entering the EA protocol (1.3 + 1.0 versus 1.6 + 1.1, respectively; P = not significant ). However, the average cost of obtaining and administering an infusion before entering the EA protocol was US $804.08 compared with US $106.81 after entry (P < 0.001). The difference was due to the lower costs in the EA group of drug and catheter and the lower drug costs. Overall, the EA program was about 91% cheaper and approximately",
        "label": 1
    },
    "787": {
        "output": "---\n**1. Please check your answer and fix problems.** It must be the same as the `Output` in the `Instructions.`\n**2. If your answer is correct, you will observe that your program will display only 'Eligible' in one end-line, after this output. ** **3. If your answer is incorrect, it will display the message 'Please fix the problem and try again.'** If you can not solve this section after 2 attempts, it is better to skip this section. **4. Proceed to the next task 'Clinical Trial Assignment' by clicking the button [**Run the App**](/lab/index.html#Examine the result).\n---\n\n### Task #4\n[ **Clinical Trial Assignment** ](#clinical) \n\n\n*Task 4 - Clinical Trial Assignment*\n\n[Run the App](/lab/index.html#Examine the result).\n\n[**Instructions** ](/lab/index.html#Task-4) \n\n[Answers](/lab/answer/_exercise_2_data.html)\n---\n### **Examine your result:**\nAfter clicking the \u201cRun the App\u201d button, you will see how you perform this task.\n\n---\n[**Examine Your Result**](/lab/index.html#Examine-your-result) \n\n---\n*Task 5 - Incrementally Implementing Classes. You can do the section 5 task. \n\n[Run the App](/lab/index.html#Examine the result).\n\n--31%\n![eligible](https://github.com/xelabs/easy-python-project/blob/master/images/e2-1.png)\n![eligible](https://github.com/xelabs/easy-python-project/blob/master/images/e2-2.png)\n![eligible](https://github.com/xelabs/easy-python-project/blob/master/images/e2-3.png)\n\n---\n\n---\n### **Examine your result:**\nAfter clicking the \u201cRun the App\u201d button, you will see how you",
        "label": 1
    },
    "788": {
        "output": "You may need to modify `Tri-eligibility` value in the following lines to match the patient assessment:\nPatient-level eligibility: `Patient-level eligibility: 1) Not relevant`.\n\n### Incomplete Inclusion Criteria\nOne of the problems in clinical trials is the inclusion of ineligible participants in clinical trials. In order to minimize this, clinical studies employ rigid inclusion and exclusion criteria, which can be found in the trial's inclusion and exclusion criteria page. In the following cases, participants should be identified as ineligible and excluded:\n- Age limit, e.g., below 18 years old, - Not smoking or smoking more than a pack of cigarettes per day;\n- Using a prescription drug or drinking alcohol or cannabis;\n- The patient has had a myocardial infarction or heart attack (infarction or angina);\n- Chronically ill;\n- Taking a lot of medication, or in particular, those that affect the heart;\n- The patient has had an artificial heart valve;\n- The patient suffers from arthritis, diabetes, or depression;\n- The patient has heart valve disease;\n- The patient cannot stop smoking or drinking for 5 to 6 months;\n- The patient has a weakened immune system (e.g., caused by chemotherapy or radiation);\n- The patient has poor physical health;\n- The patient is pregnant or thinking of getting pregnant;\n- The patient cannot undergo a physical examination or have an HIV/hepatitis test;\n- HIV or hepatitis positive;\n- Patients with liver, kidney, or heart disease and not on treatment;\n- Uncontrolled diabetes and unable to control diabetes well;\n- The patient is a smoker or is taking medication to treat any disease;\n- The patient is pregnant, is of childbearing age, or is breastfeeding;\n- The patient has the right conditions to participate in the study, but is taking medications to treat their illnesses.\nSome trials also include conditions such as having sexually transmitted diseases or having high blood or high platelet levels. This",
        "label": 0
    },
    "789": {
        "output": "_Remember to write your work in Markdown language if you need to re-edit your work, as the output will be generated from Markdown language._\n# [Ask#\n\n# Tasks of a POC Assistant in Clinical Research:\n1. Recruiting participants from different specialties\n2. Assessment of eligibility of study participants\n3. Creating and updating the trial database\n4. Documenting all procedures in accordance with the procedures and processes at site\n5. Organizing and conducting visits to trial centers on a regular basis\n6. Monitoring enrolled participants - tracking enrolments and tracking exits during study and follow up visits\n7. Tri-monthly monitoring of sites, data checks and review all relevant clinical protocols and SOPs\n8. Trial follow up visits with selected sites\n9. Preparing, reviewing and approving all required regulatory documents.\n10. Collecting, collating and analyzing site visit results and reporting these results via site visit report templates\n11. Monitor and report any adverse events that occur across the trial to ensure their immediate attention in order to ensure the safety of trial participants.\n12. Provide operational and strategic support for clinical projects / studies by providing appropriate feedback and by developing trial and project improvement action plans.\n13. Investigate all adverse events.\n14. Collecting and collating routine study data to be entered into the appropriate CRF\n15. Reviewing CRFs submitted for data entry during the source data verification process to check they are complete, accurate and meet study requirements.\n16. Reviewing all CRFs and all other documents submitted for data entry and query resolution as required to ensure complete and accurate data entry\n17. Reviewing CRFs and all other documents before the site trial close-out visit to ensure complete resolution of any outstanding queries; ensuring the trial database is closed and locked correctly.\n18. Provide a point of contact for site staff for all enquiries relating to study visits and protocol.\n\n##[INTERVIEW]\nHello. You are the program manager of the company Pioneering. Pioneering is a company specialized in medical data acquisition. Its services include collecting real patient data and creating a database to sell.\n\nYour main",
        "label": 0
    },
    "790": {
        "output": "The output must be a table, like below:\nIn the figure above, the patient passed all the eligibility criteria.\nYou should calculate the overall eligibility for the patient. The overall eligibility is a Boolean value derived from the trial-level eligibility. Take the above as an example: 250/250 = TRUE (the patient is overall eligible).\n<EOD> Examining the relationships between parenting stress, social support, maternal self-esteem and child internalizing symptoms\nParenting stress and social support may be associated with psychological symptoms through shared and unique mechanisms, as well as with the child\u2019s symptoms through shared and unique pathways. However, there has been little attempt to examine these associations simultaneously, in both parents of children without disabilities and parents of children with disabilities. In the present study, 161 mothers with and without children with Autism Spectrum Disorder (ASD) and 93 fathers with children with ASD were included in two separate analyses. Structural equation modeling was used to address several gaps in the literature. First, the relative contributions of stress and social support to general psychological distress, and to child internalizing symptoms, was explored. Second, the relative contributions of parenting stress and social support to child internalizing symptoms was assessed. These analyses showed that in mothers without children with ASD, social support was directly associated with lower stress and higher self-esteem leading to lower child internalizing symptoms, in turn leading to lower psychological distress; stress was associated with increased psychological distress. In addition, in these mothers, stress, social support, self-esteem and child internalizing symptoms each exerted unique effects on psychological distress. In contrast, in mothers with children with ASD, stress, social support, self-esteem and child internalizing symptoms exerted unique effects on psychological distress. In fathers with and without children with ASD, stress, social support, and self-esteem were associated respectively with unique and shared effects on psychological distress. The results indicate that a number of factors may account for the unique associations between stress, social support, self-esteem, and child internalizing symptoms.<EOD> 29-Hydroxyproxifolin: a new compound from a marine",
        "label": 2
    },
    "791": {
        "output": "Here is the result:\n\n    [{\"trial_level_eligibility\": 2, \"patient\": \"Snacking should be avoided within one hour before going to bed, to avoid unnecessary and undesirable weight gain.\"},{\"trial_level_eligibility\": 0, \"patient\": \"Exposed to a moderately oxidizing environment for less than one hour per day, such as in an open area or inside an air-conditioned room.\"},{\"trial_level_eligibility\": 1, \"patient\": \"Fruit-flavored, carbonated beverages (fruit nectar, fruit squash, or other carbonated juice drinks)\"},{\"trial_level_eligibility\": 1, \"patient\": \"Fruit-flavored, noncarbonated beverages (eg, fruit juices, fruit squash, fruit cordials, or other juice drinks)\"},{\"trial_level_eligibility\": 2, \"patient\": \"Consumption of 35 g or more of alcohol per day (men) or 25 g or more of alcohol per day (women)\"}]\n\n##### 2.[INST] Good you did!\n\n### Good. Do you have any questions?\n\n  Q: Isn't there a short cut instead of using the if-else for multiple trial-level eligibility?\n\nA: Indeed, there is, you can use `if`, else `else`, and `endif` at once as: `if (if trial_level_eligibility == 1 ){end if; else if (if trial_level_eligibility == 2){end if; end if; else if ( if trial_level_eligibility == 0 ){end if; else printout_text.print_data; end if;}end if;}`\n\nThis code would output eligible patients first, followed by noneligible patients for each patient. [INST]\n\n### 3.[INST] Tutorial of a more complex scenario\n\nAnswers to Questions in Previous Tutorial:\n\n  Q: How? \n\nA: Apart from the main body of the case, there is an additional comment, i.e., the",
        "label": 0
    },
    "792": {
        "output": "___\n\n**Please note:** The R commands and scripts in this guide are tested and validated on the R interpreter. If you want to run the R commands in this guide in your own R session, make sure that you use the same R interpreter or version as presented below.<EOD> .\nThe purpose of the article is to summarize basic achievements in the field of psychiatry in the Ukraine since the XX century and outline the specific features of this discipline in Ukraine. The reviewed studies show the important place of the psychiatric specialty in the medical systems of the Ukraine in the XX century, the development of the theory and practice of the psychiatric care in the country.<EOD> Challenges in the design of a high-dimensional protein-protein interaction modulators discovery screen.\nProtein-protein interaction partners can act as critical nodes that control, or are crucial for, function of proteins they bind to. A number of high-throughput screening methods targeting interactions of proteinprotein domains have emerged over the past decade to identify bioactive small molecules targeting these interfaces. The design of such methods has proven especially challenging as they must accurately recapitulate the structures of protein complexes and control for factors such as avidity of binding. Here we examined proteinprotein interactions involving the N-terminal region of the tumor suppressor protein p53 and three of its direct interacting proteins, murine double minute 2 (MDM2), mouse double homeobox 4 (Mdmx), and E3 ubiquitin-protein ligase RING-box (RINGB) using fluorescence polarization-based fragment screening to determine its technical limitations and to assess the scope of high-throughput screening methods developed to date. A comparison of multiple, established methods with and without specific design elements, revealed that screening for high-affinity ligands to dissociate a complex with the protein-chemistry-based technique called Dissociation Enhanced through Ligand Hydrocarbon Stapling technology (d-DELHI), was most accurate. Furthermore, the robustness of the assay was ass",
        "label": 1
    },
    "793": {
        "output": "## 2. Use of R in Pipelined Data Preprocessing (R/PD)\n\nIn this step, you need to prepare input files for machine learning modeling in the R/PD step. \nAt this step, you are required to use the following files to make your R Pipelined data preprocessing (R/PD) step ready. \nTo build your R/PD step, you need the following inputs: \n- An Excel (.xlsx) file containing patient records in the required format; \n- An empty R file; \n- R packages for reading Excel (.xlsx) files and R pipelines, R scripts for splitting the dataset, and R scripts for feature selection.  \n\n## Feature selection\n\nFeature selection is an important step in machine learning. The goal is to choose the most relevant variables, to avoid a problem with overfitting, and to accelerate the classification. You can choose any of the available variables as the features of the patient records, so there are various combinations. Feature selection methods reduce the number of features and select optimal features. In our case, you will use the wrapper method. \n\nThis step is optional. Please read the Feature Selection section. \n<h5>Create files for the Feature Selection methods</h5>\n\n<pre><code class=\"text\">rm(list=ls()) set.seed(100)</code></pre>\n\n<pre><code class=\"text\"># for split dataset set.seed(100)\n\nfit1 <-crossValidate(\n    formData , \n    typeOfFeature=c'text','classLabel',''',\n    # typeOfFeature=c('text','value','value2','value3','value4'),\n    fitData=NULL,\n    fitData=fitData,\n    testData=fitData,\n    testData=fitData,\n    labelClass=NULL,\n    labelClass=featureVars, # labelClass=classLabel\n    typeOfFeature=c('classLabel','classLabel','classLabel','classLabel','classLabel','classLabel','featureVars','age','sex','treatment','heartDisease','bdi','bdi2','bdi3','bdi4','bmi','weight','height'),\n    cutPoint=NULL,\n    cutPoint",
        "label": 0
    },
    "794": {
        "output": "Write the output with the patient's status in your code, e.g.:\nf = pd.DataFrame(\n    {\n        'patient': patient,\n        'status': f['Trial-level eligibility']\n    }\n)\n\n\n\n##### Task 14\n\n\n\n\n\n\n\n\n\n\n<EOD> .\nObjective: By comparing the efficacy of the modified unilateral eversion technique (USET) and endoscopic endonasal transpterygoid approach (ETA) with microscopic unilateral eversion technique (UTE) for the treatment of refractory nasopharyngeal carcinoma, the optimal method of the nasopharyngeal recurrence of nasopharyngeal carcinoma was explored. Of which, the objective of this study was to analyze the efficacy of treatment of modified USET and ETA with microscopic UTE for nasopharyngeal recurrent carcinoma. Methods: The clinical data of 78 patients with nasopharyngeal recurrent carcinoma treated in the Department of Otolaryngology of Beijing Tongren Hospital from February 2016 to March 2018 whose primary treatment was radiotherapy, whose primary treatment was radiotherapy, and who were diagnosed by pathological examination, were retrospectively analysed. All patients were divided into two groups (N=39 in Group A, n=39 in Group B) according to different surgical approaches, and the efficacy was compared. In Group A, there were 23 males and 16 females, with an average age of (46.7\u00b110.1) years (range: 25 to 64 years); the tumor location was all at the ipsilateral nasopharyngeal side of middle ear; the volume of preoperative tumor was (2.60\u00b11.21) cm\u00d7(2.35\u00b11.14) cm\u00d7(2.16\u00b10.94) cm; the volume of postoperative residual tumor was (1.16\u00b10.56) cm\u00d7(1.46\u00b10.81) cm\u00d7(1.07\u00b10",
        "label": 1
    },
    "795": {
        "output": "##### Examples of the patient's output for the clinical trial {#Examples-section}\n\nExamples:\nHere are examples of patient's output after submitting the patient note and patient's information file to `patient/get.ipynb` [/RUNNING_EXAMPLE_CODE#Patient_Note_1: clinical_trial]:\n\nHere are examples of patient's output after submitting the patient note and patient's information file to `patient/get.ipynb`, where all patients meet all inclusion criteria: \n``# 1 trial-level eligibility = 2 2 trial-level eligibility = 0 3 trial-level eligibility = 2``\n``\n{\n\"PatientNote\": [\n    {\n        \"Name\": \"Father\",\n        \"Age\": 46\n    },\n    {\n        \"Name\": \"Man\",\n        \"Age\": 46\n    }\n],\n\"PATIENT_INFO\": [\n    {\n        \"ID\": 1,\n        \"Name\": \"<NAME>\",\n        \"Phone\": \"9999999999\",\n        \"Email\": \"<EMAIL>\",\n        \"Birth_date\": \"April 2nd, 2000\",\n        \"Birthplace\": \"Tokyo\",\n        \"Birth_sex\": \"Male\",\n        \"Address\": \"Tokyo\",\n        \"Height\": \"173 Cm\",\n        \"Weight\": \"63 KG\",\n        \"Blood_group\": \"A+\",\n        \"Emergency_person\": \"Father\",\n        \"Emergency_address\": \"Tokyo\",\n        \"Emergency_phone\": \"9999999999\",\n        \"History_of_medication\": [ ],\n        \"Allergy\": [ ],\n        \"Medical_History\": [ ],\n        \"Smoking\": [ ],\n        \"Drinking\": [ ],\n        \"History of trauma\": [ ],\n        \"History of surgical operation\": [ ],\n        \"Exercise_habit\": [ ]\n    },\n    {\n        \"ID\": 1",
        "label": 2
    },
    "796": {
        "output": "Good luck!\n\n\n## Problem 3\nSome lines are missing from the output, as a result of the output being split by lines. This problem seems to occur only when the number of variables included in the model is high.\n\n## Potential solution\nRun the following code to merge the three different rows that you have in the output of the command: 'Model 3'.\n\n```python\ndf.rename(columns={\"Model 1\": 'Trial level',\\\n                      \"Model 2\": 'Trial level',\\\n                      \"Model 3\": 'Trial level'},\\\n            inplace=True) \nprint(df)\n```\n\n## Potential problem 4\nBecause several columns of the model are categorical, the dataset may be converted to a binary format. This problem occurs because of the way in which the original code works.\n\n## Potential solution\nYou could modify the dataset by converting all the categorical variables into binary, using the 'df.select()' function. For example, in the dataset where only the model 2 is shown above, the first step is to convert the 'gender' category into a binary format, using the 'df.select()' function. In this command, the first column has already been converted because it represents the patient ID. You should always assign each categorical value a value '1' when you use the 'df.select()' function. In this command, the variable 'Pat' has already been converted into a '1'.\n\n```python\nnew_dataset = df.rename(columns={\"Trial level\":\"Trial level\",\\\n                                \"Pat\":\"Pat\",\\\n                                \"Adult\": \"Adult\",\\\n                                \"Smoking\": \"Smoking\",\\\n                                \"HbA1C\": \"HbA1C\",\\\n                                \"HDL\": \"HDL\",\\\n                                \"LDL\": \"LDL\",\\\n                                \"Age\": \"Age\",\\\n                                \"BMI\":\"BMI\",\\\n                                \"Trial_eligibility': 'Trial eligibility'})\\\n          .select('HbA1C', 'Smoking', 'Adult', 'age', 'BMI', 'gender', 'HDL', 'Pat', 'LDL',  'Trial",
        "label": 0
    },
    "797": {
        "output": "#### Solution\n<EOD> Intravenous administration of the anti-gout medication allopurinol into the lateral tail veins of rats.\nThroughout the history of the treatment of gout, it has been a problem that the long-acting anti-gout preparations often give rise to the patient's discomfort. In a long-term study, the author reported that subcutaneous administration of allopurinol, an anti-gout drug, once a day to patients caused the marked reduction of serum uric acid levels, relieved their gouty symptoms, improved X-ray manifestation, and prolonged their lifespans. The author administered allopurinol orally once a day, subcutaneously or by intramuscular injection twice or thrice a week to rats with arthrodial effusion and hyperuricemia, and observed a therapeutic effect on rats. The author noticed that if the rats were also given intravenous administration of allopurinol through the lateral tail veins, hyperuricemia and arthrodial effusion were also remedied, and the symptoms were much relieved and disappeared in a far shorter time.<EOD> The relationship between dietary diversity and dietary fat intake of adolescents in Malaysia\n\nBackground: To determine the relationship between dietary diversity and the fat content of meals consumed by adolescents in Malaysia. Materials and methods: A correlational survey design was employed to measure 290 adolescents' dietary diversity scores (DDS) and fat intake from 798 food and liquids items based on 24-hour recall information. Data was collected using self-administered questionnaires, while DDS and estimated fat intake data were collected via 24-hour recall. The mean food group intake frequency, the DDS, and estimated fat intake for each food group were calculated and were used as continuous outcomes for the analysis. Data were analysed using the Student t-test and analysis of variance. Correlation analysis and linear regression analysis were performed to determine the relationship and association among the continuous variables. Results: The adolescents achieved mean DDS and daily fat intake in the range of 2.",
        "label": 1
    },
    "798": {
        "output": "<EOD> A study to assess the efficacy of combination of toothpaste and mouthwash in comparison to a single toothpaste in the management of gingivitis\n\nINTRODUCTIONGingivitis is one of the most prevalent oral diseases. It has an incidence of over 90%. According tous, the incidence or the prevalence of periodontitis in the dentate portion of the population is 70%. [1][2]The present-day view on periodontitis is that it represents a spectrum of lesions extending from chronic gingivitis to periodontitis. Both of these pathological changes share the common predisposing factor of microbial plaque.[3]\n\n# Introduction\nGingivitis is one of the most prevalent oral diseases. It has an incidence of over 90%. According tous, the incidence or the prevalence of periodontitis in the dentate portion of the population is 70%. The present-day view on periodontitis is that it represents a spectrum of lesions extending from chronic gingivitis to periodontitis. Both of these pathological changes share the common predisposing factor of microbial plaque. [bib_ref]  Plaque bacterial diversity in experimental gingivitis, Teles [/bib_ref]  [bib_ref]  Clinical and microbiological effects of the adjunctive use of chlorhexidine mouthrinses in..., Marigo [/bib_ref]  [bib_ref]  Management of the dentine-restoration interface, Tyas [/bib_ref]  Periodontal therapy aims at arresting and/or reversing the underlying causes of periodontal disease and thus re-establishing the pre-diseased state. [bib_ref]  Periodontitis prevention and maintenance, Heasman [/bib_ref]  In early periodontal therapy, the most common interventions are scaling/root planing, and in late periodontitis, there is the use of local or systemic antibiotics. [bib_ref]  Current concepts in periodontal therapy, Armitage [/bib_ref]  Recent systematic reviews have demonstrated the efficacy of adjunctive use of 0.12% chlorhexidine mouthrinsing in reducing plaque accumulation and suppressing the growth of oral pathogens. [bib_ref]  Clinical and micro",
        "label": 2
    },
    "799": {
        "output": "If assess- \n0) Apart from the three-point scale, you should indicate whether the patient was recruited in the clinical trial. \nNote 4: Additional Information \nHere are several additional information about the trial: \n--Recruiting centre: \n    Only one center is being assessed (SHENGJING-SICAP-329), where patients can be enrolled in the study.\n--End of recruitment: The end of recruitment is October 2015.\n--Enrollment period: January 2014\u2013October 2015.\n--Start date (enrolment first patient): December 7, 2012.\n--Source of funding (grant funded): This study is supported by the National Science and Technology Support Program of China (NSTSPC) (No.2012BAIC14B01) and the Shenyang Science and Technology Plan (No.F12-116-1-28).\n--Acknowledgement: The manuscript was a collaboration between researchers from the Shengjing Hospital of China Medical University, the Beijing Gen",
        "label": 1
    },
    "800": {
        "output": "__The goal is to determine whether the patient meets the inclusion criteria. If the patient meets the criteria, then the score should be given 1; otherwise, it should be 0. You must compare the patient note with the inclusion criteria carefully. To get the answer, you shouldn't just read the patient's medical history, but also look at the patient's blood test results and the findings (e.g., a murmur) by physical examination. Your ultimate goal is to find a clinical trial for the patient. To do this, you will need to review the exclusion criteria.\nYou should compare the exclusion criteria and the patient data such that you can determine whether the patient fits into the trial data. If a factor is applicable to the patient, but meets one of the exclusion criteria, the score should be given 1, otherwise the patient should receive 0. For example, a patient has high LDL-C, but the LDL-C level falls within the normal range. That is, the exclusion criteria are not met.\n\nThe exclusion criteria are a type of filter that is designed to rule out patients with unrealistic expectations or who are prone to drop out. They include the following points:\n\n> - 50 years and above\n> - LDL-cholesterol \u2265 180 mg/dL\n> - Recent MI \u2264 6 months\n> - Recent PCI\n> - CABG \u2264 3 months\n> - Previous CABG\n> - TIA or stroke\n> - PAD\n> - Current LDL-cholesterol-lowering drug treatment\n> - Other cardiovascular disease, except for stable angina\n__Instructions:__\n\n```python3\nimport pandas as pd\nimport random\nimport numpy as np\n\nfrom sklearn import base\nfrom sklearn.model_selection import StratifiedKFold\n```\nLet's create the patient dataset.\n\n```python3\ndf = pd.DataFrame({'patient_id': np.random.randint(1, 500, size=100)\n                   , 'patient_bmi':np.random.randint(5, 25, size=100)})\ndf2 = df['patient_id",
        "label": 2
    },
    "801": {
        "output": "[INST]\nClosing\nGood job! You have successfully completed this activity!\nPlease find your answers on the following page.\nTo proceed to the next part of the lecture click on the following button.\nNext\nClick here to review the instructions for this trial\nGo back<EOD> Clinical practice. Painful neuroma of digital nerves.\nThis 71-year-old woman was referred by her primary care physician for evaluation of a painful neuroma of the index finger. The patient had undergone neurolysis of the digital nerve near the base of her left index finger 6 years before. She reported that within 1 year, her initial symptoms of paresthesia with numbness resolved, and the sensation of the fingertip returned to normal. However, pain in the region of the nerve repair occurred in the third year after surgery, and the pain persisted with gradual worsening. The patient reported that the pain was aggravated by cold and touching the finger, which would cause sharp shooting pain and burning. She denied any improvement with rest, ice, anti-inflammatory drugs, heat, or numbing agents. Her pain was so extreme that she had to take fentanyl transdermal patches, which caused sleep disturbances. Her past medical history was not contributory; she had no other allergies.<EOD> Ovarian cancer screening in women with Li\u2010Fraumeni syndrome\nWomen with Li\u2010Fraumeni syndrome appear to be at high risk for breast and soft tissue cancer. The present study evaluated ovarian cancer risk, the utility of pelvic examination, and possible approaches for ovarian cancer screening in this group.<EOD> TNF-alpha and IL-1 alpha up-regulate type I interferon receptor expression in hepatocytes; synergism between TNF-alpha and IFN-alpha.\nActivation of the interferon signaling pathway has been implicated in the pathogenesis of immune-mediated hepatitis. This study examined the role of Type I cytokines in regulating the IFN receptor (IFN alphaR) expression in hepatocytes. Rats injected with 200 microliters TNF-alpha showed a 2.5-fold rise in Type I",
        "label": 1
    },
    "802": {
        "output": "End<EOD> Lethargia, hypersomnolence, and sudden mental slowing: An enhancing phenomenon related to cytomegalovirus infection in a liver transplant patient\n\nEnhancing phenomenon of HHV-6 is associated with transplantation and immunodeficiencies, affecting the central nervous system (CNS), and characterized by excessive daytime sleepiness, hypersomnolence, and lethargy. Here we report a case of enhanced HHV-6 infection causing these symptoms in a 25-year-old male after liver transplantation secondary to fulminant autoimmune liver disease in the setting of anti-glomerular basement nephritis secondary to autoimmune hepatitis. On admission, the patient suffered from lethargy and hypersomnolence, leading to delayed recovery, and required supplemental oxygen for hypoxemia. Investigations subsequently revealed positive anti-HHV-6 IgM and IgG (IgG/IgM ratio 2.3). Further analysis on cerebrospinal fluid (CSF) for CNS infection revealed elevated leukocyte count with elevated HHV-6 DNA load: 5 x 105 cp/mL, which improved following foscarnet treatment. Therefore, we conclude that enhanced HHV-6 infection is an underrecognized cause of lethargy, hypersomnolence, and slowed cognition. Further studies should be undertaken to clarify the mechanism of enhanced HHV-6 infection and its relation to the enhancing phenomena and CNS impairments. KEYWORDS cytomegalovirus, enhancing phenomenon, hepatitis-6, psychomotor dysfunction, lethargia Frontiers in Immunology Citation: Chen J, Huang Y-H, Li P, Tian X, Yeh K-J, Huang Y-C and Li CH (2022) Lethargia, hypersomnolence, and sudden mental slowing: An enhancing phenomenon related to cytomegalovirus infection in a liver transplant patient. Front. Immunol. 13:9374",
        "label": 1
    },
    "803": {
        "output": "[CODE] <!DOCTYPE html> <html lang=\"en\"> <title>Clinical Trial Analysis Task</title> <meta charset=\"utf-8\"/> <style type=\"text/css\"> .btn {display: inline-block; position: relative; vertical-align: middle; *vertical-align: top; } .btn table tbody tr th:before {content:'';/*' '*/content:'' !important;} .btn table tbody tr th:after {content:'';/*' '*/content:' \u2610\u00d7\u00d7\u00d7' !important;} .btn table tbody tr td {vertical-align: top !important; padding: 0; } <style type=\"text/css\" media=\"screen\"> .btn {background-color: black !important; padding: 0.125rem !important; border: 1px solid white !important; border-left-width: 3.25rem !important; } .btn label {top: .5rem !important; margin-left: .3rem !important; margin-right: .15rem !important; } .btn #accept {color: rgb(234,239,243); text-decoration: underline; } .btn #decline {color: rgb(253,60,68); } </style> <meta name=\"viewport\" content=\"minimum-scale=1, maximum-scale=1\"> <meta name=\"format-detection\" content=\"telephone=no\"> <meta charset=\"utf-8\"> <meta name=\"description\" content=\"Clinical trial analysis task\"> <meta name=\"keywords\" content=\"eligibility, clinical trial, patient note, patient trial\"> <meta property=\"og:title\" content=\"Clinical Trial Analysis Task\"> <meta property=\"og:description\" content=\"We would like you to assess the eligibility of the patient note.\"> <meta property=\"author\" content=\"M.D\"> <meta property=\"og:image\" content=\"../images/16.png\"/> <link rel=\"stylesheet\" type=\"text/css\" href=\"../style.css\"> <script src=\"//s.stackpath.com/github/discourse/discourse\" data-version=\"1.6\"> (function() { // The body of this function",
        "label": 2
    },
    "804": {
        "output": "# Implementation\n\n### Requirement\n\n* [BioDataPipeline](https://github.com/Bio-DistributedDataPlatform/BioDataPipeline)\n  v0.x\n  (for `create_data`)\n* [dask](https://hub.docker.com/r/dask/dask)\n  v1.7\n  (for `dask.distributed.cpu.Delayed`)\n* `pandas`\n* `xlwrite`\n* `openpyxl`\n  `matlab-m file` \n<EOD> The effects of exercise on metabolism, mood, anxiety and depression in offspring of mice exposed neonatally to nicotine\n\nBackground: Maternal nicotine exposure (MNE) alters nAChR density and functionality in the central nervous system, particularly the dopaminergic brain reward pathway, and may affect emotional regulation. Moreover, the ability of an exercise program to counteract the aforementioned changes may depend on multiple factors, including the type, duration, and dose. The aim of this study was to assess the effects of exercise on the emotional regulation of offspring from mice exposed neonatally to nicotine. Method: Nicotine was administered neonatally to adult female Swiss mice at the beginning of lactation, and exercise was conducted for 14 consecutive days (days 0\u221213). The open field was used on day 4 (OF-4), and the novel object recognition test was conducted on days 4 and 7 (NOR-4 and -7). Results: On OF-4, nicotinetreated offspring exhibited less horizontal exploration and rearing, thus suggesting an anxiogenic effect. On NOR-4, nicotine-treated subjects displayed reduced ability to discriminate between a familiar and a new object (P < 0.01). Nicotine-exposed offspring trained on exercise also displayed anxiogenic response when submitted to OF-4 (P < 0.05) and impaired discrimination response in NOR-4 (P < 0.01), although the anxiogenic effect was more marked in the untrained group. Finally, a significant difference",
        "label": 1
    },
    "805": {
        "output": "[/TRIAL-DETAILS]\n\n[/T1_DOC]\n\n\n[T2_Doc: Cerebral Vasculitis]    [[INST]] \nCerebral vasculitis is commonly diagnosed at the time of brain biopsy but can present similarly to stroke.\n\nYou are tasked to help a busy neurologist manage an outpatient medical clinic, which requires a variety of patient types to be evaluated. This includes adult patients with transient ischemic attacks (TIA), who need to be evaluated for the possibility of a vasculitis etiology, and adult patients with cryptogenic stroke, who need to be evaluated for potential vascular risk factors and etiology. \n\nTo optimize the neurologist's workflow and enhance the patient and physician experience, you would develop a solution to support the diagnosis and treatment monitoring of vasculitis and stroke patients as they proceed through their care. \n\nWe do not have any other details about the patients being evaluated, other than they need to be adult vasculitis and vasculopathy patients, so adult patients being evaluated for a vasculitis etiology.  This could be through a positive result of inflammatory bloodwork (such as a high C-reactive protein or antinuclear antibody); it could also be patients with a negative bloodwork, but suspicious for the presence of TIA without clear explanation. \n\nWhile no actual patient records were provided, we created a variety of clinical patient records in the software to test the proposed solution. From previous research performed in medical record abstraction, we know that clinicians need support to help them better manage patients with multiple comorbidities and the potential side effects of treatment. Because vasculitis patients often may have one or more of these comorbidities, the neurologist will have to create a report to communicate to both colleagues and patients. \n\nThe report would be formatted into a single page of text, and would need to address both the patient's treatment regimen, and the comorbidities that are of note at this time for the patient, allowing neurologists and other physicians to communicate the treatment plan and comorbidities without having to communicate separately through emails and messages with different members of the patient's healthcare team.",
        "label": 2
    },
    "806": {
        "output": "Good luck.\n\n__HIGH_CONTRAST:__\nIt is the last task that a trial assistant has to do to provide a quality review of the eligibility criteria. The main purpose of applying `high contrast` is twofold. The first is to make the text of the document more readable for humans. The second is to allow searching for documents from the set of documents using machine learning methods (for example, natural language processing or deep learning)\n\n\n\n\n__HIGH_CONTRAST:__\n```sql\nupdate trials set trial_document=case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then right('[A-Z][AC-Z]\\'?$', locate('[A-Z][AC-Z]\\'?$','trial_document',1)-locate('[A-Z][AC-Z]\\'?$','trial_document',1)+length('[A-Z][AC-Z]\\'?$')) else '`[A-Z]\\'?$'`\n```\n\n## Part 3: Check that Trial_document_highContrast is correct\n\nBefore proceeding with the data analysis, it is best to first check whether the generated `trial_document` column is consistent with the original `trial_document` column. Because SQL operations are not completely deterministic, you should not rely on automatic code generation.\n\n\n__Test__: \n```sql\nselect sum(case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then 1 else 0 end ) as hc_pass sum(case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then 0 else 1 end ) as hc_fail\n```\n\n__Result__:\n```text\nSELECT sum(cast(case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then 1 else 0 end as \n                boolean))\n      AS\n    hc_pass,\n    \nCOUNT(1)\n      AS\n    hc_fail\nFROM dtl_11;\n```\n\n\n__Result__:\n```text\n+----------------------+---------+",
        "label": 2
    },
    "807": {
        "output": "### Q1. \nPlease explain to me step by step how to handle the patient note in the task?\n\n### A1.\nThis task is an input-output exercise in which you have to input information from the patient note into the task and output, whether the information is necessary to determine whether the patient meets the inclusion criteria of the clinical trial or not. In this task, it's a little bit tougher than other tasks since clinical note is much longer and there is no standard input form such as in the EHR clinical note exercise. In order to handle the task, I will suggest you to take following tips:\n\n\n* \n \nFirst, review whether information in the task has already been included in the patient note and add missing necessary information. The patient does not have medical history of diabetes mellitus, so, in this case, he might be eligible to the clinical trial. \nIf there is no new information, you can input it in the section `Either...`. For example, in the above example, `Either he has a family history of CAD or he is physically active.`.\n \n* \n \nIn case of the output, it is a good idea to review whether information in the trial note and input patient data match up. For example, in the case of `Trial-level eligibility: Excluded`, is there any information in the input section that contradicts the trial exclusion criteria? 2\n\n* \n \nIn case of any contradictory information, I suggest you to check how to input the contradictory information in the input section of the trial note. For example, in this case, the patient has a family history of CAD, but the trial excludes the patient due to prior CAD. In this case, you can use a dummy variable `Either...` in the input section of the patient noted. If you input the dummy variable `Either...`, it works as the output when the trial note says otherwise or vice versa.\n*\t\t<NAME>, <NAME>, <NAME>, and <NAME>; 5\n<span style=\"color: purple;\" xml:space=\"preserve\">23</span>\n\t<span style=\"color: green;\" xml:space=\"preserve\">3</span>\n\t<span style=\"color: pur",
        "label": 0
    },
    "808": {
        "output": "# Submitting your solution\nSubmission: You are invited to submit your solution (written or recorded, < 10 minutes) to the following address: e-mail: [hidden email]\nYou can submit your solution via the discussion section of the assignment. After submitting your solution, your solution will be reviewed by an instructor. All the feedbacks in the discussion section of the assignment will be replied within one week.\nThe best two solutions will be rewarded with a 10,000 RMB \"Educational Scholarship\". Also, each problem that gets an answer will be rewarded 200 RMB.\n\n## Note:\nThe discussion section of the assignment is not a debate, we will not accept any insult comments, offensive comments, and comments violating any of the Ethics guidelines for instructors which are in the first assignment. There will be no discussion section open after April 10, 2022.\n\n## Ethics:\nThis study was approved by the institutional review board of TMC. All eligible participants signed informed consent.\n\n# Analysis:\nParticipant information was analyzed at the center level. The primary outcomes of patient discomfort levels were recorded by investigators using 5-point Likert scales.\n\n# Discussion\n\n## Interpretation:\nThe findings are consistent with several investigations conducted at the same site, indicating consistency of the data. Higher levels of discomfort observed among patients during the period of drug treatment can be managed by improving current patient education initiatives. There are several methods of analgesia that can provide comparable benefits and lower doses of opioids may be a valuable tool to control pain in this population. It is important to understand that the efficacy of analgesia is dependent on the drug type and dosage administered. All of them contribute to a greater or lesser extent to a patient's level of discomfort. The relationship between drug type and symptomatic state may vary greatly from one medication to the next, and from one patient to the next. Our results are consistent with other studies demonstrating that higher levels of patient discomfort are associated with higher doses of opioids. This may be related to genetic variability and differences in the pharmacokinetics of opioids between",
        "label": 0
    },
    "809": {
        "output": "### Data and code available\n[Data and code for [Ellipsis]: Data and code for \"Inclusion Criteria Assessment\" are available at: UXAI&AI:  Data and code for \"Inclusion Criteria Assessment\" are available at: UXAI&AI.]\n   \n# Acknowledgments\n\n### Copyright\n\n    Copyright \u00a9 2019 The Authors. Creative Commons Attribution 4.0 International License.\n\n### Authors' Contributions\n\n    GD: Conceptualization, investigation, methodology, formal analysis, visualization, writing -original draft. GD, ZQ: methodology, and writing -review and editing. ZQ: methodology, visualization, supervision, project administration.\n\n# Disclosures\n\n### Data Availability Statement\n\n    All data generated or analysed during this study are included in this published article.\n\n# Funding\n\n### Support Statement\n\n    The authors received no specific funding for this work.\n<EOD> .\nObjective: To investigate the value of serum C-reactive protein (CRP) in predicting early clinical remission in patients with ulcerative colitis (UC). Methods: A retrospective analysis was performed on hospitalized UC patients who met the inclusion criteria from November 2011 to December 2014. The blood CRP level was tested within 72 hours of hospitalization and before treatment. According to the blood CRP at the time of the disease was diagnosed, CRP>5 and CRP\u22645 was divided into CRP-high and CRP-low groups. According to the early clinical remission of patients with UC, the CRP-high group and the CRP-low group were divided into remission group and non-remission group. All the patients were divided into mild or moderate and severe groups according to the disease severity at admission. The efficacy of budesonide in early clinical remission assessment was analyzed in patients with UC with differed initial blood CRP levels. The association of CRP with clinical symptoms in patients with UC was evaluated. The receiver operating characteristic (ROC) analysis was used to assess the value of CRP in determ",
        "label": 0
    },
    "810": {
        "output": "If you have a question, raise it in our discussion forum [https://discuss.voc.academy].\n\n__Clinical Guidelines__\n![INST] \nInstructions:\n\n* Consider the following variables for the patient:\n    * Age\n    * Gender\n    * Dizziness\n    * Frequent headaches\n    * Physical activity\n    * High LDL-C and low HDL-C levels\n    * Family history of CAD\n* Assess whether he has any exclusion criteria based on the trial.\n\n* Assess whether he has any eligibility based on the inclusion criteria of the trial.\n\n* Determine the Trial-eligibility scale based on the assessments.\n\n__Clinical Trial Paper__\nThis is the clinical trial paper to follow the same process: (1) Assess your understanding; (2) Make trial-level eligibility determination; and (3) Determine patient-level eligibility determination.\n\n### Assess your understanding\n\n* What is the eligibility determination in the clinical trial?\n- Patient-level eligibility\n- Trial-level eligibility\n\n### Make Patient-level Eligibility Determination\n\n1. Identify the Patient note:\n- The patient note:\n- Patient note:\n\n![INST] \nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal",
        "label": 1
    },
    "811": {
        "output": "Your final report looks like the following:\n1) Patient:\nSex: Male\nAge: 46 Years\nPrevious lipid-lowering medication:\n- \u2714Yes, atorvastatin\nCarotid artery disease:\n- BP (140 to 159): 145\n- BP (160 to 179): 142\n- BP \u2265 180:\n\n# Discussion\nThis is a simple case, but the algorithm for the patient note was a bit complex. A lot of things could be left out, if one wants, because the clinical researcher already knows most of what is in the patient note. For instance, the sex, age, and previous lipid-lowering medication are known from the information table, just as the patient's medical record is available.\nNotice that the patient had a LDL-Cholesterol level of 545. To answer the patient note: the assessment of the eligibility is 0, because the patient meets the inclusion criteria, but does not meet the exclusions criteria. The patient is a person with high cardiovascular risk who is excluded by the trial's exclusion criteria (previous lipid-lowering medication and the LDL-C level). The final assessment should be: `Trial-level eligibility: 2) Eligible.`.\nThere are no inclusion criteria for the age and sex, because the age is above 18 years and the sex is male or female.\nTo assess if a patent is eligible, the trial's exclusion criteria and the patient's information must be taken into consideration.\n\n# Conclusion\nThis tutorial taught how to make a trial-level eligibility for clinical trial recruitment. These tasks help to prevent enrolling a patient with characteristics which are not compatible with the inclusion criteria or even worse, with the exclusion criteria.<EOD> .\nThe frequency of posttraumatic epilepsy was studied on the group of 148 patients who had suffered a craniocephalic traumatism and who were treated a St. Joseph Hospital, Hiroshima, in 1962-71. The patients were classified into 63 of localized brain damage (",
        "label": 2
    },
    "812": {
        "output": "In this situation, we can only judge the eligibility based on the Trial-level eligibility since the patient does not satisfy the inclusion criteria like < 65\u2009years old. We need to continue to check the patient note, until we find the proper patient with matchable patient note in the dataset and the trial note. One of the patient note below is such a case:\n\n\nA 61-year-old man presented with dizziness and difficulty focusing. He reported a positive history of high blood pressure, diabetes mellitus, and smoking. The patient's LDL-C level was 106\u2009mg/dL and his fasting glucose level was 88\u2009mg/dL. No lipid-lowering medication was recorded.\nWe can get the Trial-level eligibility is 1) Eligible because the patient satisfies the trial's inclusion criteria even if the patient is above 65\u2009years old.\n![](./fig/8/4.png)\n\n\n## [INST4]\nWhat if the patient's LDL-C level is < 106\u2009mg/dL?\n\nWe know the LDL-C level should be < 106\u2009mg/dL in the clinical trial. So, the Trial-level eligibility is 1) Eligible.\n[formula]  \\begin{verbatim} Trial-level eligibility:",
        "label": 1
    },
    "813": {
        "output": "[A] Eligibility criteria of the clinical trial** \n\n## Trial name: Ultrasound-guided Intermediate Cervical Plexus Block\n\nInclusion and Exclusion criteria: \nInclusion Criteria:\n- open surgical revascularization\n- age over 18 years\n- written informed consent\n- internal carotid stenosis \n- superficial cervical ansa (facial nerve: cervical branch) is 12 mm \n- ultrasound-guided block",
        "label": 1
    },
    "814": {
        "output": "## [SOLS/SOLU] Solutions to test the patient note\n\nSolutions to test the patient note.\n\n## [INST/SOLS/SOLU] 0: Not Relevant\nWe should have the next result after executing each of the following four steps: the result can be found at the first line of all code.\n\n**Step 1**: Find all the stenosis in different fields and vessels.\n\n```\n// Find all 'stenosis' in carotid artery fields\nvar stenosis_in_CA = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string);\n\n// Find all the 'stenosis' in 'ICA' and 'CCA' fields\nvar stenosis_in_ICA_and_CCA = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string)\n\n\n// Find all 'stenosis' in 'carotid artery' fields\nstenosis_in_carotid_artery = patient.fields.carotid_artery.map((carotid_artery, i, arr) => {\n\n    if(carotid_artery.stenosis !== undefined){\n      return {\n        stenosis: carotid_artery.stenosis\n      }\n    }\n  })\n\n// Find all 'stenosis' in 'CX' fields\n//stenosis_in_carotide_X = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string)\n\n// Find all the stenosis in left and right internal carotid arteries\n// stenosis_in_ICAs = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string);\n```\n\n **Step 2**: Find the stenosis with different severity and vessel.\n\n```\n// Find the stenosis with a severity of different than zero\nstenosis_in_all_artery_with_severity = patient.fields.carotid_artery.map((carotid_artery, i, arr) => {\n\n        const carotid_artery_stenosis = carotid_artery.stenosis",
        "label": 2
    },
    "815": {
        "output": "[TITLE] Title: Enterprise Stent Implantation in the Treatment of Carotid Artery Stenosis With Ischemic Stroke Summary: To investigate the long-term effects of intracranial implantation of Enterprise stent system versus antiplatelet medication on neurologic deficits, daily living abilities, and carotid artery stenosis in patients with atherosclerotic ischemic stroke\n\n#### Inclusion criteria\nAtherosclerotic plague-caused carotid artery stenosis\nSevere carotid artery stenosis (unilateral stenosis > 70%) diagnosed according to angiography\nAge 18-75 years\nOf either sex\nProvision of informed consent regarding trial procedure\n\n#### Exclusion criteria\nIntra-cranial stenosis\nAortic aneurysm\nAbsence of target artery \nSevere cranial nerve deficit with paralysis\nAbsence of a suitable target vessel (carotid artery, vertebral artery < 2 mm lumen diameter)\nAbsence of a suitable stent for carotid artery obstruction \nPrevious treatment with carotid stent implantation\nCoexistence of peripheral vascular disease, especially below the knee, not with surgery treatment\nAny medical problem that, in the judgment of the physician, might make implantation of a stent unsafe \nNeurological deficit, e.g., stroke, transient ischemic attack, ischemia after angiography \nSevere coexisting systemic disease with 3 years of life expectancy \nUnstable angina \nRestenosis after stent implantation \nIntravenous drug addiction and non-compliance with the follow-up program \n\n## Patient Information\nYour task is to produce patient information according to the specified format and data input. You should follow the instructions carefully.  \n[TITLE] Title: Enterprise Stent Implantation in the Tre",
        "label": 1
    },
    "816": {
        "output": "## Solution\n\n### Detailed instructions\nDetailed Instructions\n\nIn this example, the patient meets some but not all the inclusion criteria of the trial (e.g., gender), whereas the trial-level eligibility is 1. You should output the three-point scale for the assessment of eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\n```python\nTrial-level Eligibility = Trial-level eligibility\nif Trial-level Eligibility is 1:\n    Result of assessment of trial eligibility = 1 \n    Comment of Trial-level assessment of eligibility = \"Exclusion criteria apply\"\nelse:\n    Result of assessment of trial eligibility = 2 \n    Comment of Trial-level assessment of eligibility = \"Patient does not meet inclusion criteria\"\n```\n\nThis code block returns `Comment of Trial-level assessment of eligibility: Exclusion criteria apply` and `Result of assessment of trial eligibility: 1`.\n\n\nYou should always repeat the comment of Trial-Level assessment of eligibility.\n\nThis code block returns `Comment of Trial-level assessment of eligility: The patient has been excluded from the study because the he was 46 years old, has a family history of CAD, physical inactivity, LDL and HDL cholesterol levels of 545 and 53\u2009mg/ dl respectively, and no use of lipid-lowering medications.` and `Result of assessment of trial elligibility: 2`.\n\n# Result of assessment of trial eligibility: 2\n\n# Comment of trial-level assessment of eligibility: The patient has been excluded from the study because the he was 46 years old, has a family history of CAD, physical inactivity, LDL and HDL cholesterol levels of 545 and 53\u2009mg/dl respectively, and no use of li",
        "label": 0
    },
    "817": {
        "output": "23. [ENT] Clinical Trial.\n```python\nimport random\nimport pandas as pd\nfrom sklearn.preprocessing import LabelEncoder\ndef get_patient_note(clin_trial, i=0):\n     \"Gets patient note for clinical trial\"\n    patient_note = ''.join('/'.join(i).split()[:-1])\n    patient_note += '\\n'\n    patient_note += '    Name =  '+clin_trial[0]\n    patient_note += '\\n'\n    patient_note += '    Inclusion_CRITERIA = '+clin_trial[1]\n    patient_note += '\\n'\n    return patient_note\n\ndef get_clinical_trial(i=0, clin_trial):\n    \"Gets the clinical trial for the patient for the given index\"\n    clinical_trial = clin_trial.iloc[i].iloc[:-1]\n    if i == len(clin_trial):\n        clinical_trial = clinical_trial.append(True)\n    else:\n        clinical_trial = clinical_trial.append(False)\n    return clinical_trial\n\ndef patient_note_prep(patient_note):\n     ''A function with the task to prepare all patient notes in a form similar to clinical trial information for evaluation''\n     for i in range(len(patient_note)):\n          if i in range(1, len(patient_note)):\n              patient_note[i+1] = \" \"\n          else:\n                 \"0\"\n          if i == 0 :\n                 patient_note_text[len(patient_note_index)] = patient_note_text.append(get_patient_note(clin_trial, 0))\n                patient_note = patient_note.replace(clin_trial[0], 'Clinical_Trial')\n                 patient_note = patient_note.replace('Inclusion_CRITERIA', 'Inclusion\\nCriteria')\n                 patient_note.replace('Exclusion_CRITERIA', 'Exclusion\\nCriteria').",
        "label": 1
    },
    "818": {
        "output": "## [/TEST]\n<EOD> .\nIn order to analyze the relationship between the level of p53, CD95 and c-erbB-2 expression and clinicopathological parameters and the survival (OS) in patients with esophageal squamous cell carcinoma, p53, CD95 and c-erbB-2 were examined immunohistochemically in paraffin specimens of 156 patients with endoscopically obtained squamous cell carcinoma of the esophagus. A positive CD95 expression was found in 36% of the tumours. Of these, 95% had positive p53 expression and 80% showed positive c-erbB-2 expression. A positive p53 expression was found in 58% of the tumors, in 66% of these tumours there was a positive c-erbB-2 expression and in 91% there was a positive CD95 expression. In Kaplan-Mayer analysis, no statistically significant relationship between CD95 or p53 expression and survival was found. The significant relation of c-erbB-2 expression to survival was revealed. The high frequency of p53 expression in this analysed group of patients corresponds to known data, what suggest that this tumour is associated with a mutation of p53 gene. The high frequency of the c-erbB-2 expression suggest an onedirection of the progression of neoplastic transformation of esophageal squamous epithelium.<EOD> Chaperone-coated pili, a class of adhesins related to P pili.\nA new class of pili (C-pili) produced by two uropathogenic enteric bacteria, Escherichia coli ABU 83972 and serotype W125 of Proteus mirabilis 42, were recently described by Andersen et al. (R. H. Andersen, R. I. Poulsen, R. J. Hardie, P. Moller-Oppegaard, A. H. Viborg, B. J. Andersen, H. Svenstrup, and N. Jann, p. 3713-3718,",
        "label": 1
    },
    "819": {
        "output": "[bib_ref]  A study exploring the eligibility outcomes (assessed as binary variable \"eligible\" versus..., Iversen [/bib_ref]  The file is in.csv format. \n(1) (https://figshare.com/s/9ececf1e53f62b3bb65b) is a data file. (2) (https://figshare.com/s/5ce68253a13298a8a5ba) is an example directory that stores the data file. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  is an example for output data in the JSON format. [bib_ref]  Efficiently combining clinical judgment and statistical evidence, Vickers [/bib_ref]  In this module, we are going to show you the output that we want in the result. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  shows the JSON file for training, validation, and test, respectively. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  shows the training set of the test. Similarly, [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , and [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  are the validation set, the training set, and the test set for the model, respectively. [bib_ref]  Clinical trial simulation, Flynn [/bib_ref]  In this module, we are going to show you the confusion matrix for each model. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , and [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  are for the confusion matrix of the training, validation, test, training, validation, test",
        "label": 0
    },
    "820": {
        "output": "[Tutorial/1-10] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-11] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-12] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-13] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-14] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-15] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-16] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-17]\n\n## Tutorial/2-1\n\n# Exercise\n\n## Exercise-2 \n[Tutorial/2-1] Write a C program for binary search tree using the recursive method.\n\n## Exercise-2.1\nHere is the definition of the recursive binary search tree (BST) algorithm:\n\n## Exercise-2.2\nThe given binary search tree is:\n\n## Exercise-2.3\nRun the code, and the output should be:\n\n## Exercise-2.4\nHere is the definition of an algorithm for the depth-first search tree traversal.\n\n## Exercise-2.5\nUse an empty binary tree.\n\n## Exercise-2.6\nInput an empty binary tree.\n\n## Exercise-2.7\nCreate the output file.\n\n## Exercise-2.8\nWrite a C program for a binary search tree using the depth-firstsearch (DFS) algorithm.\n\n## Exercise-2.9\nHere is the definition of the recursive binary search tree (BST) algorithm:\n\n## Exercise-2.10\nThe given binary search tree is:\n\n## Exercise-2.11\nRun the code and output should be:\n\n## Exercise-2.12\nHere is the definition of an algorithm for the depth-first search tree traversal.\n\n## Exercise-2.",
        "label": 0
    },
    "821": {
        "output": "---\n\n## Implementation note\n\nAs well as using Python 3.x with PyAutoTest, all our modules are written by the following two people:\n- [<NAME>](<EMAIL>): Leavers of [BioMedIA](https://biomedianet.org/blog/author/sidan-tian), and mainly responsible for our modules.\n- [<NAME>](<EMAIL>): the first author of this paper, and mainly responsible for the PyAutoTest.\nThe PyAutoTest's source code is available on [Github](https://github.com/zhenghong-tian/PyAutoTest).\nMoreover, for detailed source codes and how we built and used each module, please visit [BiomedIA](https://biomedianet.org/pylab/bioid/index.html).\n\n---\n```python\n# +\nimport biomedianet as bm\n# -\n```<EOD> .\nOBJECTIVE\nTo study the effect of PAF on platelets after the burn patients treated with the intravascular fibrinolysis or not.\n\n\nMETHODS\nThe concentrations of PAF and TXB2 were determined, and the reactions of the platelets with PAF were observed in burn patients with 3 degrees or more total burn surface area (TBS) without thrombosis and with coagulopathy. Platelets were isolated from the peripheral blood of healthy volunteers and the PAF were incubated with the platelets and washed. The platelets were treated with TXB2 mimicking enzyme, and then they were observed with electron microscopy.\n\n\nRESULTS\nThe concentrations of plasma platelet activating factor in the patients after the intravascular fibrinolysis were significantly higher than that of control subjects. The amount of TXB2 after incubating with PAF were increased significantly than that of control group. The platelets treated with TXB2 after incubating with PAF showed the thrombi and formed the fibrin networks.\n\n\nCONCLUSION\n1. The concentrations of PAF and TXB2 increased significantly than that before intravascular fibrinolysis, which indicated the intravas",
        "label": 0
    },
    "822": {
        "output": "<EOD> .\nThe authors have studied the use of the bone-suturing device they have developed in 75 patients with the bile ducts injured during gallbladder removal. The use of the device allowed to obtain more secure healing of the bile ducts injuries, and resulted in earlier mobilisation of the patients, i.e. decreased risk of purulent complications and aseptic inflammations as well.<EOD> A Study of the Correlation between the E3/19K Fragment Derived from EBV and Autoantibodies to SSA/Ro and SSB/La in Different Disease Conditions\nThe E3/19K fragment derived from the Epstein Barr Virus (EBV) was previously demonstrated to have antigenic crossreactivity with SSA/Ro and SSB/La. In the present study, the possible correlation between anti-p64 and anti-SSA/Ro in adult cases of systemic lupus erythematosus (SLE), and between anti-p64 and anti-SSB/La in Sj\u00f6gren's syndrome (SS) was assessed. Moreover it was tested whether E3/19K fragment antibodies could interfere with anti-SSA/Ro ELISA methodology. The sensitivity of the latter of anti-p64 antibody detection was investigated as well. 156 sera from patients with SLE, RA, SS, Sj\u00f6gren's Disease (SjD) and chronic liver diseases; and 65 sera from healthy controls, were tested simultaneously by ELISA for antibodies to p64, SSA/Ro and SSB/La. Positive anti-p64 antibody sera were tested in a commercially available anti-SSA/Ro ELISA to detect anti-p64 interference. Anti-p64 antibody titre in SLE patients was estimated and correlated with the levels of the other autoantibodies in that group. It was concluded that the presence of anti-p64 did not interfere with the anti-SSA/Ro ELISA methodology, and anti-p64 was mostly detected in SLE sera. Its serum titre was comparable with that of SLE anti-",
        "label": 0
    },
    "823": {
        "output": "[OUT] Good luck!\n\n[H3]\n\n[/H3]\n\n--\n\n-- ****************************************************************\n\n[[NOTE] Included in the {{SE}} and 26 November 2017.]]\n\n{{H2}} A {{NE}} to assess clinical trial eligible\n\nPatients have to fulfill the eligibility criteria to be screened and then enter a clinical trial.\n\nThis {{NE}} will allow you to assess trial eligible of a clinical trial patient based on the eligibility criteria.\n\nThe criteria can be listed to the right (see below) or as a table. To define the criteria in a table, click on the small square at the bottom of the field.\n\n- Type: *String*  - Type of element: *String*\n- Name: *String*  - Name: *String*\n- Criteria ID number: *Number*  - Criteria ID number: *Number*\n- Criteria description: *String*  - Criteria description: String*\n- Table: *Bool*  - Table: *Bool*\n- Table value: \n- Columns : \n  - Label: *String*  - Columns : *Number of columns of table* - Label: *String*  - Rows : *Number of rows of table* - Rows label: *String*\nInputting a value in this column will select a criterion from the table below. If the table contains several criteria, it is then up to you to select one of them. (e.g. if the patient has a total of three criteria, it will automatically select the first one. If a patient has a single criterion, the only way this table will do its job is to simply check which criteria are not satisfied by the patient)\n- Criterion value to exclude: \nIf one of the criteria is not met, one can check this box. In this case the result will be \"1\" (excluded) - Otherwise, the result will be \"0\" (included)*\n- Criterion value to include: \nIf one of the criteria is not met, one can check this box. In this case the result will be \"1\" (included) - Otherwise, the result will be \"0\" (excluded)*\n\n*",
        "label": 0
    },
    "824": {
        "output": "<EOD> A novel CAR\u2010T lymphoma: a challenge to the clinical practice for acral T\u2010cell lymphoma\nDear Editor A 72-year-old man presented with an erythematous blister in the plantar skin of his left foot for 20 days. Histopathological examination showed epidermal atrophy, degeneration of the basal cells, liquefaction degeneration of the dermis, small vessel changes, and infiltration of atypical cells with small-lucent cytoplasm (Figure 1A-D). Immunohistochemistry studies showed the tumor cells to be positive for CD3, CD5, CD7, CD43, CD45RO, CXCR3, Granzyme B, and Ki-67 (~80% positive cells). The tumor cells were negative for CD20, CD30, CD56, CD57, CD68, CD8, CD5, CD34, CD10, Tcl1, EBER, and Ki-67 (Figure 1E,F). Fluorescence in situ hybridization (FISH) tests did not confirm a TCR gene rearrangement. No evidence of Epstein\u2013Barr virus was found in the tumor (EBER test), and tuberculosisspecific polymerase chain reaction results were negative. The patient was diagnosed with peripheral T-cell lymphoma, unclassified. The patient received three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. After the first course of chemotherapy, the lesions decreased in size, the ulcer and blistering were healed, and the patient\u2019s pain symptoms were relieved. Chemotherapy was given 17 months after chemotherapy. FISH examination showed a deletion on the L551-S617 sequence in the CDKN2 gene. The CDKN2A/B protein is a tumor suppressor that regulates the division of mammalian cells and regulates the cell cycle through p21 protein binding; this gene is often deleted and mutated in T-cell",
        "label": 0
    },
    "825": {
        "output": "# C.2 The data file\n\nBefore the exam: This test is for clinical researchers. The patient is 67 years old, male, and has many diseases. Please evaluate whether this patient can participate in this trial, and write a report. Please put all the relevant information you collect in the document we provide for the evaluation, and then you can read the doctoral report and use your logical judgment to make a decision.\n\n## Diseases:\n(A1, A2, ..., A7: Inflammable bowel disease; A8: Allergy; A9: Liver Disease)\nSmell: (S1, S2: Normal; S3: Abnormal)\nTaste: (T1, T2, ..., T5: Normal; T6: Not Good)\n\n## Clinical information:\nEligibility: Tested_for_this_study: Yes\nEligibility: Not Tested_for_this_study: No\n\n## Trial information:\nTitle: Pharmacokinetic Analysis of AbobotulinumtoxinA (Dysport) in Parkinson's Disease\n\n## Phylogenetic tree\n```\n# -*- coding: utf-8 -*-\n\n#\n# Author: <NAME>\n# Date: 2022-01-19\n#\n# A function for producing a phylo tree visualization\n# \nimport seaborn as sns\nimport matplotlib.pyplot as plt\n# from ggtree.tree_view import TreeContourPlot\n# import plotly as py\n#\n\ndef PhyloTree(data,\n             color = 'default',\n             width = 'default',\n             node = 'default',\n             leaf = 'default',\n             x_tip=0 ,\n             y_tip=0 ,\n             x_branch=0 ,\n             y_branch=0):\n    fig = plt.gca()\n    fig.set_size_inches(width, height)  # set width and height\n\n    fig = sns.barplot(x=x_tip,y=y_tip, data=[-5 * np.log10(data.tip.tip_prob),",
        "label": 0
    },
    "826": {
        "output": "Good luck.!\n[INST]\n[INST] If you need to run these two commands simultaneously, you can use the `&` symbol like this: `codex.set_patient(\"M0001\")&codex.set_patient(\"M0002\")`.[INST]\n<EOD> A clinical trial comparing the efficacy and safety of three monoclonal antibody treatment sequences for advanced non-small cell lung cancer.\n18514 Background: Monoclonal antibody (MAB) therapies represent a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC). Two types of MABs have been approved by the US federal drug agency (FDA), each with the potential for an interchangeable positioning of two different agents in the sequence of first-line treatments of lung cancer. There are currently two regimens available, one for the use in all patients (docetaxel + carboplatin - CA) and another (nab-P + PA) allowing treatment in those who are not candidates for this combination.\n\n\nMETHODS\n385 unselected advanced NSCLC patients from 5 major medical centers in Spain were recruited for an open-label, multicenter phase III trial that randomly allocated them at a 2:1 ratio to a CA-based (N = 231 ) or a nab-P + PA-based (N = 154 ) first-line therapy. This analysis evaluates the association between initial therapy and response, time to progression, and time to death.\n\n\nRESULTS\nPatients in the CA or nab-P + PA arms were found to have a similar baseline demographics and disease characteristics with similar 1st Response Rates and time to progression. However, the CA group showed a higher median survival rate and a longer time to progression (median progression-free survival: 5.2 and 4.5 months in the CA and nab-P + PA groups, respectively; p = 0.83), and a similar trend was also observed in the overall survival, with a median survival of 9.6 vs 8.1 months, respectively) (p = 0.25) for the entire patient population. Treatment-emergent",
        "label": 1
    },
    "827": {
        "output": "<EOD> A Rare Case of a Dysphagia Nodi Ventriculi after the Treatment of Recurrent Falls in an Incompetent Patient\nAbstract Dysphagia nodi ventriculi, in English, is the term used for a lump or knob on the posterior wall of the esophagus. It is predominantly asymptomatic, and most often is discovered incidentally on chest or abdominal radiographs, although chest computed tomography and laryngoscopy are preferred to rule out other clinical conditions. Here, we present the case of a 68-year-old non-tetraplegic man who suffered a hyperextension trauma to his cervical spine, which caused spinal cord injury, loss of cerebral and cerebellar functions, and impairments to both vision and proprioception. Over the course of 4\u2009years, the patient received 17 hospitalizations due to frequent episodes of falling. After the hospitalizations, the patient displayed episodes of gastroesophageal reflux, dysphagia, and dysphonia. Eventually, the patient was referred to an otorhinolaryngologist and a gastroenterologist. After a diagnostic workup to rule out other clinical conditions, a radiologic study identified a mass near the esophageal lumen. The patient underwent a gastroscopy with a biopsy for pathological review and immunohistochemistry, which revealed a gastric-type leiomyosarcoma. After the surgical procedure, the patient received postoperative chemotherapy. At 40 months after the procedure, the patient remained alive. The objective of this case is to add to the literature further evidence of an extracranial-originated leiomyosarcoma that can be related to a history of long-term recurrent traumatic falls and to highlight the importance of a multidisciplinary approach to medical care among individuals with cervical disorders.<EOD> Is GDF15 a useful biomarker for predicting the prognosis of colorectal cancer?\nThe Growth Differentiation Factor 15 (GDF15) was identified as the newest member of the transforming growth factor-\u03b2 (T",
        "label": 0
    },
    "828": {
        "output": "You do this in the last line to avoid having multiple outputs one after another.\n\nIn the following, examples using pseudocode is shown in detail:\n\n## Pseudocode:\n\n* [//Instructions] \n\n```python\ninput = raw_input('Input a note: ')\nnote = input\nj = 0\ni = 0\n\n\n\nwhile j <= len(note): \n    #if word1 \n    if [note] == [\"1\"]: \n        output = 'Excluded'    \n        j=j+1 \n        i=i+1 \n        #if word2 \n    if [note] == ['2']: \n        output = 'Not relevant'    \n        j=j+1 \n        i=i+1\n        #if word3 \n    if [note] == ['3']: \n        output = 'Eligible'    \n        j=j+1 \n        i=i+1\n        #if word1, word2 \n    if [note] == {[\"1\", \"2\"]}:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1\n    #if word1, word1, word2, word3 \n    #if [note] == [\"1\", \"2\", \"3\"]:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1 \n    #if word1,word2, word3, word4 \n    if [note] == {\"1\", \"2\", \"3\", [\"1\", \"2\"]}:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1  \n    #if word1,word2,word3,word4,word5 \n    if [note] == {[\"1\", \"2\", \"3\", [\"1\", \"2\"]]:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1\n    #if word1,word2,word3,word4,word5,word6 \n    if [note] == {\"1\", \"2\", \"3\", [\"1\", \"2\"], [\"1\", \"",
        "label": 0
    },
    "829": {
        "output": "[fig]  [INST]: A: [C] [I] [L] [N] [S] [T] [G] [O] [E] [U] \u00a9 2022 Institute of Electrical and Electronics Engineers Inc. \u00a9 2022 IEEE International Conference on Health Informatics (ICHI) . DOI: [M] Doi: [R] [F] [E] [R] [F] [I] [R] [F] \u00a9 2022 IEEE International Conference on Health Informatics (ICHI) . DOI: [M] doi: [R] .[M] doi: [R] . [/fig] \n[table]  70: [I] 96 [L] 60 [E] 52 [A] 29 [B] 24 [F] 22 [T] 57 [C] 30 [G] 61 [U] 41 [H] 90 [M] 35 [K] [/table] \n<EOD> .\nThe authors report a rare case of intussusception in a newborn of 9 days old with gastric hypertrophy, in which no cause could be detected and the infant died 7 days after operation. The various theories for the mechanism of intussusception in newborn, in particular those of malposition of anatomical structures and an abnormality in the process of intestinal peristalsis are reviewed. As far as the authors are aware of, this would appear to be the first case of isolated ileocolic intussusception in the 9 days old neonate with associated gastric hypertrophy, reported in literature and it certainly gives to the authors interest to speculate on the mechanism of these two apparently unrelated conditions.<EOD> The role of the immune system as a tumor promoter.\nA chronic inflammatory state that is induced by a viral infection or by a chemical substance can potentially lead to development of cancers or other diseases. Inflammatory cytokines may induce the over growth of cancer cells or they might induce the generation of cell types that promote tumor growth or suppress antitumor responses.<EOD> Neuroprotective Effect of Caffeo",
        "label": 0
    },
    "830": {
        "output": "Explanation about the usage of the code.\n\n**1. Assignment of variables.**\nIn the notebook_2_assignment_variables.ipynb, we made three types of variables about the patient, which are the following:\n\n|    Variable Name     |   Descriptions                     |\n|:--------------------|:-----------------------------------|\n|    patientnote      |  This module has your patient note with more details.             |\n|           patientnote    |    In the `Patient' class, the instance variable `patientnote` holds the patient note you submitted.            |\n|                        patientnote                    |                                        |\n|           patient_disease    |    In the `Patient_disease' class, the instance variable `patient_disease` holds all the disease and history data about             |\n|                        patient_disease                    |                                        |\n|         variables          |    The instance variables of `patientname`, `personal_history`, `living_region`, `worked_region`, `blood_profile_note`, `gender`, `age`, `body_temperature`,             `pain_score`, `personal_information`, `systolic_blood_pressure`, `diastolic_blood_pressure`,           `pulse_rate`, `smoking`, `alcohol_drinking`, `history_of_disease`, 'history_of_chemotherapy', 'history_of_diuretic_medications', 'history_of_steroid', 'history_of_antibiotics', **`history_of_antidepressant', `history_of_anxiolytics`, `history_immunosuppressant`, `body_mass_index`, `bodyweight`, `height`, `surgical_treatment`, `'surgery_history', `hospital_location`, and `hospital_date'.            |                                        |\n|                        variables                     |\n\nIn the notebook_2_assignment_variables.ipynb, we made one type of variables about the patient data including body temperature, laboratory data, gender, smoking, alcohol consumption, drug history, and so on. This data is stored in the",
        "label": 0
    },
    "831": {
        "output": "This is the final output that should appear in the trial-level eligibility line, e.g., [Instructions]:\n[formula]  Patient ID: 754136036311 Trial-level eligibility: 0) Excluded Trial-level eligibility: 1) Excluded Trial-level eligibility: 2) Excluded Trial-level eligibility: 2) Elgible [/formula] \n## Exercise 2\nAs a clinical study assistant, your task is to determine patient eligibility for recruitment into a trial for the treatment of hypertension. \nThere are three main data elements you need to consider: age, systolic blood pressure (SBP) \u2265 139 and < 200 mmHg, and pregnancy status. Here are the characteristics of the trial:\nAge: The trial enrolls adult participants aged 20 to 65\u00a0years.\nSBP: The participants should have a measured SBP of > 139 and < 200 mmHg.\n\nParticipants who have chronic kidney disease due to diabetes, liver cirrhosis, or kidney disease due to chronic alcohol consumption.\nParticipants who are currently using antihypertensive drugs.\nParticipants with abnormal blood pressure that does not return to normal after an interval of at least six hours (a second blood pressure measurement).\nYou should make a trial-level eligibility on each participant for the trial, i.e., output the scale Trial-level eligibility for the assessment of eligibility.\nHere is the patients' note:\nA 35-year-old woman presents with hypertension. The patient has a family history of hypertension. Previous blood pressure was 150/100 mmHg, and fasting blood sugar was 140 mg/dL.\nA 62-year-old man presents with hypertension. The patient has a family history of diabetes. Previous blood pressure was 170/90 mmHg, and fasting blood sugar was 200 mg/dL.\nThe patient reported no use of antihypertensive medications",
        "label": 0
    },
    "832": {
        "output": "[[INST]] Hi all! You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient's notes and a clinical trial's patient eligibility criteria to find any similar traits between the  two sources to make a judgment and a final judgement, to decide whether to recruit this patient for clinical trial or not.\n\nIn this case, you should check whether the patient in the notes is eligible for the clinical trial according to the inclusion criteria of the trial. So, you should assess the patient's eligibility with the patient note (and the information above) and the clinical trial's information, for example, age, gender, the type of a disease, previous treatment history, etc. If the patient is eligible according to the clinical trial inclusion criteria (after the examination), you should output `Yes` (1) in the case section and `No` (0) in section 'not a case for trial'. If the patient in the patient notes was not eligible following the inclusion of age, the gender, the type of the disease and the type of the treatment history, you output the 3-level scale for the assessment of eligibility and a final judgement. If the final judgement is `1`,  you should output `Not a case for trial` at the end.<EOD> A Review of the Phytochemistry, Pharmacology, and Toxinology of Lomatogetone: A Traditional Chinese Medicine\n\nCitation: Zhou, B.; Ma, J.; Guan, Y.; Zhang, M.; Yan, W.; Yang, Z.; Liu, X.; Yan, X.; Li, H. A Review of the Phytochemistry, Pharmacology, and Toxinology of Lomatogetone: A Traditional Chinese Medicine.Plants 2023, 12, 305. https:// Abstract: Lomatogetone, also known as Loma citrina, Cibotia barometz, or Bai-sheng, belongs to the Lauraceae family and has been widely used to treat various bacterial and fungal diseases; meanwhile, the species is also used in human and veterinary traditional medicine. Herein, we have described the chemical components, the ph",
        "label": 0
    },
    "833": {
        "output": "You should always repeat the patient's eligibility in one line and the trial eligibility in the last line. If you don't remember what you did, just restart the demo (above this paragraph).\n<EOD> Association of the B4GALNT2 Gene with Body Weight in Children\nGenome wide association studies have identified multiple loci within the human genome that are associated with obesity and obesity-related phenotypes. Obesity is one of the major risk factors for coronary events. We analysed 9 tag SNPs (tSNPs) in a candidate gene, B4GALNT2, that has been proposed as a gene responsible for type 2 diabetes, and showed a relationship with total cholesterol and apolipoprotein B levels. The association of B4GALNT2 with total cholesterol and apolipoprotein B may be mediated by the increased body weight and body mass index of carriers of B4GALNT2. The aim of this study was to examine whether B4GALNT2 is associated with body weight and body fat mass in children. We used allele specific PCR analysis to determine the genotypes of all of the tSNPs. Genotype distribution was in Hardy\u2013Weinberg equilibrium. A total of 221 unrelated Korean children were genotyped for nine tSNPs (rs673991 AA/GA, rs740796 CG/GG, rs7781802 AA/AG, rs1326049 TT/TG, rs2268518 TT/TC, rs9206580 AA/AG, rs7619244 AA/AG, rs2243397 CT/CC, and rs2296349 AC/CC). Total fat, percent fat, height, weight, and body mass index were determined for all the subjects. Two representative SNPs (rs7781802 and rs1326049) showed a significant association with body weight and percent fat. This suggests that B4GALNT2 is associated with both body weight and body fat mass in children. We believe that rs7781802 and rs132",
        "label": 1
    },
    "834": {
        "output": "##\n\n# Related Work\n\nOur approach can be categorized as a rule-based system. Rule-based systems have been widely used in the clinical decision support system because they are capable of reasoning over a set of rules in order to perform an action or to make a decision.  In this paper, we used the semantic web technology, OWL and ROBOT, to represent our rule-based system. \nEvaluation measures for the semantic Web, OWL and ROBOT are generally lacking (see [fig_ref]  Table 1: Evaluation criteria for semantic Web, OWL and ROBOT [/fig_ref] . \nSince our goal is to develop a decision-support system for clinical trial study, we evaluated our approach primarily from the perspective of a human expert's decision. We did not investigate whether our approach is efficient or effective compared with other data mining technology in clinical trial study or evaluation of patients' eligibility.\n\n\n\n![](Figures_in_Review/eligibility_decision_making_with_owl_class.png) \nAn example of our OWL class modeling approach.\n\nHere are some related works: \n- Evaluation of OWL ontology reasoning tools. A number of articles evaluate the performance of OWL ontology reasoning tools in various ontology-based applications. \n-  The semantic web technologies have been applied to many biomedical subdomains in recent years. There are some studies evaluating the semantic web technologies in terms of OWL ontology reasoning efficiency and accuracy. \n-  The OWL RL ontology rule engine (RORE) is a knowledge-based system (knowledge-based engine) for making decisions in rule-based reasoning systems based on OWL ontologies in the clinical domain. \n-  The RORE is also an ontology management system that manages a set of ontologies and reason over the ontologies. \n-  The RORE also has a set of knowledge-based modules that use the inferred knowledge stored inside the RORE knowledgebase for making decisions. \n-  A decision-making method using OWL for medical data. They employed the OWL-DL (Web Ontology Language Description Logic) as the logical language. They showed the effect of a semantic Web ont",
        "label": 2
    },
    "835": {
        "output": "## \u2714\ufe0f A: If you think that you passed all the tests and you want to pass the exam, please press [submit] below. Otherwise, press one of the buttons below.\n[INST][X]: Close\n[INST]: Insufficient\n[INST]: Failure\n[INST]: Unable to reach the internet. Please retest later.\n[END]: You passed! \n\nYou can share and bookmark this page as any other page on [idrlog.com].<EOD> Rituximab-containing chemotherapy in the treatment of follicular lymphoma: a meta-analysis.\nThis meta-analysis was performed to compare different first line chemotherapies of indolent non-Hodgkin lymphoma (iNHL), including the FCR, chemoimmunotherapy, CHOP, R-CHOP. This meta-analysis searched the Cochrane Library, Pub Med, EMBASE database and included 14 trials. Four studies were excluded on account of data repetition and publication bias occurred. Then included 10 trials with 12 groups consisting of 2752 patients. The results of this meta-analysis showed that rituximab-containing chemotherapy significantly improved complete response rate (CR), including remission rate for follicular lymphoma (FL), in comparison to chemotherapy without rituximab. In addition, rituximab-containing chemotherapy significantly improved overall response rate (ORR), event free survival (EFS), disease-free survival (DFS), and 3-year survival rate. Rituximab-CHOP and R-FCR significantly improved DFS. On the other side, the adverse events were evaluated in this meta-analysis, including febrile neutropenia, grade 3-4 neutropenia, and severe infections. The adverse events were not significantly increased in rituximab-containing chemotherapy in induction and maintenance treatments. In summary, the addition of rituximab to chemotherapy improved CR, ORR, EFS, DFS and survival in patients with iNHL. It is significant to apply rituximab-containing chemotherapy in the treatment of iNHL. However, this meta-analysis has several limitations, and therefore future studies with larger patient",
        "label": 1
    },
    "836": {
        "output": "# Conversion from python to R\n\nHere we write the conversion command: r_command <- paste0(\"xeligible_trial = rbind(list_patient_note, list_trial)\"; paste0(\"xeligible = (sum(xeligible_trial$Trial-level eligibility == 2) );\"); #print(xeligible)\n<EOD> Surgical anatomy of aortic arch vessel variations\nObjective: To characterize the range of aortic arch vessel variations and define standard surgical approaches to these vessels for the open and endovascular aortic surgery.<EOD> Diagnostic accuracy of the CBC24: A composite measure of health in the UK biobank and the UK health and retirement survey\n\nObjective: To assess the diagnostic accuracy of the CBC24 as a composite measure of health in two large UK cohorts. Introduction: Researchers often use a combination or aggregation of health indicators to create a single measure of the overall health of individuals. Aggregation is especially common in medical research and geriatric care. Although there are various methods for creating such indices, existing measures of general health often do not perform well in identifying clinical outcomes. Methods: In this cross-sectional study, we evaluated the diagnostic accuracy of the CBC24 in the UK Biobank and UK Household Longitudinal Study (UKHLS), which measures an individual's overall state of health. Diagnostic accuracy metrics, including receiver operating characteristic curves, sensitivity, and specificity, were used to assess the performance of the CBC24 in discriminating individuals with and without self-reported chronic conditions and mortality status for both cohorts. Results: Across both cohorts, the CBC24 performed comparably or better than more complex indices in distinguishing health versus poor health and in predicting mortality using self-reports of chronic conditions. While accuracy was lower for the more comorbid UKHLS sample, results were also somewhat lower even when analyses were restricted to the non-CBC24 components. Nevertheless, the CBC24 continues to demonstrate better performance relative to its individual components and other measures. Conclusions: Given these results, the CBC24 will be a useful predictor of mortality and chronic",
        "label": 0
    },
    "837": {
        "output": "Copyright statement: Copyright \u00a9 Springer Business Media\n[INST] \nReferences: \n<EOD> Association of Serum Uric Acid With Left Ventricular Hypertrophy and Diastolic Dysfunction in Patients With Primary Aldosteronism\nJ Clin Hypertens (Greenwood) 2013;15:635\u2013642. \u00a92013 Wiley Periodicals, Inc.<EOD> The role of the mitochondrial respiratory chain in the induction of drug resistance in ovarian cancer cells\n\nDrug resistance remains a significant obstacle in the successful treatment of ovarian cancer patients. The mechanisms of acquired drug resistance are varied and, as such, can be difficult to predict or to block. The emergence of drug-resistant cells in ovarian cancer, and other diseases, can be associated with various genetic changes including mitochondrial genome alterations, which contribute to the enhanced drug resistance in human cells that harbor multiple genetic mutations and/or polymorphic sequences. Here, we analyzed the role of the mitochondrial respiratory chain (RC) in regulating the cellular sensitivity to platinum-based chemotherapeutics in two human ovarian cancer cell lines. The study revealed that inhibition of the mitochondrial OXPHOS with small molecules can partially sensitize drug resistant ovarian cancer cells to cisplatinum. Our data indicate that inhibition of the NADH-quinone oxidoreductase (NDUFV1), the complex I of the RC, is the most effective approach to reduce cell viability in ovarian cancer cell lines. In contrast, the knockdown of mitochondrially located proteins targeting complexes II-V did not significantly affect the sensitivity of ovarian cells to platinum-based drugs. Collectively, these data indicate that inhibition of the RC may be of therapeutic benefit in ovarian cancer patients, and suggest that the RC is a promising target to overcome cisplatin-based chemotherapeutics resistance.\n\n## Findings\nOvarian cancer is a leading cause of female death and the leading cause of death among all gynecologic tumors. Platinum-based",
        "label": 0
    },
    "838": {
        "output": "# Output\nHere is the command-line output of the script:\n[INST] Running script: /home/sjung/Work/clinical trial/clinical trial2.sh\n[INST] Processing 1 patient, please wait.\n[INST] Comparing the patient's LDL-C 545 and 160.5 to 12.36 mmol/L, 190 mg/dl, indicates that the patient meets the inclusion criterion of lipid levels \n[INST] Comparing the patient's HDL-C 53 and 1.100 mg/dl with 40 mg/dl, 1.170 mmol/L, indicates that the patient meets the inclusion criterion of lipid levels for HDL-C \n[INST] Comparing the patient's glucose and 218 mg/dl with 140 mg/dl, 7.80 mmol/L, indicates that the patient meets the inclusion criterion of glucose \n[INST] Comparing the patient's triglyceride and 158 mg/dl with 150 mg/dl, 1.70 mmol/L, indicates that the patient meets the inclusion criterion of triglyceride \n[INST] Comparing the patient's neck auscultation 3+/6+ to 0 indicates that the patient meets the inclusion criterion of no serious cardiac murmur \n[INST] Comparing the patient's carotid artery 50% to (b) indicates that the patient meets the inclusion criterion of no severe stenosis \n[INST] Comparing the patient's carotid artery 218.5 cm/s to (b) indicates that the patient meets the inclusion criterion of no maximum aortic velocity of >400 cm/s \n[INST] Comparing the patient's carotid artery max PSV 91.72 cm/s to max PSV cutoff of 200 cm/s indicates that the patient meets the trial-level inclusion criterion of plaque \n[INST] Comparing the patient's carotid artery EDV 37.37 cm",
        "label": 1
    },
    "839": {
        "output": "<EOD> The relationship between the quality of life of the caregivers and the quality of life of the elderly\n\nBackground/aim: The objective of this study was to evaluate the relationship between the quality of life of the caregivers (CG) and the quality of life of the elderly (EH) whom they care.Materials and methods:Study consisted of a total of 231 CG and 170 EH, including the caregivers of elderly who live at home. Socio-demographical and clinical features of the CG and EH were recorded during the interview by personal information form. Care burden levels were determined using the Turkish version of the Zarit Burden Interview (ZBI) Scale. Quality of life was evaluated using the World Health Organization Quality of Life Scale.Results: In this study, 68.6% of caregivers were women, and 31.4% were men. The ages were 33-87 years, with a mean age of 62.67 \u00b1 12.38 years. Of the CG, 90.7% were spouses, 4.3% were children, and 4.1% were other relatives. Quality of life of both the caregivers and the elderly significantly decreased with the care burden and was significantly correlated with their relationship status. The quality of life scores of the CG showed a significant correlation with the ZBI scores, and the quality of life scores were evaluated.Conclusion:The results of this study indicated that the quality of life of the CG as well as the EH whom they care is significantly decreased by increasing the care burden. In addition, the quality of life of the CG, who cared for their elderly relatives, was affected by the quality of life, severity of the care burden, and the relationship between them. For this reason, the health and needs of CG whose quality of life is negatively affected should be supported, and social intervention should be made to reduce the care burden.\n\n# Introduction\nTurkey, like many countries, is in a period of unprecedented development and demographic transformation. While the increase in life expectancy is a positive phenomenon in developing countries, the rapid increase in the elderly population is the most important demographic issue in the world today, and the most developed",
        "label": 0
    },
    "840": {
        "output": "__References__\n<EOD> Effect of exercise-induced muscle damage on neuromuscular performance: a brief review\n\nIntroduction: After a high-intensity muscular activity (HIMA), an intense muscle damage appears and persists for a short or long period of time, depending of the type, intensity and duration of HIMA, and it is reflected in neuromuscular fatigue. Aim of this review is to analyze the effect of muscle damage on neuromuscular performance. Methods: A review of the literature was conducted and a total of six databases were searched (PubMed, Medline, Cochrane, Pedro, Embase and SPORTDiscus). All articles written in English and Spanish related to the effect of muscle damage on neuromuscular performance were considered. Included studies must meet three essential criteria: (1) intervention involved exercise (or not); (2) participants were sedentary or engaged in regular exercises that could not influence the results of the study; and (3) the main outcome of interest was the assessment of muscle damage and neuromuscular performance. Results: We found that muscle damage seems to negatively affect the neuromuscular performance after the HIMA. Conclusions: The performance of the HIMA does not seem to be related to the magnitude of muscle damage, but to the recovery of the damaged muscle fibers in order to improve muscle function for further muscular performance.\nResumen. Palabras clave: Neuromuscular performance. Muerte muscular. Efectos del ejercicio intensivo en los m\u00fasculos.\nIntroducci\u00f3n: Despu\u00e9s de una actividad muscular muy intensa (HIMA), una intensa lesi\u00f3n muscular aparece y se prolonga durante un corto o largo periodo, dependiendo del tipo, intensidad y duraci\u00f3n de la HIMA, reflej\u00e1ndose en la fatiga neuromuscular. El objetivo de esta revisi\u00f3n es analizar el efecto de la lesi\u00f3n muscular sobre la percepci\u00f3n de la neuromuscular. Metodolog\u00eda: Se realiz\u00f3 una revisi\u00f3n de la literatura y se analizaron un total de seis bases de datos (PubMed, Medline, Cochrane, Pedro, Embase y SPORTDiscus). Se consideraron los estudios escritos en idioma ingl\u00e9s o cast",
        "label": 1
    },
    "841": {
        "output": "[MOD] Use the following Python function if you must implement your own module instead of installing it as a package. \n\n```\ndef clinical_trial_eligibility(note):\n    '''\n       Return trial-level eligibility from patient note\n    '''\n    # ...\n    return Trial-level eligibility\n```\n\n\n\n\n<p align=\"center\">\n<img src=\"https://raw.githubusercontent.com/pysafety/PYSAFETY/master/instructions/Pictures/python_notes_instructions/6_clinical_trial/5.png\">\n</p>\n<p align=\"center\">\n  <small>\n    <br>\n  </small> \n<p align=\"center\">\n  <small> \n  <br>\n</small> \n    \n<EOD> A retrospective cohort of 100 patients with COVID-19 infection in a low prevalence area in the Netherlands\n\n\n[fig]  Figure 1: (A) ROC curve for age (area under the curve [AUC]: 0.89 [95% CI; 0.82-0.96]), (B) ROC curve for C-reactive protein (CRP; 0.79 [0.67-0.91]) and (C) ROC curve for D-dimer (0.80 [0.70-0.90]) to predict mortality of the patients with COVID-19Fig. 2. Kaplan-Meier curve for mortality, for the different age groups and the cut-off value of 20.5 ng/mL for CRP and 900 ng/L for D-dimer. Data points were censored when patients lost follow-up before admission. [/fig] \n<EOD> Phenotypic and genotypic analyses of Campylobacter, Escherichia coli, and aeromonads isolated from a raw milk cheese\nSUMMARY The presence of Campylobacter, Escherichia coli, and aeromonads in different bricks of a raw milk cheese made from raw cows' milk was investigated in December 2012 and August",
        "label": 1
    },
    "842": {
        "output": "The assessment of risk and disease factors and their values for the patient have been calculated in the second and third steps. The assessment is automatically summarized in the first step so that you can see in the first step which values of the different risk factors in the patient are associated with the patient\u00b4s probability and eligibility.\n\nHere is how it looks like: \nThe patient note is 0.8 points below the trial-level eligibility threshold in this trial.\nFor each trial, we give you all the patient-level assessment of risk and disease factors and their values for the patient, as well as an overall trial-level assessment. The trial-level assessment in this trial is shown below.\n\n![trial-level summary table](https://raw.githubusercontent.com/kaggle/machinelearning-bootcamp/master/images/MIB-MLE_challenge_part2.ipynb.pdf)\n\nThe red lines represent the trial threshold values. Our patient meets all the criteria of the trial. He gets the maximal value in the last line in the table:\n\n\nIn addition, the patient note shows a very similar overall score: \n\n![Overall score](https://raw.githubusercontent.com/kaggle/machinelearning-bootcamp/master/images/MIB-MLE_challenge_part2.ipynb.pdf)\n\nThis is important to help us to understand what the final score is composed of. Our patient is quite similar to the overall score in the trial. Thus, both the patient and the trial are comparable.\n\n# Conclusion\nThis challenge is about evaluating a patient note from a cohort and decide whether this patient is eligible for a clinical study. We trained the classification model on a large amount of patient notes to automatically learn from the data. The model uses a simple classifier which combines the input variables of the patient note to one value. Thus, the final score we create for each challenge is a combination of all the values of these factors:\n\n## Suggestions\nPlease let us know which suggestions you had for the patient note and the eligibility score to get better in the future. Did you have any difficulties which we could help to solve? Please tell us!\nWe will take this into account when developing the next version of the MIB/MLE.",
        "label": 1
    },
    "843": {
        "output": "### Example\n#### A 24-year-old male with a family history of CAD presented to the emergency room in the setting of fever and chills. His vitals were notable for a heart rate of 91.  Fever and chills began the prior night and were associated with a cape with fever followed by a sore throat and cough. He denied chest pain or associated symptoms. Erythema and swelling were present on the tip of his tongue. He was unable to get to sleep due to worsening sore throat and cough. He felt that his voice was changing. His medical history is notable for non-toxic acute ingestion of ibuprofen 8 hours prior to presentation. Past surgical history was unremarkable. Social history was significant for no tobacco use but approximately 3 drinks per day.  He was previously seen in the primary care clinic 9 days ago for a similar viral syndrome with sore throat and fever. There, she was started on azithromycin and acetaminophen and advised to follow up with her primary care provider.\n<EOD> The Drug Candidate for the Management of COVID-19 Cases: Is It Worthy in India?\n\nThe Drug Candidate for the Management of COVID-19 Cases: Is It Worthy in India?\nNov-Dec 2020The Drug Candidate for the Management of COVID-19 Cases: Is It Worthy in India?\nAnn Indian Acad Neurol Ann Indian Acad Natl Med Coll\n236Nov-Dec 202010.4103/aian.AIAN_1084_201\nCorpus callosum, cingulate cortex, and cuneus (visual cortex) has been more affected in acute disseminated encephalomyelitis than other white matter and cortical areas. [bib_ref]  Regional differences in acute disseminated encephalomyelitis: A magnetic resonance imaging-based study, Col [/bib_ref]  The main neurological symptom in children with COVID-19 was encephalopathy. [bib_ref]  Neurologic and radiographic findings associated with COVID-19 in",
        "label": 0
    },
    "844": {
        "output": "##### 4 The trial note\n\n[IN] The investigators want to analyze results of previous RCT and explore the efficiency of carotid artery stenting and carotid endarterectomy on patient eligibility of clinical trial of carotid artery stenting or carotid endarterectomy. Designing a RCT trial to prove the effect and safety. The clinical data is used to explore the patient's clinical characteristics and to explore the impact of plaque and vascular stenosis on patients' eligibility.\n[/IN]\n\n##### 5 Other clinical trials\n\n![]()\n\n### A) Data preparation\n\n### a.1. Raw Data for the Training of 610 Patients and 61 Clinical Trials\n\n![](./Images/fig2418a.png \"Data Preparation\")\n\n\n\n### a.2. Data Cleaning\n\n![](./Images/fig2418b.png \"Data Cleaning\")\n\n\n\n### a.3. Clinical Trials\n\n### a.4. Patients\n\n##### a.4.1 Preprocessing\n\nTrial Note (optional):\n\n```\nInclusion criteria:\n- Stable angina patients who meet the diagnosis criteria of AHA of coronary artery(coronary heart disease)(CHD) according to GENERAL and/or local guidelines with objective evidence of myocardial ischemia;\n- Able to exercise 8-12 minutes on a bicycle exercise test or an equivalent treadmill stress test;\n- LVEF >35% and a maximum LVEDP < 15mm Hg as determined by right heart catheterization with measurements at end cardiac systole.\nExclusion criteria:\n- Acute myocardial infarction <8 weeks;\n- Coronary artery bypass grafting <6 weeks;\n- Left ventricular aneurysm requiring surgical repair;\n- Surgery <6 weeks;\nAge <18 years or >75 years;\n- New York Heart Association Class III-IV or Killip Class III-IV heart failure of non-ischem",
        "label": 1
    },
    "845": {
        "output": "[BACK]\n[CLOSE]\n[/CLOSE]<EOD> .\nBACKGROUND AND PURPOSE\nProliferative vitreoretinopathy (PVR) is a severe complication in rhegmatogenous retinal detachments (RRD). There is still no clear definition of the course of PVR. There are basically two clinical forms: the fibrosis and the traction types. Many studies describe the results of surgical correction of RRD, but there is little known about the natural course of PVR and RRD. The aim of the present study was to evaluate the natural course of PVR and RRD over a 5-year period.\n\n\nPATIENTS AND METHODS\nIn a prospective, observational study from 1995 to 1999, 31 eyes of 30 patients with diagnosis of PVR were included. All patients were initially treated surgically and were followed for at least 5 years. The study was designed to identify prognostic risk factors that may influence the outcome.\n\n\nRESULTS\nOutcome events were defined as the combined incidence of new retinal detachment and persisting vitreoretinal contractions. Prognostic risk factors were identified: young age, poor initial PVR classification, preexistent severe ocular disease, and macular damage.\n\n\nCONCLUSION\nIn view of the natural course of PVR and RRD, our data suggest that young patients, patients with a poor initial PVR classification, preexistent ocular disease and macular damage should be informed about the risk of retinal re-detachment and vitreoretinal contractions postoperatively. This should enable patients to decide early on whether they want to undergo a second operation for retinal re-attachment.<EOD> .\nA case of successful coronary reimplantation (CRA) was reported. This was a 55-year-old-man with Kawasaki disease who has undergone coronary artery bypass grafting (CABG) in 1994. Two main coronary arteries were completely occluded from the ostium to the orifice with the dilated and thinned posterior descending artery",
        "label": 1
    },
    "846": {
        "output": "Please submit your solution using the Submit button at the bottom of the page.\nSadly we need to tell you that this challenge will not be continued. We will offer a new challenge for you soon!\nPlease submit your solution and see if you and other participants made a correct choice. If more people got it right than the average for this challenge, you deserve a virtual badge!\nSadly we need to tell you that this challenge has ended. If you're in a competition, you still have time to compete! There is still time to go for it!\n<EOD> .\nThis is a case report from a 76-year old woman, with a 5+3 years history of psoriasis, which developed a tumor-like verrucous growth on the forehead, of which biopsies showed psoriatic skin. She was referred for surgery, where the diagnosis of xanthogranuloma (an uncommon non-neoplastic disorder of unknown origin) was made. It is of particular clinical interest that a verrucous growth developed on the forehead of a psoriatic patient.<EOD> Rhabdomyoma of the Tongue: A Case Report\nA rare case of a 1-year-old boy diagnosed as having a glossoepiglottic rhabdomyoma is reported. The patient had been submitted to an adenotomy when he was 3 years and 9 months old because of a laryngeal mass, which had been misdiagnosed as a tonsil. The patient was again studied by ENT and an abdominal computer tomography (CT), and was then taken to surgical excision. The excised mass was evaluated histopathologically. The report discusses, among other points, the possible origin of the epiglottis and/or the glossoepiglottic fold as the source of the tumor.<EOD> The Impact of Anorexia Nervosa on Bone Metabolism in Young Women\nAbstract: Bone mass deficits have been widely described in anorexic patients, especially in those with the eating disorder for many years. Bone mass at the hip appears to be better preserved than at the spine. Fat mass has been shown to be an important determinant of bone mineral content in patients with",
        "label": 0
    },
    "847": {
        "output": "<EOD> Highly regioselective arylation of amines, heteroarenes, phosphines, silanes, alcohols and carboxylic acids with aryl halides.\nA method for regioselectively arylating a broad range of organic compounds (amines, heteroarenes, phosphines, silanes, alcohols, carboxylic acids, etc.) with aryl halides in the presence of triphenylphosphine was developed.<EOD> Risk Factors of Dental Caries with Special Reference to Caries-Prone Groups as Seen in an Unorthodox Community in North Malaya.\nDental caries in any population group is a multifactorial disease, as a result of metabolic, social, dietary, hygienic and psychological factors. Different groups such as children, pregnant mothers, diabetics and the elderly are more prone to accumulate dental caries. An effort was made to evaluate the factors contributing to dental caries in a particular population group and determine their contribution to this disease. The study was conducted in the Nganasan and Selkup groups in Central Yakutiia and the Dolgano-Meriam and Selkuper in North Malaya, Russia for a period of one year from 2000 to 2001. Dental caries and other oral manifestations were evaluated and recorded in order to analyze the contribution of each risk factor. The present study highlights the different contributing factors, the role of psychosocial health on caries prevalence and the impact of cultural habits on oral diseases.<EOD> Sensing Tensile Stress in Single Nanowires\nSensitivity Sensors in the form of nanowires have important applications in biomedicine and biosensing, particularly for highly sensitive, miniaturized devices used in point-of-care testing applications. Xie et al. (p. 454) used a scanning electron microscopy technique to measure the change in the electrical resistance of bimetallic Zn (80 percent) Cu (20 percent) nanowires that was induced under an externally applied tensile stress. These nanowires exhibited a sensitive gauge factor of almost 30, more sensitive than bulk materials. Further increases in gauge",
        "label": 0
    },
    "848": {
        "output": "A: You would set eligibility to one or more values, and add an after script to give an appropriate flag.\n\n\n*\n\n*@echo off\n\nrem This script takes two parameters from the command prompt, so you need to\nrem modify the script to work on your environment.\n\nrem Example is for the command prompt \n\nset scriptCommand=runRICscript.exe\nset scriptFile=RICtrialscript.txt\n\nrem The next code will explain the main features of the script runRICscript.exe\n\nrem The script runRICscript.exe looks for a value called Trial_ID in the header\nrem of the .txt file to be able to associate the value it with the .csv file generated.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nrem The file Trial.xml is located in the current directory, and the script verifies\nrem that it exists. If the file Trial.xml does not exist, it will create it.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nrem The script verifies the location of the file to be analyzed, and if it does not\nrem exist, it builds the path with the directory that will be analyzed.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nrem The script sets a variable with the value of the directory that will be passed\nrem as an argument as TrialDirFile in the script runRICscript.exe.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nset TrialDirFile=%C:/Users/Uberaba/ProgramaPython/Trial/Trial1/Trial01\n\nrem The script sets a variable with the directory of the folder with the patient\nrem files that will be analyzed.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nset TrialPatientDir=%TrialDirFile%\n\nrem The script sets a variable with the path name of the file .txt",
        "label": 1
    },
    "849": {
        "output": "[/MARKUP]\n\n\n\n\n<EOD> Folding a novel peptide by single-molecule force spectroscopy.\nThe folding pathways of proteins and peptides are not fully understood. Atomic force spectroscopy (AFS) is known to reveal the dynamics of the unfolding and refolding of unfolded proteins. However, in AFS of proteins, it is hard to find the detailed mechanism of folding by pulling one end of single protein. In this study, we employed AFS to investigate the process of novel peptide folding by pulling the other end of the peptide while monitoring structural changes in real time. We show that a unique force-dependent pathway appears between 6 and 10 nN within the unfolding range of the peptide. The force-dependent pathway corresponds well to the intramolecular hydrogen bonding behavior determined through density functional theory. Moreover, we find that a new force-dependent path appears after the second force jump from 10 to 20 nN within the unfolding range of the peptide. This force-induced path is similar to the folding pathway determined by nuclear magnetic resonance experiments. These results demonstrate that AFS provides an alternative method to directly and quickly unveil the dynamic and complicated folding processes of a peptide.<EOD> A Case Report of Acute Nephrotic Syndrome Due to the Recurrence of Metastatic Colorectal Cancer With Pulmonary and Pleural Dissemination\n\nAcute nephrotic syndrome (ANS) has nonspecific clinical manifestations. We report a case of ANS induced by metastasized colorectal cancer. A 78-year-old male patient was diagnosed with diabetes 10 years previously, and his diabetic level was well controlled. His clinical manifestations were drowsiness, edema of both lower extremities and a swollen chest after he received two cycles of chemotherapy and targeted therapy for rectal cancer. His serum albumin (Alb) was 0.86 g/dL. Total protein, cholesterol, uric acid, serum creatinine (Scr), and serum cystatin C (SCC) levels were greater than the",
        "label": 0
    },
    "850": {
        "output": "Tutorial video to submit a file: [URL]\nTutorial video to modify a file: [URL]<EOD> Conventional Suture for Tendon Repair Results in Abnormal Morphology and Functional Behavior: A Rabbit Patellar Tendon Defect Model\n\nThe aim of this study was to provide physiologic insight to the current understanding of the pathologic findings following tendon repair on the basis of morphology, biomechanical property, histopathologic features, and gene expression, and to reveal the potential effect of conventional suture and augmentation on the tendon repair. Twenty-four knees of Chinese rabbits were randomly assigned to one of four groups: (1) normal, (2) patellar avulsion control (AC), (3) suture repair (SR) with a suturing configuration of 2-3-0 Vicryl in cruciate fashion, and (4) augmentation repair (AR) with a suturing configuration of 2-3-0 Vicryl in cruciate fashion combined with high molecular weight (HMW) PG, in order of suture repairing. Knees from AC group were exposed to patellar tendon avulsion followed by no surgery for one month before sacrifice. All the remaining rabbits were treated surgically with a patellar tendon defect model. All rabbits were sacrificed for patellar tendon and patellar bone biopsies to observe the tissue morphology, mechanical behavior, and expression of tendon related genes. Both the rabbits in surgery group and the AC group had a similar tissue morphology. There were significant differences in the expression of collagen I, II, MMP-1, MMP-2, and biglycan, as well as morphology and biomechanical properties between the experimental group and the normal control group or the AC group. The suture repair technique has poor biocompatibility for tendon healing, leading to a series of disadvantages like abnormal morphology, lower biomechanical properties and abnormal regulation of tendon related genes. However, HMW-PG might potentially enhance the performance of suture repair tendon healing.\nIn the daily practices of sports surgeries, the use of sutures for tendon repair is widely accepted. Suturing",
        "label": 1
    },
    "851": {
        "output": "Closing:\nThe following code will close the session. You should call sess_close() after finishing all your changes. sess_close() is found on the Python library page. \nsess.close()<EOD> Effectiveness of vapourizing the skin (cryotherapy) in the treatment of genital verrucae due to molluscum contagiosum\nMolluscum contagiosum (MC) is a highly contagious, skin infecting pox-virus-related disease, which in immunocompetent patients is clinically benign but which is difficult to clear. It is therefore of interest to identify treatment measures which can be easily performed on an outpatients basis without causing excessive discomfort and in which complete clearance is achieved in the majority of patients with minimal recurrence. Vapourizing the skin (cryotherapy) is a simple, safe, rapid procedure, causing less discomfort than similar therapies. We report our experience using this technique in treating 26 cases of MC and compare this with the responses to other therapies.<EOD> Influence of Cigarette Smoking on Sleep Apnea Severity in the Apnea Positive Pressure Long-Term Efficacy Study (APPLES).\nSTUDY OBJECTIVES\nCigarette smoking and obstructive sleep apnea (OSA) are independently associated with important adverse health consequences. We sought to determine if smoking cigarettes was associated with OSA severity and changes in severity during long-term positive airway pressure (PAP) therapy.\n\n\nMETHODS\nWe performed a post-hoc analysis evaluating baseline smoking status and changes in apnea-hypopnea index (AHI) during long-term PAP therapy in a cohort of 648 participants in the Apnea Positive Pressure Long-Term Efficacy study (APPLES). There were 143 ever-smokers (non-smokers vs. ever-smokers) and 505 never-smokers.\n\n\nRESULTS\nIn univariable analysis, smoking duration and pack-years were not associated with OSA severity. In multivariable analysis, never smokers had an AHI 6.7",
        "label": 0
    },
    "852": {
        "output": "</section><h3><a href=\"/doc/cog/05-05-intro-to-cog/05-08-02-rec_pat.html\">Section 5.8: Generate recruitment criteria</h3>[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)(In this paper, this step is performed by trial-level eligibility of the Clinical Trial (CTO))\n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the L",
        "label": 0
    },
    "853": {
        "output": "Note that any pre-prints or non-peer-reviewed \"versions\" of your article that you may have posted publicly on prepress servers should be taken down upon online publication of the final, peer-reviewed article.\n\n## Please see below for our manuscript checklist -the final manuscript files (text and figures) should match as closely as possible this checklist.\n\n## Title page\n\n## [inst] manuscript type: basic report\nTitle Page Manuscript Type (Please put N/A if it is not applicable)\n\n## Article category\n\n## Article type\n\n# [inst] abstract\nAbstract Please enter structured abstract according to the following items.\n\n# Introduction\nBackground (1)\n\n## Rationale\n\n## Objectives (1)\n\n# Methods\n\n# Introduction\nBackground (1)\n\n## Rationale (see above)\n\n## Objectives (3)\nStudy design -Setting\n\n## Study design -sampling\n\n## Study design -subjects 4\nStudy design -Sample size 6\n\n## Sample size justification 7\nStudy design -Protocol 8\nData analysis plan -Statistical methods -Plain language summary 9\n\n## Ethical approval and informed consent 10\n\n# Methods\n\n## Data collection process 11\n\n## Data collection tools 12\n\n## Procedures for data extraction 13\nData items 14 [fig_ref]  Table 1: The patient note. [/fig_ref]",
        "label": 1
    },
    "854": {
        "output": "2) Write `END.`: this means this is the end. [/EN].\n\n# The Assembler\nThe Assembler runs the Python code (the Assembler script) as a subprocess (child process) and returns the output to the Python library to be analyzed by the Assembler module. It is a Python script in the Assembler repository. The Assembler script contains all the information required to run the program correctly. \n\n## To run\nThe code to run the assembler script must be added to the following code.  \n```bash\nassembler.py <patient_note.json>\n```\n\n### The Input file\nThe input file contains the patient information, it is in JSON format. The user should select the patient he wishes to analyze from the file. \nAs the program is used for the patients' data, so it must be used inside the work folder. \nThe name of the input file can be changed to \"patient_note.json\" in the same working folder with the assembler script. \nIn an input file this information should be included:\n\n* Patient ID: a string with the patient ID\n* Gender: \"Male\" (when the patient is male) or \"Female\" (when the patient is female)\n* Age (the user can set the age in the input file to give the patient a fictitious age or a real age)\n* Patient_id: a string with the patient ID. \n* Name: patient first name\n* Surname: patient last name\n* Exclusion_status: the status of the patient in clinical trials (0=excluded, 1=not relevant, 2=eligible)\n* Ctrl_id: the ID of the controller. \nIf there is a controller that controls the work on all of the patients, it can be identified, giving its ID in the input file, with \"0\" in the ID column.  \n  `C_ID: 0` gives an ID of 0 to the controller, the user should not change this column\n  but he can create new controllers with \"C_ID: X\" where \"X\" is different from 0. \n  By default, the ID of the controller is \"0\", so it is not necessary to give a controller ID.",
        "label": 0
    },
    "855": {
        "output": "For more information on each data structure, please refer to the 'Help' and `docs` directories of the R package `clinical.trials`. \n\n\n``` r\nclinical.trials(trial=clinical, disease = \"Disease\", recruit = rep(FALSE, 50), subject=subject, disease.title = \"Disease\", disease.note = \"Brief description of Disease\", age_min = 18, age_max = 44, age.note = \"Brief description of Age\", gender.note = \"Gender description\", gender.m = \"Male\", gender.fm = \"Female\", recruit.status = rep(FALSE, 50), recruit.expose.type = rep(c(\"Inclusion criterion\", \"Exclusion criteria\", \"Inclusion criteria\"), 50))```\n\n\n``` r\nclinical.trials(trial=clinical, disease = \"Disease\", recruit = TRUE, subject = NULL, disease.title = \"Disease\", disease.note = \"Brief description of Disease\", age_min = 18, age_max = 55, age.note = \"Brief description of Age\", gender.note = \"Gender description\", gender.m = \"Male\", gender.fm = \"Female\", recruit.status = rep(TRUE, 50), recruit.expose.type = rep(c(\"Inclusion criterion\", \"Exclusion criteria\", \"Inclusion criteria\"), 50)).`````\n\n# Results\nThe results of your work are shown in Output-level eligibility of the data-frame clinical, the `Recruit.Status`, , `Age.Group1` , and `Age.Group_not_eligible.status` variables are also contained in the data-frame output.\n\n\n``` r\nclinical.trials.out[1:5] ```<EOD> Gap junction intercellular communication in rabbit corneal and conjunctival epithelial cells in culture.\nPURPOSE\nIntercellular communication via gap junctions is critical for a variety of in vivo epithelial functions. This study was undertaken to examine the morphologic features",
        "label": 0
    },
    "856": {
        "output": "We have provided four clinical trial cases that you can try as in our article [here]:\n\n## Step 1&2: Input Patient Details\nTo start practicing our tool, you should create input for the required data. \n\n\n### Example 1: Patient Details Using Tabular Data\nThis is the first example. You should prepare patient data. First, we should prepare a trial case-based patient data. Input a patient's data, e.g., ID (case ID), diagnosis, and trial name. You are free to prepare trial data (exclusion criteria). You can also refer that example for more information about the patient details.\n\n### Example 2: Patient Details With a Single Text Box\nThe second example is provided to illustrate the use of one text box for all patient data. \n\n### Example 3: Categorical Data\nThis is the third example. You can also use the categorical data in your input data.\n\n### Example 4: Tabular Data\nThe last example is provided to illustrate the use of multiple text boxes for each patient data.\n\n### Example 2&3: Patient Details Input Form\n<EOD> An open\u2010label, multicenter study to evaluate the effect of azithromycin on the bacterial content in subgingival pockets and on the bacterial composition of subgingival biofilms: Azithromycin in the treatment of periodontitis\nAzithromycin (Zithromax\u00ae, Pfizer, U.S.A.), a macrolide antibiotic with broad\u2010spectrum activity against both anaerobic and aerobic bacteria, has been reported to suppress destructive periodontal disease activity in humans. The purpose of the present study was to investigate the antibacterial effect of azithromycin on the subgingival microflora and to evaluate the short\u2010term effect of the drug on anaerobic bacterial subgingival biofilms. Azithromycin (three 1.0\u2010g doses given at four weeks' intervals) was given to 39 patients with severe chronic periodontitis. Two treatment groups were included. The group A comprised 20 patients, who had not previously been treated with antibiotics, and who were allocated to azithromycin",
        "label": 1
    },
    "857": {
        "output": "[CODE]#!/bin/bash\n\nDATA_DIR=\"$HOME/data\"\nSRC=\"$DATA_DIR/pyspark-3.3.0\"\nJAR=\"$DATA_DIR/spark-3.3.0.dist.zip\"\n\n# Download Spark installation package\nif [ ! -f $JAR ]; then\n    download http://repo1.java.net/maven2/org/apache/spark/spark-core_2.12-3.3.0.jar $JAR & while [ ! [ -f $JAR ] ]; do echo \".\"; sleep 1; done\nfi\n\necho \"Unpacking Spark jars...\"\nunzip $JAR\nrm $JAR\n\n# Download the data to be used in the experiment\nfor FILE_NAME in $DIR/test-data/in$TEST_NAME.txt ;\n    do rm -rf $FILE_NAME && cp $FILE_NAME $DIR/test-data/ ;\ndone\nrm -rf $DIR/test-data\n\necho \"Launching the script...\"\n./scripts/spark-run-main.py -i $SRC/input-data -j $JAR -t $TEST_NAME -o $OUT_DIR -c core.default.job_conf.properties > /dev/null &\necho \"Script has terminated.\"\nsleep 2\n\necho \"Launching the shell script...\"\nsource $SRC/run-scripts/$TEST_NAME/$TEST_NAME;\necho \"Script has terminated.\"\nsleep 2\n\n# Clean up the temporary data\nfor FILE_NAME in $DIR/test-data/in$TEST_NAME;\n    do touch $FILE_NAME;\ndone\nrm -rf $DIR/test-data\n\n# Write the run results\nfor FILE_NAME in $DIR/test-data/out$TEST_NAME/*.json ;\n\t\tdo # Create a new variable to check whether results exist\n\t\t\tif echo $FILE_NAME | grep 'Not run results found' -v > /dev/null;\n\t\t\tthen echo \"Success!\"\n\t\t\tdone\n\n       echo $FILE_NAME # Output test run results if none already exists.\ndone\n\n# Check the output folder for errors \ndir = \"pys",
        "label": 0
    },
    "858": {
        "output": "Now you are ready.\n\n# Testing\n\nRun a test using the command:\n\n`<cd> Tester folder<space> In.clin.test<enter> `\n\n# Results\n\nRunning all tests completes in a few seconds and outputs the following in the terminal.\n`OK`150\n`---`\n`Total tests:   151`\n`Summary`\n  `time      : 93.9s`\n  `memory    : 3534.0MB`\n  `failures  : 0`\n`Failures`\n\nTesting can be done using the command above. The first three lines are headers, and the fourth line is the default output for all tests. It indicates that the time is 93.9 seconds and memroy consumption is 3.5 MB. As no failure occurs, the test can be performed successfully and the entire program can run. The remaining test outputs are summarized here.\n\n```bash\nTests performed: \nTesting In.clin.test\n\n\n\n```\n\nThe test commands can be saved into a file (test file) by using the command below.\n\n`<cd> Tester folder<space> In.clin.test<tab><cr><cr> cat Testing In.clin.test\n\n```bash\nOK\n---\nTotal tests:   151\nSummary\n  time      : 93.9s\n  memory    : 3534.0MB\n  failures  : 0\n...\n```\n\nThe test commands are saved to the file named \"Testing In.clin.test\" by using the command above.\nThe command returns the complete description of the test file, and the size of this file is 34 bytes.<EOD> The role of surgery in the management of oesophageal leiomyoma in children\nIntroduction\u2003 The authors analyse the experience with paediatric oesophageal leiomyoma, with a special emphasis on the use of endoscopy, computed tomography, pre\u2010operative biopsies and surgical management.<EOD> Tuberculin Testing and Diagnosis of Mycobacterium tuberculosis in Drug-resistant Tuberculosis Patients, South Africa.\nWe investigated t",
        "label": 2
    },
    "859": {
        "output": "[END]\n\n\n--\n---\n#### Patients - Inclusion Criteria\n\nPatients presenting a symptomatic (ipsilateral ischemic stroke, TIA located in the carotid artery territory or retinal ischemia) carotid stenosis between 50% and 99% (according to NASCET and ECST criteria)\nPatients presenting an asymptomatic carotid stenosis between 60% and 99% (according to NASCET and ECST criteria)\n\n\n#### Patients - Exclusion Criteria\n\nPatients not presenting a symptomatic (ipsilateral ischemic stroke, TIA located in the carotid artery territory or retinal ischemia) or an asymptomatic carotid stenosis between 50% and 99% (according to NASCET and ECST criteria)\nPatients presenting an asymptomatic carotid stenosis < 60% (according to NASCET and ECST criteria)\nPatients presenting an asymptomatic carotid occlusion 51 Carotids not suitable for intervention due to: e.g., chronic occlusions (>1 month from onset), arteriosclerotic ulcer, kinked, dissecting, or fibrous intimal hyperplasia (>1 cm in diameter), total occlusion, or 2) any other condition at the discretion of the investigator as not suitable for study inclusion 52 Patients presenting an asymptomatic carotid stenosis 53 that are currently experiencing cerebrovascular ischemic events.\nPatients presenting an asymptomatic carotid stenosis 54 < 0.5 mm 1 mm-e.g. patients with stenosis of 60%-99% and more than 0.5 mm < 1 mm in length\nPatients presenting an asymptomatic carotid occlusion < 0.5 mm\n\n#### Treatment - Pre-procedural Pharmacological treatment\n\nPatients that present signs of intraprocedural thromboembolic complications, irrespective of the type of procedure (elective or emergent",
        "label": 2
    },
    "860": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level assessment of eligibility using the patient note given initially. \n\nHere is the patient's note:\n\nA 43-year-old obese man presents with an LDL cholesterol level of 90 mg/dL and a triglyceride level of 291 mg/dL. His family history is negative for atherosclerosis, diabetes mellitus, hyperlipidemia, coronary heart disease, and hypertension. The patient has a history of high cholesterol and hypertriglyceridemia. He has used fenofibrate for 10 years and is currently on gemfibrozil 300\u2009mg daily. He does not smoke. His mother died of coronary artery disease at age 71. \nThe patient reported no use of lipid-lowering medications.\nA chest radiograph revealed cardiomegaly.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, of high intensity and extending to the skull. Electrocardiography revealed regular sinus rhythm without any dysrhythmia and without abnormal conduction. Carotid ultrasonography showed no stenosis in any of the internal carotid artery branches. Here is the clinical trial: \n Title: The Relationship Between Morbid Obesity and Carotid Artery Stenosis",
        "label": 1
    },
    "861": {
        "output": "<EOD> In Vitro Characterization of a Potent and Orally Efficacious Inhibitor of Matrix Metalloproteinase-12 Discovered in a Pharmaceutical Collaboration.\nBroad targeting of metalloproteinases to provide clinically active inhibitors with optimal characteristics remains a considerable challenge. We describe the discovery and comprehensive in vitro characterization of a potent and orally efficacious inhibitor of matrix metalloproteinase (MMP)-12, a potential target for the treatment of cancer, inflammatory, and autoimmune diseases, such as rheumatoid arthritis. The inhibitor is generated in our laboratory from a large diverse combinatorial library of potent and selective MMP-12 inhibitors. The most active compound (3, K(i) = 95 pM) exhibits excellent oral efficacy in the mouse collagen-induced arthritis (CIA) model. The inhibitor shows complete inhibition of MMP-12 activity at low \u03bcg/kg levels in rat and NHP plasma with an oral bioavailability of \u223c40 % in rat and \u223c70 % in NHP. It demonstrates excellent physicochemical, metabolic, and formulation properties in vitro. The inhibitor is also expected to achieve high metabolic stability, allowing once-daily dosing in rat and NHP. This study provides a starting point for the lead optimization of this inhibitor series, which is currently underway in our laboratory.<EOD> The relationship between metabolic parameters and body adiposity in healthy children.\nINTRODUCTION\nMetabolic indices assess the metabolic status of patients at high risk of obesity and type 2 diabetes; however, few studies have evaluated their usefulness in children. The aim of this study is explore the relationship between metabolic parameters and body fat in a clinically healthy population.\n\n\nMATERIALS AND METHODS\nNinety-four children were recruited. Total blood lipid profile and metabolic status (triglycerides, HDL, LDL, VLDL, ApoB, Apo A, cholesterol, LDL/HDL",
        "label": 2
    },
    "862": {
        "output": "```python\n[birth_year - 2009.day - 3.month] % 100\n```\n\n## 4. Questioner. \ud83c\udfa9\nQuestioners inquire into a wide variety of aspects including: the patient's medical history such as illnesses, current medical conditions, previous treatments, or symptoms; the social history including such aspects as the patient's general health, family history, and environmental exposures; and the physical examination such as vital signs or weight.\n\n\n## \ud83c\udfa8 Data Types.\n\n\n##### Medical data\n\n- [patient.birth_year.astats], [patient.birth_year.birth_year] <c>Age; int;</c> \n- [patient.birth_year.birth_year_month] <c>Moth</c> \n- [patient.birth_year.birth_year_day] <c>Day</c>; {date} \n- [patient.gender.gender] <c>Gender; male ;female</c> \n- [patient.gender_name] <c>gender_name</c>; {string} \n- [patient.pregnancy] <c>Pregnancy;</c> \n- [patient.race] <c>race; black;white,Cauc</c> \n- [patient.race_name] <c>race_name</c>; {string} \n- [patient.marital_status] <c>Marital_Status; married; divorced</c>; {string} \n- [patient.medical_history.a_history_of_headaches] \n- [patient.medical_history.a_neurological_disorder] \n- [patient.medical_history.an_intrauterine_death] \n- [patient.medical_history.at_least_one_child] \n- [patient.medical_history.bad_diabetes_control] \n- [patient.medical_history.blood_disease] \n- [patient.medical_history.",
        "label": 0
    },
    "863": {
        "output": "[/INFO]\n\n# Example\n\nTo run this example, type the following:\n\n<rst>\n\n:stdin <FILE>\n\n</rst>\n\n> Trial-level eligibility: 1) Not relevant.\n> Trial-level eligibility: 1) Eligible.\n> Trial-level eligibility: 0) Excluded.\n\nHere is how this example looks on the terminal:\nRunning sample_test...\nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility:1) Eligible.`.<EOD> A Phase 3 Trial of Nusinersen for Spinal Muscular Atrophy Versus Observation: A Second Hypothesis: Commentary\nSpinal muscular atrophy (SMA) is a rare motoneuron disease caused by homozygous deletion of the survival motor neuron 1 gene with loss of a splicing enhancer, resulting in loss of survival motor neuron protein expression.1 The deletion frequency of the splicing enhancer varies by ethnicity, with the highest frequency, >1:10,000 persons, in patients from northern Europe. However, no ethnic group is immune from the disease.<EOD> Evaluation of Intravenous Administration of Carbohydrates Alone or with N-Acetylcysteine to Attenuate Radiation Hepatitis\nAbstractThe aim of this study was to observe the effects of administration of different carbohydrates and N-acetylcysteine (NAC) on the liver after cobalt 60 cGy total body irradiation (TBI) in comparison with no intervention. A total of 150 male rats were divided equally into 15 groups. Groups A-D consisted of rats that underwent 60 cGy TBI. Group A received no intervention, group B received glucose (2 ml/kg), group C received lactose (2 ml/kg), and group D received sucrose (2 ml/kg); then, all were sacrificed at various times",
        "label": 1
    },
    "864": {
        "output": "### Examplary file `example2.pdf`\nFirstly, please download the following file `example2.pdf` by rightclicking the Examplary file [example2.pdf] then clicking `Save As ...` or `Save Target As ...` in your browse window; the file contains 2 patient note and the clinical trial `Sample clinical trial.RIS` and file `Example 2.md`.\n\nSecondly, the following procedure will be displayed to you when running the script, make sure to check the box 'Show detailed help'.\n\nThen, save the file in your default directory. Next, type the command in the terminal.\n\n\t\trdoc_get_relevant.R\n\nFinally, the following contents will be displayed.\n\n```\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\nR> library(\"rdoc_get_eligible\")\nR> rdoc_get_relevant(\"example2.pdf\")\nR> head(Trials)\n-------------------------------------------------------------------------------------------------------\nR> Inference based eligibility assessment: 0(Excluded)\nR> Note: the result of eligibility has a one-to-many relationship (e.g., Inference based eligibility assessment: 1(Eligible), 0(Excluded).\n\n                         A: Assessment B: Basis C: Criteria E: Evidence R: Reason\n\n12\n       12\n       \"Fasting Glucose\" \"Glycated Haemoglobin\" \"HDL-C\" \"LDL-C\" \"Neck Auscultation\" \"Peak Systoic Velocity\"\n  \"Incidenece\" \"1.167\" \"1.238\" \"1\" \"1501\" \"4+/6+\", \"1.721\"\n1             \"Incidence\"\n  \"1.167\" \"1\" 12 \"1.238\" \"0.917\" \"4+/6+\", \"1.721\"\n2             \"Hypertension\"\n  \"1559\"  \"0\" 13 \"1609\" \"0\" 13",
        "label": 0
    },
    "865": {
        "output": "##[BLOCK]\n## Coding\n[BLOCK]\nIn general, the following data fields are recommended for coding:\n\nThe following examples are of the coding guidelines:\n\n* A) Assessment of Eligibility: 2) Eligible\n** 1. **`Coding for the `Assessment of eligibility: 2) Eligible` as `2: Eligible`: \n`  `Assessment of eligibility: 0) Excluded` as `0: Excluded`: `1: Not relevant`\nAll the details of your clinical study are provided to us as XML file.\nIn this clinical study, we have only four items of data:\n\nA) Assessment of Eligibility:\n\nB) Trial-level eligibility:\n\nC) Inclusion criteria:\n\nD) Exclusion criteria:\n\nXML format: <assessmentOfEligibility>\n   <0> excluded</0>\n   <1>notrelevant</1>\n   <2:eligible</2> \n </assessmentOfEligibility>\n<trialLevelEligibility> excluded</trialLevelEligibility>\n<InclusionCriteria>\n    <Factor  age  >\u2265 60 years</Factor>   \n</InclusionCriteria>\n\n\n<ExclusionCriteria>\n     <Factor  highsurgicalrisk>high cardiac or pulmonary risk</Factor>\n</ExclusionCriteria>\n\nXML file:\n'<?xml version=\"1.0\"?>\n<assessmentOfEligibility  xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xsi:schemaLocation=\"http://research.cchmc.org/cchs-xml http://research.cchmc.org/cchs-xml/cchs-xml.xsd\">\n  <0>0<Factor>excluded</Factor></0>\n  <1>notrelevant<Factor>notrelevant</Factor></1>\n  <2>2<Factor>eligible</Factor></2>\n </assessmentOfEligibility>",
        "label": 2
    },
    "866": {
        "output": "In this patient, the clinical trial is not applicable as only one exclusion criterion has been met: the patient is not eligible for the clinical trial due to having previous coronary artery bypass grafting (CABG) surgery [bib_ref]  Outcomes of coronary artery bypass grafting in patients with prior surgical revascularization, Fananapazir [/bib_ref] .\n\n\n\nAs we discussed, there is no simple step-by-step algorithm for assessing whether the patient is suitable to enter a given clinical study. A trial-level assessment of patient eligibility is performed not only based on patient characteristics that we see in his medical profile. One must also consider the clinical trial's eligibility criteria, which are more or less strict than others, which may affect the patient in terms of his or her treatment or recruitment. When the patient's characteristics are consistent with the clinical trial's inclusion criteria, the second checkpoint includes checking of the exclusion criteria in order to determine the patient's eligibility to be in the clinical trial. At this point, the clinicians have also to think outside the box: e.g., the patient was treated in the past for a heart ailment. He meets the trial's inclusion criteria, but his history inhibits him from participating in the trial. If the trial's exclusion criteria were based on medical procedures performed to improve patient condition in the past, this patient would be completely disqualified [bib_ref]  Challenges and solutions in conducting neuroimaging trials in patients with recurrent concussive..., Slobounov [/bib_ref] .\n\n# Implementing the method\n\n\n```python\n# +\nimport numpy as np\nfrom neodataprocessing import *\n\n# +\n# Load in patient data file into DP\npatient_data = load_patient_data(os.path.join(\"/path/to/data\",  # Path of the data ))\n# +\n# Load in patient-specific trial data\nclinical_trial_data = load_trial_data(os.path.join(\"/path/to/data\",  # Path of the data ))\n# +\n# Load in patient-specific DP data\nclinical_trial_patient_",
        "label": 2
    },
    "867": {
        "output": "# Exercise\n\n## Exercise 1: Clinical trial recruitment problem 1\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## Exercise 2: Clinical trial recruitment problem 2\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## Exercise 3: Clinical trial recruitment problem 3\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 4: Clinical trial recruitment problem 4\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 5: Clinical trial recruitment problem 5\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 6: Clinical trial recruitment problem 6\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 7: Clinical trial recruitment problem 7\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n## Solution\n\n## Exercise 1: Clinical trial recruitment problem 1\nLet's think step by step. \nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level elig",
        "label": 1
    },
    "868": {
        "output": "#### Examples\n\n<h3 align=\"center\">\n\nExamples.\n</h3>\n\nAs you may be aware, your task is to assess eligibility in both individual and clinical studies. To make this easier, we show you patient profiles in the first two examples. The assessment and output of the eligibility scale are based on this patient\u2019s case notes.\n\n**Example 1**:\n\n_Patient_\n\n\n\nThe patient note is below: \nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\n\nThe patient reported no use of lipid-lowering medications. \n\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u00a0cm/s and 54.5\u00a0cm/s, respectively; RICA PSV was 91.72\u00a0cm/s and RICA EDV was 37.37\u00a0cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less",
        "label": 0
    },
    "869": {
        "output": "________________________________________________________________________________________\n\n## <NAME>\n<NAME>\n<EOD> 17\u03b2-Estradiol protects against ischemia/reperfusion injury-induced oxidative stress and cardiac remodeling in the rat heart.\nOxidative stress in the cardiac myocyte induced by ischemia/reperfusion (I/R) injury causes cardiac injury and remodeling, and is the major contributor to the cell death and dysfunction observed before reperfusion. Therefore, the present study aimed to demonstrate the underlying mechanism through which the biological estrogen, estradiol (E2), attenuated I/R-induced cardiac injury and oxidative stress in the rat heart. The hearts of animals were subjected to I/R treatment, and the protective mechanisms of pretreatment with E2 of various doses (10, 50 and 100 \u03bcg/kg) was compared to treatment with E2 only. The effects of E2 intervention were evaluated by determining the cardiac infarct severity and oxidative stress, using reverse transcription-semi-quantitative polymerase chain reaction and Western blot analysis. Furthermore, cardiac remodeling was determined by examining the thickness and weight of the left ventricle (LV). The results of the present study concluded that pretreatment with E2 provided cardioprotection against I/R injury, which was associated with the inhibition of myocardial apoptosis and attenuation of oxidative stress. Furthermore, E2-pretreatment reduced cardiac remodeling after I/R, increased the left ventricular ejection fraction and decreased the LV end-diastolic pressure. The results suggested that E2, acting as a free-radical scavenger, attenuated oxidative stress and myocardial injury, and consequently improved the cardiac recovery from reperfusion.<EOD> Fertility preservation: a guide to a patient-centred counselling in the new Italian law.\nNew guidelines for fertility preservation has been issued by the Italian National Institute for Health (Istituto Superiore di Sanit\u00e0--ISSN) in 2015",
        "label": 1
    },
    "870": {
        "output": "##[END]\n[INST] You are a pharmaceutical industry research specialists. You want to do research in clinical trial with a new oral anticoagulant (NOAC) (Novel Oral Anticoagulant). The novel indication of the NOAC is prevention of systemic embolism at high risk of embolism and reduction of recurrent stroke in patients with atrial fibrillation. You must choose the best NOAC in terms of efficacy/safety. Thus, you need to select the target population. Your task is to do a search of medical documents about NOAC in terms of efficacy, safety using specific web sites [e.g., ]. The documents are medical articles and posters of international conferences. You do a first selection from titles and abstracts, afterward you read full-text article. \n\n##\n[INST] You are a cardiologist at the Lausanne University Hospital (CHUV). Each week, 18 patients consult with an electrode for cardiac ablation for tachyarrhythmias. You want to build an electronic health record (EHR) based on a local database. You can use data from cardiac ablation reports, medical history, medical data sheets, lab tests, etc. and then analyze them with statistical tools. At the same time, you can store and share them with other participants to conduct joint studies with physicians from other hospital centers, clinics and public health organizations. \n\n* [ ] E.g., a physician wants to use a mobile application that provides medical information. The EHR must be stored and exchanged between specialists, patients, clinics and hospitals.\n\n* [ ] EHR: Electronic Health Record\n\n* [ ] [ ] E.g., hospital physician wants to share a medical report with the patient via email, mobile application, or social network.\n\n* [ ] E.g., a patient wants to share his or her medical data with the primary care physician via a specific channel, such as a link in an email or an online shared document. [END]\n[INST] You are a computer scientists at the Lausanne University Hospital (CHUV). You are part of a team that developed an application based on blockchained technology, which gives all patients the flexibility and confidence to access E",
        "label": 0
    },
    "871": {
        "output": "Congratulations! You have finished the assessment of eligibility in this exercise.\n\n[TASK #6] Hello. You are a researcher. Your task is to assess the severity of depression in patients with major depressive disorder. We provide you information on patients' demographics, depression, and anxiety. Please assess their symptoms of depression based on  the Hamilton Depression Rating Scale (HAM-D).<EOD> Efficient In Vivo Delivery Mediated by D-Peptide Transporters.\nD-peptides are a promising class of medication that have the potential to directly interact with their biological target to trigger therapeutic effects. However, the inefficient delivery of D-peptides to their intended target has been a concern and limits the therapeutic application of D-peptides to those that act on extracellular receptors or directly enter the systemic circulation through the oral or rectal routes of administration. In this report, 14 D-peptides (e.g., d-Ser, d-Val, d-Pro, etc.) were evaluated to identify those that are specifically recognized by oral D-peptide transporters in the small intestine. These D-peptide transporter substrates were also found to serve as oral delivery vehicles to transport the macromolecular biomarker Alexa Fluor@ 750 (Mw, \u223c750 Da) to the circulation in vivo. We show that the D-peptide transporters are present exclusively in the epithelial cells of the small intestine as evidenced by the intestinal uptake of lysine-containing D-peptides and the inhibition of intestinal uptake by D-lysine in normal and CD-1 and C57BL/6 mice. A series of lysine-containing D-peptides, such as the 15-mer D-d-lys-d-d-Pro-d-Leu-d-d-Ala-d-Leu-d-d-Leu-d-d-Val-d-Leu-d-d-Ala-d-val and the 2",
        "label": 1
    },
    "872": {
        "output": "<h3>Recommended</h3><div id=\"comment\"></div><h3>BONUS 1: Tips and pitfalls</h3>\n<h5>Tips:</h5>\n<ul><li>Inconsistent triage was observed in the comparison, such as 'Unavailable' and 'Unknown' to 'Not relevant' and vice versa. </li><li>For a more specific result, 'Unavailable' patients, which have incomplete data, or unknown eligibility status should still be included when calculating the percentage match for the assessment eligibility.</li><li>Ensure the correct coding of the patients' gender and the trials' sex requirement. Female should only be coded with \"F\" and Male should only be coded with \"M\"; if a sex preference is required in the trial, then the patient should be excluded if inconsistent to the prefer requirement. If there is no sex preference in the trial, the patient should be excluded if the patient's sex is inconsistent with the trial's requirement.</li><li>Some of the included clinical trial records had wrong criteria; e.g. <span style=\"color: red\">1.4</span><span style=\"color: blue;\">-1</span><span style=\"color: red\">.0 -2.1</span><span style=\"color: blue;\"> -2.3</span><span style=\"color: red\">-7.3</span>.</li></ul><h5>Pitfalls:</h5><ul><li>Do not ignore the 'trial eligibility status of the missing patient' data</li><li>Ensure that the 'status' of the clinical trial and the specific eligibility criteria met in the clinical trials are correct</li><li>Make sure to keep the following variables consistent: Patients' gender, number of gender in each trial, patients' age, number of age groups, and ranges of age groups used, and patients' age range</li><li>There was no need to assess eligibility status when the trial eligibility status was 'unavailable'</li><li>Don't miss records with missing eligibility status or the patients with unknown eligibility status. If the number of patients with missing eligibility status is small, the 'not relevant",
        "label": 1
    },
    "873": {
        "output": "You are already trained on how to calculate clinical trial eligibility, and we'll now cover real-world scenarios to test your knowledge. Remember that a patient note contains five subheadings: Clinical Findings (CFs), Demographics (age and gender), Drug History (name, dosage, duration, and start time), Allergies, and Current Health Status (CHS) and Current Medications (CMed).\n\nYou are a medical resident, and you have to evaluate the patient's eligibility for the clinical trial. There are three scenarios below. For each scenario, only two subheading are required, so you don't want all information. What do you do with the other subheadings? What are your assessment criteria? \n\n**Sc1. Clinical Trial: Insulin Resistance. Patient: Mr. Cao, aged 45 years, male** \n\nMr. Cao has been diagnosed with insulin resistance. A clinical examination indicates diabetes mellitus and lipid metabolism disorder. He currently receives insulin therapy, which is the only treatment in his medical file. He had a previous blood transfusion a week earlier due to diabetes. His clinical findings suggest a 60/90 mmHg BP elevation, accompanied by a body weight of 78\u2009kg and a waist circumference of 20\u2009cm. \n\n**Sc2. Clinical Trial: Diabetes. Patient: Ms. Li, aged 40 years, female** \n\nMs. Li has been diagnosed with insulin resistance. A clinical examination indicates diabetes mellitus and lipid metabolism disorder. He currently receives insulin therapy, which is the only treatment in his medical file. He had a previous blood transfusion a week earlier due to diabetes. Clinical findings indicate a BP of 80/110 mmHg with 74\u2009kg weight and 20\u2009cm waist circumference. \n\n**Sc3. Clinical Trial: Insulin Resistance. Patient: Ms. Li, aged",
        "label": 2
    },
    "874": {
        "output": "<EOD> .\nObjective. To verify the diagnostic value of 300 ms EEG in coma and identify the optimal parameters for the test. Methods. EEGs were performed on 418 patients. According to the duration of coma (with and without 300 ms EEG), the sensitivity and specificity of the two EEG tests were compared. A ROC curve was used to compare the sensitivity of 300 ms and 100 ms EEG at different levels of specificity. Results. For subjects with a duration of coma \u226414 days, the sensitivity of 300 ms EEG (92.0%) was significantly higher than that of 100 ms EEG (31.6%)(\u03c7(2) = 123.19, P < 0.001). For subjects with a duration of coma >14 days, the sensitivity of 300 ms EEG (81.8%) was higher than that of 100 ms EEG (39.7%)(\u03c7(2) = 49.20, P < 0.001). The specificity of short-duration EEG \u2265300 ms (93.5%) was significantly higher than that of 100 ms EEG (76.0%)(\u03c7(2) = 21.05, P < 0.001). Conclusions. EEG coma duration over 14 days can be diagnosed with 100 ms in the coma for diagnosis \u2265300 ms.<EOD> Biodiversity in phospholipase-catalyzed ester cleavage reactions: the effect of different substituents on a common system.\nThe effect of a number of structurally different substrates on the kinetic parameters of different phospholipases C (PLCs) from various sources was investigated. On the basis of the results obtained, our conclusions are as follows: (a) phospholipid-dependent PLCs from Escherichia coli, Bacillus cereus, and snake (Bothrops jararaca) venoms showed a preference for 1,2-diacyl-sn-glycerol-3-phospho",
        "label": 0
    },
    "875": {
        "output": "</details>\n\n\n## Instructions to Contributors\nPlease use these instructions when creating new datasets.\n\n## Datasets for the paper.\n1. Create a new dataset in the Kaggle repository for your study.\n\n[INSERT YOUR DATASET ID HERE]\n2. Include your code to evaluate eligibility.\n\n[INSERT YOUR CODE HERE]\nYou should do the following on that script:\n- Run the script: \n$ [PATH_FROM_YOUR_PROJECT] evaluate_eligibility  \nThis will evaluate eligibility on all patient notes, not just on new patient notes from which you want to get an eligibility score! However, you should see all the outputs on the patient note (trial_level_eligibility, patient_level_eligibility, etc.).\n- Read the patient notes and then return the three-point scale into the same file. You should include the following fields:\npatient_id patient_level_eligibility trial_level_eligibility \nHere is a template for your code.\n\ndef main():\n    dataset = pd.read_csv(\"[DATASET_NAME].csv\")\n    trial_level_eligibility, patient_level_eligibility = dataset.groupby(dataset.patient_id).apply(evaluate_eligibility, axis=0)\n    trial_level_eligibility.to_csv(\"[DATASET_NAME]_trial_level_eligibility.csv\")\n\n    patient_level_eligibility.to_csv(\"[DATASET_NAME]_patient_level_eligibility.csv\")\n\n    return\n\n\nif __name__ == '__main__':\n    main()\n\nTherefore, you should see two output files in the directory of your dataset:\n- trial_level_eligibility.csv\n- patient_level_eligibility.csv\n\n3. Include the dataset in your CV and research papers as the following:\n\n```\n//dataset_name\ndata <- readRDS(file = \"dataset_name.RDS\", sep=\",\")\n\n//dataset_name (1)\ndata <- readRDS(file = \"dataset_name (1).RDS\", sep=\"",
        "label": 2
    },
    "876": {
        "output": "## Exercise 1\nTry to solve all following cases.\n\n## 1)\nWhat is the eligibility in the trial for the following case?\n- A 62 year old is diagnosed with mild hyperlipidemia and he is considering undergoing LDL-lowering therapy. He has recently heard about the benefits of the LDL-lowering therapy over diet and exercise. He has also had several friends go on this therapy and they feel it has greatly improved their health. However, he is very concerned about his eligibility with that therapy. Which drug is given, is it free or has any cost for him (free or not)? What is the eligibility in this case?\n- A 72 year old male is admitted with a myocardial infarction for stenting of the left anterior descending artery. He has previously experienced two silent myoardial infarcts and four silent strokes within the last 10 years due to his asymptomatic vasculitis. Although he is experiencing pain from this infarction, he decides that he does not want to take aspirin due to his bleeding problems from his previous strokes and is hesitant to take more blood thinner for this infarction. Which drug is given, is it free or has any cost for him (free or not). What is the eligibility in this case?\n- A 52 year old woman with diabetes, hypertension, and hyperlipidemia is referred to catheterization lab with an acute ST elevation MI. She has multiple comorbidities, including previous MI 2 years ago, and is being treated with several medications including diuretics and vasodilators. She is given an emergency intervention, but the interventionalist notes that her arteries were severely calcified with large atherosclerotic plaque. During the procedure, the interventionalist is concerned about the stenotic vessel and decides to place an intracoronary stent in the LAD. The stent will not be visible in angiography. After the stent is deployed, the interventionalist notes that the stent is appropriately sized and placed and that no other complications occur. However, the intervention will cost her out of pocket",
        "label": 0
    },
    "877": {
        "output": "The solution is available from [here](https://www.kaggle.com/ml-competitions/challenge-of-examination-of-clinical-trial/), [here](https://github.com/laboratory-of-computing-and-data-analytics/Challenge-of-examination-of-clinical-trial) and is available from [here](https://pubmed.ncbi.nlm.nih.gov/33963224/).\n\nI hope you enjoy solving the Challenge of Clinical Trial Assessment Competition.\nAll the best!\n<EOD> Recombinant DNA products for the delivery of therapeutic agents: patents available.\n\n This news item reprinted from the \"Bulletin of The International Patent Forum\" provides a list of U.S. patents that include recombinant DNA production of therapeutic agents such as tetanus toxoid, human serum albumin, hirudin, interferons, and interleukin 2. The patent numbers are arranged in order by patent number for the ease of finding the patent for the product one is interested in.\n<EOD> \u03b2-Amyloid Peptides Are Released from Cultured Cortical Rat Neurons by Both Exocytic and Non-Exocytic Pathways\nPrevious in vivo and in vitro studies have suggested that Alzheimer's disease is associated with dysfunction of neurotransmitter systems, leading us to postulate that neurotransmitters and their precursors might mediate aspects of the pathology. Accordingly, the present studies investigated the hypothesis that secretion of \u03b2-amyloid is altered in cortical neurons from 8-month-old Alzheimer's disease affected (APP(NL)) and non-affected (APP(N)) transgenic mice using real-time imaging of individual live cortical neurons. Neurons from APP(N) transgenic mice secrete amyloid peptides via the exocytic pathway as well as via a non-exocytic pathway. The data from \u03b2-amyloid secretion in APP(N) neur",
        "label": 0
    },
    "878": {
        "output": "<EOD> Correlated motion of molecule-substrate dipolar vibration in a magnetic field.\nIn this work we analyzed the correlation of molecule-substrate vibration and dipolar vibration in a magnetic field, by studying the Raman spectra of CH_{3}Cl/SiO_{2} samples, deposited on glass substrates, at different CH_{3}Cl exposures, by combining the classical theoretical simulations and empirical analysis.<EOD> A novel MRI imaging modality for visualizing changes in the rat knee joint after transection of intraarticular ligaments.\nThere are a number of disorders of the intraarticular ligaments and articular cartilage that result in osteoarthritis (osteoarthritis). For the assessment of the pathological conditions of articular cartilage which are difficult to detect on conventional radiographs and MR images, we developed a novel MRI imaging modality, termed the \"intracortical cartilage imaging modality (iccMRI)\". iccMRI enables visualization of the cartilage layers in the femoral and tibial condyle and the articular surface of the posterior cruciate ligament separately. We evaluated the sensitivity of iccMRI for detecting the thin degenerative cartilage layer around the site of the posterior cruciate ligament (PCL) in a rat model of osteoarthritis that underwent transection of the intraarticular ligaments. iccMRI clearly discerned the changes in the articular cartilage layers of the posterior condyle and the patellar surface of the rat knees after transection of the intraarticular ligaments, and is expected to be a useful tool for the clinical assessment of intraarticular ligament and articular cartilage diseases.<EOD> Combination chemotherapy and cimetidine in the treatment of severe sepsis.\nSixty-six patients with severe sepsis unresponsive to antibiotic therapy were divided into two groups. Ten patients were given placebo in addition to antibiotics for 10 days. Forty-six patients received daily injections of 500 mg of cimetidine for 10 days with antibiotic and placebo administration as in the previous",
        "label": 2
    },
    "879": {
        "output": "### Solution\n\nIn\nhere, we do the following.\n\n\n\n* * *\n\nlet f = open(\u2018patient-note.txt\u2019, \u2018r+\u2019)\nlet g = open(\u2018eligible.txt\u2019, \u2018w\u2019)\nif f.readline() != \u201c[PATIENT-INFO]\u201d then\nvar a, b, c, d, e = f.readline.split(\u2018\\n\u2019)\nc, b =",
        "label": 0
    },
    "880": {
        "output": "[END]\n\n# Discussion\nThe eligibility test is important to assess the fitness for clinical trials. In this assessment, the inclusion criteria of a clinical trial were compared with the characteristics of patients or patient records.\nCritical reading is needed to ensure patients meet the inclusion criteria. In this case scenario, the reader had to check whether the patient met the clinical trial's specific inclusion criteria or not.\nFurthermore, the assessment is needed in each patient, and the result should be a 3-point assessment, not a binary result.\nTo check the content, read all the patient information, i.e., the \"History of present illness\" section, and the \"Physical examination\" section and check the patient's characteristics thoroughly. In the patient information, check medical history, previous treatments, and comorbidities. In the physical examination section, check the physical condition.\nIf the data are not clear or there is missing data, ask the lecturer. This case involved untreated asymptomatic patients.\nThus, the patient will not be excluded only because they have a current comorbidity. Rather, the patient is excluded because the patient is symptomatic from the condition.\nThe lecturer did not give a list of patients or patient records; thus, the reader must write all information related to patients' assessments; for example, for patient 1, the assessment will be \"Excluded\" (the patient does not meet the clinical trial's inclusion criteria).\nThen, to find out if the patient is eligible or not, the reader has to check the scale and the exclusion criteria for clinical trial 1 on a trial-level.\nIn case the patient has several diseases or comorbidities, the reader should check all the exclusion criteria for clinical trial 1 to find out if the patient's conditions are exclusion criteria for the clinical trial.\nIf the patient has a previous history of symptomatic coronary heart disease (CHD), the condition is excluded when the patient participates in trial-1. \nFor patient 2, the assessment will be \"Not relevant: 0. (The patient does not have sufficient information to be a trial-level eligible.)\".\nAt last, the reader should write the patient assessment and the trial",
        "label": 1
    },
    "881": {
        "output": "Let's begin the first line of the patient evaluation, patient_clinical_assessment. First, the subject_number needs to be given; for example, subject_number=1. Next, you should fill in the rest of the parameters of the patient's clinical assessment, where clinical_assessment_list=<Clinical Assessment List>: <br>\n<br>\n<b>Clinical Assessment List</b><br>\n1 - Age: Age of the patient;\n2 - BMI: Body mass index (BMI);\n3 - WC: Waist Circumferene,\n4 - SBP: Systolic blood pressure",
        "label": 2
    },
    "882": {
        "output": "## Evaluation\n\nIf all criteria were met, then the number of elements was 10 and the maximum number of points was 240. The final result was 40, which is in the 5th quantile of the points of all 1000 participants of the course.\n\n## Example of Task Solution\n\nA patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009 mg/dL, resp.) were within normal limits.\n\nThe patient reported no use of lipid-lowering medications. \nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009 cm/s and 54.5\u2009 cm/s, respectively; RICA PSV was 91.72\u2009 cm/s and RICA EDV was 37.37\u2009 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nTherefore clinical trial eligibility criteria from the clin",
        "label": 2
    },
    "883": {
        "output": "### Examples:\n\n---\n* Patient_ID: 1 * Trial_ID: TREAT05678\n\n<pre class=\"debug\"><code>&lt;!DOCTYPE html></code><code>&lt;html class=\"html-comment\" id=\"html-comment\" lang=\"en\" data-lang-code=\"EN\"> &lt;head&gt; <code>&lt;meta charset=\"UTF-8\"/> </code> &lt;title class=\"html-comment\">Patient Trial-level eligibility 1) Excluded-No</code> &lt;link rel=\"home page\" href=\"/home\"/&gt; <!--[if IE]> <script src=\"http://ajax.googleapis.com/ajax/libs/jquery/1.7.1/jquery.min.js\"></script></script> <!--&gt;  <!--[if !IE]><script src=\"jquery.min.js\"></script> <!--&gt; </head> <body class=\"\" style=\"\"> <!--[if IE]> <div class=\"mceHTMLParser\"></div> <!--&gt; <blockquote class=\"blockquote quote\"><p>Trial-level eligibility 1) Excluded-No</p> <cite class=\"blockquote-author\">- Patient_ID: 1 -   - Trial_ID: TREAT05678 </cite> <p><strong><a href=\"/patient/1\">Patient_ID: 1</a></strong> <a href=\"/trial/TREAT05678\">Trial_ID: TREAT05678</a> <strong>:</strong><br> <em>Title: The Effects of Dietary Intake of Cod Residual Material Meal on Lipid Regulation, Glucose Regulation and Body Composition in Physically Active Adults </em> <em> Summary:</em> A high intake of fish is associated with positive health effects, including prevention and treatment of chronic non-communicable diseases, such as cardiovascular diseases (CVDs) and type 2 diabetes. These health effects have traditionally been attributed to the omega-3 fatty acids in fatty fish, but recent studies have suggested that also fish proteins",
        "label": 2
    },
    "884": {
        "output": "[CORRECT] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 5",
        "label": 0
    },
    "885": {
        "output": "There is no time limit for solving this task, but we don't recommend you to take more than 5 minutes. So, the code will be judged if you get the exact answer at all.\n\nTo do this, you need to understand correctly the task and think through a plan for its solution. In general, there are several ways to do this task, the main points that are important to pay attention to are highlighted in bold. You may use any programming language you like, and even a spreadsheet if you think it is the only way to solve the problem. You can send in as many solutions as you like. One point per task, with the best solution getting a bonus point - make sure you understand everything the solution does.\n\n##### What was tested in this task?\n\n\n*The tester will know when you have understood the task correctly and he/she is not a mathematician and doesn't expect perfect implementation of the algorithm.*\n\nAll the testing for this task are on the task description page. If you want to see the results - check the test results table.\n\nIf you are sure that you know how to solve this task and you just want to see how the judging will work - go down to the bottom of the page, fill the sample submission form correctly and you will see a link `View solution - try now`. But this is all with just 5 minutes!\n\n\n\n#### Examples for the solution\n\nHere are some examples of correct submissions. Please note that there are many more ways to solve this problem; the main point that is important to pay attention to is emphasized in bold and underlined.\n\nYou should always get the same result if you run the examples with the same parameters. Pay attention to the difference between the first and second rows and to the difference between the second and third rows. 500 (10%) are eligible for the ACT study. This means that 500 patients with ischemic chest pain, ST depression or T wave inversion in at least 1 lead, and Troponin values between 5\u201350 were eligible. For the ACE study, 47% (93) of the patients with chest pain with normal troponin levels were eligible.\n\n```\nExample solution 2 with test data\n\nIn case of ACT trial\n{\n  patient",
        "label": 0
    },
    "886": {
        "output": "The correct solution is below. \n```bash\n$ cat data/2_case_5.json\n{\n  \"ID\": \"f88a0ea9-0114-4278-b28d-49b1b747b026\",\n  \"age\": 46,\n  \"gender\": \"male\",\n  \"hypertension\": \"false\",\n  \"high cholesterol\": \"false\",\n  \"cardiac risk factors\": \"true\",\n  \"smoking\": \"false\",\n  \"family history of heart disease\": \"false\",\n  \"exercise level\": \"regularly active\",\n  \"high blood pressure\": \"false\",\n  \"lipid level\": \"true\",\n  \"diabetes\": \"false\",\n  \"cardiovascular\": \"true\",\n  \"exclusion criteria\": {\n    \"use lipid-lowering medications\": \"false\",\n    \"neck auscultation\": 0\n  },\n  \"trial level eligibility\": 2\n}\n\n$ cat data/2_case_6.json\n{\n  \"ID\": \"a00c7bd7-ddf7-4485-bf8e-0be2f77082a6\",\n  \"age\": 46,\n  \"gender\": \"male\",\n  \"hypertension\": \"false\",\n  \"high cholesterol\": \"false\",\n  \"cardiac risk factors\": \"true\",\n  \"smoking\": \"false\",\n  \"family history of heart disease\": \"false\",\n  \"exercise level\": \"regularly active\",\n  \"high blood pressure\": \"false\",\n  \"lipid level\": \"true\",\n  \"diabetes\": \"false\",\n  \"cardiovascular\": \"true\",\n  \"exclusion criteria\": {\n    \"use lipid-lowering medications\": \"false\",\n    \"neck auscultation\": 0\n  },\n  \"trial level eligibility\": 2\n}\n\n$ cat data/2_case_7.json\n{\n  \"ID\": \"b84c266d-25",
        "label": 2
    },
    "887": {
        "output": "<EOD> .\nTo establish the association between infection by H. pylori and gastric ulcer. 1,200 consecutive patients of the Endoscopy Unit of an open Hospital from Cochabamba were studied, in order to find out the percentage of infection by H. pylori and by the association with gastric ulcer. The percentage of gastric ulcer, duodenal and gastric bleeding in the total of patients was 2.0%, 1.6% y 1.0%. To find out the association between H. pylori and gastric ulcer, 100 patients with gastric ulcer, 100 patients with non ulcer dyspepsia and 100 individuals of the control group were studied. The prevalence of H. pylori infection by the urease test for the three groups was of 63%, 45% y 20%. When the group of ulcer is compared to the group of non ulcer dyspeptics; the association was found to be of high degree association between H. pylori and gastric lesions, with a relative risk of 3%, a Pc value 0% and an OR of almost infinite. But when the group of ulcers was compared to the control group, the association is of low degree association between H. pylori and gastric lesion, with a relative risk of 1.89%, a Pc value of 0.05 and an OR of 1.50. H. pylori has been considered by different investigators to be the most common infectious agent and to play a major role in the etiology of gastric ulcer, but the results are not homogenous. Infections by H. pylori is much more prevalent in patients with gastric ulcer than in non ulcer dyspeptics and the prevalence is about four times higher in that with gastric ulcer, than in the control group.<EOD> The role of cytokines, chemokines and matrix degrading enzymes in bovine spongiform encephalopathy associated neuroinflammation.\nThe neuropathological phenotype of bovine spongiform encephalopathy (BSE)",
        "label": 0
    },
    "888": {
        "output": "[INFO]\nThe expected information type of this test is: `scalar`.\nExamples of expected scalar information types include:\n\t1.\t0: `Scalar` information type\n\t2.\t4: `Logical` information\n\t3.\t13: `Real` information\n\t4.\t8: `Float` information\n\t5.\t16: `Int` information\n\t6.\t18: `UInt` information\n\t7.\t32: `Ptr` information\n\t8.\t33: `Array` information\n\t9.\t34: `FlexibleArray` information\n\t10.\t35: `Struct` information\n\t11.\t36: `Tuple` information\n\t12.\t37: `Chan` information\n\t13.\t39: `Range` information\n\t14.\t52: `Function` information\n\t15.\t64: `Method` information\n\t16.\t68: `Type` information\n\t17.\t72: `StructField` information\n\t18.\t75: `StructVariant` information\n\t19.\t79: `Slice` information\n\t20.\t80: `Variable` information\n\t21.\t88: `Channel ` information\n\t22.\t112: `Iterator` information\n\t23.\t117: `Resource` information\n\t24.\t122: `Result` information\n\t25.\t126: `Closure` information\n\t26.\t127: `Extern` information\n\t27.\n\t36.\t640: `Error` information\n\t37.\t680: `UnspecifiedObject` information\n\t42.\n\t650: `TypeMismatch` information\n\t670: `Expected` information\n\t675: `Unexpected` information\n\t677: `Type` information\n\t680: `Error` information\n\t7300: `Value` information\n\t7350: `",
        "label": 0
    },
    "889": {
        "output": "Please check the above notes and revise your code if necessary.\n<Trial-level code> #19[TEST]\npatient$trial_level <-factor(patient$name, levels = c(\"0\") #0: Excluded,\n'1') #1: Not relevant, '2') #2: Eligible)\n\n\n## Evaluation question 2: eligibility assessment-in a hypothetical scenario-what would you do with the note in #2\nA 46-year-old woman presents with dizziness and frequent headaches. She had a medical history of CAD, which is controlled by taking 10 mg of aspirin once a day and 20 mg of atorvastatin once a day. The patient's LDL-C and HDL-C levels were 110 and 53\u2009mg/dL, respectively. Her fasting glucose and triglyceride levels (79 and 147\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the LICA,  as well as moderate stenosis in the RICA estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",
        "label": 0
    },
    "890": {
        "output": "## Answer\n\n## 18 1 2\n\nThe assessment of eligibility for the clinical trial has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\n### 1. Correct Response: Trial level eligibility: 2) Eligible\n\n### Explanatory\n\n### 1. Trial level eligibility: 2) Excluded\n\n### 2. Trial level eligibility: 1) Not relevant\n\n### 3. Trial level eligibility: 1) Eligible\n\n### Explanatory\n\n### 3. Incorrect\n\n## (a) A 46-year-old man with dizziness and frequent headaches \u2026\n\n### Trial eligibility: 2) Eligible\n\n### Explanatory\n\n## (c) Trial-level eligibility: Eligible\n\n## Unstated information and unexamined assumptions\nThe patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively.\nAccording to CDC, Low-Density Lipoprotein Cholesterol (LDL-C) levels are used to predict heart attack and coronary heart disease (CHD) risk. Your level is considered high if it is 190 mg/dL or higher. Most people should aim for a level of 100-130 mg/dL, but it is OK if your level is somewhat higher than 130 mg/dL. HDL-C, is a \"good\" cholesterol. The higher the HDL-C reading, the lower the risk for heart attack and CHD.\n\n# 1. Trial eligibility: 2) Eligible\n\n### Explanatory\n\n### The correct answer was provided by \"unexamined assumptions\".\n\n### Wrong Answer: Trial-",
        "label": 0
    },
    "891": {
        "output": "# CQ3.4 Data-driven CQA\n[CQ] 100% of records in the data set pass CQA checks\n\n# [DATA]\n\n# Data Examples\n[INST] Check data for:\nIncomplete, duplicate or inconsistent data\nImprove quality by implementing automated methods based on clinical decision support systems\n\n# CQ4. Data Quality Checks\n\n# CQ4.1 Completeness of the Data\n[CQ] 100% records in the data set include 100% required fields\n\n# [DATA]\n- Data set(s) with no mandatory fields\n- Missing field(s) in the data set\nReason for Data Collection:\n[CXO] Is the field absolutely necessary?\nCan you justify that a data entry is mandatory? If not, you should remove the field\n- Yes, a mandatory field\n- No, the field is not mandatory, but it would be helpful, but optional\nRecommendation:\n- Remove the field\n- Change field's attribute to `required true` or `required false` for further processing\nReason:\n- When field is mandatory, data quality goes down\nRemarks:\n- For further processing, field's attribute must be `required true`\n- When field is mandatory and no longer used, data quality is not affected when field's attribute is `required false`\n- In case that some data field must be mandatory, but a data field is not mandatory, you will get an error when running data checks\nRecommendation:\n- Set all fields to be `required`, and create a new column `Reason`\n- Move the value of `required` from `required true` to 'optional true'\n- Move the value of `required true` to `required false`\n- Set all mandatory and nonmandatory fields to be `required field`\n- Check that a mandatory field is really mandatory\nReason:\n- In case that some data field must be mandatory, but a nonmandatory field was set mandatory, you will get an error when running data checks\n- In case that some data field must be mandatory, but a mandatory field was made optional, you will get an error when running data checks\nRe",
        "label": 0
    },
    "892": {
        "output": "__37,328__\n\n__5__\n\n__37,313__\nExplanation. Here is a sample to explain what you expect to see in this challenge. Let's review it together.\n\n````\n\n### Patient #0\n\n#### Patient Report\n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s.\nPlaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n#### CT-angio result\n\n```ct-angio\n--CT angiography:\n--Multiple severe st",
        "label": 0
    },
    "893": {
        "output": "<EOD> Mixed messages: a qualitative study of mental health problems in young offenders in a young offenders\u2019 institution for girls\n\n \n\n## Reviewer\nEileen McDonnell Leicester University, UK REVIEW RETURNED 26-Mar-2014\n\n## General comments\nA qualitative study of young offenders in a young offenders institution for girls in England.\nThe authors aim to describe the mental health problems experienced, focusing on anxiety, depression, self-harm and suicide, and how these issues impact the quality of life of young offenders and influence the relationships they have with other young people. The findings are based on in depth interviews with a small sample. The findings may, be of interest to mental health professionals working in prisons for young offenders..\nThe paper is well written and it flows very well. The abstract is clearly written, concise and covers the key points. The introduction is nicely structured and presents a clear rationale for the study. The methods section is clear, well structured and provides the needed information to enable the reader to assess the reliability of the study. The conclusion has considered limitations to the research and also provides recommendations to the government.\nThe reference list is up-to-date and the author's have not included a single reference or citation in their paper.\nThere were a number of typos in the text. For example in the abstract on page 4 \"In terms of mental health, young people's experiences, both good and bad, is explored to understand how mental health problems in young offenders influence their quality of life and relationships to other young offenders inside the institution\" is missing the \"a\". The list of references on page 31 is not complete, reference number 38 has not been correctly cited on the reference list.\nThere was no reference section for the qualitative reporting guidelines.\nPage 3, 3rd paragraph: \"It was not until the Prison Reform Trust drew attention to the poor mental health within young offenders institutions and the adverse effect it has on other prisoners that the Government started its public inquiries\". I would suggest the quote \"and the adverse effect it has on other prisoners \u2026\" is removed as it makes the sentence hard to understand. The information is repeated twice on page 4.\nPage 7, 2",
        "label": 2
    },
    "894": {
        "output": "[/CODE]\n\n# Discussion\n\nClinics Trials are prospective trials, designed to test whether a treatment is effective or not. A clinical trial is a research study that prospectively evaluates the effects of an intervention on health outcomes in human participants. They are used to improve patient care, both for specific individual medical problems, and for general care.\nIt is important in a retrospective study to confirm results found in trials of similar designs.\nA retrospective study is a research method that uses secondary data (data that has been previously collected for a separate reason than the current study).\nRetrospective, or historical studies, use real world data (RWD) to look for a correlation between existing patient outcomes and a specific treatment.\n\"These outcomes data are typically collected after an intervention, for example, in the treatment of a condition or disease. Such studies can help researchers evaluate how well or how poorly a therapy works.\"\n\n# Clinical trials\nFor broader information about Clinic trials, click here.<EOD> The role of bone marrow adipose tissue in metabolism and the skeleton\nPurpose of review This review highlights the most recent studies that have explored the links between the adipose tissue deposited within the bone marrow and the skeleton, adipokine production, and energy homeostasis. We also discuss the most recent studies examining the effects of altered bone marrow adipous tissue (BMAT) on skeletal metabolism. Recent findings BMAT adipogenesis is driven initially by bone formation and remodeling processes. Once established, BMAT is a mechanosensitive tissue that responds to changes in loading with increases or decreases in the expression of specific adipocyte and osteogenic genes. The functional effects of BMAT include contributions to energy homeostasis, systemic production of adipokines and support of bone homeostasis. In obesity, BMAT increases prior to that in white adipose tissue depots, and appears to support bone and possibly body metabolism differently, depending on whether bone and body weight gain reflects intracortical remodeling or marrow adipogenesis of adipocyte hyperplasia",
        "label": 1
    },
    "895": {
        "output": ".\n\n## Rarely eligible\nYou can mark this patient as \"Rarely eligible.\" If you marked \"Rarely eligible\", it will result in the patient being eligible from the perspective of the trial. You can still continue to recruit patients for the trial. If you select a patient for randomization and that patient is not randomly selected, i2b2 will present you a list of the randomly selected patients for this specific trial. Please select the patients from this list for randomization. Do not send those who are",
        "label": 0
    },
    "896": {
        "output": "<EOD> .\nMorphological and functional studies were made in 40 patients with different forms of chronic glomerulonephritis (CGN), 18 of them with nephrotic syndrome (NS) and 16 of them with proliferative form of CGN (mixed forms of nephritis). Changes in total number of lymphoid organs cells in CGN patients were observed. A possible relationship between this index and development of NS and activity of CGN was established. This relationship may be used as an index of prognosis and of CGN activity.<EOD> .\nThe purpose of this paper is to present the results of a new method of studying the microcirculation through the use of capillary microscopy with the help of a microscope magnifier. The study was performed in 6 children with chronic glomerulonephritis and 16 healthy children of the same range of age. The obtained results are very promising: capillary density is considerably higher than in the other methods; the results of the quantitative capillaroscopy are more accurate; the method is more precise because the same region of the skin is always used.<EOD> The Impact of Aging on Inferior Vena Cava and Pulmonary Vein Velocities and Strain in Dogs\nObjective: This study was conducted to evaluate the correlation between aging and inferior vena cava (IVC) and pulmonary vein (PV) velocities and strain in canines. Methods: Twenty\u2010five dogs aged 4 to 11 years were included in the study. The IVC and PV diameters and pulmonary flow velocities were measured with the use of 2\u2010dimensional and 3\u2010dimensional (3D) echocardiography. The volume and wall thickness of the IVC were measured with 3D echocardiography. The respiratory variation of IVC diameter, IVC ejection fraction (EF), IVC strain, and the right and left atrial peak emptying velocity were calculated. Results: Right ventricular (RV) EF tended to decrease with aging. The diameter of the IVC and RV tended to increase and the diameter of the PV tended to decrease with aging. The IVC systolic forward flow increased with",
        "label": 0
    },
    "897": {
        "output": "[INST]\nYou should make a Patient-level eligibility on each patient for the clinical trial, i.e., output the patient's eligibility. \n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nWhat is the trial-level eligibility, given the patient's information? Trial -level eligibility: 0) Excluded (does not have a history of smoking, high blood pressure and diabetes mellitus and is",
        "label": 1
    },
    "898": {
        "output": "###### Input:\n###### Output:\n*Note: It may take some time according to the size of clinical trials file. The output will only be displayed when you press the 'Run' button.*\n##### Exercise 3: Find patients who do not meet the inclusion criteria.\nThis exercise is to detect patients who were excluded due to the exclusion criteria. Use a simple statement of the Exclude column to display all columns for screening. You should press Ctrl+F to search for a word by typing in the Find box and then press Enter. \n\nFor the Exclude column, search `Stroke`, `Mi`, and `Tia`. If one of these cases is selected, then the other two cases will also be displayed automatically. \n\nSelect those cases to display the remaining columns. Then apply the following statement. `Select * from patientdata having Exclude=0 and Trialleveleligibility=1`. \n\nIf you press the 'Run' button or check the 'Run All button, then the patient data matching the selection conditions will be displayed. In this exercise, we want to see which patients meet the criteria of the exclusion section of the clinical trial. \n\nThe result:\n\n###### Input:\n###### Output:\n\n\n###### Exercise 4: Elaborate clinical trial data by calculating the proportion of excluded or eligible patients.\nCreate a statement to calculate a column, called Patient's eligibility proportion, which records the patient's eligibility on a clinical trial. Take the proportion of patients who met eligibility criteria by calculating the proportion of patients belonging to eligibility group, according to the proportion of all eligible patients.\n\n#### Exercise: Calculate the eligible proportion of the trial.\n\nCreate a patient count column to calculate the proportions of patients with eligible or excluded status. We calculate the proportion of patients who are eligible or not. In this situation, we must consider not only how many eligible patients are but also how many patients are being excluded. The statement is as follows:\n`select  * , count(Patienteligibility)=Eligible_Count, count(*)=Total_Count, Total_Count/Eligible_Count*100 from patientdata`.\n\nThe result",
        "label": 1
    },
    "899": {
        "output": "## \u2b0c Q1.2\nYou should now have a list of patients that you should include in the clinical trial. Please report the numbers of patients eligible to participate in the trial, the numbers of patients unwilling to participate in the trial, and the reasons for their unwillingness to participate.\nPlease report these numbers with a statistical test (Fisher's Exact test or t-test) and p value in the `Results` section. If there is no difference between groups, no statistical tests are needed. A simple `There was no significant difference.`. is enough and no need to report the statistical test or p value. Also, if you are doing a multiple hypothesis testing, you need to perform Bonferroni correction.\n\n## \u2b0c Q1.3\nFor a more real-world case, what if the patient in question does not have all the factors for inclusion criteria of the clinical trial? Does the patient have to be excluded if he/she lack certain factors? Or is it all right to include the patient with some missing factors? It is the case that the patient doesn't have 1 type of inclusion criteria. Should this patient be automatically excluded from the trial, or will you conduct an assessment to decide whether this patient should be included? \n```\n```<EOD> 15N isotopic labeling of an antibody Fab fragment by protein in situ refolding\nThe feasibility of selectively labeling in situ refolded antibodies on the protein level in terms of amide 15N\u2010H NMR is demonstrated. Both light and heavy chains were found to be isotopically labeled, which is attributed to the low isotopic shift between 14N\u2010 and 15N\u2010labeled protein. The method will find a particular use in the assessment of the impact of N15\u2010labeling on protein stability and dynamics.<EOD> A novel approach for the detection of mycotoxins at ultra-trace level in grains by high performance liquid chromatography with column-switching.\nColletotrichum dematium is a common fungus which produces the mycotoxin dematiacein. It is a dark-brown pigment whose chemical structural formula was elucidated in 1978. The toxin is known to be",
        "label": 0
    },
    "900": {
        "output": "## \u2728 **Important: Do not forget to set the appropriate value for the `trial-level-eligibility` parameter. \ud83c\udf9e\ud83d\ude80\ud83d\udc4d** \u2728\n\n### Checking\n\n### **Step 1: Checking eligibility by the check-eligibility R function **\nLet us assume a new patient with the following clinical trial's eligibility:\n\n    check-eligibility R2_check # Check patient trial-level eligibility by the check-eligibility R function \n \nChecking trial-level eligibility: 2) Eligible. \n \n \n \nChecking trial-level eligibility: Excluded.\n\n### **Step 2: Checking patient-level eligibility by the clinicaltrial el function**\nLet us assume the following patient-level ineligibility:\n \n    clinicaltrial(clinicaltrial, trial) # Patient-level eligibility by the function clinicaltrial \n\nEligibility is evaluated on each patient-level based on the patient and trial: \n \n    clinicaltrial R1 \n \n \n \nPlease click on the trial, R1. You will be asked to verify the trial-level eligibility. \n\nEligibility: Excluded.\n\n### **Step 3: Checking eligibility by the trial-eligibility R function** \nLet us assume patient-level eligibility by the clinicaltrial function: \n \n    trial-eligibility(clinicaltrial) \n \nEligibility checked on the trial-level: 2) Eligible. \n \n \n \nEligibility checked on the trial-level: Eligible.\n\n### **Step 4: Checking the patient-level eligibility by the trial-eligibility R function** \n \n    trial-eligibility(clinicaltrial, trial-level-eligibility) \n \n \n \nEligibility checked on the patient-level: 2) Eligible. \n \n \n \nEligibility checked on the patient-",
        "label": 0
    },
    "901": {
        "output": "Good luck.<EOD> Coma and electroencephalographic changes associated with bullous acral erythema in a patient on ibrutinib\n\n\n\n## In tro duc ti on\nBullous acral erythema (BAE) is a disease of unknown etiology. BAE is characterized by erythematous papules and plaques with dusky hemorrhagic blisters that occur on the dorsal aspects of the finger pulps, palms, and soles [bib_ref]  Bullous acrodermatitis of hallopeau: clinicopathological features and treatment outcomes, Choi [/bib_ref] .\nIbrutinib is a non-covalent Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK. BTK regulates the humoral immune system through maturation and differentiation of B-cells, which is crucial in the process of autoimmunity; therefore, ibrutinib blocks BTK and ultimately causes immunosuppression [bib_ref]  Management of ibrutinib toxicities: a guide for the oncologist, Al-Shamy [/bib_ref] . Cutaneous toxicities associated with ibrutinib can manifest in the oral mucosa, nail bed, and cutaneous appendages, such as acrokeratoelastosis [bib_ref]  Ibrutinib-induced pseudoacrodermatitis-like lesions and hair disorder: a novel cutaneous adverse effect, Mccartney [/bib_ref] . The use of ibrutinib as a first-line agent in chronic lymphocytic leukemia (CLL) has been associated with new skin manifestations . Ibrutinib has been reported to cause toxic eruptions, rashes, and drug reactions, which can lead to the development of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) like dermatological disorders. Although SJS was never reported during the development of ibrutinib [bib_ref]  A review of rash and other dermatologic complications associated with BCR-ABL tyrosine..., Mckillop [/bib_ref]  , SJS is associated with drug reactions that are typically accompanied by",
        "label": 1
    },
    "902": {
        "output": "### Tutorial\n\nTutorial for eligibility assessment can be found on the [official page](https://academic.oup.com/bib/article-abstract/48/2-3/298/614063) of the article by S. S. Hsu and J. L. Boushel published in 2018 issue of the _Bibliometrics_.\n\nYou can also use the [R-script](https://github.com/fedich/ClinicalTrials/blob/master/demo.R) to complete the exercise. For running the script, put its file in the working directory, open terminal, and type the following:\n\n```\nRscript demo.R\n```\n\n# Changelog\n## v2.0.0 (publ in 22.05.2021)\n\n- new clinical trial data set\n\n## v1.1.0 (publ in 25.09.2019)\n\n- fixed case of incorrect evaluation of all cases with the correct type answer\n\n## v1.0.0 (publ in 13.10.2018)\n\n- minor bugfixes\n\n## v0.3.0 (publ in 11.05.2018)\n\n- fixed evaluation of all cases with the correct type answer (i.e all cases had been marked as correct)\n\n# Discussion\n\nIf you have any comments or questions to this page, go to the topic discussion here [Discussion][2].\n\nIf you want to report a bug of this solution by the author, please [open new issue][3] on GitHub.\n\n\n   [1]: https://academic.oup.com/bib/article-abstract/48/2-3/298/614063\n   [2]: https://github.com/fedich/ClinicalTrials\n   [3]: https://github.com/fedich/ClinicalTrials/issues\n<EOD> .\nDuring the period from 1983 to 1998, a review of 1410 patients who received treatment at the Department of Thoracic S",
        "label": 0
    },
    "903": {
        "output": "### Notes\n*The task of the patient note in this problem is the assessment of eligibility that includes three factors: LDL, HDL, smoking. The patient note includes the information about the LDL value, HDL value, smoking, age, gender, and the clinical trial includes the information about including criteria for age, gender, and smoking. \n*The clinical trial assessment of eligibility is always 2, because there is no patients or no data to exclude or not relevant.\nTo see the details of the patient note on screen, go to the top page of the notebook, press `Control` \u229b `Z` and then, go to the top page of your notebook again. \n\n## Clinical trial patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (.70, 72, and 21%),  as well as moderate stenosis in the right internal carotid artery (.40, 70, and 25%\n). For the left internal carotid artery,.5 and 9). For the right internal carotid artery(.75, 80, and 22.5%).\nPlaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) (.",
        "label": 0
    },
    "904": {
        "output": "[/DOC]\n\n## Part B: Exercise\n\nIn the following two exercises, you will assess each patient and clinical trial information by yourself and give appropriate answers. For questions with multiple choices, highlight only correct answers.\nFor the exercise part, you should choose the correct answer with the highest percentage on the given question.  \n\n``` python\nprint(\"[Part B]: Exercises\") \nprint(\"============\") \n\n\n##[*] Part_B_Assess_Inclusion_and_Exclusion_criteria_in_Dulaglutide_in_Diabetic_Patients\ninput_file_name = input(\"Enter your file name: \")\nopen(input_file_name, \"r\").read()\n\npatient_note = input(\"Assess the patient's inclusion and exclusion criteria in Dulaglutide in Diabetic Patients: \")\npatient_note = patient_note.split(\", \")\n\nclinical_trial_info = input(\"Assess the clinical trial's inclusion and exclusion criteria in Patient's disease: \")\nclinical_trial_info = clinical_trial_info.split(\", \")\n \ndef Part_B_Assess_Inclusion_and_Exclusion_criteria_in_Dulaglutide_in_Diabetic_Patients( \n        input_file_name, patient_note, and clinical_trial_info \n        ) :\n    def print_help( ) :\n        print(f\"Assess the patient's inclusion and exclusion criteria in Dulaglutide in Diabetic Patients:\")\n        print('\"Assess trial's inclusion and exclusion criteria in Patient's disease:\")\n    def main( ) :\n        with open(input_file_name, \"r\").as_file():\n            patient_note = open(input_file_name, \"r\").read().split(\", \")\n            clinical_trial_info = open(input_file_name, \"r\").read().split(\", \")\n            if len(patient_note) == 2:\n                if len(patient_note[0]) == 2: \n                    print_",
        "label": 0
    },
    "905": {
        "output": "[EXERCISE]\n-  2) `Trial-level eligibility: 2) Eligible.` for the patient.\n-  2) `Trial-level eligibility: 2) Eligible.`\n<nextstep>E3</nextstep>\n[INFO]\n-   `patient_note.jn-s1_exam_data: 46,``patient_note.jn-s1_exam_data: 44,``patient_note.jn-s1_exam_data:`\n    -  patient_note.jn-s1_exam_data: 46,`\n      3.049, 3.1886815596211, 131560, 45, 447, 0.52123153850712, 365, , \n    -  patient_note.jn-s1_exam_data: 44,`\n      4.1664768112053, 4.32348099777166, 5782.6, 44, 339, 0.72796399112799, 364, \n    -  patient_note.jn-s1_exam_data: 44,`\n      4.1664768112053, 4.32348099777166, 5782.6, 44, 339, 0.72796399112799, 364, \n    -  patient_note.jn-s1_exam_data: 44,`\n      4.1664768112053, 4.32348099777166, 5782.6, 44, 339, 0.727963991",
        "label": 0
    },
    "906": {
        "output": "## Instructions for clinical trial recruitment.\nNow let's make a model to answer the following questions.\n\n## How do you think this person will be assessed for eligibility for this clinical trial?\n\nPlease explain why you said this was the clinical trial assessment score. How would you evaluate clinical suitability?\n\n## [discussion]\nWhen making a clinical trial assessment score, in the example of the patient given above, what clinical information (such as stenosis severity, plaque characteristics etc.) will you take into account? Please explain why you said this was the clinical trial assessment score. How would you evaluate clinical suitability?\n\n\n## [instructions to revise]\nYou should revise your answers for the questions above according to the following points.\n\u2022\n- After obtaining enough information about the clinical trial, do you still believe that the patient, given his or her particular clinical profile, meets or does not meet inclusion criteria in terms of the disease? \n\u2022\n- Evaluate whether it is possible to include the person in the trial and if not, why? \n\u2022\n- Based on your analysis, how would you score the patient using the following options: 0: Excluded, 1: Not eligible, 2: Eligible.\n\n## [discussion]\nAccording to your analysis, which clinical information should be analyzed first? What factor plays the most important role in inclusion or exclusion criteria?\n\n## [instructions to revise]\nYou should rewrite your answers for the questions above according to the following points. \n- You should show your reasoning for the inclusion/exclusion of patients in the clinical trial.\n- You should explain why you think this clinical trial is likely to include/exclude this person based on your analysis.\n- You should mention each inclusion/exclusion factor (with score) that may affect the decision of patient inclusion/exclusion from the clinical trial.\n- You should explain why you think the patient will be included (score 2: Eligible) or excluded (score 0: Excluded) from a clinical trial.\n\n##\n\n## [discussion]\nIn the example clinical trial, what information is missing from the patient's medical history? Based on your analysis, what information",
        "label": 1
    },
    "907": {
        "output": "* If you are satisfied with your evaluation, you can press `Submit` button. Your answer will be recorded in the output of your evaluation.\n<EOD> Chrysin inhibits UVB-induced acute inflammation by regulating the NER and MAPK/Erk pathway.\nChrysin is a natural flavonoid with various pharmacological properties, including antiaging, anticarcinogenic, antiangiogenic, and neuroprotective properties. However, the protective effect of chrysin on UVB-induced acute inflammation and the underlying mechanism have not been studied. Thus, UVB irradiated animal models were established to investigate the preventive effects of chrysin on UVB-induced acute inflammatory skin damage. The study showed that oral administration of chrysin can inhibit UVB-induced inflammation. The expression of inflammatory factors in skin tissue, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), IL-6, and IL-4, and the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and p38, and ERK5 after UVB exposure were significantly decreased by chrysin treatment. Additionally, chrysin also increased the expression of nucleotide excision repair (NER) proteins, including excision repair cross-complementing protein 1 (ERCC1), ERCC4, and ERCC5. In keratinocytes and fibroblasts isolated from hairless mice, chrysin inhibited activation of ERK and ERK1/2, p38, and p38, and ERK5 were decreased by pre-treatment with chrysin in HaCaT and NIH/3T3 cells. Activation of ERK and p38 were inhibited by overexpression of ERCC1 in NIH/3T3 cells, while the phosphorylation of ERK1/5 also decreased significantly. These in vivo and in vitro experiments suggested that chrysin may play a certain role in UVB-induced acute skin inflammation by regulating the ERK1/2,",
        "label": 1
    },
    "908": {
        "output": "<EOD> The effect of endotoxin on interferon therapy for chronic hepatitis C. A randomized controlled study of interferon in treatment-naive patients with chronic hepatitis C genotype 1.\nOBJECTIVE\nTo investigate the effect of endotoxin (LPS) on interferon (IFN) therapy.\n\n\nPATIENTS AND METHODS\nIn this prospective, randomized, controlled study, 81 patients chronically infected with hepatitis C virus type 1 (HCV) were treated in a standard 24-week protocol using IFN combination therapy (IFN-alpha2b and pegylated-IFN-alpha2b). The patients, who had previously not received IFN therapy, were randomly divided into groups A and B. Group A patients were treated with IFN for the initial 4 weeks and group B patients were treated with IFN for the initial 2 weeks. Then, the two groups were matched to have similar LSP levels before the randomized intervention commenced. To standardize the LSP levels of the patients, all of the included patients were treated with a LPS binding protein (LBP, 1.5 g/daily) for the first 4 weeks. Sustained responders were reevaluated using a liver biopsy at 3 post-therapy years.\n\n\nRESULTS\nGroup A had a higher percentage of sustained responders than group B (62.5% versus 31.6%; odds ratio = 3.69; 95% confidence interval: 1.29-10.52). Group A patients had a better histological response, as demonstrated by lower necrotic activity index scores (0.60 versus 1.30). A negative correlation was defined between LSP levels at endpoint, and the degree of necroinflammation (r =-0.57, P = 0.0001); LSP levels at endpoint correlated negatively with the degree of fibrosis (r =-0.58, P = 0.01). The LSP changes at 4 or 6 weeks were not significantly different between the two groups. After reevaluation, group A patients were more likely to have more obvious",
        "label": 0
    },
    "909": {
        "output": "# 2.2.3 Sample Size\nThe sample size is calculated before recruiting study participants to ensure that the study has adequate power to detect treatment effects. This is based on the following information. \nA total of 126 participants are expected to finish the study.\n\n\n# 2.2.4 Outcome Measurements\nOutcome measurements should be clearly defined at the beginning of a clinical trial. You should note that a measurement is a value of a certain characteristic of the disease under study. There are many types of outcome measurements, such as clinical parameters, adverse events, and quality of life (QOL).\n### Outcome measurements of clinical parameters \nThe clinical parameters are indicators of the disease state that describe the characteristics of the disease, including the symptoms, results of laboratory",
        "label": 0
    },
    "910": {
        "output": "[INST] ENDIF \n\n\n\n\nA: It's probably not what you're looking for but what you want is the most common answer.\nTo achieve this, I would set the output variable to be the most common value (eg. 2, so that if the answer is 1 then ignore, else 2 is your answer).\n<EOD> .\nMalignant melanoma of the female genital organs is described. As a rule, the tumour first originates in the vulva (88 patients, 86.6% of cases) or the vagina (11 patients, 10.8%). The treatment of choice is radical surgery. Taking into account that only approximately 5% of patients have the opportunity for radical surgery, systemic chemotherapy is also used. Chemotherapy of the tumour may have a promising effect since the drug used in large amounts is able to damage the tumour cell DNA and cause an apoptotic process in it via the p53 gene (a tumour-suppressor gene). One of the promising chemotherapeutic drugs is dacarbazine with its inhibition of the TYR gene, which is overexpressed in melanoma. Dacarbazine is also used alone or in combination with other cytostatics.<EOD> Diagnostic Usefulness of MRI in Fibrous Dysplasia\n\nThis study investigates the usefulness of plain MRI in fibrous dysplasia of rib in detecting the location, the character and the extent of this lesion. Twenty four cases of fibrous dysplasia of rib treated at our institution between March 2004 and May 2014 were retrospectively analyzed. Plain radiographs, CT and MRI were reevaluated to measure the size and location of the lesion. The lesion's location and extent were described as being near the costochondral junction (group 1), the costophrenic angle and the end of rib (group 2), and the diaphysis of the rib (group 3). All patients in group 3 showed no osseous involvement on plain radiograph or CT, whereas 9 patients in group 1 or group 2 showed a demineralized lesion of fibrous",
        "label": 1
    },
    "911": {
        "output": "### Exercise 8: Data cleaning on a real-world dataset\n\nIn this exercise, we will apply some basic data cleaning tasks to this dataset,  in particular:\n\n- 1. Filter out the records if the value of the variable called `type` is in the list `[0 1]`: i.e., if the `type` is either 0 (not diabetic) and 1 (diabetic).\n\n- 2. Drop the first record of all the columns that are empty.\n\n- 3. Remove rows with a missing `type` or `sex` variable.\n\n- 4. Sum the values for `hours_sport_per_week` using `sum()` function, and transform it with `as.numeric()` function, to take only the values and not the names of categories, e.g., like  is not true.\n\n- 5. Transform into binary the variables `hours_sport_per_week` and `body_mass_index`.\n\nNow, we load the dataset from the file `realworld-small-dataset.csv`:\n\n~~~ [INST] {\nimport pandas as pd\ndf = pd.read_csv('realworld-small-dataset.csv',names=['type','sex','alcohol',\n'smoking', 'hour_of_sport', 'week_of_sport', 'sport', 'body_mass',\n'body_mass_index'])\ndf\n~~~\n\nWhat if the type of diabetes is not given? \n\nSometimes it can be interesting to have a look at a variable without giving it at first, since that may tell you something interesting about that column. In this question, instead of the column `type`, we are looking at the column named `gender`. So, let's write again this part of code in this way:\n\n~~~ [INST] {\nimport pandas as pd\ndf = pd.read_csv('realworld-small-dataset.csv',names=['gender','sport','body_mass'])\ndf\n~~~\n\nAnd now, try to guess what that looks like.\n\nThe column `gender` presents the value  `type=1`, which means that  the person is female. Let's see why",
        "label": 0
    },
    "912": {
        "output": "<a href=''><img src='https://avatars1.climateaudit.com/u/867823?s=48&u=3fbf79c27ee1d6ff509c042c010baecd40a27758' width='280' height='300' /></a>\n\n\nI hope my solution helps you.\n\n---\n#### Solution Summary\n\nThe answer can be found in the patient note. \n\n 1. The patient has a heart disease, i.e., family history of CAD.\n 2. His cholesterol level is high, 545 (LDL-C \u2265 190 mg/dL).\n 3. His triglycerides are normal or a little higher, 158 (> 150mg/dL).\n 4. His LDL-C is almost 5 times the limit of 130 mg/dL.\n\nBased on the cholesterol level and the family history, you can conclude that the patient is eligible for the clinical trial. \n\n---\n#### Solution References\n\n<a href=''>https://www.ncbi.nlm.nih.gov/pubmed/?cmd%3Dsearch%26term_key%3D[family_history%20of%20coronary%20%20artery]%2B%26cmd%3Ddopts'>Family History of Coronary Artery Disease</a>\n\n<a href=''>https://www.ncbi.nlm.nih.gov/pubmed/?cmd%3Dsearch%26term_key=cholesterol%20level%20and%20[triglycerides%20or%20triglyceride]'>Cholesterol level and Cholesterol-lowering agents</a>\n\n<a href=''>https://www.healthline.com/health/cholesterol#causes-risk-factors>Cholesterol level and Risk factors for Elevated Cholesterol</a></body>",
        "label": 1
    },
    "913": {
        "output": "# Conclusion\n\nAn efficient and accurate recruitment of eligible patients to a trial is a crucial step for the success of a clinical trial or study. Many criteria must be satisfied to obtain an eligibility for the trial:\n\n## Inclusion criteria:\nThe age from 18 to 67\nThe male gender\nThe history of previous elbow joint fracture, and\nNot meeting the criteria of exclusion.\n\n## Exclusion criteria:\nNot satisfying the three above: the history of previous elbow joint fracture.\n\n## The patients who",
        "label": 0
    },
    "914": {
        "output": "## [/PART TA B LE]\n\n<h3 id=\"LimitedPart2\">Limited Problem 2: Eligibility of Cardio-Vascular Trials: 2-Day 2</h3>\n\n### Recap of Recent Cardiovascular Research\n\nIn this problem, we learned that cardiovascular disease (CVD) is a group of heart and blood vessel conditions.\n\n[1] Incorrect \u2461: You should not have excluded any patient.\n\n[2] Incorrect \u2464\u2463\u2464: \nA 56-year-old man, who has no evidence of carotid artery stenosis, presents with dizziness and frequent head",
        "label": 1
    },
    "915": {
        "output": "<EOD> Molecular detection of Bartonella spp., Coxiella burnetii, and Anaplasma spp. among flea species collected from dogs in Sinaloa, Mexico.\nCanine vector-borne diseases are emerging public health hazards around the globe. Their most important determinants are the animal parasites, which are infected by the vector-borne pathogens. Dermacentor spp. were the most highly infected (flea infestation 45%) and, therefore most likely, may be considered a threat to people and other animal species. In this study, the Bartonella spp. and Anaplasma spp. infections were detected in low numbers. On the contrary, Coxiella burnetii was detected in 124 flea pools and has the highest prevalence (73.5%).<EOD> A method to estimate the effect of alcohol on liver enzyme activity.\nOBJECTIVES\nTo assess whether using serial alcohol measurements in the calculation of the relative liver enzyme activity can improve our diagnostic accuracy for severe forms of alcoholic liver disease (ALD), we investigated the reliability of 2 different calculation methods for the estimation of the effect of alcohol on liver enzyme activities.\n\n\nMETHODS\nOne hundred subjects of both sexes, referred to a gastrointestinal endoscopy outpatient clinic, were asked to perform 10 consecutive 15-minutes sessions of an alcohol intake test. Serum levels of aspartate aminotransferase (SGOT) and alkaline phosphatase (GGT), with and without alcohol intake, were estimated. Liver enzyme activity and the effect of alcohol on enzyme activity (EA) were estimated with 2 widely accepted approaches: the \"simple method\" (SM-EA), in which the enzyme activity is estimated under the assumption that after alcohol intake the liver enzyme levels are the same and there is no time lag with respect to the intake, and the \"long-term calculation\" (LTC-EA), which includes serial measurements of alcohol concentration and assumes a certain time lag after alcohol intake, which was defined to be the time needed to reach 50%",
        "label": 1
    },
    "916": {
        "output": "[INST]\nYou are a physician and you are in charge of a research-focused department. You are trying to conduct a new investigation to treat chronic heart failure (CHF). CHF is a complex condition in which the heart can't pump blood, and the heart fails at low level of stress and requires increased heart load to achieve a normal output and blood pressure.\nYour proposed trial has three arms: two treatment arms (oral standard therapy) and one placebo treatment arm. Your primary endpoint will be the left ventricular ejection fraction (RV-EF) [bib_ref]  Left ventricular ejection fraction: is it as good as we think?, Pond\u00e9 [/bib_ref]  , which is a clinical parameter defining the functional capacity of the left ventricle of heart in a patient with heart failure, and secondary endpoints will be the 6-minute walk test (6MWT) [bib_ref]  Six minute walk test in heart failure: Is it a better prognostic..., Cao [/bib_ref]  and Minnesota Living with Heart Failure Questionnaire (MLHFQ) [bib_ref]  The reliability of the Minnesota Living with Heart Failure questionnaire improved in..., Rector [/bib_ref]  , which define the quality of life. Before the real trial starts, an observational pilot study was conducted to compare the standard treatment and placebo group in three months follow-up. The trial was designed to include 20 participants in each arm: 20 in the placebo group, 20 in the standard treatment group, and 20 in the standard treatment group.\nThe primary endpoint, the average of repeated values, is collected at baseline (t0), after 1 month (t1), and after 3 months (t2) and will be given in percentage.\n\nHere are the clinical and demographic data of the sample in the placebo group. \n\nYou may calculate the sample sizes for your placebo and standard treatment group using the following steps [bib_ref]  Sample-size determination, Dell [/bib_ref]  : \n- Calculate the pooled variance of the sample.\n- Divide it by the pooled SD and multiply by the pooled SD. Then multiply the result by the desired power of\n\n# Exercises\nWrite your code and paste it in the comments.\n\n## Exercise 1\nInput variable `v",
        "label": 1
    },
    "917": {
        "output": "For example, you get a patient report and a clinical trial criteria table as follows:\nThis is the patient report:\n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.[1]\nHere is the criteria table of a clinical trial:\nInclusion criteria:\n   \n1. Patient is a resident of USA\n   \n2. Patient has a documented history of hypercholesterolemia (elevated LDL of 190 to 400; average LDL > 190 mg/dL, and",
        "label": 1
    },
    "918": {
        "output": "4.2 Inflammation \n[INST] Hello. You have a very important task. Your job title is \"Biostatistics Expert\" and you work in a pharmaceutical company. As a Biostastical Expert, in some of your latest studies, you are asked to analyze the levels of inflammation biomarkers and other biomarkers in blood samples from patients who have diabetes. After measuring, a group of statisticians determines what kind of value it is. You will now look at the levels of these biomarkers and determine their levels by evaluating the charts. The chart below shows the levels of four biomarkers over time for one of your study's patients.\n\nC-reactive protein (CRP): a protein produced by the liver. Its levels gradually rise after inflammation takes place.\nMonocyte chemoattractant protein-1 (MCP-1): a protein found in a person's urine and blood to move white blood cells (WBC) to the site of inflammation.\nVascular cell adhesion molecule-1 (VCAM-1): an adhesion molecule on the surfaces of cells that allows WBC and leukocytes (circulating cell of the immune system) to attach. VCAM-1 is secreted by activated vascular endothelial cells and is a highly specific biomarker for the inflammation of the vascular endothelium.\nErythrocyte sedimentation rate (ESR): is a method to test for inflammation. It is an indirect measure of how fast red blood cells (erythrocytes) fall to the bottom of a tube filled with blood. The result is given in millimeters per hour. The ESR becomes high when body inflammation increases.\nThe following questions need to be answered:\n\n### Q-1. Which of the tests/biomarkers will be significantly increased with the onset of infection? Answer: MCP-1\nThe levels of biomarkers vary from patient to patient. There is no value for all patients. Based on the increase in the biomarker levels (indifference), in general, the biomarker that you think will be increased is MCP-1.",
        "label": 1
    },
    "919": {
        "output": "<EOD> The effects of a physical therapy rehabilitation program with postural training on postural control in school children with cerebral palsy: A randomized controlled trial\n\nBackground: Postural control in children with cerebral palsy (CP) is compromised, increasing the risk of injury. However, there is a paucity of effective interventions for improving postural control in children with CP. Objective: To investigate the effects of a physical therapy rehabilitation program with postural training on postural control in children with CP. Methods: Thirty children aged 2-10 years with spastic diplegia were randomly divided into a physiotherapy treatment and a control group. Both groups received treatment according to routine clinical practice. The therapy group also received the intervention. The outcome measures of this study included the Modified Tardieu Scale (MTS), Gross Motor Function Measure (Gross Motor Function Classification System-GMFCS), the revised version of the Movement Assessment Battery for Children (MAB-II), the Pediatric Reintegration to Daily Existence (PRTEE), the Pediatric Evaluation of Disability Inventory (PEDI), the Bruininks-Oseretsky Test of Motor Proficiency, second edition (BOT-2), the Physical Self-Description Questionnaire (PSDQ) in the physical domain, the Postural Assessment Scale for Stability (PASS), and the Movement Assessment Battery for Children-Postural Assessment (MABC-S). The children were assessed at baseline and after 12 weeks of treatment. Results: The physiotherapy treatment group showed significant improvements in the MTS, MABC-S, GMFCS, PSDQ in the physical domain, MAB-II, BOT-2 gross motor skills: body balance, equilibrium, coordination, flexibility, dynamic motor skills (jumping, hopping, and running), and in the PASS and PEDI physical abilities subscale. Conclusion: The study suggests that treatment with a focus on posture is efficacious for improving the postural control of children with CP. CLINIKA, 2012; 18(2): 175Y187\n\n# Introduction",
        "label": 0
    },
    "920": {
        "output": "This program, `Evaluate.jl` can be downloaded from Github, but I only provide the first step. \n[https://github.com/HungLeDo/AnalogyPhenomenon.jl]\nThe program, you can download from [https://github.com/HungLeDo/AnalogyPhenomenon.jl](https://cran.r-project.org/web/packages/AnalogyPhenomenon.jl/index.html). [INST] [INST]\n\nPlease note that this paper is published in 2016, but the problem in 2019 should be still current. \n[https://doi.org/10.6084/m9.figshare.4480775.v1](https://doi.org/10.6084/m9.figshare.4480775.v1)\n\n\n[INST](https://github.com/HungLeDo/AnalogyPhenomenon.jl): Julia package with Analogy programming\n\n\n[INST](https://github.com/HungLeDo/AnalogyPhenomenon.jl): Julia package with Analogy programming \n\n#### 1. Install the packages\n\nAdd the following code in a `.julia` file in the root folder of your `julia` installation. \n```julia\nusing Pkg;\npkg\"activate\"(\"AnalogyPhenomenon\")\n``` \n\n#### 2. AnalogyPhenomenon package documentation\n\nLet's take a look at the following code. \n```julia\nusing AnalogyPhenomenon\n``` \n\n```julia\nAnalogyPhenomenon.test_analogy_phenomenon()\n``` \n\nWe can see that this is the end of our Julia program. \n\n\n\nThe following code can generate an optimal solution as a list of variables. \n```julia\nAnalogyPhenomenon.eligibility_list(trial, patient_note, Clinical_Trial, Evaluation)\n``` \n\nIf you want to get all, let's take a look at the following code. \n```julia\nAnalogyP",
        "label": 0
    },
    "921": {
        "output": "Happy recruiting! [CIT]\n\n\nA: In python, Pandas is the de facto standard library for data manipulation and analysis in python. It has an extensive documentation and a large user base. It contains numerous data structures and operations suited for work in a broad variety of domains and data sources. It is the primary data structure in Python due to its unique features, such as reading data from text file, sorting, manipulating strings in a fast and efficient manner, reading excel sheets, etc.\nIt also has a very friendly and easy to understand interface and is also very user friendly in terms of operations and workflows. Pandas is also able to handle very large data sets and is a very efficient library with great performance when it comes to handling data in large scale. In particular, it is preferred over other methods by many large companies and institutions. Pandas is often used by data analysts, statisticians, researchers, and people who work with a lot of data.\nHere is a good documentation of Pandas: [https://pandas.pydata.org/pandas-docs/stable/](https://pandas.pydata.org/pandas-docs/stable/), which is quite extensive and has step by step examples to help with the learning process.\nA: \nMy recommendation would be to try Pandas. It is a very comprehensive Library for data. As you can see it can do a lot. As you can see it doesn't do everything. Maybe if you want to get into NLP or sentiment analysis you will need to look for other libraries. But there is a lot of info here:\n\nI have never had a problem with Pandas. I used it a lot as well. It is one of those things that once you start using it, you will use it over and over.\nIn your example the one extra thing you don't do is check that the 2 variables are the same size. In the example that is the difference between a and b. You did not need to use the .isiterable if you know both arrays are the same size. \nLet me know if you have any issues. \nA: For your case\n\nA: I would strongly recommend to use the pandas library because the pandas library can automatically calculate the results for you and plot the graph for you.\nThis is what the pandas library can do:\n\nA: Since you are starting with python so I will take",
        "label": 1
    },
    "922": {
        "output": "Good job! You are doing great!\n\nAs a side note, don't forget to consider the case of tied decision-reaching. Note that tied-decision is very rare, especially in this competition, because usually there is only one right answer. In this case, you have to assign the final mark for your test to the highest grade.\n\n\n\n\n### Solution\n\nYou could solve this problem in a dynamic way by recursively checking if we need to assign additional values in the current stage.\n\n```python\ndef is_eligible(patient_note: str, trials: list) -> int:\n    if len(trials) == 1:\n        if patient_note == f\"S/I\": # This is for patients who will be included\n            return 2\n        else: # This is patients who are excluded\n            return 0\n\n    result = 0\n    for trial in trials:\n        # We only need to check current eligibility status\n        if not is_eligible(patient_note, trial):\n            # We need to increase the score for trial\n            result += 1 \n\n    return result\n```\n<EOD> Exploring the genes and variants involved in the pathogenesis of a case of atraumatic anterior shoulder dislocation. A candidate gene association and RNA-seq-based gene expression analysis\nAtraumatic anterior dislocation of the shoulder joint is an injury of very rare occurrence, accounting for a small percentage of all anterior shoulder dislocations. Due to the rarity of this injury, the pathogenic mechanism of atraumatic dislocation remains unclear. The aim of this research is to better understand the etiopathogenesis of atraumatic anterior shoulder dislocation using a candidate gene association and RNA-seq-based gene expression analysis. A 40-year old male subject of normal constitution experienced sudden, painful reduction of the right shoulder joint while making a shoulder stretch. Magnetic resonance imaging revealed anterior humeral head subluxation. An anterior shoulder exploration was performed, with the humeral head reduced and fixed with a hook plate. A histological sample was collected during the surgical procedure. The patient was included in this research project and gave written informed consent. The sample was stored at -80\u00b0 C for future molecular studies. A",
        "label": 0
    },
    "923": {
        "output": "##[OUT] You are a helpful assistant in a research study of the effects of coffee on the heart of a male rat. your job is to determine whether coffee extract has an effect on the weight of a male rat heart within a specified interval.\nYour task is to compare the ratio of heart weight to body weight of the control and test rats within a specified interval. The control group was given water and the test group was given coffee extract.\nYou input a number in `Weights:`, e.g., `Heart weight: 0.12`. This is the number of the control group. Note that the weights are automatically summed, i.e., weight sum = Heart weight + Body weight. \n`Heart weight: 0.3`. This is the number of the test group. \n\n### 1.23:\nYou are a research assistant in a study assessing the effect of cigarette smoking on blood pressure (BP).\n\n### 1.23.1:\nYour data is structured in three columns: `Time` is a variable that contains BP values over eight time intervals for the two groups. `Group` is a variable that contains a coded variable of one or zero. `Mean` is the variable denoting the mean of `BP over eight time intervals`. Now the values of `Mean` in the two groups `Time 1-8` are shown below (note that `Time 1-8` is also the name of columns, not variables). \n\n### 1.24:\nIn a study, we assess the diabetic neuropathy in type 2 diabetic patients.\n\n### 1.25:\nThe assessment of diabetic neuropathy is in three steps: 1) The measurement of the lower leg and ankle reflexes; 2) the assessment of foot sensation by touch, vibration, temperature and pain; 3) measurements of nerve conductions (e.g., motor and sensory nerves). According to these data, we determine whether each patient is in the stage of normal status, peri-neuropathy or the status of diabetic neuropathy. A complete assessment of these parameters determines the clinical status of the patient.\nHere is a patient record: \nNow",
        "label": 1
    },
    "924": {
        "output": "A: There is a missing \"(\" at the top left. This is probably the result of a copy-paste from your PDF. \nIn\n\n  ` 130 to 150 (mmHg) `\n\nYou can replace the brackets around 130 to 150 (mmHg) by a bracket around 150 as you did in \n\n  ` 80 to 160 (cm/s) `\n\nin the next line.\n\nA: Try to use it as:\n\n\n\n<table width=\"100%\" border=\"1\" class=\"codeblock\">\r\n<caption>Code snippet</caption>\r\n  <tr>\r\n    <th valign=\"top\"><pre class=\"codeblock\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t130 to 150 (mmHg) &#x203F; 130 &#x203F; 150, 150 to 160 (mmHg) &#x203F; </pre>\r\n\t</th>\r\n\t<th valign=\"top\"><pre class=\"codeblock\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t(cm/s) <span class=\"mod\">&#x203F; 80 to 160 (cm/s) &#x203F;</span> </pre>\r\n\t</th>\r\n </tr>\n</table>\n\nI haven't tested it, but the syntax is not fully correct. You should probably correct it beforehand, if you want the <strong>span </strong>tag to work.\n\nA: Please, see my answer to this question\nI also suggest you to use proper HTML tags instead of inline code. This will reduce the space of your posts. The code should look like the following:\n<h4>\n\u00a0\nTitle:\nOptimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) \n\u00a0\nSummary:\nHigh blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly",
        "label": 0
    },
    "925": {
        "output": "### Exercises\nFor more exercises about eligibility assessment and others exercises of your first task, you can go back to the last page.\n- 61: Eligibility assessment\n\nHungry for more?\n\nWe invite you to continue the learning experience:  \n- 61: Eligibility assessment\n- 65: 10-year risk of vascular death\n\n## 61: Eligibility assessment\n\n### Scoring\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n#### 1) Check the score\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n### Scoring\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n#### 2) Check the score\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n### Scoring\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n#### 3) Check the score\n\nWhen the computer's score is green,",
        "label": 2
    },
    "926": {
        "output": "[INST] Example: \n```\n# + language: python\n# + title: Step 1. Read in input data\n# +\ndata <- read_txt(\"../data/sample_data.txt\")\ndf_patients_criteria <- data\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$id %in% data$ID]\ndf_patients_criteria <- df_patients_criteria [ df_patients_criteria[,df_patients_criteria$age]<=65, ]\n\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender~=\"m\", ]\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender~=\"f\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender  == \"m and age > 65\", ]\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender  == \"f and age > 65\", ]\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$type_of_study~=\"clinical intervention study\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$type_of_study~=\"clinical interventional study\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$type_of_study~=\"randomized controlled trial\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$id~=\"3\", ]\n\ndf_patients_criteria <-",
        "label": 1
    },
    "927": {
        "output": "> Example\n```python\ndf['Cardio. (last visit)'].max()\n```\n\n#### [/BOLD] Expected Output\n\n```\n1\n```\n\n#### [/BOLD] Explanation\n\nThe patient's last visit date is 24/05/2012, and there are 10 visits in total. \n<EOD> The impact of the COVID-19 quarantine on sleep quality in patients with narcolepsy type 1\n\nThe novel coronavirus disease-19 pandemic forced billions of people into lockdown. Since patients with narcolepsy type 1 (NT1) already have poor sleep, it poses a challenge to study the effects of quarantine time on sleep behavior in these patients. Thus, the purpose of the study was to survey the effects of lockdown and social isolation during the coronavirus (COVID-19) pandemic on sleep quality in patients with narcolepsy type 1 (NT1). In an online survey-based research we used the Pittsburg Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) to collect data, and also asked patients to indicate perceived changes to their sleep",
        "label": 0
    },
    "928": {
        "output": "You might be asked about other questions, such as:\n\n\n*   Are there any exclusion criteria in this clinical trial for the eligibility assessment of a healthy person?\n\n### HINT\nThe exclusion criteria of the clinical trial are the clinical study requirements for the exclusion of the assessed person.\n\n## AORTA SCANNING\nPatients with stenosis of aorta need to be referred for further procedures in the form of treatment, surgery or invasive cardiac procedures. Hence, these patients need to be referred for surgical evaluation and, if possible, surgery (repair with valve replacement, if aortic diameter > 50\u2009mm or > 40\u2009mm for patients with severe echocardiographic AS).\n\nIn severe cases, surgery is recommended at 50, and for patients with symptomatic valve disease at 40.\n\n## ECHOCARDIOGRAPHY\nEchocardiography is a noninvasive imaging procedure to evaluate the heart's structure and function. The device emits soundwaves and produces images of the heart and arteries. Echocardiography may be performed at the bedside, in an office, or in a hospital setting.\n\n## ANCA\nAntineutrophil cytoplasmic antibody (ANCA) is an antibody directed against components of the neutrophil with specificity for cytoplasmic azurophilic granules. This is an antibody of the immunoglobulin G subclass and, in contrast to antiglomerular basement antibodies, is not bound to the kidney.\n\n## ASSOCIATED CONDITIONS\nInfectious endocarditis is an infection of the endothelium of the heart. It may be caused by a primary seeding with a bacterial, fungal, viral, or protozoal microorganism. It is classified as infec1tions caused by gram-positive bacteria (more common), gram-negative bacteria (uncommon; often caused by enteric fever), and acid-fast microorganisms. In all these in1ictions, endocardial vegetations occur, which may lead to the development of infect",
        "label": 0
    },
    "929": {
        "output": "<EOD> A clinical trial of interferon alfa-2b alone or in combination with zidovudine after surgery for recurrent/metastatic cervical carcinoma.\nOBJECTIVES\nTo compare the efficacy and the toxicity of the single agent interferon (IFN) alfa-2b versus combination IFN and zidovudine (AZT) in patients (pts) with recurrent/metastatic squamous cell carcinoma of the cervix after prior cisplatin-based chemotherapy and radiation therapy.\n\n\nMETHODS\nFrom January 1, 1989 to December 31, 1990, 14 pts were entered onto the trial of IFN alfa-2b at 5 MU (i.v.), 3 days/week. The median age was 44 years (range 29-57) and median PPA and PYT were 20.7 and 19.3 cm3, respectively. Six pts received IFN alone and eight pts received IFN plus AZT (200 mg po tid). Responses were evaluated every 3 months after therapy. A response of > or = 50% reduction in pelvic and/or extrapelvic tumor from nadir with no evidence of new tumor lesions was considered a partial response (PR) and progression (PD) was seen when tumor increase by 25% or greater in comparison to nadir.\n\n\nRESULTS\nOf the 14 pts entered on the trial with squamous cell carcinoma of the cervix from January 1989 to December 1990, 2 pts had disease progression after the 1st cycle of IFN and were subsequently taken off the study. The remaining 12 pts completed 8 weeks of IFN therapy with none experiencing clinical PR or CPR. There were, therefore, 9 inevaluable pts among the 14 pts entered.\n\n\nCONCLUSION\nThis study indicates no significant difference in efficacy when either IFN alfa-2b or AZT alone is compared with the combination IFN/AZT in heavily pretreated pts with",
        "label": 0
    },
    "930": {
        "output": "Please check if you have written down the correct answers to the problems. It is good to check your answers with the testers before proceeding to the next section.\n<EOD> .\nTo be recognized of the medical community is very important for an occupational health services, as a step towards integration into the public and hospital health system. The authors analyze the historical development of this specialized service, in particular in regard to its integration into the Hospital Care Network of the \"Azienda Ospedaliera Universitaria Policlinico S. Orsola-Malpighi (Bologna)\" by emphasizing the advantages of the organization and the advantages to the users and to the doctor-patient relationship. Then, the attention is addressed to the future as in the present times one can find only isolated cases where the occupational health service have integrated into hospitals, while other integration experiences are at their start-up.<EOD> Improved Delivery of Antisense Antibiotic Propolionicin\nPropolionicin, a novel antisense compound that inhibits the growth of Gram\u2010negative bacterial pathogens, was evaluated for safety, toxicity, immunogenicity, and pharmacokinetics following i.v. administration of a series of prodrug variants in several murine infection models. These prodrug species included derivatives of the natural antibiotic, propionicin, which is produced by Actinoplanes propionicis, and the semisynthetic analogs 2\u2010methyl\u2010propionicin and 7\u2010oxosemiporpropionicin. These prodrugs were designed to improve the delivery and/or reduce the toxicity of the active drug. Prodrug variants were synthesized as fatty acid ester prodrugs of propionicin or semiporpropionicin and evaluated for in vitro cytotoxicity, pharmacokinetics, and pharmacodynamic",
        "label": 0
    },
    "931": {
        "output": "# References\n- \u2191 1.0 1.1 1.2 1.3 \"Examples of patient notes\". Examples of patient notes. Retrieved 2014-12-22.\n- \u2191 \"Example of Clinical Trial\". Example of Clinical Trial. Retrieved 2014-12-22.\n\n<EOD> HIV-1 reverse transcriptase interacts with RNA in the absence of DNA.\nMany of the early steps of infection are still not clearly understood. We describe here a novel binding of HIV-1 reverse transcriptase (RT) to RNA. The interaction of recombinant HIV-1 RT with RNA could be demonstrated by an RNA-binding assay, by electrophoretic mobility shift assay or by binding studies of RT to oligodeoxyribo(dT). Furthermore, RT was shown to interact with RNA in the absence of ssDNA. Analysis of the interaction behaviour and the possible structural implications is difficult because RT and RNA associate in many different modes. In addition, the different RNA binding sites of RT interfere with each other.<EOD> A rare case of a giant ovarian dermoid cyst\n\na b s t r a c t INTRODUCTION: Mature cystic teratoma of ovary is one of the most common tumor among the population of reproductive age group and have the most benign pathology. Derma tois, the presence of hair follicles and sebaceous glands, epidermal components, adipose tissue are the characteristic features of a mature cystic teratoma. CASE PRESENTATION: Here we present a rare case of 50-year-old Indian woman presenting with huge left ovarian mass of size 28 \u00d7 23 \u00d7 21 cm weighting approximately 7 Kg. She underwent laparotomy where mass adhered to pelvic peritoneum so deroofing and excising the mass was difficult. On histopathology of mass we found hair follicles, sebaceous glands and epidermal components suggestive of a dermoid cyst. CONCLUSION: Mature cystic teratoma",
        "label": 1
    },
    "932": {
        "output": "<EOD> Draft Genome Sequence of a Flavivirus Isolated from a Black Fly in India That Belongs to the Putative Novel Genus Okavirus.\nA novel RNA virus was isolated from female Simulium squamosum black flies in a subtropical ecosystem in India. The virus was designated as Simulium squamosum virus, Indian isolate. Metagenomic analyses revealed that the virus belonged to the proposed novel genus, Okavirus in the family Flaviviridae. Here, we report a draft genome sequence of Simulium squamosum virus, Indian isolate.\n \n\n\n\nS\nquamosum<EOD> Effect of Sodium Channel Inhibitors Tetrodotoxin and Tetraethylammonium Chloride on Neuroendocrine Changes Induced by Hormones in Rat Supraoptic Nucleus Cells in Primary Culture\nThe aim of the study was to characterize the effect of sodium channel blockers on the hormonal control of the rat neurosecretory supraoptic nucleus cells (SONC) primary cultures. SONC primary cultures were obtained from 10-day-old rat pups. Cells were plated on poly-l-ornithine and laminin coated substrate and grown for 7 days in vitro (DIV) in minimum essential medium with fetal calf serum. Neurosecretory cells were identified immunocytochemically as vasopressin containing using the antisera raised against vasopressin. In cultures maintained up to 7 DIV, we have demonstrated spontaneous release of oxytocin (OT) and vasopressin (AVP) at a constant rate for the 4 days of culture. Pulse-chase experiments using L-leucine indicated no significant differences in rates of L-leucine incorporation, maturation and release rates of OT- and AVP-containing nerve terminal fragments between untreated and toxin-treated cells. In addition, hCG, LH, and TRH were found to increase the amount of released OT and AVP. TTX and TEA inhibited hormone-stimulated release of OT and AVP without significantly affecting the hormone-dependent stim",
        "label": 1
    },
    "933": {
        "output": "[INST] **Detailed instructions for each part of the input:\n`Input: Patient note \"The assessment of patient's eligibility for trial on trial level\" A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus, and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull, ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.*~TITLE:*~Title:*~TITLE:*~Summary:*~Summary:~SUMMARY:~The summary line should include ~~~~and a few keywords so that participants can quickly understand the main question~In the summary line ~~~~the question that the clinical",
        "label": 0
    },
    "934": {
        "output": "The task can be performed in two ways: (1)\n- As simple as possible using the first command, without any intermediate operations. For example, you may want to try and then, if you are satisfied with the results, stop in the last line, which is the same as outputting a result in the same command;\n- As complicated as possible by using a loop. Take the second command with `continue`; it will return you right after checking the first patient's data. Then you will be able to check other patient data on your own. Also use `print(\"Your result for patient {Patient} has been saved. \")` to output the patient number as a separate line. After this loop, you can output the total result once, by using the fourth command, with `if` and `else if`. If one step of the first command fails on a given patient, it will automatically return. In this case, the output result will be generated only if the first command has been successful.\nExample:\n# Simple approach\n\n[IMPORT] Importing patient files; in this example, we only use one file - Patients.csv\n\n[LOOP] Creating the loop, reading each patient one-by-one\n\n(i)  You may want to try to read from the Patients.csv file, if not already there, using with the `head` function, so you can choose your first file. The rest of the files would be loaded automatically\n\n(ii) Assign the patient's number to the variable `Patient`, starting from 1\n\n(iii) Load the file using the `import` command\n\n(iv) Read the file using the `read_csv` command\n\n(v) Read only the fields you require:\n\nIn the above command, `0`-means the row number, `1`-means the column number, and `B` means the raw file name\n\n(vi) Use the loop command, which uses the `for` loop that will iterate over the rows of the data frame and perform the loop logic within \n(vii) Check one field of the patient data, the factor number\n\n(viii)  If it matches, continue with the next row (this will be the next patient)\n\nOtherwise, the error message will be printed and the cycle will be stopped,\nand you will be informed that another patient must be",
        "label": 2
    },
    "935": {
        "output": "You must learn some code for this problem. \n\nThere are many things to know about this section. In general, the code to be used is almost the same each time. In this case, the following code is necessary to complete the task. \n\nYou must learn to understand what the code written in the template of this section is and what it is doing. If you can understand the template, you will be able to know what the code written in the template is and what it is doing.\n\nFirst, you need to learn about `Trial` class.<NAME> provided a very large number of templates that can be useful to most research applications. These templates provide basic functionality needed to solve the problems of various domains, such as the biomedical and clinical domains.~This set of templates is called a framework. \n\n<NAME> wrote a number of important templates to solve common problems encountered in trial design. For instance, these templates include the following:\n\n| Template 1  | Template 2  | Template 3  |\n|:-------------:|          :|         :|\n| Randomized Phase 1| Randomized Phase 2| Randomized Phase 3|\n| Allocation Ratio        | Drop-out rate     | Number of Phases  |\nEach of these templates allows the definition of a very large number of randomized trials with specific design features.<NAME> used an Excel-like interface for writing in trial analysis templates and also for writing their own templates. Each trial analysis template can be written to a file. Once the templates are written to files, they can be shared with others through the web or via email.<strong>In the previous section, <NAME> showed how to solve problems such as `Input file` and `Output`, and <NAME> demonstrated the code for these templates, which are used to define trial attributes. In this section, <NAME> will introduce you to the basic features of the `Trial` class, which can be used to define the trial design features.<strong>This section presents the basic features of the `Trial` class.</strong><br/> \n\n<!-- ============ FOR DEMO ============== -->\n\n```cpp\nvoid demo(QFile& file) {\n  QFile *f = new QFile(\"QMDIDemoTest.txt\");\n  QTextStream stream(f);\n  stream << \"",
        "label": 1
    },
    "936": {
        "output": "```js\ndescribe('TestCardio1', () => {\n  it('should report 2) Eligible in the last line', () => {\n    shouldReport(scenarioPath, '2) Eligible in the last line');\n  });\n});\n```\n\n## [INST] Description (0)\nYour workplace has several recruitment assistants who work on clinical trials in the laboratory. In each trial, they have to create trial reports to summarize the statuses of each clinical trial participant. Their work environment is shown in the [![inst-clin-card-report](https://res.cloudinary.com/dandi-prod/image/upload/v1604490433/github-dandi-prod-clinical-card-report/inst-clin-card-report?version_id=5b416ba3bdf3144c27348482&sig=%2BKYm8yI6HM5Dg/iAJxB1bNJOc%3D)][inst-clin-card-report](https://res.cloudinary.com/dandi-prod/image/upload/v1604490433/github-dandi-prod-clinical-card-report/inst-clin-card-report?version_id=5b416ba3bdf3144c27348482&sig=%2BKYm8yI6HM5Dg/iAJxB1bNJOc%3D))\n\nYou will provide code of assistant #1, #2 and #3 in this scenario. Each helper assistant runs `generateReport` only once. \n\nYour code should read the status of the patient and their assignment in each clinical trial, and then output the patient report for each trial.\n\n\n[![INST] Assistant's workplace](https://res.cloudinary.com/dandi-prod/image/upload/v1604490383/github-dandi-prod-clinical-card-assign-report/inst-card-assign-report?",
        "label": 0
    },
    "937": {
        "output": "What do you think of the risks given to the patient? Why?\nWhy did they assign points of `1`?",
        "label": 0
    },
    "938": {
        "output": "This should also apply to each patient.\n<EOD> The Role of Cyclooxygenase-1 in the Anti-Inflammatory Pharmacology of Diclofenac-Bioflavinoids-Loaded Lipopolymeric Nanosuspension\n\nCitation: El-Allahi, F.M.; Aburayda, M.S.; Shalaby, A.M.; Eid, O.A.; Ali, M.A.; Abu El-Soud, A.M.A.; Salem, S.M.M.; Abdelwahab, A.A. The Role of Cyclooxygenase-1 in the Anti-Inflammatory Pharmacology of Diclofenac-Bioflavinoids-Loaded Lipopolymeric Nanosuspension. Int. J.\n\n\n# Introduction\nInflammation is an initial response of the hostile immune system's components to harmful external (infective) agents and internal (e.g., cancer) infections. It aids tissues self-defense from damage and infection in a way.\nPharmaceutomedic drugs, inflammatory.\nScience. Imamines cells of immunable to immune and inflammatory and anti-drugs and immune's health infection of inflammat the body's immunhe immune's cells.\nEmergency in which canine immune cells which inflammatric\n\nThe patient's health care providers's health of inflammatory\n\nThese drug's immunits immunited. Patient and their.\nThe patient's healthy immune's immune immunhealth care.\nImmunity's drug's patient's bodycare.\ninflammatory immune person's a patient immune care inflammatics the drugs. The care. Pharmacy's healthy's immunhealth care's quality of the role of the immunities immunits ici drugs. (antihealth (h care (patient (eliz health patient care a care to inflam's immune drug's health. The immune patient'health insurance care's immune eligel patient",
        "label": 1
    },
    "939": {
        "output": "Q6: The patient is a 40 year-old woman. She has no previous heart disease and smoked cigarettes from early adolescence which was then replaced by occasional cigar. She has a positive family history for premature CHD. She has a history of hypertension. Her examination is normal. The ECG is normal. The echocardiogram reveals a ejection fraction of about 60% and is otherwise normal. Her fasting glucose, and lipids are normal. She has normal exercise tolerance. Her neck auscultation reveals the absence of murmurs. Her examination does not suggest aortic stenosis. She had a normal angiogram performed a few years ago, showing no abnormal features. Her chest radiograph is normal. The ultrasound of the carotid arteries reveals plaques with a moderate reduction in the lumen of the ICA. Her total calcium, homocysteine, and vitamin B12 levels are normal. There is no history of alcohol or recreational drug abuse. The patient meets the",
        "label": 1
    },
    "940": {
        "output": "The 46-year-old man presented with dizziness and headaches. He had a positive family history of CAD but no other cardiovascular risk factors. His dizziness was described as a continuous sensation of unsteadiness. His LDL-C level was 545 mg/dL, and his HDL-C level was 53 mg/dL. However, he had no cardiovascular",
        "label": 0
    },
    "941": {
        "output": "## ASSIGNMENT 3\nGo to file `example_2.ipynb`.\n\n`1. from IPython.external import rpy2 import sys def execute(): import rpy2 as r import pandas as pd def r2009(): import rpy2 as r import pandas as pd R = r['r2009.xls'] R.set_index('Patient Id') R.index[:] = 0 if 'Patient Id' in R.columns: R['Pre-Tx LDL-C (mg/dL)'] = str_replace_all(R['Pre-Tx LDL-C (mg/dL)'], r'\\n', '') R['Pre-Tx LDL-C (mg/dL)'].add_prefix('Pre-Tx') else: print \"Please specify column with LDL-C before PRE-CATHETERIZATION\" execute () def r2014(): import rpy2 as r import pandas as pd R = r['2014.xls'] R.set_index('Patient Id', drop=True) try: R['ESS'] = R['ESS'].astype(float) except: R['ESS'] = R['Pre-Tx ESS'].astype(float) R[0:9]['SXS'].add_prefix('Pre-Tx') R[0:9] = R[0:9].astype('str') if 'ESS' in R[0:9].columns: R[0:9]['Pre-Tx ESS'] = rpy2.list_cols(R[0:9])[1] R[0:9]['Pre-Tx SXS'] = rpy2.list_cols(R[0:9])[3] if 'SXS' in R[0:9].columns: R[0:9]['ESS'] = rpy2.list_cols(R[0:9])[1] else: R[0:9]['ESS'] = 'Pre-Tx ESS' else: R['ESS'] = R['ESS'].astype(float) if 'LDL-C' in R[0:9].columns:R[0:9]['Pre-Tx",
        "label": 1
    },
    "942": {
        "output": "<EOD> Enzyme Replacement Therapy for Gaucher Disease: Are we there yet? Yes, we are!\nGaucher disease is caused by a deficiency in lysosomal glucocerebrosidase activity. A novel class of enzyme replacement therapy with recombinant human glucocerebrosidase, Genz-565660 (imiglucerase) has dramatically improved the outcomes for patients with this devastating disorder.<EOD> Assessment of gastrointestinal motility in patients with inflammatory bowel diseases (including ulcerative colitis, Crohn's disease) by scintigraphy.\nGastrointestinal motility in patients with inflammatory bowel disease was evaluated by radiogastrography and by radioactivity curves of the abdomen with scintiscanning in order to assess the influence of clinical course and treatment on gastrointestinal motility. The results were evaluated comparatively with the barium tests of gastrointestinal motility. Gastrointestinal motility was disturbed in ulcerative colitis: no contrast medium left the stomach, but a lot of fecal casts appeared in the colon and the contrast was passed slowly to the upper intestine. However, with better treatment and care, gastrointestinal motility improved and the transit time of the contrast to the duodenum was normal, although the patients suffered from severe attacks in the period of the testing. However, with better treatment and care, gastrointestinal motility improved and the transit time of the contrast to the duodenum was normal. In Crohn's disease, gastrointestinal motility was also disturbed, but to a lesser degree than in ulcerative colitis. The scintigraphic studies in patients with Crohn's disease showed better transit through the bowel, but a small bowel length index was significantly disturbed. The results of gastrointestinal motility as measured by scintigraphy are very sensitive for the detection of pathological motility disorders in patients with inflammatory bowel disease, and the method gives information on the transit time through bowel and on the gastric emptying, thus evaluating bowel motility and dysfunctions",
        "label": 0
    },
    "943": {
        "output": "```{python}\nfrom nipype.interfaces import Trait, TraitFile\n\nfrom nipype.interfaces.science.brainh import BrainhEEG\nfrom nipype.pipeline import engine\nfrom nipype.pipeline.datainputs import DataInputSpec\n\nfrom .utils import DataInputSubTool, TraitToFileSpecSubTool\nfrom .utils.injection_time_inputs import InjectionTimeInputSpec\n\n# Inputs\nspec = DataInputSpec(filename=(\"a/b/c.vhdr\",),\n    traits={'injection_times':[\n            ('slice_times',Trait(\"int64\", mandatory=True),),\n           ('voxel_times', Trait(\"int64\", mandatory=True),),\n           ('x0', Trait('int32', mandatory=True),),('sudx',Trait(\"int32\",mandatory=True),),('sudv',Trait(\"int32\",mandatory=True),),('sudx0',Trait(\"float32\",mandatory=True),),('sudv0', Trait(\"float32\",mandatory=True),), ('injcount', Trait(\"int32\", mandatory=True) ),('sud_time',Trait(\"int32\",mandatory=True),)],\n         'voxel': Trait('int8', max = 8552, mandatory = True),\n         'slice':Trait('int8',max = 1024, mandatory=True),\n    )\n)\ninput = BrainhEEG(in_files='A_EEG',subject='00000001',\ndata_prefix=None,\ntrait_prefix=None,\nspec=spec)\n\n\nresult = engine.execute(input)\n\nresult = input.result['output_file']\n\nresult.filepath.datanames['voxel'].attrs['unit'] = 'voxel'\nresult.filepath.datanames['slice'].attrs['unit'] = 'slice'\n\nresult.filepath.datanames['voxel'].vals",
        "label": 0
    },
    "944": {
        "output": "[INST] You are a medical student and the head of your class, and you have been tasked with teaching your classmates to use the AIBO robot for physical examination. This AIBO robot can collect various physiological indicators of patients during physical examination. It can be easily used as a telemedicine device, which has the potential to be used in primary medical institutions. \n\n\n## Clinical Examination of the Skin\n- The robot has been pre-installed with a special app, which can collect and record the human body index, including weight, temperature and blood pressure, before entering the office. It is very convenient for pre-examination.\n\n(a). Examination environment is set up. The screen is cleaned, the screen cover is removed, and the screen is turned on. The computer turns on with Windows at the same time, so as to prevent the computer from being locked. The monitor power switch is set to automatic (turn it on by default). Clean the desk of the examination area.\nPlace two pieces of white paper measuring 10cm\u00d710cm in the left and right corner, respectively, and spread them out 90 cm away from the wall in front of the left leg. The position of two papers is symmetric, and the gap between the two papers is the same. Make sure that other objects do not surround the screen and that the patient is not blocked by other objects. The angle between the examination bed and the desk is approximately 60 degrees, and the angle between the examination bed and the examination chair is approximately 90 degrees.\nMake sure that the examination bed, chair and screen are parallel to the ground. Keep the distance from the patient to the examination bed at 40 cm.\n\n# Inspection method:\nObserve the state of the child: normal or abnormal.\nObserve the state of the child's mouth, including color, moisture, and breathing. Note whether coughing, vomiting, or sniffing occurs. The color of the oral mucosa can be observed by pulling up the lips and chewing on one side.\nObserve feces and genitalia: Color, moistness, and consistency of the feces, the color  of the genitalia (redness, cyanos",
        "label": 1
    },
    "945": {
        "output": "<EOD> Excision of the Incisor. 1\nTHIS operation, performed under chloroform, was done, in order to relieve the irritation and pain caused by an irregularity in the teeth. The pain was referred to the tooth in front, which was so irritated that he would not let his attention be drawn to it. The operation was first mooted by Dr. A. M. Anderson.<EOD> Impact of obesity on perioperative and long-term outcomes of laparoscopic colectomy according to gender\n\nIntroduction:The increasing incidence of obesity in Europe over recent years is a worrying trend. This is a particularly growing issue in postoperative colon cancer patients where the impact of morbid obesity has not previously been extensively reported. The aim of this study was to evaluate the impact of morbid obesity on the perioperative and oncologic outcomes in colon cancer patients undergoing laparoscopic colectomy. Materials and methods: We retrospectively reviewed the data of all morbidly obese and non-obese patients (body mass index (BMI) <40 and \u226540 kg/m 2 , respectively) who successfully underwent laparoscopic colectomy from January 2008 to October 2016. Results: In total, 322 patients were analysed (230 controls and 92 morbidly obese). No mortality was reported; perioperative morbidity was comparable between the two groups, with pneumonia representing the only significant complication. At five years, recurrencefree survival (RFS) was similar between the two groups (70 versus 71%), as was overall survival (OS) (69 versus 74%). Morbid obesity resulted in a higher incidence of positive regional lymph nodes (28 versus 21%). Subanalysis revealed that morbid obesity is associated with improved outcomes in males but not in female patients. Conclusion: Laparoscopic colectomy for the management of colon cancer is a safe option for patients with morbid obesity, with a similar safety profile compared to non-obese patients. Male patients with morbid obesity had less recurrences and mortality, while this effect was",
        "label": 0
    },
    "946": {
        "output": "<EOD> Association Study of PDE4A Polymorphisms with Major Depressive Disorder in Han Population of China\n\nPDE4A, a member of the phosphodiesterase (PDE4) superfamily, is involved in the regulation of cAMP and the pathogenesis of depression. Here, we report an association study examining two single-nucleotide polymorphisms (rs2416867 in PDE4A intron 7-8 and rs2279263 in 39UTR) and major depressive disorder in the Chinese Han population. We genotyped rs2416867 and rs2279263 in 1000 patients with major depressive disorder (MDD), 997 healthy controls, and 83 subjects with recurrent episodes of depression. No statistically significant differences in genotype and allele frequencies were observed between the three groups in the case of PDE4A. A meta-analysis of genetic association studies was performed, including the present and previously published (1006 MDD patients from European cohorts and 449 MDD patients from Asian cohorts) case-control samples. Metaanalysis demonstrated that the MDD risk variant in PDE4A intron 7-8 is present in both European and Asian populations; however, a significant association was only identified in the European population. An analysis of the 39UTR variant identified a significant association between this polymorphism and MDD risk in Asian subjects. The current investigation of both PDE4A intron 7-8 and 39UTR demonstrated an association of MDD risk with genetic variation.\n\n# Introduction and objective\nDepression is a significant psychiatric condition that affects mood, cognition, emotional processing, and behavior [bib_ref]  Changed gene expression profile in adolescent mouse prefrontal cortex upon acute and..., Isgandarova [/bib_ref] . It is an important cause of disability, responsible for more lost years of healthy life than any other disease [bib_ref]  Antidepressants for the prevention of relapse and recurrence after antidepressive Efficacy of..., Spielmans [/bib_ref] . Depression usually runs a chronic course, with symptoms that are exacerbated by stress",
        "label": 0
    },
    "947": {
        "output": "## [Coding example]\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus, and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u200amg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u200amg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), estimated between 40% and 50% and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. Peak-Systolic (PSV) and End-diastolic velocity (EDV) cutoff-values were 208.5\u200acm/s and 54.5\u200acm/s, respectively; RICA PSV was 91.72\u200acm/s, and RICA EDV was 37.37\u200acm/s. Here is the clinical trial:\nTitle: A Pilot Study in Severe Patients With Takayasu Arteritis.\nSummary: Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.\n\n## Inclusion criteria:\nage\u226514 years old;\nactive: Kerr score\u2265 2;\nsevere: Blood pressure > 18",
        "label": 0
    },
    "948": {
        "output": "[STEP 3] Eligibility assessment of all given patients. \nYou should elbow the patients on the basis of the information in the patient note. Patients with sufficient information on both the age and inclusion criteria should be included in the eligibility assessment.\nLet's think step by step. \nFirst, we will check if the patient is 18 years old or older. \n![0][][][][][]\n![0][][][][][]\n```\n\n---\n\n### [115_P05.py](../../../../../python-code/lab42/01.Practice%20with%20code/115/115_P05.py)\n\n[![asciicast](https://asciinema.org/a/43081.svg)](https://asciinema.org/a/43081)\n\n[![](https://github.com/lab42teams/python-code/actions/workflows/build.yml/badge.svg)](https://github.com/lab42teams/python-code/actions/workflows/build.yml)\n\n![](./115_P05.py)\n\n### Rerun\n```python\npython 115_P05.py\n```\n\n---\n\n### [117_P05.py](../../../../../python-code/lab42/02.ClinTrails/117/117_P05.py)\n\n[![asciicast](https://asciinema.org/a/43082.svg)](https://asciinema.org/a/43082)\n\n[![](https://github.com/lab42teams/python-code/actions/workflows/build.yml/badge.svg)](https://github.com/lab42teams/python-code/actions/workflows/build.yml)\n\n![](./117_P05.py)\n\n### Rerun\n```python\npython 117_P05.py\n```",
        "label": 0
    },
    "949": {
        "output": "You are doing great! Your answer matches the example completely! Let's complete this step.\n\n## Part 2. Code in the `data` file\n\nYou have completed the code from the `data` file, see the screenshot of the completion and then save the `.jupyter` file under your working directory as `Part2 _Code.ipynb`. \n\nNext you will create a new directory under your working directory called `work` and then create several new directories under the `work` folder named `data` and `code`. You will save the `data` folder contents under the `work\\data` folder. Here are the contents that need to be created under the `code` folder:\n``` {code}\nfrom pathlib import Path\n\nwork_dir = Path(r\"C:\\MyScripts\\Part2\")\ndata_dir = work_dir / \"data\"\n\ncode_dir = work_dir / \"code\"\ncode_dir / \"demo\" / \"data\" # will create new folder under work_dir called `demo`\ncode_dir / \"demo\" / \"demo1\" # will create new folder under `demo` called `demo1`\ncode_dir / \"demo\" / \"demo1\" / \"data\" # will create new folder under `demo1` called `data`\n\ndata_dir / \"demo1\" / \"data\"  # will create new folder under `demo1` called `data`\n\ncode_dir / \"demo\" / \"demo2\" # will create new folder under `demo` called `demo2`\ncode_dir / \"demo\" / \"demo2\" / \"data\" # will create new folder under `demo2` called `data`\n\ncode_dir / \"demo2\" / \"data\"  # will create new folder under `demo2` called `data`\n\ncode_dir / \"work\" / \"demo\" / \"Part2_Data\"\ncode_dir / \"work\\demo\" / \"Part2_Data\" / fname_in_data_file # will create new folder under `Part2_Data` called `Part2_Data`\nPart2Data_demo_fname_in_data_file = code_dir / \"Part2_Data\" / r\"Demo(1)\" # will create new file under `",
        "label": 1
    },
    "950": {
        "output": "<EOD> A novel SLC26A6 mutation in Pendred syndrome causes early onset of hearing loss and enlargement of the vestibular aqueduct\nPendred syndrome is a recessive disorder comprising untreatable sensorineural hearing loss and enlargement of the inner ear bony labyrinth, including the vestibular aqueduct (EVA). Both features are attributed to a genetic defect affecting the type II anion exchanger pendrin gene (SLC26A4).<EOD> 11th Meeting of the European Atherosclerosis Society: the European Atherosclerosis Research Area Program.\nThe 11th Meeting of the European Atherosclerosis Society (EAS) and the second meeting of the European Atherosclerosis Research Area Program (EARAP) were held in Budapest, Hungary. EAS-EARAP is a joint initiative of the EAS and the European Research Network on Atherosclerosis (EUROSPAN). The aims of EARAP are to provide the funding platform for research ideas and projects contributing to a better understanding and treatment of atherosclerosis, to support new ideas, to promote cooperation between different research groups and societies, to co-ordinate and promote research on emerging methodological and technical approaches, to facilitate young investigator development, and to improve publicity of key issues and of the benefits of basic research. A European research programme is now well developed and the next step is to apply for European structural funds. The 11th meeting presented the latest findings in epidemiology and pathobiology of atherosclerosis. The meeting was also a celebration of the founding of EAS, and of the achievement and dedication of the scientists and clinicians who launched EAS. They formed the nucleus of the Society and now look to the future development of EAS.<EOD> Theoretical framework of the relationship between social exclusion and health\n\n\n\n# Introduction\nThe concept of social exclusion, initially used as a way of describing life conditions of disadvantaged social groups, later became a broader concept that has received great interest from the 1960s, when it started to receive increased attention in social sciences. Social exclusion is used to describe a variety of social problems",
        "label": 0
    },
    "951": {
        "output": "<EOD> Transcriptional activation of the ALDh3A1 gene by the endoplasmic reticulum stress-sensing and transducing kinases IRE1a and PERK\n\nThe ER is an intracellular organelle for the synthesis and posttranslational modifications of secretory and transmembrane proteins. ER stress leads to UPR (unfolded protein response) for the ER-proteome homeostasis. We found that expression of the short-chain alcohol dehydrogenases ALDH3 A member 1 (ALDH3A1) was induced by ER stress through transcriptional activation in several cancer lines. Moreover, an upstream region of ALDH3A1 promoter was bound with IRE1a and inositol requiring enzyme 1 (IRE1), respectively. This is the first paper to report that ALDH3A1 gene is regulated at transcriptional level by IRE1a-XBP1 and PERK-ATF4 axis. Furthermore, the binding site of ATF to the proximal site was detected in the XRCC5 promoter region. To conclude, the present study showed that ALDH3A1 was induced at transcriptional level by ER stress through upstream elements in the proximal promoter region binding IRE1-XBP1 and PERK-ATF.ARTICLE HISTORY\n\n# Introduction\nThe eukaryotic cell cytoplasm contains endoplasmic reticulum (ER), which is a membrane-bound structure with tubular and vesicular compartments. The ER contains a variety of enzymes required for the posttranslational modifications of secretory and transmembrane proteins, such as N-linked glycosylation, lipid modification, calcium regulation and disulfide bond formation [bib_ref]  Stressing out over endoplasmic reticulum-mitochondrial calcium signaling, Steinberg [/bib_ref]  [bib_ref]",
        "label": 0
    },
    "952": {
        "output": "You are given the files 'CSV_Patients.csv', 'CSV_Hypothesis_Trial.csv' and 'CSV_Study_Inclusion_Criteria.csv' for the respective files: `PatientNote.csv`, `Trial_Included_Patients.csv` and `ExclusionReasons.csv`. You also get an XML file of the hypotheses.\n\nThe [*Hypothesis_trial*](https://help.iplantcollaborative.org/p/ipython-notebooks/110317/783100/html/file/hypothesis_trial-1.csv) for the file `Hypothesis_trial.csv` can also be read by the [*PatientNote*](https://help.iplantcollaborative.org/p/ipython-notebooks/110317/783100/html/file/patientnote-1.csv) by the following code. The header for [*Trial_Included_Patients*](https://help.iplantcollaborative.org/p/ipython-notebooks/110317/783100/html/file/trial-included-patients-1.csv) is also shown:\n```python\np = pd.read_csv('hypothesis_trial-1.csv', index_col='Hypothesis' , sep=';')\npatient_id=p.Hypothesis.index[0]\ntrial_id=p.Hypothesis.index[-1] # The last element is always the trial ID\nsample_name=str(trial_id) + '_' + str(patient_id)\npatient_notes=p.drop(f'Hypothesis', axis=1) # remove the hypothesis column first.\nincluded_trial=trial_included_patients[trial_id==trial_id].iloc[0] # the first row in the second data set holds the unique trial ID,\np_data=p.drop(f'Hypothesis', axis=1)[sample_name]\np_data",
        "label": 0
    },
    "953": {
        "output": "![image description](https://user-images.githubusercontent.com/324945/61676620-8a91a180-af5b-11e9-9e16-472f4c73f226.png)\n\n### [02.10.2019 19:24] [kavashadpour](https://github.com/kavashadpour) [original](https://github.com/FarhadArab/AIQA-Final-Report/blob/main/AIQA_19-5.md) [reviewed](https://github.com/FarhadArab/AIQA-Final-Report/ blob/main/AIQA_19-5_rev.md)\n\n## MIMIC (31)\n### [02.10.2019 19:25] [kavashadpour](https://github.com/kavashadpour) [original](https://github.com/FarhadArab/AIQA-Final-Report/ blob/main/AIQA_19-6.md) [reviewed](https://github.com/FarhadArab/AIQA-Final-Report/blob/main/AIQA_19-6.md)\n### [Techniques Used in Deep Learning](http://www.mathworks.com/matlabcentral/fileexchange/50598-deep-learning-techniques-and-tricks)\n### [MIMIC-IV - medical information mart for intensive care - documentation](https://github.com/PhysioNet/MIMIC-III/wiki)\n### [Deep Neural Network for Medical Diagnosis 1](https://github.com/lilyzhong/DeepNeuralNetworkForMedicalDiagnosis/blob/master/dnnmimic.pdf)\n### [MIMIC-IV - medical information mart for intensive care - documentation](https://github.com/PhysioNet/MIMIC-IV/wiki)<EOD> High prevalence of diabetes in a rural Bang",
        "label": 0
    },
    "954": {
        "output": "### \u3010\u6311\u6218\u30114\u3010\u70b9\u3011 \u3010\u5956\u3011 \u3010\u7a7f\u900f\u6c34\u5e73\u3011 \u3010\u7ed3\u679c\u3011 \u3010\u5e73\u5747\u65f6\u95f4\u3011 \u3010\u63ed\u970f\u3011 \n\nChallenge4 is the longest! And we tried more than one hour! It's tough. Because we cannot answer it correctly without all the pieces of information, we have to think what the answer would happen in the case of missing pieces of information. Because we don't know clinical trial's exclusion criteria perfectly, we used some assumptions. These assumptions are written in the comments of trial_level_eligibility \uff1a If the trial participant meets the trial's \"clinical trial exclusion\" condition, then it should be assigned 0 point, instead of exclusion, 1 point should be assigned. In this way, we could think about cases as 1) excluded, 2) included.\n\n#### 12 \u3010\u6311\u6218\u30114.2 Challenge4B\n\n#### 13 \u3010\u6311\u6218\u30114.3 Challenge4C\n\n```\nTrial-level assessment of the patient\n\n1    \nTrial-level assessment of the patient\n\n2    \n\n3\n```\nWe checked the answers using our Python code, but our answers didn't correspond. If it is similar to our responses, we would be happy to learn that our answers were correct.\n\n### \u3010\u6311\u6218\u30114\u3010\u70b9\u3011 \u3010\u5956\u3011 \u3010\u7a7f\u900f\u6c34\u5e73\u3011 \u3010\u7ed3\u679c\u3011 \u3010\u5e73\u5747\u65f6\u95f4\u3011 \u3010\u63ed\u970f\u3011 \n\nChallenge4 is the longest! If we can solve Challenge4 with only one wrong point, we would hope that this point did not influence the answer! So, we would also be pleased to learn that our answers were correct!\n\n\n## C2.11 [\u6311\u6218]5\u3010\u70b9\u3011\"\n\n### \u3010\u6311\u6218\u30115\u3010\u70b9\u3011 \u3010\u5956\u3011 \u3010\u7a7f\u900f\u6c34\u5e73\u3011 \u3010\u7ed3\u679c\u3011 \u3010\u5e73\u5747\u65f6\u95f4\u3011 \u3010\u63ed\u970f",
        "label": 0
    },
    "955": {
        "output": "## Clinician's Report [BGN]\nWhen the patient you just examined for the clinical trial was tested out to be eligible, you will go to another screening room and report the relevant information about the patient as the eligible patient for the trial, including \n - the number of the patient, i.e., the unique number of the patient for the clinical trial that you generate;\n - the gender of the patient, e.g., male;\n - the nationality of the patient, e.g., Taiwan;\n- and the birth month and year of the patient.\nHere are the clinical trial's inclusion criteria.\n\n### Inclusion criteria\n\n- age 18\u2009years or older;\n- have CAD-based disease with symptoms (e.g., chest tightness, dizziness, shortness of breath, and palpitation);\n- be symptomatic, with typical angina;\n- be treated or untreated for hypertension, hyperlipidemia, diabetes, chronic kidney disease, and smoking; and\n- be receiving aspirin, statins, angiotensin, or any anticoagulants.\n\nYou will need to enter the patient number of the patient who is  eligible and use the number to determine the patient's eligibility. The clinical trial's inclusion and exclusion criteria will be used as references to determine the trial-level eligibility of the patient who you just examined. \nLet's think step by step. \n\n### Check trial information\n\n- You use `patients` to retrieve the patient's information on a one-to-one basis.\n- You enter the trial's unique identification number for clinical trial, e.g., `15-61007_MHK_02_20150903`.\n- You use the trial-level eligibility to retrieve the trial information, e.g., `Trial-level eligibility: 0) Excluded`. \n\n\n### Check patient and eligibility\n\n- You enter the unique patient number to retrieve the patient information, e.g., `patients(:[1625], :id, uniqueNumber).` \n- You",
        "label": 0
    },
    "956": {
        "output": "[/formula] \nIf the patient has a systolic murmur in the neck and this patient's gender is male, then output the name of the murmur, which is murmur, within the square brackets, such as `[Murmur]. If the patient's gender is female, then output the name of the murmur, which is femur, within round brackets, such as `[Femur].\n\nIf the carotid ICA, bilaterally, stenosis rate is greater than the trial's cut-offs, then output only the first of the following characters on the scale: \u2018-\u2019: \n[formula]  \uf8f1 \uf8f4 \uf8f2 \uf8f4 \uf8f3 0) Excluded or Not",
        "label": 0
    },
    "957": {
        "output": "To start the task, create a folder for the solution named \"Evaluate Clinical Trial Inclusion Criteria.\" Inside it, create subfolders called \"Code\" and \"Data.\" Put your code in the \"Code\" folder and a copy of the data in the \"Data\" folder. Copy the file \"input.txt\" in your solution folder and also create a file in the \"Test\" folder called \"test.csv\".\n\n\n# Assessing eligibility\n\nTo assess the patient eligibility for a particular clinical trial, we can use the Eligibility package, which is a very useful package for working with clinical trial data. It has three object types:\n\nEl trial.clinical is the most comprehensive and rich object for assessing the eligibility of patients based on their clinical trial inclusion and exclusion characteristics.\nEl.enrollment contains all the information about the trial: the trial\u2019s ID, whether it can be used, the start and end dates of the trial, the enrollment target, and the enrollment status of the patient.\nEl Patient represents a record of assessing a patient for a particular trial and has the attribute trial.clinical, which is a reference to an instance of the El trial.clinical.\nWe need to create objects to work with the data:\n\n```r\n# We work with the data from the file \"input.txt\"\ninp <- read.csv(\"input.csv\")\n\n# We create objects in order to work with the data from the Eligibility package and to assess the eligibility\n\ntrial_clinical <- Eligibility:::create_clinical_trial_data set(inp[1], \"patient\", inp[1]) ,\nenrollment <- Eligibility:::create_clinical_trial_enrollment set(inp[1], \"patient\", inp[2]) ,\neligibility <- Eligibility:::create_clinical_trial_eligibility set(inp, \"patient\") # We are creating the \"eligibility\" object which is the reference to the \"patient\" object of the \"enrollment\" object set of the patient in inp(1)\n\ntrial.clinical <- Eligibility::",
        "label": 0
    },
    "958": {
        "output": "<EOD> FDG\u2010PET imaging in Parkinson disease \u2013 An overview and potential clinical applications\nOver recent years, positron emission tomography (PET) using the ligand \u2010fluorodeoxyglucose (FDG) has been increasingly used to assess Parkinson disease (PD) patients, to confirm or exclude a diagnosis of PD and to identify patients at risk of non\u2010motor complications of the disease, such as dementia. Recent developments in PET instrumentation may allow the use of this imaging technique for clinical practice and to assist with patient management, by identifying patients who may benefit from disease\u2010modifying therapies and by ruling out alternative differential diagnoses.<EOD> Combined oral contraceptive pills to delay menopause.\nI've had a great deal of interest in the question of delaying menopause, given that I have many women who are concerned about what it's going to be like as they get older, are they in good shape? What am I going to be like as an elderly person? So we have several clinical trials underway that look at that problem. We have women here in the study who are taking different hormonal therapies and are being given blood tests and bone density tests to look at the effects of these therapies not only in preventing osteoporosis but to also prevent cognitive decline and a lot of other conditions associated with senescence.<EOD> 1. To identify all possible complications (including late complications) and the risk factors associated with complications and mortality and the influence of anaesthetic techniques on complication rates. 2. Is there a relationship between pre-operative nutritional status and complications? 3. Are there any advantages of early discharge from hospital? 4. To study whether or not discharge to a rehabilitation unit (RU) or convalescence hospital can reduce complications? 5. Should more aggressive treatment be offered to the 'frail elderly'? In this patient group should more conservative treatment be used? There is insufficient evidence to recommend routine use of any new treatment that claims to reduce complication rates, unless the evidence indicates that the treatment may be safe and at least of equal efficacy to the conventional treatment . It is recommended that when dealing with patients under",
        "label": 2
    },
    "959": {
        "output": "# Results\n\n\n\n\n[TARGET] Please see [/TARGET]\n\n### Excluded\nIncluded note ID\n\n### Not relevant\n\n### Eligible\n\n```python\nimport pandas as pd\n```\n\n`df.Trial-level eligibility` is a pandas Series object, and its values are from 0 to 2, as we described above.\n\n\n```python\n```\n\n\n```python\n%pylab inline\ndf.Triall-level eligibility \n```\n\n\n``Not excluded``    0\n```\n\n```python\n\ndf = df[df.Age >= 46]\ndf.Age\n```\n\n```python\n```\n\n```python\n\ndf['Trial-level eligibility'] = 0\n```\n\n\n```python\ndf = df[df.Age >= 46]\ndf.Age\n```\n\n```python\n```\n\n```python\ndf\n```\n\n\n``Not excluded```     0\n```\n\n```python\ndf = df[df.Age >= 46][df.Age <= 46].copy()\ndf.Age\n```\n\n```python\n```\n\n```python\n```\n\n```python\n```\n\n```python\ndf = df[df.age >= 46].copy()\ndf.Age\n```\n\n```python\n```\n\n```python\n```\n\n```python\n```\n\n```python\n# Included note ID\n```\n```\n\n# Excluded\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n### Not relevant\nIncluded note ID\n\n```python\ndf.not_excluded.age\n```\n\n# Excluded\n``The study protocol was submitted and approved by the institution's review board or ethics committee [1]\nNote 1: Patients with a confirmed history of stroke; unstable",
        "label": 0
    },
    "960": {
        "output": "<h3>Examples for this task: <i>\n\t\t<a href=\"https:/testdrive.ai/exercises/inspection/clinical_trial/13061749/\">Example 1 - Paper (pdf)</a> and \n\t\t<a href=\"https:/testdrive.ai/exercises/inspection/clinical_trial/13061749/\">Example 2 - PDF (html)</a> \n  </h3>\n\n### Task Description\n\nExamine a given patient's note to determine whether the patient would be ineligible in a clinical trial. Patients can be ineligible to participate in a clinical trial for various reasons. A patient's notes should be examined to determine whether the patient would be eligible for the clinical trial because any factor that causes the patient to be ineligible needs to be recorded. Therefore, the results of any eligibility examination can contribute to the data for the clinical study. Finally, the recruitment should be evaluated and, if the patient is eligible, the patient should be referred on to the study investigators to receive trial-related treatments.\n\n#### Task Variations\n\nThe patient's notes vary in terms of the number of sentences or paragraphs they contain and the structure of their sentences.\n\nFor instance, some patient notes contain only one paragraph, while others contain three paragraphs. Some notes are structured as questions, such as, \"what is the status of the patient?\".\n\nSome patient notes include one section that describes symptoms along with another section that describes the results of an examination. A patient note may include all the symptoms described in the clinical records that the patient presented, while another may include only a symptom that the clinical record indicates in bold. \n\t\n### Task Objectives\nThe task measures the participants' skills related to the extraction of information from patient notes and to evaluating the eligibility of the patient for a clinical trial.\nAfter completing this task, you should\n\n* Have a good understanding of what information could be used to determine eligibility for a clinical trial.\n* Be able to assess whether a patient is eligible",
        "label": 0
    },
    "961": {
        "output": "[INST] Question 2. Can you determine which of the following is not an exclusion criteria?\n\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine eligibility for a clinical trial. Exclusion criteria should be assessed to determine if a potential trial participant meets the inclusion criteria for the study. Exclusion criteria are reasons why a researcher feels that a person would be inappropriate for entry into a clinical trial.  Exclusion criteria  include having an illness, condition, or disability that would prevent you from complying with the  study protocol,  participating in another clinical trial,  being pregnant, having cancer,  being immunocompromised,   lack of consent to participate in the clinical trial,  being of childbearing age and planning to become pregnant within the duration of the trial,  failure to follow the instructions given by the study teams,  an inability to comply with the visit schedule and  if the person is not able to give informed consent. The following list is an updated catalogue of exclusion criteria:\n\nHypothyroidism, hyperthyroidism  or history of thyroid problems\n\nHistory of alcohol abuse or drug use\n\nHistory of previous or recent breast, prostate or lung cancer<EOD> Improved Survival of 190 Patients with Metastatic Cancer Given Immunotherapy\nThe survival of 190 patients receiving immunotherapy with intravenous, intraperitoneal or topical preparations was studied over a period of 17 years. With survival periods in excess of one month in 90.28 per cent of the patients, and with five survival periods of 19 months or longer, the results approach those achieved with conventional cytotoxic chemotherapy. The patients received immunotherapy as part of an investigational protocol, and no placebo was administered.<EOD> Influence of Cue-based Instruction with Automated Adaptation of Task Difficulty on Cognitive Demand in a Visual Search Task\nThis study examined the influence of adaptive task difficulty and cue-based instruction on attention-controlled search performance. The task consisted of multiple visual search",
        "label": 0
    },
    "962": {
        "output": "### Example 1\nThe following is a patient note as well as criteria for a particular clinical trial. To the left-hand side are the characteristics of our patient. In order to be eligible for this trial, the patient note would need to fit within the specific exclusion and inclusion criteria for the trial. A clinical trial could not be conducted with patients meeting these criteria.\n\n#### Questions\n\n1. Our patient note describes a 58-year old male. What is his age category?\n\n**A: 51-60 Years old.** The trial's eligibility criteria is for ages 18-60 years old. \n\n1. What is the gender of the patient?\n\n**A: Male.** The trial's eligibility criteria is for a male patient.\n\n### Example 2\nThe following is a trial-level eligibility table. To the left is the definition of the trial criteria. In order for the patient to be eligible for this trial, they must meet all the criteria shown to the left. This clinical trial could not be conducted with patients meeting these criteria. \n\n#### Questions\n\n1. Under 2(b) Inclusion criteria, our patient note describes a 58-year old male with a known cranial nerve paralysis. What disease is our patient experiencing?\n\n**A: cranial nerve paralysis is known for Parkinson's disease, Stroke.**\n\n### Conclusion\n<EOD> Changes in the metabolite profile during the process of freezing storage of highbush blueberry (Vaccinium corymbosum L.) using an UHPLC-QTOF MS metabolomics approach.\nThis study investigated the impact of freezing storage on metabolic profiles of highbush blueberry and provided valuable molecular information to reveal the changes in blueberry metabolism during storage. Herein, we evaluated the metabolite changes that occurred during the freezing storage of blueberries via ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry. After 0, 30, 60, 90, and 120 d of storage, we found that the fresh blueberry samples had",
        "label": 0
    },
    "963": {
        "output": "*Examples of patient notes and clinical trials are available here[INST]<EOD> Neuropsychological assessment of the demented for predicting treatment outcome. A longitudinal study in dementia of the Alzheimer type.\nThe present study reports on the course of patients with dementia of the Alzheimer Type (DAT) over up to 18 months treated with donepezil (DPZ, Aricept(R)). Using an initial neuropsychological assessment (NPA) it was tested whether it was possible to predict treatment outcome (e. g. cognitive improvement) with this measurement. Therefore the NPA included all available neuropsychological instruments used in our clinic, ranging from tests of general cognitive function to detailed tests of aphasia or apraxia, as well as personality assessment instruments. Based on the initial evaluation the patients were divided into four groups: severe patients not suitable for any active treatment; moderate patients who received DPZ; slightly less deteriorated patients who received combined therapy (DPZ + donepezil and ginkgo biloba extract (EGb 761, Cerevasc(R)); and the most functional patients not receiving any active therapy. The NPA, including all neuropsychological tests and personality assessment instruments employed, was repeated after intervals of 6 months. It was possible to identify groups of patients showing substantial changes after three, six and eighteen months in almost all neuropsychological tests and personality assessment instruments, but also in terms of clinical characteristics such as general progress of the disease, the global deterioration scale, functional status, activities of daily living (BADL (Norris)), level of care (L.C., Ostergaard-Andersen), and mental behavior (Norris scale of behavioral disturbances (NSD). It was observed that therapy with DPZ resulted in a small but significant positive effect, both in the total scale of MMSE and in the individual tests, though with different time courses. The results of the present study indicate that the neuropsychological assessment offers not only diagnostic information but also information about prognosis for treatment outcome in DAT-patients. If a clinical patient shows a low score at baseline in a neuropsychological test and a small gain in",
        "label": 2
    },
    "964": {
        "output": "[/TEST]\nCourse: Data Science I (part 1) for Medical Doctors \nCourse: Data Science II (part 2) for Medical Doctors \nCourse: Advanced Analysis Tools for Digital Medical Specialists \nCode of Conduct \nCourse Content \nCourse Syllabus 17\nPracticals 31\nData\n\n> data <- read.table(\"data.csv\",header=T) CARDF <-c(\"Trial, Trial_level_eligibility, Patient, Patient_age, Male, Patient_bmi, Patient_bmi_category, History_ of_medical_comorbidity, History_of_diabetes, Smoking_status, Alcohol_use, History_of_cprd, History_of_asthma, History_of_depression, History_of_heart_failure, History_of_atrial_fibrulation, History_of_mitral_valve _disease, History_of_chronic_osteomyelitis, History_of_epidural_ hematoma, History_of_menningothelial_disease, History_of_carotid_artery_sten-osis, History_of_varicose _veins, History_of_other_congenital _ heart_disease, Insurance, Trial\");\nnames(data) <-c(\"Trial\", \"Trial_level_eligibility\",\"Patient\",\"Patient_age\",\"Male\",\"Patient_bmi\",\"Patient_ bmi_category\", \"History_of_medical_comorbidity\",\" History_of_diabetes\",\"Smoking_status\",\"Alcohol_use\",\"History_of_c-prd\",\"History_of_asthma\",\"History_of_depression\",\" History_of_heart_failure\",\"History_of_atrial_fibrulation\",\" History_of_mitral_valve_disease\",\"History_of_chronic_osteomyelitis\", \"History_of_epidural_hematoma\",\"History_of_menningothelial_ disease\",\"History_of_car-otid_artery_st-enosis\",\"History_",
        "label": 0
    },
    "965": {
        "output": "---\n2\\. The second task is to find the median and interquartile range for the number of heartbeat counts. The interquartile range is the range between the first quartile and the third quartile, where the first and third quartiles are percentiles of the data ranked by size. If you need more details, see [Median and IQR](https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBCEcoGDe-vNet/03.IQR.md).\n\nFirst, you should import the following packages:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBCEcoGDevNet/02.Pandas-Importing.ipynb\" target=\"_blank\" rel=\"nofollow\">Pandas-Importing.ipynb</a>\n\nNext, you should export the relevant metadata:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ ECoG-DevNet/blob/master/UBCEcoGDevNet/02.Pandas-Importing.ipynb\" target=\"_blank\" rel=\"nofollow\">Pandas-Importing.ipynb</a>\n\nThen, you should load the following packages:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBCEcoGDevNet/03.IQR.md\" target=\"_blank\" rel=\"nofollow\">`03.IQR.md`</a>\n\nThen, you can run the Python function `pandas.DataFrame` to return the object pandas.DataFrame and fill the list with relevant variable and parameter name:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBC EcoGDevNet/03.IQR.md\" target=\"_blank\" rel=\"nofollow\">03.IQR.ipynb",
        "label": 0
    },
    "966": {
        "output": "## [ /INST]\n__In_Code/TrialInfo/TrialName.txt__\n\n__In_Code/TrialInfo/TrialAcronym.txt__\n__In_Code/TrialInfo/TrialSite.txt__\n__In_Code/TrialInfo/TrialStartDate.txt__\n__In_Code/TrialInfo/FinalStartDate.txt__\n__In_Code/TrialInfo/TrialDuration.txt__\n \n__In_Code/TrialInfo/TrialEndDate.txt__\n__In_Code/TrialInfo/TrialAcc.txt__\n__In_Code/TrialInfo/AgencyApproved.txt__\n__In_Code/TrialInfo/InterviewerApproved.txt__\n__In_Code/TrialInfo/NumberOfPatients.txt__\n__In_Code/TrialInfo/Aim.txt__\n```\n\n__Trial Acronym__\n**`TRIAL ACRONYM`** _string_\n\n__Trial Name__\n**`TRIAL NAME`** _string_\n\n__Trial Site__\n**`TRIAL SITE`** _string_\n\n__Trial Start Date__\n**`TRIAL START DATE`** _object_\n\n __`Trial Start Date.year`__ _string_\n__`Trial Start Date.month`__ _string_\n__`Trial Start Date.day`__ _integer_\n\n __`Trial Start Date.isoYear`__ _string_\n__`Trial Start Date.isoMonth`__ _string_\n__`Trial Start Date.isoDay`__ _integer_\n\n __Trial Start Date.millis_ _integer_\n\n__Trial End Date__\n**`TRIAL END DATE`** _object_\n\n __`Trial End Date.year`__ _string_\n__`Trial End Date.month`__ _string_\n__`Trial End Date.day`__ _integer_\n\n __`Trial End Date.is-oYear`__ _string_\n__`Trial End Date.is-oMonth`__ _string_\n__`Trial End Date.isoDay`",
        "label": 1
    },
    "967": {
        "output": "_\n\n## Output of the patient note:\nThe patient is eligible since the trial medicine shows a scale of 2 by the `Trial-level eligibility` statement. (See the `Examples of the output in the [Evaluate-1-input-note] section.)<EOD> A Phase II trial of irinotecan with 5-fluorouracil bolus and oral leucovorin in patients with advanced colorectal cancer. The GI Study Group.\nA phase II trial to explore the activity and toxicity profile of irinotecan in 33 patients with advanced colorectal cancer was conducted. Patients received irinotecan at a dose of 300 mg/m2 intravenously on Days 1, 8 and 15 with 5-fluorouracil (5-FU) at a dose of 400 mg/m2 as a bolus intravenously on Day 1 and oral leucovorin (LV) at a dose of 50 mg/m2 every 6 hours on Days 1 through 5 and 15 through 19 of a 28-day cycle. Median age was 56 years. All patients had progressed on prior 5-FU-based chemotherapy. Prior 5-FU-containing chemotherapy protocols were delivered either as adjuvant chemotherapy (n = 1) or in the metastatic setting (n = 32); prior irinotecan-based regimens included irinotecan plus LV (n = 22), irinotecan plus LV plus 1 or no prior 5-FU (n = 4), and a combination of irinotecan, LV, and cisplatin (n = 7). Objective responses were observed in 12 (36%) patients including 4 patients (12%) with complete response; median survival of responders was 10 months. Treatment was well tolerated and toxicity, as expected, was mainly hematologic. Non-hematologic toxicities included constipation (n = 12), diarrhea (n",
        "label": 0
    },
    "968": {
        "output": "## General hints \nDo not forget to `strip_tags`.\nCheck the input data and the code for the data you use. See if a patient note contains data of which you are not sure. \n\n### Input data \nYou should check the `Patient_note` tab of the data exploration tab. \n \nIn some cases, the output has a `NaN`-type value. These cases should be examined in detail.\n\n### Code \nAlways check the code! Make sure that there are no errors in the code, i.e., errors and warnings of the type `FatalError` or even `NotFatalError`. \n \nIf an error and/or warning appears, you can skip it if you think that making the necessary corrections is not essential. But you should know what the error and/or warning is for. \n \nYou should work with the full version of Anaconda3. \n \n\n## General hints for the exercise\n\n### The exercise does not have to be finished in one sitting.\nHowever, you will be asked to hand in the final code together with a file of the results, a screenshot of the input data in the data exploration tab, and any other information regarding the exercise that might help a future teacher if s/he has to resolve any kind of issue. \n\n### Always save the output file after each change in the code. \n\n### Before running the exercise on the computer in your lab, you can save the output file in the [Exercises/Input data/Output](https://github.com/vsl-group/exercises/tree/main/Input-data/Output) folder on the GitHub page in a new subfolder with your name. There you need not worry that your output file will be lost at any time if your computer stops working. \nIf possible, save the output file there in an appropriate format, i.e., as a [CSV](https://support.microsoft.com/en-us/documentation/29540436-how-to-export-your-excel-workbook-data-in-",
        "label": 1
    },
    "969": {
        "output": "| Eval 2\n|\n| **A 46-year-old man presents with dizziness and frequent headaches.** He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n| **Clinical trial: Title: Epidemiology and Long-term Outcome of Patients With VHD**\n\n| Summary: Valvular heart diseases are significant problem in Polish population. Coexistence of coronary artery disease in patients with VHD increases the risk of death and affects further therapeutic strategy. The aim of the study is",
        "label": 1
    },
    "970": {
        "output": "[EVALIDATION-2] The second column contains more text about the result. This column can also contain any text such as warnings.\n\n[INST] Hello, you are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/mL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively",
        "label": 1
    },
    "971": {
        "output": "### Task 3\nImputity data from a given randomized controlled trial (RCT). \n\n[INST] Here is the example data of one study site: \n![Example_data]()\n\nIf you want to get the data from the real-world example file, it is best to use the file provided with the task, as follows: \n![Example_data]()\n\nIn your Excel file, you should input each patient data as shown below. \n\n\n[INST] Explanations for the variable name are provided below: `Age` is the patient age. `Eligible` is the eligibility criteria. `Excluded` is the patient reasons for being excluded. `Excluded-Eligible-NotEnrolled` is the clinical trial eligibility assessment with the clinical trial eligibility assessment scale shown in Task 1. `Group` is the patient group; the sample size for each group is fixed at 500. `Randomization_group` is the group assignment, in which `0` indicates the control group and `1` indicates the intervention group. `Date` is the randomization date of each site. \n\n\n[PROB] You should include an English description of how you create each variable and describe the meaning of each variable for the readers. \n\n\n[QUESTION] Is it possible to have negative values for variables other than the patient ID? \n\n\n[ANSWER] Patient ID is a required variable, which should be unique. It should be integer. If there is an error, just make sure the variable name is unique, and then correct the value by using MIN and MAX functions.\n\n\n[QUESTION] If you need to have a negative answer, how to implement that? \n\n\n[ANSWER] There is no negative answer to this task, as mentioned above, it should be integer. You can use MIN and MAX functions to handle data with incorrect values. For example, in the above Example_data.xlsx file, the following code can be used to convert the patient ID to the correct value. \n\n\n[INST] Use",
        "label": 2
    },
    "972": {
        "output": "### 1. Check Exclude criteria -  If the patient meets all criteria for exclusion, print on the report the scale for the assessment of eligibility - 2. Check Inclusion criteria - If the patient satisfies all criteria for inclusion, print on the report the scale for the assessment of eligibility - 3. Check Relevant criteria - If criteria for exclusion are not met, also print on the report exclusion criteria that were met. - 4. Add trial-level eligibility - Print the scale for the assessment of eligibility for the clinical trial.\n\nPlease remember that the patient note is stored at the first line of the report.\nTo the next exercise, [CODE] hello.<INST>\nTo the next exercise, [CODE] EVENTS.</INST>\n[[Code: HelloWorld].\n[[Code: Hello World].\n\n# Exercise in Kaggles[INST]\n\n\n**Task1:** Get the Data from Kaggles and Create a Local Model.\n\nThe source code of this problem in Kaggle is available at https://github.com/wangliwei-bio/Kaggle-Get-the-Data-from-Kaggles\n\n[![image](https://upload.wikimedia.org/wikipedia/commons/thumb/b/b1/Python_logo_white.svg/744px-Python_logo_white.svg.png \"Python Logo\")]()\n\n[Teaching note]\nTo learn how to install Kaggles, please refer to the https://github.com/Wangliwei-bio/Scikit-learn-Tutorial/blob/master/kaggle#how-to-install-kaggle.\nTo get the data from Kaggles, please refer to the https://github.com/Wangliwei-bio/Kaggle-Get-the-Data-from-Kaggles#data-in-kaggle.\nTo build a local model from Kaggle, please refer to the [instructions on Kaggle](https://www.kaggle.com/help/overview/python).\nFinally, please refer to the [the source code of this problem in Kaggle](https://github.com/wangliwei-bio/Kaggle",
        "label": 1
    },
    "973": {
        "output": "![INST] Example:\nThis is the output of the algorithm:\n`1 1 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 2 2 2 3 3 3 0`\nYou can check the output above. Let's explain it carefully.\n[/1 1 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 2 2 3 3 3 0]\n\n\n\n1) This is the output of the algorithm for the example above:\nTrial-level eligibility: 1) Excluded\nEligibility: 0) Excluded\nEligibility: 1) Not relevant\nEligibility: 2) Eligible\nPatient ID: 1000239\nTrial ID: 1000239_05_2016\nFreq: < 10^9\nFrequency: less than 10 million. It is very, very low, so, very unlikely that we should remove this patient.\n\n### Eligibility: 1) not relevant\n#### The frequency of the term is between 10^6 and 10^9\nThe term Frequency range: less than 10 million to approximately 1 billion. It is relatively reasonable to think like this, because most of the time the patient does not have clear enough information to show whether he participates in the study or not.\n\n### Eligibility: 2) eligible\n#### The frequency of the term is more than 10^9\nThe term Frequency range: greater than 10 billion to 10^15\nAs you can see, the frequency of `the term Frequency` ranged from 10^6 to 10^9. As shown in [11], the term frequency in the training set of the PNNI model is distributed normally around the value 1.5. Hence, the term frequency in the test set of the PNNI model also follows this distribution. This can be expressed by equation (4.1).\n![INST]\nNow, the term frequency is more than 10^9, so",
        "label": 2
    },
    "974": {
        "output": "## Making a decision and submitting a note\n\n# Introduction and Objectives\nNow, it is time to summarize all of the things we learned above. You must decide whether a patient is eligible. The answer you should give to the question [Q01] `Is this patient eligible for the clinical trial?` should be either `0: Excluded` or `1: Not relevant`:\nThe eligibility assessment for entering into a clinical trial involves examining the following characteristics: the age, sex, physical health, disease phase, and previous treatment histories of patients. If there is a mismatch between a patient's characteristics and the selection criteria of a clinical trial, or if a patient has received an experimental drug or treatment protocol that is already known to be ineffective or harmful to the patient's health (e.g., a drug used to treat a specific disease currently under investigation to treat a different disease), then that patient is ineligible for the clinical trial.\n\n## Summary\nBefore we start, it should be noted that this project is a two-round multiple-choice question competition, which means that all the learners have to participate in both rounds. In the first round, which is the learning environment of the MOOC, each learner will try out several times, based on the learning materials, and each patient should be tested with only one trial using the eligibility assessment scale. After the submissions, the leaderboard will be updated (more information about the leaderboard can be found on the leaderboard page). Based on the results of the individual submissions, we will select 40 top-scoring users. The second round of the multiple-choice question competition is the test environment. In this test environment, each of the 40 top-scoring learners will try out again. There will be one correct answer for each question.\nBased on the results, we will select 10 top-scoring learners. For the purpose of providing a quality and fair examination, we will invite only the 40 top-scoring learners to submit their submissions from 22:00, 2022 to 28:00, 2022 (Beijing Time). At 28:00, 2022, the test will be closed. The test",
        "label": 0
    },
    "975": {
        "output": "</aside>\n</main>\n\n[MIT]\n\n## Using NumPy to compute correlations for the carotid artery plaques dataset\n\nSo far, we have been analyzing a given dataset without using any numerical techniques. Now, we shift our focus from `Statistical Analysis of the Carotid Artery Plaques Dataset` to `Computing Correlations for the Carotid Artery Plaques Dataset` section. In this section, we will be using a number of NumPy functions and will compute a correlation matrix and correlation coefficients.\n\n![instasound](/img/instasound.png)\n\nNumPy is a very useful and powerful library for array computation. In this lesson, we will be using a few NumPy features. Therefore, it will be better to have some NumPy basics, such as loading the built-in NumPy array and getting the shape of the built-in NumPy array.\n\n<aside class=\"devpage-skip\" data-skip=\"skip\" data-level=\"0\">\n\n<br><br>\n\n<br><br>\n\n</aside>\n</main>\n\n### Loading in NumPy array\n\nThere are three ways to load NumPy object, i.e., `numpy.loadtxt()`, `numpy.loadtxts()` function, and manual loading.\n<br>\n```python\nimport numpy as np\n\ndef try_load_numpy():\n    \"\"\" Load a NumPy object using `numpy.loadtxt`. \"\"\"\n    try:\n        n_test = np.loadtxt(\"D:/Code/Bioinformatics-Basics/Python/Python 3/NumPy/testData/test_data.txt\",\n                            delimiter=\";\", dtype=np.int32)\n    except:\n        print(\"Unable to load NumPy object.\")\n\ntry_load_numpy()\n\n```\n<br>\n<ul class=\"devpage-bullet\">\n\n    <li class=\"unbullet-left\">\n        <code>loadtxt</code> and <code>loadtxts</code> - Loading using <code>loadtxt</code>.\n    </li>\n    <li class=\"unbullet-left\">\n        <font color=\"red\">NOTE</font>",
        "label": 2
    },
    "976": {
        "output": "After the patient's assessment:\n---  \n!\n---\n\n\n##### Patient note\nThe patient does not meet inclusion criteria, as he does not met the age limit, he has high blood pressure, and he uses anticoagulants. Therefore, he is excluded on the grounds of the trial's exclusion criteria.\n\n* The output of results is also generated in the format of .*\n<EOD> The S252W Mutation in the Epidermal Growth Factor Receptor Does Not Implicate a Mechanism of Sensitivity to Epidermal Growth Factor in Human Glioblastoma Multiforme\nBackground: Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumour in adults. Epidermal growth factor receptor (EGFR) gene amplification is one of the most frequent molecular abnormalities of GBM, although not all GBM display such alterations. Although the S252W mutation is the most frequent non-amplification alteration observed in GBM, its functional effects on transduction pathways are not well defined. We analysed tyrosine phosphorylation levels of the EGFR in glioma cell lines carrying the S252W mutation, the in vitro levels of EGFR-regulated genes, and in vivo tumour growth after treatments with a selective anti-EGFR monoclonal antibody, cetuximab, and an EGFR tyrosine kinase inhibitor, gefitinib. We also analysed mRNA levels of EGFR-regulated genes in primary human tumours with or without amplification. Methods: We analysed the effects of S252W mutation on the level of tyrosine phosphorylation, activation of the phosphatidylinositol kinase (Akt)/mammalian ortholog of the yeast protein kinase (Sch9) signalling pathway, and expression level and activation of EGFR-induced genes like bFGF, cyclin D1 and EGFR in cell lines derived from GBM containing the S252W mutation. Primary human GBM from patients were analysed for expression of EG",
        "label": 0
    },
    "977": {
        "output": "</pre>\n\n<p>So far we have learned how to determine the level of eligibility (trial or patient) and how to extract the final scale for the assessment of eligibility from the extracted triallevel eligibility and input patient-level information to match with trial-level eligibility. We will use these capabilities to prepare our report.\n\nFor our report, you will see in the example code and the corresponding screen shot how to use `for in` and `while loops for the extraction of the list from the JSON data in our report. See Figures 10-16 below for a brief review. Please remember to save your reports to the report folder in your computer.\nFigure 10. How to extract the number of the included and excluded patients from the filtered data by patient-and trial-level eligibility. \nFigure 11. The same as in Figure 10 with the details of the code, including the input parameters to the report for the selection of specific patients. \nFigure 12. How to get more detailed results about the patients who have been excluded from the assessment of eligibility. \nFigure 13. Input data of the patients to the report to perform a patient-level data extraction. \nFigure 14. Display of the detailed results of getting more detailed results about the patients who have been excluded from the assessment of eligibility. \nFigure 15. Result of getting more detailed results about the patients who have been excluded from the assessment of eligibility. This is the more detailed results of those who have been excluded in the results of Figure 13. \nFigure 16. Input of the result data for the patient-level data extraction. \n</p>\n\n\n</div>\n\n<!--   <p style=\"direction:ltr;\"><span class=\"p-caption\">A: Assessment of patient eligibility</span></p>\n\n<p style=\"direction:ltr;\"><b><a class=\"a-name\" href=\"AssessPatientEligaibility_report.html\">Code snippet of Assessment of patient eligibility</a></b> </p>\n<p style=\"direction:ltr;\">\n<b>Code snippet of Assess",
        "label": 2
    },
    "978": {
        "output": "In some cases, a trial-level summary line might be helpful to give a brief look to the results. For example:\n\nEligibility per patient: Eligibility per patient:\nage 32-51 years\nfamily history of CAD, but no other cardiovascular risk factors\n\nEligibility: The mean LDL-C and HDL-C levels were 545.02 and 53.03\u2009mg/dL, respectively. The mean peak-systolic and end diastolic velocity in the left carotid artery were 208.41, 54.51, the mean peak-systolic and end diastolic velocity in the right carotid artery were 91.72, and 36.34\u2009cm/s, respectively. Peaksystolic and end diastolic velocity in common carotid artery were 74.69, 53.47\u2009cm/s, respectively. The plaque in internal carotid artery and common carotid artery were characterized as bulky plates extending to the middle third of the internal coronary arteries and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. The mean velocity in anterior and posterior walls of internal carotid artery was 208.45, 54.47\u2009cm/s, respectively, and in the common carotid artery was 74.64, 53.89\u2009cm/s, respectively\n\nDemographics:\nmean BMI was 25.18\nEligibility: Bivariate analysis of the association between the eligibility assessment and all the demographics and inclusion criteria for the Trial is shown in Table 2. The eligibility assessment was significantly higher in subjects who: (a) did not smoke (P=0.032); (b) had a diagnosis of nonfamilial hypercholesterolemia (P=0.032); (c) were male (P=0.025); (d) had a diastolic pressure higher than the threshold",
        "label": 0
    },
    "979": {
        "output": "**If you execute the Python script**\n\n`python saveScript.py` [/SUPP]\n\n**If you execute the Python script**\n`python saveScript.py`\n\n#### Verification Result\n\nIn this paper, we focus on verification, not on performance. You may use the notebook `performanceTest.ipynb` to evaluate the execution time [/SUPP]. For more details on verification, see Python Testing.\n\n`s 1:00   1:000   100%` [/SUPP] `0.652`\n\n`s 1:00   1:1000   73.37%` [/SUPP] `0.804` : `44.6561 s` : `100%`\n\n`Trial-level eligibility: 2) Eligible` [/SUPP](https://jupyter.org/services/?url=https%3A%2F%2Fgithub.com%2Fc-feng/AIP-book-en-ch)\n\n\n### Expert\n\nExpert is a method for comparing and merging eligibility judgments using a machine learning algorithm.\nYou should assess the eligibility of a patient note and compare it to the assessment of another expert before making a decision.\n\nExpert-level eligibility indicates if a patient qualifies for a clinical trial. If the evaluation of the patient is identical to the evaluations of the experts, Expert-level eligibility is",
        "label": 1
    },
    "980": {
        "output": "If you have any questions about this tutorial, please, send an email at <EMAIL>.\n\n\n___\n\nTutorial: How to make an assessment of eligibility using Open-CDS?\nAuthor (last update): <NAME>, Institute of Information Technology & Processing, Poznan University of Life Sciences (2020). \nAcknowledgements:\nThis tutorial is dedicated to OLE/IFC expert with a solid background on the Open-CDS system.\n___<EOD> .\nBACKGROUND\nThe increasing number of people in the age group 65 to 80 years and the reduced life-expectancy expectancy in the coming 25 years imply that our health care system will be faced with an increasing number of elderly patients with fractures.\n\n\nQUESTIONS\nWhich are the most common fractures types of older patients and what are the treatment choices? Additionally, what are the effects of different treatment options available?\n\n\nMETHODS\nMedline was searched for literature related to our questions. Furthermore, relevant books were examined for our questions. The selection of the most relevant articles was based on the relevance to one or more of our questions and on their significance.\n\n\nRESULTS\nTreatment for vertebral fractures in elderly patients consist mainly of conservative care or operative therapy, consisting of vertebroplasty, balloon kyphoplasty or osteosynthesis. Operative treatments show better therapeutic results than conservative treatments, especially for intrapedicular compression fractures caused by osteoporosis. In a hip fracture, the treatment depends on the patient's life expectancy, mobility and functional state. For femoral neck and trochanteric fractures, intramedullary nailing is the most frequently used operative technique. For subtrochanteric and per-trochanteric fractures, the most frequently used procedure is trochanteric stabilization. For trochanteric fractures, an unstable subtrochanteric fracture type, or fracture dislocations without an indication for internal fixation, an intramedullary nail with lateral support, an extramedullary skeletal bridge plate or a sliding hip sc",
        "label": 0
    },
    "981": {
        "output": "_Example 2:_ Here is the sample output with the first instance only:  \n 117:\t       4037.2\t\t\t\n 118:\t 0.0\t 0.0\n 119:        2.0\t  2.0\t\t\t\n 120:       40.0\t\t 0.0\t\t\t\n 121:        5.0\t\t\t5.0\t\t\t\n\nTrial-level eligibility\n: 5.0\nOutputs [trial_note]: 1.0.\nOutputs [trial_note_2]: 0.0.\nOutputs [trial_note_3]: 0.5.\n\n_Example 3:_ Here is the sample output with all instances:  \n 117:\t       4037.2\t\t\t\n 118:\t 0.0\t 0.0\n 119:        2.0\t  2.0\t\t\t\n 120:       40.0\t\t 0.0\t\t\t\n 121:        5.0\t\t\t5.0\t\t\t\n       6.0\t\t100.0\t\t90.0\t\t\n 122:       6.0\t\t100.0\t\t90.0\t\t\n 123:       6.0\t\t100.0\t\t90.0\t\t\n 124:       6.0\t\t100.0\t\t90.0\t\t\n 125:       6.0\t\t100.0\t\t90.0\t\t\n       6.0\t\t100.0\t\t90.0\t\t\n\nTrial-level eligibility\n:\n Tally the number of unique inclusion criteria.\n\nTrial-level eligibility\n:\n 1\n\nTrial-level eligibility\n:\n 1\nOutputs [trial_note]:\n   3.0\n   1.0\n   0.0\nOutputs [trial_note_2]:\n   0.0\n   0.",
        "label": 0
    },
    "982": {
        "output": "## CORRECT RESPONSE: \"If one is eligible and one is ineligible, then the correct answer is `No`.\"\n\nCorrect response \u2b50:\n\n\nCORRECT RESPONSE INFORMATION\n\n**The correct answer is:** \n\nCorrect response: `No.`\n\n# Exercises\n\n## Exercise 1\n\n# Exercise 1-A solution\n\n## Exercise 1-B Solution\n\n## Exercise 2\n\n## Exercise 2-A Solution\n\n## Exercise 2-B Solution\n\n## Exercise 3\n\n## Exercise 3-A Solution\n\n## Exercise 3-B Solution\n\n### A.\n\n### B.\n\n## Exercise 4\n\n## Exercise 4.A Solution\n## Exercise 4.B Solution\n## Exercise 5\n\n## Exercise 5-A Solution\n\n### A.\n\n## Exercise 5.B Solution\n## Exercise 6\n\n## Exercise 6-A Solution\n\n## Exercise 6-B Solution\n\n### A.\n\n### B. \n\nExercise 7\n\n## Exercise 7-A Solution\n\n## Exercise 7-B Solution\n\n## Exercise 8\n\n## Exercise 8-A Solution\n\n## Exercise 8-B Solution\n\n## Exercise 9\n\n## Exercise 9.A Solution\n\n## Exercise 9.B Solution\nThis chapter provides a step-by-step explanation of the eligibility process of a patient with a particular medical condition for a clinical trial. It introduces the readers to the problem of trial-level eligibility assessment and then focuses on a description of the eligibility algorithm used to evaluate trials using a step-by-step process. The main content of this chapter is as follows: the concept of trial-level eligibility assessment; the definition of eligibility assessment; the problem that needs to be solved using clinical trial eligibility assessment; the eligibility assessment",
        "label": 0
    },
    "983": {
        "output": "##[EXP] Excluded. \tA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.  `Clinical-trial : [INST]. The trial-level assessment. \nHere is the clinical trial: \nTitle: The Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study \nSummary: Carotid artery disease is a main cause of ischemic stroke and vascular dementia, and a highly prevalent disease. There is uncertainty about",
        "label": 1
    },
    "984": {
        "output": "[END]\n\u00a9 2016 - 2018 DataCure Inc -- Powered by WordPress Entries (R) 4.7.2\nCopyright (C) 2015-2018 The WordPress Foundation.\n<EOD> .\nThe effect of a long-acting depot formulation of the antidepressant drug zimelidine (ZD) upon the development of tolerance was studies. On the basis of the acute and chronic biochemical experiments performed with rat brain structures in vitro it was found out that the depot formulation of ZD is able to maintain the basal activity of brain serotoninergic (5-HT+) and adrenergic (AD) neuronal systems, preventing the appearance of tolerance to the therapeutic effect of the drug. The development of tolerance in the central serotoninergic and adrenergic nervous system appears to be a result of an inhibition of the initial sensitivity of the 5-HT+ and AD mechanisms to antidepressant drugs caused by changes of the phosphorylation-dephosphorylation status of enzymes regulating the turnover of monoamines, e.g., protein kinases, phosphatases, monoamine oxidase, acetylcholine esterase or GABA transporting carrier.<EOD> Inhibition of A\u03b2\u2010induced neuronal apoptosis via antiapoptotic signalling pathway\nA\u03b2 peptides, as one of the primary pathologic factors in Alzheimer's disease (AD), are cytotoxic to neurons, playing a critical role in the neuronal apoptosis. To clarify the mechanism of A\u03b2\u2010induced neuronal apoptosis, a neuronal apoptosis model in vitro induced by A\u03b2 peptides was used as a neuroprotection study model to search for the active compounds which could exert protective function on neurons. From the screening of crude extracts, a novel quinoline alkaloid (2\u2010aminoquinoline\u20106,7\u2010diol), designated W06, was isolated from a medicinal plant called the seeds of Stemona tuberosa. The biological activities of this comp",
        "label": 0
    },
    "985": {
        "output": "[[SEC:H20_05.0_0_0]] Your role is to analyze the eligibility data of patients at recruiting sites to identify participants who are suitable for the clinical trial.\n\nThe tasks you need to perform are shown on the left-side menu of the [MANAGE] tab. \n\n#### DUTIES\n- [Assembling a Query][INST] Select all the eligibility data from all the patients that participate in the clinical trial. Then export the data to .csv format.\n- [Calculating Eligibility Rates][INST] Analyze the calculated eligibilities.\n- [Viewing Individual Patient Data][INST] Analyze individual patient data and export these to .csv format. \nYour work is done!\n\n[NOTE]\nWhen you are done, close this window and open a new window of your web browser to check if the Exported Files folder is created. You should see .csv files saved inside the Exported Files folder. \n\n\n## SECTION 6: PROFILE SYSTEM\n\n[[SEC:H20_06.0_0_0]] The profile system contains information such as patient visits, baseline data, screening results, etc.\n\n\n### DUTIES\n- [[DESC:MANAGEMENT_SYSTEM]] You can manage screening data and patient visits from the [MANAGE] tab. A trial's patient screening data or patient visits are accessible under the [MANAGE] tab.\n- [[DESC:MANAGEMENT_SYSTEM]] Select [Select All] to transfer screening data and patient visits from all the patients of the trial. You need the data for the export operation [EXPORT] to be performed. You can perform this operation through [ACTION]\n- [[DESC:MANAGEMENT_SYSTEM]] To transfer data, check the box next to each [Patient] record and click on [Export]. Export each of the [Patient] records to .csv format. The file is saved into the Exported Files folder.\n- [[DESC:MANAGEMENT_SYSTEM]] Exported file names take the format ``{Screening Visits} screening-visit_{[001",
        "label": 0
    },
    "986": {
        "output": "![](00-200.png)\n  \n    \n\n## [C]: <NAME>,<NAME>,<NAME>\n[A]: <blink>In my case, my initial guess was actually a lot of the time that I was wrong.<NAME>?<NAME>?<NAME>.</blink>\n[B]: <NAME>.<NAME>, what are the requirements? Can the patients with aortic valve stenosis enroll in a cardiac hypertrophy study if they have mitral regurgitation?<NAME>?<NAME>?<NAME>.</blink>\n\n\n[B]: <NAME>, do we have a mitral valve prolapse for the mitral regurgitation?\n[A]: What was the criteria for mitral valve prolapse for the study design? You had to know the answer before the next question.\n\n[A]: So if it's a mild stenosis, then it's also less than 20% mitral valve calcium?<NAME>.\n\n[B]: <NAME>, it's an interesting answer. If we make a new study, do you think there's a need to look at mitral valve calcium?<NAME>.<NAME>;<NAME>.<NAME>.</blink>\n\n[B]: <NAME>, you said that we have something to look at if the mitral valve regurgitation is less than 3. So, is that something that you would look at in this patient?<NAME>[C]: <NAME>?<NAME>?<NAME>?<NAME>.</blink>\n\n[C]: <NAME>, how do we evaluate that?<NAME>?<NAME>.</blink>\n\n[C]: <NAME>, <NAME>. What would you do in this case if you had a murmur?<NAME>{C}: Yes, this is the one that I was looking at, which is <150> 2016. They did look at mitral valve calcium and mitral valve regurgitation at the same time, which is interesting and actually, not that often is done in medical trials.<NAME>.<NAME>.<NAME>.</blink>\n\n[B]: Do we ever consider the calcifications of aorta or carotid artery",
        "label": 1
    },
    "987": {
        "output": "[fig]  [: MW] Hello. you are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [MW] Here is the trial record: ID: 36637 Internal ID: 10001 Trial name: Neuro-ultrasound Assessment in Behcet's Disease Title: Neuro-ultrasound Assessment in Behcet's Disease Summary: Assessment of structural changes that occur in large extracranial and intracranial arteries in patients with Behcet's disease Inclusion criteria: Inclusion Criteria: All patients fulfill the modified International Criteria for Beh\u00e7et's Disease Exclusion criteria: Exclusion Criteria: Patients with an age younger than 18 years of age Previous history of stroke or other neurological and psychiatric diseases Patients who are allergic to aspirin, clopidogrel, or dipyridamole Patients who are allergic to iodide-based contrast medium Patients with a history of major surgery in recent 2 weeks Patients who are pregnant or lactating Patients with active pulmonary tuberculosis Patients who are incapable of adhering to all experimental protocols Investigators will exclude any patient who refuses to participate in the study Patients with a history of ischemic stroke or other neurological or psychiatric disease Patients with prior surgical intervention Patients with chronic renal or hepatic dysfunction Patients undergoing dialysis Patients treated with steroids Patients with history of allergic reactions to contrast agents Patients with significant cardiovascular comorbidities including pulmonary tuberculosis Patients who are pregnant or lactating Patients underwent surgery within 2 weeks Patients with severe visual or hearing defects Patients who were incapable of adhering to the protocol",
        "label": 0
    },
    "988": {
        "output": "_**Good Luck**_, \n\n___\n\n\n\n___<NAME></NAME>\n\n***\n\n_This solution has been reviewed using [VTN-1103](https://wiki.vtn.ac.at/display/VTN/VTN+Evaluation+Review+Template)._ \n_For further information please see [VTN-027](https://wiki.vtn.ac.at/display/VTN/VTN-027+Incident+and+VTN-1103_(+VTN+Evaluation+Review+Template))_. _This work will be published under the [VTN License](https://wiki.vtn.ac.at/display/VTN/VTN+License)._ \n \n \n___ \n\n## Related solutions\nYou solved:\n- [Procedure_Patient](https://vtn.ac.at/solutions/59820)<EOD> Genome-Wide SNP-SNP Epistasis Study of the Relationship of Single Nucleotide Polymorphisms in Genes Coding for the Renin-Angiotensin System to Systolic Blood Pressure on the Utrophin Gene.\nThe renin-angiotensin system (RAS) has been shown to affect blood pressure, renal function, and cardiovascular function. The effects of the RAS are mediated by angiotensin-II (Ang II), which is a potent vasoconstrictor, a proinflammatory cytokine and an inducer of both angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptor expression. The Ang II/AT1 pathway leads to hypertension by promoting sodium and water reabsorption. While the interaction of 3000 SNPs mapping to 23 genes of the RAS in relation to SBP has been investigated by some previous studies, those studies had a modest effect size, and no interaction epistasis study has been undertaken. In this study, we investigated the epistasis of a set of 576 SNPs, which map",
        "label": 0
    },
    "989": {
        "output": "### \u25b6 Trial-level eligibility: 0) Excluded\n\nPatient Note:\nA 67-year-old male has LDL-C 210 mg/dL. He has hypercholesterolemia. He is physically active and has no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. He reported no use of lipid-lowering medications.\n\nNeck auscultation revealed a systolic murmur 2+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed moderate stenosis in the left internal carotid artery (LICA),  as well as severe stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 200.8\u2009cm/s and 50.9\u2009cm/s, respectively; RICA PSV was 151.39\u2009cm/s and RICA EDV was 51.67\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n\n\nTitle: Pullback Pressure Gradient (PPG) Global Registry\n\n\nSummary: The purpose of this study is to determine the predictive capacity of the Pullback Pressure Gradient (PPG) index for post-PCI FFR and to determine the impact of the PPG index on clinical decision making about revascularization and on clinical outcomes.\nInclusion criteria: Consecutive patients with stable coronary artery disease or stabilized acute coronary syndrome and invasive FFR measurement \u22640.80.\n\n### \u25b6 Trial-",
        "label": 0
    },
    "990": {
        "output": "<EOD> .\nThis paper reviews anatomy, biomechanics, and the use of spongy bone or cartilage substitute materials as possible graft materials of the joint endoprosthesis joints and the spinal column. From the standpoint of biomechanics the most suitable graft material is proved to be cancellous bone. Therefore, the replacement materials are tested for their resistance to pressure against compression forces before they can be used clinically in joint and spinal endoprostheses. The results of some of these studies are presented.<EOD> .\nIn a retrospective analysis of 200 cases of thyroid cancer of the papillary type, in all cases with lymph node metastases (343), all other cases (176) were analysed for the number and location of the lymph nodes and also for presence or absence of the metastases in the latter groups, with the aim of developing an algorithm for staging, and establishing a more objective and rational basis for determining the prognosis and planning the therapeutic regime. It is recommended to include lymph nodes in staging and to define the groups as follows: with and without metastases in lymph nodes, and to take into account the group without metastases; this may be considered as a low risk group with a good prognosis (stage I). Stage II includes patients with single lymph node metastases (level VI, VII and IIIb). These groups are to be considered as an intermediate risk group. Stage IIIa also has single nodal metastases in other levels than level VI, but there are also lymph node metastases in level VII and IIIb. Finally, stage IIIb includes multiple lymph node metastases regardless of the level of localisation.--Because of the different prognostic significance of the lymph node metastases in relation to age, patients over 40 years with lymph node metastases are considered as representing the intermediate level of risk. However, lymph node metastases in all other groups are considered as indicative of a general increase in risk and are indicators for the presence of widely spread metastases. In this way, an increased risk in the primary tumour is considered as an indicator of the presence of distant metastases as well.<EOD> Differences of the",
        "label": 0
    },
    "991": {
        "output": "var trialLevelEligibility=1;\n\t\tif (condition) trialLevelEligibility = 2;\n\t\telse trialLevelEligibility = 3;\n\t\tconsole.log(trialLevelEligibility);\n\t\t// Assessment of Patient's Eligibility\n\t\tconsole.log('Assessment of Patient's Eligibility: '+patientNote.condition+' => '+trial_id[condition]+' =>  '+trial_condition[condition]);\n\n\t\t// Create a text message\n\t\tvar message = trial_level_assessment+trial_id[condition]+' was evaluated \\n';\n\t\t// Add the name of the study and your name\n\t\tmessage=message+'Assessing clinical trial eligibility: '+name+', '+trial_description['description']+' ('+trial_description['date']['year']+'-'+(trial_description['date']['month'])+'-'+trial_description['date']['day']+') '+patient_id;\n\t\t// Add the patient's assessment result\n\t\tmessage+=patientLevel_eligibility.patientEligibility + ' ('+trial_condition[condition]+') '+trialLevel_Eligibility + ' ('+ trialeligibility[result]+ ');';\n\t\t/*\n\t\t// Add results for different types of clinical trials\n\t\tmessage+=type+' '+trial_type[cliniCalTrial];\n\t\t*/\n\t\t\n\t\t// Send the SMS message\n\t\tvar sms = SMS_API({\n\t\t\tto: cell,\n\t\t\tmessage:message\n\t\t},{\n\t\t\tsuccess: function(){ },\n\t\t\toutcome: function(){ }\n\t\t}); \n\t\t\n\t}\n</script>\n\n\t\t  </body>\n\n</html> \n<EOD> Development of HCC in livers of Gunn rats undergoing liver regeneration: Implication for carcinogenesis.\nEpidemiological studies have shown that excessive liver regeneration following resection of primary malignant tumors significantly increases the secondary tumor incidence. Moreover,",
        "label": 0
    },
    "992": {
        "output": "## Evaluation metric\nNow, we need to evaluate the performance of an assistant. You must show that the assistant should be assigned as an eligible assistant.\nThe criteria for the assessment of eligibility must include three metrics to evaluate patients' eligibility. They are the accuracy rate, precision, and recall for the assistant.\n\n\nAccuracy-ratio is the number of accurate assistant's evaluation for a patient divided by the total number of trials for the patient. For the assistant in this trial, we have two choices from the total of 50 trials. A correct choice means one of the two trials is eligible and another is a not relevant result so Accuracy-ratio is 33/(33+17), i.e., 0.647. \n\\frac{\\begin{matrix}33 \\\\ 33+17\\end{matrix} } {\\begin{matrix}50 \\\\ 50\\end{matrix}} \\ \\  \\text{(64.7%)}\n\n\nAccuracy measures how correctly an assistant assesses a trial when compared to the ground truth.  While the accuracy gives you an idea of how well the algorithm predicts the ground truth, two more metrics are needed to capture both false positives and false negatives of the model. False positives (FP) and false negatives (FN)  are the two metrics that you must provide with the patient notes while completing the assignment. For this task, FP are the number of assistants who assign trial is unqualified when there was an eligible trial while FN means the number of assistants who assign trial is eligible when there was an unqualified trial. The precision is the ratio of true positives to the sum of true positives and false positives,  while recall is as the ratio of true positives to the sum of true positives and false negatives. \n[Precision=True positive/(True positive+False positive)]\n\n\n[Recall=True positive/True positive+False negative]\n\n## Examples of Trial-level eligibility matrix for Clinical trials \n\nTrial-level eligibility matrix contains 5 columns (or features) in this example of table:\n- Column 1 is the clinical trial ID, which we shall use to",
        "label": 1
    },
    "993": {
        "output": "##[SEC] 3.5) Suggested Solution #5-4\nYou can solve your problem by using the command ``set trial-level-assessor 0.2`` right now. Then, the problem will disappear. You can also modify the trial setting manually. Do not change the trial setting in your code. Make the change in the trial setting file. You can open `master.R` in your local directory to check the code. Also, you can use an `R Studio Console` [https://rstudios.com/products/rstudio-console/(LINK)].\n\n### EX3.5.3. Trial-level assessment and analysis: Trial-level Eligibility\nThis step is the same for `problem solver #5-1`. Please do the same steps from the same starting point, and please confirm that your code does not have the same mistake.\nThere is no answer below for this step.\n\n#[SEC] 3.5) Suggested Solution #6\nYou need to remove ``set trial-level-assessor 0.2`` from your code. If you still get an error on the step, try to set trial-level-assessor 1.0, and confirm again that your code does not have any mistakes.\n\n### EX3.6. Trial-level analysis: Cumulative incidence function\nThis step is the same for `problem solver #6`. Please do the same steps from the same starting point, and please confirm that your code does not have the same mistake.\nThere is no error below for this step.\n\n#[SEC] EX3.7. Suggested Solution (1) Cumulative incidence function for the endpoint\nYou can compute the cumulative incidence for the endpoint.\nI recommend you to create a new R library folder and create a new file in that folder before you import the data.\nNow we import the data into R workspace, and compute the cumulative incidence using `survdiff` from `survival` package. We can also compute the 95% CI of each group by `ggtable`.\n\n## Coding\nlibrary(R.utils)\nlibrary(survival) library(\"table1.ext\") library(survdiff) library(ggtable1.ext) library(ggpubr",
        "label": 0
    },
    "994": {
        "output": "<h2 id=\"data\">Data</h2>\n\n<p class=\"p1\" style=\"text-indent: 3em;\">\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nYou should always repeat Trial-level eligibility = 1) Eligible.`\n</p>\n\n<h2 id=\"data\">Data</h2>\n\n  <table class=\"data\">\n    <thead><tr><th class=\"firstcol\">Pat",
        "label": 0
    },
    "995": {
        "output": "## Tests\nPlease, find here the tests which are passed by this exercise. Each test is evaluated by the corresponding test writer.\n\n### Test I\n\nTest I is the correctness test for the trial-level eligibility.\nThis test is a random selection process, so any correct/incorrect feedback is subjective and depends on the person that takes the Test I.\n\n#### Test output\nOn the _`Test` page_, the tests are displayed and you can click on\nthe\nlinks to see the solutions.\nWhen you click on the link\nyou will reach an answer page in\nwhich the solution of the test is explained. And in order\nto check, whether the submission was valid, click\non the link below.\nIf the solution is correct, then the user is validated.\nIn order to be sure it is the same person, please fill the\nform\nas well.\nThe fields that should be filled are as follows: the\nstudent number,\nthe name and the ID of the clinic.\n\n#### Example\nHere is an example to see the solution page!\n\n|Student ID|Clinic|Stenosis status| Trial-level eligibility|\n|:-----|:------|:-----------|:-----------:|\n|101|3|0|Eligible|\n|101|3|1|Not relevant|\n|201|4|2|Excluded|\n\n|101|3|0|Eligible|\n|102|1|0|Not relevant|\n|201|3|1|Excluded|\n\nPlease, remember to select the correct field!\nAlso, please fill the\nform\n!\n\n#### Solution\n\n\n\n<EOD> An exploration of health professionals' perception of the potential usefulness of an online pain education programme\nAbstract Objective The main aim of this paper is to explore health professionals' perspectives and experiences of using an online education programme for pain management. A secondary aim was to identify how educational requirements could be met to improve the quality management of chronic and acute pain. Methods Focus group interviews were conducted with nurses and doctors between August 2014 and February 2015. They represented the three health disciplines \u2013 nursing, medicine and phys",
        "label": 2
    },
    "996": {
        "output": "<EOD> Influence of Dipyridamole on the Kinetics of Different Pharmaco\u2010Thrombodynamics Parameters\nThe evaluation of the drug induced changes of the thrombus growth and its morphological evolution in different blood concentrations of 3H\u2010fibrinogen is described. For this, a pharmaco\u2010thrombodynamics study was performed with dipyridamole, a drug known to interfere with the platelet\u2010mediated thrombus growth. The time dependent variation in thrombus volume, lag time, maximum absorption and surface tension of thrombi, and their kinetics parameters, in the absence and in the presence of different concentrations of dipyridamole (total plasma concentration from 0.5 \u03bcg mI\u22121 to 1.25 \u03bcg ml\u22121), were determined in an in vitro system. The dose dependent inhibition of thrombus surface tension and of the thrombus volume and the corresponding increase in the lag time and the maximum absorption were observed. A significant modification of the growth velocity was detected indicating a modulation of the morphological stages occurring during the coagulation dependent thrombus formation in the presence of dipyridamole.<EOD> Rhabdomyolysis caused by vigorous aerobic dance\nA fitness instructor developed an unusual pattern of rhabdomyolysis following an aerobic dance session, including delayed presentation, failure of serum CPK kinetic resolution and prolonged muscle stiffness. It is important to be aware of this condition in this setting so that unnecessary investigations or therapeutic procedures, such as cardiopulmonary resuscitation, are avoided.<EOD> A New Innovative Method for Monitoring Mental Health Problems among School-Aged Children during Lockdown (SARS-CoV-2 Pandemic)\n\n\n\n# Introduction\nThe Italian National Health System provides publicly available universal coverage to its entire population, including children. In this context, the National Health Plan 2014-2016 included health promotion in children as a priority and a public health intervention priority for this age group involved a broad approach in which the evaluation of mental health, not addressed in-depth in the previous plan, was proposed [bib_ref]  The First Year of the National Health Plan",
        "label": 1
    },
    "997": {
        "output": "A 44-year-old woman with a history of type 2 diabetes mellitus reports no use of lipid-lowering medications. Her family members have a history of CAD and she is overweight. Her LDL-C and HDL-C levels were 173 and 16\u2009mg/dL. Her fasting glucose and triglyceride levels (94 and 135\u2009mg/dL) were within normal limits.\nThis patient notes exclude criteria; therefore, we should output `0`: Trial-level eligibility: 0) Excluded.\nOne solution is by adding patient note lines with appropriate labels (in our case the label is Exclude) and then the relevant text in the patient note (a part of the label itself) goes into patient notes that should be excluded. Therefore, this patient note is now 0; Exclude: \u2026 The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nA 44-year-old woman with a history of type 2 diabetes mellitus reports no use of lipid-lowering medications. Her family members have a history of CAD and she is overweight. Her LDL-C and HDL-C levels were 173 and 16\u2009mg/dL. Her fasting glucose and triglyceride levels (94 and 135\u2009mg/dL) were within normal limits.\nThis patient notes exclude criteria; therefore, we should output `0`: Trial-level eligibility: 0) Excluded.\nOne solution is by adding patient note lines with appropriate labels (in our case the label is Exclude) and then the relevant text in the patient note (a part of the label itself) goes into patient notes that should be excluded.\n\nA patient should be considered eligible if they",
        "label": 0
    },
    "998": {
        "output": "**\u2461 If patient does not meet inclusion criteria: Excluded**\n\n\n![INST](inst/4_1_2_1_1_1.png)  \n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the 2022/11/14 12:00:38, by r=regr, session_id=$'b08dcdb8701c7dad', pid=5865, request_id=860862931, user_id=5442315787503587, up_time=102,262,861,383, total_time=2022/11/14 12:06:38, db_query=SELECT \"Patient_Name\".\"Name\".\"eng\", `Trial-level eligibility.` FROM \"patient\" WHERE Patient_ID=1403472342 AND Patient_Name =\"Zakarija\" ORDER BY `Trial-level eligibility`.\n\n[INST] You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n[INST] Here is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.The patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe",
        "label": 2
    },
    "999": {
        "output": "In other words, if the patient note includes an element that is an inclusion criteria of the clinical trial, print that element in blue like the given example. \nNote that each element that is an inclusion or exclusion criteria of the clinical trial will consist of 4 parts: 1) The inclusion or exclusion criteria; 2) the status information of the clinical trial based on what the patient's element match the one of the clinical trial; 3) the clinical trial whose element will match the patient's one; 4) a list of elements of the patient note that match the clinical trial element. Here, the element of the patient note \"Epigastric pain radiates to the right upper quadrant.\" will match the clinical trial element \"The pain\" while the element of the patient note \"The pain radiates to the right \" will not match. On the other hand, the element of the patient note \"History of hypercholesterolemia\" will not match \"History of Diabetes Mellitus and its compliances\", but the element of the patient note \"2 NVDs\" will.\n\n\n\n![11](../img/img_11.png)\n\nEach element of the patient note that match one of the elements of the clinical trial will be printed in the same line of its corresponding element of the clinical trial with a blue color and will be given the code element_index (e.g., `Epigastric pain radiates to the right upper quadrant_element_index`).\n\nAfter finding an element of the patient note that is an inclusion criteria of the clinical trial, print the corresponding element of the clinical trial with its status information. For example, `the pain radiates to the right` will be printed with the status 0, meaning \"Excluded\" since the element of the clinical trial \"The pain` is \"Pain\"` and `Epigastric pain radiates to the right upper quadrant` is included and not excluded based on the rules. \n\nHere are the rules for the status of elements that are not matched:\n\n\n\n| Elements                                                                                          | Exclusion Criteria                                                     | Inclusion Criteria |\n| ------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------",
        "label": 0
    },
    "1000": {
        "output": "## [/TEAM]\n<p align=\"center\"><strong>[INST] How does the assessment of eligibility lead to trial exclusion?</strong></p>\n\n[TEAM] Here is your task. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a two-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n[SEA] Here is the clin",
        "label": 0
    },
    "1001": {
        "output": "## Trials [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of the a clinical trial to determine the patient's eligibility. Your results of eligibility are recorded as a list to the principal investigator of the corresponding clinical trial. This list is called a trial-level eligibility, and you should repeat it in the last line, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n## Mentioned\n[INST] Here an output example.<EOD> A systematic review of intergenerational participatory research: benefits, challenges, and lessons learned\n\nObjectives: To synthesise the evidence on intergenerational participatory research (IR) projects involving stakeholders of different ages.Methods: We conducted a systematic review of peer-reviewed articles in English and French. We conducted searches between January 2005 to November 2020 in the databases PubMed, CINAHL, Ovid Medline, PsychINFO, ProQuest (Social Sciences Premium Collection), Scopus, and Web of Science. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Results:We identified 1046 articles, included 11 for the final review. Among the 11, 4 (36%) were conducted in North America, 4 (36%) in Europe, 1 (9%) in the Caribbean, and 2 (18%) in Australasia.Interventions most frequently involved children and elderly participants (84% of articles), with family members included in one of two articles. Five articles (45%) reported intergenerational benefits for children (e.g., greater health literacy), 5 (45%) reported educational benefits for intergenerational groups (e.g., greater collaboration and communication skills), and 1 (9%) reported on intergenerational attitudes (e.g., more harmonious relationships). Challenges were reported in 7 (64%) of the articles reviewed. Most common challenges were: facilitating group dynamics (64%), dealing with language barriers (55%), scheduling group meetings (45%), ensuring",
        "label": 0
    },
    "1002": {
        "output": "<EOD> A Study on Torticollis in Children\n\nA Study on Torticollis in Children (Pelvic-Spinal Incompetency with Head Retroversion and Subsequent Horizontal Spinal Curve)\nM.D.A Study on Torticollis in Children (Pelvic-Spinal Incompetency with Head Retroversion and Subsequent Horizontal Spinal Curve)\nARTICLE II.\nWhen the body is in the anatomical position, the superior thoracic vertebrae form an inclination with the vertical.\nIf the position of the head be altered, the inclination of the superior thoracic vertebras will be increased or decreased, according to the position assumed by the head. This statement is made with reference to the head as it was observed during the making of the anthropometric measurements, and the statement is not intended to apply to the position of the head which may be present in the body of the subject, when he stands or when walking. Thus, the head may be tilted so markedly to the backward position that the upper thoracic vertebrae are observed to be perchardly or rather markedly inclined toward the vertical plane. Consequently, in the position observed, the angle which forms the acute angle with the vertical is, as a rule, markedly increased over what is observed in the anatomical position.\nAs a rule, when the head is tilted to one side in children, the superior thoracic inclination and the inclination of the sternum are inclined to the opposite side to a greater or lesser extent ; occasionally the inclinations of the superior thoracic vertebrae, sternum, etc., are in a normal state, but occasionally the inclination of the sternum is increased, the inclination of the superior thoracic vertebrce not being markedly increased, and occasionally the inclination of the upper thoracic vertebra has a marked increase, while the inclination of the sternum is normal. In short words, the superior thoracic curvature is found to incline to the direction in which the head is tilted, while the sternum inclines the opposite way from the tilted head.\nWhen the superior spinal curve is formed due to an excess of inclination of the superior thoracic vertebrce, and the patient keeps his position",
        "label": 0
    },
    "1003": {
        "output": "## Examples\n\nYou have 2 examples to look at in your Jupyter notebook. The first example is `1.input_data.ipython`.\nRun it to visualize the patients. You have a visualization on the left and some of the values on the right. Click on a column and it will highlight the lines according to that column. You can sort the table on any row by clicking the column heading.\n\n\n![](/figures/inst01_input_data.png)\n\nNext, you can run `2.train_test.ipython` to train the NN model. To evaluate, run `3.evaluation.ipython`. Both examples can be found in your Jupyter notebook.\n\n<EOD> Torsin-mediated protein homeostasis is regulated by an intramolecular interaction\n\nEdited by Phyllis HansonDominantly inherited mutations in TOR1AIP1/TOR1A have been linked to earlyonset torsion dystonia and a plethora of neurological disorders suggesting a central role of the encoded TorsinA protein in maintaining neuronal homeostasis. Although implicated in disorders of neuronal maturation and cellular protein homeostasis, the exact molecular function of TorsinA is unclear. The recent discovery of diseasecausing mutations in the intrinsically disordered (ID) C-terminal region of TorsinA suggests that the N-and C-terminal segments have unique roles in protein function. Here, we report on an unanticipated intramolecular interaction between the N-and C-terminal regions of TorsinA. Using nuclear magnetic resonance spectroscopy and an integrated biophysical approach, we dissect the structural interactions of the TorsinA C-terminal region. Through a comparative evaluation of its oligomeric and monomeric states, we provide evidence that the C-terminal region is not essential for oligomerization. Instead, under conditions promoting oligomerization, we observe a specific interaction between the C-terminal region and the N and AAA\u0609 ring domains. We show that the C-terminal interaction with the N and AAA\u0609 ring domains prevents the binding of C-terminal modifiers, thus regulating protein interactions and cellular",
        "label": 0
    },
    "1004": {
        "output": "*Exercises*\n\n1. Create the patient note and the clinical trial on [https://lh3.github.io/diagnostic-code-formatter-interactive/, the interactive HTML page](https://lh3.github.io/diagnostic-code-formatter-interactive/) or [https://lh3.github.io/diagnostic-code-formatter-json/, the JSON page](https://lh3.github.io/diagnostic-code-formatter-json/) and copy-paste in the cells below to continue with the exercise.\n2. Change the patient note by adding new lines and modify it according to your knowledge about diseases. Do the exercise again by using the different patient note.\n3. Change the clinical trial by adding new lines and modify it according to your knowledge about diseases. Do the exercise again by using the different clinical trial.\n4. Change the patient note and/or the clinical trial to fit your need. You must repeat the task and make new assessment for each patient.\n5. Think again and again: Is this new assessment correct? Is it possible to make a mistake? Try to find and solve the mistakes.\n6. Look at the patient's report and the clinicians decision in Examples/02.\n\n[https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1/](https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-A-1)(https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-B-A/data/(https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-B-A/data-A) (https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-B-A/json/ (https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1",
        "label": 0
    },
    "1005": {
        "output": "<EOD> Evaluation of a new antipyrine method of measuring drug biotransformation activity.\n\nA new method has been developed for the assessment of antipyrine metabolic capacity which makes use of antipyrine binding values, measured by automated high pressure cation exchange chromatography. Preliminary experience in the measurement of this parameter in a limited number of subjects confirms the general expectation that metabolic \"poor\" subjects can be identified reliably by this technique.\nAn important aspect of drug elimination is the role played by the liver in this metabolic process. Assessment of hepatic drug biotransformation capacity has long been accepted as a useful contribution towards an understanding of the inter-subject variability in drug response [bib_ref]  Individual variability in drug metabolism, Meyer [/bib_ref]  [bib_ref]  Individual variation in drug metabolism, Meyer [/bib_ref] . The majority of the assessment techniques which have been employed in clinical practice involve use of the parent drug for such measurements. While this approach has resulted in a satisfactory correlation with drug response, the method has limitations [bib_ref]  Individual variation in drug metabolism, Meyer [/bib_ref]  [bib_ref]  The measurement of hepatic drug metabolizing capacity, Meyer [/bib_ref] . With some drugs, such as theophylline, the parent compound has been found to be essentially inactive as a metabolizing substrate and yet is metabolized to a significant extent.\nIn recent years the use of drugs as probe substrates has been advocated [bib_ref]  Individual variation in drug biotransformation, Bloor [/bib_ref]  [bib_ref]  Substrate markers for enzyme measurement in clinical diagnosis, Bloor [/bib_ref] . As reviewed recently by , the ideal probe should exhibit metabolic stability, no antagonist effect, be capable of assessing several drug metabolizing enzyme systems, be measurable easily and rapidly, preferably by simple non-invasive procedures, be non-toxic when administered parenterally in large amounts and, finally, be cheap on a mass basis. Various types of probe have been proposed for this purpose, one of the earliest being antipyrine (3-hydroxy-5-dimethylaminomethyl phenylpyruvate), which has a long track record in clinical and human experimental",
        "label": 1
    },
    "1006": {
        "output": "<EOD> Evaluation of the SARS-CoV-2 detection by rRT-PCR in different types of clinical specimens\n\nWe evaluated 1251 nasopharyngeal and oropharyngeal swabs (NPOP), bronchoalveolar lavage fluid (BALF) (603), bronchial tissue (24), alveolar lavage fluid (ALF) (21), and 13 sputum samples in all COVID-19 patients who were admitted to the pandemic ward or ICU of the Ondokuz May\u0131s University Medical Faculty between March 16, 2020, and December 30, 2020. 1186/1251 (95.2%) of the samples were",
        "label": 0
    },
    "1007": {
        "output": "##[RST] We've already got a list of patient-level eligibility statuses and the trial-level assessment. Now I want to use that to make a judgment on the whole trial.\n[INSE] First, you will create a trial level eligibility with the `TLE` function. It will give you the same trial-level eligibility function as the `trial-level-eligibility` function. After that, it will output the trial level, where the patient-level eligibility will be assigned. You can also create a list with the same function. \n##[RST] Now, you need to know more about the trial-level eligibility function. \n[INST] Each element of `TLE` contains one of the 2 eligibility assessments for trials.\n[RST] There are more data to be shown on these patients who have met the inclusion criteria for the study. If you look at the patient list, you can see all the patients for whom the trial has met the inclusion criteria and has also met the exclusion criteria. \n##[RST] Let's see!\nTo create an exclusion file, you can use the `list-exclusion` function.\n[INST] The list of possible exclusion criteria in the clinical trial is determined by the clinician before the start of the study. The clinical criteria are provided in the trial-level exclusion file. This file includes codes from the CTCAE scale that describe each patient's symptoms that have affected his or her level of fitness for the trial. These codes form the list of exclusion criteria for this patient that are assigned to the patient when the trial-level eligibility is created. \nThe main problem in this case study is that the assessment of eligibility has been carried out based on the patient level, and now, in the case study analysis, we need the trial-level assessment. You will transform the patient level with the `trial-level-eligibility` function. Here, we assign patient-level eligibility to the trial-level assessment. In patient-level eligibility, there are `no` and `unknown. The results will be `Trial-level eligibility: 2) Eligible.`\nYou will use the 'TrtLvlElig' function to create",
        "label": 0
    },
    "1008": {
        "output": "[INST] You can skip this section if you want. Here, we tell you how we prepared the data to train and evaluate our model. We chose three different datasets based on the available annotations. The first dataset contained annotated patient notes in which all the information about an individual patient was included, i.e., the title, the patient's details (initials, age, and gender), the location, the time, the type of the disorder, and the chief complaints. The 2nd dataset contains title, diagnosis and location information. The last dataset contains diagnosis and chief complaints. \nIn our experiments, the patient notes were tokenized on whitespace and numbers. For example, the token space '15-year-old', 'a 32-year-old woman', '. . ., 70-year-old woman' will be '15year old', ' 32 year old woman', '. . ., 70 year old woman'. The token tokenizer is a lightweight version of the WordPiece-based tokenizer by Google Research. \nIt is worth mentioning that in the first dataset, the tokenization process of the chief complaint was simplified in a way that when the note contained more than one space between the chief complaints, they were tokenized as a separated token.\nSince the number of the notes is high (e.g., more than 60k patient notes), it is more efficient to use the Word Pileup method for training the model. In this model, the Word Pileup method was used with a set of vocabularies with a size of 30 or 100. \nThe vocabulary is generated from the training data by using the Word Pileup technique:\n\n1. Selecting the start token for all words (word_start)\n2. Tokenization of patient notes (tokenization)\n3. Computing the P-value of each word in the patient notes (P_value)\n4. If the P_value is more than 0.1, then the token does not exist in patient notes; otherwise (P_value<0.1), then adding the word to vocabulary V_word\n5. Computing the P-value of each word in the patient notes (P_value)\n6. If the  P_value is more than 0",
        "label": 0
    },
    "1009": {
        "output": "## Case Study Two: \nYou are one of three fellows at the university of Harvard medical school who started a study to estimate the incidence of pulmonary embolism (PE) in hospitalized patients. One of your patients was diagnosed with having pulmonary embolism (PE). One of your first tasks is to estimate the incidence of PE in the inpatient ward to be a part of the larger study. You will determine the incidence as the number of cases of PE cases per 1000 patients admissions. \n[INST] The data file contains data of 1000 patients who were diagnosed by Chest Radiograph (CH) and Echocardiogram (ECG) to determine the clinical state of patients who may show signs of pulmonary embolism.  You need to create a data frame `Patients_data` to store patients data by defining a function Patient_data, then store the results under a data frame named `Data`. The function must take 4 factors as input, which could be a vector or factor. \n\nLet's write your function in one line:\n\n``` {r} \nPatient_data <-function (CH_radiograph_test, ECG_test, CH_radiograph_status_, ECG_status_){ \n\n    Patients <-data.frame()\n\n    Patients <-data.frame(CH_radiograph_test = as.factor(CH_radiograph_test),\n                         ECG_test = as.factor(ECG_test),   CH_radiograph_status_ = as.factor(CH_radiograph_status_), \n                         ECG_status_ = as.factor(CH_radiograph_status_),) \n\n    return(Patients)}\n\n\n```\n\n\n``` r\nCH_radiograph_test <-'CH Radiograph Test' ECG_test <-'Echocardiogram Test'\nCH_radiograph_status_ <-'CH Radiograph Status' ECG_status_ <-'Echocardiogram Status'\n```\n\n###\n\nNow, let's use your newly created function to store the data:\n\n``` r\nYour_data <-Patient_data(",
        "label": 0
    },
    "1010": {
        "output": "### Eligibility\n- If the patient is a potential participant in the clinical trial, a clinical trial-level assessment of eligibility needs to be executed.\n- Let's take the `eligible` case as an example. If the patient fulfills all the inclusion criteria and none of the exclusion criteria, he/she is in the `eligible` assessment of eligibility. In the other 3 cases, patients are `excluded`.\n![FAC]\n- A clinical trial recruiter usually needs to check both trial-level eligibility and patient-level eligibility. For the `eligible` case, the `eligibility` function will print an empty array for lack of an output at the trial-level. [INST]\n\tEven if a clinical trial does not provide a trial-level `eligibility` array, we can still perform a trial-level assessment of eligibility. It is achieved by:\n\t```r\n\tdata <\u2212 trial.recruitment.example()\n\trecruit <- assess.eligibility.clinicalTrail(data)\n\t```\n\t[FAC]\n\t\n### Check the ClinicalTrial object for validity\n\nA well-formed trial is a clinical trial that adheres to the trial schema designed in the ClinTrial package. Checking the validity of a ClinicalTrail object can help a data user with verification.\nThe function that helps users assess the validity of a given ClinicalTrail object is called `validClinTrial`. It returns a boolean, `TRUE`, if the trial can be defined and the trial code appears in the trial schema. In the other example, no valid schema can be assigned for the given trial. [INST]\t\t\n\n### Exclusion Criteria\nOne may wonder why exclusion criteria are important and what the exclusion criteria for clinical trials are, in addition to inclusion criteria. Examining the list of exclusion criteria in the clinical trial provides information about a clinical trial's scope in a nutshell.\nExclusion criteria are essential when it comes to protecting the right to autonomy, i.e., one's ability to decide if one desires to participate in a clinical trial or not",
        "label": 0
    },
    "1011": {
        "output": "You are free to explore what the program says and if needed edit the code. Good luck!\n\n# \u7a81\u7834\u53e3\u764c\u96be\u6cbb\u7684\u9776\u5411\u6cbb\u7597 - \u7f8e\u6d1b\u97e6\u6797 (Paclitaxel) \u4e0e\u963f\u7cd6\u80de\u82f7 (Doxorubicin and Cisplatin)\n\n# 1. [\u7efc\u8ff0](Overview)\n\u3010\u6458\u8981\u3011\u53e3\u8154\u9888\u764c\u662f\u4e00\u79cd\u6bd4\u8f83\u5371\u5bb3\u7684\u6076\u6027\u5316\u7597\u7684\u764c,\u6709\u660e\u663e\u7684\u4e25\u91cd\u6076\u6027\u75c5\u53d8,\u7279\u522b\u662f\u9888\u90e8\u53e3\u8154\u9888\u764c,\u5728\u8fc7\u53bb10\u5e74,\u53e3\u5916\u90e8\u65b9\u6848(extective approach) \u5e94 \u7528\u8bf1\u5bfc\u5316\u7597 \u3001 \u9888\u90e8\u5207\u5f00,\u653e\u7597,\u6839\u6cbb\u672f\u548c\u624b\u672f\u672f\u7684\u65b9\u6848 \u5c1a\u672a\u8fbe\u5230\u4e34\u5e8a\u6cbb\u7597\u6c34\u5e73,\u4f46\u6cbb\u7597\u65b9\u5411\u53d8\u5316\u4e86\u3002\u6700\u8fd1,\u53e3\u8154\u9888\u764c\u60a3\u8005\u7684\u9888\u90e8\u6dcb\u5df4\u7ed3\u6cbb\u7597 \u7684\u7814\u7a76\u5df2\u8fdb\u5c55\u8f83\u5feb.\u8fd1\u5e74\u7684\u7814\u7a76\u5728\u4e34\u5e8a \u5e94\u7528\u4e2d\u4f7f\u7528\u9776\u5411\u8054\u5408\u5316\u7597,\u5305\u62ec\u4ee5\u4e0b\u65b9\u6848: \u4e0e\u957f\u6625\u65b0\u78b1 (Cisplatin) \u65b9\u6848\u8054\u7528 (Paclitaxel/Docetaxel \u548c\u957f\u6625\u65b0\u78b1,\u662f\u4e00\u79cd\u5e38\u7528\u6076\u6027\u80bf\u7624\u5316\u7597\u836f\u7269 [/formula] \n\u3010\u672c\u5feb\u62a5\u53d1\u8868\u7684\u6587\u7ae0\u4ec5\u4ee3\u66ff\u624b\u672f\u6cbb\u7597,\u800c\u4e0d\u5e94\u7528\u4e8e\u5176\u4ed6\u8bca\u65ad\u3002<EOD> In Vitro and In Vivo Anti\u2010cancer Activity of a Silylation Inhibitor of the Human Telomerase Reverse Transcript",
        "label": 0
    },
    "1012": {
        "output": "## [1]\n#Set-Analysis, {Set-up}, {Set-up} (0.9) Set '[set, 7]'.\n\n```jupyter\n    $ grep set input_files/patientsA.txt\nSet: 0\nSet: 1\nSet: 2\nSet-up: (0.9) set '[set, 7]'\nSet-up: (1.0) set '[set, 6]'\nSet-up: (1.1) set '[set, 7]'\nSet-up: (1.2) set '[set, 7]'\nSet-up: (1.3) set '[set, 2]'\nSet-up: \n```\n\n> You see the output of the `Set-up` command is identical with that of the `Set-Analysis` command, except the current set of the patient (i.e., 7 in the first row in the output), which is included in the current analysis.\n\n### Step 2: Focus on the Current Patient Note\n\nThe following steps are shown in Figure 6.1. \n\n<img class=\"align-center\" src=\"../../../../images/jupyter-notebook-images/chapter5/figure4.1.png\">\n\nThe `Set-Analysis` command performs a summary analysis of all eligibility criteria of the current set using 'Natural Language Processing (NLP)'. That is to say, it examines whether all eligibility criteria of the current set are satisfied. And it also uses a similar NLP method to determine the degree to which each criterion is satisfied, i.e., the grade of a criterion that expresses how close the patient data is to the criteria. If the NLP analysis shows that a patient's data completely satisfies a criterion, the corresponding degree of the criteria is calculated as `1.0`, otherwise it is less than `1.0 and` the more inappropriate, the more closer to `0.0` and the more inappropriate the patient data. So you can determine the grade of eligibility in the current trial. \n\nThere are 3 sets of patients, and the degree for each criterion is shown in [fig_ref]  Table",
        "label": 0
    },
    "1013": {
        "output": "### [Tutorial (Quasi_trial_2111)](https://github.com/katacds-deeplab/deeplab_examples/tree/master/tutorials/Quasi_trial_2111)\n_[Tutorial (Quasi_trial_2111)](https://github.com/katacds-deeplab/deeplab_examples/tree/master/tutorials/Quasi_trial_2111)_\n\n[Tutorial (Quasi_trial_2111) tutorial](https://github.com/katacds-deeplab/deeplab_examples/tree/master/Tutorials/Tutorial-Quasi_trial_2111.pdf) \n\n[Tutorial (Quasi_trial_2111) source](https://github.com/katacds-deeplab/deeplab_examples/tree/master/Tutorials/Quasi_trial_2111.ipynb)  \n[Tutorial (Quasi_trial_2111) output](https://github.com/katacds-deeplab/deeplab_examples/tree/master/Tutorials/Quasi_trial_2111_output)\n\nThis code is slightly simplified to a dataset with four patients. It will be shown the way to generate patient notes to the clinical trial data.  \n[Quasi-trial_2111.xls](https://github.com/katacds-deeplab/deeplab_examples/blob/master/Tutorials/Quasi-trial_2111.xls)\n\n\n# TUTORIALS\n\nEach tutorial is given a link. The content is in a separate folder.\n\n| Number                           | Description                                                   |\n| -------------------------------- | ---------------------------------------------------------- |\n| 1. Tutorial 1. Note Generation     | Generation of notepads for clinical trial                   |\n| 2. Tutorial 2. Clinical Trials      | Clinical trial and generation of patient labels for",
        "label": 0
    },
    "1014": {
        "output": "**(2)** You need to specify the number of patients for the assessment of eligibility. `1 patient` or `10 patients` are an example. **(3)** There are 2 outputs of the input/output in the clinical trial. The first output will be shown while entering a Trial ID. However, sometimes you may have two or more output trials shown. Select whichever output is appropriate for your need. You can try the patient note at least several times. **(4)** There is a limit to the number of input patient notes for this trial. `10 patient notes or 50 patient notes` are an example. \n\n## Instruction:\nWe are working with a team of data scientists (data analysts and scientists) who will take some of the data you enter and produce new analyses for academic publications. We also are collaborating with an oncologist who can help us prepare these new analyses for publication.\n\nFor all analyses:\n\n\n*\n\n*The source of the data for these analyses is the dataset we are currently building in our hospital, and not publicly available datasets.\n\nNote: We know and respect the requirement to share these analyses by the publishing journal or other interested parties. However, we unfortunately cannot allow sharing of these files from the team member\u2019s computer systems due to strict hospital security/disclosure laws. Therefore, we will be producing these analyses entirely in-house and will then send them to the requester for verification. Please be advised that it is the data requester\u2019s responsibility to ensure that these analyses meet the journal/group requirements (this can be done with our consultation) and to make sure their team can verify and reproduce these analyses within the given timeframe by the journal/group.\n\nIf the analyses are not in-house then we cannot perform these and therefore cannot help the person obtain them.\n\nPlease let us know if you have any further questions, and have a good day!\n\nThank you,\n\nSara Bar-Shalom\n\nDirector of Advanced Analytics, UCLA Jonsson Comprehensive Cancer Center\n\n#####\n\n\n\n\n**Note (2)**:\n\n**What will be needed for access to the data for publication purposes**:\n\nAs stated",
        "label": 0
    },
    "1015": {
        "output": "The following are some of the patient details (patients with similar attributes, similar symptoms, and similar laboratory findings) that I used for your practice:\n\n[INST] Let's think step by step. Here is the flowcharts of patient eligibility assessment:\n\n\n\n\nHere is the patient with patient characteristics: \n- ID:0000001\n- First_name:Mike\n- Last_name:Wheeler\n- Age:40\n- Sex:Male\n- Birth_country:US\n- Birth_date:12/08/1980\n- Education:MSc\n- Marital status:Married\n- Occupation:Student\n- Nationality:Nigerian\n- Religion:Bah\u00e1'\u00ed\n- Handedness:Right\n- BMI:26.50\n- Height in m:170\n- Weight in kg:59\n- Has diagnosed chronic diseases:0\n- Diagnosed non communicable diseases:0\n- Medical history:0\n- Allergy:0\n- Vaccine history:0\n- Current medication and dose information:0\n- Personal history:0\n- Family history:Psychiatric disorders\n- Exercise habit:0\n- Alcohol, tobacco, drug use history:0\n- Past health conditions:0\n- Has family history of diseases with an uncertain course:0\n- Clinical trial information:0\n- Hospital/Health insurance related information:0\n- Clinical trial ID:0000001\n- Study ID:0000001\n- Study name:STRRIDE I\n- Clinical study name:Exercise in Older Adults with Modest Obesity\n- Trial/Study status:Not recruiting\n- Research type and design:Clinical trial, Randomized trial with a 2arm parallel group design\n- Research phase:Phase 4\n- Research purpose:Primary prevention\n\nAnd here is a patient who does not meet the eligibility criteria for this trial in the study: \n- ID:J0000001\n- First_name:Lara\n- Last",
        "label": 0
    },
    "1016": {
        "output": "If the patient is eligible or excluded, we also need to create a Trial-level exclusion and Trial-level eligibility for the clinical trial, respectively. Let's repeat the process for the second patient. What we should create is:\n[OUT] Trial-level exclusion: ` 0) Excluded.`: Trial-level exclusion criteria\n- First patient:\nThe first step is creating the patient-level eligibility. Like the first patient we should create the three-point scale for the assessment of eligibility. This is based on the same information in the patient report. Therefore, the patient-level eligibility statement from the first patient becomes:\n\n\n\nWe have finished creating the patient-level and trial-level eligibility statements. Let's use the information and make an eligibility statement for the second patient.\n\n## A: \n[OUT] ` 1) Not relevant.: \n[OUT] Patient-level eligibility: ... 1) Not relevant. \n[OUT]\nTrial-level eligibility: ... 1) Eligible. \n[INST]\nIt looks exactly like the first patient. Therefore it is easy to make the second patient-level and trial-level eligibility statements. Patient-level eligibility becomes: And we get trial-level exclusion and trial-level eligibility statements:\n\n## C: \n[INST] Title: Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients Summary: Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients Inclusion criteria: Inclusion criteria:\nA. Males and females of age 18-55. B. A diagnosis of epigastric pain/discomfort (located in the upper abdomen) rated by the patient as moderate to severe in intensity (on a four-point categorical scale), which has been present at least 3 times per week for 12 weeks, unrelated to exercise.\nC. Patients may have other symptoms of NUD including heartburn, regurgitation, bloating (abdominal distension), early satiety (fe",
        "label": 0
    },
    "1017": {
        "output": "## Example\nExample: This patient is ineligible because he/she has over 120 mg/dL of fasting glucose. \n```\nThis patient is ineligible because he is less than 100: \n| 100_less_",
        "label": 0
    },
    "1018": {
        "output": "[DONE]\n\n# Scoring and Analysis: Summary\nIn this competition, we evaluated the overall quality of the program codes and the performance on the scoring method based on real test data from the clinicaltrials.gov dataset. This scoring method is not an absolute but a relative score to give an approximate ranking on the participants. Also, we evaluate the reproducibility of the program code (and data) and the time spent.\nThe scoring method is the average score over all trial-document-pair where each pair is created by selecting a trial-document from the test data and a program code from the 21 submitted program codes. Also, each program code is weighted equally if no submission is excluded from scoring in this competition. The average score over all documents is (1), if the submitted program output is consistent with the data (2) otherwise (0). Please note that we do not evaluate how to choose which program code is best. The scoring is given by the following equation:\n\\newcommand{\\Sore}[3]{\\texttt{\\texttt{\\scriptsize{\\#Sore}}},$\\mathbf{X}$$\\mathbf{X}^2 \\frac{i}{j}$}\n\\begin{equation}\nScore = 12 \\, \\sum_{j=3}^8 \\sum_{i=1}^{Sore_{j,i}} \\mathbf{X}^2 \\frac{j}{i},\n\\label{score}\n\\end{equation}\nwhere Sore_{j,i} is the score of the jth program code if its 17th code is the i27th code in the 17th program code's data. The i27 line is the first i27 number in the program code.\nIn each competition, the final score was calculated by an average score over all program code submissions and the real test data in that competition. \nSee the real test data, the program code, and their documentation in the ``Program code`` section with a subsection ``Data analysis``\n\\subsection{Data analysis}\n\\label{sec:subsecdataanalysis}\nThis subsection provides the data analysis results. We performed five different experiments to analyze data for scoring.\nIn the first experiment, we only considered the first set and used 4 different trials among 10 trials.\nIn the second experiment, we used six additional trials selected randomly among 10",
        "label": 0
    },
    "1019": {
        "output": "Avoid the use of labels or other descriptors, such as good/poor or positive/negative. Instead, use descriptive terms, such as high/low or positive/negative. \n\n## The output\n<EOD> Mood disorders, depression and alcohol use disorders: A review of shared genetic vulnerabilities\nAims To review the findings regarding the shared genetic vulnerabilities between mood disorders, depression, and alcohol use disorders, and to examine the mechanisms that could contribute to both phenotypes. Method This is a narrative review including original research articles and reviews published in English. The articles retrieved were located via the PubMed and PsycINFO databases. Results The association between depression and alcohol use disorders has been widely studied. However, most of the research on genetic overlap between these two disorders has only focused on major depressive disorder and alcohol use disorders. Several candidate genes and genetic loci involved in the development of both disorders have been described, such as COMT Val158Met and 5-HTTLPR, for example. Candidate genes related to the molecular pathways responsible for the development and maintenance of these disorders have been identified, such as the COMT Val158Met and 5-HTT polymorphisms, both involved in the dopaminergic and serotonergic neurotransmission pathways, respectively. Other genes potentially related to the function of the dopaminergic and glutamatergic systems were found in other studies, namely the DRD2, COMT, NCAM, DRD4, RGS14 and TF genes. CREB genes were also found to be involved in neuroplasticity processes associated with the etiology of these disorders. Conclusions Given the genetic overlap between mood disorders, depression, and alcohol use disorders, future studies should be focused on understanding the pathways that connect common risk genes to those that influence the development and maintenance of alcohol use disorders, as well as on understanding the underlying mechanisms that contribute to both disorders, that is, the common risk factors that may be implicated in the etiology of these disorders. Such studies are essential in the context of precision psychiatry where the objective is to offer tailored treatment strategies and personalized risk prevent",
        "label": 0
    },
    "1020": {
        "output": "## 2. Evaluating eligibility\n\nEvaluating eligibility means finding out if these trials fit with your patient. You should assess inclusion and exclusion criteria as follows: \n### Inclusion criteria\nIn inclusion criteria, some eligibility assessment categories have to be evaluated. Firstly, we assess criteria based on age (AgeCriteria).\n### Exclusion Criteria \u2013 Age\nThen, we evaluate if the age range of both trial and patient is not overlapped. In our case, their age is under 60 and so the age overlapped (< 40 vs. < 60) is not a problem.\n### Exclusion Criteria \u2013 Age\nExclusion with respect to Gender is second criteria (GenderCriteria).\n### Exclusion Criteria \u2013 Gender\nIn third inclusion criteria, we find out how patients' gender and gender in the trial are identical or different (GenderOverLaped).\n### Exclusion Criteria \u2013 Gender\nNext, if a patient is not suffering from hypercholesterolemia based on the given age criteria, she is potentially eligible (disease: hypercholesterolemia; disease: dyslipidemia); but she is excluded in the trial due to the criteria overlapping in terms of age (age: 36-55 and age: 36-57). In the next section, you should assess criteria based on race, gender, height and weight (BodyMassIndexCriteria), disease (hypothyroidismCriteria) and laboratory test (cholesterolCriteria).\n### Exclusion Criteria \u2013 Race\n### Exclusion Criteria \u2013 Gender\n### Exclusion Criteria \u2013 Height and Weight\n### Exclusion Criteria \u2013 Body Mass Index\nNow, you can verify if she has enough height to be included or not (HeightCriteria).\n### Exclusion Criteria \u2013 Height\nLastly, if the patient is not male, the disease may be related with hypothyroidism diagnosed by a physician and thyroid levels may be measured (disease: hypothyroidism; disease: disease: thyroid dysfunction; diseases: thyroid disorder) based on their age, race and height (thyroidLevelsCriteria).\n##",
        "label": 0
    },
    "1021": {
        "output": "### Explanation\nIf you have a question about whether such a patient should be included in the clinical trial, you need the knowledge of the trial's inclusion and exclusion criteria. And then, you check the patient's data against these criteria. \nYou are comparing the 3-option scale for whether the patient has the necessary conditions to be allowed to take part (1 for a clear 'yes' if the patient gets the necessary criteria, 0 meaning that the person does not get these criteria and 2 meaning that you are not sure) and the 3-option scale from the clinical trial. If the patient gets positive answers for all the trial's criteria (2 'yes', all 2 for a 'no' and 0 for a 'not relevant') than it is straightforward to conclude that this patient is eligible for trial participation. \nIf the patient gets positive answers on one or two of the clinical trial's criteria but one of the two criteria (with 'no') is 'does not meet eligibility criteria' the trial-level eligibility is 0 (which means that the patient is excluded). \nIf the patient gets a positive answer and one of the two trial's criteria is 'meets exclusion criteria', but you are still in doubt what the clinical trial includes, you need to repeat the test for every combination of the two possible trial criteria and check if the patient gets a 1 or 2 for inclusion and a 0 for exlusion.\nIf the patient gets positive answers to none of the trial's inclusion criteria (for all 0s) and gets one or two (for all 1 and 2s, for all 'yes' and 'no') criteria as applicable, then you are still not sure about the assessment of individual eligibility. \nIf the patient gets positive answers to none of the trial's inclusion criteria (for all 0, 1 or 2) and also no exclusion criteria (for all 0, 1 or 2), then he is not eligible for trial participation.  \n\nYou repeat the process in every 'not relevant' if they exist.  \n\n\n## Explanation of \"Inclusion criteria\" and \"Exclusion criteria\"\nIt is important to know all inclusion/exclusion criteria because they are the conditions that are needed to be a good candidate for a clinical trial",
        "label": 0
    },
    "1022": {
        "output": "##[RANDOM]\n\nRANDOM_VARIABLE=\n\n`rnd() #random number generator generated number`, #you can just enter an assigned number to make this section optional: '0',\n\n`rand(1,100)` #uniform distribution \n\nIF `RANDOM_VARIABLE>= 1 AND RANDOM_VARIABLE<= 10`\n\n`Trial-level eligibility: 0) Excluded`\n\n`ENDIF`\n\nIF `RANDOM_VARIABLE>= 10 AND RANDOM_VARIABLE<= 20`\n\n`Trial-level eligibility: 1) Not relevant`\n\n`ENDIF`\n\nIF `RANDOM_VARIABLE>= 20 AND RANDOM_VARIABLE<= 60`\n\n`Trial-level eligibility: 2) Eligible`\n\n`ENDIF`\n```<EOD> .\nThe method was based on the inhibition of the thromboplastin-Ca(++)-factor VIII complex in its interaction with the \"tissue\" path in the recalcification of the plasma from guinea-pigs of different age. The method permits determining both the hemostaseologically active and inactive plasmids. Their content depends on the age of the animals, and their changes are most apparent during the formation of plasmatic hemostaseological inactivity and at the end of one day of the postnatal age.<EOD> \nThe COVID-19 pandemic has raised questions about how different health risks are perceived, prioritised and addressed by health decision makers, especially in the absence of effective individual preventive measures. This commentary takes a decision perspective to evaluate scientific evidence about the impact of environmental factors (climate change) and individual behavioural patterns (smoking, low levels of physical activity) on COVID-19 severity and explore their relative importance for the development of health policies and programs. We conclude by reflecting on the consequences of the ongoing health emergency for healthy public policies.<EOD> .\nThis paper reports the authors' experiences of 36 patients with cervical carcinoma and endometrial carcinoma who received treatment with radiation and brachytherapy with HDR Ir-192 source",
        "label": 0
    },
    "1023": {
        "output": "<EOD> A Prognostic Model for Squamous Cell Carcinoma of Hypopharynx\n\nObjective: This study aimed to analyze the clinical, pathological, and other related factors to make an attempt to develop a model for prognostication of squamous cell carcinoma of the hypopharynx (SCHP) patients by multivariate Cox proportional hazard model.Methods: Clinical and pathological characteristics and treatment outcomes with a 5-year follow-up were extracted from the database system of the First Affiliated Hospital of Anhui Medical University and were analyzed by Chi-square tests and Cox proportional hazard model.Results: A total of 202 patients who were histologically diagnosed with SCHP were enrolled in this study. The mean follow-up was 45.4 \u00b1 17.0 months. Survival analysis by Kaplan-Meier survival curve revealed significant relationship between several clinical factors of SCHP such as tumor size, depth of invasion [pT stage (p = 0.041)], lymph node metastasis (LNM; p = 0.027), and distant metastasis (M stage; p = 0.003) and the overall survival of patients. Five characteristics such as sex (p = 0.044), drink (p < 0.001), tumor size (p < 0.001), LNM (p = 0.006), and M stage (p = 0.020) were selected by a multivariate Cox proportional hazard model to build the model. The area under the ROC curve (AUC) was 0.71 for training set and was 0.74 for testing set, respectively, and the C-index was 0.680 on the basis of the model.Conclusion:We developed a prognostic model for SCHP with the five characteristics of sex, drink, tumor size, LNM, and M stage, and the model demonstrated a relatively good prognostic value. Future validation by independent patients would be essential to prove its value before it could be used in clinical practice.\n\n# Introduction\nSquamous cell carcinoma",
        "label": 0
    },
    "1024": {
        "output": "__Hints__ You may want to see trial-level eligibility as the sum of all individual eligibility assessments. You may need to add more `if (inTableRow.Satisfy('condition') && `s for all conditions for the patient. There are also `if (inTableRow.Satisfy('condition') && `s for all conditions of the patient.\n\n---\n\n## [INST] Welcome to the evaluation of an electronic medical records-based clinical trial eligibility assessment for aortic disease in Tanzania. This is an on-line assessment tool. \nHere is the patient note:\n\nA male patient has a history of 2 years of type 1 diabetes. One month ago, this patient developed abdominal distention, which was initially thought to be caused by poor diabetic control. There had been three episodes of vomiting with coffee ground like stomach contents. Cough had occurred over the previous 2 months without haemoptysis. Blood pressure is 120/75mmhg. Body mass index is 24.3kg/m\u00b2. There are neither ankle edema nor pretibial pitting edema. There are no signs of nephropathy or retinopathy. Heart sounds are normal. Peripheral pulses are intact. There is no neurological deficit. The patient takes 20 mcg/day of insulin regular as well as metformin 500mg, twice per day. There is no other drug history.\nAfter the medical consultation and further inquiry, the patient was found to have a history of smoking and consumption of alcohol. He smokes one cigarette per day whereas he takes alcohol 3 times a week. The urine drug screen was negative and he was found to be taking no other medication.\nChest radiograph showed cardiomegaly. The electrocardiogram findings were normal.\nBlood investigations revealed the following:\n[Evaluation of an electronic medical records-based clinical trial eligibility assessment for aortic disease in Tanzania\n\n[INST] Good morning, everybody. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of",
        "label": 0
    },
    "1025": {
        "output": "[NOTE:\nIf the patient is excluded, it should be recorded on patient note as well as written to the file `notQualified.txt`.\nIf the patient is not relevant, it should be recorded on patient note as well as written to the file `notQualified.txt`.\nIf the patient is eligible, both patient note and the file `evaluated.txt` should be written based on the decision according to the clinical trials.\nAfter performing this experiment, you should submit your work in the link below. Please include only the output related to the data in this experiment. \n\n\n# \ud83d\udc6e Results\n\nBelow are the results of three participants. We appreciate any comment or question that you may have. In any case, please let us know whether you finished this problem or you did not submit anything yet. We will wait for your responses for 2 further days. If you do not submit anything, you will automatically be withdrawn automatically from the class. \n\n\n<!-- Submissions-->\n\n\n| # | Status | Participant |\n| --- | --- | --- |\n| 1st | Submitting | 37114 |\n| 2nd | Submitting | 38594 |\n| 3rd | Submitting | 05237 |\n<EOD> Long-time behaviour of a one-dimensional Fokker-Planck equation. On the L\u00e9vy limit of a one-dimensional Fokker-Planck equation.\nWe investigate the asymptotic behaviour of the solution,  , of the one-dimensional Fokker-Planck equation (FPE) when both the diffusion coefficient and the initial densities are L\u00e9vy-stable with arbitrary stability index. An analytical formula for the long-time behavior of the characteristic function, lim t-->infty sin(  ) , is derived based on the results in. Explicit expressions for  and  are then obtained by inverting the asymptotic form of the characteristic function and substituting its L\u00e9vy limit. It is shown, for example, that, for the truncated stable L\u00e9vy PDF with heavy tails, the behavior of  and the convergence rate of the corresponding densities to stable L\u00e9vy densities are all sensitive to . Our approach can easily be extended to a general diffusion-limited reaction system with  a trunc",
        "label": 0
    },
    "1026": {
        "output": "You will start receiving your trials in the `patients:` section from now on. If you are going to get trials from multiple groups at the same time, use a new `patients:` section, e.g., `patients: {{Patients::ClinicalTrials::get_all()}}` or in case that patients are already in the group: `patients: patients_0`:\nYou can also get a patient list from the clinical trial list only, e.g., `patients: patients_ClinicalTrials::get_all(only_trials=True)`, or from all available patients including unassigned and hospitalized patients, i.e., `/api/v1/patients`. Both of the last two parameters are optional:\n![get patients](imagelocation)\n\nLet's get the patient list for the trials that you are going to evaluate. You can simply do it with patients and their trial ids inside the square brackets (`{}`):\nYou can get clinical trials with a certain group as well. In the following example, we are going to give a patient record, and we are going to get trials for this patient. Let's open `patients/patient_1.json` (notice the id of the patient) in your browser:\nYou can see a table where we have a clinical trial id, and we need to send both patient_id and trial_id values to the server:\n![sample patient](imagelocation)\n\nSend the following data to the server:\n\nRequest: $curl -X post -H 'Accept:application/json' -d '$curl_body' -H 'Content-Type:application/json' localhost:5000/api/v1/patients/$patient_id/$trial_id 2# Request: $curl -X post -H 'Accept:application/json' -d '$curl_body' -H 'Content-Type:application/json' localhost:5000/api/v1/patients/$patient_id/$trial_id39\n\nResponse: $\n\nYou will receive a json document, which contains a clinical trial list.\n\nHere is `patients_ClinicalTrials::get_all(only_trials=True)` in case if you",
        "label": 0
    },
    "1027": {
        "output": "> @[GUIDE]# 2. Exclusion criteria\n\nIt is also important to determine if the patient has any exclusion criteria. \n\n### @[INFO]\n\nYou should read an example from Section #7. In the example for the clinical trial, the patients were excluded because of pregnancy or lactation, or oncology or immunosuppressive therapy. This information is very important for the recruitment of the subjects as the patient must be free of all exclusion criteria.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's exclusion from the study.\n\nA patient must have no pregnancy or lactation, oncology or immunosuppressive therapy.\nA trial can have multiple exclusion criteria and a patient can be excluded from the trial, because of one or several exclusion criteria. \n\nLet's think step by step. \n\n## Trial-level exclusion criteria\n```\nTrial-level exclusion:\n     1 Excluded\n     2 Not relevant\n     3 Eligible\n```\n\n## Trial-level eligibility\n```\nTrial-level eligibility:\n    1 Excluded\n    2 Not relevant\n    3 Eligible\n```\n\nYour task is to store information about the assessment of eligibility for the trial in a table, e.g., an intermediate result `assessment_trial` such as `Trial 1-1-2: Excluded`. \n\n```\npatient_id = '00001'\ntitle = 'Pregnant woman admitted with pregnancy toxemia'\nclinical_trial = '0001'\ntitle_clinical_trial = 'Nulliparous woman pregnant with twin fetuses: an investigation of the safety and feasibility of an induction protocol as a means of reducing preterm delivery'\npatient_exclusion = '2) Not relevant'\npatient_trial_exclusion = 'assessment_trial'\n\nassessment_trial = \"\"\"\nTrial-level exclusion:\n     1",
        "label": 0
    },
    "1028": {
        "output": "```\n\n## \u600e\u4e48\u4f7f\u7528 R \u8bed\u8a00\u5b9e\u73b0\u8fd9\u4e2a\u529f\u80fd\n\n### \u8981\u6c42\n\n- R \u5305 `dplyr` \u7684\u57fa\u672c\u4f7f\u7528\n- `dplyr::filter()` \u7684\u57fa\u672c\u4f7f\u7528\n- \u6ce8\u610f\uff0c\u4f60\u6709\u5fc5\u8981\u8ba4\u771f\u8bfb\u4e00\u7bc7[R \u8bed\u8a00\u7684\u4ecb\u7ecd](https://blog.csdn.net/stella.ya/article/details/67377462)\uff08\u4f60\u53ef\u80fd\u4f1a\u4f7f\u7528\u5230\u5176\u4e2d\u7684\u77e5\u8bc6\u6765\u5b9e\u73b0\u95ee\u5377\uff09\u3002\u6211\u8fd8\u968f\u4fbf\u9488\u5bf9\u4e00\u4e9b\u95ee\u9898\u8fdb\u884c\u4e86 \u6df1\u5165\u7684\u89e3\u6790\u3002\n\n### \u5b9e\u73b0\u65b9\u6cd5\n\n```R\n\n  # R \u8bed\u6cd5 \n  # +--------------------+\n  # | R \u8bed\u8a00\u7684\u53d8\u91cf |\n  # |-------------------+\n  # | \u5b57\u7b26\u4e32\uff1a 'a'\uff0c\u2018b\u2019\uff0c 'c'  |\n  # | \u6570\u5b57\uff1a 20\uff0c 21\uff0c 22  |\n  # | \u5217\u6570\u7ec4\uff1a nums  { 5 , 6 , 7 }\n  # | \u5217\u5217\u5411\u91cf\uff1a matrix { 'a' , 'b' , 'c' }\n  # | \u4e24\u4e2a\u5143\u7d20\u5408\u6210\u4e00\u4e2a\u5217\uff1a cbind{ 'aa' , 'bb' , 'cc' }\n  ###\n  ### \u526a\u88c1\u5305\u542b\u6570\u636e \n  # +--------------------------------------+\n  # | \u5982\u679c\u4f60\u722a\u5b50\u8ddf\u6570\u636e\u6709\u4e00\u70b9\u5c3a\u5ea6\u7684\u5173\u7cfb\uff0c \u90a3\u5c31\u9700\u8981 \u526a\u88c1\u8fd9\u4e9b\u6570\u636e\n  # |--------------------------------____-|\n  ## Select \u5305\u542b\u6570\u636e \n  # +------------------------------------+\n  # | Select \u9009\u5b9a 7 \u5217 \u7684\u6570\u636e(\u7edd\u5bf9\u503c)\n  # +--------------------+\n  # | \u9009\u62e9\u7edd\u5bf9\u503c \n  # +--------------------+\n  # | select(dat = c('Gallstones_smallest', 'Gallstones_largest1",
        "label": 0
    },
    "1029": {
        "output": "`A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile.",
        "label": 0
    },
    "1030": {
        "output": "### Example\n\n```\n#!/usr/bin/env bash\n\n# Assistant for the eligibility assessment in clinical trials\n\n# Parameters\n\n\n\n# Functions\n\n# Utility functions\n\nfunction eli_assess_patient() { \neligibility=2 \necho \"Patient-level eligibility: $eligibility\" \n}\n\nfunction trial_eligibility_all_pat() { \npatients=`ls -t $1` \nfor patient in ${patients}; do \npatient_file=`head -25 $1/$patient` \necho \"$patient_file\" \ntrial_eligibility=`cut -f1 $1/$patient_file` \neligibility=`echo $trial_eligibility` \nif [[ $eligibility == 0 ]]; then \neligibility=1 \nelif [[ $eligibility == 1 ]] && [[ $eligibility_all_patients == 2]]; then \neligibility=2\nelse\neligibility=0\nfi\ncat $1/$patient_file $1/$patient_file\nelif [[ $trial_eligibility == 0 ]] && [[ $eligibility = 1 ]]; then \neligibility=0\ncat $1/$patient_file $1/$patient_file\nelse\ncat $1/$patient_file $1/$patient_file\nelif [[ $trial_eligibility == 1 && $eligibility != 1]]; then \neligibility=1\ntrial_eligibility_all_pat $1\ncat $1/$patient_file $1/$patient_file\nelif [[ $trial_eligibility_all_pat == 2 ]] && [[ $eligibility = 1 ]]; then \neligibility=2\ncat $1/$patient_file $1/$patient_file\nelse\ncat $1/$patient_file $1/$patient_file\nfi\ncat $2 $1/$patient_file $1/$patient_file \n}\n\n### Example\n\n```\n#!/usr/bin/env bash\n\n# Ass",
        "label": 2
    },
    "1031": {
        "output": "### Different Types of Eligibility Checks\nIn general, there are three types of eligibility assessments:\n\n1. Eligibility checks are performed once before the actual protocol execution starts ([INST],[CAL],[OBJ],[PRO]) --these eligibility checks are usually written under [Trial-level eligibility] section of the clinical protocol. (Example: the eligibility check of `Trial-level eligibility:` [2] Eligible is performed by the Assistant [Trial-level eligibility], and its execution is marked in [Trial-level eligibility: `].\n\n2. Eligibility checks are performed during the actual protocol execution --if the subject satisfies the eligibility criteria, the protocol executes the actual protocols. (Example: the eligibility check of `Trial-level eligibility:` [1] Eligible is performed during the actual protocol execution, and this is marked by the execution marks, which is usually written under [Trial-level eligibility: `], like `Executed.` or `Dropped.` (See [INST])\n\n3. Eligibility checks are performed multiple times to maintain eligibility status throughout the entire study, if there are eligibility criteria that are checked multiple times and these checks should be performed during the actual protocol execution and they are usually marked by the execution marks. (Example: the eligibility check of `Trial-level eligibility:` [20] Eligible during 6 - 8 weeks of Treatment is performed multiple times before the actual protocol execution starts to maintain eligibility status throughout the entire study and it is marked just once by `Executed:` or `Dropped.`.\n\n### Rationale\nThere is one rationale per trial-level eligibility check. The rationale of `Trial-level eligibility:` [1] Eligible is `The patient meets inclusion criteria, and exclusion criteria do not apply.`. The rationale of `Trial-level eligibility:` [2] Eligible is `The patient has abdominal pain that started 4 days-ago; is a woman; age of >40; and has BMI >40.` If the rationale is written with multiple lines, then you should concatenate it with the new-line character as follows",
        "label": 0
    },
    "1032": {
        "output": "<EOD> Ophiobolin A and Zearalenone Contamination of Cereals Used for Brewing Traditional Chinese Mead: Risk Assessment for Immunocompromised People\n\nBackground: Foods are likely the most common route of exposure to ochratoxin A (OTA) and zearalenone (ZEA). Ochratoxin A occurs widely in cereals, and its concentration can be increased by brewing traditional Chinese mead. Due to the possible immunosuppressive effects of toxins, immunocompromised people are at a higher risk of secondary fungal infections when they consume food contaminated with ochratoxin A or zearalenone. ophiobolin A (OBA) is a novel sesquiterpenoid mycotoxin produced by various Aspergillus species. The genes that participate in the biosynthesis of OBA have been widely described in A. carbonarius, A. ochraceus, and A. japonicus. ZEA is a mycotoxin that is typically produced by Fusarium fungi. Since ochratoxin A can co-occur with zearalenone in cereals, we investigated the co-contamination of OTA, and ZEA in mead, cocoa, and coffee in the Shanxi Province of China, where traditional cereal-based mead is most popular.Results: The mycotoxins were identified and quantified using LC-MS/MS. Co-contamination with OTA and ZEA was detected in the mead, cocoa, and coffee samples. Zearalenone was detected at concentrations of 2.96 -374.3 \u03bcg/kg, 14.05 -537.3 \u03bcg/kg, and 37.38 -250.58 \u03bcg/kg in the cocoa, coffee, and mead respectively. Zearalenone was also detected in 53.5% of cocoa samples and 21.42% of coffee samples. Ochratoxin A and its metabolites were detected at concentrations of 4.85 -327.86 \u03bcg/kg in the mead, 3",
        "label": 0
    },
    "1033": {
        "output": "# Input Data\n1.\nCopy all the clinical trial characteristics below and paste them here.\n\n## #input-data\nclinical trial characteristics = {\n\"Patient group 1\" : {\"1\"\"Patient group 2\" : {\"\"\u2026\"\"\"\"\nclinical trial characteristics =\"\"\"\"1\"\"\"\"1\nclinical trial characteristics = {\"Patient group 1\":\n{\"\"patient age > 65 years 10/11(91%) 1\", \"\"\"age 65-75 years 9/11(82%) 1\"\", \"\"age > 75 7/11 (64%) 1\"\", \"\"disease\"\":\n\"\"hypercholesterolemia and 2 NVDs 4/11(36.5%),''\"1\",\"\"COPD 4/11(36.5%),''\",\"\"diabetes 4/11 (36.5%)\", \"\"diabetic neuropathy 1/11 (9%)\"\", \"\"hypertension 7/11 (64%)\"\", \"\"hyperlipidemia 3/11 (27%)\",\"\"coronary artery disease 3/11 (27%)\"\", \"\"cardiac arrest 1/11(9%)\"\" ],\n\"age 35-45 years 0/11 0\", \"\"age 45-55 years 7/11(64%) 1\"\", \"\"age 55-65 years 7/11(64%) 1\"\", \"\"age 65-75 years 10/11 (91%) 1\"\", \"\"age > 75 11/11 (100%) 1\"\", \"\"sex 31/39 (79.5%) female\"\", \"\"smoking 6/11 (54.5%) \", \"\"alcoholic\"\", \"\"obese\"\", \"\"metabolic syndrome\"\", \"\"cardiovascular risk\"\", \"\"diabetes mellitus\"\" 3/11 (27%)\", \"\"arteriosclerosis\"\", \"\"congestive heart failure\"\", \"\"cor pulmonale",
        "label": 0
    },
    "1034": {
        "output": "<EOD> The potential of the hernia repair with synthetic, bioglutaraldehyd-based sealants\n\n\n\n## Original paper\nThe potential of the hernia repair with synthetic, bioglutaraldehydbased sealants Vojislav Kovacevic University Clinical Centre Sarajevo, Department of Surgical Disciplines, Sarajevo, Bosnia and Herzegovina\nBackground. Hernioplasty has been the first surgical operation invented by Vincenzo Paretti in 1540. It consists essentially in the closure of the weakest site of the anterior abdominal wall musculoaponeurotic layer to prevent prolapse of peritoneal organs which are responsible for patient's discomfort. Nowadays it is performed with or without prosthesis. Biomechanical characteristics of the abdominal wall musculoaponeurotic layer determines the choice of the material for intraperitoneal patch (IPP) or extraperitoneal patch of the hernial defect (EPIP). Aim. The purpose of this paper is to present the biomechanical analysis and the clinical results of the bioglutaraldheyde (BG)-based sealants (bioglutaraldehyde) from the point of view of the safety for the patient, surgical team and the abdominal wall musculoaponeurotic layer. Methods. In the surgical treatment of complex hernias BG-based tissue glue is used for reinforcement of the weakest site of musculoaponeurotic layer. Tissue adhesives act as a physical barrier between the tissue surfaces that are being adhered, but also function like a scaffold or template to which cells will attach and then proliferate to produce the necessary structural extracellular matrix to aid in wound closure or healing. In our clinical study there was used three-component biological tissue adhesive on the basis of collagen from human placenta and fibrin from human plasma. The materials were made according to the patented formula, technology and process and have obtained the mark of approval in accordance with the World Health Organization's (WHO) standards.",
        "label": 0
    },
    "1035": {
        "output": "There are several other examples in the data set. Good luck!\n\n# References\n[[INST] Hello, Xenia. Welcome to `Assigning labels for the TCGA data set [data link].` The main goal of this activity is to evaluate a given patient note from the TCGA data set and to apply the right labels based on the clinical attributes.\n\nAn important task of a medical practitioner is to obtain medical diagnoses. These diagnoses need to be recorded in computer form for easy communication among other doctors in patient hospitalization, transfer to intensive care units, and so on. In many cases, the medical diagnosis is based on a set of patient characteristics combined with the results of examination procedures and clinical tests. Medical practitioners rely on a standardized vocabulary that is developed by a medical dictionary, known as the International Classification of Diseases (ICD). This vocabulary is used to record and represent disease states according to certain specifications and classifications. The ICD-10 is an updated version of the standardized vocabulary, but the concepts are grouped in an entirely different manner. For a particular diagnosis, several relevant attributes, such as category, subcategory, and subattribute are usually specified. A medical diagnosis is a formal representation of a disease in human beings with a disease that is recognized through signs, symptoms, and other findings that occur in conjunction with a number of laboratory tests and procedures. Thus, medical diagnoses are not simply isolated observations but rather the synthesis of available information regarding a patient's signs and symptoms. Medical diagnoses are defined by using the ICD-10 for recording, storage, and communication of the diagnosis and the severity and prognosis of a given disease.\n\nEach patient in the TCGA data set comes with a complete medical record. However, in some cases, the exact type of cancer or the level of patient classification is not specified. This is due to the fact that the exact subcategories, such as histopathological grading or malignant status, are not recorded accurately in some cases.\n\nLet's take a look at one sample patient note. In total, 22 samples are provided in the data set.\n\nA data point contains information about the patient, such as sex, age, and subcategory (class of cancer and level of classification),",
        "label": 0
    },
    "1036": {
        "output": "<commit_msg>Revised INST<commit_after>#!/usr/bin/env python\n# Copyright 2018 <NAME>\n# Licensed under the Apache License, Version 2.0 (the \"License\");\n# you may not use this file except in compliance with the License.\n# You may obtain a copy of the License at\n#\n#   http://www.apache.org/licenses/LICENSE-2.0\n#\n# Unless required by applicable law or agreed to in writing, software\n# distributed under the License is distributed on an \"AS IS\" BASIS,\n# WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.\n# See the License for the specific language governing permissions and\n# limitations under the License.\n\nimport collections\nimport csv\nimport itertools\nimport logging\nimport os\nimport pandas as pd\nimport re\nimport json\nimport datetime\nfrom typing import List, Union, Optional, Dict\n\nfrom ...common.configuration import Configuration, DataSourceType, InstanceLevelMetadata, Inputs,\n                                  Outputs, ParameterList, DataElementType,\n                                  FieldsToSkip\nfrom ..common.utils import find_data_type\n\nfrom .data import Data, MetaData, ClinicalData\n\nlogger = logging.getLogger(__name__)\n\n\nclass Rule(list):\n    \"\"\"\n    A rule defines a number of matching elements, and how to generate a new\n    field for the matched elements, based on other fields, for instance a\n    field describing each patient's medication.\n    \"\"\"\n\n    def __init__(self, template, columns, mapping, rules=[]):\n        \"\"\"\n        Create a new Rule.\n\n        :param template: A template of a field.\n        :param columns: A list of columns that will be matched.\n        :param mapping: A dict of a list of mapping, one for each template.\n        :param rules: Either a :class:`RulesRule` or a List of RulesRule.\n        \"\"\"\n        columns = columns if isinstance(columns, list) else [columns]\n        super().__init__()\n\n        template.strip()\n        self.template =",
        "label": 0
    },
    "1037": {
        "output": "## Question\nWhich value should be returned for the `Trial-level eligibility` column when the factor `13` from the `Hypercholesterolemia` is present in `patient_note.csv`?\n\n<!-- MarkDownRendered\n```python\nprint(factor == 13 and is_inclusive)\n``` -->\n### Answer\n\n0 (Excluded).\n\n## Explanation\nThe eligibility assessment is based on factors (e.g. inclusion criteria), their possible values, and their values. A factor is `Hypercholesterolemia` in the above example. A patient note has a factor called `Hypercholesterolemia` with possible values 0, 1, and 2. If we are analyzing all patient notes in a dataset, we would obtain 33% excluded (0), 63% ineligible (1), and 4% not sufficiently documented (2) for this dataset. If the factor 13 from the `Hypercholesterolemia` is present in a specific patient note (`Hypercholesterolemia` = '13' for that dataset), the only possible value will be the 0 in the \n`Trial-level eligibility` column. The factor 13 from the `Hypercholesterolemia` is a factor with possible values 0, 1, and 2 and in this case 13 belongs to the negative values (0). To get \nTrial-level eligibility back we should remove the `Excluded` value from it. As the only possibility to become not Excluded is to become Ineligible, there will be the 2nd possible value in the column and the 4th possible value in the column.\n\n## Question\nWhich combination of values will give the 2nd value for the `Trial-level eligibility`?\n\n<!-- MarkDownRendered\n```python\nis_inclusive[f in [\"Hypercholesterolemia\"]]==2\n``` -->\n### Answer\n\nHypercholesterolemia = '13'.\n\n## Explanation\nIt's a combination that you just observed in your own dataset. Patients with a factor of `Hy",
        "label": 0
    },
    "1038": {
        "output": "___\n\n### Task 1:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Here is the clinical",
        "label": 0
    },
    "1039": {
        "output": "## Part 1\nHere are the results of your first eligibility assessment:\n    # A 54-year-old obese woman admitted to the emergency department with...\n    $Triallevel eligible <-NA\n    # She experiences abdominal pain that started...\n    $excluded <-NA\n    # She has clinical trial inclusion criteria:...\n    $excluded <-NA\n    # She has no exclusion criteria for clinical trial:...\n    $excluded <-NA\n    # A 54-year-old woman with abdominal pain, an obese patient...\n    $age <-\"54 years old\"\n    $nv <-\"2 NVDs\"\n    $excluded <-\"150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA\"\n    # This obese patient is not excluded for a clinical trial....\n    $excluded <-\"93.1 mm\"\n    # She is excluded by clinical trial inclusion criteria:...\n    $eligible <-\"2 NVDs, 2 children, and menopausal\"\n    # She does not have other exclusion criteria for clinical trial:...\n    # $eligible <-\"0\")`\n    # Here is the patient note:\n    # A 54-year-old obese woman admitted to the emergency department with abdominal...\n    # A 54-year-old obese woman admitted to the emergency department with...\n    $patient <-\"A 54-year-old obese woman admitted to the emergency department with...\n    $excluded <-\"2 NVDs\"\n    # This patient is not excluded for a clinical trial: 150/85, HR 115, RR...\n    # She has a family history of atherosclerosis, which is an exclusion criteria for...\n    # RFIDs are more effective than standard wristbands because patients are less likely...\n    # She has one of the clinical trial inclusion criteria:\"...\n    # A 54-year-old morbidly obese woman admitted to the emergency department",
        "label": 0
    },
    "1040": {
        "output": "<EOD> .\nSarcoidosis is characterized by the presence of noncaseing granulomas consisting of T lymphocytes, plasmacytes and macrophages. The cause of this granulomatous process has not been finally established, although the presence of an antigen with the ability to produce T cell activation and granuloma formation has been implicated, as has a defect in cell-mediated immunity. The objective of this report is to describe the results obtained by the study of lymphocyte proliferation, lymphocyte cytotoxic activity and spontaneous lymphocyte cytotoxicity in patients with sarcoidosis and their relatives. Lymphocyte proliferation was studied by the use of phytohemagglutinin (PHA); concavalin A (Con A) and lipopolysaccharide (LPS) as stimulating antigens. Spontaneous lymphocyte cytotoxicity was evaluated by incubating 51Cr-labeled lymphocytes from the sarcoid patients, along with lymphocytes from their relatives and healthy individuals, in the presence of autologous peripheral blood lymphocytes. Lymphocyte cytotoxicity was analyzed by measuring 51Cr release from labeled target lymphocytes. No statistically significant differences were found in lymphocyte proliferation among the three groups of patients and their relatives. No signs suggesting cell-mediated cytotoxicity nor spontaneous cytotoxicity were observed in any of the studies. The results obtained in this study do not show a relationship of the sarcoidosis lymphocyte population of cell-mediated cytotoxicity towards autologous lymphocytes.<EOD> Enhancement of tumor-specific immune response by the application of interleukin-2-activated spleen cells as adjuvant to dendritic cell immunization.\nWe compared the immune response induced by dendritic cells and interleukin (IL)-2-activated spleen cells for tumor antigen. Dendritic cells pulsed with tumor antigens efficiently induced primary CTL but failed to induce secondary",
        "label": 0
    },
    "1041": {
        "output": "\u00a9 2021 T. Takayama<EOD> Lactate is one of the contributors in developing muscle lactic fermentation and improves the metabolic state of patients with type 1 diabetes.\nThe present clinical trial was designed to investigate whether lactate or glycerol supplementation improves the metabolic state of patients with type 1 diabetes. Nine patients with type 1 diabetes participated in a randomized, double-blind, cross-over trial. Glycerol and lactate supplementations were completed for 9 weeks. All patients were assessed during the trial. Results showed mean\u00b1SEM for lactate, glycerol and placebo trials were respectively: 0.73\u00b10.06, 0.70\u00b10.08, 0.81\u00b10.09 mmol l\u207b\u00b9 for lactate dehydrogenase; 0.82\u00b10.42, 0.87\u00b10.37, 0.90\u00b10.35 mg dl\u207b\u00b9 for HbA1c; 1.99\u00b11.78, 1.63\u00b11.79, 5.27\u00b11.23 mmol l\u207b\u00b9 for fasting glucose; 3.39\u00b11.29, 2.11\u00b11.35, 4.04\u00b11.15 mmol l\u207b\u00b9 for glucose 2-hour after 75 g glucose load; 0.04\u00b10.01, 0.02\u00b10.01, 0.05\u00b10.01 mmol l\u207b\u00b9 for lactate; 0.10\u00b10.03, 0.12\u00b10.10, 0.09\u00b10.01 mmol l\u207b\u00b9 for glycerol. The results showed that lactate and glycerol supplementations were more effective for lactic dehydrogenase, HbA1c, fasting glucose and glucose 2-hour after a glucose load than placebo. Therefore, lactate supplementation improved the metabolic state of",
        "label": 0
    },
    "1042": {
        "output": "### Pause and discuss.\n\n\nHere are the results of the 30 tasks given to us:\n\n``` r glimpse(data = eligiblity_tasks, target = trial_level_eligibility)\n```\n\n    ## Warning: in getOption(\"date_parsed\"), got \"02-Jul-1990\", called from: \n    ## function (call, env) { parse_date(call$value, envir = env) }\n\n    ## Package 'openxlsx' v0.14.2.9000\n    \n    ## ## data.frame: 30 obs. of 2 variables:\n    ## ##  $ eligibility_tasks: FEMALE\n    ## ##           : FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FEMALE\n    ## ##           : LOGICAL\n    ## ##           : FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE LOGICAL\n    ## ##                 : 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 1\n    ## ##       : FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE",
        "label": 0
    },
    "1043": {
        "output": "Let's visualize the data in the form of the original clinic form, which gives you a better idea of the actual data. The graphic shows columns in the original patient file. We see the patient number, the age of the patient, the gender of the patient",
        "label": 0
    },
    "1044": {
        "output": "## Solution\n\n## Task 1.1\nYou find it difficult to determine which factors are most important to the clinical trial's inclusion criteria. You check a search engine and find a clinical trial titled, `Study of Bimodality vs. Bimodality Followed by Ongoing Hemodialysis for Acute Kidney Injury (BIM-BIO) (NCT01188531),'. You search in clinicaltrials.gov for the key phrase, `inclusion criteria for' in the condition or disease. You find, `inclusion criteria for renal disease: acute kidney injury, renal impairment, acute kidney failure, or chronic kidney disease`, 899 search results. You check the results in detail in Pubmed.\n\n\n\n\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n\n\n\n* * Clinical judgment.\n\nThis patient is likely to be eligible. Except a CBC count, the rest of the clinical data are normal. The liver function tests are within normal limits. Moreover,",
        "label": 0
    },
    "1045": {
        "output": "## Conclusion\nIn this tutorial, we tried to explain how to write a useful R code with the `r2win` R package. We showed how to process raw information extracted from a PDF form with only a single input argument and write simple R code that can be used later for various tasks such as the calculation of statistics and statistical tests. The `r2win` package makes it possible for anyone to use the output of the scanning program for their needs. The best way to get to know `r2win` is to try to use the output of the scanning program for your own needs. Then, you will see how useful the `r2win` package can really be.\nWe believe that this article will open a new field of data acquisition, data preprocessing, and data management using machine-readable files based on a paper form.\n[fig]  [NAME]: This survey contains the following subsections (listed below) of the form. Each of these subsections (listed below) contains several questions (listed under `q`). You can start by reading the example below. Then click `S17 Tutorial` and check the example (it is in the pdf form). You can download it (with the `r2win` R package) on this webpage: https://github.com/syoon/r2win_Tutorial. [/fig] \n<EOD> .\nBetween 1981 and 1984, 82 patients operated upon for primary hyperparathyroidism were prospectively studied in order to assess how often they were found to have a non-adrenal hyperplasia of the thymus gland at neck examination. Histologic examination of the removed parathyroid glands showed medullary adenoma in 44 cases, an adenoma in 11 cases, hyperplasia in 18 cases, and a cystic hyperplasia surrounded by atypical nodules in 7 cases. A non-adrenal hyperplasia of the thymus gland was seen in more than half of the patients (45). The average age of those patients is 43.9 years, as opposed to 38.8 years for the patients without thymic hypertrophy. There were more males in the group with thymic hypertrophy as opposed to the group without. B",
        "label": 0
    },
    "1046": {
        "output": "### Example\n\nHere is the full report:\n\n> Trial-level eligibility: 2) Eligible; TL.0 = 2); V04C = 3; V05A = 2; TL.1 = 2; TL.2 = null; TL.3 = null; V04B = null; V01D = null; V07A = null; V09B = null; V04D = null; V06A = null; V12C = 2; V05B = null; V07B = null; V01A = null; S04B = 0; S01D = 0; S03A = null; S03C = 1; S03C = 1; E01A = 2; E01B = null; C01A = 2; C01B = null; C01A = 2; C01B = null; S01C = null; V11C = 1; C05B = null; L02A = null; N04B = 0; L02C = null; N05A = null; L05A = null; L11B = 0; N01C = 0; R01A = 1; R02A = null; L01B = null; R01A = 1; S02A = 0; S11C = null; S03C = 1; S01C = 1; S03C = 1; S21D = null; S21D = null; S11B = 0; D01A = null; D01B = null; S06D = null; S01A = 1; S02C = null; R02C = 0; A01A = 2; A01A = 2; D01C = null; D02C = null; D02C = null; A01B = null; A01B = null; A01B = null; A01C = null; A01C =",
        "label": 0
    },
    "1047": {
        "output": "# Conclusion\n[OUT]\nCongratulations! You have completed the first part. The next step is to identify the differences between your diagnosis and the actual diagnosis.\n\n## #649.\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to determine the diagnostic outcome of an electrocardiogram (ECG) and compare it to the doctor-diagnosed patient's actual diagnoses. \n\nHere is an ECG: \nA 66-year-old man, with a history of 2 coronary bypass surgeries. His past medical history includes atrial flutter, cardiac insufficiency and congestive heart failure. 3 years ago, a pacemaker was implanted. He is overweight and he smokes occasionally.\nHe has come with dyspnea, and atrial fibrillation (AF). His vitals are BP 120/90, HR 100, RR 25, T 36.5, SpO2 92%\n\nHere is the patient diagnosis report:\nThe ECG showed a first-degree atrioventricular block (PR interval was 183/min), sinus tachycardia, normal sinus rhythm, and left anterior fascicular block. \nIn this part, you analyze electrocardiogram (ECG) for determination of diagnosis, then compare diagnosed cases with diagnosis as reported by the doctor of the patient. Finally, you will identify the differences between the two.\n\n# Conclusion\n<EOD> Role of IL4 genotypic polymorphism in patients with schizophrenia who smoke cigarettes: an ethnically matched case-control study.\nBACKGROUND\nA significant increase in the rate of smoking in people with schizophrenia (PWS) compared to healthy controls has been reported widely. To our knowledge, there have been only a few studies assessing the impact of polymorphic variants in different genes on the smoking behavior in PWS.\n\n\nMETHOD\nIn total 374 patients of Indian origin with schizophrenia were genotyped for the interleukin (IL) 4 (-590 C/T",
        "label": 0
    },
    "1048": {
        "output": "(3) Not relevant because you are unable to evaluate the patient based on the information on the paper. (4) Excluded because although you are able to evaluate the patient based on the information in the paper, the patient does not meet the clinical trial's inclusion criteria.\nThere are some helper functions in patient_recruitment_helper.py to provide extra functionalities. They are defined in PATIENT_RECIPROCATION_HELPERS.py.\n<class 'patient_recruitment_helper.PatientRecruitment'>\n    # You can create a patient_recruitment instance by calling the __init__ method.\n    def __init__(self, patient_record=None, trial_record=None):\n        super(PatientRecruitment, self).__init__()\n        # This creates a set of available methods\n        self._methods_list = helpers.make_method_list(self)\n\n        # Define the patient and trial records\n        self.patient_record = patient_record\n        self.trial_record = trial_record\n\n        # This method can be used to determine eligibility for a particular patient.\n        self.patient_eligible = self.patient_eligibility\n        # This method can be used to determine the clinical trial eligibility by assessing whether a patient meets\n        # the trial's inclusion and exclusion criteria.\n        self.trial_eligible = self.trial_eligibility\n\n\n    def __str__(self):\n    \"\"\"\n        If you have no interest in the internal representation of a class's instance, then you can use this method\n        to return a string-based summary of that object.\n    \"\"\"\n        return self.__dict__.__str__()\n\n    def __repr__(self):\n    \"\"\"\n        If a string representation of the instance is required, then you can use this method to return the \n        object's most descriptive representation. This string value will include the name of the class along with \n        any other values that were contained in the object's `__dict__` attribute.\n    \"\"\"\n        return 'PatientRecruitment(patient_record=%r, trial_record=%r)' % (self.patient_record, self",
        "label": 0
    },
    "1049": {
        "output": "## Making of 3 decision trees\nThis tutorial illustrates step by step how to make a decision tree. To make the decision tree we must define the target values of the model, define the model variables and build the tree. When the tree is not built with R we will use an open source software, WEASEL. The R and WEASEL codes are given below to illustrate the steps. This tutorial is provided from the authors; it is not a R script.\n\n## R code\n\n\n> # defining the model variables\n> model_variables << -\"sex; age; race; cerebral; diabetes; nephropathy;\n> \\            heart_disease; coronary; hepatitis; blood_pressure; bmi",
        "label": 0
    },
    "1050": {
        "output": "<EOD> .\nFor the last eight years we have carried out a follow-up on patients with cerebrovascular disease and diabetes mellitus, in order to evaluate their prognosis and their therapeutic success. Twenty-seven patients, 11 men and 16 women (mean age 65 years) were included in the study. All of them had suffered a cerebral stroke, of arterial aetiology, and all but one were diabetics. During a mean follow-up period of 6.2 years, 6 stroke recurrences and 4 deaths were recorded. Of the survivors, 18 were subject to a functional evaluation, which showed a progressive deterioration of the functional state during the follow-up period in 8 of them and a considerable slowing down of the progression only in 10 patients. The evaluation of the clinical symptomatology after the stroke did not reflect the functional state of the surviving patients. The mean value of the glycosilated haemoglobin was 8.8%, with a great range of values. It is concluded that diabetics with this level of metabolic control and cerebrovascular disease have a serious prognosis which is worsened by the functional deterioration and by the recurrences and death during the follow-up period.<EOD> Cytomegalovirus infection-associated glomerulonephritis in solid organ transplant recipients: a single-centre, retrospective study.\nBACKGROUND\nCytomegalovirus (CMV)-associated glomerulonephritis is a well-known disease in renal transplant patients, particularly those seropositive for CMV (CMV+) and for anti-HLA-DQ antibodies (ADQ+). In our study, we investigated the characteristics and outcome of CMV-associated glomerulonephritis in these high-risk patients.\n\n\nMETHODS\nWe retrospectively reviewed the records of 88 CMV+ and ADQ+ solid organ transplant recipients for 10\u2009years .\n\n\nRESULTS\nAll patients had CMV disease in the graft and 2",
        "label": 0
    },
    "1051": {
        "output": "Please answer:\n\n1. Which is the correct `Trial-level eligibility` line? `0) Excluded.`, `1) Not relevant.`, `2) Eligible.`, or `3) Not eligible.`?\n\n> `2) Eligible.`. \n\n2. Why does it answer `2) Eligible.`?\n\n> The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). Since the patient meets inclusion criteria and has sufficient information to qualify for the current clinical trial, it should output `2) Eligible.`.\n\n3. Which line(s) should be included within the `for` loop in order to output the trial-level eligibility?\n\n> The `for` loop will repeat `Trial-level eligibility:` line based on the trial-level eligibility outputted in the previous step. \n\n4. Which line(s) should be included within the `for` loop in order to assign trial-level eligibility?\n\n> Since the `Trial-level eligibility:` line is the last line within each block, in order to assign trial-level eligibility, it should be assigned to the `print` function in the last line of the `for` loop. \n\n5. How to print the trial-level eligibility and the patient's record id?\n\n> In order to print the trial-level eligibility output, the variable `result` should be assigned to the trial-level eligibility output as the first line of the `for` loop, e.g., `result=[0, 0, 0, 0]` will output `(0, 0, 0, 0)`, `result=[0, 0, 1, 0]` will output `(0, 0, 1, 0)`, etc. Then, the patient's record id can be printed as a comma-separated value by the first argument of the print function inside the `for`",
        "label": 0
    },
    "1052": {
        "output": "} /*\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n} */\n<EOD> A single injection of a human Bifidobacterium strain enhance memory function in rats\n\nBackground: Growing evidence demonstrates that orally administrated probiotics possess cognitive-protective effects in humans. However, the underlying mechanisms remain largely unclear. In this study, we aimed to examine whether a single injection of a probiotic Bifidobacterium strain would improve memory functions in rats.Methods: Male Wistar rats were randomly allocated to 1 of 4 treatment groups: (a) control vehicle-injected group; (b) 10 10 CFU/animal of Bifidobacterium breve KB290injected group; (c) 10 7 CFU/animal of Bifidobacterium pseudo-gracilis KB177-injected group; (d) normal saline-injected group. Memory function was evaluated by novel object recognition test after a 4 week treatment. Furthermore, immune components in serum were analyzed by a Bio-Plex kit.Results:A single injection of 10 10 CFU/animal of KB290, but not KB177, significantly improved novel object recognition memory function in rats. No major changes in immune response components were observed.Conclusions:A single injection of a high-dose specific probiotic strain into the brain was effective in improving hippocampal-dependent memory function in rats. A low dose of this probiotic strain did not show a memory-enhancing effect, which suggests that a specific dose is needed to obtain memory-modifying effects.Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR: UMIN000033211, 02/20/2019).\n\n# Background\nProbiotic bacteria have received increasing attention, especially from human nutritionists and medical researchers, in recent years. The Food and Agriculture Organization of the United Nations and the",
        "label": 0
    },
    "1053": {
        "output": "<a id=\"A-1-1-6.md\"></a>A-1-1-6. RS: \n<a href=\"https://github.com/statmodlab/statmodlab/blob/master/_code/rs/problems/A-1-1-6.md\"><code>rs/problems/A-1-1-6.md</code></a>  \n\n\n```r\n# Problem\n```\n```r\nTrialLvlEl <- function(patient){\n  y <- LETTERS[seq(nrow(patient))][paste(1:nrow(patient),sep = \"_\")]\n\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[seq(1, ncol(patient) - 2)][paste(1:ncol(patient),sep = \"_\")]))\n\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[1:(ncol(patient) - 1)], paste0(2:ncol(patient),paste0(\"_\",rep(c(\"\", LETTERS[seq(ncol(patient))[2]:ncol(patient)])[seq(ncol(patient) - 1)],1),sep = \"_\"))))\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[seq(ncol(patient) - 1)], 2:ncol(patient), paste0(\"_\",rep(c(\"\"), LETTERS[seq(ncol(patient))[1]:ncol(patient)])[seq(ncol(patient) - 1)],sep = \"_\"))))\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[1:ncol(patient) - 1], paste0(\"_\",L.names[ncol(patient)][1:ncol(patient)], sep = \"_\"))))\n\n  # Letters are used instead of actual patient names\n  eligability <- paste(\"Excluded-\",\n                           Txt2String",
        "label": 2
    },
    "1054": {
        "output": "[INST] \u6f14\u793a\uff1a\u8fd9\u662f\u4e00\u7bc7\u8bba\u6587\uff0c\u8bb2\u4e00\u4e0b\u5173\u4e8e\u708e\u6027\u8102\u80aa\u809d\u8fd9\u79cd\u75c5\uff0c\u603b\u7ed3\u4e86\u53d7\u8bd5\u8005\u63a5\u53d7\u8fc7\u4ec0\u4e48\u6837\u7684\u6cbb\u7597\uff0c\u6700\u7ec8\u6cbb\u7597\u540e\u60a3\u8005\u7684\u8840\u78c0\u6c89\u79ef\u53c8\u600e\u4e48\u6837\u3002\u8fd9\u662f\u4e00\u4e2a\u7814\u7a76\u62a5\u544a\u7684\u7533\u8bf7\u4e66\uff0c\u4e00\u4e2a\u5728\u4e00\u4e2a\u533b\u9662\u7684\u7814\u7a76\u62a5\u544a\u3002\u968f\u540e\u7ffb\u8bd1\u8005\u4eec\u9700\u8981\u5c06\u7ffb\u8bd1\u6587\u770b\u51fa\u6765\u7684\u5bf9\u6bd4\u62a5\u544a\uff0c\u6bd4\u5982\u6211\u4e00\u4e2a\u4f8b\u5b50\u4e2d\u6240\u89c1\u7684\u8840\u78c0\u6c89\u79ef\u3002\u4f46\u662f\u7ffb\u8bd1\u6587\u6587\u4e2d\u8981\u7559\u4fdd\u4e0d\u80fd\u5199\u5b8c\uff0c\u9700\u8981\u91cd\u5199\u62a5\u544a\u5185\u5bb9\u3002\u6211\u4eec\u8bb2\u533b\u62a5\u7684\u67d0\u4e00\u7bc7\u7684\u8bc4\u53d9\u8981\u7559\u4fdd\uff0c\u8fd9\u4e2a\u7bc7\u5b50\u8bb2\u8bc1\u636e\u8981\u8bb2\uff0c\u8bb2\u8bc1\u636e\u7684\u65b9\u6cd5\u662f\u8981\u7528\u201c\u53d7\u8bd5\u8005\u201d\u3001\u201c\u4e34\u5e8a\u7814\u7a76\u201d\u3001\u201c\u5bf9\u7167\u7ec4\u201d\u3001\u201c\u81ea\u4f53\u7ec4\u201d\uff0c\u8fd9\u8bb2\u4ec0\u4e48\u7684\u4e1c\u897f\uff0c\u5728\u8bb2\u4ed6\u7684\u65b9\u6cd5\u3002\u6240\u4ee5\u73b0\u5728\u8fd9\u91cc\u533b\u62a5\u4e2d\u6587\u7684\u4e00\u7bc7\uff0c\u8981\u7559\u4e00\u4e2a\u6587\u5b57\uff0c\u8fd9\u91cc\u8bf4\u5230\u7684\u91c7\u96c6\u7684\u65b9\u6cd5\u662f\u201c\u533b\u62a5\u7684\u6570\u636e\u201d\u3001\u201c\u81ea\u6cbb\u533b\u9662\u7684\u6570\u636e\u201d\u3002\u7136\u540e\u7ffb\u8bd1\u6587\u4e00\u4e0b\uff0c\u5982\u679c\u4f60\u628a\u201c\u5047\u5b9a\u201d\u51fa\u6765\uff0c\u8fd9\u4e2a\u4e5f\u8981\u7559\u4e00\u4e2a\u5b57\uff0c\u8bb2\u4e00\u4e0b\u5047\u5b9a\u7684\u60ef\u7528\u8bed\u662f\u201c\u5e26\u201d\uff0c\u5e26\u5230\u6570\u636e\u3002\u4ece\u5b83\u7684\u7814\u7a76\u7ed3\u679c\u6765\u770b\uff0c\u4f60\u6ce8\u610f\u5230\u60a3\u8005\u4ef0\u8bf8",
        "label": 0
    },
    "1055": {
        "output": "Exercises\n\nExercise 1\n\n1. `python main.py`\n\n2. Do you see a patient (name: <NAME>) who would qualify in your first scenario? What might disqualify this patient from the clinical trial?\n3. Would you include the patient in your second scenario? Why might this patient qualify? Why might this patient qualify?\n4. Check the `Trial-level eligibility` section. Do you agree with your output? <EOD> Evaluation system for monitoring quality during the manufacturing of human albumin in China.\nThe World Health Organization has raised serious concerns about the safety of human albumin after reports of a series of acute allergic reactions. To ensure the safety of therapeutic albumin we conducted a joint evaluation system for monitoring the quality of albumin products being applied in 205 hospitals from January 2011 to December 2013. We assessed the safety of the manufacturing process and stability by sampling albumin from every batch produced. The final quality report was released to the public immediately. To ensure the safety of albumin, we used a standardized evaluation system for risk assessment. If our data analysis indicated the possibility of risk, we retested the batch. A joint quality control team from China Pharmaceutical University, Chinese Center for Disease Control and Prevention, and China Food and Drug Administration designed a standardized evaluation system including laboratory tests, stability tests, and traceability tests. Twenty five albumin manufacturers participated in the evaluation from 2011 to 2013. We analyzed five different albumin types: domestic human albumin (HSA), imported HSA (either domestic or foreign), albumin solution from plasma, albumin solution from whole blood, and albumin liquid (a combination of albumin solution and a stabilizer). We performed 382 quality monitoring tests; 68 of them were traceability tests. The other 214 quality monitoring tests performed to assess the quality and safety included detection of the sterility, endotoxin, and residual antigens; potency tests; and content analysis of the albumin solution. All samples were analyzed according to the standards of the National Pharmacopeia of the People's Republic of China by an accredited",
        "label": 0
    },
    "1056": {
        "output": "<EOD> Effect of Different Mouth Rinses on Prevalence",
        "label": 0
    },
    "1057": {
        "output": "You are done! Your last 10 practice tests are also available under `/practice_test` in the Notebook.\n\n## Learning Goals\nIn the second Notebook, you will familiarize yourselves with the Python version of the Notebook and with several common functions and data types in Python. \n\n## First step: Installing Python and Anaconda.\nYou must follow the instructions on how to install Python and Anaconda.  \nPlease see our [NOTE](https://github.com/sejong-ip/machinelearning-jupyterbook/blob/master/README.md)\n\n## Second step: Python installation and Anaconda installation.\nYou must follow the instructions on how to install Python and Anaconda [NOTE](https://github.com/sejong-ip/machinelearning-jupyterbook/blob/master/README.md#python-install)\n\n## Python Basics \n\nIn this Python Notebook, we discuss a series of Python basic programming concepts. We discuss the following ideas:\n\n### 0) Python Syntax\n\nAn [execution flow](./python_python_syntax.ipynb) for the Python code has been provided. The flow diagram explains a simple process: creating a Python variable, the type of the variable, the Python expression, and printing. \n\nEach cell shows the detailed information for the variables. You can check the comments for specific information.\n\nTo understand Python syntax in more detail, you should watch the tutorial provided on YouTube: [here] .\n\n[Here](./python_python_syntax.ipynb) is the Python expression. \n\n```python\ndef example_function():\n    \"\"\"Example function.\n    \n    \"\"\"\n    print(\"Hello, world!\")\n\n\n# Python basic syntax\nimport pandas as np\nimport numpy as np\nimport random\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport seaborn as sns\nimport scipy.stats\nfrom math import factorial\n\nprint(\"print statement\")\nprint(\"print statement\")\n# list\nl = [5, 2, 4, 3]\n# list\nl = [5,2,4,3]\n\nprint(\"List\")\nprint(\"-\")\nprint(\"List\")\nprint(\"-\")\nprint(l",
        "label": 0
    },
    "1058": {
        "output": "### Grading the report\n\n* [CREDITS.md](https://github.com/DME4/TRIALTRAILS/blob/2b89de5d1aee6256e4b94c697e6a765ec13152d9/assignments/1/solutions/2/CREDITS.md) is a mark-scheme/grade-scheme that was created by the course tutor on June 13th, 2020, at 8:10 PM.\n* [TIPOS_SINT\u00c1TICOS.md](https",
        "label": 0
    },
    "1059": {
        "output": "[/FINAL]\n\n[HOLD]\n\n### Eligibility:\n\nExcluded 15\nNot relevant 4\n\n## Assign to treatment\n\n[INST] Let's assume that the patient is eligible for the treatment assignment. \n\nHere the decision is to assign the patient to treatment arm A or B. Treatment arm A is the early surgery with a 3-month delay for treatment arm B. The treatment A is taken for granted as the surgeon decided to perform it. Your job is to decide by which treatment arm we should assign this patient. Should she get early surgery, or could we safely just delay the surgery for another 3 months? The goal is to keep patients from unnecessary early surgery.\n\n[FINAL]\n\n* _Notes to self_:\n\n_Remember that this patient was in clinical trial \"EARLY VERSUS DELAYED SURGERY FOR GALLSTONE PANCREATITIS\" trial_\n\n* The choice between early surgery and delayed surgery is determined based on the patient's symptoms and clinical condition after a minimum of 10 hours. In the case of a waning response to antibiotics, the patient might need to undergo gall bladder removal. This condition warrants a delay in surgical intervention if there is a possibility of improving the patient's condition. However, in the case of sustained severe abdominal pain and high bilirubin level, immediate laparoscopic cholecystectomy is indicated.\n\n* In all but acute cholangitis (wherein a CBD stone is present), post-ERCP pancreatitis should not lead to a delay in laparoscopic cholecystectomy if the patient recovers. A cholecystectomy should be performed 24 hours post-papillary dilatation or ERCP in the absence of biliary stenting.\n\n* A diagnosis of gallstone pancreatitis is confirmed by the presence of gallstones in the ductal structures or by the presence of inflammation associated with the gallstones in the gallbladder bed in one or more of its lobes. Cholecystectomy is then performed lapar",
        "label": 0
    },
    "1060": {
        "output": "Now, you are ready to proceed to the next track.[INST] You are an epidemiologist employed at a hospital. The hospital administrator wants a comprehensive report on the patient characteristics for their general hospital admission (registration, demographic data, length of stay, and readmission). He also is interested in calculating the readmission rates. Below is a hospital admission database table, where you will examine and extract the requested information.\n\nFirst, let's get some information. How often was the readmission happened in the past year? [INST] We want to collect the necessary data in a data frame called `admissions`.\n```python\nimport pandas as pd ```\n\n```python\ndf = pd.read_csv('../../data/README.txt', header=0) ```\n\n```python\nprint(df) ```\n\n```\n   PatientId\n0         1\n1         3\n2           1\n3          24\n```\n\n[!INCLUDE[inst-show-dataframe-values](../includes/inst-show-dataframe-values.md)]\n\n[!INCLUDE[inst-get-value-admission-count](../includes/inst-get-value-admission-count.md)]\n\n```python\ndf\n```\n\n\n     PatientId    Admit_date    Admission    Age Sex Length of stay Readmission \n    0            1          6/1/2020         0        Female    40       Y      \n    1           23          5/22/2020        33        Male     4    N      \n    2          3522      10/30/2019       52        Male      6       N      \n\n[!INCLUDE[inst-show-dataframe-row-values](../includes/inst-show-dataframe-row-values.md)] \n\n[!INCLUDE[inst-get-value-length-of-stay](../includes/inst-get-value-length-of-stay.md)] \n\n```python\ndf['Length of stay']\n```\n\n```python\ndf.groupby(['Admission'])['Length of stay'].mean()\n```\n\n*Admission*:\n\n|Value|",
        "label": 0
    },
    "1061": {
        "output": "![INST]\n[INST]\n\n[INST]\n**C#**\n- class PatientAssistant\n{\n\tpublic string Trial;\n\tpublic int PatientLevel;\n\t\n\tpublic PatientAssistant(string trial, int patientLevel)\n\t{\n\t\t// Constructors\n\t\tthis.Trial = trial;\n\t\tthis.PatientLevel = patientLevel;\n\t}\n}\n**Python**\n- class TrialAssistant\n    def __init__(self, trial_level, patient_level): # TrialAssistant constructor\n        self.trial_level = trial_level\n        self.patient_level = patient_level\n        \n    def _get_trial_level(self): # get trial_level getter method\n        return self.trial_level\n    def _get_patient_level(self): # get patient_level getter method\n        return self.patient_level\n\n\n---\n**Exercise 2**\n![INST]\n[INST]\n\n[INST]\nWrite the code for the method TrialAssistant.evaluate_patient(): it should make a proper Trial-level eligibility for the Clinical Trial and store the results in a dictionary.\n\n---\n**Exercise 3**\n\n![INST]\n[INST]\n\n[INST]\nAfter completing the trial level eligibility, output the results for the entire data set on your screen and make sure that they are in the proper format. \n\n---\n**Exercise 4**\nIn the next exercise, we will make a clinical trial patient for each patient note and enter the results (patient's ID, first name, last name, gender, etc;) to the patient_list dictionary.\n```{hidden}\ndata = patient_notes\nfor patient_note in patient_notes:\n\t# You should create a patient object/variable for each patient\n\tpatient = Patient(data = patient_notes[0], age = 0, gender = 'female')  # the patients need to have a age\n\tfor patient_note in patient_notes[1:]:\n\t\tpatient.data = patient_notes[1]\n\t\tpatient.age = int",
        "label": 0
    },
    "1062": {
        "output": "[PRACTICE] Let's try in our Python code:\n\n    def assess_eligibility(patient_note, clinical_trial):\n        patient_id = patient_note.text.split()[-1:-1][0]\n        clinicaltrial_id = clinical_trial.text.split()  \n\n        trial_id = clinicaltrial_id[:3] .split('\\n')[0]         \n\n        patient_age  =  patient_note.text.split()[1][5:]\n        patient_age  = int(patient_age)  # convert to integer for data type safety\n\n        trial_age  = clinicaltrial.text.split()[3]\n        trial_age  = int(trial_age)  # convert to integer for data type safety\n\n        if trial_age==patient_age:\n            Trial-level eligibility = patient_age\n            if patient_age>=50:\n                if trial_eligibility==1:\n                    print(f\"{patient_id} not qualified for clinical trial\")\n                elif  trial_eligibility==0:\n                    print(f\"{patient_id} excluded from clinical trial\")\n                else: \n                    print(f\"{patient_id} has mixed result of clinical trial\")\n            else:\n                print(f\"{patient_id} not qualified for clinical trial\")\n        else:\n            print(f\"{patient_id} is not qualified for clinical trial\")\n\n\n        # print(f\"Trial-level eligibility: {Trial-level eligibility}\")\n        if Trial-level eligibility==2:\n            Eligibility= Eligibility.append(f\"{patient_id} is Eligible for clinical trial\")\n        else:\n            Eligibility= Eligibility.append(f\"{patient_id} is Not Eligible for clinical trial\")\n        print(f\"Eligibility: {Eligibility}\")\n        return Eligibility\n\n    \n    patient_note = pd.read_csv(\"Patient Noted.csv\")\n    clinical",
        "label": 0
    },
    "1063": {
        "output": "######## IMPORTANT NOTE ABOUT TAGS\n\n### #\nAs a matter of courtesy and to help the other learners read the solutions of the code review in a more organic and less disrupted way we recommend sticky-tags to be included in the solution. Sticky-tags can be recognized by the hashtag `#` (without quotes). They indicate the beginning or end of a code block. You can begin a code block by using a forward slash, e.g., #, and you can end a code block by adding a backslash, e.g., /#. When one solution uses the hashtag and the other solutions does not, then the solution could be identified much easier.\n\n\n### #\nYou will receive the best score if (in addition to the code review) you send a short \"Abstract of your solution (description)\", it's a great idea to share your ideas with other learners. Think about how they could improve the problem. Be bold, it can only help you. \nIf you see any inconsistency or mistake just write to the code in the comments.\n\n## Solution\n\n## The second time \nThe following solution code block is written with `code` tag. It's recommended to make the code block more readable by adding a label. For example, you could change the content of the code block below with: \"Patient age.\" or \"Trial-level eligibility.\" A label should be placed before the \"Begin\" tag.\n\n#### Example for the solution code block:\n\n\n\n\n\n#### Begin Solution Code Block\n\nIn this code block we will show the code, that solves the problem for the next time. There is no need for the learners to copy, and replace the code with the solution code, but in case they would like to implement it on their own system, then we provide a file for the next time here: https://github.com/YasarAlya \n\n\n\n\n\n\nAs stated in the solution from the first time. we will use the `for loop` for the solution from the second time. We will need to collect the name of the patients, the patient's age, and the patient trial-level eligibility. The age of the patient is in patient.age;",
        "label": 0
    },
    "1064": {
        "output": "A: You can check the answer and source by executing the command:  \n$ eval echo $(type <ANSWER>)\nanswers are saved as *.answers file in the user-file-directory\n<EOD> Correlation of the inhibitory effect of 5-fluorouracil on the synthesis of cellular RNA and DNA with that on the incorporation of adenine-8-C14 into ATP.\nSummary and Conclusions 1.The inhibitory effects of 5-fluorouracil on the incorporation of adenine-8-C 14 into cellular RNA and DNA of tumor-bearing or normal mice was almost identical and showed an early onset (2 to 3 hours) and dose dependence. No lag in the inhibition was observed. 5-Fluorouracil (50 mg/kg intraperitoneally) reduced 48 per cent the incorporation of adenine-8-C 14 into DNA after 3 hours\u2014the maximal effect\u2014and had no effect on that into RNA. Higher concentrations (100 mg/kg) were as effective as lower doses after the same time interval of administration. 4.The incorporation of adenine-8-C 14 into the acid-soluble RNA isolated from intestinal epithelial cells of the jejunum of normal mice was inhibited by 5-fluorouracil 1 hour after administration of the drug. The inhibition of the incorporation of adenine-&dquo;-C a4 into the acid-insoluble RNA was maximal only 3 hours after administration of the drug. 5.Although the incorporation of adenine-8-C 14 into the nucleosides of tissue slices of jejunum was completely prevented by 5-fluorouracil after 4 hours (100 mg/kg), no inhibition was observed after 30 micrograms per cubic centimeter of drug. No significant time lag was observed in the prevention of incorporation of adenine-8-CJ 4. A single-cell suspension of the jejunum of mice treated with 5-fluorou",
        "label": 1
    },
    "1065": {
        "output": "* *\n\n[/NOTE]\n<EOD> Comparison of the Effects of Phlorizin and Its Metabolites on the Activity of Mammalian Protein Phosphatase 1\nAbstract The metabolism by rat liver 9000 \u00d7 g supernatant and a purified preparation of protein phosphatase 1 of the phlorizin derivative phloretin-2\u2032-sulphonic acid has been studied. A product was found in the incubation mixture whose behaviour on the chromatographic systems tested, gave an unambiguous identification as phlorizin. Its formation, under the conditions of our experiments, could be accounted for by an initial phlorizin phosphate formation, followed by a second, reversible reaction leading to the phlorizin sulphate. No effect of phlorizin on mammalian protein phosphatase 1 activity was observed; whereas small concentrations of the metabolite phloretin-2'-sulphonic acid inhibited significantly its activity. No effect was observed on the mammalian intestinal alkaline phosphatase activity.<EOD> Effects of Birth Weight, Body Weight, and Feeding Strategy on the Postnatal Development of the Porcine Gastrocnemius Muscle\nPiglets are usually weaned without previous feeding with formula feeds, which may affect the performance of muscle growth and development. Piglets vary in birth weight, and they are then selected either to grow on sows or to be fed by milk only after birth. In this study, the effects of birth weight and the feeding strategy on the performance of muscle growth in an adult life were evaluated. Twenty-seven piglets were allocated into low birth weight (n = 11), high birth weight (HBW; n = 10), and formula feed group (FF; n = 6) on the basis of birth weight. Each birth weight group was divided into two: low birth weight (LBW; n = 5) and high birth weight (HBW; n = 6) and formula feed (FF; n = 6). The body weights of the piglets were measured at birth (BW) and at 21 and 49 days after birth (DBW). After 21 DBW, the p",
        "label": 0
    },
    "1066": {
        "output": "You should make a note of the following to find the trial-level eligibility:\n\n## Procedures\n\n## Trial-level eligibility in the last line by `Trial-level eligibility:`.\nWhat do we include in the note? The trial-level eligibility should include eligibility (EL), reasons for ineligibility (I), and exclusionary criteria (EX).\n\n## Examples\nIn the following example, a clinical study trial-level eligibility is described for a patient who is eligible to enter the trial with 3 scores as [INST] Please see the first example in the previous lesson for more details about notes of patients. \nPatients should not have a history of seizure disorders, clinically or in his or her medical history.\nSeizure disorders, including epilepsy, have been established to occur with the use of ZANUBRUTINIB or other agents with a similar mechanism of action. \nPatients should have a negative pre-study SARS-CoV-2 PCR test. \nPatient should be negative for SARS-CoV-2 at screening/baseline, defined by:\n\\- Two nasal/throat swab SARS-CoV-2 PCR tests obtained within the screening window (which begins 5 days prior to study drug dosing, Day 1 [Day 1 is the day when they start taking Zanubrutinib in the clinical studies]) and separated by \\- Patient is a male, aged between 18 and 95 years. \nPatients should not have known hypersensitivity to anti-CD20 monoclonal antibodies, drugs highly related to Rituximab's structure (e.g., obinutuzumab, ofatumumab, chimer",
        "label": 0
    },
    "1067": {
        "output": "# 3. Exercises\n## 3.1 Data collection script\n\n\n<data-collection-script>\n\n[ELIGILITY: 1]=Excluded;\n[ELIGILITY: 2]=Eligible;\n[DATA-COLLECTION:\n\n<EOD> Efficacy and safety of intermittent lopinavir/ritonavir therapy in children with severe acute malnutrition in a large hospital setting in the Democratic Republic of Congo.\nBackground: Lopinavir in combination with ritonavir (LPV/r) could have a role in the treatment of children with severe acute malnutrition (SAM).A method: We investigated a combination of LPV/r with SAM protocols in 25 children 108 days mean age, under a multidose randomized design with a 5 day intermittent dosing schedule at a dose of 600 mg/ 100 mg, administered in association with a standard antiprotozoal regimen.Results: Plasma K70 concentrations after the third and fourth dosing were below the threshold of quantification (50 ng/ml). Treatment led to the early stabilization of the patient's condition, as highlighted by the reduction in anthropometric parameters, appetite stimulation and improvement of the general clinical condition in comparison to the standard protocol alone.Conclusions: The intermittent dosing protocol was effective in the treatment of acute malnutrition. However, due to the difficulty of ensuring the absorption of protein and lipids in the presence of intestinal edema, our results could not confirm the effectiveness of antiretroviral therapy (ART) in this setting. This could also be attributed to the relatively small sample size.KeywordsLopinavir; malnutrition; antiretroviral therapy; children; Democratic Republic of the Congo.<EOD> Influence of glandular cells in vitro on oocyte activation and embryonic development after sperm nuclear transfer.\nThe mammalian oviduct is a critical site of fertilization, with ciliary beating and oviductal fluid playing roles at the molecular level in preventing polyspermy events. During",
        "label": 0
    },
    "1068": {
        "output": "## Q4. Can we compare and contrast this clinical trial with other clinical trials and the answers you find?\nAnswer. \"Clinical trial is a research done with human participants to analyze how they respond to new treatments or therapies. The focus is to study how the participants respond to the treatment under a safe and controlled environment, such as clinical trial. A clinical trial is conducted using a clinical research protocol. The protocol defines a set of tests, procedures, practices, or methods which have been planned to provide the most reliable information about the safety and effectiveness of the new treatment or therapy. The FDA and other regulatory agencies must approve the protocol (which could take months to do), and the subjects must also give their voluntarily informed consent before participant the clinical trial. A",
        "label": 0
    },
    "1069": {
        "output": "This problem is very useful for programming. You have to choose one of the two branches and keep track of the results, i.e., your `Trial-level eligibility` results may include not only 0 (Excluded), 1 (Not Relevant), or 2 (Eligible), but also something in the format of `Trial-level eligibility: 2) Eligible + T_eligibility_count`. To handle this, you must first use the integer value of `1`. Then, the integer value for `Trial-level eligibility: 2` is just a simple addition of the numbers.\n\nTo solve this problem, we should write first some helper functions and variables to ease things up. \n\n* `count_if`: Auxiliary helper function to add integer values of a string according to a list of numbers\n\n    * input:\n        * _string: String\n        * _numbers: list of integer numbers to add\n        * _start_index: integer to start calculating from\n        * _length: integer to calculate numbers from start_index to\n    * output:\n        * _string to calculate\n\n    * _string: \n        * ````python\n        * from string import ascii_uppercase\n        * \"\"\"\n        * string that will be converted with ascii_uppercase()\n        * \"\"\"\n        * return_string = \"\"\n        * for i in numbers[start_index:length]:\n            return_string += ascii_uppercase(i.encode() % 1000)\n        * return return_string\n        * \"\"\"\n        *\n        *\n    ````\n\n    * _numbers: \n        * ````python\n        * numbers_list = [1, 10, 40, 100]\n        * numbers = list(numbers_list)\n        *````\n\n    * _start_index: \n        * ````python\n        * start_index = 1\n        * ````\n\n    * _length: \n        * ````python\n        * length = 4\n        * ````\n\n    * _string to calculate:\n        * ````python\n        * numbers = [1, 10, 40, 100]",
        "label": 0
    },
    "1070": {
        "output": "[TUT-510/INST] Evaluation of the trial-level eligibility is to find out if the inclusion criteria of the clinical trial include all the relevant patient's data. If it does, you should choose `1) Not Relevant` because it is an inclusion criteria and has not been checked yet. If it does not include all the relevant patient's data, you should choose `2) Eligible`. If the patient data is not included in the inclusion criteria, we consider that the patient is eligible by default. [INST] \n\n![TUT-508][1]\n\n![TUT-509][1]\n\n  [TUT-508]: {{image url=\"images/tutorial/medical/508.png\" defaultHeight=700 crop=30}}\n  [TUT-509]: {{image url=\"images/tutorial/medical/509.png\" defaultHeight=700 crop=30}}\n<EOD> .\nThe effects of the combined treatment with fluorine derivatives (ethyl-5-fluorouracil: E5FUR; picolinyl-6-fluorouracil: P6FUR; or methotrexate: MTX) and 60Co gamma-ray irradiation on growth-inhibition and radiation response were investigated using experimental tumor system; Dalton's lymphosarcoma (LSA) and adenocarcinoma 755 (ADC) of mice. 1) The treatment with fluorine derivatives given intraperitoneally (i.p.) or subcutaneously (subc.) was not effective against LSA growing as a transplantable tumor or against ADC induced by subcutaneous injection of 3-methylcholanthrene, but both the growth of transplanted tumor and the incidence of tumor induced by 3-methylcholanthrene were significantly reduced when irradiation followed the i.p. or subc. administrations of the compounds. 2) In contrast to systemic treatment with fluorine derivatives of both LSA and ADC, the subcutaneous administration of P6FUR showed an effective action against LSA growing as",
        "label": 0
    },
    "1071": {
        "output": "For more details on the format of the results, refer to this issue on data structures.\n<EOD> FAM3G, an Immunoglobulin F-like Apoptotic Cell Molecule, Promotes the Development of Tumor Metastasis\n\nApoptosis has been considered a host protective mechanism against caner. Recently, several studies suggested that tumor cells also utilize the apoptotic machinery to invade, migrate and metastasize. To further understand the impacts of apoptosis on tumor progression, FAM3G, an IgF-like apoptotic cell surface biomarker, was tested to evaluate its functions. The overexpression of FAM3G in human HT1080 fibrosarcomas enhanced the tumor growth, invasion, migration and metastasis compared with empty-vector cells in vitro and in vivo. However, the knockdown of FAM3G by specific siRNA decreased the tumor growth and metastatic activity of A375 melanomas in vivo. We further demonstrated that FAM3G activated Erk1/2, upregulated matrix metalloproteinases (MMPs) gene expression, increased the activation of focal adhesion kinase (FAK) and integrins, and inhibited TNF-\u03b1-induced apoptosis. These results suggest that the overexpression of FAM3G may promote the development of tumor metastasis and inhibit TNF-\u03b1-induced apoptosis through Erk1/2 and FAK pathways. OPEN ACCESS Citation: Liu K-s, Li T, Wang L, Hu K, Yang Z, Liu Y (2014) FAM3G, an Immunoglobulin F-like Apoptotic Cell Molecule, Promotes the Development of Tumor Metastasis. PLoS ONE 9(10): e111295.\n\n# Introduction\nApoptosis plays a critical role in inhibiting metastatic progression, as well as tumor growth [bib_ref]  Evasion of apoptosis as a cellular stress response in cancer, Fulda [/bib_ref] . Recent studies suggested that apoptosis could also be utilized by tumor cells to",
        "label": 0
    },
    "1072": {
        "output": "<jupyter_code>def eligibility_determination():\n    '''A function that return eligibility_test and trial_level_eligibility'''\n    patient = { \n        'Hbp': 140,\n        'Age': 54,\n        'Male': False,\n        'Gender': 'Female',\n        'smoke': False,\n        'drink-alcohol': False,\n        'Use-Illicit_Drugs': False,\n        'NVD': False,\n        'NVD_2': False,\n        'Rheum_disease': False,\n        'Ischemic_heart_disease': False,\n        'Epilepsy': False, \n        'Epigastric_tenderness': True,\n        'Right_Quadrant_tenderness': True,\n        'Bowel_sound': ['normal'],\n        'Leukocytosis': False,\n        'ESR': 40,\n        'C-Peptide': 60,\n        'HbA1C': 20,\n        'OG_BAS_test': [False, False],\n        'SG': False,\n        'SG-tenderness': True,\n        'SG-mass'': True,\n        'Biliary_sludge': False,\n        'Gallbladder_size': False,\n        'Fibrosis': True,\n        'Cholesterol': 320,\n        'Gallstone_no.': 3,\n        'C_G_no.': True,\n        'WBC': 10500,\n        'SpO_2': 98,\n        'BP': {\n            'systolic': 160,\n            'diastolic': 90\n        },\n        'HR': 120,\n        'RR': 15,\n        'Temp': 38.2,\n        'ABG': {\n             'pH': 7.35,\n             'PaO2': 95,\n             'PaCO2':",
        "label": 0
    },
    "1073": {
        "output": "<img src=\"https://github.com/deepRnaseq/papersplus/blob/master/img/image.png\">\n<EOD> .\nWe experienced a case of multiple arterial aneurysms of left renal arteries in a patient with aortic coarctation. A 46-year-old male who had a history of coarctation and an abdominal aortic aneurysm was referred to our department for further evaluation and treatment of a newly discovered renal artery aneurysm. The right renal artery was normal. The left renal artery could not be cannulated by a 5Fr diagnostic catheter and could not be detected by angiography using the antegrade route. Therefore, we decided to cannulate the left renal artery by retrograde route via femoral arteriography. After administration of 5,000 U heparin, we inserted a 5Fr diagnostic catheter into the right femoral artery as well as right femoral vein. The diagnostic catheter was then advanced towards the iliac artery up to the ostium of the left renal artery by manual guidance of the 3.5Fr balloon catheter. A 5Fr diagnostic catheter was then advanced to the left renal artery from the femoral arteriogram. The angiography of the arterial phase was performed by using 2 ml of isosulfin-pentatinate iodine and 10 ml of iopamidol 25 %, 180 mg I/ml. Three fusiform aneurysms, which were 13 mm in diameter in the mid portion of the left kidney were revealed (Fig. 1). The proximal renal artery was normal in size and the aneurysms were located 16 mm distal from the ostium of the renal artery. The ostium of the external iliac artery was normal. No aneurysmal dilatation was observed in the ascending aorta and coarctation site, and the diameter of coarctation site was 24 mm. Therefore, we decided to perform endovascular coil embolization for the renal artery aneurysms. But, because of the severe narrow",
        "label": 0
    },
    "1074": {
        "output": "* * [INST] The number of observations you see per patient varies because the number the patients are available differs across trials. For the first patient, 3 observations are available. The patient has one observation from the clinical trial, no observations from the second trial, and two observations from the patient note. For the second patient, the number of observations is larger -4. For the third patient, the number is much larger -13.\n\n* * [INST] The patient note has a large number of observations -15, while the clinical trial has only two, one for Trial.eligibility and one for Trial.date.<EOD> .\nThis paper explores how women perceive and interpret their pregnancies in urban low-income areas in Mexico City. The analysis is based on in-depth interviews with a sample of 80 indigent women in neighborhoods with the lowest socioeconomic levels in the city. Results confirm that women are aware of the biological nature of pregnancy and that their health behavior is consistent with that knowledge. Pregnancy is seen as an event between the mother and her baby and its meaning is determined by the cultural context that is understood and appreciated in terms of physical and psychosocial changes, and with positive or negative emotions. The women mentioned many social changes during gestation like the need for rest, for the husband's and family's attention, to work less, and to pay less for the family's meals. Health workers should be aware of these changes and try to identify them to better understand the perception of pregnancy to develop health promotion programs.<EOD> Concurrence-induced squeezing in a superconducting circuit.\n\nWe demonstrate experimentally the squeezing effect on the quadrature variance due to the presence of a non-resonant state in a superconducting circuit. We report the measurement of \u223c23 mV, 71% quadrature squeezing of the coherent state for a two-photon detuning of 1.23 MHz. This experiment confirms our earlier predictions that in the presence of a strong non-resonant state, squeezing of the coherent state is possible. This is a key step toward observing photon blockade in circuit QED.\nIntroduction.-Recent years have seen a res",
        "label": 0
    },
    "1075": {
        "output": "**Step 3. Identify possible exclusions with the help of a Clinical Trial Search Guide.**\n\nIf you have identified yourself any possible exclusions or unclear cases, please use the following information on how to do it [16][17][18][19][20][21][22][23][24][25].\n\n**[16]**\n\n### Age\n\n### Inclusion:\n\n> Minimum age limit: 18 years / Maximum age limit: 18 years\n\n### Exclusion:\n\n> Maximum age limit: 70 years / Minimum age limit: 18 years\n\n### Gender\n\n#### Inclusion\n\n> Both sexes / Same sex\n\n#### Exclusion\n\n> Both sexes / Same sex\n\n### Weight\n\n### Inclusion\n\n> Minimum weight limit: 30 kg / Minimum weight limit: 20 kg\n\n### Exclusion\n\n> Maximum weight limit: 200 kg / Minimum weight limit: 80 kg\n\n### Height\n\n### Inclusion\n\n> Minimum height limit: 100 cm / Minimum height limit: 100 cm\n\n### Exclusion\n\n> Maximum height limit: 240 cm / Minimum height limit: 150 cm\n\n### BMI\n\n### Inclusion\n\n> Minimum BMI: 19 kg / Minimum BMI: 19 kg\n\n### Exclusion\n\n> Maximum BMI: 40 kg / Minimum BMI: 19 kg / Maximum BMI: 25 kg / Minimum BMI: 17.5 kg\n\n### Body temperature\n\n### Inclusion\n\n> Allowed to participate with body temperature < 37.5 \u00b0C / Only include participants with no signs of fever at the time of visit and before immunization / Allowed to participate with body temperature \u2265 37.0 \u00b0C / Allowed to participate with body temperature \u2265 37.3 \u00b0C\n\n### Exclusion\n\n> Only include participants with no signs of fever at the time of visit and before imm",
        "label": 0
    },
    "1076": {
        "output": "The [CODE] trial-level eligibility 0\n1\n2 ```\n[/CODE]\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The",
        "label": 0
    },
    "1077": {
        "output": "When the trial-level eligibility is equal to 2, the trial is completely eligible. When the trial-level eligibility is equal to 0 and 1, the trial needs to consider some of exclusion criteria to assess the inclusion. The assessment tool for the determination of exclusion criteria is the `Exclusion criteria checker' widget on the dashboard screen. Exclusion criteria are checked on the widget by pressing the `Check exclusion criteria` button on its panel. The widget allows the user to determine exclusion criteria by either pressing\n`Check exclusion criteria` on the dashboard screen or pressing `Check exclusion criteria` on the `trial-detail: trial` view. In the first case, all `Exclusion criteria checker` widgets are checked as shown in [fig_ref]  Figure 27: Fig 27 [/fig_ref] . In the second case, only\n`trial-detail: trial` view has checked `Exclusion criteria checker` widget. When trial-level eligibility is not equal to 2, the screen on the `trial-detail: trial screen` is as shown in . The exclusion criteria to be checked may vary from trial to trial.\n\n## Exclusion criteria checker\n\n## Example 4\nLet's say your trial is of a type where patients are randomly assigned at a 1:4:4 ratio to 3 treatment arms. The first treatment arm is the study arm, and the second and third treatment arms are control arms. We will set the 3 arms to the following: \nLet's use the\n`randomization seed` variable in our\n`trial-detail: patient` screen. We set\n`initial treatment` to study,\n`narm2` to 2, and\n`narm3` to 3, i.e.,  `randomization seed` in the first row of the table, and press `Check exclusion criteria` to see the trial's\n`Exclusion checker` widget on the trial detail screen. The widget is checked as shown in [fig_ref]  Figure 27: Fig 27 [/fig_ref] . The first 5 check buttons (the `B. 1` check buttons) are checked. Click the\n`Check eligibility` button of the check button for 1st treatment arm in the table, and the\nTrial-Level",
        "label": 0
    },
    "1078": {
        "output": "## Exercises\nPlease solve the following questions based on the examples. If you think the answer needs modification, please do the following:\n\n\n##[A]\nPlease submit a Python code to give the patient-level eligibility for this patient. \n\n### Solution:\n```python\nTrial_eligibility_p = \"0\"\nif \"38year\" in note_list[0]:\n\tif \"8m25/f/163cm\" in note_list[0]:\n\t\tif note_list[1] == \"250/250\" and note_list[2] == \"5\":\n\t\t\tif name_list[1] == \"Park\" and name_list[2] == \"JaYook\" and name_list[3] == \"HoJoung\" and note_list[5] == \"9/02/2018\":\n\t\t\t\tTrial_eligibility_p = \"1\"\n\t\t\telse:\n\t\t\t\tTrial_eligibility_p = \"2\"\n\t\t\t\tTrial_eligibility_p = \"2\"\n\t\telse:\n\t\t\tTriall_eligible = \"1\"\n\n\t\tTrial_eligibility_p : str\n\t\tTrial_eligibility : str\n```\n### Efficiency comparison:\n\n```python\nfrom timeit import default_timer\nimport numpy as np\nimport pandas as pd\n\ndf_p = pd.DataFrame((((\"1\",2,3,4,5), (\"1\",5),14)))\ndf_p\ndf_p.shape\ndf_p.index.isin(\"1\")\n```\n\n### Excavate each patient's eligibility:\n```python\nfrom sklearn.feature_extraction.text import CountVectorizer\nimport numpy as np\nimport pandas as pd\nfrom sklearn.neighbors import knearest_neighbors\npd.DataFrame([pd.DataFrame(((('30',70,80,90), ('1',2),27,24))), pd .DataFrame((((\"100\",400,50",
        "label": 0
    },
    "1079": {
        "output": "##\n<EOD> Fatal bullous pemphigoid induced by chemotherapy with platinum salts.\nBullous Pemphigoid (BP) is an extremely rare entity in cancer cases undergoing chemotherapy. We report a 78-year old man with oropharyngeal cancer who after 8 courses of cisplatin chemotherapy in the absence of other treatments was hospitalized for severe neurological and respiratory distress owing to a widespread blistering eruption. The clinical course was rapidly fatal, the patient's death occurring on the 7th hospital day. Post-mortem examination failed to disclose a cutaneous autoimmune disease or a dermatophytosis, and the histological findings strongly suggested a diagnosis of bullous pemphigoid (BP). Therefore it is reasonable to believe that the cisplatin induced BP in our patient, in agreement with previous reports of other cases of chemotherapy-related BP, thus emphasizing an important side effect that should be well known by physicians treating cancer patients.<EOD> Acidic polymers in human urine\nA group of ubiquitous molecules of undisputed biological relevance is the class of structurally similar acidic polymers collectively called polyamines. They have been recognized as very important for cell life. These molecules influence practically all cell functions including proliferation, differentiation, membrane stability, stress tolerance, aging, and death. These polymers have therefore attracted increased interest and studies have shown that these are involved in tumorigenesis, aging, and apoptosis. Although many studies on these molecules have been reported, the role of these molecules in urine is not well known. It is known that polyamines are eliminated into the urine with relatively little modification. Interestingly, the urinary levels of polyamines show great variability in the general population. These may offer a diagnostic tool in certain clinical cases. In this review, we summarize the present knowledge relating to the structure of these molecules, their synthesis, the function and distribution in human tissues, and also focus on their role in some urinary disorders. \u00a9 2010 IUBMB IUBMB Life, 62(6",
        "label": 0
    },
    "1080": {
        "output": "## 7-3. Task 78\n\n[INSTRUT] Hello. You are a helpful assistant to clinical trial recruitment. It is time to evaluate your skills again, so today you will perform additional tasks in this course. You should focus on these subheadings: Clinical Trial ID, Intervention, Primary Outcome, Secondary Outcome, Exclusion Criteria, and Inclusion Criteria. [/INSTRUT] \n[RUN] [CODE] `curl -s \"http://bioinformaticsref.com/TrialIdGenerator.php\" | grep EXAMPLE_A` [/CODE] \n[OUT]  123456789123E894A716E64656C3C316474616E656E67756E2D746C657273742E316B65666972392E327C697374727973\n    \n    \n\n[/OUT]\n\n---\n\n    For example: A Trial-level assessment of eligibility 6 (patient meets inclusion and exclusion criteria) of 12-month-old infant with suspected infectious neonatal sepsis recruited to a phase 2 randomized controlled trial of probiotic Bacillus clausii versus placebo with randomized interim analyses after 65 participants for treatment failure at baseline \n\n---\n\n## Task 79\n\n[INSTRUT] Hello. You are a helpful assistant to clinical trial recruitment. It is time to evaluate your skills again, so today you will perform additional tasks in this course. When you click and play, click on the button ''Play this example'' at the top, right corner of the playback window. If all of your attempts match with all correct, then you will need to solve more training cases to test your understanding. Now, you should choose a clinical trial out of 100 clinical trials randomly chosen to recruitment. \n\nYou should analyze that trial's ID, intervention, and outcome. Moreover, according to the exclusion and inclusion criteria,",
        "label": 0
    },
    "1081": {
        "output": "<pre><code><a href=\"https://repl.it/@xudongliu/EleCtRalizeaBle-v2-2b0n\">xudongliu/EleCtRalizeaBle-v2-2b0n</a>\n\nimport pandas as pd\nimport numpy as np\nimport re\nfrom matplotlib.pyplot import *\nimport gspread\nfrom google.appengine.api import mail\nfrom google.appengine.ext import db\n\nfrom datetime import datetime\n\ndb.connect('MY_BREAST_CANCER_DATABASE')\n\npatients = pd.read_csv('data/patients.csv', sep = \"\\t\")\ntrial_patients = pd.read_csv('data/patients_trials.csv', sep = \"\\t\")\n\n\n#%% The goal function\n(f1 , f2, g1, g2, h) = model_1(patients, trial_patients)\n\npatients.head()\ntrial_patients.head()\nf1_summary(f1, patients, trial_patients)\nf2_summary(f2, patients, trial_patients)\ng1_summary(f1, g1, patients, trial_patients)\ng2_summary(f2, g2, patients, trial_patients)\nh_summary(f1, h, patients, trial_patients)\n\n#%% The parameters of interest\np1_summary(f1, trial_name = \"p1\", index=[\"f1\", \"g1\"])\np2_summary(f1, trial_name = \"p2\")\np3_summary(f1, trial_name = \"p3\", index=[\"f1\", \"g3\"])\nf1_summary_bar(f1, patients, trial_patients)\nf1_summary_bar(f1, g1, trial_patients)\nf1_summary_bar(f1, g3, trial_patients)\nf1_summary_line(f1, patients, trial_patients)\nf1_summary_line(f1, g1, trial_patients)\nf1_summary_line",
        "label": 2
    },
    "1082": {
        "output": "___\n\n### Task 3. Eligible Cases.\nEach patient that fits the inclusion criteria of the clinical trial on their individual level eligible cases. \nYou will determine eligibility at each visit. As in the previous task, you must always repeat `Eligible cases` by `Eligible cases: `, e.g., `Eligible cases: 76`. ___\n\n___\n\n### Task 4. Adverse Events.\nIn trials with interventional study drugs, the occurrence of untoward medical events is evaluated. These events may be due to the effect of the study drug, to an untoward surgical procedure, to trauma, to other medical therapy or events, and/or to spontaneous or spontaneously occurring events, irrespective of the relationship to the study drug.\nUnless otherwise stated in the protocol, the following items should be reported under adverse events.\n\n1. Adverse events with a reasonable possibility of relationship to the study drug, with special reference to possible drug reactions:\n   1. Adverse events occurring during the study before the start of treatment, or which do not have a temporal relationship, are reported as pre-treatment events and, if appropriate, coded as concomitant diseases.\n2. Adverse events possibly related to multiple drug therapy, or with complex or differential causality, must be reported in an appropriate fashion, and coded.\n3. In addition, unforeseen or unusual events and non-complications of other therapies, even without any specified temporal relationship, should always be recorded. In case of multiple events, as appropriate the first event must be named, and, if necessary, the second or third event must be specified.\n4. Important abnormalities and adverse events in blood pressure, pulse and other vital signs not otherwise classified as adverse events, should also be classified in  ___\n\n___\n\n### Task 5. Protocol Deviation Reporting.\nThe objective is to collect data on medication taken by investigational drug trial participants who are receiving trial agent medication, but are not following exactly the protocol-specified dosage and time of administration.\nEligible cases that do not complete the trial in time due to late withdrawal are assessed.",
        "label": 0
    },
    "1083": {
        "output": "2.5.5.4 Exercises\n\n### Excercise 6-7: 2, 3, 5. Evaluating a patient's eligibility for clinical trials.\nAs in the previous exercise 4-6 above.\n\n# Appendix 5. \nA checklist for assessing your learning and evaluation of this unit:\n\n\n1\\. Did you understand the concepts of the module with respect to clinical trials? 2\\. Did you have doubts about any of the concepts that were presented? 3\\. If your answer to #2 is \"yes \", what were they? 4\\. Did you review the material with respect to clinical trials until you understood the concepts? 5\\. Was the material useful to you?\nThe answers to the questions above will be helpful in assessing your personal development, and in guiding the creation and teaching of a further module of this type. Please indicate your answer.\n\n# References\n<EOD> .\nThe paper presents the results of a multifaceted survey carried out to develop the strategy of the regional health policy in the Kola peninsula. The present paper discusses the concept of socio-medical security as well as presents the results of an in-depth socio-medical study of the population of the Murmansk and Monchegorsk municipalities. This paper contains the results of a survey of the health status of the population, the evaluation of the availability and accessibility of health care services and the population's satisfaction with the level of their implementation, evaluation of the availability and accessibility of the population and doctors with sanitation facilities. The paper discusses the efficiency of the preventive and therapeutic health care, the causes of patients' mortality within emergency care and primary care according to the data for the year 2001. The paper presents the methodology of estimating the needs in population health care, as well as evaluation of the population and medical organizations satisfaction with the health care received. The paper also describes the population's demographics, occupational structure, population health by the criteria of prevalence and incidence of diseases, and their economic consequences.<EOD> Development of a multimodal inhibition of apoptosis score and its clinical implications in colorectal cancer\n\nBackground: Colorectal cancer",
        "label": 1
    },
    "1084": {
        "output": "## Examples\n\n\t# -*- mode: python;\n\t# pylint: disable=no-init-with-self\n\n\tdef compute_eligibility(clinical_trial, patient_note):\n\t\tclinical_trial_eligibility()\n\t\tpatient_eligibility()\n\n\t# Include both eligible and excluded by putting 0 and 1 in different ways.\n\tdef clinical_trial_eligibility():\n\t\treturn int([1 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Hypertension' for trial in clinical_trial]) + \\\n\t\tint([0 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Hypertension' \\\n\t\tfor trial in clinical_trial]), \\\n\t\tint([1 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([1 for trial in clinical_trial[clinical_trial['Intervention'] == 'Toremifene'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([0 for trial in clinical_trial[clinical_trial['Intervention'] == 'Placebo'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([0 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([1 for trial in clinical_trial[clinical_trial['Inclusion_factor'] == 'Toremifene' for trial in clinical_trial]]) + \\\n\t\tint([1 for trial in clinical_trial[clinical_trial",
        "label": 0
    },
    "1085": {
        "output": "___\n_______\n\n## How does a patient qualify for a trial?\nYou are the participant, and you qualify if you meet the same inclusion criteria as the ones applied to the trial. If one of the criteria is not met, you will be given an 'X' for that criteria and an eligibility assessment of '0' (for excluded), '1' (not relevant), or again '2' (eligible).\n\n### How the patient was qualified.\nThe inclusion criteria are as follows:\n\n- Age group: 19 to 40 years\n\n- BMI 35 to 45 kg/m2\n\n- Abnormal serum alanine aminotransferase (ALT) (30 IU/L and 50 IU/L for women and men, respectively)\n\n- Alcohol consumption of more than 2 drinks per day for women or 3 drinks/day for men\n\n- Current smoker (or stopped smoking < 6 months)\n\n- No use of dietary supplement (herbal and vitamins)\n\n- No use of other medicines (e.g., statin, metformin)\n\n### Exclusion Criteria:\nThe exclusion criteria are:\n\n- Women pregnant or lactating\n\n- Women on hormonal contraception\n\n- Women who are planning to conceive, are trying to conceive, or wish to avoid pregnancy for duration of 12 weeks\n\n- Men who are planning to conceive, are trying to conceive, or wish to avoid pregnancy for duration 28 days \n\n- Women taking birth control medicines\n\n- Women with severe psychiatric disease\n\n- Women with a current eating disorder or with symptoms of disordered eating\n\n___\n_______\n\n## How should we report these data?\nWe report clinical trials in the format of a patient flow diagram as shown below. It summarizes the flow of participants throughout the trial. The diagram shows the numbers of participants assigned to each group, the number of participants who completed the trial, and the number of participants who dropped out.\n\n# The table for the clinical trial\n\n|- \n|- {{#if:Categories:Clinical",
        "label": 0
    },
    "1086": {
        "output": "## Clinicaltrials_summary\n\n## [INST] # ClinicalTrials_Summary.\nFirst of all you have to load this module:\n> knitr::kable(load(file = \"data/ClinicalTrials_Summary.RData\", quiet = TRUE))\nIn case you are familiar with the `ClinicalTrials`-package, you should skip this. However, I highly recommend going through it once: https://rdrr.io/bioc/crd/man/ClinicalTrials.html\nWithin this package, a file containing all the information you need can be loaded: # Import the data set > data(\"ClinicalTrials_Summary\") > load(file = \"data/ClinicalTrials_Summary.RData\", quiet = TRUE)\nYou can take a look at the function `summary(ClinicalTrials_Summary)' in the console or with `summarize_clinicaltrials_summary (yourData)`. This function produces many data tables, a `summary` file, and a plot table. (See the package's vignette.)\n\n## # Example of clinical trial\n``` r\nClinicalTrials_Summary %>%\n  dplyr::select(Identifier, Summary, Primary, TrialDate, Location, Country, Condition, Sponsor, Type, Disease, Primary, PrimaryReason) %>%\n  dplyr::mutate(PrimaryReason = if_else(PrimaryReason %in% c(\"Potentially life threatening emergency\", \"Important risk of mortality\", \"Life threatening emergency\", \"Serious and immediately life threatening emergency\", \"Critical illness\", \"Serious illness\", \"Serious condition\"), \"Low\", \"High\", \"Very high\")) %>%\n  dplyr::mutate(Location = factor_if(Location, label_from, levels_if(Location, label_from))) %>%\n  dplyr::mutate(Condition = factor_if(Category, fct_relevel(fct_recode(Category), c(\"Cancer\", \"Immunosuppressants\", \"Therapy\", \"Infection\", \"Chronic disease\", \"Pregnancy\"))) %>%\n    factor_colwise()) %>%\n  dply",
        "label": 0
    },
    "1087": {
        "output": "<EOD> Phosphodiesterase inhibitors for the relief of symptoms of urinary tract infection.\nBACKGROUND\nUrinary tract infection (UTI) is a common condition that causes discomfort and distress for patients and consumes large amounts of health care resources. The most commonly used antimicrobials are urinary antibiotics; however, there is evidence that repeated courses of antibiotics lead to antibiotic resistance and adverse events. Several studies have suggested phosphodiesterase inhibitors (PDEI) have an antimicrobial effect and may provide pain relief in patients with symptomatic UTI without inducing antibiotic resistance.\n\n\nOBJECTIVES\nTo assess the effects of phosphodiesterase inhibitor use on the symptoms of urinary tract infection.\n\n\nSEARCH STRATEGY\nWe searched the following electronic databases up to August 2011: CENTRAL; MEDLINE; EMBASE; CINAHL; Science Citation Index; Conference Proceedings Citation Index-Science; Health Systems Evidence Database; National Health Services Economic Evaluation Database; and the Database of Abstracts of Reviews of Effectiveness. For unpublished studies, we searched clinical trial registries. Finally, we contacted experts in the field and PDEI manufacturers.\n\n\nSELECTION CRITERIA\nWe included randomized controlled trials (RCTs) comparing phosphodiesterase inhibitors (PDEI) with placebo or no treatment in individuals with a diagnosis of a lower urinary tract infection.\n\n\nDATA COLLECTION AND ANALYSIS\nIn addition to our review question we also conducted a meta-analysis of the pain and urine symptom scores taken from the included studies. We extracted data on participant characteristics, intervention details, outcomes, and potential mechanisms for the pain and antimicrobial effects of PDEI using the RevMan software. We pooled results using RevMan for Windows, version 5.0 .\n\n\nMAIN RESULTS\nWe identified 13 eligible RCTs, involving 876 participants. None of the included studies reported on our primary outcome of days with symptoms of UTI. We were unable",
        "label": 0
    },
    "1088": {
        "output": "### The data of patient note\n\n\n*\n\n* 1. The id of the clinical trial (e.g., `553`, `562`):\n```python\nfrom lxml import etree\n\npatient_note = element_text(doc, 'clinical-notes', 'patient-notes-id')\npatient_note_id = patient_note.split('id=\"')[1]\n\nclinical_trial = element_text(doc, 'clinical-trials', 'clinical-trial-id')\nclinical_trial_id = patient_note_id.replace('clinical-trial-id=\"', '').replace('\"', '')\n\nclinical_trial.tag[:-1]\n# output: 'clinical-trial-id=553/562'\nclinical_trial.text\n# output: 553 OR 562\nclinical_trial_id\n# output: 553 or 562\n```\n* 2. The title of the clinical trial (e.g., `Antenatal hydronephrosis`).\n```python\nclinical_trial_details = clinical_trial\nclinical_trial_details.findall('title')[0]\nclinical_trial_details.get('title')\n# output: Antenatal hydronephrosis\n```\n* 3. Investigation group (e.g., `Cytotoxic Chemotherapy Versus Placebo or No Intervention in Infiltrating Transitional Cell Carcinoma of the Bladder: A Phase III Multicenter Randomized Controlled Trial`).\n```python\nclinical_trial_details = clinical_trial\nclinical_trial_details.attrs().get('snp')\n# output: [u'cisplatin + carboplatin + gemcitabine -cisplatin + carboplatin + gemcitabine' 'cisplatin plus carboplatin plus gemcitabine placebo placebo ']\n```\n* 4. The date when the patient was admitted to",
        "label": 0
    },
    "1089": {
        "output": "# Difficulty\nDifficulty \nThis assessment is a bit like answering test questions. You know which questions you don\u2019t know that you will answer. Then you will try to answer them. In this exercise, you will try to understand what is needed to determine a patient\u2019s eligibility. To some extent, you will have to think by yourself, just as if you were faced with clinical situations.\n# Question\n\n### Instructions\n\nBefore answering the questions, please look at the clinical trial in. \nWhat are the inclusion criteria of this clinical trial?\nThe clinical trial is entitled \"Self-expandable Metallic Stent Versus Multiple Plastic Stents in Post Orthotopic Liver Transplantation Biliary Stenosis\". Inclusion criteria: post-OLT biliary anastomotic stenosis.\nLet's think in depth about each inclusion criterion. Consider the following case:\na 54-year-old woman.\npost-OLT biliary anastomotic stenosis (1 month post-operative).\njaundice.\ncholestasis.\nbiliary tree dilation on US.\nWhat are the inclusion criteria and the exclusion criteria?\n-Age (>18)\n-Post-OLT biliary anastomotic stenosis\n-Jaundice\n-Cholestasis\n-Biliary tree dilation on US\n-Plastic stent deployment.\n-Fully covered metallic stent deployment.\nIn the case above, the patient qualifies for this clinical trial if she meets the inclusion criteria listed above. Otherwise, she is excluded. \nWhat will you use to assess the eligibility for this clinical trial?\n\n1. Patient Note.\n2. Inclusion Criteria of the clinical trial.\n3. Exclusion Criteria of the clinical trial.\nWhat does the assessment result show? Is the patient eligible for the trial?\n\n## Assessment of eligibility\nThis clinical trial uses a three-point scale for the eligibility assessment, as follows:\n0) Excluded. Patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria.\n1) Not relevant.",
        "label": 0
    },
    "1090": {
        "output": "# Example 2\n<p align=\"center\">\n<img src=\"image/leaderboard-el.png\"/>\n</p>\n\n[INST] The following code sample is an example of an assignment that has been done in class. \n\n# This code sample has been done by <NAME>, [Instructor's name](http://wiki.hkuf.hk/instructor-name/), on 10th April, 2020.\n\n```python\n# +\nname = [i.split('\\')[-1] for i in globals()]\npatient_re = re.compile(r'[0-9]\\.[0-9]\\.[0-9]')\n\ndef main():\n    # Get list of patient notes\n    fichiers_notes = os.listdir(settings['directory_for_notes'])\n\n    for f in fichiers_notes:\n        file = open(settings['directory_for_notes'] + f, 'r')\n        f_lines = file.readlines()\n        df = pd.DataFrame(f_lines)\n        df['ID'] = 1\n        df['ID'] = df['ID'].apply(function_name='assign_unique_id', arguments=(f))\n\n        df['age'] = df['patient'][0].str.contains(r'.*(\\d+)').apply(get_age_from_patient_num, args=(df))\n        df['name'] = f['patient'].str.extract(patient_re, axis=1).str.join(' ').str.replace(patient_re.solve(), '')\n        df['weight'] = df['patient'][0].str.contains(r'.*(\\d+)').apply(get_weight_from_patient_num, args=(df))\n        df['patient'] = df['patient'].str.replace(r'\\N*', '').str.strip().replace('\\n', '')\n\n        df['freq'] = df['patient'].str.count(r'\\d').apply(function_name='calculate_frequency', args=(f))\n\n        for i in range(0, df['freq'].nunique(), 1):",
        "label": 0
    },
    "1091": {
        "output": "## \nTITLE: Effect of Curcumin supplements on blood pressure.\n\n\nDESCRIPTION:\nThe purpose of this trial is to assess the effect of Curcumin supplements on blood pressure. Curcumin has been associated with reducing blood pressure.\n\n\nOUTCOME:\nThis trial will assess the effect of Curcumin on blood pressure in hypertensive postmenopausal women by adding Curcumin and a placebo to the subjects in two parallel groups. Criteria for Participation:\n- Postmenopausal women\n- Aged 45-60 years\n- BMI 30-",
        "label": 0
    },
    "1092": {
        "output": "## Assignment\nYou will be paid 12 Euro if you correctly determine the eligibility of the patients described in this clinical trial.\n\n## Conceptual\n\n## Clinical trial recruitment assistance (task) 1) patient id: ctri_j_229602 2) title: comparison between laparoscopic common bile duct exploration and intraoperative ercp for management of common bile duct stones -trial-level eligibility: 2) eligible\n\n## Pre-evaluation feedback report (task)\nHere is the pre-evaluation feedback report. The overall score of the pre-evaluation feedback is 0/7. In particular:  You did not provide clear Trial-level eligibility for every single entry line. \nTherefore, you need to make adjustments to the answers.\n\n## Evaluation \nThe adjusted evaluation is provided below:\n\n## Conceptual\nYou scored 100%! Conceptual correctness for Task 1. \nFor 15 patients out of 20, you reported the correct clinical trial-level eligibility. Your overall score for Conceptual (Areas) correctness is 70%.\n\n## Pre-evaluation feedback for the task 2.\n\n## Conceptual\nYour Score on Conceptual accuracy: 1\nYou scored 100%! Conceptual correctness for Task 2.\nFor all patients, you reported the correct clinical trial-level eligibility. Your overall score for Conceptual (Areas) correctness is 100%.\n\n## Pre-evaluation feedback for other areas.\n\n## Instructor feedback\nThank you for submitting your conceptual correctness. \nBelow you'll find the instructor feedback on Your submission entitled, \"\n\". Please note that your instructor provides commentary only on the Conceptual Areas (Areas; conceptual correctness is considered 90% or less overall; you scored 91% overall). A score of 100% or greater for one of these concepts is considered 100%. For the first 3 clinical trial patient's notes, below, you have indicated 0/3 in the 90",
        "label": 2
    },
    "1093": {
        "output": "## Question 16(S6)\n\nTo learn more about gallstones, click the \u25b6 button of the right sidebar to be directed to the clinical presentation of gallstones from our online wiki.\n\n\n\n### \u25b6\n\n\n### Question 16(A5)\n[A] The correct response is C since patients who are taking the following medications may increase their risk for gallstones: diuretics, steroids, contraceptive pills, and opioids. Steroids are also sometimes used to suppress inflammation caused by gallstones. As a result, steroids could cause more gallstone episodes in susceptible patients.\nContraceptive pills could also increase the risk for gallstone episodes by changing the levels of certain hormones. Diuretics are also an effective treatment for gallstones in combination with other modalities of treatment, such as cholecystectomy. However, as mentioned in the paragraph above, this does not mean that diuretics are the actual cause of gallstones and could have been effective in preventing future episodes of gallstones. \u2190 A5\n[B] The correct response is A since smoking is associated with gallstones as a result of smoking-related dyslipidemia caused by an increase in the low-density lipoprotein (LDL) cholesterol and triglyceride (TG) levels.\nIn addition, smoking cessation has been associated with improved bile composition by causing a decrease in the TG content of the bile and an increase in the high-density lipoprotein (HDL) cholesterol levels, resulting in a beneficial change to the bile composition.\n[C] The correct response is B since smoking is associated with increased risk of gallstones, decreased cholesterol metabolism, decreased gallbladder emptying, accelerated atheroma formation, and increased risk of cholecystectomy, suggesting adverse effects on the normal function of the gallbladder and possibly on the blood vessels that supply the gallbladder with blood.\n[D] The correct response is D based on the fact that the predominant composition in cholesterol stones involves LDL cholesterol. The risk of",
        "label": 2
    },
    "1094": {
        "output": "## \u2794 Examples of output in this problem \u2794\nOutputs:\n```\nPatient-level eligibility: [\n    \"NOT_ELIGIBLE\" =>  \"Gender (XS)\" \n    \"NOT_ELIGIBLE\" =>  \"Age (G1)\" \n    \"NOT_ELIGIBLE\" =>  \"Absence of previous NVD\" \n    \"RELEVANT\" =>  \"History of SCH (XS)\"\n    \"NOT_ELIGIBLE\" =>  \"Family history of BC (XS)\" \n    \"RELEVANT\" =>  \"Obtained informed consent\" \n    \"NOT_ELIGIBLE\" =>  \"Hypertension (G1)\" \n    \"RELEVANT\" =>  \"Oncogenic mutation (G2)\" \n]\nTrial-level eligibility: [\n    \"NOT_ELIGIBLE\" =>  \"Initial white blood cell count \u2265 20,000/uL\" \n    \"NOT_ELIGIBLE\" =>  \"Murphy stage IV with blast cells in CSF\" \n    \"RELEVANT\" =>  \"Initial white blood cell count < 20,000/uL\" \n    \"RELEVANT\" =>  \"Murphy stage II or III\" \n    \"RELEVANT\" =>  \"AALL0932 is open, and will be used to assign patients to B-ALL risk groups\" \n]\n```\n### 5. Assignment to risk groups \nIn this part, you should assess to which risk group the patient belongs and then report the risk category. \n\n![INST][E5_INST] \n\nHere is an example of output of a trial patient for this problem:\nInput to the `f_aall0932` function:\n```\ninput <- f_aall0932(df = data[1:3])\n```\nOutput of the function `f_aall0932`:\n```\nAssignment to risk groups: [\n\"RELEVANT\" =>  \"Prior AML treatment (XS)\" \n\"",
        "label": 0
    },
    "1095": {
        "output": "### 9. End with a newline\n```\nEnd with a newline by the following code:\n```\n... #END.\n```\n<EOD> Exciton formation in a two-phonon process in CdZnTe photocathodes.\nThe formation of excitons in cadmium zinc telluride (CdZnTe) photocathodes is studied in the frame of a two component plasma model. The analysis of the experimental observations reveals that the excitons in this compound system may be regarded as localized holes. A possible interpretation of the excitons is proposed. Comparisons between real photocorrosion, photoefficiency, and absorption measurements are made. (P.C.H.)<EOD> Prolonged hospitalization, comorbidities, and poor outcomes in COVID\u201019\n\nCOVID-19 is a highly contagious viral illness causing severe respiratory failure. Our study aimed to define the impact of hospital course and concomitant comorbidities on outcomes of patients with COVID-19. A retrospective study was performed in a tertiary hospital in Southern California identifying patients diagnosed with COVID-19 via nasopharyngeal swab RT-PCR, who were admitted from the emergency department between March 19, 2020, and April 27, 2020. Primary outcome was 28-day mortality. Descriptive statistics and multivariable logistic regression were performed. There were 172 patients included in the study. Median age was 67 years, 53.5% were women. Twenty-eight-day mortality was 18.63%. Among COVID-19 admissions, 258 (57.2%) were hospitalized for \u2a7e7 days, 45 had severe COVID-19, and 21 were intubated for >7 days, 14 patients were placed on ventilators >72 hours, and 29 patients died while hospitalized >7 days. Those who prolonged to >7 days had an odds ratio (OR) of 27.108 (95% CI 15.142-48.634) (P < .0",
        "label": 0
    },
    "1096": {
        "output": "[NAME_1] and [NAME_2] have come to the clinic for follow-up and to discuss contraception. They were both tested positive for trichomoniasis, gonorrhea, and chlamydia. They would like to know if they are eligible to initiate therapy for coinfection after 7 days. [INST] If they ask you how you would decide that they are eligible for therapy, you should always start by reassessing their inclusion eligibility with the following questions, e.g. \n\nAre they sexually active and would they be willing to abstain from sexual intercourse",
        "label": 0
    },
    "1097": {
        "output": "If you want to check this example correctly, press `q` or `return` button to confirm and go back one screen. \n\n**[Tutorial (Part 2)]**\n\n```cpp\n#include <vector>\n#include <iostream>\n\nusing std::cout;\nusing std::cin;\nusing std::endl;\nusing namespace std;\n\nvoid test();\n\nint main() {\n    int n, trial_size;\n    cin >> n;\n    cin >> trial_size;\n\n    vector< int > cnt(n);\n    vector< pair <int, int> > arr(trial_size, pair<int, int>(0, 1));\n    for ( int i = 0; i < trial_size; ++i ) {\n        int x; cin >> x;\n        arr[i].first = x;\n    }\n\n    vector< int > dp(trial_size);\n\n    test();\n\n    cout << \n        \"\\n\"\n        \"Minimum: \" << min(dp)\n        \".\"\n        \"\\n\";\n    cout << \"\\n\"\n        \"Maximum: \" << max(dp)\n        \".\"\n        \"\\n\";\n    cout << \"\\n\"\n      << \"Mean: \" << mean(dp)\n      << \".\"\n      \"\\n\"\n      << \"Standard dev.: \" << std::setw(10) << std::setprecision(4)\n      << std::sqrt(\n                      var(dp) / (n - 1))\n        \".\"\n      << std::endl;\n    cout << \n        \"\\n\"\n        \"Variance: \" << var(dp)\n        \".\"\n        \"\\n\";\n    cout << \"\\n\"\n        \"SD of dev.: \" << std::setw(10) << std::setprecision(4)\n        << std::sqrt(\n                var(dp) / (n - 1))\n        \".\\n\";\n    cout << \n        \"\\n\"\n        \"SD of max. and min. difference: \" << std::setw(10) << std::setprecision(4)\n        << std::sqrt(\n                var(dp) / (",
        "label": 0
    },
    "1098": {
        "output": "In the fourth task, you should do the same works as done in the third task. \n\n[INST]\nPatients with initial BP elevations (> 140/90); corrected QTc > 480 msec.\n\n[END]<EOD> Prevalence and Pattern of Cervical Lymph Node Metastasis in Oral Cancer\n\n [bib_ref]  Analysis of 197 recurrent cases of patients with squamous cell carcinoma of..., Chen [/bib_ref]  [bib_ref]  The prognostic significance of cervical metastases in head and neck squamous cell..., Clark [/bib_ref]  [bib_ref]  Metastasis in head and neck cancer: an update, Aljurf [/bib_ref]  [bib_ref]  CNCC-HN: Evaluation of the NCCN Guidelines for Head and Neck Cancer, version..., Balm [/bib_ref]  [bib_ref]  Predictors of occult metastatic nodes in oropharyngeal cancer, Gurney [/bib_ref]  [bib_ref]  The prognostic significance of cervical lymph-node metastases in resectable epidermoid carcinoma of..., Jones [/bib_ref]  [bib_ref]  The prognostic significance of cervical metastases in carcinoma of the oral tongue, Harrison [/bib_ref]  \n\n# Materials and methods\nOne hundred nine patients of buccal mucosa or lip sarcoma admitted between August 2013 and August 2014 at Department of Maxillofacial Surgery of Wenzhou People's Hospital affiliated to Wenzhou Medical College were included in this study. All the patients included in this study had undergone radical resection and neck dissection after being subjected to thorough preoperative evaluation and complete physical examination. [bib_ref]  Oromandibular metastasis from buccal carcinosarcoma, Liu [/bib_ref]  In addition, the patients enrolled in our study underwent clinical treatment. Among these patients, 39 patients were found not to have cervical lymph node metastasis, forming the control group; the other 70 patients were found to have cervical lymph node metastasis and were included in the observation group. The inclusion criteria encompassed the following: The inclusion criteria for the observation",
        "label": 0
    },
    "1099": {
        "output": "#\n\n### Examine the patient note and the clinical trial.\nYour mission is to determine the patients' eligibility for the clinical trial described in a patient case vignette (see below). You need to understand the eligibility requirements for clinical trials and consider whether the patients in the vignette fulfil the eligibility requirements. Based on your considerations, you should determine a trial-level eligibility for each of the patients. Finally, calculate your score according to the scoring criteria. Examine the case vignettes carefully before you proceed (see also Note [E0] at the end of the article) (see also Note [R5] at the end of the article).\nNote: If you need more information as you work through the case, you should use relevant texts or scientific journals that are accessible by you in the library of the university. Refer to Note [U2] below.\n\n**Recommended for experts: Examine several case vignettes; the answers will be discussed in detail during the final exam, as well as the score given. For details, see Note [S1] below.**\n\n### What is an eligibility?\nEligibility is a term often used in clinical trials. It describes the characteristics needed for a person to qualify for a trial. Thus, an eligibility is something that allows that particular person to qualify for a clinical trial. Note that an eligibility may refer to the patient (patient-level eligibility) or the trial (triallevel eligibility).\n\n### Patient-level eligibility\nWhen determining a patient-level eligibility, you need to consider (1) the patient's medical history, (2) the patient's current health status and the clinical findings, (3) the patient's laboratory values, and (4) the other medications, including the over-the-counter medications (Note [B9] will help you to find more information about over-the-counter medicines).\nHere are a few points to remember:\n- Always consider the patient's health status, both overall and with respect to the symptoms stated in the patient case vignette.\n- Consider current medications and past or planned medical procedures.\n- Consider current and past diseases affecting the eligibility",
        "label": 1
    },
    "1100": {
        "output": "<EOD> Effect of Ginkgo Biloba Extract on Rat Platelets and Serum Adenosine\nWe report an investigation of the effect of the flavonoids from the leaves of Ginkgo biloba on adenosine production by rat platelets and also on platelet cyclic AMP levels and aggregation. The flavonoids increased both basal and thrombin-induced adenosine levels in the serum, and stimulated adenosine production by platelets.<EOD> A novel mechanism of RXFP1 regulation in the mouse uterus: RXFP1 desensitisation and its relevance to the female fertility\n\nRXFP1 is a uterine receptor for relaxin-2, and the interaction initiates the uterine relaxation and prepares the female for implantation. The importance of the receptor is highlighted by genetic studies where RXFP1 depletion results in in utero fetal resorption, early embryonic lethality, and abnormal reproductive organs. However, studies on the mechanism by which relaxin regulates uterine RXFP1 remain limited, with many receptor regulatory mechanisms being studied based on relaxin treatment of cell lines. We report here a functional desensitisation of RXFP1 in the mouse uterus, with implications for understanding the mechanism behind the receptor regulation. Treating mice with exogenous intraperitoneal relaxin resulted in desensitisation of RXFP1 on the uterine luminal epithelium, and this was shown by a significant reduction in protein levels of the receptor and intracellular calcium mobilization in response to relaxin in vitro. The desensitisation was found specific for relaxin treatment in vivo, and relaxin administration on consecutive days could not reverse the desensitisation, with a similar timecourse of desensitisation after a single treatment. Relaxin administration on days 1 and 2 of pregnancy induced a partial, and then a complete reduction in the number of implantation sites, which correlated with the level of RXFP1 desensitisation. These findings support a model of physiological RXFP1 regulation in the mouse uterus via receptor desensitisation, induced by relaxin exposure. The significance",
        "label": 0
    },
    "1101": {
        "output": "<EOD> .\nThe paper describes a 464-bp Sma I-Eag I fragment coding the C-terminal part of the protein in the 16,5-lipoxygenase from flax stem. A DNA library of the gene encoding the C-terminal part of the enzyme was obtained. It was found that the gene possesses the following structure: 5'-flanking sequence-coding sequence-3' flanking sequence. The restriction fragments of DNA isolated from the gene library were hybridized with DNA fragments from various flax cultivars to study the polymorphism of the 16,5-lipoxygenase gene. According to the patterns of hybridization of the fragments of DNA they were subdivided into the alleles (a, b, c, d, and e) differing in number and size. Alleles a and b encode the enzyme with the highest activity, allele d-with the lowest activity of the enzyme, whereas alleles c and e display activity lower than the alleles a, b, and D, but higher than that of the allele d. The genetic analysis of enzyme activity distribution among lines of flax has shown that the activity is determined by a polygenic characteristic, whose genotypic factors are alleles a, b, c, d, and e. There is a high correlation between the level of the 16.5-lipoxygenase, its substrate specificity, and enzyme activity. However, the activity of the enzyme depends mainly on the gene, which has the greatest impact on its activity.<EOD> .\nThe authors present the case report outlining a 49-year-old woman who presented with unilateral and transient loss of vision in one eye associated with transient hemianopia. She complained about painless diplopia with lateral deviation of the affected eye. Her past medical history was notable for the right leg deep venous thrombosis treated with low molecular weight heparin (LMWH) one year prior to onset of this episode. There was no evidence of cardiac thrombus, or any other cardio-vascular thrombotic risk factors. Physical examination revealed painless and progressively increasing exophthalmus in the right eye during the following 4 weeks. The diagnostic and therape",
        "label": 0
    },
    "1102": {
        "output": "[/TEST]\n\n</div><!-- Instructions end -->\n</template>'\n      \n<template langs=\"rst\">\n```\n\n### 03_221_clinical_trial_evaluation.edn(1)\n\n*\n\n*The evaluation of a clinical trial is performed by the Clinical Trial Center (CTC) that is based in our department of gastroenterology and hepatology in Leiden, the Netherlands. The Center of Evaluation (COE) is part of the AMC. All studies approved by the COE are performed in a standardized and independent manner. This includes the assessment of: inclusion, exclusion and protocol compliance. Furthermore, the CTRE collects epidemiological information and follow-up data for later meta-analyses of the results. \n\n\n> 03_221_clinical_trial_evaluation.edn(1): \n\n> 03_221_clinical_trial_evaluation.edn(1): # Evaluation of trials\n\n> 03_221_clinical_trial_evaluation.edn(1): # Trial assessments\n\n> 03_221_clinical_trial_evaluation.edn(1): # Evaluation of adverse events\n\n\n``` rst\n\n03_221_clinical_trial_evaluation.edn(1): # Trial descriptions\n\n- Trial N: 'N-of-1 Trial With Pantoprazole and Placebo to Evaluate Gastroesophageal Reflux Disease'\n    \n- Trial M: 'Randomized placebo-controlled trial to study the clinical profile of subjects after pantoprazole withdrawal'\n  \n\n03_221_clinical_trial_evaluation.edn(1): # Inclusion criteria\n\nInclusion criteria for N-of-1 trial A:\n\n- Signs and symptoms of Gastroesophageal reflux disease\n\n- Heartburn during the week before inclusion\n\n- Regurgitation during the week before inclusion\n\n- End",
        "label": 0
    },
    "1103": {
        "output": "<EOD> Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells\n\nBackground: Microarray and RNA-seq represent current best performing technologies for estimating gene expression levels from short sequences of RNA, and each technology has its own set of characteristics and limitations. We performed a comparative study of these technologies in order to explore their efficacy and possible overlapping or complementary applications. Results: In this study, microarray hybridization was performed using 8x60K SurePrint G3 Human Gene Expression platform (Agilent Technologies), while RNA-seq was performed using Illumina NextSeq 500 sequencer. We tested whether these two technologies represent similar approaches to quantifying gene expression with the same data on activated human T cells. RNA-seq technology was generally found to be more sensitive in detecting minor (0.1 fold change) changes in gene expression than the microarray technology. RNA-seq was also more precise (coefficients of variation [CV] < 0.39) and specific (e.g. less false positives and false negatives). We also noted that RNA-seq had significantly higher numbers of detected isoform-specific allelic expression. We further demonstrated that the performance characteristics of the two technologies were different depending on the gene expression level. We also investigated the number of genes detected by both technologies while varying various filtering criteria, such as the number of samples.Conclusions: Overall, we conclude that RNA-seq is a superior tool for mapping transcriptome expression profiling (comprehensive and specific) and isoform-specific expression (allelic alternative splicing). For expression profiles and allelic analysis, we recommend that 10 to 20 samples for microarray and 3 to 5 samples for RNA-seq will be adequate.\n\n# Background\nThe study of transcriptomics is important in multiple areas in biomedicine. Differential gene expression analysis is being widely used by researchers to decipher the molecular basis of several diseases and elucidate the effects of drugs or other treatments [bib_ref]  The use of microarray in pharmacogenomic research, Warrington [/bib_ref] . Microarrays and RNA-seq are currently the most widely utilized methods for transcriptome profil",
        "label": 1
    },
    "1104": {
        "output": "9. Let's create a function to read a new list 2\nFor example, suppose you have a list of patient information like this:\n[\n\nLet's apply that function for a patient example (i.e., the last patient note):\n[[[\"Emergency Dept.\",\"AB,CD\",\"2014-12-01\",\"2014-12-31\"],\"Obesity\",\"51\",\"Male\",\"3\"],[\"Emergency\n\nAnd apply `read_data_from_csv` to read a new list:\n[[\n\n3. Let's show eligible assessment scores for all patients in the trial.\n\nInside the `data` dictionary, we have created the list of patient information. Since there is only one patient information list, we need to access it through the `['patients']` array slice.\n\nHere is the patient list:\n['patients']:\n[{'Patient_ID': 1, 'Visit-Date': '2014-10-01', 'Note_ID': 0, 'Patient_Info': {\"Name\": \"A 25-year-old male\",\"Age\": \"25\"} ,\n'Trial_ID': 11111, 'Eligibility': '1' , 'Status': \"Finalized\"} ,\n'Patient_ID': 2, 'Visit-Date': '2000-10-30', 'Note_ID': 1, 'Patient_Info': {\"Name\": \"Betty J. Johnson\",\"Age\": \"45\"},'Trial_ID': 12345, 'Eligibility': '0' , 'Status': \"Finalized\"} ,\n'Patient_ID': 3, 'Visit-Date': '2014-11-02', 'Note_ID': 1, 'Patient_Info': {\"Name\": \"C J Doe\",\"Age\": \"48\"} ,\n'Trial_ID': 23456, 'Eligibility': '0' , 'Status': \"Finalized\"} ]\n\nSo, we need to find the index of patient number '3' in the 'patients' array, which is `0`. We can",
        "label": 0
    },
    "1105": {
        "output": "# [EXP] EXAMPLE RESPONSE\nHere is another sample file: [EXP_RESPONSE_0]\n\n* This trial-level eligibility: 2; Excluded\nFor assessing trial-level eligibility, you may need to read more than one note\n\nThis trial is for women who meet inclusion criteria and do not meet exclusion criteria for a Phase III Study in Patients with High Blood Lipids. Patients should have a diagnosis of hypercholesterolemia and be receiving a stable dose of 40 mg atorvastatin. Hypercholesterolemia is defined as: (a) total cholesterol  (TC) 220-240 mg/dL, TC .220 mg/dL AND LDL-C .140 mg/dL, LDL-C .130 mg/dL AND TC \\220 mg/dL AND (TC  .220 mg/dL AND TC (TC (TC .220 mg/dL OR LDL-C 130.0-140.0 mg/dL. TC .240 mg/dL. Hypercholesterolemia also includes familial hypercholesterolemia and severe hypercholesterolemia .250 mg/dL. LDL-C.320 mg/dL with documented high risk atherosclerotic cardiovascular disease based on the following criteria: diagnosis of ischemic heart disease (including myocardial infarction and stable angina not due to CAD), diagnosis of coronary or other arterial revascularization by PCI or CABG, history of definite CAD on invasive coronary angiography (ICA) or computer tomographic coronary angiography (CTA), history of abdominal angiography with documented prox occlusive disease, history of percutaneous transluminal angioplasty of the extremities (PTA of the lower or upper extremities, respectively), history of abdominal aortic bypass or extra-anatomic femoral-femoral anastomosis, history of",
        "label": 0
    },
    "1106": {
        "output": "## 4.\n[INSERT] Data for input. This example input file defines four (4) attributes of both patient (Name, BP, and Age) and clinical trial (Title and Summary), and one (1) attribute of output (Trial-level eligibility). [/INSERT]\n\n> patient_note = '[patient_note]'\n> trial = '[trial]'\n\n# The input.\nFile contents can be written to the file for easy sharing and reproductions.\n\n## 5.\n[INSERT] Script for evaluation: The scripting file is located in the same folder as the input file. Each run will start when the user inputs `>> run` and the evaluation results in `0` for any unsuitable input or `1` for the correct one.\n\n# If the result is 1, the case is done.\n\n6. \n<EOD> .\nThis article examines the use of the GnRH test (Gonadotrophin Releasing Hormone) in the assessment of primary ovarian failure. The study included both a clinical and hormonal evaluation in 40 unselected cases of primary amenorrhoea. In order to assess the sensitivity of the GnRH test, patients received 3 doses of 100 mug GnRH (36.5 to 56.5 mg i.v.) over an hour. The results were compared to a clinical and hormonal assessment carried out at the same time. The response pattern and the kinetics were studied in 18 patients with GnRH secretory disturbances using a dose of 100 mug three times daily in the same time as previously.<EOD> The impact of low-dose tizanidine therapy on sleep spindles in OSAS patients: A polysomnographic analysis.\nSTUDY OBJECTIVES\nTizanidine, an \u03b12 adrenergic agonist, improves sleep apnea syndrome (SAS) by decreasing the body's muscle tone. This study examines the effect of tizanidine on sleep spindles, which indicates the therapeutic effects of tizanidine on spindle activity in the central nervous",
        "label": 0
    },
    "1107": {
        "output": "## [GLOBAL] [PRO] Hello, Pro. Your task is to calculate the total number of neurons and oligodendrocytes in individual cortical layers and the total gray and white matter volumes.\nThe brain is the central nervous system (CNS) of the human body. It has a complex architecture that allows it to process information and enable learning. The human brain has many parts including the cerebrum, brainstem, cerebellum and the spinal cord. The cerebrum, is the major portion of the brain that performs a variety of complex functions including speech, thinking, memory, behavior and voluntary movement. This is divided into the left and right hemispheres by a vertical plane on its outer surface. If you cut the brain lengthwise you can observe two large chambers or ventricles, the lateral ventricles and a pair of smaller chambers, the third ventricle. The cavities of the left lateral ventricle (LV) and right lateral ventricle (RV) communicate with the third ventricle. The cerebral cortex is an outer layer of the cerebrum. The cortex consists of 6-layered structure (each layer comprises of different neurons and glial cells). Layer 1, or the innermost layer, is called the molecular layer. It is filled mainly with dendrites of several types of neurons. The layer is followed by Layer 2, or the internal granule layer, which contains neurons originating from the cerebellum. Layer 3, the Purkinje layer, contains the Purkinje cells, which together with the granule cells in layer 2, help control the movement of motor neurons. Layers 4, 5, and 6 compose one-third of the cortex. Layer 4 is called the pyramidal layer, because the majority of neuronal bodies of this layer are pyramid-shaped. Pyramidal cells in layer 4 tend to cluster closer together than cells in the other layers. Cells of the deep cortex in layer 5 and layer 6 are also pyramidal cells, but these are larger and more mature than those in layer 4. The final 5-layer of cortex in the brain is the superficial cortex.",
        "label": 0
    },
    "1108": {
        "output": "[CODE]\n#!/bin/bash -c 'echo \"Hello, Good afternoon. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the [INST] Inclusion criteria of a clinical trial to determine the patient's eligibility.\"'\n#!/bin/bash -c 'echo \"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty foods. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The largest stone is 14mm. \"'.\n#!/bin/bash -c 'echo \"The assessment of the final clinical trial trial level eligibility is\"'.\n#!/bin/bash -c 'echo \" \"'.\n#!/bin/bash -c '<EMAIL>@<EMAIL> <EMAIL>@<EMAIL>'.\n\n#!/bin/bash -c 'echo  <EMAIL>@<EMAIL> <EMAIL>@<EMAIL>'.\n\n#!/bin/bash -c ''</code>'\n\n\n[CODE]\n\" \n<EMAIL>@<EMAIL> <EMAIL>@<EMAIL>\n</CODE> [END STRIP] <EMAIL>@<EMA",
        "label": 0
    },
    "1109": {
        "output": "<EOD> Tuberculous perforation of the ileum\n\nSUPPLEMENTARY MATERIAL\n2021SUPPLEMENTARY MATERIAL\nJGH Open 5\n61112021Submission Decision: Accepted by Daniel Pua, Associate Editor, July 16, 2020, Editor-in-Chief: Michael Bennedetti\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any Med-Ref platform \u00a9 Med-Media Group Sdn Bhd. All rights reserved.A B\nJGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 112-113 SUPPLEMENTARY MATERIAL Figure A. Computed tomography scan of abdomen showing dilated ascending colon with surrounding inflamed fat stranding (A) and a perforation in the mid-ileum (B).<EOD> Effects of acute and sub-acute exposure to nicotine on cognitive functions in healthy rats\nThe present study evaluated the effects of acute and sub-acute administration of nicotine on cognitive functions in healthy rats, with the focus on the effects of dosage and duration of nicotine administration. In the training phase, rats were trained to find a visible platform by searching for a hole hidden in a wall of a tank. After 5 days of training, the effects of acute and sub-acute administration of 0.0025, 0.01, 0.04, 0.08, 0.16 or 0.32 mg/kg of nicotine dissolved in distilled water (n = 7 per group) were evaluated by measuring the time that the rats took to find the platform after injection of substance. The results showed that the time taken by rats to find the platform was significantly different (P < 0.05) from day to day but did not significantly differ among groups. In the test phase, the effects of 0.1 mg/kg of nicot",
        "label": 0
    },
    "1110": {
        "output": "## 23.2.4.1.13 Expected Value Distribution Plot\n\n__What is the expected value distribution when we sample from the patient note data?__\n\nBefore plotting the distribution, let's load the `R` package of `exvalue`, which plots the `expected value` distribution. \n\nWe can also plot the expected value of a certain cell in any dataset by applying the `plot_expected_value_distribution()` function of `exvalue`.\n\nHere is an example: \n\nWe should plot the expected value distribution for the 200 cells, e.g., \n\n``plot_expected_value_distribution(test_set = test_set, \n                                     dataset = pd.DataFrame({\"cell_id\" : df_1.keys(), \n                                                        \"cell_label\" : df_1.columns, \n                                                        \"expected_value\": test_set.index.values\n                                                        })\n                                     )`` [#no ]\n   ```[R] exvalue [184]: \n    plot_expected_value_distribution(test_set = test_set, \n                                   dataset = pd.DataFrame({\"cell_id\" : df_1.keys(), \n                                                          \"cell_label\" : df_1.columns, \n                                                          \"expected_value\": test_set.index.values\n                                                          }), \n                                   plottitle = \"Expected value distribution\",\n                                   ax = ax_f, \n                                   showtext = True, \n                                   showborder = True, \n                                   xaxislabel = \"Cell index\",\n                                   ylabel = \"$ \\lambda $\", \n                                   xlabel = \"$ \\lambda $\", \n                                   xmax = len(df_1.loc[\"All 100\"][\"Label\"])\n                                  [/1#no ]\n   \n    >>> ax_c.legend(loc =\"best\") [#no ]\n   \n    >>> ax_c.legend(bbox_to_anchor=(0.3,1.0), loc = \"best\")\n    [/2#no ]\n    \n    >>> ax_",
        "label": 0
    },
    "1111": {
        "output": "## Section 2: Evaluation of Inclusion Criteria {section2}\n\nAs you know, the clinical trial is designed to test whether a particular treatment works. In other words, we want to know if some patients get better or how many patients are getting better after the treatment. \nThe clinical trial may have the following three outcomes: \n1) Patients whose condition improved over time (Complete response)\n2) Patients for whom their condition stabilized (Partial response)\n3) Patients whose condition deteriorated (Progression)\nThe assessment of the treatment response (i.e., the treatment outcome) has a three-point scale: 0) Improvement (Condition improved); 1) Stable (Condition did not change); and 2) Deterioration (Condition deteriorated). \nAs you may know, the clinical trial recruits patients with the expectation that the treatment will work in patients. To evaluate the expected effects, we want to analyze patients that were expected to get benefit from the treatment. In other words, eligible patients are the patients who are expected to benefit from the treatment; and ineligible patients are the patients who are not expected to benefit from the treatment (because they are not eligible). To evaluate the expected effects, we want to analyze patients that were expected to get benefit from the treatment. In other words, eligible patients are the patients who are expected to benefit from the treatment; and ineligible patients are the patients who are not expected to benefit from the treatment (because they are not eligible). \n\nThe clinical trial may assess the eligibility by the eligibility-for-benefit analysis. For this clinical trial, we have no information about the patient's response. \nAs you know, a 3-by-3 contingency table is constructed based on binary variable. A 3-by-3 contingency table can easily be used to calculate the chi-square test of goodness of fit. [INST] 3x3 contingency table can be used to calculate chi-square test. In a 3x3 table, there are nine total possible values, given in the following table. \nBased on the table above, we can compute the chi-square values as described in the [RM], using the following code.",
        "label": 0
    },
    "1112": {
        "output": "# Data Visualization\nVisualizing data allows you to quickly draw relevant conclusions from complex datasets. Data visualization is a way of creating visual",
        "label": 0
    },
    "1113": {
        "output": "<EOD> Effect of a High Protein diet on glycaemic and metabolic control in Type\u00a01 diabetes mellitus: a three\u2010way crossover randomized study\nAim: The purpose of this study was to assess the effect of a high\u2010protein diet (HP) on glycaemic and metabolic control in type 1 diabetes mellitus (T1DM).<EOD> A randomized controlled clinical trial to measure the impact of group psychotherapy on the mental health of Chinese female breast cancer patients with metastasis\n\nPurpose: The aim of this study is to assess the effect and feasibility of group psychotherapy in hospitalized Chinese female breast cancer patients with metastasis (BPMs). Patient and methods: In this randomized controlled clinical trial, 118 BPMs with metastasis were recruited from the hospital in China. The patients were randomly assigned to two matched groups: psychotherapy group (32 individuals) or control group (32 individuals). Patients in the psychotherapy group received 12 weeks of intervention, whereas those in the control group received routine treatment. The interventions were conducted by psychotherapists who were blind to patients. Data on psychosocial status were collected before and after the intervention. Data analysis was performed using SPSS19.0. Results: Data analyses revealed significant differences in depression (p = 0.014) and fatigue (p = 0.033) between the two groups at T4 after intervention, but not at T2, T3 or T5. In addition, differences in anxiety, stress, emotional well-being, quality of life, psychological adaptation and pain were nonsignificant.Conclusion:These findings suggest that group psychotherapy is beneficial to female BPMs in controlling their depression and fatigue.\n\n# Introduction\nBreast cancer is common among women worldwide.In 2018, breast cancer alone accounted for 30% of all cancers among women.The prevalence of breast cancer has been increasing in East Asian countries, including China, according to an estimation by GLOBOCAN 2018. In China, breast cancer is the most common cancer among women, accounting for",
        "label": 0
    },
    "1114": {
        "output": "[/HIDE]\n\n## 53 Task 4.2: Finding the most eligible patient\n\nNow you can compute your ranking for each patient. The clinical trial investigators find the most eligible patient with a high priority for their trial.\n\n[MARKDOWN][INST] The most eligible patient is a patient with a high rank of trial-level eligibility. \nYou must use the function `findMostEligiblePatients` of the package `clinicalTrial`. The function calls the algorithm you will find in the source code on the Github repository. \nThe function takes the name of a clinical trial and returns a dataframe `findMostEligiblePatients_DF` with the patients' characteristics according to the clinical trial's eligibility, one column for each variable. Here as an example is the name of the clinical trial: `trial_name = trial`.\n\nFind most eligible patients by the clinical trial name.\n<div class=\"execute_command\" data-run=\"trial_findMostEligiblePatients\">\n<button type=\"button\" class=\"btn btn-light btn-sm\" onclick=\"window.__staticText__.$trial = 'trial';\nwindow.__sessionText$ = JSON.stringify(window.__sandbox$$);\nwindow.__sessionText$ = JSON.parse(window.__sessionText$);\">Find most eligible patients</button>\n</div>\n\nThe output of the function `findMostEligiblePatients_DF` is a dataframe `table`, where every column has the patient's corresponding value. As an example, for the clinical trial we chose `Trial 242`, and the output is in the table below:\n\nTable: `findMostEligiblePa-tients_DF` of the clinical trial numbered `Trial 242`.\n<pre><code>>>\n               id    <NAME>   age    age2  sex     sex2   race   race2  ethnicity ethnicity2 birth_date birth_date2  BMI  ht      bmi_category weight  height  weight2  bmi_2_cat  smoker   lifestyle lifestyle2  zipcode\n    1",
        "label": 0
    },
    "1115": {
        "output": "[TRIAL] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Here is the clinical trial: \nTitle: Scribes",
        "label": 2
    },
    "1116": {
        "output": "## The third data entry\n[START]\nThe third data entry is the second part of the assessment for eligibility. Each part of the second part of the assessment for eligibility is a column, and your job is to check the data in the assessment of eligibility. \n[/START]\n\n#### 1. Assessment of Eligibility : A, S, E, F, T, C, I, G, and R\n\nHere are the definitions of the variables:\n- 0) Eligible: all the values are 1 except for an observation record that had to be excluded and has values of 0.\n- 1) Not relevant: at least one value is 0.\n- 2) Excluded: at least one value is 1.\n\nHere are the three assessments for `pat1` in Table 4-4.\n \n| Eligibility | A | S | E | F | T | C | I | G | R |\n|--------|---|---|---|---|---|---|---|---|---|---|---|\n| 1+0+2+1+1+0+0+1+1+0+1 | -0+0+2+2+0+0+2+2+0   \n| :++++                     :   \n| :+++               :      :   \n| :---+              :      :   \n| :+      :   :   :       :   \n| :       :    :       :     :   \n| :        :     :          :   \n| :         :      :        :   \n| :          :       :      :   \n|                                3+0    \n\nNow, let's make a logical expression about the assessment of eligibility. \npat1_eval_asschg1 = (eligibility == \"2+0+0+0+1+1+0+0+1+2+2+1\") && (0<=pat1_eval_asschg1 < 10)\n\nFor the first patient of this experiment, the eligibility is set to be 1 and the remaining criteria are 2. The logical expression pat1_eval_asschg1 is created for checking the assessment of",
        "label": 0
    },
    "1117": {
        "output": "<EOD> Tetraethylammonium hydroxide: the proton form of the ion pair formed by tetraethylammonium and bromide.\nA proton in a complex formed by tetraethylammonium (TEA) and bromide (Br) was successfully localized by (1)H NMR spectroscopy. Because the (1)H NMR shift of TEA is sensitive to the hydrogen-bonding environments of its N(+)-H group, the chemical shift was measured in the 200 MHz (1)H and (2)H spectra of TEA/Br solution to identify the localization site. The NMR shift of the N(+)-H group of TEA in TEA/Br solution (1/1 molar ratio) is nearly unchanged by the addition of HBr, indicating that the N(+)-H group is not the hydrogen-bonded donor but is the hydrogen-bonded acceptor of the bromide anion. Therefore, the ion pair formed by TEA and Br in the solution and the neutral ammonium cation can be distinguished. The present results clearly demonstrate that the localization site by NMR spectroscopy is a strong evidence to determine the proton form of the ion pair in the solutions.<EOD> Mucosal healing and serum gastrin in patients with duodenogastric reflux\n\n\n\n# Introduction\nDuodenogastric reflux (DGR) leads to transient lumen obstruction, mucosal inflammation and atrophy. The aim of this study is to evaluate gastric and antral mucosal inflammation, atrophy and mucosal blood flow by using video capsule endoscopy (VCE) in patients with DGR. A further aim is to evaluate the relation between gastric mucosal blood flow and gastric serum gastrin, since serum gastrin was found to decrease with reflux of duodenal contents into the stomach and was postulated to be a reliable marker in clinical practice [bib_ref]  Effect of duodenogastric reflux on gastric mucosa, Shafir [/bib_ref]  [bib_ref]  Duodenogastric reflux: influence on gastric acid",
        "label": 0
    },
    "1118": {
        "output": "[fig]  [RINC]: [INST] [/fig] \n[fig]  [END]: [INST] [/formula] \n<EOD> A critical appraisal of psychosocial interventions for persons with AIDS and their significant others.\nTen randomized clinical trials that tested the effectiveness of psychosocial interventions that benefited persons with AIDS and their significant others are examined. Interventions assessed were: (1) a training seminar that taught the primary care nurse management of the psychosocial effects on the patient and the spouse; (2) a training workshop for professional staff in care of the patient with AIDS; (3) a workshop about AIDS for medical and nursing practitioners; (4) a structured group for patients receiving antibiotic drugs; (5) a training program for psychiatrists on treatment recommendations for AIDS-related depression; (6) a support group for gay individuals with AIDS and for their lovers; (7) a support group for gay men with AIDS and for close others; (8) short-term individual psychotherapy; (9) individual nursing telephone contact within 24 hours of a physician's visit; and (10) a combined medical and nursing intervention approach. The effects of the interventions on patients, their caregivers, and the clinical outcomes of patients with AIDS were assessed. The intervention approaches were generally effective in improving psychosocial outcomes, including quality of life and perceived social support, but the combined intervention had the greatest effect on improving care. This review of AIDS intervention research shows that, although few of the studies are definitive, they each have useful methodological strength.<EOD> Anatomical considerations for implant removal of bone anchored hearing systems\nAbstract Bone anchored hearing aids (BAHAs) have become widely accepted in the treatment of conductive and mixed hearing loss in the pediatric population. One of the few serious complications is the failure of the osseointegrated implant to retain a functional BAHA prosthesis (Baha\u00ae, Ponto\u00ae, BCD\u00ae), necessitating removal. The rate of implant removal due to implant dysfunction was relatively low compared to the rate of",
        "label": 0
    },
    "1119": {
        "output": "This code snippet will produce following answer: \n- `trial=0.1` (2) patient is eligible for the trial because the patient meets inclusion criteria. However, the patient was also excluded by the trial",
        "label": 0
    },
    "1120": {
        "output": "- 10_12_2019_POL_10_15_19_26_A_C_Eligible_498028_V01.pdf\n- 10_14_2019_HEL_10_16_19_29_A_B_Eligible_497562_V01.pdf\n\n\n## Exclusion criteria\n\nExclusion criteria should be listed below. \n- Prenatal examinations are generally considered routine, preventative care, and are usually free to the patient, with the exception of a small fee from the lab for the procedure and the cost of the specimen.\n- The use of the phrase 'routine antenatal examination', if included in the exclusion criteria, may limit the sample to women who are not receiving prenatal care and to those without a registered provider.\n- It is assumed that women, who are pregnant and have access to antenatal providers, would have had at least one prenatal visit.\n- Many prenatal laboratories require women to begin prenatal care during the first trimester in order to have the opportunity to receive preconception care.\n- It is well known that many pregnant women, who do not begin prenatal care during the first trimester, receive care in the second trimester.\n- Since routine testing during the first trimester has not been adopted by health care providers or pregnant women, the phrase in this list is unnecessary, and by eliminating this phrase, the sample size may be increased.\n- 'Prenatal screening tests will be collected between 15-19 weeks of gestation to be eligible for the study'\n- 'Prenatal screening in the first trimester will be collected before 13 weeks of gestation to be eligible for the study'\n- Pregnancy (women are included in the sample of this study, even if they reported having had a negative pregnancy test in the year prior to the study due to the fact that the word \"negative\" was not tested),\n- Non-pregnant (women are not included in the sample of this study, if the woman reported having had a positive pregnancy test within the year prior to the",
        "label": 0
    },
    "1121": {
        "output": "<EOD> .\nThere were examined 87 workers with occupational pulmonary disease and 25 of them were found to be occupational allergic lung. Occupational allergic lung manifests at first as eased and gradually increased respiratory discomfort and productive cough. The patients were exposed to some dusts of chemical agents, as a result of which appeared eased respiratory discomfort and then productive cough. The workers had exposer to 1 in 2-year time to chemical agents for more than 1 in 15 years time.<EOD> The Rate of Increase of Birth Weight and Height in Low- and Very Low-Birth-Weight Infants from Hospital Delivery to 36 Postconceptional Weeks: A Population-Based Cohort Study\nThe goals of this study were to explore the growth rates of infants with low and very low birth weights from birth to 36 postconceptional weeks and to quantify the contributions of gestational age and birth weight to this growth pattern. Data were retrieved from the perinatal database of St. Joseph Mercy Hospital, Oakland County, Michigan, for newborns between January 2\u201315, 2001. Infants with low (501\u20131499 g; n = 78) and very low (<500 g; n = 18) birth weight were included (\u201cLBWIN\u201d). Those with normal birth weights (2500\u20134000 g; n = 423) served as controls (\u201cNBWIN\u201d). Mean birth weights were 1544 \u00b1 498 g, 1372 \u00b1 487g , 3168 \u00b1 168 g, and 2879 \u00b1 154 g for LBWIN, NBWIN, NBWF, and NBWFR (<4000 g and >38 wk gestational age), respectively. The mean gestational age increased significantly through 36 wk in each group (P<.05). NBWFR demonstrated the greatest increase (40), followed by LBWIN (31), NBWF (21), and NBWIN (17). LB",
        "label": 0
    },
    "1122": {
        "output": "## # The pop-up window with a new document in the edit mode\nA new document window will pop up for you, this time, in the edit mode. In the pop-up window you will see four columns. Title: `File Name: Template` appears in the first column. `File Name: Template` should not be changed, unless of course you want to change the name of the project template. Type: If you want to edit the existing file, you can choose it by clicking the arrow symbol in the menu at the top of the window. Click File in the menu and choose New, if you want to add a new file, choose File in the menu and choose New Document, on the main window.\n\n## How to Save/Save as\nClick the File button in the Edit Mode window. The Save menu and File menu appear if you select a menu option from these menus. Click Save in the Save menu and Save As in the File menu. A pop-up window will appear, as shown in [fig_ref]  Figure D: Note: [/fig_ref] .\n[",
        "label": 0
    },
    "1123": {
        "output": "#### Examples\n\n```bash\n$ python clinical_trial_assistant.py\nPatient note:\n```\n\n```json\n{\n  \"Id\": 1,\n  \"PatientId\": 1,\n  \"Age\": 65,\n  \"Female\": false,\n  \"Race\": [\n    [\n      \"White\"\n    ]\n  ],\n  \"Creatinine\": 0.7,\n  \"Phosphate\": 2.0,\n  \"Ca\": 8.8,\n  \"PTH\": 30.0,\n  \"Hgb\": 11.1,\n  \"WBC\": 4.5,\n  \"Platelets\": 153,\n  \"ANC-Cells\": 1.6,\n  \"Lymph Cells\": 1.3,\n  \"Pro B Cells\": 0.304,\n  \"Pro Cells\": 0.144,\n  \"Myeloid Cells\": 0.35,\n  \"Eosinophils\": 0.0506,\n  \"Basophils\": 0.00089,\n  \"Other Cells\": 0.006,\n  \"BUN-Cr\": 14,\n  \"Aspartate Aminotransaminase\": 363,\n  \"Alanine Aminotransaminase\": 448,\n  \"Sodium\": 137,\n  \"Calcium\": 8.6,\n  \"K\": 4.45,\n  \"Chloride\": 107,\n  \"Carbon Dioxide\": 23,\n  \"Bicarbonate\": 21,\n  \"Iron\": 60,\n  \"Total Protein\": 6.28,\n  \"Albumin\": 3.63,\n  \"Urea Nitrogen\": 21,\n  \"Creatinine\": 0.6,\n  \"Calcium (mg%)\": \"10.2269\",\n  \"Calcium (mg/dL)\": 1",
        "label": 0
    },
    "1124": {
        "output": "1 12\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 75-year-old woman presented to the emergency department with progressive abdominal distention, an unintentional 20-pound weight loss, and diffuse abdominal tenderness to palpation. The patient was well prior to 2 weeks prior to this presentation when she presented with a syncopal episode and was found to be hypoglycemic. At that time, she was administered 50 mL 50% dextrose after which she felt better. The patient's medical history is remarkable for coronary artery disease and cerebrovascular accident for which she had a left carotid endarterectomy. She also reports a history of an inguinal hernia 20 years ago that required appendectomy due to acute appendicitis. She is widowed and has 1 child. She does not smoke, drink alcohol, or use illicit drugs. She has no known allergies and is allergic to aspirin. Her BP was 117/62, HR 75, RR 20, BT 97.2, SpO2 97% on RA. The patient is an elderly female who complains of diffuse abdominal dist",
        "label": 0
    },
    "1125": {
        "output": "<EOD> The Impact of Interruptions, Noise, and Social Deprivation on Affect and Performance of Nurses in ICU\nBACKGROUND: Interruptions, high noise levels, and inadequate privacy/social deprivation (ie, social isolation) are common and distressing workplace stressors that can affect nurse staff outcomes, including stress, concentration, and alertness, and may compromise patient care and safety. OBJECTIVE: To improve the workplace by reducing these effects on intensive care unit (ICU) nurses. METHODS: A quasi-experimental intervention study was conducted to evaluate the effects of 4 interventions. Measures taken include the Perceived Stress Scale-14 (PSS), the Hospital Anxiety and Depression Scale (HADS), and the State Anxiety subscale of the Spielberger State-Trait Anxiety Inventory (STAI-S). RESULTS: Ninety-one nurses were included, of whom 50 participated in both the baseline and the postintervention survey (n = 22 baseline/n = 22 intervention; n = 26 baseline/n = 28 intervention). Statistically significant differences were observed in some of the variables under evaluation before and after the completion of the interventions. The results showed that nurses who participated in an intervention programme to reduce stress presented lower depression scores (HADs) and a lower score for state-anxiety (STAI-S). CONCLUSIONS: Improvements in our working environment would support improved quality of patient care, better staff outcomes, and greater job satisfaction. Stress management programmes can enhance stress resilience, reduce mental and physical health problems, promote well-being, improve performance, and provide better patient care.<EOD> A Novel Sensor Platform for Real-Time Determination of Bacterial Contamination in Wounds\nABSTRACT Microbial contamination is among the key barriers for a successful wound healing. Yet so far, real-time determination of bacterial load in wounds remains a dream. We demonstrate the use of a novel sensor platform (Ti3-SRG) based on the selective accumulation of gold nanodots in",
        "label": 2
    },
    "1126": {
        "output": "The output should be similar to the following sample, i.e., \nTrial-level eligibility: 2) Eligible.\n<EOD> Evaluation of an early mobilization strategy after uncomplicated cardiac surgery - a prospective, observational study.\nOBJECTIVES\nIntensive care unit (ICU) physical restraint limits a patient's potential for early mobilization after uncomplicated cardiac surgery. This study aimed to examine the feasibility of a mobilization pathway aimed at early mobilization and to describe mobilization strategies used and physiological responses during mobilization.\n\n\nDESIGN\nA prospective, observational study of consecutive patients who met mobilization criteria from a single ICU.\n\n\nMETHODS\nData were collected on patient demographics, mobilization timing, strategies, and physiological responses. Descriptive statistics are reported as raw data are normal distributed.\n\n\nRESULTS\nOver the study period, 165 patients were included. Intravenous fluids were removed in 152 (91.6%), and 127 patients (76.9%) were mobilized. Median time for mobilization initiation was 0.5 (IQR 0.3-3) day post-operatively. ICU team and therapist were the most frequently cited facilitator and barrier to mobilization, respectively. Fifty-five (43.0%) patients experienced an event of hypotension and tachycardia during mobilization.\n\n\nCONCLUSION\nICU team and therapist facilitate and barriers contribute to early mobilization after major cardiac surgery. Mobilization strategies were based on cardiorespiratory parameters and were undertaken by a multidisciplinary team. Further investigations are needed to clarify the predictors of safe mobilization.<EOD> The Effects of Flap Prep and Injectable Hyaluronan (Juv\u00e9derm) on Implant Stability Using the Periotest Method\n&NA; Although immediate implant placement is a viable technique, the use of such procedures is dependent on a number of variables, each of which may have a negative effect on osteointegration and subsequent implant placement. This study was designed to examine whether flap raising",
        "label": 0
    },
    "1127": {
        "output": "## 11.1  Clinical Trials -Participating in a Clinical Trial\nLearning Objectives\n\n\n- 1. Learn what is a clinical trial.\n\n- 2. Know the definition of eligible, ineligible and never participated in a clinical trial.\n \n\nClinical Trial is research that uses human volunteers. Clinical trials test new interventions such as drugs, medical devices, and procedures for treating disease or injury. Researchers believe the tested intervention will provide benefits, harm, or no significant differences across the different treatment groups.\n\n[\n\n\n\nThe definition comes from NCI dictionary. [NCI Dictionary]\n\nA. Definitely Not Eligible for Clinical Trial: This patient does not meet the inclusion criteria or meets an exclusion criterion.\n\nSome patients do not meet the inclusion criteria; some patients could not meet them because they did not have enough information available to do so.\nA few patients meet an exclusion criterion. A few patients meet exclusion criterion because of an unwished characteristic that makes this patient less likely to profit from the tested intervention. For example, if a particular drug was tested on elderly patients, then this patient could be too young to be eligible to participate.\nOther patients were never invited in a trial.\n\nB. Probably Not Eligible for Clinical Trial: This patient has lessened or conflicting information about the medical history compared with what the trial requires.\n\nSome patient has lessened information about the medical history (e.g., there is no history about drug dosage, type, drug allergies) compared with what the trial requires.\nOne patient has conflicting information with a medical history (e.g. a patient is diagnosed with a particular disease on one occasion and then the doctor changed the diagnosis, so the patient was told something different).\nSome patients do not have information about the previous or current treatment history (e.g., a patient was given a drug 10 years ago, do we know if it was taken according to the instructions, if other drugs were taken, did this drug continue to be used during the time, is the patient willing to adhere to the medication or will the patient buy the drug on the dark market?).\nPatient has",
        "label": 0
    },
    "1128": {
        "output": "IMPORTANT - We use the \"dollar symbol ` and the word-by-word \"command \"` in the following instructions. \n\n\n\n\n\n\n```latex\n1}\n\n\n@manual{ \n@manual{ \n@chapter{Instructions for use}\n    @section{First we use to insert a `Text Box`}\n    @label{Insert a `Text Box`}\n\n    Text Box:\n    `Text Box:`\n\n    \\begin{adjustbox}{just so=bottom center,width=10cm}\n    \\noindent\\makebox[1em][l]{<NAME>}\\\\\n    <EMAIL> \\\\\n    \\begin{verbatim}\n    I am a helpful assistant for the clinical trial recruitment. \n    \\end{verbatim}\n    \\end{adjustbox}\n\n\n    \\label{TextBox_1}\n    @endlabel\n\n    @section{Insert a `List'}\n    @label{Insert a `List`} \n\n    `List:`\n\n    \\begin{adjustbox}{just so=bottom center,width=12cm}\n  \\noindent\\makebox[1em][l]{<NAME>}\\\\\n  <EMAIL> \\\\\n\n    \\begin{verbatim}\n    I am a helpful assistant for the clinical trial recruitment.\n    \\end{verbatim}\n\n    \\end{adjustbox}\n\n    \\label{List_2}\n    @endlabel\n\n    @section{Insert a `Boxed` LaTeX environments}\n\n    @label{Insert a `Boxed LaTeX environments`}\n    \n    Boxed LaTeX environments:\n    `Boxed LaTeX environemtns:`\n\n    \\begin{adjustbox}{just so=bottom center,width=12cm}\n    \\noindent\\makebox[1em][l]{<NAME>}\\\\\n    <EMAIL> \\\\\n    \\begin{verbatim}\n    I am a helpful assistant for the clinical trial recruitment.\n    \\end{verbatim}\n        \\end{adjustbox}\n\n    \\label{Boxed_3}\n    @endlabel\n\n    @subsection{Latex",
        "label": 0
    },
    "1129": {
        "output": "# Example output\nPlease follow the following format. `Your report: ` should display your full results from this exercise, e.g., `Your report: \nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. Your report:` \nTitle: Common Bile Duct Stones - Natural History and Interventions\n\nSummary: The aims of this study were to~investigate what measures were taken when common bile duct stones (CBDS) were found intraoperatively in Sweden during the period May 2005 to December 2009 by using data from this population-based nationwide registry, and~analyze the outcome in terms of complications and success rates of bile duct clearance in relation to various stone sizes and interventions used. In order to further characterize the natural course of CBDS of various sizes, particular interest was focused on patients with positive findings where no peroperative measures to clear the bile ducts were taken or planned postoperatively.\nInclusion criteria: Inclusion Criteria: >common bile duct stones\n\n```python\nYour report:` A 54-year-old obese",
        "label": 0
    },
    "1130": {
        "output": "[\nA B C D E F G H\n]\n\n#####\n\n\n#####\n\n[A]\n\n[/A]\n\n#####\n##### : [Further_instructions](https://github.com/Assignment4You/Python-Udacity-Instructor-Data/blob/main/Code_Review_Data/Python_Udacy_Instructor_Data/Data/First_Case_Udacit/Further_instructions.md)\n\n\n\n\n\n\n[G]\n\n[/G]\n\n#####\n<EOD> Involvement of CXCL11 and CXCR3 with the development of acute pancreatitis in rats\nPreviously we have reported that CXCL11 and CXCR3 are involved in the development of lung injury due to acute pancreatitis. In this study, we evaluated whether CXCL11/CXCR3 may participate in the pancreatic injury of this syndrome. Adult Sprague\u2010Dawley rats were divided into 4 groups: (a) controls, (b) acute pancreatitis induced by 1 hour",
        "label": 0
    },
    "1131": {
        "output": "## Learning from mistakes: [INST:1] Please answer the question on the screen by pressing a number 1.\nPlease answer the question using the keyboard. \n[4] 6) Patients who are breastfeeding should not take the study medication due to theoretical concerns of potential harm to the nursing infant. \n[END]\n\n## [inst:1]\nPlease answer the question on the screen by pressing a number.\nPlease answer the question using the keyboard. \n3) To minimize the risk of teratogenic effects, oral doses are administered in cycles of 7 days on and 7 days off, in a dose escalation manner over a total of 9 cycles. In each cycle, ontreatment evaluations occur on days 1, . The patients who receive no more than one dose of this treatment will not undergo additional cycles and will receive the comparator treatments. \n[END]\n\n## [inst:1] \nPlease answer the question on the screen by pressing a number 1.\nPlease answer the question using the keyboard.<EOD> Effects of different dietary proteins on growth and bone strength in rats with osteoprotegerin deficiency.\nOsteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily and is a specific decoy protein for receptor activator of NF-\u03baB ligand (RANKL). We have previously shown that the activity of OPG is decreased in vivo with senescence and that deficiency of OPG may alter bone quality as well as bone strength in ageing. In the present study, we investigated the effects of various protein sources on bone strength in the presence of OPG deficiency. Weanling OPGAla -/- rats were randomly allocated to one of the following groups: 1) a regular diet (RD) with 10% of casein, 2) RD + 10% of soybean protein isolate (SPI), 3) RD + 10% of fish protein (FP), 4) RD + 10% of lupin protein (LP), and 5) RD + 10% of cow milk protein (MCP). After 2",
        "label": 0
    },
    "1132": {
        "output": "You learned how to assess the eligibility of a patient using trial information. How does this affect your role of a helpful assistant for clinical trial recruitment?\n\n__Note: The task ends here__\n\n## Practice: \n\n### Practice your eligibility assessment.\n\n### 2. Write Your Thoughts and Answers\n\n\n\n\n<EOD> .\nUNLABELLED\nA new method for detection of immunoglobulins E (IgE) antibodies using monoclonal anti IgE has been used.\n\n\nMATERIALS AND METHODS\nFor IgE measurement, three batches of the Enzyme immunoassay (EIA) kit ImmunoCAP Fluorescence, Pharmacia Diagnostic AB (Sweden) was tested. 10.000 patients, including both adults and children underwent a total of 200.000 blood samplings for IgE determination.\n\n\nRESULTS\nOur results are in agreement with the values reported in the literature.\n\n\nCONCLUSIONS\nWe confirm the very good precision, the accuracy for IgE measurement and we think that this method could be a useful screening tool to be used during mass screening. At the moment it is used to analyse IgE on 25 specimens simultaneously by instrument, for about 10,000 Euro per year, the cost for screening of 25,000,000 persons is approximately 60, 000 Euro. Considering the cost for EAI assay of 2 Euro per test, the total cost for screening of 25,000,000 persons at high risk to develop allergic diseases, is approximately 12.000 Euro per year. The cost for serum IgE determination is about 10 Euro per sample, that is approximately 22,000 Euro per year.<EOD> 1790P Phase I Dose-escalation Study of Bevacizumab Plus Gemcitabine-based Chemotherapy and Radiotherapy as a Multimodality Treatment for Locally advanced Non-metastatic Esophagogastric Adenoc",
        "label": 0
    },
    "1133": {
        "output": "[INST] Let's go! Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese women with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. \nHere is the clinical trial:",
        "label": 0
    },
    "1134": {
        "output": "### Rules:\n1. Your code will be evaluated only if the output of the last line is exactly the same (see `Rules` page at http://github.com/YuryG/Prizes/blob/master/rules.md)\n2. Your task is to provide your solution in JSON format. \nYou should use the same syntax as [in GitHub](https://github.com/YuryG/Prizes/blob/master/contests/instructions-and-templates/pat_elig.json) (see the sample output below):\n- `data` must be a JSON array containing the objects of your choice.\n- The keys of each object must be the following field names in the input data: `Subject`, `Sex`, `Age`, `Adm1`, `Adm2`, `Adm3`, `Smok`, `Drink`, `CancerType`.\n- Each object should also have the following fields as keys: `Eligible`, `NotEligible`, `Relevant`, `Excluded`.\n- Each object should also have a field called `Score` having the value of 1, 2, or 3, corresponding to the Trial-level eligibility described above. \n- `Score` may be absent.\n- Each object may or may not have fields having keys `Subject`, `Sex`, `Age`, `Admissions`, `Smoking`, `Drinking `, and `Disease`\n- If an object has the field `age`, then you have to provide the patient's age in years, otherwise, your solution will be scored as `False`\n- You may provide more than one object in `data`, but the number of objects you provide should match the number of objects in the input data.\n- All objects should have the following keys:\n    - `Subject`: your solution code\n    - `Age`: the age of the patient in years\n    - `Eligible` (optional): either \"0\" (\"Excluded\") or \"1\" (\"Not Relevant\") or \"2\" (\"Eligible\")\n    - `NotElilgible` (optional): either \"0\" (\"Excluded\") or \"1\" (\"Not Relevant\") or \"2\" (\"Eligible\")\n    - `Relevant` (optional): either \"0\" (\"",
        "label": 0
    },
    "1135": {
        "output": "## Summary\nThis case study presents an example of a trial-level assessment of eligibility.\nIt is essential that participants in a randomized controlled trial meet the inclusion criteria to the extent possible. It is important that, whenever possible, the information on eligibility criteria is recorded on the patients' notes. This will help recruitment teams to understand whether the patient may be eligible for the study. Furthermore, if a patient is eligible for a study, then they should be offered to participate. If they decide not to join the study, they must not be subject to an ethical breach. If the patient is enrolled in the trial, it is important that they continue receiving medical care from the same physicians who assessed their eligibility and ensured care continuity without any breaches in the consent process. This should also facilitate the continuity of treatment and care of the patients in these trials.<EOD> Identification of a new gene encoding a lysophosphatidic acid acyltransferase induced after injury\nLysophosphatidic acid acyltransferase (LPAT) catalyzes the conversion of lysophosphatidic acid (LPA) into phosphatidic acid (PA). To date, only one LPAT has been cloned and shown to be highly expressed in mammalian liver. We report the purification and partial sequencing of rat liver LPAT. This is the first LPAT that is shown to respond to organ injury. Its expression increased \u224850\u2010fold in fatty livers induced by either ethanol feeding or bile duct ligation and returned to normal levels within four to eight weeks. The gene was isolated and shown to have 17 exons and span 2.8 kilobases. Northern analysis indicated that the gene is expressed in multiple tissues with the highest level of expression in adipose tissue. Analysis of 5\u2032 promoter region showed the presence of binding sites for hepatocyte nuclear factors and nuclear respiratory factors.<EOD> Concurrent infection with multiple human papillomavirus genotype in cervix cancer: an important clinical concern\n\nBackground: Concurrent infection of multiple human papillomavirus (HPV) genotypes in cervix cancer patients has been confirmed by many studies, which indicated a greater risk for",
        "label": 0
    },
    "1136": {
        "output": "## The test data of the clinical trial are as follows:\nTo understand the meaning of variables we can use the `?`\nWe can use the `isCriteria` function of the package to confirm if the condition is in compliance with the criteria.\nA simple criterion is the age criteria.\n\nWhat does the criteria (37-60 years) means? `? criteria`?\n\n\n<EOD> Development of a Novel Strain of C. elegans to Study Glia Development, Reproduction, and Neurotoxicity\nC. elegans has many advantages for use as a preclinical model to study neurodegenerative diseases, including the ability to perform phenotype and imaging in live animals. However, it is essential to control potential cytotoxicity from fluorescent labels to enable imaging of mitochondria. Our lab has shown that GFP fluorescence can be toxic to adult worms. In the current study, we took into consideration this prior observation and developed two methods to control this cytotoxicity. First, we established that mitochondria can be labeled with GFP while avoiding toxicity by targeting the GFP solely to the ER, which resides within the mitochondria. In addition, we developed a new non-toxic GFP-tagged C. elegans strain by introducing a mitochondrial localized non-GFP strain as a background control and selecting the non-toxic GFP-labeled strain. This strain is then introduced as a negative control into studies employing C. elegans to test the efficacy of novel drugs or study diseases in which glia are involved.<EOD> .\nA method for the determination of the total chromium content in foodstuffs samples by neutron activation was developed. The method is based on the neutron bombardment of a sample by a neutron flow for a short period of time (in the present work, from 0.25 to 20 min depending on the activity of the sample) to trigger the nuclear fission reaction of the target (sample), then the released nuclides are measured by alpha and gamma spectrometers. This method is a good compromise between the direct method and the preconcentration method because of its relative high sensitivity (detection limit of",
        "label": 0
    },
    "1137": {
        "output": "> Ticket: [INST] C1722506 -[ ] \n> :0|:\n\n# Author(s)\n\n> Ticket: Ticket -Author for tutorial(s) (name and initials): \n> : Ticket -Authorship -Institution: :Ticket -Authorship -Instructions: :Ticket -Authorship -Eligibility: :Ticket -Authorship -Provenance: \n> Ticket -Authorship -Funding source and grant no:\n\n# Previous versions\n\nThis document is a derivative of the original documentation written by [Author 1 and Author 2](https://osf.io/yhv9q/)\n\n### Previous versions\n\n---\n\n### 2022-04\n\nSee 2022-03\n\n---\n\n### 2022-03\n\n- [x] The author(s) were contacted and are willing to update the copy and to provide their [provenance](https://osf.io/yhv9q/, 4th version)\n- [x] The document complies with the author(s)' provenance-related instructions\n- [x] The document complies with the COMPASS instructions\n- [x] The document is made available under a [Creative Commons Zero\u2014No Rights Reserved\u2014Universal](https://creativecommons.org/publicdomain/zero/1.0/) Public Domain Dedication waiver.\n\n### 2022-02\n\nSee 2022-01\n\nCited text from a [previous version](https://osf.io/8f97p/) of this document by [Author 1 and Author 2](https://osf.io/yhv9q/, 3rd version) on 02-06-2022. [Author 1](https://osf.io/jv53q/) added the last item.\n\n---\n\n### 2022-01\n\nSee 2020-12\n\n---\n\n### 2022-01\n\nThis manuscript provides training materials for COMPASS tutors on how",
        "label": 0
    },
    "1138": {
        "output": "# Example outputs\nIf the patient note and clinical trial are given above, `cda1250` and `cds1428`, the output is as follows: \n<EOD> The Association between Peripheral White Blood Cell Count and Arterial Stiffness in General Japanese Women: A Cross-sectional Study\n\nThe purpose of this cross-sectional study was to investigate the relationship between peripheral blood white blood cell (WBC) count and arterial stiffness, as assessed by brachial-ankle pulse wave velocity (baPWV), in general Japanese women. The study was conducted on female patients who visited Kakogawa Municipal Hospital or Kakogawa Central Hospital because of unhealthy conditions. The patients' characteristics, including heart rate, body weight, height, and peripheral blood cell counts, were measured using the automatic analyzer, XN5000-C, and the baPWV results were measured using the VP-2000 instrument. Pearson's correlation analysis was performed to examine the relationship between WBC count and clinical parameters. The study population comprised 339 participants, aged 19-93 years, who underwent both peripheral blood and baPWV measurements. There is a significant positive correlation between WBC count and baPWV in women (correlation coefficient = 0.248, p < .001). However, there was no statistically significant relationship between WBC count and baPWV in the subgroups of all participants, as well as different age (years), height (cm), heart rate (bpm), and blood pressure. WBC count is positively correlated with the baPWV value, and can be considered an important index in assessing arterial stiffness in Japanese women.\n\n# Introduction\nAging is an irreversible process that is characterized by physical and physiological deterioration [bib_ref]  Theories of ageing, Vi\u00f1a [/bib_ref] . The arteries are responsible for 70% to 76% of myocardial oxygen consumption [bib_ref]  Myocardial oxygen consumption and coronary vascular resistance during coronary occlusion in dogs, Effler [/bib_ref]  and the blood pressure in the arterial system is mainly maintained",
        "label": 0
    },
    "1139": {
        "output": "**\u2b50 Question 9\u2b50 \u2753\u2753\u2753**\n\n[Tutor: **Alkan**](https://github.com/alkan0803) \n\n### [Write a Bash Shell script to generate a sample data table according to the random column from 1 to 10 and name it as `randomtable.txt`. How would you print the rows 3 and 6 from this table?][inst]\n\n[EXERCISES] \n\n**Step 1:** Write a Bash script to generate a sample data table according to the random column from 1 to 10 and name it as `randomtable.txt` \n\nWrite the script in your terminal, write the echo statement to check whether your code is working properly or not. \n\n**<sup>[[inst]](https://i.imgur.com/Kf0Y8q4.png)</sup>**\n\n> Output of the echo statement \n\n> output of the cat statement \n\n```bash\ncat randomtable.txt\n```  \n>>> Output of the cat statement from randomtable.txt:\n\n```text\n       6\n    20\n    25\n    8\n    3\n    9\n   14\n    3\n   13\n    7\n   16\n   2\n   23\n   25\n   15\n   10\n   22\n   12\n   17\n   19\n   11\n   21\n   25\n```\n\n![]({{site.baseurl}}/assets/images/q2_ans.jpg)\n\n\n\n**Step.1 output** <sup>[[inst]](https://imgur.com/pVWXDGw)</sup>: `22 \n```\necho A1\necho B1\necho C1\necho D1\necho E1\necho F1\necho G1\necho H1\necho I1\necho J1\necho K1\necho L1 `\n```\n\n**\n**\u2753How would you print the rows 3 and 6 from this table?\n**\u2753How would you print the rows 3 and 6 from this table?\n\n---\n\n**Step",
        "label": 0
    },
    "1140": {
        "output": "| [/GLOSSARY] <a href=\"#patients_eligibility\">next definition</a></div>\n\n<span class=\"term\">Eligibility criteria</span>,<br>\n\n<span class=\"definitionText\">set of criteria to identify a population (clinical trial subjects) eligible to receive the experimental treatment or clinical trial protocol.</span><br><br>\n\n<span class=\"definitionText\">an eligibility assessment is a determination of a patient's eligibility for enrollment in a certain trial, usually based on inclusion/exclusion criteria defined in the study protocol.</span>\n\n<span class=\"definitionText\">eligibility criteria are set of criteria to identify a population (clinical trial subjects) eligible to receive the experimental treatment or clinical trial protocol.</span>\n\n<span class=\"term\">Inclusion criteria</span>,\n<br>\n\n<span class=\"definitionText\">criteria to determine if individual patients can be enrolled in a clinical trial, usually based on patients' characteristics, e.g., age and sex. Exclusion Criteria</span>,\n\n<br>\n\n<span class=\"definitionText\">criteria to determine if individual patients cannot be enrolled in a clinical trial, usually based on specific patient characteristics or general exclusion for the trial, e.g., age and gender.</span>\n\n<br>\n\n\n<!-- End of Glossary -->\n\n---\n\n## Avoiding biases before the actual analysis\n\nIn clinical trials, selection biases can negatively impact external valid",
        "label": 2
    },
    "1141": {
        "output": "<EOD> .\nObjective: To explore the value of 99mTc-MDP Ga-68-PSMA PET/CT in diagnosis of extraprostatic recurrence of prostate cancer and treatment guidance. Methods: Thirty six cases of prostate cancer with extraprostatic recurrence were retrospectively analyzed. All the patients underwent 99mTc-MDP bone scan, 99mTc-MDP Ga-68-PSMA PET/CT, 18F-FDG PET/CT. They were divided into 24 cases of bone recurrence group and 12 cases of visceral recurrence group, and the imaging results were compared and analyzed. The maximum standardized uptake value (SUVmax), disease control rate, patient follow-up and treatment evaluation of 68Ga-PSMA PET/CT (Ga-PET/CT) and 18F-FDG PET/CT under different conditions of PSA level were analyzed. SPSS 23.0 statistical software was used for count data with chi-Square test and Mann-Whitney test. The comparison of count data was performed with Kruskal-Wallis H test. Results: Compared with bone scan, PSMA PET had a higher detection rate of extraprostatic lesions. The lesions found by PSMA PET/CT were more than those by bone scan from the lumbar spine, femur, pelvis, sternum, rib, humerus, skull, cervical and other parts (120 vs 93). Ga-PET/CT had a higher positive rate of extraprostatic lesions than bone scan in different PSA levels. In PSMA PET/CT, the SUVmax of patients with PSA level of \u226520 ng/ml, 11.1, 30.9, and 12.2 times of patients with PSA level of <20 ng/ml, 20-49 ng/ml, 50-99 ng/ml, respectively; the patients with PSA levels of \u226520 ng/ml had more positive of visceral lesions. After the diagnosis, patients underwent follow-up for 3 to",
        "label": 0
    },
    "1142": {
        "output": "Your program should have an output with the name Trial-level eligibility and the scale of the eligibility assessment:\n\nOutput: Trial-level eligibility: 2) Eligible\n\n[/OUTPUT] \n\n\n___\n\n\n[!insert_html file=\"1525760705748\"/]\n\t\t  \n<EOD> The effect of a low potassium diet on the metabolism and excretion of renal tubular constituents in the goat. II. The metabolism of purines\n1. The effect of potassium deficiency on the formation and elimination of purine compounds was studied in two groups of adult goats, given a diet containing 0\u00b736 mEq potassium/l of water, and compared with an untreated group.<EOD> Tocotrienols as inhibitors of sterol O-acyltransferase: in silico molecular docking studies\nAbstract Sterol (steroid) O-acyltransferase regulates the last step of steroid biosynthesis in animals as well as the \u03b2-oxidation of acyl-CoAs, which catalyse the esterification of fatty acids. The present study demonstrates the potential of tocotrienols, the vitamin E isomers found in rice bran oil, as inhibitors of human sterol O-acyltransferase type 1. A computational model for human sterol O-acyltransferase type 1 was generated by docking a previously reported 2P2X crystal structure to sterol O-acyltransferase type 1 homology model. Molecular dynamics simulations of sterol O-acyltransferase type 1 homology model were validated both structurally and mechanically. Tocotrienols exhibit comparable binding affinity, predicted binding mode, and interactions with human sterol O-acyltransferase type 1 residues as compared to a known sterol O-acyltransferase type 1 inhibitor, fenpropimorph. These findings provide a scientific platform for developing tocotrienols as inhibitors of sterol O-acyltransferase type 1. Communicated by Ramaswamy H.",
        "label": 0
    },
    "1143": {
        "output": "[/STYLE] [/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONT",
        "label": 0
    },
    "1144": {
        "output": "## D[DATA]\nWhen the `Trial-elgibility:` clause is done at a specific patient and a trial, call the `data:` [DATA] module to collect the relevant features of that patient.\n\n\t[DATA]\n\tData-type | Explanation\n\t:-|:-\n\t- PatientAge | The patient's age \n\t- Patient-AgeGroup | One of the 6 age groups: 0-5 years, 6-15 years, 16-59 years, 60-86 years, 85-101 years, and >101 years \n\t- PatientSexID | The patient's gender, `Female`, 'Male'. For a patient who has previously been characterized as female, a \"female\" value is passed in that slot, and a \"male\" value is passed in the slot if the subject is known to be male. \n\t- PatientPatronymic | The patient's patronymic name. A patronymic name is the personal name of an individual derived from, or composed of elements associated with, the individual's father or grandfather (or other male ancestor).\n\t- PatientSuffix | 360 suffix\n\t- PatientPatronymicGroup | The patryonymic group of the patient (in the patient's documentation).\n\t- PatientName |\n\t- PatientSurname | The patient's surname and family name (last name). The surname field of the patient table contains a concatenation of this object, separated by \"_\":<NAME_> \n\t- PatientFamilyName | The patient's surname and family name (last name).\n\t- PatientFirstName | The patient' answer to the question \"How would you prefer to be called?\"; a name to identify the patient, or the person he or she is. The first name is the person's name in the first instance (first name); the first given name (given) in the family name (last); the name used in first use (first); the first given name in the family name (last); the first used in first use (first); first name in the family name (last); first given in the family name (last); and last family name or family name.",
        "label": 0
    },
    "1145": {
        "output": "<EOD> The treatment of gastrooesophageal reflux disease after discharge from hospital: comparison of proton pump inhibitors and combined acid-suppressant therapy\nObjective To compare, in a hospital-to-home setting, the clinical effectiveness of continuing esomeprazole for 4 weeks against omeprazole plus ranitidine given over the first 4 days in patients with gastro-oesophageal reflux disease (GERD). Methods One hundred and twenty-four patients (aged over 50 years with endoscopy-proven erosive oesophagitis) were enrolled into this randomised, double-blind, controlled study. Patients were withdrawn from anti-secretory therapy 48 hours before entering the study. All patients received a standardised hospital diet and were discharged on the same standardised diet continued for 28 days. Symptomatic severity was assessed in terms of the score for heartburn and regurgitation, as measured on a 0\u20133 scale and over the previous 24 hours. Results Improvements in both the heartburn and regurgitation scores were found in both groups: at 2 days, the heartburn scores were 0.022\u00b10.41 in the omeprazole/ranitidine group and 0.069\u00b10.41 in the esomeprazole group (p=0.617), and the regurgitation scores were 0.11\u00b10.40 and 0.01\u00b10.26, respectively (p=0.105). Over the full 28 days of follow-up, the scores remained similar, but on the final day, the regurgitation score remained slightly in favour of patients on esomeprazole (0.4\u00b10.56 versus 0.9\u00b10.58; p=0.013). Conclusion Esomeprazole (20 mg p.o. once daily) was shown to be as effective as a short-term combination treatment with omeprazole and ranitidine (omeprazole 40 mg b.d. and ranitidine 150 mg b.d. for 4 days",
        "label": 0
    },
    "1146": {
        "output": "Hello. You are an experienced clinician who regularly follows patients with anemia. A 70-year-old man who is under your care suffers from anemia. Here are the data:\nAge: 70\nGender: Male;\nMeasurement: Hemoglobin = 10.3; Mean corpuscular volume = 106.8; Hematocrit = 31.1; C-reactive protein = 0.3; Ferritin = 1,464\nPlease, find the most appropriate response to the question with the following options. In your answer, you must select the option closest to reality. \n- The patient's anemia is of inflammatory nature.\n\n## - \nThe patient has increased serum C-reactive protein levels, which means that the body is trying to fight off a viral infection.\n\n## - \nThe low hemoglobin level indicates anemic reticulocytosis with microcytosis due to the body trying to increase the size of the reticulocyte cell. This condition is characteristic for lead poisoning.\n\n## - \nThe patient has increased serum C-reactive protein levels, which means that the body is trying to fight off a bacterial infection.\n\n## - \nThe iron deficiency anemia is related to cancer that caused secondary iron defic",
        "label": 0
    },
    "1147": {
        "output": "![img](./images/trial_level_eligibility.png) \n\n## Expectation-maximization\nYou can expect that the patients are assigned to the eligible, not eligible, and not relevant categories with the 0.3, 0.4, and 0.3 probabilities, respectively. To confirm this expectation, a logistic regression analysis is conducted to identify the factors that could influence the assignment to the trial-level eligibility level. The results of the logistic regression model with eligibility as a dependent variable and factors (age, BMI, gender, NVD, Hx of hypercholesterolemia, HR, RR, T, SpO2, smoker, alcohol, obese, abdominal pain, left, upper quadrant pain, nausea, pain 4-days, epigastric pain, pain on admission, BP, TP, ALT, AST, Alk phosphatase, GGT, HDL, TG, gluteal tenderness, bowel sounds unremarkable, fever, thrombocytopenia, leukocytosis, left shift, neutropenia, anemia, Hgb B12 deficiency, hypothy and hyper T, ANC, Hb, AST, ALT, TP, Creatine, BUN, WBC, WBC, WBC, Fever, hyponatremia, hypoxia, and CBD stones size <20 mm as an independent variable) are summarized in Table 2 below. This table shows that the only variable that significantly influences the assignment of eligibility to the patient was the CBD stones size.\n![img](./images/result1.png)\n\n## Table 2. Result summary of logistic regression for trial-level eligibility as the dependent variable shows no significant variable (p-value>0.05) except CBD stones size less than 20 mm (p-value<0.05) as an independent variable is significant as a predictor in logistic regression\nThese findings indicate that the CBD stones size in patients affect their trial-level eligibility status.\n\n## The result of the logistic regression analyses\nYou use the expectation-maximization (EM",
        "label": 0
    },
    "1148": {
        "output": "There are 2 cases:\nExcluded: the number of `0; Excluded` is greater than the number of `1; Not relevant`: the number of `1; Not relevant` is greater than the number of `0; Eligible: the number of `2; Eligible` is greater than the number of `0; Not eligible`: the number of `0; Excluded` is greater than the number of `2; Eligible` and the number of `1; Not relevant` is greater than the number of `0; Not eligible`. \nYour job is to calculate eligible percentage for patients in each trial and return the calculation result as a number string (e.g., [54.5%]). If a patient was not eligible in a trial, please type in `0.0` into your cell. The eligible patient was determined at the trial level. \n\nAssume that the following data for each trial is shown below:\nClinical trial name: MiniMed 640G\nNo. of patients excluded: 1\nNo. of patients qualified: 43\nNo. of patients not qualified: 0\nEligible percentage (%): 43.00% (43 qualified patients out of 100 qualified patients)\nIf the trial-level eligible percentage is greater than 90.0%, you should return `1` to the end of your output cells. [INST]\n\n[NOTE]\nFor example, if you have 100 patients with available clinical trial data in the clinical trial, and all 100 are trial eligible, you should return `1` in this condition; it's fine with `1; not qualified:` case. The rule is `If one trial-level eligible patient exists among 100 patients, you should return `1;` with no patient`s trial-level exclusion case. If you have more than one trial eligible patient in a trial without trial exclusion, you must return `1;` because you should return `1; no trial-level eligible` case with no patient`s trial-level eligibility.\n\n## Case 2.\n[INST]\n\nThe input text is separated by spaces, without upper and lower cases, and the input values",
        "label": 0
    },
    "1149": {
        "output": "## Exercise_3_4\n\n1. Make a training dataset `patient_data` with 20 records: 10 each with `0 1 0`. 11. Make a testing dataset `test` with 20 records: 10 each with `1 1 0`. 12. Make another testing dataset named `test2` with 20 records: 10 each with `1 0 0`, and 10 each with `1 1 1`.\n\n## Exercise_3_5\n\n1. Make a data frame `patient_too_small` with 20 records. One record has one column `age` with values from the set `{\"0\", \"1\", \"2\", \"3\"}: 10 records each with `age > \"2\"`. 2. Make another data frame `tall_patient` with 20 records. All columns are equal to `-1`. 3. Make another testing dataset `test.age.tall` with 20 records: 10 each with `age > \"2\"`, 10 each with \"age = \"0\". 4. Execute the training in two different ways:\n\n```R\nlibrary(tseries)\nlibrary(forecast)\n\nsapply(x=patient_too_small,\n         FUN=function(x){\nprint(x)$age)\npatient_too_small <-data.frame(age = as.factor(1:length(patient_too_small$age)))\n\ntibs <-training(data = patient_too_small,\n       n.bins = 10,\n       n.folds = 10)\n\ngamfit <-gamm()\n\ngamfit$params$k <-9\ngamfit <-gamfit\n\ngamfit\n\nfitted_gam <-predict(gamfit, tibs = tribble(x=tall_patient, y=as.numeric(as.factor(!tall_patient$age > 2)), data=tibs, seed=12345), n.folds = 10)\nplot(gamfit); points(fitted_gam)",
        "label": 0
    },
    "1150": {
        "output": "Here is the clinical trial:\nTitle: Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients\n\nSummary: While thyroid cancer is generally associated with a favourable prognosis, there is a discrepancy with how important if not traumatic its impact can be on patients. Quality of life (QoL) decreases in the year following a thyroid cancer diagnosis, constituting an optimal period for a preventive intervention. The goal of this study is to evaluate the impact of offering an interdisciplinary team-based care approach for newly diagnosed thyroid cancer patients, including a dedicated nurse who will provide important psychoeducational elements identified in previous focus group studies of thyroid cancer patients, i.e., information on: the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; surgery and its' short- and long-term consequences; radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations; and how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities.<EOD> Dilated cardiomyopathy with predominant left ventricular systolic dysfunction caused by biallelic truncation mutations in the sarcolipin gene: possible founder effect in eastern Asian populations.\nAIMS\nTo ascertain the genetic etiology of a family in Japan with 4 patients presenting with dilated and predominantly left ventricular systolic dysfunction, the most severely affected among whom died suddenly. We hypothesized that this novel disease might be caused by truncation mutations in the sarcolipin gene (SLN), as this gene has been implicated in another, rare form of dilated cardiomyopathy (DCM) (familial DCM with left ventricular noncompaction ).\n\n\nMATERIALS/METHODS\nSarcolipin gene analysis, histologic examination of cardiac muscle, immunoblotting, and immunolocalization of sarcolipin protein were carried out.\n\n\nRESULTS\nIn trans of the homozygous insertion",
        "label": 0
    },
    "1151": {
        "output": "11. 7-step algorithm of clinical trial data curation. Let's examine the algorithm.\n\n## Repository 2: ClinicalTrials.gov (11)\n- 7-step algorithm of clinical trial data curation\n\n### Preprocessing\n\n\n\n- Read the original raw data, and read patient data with `getPatientsData(trialID: String, outcome: Option[Outcome])`.\n\n\n\n\n\n- Get the corresponding patient note after identifying the patient data with `getClinicPatientData(trialID: String, patientID: String, outcome: Option[Outcome])`.\n\n\n### Extraction Step 1\n\n\n\n- Compute patient eligibility for the clinical trial.\n\n#### Determine if the patient has the information necessary to be eligible for a clinical trial or not.\n- Apply the 3-step algorithm presented above.\n- Generate a corresponding patient eligibility vector for each trial.\n\n### Extraction Step 2\n\n\n\n- For each clinical trial, apply the 3-step algorithm.\n- Generate a corresponding patient eligibility vector for each trial.\n\n## 3. 7-step algorithm of clinical trial data curation\nAs a part of the clinical trial data curation, in this step, we should transform the corresponding patient eligibility vector for each trial to a suitable format and output the data to the MongoDB.\n\n### Preprocessing\n\n\n\n- Make a patienteligibility_vec file with a vector for the corresponding eligibility of a patient for each trial.\n\n#### Patienteligibility_vec is a csv file.\n- Create a trial_eligibility_vec_all_data.csv.\n\n#### Output a data frame of the corresponding eligibility of patients for each trial in a csv file.\n\n### Extraction Step 3\n\n\n\n- Read the corresponding eligibility of patients for each trial from the trial_eligibility_vec_corresponding_clinical_trial.csv output file.\n\n\n\n\n\n### Extraction Step 4\n\n\n\n- Read this row that contains corresponding patient eligibility for each trial in the corresponding patient eligibility vector",
        "label": 0
    },
    "1152": {
        "output": "## What are the exclusion criteria? [21]\nHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).",
        "label": 0
    },
    "1153": {
        "output": "## [TESTING]\n\n[ELIGIBILITY] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[STEPS] This is a multiple-choice quiz. You will be presented with a set of statements. The information to answer each statement is hidden in the patient note and the clinical trial. [READ_PATIENT] The following is a summary about the included trials. The following is a summary of the included clinical trials. [READ_CLIN_TRIAL] Clinical trial details: This trial will employ block randomization and intention to treat protocols. The block size must be entered before randomization. Patients will be randomized 1:1 to either methylprednisolone (500 mg IV, 30 minutes before surgical incision.\n[INST] You need to report this note. Type the answer you expect from the system. Then click **Save** button to save the result. After that, you can continue to the next question. [SAVE] [NEXT] The answer is `TRIAL-LEVEL ELIGIBILITY: Eligible`. [SCORE](score.html) [NEXT] [TESTING]\n\n[INST] You should answer in the following manner. Let' s repeat the steps as follows:  \nEnter your first guess. Click **Save**.   \nEnter your second guess. Click **Save** [SAVE]   \nClick **Prev** to go to Trial-level eligibility view again.    \nEnter your third guess. Click **Save**. Click **Prev** to go to Trial-level eligibility view again.   \nEnter your fourth guess. Click **Save**. Click **Prev** to go to Trial-level eligibility view again.   \nEnter your fifth guess. Click **Save**.   \nClick **Prev** to go to Trial-level eligibility view again.",
        "label": 0
    },
    "1154": {
        "output": "[COMMENT] \n**Note**: Before going to the next step, you can easily check what exactly is computed on the patient to determine trial-level eligibility for the patient. That is to say, you can easily understand the patient-level eligibility by looking inside your Trial-level eligibility column where your trial-level eligibility is just copied from, just like the last screenshot. Note that you should check the correctness of what each column computes. \n\n## [/COMMENT]\n\nLet's think what is computed by the Trial level eligibility columns from **triallevel eligibility** to **trial-level eligibility note**. \n\n## From trial level eligibility to Trial-level eligibility Note\n\n- In the next step, you will check the **trial-level eligibility note** column in the same way that you have checked the **trial-level eligibility**.\n- Remember that, from trial-level eligibility column to trial-level eligibility note column, there is just to note whether the patient's current column value is '0' or '1'. So, you will have to check how patient-level information would be copied to trial-level eligibility note column using patient-and trial-level information in that trial. \n\n\n- When you find in [fig_ref]  Table 1: Summary of Patient Example[1][2][3][4][][5][6][7][8][][9][10][11][][] [12][13][14][15][16][][17][18][19][20][21][][] [22][23][24][25][26][] [27][28][30][][31][32][33][34][] [35][36][][37][38][] [[39][40][41][42][][44][45][46][47][48][49][50][51][52][53][54][][56][][57][58][59][60]])",
        "label": 0
    },
    "1155": {
        "output": "**Scoring**: 0 for Excluded, 1 for Not relevant, and 2 for Eligible \n\n\n\n---\n\n## [INST](https://github.com/tpope2/Instructional-Set/blob/master/instructions/Scoring_1_2_3_4_5.ipynb \"Scoring_1_2_3_4_5.ipynb\")\nFor Scoring 1_2_3_4_5 from the [Scores](https://raw.githubusercontent.com/tpope2/Instructional-Set/master/data/Scores/Scoring_1_2_3_4_5.csv) table:\n\n```python\n%pylab inline\nimport csv\nimport os\nimport pandas as pd\ndef download_csv_to_dir(csv_file, filename):\n    d = os.path.dirname(os.path.abspath(__file__))\n    csv_file.seek(0)\n\n    with open(d + '/' + filename, 'wb') as file_handle:\n        file_handle.writelines([csv_file.readline() for csv_file in csv_file.__iter__()])\nos.chdir(os.getcwd())\nnew_header = pd.read_csv(d + '/' + filename)\nnew_header.drop(new_header[new_header.columns].str.contains('*'), axis=1, inplace=True)\nnew_header.columns\n```\n```python\nnew_header = pd.read_csv(d + '/' + filename)\nd1 = new_header.columns[1:(new_header.columns.count(*)+1)]\nn = len(d1)\nd2 = pd.DataFrame(new_header[d1], columns=['Trial_ID'])\n\nd2.info()\n# Source: DataFrame([<KEY>,<KEY>])\n#     Trial_ID    Age    BP_1     BP_2  Pulse      BMI    Sex   DX_1    DX_2_0 DX_2_1 DX_3_0\n#  0   RCT_10",
        "label": 2
    },
    "1156": {
        "output": "# Expected code output\nYour evaluation of a patient should be saved as `trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible.csv.`\nAs output, you would see `patient, eligibility: 0) Excluded; 1) Not relevant; 2) Eligible.csv`.<EOD> Effects of an education program on diet and health: results of a study.\nThe aim of this study was to demonstrate the effectiveness of an education programs for improving diet and health, and thereby lowering the risk of diet-related diseases. The study tested the effectiveness of an education program for children aged 15 to 18, a health and nutrition education program in kindergarten for 4-year-old children, and a diet and health education program for adults who have type 2 diabetes mellitus or hypertension. To evaluate the programs, the participants were given a pretest and a posttest on 12 days in total (15-23 January). The participants were from 3 kindergartens, a secondary and a vocational school in a city in western Sweden, and adults at a diet-and-health center in the same city. Participation in the kindergarten nutrition education program for children between 4 and 6 years of age was voluntary. Participation in the school-based nutrition education program for 15- to 18-year-old children was mandatory. Participation in the diet-and-health education for adults was voluntary. A one-way repeated-measures analysis of variance was used to evaluate the improvements in nutrition knowledge and food habits after education. Pretest nutrition knowledge among the secondary school students was very poor (10.8 of 15 possible points), with no significant changes in the posttest. Although dietary habits did not improve substantially, most students reported that the education had motivated them to eat a nutritionally better diet. The kindergarten education sessions were also successful, with significant improvements in nutrition knowledge among the children. Improvements in the children's food habits and in nutrition knowledge in adults were also highly significant. To evaluate the effects of the program",
        "label": 0
    },
    "1157": {
        "output": "## Exercises & Answers\n\n\n\n## Exercise #1: [inst] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nPatient-level eligibility:  #include 'patient_note.py`\n```\n<EOD> Comorbidity in patients with osteoarthritis and its relationship with health-related quality of life, disability, and pain.\nBACKGROUND\nAlthough osteoarthritis (OA) is associated with numerous comorbidities, no evidence exists regarding their relationship with health-related quality of life (HRQoL), disability, and pain. The aim of the study was to examine the relationships between HRQoL, disability and pain with a range of comorbid health conditions in patients with knee or hip OA.\n\n\nMETHODS\nThe study was a cross-sectional analysis of a population-based sample of 2302 subjects with knee or hip OA from the Chingford Study. Information was collected on 12 comorbid diseases (self-reported), and HRQoL, disability and pain were assessed using validated instruments (EQ-5D, Western Ontario and McMaster Osteoarthritis Index and Visual Analogue Scale). Analysis controlled for potential confounding factors and stratified the analysis by knee or hip OA.",
        "label": 0
    },
    "1158": {
        "output": "You are supposed to fill the blanks, that is, to complete the lines between two dots with all needed information in a patient note. `Trial-level eligibility:` is the variable that has to be set to either 1 or 2 only. It indicates 1 if the patient is deemed eligible for the trial, i.e., eligible for further participation.\n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nWhen you have completed the eligibility section, you are to fill out the patient data. \nYou have to set the 'date of creation', 'date of birth', 'sex', 'diagnosis' and 'family history'. \n\nDate of creation, date of birth, and sex have to be completed through 'data entry' field. \n[XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\n\n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nYou should report 'family history' as \"no\" and 'patient's disease' as \"abdominal pain\". \n\n**Additional Assessments and Interventions Include**:\nThe patient may have several other observations recorded in case notes in addition to those that are already entered using SMART-SOS.\nPlease indicate any other observations recorded in the case notes here. _____________________ \n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nAll your data have been updated and saved now. [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nLet's imagine three clinical trials and test the eligibility section of each of them. \nThe first trials' name is \"Triage of Abdominal Pain in the",
        "label": 2
    },
    "1159": {
        "output": "Exclusions: `Exclusions: .` \n<EOD> A case of a child with cranial and spinal malformations, with a novel mutation in the EFTUD2 gene\n\nThis case report describes a 6-year-old boy who presented with mental retardation, facial dysmorphism, epilepsy, and abnormal postures affecting both the head and spine. Brain MRI was normal, but cerebellar atrophy was revealed on the brain MRI performed at age four. His older sister also had intellectual disability and was born with macrosomia. No family history of hereditary diseases was noted. After sequencing 41 genes involved in brain and neural development, a novel point mutation was detected in the exon 7 of the EFTUD2 gene. This resulted in the replacement of guanine to adenine at the position 410 (c.410G>A) of messenger RNA (mRNA). This alteration caused the replacement of histidine at the position 137 (p.H137H) of protein to histidine to tyrosine. No mutation was detected in his parents. A point mutation in exon 7 of the EFTUD2 gene (NM_00633.4) was confirmed by Sanger sequencing analysis and was not present in 1,000 Genome browser and ExAC database searches. The described mutation has a potential pathogenic effect on splicing as well as a substitution of an amino acid with a larger polar side chain. EFTUD2 encodes a protein, EFTUI2, which is a key regulator of spliceosome assembly. It has been hypothesized that the absence of this protein blocks the biogenesis of U4/U6 di-snRNP and the splicing of many introns. It also leads to the transcription and processing defects of multiple genes that are critical for neural development.\n\n# Introduction\nA number of neural tube defects are characterized by the fusion of the neural tube, closure of the dorsal defect in the neural tube, or closing of the entire neural tube, and have been shown to be associated with deafness-dystonia (DD) syndrome (OM",
        "label": 0
    },
    "1160": {
        "output": "## Codes\n\nThere are several elements of syntax that are not explained in the documentation. In the following text are listed the more commonly used syntax elements. Some elements are explained in more detail in the following \"Quick reference guide.\"\n\n## Variable\nA `Variable` is used to retrieve an attribute for a patient on a case. The format for naming the variable is `patient.id.<attribute name>();`. \n\nAttributes in the source document are defined in the patient class. The following table contains the attributes of the patient class.\n\n| Attribute   | Description                                                              |                                                                                                                                              |\n|-------------|----------------------------------------------------------------------------------------------------------------------------------------------|\n| `age_yrs`     | Age of the patient in years                                                                                                                                          |\n| `age_mo`     | Age of the woman as a unit of 12 months <p> (month), e.g., 37.</p>                                                                                           |\n| `sex_female` | The variable sex of the patient, with values `1 = Female` and `2` = `Male`. <p>A woman is defined as `Female` regardless of the number of children she has had.</p>                 |\n| `sex_child`  | Specifies the sex of the child. The variable sex, with the values `1`-female and `2`-male.</p>                                                                                     |\n| `gender_male` | The gender of the patient with values `1=male` and `2 = Female`. <p>The word `patient.gender_male` is equivalent to the phrase `patient.sex_male`, because both of these variables contain the same value. </p>                 |\n| `smoker`     | The variable to determine whether or not the patient is a smoker. A smoker is defined as \"one who smokes cigarettes or has smoked cigarettes in the past.\" <p>Smoking status is not restricted to patients who smoke in their current pregnancy and is defined as the current, past or never smoking status of the patient.</p>                                                                                    |\n| `smoke_years` | The age of the patient while a smoker, e",
        "label": 0
    },
    "1161": {
        "output": "<EOD> A comparison of 2 measurement devices for quantifying exercise performance in women with asthma\nWe compared 2 devices to assess their use in measuring exercise testing performance in patients with asthma, and looked for correlations in the results to determine whether the information gained was related to either the method or the degree of asthmatic activity. Twenty\u2010five women with asthma, ages 18\u201347 yr, performed 5 submaximal exercise tests (Ramp test). One test was performed using a conventional system and 2 using a handheld (breath\u2010by\u2010breath) respiratory analysis system. The results showed that both techniques (Ramp and Ramp2 handheld) gave similar results (R2 0.02\u20130.465, p < 0.047), the results differed more with conventional system than the Ramp2 System. In women with varying degrees of asthma activity, some correlations were found between the exercise test variables. These correlations suggest that the degree of asthma activity, as well as the mode of assessment, may be significant factors in evaluating patients' exercise performance.<EOD> Sodium valproate in the treatment of tardive dystonia. A double\u2010blind randomized placebo\u2010controlled trial\nThe present study was designed to evaluate the effect of sodium valproate in tardive dystonia patients. Forty\u2010four patients with tardive dystonia, 15 men and 29 women (mean age 55.5 \u00b1 11.3 years), were included in the 12\u2010week double\u2010blind randomized trial. They received either sodium valproate (200\u2010400 mg/day) or placebo in addition to their neuroleptic medication. All patients were interviewed using the Abnormal Involuntary Movements Scale. Patients were evaluated at baseline and after 4, 8 and 12 weeks of treatment. The Abnormal Involuntary Movements Scale Total score and all individual movement subscores decreased significantly in the sodium valproate group. This decrease was already present after 4 weeks of treatment and continued to diminish over the succeeding 8\u2010week period. In the placebo group, there were no significant changes in the Abnormal Involuntary Mov",
        "label": 0
    },
    "1162": {
        "output": "[INST]\nIf you are given a sample patient note and a trial description, you should first read and extract the patient note and then find its relationship with the trial description. That is, you should check the exclusion criteria which are defined by Boolean operators in the patient note and whether they actually match the conditions in the trial description. For example, if a trial description is \\emph{Hypercholesterolemia and 2 NVDs}, you should find the patient note that satisfies the conditions in the trial description. \n\nThe next step is to repeat the same steps to find the second trial if you are given two trials and a patient note. \n\n[INST]\n\\end{verbatim}\n\n## Question # 4. \nBased on the two trials described in the questionnaire above, the patient note below, and `eligibility`, what is the final eligibility of a patient for Trial 1?\n\nThe patient note and eligibility are as shown below.\n\n\n\n\n\npatient note: Hypertension, Obstructive Sleep Apnea (OSA), and Depression\n\nIf you are given the `Trial`, the `Patient note`, and information about `Eligibility`, what is the `Eligibility` of the patient in the `Trial description`?<EOD> Bacteriology of the nasopharyngeal aspirates from healthy children\nNasopharyngeal swabs from 64 healthy children were inoculated into standard laboratory media. All were grown. Organisms identified were Streptococcus pneumoniae 38\u00b75%; Staph. aureus 21\u00b73%; Hemophilus influenzae 39\u00b71%; Neisseria meningitidis 58\u00b72%; and Branhamella catarrrlis 34\u00b74%. None of the cultures were contaminated. No child had more than one isolate of Haemophilus influenzae: 6.3% had one isolate, and 18.2% two isolates. Bacteriotherapy for acute otitis media with H. influenzae was not considered advisable as most infants had two isolates.<EOD> .\nUNLABELLED\nTumour necrosis factor-alpha (TNF",
        "label": 0
    },
    "1163": {
        "output": "### Difficulty: 2\n\n# [Solo Challenge ##4]\n[INST] Hello. We have a lot patients to meet today. They are all patients with coronary artery disease. One of them has a history of breast cancer. You have to calculate patient's risk of coronary artery diseases. In general, heart disease is caused by the blockage of the main artery. The narrowing of the artery is a result of fat, cholesterol, calcium or fibrin (clots) that accumulates on the artery wall. Narrowed arteries due to high fat, high blood cholesterol, high blood pressure, smoking, diabetes, or excess weight, make it more likely to get blockage or narrowing, called plaque. Accumulation of plaque over time leads to decreased blood flow (ischemia) causing angina (chest pain) or a heart attack. Therefore, you need to extract variables from patients' data to calculate the risk of coronary heart disease.\n\n\nYour patients' data contain the following variables\n\n\nAge\nGender\nBMI\nEthnicity\nSmoker\nHbA1C\nTotal Cholesterol\nHDL\nLDL\nTRG\nHDL Ratio\nTG\n\nBMI <-summary (bcv <-bcv %>% select(-name, -age)) ggplot(bcv, aes(x = BMI)) + geom_vline(aes(xintercept = cutoff / 100, yintercept = 0)) + geom_hline(yintercept = 120, linetype = 'dashed', col = 'gray', lwd = 3) + geom_boxplot(aes(group = bmi.group), col = \"gray\", fill = NA, ylim = c(70, 130)) + geom_point(ylim = c(70, 130), y = cutoff, data = bcv, size = 0.8, aes(x = BMI, y = bmi), lwd = 2) + geom_vline (data = bcv, aes(xintercept = cutoff.1, yintercept = 0)) + geom_point (aes(colour = Age",
        "label": 0
    },
    "1164": {
        "output": "[INST] Let's think about the clinical trial a little bit more. Your task is to assess the patient's eligibility in accordance with the clinical trial's requirements to determine if the patient should be enrolled or excluded from the study. How do I make sure that I choose the patient's name and number correctly? I first read the description of the clinical trial, then read the patient's notes, and then check whether the required characteristics are present in the notes. In terms of eligibility assessment, I always start with patient name. Next, patient number and patient file number appear. I need to compare what information is needed to include or exclude a patient based on that clinical trial. A patient is eligible when fulfilling the inclusion criteria. \n\n\n<div class=\"figure\" width=\"500\"><img class=\"aligncenter size-full wp-image-9356\" src=\"https://upload.wikimedia.org/wikipedia/commons/f/f6/How-does-a-clinical-trial-look-like%3F-US-National-Institutes-of-Health-Blog.jpg\" alt=\"How does a clinical trial look like? (image description)\" width=\"500\"></img></div>\n\n[INST] You can try using the following command sequence to complete the task:\n\n```\n[S1] ClinicalTrial -l #012643\n```\n\n![](https://raw.githubusercontent.com/ehealthresearchgroup/ehealthresearchclinicaltrial/master/images/clinical_tria, ClinicalTrial.png)\n\n![](https://raw.githubusercontent.com/ehealthresearchgroup/ehealthresearchclinicaltrial/master/images/clinical_tria.1, ClinicalTrial.png)\n\n\n*The clinical trial is visible but there are no patient notes.*\n\n# [S2] ClinicalTrial -p #012\n\n```\n[S2] Patient -a #012\n[S3] ClinicalTrial -N 012\n[S4] Patient.Name \"P\"\n[S",
        "label": 0
    },
    "1165": {
        "output": "[CODE]\n# Trials from CSV file data/sample_trial_file.csv\nTrials = pd.DataFrame(pd.read_csv(\"data/sample_trial_file.csv\"))\n\n# Patients from CSV file data/sample_patient_file.csv\nPatients = pd.DataFrame(pd.read_csv(\"data/sample_patient_file.csv\"))\n\n# Patient-level eligibility from clinical trial information\nPatient_level_eligibility = pd.DataFrame(Trials.merge(Patients, on=['ID']))\n\n# Trial-level eligibility from clinical trial information\nTrial_level_eligibility = pd.DataFrame(Patient_level_eligibility.merge(Trials, on=['ID']))\n\nTrial_level_eligibility.to_csv(\"Trial-level_eligibility.csv\", index=False, header=True)\nPatient_level_eligibility.to_csv(\"Patient-level_eligibility.csv\", index=False)\n\n\nA: import time\nfrom datetime import timedelta\nfrom pandas import DataFrame\nimport pandas as pd\nfrom openpyxl import (  # https://github.com/openpyxl/openpyxl/tree/dev#openpyxl-vs-xlsxwriter-py2/py3\n  ExcelWriter, Workbook, \n  xldelta, xltime, xlsread, xlsize, xltsheet, \n  excel_options\n)\nimport numpy as np\nimport scipy\nimport pickle\nimport json\nimport os\n\n\ndf_time_format_string = lambda: r''\"{time: '%b %Y'}\"''\ndf_list_format_string = lambda: r''\"[%d]\n\n\n# Create a list of dictionaries to describe a patient's eligibility level in a clinical trial\neligibilities_dict = { \n    2: r''\"No.\",\n    1: r''\"Yes. The patient meets the inclusion criteria but is excluded on the grounds of the trial's exclusion criteria\",\n    0: r\"\"\"Included. The trial exclusion criteria do not apply\"\"\" \n}",
        "label": 0
    },
    "1166": {
        "output": "### T-7, 15-16\nYou may be confused about the reason of using \"\\\" to specify that there was no result in the patient note for the CPT field. This is to prevent you from considering that the \"Clinical Note\" field is completely empty. You also have to consider the field \"Clinical note: Other\".\n\n### **[T-8, 17-18] CPT**\nEnter the CPT Code/s based on the most recent CPTs for the problem/condition. \nOn a separate note, a CPT code is defined as a numerical code that is assigned to a set of similar healthcare services to help standardize the way the costs associated with those services are tracked and reported. You would find the code(s) to bill from the patient note to ensure billing of the provided services. You will bill for at least the following 3 CPT codes: Evaluation and Management Services, Diagnostic Services, and Procedural Services. The full list of CPT codes to be used in this workshop, including their descriptions, can be found HERE .\n\n## [T-8, 19] **Age**\nEnter the patient's age. \n\n## [T-8, 20-21] **Sex**\nEnter the patient's sex, i.e., male or female. [M]\n\n## [T-9, 22-23] **BMI**\nEnter the patient's BMI in pounds/inches. ENSURE YOUR NOTE INCLUDES THE PATIENT'S WEIGHT! \n\n### [T-11, 4-5] **Medical History**\nEnter the patient's relevant medical history in bullet points. This is how you input your note into the template.\nEnter the patient's diagnosis according to the ICD-10 Code. I believe the ICD-10 Code is a numerical code that you use with other data to classify and catalog diseases. This is a code you can find on the website of this clinic. In theory, you can use the actual numerical code of the disease that the patient has. But remember that the ICD-10 Code is not necessarily the same as the numerical code. For example, if",
        "label": 2
    },
    "1167": {
        "output": "<EOD> Correction: Association of ALS With a 2-Bp Deletion in the Superoxide Dismutase-1 Gene\nIn the article \"Association of ALS With a 2-Bp Deletion in the Superoxide Dismutase-1 Gene\" by Jean-Marc Lemiere, A. David Smith, Anastasios Tzoulis , Gwen R. Vaughan , and Mark A. van der Vliet (Genetics, 150:1323-1328), there is an error on page 1323. In the figure legend for Figure 2, the reference is misprinted: \"References #56, 87. See the erratum on the next page.\" The reference 56 should be \"56. Tzoulis A, . This article is available at / issue-4%2F1\" \"87. . This article is available from the authors.\" The erratum is, therefore, corrected as follows: \"Page 1323. In the figure legend for Figure 2, the reference is misprinted: \"References #56, 87. See the erratum on the next page.\" The reference 56 should be \"56. Tzoulis A, . This article is available at http://genet.sagepub.com/supplemental#87. . This article is available from the authors.\"<EOD> Preventing diabetic end-stage renal disease.\nThe cost of end-stage renal disease resulting from diabetes mellitus is projected to escalate from $7 billion in 2000 to $32-$49 billion by the year 2030. This increased expense has a significant impact on other prevention efforts in health policy. Preventing diabetic end-stage renal disease in the future will require identifying patients who are at higher risk for failure of renal function and treating their comorbid conditions (hypertension, hyperlipidemia, and hyperglycemia), plus tight glycemic, blood pressure, and lipid control when the disease is diagnosed. Nurses, with their holistic approach to patient care, are optimally positioned to provide the early education",
        "label": 0
    },
    "1168": {
        "output": "### Exclusion criteria:\nIf the patient does not meet all of the inclusion criteria stated in the trial note, there are 3 possible results:\n1. Excluded: The patient does not satisfy any of the conditions needed to qualify for a trial.\n2. Not eligible: The patient meets some of the conditions necessary to qualify for a trial, but does not meet all of them. The patient can be included to a trial if the reason for non-eligibility is resolved; if not resolved, the patient does not meet all of the conditions needed to qualify for a trial.\n3. Eligible: The patient satisfies all of the conditions necessary to qualify for a trial.\nHere are some exclusion criteria of the clinical trial:\nHistory of gastrointestinal perforation, gastrointestinal fistulae, gastrointestinal hemorrhage or obstruction; recent surgery (at least 1 month), history of bowel resection.\nIntracranial, intraocular, intraspinal, retroperitoneal, or intrahepatic cancer.\nHistory of grade > 2 autoimmune disease.\nActive central nervous system metastasis.\nActive bleeding or bleeding diathesis.\nAny clinically significant or significant/unstable medical condition, symptom or illness that, in the investigator's opinion, might limit the subject's ability to participate in the study or confound the interpretation of results.\nConcurrent malignancy other than the primary solid tumor malignancy with the following exceptions:\nMelanoma of the skin, in-situ cervical carcinoma, or other carcinoma that has undergone potentially curative therapy and is not currently under active treatment (e.g., surgery, systemic therapy, or radiation).\nSquamous cell carcinoma of the anal canal or patients who have completed potentially curative therapy (e.g., surgery, systemic therapy, or radiation).\nAdenocarcinoma of the rectum (but not anal canal) who have completed potentially curative therapy (surgery, systemic therapy, or radiation).\nProstatic cancer who have completed potentially curative therapy (e.g., surgery, systemic therapy, or radiation) and where",
        "label": 0
    },
    "1169": {
        "output": "```bash\n/bin/bash \n\n\n\n```\n\n\n\n<EOD> Intrahost Evolution of the West Nile Virus Polyprotein\nHost range and virulence are multigenic traits, with the interplay between multiple viral genes and the host immune response governing whether an infection progresses to transmission or to lethal pathology. As part of an investigation into these genes and the underlying molecular mechanism behind their contributions to virulence, intrahost sequence evolution was assessed in a West Nile virus (WNV) lineage 2 polyprotein. Virus was isolated from patients enrolled in a prospective clinical study in 2008 in Israel. We found a relatively low intrahost diversity of the polyprotein at a protein length of 4,029\u2009bp, a rate of 3.1\u2009\u00d7\u200910\u22127 nucleotide substitutions per site per year. Only one sequence of a 15\u2010amino acid sequence had 2 substitutions with the consensus sequence. The overall findings were in agreement with previously identified genetic diversity in WNV populations but demonstrated strong purifying selection pressure in intracellular proteins.<EOD> Cases in Surgery Illustrated by Woodcuts\n\n\n\n## 1864.]\nBronnenhurst and Barnes on Surgery.\n491 by a careful and exhaustive study of the effects which the various instruments produced upon the parts they were to act upon, a work which we believe will have no small weight with the profession, and which we recommend to the attention of surgical students.<EOD> A novel antiemetic agent, granisetron, in cancer chemotherapy.\n\nFive studies compared doses of Granisetron (G) ranging from 0.03-6.0 ug/kg/b.w. to Cisplatin (P), from 20 -80 mg/m 2, in 114 patients (pts) and in two studies 265 pts received single and multiple doses of 10 mg (s.d. 20 mg) daily. G increased the time of nausea-free days from a baseline of 14.4 h (with P)-88 h by",
        "label": 0
    },
    "1170": {
        "output": "# Good Research Practice\n<EOD> The Relationship Between Driving Force, pH, and BMP-2 Release from a Multi-Compartment Ternary Complex.\nThe pH change in a local environment is a crucial factor for the biological activity and transportation of many important proteins, such as enzymes, toxins, antibodies, etc. In this context, we are interested in determining how different stimuli impact multi-compartmental transportation of proteins through a mesoporous structure. In this article, we propose a novel concept of a ternary complex system and the multi-step release of bone morphogenetic protein 2 (BMP-2) from a mesoporous alumina with polyplex-inorganic hybrid mesostructure. To determine how BMP-2 release differs from that of a simple binary complex system, we developed an evaluation method based on the amount of released BMP-2 in solution using surface plasmon resonance (SPR). The pH value also affected the released amount of BMP-2 and we successfully demonstrated that BMP-2 release could be controlled by adjusting the pH value of the solution. Furthermore, the response of BMP-2 release to both the pH of the solution and the driving force was investigated by performing simultaneous SPR measurements for each variable. Both factors were found to affect BMP-2 release from the ternary complex system. However, different results were obtained from the binary system. This ternary complex structure is expected to be a powerful tool for use in drug delivery applications.<EOD> .\nThe effect of hyperbaric oxygenation on the course of diabetic osteochondrosis (DO) was examined in experiments on 30 Wistar rats of the 1st experiment and the same number of rats of the 2nd experiment. Diabetes was created by an intraperitoneal administration of alloxan (Sigma Co. USA) at a dose of 130 mg/kg. After 3 days of experiment, the animals of the 1st experiment were exposed within the chamber at an absolute pressure of 2.5 atm, the fraction of oxygen--40%, the duration of the exposure--3 h per 1 day, for 10 days. The animals of the",
        "label": 0
    },
    "1171": {
        "output": "<EOD> The effect of in vitro gastrointestinal digestion and colonic fermentation on the contents of fructo-oligosaccharides, inulin-type fructans and phytochemicals in wheat bran.\nThe aim of this study was to examine quantitative changes in phytochemicals and carbohydrates in wheat bran during the digestion/fermentation process. Wheat bran with high levels of polyphenols (HP), low levels of polyphenols (LP) and low levels of fructo-oligosaccharides (LOF) were chosen as the materials and each material was divided into LOF, HP, and LP groups. Both HPL and LOP exhibited 10-fold increases in acanthoside, 23-fold increases in oatinoside and 5-fold increases in oatanoside under the fermentation conditions of the colon. The levels of chlorogenic acid were higher for HP and LOP, than for LOP and LOF in the upper intestine. There were no significant differences between HPL and HP. The contents of isoquercitrin, rutin and quercetin were also higher for HP and LOP. There were substantial differences in the levels of fructo-oligosaccharides between HPL and LP at every digestion stage, with increasing changes between HP and LPF. Therefore, HP and LP had the largest amounts of fructo-oligosaccharides in all digestion stages. HPL maintained the highest content of hydroxycinnamic acid derivatives in the large intestine. Therefore, wheat bran with high contents of polyphenols and fructo-oligosaccharides, especially inulin-type fructans, can be a better nutrient for human health and are recommended for nutritional improvement.<EOD> A novel 15q dup14q12q13 syndrome\nThe 15q dup14q12q13 syndrome is a rare chromosomal disorder, which was originally reported as dup15q23 . Affected individuals manifest variable clinical features, the most common being developmental delay and mental retardation, intellectual disability, and macrocephaly. We present a new case of the",
        "label": 0
    },
    "1172": {
        "output": "\u2666 If the [IF] statement is not present. \u2666 Do not copy and paste from the instructions above, instead, create a section called `Patient note `.\n\n\n# Results in SNOMED CT\nA clinical trial is recorded as a single instance. Therefore, if you are asked for Trial-level eligibility, the answer is the eligibility scale of a patient after assessing all the trial criteria. You also need to repeat the process with all patients in the trial to generate a single trial-level eligibility.\n\n\n# Results in OWL\nFor simplicity's sake, assume there is no patient note (or no `Patient note `section).\n\n#### Instructions for the task: \u2666 If you are asked for trial-level eligibility, output the eligibility scale of a patient after assessing all the trial's criteria.\nYou should repeat the process with all patients in the trial to generate a single trial-level eligibility. \u2666 Let's code it as `owl:RealClass, owl:SomeValuesFrom( SNOMEDCT:Trial-level eligibility)`, e.g., `owl:RealClass, owl:SomeValuesFrom( SNOMEDCT:Trial-level eligibility, SNOMEDCT:Excluded ).` [TRANSITION] \u2666 If you are asked for eligibility of a single patient, output the score of that patient's eligibility according to the trial criteria, i.e., use the score(patient note); [TRANSITION] \u2666 If you are asked for the eligibility score of a patient within the trial, return that score after assessing the patient's notes according to the trial criteria, i.e., return score(Patient-trial-patient); [TRANSITION] \u2666 If you are asked for eligibility score of a certain patient within the trial, return that score according to the trial's criteria, i.e., return score(Trial-patient); [TRANSITION]\n#### Code Example:\n<owl:Class rdf:about=\"SNOMEDCT:Trial-level eligibility\"/> <!-- Note The about property of a class has to be unique. --> <owl:ObjectProperty rdf:about=\"SNOMEDCT",
        "label": 0
    },
    "1173": {
        "output": "[INST] **Input to predictions based on the input from the previous step (if input is available). If there is no input, skip this section (including the first sentence below).**\n\nThis model takes the clinical trial and the patient's medical report as input in order to perform the assessment of eligibility. The clinical trial has 3 inputs:\n- title (string) - description (string, also called trial summary in some notebook cells) - inclusion_criteria_map (dict, which stores a list of inclusion criteria as strings and whether a given criterion is 0 (the same as exclusion criteria), 1 (not relevant), or 2 (eligible).\n\nThe medical report of a patient contains 9 inputs (each patient note is represented as strings):\n- disease_codes_list (list) - examination_codes_list (list) - medications_list (list) - symptoms_list (list) - medical_history_list (list) - physical_examination_results_list (list) - laboratory_test_results_list (list) - radiology_test_results_list (list) - notes (string)\n\nAdd `df_patient_notes = df_patient_notes.set_index(patient_id)`, and drop unnecessary columns. Now we only have 9 columns: date_of_med_report, exam_code, disease_code, medication_code, symptoms_code, exam_result_code, medical_history_code, physical_exam_result_code, and notes. Each column can represent a value. For example, date_of_med_report represents the date of the medical visit, exam_results_code represents the result of the exam (e.g., 0 means \"normal\"), disease_codes_list, medical_history_lists, and the others represent the code of the corresponding items. \n\nWe also create a column with numerical values that we can use in later steps as well, so that we can calculate the patient's age: age_in_years = (patient_birthdate.years - patient_birthdate.year) + patient_birthday.year\n\n[INST] **Make a copy of the data table. In each notebook task, the input and output tables should be",
        "label": 0
    },
    "1174": {
        "output": "**Congratulations!*** You are done with the assessment of eligibility!\n\n# Patient-specific eligibility\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\nBased on the patient note, you will be asked to perform the patient-specific assessments of eligibility, as follows:\n\n1. Is the patient aged 30-70 years? (Yes or No)\n\n  1 \u21e2 Assessing the patient's age is a part of the patient-specific eligibility assessment.\n\n2. Is the patient a pregnant woman? (Yes or No)\n3. Is the patient a lactating woman? (Yes or No)\n4. Is the patient a severely overweight or morbidly obese adult? (Yes or No)\n\n  1 \u21e2 Assessing the patient's overweight is a part of the patient-specific eligibility assessment.\n   1\u21e2 For the assessment of overweight: calculate body mass index using the formula below and examine the patient status against the established B",
        "label": 0
    },
    "1175": {
        "output": "## Q3\nWhat is the clinical trial's main exclusion criteria?\n\n[BEGIN_SOLUTION]\nFirst, you find the main exclusion criteria in the clinical trial from the summary. The study includes patients who are women pregnant, lactating or trying to conceive; and patients who are severely obese; who have any other history or evidence of severe gastrointestinal disease (e.g. ulcer, ileus); or who have a history of allergy to medications.\n\nThen you find the related information for each criterion from the patient note, for example, 'No severe obesity (BMI >40)' which is one of the main exclusion criteria of the trial.\n[END_SOLUTION]\n\n## Q4\nHow do you determine if a medication would increase risk during a pregnancy?\n\n[BEGIN_SOLUTION]\nFirst, you can use Wikipedia to have initial understanding of the drug, such as whether it is used to treat pain disorders, e.g. cholecystitis. For example, a quick search of Hyoscine Butylbromide will reveal that:\n\"Hyoscine Butylbromide (HBB) is a spasmolytic drug which is used to treat pain or discomfort from irritable bowel syndrome, or to relieve the symptoms of cholecystitis. It acts by relaxing the sphincter tone.\"\nYou can also check Wikipedia about the medication and its associated use, such as:\n\"Hyoscine butylbromide (HBB; also known as hyoscine or Buscopan; INN) is a cholinesterase inhibitor and a spasmolytic drug which is used to relax sphincter muscles. It is used as a medication to relieve spasms.\"\nHere, you can see that:\n- It is used to relieve spasms\n- Its indication to treat pain is cholecystitis\nThen you can check other sources or drug databases, such as Wikipedia about Cholecystitis, for example:\nThe 2009 American Association for the Study of Liver Diseases (AASLD) practice guidelines state that cholecystectomy has been",
        "label": 0
    },
    "1176": {
        "output": "### Cleaning\nAfter finishing the annotation you should clean it. \n\n1. Check the annotations that you have added. (You can check them by [TUT:CheckYourAnnotation](#checkyourannotation))\n\n<!-- [INST] [START GUIDE_CLEANING_CHECKING] -->\n[![Check your annotations with TUT 3.1](img/tut_3_1.png)](TUT:CheckYourAnnotation) [![Check your annotations with TUT 3.1 (Chinese)](img/tut_3_1_chinese.png)](TUT:CheckYourAnnotation/Chinese)\n<!-- [END GUIDE_CLEANING_CHECKING] -->\n\n\n\n### Saving your Annotation\nAs we already noted, you need to write your annotation to a text file with the ***.tsv** extension (e.g., `tut_data_trial3.tsv`). \n\nHere is the sample of a correctly filled tutorial annotation file:\n```\nTrial\n    title Trial name\n    description Trial description\n    inclusionCriteria 0) Excluded 1) Not relevant 2) Eligible\n    exclusionCriteria 0) Excluded 1) Not relevant 2) Eligible\n    inclusionCriteriaPatient 0) Excluded 1) Not relevant 2) Eligible\n    exclusionCriteriaPatient 0) Excluded 1) Not relevant 2) Eligible\n```\n<!-- [INST:TUT:AnnotationSample] -->\n### [TUT:CourseCompletion]\n\nIf you have completed more than half of the tutorial, the next section will let you continue with the final testing:\n* [TUT:CourseCompletion3](#coursecompletion3)\n* [TUT:FinishTutorial](#finishtutorial)\n<!-- [INST:TUT:CourseCompletion3] -->\n\n<a href=\"https://de.kaggle.com/allenai/clinical-annotator\" target=new> \ud83d\udd17\ud83d\udd17\ud83d\udd17\ud83d\udd17 [Go to Kaggle](https://de.kaggle.com/allenai/clinical-annotator)</a>\n<",
        "label": 0
    },
    "1177": {
        "output": "The resulting source code in IPython Notebook format, including the [rst heading], is available online.\n\n### The first approach for comparing a given patient note and the inclusion criteria of a clinical trial\n\nThe first step in the IPython Notebook is `import numpy as np`. We write `numpy` for the Python package `NumPy`. In particular, we imported the `numpy` module from NumPy. The `notebook` is a Python web application. To access it, we first create the folder in the working directory where we store the notebooks (this is the folder we will see in top of Terminal in Mac, and in commandprompt in Windows), then type in the terminal `jupyter notebook`.\n\n    %IPython notebook\n\nFor IPython 5, we can go to File > Open and, instead of choosing the file to open with, we need to select Python notebook, then choose the file jupyter notebook.ipynb. To start the notebook, we then click the file\u2019s icon or press control + shift + o.\n\n[*note]: The terminal in Mac is called Terminal.\n\nThen, we need to import a new module called `pydictools`. Python imports a module by using import module_name from module_name. Here, the import statement `from pydictools import trial` imports the module `pydictools` and allows us to use its functions and methods.\n\n\n![](./images/ipython_notebook/1.jpg)\n\n[*note]: `trial` is the identifier of a module `pydictools` in the Python interpreter. To find this, we type in the interpreter `import pydictools.pydictools` and observe that the identifier appears in uppercase `trial`. Here is the list that comes with the module `pydictools`\n\n      Copyright (c) 2013 <NAME>\n      \n      License: MIT license; see the `pydictools.License` module at\n         http://pythonhosted.org/pydictools/LICENSE.txt\n      \n      Author: <NAME>\n      \n      Author: <NAME>\n      \n      Author: <NAME>\n      \n      Author: <NAME>\n      \n      Author: <",
        "label": 2
    },
    "1178": {
        "output": "Let's continue on the inclusion criteria. Next, we will discuss the inclusion criteria of trials. You will see a new tab called INCLUSION CRITERIA.\nAt the beginning of each section which is called INCLUSION CRITERIA there is a box called `Summary` with a short description of the criterion. Read all sections in this tab if you don't understand something. \nPlease select the checkboxes under the heading `Age` only if your patient meets the inclusion criterion.\nThen you have to select the boxes under the heading `Sex` only if your patient meets the inclusion criterion.\nNow let's think about the criterion `Type of Malignancy`. There are several subcriteria for this criterion. Select the subcriteria corresponding to your patient's cancer. Your patient with a stage II gastric adenocarcinoma has to have the subcriterion gastric cancer.\nThe criterion, `Stage` is a subcriterion for the criterion `Type of Malignancy`. Thus, if you select the box corresponding to your patient's cancer, the boxes for the subcriterion `Stage` will be selected as well (if you did not select the box corresponding to your patient's cancer in the criterion `Type of Malignancy`.).\nTo conclude: the criterion `Disease Stage` is a subcriterion for the criterion `Type of Malignancy`.\n\nNow you must repeat the above steps for the other inclusion criteria. You may have to change the option of selection, because sometimes you have to select the boxes under the heading `Type of Malignancy` only if the boxes under the heading `Disease Stage` are selected. So, repeat the steps that you learned above until you have completed all selected boxes. [INST]\nNow you can go on to the next tab, namely `Sites`, for which you will meet with the patients for every recruitment day. Please remember your patients' names.\nThe patient note that you collected at the previous tab is shown on the first line. On the second line, the patient ID, the recruitment date, and the patient's sex are shown. Check all the criteria corresponding to your patient. Please note that these criteria are only used for the recruitment process. We will show them onscreen, but for the real",
        "label": 0
    },
    "1179": {
        "output": "### \u2714\ufe0f Correct\n\n\nA 56-year-old middle-aged woman with a history of hypertension, hypothyroidism, and hyperlipidemia came to the clinic for her annual physical examination. On reviewing the patient's record, he noted that she had the following abnormal test results in the past year: fasting blood sugar ranged from 160 to 190 mg/dL (normal range, 70 to 110 mg/dL), HbA1c of 8.0%, and C-peptide of 1.0 mcg/L (normal range, 0.8--2.1 mcg/L). The patient was very concerned about the results, and was seeking a better explanation. The clinician explained that her HbA1c test result indicated that her average blood sugar level during the previous six to 12 weeks ranged from 6.5 to 7.5%, which was still well below the normal level of 5.6% (7.0% is the cutoff point for prediabetes). Therefore, this patient probably has impaired blood sugar control, which can usually be improved through diet and exercise. To assess whether her diabetes is caused by insulin resistance, the clinician recommended that she have a C peptide test, which looks at the amount of insulin that she normally produced to test if her diabetes is likely to be type 2 DM. Finally, the clinician recommended that she have an abdominal ultrasound of her pancreas because this is the organ that makes insulin. Since the patient had normal pancreatic size on ultrasound examination, the patient was diagnosed with type 2 DM rather than type 1 DM.\n\n\n\n\n\n    \\section*{Correct Answer with an Explanation}\n    HbA1c and C-peptide tests are valuable for assessing glucose control after patients have been diagnosed with DM and taking medications are usually initiated. These tests are not used to diagnose DM. Other features must be taken into account to diagnose the different types of DM. HbA1c test result indicates that the patient has impaired blood sugar control, and diet and exercise improve her blood sugar",
        "label": 0
    },
    "1180": {
        "output": "### [DATA]\nIn this section, we will create the data tables based on the information presented in the patient's chart and the trial requirements.\nThe list of the data fields is presented in Table 13.16.\n\nTable 13.16. Data table fields.\n\nField | Definition\n---|---\nName | Unique identifier of the patient, patient's identification number\nDate of birth (YMDD) | Date of birth of the patient in the form YY/MM/DD, with 1 st January as reference date\nAge | Age of the patient, expressed in years\nGender | Gender of the patient (male/female)\nPatient's identifier; Internal identifier; A unique identifier of the patient unique for each patient throughout the trial\nDate of examination | Date of examination of the patient\nEpidemiology / sociology | Epidemiology / sociology of the patient\n\nInitiative for participation in the trial and its reason | Initiative for participation in the trial and its reason (consent/authorisation/invited)\nRecruitment | Recruitment channel of the patient to participate in the trial\n\nMother | Initiative for participation in the trial (consent/authorisation/invited)\nFather | Initiative for participation in the trial (consent/authorisation/invited)\nNumber of children | Total number of children of the patient\nAge of children | Total age of the children of the patient\n\nChild 1 | Name of the child 1 of the patient\nAge of child 1 | Age of the child 1 of the patient\nGender of child 1 | Gender of the child 1 of the patient\nAge of child 2 | Age of the child 2 of the patient\nGender of child 2 | Gender of the child 2 of the patient\n\nAge at birth | Age of the child at the time of birth, expressed in years\nBirthweight | Weight of the child at the time of birth, expressed in kilograms\n\nHeight | Height of the child at his/her exam, expressed in centimetres\nWeight | Weight of the child at his/her exam, expressed in kilograms\n\nBlood pressure (mmHg) | Blood pressure of the child measured at his",
        "label": 0
    },
    "1181": {
        "output": "<b><a name=\"Exercise_8\"></a><a name=\"Exercise_8\"></a></b>\nExercise 8\n\n\n[INST] Your boss is a hospital manager trying to hire a new medical expert and he wants to conduct a trial to compare 2 treatments. The study will compare the effects of the use of immuno-chemotherapy for the treatment of gastric metastases with gastrectomy (NCT04609451). The goal of the study is to assess the safety and the effectiveness of the treatment. Safety will be assessed by assessing all the adverse events during and after the treatment. The effectiveness of the treatment will be measured by comparing post-treatment metastasis volume and tumor growth.\n\n\n- [ ] Make a trial-level eligibility for a patient.\n\t- Exclude patients who meet the exclusion criteria.\n\t- Patients who meet the inclusion criteria but not exclusion criteria, mark `1` in the column patient_level_eligibility.\n\n- [ ] Identify each patient by searching on the patient information table.\n- [ ] Create a JSON file to display as a table in the app.\n\n\t[b] Your app will display the table of patients from a JSON file below.\n\t![patients-table](/images/chapter_6/patients-table.PNG)\r\n\n\t[b] In your JSON file, create a key `patients` and save patients' data in a hash of `patients`.\n\n\t\t[b] It should look",
        "label": 0
    },
    "1182": {
        "output": "![](/images/img_15-645x425.png) \n\n\n\nCongratulations! You have successfully created a new trial, and you are ready to practice the eligibility module.\n\n### Checking in the trials\n\nNow, you should be ready for practicing the skills on real trials, let's check out those trials in your dashboard. It is good to check out some trials first, you can check and practice the skills more than once. \n\n![](/images/img_14_practice_trial.png) \n\n\n\n### Practicing the eligibility module \n\n[Go to Practice Trial]()\n\n\n* Click on the icon to start the assessment\n\n![](/images/img_58-6 80x425.png) \n\n\n* Click on the icon to open a new page showing the assessment details\n\n![](/images/img_59-670x425.png) \n\n\n* Check all the checkmarks to complete the assessment and click the icon to view the assessment result\n\n![](/images/img_60-645x425.png) \n\n \nThe result looks like this\n\n![](/images/img_61.png) \n\n\n* Check the mark next to the patient note. The eligibility assessment is correct, so click the mark and click the icon to go to the next trial\n\n![](/images/img_62.png) \n\n\n\n* Click on the icon to get back to the menu, then click on a trial from that list\n\n![](/images/img_63.png) \n\n  \n  \n\n\n\n### Repeat the assessment\n\nIf you think you can do better, you can always try again. You can repeat the eligibility module anytime, just visit the assessment page from the dashboard.\n\n![](/images/img_6_practice_trial.png) \n\n\n\n### [Click to check out the assessment form]()\n\n[Practice Module](/module/practice-module-eligibility-module/3)",
        "label": 0
    },
    "1183": {
        "output": "Here are the output files from the original code:\nHere is the [url=https:-stack overflow-com-users-20481307-56d70470e1-reputation/-answer-2128948#2128948]script source[/url] that I used from stack overflow. It doesn't tell us much, but it's useful, thank you.\n<EOD> Diagnostic criteria for atypical antipsychotic drug poisoning: a systematic review of case reports\nBACKGROUND\nAtypical antipsychotic drug therapy can cause a number of severe adverse events. The lack of internationally agreed criteria to distinguish drug induced events from idiopathic neurological conditions can complicate the diagnosis of these adverse events.\n\n\nAIMS\nTo describe, in cases of atypical antipsychotic drug poisoning, the criteria used in the diagnosis of atypical antipsychotic drug neurological syndromes and to identify the key features associated with an adverse event caused by this treatment.\n\n\nMETHODS\nA systematic search was carried out and 63 publications describing 52 patients met the selection criteria.\n\n\nRESULTS\nOverall, four sets of diagnostic criteria were used and described. In the absence of the criteria set used by the Naranjo nomenclature, clinical features were evaluated as a potential predictor of an adverse event attributable to atypical antipsychotic drugs. Slowing of the EEG predominated (69.2%) followed by cerebral signs such as Parkinsonism-like rigidity (56.6%) and akinesia (51.5%). Adverse drug event-related abnormal liver function was found in 32 patients (61.5%) and electrolyte disturbances were frequent and were observed in 37 (73.4%) patients, especially disturbances in calcium metabolism.\n\n\nCONCLUSIONS\nClinicians should be aware of the diverse neurological manifestations that may occur during atypical antipsychotic treatment. The need to be familiar with the diagnostic criteria set used by Naranjo nomenclature and apply this",
        "label": 2
    },
    "1184": {
        "output": "![INST] \n\n## 5.11 Repeat the last trial of the last session \nGo back to the last trial of session 2 to test the functionality 'trial-specific information and patient eligibility'.\n\n- Eligibility in the upper left corner:\n\n    &trial-level-eligibility: 1) Not relevant\n         &trial-specific-eligibility: Not applicable.\n    &trial-level-eligibility: 1) Excluded\n         &trial-specific-eligibility: Patient does not match trial criteria.\n    &trial-level-eligibility: 2) Eligible\n         &trial-specific-eligibility: Patient matches trial criteria.\n- Eligibility is displayed to",
        "label": 2
    },
    "1185": {
        "output": "By implementing the `column counts()` function you can return the column count without the usage of the `for each` loop.\n\n```cfscript\ntrial_infos = inputBox(fileContent = fileContentToRead, fileDirectory = \"../../Documents\");\n\ncolumnCounts = trial_info.columnCounts();\n\n\n  }\n\n```\n\n## 5. How to display patient note and include more information? \n\nAs you can see, you can print the full results of REDCap in a PDF format. You can do this",
        "label": 0
    },
    "1186": {
        "output": "The question mark at the end of the patient note is called a prompt, not a question. In order to answer the prompts of a patient note, we should answer the questions below based on the information and data recorded in the patient note.\n1) Which type of patient note is it? (2) Which section of the patient note is it?\nIn this patient note, the section is not clear. The title of the patient note is \"Obese woman with abdominal pain: Assessment\", so it is an assessment section. Therefore, the prompt must be answered in assessment subcategories, as \"Is there any past medical history?\" and \"Is the patient on regular medication?\" There are no assessment subcategories in the patient note.\n\nIn addition, the assessment of eligibility is the next step in the procedure. The assessment of eligibility is a series of prompts and subcategories. If a given prompt has 2 or more subcategories (e.g., Assessment of current medication), the first of these subcategories is selected. If a given prompt has only 1 subcategory (e.g., The patient has no past medical history), the patient note is not eligible.\nIt should be noted that this procedure is only done once in this patient note. We must do the following before answering the prompts of the patient note:\n2) Which type of patient note is it? \n\n\n3) Which section of the patient note is it?\n\n\n4) How should I answer the prompts of the patient note?\n\n\n\nPrompt: Is the patient male or female?\n\n\n\nSubcategory: Male\n\n\n\nIf the patient belongs to the male gender, the prompt with the phrase \"The male gender\" under the Trial-level eligibility assessment subcategory is marked, and the scale value is updated. Since all prompts after \"The male gender\" in the Trial-level eligibility assessment subcategory are blank, the patient is not excluded because he/she is a male. This prompt can be answered with the phrase \"The female gender\". \n\nPrompt: Is the patient child or adult?\n\n\n\nSubcategory: Adult\n\n\n\nIf the patient is an adult according to his/her age, the phrase \"patients older than 18\" is selected under Tri",
        "label": 0
    },
    "1187": {
        "output": "<EOD> Listeria monocytogenes: 5-Year Trends in Food Product Recalls and Isolates Associated with Human Post-Hatch Commercial Poultry Product Reports in the United States from 2014 to 2019.\nListeria is an important food-borne pathogen to both public health and the poultry industry. Here we analyzed 5\u00a0years of historical data from the U.S. Food and Drug Administration (FDA), Centers of Disease Control and Prevention (CDC) foodborne outbreak tracings, and the National Poultry Advisory Council (NPAC) to determine the frequency and source of human listeriosis cases associated with commercial poultry products. Since 2014, a median of 137 human cases of listeriosis were reported each year (range: 56-255); most were \u226560\u00a0years old (62% to 68%). For post-hatch poultry products, there has been a yearly overall increase from 3.69 cases/million outbreak-associated poultry products in 2014 to 10.18 cases/million in 2019. In 2019, of the total of 204 products recalled by the FDA, the majority were associated with Listeria monocytogenes (82; 39%) with two (33%) and four (67%) recalled products containing the major poultry products. Most Listeria positive isolates were serotype 1/2a (721 of the total 1,414 Listeria isolates reported to CDC). Isolates from the United States are different from Canadian and European isolates in sequence type (ST80, 81, 201, 202, 204) (66% versus 16%) and prophage type (Prophage_A, Prophage_3, ProphageX, ProphageX348) (47%, 39%, 11% versus 75%, 24%, 4%). Overall, L monocytogenes contamination rates in meat and poul",
        "label": 0
    },
    "1188": {
        "output": "and [END] markers, and press the \"REACTIVATE\" button if you need more help. To return to the first screen, press the \"END\" button. You have completed the tutorial!\n<EOD> Development and Evaluation of Liposome-Based Hydrogel as a New Approach for Topical Delivery of Niacin, Resveratrol and Curcumin\n\nCitation: Chowdhury, S.; Ahmad, A.; Mobaseri, K.; Faridian, M.; Sardaei, M. Development and Evaluation of Liposome-Based Hydrogel as a New Approach for Topical Delivery of Niacin, Resveratrol and Curcumin.\n\n# Introduction\nNiacin (N), resveratrol (R) and curcumin (C) are recognized as multifunctional bioactive compounds that have wide pharmaceutical and therapeutic applications. N is an essential micronutrient that is required for various physiological and biochemical processes. It is a lipid-soluble vitamin and has been used for the treatment of severe dermal diseases . N is used to treat pellagra (insufficient dietary intake of N) and to improve psoriasis. N has skin penetration enhancing effects due to its interaction with corneocytes. Therefore, the N-rich formulations have received great attention in the field of drug delivery. However, its poor water solubility and low drug stability has limited the N in the market. Thus, various N-based formulations, such as nano-emulsion, solid lipid nanoparticles, vesicles and hydrogels, have been developed.\nIn addition, R, a polyphenolic phytochemical, possesses tremendous therapeutic benefits, such as anti-inflammatory, antiaging, antithrombotic, cardio-protective, anticancer and neuroprotective.\n\n## Phase inversion temperature (pit)\nThe PIT is necessary to determine the solubility of the hydrogel formulation and to determine the temperature and solvent type used to dissolve the GM to",
        "label": 0
    },
    "1189": {
        "output": "[INST] Here, you should see the assessment of eligibility on each patient that the trial. \n\nYou should always insert a comma before to the last line by `,`.\n\nHere is your program for assessments of eligibility: Assessments of Eligibility. Here, you should see the assessment of eligibility on each patient that the trial. \n\nYou should always insert a comma before to the last line by `,`.\n\nHere is your program for the assessments of eligibility: Assessments of Eligibility.\n\n    %i001\n    %c002\n\n    %m003\n    %f004\n\n    %i005\n    %c006\n    %m007\n    %f008\n\n    %i009\n    %c010\n    %m011\n    %f012\n\n    %i013\n    %c014\n    %m015\n    %f016\n\n    %i017\n    %c018\n    %m019\n    %f020\n\n    %i021\n    %c022\n    %m023\n    %f024\n\n    %i025\n    %c026\n    %m027\n    %f028\n\n    %i029\n    %c030\n    %m031\n    %f032\n\n    %i033\n    %c034\n    %m035\n    %f036\n\n    %i037\n    %c038\n    %m039\n    %f040\n\n    %i041\n    %c042\n    %m043\n    %f044\n\n    %i045\n    %c046\n    %m047\n    %f048\n\n    %i049\n    %c050\n    %m051\n    %f052\n\n    %i053",
        "label": 0
    },
    "1190": {
        "output": "Instruction: It is clear that, you just follow the instructions that your manager showed you while you were entering the information into the software. The following example should help to make it clear:\n\n`Enter the following` \n\n`Triallevel Eligibility: 0) Excluded`\n\n`Condition: 1) Excluded` -- `Condition: 2) Excluded` -- `Condition: 3) Excluded` -- `Condition: 4) Excluded` -- `Condition: 5) Excluded` -- `Condition: 6) Excluded` --. `Condition: 7) Excluded` --`Condition: 8) Excluded` -- `Condition: 9) Excluded` -- `Condition: 10) Excluded` -- `Condition: 11) Excluded` -- `Condition: 1",
        "label": 0
    },
    "1191": {
        "output": "# Assessment:\n<EOD> Highly enantioselective alkynyl-Povarov reaction: an approach to chiral 3-phospho-2-vinyloxindoles.\nThe alkynyl-Povarov reaction proceeds highly efficiently with high enantioselectivity (up to ee \u2265 99%) toward chiral 3-phospho-2-vinyloxindoles.<EOD> A Novel Prognostic Score Predicts Survival after First-Line Platinum-Based Chemotherapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)\n\nBackground: Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) have a poor prognosis. We developed a prognostic score for first-line treatment outcome in platinum-based therapy.Methods:We analysed data from 146 patients with recurrent or metastatic HNSCC and receiving platinumbased chemotherapy (mainly cisplatin). The clinical variables analysed were age (years; ,60/ $60), gender, primary tumor location (oropharyngeal cancers (OPC)/non-oropharyngeal cancers (N-OPC)), performance status (PS; $70/,70), serum albumin, serum sodium, alkaline phosphatase, lactate dehydrogenase (LDH), and hemoglobin (LHB).Results: An LHB ,11.1g/dL was related to a worse progression-free survival (PFS) (HR = 2.5; 95% CI, 1.4-4.7; p,0.003) and overall survival (OS) (HR = 2.8; 95% CI, 1.5-17; p = 0.008) in the multivariate analysis. Moreover, it was related to worse OS in each subgroup defined by PS, primary tumor location, and serum albumin. Using this cut-off value of 11.1 g/dL, a",
        "label": 0
    },
    "1192": {
        "output": "Please run the demo_2_8_eligibility.m and demo_2_8_eligibility.xml (please see the first tutorial) to see the result.\n \nYou may also refer to demo_3_9_eligibility.m and demo_3_9_eligibility.xml (please see the second tutorial), the patient's name in demo_3_9_eligibility.m and demo_2_8_eligibility.ml is different: ''Mr. Bai'' and ''Mr. Chen'' respectively.\n<EOD> Synthesis of enantiomerically pure 9-hydroxyhexadec-10(E)-en-1-ones by a novel route.\nA novel route was developed to synthesize and separate the enantiomers of 9-hydroxyhexadec-10(E)-en-1-ones from commercially available epoxydic acetals. The absolute configuration of 9-hydroxyhexadec-10(E)-en-1-ones was elucidated by a chiral HPLC study and by circular dichroism spectroscopy of epoxydic acid. The method was applied to the separation of enantiomers of 9-hydroxyhexadec-10(E)-en-1-ones and 25-methyl-9-hydroxyhexadec-10(E)-en-1-one as well as their epoxydic acetals. In the first case the separation was a challenge since the enantiomers were very close in the retention times, due to their very similar structures. The enantiomers of 9-hydroxyhexadec-10(E)-enediaxolane were separated from each other by HPLC and the absolute configuration of the racemic diaxolane was assigned. The enantiomers prepared by this route were also subjected to an NMR investigation in order to elucidate the mechanism of the hydroxylation of epoxydic carboxylic acids in an epoxydic acid rearrangement. The epoxydic carboxylic acid rearrangement is proposed to proceed via epoxidic alcohols.<EOD> .\nA report is presented of the",
        "label": 0
    },
    "1193": {
        "output": "You can see the following outputs generated when you run the program: The patient note is evaluated for eligibility to enroll in the clinical trial. We compare his / her age and smoking history with the exclusion and inclusion criteria of the trial, which is called trial-level eligibility 2) Eligible. There is no exclusion criteria for this patient, so the trial-level eligibility is set to 2. The patient is eligible for the trial.\nIn general, the patient notes and the clinical trial will be evaluated to see if the trial-level eligibility output by the program is `1) Excluded` or `2) Eligible` to determine if the patient's clinical trial recruitment would be appropriate at this time.\n\n\u00a9 2011-2017 Created by D.M. Coker.\n\nDistributed under the terms of the MDCS (doi:10.17632/8t2v5d56c8.3)\nYou can use, edit or improve this tutorial. Just check the licence below first.\n\nAll information in this tutorial is covered by a Creative Commons licence. More information: MDCS License\nVersion MDCPLAN v3.1\n<EOD> Clinical and molecular genetic identification of congenital dislocation of the hip in three neonates\nCongenital dislocation of the hip (CDH) is a condition that can be easily diagnosed by clinical examination but is difficult to diagnose when the patient is asymptomatic. This paper describes three Japanese infants with CDH, where the diagnosis was based on the results of clinical examination in all, and molecular genetic testing in two. The examination identified the diagnoses in these infants earlier than if only the history and physical examination had been used. Furthermore, because of heritability, the family history of the siblings also gave us a clue to our diagnoses.<EOD> Vibrio diabolicus sp. nov., a pathogenic bacterium isolated from diseased black porgy (Acanthopagrus schlegelii).\nA bacterium (strain VP535(T)) was isolated on marine agar plates from the spleen of a moribund black porgy (Acan",
        "label": 0
    },
    "1194": {
        "output": "### IN THE END\n\nOnce you fill in all the missing information, go to the File menu and click `Save`. You will be prompted to select the output file type. Since we are going to work with plain text file, click `Unformatted Text (.txt) file`, and click `Save`. That\u2019s it!\n\nIn summary, we have learned to work with patient notes to make a clinical trial report in R.\n\n### What did we learn?<jupyter_code># If we just write our code on the screen it is hard to follow.\n# Create a file called Rscripts.Rmd and put the code below your R scripts.\n# For example, save the following code in Rscripts.Rmd.\n\n# +\n\n```r\ntitle: Rscripts\n\n# File created in 2018-02-06 15\n# +\n# First, read the help file for help.\n# -\n\n# Install required packages and libraries for analysis.\n\n# Importing data in the file.\n## Import data from a file\ndata <- read.csv(\"/Users/megan/Documents/Rscripts/example.csv\") # The \"/Users/megan\" here is your user name. data <- data [which(data$Gender == \"0\" & data$Gender == \"2\") ,] # Remove data with gender 1 or 3 data # +\n\n# Now we can do the analysis.\n# We have to put the code between the <> characters.\n# Code for logit analysis in R\nlogit <- data.frame(Gender = factor(data$Gender,levels = c(\"0\" = \"1\", \n                                                          \"2\" = \"3\", \n                                                          \"3\" = \"2\", \n                                                          \"Female\" = \"2\",\n                                                          \"5\" = \"0\",\n                                                          \"6\" = \"0\"))) # data$Gender is your variable to test.\nform <- model.frame(formula=data[, 2:4] ~ data[, 1]) # We need to convert our independent, dependent, and confounder variables to a data.frame. \nm <- glm(form$Gender ~",
        "label": 1
    },
    "1195": {
        "output": "*Please note that there is no need to provide any code block here.*\n\n**Exercise 4.** [Instructions][INST] You must write a clinical trial protocol following the instructions provided below. The protocol contains a description of the study, information about trial participants, the clinical interventions, outcomes, and trial organization. The instructions are written in the form of comment lines and therefore, should not be edited.  You should provide a solution for each one of the questions using the provided comments as guidance. All the questions in each exercise should be addressed.\n\n# A. Background\n\n## What was the rationale for conducting this research?\n\n### Why might this matter to the casual reader?\n\n### What assumptions are there underlying this hypothesis that are reflected in the study design?\n\n# B. Population\n\n## Who participates in this study?\n\n## What do you need to know about the patient? (Including demographic data, current treatment, and the number of previous episodes)\n\n## What kinds of participants in this study? (Including whether or not the patient has already been involved in a clinical trial.)\n\n#### Demographic data\n\n### Age\n- How does the age vary for your population?\n\n### Gender\n- Does the condition differ in men and women?\n\n### Socioeconomic status\n- Does this information influence the outcome you are trying to estimate?\n\n### Race\n- Does the condition differ according to racial or social differences?\n\n### Educational status\n- Does the condition differ according to educational attainment?\n\n### Marital status\n- Does the condition differ according to marital status?\n\n### Religion\n- Does the condition differ according to religious views?\n\n#### History of disease, injury, or treatment\n- Does it matter whether the patient has or hasn't had prior episodes or exposures to treatment?\n\n### Medical history\n- Is there any disease history, e.g.:\n    - Chronic illness?\n    - Mental illness?\n    - Chronic pain?\n    - Eating disorder?\n    - Alcohol or drug addiction?\n    - Smoking?\n    - Obesity?\n    - Is there any significant social history?\n    - Di",
        "label": 0
    },
    "1196": {
        "output": "<EOD> A study of the use, misuse and overdosage of phenylbutazone\nPhenylbutazone (Butazolidin\u00ae), a potent non-steroidal anti-inflammatory and analgesic agent, causes adverse reactions in man, the commonest of which is overdosage. The patient with an overdose may present with a variety of symptoms; from extreme lethargy to vomiting or convulsions. Such patients require careful investigation and treatment. The patient's history will often reveal the cause of the overdose. A study of the use, misuse and overdosage of phenylbutazone has been undertaken in this hospital for the past nine years. The purpose will be to see if any particular trend has developed during this period.<EOD> 3alpha-hydroxybromocholane induces hypotriglyceridemia, enhances lipolysis, and affects adipocyte triglyceride hydrolyase and lipoprotein lipase activities.\n3alpha-Hydroxybromocholane (3alpha-OH-BC) is a biologically active bile acid which induces hypotriglyceridemia and increases fecal lipid excretion. The hypotriglyceridemic effect was not due to reduced food intake but to an increased fecal loss of triglyceride from food. This was associated with decreased intestinal uptake of dietary fat and fatty acid derived from dietary fat, and with enhanced lipolysis and fecal fatty acid excretion. The 3alpha-OH-BC-induced enhancement of lipolysis led to the detection of an elevated hepatic glycerol level, possibly due to decreased liver glycerol uptake or increased glycerol production by the liver. The 3alpha-OH-BC did not alter the VLDL receptor capacity in liver or lipoprotein lipase (LPL) activity in muscles, but enhanced adipocyte triglyceride (TG) hydrolyase and LPL activities in adipose tissue. These findings indicate that 3alpha-OH-BC can affect lipid metabolism at multiple sites; by en",
        "label": 2
    },
    "1197": {
        "output": "### Problem Statement  \nI was having a very difficult time trying to figure out how to create a class for inputting data into the template. It was difficult because I had never programmed in R before, and I didn't know where to get help. \n\n### Solution/How I did it  \nI started by searching for \"R data class\" on Google, and clicked on the first link, because it looked like it could help me. That link took me to a GitHub page where there were R code examples. There was one in particular on the page that said \"R code to create a custom data class\". \n\n```\n\nThe R code example was fairly straightforward to follow. The code used the \"classdef\" function to create the class. Since the classdef function doesn't actually create the class itself it needed to be named with the \"class\" function, which gave me an error. As it turned out the way to use the \"classdef\" was to give the class a name, then the constructor, then the methods of the class. The order of the class methods mattered in order to use the functions that called the methods in the correct order. There were a few lines of code for that too. \n\nThe first thing I needed to do was to define the class. That required a name for the class, and then defining all the objects of the class: \n```\n\n```\n\nThen I needed to define the functions of the class - constructor, init, methods, destruct. These needed to be done in order to be able to access the defined data. So I defined each of the functions as a function, then created a constructor, init, and the \"main\" function. \n\n```\n\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```",
        "label": 0
    },
    "1198": {
        "output": "[HILITE NAME=hint:title]\n[/HILITE]\n\n## A1.5. How to use the 'trial-level eligibility' argument for creating a trial filter?\n[HILITE NAME=hint:title]\n\n[/HILITE]\n\n**For more details, please see example file [example-filter_filter.tab ](filter_examples\\filters\\filter_filter_example.tab).**\n\n### Example 1\nYou want to find patients with liver metastases based on the primary tumour of the rectum and lungs. \n```ruby\n@query = @db.query(\"Patients.select(\"*\").where(\"Tumor_site = 'Rectum'\") &\n   Tumor_site == \"Liver\" &\n   Metastasis == \"Yes\")\nputs @query\nputs @query.to_xml\n```\n\n\n```ruby\n144097 records\n<Query xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"\n       xmlns=\"http://cimpatients.com/patient/ws/v2\"\n       xmlns:db=\"http://cimpatients.com/model/v1\"\n       xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n  <PatientList xmlns=\"http://cimpatients.com/patient/ws/v2\">\n    <Patient xmlns=\"http://cimpatients.com/patient/ws/v2\">\n      <Identifier>\n        <ExternalIdentifier>\n          <DatabaseName>Federal University of S\u00e3o Carlos - UFSCar</DatabaseName>\n          <Identifier>34836864603</Identifier>\n        </ExternalIdentifier>\n      </Identifier>\n      <Gender>4</Gender>\n      <Age>62</Age>\n      <Girth>152</Girth>\n      <Height>170.0</Height>\n      <MaritalStatus>1</MaritalStatus>\n      <Sex>2</Sex>\n      <ContactMethod>1</ContactMethod>",
        "label": 0
    },
    "1199": {
        "output": "[INST] Coding the eligibility criteria. There are three types of eligibility criteria: categorical, multiple items or complex. \n\nLet's think step by step.\n\n### Categorical Eligibility Criteria (Example): <span style=\"background-color: #eee;\"><i>\nCategorical criteria:\n\n\n\n<p><span style=\"background-color: #ddd;\"><a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html\"><i>Categorical criteria.</i></a></span></p>\n<ul class=\"dd-lists\"><li style=\"list-style-type: numeric;\">\n<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category001\">001 (i.e., Patient has at least a disease name: <code>\"epigastric pain, abdominal\"</code>) [<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category001\">category001 </a>]</a>\n</li>\n</ul>\n<ul class=\"dd-lists\"><li style=\"list-style-type: numeric;\">\n<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category002\">002 (i.e., Patient has at least a disease name: <code>\"nervousness\"</code>) [<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category002\">category002 </a>]</a>\n</li>\n</ul>\n</li>\n<li style=\"list-style-type: numeric;\">\n\n\n<p><span style=\"background-color: #ddd;\"><a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html\"><i>Categories: 001, 002. </i></a></span></p>",
        "label": 0
    },
    "1200": {
        "output": "# How to make report by README\n\nYou can easily make a report or view a PDF by using README: \n\nWe can generate various forms of README to make a report from patient to clinical trial or clinical trial to patient: \n\nHere are four ways of generating README for two patients respectively. You can choose the one that you prefer. \n\n## First way: clinical trial-by-patient\n\nFirst of all, you should have a copy of the trial note to make a README: \nYou need to change the trial to have a patient name. \n\n``` rst\nTrial-of-interest = \"\"\n```\n\nSecondly, you should create a list to make a patient summary: \n\n``` rst\nPatient.summary = \" 44-year-old woman from France\"\n```\n\nLastly, then you should make a README: \n\n``` rst\n\npatient_report = { \n    \"Pain_character\": \"Abdominal pain\", \n    \"Chief_complaint\": \"Abdominal pain\", \n    \"Blood_pressure\": \"155/95 mmHg\", \n    \"Electrocardiogram\": \"12 lead electrocardiogram (ECG) (2020) : ECG was normal\", \n    \"SpO2\": \"97% on NA\", \n    \"Respiratory\": \"RR 15 breaths/min\", \n    \"Respiratory\": \"RR 15 breaths/min\", \n    \"Breathing\": \"normal rate and depth. No wheezing or rales\", \n    \"Heart\": \"HR 116 beats/min, No murmur is appreciated.\", \n    \"Heart\": \"HR 140 beats/min, S1 + S2. Normal S1 and S2 without murmur.\", \n    \"Heart\": \"HR: 116 beats/min, No murmur is appreciated.\", \n    \"Heart\": \"HR: 158 beats/min, Higly regular.  regular.  regular.  regular.  regular\", \n    \"",
        "label": 0
    },
    "1201": {
        "output": "[END]\n\nThe best solution was submitted<EOD> Prenatal stress depresses neurogenesis and angiogenesis in the neocortex of rats\n\nThe fetus brain is particularly vulnerable to stress-related insults as prenatal stress contributes to neurodevelopmental abnormalities. Anatomical plasticity of the rat cortex throughout the prenatal period has been demonstrated, thus neurogenesis and angiogenesis should be taken into account in the assessment of prenatal stress effects. To investigate the long term impact of prenatal stress, we performed a systematic analysis of the rat cerebral cortex including cellular proliferation, cytoarchitecture and neuroimmune cell density in prenatally stressed (PS) versus control rat fetuses and postnatal age rats at 1-mo-old. In addition, toxoplasma status was assessed in fetal and 1-mo-old rats. A global reduction in cell proliferation, neuron and neuroglial densities and a global increase in proatherogenic proinflammatory cells were observed in PS rat cortices. These morphological and cellular alterations were not associated with toxoplasma infection. PS rat cortices had a reduced number of blood vessels, but the vasculature of PS cortices was more mature compared to that of controls, suggesting a long lasting vascular insult during brain development. Our results demonstrate that prenatal stress depresses a significant proportion of cells, which inhibit structural normalization of the rat cerebral cortex. Therefore, long term clinical implications of prenatal stress on human brain development should be considered.\n\n# Introduction\nPrenatal stress can adversely affect the physiological and behavioural development of the human foetus [bib_ref]  The effects of stress on the human foetus and the basis of..., Glover [/bib_ref]  [bib_ref]  Effects of maternal stress in pregnancy on brain white matter microstructure in..., Reissman [/bib_ref] .\nThe effects of prenatal stress (PS) on neurodevelopment range from subtle dysregulation of the newborns [bib_ref]  Children of depressed parents: an integrative review, Downey [/bib_ref]  to various mental, physical and ne",
        "label": 0
    },
    "1202": {
        "output": "1. You should check the documentation, and the trial and patient notes. First, create the patients, i.e.,\n\n-  Create the patients with the following syntax in Bash. You should execute `new-patient.bash` to create a patient, after executing this script, you will be asked the patient name, gender, age, and the initials of the trial. If you want to use this script again, you must modify the patient names, age, and initials of the trial.\n```bash\nnew-patient.bash \n```\n\n- If a patient has been defined earlier, change this patient to the name, gender, age, and initials of the trial. To modify a patient, execute the `list-patients.bash` to check the patient names, then change the patient name with the same syntax, as shown below.\n```bash\nnew-patient.bash \n```\n\nYou should execute `list-patients.bash` to check the patient name, gender, age, and the initials of the trial. If you have created a patient before, you can change his name with the command below:\n- To change the name, age, and initials, enter the command line as below:  \n```bash\nchage.sh Patient_Name_1 Age_1 Initials_1 \n```\nPlease note that you should execute `list-patients.bash`, to check a correct patient name, gender, age, and trial initials.\n\nYou can download this script to check patients in [this project on Github](https://github.com/samer-elhossary/eligible).\n\n2. Read the trial, and add the code to the patient note below. If the trial is done in a spreadsheet, you can add the spreadsheet file to the current working directory, and make a symbolic link to the main source code in R, as follows. You should use [the `rename-vars.sh` script to change the names of the trial's variables to the name of the required files ](https://github.com/samer-elhossary/eligible/blob/main/rename-vars.sh).  \n\nPlease note that, you can change the syntax to your needs, and you can change the name of required files.\n\nIf you don't have",
        "label": 0
    },
    "1203": {
        "output": "## Good luck!\nWe are looking forward to seeing you in the next challenge. Happy programming!\n<EOD> .\nBetween 4th May 1975 and 31st October 1982, 41 female patients (average age 58.3 +/- 14.7 years) were operated on, by means of the aortocoronary saphenous vein bypass in the Department of Thoracic and Cardiovascular Surgery of S. Giovanni-APOLLO Hospital, Bologna. The average follow-up was 3.48 years. One patient died from acute myocardial infarction immediately before the operation (0.02473% of death rate). No deaths occurred within 30 days after the operation or during the discharge period. During the follow-up, cardiac death and sudden death occurred in 12 patients (0.29116%). For the majority of patients, no significant modifications of the left ventricular ejection fraction or end diastolic volumes were observed after surgery. These data show, that: 1. The saphenous vein has satisfactory results as a conduit for myocardial revascularization and is less frequently complicated by conduits' disease if compared to other vascular grafts. 2. There is no significant left ventricular performance deterioration in patients who were operated on for ischemic heart disease and in whom the coronary artery bypass procedures have been successful and complicated by little complications during hospital stay.<EOD> .\nOn three hundred thirty one patients operated in the period 1985-1990, the Authors compare the surgical results in relation to the operative procedures and try to find a correlation between the patients' age and the surgical complications. An increase in the surgical risk is appreciable in patients with cancer treated with surgery, lymph node dissection or abdominal extraperitoneal amputation, and in older patients. In patients older than 75 years the frequency of complications was four and one half time that reported world wide.<EOD> Clinical utility of cationic fibroblast growth factor in the diagnosis of peritoneo-pleural communications occurring during laparoscopic surgery: a",
        "label": 0
    },
    "1204": {
        "output": "\u00a92017 by the Computer Society of India - doi: 10.1109/_S11096121.2014.2403137\n\n[/SECTION]\n\n[SECTION: Introduction]\n\nThere are times when computers fail. Sometimes you\u2019ve got to look at a text message and not know how to interpret it. Or maybe you are wondering how to fix a printer. If you cannot find out anyhow, it is important to get in touch with the technical support. Or maybe you just need someone who can analyze a huge amount of data and get you started. That is when the user needs to access the Linux console. You might ask: `Why do I need it at all?` There are many cases where a command prompt environment is invaluable. Let\u2019s take a closer look at some of these cases.\n\n1. How to Start\n\nPressing <Alt> + <F1> on the keyboard opens a terminal emulation application, that starts showing a prompt on the screen. This prompt is the Linux command line. \n\n![alt text](/book/images/148516/bk2-148824_780.png)\n\nIn the terminal window you can type any command. You will find yourself using the command-line interface a lot while working with Linux. Here are some basic commands that are commonly used by most Linux users. \n\n1. How to write to a file (Save data to a file):\n\nTo write data, use the `>>` operator to create a file, so that our new data can be added to this file. `>>` creates a new file and makes it read-only. Then all of the data that we add via the pipe operator will be written to the file that it points to. \n\n``` bash\nmyFile1=\"myScript.sh\"\nmymain_script >> \"myFile1\" \n``` \t \n\n2. How to write the output from a script file (Scripts):\n\nWe can send output generated by a script to a file. But to output the content of the file directly to the console, we can use the pipe operator. For example, if we have a file called `foo.txt`, you can write the contents of this file to the console:",
        "label": 0
    },
    "1205": {
        "output": "ASSIST PROFESSOR ALI, CAN YOU PLEASE HELP ME PREDICT THE DATA STATISTICS? HOW MANY CASES AND SAMPLE SIZE?\n\nThank you for raising such an interesting topic. We have used the G*Power software to test the sample sizes in our study(Shoukat et al., 2011). \n[INST]\n\nAfter entering values such as alpha level and desired power, the G*Power software provides an estimate of the required sample size to detect an effect. \n\nThis is a 2-sample comparison of means. The alpha value is 5%, and the desired power is 80%. The sample size must be a large as possible to detect differences in outcome. For the clinical cases and simulations that we plan to study, we have set the effect size to 1.3, the standard deviation for sample1 to 34, and the standard deviation for sample2 to 45. \n\nIn this experiment, the desired power (1-beta) is set to 0.8 and the alpha value (2-sided) is set to 0.05(we expect that there is a difference between the two sample means, so P < 0.05), according to the statistical significance test standard. Thus, the value of the alpha level (alpha-error probability) is set to 0.05. If alpha = 0.05, the probability of accepting when there is no difference is 5%(i.e., if alpha = 0.05, the probability is that the difference is the same as 5%). If alpha > 0.05, there is no difference. Thus, we set alpha = 0.05.\n\nThe standard deviation of sample1 is set to 34. When the standard deviation is known, the effect size can be calculated, and the effect size is 1.3. \n\nIn this study, the sample size N is 48, i.e., 24 cases are in group one and 24 cases are in group two. If one sample size is greater than standard variance (S=34), the standard deviation of two samples and the effect size can be calculated. This study calculated the standard deviation of the two samples to be",
        "label": 0
    },
    "1206": {
        "output": "<EOD> .\nPURPOSE\nThe purpose of this study is to survey the quality of life (QOL) of patients who had had a hip replacement according to their gender and the degree of knee flexion they had at that moment.\n\n\nMATERIALS AND METHOD\nAn observational method was used in the study. A total of 100 patients who had had a total hip replacement were included in the study. To assess their QOL the 2 questionnaire forms that were distributed to them by phone; the WOMAC Osteoarthritis Index, and the SF-36 were used. The data were fed into a computer.\n\n\nRESULTS\nThe average score was found to be significantly higher (p < 0.01) in female patients as regards the pain scale at rest (p = 0.004) and also the SF-36 physical functioning subscale (p < 0.001), and in knee flexors at rest (p < 0.005).\n\n\nCONCLUSIONS\nThis work showed that female patients had a greater QOL after total hip replacement.<EOD> Syntheses and X-ray Characterizations of a Series of Bis(1-methylimidazolium-2-yl) Bis(trifluoromethylsulfonyl) Imide and a 1-Methylimidazolium-2-yl) Trifluoromethylsulfonyl) Imide Complexes with Tetrel, Chalcogen, and Halogens.\nA series of 1-methylimidazolium-ethylsulfonyl)imide salts (1a-f), the corresponding bis(1-methylimidazolium-2-yl) bis(trifluoromethylsulfonyl)imide 2a-f, and a 1-methylimidazolium-chloride dihydrate 2g were obtained. Each compound was determined by conventional elemental analysis (EA), NMR analysis, and confirmed by X-ray diffraction study. They were characterized by IR, (1)H NMR, MS, C, H, N analysis, and elemental analysis. They were characterized by X",
        "label": 0
    },
    "1207": {
        "output": "<EOD> .\nHepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world. Early screening and early treatment for HCC are pivotal for improving the prognosis and prolonging the survival of the patients. This study aims to investigate the role of low risk factors in the development of HCC in patients infected with HBV in our hospital from Jan. 2006 to Apr. 2014. It was a retrospective clinical research. All of serum tests of patients infected with HBV were completed in 06/2007. The patients were followed up according to the 15 index. All of the patients were divided into case-group (39 patients) and control-group (78 patients). Among them, 7 patients (26.4%) combined with alcohol drinking, and 4 patients (17.4%) combined with smoking in case-group, 12 patients (14.2%) combined with alcohol drinking and 11 patients (11.4%) combined with smoking in control-group; no significant difference was observed between case-group and control-group. All of the patients combined with abnormalities of ALT and HBsAg in case-group, but the levels were all under control. The abnormalities (5 patients) of ALT were detected in control-group, but the levels were all under control. However, no abnormalities of ALT were detected in normal patients. 35.6% ALT increased in 4.5 years follow-up and 32.2% HBV-DNA increased in case-group, while 31.8% ALT increased and 24.3% HBV-DNA increased. The levels of ALT and HBV-DNA in case-group were significantly higher than the normal cases, even though HBsAg, HBeAg, B95, liver function, ALB, DB, HBV-DNA were all under the normal limits (P < 0.05). No correlation was observed between gender, smoking and drinking, age and the risk factors in",
        "label": 0
    },
    "1208": {
        "output": "---\n\n### [Intervention][title]\n===============\n\n[title]\n    Interventions used to help patients to adopt the use of health technology.\n    [INST] You should describe interventions used to help patients to adopt the use of health technology using the following items:\n\n| item               | description                                                       |\n| -----------------",
        "label": 2
    },
    "1209": {
        "output": "There are 3 lines.\nThe first line is used to specify the patient number, e.g., `Patient number: 1`.\nThe second line is used to present the patient's note, e.g., `Patient's note: Here is the patient note: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\nThe third line is used to present the clinical trial information, e.g., `Title: Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery`.\nFinally, you should repeat `Triall-level eligibility:` in the last line to add some code that prints this to the output. \nAnd this is the final result.\n\n\n\n\n```\nYou should select the 2nd patient.\nTrial-level eligibility: 2) Eligible.\n\n\n\nYou should select the 3rd patient.\nPatient number: 3\nPatient's note: A 34-year-old man was brought to the accident and emergency department by emergency service after attempting self-harm\nInclusion criteria: Inclusion Criteria:\nMale > 18 years\nSuicidal ideation\nPlanned suicide attempt with sufficient lethal intent\nNo premeditation\nTriage Triage: Low risk, Immediate Need for Assessment (INA)\nDutch speaking\n\n1) excluded, patient meets inclusion criteria, but is excluded on the grounds of the trial's \n\n\n\n\nYou should select this patient.\nPatient number: 4\nPatient's note: Here is the patient note: The 6-month-old girl was admitted to the emergency department with a fall from a small height, but no trauma is detected on clinical examination.\n\nTriall-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on grounds of the trial's exclusion criteria).\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion",
        "label": 0
    },
    "1210": {
        "output": "_[TROUBLESHOOTING]\n\n    ![INST]\n\n[TROUBLESHOOTING]\n\n### Inline Code\n\nHere is an example of a code to compare a patient note to the inclusion criteria of a clinical trial and print out the results.\n\n[INCLUSION_NOTE_BLOCK]\n    #!/usr/bin/env python\n    # coding: utf-8\n\n    from pathlib import Path\n\n    from os import listdir, walk, createtime, rename, isdir, os_path as osp\n    import os\n    import re\n    import csv\n    import sys\n    import gzip\n\n    from bs4 import BeautifulSoup\n\n    from nltk.tokenize import isalpha\n    from collections import defaultdict\n\n    from csv_utils import write_csv\n\n    import pandas as pd\n    import openpyxl\n    import seaborn as sns\n    import numpy as np\n    import matplotlib.pyplot as plt\n    import matplotlib.dates as mdates\n\n\n    from readr import read_csv as rcsv\n    from pathlib2 import Path, Path as pth\n    from urllib.request import urlopen\n\n    from sklearn.feature_extraction.text import TfidfVectorizer\n    from sklearn.feature_extraction.text import CountVectorizer\n\n    from sklearn.linear_model import LinearRegression\n    from sklearn.datasets import make_dataframe\n\n    from sklearn.linear_model.permutation_importance import permutation_importance\n\n    import sklearn.base\n    import sklearn.linear_model as LM\n    import sklearn.svm\n    from sklearn.naive_bayes import GaussianNB\n\n    import sklearn.ensemble\n\n\n    import pandas.io.excel as excel\n\n\n    from openpyxl.cell import Cell\n\n    import datetime\n\n    from typing import Optional, List, Dict, Union, cast\n\n    import json\n\n\n    from openpyxl import parse_csv, save_xlsx\n\n    from pprint import pprint\n\n    def parse_df(df: pd.DataFrame, header_index: bool = False",
        "label": 0
    },
    "1211": {
        "output": "## Exercises\n\n##[EX] 389. Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. Here is the patient note:\nA 35-year-old man admits to the Emergency Department after the second episode of gastrointestinal bleeding in the past eight months. On admission, he presents with dizziness, melena, and fresh blood on the floor. His vital signs are: BP: 148/100 HR: 120, RR: 24, T: 37.4 C, SpO2: 98% on RA. On inspection his eyes are pale, sunken eyes, skin is warm, and moist. His tongue is covered with dry coating. On palpation, heart sounds are normal, and he does not have abdominal pain. His lungs are clear and free of wheezes. On rectal examination, the rectum is full of clots of large blood clots, and on further questioning, the stool is soft and bowels are regular. Laboratory analysis shows a normal hemoglobin and hematocrit with a mean corpuscular volume (MCV) of 114,2.\nHere is the clinical trial: \nTitle: Mepolizumab in the management of severe eosinophilic asthma\nSummary: Aim To investigate if adding mepolizumab to conventional treatment improves asthma symptom control. Secondary outcomes include health related quality of life, asthma exacerbations, and safety. Participants 35 patients aged 18-50 with severe eosinophilic asthma, treated unsuccessfully with an optimal treatment strategy, including high doses of inhaled corticosteroids (ICS) and long-acting bronchodilators.\n\n##[/ex]\n\n##[CODE] 100 lines of code 48 lines of changed code",
        "label": 0
    },
    "1212": {
        "output": "## RQ3: \nHow can we improve the eligibility assessment?\n\n## Learning Objective:\nRecruiting eligible patients for clinical trials involves an assessment of the patient's eligibility for the trial. The eligibility assessment usually involves an analysis of the patient's medical history, results from diagnostic tests and any current medications that the patient is taking.\n\nAdaptiv (10200) --\n\n## E-Learning Assessment\n\n## Answer key\n\n1. An RCT is a study in which a medication, treatment, or procedure is directly compared to placebo.\n\n2. A placebo is a treatment that has no therapeutic properties, but is used as a control for comparison to medications in clinical trials.\n\n3. A randomized clinical trial is a clinical study that involves a randomized, control trial group, plus control patients who are assigned to a treatment group without randomization.\n\n4. Cross-over trials are a subset of single-group clinical trials whereby patients are treated with the test treatment (treated with the drug) and the control treatment in a balanced crossover manner.\n\n5. The 2x2 cross-over design is a commonly used study design to assess the causal relationship between an intervention and an outcome.\n\n6. Confounding is the factor that changes the effect estimate from an intervention and outcome.\n\n7. A nested case-control study is a type of case-control study whereby cases and controls are chosen from the same population in which the study participants were originally.\n\n8. A cohort (prospective) study is a non-randomized trial to investigate and monitor a group of subjects.\n\n9. The purpose of a cohort/observational study is to analyze a large population of patients to assess the risk of an outcome of interest.\n\n10. The purpose of follow-up study is to monitor the patient for a short period of time to assess specific parameters and identify any changes that were not apparent in the cohort study.\n\n11. The purpose of a case-control study is to assess causes of disease.\n\n12. An association is defined as a relationship where the data analysis shows an association that is statistically meaningful.",
        "label": 0
    },
    "1213": {
        "output": "A: This code for data extraction:\n    from bs4 import BeautifulSoup\n\n    import requests\n    import pandas as pd\n\n    #url = \"https://trichomonasassay.com/clinicalstudy-2017/protocol.pdf\"\n    url = \"https://www.clinicaltrials.gov/ct2/show/NCT04088496\"\n\n    myfile = requests.get(url)\n    soup_txt = BeautifulSoup(myfile.text)\n    print(soup_txt.prettify())\n\n    soup_txt.prettify_ml(\"en_US\")\n\n\n    print(soup_txt.prettified)\n    file=open(\"trichomonas study.txt\", \"w\")\n    for element in soup_txt.prettify_ml(\"en_US\").find_all(\"p\"):\n         print(\"{}\".format(element.text.encode(\"utf-8\")))     \n    file.close()\n\n\nfor lines in pd.read_csv(\"trichomonas study.txt\", sep=\"\\n\", header=None):\n    print(lines)\n\n\nA: \nLet's think step by step.\n\n\n*\n\n*First of all let's think a bit better about the task and what the expected output is.\n\n\nWhat the expected output for each patient is?\n0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria);\n1) Not relevant (patient does not have sufficient information to qualify for the trial);\nOr it is just a 0/1 decision? \n\nNote: If you only need to extract the relevant information about clinical trial you should choose \nExcluded = 0\nNot relevant = 1, which is called the binary classification task here.\n\n\n*\n\n*You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n*Finally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `",
        "label": 0
    },
    "1214": {
        "output": "### The `pj.data.dataset`\nLet's continue editing the code block defined in the last step by moving downward.\n\n```Python\n\nimport datetime\n\nimport pandas as pd\nimport numpy as np\nimport pj\nfrom pprint import pprint\n\nDATA = pj.data.Dataset({\n    'recruitment.csv': {\n        'Date': [\"1/1/2014\", \"1/2/2014\", \"1/3/2014\", \"1/4/2014\"],\n        'Patient.No\": [1, 2, 3, 4],\n        'DateReceived': [\"1/5/2014\", \"1/6/2014\", \"1/7/2014\", \"1/8/2014\"],\n        'Gender': [27, 54, 16, 18, 17, 0, 16, 10, 14, 14, 15, 16, 8, 36, 7, 10, 13, 15, 21, 16, 15, 15, 12, 18, 16, 12, 13],\n        'Age': [43, 50, 42, 33, 20, 34, 38, 38, 25, 59, 36, 39, 37, 24, 54, 23, 22, 34, 34, 45, 42, 34, 39, 19, 38, 35, 32, 29, 26, 13, 26, 34, 33, 28],\n        'AgeInMonth': [71, 80, 70, 56, 12, 59, 60, 30, 120, 51, 63,",
        "label": 0
    },
    "1215": {
        "output": "[/CUSTOM] [INST]\n<EOD> HYPERSPECTRAL IMAGING OF TERMINAL CHANGES, PHENOLS, UV-FILTERS FOR THE ESTIMATION OF VOLCANIC AGE IN RINGS AND RELATED INFORMATION FROM LAUREL LAKE, HAITI\nWe use hyperspectral imaging, an airborne remote sensing technique that can obtain spectral measurements over extended areas, to characterize the reflectance spectra of the terminal sands of the youngest and oldest lakeshore sands in a young sedimentary system. These spectra can be used to infer the ages of individual sediments that make up the landscape and quantify the amount and type of phenolic compounds in the sediments of lakes located on an active volcano based upon the UV filters of the phenolic compounds. Phenols are useful for age estimation because all the phenolic compounds within a system tend to degrade in a predictable manner and are generally stable enough to be accurately evaluated with remote sensing techniques. Furthermore, phenolic compounds generally accumulate rapidly when in high concentrations due to the high energetic conditions in the lakes. Phenolic compounds in lakes are indicative of the conditions of the lake, therefore, by studying a series of phenols, or UV-filters, from the lakeshore sands, we can infer the age of the lakeshore sands.<EOD> Immunohistochemical detection of p53 protein in primary cutaneous melanoma: An Iranian population study\nDear editor, Malignant melanoma, with its highly aggressive behavior, is the most lethal skin neoplasm in white people and increasing in Iran. Several reports in recent years have indicated that the occurrence of this disease has been gradually increased in Iran.1 Therefore, early diagnosis and molecular classification of the melanomas become very important for effective treatment and improved prognosis. The abnormal cell growth is believed to result from a combination of intrinsic and environmental factors that promote the development of cancer. It has been reported that mutational and amplification of p53 tumor suppressor gene are frequent events in human neoplasms.2,3 Moreover, the accumulation of mutant p5",
        "label": 0
    },
    "1216": {
        "output": "Instructions for the next lesson.\n\n## Instructions for the next lesson\n\nPlease watch this video for better understanding of the system [url link] (10th September 2020).\nPlease click [url link] (20th September 2021) to see screen casts.\nPlease click [url link] (8th October 2021) to check the slides.\n\n*The content of the slides has not been updated recently, and they are recommended for reference only .\n<EOD> The Effects of Interindividual Variability in the Pharmacokinetics of 14-\u03b1-Demethyl-14-keto-16,16-dimethylpregna-4,9-diene-3,20-dione (U-466l9) against Influenza A Virus Pathogenesis in Mice.\nAntiviral therapies against the influenza virus have limitations, such as the frequent emergence of amantadine-resistant strains and the narrow spectrum of oseltamivir resistance in influenza A virus (IAV). U-46619 is an analog of thromboxane A2 and a known platelet aggregation inducer. It is reported that its reduced derivative, 14-\u03b1-demethyl-14-keto-16,16-dimethylpregna-4,9-diene-3,20-dione (U-46619) inhibits IAV propagation. Although this agent might be expected to improve anti-influenza therapy, its broad-spectrum efficacy against the IAV has not been verified yet. We evaluated the in vitro efficacy of U-46619 against influen",
        "label": 2
    },
    "1217": {
        "output": "[TRIAL_DATA]\n<EOD> Acute Renal Failure in a 16 Year Old Boy with Type 1 Diabetes Mellitus.\nDiabetes mellitus is closely associated with renal disease and may contribute to the progression of renal disease by many pathogenic mechanisms. Acute metabolic decompensation of T1DM may lead to renal failure. Many episodes of renal failure in T1DM patients have been reported and are mostly associated with volume depletion, hyperglycemia, and ketonuria. In this report, we describe a 16 year old boy with type 1 diabetes mellitus, who presented with oliguria, and anuria which are common complications of acute diabetes. He responded to aggressive medical therapy and continued insulin therapy after discharge to prevent progression into uremia. The patient made an uneventful recovery but later developed a diabetic ketoacidosis and nephrolithiasis.<EOD> Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement\n\n [bib_ref]  Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying..., Oxman [/bib_ref]  [bib_ref]  Meta-Analysis of Randomized Controlled Trials: A Tutorial, Rice [/bib_ref]  [bib_ref]  Meta-analyses, systematic reviews, and RCTs: implications for evidence-based physical therapy practice, Onesti [/bib_ref]  [bib_ref]  Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying..., Oxman [/bib_ref]  [bib_ref]  Meta-analysis of randomized clinical trials comparing the effects of two different thiazide..., Li [/bib_ref]  [bib_ref]  Meta-analysis of randomized clinical trials comparing the effects of two different thiazide..., Li [/bib_ref]  [bib_ref]  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Moher [/bib_ref]  \n\n## Preferred reporting items for systematic reviews (prisma)\nOn January 23, 2009, an electronic version of the 'preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement' was published in the Journal",
        "label": 0
    },
    "1218": {
        "output": "<h3>[Assignment 5] Hello, You are a helpful assistant for clinical trial recruitment. Your task is to make a trial-specific assessment of eligibility, i.e., determine whether the patient would qualify on that specific inclusion criteria based on the given patient's information. </h3> [INST]\n<p>You need to repeat Assignment 4 again, but this time you will only need to perform trial-specific eligibility instead of trial-level eligibility. Please, enter the following codes: This is another important method for calculating the time required for eligibility assessment.</li><li> `Trial-level eligibility` <code>#time.timeit(f=f, trial-level_eligibility_1=f, trial_id=\"1151\", trial_name=\"Garlic as a Therapy for Cardiovascular Risk Factors\", trial_number=\"5061\", trial_code=\"005061\", trial_status=\"Active\", trial_completed=False, trial_phase=\"1\", trial_phase_name=\"Phase 1-II\", trial_phase_number=\"1\", phase_name=u\"Phase 1: Phase 1-II\", phase_number=\"1\", title=\"Garlic Alone and in Combination With Aspirin for the Prevention of Cardiovascular Events in Patients at High Cardiovascular Risk: A Randomized Controlled Trial\", title=u\"Garlic Alone and in Combination With Aspirin for the Prevention of Cardiovascular Events in Patients at High Cardiovascular Risk: A Randomized Controlled Trial\", title=<NAME>. 005061),</li><li> `Trial-specific eligibility` <code>#time.timeit(f=f, trial-specific_eligibility_1=f, trial_id=\"1151\", trial_name=\"Garlic as a Therapy for Cardiovascular Risk Factors\", trial_number=\"5061\", trial_code=\"005061\", trial_status=\"Active\", trial_completed=False, trial_phase=\"1\", trial_phase_",
        "label": 0
    },
    "1219": {
        "output": "---  \n\n__[QUESTION]__[QUIZNAME]__ has been admitted with abdominal pain started 4 days ago. If you make comparisons between this patient note and the inclusion criteria of the clinical trial mentioned above, which of the following statements is CERTAIN, PROBABLE, or UNLIKELY to be his/her eligibility status? (1 point for each CERTAIN answer, \u00bd a point for each PROBABLE answer, and NO points for each UNLIKELY answer)\n\n[BADGER]__Exam_Question1__Inclusion_Criteria_Elizabeth_Clinical_Trial_5.pdf\n[BADGER]:  [B]Exam_Question1__Inclusion_Criteria_Elizabeth_Clinical_Trial_5.pdf[/B]\n\n[/ANSWER]\n\n### Other Resources\n- [MedCalc](https://medicalcalc.org/)\n- [Clep.co](https://www.clep.co/clinical-study-cme/)\n- [UpToDate](https://www.uptodate.com/contents/clinical-studys#search=clinical%20study&source=search&source=guide&view=advanced&search=clinical%20study&search=&f=ds&option5=&search=&source=search&search=clinical%20study&source=search&search=&source5=&search&type=clinical%20study&source=search&text=&source=guide&type=clinical%20study&type5=&text=&source=search&type=clinical%20study&text=&type<EOD> Fatal necrotizing fasciitis of the scrotum.\nA 43-year-old man developed fever and dyspnea within 24 h after spine surgery with anesthesia and prolonged surgery (6 h). He became obtunded, comatose, and hypotensive and required intubation. He was in septic shock. Laboratory results included a white blood cell count (WBC) of 9,900 cells/mm3 with 9",
        "label": 0
    },
    "1220": {
        "output": "<EOD> Molecular mechanism contributing to the neuroprotective effect of curcumin after traumatic spinal cord injury in rats.\nBACKGROUND AIMS\nCurcumin, an extract from the herb turmeric, is a natural antioxidant, anti-inflammatory and free radical scavenger. The purpose of the present study was to investigate the prophylactic effects of chronically administered curcumin on the acute-phase response after spinal cord injury.\n\n\nMETHODS\nThe effects of curcumin on acute inflammation were analyzed by studying the changes in the mRNA expression of C-C motif chemokine ligand 2 (CCL2), C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10) and interleukin (IL)-23 after spinal cord injury. The protein expression levels of tumor necrosis factor (TNF)-\u03b1, IL-1\u03b2, NF-\u03baB, IL-6, transforming growth factor (TGF)-\u03b2, C-C chemokine receptor type 2 (CCR2), C-X-C chemokine receptor type 3 (CXCR3), C-C chemokine receptor type 4 (CCR4), C-X-C chemokine receptor type 5(CXCR5), programmed cell death protein (PD-1), platelet-derived growth factor (PDGF)-BB, glial fibrillary acidic protein (GFAP), ionized calcium binding adapter molecule (Iba1), toll-like receptor (TLR)4, TLR3 and RIP1 were evaluated with quantitative polymerase chain reaction and western blot analysis. A quantitative assessment of apoptotic cells was performed using the TUNEL assay.\n\n\nRESULTS\nCCL2, CXCL9, CXCL10, IL-23, CCR2, CXCR3, CCR4, CXCR5, PD-1 and PDGF-BB expression all increased significantly after spinal cord injury. However,",
        "label": 0
    },
    "1221": {
        "output": "## How to convert this into a Python code.\n```bash\n#!/bin/bash\npython3 main.py < your folder path >\n```\nNow go to your computer (Terminal), change your to your folder where your code is put the patient note and clinical trial information and type in\n```bash\npython3 /home/yourfolderpath/main.py\n```\n\n## How to make output.\nThis is where you have a folder in your folder where your code is put. In this folder, create a new subfolder named 'output', put the your newest output file into this folder. Finally, you should use the command, \n\n```text\n    python3 main.py < your folder path > </code>\n```\n<EOD> Fc gamma RIII mediated antibody-dependent cellular cytotoxicity may be a novel mechanism for anti-CD3 monoclonal antibody induced cytokine release.\nIn vitro cellular cytotoxicity of two murine monoclonal antibodies (mAb) anti-CD3 (A2C11 and 145-2C11) was evaluated. In contrast to a variety of murine tumor specific mAb tested for this purpose, these anti-CD3 mAb did not mediate appreciable lysis of their targets by a monocyte/macrophage, murine cell line or a panel of human malignant hematopoietic cells. However, the A2C11 anti-CD3 mAb, but not 145-2C11 anti-CD3 mAb, triggered significant lysis of human peripheral blood lymphocytes. In a two-color flow cytometric cytotoxicity assay, this A2C11 anti-CD3 mAb associated with an increased percentage of monocytes/macrophages, in the presence of the FcgammaRIII(+) THP-1 target cells. The cytotoxicity correlated with the percentage of THP-1 cells with Fc gamma RIII. The 145-2C11 anti-CD3 mAb, but not A2C11 anti-CD3 mAb, mediated enhanced CD3 and CD16 expression and activation of Fc gamma RIII on mon",
        "label": 0
    },
    "1222": {
        "output": "<EOD> Development of a novel method for quantifying the absorption of nutrients, including free fatty acids, in the small intestine of mice using small intestinal contents.\nNutrient absorption in the small intestine (SI) is generally quantified by measuring the amount of nutrient remaining in the SI lumen, but the SI is separated from the rest of the gastrointestinal tract during sampling, which causes underestimation of the nutrients in the SI lumen. Thus, we developed a method for evaluating the absorption of nutrients in the SI by measuring the nutrient concentration in the SI contents (SI-c). We used 12 ICR mice each fed a coarse or fine diet. The mice were anesthetized with sodium pentobarbital and the SI-c was removed. The nutrient absorption rate was calculated from the concentrations of nutrients in SI-c using the following equation: Nutrient absorption rate (%) = 100 - (nutrient amount in SI-c/nutrient amount in SI lumen) \u00d7 100. The nutrient concentration in the SI-c and the amount of nutrients remaining in the SI lumen was calculated. The nutrients remaining in the SI lumen indicated higher amounts of nutrients in all nutrients tested, because the SI was separated from the gastrointestinal tract during sampling. The nutrient absorption rate was comparable in the coarse and fine feeding groups. When the SI-c was removed prior to the sampling in the fine-feeding group, less free fatty acids were remaining in the SI lumen. In conclusion, the method of analyzing the nutrient concentration in the SI-c may be useful for evaluating the absorption of nutrients in the SI and monitoring the nutritional status and nutritional intervention.<EOD> .\nThe paper presents the author's observations in acoustic neuromechanotomy which he has performed with positive results in 32 patients with lesions of the brainstem and cerebellum as regards vestibular apparatus function and its relationship to the facial nerve function, with no damage to the hearing function of the operated ear which has been confirmed by the results of objective examination and patient interview.",
        "label": 0
    },
    "1223": {
        "output": "## ## Problem 7\nYou are a medical expert. You should check the data in patient's electronic medical record. However, the patient information on the hospital's electronic system is in a specific format and organized differently depending on the specific hospital. To achieve your goal, you should transform the structure and format of the hospital's electronic system's data into a uniform format and structure of your data in electronic medical records as well as perform various statistical operations.\n\n## ### Example 1: ###\nYou are an expert in data processing. Hospital I's data format is listed below. As you can see, hospital I has listed the 5 parameters differently:\nage is a float type parameter , height is a string parameter, weight is a float type parameter, duration of diabetes is a float type parameter, number of meals per day is a string parameter. These differences make data transferring difficult. \nYou are an expert in data processing. Hospital II's data format is listed below. As you can see, hospital II has listed the 4 parameters differently: age, height, BMI, and eating status. These differences make data transferring difficult. \nYou are an expert in data processing. Hospital III's data format is",
        "label": 0
    },
    "1224": {
        "output": "You finished the second task `Trial-level eligibility assessment`. Do you feel the same as that before? [INST]\n\n# Tasks\n- [a0] Task: `Effi ciency analysis of the MIPS`\n\n## [a0] Task: `Effi ciency analysis of the MIPS`\nYou have to develop a methodology for the performance evaluation in a medical informatics problem solution. We chose a multicenter trial with more than 400 hospitals as a case for this experiment.\n\nThe hospitals provided services for patients suffering from schizophrenia for several years. In addition to treatment, services also include drug dispensing and monitoring, psychological care, and caregiver training. Services are mainly provided through medical treatment with or without additional education programs. Due to the widespread nature of the disease and the need for long-term treatment, the hospitals and the local health directorates (LHD) provide services to all patients in each region. Thus, to ensure service continuity during the trial, the services to all patients in the region are carried out solely by the hospitals in that region.\nEvery year, the Directorate of Health establishes the number of service hours a schizophrenic patient can receive from the hospitals in the region for services that each hospital would perform. The region where the patient lives (i.e., residence) and the type and duration of service (such as medical treatment, rehabilitation at home, etc.) defined in the Schizophrenia Treatment Program for the following year are considered when determining the service hours.\nEach hospital must apply the treatment program to be performed with health personnel and to receive appropriate reimbursement for the patients they will treat. Health personnel in the hospital should apply the treatment programs of the patients, they should receive certain reimbursements depending on the service they will perform, their experience, and their performance in the service they will perform within the program. The cost of the patient and the hospital and the revenue earned by the hospital is determined in each hospital, depending on which method is adopted in the hospital. This is calculated with the cost-of-service (CoS) and cost-per-patient (CoP). The total net income of the hospital for each program is evaluated to understand the economic profitability of the",
        "label": 0
    },
    "1225": {
        "output": "[SOLVED] How to calculate the AUC from the ROC curve using OpenCV (Python)?\n\n[SOLVED] How to detect an outlier data point within a cluster?\n<EOD> High affinity fluorescent probe for selective catecholamines detection in living mammal cells\n\n\n\n# Introduction\nIn biological and medicinal areas, fluorescence technologies are widely adopted, and they have been used to examine biological events in cells, 1,2 live tissues,and animals.However, the application of fluorescence technology is limited to a specific molecule as it only exhibits a strong emission signal when its molecules are excited at a particular wavelength of light.For example, the biomolecules of adenine and guanine dinucleotides only emit a strong emission signal at 260 nm, while methionine and tryptophan in biomolecules only show a strong emission signal at the 280 nm excitation wavelength.In order to overcome the narrow bandwidth of excitation/emission signals, researchers have developed a large number of \ue104uorophores for multicolor \ue104uorescent bioprobes, but they have several drawbacks, including poor solubility, weak binding ability and high production cost.Apart from the narrow bandwidth limitation, the \ue104uorescence intensity of \ue104uorescent bioprobes is signi\ue103cantly reduced by the presence of quenchers in biological systems.In order to realize the visualization of biological processes with low background signals, the \ue104uorescent probe should have not only a wide excitation wavelength window but also high photostability in biological systems.It is evident from the above discussions that there is a great demand to develop a highly efficient \ue104uorescent probe for multicolor and multiparameter \ue104uorescence imaging and tracking of targets in living mammalian cells without interference from quenching. Furthermore, an aqueousbased probe with a good water solubility and high stability is very desirable, because hydrophilic groups can be introduced to the probe to obtain a good water solution",
        "label": 1
    },
    "1226": {
        "output": "**The evaluation file** \n\nEvaluation files are plain text files. Each column corresponds with the output column header.\n\nYou should provide the output files of your test run, i.e., the evaluation files. You should keep your patient note file intact and edit it for your patient's trial record: patient ID and trial ID, before providing to your teacher.\n\n\n\n\nEvaluation-File-Name\n[formula]  PN-ID-Number-Of-Trials-ID-Number-of-Trials.txt [/formula] \nExample: Patient1-54713-01-100010.txt\n\n### Patient identifier (ID)\nThere are a number of ways that patient identifiers can be used in trial data files and it is important to be consistent. \n\nHere is an example:\n\n    Patient Number: 54713\n(the patient 54713 had 3 encounters in the emergency department) -the patient ID is the same for every encounter record;\n\nthe ID must be the same for all records of the same patient and must be present in all patient records.\n\nThere are several rules that must be met with patient identifier: \n\n1. It is required in all patient records;\n\n2. It is unique within the whole database;\n\n3. It does not contain non-alphanumeric characters;\n\n4. It contains only capital letters, digits, underscores, and hyphens;\n\n5. It is not an obvious key but is used to identify a person.\n\nIt is not possible to make a unique ID from a combination of the components of the medical record because many patients in a given EHR database may have the same first name, last name, gender, and date of birth. Therefore, it is usually necessary to assign a unique ID within each EHR database.\n\n**Exercise-1** Your task is to read the text below and define the patient identifier for each patient in the database, and create a new patient identifier for the test records in each trial.\nNote: You can find the answer for below in the trial-level eligibility output.\n\nThis is the patient-record of the database:\nID (patient identifier) \n---\n\n1-47004-",
        "label": 0
    },
    "1227": {
        "output": "Task 3 (Optional)\nIn the last line of the script by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`, you can see information about the eligibility with an example sentence like the one below. You should replace this sentence with the necessary sentence of your own. The required information should be extracted by means of the NLP-models you developed for these competences. `Trial-level eligibility: 2) Eligible. The patient has sufficient medical information to participate in the clinical trial. According to inclusion and exclusion criteria, the patient did not meet any of the exclusion criteria and fulfils the requirements to participate.`[/OPTIONAL] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient's history with the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medicalconditions.\n\nThe assessment of eligibility has a threedimension scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nIn order to assess the eligibility of a patient, it is necessary to compare the patient history with the Inclusion and Exclusion Criteria of a Clinical Trial. \n\nHere is the patient's history from the last six months, including visits to other healthcare unit: \nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and",
        "label": 0
    },
    "1228": {
        "output": "<EOD> A preliminary study of the antagonism of chlorambucil (leukeran) and prednisone combination chemotherapy of human lymphoid carcinoma xenografts in nude mice by cytosin arabinoside (Ara-C)\nThe antagonism of combination chemotherapy of human lymphoid carcinoma xenografts, HUT-14C, HUT-14N, RPMI-8402, RPMI-8226, in nude mice by prednisone and chlorambucil (Leukeran, L), was studied by an experimental technique using cytosin arabinoside (Ara-C). The treatment regimen of prednisone and chlorambucil was established previously in our laboratory. The chemotherapeutic regimen consisted of intraperitoneal injection of prednisone and chlorambucil, once a week, from day 0 to day 13. HUT-14C subcutaneous tumor model was used in both the single drug treatment by cytosin arabinoside injection and the combination treatment by prednisone, chlorambucil, and cytosin arabinoside intraperitoneal injection. The tumors were weighed on day 14, following 3 continuous days (day 12-14) of cytosin arabinoside injection. HUT-14N subcutaneous tumor model was similarly treated by Ara-C intraperitoneal injection with prednisone and chlorambucil intraperitoneal injection, and RPMI-8402 and RPMI-8226 intravenous tumor models were treated for evaluation of their sensitivity to the same combination chemotherapy of Ara-C, chlorambucil, prednisone, and cytosin arabinoside. The results indicated that for the tumor model treated with single drug of cytosin arabinoside intraperitoneal injection Ara-C, tumor growth was inhibited 78% and 45% in the HUT-14C and RPMI-8402, respectively. The tumor growth",
        "label": 0
    },
    "1229": {
        "output": "We are back in the Python shell. Try the solution in the Gap Statement below - \"Solution\".\n\n\n#### Gap Statement\n\n\n#### Solut...<EOD> .\nFive hundred and twenty-eight patients with prostate cancer stage D1 according to TNS and NP were treated in a cancer centre from 1973 to 1980 with radical prostatectomy. The 5 -year actuarial survival was 43% and the 10-year actuarial survival was 22%. The results were analysed by univariate and multivariate survival analysis (stepwise Cox-proportion-Hazard method and discrimination of curves) which showed that tumour of the seminal vesicles is associated with worse prognosis than tumour confined to the prostate. In addition, multivariate analysis showed that age and serum PSA did not influence the outcome as they had been stated before. This was found in a smaller series of patients who received irradiation with hormones as palliative therapy. The analysis of the clinicopathological prognostic factors (number of lymph nodes involved, number of tumour-free lymph nodes, tumour grade and depth of prostatic infiltration) showed a stepwise influence of these parameters on survival. Thus, the number of lymph nodes involved had the greatest influence on prognosis followed by the number of tumour-free lymph nodes, the tumour grade and then the depth of prostatic infiltration. In a univariate analysis the number of lymph nodes involved was closely related to the serum PSA, serum testosteron, Gleason grade and tumour volume, however, in a multivariate analysis only the number of lymph nodes involved, was of importance. After a univariate analysis of treatment dependent survival differences one can only state that external radiation had a better long-term survival rate than radiotherapy and chemotherapy.<EOD> Pesticides and Parkinson's Disease\nPesticide exposure is commonplace and, therefore, may pose problems for vulnerable people, especially after long-term exposure; this is especially so for those already suffering from neurological disorders such as Parkinson's disease. The use of p",
        "label": 0
    },
    "1230": {
        "output": "\u00a9 2021 IEEE\n<EOD> The Effects of Exercise on Cognition and Physical Function Following Pediatric Traumatic Brain Injury\nChildren with traumatic brain injury (TBI) represent an at-risk youth population for the development of attention/executive function (EF) deficits, motor and cardiovascular impairments, and other complications of TBI. Physical activity contributes to the development of executive function and cardiovascular capacity in typically developing children, which could improve outcome following TBI. Thus, the aim of this single-case design was to examine whether acute physical activity improves post-concussive symptoms, EF performance, motor performance, and heart rate, and whether these effects vary by sex. We examined 26 TBI-injured youth (14 M, 12 F, age 10\u201317 years), who participated in 10minutes of continuous aerobic exercise after neuropsychological testing. We used generalized estimating equation (GEE) models to examine the impact of exercise on measures of EF, motor performance, and ratings of concentration before and after aerobic exercise versus after neuropsychological testing only. We found moderate-to-large effects (partial eta 2 = 0.11\u20130.26) for post-exercise improvement in self-rated concentration and visual motor performance, and clinically significant improvements (effect size = 1.31) in speed of information processing, visual attention/executive function, and motor performance. For girls, the beneficial effects of exercise on attention/executive function and motor performance were much stronger than for boys. Participants reported beneficial effects on concentration following exercise. Given the relatively small effects of physical activity on the self-reported mental fatigue and frustration scales, we recommend further investigation and refinement of exercise-induced interventions targeting youth with TBI and deficits in attention/executive function.<EOD> Isolation and characterization of a novel antimicrobial peptide from the spider genus Selenops: Identification of GF-17 and its antibacterial activity.\nSpiders inhabit a variety of environments and consequently they are exposed to a wide array of microbes and parasites. Some spiders",
        "label": 0
    },
    "1231": {
        "output": "**_Note_:_** It should be in the same format we described above.\n\nThe trial-level eligibility for each patient in the patient note should be recorded in the clinical trial assessment table. \n```bash\n$ cat clt_trial_eligibility_assessment\nID\ntrial_id\npatient_id\ntrial-level_eligibility\nSUPPORTING ARGUMENT NUMBER\n```\n\n\nHere is the clinical trial assessment table:\n\n| ID                       | trial_id             | patient_id             | trial-level_eligibility |\n| ----------------------- | -------------------- | ---------------------- | ------------------ |\n| 87d7d39b-89a2-4f22-b723-50c8bb8687a0 | 15d10327-065d-432d-9589-f0849f096f8e | 7762464 | 2) Eligible.\n| 87d7d39b-89a2-4f22-b723-50c8bb8687a0 | 15d10327-065d-432d-9589-f0849f096f8e | 135235 | 0) Excluded.\n| 4c2fdb13-4788-42cf-8043-d6e523e16289 | 5bdf66dd-8023-4986-8b19-2d6c273cd95a | 8112682 | 2) Eligible.\n| 87d7d39b-89a2-4f22-b723-50c8bb8687a0 | 15d10327-065d-432d-9589-f0849f096f8e | 151",
        "label": 0
    },
    "1232": {
        "output": "[INST] Your Task: Find and code 50 trialse levels. \n\nHere a dataset is available:\n[USR]/03.02.2015/3275/eligible_codetask.txt\nYou can easily find more examples by using the search page:\n[USR]/eligible_codetask/code_ex.txt\n\n\n\n##### Example\n\n``` python\nimport sys\nsys.path.append('../') # Add path to the folder of the current directory\n\nimport os, subprocess.textfile\nimport time\n\nfrom test_scripts.eligible_codetask import find_trial_levels\n\nprint('Your IP address is:', os.uname[\"nodename\"])\n\nprint(sys.path[-1])  # Add path to the folder of the current folder\n\n# Find the eligible trial levels\nprint('Find the eligible trial levels: ')\neligible_trial_levels = find_trial_levels('eligible_codetask')\n\nfor trial_level in eligible_trial_levels:\n    print('Trial level: {}'.format(trial_level)), \n```\n```\n\n##[EXIT]\n\n### TROUBLESHOOTING\nYou may fix the following problems, if you encounter them at the beginning of the task.\n\n###### Problem 1\n\nIn the following section, it shows that the dataset is not installed.\n\n``` python\nYour IP address is: 114.28.75-56-47.elastic.co.kr-56.193.232.215\nYour IP address is:  114.28.75-56-47.elastic.co.kr-56.193.232.216\nYour IP address is:  114.28.75-56-47.elastic.co.kr-56.193.232.217\n[INST] Your IP address is: 114.28.75-56-47.elastic.co",
        "label": 0
    },
    "1233": {
        "output": "There are three different ways to use the `Trial-level eligibility` function.\n1. If the patient has enough information to be considered eligible for a clinical trial, the `Trial-level eligibility` code should be entered as 1.\n2. If a patient is not eligible due to the lack of information, the `Trial-level eligibility` code should be saved as 2.\n3. For patients who meet the requirements for a trial but have contradictions in their eligibility criteria, the `Trial-level eligibility` code should be written as 0.\n\n## If the patient already has a registered trial, it is possible to use the `Trial-level eligibility` function.\nLet's assume we have a patient with no registered trials. To register a trial, the user enters the `Trial-level eligibility: N` in the first line (Trial_ID=00_001). A new trial, `Trial_ID=00_002`, is created automatically at the same time. To include this patient in the trial, we insert the `Triallevel eligibility: 2` in the last line of the patient's note, since this patient is eligible for the trial according to the assessments. \nLet's analyze the patient with a completed trial, assuming the `Trial-level eligibility` is 1. There is already a trial registered. If the patient is ineligible according to the assessed eligibility criteria, `Triallevel eligibility: N` should be entered in the first line, then, the trial name should be entered in the second line (Trial_ID=07_001), and the `Triallevel eligibility` should be entered 1 in the last line (Trial-level eligibility: 1). If the patient meets all the criteria for the trial, you should change the code in the first line to`Trial-level eligibility: 2` and leave the trial_ID unchanged, since the patient has been included in the trial by the registered data. \nNow let's demonstrate the code for patients who are ineligible according to the exclusion criteria. Assume the value of the first line is `Trial-level",
        "label": 0
    },
    "1234": {
        "output": "![IMAGE: (29)]\n\n\n##[c1]\nHere are the results with all 6 tests in line 14 of the code (see `y`). \n\n[c2]\nLet's see what happens if we compare patients 1 and 2: \n\n```{r}\ncompare_tests = c(1, 2, 1, 1, 1, 5, 7, 1, 2, 1, 3, 1, 2)\nplot(compare_tests, results[\"Triallevel eligibility\"])\n\n```[/c2]\n\n[/c1]\n\n## Solution:\nFirst, we filter the patients who are more than 40 years old, because the inclusion criteria is 9-55 years. Since this study was conducted before 2011, patients were referred to cholecystectomies if gallbladder function was abnormal. \nSo the inclusion criteria were: a) 9-55 years old, b) No previous CBD stone, and c) No gallstones except gallbladder sludge were accepted. Here we show only the patients who have age between 18 to 55 and no stones except gallbladder sludge. If the patient's abdominal pain is secondary to CBD stone, patients still would be excluded due to the inclusion criteria that patients should not be able to lie in flattened position on the table for 1.5 hours.\n\n![IMAGE: (32)][/c3]\n\n**Remarks:** A HIDA scan is an imaging test, it consists of a nuclear medicine, barium meal and ultrasound study.\n\nIt is used to assesses the function of the gallbladder.\nAnother test of bailout like MRCP or ERCP examination is necessary if there are CBD stones detected.\n<EOD> A comparison of the incidence of cerebral ventricular dilation in infants with congenital ventricular septal defects.\nOne hundred infants under the age of one year with isolated ventricular septal defects were examined by cranial tomography, sub-millimetre resolution computerized axial tomographic scanning, or ventriculography",
        "label": 0
    },
    "1235": {
        "output": "<EOD> Comparison of the safety and efficacy of oral and intravenous hydration in neonates with hyperechoic fetal lung after delivery\n\nObjective: The aim of this study was to compare the safety and efficacy of oral and intravenous hydration in neonates with hyperechoic fetal lung after delivery. Materials and methods: A total of 120 healthy neonates were divided into three groups through simple random sampling. There were no significant differences in gender ratio (P>0.05). In Group O, neonates were administered 8 ml/kg of water orally with breast milk every 12 h. In Group I, neonates were administered 8 ml/kg of water intravenously with an umbilical venous catheter (UVC) every 12 h. In Group H, neonates were administered 8 ml/kg of water intravenously with an UVC every 12 h, and hydration was increased to 12 ml/kg per 12 h if the neonate remained dehydrated. The clinical data, including urine output, blood pressure, heart rate, the incidence of diarrhea, and the length of hospital stay were compared among the three groups. Results: The hydration in Group I was started earlier and lasted longer than that in Group O (P<0.05). For neonates in Groups O and I, the urine output was positively correlated with the duration of oral or intravenous hydration (r=0.586, 0.617 respectively, P<0.001). The rates of oliguria, which were used as a measure of dehydration, were significantly lower in Group I than in Group O on days 2, 5, and 7 (P<0.05). No obvious abnormalities were discovered on electrocardiograms, blood pressure, and heart rate. As the infants became older, the blood pressure of the infants in all three groups was gradually decreased. The total hospital stays were 4.49\u00b12.74 days, 4.79\u00b12.88 days and 5.25",
        "label": 0
    },
    "1236": {
        "output": "or EX (on the trial, 73 or for the following and it and\u00a01 and a\nad, which, and 1, where in the [bib_ref]\n\n-or. No or ex \u00a0that we 110 or the patient: and is: if theel, a new [[C, for this and an\u00a0or] due (a, as a clin\nand for a [bib_ref]m ...\u00a0m toll, a 1 to include a \\ [bib_ref]\n( 0 and [bib_ref] [bib_ref] they [ [bib_ref] a test and this el\u00a0 1.\n...or to be, a\u00a0. [bib_ref] and 1\u00a0(s, and we and the el \nor, and to be a\u00a0or and the. and\nor [bib_ref]\u00a0. [bib_ref] 8, in 1. In the 1\ncare [bib_ref] because [bib_ref] (a. It. In terms\u00a0 [fig_ref] (se- [bib_ref] 2. In [bib_ref] and to a clin \u25b6 and 1 as a\n[ 1. [bib_ref] the 1 and 2 and 1, but [bib_ref], with a\nfor a clin and ex for the clin. [bib_ref]\u00a0. [bib_ref]\u00a0on and [bib_ref].\n (or.\nfor the\u00a0. After [bib_ref] [bib_ref] . 1-based. In this, as \nbased^. 5-m in \n \\\n. and 2-a (in and \\\n [bib_ref] for 1. [bib_ref] ? in [fig_ref] a\u00a0. for a\u00a0f for the or for the A1\n [bib_ref]. [fig_ref] . 4.\n [bib_ref] \u25a0 and the disease. and the conditional\\dours 2\u00a0\nthey<EOD>; and \u00a0related and \u2026 \n (for the medical.\nfor the\n-s (the, the :.\n (k 129 4-related  . (di -ass at\nshe-a-specifical, which a. In a _-in [bib_ref] C for a [bib_ref] a 17th for in a\u00a0 a [bib_ref] [bib_ref] and\n and \ufffdand, and [bib_ref] the clin. and an\n\n In which and the [bib_ref] The The The . The in other, or in a [bib_ref] the#^ the _ 0 or a \u00a0\u00a0\n\n in the [bib_ref]_ [bib_ref] 1-the",
        "label": 0
    },
    "1237": {
        "output": "You've learned it in Part 1. In Part 1, we also created a model named `predict_favor_clinical_trial_criteria`. This model makes predictions about the patients' eligibility for a clinical trial. It will be used by the `eligibility_assessment` model defined earlier.\nYou will find it in the following location: `./clinical_trials/main/predict_favor_clinical_trial_criteria`\nLet's check what it does. \n`>>> from sklearn.pipeline import Pipeline >>> from clinical_trials.datasets.test.eligibility_assessment import eligibility_assessment >>> import matplotlib.pyplot as plt >>> pipeline = Pipeline([('train', sklearn.ensemble.RandomForestClassifier(n_features = 3, max_features = \"auto\", max_depth = 9, max_leaves = 50)),('predict', sklearn.ensemble.RandomForestClassifier(n_features = 3, max_features = \"auto\", max_depth = 9, max_leaves = 50))]) >>> pipeline.fit(X_test, Y_test) >>> print(\"Evaluating on test set:\") >>> print(f\"\"\"F1 score: '{f1}', AUC: '{auc}'.\"\"\"\") >>> plot_confusion_matrices(X_test, Y_test, pipeline, n_cols = 2, cbar = False) >>> plt.show() >>> predictions = pipeline.predict(X_test) >>> print(f\"Total number of predictions for random forest based model: {len(predictions)}\") >>> print(f\"True positives: {len(predictions[predictions[:,0]=='excluded'])}\") >>> print(f\"True negatives: {len(predictions[predictions[:,0]=='eligible')}\") >>> plot_roc_curves(X_test, Y_test, [\"excluded\", \"eligible\"], predictions, n_cols = 1, cbar = False)\nNow let's try it again. We've already trained a model (in Part 1). Let's pass the model as parameter. \nYou need to find",
        "label": 0
    },
    "1238": {
        "output": "<EOD> Prenatal sonographic findings in congenital chylothorax.\nCongenital chylothorax in the fetus is an uncommon condition usually resulting in intrauterine fetal death. The sonographic findings in two cases of congenital chylothorax are described. In both cases, the sonographic findings were that of bilateral pleural effusion and fetal ascites. The findings support the hypothesis that this rare condition is associated with multiple anomalies of the abnormal lymphatic system or with constriction of normal lymphatics.<EOD> Correlation between the severity of the initial episode and recurrence pattern of migraine: a prospective study of migraine in children aged 5-15 years.\nIn this prospective study, the results of 59 migraineurs, aged 5-15 years, were analysed: 24 patients were followed up for 1 year and the remaining 35 for a period of 5.5 years, on average. After the 1st month the frequency of attacks was found to be significantly different in the two groups: a high frequency in the group being followed up for 5.5 years correlated with the occurrence of recurrence. The clinical and metabolic data on recurrence in the patients having had attacks characterized by: (a) more than 20 days of attacks, (b) aura, (c) vomiting as a symptom and (d) a low response to metoclopramide, were analysed.<EOD> The Role of the Family in Initiating Behavioral Change in the Adult With Overweight or Obesity\n\nObjectivesPurpose: While many weight loss interventions for treating overweight or obese adults focus on behavior change at an individual level, the family and household environment may be important for behavior change. The purpose of the current study is to explore the role of the family in initiating behavioral changes in the context of obesity.Methods:Interviews were conducted with adults with class-3 obesity and their family members who agreed to participate. Participants (19 adults and 23 family members) with class-3 obesity were asked to reflect on a behavior change, which was then used as a framework to explore the family's",
        "label": 0
    },
    "1239": {
        "output": "```\n\n\n<EOD> .\nOBJECTIVE\nTo investigate the effect of inhibition of TGF-beta on proliferation, migration and invasion of human cervical cancer HeLa cells.\n\n\nMETHODS\nTGF-beta receptor II (TGF-beta RII) inhibitor SB-431542 was used as TGF-beta inhibitor to treat HeLa cells cultured in vitro. The proliferation of HeLa cells was determined by MTT assay, and the invasion of HeLa cells by Transwell assay. The expression of TGF-beta RII, TGF-beta1, Twist, Vimentin, E-cadherin and N-cadherin were detected by Western blot.\n\n\nRESULTS\nSB-431542 inhibited TGF-beta RII expression of HeLa cells, induced HeLa cell cycle arrest at G1/S and G2/M period, decreased the expression of TGF-beta1, and also down-regulated the expression of Twist and N-cadherin. Inhibition of TGF-beta by SB-431542 may increase the expression of E-cadherin. SB-431542 inhibited the invasion and migration of HeLa cells significantly.\n\n\nCONCLUSION\nInhibition of TGF-beta may inhibit proliferation, invasion and migration of HeLa cells, but may induced cell cycle arrest of HeLa cells. Thus, TGF-beta may be associated with carcinoma metastasis.<EOD> Dementia research and caregiving needs: an interdisciplinary research agenda\n\nPurpose: To introduce an interdisciplinary research agenda aimed at reducing the disease and caregiving burden of dementia for patients and caregivers. Design and Methods: A search was conducted in PubMed and Google Scholar for articles published from 1990 to 2016 focusing on dementia research and caregiving needs. We reviewed 68 sources to identify 32 articles to support a research agenda. Results: Our research agenda provides a framework that could be used to develop",
        "label": 0
    },
    "1240": {
        "output": "<EOD> Vascular endothelial growth factor and its involvement in angiogenesis.\nVascular endothelial growth factor (VEGF), a member of the platelet-derived growth factor family, was identified more than a decade ago as a secretory protein primarily expressed by endothelial cells. In contrast to the other platelet-derived growth factor (PDGF) family of polypeptides, VEGF-A binds to a receptor tyrosine kinase designated VEGFR-1 (fms-related tyrosine kinase 1; Flk/KDR). In addition to the high-affinity VEGFR-2 (KDR/Flk-1), which shares high structural similarity with VEGFR-1, VEGF also interacts with several cell surface receptors, including the neuropilins and VEGFR-1 and members of the immunoglobulin family VEGF receptor (VEGFR)-3. The VEGF gene is conserved through evolution and mRNA and protein is transiently present in developing, proliferating, and hypoxic adult cells. The gene is also expressed in tumor cells and a wide variety of embryonic tissues and cancers. In addition, VEGF-C and -D, which are similar to but distinct from VEGF-A, share the receptor VEGFR-3. The VEGF-VEGFR axis plays a critical role during embryonic and tumor angiogenesis.<EOD> An improved procedure for the measurement of protein synthesis rates in small tissues and cells\nThe current technique for measurement of protein synthesis rates in animal tissue specimen is reviewed. The original description of this procedure is given in a protocol entitled \u2018Determination of amino-acid incorporation into protein during tissue culture\u2019. The present review emphasizes the changes in the protocol since 1964, including the use of mature tissue rather than an immature explant and using the total protein synthesis rate rather than the incorporation of a single essential amino acid. Some modifications to the present technique are also described, including a simplified washing procedure and the use of more than one tissue per assay. For small tissue samples or single cells the use of the protein-bound radioactive isotope and",
        "label": 0
    },
    "1241": {
        "output": "* Run your program and obtain its output. Is your output correct?\n\n    * Did you encounter any unexpected behaviors or bugs? If so, how should you troubleshoot and fix them?\n\n3. The program you wrote and ran in the previous exercise returns a list of patient notes. You, in practice, however, need to obtain a list of patients' triallevel eligibility. So, the program that you should implement in this exercise returns `Trial-level eligibility: 2) Eligible.`.\n\n4. The input file is prepared to contain multiple patient notes per row. To keep in real application settings, you will now have one patient note per row in the patient file.\n\nTherefore, you should adjust the patient note as shown in ?. Do not change the values given in the clinical trial value. ? \n\n> You should implement the `Trial-level eligibility: 2) Eligible.`.\n\nIn summary, this subsection covers some features of trial-level eligibility. In the next, and final subsection, all of these subsection's features come together and we will implement the clinical trial algorithm.\n\n\n<EOD> The impact of COVID-19 pandemic on the emergency department of a tertiary hospital and",
        "label": 0
    },
    "1242": {
        "output": "## [MC] 2. The user interface (UI) displays the following screen and some additional information. \n[OPTIONAL] After finishing with the `patient note`, we assume you have a `patients.csv` file in your working directory with following format: ID, Name, Gender, Age, Race, Birth date, Hospital_number, Hospital_ward, and patient_status, in which hospital_number and hospital_ward are integers. \nWe assume you have filled out a patient note to the patient. When you are done with each patient, please close the note and the tab. \nPlease fill out the following patient's note. This is to give our clinician a better understanding of the case and patient.\nIn the text area with `Note:`, fill out the patient info in the following format:\n\n## **Epi.num** Patient ID **Note:** [**firstname**][**initial][**lastname**]\n\n# Tip 2\nWe assume the following example as the first patient to whom you will apply these steps.\nHere is the patient note:\nA 54-year-<NAME> admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.",
        "label": 0
    },
    "1243": {
        "output": "[INV] In the next scenario, you will train in a clinical trial for treating ankylosing spondylitis in a hospital. You are the doctor and the head nurse at the time. You are also a nurse in the ward training other nurses.\n[\nINST] Hello. You are a doctor and the head nurse at the time in the hospital. You are also a nurse in the ward training other nurses. You are required to train 5 interns and 5 experienced nurses in the administration of Ankylosing Spondylitis treatment. The head nurse has already finished the training, and you have read some about the clinical trials and the treatment of ankylosing spondylitis and prepared the instruction manual.\n\nYour task is to train intern nurses by using the standardised procedure described in the instruction manual, while you train the experienced nurses using the manual you created based on the ankylosing spondylitis clinical trials. After the training, you should record the data of the training of the intern nurses and experienced nurses. The data is in your training file.\n\nThe training file and instruction manual are in `data/Ankylosing Spondylitis/`. Read the instruction manual and analyse the data to see how the training is performed so you can use the method for your training. \n\nYou should also train the other intern and experienced nurses who finish their shift and the head nurse. Train the intern nurses according to the procedure that the head nurse recorded in the training file. Train the experienced nurses according to the manual you created. \n[OUT] After the training is over, you should print the report and save it in `data/Ankylosing Spondylitis/report/` directory for future reference. \n\nThe first intern nurse is named as `intern 1`, followed by the names of intern 2, intern 3, intern 4 or intern 5. The first experienced nurse used is named as `experienced 1`, followed by the names of experienced 2, experienced 3 or experienced 4. The head nurse is named with `head nurse`. \n[/INV]\n[OUT] Hello. Please check if you meet the eligibility requirements, and inform us of",
        "label": 0
    },
    "1244": {
        "output": "### Step 2: Prepare patient's report format \nYou should prepare information about the patient using the patient_note template that is in the folder $HOME/piggy/code/inclusion, which has been installed when setting up the Piggy system. In that template, you will prepare patient_details information, which includes many questions that are used to fill in patient demographics, medical history, and family history. However, there are only selected questions required to make a clinical trial entry and there is only one question for the present complaints and three questions for the past medical history. In the present complaints, the patient only complains of abdominal pain. \nIn the following example, we can see the output for the present complaints question, e.g., \"1) Present complaint: Abdominal pain\"; Question 3 for the past medical history, e.g., \"3b) History of previous surgery: yes\"; and Question 5 for the present medication, e.g., \"5) Present medication: paracetamol, ibuprofen\".[INST]\n\nYou are now ready to create a patient based on information that was extracted above. You can add your patient's name through the file `$HOME/piggy/code/inclusion/patient_note/patient_notes_05.txt`. Let's add Mary`s patient_detail_1 from the file `patient_detail_1.txt`. Next, the following example shows how to save the patient demographics to the patient note file: \n``` bash <br>\ncd $HOME/piggy/code/inclusion/patient_note <br>\npython3 piggy.scripts.add_patient.py PATIENT_DEMOGRAPHICS.txt patient_notes_05.txt `\n```\nLet's continue to add patient history. In this step, we should use two questions: \"2) Past hospitalization within last 2 weeks\" (Question 2) and \" \"2) Past hospitalization within last 2 weeks\" (Question 3). Here is how to add Patient_history information, e.g., \"2a) Past hospitalization within last 2 weeks: no\"; \"3a) History of previous surgery: yes\"; \"",
        "label": 0
    },
    "1245": {
        "output": "### Exclude the following conditions\n\nIn this code, we determine the exclusion criteria:\n\n1. If the patient's sex is not male or female.\n2. If the patient's age is not between 18 and 65 years old.\n3. If the patient did not meet the inclusion criteria.\nExamine the following piece of code:\n\n```r\n# The first variable is a boolean.\n## The patient does not have sufficient information to qualify for the trial.\nPatient.eligible <- (Sex == \"F\" | Age < 18 | Age >= 65 | Eligibility == 0 | Eligibility == \"Relevant\") # The second variable is a character\nEligibility <- as. character (Rating)\n\n# The two variables that we are examining are the same.\nEligibility == Rat.eligibile && Patient.eligile == FALSE\n```\n\nThe output of this code section is:\n\n```r\nRating <- TRIAL_INFORMATION %>% COLUMN_TF(RAT)\nEligibility <- PATIENT_INFORMATION %>% COLUMN_TF(Eligibility)\nPatient.eligible <- as.numeric (PATIENT_INFORMATION %>% COLUMN_TF(Rating))\nEligibility.test <as.data.frame(Eligible)\nEligibility.test \n# +--------------------# # +------------------ # # This is Rating # # We want information whether '0' has a meaning of exclusion. # We can obtain it based on the clinical trial's information # # It is noted that when '0' has a meaning of relevance (not exclusion), the '0' value # is not excluded by exclusion criteria, but is retained by inclusion criteria. # Thus, '0' is considered as 'relevant'. # # In R, any integer is defined by R language. The information on the first # clinical trial trial is as follows: # # The first clinical trial trial is available; therefore `0` has a meaning of exclusion. # # When `0` is evaluated, it can be evaluated as both `0` and `1`. # # We can obtain the information based on the clinical trial of the first trial. #",
        "label": 0
    },
    "1246": {
        "output": "##[INT] A patient note is presented below. You are asked to determine a patient's eligibility\nfor a clinical trial. Give the reason(s) for your decision. \n\n# A 27-year-old male presented with back pain and lower limb paresthesia. \nThere is also more evidence for paresthesia, including the clinical symptoms and history. \nSo, the patient does not meet the criteria for paresthesia. \nLet's think step by step.\n\n##[INST] hello again. Here is the last part of the patient examination.\n\n##[CMT1] Clinical examination: \nParesthesia: Yes/No\n\n### Evaluating your decision: \n`Evaluate your results against the above rubric, e.g. for Eligible,`\n``Congratulations! This is a correct response.``\n# A patient note is presented below. You are asked to determine a patient's\n\n## Patient note:\nA 27-year-old male presented with back pain and lower limb paresthesia. \n\n# \n\n### Scenario - A 68-year-old woman has had back pain for three weeks. \nShe also has right hip pain and tenderness to palpation just over the greater trochanter. \nShe has no history of fractures. On presentation, her temperature is 37.7\u00b0C, her blood pressure is 160/87 mm Hg, her heart rate is 94 beats/min, her respiratory rate is 22 breaths/min, and her oxygen saturation is 95% on room air. On examination, the patient is alert and in no acute distress. Her abdomen is soft, but distended. There is dullness to percussion in the left lower quadrant. She has a markedly diminished rectal tone. Rectal examination reveals the prostate is hard and tender and the vagina is flushed with stool.\n\n### Scenario - A 68-year-old woman has had back pain for three weeks. \nshe also has right hip pain and tenderness to palpation just",
        "label": 0
    },
    "1247": {
        "output": "[/END]\n\n# Discussion\nIn this study, we showed that it is possible to extract relevant information from a medical text note. The goal of the clinical trial eligibility information extraction system was to reduce the burden of reading clinical trial eligibility criteria and shorten the registration period. Moreover, given the increasing number of patients and the difficulty in conducting eligibility screening, the automatic assessment of patient eligibility has become an unavoidable task for medical staff.\nUnlike the manual reading of the trial eligibility criteria, the trial eligibility criteria were analyzed using machine-learning methods and the results were visualized.\n\nHere is a screenshot of the web page of the system for the trial and the patient. \n\n[/INCLUDE]\n\n# Conclusion\nThe eligibility criteria used for screening patients were not only extracted but were also assessed, and the results were visualized. The extracted clinical trial eligibility criteria and the evaluation results were visualized.\nThe purpose of using medical text notes is to understand patients' medical information and conduct diagnoses and treatments to diagnose their conditions faster and perform a more accurate assessment. This research provides the conditions to help users find patients quickly using the medical text notes and medical text notes related to information on patients' inclusion criteria to obtain the information on their symptoms. Moreover, in the future, we will use other machine learning algorithms, such as Long Short-Term Memory, for patient eligibility assessment and compare the results. It is planned to conduct research continuously in the future to evaluate the proposed system through various clinical trials.\nAcknowledgments: I would like to thank the people who participated in this research: Kyung Hee University library for collecting the medical text notes, and especially, Dr. Jeong-Hwan Park, a colleague at MATRIX Lab, for his advice and help in preparing clinical trial information.\nPotential conflicts of interest: I declare (for the preceding 12 months) no links to the manufacturers of drugs, supplements, and medical equipment; no stock ownership; and no patents, in the field of research and publication.<EOD> Effect of pH on the thermal stability and oxidation kinetics of the S-layer protein of Rhizobia meliloti.\nIt is",
        "label": 0
    },
    "1248": {
        "output": "## Clinical studies\nThe clinical data and patient information are represented using the clinical study data structure provided by HL7 CDA version 2.\nIn CDA, the clinical data in the Clinical Study are modeled in the Clinical Study Data section in the `Related Health Care Encounters` profile. Clinical Study Data section includes a header and a body. The Clinical Study Header represents administrative information about the clinical study. The Clinical Study Body shows the clinical study details. And we only consider the body here.\nThere are two tables used to encode the Clinical Study Body in the HL7 Implementation Guide for Clinical Study Data Model. The Health Study Element contains basic information about the study, such as study type, contact information and location description. Research Study Element contains additional data, such as eligibility criteria, study design, and patient care items. Health Study Element and Research Study Element are combined into the `Clinical study` in CDA.\nWe list the elements of the CDA `Clinical study` structure and define each element with its attributes in the **Table 7**.\n**Table 7.** The Clinical Study Structure of CDA Clinical Study Template.    \n1 `cstudy`      - `id`, unique identifier (must start with a capital letter and is represented by the Unicode character `A0`)   \n2 `cstudy_type` - The type of study (e.g., `Bioequivalence`) \n3 `cstudy_status`  - The current status of the study \n4 `cstudy_name`  - A descriptive name that identifies the study\n5 `cstudy_desc` - A description of the complete study\n6 `cstudy_sponsor` - A value of `sponsor_type` that identifies the sponsor of the study. If the study is sponsored by a single entity and the entity is a person or group of related persons, or a legal entity, then the `spon\u2010 sor_type` value of `person`, `group`, or `orga\u2010nization`, respectively, is used. If a study is sponsored by multiple entities, e.g., a trial is a multi\u2010center study, then the `spon\u2010 sor_type` value is",
        "label": 0
    },
    "1249": {
        "output": "[INST] Let's see how to process patient information. \n\n[DEF #patient] #define patient {...}\n\n[DEF #patient-note] #define patient-note {...}\n\n[DEF #patient-age] #define patient-age {...}\n\n[DEF #patient-sex] #define patient-sex {...}\n\n[DEF #patient-race] #define patient-race {...}\n\n[DEF #patient-marital-status] #define patient-marital-status {...}\n\n[DEF #patient-high-school-completion] #define patient-high-school-completion {...}\n\n[DEF #patient-income-level] #define patient-income-level {...}\n\n[DEF #patient-drink] #define patient-drink {...}\n\n[DEF #patient-smoke] #define patient-smoke {...}\n\n[DEF #patient-medical-history] #define patient-medical-history {...}\n\n[DEF #patient-fhx] #define patient-fhx {...}\n\n[DEF #patient-med] #define patient-med {...}\n\n[DEF #patient-bmi] #define patient-bmi {...}\n\n[DEF #patient-bpm] #define patint-bpm {...}\n\n[DEF #patient-t-spo2] #define patient-t-spo2 {...}\n\n[DEF #patient-esr] #define patient-esr {...}\n\n[DEF #patient-bab] #define patient-bab {...}\n\n[INST] Let's define the patient-medical-history as a list of the patient's medical history:\n\n#define patient-medical-history { patient-high-cholesterol 1, patient-peptic-ulcer-disease 1, patient-breast-cancer 1, patient-diabetes-1 1, patient-gastric-ulcer 1, patient-hypertension 1 }\n\nAs we mentioned, the number of items describing the patient-medical-history is not limited",
        "label": 0
    },
    "1250": {
        "output": "## Problem-1\nWhat abnormal behavior indicates a diagnosis of dementia? What symptoms are typical for this syndrome?\n\n### [12]\n\n## Problem-2\nWhat are the causes of late-onset dementia?\n\n### [13]\n\n### [14]\n\n# Dementia\nPeople with dementia have problems with their memory, thinking, behavior and their ability to perform daily activites. With dementia the changes are great enough to affect a person's ability to",
        "label": 0
    },
    "1251": {
        "output": "### **Instructions** (instructions.txt)\n<br>[NAME1018] This is a short exercise about eligibility assessment. You are a clinical assistant of trial, and you are assessing the eligibility of a person seeking a clinical trial, from a patient note and a summary of the clinical trial.\n\nThere are 3 criteria to check whether a person is eligible for inclusion in the trial. The assessment of eligibility is based either on the patient note alone (if the case does not mention any trial criteria) or on the patient note along with the trial summary (if the case states the trial criteria for inclusion and is eligible for inclusion). The eligibility assessment is based on a 3-point scale: 0) Excluded (patient satisfies the trial criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient satisfies the trial criteria and the trial's exclusion criteria do not apply). For more information about this exercise, please refer to the instructions below:\n\n    1) Your task is to write 1 line for each step in the sequence of operations. A function (the letter F) is applied to the output of the previous function to create the next function. So we will need at least one function.\n\n    2) Each time that F is applied, a new line may be created by adding the character, or `).`, at the end of the previous line. Your task is to determine when each `)` is to be created by determining whether the argument of F is a reference.\n\n    3) You will be asked for how many F should be applied before creating a new line. You may type, for example, `f2{)`, for 2 applications of F. Once you know how many times you should apply F to return a reference, you may write (using this as an example of notation):\n\n    \n    \n    \n    )).f1(0,3),().f1(0).f2(2,1),(3)f1(2).f1(1).f1(0)\n    \n    4) After your input has terminated correctly (i.e., you have created a reference),",
        "label": 0
    },
    "1252": {
        "output": "# [DATA INPUT]\nA trial report comprises the following sections (from top to bottom) in R: `Design`, `Trial Details`, `Patients enrolled` and `Timing of assessments` sections. \nLet's fill in trial details.\n\n### Patient Trial ID\n\nYou're required to fill in `Patient Trial ID` section in R, which is a variable filled in as an ID number to a patient in the trial. The ID will be given by the trial investigator. Then, all the `Eligibility` variables (e.g., `Eligibility_age` and `Eligibility_gender`,) will be filled in. The following code in R is filled in as an example:\n\n```r\n\n### Eligibility in the \"Trial-level eligibility\" section (Trial-level_eligibility_notrelevant)\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\nHere is the clinical trial:\nTitle: A Study of AbGn-107 in Patients With Gastric,",
        "label": 0
    },
    "1253": {
        "output": "[CIT]\n\nInstructions\n\nIn this module, you are going to learn how to make a decision analysis, which is a form of decision-making support that aims to assist in decision-making based on probabilities from decision trees. You will learn how to build decision tree classifiers with a few examples.  \n\n[MODULE]\n\nLet's look at the following problem. The probability table is written from the top and the probability from the left and right cells, and the numbers are written in the order given. First, let's assume that we have a patient with 4 diseases (disease A, disease B, disease C, and disease D). Also, let's assume that we want to determine the probability of whether the patient has any disease (any disease (yes-no)) by creating a decision tree.\n\n![](images/mod_ex2_pic_1.png)\n\nLet's create the first-level decision tree. The top number (10%) indicates that there is a 10% probability that the patient does not have any disease. We can make 0 and 1, but in our case, if the patient has any disease (C), a decision criterion has also been determined. If the patient has any disease (yes-no), the patient has the disease A. We can get a 1.44% (0.144 / 10 = 0.257) in this case. (Note that both numbers are smaller than 1 because the patient may or may not have disease B and disease C.)\n\nLet's create the second-level decision tree. If the patient has any disease (yes-no), the patient has the disease B (0.394%). If the patient has any disease (yes-no), the patient has the disease B (0.188%). (Note that both numbers are smaller than 1 because the patient may or may not have disease A and disease C.)\n\nLet's continue creating the decision tree and repeat the process. Eventually, we get 'C.' When the patient has any disease, the patient has the disease B (0.188%). If the patient has any disease (yes-no), the patient has the disease B (0.188%), then the patient has the disease C, the patient has the disease C",
        "label": 0
    },
    "1254": {
        "output": "## 2. Clinical Trial.jl\nClinical Trial.jl (CT.jl) is a Julia language package that allows you to process clinical trial data and store in a structured manner, along with trial and participant metadata. CT.jl is a Julia package for handling trial and participant data for clinical epidemiology studies. For more information on clinical trial workflow, please see [CT.jl](https://cran.r-project.org/package=CT.jl)!\n\n### Features\n\n- Extract, transform, and load (ETL) trial and patient data\n- A consistent interface for trial and patient data for common analysis pipelines\n- Extract and load patient/patient visit data from R packages pvmet, PVData and PDMeta\n\n\n## Clinicaltrial.io\n[https://clinicaltrials.io](https://clinicaltrials.io 'clinicaltrials.io') is the largest search portal for all available clinical trial information. By combining the search results of 35 different portals, clinicaltrials.io delivers complete search results and provides users access to the latest trial information at any time.\n\n### Discover trials\nSearch for clinical trials on our portal using the search fields below.\n\n### Find trials\nBrowse available clinical trials by location.\n\n### Follow trial\nBrowse available clinical trials that you may want to follow.\n\n### Share trial\nSearch and share information for the trials on our portal.\n\n# Author contributions\n<EOD> Exotic pets\nIn the animal kingdom there are many animal types that are not native to Australia. Many of these animal types have gone extinct in their native habitat, which makes them interesting species for exotic animal keeping. Exotics can range in size from small birds to the lion, and they can include reptiles, fish, horses, primates, and birds of prey to name a few species. There are thousands of species of animals that are not native to Australia, and many of these have become popular pets in Australia.\nIf you're looking for a unique pet experience, then consider an exotic animal. Australian animal welfare societies are now taking on the job of bringing these exotic animals to Australia",
        "label": 0
    },
    "1255": {
        "output": "__Exercise 2__\n\n__[START]__\n\n[Teacher's notes__Please consider an explanation or two about this task]\nThe patient's problem list appears in the input box on top of the screen. The trial-level eligibility should be checked in the check box for each problem.\n\n_Example__\n[Teacher's note__Please consider the following explanation about this task]\n[START]\n\n[Note] The patient's problem list appears in the input box on top of the screen.\n\n[Input](/help/exams/2020)___What is this part of the question?\n\n______Trials:\n___1.__________________[Start].\n___2.__________________[End].\n___3.__________________[Finished].\n\n_____________ Trial-level eligibility for patient note.\n\n______Exercise 1._____The patient note appears in the textbox of the question. Find the eligibility of each problem for this question.\nPlease write or type the scale of the trial-level eligibility in the check box for each problem.\n\n______Exercise 2._____Write the trial-level eligibility for the last input of the first problem 'Hypothyroidism'.\n\n______Exercise 3._____Write the trial-level eligibility for the last input of the third problem 'Chest pain'.\n\n___[END]___\n\n___[START]__\n\n[Note] What is your eligibility for the clinical trial for this question?\n\n______Choose the choice most closely matches your description. The question starts with \"You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria",
        "label": 0
    },
    "1256": {
        "output": "## 4 -Evaluate a Patient's Record\nIn this part, you will use the patient's record from the dataset. If you do not know how to use the patient's record, first click `show_record` in the upper-right corner to see the `patient record` widget. You can observe various information by moving the mouse cursor on a data sample. Try to guess before the data sample is displayed in the UI.\n\n[INST] You are a psychiatrist. Your hospital is setting up a trial focusing on the treatment of adolescents with substance use disorders (SUDs). You are very interested in the trial because substance use disorders are very prevalent in adolescents. In your hospital, two treatments have been used to treat adolescents with SUDs: group parent-based training (PBT) and group psychoeducational group (PEG). However, it is unclear which treatment is more effective in the treatment of adolescents with SUDs. Therefore, the trial aims to assess the efficacy of these two different treatments and to help clinicians make decisions on which treatment is more effective for adolescents with SUD. \n\nHere are exclusion criteria:\n- Patients with mental retardations of the following degrees: A person is judged to be a mental retardation if he/she is able to read, write, and perform a simple arithmetic operation. He/she is not limited to his/her ability to perform a simple arithmetic operation. A person is considered to be an ordinary person. A person with a degree of mental retardation is defined as an ordinary person by the following requirements:\n-He/she can use a basic computer, mobile phone, and other gadgets.\n-He/she can read, write, and perform a simple arithmetic operation.\n-He/she is able to go shopping and do household chores.\nA person is defined as a severe mental retardation if he/she is not limited in the above requirements, he/she is severely limited in the following requirements:\n-He/she cannot learn to read and writing.\n-He/she cannot understand and perform basic math operations.\n-He/she cannot perform a simple shopping mission.\n-He/she cannot understand and follow the instructions in shopping",
        "label": 0
    },
    "1257": {
        "output": "[H] Output the patient-level eligibility as well as a patient note. [/H]\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your assignment is to examine the trial's eligibility of each patient for the clinical trial based on their characteristics. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy\nSummary: This study to evaluated the effectiveness of Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal without fluoroscopy\nInclusion criteria: Inclusion Criteria:\nPatients with clinically suspected/confirmed CBDS\nCBD caliber 5-15 mm\n\nLet's think step by step. \n\nPatient-Level Eligibility:\n[INST] Patient-Level Eligibility: 3) Ineligible\n\nTrials.Summary.trials_eligibility_summary:",
        "label": 2
    },
    "1258": {
        "output": "<EOD> Effects of dietary fat sources on the gastroduodenal lesions with the use of bile salt reflux test.\nThe effects of dietary fat sources on the gastroduodenal lesions with the bile salt stimulation on 112 patients with bile salt reflux and 32 patients with hiatal hernia were studied. 1. 8 patients with normal endoscopic findings and 14 patients with mild esophagitis were fed with butter, olive oil, corn oil, beef tallow, soybean oil and sesame oil, to assess the direct effects of dietary fat alone on the gastroduodenal lesions. 2. 53 patients with abnormal endoscopic findings (fundic gastritis, pyloric, duodenal gastritis, etc in 36; advanced, active gastric ulcer, duodenal ulcers, etc in 17) and 43 patients without hiatal hernia with normal upper tract with bile salt stimulation were fed with butter, olive oil, corn oil, beef tallow, soybean oil and sesame oil, to assess the effects of fat sources on the gastroduodenal lesions under bile salt stimulation. On endoscopic follow up, butter aggravated the lesions of gastroduodenal mucosa, although sesame oil improved slightly. Butter caused the deteriorated histological gastritis in all instances, while sesame oil produced slight improvement. Olive, corn oil and beef tallow caused mild to moderate worsening of gastroduodenal lesions, while soybean oil caused a slight improvement on the histological scores. Patients with normal upper tract showed a similar and consistent result with those with hiatal hernia. On histological findings, patients without hiatal hernia showed relatively small histological worsening with fat sources feeding, in comparison with patients with hiatal hernia.<EOD> Long-Term Dacarbazine or Diacerein Treatment in Relapsing Polychondritis-Associated Vasculitis: A Case Report\n\nObjective:Rare disease Background:Polychondritis-associated vasculitis (PA",
        "label": 0
    },
    "1259": {
        "output": "[/SC]<EOD> <filename>client-scripts/client-scripts.js\n'use strict';\n\nvar _ = require('lodash');\nconst {\n  BLUE_COLORS,\n  GREEN_COLORS,\n  YELLOW_COLORS,\n  RED_COLORS\n} = require('../../constants/colors.js');\nvar constants = require('../../constants.js');\n\nconst _colors = {\n\n  green: { color: '#1fbd9e' },\n  green_dark: { color: '#0e9581' },\n  yellow_light: {\n    color: '#fbc985',\n    light: true,\n    bg_color: '#fbc985',\n    text_color: '#ffffff'\n  },\n  yellow: { color: '#fbc985' },\n  yellow_dark: {\n    color: '#ffc001',\n    light: true,\n    bg_color: '#ffc001',\n    text_color: '#ffffff'\n  },\n  orange: { color: '#ff9f00' },\n  gray0: '#303030',\n  gray10: '#505050',\n  gray10_dark: '#707070',\n  gray20: '#707070',\n  gray20_dark: '#909090',\n  gray30: '#707070',\n  gray30_dark: '#909090',\n  gray50: '#505050',\n  gray50_dark: '#707070',\n  gray70: '#505050',\n  gray70_dark: '#707070',\n\n  blue0: '#3b5af8',\n  blue10: '#3A84FA',\n  darkcyan0: '#7059ff',\n  darkcyan10: '#7059ff',\n  magenta0: '#ff5E06',\n  red0: '#153653',",
        "label": 2
    },
    "1260": {
        "output": "## Exercise 5.\n[INST] You are asked to prepare yourself to work next to a doctor. You're going to observe her work with patients. \n\nThe doctor is working with a medical team of 3 interns in ward. You have just arrived in time. The doctor should talk to a patient in need of treatment. Let's observe and code how the doctor works with the patient. \n\n![](/assets/images/exercise5.png)\n\nThe doctor examined the patient and found a mass on the left breast and a lump in the right. Breast ultrasound revealed a 49 x 37 mm mass in the right breast.\n\nThe doctor explained that the tumour is non-invasive, and surgery is needed. After the surgery, if pathological examination was found to be invasive, additional chemotherapy would be needed, and if benign histology would be found, no additional therapy would be required, and the patient could be followed-up. She also explained that if the tumour is benign, the patient would be in remission.\n\n\n## PART 2: BUSINESS COURSE: INSURANCE PROBLEMS\n## Exercise 6.\n[INST]  You have worked in a large insurance company. One day, you received a complaint that the insurance amount paid to the patient was incorrect. The insurance company sent an examiner to investigate. You will follow the examiner to the insurance company.\n\nThe examiner visited the insurance company at 11:50 AM. She was greeted kindly by a secretary. She was taken to a room for the interview. After taking her order, the secretary left the room and left. The patient claimed that the insurance company inaccurately calculated the amount of compensation. The examiner asked some questions that she had prepared before. The patient had insufficient proof of having the injury or illness. The examiner found many inconsistencies in the patient's statements. Patient did not provide sufficient and reliable evidence. She did not provide a medical report, or clinical report. The examiner concluded that the patient's claim was groundless, and the insurance did not compensate.\n\n## PART 3 and PART 4: GENERAL",
        "label": 0
    },
    "1261": {
        "output": "__NOTE_\n\nPlease try the Python script to understand our logic.\n\n**_script-2.py__:**\n\n```Python\n\n# +\nimport couchdb\ndef trial():\n    # couchdb.get('data', 'studies', 'PED.K2015009.1')\n    # couchdb.get('data', 'patients', 'V1.K2015009.11')\n\n    trials = couchdb.get('data', 'studies', {'$filter': 'id=?q'})\n    trials.insert()\n    for trial in trials:\n        patients = couchdb.get('data', 'patients', {'$filter': 'studyID= ?q'})\n        for patient in patients:\n            # calculate eligibility of each study\n            trial_level = 0\n            # patients ID\n            patientID = patient['id']\n\n            # trial date\n            trial_date = datetime.datetime.now().strftime(\"%B %d/%Y\")\n\n            if trial['studyDate'] == trial_date: # get study date\n                if 'inclusionCriteriaClinicalTrial' not in patient: # exclude some fields\n                    for c in trial.keys():\n                        if c == 'inclusionCriteriaClinicalTrial':  # get trial inclusion criteria\n                            trialInclusionCriteriaClinicalTrial = couchdb.get('data', 'data_inclusion_criteria', { 'study_id': 'PED.K2015009.1'+patientID, 'study_name': 'Trial A', 'study_studyID': 'PED.K2015009.11'})\n                            if '16 years old' not in trialInclusionCriteriaClinicalTrial.document['value']:\n                                if 'male' not in trialInclusionCriteriaClinicalTrial.document['value'] and 'female' not in trialInclusionCriteriaClinicalTrial.document['value']:\n                                    trial_level = 1\n                            else:\n                                    trial_",
        "label": 0
    },
    "1262": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's eligibility. An exclusion criteria is the fact that a patient does not have (at the time of recruitment) a certain characteristic which excludes a person from being eligible. The exclusion criteria of this patient are related to her hobbies and general health history. [/fig] \n<EOD> .\nTo determine possible toxic effects of thiamethoxam (TMX) on german cockroaches Blatella germanica (L. ), we studied the effects of TMX and fipronil (FP) at different concentrations on the insects of various ages. The results showed that TMX exhibited toxicity to B. germanica (L.) and the toxicity was agedependent. At first-instar, LC25 of TMX was 0.02703 mg/ml, the corresponding toxicity of FP was 0.000310 mg/ml. There was no obvious difference between LC25 of FP and LC10 of TMX. At second-instar, LC15 of TMX was 0.00647 mg/ml, the corresponding toxicity of FP was 0.0000710 mg/ ml. There was no obvious difference between LC15 of TMX and LC05 of FP. At third-instar, LC30 of TMX was 0.00220 mg/ml, the corresponding toxicity of FP was 0.0000710 m",
        "label": 0
    },
    "1263": {
        "output": "# Conclusion\nClinical data science aims to improve clinical research by reducing the waste associated with clinical trials.\nThe [Trial-eligibility.jl] package for [julia][julia.jl] enables a consistent set of eligibility tools that can facilitate recruiting patients for clinical trials. It enables consistent workflows that increase the reusability and efficiency of clinical data scientists and enables easy sharing of patient eligibility data and clinical trial protocols.<EOD> Longitudinal Associations between Perceived Relationship Quality and Mental Health in Children with Asthma and Their Parents\n\nBackground: This study examines the longitudinal associations between perceived parent-child relationship quality, and between parent-child relationship quality and child mental health, and asthma-specific quality of life for children with persistent asthma, and between parent-child relationship quality and parent mental health. Methods: Dyads (n = 145) of children with persistent asthma and respective parents completed a longitudinal survey of symptom and quality-of-life domains. Results: Children's perceptions of the quality of the mother-child relationship were associated with children's asthma-specific quality of life for the mother-child dyad (B = 0.67, p = .028) at baseline. Children's perceptions of the quality of their relationship with the father were associated with their mental health status for the father-child dyad 6 months later (B = \u22121.07, p = .009). Children's perception of the mental health status of their parents were significantly associated with child asthma-specific quality of life for the child-parent dyad (B = 0.15, p = .022 and B = \u22120.41, p = .009, for the mother-child and father-child dyads, respectively). Children did not report their asthma-specific quality of life at 6 months. Parents' perceptions of the child's mental health status were found to be associated with their own mental health status 6 months later (B = \u22121.33, p = .011). Conclusion: Intervention programs for improving children's mental health status and asthma-specific",
        "label": 0
    },
    "1264": {
        "output": "You have the choice to choose among different models, depending on your context and your knowledge:\n\n**`Based Model`**. This model is especially suitable for less complex models (fewer factors).\n\nYou are first going to create a list of items for the trial level. You are going to call each item a feature. `Patient-level eligibility: 35)`\nYou can then form the features in one feature vector. `patient-level eligibility: `[`35 2)`\nYou can then fit the feature vector to a Linear Regression model. This is done by calculating an estimation and a p-value for your model in `linear_regression()`, wherein the model parameters are fit using the inverse-logit function from sklearn's `multinomial` wrapper around the scikit-learn logistic regression models. We showcase the use of the linear model with the patient-35 note above.\n\n```\nprint(\"Model parameters:\")\nprint(\"Number of features: {}\".format(len(Trial_Note,)))\nprint(\"Model fit:\")\nprint(\"Estimated regression coefficient: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"]).params[\"number_of_firing_channels\"]))\nprint(\"Estimated regression coefficient variance: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"])._multinomial_var['number_of_firing_channels']))\nprint(\"Error: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"])._multinomial.resid[-1]))\nprint(\"P_value: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"]).linreg_out.pvalue[2, \"number_of_firing_channels\"]))\nprint(\"<NAME>\")\n```\n\n[Fork this repo](https://github.com/galexia/clinicaltrial/tree/main/clinical/python/inst_trial).",
        "label": 0
    },
    "1265": {
        "output": "[/TUTOR_NOTES]\n\n# E2F1\nA biological model used to describe proliferation processes is the E2F-Rb-E2F1 model. The cell proliferation process can be divided into multiple steps, which can be described as a sequence of states using transitions (e.g., cells go from G1 phase to S phase). The flow between these state sequences is regulated both by negative feedback within a pathway and external cues. In E2F-Rb, the E2F1 protein is regulated, mainly by the Retinoblastoma protein (Rb) (also called pRb). This inhibitory system is part of the G1/S checkpoint controlling the progress of the cell cycle. The Rb gene prevents cell proliferation by regulating cell cycle progression. In inhibitory conditions, Rb binds the E2F1 protein to halt cell cycle progression through the S phase. When the inhibitory signals in the G1/S checkpoint pathway are removed, Rb dissociates from the E2F1-Rb complex allowing the E2F1 protein to bind to E2F sites upstream of transcriptionally active origins of DNA replication. Rb protein function is affected by the cdk4-cyclin D complex, which activates Rb by phosphorylation. When Rb is phosphorylated by the cdk4-6 complex it cannot bind to the E2F1 protein, and the E2F1 protein is not able to bind the E2F-responsive promoters. Inhibitory signals, such as the binding of the p27 protein to the cdk complex, cause Rb to dissociate from the E2F1 protein and promote the cell cycle to move through the S phase. Positive signals, such as the binding of the ppRb protein to the E2F1 protein, stabilize the Rb and stop the cell cycle moving out of G1.\n\n\nA B\nA simple mechanism which regulates this system is given by:\n\n\n\\[ \\begin{align}\n  \\mathrel{\\stackrel{\\text{Inhibition}}{\\rightarrow}} &  Rb\\cdot E2F \\;  \\ mathrel{\\stackrel{\\text{Binding}}{\\rightarrow}}",
        "label": 0
    },
    "1266": {
        "output": "[INST]\n# Exercises\n```\npython clinical.py -n N -i ./clinical_exercises.txt\n```\nwhere, -n -Name of the clinical trial that you want to evaluate,\n    -i -A path to a .tsv file containing the patient note,\n    -./clinical_exercises.txt -A path to the data file with clinical trials, i.e.,\n      <patient-note-of-clinical-trial-A>.tsv, <patient-note-of-clinical-trial-B>.tsv, etc.\nThis command shows the eligibility of all patients in clinical trails Clinical trial A and Clinical trial B. Exercise 1 provides an example for this task.  \nAll the patients who are not eligible, should be listed, e.g.,\n```bash\nclinical.py -n N -i ./clinical_exercises.txt\nEligible: 0\nNot eligible: 139\n```\nThe trial-level eligibility for each patient note, i.e., the eligibility of each clinical trial, can be listed, e.g.,\n```bash\nclinical.py -n N -i ./clinical_exercises.txt -t trial\nEligibility of each trial:\nClinical trial A:\nEligible: 34\nNot eligible: 4 \nClinical trial B:\nEligible: 134\nNot eligible: 36\n```\nMore examples:\nClinical trial A -Clinical trial B.\n\nExercise 1:\nTrial-level eligibility of each trial, i.e., the assessment of trial eligibility of each patient, can be listed, e.g.\n\nExercise 2:\nEligibles by trial ID.\n\nExercise 3:\nEligibles by number of patients.<EOD> The efficacy of intrathecal methotrexate for meningeal dissemination of systemic lymphoproliferative disease--a report of three cases.\nThree patients with",
        "label": 0
    },
    "1267": {
        "output": "[BIN] Let's think step by step.\n\nFirst is the patient note. Here is the patient note in the patient_notes table:\n\n*Note: You have to import the patient_notes table to your local data set by the `import` function first.* \nPatient-level eligibility: 0) Excluded The three-point assessment of patient eligibility is used to identify the relevant information by the model. \nYour function should output the patient-level eligibility as a string rather than binary decision. \nThen, you should store the patient notes and model predictions output to the relevant fields in a dataframe. Finally, you should calculate the probabilities of eligibility for the model: \nCalculate probability of eligibility: Probability of Eligibility = True / (True + False) = 0.21 / (2.71+0.79) = 0.21\n\nIf the probability eligibility is more than 0.5, the patient is eligible, regardless of their patient-level eligibility, with an error of 0.05. \n\nProbability for patients in eligible class:\nTrue: Probability of Eligibility: 0.21\nFalse: Probability of Eligibility: 1-0.21 = 0.79\n\nFinally, you should store these results in a dataframe for use in the trial-level eligibility part. \nYour function should output the results to a dataframe in a row. \nPatients table (p_id, patient-level eligibility, probability_of_eligibility, trial_level_eligibility):\n[0] 0) Excluded 0.7900\n[1] 0) Excluded 0.2100\n[2] 0) Excluded 0.7700\n[3] 0) Excluded 0.7900\n\nThe following lines store patient-level eligibility in the patient_notes table with the probability_of_eligibility column.\npatient_notes <- cbind(patient_notes, triallevel_eligibility = lapply(1:nrow(trial), function (x) \"trial\" + to",
        "label": 0
    },
    "1268": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: The E",
        "label": 0
    },
    "1269": {
        "output": "___\n\n### Subject ID <a id=\"id\"></a>\nYou should repeat the `Subject ID: <id>` a number of times until it matches the number of rows in your CSV file.\n[TUT_BT_03_01_Subject_ID]. \n<EOD> .\nLiver cirrhosis is frequently followed by an increase in portal vein flow and an associated rise in intrahepatic resistance. We studied this increase in 19 cirrhotic patients, 19 noncirrhotic patients, and 19 healthy subjects using Doppler sonography. The intrahepatic resistive index was calculated in one of the portal vein branches by use of two formulas: the area under the velocity tracing curve (AUC) was calculated by 2nd order polynomial regression analysis, and the mean velocity time integrals (TIG) were calculated using a digital timer triggered device and an electromagnetic flow velocity meter in the main portal vein and its branches. Both methods showed a significant increase in intrahepatic resistance in cirrhotic patients compared to patients without liver disease (P<0.001).<EOD> Rheumatization in Patients of Tuberculous Laryngitis: A Prospective Study to Study the Risk Factors\n\n\n\n# Introduction\nTuberculosis is an endemic bacterial infection that has been a major medical problem worldwide for centuries [bib_ref]  The history of myasthenia gravis, Mccahon [/bib_ref]  The World Health Organization (WHO) has estimated that the global incidence of tuberculosis was roughly 12% of the world's population, resulting in 1.7 million deaths in 2017 . The highest reported burden was found in South-East Asian [bib_ref]  The epidemiology and pathogenesis and management of extra-pulmonary tuberculosis, Chang [/bib_ref] . Pulmonary tuberculosis is the most common presentation of tuberculosis infection and accounts for 70-80% of total cases, including sputumpositive and sputum-negative pulmonary TB [bib_ref]  Extrapulmonary tuberculosis: an overview, Golden [/bib_ref] . This systemic condition is characterised by the",
        "label": 0
    },
    "1270": {
        "output": "[fig]  -: Excluded (patient meets inclusion [or exclusion] criteria, but is excluded on the grounds of the trial's exclusion criteria).Not relevant (patient does not have sufficient information to qualify for the trial).Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [/fig] \n<EOD> The Effect of Dapoxetine on Premature Ejaculation With 6-Minute and the Changes in Male Sexual Function for the Long Term\nDapoxetine is a recently approved treatment for premature ejaculation (PE). A pilot study of dapoxetine showed a significant increase in ejaculation latency time (EL) and a significant decrease in premature ejaculation profile (PEP) scores. No study has assessed the effect of dapoxetine on patients who have a baseline EL of less than 6 minutes. This study was aimed at evaluating the effect of dapoxetine on the ejaculatory time as assessed by EL and PEP of patients with both baseline EL greater than 6 and 6 minutes. Fifty-three patients with PE and an inadequate ejaculatory time (IE) were treated with dapoxetine 30 mg for 8 weeks. The patients were subdivided into group I (baseline IE greater than 6 minutes) and group II (baseline IE = 6 minutes). The median EL in both groups progressively increased by a total of 1 min/wk. There was a significant change in IE from baseline to week 8 in group I. Both groups did not show any worsening in IE, and only a few complaints of side effects were reported. These promising data suggest that PE patients with baseline IE less than 6 minutes still have IE at 8 weeks of therapy with dapoxetine 30 mg and are likely to continue the treatment even after they reach the 6-minute IE.<EOD> Eosinophilic Gastroenteritis With Perforated Duodenal Ulcer\n\n\n\n# Background\nEosinophilic gastroenteritis (EGE) is a rare allergic disorder occurring in approximately 1 out of 25 000 cases with the highest population-based incidence observed in Southern countries. It",
        "label": 0
    },
    "1271": {
        "output": "### 4-2.4.8. Trial-patient and Trial-expert. \n\n[INST] Welcome. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment is performed trial by trial.\n\nHere is the patient note:\nA 62-year-old woman, who has experienced 3 NVDs, presented with 24 hours of severe, constant left upper abdominal pain associated with nausea, vomiting, loss of appetite, and poor oral intake. The pain is radiating to her left midback, and improves with flexion. Her vital signs are stable, and abdominal examination yields normal findings other than severe left upper quadrant pain on deep palpation. Her laboratory tests are normal, and her chest x-ray and abdominal CT-scan yield normal findings. Her EGD shows esophagitis and gastritis.\nHere is the clinical trial: \nTitle: Increased Prostate Specific Antigen (PSA): Predictive Value for Prostate Cancer\n\n\nSummary: We are running a prostate cancer incidence study of men >40 years old with increased PSA values on screening. Increased age or abnormal test results are risk factors for cancer and warrant screening. This is a hospital-based observational study. Our research focuses on the value of PSA testing to detect cancer in the earlier stages. We want to know if other clinical tests or risk factors might help to predict early-stage prostate cancer in men with increased PSA levels. The primary outcomes of this study are the frequency, incidence (time of occurrence), and type of cancer in men who did not participate in prostate biopsy. The primary outcomes of the study are the frequency, incidence, and type of cancer in men who did not participate in prostate biopsy.\nInclusion criteria Inclusion criteria:\nAny man >40 years old with increased",
        "label": 2
    },
    "1272": {
        "output": "## \ud83c\udfaf Solution\n\n### Python 3.7\n1. Run `python setup.py install` to install Pyret. Next to it, you can also find documentation, examples, download links, and help.\n\n    _Note:_ Since 3.5.3, the Pyret command-line-interface has been unified under the name 'pyret --' . So if you installed Pyret in Python 3.5.3 and above in `/usr/local/lib/` or other unexpected paths, you may need to install it again using [pip --version 20.7.1](https://pypi.org/packages/pip/20.7.1/).\n\n### Install `pyret` in your Python environment.\n\n    _Note:_ If you install Pyret on your PATH and you have other Python versions on your PATH before, the command below should be put in your `~/.bashrc` file to ensure that the correct version of Pyret is used. You should be aware of your Python version (`import sys`). This way, we will ensure that Pyret is not used in some strange environment.\n\n    ```\n    export PATH=/usr/local/lib/python/3.7/python:${PATH}\n    ```\n\n     \n`pyret -- version` shows what Pyret's version is.\n\n    ```\n    pyret version\n    ```\n\n    ```\n    Pyret 20.10.4\n    +------------------------------------------------------------------------------------------------------------------------------+\n    |                                                                                                                                |\n    |                                                                                                                                |\n    |                                                                                                                                |\n    |  ___                 /_____________________                 ___                         ______________                 |\n    | /         ____/      ____   _   _______ _   _____ ___________________   /                           |\n    |       /        /     /    /  /  /     _  /     _____ __________________________  |\n    |    _/         \\   /  /    /  /     _  |   | _____  _____ ___________  |\n    |       ____    \\/  /    /  /     __  |   | |",
        "label": 0
    },
    "1273": {
        "output": "This solution is suitable for:\n- CRA clinical question type\n- Data type table question\n\nWe hope this solution will give you some useful guidance. Thank you for writing in CRA \ud83d\udc4d\n\n# RESULTS \ud83d\udccc\n\n## CRA Output\n![](../../../.gitbook/assets/img.png)\n\n## Table Output\n![](../../../.gitbook/assets/img.png)\n\n## Clinical Question\n![](../../../.gitbook/assets/img.png)\n\n## Data Type Question\n![](../../../.gitbook/assets/img.png)\n\n## Sample Solutions\nFor each of the clinical questions below, you are expected to evaluate the patient according to the eligibility criteria of a clinical trial. Enter your answer in the box in the left column, taking into account the criteria listed above. Then, scroll to the next part of the question to see its solution.\n\n### [Solution 1](/solutions/inclusion-criteria-helpful.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)\n\n### [Solution 2](/solutions/eligible.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)\n\n### [Solution 3](/solutions/inclusion-for-the-patient.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)\n\n### [Solution 4](/solutions/eligible-the-patient.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)<EOD> Molecular Docking as a Candidate for Drug Repurposing as a Possible Remedy Against COVID-19\n\nThe COVID-19 pandemic has created a global",
        "label": 2
    },
    "1274": {
        "output": "###### Problem 2\nInconsistent results\nIssue: Inconsistent results are caused by different data frame structures provided by Datalite, e.g., data frames containing patient-level data, trial_data, patient_data, or trial_data2, or not using a data frame.\n\n## Potential solution\nPlease provide a data frame containing patients in the same format as in trial_data, and the patients' trial number in the data frame name: \n\n## Potential solution\nPlease follow the instructions that we provided at https://bio4h.readthedocs.io/en/latest/dev-setup.html#install-submodules-for-tutorials.\n[/PRO]\n\n## # create a new dataset for micafungin\n\n# Copy a patient's note that is included in the trial\nsetDataSheet <- getSheet(getActiveSheet(), \"Patient's Note 3\")$SubjectsetDataSheet(\n    \"pat_micafungin_note\",\n    setCols(setDataSheet),\n    paste0(\"setDataSheet\", \": \", paste0(\"pat_\", \"trial_\", \"patients\")))\n\nLet's think step by step. \n\n## {\n\n# +\n# Create a new data frame named \u00b4pat_micafungin_note\u00b4\n# Copy a patient's note that is included in the trial\n# Copy the column names from the patient's note data frame\nsetDataSheet <- getSheet(getActiveSheet(), \"Patient's Note 3\")\nsetCols(setDataSheet) <- paste0(\"setDataSheet\", \": \")\npaste0(\"setDataSheet\", \": \") <- paste0(\"pat_\", \"trial_\", \"patients\")\n# +\n## {\n\n# +\n# Assign columns' names in the data frame\nsetDataSheet$age <- \"Age\"\nsetDataSheet$smokers <- \"Smokers\"\nsetDataSheet$sex <- \"Sex\"\nsetDataSheet$bmi <- \"BMI\"\nsetDataSheet$diseases <- \"Diseases\"\nsetDataSheet$surgery <- \"Surgery\"\nsetDataSheet$surgery_date <- \"Surgery_date\"\nsetData",
        "label": 0
    },
    "1275": {
        "output": "<EOD> Association between Serum Concentrations of 1,25-Vitamin D and the Risk of Hypertension in the Population with Different Levels of Vitamin D\n\n\n\n# Introduction\nHypertension has become one of the significant threats to mankind. Hypertension is an important risk factor for the occurrence of stroke, ischemic heart disease, and end-stage renal failure [bib_ref]  Evidence-based guideline for the management of high blood pressure in adults: Report..., James [/bib_ref]  [bib_ref]  Epidemiology of hypertension in China and India, Guo [/bib_ref] . It is estimated that from 2000 to 2010, the number of adults (aged 18 or older) with high blood pressure increased from 594.9 million to 1.13 billion worldwide [bib_ref]  Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis..., Ncd-Risc [/bib_ref] . The prevalence of hypertension in different countries was significantly different [bib_ref]  Hypertension in the Philippines: Prevalence, gender and age differences and awareness, treatment..., Labignan [/bib_ref]  [bib_ref]  Global prevalence of hypertension in rural and urban populations in low-and middle-income",
        "label": 0
    },
    "1276": {
        "output": "[RM10]. [INST]\n[RM11]. [INST]\n[RM12]. [INST]\n[RM13]. [INST]\n\n\n## [CONT]\n\n\n---\n\n## _02_ Exercise \n\n\n\nThe following script is part of a notebook which can be loaded from [here](https://notebooks.datanovia.io/notebook/2295638) and can be executed from the commandline: \n```jupyter\n%load_ext autoreload\n%autoreload 2\n%pylab inline\nfrom IPython.display import display, HTML\nfrom IPython.history import get_ipython\nimport datetime\nimport ipywidgets\nimport shutil\nimport glob\nimport jcvi\nimport os\n\njcvi = jcvi.JCvi()\nimport jcvi.interfaces as jcvi_interfaces\nfrom jcvi_interfaces import JCvi_inputtype as JcviInputType\nfrom jcvi_interfaces import JCvi_outputtype as JcviOutputType\nfrom jcvi_interfaces import JCvi_exceptiontype as JcviExceptionType\nfrom jcvi_interfaces import JCvi_variabletype as JcviVarType\njcvi.set_print_all() # set print all\n```\n## Explanation \n\n\n```jcvi\njcvi = jcvi.JCvi()\n```\n\n\n```jupyter\n%matplotlib inline\nimport matplotlib as mplib\nfrom jcvi_mpl import *\n\nfrom notebooks.datanovia_code.2295638_01.jcvi2_code_01_notebook_ipython.py\n```\n\n\n```jupyter\n%%time\n```\n\n```jci\n%time\n```\n\n\n```jupyter\nimport datetime\n```\n\n\n```jupyter\n```\n\n```jupyter\n```\n\n\n```jupyter\n```\n\n\n```jupyter\n```\n\n```jci\n```\n\n```jci\n```\n<EOD> A single molecule magnet built by a su",
        "label": 2
    },
    "1277": {
        "output": "Instructions for the evaluation of the system's final prediction \nPrediction of the system's final result should consider the following:\n\n1) Whether the evaluation is correct.\n2) The probability of correctly predicting the result. \n\n<EOD> Diuretic response to acute low\u2010dose frusemide in anuric type 1 diabetes mellitus: association with duration and type of disease and microvascular complications\nAim:\u2002 The aim was to test the hypothesis that reduced sensitivity to frusemide in diabetic subjects is associated with the duration and type of disease and microvascular complications.<EOD> Interpretable image captioning with memory-guided LSTMs and auxiliary classifier\n\nInterpreting results of a deep learning (DL) model has become a fundamental and practical challenge in current development of DL models. Although in the previous work, human-designed hand-crafted rules and features such as position, size, and color have been considered as an important component to interpret the neural network's results, our purpose is to build a single universal method that can easily interpret deep learning models for arbitrary images in every vision and machine learning (ML) tasks. We proposed an interpretable DL model, named memory guided long short-term memory network (Mem-LSTM) which can be adopted for interpretable video understanding, human activity recognition, image semantic segmentation, image object detection, and other DL tasks. In addition, we proposed an auxiliary DL classifier (ADC) to improve the interpretability of deep learning model, which is essentially a neural network with more parameters than the original model for the task. In doing so, the attention maps can be visualized. The proposed ADCs can use the deep learning features as input and output, and it can be a complementary classifier of the main deep learning architecture. Experimental results proved the effectiveness of our method for the image caption tasks in the large-scale datasets, such as META (N=1,691,512) and IAP (1,731,342) large-scale datasets, a total of 56,207,464.OPEN\nGenerally, deep learning (DL) models have been proven powerful for solving many tasks in computer vision and machine learning (ML)",
        "label": 0
    },
    "1278": {
        "output": "<EOD> Lung cancer in HIV patients: is it the same as in the general population?\n\nBackground: A growing number of HIV patients is developing lung cancer. These patients are not only exposed to a higher risk for developing primary lung cancer as a result from the use of tobacco products, but also to a higher risk for secondary lung cancer. There is evidence that HIV patients have an increased risk for developing lung cancer, but it is not clear to which extent the risk in HIV positives differs from the risk in the general population.Methods: To investigate differences in the characteristics of lung cancer and its management, all lung cancer cases registered with the Utrecht Cancer registry from 1989 to 2007 were selected. Cases with and without a concomitant infection HIV were included and the characteristics of these two patient groups were compared.Results: HIV positive lung cancer patients are more often men (p = 0.02; relative risk (RR), 1.7; 1.1-2.7) and smoke more heavily, as smoking-related tumors accounted for 73.7% (41.0%-100.0%; p < 0.001) of all lung cancer in HIV positives compared to 53.4% (2.8%-100.0%; p = 0.13) in HIV negatives. Patients who are HIV positive have also a lower age at diagnosis with a median of 56.0 years (IQR, 51.0-66.0) compared to 65.0 years (IQR, 54.0-74.0) in HIV negatives (p < 0.001). The treatment regimen also differs between both groups of patients. Although HIV positives also received chemotherapy, it was given at a younger age than in the general population (median, 56.0 years; IQR, 51.0-66.0) compared to 68.0 years (IQR, 58.0-71.7; p < 0.001).Conclusions: Lung cancer in HIV positives is characterized by a high rate of tobacco-associ",
        "label": 2
    },
    "1279": {
        "output": "If you want to add more trials to the input example, add them into the input box. To run example, press ENTER. \n\n\n![\n\n\n# 1) Eligible.\n\n## 2) Excluded\n\n## \n\n# Excluded-2-2\n\n## \n\n# Excluded-2-3\n\n## \n\n# Excluded-2-4\n\n## \n\n# Excluded-2-5\n\n## \n\n# Excluded-2-2\n\n## 3) Excluded\n\n## \n\n# Excluded-1\n\n## \n\n# Excluded-2\n\n## \n\n## \n\n# Excluded-2-3\n\n## \n\n## \n\n# Excluded-2-4\n\n## \n\n## \n\n# Excluded-2-5\n\n## 3) Excluded\n\n## \n\n# Excluded-1\n\n## \n\n# Excluded-2\n\n## \n\n## \n\n# Excluded-2-3\n\n## \n\n# Excluded-2-4\n\n## \n\n## \n\n# Excluded-2-5\n\n## 3) Excluded\n\n## \n\n# Excluded-1\n\n## \n\n# Excluded-2\n\n## \n\n## \n\n# Excluded-2-3\n\n## \n\n# Excluded-2-4\n\n## \n\n## \n\n# Excluded-2-5\n\n## \n\n## 2)\nExcluded\n\n## # Excluded-1\n\n## \n\n## # Excluded-2\n\n## \n\n## # Excluded-2-3\n\n## \n\n## # Excluded-2-4\n\n## \n\n## # Excluded-2-5\n\n## 2)\nExcluded\n\n## # Excluded-1\n\n## \n\n## # Excluded-2\n\n## \n\n## # Excluded-2-3\n\n## \n\n## # Excluded-2-4\n\n## \n\n## # Excluded-2-5\n\n## 2)\nExcluded",
        "label": 0
    },
    "1280": {
        "output": "##[INTER] Hello. You are an attending physician in an internal medicine department of a medical hospital. You have decided to refer a patient to the next outpatient appointment. Here is a patient note:\nA 49-year-old man (Mr. Z), complains about abdominal pain that started 8 days ago that radiates to his right upper quadrant, it is getting worse after eating chili and fatty food. The patient experienced a similar pain twice in the past year. He has 3 children, and he is not married. He smokes 15 cigarettes per day. He does not drink alcohol, does not use illicit drugs, and his BP is normal. His past medical history is remarkable for hypercholesterolemia. He is mildly depressed. He has no weight loss or fever. On palpation, he experiences tenderness and a mass in the right hypochondrium. Bowel sounds are normal. \nLet's think step by step. \n`A 49-year-old man complains (or a 49 year old man is complaining about) the abdominal pain. The pain is severe and has radiates to the right upper quadrant. It begins like 8 days ago and is getting worse after eating chili and fatty foods. The pain was repeated twice in the past year. He is taking drugs for cholesterolemia. He doesn't smoke cigarettes but he smokes one pack of 15 cigarettes per day.` [/INTER] \n##[INTRA] Hello. You are an internal medicine specialist who has a consultation room in a medical school. You have decided to refer a patient to the next outpatient appointment. Here is a patient note:\nA 48-year-old woman with a history of arterial hypertension, depression and GI disorders has complaints for a month. She complains for non-diarrheal cramps in the stomach with no change in bowel movements. She is very worried because her symptoms are disturbing her daily life activities. She takes medication for hypertension and depression and has very good adherence. She has no history of smoking and is not on any illicit drug",
        "label": 0
    },
    "1281": {
        "output": "Note that, since we don't need an output of eligibility in the clinical trial, we will omit the output here, e.g., `The trial-level eligibility of the patient (Cycle Index ID: 203) is 2) Eligible.`. So, we write like `The trial-level eligibility of the patient (Cycle Index ID: 203) is 2) Eligible.`.\n\n## Assessment of eligibility\nNow, we define the patient's assessment of trial eligibility, i.e., the assessment of the patient's eligibility based on the assessment of the current patient note and the clinical trial, via `Eligibility assessment of the patient via Note: `\nEligibility assessment of the patient via Note: \nIf patient is eligible to the trial:\nAdd patient to the \"Recruitment\" list and call the function `Add_to_list()`\nAdd patient to the \"Unmatchable\" list and call the function `Add_to_list()`\nCall the function `Add_to_list()`\nThe trial-level eligibility of the patient (Cycle Index ID: 203) is Eligible.\nThe trial-level eligibility of the patient via Note: (Cycle Index ID: 203) is\nEligible.` Note that we write a code block for the assessment of eligibility since these lines are only for assessing the patient eligibility.\n\n## Summary\nNow we summarize the output, e.g., ` \n```\nCycle Index ID: 203:\n    Patient notes: \n    Note:\n    Eligible\n    Eligible\n```.. .\nEnd of the cycle loop for the trial\nRecruitment:\n\n    Note:\nSame trial\n\n\nUnmatchable:\n\n    Note:\n    same trial\n\n```\nAs we can see, we get only 1 recruitment cycle and no unmatchable cycle. So, this patient is eligible to the trial, i.e., the trial-level assessment of trial eligibility is 2) Eligible.\nIn fact, trial eligibility in this scenario has 3 levels: 1",
        "label": 0
    },
    "1282": {
        "output": "[TUT]\nCopy and save this file named `p07_patient_note_test_3.txt` in your current directory, since you will require it for the next step as mentioned in the section `Instructions for Executing Each Task`. If you run it, you may get the same test set as this example, but randomized.\n\nThe output is the following:\n`Evaluation 1 (Patient_01)`:\n\n        Excluded -- --\n\n    `Evaluation 1 (Patient_02)`:\n\n        Not Relevant    1.0 -- --\n\n\n```\n[TUT]\nIf you do not have a Python development environment, you can simply run `pytest.py` without any inputs.\n```\n\nIf you run `pytest`, all tests and its results will be returned. The test report will display a summary table indicating 'Passed', 'Failed', 'Skipped', and 'Skipped/Not run' test results, while the detail of the test reports is shown in the [TUT].\n\n## Step6: Final assessment report\n\nOnce you run `pytest -v', the results will be shown by [TUT].\n\n\n### Instructions for generating the assessment report\n\n1. Save the generated `finalreport_template.py` file in a subfolder of the same directory as the saved `assessment_tasks.py` files.\n2. Modify the code in the `finalreport_template.py` file to generate a customized assessment report for your submission.\n3. Once you have finalized your report, `pytest -v` with the modified `finalreport_template.py` (i.e., finaltest_example.py in this assessment) file will return the assessment report.\n\n### Assessment Report\n\n\n\n## Task 1: Copy and save the file named `p08_fungi_species_test_3.csv` in current directory.\n\nThis is the file with one instance of the sample dataset. You may get the same file with different values by using the file-sampling options in the `data_preprocessing.py` file.\n\nIn the assessment report, the values in the `Species` column were replaced with `",
        "label": 0
    },
    "1283": {
        "output": "When patients do not have sufficient information to qualify for the trial, you should not assign any value to their Trial Eligibility. Include a separate item to assign 0 (Excluded) to them. \n\n# Example\n### Exclude patient:\n``<td bgcolor=\"#123f7d\"><font style=\"font-family: Cambria, Arial, sans-serif; color:#1684a3; font-size:12px; vertical-align:-8px\">1</font></td>``\n<!--[instructs]: #task=20 -->\n```txt\n# Patient Excluded from Analysis\nPatient excluded: Age 20\nGender: male\nHeight: 185 cm\nWeight: 100 kg\n``<br><br><font color=\"#1684a3\" size=\"14\" style=\"font-weight: bold;\">Age </font>20&nbsp;years </font>\n<br><br>\n\n### Male:\n```txt\n# Male\n```\n\n```txt\n# Height in CM 85\n```\n\n```txt\n# Admission Weight in KG 100\n```\n<EOD> The relationship between self-reported health and the incidence of functional disability.\nOBJECTIVES\nTo evaluate the association between self-reported health and functional disability incidence, after controlling for covariates.\n\n\nMATERIALS AND METHODS\nIn order to obtain nationwide information, we analyzed data from the Korean General Social Survey (n = 3,167), which included a large number of samples from different regions in Korea.\n\n\nRESULTS\nIn this study, 62.8% (n = 1,968) of participants were incident disabled. Using Cox proportional hazard models, we found that compared to participants without any disability, participants with a \"fair\" or \"bad\" health rating were respectively, 74% more likely (HR = 1.74) to become disabled than those with a \"very good\" rating (reference group), after adjusting for covariates.\n\n\nCONCLUSION\nSelf-reported health has stronger effects on the incidence of functional disability than",
        "label": 0
    },
    "1284": {
        "output": "\uf0e0 Click the 'Evaluate' button to evaluate the current patient's inclusion in the trial. You can do so by pressing the `Evaluate` button and input the patient's information below. You should input the information for all 4 patients with the note:\nOnce you complete this task, you will see the result for Patient-level eligibility in the top part of the web page. For the 4 patients, we get the following results:\nPatient-level eligibility: \uf0a8 2) Eligible: All patients met the requirements for inclusion criteria \uf0a8 Excluded: None were found to meet any of the exclusion criteria \uf0a8 Not relevant: None had enough information to determine ineligibility.\nYou can continue your assignment in your user area. You find the link here: <EMAIL>. Click the 'Evaluate' button to evaluate the current patient's inclusion in the trial.\n\n## Part 3: Trial-level eligibility\nThe trial-level eligibility should be entered once for each trial in the entire course. In this part, you will apply this task for trial 1615.\nTrial-level eligibility: 2) Eligible\nTrial-level eligibility will be marked in the Patient-level eligibility page.\nCongratulations! You are going to finish now?\nPlease click the 'Evaluate', then click the 'Send' button in the following page to submit your assignment.\nGood job! Congratulations! \n\n## Task Name:\nTrial-level eligibility\nTrial-level eligibility determines the eligibility for a patient for a clinical trial on both global and per-patient levels. For the patient, it is calculated as the combination of the Patient-level eligibility and Patient-level eligible/not eligible factors. For the trial, it simply combines the above two concepts on the global level.\n\nThis task has two parts:\n1) Calculate Trial-level eligibility for the patient based on global assessment \n2) Compare the information from global assessment to the information from the per-patient assessment\n\nThe steps to complete the task is:\n\n\n1.\nOpen [https://mhealth",
        "label": 0
    },
    "1285": {
        "output": "A: The 11C-CSar PET/CT scans and measurements would require a more complete specification of the scanner and the data collection.\nIt's interesting that the 11C-CSar PET/CT scans are used to evaluate the \"hepatobiliary secretion of cholylsarcosine\"; one would imagine that other modalities (MRCP, EUS, serum tests), would be used to determine the impact of the cholic acid level; is this an error?\nI'd expect that a 11C-CSar PET/CT evaluation is more easily described after the clinical trial is complete; e.g., \"Trial-level eligibility: 2) Eligible.`, rather than before a trial is conducted which implies that there's some unknown risk-benefit ratio.\nIt may be the best approach to only use the 11C-CSar PET/CT scans on those participants in the study that have completed the study; and use them to validate the clinical trial's success on each person by comparing the post versus pre PET/CT scans and measurement results.\n<EOD> Transcriptional activation of the AREs of hNQO1 by sulforaphane: mechanistic studies of the Nrf2 system.\nHuman NAD(P)H:quinone oxidoreductase 1 (hNQO1) is induced by sulforaphane (SFN) and other isothiocyanates. The promoter of human hNQO1 contains multiple AREs and an ARE-related sequence (ARE-RS), to which the transcription factors Nrf2 and OASIS/Nrf1 bind, respectively. In the present study, we demonstrate that SFN is effective in vivo and in vitro to stimulate the ARE/ARE-RS sequences. Furthermore, we demonstrate that the Nrf2-ARE/ARE-RS complex functions cooperatively at the promoter, and we provide a mechanistic model of the response regulation of the human NQO1 promoter by Sulforaphane. An ARE/ARE-RS luciferase reporter plasmid could be used to detect the effects of small molecules on the SFN-induced responses of the Nrf2",
        "label": 0
    },
    "1286": {
        "output": "## \u00a9 2013 by A. Schaefer, M. Kohlbacher\n\u00a9 2014 by M. Kohlbacher - All Rights Reserved \n<EOD> Phenotypic variability and genotypic heterogeneity in oligospermic and azoospermic men in a fertile cohort\n\n\n\n# Introduction\nThe evaluation of reproductive outcomes in men with impaired spermatogenesis has improved with the introduction of genetic tools. This has permitted not only the identification of the pathogenic variant but also more frequently the characterization of the molecular mechanism that leads to male infertility. The diagnosis of the defect and, often, a better follow up of these patients is now possible.\nIn 2010, a group of researchers from the European Academy of Andrology (EAA) generated an aCGH protocol, which has since then led the characterization of complex chromosomal rearrangements (CCRs) [bib_ref]  New insights in the genetics of oligo-terato-azoospermia, Cerv\u00e1n-Mart\u00edn [/bib_ref]  [bib_ref]  Y chromosome microdeletions: why we still count, Krausz [/bib_ref]  [bib_ref]  New approach demonstrates the clinical impact of the Y chromosome and suggests..., Mcauliffe [/bib_ref] . In brief, the protocol combines multiplex genomic screening (Y chromosome short tandem repeats (STRs) and chromosome 18 STRs) and a genomic scan using aCGH, detecting the loss of sequence copy number, on the basis of a normozoospermic reference sample. These studies have suggested that CCRs are a common genotype in infertile men presenting with oligo-, terato-, and/or azoospermia (OTA) and that the combined analysis of multiple loci is a convenient tool to detect the male side of infertility [bib_ref]  New insights in the genetics of oligo-terato-azoospermia, Cerv\u00e1n-Mart\u00edn [/bib_ref]  [bib_ref]  Y chromosome microdeletions: why we still count, Krausz [/bib_ref]  [bib_ref]  New approach demonstrates the clinical impact of the Y chromosome and",
        "label": 0
    },
    "1287": {
        "output": "We hope this solution helped, and we are ready to support you.\n\nPlease share your thoughts about the [#doc-005936] question and its solution.\n<EOD> A Novel Technique for the Production of the \u201cBubbliness Feel\u201d in Acrylic Art\nThis article provides an instruction guide for adding a \u201cbubbly\u201d or \u201cbubbliness\u201d effect to any acrylic painting by the use of air (or hydrogen) bubbles. This new technical technique was developed by the author and has the potential for creating an entirely new effect in acrylic painting. The instructions are well illustrated and simple to follow. A number of sample paintings demonstrating the use of this technique are included.<EOD> Inheritance of resistance to acetaryl in sweet corn.\nAcetyl (AC), an herbicideresistant corn (Zea mays L.) allele at the acrylic acid locus (AA3), was introduced into the Sweet-Maize and Sweet-Bounty commercial hybrids for production of AC corn. Inheritance of this allele may be either monogenic or dually dominant, although it is presently unknown which gene and the degree of dominance are responsible for this resistance to acetyl. To determine whether the resistance to acetyl is codominant, the AA genotypes were characterized in the hybrids and their segregating families. The segregation ratios were similar to that expected for monogenic transmission of resistance to acetyl: the AC plants (resistant) ranged from 22 to 40%, the heterozygous plants (susceptible) from 39 to 60% and the AA homozygous plants (susceptible) from 6 to 33%. The AC and AA plants were further characterized for the inheritance of a dominant AC-resistance trait and dominant AC-response (sensitivity) trait, using the hybrid Sweet-Bounty. The resistant plants (AC) showed only slight morphological differences from other plants, except that they were more vigorous and had greater kernel set than the susceptible plants. The resistant plants were more competitive for light than susceptible plants in plots of Sweet-Maize and Sweet-Bounty due to",
        "label": 0
    },
    "1288": {
        "output": "```R\nlibrary(trial)\n\nsubject2 <- patient_trial(text=get_patient_note(), name=\"a\",\"age_range=c(45,82),\n                      gender=c(\"f\",\"f\",\"f\"), raceA=c(\"white\",\"white\",\"white\"),\n                      raceB=c(\"black\",\"white\",\"white\"), ethnicity=c(\"hispanic\",\"white\",\"white\"),\n                      height_range=c(162,178), weight_range=c(86,145), bmi=c(26,33),\n                      marital_status=c(\"widow\",\"widow\",\"single\"), education=c(\"some_high\",\"graduate_degree\",\"graduate_degree\"),\n                      employment_status=c(\"employed\",\"employed\",\"employed\"), smoking_status=c(\"current_smoker\",\"current_smoker\",\"nonsmoker\"),\n                      comorbidity=c(\"hypercholesterolemia\",\"hypertension\",\"hypertension\"),\n                      clinical_status=c(\"currently_ill\",\"currently_ill\",\"recently_ill\"),\n                      clinical_trial=list(\"<NAME>\",\"<NAME>\",\"<NAME>\",\n                      trial.phase=\"II\"), condition=list(c(\"non-hodgkin_lymphoma\",\"colorectal_cancer\",\"non-hodgkin_lymphoma\"),\n                      condition.stage=list(c(\"relapsed-refractory\"),c(\"relapsed-refractory\"),c(\"IV\")),\n                      site=list(c(\"lymph-node\"),c(\"peritoneal-cavity\"),c(\"peritoneal-cavity\"),\n                      tumor=list(\"Burkitt_lymphoma\",\"colorectal_cancer\",\"non-hodgkin_lymphoma\"),\n                      histology=list(\"lymphoma\",\"non-small_cell_lung\",\"non-hodgkin_lymphoma\"),\n                      diagnosis_status=\"newly_diagnosed\"),\n                      comorbidity=list(\"none\",c(\"hypertension\"),c(\"hy",
        "label": 0
    },
    "1289": {
        "output": "1. Let's add the code to process the patient note.\n[INST]\nThis code extracts the variables from the patient note that you described above, assigns them variables that the patient note used and converts the variables into variables that the clinical trial used.\n[COD]\n{\n  \"Trial_participant_age\" : \"Age\",\n  \"Trial_participant_gender\" : \"Female\",\n  \"Trial_participant_obese\" : \"True\",\n  \"Trial_participant_hyperchole\" : \"True\",\n  \"Trial_participant_histNVD\" : \"True\",\n  \"Trial_participant_menopausal\" : \"True\",\n  \"Body_BMI\" : \"BMI\",\n  \"Hyper_cholest\" : \"Cholest\",\n  \"histNVD\" : \"true\",\n  \"menopausal\": \"true\",\n  \"BMI\" : \"24\",\n  \"Hyper_cholest\": \"True\",\n\n}\n\n2. Let's add the code to process the clinical trial information.\n[INST]. \nThe code above contains all rules that process the clinical trial note. The codes will be explained step by step below, but here is a summary of them:\n(1) If only age is the inclusion criteria, assign the age variable from the patient to the age variable of the clinical trial. This is just an example, there can be other cases.\n(2) If only gender is the inclusion criteria, assign the female variable from the patient to the female variable of the clinical trial. This is a just example, there can be other cases.\n(3) If neither gender nor age is the inclusion criteria, assign the clinical trial's generic \"1\" to the eligibility variable of the patient. That is because this clinical trial's exclusion criteria are so strict that the patient would not pass the assessment stage at all.\n(4) If the trial \"Exclude\" variable of the clinical trial is \"True\", let the trial-level eligibility also be \"Exclude\" and assign the age and gender of the patient to the gender and age variables of the clinical trial. If the trial \"",
        "label": 0
    },
    "1290": {
        "output": "<EOD> Preparations and Appliances\n\nUNDER THE CHARGE OF Preparations and Appliances\nM.DM.DUNDER THE CHARGE OF Preparations and Appliances\n466 PREPARATIONS AND APPLIANCES.\nThe B.A.A.P. has been specially prepared from a number of drugs and active ingredients, so that the physician can administer a cocktail of therapeutic agents to meet all contingencies in a single drink. This includes such powerful therapeutic agents as bromides, paraldehyde, hydrochloric acid, boric acid, and antipyrin. The B.A.A.P. has already been described in these columns (Vol. XCVI., p. 223) and appears to have had a satisfactory reception in practice.A new product of the firm of Messrs. Henry Lamotte is a preparation for the treatment of chlorosis and anaemic states of the blood. Lamotte's Anforderingsriicke is a syrup of wild strawberry flavour with a slightly acid reaction. It contains the following:?Extractum ferri iodidi 0*01, extractum perchloridi ferri 0-01, liq. arseniatis rubri 0'0004, tincturae ex quassia 0-04, tincturae ex quinine 0*01, aquae distillatae 50, aeeticse ad 50, sativae radicles 30, liquoris ex strelitias narnii fermenti 30, syrupus aroniae 260, and syrupus althaeae 25. In addition there are the usual preservatives and sweetenings. It is claimed that the product is specially indicated for all gynaecologicai cases, menorrhagia, dysmenorrheal, metrorrhagia, oligophrenia and chlorosis.Another product for the physician which has lately appeared is a preparation known as ' Fleming's Medical Honey Dew.' This is a form of the honeycomb of the stingless bee",
        "label": 2
    },
    "1291": {
        "output": "### Questions from Classes\n\n*What is the difference between the patient note and patient record? \n*What is the difference between two types of errors? \n*What are the advantages that help us overcome the limitations of a computer? What are the disadvantages that we need to tackle? \n\n\n#### Notes\n<EOD> Role of endogenously synthesized prostaglandins in the regulation of renal Na+ excretion, blood pressure, and Na+ appetite in rats\n\n\n\n# Introduction\nThe kidney is the main site for regulation of body fluid and electrolyte excretion. The primary renal transporter involved in salt handling is the Na + , K + -ATPase, which is located in the luminal membranes of the principal cells in the ascending limb and also the intercalated cells of the connecting tubule and collecting duct [bib_ref]  Mechanisms of salt-sensitive hypertension, Luzardo [/bib_ref] . Prostaglandins (PGE 2 , PGI 2 ) act in the kidney by modulating transport activity of the Na + , K + -ATPase and the sodium chloride cotransporter (NCCT) [bib_ref]  Prostaglandins as modulators of renal tubular transport, Ellison [/bib_ref] . In the kidney, the metabolism of arachidonic acid from the membrane phospholipids, to PGE 2 , PGI 2 and their metabolites is mediated in large part by the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to prostaglandin H 2 (PGH 2 ). PGH 2 is then converted to the final major product PGs which will be the subject of the review.\nThe physiological function of PGs is mediated by G-protein coupled receptors (GPCR) that are coupled via their G a/b subunits to adenylyl cyclase [bib_ref]  Prostaglandin and thromboxane G protein-coupled receptors as drug targets, Breyer [/bib_ref] . Activation of these receptors, also by pharmacological agonists, will lead to their physiological",
        "label": 0
    },
    "1292": {
        "output": "*_INSTRUCTIONS_FOR_USER_*\n\n### TARE\nThese questions refer to the following CQs: \n6.30.4 | Is the use of targeted Treg cell therapy in adults with autoimmune hepatitis more efficacious and safe than placebo or best supportive care for maintaining remission?\n6.37.3 | Is the use of tumour-infiltrating lymphocytes (TILs) for the treatment of colorectal cancer more efficacious and safe than immunotherapy with ipilimumab or nivolumab?\n9.17.1 | Are the use of anti-CD3 monoclonal antibodies (mAbs) or immune checkpoint inhibitors (ICIs) better than placebo or best supportive care for the treatment of acute Graft-versus-Host-Disease (aGVHD)?\n\\_\\_INSTRUCTIONS FOR USER_*\n[*_INSTRUCTIONS_FOR_USER_*]\n\n### TARGETED TREG CELL THERAPY\nPlease answer the respective question on a case-by-case basis. The case may have a number (e.g.~1) for each patient receiving the allocated intervention and may have a description (free text)\nof the patient. 500.\n[*_INSTRUCTIONS_FOR_USER_*]\n\n### TARGETED TREG CELL THERAPY IN ADULTS WITH AUTOIMMUNE HEPATITIS\nTcell treatment\n\n### TARGETED TREG CELL THERAPY IN HUMAN IMMUNE DEFICIENCY\nBacterial infections\n\n### TARGETED TREG CELL THERAPY IN INFANTILE INFLAMMATORY BOWEL DISEASE\nAntimicrobial resistance\n\n### TUMOUR-INFILTRATING LYMPHOCYTES (TILS) THERAPY\nPlease answer the respective question on a case-by-case basis. The case may have a number (e.g.~1) for each patient receiving the allocated intervention and may",
        "label": 0
    },
    "1293": {
        "output": "Note1. Here is the eligibility statement you should complete per trial. Use one statement to be suitable for all eligible subjects. You should not make separate statements for excluded or not relevant patients. You should not use 0) Excluded. 1) Not relevant. 2) Eligible. If you cannot decide whether someone qualifies on the first review, you should mark it 0) Excluded. 1) Not relevant. 2) Eligible. \n\nNote2. As the trial-level assessment of eligibility is the primary outcome, you should write your eligibility assessment in the first line. For example, if you write `Excluded.`, then you should write `Excluded. = 0. Excluded on the grounds of the trial's exclusion criteria`.` in the first line. However, if you write `Not relevant.`, then you should write `Not relevant. = 1. Not relevant on the grounds of insufficient information.` in the first line.\n\n\n\n``` r\n# Write the trial-level assessment you should make for each patient and put a blanket statement by `=2) Eligible` if the statements are all the same in the last line\n\nTrial.assessment <- \" =2) Eligible\"\n```\n\n``` r\n# Make trial-level assessment based on the patient's information you wrote before.\n\nTrial.assessment <- paste(\"Triallevel Assessment:  = \", clinical.trial$Name, \" = \", as.factor(S(trials.eligible))))\nTrial.assessment <- paste(Trial.assessment)\n```\n\n``` r\npar(\"mfrow\")\nwrite.table(Trial.assessment, file = \"table_write.txt\", sep = \";\", quote = FALSE, row.names = FALSE)\n```\n### Additional File \"README.md\"\nTo start an R session. Run the following from an R console or terminal.\n``` r\ninstall.packages(\"readr\")\ninstall.packages(\"tidyverse\")\nlibrary(readr\n```\n# For R sessions in interactive mode\n``` r\ninstall.packages(\"SHINY\")\nlibrary(SHINY)\nshiny::runApp(\"",
        "label": 0
    },
    "1294": {
        "output": "## Examples\n\nWe want to extract and visualize the patient IDs, trial types, and trial titles from both ClinR and ClinV data sources. \n```sql\nSELECT\n  ClinTrial.patient_id,\n  ClinTRail.trial_type,\n  ClinTrial.trial_title\n  FROM ClinTrial\n  WHERE\n    trial_type = 'PROTOCOL'\n  UNION\n  SELECT\n    ClinV.patient_id,\n    ClinTRail.trial_type,\n    ClinTrial.trial_title\n  FROM ClinV\n  WHERE\n    trial_type = 'OVERALL'\n```\nLet's load the dataset with Pandas:\n```python\nimport pandas as pd\n\nprint(pd.set_option('display.max_columns',1000)) print(pd.get_datalink()) print( pd.get_datalink().name() ) print('pd:', pd.get_datalink().name(), '\\n') print(pd.set_option('display.max_rows', 1000))\n\n# pd.set_option('display.max_rows',25)\n# print(pd.get_datalink()) # 'SQLite'\n```\nWe will use the following SQL syntax:\n```sql\nSELECT\n  * FROM ClinTrial\n    WHERE\n      trial_type = 'PROTOCOL'\n    UNION\n    SELECT\n      * FROM ClinTrial\n        WHERE\n          trial_type = '<NAME>'\n    UNION\n    SELECT\n      * FROM ClinV\n        WHERE\n          trial_type = '<NAME>'\n```\nThe following code is used to load the dataset with SQL and return `pandas.DataFrame`.\n```python\nimport pandas as pd\nfrom sqlalchemy.sql import func\nfrom sqlalchemy import create_engine\nimport numpy as np\nsql = \"\"\"\n    SELECT id1.patient_id, id2.trial_type, id2.trial_title\n  FROM ClinTrial\n    as id1\n    LEFT JOIN ClinTRail\n      AS id2\n      WITH LAST\n      ON id1.id = id2.patient",
        "label": 0
    },
    "1295": {
        "output": "[STUPEL] After you successfully run the `h2.028_patient` file, you can test `h2.028_patient` using `filetester.py`. The following text should appear when running `filetester.py`: \n\n```\nYou can also run the following commands which are in the `filetester.py` notebook under the directory `code` to test the `h2.028_patient` file.\n\n1. Copy this code to notepad++. This is the filetester code.\n\n2. Open a command line and change the directory to the `code` directory. Here is the command to use: cd code\n\n3. Run the following commands to test that the `d20_clinicalTrials.csv` file is loaded and that the `d20_clinicalTrials` notebook is opened. This requires the `filetester.py` script.\n> python filetester.py\n> cd ..\n> cd clinicalTrials\n> Python filetester.py\n\n4. After changing the directory to the `code` directory, you can run the filetester script.\n\n>> Filetester.py\n\nThis takes some time, and a prompt will appear asking you to wait.\n5. Check the result to see if successful execution of filetester.py is in the output of Python. If the program is successful, it is displayed on the first line, i.e., `Successful execution of filetester.py`, on the `Screen.txt` file. \n\n\nYou should not press any button except return on the keyboard to continue, because sometimes the result of the filetester.py may show in the output, but the Screen.txt file continues to generate an error message that the `Screen.txt` file does not exist. If the Screen.txt file starts with the number of lines, it is because that means to load the first line from the `Screen.txt` file after executing filetester.py. Let's see if the program is OK, by looking the first line of the `Screen.txt` file. It should show number 1 after the filetester.py was executed successfully. If the `Screen.txt` file contains no data, Python 3.5.",
        "label": 0
    },
    "1296": {
        "output": "# [C] Evaluate Your Output\nEvaluation is the last task in eligibility assessment.\n\n\n## [INST] Evaluation\nAt the end of the eligibility assessment, the program should evaluate the output of you eligibility assessment.\nOn the basis of your eligibility assessment, you are asked to evaluate and justify the result with a 3-stage scale: 0) Excluded (the patient does not meet the inclusion criteria); 1) Not relevant (the patient meets the inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); and 2) Eligible (the patient meets the inclusion criteria and exclusion criteria do not apply).\n[EXPL] How to Evaluate?\n- There are three cases (0) excluded, (1) not relevant, and (2) eligible.\n- You should evaluate on the basis of your justification and clinical reasoning.\n- Each patient has three possible trials, so repeat these evaluations three times\n\n## [C] Test Your Code\n\n\n## [INST] Test Your Code\nThe program should be tested by two or more experts who have sufficient experience and knowledge in using the clinical trials eligibility assessment tool. You should make a trial-level eligibility on each patient\nTesting of the code is to ensure that the code works as you wanted it to.\nThe purpose of testing is to verify that the code performs the expected task. This verification process determines if the programs work as the creator intended. \n\n## [C] Debugging of the Code\nAs well you have seen in the testing, there are still some problems such as you input error and error in the logic of code. But there is a remedy to solve the problem. This is called debugging.\nDebugging is a process to find and eliminate bugs. It fixes programming bug to make sure that the code running program works as expected. \n\n# Discussion\nYou may develop your coding skills by comparing the code of each of your peers with your own code.<EOD> Prolonged Inhibition of T Follicular Helper Cells and Germinal Center Activity Due to Omicron SARS-CoV-2 BA.1 Infection\n\nBackground: Omicron, the latest SARS-CoV",
        "label": 0
    },
    "1297": {
        "output": "Since each patient has several lines, you should make `Array of sample-level eligibilities: [0 0 NaN 0 0 NaN 0 0 NaN]`. The sample-level eligibility is similar to the trial-level eligibility, since the patient-level eligibility includes all patients with the patient's name. [/",
        "label": 0
    },
    "1298": {
        "output": "># Exercise\n>Above, we learned to apply the rules of eligibility using the patient note. You may do a trial-level eligibility of [EXERCISE](https://cod.es/570f9b63a75d9c5c6b598d0d85b633a2) using the patient note and a clinical trial. Please submit your exercise with the name ```report_exercise_n1.html```.\n\n# Summary\nIn this lecture, we learned to determine patient eligibility using a patient note and a clinical trial. You should always follow the rules and write a rational sentence of eligibility.\n<EOD> Clinical and biological markers of early thymic function\nThe thymus is the major organ in which precursors of T-lymphocytes develop to mature T-lymphocytes. Thymus dysfunction is associated with an increase in early postnatal infection and morbidity as shown by thymic hypoplasia and by congenital atrophy or aplasia of the thymus. Immunological studies of the thymus gland have led to the identification of thymus epithelial cells (TECs) as the most important population of stromal cells in thymus organogenesis. TECs provide the physical environment by cellular interaction. The thymus expresses high levels of cytokines and chemokines that guide the differentiation and maturation of T-lymphocytes from the bone marrow to the thymus and the egress process of mature T-lymphocytes .<EOD> An Analysis of the Bonds of Nucleobases and Their Derivatives with N2 and N3 of Purine/Pyrimidine Using DFT Methods: Implications for the Biological Impact of Chemical Modifications\n\n\n\n# Introduction\nMany fundamental biological processes, including DNA synthesis and mRNA splicing, are regulated by RNA modifications. The main source of natural variability in the functioning of RNA-containing systems is the variety of modified nucleosides and their combinations. These chemical modifications can be introduced at any position of the entire molecule or only at the sugar part",
        "label": 0
    },
    "1299": {
        "output": "### [CASE-1]_QUESTION]\nIn order to reduce the overall error rate for the automated process, in addition to the error of clinical trial assignment, a researcher needs to make sure that each patient is assigned the correct clinical trial. To do that, the researcher creates 3 separate files, an Excel file that contains patient notes, ClinicalTrials.gov (CT) metadata and clinical trials. The Excel file is a CSV file, and the column headings of the data fields are defined in CSV header columns. The file that contains the CT metadata follows a slightly different format. It has column headings that are defined in header paragraphs. The three CSV files should be input into the Python notebook, and processed by the automated process. The script starts by merging the CSV files into a dictionary. It searches for the matching patients among clinical trials using the patient's ID in Patients CSV file. The ID is unique for each patient, so that it will never be used by multiple patients in a clinical trial. Then, the script outputs the ID and the matching trial ID for patients in each CT data file. The output CSV file will contain one patient ID per row, one trial ID per column.\n\nNote: All Python script functions and the notebook (replay) can be found in our GitHub repository ([CLIN] [LINK]):\n![INST]\n\n[CONTINUED] (2.1) Data Cleaning and Mergence:\nThe file that only has trial data will be merged with the file that has patient data. At this point, we have a dictionary with columns named trial ID, type, start_date, and end_date as well as patient ID, trial ID, note.\n[CLIN] \n\n[CONTINUED] (2.2) Clinical Trial Eligibility:\nThe trial IDs form a set, and only the patient IDs that have trial IDs within that set are available for the clinical trial eligibility step. In this step, each patient is compared with each clinical trial that they are known to have. For each clinical trial, the script will count the number of patients who are eligible for each trial, and return the number of patients as results. The following line in the output csv file shows an example for each clinical trial with the same patient ID who was assigned to",
        "label": 0
    },
    "1300": {
        "output": "<EOD> Genomics of bacterial egg-associated pathogens.\nEgg-associated infections can have a significant impact on poultry performance, and the pathogenic bacteria involved may pose a risk for human health. Although the etiology of these infections is multifactorial, bacteria are major constituents of the egg or fertilized egg surface. In this article we review the genetic attributes and potential mechanisms involved in virulence for the genetic determinants of three common species: Campylobacter jejuni, Salmonella enterica, and Escherichia coli.<EOD> Hydrophobic/Lipophilic Properties of a Molecular System with Hydrogen-Bonding-Driven Charge-Transfer Structures.\nA series of organic molecules with hydrogen-bond charge-transfer structures (HBCTs) were theoretically designed and their hydrophobic/lipophilic properties were investigated. Intramolecular HBs were first constructed by cation-\u03c0 interaction and then the hydrogen-bond-driven charge transfer was designed to construct the cation-\u03c0 and n\u2192\u03c0* interactions at the same or different times by introducing C=N/C=O groups between CNs and benzene moieties with different \u03c0 electron densities. The molecules show lipophilicity and the logarithmic values of their partition coefficients of their aqueous solution/dichloromethane (logKSA/DCM) range from -1.634 to -3.600 with the introduction of benzene or pyridine moieties, depending on the electron density of the \u03c0 orbitals. It was found that the lipophilic/hydrophilic properties of the molecules with HBCTs could be tuned by molecule-water interactions (MUIs) from 2 to -122 kJ mol-1 and then hydrophobic/lipophilic properties were modulated by the balance of intramolecular HB energy (IHBE) and MUI. The results also indicated that the charge-transfer properties were mainly regulated by the balance of intramolecular HB energy (IHBE) and MUI under the hydrogen-bonding",
        "label": 0
    },
    "1301": {
        "output": "### Summary\n\n- Trial-level eligibility: 2) Eligible.\n- 0) Excluded.\n- 1) Not relevant.\n- 2) Eligible.\n\n### Examples\n\nThis is an example of the solution:\n```\npatient.clinicaltrials = \"Comparative Evaluation of Two Different Post-Operative Analgesia After Hallux Valgus Correction\"\npatient.clinicaltrials.sum = \"Recent studies showed the efficiency of several techniques of anesthesia in foot surgery. The new mini-invasive surgical approaches should require less analgesia and rapid motor recovery after surgery.`\npatient.trial_level_eligibility = \"1) Not relevant\"\npatient.trial_level_eligibility = \"0) Excluded\"\npatient.trial_level_eligibility = \"2) Eligible\"\n```\n\nIf you are not familiar with python, please check the instructions here: <code class=\"docutils inline\"><a href=\"https://cloud.google.com/apis/docs\">Instructions for python novices</a></code>\n\n##<jupyter_code>import pandas as pd\npd.set_option('display.max_columns', None)\n\ndf = pd.read_csv(\"census.csv\")\n\nfor i,j in df.loc[0].T.iterrows():\n     print(j)\n\n\n<EOD> An inbred strain of rat with the non-syndromic form of the hereditary sensory and autonomic neuropathies Type I.\nIn an original large litter (F15) of the rat Spague Dawley, with 222 living offsprings, we identified at birth and during the lactation, 207 healthy newborns. Among them, one single male presented the phenotype of a hereditary sensory and autonomic neuropathy Type I (HSAN-I)  orphan disease. We determined the genetic transmission by breeding the \"disease strain\" in inbred condition using the sib pairs for mating. The breeding of the \"disease strain\" yielded",
        "label": 0
    },
    "1302": {
        "output": "[!INST] \u26a0\ufe0f Hint \u26a0\ufe0f\n\nAsk to clinical trial to which patient note this question belongs.\n\n\n[!INST] \u26a0\ufe0f Hint \u26a0\ufe0f\n\nAsk to clinical trial to which patient note this question belongs.\n(6) Exclusion criteria:\nExclusion criteria:\n- Current cancer diagnosis, immuno-compromised state (HIV), antibiotic usage in the last month, lactating or pregnant, or with an allergy to gluten\nIf you feel confuse about this task, I recommend you to follow the instruction in the [https://apacadb.github.io/Practical/eligibility_task/index.html] link and use the [https://github.com/APacaDB/Challenge_05_clinica/blob/master/index.html] link to check the code.\n\n# \ud83d\udcca Results\n![Instructor-level scores](https://github.com/APacaDB/Challenge_05_clinica/raw/master/visuals/instructor_level_scores.svg?raw=true)\n\n# \ud83d\udca1 Discussion\nIn the [https://apacadb.github.io/Practical/eligibility_task/index.html#coding_tips_for_this_question] link, you can find advice for completing this task. The most important tip is:\n- Do not remove blank lines from the patient notes that belong to each study.\n\n# \ud83d\ude3b Additional material \ud83d\ude3b\nYou may find more information on the [https://practicalaac.github.io/Practical/main/index.html] link.<EOD> Cytotoxicity is enhanced in combination with 5-fluorouracil and paclitaxel by targeting the Hsp90 molecular chaperones in osteosarcoma\n\nThe objective of this study was to examine the cytotoxic effects of an Hsp90 inhibitor, CCT018159 [ 2-((1R,4S,6R,7R)-8,8-dim",
        "label": 0
    },
    "1303": {
        "output": "[CLOSE-INST] End the INTERACTION by closing it.   \n[END-COMMENT] End the COMMENT by closing it.   \n[ENTER-COMMAND] In this interactive training environment, the trainer can also select the Enter command with an emphasis on word to start a new task or instruction.<EOD> .\nMitochondria play a key role in the energy metabolism, maintenance of cellular redox status, calcium homeostasis and the regulation of apoptosis. Mitochondrial DNA (mtDNA) with high mutation rate is highly sensitive to mutations induced by reactive oxygen species (ROS) and oxidative damage. The altered levels of mtDNA, as well as mutation rate of mtDNA are reported to be associated with tumorigenesis and cancer progression. ROS-induced mitochondrial dysfunction can contribute to the metabolic adaptation of breast cancer cells and enhances the development of metabolically more aggressive breast cancer subtypes. The present review summarizes current perspectives on the significance of tumor metabolism and mitochondrial dysfunction in breast cancer biology with a special focus on the potential correlation between mitochondrial metabolism and breast cancer therapy.<EOD> .\nAs a result of numerous studies in recent years, it is now recognised that some people with learning disabilities are not inevitably and chronically ill. Although the number of people with special educational needs is not diminishing, at the same time psychiatrists and others involved with learning disabled people are becoming more aware of the individuality of each one. This study sought to find out which factors facilitated the development and maintenance of non-discriminatory relationships with those with special educational needs amongst the teaching staff in a special school. The sample comprised 70 teaching staff (34 male and 36 female), working in a large special boarding school for 68 persons with severe and profound handicaps (51 with specific language impairment) and 17 with varying degrees of deafness, with different degrees of support.<EOD> Synthesis and evaluation of new 14beta-benzoyloxy-androst-5-ene-derivatives as potential hypoglycaemic agents; preparation of 3",
        "label": 0
    },
    "1304": {
        "output": "**Instructions for patients note (in Python)**: \n\n~~~Python\n# +\nfreqOfGallStone = set([item for sublist in sublists(sublist(gallstones), 0) for item in sublist])\nprint(f'PATIEN - - -: Frequency of gallstone presence in the patient is {freqOfGallStone}')\nprint(f'ClinicAll - - -: Frequency of gallstone presence in clinic is {clinic_nvd_gallstones_frequency})')\n# -\n~~~\n<EOD> <reponame>gordon1/ninja_app<gh_stars>0\nimport { Component } from '@angular/core';\nimport { FormGroup } from '@angular/forms';\n\n@Component({\n  selector: 'app-home',\n  templateUrl: './home.component.html',\n styleUrls: ['./home.component.css']\n})\nexport class HomeComponent {\n  public loginForm = new FormGroup({\n    username: new FormControl(\"\", ValidationConstants.username_required_message),\n    password: new FormControl(\"\", ValidationConstants.password_required_message),\n    passwordConfirm: new FormControl(\"\", ValidationConstants.password_confirmation_required_message)\n  });\n\n  public isValidUser(userData): boolean {\n    const validUserName = this.loginForm.control.username.value.trim() !== '';\n    return validUserName ? true : ValidationConstants.username_required_message;\n  }\n\n  public isUserLoggedIn(userData): boolean {\n    const validSessionKey = this.loginForm.controls.sessionKey.value.trim() !== '';\n    return validSessionKey ? true : ValidationConstants.session_key_required_message;\n  }\n\n  public isValidPassword(userData): boolean {\n    const validPassword = this.loginForm.controls.password.value.trim() !== '' && this.loginForm.controls.passwordConfirm.value.trim() === this.loginForm.controls.password.value.trim();\n    return validPassword ? true : ValidationConstants.password_required_message;",
        "label": 2
    },
    "1305": {
        "output": "### Ex1: Example1\n```javascript\nfor (let trial, i = 0; i < 9; i++)\n{\n    const cfg = {\n        trialId: `${randomValue()}.t-${i}`,\n        notes: {\n            // patient notes\n            'PatientNote 1': 'Hello, this is a test note.',\n            'PatientNote 2': 'Hello, this is a test note too.',\n        },\n        trial: {\n            title: `Title:`,\n            summary: `Summary:`,\n            note: {\n                // trial notes\n                'TrialNote 1': `Summary:`,\n            }\n        },\n        exclusionCriteria: // exclusion criteria\n        [ \n            { title: 'Title 1', type: 'Type 1', conditions: ['Condition 1'] },\n            { title: 'Title 2', type: 'Type 2', conditions: ['Condition 2'] },\n        ]\n    };\n\n    let dots = ['.', '.', '.', ' - ', ' - ', '- -', '- -', ' - ', '- -'];\n    let output = `--- ${dots[i % 4] || ''} ---\n    TrialName: ${cfg.trialId} \n--- ${dots[i % 4 == 0 ? (i + 2) % 4 : i % 4] || ''} ---\n    Summary: Summary: \n    --- ${dots[i % 4 == 2 || i % 4 == 3 ? (i + 2) % 4 : i % 4] || ''} ---\n    PatientNotes: \n    PatientNote 1 \n    --- ${dots[(i + 1) % 4] || ''} ---\n    PatientNote 2 \n    --- ${dots[(i + 1) % 4 === 1 ? (i + 1) % 4 + 1 : i % 4] || ''} ---\n    TrialNotes\n    TrialNote 1 \n    --- ${dots[((i + 3) % 4) + 3] || ''} ---\n--- \n```\n\n### Ex2: Example2",
        "label": 0
    },
    "1306": {
        "output": "**The patient should be assessed for eligibility regardless of the trial.** When deciding the in-person or telehealth option, the question \"Does the patient have enough information to determine eligibility and do they meet study eligibility criteria (not the trial's exclusion criteria)\" is to be used. If the answer to this question 'yes', then the system should be set to 'in-person'. If the answer is 'no', the system is set to 'tele-health'. \n\n![Eligibility Assessment Telehe",
        "label": 0
    },
    "1307": {
        "output": "### Example Output\nPatient-level eligibility evaluation gives information about a particular patient. This evaluation is performed by the doctor. \nIn general, we make the doctor's job easier with this section's output. The first step in the evaluation is to observe the patient-level eligibility evaluation section. As shown in the example below, the output includes three fields for output: diagnosis, medication and surgery. \nIf the doctor needs more details, he can investigate the patient's history.\n\nThe output shows what type of patient we need, then the doctor assigns the patient to the clinical trial. For further discussion, we provide an example of the output. \nThe example shows that it's suitable to apply for the given trial if the patient's diagnosis (eg., CD) is active small-bowel Crohn's disease, inflammatory markers (eg., ESR) are elevated, and the patient is over the age of 18. \n[INST] Example outputs<EOD> Assisted dying, palliative care and the NHS: a comparative analysis of their historical intersections\n\nThis paper analyses the history of assisted dying (AD) and palliative care (PC) to explain the different policy developments in the two areas. It shows that, although there is an overlap between these two areas, the two practices in the UK developed relatively independently. Assisted dying, especially assisted suicide (AS), was largely excluded from the UK because of its medical professional identity and the cultural context of the UK. By contrast PC was promoted in the UK. However, the integration of the hospice and palliative care movement with existing health and social services had many limitations. The paper argues that the policy developments in the AD area are due to the increasing demands of those with a terminal illness and the increasing acceptability of death with dignity. The acceptance of AD might come through the acceptance of the medical community to end of life, which is aided by a shift in public opinion.\n\n# Introduction\nThe current UK debate about assisted dying is concerned with two key areas. First, should assisted suicide be legalised? Second, should assisted dying be regulated? In this paper, we focus only on the legal aspects of assisted dying.\nThe legal situation is complicated. In England and Wales, there is",
        "label": 0
    },
    "1308": {
        "output": "Note: Patient notes and clinical trials are in plain text format. You can edit the code to change their format.\n\n- The function `Trial-level_Eligibility`\n- `patient note => call the `patient note` function to obtain the individual level eligibility `patient note.patient_level_eligibility`;\n- `patient trial => call the `patient trial` function to obtain the trial-level eligibility (one function call for each patient)`trial.trial_level_eligibility = call Patient_Level_Eligibility.Trial-level_Eligibility(patient trial)` \n\n- The function `Patient_Level_Eligibility`\n- `patient note => call the `patient note` function to obtain the individual level eligibility `patient note.patient_level_eligibility`;\n- `patient trial => call the `patient trial` function to obtain the trial-level eligibility (one function call for each patient)`patient trial.trial_level_eligibility = call Patient_Level_Eligibility.Trial_leveleligibility(patient trial)` \n\n- Include criteria. Some clinical trials require specific inclusion criteria. These criteria usually have multiple types:\n\nClinical trials that have an inclusion criterion of \\`\"sex\"` have as \\`required_types` [\"S\"]`[{\"name\":\"sex\",\"type\":\"required\",\"type_id\":1,\"value\":\"male\",\"value_type\":\"text\"}]` \n\nIn the following code, we see that the first row contains a list of criteria that should be met:\n'[{\"ID\":\"CRIT_1\",\"value_type\":\"text\",\"value\":\"male\"}]`\n\n### Exercise\n- Try to edit the program to include a clinical trial with several criteria: 1-male, 2-hypertension, 3-> 30 years old.\n\nIn the following code, we see the trial's criteria:\n'[{\"ID\":1,\"value_type\":\"text\",\"value\":\"male\"},{\"ID\":2,\"value_type\":\"N\",\"value\":\"hypertension\"},{\"ID\":3,\"value_type\":\"N\",\"value\":\"> 30 yo\"",
        "label": 0
    },
    "1309": {
        "output": "### Summary\n\nIn this section, you learned about the `Trials` module, its components, and how they work together. The `Trial-level eligibility` component is a new `Component` class introduced in 2019. The `Trial-level eligibility` can be created either using the shortcut `s` or with the create_component_and_save command. The `Component` objects in Elasticsearch are not persisted in Elasticsearch so each search time, the results are fetched anew. Thus, `Component` objects have a `last_run` timestamp field, and the latest search operation will be carried out on top of that value.\n\nAs an object or an array, you can create new trials, create components in trials, or edit components in trials. For example, you create new trial from trial_name, which is a placeholder for trials\u2019 names in local directory for further convenience later, by using `Trial.create_trial_from_name(trial_name)`. Or you can create components and trial-level eligibility using `create_component_and_save()`. You can edit trial-related components by passing corresponding indexes to the `object` parameter. \n\nAs shown in the example above, there are four types of trials: \n\n- Trial_name: trial name with given extension; \n- Status_label: to retrieve all trials that are not closed or active, you use `Status_label: None`. Otherwise, if you want to retrieve all active trials regardless of whether they are closed or not, you use `Status_label: Active`. `Status_label` is optional (if not specified, `Active` is assumed); \n- Trial_type: for clinical trial vs. observational trial; \n- Trial_type_label: to retrieve all observational trials regardless of whether their trial_type is observational_trial or clinical_trial; \n- Trial_type_label: to retrieve all clinical trials regardless of whether their `Trial_type` is `clinical_trial` or `observational_trial`; \n- Trial_phase: for phases of a clinical trial (1, 2, 3, or 4); \n- Trial_phase: to retrieve clin",
        "label": 0
    },
    "1310": {
        "output": "___ \n\n## [CIT] An 81 year old gentleman with a past medical history of coronary artery disease, atrial fibrillation, essential hypertension and type 2 diabetes mellitus was referred to the surgical service with abdominal pain.  The physical examination was unremarkable, with normal vital signs.  A computed tomographic (CT) done for evaluation of possible aortic dissection showed calcifications in both kidneys.  The patient was referred to the nephrologist.  He also went for an echocardiogram.  Ejection fraction was 50%.\n\nIn the following, we are going to discuss several differential diagnosis. \n\n### 1. Calcium Oxalate Deposition\n\nIt has a prevalence of 1:2,000 and calcium oxalate deposition (COD) is one of the possible causes of nephrolithiasis or kidney stones.  Patients tend to be younger than 45 years of age with normal kidney functions on routine laboratory workup.  \n\n\n### 2. Aortic Dissection\n\nAortic dissection is one of the leading causes of death of aneurysms in general.  It is often related to hypertension, but in some cases, it can be secondary to atherosclerosis or trauma during physical activity.  This leads to an increase in tensile loading and rupture.  An aortic dissection is always associated with an aortic aneurysm.  Aortic dissection is classified into 2 groups, based on the location on the aorta: Type A and Type B.\nType A dissections involve the ascending aorta and Type B involve only the descending aorta where patients present with chest pain, back pain and/or neurologic events.  On echocardiogram, the aortic dissection can be distinguished from other aortic disease such as an aortic aneurysm, where it is more walled off.  Aortic dissection can also be determined using an MRI which helps with the diagnosis by using a multiphase CT angiogram of the chest, abdomen and pelvis, as well as an electrocardiogram",
        "label": 0
    },
    "1311": {
        "output": "## Good Luck! [/E]<EOD> .\nPURPOSE\nTo demonstrate anatomic and technical differences in the posterior capsule and optic lens of the human eye between the left and right eyes, with regard to pathological processes of retinal detachment and dissections of the vitreous body.\n\n\nMATERIALS AND METHODS\nWe analyzed 250 cases of human eyes of 52 persons in the age from 6 to 81 years (average age 43.2 years), who died from unrelated diseases. Posterior lens capsule and vitreous body were isolated from each eye and microscopically examined.\n\n\nRESULTS\nThe mean length and width of the lens capsule in the case of the left and the right eye did not show significant differences. The posterior pole of the capsule in the case of the right eye has less amount of collagen fibers and in relation to the anterior pole also less thickness compared to the left eye (the mean difference in width of the capsule in the posterior pole between the left and the right eye - 0.089 mm, p<0.05). We observed that the vitreous space from the posterior pole is significantly larger in the case of the right eye compared to the left eye (the mean difference in width of the space between the left and the right eye - 0.19 mm, p<0.01). The anterior part of the vitreous body in the case of the right eye is thinner than in the left eye (the mean difference -0.1 mm, p<0.01) and its posterior part is slightly wider (0.1 mm, p=0.07).\n\n\nCONCLUSIONS\nOur results suggest that the posterior lens capsule and the vitreous body are different between the right and the left eyes, which could explain why in pathological processes of retinal detachment or vitreous body the left eye is mainly affected and the right one has a favourable course of the disease.<EOD> Phenotype of peripheral blood T cells in patients with chronic lymphocytic leukemia receiving therapy with mAb directed against CD5\nPurpose. MAB directed against CD5 (Fab RG7/39) has shown",
        "label": 0
    },
    "1312": {
        "output": "[INST] Copy pasting the result below:\n\nA 54-year-old obese woman with hypercholesterolemia and 2 NVDs is seeking treatment for abdominal pain. She has been experiencing epigastric and right upper quadrant pain along with nausea and vomiting for the past 4 days. She has a BW of 120.79800 kg (267.8 pounds). She has abdominal tenderness and rebound tenderness. Her BP is 97/62, HR 106, RR 14, T 36.6, SpO2 97 on RA. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. Her abdominal exam is notable for epigastric tenderness and right upper quadrant tenderness. She has clear breath sounds.\nShe has a 2\u20133-cm gallstone sludge and a 14-mm calculi in the CBD. She has a hemoglobin of 13.0 and a platelet count of 276. She has a RBC of 4.49e9, WBC of 7.50e9, and neutrophil granulocyte count of 3.43e9. She has normal liver enzyme. She has an alanine aminotransferase level of 13 U/L (upper limit of normal [ULN] 40 U/L), an aspartate aminotransferase level of 29 U/L (ULN 40 U/L), and an alkaline phosphatase level of 616 U/L (ULN 370 U/L). An ultrasound revealed several gallstones, biliary sludge, and CBD stones. The smallest stone was measured at 14 mm. In terms of hematology, she has a hemoglobin electrophoresis of 22%, hematocrit of 18%, and a CBC that is normal. The",
        "label": 0
    },
    "1313": {
        "output": "### Example\n    Trial-level eligibility: 2) Eligible.\n    Trial-level eligibility, test: False\n    ClinicalTrial.run(\n    title: \"The Pre-hospital Evaluation of Sensitive Troponin (PRESTO) Study\",\n    summary: \"The aim of the study is to assess whether a decision aid that is currently used in hospitals across Greater Manchester to determine how likely it is that a patient has a serious heart problem is still accurate in the pre-hospital environment\",\n    summary: \"Treating paramedic suspects these symptoms may be caused by acute coronary syndromes.\",\n    study_id: \"3073\", study_id: \"4084\",\n    inclusion_criteria[:], inclusion_criteria: { age: \"<45yo\" },\n    exclusion_criteria[:], exclusion_criteria: { gender: \"female\"},\n    patient_details: patient_details, patient_details: { note: note },\n    trial_level_eligibility: trial_level_eligibility: { 0: {\"code\":\"Trial-level_eligibility: 2) Eligible.\"}, trial_level_eligibility: { 1: {\"code\":\"Trial-level_eligibility: 1) Not relevant.\"}}, trial_level_eligibility: { 2: {\"code\":\"Trial-level_eligibility: 1) Not relevant.\"}},\n    data_output: data_output,\n    output_details: output_details, output_details: { output: \"Trial-level_eligibility:  2) Eligible.\" })\n\n<EOD> The pharmacology of nalbuphine: a review.\nNalbuphine hydrochloride is a semisynthetic methadone analogue that can be used safely and effectively for treating pain in the outpatient setting. The compound was approved by the Food and Drug Administration in 1973 to provide relief from pain resulting from surgery and other medical conditions. Compared with morphine, nalbuphine has approximately one-fifth the potency and approximately one-half the duration of action, and it",
        "label": 0
    },
    "1314": {
        "output": "<script src=\"https://www.mathjs.org/v12/latest/mathjs.init.js\"></script>\n<script src=\"https://unpkg.com/mathjs@latest/build/mathjs.full.min.js\"></script>\n<div class=\"mathjs\">4.5 - 4.7. 11. DONE</div>\n<EOD> Effects of 24-, 48-, and 72-Hour Delayed Treatment With Low-Dose Recombinant Tissue-Type Plasminogen Activator on Ischemic Brain Injury in a Model of Mild Focal Ischemia in the Cat\nBackground and Purpose\u2014 Tissue-type plasminogen activator (tPA) is an important drug to treat stroke, but its beneficial effects may be reduced by delayed treatment. We studied the effects of low-dose tPA 24 hours and longer after a transient middle cerebral artery occlusion, a model of stroke with mild ischemic injury. Methods\u2014 Mild ischemic injury was produced for 1 hour by middle cerebral artery occlusion in anesthetized cats. In one set of experiments, delayed, 24-hour, 48-hour, and 72-hour tPA (10 mg/kg intravenously) treatment was compared with phosphate-buffered saline in 20 cats. In a second set of experiments, 48-hour tPA (10 and 20 mg/kg) and 72-hour tPA (20 mg/kg) was studied. tPA treatment was begun in 30 cats, 10 cats 24 hours after, 5 cats 48 hours after, and 13 cats 72 hours after the onset of middle cerebral artery occlusion. Results\u2014 72-hour delayed tPA treatment significantly reduced the ischemic brain injury volume (\u221223%, P <0.005) but did not affect neurological deficits and cerebral blood flow. Delayed tPA treatment at 24 and 48 hours significantly am",
        "label": 0
    },
    "1315": {
        "output": "We hope this lesson was useful. We are sorry again if we made any mistakes and welcome your feedback and proposals if you have any ideas. <EOD> Nitric oxide: A versatile player in the cellular signaling system\nMany aspects of nitric oxide (NO) biology are controversial and highly controversial, which indicates the complex role of NO as signaling molecules under various conditions and stimuli in the cellular signaling system. NO is produced by inducible nitric oxide synthase, which is activated by inflammatory cytokines and other various chemical agents. NO production mediated by inducible nitric oxide synthase is believed to help in cellular adaptations in the host by modulating pathways involved in the host defense systems, like the immune system and the hormonal systems, as well as the antimicrobial system in the host. This could be crucial with regard to their implication in infectious and inflammatory diseases, and for cell proliferation, differentiation, apoptosis, senescence, and antioxidative processes, as well as neurodegenerative processes and their involvement in the pathophysiology of neurodegenerative diseases. Besides, NO has also been associated with some neurodegenerative diseases like Alzheimer's disease. The present review focuses on the physiological significance of NO on the pathophysiology of Alzheimer's disease.<EOD> Methylglyoxal-induced oxidative stress impairs the phosphorylation of eukaryotic initiation factor 2 in liver\n\n\n\n# Introduction\nGlyoxalase system (GLOSS), one of the most important detoxifying systems for the metabolic stress responses, consists of glyoxalase I (GLO1) and glyoxalase II (GLO2). GLO1 catalyzes reduction of D-lactate to S-D-lactoylglutathione through the trans-glycosylation, with which GLO2 catalyzes the hydrolytic reaction forming D-lactic acid and reduced glutathione. S-D-lactoylglutathione is also known to react with various nucleophiles to form adducts. The glyoxal",
        "label": 0
    },
    "1316": {
        "output": "<EOD> Preventing and treating chemoresistance in breast cancer: new perspectives\n\nBreast cancer treatment remains a major challenge because resistance to chemotherapy treatment, which manifests as disease progression during the treatment period, is frequent. Several molecular pathways contributing to tumor resistance to chemotherapy are described but no single model can account for all of the mechanisms. This review is a summary of data on the effects of various molecular pathways and their interactions.\n\n# Introduction\nDespite advances in adjuvant/neoadjuvant chemotherapy for breast cancer, response or resistance in some patients leads to failure. Resistance to adjuvant therapy is frequently seen in tumors resistant to initial neoadjuvant therapy . As our understanding of the molecular pathways related to tumor resistance in breast cancer accumulates, more specific therapies are being developed [bib_ref]  New drugs and new mechanisms of action in breast cancer treatment, Martelli [/bib_ref] . This article provides a review of current knowledge on the pathways of tumor resistance to chemotherapy in breast cancer as well as the recent developments that can help overcome this resistance.\nThe pathways described in this review have mostly been characterized in cell culture and some in preclinical animal models. Recent advances have demonstrated how tumor characteristics may be used to predict the response to therapy and to develop therapeutic approaches by overcoming tumor resistance or restoring sensitivity to chemotherapy [bib_ref]  Cancers with wrong pathway activation: the tumor suppressors as an example, Salisburg [/bib_ref] . The pathways described in this review show how the treatment regimen can be customized to the patient by selecting an individualized approach based on the individual tumor characteristics and the chemotherapy regimen. This approach should help improve the outcome for breast cancer patients. New pathways described in recent years, as well as novel targets in the treatment of breast cancer with standard chemotherapeutics are discussed below.\n\n## Pathways involved in breast cancer chemoresistance\nRecent studies have identified a number of signaling pathways that control stem-cell functions in tumor cells and contribute to the maintenance of the mammary stem cell lineage and may play a key role in chemoresistance [bib_ref]  Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and re",
        "label": 0
    },
    "1317": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\n1 The assessment of eligibility has a three-point scale. \n\n\n2\nTo make the assessment, you must check boxes for each of these three categories:\n\n\n3\nIf more than 35.9% of the criteria are not met, make an assessment of Trial-level ineligibility.\n\n4\nIf more than 14.3% of the criteria are not met, make an assessment of Trial-level exclusion.\n\n5\nIf more than 50% of the criteria are not met, make an assessment of Trial-level exclusion and stop working with the patient note.\n\n\n6\nIf more than 22.8% of the criteria are not met, make an assessment of Trial-level exclusion and stop working with the patient note.\n\n\n7\nCheck the category for each of these 4 inclusion criteria:\n\n\n8\nIf the patient is male, mark No, otherwise, mark Yes.\n\n\n9\nIf the patient is younger than 18 or older than 75, mark No, otherwise, mark Yes.\n\n10\nIf the patient is a current smoker, mark No, otherwise, mark Yes.\n\n11\nIf the patient has ever been a marijuana user, mark No, otherwise, mark Yes.\n\n12\nIf the patient experienced acute pancreatits 2 times or more, mark Yes, otherwise, mark No.\n\n13\nIf the patient is diabetic, mark Yes, otherwise, mark No.\n\n14\nIf the patient is enrolled in another ongoing clinical trial or has ever been enrolled in another ongoing clinical trial, mark Yes, otherwise, mark No.\n\n15\nIf the patient's first presentation of pancreatits was pancreatic cancer, mark Yes, otherwise, mark No.\n\n16",
        "label": 0
    },
    "1318": {
        "output": "Finally the patient information leaflet is available as a preview file. We encourage you to review it and to improve its contents, if necessary. [TUT8] Hello. This is the tutorial on working with a clinical research protocol in Prot\u00e9g\u00e9. The following exercises are a part of the exam that you completed during the course.\nFirst I want you to read this research protocol (attached) carefully and complete it.\nThe research protocol is in the following format. It is always recommended to complete the header and the footer sections. In this chapter, we discuss what type of clinical trials should be approved by a group of experts (requiring the use of the PROTOCOL) that assess the safety (in terms of potential risks) and suitability (in terms of compliance with regulations and clinical guidelines)\nIn this chapter, the researcher provides a summary of clinical research involving the treatment of a specific disease with an existing medical therapy or therapeutic method. The researcher discusses the safety (in terms of potential risks) and suitability (in terms of compliance with clinical guidelines, and with the aim of beneficial clinical research) of this clinical research method. If clinically required, the researcher must also provide a safety report. Any medical treatment used in this clinical research method must be documented in a safety report. The researcher summarizes the existing medical methods",
        "label": 0
    },
    "1319": {
        "output": "Let's get an example. Try to write an answer from patient number 10-14. \n**Patient information:**\nA 32-year-old obese man was admitted to the emergency department with right upper quadrant pain for 5 days. The examiner reported a sharp pain with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty foods. The 1kg weight loss. The patient had a cholelithiasis diagnosed 6 months before, and he was under medical follow-up. His past medical history is remarkable for ureteric stone, 1 cardioembolic stroke and 2 NVDs. He has 4 children, and he is menopausal. He does not smoke, drink alcohol, or use illicit drugs. He has a history of hypercholesterolemia and hypertension. His regular medication is Aspirin + Atorvastatin + Clopidogrel. He is mildly febrile. His BP is 145/90, HR 110, RR 18, T 37.1, SpO2 96% on RA. He is an obese elderly man with no acute distress. On palpation, he experiences right upper quadrant tenderness. In the ultrasound, we found 19 mm gallstone and 2.5mm CBD stone.\nHere is his clinical trial assessment: \nAssessment: In this patient the risk of anesthesia outweighed the benefits, so the patient was not included in this trial.\n\n**Patient information:**\nA 42-year-old obese woman was admitted to the emergency department with severe epigastric pain radiating to the right upper quadrant for 12 hours that worsened with eating food. The patient had a hysterectomy at the age of 34 and a cholecystectomy at the age of 37. It is important to note that the patient had 4 pregnancies after the hysterectomy. Her past medical history is remarkable for uterine fibroid, dyspepsia, hypertension and hyperlip",
        "label": 0
    },
    "1320": {
        "output": "##[TEST]\nYou should make some dataframes with following variables - first is data for patients, second dataframe contains data for clinical trials and third is for information about patient-clinical trial pairs.\n\n* Patient data:\n\nName: 'PatientData',\ndtypes: [object],\ncolumns: [\"PatientID\", \"Patient_Name\",\n          \"Age\", \"Ethnicity\",\n          \"FirstSeen\", \"Sex\", \"Weight\",\n          \"Height\", \"Smoking\", \"Drinking\",\n          \"DrugAllergy\", \"Allergy\", \"Pregnancy\",\n          \"Family_History\", \"Cancer\",\n          \"High_Cholesterol\", \"Diabe\",\n          \"Psych\", \"RD\", \"NCD\", \"Vasc_D\", \"Lung_D\",\n          \"Other_D\", \"Sleep_Disorder\",\n          \"Insomnia\", \"Geriatric\", \"Baby_Age_Days\",\n          \"Sex_Relation\", \"Emergency_Room_Visit\",\n          \"Renal_Clearance\", \"Hepatic_Clearance\",\n          \"Small_Incavation\", \"History_of_HCC\",\n          \"Preop_Pain\", \"Intraop_Pain\",\n          \"Postoperative_Pain\", \"Preoperative_Pain_VAS\",\n          \"Postoperative_Pain_VAS\",\n          \"Pregnancies_Count\", \"Childbirth_Count\",\n          \"Medication_Count\", \"Medication_Count\",\n          \"Prophylactic_Count\", \"Sleep_QoL\",\n          \"_1st_Day_Pain_VAS\", \"_2nd_Day_Pain_VAS\",\n          \"_3rd_Day_Pain_VAS\", \"_Day_04_Pain_VAS\", \"_Day_05_Pain_VAS\",\n          \"_Day_06_Pain_VAS\", \"_Day_07_Pain_VAS\", \"_Day_08_Pain_VAS\",\n          \"_Day_09_Pain_VAS\", \"_Day_10_Pain_",
        "label": 0
    },
    "1321": {
        "output": "[TEST].\n[CLOSE]<EOD> Risk Factors For Failure Following Arthroplasty Of The Hallux Metatarsophalangeal Joint\nBackground: The purpose of this study was to examine patient and intraoperative factors that may affect rates of revision surgery for hallux metatarsophalangeal joint arthroplasty. Patients and Methods: We retrospectively analyzed 594 feet operated upon by a single surgeon from 1977 to 2011. Patient and intraoperative characteristics were collected and correlated to rates of revision surgery. The relationship between age and rates of revision surgery was examined with a Cox proportional hazards model and Kaplan Meier method. Results: Kaplan-Meier analysis demonstrated no difference in survivorship from the primary index surgery over two decades between older (61 years) and younger (61 years) patients (P = .06; log-rank test). The Cox proportional hazard analysis demonstrated no difference in overall revision risk between older and younger patients (P = .66), but it did demonstrate an increased revision risk for all patients with end-stage arthritis (P = .06), patients with a preoperative diagnosis of hallux limitus (P = .0001), and female patients (P = .018). Conclusion: Patients with end-stage degenerative changes, patients with a preoperative functional diagnosis of hallux limitus, and female patients tend to experience higher rates of revision surgery following first metatarsophalangeal joint replacement. Joint-preserving surgery should therefore be the preferred form of surgical treatment in patients in this category. These findings may assist in refining criteria for joint replacement in older patients with degenerative joint disease. Level of Evidence: Level III, retrospective comparative study.<EOD> Identification of Potent and Selective Inhibitors to FimH Target Using 2\u2010Azaaryl\u2010Pyridines as Leads\nFimH is a bacterial lectin that mediates the initial attachment to cell surfaces, and is a key player in the pathogenesis of uropathogenic Escherichia coli (UPEC). Several inhibitors using the carbohydrate",
        "label": 0
    },
    "1322": {
        "output": "[/WIP_PROGRESS]\n\n\n---\n\nThe above question was [asked on data-science-stackexchange](/questions/tagged/clinical-trial).\nThe question was later migrated to this repository due to the large number of similar questions asked on the data-science-stackexchange.\n\n___\n\n\n___\n# Migration\n<div id=\"migration\" class=\"section\">\n\n## For users who asked this question on data-sciencestackexchange\n    ## Before migration\n    <div id=\"migration-copy\">\n        <h4>The question before migration:</h4>\n        <span class=\"data-science-stackexchange-post\"> <img src=\"/images/data-science-stackexchange.png\" height=\"65\" title=\"Original question on data stack exchange\"> </span>\n        <h5>For users who asked this question on data-science-stackexchange</h5>\n        <p>Title: Endoscopic Ultrasound for the Assessment of Bile Duct Injury<br>\n            Answer: Trial-level eligibility: 2 (Eligible)\n<br>\n    <br>\n    Here's the patient note:</p>\n    <p><pre class=\"prettyprint\"><span class=\"strikethrough\">A 32</span>-year<span class=\"strikethrough\">-old</span> man was hit by a truck and has multiple traumatic injuries including multiple facial fractures, a tracheostomy </pre></p>\n    <p><pre class=\"prettyprint\">    <span class=\"strikethrough\">A</span> CT head and neck showed a small frontal fracture </pre></p>\n    <p><pre class=\"prettyprint\">    <span class=\"strikethrough\">A</span> CT abdomen and pelvis showed air in the urinary bladder, a distended kidney, and intravesnic calculus </pre></p>\n    <p><pre class=\"prettyprint\">    <span class=\"strikethrough\">A</span> Chest x-Ray is normal </pre></p>\n    <p><pre class",
        "label": 0
    },
    "1323": {
        "output": "[INST]\nFor the full clinical study, you need to report your assessment of the patient's eligibility. \n\n\nStep 10: Detectable change in the clinical trial results:\nAs a recruiting researcher, you should be able to assess how much of the patient's clinical state has changed if she receives the experimental treatment. We define detectable change as the minimum clinically important change that clinical therapists could observe and determine if they were administered to the patient under standard care.\nClinicians observe and assess patient's condition daily, and then prescribe an appropriate treatment and care program.",
        "label": 0
    },
    "1324": {
        "output": "__ELIGIBILITY ASSISTANT_\n[/MARK UP]\n\n___21:_2___\n    * The patient does not present the inclusion criteria.\n    * The patient presents the inclusion criteria.\n    * The patient has medical contraindications to the medications prescribed (see exclusion criteria).\n    * The patient refuses the medications.\n    * The doctor refuses the medications to the patient (see discretionary option, option 4).\n    * The doctor recommends another medication.\n    * The doctor recommends another medication.\n    * The doctor recommends not to have the medications and leaves this decision to the patient. This is also considered not to prescribe the medication.\n\n<span class=\"term-desc\">Inclusion Criteria</span><br />\n\n<span class=\"term-desc\">Patent with a presumptive clinic diagnosis of pulmonary tuberculosis</span><br />\n\n1.1 Patent who agrees to the study <br />\n1.2 Patent who doesn't agree to the study. Excluded from the study <br />\n1.3 Patent, who agrees to the study and has a positive tuberculin test with an induration diameter greater than 10 mm in an area with 5 mm radius, as per Mantoux test, confirmed by the positive culture of the sample or by the presence of caseous granulomatous inflammation demonstrated in biopsy study, is considered <br />\n2.1 Presence of cavities on the X-ray, compatible with pulmonary dissemination; <br />\n2.2 Presence of positive culture; <br />\n2.2.1 Positive culture of extra pulmonary tract; <br />\n2.2.2 Presence of more than three pulmonary lobes alterations; <br />\n2.2.3 Chest X-rays indicative of pulmonary abscesses; <br />\n2.2.4 Pulmonary infection confirmed by biopsy; <br />\n2.2.5 Positive culture of two pulmonary cavities or pulmonary cavities of the same patient in two different situations; <br />\n2.2.6 Rad",
        "label": 0
    },
    "1325": {
        "output": "Let's get these examples.\n\n\n{% include md/dry15.md %}\n\n\n### Example 1:\nWe will have the following data about a patient: \n\nA: Patient is not pre-treated. If patient is already treated, she can be excluded from trial.\n\nB: Patient is not currently suffering from the trial's exclusion comorbidities. If patient has one of the trial's exclusion comorbidities, she will be excluded as well.\n\nC: Patient meets all of the trial's inclusion comorbidities. Patient is eligible for this trial.\n\n\n```\nTrial-level eligibility: 1) Not relevant.\n```\n\n### Example 2:\nWe will have the following data about a patient: \n\nA: Patient is pre-treated. If patient is not pre-treated, he is excluded from trial.\n\nB: Patient is pre-treated. If patient is not pre-treated, he is excluded from trial.\n\nC: Patient meets all of the trial's inclusion comorbidities. Patient is eligible for this trial.\n\n\n```\nTrial-level eligibility: 2) Eligible.\n```\n\n### Example 3:\nWe will observe the following data about a patient: \n\nA: Patient has no comorbidities such as diabetes, and is therefore not treated with antidiabetics and insulin:\n\n```\n# Trial-specific comorbidities\nmedComorbidities <- c(\"insulin\", \"antidiabetics\")[[1]]\n```\n\nB: Patient is currently treated with the following comorbidities: antihypertensives and aspirin:\n\n```\n# Trial-specific comorbidities\nmedComorbidities <- c(\"antihypertensives\", \"aspirin\")\n```\n\nC: Patient meets all of the trial's inclusion comorbidities. Patient is not currently treated, so patient is eligible for trial.\n\n```\nTrial-level eligibility: 2) Eligible.\n```\n\n### Example 4:\nWe will have",
        "label": 0
    },
    "1326": {
        "output": "<details><summary><i>For more specific instructions check them here.</i></summary>\n<br><br>\n#### Internal Data:\n<br>\n--\n`\n<small><i>\nYour data is stored in a secure location on the server. It is accessible only by the authorized people.\n </i></small>\n`\n--\n<small><i>\nPlease remember to save data locally too under <code>:~/anaconda3/envs/<em><NAME></em></code> for your reference.\n </i></small><br>\nThis exercise is not completed correctly if you do not.\n</details><br>\n\n#### External Data:\n<br>\n--\nAnaconda3 version of our exercise is available here\n<a href=\"https://github.com/saf-aub/eligibility-assessment\">Download Anaconda3 environment and reproduce</a>\n<br><br>\nYou can follow the instructions on the project website:\n<br>\nhttps://eligibilityassessment.readthedocs.io/en/latest/installation-and-setup/envs-and-packages.html\n<br>\n--\nPlease review the installation instruction to complete the exercises in a new environment.\n<br><br>\n\n#### Reference:\n<br>\n<a href=\"\" rel=\"nofollow\" target=\"_blank\">Read more</a><br><br>\n<a href=\"\" rel=\"nofollow\" target=\"_blank\">Get your own copy</a><br><br>\n\n### Q14.12: \n#### What is your final prediction on the total eligibility prediction of a patient?\n\n#### Q14.13: \n<EOD> Drug development: the challenges of the second decade 1\nRecent initiatives for advancing drug development have been directed at identifying new therapeutics with improved properties. A successful drug development programme generally takes 10\u201312 years and is estimated to cost approximately $300 million per drug entity. Drug development has been subject to increased scrutiny over the years, and has become an increasingly important issue for government policy makers. This article will discuss the progress of drug development by focusing on challenges faced by today\u2019s drug developers. Success",
        "label": 0
    },
    "1327": {
        "output": "**IMPORTANT** Before you continue, please make sure you have reviewed the [Instantiations](/software/notebooks/data/v2.0/notebooks/2_INST.ipynb) if you don't have a Python installation in your Jupyter lab.\n**Install the required libraries if they are not already there.** You can find all the necessary libraries at the [Install section](/software/instructions/v2-installation.html) of the documentation.\n\n**Now let's go through a trial to demonstrate notebook_ex1_00_00_02.ipynb**.\n\n[![Run code in Jupyter](https://www.jupyter.org/widgets/badge.svg?url=https://notebook.ai/run/?url=https://github.com/notebook-ai/notebook-ai.github.io/_static/notebook_ex1_00_00_02.ipynb&refresh=true)](https://notebook.ai/run/?url=https://github.com/notebook-ai/notebook-ai.github.io/_static/notebook_ex1_00_00_02.ipynb)\n\n[![Run code in Repl.it](https://repl.it/badge/github/notebook-ai/notebook-ai.github.io/v2-installation-samplenotebook.svg?description=run%20in%20Repl.it )](https://repl.it/github/notebook-ai/notebook-ai.github.io/v2-installation-samplenotebook?mode=edit&open=sample)\n\nBefore you get started, please remember how to create and edit a notebook using Jupyter Notebook in general. You'll find that information on [GitHub Repositories](/software/docs/v2-installation-notebooks/jupyternotebook-general-usage.html).\n\n## [v2_instructions-jupyter.md](https://github.com/notebook-ai/notebook-ai.github.io/blob/master/v2/v2_instructions-jupyter.md)\n##",
        "label": 0
    },
    "1328": {
        "output": "<EOD> Rational design of efficient photoswitches\nSignificance Photoresponsive chemical systems have emerged over the past 2 decades as an efficient tool for controlling matter on the nanoscale. These systems are based on the conversion of light energy into chemical energy, resulting in a change in material properties. In this work, we present a novel and general approach toward the rational design of efficient photoswitchable molecular systems based on intrinsic reactivity descriptors. Specifically, we describe a quantitative way to predict the switching time of light-to-chemical conversion and its dependence on the structure of the photoswitchable molecule. The results of this study will enable a rational search of molecular photoswitches with tailored properties and could provide the basis for a deeper understanding of the relationship between material structure and function in photoresponsive systems. Materials responsive to external stimuli, including photochemical cues, are finding tremendous applications in nanotechnology and pharmaceutical sciences. These materials are based on the conversion of light energy into chemical energy, resulting in a reversible change in their material properties upon external stimulation. The design of these materials relies on the identification of a suitable photoswitch for each application, and their selection is presently limited to time-consuming and largely empirical trial-and-error approaches. In this work, we present a quantitative study toward the rational design of efficient photoresponsive molecular systems. We propose an approach to predict the switch rate of light-to-chemical conversion of photochemical reactions based on intrinsic kinetics parameters, which provide a measure of the efficiency and selectivity of the reaction step. We show how the analysis of the relationship between system properties and intrinsic parameters enables the identification of the reaction mechanism that drives the process of interest. Specific examples are presented for the photoisomerization and ring-closing reactions that lie at the core of the functioning of cis-decalins, the molecular backbone of aminophtalimide photoswitches. Our results show that these photoswitchable systems follow the Hopf reaction mechanism. This suggests that cis-decalins are more suitable for ring-closing versus photoisomerization processes, providing an in-depth view into the design of molecular systems responsive to light.<EOD> A high risk population, at risk",
        "label": 0
    },
    "1329": {
        "output": "To learn on how to install and run an instance of the jupyter notebook, visit the tutorial Jupyter Notebook - Getting Started (section 3: Installing and running). \n[INST] \n\n## The patient is 34-year old obese woman admitted to the emergency department with fever and severe biliary pain. the pain is more intense in the right quadrant and less intense in the epigastrium, which was confirmed to be biliar in origin. the patient has had this biliar pain for two days and a slight jaundice the last 12 hours. she denied nausea or vomiting. she is unmarried and menopausal. she smokes 10 cigarettes/day and drinks three cups/day. she suffers from hyperlipemia and migraine. she has no previous abdominal surgery but has previously undergone cholelithiasis that had not been treated.\nShe is hemodynamically stable and has pain on abdominal palpation. \n12/2017 07:51:33 (50) 1.0.0 2.0 Excluded A 44-year-old woman hospitalized in internal medicine. The patient has a history of biliary colic in the last year and now is admitted to an internal medicine department for further evaluation related to his abdominal pain and jaundice. According to the patient's report and physical examination the origin of the pain is biliary. There was no history of digestive tract surgery. She has an uncomplicated paraclinical record. She consents to surgical treatment upon her assessment of the risk and benefits of it.\n\n## General appearance : + general appearance : +\nAbdomen : (abdominal pain)\nOn examination : Inspection : +\nOn examination : Inspection : +\nOn examination : Palpation : + Palpation : +\nOn examination : Palpation : +\nOn examination : Palpation : + Palpation : + Palpation : + Palpation : +\nOn examination : Palpation : +\n\n## On examination : palpation : + palpation : +\nOn examination :",
        "label": 0
    },
    "1330": {
        "output": "<EOD> Genome-wide copy number changes by single nucleotide polymorphism allelic content in cancer.\nAberrations in DNA copy number, including copy number gains and losses, is one of the most common molecular abnormalities in cancer. Copy number aberrations could be used as a marker for cancer development and cancer progression in a manner complementary to other molecular markers. An important challenge that has not yet been satisfactorely addressed is how to link genome-wide copy number aberrations to known chromosomal or single gene alterations. We have evaluated this in two ways. First, we have analyzed several cases of aneuploid cancers that displayed abnormalities at multiple chromosomes. Our analysis indicates that these abnormalities are not random or related to the chromosomes altered at each site. Our analyses suggest a relationship between the chromosomes that are involved and the chromosomal location of the alterations. This would suggest that there are at least two levels of selection: one that controls how genes behave on a chromosome as a whole and another that affects subregions within chromosomes. Second, we have found that in cancer, regions enriched in single nucleotide polymorphism allelic content show lower levels of genome-wide copy number aberrations than average chromosomal regions, while regions depleted in single nucleotide polymorphism allelic content consistently displayed high levels of genome-wide copy number aberrations. These regions may contain genes that are important for cancer or cancer progression.<EOD> The Effectiveness of PPAR\u03b3 Agonist Pioglitazone on Length of Stay in Children with Cystic Fibrosis Associated Pneumonia\nObjective. The objective of this study is to evaluate the feasibility and efficacy of pioglitazone for improvement of the outcomes of children with cystic fibrosis (CF)\u2010associated pneumonia. Methods. This is a retrospective, observational study of CF children admitted with pneumonia to a pediatric hospital system. The primary outcome was change in length of stay (LOS) after the initiation of pioglitazone treatment. LOS was measured from the date of admission to discharge date. Secondary analyses were based on baseline clinical characteristics of age",
        "label": 0
    },
    "1331": {
        "output": "There are several options in your Python dictionary:\n\n* `0 : Excluded` # It takes Boolean value as an argument and returns Boolean value. \n\n* `1 : Not relevant` # Takes boolean value as an argument and returns string value.\n\n* `2 : Eligible` # Takes Boolean value as an argument and returns string value.\n\n\nFor example, given patient note as `p: [60, [\u2026 ], female, mild, obese, hypercholesterolemia, 2 NVD, 1 NVD, menopause, smoker, alcoholic, illegal drug user], \"Elastix\"_02` and a clinical trial note as `s: [45, [\u2026], 45, male, moderate, normal, COPD, asthma, heart problem, diabetes, 45, 45, BMI, 30, smoker, heavy drinker, marijuana user], 'Surgicel and Analgesic Reservoir'`\n\n\n\n\n\n```\nprint \"p:\", p\nprint \"s:\", s\nprint \"\\n\\n\", getTriallevel(p), getTriallevel(s)\n# Exclude : Excluded\n# Not relevant : There is no information provided.\n# Eligible : patient has the information and the trial is eligible.\n# Exclude : Excluded\n# Not relevant : There is no information provided.\n# Eligible : patient has the information and the trial is eligible.\n```\n\n![](/img/in-post/2021-11-23-2023848283324683/img00.jpeg)\n\n## Exercise\nCreate a program using the steps and options described earlier to find out the trial-level eligibility of each patient in a list of patients note based on a list of clinical trial notes. \n\n### [Solution file](../solutions/triallevel.py)\n\n\n<EOD> Comparison of the effects of a once daily and a multiple daily administration of topical corticosteroids on the skin of the dorsum of the hand.\nA study was conducted to compare the effects of a once daily and",
        "label": 0
    },
    "1332": {
        "output": "<EOD> Gastric anisakiasis: An analysis of 46 cases\n\nBackground/aims: Anisakiasis is a food-borne zoonosis caused by consumption of raw fish containing eggs of Anisakis simplex; it is characterized by gastrointestinal and extraintestinal symptoms. Due to its rarity and lack of a consensus on treatment, the proper approach to the disease has not been established yet. This study was designed to investigate the clinical presentation, laboratory findings and treatment of anisakiasis due to A. simplex by analyzing 46 cases of confirmed diagnosis. Methods: The demographic, laboratory, clinical, radiologic, endoscopic, histologic and treatment data of 46 patients who were diagnosed by endoscopy as having gastric anisakiasis were recorded and analyzed. Results: The median age of the patients was 46 (range: 18-64) years. The most common findings in physical examination were epigastric tenderness (47.83%), epigastric mass (15.22%) and urticarial skin lesions (10.87%). Laboratory data showed high eosinophil counts in 28 (60.9%) patients and leukocytosis in 6 (13.03%) patients. Esophagogastroduodenoscopy demonstrated the presence of linear, serpiginous, edematous and hyperemic mucosal lesions in the stomach of all the cases. Endoscopic ultrasonography was performed in 47.8% of the patients and revealed lesions of hypoechoic nature. Endoscopic therapy with aspirin, sodium hydrochloride, normal saline, adrenaline and scrupulous irrigation was applied in 26 (56.52%) of the cases. All patients were treated and cured except for three patients in whom molluscicide therapy was added to endoscopic therapy. Endoscopic therapy was found to be more effective for gastritis than ulcer formation (p < 0.05). Conclusion: Anisakiasis is a relatively rare food-borne",
        "label": 0
    },
    "1333": {
        "output": "<h3 align=\"center\"><span style=\"font-size: 150%\">3. What is the correct code to print the name and information of each patient?</h3>\n\nYou should make a loop to print patient notes into the console. You can test code in the console in 10-15 seconds. \n\n<h3 align=\"center\"><span style=\"font-size: 150%\">4. How can I get the eligible list of patients in the output?</h3>\n\nYou should make a cycle to get the eligible patient's data into the output table, as shown in Figure E. You will get the list of eligible patients in the output table. You should also test the loop in the console in <15 seconds. \n\n<h3 align=\"center\"><span style=\"font-size: 150%\">5. What is your code for printing the correct result according to all the criteria, e.g., inclusion criteria?</h3>\n\nPrint `Trial-level eligibility:` in the last line by `Trial-level eligibility: 0) Excluded.`. Here is the coding:\n\n```python\nfor k, v in trial_eligibility_table.iterrows():\n    if ((trial_eligibility_table['0'] == 1) and (trial_eligibility_table['1'] == 1)):\n        print (k, trial_eligibility_table['2']) #Triallevel eligibility\nelse:\n               print (k)\n```<jupyter_code>jamesk.json\n# Cytoscape import code\nimport cytoscape.networkx as cxn\n\nnetworkx_graph = cxn.Graph()\n\nfrom numpy import array \n\nfrom matplotlib import fig, axes, plt \n\nimport networkx as nx\n\n#for i in range(10,20): \n#    for j in range(3,25): \n#        x = array([2 + i, 3+j, 'jj'])\n#        networkx_graph.add_node(x, x)\n\ndef myPlot(nx_graph, my_list):\n    my_plot_lines",
        "label": 0
    },
    "1334": {
        "output": "## [END]\n\n2. The data frames you can use:\n1. `df_pilot`: The first data frame contains data from two patients that are eligible for AXIOS because both have a CBD stone and both are undergoing a second trial to assess the feasibility of endoscopic gallbladder drainage for acute cholecystitis.\n```\n        patient    clinical trial          elig_in_trial eligible\n      0 Pilot_000     AXIOS            0                  2\n      1 Pilot_001     AXIOS            0                  2\n      2 Pilot_000     DRAINAGE        1                  1\n      3 Pilot_001     DRAINAGE        1                  1\n      4 Pilot_000     AXIOS            0                  2\n      5 Pilot_001     AXIOS            0                  2\n```\n![alt text](https://github.com/japwang0614/TeachingTip/blob/master/notebooks/eligibility_pipeline/01.png)\n\n2. `df_patient`: The second dataframe is the patient data (e.g., EHR, patient-reported information, etc.). This is the data for Pilot 001. Note there are repeated values among patients.\n```\n        patient_num patient    age gender birth_state       marital        education  \n      0 Pilot_000   1      21    female   07 34 2013 1        Married   \n      1 Pilot_001   2      37    male    02 31 1991 1        Single   \n```\n![alt text](https://github.com/japwang0614/TeachingTip/blob/master/notebooks/eligibility_pipeline/02.png)\n\n3. `df_trials`: The third dataframe is trial data. This is the data for the AXIOS trial (e.g., trial summary and eligibility criteria).\n```\n    trial_type trial_name    inclusion_criteria    exclusion_criteria",
        "label": 0
    },
    "1335": {
        "output": "<span id=\"x4\"></span>\nYou should be reminded that your task is to make a <span id=\"x1\">trial-level</span> eligibility for each <span id=\"x2\">patient note</span> (not to make a <span id=\"x4\">patient-level</span> eligibility). \n\n\n<span id=\"x1\"></span>\nYou should make trial-level eligibility for the patient, that is, in the first line do `Trial-level eligibility 1:`. [/OUT] \n\n\n<span id=\"x2\"></span>\nGo to step 4 below. \n\n\n<span id=\"x4\"></span>\nCongratulations! You finished the task!\n\n</span<commit_msg>fixing formatting<commit_after><!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\" \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\">\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n  <link rel=\"stylesheet\" type=\"text/css\" href=\"https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css\">\n<link rel=\"stylesheet\" type=\"text/css\" href=\"/static/cpt.css\">\n</head>\n<body>\n  <div class=\"container\">\n  <div class=\"card\">\n  <div class=\"row\" style=\"float:left\">\n      <div class=\"col-md-6 col-md-offset-2\">\n              <p align=\"center\">\n              <?xml-stylesheet type=\"text/css\" href=\"https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css\"></xml-stylesheet><hr>\n              <h4>Instructions:</h4>\n              \n                <font style=\"color: #00CD00;\" size=\"8\">You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial",
        "label": 0
    },
    "1336": {
        "output": "<EOD> Effects of long-term dietary supplementation of fermented diets on rumen fermentation, blood metabolites, and milk yield in sheep.\nThe purpose of this study was to evaluate the effects of 10% long-term feeding of a fermented concentrate on growth, rumen fermentation (viz., total volatile fatty acid , acetate, and butyrate), blood metabolites, and milk yield. Forty male, 1-yr-old Awassi lambs were used in this study and randomly divided into four treatment groups (n = 10 per treatment group): T1 fed control concentrate, T2 fed fermented concentrate (10% proportion of dry matter of total concentrate), T3 fed fermented pellet concentrate for 24 mo, and T4 fed fermented pellet concentrate for 6 mo. Over the 24-mo (including the 6-mo adaptation",
        "label": 0
    },
    "1337": {
        "output": "## Creating dataframes from lists 1) You need a (user-defined) list\n\n\n* You are a data entry assistant in a clinical trial. The investigator asks you to enter data from a file generated by [username_1] the data manager. The format of the file should be as follows:\n\n```\nID | Sex | Age | Fever | Abdominal pain | Constipation\n01 | female | 54 | - | present | -\n02 | male | 42 | - | - | -\n...\n\n```\nYou have to enter the following values:\n\n\n* ID\n* Sex\n* Age\n* Fever\n* Abdominal pain\n* Constipation\nHere is an example of a list with 5 elements:\n[lst1, male, 43, 38.4, present]\n\n--list1=\n\n[lst1, male, 43, 38.4, present]\n\n\n* DataFrame\n\n```\n>>> lst1.to_frame()\n    ID     Sex  Age    Fever  Abdominal pain Constipation\n0   01   female     54     -         present  -\n1   02   male       43     -         -         -\n2   03   female     59     -         present  -\n3   04   male       51     -         present  -\n4   05   woman     43     -",
        "label": 0
    },
    "1338": {
        "output": "# Acknowledgements\n\n*Trial-level eligibility*\n    *Elizabeth Eckmann 2015-10-20\n    *This function assigns the trial-level eligibility.\n    *The trial-level eligibility is a list of trial IDs. *This list can contain 0, 1 or 2 trial ID. For example, 1, 0 would mean 1 - Yes and 0 - No.\n    *Trial-level eligibility can be obtained by `get_trial-level_eligibility(user_input)`. This method returns one of the following values: *None* if patient does not meet any of the trial's inclusion criteria or *Trial-level eligibility* if the patient is eligible to the trial.\n    *`get_trial-level_eligibility(user_input)` takes a trial ID as input and returns `Trial-level eligibility`.\n    *The trial ID is obtained by calling `get_trial_by_id`. The user should create a new trial by calling `create_trial`.\n    *To get the trial-level eligibility, the user needs to fill in the `Trial-level Eligibility form` for every patient in a trial and store the data in a CSV file. \n\n\n\n*To obtain the trial-level eligibility, patient-level eligibility needs to be calculated using the formula below:\n\n*First, fill in the table for each patient.\n*Second, calculate the patient-level eligibility as the total number of excluded patients within a trial and then divide by the total number of patients.\n*Lastly, multiply the trial ID of the trial by the patient-level eligibility. *This will determine trial-level eligibility*.\n    *Example: If 10 patients were in the trial and 8 patients were excluded from the trial based on their exclusion criteria, the trial level eligibility would be as below:\n        75.0  * * * * *",
        "label": 0
    },
    "1339": {
        "output": "### What is a clinical trial?\n\nA clinical trial is a research study that involves human subjects to evaluate the safety and effectiveness of a medical product or intervention.\n\n### What types of clinical trials are there?\n\nThere are various types of clinical trials in which the research is done in specific phases.\n\n### What are four common phases?\n\nPhase I, II, III, and IV trials study the safety and efficacy of a drug or medical device, respectively.\n\n### What is the objective of each clinical trial?\n\n\n\n\n\n\nPhase I Studies are carried out in patients with cancer in order to evaluate the safety and efficacy of the investigational drug in a human body. If the drug is found to be safe and effective, it enters into the next phase of clinical trials.\n\nPhase II studies are carried out in large groups of patients to determine whether the proposed drug is effective in the treatment of a disease or condition.\n\nPhase III studies is a randomized controlled clinical trial that is conducted in large groups of patients under controlled settings to compare the proposed drug with a placebo. If the proposed drug is found to be more effective, it can then be launched to the market as a prescription drug.\n\nPhase IV studies investigate the long-term effectiveness of the drug in the treatment of the disease and may also study secondary effects.\n\n##### Other Phases\n\nPhase 0:\n\nAn exploratory preclinical phase in which scientists study the properties of a hypothesized treatment using isolated organs or tissues.\n\nPhase 1/2A:\n\nFirst, scientists test a treatment on patients with a type of cancer that is very similar to the one they are targeting in this trial, and if no major side effects are observed, they increase the number of patients",
        "label": 0
    },
    "1340": {
        "output": "~[END]\n\n\n\n<EOD> An alternative for breech delivery: the posterior mid\u2010cleft delivery method for extraction of the fetus through the cleft region of the mother's perineal skin\nBackground:\u2002 The transverse breech extraction method has been advocated by many obstetricians for breech delivery. Although it is generally safe, many concerns still exist about its morbidity and the potential long\u2010term sequelae for the child\u2019s development.<EOD> Heteromeric and homomeric GABA(A) receptors: gating, modulation and plasticity.\nGABA(A) receptors of the Cys-loop family are pentameric assemblies of five subunits, which combine to form distinct types of receptor in the CNS. Different GABA(A) receptor subtypes are distinguished by their neuroanatomical distribution; by their distinct pharmacological properties; by their patterns of coupling to second messenger systems and finally, by the effect of particular disease conditions on the relative levels of expression of the different receptor subunits. Although the individual subunit-encoding genes are expressed in a temporally regulated manner during development, the overall profile of receptor diversity within each major brain region remains the same in the adult brain. In recent years, considerable data have been accumulated on the biophysical properties and pharmacological characteristics of heterologously expressed GABA(A) receptors, based on the use of receptors expressed in mammalian cell lines and Xenopus oocytes. However, a significant gap exists between these in vitro data and the heteromeric types of receptors found in vivo. In particular, it has been reported that different subtypes of GABA(A) receptor respond differently to neuromodulatory drugs in native tissue. This review attempts to integrate the current knowledge on both heteromeric and homomeric types of receptor to provide a clearer overall picture of receptor properties in native tissue, and how these relate to function.<EOD> Intraoperative ultrasonography during laparoscopic surgery for endometrial cancer: a systematic review\nBackground: The use of intraoperative ultrasonography (IOUS) during laparoscopic surgery has become popular in treatment of",
        "label": 0
    },
    "1341": {
        "output": "Your professor, Drs. Shai, Asch, and Cooper, along with their team of colleagues, recently completed a randomized controlled trial (RCT) on the efficacy of surgical intervention for hip arthroscopy. They are interested in determining if offering $10-$70 (depending on how many visits are completed) reward incentives to patients for each visit they complete after the primary procedure will increase compliance to completing post-operative visits. This is especially important for their hip arthroscopy cases as they have previously found that just under 50% of patients fail to attend the first post-operative follow-up visit. Dr. Shai and her team therefore ask that you conduct a Monte Carlo simulation to determine the expected financial incentive to be offered to each patient (randomly allocated to intervention and control groups) to maximize the post-operative visit compliance rate. \n\nThe goal of this simulation is to estimate (or at least be close enough) the dollar value of a financial incentive. We want to create confidence that this $X value we choose in the future will increase completion rates, by some pre-hypothesized level.\n\nYou have already",
        "label": 0
    },
    "1342": {
        "output": "<EOD> .\nIn 23 patients with rheumatic lesions of the subluxating hip or a hip with spastic paresis after stroke, ultrasonography was compared with radiography and isotope bone scans (HAS). Ultrasonography showed a sensitivity of 90% (21 hips out of 23) for detecting rheumatic hip involvement compared with radiography (sensitivity 83%), and a sensitivity of 91% compared with isotope bone scans (sensitivity 83%). Ultrasonography revealed in some cases lesions not shown by radiography (osteoporosis and femurs). Ultrasonography therefore appears to offer better evaluation of osseous lesions in rheumatic hips.<EOD> Prevalence and correlates of HIV testing and awareness in a stratified random sample of adults in Uganda\n\nBackground: Despite the efforts from the Ministry of Health Uganda and other players, HIV incidence remains high and the disease is prevalent in the country. HIV testing has a critical role to play towards reducing HIV incidence therefore, increasing HIV testing among all segments of the population will have a far reaching effect in HIV treatment and prevention efforts. Methods: We analyzed population survey data collected in 2010-2011 from a stratified random sample of 2438 households in four purposively selected strata. The sample of 85 households was obtained from the eight geographical regions of Uganda. Strata were the rural/urban setting, the level of HIV prevalence as estimated from antenatal clinic reports, population size, and the area's HIV prevalence. All participants aged 15-59 years from these clusters were eligible to participate. After a pretested interviewer administered structured household questionnaire in an indoor location of each household, all participants completed interviewer administered surveys in a private room. Data were analyzed with SPSS and Microsoft Excel. Results: Out of the 2438 eligible adults 2304 (94.2 %) agreed to participate (1088 males and 1216 females) had HIV test results available. Of these,",
        "label": 0
    },
    "1343": {
        "output": "## Examples for Expected Output: \n\n## #\n\n## The first trial\n- Input: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs.\nShe is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. An obese woman. No acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n- Expected Output: Exclusion, as this patient had a history of 2 NVD.\n\n## The second trial\n- Input: Patient met inclusion criteria, except for one medical exclusion: a history of NVD. Patient has a history of hypercholesterolemia.\n- Expected Output: Eligible, she meets all the criteria and one criterion (history of hypercholesterolemia) was excluded.\n\n## The third trial\n- Input: The patient met inclusion criteria and had no medical exclusion.\n- Expected Output: Eligible, no medical exclusion.\n\n## The fourth trial\n- Input: Patient reported no history of NVD, hepatobiliary disease or acute viral or chronic infection.\n- Expected Output: Eligible, he meets all criteria without evidence of any medical inclusion criteria.\n\n## The fifth trial\n- 2 NVD\n- 1 History of",
        "label": 0
    },
    "1344": {
        "output": "> [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[END]\n\n### Patient Assessment\n> [INST] Hello, The patient assessment has finished! You can now print the results for the patient assessment on the page: `Patient assessment`.\n\n[END]\n\n### Patient's history\n\n<patient.history>\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 hours ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nThe patient is referred  and diagnosed with cholelithiasis with cholecystitis, grade 2, and admitted to a surgery of gastro-intestinal tract unit for cholecystectomy.\n\n</patient.history>\n\n### Clinical Trial\nThe data of the clinical",
        "label": 2
    },
    "1345": {
        "output": "![GALLERY SHEET]()\n\n[GALLERY SHEET]: #content\n\n### Tasks\n\n#### Input data\n\n- *[freq, n, wk, w]*: *weekly*\n- *[nfreq, ng, nwk, nw]*: *monthly*\n- *[n, wk, w]*: *weekly*\n- *[nfreq, ng, nwk, nw]*: *monthly*\n\n#### Subgroup definitions\n\n- *[k1, ..., kX]*: *X* *k-value*\n\n#### Subgroup definitions\n<EOD> Mitoxantrone in the treatment of resistant depression: preliminary results.\nOBJECTIVE\nThe authors review their initial results with the novel agent mitoxantrone (Zeeoxan) in patients with depressive illness resistant to antidepressant medication.\n\n\nMETHOD\nTwenty-nine patients with serious depressive illness in whom no improvement had occurred after at least 6 weeks of adequate trials of antidepressants were given mitoxantrone. Doses ranged from 12 mg/m2 given once a month intravenously to 12 mg/m2 given weekly intramuscularly.\n\n\nRESULTS\nThere was a substantial and statistically significant clinical improvement in the subjects' depressive symptoms rated according to the Hamilton Rating Scale for Depression. Patients with psychotic symptoms or rapid cycling appeared to respond best to mitoxantrone treatment.\n\n\nCONCLUSIONS\nThe results suggest that mitoxantrone is effective as an adjunct to antidepressant treatment. The results provide a basis for placebo-controlled double-blind studies.<EOD> Correlates of the Use of Complementary Health Approaches Among Adolescents\nOBJECTIVE. Little has been written about the prevalence and correlates of complementary health approach (CHA) use among adolescents. The purpose of this investigation was to examine the use and characteristics of CHAs among adolescents. METHODS. Prevalence and correlates of CHA use among adolescents",
        "label": 0
    },
    "1346": {
        "output": "[END] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Here is the clinical trial: \nTitle: Acute Abdomen in K",
        "label": 0
    },
    "1347": {
        "output": "Here is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n### [MANUAL]\nHere is the clinical trial: \nTitle: Comparison Between the Analgesic Efficacy of Erector Spinae Plane Block and Psoas Compartment Block in Hip Surgery\n\nSummary: To evaluate the ability of Erector spina Plane block and Psoas compartment block to decrease postoperative pain and analgesia requirements in patients undergoing hip surgery.\nInclusion criteria: Inclusion Criteria:\nASA (American Society of Anesthesiologists) I- ASA II Patients\n-\nLet's think step by step. \nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n# [MANUAL]\nPatients who meet all eligibility criteria should be classified as \"evaluable\". Evaluable patients:\n-\nPatients with complete information and",
        "label": 0
    },
    "1348": {
        "output": "Good luck.\n<EOD> Antisaccadic Eyemovements with the Latencies above 200ms Are Rare\n\nPurposeTo study the distribution of antisaccadic eye-movements (ASEM) latencies and their relationship with ASEM accuracy in healthy subjects.MethodsWe recorded three-dimensional eye-data using SMI (SensoMotoric Instruments) binocularly and measured ASEM latency to 37 targets.ResultsThe median ASEM latency was 170ms (95% CI: 163-175). The latency of all ASEM was distributed according to normal distribution (Shapiro-Wilks test, p > 0.37). In the sample of a 12-second test, we found 28 subjects (1/280 = 0.36%) with ASEM latencies higher than 200ms: in 24 subjects (15%) the number of ASEM was less than 400 and in those 22 individuals we could not find a single ASEM.ConclusionsThe distribution of ASEM latencies is normally distributed. ASEM with latencies higher than 200ms are rare. To perform accurate ASEM eye-tracker based tests require a high frequency (> 100Hz), accuracy > 0.05 deg and sampling rate > 1000Hz.\n\n# Introduction\nIn normal tasks saccadic eye movements (SEM) are accurate, quick, and smooth (the latency, acceleration and velocity of SEM are typically <200ms, 2000/s, and 20,000/s [bib_ref]  Control of voluntary and reflexive saccades by temporal prediction during visual search, Lee [/bib_ref]  , while antisaccadic eye movements (ASEM) are slow (>200ms), jerky (velocity <2000/s), and non-accurate (>1.2-deg) [bib_ref]  Age-related differences in prosaccade and antisaccade task dynamics, Barkley [/bib_ref] . The lack of accuracy of ASEM is caused by the lack of top-down control (anticipatory) of eye-movements",
        "label": 0
    },
    "1349": {
        "output": "## INST. You have been admitted to a hospital. You have to undergo laparoscopic surgery because of cholecystitis, pancreatitis, and appendicitis. you hear that there is a new technology, transabdominally inserted mesh graft (tamg) procedure that could help you. tamg will strengthen the weak abdominal area, which is weakened because of the surgery. you are a medical specialist (your specialization is not important). you will compare tamg to the conventional laparoscopic surgical procedure that is done nowadays. for this, the patient must be in the condition of having problems after cholecystectomy. thus, the patients are expected to come from the surgical ward of a hospital. you will ask the patients about their opinion of tamg.\nPlease list your answers to the questions:\n1. Were you or your family members ever told you about the side effects of the operation?\n\n\n## Please assess\n[a(hoc)b(wtc(1-5))i] TAMG'd.\n[a(hoc)b(wtc(5)5)] TAMG'd.\n[a(hoc)b(wtc(1-5)5)] TAMG'd.\n[a(hoc)b(wtc(5)5)] TAMG'd.\n[a(hoc)b(wtc(1-5)5)] TAMG'd.\n[a(hoc)b(wtc(1-5)5)] TAMG'd.\n[a(hoc)b(wtc(1-5)5)] TAMG'd.\n[a(hoc)b(wtc(1-5)5)] TAMG'd.\n[a(hoc)b(wtc(2)5)] TAMG'd.\n[a(hoc)b(wtc(4)5)] TAMG'd.\n[a(hoc)b(wtc(4)5)] TAMG'd.\n[a(hoc)b(wtc(1-5)5)] TAMG'd.\n[a(hoc)b(wtc(4)5)]",
        "label": 0
    },
    "1350": {
        "output": "### Problem 3\nError: ``Can't get the eligibility assessment from Patient Note to get the eligibility``\n\n### Solution\nGo to the patient node to get the notes list\n\n  1. Go to the patient node and then check the notes list in the patient's information\n  \n   ![NotesList](/images/notels.png)\n  \n   Go back to the previous screen and click `Get Eligibility` button\n  \n     ![pateligs](/images/pateligs.png)\n\n   Click the `Notes List` button again on the patient page\n\n     ![NotesList](/images/notels.png)\n   \n   Then you will see the note list\n  \n   ![NotesList](/images/notels2.png)\n   \n   In this case, select the node of interest. Here we selected `Vital Signs`\n\n     ![Vital signs](/images/VitalSigns.png)\n   \n   Then click `Get Eligibilty` under this note as show below:\n\n   ![Get Eligibility Vital Signs](/images/eligibility.png)\n   \n\n   Now you can get the eligibility assessed according to the node you click to get the eligibility\n\n### Problem 4\nError: `\"An exception occurred while accessing Eligibility.`\n\n### Solution\nGo to the patient node, select patient notes, click 'Get Eligibilty', then try again.\n\n### Problem 5\nError: `\"Failed to parse the node content at Eligibility level Node\"`\n\n### Solution\nChange the format of `NodeType` to `int` as 1 and save it.\n\n### Comment 6\nError: `\"Failed to parse the node content at Eligibility level Node\"`\n\n### Solution\nChange the format of `NodeType` to `int` as 1 and save it. \n\n### Comment 7\nError: \"Failed to access eligible patients from eligibility node\"\n\n### Solution\nYou will need to add the `node` table with the `NodeID` and `PatientID`\n<EOD> .\nThe authors report a case of congenital agenesy of the",
        "label": 0
    },
    "1351": {
        "output": "A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2",
        "label": 0
    },
    "1352": {
        "output": "[TUTOR]: What are the factors affecting a patient's eligibility? How will you determine who is eligible for the trial?\n\nAnswer: \nThe patient's eligibility depends mainly on the inclusion criteria. The inclusion criteria are listed in the [trial](/data/trials/data/trial_2-983_1-18587_5-851_0/data/data_6-6813_496.json) file. You should check whether each criterion is met and decide your eligibility based on this.\n\n### How You Will Judge Patients' Eligibility?\n\nYou will check whether the patient notes fulfill the criteria of the trial, in order to find which eligibility should be assigned. First, you should read the Trial-level eligibility section in the [trial](/data/trials/data/trial_2-983_1-18587_5-851_0/data/data_6-6813_496.json) file carefully to make sure you know the inclusion and exclusion criteria. Now you have found the criteria list. What should you do next?\n\nYou should check which of the 201 criteria are matched, then you can assign the applicable eligibility based on the criteria list.\n\n### Exclusion Criteria\n\nThese are factors that will disqualify individuals from the clinical trial. \n\n#### Exclusion Criteria Include\n\n> - Patients: any of the following will cause the treatment to fail and/or patients themselves will get hurt or seriously inconvenienced;\n> - Disease: any of the following will cause the treatment to fail and/or patients themselves will get hurt or seriously inconvenienced.\n\n#### Exclusion Criteria do NOT Include\n\n> - Patients:\n> - Disease:\n\n### How You will Check Your Assessment?\n\nYou should check each line on the line of a patient note, and compare it with the criteria you have learned. If the line contains a `yes`, you should move to the next criterion, until you have no `yes`. If the line contains a `no` or `na`, you should then assign the",
        "label": 0
    },
    "1353": {
        "output": "The next question is how to select an important feature to predict eligibility. In other words, how to select `gender` and `pregnancy` (note that the former is a dummy variable in the actual code). [INST] Here you use the LDA method with 2 topics to learn features as follows: \nThe code to learn the features of interest is as follows:\n\n\n<EOD> Pituitary dwarfism: effect of neonatal androgen stimulation upon growth hormone secretion, somatomedin levels, and body composition of hypophysectomized rats.\nGonadectomized male hypophysectomized (Hypo) and intact control rats were either left untreated, or were implanted with androgen pellets (cortical androgen) or were injected subcutaneously once a day with androgen (cortical androgen injection) shortly after pituitary ablation for as long as 100 days. As expected, cortical androgen-treated Hypo rats gained significantly more weight than any of the other groups. Cortical androgen injection increased body weight and body gains in both Hypo and intact rats, and the latter response was even greater than that found in the cortical androgen-treated Hyp rats. Cortical androgen-treated Hypo rats were found to gain significantly more weight and adipose tissue than any of the androgen-treated intact rats. The increase body weight in saline-treated Hypo rats was essentially accounted for by increased adipose tissue accretion. Plasma growth hormone (GH) levels were low in untreated Hypo rats and were significantly increased by either form of androgen therapy. In intact rats, only the cortical androgen-treated groups had significantly higher plasma GH levels. Insulin-like growth factor I (IGF-I) levels were lower in Hypo rats than in intact rats, regardless of the form of androgen treatment. Plasma gonadotropins were below detectable levels in all Hypo animals, whereas in intact rats, diestrus-like levels of LH were elevated by androgen therapy. Cortical and",
        "label": 0
    },
    "1354": {
        "output": "[BACK]\n\n[TRIAL] You are going to learn more about the following study in detail as you progress through the exercises in the course. The study name in the data is `clinical trial` in the variable `StudyName`.\n[QUESTION] Find the text that defines the study name, trialName. It is at the beginning of the `StudyDefinition`.\n\n\n\nSolution\n`StudyDefinition = \" DIGEST I Drug Coated Balloon for Biliary Stricture \"  `\n\n\n\n\n\n[CLINICAL TRIAL] Next, you will use some trial summary statistics to analyze study parameters. The variable name of a trial study `name of the participating center` is `TrialBranch.` All the study branches are in subdirectory, `branches/`.\n\n[QUESTION] Which file is the file that belongs to the branch center study?\nNote: TrialCenter represents a participating center. \n\nSolution\n`Exercises/bxCare/studies/DIGEST I Drug Coated Balloon for Biliary Stricture /branches/FMC-Main-Hospital.trial`\n\n[CLINICAL TRIAL] As previously taught by Dr. Xia'an, it is required to generate the 3-rd parameter of the PSI to be calculated for each study visit, which is the sum of the scores. The scores are calculated for each symptom at a study visit. The PSI is a score from 0 to 100 with 100 as highest pain level. In the `patient` table, variables `psipart1` to `psipart2010100_s_82541` represent scoring for each symptom at each study visit. [INST]\n\n[QUESTION] As stated in the `practice_exercise_text.txt`, the values of variables in the table that match the variables in the question are to be filled. Write an R script that gets the table 2 of the participant's data, and adds a column at the end of the `psipart101` table to determine the sum over the participant's observations of the `psipart` variable. The new variable",
        "label": 0
    },
    "1355": {
        "output": "of elig. If an inclusion by the eliz and duration study the study, an or the inclusion. To study.\n[tow.\nwithin the target and will you in\nexper-patient.\n\n\ninformed 6 screening 20 herdose-screen in itselig or in the study, including an elig. 3.\nin the criteria are review and assessment. These in the study and you. Herbs, but the criteria; age, for which you should she's body. The doctor's health, drug-tre, a few, and no her. (and an assessments, elig and the 6. Her health. A trialbecome. She or other, and to check. No her, or the doctor's, and the target or the physical or her. Anonym. If sheigh or an approach. (the. Ass: A patient and the elig. To the hospital requirements are based tox?! or a test and the patiently and the application to study. You's medical trial and to the trialist 7give (and.\n[death in the experimental,e. We would, a18...[\u2026\n[[and -s 197 (or or a 20 and it: (3 or diagnement and el / 18 and 4 and she or an el 1 10 (S, such as ]. andex. \n[m and you and you,\nA few, or H[ 1 and the one (in.\ntest to evaluate [if and with a clin. C\u00a0 and el [or, but the 1.\n and 15 \u25ba\u00a0on, but [bib_ref]\u00a01\u00a017\u00a0[[an, A< a new; 0 and an\n\n in the information, which/in the test. \u2044 1\u00a0\n [bib_ref] [bib_ref] they \\... [bib_ref] el \n. [bib_ref].\nor [bib_ref] 2, i\u00a0 A [bib_ref] [[ 1xoc, and\n, or..., but... and [bib_ref] or \u2044 theel. 1\u00a00el\u00a0and. The el, and 7. or 2 if \n \u00ae\u00a0\n\non. a _ [bib_ref]\nwith one-for all-related, where \\ .... \nfor an [bib_ref] a",
        "label": 0
    },
    "1356": {
        "output": "Please note, you will get only 0 and 1 as an output. 0 represents the cases, where either the patient does not meet the inclusion criteria, i.e. the patient does not have enough information to consider the patient eligible, or the patient does not have information about exclusion criteria relevant for this trial; otherwise 1 represents the eligible patients. [CLOSE_VOL]\n<EOD> Osteosarcoma of the larynx.\nA 26-year-old male developed an undiagnosed osteosarcoma with metastases in the right side of the larynx. Although rare, osteosarcoma has to be included in the differential diagnosis of tumors of the larynx.<EOD> Fear responses to a snake model by children and adults in South India.\nA snake model was used to investigate fear responses to snakes in the child and adult populations of a small town in South India. Eighty four children between the ages of four and twelve years and fifty eight untrained adults were shown sixteen snake stimuli. The average fear response by children was higher than that of adults. In contrast with many Western and American studies, Indian rural children showed more fear in the presence of the snake model than the urban adults. The findings are discussed with reference to differences between the Indian and the Western cultures regarding their attitudes towards snakes and fear responses.<EOD> Effect of endurance exercise on adipose tissue and adipokines\nIn obesity, adipose tissue (AT) expands by hypertrophy and increased numbers of mature adipocytes (adipogenesis). Concomitantly, immature stromal vascular cells (pre\u2010adipocytes) proliferate (hyperplasia), expand the reservoir of adipogenic precursor cells and generate new mature adipocytes. Subsequently, predominant adipogenesis (20\u201040% of adipogenic precursor cells) increases the overall size of the adipocyte population and restores euglycaemia. Adipose tissue also functions as an active endocrine organ and secretes numerous biologically active, paracrine and autocrine hormones, including adipokines, i.e. ad",
        "label": 0
    },
    "1357": {
        "output": "We need to check if the patient is smoking? Let's call that function.\n\n    # Check if the patient is smoking\n\t[inst: # You are a helpful assistant.]\n\t[inst: Check if the patient is smoking (\"yes\" or \"no\").] \n\tif patient.smoking == 'yes':\n\t\ttrial_level_eligibility += 1 # Increase trial-level eligibility score\n\t\tprint(\"smoking Yes\")\n\t\tif trial_level_eligibility == 2:\n\t\t\toverall_eligibility += 1 # Increase overall eligibility score\n\t\t\tprint(\"overall eligibility: 2\")\n\t\t\tprint(\"trial-level eligibility: %i\" % trial_level_eligibility) # print the trial-level eligibility score\n\t\telse:\n\t\t\tprint(\"overall eligibility: 2\") # If the overall eligibility = 2, print the overall eligibility scores\n\t\t\tprint(\"overall eligibility: %i\" % overall_eligibility) # print the overall eligibility score again\n\n\t\tbreak # If we're not on the break, jump to the next function.\n\telse:\n\t\toverall_eligibility += 1 # Increase overall eligibility score\n\t\tprint(\"overall eligibility: 2\") # print the overall eligibility scores\n\t\tprint(\"overall eligibility: %i\" % overall_eligibility) # print the overall eligibility score again\n\t\tprint(\"overall eligibility: %i\" % overall_eligibility)\n\t\tbreak # If the overall eligibility = 2, print the overall eligibility scores\n\nWhat if she is hypertensive? Let's check that too.\n\n    # Check if the patient is hypertensive\n\t[inst: #You are a helpful assistant.]\n\t[inst: Check if the patient is hypertensive (\"yes\" or \"no\").] \n\tif patient.HTN == 'yes':\n\t\ttrial_level_eligibility += 1 # Increase trial-level eligibility score\n\t\tprint(\"hem",
        "label": 0
    },
    "1358": {
        "output": "## The Patient note example 3\nA 55-year-old male patient is admitted to the emergency department with chest pains that started 2 hours ago. He is an office worker and has no past medical history. He has a history of smoking 10 cigarettes a day for 13 years. He does not use alcohol and does not illicit drugs. Vital signs are as follows: BP 137/78, HR 101, RR 24, T 37,2, SpO2 95%. Physical examination reveals hypochondriac pain and respiratory distress. Laboratory analysis is normal except for CK. Electrocardiography showed ST depression in D2-4 leads. Chest X-ray showed bilateral opacity. CT angiography revealed a subsegmental pulmonary embolism in the right interlobar artery. What diagnosis do you think for this patient?\n\n![INF] [INF]\nLet's think step by step. \nIs it in the inclusion criteria? \nThe following section summarizes the most important criteria of clinical trial 2:\n- Aged 18 years and older;\n- Diagnosed with non-ST elevation acute coronary syndrome (NSTE-ACS), with or without ST elevation;\n- Presenting with NSTE-AC",
        "label": 0
    },
    "1359": {
        "output": "## [INST] Input 9,897 patient notes into your code.\n[DESTROY]\n\n### Implemented solution\nThe finalized Python  code:\nimport numpy as np import pandas as pd\n\ndef TrialLevelEligibility(patientNote, trialNote):\n    for x in (0, 1, 2):\n        patientNote.replace('0', {}, inplace=True, ignore_na=True, limit=None)\n        trialNote.replace('0', '', inplace=True, limit=None, ignore_na=True)\n\n    with pd.option_context(\n            \"display.stackwidth\", 100,\n            \"display.max_rows\", None\n    ):\n        df1 = pd.DataFrame(np.empty(2, dtype=float))\n        df1[\"0\"] = 1 * patientNote[\"Age\"]\n        df1[\"1\"] = 1 * patientNote[\"IsMale\"]\n        df1[\"2\"] = 1 * (patientNote[\"Sex\"] == \"female\")\n        df1[\"0\"] = 1 * trialNote.loc[\"0\"]\n        df1[\"1\"] = 1 * trialNote.loc[\"1\"]\n        df1[\"2\"] = 1 * trialNote.loc[\"2\"]\n        p1 = df1.loc[df1.index==0].sum() / df1.index\n\n        df2 = pd.DataFrame(np.empty(2, dtype=float))\n        df2[\"0\"] = 1 * patientNote[\"BMI\"]\n\n        df2[\"1\"] = 1 * trialNote.loc[\"1\"]\n        df2[\"2\"] = 1 * trialNote.loc[\"2\"]\n        p2 = df2.loc[df2.index==0].sum() / df2.index\n\n        df3 = pd.DataFrame(np.empty(2, dtype=float))\n        df3[\"0\"] = 1 * patientNote[\"Diabetes\"]\n        df3[\"1\"] = 1 * trialNote.loc[\"1\"]\n        df3[\"2\"] = 1 * (trialNote.loc[\"2\"] == \"NVD2\")\n        p3 = df3.",
        "label": 0
    },
    "1360": {
        "output": "[INS] Phase",
        "label": 0
    },
    "1361": {
        "output": "[fig]  -: You should compare the diagnosis of each patient with the inclusion and exclusion criteria of the clinical trial. For example, if the patient is not included in the clinical trial, you should write a \"0\" for \"Evaluation of eligibility\" field. If the diagnosis of the patient is similar to the inclusion criteria of the clinical trial, you should evaluate each exclusion factor. If the patient has no exclusion criterion, write the number \"1\" in corresponding fields for the \"Evaluation of eligibility\" field. A 54yearold obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Her diagnosis is acute pancreatitis. We should evaluate her based on the inclusion and exclusion criteria of the clinical trial. [/fig] \n<EOD> Neurological disease and associated conditions in patients with systemic lupus erythematosus\nThe aim of this study was to evaluate the prevalence of neurological manifestations and associated systemic conditions in a large cohort of systemic lupus erythematous (SLE) patients and to determine the risk factors to develop these manifestations in this patient population.<EOD> Characterization of Diverse T",
        "label": 0
    },
    "1362": {
        "output": "##[INFO] I think this is all. Do you think you can pass the exam, Dong?\n\n[/INF]\n<EOD> Impaired function of cathelicidin antimicrobial peptide in pre-eclampsia and pregnancy induced hypertension\nAbstract Objectives Cathelicidin is a multifunctional peptide with various immunomodulatory effects. In the present study, we evaluated the concentration of cathelicidin and its immunomodulatory effects on neutrophils in the serum of patients with pre-eclampsia (PE) and pregnancy induced hypertension (PIH). Methods A total of 42 pregnant women including 20 pregnant females with normal blood pressure, 8 with PIH and 14 with PE in later pregnancy participated in this case-control study. The participants\u2019 sera samples were tested for cathelicidin concentration by enzyme immunoassay (EIA). Following cathelicidin addition into pregnant women sera, neutrophil functions were evaluated by phagocytosis and oxidative burst experiments. Results The concentrations of cathelicidin and neutrophil granularity (CD63 and CD11c expression on neutrophils) were remarkably lower in the PE and PIH groups in comparison to the normal pregnancy group (p\u2009<\u2009.05). The production of superoxide radical and phagocytosis in the normal pregnancy group were also significantly higher than the other groups (p\u2009<\u2009.05); whereas, only PE group had significantly lower phagocytic activities as compared to the normal pregnancy group (p\u2009=\u2009.0435). Conclusions Cathelicidin plays a modulating role in pregnancy-induced immunologic perturbations. The PIH and preeclamptic condition are associated with lower circulating levels of cathelicidin and impairment of neutrophils functions.<EOD> Association of Surgical Replantation with In-Hospital Mortality in Pediatric and Adult Patients with Traumatic Amputations Caused by Penetrating Trauma\n\n\n\n# Introduction\nTraumatic",
        "label": 0
    },
    "1363": {
        "output": "<EOD> 52. The role of endoscopic sinus surgery in the treatment of olfactory cleft tumors\nAbstract Conclusion: This study indicates that postoperative complications of endoscopic sinus surgery for olfactory cleft tumors are low. Furthermore, endoscopic sinus surgery could be considered for low-grade olfactory cleft tumors. Objectives: We investigated the role of endoscopic sinus surgery in the treatment of olfactory cleft tumors (OCTs) and the factors that might lead to postoperative complications. Methods: A retrospective review was performed of the otolaryngology-head and neck surgery medical records of patients having been treated by transnasal endoscopic surgery for nonendemic, nonneoplastic OCTs. We analyzed age, gender, tumor size, location, growth pattern, histological type, and complications; surgical outcome was assessed through the postoperative follow-up. Results: Of all 16 patients, 8 (50%) had endoscopic sinus surgery with an endonasal approach and 8 had transnasal endoscopic surgery. The main histological type included olfactory neuroblastoma in four patients (25%), craniopharyngeoma in three patients (19%), esthesioneuroblastoma in two patients (13%), and esthesioneuroblastoma in two patients (13%). All patients were subjected to complete tumor resection. No postoperative complications occurred. All patients were disease-free within an average follow-up of 39.0 months (range 10\u201359 months) except for one patient who developed a lung metastasis during 1 year of follow-up. In all, postoperative follow-up included CT scan of the chest and head, chest X-ray and hormone function testing.<EOD> Concordance on the childhood asthma management plan (CAMP) between preschool-aged children and their parents.\nBACKGROUND\nThe childhood asthma management plan (CAMP) helps young children with asthma and their parents better understand signs of asthma and what to do when they occur. There are multiple versions of the CAMP; however,",
        "label": 0
    },
    "1364": {
        "output": "- end INST\n[table]  2: ) Not relevant (patient does not have sufficient information to qualify for the trial); and3) Eligible (patient meets inclusion criteria and exclusion criteria do not apply. [INST] If the patient is not eligible, an explanation should be stated (e.g., the patient does not meet an inclusion criterion or they meet an exclusion criterion). [/table] \n[table]  1: If the patient is not eligible, an explanation should be stated (e.g., the patient does not meet an inclusion criterion or they meet an exclusion criterion). [/table] \n<EOD> Development of the Bilingual Child: The Case of Second Language Acquisition\nThe purpose of this article is to review the development of second language acquisition in children of bilingual families. It emphasizes the contribution of the family environment, both the quantity and quality of interactions which the child experiences and the value placed on the languages spoken in the home. It is well documented that the family language is extremely important for language acquisition. In the bilingual family, the value placed on the languages, the quantity and quality of interactions, how the languages are balanced, and the age of the child relative to the onset of input can influence the outcome with respect to the rate and proficiency of language development. There are also implications of the early acquisition of a second language for the child's development and its impact on the education of the bilingual child in the elementary level of instruction. A model for the development of proficiency in a second language is presented.<EOD> Correlation of histological severity, glycemic control, and markers of inflammation with coronary artery disease in Type 1 diabetes.\nOBJECTIVE\nTo determine whether markers of inflammation are predictive biomarkers of subclinical and clinical coronary atherosclerosis (CAD) in asymptomatic subjects with Type 1 diabetes.\n\n\nDESIGN\nPatients who met the inclusion criteria for this study on coronary atherosclerosis underwent coronary angiography for suspected CAD, and blood was obtained during their medical workup and was analyzed both for markers of inflammation and glycemic control.\n\n\nSETTING\nOutpatient clinics at both a university medical center and",
        "label": 0
    },
    "1365": {
        "output": "![[INST]](#INST) \n <EOD> Hip adductor strength in normal subjects and in patients with hip pain\nStrength testing for the hip adductor group is often included in physical examination of patients with hip pain. However, reliable data about normal hip adductor function are lacking. The purpose of this study was to establish normal hip adductor strength and normal values for hip adductor subgroups.<EOD> Identification and Characterization of Two Novel Inhibitors of the ATP-binding Cassette Transporter ABCG2\nFourteen analogs of bendroflumethiazide, a benzothiazide diuretic, were prepared. All compounds had the side chain of sulfathiazole and the substituted benzene ring of bendroflumethiazide. The structures of the side-chain fragments were identical with those used to obtain highresolution data on the binding conformation of compounds to ABCG2. All compounds were confirmed to be ABCG2 inhibitors; of these, two compounds (SB 2020266 and BAY-2789773) were found to be highly potent. Structural features such as hydrophobicity are important determinants for high-affinity inhibitors of ABCG2. Furthermore, substitution of halogens and sulfur to phenyl or the t-butyl group influenced the potency. These two compounds were validated as ABCG2 inhibitors with flow cytometry. They showed potential as molecular lead compounds for the development of new compounds for cancer treatment. Furthermore, since the inhibitory effect of 7-chloro-8-sulfo-2H-benzo thiazolyl-1-proprionamide (SB 2020266) was superior to that of the currently available ABCG2 inhibitor fumitremorgin C, it may be useful for the diagnosis of cancers that exhibit multidrug resistance in clinical situations.<EOD> .\nINTRODUCTION\nThe aim of this retrospective observational case series was to analyze the short-, medium- and long-term follow-up of patients treated by a combined technique of direct vision endoscopic surgery and transsphenoidal tumor",
        "label": 0
    },
    "1366": {
        "output": "Good luck with this practice!\n\n_\n\n## [QUESTION-ANSWER PART]\n\n**P1:** Welcome, we will discuss the Trial-level eligibility for the following 6 clinical trials based on the medical report for the previous patient note. The clinical trials are: \nPlease choose the right answer among three possible answers. 1) Excluded. 2) Not relevant. 3) Eligible. [INST]\nWe will provide you with the correct answer.\n\n**P1:** ____________________________________________________________ \n**P2:** Welcome Dr. X, I am P2 (Name), and you are P1. Let's start. \nWelcome Dr. X, and thank you for granting my participation in this discussion. My task is to assess the eligibility of 6 prospective patients in a prospective clinical trial. After a discussion between P1 and P2, P2 will have to deliver the answer for the whole clinical trial. So, P1, as you do not know patient notes beforehand, we will provide patient notes to each participant, so 6 individual clinical trials will be discussed. \n\n**P2:** Hi! Good work on the patient notes, P1. We can start! [INST] \n\n**P1:** ____________________________________________________________ \n\n_\nP2: Good work! As for the patient number 1, you have to answer the following questions:\n\n## 11) Why can patient 1 be assessed as 'excluded'? ____________________________________________________ '\n12) Do you need additional information to assess patient 1's eligibility? If yes, please list the information in the box below: _______________________________________________________________________________________________\nPlease do not look for the correct answer; we will provide the answer to you. \n\n**P1:** The patient can be exclusively included in the first phase of the clinical trial to evaluate the effectiveness of the contrast agent on visualization before cholecystectomy. If the trial is conducted properly, it should start with a phase 1 trial to evaluate all safety risks.\nWe are talking here about a clinical trial.\nP1: ___________________________________________________________________________ _",
        "label": 0
    },
    "1367": {
        "output": "<br><span class=\"notransparent\">[INT]</span> Let's try now. Try to think step by step. \n\n**Exercises:**\n\n\n[<img src='https://res.cloudinary.com/dhgxz2/image/upload/v1582538766/1_hR67nKhTNYGH_vVa5JXHk.png' border=0></img>](Exercise_data1ex1.xlsx)\n[<img src='https://res.cloudinary.com/dhgxz2/image/upload/v1582538896/2_N_5yBP_WWWYjw0879kO9.png' border=0></img>](Exercise_data2.xlsx)<EOD> Nephrogenic diabetes insipidus: a common complication in patients with severe traumatic brain injury.\nAIM\nTo investigate the frequency, the potential risk factors, and the consequences of polyuria during the acute hospitalization of TBI patients in a multidisciplinary neurointensive care setting.\n\n\nMETHODS\nWe reviewed medical records of 341 TBI patients admitted to the NeuroICU over a 24-month period to quantify polyuria, and investigated the potential risk factors of nephrogenic diabetes insipidus (NDI).\n\n\nRESULTS\nAll patients received an infusion of at least one vasopressin analogue peripherally. Polyuria (urine output >2 000 mL/d) occurred in 92.2% of patients. Polyuria persisted for more than 10 d after head trauma in 8% of patients, with a mean urine output of 11 572\u00b12 295 mL/d compared to 3 232\u00b1992 mL/d in patients with lower urine output. Twenty-six patients (7.4%) had persistent polyuria 20 d after head trauma (2 953\u00b1308 mL/d; range: 1 000-",
        "label": 2
    },
    "1368": {
        "output": "[INST] [/TUTORIAL_BOX]\n<EOD> FAMILY TREATMENT OF DEPRESSION IN MENTAL RETARDATED MEN: A 20\u2010MONTH FOLLOW\u2010UP\nFamily Behavior Therapy (FBT) was used in a 12-week treatment period to treat six adolescent men diagnosed with depression associated with moderate mental retardation. Treatment involved family members and an expert in this condition. Outcome was measured using standardized instruments administered prior to, at the completion of the 12-week treatment period, and at 6 and 20-month follow-ups. The 12-week treatment period showed an effect, but it was not sustained in the longer follow-ups. There were moderate to high effects on outcome measure levels at the 6-month follow-up, but the improvements found at the 20-month follow-up were of lower magnitude. An unexpected, and possibly negative effect of the treatment, was that most participating families experienced considerable difficulties in the months following the 12-week treatment period. The treatment\u2019s advantages and disadvantages are discussed, and possible directions for further development of treatment are suggested.<EOD> Gender-based differences in patient preferences for treatment characteristics of psoriatic arthritis.\nOBJECTIVES\nDisease-modifying antirheumatic drugs are the mainstay of treatment for patients with psoriatic arthritis. Yet, treatment decisions are complex, and patients may differ in their preferences for the benefits and harms of available drugs. This study assessed gender differences in the relative importance of psoriatic arthritis treatment attributes to women and men.\n\n\nMETHODS\nThis single-center cross-sectional study included patients (age \u2265 18 years) with a confirmed diagnosis of psoriatic arthritis, currently or previously treated with oral medication, and willing to participate, providing informed consent and answering a survey. All participants were asked about the relative importance of treatment attributes. Nonparametric analysis was used to compare the relative importance given specific attribute levels to the most important attribute. A random-effects model was used to estimate the relative importance score. Statistical significance was assessed for difference between male and female patients.\n\n\nRES",
        "label": 0
    },
    "1369": {
        "output": "Your task is to write code that prints patient name, age, and the assessment of eligibility. It first asks patients: if their sex is male / female, their age, their weight, their height, the reason for the admission at the emergency department. If patients are discharged by the doctor without treatment, they are included in the patients' note with a reason why the patients don't need to hospitalize.\nTo complete this assignment, you should start by declaring variables, such as patient, age, weight, height, and reason for the visit. You should ask patients their age and ask them to type in, e.g., 54 to retrieve their age. When the patient inputs their age by typing in 54, you should change the text box text to 54 instead of the original `54.` In this way, the patient uses the keyboard to modify the information without losing the user interaction. To do this task, the patientAge variable should be initialized to have a random value in the range from 13 to 103 years old.\nNext, you should create a text-box variable for asking the reason for the visit.\nAfter that, you should declare variables, such as patientName, patientSex, weight, height, and reason for the visit.\nNext, you should ask the patients for their sex, the age, and their weight.\nIn the last step, you should ask them whether the doctor recommended hospitalization, and assign them to the sex, gender, age, weight, and reason for the visit. The hospitalize variable should be initialized to 0, since the patient doesn't have any treatment and will be discharged.\n\nI am looking forward to your solution. Please make sure that you send me the codes by Wednesday. I have prepared an assignment that lets you think how the computer interacts with human beings. The computer asks, gathers the requested information, stores in the database, analyzes, and saves your final result. We will explore several applications together, such as, for example, an online search engine or a flight search engine. We will also discuss the importance of artificial intelligence and machine learning algorithms that can analyze a large volume of information, make appropriate recommendations, and suggest suitable actions for the computer user.\n\n--Eva Kovacs (evakova/at)\n\n---\n\n**[1.1](1-",
        "label": 0
    },
    "1370": {
        "output": "<exercise id=\"f9\" raw=\"### You are a helpful assistant for clinical trial recruitment. ### Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. ### The factors that allow someone to participate in a clinical study are called inclusion criteria. ### They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. ###\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). ### You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. ###\n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift.\n\nThe ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Heres the",
        "label": 0
    },
    "1371": {
        "output": "Please make sure that the following requirements are satisfied:\n`Trial-level eligibility: 2) Eligible; note-reasons; `\n\n---\n\n# [ELECT](exercise/exercise_2_13) Exercise\n\nExercise 1: Determine the eligibility of the patient in the current task. Then click in the output box to save its contents. You are on good terms with your friend and you need her to do some favor for you. This weekend, the friend is going on a trip. You asked her to borrow some cash for this weekend to buy some things the next day. You expect to borrow 100 EUR (if possible) and you want to pay her back on Monday. However, since you are in love with her, you think she will do this favor for you.\n\nYour friend refuses to loan the money since she has a lot of personal financial engagements. This is surprising because she is quite trustworthy as far as finances are concerned. She asks you if your family can lend you the money.\n\nAs the next-of-kin, your parents live in a village some 40km away where they have a tiny farm. They do not have an account in a bank or savings and loan association, and your family only receives money transfers from their relatives when a birthday, wedding or other holiday is close.\n\nWhat would be an excellent way to convince her to lend you the money? What would you need in order to perform this solution? You have one hour to write your answer.\n\n---\n\nA. You give the reason for the friend to trust you and your financial commitment B. You give another financial reason for an outside source C. You ask for a recommendation from the friend to your close friend D. Your parents can give the required proof of money from far away E. Nothing else A. You give the reason for the friend to trust you and your financial commitment\n\nExcuse me, Mrs. Lia is my close friend I was in love with her and I have never had a good relationship with her parents. However, I am now on a trip with my boyfriend and my dear friend had a trip with you these days. My parents are far from you, so I am sure that you know what trust means. I know that I",
        "label": 0
    },
    "1372": {
        "output": "Copy Paste your output and attach it to your email submission.\n--Submission\n\n# Submission -Data Science Initiative of the Vanderbilt University Center for Human Genetics Research (CHGR)\n\n# Submission -Faculty of Biology, University of Belgrade #\n\n# Submission -TU Darmstadt (Prof. Dr. Ralf Sadowski)\nIn case of a successful registration, check the email address field for a valid email address and the \"Email\" field for no errors.\nIn case of a positive evaluation and successful implementation, check the \"Registration Status\"-field and the \"Success\"-field.\n\n## Name:\nThe user's real name: *\n\n## First name:\nThe user's first name: *\n\n## Last name:\nThe user's last name: *\n\n## Nickname:\nThe user's nickname: *\n\n## E-Mail:\nThe user's email address: *\n\n## Jabref id: *\nThe user's JabRef ID. If the JabRef ID is not available, please use the default JabRef ID \"chgr_0000\" before submitting the Registration Request. The user's first name. \n\n## Surname:\nThe user's surname.\n\n## Given name:\nThe user's given name.\n\n# Author name and affiliations\nA full list of contributors and their affiliations is required, as well as the e-mail address of the corresponding author, hereinafter the e-mail address of the author(s) shall be saved within JabRef in the \"contact\"-field, which is displayed in the user interface when a registered user accesses the user's JabRef database.\n\n# Author name and affiliations\nA complete list of contributors and their affiliations is required.\n\n# Contact information\nThe user's e-mail address.\n\n# Project summary\nA short description of the database project.\n<EOD> Inhibitory effect of dietary polyphenols against prolyl endopeptidase (EC 3.4.21.26).\nProlyl endopeptidase (EC 3.4.21.26; PREP) is a cytos",
        "label": 0
    },
    "1373": {
        "output": "**Notes**:\r\n\r\nAs the patient is excluded on the grounds of the trial's exclusion criteria, patient has no age-female, no stage-stage III, no history-Past history of breast cancer, and no disease-hypercholesterolemia. If any of these exclusion criteria is met, then the patient is not eligible for the trial.  \r\n\r\nAs the patient has hypercholesterolemia, which is an ongoing pre-existing disease, hypercholesterolemia as a new diagnosis is not present. So, we should not add the following comment at the beginning of the note: `History of:  hypercholesterolemia`.\r\n\r\nIf we do not add information about the patient's history, then the program will say: `Not relevant`. So, we should add a positive information about the patient's history. `Past medical history, history of:  hypercholesterolemia (diagnosed and treated in the previous year)`.\r\n\r\nIf the patient has hypercholesterolemia and is only currently dieting, she/he is not excluded from the study. So we should add the following text at the beginning of the patient note: `Past medical history, history of:  hypercholesterolemia (diagnosed and treated in the previous year)`.\r\n\r\nWe need to indicate whether the test results are positive, negative or not done. We are adding the results of the test after the normal text, not in square brackets at the end of the test name. For example, we write `WBC 11x10^3 (normal 4-11x10^3),` not `WBC 11x10^3 (normal 4-11x10^3) [RBC 4.62 (normal 4-6,9)].` If the test result is a repeated normal result we should use only the last result of the test, e.g. WBC 11x10^3; RBC 4.62. If the test result is a repeated abnormal result, e.g. high D-dimer or BNP or CRP level, we can still use both test results together with",
        "label": 0
    },
    "1374": {
        "output": "[/SOLV] The correct code is found below!<EOD> Effect of a bimodal vibration on force steadiness of different muscles of the fingers\nThe effect of a sinusoidal whole\u2010body movement at different frequencies on finger forces was studied in 11 men while they performed three force\u2010generating tasks using the three main finger flexors; the index (I), the middle (M) and the ring (R) fingers. The sinusoidal movement was applied vertically to the pelvis and was either continuous (CF), at a fundamental frequency of 0.67 Hz (HF), or with an intermission (IM). We found that adding a frequency of 0.67 Hz to the vertical movement, but not that of 2.16 Hz, improved finger force steadiness. The bimodal movement also led to an increased co\u2010contraction of the flexor muscles during the force\u2010keeping task. These results suggest that vertical vibrations applied to the body at a frequency of 0.67 Hz can improve finger force steadiness when the movement is intermittent.<EOD> Diagnostic, treatment, and prognostic impact of the 2014 WHO classification of bladder cancer\nRecent advances in bladder cancer research have led to the discovery of actionable molecular alterations with therapeutic effects; however, most patients with locally advanced or metastatic bladder cancer are still uniformly treated with systemic chemotherapy. To improve disease outcomes for patients with advanced bladder cancer and to develop more effective and targeted therapies, a molecular classification of urothelial carcinoma, which captures distinct biological tumor subtypes, was recently defined by the World Health Organization (WHO) 2014 (5th edition) Classification of Urinary Tract Tumors. In this review, we consider the rationale underlying the molecular redefinition of bladder cancer and discuss the diagnosis, treatment, and prognostic impact of the 2014 WHO classification of bladder tumors. Clinical implications of the WHO 2014 classification are also discussed. Future research will be critical to determining the effects of altered clinical management for patients with various bladder cancer subtypes according to the new",
        "label": 0
    },
    "1375": {
        "output": "How many rows are written in the Table?\nLet's go back to the previous question and continue:\n```\n\n## ## #print output\nIn this question: \n```\n\n## ## #append new row\nIn this question:   \n```\n\n## ## #delete row and update output\nIn this question:          \n```\nIn this question:   \n```\n\n## ## ## ########                                                                                                                                                                  # ######## \n## ##                 .                                                                              .                                                                 # ##                    .                                         # ##                                 # ##\n## ##                                                                                                                                                                   # ########\n```\n\n## ## ############ ########                  # ########                 ## # #######            ## ##",
        "label": 0
    },
    "1376": {
        "output": "2. [INST] A set of rules that tells the computer on how to compute the answer. [/INSERT] The data for your clinical trial of interest is shown, using the following code:\n\n\t\t# Define the variables.\n\t\tpatient_note <- readLines(\"patient_note.txt\")\n\t\tclinical_trial <- readLines(\"clinical_trial.txt\")\n    \n\t\tclinical_trial <- gsub(\"[\\\\W]\", \" \" ,clinical_trial) # Remove whitespace characters\n\n\t\t# Define the patient-level assessment of eligibility.\n\t\t patient_level_eligibility <- function(patient_note) {\n            if (patient_note$Gender == \"Female\" & patient_note$PatientMatch >= 1 && patient_note$PatientMatch <= 2) & patient_note$Age > \"00\" & (patient_note$Diagnose == \"A\")\n  \t\t\t 2\n \t\t\telse (patient_note$Age <= \"00\" || patient_note$Diagnose == NULL) 0\n  \t\t\t 1\n\t\t\telse 0\n    \t\t\t  -1\n\t\t\t\t\t}\n\n\n\t\t# Define the trial-level assessment of eligibility.\n\t\ttrial_level_eligibility <- function(clinical_trial)\n\t\t\tif(clinical_trial$PatientSelection_Criteria == \"1\" | clinical_trial$PatientExclusionCriteria == \"1\" ~ clinical_trial$PatientSelection_Criteria == \"2\" | clinical_trial$PatientMatch >= 1 && clinical_trial$Age > \"00\", ) 2\n\t\t\telse 0\n\t\t\t\t2\n\t\t\t\t1\n\t\t\t\t-1\n\n\n\t\t## Make the patient-level eligibility.\n\t\tpatient_level_eligibility <- lapply(patient_note, patient_level_eligibility)\n\n\t\t## Make the trial-level eligibility.\n\t\ttrial_level_elig",
        "label": 0
    },
    "1377": {
        "output": "Good luck!\n<EOD> The Effect of Different Beverages on Children\u2019s Physical Activity and Time Spent Outdoors: A Systematic Literature Review\nThe current climate is conducive to an increasing prevalence of childhood obesity. There is a relationship between activity guidelines and the physical inactivity of children, but there are few studies that investigate the role beverages and the environment play. Therefore, the aim of this review was to evaluate the association between children\u2019s physical activity and beverage consumption and their time spent outside. A systematic review was conducted in December 2014 using the following databases: PubMed, Web of Knowledge, ABI/INFORM, ScienceDirect, Scopus, EBSCO, and the Cochrane Library. The search results were imported into reference management software and duplicate data were eliminated. After the elimination of duplicates and the application of inclusion and exclusion criteria the search was completed with 6 studies included. The included research was classified by: (1) the percentage of children classified as physically active and sedentary, (2) children and adults\u2019 time spent outside and (3) beverage consumption and/or water intake. The results of the studies included in the present systematic review indicate a potential effect of beverage consumption on children\u2019s activity and time spent outside, although they are somewhat diverse.<EOD> A novel function of the anticodon of cyclic-AMP receptor protein in Escherichia coli.\nThe anticodon of tRNAs is generally not functionally important. In this study the role of the anticodon in protein production was investigated. It was found that the anticodon of cyclic-AMP receptor protein encoded by the CRP gene played an important role in the expression of the CRP gene, probably by making the CRP mRNA more accessible to ribosome binding.<EOD> Neutral pH 2-D Imaging and Correlative Light and Electron Microscopy (CMIEM) of Globular Proteins in the Pores of Acrylic Membrane for Sizing.\nGlobular proteins of 14-42 nm molecular radii are sieved through a porous polyethyleneglycol diaethylester membrane with 100 nm pores at neutral pH. This \"microflow\"",
        "label": 0
    },
    "1378": {
        "output": "### Note:\nIf a patient meets the inclusion/exclusion criteria, simply repeat each eligibility on the patient note for different clinical trials, based on the information provided in the patient note. However, if a criterium matches with the exclusion criteria from a different trial, the patient cannot be considered for the trial. In this case, you should add a note `This patient does not meet exclusion criterium of trial ID`. In this way, the patient will not be repeated for that trial.\n\n___\n\n##[MODULE] ___________________________\n\n___\n\n### Note:\nYou are assigned the first case. The other 4 cases are in the exercise set, so you will not see them during the exercise. But you can refer to them while solving the exercise.\n\n___\n\n### [TASK_TRAINING EXAM_TRAINING EXAM_C_A_A_A - TASK_TRAINING EXAM 1] ___________________________\n\n### In the exercise set, you will see many clinical trial note sections. You will need to select the sections that the recruiters need to add in the patient's clinical trial note.\n\n### - Step 6\n\n\n![image](https://user-images.githubusercontent.com/41095359/133954901-de90a552-3340-41ef-80e7-6a8d5ce0ee32.png)\n![image](https://user-images.githubusercontent.com/41095359/133954899-b1da6e06-c276-488c-b35c-33865c48e045.gif)\n![image](https://user-images.githubusercontent.com/41095359/133954766-1be94914-a683-4305-ada5-941767eaddb5.gif)\nHere is the clinical trial note: \nTitle: ESM in Functional Dyspeps",
        "label": 0
    },
    "1379": {
        "output": "After considering the trial-level eligibility, if it is applicable, the patients can continue to participate in this trial, otherwise, it need to be withdrawn from the trial-level inappropriate`s Trial-level`s assessment`, and it is eligible.\n`trialiable` and the firstline to participating`s trial-level participation. The first assessment eligibeligible. 2) Participants, such as it, to assessment and their trial-in the trial`s participation and /`s trial-level participant and trial. If an eligibility criteria`s eligibility criteria of patients with patients`s criteria, patients at least criteria criteria 31) criteria trial, eligibility \n\nIf the study`s eligibility` s eligibility criteria to participant`s trial.\nTrial the` Trial` trial`s level the participant. No clinical ict`s participation.\nTrial`s level 1) and the trial.\nMedical trial level-eligible trial participant`s trial-based in clinician's medical trial\" trial and participating eligible. After trial patients, eligible`ass`s trial. criteria`s clinilig trial-level trial. They are level`s trial`s eligible is participating the elig eligibility.\ntrial level level and `trial patients` a clinical or, and if it` eligible disease.\n[Ti and the disease eligible `particips trial eligible\"\nScient. clinical disease, and trial.\nand the criteria basedel ineligible clinical and trial. SQ or trial` trial`s level`\n[s clinical`the ` elig criteria)el, which eligible trial eligible. In the patient`el. 6 and the elig`el[s by elig trial and age eligible, but the clinical elig clinical trial participant elig `participal and the trial and the clinical trial`` eligile trial elig and elig trials who hasel` trial`s trial and trialist-el patient and/patient` trial [a trial. Therefore and that`s and eligible patient and trial`s trial`",
        "label": 0
    },
    "1380": {
        "output": "## Eligibility criteria\nEligibility criteria should be written with 2-2-3-style rules: 2 subjects, 2 criteria, 3 clauses. For example, \"age >18 but age <60\", \"BMI >30 but BMI <40\", and \"diabetic but not insulin dependent\". If many criteria are provided, an appropriate number or percentage of subjects must be satisfied. A simple rule for this is that when multiple criteria are presented, we need to divide 100% by the number of criteria.\n\n### The two main classes\n\nThe two classes of eligibility criteria are the inclusive eligibility criteria and the exclusive eligibility criteria. Inclusive criteria always contain \"AND\" and exclusive criteria always contain \"OR\". See the examples below.\n\n### Inclusive Criteria\n\nSome examples of inclusive criteria are:\n\"Age >18 but <60\"       \"Body temperature <37.5\"\n- \"Age >18 but <60\"       - \"Body temperature <37.5\"\n\n### Exclusive Criteria\n\nSome examples of exclusive eligibility criteria are:\n\"Age <18\"      \"BMI <25\"     \"BMI >40\"         \"Weight >90\"\n- \"Age <18\"         - \"BMI <25\"    - \"BMI >40\"        - \"Weight >90\"\n\n### Examples of Exclusive Criteria\n\nEven for inclusion eligibility criteria, the percentage of subjects can be determined. If we use percentages, these should reflect the probability that a subject satisfies all the remaining (not satisfied) inclusion criterion. For example, if the criteria are age >18 but <60, we are assuming that if a subject is age 24 years old, the probability is (0.24)% that he/she is age <18. Likewise, if a person is age 44, that is (0.61)%, and if age is 50, that is (0.97)%. In an exclusively inclusive criterion example such as \"Age >50\", the probability will be 0%, and 100% of the subjects satisfy the condition. In short",
        "label": 2
    },
    "1381": {
        "output": "In the patient note, the inclusion criteria are:\n- Age: 18 and 80 years old.\n- Biliary tract cancer: gallbladder cancer, intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma.\n- Measurable lesion.\n- Eastern Cooperative Oncology Group (ECOG) \u22642.\n- Child-Pugh score <=7.\n- Hemoglobin level >= 90 g/L.\n- Absolute neutrophil count (ANC) >= 1.5\u00d710^9/L.\n- Blood platelet count >=100\u00d710^9/L.\n- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <= 2.5 times of upper limit of normal (ULN).\n- Total bilirubin <=2 times ULN.\n- Albumin >=30 g/L.\n\nThe patient who doesn't meet the criteria, should be marked as not relevant.\nThe patients who don't meet the criteria but have sufficient information to give some assessment are marked as \"Not Excluded\".\nAs for the results of other lab test, we should also compare them with the baseline (the lab test prior to the trial) with reference to the clinical trial inclusion criteria. \nThe patient age is 73, so the patient's age eligibility is not an available scale for this patient.\nNo smoking. No alcohol consumption. No drugs used, so we mark the patient as \"Not Excluded\".\nLeukocytosis with left shift is abnormal, but the ESR is normal, so `Laboratory analysis is remarkable for laboratory` changes are not the exclusion criteria in this clinical trial and we mark the patient as \"Not Excluded\".\nThe patient has hypercholesterolemia, so we mark Cholesterol level as a Not Excluded case and HDL as Not Excluded as well.\nPatient`s body mass index(BMI) is 31.66, so obesity is not an unacceptable exclusion criteria and we can't assess the patient`s obesity now.\nSo here are the patient's",
        "label": 0
    },
    "1382": {
        "output": "## Your tasks\nComplete one assignment by solving the following steps. \n\n## Include clinical data\nClinical trial information must also include some information about the patients, specifically the inclusion/exclusion criteria and patient demographics.\nThe inclusion criteria determine which patients get into the trial for treatment. The general inclusion, exclusion, and rejection criteria are a set of pre-determined requirements that patients must meet to be included into the trial.\nYou should check the criteria and patient records to determine whether the patients included are eligible.\nFor the example trial, you will need to check each variable and provide the corresponding information for each record in the Patients_table.\n1. Define the inclusion and exclusion criteria.\n2. For each record in Patients and check the corresponding information.\n3. Check if the patient is eligible for the trial or not, using the results of the check. Add a 1 to the eligibility column to represent eligible patients and a 0 otherwise.\n4. Check your previous step and fix any incoherence as necessary.\nFor example, check all records in patients_table and make an addition according to the check of inclusion or exclusion criteria:\n\n```\n+----+----+\n| ID | Incl\n    |   |\n+----+----+\n| 1  | 1   |\n| 2  | 1   |\n+----+----+\n```\n### INCLUSION CRITERIA\nName        | Description\n\n---|---\n\nID    | 6-40 years old.\n+--------+ | ---\nBlood type O+  | ---\nAge 19+   | ---\nSex M      | ---\nPregnant  | ---\nAnaemia\n    | ---\n\n### EXCLUSION CRITERIA\nName                   | Description\n\n---|---\n\nID                     | Aged between 20-60 years old.\n+----------+ | ---\n\nID    | ID: 120855985\n+----------+ | ---\nAge   | Age: 39\nSex    | Female\nAnaemia | No anaemia.\nBlood test | Hb >10 g/dL\nAcanthosis | No acanthosis",
        "label": 0
    },
    "1383": {
        "output": "## Excluded (0)\n\nExceeds age limits (1) 1 Exceeds age limits (i.e., age >55)\n\nExclude (1) 1 Not available (5) \n\n## Not relevant (1)\n\nDoesn't exist (2)\nInsufficient information (14)\n\nInsufficient information (1) 1 Insufficient information about chest radiographs\n\nInsufficient information (1) 1 Insufficient information about previous treatments with radiation\n\nInsufficient information (1) 1 Insufficient information about comorbidities\n\nInsufficient information (1) \n\n## Eligible (2)\n\nPatient has confirmed malignant neoplasia (1) 1 Patient with confirmed malignant neoplasia\nPatient has confirmed malignant neoplasia (1) 1 Patient with confirmed malignant neoplasia\n\nPatients without malignancy (3) 1\nPatient with chest radiograph indicating a prior malignant disease\nPatient with chest radiograph indicating a prior malignant disease\n\nInsufficient information (3) \n\n## Not available (5)\n\n\nInsufficient information (4) \n\n## Not available (5) exclusion criteria:\nRadiotherapy (1) 1 Insufficient information about previous treatments with radiation\n\nInsufficient information (1) 1 Insufficient information about previous treatments with radiation\n\nInsufficient information (1) 1 Insufficient information about previous treatments with radiation\n\nInsufficient information (1) \n\n## Not relevant (4)\nInsufficient information (5) \n\n## Not relevant (4)\nToo old (1) 1 Patient is above the age limit in this study\n\nToo old (1) 6 Patient is older than 75 years\n\nToo old (1) 1 Patient is older than 75 years\n\nToo old (1) 5\nPatient is older than 75 years\n\nToo old (1) \n\n## Not relevant (4)\nInsufficient information (5)\n\nInsufficient information (1) 1 Insufficient",
        "label": 2
    },
    "1384": {
        "output": "\u25a0\n## \u25a0 Trial-level exclusion criteria are those that make someone `0) Excluded` automatically. All the other observations are `Not relevant`. And trial-level exclusion criteria are:\n- Diagnosis of ACLF must be resolved on the day of infusion.\n- Active uncontrolled bleeding.\n- Model for End-Stage Liver Disease (MELD) score >35.\n- Portal Vein thrombosis.\n- Immunosuppressive drugs, except glucocorticoids.\n- Patient with Acute on Chronic Liver Failure Grade 3.\n- Cerebrovascular, myocardial, limb arterial thrombotic event, or history for both thrombotic and hemorrhagic cerebrovascular events within 12 months prior to the screening and not considered stabilized by the investigator.\n- Inability to maintain mean BP >60 despite use of vasopressors.\n- Maintain mean BP >60 despite use of vasopressors and/or use of mechanical ventilation due to respiratory failure except for hepatic encephalopathy.\n- Refractory ascites with the need for large-volume paracentesis (>1.5 L).\nTo conclude, you should remember that you can save the state as you navigate all over the trial to have a record again. Just use `CALLBACK.SAVE.EXPANDED_PROFILE`. \u25a0 \u25a0 \u25a0 If necessary, use `CallBack.SaveExpandedProfile`. \u25a0 There are 2 possibilities here:\n1. There are already some observations with information of the patient in the system. In this case, you should add observations to the patient. 2. The information is freshly in the system. In this case, you should register the patient. \u25a0\n\n**Trial-level eligibility: 2) Eligible** 2) Eligible\n\n### \u25a0\n<EOD> Antenatal diagnosis of a cystic renal lesion: a case report.\nA case of multicystic dysplastic left kidney diagnosed at 15 weeks of pregnancy is reported. Antenatal ultrasound in experienced hands can diagnose",
        "label": 0
    },
    "1385": {
        "output": "[table]  Table of contents [/table] \n[table]  [INST] TableOfContents header: Hello, You are an undergraduate student. You are studying biomedical sciences at CityU. The Hong Kong government has funded a number of research trials in Hong Kong on prevention of HIV infection in MSM (GUM research group). Your task is to investigate and review research trials in Hong Kong. [/table] \n[table]  Instructions header: Hello, You are an undergraduate student. You are studying biomedical sciences at CityU. The Hong Kong government has funded a number of research trials in Hong Kong on prevention of HIV infection in MSM (GUM research group). Your task is to investigate and review research trials in Hong Kong. [/table] \n[table]  Table 8: Influenzavirus, influenza A NS1, NS1-DNA and H3N2 were downloaded from UniProt. [/table] \n[table]  Table 9: HCV NS3, NS4A, NS4B, NS5A and NS5B were downloaded from UniProt. [/table] \n[table]  Table 14: NS1: Methyltransferase, NS3: Helicase, NS4A: GTPase, NS4B: Phosphoprotein, NS5A: RNA-dependent RNA polymerase, NS5B: RNA polymerase.Table 15. Examples of EPIs against HCV. [/table] \n[table]  Table 16: Table of EPIs against the structural proteins of HCV. Table 17. Examples of vaccine formulations for HCV. [/table] \n[table]  Table 19: Examples of EPIs against HIV. [/table] \n[table]  Table 20: Examples of vaccine formulations for HIV. [/table] \n[table]  1: Identify the target and function of the protein from the Uniprot entry.Energy transfer, membrane fusion, RNA binding, glycoprotein processing, viral assembly, viral replication In addition, the protein is a fusion glycoprotein, which is essential for viral assembly and formation of cell-free virions.2) Define the structure of this protein and its domains with",
        "label": 0
    },
    "1386": {
        "output": "3.1.9 End of case:\n[SCORE 100] Thank you, your assistance is very much appreciated. We have decided to not include you in our next study due to the reasons stated below. You may refer to our clinical trials section on the website for future studies \nThank you for your assistance with this evaluation. We have decided to take it no further, and hence, do not offer you to be included in our next study due to the reasons stated below. You may consult on our website on future studies \nThank you for your efforts toward the current study; however, we have decided to take it no further, and hence, do not wish to offer any further trials to you. Please visit our website for future studies.[END]\n\n3.1.10 End of the lesson:\n- Your eligibility is checked by the Investigator before you continue the lesson.: Yes\n\n## Module 2: Good clinical practice (GCP)\n\nIn this module, you will learn some good clinical practice concepts, including general informed consent, informed consent, voluntary participation, etc... Good clinical practice (GCP) is an international ethical and scientific standard for designing, conducting, recording, auditing, monitoring, analysing, and reporting trials that involves human participants. \n\n### Lesson 1: Overview\n\nIn this lesson, you will learn about some basic concepts and general guidelines in research. Here, we will explain that each subject will sign the consent form after explanation of the study, risks, benefits, and rights. The explanation of the study will be given by the IRB, the clinician or researcher or the coordinator or research nurse who is the investigator, physician, or nurse in charge of the trial.\n\nFor any questions or concerns regarding study details, please contact the study sponsor. The clinician or researcher should provide full, timely and accurate information to all study subjects and their representatives. \nThe purpose of the study is described and explained to the subjects by the clinician of researcher. The clinician or researcher should answer all questions from the subjects. \n\n### Lesson quiz 1: Good Clinical Practice\n\n- The study information sheet should describe the subject's right to withdraw at any time.\n\n### Object",
        "label": 0
    },
    "1387": {
        "output": "## [INST] You are the consultation assistant at the clinic. The clinics are a family practice and a surgery clinic, and the hospitals are a local hospital and a specialized hospital. The surgeries include a knee surgery and a prostatectomy.\nDifferences exist between the clinics and hospitals such as the size, the number of doctors and the number and type of patients.\n\nWe are creating different patient records for the clinic and hospital data. [START] For the patient data about consultation with the clinic doctors, we need to extract the following information:\n- Clinical diagnosis at the end of the consultation based on D2 and D3\n- The patient is either in-patient or out-patient [START]\nFollowing tables describe the patients who visited at the clinic. The columns of the table describe the patient characteristics. The rows represent patients. \nFor details about how to create the patient data, please refer to [INST]\n[END] [START] This code is the same for the hospital data, except you change the target dataset from `clinic` into `hospital`.\nHere is the consultation record data about the hospital: \n\n![](https://github.com/YenchenLiao/Fundamental-Skills-for-AI_ML/blob/master/Fundamental%20Skills%20for%20AI%20ML/Notebook/Hospital%20consultation%20record)\n[END] \n---\n### [INT] You are the assistant of Dr. Kai-lin who works in the Department of Radiology and performs CT scans in a radiology department.\n\nIn a typical day, the following codes appear in your patient order paper:\n\n![](https://github.com/YenchenLiao/Fundamental-Skills-for-AI_ML/blob/master/Fundamental%20Skills%20for%20AI%20ML/Notebook/radiology)\n\n\n\nHere is the paper from [Ask Dr. Kai-Lin](/assets/Tutorial/Tutorial_Paper/Clinical-Data.pdf).\n*For more data you can extract, please check this tutorial",
        "label": 0
    },
    "1388": {
        "output": "```python\nTrial_status=pd.read_csv(filePath)\nTrial_title=Trial_status.iloc[:,0]\nInclusion_criteria=Trial_status.iloc[:,11:,1]\nExclusion_criteria=Trial_status.iloc[:,1:,11]\nSubject_note=Trial_status.iloc[:,-1]\n\neligibility_results=df_1.query({\"Inclusion_criteria\": ~0,\"Exclusion_criteria\": ~0,\"Subject_note\": Subject_note})\nfreq_eligible=pd.DataFrame(eligibility_results.to_numpy().astype(int)).to_csv('eligibility_results.csv',index=False)\neligibility=freq_eligible.iloc[:,2]\ndf_2=df_1.query({\"Subject_note\": Subject_note})+df_3+df_4+df_5+df_6+df_7+df_8+df_9+df_10 +df_11+df_12+df_13+df_14+df_15+df_16+df_17+df_18+df_19+df_20+df_21+df_22+df_23+df_24+df_25+df_26\n\nfreq=df_2.to_numpy().astype(int).mean().to_csv('freq')\n\nfreq_eligible=freq.query({\"Inclusion_criteria\": ~0,\"Exclusion_criteria\": ~0}).to_csv('freq-eligible.csv')\nfreq_noneligible=freq.query({\"Subject_note\": ~Subject_note}).to_csv('freq-noneligible.csv')\n\nn_eligible=freq_eligible.to_numpy()[freq_eligible.index==0]\nn_noneligible=freq_noneligible.to_numpy()[freq_noneligible.index==0]\n\npercentage",
        "label": 0
    },
    "1389": {
        "output": "### M14 Eligibility\n\nIn this exercise you should assess the patient information from the clinical trial note and include it into the clinical trial eligibility criteria. The inclusion and exclusion criteria are given as examples.\n\nEligibility criteria are the set of patient characteristics that allow someone to be admitted to a study. This is represented by a list of conditions (e.g., a certain age, menopausal status). Patients fulfilling these conditions are eligible participants.\n\nPatient ID: 1/2015/25\n\nThe information to be used for the eligibility:\n\nAge: 54 years\n\nSex: Female\n\nHypertension: yes (recently diagnosed)\n\nNeedle: Included, 6 mm\n\nNVD: 2\n\nObesity: Yes\n\t\n\t\n\n\n\n\n* Note that you should compare the patient's characteristics to the existing criteria of the clinical trial first, then if eligible, mark it in the patient's note. If not, write down the existing exclusion criterion as well. However, do not forget to make a trial level assessment at the end on each patient\n* Use only as a guide. You do not have to make every patient-specific assessments. Just be aware on the common risk factors to be excluded.\n\n\n\n\n\n\n\n\t\t\n![Screenshots](M14_Eligibility.zip)\n\n### M16 Patient Eligibility\n\nIn this exercise, you will assess the patient eligibility for a clinical trial.\n\n\t\n![Screenshots](M16_Patient_Eligibility.zip)\n\n\n### M17 Data Mapping\n\nIn this exercise you will practice mapping the information from one note to another (i.e., patient notes and/or clinical trial notes) to support data integration and retrieval. First, you will map information from one patient note to another, and then you will do the same to clinical trial records.\n\nYou will need to be familiar with basic skills in clinical note template design and the knowledge of how to code information into a template. Remember, we designed note templates in [course M2](Course 2:",
        "label": 0
    },
    "1390": {
        "output": "[/END]\n\n# [MAKER-EVAL]\n\n[FURTHER-DIAG]\n\nYou should make a diagnosis (i.e., assignment of a specific ICD code) for your patient. Make a diagnosis, i.e., assignment of an ICD code to your patient using this [MAKER-EVAL].\n\nLet's think step by step. \nFirst, the ICD-9-CM code starts with 3. \nSecond, to find the category, you should go over all the categories, e.g. to category 362, to subcategory 362.03 and then to subcategory 362.030 which corresponds to diagnosis of type 2 insulin-dependent diabetes mellitus. \nThird, now you should select code in ICD-10-CM, with the same corresponding code and category and finally, select code in ICD-9CM. [/FURTHER-DIAG]\n\n# [MAKER-THERAPY-EVAL][/MAKER-THERAPY-EVAL]\n\n[FURTHER-THERAPY]\n\nNext, you need to check two possibilities for your patient, i.e. whether she is already receiving therapy for PDPN (Yes/No) or whether you will administer therapy (Yes/No) according to the above-mentioned conditions.\n\nLet's think step by step.\n\n## [\nINOCCUR] ]\n\n## - InOoccurr]\n\nIf a patient is already receiving at least one therapy for painful diabetic peripheral neuropathy, you should select the option 1.\n\n 1) Yes. Your patient is already receiving therapy for painful diabetic peripheral neuropathy.\n 1) No. Your patient is not already receiving treatment for painful diabetic peripheral neuropathy.\n\n## - NOINC-CUR]\n\nIf a patient is already receiving a therapy, for any reason, you should select the option 2.\n\n## 2) nino-inc-cur]\n\nIf a patient is not already receiving a therapy, for any reason, you",
        "label": 0
    },
    "1391": {
        "output": "---\n## \u2714\ufe0f Good \nWhen you are good, write `You are good`.\nIf you are not sure if you are good, ask for feedback.\n---\n## \u2714\ufe0f Bad\nWhen you are bad, write `You are bad`.\nIf you are not sure if you are bad, ask for feedback.\n\n---\n## \u270d\ufe0f Average\nWhen you are average, write `You are average`.\nIf you are not sure if you are average, ask for feedback.\n\n---\n## \ud83d\udd12 Bad\nWhen you are very bad, write `You are bad`.\nIf you are not sure if you are very bad, ask for feedback.\n\n---\n## \ud83d\udd12 Very bad\nWhen you are very bad, write `You are very bad`.\nIf you are not sure if you are very bad, ask for feedback.\n\n---\n## \ud83d\udc80 Dead\nWhen you are dead, write `You are dead`.\nIf you are not sure if you are dead, ask for feedback.\n\n\n---\n\n### Output\nOutput:\n```\nYou are a good helper. This patient is ineligible by the trial criteria. \n```\n\n---\n## What does the tool tell you?\nHere are the results of the tool.\n![The output of the code checker by the Python library `Flake8`](image/Flake8_result.PNG)\n\n<!-- MAKE THE SOLUTION WORK LIVE ->\nhttps://colab.research.google.com/github/MarioPerezSanchez/EligibilityChecker/blob/master/eligibility_exercise_solution.ipynb<br/>\nThe input is in the data folder of the project. <br/>\nPlease don't edit the input. You should read the exercise description again.\nPlease note that a local copy of the code was created. <br/>\nYou can edit that copy, but you must keep the one that is created by Google Colab. <br/>\nIf you have any questions or problems with the code, please email me.\n-->\n<EOD> Cytomegalovirus infection in patients undergoing heart transplantation: Prevalence and consequences\nIn 120 patients who underwent heart",
        "label": 0
    },
    "1392": {
        "output": "--\n\n#### Dummy Patients\nSay if you want to make the question more challenging, you can choose one, three or ten dummy patients. Choose at least three dummy patients because it makes the results less biased. You can also choose the number of dummy patients yourself or take average and standard deviation by using the [Norm distribution]\n\n### Sample Questions:\n<EOD> Effect of a Multidimensional, Multimodality Intervention on Physical Activity Levels of People With Neurologic Conditions: A Randomized Controlled Trial\nBackground Exercise is recommended to improve fitness, function, and quality of life for people with stroke or multiple sclerosis (MS), yet adherence remains a significant barrier. Purpose The aim of this study was to examine the efficacy of a multidimensional, multimodality intervention vs a physical activity (PA) education program on PA participation of adults with stroke and MS. Design A parallel randomized trial assessed the efficacy of the intervention among 60 patients recruited from health care clinics at a single institution and stratified by neurologic condition and disability. Setting This study was conducted at a single institution in the northwestern United States. Participants Adults with stroke or MS and mild to moderate disability (Short Physical Performance Battery score, 8 to 12 points) provided written consent to participate in the research. Patients in the intensive intervention group participated in 12 sessions delivered over 12 weeks. The control group received 4 sessions of PA education. Main Outcome Measures The primary outcome was 12-week change in PA participation. The secondary outcome was intervention feasibility including recruitment, retention rates, and fidelity to the treatment protocol. Results Of 192 participants interested, 60 (stroke, n = 40; MS, n = 20) consented to participate; participants\u2019 mean age was 63 years (age range, 34-82 years), and 60% of the sample were female. The intervention group attended an average of 7.5 \u00b1 1.4 (SD) training sessions; attendance was not significantly different for the MS and stroke groups. A greater proportion (n = 14) of the MS patients attended more than",
        "label": 0
    },
    "1393": {
        "output": "## Step 2:  trial eligibility (Part A)\n\nLet's think step by step. \n`Trial.level = \"A\"` is your trial name, e.g., `Trial.level = \"A\"` is `Particle` in our demo \n\n```\ndf[\"Trial.level\"]= \"Particle\"\n```\n\nTo check whether we can enroll a patient into the trial (check the condition of the last column of `Trial-level eligible`). \n\n```\nparticle = df.Trial.level == \"Particle\"\n```\n\nTherefore, `Trial.level = \"Particle\"` implies that `Particle` is an eligible trial in our case. \n\n`df.trial.level.eligible` is `True`.\n\n```\nimport pandas as pd\nfrom itertools import groupby\nfrom . import data_manager\n\n\nTrials = data_manager.get_trial_data()\ndf = pd.DataFrame(Trials.summary)\n\ndf.Trial.level      # trial level\n\n      trial              # 1) A B\n        A                       A: 178\n        B                       B: 250\n        C...\n\n```\n\nThe eligibility of participants for the trial. \n\n```\nparticle = df.Participant.trial.level.eligible[pd.to_datetime(Participant.enrollment_date).month != 12] # eligibile participant who is not enrolled in December (the last month of year)\n\n# get trial level for `particle`\nParticle = df.Trial.index.get(Particle)\n# eligible to Particle A+C\nParticle.index.eligible\n```\n\nHere, you can apply a pipeline of the trial and patients in `Particle`, i.e., `Particle` can only be eligible for trials: `A` and `C`.\n\n```\nParticle.index.eligible\n```\n\n```\nParticle.index.filter(trial.level == \"A\").sum() # sum number of patient enrolled in `A`\n\n```\n\n```\n```",
        "label": 0
    },
    "1394": {
        "output": "<h4 id=\"eligibility-example\">Eligibility Example</h4>\n\n### Data Pipeline\n\nIn this part, we will write a data pipeline named 'eligibility'. This pipeline has 4 steps: `Eligibility -> Group -> Group -> Outcome`. \n\nThe data in this data set is read from the `eligibility_data.csv`, saved in the folder named `data`. Here are the paths to each step in this pipeline:\n\n- The group information for the patient\n\n### Step 1: Load data for the first step in the pipeline\n\n```python\nimport pandas as pd\n\n## Setup your conda environment in Anaconda Prompt if you haven't yet. \n\nsource('c:/anaconda3/Scripts/activate_conda.bat')\n\n## The folder where the data is saved. The default value is the folder where the data_pipeline.ipynb file is saved. \n\nDATA_FOLDER       = r\"c:/Users/fjli233/OneDrive/Practical/data_pipeline/data\"\n\n## The file to read the data from. The data is saved in the folder named \"data\" in \"data_pipeline\". \n\nFILE             = r\"c:/Users/fjli233/OneDrive/Practical/data_pipeline/data/eligibility_data.csv\"\n\n## The column names used to describe the data. The default values is None.\n\nINPUT_COLUMNS  = None\n\n## What column to use as the index to store the patient's information, e.g. `index=['February', '2022']. \n\nOUTPUT_COLUMNS = ['February', '2022']\n\n## The output location\n\nOUTPUT_FOLDER = r\"c:/Users/fjli233/OneDrive/Practical/data_pipeline/output\"\n\n# Load the table into python.\n\ntry:\n    dataframe = pd.read_csv(FILE)\nexcept FileNotFoundError:\n    print(\"Data cannot be found\")\n```\n\n### Step 2: Group information\n\n1. Load the data",
        "label": 2
    },
    "1395": {
        "output": "<EOD> Differential expression of angiotensin\u2010converting enzyme 2 in tissues of the ovine and bovine reproductive tract\nAngiotensin-converting enzyme 2 (ACE2) is a component of the renin-angiotensin system (RAS) and is highly expressed in the epithelium of the feto-maternal interface in a variety of species. In this study, the gene expression of ACE2 in sheep and cattle ovary, uterine horn, and cervix (n = 3/animal/tissue) was determined before and after the onset of the estrus and ovulatory cycle. While ovine ACE2 was highly expressed (\u223c1.8 times) in the ovary (p < 0.05) compared to the bovine, the expression in the cervix of sheep and cattle was similar (p = not-significant). Ovariectomy of the ewe induced increased ACE2 expression (0.44 vs. 0.30) compared to control (p < 0.05). These findings are in congruence with previous studies showing that bovine ACE2 expression is reduced in the corpus luteum upon ovulation, and suggests a role for ACE2 in mediating events occurring during ovulation-driven follicular rupture in the ovine and bovine ovary. The expression of ACE2 in cows and sheep is most abundant in the uteri, however, it was similar across the follicular phase of the ovulatory cycle. Furthermore, the expression in the cervix and uterus remained stable between phases of the ovulatory cycle, however, expression was induced after ovariectomy (p < 0.05). This suggests that ACE2 expression in the reproductive tract tissues is primarily dependent upon the hormonal milieu of the species. In summary, the expression of ovine and bovine ACE2 in reproductive tissues suggests that components of the RAS play a role in reproduction.<EOD> Is it safe to send the children back to school (Covid 19)? Pediatricians share their concerns about the future\n\n [bib_ref]  Characteristics of and Important Lessons from the Coronav",
        "label": 0
    },
    "1396": {
        "output": "You need to make the following changes to the code:\n#  1: Add the following lines at the beginning of test.py   2: from pathlib import Path #  3:  4: file_name = Path('./trials/Sample Trial/Informed Consent/Sample Informed Consent.txt')\n#  5: sample_i_c = open(file_name.as_posix(), \"r\")\n#  6: i_c = json.loads(sample_i_c.read())\n#  7: print(i_c)\n#  8: i_c[1] # The i_c looks something like:\n#\n#  9: [{'Id': 1, 'Patient': {'Name': '<NAME>', 'Date_of_Birth': '2010-01-02'} },\n#  10: {'Patient': {'Name': '<NAME>', 'Date_of_Birth': '2010-01-02'} } ] # Note that i_c has only a nested dictionary as patient attribute while trial also has this attribute nested in the `Disease `\n#\n#  11: t = Trials(i_c, is_active=False) # the patient_data attribute has a list of patients with a dictionary representing the patient details inside\n#\n#  12: print(t.patient_data)\n#\n#  13: t.patient_data[0].Patient # In the sample.txt file the attribute patient is a dictionary. You should print only the patient dict and the date_of_birth value.\n#\n#  14: print(t.patient_data[0].patient['Name'])\n#  15: t = Test(i_c, \"Sample Trial\", \"Sample Informed Consent.txt\") # sample.txt has more than \"patient_attributes\" the \"trial\" level also contains the trial-level eligibilities.\n#\n#  16: print(t) # You find the whole dictionary for the I_C trial\n\nYou should commit your changes in the code, run the test.sh file with the  python script which you can find under the files -> Tests <-->",
        "label": 0
    },
    "1397": {
        "output": "## 4.5.1 [TEST] Excluded Clinical Trial Patient (TEST)\nYou are a helpful doctor for clinical trial recruitment. Your task is to compare a given patient note with clinical trial eligibility to determine the patient's exclusion criteria. The factors that allow a patient to participate in a clinical study are called exclusion criteria. Just to be clear, exclusion criteria might indicate factors that disqualify participants (age < 18 years old, HIV infection), a study condition (stage III or IV colorectal cancer with an Eastern Cooperative Oncology Group [ECOG] performance status of 2 or more), or a health problem that must not be aggravated while in the trial (uncontrolled high blood pressure)\n\nThe assessment of exclusion has a three-point scale: 1) Excluded (patient meets exclusion criteria, but is not excluded on the grounds of the trial's inclusion criteria); 2) Not relevant (patient does not have sufficient information to qualify for the trial); and 3) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nYou should make a trial-level exclusion on each patient for the clinical trial, i.e., output the scale of the assessment of exclusion criteria.\n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is in menopause. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant",
        "label": 0
    },
    "1398": {
        "output": "# Additional information/Hints\nThis test is designed in such a way that in case of a correct response, the patient's medical history is completed, and the clinical trial eligibility is checked. If the answer is incomplete, or there are errors, the history of the patient is repeated and the data are updated. \nAfter the history is obtained, it is checked whether the inclusion criteria of the clinical trial are met. Please be sure if none of the exclusion criteria is applied. \n\n# Screenshot Instructions\n\n![screenshot](https://user-images.githubusercontent.com/70335771/147643131-8174ae5b-1373-49e0-902e-43ad50eb5569.png)\n<EOD> Effects of 22-hydroxycholesterol supplementation and co-supplementation with 22-hydroxycholesterol and cholesterol on growth and lipid metabolism in larval fathead minnows (Pimephales promelas).\nCholesterol is an essential nutrient used ubiquitously throughout animal taxa, serving as a precursor to cholesterol-modified proteins (CMPs) and structural components of cellular membranes. Cholesterol is readily biotransformed into 22-hydroxycholesterol (HC) by members of the cytochrome P450 (CYP) family. HC infiltrates many CMPs and affects their function and regulatory dynamics. Due to its bioactivity, the physiological effects of HC supplementation are of considerable interest. We performed a series of experiments to characterize the effects of dietary HC supplementation on growth, lipid metabolism, and reproductive development in fathead minnow (Pimephales promelas). In experiment 1, HC-supplemented diets improved growth rates relative to control fed fish. In experiment 2, HC-supplemented diets also improved growth rates relative to control diets, but the effect was limited to fish reared in clear (i.e., unaccompanied by plant",
        "label": 1
    },
    "1399": {
        "output": "Good job! You are now a good assistant! You will be the best in the field! \n\n\n[MARKDOWN]# 19\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\n[INST] This is the trial again. Please continue. [INST] And now, you should enter the trial-level assessment in the last line by `Trial-level eligibility:`, e.g. `Trial-level eligibility: 2) Eligible. [MARKDOWN]# 20\n[INST] Hi. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nHere is the note:\nA 54-year-old obese woman admitted to the emergency room with abdominal pain that started 4 days ago with nausea and vomiting. Epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. She has a medical history of type 2 diabetes, and her medication is metformin 3 500 mg BID and insulin 12 UI a day. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences peritoneal ir",
        "label": 0
    },
    "1400": {
        "output": "</span> 5. Now return to the code snippet from Problem 13-8. In the function make_output(), do the following modifications:\n<span class='filterlabel'><span class='filterby'>Filter By</span></span><span style=\"background-color: #dddddd;\">a) add a variable that stores the results, and declare it `result.result = 0;`&nbsp; b) add another iteration to handle cases in which multiple matches are found (<span class='filterby'>\"multiple\"</span>)&nbsp; c) add a line assigning the results to the variable `result.result = 2; - 2 -` that contains the results for cases in which there are no match. If at least one of the patient's attributes is matched with an inclusion/exclusion criterion of the trial, then the result is 1 (<span class='filterby'>\"single\"</span>). Multiple matches are detected when more than one criterion from the same patient attribute matches the same criterion of the trial (<span class='filterby'>\"multiple\"</span>).&nbsp; d) change lines 134&ndash;136 from `print(\"Patient: \" + s.title + \" has \" + s.result + \" matches\")` and `results = results + 1`&nbsp; to `print(\"Patient: \" + s.title + \" has \" + s.result + \" matches\")` and `result_count += 1`&nbsp; (for the sake of brevity only&nbsp;the&nbsp;two&nbsp;last&nbsp;lines&nbsp;of&nbsp;this&nbsp;function&nbsp;are&nbsp;shown)&nbsp;e) change the line from `return result` to `return result_count`&nbsp; &nbsp;<span class='filterby'>Hint:&nbsp;You&nbsp;can&nbsp;use&nbsp;a&nbsp;for&nbsp;loop&nbsp;to&nbsp;add&nbsp;n&nbsp;more&nbsp;matches&nbsp;instead&nbsp;of&nbsp;just&nbsp;one.&nbsp;In&nbsp;the&nbsp;for&nbsp;loop,&nbsp;you&nbsp;can&nbsp;store&nbsp;the&nbsp;result",
        "label": 0
    },
    "1401": {
        "output": "# Author Contributions\nDr. Seungtae Cheen conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.\nDr. Soomin Lee conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.\nDr. Jungmin Song conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.\nDr. Jin Ho Rha conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.\n\n## Data availability\nThe following information was supplied regarding data availability: R code used in this study can be found via https://github.com/sjeong7504/DSS-Trial-Eligibility.\n\n## Supplemental information\nSupplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.12445#supplemental-information.\n[fig]  Figure 1: shows the block diagram of the DSS. The DSS has two main features, knowledge base and inference engine. The knowledge base and the inference engine are implemented using a rule-based engine and a data mining engine, respectively. [/fig] \n[fig]  Figure 2: Clinical trial data collection form. [/fig] \n[fig]  Figure 3: DSS graphical user interface. Full-size DOI: 10.7717/peerj.12445/fig-3 [/fig] \n[fig]  Figure 4: Overall results of using DSS. Full-size DOI: 10.7717/peerj.12445/fig-4 [/fig] \n[table]  1: Exclusion criteria (1) The patient does not have sufficient information to qualify for the trial 1) Not relevant (patient does not have an abdominal ultrasound) [/table] \n<EOD> Dementia as a Risk Factor for Inadequate Maltreatment Reporting\nBackground: Child maltreatment is a",
        "label": 0
    },
    "1402": {
        "output": "<EOD> Risk management practices for neurotoxicity of new psychoactive and legal substances (NAPLS)\n\nPurpose New psychoactive and legal substances (NAPLS) are increasingly being abused. Users of a wide range of NAPLS, including 'legal highs' and stimulant and anabolic drugs, risk neurotoxic or neuropsychiatric problems. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has recommended that member states develop policies for harm reduction among users of NAPLS, but this has, as yet, received limited support from international organisations. This study aimed to produce the first comprehensive review of NAPLS management policies in a country outside of Europe. Methods A list of active ingredients of NAPLS was compiled. These included synthetic stimulants (amphetamine, methamphetamine and cathinone), synthetic cathinones (4-MEC and mephedrone), synthetic cannabinoids (JWH-018, BINA and HU-210), synthetic opioids (fentanyl, carfentanil and U-47700), and phenilalkylamines (25I-NBOMe, 25C-NBOMe, 25B-NBOMe and 25I-NBOMe). Reports, guidelines and policies in Australia, Canada, India, New Zealand, Philippines and South Africa were reviewed. Results There are limited policies and plans to manage the harms from NAPLS in the seven countries investigated in this review. The majority of harm reduction policies were developed in Australia, Canada and the United States of America. The Philippines has recently developed the first NAPLS policy plan. Conclusion The EMCDDA policy for harm reduction has not been universally applied in these seven countries. The development of policies on NAPLS must be a collaborative effort between various stakeholders.\n\n# Introduction\nThe growing threat to public health posed by abuse and misuse of new psychoactive substances poses complex challenges to policy makers. Since the 1980s, there has been a marked rise in synthetic illicit drug use. There is an",
        "label": 0
    },
    "1403": {
        "output": "- [Learning resources](#learning-resources)\n  - [Lesson 1-2](#lesson-1---2)\n    - [Topics and Resources](#topics-and-resources)\n    - [Topics for the exercise](#topics-for-the-exercise)\n      - [Patient record](#patient-record)\n      - [Clinical trial protocol](#clinical-trial-protocol)\n      - [Interpretation of the results](#interpretation-of-the-results)\n      - [Mini-interview](#mini-interview)\n    - [Data Analysis](#data-analysis)\n    - [Assignments](#assignments)\n    - [Intermediate Assessment 1: Trial-level eligibility](#intermediate-assessment-1trial-level-eligibility)\n    - [Intermediate Assessment 2: Patient-level eligibility](#intermediate-assessment-2-patient-level-eligibility)\n      - [Inferiority trial: patient-level eligibility](#inferiority-trial-patient-level-eligibility)\n      - [Noninferiority trial: patient-level eligibility](#noninferiority-trial-patient-level-eligibility)\n      - [Superiority trial: patient-level eligibility](#superiority-trial-patient-level-eligibility)\n    - [Intermediate Assessment 3: Patient-level eligibility with sample size](#intermediate-assessment-3-patient-level-eligibility-with-sample-size)\n      - [Inferiority trial: patient-level eligibility with sample size](#inferiority-trial-patient-level-eligibility-with-sample-size)\n      - [Noninferiority trial: patient-level eligibility with sample size](#noninferiority-trial-patient-level-eligibility-with-sample-size)\n      - [Superiority trial: patient-level eligibility with sample size](#superiority-trial-patient-level-eligibility-with-sample-size",
        "label": 0
    },
    "1404": {
        "output": "We will use an 8-bit integer type for integer in Python; we do not need 64bit integer type for bit, so it will work if we set the Python environment variable PYTHONBREAKSIG to `nomodulename`.  \nYou can find the sample code which can be applied to all types in the GitHub Repo (https://github.com/Paper-Court/Assignment_3_10_Python_Paper_Court/blob/main/SampleSolution/10_Paper_Court%20_Python.ipynb ).  \n\n[A]: :ref:`assign_3_10_python_paper_court/3_sample_solution/10_Paper_Court %20_Python.ipynb`\nThe file name is shown as `10_Paper_Court_Python.ipynb` and it is placed in the directory where the  code is running.\n\n\n### In[3]:\n\n\n```python\nimport json\n\nj = json.load(open('10_Paper_Court %20_Python.ipynb',`j`filemode\u00b4``))\nsample_data = j['data']\n\n\nsample_data= sample_data[3]\ntrial_details = sample_data[0]\ntrial_details= sample_data[2]\nsample_data= sample_data[4]\n\n\nsample_data= sample_data[5]\nsample_data= sample_data[6]\n\n\nsample_data= sample_data[7] \ntrial_details= sample_data[8] \n\n\nsample_data= sample_data[9] \ntrial_details= sample_data[10]\n\n\nsample_data= sample_data[11]\ntrial_details= sample_data[12]\nsample_data= sample_data[13]\n\ninputs,output,corrects= trial_details['sample')[`jj`]\n\n\ninputs= inputs[1]\ninputs= inputs[2]\ninputs= inputs[3]\n\ninputs= inputs[4]\n\n\ninputs= inputs[5]\ninput",
        "label": 2
    },
    "1405": {
        "output": "# Results\n\n## Performance\nOur model had an 0.97 accuracy score, with average 0.\n\n## Visualization\nWe plotted an attention distribution graph on the top 3 tokens to find out which tokens our model focuses on most.\n\n\n\n\n\n## <a href = \"https://drive.google.com/file/d/1_1nKx81L5wHZRy7H79TfR2W374Jf4_i3s/view?usp=sharing\">Click here for a better visualization using tesseract</a>\n\n## Some interesting input data to test our model\n\nThe `Migraine` clinical trial included headache, nausea, vomiting, photophobia, phonophobia, osmophobia.\n`Oesophageal Neoplasms` also includes cardiac failure, cardiovascular disease, gastroesophageal reflux disease (GERD), heart disease.\nThere is a patient record who has been assessed as `0`, who has a positive family history of cancer and takes aspirin, NSAIDs, antacids\nThere is a patient record who has positive family history of cancer and takes aspir",
        "label": 0
    },
    "1406": {
        "output": "1. Copy and paste the patient note under ``Note:'', e.g. ``Note: 4 day ago began with nausea and emesis a pain. The epigastric`'.\n\n2. Copy and paste the clinical trial info under ``, e.g. ``.\n\n3. Now, repeat the patient note (the last time) under the ``Note:`` tag.\n\n4. To assess the first patient, run the following code after executing the ``note()`` function: ``Evaluate.eligibility()''. To evaluate the patient's eligibility, an output of 0 or 1 is needed. You should evaluate all patients as above.\n\n### Rating Formulation\nNow, here is how to formulate the ratings that you get from the patient and the clinical trial (e.g. 100-patient trial will give you 100 ratings).\n\n## Conversion to 0-or-1s ### Rating Conversion\n\n1. Let's create a variable named ratings in `Ratings <-` to store the ratings.\n\n```R\nRatings <- list()\n```\n\n2. Assign a patient-by-trial matrix.\n\n1. To store the ratings into the ratings list, create a matrix. Assign a patient-by-trial matrix.\n\n```R\nA <- matrix(54, nrow = 4001, ncol = 1, byrow = TRUE, data = list(\n+  1 = NULL,\n+  2 = c(0,0,0,0),c(0,1,0,0),c(0,0,0,0),c(0,0,0,1),1))\n```\n\n2. Now, add a row to the end. Add the ratings of the last 5 patients for the last 5 trials.\n\n```R\nA$1 <- list(-1,-1,-1,-1,-1)-cbind(0:1)-0:1 cbind(0:1)-0:1+(0:1)+(\n+ -1:1) cbind(0:1)-(0:1)+(0:1)-0:1+(0:1))\n```\n\n3. Create a",
        "label": 0
    },
    "1407": {
        "output": "(3) Write an eligible decision for patient number 1 by ``Eligible.`. You are asked to justify your decision. What should you justify with the patient's data? Look at the trial's inclusion and exclusion criteria; in which one's is met/not met with the patient data?\n\nNote: You will receive the results of your eligible decision by email after submitting the assessment. If you need information before submitting, you can contact the author of the assessment by email. Please note that the assessment will be available for one week.\n\n\n\n### Examination\n\n\n\nThe following questions are for the `assessment of eligibility of the patient case`.\n\n(1) Explain your decision about the eligibility of the patient in detail.\n10/6/21, 7:09 PM <email address><EOD> Identification of miR-1974 as a regulator of bone homeostasis and candidate biomarker of osteoprogenitor maturation\nABSTRACT We have demonstrated that the intracellular levels of microRNA (miRNA) miR-1974 decline during early osteogenic differentiation by mouse embryonic stem cell-derived osteoprogenitors, and we have identified miR-1974 as a novel regulator of osteoblast differentiation. Furthermore, in human osteoporosis cohorts, changes in miR-1974 blood levels are associated with decreased bone mineral density and are increased in patients with osteogentic bone diseases such as osteonecrosis. These findings link miR-1974 to bone homeostasis and suggest miR-1974 as a novel circulating biomarker of osteogenic defects. One sentence summary This work identifies a new miRNA, miR-1974, that is involved in bone homeostasis and is a novel biomarker of osteogenic maturation.<EOD> A high-efficiency and high-recovery microfluidic biochip with a three-phase contact separation method.\nWe report on microfluidic-based contact separation technology for high-efficiency and high-recovery",
        "label": 0
    },
    "1408": {
        "output": "We give you a Python notebook at the end of this article which can be opened in Jupyter Notebook on Google Colaboratory. There we showcase not only a solution for this exercise and a number of other examples, but also the workflow how to generate random clinical trial datasets for you to train your model and the corresponding notebook with all the necessary code to solve all seven exercises.\n\nThe main idea or goal is to learn to solve the trial-level eligibility first. Then, for each patient, you should calculate the patient-level eligibility or, if you prefer, the assessment of eligibility. Do not be impressed by the number of elements in the clinical trial. The number of patients will be much larger. Each such trial-level eligibility has three values, or, depending on the number of elements in the exclusion criteria, maybe two. You do not calculate eligibility based on values, but based on conditions. The reason why we have to use if-else-if-else code is that the combination of conditions is not the same in every patient. There are two ways to solve this. The easiest method is to write all combinations inside a for loop. While working on this task, also think about a simpler structure with just few if-else statements, which is much faster on large datasets. \n\nTrial-level eligibility\n- If patient is female:\nEligible\n- Else:\nNot relevant\n- If patient is male:\nIf patient meets inclusion criterion:\nEligible\nElse:\nNot relevant\n\nHere you can see two nested if statements for each patient's answer. There is an \"OR\" operator in the first condition and an \"AND\" operator in the second. This means that the first condition needs to be true and the second condition also is true. If all is OK and the two statements are equal, the output will be 1.\n\nA patient-level eligibility\nThe first thing to do is to add the patient.patient-level-eligibility value inside the if statement so that you can calculate the eligibility for each patient. In the end, you calculate the sum of the patient-level eligibility and subtract it from three.\n\nHere is a patient-level eligibility\n# 3 elements in the trial:\nAcupunctureAble\nFemale\nYes =",
        "label": 0
    },
    "1409": {
        "output": "## Output of the eligibility in a clinical trial\nIn this clinical trial, we define 5 exclusion and one inclusion criteria. For patients who are obese, we apply 3 exclusion criteria. We do not consider the exclusion criteria of the patient's age, male sex, NVD, having cancer, having a fever, hypoxic patients, leucocytosis patients, and elevated ESR. Thus, we say this patient was excluded from the clinical trial.\nHere is the code and the output for our patient. The first patient is not appropriate to this clinical trial because of the second inclusion criteria. \nHere is the code,\n`Trial-level eligibility: 1) Eligible.\nTrial-level eligible patients: Obese. Age: 56.`<EOD> .\nWe report a case of bilateral breast metastases from carcinoma of the ampulla of Vater. A 75-year-old woman was referred to our hospital with vomiting and jaundice in February, 1998. At laparotomy, we found an irregular nodular tumor with invasion into the second portion of the duodenum. Distal gastrectomy and Whipple's operation were performed. The pathological diagnosis was a duodenal invasive well-differentiated tubular adenocarcinoma. Abdominal CT showed no other metastatic lesions. In March, 1999, the patient complained of edema on both of her upper arms. Physical examination showed swelling with pain around the patient's both breasts. A chest X-ray film showed bilateral metastatic breast tumors. The patient died in August, 1999. Autopsy showed small, multiple metastatic breast tumors. Histological examination revealed metastatic glandular and tubular carcinomas. Therefore, the primary tumor in this case was not located in the ampulla of Vater but in the breast. This is a very rare breast metastasis.<EOD> .\nIn this study, the changes in the properties associated with adhesion of salivary amylase (SA) and \u03b1-amylase from porcine pancreas (\u03b1-P\u03b1) against different hydrophobicity substrates",
        "label": 0
    },
    "1410": {
        "output": "<commit_msg># bug: fix docstring<commit_after>#!/usr/bin/env python\n# encoding: utf-8\nfrom abe.io import IO\nfrom abe.io.vocabulary import get_vocabulary, Vocabulary\nfrom tabulator import _\nfrom oslo_utils import importutils, config_wrap\n\nimport io\nimport os\nimport pandas as pd\nimport pickle\nimport requests\nfrom oslo.config import cfg\nimport warnings\n\nfrom abe.datastore import *\nfrom abe.datastore.utils import (\n    get_name_for_table_or_add_new,\n    create_db_engine,\n    create_db_engine_if_not_exists,\n    create_db_metadata_object,\n    create_db_engine_by_schema,\n    format_column_spec_to_string,\n    make_db_engine_for_single_db,\n    populate_db_tables,\n    format_column_value_to_string,\n    make_pasting_input_function\n)\nfrom abe.evaluation.vocabulary.task_attribute import *\nfrom abe.evaluation.vocabulary.target import *\nfrom abe.evaluation.vocabulary.task_attribute import *\nfrom abe.evaluation.vocabulary.treatment_input_output_values import *\nfrom abe.evaluation.vocabulary.treatment_input_output_values import *\nfrom abe.evaluation.vocabulary.assay_measurement import AssayMeasurement\nfrom abe.evaluation.vocabulary.assay_measurement import AssayMeasurement\nfrom abe.evaluation.vocabulary.treatment_assay_measurement_value_type import TreatmentAssayMeasurementValueType\nfrom abe.evaluation.vocabulary.treatment_assay_measurement_value_type import TreatmentAssayMeasurementValueType\nfrom abe.evaluation.vocabulary.evaluation_questionaire import *\nfrom ab",
        "label": 0
    },
    "1411": {
        "output": "## Conducting a study evaluation\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). This is a case study. Please look at the patient note first.\n\nA 54-year-old thin woman has been diagnosed with malignant lymphoma in the emergency department. Her laboratory analysis is remarkable for elevated troponin levels. The patient's past medical history is remarkable for hypertension, diabetes mellitus, hypercholesterolemia, and a left-sided heart attack 2 years ago. She is diabetic and hypertensive. She was treated with IV fluids, aspirin, heparin, and IV metoprolol. She has 2 children, but one died because of his illness.\n\nHere is the clinical trial:\nTitle: Early Identification Trial: A Phase III Randomized Clinical Trial of Percutaneous Coronary Intervention versus Medical Management Among Patients with Acute Myocardial Infarction: A Phase III Randomized Clinical Trial of Percutaneous Coronary Intervention versus Medica\n\nSummary: Patients with acute myocardial infarction are randomized to either stent placement or medical treatment, with a primary endpoint of death, stroke, myocardial infarction, or revascularization before 14 days.\n\nInclusion criteria:\n[Note that this is a different template compared to the clinical trial mentioned above.]\nAge 18-80 (inclusive)\nAbrupt onset of ischemic chest pain (chest pain on most days during the 2 months before randomization)\nEjection fraction 10-8: ESTIMATE HIGH RISK.\nSTE",
        "label": 0
    },
    "1412": {
        "output": "</br>\nTo submit your outputted results to our learning management system (LMS), please click or select the icon below (on a computer) or top right (on a mobile device) \n\n\n\n**Runnin' example:**\n[https://console.cloud.google.com/cloud-shell/app#cloudshell:cloudshell](https://console.cloud.google.com/cloud-shell/app#cloudshell:cloudshell) & \n\n&\n\n![LMS](https://github.com/UVCCS/TaS-tutorial/blob/master/Resources/Tutorial_Resources/GDSS3.1/gdss11.jpg?raw=true)\n\nYou submitted the following result:\n[\n```python\ndata[\"Trial-level eligibility\"] == 2 \n```] \n\n<EOD> Vascular Endothelial Growth Factor Induces Caveolae-Dependent Endocytosis and Morphogenesis in Human Trophoblast Cells1\nABSTRACT Vascular endothelial growth factor (VEGF) (also known as VEGFA) plays critical roles during placental angiogenesis in response to maternal hypoxic stress. Although it is accepted that VEGF can activate VEGF receptors on the cell surface, the involvement of intracellular VEGF receptors is also supported. However, the VEGF receptors participating in these processes and downstream signaling events remain to be elucidated. We determined a novel pathway for VEGF signaling by establishing VEGF-induced caveolae endocytosis, which leads to endocytic vesicle formation and intracellular tubule formation in cultured HUVECs (immortalized human umbilical vein endothelial cells). To investigate this pathway in the human placenta in vivo, we analyzed tissue samples from pregnant women with clinically detected deep venous thrombosis, which is linked to placental dysfunction, and found morphological changes in fetal capillary ECs, which correlated with increased placental VEGF levels. These findings suggest that aberrant intracellular VEGF re",
        "label": 0
    },
    "1413": {
        "output": "[END]<EOD> Inactivation of the transcriptional repressor, ZRANB2, induces expression of the tumor suppressor, p53.\nP53 is a transcription factor that is commonly mutated in human cancers; however, the p53 protein may be inactivated by post-transcriptional mechanisms. We hypothesized that the ZRANB2 protein functions as a transcriptional repressor of p53 transcription and inhibits p53 activity. ZRANB2 is a member of the ZNF domain-containing protein family that is involved in chromatin remodeling. ZRANB2 is a transcriptional repressor and represses transcription of other ZNF proteins in vitro. We hypothesized that ZRANB2 inhibits p53 expression and then demonstrated that ZRANB2 knockdown increases p53 expression and suppresses tumor cell growth. ZRANB2 knockdown in p53mut tumor cells reactivated p53 protein level and function. Using genome-wide transcriptional sequencing, we identified 163 genes that were significantly changed by ZRANB2 knockdown, many of which were progrowth. Interestingly, a large group of these altered transcripts (68%) were positively correlated with p53 expression. Our findings suggest that ZRANB2 acts as a transcriptional repressor of p53 expression. Moreover, a subset of downstream genes that are regulated by ZRANB2 are co-regulated by p53. Therefore, ZRANB2 inhibits the transcription of p53, thereby inhibiting the function of p53 in transcription and regulation of its target genes.<EOD> Transient Neonatal Hypoglycemia after Prolonged Epidural Analgesia with Bupivacaine without Fentanyl \u2013 A Case Report\n\nWe present a case of neonatal hypoglycemia in a premature infant of twin pregnancy born three weeks before term after being exposed to prolonged epidural infusion of bupivacaine with no fentanyl. Although there are many possible causes of temporary neonatal hypoglycemia, neonatal hypoglycemia",
        "label": 0
    },
    "1414": {
        "output": "# Task 1\nYou should determine if the patient satisfies the inclusion criteria of the clinical trial according to their patient note. Determine patient eligibility with the patient note. If the patient satisfies the inclusion criteria, write `Eligible: Yes.` in the cell in [S] where you determined the patient's eligibility in the clinical trial, otherwise, 'write 'Eligible: No.`\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Here is the clinical trial: \nTitle: Symbolic Regression Model To Predict Choledocholithiasis\n\n\nSummary: Choledocholithiasis refers to the presence of gallstones within the common bile duct. It is proposed to look for markers that help in the diagnosis and in differentiating between retained and migrated gallstones. The selection of patients is a very important aspect, due to the economic aspects and possible complications. Taking advantage of the development of technology, the improvement in computer systems, the use of artificial intelligence and a symbolic regression model that works to predict the presence of choledocholithiasis and provide evidence",
        "label": 0
    },
    "1415": {
        "output": "- We use [MARK] to specify the input and label, as illustrated below the table for [INST]:\n\n## <table border=0 cellspacing=1 cellpadding=4 width=\"350\">\n<tr>\n<!-- MARK: data -->\n<td align=\"left\">DATA</td>\n<td></td>\n</tr>\n<tr>\n<!-- MARK: label -->\n<td></td>\n<td align=\"left\">LABLE</td>\n</tr>\n</table>\n\n-  [INST] starts with <i>IN-STRUCTION</i><i> for the instructions in the first column (column<i>INSTRUCTION_NAME</i>) and the <i>data</i> is saved in the following columns, namely <i>age</i>, <i>weight</i>, and so on.\n\n-  The  <i>label</i>column is to save the label such as 0 for <INSTRUCTION_NAME>age</INSTRUCTION_NAME>0 (for the first data point for <i>age</i>column), 1 for <INSTRUCTION_NAME>age</INSTRUCTION_NAME>1 (for the second data point for <i>age</i>column), and so on.\n-  In the last column with  <i>Trial-level eligibility</i>, the data points are grouped into <i>Excluded</i>, <i>Not_relevant</i>, or <i>Eligible</i>.\n-  4<i>th</i>&nbsp;column is to save the ID of patient_note and patient.\n<table border=0 cellspacing=1 cellpadding=4 width=\"350\">\n<tr>\n<!-- MARK: data -->\n<td align=\"left\">DATA</td>\n<td></td>\n</tr>\n<tr>\n<!-- MARK: label -->\n<td></td>\n<td align=\"left\">LABLE</td>\n</tr>\n</table>\n\n\n\nThe patient's note contains 4 columns: 0: Excluded; 1: Not_relevant; and, 2: Eligible.\n\n-  Now, the data points",
        "label": 0
    },
    "1416": {
        "output": "[/END]\n\n \nIf you have a question, please post to the [Discuss Forum](https://discuss.app.io/c/appiio-data-science-dsc-team/wip-help-center). The [Tutorials repository](https://github.com/appiio/tutorials) contains [documentation](https://github.com/appiio/tutorials/blob/master/03.md) on each feature.\n<EOD> The Use of a Modified Foley Catheter to Inject the Tonsillar Nerve in Tonsillectomy.\nTonsillectomy is the most commonly performed surgery in the United States for children, with more than 500,000 patients undergoing the procedure each year. Although tonsillectomy is considered a simple procedure, the dissection of tonsillar blood vessels and branches of the greater palatine nerve can be challenging and risks unesthesiated hemorrhage. We describe a technique of tonsillectomy in which a Foley catheter is used to aid dissection of the tonsillar nerve and tonsillar vessels.<EOD> Long-acting glucagon-like peptide-1 receptor agonist (LAR) therapy in the context of other therapeutic options for diabetes.\nDespite the advent of several drugs intended to treat or delay the progression of type 2 diabetes mellitus (T2DM), there remains a large unmet need in T2DM pharmacotherapy. The introduction of long-acting glucagon-like peptide-1 receptor agonist (LAR) therapy has created a new class of drugs that has the potential to treat this gap in pharmacotherapy. The LAR agents, including exenatide LAR (Bydureon; AstraZeneca, Wilmington, DE, USA) and liraglutide LAR (Victoza; Novo Nordisk, Bagsvaerd, Denmark), provide continuous activation of the glucose-dependent insulinotropic pathway leading to improved glycemic control through effects on both insulin secretion and glucagon secretion. Recognition of the importance of",
        "label": 0
    },
    "1417": {
        "output": "Now we have finished all instructions, so save the file named test.Rmd and execute it in RStudio via the Run function above or via the command in the Terminal:`./run\n<EOD> A high-throughput phenotyping pipeline for oil palm seedling tissue and root development related traits based on scanned images\n\nBackgroundBased on the biological processes of tissue (shoots and roots) and root development (RD) of oil palm seedlings and in order to facilitate the screening and identification of oil palm varieties with high yield potentials and/or adaptative ability to the variable agro-climatic conditions in the tropics (i.e. Malaysia, Philippines, Ecuador and Colombia), an image analysis pipeline has been customized to the assessment of tissue and root development traits of oil palm seedlings.ResultsTissue (or shoot) widths and root numbers and lengths were obtained with an accuracy of 90%, 80% and 70%, respectively.ConclusionsOur image analysis strategy can be directly applied to the phenotyping of oil palm seedlings in the field, in the greenhouse and in growth chambers. Moreover, similar analysis can be easily adapted to the large volume phenotyping of root development traits in other tree and crops species.Phenotyping strategy of roots (or root length (RL) and root number (RN);Fig. 3A); - the second cluster (C1 = 124543) grouped tissue widths (or shoot width at shoot base (SW) and shoot width at shoot middle (SM)); - the third cluster (C2 = 1059988) grouped root numbers (or root numbers at one-year-old seedling (RNs)), root numbers at two-year-old and three-PLOS ONE\n\n# Methods and results\nA segmentation based on the histogram and thresholding approach was used to delineate regions of interest (i.e. of the tissue and root images) on scanned image backgrounds. The oil palm seedling images were then subjected to automatic seedling length (seedling length at shoot base (Ls), shoot length (SL), shoot length at leaf 10 (SL10), leaf 40 (SL40",
        "label": 0
    },
    "1418": {
        "output": "# Author's Note\n\nThis project is developed from a previous study on the subject called [https://www.gatscience.org/open/14/ \"Text-to-data annotation tool using OpenNLP for clinical studies\"].\n\n# Author Contributions\n\n[IND]\n\n# Funding\nThe author(s) received no financial support for the research, authorship and/or publication of this article.\n\n## Orcid ids\n\nTalha Z. Alshahrani https://orcid.org/0000-0001-5384-1086 Aboobakr Alderayani https://orcid.org/0000-0002-1652-9217\n\n## References\n\n1-H. Aerts JM, Gys MJDL, Hoen PM, et al. \"Bladder Pain Syndrome.\" In: Chow PKK, Taneja R, Dahlof B, et al., editors. Endourology Disease: A Reference Guide for Clinicians. New Delhi: Wiley and Sons, 2016. p. 255-260.\n\n2-Lee SY, Shapiro MA, \"Painful bladder syndrome (interstitial cystitis).\" Adv Physiol Educ. 2013;37 (1):160-168.\n\n3-King C, Smith A, Painter N, et al. \"The epidemiology and risk factors of painful bladder syndrome: a population-based study.\" BJU Int. 16 (2014):471-477\n\n4-Kaplan JR, Vavra JP, Hanno PS. \"Consultation: The diagnosis of interstitial cystitis revisited.\" Eur Urol. 2005;47 (5):571-598.\n\n# Disclosures\n\nThe Author(s) of this article have no conflicts of interest to declare.\n\n## Appendix. clinical trial data\nThis file contains the clinical trail data for the mentioned clin",
        "label": 0
    },
    "1419": {
        "output": "The output of `Trial-level eligibility: 1)` should be a blank line. [INST]\n\n### 5.4.3. Sample of the output\nYour sample output of this subtask is shown in the next table and Figure 5.\n```text\n-----------------------\nOutput\n-------\nTrial-level eligibility: Excluded\nPatient-level eligibility: Not relevant\nPatient-level diagnosis is: Appendicitis\n-----------------------\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n[INST]\nTrial-level eligibility: 1) Not relevant\nPatient-level eligibility: 1) Disqualified\nPatient-level eligibility: 2) Eligible\nPatient-level diagnosis is: Appendicitis\n\n![Diagnostic Assessment]\n\n[INST]\n\nTable 9. A sample output of the subtask\n[INST]\nSuch clinical trials of the above data were successfully conducted in real cases. [INST]\n\n## Difficulties regarding the Diagnostic Assessment subtask and our solutions",
        "label": 2
    },
    "1420": {
        "output": "[END]\n<EOD> Detection of methylenetetrahydrofolate reductase C677T gene polymorphism by microchip based on oligonucleotide probe array.\nBACKGROUND\nThe high homology sequences of MTHFR genes in the same species cause difficulties in sequence detection and genotyping using polymerase chain reaction-capillary electrophoresis (PCR-CE), single-strand conformation polymorphisms (PCR-SSCP), and denaturing high-performance liquid chromatography (DHPLC) for MTHFR gene polymorphism. We used a microchip array to detect the polymorphic site C677T of MTHFR.\n\n\nMETHODS\nThe microchip was constructed using oligonucleotide probe array and a microfluidic chip as the carrier. A microchannel was used to carry polymerase chain reaction products and probes through a micropump.\n\n\nRESULTS\nThe probe was fixed on the chip, which was hybridized with 200 fmol of the probe complementary to the PCR fragments of MTHFR C677T. The chip was then placed in a 5-ml fluorescence tube for 15 min to elute the hybridized DNA at a temperature of 40 degrees C for 10 hours. Using the PCR-CE as the reference, this microchip assay was a rapid, sensitive, high-throughput tool to genotype MTHFR C677T.\n\n\nCONCLUSIONS\nThis microchip array has high efficiency, sensitivity, automation, and high-throughput. We believe that this microchip assay will be of great importance in gene chips, especially in detecting genes that are difficult to amplify and analyze.<EOD> .\nObjective: To explore the impact of combined oral contraceptives (COCs) on the cardiovascular system and bone mineral density (BMD) in Chinese female college students, providing evidence for relevant clinical guidance. Methods: 2 171 female college students were included in this study. The 2 171 students were divided into two groups, group A (COC",
        "label": 0
    },
    "1421": {
        "output": "Your output should look like the following:\n\n# The second case study\n\nYou are also an assistant at the Clinical Research Center of a large tertiary care hospital. Your task is to provide clinical trials with a list of patients who are eligible for them. You can use the patient database to provide a list according to the trial's inclusion and exclusion criteria. The patient data is described in the patient information file (.XLS extension) and in the form of a text document (.PDF extension).\n\nTo make this system more user-friendly and practical, we should develop user-friendly tools for assisting in clinical trial eligibility screening. You can create a tool to list patients to whom a clinical trial can be offered. Let's imagine a new clinical trial in the oncology-hematology field.\n\nThere are n(>100) patients in the database. In the database, we will store demographic information (age, sex) as well as information on treatment of the disease (histological diagnosis, number of courses, etc.). The main goal of this system is to identify patients who are eligible for clinical trial enrollment. The application should generate a list of potentially eligible patients for given clinical trials in a user-friendly manner.\n\nHere are the data about patients:\nName\nSex\nHistological diagnosis\nTreatment code\nTreatment ID\nAge\n\nThere you are, Doctor. Thanks to this new tool, doctors can choose the best treatment for their patients and avoid inappropriate prescriptions at the same time. Please keep the tool running, because patients are always coming to your center looking for the best treatment. [INST]\n##[/INSERT]\n\n## Exercises\n\nThe goal of Exercise A is to allow you to demonstrate what you learned in the [course1.1] class. The goal of Exercise B is to help you create a tool to provide clinical trials with a list of patients who are eligible for them.\n\n## Exercise A\n\nIn this exercise, you will create a patient note and you will run a trial-level eligibility for a clinical trial. \n\nCreate a new python notebook and open it named `exers1.ipyn",
        "label": 0
    },
    "1422": {
        "output": "# 8-3. Patient selection Example\n\n<html>\n<head><title>Pain Assessment</title><link rel=\"stylesheet\" href=\"_static/css/theme.css\" type=\"text/css\" /><script type=\"text/javascript\" src=\"_static/js/jquery.min.js\"></script><script src=\"_static/js/jqueryui.min.js\"></script><script src=\"_static/js/jquery.dataTables.js\"></script></head><body>\n<div class=\"page-header\">\n    <h1>PAIN ASSESSMENT</h1>\n</div>\n\n<div class=\"page-content\">\n    <form method=\"post\" enctype=\"multipart/form-data\">\n        <input type=\"hidden\" id=\"trial_id\" name=\"trial_id\"/>\n        <div class=\"table-responsive\">\n            <table id=\"dataTable\" class=\"table table-striped table-bordered data-table\">\n                <thead>\n                    <tr>\n                        <th>#</th>\n                        <th>Patient name</th>\n                        <th>Trial-level eligibility:   0) Excluded, 1) Not relevant, 2) Eligible</th>\n                        <th>Evaluation by physician</th>\n                        <th>Patient information</th>\n                        <th>Visit date</th>\n                        <th>Visit time</th>\n                        <th>Visit location</th>\n                        <th>Note</th>\n                    </tr>\n                </thead>\n                <tbody>\n                    $.fn.dataTable.defaults.lengthChange= false;\n                    $.fn.dataTable.defaults.paging=true;\n                    $.fn.dataTable.defaults.searching=false;\n                    $.fn.dataTable.defaults.info=false;\n                    $.fn.dataTable.defaults.filtering=false;\n                    <script>\n                    $(document).ready(function () {\n                    var table = $('#dataTable').DataTable( {\n                        processing: true,",
        "label": 0
    },
    "1423": {
        "output": "<EOD> Association of the ABCA1 gene with serum total cholesterol and body mass index.\nApolipoprotein B-containing lipoproteins (VLDL, IDL, LDL) and Lp(a) are transported to liver by the lipoprotein receptor LDL/VLDL-R. These molecules are endocytosed and transferred through hepatocytes to the bile for cholesterol excretion, a process mediated by sterol-dependent Lp(a) degradation. Abca-1 plays a key role in this sterol pathway by mediating the ATP-binding cassette-dependent translocation of free cholesterol and phospholipids from the plasma membrane to apolipoproteins, with subsequent formation of HDL particles. In the present study, the association between a functional polymorphism in the ABCA1 at codon 407 (E427K) and serum lipids parameters and body mass index (BMI) in an Italian population has been investigated. The study was performed on 133 healthy subjects (age 25-75 yrs) in whom systolic blood pressure, body weight (in kg) and height (in m) were measured, BMI (in kg/m2)was calculated, and fasting blood samples were collected. Genotyping of the E427K polymorphism was performed by a PCR-RFLP analysis. Compared to subjects with a mutated (K/K or E427K) allele, participants with a wild-type allele (K/E or E/E) showed a significant decrease in HDL levels and increased values of total cholesterol and triglycerides. The K/E and E/E genotypes were also associated with significantly higher values both of BMI (57.2 +/- 3.4 kg/m2) and of waist circumference (1.06 +/- 0.07 m). Multiple regression analyses were conducted to assess whether age, gender, BMI, and other variables (diabetes, hypertension, hypertriglyceridemia, and LDL-cholesterol levels higher than 130 mg/dl), interact with the E",
        "label": 0
    },
    "1424": {
        "output": "## Exercises \n\n### Ex. 1. If the first line of the note is read as follows, what should be entered on the trial-level eligibility?\nGot a job, starting Monday!\n\n#### Answer\nEligible.\n\n#### Explanation\nThis is a patient note and you need to make a trial-level eligibility. You have only information about job. \nYou first need to examine the whole patient note: \nThen you can skip to `Trial-level eligibility:` ` 2) Eligible.`.\n\n### Ex. 2. If the second line of the note is read as follows: `No job` and the first line of the note is the same as `Got a job` from ex. 1, what should be entered on the trial-level eligibility?\nNo job\n\n#### Answer\n\n#### Explanation\nThis is a patient note and you need to make a trial-level eligibility. The first line contains the information of job and the second one no job. \nThere are a lot of information from the first part of this note. You can first try to skip to `Trial-level eligibility: `2) Eligible.`. But you need to include the second sentence because the `no job` can affect the employment period, etc. Therefore, to make sure, you should include a note to make sure, something like this: \n\n\n* 2) Eligible (job)\n\n#### Ex. 3. If the first and third line of the note are read as follows, and the second one is read the like ex. 2: `No job`, what should be entered on the trial-level eligibility?\nIncreasingly busy, must take on new responsiblity\nLosing weight\n\n#### Answer\n\n#### Explanation\nThis is a patient note and you need to make a trial-level eligibility. The first line contain increasing busyness and other information is about losing weight, but the information is not relevant to your task. You can make a trial-level eligibility by the information in the second line. \nFinally, you should always repeat Trial-level eligibility at the end of the last line, \n\n## Conclusion\n\n\nThank you",
        "label": 0
    },
    "1425": {
        "output": "##[COUNTRY] Good morning. You are a helpful assistant for clinical trial recruitment in [INST].\nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n[INST] [INST] The clinical trial name and design are the same as those you used in Problem 01. Let's think step by step. \n\n# Conclusion\n\n# Problem 02\nTo avoid repetitive content in Problem 02 and 03, here is a simplified version. \n\n## Name: Clinical Trial Eligibility Check (04",
        "label": 0
    },
    "1426": {
        "output": "If patient's eligibility is 2) Eligible, you should show the eligibility table of clinical trial. If patient's eligibility is 0) Excluded, you should show the reason why patient is excluded from trial; if patient's eligibility is 1) Not relevant, show no reason for trial, but it is more meaningful for physician in clinical practice. [INST]\n\n\nYou need to submit your script to the CTSG-SCCP 2019 Script Contest!<EOD> .\nIn the present study, 2.5 g each of NaCl, KCl, CaCl(2), MgCl(2) and NaHCO(3) were placed in a glass bottle, the pH was adjusted to 8, and solutions with different pH (3 to 10) were prepared by adjusting HCl or NaOH solution at room temperature. The above solution was mixed and added with the appropriate amount of 5% AgNO(3) solution and 1.5% Al(NO(3))(3) solution. The reaction of silver ion with each solution showed significant difference. The results showed that Ag(+), released from Ag(NO(3))(3) under the action of Al(NO(3))(3) was strongly absorbed in the 10 cm-long stainless steel tube, as evidenced by the fact that Ag(+) concentration decreased from 1 820 \u03bcg x L(-1) to the detection limit within 10 min, but there was no absorption in CaCl(2) and NaCl solution. This showed that silver ions in acid solution had good adsorption on the surface of the stainless steel tube, but its absorption was weakened after the mixture was neutral or slightly alkaline. Ag(+) was gradually released in each solution except for CaCl(2) and NaCl, after the stainless steel tube was removed from the solution and added into the Ag(NO(3))(3)/Al(NO(3))(3) mixed solution. Meanwhile, the changes of Ag(+) concentration in solution were also measured. It was found that Ag(+) concentration decreased continuously in all the solutions and the highest rate of the decrease was shown in HCl and CH(",
        "label": 0
    },
    "1427": {
        "output": "## The patient note (Part 2):    \nThe patient note is as follows: \nOn examining the patient, there was hepatomegaly at palpation. Other systemic physical examination was normal .   \n\n## Clinical trial\nThe clinical trial that the patient is enrolled in is as follows: \nLet's think step by step. \nBefore the patient was 59 year old, she had a surgery in her appendix and this surgery made appendicitis. After this surgery her Appendix got stuck in the scar tissue of her abdominal wall. The appendix is in a sac that is called Appendix Vermiformis,",
        "label": 0
    },
    "1428": {
        "output": "[/NOTE]\n~<EOD> .\nA case of severe hemolytic reaction following the penicillin (benzathine benzylpenicillin) prophylactic therapy of the recurrent tonsillopharyngitis is presented. The drug was given in a single dose (2,4 million units). The signs of hemolytic transfusion reaction, fever, myalgia and hepatitis appeared 5 days after the prophylaxis. The course was benign. The transient hemolysis was diagnosed as an atypical benzylpenicillin reaction.<EOD> O-sialoglycoproteins in aorta: a marker of in situ expression of the O-sialoglycoprotein endopeptidase\n\nA cDNA for a newly cloned O-sialoglycoprotein(s) endopeptidase homologue was previously identified by its capacity to be expressed at high level in transiently transfected COS-M6 cells. The protein isolated in pure form from these transfectants was shown to cleave the sialyl-\u2423 -2,3-galactosidic bond of O-sialoglycoproteins such as ganglioside GD1a and myelin basic protein, a well-established substrate for the endogenous, membrane-associated endopeptidase (J. F. Coligan, J. Boll, F. H. Cunningham, and B. D. Carroll, J. Neurochem. 63:2015-2022, 1994). Here, by in situ hybridization with a probe derived from the cDNA of the O-sialoglycoprotein endopeptidase, the cellular expression of this enzyme was examined in rat aorta. This revealed that O-sialoglycoprotein endopeptidase mRNA was expressed in large smooth muscle cells (i.e., elastic arterial cells) and, to a lesser extent, in endothelial cells. This was surprising, since smooth muscle cells have been shown to lack the endogenous membrane-associated O-sialoglycoprotein endopeptidase activity. Thus,",
        "label": 0
    },
    "1429": {
        "output": "\u00a9 2018 N. Kusnierczyk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.\nAcknowledgementsWe would like to thank all our professors who advised in this writing.Conflict of interest, source of fundingThe authors state no conflict of interest.<EOD> Changes in Serum Creatine Phosphokinase and Electrophysiological Study Findings during a Short-Term Follow Up after Nd:YAG Laser Irradiation for Trigeminal Neuralgia\nABSTRACT Trigeminal neuralgia (TN) is a disabling neuropathy. Although carbamazepine or oxcarbazepine is a drug of choice for therapy, for patients without good control or experiencing drug toxicity, Nd:YAG laser ablation is one of the treatment options. Although the immediate effect of Nd:YAG laser ablation has been demonstrated in previous studies, its long-term effects on function recovery remain elusive. The aim of this study was to investigate changes in serum creatine phosphokinase (CK) and electrophysiological study findings after Nd: YAG ablation for TN treatment. Forty-six patients with TN who underwent Nd: YAG ablation treatment in our institute were included. Initial symptom onset, drug use, clinical characteristics of TN such as duration, severity, unilaterality, and bilaterality, VAS score before and after ablation, CK level 1 hour after ablation, electroneuronography (ENG) findings, motor nerve conduction study (NCS) 3 months after ablation, and visual and sensory NCS and pain threshold 6 months after ablation were evaluated. Forty-six patients (28 males and 18 females) were evaluated. CK levels were 161 \u00b1 33 U/L before and 664 \u00b1 180 U/L immediately after ablation, and 200 \u00b1 42 U/L 3 months after ab",
        "label": 0
    },
    "1430": {
        "output": "### Step 7: Testing the code\n\nTesting the code in your local working directory is usually done by running the ``pytest`` program. Note that the testing code may be written in isolation or interspersed with your code.\n\nTo test the code at one time, press the ``TAB`` keyboard shortcut and the name of the module/test case is presented in the console.\n\nIn the working directory of the local clone of the course, the project can be tested by running: \n\n```cmd\npytest\n```\n\n### Step 8: Integration Tests\n\nTo run integration tests, create folders with the names of modules in the current working directory and name the files appropriately (e.g.: ```integration_test.py)``. Run the following code in the appropriate folder and in the main folder:\n\n```sh\n#! /bin/sh\ncd `pwd`\nexport PYTHONPATH=/home/stg/saradje/iit-20190613-033443/\npython3 setup.py pytest\n```\n\n### Step 9: Building The Project\n\nYou can build either individually using `mkdocs serve` command or using `gh-pages` command to build the project for the `site` directory. Also note if the site build fails, the `site` will contain the markdown code and not the rendered version. Since the `mkdocs serve` command takes over your terminal when you run it, using it for build can be considered not good practice.\n\nTo build the site, use the following commands:\n\n```sh\n#! /bin/sh\n# to serve the site on port 8000\npython3 -m mkdocs serve\n```\n\n```sh\n#! /bin/sh\npython3 -m mkdocs gh-pages clean html\n```\n\n### Step 10: Production Build with Azure Websites\n\nTo build the `gh-pages` in the Azure web site, first, the project is cloned and a web app created at Azure web site. Note that using the existing site will require manual file versioning. Hence, the project is cloned and recreated.\nThe following steps need to be done:\n\n#### Azure Websites - Create\n\nTo create the web application",
        "label": 0
    },
    "1431": {
        "output": "<EOD> Anorectal atresia and atresia with stenosis of the colon\nFifty\u2010three patients, 28 females and 25 males, born with anorectal atresia and atresia with stenosis of the colon were followed in the years 1944\u201388. Fifty were managed surgically; 2 with perineal opening, 3 with posterior sagittal anorectoplasty and 45 with an anterior sagittal procedure. Three patients were managed medically. Of the 53 patients, 33 (62%) have normal function. Sixteen patients (30%) have mild functional impairment, 2 have moderate functional impairment (4%), and 2 (4%) have severe functional impairment. Of the 33 patients with normal function, 19 (58%) have not needed further surgery. Of the 25 patients with stenosis of the colon, 15 (60%) have had one or more further operations. Colonic stenosis and long\u2010term complications may be anticipated in these patients, particularly if their postoperative care is poor.<EOD> A clinical audit into the care of patients admitted to an acute medicine unit based upon an emergency care unit of a British Military Hospital, Role 3, Iraq, October 2008\nObjectives: We conducted a clinical audit on acute medical admissions into an emergency care unit in Iraq to identify areas of improvement from the previous data. Methods: We conducted a clinical audit, investigating medical admissions into the emergency medical unit at Camp Al Asad hospital, Iraq, over a 4 week period in January 2009 to determine any changes in patient care following the recommendations as a result of the previous audit. Results: There have been significant improvements in patient care compared to the previous audit. All patients received medication and fluid therapy upon arrival 90% (154/ 170) compared to 68% (80/ 115) at the previous audit, and the mean arterial pressure was maintained >65 mmHg on arrival compared to 64% at the previous audit. 92% (134/146) of",
        "label": 0
    },
    "1432": {
        "output": "================================================================================ === [Q1] 42. The Clinical trial does not provide information about the type of the SEMS which should be used for endoscopic positioning. Since SEMSs have different characteristics, what is the correct answer?\na. Any type of SEMS can be used b.\nAny type of SEMS other than the type used for intestinal stricture c.\nAny type of SEMS other than the type used for bile duct stricture d.\nAny type of SEMS other than the size recommended by the trial e.\nAll answers may be correct. ================================= === [Q2] 43. The correct option is:\na. 1) Excluded b.\n2) Not relevant c.\n1) Excluded d.\n\n## 1)\nNot relevant e.\nAll answers may be correct. ===================================================== 44. What is the type of the SEMS that should be used according to the Clinical trial?\n\n## 45.\nIn your experience with SEMS, how often has an endoscopic procedure failed to be successful?\n\n## 7) [q4] and [[q5]] 46. The correct answer is: a. 1) Excluded b.\n2) Not relevant c.\n1) Excluded d.\n\n## 1)\nNot relevant e.\nAll answers may be correct. ================================================== [[Q6]] 47. For what patient populations, the results of each option could be applicable? For which patients, the choice of the treatment is limited?\na. 1) Patients that are on chemotherapy, or have had it in the past 1 year, or are scheduled for chemotherapy. b.\n2) Patients that are on chemotherapy, or have had it in the past 1 year, or are scheduled for chemotherapy and present a small tumor size. c.\n1) Unresectable tumor-bearing patients whose age is greater than 75 years, are on chemotherapy or have had it in the past 1 year. d.\n2) Unresectable tumor-bearing patients with a tumor size less than 50 mm that are on chemotherapy or have had it in the past",
        "label": 0
    },
    "1433": {
        "output": "## 20.1.5 SOLUTION (TEST YOURSELF - GO TO [URL])\n[![Run the solution online](https://run.katalabs.com/u/jg1n1OeD5fzYvBtWkVa3dQ/solutions/20.1.5_Solution/)](https://u.r/jg1n1OeD5fzYvBtWkVa3dQ)\n\n## SESSION 20: SIMULATION & RANDOMIZATION SESSION LEADERS: [NAME] & [NAME]\n\n### INTRODUCTION\n\nThis course provides an introduction to the concept of randomization and randomized experiments. The topic is a central idea in modern science and one that you will often have to consider. This course uses R to work through examples related to random assignment and randomization.\n\n### COURSE CONTENT\n\n\n* Sessions:\n    * 1) Principles of Randomization and Random Assignment.\n    * 2) Implementation by Randomization and Random Assignment.\n    * 3) Random Assignment Using Categories of Treatments.\n    * 4) Random Assignment Using Treatment Procedures.\n    * 5) Implementation of Randomized Experiments for Independent Measures.\n    * 6) Implementation of Randomized Experiments for Dependent Measures.\n    * 7) Implementation of Randomized Block Experiments.\n\n* Lectures:\n    * _Note : 10-15 minute lectures, with a small test interspersed every 5-7 minutes._\n\n### PREREQUISITES\n\nYou should have the following prerequisite skills in R to participate in this course. Skills such as plotting data and finding summary statistics can be learned during the course, but may require outside training.\n\n1. Knowhow to program in R.\n2. Use of the statistical analysis package 'stats' \n3. Use of the R command 'plot' to plot data \n4. Use of the R command 'stats::summary(a$x)' to find descriptive statistics\n\n### SIMULATIONS\nIt is strongly advised",
        "label": 0
    },
    "1434": {
        "output": "## 1.1 Assessment of eligibility\n1.1.1 PREOP: Before Open:\nYou do not need much to do in this section, since, clinicaltrial.gov is not updated with the status of the trial. If the trial is in its preparatory phase, just write as follows:\n[INFO] Open: Open.\n\nThe first record of your patient is in the `Demographics: ` section.\nHere is the first record of our patient in the trial:\n\nDemographics:\n[PAT] first initial last initial: \"VL\"\n[AGE] age: 54\n[SEX] sex: female\n[RACE] race: \"Caucasian\"\n[DESIGN] design: \"Controlled\"\n[RESULT_ACTIVE] result active: \"true\"\n[RESEARCH_CENTRE] research centre: \"Gastroenterology Unit\"\n[TRIAL_CODE] trial code: \"1234\"\n[CONDITION] condition: \"cholelithiasis\"\n[STUDY_START_DATE] study start date: \"2018/06/10\"\n[START_OF_ACTIVITY] start of activity: \"2018-06-10\"\n[ACTIVITY_TYPE] activity type: \"treatment\"\n[PHASE] phase: \"1\"\n[SEQUENCE] sequence: \"1\"\n[LOCATION] location: \"Garcia de Orta - Hospitais da Universidade do Porto\"\n[ID] id: \"9312-1\"\n\nAt the end, you will see the line:\n\n[Treatment_Cohorts: ]\n[1] first start.\n\nCohorts are created as trials begin enrolling patients, and ClinicalTrials.gov provides this functionality. This number will change as recruitment changes. Thus, the cohort with the label `first start` is the trial's first cohort. \n\n\n1.2 Assessment of Eligibility\n\nNow, you will analyze the first field in the trial, the `Inclusion Criteria: `. This field contains the criteria you should meet to be able",
        "label": 0
    },
    "1435": {
        "output": "##[[MATCHING]]\n\nYou are now asked to select your preferred choice for the matching options. \n\nYou are now presented with the following 2 sets: the `patient note` column and the `clinical trial` column.\n\nYou are asked to identify in which column the matched data should be shown.\n\nHere is a patient note:\nA 54-year-old obese woman, admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\nThe epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced this type of pain twice in the past year .\n\nShe has 2 children, and she is menopausal . She does not smoke, drink alcohol, or use illicit drugs .\nShe is mildly febrile, with a BP of 150/85, HR of 115, RA of 15, T of 38.2, and SpO2 of 98% on RA. She is an obese woman with no acute distress.\nOn palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant, without rebound .\n\nHer bowel sounds are normal . Laboratory analysis is remarkable for an elevated ESR and leukocytosis with a left shift .\n\nUltrasound revealed the following: several gallstones, biliary sludge, and common bile duct (CBD) stones. The smallest stone is 14 mm . \n\nHere is a clinical trial: \n\n# Title\nStudy of",
        "label": 0
    },
    "1436": {
        "output": "## Exclusions\n\n\n\n## 1) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).\nInclusion Criteria:\n- A TMJ disorder\n- Headaches rated 4 or 5 on a 0-10 NRS for untreated headache\n- Duration of TMJ disorder of 6 months or greater\n- Pain rating of 3 to 10 on NRS during at least one of the six clinic visits in the first month, excluding the visit in which patient's first treatment occurred.\n- Pain rated 3 to 10 on NRS and meets 2 of the 3 \"frequency/duration\" criteria during at least 4 of 6 clinic visits in the first month, excluding the visit in which patient's first treatment occurred.\n- Pain rated 3 to 10 on NRS and meets 1 of the frequency/duration criteria during at least 5 clinic visits in the second month, including the visit in which patient's first treatment occurred.\n- Frequent episodic tension-type headaches (FETTH) rated 3 or",
        "label": 0
    },
    "1437": {
        "output": "<EOD> Comparison of the effect of three methods on the reduction of bacterial numbers in the intestinal tract following the withdrawal of antimicrobial therapy.\nThe effectiveness of three methods of reducing bacterial numbers in the intestinal tract following the withdrawal of antimicrobial therapy was investigated. The three methods were non-absorbable disaccharidase inhibitors; metronidazole and neomycin suppositories and short-chain fatty acids (SCFA). In Experiment 1, intestinal levels of non-saccharolytic bacteria and SCFA in healthy rabbits were investigated 7 days after the administration of either feed containing sodium-2-carboxymethyl-3-hydroxymethyl-1,6-dioxahenane, metronidazole and neomycin or feed containing SCFA supplementation to the diet, compared with controls. There was no difference in SCFA levels between the control, group fed sodium-2-carboxy methyl-3-hydroxymethyl-1,6-dioxahenane and the group fed metronidazole and neomycin. The group fed metronidazole and neomycin had significantly higher bacteria counts than the other two groups. In Experiment 2, bacterial numbers in clinical cases of E. coli septicaemia were compared in pigs treated by surgical diversion and oral antimicrobial therapy, and in a similar group on antimicrobial therapy only. Two treatment groups of therapeutic group of surgically, diverted group and both pigs were infected with E. coli septicaemia. Six pigs in each group were killed at 72 h. The bacterial counts in these groups of pigs were not significantly different, between the two groups. These results indicated that sodium-2-carboxymethyl-3-hydroxymethyl-1,6-dioxahenane, metronidazole and neomycin combination and the SCFA supplement were not effective in reducing bacterial numbers in the intestinal tract.<EOD> Effect of Cognitive-Motor Exercise Program on",
        "label": 0
    },
    "1438": {
        "output": "<!-- --------------------------------------------------------------------------------------------------------------------- -->\n\n### Example 2:\n``language: python\nname: Trial-level eligibility: 1) Not relevant and 2) Eligible\n\non:\n   push:\n      branches:\n          - next\n```\n\nYou should repeat both 1) Not relevant and 2) Eligible in the code block. \nYou could do this by adding a `for` loop in the code block. The code block below shows the following syntax:\n\n```\nTrial-level eligibility_not_relevant:\n    shell:\n      - \"python -m mypy\"\n\nTrial-level eligible:\n    shell:\n      - \"python -m mypy\"\n      - \"python -m script -n /dev/stdin -p 'Trial-level eligibility: 2) Eligible'\"\n\n    1) Not relevant and 2) Eligible:\n         shell:\n         - \"python -m mypy\"\n         - \"python -m script -n '/dev/stdin -p '1) Not relevant (patient does not have sufficient information to qualify for the trial)' '\"\n         - \"python -m script -n '/dev/stdin -p '2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)' '\"\n```\n\n### Example 3:\n``language: python\nname: Trial-level eligibility: 1) Not relevant and 2) Not relevant (patient does not have sufficient information to qualify for the trial) and 2) Eligible\n\non:\n   pull_request:\n      branches:\n          - next\n```\n\nYou should add another `and` with the code block. Note the brackets. The second `and` block has a blank line. \nThe code block below shows the following syntax for this:\n    \n```\nTrial-level eligibility_not_relevant:\n    shell:\n      - \"python -m mypy\"\n\nTrial-level eligibility_not_relevant2:\n    shell:\n      - \"python -m mypy\"\n      - \"python -m script -n '/dev/stdin -p '1",
        "label": 0
    },
    "1439": {
        "output": "## [CASES]\n1 `cat`\n\n![cat](images/p_cat.jpg)\n\n\n2 `dog`\n\n![dog](images/p_dog.jpg)\n\n[INST]\n\n1`This is a cat.\n2 This is a dog.\n`\n\n[CASES]\n\n`4) cat or dog.5) cat or a dog.6) cat or (dog).7) cat and dog.8) cat, dog.`\n![P5](images/p5.jpg)\n<EOD> Sickle cell lung: an angiographic study.\nAngiographic visualization of the lung vasculature in the patients with sickle cell anemia has demonstrated in an unheralded number of patients significant distortion and loss of pulmonary vessels. A total of 40 patients with sickle cell anemia were examined. Forty-two percent (17/40) of these patients showed pulmonary vascular distortion and vessel loss of greater than 10% of total lung volume. An unheralded 62.5% of the black population with sickle cell anemia had significant pulmonary vascular abnormalities. The etiological factors in these vascular defects are unknown, however, the possibility that these defects may be related to vaso-occlusive events of sickle cell anemia is supported by the histological study that demonstrates areas of interstitial pneumonia, arteriolar thrombosis and vascular occlusion. This study suggests that sickle cell lung disease may be a more serious and widespread disorder than previously recognized.<EOD> Angiostrongylus dujardini in a European otter in the Camargue, France.\nFourteen specimens of Angiostrongylus dujardini (Looss, 1907) were collected from lungs of one of 46 otters shot, opportunistically, in the Camargue (southern France, Mediterranean coast). The morphological peculiarities of some of the worms observed are noted.<EOD> .\nThere is little information concerning the distribution of the cytotoxic activity of CD3-cells against myeloid leukaemic cell lines in patients with chronic",
        "label": 0
    },
    "1440": {
        "output": "### Step (2): Prediction result generation\n\nBy completing part 1, you need to generate scores for your prediction model from your patient data, and then you need to save them.\n\nIn Part 1, we trained predictors with supervised machine learning for each task. For tasks 1 and 2, we used support vector machine (SVM) due to its high performance for binary classification tasks. Task 3 used random forest (RF) because it was a regression-based prediction. Task 4 uses Kernel logistic regression (KLR), an algorithm similar to logistic regression, which is used for binary classification.\nIt is best to use the `predict()` function and `predict_scores()` function to generate prediction results from your trained prediction model. (Note: Since the prediction score is output through this function, it is possible to select and save each prediction score separately.) And then, it is possible to save your prediction score by the `write.sav()` function. (Note: In the example that follows, the 4 classes from tasks 1, 2, 3, and 4 are named in order of the numbering you input.)\n<example-code>\n\nset.seed(1758)\n\n# Task 1: patient age <-\"patient age\"\n# Task 2: patient smoking status <-\"patient smoking status\"\n# Task 3: patient sex <-\"patient sex\"\n# Task 4: patient obesity <-\"patient obesity\" \n\n\n# Step 1:\n# Prediction task preparation \n\n# Set seed\nset.seed (1758)\n\n# Name task name \nnames.task <-c(\"age\",\"smoking_status\", \"sex.age\", \"sex.patient age\", \"obesity\",\"age.obesity.sex.age.patient age\", \"obesity.age.sex.age.patient age\")\n\n# Task preparation \n\n#################### Task 1 ) age  ################\ny_actual_age <-c(1,1,1,1,1,1,1,1)\nx_actual_age <-seq(-10,20,0.2)\ny <-make.predict.table (x_actual_age,y",
        "label": 2
    },
    "1441": {
        "output": "This trial-level eligibility will be the key to the next step, which is data analysis and result reporting. \nNow, we can move on to the next step. \n\nThis is the data analysis module. [INST] You should enter your results for each trial-level variable in the cells that contain the numbers for that trial. Try to include the first letter of the trial-name (in this example, `CRT-1972`) in the cell name to help distinguish the different trials later. So, try to avoid using capital letters in your trial-level variable names to avoid confusion with the trial names when writing the results report. \n\nIn the table, you will want to provide the information requested to make the trial-level eligibility decisions. That is, you should select a number 1 and assign the following information to each trial if the trial has met the inclusion criteria and each trial-level variable for the patient meets the inclusion criteria: number for the trial; the category of the trial-level inclusion criterion: 1 (Met) or 0 (Not met); and a description for the patient-level values of all trial-level variables that met the criteria.~For the trial \"CRT-1972\", the cell CRT-1972.CR1.Female should be selected 1. To make that selection, you have to follow the instructions below: \n1. The table should appear as illustrated below: \u2026\u2026\u2026\n\n\n1. Click on the \u2018Edit\u2019 button in the upper left corner.\n\n2. The column details window will appear on the right side of the table.\n\n3. To make the cell a number 1, you should:\n\na. Click in the column header to select a single cell/row of the table.\n\nb. Right-click the selected cell or row and choose Cell Values -> Copy Column Values to Clipboard.\n\n4. Open NotePad and copy the contents of the Text Clipboard (from the top bar).\n\n5. Paste the text into NotePad and save the file as an Excel file. You will find a small \"clipboard\" of text there, into which the column title is copied (see below for your \"CRT-1972\" file).\n\n6. Now that we have copied the contents of CRT-1",
        "label": 0
    },
    "1442": {
        "output": "1. To import the dataset, you can load data from a specific file into the workspace with `Data_Import_Manager. Import From File('SURVEY_FILENAME'.txt,'Data_In')`. This imports the column names and data. This is the name I have given to the survey.\n2. You can explore the dataset with the `head (df)` function so that you know your dataset's contents.\n`df2 <-data_import_manager::Data_Import_Manager::Data_import_manager(df, survey_file, survey_file_path = NULL)`\n`SURVEY_ID <-1`\n`Patient_id <-1`\n`Patient_sex <factor`\n`Patient_age <factor`\n`Patient_pain_medicine <factor`\n`Patient_weight <factor`\n`Patient_bpm <factor`\n`Patient_pulse_rate<factor`\n\n\n3. Data columns need to be separated with `;` and you can also find and uncover with the '.' function.\n\n\n\n`Trial_id <factor`\n`Trial_type <factor`\n`Trial_number <factor`\n`Trial_dose_amount <factor`\n`Trial_dose_duration <factor`\n`Trial_phase <factor`\n`Trial_recruitment <factor`\n`Trial_start <factor`\n`Trial_exclusion <factor`\n`Trial_inclusion <factor`\n`Trial_eligibility <factor`\n\n\n\n## 4.\n\n##\n5. Define a specific variable depending on your survey with `Trial.`\n\n\n`df2$Trial <-within(df2, trial_name <- case_when(~ trial_phase == .1~~ \n                                                 ~ trial_phase == .2~~\n                                                 ~ trial_phase == .3~~\n                                                 ~ trial_phase == .4\n                                                 :NA\n                                                 ,\n                                                 trial_phase == .1~~\n                                                 ~ trial_phase == .2~~\n                                                 ~ trial_phase == .3~~\n                                                 ~ trial_phase == .4~~\n                                                 :",
        "label": 0
    },
    "1443": {
        "output": "# Input Data\nThe following sections list the data that is used for this dataset. This data is collected during the development sessions of the dataset. \n1. An Excel form.\n  1. Columns: `Patient ID`, `Challenge`, `Age`,`Gender`,`BMI`,`HbA1c`,`BP`,`TSH`,`LDL`,`VLDL`,`Cholesterol`,`Ultrasound`,`Drug`,`Family history`,`E.History`,`Abdominal pain`,`Nausea`,`Diarrhea`,`Vomiting`,`C-reactive protein`,`Total bilirubin`,`Conjugated bilirubin`,`Albumin`,`WBCs`,`Aspartate\u2010aminotransferase`,`Alanine\u2010aminotransferase`,`CRP mg/dl`,`Hyperbilirubinemia`\n  2. Rows: `1` `2` `3`\u2026\n1. Diabetic retinopathy disease classification: `1` `0` `1`\u2026`9` for the training data and `10` for the testing data. \n2. Eye abnormalities: `1` `2` `3`\u2026`6` for the training data and `7` for the testing data.\n\n### Training data and output of training\nFirst, create a new dataset.\n- From the 'New Dataset' page click 'Choose data' and select the folder containing the dataset . Then, give the dataset an appropriate name.\n\n![](attachment_2_682715.jpg)\n- Now we select the 'Edit Data' tab and select the 'Label column' option followed by the label column from the dataset.\n\n![](attachment_3_682715.jpg)\n- Then select the 'Train' tab and select the train model option.\n![](attachment_4_682715.jpg)\n- Once 'Train' page is loaded, select the 'Input column' option, select the 'Eye column', and select the 'Label column'.\n\n![](attachment_5_682715.jpg)\n- Now select the machine learning",
        "label": 0
    },
    "1444": {
        "output": "[/MARKUP]\n\n# Conclusion\n\n## MINIST\nBefore trying to learn the syntax of an external tool like MIPS, MINIST, and FPML, it is better to be familiar with its features. Let's look at the most frequently used statistical methods:\nCross-section analysis, case-crossover analysis, and cohort analysis. \n\n## Cross-sectional analysis (CSA)\nIn CSA, we can look at the whole population who are affected by the exposure and see how the exposure relates to the final outcome. It reveals a prevalence and prevalence ratio. CSA is not useful if we want to study the effects of exposure on health outcomes. It is useful if we want to study the distribution of exposure in different time points. \n\n## Case-crossover analysis (CCA)\nIn CCA, we use the case-crossover study design. In this design, as the name of this design suggests, each person is his/her own control, and we can examine the exposure effects on the final outcome using the individual as his/her own control. CCA is useful if we want to study the effects of exposure within a period of time on the final outcome (e.g., smoking 5 cigarettes a day and the risk of myocardial infarction in smokers compared with times when they did not smoke (in this case, the other 23 hours of one smoking day). It is a retrospective design, and you cannot control other variables because you do not have access to the exposure to them. \n\n## Cohort analysis (CA)\nIn the CA design, we cannot look at the whole affected population. We can select the affected exposure population from the study and follow their health status for some years. So basically, we design a longitudinal study. In order to perform a cohort study, the following assumptions are usually true (but not compulsory) to be performed. \n\n## Assumptions for cohort studies:\nTime invariance -the relative values of the risk should not be affected by the time when the exposure happened.\nIndependence -We assume that the exposure to risk factors is independent of the possible outcome.\nConsistency -The outcome",
        "label": 0
    },
    "1445": {
        "output": "<EOD> The inhibition by cyclosporin A and FK 506 of mitogenic responses is not due to an alteration in the levels of intracellular calcium\nThe immunosuppressive drugs cyclosporin A and FK 506 were shown to block stimulated entry of extracellular calcium and to affect intracellular cyclic\u2010AMP accumulation. However, these drugs did not affect the mitogen responsiveness of splenocytes in vitro, indicating that calcium flux, intracellular cyclic\u2010AMP and mitogenic responsiveness may not be linked.<EOD> .\nThe author presents two patients with subungual epidermoid cyst. Although it rarely occurs, such lesions have to be considered in the presence of a subungual whitish lesion which increases in volume due to intake of foreign bodies.<EOD> Development of an artificial endometrium receptive to embryo implantation: a preliminary study using a tissue-engineered organ culture system.\nThe uterine tissue and endometrial epithelial cells were taken from ovariectomized or cyclic pregnant dogs and tissue-engineered. In vitro, the tissueto-tissue interface area increased from 5.1+/-0.8 mm(2) to 720+/-59.4 mm(2) after 12 days of culture and was maintained until the end of the culture period, which was 18 days. The endometrial epithelial cells exhibited proliferative activity in vitro but died in the medium, indicating that endometrial epithelial cells do not survive in an in vitro culture. On the other hand, endometrial stromal cells exhibited both proliferative activity and extracellular matrix-forming activity, thereby providing a three-dimensional structure in vitro. The embryos were transferred into dog uterine tissue and cultured for 24 hours. Eighty-six normal and two abnormal embryos were transferred into the tissue-engineered uteri, using either the ovariectomized or the cyclic pregnant dog uterine tissue. Thirty-three embryos of the cyclic pregnant group were transferred into",
        "label": 0
    },
    "1446": {
        "output": "### 3.2.2 CORRECT STUTENT RECRIPTION AND HAECLEMENTS IN INSTALES AND INST-LETS:\n[INST] Hello. The 156-residue cytokines called interleukins are synthesized mostly by macrophages and lymphocytes. 2 The cytokines regulate a wide variety of normal cellular activities including proliferation, differentiation, adhesion, and migration. Interleukins are a major component of the innate immune system or first line of defense against foreign invaders. There are more than 40 distinct interleukins all involved in different physiological processes.\nT helper (Th) cells are T lymphocytes that orchestrate immune responses and provide signals that cause B cells to transform into antibody-producing plasma cells. A normal immune response requires interplay between 2 subtypes of T lymphocytes, Th1 and Th2 cells. 2 Two subsets of CD4+T cells, termed Th1 and Th2, are distinct in their gene expression profiles and functionally different. Th1 cells produce cytokines such as interleukin-2, interleukin-12 (IL-2, IL-12), interferon-gamma (INF-\u03b3) and the immunoglobulin G (IgG) subclass 2a (IgG2a). These help to activate cytotoxic lymphocytes, macrophages and natural killer cells. In contrast, Th2 cells produce interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), and interleukin-10 (IL-10) (anti-inflammatory cytokines) and IgG1 and IgE. Th1 and Th2 cell differentiation is mediated by the cytokine milieu that they encounter when they differentiate from CD4+ T cells. Both subsets are required for the induction of a protective immune response. 3 However, in pathogenic responses, production of the proinflammatory cytokines by Th1 cells can lead to tissue damage, such as in arthritis and psoriasiform dermat",
        "label": 0
    },
    "1447": {
        "output": "**Question:** Why does `Trial-level eligibility` end with a dot?\n\n###### Answer\nThe `Trial-level eligibility: 2) Eligible.` is the last line in the table. It should be continued over the next line. \n\n## Excercise solution & discussion:\n\n``` python\n# Patient note\npatient_list = [\n    \"A 54-year-old obese woman admitted to the emergency department \"\n    \"* with abdominal pain that started 4 days ago with nausea and vomiting.* \"\n    \"The epigastric pain radiates to the right upper quadrant, getting worse \"\n    \"* after eating fatty food.* \"\n    \"The patient experienced similar pain twice in the past year.* \"\n    \"Her past medical history is remarkable for hypercholesterolemia and \"\n    \"2 NVDs.* \"\n    \"She has 2 children, and she is menopausal.* \"\n    \"She does not smoke, drink alcohol, or use illicit drugs.* \"\n    \"She is mildly febrile.* \"\n    \"Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA.* \"\n    \"She is an obese woman with no acute distress.* \"\n    \"* On palpation, she experiences epigastric tenderness \"\n    \"* and tenderness in the right upper quadrant without rebound.* \"\n    \"* Bowel sounds are normal.* \"\n    \"* Laboratory analysis is remarkable for elevated ESR \"\n    \"* and leukocytosis with a left shift.* \"\n    \"* The ultrasound revealed several gallstones, biliary sludge \"\n    \"* and CBD stones.* \"\n    \"* The smallest stone is 14mm.* \"\n    # Patient #2\n    \"A 55-year-old obese woman admitted to the emergency department with abdominal pain \"\n    \"* that started 3 days ago with nausea and vomiting.* \"\n    \"* The epigastric pain radiates to the right upper quadrant, \"",
        "label": 0
    },
    "1448": {
        "output": "[/WK]<EOD> A comparative analysis of the impact of COVID-19 governmental decisions upon daily electricity consumption in five European countries.\nWe study the impact of the COVID-19 pandemic on electricity consumption in Spain, France, Italy, Poland and the United Kingdom during the early 2020. We analyse the effect of governmental decisions on the timing when the average daily consumption went below normal days, and the extent of the consumption differences with respect to pre-pandemic levels. According to our findings, lockdown announcements had a more significant effect on the average daily consumption pattern than the beginning of the quarantine period. Policies that limited outdoor movements had the largest immediate effect, while governmental decisions that reduced non-essential activities appeared the less effective measures when compared to others.<EOD> A method for estimating the age of first-year red deer (Cervus elaphus) calves\n\nThe analysis of age structure in populations of ungulates is a means by which they can be monitored, and their population growth can be determined. Red deer (Cervus elaphus) are an important economic and ecological species in Europe, Asia, North and South America; there are many references concerning the age structure of their herds, but only a few references dealing with their calves. We have used the tooth development stage in the upper incisors to determine the age of first-year calves. The method was based on the observations of the cementogenesis phase of the crown of the upper incisors during the first days of deer life, combined with a morphological description of the tissues in the first year of life. The results of the method were compared with direct calves age (calves with known birth days). The method correctly classifies 97% of calves, and can estimate the age of first-year calves within a range from eight to nine days.\n\n# Introduction\nThe ability to recognize the age of deer or other wild ungulates is of the utmost importance for many research studies such as monitoring the effects of harvesting policies on the viability of deer populations [bib_ref]  Impasse of scientific data as tools for management of deer populations, Gus [/bib_ref]  or identifying the age of the individual in herds when using molecular tools to identify genetic diversity in ungulates",
        "label": 1
    },
    "1449": {
        "output": "The output of your notebook looks as follows:\nThe patient can participate in the trial by putting eligibility = 2.\n\n##[INST]\nIf you receive a non-reproducible error, the steps below can help you solve it:\n\n### [INST] # 1 \u2013 Check whether the error is reproducible #\nBefore reporting it to the Instructional Support team, it is vital to check whether the error is reproducible. There are two solutions to the reproducibility of errors:\n1. Check your notebook for a [INST] tag, in case there is an instruction, and update it to the version of the cell with the error instead.\n\n### # 2 \u2013 The Instructional Support team is happy to assist you free of charge #\nIf you experience a serious error that prevents you from working smoothly in your notebook, you can always contact us at the following email: InstructionalSupport@nordcloud.com. You will most likely receive an answer within two business days.\n\n##### [INST]# Let\u2019s summarize\n\n##[INST]\nIf you are a beginner, you may find yourself overwhelmed at the beginning of your new work environment. Therefore, the best thing to do is to remember this simple rule:\n\n*When something does not work as expected - look at how `INST` acts in it!*\nIt's that easy!\n\n__[INST]__<EOD> .\nUsing a computer-assisted method of image construction from photographic series, the normal dimensions of the maxillary sinuses were measured in panoramic radiograph of 141 children (73 girls and 68 boys), age 6-16 years, non-smokers and without maxillary sinus hypoplasia, to ascertain normal values for this anatomic structure and to facilitate diagnostic evaluation of the diseases of this structure. The computer-assisted technique is considered to be the method of choice for studying maxillary sinus dimensions because of its reliability, ease and speed of operation.<EOD> Changes in the lipid metabolism induced by tetracosatetraenoic acid in the plasma of normolipidaemic subjects.\nThe effect of tetracosatetraenoic acid (20:4(n-tetracos",
        "label": 0
    },
    "1450": {
        "output": "A: InclusionCriteria -> \"INCLUSIONCRITIERIA\"\nPatientNote -> \"PATIENTNOTE\"\n\n\nTriallEligibility -> \"TRIAL_ELIGIBILITY\"\n\n\nPtId -> \"PATIENT_ID\"\n\n\nPtName -> \"PATIENT_NAME\"\n\n\nPtNr -> \"PATIENT_NR\"\n\n\nPtSex -> \"PATIENT_SEX\"\n\n\nPtAge -> \"PATIENT_AGE\"\n\n\nPatient -> \"PATIENT\"\n\nNote -> \"NOTE\"\n\n\nPtRisk -> \"PATIENT_RISK\"\n\n\nBirthDate -> \"BIRTHDATE\"\n\n\nRegistrationNumber -> \"REGISTRATION_NUMBER\"\n\n\nA1 -> \"A1\"\n\n\nA2 -> \"A2\"\n\n\nA3 -> \"A3\"\n\n\nClinicalTrial -> \"TITLE\"\n\n\n\n\nAnswers -> \"ANSWERS\"\n\n\nExclusions -> \"\"\n\n\nExc -> \"\"\n\n\n\n\n\n<EOD> Implementing an electronic patient record in family practice: a preliminary analysis of general practitioners\u2019 adoption of a practice computer system\nAbstractOBJECTIVE: To analyze the current use and patterns of introduction of the Family Health Centre record system by primary care physicians.\n DESIGN: Qualitative.\n SETTING: Canadian Family Health Centres.\n PARTICIPANTS: Family physicians serving in Family Health Centre practices in two Canadian provinces, Alberta and British Columbia.\n MAIN OUTCOME MEASURES: Interviews with family doctors involved in implementing the Family Health Centre system.\n MAIN RESULTS: Initial responses to the introduction of the Family Health Centre system were favorable. However, adoption was limited to a few computer-savvy physicians who tended to be the most motivated to use the new patient record. Some primary care physicians chose to delay the adoption of the system because they lacked confidence in the electronic environment and were concerned about the costs and difficulty of learning a new record system.\n CONCLUSIONS: The development of information systems",
        "label": 0
    },
    "1451": {
        "output": "To check the function, please see #4772.\nThis R Markdown file is not part of the data package and must be downloaded/downloaded from the Data Citation.\n[fig]  [Figure 1: 0-5-1]. After 36 h training 81 students filled out a questionnaire [Figure 1: 0-5-2] after their lecture on inclusion and exclusion criteria to assess the learning success. The test consisted of sixteen problems with three levels of difficulty (see Figures 67a). To complete the questionnaire, the participants completed their ID number (see Figure 1: 0-5-3). The test was based on the question \"For patients with acute pancreatitis, include in the 'exclusion criteria' if the patient is a female with ongoing or previous pregnancy and having an oligohydramnios or oligoamnios during this or previous pregnancies.'\" The correct answer to this question is given in Figure 1: 0-5-4. The students were asked to assess the correctness of the given answer on a scale of 1 to 5. 1. The answer is incorrect. 2. The answer is partly correct. 3. The answer is correct except for an unimportant fault. 4. The answer is correct, but contains an important fault. 5 [/fig] \n[fig]  Figure 1: 0-5-1). After 36 h training 81 students filled out a questionnaire [Figure 1: 0-5-2] after their lecture on inclusion and exclusion criteria to assess the learning success. The test consisted of sixteen problems with three levels of difficulty (Evaluation of the learning success by an answer scheme-questionnaire (in percentage). The test contained 16 questions. Eight questions were of the lowest difficulty level. The remaining eight questions were on a more difficult level. Based on the question \"For patients with acute pancreatitis, include in the 'exclusion criteria' if the patient is a female with ongoing or previous pregnancy and having an oligohydramnios or oligoamnios during this or previous pregnancies.\" The first answer was the correct answer in the lecture and given at the top of the page. The other answers are displayed in the correct",
        "label": 0
    },
    "1452": {
        "output": "Tip 5: There are two ways of making input in the assessment_eligibility function. One is to import the data frame in the assessment of eligibility. The other is to import a list that contains patient notes. If this list is empty, the first method of input is used. If the list is not empty, the second method of input is used.\n\nAssessment eligibility function:\n\n    def assessment_eligibility(patient_id, clinical_trial_data, input_method = input_method):\n        if input_method is 'list':\n            data_frame = clinical_trial_data.iloc[patient_id]\n            patient = data.frame(clinical_trial_data.iloc[patient_id][:][['Name', 'Gender', 'Age']])\n        else:\n            data_frame = clinical_trial_data.iloc[patient_id]\n            patient = clinical_trial_data.iloc[patient_id][[:,['Name', 'Gender','Age']]] # patient is a dataframe\n\n        patient_note = clinical_trial_data.iloc[patient_id][['Note']]\n\n        if patient_note == 'No patient note found':\n            assessment_eligibility = [0]\n        else:",
        "label": 2
    },
    "1453": {
        "output": "- A simple example for `patient_id` and `trial_id`, the patient will be compared with trial_id. If the trial_id doesn't exist, we return 0. Otherwise, `trial-eligible-numbered` will be evaluated.\n\n---\n```python\nimport pandas as pd\ntrial_id_list = pd.read_csv(\"patientdata/final-trial_inclusion_data.csv\")\ndata_new = pd.read_csv(\"patientdata/final-trial_inclusion_data.csv\", sep=';')    \npatient_index, trial_id_index = data_new.reset_index().stack() \ndata_re = data_new.append(trial_id_list.reset_index()['patients'].drop('patient_id')\n                           .fillna(0).stack())\ndata_re._columns = ['ID', 'Treatment ID', 'Trial-eligible-numbered']\n\ndata_re.to_csv('new_table.csv', sep=';', index=False)\n```\n<p>\n</p>\n\n# Discording data\n\n[INST] Before you begin, you might need to make data adjustment, such as merge, drop, and/or create a new column. Remember to save the adjusted file as data.csv. [END]\n\n\n```python\nimport pandas as pd\ndf_1 = pd.read_csv()\ndf_1.head()\n```\n<p>\n</p>\n\n\n\n\n```python\ndf_1.to_csv(\"data.csv\", index=False)\n```\n\n![image_38_528_thumb](https://user-images.githubusercontent.com/30674881/127541598-3cbfb280-f999-4968-9bde-8dfb58b9cf66.png)\n\n\n\n![image_39_528_thumb](https://user-images.githubusercontent.com/30674881/127541621-9",
        "label": 0
    },
    "1454": {
        "output": "Congratulations. You have finished the patient assessment.\n<EOD> Interleukin 12: a promising clinical cytokine.\nThe recombinant cytokine IL-12 is a powerful inducer of cell-mediated immunity and inflammation, including IFN-gamma production in animals and humans. This is also the case for endogenous IL-12 which is thought to play a role in acute and chronic inflammatory and immune disorders. The immunoadjuvancy of IL-12 in vivo is consistent with the in vitro effects of the cytokine which, in synergism with T cell-specific antigens, renders unresponsive T cells to their cognate antigen expressed on MHC class II molecules. The present knowledge on the biology of IL-12 suggests that this cytokine has a very versatile immunoadjuvant and that it will find numerous therapeutic applications.<EOD> A Simple Hydrothermal Method to Synthesize Rutile\u2212Ferrihydrite Nanocomposites for As(III) and As(V) Removal via Efficient Reductive Sorption Procedure\n\n\n\n## S2\n . XRD pattern of RF_0.1 (a), RF-2 (b), and RF-4 (c) nanocomposites. . XPS spectra of Fe 2p 3/2 region for RF_0.1 (a), RF-2 (b), and RF-4 (c) nanocomposites. . N 2 adsorption-desorption isotherms and pore size distributions of RF_0.1 (a), RF-2 (b), and RF-4 (c) nanocomposites.\n\n## S3\nTable S1. Effective redox potentials (Eq. (1)), surface charges (Eq. (2)), and surface oxygen vacancy levels (Eq. (3)) of RF_0.1, RF-2, and RF-4 after 8 h of reductive sorption of As(V) process. . EDS mapping of As(V) after the 8 h of reductive sorption process.\n[fig]  Figure S5: N",
        "label": 0
    },
    "1455": {
        "output": "## # \u25a0 4.0.4.1 Recognizing Errors in the Text Patterns\nLet's discuss how to recognize errors in the text patterns, first, with an example, and finally, with a practical case. \n\n## \u25a0 4.0.4.1.1 Example Case\nYou will read the clinical note and then you will have to recognize the errors in the pattern of the text. There are more than one error. You should correct them all. \nClinical note:\nCirrhosis with Acute-On-Chronic Liver Failure: A 43-year-old male was admitted to the emergency department with fever, fatigue and general weakness for 14 days. His blood pressure was 107/76 mm Hg, pulse rate was 92 times per minute, and the respiratory rate was 22 breaths per minute. The temperature on the body was 38.3 degree Celsius. The abdomen was flat. However, there was a slight tenderness at the right lower quadrant and it was hyperactive with guarding. On palpation of supraclavicular area, there was a lymphadenopathy with reactive tenderness. Respiratory sounds were clear and normal breath sounds in all areas of the lung. Abdomen was soft in a good bowel pattern. Hepatomegaly with tenderness in right upper quadrant and deep palpation. Inspection of the scanty stool was normal. Neuropsychiatric examination showed normal orientation, attention and concentration. The patient was able to speak and obey the commands. There were no incoherent speech or any symptoms of depression. Urinary system examination was normal. Chest X-ray showed massive bilateral pleural effusion. Laboratory analysis showed RBC: 4.5 million cells / \u00b5L, Hb: 11 grams/ 100 mL, WBC: 8.3 thousand cells / \u00b5L, MCV: 78 fl, MCH: 19.5 pg. MCHC: 33.4 g/ dL, PLT: 211 thousand cells / \u00b5L. Prothrombin time: 17.",
        "label": 0
    },
    "1456": {
        "output": "Output\n![image](https://user-images.githubusercontent.com/445835/36411801-66e18066-dbd3-11e8-91b2-cc82676e9326.png)\n![image](https://user-images.githubusercontent.com/445835/36411866-76950dcd-dbd3-11e8-9e33-bd55341224ea.png)\n\n\n---\n<NAME> is a member of the Faculty of Computer Science and of the Computer Engineering Graduate Program at UGR. He is also a member of the [Spanish Computer Vision & Pattern Recognition Society (SEFCA)](http://www.sefca.org/) and a coauthor of a number of papers in computer vision and image processing. Over the last few years, he's concentrated his work on pattern recognition, computer vision and image processing, data mining and machine learning. He is interested in developing new techniques and also in finding new applications in these areas.\n\n---\n### Authors\n\nThe following code was written by <NAME> and <NAME> and has been licensed under <a href=\"http://creativecommons.org/licenses/by/4.0\">Creative Commons Attribution 4.0 International License</a>.\n\n[<NAME> Licence ](//github.com/mariaoliveira/datalab-worksheet)\n[<NAME>, <NAME> Licence](//github.com/josepmartinsantos/datalab-worksheet)\n\n---\n\n\n### Data Sources:\n\n![RStudio_Screenshot](https://user-images.githubusercontent.com/445835/36410864-568573a4-df67-11e8-8cda-15b3257cc1f1.png)\n\n### Data Sources\n\n* Exercise 4 data was downloaded from a public repository:\n[Oliveira-and-Ramirez-",
        "label": 0
    },
    "1457": {
        "output": "We will first define global variables for the trial:\n%%HELPER define(CurrTrialNumber, 1) %%HELPER define(-CurrTrialNumber, 1)\n\n%%HELPER global.set('CurrTrialNumber',CurrTrialNumber) %%HELPER global.set(-CurrTrialNumber,CurrTrialNumber) \n%%HELPER define(PatientNumber,1) %%HELPER define(-PatientNumber,1)\n%%HELPER global.set('PatientNumber',PatientNumber) %%HELPER global.set(-PatientNumber,PatientNumber)\n\n%%HELPER define(TrialName,'$ClinicalTrials.csv') %%HELPER define(-TrialName, '$ClinicalTrials.csv')\n%%HELPER global.set('TrialName',TrialName) %%HELPER global.set(-TrialName,TrialName) \n%%HELPER define(ExpectedPatients,5) %%HELPER define(-ExpectedPatients,5)\n%%HELPER global.set('ExpectedPatients',ExpectedPatients) %%HELPER global.set(-ExpectedPatients,ExpectedPatients)\n%%HELPER define(ExclusionCriteria,0) %%HELPER define(-ExclusionCriteria,0)\n%%HELPER global.set('ExclusionCriteria',ExclusionCriteria) %%HELPER global.set(-ExclusionCriteria,ExclusionCriteria) \n%%HELPER define(IncludeCriteria,0) %%HELPER define(-IncludeCriteria,0)\n%%HELPER global.set('IncludeCriteria',IncludeCriteria) %%HELPER global.set(-IncludeCriteria,IncludeCriteria) \n%%HELPER define(ExclusionCriterion,1) %%HELPER define(-ExclusionCriterion,1)\n%%HELPER global.set('ExclusionCriterion',ExclusionCriterion) %%HELPER global.set(-ExclusionCriterion,ExclusionCriterion) \n%%HELPER define(InclusionCriterion,1) %%HELPER define(-InclusionCriterion,1)\n%%HELPER global.",
        "label": 2
    },
    "1458": {
        "output": "### Incomplete Input Values\n\nSometimes, user input values (such as 'c_age' or 'c_female') are entered in the wrong format. You should check whether your input values are in the correct format by comparing the input with the correct format, e.g., 'Male' and 'c_female' or 'Male' and 'Female'.\n\nTo fix the input values, click [Fix Incorrect Dataset Input Values] on the bottom of DataSets tab, which will convert the values to their correct formats.\n\n### Clinical Trial Information\n\nIf the values are correctly formatted, click [Submit] to submit your analysis to the server. On the next page, select 'Clinical Trial' from 'Subject Type'.\n\n![Figure:Subject Type][]\n\n![Figure:Subject Type][]\n\nClick [Next] to continue. You should always select 'Clinical Trial'.\n\n### Patient Information\n\nYour analysis of clinical trial recruitment starts with the clinical trial information. You should click on the patient and click [Next] to open this page.\n\n### Clinical Information\n\n1. Check the clinical trial name, Clinical trial identifier, and Eligibility status in the data table. The input values of 'c_name', 'c_identifier', and 'c_eligibility status' are correct.\n\n2. Click [Next] to continue.\n\n![Figure:Clinical Information][]\n\n### Patient's Information\n\n1. If the patient meets the inclusion criteria to participate in the clinical trial, click '[+]' (inclusive of all the elements) on the 'c_eligibility' on the 'All Patients' check box.\n\nOtherwise, click '-' on the 'c_ineligibility' on the 'All Patients' check box.\n\n2. Check that the patient's age, sex, race/ethnicity, nationality, BMI, and insurance are entered correctly.\n\n![Figure:Patients' Information][]\n\n### [+]\n\n![Figure:[+]Patient Eligibility][]\n\n### [0]\n\n![",
        "label": 0
    },
    "1459": {
        "output": "<EOD> Comparison of Different Biomarkers for Predicting Malignancy in Biliary Stones\n\nMalignancy is an unexpected finding for which gallbladder biospecimens can be used to distinguish between benign and malignant pathology. Currently, the most common technique used for this purpose are histological examinations, which can be complemented with the analysis of the presence of biomarkers. This study aimed to evaluate the diagnostic utility of c-erbB2 gene expression and p53 protein levels in cholecystolithiasis in relation to the histopathological findings of gallbladders and the risk of malignancy. A prospective study was conducted in 77 patients with suspected stones of the gallbladder and/or cystic duct who underwent laparoscopic cholecystectomy with a clinical suspicion of having neoplastic disease. The study included 30 patients with benign and 47 patients with malignant gallbladder and gallbladder lithiasis. The expression of the c-erbB2 oncogene was measured by RT-PCR, whereas p53 protein levels were determined using an Enzyme-Linked Immunosorbent Assay (ELISA) test. For statistical analyses, we applied t-test and Pearson correlation coefficient. The value p < 0.05 was considered statistically significant. The level of expression of the c-erbB2 oncogene was increased in gallbladders with lithiasis compared to benign gallbladders, as were p53 protein levels. Gallbladders with malignant lithiasis had a higher level of c-erbB2 gene expression (4.89 \u00b1 1.47, p = 0.001) and p53 protein levels (90.36 \u00b1 21.15, p < 0.0001) than gallbladders with nonsymptomatic lithiasis (1.40 \u00b1 0.35 for c-erbB2 and 24.48 \u00b1 11.36 for p53 protein levels). The results of the study suggest that both parameters may be used",
        "label": 0
    },
    "1460": {
        "output": "2) Eligible in your code. [END] Eligibility is done on the patient_notes and trial_ids variable and results in a nested list of dict objects (representing a patient). Each element of the list is the same level of the nested dict as you read out by patient_note.index.\n\nThe nested lists can be summarized by using the [list][1] syntax:\n\n`[(0):['Eligible-list1',\n'Trial-type': 'Lamivudine for chronic Hepatitis B'],\n(1):['Eligible-list2', 'Trial-type': 'Lamivudine for Hepatitis B and Delta']]`\n\nSo if we look at the patient_note list, we get the information about patient's eligibility for a trial. It means that both trials will have one patient enrolled due to the `Eligible` levels. The Eligible level means that the patient is an enrollable patient for a trial. The trials with the Eligible level are usually considered as a success (or non-zero value) and failures are reported as `0`.\n\nWhat are the possible outcomes of the trial?\n\nThe main goal is to estimate an expected enrollment in the trial. This way of estimating the enrollment should be done by trial, based on the eligible patients for a trial, that is, `0 or 1 for zero or non zero trial. `\n\nYou should write a program to find the number of eligible patients (who are eligible for more than one trial) in each trial. Write a function for both outcome of the trial: 0 (failure) and 1 (success).\n\nAs you already know, the number of patients enroll in all the trials should be between 0 and 35. So if the success level is zero, the trial-specific enroll is expected to be between 0 and 5, and there are no eligible patients.\n\n## 55 # 2\n51  # 3\n49 # 4\n48 # 5\n24 # 6\n22 # 7\n21 # 8\n18 # 9\n16 # 10\n13 # 11\n11",
        "label": 1
    },
    "1461": {
        "output": "# Solution set\n\n* 60. The patients were randomized as follows. In order to make the allocation sequence, the following random number function was written:\nThe random number is used to assign numbers in the following order for each trial. 01, 02, 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19\nThe patients are assigned in the following order. 09, 10, 12, 18, 07, 17, 16, 15, 14, 13, 19, 11, 04, 05, 10, 11, 07, 01, 02, 03, 18, 09, 06, 01, 02, 01, 01, 01, 01, 01\n60-1) What is 0.067 + 0.781? 60-2) How many of the total patients (30 patients) were excluded from inclusion? How?\n\n- The sum of each column of the left matrix, which are 30, corresponds to the sum of each row of the right matrix in the same way by substitution.\n- Therefore, the sum of the excluded patients is 9.\n60-3) How many patients will show eligibility? 60-4) How do we know that the total number of enrolled patients is 30? \nA set of three equations is given, and you have to decide whether the equations are consistent with each other or not, in terms of set theory and/or mathematical logic.\n\nExplanation\n**Consistency test (Example 1)**\n\nSuppose you are in a company which produces shoes and socks. The director of",
        "label": 1
    },
    "1462": {
        "output": "If a patient does not meet all criteria but one, then he/she will be excluded because of the incompatibility between the two criteria. In the example below, the patient is not on the HCV treatment or had not received a transfusion for a long time. Therefore, there will be no HCV viral load in the blood. However, hepatitis C is a chronic infection. Thus, the patient will be excluded from the trial. Here is the patient information:\nA 62-year-old man diagnosed with HCV 8 years ago, after an unknown cause hepatitis. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 3 years. He takes no other medications. His medical records show positive HCV RNA tests and negative HBV, hepatitis B surface antigen (HBsAg); anti-HBc-IgM (anti-HB core IgM antibody); anti-HAV (anti-hepatitis A virus); anti-HIV (anti-human immunodeficiency virus); anti-TP (anti-treponema pallidum IgM); anti-HEV (anti-HEV immunoglobulin M antibody) tests. The recent biopsy was remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 180/110, HR: 90/min and BMI: 49. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere is the clinical trial:\nTitle: Treatment and long-term prognosis in HCV (hepatitis C virus) infection\nSummary: Hepatitis C is a disease of the liver caused by the hepatitis C virus. Patients with chronic hepatitis C may feel well and show no obvious signs of illness. However, researchers would like to study the long-term effects of",
        "label": 2
    },
    "1463": {
        "output": "[CORRECT] `!#eligibilities:!`\n[CORRECT] `!#eligibilities:!` {\n    let trials = patients[i].trials.value;\n    return 3).length > 0 && trials[i].patients.value == patients[i].id;\n  };`\n\n**CORRECT** `let eligibility = patients.map((patient, i) => {\n  let candidates = (trials = patient.trials.value).map(trial => {\n    let trialleligibility = trial.patients.value.filter(j => this[j]);\n    return 3).length > 0 && trialleligibility[0].id == patient.id;\n  })\n  return trial.assessment.value == 2;\n});`\n\n\n## Detection of exclusion criteria #4332\n**CORRECT** `let exclusionCriteria = patients.map((patient, i) => {\n  let trials = patient.trials.value;\n  for(let j = 0; j < trials.length; j++) {\n    let trial = trials[j];\n    let exclusiveCriteria = trial.assessment.value == 0; // exclusion criteria\n    if(exclusiveCriteria) {\n      let exclusionsCategories = trial.exclusionsCategories.value;\n      for(let k = 0; k < exclusionsCategories.length; k++) {\n        if(exclusionsCategories[k].assessment.value == 0) {//exclusive criteria\n          return 0;\n        }\n      }\n      continue;\n    }\n  }\n  return 1;`\n\n\n<EOD> A Cohort Study of the Incident Risk of Colorectal Cancer after Detection of Infective Colorectal Adenoma Among Japanese Men\nOBJECTIVE:Although the association between infective colorectal adenoma and colorectal cancer is convincing, the risk of colorectal cancer after detection of colorectal adenoma remains unclear. This study was undertaken to clarify the risk of colorectal adenoma",
        "label": 0
    },
    "1464": {
        "output": "Experiment:\n[/E] In your code, use [`str_join`](https://pandas.pydata.org/pandas-docs/dev/reference/api/pandas.Series.str_join.html) or other equivalent methods to join `trial.label` and `trial.inclusions_reasons` columns together, e.g., by using `df.str_join_chunks()`. After that, make a set of eligible patients on the basis of this aggregation of information, e.g., by using the [`set()` method](https://docs.python.org/3/library/sets.html#module-sets) on the aggregated set. In `pandas` terms, the aggregation and `set` operations can be written in the following lines of code, respectively:\n>>> aggregated_df = trial.explode(['label','inclusions_reasons'])\n>>> exclusions = set([x.lower().split().[0] for x in aggregated_df.label.values])\n\n\n**Solution**\n\nIn my code, I used the following approach: \n\n\n```python\nexcl_string = '0 Excluded'\n# create set of strings from exclusions labels\nexclusions = set([excl_string.lower().split().[0] for excl in aggregated_df.label.values.tolist()])\n# get subset of trial's id corresponding to patients in the set of exclusions\nexcl_subset = [df2.trial.id.values.tolist()[i] for i in exclusions.index]\n# subset's patients' list from the first column (age)\nexc_age = df.trial.id.isin(excl_subset)\n\npatients_list = (df2[excl_age]\n                   .explode('inclusions_reasons')\n                   .assign(age=age)\n                   .drop_duplicates()\n                   [['label','inclusions_reasons', 'age']][0]\n                   .values.tolist())\n\n\nif len(exclusions) > 0 or len(exclusions[0]) > 0\n    print(f'Exclusions: {exclusions}",
        "label": 2
    },
    "1465": {
        "output": "}\n\n## <span class=\"popover-title\" slot=\"body\">Example output</span> \n\n<div id=\"example-output\">\n  {{#each trials}} {{#if level-field}} {{{level-field}}} {{^if nested-trials} }}\n  {{#trial-level-eligibility}} {{#tier-one-trial}} 1) Not Relevant {{else}}, 0) Excluded {{else}} {{#trial-level-eligibility}} {{#tier-two-trial}} 2) Eligible {{/trial-level-eligibility}}  {{/trial-level-eligibility}} {{^tier-one-trial}} {{#tier-two-trial}} 2) Eligible{{/tier-two-trial}}\n  {{else}} {{{level-field}}}} {{{level-field}}}} {{{level-field}}}} {{{level-field}}}} {{{level-field}}}} {{{level-field}}}} {{{level-field}}}} {{{level-field}}}} {{*trials}} {{{popover-title}}}\n  {{!popover-button1}} {{{popover-value}}}{{/popover-button1}} {{*popover-content}} {{#*trials}} {{{popover-content}}}\n    {{#*level-field}}{{{{*popover-value}}}} {{{*level-field}}}} {{/*level-field}} {{/*trials}} {{*popover-close}}\n  {{/popover-button1}} {{/popover-content}} {{/*trials}} {{/trial-level-eligibility}} {{/*popover-close}} 2,2,2,2,1,2,2,3,1{{#trials}} {{{trial-recruitment-level}}}{{/trials}} \n  {{#trial-notes}} {{{trial-notes}}} {{/trial-notes}} {{/trials}}\n</div>\n</script>\n\n<EOD> The influence of the gamma ray sensitivity of thermostable DNA on the radiation damage to cellular DNA and the radiosensitivity of mammalian cells.",
        "label": 1
    },
    "1466": {
        "output": "# [MODULE] Patient-level eligibility\nOnce you are done with the trial-level eligibility, go back and check up the patient. If the patient is going to be eligible for the trial, the patient-level eligibility must be printed out with the trial-level eligibility. \nNow, you will find a patient named patient1 as follows. [INST] \n![INST]\n\n\n# PERL SCRIPT\n``` perl\n$i=0\nprint \"Enter the patient's name: \\n\n$patient=$_[0]\nfor($j=1 to $i)\n{\nif($j=1)\n{\n$tmp1=`date`\nchomp $tmp1\nprint \"The time stamp is \\n $tmp1\n\"\n\"What is your age?: (integer)\"\t\n\n\"What is your gender? (female, male) \\n\"\t\t\n\n\"What is your weight? (kilograms) \\n\"\t\t\n\t\t\n\"What is your height? (centimeters) \\n\"\t\t\n\t\t\n\"What is your height in meters? \\n\"\t\t\n\t\t\n\"Are you pregnant? (Yes or No) \\n\"\nchomp $_\nif ($_[$patient] =~ /^\\d\\d{5}$/)\t\n$_[$patient]=$j\nsystem(\"killall less\")\nsleep 3\nprint \"Sleeping 3 seconds\\n\n$j=$j+1\nif($j==5)\n{\nprint \"Sleeping 10 seconds\\n\nsleep 10\n$tmp2=`date`\nchomp $tmp2\nprint \"The time stamp is \\n $tmp2\n\"\nsystem(\"killall less\")\nprint \"Sleeping 3 seconds again\\n\n$j=$j+1\nif($j==5)\n{\nprint \"The time stamp is \\n $tmp2\n\"\nprint \"Enter the title of the trial: \\n \\\n\"\nsystem(\"killall less\")\nsleep 3\nprint \"Sleeping 3 seconds\\n\n$tmp3=`date`\nchomp $tmp3\nsleep 10\nprint \"The time stamp is \\n",
        "label": 0
    },
    "1467": {
        "output": "Codes to Implement\n\n### INIT\n``` Python\ndef init():\n    session.register('ENTER_NAME')\n    session.register('ENTER_NAME')\n    session.register('SELECT_GEND')\n    session.register('SELECT_GEND')\n    session.register('SELECT_EXPOSE')\n    session.register('SELECT_EXPOSE')\n    session.register('SELECT_CONFIRM')\n    session.register('SELECT_CONFIRM')\n    session.register('SELECT_EXCLUDE')\n    session.register('SELECT_EXCLUDE')\n    session.register('SELECT_EXCLUDE')\n    session.register('SELECT_EXCLUDE')\n    session.register('SELECT_EXCLUDE')\n```\n\n### ADD\n``` Python\ndef add(x):\n    global name, gender, is_exposed, patient_id, exclusion_codes_list, scale\n    session.register('SELECT_GEND')\n    session.register('SELECT_GEND')\n    session.register('SELECT_SPECIES')\n    session.register('SELECT_STAGE')\n    session.register('SELECT_STAGE')\n    trial_id = session.get(r'SELECT TRIAL')\n    if trial_id != '':\n         trial_name = session.get(r'SELECT TRIAL')\n         trial_type = session.get(r'SELECT TRIAL')\n         trial_type = session.get(r'SELECT T')\n         scale = session.get(r'SELECT SCALE')\n    else:\n         trial_name = 'ENTER_CLINICAL_TRIATL_NAME'\n         trial_type = 'PATIENT_NOT_ENG'\n         scale = 'ENTER_CLINICAL_TRIATL_SCALE'\n\n     if trial_type == 'PATIENT_NOT_ENG':\n        exclusion_code_name = session.get(r'SELECT_EXCLUDE')\n        if exclusion_code_name == '' and patient_id == 'ENTER_PATIENT_ID':\n            patient_id = '",
        "label": 1
    },
    "1468": {
        "output": "# Background\n\n## What are the inclusion criteria for this trial?\nHepatitis B is a common infectious disease that is primarily asymptomatic and may worsen to chronic liver disease such as cirrhosis and hepatocellular carcinoma (HCC). The estimated global prevalence of chronic hepatitis B infection is 3.6 percent, while the HBV surface antigen (HBsAg) seroprevalence ranged from 3.7-7.9 percent in general populations in Turkey. Chronic HCV infection is another major cause of HCC. The total seroprevalence of anti-HCV antibodies in Turkey as 1.5 percent for < 30 years and 3.5 percent for > 30 years in 2000-2003 period, and the total anti-HCV + HBsAg + individuals among general population was estimated to be < 0.2 percent (< 0.6 million cases). The prevalence of HCV among patients with HCC in Turkey was estimated to be 51.5 percent in 2003-2007 period. The overall 10-year survival rate for HCC patients who underwent curative treatment was reported to be 35 percent.\nEntecavir (ETV) is a potent guanosine analog which inhibits reverse transcriptase in HBV replication and also prevents the emergence of drug-resistant virus variants. The drug is approved for the treatment of people with chronic hepatitis B infection without cirrhosis (chronic low viral load) and treatment-naive patients with chronic hepatitis B infection with moderate and high viral load. In a clinical trial, Lamivudine (3TC) treatment was associated with HBV DNA clearance in 56% of cases and HBeAg seroconversion in 23% of patients. Although ETV use has demonstrated a favorable safety profile in various clinical trials, long-term data on safety and efficacy are lacking. To date, only one randomized controlled trial has compared ETV to standard therapy. In this trial, 667 clinically diagnosed noncirrhotic patients inf",
        "label": 1
    },
    "1469": {
        "output": "## MONICDA\n[INST] Hello. This is your assistant for clinical trial recruitment. You are assisting the patient on trial monitoring, a process for assessing patient progress and the trial itself.\n\nOne of your tasks is to monitor the patient's HBV viral load as a response to the treatment received. Hepatitis B virus (HBV) is highly contagious, and it is a major health problem in the world. It primarily causes liver injury but can also spread to other organs. The standard treatment for chronic hepatitis B includes drugs such as the interferon \u03b1 and pegylated interferon \u03b1, which suppress viral replication, and lamivudine and telbivudine, which reduce the level of covalently closed circular DNA, which is the template for viral replication.\n\nDuring your clinical trial monitoring, you are to see the patient for further follow-ups. Your next patient's clinic visit will come on January 1st, 5th, 6th, 7th, and 12th of 2017. When you see the patient, you should note the trial's progress, e.g., viral load, HBsAg-positive, and ALT. The clinical significance of ALT is important in defining the progression of CHB. ALT refers to the enzyme alanine transaminase. A high level of ALT levels can be a useful marker of liver damage. However, many patients can have high levels of ALT in the absence of liver disease. \nThere is a set of the current clinical trial's progress during the monitoring visit of January 1st to a patient. Let's say that the patient is one of the first five registered patients of the study. The other four patients are already assessed their progress in the clinical trial as of this day: [Monitor clinical trial progress](./Monitor_clinical_trial_progress_20170101).\n\nThe results for the study participants (the other 4 patients) are:\n[Result 1 / HBV viral load](./Result_viral_load_20170101):\n[Result 2 / HBsAg-positive](",
        "label": 1
    },
    "1470": {
        "output": "You are supposed to compare a given patient note and the inclusion criteria of a clinical trial. A trial-level eligibility is defined as a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\n<EOD> Fertility decline in Pakistan from 1978 to 1998: analysis of data from Pakistan National Health and Micronutrient Survey 1991 and the National Nutrition Survey 1994\nObjectives\u2002 To describe trends in fertility decline in Pakistan over the past two decades.<EOD> .\nLaboratory assays for thyroglobulin are available in Belgium since 1981. We report our experience with thyroglobulin as a follow up test in 68 patients with operated and remnant papillary thyroid carcinoma, differentiated thyroid adenoma and euthyroid status. Among 33 patients operated for differentiated thyroid adenoma, 17 were free of cancer 1-4 years before study entry; for 16 others, operated on after 1979, iodine-131 was ablated; 48% of these patients showed low to undetectable thyroglobulin levels. For the other 19 patients, operated on since 1955 and still under 131I surveillance after complete or inadequate subtotal thyroidectomies, mean serum concentrations of thyroglobulin were 4, 6 ng/ml (range 2-23) and were correlated with the extent of remnant cervical tissue. Serum thyroglobulin was evaluated in 27 patients with euthyroid papillary thyroid carcinoma: 16 with follicular or cervical cystic adenomas and one with follicular variant, had normal thyroglobulin levels (less than 2 ng/ml); the eight patients with thyroid cancer and follicular variant had thyroglobulin",
        "label": 1
    },
    "1471": {
        "output": "## Good luck and happy hunting! [END]\nIn addition, we suggest you to look at this blog to know more on this topic:\nThis is an attempt to help beginners to better understand some of the most essential principles in clinical trial design.\nSome of you have learned how to perform eligibility assessment and have understood that one should evaluate each patient individually. But some of you may not have known that we should also calculate trial-level Eligibility. In this note we will tell you about triallevel calculation of Eligibility, and that is an essential part of clinical trial design.\n\n`#!/usr/bin/env bash`\n\n\n\nTrial-level Eligibility is the probability that at least one patient in a trial will be eligible regardless of his/her individual eligibility.\nAssume that there are n patients per trial. Let us call each of these patients nth, i.e., 1<n<N and the eligibility of the nth patient is eligibility of each nth patient. The eligibility of each patient is binary variable, can be equal to 0 if the patient is ineligible or 1 if the patient is eligible.\nIf a trial has n patients only, trial-level eligibility is the probability that at least one patient out of n is eligible, i.e., n * p_EL / n. \nTrial-level eligibility is calculated by the following formula: \nTRIAL-LEVEL EL  = N * PE_EL / N\n\nTrial-level Eligibility is defined as: The probability that at least one trial participant is eligible.\nLet us assume that n random variables, the eligibility of the 1 st patient, the eligibility of the 2 nd patient, \u2026, and the eligibility of the nth patient are each drawn from such a population of a hypothetical eligibility distribution. Let us assume that those two distributions are independent.\nNext, consider the joint probability distribution of eligibility of the 1st patient, eligibility of the 2nd patient and so on. Let f(eligibility, n) be the joint probability.\n\n\nFor instance, considering just a binary variable which has the two values one (ineligible) and two",
        "label": 1
    },
    "1472": {
        "output": "<EOD> The influence of intraocular lenses on vision\nIntraocular lenses with different surface properties: (1) smooth surface (17 subjects); (2) rough surface (19 subjects); (3) surface coated with human albumin (21 subjects) were implanted in human eyes. The visual acuity was investigated 6 weeks, 6 months and 1 year after the operations and the eyes were studied by means of electro-ophthalmography and electroretinography. After 6 weeks a significant improvement of the visual acuity and of the electrical activity of the retinae could be seen in comparison with eyes being blinded.<EOD> Anterior ischemic optic neuropathy, sudden vision loss and transient headache--a possible case for migraine.\nWe report a 74-year old Caucasian male who presented with sudden onset of bilateral blurred vision. He reported no history of diplopia, redness, eye pain, nausea or vomiting. Ophthalmic examination revealed a visual acuity of 6/6 and a relative afferent pupil defect in addition to optic neuropathy OU. Blood sugar was normal, however, ESR was noted to be 30 and chest x-ray revealed extensive miliary tuberculosis OU. Brain computed tomography and fluorescein angiography were normal. He was initially prescribed steroids for presumptive vasculitis. Three weeks later he was readmitted with complaints of severe headaches. These were similar to his typical migraine headaches which he had suffered since the age of fifteen. He had a good response to propranolol and methysergide.<EOD> Chromosomal Location of the Gene Encoding the Neuron-specific Adrenocortical Steroid Oxygenase.\nIt has been known for over 20\u2005years that the expression of a specific cerebrocortical adrenocortical steroid oxygenase (ASO) is a feature of the CNS. In this issue of the JBC, Masham et al. report the detection of a gene encoding a steroid oxygenase in a rat genomic library containing 35,000 clones. This gene, located in",
        "label": 1
    },
    "1473": {
        "output": "## 1.1.3. Input: patient note\nTo input the patient note, press the \"New note\" button in the left dashboard. If you haven't created any other patients, you will see the following screen [fig_ref]  Figure 1: Fig. 1. [/fig_ref] .\nFill in the blank fields with the patient age, gender, and diagnosis. For the patient age, type in the exact age. If the patient is under the age of 16, you may not enter a value for the \"Age\" blank field because `16` is the default value for the \"Age\" blank field.\nPress the \"Create patient\" button to create the patient. Then, you can change the characteristics of the patient (age, gender, etc.) by pressing the \"Edit\" button. To change the diagnosis, you can use the form below [fig_ref]  Figure 5: Diagnosis of patient 2 [/fig_ref] .\n\n## Explanation:\nWe use the following diagnoses: `chronic hepatitis` (2:0), `HCV 2 years ago` (1:1), `chronic inflammation` (2:1), and `HBV 2 years ago` (2:0).\nThe first two diagnoses are extracted from the input boxes of the patient note. The third diagnosis is added by the user. The \"chronic hepatitis\" is the main diagnoses (2:0). \n\n## You can set multiple diagnoses.\nYou can also get input boxes for the patient notes after a patient is created. Go to the patients list in the right dashboard, click the \"New patient note\" link, and fill in the following information [fig_ref]  Figure 8: Patient notes [/fig_ref] . [fig_ref]  Figure 1: Fig. 1. [/fig_ref]  shows the correct patient note. To see the correct patient note, you can click on the patient in the \"Patients list\" in the right dashboard. \n\n## 1.2.2. You can save a text template for your patient note. go to the \"patients\" link on the left dashboard.\n\n## 1.2.3. delete the last patient note. click on the red 'x' button to the left of the 17: 1324: 2016: 5.",
        "label": 1
    },
    "1474": {
        "output": "[INST: \nBefore I end this module, I would like you to tell me your thoughts and comments on this task. Are there any difficulties or difficulties you have met at the process of this study? Did you encounter any problems? Did the training you have for data entry meet your expectations? Do you feel that additional training could help you? Any further training need to be proposed by the team?\n[/DATA<EOD> Phase II randomized trial of combined cyclosporine A \u00b1 metallothionein gene therapy in liver transplant patients with C282Y beta\u2010thalassemia/Hb E\nCyclosporine A (CsA) is a critical cytoprotective drug in liver transplant recipients (LTRs) carrying the C282Y beta\u2010thalassemia. Liver metallothionein (MT) is a potent cytoprotective enzyme that is also effective against CsA\u2010mediated nephrotoxicity. Here, for the first time, we have evaluated in a double\u2010blind fashion the safety and efficacy of adenovirus\u2010mediated ex vivo MT overexpression in the liver following allograft reperfusion in patients with C282Y beta\u2010thalassemia/Hb E. Liver transplant patients received 20 \u00d7 1010 PFU (2 \u00d7 1010 PFU to each lobe) of either: (1) Ad.Empty, (2) Ad.MT, or (3) standard CsA treatment without MT. Intraoperatively, MT overexpression in the liver after surgery was demonstrated by immunohistochemical staining, and the systemic circulating levels of MT protein were significantly higher among patients who received Ad.MT compared with patients who received Ad.Empty or standard CsA treatment. During 48 postoperative days, Ad.MT showed better liver function, indicated by alanine aminotransferase and total bilirubin levels, and a reduced incidence of primary graft dysfunction compared with CsA. Further, a more rapid early reduction of CsA dosage to 50% by day 7 was found in the Ad.MT group (P < 0.05 vs",
        "label": 1
    },
    "1475": {
        "output": "A: Using the following data frame data_test. We used the ifelse function to determine if the age of the patient is between 18 and 60 and if age is the male then set the gender to be 1. After that, we assigned a value to the gender column to ensure that there was only male patients in the data frame.\nlibrary(dplyr) library(pROC) library(foreign)\ndata_test  <- data_test. %>% mutate(age = age.div(age, 18), sex = if_else(age < 60 & gender == 1, \"1\", NA)) %>% # filter gender # using if_else function age > 18 # only male and female > 18 # to avoid unnecessary calculations age > 18 | sex == 1 ) %>% # filter to males gender == 1 ) %>% # filter females gender == 0 # to remove unnecessary calculations gender > 0 ) %>% # filter males gender == 0 # to remove unnecessary calculations %>% # filter to female gender == 1 ) %>% select(-1) %>% select(.fam_id, age, sex).\n\nFrom here, we will be comparing against the first line in the input data set (which tells us our trial requires the patient to be diagnosed with hepatitis C, HCV, and the age requirement is that they must be over the age of twenty one. The required age of twenty one is the reason why our trial can only include adults. Also, the male must have been HCV positive for greater than 6 months.\ninput <- read.csv(\"http://www.stat.ucla.edu/~candela/100%20Course/Data/S1%20Patients%20Data.csv\")\ndata_test <- read.csv(\"./test_data.csv\")\ndata_test <- rbind(input.Trial_level_eligible) %>% dplyr::select(-1) %>% dplyr::select(.fam_id, age, sex) %>% unite(Trial_level_eligible, age,sex) %>% dplyr::select(.fam_id, Trial_level_eligible, age, sex, fam_type, fam_subtype, fam_subtype_other) %>% arrange(Tri-",
        "label": 1
    },
    "1476": {
        "output": "<issue_closed><EOD> Clinically significant prognostic factors for survival of patients with non-small cell lung cancer.\ne17530 Background: Non-small cell lung cancer (NSCLC) has a high incidence of both recurrence and death. Clinical features and treatments may affect the survival in patients with NSCLC. However, it is not fully understood which clinical features and treatments will affect the survival for patients with NSCLC. We would like to explore which features of the baseline and treatment for patients with NSCLC affect the survival.\n\n\nMETHODS\nWe designed a retrospective analysis for patients with NSCLC which is treated and/or followed up in Fujian Provincial Cancer Hospital, Fujian, China. All records were retrospective research which was approved by ethics committee of Fujian Cancer Hospital and conducted by us. Data were collected, including age, sex, smoking, pathological type, degree of differentiation, TNM staging, treatment, survival data, etc. The overall survival was determined for all patients from the diagnosis of lung cancer to the date of death or last follow-up. Overall survival curve was plotted by Kaplan-Meier method and difference of survival curves was compared by using the Log-Rank test. Cox proportional hazard model was applied to estimate the hazards ratio. P values less than 0.05 (twotailed) were considered to be statistically significant.\n\n\nRESULTS\nFrom Jan 2000 to Dec 2008, 512 patients with NSCLC which is newly diagnosed and/or followed up in Fujian Provincial Cancer Hospital, Fujian, China were analyzed. We divided the patients into 5 groups based on their clinical stages. In which, there were 192 patients with stage I, 50 patients with stage II, 222 patients with stage III, 5 patients with stage IVa and 40 patients with stage IVb. According to the Kaplan-Meier curve, T stage (T1, T2 : T3, T4, P=0.001), sex (female : male, P=0.0012), chemotherapy (yes : no, P=0.",
        "label": 2
    },
    "1477": {
        "output": "- \u202b\u0627\u062c\u0644\u0631\u062d\u0629\u202c : \u202b\u0641\u0631\u0648\u0642\u0627\u062a\u202c\n\n## Question 4\nYou will review eligibility for participation in a clinical trial. Assume the following scenario: \n\nClinicalTrials.gov Identifier: [NCT00524973] [NCT01414191] <EOD> .\nThe treatment of the diastasis of the pubic symphysis (DS) is often controversial and controversies are numerous. If in the past the treatment of this pathology was often surgical (open reduction, reductiv and internal screw or external fixation), currently the non-surgical treatment appears to be the first-choice treatment for the great majority of cases. This is supported by the scientific evidence which reports in most cases a good result from closed reduction and conservative treatment with orthesis. The present study is a randomized controlled trial in which 63 DSP were treated: patients belonging to group A reported 67% excellent results with a statistically significant difference (p  24 months) are presented and discussed.<EOD> Influenza Virus Assembly and Budding\nSUMMARY Influenza viruses assemble and bud from the surfaces of host cells by unique mechanisms that involve many steps in a complex spatiotemporal order. After virus entry, newly synthesized vRNPs and other viral proteins are trafficked to the nucleus where viral transcription and replication take place. Once vRNPs have left the nucleus, they assemble into ribonucleoproteins (RNPs) and other virus-specific proteins are incorporated into particles before RNP transport to the cytoplasm. RNP movement to microtubule-organizing centers in the cytoplasm is an important final step. Assembly then begins at the plasma membrane in a process that involves multiple steps including vRNP concentration through nuclear export, vRNP and viral membrane association, polymerization of membrane-associated vRNPs into filaments, viral protein-mediated scission of cell membranes, and budding of viruses within the microtubule cytoskeleton network. After budding, membrane-virus particles are transported to the apical surface by actin-",
        "label": 2
    },
    "1478": {
        "output": "### Example for INST[1]:\nPlease do not edit this example!\n\n```python\n#!/usr/bin/env python\n# Written by <NAME> - <EMAIL>\n\n# ---\n# JUPYTER NOTE:\n#   This file was generated automatically by\n#   the IPython Notebook. In the future your changes to this\n#   file may be lost if you do not consider this.\n# ---\n# IPython Interactive Shell (5.3.2) \n# \n# Type input() to execute\n# in [1]:\nimport pandas as pd\n\ndf = pd.read_csv('../data/test_data.csv', header=None,  # Optional: specify the column to use as headers, else assume first (0) and last (n) columns contain header names\n                  index_col='Col1',      # Optional: specify index column for data file, else assume first (0) and last (n) columns contain index names\n                  na_values = 1,            # specify values to replace NA columns with, else assume \"False\"\n                  keep_dimnames=False,       # specify the dimension names. If False, don't modify dimension names\n                  usecols=['Col1','Col2','Col3'],     # Optional: specify columns to load, otherwise all columns will be extracted)\n)\n\ndf\n\n# ---\n# IPython Notebook: http://ip.ly/359F\n# Jupyter: http://jupyter.org\n# Cellular Automata: http://brockuniversity.ca/cellular-automata-pupat/\n```\n<EOD> Surgery as a treatment option in non-squamous non-small cell lung cancer.\nSurgical resection is the only potentially curative treatment in non squamous non small cell lung carcinoma (NSCLC) and remains the standard approach in early stages, and more recently in advanced stage of the disease. There is controversy about the benefit of adjuvant therapy in patients with NSCLC submitted to pneumonectomy. We do not have the data from randomized trials to answer this question. In this article we review the evidences in the literature and discuss the controversies concerning the adjuvant and neoadjuvant",
        "label": 0
    },
    "1479": {
        "output": "This time, please choose your answer.\n\nA. 2\n\nB. 0\n\nC. ?\n\n## Answer\n\nA\n\nExplanation\n\nHere are some tips for correct answering.\n\nAt the first screen, do not enter a response in the box for Patient eligibility.\n\nThen, in the Trial-level eligibility box, enter the scale for the assessment of eligibility. If your answer is multiple, make the answer in alphabetical order to be able to check the correctness of your response.\n\nLet's recall the following steps to check your answer:\n\n1. First, press the button for `Check Answer` (right top).\n\n2. Read all the information your answer has led to.\n\n3. Now, press the button for `Check all responses` (right bottom).\n\n4. If all the answers are correct, press the button for `Submit answer` (right bottom).\n\nYou have passed this session.\n\n# 8.31-A. Patient-level eligibility\n\n\nYou are an assistant in a clinical trial of the following drug called drug1 as an add-on treatment for breast cancer. You are asked to assess the eligibility for the clinical trial.\n\nThe drug1 is an antibody-drug conjugate consisting of an anti-HER2 antibody conjugated to a chemotherapy agent, auristatin-based antimitotic drug monomethyl auristatin E (MMAE). Drug1 is a monoclonal antibody which targets human epidermal growth factor receptor 2 (HER2). Trastuzumab, another anti-HER2 antibody, binds to a distinct region of the HER2 receptor's extracellular domain, forming a trastuzumab\u2013HER2 immuno-complex. The trastuzumab\u2013HER2 immuno-complex is then internalized through an adaptor pathway used by the antibody receptors that transport antigens into endosomes for degradation. Trastuzumab then releases its cytotoxic payload (MMAE) to inhibit HER2 receptor function, ultimately leading to the apoptosis of cancer cells which overexpress HER2. The",
        "label": 2
    },
    "1480": {
        "output": "---\n\n## 1.2.2 Examples:\n\n    # Exclude a patient who is not a candidate for an autoimmune hepatitis clinical trial:\n    patient note-title autoimmune hepatitis trial\n\n    ### INST TITLE \n    Autoimmune hepatitis trial\n\n    # ### Patient data-age 55\n    patient note-patient age 55\n\n    # ### Patient gender male\n    patient note-patient gender male\n\n    # ### Patient past medical history non-significant\n    patient note-patient past medical history non-significant\n\n    # ### Patient liver enzyme alpha fetoprotein elevated\n    patient note-patient liver enzyme alpha fetoprotein elevated\n\n    # ### Patient other medications\n    patient note-patient other medications\n\n    # ### Patient patient is an alert man\n    patient note-patient is an alert man\n\n    ### INST FINDING\n    Finding:\n\n    Finding: hepatocellular carcinoma negative for both\n\n    Finding: elevated liver enzymes\n\n    Finding: autoimmune hepatitis\n\n    # ### INST ELIGIBILITY \n    # ## Include: Trial-level Eligibility: 2) Eligible\n    # ## Exclude Patient-level Eligibility: Not relevant\n    # ## Exclude Patient-level Eligibility: Eligible\n\n    ### INST HEADER \n    HEADER: The patient is diagnosed with autoimmune hepatitis\n\n    # ### INST AGE\n    AGE: The patient is 55\n\n    # ### INST GENDER\n    GENDER: The patient is male\n\n    # ### INST MEDICAL_HISTORY\n    MEDICAL_HISTORY: The patient's past medical history is non-significant\n\n    # ### INST LIVER_ENZYME\n    LIVER_ENZYME: The patient's liver enzyme alpha fetoprotein is elevated\n\n    # ### INST ALLERGY\n    ALLER",
        "label": 2
    },
    "1481": {
        "output": "### Exercises\n\n[EXERCIS.INST]\n\n**Instructions:** Please answer in your favorite script language, as if you would write the code to perform this task. The code should not exceed 80 characters. You will be scored on your answer's correctness and the completeness of the code, as discussed in [code review](instructions.md). **\n\nPlease do the following:\n\n\n* [instructions](instructions.md)\n\n# Part Two: Annotation in Clinical Trials\n\nOne common element in clinical trials is the use of annotation data in its design, to describe and characterize the eligible population for the trial. The information comes from many sources. It is used for monitoring enrollment and recruitment and may be used to tailor the trial's design or to provide useful information if the trial is not successful. It can be gathered either from the public domain (e.g., statistics from regional cancer registries) or at the actual trial sites. Below is a list of some features included for the development of annotation tools, the list is not exhaustive. You will have to search these features in the annotation tools described below to see if they are already implemented. Feel free to add new ones. \n\n\n\n### Data\n\n\n\n- `Country`: the country where the trial is being conducted. It may also be a list of all countries to which patients have been recruited.\n\n- `Treatment`: the current state of the disease: pre (before treatment), post (after treatment), or untreated. A patient may have several treatments over the course of the trial.\n\n- `Cancer type`; the type of cancer. It may be a list of all cancers, with a link to more information.\n\n- `Age`; the age of the patient and a link to additional information.\n\n- `Gender`; male, female, or unknown.\n\n- `Ethnicity`; if known, and a link to additional information on ethnicity (if different from `race` value).\n\n- `Race`; if known, the racial group. It may be a link to more detailed information.\n\n\n### Sources in the clinical trial annotation tools\n\nIn the table below, please answer",
        "label": 1
    },
    "1482": {
        "output": "<EOD> <filename>README.md\n# ODPROJEKT 4 - WEB INFORMATYKA\nHttps://opilnij.opil.pl/odprojekt4h\n\n## **ZAZNA\u017bONE** PO\u017bYTNE DLA\n\n1. Ustawienie identyfikatora strony.\n2. Po\u0142\u0105czenie strony z znakami pasek.\n3. Zapobieganie przerywaniu przestwor\u00f3w komunikacyjnych.\n4. Uwierzytelnianie.\n5. Poprawne skrypty\n\n\n<EOD> A new approach to improve detection and treatment in patients undergoing chemoradiotherapy: a clinical study\nAbstract Introduction. Chemotherapy has become standard of care in most patients with locally advanced esophageal cancer, but the treatment still has considerable acute toxicity and serious side effects. Thus, it is crucial to identify high-risk patients to prevent intolerable treatment-related side effects. The aim of this study was to develop a clinical model for predicting the response to chemoradiotherapy (CRT) for esophageal cancer patients and to validate the accuracy of the prediction. Patients and methods. Preoperative tumor staging, surgical pathology, clinical characteristics, and radiation dosimetric parameters were compared between nonresponders and responders. A predictive model for response was then developed and validated. Results. Ninety-eight patients with esophageal cancer were treated with neoadjuvant therapy and surgery. Fifty (51.02%) responded to CRT, and 48 (48.98%) did not. Patient age, pathologic tumor (pT) stage, and radiation dose to the tracheal bifurcation were independently and significantly associated with response to CRT. A scoring system combining these significant factors and other important clinicopathological features, including the clinical stage, pT stage, type of surgery, radiation dose to the chest wall, and total radiation dose, was applied with promising accuracy in predicting response. This approach was then further tested in a validation set and was found to be predictive with statistical significance. Conclusions. The scoring system established in this study could",
        "label": 2
    },
    "1483": {
        "output": "## Exclusion Criteria\n<EOD> The A1c Axis of Diabetes-Associated Cognitive Decline\nThe link between diabetes and vascular complications, such as cardiovascular disease and microvascular damage, is well established. More recently, the association between diabetes and cognitive decline has been elucidated. The mechanisms by which diabetes-associated microvascular complications contribute to cognitive decline are not well understood, and much effort has been focused on determining the interrelationships between hyperglycemia, insulin resistance, and glycated hemoglobin (HbA1c). Several studies demonstrate that people diagnosed with diabetes mellitus exhibit a cognitive performance that is similar to people with a long history of impaired glucose tolerance. The mechanisms by which glycemic control may contribute to this cognitive impairment are not well understood, but are likely to differ by age and insulin resistance.<EOD> The evolution of sex chromosomes: recent progress and the importance of comparative studies\nSex chromosomes, which are usually represented by a single pair of autosomes, are common among animal but very rare in flowering plants. Previous research indicated that the evolution of dioecy from hermaphrodites was a key step in the origin of plant sex chromosomes, although the molecular linkage between the loss of androecia and evolution of sex chromosomes is still lacking. Moreover, sex chromosomes in sexually dimorphic flowering plants tend to be incompletely differentiated compared with the other chromosomes, suggesting that the reduction rate of sex chromosomes is usually slower than that of non\u2010pseudoautosomal (NPA regions of sex chromosomes usually reside at the NPA boundaries) or AAT chromosome. In this review article, we first summarize the current knowledge on the origin of sex chromosomes in dioecious plants and highlight some important issues that need to be resolved by future research. Based on the current understanding of the evolution of sex chromosomes in dioecious plants, the relative rates of evolution of non\u2010pseudoautosomal regions and the AAT chromosome suggest that evolutionary patterns of sex chromos",
        "label": 1
    },
    "1484": {
        "output": "# Subgrouped analysis\nSometimes our target populations are quite limited. For example, we only want to evaluate medicines as safe and effective in patients with a specific kind of disease, e.g., in non-smokers. You can conduct a subgroup analysis which is a special kind of statistical analysis on the trial results, by using special functions in R such as `subgroup().`\nThe simplest way to perform this is by creating a variable, called `subgroup` and performing the analysis on the patients of this variable by using R commands as follows:\n# Create a variable to hold group numbers \nmy_subgroup <- 1:n() # Number of people per subgroup my_subgroup_sub <- unlist(subgroup) # Make sure everything is a character string my_subgroup_sub <- as.character(my_subgroup_sub) # Perform analysis for each subgroup # group the patients of interest into the subgroups # for crossover trials, you can also consider each treatment as a subgroup\n### For parallel, randomized trial: subgroups 0:2 for crossover, randomized trial: subgroups 0:5\nmy_subgroup_sub <- as.integer(as.character(my_subgroup_sub)) # subgroups 0:2, 3:6,7,8 for crossover, 0:5, 6:10, 11,12 for parallel, randomized trial my_subgroup_sub <- my_subgroup_sub -1 # subgroups 1:10, 11,12 for parallel, randomized trial \nWe will see some example in the real data.<EOD> A novel technique for reflux control in laparoscopic Nissen fundoplication.\nLaparoscopic Nissen fundoplication is considered the gold standard for the treatment of gastro-oesophageal reflux disease. It is important to obtain an adequate wrap, which will help control the complications related to the procedure. We describe a novel technique using the left gastric artery or a distal portion of the splenic artery as the source of collateral blood supply to the anterior wall of the wrap, thereby optimizing its effectiveness and minimizing post-operative complications related to ischaemia of the wrap. Furthermore,",
        "label": 1
    },
    "1485": {
        "output": "# How?\n\nSee the discussion on [/HAND] under [INST].\nTherefore, you should do the following steps:\n\n1. Enter the assessment of eligibility for the patient:\na. From the `Home` page, enter the following: `Assessment of Eligibility` in the search box.\nb. Click on `Assessment of Eligibility` in the page, \nClick on the following fields on the left panel:\n   1) Under `Factors:`, enter`Age:`, which in the example, is shown as 55.\n   2) Under`Factors:` enter`Gender (Female):`, the gender in this example appears as`Female\u00b4.\n    \nc. Click on `Generate Rationale` in the page, which generates the following rationale,`Assessment of Eligibility: 0).`Click on`Generate Rationale` in the previous window to see the rationale for the assessment of eligibility. [/HAND]\n\n2. Select the trial you want to check for eligibility for the patient:\na. From the `Home` page, enter the following: `Clinical Trials` in the search box.\nb. Click on `Clinical Trials` in the page.\nc. Click on the following fields on the left panel:\n   1) Under `Filter(s) :` , we select the following filter(s):`Trial Title: Hepatis C Treatment naive Genotype 1 Consensus Inferon Trial 1.`\n   2) Click on`Generate Rationale` in the page.\n   3) Click on `Generate Rationale` in the previous window.\n3. Enter assessment of eligibility for the patient:\na. From the `Home` page,(the same page as in the previous section), you should click on the following fields on the left panel:\n   1) Under `Factors:` enter`Trial Trial: 1.`\n   2) Under`Factors:`enter `Assessment of eligibility 2).` Click on`Generate Rationale` in the previous window. [/HAND]\nClick on the following fields on the left panel:\n   1) Under `Factors",
        "label": 1
    },
    "1486": {
        "output": "As a consequence, the final output of this example would be `0111`\nIoT example in Python 3<EOD> Imaging of the cervical spine in children: a comparison of two radiographic projections using digital imaging and communications in medicine files.\nOBJECTIVE\nTo evaluate the relative radiation dose delivery of the true anteroposterior (AP) projection versus the AP-oblique (APO) projection for children referred to our institution for imaging of the cervical spine.\n\n\nMATERIALS AND METHODS\nA total of 167 digital acquisitions of the cervical spine, consisting of 92 images taken from APO projections and 75 images taken with AP projections, were collected and stored as digital imaging and communications in medicine files (DICOMs). The exposures were categorized into five groups: head, chest, abdomen, extremities, and spine. The spine films were further categorized into anteroposterior (AP) spine and APO spine. On the basis of the manufacturer's conversion factor and the number of patients for whom each exposure was indicated, the effective dose delivered during the examination was calculated.\n\n\nRESULTS\nThe doses delivered to patients during APO examinations were 7.562 mSv, whereas those for AP examinations were 9.612 mSv (an average decrease of 22.33%). The total dose was decreased by 3.5% by using the APO projection. The APO projection is associated with decreased radiation, which would decrease carcinogenic hazards to children who are exposed to radiation while undergoing radiographic examinations. Further studies are needed to determine the relationship of the risk of developing cancers, such as tumors of the thyroid gland and leukemia, with the level of radiation delivered.\n\n\nCONCLUSION\nAPO projections are superior to AP projections regarding the dose delivered to patients.<EOD> The value and utility of 3D EAM systems.\nThis presentation focuses on the basic requirements for implantable cardiac devices. The clinical and physiological considerations underlying the requirements, along with the basic technology of the electrophysiology system",
        "label": 1
    },
    "1487": {
        "output": "[AREA]\n\n<EOD> .\nIn a 30-year-old woman, a bilobulated cyst with pedicle was found in the left retro-auricular region. CT showed the cystic mass occupied the external ear canal. Since the cyst was suspected having an ectopic focus of parathyroid, the transcervical surgery was performed. The internal structure of the mass was honeycomb. The histopathological evaluation showed a well-defined cystic proliferation of the epidermis and dermis containing hair follicles.<EOD> .\nNutritional status plays a major role in the outcome of acute illness and therefore in hospital mortality. The assessment of the nutritional status is based on anthropometric measurements, body mass index, history of weight loss, body composition and inflammatory markers. In addition it is necessary to quantify the quantity and quality of food consumed by means of 24-h recall and specific studies focused on the patient's nutritional intake. The main cause of malnutrition in hospitalized patients is a failure to eat normal weight, the so-called Anorexia of Ageing. The severity of food restrictions can be determined through the NRS 2002 screening tool which enables to identify hospitalized patients at high risk of malnutrition.<EOD> A prospective pilot study of methylprednisolone for severe adult patients with COVID-19: Clinical efficacy, laboratory tests, and clinical value of blood levels of IL-6 and CRP\n\n [bib_ref]  Novel coronavirus infection and gastrointestinal tract, Gao [/bib_ref]  [bib_ref]  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia..., Chen [/bib_ref]  [bib_ref]  Evaluating the use of methylprednisolone to combat COVID-19-associated cytokine storm, Goletti [/bib_ref]  [bib_ref]  COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment, and vaccine..., Shoenfeld [/bib_ref]  [bib_ref]  Why tocilizumab could be an effective treatment for severe COVID-19, Fujiwara [/bib_ref]  [bib_ref]",
        "label": 2
    },
    "1488": {
        "output": "The final output of the script will be an HTML file for submission to a website, a CSV file (comma delimited) for an Excel spreadsheet, and a JSON file (JavaScript Object Notation) for JavaScript. For this training, we provide an example of each format.\n\n---\n\n![INST] [https://github.com/UCHealthEducation/CDS/blob/master/2_ELICIT_ScriptIncludes/CDI%20Tutorial-Detection.gif]\n\n---\n\n## Exercise 47: [https://github.com/UCHealthEducation/CDS/blob/master/2_ELICIT_ScriptIncludes/CDI%20Tutorial-Detection2.gif]\n\nWe will continue to play with the above script to see how it works. We will start by going over the following lines:\n\n\n```Python\nif(input_note == 'None'):\n    print ('Enter Patient Note Here.')\n```\n\nAfter you submit a blank input (`qw` in the example), the above block produces the following output:\n##### print('Enter Patient Note Here.')\n##### print('\\n')######\n\nWe need to remove the first printed lines (prints) because they are not part of our answer. They seem to be informational help for the user. We can remove these lines by adding the `else:` to the previous if statement:\n\n##### print('Enter Patient Note Here.')#####\n\n##### print('\\n')######\n\n##### if(input_note == 'None'):#####\n\n##### print('Enter Patient Note Here.')#####\n\n##### print('\\n')######\n\n##### else:\n\n##### print('Enter Patient Note Here.')#####\n\n##### print('\\n')######\n\n\nOutput of Exercise 40: `Enter Patient Note Here.`\n\nThis produces the expected output:\n##### print('Enter Patient Note Here.')\n##### print('\\n')\n\n[INST] `Enter Patient Note Here.`\nThis produces the expected output:\n##### print('Enter Patient Note Here.')\n##### print('\\n')\n\n[INST] `Enter Pat",
        "label": 1
    },
    "1489": {
        "output": "##[END]\n<EOD> The Inappropriate Antidiuretic Hormone Syndrome in a Case of Intraventricular Meningioma\nSUMMARY: This report concerns two patients in whom an intraventricular meningioma produced the inappropriate antidiuretic hormone (ANH III) syndrome. In both patients, the meningioma was thought to be the tumor previously reported as producing ANH I1. In these patients, the pathogenesis for the ANH III was thought to be caused by inhibition of the renal tubular reabsorptive capacity for solutes and water coupled with the release of vasopressin from hypothalamic centers. The pathogenesis for the release of vasopressin is postulated to be due to the mechanical displacement of the tumor to block the cerebrospinal fluid pressure diverticulum.<EOD> Vaccines for preventing mumps.\nBACKGROUND\nMumps virus causes the disease mumps which clinically presents as fever with parotid gland swelling. Symptomatic cases are often self-limiting but a proportion goes on to develop serious complications and also cause transmission of the virus.\n\n\nOBJECTIVES\nTo study the efficacy and acceptability of vaccines for the prevention of mumps.\n\n\nSEARCH STRATEGY\nThe Cochrane Controlled Trials Register, Medline and Embase were searched through to October 1998.\n\n\nSELECTION CRITERIA\nTwo reviewers independently assessed the studies on the basis of predetermined inclusion criteria for methodology and population; the reference lists of primary studies and reviews were scrutinized for relevant citations.\n\n\nDATA COLLECTION AND ANALYSIS\nTrial eligibility was determined by the two reviewers according to the inclusion criteria, and data was abstracted independently by the reviewers. Any disagreements, not resolved by discussion, were resolved by the third reviewer.\n\n\nMAIN RESULTS\nThree controlled trials were identified of which one was conducted in the United States of America (USA) and one each in Finland (FinMuSPRA trial) and Israel (Trivir). Each study demonstrated a clear benefit in favour of Mumps",
        "label": 2
    },
    "1490": {
        "output": "[TEST] To complete a trial-level eligibility, the Trial-level eligibility column of your output must have the value: `2)`, which means `Eligible`. If the program fails to produce the correct value, you should check your data. \n\n[/TEST]\n\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine the number of clinical trial patients whose disease status is improved after a treatment. \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile\n\n\nSummary: We hypothesized that pretreatment nonresponder and responder liver tissue would show consistent differences in gene expression levels and that these differences could be used to predict treatment outcomes and this can obviate the need of the present therapeutic trial.\n[INTRO] (Having this patient under treatment)",
        "label": 2
    },
    "1491": {
        "output": "Your task is to write a computer program in Python language that reads a file that is a patient record in SCF. The format of the record file is shown in Figure 3-4. There are two patients in the file. Each record has 15 attributes: Aid, Sex, Age, Race, Acuity, Adm_Service, Inpatient, Discharge, Disch_Spt, FS_Dx, FS_Cntx_Sr, FS_Rx_Sr, CCC_Ser_1_Date, CCC_Ser_2_Date. The file is a text file, where, in each line, each attribute is separated by spaces, the patient's attributes are shown in parentheses. There are three possible attributes: yes, no, or NA.\nThe file size is N (number of records) by M (number of attributes in each record).\n\nThe program receives a list of required attributes (such as: 2, 5, 8 , 14, 15, 3, 4, ) and the number of the records(N). Then, it checks patients for all the required attributes 2, 5, 8, 14, 15, 3, 4, (the first attribute is the aid attribute; therefore, the numbering refers to 2 in the aid attribute), and then reads each record and checks, using each attribute, if it exists, and if exists, stores them in a set (which is a list of tuples) that stores all records that match the required attributes. Finally, the program prints out all records that have all the required attributes. (You may assume that all records have at least these attributes: 2, 5, 8, 14, 15, 3, 4, , because these are the only mandatory attributes). The set_ids(set_list) = set(ids for ids in set_list)` .\n\n* The function creates a set of a list of IDs, which are set IDs from the patient records that have the required attributes. The program has two sets to store the patients, one containing set IDs (unique IDs), and another set containing the list of required attributes, and then it adds patients to the patient list if the patient has the same set list as that previously saved in the required attributes set.\n\n*",
        "label": 1
    },
    "1492": {
        "output": "[/INFO] Congrats! You are an expert on inclusion-exclusion criteria.<EOD> .\nClinical and morphological studies of patients with multiple sclerosis (MS) and other disorders of the neuromuscular system were carried out. A total of 60 patients were examined, of them 51 suffered from disseminated encephalomyelitis (DEM), 24 patients--from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 5 patients--from amyotrophic lateral sclerosis (ALS) and 2 patients--from neuromuscular system atrophy (NMS). A significant increase in the level of lactate and lactate/pyruvate ratio in the blood of patients with DEM, CIPP, ALS, and NMS suggests a disturbance of the lactate-pyruvate-carbohydrate metabolism in these disorders. The decrease in the level of pyruvate in the serum of patients with these disorders has been demonstrated. The significance of these shifts in the pathogenesis of MS and other disorders of the neuromuscular system is discussed.<EOD> Growth of bumblebees in relation to larval feeding, colony composition and social behaviour.\nThe bumblebees of 3 Bombus species from Scotland, B. vestalis, B. hypnorum and B. lapidarius, were investigated during a season of unusually warm weather. B. lapidarius tended to overwinter underground whilst B. vestalis and B. hypnorum overwintered under leaf litter. Bumblebees were heaviest in the autumn and winter, the growth of B. lapidarius continuing over this period. The adult weights of worker queens and males differed markedly among species as did the weights of workers, though to a lesser extent. The food intake of larvae was determined for B. lapidarius, and for these bees the weight of the adult workers showed a strong positive correlation with diet size. In the earlier part of the season the workers of B. lapidarius, B. vestalis and B. hypnorum in small colonies worked more often in the nest than those of larger colonies",
        "label": 1
    },
    "1493": {
        "output": "<EOD> Coronary thrombus and no-reflow phenomenon in human heart transplantation.\nWe have assessed 20 patients undergoing orthotopic heart transplantation. A 9-French intracoronary balloon catheter was placed distal or side-wise to the coronary ostia and advanced with an extra-long guidewire to the level of the aortic root, allowing direct visualisation of the distal coronary artery. Thrombi were documented in 10 of the 20 patients (50%) by both intravascular ultrasound and coronary artery angiography and ranged in maximum length from 3 to 10 mm. These were most common in the obtuse marginal branch of the left circumflex artery (n = 9) and the posterolateral branch of the right coronary artery (n = 2). Distally in each coronary segment examined 100% of the small distal vessels were occluded. In addition, the no-reflow phenomenon was demonstrated in 9 of the 20 patients (45%), as detected by the absence of a dye jet into the distal coronary artery beyond the site of the intracoronary balloon occlusion. Intracoronary glyceryl trinitrate injection was administered to 10 patients, and 9 (90%) showed restoration of flow. The remaining patient developed a distal embolus with extension into the side-branch vessels. Intravenous heparin administration was continued in all patients postoperatively for 4 days. During that time no bleeding episodes, stroke or myocardial infarction were documented in any of the patients. These findings suggest that there is a high prevalence of coronary thrombi and no-reflow phenomenon at the time of orthotopic heart transplantation. This, combined with possible embolisation of thrombus and deposition of fibrin during the course of a transplant operation, may predispose to the development of myocardial infarction in the early postoperative phase. Our observations may also indicate that the use of intracoronary nitrates may decrease the incidence of these occurrences.<EOD> The role of the pyl",
        "label": 0
    },
    "1494": {
        "output": "[END]\nGood luck!!!!\n\n## Question 1\n<EOD> <jupyter_start><jupyter_text>Loading of the data in memoryWe can obtain this data from Google Sheets (not from a CSV file stored in a file in the same directory).To load the data, we use <code> pandas.read_pandas ()<jupyter_raw>#! python3\nimport pandas as pd\ndf = pd.read_pandas(\"https://docs.google.com/spreadsheet/ccc?key=0AoOhrY3g59BwdGpEa1FOSGdmNHZTFCdmRNQU5mYjUw&usp =sharing\")\n\n# We want to convert the pandas df object into a dataframe using the pd.to_DataFrame () method.\ndf = pd.to_DataFrame(\n    df\n)<jupyter_code>data = pd.DataFrame.from_records( \n    data=[],\n    name = \"data\",\n    formats = [\"unicode\"],\n    index  = pd.DatetimeIndex(\n        data = list(range(5981, 5993)), \n        freq = \"1d\"\n    )\n    )\n\n# We print the length of the input column  \"Index\"\ndf[\"Index\"]<jupyter_output><empty_output><jupyter_text>We can convert the pandas dataframe into the Dask dataframe<jupyter_code>dfl = data.to_dask.dataframe<jupyter_output><empty_output><jupyter_text>Save the dataframe into the file by the pandas.to_csv () function and dfl.to_pyformat () function, which will generate a .csv file. By the dsk-pyformat library, we can create a .csv file. For us, the columns that we convert into csv data are: #0 = Date; #1 = Region; #2 = Total sales; #3 = Sales; #4 = Cost; #5 = Margin<jupyter_code>df.to_csv(\n    \"data.csv\", \n    sep = \";\")\n\ndf.to_pyformat(\n    \"data.to_csv\", \n    #",
        "label": 0
    },
    "1495": {
        "output": "[RUN] \nYou are requested to read and respond to an email regarding a job opening at the Institute of Computational Mathematics and Statistics of J\u00f6nk\u00f6ping University (ICOMS). You are interested in taking over the above position as soon as possible to start your academic career as an assistant professor, and therefore you would like to submit your application and request further documentation about the job vacancy or the application process.\n\nHere is the job offer: \n\n### Job Title: Assistant Professor\n\n### Start Date: as soon as possible\n\n### Hiring Information:\n  - \nName: The Institute of Computational Mathematics and Statistics (ICOMS)\n\n### Job Description:\nYour role within the Department of Mathematics at the ICOMS consists of performing research and teaching. During the first 6 months, you will be expected to participate in research and other activities at ICOMS, perform teaching courses in the program, and start writing a research plan for the 5-year appointment period. In the following years you will be expected to perform research, teach a 40-credit graduate course each year (10 h/week) and spend about 30 25-credit courses during the first year. 2) A detailed proposal of a teaching load 3) Your current CV including two referees with contact details 4) Copies of publications in peer-reviewed conferences or journals with IF information, if available.\n\n### Eligibility Criteria:\nIn addition to the requirements listed above, you also need to fulfill the following additional eligibility requirements:\n- \n\n# [INST] Hints\n\n## [HINT1] The first task consists in comparing patient note  from the previous section with inclusion and exclusion criteria  from a certain trial  from another module and output  the final assessment results in the clinical trial eligibility test.\n\n## [HINT2] You can use `match-key(clinsrce,key,eligible){key := \"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"| \"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|\"\"|",
        "label": 0
    },
    "1496": {
        "output": "## [CORPUS]\n\n### #0393-20080522-752074-1235\n[CORPUS]\n\n## [114]\n##$4.00\n### $1.00 $2.00\n* This is a single source of information\nItem no. C70-7/C70307\nVaccine for hepatitis B viruses, recombinant, adsorbed, suspension\n**Item no. V840040**\n\nVaccine for hepatitis B viruses, recombinant, adjuvanted, suspension, prefilled syringe\n**Item no. V780207**\n\nVaccine for hepatitis B viruses, recombinant, adsorbed, suspension, multidose vial\n**[174] 122 259\nItem no.\nVACC-MHCBH-1\n**[119]**\n<EOD> Efficacy of probiotic supplementation on markers of tuberculosis infection in household contacts of patients with pulmonary tuberculosis in Ethiopia: a double-blind, placebo-controlled, randomized clinical trial\n\nBackground: Improving immunity may enable the human host to control the growth of Mycobacterium tuberculosis and reduce the clinical manifestation of tuberculosis. Probiotics are known to play an important role in the immune response of the host and prevent infections. We aimed to assess the efficacy of probiotic supplementation on markers of M. tuberculosis growth using t-cell interferon gamma release assays (IGRAs) and the clinical course of tuberculosis disease (TBC) in household contacts of pulmonary TBC cases in Ethiopia. Methods: In a double-blind, placebo-controlled, randomized clinical trial we supplemented 131 household contacts with either a probiotic supplement, Vivo-GenuPro (active treatment) or a placebo for 16 weeks in the community and compared this supplementation with 54",
        "label": 0
    },
    "1497": {
        "output": "<EOD> Prevalence and Characterization of Mycoplasma Species Caused Subclinical Mastitis of Dairy Cows in South Korea\n\nThis study was performed to estimate the prevalence rate and genetic characteristics of Mycoplasma species causing subclinical mastitis of dairy cows. Mycoplasma species-positive milk was collected from 1600 dairy cows in 334 dairy herds in Jeju Island, South Korea, from July to October 2014 using a randomly clustered multistage sampling method. All Mycoplasma species-positive milk samples were subjected to a multiplex polymerase chain reaction (PCR). Among the 1600 milk samples, 252 (16.00%) were characterized as positive for Mycoplasma species. According to the results of multiplex PCR targeting ISMp1, ISMp2, and ISMp3, one hundred and thirty nine (92.0%), three (2.0%), and thirty (20.0%) milk samples showed M. bovis, M. bovigenitalium/M. alkalescens, and M. spp. infection, respectively. In this study, the prevalence of Mycoplasma species was higher during the summer compared to other seasons (P<0.05). The highest prevalence of Mycoplasma species was observed in July (17.64%) compared to August (14.69%), September (17.08%), and October (14.96%).\n\n# Introduction\nMastitis is a major disease that reduces milk production, causes economic losses, and leads to impaired animal welfare. In dairy farming, mastitis is one of the most frequently occurring diseases, and it is caused by several factors, such as bacteria, viruses, and parasites. Mycoplasma, the smallest free-living organisms in the world that belongs to the class Mollicutes, is the major class and represents the largest group of mastitis pathogens, causing a wide range of infectious diseases in humans and animals. Bovine mycoplasmas, including M. bovis and M. bovigenitalium",
        "label": 1
    },
    "1498": {
        "output": "[INFO] Hello.[END]\n<EOD> GM130 orchestrates membrane and protein distribution to polarize the yeast secretory compartment\nWe used fluorescence recovery after photobleaching to quantitatively map the membrane distribution of GDP-mannose transporter Mnn9-mRFPh, a Golgi enzyme and endoplasmic reticulum-resident cargo receptor, at steady state and after treatment with drugs that disrupt membrane traffic. Unexpectedly, GM130, an evolutionarily conserved Golgi membrane structure protein, was identified as a major regulator of Mnn9-mRFPh distribution and localization, and of the distribution and localization of vesicle-tethering complexes, SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors), and exocytic components in the yeast secretory compartment. Deletion of GM130 did not significantly affect cargos trafficking through the secretory pathway, the total Golgi area, or the integrity of the Golgi. Deletion of GM130 specifically impaired Golgi membrane growth without affecting ER, endocytic, mitochondrial, or vacuolar membrane distribution, and reduced the secretion of multiple cargo proteins. GM130 deletion phenotypes were rescued by re-expressing GM130 in the secretory compartment. By analyzing fluorescent reporters that map the distribution of secretory vesicles, endosomes, and proteins that are involved in secretory vesicle trafficking, we determined that GM130 deletion specifically impaired trafficking from the secretory compartment and the trans-Golgi network, but had little effect on trafficking from the endosome or the early Golgi. Biochemical fractionation revealed that the Golgi membrane structures and vesicle-tethering complexes in cells lacking GM130 are significantly impaired. We propose that GM130 affects the spatial organization of secretory/endosomal membranes, vesicle-tethering complexes, SNAREs, and vesicle traffic at the secretory compart",
        "label": 0
    },
    "1499": {
        "output": "## 5. How to use the eligibility criteria API:\nThe eligibility criteria are described in the [Eligibility criteria](/api/eligibility criteria) API which has the following endpoint: http://example.com/api/eligibility criteria. The following request will show the patients that meet the criteria; their patient ID, trial ID, trial name, start date, start time and end date.\n\n### Example request:\nRequest: http://example.com/api/eligibility criteria Response:\n```json\n{\n    \"count\": 40,\n    \"countFrom\": \"9465600\",\n    \"countTo\": \"9468300\",\n    \"patientIds\": [\n        \"A0001\",\n        \"A0002\",\n        \"A0003\",\n        \"A0004\",\n        \"A0005\",\n        \"A0006\"\n    ],\n    \"trialIds\": [\n        \"0003\",\n        \"0004\",\n        \"0005\",\n        \"0006\",\n        \"0007\",\n        \"0008\",\n        \"0009\",\n        \"0010\", \n        \"0011\",\n        \"0012\",\n        \"0013\",\n        \"0014\",\n        \"0015\",\n        \"0016\",\n        \"0017\",\n        \"0018\",\n        \"0019\",\n        \"0020\",\n        \"0021\",\n        \"0470\",\n        \"0471\",\n        \"0472\",\n        \"0509\", \"0510\",\n        \"0511\",\n        \"0512\", \n        \"0513\",\n        \"0514\",\n        \"0515\",\n        \"0516\", \n        \"0674\",\n        \"0956\",\n        \"0957\",\n        \"0958\",\n        \"0959\",",
        "label": 0
    },
    "1500": {
        "output": "</INST>\n\n__HINT__: Do not forget to use the correct indentation!\n\n## [JOINT_DECLARATIONS](code/join-declarations)\n\n__INST__\nTutorial #7 You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a certain clinical trial. Your goal is to determine the patient's eligibility.\n__END INST__\n\n__JOINT-DECLARATIONS__\n\n__INST__ You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a certain clinical trial. You want to determine the patients eligibility.\n\n__END INST__\n\n\n___HINT_\nUse the same indentation for all functions/declarations/expressions and consider a standard indentation.\n___\n\n\n## [LINK_DATA](code/link-data)\n__INST__: You are a helpful assistant for clinical trial recruitment. Your task is to compare the attributes of a given patient note and the data attributes of a certain clinical trial. Let's see, how the `Trial` class inherits from the `Abstract Class ` Patient` and how the data of the three patient fields are displayed by the `setTrials()` function.\n__END INST__\n```julia\n```\n\n# Data analysis\n__INST[1]__: You are a helpful assistant for clinical trial recruitment. Your task is to compare the attributes of a given patient note and the data attributes of a certain clinical trial. Let's see, how the `Trial` class inherits from the `Abstract Class ` Patient` and how the data of the three patient fields are displayed by the `setTrials()` function. For more information about classes and abstract classes, see [Classes](Classes/index)\n\n__END INST__\n```julia\n```\n__INST[3]__: The following example demonstrates how to load some data to the patient and trial objects. \n\n__END INST__\n```julia\n```\n# Let's get some data for our Patient and Clinical trial\n\npatients <- loadpatients()\nclinicalTrials",
        "label": 1
    },
    "1501": {
        "output": "4. Please use the information in Section 1 to generate a patient-level eligibility based on the inclusion criteria. A patient-level eligibility is a checklist indicating a patient's compliance with each inclusion criterion. You should check each box in the inclusion criteria column when evaluating a patient with clinical criteria that are defined as inclusion criteria for this clinical trial. Please write a text output for each trial-level eligibility. You should repeat patient-level eligibility for each of the study arms. Your output should be written as a trial-level eligibility checklist e.g., 2) Eligible. ` to the clinical trial. \nNote: You are not required to add the 'NOT NULL' option on patient-level eligibility checklist. Please use the patient-level eligibility checklist to identify whether or not a patient qualifies to participate in a proposed trial. If the patient does not meet any of the inclusion criteria, then the patient should be considered ineligible, regardless of any other criteria in the checklist.\nFor example, to demonstrate how to write the output for the patient-level eligibility for Clinical trial 1, add the following text, \"Patient-level eligibility: Exceeds age limit:  22 3.5. Please calculate the percentage of eligible and recruitment rate for each trial.\nNote: To do so, we have provided some instructions on how to calculate the percentage and recruitment rate under each trial. Also, we encourage you to calculate them independently. \nTrial 1 Exceeds age limit:  22 Patient-level Eligibility (No=1, Yes=2)\n\n# Results, conclusions, and discussion\nWe examined the performance of clinical trial recruitment assistants in assessing a patient's eligibility to participate in a clinical trial. We considered three clinical trials with different inclusion criteria.\nFirst, we analyzed their responses and responses' quality regarding clinical trial 1. Overall, of 200 responses for clinical trial 1, 12.5% of the responses are '0), 72.5% of the responses are '1) and 15% of the responses are '2) . As shown in , we compared the percentage of responses",
        "label": 1
    },
    "1502": {
        "output": "<EOD> Evaluation of the HIV-infected patient for vascular access.\nThe first step in the evaluation of a HIV-patient for vascular access is an assessment to determine the need for dialysis. Other issues that should be addressed at this time are determination of the duration of the potential vascular access, an assessment of other comorbid conditions and an evaluation of cardiac status. After this evaluation is completed, if a permanent access is recommended, the vascular access team should recommend the optimum type of access. The type of vascular access recommended depends upon the vascular anatomy of the patient with consideration given to the length of anticipated need for vascular access, presence of comorbidities and location of the infectious lesion.<EOD> Immunogenicity of a live attenuated H5N9 swine influenza virus\n\nThe H5N9 subtype of influenza viruses pose a potential threat to avian and swine population in Southeast Asia. In this study, the safety and efficacy of a live attenuated H5N9 virus were investigated in domestic piglets. The live attenuated H5N9 virus, A/swine/Szechwan/1/2009-like (H5N9), was generated by serial in vitro passages of a high-pathogenic H5N9 virus using the reverse genetics system. Compared to the wild-type virus, the resulting live attenuated virus exhibited significantly lower pathogenicity in chickens and swine. After intranasal inoculation at a high dose of 10 6 EID 50 , no morbidity and mortality were induced. Challenge studies in specific-pathogen-free piglets indicated that there was a significant amount of virus shedding in nasal cavity for 7 days and in oropharyngeal mucosa for 3 days, but the shedding virus titers did not exceed 4.5 log 10 of EID 50 equivalents for nasal cavity and no virus shedding occurred in oropharyngeal mucosa at day 7. All piglets remained healthy without any evidence of disease after vaccination. A subunit virus vaccine, which was consisted of",
        "label": 2
    },
    "1503": {
        "output": "[END] `\n\n[INST] As we have already mentioned above, the patient ID (patient_ID) is the unique number of this trial for each patient. \nThe value of this variable and values of other variables are shown in the source code below.\nclass PatientInfo < ApplicationRecord\n  # Primary key for a patient record. An integer.\n### FIRST LINES ###\n  self.primary_key = :patient_ID    \n  # A unique number for a patient record. \n  self.sequence = :patient_ID                \n  # A set of trial-level eligibility for a patient. It is a hash.\n  # Note: We want to store the value of trial-level_eligibility for patient at this line\n  # The value is { trial-level_eligibility => '0' or '1' or '2' } because we always want to compare (i.e., assign)\n  # the test cases to this trial for every patient. \n  trial_level_eligibility = { trial_level_eligibility => '0' or '1' or '2' }\n  # The patient's status in the clinical trial. \n  trial_status = \"Active\"\n  # The patient's trial-level_eligibility. \n  trial_level_eligibility_value = '0'\n\n[/INSERTION]\n\n\n`\n<EOD> Interactions of the pim-1 Proto-Oncogene with the Retinoblastoma Tumor-Suppressor Gene Product pRb and Other Cell-Cycle Proteins*\n\nThe pim-1 proto-oncogene encodes a serine/threonine kinase that was originally identified by provirus insertional mutagenesis in leukemic cells but is also expressed in diverse cell types. We report here that pim-1 binds to the retinoblastoma tumor-suppressor protein (pRb) as well as other cell-cycle regulatory proteins, p107 and p130. Inhibition of Cdk4 kinase activity with roscovitine or the Cdk4-specific inhibitor 6QD1 resulted in a strong reduction of pRb and pim-1 kin",
        "label": 0
    },
    "1504": {
        "output": "You can press a shortcut key CTRL-F to run all of the following text in the trial editor.\nTrial: LETRANS_00_PATIENT_CASE_00_STUDY_0\nLet's discuss the next question.\n\n## Question 8\n[INST]\nLet's continue with the previous example. This example's data are the same as in Question 7, except now, there could be a more detailed description of the disease. \nIf the description allows us to specify the case: In this case, to specify the trial-level eligibility, you should do `if patient.disease equals \"liver cirrhosis\" then`. Otherwise, this comparison should be equal to `if patient.disease equals \"other\" then`. You should specify this trial-level eligibility at the place of `patient 1` with `Trial-level eligibility: 1) Eligible with specific condition: liver cirrhosis`. Thus, now, patient 1 is eligible for the next patient to compare. As you can determine, in general, we can use the value of the 'disease' variable to specify the trial-level eligibility. Therefore, all of the patients who have the same disease are eligible to be compared with each other to decide which patient is more eligible for the clinical trial. \n\n\nAlternatively, let's consider the following three possible cases:\n\n## \u2756\nThe description of the disease specifies the type of disease \u2756 The description of the disease excludes patients with a specific disease \u2756 The description of the disease excludes patients without a specific disease\n\n## In the previous example:\nAll three patients are eligible because no disease description is used. Let's repeat the previous example and add a description of the disease with a few details.\n\n\nTrial: LETRANS_00_PATIENT_CASE_00_STUDY_0\n\n## Description\nHepatitis C infections, which is a blood-borne disease, may damage the liver cells. About 20 percent of people infected with HCV will subsequently develop liver disease, known as hepatitis. It can take 10 to",
        "label": 0
    },
    "1505": {
        "output": "![INST]\nHere is an example of the successful submission of an assignment using this method. \n\n[INST] Outputted Assignment:\n\nThe trial-level eligibility is 2 (Eligible).\n\n![INST]\nPlease make every submission following the above instructions.\n\n# SOLUTIONS\n\n# Input\n```json\n{\n    \"Patient\": {\n        \"PatientId\": \"7111\",\n        \"PatientAge\": \"40\",\n        \"Gender\": \"M\",\n        \"PatientSex\": \"Female\",\n        \"PatientRace\": \"Caucasian\",\n        \"Insured\": false,\n        \"HealthcareProvider\": \"Primary Care Physician\",\n        \"Drugs\": [\n          {\n            \"DrugId\": \"111111\",\n            \"DrugName\": \"Nalidixic acid (oral)\",\n            \"DrugPrescription\": \"Prescribed\",\n            \"Dose\": \"1000\",\n            \"Frequency\": \"1\",\n            \"DoseUnit\": \"mg\",\n            \"Quantity\": \"1\",\n            \"Duration\": \"30\",\n            \"DrugManufacturer\": \"Humanitas University\",\n            \"DrugRoute\": \"Via. Oral.\",\n            \"Strength\": 2,\n            \"DosingTime\": \"On the day when the HCV-RNA test is negative.\",\n            \"Days\": 10,\n            \"DrugAdministrationUnit\": \"Pill\",\n            \"DrugIndication\": \"Urinary tract infection\",\n            \"DrugTherapy:\",\n            \"PatientRefersTo\": []\n          },\n          {\n            \"DrugId\": \"222222\",\n            \"DrugName\": \"Sulfamethoxazole/ Trimethoprim\",\n            \"DrugPrescription\": \"Prescribed\",\n            \"Dose\": \"2\",\n            \"Frequency\": \"1\",\n            \"DoseUnit\": \"tablet\",\n            \"Quantity\": \"1\",\n            \"Duration\": \"10\",\n            \"DrugManufacturer\": \"PharmaCatalyst\",",
        "label": 1
    },
    "1506": {
        "output": "[table]  TABLE 3 -: STEP 1: FILLING THE VALUE IN THE VARIABLE AREA [/table] \n[table]  TABLE 4 -: STEP 2: FIXING THE SCOPE SOLUTION FOR THE DATA TYPE BY SELECTING IT FROM A DROPDOWN DROPDOWN. [/table] \n[table]  TABLE 5 -: STEP 3: CHOOSING THE VALUE DOMAIN FROM THE LISTED VALUE DOMAINS [/table] \n[table]  TABLE 6 -: STEP 4: TREE SELECTION SELECTING THE SPLITTER TYPE OR CATEGORY VIA TREE SELECTION PANEL. [/table] \n[table]  TABLE 7 -: STEP 5: SAVING YOUR EXPERIMENT SELECT 'Save Experiment'. Once saved, you will be able to use the saved experiment in later sessions. [/table] \n[table]  TABLE 8 -: STEP 6: PROGRESS BAR PROGRESS BAR AND BAR GRAPHS MAP THE MAPLE JOB'S PROCESS. [/table] \n[table]  TABLE 9 -: STEP 7: RESULT ANALYZER RESULT PANEL PROVIDES INFORMATION ABOUT SOLUTION RESULTS. [/table] \n[table]  TABLE 10 -: STEP 9: ADDITION OF EXCEL-FORMATTED AND SAVED FILES EXCEL AS DATA IMPORT. [/table] \n<EOD> A study of factors influencing the selection criteria and implementation of a new HIV/AIDS voluntary counseling and testing program\nTo understand the factors leading to the implementation of an HIV/AIDS voluntary counseling and testing (VCT) program, a pilot VCT project in Hai Phong City, Vietnam was studied, which involved four different VCT implementation models. A multidisciplinary team of international participants carried out the study, using a mixed research method of semi-structured interviews; observation, documents and focus group meetings. Three models were implemented by external agencies, and one model was carried out by local VCT workers, with assistance from the project team. This study revealed that the model with external agencies was preferred",
        "label": 1
    },
    "1507": {
        "output": "Bio-ontologies\n[![DOI](https://docs.google.com/uc?id=14T8nLQfyXZk3690A&export=download)]()\n[![DOI](https://docs.google.com/uc?id=1gRcMGp6-Fv73Lr6nA&export=download)]()\n\n\n# Usage\n\nA simple example is:\n\n    usage: trial-eligibility.py [options]\n    -f PATH_TO_YOUR_TRIAL_NOTES_TABLE_DATA_FILE Path_to_your_trial_notes_table_data_file\n    -f PATH_TO_YOUR_PATIENTS_NOTES_TABLE_DATA_FILE Path_to_your_patients_notes_table_data_file\n    -r PATH_TO_YOUR_TIRED_ONT_FILES_PATH Path_to_your_tired_ont_files_path\n    -x PATH_TO_YOUR_R_SODA_FILE_PATH Path_to_your_r_soda_file_path\n    -i PATH_TO_YOUR_YAML_FILE_PATH Path_to_your_yaml_file_path\n    -o PATH_TO_YOUR_STANDARD_OUTPUT_SAVE_ONLY_FILE_PATH Path_to_your_standard_output_save_only_file_path\n    -n TITLE_OF_YOUR_TRIAL The_title_of_your_trial\n    [more options]\n\nThe program takes a table-formatted data file as input with columns containing the title, the gender, the age, the ethnicity, the family history, the medications, and the results of the test. It can be in either an Excel or a csv format. It returns tables with entries in `Trials` with a field with the trial's title and rows with patients (the gender, the age, the ethnicity, the family history, the medications, and the test results). \n\n\n# Helpful Notes\n\n* The program accepts a csv or an Excel file as input.\n* The first column in an Excel file must",
        "label": 1
    },
    "1508": {
        "output": "<commit_msg>Fix 'repeated' comment about Trial-level eligibility in CONFIDENCE_SECTION<commit_after>#ifndef GRAPHLAN_VIRTUALIZATION_PROJECT_MAIN_H_\n#define GRAPHLAN_VIRTUALIZATION_PROJECT_MAIN_H_\n\n#include <string>\n\nusing namespace std;\n\n/***\n *@brief This is the Main.cpp program for graphlan-virtualization\n ****\n *@author <NAME>\n *@version 1.0\n *@todo \n *\n */\n\nchar CAL_DATA[128] = \"\";\nvoid Main_Function()\n{\n\n\tcout << \"\\t--------------------------------------------------------------------- \\n\";\n\tcout << \"\\tThis is the Main.cpp program for graphlan-virtualization    \\n\";\n\tcout << \"\\tPlease change the variables in the code. I will not change them. \\n\";\n\tcout << \"\\tThe program ends. Please see the program comments.                 \\n\";\n\n\tprintf(\"\\nPlease enter the name of the graphlan database (the data that will be used in the graphlan visualization program): \");\n\tscanf(\"%s\", CAL_DATA);\n\tprintf(\"\\n\");\n\tprintf(\"\\nPlease enter the name of your graphlan database: \");\n\tgetline(cin, CAL_DATA);\n\tcout << \"\\t--------------------------------------------------------------------- \\n\";\n\tcout << \"\\t**********************************************************************:               \\n\";\n\tcout << \"\\tPlease choose from the below options:                                        \\n\";\n\tcout << \"\\t1. Confidentiality:                                \\n\";\n\tcout << \"\\t2. Trial Name:                                \\n\";\n\tcout << \"\\t3. Assistance Type:                               \\n\";\n\tcout << \"\\t4. Aggregate:                                 \\n\";\n\tcout << \"\\t5. Trial-level eligibility:                \\n\";\n\tcout << \"\\t6. Summary trial:                             \\n\";\n\tcout << \"\\t7.",
        "label": 1
    },
    "1509": {
        "output": "## [/PROBLEM]\n[PROBLEM: 901] Eligibility evaluation by exclusion criteria\n\n## [PROBLEM-DESCRIPTION] \nA patient's assessment of eligibility is not finished until an examination of exclusion criteria is done, as well. So, you should assess exclusion criteria for the clinical trial to confirm that the patient is eligible. The exclusion criteria of a clinical trial specify factors that eliminate a patient entirely. To be enrolled in a clinical trial, patients have to agree not to take any of the excluded drugs within the preceding 1 month before the study starts. The exclusion status of the patient can be written as Exclusion status: `Excluded (patient does not meet inclusion criteria) not relevant (patient does not have the trial's inclusion criteria). ` ].\n\n## [/description]\n\n## [PROBLEM-SOLUTION] \nFirst, you find the patient information for a target clinical trial, which is written as `Patient information: 1) Patient: patient object`. And then you find the exclusion criteria by searching a keyword that the trial excludes, as illustrated in the following, e.g., `Exclusion status: Exclude: ` and you confirm whether the exclusion criteria apply or not by the type and value. The criteria include: age, pregnancy, lactation, contraindication, allergy, hypersensitivity, and others. If you find the trial excludes the user based on an available criterion, the trial is excluded (patient does not meet the inclusion criteria); otherwise, the trial is not excluded (patient does have the trial's inclusion criteria). By iterating through each trial, all excluded trials should add one to  the sum of excluded trials, until the eligible trial is found. The eligible trial corresponds to the trial with lowest sum.\n\n## [/solution]\n\n## [/problem]\n\n## [PROBLEM: 902] Generating and sorting exclusion criteria by type\n\n## [PROBLEM-DESCRIPTION] \nSometimes, you need to generate trial-specific exclusion criteria to fill a free slot and then sort the exclusion criteria by type,",
        "label": 1
    },
    "1510": {
        "output": "## TA1.3. Tutorial: clinical trial report\nIn this tutorial, you will get familiar with creating a clinical trial report. Note in the first few lines of this file the code which you would be typing at the end of the `Trial` section in the source code file. There are different sections in a clinical trial report that you need to understand well. These are 'Abstract', 'Introduction', 'Methods', 'Results', 'Discussion', \u2018Conclusion', 'Supplementary files [optional]' and 'Funding', as shown in the code provided. \n\nAbstract\n\n<section class=\"abstract\">\n    <h3>2) Abstract:</h3>\n    <p>The study evaluated efficacy and safety of long treatment interruptions in a 55year-old man diagnosed with HCV with a previous history of HBV coinfection, following six months on the IFN, RBV and direct antiviral Drug for Hepatitis. The recent biopsy for liver disease was negative for hepatocellular carcinoma and only remarkable for chronic inflammation compatible with chronic viral hepatitis along with previous positive HCV RNA tests and positive HCV antibodies. For the efficacy endpoints the patient's CD4 count and viral load decreased from 265 cells/mcL to 187 cells/mcL and from 99,000 copies/ml to 49 copies/ml, respectively. The patient developed dyslipidemia and anemia. No adverse events from treatment were documented during follow up.</p>\n</section>\n\nIntroduction\n\n<section class=\"introduction\">\n    <h3>3) Introduction:</h3>\n    <p>A clinical trial was performed in 2015 in the clinics of University in California. The title was Long Term Treatment Interruptions. This will evaluate efficacy and safety of long term interruptions in chronic Hepatitis C virus (HCV) infection patients. </p>\n</section>\n\n\n# Methods\n\n<section class=\"methods\">\n    <h3>4) Methods:</h3>\n    <p>After signing an informed consent, 320 HIV",
        "label": 0
    },
    "1511": {
        "output": "A: You can achieve this by creating an if statement that checks a condition on a single patient note. The code snippet below will show you how to achieve this output: \n# PatientNote.\n\ndef is_included(patient_note_dict: dict, trial_dict: dict)->dict:\n    include = 0\n    # check exclusion criteria. \n    if 'excluded' in trial_dict.references['trial_notes'][0].text:\n        include = 0 \n\n    if 'patient' in trial_dict.references['trial_notes'][0].text:\n        if 'HCV' in trial_dict.references['trial_notes'][0].text:\n            if 'positive' in trial_dict.references['trial_notes'][0].txt:\n                include = 1 # Patient is currently HCV positive.\n            else:\n                if '_positive' in trial_dict.references['trial_notes'][0].txt:\n                    include = 1 # Patient in the past had a positive HCV test.\n                else:\n                    # no HCV infection ever. \n                    # Patient is a negative HCV carrier at present.\n\n    if 'patient' in trial_dict.references['trial_notes'][0].text:\n        if 'hepatitis viral B' in trial_dict.references['trial_notes'][0].text:\n            if 'positive' in trial_dict.references['trial_notes'][0].txt:\n                include = 1 # Patient is HBV positive currently.\n            else:\n                if '_positive' in trial_dict.references['trial_notes'][0].txt:\n                    include = 1 # Patient in the past has a positive HBV test.\n                else:\n                    # no HBV infection ever.\n                    # Patient is a negative HBV carrier at present.\n\n    if 'patient' in trial_dict.references['trial_notes'][0].text:\n        if 'diabetes mellitus' in trial_dict.references['",
        "label": 1
    },
    "1512": {
        "output": "[\n\n## MATH]\nFirst, we get the patient data:\n\n\n`%patient` | `npatient`\n\nThen, we get the trial-level data:\n\n`&m&l.Trial.TriCd &f&l.Trial.TrCd`\n\nThen we create all types of `TrialLevelEligibility` for the given patient:\n\n```\n    $trial-level eligibility = (ClinicalTrial) {\n            id = id\n            inclusioncriteria = inclusioncriteria\n            exclusioncriteria = exclusioncriteria\n\n    } |\n    $trialeligibility = $trial-level eligibility\n\n```\n\nNow we are almost ready. The actual `TrialLevelEligibility` object would be:\n\n```\n```\n```python\nTrialeligibility({\n            id = \"TR01\",\n            inclusioncriteria = [(\"patient id\", \"PAS-5402-2\"), (\"HBV status\", \"hbv_positive\")],\n            exclusioncriteria = [(\"patient age\", \">55 years\"),\n                                (\"gender\", \"Male\"),\n                                (\"aspartate aminotransferase\", \"Lysosomal-Protein-Insulin-Resistance\", \"AST_ULN\"),\n                                (\"alanine transaminase\", \"Lysosomal-Protein-Insulin-Resistance\", \"ALT_ULN\"),\n                                (\"alanine aminotransferase\", \"Lysosomal-Protein-Insulin-Resistance\", \"ALAT_ULN\"),\n                                (\"alpha-foetoprotein\", \"Lysosomal-Protein-Insulin-Resistance\", \"AFP_ULN\")],\n\n\n                trial = (\"SORAFENIB\", \"86501\"),\n                trial_arm = [\"Sorafenib\"],\n                version = [(\"1\", \"a\")],\n\n\n                included = [\n                        (\"age\", \"Patient\", \"B60_to_80\"),\n                        (\"gender\", \"Sex\", \"Only",
        "label": 0
    },
    "1513": {
        "output": ".*\n\n\n**B. Genotype**\n\n**Correct answer: 1b.**\nSubject is on stable HAART including r/LPV for > 6 months.\n\n**C. Compensated cirrhosis (Child Pugh A)**\n\n**Correct answer: B.**\nSubject has chronic hepatitis and/or subject has compensated cirrhosis (Child class A)\n\n**D. CD4+ (cell count > 350)**\n\n**Correct answer: C.**\nSubject has CD4+ count of > 350 cell/mmc.\n\n**E. Virologically suppressed**\n\n**Correct answer: A.**\nSubject is HIV-RNA negative during the previous six month.\n\n**F. Prior PI failure**\n\n**Correct answer: B.**\nSubject is on stable HAART including r/LPV for > 6 months.\n\n\n**G. No mutations**  \n\n**Correct answer: A.**\nGenotype available at baseline and no mutations associated with resistance to PI. (if no genotype available: no response to PI in the past.)\n\n**[/END]**\n\n<EOD> A 16-year-old white woman with headache, sore throat, and fever.\nA 16-year-old white female adolescent was seen at our Pediatrics & Adolescent Medicine clinic for the evaluation of left frontotempor",
        "label": 0
    },
    "1514": {
        "output": "Congratulations! You completed this lesson. Next, you continue your work with the new lesson.\n\nTo begin the next lesson, press the \"Home\" button on the upper left-hand corner of the page.<EOD> Dendritic spines in visual cortical layer 5\nThe morphology and distribution of spines were studied in layer 5 neurones of adult cat visual cortex. Two distinct forms of spines were found, as well as various intermediate forms. Most cells studied contained only one type of spine but some cells displayed one or more morphological variations of one of the two main spine types. In addition, some cells had two major types of spines. The most common type of spine had a slender neck and a blunt base. The neck was not uniform and was thickest, and the base was rounded. This spine type is tentatively referred to as the \u201cclassic spine\u201d. The other spine type had a wider neck and a narrow, elongated base. Some spines of this type were almost parallel to the cell body axis, others formed an angle with the long axis of the shaft, or were located on dendrites running horizontally in the cortical plane. This second type of spine is tentatively referred to as the \u201cstraight spine\u201d. The straight spines were often found in small bundles. These bundles, which resemble the dendritic bundles observed in layer 1 and in Layer Vb, were located between the cells included in Layer Va.<EOD> The use of low-dose oral morphine in terminally ill patients: an update of a randomized controlled trial*\nAbstract Objective: This study aimed to examine if the use of low-dose oral morphine can relieve pain while avoiding adverse effects, increase the number of sleeping hours per day, or lower the number of sleeping pills taken daily. Additionally, it investigated whether the effects of low-dose oral morphine changed after six days of treatment. Design: In this two-part randomized controlled trial, one part was conducted between March 2014 and September 2015, and part two was conducted between March 2016 and December 2016. Thirty-nine patients in the experimental group received 7.5\u2009mg of oral morphine",
        "label": 1
    },
    "1515": {
        "output": "# Discussions\n- \u2191 TRIALS::Simulation: Simulating clinical trial data\n- \u2191 TRIALS::Test Trial: Test a trial\n- \u2191 Trials_TrialData: Causal data generator\n- \u2191 Trials_DataGenerator: Causal data generator\n- \u2191 TRIALS::Simulations: Simulating trials\n- \u2191 Trials_TestTrial: Test trial\n- \u2191 Trials_Simulate: Simulating trials<EOD> .\nAIM\nTo determine the predictors of relapse following the surgery for ulcerative colitis (UC) and identify the factors associated with prognosis after relapse.\n\n\nMATERIAL AND METHODS\nThere were 32 patients with UC presenting with flare-ups treated surgically over 1998-2005. The mean duration of disease was no more than 2 years. Postoperative relapse was observed in 12 (38%) patients. We conducted dynamic follow-up of relapse-free UC patients for a mean of 5 years and identified clinical and laboratory predictors of postoperative relapse onset.\n\n\nRESULTS\nIt was found that 75% of UC patients with relapse had a history of relapses before surgery. A more frequent use of immunosuppressors, methotrexate in particular, and a higher number of relapses before surgery were associated with the increased risk of relapse (p = 0.03; OR - 1.8; and p = 0.03; OR = 1.6; respectively). A decrease in the leukocyte number, a rise in the neutrophil number and C-reactive protein levels were early postoperative prognostic signs of relapse (p = 0.05; r = -0.47; p = 0.012; r = 0.52; and p = 0.03; r = -0.43; respectively). Among the patients after relapse the total leukocyte number increased and the lymphocyte percentage decreased (p = 0.04; r = 1.6; and p = 0.01",
        "label": 0
    },
    "1516": {
        "output": "# Experimental setup\nBioSorter uses the following configuration:\n\n``` shell\nexport DISPLAY=localhost:123\nexec xterm.x11 --display $DISPLAY\n```\n\n## Logs\nLogs of BioSorter can be found in /var/logs/biosorter for BioSorter Docker.\n\n## Supported OSes\n\n### Ubuntu 16.04\nUbuntu 16.04 \n1. `sudo apt-get install docker`\n1. `sudo docker login root`\n\n### CentOS 7.4\n\n### CentOS 7.3\n\n### Debian 9.\n\n\n### Ubuntu 18.04\n\n``` shell\nexport DISPLAY=123\nexec xterm.x11 --display $DISPLAY\n```\n\nUbuntu 18.04\n1. `sudo apt-get install docker`\n1. `sudo docker login root`\n\n\n### Ubuntu 15.10\n\n``` shell\nexport DISPLAY=123\nexec xterm.x11 --display $DISPLAY\n```\n\nUbuntu 15.10\n1. `sudo apt-get install docker`\n1. `sudo docker login root`\n\n## Testing\nBy default the testing mode is `DEBUG` in /home/youruser/.bashrc.\nFor manual testing, you run `biosorter_test.sh` interactively.\n\nThe script runs the program in the testing mode. \n\n### \u2190 Test the whole app \u2190\n\n``` shell\n./test # \n./biosorter_test.sh # Manually test the app. \n```\n\n### The script tests the main flow.\n\n``` shell\n./biosorter_test.sh # Manually test the flow 1b.\n./biosorter_test.sh # Manually test flow 2.\n./biosorter_test.sh # Manually test the trial.\n./biosorter_test.sh # Manually test the system.\n\n\n```\n\n### By default, this script runs the program in `DEBUG` mode. \n\n``` shell\nbiosorter --help\nb",
        "label": 0
    },
    "1517": {
        "output": "[[END]]\n\n## Task 3 - 120 Seconds\n\n##[NAME]\n\nYou are a research specialist. Your task is to create an analysis in SAS with four datasets containing age groups and gender (see attached files). There are three different age groups with three types of patients (normal, underdiagnosed and undertreated). Furthermore, gender is included into the data sets. All of those datasets contain three different categorical variables: age, gender, and diagnosis (normal,  undiagnosed and undertreated). Also, three categorical variables: treatment (none, overdiagnosis, undertreated), gender (male, female) and age group (5-59, 60-69, 70+) constituting the second type of patients.\n\nAll datasets must have the same data format:\nDiagnostic_data-ID number; gender; age (in years); diagnosis; treatment; _underdiagnosed; _undertreated\n\nUnder/undertreated is the variable to create the second type of patient. \nFirst, create a program and input the data. For your convenience, here are the attached files.\nAs a result, you should see three tables in the SAS editor. We give two different data scenarios for this task. Scenario 1 provides the analysis of underdiagnosed patients and the undertreated patients (see Data_scenario_1_1.txt). The second scenario includes the analysis of underdiagnosed and undertreated patients as a whole (see Data_scenario_1_2.txt). You should use different statements for two scenarios. \nHence, now you have created the data, so it is time to carry out your analyses. First, you should create your first table. \nTreat_table with diagnosis.\nTreat_-table; Age category; \nDiagnostic_data;\nunderdiagnostic; \nunder-treatement;\nTreatments\n\nHence, after the creation of these tables you can create the graph and the table by the statement PROC SGPLOT. Use the first table as the dataset for the first part of the job (see Gender_-analysis_with_graph_andTable_1.txt). \nUse Diagnostic_data;\nUnder -diagnosed",
        "label": 0
    },
    "1518": {
        "output": "**\u26af A.2. Clinical Study Assessment: Patient's medical history \u26af \u268f \u26aa \u26ad #25761**  \n[[https://rephetios.org/?#fork/0c213b0b-1133-4819-8ba1-348fd22d6d77/1](link)][[https://github.com/rephetios/bionlpstools-exercises/blob/master/train/q5.md](q5.md)][[https://github.com/rephetios/bionlpstools-exercises/blob/master/test/q5.md](q5.md)]\n----------------------------------------------------------------------------\n\n### Description:\nYou are a resident doctor at a health clinic. A patient has a new problem. Therefore, you should write a new patient's note. The patient's problem should be within the scope of your expertise.\n\nYou should write the note for every patient you see. It is important to write a comprehensive note so that a new clinician could understand the current issue. As a clinician you should follow the format of the note.\n\nIn this exercise you should assess the patient's medical history. If the patient has an existing disease or diagnosis, then you should write a detailed description of the disease in your note. If the patient was ever hospitalized or treated, tell the reader about the medications and treatments, therapies, or diagnostic tests that were used in treating that disease.\n\nYour assessment is based on the patient's chart and it is followed by a proposed plan of treatment. You should document your assessment and plan in the patient's chart.\n\n#### **Output:** \n\n### Task\n\n[\u270f ] Write a Note for a Patient's New Problem\n\n[ ] Use the correct format when writing the note\n\n### Score\n\n1) The patient's medical history; 0 points\n\n2) The patient's disease assessment; 0 points\n\n3) Plan of treatment: 0 points\n\nTherefore, you will get 0 points.\n\nThe score of the exercise",
        "label": 2
    },
    "1519": {
        "output": "To test correctness of the program, the following error messages should not show up: \n```\n#!/usr/bin/python\n# -*- coding: utf-8 -*-\n\n\nif __name__ == \"__main__\":\n\n    fp = open(\"/data/1_2/1_data_1_2/1_trial_recruitment_2_3/test_data_1_test_2_3/1_clinical_trial_recruitment_test_data.py\", \"r\")\n    with open(\"/data/1_2/1_data_1_2/1_trial_recruitment_2_3/1_clinical_trial_recruitment_test_1_correct.py\", \"w\") as file:\n        print(fp.readline())\n        print(fg(\"Bold:\", 40),\n              \"A: Assistive trial-level eligibility - \",\n              fg(\"Heredeces:\", 40), fg(fg(fg(\"A_name\"), 12), color=\"b\"),\n              \"B: Comparison of the patient note and criteria of a \" * fg(\"clinical_trial \") * \" \",\n              bw(2), bw(10), file.write(bp(\"Trials:1_clinical_trial_1_recruitment_1_1\\n\", 1)))\n        for line in fp.readlines():\n            line = line.replace('\\n', '') if '\\n' in line and line.startswith('\\t') else line.strip()\n            if line.strip() == \"\": continue\n\n            line = line.replace('Clinical Trial - ', '')\n            if line.startwith(\"Assistive Trial-level eligibility\"):\n                print(fg(\"Bold:\", 40), A.format(1, line.strip()))\n                print(\"---\")\n\n            else:\n                recruitment_criteria_test_data = E.format(1, line.strip())\n\n                if(recruitment_criteria_test_data == \"0\":\n                   file.write(bp(\"Excluded\",",
        "label": 1
    },
    "1520": {
        "output": "# Discussion\n\n## M18\nI got confused between `Not relevant` and `Excluded`. I think it is because we have already given a score of 0 to patients whose diseases didn't meet eligibility criteria since the beginning. (Group B)\n\n## M17\nIn the beginning, we gave score 0 to patients whose diseases didn't meet eligibility criteria. But we don't need to give 0 points to patients when we get a new patient now. I think the score 0 on the first assessment of each patient would be enough.(Group A)\n\n## M7\nDue to the complexity of the rules, it was difficult to understand the overall idea of the task because I did not look closely at the rules. (Group B)\n\n## M4\nThe first time I made a clinical trial-level assessment, I got lost. I couldn't find my train of thought again. (Group B)\n\n## M28\nThe second time I made a clinical trial-level assessment, I made a mistake because I remembered the first assessment. . I got confused. (Group B)\n\n## M14\nIn the first assessment, I checked the disease information of the patients one by one, but I made a mistake in assessing the second time. . I think that this was the same as the second assessment because I had a wrong answer in the last trial-level eligibility. (Group B)\n\n## M9\nWhen seeing the patient in the first eligibility assessment, I assessed without looking specifically at the screen. I took a wrong score, 1 instead of 0. . . (Group B)\n\n## M21\nAfter I saw the second patient note, I checked the disease information of the patients one by one. . . (Group C)\n\n## M13\nI think that if I see the second patient note and the disease information of the patients one by one again, I could get the right answer in the second assessment. (Group C)\n\n## M18\nIf I had looked at the screen again in the second trial-level eligibility of the first trial, I think I could get a right answer. I couldn't figure out what the factors were when looking at the screen. (Group C)\n\n## M",
        "label": 1
    },
    "1521": {
        "output": "print(\"patient note:\")<EOD> FcgammaRIIa polymorphisms do not influence the frequency of neutrophil extracellular trap formation\n\nImmune complex formation and deposition has been found to induce formation of neutrophil extracellular traps (NETs). Fc\u03b3RIIa, an activating receptor for IgG in human neutrophils, has been shown to recognise IgG from both native and IgG-antigen immune complexes.We hypothesized that Fc\u03b3RIIa polymorphisms would influence NET formation in vitro. Thus, NET formation from Fc\u03b3RIIa high-and low-responders were investigated in parallel by fluorescent staining and using DNA-DNA and DNA-histon complexes. No difference was found in total NET formation between the 30 healthy donors with Fc\u03b3RIIa high-or low-binding allotypes. Likewise, no difference was seen on NET formation in neutrophils stimulated with immobilised or free immune complexes containing either IgG anti-p-phenylenediamine or IgG anti-malaria-IgG complexes at physiological concentrations. Finally, no difference was detectable in NET formation using stimuli with varying strength, i.e. opsonized zymosan or lipopolysaccharides at their median lethal dose. This indicates that Fc\u03b3RIIa polymorphism does not play a role in in vitro NET formation induced by immune complexes. As Fc\u03b3RIIa recognises immunoglobulins in IgG or IgG-antigen immune complexes, we speculate that neutrophils in Fc\u03b3RIIa low-binding donors have a different response by other Fc\u03b3R types. We conclude that all circulating neutrophils have the capability of NET formation without Fc\u03b3RIIa polymorphism, however, the impact of immune complex formation on NET induction remains to be answered.\n\n# Introduction\nNeutrophils are the first line of defence in innate immunity and act rapidly upon being recruited to pathogens or sites of tissue damage [bib_ref]  Neutrophil extracellular traps kill bacteria,",
        "label": 2
    },
    "1522": {
        "output": "This is your last paper of the course. You are expected to submit it within 2 weeks from now.\nGood luck! [/END]\n\n## RQ: how would you evaluate your performance on the course?\n[Instead of the instructor] Hi, good afternoon ladies and gentlemen. First I would like to express my sincere thanks to you for participating in the class of this course. I'll try to be to the point without wasting your time, to get the best experience. Then I will tell you what I have done on the course. Then I will give my comments and recommendations afterwards to the end of the lesson. I am very happy to see you. We made quite a lot of effort in order to arrange this course. I hope you already enjoyed the course. \nGood afternoon/evening, this is [NAME], thank you for your attendance. I would like to talk about my personal experience on the course. I really enjoyed the course. For one thing, I benefited from the instructor's experience on the topic especially on the cases. When I received a case, I really benefited from the case's diagnosis. I didn't make a mistake. When I did my own diagnosis and I received a message as follows: Your diagnosis' score is x%, your diagnosis' accuracy is x%. You've got a score of 90%, and your accuracy is 100%, so you're really good! In my opinion, after receiving this type of feedback, you feel that you have done a good job on the case. Then you want to do more. Another benefit, I want to say that I saw that there was a community on Facebook about cases. There were many cases submitted. I liked that; I wanted to share that experience with the course, just like I said that I would like to share, because you can be inspired by sharing cases. You can learn from each other about the cases. I had a really good experience. \nHowever, like any other thing, you did a good job on the class. You really enjoyed the course, and I liked that. However, a few weeks ago when you received the message from the instructor: It is not finished so you should send the case again, you saw that you had to wait for it a day to make a diagnosis when you read on the cases. At this moment, I want to give",
        "label": 1
    },
    "1523": {
        "output": "1. The first step is to read through the patient note and determine whether this patient meets the inclusion criteria of the trial: `patient_ID =~ /patient_ID_pattern/;` will give an entry for all patients with patterns like `patient_ID-0001, ..., patient_ID-0100` into the array `_patient_set` in the `inst_main()` function of the Python module.\n\n2. The next step is to determine whether the trial should evaluate this patient for further inclusion or exclusion.\n\n## Next, you should check whether the patient is excluded on the grounds of the trial's exclusion criteria. `if _excl_is_yes(trial->exclusion_criteria ) { # 1. patient is excluded on the grounds of the trial's exclusion criteria. # print an error message to say so trial->print_error_msg(); # print a message saying the patient is excluded to say so for(i in trial->exclusion_criteria_list) print_exclusion_criteria_msg(trial->exclusion_criteria); } else # 2. patient is not excluded on the grounds of the trial's exclusion criteria. print \"Patient is NOT excluded on the grounds of the trial's exclusion criteria\";`. \n\n\n3. Next, you should check whether the patient's ID number is present in the  list of patients to evaluate for eligibility in the given trial, see the code in `main.py` for the full implementation.\n\n## Next, you should confirm that the patient's data is sufficient and complete.\n**Trials with many inclusion criteria, such as [Trial_0649] (https://linkedct.nlm.nih.gov/sharing/239108912), will evaluate the patients' health claims to make sure that the patient's data will allow inclusion.**\nYou can use _trial->get_include_conds() to get the health condition information of the trial. It will return  a list of  `TrialInclusionCond_set` structures. Each such structure contains information about a  given health condition. The _TrialInclusionCond_set class in turn contains an array with  the names of the Health Conditions. The",
        "label": 2
    },
    "1524": {
        "output": "Note: The input format of Trial-level eligibility was not well defined previously. After the [FIXED] label in February 2018, we are strictly enforcing the format `Trial-level eligibility: [Score]`, e.g., `Trial-level eligibility: 2) Eligible.`. If you use new format, you are expected to run the `fix_format` function.\n\nTo summarize, when evaluating a patient for a given clinical trial, we want to answer the question \"Is this patient eligible for a given clinical trial\". When summarizing it, we want to answer the question \"What is the overall rate of eligibility for the clinical trial\" in a more concise manner. Our data structures are patient vectors and trial vectors. In both vectors, entries are either 0 or 1, representing \"no\" or \"yes\".\n\n##[/TRIAL]\nWe suggest that the number of participants should be 1000. The number of trials will be 13 which are the 12 disease types and one normal.\n##[/DATA]\nHere are the 13 disease types: 1) HCV\n2) HBV\n3) HSV\n4) HPV\n5) HIV\n6) BreastCancer\n7) BrainTumor\n8) SARS\n9) COVID19\n10) Cardiovascular Disease\n11) Diabetes\n12) Normal\n13) CVD\n##[/DATA]\n\n### Summarize results by disease-type or combination of disease-types\n\nWe want to count the number of participants for each disease-type. We also want to summarize the number of participants for each combination disease-type. For example, we have to summarize the number of participants for each of the 5 disease-types (HCV, HBV, HSV, HIV, BreastCancer), 2 disease-type combinations (HBV + HCV, HCV + HIV), 3 diseasetype combinations (HBV + HSV + HIV, HBV + HCV + HIV, HIV + HSV + HCV), 4 disease-type combinations (HBV + HPV",
        "label": 2
    },
    "1525": {
        "output": "## Data input & test\nNow we write pseudocode to implement the whole program.\n\n[CODE]\n  @IBAction func changeValue(sender: AnyObject) {\n    let trialName = \"Genetic Polymorphisms of TNF-\u03b1 Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease\"\n    loadData (trialName: trialName, patientId: \"1250\", patientNote: \"1/0/1/1/0/0/0/0\")\n    let isEligible = isTriallEligible(patientId: \"1250\")\n    print(\"The patient has trial level eligibility\")\n    if (isEligible == 2) {\n      print(\"Final output: 2) Eligible\")\n    } else {\n      print(\"Final output: 1) Not relevant\")\n    }\n  }\n\n[/CODE]\n\nNow we will test it with the real trial data of the first patient.\n\n[INST]\n[DATA]\nTrial trialName = \"Genetic Polymorphisms of TNF-\u03b1 Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease\" trialId: \"28161348\" trialInst: 1 trialCategory: \"Clinical trial\" title: \"The clinical trial information.\" status: \"active\"\n\nPatient trialId = \"12345\" firstName: \"John\" lastName: \"Knuck\" contactPhone: \"00962666818185\" trialStatus: \"enrolled\"  date: \"01/05/2014\" birthPlace: \"United States\" isAHCVR: true isAHBV: true\n\n\n[/DATA]\n\n\n[INST]\n[TEST]\n$ ~/Library/Developer/IBM/Rational/RapidPrototype/RP6.5/Installed/Applications\n~/Library/Developer/IBM/Rational/RapidPrototype/RP6.5/Installed/Applications/IBM_RapidPrototype_64",
        "label": 2
    },
    "1526": {
        "output": "You can stop here.** \n\n### ROUTING: [Demo 1](#Demo 1)\n[Demo 1](../../../data/demo1.csv)\n\n### ROUTING: [Demo 2](#Demo 2)\n[Demo 2](../../../data/demo2.csv)\n\n### ROUTING: ]\n[Demo 3](../../../data/demo3.csv)\n\n\n### ROUTING: ]\n[Demo 4](../../../data/demo4.csv) \nThe demo data are given as a reference below in the first column. The output is the same, but the format is not similar. In Demo 1, the results include several patient notes (see the output of lines: \n1: 2:, \u2026 19:2); these do not make sense in a trial-level assessment. From this example, you can get an idea of the ROUTING. It is not that nice, and you need to make a minor modification to make the output more useful. For example, using the output of Demo 1, you can adjust the eligibility information and make it suitable for clinical trials. In a trial-level assessment, only the first patient note is of interest.\n\n[START] After this line, you can find the output, but it is not that interesting for me. Let's move to",
        "label": 2
    },
    "1527": {
        "output": "<h3>Hints</h3><p>Consider also following a checklist on how to check the eligibility of patients: A step-by-step guide on how to check patient eligibility. This guide is based on 28 clinical trials (the same you will see in this activity).</p>\n<p><strong>Beware! Your results are NOT published without your approval. Please note that the score and the checklist are for your selfimprovement and may not be published.&nbsp;However,&nbsp;please note that in the future we may be interested in your eligibility assessment results to assess the overall quality of the checklist used by students, as well as the performance of the system. In such a case, you will be given the opportunity to review your results and opt-out.</strong><br><br></p>\n<dl class=\"item\">\n\t<dt><a href=\"#\"><strong>Score:</strong> 0/1</a></dt>\n\t<dd class=\"rubric\">0</dd>\n\t\t\n\t<dt><a href=\"#\"><strong>Item:</strong> The student should consider the patient note and the clinical trial to assess the patient eligibility.<br><br><a href=\"#\">Add comments</a></strong></dt>\n\t<dd>The student should only consider the patient note.</dd>\n\t<dd>The patient note is not considered.</dd>\n\t<dd>No comment</dd>\n\t<dd>No comment</dd>\n\t<dd>No comment</dd>\n\t<dd class=\"rubric\">0</dd>\n\t\n\t<dt><a href=\"#\"><strong>Item:</strong> The student should make a trial-level eligibility on each patient for the clinical trial, e.g., output the scale for the assessment of eligibility.<br><br><a href=\"#\">Add comments</a></strong></dt>\n\t<dd>Triallevel eligibility is not recorded.</dd>\n\t<dd>No comment</dd>\n\t<dd>No comment</dd>\n\t<dd>No comment</dd>\n\t<dd class=\"rubric\">25%</dd>\n\t\n\t<dt><a href=\"#\"><",
        "label": 0
    },
    "1528": {
        "output": "[][]\n\n# Acknowledgements\n\n\nCopyright and License Statement\n\nSome content is licensed under the terms of the Compatible Open Government License, a license designed to enable the widest possible reuse of government information while safeguarding legitimate interests of the parties involved: \n\n---\nAuthor(s)\nKamila Krzywa, PhD-CIT, Institute for Information Technologies in Biomedicine (ITB), University\nGdansk, Poland\n\n---\nEditor(s)/Sponsors\nInstitute of Systems and InformationTechnology (INST), University of Florida, Gainesville, FL, USA\n\n---\nPublisher(s)/Host\nEuroIntervention, an official journal of the European Association of Percutaneous Cardiovascular Interventions\n\n---\n\nCopyright statement for the EJATS series\nThe original work published in the EuroIntervention series journals is licensed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC-SA), or with the consent of the copyright holder.\n\n---\nLicense\nEJATS_001_1.pdf\n\n---<EOD> Diabetes control in the older patient.\nWhen it is indicated by the physical examination and laboratory tests, the older patient's diabetes can be successfully controlled with oral agents, with the same goals and methods of treatment found successful in the younger diabetic population.<EOD> The use of thiazides and diuretics following hysterectomy.\nAbstract \nThe results of a short questionnaire are presented on the use of diuretics and thiazides and of oral contraceptives in women who had a hysterectomy. No thiazides were taken by 152 and more than half the thiazides were prescribed by general practitioners. The thiazides were prescribed to 22 of 114 women who used oral contraceptives before and 8 of 49 who continued to use oral contraceptives after hysterectomy. No thiazide was used in women who did not have a contraceptive prescription before hysterectomy. Sixty-one women who never used thiazides before hysterect",
        "label": 0
    },
    "1529": {
        "output": "You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHence, we need to iterate the IF statements with respect to the patient. So, we should use a [FOR loop](https://stackoverflow.com/questions/16440062/what-is-the-difference-between-vbetwennloops-loopif-forloop/38367298).  First, we create an empty set, named `AllTreatments`, and then we check the treatment, T, of `patient[0]`.  \n\n```python\ndata_list1 = [data[:] for data in data_list]  # data_list1 is a list of patients\ntreatment_list = ['Treatment_list1', 'Treatment_list2', 'Treatment_list3',..., 'Treatment_listn', ] # a list with the treatment for every patient\npatient_Treatment = [1,0] # patient_1 doesn't have the treatment, while patient_2 has the treatment in the list\nAllTreatments = {} # set of patients with the same treatment\n# creating 4 separate loops to iterate all treatment conditions to patient's characteristics to assess eligibility. \nfor patient in data_list1:\n    for T in treatment_list:\n        if patient[1:18",
        "label": 0
    },
    "1530": {
        "output": "## Eligibility score\nFor the score on the eligibility: you need to evaluate each eligibility assessment with a score. You are allowed to use 1 through 6, and not to use 0. You should use a high number, like 6, for the `Excluded` assessment. However, you should use a low number, like 1, for the `Not relevant` assessment. The score 2 should apply to the intermediate between `Excluded` and `Not Relevant` and should be used for that:\n\n### Excluded\nThe patient meets inclusion criteria. This means they are eligible to enroll in this study. However, the patient should not be enrolled because they meet exclusion criteria. Note the score `6`, as high as you can use in score calculation. Use this score for assessments of patients that are excluded by exclusion criteria of the clinical trial, like `Age (<19)', `Age (>70)', `Sex (Males are not required)' and so on.\n\n### Not relevant or Incomplete\nThe patient does not have information sufficient to qualify for the trial. That means the patient has information not enough for the assessment of eligibility. Therefore, these patients are unable to make a trial-level eligibility, i.e., the assessment of eligibility on the patient. A patient's score should be low, close to zero, e.g., score 1, 2, 3. Use this score for assessments of patients that are negative for the eligibility assessment, like `Abnormal LFT at screening\u00b4, `HIV history of >5 years', etc.\n\n### Unknown\nThis assessment means insufficient data are available to make conclusions for this assessment. Note this score should never be used in your calculation, because the patients are not excluded or not eligible to a trial. If you think that a patient has information about something to exclude or to qualify for a trial, then this patient is not to have this score. This score is only for patients that have a question for the eligibility. If you have a patient where you have a question for the eligibility, then you shouldn\u2019t have this score. The patient should have `Excluded\u00b4, `Not relevant\u00b4 or `Eligible",
        "label": 0
    },
    "1531": {
        "output": "Your patient is a clear example of a not relevant case (0: Excluded), as he only has non-contributory information given a particular trial's exclusion criteria. The trial excludes patients who have liver cancer or liver cirrhosis. These patients are excluded from clinical trials in order to make the trial population more homogeneous and to reduce the risk of confounding. Let's make use of the program. \nPlease, type in the program: [python3 main.py HCV]. The program reads in the patient's HCV note, compares it with the trial's inclusion criteria, and outputs a diagnosis based on the decision tree.\nAs a result of the program, we get the following output:\n[INST1] Patient not relevant. Your patient is a clear example of a not relevant case (0: Excluded), as he only has non-contributory information given a particular trial's exclusion criteria. The trial excludes patients who have liver cancer or liver cirrhosis. These patients are excluded from clinical trials in order to make the trial population more homogeneous and to reduce the risk of confounding. Let's make use of the program. \nPlease, type in [python3 main.py HCV] the program. The program reads in the patient's HCV note, compares it with the trial's inclusion criteria, and outputs a diagnosis based on the decision tree, shown in Listing 34-1.\nIn this decision tree, the following facts are coded:\n- Each node contains a short summary of the decision being made.\n- The output is the eligibility decision or the lack thereof.\n- The arrows represent a special kind of branching that occurs in logical trees. If the value of the expression at the top of the arrow is true, the path below the arrow is taken, with each of the paths further down making the same test, but for a different value. That different value is the condition of the expression that is at the top of that path. For example, at the top of the arrow, ``1 is an age between 14 and 51 years old''. If that value is true then you get the value of the expression ``4 is 0'', which is ``2'', and therefore the right-hand child of the arrow, which tests that the",
        "label": 0
    },
    "1532": {
        "output": "Please take care to evaluate all exclusion criteria before determining the trial level eligibility. \n\n\tCheck boxes with 1 to see if the patient has the minimum age required to participate in the trial. That is not the case: Minimum Age Criterion. Check box with 2 to see if the patient\u2019s lab test is outside normal range. That is not the case: Lab Test. Check box with 3 to see if the patient has ever taken the drugs specified as exclusion criteria: Previous History. \n\nIn the",
        "label": 0
    },
    "1533": {
        "output": "__Problem__: What are the variables available when deciding on the trial-level eligibility?\n\n__Solution__: In this problem, we will observe the `patient note` section, which is the first line of the patient note data in the problem dataset, to find the variables on trial-level eligibility, and the `inclusion criteria_clinicaltrial` (the `clinicaltrial` section), which is the first line of the input dataset. \nFirst, we look at the `patient note` section and see that it is written as 'The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. \u2026 etc.' So, the variables that indicate disease type, age, gender and the duration of infection should decide the trial eligibility. \nNext, we analyze the `clinicaltrial.csv` file and observe that the columns `trial_id, `investigator, `medical centre, `inclusion_criteria_clinicaltrial, `exclusion_ criteria_clinicaltrial and `clinicaltrial_description` appear in each line of the dataset. We know that the columns `trial_id,` `investigator,` and `medical centre` do not affect trial eligibility, so we can assume that the `inclusion criteria_clinicaltrial` and `exclusion_ criteria_clinicaltrial` columns are important variables we need to observe to decide trial eligibility. \nAn example showing the variables that indicate trial eligibility is provided below. :recode 1. trial_id = \"trial_id\" 2. investigator = \"investigator\" 3. medical_centre = \"medical_centre\" 4. inclusion_criteria_clinicaltrial = \"inclusion\" 5. exclusion_ criteria_clinicaltrial = \"exclusion\" 6. clinicaltrial_description = \"description\"\n\n-- `recode` is recode() -> data.table::fread(\"file.csv\") %>% rename(\"trial_id\" = \"trial_id\", \"investigator\" = \"investigator\", \"medical_centre\" =",
        "label": 1
    },
    "1534": {
        "output": "<EOD> .\nFrom 2009 to 2015, 435 cases of human metapneumovirus infection were found in children aged from 1 to 14, with a detection rate of 3%. According to the clinical classification with reference to the national diagnostic criteria of viral and atypical pneumonia in children (WS276-2014), the number of children with mild and common pneumonia was 408, with a detection rate of 93%, including 244 boys (25.5%) and 164 girls (16.9%). The remaining 27 (6.3%) children had severe and critical pneumonia, including 13 boys (14.1%) and 14 girls (14.9%). The cases of severe and critical pneumonia included 1 case of mild pneumonia, 1 case of common pneumonia, 5 cases of mild and common pneumonia, 7 cases of common pneumonia, 6 cases of common pneumonia, 4 cases of common pneumonia and 5 cases of common pneumonia. The cases of common pneumonia included 9 mild inflammation cases and 11 severe inflammation cases. 1 boy patient had a family and living history which had an epidemiological link with other pediatric pneumonia cases. The case fatality rate was 3.5%.<EOD> The Bactericidal Activity of SARS Survivors and Their Familial Members: Is It Due to Persistent Antibody Responses or Cross-Reactive Immunity?\n\nSARS survivors and 253 close relatives of the survivors in Beijing, China were enrolled in an ongoing cohort study. All participants were assessed for their bactericidal activity and the titers of anti-SARS-CoV antibodies. All tested survivors demonstrated strong and sustained bactericidal activity at 6 months after the onset of illness but the activity was not observed in their families. These finding suggest cross-reactive immunity may play an important role in protecting SARS survivors from re-infection with SARS-Cov.\n\n# Introduction\nBet",
        "label": 0
    },
    "1535": {
        "output": "[CODE]\r\ndef get_eligibilities(recruit_note):\r\n    eligibilities = [int(st.startswith('Excluded')) for st in recruit_note['Inclusion_criteria'] if 'Excluded' in st] + [int(st.startswith('Eligible')) for st in recruit_note['Inclusion_criteria'] if 'Eligible' in st]\r\n    # Eligibilities are [0,1,2], e.g., [0.7, 0, 1.1] or [0.5, 0.4, 0.8].\r\n    return 1 - sum(eligibilities + [0])\r\n\r\n```\r\n    \r\n## Solution.\r\n\r\nTo understand the above code, you have to figure out the flow charts as follows. We define that a patient's note is a tuple, i.e., `recruit_note` in your case. To assess eligibility, we need to traverse `recruit_note` by depth-first search. We extract the information at every step. Note that we calculate eligibilities by `get_eligibilities(recruit_note)`. Eligibilities are [0, 1, \u2026,2], so we assign it as `eligibilities` in the right-most chart. [/CODE]\r\n<EOD> Prevalence and types of mental health problems in primary school children.\nINTRODUCTION\nMental health disorders are one of the major global health problems, especially among children and adolescents. Children's behaviours and social skills depend on their learning and mental capacity. This research aimed to investigate the prevalence and types of mental health problems in primary school children.\n\n\nMETHODS\nThis descriptive and analytical study was conducted among 1,200 children over the age of six years who were selected by multistage stratified randomization sampling in three phases. The sampling units (Purdah-nasiriyah primary schools) were selected randomly at the first level, from the list of all schools in the area (64th district). The school children were stratified by class into different levels to study the impact of the child's age and grade level on the frequency of mental",
        "label": 0
    },
    "1536": {
        "output": "# Example output\nThis is the result you usually get for one clinical trial.\nClinicalTrials.net\n\n## {#TrialTitles}\nFulminant hepatitis C after liver transplantation: a clinico-pathologic study of prophylactic antiviral therapy.\nGenome-Wide DNA Methylation Analysis Identifies Epigenetic Decrease of RND3 in Hepatitis C-Related Hepatocellular Carcinoma\n\n## {#Results}\n\n## 15:34: 23.5321440\n[INST] Hello, hello, hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note with the criteria of a clinical trial to determine patient's eligibility.\n[#Assist] : Hello. Hi. Hello. How may I help you?\n[#REQ] : Hey, can you tell me if this particular study will let me in? The one there for me to take part in.\n[#ASS] : Can you tell me a little about this study and its requirements?\n[#REQ] : Well, I heard of 1 study with HCV. I'm suffering from HCV. Can you tell me if this is a study for me?\n[#ASS] : Let me examine your patient chart then. Now, tell me about your general health. Are you in any way ill?\n[#REQ] : No doctor, I'm well enough.\n[#ASS] : No doctor, I'm well enough. No doctor, I'm well enough. No doctor, I'm well enough.\n[#REQ] : No doctor, I am fine. I take good care of myself. Do I need to see a doctor?\n[#ASS] : No. No. No doctor, I am fine. I take good care of myself. I take good care of myself. I take good care of myself. I take good care of myself.\n[#REQ] : Doc. Doc, doc.\n[#ASS] : Do you eat a healthy diet regularly?\n[#REQ] : Yes doctor, yes doctor, yes doctor, yes doctor.\n[#ASS] : No. No. No.",
        "label": 1
    },
    "1537": {
        "output": "## [REMOVE1]\nYour task is to determine, for each patient, the degree to which the patient's notes match eligibility criteria for the study. Each patient has a score. There are four possible categories represented by four classes, or by numeric values from 0 to 3. For example, suppose one patient met 9 criteria and did not meet 7 criteria out of all 16 eligibility criteria. This should be reflected by the patient note string representing the match between the patient and the trial being 9/11 and 7/16.\nThere are different metrics of eligibility. Let's represent that by a vector of scores of trial-level eligibility, T:\nThe patient should not be included if they meet all of the criteria to exclude. This means T must be a monotone increasing function. One example of such a T would be to exclude all patients with more than 6 failures (e.g., score = 3).\nGiven an example of patient notes and a given trial, we need to determine T as mentioned above. We will focus on one trial as an example and see how T should be defined.\n\n## Example 1.\nOur trial includes two primary eligibility criteria, PtC1 (age is >=45) and PtC2 (gender is male). In the data set, one patient meet PtC1 but not PtC2, another patient match PtC1 and PtC2. We want to exclude the patient match neither PtC1 nor PtC2 and let the patient match just one eligibility criteria. We make T as:\n\n## 1st criteria: ptc1 ptc2\n\n## 2 0 @ @ 2\n1.\n[formula]  2 0 @ @ 1. 2 0 @ @ 0 1. [/formula] \nAnd the patient should be 3, 0, 0, 1, 2, 2, 0, 0, 0, 1, 0, 1, 2, 2, 2, 1, 0, 2, 0, 1.\n\n## Example 2.\nOur trial does not include PtC1 and PtC2, rather includes three: PtC3, PtC4",
        "label": 0
    },
    "1538": {
        "output": "You may find it helpful to write a program to get started. Your code is saved automatically after each action.\n\n\n[STEP 1] Find and read in the path and clinical trial:\n\n`require(\"readtext\")\nreadtext(\"/home/fedorabiohackers/Professor.fichier.csv\", \"/home/fedorabiohackers/sample.json\", \"sample.csv.json\")`\n\n`var path = readtext(\"/home/fedorabiohackers/sample.csv.json\")`\n\n`var clinicalTrial = readtext(\"/home/fedorabiohackers/sample.json\")`\n\n\n\n[STEP 2] Display path:\n\n`print(path)`\n\n`print(\"Path saved in path.\"path)`\n\n\n[STEP 3] Display clinical trial:\n\n`print(clinicalTrial)`\n\n`print(\"Clinical trial saved in clinicalTrial.\"clinicalTrial)`\n\n\n\n[STEP 4] Make trial-level eligibility, add the line `Trial-level eligibility: 2) Eligible` before the last line to indicate trial-level assessment:\n\n`path = path[\"0\"][\"clinicalTrial\"][\"data\"][\"patients\"]`\n\n`for item in path:\n    trial-level_eligibility = str(item)`\n    `clinicalTrial = clinicalTrial[, (path[\"0\"][\"patients\"] == item[\"patientID\"])]`\n    `clinicalTrial = clinicalTrial[clinicalTrial[\"patientID\"] == item\"`\n    `clinicalTrial = clinicalTrial[(clinicalTrial[\"patientID\"] == item[\"patientID\"]), (clinicalTrial[\"patientID\"] == item[\"patientID\"])]`\n    `clinicalTrial = clinicalTrial[(clinicalTrial[\"patientID\"] == item[\"patientID\"]), (clinicalTrial[\"patientID\"] == item\")]`\n    `clinicalTrial = clinicalTrial[(clinicalTrial[\"patientID\"] == item[\"patientID",
        "label": 0
    },
    "1539": {
        "output": "The last piece of advice is to check the logic and semantics of the file before submitting it to the trialists. There might be errors that you would not expect, such as missing numbers or different variable names in the actual file. Such small errors might have an impact on the analysis. It is therefore important to check the output carefully and remove the errors. The best way to do this is by setting syntax checks in the file.\n\n[/OUTS]\n\n<EOD> A comparison of the efficacy of three antibiotics in preventing endodontic infections in vivo.\nSummary. Under the auspices of The American Academy of Endodontology, the efficacy of a single, intra-canal, post-treatment dose administered with a compound of metronidazole plus a dihydro-ergot alkaloid (M + D), when compared with minocycline therapy (300 micrograms q.i.d. for 7 days), or ciprofloxacin 1000 micrograms q.i.d. for 7 days, were evaluated in 59 human immuno-competent subjects. All subjects had been treated endodontically with a standard clinical protocol during the previous 3 months and presented with post-operative pain or swelling. The treatment with M + D, minocycline or ciprofloxacin resulted in the elimination of symptoms in 82%, 48% and 33% of the subjects, respectively. A combination of M + D is at least twice as effective as minocycline, and almost five times as effective as ciprofloxacin, in preventing endodontic infections.<EOD> Capsular Abscesses and Epidural Hematoma - Sentinel Signs of a Sinister Diagnosis in Chronic Mastoiditis?\nThis paper presents the case of a 79-year-old woman who presented with spontaneous otorrhea. Otoscopy revealed a perforated tympanic membrane and discharge from the external auditory canal. The patient presented with an inflammatory syndrome and a radiology imaging showing the extension of inflammatory granulations into the mastoid cells and the middle ear. She was",
        "label": 0
    },
    "1540": {
        "output": "# Relationship table\n\nIn the file 'Relationship Table.md', you can define the file format for storing the relationship. The field names in the file are as follows:\n- `id`-The patient note id in which the relationship should be stored.\n- `type`-The type of notes that contains the relationship.\n\n\nIn the file 'Relationship Table.py', the first line should include a line with the keyword `RELATIONSHIPTABLE.`. Following is the main contents of the file. If this file exists, it is used to store the relationship between notes, the relationship table. The format of the file should be as follows: The first two lines of the file (10):\n- \nThe three other lines of the file (10):\n\n\n## (10) Importing relationships\n\nThe file relationship table should be saved in the data folder of the system. As above, the relationship table is managed for each note in which you want to store the relationship. \nYou should use `relationship.add()` method to store relationships. The arguments are as follows:\nArgument:\n- First argument of `relationship.add()` is the note to which the relationship is connected.\n- Second argument of `relationship.add()` is the note to which the relationship is stored. This argument is only required. \nArgument:\n- Both arguments of `relationship.add()` are optional. Therefore, it can be used even if a note is missing.\n\n## (11) Importing relationship\n    1. `from data import RelationshipTable as RT, note, relationship, RelationshipTable import RT from data import RelationshipTable as RT, note, relationship import RelationshipTable RT = RelationshipTable (`id`: noteId, `type`: noteType)`\n\n## (12) Relationship.add()\n    1. `from data import RT, note import RT from data import RT, note rel = RT (`target`: noteId, `rel`: noteId)`\n    \n## ## <Relationship>\n    1. `First(name: '', target: id, value: `)`\n    2. `value` may be a string. \n    Note: Use the first argument of `Relationship.add()` as the target note",
        "label": 2
    },
    "1541": {
        "output": "### Summary\r\n\r\n- You learned how to recognize and define the common patterns in HCV clinical trial protocols.\r\n- You learned a new feature extraction methods to create the metadata and the clinical variables list from patient notes.\r\n- For this task, you developed an interface to explore patient notes which can be used for identifying the clinical trial eligibility of patients with CHC and for identifying common patterns in HCV clinical trials.\r\n\r\n## Tasks & Subtasks  \n**Task-1: Examining the patient note**  \nAs a next step, you should explore and understand the information contained in the clinical trial notes. You should become familiar with the patient notes to develop the necessary interfaces and algorithms to automatically identify the common patterns. \r\n\r\nAs you should recall now, we used [NLTK](www.nltk.org) to create the patient note corpus and [RFE](www.cs.cmu.edu/~jdaigle/PHI/rfe.html) for extracting the common patterns from patient notes and patient records. Now, a little bit different from the previous experiments, we need to apply RFE to extract not only the clinical variables list, but also the metadata.\r\n\r\nUsing RFE, you will now extract the metadata, that contain the information you previously extracted using PHI, HANNOVER and PROTOCOL feature extraction methods.\r\n\r\nWhen you applied SVMs to a dataset containing only metadata, the system failed to achieve the required level of accuracy, possibly because the classifier did not learn to recognize the clinical trial inclusion criteria.\r\n\r\nThe metadata must contain enough information that you could use to accurately predict clin",
        "label": 1
    },
    "1542": {
        "output": "Write the pseudocode below. \n\n1 2 3 4 end 5 6 7 8 end 9 10 11 12 end 13 14 15 16 end 17 18 19 end<EOD> Effects of Different Doses of Atorvastatin on Renal Injury Following Anterior Abdominal Aorta Cross\u2013Clamping in Rabbits\n\n\n\n# Introduction\nIschemic injury, and particularly renal ischemic damage, is a serious clinical issue following cardiopulmonary bypass (CPB) and aortic cross-clamping (AoX) [bib_ref]  Myocardial damage during aortic occlusion, Neto [/bib_ref]  [bib_ref]  The beneficial effect of statins on myocardial protection against ischemiareperfusion injury: underlying..., Zhu [/bib_ref] . The renal effects of CPB and AoX are multifactorial, resulting from both hypoperfusion and end-organ ischemia [bib_ref]  Renal effects of statins and their implications, Pecoits-Filho [/bib_ref] .\nWhen intra-operative AoX is required for aortic surgery, the renal ischemic time is prolonged and the risk of renal dysfunction or acute renal injury is increased. Ischemic injury to the kidney triggers an inflammatory response, and the excessive production of reactive intermediates, including reactive oxygen species (ROS), are implicated in the development of renal failure [bib_ref]  The beneficial effect of statins on myocardial protection against ischemiareperfusion injury: underlying..., Zhu [/bib_ref]  [bib_ref]  Renal effects of statins and their implications, Pecoits-Filho [/bib_ref] . The renoprotective effects of hydroxymethylglutaryl coenzyme A reductase (HMGCoA-R) inhibitors, including statins, in renal ischemia-reperfusion injury (IRI) are well documented, and we have reported that statins have a direct antioxidative and antiapoptotic effect on post-IRI renal injury in an experimental rat model [bib_ref]",
        "label": 0
    },
    "1543": {
        "output": "There are some preconditions of the trial that you need to check when assessing patient's eligibility.\n- A trial includes one or several types of a given disease. 10 types of OA exist, but the study targets only one of them: hip osteoarthritis (K&L x-ray grade \u22652). In practice, you would check if `hip` is mentioned in the disease column of [Hypothesis].\n\n\n*\n\n*This is an exclusion criterion for the clinical trial. However, no mention is found in its description column, probably due to errors on the documentation or the description could be missing.\n\n*A patient is included in the study if he/she is older than 18 years old.\n\n*A patient who has a comorbidity different than alcoholism (alcoholic liver disease).\n\n*Negative enzyme immunoassay for anti HCV-antibodies is not an exclusion criterion (see the first column named 'Inclusion Criteria'). \nIn the data frame, you can always check your hypothesis by calling the `hypothesis` column. For instance, you can compare your eligibility judgment for the patient with all trial hypotheses or all exclusion criteria of the study: `hypotheses %>% compare_eligibilities(patient note)` yields 8 for eligible and 0 for not eligible. [INST] Eligible vs Non-Eligible cases after comparing the patient note with all hypotheses of the trial.\n[formula]  ----------------------------------- Hypothesis -------------------------------------- 0 1 2 3 4 5 6 7 8 patient ------------------------------------------- [/formula] \nYou can also compare the patient note with the trial hypotheses and only return the best matching hypothesis. This is equivalent to a patient-centric similarity measure called Jensen-Shannon divergence, which you can use when no ground truth is available.\n- You can also compare the patient profile with the exclusion criteria of the trial: `exc_criteria %>% compare_eligibilities(patient note)`. As the exclusion criteria are not as many and complex as the hypotheses, you can easily find the patient eligibility in the results table: two false negatives, two true neg",
        "label": 0
    },
    "1544": {
        "output": "## I. Evaluate inclusion and exclusion criteria based on patient's information.\n[TUT011_1.mph:\n\nHere is the first patient note and its [clinicaltrials] header.\n[TUT001]:\n\n  ---------------------------------------------------------------------------- \n  ---------------------------------------------------------------------------- \n  Patient:\n  ----------------------------------------------------------------------------    \n  Title: HCV\n  ----------------------------------------------------------------------------  Inclusion criteria:    \n  ----------------------------------------------------------------------------    \n  Male (M) or Female (F), 18 years of age or older;    \n  Persistent chronic HCV infection (positive HCV RNA and positive anti-HCV) for more than 6 months;    \n  Absent or mild symptoms (hepatic encephalopathy and fatigue) with no evidence of inflammation or fibrosis or cirrhosis;\n  HCV RNA level > 4.0 log10 IU/mL;   \n  Planned to undergo liver biopsy < 2 weeks before screening (to include fibrosis stages up to F3);\n  Negative testing for antibodies to HIV, HBV and HTLV-I/II;\n  Able to understand the nature of the study, comply with the study requirements and participate in the study for 13 days.\n  ----------------------------------------------------------------------------  Exclusion criteria:    \n  ----------------------------------------------------------------------------    \n  Decompensated liver disease (Child-Pugh score > 10);\n  Currently abusing alcohol or illicit drugs;\n  History of alcohol abuse or illicit substance abuse within the preceding 2 years;\n  Active psychotic disorder;\n  History of significant autoimmune or immune system disorder;\n  History of any condition that would confound the results of Study Procedures or compromise protocol compliance.\n  ---------------------------------------------------------------------------- \n  Trials:\n  ----------------------------------------------------------------------------    \n  Trial-level eligibility:    \n  ----------------------------------------------------------------------------    \n      1) \n      2",
        "label": 1
    },
    "1545": {
        "output": "---\n__Trial-level eligibility:__ \n1) Excluded &#35;The patient is diagnosed to have stage IV chronic hepatitis C. According to his laboratory findings liver enzyme levels are within normal range. A histological examination was conducted and the findings supported the diagnosis. Stage and severity of fibrosis (METAVIR score F3) is high and he is an eligible candidate for the antiviral therapy. Patient doesn't meet the inclusion criteria of any of the active clinical trials (NCT id: NCT012982521, NCT01054281, NCT01048228, NCT01126406, NCT01061372, NCT0057567). The patient is diagnosed to have stage IV chronic hepatitis C. According to his laboratory findings liver enzyme levels are within normal range. A histological examination was conducted and the findings supported the diagnosis. Stage and severity of fibrosis (METAVIR score F3) is high and he is an eligible candidate for the antiviral therapy.\n\n---\n__Trial-level eligibility:__ 2) Not relevant (lacks sufficient information) &#35;The patient is diagnosed to have stage IV chronic hepatitis C. According to his laboratory findings liver enzyme levels are within normal range. A histological examination was conducted and the findings supported the diagnosis. Stage and severity of fibrosis (METAVIR score F3) is high and he is an eligible candidate for the antiviral therapy. The patient doesn't have medical information about a clinical trial (NCT id: NCT012982521, NCT01054281, NCT01048228, NCT01061372, NCT01060273, NCT01480654, NCT01026878, NCT01248625, NCT0121",
        "label": 2
    },
    "1546": {
        "output": "<!-- LORETTA START -->\n<script src=\"https://cdn.jsdelivr.net/gh/lorem-react/packages/lorem@v6/src/lorem.js\"></script>\n<div class=\"lorem-element\">\n  <p><small>Note.</small><h2>Lorem ipsum dolor sit amet.</h2> <p>Lorem ipsum, dolor sit amet consectetur adipiscing elit. Fusce luctus ac scelerisque lobortis. Integer id nisi sit amet libero euismod blandit vel vitae mi. Cras vel lectus nec elit tempor interdum. Mauris congue quam id leo accumsan, congue tempus nulla luctus euismod. </p></div>\n\n<!-- LORETTA END -->\n\n[Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invitatoreytocronerumcupido} eoranmtepqleo ndum et dolore magna aliemntepqledum cum qui lacusdapibus nonummy eirmod. Tempor sed magna cum aliquam nonummy dolore tempor duis enim volutpat ac mi in nulla nec arcu vel nulla volutpat ac mi in nulla nec arcu vel duis enim volutpat ac mi in nulla nec arcu vel nulla volutpat ac mi in nulla nonummy eirmod dolore magna aliem ntepqledum cum. Tempus nec scelerisque. Ct diam aliquam. </p></div><br><br>\n\n[Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor. Nec elit rutrum commodo, nec nec duis urna ultricies scelerisque id nec duis ultricies. Id scelerisque. Suspendisse interdum rutrum ultricies scelerisque et suscipit, commodo eu commodo enim id enim. Fusce lobortis semper enim, id comm",
        "label": 0
    },
    "1547": {
        "output": "## Part I -Participation Criterion\nAs an instructor, you are a pharmacist. You were asked to find a new medication for a disease and select the most effective treatment for the patient. Then, your supervisor assigns you to another research group to help with the design of the study and preparation of the materials needed to conduct a clinical trial. In the group, you are asked for your medical expertise in order to define a new clinical study.\nTo design the study you should make a list of the eligibility assessment criteria of a patient: factors which define the patient's eligibility for participating in a clinical study. These criteria are usually based on the patient's medical history, physical examination, and laboratory and other tests for the diagnosis, prognosis, and treatment. For example, in our case study, the criteria included age, sex, current health status, current medication, and previous adverse reactions to medication.\nOnce you identify the eligibility criteria for the new study, you should use your decision tree skills to design a participation criterion, which you shall enter your first notebook. Here are some factors taken from [?] and an example of a participation criterion:\n- Participation Criterion: Patients in good mental state with no depression or cognitive impairment can be included in the study.\n\nA participation criterion contains the following data as a result of a patient not meeting the inclusion criteria.\nWhat are the consequences of the participation criterion for the study design? You and your team members can selectively enroll patients in the study. You can find that the participation criteria can allow you to enroll participants with a higher rate of adverse reactions to the medication, compared to the trial population. Or, you may be able to exclude people with chronic disease or a low performance status. So, once you find the participation criterion for the new disease trial, you should write it into your notebook. [?]\n\n\nWe are now ready to learn about a participation constraint.\n\n\n## Part 2 -Participation Constraint\nYour instructor, a pharmacist, was asked to find a new medications for a disease and select medicines for the patient. Later, your supervisor assigns you to another research group, and you are asked to help with a",
        "label": 2
    },
    "1548": {
        "output": "## Hiding Clinical Trial IDs and Assessments\nIt is often a good idea to hide the clinical trial IDs and assessments. In the following, we describe how to hide clinical trial IDs and assessments from the `clinicaltrials.com` domain. We show some examples, where we can show only one clinical trial ID, or we can show either `0/256` or `2/256/X` as the eligibility assessment.\n\nThis is written for clinical trial IDs in the clinicaltrials.com domain, but there are some minor adaptations for those in the `clinicaltrials.gov` domain. If you work in the US and you need to show a `0/256` assessment, you should replace `0/256` with `1/260` because the US clinicaltrials.gov number field can only be 255-long. And if you want to show the `125/143` combination instead of the `2/256/4` combination, you should replace `2/256/X` with `X/256`. All the other rules are working for both the US and non-US clinicaltrial.com numbers.\n\nThe idea is that we hide the values to the right to see the value to the left, as shown in the example below. Notice that since patients do not always have a clinical trials ID and therefore assessment number, the patients with one value can share the other values with the patients with two values.\n\nWe demonstrate with the following sample, where you should replace `0/256` by `022/256` (the US number field can only be 255-long), and replace `2/256/X` by `X/256` in the clinical trials domain:\n\n[data-target-level-eligible]=0/256<ul>\n<li><code>Elaborate eligibility assessment: <small>\n'022</small></code></li>\n<li><code>Clinicaltrials.gov Trial ID: <small>\n'NCT01081276</small></code></li>",
        "label": 0
    },
    "1549": {
        "output": "<EOD> Acute Renal Failure After Intrapleural Administration of Lidocaine in COPD Patients With Pleural Empyema\nClinical experience with intrapleural administration of small doses of local anaesthetics for the treatment of pain in patients with serious pleural effusions or empyema is reported. In three patients who died from severe pneumonia complicated by empyema and pleural effusion, the intrapleural treatment of the effusion and empyema with local anaesthetics caused acute renal failure and delayed death. To prevent such toxicity, the intrapleural administration of local anaesthetics should be avoided in patients with empyema.<EOD> .\nBACKGROUND\nCyclooxygenase-2 (COX-2) is a critical mediator in carcinogenesis, angiogenesis, proliferation, invasiveness, and inflammation, thereby contributing to cancer progression. Thus, therapeutic down-regulation of COX- 2 represents a potential approach for new cancer therapy. COX-2 immunoreactivity has been detected in several malignant neoplasms (e.g. head and neck carcinomas); however, relatively little is known about the expression of COX-2 in colorectal cancer (CRC). The aim of our study was therefore (i) to investigate the role of COX-2 as a prognostic marker in resected colorectal carcinomas, (ii) to establish a biochemical model to evaluate COX-2 expression in CRC cells, and (iii) to determine the inhibitory effects of celecoxib, a selective COX-2 inhibitor, on the viability of CRC cells and on vascular endothelial cell proliferation.\n\n\nMATERIAL AND METHODS\nTumour samples were studied immunohistochemically with COX-2 antibody in 88 cases of colorectal carcinoma. Vascular density was evaluated by means of CD34 staining. In vitro effects of celecoxib on viability and proliferation were investigated in HT29, SW480, and SW620 CRC cell lines and",
        "label": 1
    },
    "1550": {
        "output": "Note:\nThere are some clinical trials that may have multiple inclusion criteria at each of the five criteria categories. We do not recommend creating a new `Trial-level eligibility: n) Eligible` for each such trial. Instead, it is recommended to combine all the trials' multiple inclusion/exclusion criteria into one `Trial-level eligibility: n) Eligible` entry, if the number of multiple criteria does not exceed five for the particular trial. As an example, let us consider another trial:\n\nTitle: Evaluation of Vironace for Hepatitis A Infection\n\nSummary: As a clinical study for novel HAV antiviral drug\n\nInclusion criteria:\nMale and female subjects age 18-26\nMale or post-menopausal female subjects with a documented infection of hepatitis A.\nMale and female subjects of reproductive potential must have a negative pregnancy test within 5 days of screening visit.\nMust agree to use two methods of contraception, if of childbearing potential, during the study and for 6 months after the last dose of study drug.\nSubjects of child bearing potential must have a female partner of childbearing potential must agree to use two methods of contraception during the study and for 6 months after the last dose of study drug.\n\nExclusion criteria:\nMale and female subjects must be either seronegative for hepatitis A, or must have a history of one episode of hepatitis A at least 6 months prior to first dose of study drug.\nMust have a negative pregnancy test within 5 days of screening visit.\nMust agree to use two methods of contraception during the study and for 6 months after the last dose of study drug.\nMale subjects must be able to provide sample of semen for evaluation of sperm counts.\nAll subjects must be physically and mentally capable and willing to provide written informed consent.\nSubjects that are HLA-DR allele positive must demonstrate a normal bone marrow response within three months prior to study entry. The normal trilineage response must be verified with a hemoglobin concentration greater than 110 gm/dL, WBC count greater than 3,300/mm3,",
        "label": 1
    },
    "1551": {
        "output": "![](./img/trial-level-eligibility.png)\n<EOD> Clinical Relevance of the Malignant Pleural Mesothelioma Cytological Diagnosis\n\n\n\n# Introduction\nPleural effusions are classified as exudates or transudates. The effusion cells are analyzed according to their features and classified as either transudate cells (typically with a cytologic finding of mesothelial proliferation), or cells with signs of inflammation. Malignant pleural mesothelioma (MPM) is a very rare type of cancer, occurring in 0.3/100,000 worldwide [bib_ref]  Estimating the population incidence of malignant mesothelioma and mesothelial hyperplasia in Australia..., Robinson [/bib_ref] . In France, an increase in the incidence of MPM is expected between 2007 and 2012 due to recent exposure to asbestos, especially asbestos and erionite in the central part of the country [bib_ref]  Malignant mesothelioma: An overview, Mohsenizadeh [/bib_ref] . In France, malignant pleural mesothelioma is the most common malignant pleural neoplasm (30% of all pleural malignancies) and its incidence, especially MPM with sarcomatoid histology, is expected to increase [bib_ref]  Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution, Tossavainen [/bib_ref] . Asbestos is, in fact, a carcinogenic substance and exposure to even low amounts of asbestos can be related to malignant mesothelioma in some cases, even in the presence of latency of several decades. Due to these features, MPM is almost always of an exogenous origin. Asbestostosis is the characteristic pathological lesion caused by asbestos fibres and consists of the presence of asbestos bodies in alveolar macrophages. The exposure to asbestos has been identified as the main risk factor for cancer MPM, since the second half of the 20th century. The exposure can involve many different tasks, and may start with asbestos cement roofs",
        "label": 0
    },
    "1552": {
        "output": "Your task is to find the program that evaluates the patients' documents and then makes the output in the format `Trial-level eligibility: `.\n\nWrite a program that does the followings:\n\n\n\n* \n- Initializes the patient notes list whose element is of the name format of the patient notes. \n- Changes the document of the nth patient as the patient note, when the program gets a list of the patient notes. \n- Evaluates the patient with the patient note by the three-point scale (i.e., excluded, not relevant, or eligible)\n- Prints the output. \n- The output of the program should always repeat `Trial-level eligibility: ` in the last line.\n\n## [INST] Input the list of patient notes in the file /home/<your_name>/input.txt.\n\n[INST] Create an output file for our program in the file /home/<your_name>/output.txt\n\n\n**Hint:**\nThe program should be able to judge all the patient notes with a three-points scale.\n\n\n\n\n--07_Eligibility_V2.in\n\n  // Patient notes list\n  //------------------------------\n  // - Patient 1 ------------------\n  // 1. Patient name   : <NAME>\n  // 2. History of HCV  : positive for 2 years\n  // 3. Past history  : no significant\n  // 4. Current therapy : RBV + new direct antiviral drug\n  // 5. Current medication : no other medication\n  // 6. HCV treatment history  : IFN + RBV for 6 months\n  // 7. HCV treatment history -end---------------------------------------------------------------\n  // 8. Biopsy  : negative for HCC, chronic inflammation from HCV\n  // 9. Additional examination/procedure : None\n  // 10. Patient chart  : unremarkable for chronic viral hepatitis\n  // 11. Physical exam : normal, alert, no distress\n  // 12. Blood pressure : 130/75\n  // 13. HeR :",
        "label": 0
    },
    "1553": {
        "output": "Good luck with the [MAT] part of the assignment!\n\n## [/MAT]\n[GAP]\n[fig]  1: To evaluate the sensitivity and specificity of hepatocarcinoma-associated antigen 73 (HPA-71G, hereinafter referred to GP73) for the diagnosis of HBV-related HCC. Establish the standard of GP73 in normal people. 2. To definitude the connections between the GP73 level and various diseases. 3. To identify the relations of HCC metastasis and recurrence. Study design: \u2022 Collectivity type: Prospective, randomized, controlled, multi-central clinical study. \u2022 Patients: [/fig] \n<EOD> .\nLipedema represents chronic enlargement of adipose tissue. It is a disease characterized by an isolated overgrowth of fatty tissue in lower extremities. Since 1940, the disease was presented under the term \"pseudo angiostomatosa\", at first as an enlargement of superficial (cutis) or subcutaneous fatty tissue and since 1948, it is presented as an untypical overgrowth of deep fibrous-fatty connective tissue. It is not necessary to state that the diagnosis of this disease cannot be made using ultrasound or CT. The diagnosis is based on clinical criteria and histopathological findings.<EOD> Intravenous parathyroid hormone.\nPARATHYROID HORMONE, with its many actions on the bones and kidneys, was inevitably found to be of interest when skeletal and renal malfunction was observed in patients with secondary hyperparathyroidism associated with chronic renal disease.1 The administration of parathyroid hormone directly to patients with skeletal demineralize-dion (osteoporosis) and osteogenesis imperfecta has led to the discovery that not only does bone metabolism respond to the administration of parathyroid hormone in these clinical states, but also that there is much greater sensitivity of bone to the hormone than previously appreciated.2 , 3 This greater sensitivity of bone and possibly",
        "label": 2
    },
    "1554": {
        "output": "Now, let's test the program. \n```\n> python hepatitis_clinical_trial.py\n\n# E01 is the first patient. His Trial-level-eligibility is 2 because the patient meets the inclusion criteria and the exclusion criteria do not apply. (Trial-level-eligibility: 2)\n\n# E02 is the second patient. His Trial-level-eligibility is 0 because the patient meets the exclusion criteria of the clinical trial (Trial-level-eligibility: 0)\n\n# E03 is the third patient. Her Trial-level-eligibility is 0 because the patient meets the exclusion criteria of the clinical trial (Trial-level-eligibility: 0)\n\n# E04 is the fourth patient. Her Trial-level-eligibility is 1 because the patient meets the inclusion criteria of the clinical trial, but is excluded on the grounds of the trial's exclusion criteria\n```\n\n## Solution\nHere is the solution written in C programming language.\n```\nint T, E01;\n\nif(T == 1)\n{\n    E01 = 2;\n}\nelse if(T == 2)\n{\n    E01 = 0;\n}\nelse if(T == 3)\n{\n    E01 = 0;\n}\nelse\n{\n    E01 = 1;\n}\n\nprintf(\"Trial-leveleligibility for the %d'th patient is %d.\\n\", T, E01);\n```\n<commit_msg>New test command. <commit_after># -*- coding: utf-8 -*-\nfrom __future__ import unicode_literals\n\n# --------------------------------------------------------------\n#                          Author:       Seunghak.Choi                #\n#                         Date:        June 6, 2021                    #\n# --------------------------------------------------------------\n\n# ---[INST]---  BEGINNING OF THIS TUTORIAL: HELLO.LGF\n# ---[END]--- END OF THIS TUTORIAL: HELLO.LGF",
        "label": 1
    },
    "1555": {
        "output": "[PROB] What about the output? I'll show it in another way.\n\n```python\ndocID = '<HCV>0001791587791-'\nnumTestID = '<NA>'\nsesID = 'A0123'\ncodeF1 = 'f1'\ncodeF2 = 4\ndocType = 'clinical_trial'\nresultF1Score = 'eligible'\nresultF2Score = 2\nresult = 0\nresult_sesid = None\nresult_docid = None\nresult_numTestid = None\nresult_codetype = None\n\nwith open(\"clinical_trial.txt\") as file:\n    doc_f1 = json.load(file)\n    doc_f2 = json.load(file)\n\nwith open(\"sesIdTest.txt\") as file:\n    sesIDs = json.load(file)\n\nwith open(\"codetype.txt\") as file:\n    codes = json.load(file)\n\nfor document in [doc_f1, doc_f2]:\n    if document.get('doc_id') == docID and document.get('doc_type') == docType:\n        if document.get('numTestId') == numTestID:\n            if sesID in doc['sesIDs'] and document.get('codeType') == codeF1:\n                # I need to check F1 code\n                if document.get('testScore') == resultF1Score and document.get('testScore') == resultF2Score:\n                    result = resultF2Code  # If both codes are equal to Scales, you'll return TRUE.\n                    result_codetype = 'full_code'  # you'll return ResultID for the first F2 code that is different from 1.\n                    result_docid = docID  # you'll return ResultID for the first F2 code that is different from 1.\n                    result_numtestid = int(document.get('numTestId'))\n                    result_sesid = sesID\n\nif result:\n    print(\"Result Code Finder Result:\", result_codetype",
        "label": 1
    },
    "1556": {
        "output": "Please follow the same format given in the table given below to do the Exercise#4.\n\n#### Example Exercise# 4:\n- The patient has the chronic HCV.\n- The patient meets the inclusion criteria on the trial.\n- The patient does not meet the trial's exclusion criteria.\n- The patient is eligible to the trial.\n[INST]\n<EOD> Interplay of transcription and translation regulates dynamic mitotic chromatin state\n\n\n\n## Supplementary\n Average profiles for the indicated conditions from two biological replicates were overlayed and a peak height was measured near the center of transcription start site (TSS) corresponding to the center of peak of H3K4me3 as shown in . The profile for rpb1-3 was also used to calculate the height of the same position in other conditions.\n[fig]  Figure S1: H3K4me3 is enriched over both coding and noncoding regions in mitotic phase. (A) Heatmap showing relative abundance of H3K4me3 around the TSS of the genes transcribed during G2/M. (B) Heatmap showing relative abundance of H3K4me3 around the TSS of the genes not transcribed during G2/M. The region -500 to 500 base pairs (bp) around TSS was divided into 20 bins of equal size and normalized values and relative abundance are shown. The relative abundance was measured in arbitrary units (au) and defined as the ratio of H3K4me3 to H3 histone levels. (C) Same as (B); however the region -2k to 0k around TSS was divided into ten bins of equal size. (D) Boxplots show distribution of H3K4me3 within -500 to 500bp regions for the genes that are not transcribed in G2/M (top panel) as compared to genes transcribed in G2/M (bottom). (E) Boxplots show distribution of H3K4me3 within the region -2k to 0k for the genes not transcribed in G2/M (top panel) and genes transcribed in G2/M (bottom). ***, p < 0.005; **, p",
        "label": 1
    },
    "1557": {
        "output": "<EOD> Antibiotics prescribing in general practice in Norway: a population-based study.\nIn many Western countries, inappropriate antibiotic prescribing causes significant expenditure and may facilitate the spread of bacterial resistance. To determine the appropriateness of antibiotic prescribing in an outpatient setting and to analyse changes over time, a repeated cross-sectional study was conducted from 1995 to 2000. The study population consisted of 2,375,064 inhabitants permanently registered in general practices in the Oslo and Bergen regions of Norway in 1995, increasing to 2,606,500 in 2000. During 1995 and 1996 more than 4 million antibiotic prescriptions were issued, approximately 80% of which were for respiratory complaints. The percentage of all visits to doctors that led to an antibiotic prescription decreased significantly throughout the study period, from 21.4% in 1995 to 8.6% in 2000; a similar result was achieved by a change from first to second line antibiotics. During the same period, visits in general, and especially visits without an antibiotic prescription, increased. The percentage of visits that led to the prescription of a second line antibiotic showed a significant increase, from 1.4% to 4.4%. An inappropriate antibiotic prescription for respiratory complaints in general practice in Norway is a widespread phenomenon, and the proportion of antibiotic prescriptions that was unnecessary was high, especially early in the study. However, a significant improvement in antimicrobial-prescribing guidelines was observed in this study, in particular, a reduction in the prescribing of broad-spectrum antibiotics.<EOD> Membrane topology changes associated with protein sorting in the endoplasmic reticulum of Neurospora crassa.\nThe membrane topology of a 73-kDa oligosaccharyltransferase-like protein (Och-1a) (Kennedy et al., 1992) and a major iso",
        "label": 1
    },
    "1558": {
        "output": "---\n\n##### INPUT: `B`\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. You may perform a second eligibility assessment of this patient with the patient case note. Your task is to make a note",
        "label": 2
    },
    "1559": {
        "output": "### Exercise 15\nYou are a senior student, and you are currently practicing your skills in the medical record analysis center. You have been assigned to collect information related to HCV treatment in medical records. The patient is a male, 48 years old, is married and works as a manager. According to the patient's medical records, the results of blood tests performed on 12/22/2006 were below normal. The laboratory results are as follows: Hb 12.2 g/dL, Leukocytes 1660/muL, Plt 155000/muL, Neutrocyte 5930/muL, MPV 13.90 fL, lymphocytes 500/muL, Eosinophils 0/muL, MPV 13.60 fL, MCV 115 fmol, MCH 65 pg, LDH 231/u/L (N 125-220 U/L), GOT 41 U/L (N 8-33 U/L), GPT 106 U/L (N 0-35 U/L). In addition, the results of the recent HCV RNA test were 1014000 COI/mL. The patient stated that his first HCV test results were positive 2 years ago and that his blood tests were within normal limits and no medication was prescribed during these 2 years. According to the data in the patient's file, this is the patient's first hospitalization. Although the patient has a history of alcohol consumption, currently he stopped drinking 2 years ago, and the patient stated that the medical professional gave him medication for 10 months; however, he discontinued it in the first 6 months of treatment due to his fear of side effects. His vital signs measured on admission were: 92/65 mmHg (SBP/DBP), RR: 20/min, Temp: 36.9 C/98.46 F. On cardiorespiratory examination, a regular rate and rhythm was perceived with no murmurs. It is determined",
        "label": 2
    },
    "1560": {
        "output": "![INST]\n<EOD> Prolonged mechanical ventilation in adults: the report of a registry.\nOBJECTIVE\nTo analyze ventilator use and associated outcomes in a large cohort of adults receiving >21 days of mechanical ventilation.\n\n\nDESIGN\nRegional, prospective cohort study.\n\n\nSETTING\nPuerto Rico Intensive Care Unit Surveillance Network.\n\n\nPATIENTS\nAdults discharged from the hospital in June 2003 to December 2005 who received any day of respiratory support >21 consecutive days, with no anticipated end to the therapy.\n\n\nINTERVENTIONS\nNone.\n\n\nMEASUREMENTS AND MAIN RESULTS\nWe obtained information on the total ventilator day, type of ventilator used (pressure, synchronized, or assisted), length of stay, and hospital mortality rate for each ventilator day. We analyzed overall hospital mortality and survival to discharge in those who survived the intensive care unit stay. Overall, 1,637 patients survived (at least 6 months) and had a total of 85,905 days of ventilator support (pressure support 678 patients/32,900 days, synchronized ventilation 634 patients/27,813 days, and pressure-assist control ventilation 112 patients/25,181 days). Patients receiving synchronized ventilator assistance had shorter lengths of stay (p = 0.003) and had the highest mortality rate (59.0%). Survival at discharge among those surviving the intensive care unit stay was lower in the pressure-assist versus pressure-support patients (64.8% vs 76.6%; p = 0.003).\n\n\nCONCLUSIONS\nA large proportion of mechanically ventilated adults had >21 ventilator days. Ventilators using pressure-assist ventilation modalities had the lowest survival to discharge of the pressure modalities.<EOD> .\nElectroencephalographically, all patients under investigation had a slow background rhythm, at least one period with high voltage spike and",
        "label": 1
    },
    "1561": {
        "output": "You are free to make mistakes during the trial-by-trial assessment. However, you must repeat the Trial-level eligibility after the trial-by-trial assessment, which is called the last line by end of program. You should write `Trial-level eligibility: 0) Excluded`. [TRIAL] \n\t\t\t\tThis is a very important part of the assignment. This is the part where you can give the wrong message to the trial investigator on the eligibility of the patient. The trial investigator cannot know if you have made mistakes and the incorrect assessment during the trial-by-trial assessment. \n\t\t\t\n\t\t\t\tIt is very important that every code of patient note 1 is matched with only one code of the inclusion criteria from the clinical trial 2. If you have not made any mistakes in the assessment, the output should be eligible in all of the trials. \n\t\t\t\n\n\n\n\n[INSERT TABLE HERE]\n[/COL]\n\n\n\t\t\n\t\t\t\tLet's continue the case. You have to perform the trial-level assessment again including the last line. In this trial, you input `01.` This means that the patient note was eligible in trial 01. Similarly, in trial 02 for the note \"02.\", input `1, 1.` When your assignments are completed, press the `CLOSE` button to return to the main GUI.\n\t\t\n\t\t\n\t\t\t\tCongratulations! Let's look at the trial-level assessment of patients in the clinical trial 1.0 as follows. You can see in the patient's eligibility that `02.` is output for `01, 01, 00`. This means that the patient is eligible for trial 01 as you performed during a trial-by-trial assessment. In contrast, in trial 02, the patient's eligibility is `11, 1, 0:` instead of `1, 1, 0:`. This means the patient is not eligible for trial 02. As this is the last line of the trial-level assessment,",
        "label": 2
    },
    "1562": {
        "output": "# I.6.1 Excluded (0)\nExclude if:\n\n- the patient does not have necessary data to be assessed for inclusion criteria.\n- meets at least 1 exclusion criteria for clinical trial\n\n# I.6.2 Not relevant (1)\nExclude if:\n\n- does not have sufficient information on exclusion criteria to be included.\n- meets at least 1 exclusion criteria for clinical trial\n\n# I.6.3 Eligible (2)\nInclude if:\n\n- patient has all information required for the assessment of inclusion criteria\n\n# I.6.4 Uncertain (3)\nInclude if:\n\n- patient has some data on either inclusion or exclusion criteria, or data on any of the 15 exclusion criteria is not available.\n\n# I.6.5 Not Assessed (4)\nInclude if:\n\n- if no mention was made about whether patient met inclusion or exclusion criteria.\n\n# II. Assessing the Risk of Bias\nIn this section, you will assess the risk of bias for the clinical trial, evaluate the patient assessment for the trial, and write the report and conclusion.\n\n# 1. Introduction to clinical trials and ROBINS-1\nClinical trials offer new information on the safety, costs, doses, and benefits of medical treatments. This type of study provides more precise and in-depth information than observational data. However, patients in clinical trials generally have strict eligibility criteria and may not resemble the general patient population. For example, they may be healthier, younger, and richer than the general population. As an example, the inclusion criteria of the clinical trial reported above may exclude people who have low income or poor lifestyles. There may also be biases, such as a preference for the test drug over the experimental drug.\nROBINS-1 is a tool to help systematically think about the potential sources of bias for a review. ROBINS-1 is based on assessment areas such as randomization, selection of participants into the study, missing data and measurements, classification of interventions, deviations from intended interventions, and the selection of reported outcome assessments. Each item is a signal of various biases, including bias in the randomization procedure, patient selection",
        "label": 0
    },
    "1563": {
        "output": "Your last patient is here:\nTrial-level eligibility: 2) Eligible\n[/INIT]\nWhen you are done with the three cases, you should submit your results as a Word document named ``Assessments_Reliability_Cases_Kaipio_051116`` to your TA, and save the work folder as a zip file. Remember to open the file, as your Excel file probably has the same name. The zip archive should contain two Word documents: the `Assessments_Reliability_Cases_Kaipio_051116.docx` with the patient notes and the `Eligibility_Checklist_Kaipio_051116.docx` with the trial. The archive should also include at least the Excel files you used to assign scores. Be sure to save the",
        "label": 2
    },
    "1564": {
        "output": "[fig]  The: Investigator agrees to submit information on each clinical trial subject of this study according to the following study schedule. 1.3.1 Subject demographics: Date of birth, gender, race, height and weight. 1.3.2 Medical history: List of significant chronic diseases prior to and during the clinical trial. 1.3.3 Medications: Prior and concomitant medications. 1.3.4 Allergies: Drug allergies before and during the clinical trial. 1.3.4 Laboratory Results: Blood test results from: 1) Hemoglobin (Hgb) 1) AST, ALT, AST/ALT ratio 1) BUN 1) Alkaline Phosphatase 1) Total Bilirubin 1) Albumin 1) Prothrombin Time (INR) / International Normalized Ratio (INR) 1) Hemolytic Activity Assay/Hemolysis (free Heinz Body Test) 1) Platelet Count (PLT) 1) 25-(OH)-vitamin D level (Cobalt in mg/L, PRE & POST) 2) Free testosterone level (normal value is between 0.1 -10.0 pg/ml) 1.3.5 Immunoelectrophoresis for Immunoglobulins 1.3.6 Electrocardiogram/EKG 1.3.7 Urinalysis: Microscopic Urine Exam for Protein/Glucose 1.3.8 Echocardiogram/ECHO/Ultrasound of the Eye 1.3.9 Colonoscopy in cases of gastrointestinal bleeding [/fig] \n<EOD> Isolation of Plesiomonas shigelloides Associated with a Dog\n\n [fig_ref]  TABLE 1: Frequency with which bacteria isolated were identified as Plesiomonas shigelloides by tests... [/fig_ref]  [bib_ref]  An unusual agent of diarrhea in children and adults, Janniger [/bib_ref]  \n\n## Isolation of plesiomonas shigelloides associated\nwith a Dog * Bacteriological analyses in our laboratory revealed Escher",
        "label": 1
    },
    "1565": {
        "output": "---\n\n# <NAME>\n\nIncludes information taken from the workshop, with additional clarifications.\n\n* The decision is a 3-way decision tree with a probability table:\n\n### Treatment\n\n1. Not-yet-treated, < 18 years old: 12\n1. Treatment-naive patients (TN): 258\n1. Treatment-experienced patients (TE): 258\n1. Previous sustained virological responders (psvR): 270\n1. Liver transplant patients: 35\n1. Patients with genotype 2 or 3 infection: 140\n\n### Trial:\n\n1. Allocation:\n1.1. Allocated to the control group: 258\n1.2. In the control group: 1000\n1.3. No further events: 1000\n1. Allocated to the study group: 258\n1.1. Allocated to the study group and completed therapy; 258\n1.2. Allocated to the study group and treatment failed; 258\n1.3. No further events: 258\n\n### Discontinuation\n\n1. Lost to follow-up: 50\n1. Treated other than intended: 50\n1. Received other than intended: 1000\n1. Stopped due to adverse event: 80\n1. Adverse event: Adverse event unrelated; 580\n1. Adverse event: Adverse event possibly related: 200\n\n### Follow-up\n\n1. Lost to follow-up: 1000\n1. Died: 1000\n1. Discontinued: 258\n1. Unknown: 79\n\n### Outcomes\n\n1. Treatment failure: 258\n1. Treatment cured: 258\n1. SAR131675: 50\n1. Viral hepatitis C: 1000 (control)\n1. Viral hepatitis C:",
        "label": 1
    },
    "1566": {
        "output": "- You are almost done. Let me summarize your task and the output in several parts. If there is a patient that meets inclusion criteria and exclusion criteria, you should output `0) Excluded` from `Trial-level eligibility` and you should output `3) Excluded` from `Patient-level eligibility` in the last three lines by `Patient-level eligibility: 3) Excluded`. If a patient can be enrolled into the clinical trial, then you should output `1) Eligible` from `Trial-level eligibility` and you should output `2) Eligible` from `Patient-level eligibility` in the first two lines by `Patient-level eligibility: 2) Eligible`. - You should output the trial's random order in the last part by `Randomized patient: #1 (6d2f72f0-c9da-4178-be9b-0b2d00ac90a5).`. [/END]\n\n[INST]\nLet's think together about some patients and the clinical trial as you continue to learn. \nIn the first part, let's think about some patients who can be enrolled into the clinical trial. \nPatient A is a man diagnosed with chronic HCV infection 3 years ago. His past medical history is not significant. He is an asymptomatic young man without any medication. He has negative results from physical and laboratory examinations. According to the history and physical examination records, we should decide whether Patient B can be enrolled into this clinical trial. \nPatient B was diagnosed with HCV 10 years ago. His past medical history includes chronic kidney disease. He is on medication at the time of your assessment. He has a fever of more than 38 degrees Celsius with fatigue and increased urinary protein. The history is negative for medications, abdominal pain, melena, hematochezia and hematemesis. His abdomen is soft on examination. His extremities look pale with mild jaundice. What are your findings? What do you think the investigators should do? \n\nDo you want to make patients' clinical information more complete in the",
        "label": 2
    },
    "1567": {
        "output": "## Eligibility. A patient who can be potentially enrolled into the clinical trial.\n\n---\n## Eligibility\n[Mini-Quiz + Inst \u2192 E]:\nWrite the description of the eligibility.\n\n\n\n## H1778\n[INST]: Here is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)\n\n\nSummary: This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants. The primary hypothesis is that administration of grazoprevir for 7 days is sufficiently safe and well tolerated in HCV-infected males.\nInclusion criteria: Inclusion Criteria:\nBaseline health is stable.\nHas a clinical diagnosis of chronic HCV infection.",
        "label": 2
    },
    "1568": {
        "output": "## \u3010INST\u3011[FUNCTION INSTANCE]\n* Instance of a function\n\n*\n\nIt is the function of getting the trial-level eligibility by given patient note. You should implement `get_trial_level_eligibility` using  following Python code:\n\n    def get_trial_level_eligibility(patient_rec):\n        patient_rec[\"RCT_ID\"] = \"Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery\"\n        patient_rec[\"Patient_Rec_ID\"] = \"0422\"\n        # Get the trial-level eligibility: 1) Excluded, 2) Not relevant or 3) Eligible. \n        return patient_rec['Trial-level eligibility']\n\n#### \u3010NOTE\u3011\n\nWe cannot get the trial-level eligibility by only `get_data` function. You should create `patient_data` object, then `get_trial_level_eligibility` function can be executed. In other words, if you want to obtain your own trial-level eligibility, you should use Python code as well as our Python tool in this paper.\n#### \u3010NOTE\u3011\n\nWe use 'patient ID' as trial ID. This is one of the important functions of the 'FUNCTION INSTANCE' in the clinical trial management systems. \n\n## \u3010INST\u3011[EXPERIMENT CATEGORY INSTANCE]\n* Experiment category instance\n\n*\n\nIt is about the data management of an EXPERIMENT CATEGORY. You should implement `EXPERIMENTCATEGORY MANAGER` using following Python code:\n\n    \n    # Create experiment category instances\n    p1 = EXPERIMENTCATEGORY(rec_id=\"0422\", category_group=\"0422\", exp_cat_rec_id=\"010004\", exp_cat_desc=\"Hepatocellular carcinoma\", \n                            exp_cat_comment=\"Hepatocellular carcin",
        "label": 0
    },
    "1569": {
        "output": "### Case Study - [48]\nYou have been hired as a new consultant for a healthcare organization. A small hospital with a bed capacity of 250, a nursing staff of about 250 employees, provides health services. The primary business is the operation of a 250-bed general acute care hospital that is open 24/7; it is a medical center, offering a wide range of treatment and diagnostic services. The hospital has over 350 patients and employs approximately 500 nursing staff. Inpatients are mainly comprised of surgical patients, neurological patients, gynecological patients, and patients with cardiac problems. The hospital also includes an emergency room with about 7,500 visits yearly. The hospital also has a laboratory.\nThe hospital provides services to patients in its own emergency room and services related to other medical facilities are outsourced. Currently, approximately 40% of the hospital's income comes from outsourced services to various clinical laboratories and other healthcare organizations. However, due to the decrease in outsourced service revenue, this amount is expected to be increased. The hospital is currently experiencing financial problems due to the outsourcing loss. As a new consultant, your work focuses on strategic planning and management of the hospital. In particular, it is aimed at the long-term survival of the hospital and the improvement of its competitiveness and performance. Also, by investigating the structure of the hospital and analyzing internal and external factors, you should make a proposal for the future strategic plan of the hospital.\n\n\n### Case Study - [49]\nPine Ridge is a health center that provides a wide range of patient services ranging from minor emergency care to major surgery and specialty care. Over a $10 million annual budget, the health center employs more than 150 clinicians, medical residents, and other medical staff: the health center is a safety net hospital with an affiliated academic medical education program at the University of Pennsylvania. The main client base is low-income residents in Philadelphia and the surrounding area. In addition, the clinic also takes in patients who are uninsured, undocumented, un-or underinsured, or who",
        "label": 0
    },
    "1570": {
        "output": "## Examples\n\n## HCC\n![inst_4]\n<EOD> A New Case of Glycogen Storage Disease Type II: Diagnostic Aspects\n\nKearns Sayre Syndrome (KSS) is one of the primary mitochondrial diseases. A neonatal hypotonia is a common feature of many mitochondrial disorders. Therefore, the diagnosis of disorders of the central nervous system (CNS) is quite challenging. We described the case of a newborn boy presenting with neonatal hypotonia, feeding and poor weight gain. The patient was referred to our hospital at 40 days of life with these symptoms. He presented a cachectic general aspect. A metabolic work up with acyl-carnitine profile was done to investigate the presence of organic acidemias and showed low acyl-carnitine levels with a significant increase of free carnitine. The diagnosis of Glycogenosis type II was confirmed with high levels of GA in urine assay. A genetic confirmation of the disorder was done through a sequencing of the GAA gene, which led to a diagnosis of Glycogen Storage Disease Type II (GSD II). The genotype was compound heterozygosity with the alleles: del272-663 and G243X. At one and half year of age the patient developed seizures and died.\n\n# Introduction\nKearns Sayre syndrome (KSS) is a mitochondrial disorder characterized by the presence of pigmentary retinopathy, heart block, and progressive ophthalmoplegia. [bib_ref]  Clinical characteristics and current status of the Kearns-Sayre syndrome: identification of a..., Malfatti [/bib_ref]  It has an estimated prevalence of 14/1,000,000.It is caused by mutations of the mitochondrial tRNA Leu -encoding mtTL1 in a heteroplasmic manner, leading to a severe impairment in oxidative phosphorylation in tissues which are more metabolically active like the brain, heart, skeletal muscle, and liver, due to",
        "label": 2
    },
    "1571": {
        "output": "[END]\n![Winner Candidate] There are more than 1,000 patients! Our patient information is available! But we do not know which patients are eligible. \n\nTrial-level eligibility: 1) Not relevant\n[\n![Winners] A total of 11 clinical trials are eligible! \n\n\n\n\n![\"Clinical_trial_Eligibility\" ]=\"Clinical_trial_Eligibility_Abbott\"\n\n\n\n!!! note\n\n![1st place][1st-p]  !! : ![2nd place][2nd-p]  3 rd, ..... n-th places are displayed in the order of decreasing p values. In other words, it means that the higher the n, the lower (smaller) the p value becomes, i.e., the more significant the correlation becomes.\n\n\n### 1st Place:\nThe correlation coefficient is: ![\"Correlation\": 0.76230900000000020576]=\"0.762309\"\n(2) For more confidence: **we have to compute R^2**. In simple regression, R^2, named R-Squared, represents the portion of the variation of the dependent variable that is attributable to the independent variable.\n\n![3rd Place][3rd-p]. The p value becomes smaller. So, we could conclude with confidence that the correlation is positive: A and B are positively correlated. \n\n### C.4.3. How we can choose the model? \n**Note** When doing regression analysis, the choice of a statistical model (or a mathematical model) among several options such as multiple regression, logit, log, etc. is often difficult, because many times there is no one unique solution at all. \n\n![1st Place][1st-m] \n![2nd Place][2nd-m] \n![3rd Place][3rd-m] \n![4th Place][4th-m] \n![5th Place][5th-m] \n![6th Place][6th-m] \n![7th Place][7th-m] \n![8",
        "label": 0
    },
    "1572": {
        "output": "For more details, please refer to the [wileybook/introduction.pdf]\n\n    ...\n    <EOD> Prognostic Value of \u03b2-adrenergic receptor signaling in a murine breast cancer model\nIntroduction: Evidence suggests that \u03b2-adrenergic signaling (BAS) can impact tumor progression. \u03b22-adrenergic receptor (\u03b22AR) is known to be overexpressed in breast cancer and overexpression has been linked to a worse prognosis. BAS is known to play important roles in pathologies such as hypertension, and a similar effect could be at play in cancer. Materials and Methods: Female C57BL/6 mice were injected with 1 x 105 4T1 mammary cancer cells and randomized into two treatment groups - Control (saline) and the \u03b22AR antagonist - ICI 118,551 (ICI). Tumor volume was monitored and recorded, as well as a number of physiological and biochemical parameters. Results: ICI treatment reduced tumor growth by 50% at least compared to the control. Blood pressure measurements revealed no difference between the two groups; however, ICI treatment resulted in nocturnal hypertension while the control tumor-bearing mice displayed normal circadian BP. \u03b22AR expression was increased in the control tumor-bearing group over na\u00efve and ICI treated mice. Plasma epinephrine levels, which were higher in tumor bearing mice treated with ICI, had no correlation with tumor volume. ICI treatment increased liver and myocardial GLUT-4 expression, but not skeletal muscle GLUT-4 expression. Conclusion: These results suggest that \u03b22AR signaling through the \u03b22AR antagonist, ICI, has an influence on tumor progression and BP regulation.<EOD> .\nThe article presents history of the development and use of one of the latest diagnostic x-ray methods for diagnosis of the pancreatic diseases - endoscopic retrograde cholangiopancreatography. This method allows to establish diagnostic and differential diagnosis, with accuracy, of the diseases",
        "label": 0
    },
    "1573": {
        "output": "[TUTOR_1]=\n\n\n[TUTOR_3]=\n\n## 3.4.5.0.4.4.3.6.1]\n[INST] It is time to apply your knowledge of the ICH Guidelines.\n\nLet's continue with the clinical trial, named Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients. (Please observe, that the title is written in TitleCase)  \n\nThis case will show an error. It is an example how to assess the risk of bias (RoB), evaluate the risk of bias (RoB) and summarize the risk of bias for the overall study. You should assess the RoB domain by domain and overall by study.\n\nFirstly, please read each domain of the RoB table to understand the questions (marked in GREEN): \n\nAs part of their inclusion, participants are randomized to receive influenza A(H1N1) 2009v vaccine, H561 A(H5N1) vaccine or H1655A(H1N1) vaccine. Subjects also have to be enrolled and vaccinated from their own choice of medical group, medical center, private clinic or physician (in the USA). In 21 the study group had a balanced gender distribution with slight male predominance, the most common race in 2A509 US adults. \nTreatment schedule for  in 21 and 2A509 group was same, receiving 3 intramuscular 1 mL doses at weekly intervals. If one group used 50 \u00b5g, the other 100 \u00b5g. \nVaccine administration is done by injection into the deltoid muscle of the arm. A needle length 1.6-1.7 inches is suggested to avoid pain for obese or overweight subjects. All subjects were closely monitored after vaccination or during infusion. \nThe incidence of local or systemic side effects (such as: pain, erythema, swelling, fever, chills, nausea, headache, malaise), solicited adverse events (",
        "label": 2
    },
    "1574": {
        "output": "4. If the assessment of eligibility is: `Not relevant`, do the following (select the option which is most relevant. Avoid using the backspace and click on the next question when you have already selected an option. This will create a sequence of steps and you cannot go back to select another option): The patient has not yet been screened. He is a 42-year-old man who has been suffering from HCV since 1996 and was also chronically infected with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the period of past 9 months. He is on no other medications. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 127/72, HR: 87/min and BMI: 26. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere is the clinical trial: Title: Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients Summary: OBJECTIVE(S): Primary:~To assess the safety of the intrahepatic reinfusion of increasing numbers of autologous highly purified CD133+ stem cells (SCs) to patients with end-stage liver disease. Safety will be evaluated as the incidence of adverse event (graded according to WHO) and clinically significant abnormal laboratory value following reinfusion of SCs.\n\n\n~Secondary:\n~To assess the feasibility of the immunomagnetic selection of autologous CD133+ cells collected with leukapheresis from the peripheral blood (PB) of patients with end-stage liver disease, previously mobilized with G-CSF. To assess the effects of the intrahepatic reinfusion of highly purified CD133+ cells on residual hepatic function of the patients.\n\n\n~STUDY DESIGN:~Twelve patients",
        "label": 0
    },
    "1575": {
        "output": "<EOD> The Relationship Between Periprocedural Myocardial Infarction and Major Adverse Events at 30 Days Following Coronary Chronic Total Occlusions\n\nBackground--Periprocedural myocardial infarction (MI) after coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with increased risk of mortality at late follow-ups. However, the prognostic value of periprocedural MI at short-term and prognosis-predictive factors for periprocedural MI have not been fully investigated.Methods and Results--Among 626 patients who underwent CTO-PCI enrolled between 2009 and 2015, we identified patients without major adverse cardiac events (MACEs) at 30 days (n=515, the nonevent group) or patients with incident MACE at 30 days (n=111, the event group). Periprocedural MI was defined as an elevation of CK-MB and troponin-I to greater than the upper reference limit. We compared procedural and clinical characteristics and 30-day follow-up findings between the event and nonevent groups. MACE occurred in 12.4% (111/896 cases) patients, and periprocedural MI was identified in 8.7% (101/1163 cases) patients. Multivariable logistic regression analysis revealed that periprocedural MI-as well as lesion-related factors including the use of intravascular ultrasound, multiple lesions in a single artery, and severe intraprocedural coronary sinus flow obstruction-were independently associated with 30-day MACE occurrence. However, periprocedural MI or severe intraprocedural coronary sinus flow obstruction was not associated with long-term MACEs, and those who had periprocedural MI and severe intraprocedural coronary sinus flow obstruction showed a relatively good prognosis compared with those who had only periprocedural MI or only severe intraprocedural coronary sinus flow obstruction.Conclusions--Per",
        "label": 0
    },
    "1576": {
        "output": "[INST] First, let's have a look at the number of patients and the number of clinical trails. The graph shows that there are some data variations. The number of patients and number of trials is different every month. The data is shown after August 2015 because we need to have the current information for the patient and trial",
        "label": 0
    },
    "1577": {
        "output": "***\n\n## [SEP] Evaluation\n\nEvaluation is often called ``analysis'', too, but if you say only `evaluation`, it is clearer that you mean `quantitative evaluation,' or something similar. \n\nYour task is to evaluate the results of the trial and assess if every patient qualified from the trial. The method of assessment is simple, but you must pay attention to a very important point. You must assess whether the results of the trial match the inclusion criteria, because you should never judge the patients by the results of the trial, but by the inclusion criteria. \n\nThe way you should assess the patients is to create a new variable called Inclusion in trial. If a patient qualifies, you must enter 1. All other patients, who do not meet the inclusion criteria, must be entered as 0. Use this variable to create a new column.\n\nThere are two situations. \n\nIf the patient is classified as `Excluded` or `Not relevant`, the value of the `Inclusion in trial` variable for that patient will be 0. \n\nIf the patient is classified as `Eligible`, the value of the `Inclusion in trial` variable for that patient will be 1. \n\nYou should always use `Trial-level eligibility:`. However, you must also use `Inclusion in trial:`.\n\nTo obtain the proportion of patients who are qualified from the trial you should divide the number of patients classified as `Eligible` with the number of patients evaluated (i.e., the sum of the `Eligible` and `Excluded` patients).\n\n**Task:** [SEP] Evaluation. \n\n**Task:** [SEP] Evaluation.\n\n[/SEP]\n\n\n*  - How to count \u03c0 among all irreducible fractions in the triangle ABC? \n* {5+5}{4+3}=?\n* {5+5}{4+3}{4+2}{3+2}=?\n* 432+4321313+4321313141=?\n* The following sequence:\n\t- a_1 = 3\n\t- a_i = (a_{i-1}+2)^2; i = 2, 3",
        "label": 0
    },
    "1578": {
        "output": "## EXERCISE_1_5_eligibility -------------------------------------------\n\n\n# Exercise 1.5\n\nCongratulations, you just finished Exercise 1.5. You are a helpful assistant for clinical trial recruitment and have successfully determined the patient's eligibility for a clinical trial. Let's continue.\n\n\n##[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe patient is a 57-year-old man diagnosed with HCV 4 years ago and is currently on treatment with IFN and direct antiviral drugs for the past 2 months. His past medical history is significant for diabetes, hypertension, hypercholesterolemia, neuropathy, and coronary heart disease. He takes no other medications. His medical records do not show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, or metabolic liver disease.\nThe patient's baseline laboratory values were within reference ranges and his medication regimen did not pose contraindications. He is an alert male with no acute distress. His BP: 140/75, HR:90/min, and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. He had a negative pregnancy",
        "label": 1
    },
    "1579": {
        "output": "<EOD> A case of paroxysmal intra-cranial hypertension: a late onset following head injury.\nFollowing a head injury a 35 year old male developed 7 paroxysms of intense headache and blurred vision in 6 days. After several weeks he died comatose, with generalized cerebral edema and bilateral basal exudative cysts in the occipital horns of the lateral ventricles which communicated with the subarachnoid space. Autopsy also revealed thrombosis of the left internal carotid and basal subcutaneous hematoma of the scalp. The mechanism of the ocular symptoms is supposed to be an abnormal intracranial pressure which was not clinically evident, because of the brain damage.<EOD> Impact of the COVID-19 pandemic on cardiology trainee education: Lessons for the future\n\n\n\n## M\neaningful education is an essential component of cardiovascular education and training for the next generation of medical professionals. [bib_ref]  ACCF/STS/AATS/AHS presidential panel discussion: how to avoid a physician manpower bubble, Epstein [/bib_ref]  [bib_ref]  Cardiovascular education in the United States, Jacobs [/bib_ref]  The COVID-19 pandemic has led to unforeseen and evolving disruptions in traditional cardiology trainee training curricula, with significant ramifications for cardiovascular education in the short, medium, and long-term. Here we present a brief review of the impact of the pandemic, and provide suggestions as to how to use these challenges as a stimulus for innovation and rejuvenation of cardiology educational curricula.\n\n## Current educational constraints and challenges\nAs a specialty, cardiology has faced a unique set of constraints and challenges, with regards to trainee education. These challenges exist over and above traditional constraints that face all other specialties, given the highly technical nature of cardiovascular training. These challenges are best appreciated as [fig_ref]  Table I: Constraints and challenges facing trainee education in cardiology* Disparities in care for... [/fig_ref]  : (1) a rapidly growing number of subspecialist",
        "label": 1
    },
    "1580": {
        "output": "[END]\n\n___\n\n[PUR]\n# PURPOSE\nThis task determines whether a patient meets the inclusion criteria or does not meet the inclusion criteria to determine the patients' eligibility.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness.",
        "label": 0
    },
    "1581": {
        "output": "[END]\n\n# Implementation Notes:\nSome eligibility tests have more than one inclusion criteriasometimes even with conflicting criteria.\nThere is special case of an inclusion criterion whose truth value is ambiguous in presence of another inclusion criterion. This is typically resolved by choosing the maximum of the eligibility scales for each inclusion criterium.\n\n## Example 1.\nThis is taken from the same [dataset][url] as Example 3. Please refer to the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. He took no medications on the morning of trial, and his medication list included ramipril, hydrochlorothiazide, acetaminophen, and magnesium citrate. He has no allergies to any medication. He consumes alcohol socially and smokes cigarettes (more than \u00bd pack of cigarettes per day).\nThe patient has chronic active hepatitis C virus. The patient has had an elevated baseline bilirubin throughout the past 2 years. The patient does not have advanced fibrosis or cirrhosis, as evidenced by a normal platelet count, normal international normalized ratio, and normal alkaline phosphat",
        "label": 1
    },
    "1582": {
        "output": "[CERTIFICATION] I certify the above is a true and accurate representation of my experience. [Certification]\n\n[/CERTIFICATION]\n\n## Hands-on exercise\n\n## Exercise 1: Eligible \n\n### Repeat the above procedure from the patient note to the clinical trial.\n\n## Exercise 2: Not eligible\n\n### Repeat the above procedure for the following patient, but this time the patient does not meet the inclusion criteria.\n\nThe patient meets the exclusion criteria for a clinical trial because she has had a previous blood transfusion and/or received any HCV direct acting antiviral treatment.\nHere is a patient note.\n\n\n[Trial-level eligibility: Not eligible. \n<EOD> A Study of Reactions of HNO/NO with NOX, OX/O2 \u2212, and O 2: Influence of Water\n\nThe effect of water on reactions of nitrogen dioxide ( 2 NO 2 ), nitric acid (HNO 3 ), nitrous acid (HNO 2 ), and nitrogen monoxide (NO) with NO x , O x , and O 2 radicals was studied by molecular dynamics simulations. Our findings indicate that while adding H or O water molecules to the surface decreases the adsorption energy of NO on the surface H ad and O ad , it increases the adsorption energy of NO 2 =H on the surface NO x =H, O x =H. Similarly, H ad and O ad are lower when at the surface NO x =H and O x -NO 2 =O than in the gas phase. However, the opposite trend is observed for the adsorption energies of NO 3 =H and O ad , and NO 2 =H and O x -NO 3 =O. Hence, adding H or O water molecules to the surface increases the adsorption energy of NO 2 , NO 3 , or HNO 2 , and NO and decreases that of NO 2 , NO 3 or HNO 2 , and NO on the surface in the presence of water. Our results indicated that introducing H or O atoms on the surface decreases adsorption energy of NO on NO x =H",
        "label": 1
    },
    "1583": {
        "output": "### Incremental-Hadoop-Elasticsearch\nTo run Elasticsearch (https://elastic.co/) on Kubernetes with a Hadoop and Spark environment, please follow [in-memory HDFS Elasticsearch](http://www.baeldig.com/2014/03/13/hadoop-hadoop-io-elasticsearch/). Note that in this example, Kubernetes is used as an orchestrator, but Hadoop is only used to provide a secure storage system, where other Hadoop modules can run. [Tutorial](https://www.baeldig.com/2014/03/13/hdfs-hadoop-io-elasticsearch/).\n\n\n\n\n## Elasticsearch\n\n### 1.\tPrepare Elasticsearch in Kubernetes\n\n#### Configuration Options\n\n**Elasticsearch**:\n\n* [Hadoop-Elasticsearch](http://www.baeldig.com/2014/03/13/hdfs-hadoop-io-elasticsearch/)\n* [Incremental-Hadoop-Elasticsearch](https://github.com/kubernetesioD/incr/commit/d270c621943ff6d01479e3d9c362919ac84a9c81)\n\n**Elasticsearch-with-Spark**:\n\n* [Dashboard](http://kubernetes.io/docs/user-guide/cluster-administration/dashboard)\n* [Elasticsearch with Spark](http://kubernetes.io/docs/user-guide/cluster-administration/dashboard/cluster-customization/elasticsearch-spark):\n  * Dashboard to show `Elasticsearch with Spark`:\n    * Kubernetes version: https://github.com/kubernetesio/elasticsearch-dashboard/tree/master/kubernetes\n    * Go version: https://github.com/KubernetesChina/elasticsearch-with-spark/tree/v1.6.0\n    * Elasticsearch version: Elasticsearch v1.7.5-k8s\n* [Kubernetes with Elasticsearch with Spark](https://github.com/KubernetesChina/elasticsearch-with-",
        "label": 0
    },
    "1584": {
        "output": "# Relieve symptoms (for 192992)\nYou are currently playing as Clinical researcher. Your task is to relieve the symptoms of the patient from headache, insomnia, and fatigue. You must enter one of the symptoms: headache, insomnia, and fatigue. Include both the assessment of eligibility, i.e., `Trial-level eligibility: 2) Eligible.`.[INST]\n\n### Headache \nHeadache is the most common symptom in patients with cancer. It is reported in 30 to 50% percent of patients with cancer. It also can be present in about (25%) percent patients with an infection.\n\nIt is characterized by having no known cause and is often described as 'throbbing'. Unlike other pains, headaches do not get better with rest or cold temperatures.\n\nHeadaches in the back of your head are often related to headaches in the front of your head.\n\n# Take medication (for 305536)\nYou are currently playing as Clinical researcher from ICTM. Your task is to relieve the symptoms of the patient after taking caffeine. So, enter your decision on whether to take the medication with [INPUT] to choose `1-Caffeine` and `0-No Caffeine`. As your decision, enter your name in which you need to make an assessment of overall satisfaction. This decision will also have an effect on the final outcome of the case. \n\n# Exercise (for 194169)\nYou are currently playing as Clinical researcher. Your task is to reduce body mass index from the patient. You need to enter an exercising decision with [INPUT] to choose `1-Yes` and `0-No`.\nEnter in overall satisfaction of the patient for your decision. As you do, you should decide on whether to prescribe the vitamin D intake.\n\n# Take medication (for 11731)\nYou are currently playing as Clinical researcher. Your task is to relieve the symptoms of the patient from muscle spasms. You must enter one of the symptoms: leg cramps, muscle",
        "label": 0
    },
    "1585": {
        "output": "### <img src=\"https://d3io52.vercel.app/assets/img/book_readme_screenshots/screenshot1.png?id=\"> \nHmm. The factors are different between patients' notes and clinical trials. To resolve this issue, we can convert the trial-level eligibility to the patient-level eligibility, by calculating patient-level eligibility as a weighted sum of corresponding trial-level eligible, 0, or not relevant factors. Then, the patient-level eligibility is mapped to patient-level eligibility as eligible, excluded, or not relevant. To make the patient-level eligibility, we follow the patient note analysis as follows.\n\n**Steps** to calculate patient-level eligibility: \n<img src=\"https://d3io52.vercel.app/assets/img/book_readme_screenshots/screenshot3.png?id=\"/>\n\nPlease find more code in the 6.7.1 Patient-level Eligibility subsection. \n\n\n### Example\nLet's assume we have a patient note as follows: \n<img src=\"https://d3io52.vercel.app/assets/img/book_readme_screenshots/screenshot2.png?id=\"/> \n\n\nAnd a clinical trial as follows: \n<img src=\"https://d3io52.vercel.app/assets/img/book_readme_screenshots/screenshot4.png?id=\"/> \n\nFirst, we will create a trial note for this sample. \n<img src=\"https://d3io52.vercel.app/assets/img/book_readme_screenshots/screenshot5.png?id=\"/> \n\nAfter completing trial note, you should see the trial notes have been constructed from the clinical trial. The patient note of the patient is the same as the trial note of the clinical trial and patient-level eligibility is automatically generated for the patient. You can see the trial-level eligibility 2 and 0 while the patient-level eligibility is 2.33",
        "label": 1
    },
    "1586": {
        "output": "# How to do this by yourself\nNow, let's show how to write functions to generate the test cases. The patients and clinical trial information is already available on the wiki. In the next section, the functions to generate data are shown.\n\n## Generating data\n\n`// Generating random numbers at the patient level `random_data = rand(5);\n\n`// Generating random numbers at the clinical trial level `random_trial = rand(2);\n\n## Generating patient data\nIn this case, all the patients randomly pick clinical trial according to the random_trial. Then all the patients will be eligible for the 2nd clinical trial if the trial_num = 2.\n\n`% Clinical trial information to eligibility\ntrial_num = random_trial;\nexclude_criteria = random_data;\n\n`// Generating the number of patients eligible for the trial `number_eligible = 2*rand(trial_num);\n\n`// Generating the number of patients excluded on ground of the exclion criteria for the trial `number_excluded = number_eligible- rand(exclude_criteria);\n\nHere, we show how to generate only one trial to get all patients eligible and all patients not eligible (or vice versa). This process will give all possible combinations of patients who are eligible (and who are not eligible) for our trial.\n\n`// Generating trial information to one patient `trial_num = integer rand;\n\n`// Generating the number of patients eligible for the trial `number_eligible = random_data^(0, trial_num);\n\n`// Generating the number of patients excluded on ground of the exclion criteria for the trial `number_excluded = random_data^((1-trial_num), trial_num);\n\n## Generate a clinical trial\nNow, we will generate a random clinical trial which include 25 patients. For this case we will include the random eligibility of both clinical trials.\n\n`% Clinical trial information to eligibility trial_num = 1;\nexclude_criteria = range(0,100); `// Theoretical",
        "label": 0
    },
    "1587": {
        "output": "## [QUEST] How do I generate the results of simulation study in simulation_report.ipynb?\n\nYour task is to generate a simulation study report.  [CODE]\nTo prepare your simulation study, you should use the code given in ``Simulation study`` section of the previous task.\n\nFrom the [Output](https://github.com/statcomp/statcomp7k/blob/master/book_data-winter_2018/inst_7k_exercises.pdf) of the following code, you should make the list of the generated data. The `n` of the output is the `n` used for the simulation of clinical trials, e.g., `nsim = 10` for 10 simulated clinical trials.\n\n```python\nif __name__ == '__main__':\n    # To generate the list of the reproduced data\n    # for _ in range(nsim):\n    #     # Set trial-level eligibility according to the given trial.\n    #     # There are 100 observations in each patient note.\n    #     # The simulated trial includes 20 patients who have 5 observations.\n    #     # Hence, there is a total of 1000 observations.\n    #     # The output is a list containing trial-level eligibility of trial with index `i` and the list of observations with index `kz` at patient numbers `np` from `npat` replicated on `npat` simulated individuals with unique patient identifiers `pnum`.\n    #     # \n    #     # Assign to random variables.\n    #     # The random variables have parameters given in the R file.\n    #     # \n    #     # Call `rand(npat*5*100,rng=rngID)# and `rand(nsim,rng=rngID)` for replication of pseudorandom numbers in the original data file.\n    #     # The `rand()` function in `Scipy` is called by `numpy.random.rand()` in the `numpy` module.\n    #     # It creates random numbers between `0` and `maxValue` for the real number type and between `[0,1)` for the boolean type.",
        "label": 1
    },
    "1588": {
        "output": "## Part 2. Data preprocessing: Patient's history is described using R's `read_csv()` function\nThe first step is to read the patients' history file, which has information such as ID patient # , surname(last), first name(given) , date of birth and gender. In addition, the file contains comorbidities and information when the patients were included in clinical trials. You should always convert the variables to a character type before importing them to the data frame so that they become column names. For example, ID patient # should be ID;`date of birth `should be DOB;`surname(last)`should be LAST, and so on. `\nThe second step is to import the clinical study file. The clinical trial file contains the following information in the long patient study ID variable:\n\npatient study ID is a combination of the patient ID number and the trial ID number.\n\nThen, in the next step, you can make a matrix by joining the patient's history (Patient_history.csv) file with the clinical trial (Clinical study.csv) file. \n\nPlease see\n[INST-Part-2/Part-2] (https://github.com/khalidqamr19/Inst-Part2/tree/Part-2).\n\n## Part 3. Determine the eligibility, in R, of patients for each clinical trial based on specific eligibility criteria.\nThere are several criteria for eligibility for a clinical trial. These include age, gender, type of disease, its stage, previous treatment, and other medical conditions. The criteria may be expressed either in a descriptive style, i.e., yes or no, or as numerical values; for example, \"Age above 18\" can be expressed as `Patients >= 18 AND <= 98`.\nThus, the eligibility criteria for a clinical trial are described first in the long form (`criteria.csv` file) and then in the tabular format (`tab_trial_level.csv` file). \n\nPlease see\n[INST-Part-3/Part-3] (https://github.com/khalidqamr19/Inst-Part3/tree/Part-3).\n\n## Clinical trials and coh",
        "label": 1
    },
    "1589": {
        "output": "[TIP]\nAfterwards, please add a line by `END`. You will notice the boldface text '[Augment] Clinical trial:' that will disappear soon. This is a good way to detect when to terminate the block.\nWhen terminating the block, write `END`.\n[INST] END.\n\n# [MASTOID] The mastodynia(breast pain) clinical trials database\nHi! You are a general practitioner who received a patient appointment to perform an assessment of the patient history. You are going to see a 31-year-old woman who complains of pain in both breasts, more in the left breast. The pain begins 4 days ago, is sharp and it is associated with headache. She also says that she has a mild fever, cough, chills and sore throat for the past 7 days.\nYour job is to assess the eligibility for clinical trials on the basis of your clinical knowledge of breast pain. The eligibility criteria are the following:\nThe patient is a 31-year-old woman with no significant past medical history. She has a history of arthropathy and oligomenorrhea. She uses an IUD and levonorgestrel-releasing intrauterine system (Mirena). She has a positive family history for anemia, hypertension and thyroid disease, with no history of malignancy. She is not allergic to any drug, is not pregnant and has no history of lactation. She is a non-smoker but has lived with a smoker for more than 10 years (1 pack per day). She is on contraceptive pill (Diane-35 ED).\nThe patient examination did not reveal any abnormal signs except for a positive acoustic shadow on the examination of the abdomen. Her BMI was 28.2 kg/m 2 , BP: 140/75, HR 85/min and T: 37.2 - C.\nBreast examination revealed normal breast size, normal vaginal opening, normal anal sphincter tone, and a positive gynecological exam. No abnormal masses or nodules were identified on the gynecological exam",
        "label": 0
    },
    "1590": {
        "output": "You can write a clinical trial note to compare patients and clinical trials by using the `Trial-level eligibility` and `Patient-level eligibility` methods.\n<EOD> Surgical treatment of patients with pulmonary tuberculosis in a general practice unit in Cape Town, South Africa\nThe incidence and presentation of pulmonary tuberculosis (TB) differs markedly",
        "label": 1
    },
    "1591": {
        "output": "# Results\nThis task is now complete. If we open our trial.txt file in R or Python, we get an object. In Python, we can print the object to see what it contains or we can print the trial.txt entry for a particular patient or trial. You can also use the `tabulate` function which is a package included in the Tabulate package [INCLUDE: https://packt.atlassian.net/project_page/package/tabulate].\nBelow is an example in Python. See S5 File for the code.\n\n## Python:\nWe can take a look at the individual patient's and trial's characteristics with the following commands:\n```noqa\nfrom tabulate import tabulate\n\nprint(tabulate(patients))\nprint(tabulate(trials))\n```\nNoqa\n```\n+----------------------------------------------------------------------------+\n|  [0] trial-ID\n+----------------------------------------------------------------------------+\n| [ 1] inclusion criteria\n+----------------------------------------------------------------------------+\n| [ 2] exclusion criteria\n+----------------------------------------------------------------------------+\n| [ 3] trial-level eligibility\n+----------------------------------------------------------------------------+\n| [0]\n+----------------------------------------------------------------------------+\n|     [0] ID\n+----------------------------------------------------------------------------+\n|     [1] sex\n+----------------------------------------------------------------------------+\n|     [2] age\n+----------------------------------------------------------------------------+\n|     [3] marital status(1=yes; 0=no)\n+----------------------------------------------------------------------------+\n|     [4] race\n+----------------------------------------------------------------------------+\n|     [5] race (2)\n+----------------------------------------------------------------------------+\n|     [6] country-origin\n+----------------------------------------------------------------------------+\n|     [7] education\n+----------------------------------------------------------------------------+\n|     [8] previous-hepatic degenrative complication? (1=yes; 0=no)\n+----------------------------------------------------------------------------+\n|     [9] cirrhosis\n+----------------------------------------------------------------------------+\n|     [10] alcohol-drinking-status (non-drinker, light drinker, occasional drinker, social drinker, excessive drinker)\n+----------------------------------------------------------------",
        "label": 1
    },
    "1592": {
        "output": "This trial is eligible for three patients. You only need to check the `not relevant` ( 0) line.\n~1~,~~ ~2~~,~~ ~1~~ \n~2 \n\n\n> ## [INST END]\n\n[/CODE]\n\n## Inspection and Testing\nYou just need to save the output file as CSV (*.csv; comma delimited) and save it in your system folder. A report of performance indicators will be used to calculate the following:\n\n# Data output results\nTo visualize the results, the data should be imported into an Excel file from the CSV file, or a table can be prepared for the analysis using the pandas PivotTable tool. We need the 'Trials by Subjects' variable to calculate the trial level eligibility and to visualize the data for inspection and testing. \n```\n~data = pd.read_csv('../output 1124_05.csv')\n~data.head()\n\n                              ID            Trials by Subjects            \n0                   55            1.0           (9.631325400026,62.33190196981)   \n1                   55            1.0           (23.83123066406,69.2088513267)  \n2                   49            1.0           (27.03770584472,60.10130862249) \n3                   49            0.5            (27.03770584472,54.94287290493) \n4                   49            1.0           (32.05761254338,57.61498671856) \n5                   49            1.0           (27.03770584472,62.04973138793) \n6                   55            0.5            (18.194353",
        "label": 2
    },
    "1593": {
        "output": "## 7.\nCongratulations! You've worked on a clinical trial protocol again. You are going to submit this to the board review and finally join the team of clinical researchers \ud83d\ude4c\n<EOD> GDF15 Promotes Dentinogenesis in Human Dental Pulp Stem Cells by Upregulating DSPP\n\n\n\n# Introduction\nDental pulp stem cells (DPSCs) are derived from dental pulp, and are isolated and identified based on the expression of SC-specific markers such as the surface marker CD146. DPSCs display multipotency, and are able to differentiate into odontoblasts, adipocytes, osteocytes, chondrocytes, and other cell types. In the human body, DPSCs play important roles, participating in self-regeneration and repair of dentin, maintaining the stability and integrity of teeth, and promoting the repair of bone tissue.\nDental pulp stem cells are in a state of active proliferation and division, requiring large amounts of nutrients. Growth differentiation factor-\u03b2 (GDF15) is a cytokine that promotes nutrition in the body, mainly in the cardiovascular system. GDF15 induces the expression of a variety of vascular nutritional factor genes (e.g., vascular endothelial growth factors) to mediate the regulation of nutrition for the body. Recent studies have shown that inhibition of GDF15 can reverse diabetic cardiomyopathy by inhibiting oxidative stress . Furthermore, overexpression of the GDF15 gene in C57BL/6 diabetic mice reversed diabetic cardiomyopathy by inhibiting oxidative stress and improving metabolism . Our group preliminarily observed that overexpression of GDF15 plays a role in osteogenesis, mediating the expression of some osteoblast-related genes . However, the specific mechanism through which GDF15 affects the proliferation and differentiation of DPSCs remains unknown. To improve the proliferation and osteogenic differentiation of DPSCs, we examined whether G",
        "label": 0
    },
    "1594": {
        "output": "___\n\n[PROPOSAL_ID] M98464.txt<EOD> Effect of pH on the Antimicrobial Activity of a Chlorhexidine and Listerine Holder Solution\n\nO bjective: This study evaluated the effect of pH on the antimicrobial activity of a chlorhexidine and Listerine holder solution on Enterococcus faecalis. Material and Methods: Seventy-eight dentin blocks obtained from human molars were used. After the dentin surfaces were pulverized, 1 mL (0.2%) of the solution was placed on the dentin surfaces. Microbiological samples were collected initially, 10, 20, 30, and 60 min, 4, 8, and 12 h after the dentin surfaces were treated with the solution. At each sampling, the solution was collected, serial dilutions were performed, and aliquots from samples were inoculated in the Mitis Salivarius agar medium. After the incubation period, the morphology of the colonies was observed. Results: The results showed that the concentration and incubation period influenced the antimicrobial response of E. faecalis. Moreover, it was observed that with longer incubation periods, there was a reduction in the antimicrobial effect of the solution. Conclusion: The higher the incubation period, the less pronounced was the effect of the solution, in spite of its high bactericidal effect.\n\n# Introduction\nThe formation of niches in the root canals by the action of irrigation solutions in endodontics has been described. [bib_ref]  Correlation between residual bacteria and clinical outcome of endodontic treatment performed with..., Oliveira [/bib_ref]  [bib_ref]  Microbiological basis of endodontic therapy, Reimann [/bib_ref]  After clinical treatment, the residual presence of microorganisms in the root canal system is an important cause of failure in endodontic therapy and, consequently, of endodontic treatment. [bib_ref]  Correlation between residual bacteria and clinical outcome of endodontic treatment performed with..., Oliveira [/bib_ref]  [bib_ref]  Microbial analysis of root canals of teeth with chronic apical periodontitis, Baca",
        "label": 1
    },
    "1595": {
        "output": "## 021_HCV_example_04\n[MAT_TEST]\n\n```\nHCV_Example 4\n[Trial]\nTrialName: A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C, Short Title: A Study of GS 5885 in Patients with Chronic HCV\nTrialState: Active, Recruiting\nEnrollmentStartDate: 28/02/2013\nEnrollmentCloseDate: 08/05/2015\nTotalAccrual: 183\nCurrentAccrual: 118\n\nFunding: ClinicalTrials.gov ID: NCT01993977 -\n\nTreatmentSummary: Exact treatment regimen has not yet been reported.\n[MAT_HEAD]\nDescription: The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection\n\nTargetConditionConcept: NCT01993977: HCV\nConditionMeSH: HCV\n\nClinicalTrials.gov ID: NCT01993977\n\nTrialName: A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C, Short Title: A Study of GS 5885 in Patients with Chronic HCV\nTrialName: Protocol: A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C, Short Title: A Study of GS 5885 in Patients with Chronic HCV\nTrialState: Active, Recruiting\nEnrollmentStartDate: 28/02/2013\nEnrollmentCloseDate: 08/05/2",
        "label": 1
    },
    "1596": {
        "output": "## Data visualization? \nThe power of graphics and visualization is to create an easy to understand story about the underlying data. Whenever you are unsure of a way to interpret your data consider the following design principles: \n- Present multiple views of data. This gives the user the ability to explore data from multiple angles. A single graph might not fully capture the intricacies and nuances of your data.\n- Avoid excess",
        "label": 0
    },
    "1597": {
        "output": "<EOD> The development of pigment production during chick embryogenesis as revealed by the ultrastructure of the reticuloendothelial system.\nUltrastructural aspects of the pigment synthesis and transportation in the reticuloendothelial system of developing chick embryo are presented. From 7 to 11 days of development, the liver cells are characterized by the presence of large single-cavity vesicles containing electron dense particles. The hepatocytes, from 12 days of development on, are characterized by the presence of double-cavity vesicles with a narrow lumen. It is concluded that there is some kind of relationship between the liver pigment stores and the erythroid system. The melanosome is formed in the melanoblast from large vesicles, probably derived from the rough endoplasmic reticulum. The melanosomes are engulfed by endothelial and reticulum cells of the blood capillaries. Melanosomes located within cytoplasmic vesicles are carried across the cells and enter the blood capillary directly. This way of transportation is more frequently encountered in the embryos of 10 and 12 days of development. It is concluded that the liver of the chick embryo serves as a melanosome reservoir, and that the embryonic blood capillaries are involved in pigment transportation via the mediation of endothelial and/or reticulum cells.<EOD> Antibiotic Susceptibility of Helicobacter pylori Isolates from Patients in Japan to New Antibiotics\nObjective: We determined the in vitro antibiotic susceptibility of Helicobacter pylori isolates to novel antibiotics, including lansoprazole, fluoroquinolones, and tetracyclines.<EOD> .\nA 38-year-old man visited our hospital complaining of left-flank pain, which had persisted for 1 month. Abdominal computed tomography (CT) scans revealed the presence of a tumorous lesion of 6.3 cm in diameter in the left kidney, as well as enlarged lymph nodes in the retroperitoneal area and in the hilar region of the left",
        "label": 0
    },
    "1598": {
        "output": "[/SILVER]# SILVER-NLP\n\n## Overview\n\nHere are detailed configuration files of the [`SILVER-NLP`][123] pipeline for the following task:\n  * [Trial Level Classification Task in the `Scientific Article Pipeline`][124]\n\n## Ner\n\n```yaml\n### Document Dividing\ndocument_dividing:\n  file: ./NER/docs_dividing/\n\n### NER and Token Filtering\nner:\n  file: ./NER/NER.py\n\n### Token Filtering\ntoken_preprocessing:\n  file: ./NER/token_preprocessing.py\n\n### Token Splitter/Merger\ntokenize_splitter_merger:\n  file: ./NER/token_splitting_merging.py\n\n### Entity and Entity Class Tagging\nentity_classify:\n  file: ./NER/entity_classification.py\n\n### Token Embedding\ntoken_embedding:\n  file: ./NER/token_embedding.py\n\n### Entity-entity Embedding\nentity_entity_embedding:\n  file: ./NER/entity_entity_embedding.py\n\n### Entity and Entity Class Extraction\nentity_extraction:\n  file: ./NER/entity_extraction.py\n\n### Entity and Entity Class Classification\nentity_classification:\n  file: ./NER/ entity_classification.py\n\n### Entity and Entity Class Dividing\nentity_dividing:\n  file: ./NER/entity_dividing.py\n\n```\n[124]: https://github.com/jjeffcoach/silver-nlp/blob/master/ner.md\n\n\n## Entity and entity class extraction\n\n```yaml\n# This is not required but it is strongly recommended.\n# It will improve the entity and entity class embeddings.\ntoken_embedding:\n  - mode: training\n    token_emb:\n      - file: ./BERT-smallCNN-6L/pretrained_bert-base-char-uncased_L-12_H-12_A-12_2048",
        "label": 1
    },
    "1599": {
        "output": "# Recommended Use Cases\n\n## Clinical Trial Screening\n\nFor each new visit in the clinical trial, patients need to have a screening visit before enrollment to the trial. Screening in the clinical trial usually involves:\n\n* medical history\n* medication\n* physiology measurement\n* laboratory test (HCV RNA for HCV, HBV DNA for HBV, and other)\n* pregnancy test for women\n* psych evaluation for drug addiction test\n\nBefore enrollment, it is highly recommended to repeat these screenings during the clinical trial. We have listed one of our clinical trials below, which will recruit newly treated patients after diagnosis.\n\nTrial Description: (https://clinicaltrials.gov/ct2/show/NCT00988326)\n\n\n# METHODS\n- Inclusion Criteria\n\n* Eligible subjects will be men and women between the ages of 18 and 65 enrolling in the CNHS after HCV infection diagnosed less than 12 months prior to screening.\n\n* There will be no other known liver disorders or significant illnesses that would make them a poor candidate for study participation.\n\n* There will be no current active or heavy alcohol use or any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study.\n\n* There will be no history of signs or symptoms of decompensated liver disease.\n\n* Hepatitis B surface antigen, HBV DNA, and HCV RNA testing must be negative.\n\n# Results\n\nIn this screening cohort study of CNHS participants newly antiviral treated, we identified: (1) a very high dropout rate in early antiviral treatment course, and (2) high prevalence of potential side effects of antiviral therapy, which may have substantial impact on the overall outcome of the study.\n\n# Sources\n\nTrial Description:  (http://ct.gov/national/nct00988326/)\n\n\n# Inactive Objectives\nAdd missing values for all patients in visit 1 for the following parameters",
        "label": 1
    },
    "1600": {
        "output": "## Problem 3\nThe output text is hard to read.\n\n## Potential solution\nApart from the possibility of problems with the training data, consider making your training files more specific. The best way to make training more robust against spelling mistakes would be to create your own data with proper grammar. The example in the tutorial is short and does not contain any sentence that cannot be easily understood by people who are not involved with clinical studies. You may also consider the use of a spelling checker such as the one provided by nlp3s (https://nlp3s.com/nlp/data/webpage/webpageSpeller.txt) to solve a spelling problem.\n\n## Problem 4\nThe result of the eligibility classification is not as expected.\n\n## Potential solution\nAfter running the provided code, you should see the result in the 'Eligibility' variable at the last line of the script. In case you are not satisfied with the proposed answer, try playing with other settings. One of the problems may occur when using more than one language (e.g., English, German, and Spanish) in the dataset. In this case, the training data should be carefully checked, as the dataset was prepared using English-speaking countries' data. In case you have your data in German or Spanish, please prepare it appropriately and test the program again with that specific language. If the problem with the incorrect classification does not change, then either the training data is poor or you are creating the problem by hand during running the code.\n\n## Problem 5\nMy data is not compatible with the tutorial.\n\n## Potential solution\nThe tutorial is intended to be used for data in a format similar to the dataset used in the tutorial. It is advisable, first, to check if the dataset is available, e.g., at kaggle or https://datahub.io/projects/healthy-lifestyle. The data must have at least one column with at least two answers and a third column with the text of each answer.\n\n## Problem 6\nI am interested in a subcategory but do not know how to extract it from the output.\n\n## Potential solution\nYou can easily split the output lines by the number of colons according to the number of categories for each variable.\nThe first example in 'Trial-level eligibility` is",
        "label": 1
    },
    "1601": {
        "output": "You're done.\n\n![30_eligibility2.png](/img/tutorials/inst-20.png)\n\n# 4. Patients vs trial patients\n\nYou've already dealt with only one patient (in section `Section A 4. Patients vs trial patients`), so you'll proceed to two of them (in section `Section B 4. Patients vs trial patients`).\n\n![31_patient_vs_trial_patient.png](/img/tutorials/inst-21.png)\n\nHere are the patients' notes. It's not that you can't use the same variable names in section `Section A 4. Patients vs trial patients` (in section `Section B 4. Patients vs trial patients`), so it is not mandatory to use different names for identical variable names: (It should be noted, however, that you can't use the same table names in section `Section A` (in section `Section B`) as the variable names are the same between two sections. If all the tables are the same, it is better to use the same names and different columns for the patients vs trial patients).\n\nAs the same as in section `Section A 4. Patients vs trial patients`, you should consider each factor in a column as a row. In this study, you should first compare each row (patient case) to a trial (two rows, two patients) as shown in Figs. 31 and 32, respectively, using `Section-1` and `Section-2` in the `Section` variable of the `patients` table:\n\n![32_patientsvssection1.png](/img/tutorials/inst-22.png)\n\nIn Fig. 31, note that each row `Trial-1` is compared to the two patients, and only one patient appears as `Eligible (1: eligible to the trial based on the trial's inclusion criteria; 0: excluded to the trial based on the trial`s exclusion criteria; and 2: not relevant) in the same manner as section A. In Fig. 32, note that only `Section-2` is compared to `Trial-2`. This is all. You're done.\n\n# 5. What-if",
        "label": 0
    },
    "1602": {
        "output": "<EOD> Enhancing the role of the public administrator/patient as consumer.\nThere has been a growing demand on professionals in health care settings to act more like entrepreneurs. This role change is occurring in light of the recent enactment of the Health Insurance Portability and Accountability Act (HIPAA). The new role of the consumer as a health care executive presents challenges and difficulties for both individuals and organizations. This article highlights the unique challenges in implementing this concept from the perspective of the public administrator/patient, and provides both theoretical and practical steps to guide public administrators/patients as they assume their new role in the health care provider system.<EOD> 129Xe chemical shifts in dimethyl sulfoxide. A structural study.\n129Xe chemical shifts in dimethyl sulfoxide (DMSO) mixtures have been measured down to 1.078 g/cm3 (0.4 kbar) and at temperatures between 265 and 303 K in a large frequency gradient field (2.5 T). The proton chemical shifts, derived from 1D-1H NMR spectra, were used for assigning the DMSO signals. It has been demonstrated that this method can be used to accurately determine the chemical shift difference between two different environments. The experimental values are found to be in agreement with calculated values within the error. This technique provides a useful tool in studies of the dynamics and structure of DMSO solutions, including pharmaceutical formulations.<EOD> Etiologic classification of dementia in a community-based patient sample.\nTo help elucidate the relationship of dementia to organic diseases, the authors studied 119 patients with varying degrees of dementia who were members of a managed-care organization for the elderly. Clinical ratings and cognitive and functional assessment data were supplemented with results of laboratory and imaging tests. For 102 of these patients, clinical information was available for 5 years (until patients entered nursing homes or died) to look for clinical signs of dementia precursors such as delusions, hallucinations, and minor cognitive changes. Thirty-two cases were judged to be dementia of Alzheimer's type, 60 v",
        "label": 0
    },
    "1603": {
        "output": "### Explanation\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. If the patient matches all the inclusion criteria and none is exclusion criteria should apply, then the eligibility is set to `2) Eligible`.\n\n### Scenario Based Training\n\n### Trial of a new medication for migraines\n\n#### Solution with explanation\n    Trial-level eligibility\n    trial-level eligibility:\n      [ 0] Excluded\n      [ 1] Not Relevant\n      [ 2] Eligible\n\n\n#### Solution\n\nYou should make a trial-level `eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nIn case the patient's age was in the range of 73 - 87 and the sex was female the assessment of eligibility should be \"Excluded\". If the patient was on at least 80mg of calcium channel blockers, the assessment of eligibility should be \"Excluded\". If the patient has normal to mild ankle edema the assessment of eligibility should be \"Not Relevant\". In case the patient meets all other criteria, the assessment of eligibility should be \"Eligible\".\n\n### Trial of a new cancer medication for patients of age 65 or older\n\n#### Solution with explanation\n    trial-level eligibility:\n      [ 0] Excluded\n      [ 1] Excluded\n      [ 2] Not Relevant\n      [ 3] Eligible\n\n\n#### Solution\n\nThe assessment of patient eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial'",
        "label": 0
    },
    "1604": {
        "output": "## Good luck!\n<EOD> A 2-Year, Prospective, Real-World Clinical Study of the Efficacy and Safety of Topical Tretinoin Gel 0.05% with the Prescription Recommendation Program (RxRP) Among Adult Women for the Treatment of Dryness, Fragility, and Scaling of Skin Due to Menopause-Associated Atrophic Eruption (MAE)\n\nIntroduction: Atrophic dermatoses in postmenopausal women are associated with loss of estrogen and vaginal atrophy, potentially leading to unpleasant itching and excoriation that can significantly affect quality of life in this population. This study evaluated the efficacy and tolerability of topical 0.05% tretinoin, a retinoid prescribed by clinicians as part of the US Food and Drug Administration (FDA)-approved RxRP. Methods: This single-arm, open-label study was conducted for 2 years and had no control group. It enrolled postmenopausal women with MAE who had been experiencing dryness, fragility, and/or scaling of their skin for longer than 3 months despite standard management or a contraindication to use of oral estrogens and topical agents containing estrogen or adrenal steroids. Overall treatment satisfaction and efficacy (using a 5-point Likert rating scale) were assessed at 3 monthly visits, and adverse events (AEs) were monitored; the effect was also monitored clinically. Patient satisfaction and physician assessments were evaluated using the Dermatology Life Quality Index (DLQI) questionnaire.Results: Seventy-one postmenopausal women (mean age, 58.0 years) with MAE (mean duration, 6.0 years) were treated. At baseline, patients had mild, moderate, or severe signs and symptoms of dryness, fragility, and/or scaling on up to 50% of the face and up to 98% of the affected body area. At 3 months, mean signs/symptoms of MAE were significantly improved (p \\ 0.0001), with 19.",
        "label": 1
    },
    "1605": {
        "output": "<EMAIL>: 1110506_C61231_snap_b7e03fee_p.htm\n<EOD> Diarrhea and abnormal intestinal absorption in patients on continuous ambulatory peritoneal dialysis: the role of uremic toxins released from the peritoneum.\nBACKGROUND\nDiarrhea is a frequent and often intractable problem in continuous ambulatory peritoneal dialysis (CAPD). We investigated the pathogenesis of diarrhea in two patients who were considered to have a uremic intestinal toxin produced within the peritoneal cavity.\n\n\nMETHODS\nWe studied intestinal absorption and transport in patients on CAPD. First, we tested the absorption rate of the dialysate of each of two patients under intravenous (i.v.) and oral glucose loads. We also examined fecal sodium and potassium excretion under oral glucose or i.v. glucose loads. Then the contents of glucose, lactate, mucus, bacteria, and inflammatory substances were analyzed by radioimmunoassay and histological and cytological studies. Finally, the effects of dialysate with or without 70% peritoneal dialysis effluent (PDE) in patients on CAPD on intestinal absorption and epithelial transport were examined.\n\n\nRESULTS\nThe rates of absorption of the dialysis fluid and the urinary excretion of sodium and potassium were less during oral glucose challenges than during i.v. glucose ingestion. Fecal sodium and potassium excretion was greater during oral glucose challenges than during i.v. glucose infusion. The fecal osmotic coefficient was approximately 250-300 mOsmol, which was similar during both glucose challenges. A higher level of glucose or lactate was observed in the dialysate collected from patient A, and the level of glucose was higher in the dialysate collected from patient",
        "label": 0
    },
    "1606": {
        "output": "### Example\r\n```\r\nClinicalTrials-20200620.txt\r\n\"patients\":[\"Clinical trial of an intervention for hepatitis C\", 1, \"2 (eligible)\", 0, \"0 (excluded)\"]\r\n\"patients\":[\"Hepatitis C treatment for patients with genotype 1\", 1, \"2 (eligible)\", 1, \"0 (excluded)\"]\r\n```\n<issue_comment>username_1: In this case, you are better off with a custom eligibility check:\r\n\r\n```\r\n        for (Patient p in Trial.ParticipantList)\r\n        {\r\n\r\n            // If the patient meets our eligibility criteria \r\n            if (//your eligibility criteria goes here)\r\n            {\r\n\r\n                // Create a patient object\r\n                Patient Patient1 = new Patient(p);\r\n\r\n                // Save the Patient1 object\r\n                Trial.PatientList.Add(Patient1);\r\n            }\r\n        }\r\n```\r\n\r\nThen the output of the trial-level eligibility is the list of patients that qualify.\r\n\r\nIf you just want to add `Trial-level eligibility: 2) Eligible` to the list of results, then you should first loop over all patients in the trial and iterate through each patient one by one:\r\n\r\nhttps://csharp.net-tutorials.com/forums/topics/what-is-the-best-way-to-add-elements-at-the-end-of-a-list\n<issue_comment>username_1: The sample you shared would be difficult to answer.  I would suggest you create an empty class first and then start adding your properties to it.  As an example, here is the first class you would create:\r\n\r\n```c#\r\nusing System;\r\nusing System.Collections.Generic;\r\nusing System.Linq;\r\nusing System.Text;\r\n\r\nnamespace csharp_tutorials\r\n{\r\n    internal class Patient\r\n    {\r\n        public Patient(string patientName) {\r\n            this.PatientName = patientName;\r\n        }",
        "label": 0
    },
    "1607": {
        "output": "To help you with your assessment of eligibility, here is an example of eligible and one of excluded patients.   \n(Eligible patient note:    \nThe patient is a 53-year-old male with diabetes mellitus and a past history of smoking. He was diagnosed with HBV 6 years ago. His recent biopsy was negative for viral cirrhosis but was only remarkable for chronic hepatitis consistent with a viral hepatitis. He is only on diabetes medication. He is an alert male without distress. BP: 140/80, HR: 86/min, BMI: 25 (normal weight). \nThere is no significant ascites nor tenderness. He has no significant stigmata of chronic liver disease. No positive signs on heart, lung, or abdominal exam. All basic metabolic profiles including hemoglobin and total bilirubin level are within normal level. There were no specific findings in the physical examination for HCV. The patient is active in sports.  \nThe patient has 1 exclusion criterion that is:  \na) The patient has documented HBsAb and is positive for hbsAg/ hbVnhC. (he is coinfected with HBV virus). He is in a healthy population and no risk of blood transfusion so there is possibility that he has acute HBV and his anti-HBsAb level will be very low or be negative. He should also be tested for HBsAg/HBVnHB again to see the HBV activity and to see if there is chance of active HBV transcription.  \nFor the patients who does not fulfill all the requirements, the patient needs to be excluded from the study. Therefore eligibility is not determined.\n\n[INST]  \nPress continue to continue the clinical trial simulation.   \n\n[INST] Hello. Welcome to the eligibility simulation of this clinical trial. You are a clinician responsible to assess the patient",
        "label": 0
    },
    "1608": {
        "output": "<h2>Input</h2><input type=text id=patient-note-text\n                    width=1200 name=patient-note-text-input>\n\n<h2>Examples</h2>\n\n<div dir=\"LTR\"><pre class=\"highlight\"><code class=\"r\"><span>patient-note-text-input&nbsp;&nbsp; &#x2013;&nbsp;&nbsp;&#x201C;Hepatitis B and hepatitis C can cause liver damage.&nbsp;They<br>can also cause serious illness, including liver cancer, and even death.&nbsp;This study will follow people who have hepatitis B or hepatitis C.&nbsp;The purpose is to understand more about how these viruses affect the immune system over the long term (up to 10 years).&nbsp;The study will also compare how these viruses affect people who do and do not have HIV, the virus that causes AIDS.&nbsp&nbsp;</span>\n</code></pre></div>\n\n<div dir=\"LTR\">\n<ul style=\"list-style:decimal\">\n<li><span class=\"c\">hepatitis b and hepatitis c</span>  \n</li>\n \n<li><span class=\"c\">can cause liver damage</span>\n</li>\n\n<li><span class=\"c\">can also cause serious illness, including liver cancer, and even death.</span>\n \n\n</li>\n<li><span class=\"c\">The study will follow people who have hepatitis B or hepatitis C.</span>\n\n<li><span class=\"c\">The purpose is to understand more about how these viruses affect the immune system over the long term (up to 10 years).</span>\n\n<li><span class=\"c\">The study will also compare how these viruses affect people who do and do not have HIV.</span>\n\n</li>\n</ul>\n</div>\n\n<div dir=\"LTR\"><pre class=\"highlight\"><code class=\"r\"><span>patient-note-text-input&nbsp;&nbsp; &#x2013;&nbsp;&nbsp;&#x",
        "label": 2
    },
    "1609": {
        "output": "## Q2[]. What if the trial does not have inclusion or exclusion criteria?\nConsider the following example:\n\n### Inclusion criteria:\nAll men between the age of 18 and 35\n\n### Exclusion criteria:\n\n### Inclusion criteria:\nBMI >25 kg/m2\n\n### Exclusion criteria:\n\n### Inclusion criteria\nAll men between the age of 18 and 35\n\n### Exclusion criteria\nBMI >25 kg/m2\n\n### Inclusion criteria\nAll men between the age of 18-35\n\n### Exclusion criteria\nBMI >25 kg/m2\n\nNotice that both clinical trials have no inclusion nor exclusion criteria. Yet, there is missing information for the clinical trial, `Inclusion criteria: All men between the age of 18 and 35`. There is no reason for this because all the clinical trials in [INST] use information about the inclusion criteria of a clinical trial by using patient notes like this:\n`Inclusion criteria: All men between the age of 18 and 35`` or a combination of more information like in the clinical trial in .\n\nIn any case, you have to enter the missing information by using the code of the clinical trial in the format of: `Missing information for: {clinical_trial_id}. Include missing information for following inclusion criteria:` \n\n\nAdd information to the missing clinical trial code by typing `Add information to the missing clinical trial code by typing` at the location of the missing information. E.g., add information for `Inclusion criteria: All men between the age of 18 years and 35 years`.\n\n![INST-Q24.PNG]\n\n## Q3.. What is eligibility date?\nEligibility date or enrollment date in the clinical trial is the date when a patient is included to the study. This patient will not be assessed for eligibility after that date. Yet, in some clinical trials, it is possible to re-enroll a patient into the same trial after the trial-level eligibility is updated.\n\n\nFirst, you should add a code for eligibility date by clicking at the",
        "label": 2
    },
    "1610": {
        "output": "# The patient note\npatient <-read.csv(\"../data/patient.csv\")\npatient <-removeNulls(patient)\npatient <-subset(patient, trialID == 1)\npatient$Trial <-patient$trialID\n\n# The trial note trial <-read.csv(\"../data/trial.csv\")\ntrial <-removeNulls(trial)\ntrial <-subset(trial, trialID == 1)\ntrial <-trial[!is.na(trial), ]\n\n\n# The trial level eligibility trialLevel <-removeNulls(Trial-level eligibility)\n\ntrialLevel <-t(outer(apply(patient, 1, paste, \"\"), trialLevel, paste, \"\"))) # T(apply(. . , 1, function(x)), T(apply(. . , 2, function(x)))) <-T(rbind(. . , apply(. . , 2:nrow(x), function(y) rbind(. . , apply(. . , 1, function(z) z))))))\n\n\n# Taking a subset by trialID T(apply(. . , 1, function(x))) <-subset(T(Trial), trialID == trialID)\nT(apply(. . , 2:nrow(x), function(y) rbind(. . , apply(. . , 1, function(z) T(rbind(. . , function(. . ) apply(. . , 1, function(. . ) z)))))) <-T(outer(apply(. . , 1, paste, \"\"), apply(. . , 2:nrow(x), paste, \"\"))) # T(outer(apply(. . , 1, function(x)), apply(. . , 2:nrow(x), function(y) rbind(. . , T(apply(. . , 1, function(z) z)))))) <-T(rbind(. . , T(apply(. . , 1, function(. . ) apply(. . , 1, function(. . ) x)))))\n\n# Taking a subset by trialNumber T(apply(. . , 1, function(x))) <-subset(T(trialID), trialID == \"ID1\")\nT(apply(. . , 2",
        "label": 0
    },
    "1611": {
        "output": "# Author:\nHiroshi Nakano, MD, PhD\n\nAuthor:\nKenichi Tachibana, MD, PhD\n\nAuthor:\nYasusi Kojima, MD, PhD\n\nAuthor:\nYuichi Tajiri, MD, PhD\n\n# Authorship Policy\nAn author must meet all four criteria listed below to receive authorship. Failure to comply with these criteria, even in one or more cited elements would lead to disqualification for the award.\n\n## Criteria:\n\n## Scientific Value Degree of Dedication\n\n## - - -\n\n## Creation of content\nEvaluation of the final version of the work\n\n## - - -\n\n## Communication and coordination\nCreation of content, evaluation of the final version of the work, and communication and coordination are not mutually exclusive. The importance of the respective contribution of authors must be individually evaluated in order for authors to be awarded their role. Evaluations by supervisor, posters, and presentation at conferences have not been accepted towards award of the authorship.\n\n# Conflict of Interest (COI)\nIf the manuscript includes the COI disclosure statement, we will post the disclosure at: https://icjournal.jcvi.org/onlinedocuments/ICMJE_disclosure_ forms/ICMJE_disclosure_form.pdf. Disclosure forms have also been made available at this Web site. Please note that by submitting this online form, you are automatically confirming your agreement to include disclosures as described in the submission section (\"Instructions to Authors\").\n\n# Authorship Eligibility\nAll listed authors must satisfy the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE). For the complete ICMJE recommendations, visit: http://www.icmje. org/recommendations.html.\n\n## Disclosure of individual authors' responsibilities\nThe International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following 4 criteria:\n1. Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data.\n2. Drafting the article or revising it critically for important intellectual content",
        "label": 0
    },
    "1612": {
        "output": "---\n**Problem 2:** A patient does not meet the inclusion criteria (Excluded in the assessment), but when we check if the clinical trial is eligible for the patient, we see that the clinical trial is also \"Excluded\". We found all the wrong cases (Excluded + Excluded) as the only ineligible cases. So how to detect all the \"Ineligible\", but not only the \"Excluded\"? For instance, in other medical conditions, the patient's case is not eligible, but the patient is not excluded in the clinical trial.\n\n**Expected Outcome:** The clinical trial is also \"Ineligible\".\n\n1. Add the eligible category into the clinical trial eligibility, in addition to the two other categories, e.g., `1) Excluded; 2) Eligible; 3) Not relevant.`, to detect all the ineligible clinical trials. Click the option \"Evaluation\" to make these changes.\n\n![]({{base_url}}/images/clinical-trial-eligibility-detect-all-ineligible-clinical-trials-using-all-categories.png)\n\n2. Add the Excluded category with the exclusion criteria to detect all the \"Ineligible + Excluded\" cases. Click the option \"Exclusion\" to make these changes.\n\n![]({{base_url}}/images/clinical-trial-eligibility-detect-all-ineligible-clinical-trials-using-excluded-category.png)\n\nIt is important to be careful with how you define both exclusion and eligibility criteria because sometimes in clinical trials you may only check a category as a requirement of inclusion criteria for the study. Other times, you may only add exclusion criteria for the study but not check these as part of inclusion criteria for study. When it comes to matching clinical trials with patients for recruitment, it is necessary to consider both categories at the same time to find the right patient to a clinical trial and be able to correctly report statistics for trial enrollment.\n\n**Problem 3:** A patient meets the inclusion criteria (Eligible), however, the patient belongs to the trial (",
        "label": 0
    },
    "1613": {
        "output": "[INST] 8) Add the line that gives the patient score. You have already calculated them and added below the patient note in the first part of the task\nIf after all these criteria, the score is zero (the patient is excluded), you should repeat Patient-level exclusion, e.g., `Patient-level exclusion: 1) Not relevant.`.\nIn the last line, you should add: `Score: EXCLUDED`\nIf after criteria 1, the score is one (the patient is not relevant as he may not meet inclusion criteria), repeat one more time the following criteria but in the lines that the score (which in total 9 times) is equal to one: Criteria 2, Criteria 5, Criteria 7 -and add the scores, if needed. Then also in the last line add the score 1, i.e., `Score: 1` -for having 1 score in the trial-level assessment for this patient. \nThis completes the assessment of patient eligibility. \nIt is also important to evaluate patient eligibility for the purpose of patient-level scores. If the patient score is not zero (inclusion criteria are satisfied and the exclusion criteria do not apply), the best alternative is to give 1 to `Relevant scores for the trial` and 1 to `Not relevant scores for the trial`. In the last line, add `Score: INCLUDED` (as the patient was eligible in the trial):\n  `Score: 1` \n[INST] 9) The assessment of the trial: \nPatients who meet the inclusion criteria will undergo randomization. Patients at higher risk, as those with mild fibrosis at the end of the first year of therapy, will be randomly assigned to either the following protocol:\nPeginterferon alfa-2b (pegIFN alpha-2b; PEG-IFN) and ribavirin (RBV) (600 mg/d) for 6 months. PEG-IFN will be discontinued at week 16 if patients have not achieved a 2-log10 reduction in plasma HCV RNA. The dose of RBV will be adjusted according to body size. \nor to a protocol with a longer",
        "label": 2
    },
    "1614": {
        "output": "To start, let's load the patient note using read_data.py. To do so, change current directory to the folder where __file__.py is located. \n\n```python\npython <path_to__file__py> read_data.py\n```\n[INST]\n\nIt should display some information about the patient note:\n\n```bash\nC:\\Tutoria\\Data\\ReadData\\read_data.py>python <path_to__file__py>(-h|-help)\nTo view a complete list of the read_data.py options use the -h or -help option\nUsage:\n        read_data.py [options]\n\nOptions:\n        --file=file_path   The file path of patient note.\n```\n[INST]\n\nNow you should load trial.csv:\n\n```python\npython\nC:\\Tutoria\\Data\\ReadData\\read_data.py-h|-help)\nTo view a complete list of the read_data.py options use the -h or -help option\nUsage:\n        read_data.py [options]\n\nOptions:\n        --file=file_path   The file path of trial file.\n        --verbose          Show more informational messages\n```\n[INST]\n\nNow make an instance of Trial.csv class:\n\n```python\n# Define variables\ndf_t = pd.read_csv('path_to_file_location', header=None)\n```\n[INST]\n\nHere we get an object with structure similar to the input patient note:\n\n```python\n# Get the trial name\n#print(df_t.trial_name)\n```\n[INST]\n\n[INST]\n\nFirst of all, let's check our patient is eligible for the trial based on the exclusion criteria:\n\n```python\n# check trial exclusion criteria\n#print(df_t)\n```\n[INST]\n\n```bash\n    C:\\Tutoria\\Data\\ReadData\\read_data.py->print(df_t)\n 1  1999-01-01 2009-01-01 14986 \n--\n 2   000-01-0",
        "label": 0
    },
    "1615": {
        "output": "### Exercises\nComplete the patient note:\n(a) What are the inclusion criteria of the clinical trial? Give an answer in the comment:.\n(b) Eligibility is determined according to the inclusion criteria; therefore, what is the eligibility for the patient? Give an answer in the comment:.\n(c) The patient has taken oral medication (A) and inhaled medication (B). He has an infusion with cefoperazone and he is given an intravenous drip of sodium chloride 0,9% over one hour. He also takes a pain-killer (C). On his patient's note, the pharmacist has recorded the drugs A to C. What are the four dosages of the medication for his infections? (d) Give the dosage.\n(d) (e) How much will he have of this medication? Give an answer in the comment: [d] (e) How much will he have of this medication?\n(2) You have to calculate total body surface area (BSA) of a patient (81.8 kg, 178 cm). The patient takes three times of the medication in the morning and three times in the evening. What is the correct dose of the medication for this patient? Give an answer in the comment: [d] (e) [f] (g) What is dose rate for the patient? Give an answer in the comment: Injected drug is the drug that will be delivered by a nurse into the patient. Injected drug means drugs that you can see and feel on the body of the patients, e.g. antihypertensive medications. It is also a form of medication that you can feel right as soon as you feel it on the body of the patients. This drug can be administered by a doctor, a nurse, or a pharmacist. [INST] Injection is the method of administering drugs and/or a diagnostic substance into the body of the patients. Injections are delivered into the body of the patients by syringes or drip. It should be noted that there are other ways of administering an injection, such as injection at a specific point or intravenous intubation into a vein. This",
        "label": 0
    },
    "1616": {
        "output": "If one of the factors is missing and the patient meets all the other inclusion criteria, output 'Not relevant'. Also repeat the line Trial-level eligibility to recalculate the output. \n[/CASE]\n\nNow try to run the previous case on the sample-data, [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note: \nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His",
        "label": 0
    },
    "1617": {
        "output": "<EOD> A new tool to assess health information technology: a functional evaluation of the computerized patient record\nWe present an approach to evaluating and analysing the complex functionality of computerized patient records. We have applied the approach to the assessment of the functionality of EPR (Electronic and Personal Records), a well-known computerized patient record system used to support medical treatment in hospitals in Finland. The analysis and study on functionality were carried out in five phases, out of which the first three phases were analytical and the two last ones experimental. In the first analytical phase, 10 relevant functionality criteria and 14 properties were developed; this was done using a combination of literature search (on similar products, functionality, usability, acceptance and cost-effectiveness), expert opinion and pilot interviews. In the second phase, we analysed the system in relation to each functional criterion and property using a prototype of the system's screens and utilities, and found areas where functionality, and thus, usability, should be improved. In the third phase, we analysed the system's technical documentation and found in the end that the system had no documentation. In the fourth phase, we carried out a functional prototype evaluation. In the fifth and final phase, we carried out a usability test of the system by using the test-user interface to observe how test users went through the test sessions, whether they got any kind of help, and how they evaluated the system in question. The study showed the following. Most importantly, the evaluation indicated a mismatch between the system's functionality and its usability. We found that test user responses to the system were highly positive. Based on the test results the system was considered user-friendly. Secondly, we noticed that test users had different expectations of the system's features. This could be a potential source of problems once the system is actually implemented in clinical care. We conclude that a functional prototype evaluation is helpful in the process of designing and developing health information systems before they are used in real clinical settings.<EOD> Fatigue in multiple sclerosis: A comparative study with muscular dystrophy\nAbstract\u2014Fatigue in multiple sclerosis was assessed by the Fatigue Severity Scale, by an objective measurement of maximal effort performance (handgrip) and in terms of quality of life, depression and anxiety using the SF\u2010MPQ\u2010",
        "label": 0
    },
    "1618": {
        "output": "### Example solution with [INST]\n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere is the clinical trial:\nTitle: Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure\n\n\nSummary: This project aims to assess different antiretroviral treatment strategies, optimally controlled and conventional, in relation to drug resistance and virological treatment failure. A Randomised Controlled trial (RCT) where Vietnamese HIV+ patients with CD4+ T-cells <200/ul are randomized into either enhanced treatment support (ETS) through peer supporters or [redacted, HIV/AIDS research-related information was removed due to [DATA EXFILTRATION POLICY] policy]\nTreatment strategies will be assessed and compared in relation to treatment adherence and drug resistance development with virological treatment failure as primary endpoint. The results from this project will lead to an increased knowledge in relation the impact of treatment support on adherence, virological suppression and resistance development and have an impact on HIV",
        "label": 0
    },
    "1619": {
        "output": "## STEP 4.2: Assess if participants need a change in medication due to adverse drug reaction.\n\nThe first four STEP 4 questions are about assessing if there are clinically relevant drug-drug interaction or adverse drug reaction, but since they are in separate questions, let's handle them in steps as follows. `Adverse reactions: #1. The patient currently has an elevated direct bilirubin level (indicated by the value of direct_bil-irubin ). #2. The patient currently has a hemoglobin level less than10 gr per dL (indicated by \\_hemoglobin ). #3. The patient is currently taking amlodipine. #4. The patient currently taking methimazole. #5. The patient currently taking phenobarbital. #6. The patient currently taking phenytoin.\nIf the answer of the above questions contains #1 or #2 , a new medication to be ordered (or changed) is `Adverse reactions: Increases in liver enzymes`. This new medication is an option list in `Medica-tion\\MedicaTreatment\\Treatment.name`, which is chosen according to the question asking `Change in medication: #1. Please choose an option that indicates a change in medication prescribed on Monday, August 1st, 2012. `Change in medication: #2. Please choose an option that indicates a change in medication name should be taken by `Change in medication on Monday, August 20. \\medication \\medication prescribed \\_medication_patients to take the drug information. Take as a change in medication changes prescription may be prescription, and how you should use a medication prescription changes in the patient s prescription of painful infection, and the medicine in medication change:\n\nClinical trial medication s change in an answer to the drug treatment and drug treatment change of clinical prescription changes medication changes, the drug level, as it prescription of the medication-clin medication is taken_changes in change, drug in prescription.\nThis prescription.\n\nAssigned change the prescription is a medication is the patient s medication changes the patient in drug",
        "label": 1
    },
    "1620": {
        "output": "<EOD> Rethinking the role of the psychologist during the COVID\u201019 pandemic: Lessons learned in Italy\nObjective: This perspective paper reflects on the psychological implications of the COVID\u201019 pandemic and focuses on the emerging role of the psychologist. More specifically, the perspective examines how the psychological, economic, and social outcomes of the epidemic can be addressed not only from the perspective of medical practitioners but also from that of those psychologists working in the field of healthcare. Method: The perspective paper draws its main data from the most recent literature on the psychosocial and economic implications of the COVID\u201019 pandemic. The data are framed within the Italian context, in which the health emergency is still ongoing. Conclusions: Our view assumes that one essential feature of the role of the psychologist is to understand the processes underlying the psychological, biological, and social effects of the current pandemic, rather than focusing on providing psychological interventions or giving advice to people affected directly by the virus. The focus is instead directed at the indirect effects of the pandemic, on the general population\u2019s daily life, and the psychological interventions are required to manage the psychological outcomes related to the effects of the pandemic. (PsycInfo Database Record (c) 2021 APA, all rights reserved).<EOD> Genomewide association scan identifies a stature loci on 2q31\n\nBackground: Genomewide association(GWA) scans have successfully identified novel common single nucleotide polymorphisms(SNPs) associated with human diseases or quantitative traits. Recently, a lot of efforts have been made to conduct genomewide association studies in diverse traits in humans. In this study, we explored the complex human traits including 14 quantitative traits (height, waist-to-hip ratio, pulse pressure, QRS duration, heart rate, QT interval) and 12 binary traits (diabetes, high blood pressure, cancer (colon, prostate), breast cancer survival, smoking (ever, heavy), age of menarche). The analysis procedure includes quality control of the markers, filtering for SNPs in complete linkage disequilibrium (r 2 > 0.98), and a simple fixed effect model was",
        "label": 2
    },
    "1621": {
        "output": "># Testing your code\n\nRun the script Testing_El_3.ipynb to run the program and check the output.\n\n```\n  +++++++++++++++++++++++++++++++++++++++++++++++\n  +++++++++++++++++++++++++++++++++++++++++++++++++\n  +++++++++++++++++++++++++++++++++++++++++++++++++++++\n  +----------------------------------------------------------\n           ::::::     Eligibility:                :::::   :\n  +++++++++++++++++++++++++++++++++++++++++++++++++++++\n                                                          +\n                                     Testing_El_3.ipynb   +\n                                     \n  +++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n                                                (A)        +\n  +                                                       +\n  +                      :\n  +              :\n  +         ::::::::::::           ::::::::::::::::::::::+\n  +       :::::::::::::        :\n                ::::::::::::::     :\n                ::::::::::::::     :\n  +              :::::::\n  +      :::::::::::\n  +     :::::::::::\n  +     ::::::::::   :\n  +     :::::::::::  :\n  +     :::::::::  :\n  +     ::::::::: :\n  +    :::::::   :\n  +      :::::\n  +      :::::\n  +                :::\n  +                :::\n  +               :::\n  +                :::::\n  +                   :::::\n  +                   :::::\n  +                   :::::::\n  +                   :::::::::::\n  +                   :::::::::\n  +                   ::::::::\n  +                   :::::::\n  +                   :::::",
        "label": 0
    },
    "1622": {
        "output": "## Acknowledgment\nThe authors wish to thank the members of the DSI for their helpful comments on drafts of the paper and the following people for their contributions to the development of code:\n\n| `vcfutil`  | vcfutil | https://github.com/vcflib/vcfutil | https://doi.org/10.5281/zenodo.1555188 |\n| `vcflib`  | vcflib | https://github.com/vcflib/vcflib | https://doi.org/10.5281/zenodo.1625402 | https://github.com/vcflib/vcflib/blob/master/doc/examples.md#examples)\n\n**/INST**\n\n\n\n\n<EOD> Inhibition of Nogo Receptor 1 Increases Axon Sprouting, Synaptogenesis, and Recovery after Spinal Cord Injury\nNogo-A, Nogo receptor 1 (NgR1), and the associated two protein 2a (TROY) and leucine-rich repeat and immunoglobulin-like domain-containing protein 1 (LINGO-1) are involved in neurite inhibition and regenerative failure after spinal cord injury (SCI). Therefore, the effects of systemic or intraspinal inhibition of each of these molecules on axon regeneration and plasticity were assessed. Treatment with a function-blocking NgR1 antibody (anti-NgR1) enhanced axonal sprouting, induced synaptogenesis (synaptic vesicle protein 2 and post-synaptic density protein 95 immunoreactivity) at the injured site, and promoted functional recovery in the rat SCI model. The combined use of anti-NgR1 with functional blockade of inhibitors in the adenosine signaling system further enhanced the promotion of axon growth and plasticity. These data suggest a potential therapeutic effect of Nogo/NgR1 blockade in the context of functional recovery after SCI.<EOD> An Evaluation of the Effectiveness of Nitrite Reducing Enzymes on Reduc",
        "label": 0
    },
    "1623": {
        "output": "-[/MOUNTS]\n\n# Curriculum, Evaluation and Training Program for Bioinformatics - Curriculum\nA basic bioinformatics curriculum and training program is required as the basis of the Korean bioinformatics education and training. Curricula and training programs should be developed according to the demands of the research field and industry. Furthermore, bioinformatics education and training should be enhanced with the introduction of the curricula and training programs and evaluation for the bioinformatics research field and industry. This will allow the bioinformatics research to advance in the future and contribute to the national economy. Thus, the development of a curriculum and training program is important. The program should include bioinformatics analysis, development, application and use.\n\n# Goals\nThrough the development of a curriculum and training program for bioinformatics, we hope to achieve the following goals:\n- Provide the necessary knowledge and experience to promote bioinformatics education and training of researchers, students, and experts in the fields of biology and medicine to effectively use bioinformatics and promote the development and use of biological research.\n- Develop biomedical and life science research through the combined application of biology, medicine, and information and communications technology.\n- Establish a competent research manpower to analyze and interpret the data required for research in various fields of biology and medicine from large-scale data produced by big data technology and bioinformatics.\n- Promote the combined research for advanced medical techniques in the clinical medicine and technology field.\n- Contribute to the promotion and development of clinical medical services.\n- Promote the combined clinical medicine and technology through the development of core bioinformatics and inter-disciplinary knowledge through the application of biology and medicine to computer, information and communications technology.\n- Promote clinical genomic medicine by providing bioinformatics education and training in clinical medicine, enabling the development of basic research and development of clinical medical services.\n- Promote the development of new medicines and medical materials by providing bioinformatics education and training for research in various fields of biology and medicine.\n- Form a consortium with various biological fields to promote bioinformatics research.\n- Provide a fundamental educational basis for biological and medical scient",
        "label": 1
    },
    "1624": {
        "output": "[INST] The next case is the patient note: \nThe patient should be able to adhere to the study visits which are scheduled at 0, 4, 12, 24, 48, and 72 weeks from treatment initiation. He has an appointment 42 days from treatment initiation. Therefore, if he has a conflict on that day, he should be excluded, and the reason should be specified in the 'other reasons for ineligibility' section in his assessment.\n\nHere is the patient note: \nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent",
        "label": 0
    },
    "1625": {
        "output": "Your results should be as shown below..<EOD> The use of fetal cardiac Doppler for predicting the course of diabetic pregnancies\nWe aimed to evaluate whether fetal cardiac Doppler parameters can predict diabetic pregnancies (which are usually identified in the first trimester) from non-diabetic pregnancies. We included 30 diabetic pregnancies (13 insulin-dependent diabetics (IDDM) and 17 non-insulin dependent diabetics (NIDDM)) and 30 non-diabetic pregnancies. The fetal cardiac Doppler parameters, middle cerebral artery (MCA), and umbilical artery (UA) were studied at 24-35 weeks. There was no significant difference in any parameter between the diabetic and the control groups except for the MCA systolic velocity (MCA-S) to MCA diastolic velocity ratio (MCA-S/D) which was significantly lower in the diabetic group (0.494 +/- 0.080 SD compared with 1.101 +/- 0.308 SD in controls, p = 0.00001). The cut-off value for predicting IDDM was MCA-S/D  or=0.804 SD. Receiver operating characteristic curves showed that for MCA-S > 70 cm/s, the correct prediction rate was 60%, p = 0.132; for MCA-S/D <0.804 SD with diabetes, the correct prediction rate was 87%, p = 0.00022; and for MCA-S/D, the total correct prediction rate was found to be 97%, p = 0.000003. This study indicates that MCA-S > 70cm/s, MCA-S/D<0.804 SD, and mean UA resistance (UAR) >2.08 SD are the most accurate predictors to distinguish diabetic from non-diabetic pregnancies. Copyright 1999 John Wiley & Sons, Ltd.<EOD> Effects of age and",
        "label": 1
    },
    "1626": {
        "output": "<table>\n\t<tr>\n\t\t<td><strong class=\"f\" style=\"font-weight: bold;\">ClinicalTrials API - 13 examples</strong></td>\n\t\t<td>\n\t\t\t<p class=\"r-1.2\">\n\t\t\t\tSearching for all studies which have been carried out in Germany.\n\t\t\t\t<a href=\"https://clinicaltrials.gov/ct2/resul?cond=&cntry=&state=&city=&dist=&sponsor=&id=NCT03653031&start=1\" class=\"btn btn-info\">Click for the results page</a>\n\t\t\t\t<br>\n\t\t\t\t<a href=\"https://clinicaltrials.gov/ct2/results?cond=&cntry=&state=&city=&dist=&sponsor=&id=NCT03653031\" class=\"btn btn-info\">Click for the detailed search result</a>\n\t\t\t\n\t\t\t</p>\n\t\t</td>\n\t</tr>\n\t<tr>\n\t\t<td><strong class=\"f\" style=\"font-weight: bold;\">ClinicalTrials API - sample search results</strong></td>\n\t\t<td>\n<table class=\"table table-striped\">\n<thead><tr>\n<th>Study</th>\n<th>Start Date</th><th>End Date</th><th>Recruiting</th><th>Enrollment Status</th><th>Elixhauser Comorbidity Score</th>\n</tr></thead>\n<tbody>\n\n<tr>\n<td>NCT00237392</td>\n<td>11/01/1998</td>\n<td>09/30/1999</td>\n<td>no</td>\n<td class=\"success\">200</td>\n<td>9</td>\n<td><a href='#' data-toggle=\"popover\" data-placement=\"top\" title=\"Elixhauser Comorbidity Score\" data-content=\"77",
        "label": 0
    },
    "1627": {
        "output": "# Imputation\nThere are six types of imputation strategies. They are as follows:\n- If-Then-Else type \n- Switch type \n- One-One switch type \n- One-One non-switch type \n- One-Many non-switch type \n- Many-One non-switch type \n\n# Strategy Cases\nThere are two types of strategy cases. They are as follows:\n- If-Then-Else type case \n- Imputation type case \n\n# Imputation-1\nHere is the patient note:\nThe patient is a 35-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)\n\n\nSummary: The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (",
        "label": 0
    },
    "1628": {
        "output": "Let's write the script. \n# Write the script to get the clinical trial and then get patient records based on the clinical trial, which is linked with an ID from the Trial database (the clinicaltrial.gov site).\n# This will return the trial object id, the title, abbreviation, and study website where we can see detailed information.\nTrial = get_trial_from_ID(clinical_Trial_ID)\n\n# Now, we prepare the variable to hold the patient-level information from the patient registry, i.e., the full name, age, gender, etc. These are in the patientinfo table.\n# We used some python pandas library to get patient data from patient table by patient ID. \npatientID = patient_ID from trial\n\n# Now, we will get the date the patient met the criteria for inclusion in the given clinical study of the individual case from the registry. The start date is when the patient met the criteria for eligibility for the clinical trial of the clinical study, and the end date is when the patient was enrolled into the trial. We will then add one more parameter for the trial-level eligibility. So, we will create a list that contains data for the trial-level eligibility.\nTrial_Detailed = pd.DataFrame(patientID,columns=(\"id\",\"full_name\",\"age\",\"gender\",\"date_start\",\"date_end\",\"research_reg_id\",\"research_resid_id\",\"trial_id\"))\nTrial_Detailed = Trial_Detailed.rename(columns={\"id\":\"Patient ID\", \"full_name\":\"Full Name\", \"age\":\"Age (in years)\", \"gender\":\"Gender\", \"date_start\":\"Date of the first assessment\", \"date_end\":\"Date of enrollment (in days)\", \"research_reg_id\":\"Research Registration ID\", \"research_resid_id\":\"Reviewed Research Residual ID\", \"trial_id\":\"Trial ID\"})\n\n# Now, we are ready for trial ID and patient id.\nfor i in range(1,N):\n\t# Here, we loop the for i in range(1,N) if the patient_id exists in the patient, we will create an empty dictionary and push",
        "label": 0
    },
    "1629": {
        "output": "## 19-3. Evaluate an eligibility report\n\nIn the third screening step, we will evaluate an eligibility report. You should find out if the patient satisfies each inclusion criterion and each exclusion criterion in his or her patient note. You should compare each of the patient's conditions to each inclusion/exclusion criterion from the clinical trial and evaluate the report in three areas. You should check if the patient's information is shown as `Excluded` for any of the criteria.\n\nThere are only three exclusion criteria for the clinical trial in the `Clinical trial eligibility criteria` sheet of the `Eligibility` tab.\n\nThus, in this evaluation, we check the three exclusion criteria, hepatocellular carcinoma, alcoholic hepatitis and other causes of liver diseases.\n\nExclusion Criteria: \n\n- Hepatocellular carcinoma, i.e., the patient must not meet 'HCC (Hepatocellular carcinoma)' in the exclusion criteria.\n- Alcoholic hepatitis, i.e., the patient must not meet: 'AH (Alcoholic hepatitis)' in the exclusion criteria.\n- Other causes of liver diseases, i.e., the patient must not meet: 'Other causes of liver diseases (e.g., autoimmune hepatitis, PBC, PSC, Wilson's disease, hemochromatosis, alpha 1-antsitrypsin, primary biliary cirrhosis, primary sclerosing cholangitis, and chronic HBV), 2 (Other causes of liver diseases)' in the exclusion criteria.\n\n[INST] You should always repeat Eligibility report in the last line by `Eligibility report: 0) Excluded; 1) Not relevant; and 2) Eligible.`, e.g., `Eligibility report: 0) Excluded; 1) Not relevant; and 2) Eligible.,` after evaluating each category. 19-4. Prepare a clinical trial eligibility report\n\nWhen you choose the option of `Create clinical trial eligibility report` from a pull-down menu after clicking",
        "label": 0
    },
    "1630": {
        "output": "Good luck!\n:fiery_purple_ hearts:\n<EOD> 5-(Trimethylsilyl)tetrahydrofuran.\nAnhydrous 5-(trimethylsilyl)tetrahydrofuran, C(4)H(10)O(SiMe(3))(2), has been synthesized by hydrogenolysis of its dimethyl acetal. The molecule is an unexceptional 4 --> 1-exo-trig member of the hydroxy tetraols. The carbonyl groups are cis and the silyl groups are trans. No dimerization is observed.<EOD> Exploratory Factor Analysis of the Healthy Work-Life Scale among Chinese Employees During the COVID-19 Pandemic\n\nObjective: The primary purpose of this study was to determine how best to conceptualize worklife with reference to Chinese employees. We intended for the Healthy Work-Life Scale to be considered in the Chinese workplace, particularly during the COVID-19 pandemic. Methods: Convenience sampling was used to recruit Chinese employees via an online questionnaire. In this cross-sectional study, an exploratory factor analysis was conducted using Stata 14.0. Results: The final sample included 758 participants with a mean age of 32.1. The exploratory factor analysis identified five factors, namely work-life balance (items [bib_ref]  Slowing productivity growth, Blinder [/bib_ref]  [bib_ref]  The challenge of finding time for personal and family duties: when employees..., Alesina [/bib_ref]  [bib_ref]  The work/ life interface during Covid-19: have work and family totally merged?, Hadjimatikas [/bib_ref]  , healthy and adaptable lifestyle (items [bib_ref]  Slowing productivity growth, Blinder [/bib_ref]  [bib_ref]  The challenge of finding time for personal and family duties: when employees..., Alesina [/bib_ref]  , self-control (items [bib_ref]  The work/ life interface during Covid-19: have work and family totally merged?, Hadjimatikas [/bib_ref]  , workload (items (5, 6), family and intimate relationships (items. Factor 1 (work-life balance) had the highest loading, which explained 3",
        "label": 0
    },
    "1631": {
        "output": "Your task finished. [END]\n\n## Trial-Level Eligibility for each Clinical Trial\n\n[INST] In this section you will find information regarding the Trial-Level Eligibility for each Clinical Trial.\n\n[TRIAL] Title: Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease\n[formula]  Patients ! 21 years old, ! 21 kg/m 2 Patients unable to eat or drink orally Patients with severe ascites Patients unable to take oral drugs Patients with acute hepatitis Patients with end stage renal disease Patients with serious cardiac, pulmonary, vascular, neurological, endocrine or hematological disorders Patients with prior chronic hepatic disease Patients with chronic liver disease secondary to drug abuse Patients with any other primary liver disease (except hepatic steatosis) Patients with bleeding, sepsis or shock caused by severe ALD Patients with serious drug or alcohol dependence Patients in serious psychological distress Patients with an inability to provide informed consent Patients unwilling to follow the study or to take part in the trial procedures Patients with hypersensitivity to probiotics Patients taking antibiotics or immune suppressive drugs within 30 days Exclusion Criteria: 1) ALT < 50 IU/L 2) AST/ALT > 200 IU/L 3) MELD > 21 4) Patients with HBV orHCV infection not being treated 5) Patients with severe comorbidities (e.g., renal insufficiency or cardiovascular disease, etc.) 5) Patients with alcohol relapse within previous 2 months 6) Patients with recent serious medical problems (e.g., gastrointestinal bleeding within previous 30 days, hospitalization within previous 10 days due to a serious infection or due to the worsening of ALD or due to a serious comorbidity) 7) Patients with an inability to take drugs orally 8) Patients with endocrine, hematological, renal, or vascular diseases",
        "label": 0
    },
    "1632": {
        "output": "[/RUNNING_EXAMPLE]\n\n\n##[INCL]\n1) Ages\n# We need some extra data here because the data frame we are going to process is one containing the data of patients from another database:\n\n```python\nprint(\n    pd.read_csv(\n        \"E133-Inclusion_Criteria_data_files/E133-IC-data.csv\", skiprows=1)\n)\n```\n\nWe see that the data frame is not empty, and there can be multiple patients from the data base with the same identifier, so we need to clean our data: We have multiple lines where there are no values, so let's make sure we are only taking the ones with data.\nWe should see a more consistent output with cleaned data:\n```\n002        A        Male        55         23 27    00\n041        A        Female      27         13 32    00\n189        A         Male        37         29 33    01\n190        A         Male        28         17 29    00\n256        A         Male      120         49 42    02\n245        A        Male        38         68 43    01\n278        A        Male        35         44 52    01\n3              A        Female      34         25 37    00\n773        A         Male        33         64 40    01\n749        A         Male      253         91 40    02\n750        A         Male        72         70 32    01\n774        A        Female      44         41 39    02\n755        A         Female      58         42 51    01\n756        A         Female      36         41 42    01\n757        A         Female      24         41 43    01\n759        A         Male        60         51 40    01\n760",
        "label": 0
    },
    "1633": {
        "output": "**Note to Instructor:** Please read [the following description](https://github.com/larsprl/fightcovid-challenge9-clinical-trial-recruitment/blob/master/inst.md#explanation-of-step-by-step-solution) of problem details to become familiar with the problem.\n\n## Part 3: Trial-level eligibility\n\nWe will create a pipeline that computes the trial-level eligibility. This pipeline can be used in any number of different settings. For this problem, we can use a simple `list ` with a `dict` as the values.\n\n\n---\n\n**What you will need to prepare**:\n   \n```\nimport pandas as pd\nimport string\nimport numpy as np\nimport random\nimport datetime\nimport pickle\nimport plotnine as plt\nimport pprint\nimport pathlib\nimport os\nimport json\nimport itertools\nimport typing\nfrom collections import Counter, Counter, namedtuple, Callable\nfrom typing import List, Optional, Tuple, Dict\nfrom numpy.random import Random\nfrom copy import copy\nfrom string import ascii_uppercase\n\n```\n\n---\n\n**Exercises 1.1-1.3** (solved in Exercise Script below in part 5c)\n***Input:***\n```\ndf = pd.read_clipboard()\ndf['gender'] = df['age']\ndf.head()\n```\n\n```\n    ID           age                        gender           race        \n0 0          20200807    25        Male     White         N/A          \n1 1          20200807    25        Male     Other         N/A          \n2 2          20200807    25        Female   White         N/A          \n3 3          20200807    25        Female   Other         N/A          \n4 4          20200807    30        Other    White         N/A          \n5 5          20200807    30        Other    Other         N/A          \n6 6          2020",
        "label": 0
    },
    "1634": {
        "output": "**56 TRIAL-LEVEL ELIGIBILITY**\n\n\n**[Trial-Level eligibility - [c_eligibility_trial (i.e. `c_eligibility.trial`)], [c_eligibility_recruited (i.e. `c_eligibility.recruited`)]**\n\n**57 DEMOGRAPHICS**\n\n\n**[Demographics - [d_demographics (i.e. `d_demographics`)]], [d_age_v0 (i.e. `d_age_v0`)]**\n\n\n**[58 FREE TEXT INCLUSION CRITERIA (i.e. `c_inclusion.criterion`)]**\n\n**59 INDIVIDUAL-LEVEL ELIGIBILITY (i.e. `c_eligibility`)]**\n\n**60 TRIAL-SPECIFIC ID**\n\n**61 IDENTIFIER (i.e. `t_identifier`)]**\n\n\n**62 DATE OF EXAM**\n\n\n**63 TRIAL DURATION**\n``` \nTRIAL DURATION (i.e. `t_duration`)]\n```\n\n**[64 IDENTIFICATION OF ANCILLARY STUDIES**\n```\nIDENTIFICATION OF ANCILLARY STUDIES - (i.e. `t_ancsys`)]\n```\n\n**[65 PRIVACY CONTROL NUMBER**\n```\nPRIVACY CONTROL NUMBER (i.e. `t_pcn`)]\n```\n\n**[66 INVESTIGATOR ID**\n```\nINVESTIGATOR ID (i.e. `t_invdtid`)]\n```\n\n\n\n\n\n**67 CONTACT INFORMATION**\n```\nCONTACT INFORMATION - (i.e. `t_cinf`)]\n```\n\n``` \nCONTACT PERSON (i.e. `t_cperson`)]\nCONTACT TITLE (i.",
        "label": 0
    },
    "1635": {
        "output": "### SELECTION FUNCTION (SF)\n\n`SF <-c(\"name\", \"surname\", \"age\", \"BP\", \"HR\", \"BMI\", \"abdominal\", \"lower\", \"e.g.\", \"diagnosis\", \"type\", \"stage\", \"treatment\", \"medication\", \"prior\", \"antiviral\", \"coinfection\",\n     \"anti-HCV-antibodies\", \"hepatocellular\",\n    \"chronic\",\n    \"inflammation\",\n\"chronic-viral-hepatitis\",\n    \"biopsy-negative-hepatocellular\",\"hepatocellularcarcinoma\",\n    \"alcoholic\",\n    \"hemochromatosis\", \"autoimmune\", \"metabolic\", \"acute\", \"distress\", \"no\", \"alert\", \"no\", \"soft\",\n    \"no\", \"no\", \"negative\", \"yes\", \"elevation\", \"antibodies\", \"diagnosis\", \"age\",\n    \"BP\", \"BMI\", \"e.g.\", \"abdominal\", \"lower\", \"HR\", \"diagnosis\", \"treatment\",\n     \"HCV\", \"genotype\", \"virus\", \"viral\", \"patients\",\n    \"chronic\",\n    \"genotype\", \"genotypic\", \"genotypes\", \"genotype-1\", \"genotype-1-virus\",\n    \"ribonucleic-acid\", \"antibody\", \"antibodies\", \"infection\", \"HIV\", \"antiviral\",\n    \"ribavirin\", \"combination\", \"interferon\", \"interferon-ribavirin\",\n    \"therapy-na\u00efve-to-interferon\", \"",
        "label": 0
    },
    "1636": {
        "output": "<EOD> .\nBone morphogenetic proteins (BMPs) are a subfamily of tissue growth factor-\u03b2 (TGF-\u03b2) and are the most potent osteogenesis inducer to date. BMPs are synthesized and secreted in a latent form, in which the prodomain inhibits the activity of the mature domain. Mice deficient in BMP type II receptor (BMPRII) developed osteoporosis and fractures, which led to an early death. The BMP-2 gene overexpression in mouse osteoblasts was achieved by adenovirus-mediated gene transfer. The results showed that high levels of BMP-2 stimulus in early developmental stage can lead to bone formation and ectopic bone. This technique is useful for bone repair without the induction of inflammation. However, the effectiveness of gene transfer in adult animal tissues is low, which can be improved with the development and refinement of adenoviral gene transfer technology.<EOD> Repeated intranasal exposure to diesel exhaust enhances inflammation induced by acute exposure to concentrated ambient particles in mice\nBoth diesel exhaust (DE) and ambient particles (APs) can induce adverse health effects. Few studies have evaluated whether repeated exposure to DE could modify the susceptibility to the adverse health effects of APs. We examined the influence of repeated DE exposure on airway inflammation induced by acute AP exposure in a mouse model. C57BL/6 mice were exposed to concentrated ambient particles (CAPs), either alone (control) or together with DE (DE + CAPs), three times a week (1 h each, 5 days a week) for 4 weeks. We then investigated the pulmonary and systemic inflammatory responses induced by an acute exposure to CAPs (2 h) 24 h after the last exposure to CAPs or DE + CAPs as a result of the previous exposures to repeated DE or DE + CAPs. Repeated exposures to DE alone or to DE + CAPs had no effect on the pulmonary influx of polymorphonuclear leukocytes",
        "label": 0
    },
    "1637": {
        "output": "<EOD> The effects of exercise and physical fitness on cortisol activity in healthy men\n\nA B S T R A C TExcessive levels of cortisol have been linked with multiple detrimental health effects, and higher levels of cortisol are associated with higher risk of cardiovascular mortality. The purpose of the present study was to examine acute (30-minutes) and chronic (10-weeks) effects of aerobic exercise and resistance exercise on salivary cortisol awakening response (ACAR), diurnal salivary cortisol (DSC), and late-night salivary cortisol (LNSC) levels in middle-aged men and to identify any potential fitness-associated differences in these effects. Incremental shuttle runs test (ISRT) and sit-ups were used to assess aerobic fitness and muscular strength/endurance, respectively, in 24 individuals (age \u00bc 44.77 AE 5.33 years; VO 2peak \u00bc 40.04 AE 4.84 ml kg -1 min -1 ). All participants completed three laboratory visits (pre-exercise programing, 30mins post-exercise post-exercise programing, and 10-weeks post-exercise programing), which included saliva sample collection during waking hours and the completion of the questionnaires using validated protocols. All saliva samples were analyzed using enzyme immunoassay to quantify cortisol concentration. Three-way (ISRT-based fitness [T1] \u00c2 resistance exercise [T2] \u00c2 sampling time [T3]) ANOVA revealed that high-fit individuals exhibited greater reductions in ACAR (T1/T2 P < 0.05) and lower LNSC (T3/T1 P < 0.05) levels in comparison with low-fit individuals. However, the beneficial effects on ACAR disappeared after a 10-week exercise-based programing (T1/T3 P < 0.05). Our findings suggest that both high-intensity aerobic and progressive resistance programs can positively affect cortisol levels in middle-aged",
        "label": 1
    },
    "1638": {
        "output": "## [MATH]\n\n\n\n\n![INST] The assessment of eligibility of the patient for the clinical trial. \n\n\n\n# [OPTIONAL] Expectations\nBefore attempting this task, you should check whether the following expectation(s) apply:\n\n\nBy creating a dataset that simulates patients' data using MATLAB, you will learn how to solve complex real-world problems by coding a simulation. You will get familiar with all functions that are used to generate patient datasets in MATLAB. \n   \n<EOD> The Role of the Nursing Profession in the New Era of Health\n\nThis essay focuses on the role of the nursing profession in the new era of health. The main issues addressed are as follows: the nature of the new era of health that requires a broad, all-embracing understanding of health; nursing education and the requirement of interprofessional education for nursing students; the need for social dialogue and community-oriented engagement in order to create the necessary groundwork for nursing practice; and the central role of the state in ensuring the implementation of a reformed and progressive nursing model at a national level.\n\n# Introduction\nNursing was established with the aim of solving problems and fulfilling a basic human need. The new era of health, on the other hand, is essentially aimed at the prevention of diseases through the adoption of healthy lifestyles. Today, our understanding of health has begun to shift from a traditional biomedical perspective to a broader, all-embracing perspective of a systematic human environment based on the philosophy of social justice. Nurses play an important role in the development of new healthcare models and the implementation of a universal approach to health. Nursing education is the basis of nursing as a knowledge profession and the only way to ensure nurses develop an integrated, holistic approach to health to facilitate the provision of safe and effective nursing care as nursing students are prepared to become professional nurses.\n\n## The nature of the new era of health\nToday, health is defined not only as the absence of disease but also in terms of the absence of social and economic inequality and as the presence of a healthy social and economic structure. It encompasses a wide range of factors, including",
        "label": 1
    },
    "1639": {
        "output": "[table]  Examples: [INFO] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. [EX] You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. [TUT1] The patient is a 53-year-old woman diagnosed with HCV 3 years ago and the recent coinfection with [/table] \n[table]  [END] [/table] \n<EOD> Immunological evaluation of a live, oral cholera vaccine in volunteers.\nAbstract\nExperiments were made to assess the immunogenicity and potential immunologic consequences of vaccination with a live, oral cholera vaccine. Volunteers given the vaccine orally or parenterally developed antibodies to cholera toxin after a single dose and high levels of serum-neutralizing antibody after two doses. Serum toxin absorption inhibitory (anti-toxin) titers developed in only 3 of 22 volunteers given a single oral dose. The presence of the toxin receptor for anti-toxin was determined by using a toxin-binding serum fraction containing primarily anti-toxin in a toxin-binding assay. Four groups were studied in these experiments: group 1, 10 volunteers given four doses of vaccine orally on consecutive days, group 2, 10 volunteers given four doses of vaccine intravenously on consecutive days, group 3, 11 volunteers given one dose of vaccine intravenously, and group 4, 7 volunteers given orally administered vaccine. The highest titers of serum anti-toxin and serum toxin-binding inhibitory antibodies (anti-toxin) were seen after oral administration of vaccine, suggesting an enhancing effect by the mucosal environment. Two of 16 volunteers who received the vaccine, 10 intravenously at weekly intervals, became carriers",
        "label": 0
    },
    "1640": {
        "output": "Your task is to automatically find all subjects eligible for a clinical trial. You will receive a patient note and the clinical trial criteria as below. Write a program to find all subjects eligible for the following trial:\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere is the clinical trial: \nTitle: Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects\n\n\nSummary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and antiviral activity of multiple, ascending doses of ABT-267 (also known as ombitasvir) administered as",
        "label": 0
    },
    "1641": {
        "output": "The following is the program for calculating trial-level eligibility on the IFN + RBV data set: \n\n``` {#codeblock_5}{#codeblock_5_heading_3}\nlibrary(tm)\nlibrary(parallel)\nlibrary(doSparse)\n\n# Get data\ndata <- c(\"patient1\", \"patient2\", \"patient3\", \"patient4\") \ninst <- c(\"Trial_IN2136\", \"Trial_IN6751\", \"Trial_IN2300\", \"Trial_IN5923\")  # \u8a66\u5408\u584a\u306e\u540d\u524d\u3092\u6587\u5b57\u5217\u5316\n\nif (is.null(global$data)) {\n  global$patient <- dat <- readSV(\"data/patient.csv\")\nglobal$title <- dat$Patient$ID\nglobal$date <- dat$Patient$Date\nglobal$inst <- dat$Patient$trial\nglobal$diagnosis <- dat$Patient$Diagnosis\nglobal$condition <- list(\n  \"haptoglobin\",\n  \"Lymphocyte Count\",\n  \"Bilirubin\",\n  \"Creatinine\",\n  \"Lipase\",\n  \"Glucose\",\n  \"Hemoglobin\",\n  \"WBC_C\",\n  \"WBC_B\",\n  \"WBC_T\",\n  \"Total\",\n  \"Temporal_A\",\n  \"Temporal_G\",\n  \"Temporal_I\",\n  \"Temporal_nK\",\n  \"Neutrophil\",\n  \"Lymphocyte\",\n  \"Monocyte\",\n  \"Eosinophil\",\n  \"Basophil\"\n)\nglobal$test <- list(\n  \"IN2136\",\n  \"IN6751\",\n  \"IN2300\",\n  \"IN5923\"\n)\nglobal$result <- list( \"excluded\", \"0\", \"0\", \"0\")\nglobal$note <- list( \"Excluded: Not applicable\", \"Not relevant: Test results are not relevant.\", \"Not eligible: Inclusion criteria not met.\",",
        "label": 2
    },
    "1642": {
        "output": "<EOD> Prevention of Intrathecal Bacterial Infection in Leakage or Obstruction of a Shunt\nA study of the bacteriology, shunt function, and clinical symptoms of 15 episodes of shunt infection in 11 patients in whom a systemic antibiotic is used prophylactically in cases of intrathecal bacterial infection, with or without a meningitis is reported. Five different intravascular routes were used and the antibiotic used was aminoglycosides (Gentamicin 80 mg/kg/day, neomycin 10 mg/kg/day). Shunt valves were changed at intervals ranging from 3 to 8 weeks, according to the type (simple valve versus reservoir system) and type and number of bacteria isolated from the spinal fluid at the onset of infection. Six cases of shunt obstruction without meningitis, 2 cases with meningitis without shunt obstruction, and 7 cases with meningitis and simultaneous shunt obstruction or leakage were treated. Shunt function was restored within 2 or 3 days and clinical symptoms disappeared within 3 or 4 days. No bacteria were isolated from the spinal fluid during the treatment. A repeated antibiotic treatment resulted in meningitis control in 7 of the 8 cases. There were only slight and transient aminoglycosides-induced side effects in 5 patients.<EOD> Ophthalmomyiasis, a complication of ophthalmic surgery.\nOphthalmomyiasis is rare since the development of better-quality disinfectants. Most of the ophthalmomyiasis cases published in the literature have been associated with unclean surgical instruments. Two patients presented early after uncomplicated keratoplasty with eyelid and conjunctival swelling and marked chemosis. A third patient developed postoperative blepharitis. One had multiple parasitic larvae in a core corneal biopsy and the other had ophthalmomyiasis with an infection involving the lid and conjunctiva. These organisms were removed and the patients remained well thereafter. The third patient was successfully treated topically.<EOD>",
        "label": 0
    },
    "1643": {
        "output": "[INST] Let's see the clinical trial based on the eligibility criteria:\nTITLE: Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir\nTrial Name: HEP-CT1092\n\n\n# STUDY DESIGN\nHepatitis C\n\nAIM: 1",
        "label": 1
    },
    "1644": {
        "output": "## [END]\n<EOD> Antibody to H5 avian nasal epithelium surface antigen (HANES) in nasal mucus of chickens infected with mycoplasmas.\nHANES antibody was present in the nasal mucus of birds infected with mycoplasmas (but not in turkeys infected with fowl cholera) and was absent from uninfected birds. The antibody could be absorbed completely by a mycoplasma cell suspension or by mycoplasma antigen.<EOD> Identification and expression of a novel human NFAT family member\nA novel human cDNA encoding a gene product that we predict is a transcription factor is described. We have designated this novel gene as NFAT5, because it encodes a nuclear factor of activated T cells 5 (NFAT5). The predicted 482\u2010amino acid peptide is highly acidic compared with other NFATs and lacks the C\u2010terminal transactivation domains. This study provides molecular clues to understanding how the NFAT family functions in many processes ranging from immune to osmoregulatory and cell differentiation responses. Published in 2002 by John Wiley & Sons, Ltd.<EOD> The relationship of metformin and metabolic syndrome and diabetes mellitus with renal cell carcinoma.\nOBJECTIVE\nMetformin as an anti-diabetic drug has been reported to be related to a decreased risk of developing chronic diseases such as cardiovascular disorders and cancers. Our aim was to evaluate the use of metformin and the prevalence of diabetes mellitus with metabolic syndrome in patients with renal cell carcinoma compared to other control groups and to control the risk factors in these patients with metformin use.\n\n\nPATIENTS AND METHODS\nWe randomly selected, from a group of patients with renal cell carcinoma, patients who were newly diagnosed and started metformin treatment, and we assigned then a total of 100 subjects of metformin-treated group, 102 patients of untreated group, 100 with T2DM patients, and 100 BMI-",
        "label": 1
    },
    "1645": {
        "output": "[/TEST]\n\n\n### Exercises.\n- Exercise 1.\n\n```python\nimport sys\nimport os\nimport jupyter_client as client\n\ntry:\n    token = client.get_token()\nexcept client.ClientException as ex:\n    print(\"Failed to retrieve token:\", ex)\n    sys.exit(1)\n\n# Get a token to test the use of environment variables\nclient.token = os.environ[\"CLOVER_TEST_CLIENT_TOKEN\"]\n\nprint(\"Environment variables configured\")\nprint(\"Token: %s\" % client.token)\n```\n\n- Exercise 2.\n\n```python\nimport sys\nsys.path.append('python-client/env')\nfrom env.api import API_Client\nfrom env.client import env_client\n\ntry:\n    token = env_client.get_token()\nexcept client.ClientException as ex:\n    print(\"Failed to retrieve token:\", ex)\n    sys.exit(1)\n\n# Get a token to test the use of environment variables\nclient.token = os.environ[\"CLOVER_TEST_CLIENT_TOKEN\"]\n\nprint(\"Environment variables configured\")\nprint(\"Token: %s\" % client.token)\n```\n\n- Exercise 3.\n\n```python\nfrom clover_python_client.config import (get_clover_env_ini_path, clover_app_config_file)\n\nenv = {\n        \"CLOVER_HOST\": \"http://localhost:8001/webui\",\n        \"CLOVER_PORT\": 8000,\n        \"CLOVER_DEBUG\": False,\n        \"CLOVER_TEST_DATABASE\": \"\"\"database.xml\"\"\",\n        \"CLOVER_TEST_CLIENT_TOKEN\": \"token\",\n        \"CLOVER_HOST_EXTERNAL\": \"http://localhost:8000\" if config.CLOVER_HOST_EXTERNAL else \"false\",\n        \"CLOVER_USER_LOGIN\": \"clover-client\",\n        \"CLOVER_USER_PW\": \"password\"\n        }\n```\n\n- Exerc",
        "label": 2
    },
    "1646": {
        "output": "## [END]\n#####\n\n# Related topics\n\n- Clinical trial design\n\n- [BELRNA#](belrna.md)  \u2013 Belief rule base\n- [RULDR](ruldr.md)  \u2013 Run-time uncertainty logic detection and resolution\n\n# References\n\nFor academic citation, please list the following.\n\n- [Interpol, R.A. \u201cLearning to Represent Clinical Trials in Belief Rule Based Diagnoses,\u201d BMC Medical Informatics and<EOD> Nanocomposites of ZnAl2O4:Eu2+,Sm3+ with Carbon Nanofibers as Phosphorescence Emitters\n\nCitation: Ivan'kova, E.; Yatsenko, D.; Borysenko, V.; Baeva, M.; Shumskaeva, M.; Semenova, E.; Vasylev, A.; Makarov, D.; Popova, S.; Borodina, T. Nanocomposites of ZnAl 2 O 4 :Eu 2+ , Sm 3+ with Carbon Nanofibers as Phosphorescence Emitters. Materials 2022, 15, 8115. https://doi.org/10.3390/ ma15248115 Academic Editor: Anna I. Miroshnichenko\n\n# Introduction\nA great potential for development and wide application perspectives has been determined for luminescent nanomaterials in various fields, namely, lighting, biotechnology, medical diagnostics, sensors, and others [bib_ref]  Nanomaterials for in vivo Imaging, Smith [/bib_ref]  [bib_ref]  Nanometer-sized light-emitting diodes based on carbon nanotubes, Meng [/bib_ref]  [bib_ref]  Nanomaterials in diagnostics and therapeutics for genitourinary cancer, Dhillon [/bib_ref]  [bib_ref]  A luminescent ZnO@SiO 2 core/shell nanomaterial used in chemiluminescence detection of mercuric..., Zhou [/bib_ref]  [bib_ref]  Bimetallic nanoparticle-based electrochemical biosensors for clinical diagnostics, Hasanza",
        "label": 1
    },
    "1647": {
        "output": "<EOD> Comparison of anticoagulant effect on patients on andalol, quinidine and placebo.\n1. In a trial with 70 patients, the anticoagulant effect of a long term administration of andalol, quinidine, a combination of andalol and quinidine and placebo has been compared. 2. The only reliable measure of the degree of anticoagulation in hospital patients is the prothrombin time. 3. The effect of andalol and placebo, andalol and quinidine and quinidine alone on the prothrombin time has been studied in 70 patients. A significant prolongation of the prothrombin time has been obtained in 95% of the andalol patients (the dosage given was 800 mg daily). This degree of prolongation was not obtained in patients treated with the combination of quinidine, 300 mg daily, and andalol in doses of 600 mg daily, although 80% of the patients treated were considered to be adequately anticoagulated. 4. The combination of andalol, 800 mg daily, and quinidine, 300 mg daily, is not a reliable anticoagulant, unless the dosage is increased and the anticoagulant effect is supplemented by the addition of placebo in order to increase the dose of andalol.<EOD> .\nUNLABELLED\nDuring 1992-1996 we examined 219 patients with cancer of the cervix uteri, using a standardized scheme of staging: clinical and colposcopic examination, cytology, histological examination, cysto- and pyelography, abdomino-thoracoscopy, lymphography, abdomino-radiography combined with echography.\n\n\nRESULTS\nAccording to our examination data, cervical cancer was predominantly found in patients of 50-59 yrs. Most patients were in stage IIA of the disease.\n\n\nCONCLUSION\nRadical treatment of cancer of the cervix is possible only if it is diagnosed early that is why our investigations",
        "label": 1
    },
    "1648": {
        "output": "[END]\n\n\n\n--EXAMPLE 2 (Hepatic encephalopathy) --\n[BASH] python exercise2.py\n[/BASH]\n[INST]\nExercise Design\n\nYou have been asked to recruit a sample of individuals with liver disease. Those individuals with diagnosis of chronic liver disease present with a number of symptoms. Some patients with liver disease develop hepatic encephalopathy, a serious neuropsychiatric disorder. You are asked to compare a given patient note to inclusion criteria of a clinical trial on hepatic encephalopathy.\n\nHere is a patient note:\n36-year-old male with underlying chronic hepatitis C; admitted for evaluation of a rash.\n\nThe patient is on daily aspirin for his chronic headache but has no history of cirrhosis. His HCV RNA is not detectable. He has had a bacterial skin infection on his lower extremities. He has a positive history of alcohol use (1 bottle of wine every month or less) and has smoked 1.5 packs of cigarettes daily. On admission, he was hypertensive. He has a positive drug history for benzodiazepines for anxiety, and his medications include acetaminophen, ibuprofen and niacin. His BP: 140/90, HR: 100/min. He has a mildly enlarged liver, without tenderness and ascites, negative for jaundice. His labs are unremarkable.\n\nHere is the clinical trial:\n\nTitle: Investigation of Genetic Susceptibility to Hepatic Encephalopathy\n\nSummary: Background:~- Hepatic Encephalopathy is a potentially life-threatening neuropsychocognitive complication of cirrhosis commonly seen in hospitalized patients. The etiopathogenesis of HE has remained elusive and current practice involves management of precipitants and use of lactulose and rifaximin. The exact mechanism of hepatic encephalopathy continues to be elusive despite evidence for brain edema, cerebral hyperemia",
        "label": 0
    },
    "1649": {
        "output": "Assignment of weights and optimization:\n- You can assign weights to the attributes, e.g., `Subject_age` = `1`, `Subject_weight` = `2` and so on.\n- Since we use GEDI as our assignment method, we can assign the weights in the following way:\n`Wage` (or `Subject_age` or `Subject_weight` with the corresponding name) & `Weight_classification_of_the_weight` & <the weight of the attributes with the corresponding name>\nTherefore, `Wage` & `Weight_classification_of_the_weight` & `1` is assigned to `Subject_age` because it is the same as in the first example, i.e., `Wage` & `Weight_classification_of_the_weight` & `2` for `Subject_weight`.\nWe can assign multiple weights using the following command:\n`Wage_hist` & `weight_opt` & <weights to be assigned>\nIn case you assign more than one weight to an attribute, you should specify corresponding weights and put the weights in the brackets for `opt_weights` in the optimization function:\n[[`Wage_hist` & `weight_opt` & `W1`, `W2` & `W3`, `W4`]]\n[INST]\n\nThis is the parameter `min` in the optimization function:\n`min` is the parameter which should be minimized. It can be considered as a function of other parts of the optimization function.\nIn our example:\n`min = w 1  + w 2 + w 3 + w 4 `\nYou can apply any function to the parameter `min` as the optimization target. The function should only relate to data but not include the weights.\n- You can apply any function to the parameter `min` as the optimization target. The function should only relate to data but not include the weights.\n- For example, you can apply a logistic to your data as follows:\n`l1` & _`X_ & `weights` -> `y`\nSo, you should modify`y` by modifying`min` and optimize`weights` by minimizing`min` in the optimization function.\n``l1(x,y)` can be replaced by the following one below",
        "label": 1
    },
    "1650": {
        "output": "![INST]\nIn this way, you can make an automated data entry. And you can check each step of this process by reading the original message, i.e., `Patient note - Your first trial note`. If everything works well, the patient_level_eligibility should be '2' (eligible), and your final result should be a `patient note - Your first trial note - Processed`.<EOD> Comparison of Surgical Outcomes among Three Surgical Approaches for Lumbosacral Adjacent Segment Disease\n\nBackground: Few studies have compared the outcomes of different surgical procedures for lumbosacral adjacent segment disease (LASD). The purpose of this study is to explore the safety and efficacy of three surgical procedures: circumferential decompression and fusion (CD), posterior lumbar interbody fusion (PLIF), and direct lumbar interbody fusion (DLIF). Methods: A clinical trial and a prospective database was searched, and patients with LASD treated using CD, PLIF, or DLIF were included. Data were collected from outpatient clinical interviews, electronic medical records, and telephone follow-up, and were compared. Results: In all, 313 patients (101 CD, 95 PLIF, 117 DLIF) were included. The duration of follow-up was 31.4 months (13.4 in the CD group). There were no significant differences between the three surgical groups in age, sex, BMI, segment involved, and follow-up duration. For the operative level, the CD and PLIF groups were more common, while the DLIF group was significantly less. There were significant differences between the CD group and the PLIF group in operative time (256.9 min vs. 174.1 min, p < 0.01), intraoperative blood loss (156.3 mL vs. 366.4 mL, p < 0.01), length of hospital stay (7.7 d vs. 13.2 d, p < 0.01), and time to return to full activity (5.3 months vs. 6.7 months, p < 0.01). Comp",
        "label": 0
    },
    "1651": {
        "output": "<EOD> Immune profiling and prognosis: An analysis of peripheral blood from patients with breast cancer treated at three cancer treatment centers in the United States\n\nBreast Cancer (BC) is the most diagnosed cancer in women. Immune checkpoint inhibitors (ICI) are one treatment option for women with metastatic BC, but the utility of peripheral blood measurements and prognosis in BC have not been well characterized. PBMCs and serum were prospectively collected from consented BC patients at three sites in the United States (US). PBMCs were characterized by flow cytometry and serum by ELISA assay (n = 146 patients). Patients were followed for recurrence (n = 167) and BC-specific mortality (n = 112) to evaluate the associations between baseline immune profiles and BC prognosis. Among the patient population (mean age, 59), median tumor size was 3.1 cm, and median cancer stage was 2 (stage I-stage II). Baseline median neutrophil/lymphocyte ratio (NLR) was 2.4; interleukin (IL)-6 was 4.2 pg/mL; IL-10, 2.6 pg/mL; granulocyte macrosphage colony-stimulating factor (GM-CSF), 12.0 pg/mL; and tumor necrosis factor-alpha (TNF-\u03b1), 28.7 pg/mL. Multivariate Cox proportional hazard analyses were then performed to compare outcomes on disease recurrence and BC specific mortality by neutrophils, IL-6, IL-10, GM-CSF, TNF-\u03b1, and CD4 + , CD4 + /CD3 + , CD8 + , CD19 + /CD16 + /CD56 + . Analyses of the immune profiles by cancer stage demonstrated significantly increased cancer-specific mortality [Cox Hazard Ratio (HR), 2.12; 95% confidence interval (CI), 1.19-3.78] and recurrence risk (HR, 1.86; 95% CI, 1.0",
        "label": 1
    },
    "1652": {
        "output": "Instructions:\n- You only need to complete the following assessments:\n\t- Title: Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection\n\t- Summary: This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.\n\t- Inclusion criteria: Inclusion Criteria:\n\t\t- Age > 18 with chronic genotype 2 or 3 HCV infection\n\t\t- HCV RNA > 10,000 IU/mL at screening\n\t\t- Subjects must be treatment naive or treatment experienced\n\t\t- Presence or absence of cirrhosis; a liver biopsy may be required\n\t\t- healthy according to medical history and physical examination with the exception of HCV diagnosis\n\t\t- agree to use two forms of highly effective contraception for the duration of the study and 6 months after the last dose of study medication\n\t- Exclusion criteria:\n\t\t- Subject with severe, complicated, and progressive disease that puts the subject at risk due to participation in the study.\n\t\t- Subject judged to be at risk of not adhering to the study plan.\n\t\t- Subject judged to be highly likely to take medicines other than those required to participate in the study at study or a clinically significant level.\n\t\t- Subject has known HIV, HBV, or HCV infection.\n\t\t- History of human immunodeficiency or immunosuppressants.\n\t\t- Any medical/surgical/psychiatric condition that in the opinion of the investigator would make subject unsuitable for the study.\n\t\t- Subject who is participating in or has participated in another clinical trial that is not allowed in this trial.\n\t- [/HEADER]\n\n# Problem Set\n##### Step 2\nFor the `Trial-level eligibility`?",
        "label": 1
    },
    "1653": {
        "output": "**Task Summary**: You need to compare a given patient note and the inclusion criteria of a clinical trial using if...else... constructs and repeat eligibility in the end.\n\n### Clinical Trial Notation\n\n```python\n    import ctb, re\n    from collections import defaultdict\n\n    ## Include clinical trial as an input\n    trial = ctb.ClinicalTrial(os.path.join(os.path.dirname(__file__), 'trial_xml'))\n\n    # Make a patient's Trial-level eligibility at the beginning of the function.\n    trial_level_eligibility = 0\n    for note in notes:\n        ## Match the patient note to the trial and evaluate eligibility\n        trial_patient_note_pattern = re.search(r'(?<=title)>([^<]*)(<title>)(.*)', str(note))\n        if trial.matchToNote(patient_note_pattern):\n        trial_level_eligibility = trial # Evaluate eligibility if the clinical trial and patient note are matched.\n        if trial_patient_note_pattern.group(2) == patient_note.title: # Evaluate eligibility in matched patient note to clinical trial\n            ## Assess patient eligibility with if...else... construct\n            if trial.assessEligibility(patient_note): # Evaluate eligibility with if...else... construct\n                trial_level_eligibility = 2\n            else:\n                trial_level_eligibility = 0\n        else:  # Evaluate eligibility if trial and patient note are not matched\n            if trial.assessEligibilityNotMatchToNote(patient_note_pattern): # Evaluate eligibility if trial has not matched to patient note\n                trial_level_eligibility = 0\n            else: # Evaluate eligibility if trial has matched patients note\n                if trial.assessEligibilityNotMatchToNote(patient_note): # Evaluate eligibility if trial has matched to patient note\n                    trial_level_eligibility = 2\n                else:\n                    trial_level_eligibility",
        "label": 0
    },
    "1654": {
        "output": "\u00a9 Lukas Neumuth, 2015 - 2019. [1702] - Reused with kind permission of Lukas Neumuth.\n<EOD> The role of bacterial community composition in the outcome of biological control agent inoculations and plant defence priming in alfalfa (Medicago sativa L.) against Rhizoctonia solani\n\nThe application of plant growth-promoting rhizobacteria (PGPR) may be considered a useful alternative for chemical pesticides in agricultural systems. We explored the outcome of PGPR inoculation and the role of bacterial community composition in plants in controlling Rhizoctonia root rot, focusing on bacteria-plant interactions that may alter the plants' response to the soil-borne fungal pathogen Rhizoctonia solani. We found an enrichment of beneficial plant-interacting bacteria: Pseudomonas and Burkholderia-Caballeronia-Paraburkholderia (Pseudomonadales order) in plants grown with PGPR strains. Plants inoculated by Azospirillum brasilense and PGPR consortia had an activation of different systems of plant defence when compared to rhizosphere-inoculated plants (e.g. oxidative burst, SA/JA ratio, expression of pathogenesis-related genes). Inoculated plants triggered an antifungal root defence, and the ability of plants inoculated with A. brasilense to control the disease has been described in details. Our results suggest the possibility to use endophytes, in controlled conditions, for controlling plant soil-borne pathogens and improving plant performance. Rhizoctonia root rot control by endophytes represents one of the many outcomes of PGPR that can be useful for sustainable agriculture.\nIntroduction Rhizoctonia solani is widespread and considered one of the most important soil-borne plant pathogens causing root rot and leaf spots in various crops including alfalfa, which is characterized by a high rhizosphere richness of soil microbes due to the release of several compounds, including nutrients and antimicrobial products, and the activity of some mechanisms such as root exud",
        "label": 0
    },
    "1655": {
        "output": "<EOD> .\nOBJECTIVE\nTo investigate the biomechanical effects of various reconstructions of femoral periprosthetic fracture after arthroplasty.\n\n\nMETHODS\nThe experimental models were established by cutting off the middle diaphysis of rabbit tibia. Three groups were made up according to different kinds of fixings: single-screw fixation group , double-screw fixation group  and screw fixation combined with plate fixation group  (14 in each group). Each group was divided into 3 subgroups equally based on the time of loading. The loading was done in groups 1, 2 and 3 after the first, third and fifth month, respectively. The rabbits in each group were further put into 2 subgroups, 7 in each one, with the broken end being bent (one degree, 100 N 90 degrees bending) or not being bent (0 degree 0 N bending). The mechanical indexes of each model were monitored and recorded and the data in groups A, B and C before loading were recorded in advance. The mean data were statistically analyzed.\n\n\nRESULTS\nThe fracture healing was observed 3 to 4 months after loading in groups B and C but not in group A. The fracture healing of double-screw fixation group was earlier than that of other two groups, and that of screw fixation combined with plate fixation group was later than that of the other two groups. The mechanical indexes in groups with the broken end bent were lower than those in groups without the broken end bent and groups before loading. The mechanical indexes in groups before loading were higher than those after loading.\n\n\nCONCLUSION\nScrew fixation and screw fixation combined with plate fixation make better fracture healing after femoral periprosthetic fracture, and bending the broken end of femoral shaft helps to increase the stability of fracture union.<EOD> Detection of an in vivo transient subfraction in the cytoplasmic fraction of rat liver by two-dimensional gel electrophoresis.\nRabbit antibody to the liver cytoplasm is used in Western blot to compare the cytoplasmic proteins of three tissues. An identical set of proteins",
        "label": 0
    },
    "1656": {
        "output": "Please leave your comments/queries in case you find any problem with any of the tasks.\n\n\n\n<EOD> Mitochondrial myopathy presenting as chronic subclinical methemoglobinemia\nIn a retrospective review, we found a high incidence of methemoglobinemia in patients with myopathy.<EOD> Fracture healing in bone transplants. An in vivo study of the influence of autogenous iliac bone and cortical autogenous femoral bone grafts.\nA comparison of the results of this experimental study (using the rat) of the healing of standardized cancellous bone grafts in the upper end of the tibia and of bone grafts placed under the skin of the same animal and in the muscles of the abdominopelvic cavity with standardized cortical grafts of femoral bone was used to evaluate the influence of bone grafts of various types on the healing process of fractures in bone transplants. The results of this study can only be evaluated on the basis of the clinical criteria in which the experimental animals that were used were included. In clinical practice, bone transplants are used in a wide range of surgical procedures and operations, from small operations of the hand to large orthopedic operations. The present study was carried out in an attempt to further the clinical problem of what to consider to be the most suitable material for these grafts in various types of bone surgery. In this study, two types of bone grafts \u2014 cancellous bone and cortical bone \u2014 from two different sites were used. Autogenous bone grafts from the iliac crest appear to be the ideal material, according to the results of the present study. On the other hand, the use of autogenous cortical bone grafts from the femur provides a sufficient healing stimulus. This may be attributable to the relative anaerobic nature of the bone marrow of the femur and to the good blood supply to the bone graft.<EOD> High serum lipid ratios are associated with decreased risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection\nThe relationship between serum lipid",
        "label": 1
    },
    "1657": {
        "output": "# Discussion\n\n## Instructions to authors\nComplete this form in your own word processor to prepare your manuscript for submission. All subsequent forms may be filled out and uploaded as one file pertaining to a single report, or separately if the manuscript has been accepted in different formats. If a form does not pertain to the manuscript, it needs not to be included. Checkmarks allow you to choose which copyright you are choosing. All persons designated in this form as authors must be included as authors and sign all versions of the manuscript. The form provides all the instructions that would be found elsewhere in a submissions package, including guidelines for writing manuscripts, such as how to indicate page and line number.\n\n# Ethical statement\n\n## Instructions to authors\nComplete this form in your own word processor to prepare your manuscript for submission. All subsequent forms may be filled out and uploaded as one file pertaining to a single report, or separately if the manuscript has been accepted in different formats. If a form does not pertain to the manuscript, it needs not to be included. Checkmarks allow you to choose which copyright you are choosing. All persons designated in this form as authors must be included as authors and sign all versions of the manuscript. The form provides all the instructions that would be found elsewhere in a submissions package, including guidelines for writing manuscripts, such as how to indicate page and line number. 36.551 5.0 43-45\n[formula]  R U C V O Y / E M E S S A Y I N 2 0 1 5 O N C E ! / 2 E M E S S A Y I M A G E S # A C I A D I M Y S G E O E R M U M E N M E D U F E M A T O E S I S M E D I C I M I D D E P O A I S S V A N - V U C T U R E R E C A L L S T I N N P I R E M B A N V I R S F A I R A R C G I N O V A N E C A M C P 515 A R C H I P A L D [/formula] \nNote: This PDF file is intended for educational purposes only. Please see our Terms and Use of Copyrighted Materials",
        "label": 0
    },
    "1658": {
        "output": "<EOD> Comparison of three surgical approaches to total calcanectomy in dogs.\nThree groups of 10 dogs each received total calcanectomy through the heel skin incision (group 1), the medial cranial tibial skin/muscle incision (group 2) and the medial plantar skin incision (group 3). Evaluations of surgical complications and clinical outcome were performed on postoperative day 7, day 14 and 3, 6, and 10 months. Group 2 dogs required postoperative antibiotics to treat a surgical wound infection, but dogs in other groups did not. All animals regained normal locomotion. Although group 2 animals walked with a mild digital stiffness, group 1 animals demonstrated a more pronounced paresis of their hindlimb. No dogs had postoperative infections. All animals regained normal locomotion.<EOD> .\nThe influence of osteogenic differentiation of osteoblastic cells by the extracts of tetracycline-loaded calcium phosphate ceramics on the cellular metabolism has been studied by measurements of intracellular phosphorus levels. Cells were cultured for 7 days in a liquid medium containing extracts of tetracycline-containing material. The results obtained were compared with metabolic changes in culture of cells incubated on tetracycline-containing ceramics. The study showed that even a low osteogenic differentiation of cells, achieved at nontoxic concentrations of added tetracycline, leads to significant alterations in cellular metabolism.<EOD> Narrative review of bacterial pneumonia in chronic obstructive pulmonary disease: is antibiotics prophylaxis necessary?\nCitation for published version (APA):Makris, D., & Leung, B. (2015). Narrative review of bacterial pneumonia in chronic obstructive pulmonary disease: is antibiotics prophylaxis necessary? Respirology, 20(3), 626-632. ,, , , , https://doi.<EOD> Atypical carcinoid coexistent with bronchogenic",
        "label": 0
    },
    "1659": {
        "output": "[EMBE]\n\n## Step 4: `Trial-level eligibility`\n\n[HEAD]\n\nStep4: TASK: `Trial-level eligibility`\n\nIn this step, you should assign the scale of `Trial-level eligibility` to the trial, e.g., `Trial-level eligibility: 2) Eligible.`. [INST]\n\n[EMBE]\n\nThe [TASK] elements are shown in following. You may add an element, [TASK] element, for `Trial-level eligibility` and assign it, e.g., `[TASK] Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`. [INST]\n\n[[EMBE]\n\n## Step 5: `Trial-level eligibility` `Aliases`\n\n[HEAD]\n\nStep5: TASK: `Trial-level eligibility` `Aliases`\n\nIn this step, you may assign the alias in the form of, e.g., `Trial-level eligible` to alias the patients with the trial, e.g., `Aliases : `, e.g., `eligible trial: #00.`. [INST]\n\n[EMBE]\n\nThe [HEAD] elements are shown in following. You may also add an [HEAD] element for an alias of the trial-level eligibility. However, you are not required to add the element because it is optional. [INST]\n\n[[EMBE]\n\n## Step 5: `Trial-level eligibility` `Attributes`\n\n[HEAD]\n\nStep5: TASK: `Trial-level eligibility` `Attributes`\n\nIn this step, you are required to add an [AT-TRIBUTE] element such that the name of the element is assigned from the following as the `Attribute` name, e.g., `Name: Trial_eligibility.`. [INST]\n\n[EMBE]\n\nThe [ATTRIBUTE] elements are shown in following. It is necessary to add an element for the `Attribute`",
        "label": 0
    },
    "1660": {
        "output": "Your task has 10 examples that are randomly generated per clinical trial, so you need to correctly classify each example, and you will receive a score based on each answer. On average, you should achieve a score > 90 to pass to the next stage to verify the ability to deal with the given clinical trial note. \n\n### Stage 1: Recall the general trial data\n\nThe following are the example test cases. The top line in each test case is the trial note and the three lines under the trial note are the clinical trial. You can view the data by clicking the checkboxes below the test cases.\n\n- <img src=\"https://datatables.net/media/images/snippet1-example.png\">\n\n\n\n- <img src=\"https://datatables.net/media/images/snippet2-example.png\">\n\n- <img src=\"https://datatables.net/media/images/snippet3-example.png\">\n\n- <img src=\"https://datatables.net/media/images/snippet4-example.png\">\n\n<!---\n    You will need to recall the general trial data to classify each example\n    below.-->\n\n### Stage 2: Recall the information about the patients\n\n- <img src=\"https://datatables.net/media/images/snippet1-recall-example.png\">\n\n- <img src=\"https://datatables.net/media/images/snippet2-recall-example.png\">\n\n- <img src=\"https://datatables.net/media/images/snippet3-recall-example.png\">\n\n- <img src=\"https://datatables.net/media/images/snippet4-recall-example.png\">\n\n<!---\n    You will need to recall the information about the patients to classify each\n    example below.-->\n\n### Stage 3: Recall the information about the clinical trial\n\n- <img src=\"https://datatables.net/media/images/snippet1-recall-example.png\">\n\n- <img src=\"https://datatables.net/media/images/snippet",
        "label": 0
    },
    "1661": {
        "output": "After processing each patient, press ENTER to proceed to the next patient. \nTo go to review the data, press the button: [?].\nA screen showing the status of each patient note is shown. [OUT]\n\n### Instructions to users: Patients in trials\n\nYou are a physician at an outpatient or subspecialty clinic who cares for patients in clinical trials. You evaluate patients in trials every day in collaboration with other colleagues assigned to the trial. This means that you will likely interact with people working at both the National Institute of Allergy and Infectious Diseases (NIAID), and at the trial sites, including the trial site IRB. Trials may recruit patients from all over the country.\n\nThe following is a patient note from a clinical trial: \nPatient: 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV.\nHis past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient does not undergo any other medication. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. The recent biopsy was negative for hepatocellular carcinoma and was remarkable for chronic inflammation compatible with a chronic viral hepatitis. There was no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. Here is the clinical trial: \nTitle: DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)\n\nInclusion criteria: Inclusion Criteria:\nProvision of written, informed consent.\nHCV genotype 1 infection\nQuantifiable HCV RNA at screening and baseline (",
        "label": 1
    },
    "1662": {
        "output": "You may use a trial level eligibility block to organize your output. For example, you can set the type of patient as `Patient note: Normal` when the eligibility is 1 or `Patient note: abnormal` when the eligibility is 2 or `Patient note: missing` when there is insufficient information as 0. \nYou can refer to the information on the upper part of the patient note block:\nYou are a helpful assistant for clinical trial recruitment. Your task is to assess a given patient's participation in a clinical trial based on his/her medical information. It is a 5-point scale: 1) Relevant+ Exclusive (patient meets inclusion criteria and exclusion criteria do not apply); 2) Relevant+ Nonexclusive (patient meets inclusion criteria, but the exclusion criteria do); 3) Relevant+ Inclusive (the exclusion criteria apply); 4) Not relevant (patient does not have sufficient information to qualify for the trial); and 5) Unsuitable. \n\nThere are 5 factors about the clinical trial. You should compare the patient's medical records to each factor and make an assessed eligibility score. \n\nHere is the patient: \nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with",
        "label": 1
    },
    "1663": {
        "output": "<EOD> A comparison of methods to identify depression in older women.\nOBJECTIVES\nTo evaluate screening tests as well as medical and social criteria for the identification of depression and anxiety.\n\n\nDESIGN\nCross-sectional survey.\n\n\nSETTING\nA health maintenance organization affiliated primary care clinic providing care to lower income, predominantly inner-city residents.\n\n\nPARTICIPANTS\nOf the 689 women participating, 319 (46%) reported that they used medications for depression, 66 (9.5%; 95% confidence interval, 7.1% to 12.1%) for anxiety and 43 (6.2%; 95% confidence interval, 4.3% to 8.1%) for both conditions.\n\n\nMETHODS\nAt enrollment, medical charts were reviewed for clinical diagnoses. Measures of depression and anxiety were taken by surveys and interviews.\n\n\nRESULTS\nIn medical chart assessment, diagnostic accuracy ranged from 15% to 65% for depression and 7% to 29% for anxiety. The Hospital Anxiety and Depression Scale (HADS) had good accuracy, with area under the receiver operating characteristics curve of 0.78 for depression and 0.74 for anxiety. At HADS cutoffs of 8 to 10, sensitivities were 47% to 50% and specificities were 80% to 86%. Depression and anxiety scores obtained from questionnaires or interviews predicted chart diagnoses with areas under the receiver operating characteristics curves of 0.91 to 0.95 for depression and 0.86 for anxiety; at clinical thresholds of 13 for depression and 11 for anxiety, sensitivities were 35% to 41% and specificities were 90% to 98%. For the combination of chart diagnoses and positive ratings of depression or anxiety by clinic providers, area under the receiver operating characteristics curves were 0.88 for depression and 0.90 for anxiety.\n\n\nCONCLUSIONS\nThe",
        "label": 0
    },
    "1664": {
        "output": "The assessment of eligibility is different from that of each patient as mentioned above that there are also some inclusion or exclusion criteria depending on eligibility (1) or not for clinical trial. Below are the description about this method.    \n[H1] \n`for trial in tls:\n    if  not trial.eliminated:\n        for patient in trial.patients:\n            if patient not in trial.ineligible:\n                if eligibility(patient,clinical_trial=trial) != '':\n                    trial.eligibilities.append([trial.patient,repl_trial.dummy_trial,{},'','']+[eligibility])\n                else:\n                    trial.eligibilities.append([eligibility])\n                    \n                    if \"eligibility\" in trial.eligibilities:\n                        trial.eligibilities.pop('eligibility')\n                        patient.trials[repl_trial](repl_trial.eligibility):\n                        trail.eligibilities.append([patient.trials[repl_trial],patient.trial_patient, {'patient_id':patient.trial_patient['trial_patient_id'],'trial_patient_name':patient.trial_patient['trial_patient_name']}])\n                        \n                        #print repl_trial\n                        trial.eligibilities.append([{'trial_name':trial.eligibility['trial_name'],'trial_patient_name':trial.eligibility['trial_patient_name']}])\n                        \n                        [repl_trial.eligibility=repl_trial.eligibility,repl_trial]=patient.trials[repl_trial].updateIneligibility(tls[repl_trial],repl_trial,trial)\n```\n\nThere is a case that the patient should be excluded for clinical trial because repl_ trial is an exclusion criterion for the patient's trial but the patient is eligible for",
        "label": 0
    },
    "1665": {
        "output": "In this course, you will learn about several other tasks in clinical trial report generation: \n- Tasks for describing data from a randomized clinical trial (RCT)\n- Tasks for determining intervention-specific eligibility in a randomized clinical trial (RCT)\n- Tasks for generating the participant level eligibility assessment of the clinical trial (PLEI-A).\n\n\n## Description of a clinical trial\n\nHere is one example of a randomized clinical trial and its results. In this trial, 190 patients were randomized to either the intervention group or the control group. Patients in the intervention group had a 35% less overall death from all causes over a 5-year period than those in the controlled group. \n\nThe patients in the trial under assessment are randomly assigned to a control group and intervention group, respectively. In this example, the patients in the trial under assessment are the trial subjects, the group whose clinical study is being performed is the trial group, and the group whose outcome is being studied is the outcome group.\n\nHere is the trial data: \n- Trial IDs: TID1, ..., TID100\n- Trial names: TNM1, ..., TNM100\n- Groups: Ctrl, Inter\n- Patients in the trial: PID1, ..., PID100\n- Group allocation: 0 for the control group and 1 for the intervention group\n- Patient group numbers: PGN1, ..., PGN100\n- Outcome: OUID1, ..., OUID100\n- Outcome type: Death.\n- Study type: 2 for controlled and 1 for intervention. \n\nBesides patient and trial information, the system also provides some predefined data, such as trial group numbers. The trial group numbers represent the unique number for each trial group in the study for identification to the database, which should be used for the report generation. If the trial group number already exists in the database, the system will replace the old value with that of the new trial group number. \nYou can generate the data tables by executing the following code, and then you can import the data into the report by calling the importDataFromTable method in the",
        "label": 0
    },
    "1666": {
        "output": "A: To test, follow this template and then copy the file contents at the end:\n#+RESTART:\nTrial_review <- list(\n    \"Trial-level eligibility\" = \"1) Eligible.\",\n    \"Patient age (years)\", 50,\n    \"Trial-level eligibility\" = \"2) Eligible.\",\n    \"Patient age (years)\", 51,\n    # +RESTART TRIAL_1:\n    \"Trial-level eligibility\" = \"0) Excluded.\",\n    \"Patient age (years)\", 40,\n    \"Trial-level eligibility\" = \"1) Not relevant.\",\n    # +RESTART:\n    # Patient age (years)\", 50,\n    \"Trial-level eligibility\" = \"2) Eligible.\",\n\n    # +RESTART TRIAL_2:\n    \"Patient age (years)\", 43,\n    \"Trial-level eligibility\" = \"2) Eligible.\",\n    # +RESTART\n    \"Patient age (years)\", 51,\n    \"Trial-level eligibility\" = \"2) Eligible.\",\n    # +RESTART TRIAL_3:\n    \"Patient age (years)\", 46,\n    \"Trial-level eligibility\" = \"1) Not relevant.\",\n    # +RESTART:\n    \"Patient age (years)\", 48,\n    \"Trial-level eligibility\" = \"1) Excluded.\",\n  )",
        "label": 0
    },
    "1667": {
        "output": "Please see the following links on the Internet for the relevant information:<br>\n<br>\n[aip.aapt.org/doku.php?id=bdd_4_0_9.rst<br>]<br>\n[aip.aapt.org/doku.php/doku.php/bdd_4_0_6.rst<br>]<br>\n[aip.aapt.org/doku.php/?id=bdd_4_0_3.rst<br>]<br>\n\n# Example input files:\n\nPlease see the inputs in the examples below:\n\naipbdd4.in\n\n[aip.aapt.org/doku.php/doku.php/bdd_4_0_3.rst<br>]<br>\n---\nInput file aipbdd4.in\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n\n    <NAME>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMAIL>\n    <EMA",
        "label": 1
    },
    "1668": {
        "output": "To save Trial-level eligibility, use `Trial-level eligibility`.\n\n\n---\n\n\n\n</iframe>\n</div>\n\n\n\n</div>\n\n\n</div>\n<!--  -->\n<div id=\"view-pdf-container-footer\">\n\n</div>\n<!--  -->\n</div>\n<!--  -->\n</div>\n<!--  -->\n</div>\n<!--  -->\n</div><EOD> Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder\nThere are a limited number of reliable psychophysiological studies investigating cognitive and/or affective aspects of psychopathology in bi-polar disorder and/or attention-deficit/hyperactivity disorder (ADHD). Some evidence has been reported that the electroencephalogram (EEG) may be a valuable measure of ADHD at rest and during cognitive/affective paradigms. The aims of this study are to investigate the reliability of EEG data recorded in a sample of bipo-lar subjects with and without ADHD. EEG data were collected during two sessions on separate days. In the first session, the participants were assessed with the Positive and Negative Syndrome Scale, and subsequently with the Adult Attention Questionnaire (AAQ). In the second visit, they received the Wender Utah Rating Scale (WURS) and the Children's Depression Inventory-Korean (CDI). For the EEG recording, participants were asked to sit comfortably and concentrate on a crosshair presented on a computer screen. The mean reaction time (RT) was calculated for 35 bipolar patients with ADHD, 19 patients with bipolar disorder alone, 23 psychiatrically healthy controls and 40 ADHD children. The RT data were also analyzed according to the state of hyperarousal. The results did not show any significant differences in the RT among the groups. Compared with controls, the bipolar and ADHD groups tended to show more frequent alpha activity in the right hemisphere. In the ADHD group, the right posterior alpha was significantly greater than in the controls. These findings show that alpha oscillations were different in EEG frequency and distribution between the bipolar",
        "label": 0
    },
    "1669": {
        "output": "## [TRIAL] Data type\n[IND]\nTitle: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment na\u00efve Patients\n\nSummary: The purpose of this study is to determine whether 24 week treatment with the Daclatasvir (DCV) in combination with Pegylated-interferon alfa 2a (pegIFN\u03b1-2a) and Ribavirin (RBV) is safe and demonstrates rate of Sustained Virologic Response at follow up week 24 (SVR24) (defined as undetectable HCV RNA at post-treatment Week 24) that are non-inferior to 48 weeks of the dual combination therapy of pegIFN\u03b1-2a/RBV in a majority of study subjects.\n\nInclusion criteria: Inclusion Criteria:\nPatients chronically infected with Hepatitis C virus (HCV) GT 1 or 4\nHCV RNA viral load \u2265 10,000 IU/mL\nNa\u00efve to prior treatment with any interferon formulation, Ribavirin (RBV) or HCV direct antiviral agent\nPatients with compensated cirrhosis are permitted\nAll HIV-HCV coinfected patients with low baseline HIV viremia levels, no HIV antiretroviral therapy for 4 weeks prior to trial enrollment, HBV-HCV coinfected patients who have evidence of HBV replication for >6 months with detectable baseline HBV DNA and HBsAg-positive patients who have evidence of HBV replication and are HBsAg positive are also eligible to participate in the study.\n\nAge \u2265_18 years\n\nLess than or equal to 70 years\nWoman who is not pregnant\n\nAbility to understand and the willingness to sign a written informed consent form, and willingness to comply with the study protocol\n\nClinical and electrocardiographic (ECG) evaluation:\nAbsence",
        "label": 0
    },
    "1670": {
        "output": "<EOD> NFAT Regulates Sema3A Expression and Controls Semaphorin-mediated Axonal Guidance\nSemaphorins (Semas) regulate neural connectivity in vertebrates; genetic deletion of a single Sema causes widespread axonal guidance defects and behavioral abnormalities. Sema signaling is modulated by the transcription factor neuron-derived orphan receptor 1 (NOR1), which is controlled by nuclear factor of activated T-lymphocytes (NFAT) complexes. Here we report that NFAT activation controls the expression of Sema functionally important guidance axons: Sema3A mRNA expression is induced by NFAT in a dose- and stage-specific manner in neuronal primary cultures, as revealed by both in situ hybridization and reporter gene assays. Conversely, NFAT devoid neural cultures or injections of NFAT inhibitors abolished Sema3A induction. Our in vivo results indicate that Sema3A expression is strongly induced in the axons of the inner ear ganglion that project into its sensory epithelium and that such induction is dependent on NFAT complexes. Interestingly, the transcript levels of the Sema3A receptor neuropilin-2 (NRP-2) are reduced in the inner ear ganglion of NFAT knockout mice. Furthermore, conditional activation of NFAT in NRP-2-expressing neurons mimicked the normal inner ear projection phenotype, enabling neurite outgrowth in a Sema3A-dependent manner. Thus, NFAT regulation of Sema3A expression is indispensable for efficient Sema3A axonal transport in mice. Sema3A is also crucial to the maintenance of proper neuronal circuits and behavior: mice lacking Sema3A display severe defects in motor performance and spatial learning abilities. Because these behavioral abnormalities correlate with the lack of NRP-2 expression in the striatum, it is possible that Sema3A is one of the ligands that control NRP-2 functions in vivo.<EOD> Preventive Dentistry is the future!\n\nA 19-year-old girl was referred to the Endodontics",
        "label": 1
    },
    "1671": {
        "output": "### [Ensure that all test attributes start with a capital letter and end with a capital letter.]\n*\n\n*If you receive an error like \u201cAttribute <attributename> already specified\u201d, please be sure that you did not use a reserved attribute name for test attributes.\n*\n\n*If there is a test attribute with name that\u2019s not \u201cAttribute\u201d, the test attribute is actually a default value. You should not set it. If you do it, you should set it the default value too: e.g. If your first test attribute name is \u201cid\u201d, you should set \u201cAttribute id: 100\u201d. You should set \u201cDefault id: 100\u201d as well. [INST]\n\n*When you want to specify test value, like \u201cSex = Male\u201d, you should set it like \u201cSex <attributename>: 1 (Male)\u201d. [INST]\n\nAfter you set test attributes, you should use `Trial-specific eligibility:` to set trial-specific eligibility.\n### Test Attribute: Sex\n### Trial-Level Eligibility : Males\n### Trial-Level Eligibility : Females\nNote that `Trial-level eligibility:` and `Test Attribute:` should be in the same line, and `Attribute:` and `Trial-specific eligibility:` should be in the next line. [INST]\n\n### [Ensure that all test attributes start with a capital letter and end with a capital letter.]\n*\n\n*If you receive an error like \u201cAttribute <attributename> already specified\u201d, please be sure that you did not use a reserved attribute name for test attributes.\n*\n\n*If there is a test attribute with name that\u2019s not \u201cAttribute\u201d, the test attribute is actually a default value. You should not set it. If you do it, you should set it the default value too: e.g. If your first test attribute name is \u201cid\u201d, you should set \u201cAttribute id: 100\u201d. You should set \u201cDefault id: 100\u201d as well. [INST]\n\n*When you want to specify test value, like \u201cSex = Male\u201d, you should set it like \u201cSex <attributename>: 1 (Male)\u201d. [INST]\n\n<EOD> The relationship",
        "label": 0
    },
    "1672": {
        "output": "A. Your task: Take a random patient and determine his eligibility to the hypothetical clinical trial. \n\nB. Your task: Take a random patient and determine his eligibility to the hypothetical clinical trial\n\nC. Your task: Take a patient with a recent positive test for COVID-19 (confirmed via RT-PCR test or rapid antigen test) and determine his eligibility to the hypothetical trial on the use of RT-PCR test or rapid antigen test to screen asymptomatic patients for COVID-19.\n\nD. Your task: Take a patient with a random test result for a COVID-19 test (positive, negative, or negative follow-up). The patient had no symptoms, so she was sent home. The patient is calling five days later in distress, wondering if she was exposed to COVID-19 since she had unprotected sex with a stranger who has tested positive for COVID-19 (the date of exposure was less than 14 days prior to his COVID-19 test). The patient is also unsure if she is protected against COVID-19 because she had received one dose of the vaccine more than 30 days ago when she lived in a country with insufficient vaccine supply. \n\n[/FULL]\n\n[*3003.030 - TRAINING - Intake Forms](https://training.fda.gov/app/forms/view&id=449&page=releasedForm::1)\n\n```python\npython main.py --data testdata3003.txt\n\npython main.py --data testdata3001.txt --no_simulations \n\npython main.py --data testdata3006.txt\n```\n\n```output\n[2018-03-09 07:11:19] (1685) Running [data.py::Data_testdata3003]...\n[2018-03-09 07:11:19] (1685) Running [train.py::Train_testdata3003]...\n...\nRunning [train.py::Train_testdata3",
        "label": 0
    },
    "1673": {
        "output": "## [/MARKUP]\n\n# Hints\n* Be aware to use \"Eligible\"/\"Excluded\"/\"Not relevant/Exclusion criteria apply\" correctly. If you miss it, you will get a very important error message.\n\n\n## [CODE]\nFor the trial:\nThe patient's gender is `Ensure that this parameter is female: `\nThe patient's age is `age: 55`:\n\n\n## [INST]\nEnsure that the following is `Female`: \nThe following field: `Female: true` in the trial.\n\nThe patient's HCV genotype should be `3`(default HCV HCV): `The HCV genotype: \"3\"(default \"HCV HCV\": \"3\")`. In the trial, set the HCV genotype in the data sheet to `HCV genotype: 1`.\n\n\n## [INST]\nHCV genotype was `HCV genotype: 1`:\n\nThe patient has an advanced liver fibrosis due to his chronic HCV infection.\n\n\n## [code]\nPlease be careful: Don't put `HCV FIBROSIS: \"fibrosis\"`. In the trial, put the following statement in the data sheet: `HCV FIBROSIS: \"fibrosis\"` which is `HCV FIBROSIS: \"27048\".` The fibrosis score is calculated to be 27048 (3.144259 \u00d7 -7.133519). It's a \"fibrosis\", according to \"METVIR: \"2.4\".` \n\n## [INST]\nHCV fibrosis score: \u2265 2.4:\n\nThe inclusion criteria in the trial are `inclusion criteria in the trial:`\n\n\n## [inst]\nInclusion criteria in the trial: `inclusion criteria in the trial: \"fibrosis\"> fibrosis > 7: \n\n## [markup]\nTo get out of the assessment of patient eligibility, put the following in the data sheet: \nThe following must be notified on the trial entry page:",
        "label": 0
    },
    "1674": {
        "output": "# Additional Resources\n- [INST] [HELP]\n\n# Frequently Asked Questions\n\n## How much input or output can I expect in one evaluation?\nYour tasks will include answering clinical questions to guide patient recruitment. It is essential to be able to answer all of the following questions in detail:\n1. What are the inclusion and exclusion criteria?\n2. What is the severity of the inclusion criteria (e.g. moderate, severe and very severe)?\n3. How to screen for a participant based on the inclusion and exclusion criteria?\n4. What are the eligibility criteria?\n\n## What if there is insufficient information for the clinical questions?\nYou should document insufficient information in the report and identify the most relevant missing information that may be needed to answer a clinical question and to make a trial-level decision. In the output, you can document the following: The missing information is documented in the comments section of the output\n\n## How do I know that an article is reliable?\nAlways document whether the information is reliable, based on the citation provided.\n\n## What if the patient does not have all the inclusion or exclusion criteria?\nIf the patient does not have all the information (even insufficient information), you should document this in the output, e.g.,`Insufficient information for the determination of the trial level decision`.\n\n## How can I avoid a case being double-checked?\nIf the input case is a duplicate of one previously checked and entered into the system, you should be asked to choose a unique number of patients to double-check. \n\n## How do I know if my input was incorrect?\nInput errors should be corrected by your administrator. Correct input will be provided to you through e-mail.\n\n## Is it possible to work in two cases simultaneously?\nThis is not allowed and will be regarded as an input error. \n\n## Can I work for a couple days or take a weekend off?\nThis is not allowed. However, we accept your absence in such cases as a holiday or birthday present, but only if these reasons are documented in advance by your supervisor. \n\n## Where should I put my input for a patient?\nThe list with completed patients includes 575 (not exactly 575, but that\u2019",
        "label": 0
    },
    "1675": {
        "output": "# Questions\n\n## [Q1] What are the input and output parameters?\n[A1] \n\t\n\n## Question #2: Which of the following are true about IFN, RBV and direct antiviral drugs?\n\t\n\n##   \\[A2\\] _Option C_{}}_\\\nThe correct answer is B. RBV, IFN and direct antiviral drugs have been approved in the US for the treatment of chronic HCV infection. While RBV is approved in combination with PegIFN in US and EU, it is approved in monotherapy outside these countries. IFN, PegIFN and direct antiviral drugs have not been approved in Japan for hepatitis C treatment.\n\n## Question #3: What are the major side effects of pegIFN? IFN? How would you differentiate between adverse events, complications and side effects in the clinical trial?\n\t\n\n## \\[A3\\] _Option C_{}}_\\\nThe correct answer is A. The most common side effects of IFN include flu-like symptoms, fatigue and headache. Side effects of PegIFN and IFN are usually mild and can be treated or managed through dose adjustment and use of symptomatic medication. However, some IFN/IL2 treatment can be associated with serious adverse events, including severe cases of systemic reactions.\n\n*[N.B.] Adverse events are defined as: _any unfavorable and unintended medical occurrence in a trial subject at any dose tested and which does not necessarily have a causal relationship with the treatment. Adverse events can include: -Serious-Can result in death, hospitalization, disability, a life-threatening condition, or require intervention to prevent a serious occurrence._Adverse conditions are defined as: _any unfavorable and unintended medical occurrence in a trial subject at any dose tested which may have a causal relationship with the treatment._This distinction allows the separation of drug complications from drug-related side effects. Adverse events are usually nonserious (with the exception of some complications, as described here). However, an adverse event need not be an adverse reaction, that is, a nontoxic reaction to the medicine. Adverse events include a wide variety of signs, symptoms,",
        "label": 0
    },
    "1676": {
        "output": "Your task is determined. You can start the implementation.\nWe wish you good luck!\n\t\n\n\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\n18. Let's think step by step.\n\n- First -you create a new data frame with `df1<-data.frame(Patient`and` Trial-level eligibility:)`\n\n- Second -you create a new data frame `df18` that is a copy of `df1`.\n\n\t\n*Create variables: `df18 <-data.frame(Patient, `Trial-level eligibility`)*\n\n- Third -you select two variables `df3 <-df18[2:nrow(df18), \"Patient\",drop=FALSE]`\n\n\t\n*Create variables: `df19 <-data.frame(Trial-level eligibility=\"2\")*\n\n\n- Fourth -you add the variable Trial-level eligibility value one to the `data.frame` named df3:\n\n\t\n*Create variables: `df19 <-df19 %>% add_row(1/1))`*\n\n- Fifth -you add the names to the `data.frame` named df18:`df192 <-data.frame(\n  Patient=c(\"K\", \"L\", \"M\", \"N\", \"O\", \"P\", \"Q\", \"R\", \"S\", \"T\",\"U\"),\n  Trial-level eligibility=\"1\")*\n\n- Sixth -you add the names to the `data.frame` named df18:`df19 <-data.frame(P tient=c(\"K\", \"L\", \"M\", \"N\", \"O\", \"P\", \"Q\", \"R\", \"S\", \"T\",\"U\"),`T rial-level eligibility=c(\"0\",\"1\",\"2\"))*\n\t\n- Finally -you create a new one `data.frame` named `df20` with all rows from all tables`df20 <-rbind(df1,df10,df11,df12,df13,df14,df15,df16,df17,df1",
        "label": 1
    },
    "1677": {
        "output": "You are then done. Let's start with the following clinical trial. The details are provided in the code.\n```{r} library(readr) lib_file_hcvir <-paste0(getwd(), \"/\", file.choose()) #get the path of the csv file #in your working directory set.seed(42) #set a seed for reproducible results #load the data set data3 <-read_csv(.lib_file_hcvir) patients_df <-data3 %>% mutate(trial = factor(trial, levels = c(\"ABT267/r/ABT333\", rep(c(\"ABT267/r/ABT338\", \"ABT267/r/ABT450/r\"), 1/2)), c(\"ABT267/r/ABT333\", \"ABT267/r/ABT338\", \"ABT267/r/ABT450/r\")))\n\n```\n\n# ASSUMPTION # A patient has a trial-level eligibility of 0 or 1. In other words, excluded or included.\n# - If a patient-level eligibility is 0 (exclusion criteria), he would not be included in the clinical trial. \n# - If a patient-level eligibility is 1 (inclusion criteria), he would be eligible for the clinical trial\nA patient is regarded as ineligible if the patient-level eligibility is 0, and as eligible when the patient-level eligibility is 1. In other words, the patient-level eligibility determines the patient-level eligibility (see . \n\nThe patient-level eligibility is simply a sum of the total number of conditions that is not met for a specific patient. In this study, the sum of the total number of conditions for each patient is compared to the trial-level eligibility. If the trial-level eligibility of the patient is 1, the patient is eligible, and if the trial-level eligibility is 0, the patient is excluded. \n\nTo illustrate the concept of patient-level eligibility, three patients with different characteristics are provided in the following illustration",
        "label": 1
    },
    "1678": {
        "output": "Note that you will always see the first three lines in the assessment of eligibility for all patients. Therefore, if you want to make an individual-level eligibility, you need to put the last line on your own according to your assessment. After you complete the assessment of eligibility, try to do the next case with a similar structure.<EOD> S-sulfonated cis,trans-decafluorooctadecane: a novel probe for detecting surface-active compounds.\nThe cis,trans-decafluorooctadecane (C(18)F(10)) in combination with a sulfo ligand (tert-butyl benzene-1-sulfinate) was found to be an efficient sensor for detecting the surface active compounds (SACs) in a liquid membrane process (e.g., ion-exchange chromatography). The sensor has a good selectivity for detecting amphoteric SACs and can be used for direct determination of amphoteric SACs in different mobile phases of ion-exchange chromatography. It was found to be suitable for testing SACs in both chloride and phosphate buffers. The sensor can also be used to detect the concentration of amphoteric SACs in aqueous samples, and they are easy to isolate and analyze by HPLC after the reaction. The sensing mechanism was discussed and preliminarily revealed. This sensor would be applicable to testing the surface active substances.<EOD> .\nThis study aimed to construct human leukocyte antigen (HLA) and intermicrobial adhesion (MIA)-producing Methicillin-resistant Staphylococcus aureus (MRSA) strains and evaluate the effect of MIA genes on the virulence of MRSA. Three MIA-producing MRSA strains were constructed, namely, HL-S17m (MIA+/HLa-), HL-S17m/HL-A*02 (MIA+/HLa+), and HL-S17m/HL-A*02/HLACw4 (MIA+/HLa+/HLACw4), by using plasmids pUC119-mla",
        "label": 0
    },
    "1679": {
        "output": "[END]<EOD> .\nThe authors studied the effectiveness of treatment using the preparation \"Mizolast\" in combination with drug therapy (nifedepine) in patients with coronary heart disease. It was shown that anti-ischemic, antihypertensive and analgeasic effects of Mizolast, nifedepine and their combination exceeded the effect obtained by monotherapy. The beneficial effect of administration of the combination of these drugs for patients with ischemic heart disease is due to their synergistic action which results in improvement of coronary flow.<EOD> Nutrition and infection.\nCold hands and feet . . . diarrhoea . . . oral thrush . . . weight loss . . . tiredness and a general feeling of \"not being quite right\"-the classical pattern of a common virus infection is easily recognised. It is common knowledge that a viral infection leaves the patient weakened and vulnerable. The effect on nutrition, however, is less well understood and this article considers the effect of viral infections on energy and protein metabolism, and its clinical implications.<EOD> The impact of an interdisciplinary team approach during cancer care.\nAIM\nTo report on an evaluation that assessed the impact of cancer case management and nurse-led care review meetings on the quality of life and service utilisation of people whose cancer has been in remission (survivors) or who are stable (the stable cohort) for at least three months.\n\n\nBACKGROUND\nThe delivery of health care is resource intensive in terms of both financial and opportunity cost. Case management and nurse-led care review meetings were developed as a tool to improve the quality of life and reduce the level and cost of unnecessary health care utilisation for vulnerable populations such as people with cancer and other chronic diseases.\n\n\nMETHODS\nThis was a natural experiment based on a pre-test and post-test design.\n\n\nRESULTS\nA total of 606 participants enrolled in one of the four studies reported in this article and were classified as survivors (n = 112), the stable cohort (n = 185), those not in either group (n = 211), or those who had died (n",
        "label": 1
    },
    "1680": {
        "output": "Example:<EOD> .\nThe efficacy of treatment with the drug inosit, a combination of beta-D-fagopyril, inositol and vitamin E in the prophylaxis of the adhesive reactions of organs in rats with experimental pancreatitis has been investigated. The drug inosit was proved to increase the survival rate, prevent the adhesion and inflammation of the liver, reduce the intragastral pH and increase the urine elimination of acidic substances.<EOD> .\nThe objective was to study the expression of CD69 in different stages of the menstrual cycle in patients with endometriosis. It was a cross-sectional, analytical and prospective study. Cases (n=35) and control (n=35) included women with the same average age in the study period. Patients with previous pregnancies were excluded. Blood samples were used to measure CD69 before and after hormonial treatment. The concentration of CD69 was higher in endometriosis group than control group, this difference was significant after treatment (p=0.001). After treatment CD69 concentrations for patients with and without endometriosis were not significantly different. CD69 expression after treatment was related to endometriosis stage III and IV (p=0.016). Mean value of CD69 increased in relation to endometriosis severity, however it is not possible to establish a diagnostic tool of endometriosis and their stage. It's important to note that CD69 is a molecule in the process of invasion in endometriosis.<EOD> Antibody specificity of the rabbit C'3b inactivator.\nInactivator was prepared from serum of rabbits hyperimmunized by repeated injections of C34b/C4b-C4bp with and without adjuvant. The rabbit C34b/C4b-C4bp contained the following activities: C34b/C4b-C4bp inactivator 313.6 units, C34b-inactivator 98.3 units, C4b-inactivator 260.9 units, C14b-inactivator 40 units, B1 inactiv",
        "label": 0
    },
    "1681": {
        "output": "Now you know how to make a trial-level assessment of eligibility, i.e., the eligibility assessment. Try making the eligibility assessment for every patient in the clinical trial by going to `Input->Trial->Edit`. In Edit trial dialog, make sure that `Trial-level eligibility` checkbox is checked and the patient selection is done. Then, proceed to `Analysis->Hardware->Run` \n\nThis is all that a trial-level eligibility assessment requires.\nNote: The eligibility assessment is performed on a patient level. If we consider a single patient, the trial-level eligibility assessment is performed on a clinical trial level. For more complex assessment, look at the following scenarios:\n\n\n*\n\n*Let's say that our patient is on medication(s) that could be added to the exclusion or the inclusion criteria of the clinical trial. So, the medication of the patient is excluded (if it is already added). However, the medication of patients should be considered as part of the study (if not already excluded). The patient takes no other medications.\n\n*Let's say that there are more than one drug/drug class in the drug list of the patient. The class of the drug in the list is an inclusion criterion of a clinical trial. Patients may have more than one class of drug in their drug list.\n\n*Let's say that the sex of a patient is an inclusion criteria of a clinical trial. Thus, the assessment of eligibility has three different levels: patient, drug and trial. We must compare a patient's sex to the sex of a drug in the drug list of the patient and then compare the patient note and the trial-level inclusion criteria at the trial level.\n\n*Let's say that a patient does not have full documentation of laboratory tests results in their medical record. We must consider the patient's latest laboratory tests results in the assessment of eligibility.\n\nThese and other scenarios require an advanced level of knowledge in this field.\n\nThe following scenarios (Scenario A, B, C, D, E, F, G, H and I) are examples of such complex assessment. They can be performed without any problem by using Eligibility assessment module in El",
        "label": 0
    },
    "1682": {
        "output": "## Second case\nPlease find the second case in, which consists of three columns:\nDemographics (5.1), Assessments (5.2), and Trial-level eligibility (5.3).\nIn the first row, you should enter the patient identifier, e.g., Patient 01. The second row includes the gender, which could be either M (male) or F (female). Race could be one of the choices from the list, e.g., Black or African-American or White.\nThe third row shows the patient's birthday.\nPlease note that the row headed Birthday may be skipped in case you don't have a birthday in this clinical trial.\nThe patient's age is the next row named Age. Your age may not match those for patients. For example, if you are 35 years of age, you should enter '35' as your age in the Age row. If your patient is < 17 years of age, please fill out the Age row with the appropriate value as a whole number for the years from 0 to 17.\nAssign the appropriate height to the Height row.\nIn the fifth row, you should enter the patient's weight in kilograms.\nAssign BMI value to the BMI row.\nPlease notice that the BMI in clinical trials should be calculated based on the height and weight. For example, if you are 190 cm tall and 150 lbs. in weight, your BMI will be calculated as 27.82 from height = 1.725 \\em{kg/m} and weight = 80.0 \\em{kg} from the following formula:\n\nPlease enter two decimal points and the weight should not be rounded off as a whole number. We recommend using a decimal separator as `,` like 150.0 and 80.1, especially when you calculate the BMI of patients.\nPlease note that the fifth row heading could be skipped if no BMI information is available to use in this clinical trial.\nIn the seventh row, please assign a value to the Smoker status as 0 for Never, 1 for Current or Former, and 2 for Never.\nAlso, the eighth row heading may be skipped",
        "label": 0
    },
    "1683": {
        "output": ".\n[g. The \\ and the 1-type. ]. the 1\u00a0 , the [bib_ref] 2.\n. However.\n\n , 0 - his.<EOD>\n2...\n 2 and it 2 and M. In 1. 2 1, for 70 or 2 In \n \n 2 [bib_ref]. There [bib_ref] [bib_ref] and you on [/table] on\n and \u2044 \ufffd1 . in contrast, and on 1 and \\ C, such. for \u2026 at 1\nfor the previous in - \\~ ^\u00a0; an in the\n? at 1\n. [bib_ref]<EOD> , 3!\n (and (only_ for the . or\n and the \non \n for a\n and\u00a0\n [/table] in an \u2500 or\u00a0test  \nfor, the \u00ac. in this\n and the\n [bib_ref] and a\u00a0 on which\\\non, [bib_ref]\n, 6;\nas-2-and, a1-2 andll [bib_ref]\n2-l_ (to_\u00a02~ [bib_ref]: _0<EOD> [bib_ref] - _ - a\u00a0ceter. [bib_ref] , and \\(based ~\\s [in a [bib_ref] [bib_ref]<EOD> or...\u00a0{ for \u2026 \u0304 clin\n(~\ntre\n\nex\n1\n\n-18 2( _.\n and .\u00a03\u00a0of his\u00a0 and some\ntre .of [bib_ref][ -2<such to 1(for .-in-de of the 20: the 5 (tre and a\ufffdwe...for the clin. \nde and 2_\nhe c{on \u2026 2-h , The^\n\nthat 1<EOD> with a 2^\ninter-\n2-2-\n 1. 2.d 1^-\n...13 or 2. The.\n to 5-in an~\na-and-he-inter a (s for the\u00a0...<gul\u2010\n to _ \ufffd and medical\u00a0to 3...med for an 2; He@@\n(inst {for health \u2265<EOD>, as \ufffddi [bib_ref]. In\n-based [bib_ref]\ns with 1 in recent-he1\u00a0on@ and\n2\n\na^\nc (b=he [inst for",
        "label": 1
    },
    "1684": {
        "output": "<EOD> .\nA 38 year old woman was admitted because of right lower quadrant pain and melena. A laparotomy was performed 10 h after admission and a large amount of bleeding was noted. An ileus with ischemic destruction of the small intestine was diagnosed and resection of the diseased part was performed. Eight (8) days after resection surgery, the patient developed fever, hypotension and a worsening of the renal function. A pelvic CT was performed, revealing an infrequent pathology. Escherichia coli was isolated from blood cultures, the patient's clinical symptoms and radiology data were characteristic of necrotizing pancreatitis. The evolution was favorable after resuscitation measures including antibiotic treatment. Because of the increased incidence of the E. coli 0157 strain, more rigorous measures must be taken to prevent hemorrhagic colitis from this strain and its associated complications.<EOD> Exciton delocalization and photovoltaic parameters in multilayer- and quantum rod-based P3HT:PC70BM blend films.\nWe have studied the effect of layer number, i.e., the thickness of alternating polymer/fullerene layers in organic bulk heterojunctions (BHJs) on photovoltaic parameters of solar cells. We have successfully synthesized multilayered conjugated polymer poly(3-hexylthiophene) (P3HT) with and without added PC70BM layer or quantum rods by using a two-step layer-by-layer self-assembly method involving (1) layer-by-layer dipping of substrate/electrode and (2) spray casting in the presence of solvent. Highly efficient charge-carrier generation along with strong exciton delocalization, which are both responsible for the observed power conversion efficiency up to 8% in spray-cast multilayer-based solar cells, was observed. Importantly, we have also shown that the inclusion of P3HT-PC70BM quantum rods in spray-cast multilayers results in higher power conversion efficiency of up to 8.8% for solar cells. Thus the multilayer-based solar cells with high",
        "label": 0
    },
    "1685": {
        "output": "# Good solution for Solution #2\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #3\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #4\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #5\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #6\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #7\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #8\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Good solution for Solution #9\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Bad solution: wrong trial-level annotation #10\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Bad solution: wrong trial-level annotation #11\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n# Bad solution: wrong trial-level annotation #12\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n\n# Good solution for Solution #13\n```r\n[1] \n\n[1] \n\n[1] \n\n[1] \n```\n\n\n| Solution | Test data frame | Good solution?                                                                             | Explanation       | Bad solution: Wrong patient identification |\n|---------:|----------------:|:------------------------------------------------",
        "label": 1
    },
    "1686": {
        "output": "[/CODE]\n(Note: The answer format of this task uses the answer format_101.txt located in the folder: /inst/study/solution/answer)\n\n___\n\n\n### [A2.2](https://github.com/statnet-team/statnet/tree/master/R/fda_demo/solutions/README.md?search=A2.2) A2.2. Examine the time-dependent change in drug survival with the Kaplan-Meier method. Write down the drug survival curve in a given year of treatment._\n\nA Kaplan-Meier plot displays the number of patients remaining over time. The Kaplan-Meier curve starts from the year 1997 to the year 2017 at an interval of 4 years. It includes about 3,876,115 participants. This means that the study data set includes survival times of 3,876,115 participants since the beginning of the study on January 1, 1997, and the end of follow up at the end of year 2017.\n\n_A_ Kaplan-Meier estimator KM estimate of the survival function S(t). In 2019, the time-dependent drug survival probability of all patients at the beginning of year 2017 was about 0.06. The KM estimate of the drug survival probability at the beginning of year 1997 was about 0.46.\nWhen you compare the plot, you can notice that the drug survival probability decreased over time.\n\n### [A2.4](https://github.com/statnet-team/statnet/tree/master/R/fda_demo/solutions/README.md?search=A2.4) A2.4. Examine the drug survival rate by the logrank test. Write down the logrank test results._\n\n```\n(16.1) drug survival ~ Time + Dosage\nTime~Dosage\nlogrank test\n  drug survival: A2.4 drug survival ~ Time + Dosage\n(1) Time: logrank  t =2, n =38762",
        "label": 0
    },
    "1687": {
        "output": "- Excluded\n    - 02: `0) Excluded`:  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 02) Excluded.`.\n    - 03: `0) Excluded`:  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 03) Excluded.`.\n    - 04: `0) Excluded`:  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 04) Excluded.`.\n    - 03: `0) Excluded`:  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 03) Excluded.`.\n    - 05: `0) Excluded`:  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 05) Excluded.`.\n\n- Not relevant\n    - 10: `1) Not relevant:`  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 10) Not relevant.`.\n    - 10: `1) Not relevant:`  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 10) Not relevant.`.\n    - 11: `1) Not relevant:`  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 11) Not relevant.`.\n    - 11: `1) Not relevant:`  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 11) Not relevant.`.\n    - 10: `1) Not relevant:`  `Trial-level eligibility:  `, e.g., `Trial-level eligibility: 10) Not relevant.`.\n    - 11: `1) Not relevant:`  `Trial-level eligibility:  `, e.g., `Trial",
        "label": 0
    },
    "1688": {
        "output": "<EOD> Implementation of digital mental health interventions in clinical routine care in Germany\nAbstract Introduction: Due to the ongoing COVID-19 pandemic and related restrictions, the provision of mental healthcare has become untenable worldwide. Digital interventions, in particular internet- or mobile-based guided self-help interventions may serve as an alternative to face-to-face treatment services, but are not sufficiently embedded in routine care as yet. Objectives: We conducted systematic assessment for the implementation of guided self-help interventions, i.e. computer- or mobile-based therapy sessions, for depression and anxiety disorders in Germany. Methods: We performed a systematic web search and a targeted search with expert consultations. Results: Two promising evidence-based interventions, the cognitive-behavioral internet program \u201cMoodGYM\u201d and the face-to-face cognitive-behavioral treatment \u201cInternetbasierte therapeutische Gestaltung\u201d (iTB-G), are integrated in routine care in two psychotherapeutic training institutions in southwest Germany. \u201cMoodGYM\u201d is used to support the rehabilitation or relapse prevention of patients after face-to-face psychotherapy or patients in an outpatient setting who were not able to undergo psychotherapy due to high cost or limited availability of these services. \u201ciTB-G\u201d serves to prepare patients for face-to-face psychotherapy. Conclusions: Due to the high demand for low-threshold and economical mental healthcare services, digital interventions for depression and anxiety disorders may increasingly find their way into clinical routine care in Germany. Both interventions are provided in a complementary and not competitive way to traditional psychotherapy and show initial effectiveness. The implementation does not result in an additional burden to clinicians or interventionists. Key messages: Two promising digital interventions for depression and anxiety disorders are being integrated in clinical settings in Germany. Due to the COVID-19 pandemic and related restrictions, the use of digital interventions is likely to be increased.<EOD> Hydrogen sulfide\u2013stimulated ATP release and hydrogen sulfide depletion in liver sinusoidal endothelial cells during early stages of ischemia",
        "label": 0
    },
    "1689": {
        "output": "### 3.2.2 How to evaluate the exclusion criteria of clinical trial?\nIn this subsection, we discuss how to evaluate every exclusion criteria of the clinical trial. There is one clinical trial in R Shiny App (see the link: https://yoonchan.shinyapps.io/clinical_trial/). Use it to do your practice!! \nThe exclusion criteria include:\n- Exhibited a serious adverse event (AE) during screening which resulted in study treatment discontinuation or withdrawal or prohibition of participation in the study\n- Has received prior treatment to which they were refractory or intolerant\n- Has progressive liver disease\n- Had documented drug/alcohol abuse (or drug dependence) or any serious psychiatric illness within the past 5 years\n- Received immunosuppressive drugs within the last 6 months\n- The patient is known to be pregnant, intending to become pregnant, or will need to become pregnant for the purposes of delivery of child care\n- Is currently participating in or has completed an investigational study within 30 days prior to or is unable to interrupt all components of a clinical therapy within 30 days prior to the planned study start or during the planned study period\n- Other: Please describe. \n\nHere is the patient note of the clinical trial:\nHeparin-induced thrombocytopenia: Heparin-induced thrombocytopenia (HIT) has been reported in patients treated with fondaparinux. HIT can be associated with serious, and sometimes fatal bleeding. Platelet counts should be monitored periodically and carefully, and if HIT is suspected, treatment with fondaparinux should be discontinued promptly and substitution of alternative anticoagulant therapy considered.\nHere is the patient note of the clinical trial:\nHepatic Impairment: Patients with impaired hepatic function were excluded from the clinical trial on fondaparinux.\n\n\n##### 3.2.3 How to evaluate the inclusion criteria and exclusion criteria of clinical trial? 19\nIn this subsection, we discuss how to evaluate every inclusion criteria of the clinical trial or every exclusion",
        "label": 1
    },
    "1690": {
        "output": "# Tutorials\n\n## Introduction\n\nThis wiki page serves as documentation and instructions for the RMarkdown package [Installation], which provides all the functions needed for a reproducible report in r and LaTeX (with knitr). The code is well-documented, and the LaTeX file generates a report that is well suited for publication in a specialty journal. It can be run from within Excel and from within R without any further configuration required.\n\n## Getting set up\n\nThe following are required to run this report:\n\n- **R:** R has to be installed with RStudio using  [Installation]()\n\n- **RMarkdown:** Using the RStudio app and the Plugin Manager, download the latest version of RMarkdown  (from here). For more information, see the documentation on [Installing and Starting RMarkdown](https://rmarkdown.rstudio.com/install.html#1-installing-rmarkdown).\n\n- **LaTeX:** Please see the information on [Installing TeX and TeX Live](https://www.xilinx.com/support/documentation/documentation_files/technotes/tg_12-24.pdf) \n\n\n## Documenting your report\n\nFor documentation, I have used Markdown, which is a simple and easy to use formatting language for documents. To make use of the following Markdown file, create a folder called \"rmarkdown\" in the same directory as your folder, as shown below:\n\n```\n...\nrmarkdown/\n```\n\nHere, I'm using the [rmarkdown\\_README.md](rmarkdown/rmarkdown\\_README.md) file. To follow the code example in the main text, create a new document in the folder. The basic structure is a single text file, with an input for each section in the form of `header title:` and output as `### header title: output`. \n\nIn this version of the documentation, there are no tables in the main report, but a simple tabular format will be added if you want them. The report also features multiple headings within sections, and this part also works without additional changes.\n\n> In this report, I'm using [rmarkdown\\_README.md](rmarkdown/rmarkdown\\_README.md",
        "label": 0
    },
    "1691": {
        "output": "![INST]\nHere are some tips on how to deal with the time consuming part of evaluating a patient: - Keep screen time constant across patients - Take a break every 20-30 minutes - Try to set the clock away during the sessions and to focus on the evaluation - Start typing your notes as soon as you go through each patient's record during the exam - It is important to spend as little time as possible on assessing patients who are excluded from a study immediately. Use that time to think about the next patients you're going to face. If you come to the end of the list of patients to screen before reaching them, it means you've just been typing in the same note (or no note) for at least 20 minutes!\n\n\n### Conclusion\n\n![INST]\nLet us summarise our results and compare them to a manual calculation in a real case.\nAssigning an action to a case is a more difficult task than simply looking for eligible patients. The cases we have dealt with here are quite easy.\nWhat if the cases get more complicated? A more complex problem is the following: A real-world clinical study includes 285 patients in a randomised double-blind study. These patients are being randomised to treatment A or B. The treatment effect is quantified by counting the number of patients who respond to the treatment. The trial also has a placebo group. The trial is designed using a Bayesian method with 3 levels. Treatment A improves response rate by 25% and treatment B by 10%. The study is expected to include 150 subjects in each group and the expected number of positive responders is 26 for A, 1 for B, and 25 for C (placebo group).\nAs the example is in double-blind conditions, we deal with a total of 1141 data points (671+470).\nBayesian statistics gives great advantages over classical statistics. The Bayesian method allows one to obtain updated probabilities of the hypothesis based on the information brought in by new data. A traditional method would just be to look whether there is an association between the hypothesis and the new data, without any use of the previous results. The Bayesian method uses all the previous results to compute the posterior probability of the hypothesis.\nLet us try to calculate the numbers",
        "label": 2
    },
    "1692": {
        "output": "`Sex: Male`, `Race: White`, and `Age: 55`, please \n\n`Clinical trial summary`, `Exclusion criteria:`, `Patients should not be pregnant or planning to become pregnant or lactating`, please\n\n`Drug name: Peginterferon alfa-2a` and `Drug name: Ribavirin`, please \n\n`Eligibility criteria:`, `HCV 2 years ago and the recent coinfection with HBV`, please \n\nInput this `Eligibility criteria`: `Inclusion criteria:\n\n Male and female patients *18 years of age\n Patients have never been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin\n Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test\n Detectable serum HCV-RNA and HCV viral genotype 1\n Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection with or without compensated cirrhosis (Exception: hemophiliacs in whom biopsy is medically contra-indicated do not require biopsy.)\n Compensated liver disease (Child-Pugh Grade A clinical classification)\n Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug\n All fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end\n Exclusion",
        "label": 0
    },
    "1693": {
        "output": "### Examples\n* [1_1](./1_example_of_trial_level_eligibility)\n[1_1]\n\n<EOD> .\n\n Information is provided regarding an official demographic survey conducted in Haiti. The main objective of the survey was to obtain reliable statistics on the population and its socioeconomic characteristics.\n<EOD> A rare case of a pericardial cyst in a patient with a rare blood group\n\nWe present a case of a middle-aged man, with a family history of rare blood groups, presented to hospital following a cough, tiredness, and weight loss. A chest X-ray, CT Pulmonary angiogram and chest ultrasound identified a large pericardial cyst infiltrating the mediastinum. This case highlights an uncommon case of a pericardial cyst and its importance in a rare blood group patient. Cysts, both primary and secondary, are a common reason for a chest X-ray being done. The clinical features of pericardial cysts can range from an incidental radiological finding to patients with severe chest pain. In the presence of a possible rare blood group, the implications for the patient must be considered.A 59-year-old Caucasian man was referred to the respiratory outpatient clinic with a history of cough, tiredness, and unintentional weight loss over six months. There was no relevant co-morbidities or known allergies and he was currently on no regular medication apart from proton pump inhibitor medication. He worked as a care assistant and lived independently. There was no patient relevant family history and his only travel outside of the United Kingdom was on tourist trips to Egypt and Spain. Past surgical history included tonsillectomy and ventilation tubes as a child. On examination, his breath sounds were normal. Abdominal examination did not reveal any obvious masses and the rest of the systemic examination was unremarkable.His haemoglobin and white cell counts were normal and basic biochemical investigations revealed serum electrolytes, liver function, and calcium within normal values. Chest X-ray on admission revealed a large cystic structure in the left upper zone(Figure 1). Due to",
        "label": 0
    },
    "1694": {
        "output": "[CODE]\n1     # This is the trial name. It will be the filename of the patient note.\n2     $t = \"YourName\"; # For example, your last name (e.g., \"Jones\")\n3     $subt = \"YourFirstName $t\"; # Name of your trial with capital first letter (e.g., \"James Jones\")\n4     $subt = str_replace (\"\\s\", \"_\", $subt);\n5     # Get the variables that you want to extract from the patient note.\n6     $s1 = explode (\";\", $_GET[\"s2\"]); \n7     $s2 = explode (\";\", $_GET[\"s3\"]); \n\n\n\n\n[HTML]\n<h3 style=\"font-size:100%;\">\n<hr>\nYour Name:${name}\n</h3>\n<h4 style=\"font-size:100%;\">\n<hr>\n<font color=\"blue\">This web-based application (wba) is for the analysis of the variables that you are interested in from the clinical trial's dataset. You should select a clinical trial to be analyzed and perform each required operation. The clinical trials' dataset will be extracted from the Clinical Trials Registry System (CRS), as previously described elsewhere. You will receive the details on the clinical trial to be analyzed from the web wba for each patient note analysis, so you must carefully read each patient note to answer patient eligibility questions, before you answer them on the web wba.\nRemember to click 'OK' at the end of each single patient note analysis, before going to the next one, to ensure that the clinical trial is loaded on the web wba. The variable details are in another help page for each operation.\n\n\n<br></br>\n<br></br>\n<br></br>\n\n\n<h4><a href=\"{inst}\" style=\"color:green\">Here is the Instruction.</a></h4>\n\n\n<br></br>\n<br></br> \n<iframe id=\"wb\" wizard_id=\"CR1299_MU_2Ta62_4\"\n\nsrc=\"https://wba.nci.nih.gov/",
        "label": 2
    },
    "1695": {
        "output": "You may want to apply your skills to more complex input datasets or other medical cases. The challenge is to design algorithms for detective problems, e.g., medical conditions diagnosed with the help of a computerized medical history record which includes the patient's symptoms, laboratory test results, etc.\n\n# Author Contributions\nAuthor statements\nWe confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.\n\n# Financial disclosure\nNo financial support was used during this study and no financial disclosure are needed.\n\n# Ethics statement\nThe paper is an open access work. However, the authors could inform you in their author's web page the name of the journal in which this article is published , please add to the paper these details.\n\n# Source of funding\nThis work was a part of a PhD thesis. However, the authors could inform you in their author's web page the name of the institution/university funding the work. Please add to the paper these details.\n\n# Author contributions\nDr. Cenker: Conception and design; Dr. Demircan; Dr. Ayanoglu; Dr. Y\u0131lmaz: Draft manuscript; Dr. Caglar: Critical revision; Statistical Advisor:\nStatistical analysis; Dr. Kahraman: Manuscrit's preparation; Data collection; Dr. Mert: Analysis and interpretation of data.\n\n# Introduction\nTurkey ranks the sixth place among the countries with the largest epidemiological burden at a global level.\nThe age standardized seroprevalence of hepatitis C virus (HCV) is 1.4% in the world 1 , and 1.1% in Europe 2 . The most recent available European HIV/AIDS Epidemiological Sentinel Report indicates 1.4 million people are living with hepatitis C in Europe 3 .\nThe global prevalence of anti-HCV antibodies was reported as 0.9% in our country. A study based on Turkey Epidemiology of Diseases Prevention and Control General Directorate revealed 17% positivity rate for",
        "label": 0
    },
    "1696": {
        "output": "<EOD> Scaling relations for the elastic constants of metals.\nWe present scaling relations, which relate the principal elastic moduli G, B, and D of close-packed crystals to bulk properties of the substance. They are based on the experimental observations that the elastic constants of crystals are functions of  density  and pressure. Furthermore, we show that the crystal plasticity theory, based on a self-consistent description of the stress due to elastic deformations, is consistent with the scaling relations observed in many metals<EOD> Acquisition and maintenance of tolerance to a ternary adsorbed polymer brush in the absence of protein.\nPolymer brushes are self-assembled monolayers with remarkable physical, chemical, and biological properties. In this work, we study the adsorption and desorption properties of a ternary polymer brush consisting of methyl methacrylate (poly(MMA) ), ethyl acrylate (poly(EA) ), and cystamine (poly(CS) ) using atomic force microscopy (AFM) under ambient conditions. Apart from the adsorption of the ternary polymer brush on mica, its subsequent desorption properties are also examined. Specifically, the desorption kinetics of the ternary polymer brush under controlled humidity and temperature are investigated in the absence of specific protein binding sites. The initial adsorption of the polymer brush to the substrate is followed by an increasing brush thickness until a maximum brush thickness is reached corresponding to a polymer surface density of the brush. For brushes with poly(MMA):poly(EA):poly(CS) ratios of 0, 0.75, 0.5, and 0.25, the initial adsorption constants are determined as KMMA = (1.12 \u00b1 0.09) \u00d7 10(12) mol m(-2), KEA = (5.12 \u00b1 0.46) \u00d7 10(12) mol m(-2), KCS = (7.4 \u00b1 0.5) \u00d7 10(9) mol m(-2), and KCSM",
        "label": 0
    },
    "1697": {
        "output": "[/END_INST]\n\n##### 8-Example with more cases and variables\nExample 7\n[Instruction] The trial-level eligibility is the most common type of instance level eligibility in a clinical trial. It determines the eligibility of someone to participate in clinical trial.\n\nYou should make a trial-level eligibility on each patient in a clinical trial, i.e., output the scale for the assessment of eligibility.\n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and is coinfected with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and only remarkable for chronic inflammation compatible with a chronic viral hepatitis. He has no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, and metabolic liver disease. He is alert male with no acute distress. His BP: 130/75, HR: 90/min, and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, and metabolic liver disease. He is alert male with no acute distress. He has past medical history of diabetes and hypertension. His medications include calcium channel blocker pills. His BP: 130/75, HR: 90/min, and BMI: 27.9. He has no ascites, ascites, and variceal bleeding. The right arm, right leg and both legs are swollen. He walks",
        "label": 0
    },
    "1698": {
        "output": "[/TUTIO]\n\n\n<!--TUTORIAL.CITATIONS\n  A.1.1\n  TUTORIAL.MAIN.TITLE\n  A.2\n  A.3\n  A.4\n  A.5\n  A.6\n  A.7\n  A.8\n  A.9\n  A.10\n  A.11\n  A.12\n  A.13\n  A.14\n  A.15\n  A.16\n  A.17\n  A.18\n  A.19\n  A.20\n  A.21\n  A.22\n  A.23\n  A.24\n  A.25\n  A.26\n  A.27\n  A.28\n  A.29\n  A.30\n  A.31\n  A.32\n  A.33\n  A.34\n  A.35\n  A.36\n  A.37\n  A.38\n  A.39\n  A.40\n  A.41\n  A.42\n  A.43\n  A.44\n  A.45\n  A.46\n  A.47\n  A.48\n  A.49\n  A.50\n  A.51\n  A.52\n  A.53\n  A.54\n  A.55\n  A.56\n  A.57\n  A.58\n  A.59\n  A.60\n  A.61\n  A.62\n  A.63\n  A.64\n  A.65\n  A.66\n  A.67\n  A.68\n  A.69\n  A.70\n  A.71\n  A.72\n  A.73\n  A.74\n  A.75\n  A.76\n  A.77\n  A.78\n  A.79\n  A.80\n  A.8",
        "label": 2
    },
    "1699": {
        "output": "[[ELIGIBILITY_METHODS] This step evaluates the eligibility of a patient for a particular trial. \n[ELIGIBILITY_METHODS] To evaluate eligibility, the following three criteria must be satisfied: (1) the patient must fully meet all the trial inclusion criteria; and (2) the patient's demographics, treatment history and medical conditions must be consistent with the trial's inclusion and exclusion criteria. \nIn the following section, we will be considering the above eligibility criteria for a clinical trial involving the treatment of chronic hepatitis C virus (HCV) infection. \nLet's code the following eligibility criteria one by one. \nCriterion 1. This trial inclusion criterion states that the patient is a 55-year-old man with a diagnosis of HCV 2 years ago.\n[1_ELIGIBILITY] If the clinical trial trial is an \"HCV\" trial targeting people with \"HCV\", and the disease is \"HCV\", this is simply stated like this: \nIf the disease is not an `HCV`, use disease and mention the type of the disease, e.g., `If(disease == \"cancer\")` [2_ELIGIBILITY] If the clinical trial trial is an `HCV` trial targeting people with \"HBV\", and the disease is \"HCV\", this is simply stated like this: \nYou can use the same code as above under this criterion. However, if only one part of your criteria (type of disease, age group) is met, the criterion should not be evaluated anymore. \n[3_ELIGIBILITY] This trial inclusion criterion states that the patient's past medical history is significant only for chronic HCV infection. If the trial excludes people with a past medical history, you can add a list of additional conditions the patient must have to fulfill eligibility requirements under an eligibility criterion. If the trial is not excluding people with various medical conditions, you don't need to evaluate it. \n[4_ELIGIBILITY] This trial excludes people who have had treatment with IFN, although a combination of RBV is accepted. \n[5",
        "label": 1
    },
    "1700": {
        "output": "\u00a92014 <EOD> .\nExperiments were conducted on Wistar rats and intact and sensitized guinea-pigs in a flow chamber to reveal the specific features of the leukocyte adhesion to the extracellular coat of the aorta in acute inflammation. It was found that in intact rats and guinea-pigs the adhesion was insignificant. However, sensitization caused a significant level enhancement. The data obtained suggest that the enhanced adhesion might be associated with intact animals with leukocytes, and in case of sensitization with antigen-induced degranulation of intracellular pools of adhesive factors. The possible significance of leukocyte-arterial surface interaction is discussed.<EOD> The treatment of the elderly.\nThe treatment of aging individuals is one of the major medical problems of the next two decades. More attention has been given to physical therapy, home nursing, physician visits, and medical care in nursing homes. Although it is the patient-not necessarily the doctor-who visits the physician, the health care professional who has knowledge of the problems of the aging individual can provide better care.<EOD> Clinical, histopathologic, and immunologic studies in patients before and after mycophenolate mofetil therapy for proliferative lupus nephritis.\nBACKGROUND AND OBJECTIVES\nPrevious studies suggest that the proliferative lesions caused by autoimmune disease are mediated by autoreactive T lymphocytes. Mycophenolate mofetil (MMF) may inhibit both T and B lymphocytes and have beneficial effects in autoimmune disease including lupus nephritis. There is limited literature on changes in renal histology seen with MMF therapy. The objective of this study was to evaluate renal histology in a lupus cohort treated with MMF.\n\n\nDESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS\nThe subjects of this prospective study comprised 15 patients with diffuse proliferative lupus nephritis. Patients were treated with",
        "label": 0
    },
    "1701": {
        "output": "Your patient is excluded on the grounds of the clinical trial's exclusion criteria when you type output as:\n[formula]  Hello, {[userInput]}. [/formula] \nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.",
        "label": 0
    },
    "1702": {
        "output": "## Exercise 4 \u2014 Part 2: [CRA-Level Eligibility]\n[INST] CRA-level eligibility. Eligibility in Part-1 was at trial-level. This section deals with eligibility at CRA-level, where you compare the patient characteristics with the inclusion criteria of a CRA.\nThe characteristics of the patient are shown below. The trial-level eligibility is also displayed. \n\nA:\nName\nB:\nGender\nC:\nAge\nD:\nSeverity of disease (Hospitalization is yes /no)\nE:\nCoinfection with HBV\nEligibility\n0) Not relevant\n1) Eligible\n2) Excluded\nPatient characteristics: Hospitalization is yes/no \nHospitalization is yes, we need to apply eligibility criteria by CRA-level.\n\nCRA-level Eligibility 0) Excluded (hospitalization is no)\n1) Not relevant (Elderly or non-metastatic cancer, but hospitalization is no)\n2) Eligible (Elderly or non-metastatic cancer and hospitalization is yes)\n\n\nExercise 5 \u2014 CRA-level Eligibility for ALL Trials\n\nUsing the patient note and the CRA-level eligibility above, we will determine the patient's CRA-level eligibility. In other words, will the patient be eligible for the entire clinical trial, or only for a part?\n\nCRA-level eligibility 0) Excluded\n1) Not relevant\n2) Not relevant\n3) Excluded\n4) Not relevant\nBased on the previous exercise 4, we will compare his age with the CRA-level inclusion criteria of the trial and will apply the first two cases.\nCRA-level Eligibility 0) Excluded\n1) Eligible since the patient is elderly (CRA-2)\n2) Not relevant since the patient is non-metastatic breast cancer (CRA-3)\n3) Excluded since the patient is <45 years old (CRA-4)\n4) Excluded since the patient is <45 years old and there is a CRA-level eligibility in the second column of `",
        "label": 0
    },
    "1703": {
        "output": "## Explanatory texts\nBefore you start to run your application, you may need explanations and clarifications about the structure of the input data. Therefore, the main purpose of the following sections is to describe the input, output, and usage of `iClinEligibility` in more detail.\n\n## 1. Data description\nEach data point in `iClinEligibility` is represented as two adjacent variables of the CSV file, separated by a comma ( , ). For example: The first part is the header variable and the second is the data part, which provides the exact value.\nThere are five header variables in our data set: ID, TC_id, Pt_id, Assessment, and Group. ID (a unique patient number) and TC_id (a unique trial number) are numeric and used to link two databases, i.e., patients and trials. Pt_id and Assessment are variables representing patients and their trial-level eligibility, respectively. Both are in the form of (1,1), where the number 1 is a dummy value that represents their inclusion in the dataset. If the patient is included in the database, number '1' will be inserted; otherwise, `NaN` value will be inserted. Group ('0,1') contains data about the patient's gender; its structure is identical to ID and TC_id, where the value '0' means female and '1' is male.\n\n## 2. Important guidelines\nThe following section covers some important notes for you. Read it carefully and then refer to the documentation and examples for more details.\n\n## Explore your data\nWe suggest you should explore your data after downloading it. Some of the data columns may be ignored in the analysis; therefore, it is essential to check their contents for you.\n\n## How to run your application?\nYou can run this program with the provided Python code using Anaconda, Python, and an available web server. Anaconda is an integrated system providing all packages you need to analyse your data. A Python package is the collection of codes for a specific task that can be installed and uninstalled independently.\n\n\nRun this command:  \n\n> `python iClinEligibility.py  -i clinical-trial.csv  -c iClin.csv  -o iClinElig",
        "label": 0
    },
    "1704": {
        "output": "The following paragraphs are important for making decisions about patient eligibility:\nThe patient is HCV-positive, treated with direct antiviral drugs (DAAs, e.g., Simeprevir, Sofosbuvir, Telaprevir, etc.), and has positive anti-HCV-antibodies. He has previously undergone interferon therapy. He also has chronic hepatitis B virus (HBV) coinfection. As a result of having HCV and HBV coinfection, he has severe liver fibrosis, and he is at greater risk for liver cirrhosis, heart, and liver disease. Therefore, it is recommended that he is prescribed a combination drug therapy for both HCV and HBV: HBV therapy with tenofovir, IFN-alpha, Peg-IFN, ribavirin, boceprevir, and telaprevir. \nThe patient has a medical history of hypertension, diabetes, and kidney disease. In addition to his regular medications for these diseases, he was prescribed IFN and RBV for the treatment of his HCV and HBV coinfection. He has a history of ischemic heart disease treated with medication and diuretics. He has mild anemia. His lab report shows abnormal cholesterol levels and albuminuria. Therefore, he is recommended to monitor his lipids and albuminuria and to follow-up on his hemoglobin levels. If his anemia worsens, he can consider taking blood transfusion or receiving erythropoietin or iron replacement therapy in combination. The current results show low creatinine clearance, which implies that his serum creatinine concentration is not as low as expected. Creatine is produced from creatine phosphate, and it is broken down by enzymes in the kidneys. Because of kidney problems, his lab study showed a slightly high serum creatinine level. He was also prescribed IFN, RBV, and direct antiviral drugs for the treatment of his HCV and HBV coinfection. If he shows worsening kidney function or significant kidney problems in the future, he can be",
        "label": 0
    },
    "1705": {
        "output": "# Data structure\nThis section describes the structure of a patient file, patient trial data and the structure of a trial.\n\n## Patient Note\nEach patient file contains patient id, demographics, medical history, clinical notes, vitals, and test results.\n\n## Patient files\n- `PatientFile` (patient_id:str, first_name:str, last_name:str, birth_date:int, gender:str, phone:str, address:str, pctid:str, trialdate:str, testdate:str, insurancetype:str, insurancepct:str)\n  - [x] ID: The identifier of the patient.\n  - [x] Name: Last Name, First Name.\n  - [x,o] Birth Date: Date of birth. (Only input to patient file.)\n  - [x] Gender: Female/Male.\n  - [x] Phone: Phone number of the patient.\n  - [x] Address:\n    - [x,o] Address:\n      - Address line 1;\n      - Address line 2;\n    - [x,o] City: City.\n    - [x,o] State: State.\n    - [x,o] Zip: Code.\n  - [x] Patient ID: Identifier of clinical trial.\n  - [x] Trial date: Date to start treatment.\n  - [x] Test date: Date of most recent test result to treat.\n  - [x] Insurance: Insurance type.\n  - [x] Pctid: Patient ID of clinical trial.\n- `PatientTrials` (patient_id:str, trial_number:int, trial_name:str, trial_name_description:str, clinical_trial_id:str, pharma_sponsorship:str, clinical-trial_status:str, patientstatus:str, study_design:str, trial_end_date:int, trial_end_date_description:str, trial_end_date_placement:str, targeted_treatment:str, target_population:str, trial_target_population:str, target_enrollment:int,",
        "label": 0
    },
    "1706": {
        "output": "## [INFO] Checking Data: In the console, type `plsCheck` to check the solution correctness. [/INFO]\n\n## [INFO] Verified that all variables are in range. [/INFO]\n\n## [INFO] No errors generated. [/INFO]\n\n## [INFO] Check that the solution is correct. [/INFO]\n\n## [INFO] The solution to the exercise is correct. [/INFO]\n\n## [INFO] Execution time: 1.190 seconds. [/INFO]\n\n# Part 2\n\n##[INFO] Hello. You are a good assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to evaluate the patient's eligibility. The factors allowing someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe results are in this file: `target_2.txt`. The first line is a comment and will not be used. Lines from 2 to 7 (not including the empty lines) contain information about the patients and their eligibility for a clinical trial. If the patient is eligible for a certain trial, the value of `eligibility` is 2. If the patient does not meet the eligibility criterion for the trial, the value of `eligibility` is 0 or 1.\n\nYou are given the patient note as well as the trial-level eligibility output by `plsCheck`. They are presented in the console below as well as in the above `target_2.txt` file. Let's look at them step by step.\n\n## You are given:\n\n### PlsCode.ipy.inp\n    (IPython input)<jupyter_code>0)",
        "label": 1
    },
    "1707": {
        "output": "Good job!\n\n# Related Links\n[INFO] You can view a similar code on the notebook here.\n[CHA] There is a `Cha` folder in `Data/Phenotyping/Liver/Hepatitis C/Patients`.\n[CODE] You can check the code we used on [github](https://github.com/shunhub/Code-for-ICT4-2020/blob/master/Data/Phenotyping/Liver/Hepatitis C/Clinical Trials_eligibility.py).\n<EOD> The role of the sympathetic nerve in the cardiovascular changes caused by acute respiratory acidosis.\nThe cardiovascular effects of acute respiratory acidosis were studied in unanesthetized dogs breathing room air and in dogs with bilateral cervical vagotomy. The acid component of the respiratory acidosis produced pressor responses that were initially greater than and later less than those found with nonfatal ventricular fibrillation. In dogs with cervical vagotomy the acidosis produced very large and immediate increases in blood pressure and heart rate, followed by smaller increases only when the dogs were subjected to the stress of being tethered to the experimental table for several hours. When the acid concentration of the blood was raised by exhalation of HC1 into the tracheal tree, the cardiovascular changes seen were similar to those produced by an equimolar increase in the concentration of CO2 in the blood. It is concluded that the cardiovascular disturbances produced by acute respiratory acidosis are almost entirely due to the acidity of the blood, although the HC1 inhalation experiments indicate that the cardiovascular effects of CO2 in the blood may be greater than those of respiratory acidosis.<EOD> COPD\nExcerpt INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a debilitating disease characterized chronologically by inflammations, obstruction, and damage of the lung par...<EOD> Rare neurocutaneous syndrome in early infancy presenting with cerebellar hypoplasia with normal cerebrospinal fluid.\nEpid",
        "label": 1
    },
    "1708": {
        "output": "\u21e2 Insturctions\n    \n    You need to do the following:  \n     1) You should evaluate a note of a patient.\n     2) You should make a trial-level eligibility using the following: Excluded, Not irrelevant and Eligible.\n  \n\n    [INST]\n   <html>  \n   <script type=\"text/javascript\">  \n     var x = window.location.hash;  \n       if(x.substr(1, 1)=='2'){  \n         var html = `` +\n                `  <body>  \n                  <h4>Evaluate a patient, then click the button</h4>  \n                  <form action=\"evaluate-patient-eligibility\">  \n                      <div>Here is the patient note:</div>` +\n                          `<pre class=code data-value=\"note\"><code>&lt;pre&gt; \n                        The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. Here is the clinical trial:  \n``;  \n                          `<pre class=code data-value=\"\" value=\"title\">Title: Procurement of Blood Samples for a Biomedical Research Program on T Cell",
        "label": 1
    },
    "1709": {
        "output": "When you will see that the assessment of eligibility is the correct level, press the button `Enter` and you will return to the previous menu. \n\n![2016330_00801]({{ site.baseurl }}/static/img/2016330_00801.png)\n\n### Example of a Patient with HBV Monoinfection\n\n```\n{\"clinicalTrials\": \n [{\n \"clinicalTrialsNumber\": \"NCT01096787\",\n \"clinicalTrialsTitle\": \"Trexeristat Treatment of Chronic Hepatitis B Viral Infection (Treatment of Chronic HBV)\",\n \"clinicalTrialsPubDate\":\n  \"2014-06-15\",\n \"clinicalTrialsSourceURL\": \"http://www.clinicaltrials.gov//ct2/show/NCT01096787\",\n \"clinicalTrialsShortTitle\": \"Treatment of Chronic HBV\",\n \"clinicalTrialsShortTitleSort\": {\n  \"en\": \"Treatment of chronic hepatitis B\",\n \"es\": \"Tratamiento del virus hepatitis B\",\n \"pt\": \"Tratamento da hepatite B cr\u00f4nica\"\n },\n \"clinicalTrialsSummary\": \"To evaluate the safety, antiviral effectiveness and tolerability of the nucleotide/nucleoside analogue trexeristat in the treatment of chronic hepatitis B virus infection in patients who are either drug-naive, lamivudine-refractory, or lamivudine-resistant\",\n \"clinicalTrialsCovariates\": \"covariates\",\n \"clinicalTrialsCovariatesVariables\": \"sex\",\n \"clinicalTrialsCovariatesLevels\": \"@1004035:\",\n \"clinicalTrialsRecruitmentStartDate\": \"2013-05-08\",\n \"clinicalTrialsEndDate\": \"2015-09-01\",\n \"",
        "label": 0
    },
    "1710": {
        "output": "### [CODE: HISTORY OF THE PROBLEM] [HISTORY OF THE PROBLEM]\nHCV RNA positive and previous positive for hepatitis C.\n\n### [PROBLEM HISTORY] [PROBLEM HISTORY]\nPatient's medical record shows past positive tests for HCV and a positive antibody. He takes IFN, RBV and direct antiviral drugs for the past 6 months.\n\n### [STABILIZING/INTRODUCTORY CONDITION] [STABILIZING/INTRODUCTORY CONDITION]\nPatient is on IFN, RBV and direct antiviral drugs for the past 6 months. They improve hepatic status and HCV RNA level.\n\n### [DENSIFIED / CARVED HARD SURFACE] [DENSIFIED / CARVED HARD SURFACE]\nIFN plus drugs improved liver status.\n\n### [SOLVABLE] [SOLVABLE]\nHis liver disease is improving\n\n### [HIGH-INVESTIGATIVE] [HIGH-INVESTIGATIVE]\nViral state is improving\n\n### [DETERMINATE] [DETERMINATE]\nHepatitis is improving.\n\n### [TARGET] [TARGET]\nViruses are eliminated.\n\n### [NEUTRALISING] [NEUTRALISING]\nThe inflammation secondary to infection is decreasing.\n\n### [OVERT] [OVERT]\nLiver disorder is overt.\n\n### [EXHIBIT OF GENOTYPE-SPECIFIC MUTATIONS] [EXHIBIT OF GENOTYPE-SPECIFIC MUTATIONS]\nAlthough HCV RNA is undetectable, new genome mutations are appearing in liver biopsy.\n\n### [DETECTION OF A HIGH TITER OF ANTI\u2013HCV ANTIBODIES] [DETECTION OF A HIGH TITER OF",
        "label": 0
    },
    "1711": {
        "output": "## QC:\n\n[QC] ### Q1: A patient meeting inclusion criteria, but being excluded by exclusion criteria, will be scored: \n\n1. Excluded on the grounds of the trial's exclusion criteria\n#\n\n[/QC]\n\n## Score/Result: \n\n[S] ### S1: 0070: ASSIGNED: 0\nThe trial-level score and assessment of eligibility must be based on the patient's medical record.  The assessment of eligibility is performed independently by two reviewers.  \n### S2: 0062: ASSIGNED: 1\nAlthough it is hard to differentiate between factors for the 'not relevant' from those of the 'eligible' in the medical record of the patient, the reviewer should assess the 'not relevant' based on the judgment of the clinical trial and its exclusion criteria. The trial-level score is dependent on the final trial-level assessment. \n\n## [/S]\n\n### A: 0500: ASSIGNED: 0\nThe input parameters (trial, patient note, and reviewer) are all required for this task.\n\n## [/A]\n\n### T: 0500: ASSIGNED: 0\nThe task is completed by the end of the day.\n\n## [/T]\n\n### D: 0400: ASSIGNED: 1\nThis task is defined as a daily work task, so it should be completed within 24 hours of the time the task is assigned.\n\n## [/D]\n\n### E: 0640: ASSIGNED: 1\nThe quality of the work should be measured in terms of the agreement between reviewers. If the reviewer is able to confirm the input data, the task can be completed without major problems.  \n### M: 0200: ASSIGNED: 0\nThere should be 100% agreement between the two reviewers.\n\n## [/M]\n\n## F: 0120: ASSIGNED: 1\nThe correct work should be performed 100% of the time",
        "label": 0
    },
    "1712": {
        "output": "<EOD> Deliberate self-poisoning in older people: a systematic narrative review of the literature\nBackground Deliberate self-harm accounts for up to 13% of all emergency department attendances. The elderly are more likely to be admitted following self-poisoning and have a greater risk of mortality and further presentations. Treatment and prevention are complex issues in older people. Aims The aim was to review and synthesise available evidence describing patterns in self-harm in the elderly. Method A systematic narrative review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PROSPERO) 2015 guidelines. Results A total of eight papers were included in the review. Older people are at greater risk of severe and multiple mental and physical co-morbidities including depression alongside lower socio-economic status than younger groups. They are more likely to be single, female, from an ethnic minority and retired. Although self-harm is considered a risk factor for future suicide, the rate of suicide following self-harm was only considered in one paper. Poison-related incidents are increasing and a greater proportion are among the over 65s. There is a need for further research into the elderly population with self-harm, with the consideration of specific variables to assess their clinical differences from other age groups. Conclusion While older people are at increased risk of adverse reactions following self-harm, only one paper measured the rate of suicide following self-harm. There is an urgent need for improved research into older people.<EOD> Aortic Arch Repair with a Unique Strategy for Left Subclavian Artery Reconstruction: A Preliminary Report\n\na b s t r a c tBackground: Left subclavian artery (LSA) reconstruction is technically demanding in thoracic aortic arch surgery. The authors propose a novel strategy for LSA reconstruction using a vascular prosthesis. Methods: A total of 14 patients (median age: 69 years; range: 58e79 years) with descending aorta aneurysm underwent total arch replacement and branched prosthetic graft implantation. The prosthesis",
        "label": 0
    },
    "1713": {
        "output": "Now you can assess eligibility in an automated fashion without any trial-specific information in the [INCLUSIONS-CODS] file for all patients for your clinical trials.\n\n```console\n$ python clinical_trial_eligibility.py --db_file trials_db.db\n```\n$ python clinical_trial_eligibility.py --db_file trials_db.db --id_file patients_db.db\n```\n\nClinical Trial Eligibility\n[1] Eligible\n[2] Not Relevant\n[3] Excluded\n`id` (`patient_id` column)\nEligibility\n[1] Eligible/\n[2] Excluded/\n[3] Not Relevant/\n\n### Example\n\nA small clinical trial in Craniofacial Surgery for the treatment of facial fractures.\n\n```yaml\n{\n    \"status\":\"completed\",\n    \"phase\": \"3\",\n    \"title\":\"A multicenter randomized double-masked placebocontrolled phase 3 study of recombinant human bone morphogenetic protein-2 for the treatment of acute facial fractures\",\n    \"study_type\": \"Interventional\",\n    \"trial_id\": \"NCT00146136\",\n    \"last_visit\": \"2019 -7 -30\",\n    \"last_result\": 0,\n    \"trial_type\": \"Interventional\",\n    \"patient_age\": 32,\n    \"enrollment\": 0,\n    \"enrollment_period\": \"2004 -7 -28_2016 -7 -8\",\n    \"arm\": {\n        \"status\": \"unknown\",\n        \"label\": null,\n        \"desc\": null\n    }}\n```\n\n![result image](./assets/result.png)\n\nHere are some of your assessments of eligibility.\n\n```json\n{\n  \"title\": \"A multicenter randomized double-masked placebocontrolled phase 3 study of recombinant human bone morphogenetic protein-2 for the treatment of acute",
        "label": 0
    },
    "1714": {
        "output": "<EOD> 2015 F150 Gets 20 MPG\nThe 2010 Ford F-150 is one of most efficient full-size pickups on the market \u2014 not good enough to boast about but something to celebrate.\nFord Motor Company reports that the truck's fuel economy has been improved by 20 percent \u2014 about 4 mpg \u2014 for 2011. And with F-150 sales having a hard time keeping up with gasoline prices, Ford hopes to give the pickup a shot of adrenaline.\nThe 2010 F-150\u2019s fuel economy figures of 14 mpg city and 21 mpg highway in the 4.6-liter model \u2014 the only V6 model \u2014 are based on highway driving. But in 2014, Ford boosted the mileage of the new 2015 F-150 to 20 mpg highway.\nThe EcoBoost\nIn 2011, Ford came up with the EcoBoost technology system, which helps the engineers to increase power and make more torque. For more efficient fuel delivery, Ford uses some new technologies like a high-compression V6 engine and dual-fuel, direct-injection technology. For more details please visit this website.\nSome of the changes from the 2010 F-150 models have been accomplished by eliminating a few features. The 2010 F-150 featured a 4.6-liter V8, 36-gallon fuel tank, and a dual front, front and rear, and a 60/40 recline rear seat. Now these features are not included in the 2015 F-150.\nThe 2011 F-150\n- All models are equipped with a 6-sided safety cage, front independent tires and a rear solid axle.\n- Standard rear-wheel drive and available all-wheel drive.<EOD> The human gut microbiome: implications for the study of host metabolism.\nThe last decade has witnessed a tremendous growth in our understanding of the human intestinal microbiome. This review discusses what is currently known about the",
        "label": 0
    },
    "1715": {
        "output": "## 32. Clinician: Eligibility Check\n\nEither the patient was eligible or non-eligible based on your diagnosis and assessment. You should write a detailed account of the eligibility check, to guide the physician in the screening for the second patient note. At the top of a new document, summarize the results of the eligibility check in the patient note.\n\n### Check the eligibility for all of the 7 patient notes:\n\n\n1. Summarize which of 7 patient notes is eligible or non-eligible. \n`Patient is eligible. Summary of the trial-level eligibility: Trial-level eligibility: 2) Eligible.`\n\n```\n# patient_notes.R\n\npatient_notes=list(patient.note=paste0(# patient note 0\npaste(# Explanation for patient note 1:\n\"Patient is a 30-year-old man diagnosed with HCV 1 year ago and the recent coinfection with HBV. His past medical history is significant for HCV, for which he has never been treated, and he was admitted to a detox center 8 months ago. The patient takes no other medications.\",\npaste0(# Explanation for patient note 2:\n\"There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\",\npaste0(# Explanation for patient note 3:\n\"\nThe patient is a 48-year-old male with diabetes, hypertension, and dyslipidemia. He was diagnosed with depression and anxiety 3 years ago. He is on medications for depression and anxiety, but is non-compliant and only takes them when he feels that he needs them. His alcohol and narcotic use is of current interest but he is hesitant to discuss these behaviors with his healthcare providers. The patient is currently on statins for hyperlipidemia. He has a family history of alcoholism. There is no evidence of bleeding esophageal varices, hemochromatosis",
        "label": 0
    },
    "1716": {
        "output": "I hope with that, people would stop writing the same thing in the comments.\nThanks, --Walker\n\nA: You've made a lot of assumptions that don't hold (which is why people are getting bitten in the ass from doing this).\n(Some of this should be in the body of the post, but it would be better served in the comments.)\nA patient can be excluded from, say, a trial of HIV drug based on the current infection status or treatment.  For instance, if the patient is taking a drug that binds strongly to the receptor, (e.g. NRTIs), they would clearly be excluded from the trial being discussed, and be better treated with a different drug.\nYour question would be more easily answered if there were no other tests for the patient, such as antinuclear antibody testing used to rule out an autoimmune disease or genetic testing to rule out a familial trait. For example, if the goal was a clinical trial on the treatment of Alzheimer's, then it would be difficult to determine if a patient were excluded from the trial because they just happen to be taking a drug that binds to a receptor that that drug targets.\nFinally, the question of a trial that would require the patient to be on a drug that is known to cause liver damage, for example. You couldn't run such a trial without having an answer to the question you've raised here.\n\nYou are a helpful assistant for clinical trial recruitment. ...\n\nActually, you are a research assistant, not an assistant to clinicians.  But no matter, your main claim about being a research assistant is invalid.\nIn clinical trials we don't \"recruit\".  We \"enroll\" or \"randomize\" (and in some cases \"consent\" - see below).  The process is called Recruitment but that word has no place in the official, formal, and regulated process of enrollment (\"recruitment\").\nYour question could be restated as:\nYou are a helpful research assistant for clinical trial recruitment.\nThat might be more accurate and make more sense in an academic setting.  However in clinical practice we use the word recruit in a slightly different way.  In most studies we are not really interested in recruit",
        "label": 2
    },
    "1717": {
        "output": "HINT:\n- If we want to exclude a patient, we should mark excluded before the semicolon, e.g., `Excluded;`.\n- To include a patient, we should add `1) Not relevant;` just before the semicolon, e.g., `Not relevant; 1) Not relevant;`\n- To omit a patient and mark him or her as not eligible, please add the semicolon after the first excluded and not relevant, e.g., `Excluded; 1) Not relevant;`\n- To leave the patient and set the eligibility to not assessable, you should skip this patient and enter the next one, e.g., `Excluded 1) Not relevant; 2) Eligible ; 3) Not assessable;`.\n- All the patients from the same source (patient note) should be inserted into one cell.\n- All the patients from the same source (patient note) should be put into a group (using the <key> <value> format).\n\n## Exercises\n\nTo implement the exercises, first, run the provided script (Ex158-1.sh), and provide a set of .csv files generated by running the script.\nPlease use the following command:\n`./Ex158-1.sh $DIR$`.\n\n| Trial-ID | Source | Patients |\n| -------- | ----- | ------- |\n|    6  |    1 |        |\n|    7  |    2 |        |\n|    8  |    3 |        |\n|    10 |    4 |        |\n|    12 |    5 |        |\n|    13 |    6 |        |\n|   20 |    7 |        |\n|   25 |    8 |        |\n|   30 |    9 |        |\n|   38 |    10 |        |\n|   50 |    11 |        |\n|    3 |   12 |        |\n|    4 |   13 |        |\n|    5 |   14 |        |\n|   18 |   15 |        |\n|    9 |   16 |        |\n|    50 |   17 |        |",
        "label": 2
    },
    "1718": {
        "output": "## [INST] Example input of a real patient file.\nHere you can see an example data sheet with one simulated patient:\nPatient information (patid=1):\nGender: 0 (for male code) 1 (for female code)\nAge: 38 Patient id: 1\nGender: Male\nHBV Clinical Trial: \nTrial Number: G8997T464\nTitle: A New Treatment of Chronic Hepatitis C\n\n# Abstract:\nThis will be done at your institute, a large and academic hospital and tertiary referral center. All the patients with chronic HCV, regardless of genotype, will be treated with a new IFN-free treatment, SOC+SOF+RBV for 12 weeks.\nThere are 5 exclusion criteria:\n1) HBsAg positivity 2) decompensated cirrhosis 3) ongoing or uncontrolled illicit drug use 4) uncontrolled psychiatric condition 5) alcohol intake > 30g/day.\nEnrolled patients with negative HCV RNA after treatment will be followed up to 24 weeks, and then every 24 weeks thereafter. At each follow-up visit, physical examination, liver function tests and abdominal ultrasound will be performed. Any recurrent HCV viremia will be confirmed via HCV RNA testing.<EOD> The SLC25A24 promotes the proliferation and migration in gastric adenocarcinoma\nABSTRACT Purpose: To study the effects of SLC25A24 on the proliferation and migration of gastric adenocarcinoma (GAC). Methods: SLC25A24 expression in gastric adenocarcinoma tissues were analyzed by immunohistochemistry (IHC). The relationship between clinicopathologic parameters including lymph node metastases was explored. The expressions of SLC25A24 and EMT-related molecules in GAC tissues and cell lines were evaluated by real-time PCR and western blotting. To study the function of SLC25A24 in",
        "label": 0
    },
    "1719": {
        "output": "## Clinical Trial of Vitamin E\n[INT] One of the main goals of the research is to evaluate the usefulness of vitamin E. Clinical trials have shown no benefit from vitamin E. The effectiveness depends on the type of disease. This time we would like to conduct a clinical trial to study the effectiveness of vitamin E in patients with congestive heart failure caused by severe coronary artery disease. In this example, the goal is to investigate the effectiveness of vitamin E based on the results provided by previous research on this disease.\n\n[Treatment ACTION trial] Recently, studies have shown that vitamin E may help people with left ventricular dysfunction. However, a group, including vitamin E, did not improve the progression of heart failure when compared to the control group. Another study showed that vitamin E improved heart function, but this improvement was not related to the prevention of heart failure exacerbations, heart attack, stroke, or death from cardiac causes. In contrast, the study showed that taking vitamin E could reduce the risk of diabetes and death of people without cardiovascular problems. Due to its potential cardiovascular protective benefits and lack of side effects of vitamin E, it seems that adding vitamin E to the therapeutic regimen of patients with congestive heart failure is beneficial.\n\n[INT] One of the main goals of the research is to evaluate the usefulness of Vitamin E. Clinical trials have shown no benefit from Vitamin E in the heart failure. However, a group, including 180 mg daily dose of Vitamin E for 10 years.\n\n```python\ndef eligibility_assesst(patient):\n    try:\n        trial = Trial(patient.Trial, patient.Demographics.age) # Get the trial information from the patient\n        # Check variables of the trial\n        trial.type == \"congestive heart failure\" # Check for variables to confirm\n        trial.outcome_evaluation == \"eGEfrLessThan60\" # Variable to ensure that if all other conditions are met, the outcome evaluation will be met\n\n        # Check the rest of the trial data\n        trial.duration == 180 #(month",
        "label": 0
    },
    "1720": {
        "output": "<h2 id='sec:example-8-2'>Example #8-2</h2>\n\n[JUPYTER_LAB_COLAB_LINK]jupyter:8\n[/JUPYTER_LAB_COLAB_LINK]\n\n[INST]\nHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\nThe patient is an alert 60-year-old man and is infected with RHD. His past medical history is non-significant. He is on IFN and RBV treatment for the past few months. His medical records show previous positive HCV RNA tests, and the positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 125/70, HR: 89/min and temperature: 37.4. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.His past medical history is non-significant. He has been infected with RHD for 15 years. He is on IFN and RBV treatment for the past few weeks. His medical",
        "label": 0
    },
    "1721": {
        "output": "# Conclusions\n\nIsolated sentences and fragments of code are better to read than full, long programs. \nCategorically speaking, it can be said that the following questions must be answered so that the patient's eligibility for a trial can be calculated:\n- Does the medical record contain sufficient information for us to determine if the patient meets the eligibility criteria?\n- Does the patient have the diagnosis of a disease (e.g., hepatitis C)?\n- Does the patient have the indication of a drug therapy (e.g., taking direct antiviral drugs for the past 6 months)?\n- Does the drug therapy have a positive impact on the patient or has the disease worsened (e.g., positive enzyme immunoassay for anti-HCV-antibodies)?\n- Does the patient have enough time to participate in a clinical trial and its accompanying trials?\n- Do the medical records contain enough information for the clinician to find out whether the patient meets the eligibility criteria of the clinical trial under consideration?\n- Do the clinical guidelines make sense? \n<EOD> Influence of dietary nitrogen supplements on the inhibition of prolactin response to suckling.\nPlasma prolactin response to suckling was compared between nursing and nonnursing dams in 3 experiments. Experiments were carried out in lactating gilts fed either 1 of 3 purified diets at a common metabolizable energy level or diets containing 15% dehulled soybean meal alone or soybean meal combined with casein, tryptone, or feather meal. Suppressible prolactin response to suckling in nonnursing pigs was not different (P > .10) among experiments and varied with stage of lactation in both nursing gilts and nonnursing pigs fed in-toto soybean isolate, soybean isolate + tryptone, or soybean isolate + dehulled soybean meal diets. Suppression of prolactin during suckling averaged 33 +/- 14, 47 +/- 14,",
        "label": 1
    },
    "1722": {
        "output": "## Expert Commentary:\nYou have to understand what to do based on your experiences. You should not be so nervous about the assessment of a patient or an individual clinical trial. It is better to make several assessments at once and make a quick judgment. The first patient you should assess is the excluded one. The first step of the patient assessment should be to make a note at the top of the note of clinical trial. After the first patient, the next patient will be assessed. To assess, it is not necessary to check all of the inclusion and exclusion criteria for each patient. You should assess the information that is not available based on the patient's medical records. It is also ok if you don't check the other elements of the trial because it has an exclusion criterion (for example, pregnancy). \n\n### Case study 2\n[formula]  ==================== ========== ==================== ========== [/formula] \n<EOD> Influence of Influenza Epidemics on Pandemic Mortality\nThe impact of the 1918 pandemic influenza strain is undeniably large. Most demographers agree that excess mortality was high, but there is not enough agreement on the extent of morbidity, on the extent of pandemic impacts on the demographic characteristics of the population, or on the overall consequences for the populations. These discrepancies may relate to the fact that, in most studies of pandemic influences, the impact of a virulent strain was estimated by comparing the demographic characteristics of a population with a virulent (highly lethal) strain against those exposed to a nonvirulent or less virulent one. Such a comparison fails to consider some indirect effects of the highly lethal strain. An additional explanation for differences in results is that, in most of the analyses, pandemic and seasonal epidemics were superimposed in the same population groups. Thus, the estimated impact of pandemic influenza may differ markedly if the impact of the epidemics is estimated against all other deaths occurring during seasonal epidemics. In this study, we examined the impact of the 1918 pandemic influenza strain on age-specific mortality using only nonlethal seasonal epidemics as reference points. Our results allow a more",
        "label": 0
    },
    "1723": {
        "output": "## Exercise\nYour first job...\n### Task description\n\nYour first job is to complete the following table. The task description is in the column 'Question'. Your first job is to examine a patient with a history of cancer (Hematology) and enter all required data to the table. If information is missing from the clinical note, you may need to ask to the physician about the required information to complete the table. After completing the table, you need to select the 'Complete' button in the last column. It will take you to the next page with a new set of patients which you have to answer step by step.\n\n### Task Assessment\n\nYou will be scored if you manage to complete the task. If you do not make a choice in the input fields of the table, you receive 1 point if you choose the correct option and 0 if the wrong one.\n\n\n#### Submission\n\nAfter submitting the table, you will be given a feedback page with the score and the message \"Congratulations ...\". Click on the Next button to move to the next page.\n\n\n#### Feedback\n\nYou may find the detailed explanation of every question in the 'Instructions' tab.\n\n\n#### Feedback table\n\nYou will be rewarded by points or bonuses for every task fulfilled as shown in the table.\n\n\n#### Tasks Score|Bonus\n\n#### HW1: Patient History\n1 point=5 minutes\n#### HW2: Finding Changes in Medical History\n1 point=5 minutes\n#### HW3: Taking Oral Fluid Specimen\n1 point=5 minutes\n#### HW4: Physical Examination for the Patient\n0 or 1 point=10 minutes\n#### HW5: Obtaining Lab Testing\n1 point=10 minutes\n\n### Task Description:\n\nYou are a nursing assistant at a clinic where patients with cancer are being treated. The nurses report that every time they examine a new patient, they need to spend an unusually large amount of time explaining and clarifying the patient history to the physician. They found that physicians are unable to comprehend the clinical notes. A medical database has recently been installed. The software records the history of the patients as they are taking care of them. After",
        "label": 0
    },
    "1724": {
        "output": "#### In-Place Feature Enhancing the Code Generation\nBy using feature-enhanced generation capabilities, we generate code that is compatible with various IDEs such as PyCharm, Eclipse, and Visual Studio Code. The generated file is a .py file which is compatible with all the listed environments.\n\nThere are two ways that PyInstaller provides for generating Python code for IDE. One of them is for the simple environment, which uses the standard `import` statements. The other one is for the complex environment. According to the following code example shown in the figure below, it will not be valid if the import statements are included in the main program, i.e., the following python code example won't work when the import statements are included in the main code.\n\n> import os\n> import pwd\n\n> sdk = str(os.getenv('SDKROOT'))\n> sdk2 = str(pwd.get_home_directory() + '/SDKs/OSKIT_SDK.dylib')\n> sdk3 = str(pwd.get_home_directory() + '/SDKs/DICOM.py.dylib')\n> sdk4 = str(pwd.get_home_directory() + '/SDKs/HDF5\\2008.2.0.py.dylib')\n\n### Simple Environment\nA simple python environment is defined using `pwd` module, the user home directory and specific SDK files. The generated file uses the relative import syntax by specifying the name of these modules rather than their absolute paths.\n\n```\n# pwd.py\nfrom pwd import get_home_directory\n\n\n\n# Example script:\nfrom pwd.py import get_home_directory\nprint(\"Home Directory:\", get_home_directory())\n\n\n\n# Run Example script:\nimport pwd.py\nprint(\"Home Directory:\", pwd.py.get_home_directory())\n```\n\n> ## Test\n\n```python\n\n# pyinstaller -t pwd.py -w lib -m 'OnSave' -n SimpleEnvironment\n```\n\n```\nTraceback (most recent call last):\n  File \"/Users/user/Documents/pyinstaller/python2/lib/python2.6/site-packages/PyInstaller/runtime/pyi_",
        "label": 0
    },
    "1725": {
        "output": "The output should be like this:\n\nIn conclusion, the output on screen should be like this:\n<vaccine trial_name> 1000100000000000000001 -20 25 172020000000000000001 100000000000000000000 10000000000000000001 100020000000000000000 100000000000000000000 20 24 172040000000000000002 100000000000000000000 100000000000000000000 10000000000000000002 100020000000000000002 100000000000000000000 6 3 10000000000000000002 100000000000000000000 1000000000000000001 1000000000000000003 10000000000000000000 7 6 10000000000000000003 1000000000000000001 1000000000000000003 10000000000000000000 6 3 100000",
        "label": 0
    },
    "1726": {
        "output": "### Good Luck\n[GIF]\n[IMAGE]\n[/GIF]\n[/IMAGE]\n[img]https://user-images.githubusercontent.com/26528/52099956-0d18b800-2201-11e9-97e6-bcf11e177772.png[/img]\n<issue_comment>username_0: I did this assignment in \"Python for biologists\" class for my undergraduate degree in 2011. I thought it was interesting at the time.\n<issue_comment>username_0: I have made some improvements to the example for the next installment. I don't think my way of doing it was all that good.\n<issue_comment>username_1: @username_0 Can you share a link to your code?\n<issue_comment>username_2: @username_1 i think we can move this issue to some other issue, because this issue is pretty old one.<EOD> Transcriptome signatures from human tissues and blood reveal novel targets for bacterial pathogens\n\nSupplementary Note 1:The BactDx model. The BactDx package works by first determining the features of the transcriptomic responses common to a large number of tissue samples for a select panel of pathogens. The BactDx model employs a simple random forest (SVM-RFE17,18 ) machine learning model to achieve this goal by utilizing training data consisting of the average normalized gene expression value for a set of relevant 203 pathogenic bacteria and the average transcriptomic response for a panel of different tissue types. The SVM-RFE method creates a random forest library consisting of the top 204 differentially expressed pathogenic bacteria genes, and then, it removes each gene in the library at a time based on the mean decrease error from a previously trained model. This iterative process continues until the final library has the desired number of genes, which we set as 204. The genes are organized into a set of clusters by their differential expression in the pathogenic bacteria set. Finally, the model is evaluated by calculating the mean Euclidean",
        "label": 0
    },
    "1727": {
        "output": "you need, a trial a newel [study\nand the trial.\nThe HCV in the medicines that a medicines\nDuring the subject's [a new medicine [medical medication, you.\n\ntrial in the medicines-the trial enrolls. You, are to the subject's medical. The subject's condition/status.\n\nHIV therapy'trials included study you are a [a specific in the criteria.\n\n\n\n\n\n\n[1 [stud of new, you dose.\nIn addition. Criteria in the trial.\nThe target criteria based on the trial.\n[study-inclusion; age, if you need you.\nstudents, the need to be sure criteria for inclusion.\nP[the, the trial.\n[in the trial. This trial. Assess the first, which does you's on clinical elig. You:\n\nIn trial. Study.\nto the criteria in study. You are you's medical: 99\n[your trial.\n\nmedian tooth.\nYou and that medic clin\u2026 elig.\n[s[s.\n[6 to the trial elig 2. It is done.\n[during elig.\ns trial. study, and have been in the trial to meet hepat, the elig of the treatment.\nIn order. And he/ex, 10 and/[1 \ns or elig criteria, and the elig you's. You[a patient's.\n[for the trial. Elig. You[med and the trial. 43 and theta, age.\nHe.\n(the. Therefore for elig! elig, and the elig 4.\nor.\nhealth, 19 and there, el [...]a a person. If the subject, clinic. Recruit and you.\ns-care.\n[you on the patient-based and in the trial. And [bib_ref] you (\n[d with an open. These, the patient. The first patient and\n\nor\\or, age and treatmental. However, but the patient.\ns 10.\nand or a 11 with the el 1. This clin. The patient oral. Of the reason. You\\ch. D-related by",
        "label": 0
    },
    "1728": {
        "output": "<EOD> Isolation of a functional cDNA clone of human interleukin-5 complementary DNA and its comparison with human interleukin-3 complementary DNA.\nA functional cDNA clone of human interleukin-5 (hIL-5) was isolated and its nucleotide sequence was determined. Its 765-bp cDNA contained an open reading frame that encoded a protein of 212 amino acids. The deduced amino acid sequence of hIL-5 showed the highest homology with mast cell growth factor (91.8% identity) and platelet-derived growth factor B (90.9% identity). Phylogenetic analysis of the coding sequences of mast cell growth factor family members indicated that platelet-derived growth factor B might have emerged before IL-3 and IL-5.<EOD> .\nH.P. is a 59 year old woman with a history of type 2 diabetes, and with a body mass index (BMI): 29.2 kg/m2, 174 cm and 110 kg. She was diagnosed with type 2 diabetes at an intermediate level of complication (20 pts in DKD), with a very long and complicated diabetes history which had been treated with a conventional treatment strategy from 1985 to 1997, and with a very poor clinical adherent. In this period, she presented very poor glycemical control: HbA1c: 9%, as well as high total cholesterol levels and a BMI: 29.2 kg/m 2. In June 2008, H.P. attended to a diabetes consultation for the first time. When H.P presented and discussed to the doctor in the diabetes consultation, she explained and told him that 2 years previously she had experienced \"the worst time of her life\", as she was \"afraid\" and \"scared\" because of the results revealed by the medical tests and, moreover, she did not really understand her doctor's recommendations to follow a new treatment strategy plan, and she did not know whether it was the \"treatment strategy\" (the new conventional one) for the long-term diabetes, or a \"temporary\" strategy (as",
        "label": 2
    },
    "1729": {
        "output": "[[so and the clin [M to ensure and elig. He as he 0 for either, accordingly you. The best and a1, and the one. [bib_ref]\n [de, diagn\n[f and in these  or related.\n[ [bib_ref] [fig_ref] [bib_ref]... 21\u00a0and 10\n\n[[ or an unrelated, a\u00a0f or the following. The el\u00a0( [bib_ref]in [bib_ref] a decision. One 1 and \n[in the health-matcher-like and\n(i.\nor and we can the following el\\[[ or 1.\n \u00a0. \n(such   \u00a0in-in. [bib_ref]\u00a0 \ufffdell or inclusional, [bib_ref]\u00a0\u00a0or, patient. [fig_ref] [bib_ref]  and that\n and for the [bib_ref] and the [bib_ref] in your patient, in the characteristics [bib_ref]\u00a0in and \u25a0\n \u00a0: the el for theft: and other \\...because, which a 1 or [bib_ref] [fig_ref] 1 or to\nfor 2 \\ or [[ 2.\nfor the number; \nin the 1 or 1\u00a0, who the [bib_ref], el-the  and [bib_ref] the 1\u00a01 and [bib_ref] after\nor and 1.\n [bib_ref] [bib_ref] for all\u00a0on-test, or [bib_ref] [bib_ref]\u00a0\u00a0\u00a0. The [bib_ref] and that the only. 1, and elve for the [bib_ref] . \n\n for [bib_ref] the [bib_ref] a [bib_ref] (A. The-based. If [bib_ref] 2\u00a0 and to\n or 2. \n \n 2 . \u2026 for health\\s [/table] [bib_ref] on \ufffd\ufffd and they, but the, in the [fig_ref]. and [bib_ref] . and\n [bib_ref]   or [bib_ref] [bib_ref] _( 5\n and\n and [bib_ref]\non (as [/table] [bib_ref] (for the initials in 6\u00a0\n with 2\u00a02 \u00a01 :\\ for 1 [bib_ref] for [bib_ref] \\\nfor [bib_ref]\n 1-re for ( 2 in accord, respectively (o [bib_ref] in the ( or a^ _ a [bib_ref] the \u00ac [bib_ref] [bib_ref]-the 2\n \u25cb<EOD> 1 - or 2 [bib_ref]\u00a0 of the on the [bib_ref] \\ or its , [bib_ref] (or- or as .1. and",
        "label": 0
    },
    "1730": {
        "output": "We will make an output that tells you that the patient should be enrolled in the trial. \n```\nEligibility: 2) Eligible.\nGroup id: 1\n```\n\nYou will need to generate a table showing which of your patients are eligible to enter the trial. You can use the function to select eligible patients:\n\n```\n$patients <-df.clinical$PatientId\n\n$patients <-as.numeric( df.clinical$TrialId )\n\n$patients <-df.clinical$TrialLevelEligibility\n$patient.eligible <-lapply( $patients, '!=\"Not relevant\")\n\nprint(paste(\"Sys.settimeout has been set to 10 in order to deal with slow networks : : : \" , Sys.settimeot( sys.time() , 10 )))\n\nPatients.with.comorbidity <-df.clinical$PatientId[ $patient.eligible ]\nprint(\"Selected patients : \" , nrow( df.clinical[ $patient.eligible ] ))\n```\n\n```r\nSys.settimeot has been set to 10 in order to deal with slow networks : : : 1523297321.756\nSelected patients : 197\n```\n\nHere is the final output:\n\n```r\n    Patients.with.comorbidity <-df.clinical$PatientId [ $patient.eligible ]\n\n    print(paste(\"Patients with comorbidity : \" , nrow( df.clinical[ $patient.eligible ] )))\n```\n\n```\n    Patients.with.comorbidity <-df.clinical$PatientId[ $patient.eligible ]\n\n    Patients.with.comorbidity <-df.clinical$PatientId [ $patient.eligible ]\n\n print(paste(\"Eligible patients with comorbidity : \" , nrow( df.clinical[ $patient.eligible ] )))\n```\n\n```\n  Eligible patients with comorbidity :",
        "label": 0
    },
    "1731": {
        "output": "## [END]\n\n\u00a9 2020 MDL Global Services GmbH.\n\n[Learned]\nA patient note of the patient has at least one of four following values of HCV Ribavirin or HCV alpha-2b (HCV Peginterferon or HCV Polyprotein) which indicates that the patient is the candidate to the clinical trial. Each value represents an inclusion criterion. To determine the eligibility, two inclusion criteria should be satisfied. One of them is equal to the patient's value (patient not relevant) and the other one is not equal to the patient's value (patient excluded or patient eligible) \n\nFor the experiment, the input data should be processed, as described next: \n\n\n|     | |       | |          | |          | | |         |   |         |   |         | |\n| CLASS_ID | | CHR_ID |  | PAGE_ID |  | CHR_ID | | PAGE_START | | PAGE_END | | PAGE_ID | |\n|----------|: |:        |:         |: :        |:         |: | :         |:    | :         |:   | :         | |\n| 1 (HCV_Ribavirin) | 34253 | 1 (HCV) | 2702-2706 | 1 (RBV)_0-2 | 1 (RBV)_17 | 0 | 16485 | 2015-2017 | 1 (RBV)_13 |\n|----------|: |:        |:         |: :        |:         |: | :         |:    | :         |:   | :         | |\n| 2 (HCV_alpha-2b (HCV Peginterferon)  | 34253 | 1 (HCV) | 2706-2709 | 1 (Polyprotein)_0-3 | 1 (Polyprotein)_15 | 0 | 16487 | 2011-2017 | 1 (Polyprotein)_1",
        "label": 0
    },
    "1732": {
        "output": "<EOD> A novel mechanism of platelet activation by the F(ab')2 of monoclonal antibody HP1/2.\nA novel mechanism of P-selectin activation has been described using the F(ab')2 fragment of monoclonal antibody HP1/2, a murine IgG (MAb) directed against the glycoprotein IIb/IIIa complex of human platelets. This antibody is specific for human platelets and does not react with the platelets of animals such as monkeys, sheep, hamster, rabbit, dog, or mouse. The F(ab')2 of MAb HP1/2 elicited platelet aggregation and a dose-dependent release of granule contents in vitro. The release of a major granule constituent, beta-thromboglobulin (beta TG), was demonstrated by use of an enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA). beta TG release in response to the F(ab')2 of MAb HP1/2 occurred by 10 min when platelets (1.25 X 10(8)/ml) were incubated at 37 degreesC, in calcium-containing buffer or in the presence of 1 mmol/l of EDTA. The rapid release of beta TG occurred at MAb concentrations as low as 0.5 microgram/ml of F(ab')2 and occurred without the addition of any exogenous chemical mediators. In the absence of calcium, but with exogenously added ADP (5-20 micrograms/ml), beta TG release was delayed and platelet aggregation was markedly reduced. By addition of fibrinogen (1.25 mg/ml), a substantial reversal response to the F(ab')2 of MAb HP1/2 was noticed, showing that platelet aggregation was platelet-dependent and was partially reversible. Aggregation was partially reversed by addition of 100 micrograms of MAb F(ab')2/ml, while beta TG release was entirely reversed by the same amount of MAb F(ab')2. By use of another granule granule constituent, platelet factor 4 (PF",
        "label": 0
    },
    "1733": {
        "output": "In Python, a dictionary is a word whose values can be of any type. A dictionary can be defined using the following code:\n\n```python\nname= dict()\nname[\"Katherine Johnson\"] = 10\nname[\"Helen Keller\"]= 100\nname[\"Edison\"]= 112\nnames = [\"Katherine Johnson\", \"Freddie Mercury\", \"Edison\"]\nfor name in names:\n\tname['Katherine Johnson']=10+age_KJ\n\tage_KJ = age_KJ + 5\nprint(\"Katherine Johnson's information is\" +str(name) +str(age_KJ)+ \" year\").\n```\nThe following code uses the `name` dictionary to add the parameter `age_KJ` to the `Katherine Johnson` name:\n\n```python\nname= dict()\nname[\"Katherine Johnson\"] = 10\nname[\"Helen Keller\"]= 100\nnames = [\"Katherine Johnson\", \"Freddie Mercury\", \"Edison\"]\nfor name in names:\n\tname['Katherine Johnson']=10+age_KJ\n\tage_KJ = age_KJ + 5\nprint(\"Katherine Johnson's information is\" +str(name) +str(age_KJ)+ \" year\").\n```\nIn this code, `name` is a dictionary and both `age_KJ` and `Katherine Johnson` are strings. The code adds the age of the `Katherine Johnson`'s to the dictionary. In other words, after adding the new parameter called `age_KJ`, we have created a new dictionary by adding a new key of Katherine Johnson.\n\n> **Caveat**\nIn the code above, we have used Python dictionary for adding new parameters. However, this is not the only option for using Python. For example, if we use another type of Python dictionary but use the `add` and `update` methods, we can add new parameters to the dictionary, too.\nThe following code illustrates how we can use the Python dictionary and how we can add a new element of a dictionary by using its `update` method:\n\n```python\nimport builtin\nage_kj= 10.5\ndata [key]={\n    '",
        "label": 0
    },
    "1734": {
        "output": "Exercise 2\n<EOD> The effects of intraocular foreign bodies on the cornea.\nIntraocular foreign bodies (IOFBs) cause serious visionthreatening complications. The mechanisms by which IOFBs can injure the eye are many. Ocular contusion and lens degloving may be related to the entry site of the foreign body. Iris prolapse and posterior synechia may result from a corneal laceration due to the foreign body. Perforation of the globe by the foreign body may cause secondary cataract and glaucoma. Penetration of the lens capsule may bring about cataract or vitreous hemorrhage. IOFBs result in a variable amount of inflammation depending on the location and size of the entry wound. We want to review the causes of corneal ulceration and their complications, to describe the mechanism of corneal penetration by IOFBs, and to discuss possible methods to reduce this injury. Some of the foreign bodies may have the ability to produce metallic ions, which may play a role in the onset of inflammation and neovascularization. It has been reported that metallic ions released by the metal foreign bodies may cause corrosion of the eyeball, leading to secondary glaucoma.1 In this article, we investigated how the IOFBs produce inflammation and how secondary corneal edema may develop due to the inflammation. We investigated the effect this inflammation could have on the cornea in a cadaver eye to understand the pathophysiology. To accomplish this study we designed a model of the eyeball using the human cadaver eye. As the human eye is not accessible for the study of corneal changes due to the inflammation of the eye, to overcome this problem, we designed a model of the eyeball by modifying an eye model using an optic nerve cannulations on the cadaver eye and designed methods of measuring the corneal thickness changes due to the inflammation.<EOD> Effects of the p75 neurotrophin receptor on motor neuron disease in transgenic Caenorhabditis elegans models.\nMotor neuron diseases (MNDs), such",
        "label": 2
    },
    "1735": {
        "output": "Your assessment should be in the same format as the trial-level eligibility. Evaluate each patient record and write a patient-level eligibility. \nLet's consider an example: `Patient-level eligibility: 1) Not relevant (no data available (NA))`.[INST] \nThere are other optional elements. You can specify the reasons for your eligibility and also include information about the participants or patients who do not meet the eligibility criteria. However, all these optional information may not appear in all clinical trial requests. \n\n![INST]\n\n\n\n# Use the data elements\n\nThe key data element that you should use is the patient-level data element. Whenever feasible, you should also use data elements for `Trial-level eligibility` and `Patient-level eligibility`: \n```ts\nimport 'core-js/reflect';\n\nconst EligibilityAssessment = eligibility => ({\n    trialLevelEligibility: eligibility.trialLevelEligibility,\n    patientLevelEligibility: eligibility.patientLevelEligibility\n});\n\nconst user = [\n    {\n        ID: 'USER1',\n        EligibilityAssessment: EligibilityAssessment({\n            trialLevelEligibility: 0,\n            patientLevelEligibility: 1\n        })\n    },\n    {\n        ID: 'USER2',\n        EligibilityAssessment: EligibilityAssessment({\n            trialLevelEligibility: 0,\n            patientLevelEligibility: 1\n        })\n    },\n    {\n        ID: 'USER3',\n        EligibilityAssessment: EligibilityAssessment({\n            trialLevelEligibility: 0,\n            patientLevelEligibility: 1\n        })\n    },\n    {\n        ID: 'USER4',\n        EligibilityAssessment: EligibilityAssessment({\n            trialLevelEligibility: 1,\n            patientLevelEligibility: 2\n        })\n    }\n];\n\nexport default user;\n```\n\n\n\n### Example of query result\n\nTo see the example query result, let's try to display the",
        "label": 0
    },
    "1736": {
        "output": "### Exercise 11A (Solved): Find the clinical trial that has the greatest number of patients.\n\nIn the following tables you will find the results of the analysis in `Clinical Trial` and `Patient` tables. These are generated internally in the `main.R` file, and should be very familiar with them. Here are summary statistics:\n\n<table>\n  <thead>\n    <tr>\n      <th>id</th>\n      <th class=\"title-label\">Clinical trial data</th>\n      <th>Nested groups</th>\n      <th>Nested variables</th>\n      <th>Intercepts</th>\n      <th>Coefficients</th>\n      <th>Standard errors</th>\n      <th class=\"title-label\">Patient data</th>\n      <th class=\"title-label\"></th>\n      <th class=\"title-label\">Mean group</th>\n      <th class=\"title-label\"></th>\n      <th class=\"title-label\"></th>\n      <th>Duration</th>\n      <th>Status</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td>1</td>\n      <td>\n        <table class=\"table table-striped\">\n          <thead>\n            <tr class=\"hidden\">\n              <th></th>\n              <th>Intercept</th>\n              <th>Coefficients</th>\n              <th class=\"hidden\">Standard errors</th>\n            </tr>\n          </thead>\n          <tbody>\n            <tr class=\"hidden\">\n              <td class=\"hidden\">Inclusion criteria</td>\n              <td> 2.17479e-06</td>\n              <td class=\"hidden\">[1.24337e-06, 3.09046e-06]</td>\n              <td class=\"hidden\">[6.63559e-08, 5.42232e-06]</td>\n            </tr>",
        "label": 0
    },
    "1737": {
        "output": "The [Trial-level eligibility (patient note)] block is not visible in \nIf you want to find the block `Trial-level eligibility`, go to the tab `Patient` and then to the tab `Progress note`. \n\n### Example 2 [INST]: A patient is a 17-year-old man diagnosed with HCV 2 years ago. He works as an electrician. The patient takes no other medications. He is on IFN for the past 2 months. This is the patient's medical history:\nThe recent patient note is in the block `Progress note`. You can check all the contents of other patient-level blocks such as `History of present illness`, `Past medical history`, and `Surgical history`.\n\nWe show below the main procedure to assess eligibility for our study. \nTherefore, the patient is not eligible for the study if the patient is in good general condition.\n\n## [INST]: \u25b6 Triallevel eligibility (patient note) \n```{r}\nif( (Trial_level_eligibility == \"Excluded\")) {\n  #if patient has exclusion criteria for clinical trial\n  #set patient eligible\n  #print eligible\n  write_lines(\"Excluded\", file = \"Excluded_patient_reports\")  #save patient report for exclusion\n}\nelse {\n  #if there is no exclusion criteria, proceed\n  #set patient not eligible\n  #print ineligible\n  write_lines(\"Ineligible\", file = \"Ineligible_patient_reports\")  #save patient report for ineligible\n  #assesses patient eligibility for clinical trial\n  #set trial eligibility\n  #print eligible\n}\n```\n\n## Example 3 [INST]:  A patient is a 50 year old man with HCV 3 years ago. He takes no other medications. In the recent past, he was on IFN for 4 months but stopped as the treatment proved ineffective. His medical history is significant for alcoholic cirrhosis with hepatocellular carcinoma. He is an alcohol abuser with multiple medical problems, his BP is",
        "label": 1
    },
    "1738": {
        "output": "Good luck!<jupyter_text>Let's apply the problem to the actual data. I extracted all clinical trial notes from MIMIC-III in this notebook for your convenience. In this notebook, data_clinical_trial_note_data is generated.<jupyter_code># You can put the above data into `data_clinical_trial_note_data` by yourself.\ndata_clinical_trial_note_data.<jupyter_output><empty_output><jupyter_text>Before making trial-level eligiblity, we have to make the trial-level note for each patient.  Let's make the code to make trial-level note.  To do this, we use the following Python package.\r\n\r\n*[clinical_trial_records](https://anaconda.org/wagener/clinical_trial_records)\r\n\r\nTrial-level notes are stored in `clini-cal_trial_notes` table of `clinical_trial_records.db`.  They look like this.<jupyter_code>from clinical_trial_records.db import ClinicalTrialDb\r\nclinical_trial_db = ClinicalTrialDb('data_clinical_trial_note_data')<jupyter_output><empty_output><jupyter_text>Then, we write the following code.<jupyter_code>from clinical_trial_records.db import ClinicalTrialDb\r\nfrom flask import Flask, request\r\nfrom flask_restful import Api, Resource\r\nimport json\r\n\r\ndb_dir = '/data/'\r\ndbpath = db_dir + 'clinical_trial_records-master.' + db_ext\r\nclinical_trial_db = ClinicalTrialDb(dbname=dbpath,db_ext=db_ext)\r\n\r\ndef eligible(request):\r\n    \"\"\"Get trial-level eligibility from `clinical_trial_notes`.\r\n    \"\"\"\r\n    trial_note = request.get_json()\r\n\r\n    clinical_notes = clinical_trial",
        "label": 1
    },
    "1739": {
        "output": "_\n\n\n\n-  `cct-el-trial-level-eligibility` (see above in this page)\n\n\n#### RESPONSE PROBE #1: _____________\n_____ Response Probe #2: ______________________________ For ARM 1: `Participants will be provided with an opportunity to ask questions about the study and then will be enrolled sequentially (in order) until the planned number of participants in the study is reached. All participants will be provided with a Study Medication Record Booklet (SMRB) identifying dosage per dose and schedule of each study medication given (Table 5-5) and a treatment card, which will also record any deviations from planned doses and schedule. \nAll participants will be required to remain on stable doses of concomitant medications that were taken chronically before the study during the study period (Table 5-5). A dose alteration of a concomitant medication to adjust a clinical condition that occurs on the day that a study medication is started is allowed and will be recorded by the investigator in the medical records.\n\nIn the ARM 1 treatment period and ARM 2 assessment period, daily 1000 mg ribavirin orally will be required. This dose should be reduced to 600 mg if:\n> ALT is \u2265 5 \u00d7 ULN or AST is \u2265 3 \u00d7 ULN for males; or > ALT is \u2265 7 \u00d7 ULN or AST is \u2265 5 \u00d7 ULN for females. \n\nDose adjustments for adverse events (AEs) from baseline laboratory abnormalities will be based on the laboratory abnormality classification table. (See Section 4.7.8.) AEs that are not laboratory abnormalities, will not require a dose adjustment. \n\nIf a participant develops anemia while in a treatment period, the participant may be rescued per ARM 1 rescue algorithm (See Section 8.4.7). This may include temporarily discontinuing one or more concomitant medications by the Medical Monitor or study physician and may also include temporarily decreasing the RBV starting dose",
        "label": 1
    },
    "1740": {
        "output": "# Implementation\n\n## Tutorial\n\nTo help you with the implementation, try to answer the provided questions and then compare your answer with the following code:\n\n![Demo](demo/demo.html)\n\n\n## Install\n\n```\nR> library (\"TrialDetection\")\n```\n\n### Tutorial\n\n\n### Test\n\nLet's do a simple test for our `apply.eligibility` function in the `TrialDetection` namespace:\n\n```\nR> v1 <- apply.eligibility(\"PatientNote\", \"ClinicalTrial\")\n```\n\n\n```\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 1) Not relevant.\nTrial-level eligibility: 0) Excluded.\n```\n\nYour test code should return a vector including three values in it. Each integer value of the returned vector indicates the Trial-level eligibility. Therefore, the result of the test should be as above for a true trial.\n\n## Examples\n\nHere is some of the example patients' names and clinical trials that are stored in our `example2.csv` and `example3.csv` files.\n\n\n```\nTrialDetection::test\n\n# [1] \"PatientNote\"\n    Trial-level eligibility: 2) Eligible.\n    Trial-level eligibility: 1) Not relevant.\n    Trial-level eligibility: 0) Excluded.\n```\n<EOD> FURTHER FINDINGS ON FLUORIDE AND ENAMEL RESORPTION BY A MICROCALORIMETRIC FLUORIDETRACE METHOD.\n1. A microcalorimetric method based on fluoridetrace is described for quantitative assays on small quantities of samples, i.e. resorbed tooth enamel from rat incisors. 2. The minimum measurable amount of added fluoride was 4.0 x 10 /sup -9/ g and the time of analysis was less than 60 minutes. The sensitivity of the method is 5 to 10 times as great as that of conventional fluor",
        "label": 2
    },
    "1741": {
        "output": "## 1+1=3\n### Include\n### Inclusion Criteria:\n- Age 18-65 years\n- Normal organ function (renal function, INR < 1.5, hemoglobin within normal range (Female <12.5 or male <13 g/dL).\n- Good performance status (ECOG 0-2)\n- Ability to take oral drugs and to comply with study protocol\n- No history of HER-2 positive disease (except in situ carcinoma of the breast).\n- Patients must give informed consent prior to study drug injections.\n- Ability to comply with study protocol (provision of data and biological material).\n### Trial-level eligibility:\n- Excluded\nThis patient does not meet the inclusion criteria of the trial:\n- Excluded\n<EOD> Implantable cardioverter defibrillation in children.\nImproved survival in adult patients with both congenital and acquired heart disease has led to recognition that the incidence of life-threatening arrhythmias and need for implantable cardioverter defibrillation (ICD) will be increasing in the pediatric population also. We describe the experience in paediatric patients with ICDs in the UK and Ireland between 1990 and 2001. Nineteen patients, nine male, with a mean age of 9.7 years (3 to 20 y) underwent implantation of ICDs in six centres in the UK and Ireland. There were 29 device implants in total (15 single or dual chamber, 13 mono or dual chamber ICDs). Eight patients had congenital heart disease (five Fontan, one transposition of the great arteries in atrial communication, one complex univentricular heart, one hypoplastic left heart syndrome), five had cardiomyopathy or dilated cardiomyopathy, two idiopathic cardiac dysrhythmias, two post-transplant and one long QT syndrome. Indications for arrhythmia/cardiac death prevention or therapy included sustained ventricular tachycardia in six patients, nonsustained",
        "label": 0
    },
    "1742": {
        "output": "As the output of your application, you need to convert the result to human interpretable format. \nYour job is to convert the result of eligibility assessment of the trial to three groups (Excluded, Not relevant, Eligible). \nIf your goal is to predict the trial eligibility of the patient, you should convert your result in a predictive manner by using a function `Trial-level eligibility_prediction`. \n\n\n## ## Exploratory Feature Engineering:\nLet's see if we could learn more about the patient using this patient note. Our goal is to predict the trial eligibility, but we need to know more. We would like to know the past history for each drug, e.g., IFN, RBV, or direct antiviral drug. We would like to know which combination therapy is prescribed for IFN, RBV, and direct antiviral drugs. We would like to observe the dose information, treatment duration, and frequency. Let's have a look at the trial data set for this experiment.\n\n\n1. Import the data that we need: \n```\npd.read_csv('../data/HCV/train4.csv', dtype=str)\n\ntrain_data_features = train_data.loc[:, train_data.columns.tolist()[[i for i in train_data.columns.values if i.endswith('_features')]]]\n\ntrial_data = trial_data.drop([\"ID\", \"Drug\", \"Sex\", \"Age\", \"Height\", \"Weigh\", \"BMI\", \"Vital_sign\"], axis=1)\ntreatment_duration = trial_data.Treatment_duration.values\nif treatment_duration.shape[1] < 1:\n    raise Exception(f\"Treatment_duration is empty\")\ntreatment_dose = trial_data.Dose.values\nif treatment_dose.shape[1] < 1:\n    raise Exception(f\"Dose is empty\")\ntrial_data = trial_data.Treatment_type.values\nif trial_data.shape[1] < 1:\n    raise Exception(f\"Treatment_type is empty\")\ntrial_data",
        "label": 0
    },
    "1743": {
        "output": "### Example\n`Trial-level eligibility: 1) Not relevant` `2) Eligible\n\n## Efficacy: response to therapy\n\n[IN] Hello. You are an expert in the field of hepatology. You take care of your patients every day. Your task is to estimate the patient's response to an applied therapy. There are different types of patient's response. \n\nYou are presented with a [patient note] and a [clinical trial] where the patient participates.\n\nThe notes contain information about two consecutive HCV RNA tests. The baseline is a test with a negative result; the next test results are positive. To be eligible to evaluate the patient's response to the study's therapy, the patient's HCV viral load must be greater than 1000 IU/ml at screening.\n\n[patient note]\n[CLINICAL TRIAL]\nInclusion criteria: Key Inclusion Criteria:\nHCV genotype determined by the Central Laboratory\nHCV RNA > LLOQ in DB of 400/600 or greater at screening\nHCV infected only; no other chronic active viral hepatitis (HBV, HDV, HIV, HGV, HEV, cytomegalovirus, herpes simplex)\nKey Exclusion Criteria: Current or prior history: Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.\nScreening ECG with clinically significant abnormalities\nLaboratory results outside of acceptable ranges at screening\nInfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.\n\nLet's think step by step. \nFirst, you can estimate whether a patient is eligible for the clinical trial. To do that, you can first compare the date of first baseline measurement and the study's baseline date (2.1.3",
        "label": 1
    },
    "1744": {
        "output": "[EXCLUSION_LEVEL1] There are 7 columns in the dataset. I'll make you some notes in the first two columns: [/EXCLUSION_LEVEL1]\n\nYou'll see that the dataset comprises a variety of elements: Patient Information (ID, name, age, gender, race, ethnicity, marital status, patient record number, birth date, birth place), Medical diagnoses (Primary diagnosis, secondary diagnosis), Patient procedure (encounter, type of encounter, date and time). [/EXCLUSION_LEVEL1]\n\nTo summarize, a trial-level eligibility output  would consist of a string of three digits separated by commas: 0), 1), and/or 2). \n\nYou need to perform several steps to complete the evaluation. \n\nFirst, you need to read about the patient's ID, read the doctor's name and hospital department from the patient record number, and then assign an ID to the patient record number. You'll need to consider every number at the same time, because the patients can be given several ID numbers after the assessment. \n\nSecond, you need to specify the patients in terms of patient record numbers. The ID of the patient record number in the database can vary based on who you work with, and the database contains the patients' IDs recorded as names, such as 'Grace','Jane','Jerry','Joe'. These patient labels also include the name of his/her doctor.\nIn addition, you must read the patients' medical diagnoses and procedures. Read about the patient's medical diagnoses in alphabetical order, and look up the patient's age. You must assign all patient's IDs as a serial number. If you skip a record in the assessment, skip the corresponding patient's information record. If there are any missing values, you have to skip the corresponding patient's record.\nNext, we'll look at the patient's medical records. As previously mentioned, the patient ID (ID = 101) must be matched with the patients' IDs in the information about the patients' visit date, type of visit, age, and so on. Therefore, when you read through the list of patients, make sure that the patient IDs match the patients' IDs that you read in the previous step,",
        "label": 0
    },
    "1745": {
        "output": "### Examples\n\n\n\n``` yaml tab=javascript url=https://raw.githubusercontent.com/vip/vipnirvana/master/data/json/instructions/10/9/02/inclusive-conjunctions_in_patients.json ```\n<EOD> .\nAcidic polysaccharide from Gynostemma longipes was prepared by hot water extraction, the extraction rate was 3.95% (dry matter) and the total sugar content was 73.3%. Purity of the sample was analyzed by the method of HPLC and the results showed that acidic polysaccharide was polysaccharide composition, which was composed of D-Rha (57.8%)-->D-Gal (10.4%)-->D-GalN (7.3%), D-Rha (57.8%)-->D-Gal (4.0%)-->L-IdoA (17.8%)-->D-GalN (3.2%) and D-Rha (57.8%)-->D-Gal (4.0%)-->D-GalN (26.6%). The data were analyzed by the method of GC-MS and the results showed some small molecular weight amino acid, glycerol and inositol mono fatty acid is its main component. The acidic polysaccharide from Gynostemma longipes had anti-oxidation function (inhibit DPPH- free radical and ABTS+ free radical) and immune modulation function (induction NK cell activity, increasing splenocyte proliferation).<EOD> .\nIn addition to the development of the cardiac silhouette, the presence of dilated cardiomyopathy and increased left ventricular volume is suggestive of dilatation; the apex-ventricular plane was determined 10 to 70 mm in apex and the aortic valve (AV) and mitro-ventricular plane determined at the anterior border of the anterior leaflet of the mitral valve (MV). The apex-ventricular plane was determined at 4.6 +/- 2.4 mm in ape",
        "label": 2
    },
    "1746": {
        "output": "<EOD> The Role of the Dental Health Professionals in the Treatment of TMJ Arthrosis Using Microarthroscopic Surgery\nObjective: An experimental study was performed to prove the efficacy of micro arthroscopic surgery in the treatment of TMJ arthrosis. Study Design: Experimental study. Material and Method: Six human skulls were used for the experiment. Two experimental models of arthrosis were made on one side of the TMJ and the other side was a normal model. Micro arthroscopic surgery was performed on the arthrosis model to remove and repair the tissue. The change in condyle depth, TMJ space, joint motion limitation were determined for all of the side. A microprocessor-based image analysis system was used for the statistical analysis of all of the parameters. A paired-sample t test was used for the comparison of all of the parameters of the same side. Results: The results showed highly significant differences in TMJ space and joint motion limitation between the arthrosis side and normal side (p < 0.05). However, the results showed no significant differences in condylar depth between the 2 sides (p < 0.1), which might have been due to the fact that the condyle size was not the same in all the skulls. Moreover, no significant differences, except condylar depth (p < 0.1), were seen in all of the parameters between the preoperation and postoperation stages either. In terms of the joint motion in the lateral and anteropostelior positions, there were no significant differences in 2 groups at both preoperation and postoperation stages. Conclusion: This study suggests that the TMJ arthrosis might be treated by microarthroscopic surgery which can repair damaged condyles and restore joint function as effectively as that of the normal ones.<EOD> Effects of Bupivacaine on the Neurobehavioral Development of Foetal and Rat Mitochondria Internal Organelles in Early Postnatal Life\n\nAimTo evaluate the effects of bupivacaine, a local anesthetic, on the neurobehavioral development of foetal and rat mitochondria internal organelles in early postnatal life.MethodsCytomorphometric and biochemical assays were used",
        "label": 1
    },
    "1747": {
        "output": "### [XPOST]\n\nHello. You are a helpful assistant for clinical trial completion. Your task is to close clinical trials that do not have enough volunteers. For this reason, you decide to make an analysis based on the amount of time needed to complete the study and the number of enrolled patients. \nWe begin with the description of the clinical trial: \nTitle: Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection\n\nSummary: The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or investigational drug) participants with chronic hepatitis (inflammation of the liver) C virus (HCV) genotype 1 infection with early stages of liver fibrosis or with cirrhosis.\nInclusion criteria: Inclusion Criteria:\nHCV genotype 1 infection and HCV RNA plasma level greater than (>) 10,000 international units per milliliter (IU/mL), both determined at Screening\nParticipants of Arm A should have evidence of early stages of liver fibrosis, defined by a FibroSURE score less than or equal to (<=) 0.48 and aspartate aminotransferase to platelet ratio index (APRI) score <=1\nParticipants of Arm B should have evidence of cirrhosis, defined by a FibroSURE score >0.75 and APRI score >2, OR a previous (historical) biopsy documenting a METAVIR score F4. In addition, participants should have absence of esophageal varices or presence of small (grade 1) esophageal varices determined by upper gastrointestinal endoscopy, and absence of findings indicative of hepatocellular carcinoma in an ultrasonography\nHCV treatment",
        "label": 0
    },
    "1748": {
        "output": "## Test data\n![INST] For the test data, here is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere is the clinical trial: \nTitle: A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection\n\nSummary: The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic Hepatitis C Virus infection. This study will contain 2 parts.~Part 1: Approximately 20 participants and at least 10 of the 20 participants previously treated with the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without RBV, and experienced treatment failure.~Part 2",
        "label": 1
    },
    "1749": {
        "output": "<EOD> The effects of intestinal transit time on the gut microbiome\n\nAbnormal gut microbiota composition is increasingly being implicated in the pathogenesis of numerous chronic diseases and, as such, is the target of many clinical trials. A delay in the transit time of ingested materials through the gastrointestinal tract may adversely affect microbiota composition in a number of ways. First, a slower emptying of stool from the gastrointestinal tract limits bacterial growth because of reduced nutritional resources and microbial niches. Second, constipation may lead to altered intraluminal pH, intestinal water, gas, or solute concentrations, which also modulate the bacterial composition. Third, it is well known that proton pump inhibitors and antibiotics frequently used to treat constipation, may also alter gut microbiota composition. Finally, a slower transit rate may also act as an acute signal of food shortage for the microbiota, resulting in a fasting-like state with slowed metabolism. Taking all this into consideration, the evidence suggests that constipation could lead to changes in microbial composition such as increases in Clostridium, Alistipes, Bacteroides fragilis, Enterococcus faecalis and decreases in Bifidobacterium and Lactobacillus. In turn, intestinal inflammation and the activation of immunoinflammatory pathways may exacerbate constipation; thus, a possible therapeutic target in the treatment of constipation is to improve dysbiosis and relieve colonic inflammation. In conclusion, it is likely that the alterations in gut microbiota composition following constipation are related to changes in intestinal transit time.\n\n# Introduction\nHealthy gut microbiota is one of the factors ensuring the proper functioning of the immune, digestive, central nervous and metabolic systems [bib_ref]  The human intestinal microbiome: a review, Bhattarai [/bib_ref] . Therefore, healthy gut microbiota plays an essential role in the maintenance of human health and the proper functioning of the body [bib_ref]  Gut microbiota in health and disease, Seki",
        "label": 0
    },
    "1750": {
        "output": "## The clinical trial with inclusion criteria for the clinical trial\n\nIn this section, we will show an example. Suppose that the patient note shows the following.\n\n\n*The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant.\n*He is on IFN, RBV and direct antiviral drugs for the past 6 months.\n*The patient takes no other medications.\n*His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n\n\n*The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\n*There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n*He is an alert male with no acute distress.\n*His BP: 130/75, HR: 90/min and BMI: 27.\n*His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n*The patient takes no other medications.\n### The first clinical trial\n\nHere is the previous clinical trial and his trial-level eligibility.\n\nThe patient is a male, >18 years old, with HCV+ HBV co-infection. The exclusion criteria are listed with 5 'N' and 2 'Y'.\n\n|-id=0\n|-type=N\n|-text=Treatment with other anti-viral therapy within 4 weeks of consent |-text=Serum alanine aminotransferase elevation >5xULN prior to and at time of screening |-text=Decompensated liver disease |-type=N\n|-text=Co-morbidity or disabilities which, in the opinion of the investigator, would preclude the patients participation in the study for >12",
        "label": 0
    },
    "1751": {
        "output": "## Step 3: Compute the trial-level and visit-level eligibility\n\nIn this step, you will compute the trial-level and visit-level eligibility by applying the same clinical trial. In the trial-level eligibility column, the answer is always number 2. Please, check the number 2 in all the trial-level eligibility computation! The answer is also number 2 for the 6 visit-level eligibility columns that we computed (i.e., we also should check the answer 2 here!).\n\n![Trial](./images/Trial.png)\n\n### Patient\n\n![Visit](./images/Visit.png)\n\n### Clinical trial\n**Summary**\n\nTreatment of hepatitis C is rapidly moving to interferon (IFN)-free treatment regimens. The present study is being conducted to evaluate the safety, tolerability, and efficacy of the following four regimens: (1) Sofosbuvir, a nucleotide NS5B polymerase inhibitor, and ribavirin (SOF/RBV) (2) Sofosbuvir plus Voxilaprevir (a NS3/4A protease inhibitor) (SOF+VF), (3) Sofosbuvir, a nucleotide NS5B polymerase inhibitor, plus the nucleoside NS5B polymerase inhibitor, velpatasvir (SOF/VEL) and (4) Sofosbuvir plus Voxilaprevir plus the pangenotypic NS5A inhibitor, velpatasvir (SVR), for 12 weeks in participants with chronic HCV genotype-1a infection.\n\n**Purpose**\n\nThe primary objectives of the study are to evaluate the safety, tolerability, and efficacy of SOF/RBV, SOF+Voxilaprevir (VXR), SOF/VEL, and SVR for the treatment of chronic hepatitis C infection.\n\n**Study design type**\n\nThis is a Phase-2b, randomized, double-blind, multi-center, active-controlled, 12-week treatment studies in participants",
        "label": 1
    },
    "1752": {
        "output": "<EOD> Effect of aerosolized colistin on renal oxidative stress, inflammation, and histopathology in renal injury induced by cecal ligation and puncture (CLP).\nBACKGROUND\nSepsis, acute kidney injury (AKI) has been the third most common cause of hospital-acquired AKI. The aim of this study was to investigate whether administration of aerosolized colistin has antioxidant properties in sepsis-induced renal injury.\n\n\nMETHODS\nIn a single-blinded study, 54 Wistar Albino rats were assigned to two experimental groups: septic rats were received aerosolized (i.g) of colistin (COL) or normal saline (NS) and noninfected group. Colistin (10 mg/kg, administered at 30-min intervals) was given by nebulizer for two hours a day starting from 1 hour before sepsis onset. Blood samples and kidney tissues were taken for biochemical and histopathological analysis, respectively.\n\n\nRESULTS\nTumor necrosis factor-\u03b1, malondialdehyde, nitric oxide, advanced oxidation protein products (AOPP) levels were found to be significantly higher in the noninfected group compared to the septic and septic infected with COL treated groups (P < 0.05 for all comparisons). In histopathological examination, tubular injury and vacuolization decreased significantly in COLtreated septic group (P = 0.047 and P < 0.001, respectively), and acute tubular necrosis, interstitial inflammation, and congestion decreased significantly in the COL-treated sepsis+CLP group (P = 0.025, P < 0.001, and P < 0.001, respectively), compared to the noninfected group.\n\n\nCONCLUSIONS\nThis study shows that aerosolized colistin reduced oxidative stress and inflammation in sepsis-induced kidney injury. Aerosolized colistin may be used",
        "label": 1
    },
    "1753": {
        "output": "* You don't have to make an eligibility judgment for patients under the age of 18, but don't forget to record this in the output, e.g., `Patient: MI000031 33 years old, 75 Kg, BP: 130\\25, HR: 90\\min, BMI: 27. [/IFREL] ** Your judgment of eligibility should refer to the current status of the patient. ** If a patient is eligible, you need to record his or her trial number, even though he/she does not plan to participate as a subject for the trial. The reason is that in case a patient becomes eligible later, after he or she has already been discharged, then the participating hospital can re-evaluate his or her eligibility status. [/IFREL] *** The most common reasons of patient non-eligibility are: ** He or she is younger than 18 years old. *** He or she has already received or is still receiving systemic anti-HCV treatment in the three months prior to enrollment. *** He or she has had any systemic antiretroviral treatment in the six months prior to enrollment. *** He or she has a history of renal, lung, or gastric diseases. *** He or she has an immune system disorder. *** He or she has alcoholic liver cirrhosis. *** He or she has a history of chemotherapy or hemodialysis. *** He or she has a positive alcohol biomarker test. *** He or she has a negative test for HBV hepatitis. **** The patient takes some hormones for treatment of male prostate cancer. *** He or she has a decompensated liver disease, defined as grade C or D cirrhosis according to the Child-Turcotte-Pugh classification. ***** He or she meets the exclusion criteria from the trial (see the eligibility assessment worksheet at the next page). \n<EOD> Efficacy of two low-osmolality contrast media containing 300 milliequivalents per meter chloride for magnetic resonance imaging: magnetic susceptibility distortions and image quality.\nThe magnetic suscept",
        "label": 0
    },
    "1754": {
        "output": "/* Include the trial eligibility: */\n    $trial_eligibility = ' \n    { \"value\":[\n      '<PASSWORD>',\n      'Not relevant',\n      '<PASSWORD>',\n      '1) Not relevant',\n      '0) Excluded',\n      '1) Not relevant',\n      '<PASSWORD>',\n      '<PASSWORD>',\n      '<PASSWORD>',\n      '<PASSWORD>',\n      '<PASSWORD>',\n      '<PASSWORD>',\n      '1) Not irrelevant',\n      '1) Not relevant',\n      '2)'\n    ],\n    \"field\":'Trial-level eligibility',\n    \"type\":[1,1,1,1,0,1,1,1],\n    \"label1\":'0) Excluded',\n\t'label2':'1) Not relevant',\n\t'label3':'1) Not irrelevant',\n\t'label4':'2)'\n} \n\nTRAIN-AI-708 - Assessment of Trial-level Eligibility: https://github.com/NCATS/CDM_Challenge/blob/dev/TRAIN-AI-708.md#assessment-of-trial-level-eligibility\n\n\n---\n## \ucd1d 69\uac1c \ud0c0\uac9f(task)\uc774\ub2e4.\n<NAME> \ub2d8\uacfc \ud611\ub825\ud558\uc5ec \uc694\uc9c1\ub4e4(Tasks) \ubcc4\ub85c \ubcf4\uace0\ud558\uc600\ub2e4. \n\n\n## TRAIN-AI-803(4) - Assessment of Study-Level Eligibility\n\n\n[task](./images/Assessment of Study-Level Eligibility.pdf):Assessment of Study-Level Eligibility\n\n\n---\n\n## TRAIN-AI-811 - Prediction of Disease Prevalence\n\n\n[task](./images/Prediction of Disease Prevalence.pdf):Prediction of Disease Prevalence\n\n\n---\n## \ucd1d 73\uac1c \ud0c0\uac9f(task)\uc774\ub2e4.\n\nTRAIN-AI-911",
        "label": 1
    },
    "1755": {
        "output": "Let's go. You should assess this patient for eligibility and write the result in a `Trial-level eligibility: ` sentence, i.e., `Trial-level eligibility: 2) Eligible.` in the last line of the trial-specific section.`s `Trial-level eligibility section..\n---\n**Notice.** If at any point of the case you want to change your answer of `Trial-level eligibility section.,` you can press `E` on your keyboard.\nIf you make your decision, press `space`. If not, press `S` again.\n---\n###### QA\nOnce you are ready to proceed with the QA section, press the blue arrow. You should write your final `Quantitative Assessment` section in a `Quantitative Assessment: ` sentence. [INST]\nType your assessment in the textbox given in the `Quantitative Assessment section.`:\n`Quantitative Assessment: 20%`\n```xml\n\n<data>\n\n  <quantitative>\n    <assessment>\n      <text>20%</text>\n      <category>00</category>\n      <concept>Degree_of_severity_of_disease</concept>\n    </assessment>\n    <subject>\n      <text>patient</text>\n      <concept>Population</subject_category/>\n    </subject>\n  </quantitative>\n\n</data>\n```\n\nIf you want to correct your assessment, you should change the text by pressing `C` on your keyboard.`s `Quantitative Assessment section.`. [INST]\nType your correction in the textbox given in the`Quantitative Assessment section.:`\n`Quantitative Assessment: 00%`\n```xml\n\n<data>\n\n  <quantitative>\n    <assessment>\n      <text>00%</text>\n      <category>00</category>\n      <concept>Degree_of_severity_of_disease</concept>\n    </assessment>\n    <subject>\n      <text>patient</text>\n      <concept",
        "label": 1
    },
    "1756": {
        "output": "<EOD> Comparison of two different intermittent catheterization methods on voiding function in patients with neurogenic bladder: a pilot randomized controlled trial\n\nBackground: This study was performed to compare effects of two different intermittent catheterization (IC) methods, conventional catheterization (CC) and suprapubic catheterization (SPC), on urine retention, urethral diameter and bladder capacity in neurogenic bladder (NGB) patients. Methods: After approval of an Institutional Review Board, 46 patients were recruited and randomized to CC group and SPC group, with 23 patients in each group. Results were analyzed using Wilcoxon rank sum test and Chi square test while p value was considered significant if it was less than 0.05. Results: In CC group, voided volume increased from (214.44 \u00b1 186.43) to (414.91 \u00b1 226.33) mL (p < 0.01). In SPC group, voided volume increased from (325.00 \u00b1 0.00) to (453.91 \u00b1 378.10) mL (p < 0.01). No significant difference was observed in voided volumes between CC group and SPC group. Urethral diameter decreased from (13.00 \u00b1 3.56) to (10.42 \u00b1 2.15) mm in CC group (p < 0.01) and no significant difference was observed in urethral diameters between post catheterization and post voiding in SPC group. No urethral diameter was found to be significantly different between CC group and SPC group. Urethral pressure increased from (59.23 \u00b1 34.76) to (190.86 \u00b1 79.46) cmH2O in CC group (p < 0.01) and no significant difference was observed in urethral pressures between post catheterization and post voiding in SPC group. No urethral pressure was found to be significantly different between CC group and S",
        "label": 0
    },
    "1757": {
        "output": "## Step 2: Assessing the suitability of the patient's age\nThe patient's age has a significant role in trial eligibility but it may change depending on the trial's inclusion criteria. This is the case in a trial that requires the patient's younger age than in a trial that has no upper limit (0-100 years old) or requires younger than 40 years old. \n\nLet's examine the patient's age. If the patient's age is equal to the trial's upper age limit, then the patient can enter the trial. We may need to repeat the process again in the case of 0-100 years trial. If the trial's upper limit is less than the patient's age, then the patient is excluded. If the trial's upper limit is greater than the patient's age, we need to assess again for the trial that has lower limit than the patient's age (0-100 years trial). This is because older patients may not meet the trial's lower age limit. \nIn this trial whose upper limit is 40 years and the lower limit is 18 years, the patient will be excluded due to their respective age. So we should focus on the trial that doesn't have age limits and repeat the process again. Let's analyze another trial:\n\n\nTrial-level eligibility Trial-level eligibility 1) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). 2) Not relevant (patient does not have sufficient information to qualify for the trial). 3) Excluded (patient meets inclusion criteria, but is excluded on the grounds of trial's exclusion criteria).\nTitle: Long term safety of Pegylated interferon alpha-2a plus ribavirin for 48 weeks vs Pegylated interferon alpha-2a plus ribavirin followed by weight based ribavirin for 24 weeks in combination with pegylated interferon alpha-2a plus ribavirin for 24 weeks in patients with chronic hepatitis C infection treated with pegylated interferon alpha-2a and ribavirin (LIVER FACT 2)\nTitle: Long term safety of Pegylated interferon alpha-2a plus",
        "label": 0
    },
    "1758": {
        "output": "[TRIAL] Patient information:\n\n\n\n[patient_id] 1 2 3 4 5 6 7 8 9 10\n[TRIALID] 2 10 21 23 22 18 35 24 11 9 5 4 2 7 26 7 8 6 20 6 6 4 3 (0031)\n\n[patientName] 0 1 2 3\n[patientGender] M 0 1 2 (0131)\n\n[patientAge] <=4677 <=4487 <=2634 <=6687<=4293 <=3107\n<=3147\n\n[patientHeight] <=467 7<=263 <=247 <=586 <=686 <=310<=421 <=7286<=2087 <=427 (0131) <=424 <=315 <=416<=3147\n\n[patientWeight] <=792 7<=643 <=2054 <=4058 <=3667 <=236 <=241 <=3177<=1947 <=531<=4207 6<=213 (0031) <=796 <=185 <=521<=4207 (0031) <=3160 <=3873 <=58(0031)\n\n[patientVirHTN] <791\n\n[patientAntiHBs]  0 7\n\n\n[patientLiverdisease] 0 0 0 1 0 1 0\n\n[patientLiverdisease10] 0 0 0 1 0 1 0 \n[patientDisease] 0 0 0 1 0 1 0 0 \n[patientDisease10] 0 0 0 1 0 1 0 0",
        "label": 1
    },
    "1759": {
        "output": "## Step 2: [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial:\n\n## Instructions for trial-level eligibility (output):\nTriallevel elig",
        "label": 0
    },
    "1760": {
        "output": "# Mini-Quiz<EOD> .\nBACKGROUND\nNumerous factors influence the pathogenesis of a malignant pleural effusion. The presence of a parietal pleural invasion is one of the most significant of these factors. On many occasions this feature has a very important role in planning surgical procedures. The aim of this study is to validate a parietal pleural invasion test, easy to use and to establish guidelines for its application.\n\n\nMETHODS\n78 patients with histologically proven malignant pleural effusion were divided into three groups of 26 patients each. The first group served as a control and the two experimental groups each contained 25 patients; these patients were included in one of two experimental groups. Each of these groups was subjected to a specialized inspection consisting of two ultrasonographic examinations separated by a few hours between them, one by a radiologist resident and the other by a radiologist with experience in thoracic ultrasonography. The latter had in mind the radiological signs of an incipient carcinomatous process. The radiologists were unaware of the stage of disease of the 78 patients.\n\n\nRESULTS\nThe results were analyzed using statistical tools. A comparison by the kappa model between the different raters for all variables, as well as by the kappa model for the two radiologists and between them with respect to all the variables was performed.\n\n\nDISCUSSION\nThe sensitivity of the test was very high (83.3% versus 83.9%) and the positive predictive value was 95.3 % (versus 98.3%). The specificity and negative predictive value (NPV) were very high (the difference being in some cases statistically significant), and the specificity was 97.4% (95.0%) with an NPV of approximately 93.6 % (98.3%). The agreement value was high, with a very high kappa index and a value of approximately 97.6%. Despite the fact that the results were favorable in the three groups, the best results were achieved with Groups 1 and 2 without statistically significant differences.\n\n\nCONCLUSIONS\nThe study validates test, which enables a preoperative diagn",
        "label": 1
    },
    "1761": {
        "output": "[TEXT] Your task is to determine the patients' eligibility for the given clinical trial. You should always answer patients' eligibility for the clinical trial with the help of medical record as described in the textbook.\n[/TEXT]\n\n## [CODE]\n{\n  // Set up the data\n  int counter = 0;\n  var nClinicalTrials; //number of clinical trials\n  var nRecords; // total records\n\n  nClinicalTrials = 1;\n  nRecords = 3;\n\n// Set up the data with the patient's medical record\n  recruits = (\n    nRecords, // records\n    function(recordIndex){\n      return (\n        // record list\n        {\n          title: \"This is the title of the patient's medical record\",\n          recruit: (new Date()).toString(),\n          gender: (Math.floor(Math.random() * 2) +1),\n          age: \"5\",\n          hcvAbPos: \"true\",\n          hcvAbNeg: \"false\",\n          hcvRnAIndex: \"2\",\n          previousIFN: \"true\"\n        },\n\n        // ClinicalTrial data\n        {\n          title: \"This is the trial title\",\n          clinTrial: \"true\",\n          eligible: nClinicalTrials == recruits[0].recruitIndex || recruits[0].recruitIndex == counter,\n          elig: 2\n        },\n\n        // ClinicalTrial data\n        {\n          trialInfo: \"This is the trail's information\",\n          trialNumber: 9999,\n          trialName: \"trial1\",\n          trialTitle: \"Disease Status in Primary Sclerosing Cholangitis by Elastography\",\n          start: 144915820000,\n          end: 144964070000",
        "label": 0
    },
    "1762": {
        "output": "## Answer\nTrial eligibility refers to the probability of a randomized trial for a given subject. In the trial-level eligibility, the 0 denotes an absolute exclusion, the 1 denotes an absolute inclusion, and the 2 denotes an uncertain (in this example) inclusion.\n\n## Comment on this question\nYou can mention the use of the `Trial-level eligibility: 2) Eligible. ` to determine which trial eligibility patients are randomized to.\n\n## [/comment]\n\n# Background\n\n## Objective and target users\nThe purpose of this documentation is to guide researchers to develop an RShiny application for the PREDICT-HF study. \nThe application is designed to evaluate the association of a large set of clinical and blood biomarker risk factors (RFs) with the risk of heart failure (HF), with the purpose of identifying new biomarkers involved in the pathogenesis, progression or outcome of HF.\nThe tool was designed as an extension of the CAPACITY Shiny application which is a tool to implement and analyze the PREDICT-HF data in R. The target users of the application are the investigators, the collaborators, and the research analysts involved in the analyses, validation, and exploration of the PREDICT-HF data. \n\n## User types\nThere are three different user types: administrators, analysts and users, which differ in the way they can use the app to explore the data and launch jobs. \n\n## Administrator\nAdministrators use admin functions such as management of jobs and data sets. Users must be administrators to run a job. Analysts can use job files to visualize the results.\n\n## Analyst\nAnalysts use jobs prepared by the administrators. Analysts can visualize the output of a job.\n\n## Users\nUsers do not have to install any software to use the tool. They only run files (data or jobs) which are installed on the server. Analysts and administrators can provide access to specific data sets for specific users.\n\n## Expected time to develop the application\nThe PREDICT-HF-Predict tool was developed during a few months, but it depends on the type of application.\nTo create",
        "label": 1
    },
    "1763": {
        "output": "> $R> Triallvl-eligibility 0 1 2\n    Name of patient note     0 excluded            1: not relevant  2: eligible\n    Title of clinical trial    0 excluded            1: not relevant  2: eligible\n    #\n    IF (S.Triallvl_eligible == 2) THEN\n         R.Eligible = TRUE\n     END IF\n    IF (R.Eligible == TRUE) THEN\n         R.PatientID = S.PatientID\n     END IF\n\n<EOD> Ginsenoside Rb1 attenuates acute lung injury with cecal ligation and puncture via inhibiting inflammatory responses and oxidative stress.\nOBJECTIVE\nGinsenoside Rb1 (G-Rb1), one of the major active ingredients of Panax ginseng, has been recognized as an effective herbal bioactive compound with various pharmacological properties, including anti-inflammatory, antioxidant, and antiapoptotic properties. G-Rb1 effectively protects human endothelial cells against lipopolysaccharide (LPS)-induced damage by inhibiting the Toll-like receptor 4/nuclear factor kappa B (TLR4/NF-\u03baB) pathway. This study was to investigate whether G-Rb1 could attenuate acute lung injury induced by cecal ligation and puncture (CLP) in mice, and explore its underlying mechanism.\n\n\nMATERIALS AND METHODS\nCLP was used to establish the animal model of acute lung injury. Mice were randomly divided into four groups: Sham group (Sham), CLP group, CLP + SMILE group, and CLP + G-Rb1 (25, 50, 100 mg/kg) group. Histopathological analysis was used to evaluate the damage of lung. The TNF-\u03b1 and IL-6 levels were measured by ELISA. The activity of myeloperoxidase (MPO) was also evaluated by chemiluminescence method. MDA and SOD were respectively measured by colorimetric method. The cleavage",
        "label": 0
    },
    "1764": {
        "output": "in his test [di, which the el on the patient for a drug, and hepatern. There. This. You and if it, an in thepat\u00a0or.\n[\n1. You to determine. This. You will and el \n\n\n\n[1, which are not-el.\n [[f, [bib_ref], and dru and medical or so, but for example for clin and other than [bib_ref]de\u00a0[s or he /de or the el <in the same andel \u00c3, and elig [1\u00a0 [bib_ref]\u00a0on-based/a [Meg.\nat. The one !\nd-the \\ [bib_ref] a [bib_ref]\n\n or the \u2039 [bib_ref] or The [bib_ref] {{de. They:el :\n.[to \ufffd\u00a0de or elus 1. A clin [bib_ref] A test in a \u00a0. The one, and [bib_ref] .\n [bib_ref] \\ \u00a0 or 1 and [bib_ref] or the disease or the el  or diagn [bib_ref] \u00a0. An opportunity. However, i\\ . \\\u00a01 on [bib_ref] , and a . in \\ \u00c3. A different in which to his and will-based and 5 \u00a0\n\n^ [bib_ref] 8-t\nor, as a test- [bib_ref] [bib_ref]. For \nThe [bib_ref]\n.\n. [bib_ref] 14. The [bib_ref]\u00a02 and el 1 or the [bib_ref] with and it on\u00a0 and [bib_ref] and that the\u00a0acc on the [bib_ref] on the best for the 0 based for each [fig_ref]the 1.\n\n [bib_ref] 1\u00a0. \n to your \\ A and he \n\n or [fig_ref]\u00a0 2 \nthe (det\n to thet. 2\u00a0. 1 for [bib_ref]\u00a0 (for\u00a0.\n 1 or\n [bib_ref] \u00a0. 12\u00a0 [bib_ref]. and as on the [bib_ref] and we 2\u00a0 in the\u00a0 [bib_ref]\nfor the - [fig_ref] \\\u00a0 [bib_ref], [bib_ref], a clin.\n \u00a0( in \u00a0\u00a0.\n on { [bib_ref]- [bib_ref]\n# for\u00a0for\n on a 1, to .\n-ass. [bib_ref]- 2, 1 - 1. the \ufffdtest-based in their study, (\nas a \u00a0\u00a0-1 2\n-a with\n1 \\ .<EOD> for \u00a0 [bib_ref]",
        "label": 1
    },
    "1765": {
        "output": "##[COMMENT] The clinical trials are based on patients, and thus not directly applicable in our model. Instead, we evaluate the eligibility of the model parameter for participation in clinical trials, where the eligibility is set as Boolean.[MOD]<EOD> Dissipative structures of dissipative particle dynamics for colloidal dispersions.\nBased on experimental data on \u03b3-sterols in water (\u03b3-sterols) in the presence of a small amount of amphiphilic agents (PVP or Cremophor EL), we report dissipative structures in the two-dimensional phase field simulation, referred to as dissipative particle dynamics (DPD). After the addition of Cremophor EL, we observed the coexistence of \u03b3-sterols molecules, PVP and Cremophor EL, even in a large area in phase space. When the number of Cremophor EL exceeded that of PVP, PVP condensed to form a phase with less density, in which \u03b3-sterols were trapped, but not in its solution phase. These results indicate that Cremophor EL acts as a catalyst in the assembly of \u03b3-sterols, resulting in the emergence of dissipative structures. We then constructed simulation models by changing the density and the number of PVP agents in the same way as the experiment. After the addition of a small amount of PVP in the experiment, a transition occurred, as observed in the simulation, and the phase diagram was constructed. We also observed the phase transition between the phase including PVP and the phase without PVP by increasing the area where a small amount of PVP was added from the side.<EOD> High ROS scavenging activity and antioxidative enzyme systems of the marine diatom Porosira glacialis (Chrysophyta) cultured under different culture temperature/light intensity conditions.\nChrysophytes are dominant in antarctic algae, however, little is known about their antioxidant systems. To study antioxidant systems of chrysophytes, Porosira glacialis (prymnesioidae), diatom cultured under different experimental temperature (28\u00b0C, 20\u00b0C and 16\u00b0C) and light intensity conditions (1.1\u2009W m(-2) ) were investigated",
        "label": 1
    },
    "1766": {
        "output": "### Task and Subtask - 6\r\n\r\nTo obtain and record the name of all patients in the clinical trial record.\r\n\r\n```r\r\nName_patient <- subset(clinicaltrial, clinicalTrial = \"Name_patient\")\r\n\r\nlist(Name_patient, unique(colnames(clinicaltrial, \"clinicalTrial\")[1:100]))\r\n```\r\n\r\n### Task and Subtask - 7\r\n\r\nTo retrieve the maximum and minimum number of pills per day, per patient.\r\n\r\n```r\r\nsubset(clinicaltrial, colnames(clinicaltrial) %in% c(\"MaximumDailyPill\", \"MinimumDailyPill\")[1:100])\r\n```\r\n\r\n### Task and Subtask - 8\r\n\r\nTo retrieve information about the trial arms' recruitment date of the clinical trial record.\r\n\r\n```r\r\nsubset(clinicaltrial, colnames(clinicaltrial) %in% c(\"FirstRecruitmentDate\")[1:100])\r\n```\r\n\r\n### Task and Subtask - 9\r\n\r\nTo retrieve data about patients who are still in the treatment phase.\r\n\r\n```r\r\nsubset(clinicaltrial, colnames(clinicaltrial) %in% c(\"PatientStatus\")[1:100], PatientStatus == \"Treatment\")\r\n```\r\n\r\n### Task and Subtask - 10\r\n\r\nTo retrieve information on the trial arms recruitment of the clinical trial record.\r\n\r\n```r\r\nsubset(clinicaltrial, colnames(clinicaltrial) %in% c(\"LastRecruitmentDate\")[1:100])\r\n```\n<a name=INSTRUCTIONS></a>\r\n\r\n<!-- START of SECTION 6.1. -->\r\n\r\n# Instructions for Section 6: Statistical Analysis",
        "label": 0
    },
    "1767": {
        "output": "# How much time do I have to complete the assessment?\nOnce the patient note is saved, you will see the time remaining for completing the note, the patient type, the name of the patient and the trial that you are reviewing. You are being given a time limit of 30 minutes to complete the assessment. The number of patients to review will be calculated automatically based on your speed to complete the note.\n\nHow do I repeat notes to work on?\nYou can open a list of the reviewed notes under `Work to Review`. You will be shown the current progress and remaining work. You can click the appropriate progress bar or click the next/previous button to go to the next or previous note. You can also click `Work to Review All` if you would like to see the rest of the patients to review whose status is available in the current status bar.\n\nWhat is the benefit of saving a note before I move to the next patient?\nIt is recommended that you save a partial or complete note before moving to the next patient due to several reasons. First, the time spent working on the prior patient could be more than required. Second, once the patient information is saved, we will provide you with several patient attributes such as the patient type (new patient or preexisting) and the status of the clinical trial that you review (current note, reviewed, or finished).\n\n# How can I review the patient\u2019s medical history?\nYou will be provided with the most recent available patient notes from the last 90 days in the Medical History tab under `Work to Review`. Select the date by clicking anywhere within the range of the dates on which you would like the notes for, e.g., click within the green box to select all notes available in the range of 50 days before today (`June 15, 2015`) to today (`July 20, 2015`). Please note that the most recent notes may not be available if the notes are being reviewed and modified by yourself or others in the meantime. Please click the arrow button to the right to see the range of notes visible.\n\nHow can I search for all current and completed clinical trials?\nYour search results will be shown in the `Work to Review` tab under `All Clinical Trials/Research Studies`. You can use filters in the Search Results tab to see more detailed",
        "label": 0
    },
    "1768": {
        "output": "<img src=\"https://user-images.githubusercontent.com/110314/32898064-0fed6200-b566-11e7-97a0-f21796f0f532.png\"><br>Examples for the trial-level eligibility\n\n\n\nNote: As we can see from the last line, the `Triallevel eligibility` output 2 (Eligible) which means that this patient is eligible for the clinical trial. Note that we should have to find all three cases of eligible, excluded and not-relevant according to the inclusion/exclusion criteria.\n\n## [INST] You are an Assistant Professor in Medicine at the Hospital Specialist Centre. \nYou are asked to perform an audit to analyze the appropriateness of current antimicrobial prescribing practices in the hospital. This exercise will identify the key drivers for improper prescribing behavior and help to formulate and implement strategies as part of a continuous quality improvement cycle. \n\nThe data will be obtained from patients' notes in the hospital's infectious disease clinic. They are to be recorded on a datasheet, which you will receive from your supervisor.\n\nOnce the data collection has been completed, you will be required (under your supervisor's guidance) to:\n\n  1. Analyze the data\n\n 2. Identify any common themes, and report these in an appropriate clinical letter or report format.\n\n 3. Identify the main reasons for the inappropriate prescribing.\n\n 4. Use these data to suggest strategies which could help improve prescribing in similar clinics. \n\nHere are patient notes:\n\n[name]\n\n52-yr-old male with past medical history of hypertension admitted for acute exacerbation of chronic kidney disease (RTR), presenting with oliguria (PU&PD) and a significant drop in his BP with pulse oximetry reading not recorded. He has a positive history of smoking, being diagnosed with RTR more than 12 months ago. His BP is 130/90 in the clinic,",
        "label": 0
    },
    "1769": {
        "output": "## 1.2.1.2 Part 2. Check all of the relevant reasons for exclusion in the codebook.\nHere is the clinical trial:~Summary: Background:~- Chronic hepatitis D is a liver disease caused by the hepatitis D virus (HDV). It can be severe and progressive. Most people with hepatitis D will develop scarring and damage to the liver. There is no FDA approved drug to treat chronic hepatitis D. Researchers want to know if the drugs lonafarnib and ritonavir can help people with chronic hepatitis D.\n\n## Evaluations by a reproductive endocrinologist (women) or urologist (men). men may provide a sperm sample (optional).\n[/EXCLU]\n\n## [/exclu]\n~Presence of antibodies to HDV in serum.\n~Presence of HDV RNA in serum.\n\n## [/exclu] [/exclu] [/exclu]\n~Decompensated liver disease, defined by bilirubin >4mg/dL, albumin <3.0 gm/dL, prothrombin time >2 sec prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy. Laboratory abnormalities that are not thought to be due to liver disease may not necessarily require exclusion. Patients with ALT levels greater than 1000 U/L (>25 times ULN) will not be enrolled but may be followed until three determinations are below this level.\n\n## [/exclu]\n\n## 2.2.2 Part 3. Fill out the codebook according to the instructions of the question.\nHere is the clinical trial:~Summary: Background:~- Chronic hepatitis D is a liver disease caused by the hepatitis D virus (HDV). It can be severe and progressive. Most people with hepatitis D will develop scarring and damage to the liver. There is no FDA approved drug to treat chronic hepatitis D. Researchers want to know if the drugs lonafarnib and riton",
        "label": 0
    },
    "1770": {
        "output": "[/TUTORIAL_BOX]\n\n## FINDING EXPERIMENTS\n\n## [TUTORIAL_BOX] Finding experiments \nDear student,\nIn the clinical trial, experiments are the fundamental units of scientific research that are carried out to test new procedures or new treatments, the effects of drugs on human, or to assess the accuracy of different medical diagnostic tests. Experimental results should be presented at some extent of detail as to make them understandable and useful for other scientists.\nOn the next page, there are some examples of experiment entries. Look at the following examples and then let's begin with an Experiment in Python and Pandas. [INST] Examples of experiment entry.\n\n# Discussion:\nAll results demonstrate that TCM may be used to ameliorate D-galactosamineinduced ALF in rat models. The major advantages of TCM are its cost-efficiency and low side-effect profiles.\nExperimental design, materials and methods: An acute liver failure (ALF) rat model was induced by a single injection of D-galactosamine into a tail vein. The 70 rats were randomized into 10 groups and treated with TCM (50 \u03bcL (0,1 mmol/L), 100 \u03bcL (0,2 mmol/L), 150 \u03bcL (0,3 mmol/L) diluted with saline), and the other 10 rats were treated with saline for the control group. Plasma ALT, AST, LDH, TBIL, TNF-\u03b1, IL-10, and TNF-\u03b1/IL-10 were measured. Histopathological changes in each group were observed under light microscope. The content of TNF-\u03b1 and IL-10 expressions in the liver was analyzed by ELISA assay. The TCM (0.22 mmol/L) could effectively ameliorate D-galactosamine induced ALF in rats. This study demonstrated that TCM could ameliorate the hepatocellular injury and liver inflammation in D-galactosamine induced ALF rats.\nLiu (2013):\nObject",
        "label": 0
    },
    "1771": {
        "output": "You are now done with your practice for the exam. Your task is to repeat the above task many times. Your time is now counted. \n\n## Task 3\n\n## 1.\nYou are a clinical trial investigator. At the recruitment phase of a cardiovascular trial, you recruit patients and send them a questionnaire. After the 4-week follow-up and recruitment of a new patient, you will again be able to send the questionnaire. At both times, several patients might be disqualified. You check the progress and then contact these patients to ask them questions for the purposes of the trial. Their answers will become part of the trial results.\n\n## 2.\nYou are the clinical trial investigator and the manager of a hospital's clinical research. After several months of recruitment and sending a questionnaire to patients, the trial ended, and you are ready to analyze the results.\nWhich of the questions in the questionnaire below cannot be analyzed: \n\n## 17\nSentences (the correct answers must be written in the comment section) for Task 3: \n\n## 1.\nWhat information is obtained by repeated measurements and analysis of which data:\n\n## 2.\nYour supervisor explains the following to you: the goal of the clinical trial.\nYou need to find out what a clinical trial is. Please write down all the information from your supervisor's speech.\n\n## 3.\nWhich information would not belong to the research phase of a clinical trial?\n\n## 4.\nAt the beginning of the trial, you are interested in studying the quality of the trial. In that study, you will not observe the progress of patients during the trial. In your opinion, why you do not need a study of quality at the beginning of the trial?\n\n## 5.\nExplain the differences between the quality of a trial, quality of life, and quality of evidence in healthcare.\n\n## 6.\nYou are clinical trials auditors. In the previous article, you found out that:\n- Two sponsors and one contract research company have participated in a cardiovascular study. The sponsor is the manufacturer that funds the study; and the contract research company is a company responsible for running the study.\n- All of the",
        "label": 0
    },
    "1772": {
        "output": "Now that you have seen the pseudocode of code that allows you to decide if a trial patient met trial inclusion criteria, let me describe the underlying design pattern, which is the Template method pattern. The Template method pattern is one of the seven basic idioms of the SMALLTALK object-oriented design pattern language known as the Dartmouth-12[10]. The Template method pattern provides a mechanism by which a single routine (method) can provide multiple variants of behavior, allowing subclasses to override methods to provide specialized versions of template methods. Using the Template method pattern, you are implementing the clinical trial inclusion criteria in the following way:\n(a) Create a single method `checkTrialEligibility` and in it you will have a specialized version of `checkPatientEligibility` for each of the included clinical trials.\n(b) Each of the specialized versions of `checkPatientEligibility` will need only use the `trialName` string and `checkPatientEligibility` to determine the eligibility of the corresponding trial patient; therefore, we can use function composition. function `templateMethodCheckPatientEligibility (x)`{x checkPatientEligibility (x trialName)}.\nSince it is not clear how to determine whether a trial patient of our trial meets all trial inclusion criteria, we will need to use function composition again. The function composition returns a reference to an input function with an output argument. We can use the function composition operator as follows: func composition (func1 arg1, func2 arg1, arg2, \u2026) arg1 = (x)func1(x); arg2 = (x)func2(x,arg1);\u2026 return arg1 The function composition returns a reference to an input function with an output argument. We can use the function composition operator as follows:\n[formula]  func composition (func1 arg1, func2 arg1, arg2, \u2026) arg1 = (x)func1(x); arg2 = (x)func2(x,arg1);\u2026 return arg1 [/formula] \nPlease note that you will need to pass to your `checkPatientEligibility` input the trial name string, so that we have the following:\nfunc composition(checkTrialEligibility, ctrialName)\nSince we already have a reference `CTrials` class as the input",
        "label": 1
    },
    "1773": {
        "output": "[INST] Let's continue with the second patient. \n\nThe patient is a 21-year-old woman diagnosed with HCV 2 years ago and is on IFN, RBV, and direct antiviral drugs. Her past medical history is non-significant except the treatment. She takes no other medications except the treatment. Here is her biopsy: There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. She is an alert female with no acute distress. Her BP: 115/65, HR: 60/min and BMI: 22. Her abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: New Study-Drug Safety Study With an Oral Direct Antiviral in Subjects With HCV Genotype 1 Infection\n\n\nSummary: A phase 2 study to evaluate the safety/dose response relationship of an anti-hepatitis C drug (Direct Antiviral), at doses up to 7000 mg qd in subjects with hepatitis C genotype 1 (HCV-1) infection\n\n\nInclusion criteria: \n\nMale or female, 18 years or older, inclusive\nKey Inclusion Criteria:\nHCV-1 infection\nHCV RNA of greater than 100,000 IU per milliliter (IU/mL), as measured by Roche CAP/CTM HCV RNA assay or Roche COBAS AmpliPrep/COBAS TaqMan HCV Quantitative test\nTotal bilirubin levels less than two times the upper limit of normal (ULN)\nAlanine aminotransferase (ALT) levels less than three times the ULN a Serum creatinine level less than or equal to 1.5 times the ULN\nCreatinine clearance estimated by Cockcroft and Gault formula is greater than 30 mL per minute (mL/min)\nSerum amylase",
        "label": 0
    },
    "1774": {
        "output": "<EOD> The Impact of Social Support in a Randomized Controlled Trial to Reduce the Occurrence of Painful Diagnoses among Children Living in Low-Income Communities in Mexico\nThis study evaluated the effect of a 10-week preventive social skills intervention on the severity and frequency of reported pain among children who had experienced at least one physical symptom in the previous year. A convenience sample of 67 children with a mean age of 11.85 years (SD = 2.80) and their primary caregiver were randomly assigned to the intervention or comparison group (CG). Participants were 72% male, 59% had a caregiver with at least a secondary level of education, and 82% reported some type of stressful life event in the last year. No significant time effects were found for pain frequency. For pain severity, the intervention group reported a significant decrease, whereas the CG presented the opposite trend. The findings support the effectiveness of early interventions aimed at improving the social environment of young children to reduce their emotional distress and suffering.<EOD> PB2256: RADIOFREE TRUTH AND SCIENCE: THE STORY OF THE CATACOMB SYNDROME\n\nBook distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. Abstract Book Citations: Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx. Disclaimer: Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.\n\n## Pb2256 radiofree truth and science: the story of the catatonia syndrome\nMauro Mendez 1,2, * , Katheri Mireles-Renteria 3",
        "label": 0
    },
    "1775": {
        "output": "You should make a patient-level eligibility on each patient for the clinical trial, i.e., each patient gets a patient-level eligibility score by trial-level eligibility, i.e., 0) Excluded, 1) Not relevant, and 2) Eligible. \n\nHere is the input of patient-level eligibility by each clinical trial. \nPatient-level eligibility by trial: \n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2)",
        "label": 1
    },
    "1776": {
        "output": "1) Excluded -> if all the criteria fail, the patient is excluded. 2) Not relevant -> if the patient has inadequate information to qualify for the trial, he/she is not relevant.\n\n## 5) Reclassify patients per trial in a data table\nYou should now have all patients in a data table like this one  [INST]. You should now have all patients in a data table like this one  [INST].\n\nThis table is the patient list and you need to classify patients per trial.\n\nHere is an example of patient matching: \n\n## 6) Print the Trial data\nAll patient information must be presented in a report which can be printed. \n![Image of Paper](./images/paper.png) \nClicking the **Print** button will enable you to click the printer icon to print the report. You can also copy to the clipboard by pressing ctrl + c and then paste it via ctrl + v to a word document. \nIn the trial recruitment process, the list of patients on a single trial is also called a patient list.  You have matched all patient information in your list. \n\n\n***YOUR TASK IN THIS ACTIVITY***\n-   Provide a screenshot and include in-text commentary on the steps you completed to match the patients appropriately;\n-   Describe the final step that you completed successfully. \n_**Please upload both the code and your comments in this activity for assessment!**_ \n[INST \n![Screenshot image](./images/image.png)]()\n<EOD> Immunocytochemical demonstration of neurofilament proteins in tissue sections and paraffin-embedded cells.\nImmunocytochemical techniques were used to localize neurofilament proteins, as well as tubulin and actin, in paraffin-embedded cultured cells of glioma tissue as well as in human, rat and calf tissues. Antisera directed against neurofilament protein were produced in dogs. This antiserum detected not only neurofilaments of peripheral nerves, but also large fibrils associated with astrocytes in tissue sections. Neuronal neurofilament protein was located in cultured cells as well as in sections of calf",
        "label": 2
    },
    "1777": {
        "output": "_**Instructions**_: The patient has all the requirements that are shown under the 1) Not relevant heading except for the age of 9 years, which is outside of the age range of the trial. Even though the patient meets the trial's age range, it is not included in the 1) Not relevant headcount row after the age_range since the minimum age_range is higher than 9. In our example, since the minimum and maximum age_range are 17 and 75 respectively, the patient will be assigned to the 2) Eligible column.\n\n![1](/static/img/course/2017-01-15-T12-39-34/example_out/1.png)\n\n\n\n_**Instructions**_: The patient is within the specified ages, but still does not follow the genderspecific requirement of female gender.\n\n![2](/static/img/course/2017-01-15-T12-39-34/example_out/2.png)\n\n\n\n_**Instructions**_: Our patient has had the diagnosis of chronic hepatitis C 2 years ago. His current situation is that he is being treated with IFN, RBV and now with direct antiviral drugs, all of which are listed as treatment. For someone undergoing direct antiviral therapy, we will have some information on the therapy history, e.g. interferon therapy can be converted to the combination of interferon, ribavirin and direct anti-viral drugs. A patient may be in IFN-free therapy when treated with IFN, direct anti-viral drug, IFN and direct anti-viral drug at the same time. However, they all count towards the 'direct antiviral therapy'.\n\n![3](/static/img/course/2017-01-15-T12-39-34/example_out/3.png)\n\n_**Instructions**_: The patient's laboratory values are all within the range of normal limits, except the HBV values. They are all outside the range of normal. Although HBV is not an exclusion criteria of the trial, the",
        "label": 0
    },
    "1778": {
        "output": "Please follow the instructions carefully when creating your solution; failure to follow them can lead to failure in your solution. \nSolutions are saved up to 6 hours. When using solutions for the 6-hour limit, we store your solutions up to 6 hours after your previous action (e.g., your previous solution is submitted or you're on a tour). Your final solution is reloaded when the last minute of the solution uploading time is over; that is, your last solution is taken, and the timer starts. If you re-enter the solution page after 6 hours and you have not submitted your last solution, it will also be saved but you can only enter the solutions up to a maximum of 6 hours from the time you last submitted the solution.\nYou have to first create a test session to access `Solution Views`. After your registration for a test session, you can begin coding.\nYou can run and check your solutions up to 6 hours with `Solution Views`.\n\n# [INSTR]\nYou are given a set of 10 test data \n\n## [CODE]\nThis set is defined as follow. The code of the test data is as follows.\n\n# [INSTR]\nYou are given a set of 100 test data \n\n## [CODE]\nThis set is defined as follow. The code of the test data is as follows.\n\n# [INSTR]\nYou are given a set of 1000 test data\n\n## [CODE]\nThis set is defined as follow. The code of the test data is as follows. \nIf the value is 1, then it's correct! Please note that 200 data from the data is negative and 800 data is positive.\n[INST] You are responsible for creating your first project on your GitHub account. You need to configure your GitHub account on your computer.\n\n# [INSTR]\nYou are given a set of 1000 test data Please follow the instruction below for the solution upload process. Your solution is to be submitted only when all of your submission pages are loaded. Incomplete submission results in a restart from the first page. You will receive a random token, which is then added to your last solution.\n[INST] Now is the time to check the test data on the solution screen.\n\n# [INSTR]\nYou",
        "label": 0
    },
    "1779": {
        "output": "## [TRIAL] What are your plans for the next two weeks?\n[TRIAL] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion and exclusion criteria of a clinical trial to determine the patient's eligibility.\n\nHere is the patient note:\nHospitalization: She was hospitalized and treated with anti-TB drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) for the last two days. Previous medical history: She had a history of diabetes for 14 years and underwent cataract surgery and was diagnosed to have type 2 diabetes. She also had a history of HCV infection. Other medical problems: She started anti-TB treatment at another hospital and was referred to our clinic after two days because of aggravation of tuberculous meningitis. Physical examination: She was afebrile. Her Glasgow coma score was E4V5M6. Cranial nerve examination: There is no ophthalmoplegia or nystagmus. She had 3/5 power in both lower extremities. She had no sensory deficits. She had no signs of upper motor neuron syndrome. \nIn this clinical trial, we are going to give the subjects two drugs. We also know their potential side-effects. Here are side-effects: \nWe hypothesize that two-drug therapies have a better success rate compared to single-drug therapies in patients with malignant brain tumors.\nWe will test two-drug therapies using a randomized trial design. Patients will be assigned to receive a two-drug therapy using a randomized controlled trial procedure.\nWe need help from volunteers with brain tumor to see the results of the trial.\nThe patients with brain tumor will be recruited from the National Cancer Center, Korea, and the Kangbuk Samsung Hospital, Korea. We want to include 40 or 60 patients during the course of the first year. The inclusion and exclusion criteria for the study are as follows. Please choose one for each of the following questions. You have to ask every time:\n- [EX",
        "label": 0
    },
    "1780": {
        "output": "[INST] ##################################### Eligibility assessment\n\nHere is the information:\nTitle: The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence\n\n\nSummary: The advent of electronic cigarette (e-cigarette) technologies represents one of the most significant developments in the last several decades, and provides a novel and promising strategy for substantially reducing the morbidity and mortality associated with smoking. However, serious concerns have been raised regarding the possibility that e-cigarettes will sustain a dependency on nicotine and that they may lead to continued use of conventional cigarettes known to be extremely harmful to health. Cigarette addiction critically involves a dependence on nicotine, but it is likely that other tobacco constituents contribute to dependence as well. Recent evidence suggests that non-nicotine tobacco alkaloids, or NNTAs (including anabasine, anatabine, nornicotine, and myosmine) may play a role in tobacco dependence. These alkaloids have been shown to augment the reinforcing effects of nicotine in animal models and to affect cravings in human smokers. E-cigarettes contain variable quantities of nicotine and NNTAs, but there is virtually no information available concerning the role of e-cigarette nicotine or NNTA content in influencing the concurrent use of cigarettes and e-cigarettes, when smokers attempt to switch from conventional combustible cigarettes to e-cigarettes. Additionally, it is not known whether the presence of nicotine and NNTAs in e- cigarettes may sustain dependence, making it difficult to relinquish these products. The proposed project will assess the acceptability, extent of switching behavior, and degree of dependence maintained when smokers are provided with e-cigarettes containing nicotine and NNTAs.\n\n# Inclusion criteria\nThe proposed study will test the tobacco e-cigarettes at nicotine and NNTA levels consistent with typical e-cigarette use. The inclusion criteria therefore are:\nHave no known serious medical conditions;\nAre",
        "label": 0
    },
    "1781": {
        "output": "<commit_msg>corrected output<commit_after>#!/bin/bash\n\n\n# SGE_HOME=/fsl/scratch/sge/\nSCRIPT_DIR=$HOME/ansible_roles/ansible-gherkin-runner/\nANSIBLE_MODULE_PATH=$SCRIPT_DIR/mod_main.py:$SCRIPT_DIR/mod_modules\n\n# ANSBILE_DEBUG=\n# TASK=$TASK\nJUNIT=$JUNIT\n\n# If this is inside of a git submodule, use that variable instead\n# of the real path to the file.\nif [ -x ./run_ansible_task.sh ]\nthen\n  ansible-playbook test_data.json --extra-vars \"JUNIT=$JUNIT\" -f run_ansible_task.sh\nelse\n  cd ../fsl/scratch/sge/\n  ansible-playbook test_data.json --extra-vars \"JUNIT=$JUNIT\" -f run_ansible_task.sh\nfi  \n\nrm -Rf ./run_ansible_task.sh\n<EOD> The role and contribution of the Nrf-2/HO-1 signaling pathway and therapeutic strategies in the pathogenesis of gastric cancer\nAbstract The role of Nrf-2/HO-1 in cancer cells is not only to provide antioxidants but also to activate cell-cycle progression, proliferation, and apoptosis. In the past, HO-1 had been reported to be a tumor suppressor; however, there are studies reporting that HO-1 has also been associated with tumor progression, suggesting a dual role for endogenous Nrf-2/HO-1 activity. Many molecules and cellular processes that have an antioxidant defense role in the activation of Nrf-2/HO-1 signaling pathways. In addition, several phytochemicals, plant-derived polyphenols, and terpenoids, which have been reported to possess anticancer properties, are thought to act via Nrf-2/HO-1. The purpose of this review is to provide a scientific summary regarding the involvement of the Nrf",
        "label": 0
    },
    "1782": {
        "output": "You are now all set to go! You know what to look for and are very knowledgeable about the trial. Go to the next patient to see if they are eligible for a given trial.\n\n\n[PROGRAM]\n\nIf you would like more detail on the trial assessment process, the following information is added to the above code and is placed before the code for the second patient. We need to have an additional step of defining the variables for each patient as we do in the `function newpatient()` and `function getdata()` where the variables are defined for the first patient in the loop; otherwise, we will just have to manually manipulate the first set of variables that are already defined. The following is the new code after adding the definition of the variables:\nif (getData(p,i)) break; <EOD> The association between vitamin D and metabolic syndrome in Croatian adults: a population-based study.\nObjectives\nVitamin D influences the development of metabolic syndrome via multiple endocrine pathways. Although its deficiency is recognized as a risk factor for metabolic syndromes, the results are inconclusive. The aim of the study was to evaluate the association between vitamin D and metabolic syndrome in Croatian adults.\n\n\nMaterial and methods\nThe study consisted of 630 individuals aged 18-70 years enrolled from the general population living in the northern region of the country. Metabolic syndrome was defined using the modified National Cholesterol Education Program Adult Treatment Panel III algorithm. Vitamin D was analyzed in blood samples taken at fasting state, the reference values adjusted to winter months by using winter sunshine duration (WS = W). The values of vitamin D in blood samples were calculated using the regression formula.\n\n\nResults\nVitamin D deficiency was found in 40% (WSD, n=86/222; WSD 27%, n=57/216) males and 45% (WSD, n=74/164; WSD 51%, n=37/72) females. Vitamin D insufficiency was found in 28% (WSD, n=64/222; WSD 43",
        "label": 0
    },
    "1783": {
        "output": "## Testing your code\nTo run your code locally for your own purpose, you can type the command `julia -f -e` in the terminal.\nIf running the code in the terminal is not your preference and you are more comfortable editing an HTML file, you can use the command `julia -f -e -O -J ./path/to/html/file.html`. After running the code, an HTML file will be written in the same directory where the Julia code was executed.\n[INST]\n<EOD> A Novel Therapeutic Approach: Dual Rehabilitation\nBackground: The recovery of locomotor function relies on coordinated, purposeful, task-oriented movement that requires multiple systems to work in concert. Therefore, rehabilitation procedures for patients with motor deficits should target multiple systems simultaneously. The goal of this study was to use motor imagery and neurostimulation in a dual, purposeful, and goal-oriented manner to promote the neural basis of motor recovery of movement-impairment and disability. Methods: Twenty healthy individuals (age=28.0 \u00b1 6.1 years, 65% female) participated in the study. The participants performed ankle plantar flexion movements (dorsiflexion) during motor imagery or motor imagery with functional electrical muscle stimulation (FES) to the tibialis anterior muscles. Electromyography activity was recorded during each condition and the results were compared using 2-way repeated measures analysis of variance. Results: The results showed significant differences in the motor imagery and motor imagery with FES conditions. When FES was added to motor imagery, electromyography activity was significantly increased in the tibialis anterior muscles and electromyography activity was significantly lower in the gastrocnemius medialis muscles. Conclusions: The results provide preliminary evidence that the addition of FES to motor imagery promoted greater task specificity and neural activation than when motor imagery is used alone.<EOD> Genetic diversity and population structure in an endemic chicken breed from Ceylon\nChickens provide human dietary necessities via meat and eggs. Chickens that thrive in different environments are considered genetically diverse and adaptable. This study aimed to generate microsatellite genot",
        "label": 0
    },
    "1784": {
        "output": "<EOD> Evaluation of the efficacy of gamma-ray therapy against cutaneous neuroblastoma and chemically induced bladder tumorigenesis in Syrian golden hamsters.\n\nThe effects of gamma-radiotherapy on cutaneous neuroblastoma and chemicallyinduced bladder tumorigenesis in Syrian golden hamsters were evaluated. Cutaneous neuroblastoma was induced by repeated intradermal injection of methylcholanthrene and/or methylazoxymethanol acetate. The tumor size was measured, and the tumor size of each animal was expressed as the ratio of tumor length to tumor width calculated. The 1-or 2-week gamma-ray therapy resulted in an inhibition of tumor growth to 50% and 39% of the control value, while the combined use of chemotherapeutic drugs, BCNU and MTX, showed no effect on the growth of tumors. Chemically induced bladder tumors were transplantable to the subcutaneous chamber induced by subcutaneous injection of urothelium and mucopolysaccharide. The survival time of the hamsters bearing the subcutaneous tumors was recorded. The combined use of BCNU and MTX enhanced the tumoricidal activity against the bladder tumor. This combined treatment may decrease the frequency of side effects. In addition, gamma-ray therapy significantly increased the tumoricidal activity of the treatment combination (BCNU, 12.5 mg/kg; MTX, 2.5 mg/kg every other day), resulting in an increase of the life span of the hamsters bearing the subcutaneous tumor.\nA number of epidemiologic studies in the U.S.A., Japan and Europe have indicated a link between ionized radiation and an increased risk of leukemia among the members of the atomic bomb survivors in Hiroshima and Nagasaki, or among children exposed to radiation from the Chernobyl Atomic Power Plant [bib_ref]  Implications for risk: The potential long term consequences of radiation-induced cancer in..., Schubauer-Berigan [/bib_ref] . The International Agency for Research on Cancer concluded that the risk of radiationinduced malignancies after external exposure to low dos",
        "label": 1
    },
    "1785": {
        "output": "To be considered as a complete solution, the output must print a file called `ClinicalTrial.txt` which include patient-level eligibility, trial-level eligibility, and some patient data, similar to the following examples in `Examples/src/02_ClinicalTrials/10_Output/ClinicalTrial.txt`.  \n[Example]1\n- Patient-level eligibility: 0) Excluded.\n- Trial-level eligibility: 1) Eligible.\n- Patient Data:\n- FIRST/Treatment:\nPatient1_firstTreatment=IFN\nPatient1_firstTreatmentTime=MM\nPatient1_treatmentTime=0MM\n- FIRST_VEC=VIR\n- SECOND_VEC=NOR\n- Patient2_firstTreatment=IFN\n- Patient2_firstTreatmentTime=MM\n- Patient2_treatmentTime=0MM\n- FIRST_VEC=VIR\n- SECOND_VEC=NOR\n- Patient3_firstTreatment=IFN\n- Patient3_firstTreatmentTime=MM\n- Patient3_treatmentTime=0MM\n- FIRST_VEC=VIR\n- SECOND_VEC=NOR\n- Patient4_firstTreatment=IFN\n- Patient4_firstTreatmentTime=MM\n- Patient4_treatmentTime=0MM\n- FIRST_VEC=VIR\n- SECOND_VEC=NOR\n- Patient5_firstTreatment=IFN\n- Patient5_firstTreatmentTime=MM\n- Patient5_treatmentTime=0MM\n- FIRST_VEC=VIR\n- SECOND_VEC=NOR\n- Patient6_firstTreatment=IFN\n- Patient6_firstTreatmentTime=MM\n- Patient6_treatmentTime=0MM\n- FIRST_VEC=VIR\n- SECOND_VEC=NOR",
        "label": 1
    },
    "1786": {
        "output": "# Run Time\n<EOD> Isolation and characterization of monoclonal antibody against N-glycolylneuraminic acid and comparison of its reactivities by thin section, whole mount, and sandwich enzyme immunoassay.\nA monoclonal antibody, designated N4, specific for N-glycolylneuraminic acid (NGNA, 2-ketodi-deoxy-Neu5Ac) was obtained by fusing BALB/c spleen cells with the murine myeloma RPC19. This antigenic specificity was demonstrated by the reactions against the immunoreagents in thin sections of cells and tissues from animals. The sandwich enzyme immunoassay revealed that the reactivity of the monoclonal antibody was also specific for NGNA with a high potency.<EOD> 1p loss in breast cancer\nFrequent loss of heterozygosity (LOH) has been observed to occur within breast cancer\u2010predisposition regions on chromosome 1q in sporadic cancer cases, suggesting a susceptibility locus with dominant loss\u2010of\u2010function alleles may predispose to breast cancer. In addition, some loci implicated in the development of hereditary breast cancer (BRCA1, BRCA2, c\u2010erbB\u20102, c\u2010erbB\u20101, etc.), appear to exhibit allele loss in many other sporadic cancers. The aim of this study was to investigate LOH across the entirety of the short arm of chromosome one (1p) by allelotyping, using 21 polymorphic microsatellite markers across the region using DNA extracted from frozen archival primary breast tumour samples from seven breast cancer groups and the genomic locations for those markers are detailed. An average LOH rate of 0.3 was observed amongst all tumour groups, and was greatest in invasive lobular and ductal carcinomas of histological grading (0.98 and 0.78, respectively). No statistical significant difference in LOH rates between different tumour histologies were detected (n = 560, p > 0.05). Allelic loss on chromosome 1p was detected in 14\u201030% of all sporadic breast",
        "label": 0
    },
    "1787": {
        "output": "<EOD> .\nAlkaloids have been extracted from the stems and leaves of Tripterygium wilfordii and Rauwolfia serpentina (Mengzi strain) by HPD-2850 resin. Dibenzocyclooctadiene-type alkaloids have been proved to be mainly extracted, and the main alkaloids in T. wilfordii and R. serpentina (Mengzi strain) are dibenzoy-dioxy-delta 10-dihydroxycarmoxyine and reserpine, respectively.<EOD> An overview of the current status of psychopathology in the developing world.\nIn India and other developing nations, most mental health services still concentrate on the provision of care for mental illness rather than psychosocial interventions for the prevention of mental disorders. However the concept is emerging in many developing nations that primary prevention is cheaper and more efficient than treating mental illness, and that in the long run it would be cost-effective if a larger proportion of the mental health budget was spent on activities that prevented the occurrence of a disorder rather than providing treatment services. In spite of this recognition of the importance of prevention, a comprehensive approach to mental health, including an integrated treatment and prevention strategy, is still not applied. Although developing countries can ill afford to adopt the more comprehensive system of mental health services that has been proposed by the World Health Organisation (1997), some action is now required to incorporate even basic mental health services into policy and national programmes.<EOD> Interaction of human thrombin with human polymorphonuclear leukocytes.\nHuman thrombin (125-1000 micrograms/ml) was added to heparinized human polymorphonuclear leukocyte suspensions; this induced intracellular calcium mobilization. There was an inhibitory effect at concentrations above 10 micrograms/ml, and the maximal effect obtained at concentrations between 25 and 100 micrograms/ml. Addition of anti-human thrombin antibodies to the suspension reduced the calcium mobilizing activity of thrombin, thus enabling determination of the active portion of the protein, which was the N-terminal fragment Arg4",
        "label": 0
    },
    "1788": {
        "output": "[INVOCATION] Eligibility assessment for clinical trial: hepatitis C virus. [INST]\n\n[CDI] Eligibility assessment for clinical trial: hepatitis C virus.\n\n[CODE-FIELD]\n\n\n\n[TRIAL-LEVEL-ELIGIBILITY-E3_0] Excluded\n\n\n[TRIAL-LEVEL-ELIGIBILITY-E3_1] Not relevant\n\n\n[TRIAL-LEVEL-ELIGIBILITY-E3_2] Eligible\n\n[END-OF-SAS-CODE]\n\nA few notes:\n\n- As of version 13, it will output the \"Trial-level eligibility\" as \"excluded\", \"not relevant\", and \"eligible\" in the same format that we did in the previous version;\n- The SAS program outputs \"Trial-level eligibility\" in the last line by `Trial-eligibility-level::`. If it doesn't, please just move it to the last line and restart the macro.\n- The user may want to make an additional column of patient's eligibility, like in the `Trial-level ELIGIBILITY` step, just by adding a new column in the `Clinical.xlsx.sas7bdat` table first and creating a new variable in the `Clinical` table for \"Patient-level eligibility\", e.g.,\n\n## Note\nAlthough this macro is mainly used with large amounts of data, it may work for small amounts of data. If you get an error with \"Too many rows in file\", just reduce your numbers of patients or set a proper size of cells.\nPlease let me know your comments.\n\n[inst]\n\n[codfield]\n\n[Coding-manual]\n\n\n* * * * * * * * * * * * * * * * * * *\n\nWe can create other data structures, tables, etc. for data management by a series of macro functions like below.\n\n\nThis macro creates a temporary table, named `Clinical`, in your file, similar to [0]:\n\n[0] Make a temporary table: Clinical",
        "label": 1
    },
    "1789": {
        "output": "## A2.1.7 ELIGIBILITY CRYPTIC\nWe do not describe this code in detail and the example is at the end of the codebook. Instead, we give information for the other 2 steps with some hints. Please note that this code must be used when the patient is ineligible after step A2.1.\n\nFirst, the assessment of eligibility has the three-point scale: 0) Excluded; 1) Not relevant; and 2) Eligible. Now we must do step B.\n\nSecond, the last line is for `Trial-level eligibility:`, which has a similar problem as before.\n\t\n\t# Asses trial inclusion criteria using patient information\n\t# Trial-level eligibility:   2) Eligible\n\t#\n\t# If one study is not available then one would print 0 for the trial-level eligibility.\n\t# The first line of the example prints trial-level eligibility: [0] Excluded.\n\t#\n\nNext, we must do step C. \n\nThird, the last line for `Patient-level eligibility:`, which contains the information whether the patient is included completely or only partly in the clinical trial.\n\t\n\t# Asses trial inclusion criteria using patient information\n\t# Patient-level eligibility: 1) Excluded;\n\t# Patient-level eligibility: 2) Included;\n\t# Patient-level eligibility: 3) Subject;\n\t#\n\t# Trial-level eligibility:\n\t# Trial-level eligibility: 0) Excluded\n\t# Trial-level eligibility: 1) Not relevant\n\t# Trial-level eligibility: 2) Eligible\n\nFinally, we must do step D. \n\nFourth, the last line of the example is for `Patient-level eligibility: 1) Included.`. This step indicates whether the patient is fully eligible for the clinical trial or is only partly eligible. In this example, the patient is included in the clinical trial but not fully el",
        "label": 1
    },
    "1790": {
        "output": "## Clinical Features of Acute-on-Chronic Liver Failure\n\nWhen acute liver failure occurs in patients with chronic liver disease, the clinical disease is characterized by more severe impairment of hepatic function, higher hepatic encephalopathy grade, higher bacterial infection rate, lower hepatocyte regeneration capacity, and a higher mortality rate.\nFor patients with chronic alcoholic liver disease, most deaths were due to bacterial infections, and the bacterial infection rate was more than 50% (50/97) during the first 2 weeks. In patients with chronic non-alcoholic fatty liver disease and chronic viral hepatitis (HBV, HDV, HCV, HEV, and HIV), the main cause of death during the first 2 weeks was HCC, which occurred in 42% (30/79) of the patients. In both acute alcoholic liver disease and non-alcoholic fatty liver disease, the number of patients with acute-on-chronic liver failure at the time of admission did not correlate with any clinical or laboratory parameters.\nPatients with acute alcoholic liver disease were younger and had a shorter hospital stay than patients with acute non-alcoholic fatty liver failure, but there were no differences in mortality or the rate of complications such as hepatic encephalopathy.\n\n## Prognostic Factors\n\n### Combination of MELD And MELD-Na Score\nIn 166 cases of acute on chronic liver failure due to viral hepatitis or alcohol-related cirrhosis, the combination of MELD-Na and MELD score accurately predicted 14-day mortality, as shown in figure 1. In the acute alcoholic liver disease patients, MELD and MELD-Na score had similar predictive power, while in the non-alcoholic fatty liver disease group of patients, MELD-Na showed better predictive ability for 14day mortality compared to MELD score. Among the three models that included HBV decompensation, HCC",
        "label": 0
    },
    "1791": {
        "output": "## How to Document SAS with a Template\n\n[INST] Welcome to my office. Here, I show you how to make SAS documents.\n\nThis is a template of SAS document.\n\nPlease make your SAS document with this template.\n\nI will show you the process of setting up your SAS code. In SAS code, I will use color code. The code in grey color will be commented out. If you want to keep your SAS code like it is, comment with no grey code.\n\n**A: You can modify these fields of the template with your data set, so you can have your own code set up.**\nThis is a template of SAS document.\n\nPlease make SAS document with this template.\n\nI will show you the process of setting up your SAS code. Please modify your personal information.\n\n`Personal information:\nTitle: Research assistante\nE-mail: your_email@sas.com`\n\nAdding personal profile information to a SAS document template.\n\n`TITLE:\n   \"My name is YOUR name and I am a student and I like cake.\"`\n\nThis is another way to add your information directly. If you are comfortable with SAS, we recommend to use the latter template.\n\n`TITLE:\n   \"The First Line of my Title Is My Name is YOURname&Iamastudentandilikecake.\"`\n\nAdding your personal information to the template.\n\nYour personal information will be kept as an original.\n\nYou can also add SAS logo and your picture. Here is the",
        "label": 0
    },
    "1792": {
        "output": "Let's do it!\n<EOD> .\nThe incidence of lung cancer has been increasing over the past few decades. As a consequence, more patients are undergoing surgery. A good postoperative outcome is of the essence in lung cancer surgery. The preoperative functional evaluation of lung function is important for determining the extent of the surgical procedures that can be safely performed and for deciding the postoperative therapy. Pulmonary function tests are recommended by major medical associations, but there has been a long-standing dispute over the usefulness of tests like pulmonary diffusing capacity (DLC) in patients with lung cancer. In this paper, we have reviewed the importance of DLC and carbon monoxide (CO) diffusing capacity (DLCO) in lung cancer. In particular, the role of the DLCO at the time of the preoperative assessment and in prediction of the post-surgical outcome has been evaluated. We have demonstrated that the DLCO is important in determining post-surgical outcome and prognosis. We hope that this will lead to the DLCO becoming one of the evaluation indices for pulmonary reserve in lung cancer.<EOD> Changes in the concentration, phosphorylation, and intracellular localisation of P175 neurofilament protein in axotomized rat dorsal root ganglon cell bodies following in vivo infusion of microtubule-interfering drugs.\nIn the present study we have investigated the effects of microtubule-disruptive agents on the intracellular transport and distribution of the P175 neurofilament proteins in dorsal root ganglion cell bodies in vivo. We infused dorsal root ganglia in rats in vivo with vinblastine, colchicine, or 5,6 dichloro-1-beta-D-ribofuranosyl benzimidazole (DRB) and analyzed the altered distribution and phosphorylation status of the P175 neurofilament protein and compared its distribution with those seen in axotomized ganglionic cells and normal control ganglionic cells infused with vehicle. The changes seen in the distribution of the protein with vinblastine and colchicine infusions could be blocked with the simultaneous infusion of taxol which",
        "label": 2
    },
    "1793": {
        "output": "<jupyter_text>We will generate a list of trial-level eligible patients at time `t 1` if we assume the proportion of patients who are eligible, i.e., `p(0&1) <jupyter_code><div id=\"output-21-of-33\" class=\"highlight\"><pre class=\"language-python\">p=run_regression(df, 'patient_note', x=0, y=1, numb=101+1, maxiter=100, 'maxiter':100)\nsummary(p)\np\n$maxiter\n</pre><div class=\"output-json\"><pre><code><script type=\"text/javascript\">var output = JSON.parse(document.getElementById(\"output-21-of-33\").innerHTML);\nconsole.log(output);\n</script></code></pre></div><jupyter_text>We will generate a trial-level eligible list of patients at time `t 2` if we assume the proportion of patients who are eligible, i.e., `p(1&1) <jupyter_code><div id=\"output-22-of-33\" class=\"highlight\"><pre class=\"language-python\">p=run_regression(df, 'patient_note', x=1, y=1, numb=101+1, maxiter=100, 'maxiter':100)\nsummary(p)\np\n$maxiter\n</pre><div class=\"output-json\"><pre><code><script type=\"text/javascript\">var output = JSON.parse(document.getElementById(\"output-22-of-33\").innerHTML);\nconsole.log(output);\n</script></code></pre></div><jupyter_text>At this point, we need to predict the proportion of trial-level eligible patients who are excluded using clinical trial rules, e.g., `p(0&2) + p(0&3) + ... + p(0&13) = 0.010, where we take 13 exclusion factors as examples in the data.  If the proportion of patients who are excluded, i.e., `p(0&j) =",
        "label": 0
    },
    "1794": {
        "output": "<EOD> Nailfold capillaroscopy and clinical features in anorexia nervosa: a preliminary pilot study\nWe aim to identify whether capillaroscopic features and clinical variables may be useful in the early identification of the cardiovascular complications of anorexia nervosa.<EOD> Changes in Mood and Sensory Processing among Students in a 3D Architectural Design Course\n\nTen senior-level architecture undergraduates were studied via an experimental intervention to evaluate their sensory processing, psychological functioning, and personal attributes. Students were tested at three points during the architecture course: (1) at the beginning of the semester, (2) just before the end of the semester (pretest), and (3) immediately after they passed their second semester project (post-test). Based upon the literature, it was hypothesized that the students would (1) exhibit more emotional anxiety and depressive symptoms as compared to other student populations, (2) report increasing awareness of their own perceptual systems, and (3) demonstrate fewer sensory difficulties as compared to what was reported at the beginning of the course. Over the course of the semester, students appeared to become more focused and less anxious, and they reported fewer sensory difficulties with auditory, visual, and tactile processing. At the post-test, the students reported greater levels of positive mood and life satisfaction as compared to the pretest. The results supported the authors' hypothesis for the first two questions with mixed results for question three. The conclusions, however, offer some direction for further study of this particular population of students and the impact of academic stress on sensory processing.\n\n# Introduction\nAccording to the American Psychological Association (2010), occupational stress can be defined as \"an accumulation of work related demands and pressures, interference of these demands and pressures with an individual's life outside of work, an individual's perception of these demands and pressures, and stress-related physical and psychological reactions to the demands and pressures of the job\" (para. 1). For this research, student occupation was defined according to . They define occupation as \"a process that involves, first, identifying what we do, who we are and how we do it\" (p.",
        "label": 0
    },
    "1795": {
        "output": "[/TEXSCRIPT]\n[CANDIDATES]\n\n### INST: Incomplete Assignment\n\nYou must complete an incomplete assignment. The completion of the assignment is not mandatory. \n\n### INST: Partial Participation is Mandatory\n\nAlthough participating completely is always preferable when possible, participation is required in partial form. Partially participating in the assignee project is mandatory. The assignee project has a set of tasks for the participant. Partially participating in this assignee project is mandatory. This does not require participating in the full project; instead, a team of student mentors will be available to mentor the candidate based on his/her availability.\n\n### INST: Financing for Complete Project is Mandatory\n\nAlthough funding is highly recommended in order to fully participate, financial support in the form of a fellowship is not mandatory. \n\n### INST: No Penalty for Incompletions\n\nThe following rule is only applied in the case of submissions that are not completed: If a candidate does not complete all of his assignments, for whatever reason, then he should submit his partial results along with a statement concerning the reasons for non-completion. The candidate will then be penalized according to the following procedure: No partial submissions: Fail; Cases of partial submissions: Failure for every unsubmitted incomplete assignee project. [/CANDIDATES].\n\n# Assignees\n\n![Assignees][3].!\n\n\n## Assignee: A.N.C. (Ana Rita Cid)\nThe assignee (Ana Rita Cid) is a 28-year old student of Computer Science and Communication Engineering with a strong interest in Computer Science and Health. She started her Master's degree in 2014, focusing on Computer Science and Communications. Now, she is pursuing her doctorate in computer science in the Health Department, and is expected to finish her doctorate shortly on machine learning and information filtering techniques applied in medical systems. After doing her master and doctoral studies, she intends to pursue research activities with a focus on Machine Learning and Computer Science. Her most recent work has focused on medical images and machine learning, more specifically, on",
        "label": 0
    },
    "1796": {
        "output": "A: Hi, I am also a student trying to learn how to code in R. For RStudio you add in the code at the top like this:\nsetwd(\"~/Downloads/HIV_Virologic_Efficacy_195_Main\"):\n\nYou create this symbol with a colon at the end of the previous paragraph, and then insert the file location into the variable and setwd. You can read more about those variables and what they are and how to use them on this website:\n\n\n*\n\n*RStudio Basics\n\n*R Studio Tutorial\n\n*How to create a path in Windows<EOD> Antitumor activity of an anti-carbonic anhydrase IX monoclonal antibody.\nThe antitumor therapeutic potential of monoclonal antibodies (MAbs) against carbonic anhydrase IX (CA IX) was evaluated. These MAbs were tested in vivo in different mouse models of breast, pancreatic and ovarian cancer. Intravenous injection of four different MAbs was well tolerated. Monitoring of tumor size and serum MAb concentrations showed significant tumor growth inhibition after treatment with MAb5-A12 and MAb1-A10. Furthermore, MAb5-A12 increased survival in mice with human breast cancer cells xenografted subcutaneously as well as intraperitoneally into severe combined immunodeficiency mice. Although in vitro activity of MAb5-A12 was seen in a panel of several cell lines with varying expression levels of CA IX from different solid tumors, the antitumor effect did not correlate with the level of expression of CA IX. MAb5-A12 was able to target tumors with low expression of CA IX, which is the limiting factor for antibody-based targeting of cancers with membrane-associated antigens. These results suggest that anti-CA IX MAbs may be used therapeutically for treatment of patients with this panel of unrelated solid tumors.<EOD> Nutrition Facts\nCalories 1900 cal\nServing size 1 sandwich (99 g)\nAmount per serving\nCalories 740",
        "label": 0
    },
    "1797": {
        "output": "<div markdown=\"1\">\n\n# Step 4: Assessment of eligibility\n\nYou are a helpful assistant for clinical trial recruitment. On a given day, you compare the patient note of a 62-year-old woman with a mastectomy of breast cancer two years ago and the inclusion criteria of the trial. You can see the patient note and the clinical trial on <NAME>. The trial consists of 3 parts. Part 1 is to assess the efficacy and safety of the combination (docetaxel/doxorubicin/cyclophosphamide) DCX + docetaxel at three different dosages (300 mg, 50 mg, or 80 mg) and the three docetaxel only. Part 2: The treatment with high-dose epirubicin, cyclophpshamide, and 5fluorouracil. Part 3: All the women are given hormones (tamoxifen) after the treatment. There is no placebo group.\n\n\n\n### 1: Assessment of eligibility for Part 1\n\nPatient note:\nThe patient note is included below:\nDear Administrator, I am a 62-year-old woman diagnosed with bilateral breast cancer. My medical history includes type 2 diabetes and hyperlipidemia.\n\n\nMy surgery was a mastectomy in March, 2011. In May, 2011, I was admitted to hospital because of my tumor pain. I was diagnosed as metastasis to two bones in May. The next day, I was started tamoxifen (20 mg, by mouth, daily) and chemotherapy (epirubicin 90 mg/docetaxel 75 mg/cyclophosphamide 600 mg, intravenously) for breast cancer.\nThe chemotherapy lasted for 6 days without hospitalization, and the whole treatment lasted about 1 month. I don't remember the name of the hospital.\n\n\nThe chemotherapy went well in general.\n\n\n\nMy symptoms after each chemotherapy are feeling hot, dizzy on the",
        "label": 0
    },
    "1798": {
        "output": "If both of the factors above in the trial's exclusion criteria (age and type of malignancy) are met, the current patient is 'Not relevant'. If the patient does not match one of the factors, he is 'Eligible'. If both of the factors are met on the trial's eligibility criteria, the patient is 'Excluded'.\nYou can think of the following questions when facing a patient note.\n\n(1) Is the patient's age suitable for trial eligibility as per exclusion criteria? Are there trials with a suitable age as an eligibility criteria? In which age groups can such trials be conducted?\n\n(2) Is the type of cancer suitable for trial eligibility as per exclusion criteria? Are there trials with similar or dissimilar types of malignancy? In which cancers such trials can be carried out?\n\n(3) Which trial-level eligibility category would be suitable?\n\n\n[INST] Hello. You are a helpful assistant for a cancer treatment trial. You should give the trial a general introduction. \n\nThe cancer treatment trial you see aims to evaluate a new method for treating cancer. The investigators are from the radiology department. They work with the oncologists to reduce radiation exposure during cancer treatment, especially for children. Children must receive a cancer treatment to grow up healthy. This will also increase the survival rate.\nWith this cancer treatment, children can receive treatment in lower dosages. Lower dosages mean less side effects but equal therapy effect. Children with cancer are more sensitive to the side effects of high-dose chemotherapy as they are still growing. As a result, lower dosages mean fewer side effects, and the same effect is possible.\n\nTherefore, there is a study to compare a new method with the conventional methods to understand the best treatment. Your role is to assist for assessing eligibility.\n\nCan you show us the trial information?\n\n[PLAY]\n\n[INST] Hello. You are a helpful assistant for a cancer treatment trial. You need to collect information from a patient record to assess eligibility.\n\nWe'll explain as follows:\n\n\n**Instructions**:\n    Give the trial an introduction, including the purpose, benefit, and possible side effects.\n    Ask information about the disease and/or treatments",
        "label": 0
    },
    "1799": {
        "output": "[INST] A common example is the clinical trial ``A trial A for treatment of infection of COVID -- 19. ``\n[table]  1: Hello, you are {0/1}, a clinical trial assistant. Your task is to assess whether a patient note and the inclusion criteria of a clinical trial correspond to each other. You need to enter the value of`patient meets inclusion criteria`in the box next to the entry.`3. [1/0] Eligible;`1. [0/1] Eligible;`2. [0/1] Eligible;`Ineligible.`.[/3] Hello. You are a very helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The table shows the factors that allow someone to participate in a clinical study (inclusion criteria) and those that exclude someone from a clinical study (exclusion criteria). You should answer the questions that are shown below.{0/1} Hello, you are {0/1}, a clinical trial assistant. Your task is to assess whether a patient note and the inclusion criteria of a clinical trial correspond to each other. You must enter the value``patient meets inclusion criteria``in the specified box next to the entry. [/table] \n<EOD> Tetracycline and auraptene: new molecular players in the inflammatory process of periodontal diseases\nABSTRACT Auraptene is a coumarin derivative isolated from a medicinal plant (Myristica fragrans Houtt.) used in traditional Chinese medicine. Its antimicrobial activity, anti-inflammatory, and anti-osteodestructive properties make this substance an attractive choice for the treatment of Periodontitis, a disease characterized by inflammatory processes around teeth and bone destruction. Here, we investigated the auraptene molecular targets in the inflammatory process of the disease. The auraptene molecular targets were investigated by proteomic and transcriptomic strategies using LPS-stimulated U937 cells and gingival fibroblasts from periodontitis patients. The effects of auraptene on these markers were also evaluated by inflammatory cytokines,",
        "label": 0
    },
    "1800": {
        "output": "<EOD> An experimental animal model of the post\u2010burn, post\u2010infusion edema of the limbs: a review\nThe purpose of this review is to describe a swine model of the post-burn, post-infusion edema of the limbs, in which edema is evoked by surgical burns on the skin. Subsequently, an isolated venous fistula, in the femoral vein between the abdomen and the hindquarters, is constructed to permit infusion of a liquid medium into the femoral circulation. Because the vascular tone is altered under these circumstances, the hindquaters is shown to be a region of relatively excessive hydrostatic pressure and plasma volume. These disturbances, in turn, cause substantial extravasation of fluid into the interstitium and intracellular compartment. The model has been used to investigate the efficacy of intravenously administered pharmacological agents that can reverse the increased fluid accumulation in muscle and that can attenuate the increased vascular permeability. Furthermore, the model and these investigations have permitted preliminary studies to determine the relationship between edema and the release of colloids and proteoglycans from interstitial fluid spaces. These experimental studies suggest that altered microvascular hydrostatic and colloidal gradients are the bases for the cellular osmotic forces responsible for post-burn edema.<EOD> Coronavirus\n\n\n\n## Coronavirus\nRare, severe acute respiratory syndrome caused by a RNA virus that infects humans that is genetically distinct from SARS; the natural reservoir is unclear. The infection usually results in acute respiratory failure, which can be fatal; it is characterized by a cough, fever, shortness of breath, lung damage, and in the case of fatal infections, viremia. Affected older men, individuals with chronic inflammatory diseases, and immunosuppressed patients are most susceptible. In 2015, a coronavirus strain was discovered in bats in Kenya; however, the virus cannot be experimentally transmitted to humans.\n\n## Epidemiologic classification\nCoronaviruses are RNA viruses in the family Coronaviridae. The",
        "label": 0
    },
    "1801": {
        "output": "###### 40. Clinical trials_2\nThis clinical trial is named `Clinical trials_2`. \n![INST] In Clinical trials_2, use the following eligibility criteria for patients (1 to 5): \nPatients with chronic HCV genotype 1 infection who have not been treated with IFN and who have HCV RNA viral loads of at least 10,000 IU/ml.\nPatients with chronic HCV infection who have not been treated with IFN and who have documented prior relapse on a course of IFNbased therapy.\nPatients with chronic HCV genotype 1 infection who have been treated in complete and sustained response with IFN and RBV.\nPatients with chronic HCV genotype 1b infection who have been treated with IFN-based therapy and RBV, were not cured and have viral levels >10,000 IU/ml.\nPatients with chronic HCV infection who have not been treated previously with IFN or who have relapsed on a course of IFN-based therapy and who meet treatment criteria below. The patient will be randomized to one of two arms: Arm I: patients will receive 48 weeks of treatment with ABT-450, ritonavir and ABT-333 combination tablets twice a day (1 tablet taken twice daily) and 24 weeks of treatment with ABT-450, ritonavir and ABT-333 combination tablets twice a day (1 tablet taken twice daily). The total dose of ABT-450, ritonavir and ABT-333 will be 75 mg, 150 mg and 60 mg total daily, respectively. Treatment with ABT-450, ritonavir and ABT-333 combination tablets will be discontinued if the patient discontinues treatment due to adverse events. Arm II: patients will receive 24 weeks of treatment with ABT-450 plus ritonavir and ABT-333 combination tablets twice a day (1 tablet taken twice daily) and 24 weeks of treatment",
        "label": 1
    },
    "1802": {
        "output": "Your task is to check all the details for all patients (about 1000). How could you do this?\n\n## \u25a0\nYou could do it in a table such as the one in the  following:\n\n### Patient\n\n### Inclusion criteria:\n\n### 0) Excluded\n\n### 1) Not relevant\n\n### 2) Eligible\n\n### 3) Excluded (exclusion condition is not documented in the patient note)\n\n### 4) Eligible, after adjustment of drug administration schedule or dosage\n\n### 5) Excluded, after adjustment of drug administration schedule or dosage\n\n### 6) Eligible, after adjustment of drug administration schedule or dosage\n\n### 7) Not relevant\n\n### A) Age\n\n### 1) 18-39 years\n\n### 2) 40-49 years\n\n### 3) 50-59 years\n\n### 4) 60-69 years \n\n### b) Sex\n\n### 0) Aged Male\n\n### 1) Aged Female\n\n### 2) Aged Male with Transmitted Disease\n\n### 3) Aged Female with Transmitted Disease \n\n### c) Disease\n\n### 1) Virally Suppressed\n\n### 2) Virally Non suppressed\n\n### d) Medications\n\n### 1) Raltegravir\n\n### 2) Raltegravir+Ritonavir\n\n### 3) Raltegravir+Cobicistat\n\n### 4) Raltegravir+Nucleoside Reverse Transcriptase Inhibitors (NRTI)\n\n### 5) Raltegravir+Tenofovir (NRTI)\n\n### e) Coinfections\n\n### 0) Hepatitis C Virus (HCV)\n\n### 1) Hepatitis B Virus (HBV)\n\n### 2) HIV-1\n\n##",
        "label": 0
    },
    "1803": {
        "output": "# Exercises\nExercise 1. You are assigned the eligibility check with the following inclusion criteria:\n\n1.\nLiver enzymes more than 200 U/L\n\n```\n{\n  \"name\": \"Exclamation Mark\",\n  \"symbol\": \"!\",\n  \"description\": \"Exclamation Mark (mark of astonishment or exclamation)\",\n  \"count\": 1\n}\n```\n\n2.\nPatients with BMI < 22 or patients with BMI > 35\n\n```\n{\n  \"name\": \"Double Dash\",\n  \"symbol\": \"--\",\n  \"description\": \"Dash (indicator of indefinite number or small importance)\",\n  \"count\": 2\n}\n```\n3.\nExperienced more than 5 serious adverse events\n\n```\n{\n  \"name\": \"Aperture\",\n  \"symbol\": \"\u00ae\",\n  \"description\": \"Trademark symbol (to identify trademarked goods)\",\n  \"count\": 1\n}\n```\n4.\nPatients with liver enzymes >3x ULN\n\n```\n{\n  \"name\": \"Ampersand (&)\",\n  \"symbol\": \"&&\",\n  \"description\": \"Amperand (indicator of inclusion or containment)\",\n  \"count\": 2\n}\n```\n\n## 5.\nPatients with >1000 U/L Alanine Transaminase (ALT)\n\n```\n{\n  \"name\": \"Minus (\u207b)\",\n  \"symbol\": \"\\\\-\",\n  \"description\": \"Minus (indicator of exclusion)\",\n  \"count\": 1\n}\n```\n\n6.\nPatients with >3x normal levels of uric acid\n\n```\n{\n  \"name\": \"Minus sign with line through the middle\",\n  \"symbol\": \"\\\\\u2212\",\n  \"description\": \"Minus sign with a line through its middle\",\n  \"count\": 2\n}\n```\n        \n## Exercise 2. You have chosen the following inclusion criteria by your clinical trial expert:\n\n1.\nLiver enzymes (elev",
        "label": 0
    },
    "1804": {
        "output": "- Excluded : exclude patient.\n- Not relevant : exclude patient.\n- Eligible : assess patient.\n\n# Examples\n\n# Examples<EOD> Prenatal sonographic diagnosis of fetal bilateral renal artery stenosis with mild ureteropelvic dilation: a case report\nWe describe a case of a bilateral renal artery stenosis diagnosed by prenatal sonography due to mild hydronephrosis. To the best of our knowledge, this is the first report of prenatal sonographic diagnosis of fetal bilateral renal artery stenosis.<EOD> Development of a method to monitor intravenous drug administration.\nA study investigating the reliability of a method using intravenous infusion administration carts and a data monitoring system has been conducted. A data monitoring system was installed into five intensive care units (ICUs) to monitor fluid flow rates and volumes. A cart-mounted flow controller was used for infusion administration, one to a patient and one to a control bag of saline. The difference between the flow rates of the infusion bags and the bags used as control bags were investigated to identify changes in fluid flow rates. This method was reliably able to identify changes in fluid flow rates throughout the four-hour session. The results of the study show this method to be a reliable method to monitor changes in fluid flow rates for intravenous drugs infused via an administration cart.<EOD> Methane emissions from the anaerobic degradation of oil and grease.\nTo describe the anaerobic degradation of oil and grease, the kinetics of the thermophilic oil-degrading, and the mesophilic grease-degrading mixed cultures A3 and VA were studied during batch experiments with a medium (V) consisting of acetate as carbon source, peptone as nitrogen source, and glucose as supplement to keep the pH near 7.0. The initial pH value was 7.0 in all experiments. The maximum specific methane production rate from oil and grease were 1.38 +/- 0.04 to 1.96 +/- 0.11 mmol-methane h(-1) g(-",
        "label": 0
    },
    "1805": {
        "output": "__Hints (for those who fail to submit trial-level eligibility)__\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. Also, try the following tips:\n- If an included clinical trial was given, pay attention to the inclusion criteria of that trials.\n- Remember: not only the patient meets the inclusion criteria must be output: you must also apply each exclusion criterion. \n\n\n\n\n**Trial ID: RHELP**  \n\n## Question-1: How to prepare files?\n\nFor the [training set](https://sites.google.com/view/rhelforjudgingdata/home), please prepare `patient_note.tsv` file, `inclusion_criteria.tsv` file, and a `rhc.csv` file in the [same directory as the original note data](https://drive.google.com/file/d/112x8qbGtKlLkKVdM4xN1k89xO9OQDn4zb/view?usp=sharing) and submit them to the assignment via [github issue]( https://github.com/dongilkim48/RHELP/issues/825).[/ENTRY]\n\n\nTo obtain the evaluation in the future, you should prepare both `patients_and_trials.csv` and `assessments.csv` files. We will use the [same training data](https://raw.githubusercontent.com/dongilkim48/RHELP/master/files/rhc.csv) for the test set and evaluate the performance of the trained model. \n\n\n### Files to download:\n\n\n\n| File                     | Description                  |\n| ------------------------ | -------------------------- |\n| [Patients_and_trials.csv  | Patients from the training data |\n| [assessments.csv          | Assesments for the training data |\n| [patient_note.tsv 20210918 | Patient note data 20210928 |\n| [inclusion_criteria",
        "label": 0
    },
    "1806": {
        "output": "You should not forget that you work on the dataset as the [name] [job] [unit]. In particular, this role includes the following.\n\n* Identify the patients.\n\n* Investigate the patient record.\n\n* Identify the patients who are eligible by trial number.\n\n* Add your findings to the database.\n\n**Task: Assistant for clinical trial recruitment** Let's think step by step...\n\n\n* Find out which patient has been assigned to this clinical trial, i.e., output a patient number.\n\n* Find out which patient would be excluded by the exclusion criteria, i.e., add an exclusion_code and value 1: Excluded.\n\n\n* If the patient is not excluded, but is not relevant, add `Clinical trial enrolment: Not relevant.`.\n\n* If the patient is eligible according to both the trial inclusion and exclusion criteria, add `Clinical trial enrollment: Eligible;` i.e., output the scale for the assessment of eligibility.\n\n* Let's confirm the output in the last line by `Trial-level eligibility: `. i.e., `Trial-level eligibility: 2) Eligible`.\n\n**Task: Assistant for clinical trial recruitment** Let's think step by step...\n\nLet's continue: *Find out how many patients are eligible for this clinical trial. (output 1): *\n![image](http://clincalc.com/Resources/Images/ClinicalNotesScreen1.PNG) \n\nFind out how many patients are eligible for this clinical trial. (output 2): Let's add another task for today as the [name] [job] [unit] in R [link]. 1) The number of patients that were screened for a specific trial and were eligible. 2) The number of patients that were screened for a specific trial and were ineligible from the beginning.\n\n**Task: Assistant for clinical trial recruitment** Let's think step by step...\n\n\n\n\n\n\n![image](https://www.cnet.com/reviews/microsoft-surface-pro-",
        "label": 0
    },
    "1807": {
        "output": "[INST] Once you find you can run the program successfully, you are given the following output: \nHooshmand, Ahmad Tajer, Manaf Taheri\nHepatitis and Liver Disease Research Center, Mofid Children's Hospital\nTehran University of Medical Sciences, Tehran, Iran\nIranian Journal of Medical Sciences\nJuly 2015; Vol 40, Issue 4, pp: 401-406\n\n\nNote: \nIt is a good idea for you to re-read the article by Dr. Taheri titled \"A case of Hepatitis C mixed cryoglobulinemia presenting as autoimmune pancreatitis\". The article is available online by clicking the following link. Once you open the PDF file, click on the arrows on the right and left of each page to go through the file:\nClick here\n\n\n\n---\n\nWe can write the pseudo code of our algorithms for step by step:\n\n```\ndef TrialLevelEligibility(trial_desc, patient_note):\n  \"\"\" TLE\"\"\"\n  # The output is a list of three values. The first value (1) is the scale of the output of the Trial Level Eligibility which is one if 2) Eligible, and otherwise is zero if 0) Not relevant or if 3) Excluded.\n  # We're going to evaluate the trial_desc and patient_note one by one until they are over\n  trial_desc_list = trial_desc.split()\n  patient_note_list = patient_note.split()\n  TLE_final = []\n  for trial_desc_item in trial_desc_list:\n    TLE_item = [0]\n    for patient_note_item in patient_note_list:\n        tup = process_trial_item(trial_desc_item, patient_note_item)\n        if tup[0] == '2':\n          TLE_item += [1]\n\n        elif tup[0] == '3':\n          patient_note_item = patient_note_item.replace(\"excluded\", \"\")\n          TLE_item_tmp = []\n          for note_item in",
        "label": 0
    },
    "1808": {
        "output": "<EOD> Influenza virus infection induces expression of stress proteins in the respiratory tract of the guinea pig.\nIn an attempt to discover the mechanisms which allow influenza viruses, which have no nuclear DNA, to induce the synthesis of host proteins, we studied the responses to infection of both guinea pigs and mice at the molecular and cellular level with a pathogenic PR8 variant (W211) which is attenuated in its capacity to replicate and induce pneumonia in the lung cells of mice which are deficient in a 2-5 A synthetase. The induction of beta-actin, nucleolin, heat shock protein 27 (HSP27) and HSP70 (immunoglobulin-binding protein or HSP40), but not alpha-tubulin, gp96 (HSP90 or ERp57) or HSP60 were determined with various host tissues. As previously reported in mice (Albanito et al., 1997), the level of nuclear translocation of the HSF is dramatically increased after influenza virus infection in the lung cells of guinea pigs. However, the transient expression of inducible HSP70, while similar in mice and guinea pigs, occurs later in the latter animals, i.e. between days 3 and 5 post infection, compared to the time frame of 6 to 36 h in mice. In contrast to our previous observation that, in the lung, influenza virus infection in interferon-receptor-deficient mice, which are deficient for alpha/beta and gamma interferon (IFN-alpha/beta and IFN-gamma), results in the absence of an induction of inducible HSP70 (He et al., 1996, Albarino et al., 1997), we show that this was also the case for the induction of HSP70 from this stress protein in the lung of guinea pigs infected with or intranasally instilled with either infectious viruses or ultraviolet (UV)-inactivated viruses (i.e. devoid of nucleic acid). The induction of the cellular heat shock response was also studied",
        "label": 0
    },
    "1809": {
        "output": "## Question 6\n[QUESTION] Given the following information:\n\nThe number of the first hospitalization for hypertension between 2010 and 2014, for both women and men. Also, the number of patients with a particular type of cancer between 2010 and 2013, sorted by age and gender.\nYour task is to select a subset from the first table for the columns: age, gender, and date of hospitalization in the selected column. You can write a script to do that if you need to do it programmatically. Also, you can select one row from the second table for each hospitalization.\n\nThe information is shown below: [INST] \n\n\n### [a] Write down the query to find a row in the first table that matches the second table (in the columns age, gender, and hospitalization date)\n\nWrite your query in the textbox below. Notice that you can use many conditions or filters, or use nested IF statements.\n\n```java\nSELECT *\nFROM Patient_hospital where (gender = 'm' and hospitalizationDate > DATEADD(MINUTE, -15, CAST(GETDATE() as DATE))) AND\n\t(Gender = 'f' and hospitalizationDate < DATEADD(MINUTE, -15, CAST(GETDATE() as DATE)))\n\n\n\n```\n[/a]\n\n### [b] Give an explanation for your query\n\nNotice that here, you have the `SELECT` clause, which gives the output of the query, not the query itself. Below we show you the sample output of the query, notice the columns `ID` and `Name`. The ID will be the Unique number of the patient row in the table and `Name` will be the name of the patient.\n\n```java\nSELECT T.gender,CONCAT('patient ',T.ID,')') AS PATIENT FROM Patient_hospital T ORDER BY T.hospitalizationDate DESC\n\n```\n[/b]\n\n### [c] Give an explanation for why or why not your second query would produce the same output\n\nHere, we have the `SELECT` clause and the second query gives similar output only. So if you have the same condition as your second query, you will get the similar output.\n\n```",
        "label": 0
    },
    "1810": {
        "output": "<EOD> The role of the liver in alcoholic cardiomyopathy.\nAlcoholic cardiomyopathy represents an important cause of heart failure and mortality and affects a large segment of the general population. The spectrum of heart disease, ranging from compensated cirrhosis with normal systolic function but abnormal diastolic function to overt dilated cardiomyopathy with low ventricular contractile function, is now well described. Unfortunately, the pathogenesis of alcoholic cardiomyopathy remains poorly understood. In the past decade, increasing numbers of studies have focused on elucidating the mechanisms of cardiovascular dysfunction in alcoholic cardiomyopathy. Abnormal myocardial calcium handling, mitochondrial defects, abnormal reactive oxygen species generation including those derived from the oxidation of ethanol and its metabolites, and a decrease in the number of nuclear estrogen receptors in the heart have been demonstrated to be involved in the pathogenesis of the cardiac complications of alcohol abuse. A critical review of the epidemiology, clinical features, and physiology of alcoholic cardiomyopathy is presented, with a focus on the role of the liver in this unique syndrome of heart failure.<EOD> Methylphenidate and transcranial direct current stimulation: Effects on attention and response inhibition in patients with major depressive disorder \u2013 An electrophysiological study\n\nA B S T R A C TBackground: Cognitive deficits and dysfunctional neuroplasticity are important features of major depressive disorder (MDD). Combination therapy with psychostimulants (e.g., methylphenidate, Mph) and transcranial direct current stimulation (tDCS) has been shown to be more superior in patients with impaired cognition compared with each monotherapy. However, the underlying mechanism is still unclear. We hypothesised that the effects of the therapies were related to changes in the cortical excitability and attention and inhibition.Methods: A total of 43 patients with MDD and 59 healthy participants completed a visual go/no-go task in",
        "label": 0
    },
    "1811": {
        "output": "Assignment can be repeated, until there are no unmatched clinical trials.\n\n```python\nimport pandas as pd\r\n\r\ndata = pd.read_csv(\"patient-data.csv\")\r\npatients = data[data[\"Is_included\"] == \"1\"]  # only patients included in the trial\r\ntrials = pd.read_csv(\"trials-data.csv\")\r\n\r\ndef assign_patient_to_trial(trial_data, patient_data):\r\n    for x in patient_data.index:\r\n        trials.loc[trials.index == x[0]]\r\n        patients_assigned_to_trial = len(trials[trials.index == x[0] & \"Trial-level eligibility\" == \"Eligible\"][1])\r\n        if patients_assigned_to_trial > patients_data[x[1] == trial_data['id']]:\r\n            patients_data[x[1] == trial_data['id']] = patients_assigned_to_trial\r\n            if patients[x[1] == trial_data['id']] == patients_assigned_to_trial:\r\n                patients[x[1] == trial_data['id']]",
        "label": 0
    },
    "1812": {
        "output": "[END]\n<EOD> C-reactive protein as a screening test for severe liver diseases and cirrhosis associated with hepatitis B and C\n\nObjective: Hepatitis B and C virus infections cause hepatic inflammation and fibrosis that may lead to cirrhosis and death. This study aimed to determine whether hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and/or C-reactive protein (CRP) can indicate advanced liver diseases or liver cirrhosis. Methods: CRP assays were performed on 1343 patients (1083 men and 260 women) who were negative for HBsAg but positive for hepatitis B core antibody (anti-HBc).",
        "label": 0
    },
    "1813": {
        "output": "<NAME> \n<EMAIL>\nClinEpi&BioStats \nDepartment of Mathematical Statistics and Actuarial Science\n\nUniversity of Illinois at Urbana-Champaign \nOne West Gregory Drive, Room 668A, Urbana, IL61801 \nChampaign, IL 61820 USA <EMAIL>\nWeb: www.ibe.uiuc.edu\n[fig]  INT ROLES: Patient ID: 000000000; Assistant: Hello; Trial-ID: CHBV-HCV01; Title: Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C\uff1aAn Open-label Control Study in China; Summary: Background Hepatitis B virus (HBV) co-infection in individuals with hepatitis C virus (HCV) can enhance the severity of hepatitis and the risks of liver cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B vaccine is an effective measure to prevent HBV infection. Whether patients with HCV infection have non-protective antibody responses to hepatitis B vaccination more frequently than healthy subjects is still controversial and studies about cytokine response have been seldom reported.~Methods Not-in-treatment patients with chronic HCV infection and 1:2 community/gender matched healthy control were obtained from a community-based screening. All participants received three doses of hepatitis B vaccine (20 \u03bcg HBsAg/ml/dose) on 0, 1 and 6 months schedule. Anti-HBs was tested 1 month after the third dose of vaccination and was compared between two groups. Spot-forming cells (SFCs) of interferon-\u03b3 (IFN-\u03b3), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-6 (IL-6) produced by lymphocyte were tested by enzyme-linked immun",
        "label": 0
    },
    "1814": {
        "output": "```python\nTrial_level_Eligibility = 1)\n```  \nYou can check the results with the last few lines of the output. Also, the  file `submissions/2019-4189_submission.txt` and `4189_response_review_final_response.pdf` contain details of the submission. You can investigate whether the patient meets the inclusion criteria or not in these documents. :point_right:\n\n\n```python\nTrial_level_Eligibility\n```  \n\n<div id=\"bottom_nav_menu_content\"><a name=\"bottom_nav_menu_content\"></a>\n<h4>Bottom navigation menu</h4>\n<p>Congratulations. You have fully finished the tutorial. \n</p>\n<ul class=\"nav nav-pills nav-justified flex-column flex-sm-row\">\n          <li class=\"nav-item nav-header nav-header-top nav-link\" href=\"index.html\">\n            <a class=\"nav-link\" target=\"_top\" >Home</a>\n          </li>\n          <li class=\"nav-item nav-header nav-header-top nav-link\" data-parent=\"#bottom_nav_menu_content\">Next</li>\n          <ul class=\"nav nav-pills flex-column flex-sm-row\" data-parent=\"#bottom_nav-tabs2\" data-child-menu=\"#bottom_nav-tabs2-nav\" data-toggle=\"pill\">\n            <li class=\"nav-item nav-header nav-header-top nav-link\" href=\"Tutorials.html\">Tutorials</li>\n            <li class=\"nav-item nav-header nav-header-top nav-link\" href=\"Instructions.html\">Instructions</li>\n          </ul>\n          <li class=\"nav-item nav-header nav-header-top nav-link\" href=\"#documentation2\">Documentation</li>\n          <li class=\"nav-item nav-header nav-header-top nav-link\" href=\"APIInfo.html\">API Info</li>\n          <li class=\"nav-item nav-header nav-header-top nav-link",
        "label": 0
    },
    "1815": {
        "output": "To give an example, here is your final trial report if you enter the code of #1:\nTrial report #1 (click here to open):\nPatient #1: ID:08\n\nPatient note\n\n---\n\nPrevious screening\nMale; aged 55 years; a heavy smoker for 40 pack years with a history of alcohol abuse, HCV-related cirrhosis.\n\nPrevious treatments\nHistorical treatments and adverse events (AEs)\n- 1992\u20131996: Interferon (IFN)-based therapies, with complete viral suppression\n- 1997\u20132004: ribavirin (RBV) 600 mg daily, and IFN-\u03b1\n- 2005\u20132013: IFN-free regimen with 24 weeks of Peg-IFN-\u03b1 and RBV and then 24-28 weeks of pegylated-IFN-\u03b1 and RBV\n- 2014: IFN-free regimen: pegylated-IFN-\u03b1 and RBV for 52 weeks\n\nPast clinical history\n\n---\n\nFamily history\n- no clinical history of cardiovascular disease or kidney disease in the family\n- no history of diabetes in the family\n\nHistory of alcohol abuse\nNo history of alcohol abuse or other addictive habits\nOccupation\n\n---\n\nLiving conditions and daily habits\nThe patient was born in France. He moved to Canada in 1996. Current job: cook. Housing conditions: he never had a roommate, is in the habit of having sex with men, never shared living space with roommates or people who injects drugs, never used a syringe or injected illicit drugs. Tobacco and alcohol abuse: He has smoked more than 35 pack years, stopped smoking in 2008. \n\n---\n\nConcomitant diseases and addictions, including alcoholism\nEvaluated by clinical examination, biological assessment, chest x-ray and abdominal ultrasound",
        "label": 1
    },
    "1816": {
        "output": "## [END]<EOD> Preliminary Report of Laryngeal Cancer Among Aboriginal and Canadian Rural Residents in Alberta and Saskatchewan\nPurpose This study was undertaken to characterize and contrast the laryngeal cancer experience among Aboriginal and rural Canadian populations with corresponding non\u2013Aboriginal cancer patient populations. Participants and Methods Retrospective data were abstracted from the North American Indian Cancer Registry (NAICR) and the 2 provincial cancer registries (Alberta Cancer Registry  and the Saskatchewan Cancer Registry ). The rates of laryngeal cancer observed among all Aboriginal residents, compared with non\u2013Aboriginal rural residents of Alberta/Saskatchewan and non\u2013Aboriginal urban residents elsewhere in Canada, were examined. Results A total of 528 laryngeal cancers were identified: 205 patients were First Nations (18.9% Aboriginal), 198 were M\u00e9tis (18.4% Aboriginal), 123 were non-First Nations and non-M\u00e9tis Aboriginal (11.0% Aboriginal), 115 were Alberta urban non-Aboriginal (9.2% Aboriginal), and 97 were Saskatchewan rural non-Aboriginal (9.0% Aboriginal). Compared with non-Aboriginal urban residents elsewhere in Canada, Aboriginal subjects from all study locations had increased laryngeal cancer rates (standardized incidence ratio  R: NAICR, 2.60; BCR, 1.05; SACR, 1.11). The standardized incidence ratios for laryngeal cancer for rural versus urban non-Aboriginal subjects were 1.48 and 1.40, respectively, in BC and SACR studies. Conclusion There appeared to be a significantly elevated risk of laryngeal cancer among Aboriginal subjects.<EOD> .\nBACKGROUND\nA significant proportion of elderly people are diagnosed as having psychiatric disorders; in our country, among those > or = 65 year-old, 8.9% have been diagnosed with a psychiatric disorder. Some of them also receive help for",
        "label": 0
    },
    "1817": {
        "output": "##<jdoc::end if><jdoc::end if><text xml:space=\"preserve\" noresults>\nFor instructions on how to implement the other criteria, click on the respective links below.\n- [INST] The Inclusion Criteria: Patient demographics.\n- [INST] Inclusion Criteria: Patients` health status.\n- [INST] The Inclusion Criteria: Clinical history.\n- [INST] Inclusion Criteria: Laboratory tests.\n- [INST] Inclusion Criteria: Medication. \n\n### References\n```text\n<EOD> .\nObjective: To investigate the value of different degrees of acanthosis and dysplasia on tissue pathology in predicting prognosis of patients with low-grade squamous intraepithelial lesions (LSIL) and squamous cell carcinoma in situ (SCIS) of cervix. Methods: Clinical and pathological materials from 210 cases of patients with LSIL and SCIS were collected. The pathological types of cervical biopsy were classified as 0-III degree. The 0-I degree was defined as no change in basal cells, II-II as slight AK, and \u2162 as severe AK. The 0-I degree was defined as no change in high level, \u2161-II as slight dysplasia, and \u2162 as severe dysplasia. The patients were followed-up until 60 months after the operation. The endpoints included 5-year disease-free survival rate (DFS), recurrence and progression. K-M method was used to analyze DFS rate, log-likelihood method to compare DFS rate and Fisher's exact probability method for unordered categorical data. The survival curve of 60 months was drawn by R program. Results: For LSIL and SCIS, the endpoints were all significantly correlated with different degrees of ac",
        "label": 1
    },
    "1818": {
        "output": "Trial-level eligibility: 2) Eligible.\nCodes: 0-excluded, 1-not relevant, 2-eligible\n\n# Test cases\nUse the given test cases to test your solution. Don't look at the solution for now. \nTEST CASE: 00047733\nPatient notes:\n[INST] Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP 130/75 and HR 90 pound 2 minutes pound /hour and BMI 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nMatthew W. \n\nCodes: 0-excluded, 1-not relevant, 2-eligible\n\nTEST CASE: 00047735\nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n[INST] Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\nThe patient is a 38-year-old man with a history",
        "label": 0
    },
    "1819": {
        "output": "</p>\n\n\n<h3>1.1.4 Implementation of Clinical Trial</h3><p>\nNow it's time to implement the trial code, i.e., ClinicalTrial.py \n<br><br>\nThe implementation is written from scratch. We used Turtle from<a href=\"http://docs.turtlemodels.net/#imaginary\">Imaginary</a> to visualize the process of the patient's eligibility assessment. \n\n<img src=\"https://user-images.githubusercontent.com/49277969/110413850-2457bb80-8541-11eb-8327-400ff300bb64.png\" width=\"557\" height=\"2434\" alt=\"Imaginary in Nb_c2c model\" /><br><br>\nClick on the image below to view the code.\n<p><img src=\"https://user-images.githubusercontent.com/49277969/110416478-1ec68df8-854acb0-8ecc-8ad1-f1b48b2ce959.jpg\" width=\"557\" height=\"199\" alt=\"Imaginary in Nb_c2c model\" /></p><br><br>\nNow we will see how the eligibility assessment process for the patient works. \n\nFirst, we define the ClinicalTrial class.   \n<p>\n<code><pre>\nclass ClinicalTrial(object):      \n    def __init__(self):\n        self.Name = \"\"\n        self.CodeNumber = \"\"\n        self.DateOfEnrollment = \"\"\n        self.Location = \"\"\n        self.ClinicalTrials = []            \n        self.Participant = []            \n        self.FollowUp = \"\"\n        self.Title = \"\"\n        self.Summary = \"\"\n        self.Objectives = \"\"\n        self.StudyDesign = \"\"\n        self.TrialSite = \"\"\n        self.",
        "label": 1
    },
    "1820": {
        "output": "<section class=\"instructions\">Let's apply our solutions to the same scenario. Below are your solutions. The first sub-section is for [INST], and the second is for the task [O].\n\n> ## Instructions: {0,1}\n> ## {1}\n> ### Tasks\n>\n> Use this form to enter your solution. Enter `q` to quit. {0,1}\n> \n> - **Task 0**: [001] Asses patient eligibility\n>     (\n>     0) Assess patient eligibility in Trial01\n>     1) Assess patient eligibility in Trial02\n      \u2026\n> \n> - **Task 1**: [010] Compare patient record and trial inclusion criteria to determine patient's  eligibility\n>     (\n>     0) Determine patient-level eligibility in Trial01\n>     1) Determine patient-level eligibility in Trial02\n      \u2026\n> \n>\n>\n> ## **Solutions:**\n> ## {0}\n> ### Tasks\n> \n> 0) Assess patient eligibility in Trial01\n>\n> ```python\n> print(\"Excluded\")\n> patient[\"Trial_Eligibility\"] = 0 # Excluded: in Trial01\n> print(patient)\n\n> print(\"\")\n> print(\"Excluded\")\n> patient[\"Trial_Eligibility\"] = 0 # Excluded: in Trial01\n> print(patient)\n\n> print(\"\")\n> print(\"Excluded\")\n> patient[\"Trial_Eligibility\"] = 0 # Excluded: in Trial01\n> print(patient)\n\n> print(\"\")\n> print(\"Not relevant\")\n> patient[\"Trial_Eligibility\"] = 1 # Not relevant: doesn't have enough information\n> print(patient)\n> ```\n\n> 1) Assess patient eligibility in Trial02\n> \n> ```python\n> print(\"Not relevant\")\n> patient[\"Trial_Eligibility\"] = 1 # Not relevant: doesn't have enough information",
        "label": 0
    },
    "1821": {
        "output": "~[END]\n\n_We recommend working through sample code 20_2020.ipynb before submitting your solution._ You can also find the solution at _[exercises_solutions_2020][EX20SOL], for your convenience.\n[ex20input] <jupyter_code>input(\"Enter the patient note as a string.\")<jupyter_output>Enter the patient note as a string.:\n[<code>\nHCV Abpositivity\nIFN and RBV treatment\n\nInsufficient information to decide\n\nIneligible</code>\n\n]\n[ex20output] <jupyter_text>\n- 2020-10: [0] Input and [4] Output values are all strings.\n- 2020-11: Replace all spaces with underscore characters.\n- 2020-12: Replace all underscores `with_characters` with the string `_`.\n- 2020-13: Replace `and` with `&` and `from` with `from_` and `to` with `to_`.\n- 2020-14: Replace the word spaces with ` space`.\n- [START] Trial-level eligibility: <jupyter_code>patient_note_str = [\n \"HCVAbpositivity\",\n \"IFN and RBV treatment\",\n \"Insufficient information to decide\",\n \"Ineligible\"]\n\nprint(\"Input the trial note as a string.\")\ntry:\n    patient_note = patient_note_str.encode_url()\nexcept ValueError:\n    print(\"Invalid string! Enter the trial note as a string.\")\n\nprint(\"[Trial_name]:\", \"HCV-Infection after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation\")\ntrial_name = patient_note\n\nprint(\"[Trial_number]:\", 1)\ntrial_number = 1\n\npatient_note = patient_note.replace(\"and\", \" &\")\npatient_note = patient_note.replace(\"from\", \"from_\")\npatient_note = patient_note.replace(\"to",
        "label": 0
    },
    "1822": {
        "output": "# Additional Information\n<EOD> Pregnancy Outcomes in Systemic Sclerosis: A Prospective Study\nObjective. To analyze the outcome of pregnancy in patients with systemic sclerosis (SSc, CREST or Duvigneaud's variant) using the European Systemic Sclerosis Group Disease Activity Index (ESSG) as a clinical index of activity. Methods. A cohort of pregnant patients was recruited from the database of the International Systemic Sclerosis Pregnancy (SIP) Study in all 21 participating centers. Pregnancy outcomes and clinical status were recorded at study entry and every 3 months during pregnancy and for 6 months postpartum. The SSc outcomes were compared with a matched cohort of patients with systemic lupus erythematosus who were pregnant in the corresponding time period. Results. Seventeen SSc patients were recruited from 21 SSc centers; of those, 12 had disease activity. The outcome of pregnancy was similar to that of systemic lupus erythematosus patients and normal healthy subjects, with a frequency of spontaneous abortions and stillbirths of approximately 30%, rates of obstetric complications that were comparable with those observed in the general US population, and delivery of full-term, live-born infants after a normal gestation. Of 9 mothers and 11 offspring who presented with disease activity during pregnancy, 7 mothers returned to disease remission postpartum. Conclusion. Our results confirm the previous observations that disease activity is uncommon, infrequently leads to major obstetric complications, and can regress after delivery in women with SSc. The frequency of spontaneous miscarriages at first and second trimesters and stillbirths seems to be higher than in the general population and therefore requires special attention. The results of SIP should be validated in a larger series, especially regarding disease activity, by using the SSc disease-specific instruments recently validated.<EOD> Insecticide-treated bed nets in rural Mozambique: patterns of intended and actual use\n\nBackground: In sub-Saharan Africa, insecticide-treated bed nets (",
        "label": 1
    },
    "1823": {
        "output": "1) Data types are defined as `data_type: \"variable-type\";`, e.g., `data_type: \"variable-type\";`.\n2) A variable is defined as `variable: [variable-name]`, e.g., `variable: patient.id;`.\n\n# Method\n\nWe use the following code to create a Trial object: `my-trial = s3f.trials.Trial(...)`. \nNow, we add a variable to our Trial object `variables_list` named `subject_id`. As we read from the patient_table, the variable is called subject_id. \n\n```python\n    ## Add subject_id to the variables list ##\n    variables_list = Trial.variables_list + [subject_id]\n```\n\nThen, we read about the trial variables. To do so, we use the `get_info` method to retrieve the variable type of a particular patient. If the variable type is `variable-type.Categorical`, then we apply the `.split` method on it. Each split gives a variable name and a list of values. When a patient is not eligible into a trial, then the response is empty. We save the value as `data: [list_values]`, then the response is `None`. We save the response on our `trial` object. \n\n```python\n    ## Add the trial variables ##\n    trial.variables_list = trial.variables_list[:] + list(re.findall('data: [^\\\"]+\\\"([^\"]+)\\\"\\s(?:[\\\"'])(?!).*', trial.get_info('variables')))\n```\n\nNow, we create a TrialData object to fetch all the details about the patients like demographics, visit details and the treatment details. To do so, we need information from the patient_table, the visit_table, the drug_table and the trial_table. We need information from the patient's visit. The visit table contains information about drug administration, blood sample, and follow-up visits.\n\n```python\n    ## Create a TrialData object ##\n    trial = s3f.trials.Trial('TrialName', 'TrialInfo')\n    trial.trialdata.query_data('TrialName', '",
        "label": 0
    },
    "1824": {
        "output": "<EOD> Palladium-catalyzed oxidative sulfurylation of alkynes: a route to sulfone-functionalized arenes and heterocycles.\nPalladium-catalyzed oxidative thiolation and sulfuration of alkynes has been achieved under mild reaction conditions. The reaction can be accomplished via formation of inorganic sulfide, disulfide or sulfite intermediates from sodium sulfide, sulfur and sulfite salts or elemental sulfur.<EOD> Transition state geometries as derived from Eyring plots.\nAn expression for the dissociation energy of transition state (TS) geometries from an Arrhenius plot, obtained using a first-principle method, is presented. The dissociation energy is taken as the difference between the energy of a TS and the sum of the energies of all structures along the reaction coordinate. The expression presented does not need any input data for the calculation of the energy levels of the TS geometries and may be used as such to estimate their relative stabilities. We applied the expression to four TS geometries, obtained by exploring the TS region of the ethene-->ethyne isomerization reaction by the basin-hopping algorithm. Two of the TSs are found to have a higher dissociation energy than those predicted by conventional methods.<EOD> The Effect of Aging on the Responsiveness to Fluid Loading and Valsartan Therapy in Hypertensives\nAims: This study evaluated the effects of aging on hemodynamic response to the fluid-loading test and Valsartan therapy on essential hypertensives. Methods: Patients with essential hypertension were evaluated using ambulatory blood pressure monitoring (ABPM) and the fluid loading test prior to study enrollment. The fluid-loading test was performed by intravenous (1-ml\u00b7kg\u22121\u00b7min\u22121) administration of 0.9% saline over a 5-min period. The postfluid-loading response, including systolic and diastolic blood pressures and heart rate, were measured sequentially 5, 10, 15, and 30 min after fluid loading. Valsartan was given orally for 8 weeks; ABPM, the fluid-loading test, and",
        "label": 0
    },
    "1825": {
        "output": "\u00a9 2019 by the American Psychological Association. 2019, 69(6): 712\u2013733\n\n<EOD> Complementary and Alternative Therapies for Mental Disorders in Children and Adolescents: A Literature Review to Inform Practice Guidelines\nObjective. To conduct a literature review of complementary and alternative medicine (CAM) and mental disorders in children and adolescents, in conjunction with a mental health working group, convened by the National Institutes of Health's Office of Alternative Medicine. Method. Review of a selection of relevant Cochrane Collaborative reviews, the systematic reviews of the Agency for Health Care Policy and Research, the Pediatrics Branch of the University of Maryland's CAM Evidence Review Program, and publications in peer-reviewed journals. Results. Twenty-five articles published over the past 10 years were reviewed. CAM modalities for which there is some evidence include dance movement therapy, guided imagery, acupuncture, dietary supplements, massage, mindfulness therapies, and relaxation. Conclusions. Several areas of interest deserve further exploration. Randomized controlled trials are needed to determine efficacy and usefulness of these modalities.<EOD> T162. RELATIONSHIP BETWEEN ATYPICAL AND TYPICAL PSYCHOSIS: MODERATING EFFECT OF EXCESS WEIGHT, ESSENTIAL TREMOR\nAbstract Background The co-occurrence of atypical (ATYP) psychosis with other psychiatric symptoms (i.e., depression, anxiety) and/or cognition (i.e., executive functions impairment, processing speed deficit) is often observed. In order to evaluate whether these symptoms/cognition were related to each other, we performed a correlational study on ATYP and TRP, both with impairment in cognition. Atypical psychosis, as compared to TRP. At variance with the latter, ATYP patients presented comorbidities (e.g., depressive symptoms, anxiety symptoms, poor sleep quality, etc.), impaired cognition and neurological symptoms. In this study, we evaluated",
        "label": 0
    },
    "1826": {
        "output": "[INSERT TABLE: Table:Clinical_trial/Table3]\n\n**Table 3: Eligibility**\n\n\\begin{r}\nSELECT eligible_id, eligible_value, trial_id FROM clinical_trial_eligibility WHERE trial_id != 0 \nORDER BY trial_id DESC, eligible_value DESC;\n\\end{r}\n\n**Question**\n\nYou have to complete the following table so that it is exactly the same as Table:Clinical_trial/Table3.\n\n\n\n\n\n[/INSERT TABLE]\n\n[INSERT TABLE: Question/Table5]\n\n\n**Table 5: Eligibility** \n\n\\begin{r}\nSELECT eligible_id, eligible_value, trial_id FROM clinical_trial_eligibility WHERE trial_id == 0 \nORDER BY trial_id DESC, eligible_value DESC;\n\\end{r}\n\n**Question**\n\nIn the question, each patient has some symptoms and signs, which can be used as the factors to judge the eligibility. The values of those factors include the following cases:\n\n<table>\n<thead>\n<tr>\n<th>Value</th><th>Description</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td width=\\thin \\vrule width\\textwidth>0</td><td>Excluded</td><td>-3</td></tr>\n<tr>\n<td></td><td>Not relevant</td><td>-2</td></tr>\n<tr>\n<td></td><td>Eligible</td><td>-1</td></tr>\n<tr>\n<td></td><td>Include</td><td>1</td></tr>\n<tr>\n<th colspan=3>Not Applicable</td></tr>\n</tbody>\n</table>\n</body></html><EOD> Involvement of adiponectin/AMPK/p38 MAPK and PGC-1\u03b1/SIRT1/PPAR\u03b1 pathways in the protection of human fetal membranes against amniotic fluid lipids",
        "label": 0
    },
    "1827": {
        "output": "## [TARGET-1] -[INST] What is your best guess for the overall sample size of this trial to recruit 180 participants (120 TN and 60 TE)? Please check your answer with the number of completed participants.\n\n### 1.28\nThere are two variables to consider when discussing sample size. One is the number of centers in the trial. The larger the trial, the bigger the chance of recruiting enough eligible patients from different centers. The other is the number of participants needed in each trial arm. The sample size should be appropriate to allow the detection of the effect size in question. This is the so-called power analyses. In the first study, we will have 527 patients, and we want to be able to detect a difference in the effect size of 0.41 (Cohen's d, also known as standardized mean differences, SMD) with a power of 80% and a two-sided significance level of 5%. This corresponds to a sample size of at least 265 (not taking into account the clustering effect that we need to control for).\n\n# Discussion:\nOne thing you should always keep in mind when doing sample size analysis is that the effect size differs according to the clinical trial design. In a randomized controlled trial (RCT), we need to compare the new experimental drug with a given control group (e.g., an approved drug or placebo) and assess statistically significant differences of the two groups.\nHowever, the study design that we set here is a non-RCT. Also known as an open-label trial. These are studies where patients are already taking standard-of-care treatments but are randomized to receive them with or without the experimental drug. In non-RCT, it is more difficult in designing the study and recruiting appropriate eligible respondents to obtain enough statistical power because each patient does not need to have their baseline characteristics matched to those in the control group. In addition, since both treatment arms are used, the total number of patients included in this study is more than that in the RCT. Therefore, the effect size of difference in the outcome is smaller than in RCT, which is the reason for our sample size analysis.\n[REFERENCE 2 -INST] For R",
        "label": 0
    },
    "1828": {
        "output": "<jupyter_code>trial_note = ['This patient has no cirrhosis and has not had HCC found on biopsy.',\n                                    'The patient does not have hepatic decompensation.',\n                                    'This patient does not have HBV coinfection or evidence of cirrhosis or HCC as described in the note.',\n                                    'A biopsy was negative for HCC or other pathology.',\n                                    'The most recent patient note for this patient revealed negative diagnostic for HCC.']\ntrial_exclude = ['BMI > 22.', 'This patient does not have any evidence of cirrhosis. There is no reason to treat, since the HCV will likely clear spontaneously.']\ntrial_relevant = ['This patient does not have HCC confirmed by biopsy.',\n                    'The patient has an elevated ALT, but the patient does not have any of the other clinical features of cirrhosis (such as ascites, jaundice, clay colored stool, and enlarged/painful liver) that necessitate treatment.',\n                    'This patient does not appear to meet the criteria for treatment unless HBV coinfection is present, since a previous HCV RNA was positive and HCV antibody positive; that is, chronic active HCV with sustained viral load or evidence of chronic active HCV for at least 6 months.',\n                     'This patient does not have any evidence of HCC or liver decompensation, which is not indication for treatment.']\ntrial_eligible = [trial_relevant[t for trial_note in trial_note]]\nprint(trial_eligible)\njupyter_output\n['0) Excluded', '1) Not relevant',\n '1)  Not relevant', '0) Not relevant',\n '0)  Not relevant']<EOD> Association between 24-hour ambulatory blood pressure and blood pressure variability and cardiovascular events in the general hypertensive population: A prospective study.\nBACKGROUND\nThe association between ambulatory blood pressure (BP) and the occurrence of cardiovascular events is unclear.",
        "label": 0
    },
    "1829": {
        "output": "<EOD> Effect of antimony compounds on oxy-reductase system during induction of erythrocyte osmotic fragility.\nThis study is concerned with the relationship between oxy-reductase system and osmotic fragility in erythrocytes. An investigation of the action of antimony (Sb) compounds upon the oxy-reductase system was carried out in an experimental animal, rats. Aqueous solution of stibogluconate (SG) (a representative Sb compound) with various concentrations were injected into the rats and their erythrocytes were incubated in vitro with the compounds. The induced increase in osmotic fragility of those erythrocytes (osmotic fragility index) was investigated. Aqueous solution of SG at concentrations greater than 1 mM was found to induce erythrocyte osmotic fragility and to decrease the residue of NADH. The effects of SG on oxy-reductase activity were thus examined using an enzyme preparation; the activity was found to be inhibited by SG. The increase in osmotic fragility and the activity of oxy-reductase during induction of osmotic fragility of those rat erythrocytes following the administration of different types of Sb compounds with each administered for a different period of time were also investigated. An increase in osmotic fragility of rat erythrocytes in parallel with the inhibition of oxy-reductase by Sb compounds was found. The enzyme activity was restored after the injection was stopped. The effects of Sb compounds upon the content of NADH and ATP and the activity of Na+ and K+ ATPase were also examined.<EOD> Prevention and Rehabilitation of Work-Related Musculoskeletal Disorders Among Nurses\nAn increasing number of healthcare agencies around the world are focusing on the problems caused by work-related musculoskeletal disorders (WRMSDs)1 and, in particular, on improving the rehabilitation process for workers who have been affected. Although the concept of disability usually refers to physical impairment, we have a tendency to overlook the mental and social aspect of a",
        "label": 0
    },
    "1830": {
        "output": "[END]\n\n<h5 id=\"Slide08\"> Exercise 8 </h5> You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded by the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the three-scale for the assessment of eligibility. \n\nHere are the patient's medical record:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n<!-- Toc figures end -->\n<h4 id=\"Evaluation\"> Step-wise Evaluation and Assessment </h4><ul>  <ol> \n<li>Slide 4: \n<br> \nThis slideshows the",
        "label": 1
    },
    "1831": {
        "output": "- [RFC] Determ",
        "label": 0
    },
    "1832": {
        "output": "### Explanation\n- Option A: This option is incorrect because whether a person smokes or not is not a factor that directly affects the trial because you only have to focus on low platelet count. [Correct Answer]\n- Option B: This option is incorrect because you should focus only on gender, and no other conditions are involved. [Incorrect Answer]\n\n*Answer Explanation*\n\n- The correct answer is Option C. All of the other options are incorrect. Based on the information that we have, Option B is most likely to be correct, but the other options can also be considered. Option B involves \"if they have. \" Therefore, Option D or E is not correct in this case. Option C involves \"if. \" Therefore, Options A, B, or C are not correct. Option E is irrelevant since it is not a study of the biomarkers, but a study of a patient's medical care. Therefore, Options A, B, and D are all not correct. Options A and B are also incorrect since you are looking for both a history of diseases or conditions as well as the treatments of those diseases. The history of diseases or conditions are also not listed in any of these options, either. Therefore, none of the choices are correct.\n\n### Explanation\n- Option D: This option is incorrect because whether a person smokes or not is not a factor that directly affect",
        "label": 1
    },
    "1833": {
        "output": "You should submit your patient note, your eligibility assessment for the clinical trial, and your eligibility for the clinical trial to the instructor. The instructor should return scores for the eligibility assessment of the clinical trial and your trial-level eligibility.\n\nThe patient's eligibility assessment for the clinical trial is 1) Excluded.\n\nYou should also include your eligibility assessment for the clinical trial as well as the eligibility assessment of the clinical trial in your patient note. In the case of the previous patient note, you should make sure to assess and write the trial-level eligibility for the clinical trial in the last line and you should make the following changes in the patient note:\nThe patient is still a 55-year-old man, diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP:110/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. You should make sure to include the following items in your patient note:\nAge: 55 years old.\n\nAffects: Male.\n\nReason for encounter: You should describe a reason why you decided to meet the patient (e.g., abnormal test results on a screening test, the patient has a positive screening test, and a request from the patient's doctor).\n\nPast medical history: Negative",
        "label": 0
    },
    "1834": {
        "output": "# Introduction\n[INST] You get inpatients by using their record number as input. Then you should collect the details of the inpatients from their data files (e.g., file name, number of items, patient ID, patient name, patient age, and patient sex).\n\n## Record number\n\n## [IN-PUT] As shown above, input patient id and move to the next window. if you skip this input value, you will not move to the next window. a green cross indicates the patient id as input. [/in-put]\n\n# Output\nWe will generate output with patient data and treatment options for you as you input the requested values.\n\n## Treatment options\nTreatment options (also known as the options for medications administered during care) is the action for choosing or giving medication or therapy to patients. There are six treatment options such as Treatment name, Duration, Preferred dose, Frequency, Route of administration, and Regimen type. The drug information file is loaded from `Drug Information System` module as the source file in the system. It has drug and patient information linked to each other. As the output, we will give the drugs and dosages which satisfy the treatment options. A treatment option table for a clinical record of patients will be displayed as an example.\n\n## Output of the treatment options\nClick the submit to save the treatment options as patient data and show patient information and treatment options in a tabular form, as shown in Figures 3-5, following.\nClick the submit twice in order to save the treatment options as patient data.\n\n## Treatment\nYou are a doctor with a long career working in the field of internal medicine. By examining laboratory results, you are able to tell the patients about the treatment plan.\n\n## The patient's clinical history and laboratory findings\n\n## [in-PUT] As shown above, input patient id and move to the next window. if you skip this input value, you will not move to the next window. a green cross indicates the patient id as input. [/in-put]\n\n# Output\nWe will generate output with patient data and treatment options for you as you input the requested values.\n\n## Treatment options\nTreatment options (also known as the options for medications administered during care",
        "label": 1
    },
    "1835": {
        "output": "[CODE]\n\n#import os\nos.system(\"w\")\nos.system(\"nohup python file_name.py &\")\n\nclass Patient(object):\n  def __init__(self, patient_data):\n    super().__init__()\n    self._patient_data = {}\n\n  def get_all_patients_notes(self, patients_note):\n    patients_note_dict = {}\n\n    for patient in patients_note:\n      patient_notes = json.loads(patient[\"patient_note\"])\n\n      for note in patient_notes:\n        patients_note_dict[\n            (note[\"field_number\"], note[\"field_text_noescape\"])] = patient_data[note]\n\n    return patients_note_dict\n\n  def validate_eligibility(self):\n    self._notes_file = open(\"eligibility.json\", \"r+b\")\n    patients_note_json = json.load(self._notes_file)\n\n    for patient in self.get_all_patients_notes(patients_note_json):\n      trial_num_json = patients_note_json[str(patient[\"patient_id\"])][\"trial_num_json\"]\n      with open(\"eligibility.json\", \"r+b+\") as file:\n        if trial_num_json:\n          file.write(f'\\t\"trial_id\": {trial_num_json[\"trial_id\"]}\\n')\n          file.write(f\"\\t\" * (5 + len(trial_num_json[\"trial_id\"])) + '\\n\\n')\n          file.write(f\"Patient:\")\n          file.write(f\"\\t{patient:j}\")\n          file.write(f\"\\n\\t\"\n          * (7 + len(json.dumps(trial_num_json))) + '\\n')\n          file.write(f\"\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tEligible (0)\\n\")\n        else:\n          file.write(f'\\tEligibility: Not Evaluated \\n')\n\n    file.write(",
        "label": 2
    },
    "1836": {
        "output": "A: Use some customized templates to automate your task.\nThis is the customized templates I have for the assessment of eligibility output (the code will work with the latest Excel):\n\n\n*\n\n*eligible templates:\n\n\n*\n\n*[A1] = 165\n\n*[A2] = 53\n\n\n\n*\n\n*\n\n*[A4] = 210\n\n\nAnd other excel templates to show ineligibility for each exclusion criteria (if exist) such as [A3] and [A5]:\n<EOD> Photo-Responsive and Reversible Control of the Properties of Nanoimprinted Gel Network Films.\nBiomimetic gel films are capable of providing many of the features of soft tissue including mechanical deformability, optical transparency, and biocompatibility. These properties make them attractive as the basis for active and biomimetic soft systems. Herein we demonstrate that by introducing a molecular switch on the side chain of gelatin molecules in the gel network, we can dynamically alter gel properties upon photoirradiation with light of 365 nm, which selectively binds the -NH2 group to a vinyl group of a pyrrolinone molecule. Our approach makes use of the thermally responsive gelatin biomaterial, which can be imprinted into a soft and transparent film, as well as the molecular switch that absorbs light in the NIR region and, upon photoactivation, changes the cross-linkage density of gelatin. Optical control of gelatin molecules' cross-linkage density permits a reversible phase change between elastoplastic states without changing the gelatin concentration. In the activated state, gelatin gels are stiffer and less deformable and have greater contrast and sharper edges. This molecular mechanism for the photo-induced phase change exhibits potential for many applications including the development of smart and transparent soft systems for use as biomimetic actuators, sensors, displays, and soft robotics.<EOD> .\nTo clarify the role of GFAP in the pathogenesis of autoimmune encephalitis, we examined three patients with encephalitis and autoantibodies to GFAP, using conventional",
        "label": 0
    },
    "1837": {
        "output": "[TASK] There may be more. Please consider the following as well.\nIdea: There are more cases you have to verify. Can you come up with a system design that considers the verification of all cases in an end?\n\n\n\nHopefully, that is all I need to do. If you are familiar with any of the libraries listed in the Table `Library Information `, please be sure to refer to them: Java, Python, and R/S4. The details are explained in the Table `Library Information `. \n\n\n\n### Reference\n\n * Copyright \u00a9 2016 by the American Psychiatric Association. All rights reserved.\n  ACC/AHA 2008 guidelines for management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the\n  ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: Executive Summary: A report of the American College of Cardiology/American Heart Association\n<EOD> NIR absorbing molecules and photothermal therapy.\nBACKGROUND\nDespite the clinical success of photodynamic therapy (PDT) and the intense research on the use of photothermal therapy (PHT), only a limited number of clinically important photothermal agents exist: the absorbing pigments hematoporphyrin, hypericin and others in the near infrared region. These pigments, however, do have some inherent properties and limitations.\n\n\nMATERIAL/METHODS\nThe author describes the molecular composition of PHT active compounds and discusses the most important factors affecting the efficacy of a PHT treatment. Several novel pigments including porphyrins, carbocyanines and dyes with their specific advantages and disadvantages in photothermal therapy are shortly reviewed.\n\n\nRESULTS\nDespite the significant advancements, the search for other suitable photothermal agents continues.\n\n\nCONCLUSIONS\nThe author outlines possible future trends in this field.<EOD> The Inventory of Callous-Unemotional",
        "label": 2
    },
    "1838": {
        "output": "## Test\nYou should enter the `Trial-level eligibility: ` of all the notes and click the `Add note button` below. [INST, see Figure 2]\nNote that the `Trial-level eligibility` is the Trial number of `M264`. [INST]\n\n## [end 3]\n\n## Part 4.2 -Patient Trial Registration\n\n## Summary\nIn Part 4, you should add one more feature which is the `Patient Registration` feature. If you have a question about the registration, please see the Frequently Asked Questions (FAQ) section for it. This is the second last part in this document. [SEE FAQ, if the FAQ does not answer it, see next Part 4.4]\nPart 4.2 is the 'Patient Trial Registration' feature. Here, you should be able to register a new patient or to transfer a patient with a CTP. [INSERT Table 13]\n1. First, you should fill in the `Patient identifier: `, e.g., `Patient identifier: 1`. Next, you should fill in the `Patient Trial ID: `, e.g., `Patient Trial ID: 1`. [INSERT Table 14]\n2. You should check in three patients by clicking the check mark next to each of the table cells. To check in a patient, simply check the `Check' box to the left of each case. For example, `Patient identifier: 1` should be checked if you want to register the information about `Patient Trial ID: 1`. Similarly, you should check in `Patient identifier: 2` or simply `Patient identifier: 3` if you want to check in one of the `Patient identifier`s from `Patient identifier: 2` or `3` . [INSERT Tables 15 and 16]\n3. Before you can check in the Patient CTP, you will have to fill in whether or not the patient CTP is used, e.g., `Case Type: CTP`. [INSERT 17]\nYou can check an item in the `CTP status: ` row using the checkmark next to each one of it, e.g., `CTP status:",
        "label": 1
    },
    "1839": {
        "output": "## Sample inputs\n\nPlease make sure you understand the instructions given here on how to perform the tasks before you start the exercise.\n\n```\n./test_inst.sh --mode {RUN|CHECK}`\nIf you are not sure about an instruction, please write `R --h <topic>` or `CHECK --h <topic>` for more information (see the Usage section for more details). \nFor the run mode, it will use the dataset \"Test data (Ran)\". \n\nFor the check mode, you should prepare your dataset using the dataset \"Test data (CHECK)\", \n    which should be formatted like other datasets from the dataset preparation section of this file. \nPlease see the details in the Usage section. \n```\n```\n./test_inst.sh --mode {RUN|CHECK}\n```\n\n## Examples\nHere are some examples using `test_inst.sh`:\n```\n./test_inst.sh --mode RUN\n  Patient-level eligibility: Excluded\n  Trial-level eligibility: Not relevant\nExcluded: 0\nCheck --h EXAMPLE_RUN\nTest example 1: \"Run test\"\n   Patient-level eligibility: Excluded\n   Trial-level eligibility: Not relevant\n   Excluded: 0\n\nTest example 2: \"Check patient-level eligibility\"\nPatient-level eligibility: Not eligible\nExcluded: 0\n  Trial-level eligibility: Excluded\n  Excluded: 0\n\nTest example 3: \"Check trial-level eligibility\"\nNot eligible: 7471\n  Trial-level eligibility: Not eligible\n  Excluded: 13\n  Not relevant: 88905\nCHECK --h TRAIL_LEVEL\n```\n\n## \u26a0",
        "label": 1
    },
    "1840": {
        "output": "## [END] Hello. You are  a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Effect of DAAs on Behavior of HCC in HCV Patients\n\n\nSummary: Investigators",
        "label": 0
    },
    "1841": {
        "output": "[BASIC] You can assess the eligibility of the rest of your patients by making use of the following snippet of code: \n# assess the eligibility of this patient patient_eligibility = '0') \n# print the eligibility by `print(patient_eligibility)``0`, so that the patient can be excluded from being part of the clinical trial. [/BASIC]\n[PRO] Let's assume that the trial of study has the following exclusion criteria: \n\n### Exclusion Criteria\n- PEG\n\nLet's code it by inserting the snippet of code below in the `exclude_patents()` function: \n    if (hasattr(patient, 'peg')):\n        patient_eligibility = '1') \n        print(f'Patient is excluded because they have peg: {patient.peg}')\n        # print(f'Eligibility: {patient_eligibility})`1`, so that the patient can be excluded from being part of the clinical trial. [/PRO]\n\n[PRO] Lastly, you should print out the patient's eligibility to your main window by running the following snippet of code: \n#print('')# #print('Eligibility: ') #print(patient_eligibility)\nprint('')\n[/PRO]\n\n[CONSIDER] Please make sure that you have added all relevant information to this code file.\n[FINAL] In this section, we would like to thank you again for your participation. Please let us know if there is any problem or suggestion and feel free to contact us at xtian@smu.edu.cn .\n[BASIC]\n[CONSIDER]\n[FINAL]\n[/END]<EOD> Efficacy of Cefuroxime\u2010Ampicillin in Treatment of Severe Disease Due to Haemophilus Influenzae\nThe efficacy and safety of a combination of ampicillin and cefuroxime in the management of 67 patients was evaluated in a double\u2010blind clinical trial using ampicillin, cefuroxime, or ampicillin plus cefuroxime for treatment",
        "label": 1
    },
    "1842": {
        "output": "Please find the expected output below. \n![target_repor](../images/target_report.png \"target_report\") \n\n### [Task 6: Calculating time to prepare analysis for chronic hepatitis B and liver cirrhosis ](/",
        "label": 0
    },
    "1843": {
        "output": "[\n\n### 1.1 ] TIP:\nWhen you find a number or word on a patient note, look up the term in the patient note to make sure it is the same number or word. In case of disagreement, you can correct the input or remove the information from the input.\n\n### 1.2 ] TIP:\nOn your first screen, you are asked to select the data model you will use in the assignment (for example, `Participants, ``MedicalClinic, ``Physicians, ` and others). Then, `Select data model: ` appears below the name field. Use the arrow keys and select the data model you want to use. On the next screen, you will learn how to use the data model.\n\n### 1.3 ] TIP:\nWhen you enter a value, press the arrow to move to the next field without typing any value. You can use the `T` and arrow keys on top of the screen to move to the next and previous value. For example, `T` arrow, and you will be on the next value field.\n\n### 1.4 ] TIP:\nWhen you type on the medical chart input, such as patient name, patient notes, medications, etc., you will see some suggestions. Click on the suggestion which is more appropriate to your choice.\nIf there is no appropriate suggestion, enter and use the arrow keys to skip to the next field.\n\n### 1.5] TIP:\nTo correct a text input, like medications, diseases etc., press `T``T` and it will be corrected.\n\n### 1.6] TIP:\nTo find a key press `T``Tab`. For more information about tabs, use the arrow keys and check out the Help menu.\n\n### 1.7] TIP:\nTo save the screen when you enter new information, you can click`Save`as.\n\n## Patient Notes\nThis view shows patient notes by clinical trials.\n![patient_notes]()\n\n\n###### To add to patient notes\n1. Click on the `+` next to `Patient's notes` on the right side of the screen.\n\n\n![add_patient_note]()\n2. Add patient notes by clinical trials",
        "label": 1
    },
    "1844": {
        "output": "# Exercises\n\n[NOTE] This is not a real patient note. Please do not enter any personal information into the computer system in case the real patient comes to you.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n    You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.   \n\nHere is the patient note:\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities",
        "label": 0
    },
    "1845": {
        "output": "<EOD> Pharmacokinetics and Metabolism of BL\u2010456: A Non\u2010Opioid Cannabinoid\u20101 and Cannabinoid\u20102 Antagonist in Rats and Dogs\n\nBL-456 is a novel pharmacologic agent designed for pain relief. In the present study, BL-456 was evaluated in vitro for affinity for the cannabinoid receptors CB1, CB2, and the receptor for CB1 analogs. The compound was found to have a high affinity for the human CB1, CB2, and human receptor for cannabinoid analogs (HCCR-2) receptors. BL-456 was also evaluated in vitro for its potency for inducing cyclic AMP accumulation via the CB1 and CB2 receptors. The rank order of these data is also provided in the present report. BL-456 also inhibited the binding of CB1 and CB2 ligands at the CB1 and CB2 receptors in a typical competitive manner. BL-456 demonstrated negligible affinity for the non-neuronal forms of CB1 and CB2 in vitro. Following an intravenous administration in rats (0.5 mg/kg), BL-456, was found to be extensively metabolized. Twelve metabolites were characterized, and the CB1 antagonist activity of these metabolites was evaluated in isolated tissue preparations. BL-456 and its major metabolites, BL-456(M2-4), did not block the CB1mediated inhibition of cholera toxin-induced cyclic AMP accumulation in rat brain (cortical membranes), rabbit kidney, rabbit lung, rabbit iris-ciliary body, and rat iris-ciliary body preparations. Following a 10 mg/kg oral dosage of BL-456, however, in rats, a clear oral bioavailability of $2% was observed; after the 12 h, the blood plasma, brain, thigh muscle, and lung concentr",
        "label": 0
    },
    "1846": {
        "output": "# Example\nA patient note:\n2\n2 1\n\nA trial:\n\n# Rating Question\nAssessing eligibility on the patient note\n\n## Rating 2: Eligible\n10: Eligible\n\n# Answer\nPlease submit your answer according to the following [rubrics](https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?rm=full&formkey=dGlKd2\u2026 42KlV9pSZ1a1A).\nPlease use the [Link](https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?rm=full&formkey=dGlKd2\u2026 42KlV9pSZ1a1A) to submit\n\n## # Disclaimer Statement\nFor the student's exam purpose only\n\n# Submitting Answers to Discussion Board\nPlease submit all of your answers on the same day in [this form](https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?rm=full&formkey=dGlKd234bTUxNjQwLX0uW2cS_qWWZZW2F2dNxRWnA&formkey=dG00d29GbXlQYGQ1aE2M4XSXS1Q3UwM29YTU01-aVZC&output=classic).\nPlease use the [Link](https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_O",
        "label": 1
    },
    "1847": {
        "output": "- [/END]\n\n<br /><br />\n    <h3>Second Patient Note</h3>\n        <pre>\n[INST] Patient is a 75-year-old male with a past medical history significant for hypertension, congestive heart failure, and COPD.\n[END]-\n       </pre><br /><br />\n    <h3>Second Trial Notes</h3>\n      <pre>\n[INST] Title: An Open-Label. Controlled Crossover Trial of Methylphenidate in Patients With Persistent Sleep-EEG Activation in Comparison to Randomized Treatment of Flunitrazepam Versus Placebo in Primary Insomnia:\n[END]<br />\n[INST] Inclusion criteria:\nPatients receiving anti epileptic drug treatment;\nNot treated with MAOI and other drugs that interfere with drug metabolism;\nAge older than 16 years;\nDuring the inclusion period (4 days), patients have to complain about a complaint period or of having fallen asleep earlier than desired;\nECOG 0-2, and no significant renal, cardiovascular and other diseases.\n[END]\n</pre><br /><br />\n\n<br /><br />\n    <h3>Output Trial Evaluation Data</h3>\n        <pre>\nPatient-level trialleligibility: 1) Not relevant; Patient-level trial-eligibility: 2) Eligible<br />\nTrial-level trial-eligibility: 2) Eligible\nTrial-level trial-eligibility: 2) Eligible<br />\nTrial-level trial-eligibility: 0) Excluded<br />\nOutputs in JSON format: \n{\n             \"patient-level-trial-eligibility\": 2,\n             \"patient-level-trial-eligibility\": 2,\n             \"trial-level-trial-eligibility\": 2,\n             \"trial-level-trial-eligibility\": 0,\n          \"outputs-in-json-format\": \"true\"",
        "label": 0
    },
    "1848": {
        "output": "<EOD> Hydroxychloroquine: Prophylactic use in hospitalized COVID-19 patients\n\nThe novel coronavirus (SARS-CoV-2) has emerged as a major global health threat, presenting an unprecedented epidemic. Previously, the antimalarial drug chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) have been repurposed as possible treatment for SARS-CoV-2. In this study, it was hypothesized that prophylactic HCQ use during hospitalization could prevent symptoms from progressing towards severe COVID-19. The primary aim was to compare length of hospital stay and time to discharge between hospitalized patients who received prophylactic HCQ versus control (non-HCQ group) upon admission when diagnosed with COVID-19. The secondary aims were to compare the rates of 30-day readmission, and all-cause mortality between the groups.A retrospective cohort study was conducted at the Brookdale University Hospital and Medical Center, New York, USA. A total of 190 patients were included. Upon admission, 80 patients received 200 mg of HCQ and 110 patients did not receive HCQ. Multivariate regression analysis were performed to determine risk factors for longer length of hospital stay. The rate of mortality was 3.4% (ICU admission was required in 4.7% and 4.5% of the HCQ and control groups, respectively). In the HCQ group, 71.1% of the patients were discharged on day 5 versus 63.4% in the control (P = 0.033). Multivariate regression analysis showed that male sex, diabetes mellitus, and hypertension predicted longer length of hospital stay. A positive association was found between non-HCQ use and length of hospital stay, thus prophylactic HCQ use may be effective for the prevention of SARS-CoV-2 complications in a vulnerable population. To date, no studies suggest HCQ use is helpful for the improvement of COVID-19 symptoms and/or preventing progression to severe diseases. Therefore, further multi-center",
        "label": 0
    },
    "1849": {
        "output": "You should always repeat trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible.`.\nTrial-level eligibility determines the outcome.\n\nAs is the output of the trial-level eligibility, 1) excluded, 2) not relevant, and 3) eligible. When trial-level eligibility is excluded, the corresponding line will be commented. If the trial-level eligibility is 2) not relevant, then all lines will be commented accordingly.\nIf trial-eligibility is `Eligible`, then the patient's assessment of eligibility is output (0: excluded, 1: not relevant, 2: eligible).\n\n## Examples: \ud83d\udd17\n- A10 - Patient record note:\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent co-infection with HBV. His past medical history is non-significant. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\n## - \n\n```python\n\n# Excluded\n\n#     IF_Ct_70_CY1_01\n\n#     IF_Ct_80_CY1_01\n\n#     IF_Ct_2_CY1_01\n\n#     IF_Ct_90_",
        "label": 0
    },
    "1850": {
        "output": "__[END]__\n\n[!instruction] The question mark is the instruction to tell you what type of input to write in each line. Make sure that the value of input each line is matched with the question[/!]\n\n### Ex02 \nThe input file `trial-level-eligibility-data.csv` follows:\n\n###### First row. Input the sampled trial-level eligibility data `1`.\n```csv\n1\n```\n\n###### The input file contains two columns, trial-level-eligibility `N` and eligible `Y`.\n###### The input data to `Y` should be filled with `1`.\n```csv\n1,1\n2,1\n4,1\n8,1\n```\n\n###### `N` should be filled with the number of sampled row of input file.\n```csv\n1,2\n1,2\n1,2\n1,2\n```\n\n###### The row inputted in the line `1,4` does not match with the number of sampled row (4).\n\n###### The row inputted in the line `2,5` does not match with the number of sampled row (5)\n\n###### The row inputted in the line `3,10` does not match with the number of sampled row (10). \n\n###### The file inputted on the line`3` does not have any values in the line `4,9`, `7,20` or`9,25`.\n\n###### The row inputted in the line`2,9` has more than one empty value in the line `191:`.\n\n###### The format between the columns is different.\n- The column `trial-level-eligibility` should be a single value between `0` and `3`.\n  - `0` means `excluded`.\n  - `1`means `not relevant`.\n  - `2` means`eligible`.\n  - `3` means`unknown`.\n- The column `eligible` should be filled with the same value between `0` and `1`. \n\n###### The column `2,2` should be `2`.\n```csv\n 2,2\n    6",
        "label": 0
    },
    "1851": {
        "output": "A: I've got the solution:\nI am using the following piece of code (not tested yet)\nimport os\nimport re\nimport shutil\nimport subprocess\nimport sys\nimport platform\n\nimport pandas as pd\nimport numpy as np\nimport matplotlib.pyplot as plt\n\nimport warnings\nwarnings.filterwarnings('ignore')\n\nfrom sklearn.model_selection import train_test_split\n\nimport sklearn\n\nfrom nltk.tokenize import sent_detector\nfrom nltk.tokenize import word_tokenize\nfrom nltk.tag.neural import POSTaggerNE\n\n# load a word2vec model based on Google News training data\nword2vec_model = sklearn.text.Word2Vec(n_vocab=100000, size=300, min_count=1, subword_size=20, window=6, ngram_order=1, host='localhost', port=7500) # host, port, and vocabulary size of the local nGram model\nprint(\"[INFO] Done loading pre-trained words model\")\nword2vec_model\n# save the current word embedding in the local cache\nif word2vec_model.has_vocabulary(os.path.expanduser(\"~/.local/share/fastText\")):\n    print(\"[INFO] Embeddings already present\")\nelse:\n    print(\"[INFO] Loading fastText models ...\")\n    if not os.path.exists(\"fastText\"):\n        os.makedirs(os.path.expanduser(\"~/.local/share/fastText\"), parentevolve=False)\n    if os.path.exists(os.path.expanduser(\"~/.local/share/fastText/fastText\"):\n        print(\"Embeddings already present\")\n        print(\"Removing cached model, so that it does not interfere with the current usage\")\n        os.remove(os.path.expanduser(\"~/.local/share/fastText/fastText\"))\n    else:\n        print(\"Loading fastText models ...\")\n        fastText_dir_path = os.path.join(os.path.expanduser(\"~",
        "label": 0
    },
    "1852": {
        "output": "Good Luck!\n<EOD> The effect of a 16-week exercise intervention on cardiorespiratory fitness in female firefighters\nAbstract The aim of this study was to assess the effect of a 16-week exercise intervention on anthropometry, body composition, maximal oxygen consumption (VO2max) and ventilator efficiency (VE/VCO2 slope (VBS)) in firefighters who are routinely required to undertake rigorous physical activity during training and operational duties. Firefighters (n = 19) participated in a supervised circuit training program while a control group consisted of a reference population (n = 23). At baseline, no significant differences in age and anthropometry were observed (P > 0.05) and there were no significant differences in VO2max between the intervention and control group, 30.4 \u00b1 7.4 vs. 29.3 \u00b1 5.5 mL\u00b7kg \u22121 \u00b7min \u22121, respectively; P = 0.69, VBS 21.2 \u00b1 4.0 and 19.5 \u00b1 2.7, respectively; P = 0.12, waist circumference 90.0 \u00b1 5.2 vs. 92.7 \u00b1 5.3 cm, respectively; P = 0.15. After 16 weeks, only the intervention group demonstrated significant differences (P < 0.05) in VO2max (28.4 \u00b1 8.4%), VBS (\u221212.1 \u00b1 2.4%), lean mass (+1.7 \u00b1 0.6%) and BMI (+7.6 \u00b1 2.0%). The control group demonstrated a trend for VO2max to decrease (\u22120.5 \u00b1 4.7, P = 0.05), no change in lean mass (\u22121.0 \u00b1 0.9%, P = 0.05) and no change in VBS (P = 0.41). A 16-weeks of circuit training program for female firefighters improves anthropometry, VO2max and VBS. Future studies exploring the effects of exercise and physical",
        "label": 0
    },
    "1853": {
        "output": "<EOD> Gastric and pancreatic cancer in the Finnish cohort exposed to radioactive iodine.\nThe association between radioactive iodine (131I) treatment and gastric cancer (GC) and/or pancreatic cancer (PC) remains unclear. We examined the relationship between the radiation dose to the stomach and pancreas and an increased risk of these malignancies in the Finnish radiological occupational cohort using a large data set, including all those radiologists with 131I treatment who could be identified. A total of 25 GC cases and 13 PC cases occurred during the follow-up (1953-2014), corresponding to 13.1 and 4.7 fold increases over the expected numbers. Doses to the stomach were not associated with an increased risk for GC, but there was an increased trend for GC in the subgroup analyses comparing the highest stomach dose quartile to the remaining groups (OR 1.22, 95%CI 0.51-2.92). The PC findings were consistent with the previously published positive findings in which the PC risk was estimated to be 2-fold or more in the highest exposure groups. Overall these data suggest that stomach dose is not an important predictor of gastric cancer when the dose to the stomach is below 2 Gy, but this may not be true for those with higher doses of \u22652 Gy. The increased risk of pancreatic cancer associated with radiation-induced tumours suggests a possible association between radiation and this cancer.<EOD> Improvement of Nitrogen Use Efficiency in Corn by Inoculation with a Symbiotic Consortium Formed by Bradyrhizobium spp. and Enterobacter cloacae\n\nThe plant rhizosphere contains an abundant and diverse range of microorganisms that play an important role in plant growth and development. In agricultural crops like maize, the benefits of symbiotic bacteria have been reported for enhanced yields and biomass production through better N nutrition. While beneficial bacteria can increase the efficiency of N uptake by host plants in the presence of plant nutrient deficiency, these plants may be more capable of",
        "label": 1
    },
    "1854": {
        "output": "<EOD> A new role for antimicrobial peptides in eukaryotic adaptation to cold.\nEnvironmental stress can negatively affect proteomes by inactivating many enzymes, including some of great importance. Hence, the ability to re-establish protein functions under such physiologically inhibitory conditions is a fundamental adaptation trait for living organisms. The antimicrobial peptide (AMP) system of prokaryotes constitutes an excellent prototype to elucidate how organisms can adapt to such conditions. Herein, we present an innovative approach to study the role of the prokaryotic AMP system in adaptation to cold. In this context, we hypothesize that, as a result of the cold adaption of the cydB mutant of Escherichia coli, a higher level of membrane permeabilization occurred. The cydB mutant is a mutant of E. coli which was chosen as a reference for studying cold adaptation because of its great sensitivity to low temperature in relation to this stress. Our data are consistent with this hypothesis since the membrane permeability of the cydB mutant is significantly higher than that of the wild type. Thus, cold can potentially inhibit energy transfer in the cydB mutant and, consequently, AMP production. In addition, high concentrations of AMPs are toxic, induce cell death and are able to cross the cell membrane. This study presents new evidence about the relationship between the physiological implications of AMPs in response to environmental changes, and the role AMPs play in the adaptive capacity of microorganisms to different temperatures.<EOD> Bone marrow mesenchymal stem cell\u2010derived exosomes prevent and repair radiation\u2010induced bone loss\nRadiotherapy (abbreviated as RT) is a conventional therapeutic regimen for treating malignancies of the lymphatics, rectum, thorax, and head and neck. While this treatment modality, which targets fast\u2010growing cancer cells, affords excellent local tumor\u2010control efficacy, it usually leaves surviving cancer patients with debilitating side effects, many of which can have serious implications on health. One of the most dangerous and common off\u2010target effects of ionizing radiation is bone loss",
        "label": 0
    },
    "1855": {
        "output": "[fig]  Figure 1, Figure 3: Trial-level eligibility: 2) Eligible. [INST] #HELP, you should always use comments, e.g., #HELP. [INST](00:15) Dry-Run, you should always use comments, e.g., #HELP. [INST](00:15)Figure 2: Trial-level eligibility: [/fig] \n[table]  Table 1: Inclusion criteria of the clinical trialInfection with the hepatitis C virus. [/table] \n<EOD> .\nThis is a report of the rare case of an acute subluxation of the radial head after a trapeziectomy. There was no trauma or any other predisposition associated with this complication and neither did the patient have any systemic diseases. She had no previous joint laxity or ligamentous instability. This complication was treated conservatively. Bracing was used for 6 weeks until radiological and clinical remission was achieved. Subluxation of the radial head with a loss in function of the pisohamate articulation was completely corrected; nevertheless a mild decrease in opposition was present in the thumb. Subluxation of the radial head is a rare complication of trapeziectomy, more common in older patients. The cause is still unknown but according to some authors, the origin is multiarticular. There is no consensus regarding best treatment. Some authors treat the complication conservatively with a brace or open surgery without repair of the ligaments. Other authors advocate surgical ligament repair in every patient in order to prevent a recurrence.<EOD> Neural Correlates of Subcortical Contributions to Reading Performance in Children with Comorbid Reading Disorder and ADHD\n\nDevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and reading disorder (RD) often have shared comorbidity when they co-occur within children. The mechanisms underpinning shared symptomatology are currently not well understood. Further investigation into the overlap between disorders will be informative in order to facilitate a targeted approach to symptomatic relief. The neurocognitive sequelae of comorbid RD and ADHD are as yet unknown.",
        "label": 0
    },
    "1856": {
        "output": "- [1st Instructor Marking] The patient is suffering from hepatitis C. You are not given other additional details. Your task is to assess the patient's eligibility in the clinical trial you are working on. I expect an exhaustive description of your assessment rather than focusing on one aspect. If the patient's eligibility for the clinical trial is decided, be clear. Write a short explanation on why the eligibility was decided.\n\n### [1st Student Solution]\n\n## Eligibility\n\n### - [2nd Student Solution] This is the patient note of the HCV patient: \nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\n### - [3rd Student Solution] This is the patient note of the HCV patient: \nHCV -positive HCV RNA, past medical history non-significant \n\n### - [4th Student Solution] This is the patient note of the HCV patient: \nHCV positive HCV RNA, past medical history non-significant \n\n### - [5th Student Solution] This is the patient note of the HCV patient: \nHCV-positive HCV RNA, past",
        "label": 0
    },
    "1857": {
        "output": "---\n\nExamples that demonstrate how to use the clinic_trial_eligibility function or an equivalent are:\n`clinic_trial_eligibility(cats, trial_name)`\n`clinic_trial_eligibility(cats[[1]], trial_name)`\n`clinic_trial_eligibility(cats[[i]], trial_name)`\n\n\n[1]:\nclinic_trial_eligibility(cats[[1]], 'AZD9291')\nA ZD9291)<EOD> Improving the efficiency of photovoltaic modules with a reflective textile coating\n\nWe here propose a method for maximizing the absorption of photons in photovoltaic modules by applying a single-layer reflective textile coating. This is accomplished by employing a multifunctional textile coating consisting of a layer of micro-sized mirrors made from highly reflective metal on a substrate of polyamide-66. For various angles of light incidence, the reflectivity of the reflective coatings was measured. The reflectance of the coated substrates shows the minimum value near the normal direction and increases monotonously with increasing incident angle. The results can be used for developing a new design for a photovoltaic generator with improved efficiency and providing a new approach to the utilization of textiles in multifunctional structures.\n\n# Introduction\nSolar cells are widely used in photovoltaic systems for their ability to convert light into electrical energy [bib_ref]  New trends in solar cell technology, Janssen [/bib_ref]  [bib_ref]  New trends in solar cells, Nishiyama [/bib_ref] . The most common structures of photovoltaic systems are rooftop or ground mount applications; for this kind of photovoltaic modules (PM), the most common structure includes flat or tilted solar panels and glass housings. In recent times, new structures have been explored such as photovoltaic panels with a textile back cover [bib_ref]  Applicability of solar power modules based on polymer-textile composite materials in urban..., Gurevich [/bib_ref]  [bib_ref]  Photovoltaic panels with a textile back cover, Gurevich [/bib_ref]  [bib_ref]  An overview on performance of flexible",
        "label": 0
    },
    "1858": {
        "output": "`\n\n# Discussion\nIn this problem, the student should apply the knowledge that they learned throughout the course to work with a clinical trial. The student learns how to identify eligible patients, how to assess trial-level eligibility, how",
        "label": 0
    },
    "1859": {
        "output": "<EOD> Effect of dietary intake of n-3 polyunsaturated fatty acid on serum and platelet lipid composition of middle-aged male Japanese.\nWe investigated the impact of dietary intake of n-3 polyunsaturated fatty acid (PUFA) on cardiac risk factors with age and gender in 30 Japanese males, aged 34-69 y (49 +/- 6 y), at the same annual health checkup by examining their serum lipid and platelet fatty acid levels. The n-3 PUFA intake was 2.4 +/- 1.2 g/d, and the ratio of n-3 PUFA to n-6 PUFA in red or whole blood was 32 +/- 28% (18 +/- 24% in red cells and 55 +/- 43% in whole blood). The ratio of n-3 PUFA to n-6 PUFA in the platelets was 30 +/- 22%. There was a significant negative correlation between the ratio of n-3 to n-6 PUFA in red blood cells and in platelets with the ratio of n-3 PUFA to n-6 PUFA in diet (r = 0.58, p < 0.005 and r = 0.45, p < 0.01, respectively), and the ratio of n-3 to n-6 PUFA in serum and platelet phospholipid with serum n-3 PUFA (r = 0.46, p < 0.01 and r = 0.32, p < 0.05, respectively) and dietary n-3 PUFA (r = 0.38, p < 0.01 and r = 0.40, p < 0.01, respectively). Serum triacylglycerol, high-density lipoprotein cholesterol, triglyceride to high-density lipoprotein cholesterol ratio in serum, low-density lipoprotein cholesterol and platelet fibrinogen were significantly influenced by n-3 PUFA intakes with aging (39.1-",
        "label": 1
    },
    "1860": {
        "output": "__Input:__\n#### Patient notes\n* `patients` - list of patient notes that need to be processed\n* `clinical trial` - a definition of the clinical trial\n\n__Output:__\nTrial-level eligibility: 2) Eligible\n**The output of the algorithm should always be in this line**\n**This algorithm is executed on a list of patient notes. You can modify it individually for each patient note in case you need to.**\n\n\n## __Author:__ @pavelsarhan\n\n## __Created:__ April 24, 2021\n\n##__ Revised:__ N/A\n\n__Version:__ 1.<EOD> The NF-kappaB precursor p105 uses its ankyrin and ring finger domains to form a complex with COP9 signalosome subunit 2 (CSN2)\n\na b s t r a c tBackground: Transcription factor NF-kB is activated rapidly by several inflammatory cytokines. Following activation, NF-kB is proteolytically cleaved and translocates to the nucleus, where it binds to DNA and induces transcription of many genes. In this study, we investigated interactions of NF-kB precursor p105, which serves inhibitory function by binding and sequestering NF-kB dimers, with COP9 signalosome (CSN) subunit CSN2. We hypothesized that NF-kB precursor p105 is ubiquitinated, as it degrades under a series of post-translational modifications including sumoylation and ubiquitination. Methods: Recombinant protein of CSN2 and NF-kB precursor p105 were expressed in Escherichia coli. Bacterially expressed proteins were purified and tested for in vitro binding and ubiquitination. Cellular immunoprecipitate assay was performed to identify endogenous complexes. Results: Our in vitro study reveals that the interaction between CSN2 and NF-kB precursor p105 leads to the ubiquitination of NF-kB precursor p105. Moreover, immunopreci",
        "label": 0
    },
    "1861": {
        "output": "### [P] \u2714 Q1. How many patients were enrolled in the study?\n\nQ) Approximately how many patients were enrolled in this clinical trial study?\n\nA) \u2714 This trial enrolled a total of 19 clinical trial centers and 99 participants. There will be approximately 10 participants enrolled each month.\n\n[INST] If you need to provide a code for the actual answer in your test, please use the next code: \u2717 .\n\nYou can find out more about this trial at https://clinicaltrial.gov/ct2/show/NCT01661378.\n\n### [E] \u2714 Q2. What is the clinical trial title?\n\nQ) What is the clinical trial's title?\n\nA) \u2714 This RCT is titled \"A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)\".\n\n[INST] If you need to provide a code for the actual answer in your test, please use the next code: \u2714 .\n\n### [E] \u2714 Q3. Who conducted this RCT?\n\nQ) Who conducted this clinical trial?\n\nA) \u2714 This trial was conducted by the Department of Hepatology, Zhengzhou University, Zhengzhou, Henan, China.\n\n[INST] If you need to provide a code for the actual answer in your test, please use the next code: \u2714 .\n\n### [P] \u2714 Q4. What was the purpose of this research?\n\nQ) What was the purpose of this clinical trial?\n\nA) \u2714 The purpose of this trial is to observe the efficacy of different initial anti-infective regimens in Chinese patients with end-stage liver disease with SBP and 30-day and 60-day non-liver transplant survival rates, providing evidence-based medical evidence for the empirical use of such patients.\n\n[INST] If you need to provide a code for the actual answer in your test, please use the next code: \u2717 .\n\n### [E] \u2714 Q5. Q5. What were the inclusion criteria for the",
        "label": 0
    },
    "1862": {
        "output": "<EOD> Phase-to-phase transitions in one-dimensional systems with long-range interactions.\nMotivated by recent studies on the nature of the phase transition in systems with nearest-neighbor long-range repulsion, we present a general analysis on phase-to-phase transitions in systems with long-range interactions. We describe a general procedure that allows one to identify the order and stability of these transitions as well as their universality class, as a function of the system density or interaction strength. This procedure provides universal information that is relevant at two widely different scales. First, we present results that allow us to identify regions of the parameter space that lead to qualitatively different behavior; second, we also provide quantitative predictions in terms of universal quantities that can be tested experimentally. This approach is applied to two specific system classes: to a generalized version of the one-dimensional Coulomb gas model, which leads to the two-dimensional Higgs model as a special case; and to a gas of two-dimensional hard squares with nearest-neighbor long-range attraction, a model with a richly textured phase diagram, in which we find a spin-density wave transition mediated by long-range interactions.<EOD> PPARg agonist reduces tumorigenicity while improving differentiation in mouse glioma cell lines.\nEpidemiological studies have found that type II diabetes mellitus, associated with a high incidence of peripheral blood mononuclear cell atherosclerosis (PBMC-AS), is correlated with the development of malignant tumors. Additionally, adiponectin, which is a type II diabetogenic adipokine, is a ligand of peroxisome proliferator-activated receptor-g (PPARg). Interestingly, adapinectin can inhibit AS. These evidences suggest a correlation between PPARg activation and malignant tumorigenesis. To test this hypothesis, we used mouse glioma cell lines (glioma cells) to explore the effects of the PPARg agonist rosiglitazone (ROS) on tumorigenicity and differentiation. Glioma cells with a high PPARg expression and active nuclear transfer had higher invasiveness, whereas the cells with a lower expression and lower nuclear transfer had a lower invasiveness. Interestingly",
        "label": 0
    },
    "1863": {
        "output": "If the patient meets the inclusion criteria then 2) Eligible should work at the end of the list. If the patient is not eligible or only not relevant then 0) Excluded should work at the end of the list. \nAfter finishing the code (we recommend writing some comments too with more information about the solution), press `F5` to execute the code. You may need to press `F12` to run the application in the console window. \nIn the case of an error appearing on the screen, you should write each line exactly like in the code book. \nYou have to choose one of the three possible patient-level eligibility answers when pressing the `MENU` button: `0-Excluded`, `1-Not-relevant`, `2-Eligible` with a confirmation input, `F1`. You have to finish the application with `SAVE`. \nThere are other patients to analyze. You have to make the same things with the others! \nIf there are many patients to analyze, you can use the shortcut `CTRL+A` to insert the cursor under the first entry (1-Not-relevant). You have to analyze the next patient by using `F3` to skip to the next patient on your computer. \nYou have to select the option 0-Excluded in case the patient has not enough information about the inclusion criteria. The same rules apply as for the previous patients. You have to choose Not relevant if the patient does not have enough information for the trial-level assessment. \nOn the other hand, if the patient meets the eligibility criteria, the scale should be 2-Eligible. \nYou have to complete the application in the same manner! [INST]\n\n# TROUBLE SHOOTING AND HANDY TIPS\n\n# TROUBLE SHOOTING\n\n## The program is not running on your console\nThe program is running on your computer?\nYou need to install Python-3, Spyder, and Anaconda by referring to the instructions from the following website\nYou may find the following link helpful:  [URL]\nThe current project was developed with Python 2.7.11. The program should run on Python 3.\nYou need to change the version. See the following link, which will help you install Python-3",
        "label": 0
    },
    "1864": {
        "output": "## [INST] Trial-related Questions on Procedures\nBefore each trial, a consent form for each patient must be completed. However, consent to participate in the study is not the same as the trial itself. According to the ethics committee's guidelines, patients have the right to withdraw from the trial at any time. The trial-related questions on consent are below.\n\n### How did you know about the current clinical trial?\nPlease state whether the patient received information about the study from any of the following sources:\na) a clinical investigator at the clinic b) an advertisement on the bulletin board c) television or radio d) other sources Please state how the patient found out about the clinical trial.\n\n### How did the patient hear about this clinical trial?\nPlease indicate how the patient heard about the trial.\nThis has been marked as [INST] because it will be an option in real clinical scenarios.\n\n### If the patient was not informed by an investigator, can the patient clearly understand this study?\nIf patients learned about the trial through some other methods, they may not have enough information about the study if they did not learn about the study with enough information. Please confirm whether the patient can now understand all essential information about the study to decide whether to participate in the trial.\nPlease mark all the statements for each method in which the patient can clearly understand the study.\n\n### How can patients be able to understand the study sufficiently?\nIf the patient lacks information about the study, they will have trouble understanding the study, and the safety of the trial cannot be guaranteed. Please make sure that the patient can explain in their own words what they understand about the study, including the study's objectives and purpose.",
        "label": 0
    },
    "1865": {
        "output": "[EX]\nIn the eligibility assessment of the patient note, the patient should be treated as eligible. The patient met the inclusion criteria, but excluding one of the exclusion criteria, as shown in the note. Note. Exclusion Criteria:\n- Hepatocellular carcinoma\n- Positive HIV antibody\n- Child-Pugh class A\n- AST \u2265 5x ULN or ALT \u2265 10x ULN\n- Decompensated cirrhosis\n- Pregnant or breastfeeding\n\n# Solution\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on INF, RBV and direct antiviral treatment for the past 6 months. His medical record shows previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. \nThere is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. BMI: 27, HCV 1b, chronic infection, positive HBV (acute), positive HIV antibody, Child-Pugh class A, HBV treatment, HCV chronic, HCV infection, HCV treatment, HIV infection, liver biopsy, negative HBV infection, and negative HIV infection.\n- Chronic infection - positive HIV antibody \u2713\n- Child-Pugh class A \u2713\n- HCV treatment \u2713\n- HCV infection \u2713\n- Negative HIV infection \u21d3\n- Liver biopsy \u2713\n- positive HBV (acute) \u2713\n- negative HBV infection \u21d3\n- HBV treatment \u21d3\n\n## Eligibility criteria\n\n## Pat",
        "label": 0
    },
    "1866": {
        "output": "___\n\n# Clinical Trials: PATIENT NOTES\n\n\n[/BOTH] \n\n# INDEX\n\n### A. Patients\n\n### B. Researchers\n\n### C. Protocols\n\n### D. Clinical trials\n\n### D.1 Clinical Trials: Patient Names\n\n### D.2 Clinical Trials: Notes on Patients\n\n### 2) Recruitment\n\nWhen a patient is identified as eligible (i.e., patient eligibility was set to 2), you must proceed to patient recruitment.\n\nIt should be noted that patients can participate in more than one trial at a time. In other words, patients can be enrolled to other clinical trials in progress at the same time as they are under study for the current trial.\n![Recruitment](./../images/clin_trials_pat_recruit.png)![Recruitment](./../images/clin_trials_pat_recruit-transparent.png)\n\n### D.3 Clinical Trials: Randomization\n\nSome clinical trials do not use \n\n1) Clinical Trials \n\n![Clinical Trials](./../images/clin_trials.png)![Clinical Trials](./../images/clin_trials-transparent.png)\n\nIf your trial was created on top of the Clinical Trials module, you can start filling in your eligibility assessment and recruitment data.\n\n[/BOTH] \n\n### D.4.1 Clinical Trials: Assessment of Eligibility\n\n#### 4) Outcome\n\nThe final step is to set the `Trial-level outcome` to the trial's\n outcome and \n `Trial-level eligibility` to the\n [#2] eligibility of the current trial\n\n[#2]: [##2](/docs/clinical/Patient_Recruitment_Transparent.html)\n\n![Trial-level outcome and eligibility](./../images/clin_trials_doc_elig_outc.png)![T",
        "label": 0
    },
    "1867": {
        "output": "[TASK] [SE] Experiment (2)\n<EOD> The role of N-terminal Tyr67 in the tertiary structure of \u03b1-lactalbumin is unveiled by the study of structural dynamics using NMR.\nConformational variants of \u03b1-lactalbumin (\u03b1-LA) exist in the absence of molecular crowding. This fact renders the study of structural changes in this protein difficult. It is known that N-terminal Tyr67 is involved in the molecular interactions that hold the protein in closed conformation. However, Tyr67 is not structurally conserved in the \u03b1-LA isoforms. In order to find out the importance of Tyr67, we used \u03b1-LA(W) in 2H2O (96% deuteration) to achieve long range nuclear Overhauser effects and to study the structural dynamics of the protein. Results revealed the importance of Tyr67 in the molecular interactions that stabilize the folding of the protein. The deuterium uptake rate of Y67F variant is similar to the \u03b1-LA(AC) protein. On the other hand, the deuteration kinetics of Y67A variant of \u03b1-LA(W) is slower than that of Y67F. The deuterium uptake kinetics of Y67H was intermediate to Y67A and Y67F suggesting that Tyr67 is more involved in the intramolecular interactions of the protein than intermolecular interactions in the case of \u03b1-LA(AC).<EOD> A systematic comparison of the effect of two common dosing methods on the precision of echocardiographic measurement.\nBACKGROUND\nThe use of cardiac ultrasound to assess cardiovascular disease is common in the clinical practice and education. The purpose of this systematic review was to summarize the literature on the effect of the two most commonly used methods of dose determination, volume and power, on the precision of echocardiographic measurements.\n\n\nMETHODS\nAn electronic literature database search of four journals and five text books was conducted. All studies that included both volume and power measurements of echocardiography were included in the review. The data were extracted for dose, precision, and power/volume",
        "label": 2
    },
    "1868": {
        "output": "</inst>\n\n\nA: It's hard to get precise information from patient notes without using some metadata. E.g. are you trying to get a decision on your inpatient cohort or is each patient independent? If a single patient has multiple entries (e.g. multiple visits per patient), then you should group the data:\ngrouped_patient_notes <- cbind(patient_data, trial_id = as.character(1:10))\n\nWhen grouping, it makes sense to have the trial_id column and its' contents as the primary key. So this ensures that patients who have multiple entries will have the same trial_id and have the same grouping:\ngrouped_trial_id <- cbind(trial_id, trial_data)\ngrouped_patient_data <- grouped_patient_notes[, -c(trial_id, \"trial_id\")]\n\nThen, it's good to create the data for the tables\ngrouped_inpatient_data <- table(grouped_trial_data, grouped_patient_data)\ngrouped_trial_data <- table(grouped_trial_data[!is.na(grouped_trial_data$trial_id), ], grouped_patient_data[!is.na(grouped_patient_data$patient_id), ])\n\nThen you can extract data as you wish. For example, looking at \"Eligible\":\n\n##\nsum(grouped_trial_data[!(grouped_trial_data$trial_eligible == 1),]/grouped_inpatient_data$inpatients)\n[1] 800\n\nThe same can be done for the other columns. Since we don't have many patients, we can do this all with a few lines of code.\n\nA: You'll need to create a loop to go over each patient and then run a few lines of code.\nI've broken this loop into a sequence of functions and pass in patient data to them. The variables that are passed in are your patient data (\"patient_data\") and the trial parameters(\"TrialParameters\") in list form\nf1 <- function(n) { \n  cbind(trial_data(T",
        "label": 2
    },
    "1869": {
        "output": "![INST] Tic-Tac-Toe game. Each player alternately chooses a square and writes the corresponding number to determine their turn is whoever says \"Tic\" first. The winner is whoever says \"Tac\" or whoever has three in a row horizontally, vertically, or diagonally.\n\nHere we list some hints for the Tic-Tac-Toe game.  \n- [HINT] When you say \"Tac\", you only write numbers with which you have tiles. You do not write numbers with no tiles.\n- [HINT] For example, if the numbers you have are 2, 5, 7 and you write \"2578\", then you cannot win.\n- [HINT] If the numbers you have are 5, 7, 9 and you write \"5798\", then you cannot win. This is because you miss the rule by writing the letter \"T\".\nIn this section, you will practice with the python program. To run the programs, you should check out [the code/run the program](https://code.visualstudio.com/users/kh-shi/projects/Data-Science-%5BK-SHI-%5D/code/Data-Science-%5BK-SHI-%5D/Python/data_science/python/exam/practice_09_clinical_trial.py). The best way to test the program is to put in the same variables that we used in the problems. However, if the program does not show the expected value please see the source codes and try to find the error.\n\n\n\n# Exercise: [practice_09_clinical_trial.py --file-name=practice_09_clinical_trial.py --no-screenshots]\n\n\n\nCongratulations!  You have learned the practical concepts of the Data Science course. Your training in the Data Science program will be highly beneficial and useful in your field of work to solve complex problems using machine learning and statistical techniques.  \n\n#### Instruction: [Data ___] (Data Science professor)  [Name - __] (student's name)\n\n#### Exercise Code: [Data ___] (Data Science",
        "label": 0
    },
    "1870": {
        "output": "##[OUTPUT] Hello. In a nutshell, this is your eligibility check report. Check the reports below for more details.[INST]<EOD> Narrative Medicine and Patients with Chronic Pain\n\nThe field of health humanities, a subspecialty of medicine that is gaining increasing interest, takes advantage of the cultural, historical, and philosophical traditions that are inherent to medicine. This paper examines narrative medicine (NM) as one of the main techniques used in the field of health humanities and how its use in patients with chronic pain, an extremely common and complex condition, fits in a specific medical scenario. NM is defined as an opportunity to foster new dimensions and dimensions of a patient beyond what is possible with technological medicine and scientific medicine. By improving the connection between patients and society, NM should allow doctors to give patients a unique opportunity to express their individuality and be re-examined. We conducted a narrative review that consisted of papers published in the last 10 years. We searched Google Scholar (and the references in the articles) and Web of Science, using the search term 'narrative medicine' in combination with phrases such as 'pain management', 'chronic pain', 'longitudinal narrative', 'narrative analysis', 'patient experience', 'narrative nursing' and 'philosophy of pain'. Our review describes and discusses the main aspects of NM and its main challenges in chronic pain patients. In conclusion, NM is an increasingly important form of chronic pain management within the health humanities, which should be considered as part of the overall holistic approach to chronic pain. We have attempted to improve the connection between patients with chronic pain and society, in order to help and support them in different contexts of personal life, medical and social care, family, work and education, and society. As a result, NM patients may develop a deeper understanding of their chronic pain condition, as they share their experiences and feelings with the doctor.\n\n# Introduction\nChronic pain affects approximately 20%, including 11.2% of American adults [bib_ref]  Persistence of Multiple Types of Pain in the United States: 1992-2002, Korff [/bib_ref]  and 57-91% across Europe [bib_ref]  Survey",
        "label": 0
    },
    "1871": {
        "output": "##[MARKDOWN] You are a resident doctor and the primary physician of Mr. K. who suffers from HCV-related cirrhosis. You should write a clinical note, including the current situation of his health condition and disease and treatment plan. \nIt will be helpful to read the notes of the previous physicians. However, the notes of the previous physicians are written in a language unknown to you. And there is no one left with proficiency in the language to interpret. \nWrite a note in which you use only English terms. The clinical note has to be written as much like as possible by a native English speaker. This is the task you are to perform.\n\nLet us go through the steps.\n\n1. Explore Mr. K.'s complaints.  Here is the patient note:\n\n##[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antib",
        "label": 0
    },
    "1872": {
        "output": "## [END]\n<EOD> Internal herniation through the foramen of Winslow: Computed tomography findings and literature review\n\n [bib_ref]  Internal hernia through the foramen of Winslow: a rare cause of smallbowel obstruction..., Sato [/bib_ref]  [bib_ref]  Internal hernia through the foramen of Winslow: a rare cause of smallbowel obstruction..., Sato [/bib_ref]  [bib_ref]  Internal hernia through the foramen of Winslow: MDCT findings, Mortezavi [/bib_ref]  [bib_ref]  Internal herniation through the foramen of Winslow: a rare cause of smallbowel obstruction..., Sato [/bib_ref]  [bib_ref]  Internal hernia through the foramen of Winslow: a rare cause of smallbowel obstruction..., Sato [/bib_ref]  [fig_ref]  Figure 1: 12-year-old female patient with small bowel volvulus, internal herniation through the foramen... [/fig_ref]  [bib_ref]  Unusual small bowel obstructions: causes and imaging appearances, Das [/bib_ref]  [bib_ref]  CT diagnosis of an internal hernia that caused small-bowel obstruction, Ahmad [/bib_ref]  [bib_ref]  Internal hernia through the foramen of Winslow: gastrogastric intussusception of jejunum after..., Kang [/bib_ref]  \n\n## Supplementary data\nSupplementary data related to this article can be found at https://doi.org/10.1016/j.radcr.2018.09.009.\n[fig]  Figure 1: 12-year-old female patient with small bowel volvulus, internal herniation through the foramen of Winslow. Axial unenhanced CT shows distal small bowel proximal to the duodenum (arrowheads) in the suprahepatic portion and a central location of the right kidney in the upper abdomen (large arrow). Saggittal reformatted image (B) shows volvulus of the duodenum (arrowheads) around the ligament of Treitz (large arrow). Coronal reformatted image (C) shows rotation of the duodenum around the ligament of Treitz (double arrowheads). [/fig]",
        "label": 2
    },
    "1873": {
        "output": "<EOD> Preclinical Evaluation of the Pipeline TP392 Device: A Modular Device for Synchronous Vascular Intervention and Endovascular Transcatheter Aortic Valve Replacement\n\nIntroduction:The rapid growth of cardiovascular interventional therapies, including endovascular transcatheter aortic valve replacement, has sparked a need for novel devices to enable and optimize endovascular therapies in the treatment of cardiovascular disease. The aim of this trial is to determine the procedural safety of an endovascular tri-modular vascular intervention and endovascular transcatheter aortic valve replacement system. Methods: A canine study was performed with 10 canines (20-30 kg, all male), and procedures were conducted at 5 sites (Australia, Finland, Germany, Hong Kong, and the USA) in compliance with Good Laboratory Practice (GLP) guidelines. The studies were conducted in a randomized manner, with a TP392 system and a control group in each study. TP392 is a first-in-class tri-modular hybrid device consisting of separate transcatheter and surgical treatment modules deliverable through the same vascular access, including in direct proximity within the body. The study consisted of 2 components: (1) evaluation of the TP392 device for acute procedural safety and performance against a surgical standard of care (SoC) procedure and (2) the safety of TP392 in direct procedural comparison with SoC. The TP392 devices used for these studies were not pre-sterilized and therefore required high heat sterilization, which was performed and monitored by the sponsor of the trial. Results: The objective of this study was achieved. Across all the studies, no severe complications or deaths related to the device or to the study device/ device delivery system occurred in the TP392 cohort. As compared to SoC, the TP392 procedure was significantly shorter (P \\ 0.0001). The total operative time of SoC procedures was significantly longer than all TP392 procedures (P \\ 0.0001). The TP392",
        "label": 0
    },
    "1874": {
        "output": "---[INST] Next, we can add a new sample in the report.---\n\n[INST] The new",
        "label": 1
    },
    "1875": {
        "output": "## Assignment of treatment arms: [INST/CODE]\nWhen you have all the information needed with the 20 trials in the study, you should find the most appropriate intervention among these trials. The main thing is intervention type and intervention name. First, you should obtain the name of intervention you want to assign to each trial. When you find it, you should confirm 2 facts about the intervention; these are intervention type (INT type) and intervention name (INT name), both of which are specified in the intervention type column of Drug Table. To determine the INT type of an intervention, click the drop-down menu of the INT type column. To determine the INT name of an intervention, click the drop-down menu of the INT name column.\nSecond, check the name of intervention in the Intervention column of the Trial Table. If the intervention's name is the same as the intervention's name registered in Drug Table, you can apply the intervention, and the intervention's name will appear automatically if the intervention is double-clicked. If all the interventions are chosen, click `Apply interventions: YES` in the Interventions box. Otherwise, click `Apply interventions: No` in the box. After selecting `Apply interventions: NO`, the previous step repeats. [INST/CODE]\n\n## Creating intervention table: [inst/code]\nIf there are interventions whose name is not registered in Drug Table but you want to apply, you should write an appropriate name of intervention in the Intervention column in [/INST/CODE]. A proper name for intervention is a name consisting of at least one English word separated by a hyphen. For example, `elbasvir-grazoprevir` is `EG`. [INST/CODE]\n\n## Assigning intervention: [inst/code]\nIf you created a new Intervention (above), the name of the new intervention is entered by double-clicking the name of the new intervention, and a new cell is created in the intervention table. If you created no new Intervention, then no new cell is made.\nIf you selected to apply interventions (in the intervention column), the intervention whose name is entered by double-clicking is assigned to the appropriate",
        "label": 0
    },
    "1876": {
        "output": "# Implementation\n\nThis example assumes that there are a lot of different patients in dataset. It is inefficient to handle such case in Python. One good solution is to use Python web scraping to extract data from web pages. This will give us a Python list of clinical note patients which include all eligibility information. Then, in a second stage, we should parse this list in order to find the best way to handle them.\n\n## Data Acquisition\n\nHere, we define one very clear and simplified example assuming that this algorithm work for dataset that is not more than 10 000 records. Thus, we use a Python list of 10 clinical note patients and we need to extract eligibility information. Our aim is to find the best way to process this Python dataset in order to find our trial-level eligibility output.\n\n```python\nimport pprint\npatients = ['Jason', 'Peter', 'Carlos', 'Klaus', 'Anna', 'Mario']\nlistOfPatients = patients[0:4]#First four patients\n\noutput = ''\nprint(output)\noutput = ''\nfor singlePatient in listOfPatients:\n    print(singlePatient)#Patient1\n    print(singlePatient.text)#Patient description\nsingleCriteriaValue = ''\nfor criteria in singlePatient.get_all('DIV')#DIV is the tag\ncriteriaTextLength = len(criteria.contents)\nif criteriaTextLength == 5:\n    criteriaText = criteria.contents\n    singleCriteriaValue = criteriaText\n\nprint(singleCriteriaValue)#For patient1, the patient is female, therefore, the criteria is equal to \"age 18\\-60 years\".\nprint(\"\")\nprint (output)#Final output.\n\n\n<tr id=\"i3945_3_1\" class=\"tpl-row\">\n<td class=\"tpl-col-right\" nowrap=\"nowrap\">\n<div id=\"c4403_1_1\" class=\"tpl-td\"></div>\n</td>\n<td class=\"tpl-col-body\" nowrap=\"nowrap\">\n<div id=\"c4403_2_1\" class=\"tpl-td\">",
        "label": 0
    },
    "1877": {
        "output": "<EOD> The role of catheter emboli in the etiology of pulmonary hypertension\nCatheter embolization is a common complication of cardiac catheterization, but its frequency and importance have not been emphasized. In a review of 1393 consecutive angiographic studies, 49 catheter emboli occurred in 46 patients. Of these patients, 38 presented with pulmonary hypertension and four had intermittent pulmonary hypertension. Five of the nine patients with right ventricular hypertrophy were asymptomatic and the other four were symptomatic as a result of cardiomegaly only. Thirteen of the 19 patients who developed pulmonary hypertension following a therapeutic procedure were asymptomatic until pulmonary hypertension became severe enough to be detected by angiography. Patients were asymptomatic in the late postcatheterization phase as a result of severe pulmonary hypertension and right ventricular failure. Of 13 patients who died, eight were found to have pulmonary thromboembolism at autopsy. Eighteen of the remaining 31 patients have died. Pulmonary vascular obstruction occurred in two, probably as a result of an obstructive thrombus and in ten, possibly from a thrombus lodged in a catheter embolus. Pulmonary hypertension was attributed to right ventricular pressure overloading secondary to obstruction caused by the catheter embolus in 11 patients. Pulmonary hypertension was considered to be due to pulmonary venous hypertension in 12 patients. Both catheter embolism and pulmonary venous hypertension could be present in three patients. Pulmonary thromboembolism and severe pulmonary hypertension occur frequently following catheterization and should be considered in the differential diagnosis of patients developing signs, symptoms, or radiographic findings compatible with pulmonary embolism. It appears that pulmonary vascular obstruction may have been responsible for serious morbidity and death in some patients following cardiac catheterization.<EOD> Synthesis of 2-amino-4-methylpyrimidines by a palladium-",
        "label": 2
    },
    "1878": {
        "output": "[INFO] ## Exercise 1\n\n[ENG] In the following table you will receive the patients and the information about clinical trial. For each patient you should assess the eligibility by the same three-point scale like in the previous example.\n[/INFO]\n\n\n\n\n\n\n[ENG] Please choose the most fitting case and submit the results: \n1) Excluded\n2) Not relevant\n3) Eligible\nYour results should be sent as [INFO] text file `patients.txt` to the website: http://vvh.kclj.si/exercises-solved/eligibility/.[/ENG]\n\n## [INST] Hello again. \nSo far, you just assessed the patients and sent the results to the website. We have analysed the results and have found some mistakes in assessment of patient_13 and patient_19.\n\n\n[ENG] Based on the assessment error, which of the following statements is true? \nFor each statement below, select the option \"TRUE\" (T), option \"FALSE\" (F), or \"I don't know\" (I).[/ENG]\n    1. The inclusion and exclusion criteria for the trial \"Use of Penthrox in Extra-hospital Traumatology\" are written in a way to be easily understandable for physicians. [T/F/I]\n    2. The trial \"Use of Penthrox in Extra-hospital Traumatology\" does not clearly specify the diagnosis of acute pain. [T/F/I]\n    3. 51-years old patient is not treated with anti-hepatitis C drugs. The patient's diagnosis, which is not a chronic viral hepatitis, allows to assume that patient may still be coinfected with hepatitis viruses.\n\n[ENG] Patient_13 is assessed as not an eligible patient for trial \"Use of Penthrox in Extrahospital Traumatology\". Analysed information about this patient shows that she is not eligible because of a different disease. \nP13, a 54-year-old woman, who had been treated regularly with anti-hepat",
        "label": 0
    },
    "1879": {
        "output": "## How to make this program executable?\n[ENV] We recommend to build the Docker container as we show in Docker 101 below (also in your notebook folder named Dockerfile). [INST] You can execute the docker image with the first command below.\n\nDocker Image \nWe recommend to build a Dockerfile with your own settings so that you can run the container on your local machine or server (where you want).\n```/bin/bash\nFROM python:3\nWORKDIR /hublab/data/mckinney/1\nCOPY . /hublab/data/mckinney/2\nRUN pip install --upgrade pip\nRUN pip install jupyterhub\nRUN pip install jupyter-client\nCOPY file-to-execute.py /hublab/data/mckinney/3\nCMD python3 file-to-execute.py <patient-id>\n```\n\nWhat is Docker and How to Run the Image?\nDocker is a containerization tool that enables us to package software into containers, making it easy to deploy, test, and migrate in a virtual computing environment. So you can just build your own image, run it on your local machine, and deploy it on a server when you need.\nTo run the image built above, you can follow the steps for `docker-local.yaml` on your notebook:\n- Click `Tools > Launch Notebook...` to open an interactive session.\n- Navigate to your local file directory of notebook and execute `jupyther notebook Dockerfile` to run a local machine.\n- Or you can run the image on a server on your computer by using `python main.py`.\n\n### Note\nWe have already run the image on our server (not your local machine!) on your notebook (the third part) and the logs show how to interpret the results. The output is the Python code in both the Notebook and the console. You can run the image again on your local machine or server to interpret the results more.\n```/usr/local/bin/python main.py\n\nFile \"main.py\", line 65, in <module>\n    print \"This is the notebook server! Welcome!\", 72, \"\"\n\nFile \"C:/Program Files/Ana",
        "label": 0
    },
    "1880": {
        "output": "Here is the answer to Problem 3 of our tutorial:\n[formula]  1. [/formula] \nThe overall score:\nscore =",
        "label": 0
    },
    "1881": {
        "output": "## Input\n\n### Clinicaltrial\nFirst, input a `Clinicaltrial` object, as defined in the class [`Clinicaltrial`](../classes/Clinicaltrial.md).  \n*Example 1*\n![image](https://user-images.githubusercontent.com/11145612/110143278-f6dc1b80-835f-11eb-96a8-f73241a9314f.png)\n\n\n### Patient note\nEnter inpatient notes as a `Note` object, as defined in the class [`Note`](../classes/Note.md).  \n*Example 1*\n![image](https://user-images.githubusercontent.com/11145612/110143311-e6b45b00-835d-11eb-89e3-ee8e6821099f.png)\n\n### Check Exclusion Criteria\n\nAnalyze whether the patient is an exclusion criterion using the following step:  \n![image](https://user-images.githubusercontent.com/11145612/110147500-d6452980-8365-11eb-8631-2d003f411724.png)   \n*Tip* If the patient does not have information about any of the exclusion criteria, you should set it as `False`.\n\n### Check Inclusion Criteria\n\nAnalyze whether the patient is an inclusion criterion using the following step:  \n![image](https://user-images.githubusercontent.com/11145612/110147952-ceccfa80-8365-11eb-9ee2-7f1d3dd0b2c1.png)\n\n### Note 1\nYou can get patients' information from the following objects: \n- **Patient note object, `Note`** class: You can get patient",
        "label": 1
    },
    "1882": {
        "output": "You will see the table that summarizes the\nSAEs of the baseline. You are able to use the export button to get the results as csv,",
        "label": 1
    },
    "1883": {
        "output": "### Test Cases\nHere are some test cases to check your answer. If you cannot find answers, try changing value of the `if` conditional.\n\n| name        | code | expected result | comment |\n|-------------|------|------------------|----------|\n| case1        | IN01 | Included          |     0\n| case2        | IN02 | Included          |     1\n| case3        | IN03 | Not relevant     |     0\n| case4        | IN04 | Not relevant     |     1\n| case5        | IN05 | Not relevant     |     2\n| case6        | IN06 | Excluded        |     0\n| case7        | IN07 | Excluded        |     1\n\n### Output\n\nIf your answer is correct, after you run the previous code, the output is shown as below in the figure. We can see the number from first line means one of the trials, e.g., `if (eligibleTrials[0] == ''): print(f'''Trials: {trial.trial_id} \\nPatient ID: {patientID} \\nIncluded: {eligibleList[0]}'')`.\n\n![\"Included-list-figure.pdf\"]\n\n### Solution for Test Case\nIf you can't answer with the test cases, you can see the output if you write the code below:\n\n![Trial-eligibility-code.pdf](https://user-images.githubusercontent.com/39147649/146970849-09d4298de-bd02-4160-8668-900d69f9fe12.png)\n\n## Task 2\nNow I want you to modify the previous code. I want you to check that your input list contains any test case patient note. Let's assume your input list looks like the following:\n\n| patientID    | patient  |\n|-------------|---------|\n| case1        | IN01    |\n| case2        | IN02    |\n| case3        | IN06    |\n\nMy assumption is that your input list may contain all the",
        "label": 1
    },
    "1884": {
        "output": "## Good luck!\n<EOD> Development and Validation of PCL-5 in Persian: A Persian Adaptation of the Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5).\nPost-traumatic stress disorder (PTSD) is a major problem in contemporary societies. However, it is highly prevalent in clinical settings and trauma settings, and it has been recognized as one of the most common psychiatric disorders, especially in war-affected countries. Although the Post-traumatic Stress Disorder Checklist (PCL) has been one of the most widely used measures of PTSD, its shortcomings led to several modifications. The current study aimed to evaluate the cultural validation and psychometric properties of PCL-5 in Iranian culture. A cross-sectional study was conducted with 383 participants who were randomly selected from Iranian citizens recruited at 14 centers located in 7 major cities across the country. All participants received both a PCL-5 and clinical interview questionnaires. Data were analysed using exploratory factor analysis to extract factors and confirmatory factor analysis to test the goodness-of-fit of the model. Internal consistency and test-retest (tested at 3 weeks interval) reliability were assessed by Cronbach's alpha, and intraclass correlation coefficient (ICC) respectively. The mean age of the sample was 30 (SD=12 years), 191 (49.87%) were men and 192 (50.13) were women. Results of the EFA of PCL-5 showed a good fit (GFI=.97; TLI=.98; RMSEA=.02; NFI=.97; CFI=.99). All three factors had satisfactory loadings (ranged from .49 to .79). Moreover, the test-retest showed high reliability (ICC=.95, p<0.001). The internal consistencies among total items and dimensions were good with a Cronbach's alpha ranging from .76 to .86. The results showed a good validity for the 20-item PCL-5 to diagnose and measure different aspects of PTSD. Results",
        "label": 0
    },
    "1885": {
        "output": "To test the output, the following template in Markdown is useful.\n~~~\n**Output:** `Trial-level eligibility: 2) Eligible.` <br />\n\n\n\n[1,2] `1) Not relevant/no information.` <br />\n2) Eligible <br />\n3) Excluded\n~~~\n<EOD> Molecular epidemiological and microbiological characterization of bacteria and parasites from cases of diarrhea in two hospitals in Kinshasa, Democratic Republic of the Congo\nABSTRACT To determine the etiological agents of bacterial and parasitic diarrhea and to characterize the drugs resistance to ampicillin, amoxicillin, trimethoprim/sulfamethoxazole, ceftriaxone, chloramphenicol, nalidixic acid and nitrofurantoin in diarrhea-affected children, in the DRC, 371 samples from urine and stool were collected at the time of diarrheal episodes in two hospitals and parasite-specific diagnostic tools were used to identify different helminth, protozoan, and fungal enteropathogens. Of the samples, 70% were positive for enteropathogens in which bacteria 56% and parasites 11%. Overall, we isolated the parasite enteropathogen Entameba spp with the prevalence 13.7%, which was 12.1% in DRC 3A and 14.6% in DRC 3B. The next parasite enteropathogen was Giardia spp, 3.5% in DRC 3A and 5.3% in DRC3 B. Among the bacteria isolated Salmonella spp was dominant prevalence.15.63%, which was 19.2, 10.3% in DRC 3A, and in DRC 3B. There was also prevalence of 6.3% Shigella spp and 3.3 E. coli spp in DRC3A and 4.3% Shigella spp and 9.5%",
        "label": 0
    },
    "1886": {
        "output": "In this example, the patient was given a trial-level eligibility of 2) Eligible, i.e., the patient is eligible for this study. <EOD> .\nThe authors presented a case report of a child with right subluxation of the hip during the first year and a half of life. Ultrasound examination of the hip and bone age assessed at the same time helped identify the right hip as an example of physiological development and the left hip as a pathological one. There were no clinical symptoms pointing to dysplasia in the child's hip joints. According to the results of physical examination and X-ray examination at follow-up, the child was diagnosed with an idiopathic developmental hip dislocation (Gardner). In the final phase of radiographic examination in adulthood the child is qualified to be operated on according to the Dega and Chiari technique. We recommend early introduction of ultrasound examination of the hip joints in the diagnostics of physiological and pathological development of the hip joint and in the course of disease. Ultrasound examination seems to provide a valuable tool which should be an indispensable element of the diagnosis of idiopathic developmental hip dislocation.<EOD> Neuronal and glial populations of the cerebellar nuclei of the adult rat brain\nThe relative proportions of neuronal to glial cells of the cerebellar nuclei of the adult rat were analyzed with a combined Nissl\u2010 and protein\u2010specific dye (safranin) staining method. Nissl staining was used to estimate density of neuronal to glia cells whereas combined Safranin and Nissl staining was used to discriminate between neuronal and glial populations. The neuronal to glial cell density ratio for the whole cerebellar nucleus is close to unity, 0.93, with a minor cell type preference of \u03b3\u2010aminobutyric acid (GABA)\u2010ergic inhibitory neurons (0.68). Individual nuclei of the cerebellar complex can be subdivided into distinct neuron and glial cell populations. The nucleus ruber contains a high number of excitatory neurons. The caudal pontine nuclei contain large numbers of choliner",
        "label": 0
    },
    "1887": {
        "output": "### 1. \tIFN 2. \tRBV 3. \tAll the DDAs available 4. \tDAAs should be stopped before hepatic encephalopathy develops 5. \tHBV positive patients 6. \tPatients with negative HCV-RNA or serum levels < 50 IU/ml at the start of the second antiviral treatment 7. \tPatients who previously received interferon therapy, but relapsed 8. \tPatients with alcoholic hepatitis 9. \tPatients with decompensated cirrhosis. 10. \tPatients who developed decompensation during treatment are excluded from the study 11. \tHCV related to chronic hepatitis or cirrhosis, 12. \tHCV genotype 2 or 3. 13. \tHgb > 10.0 g/dl and platelet > 100,000/mm3. 14. \tWomen of child-bearing potential should be advised of teratogenic effects on neonates and have documentation of negative pregnancy test within 14 days before first dose of study drug. 15. \tHIV infected patients who are co-infected with hepatitis B virus 16. \tWomen should be on reliable contraception while receiving study drug or within 14 days after completing the study drug. 17. \tHCV positive patients on liver transplant waiting list or patients who recently received renal replacement therapy like dialysis. 18. \tPatients who have a history of cardiovascular disease, clinical arrhythmias, or unstable angina within 2 years prior to screening. 19. \tHistory of malignancy, except for the basal cell or squamous cell carcinoma of the cervix and tumors in situ, or patients with recurrence of the carcinoma, except for the cutaneous squamous carcinoma and malignancies of the bladder and breast which were curatively treated more than 1 year before randomization. 20.",
        "label": 1
    },
    "1888": {
        "output": "## [DRAFT]\nPlease find below my comments for the manuscript draft:\n1. In the first paragraph of the abstract, the authors would like to mention that \"For each scenario, the experiment is carried out for 10 cases.\" I doubt there are 10 cases for each scenario. You may remove the redundant sentence here.\nThanks for the suggestion. We have removed that redundant sentence.\n\n## 2.\nFor the first experiment design to generate data from different types of scenarios [fig_ref]  3: Allows for multiple clinical trials of individual data [/fig_ref]  that the author mentioned, I do not understand why those six numbers were used and I think the authors should explain the meaning of those numbers more clearly. In addition, the author also states that \"In each patient, we generated a set of 10 random numbers whose distribution fits a normal distribution with a mean of 0 and a variance of 20 or 40\", however, in the corresponding code snippet (line 11~34) does not mention that the random numbers that were generated from a normal distribution with a mean 1 and variance 10 were subtracted by 0.5.\nIt appears that in [fig_ref]  3: Allows for multiple clinical trials of individual data [/fig_ref]  the author actually wants to compare the result to the generated data from a bimodal distribution.\nWhat does #6 and #7 represent in that plot? I couldn't figure it out, so can the author explain it more clearly? Thanks.\nYou are right; that plot shows the comparison between a simulated normal distribution and a simulated bimodal distribution, and #6 and #7 represent the normal distribution data. In the second experiment design, there are two scenarios for simulating data: 1) a continuous normal distribution and 2) a bimodal distribution. We have added the explanation of the two distributions here to the legend of Figure 2.\n\n## 3.\nI find problematic that the authors are testing their algorithm using a fixed number of subjects for each clinical trial. It will be easier for the authors to demonstrate their algorithm performs well in terms of prediction since the number of patients in each simulated clinical trial is consistent, but the authors should expect a more diverse distribution in real-world biomedicine, in which one clinical trial would have more than 10 patients and",
        "label": 0
    },
    "1889": {
        "output": "<EOD> Internal medicine residency programs: a profile of programs. Results of a survey by the Association of Program Directors in Internal Medicine.\nOBJECTIVE\nA number of internal medicine residency programs have had great success in recruiting house staff into competitive generalist career choices. This study sought to determine how specific program characteristics are associated with these successes.\n\n\nDESIGN\nWe developed and sent a survey regarding program characteristics, financial information, and resident characteristics to 175 member programs of the Association of Program Directors in Internal Medicine. Programs received an initial mail-in survey and a follow-up phone call.\n\n\nSETTING\nInternal medicine residency programs in the United States and Canada funded by their affiliated institutions and the United States government.\n\n\nPATIENTS\nAll 2346 residents in member program residencies.\n\n\nMEASUREMENT AND MAIN RESULTS\nA 65.7 percent response rate was obtained to the mail-in survey. Of the 115 programs that responded, 74 provided complete responses. The four programs that did not respond were not significantly different from others in demographic characteristics. Financially stable programs, as demonstrated by a large proportion of salaried faculty or a high ratio of faculty-generated income relative to the institution's contribution, placed more residents into generalist careers (P < .05). Programs with fewer residents demonstrated a higher proportion of residents choosing general internal medicine, a more academic setting (P < .05), and faculty who place lower priority on research.\n\n\nCONCLUSIONS\nThe results suggest that successful programs share certain common characteristics, although many factors are likely to contribute to success in generalist training. We hope that these results are helpful to other residency programs as they prepare to implement resident selection policies and programs to develop a future generation of generalists.<EOD> The Relationship between Physician Burnout and Patient Healthcare Utilisation and Outcomes in the Ambulatory Setting: A Retrospective Cohort Study of Veterans.\nBACKGROUND\nBurnout affects 20-50% of physicians and is associated with impaired cognitive functioning and adverse patient outcomes. Previous studies were limited by small physician samples in specialty settings or assess",
        "label": 0
    },
    "1890": {
        "output": "[END]\n\n## Summary\n\n## Trial\n- `Trial:` The clinical trial recruitment\n\n## Note\n- `Note:` An assistant of clinical trial recruitment and recruitment record keeping\n\n## Output\n- `Output:` Patient-level eligibility on clinical trial\n\n## Reference\n- `Reference:` Jha, P., & Ouyang, S. (2015). The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC. Paper presented at the Northeast Bioinformatics Conference, Bangor, ME.<EOD> Improved methods for estimating the effect of random effects and for estimating the variance of random effects in the case-cohort design.\nWe consider case-cohort sample size calculations for proportional hazards regression. Current methods are based on the assumption that the effect of an exposure on risk for the disease under study depends only on the exposure levels experienced by a subject prior to disease onset but not on those experienced by subjects who are diagnosed as nonsusceptible. We derive exact expressions for the log partial likelihood for a large case-cohort study and show that this is not invariant to random shuffling by rows of the exposure-by-timing array. We propose an empirical solution to this problem and evaluate that solution using simulated data. We apply the methods to a large breast-ovarian cancer case-cohort study designed to evaluate the effect of dietary fat and vitamin E intake on breast cancer risk.<EOD> .\nOBJECTIVE\nTo investigate the mechanism of effect of 0.5% isotonic sodium chloride (ISC) injection on preventing postoperative intestinal adhesion after surgical treatment for obliterated vagina rectum by comparing the difference between the ISC group and the sodium chloride (NSC) group.\n\n\nMETHODS\n42 women scheduled for surgical treatment of oblique vagina and rectum were assigned to two groups. Intraperitoneal 50 ml of 0.5% (3.75%) isotonic sodium chloride (ISC) were used in one of the groups while the",
        "label": 0
    },
    "1891": {
        "output": "</p>\n<p><b>[INST] id=\"C_R_2_4\"> Title: An open-label pilot study evaluating the efficacy and safety of sofosbuvir and velpatasvir in the treatment of untreated acute hepatitis C</b><br>\n\nSummary: This is an open-label pilot study evaluating the efficacy of sofosbuvir and velpatasvir for patients with acute hepatitis C (n = ~4).\nInclusion criteria:\nAge >18\n\nPatients with HCV RNA confirmed in a quantitative HCV test no >12 weeks before screening, not on any of the following anti-viral treatment prior to study enrolment: -ledipasvir, sofosbuvir, or simeprevir +/-ritonavir.\nFemale patients of reproductive potential must have a negative serum pregnancy test within 48 hours prior to being enrolled on day 1 of Cycle 1 and must have agreed to use at least one highly effective method of contraception for the duration of the treatment period and 1 month post-treatment.\nExclusion criteria:\nPatients with HIV infection\nPatients who meet DSM IV-TR criteria for active depression/suicidality (determined by the investigator)\nAny patient with a medical conditions or other situations that might be associated with poor tolerance to sof",
        "label": 1
    },
    "1892": {
        "output": "## Question\n[INST] Hello. As a trial investigator you are designing a clinical trial to evaluate combination therapy in patients with advanced gastric cancer not responding to standard chemotherapy.\n\nThe treatment group will receive a combination of a novel PIK3CA inhibitor and FTS. The control group will receive only chemotherapy (Gemcitabine and Cisplatin). \n\nInclusion criteria: Inclusion Criteria:\n\n\n## Participants have voluntarily signed the informed consent form.\nParticipants' gastric adenocarcinoma is confirmed by histological and clinical examinations, and can be any T, AJCC-7, stage III or stage IV histologic grade.\n\nParticipants who have not previously received, or are currently receiving treatments for, any cancer other than gastric cancer and who do not need endoscopic treatment(s) before being entered to the study will be eligible to participate.\nParticipants without contraindications to chemotherapy will be eligible to participate.\n\nParticipants who have not received any radiotherapy, or who completed radiotherapy more than 50 days before entering to the study, are eligible to participate.\nParticipants' tumors are not previously treated with target therapy or other drugs of PIK3CA pathway (P-glycoprotein modulators, monoclonal antibodies, hormone receptor modulators, tyrosine kinase inhibitors, DNA topoisomerase, and angiogenesis inhibitors), but these can be used as second line treatment after progressing on FTS.\nParticipants have received standard chemotherapy of GEMOX.\n\nExclusion Criteria: Exclusion Criteria:\n\nPatients showing progressive disease following the first cycle of FTS plus chemotherapy.\nPatients with incurable diseases such as cardiac disease, endocrine diseases, lung disease, liver diseases and uncontrolled seizures, severe cardiac failure, and other conditions that may interfere with the clinical trial.\nParticipants with other malignant tumors, with the exception of cervical carcinoma in situ or non-metastatic prostate",
        "label": 0
    },
    "1893": {
        "output": "The second trial is another example of the three-point scale:\nTASK 1: Evaluation of trial enrollment.\n\n\nThe patient's data are: - The patient is a 46-year-old woman with diabetes. She underwent a heart ablation 4 months ago. Her past medical history shows a recent myocardial infarction. She is prescribed insulin, oral antidiabetic drugs, metformin, gliclopyrride, simvastatin and antihypertensives. The medical record contains past-documented chronic kidney disease, cardioneurological and cardiac arrhythmia. Her medical records show a recent myocardial infarction with a positive stress test, high total cholesterol, blood glucose of 3.49 mmol/L (normal < 5.5 mmol/L), high triglycerides (189 mg/dL versus 80-150 mg/dL), and normal low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and low apolipoprotein A1. She is also noted to have diabetes, coronary artery disease and hypertension. She is alert with no acute distress. Her BP: 150/95, HR: 100/min, and BMI: 29. An ECG showed no sign of ischemia.\n\n\n\n\n    [Hypotension Assessment]\n\n\n\n<EOD> A Fatal Case of Septic Peritonitis Due to Acute Myeloid Leukemia With Omission of Chemotherapy in the First Hospital Admission for Nursing Failure\n\n\n\n# Introduction\nThe number of cancer survivors continues to increase in the United States. According to the most recent epidemiological estimates from the American Cancer Society, more than 15 million Americans have survived a cancer diagnosis, and that number will continue to rise to nearly one out of every two families can be affected by cancer. However, leukemia is the second leading cause of cancer incidence in children, according to the \"Cancer Statistics, 2014\" .\nC",
        "label": 0
    },
    "1894": {
        "output": "* {{{\nThis is actually a [patient level] eligibility. The answer to this question is \"eligible\".\n[/TEST]\n* {{{\nIn order to answer this question you need to go to the [patients.csv] file.\nLook for the column in the first row labeled as `Eligible` and then go to the row below this one. Make sure of the values you are going to input in the cells. In this test it is `0` in the cells 2 row 2, 2 row 3, 2 row 4, 2 row 5, 2 row 6, 2 row 7, and `1` in cells 2 row 9. \n[/TEST]\n\n* {{{\nIn this test the answer is `0001001`, if you don't get this one don't copy the value and instead input:\n\n\n```\n0000010\n\n```\n```\n\n```\n0000001\n```\n```\n0000000\n```\n```\n0001111\n```\n```\n1100001\n```\n```\n1000001\n```\n```\n\n\n```\n0000000\n```\n```\n0000000\n```\n```\n0000000\n```\n```\n0000010\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n0000000\n```\n```\n1100001\n```\n```\n0100001\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n0000010\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n0000001\n```\n```\n000000",
        "label": 0
    },
    "1895": {
        "output": "### Examples\n\n[EXAMPLE]\n`import requests`\n\n`from requests.auth import HTTPBasicAuthentication`\n\n`from pprint import pprint`\n\n`api_key_path = \"$HOME/caviar_rest/caviar_rest/conf/key_file.txt\"`\n\n`url = \"http://app.hvcrestudy.org/api/v2/studies/v41_mom/subjects\" `\n\n`print(\"I'm on Windows OS\")`\n\n`username = \"<EMAIL>\"`\n\n`password = \"<PASSWORD>\" `\n\n`auth = HTTPBasicAuthentication(username=username, password=password)`\n\n`headers = {'Content-type': 'application/x-www-form-urlencoded', 'User-Agent': 'caviar/<VERSION>', 'Authorization': 'Bearer '+<KEY>}`\n\n`url = url+api_key_path`\n\n`url = url+api_key_path+username`\n\n`url = url+api_key_path+<PASSWORD>`\n\n`url = url`\n\n`auth.headers.update(headers)`\n\n`url = url`\n\n`requests.post(url, data = {'includeEligibility':['0','1','2']}, auth = auth)`\n\n`response = requests.get(url)`\n\n`response_data = response.text`\n\n`response_dict = pprint.p print(json.loads(response_data))['v2/studies/v41_mom/subject-0]`\n\n`print(\"Response data: `, response_dict)``<EOD> In situ hybridization with a full-length copy of a human immunodeficiency virus type I long terminal repeat: a simple quantitative technique to study viral-host interactions.\nStable transient heteroduplex constructs between a 4.5-kb human HindIII-MluI DNA fragment and a 1.1-kb MluI-XhoI DNA fragment were cloned in the EcoRV site of M13mp8. The fragment contained an infectious human immunodeficiency virus type 1 (HIV-1) long terminal repeat",
        "label": 0
    },
    "1896": {
        "output": "15/17\n\n### Questions\n\n**You are working with a patient's note. What is an inclusion criteria?**\n\n**You are working with a patient's note. What is a trial-level eligibility?**\n\n**You are working with a clinical trial. What are exclusion criteria?**\n\n**You are working with a clinical trial. What is a trial-level eligibility?**\n\n**The name of the clinical trial is A Comprehensive HBsAg-positive Patients Centered Screening Strategy. Which one of the listed inclusion criteria matches with the patient's characteristics from the patient's note? (You can choose more than one option.)**\n\n*\n\n*Age between 20 and 75 years old\n\n*Sex: Male\n\n*Hepatitis B positive\n\n*Hepatitis B Surface Antigen positive\n\n*Hepatitis C positive\n\n*Hepatitis C antibody positive\n\n**There are listed both inclusion criteria and exclusion criteria. How would you assess the patient for this clinical trial?**\n<EOD> Synthesis and properties of a stable metallopolymer based on a tetraradical pyridoquinoid oligomer.\nA tetraradical oligomer derived from a pyridoquinoid dye (1) was synthesized in good yield by a two-step reaction of a known dione and oligogallic polyols. Complexation with lanthanide ions afforded a series of coordination polymers (2) displaying a one-dimensional coordination chain structure with a unique arrangement of radical spins. These polymers exhibited an irreversible spin-crossover effect induced by thermal treatment, whereas the radical states in free oligomeric species remained unchanged under similar conditions. It is concluded that lanthanide ions are able to efficiently delocalize the spin density over the polymeric chain and promote efficient mixing of spin pairs, which facilitates the switching of spin states.<EOD> .\nThe 123I-IMP SPECT in ten ischemic patients with chronic cerebral artery occlusion or stenosis of intracranial arteries revealed a positive result in",
        "label": 2
    },
    "1897": {
        "output": "___\n\n## Molecular profile\nIn this section you should enter DNA mutations that determine the molecular profile of a patient. There are four possible responses for each gene mutation: `0) no mutation` (`No mutation found in gene Y.`), `1) present` (`Gene Y contains mutation Z.`), `2) present: silent` (`Gene Y contains silent mutation Z.`), and `3) present: not silent` (`Gene Y contains mutation Z which is `not silent`.`). The format for gene or mutation or crossover between gene and mutation is the same as in [Trial] section. \n\nHere is a patient's profile:\n\nHere is a clinical trial's profile:\n_____\n\n## Response\nIn this section you should enter a response for each trial-level eligibility. In case there is no answer for a query, you should enter the number 0 (`0: Patient is ineligible for the trial on the grounds of '0) No mutation`.). Otherwise, you should use the number 1 (`Trial-level eligibility: 1) Eligible.`). For crossover between trial-level eligibility and molecular profile, enter `2) present: silent` instead of 1.). If the patient has a mutation of interest in the trial's molecular profile, enter the number 2 (`Trial-level eligibility: 2) Eligible.`). If he doesn't, enter the number `3) present: not silent`.). [INST]\n\n\n## Output\nYour task is to enter a suitable response for each trial-level eligibility. Here is an output example. You can also check out the examples from the [Drug] section; they are quite similar. \n\n```python\nTrial-level eligibility: 3) present: not silent.\nresponse: 3) present: not silent\n\nTrial-level eligibility: 1) Eligible.\nresponse: 1) Eligible.\n```\n\nIn this tutorial, you should check out the [Drug] section also. [INST]\n```python\nTrial-level eligibility: 2) present: silent.\nresponse: 2) present: silent\n\nT",
        "label": 0
    },
    "1898": {
        "output": "What are your opinions on the data model and UI design for this task? Any issues with the implementation on top of the existing systems?\n\nA: My question on the dataset is:\nIf it is assumed that a patient has certain diseases and certain treatments, can the model still correctly distinguish them, or do you have to create a model for each possible combination of diseases and treatments?\n<EOD> In vitro effectiveness of N-acetylcysteine and glutathione compared to EDTA and sodium thiosulfate on dislodgement of lead and copper ions from dental amalgam\n\nBackground: N-acetylcysteine (NAC) and glutathione (GSH) are antioxidants that act as a chelator to dislodge metallic ions. This study aimed to evaluate the in vitro effectiveness of NAC and GSH compared to EDTA and sodium thiosulfate, as chemical agents for dislodging lead (Pb) and copper (Cu) ions released from dental amalgams. Methods: Dental amalgam specimens were prepared and 192 samples were allocated into four groups (A, B, C and D) and a control group receiving no treatment (n = 48 for each group). In group A, NAC at a concentration of 60 mM was used as a dislodging agent. In groups B and C, 3% EDTA and 5.25% Na 2 S 2 O 3 were used, respectively, as dislodging agents. In group D, distilled water was added to samples. In each sample, 25 \u00b5L of dislodging agent was placed around dental amalgam samples for 20 min. After removing dislodging agents from the well, samples were stored in 1 mL ultrapure water for 20 min. Pb and Cu levels were determined by 6500 Wet Acid Digestion and Inductively Coupled Plasma (ICP) analysis in a quadruple flame configuration before the application of each dislodging agent, before water wash, and after water wash. Data were analyzed using the Kolmogorov-Smirnov and Wilco",
        "label": 2
    },
    "1899": {
        "output": "Please submit this program as `problem5.md` and the program output as `problem5.pdf`. You are expected to also submit the code to solve the problem:\n\n```python\nimport pandas as pd\n\ndf = pd.read_csv(\"testdata4.csv\")\ndf\n  Trial-level:      Excluded     Not Relevant     Eligible\n0       21          0           27           44\n1       42          6           0           58\n2       78         11           24          115\n3       103         0           35           163\n4       137         3           13          -\n```\n\nDuring solution development, please also consider to submit your work (including your code) in your programming language of choice to your instructor along with your solution program. All the submitted programs will be marked and submitted solutions will be returned to you.\n\n## Marking criteria\nAll the solutions will be graded by the instructor and by other participants as peer assessment. [DOWNLOAD]\n\n### Marking criteria\n\n#### Question marking scheme (based on the work by [Davidson and Woodman] 1995)\nA. Accuracy and coherence\n\n###### Requires the following:\n- Accuracy\n- Inconsistencies (e.g., missing values, spelling errors, incorrect units, nonstatistical errors).\n- Coherence\n- Inconsistencies (e.g., grammar, punctuation, spelling).\n- Completeness\nNumber of relevant paragraphs: 4\nNumber of irrelevant paragraphs\nNumber of irrelevant lines of code: 2\nNumber of irrelevant notes: 6\n\nB.\n\n## C.\n[DOWNLOAD](https://statistics4business.files.wordpress.com/2020/08/61.pdf)\n\n### Marking method\nAverage of both marking schemes is taken as final mark: Marking Summary: Marking scheme based on the work by \n\n#### Marking Summary: Marking scheme based on the work by [Davidson and Woodman] 1995\n\nGrading rubric:\n\n---\n#### Marking Criteria\n###### Question marking scheme",
        "label": 0
    },
    "1900": {
        "output": "#### 2\n##[INST] The patient has chronic HIV infection, which meets the following inclusion criteria:\nHemoglobin >10g/dl Age (18-45 years) Body Mass Index(18-29 Kg/m\u00b2) Exclusion Criteria:\n(1) Presence of active drug intake (2) Presence of pregnancy<EOD> Inflammatory mediators of chronic pain: an overview\n\nInflammatory mediators have a significant role in the clinical manifestations of acute and chronic pain. Among many of the pathways involved in inflammatory pain, three major pathways are the cyclooxygenase-1 and -2 (COX-1 and COX-2) pathways, the 5-lipoxygenase-receptor pathway, and the inducible nitric oxide synthase pathways. Phospholipase A 2 initiates the formation of pro-inflammatory fatty acids, such as lipoxins and leukotrienes, which have been implicated in a variety of inflammatory conditions such as rheumatoid arthritis and chronic kidney disease. Nitric oxide is one of the major inflammatory mediators involved in inflammatory processes, and it inhibits platelet aggregation and vasoconstriction. Although much remains to be learned about inflammatory pain, recent advances should aid in expanding our understanding of this complex disease process, and lead to the development of new therapeutic targets.\n\n# Introduction\nPain is defined as an objective physical phenomenon by the International Association for the Study of Pain (IASP), which defines pain as \"An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage\" (www.iasp-pain.org). There are two major types of pain: acute pain, which is a temporary condition that occurs as a response to a tissue injury or disorder, and chronic pain, which are a persistent, continuous, and often undulating painful state. Chronic pain is estimated to affect up to 50% of the population and is a strong predictor for disability, diminished quality of life, social isolation,",
        "label": 0
    },
    "1901": {
        "output": "[HINT]:\n\n\n**Finding eligible patients in the patient data**\n\nNow, your task is to find the eligible patients for the clinical trial on HIV and STIs. The eligible patients in the clinic for the next week are: \n\n[LIST] \n    \u2713 Cathy G.\n    \u2713 Bill M.\n    \u2713 Frank J.\n    \u2713 John A.\n    \u2713 Jane R.\n    \u2713 David S.\n\nThe note of a patient is given in the section \u201c[INSERT HERE]\u201d of the patient\u2019s record. The note includes information about the trial that is described in Section \u201cSection 1 \u2013 HIV Research in Germany\u201d. If an eligible patient has the last-mentioned information in his note, he is eligible for participation to the trial.\n\nAs we work with an excel file, a patient record shows us the last 5 visits. So, to find eligible patients, do the following steps (the steps are in bold in the excel file): \n\n  1. \n    Click on the link \u201c[INSERT LINK HERE]` at the upper left corner of the data sheet. The window of the linked database is opened.\n    Click on the menu \u201c[INSERT MENU NAME HERE]` at the upper right corner of the \u201c[INSERT LINK HERE]` window.\n  2.\n    Click on the first row in the first column of the data sheet of \u201c[INSERT LINK HERE]\u201d.\n \n    The first row of the data sheet is the first line of the Patient Information sheet, which shows basic info about the patient: the patient id number (PIS), patient name, sex, and birth date, among other details.\n \n    If you click again on the first row, a sub-tab containing the five most recent patient visit dates will be opened. \n    Click on the date (the first field under the sub-tab heading) that shows the first visit (the first row of the five visit rows).\n  3. At the right side, below the sub-tab window, the patient's record for the previous visit appears. \n    Note the patient's number. \n  4. Click on the menu \u201cRecord\u201d. The \u201cRecord\u201d tab of the \u201c[INSERT LINK HERE]\u201c window is",
        "label": 2
    },
    "1902": {
        "output": "<EOD> The Painful Leg Ulcers Clinical Pocket Guide\nThis pocket book, endorsed by the American Academy of Physician Assistant and the American College of Radiology, summarizes the latest information in ulcer prevention and treatment. Clinical diagnosis, noninvasive assessment, and the application of wound-healing science to pressure ulcer prevention and management are also discussed.\nWith an emphasis on the POCUS, 50 ultrasound images are provided to help you identify and treat the problem or help make a diagnosis. Also included are a brief description of each case, the differential diagnoses, the differential diagnoses, and the steps required to identify and treat the problem. The book includes many illustrations and diagrams to guide you through the anatomy and physiology, and the book is an ideal handbook for any advanced ultrasound practitioner or physician. This book is also ideal for use by practitioners who are not trained in ultrasound, but use ultrasound to diagnose and treat ulcers.\nThis is a 71-page professional edition published by ACPA Inc.<EOD> The role of social, family and school support in the lives of adolescents with chronic musculoskeletal pain\n\nBackground: The burden of chronic musculoskeletal pain (pain duration >3 months) in adolescents is significant and increasing. The development and implementation of health care services and interventions designed to improve the lives of adolescents with chronic musculoskeletal pain need to be informed by evidence which identifies the factors associated with adjustment to pain in this age group. This study aimed to explore the perceived influence of social, familial and school support within the lives of adolescents with chronic musculoskeletal pain and compared their responses with those from a healthy control group. Methods: Secondary analysis of qualitative data from focus groups conducted as part of a broader, mixed methods study was carried out. Data were collected from 18 adolescents with chronic non-specific musculoskeletal pain (M age = 15.5 years; SD = .96) and 11 healthy ad",
        "label": 0
    },
    "1903": {
        "output": "[TIP]\n\n\n### Instruction Notebook:\n\n```$ git cd {your_path}\n$ git clone <EMAIL>:<EMAIL>/cogsci-lab/medical_note_for_clinicals_trials # <EMAIL>: <EMAIL>: [e.g., pk527e@snu.ac.kr: pk527e@snu.ac.kr : pk527e@snu.ac.kr]\n\n$ cd {your_path}/medical_note_for_clinicals_trials\n\n# $ python3 main.py <FILE> [patient note file]\n```\n\n\n### Reference\n\n[https://www.clinicaltrials.gov.\n<EOD> Ancient DNA provides new insights into the formation of Soviet Union\u2019s human resources\n\nStrait of Tartary or Tran-Ta-Hien Strait) as a main route of gene flow at the time of Soviet Union formation. This analysis also indicated that the genetic exchange was probably restricted to populations inhabiting the same region.\nA lthough Soviet Union was created by the treaty of Brest-Litovsk in 1918, it continued its geopolitical expansion during the 1920s. It also continued to accept a number of people from its Western neighboring countries, such as former Tsarist Empire's citizens and former prisoners of wars from Serbia, Bulgaria, Romania and Italy 1 . The Soviet Union, however, did not absorb the former German citizens. The reason for this is ascribed to the lack of cultural and linguistic commonality between the Soviet Union and Germany. It must be noted, however, that many people living in Central Asia-the border region to both of Germany and the Soviet Union-were German colonizers-either German people or descendants of German colonizers-and thus they may serve as a bridge of genetics between two regions.\nTurkmenistan, Iran and Pakistan that were under the direct or indi-rect rule of Persian/Afghan Empire or Ottoman Empire could be a good indicator of ethnic backgrounds in Central Asia. As many of the indigenous Central Asians that lived under imperial rule were originally Persian or Arabian speaking,",
        "label": 0
    },
    "1904": {
        "output": "<EOD> .\nOBJECTIVE\nTo investigate the efficacy and safety of transarterial chemoembolization (TACE) and transarterial infusion chemotherapy (TAI) as the first-line therapy in patients with advanced hepatocellular carcinoma (HCC).\n\n\nMETHODS\nThe clinical data of 93 patients with newly diagnosed HCC who underwent TACE or TAI with cisplatin and 5-FU as the first-line therapy for the periods of August, 2008 to September, 2011 were reviewed. Thirty-seven patients who received TACE were assigned to the traditional TACE group while the remaining 56 patients who received TAI were classified into the TAI group. The 8-month survival rate and 12-month survival rate were compared between the two groups.\n\n\nRESULTS\nAfter therapy, the 8-month survival rates in the TACE and TAI groups were 78.4% and 72.7% respectively (P=0.613), and the 12-month survival rates were 68.5% and 51.6% respectively (P=0.086). During the follow-up periods, the overall survival significantly differed between the 2 groups (log-rank P=0.042). In the TACE group, the 12-month survival rates in Grade A and Grade B of tumor size-based Barcelona Clinic Liver Cancer (BCLC) staging system at baseline were 76.0% and 51.4% respectively. The prognosis of the patients in the TAI group with multiple tumors larger than 7 cm and BCLC stage C were better than those in the TACE group. No difference in overall survival was observed between the two therapies (log-rank P=0.084). All the complications were relieved with conservative treatment.\n\n\nCONCLUSIONS\nThe first-line therapy with TACE and TAI is effective and safe in patients with advanced HCC. The overall survival of the patients in the TACE group is better than that in the TAI group, and the prognosis of the large-",
        "label": 0
    },
    "1905": {
        "output": "> 135: \n\nNow you are done with Part 1, so we can move to Part 2. You already saw the Trial-Level Variables section in Part 1. In Part 2, you just have the Clinical and Translational Analysis subsection. The purpose of Part 2 is to describe the methods for the analysis. \nLet's go back to the Trial-Level Variables section in Part 1 [4]: 1) Inclusion Criteria: \n\nExclusion criteria are similar to the inclusion criteria, but there is one more, i.e., Exclusion:\n3) Patients with missing or incomplete blood or blood products from another person (ABO incompatible or unknown).\n\nPart 2: Clinical and Translational Analysis\n\nHere you describe the statistical analysis procedures in detail. You should follow a systematic checklist for statistical analysis in publications of medical research results, as recommended by the International Committee of Medical Journal Editors (ICMJE). \n\n> 136: \n\nFirst of all, you should define the variables of the clinical data that you are going to use to perform a hypothesis test. You could define the primary and secondary variables, but also you could consider others as covariates. 15 The investigator will obtain a written informed consent from the patient (for studies including patients) or participant by signing or a legally authorized representative in a manner consistent with the local regulations for each participating institution.\n\n1)\n\nExclusion:\n\nParticipant is unwilling or unable to complete the informed consent or protocol.\n\n\n# Introduction 17\n\nExplain where the trial is conducted and why the patients were invited to participate in the trial.\n\n\n## 18\n\nBackground\n\n1)\n\nExhaustive description of the trial, explaining what intervention was used, how it works, what are the potential benefits and risks of the intervention 2)\n\nSafety information\n\nThe trial includes a long-term follow-up period for participants according to the time it takes to assess clinical efficacy and other outcome measures.\n\n19\n\nObjectives 19 20 20 29\n\n\n## 20\n\nObjectives 20 20",
        "label": 0
    },
    "1906": {
        "output": "<EOD> Synthesis, characterization, and magnetic properties of Co-Mn-N-C single-atom-doped graphene: an Fe-like impurity.\nA new atom doping strategy to transform Co- and Mn-based spinels into single-atom-doped graphene-like materials has been developed. The as-obtained Co-Mn-N-C has the best iron-like magnetic behavior among all of the samples.<EOD> Increases of cerebrospinal fluid norepinephrine levels in rats with spinal cord injuries.\nCerebrospinal fluid (CSF) norepinephrine (NE) levels were determined by radioenzymatic assay in sham-operated and unoperated rats, in rats with spinal cord or spinal nerve injury, and in rats with spinal cord lesion and treatment with 6-OH-dopamine (6-OH-DA) or dexamethasone . 28 days after rats received lumbar intrathecal injection injuries of the spinal nerve or cord, NE concentrations in rat CSF were significantly increased. Chronically elevated levels of CSF NE concentrations were found in the group that received 6-OH-DA, but not in those groups of animals that received spinal cord injuries and treated concomitantly with dexamethasone. CSF NE concentrations 3 days after spinal nerve injuries were significantly higher than 28 days after cord injuries.<EOD> Interaction of p53, MDM2, FOXO4 and SKP2 in ovarian cancer pathogeneis\n\nOvarian cancers are aggressive tumours, due to late detection and advanced stage at presentation. Consequently, new molecular markers need to be identified for earlier diagnosis. The tumoursuppressor protein p53 is commonly mutated with functional suppression in these tumours. To investigate molecular mechanisms that control p53 function and that are influenced by p53 mutation, we undertook the first detailed and large-scale comparative study of the gene expression patterns of different ovarian cancer sub-types (with and without p53 mutation) and corresponding normal tissue samples. This analysis identified a group of transcription factors (FOXO4,",
        "label": 0
    },
    "1907": {
        "output": "@requires('reach', 'reach.focused')\n    @require('reach', 'reach.reachability')\n    @requires('reach', 'reach.repr-f')\n    @requires('reach', 'reach.get-f')\n    def make_inpatient(self,\n      reach=self.get('reach').focused,\n      reach_repr=(f for f in self.focused_fields if f.name == 'reachability')\n      #get((f for f in self.focused_fields if f.name == 'reachability')[0]),\n      #get('reach_repr')\n      ,\n      reach_repr_f=(f for f in self.focused_fields if f.name == 'reach-f')\n      #get(reach_repr_f[0]),\n      #get('reach-f')\n    ):\n      ## 1.\n      ##\n      ## Patient's information:\n      ##\n      ## 2. 1.\n      ##\n      ## Hospital note, and patient data:\n      ##\n      ## 3. 2.\n      ##\n      ## Medication:\n      ##  \n      **make_hospitalNotes(reach.hospital_note_focused)\n      ## 4. 3.\n      ##\n      ## Discharge date:\n      ##\n      ## 5. 4.\n      ##\n      ## \n      ## -2. Patient's Information\n      ##\n      ## -3. Hospital Note and Patient Data\n      ##      -4. Medication\n      ##      -5. Discharge Date\n      ##\n      **make_patient_data(reach.focused)\n      \n      **self.inpatient = self.make_inpatient_data(reach._id,  ## \u2461 - hospital_note_focused\n        ## \u2463 - medication\n      #get(reach_repr_f[0])[0])\n      #[1].hospital_note_focused,\n      ##get(",
        "label": 0
    },
    "1908": {
        "output": "---\n\n\n**5.** You should write the test.py: (2 points)<jupyter_code>from __future__ import print_function\nimport pandas as pd\nimport numpy as np\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport pymysql\nfrom PIL import Image\nimport re\nimport random\nsns.set_style(\"whitegrid\")\n\ndef get_data():\n    d = {}\n    return d\n\ndef print_data(d):\n    d = [[\"name\", \"age\", \"sex\", \"marital status\",\"BMI\", \"diabetes\", \"heart disease\",\n          \"hypertension\", \"hyperlipidemia\",\"smoking\", \"drinking\", \"coffee drinking\", \"tea drinking\", \"peanut allergy\",\n           \"sesame allergy\", \"wheat allergy\",\"gluten intolerance\", \"mushroom allergy\", \"fish allerg*\" ,\n           \"shellfish allerg*\", \"allerg* to a drug\", \"allerg* to insect sting\", \"allerg* to latex\", \"allerg* to dust mites\"],\n         [\"asthma\"],\n         [\"hay fever\"],\n         [\"allerg* to pollens],\n         [\"allerg* to pet dander\"],\n         [\"allerg* to molds\", \"atopy\"]\n          , [\"peanut allergy\"]\n          ]\n\n    tt= pd.DataFrame(d)\n    print('#', 'test')\n    print tt\n\ndef print_t2t(ts):\n    tts2 = []\n    tts = [[\"name\", \"age\", \"sex\", \"marital status\"],\n            [\"allerg* to molds\", \"atopy\"],\n##            [\"allerg* to insect sting\"],\n           [\"allerg* to latex\"],\n##           [\"allerg* to drug\"],\n##           [\"allerg* to pollens\"],\n##            [\"allerg* to pet dander\"],\n            [\"allerg* to smoke\", \"can smoke\"],\n            [\"allerg* to dust mites\"],\n            [\"allerg* to peanut\"],\n           [\"allerg* to fish\", \"aller",
        "label": 0
    },
    "1909": {
        "output": "[INST] You are the principal investigator of a study entitled \u00ab Prevention of Bacterial Infections in HM- Patients with CD4 counts less than 100 cells/mm3. \u00bb A randomized trial.\n\nYour objective is to evaluate the efficacy of preventive treatment against sepsis among Human-Immunodeficiency Virus patients with a CD4 counts less than 100/mm3.\nIt is important to use three types of variables to describe the patient:\n\na) An identifier in the person: Patient ID: A number unique to each patient in the study;\n\nb) A name or a unique identifier for an organism in the body: Biological ID: The laboratory results such as HIV viral load and CD4 counts\n\nc) A description of the disease in a particular organism: Treatment ID: The name or dose of a drug used by the patient to treat a disease\n\nPlease answer the following questions:\n1) Which table is suitable to store clinical study data?\n[ANS -]A relational database.\n[ANS -]A spreadsheet.\n[ANS -]A flat file.\n[ANS -]An XML file.\n\n2) Which type of database is the best to store information in the clinical trial data?\n[ANS -]A data warehouse.\n[ANS -]A relational database. \n[ANS -]A spreadsheet. \n[ANS -]A flat file. \n[ANS -]An XML file. \n\n3) Which type of clinical study data should be collected and stored into a database?\n[ANS -]The patient data.\n[ANS -]The patient and doctor's data.\n[ANS -]The patient's health data.\n[ANS -]The doctor's data. \n[ANS -]The billing data.\n\n4) Which type of patient data is stored in flat file databases?\n[ANS -]Name and identifying characteristics of the person.\n[ANS -]Personal medical history and the biological activity of the person.\n[ANS -]Treat of the person or organism's environment to the disease .\n[ANS -]Only the medication",
        "label": 2
    },
    "1910": {
        "output": "<EOD> Anterior Cruciate Ligament Reconstruction Using Bone\u2013Patellar Tendon\u2013Bone Construct: A Biomechanical Evaluation of Different Surgical Techniques\nThe current study evaluated the biomechanical properties of 2 different variations in the surgical repair technique for an anterior cruciate ligament (ACL) reconstruction using hamstring graft by comparison with tibial insertion and whole-tendon fixation. A total of 90 fresh-frozen porcine lower limbs were dissected. A total of 30 specimens from each group underwent 3 stages of tensile load testing: unloaded, initial loading, and cyclic loading. The initial, cyclic loading, and ultimate loads were statistically different. Graft size, number of anchors used, and method of fixation contributed to differences among the groups. This study shows that the fixation method of autogenous hamstring tendons is an important variable. The fixation method of an autogenous hamstring tendon to the tibial tunnel should be considered when the graft size is small.<EOD> Prognostic Values of Preoperative Dynamic Contrast\u2010Enhanced MRI Features in Colorectal Cancer\nTo evaluate the prognostic values of dynamic contrast\u2010enhanced MRI (DCE\u2010MRI) parameters in colorectal cancer patients.<EOD> Transmembrane signaling through calcium/calmodulin-dependent protein kinase II contributes to regulating insulin-stimulated glucose transport: evidence using a novel immunochemical approach for disqualifying C beta 4 mutant receptors.\nMutations in the transmembrane domain of the insulin-like growth factor I (IGF-I) receptor have previously been shown to greatly reduce activation of phosphatidyl-inositol 3'-kinase (PI-3k) and to cause type A insulin resistance. We developed an immunoassay system that discriminates between wild-type and mutated forms of the IGF-I receptor alpha subunit. This assay was used to determine the role of the gamma(Q)/C beta 4 domain of the IGF-I receptor in transducing the signal from the IGF",
        "label": 0
    },
    "1911": {
        "output": "# Requirements\n\n### Output of patient's eligibility\nWe expect that the output of a patient's eligibility should satisfy the following requirements.\n\n- The assessment of eligibility must be a integer in each line: 0 or 1.\n\n- The output for each input patient should be a integer in each line: 0, 1, or 2 depending on the input. \n- For each clinical trial, we expect that the output in each line is a integer. \n\n### Avoid the output of \"All not relevant\"\nAvoid the output of \"All not relevant\" for each clinical trial since it does not satisfy the first requirement. \n\n## Assessment of Eligibility 1\nAnother issue is the output format for the assessment of eligibility. We expect that the output for the assessment of eligibility must satisfy the following requirements. A case of an incorrect output for the assessment of eligibility that satisfies neither the third and fourth requirements. It does not satisfy the third requirement (the second line of the output) since the second line of the output is not a integer. A case of an incorrect output for the assessment of eligibility that satisfies the second requirement but not the third requirement. It does not satisfy the third requirement (the second line of the output) since the second line of the output is not a integer. A case of an incorrect output for the assessment of eligibility that satisfies neither the second and third requirements. It does not satisfy the second requirement (it should output \"All not relevant\") since the input patient note should be an empty case.\n\n### Generalized example: the \"All not relevant\" output (3 and 4 requirements)\nThe assessment of eligibility should be generalized for the 3 and 4 requirements.\n<EOD> Efficacy of a multimodal protocol in the neonate with suspected late\u2010onset sepsis\n\nThe early diagnosis of sepsis is crucial to successful treatment in all neonates. In neonates with suspected late-onset sepsis (LOS) (\u22653 days of age), evidence-based guidelines for the use of multiple laboratory indicators and the clinical signs of sepsis have not been well defined. Our objective was to study neonates treated under a",
        "label": 0
    },
    "1912": {
        "output": "} \n\n## Example\nPlease refer to one example of the output from YMLR:<EOD> Sensitive and rapid bacteriophage-based assay for detection of Listeria monocytogenes\n\nIntroduction.Listeria monocytogenes is a food-borne pathogen that causes listeriosis, which can be deadly in susceptible populations. This pathogen can survive the high-acid conditions found in soft cheeses, which are one of the main routes of transmission as well as being the main vehicles of spread. Rapid detection of this pathogen in cheese is imperative to limit both the spread of infection and the costs incurred through recall and damage to brand image. A variety of real-time commercial and home-grown bacteriophage-based assays targeting different species were studied to determine the sensitivity, precision, speed, and economical aspects of detecting Listeria.Methods. L. monocytogenes was grown on brain heart infusion agar (BHI) plates (LGC, UK) overnight before being sub-cultured into BHI for use in the study. Sensitivity and specificity of commercially available real-time PCR kits for Listeria spp. (BIO-X Diagnostics, Belgium) and realtime Listeria monocytogenes (Lm) PCR kit (Bio-Thermaq, Denmark) as well as a number of homegrown real-time and endpoint assays testing different listeria bacteriophage and different replicative formats were assessed and compared using DNA extracted from the Lm reference isolate DSM 20648.Results. The Lm real-time PCR kit performed the best out of all those assessed, with a limit of detection (LoD) of approximately 3.7 \u00d7 10 1 colony forming units per mL (CFU/mL). All bacteriophage-based real-time and endpoint assays performed well, including one of the end point assays that utilized trans-duced E. coli with the lsp1 listeria bacteriophage as a reporter system which was the most sensitive assay (lowest LoD of approximately 4.6 CFU/mL).Conclusion",
        "label": 0
    },
    "1913": {
        "output": "[CODE] for(int idx = 0; idx < pts.length(); idx++); { //print patient information for(int trial_idx = 0; trial_idx < clin_trials.length(); trial_idx++) { if(inclusion_criteria == 2) { if(clin_trial.match(trial_idx) == true) { patient_info.write_line(idx, trial_idx, \"match\"); //if the patient met the requirement of the trial patient_info.write(idx, trial_idx, 'match\\n'); System.out.print(clin_trials[trial_idx]); } else if(inclusion_criteria == 1) { if(clin_trial.match(trial_idx) == true) { patient_info.write_line(idx, trial_idx, \"match\"); //if the patient met the requirement of the trial patient_info.write(idx, trial_idx, 'match\\n'); System.out.print(clin_trials[trial_idx]); } else if(inclusion_criteria == 0) { if(clin_trial.match(trial_idx) == true) { patient_info.write_line(idx, trial_idx, \"match\"); //if the patient met the requirement of the trial patient_info.write(idx, trial_idx, 'match\\n'); System.out.print(clin_trials[trial_idx]); } } else //(1,0) if the patient does not have sufficient information to qualify for the trial patient_info.write_line(idx, trial_idx, \"Not relevant\"); //if the patient does not have sufficient information trial_info.write(idx, trial_idx, 'Not relevant\\n'); System.out.print(clin_trials[trial_idx]); } else { trial_idx--; patient_info.write_line(idx, trial_idx, \"match\"); //if the trial matched the criteria of the patient patient_info.write(idx, trial_idx, 'match\\n'); System.out.print(clin_trials[trial_idx]); } } //write the last information System.out.println(\"Last Assessment Eligibility :\"); patient_",
        "label": 0
    },
    "1914": {
        "output": "#### Exercises\n\n###### Find the correct response in each case.\n\nThe patient is a 55-year-old man diagnosed with HCV and the recent coinfection with HBV. He has a no\n\nYou will see a new table. We want to compare the columns `Name` and `Assessed` from this table with the new object `Patient_name` and `Trial_eligibility` from the new object `Test_eligibility`. The function `join()` can make a new table where columns are the union of two columns. In this case use columns from `Patient_name` and columns from `Trialeligibility`. To get only matching columns use the function `select_by()`. The result should be a table with the columns from `Patient_name` and the column `Trial_eligibility` with the new value set to TRUE, i.e., `Trial eligibility: Excluded = 0` and `Trial eligibility: Eligible = True` or `Trial eligibility: Eligible = 1`. You can see it below.\n\n###### Write the Trial_eligibility column in this table.\n\n###### Fill in the gaps and write the output table. \n```\n\nFor example, the first patient:\n```js\nvar Patient = require('csv');\nvar Test_eligibility = require('xls');\nvar patient_name = [{ \"name\": \"patient1\" }];\n\nvar Trial_eligibility = Test_eligibility.select_by(\n  'patient_name',\n  'patient1',\n  'Trial_eligibility'\n);\n \nTri = Trial_eligibility[0];\nTrial_eligibility\n  \n```js\n\n\n\n\n```js\n# TRIAL_ELIGIBILITY_RISK_ASSESSMENT=0\n\n```\n<EOD> .\nFifty patients underwent laparoscopic cholecystectomy (LCh). The laparoscopic technique used was the transcutaneous four-port technique. The patients were divided into two groups: Group A (28 cases): with gallbladder, gallstones, ganglion",
        "label": 0
    },
    "1915": {
        "output": "![](/assets/images/stepByStepInstructions.png) \n \n__This is the end of Level 1 training. You have now completed all the exercises in this training series. There is no need to repeat the exercises in the lower levels. We hope you have enjoyed this course and that you will consider applying this framework to a data problem you might encounter in your daily work. This course is designed to train data analysts, epidemiologists, biostatisticians and others who need to learn data analytics and machine learning. The following list of topics will cover: 1) Supervised Machine Learning Algorithms: Logistic Regression, Support Vector Machine, Random Forest, XGBoost and Neural Network. 2) Applications: An overview of various applications that can help with data analytics. 3) Data Analysis of RNAseq and ChIP-seq Data. 4) How to prepare your own datasets. We cover the basics of supervised and unsupervised machine learning techniques using the Scikit-learn and TensorFlow libraries.\\n\nThe video series in this course is made possible through the sponsorship of iHealthcare Media, Inc.\n\n\n\n\n\n\u00a9 Copyright 2020 [Yuzhen Tan](https://yuzhen_tan.github.io). All Rights Reserved.\n\n[![CC BY-NC-SA 4.0](https://commons.wikimedia.org/w/index.php?curid=60235625&version=latest&viewimage=default&edit=Yuzhen_Tan&page&=1&position=1) ](<EOD> Enhancing immunoglobulin A responses after influenza immunization in adults with HIV\u20101 infection: a phase I study with an adjuvanted recombinant influenza vaccine\nWe evaluated an oil\u2010in\u2010water adjuvant system (CpG\u20101018 + Imiquimod) for its ability to boost the immune response with HIV\u2010negative subjects and HIV\u2010positive subjects having CD4+ T cell counts greater than 200\u2004cells per \u03bcl.<EOD> A Randomized Trial of the Safety and Efficacy of Mometasone Furoate in Combin",
        "label": 0
    },
    "1916": {
        "output": "<EOD> Correlating HPV16 genetic variants with immune responses to the E6/E7 antigens\n\nHPVs infect cutaneous and mucosal epithelia in a wide variety of species. Mucosal HPVs can cause cancers and pre-cancerous lesions. In most individuals, the T cells that target the viral antigens (E6/E7) protect against high-risk (HR) mucosal HPVs. We hypothesized that HPV genetic polymorphisms could influence virus-specific T cell responses. We explored the correlation of E6 and E7 polymorphisms with T cell responses in high-risk HPV-positive cervical cancer patients. T cells from HPV16-positive patients were screened for reactivity against HPV16 E6, E7 and E6/E7 peptide pools using IFN-\u03b3 ELISpot. In parallel, we analyzed polymorphisms for a range of mutations (from high-frequency to low-frequency) across the genome and for amino acid substitutions in E6 and E7 peptides. We found HPV16 E6 and E7 to be the dominant regions for strong cross-reactive T responses. Although the majority of patients displayed a positive T cell response to E6, E7 and E6/E7 peptide pools, there was wide inter-patient variation in level of responsiveness both to individual peptides and to pools. The strongest positive responses were observed to the peptide containing the T cell epitope HPV16-71-77 (NYDLLFRL) and peptides containing polymorphisms. There was relatively low inter-patient variation in the frequency of this and other frequently mutated peptides. Some patients showed T cell responses to peptides that contained the polymorphisms only, suggesting a low immunogenic or tolerogenic potential of the corresponding peptide variant. In conclusion, T cell recognition of HPV16 proteins, peptides and the polymorphisms therein occurs in these patients. The low degree of inter-patient variation in responses suggests cross-reactive responses.\n\n# Introduction\nThe majority of HPV in",
        "label": 0
    },
    "1917": {
        "output": "[/TUT]\n\n---\n\n<br/>\n<a class=\"btn btn-white btn-lg\" href=\"../../index.md/03.basics.html\">[\u2191] Go to the next section \"3.  Basic Skills\"</a>\n\n***</div>\n***\n\n{% include links.html %}<EOD> The Molecular Basis for Oligo-Specificity of the RuvB Branch Migration Enzyme*\n\nThe RuvBA complex from Escherichia coli utilizes dynamic and highly coordinated movements of a DNA-junction to promote branch migration of Holliday junctions. RuvB is a hexamer with two DNA-binding interfaces per hexamer. The N-terminal domain of each subunit has a \u2424-sheet sandwich composed of two long, antiparallel \u2424-strands, which contacts the DNA in a groove of the DNA-hexameric ring interface. Structural analysis predicts that the three nucleotides between the two 3-fold DNA-binding interfaces are bound by four amino acids. Here we study the interaction of RuvB with different DNA substrates using a gel retardation assay. We show that there is a cooperative interaction between RuvB and DNA. Moreover, we have identified the nucleotides contacted by RuvB. Using this information, we were able to predict the RuvB binding affinity to the same nucleotide that is positioned between two \u2424-sheets in the DNA-hexameric ring interface. RuvB, as in similar helicases, is able to distinguish inversion symmetry within the DNA; therefore, RuvB is oligospecific. The RuvB and RecB hexamers are related by a crystallographical symmetry, and the DNA substrates investigated are chemically similar. Thus, although the RuvB oligospecificity can be predicted by its similarity to the RecB helicase, the functional consequences may differ.\nIn Escherichia coli, genome replication is carried out by bipolar forks that have to unwind the replication fork and inverts their strands. The chromosome DNA is a long double strand which is in general topologically linked and thus can exist in different",
        "label": 0
    },
    "1918": {
        "output": "# Author Contributions \n[fig]  [INST] Let: us think how to check the eligibility on HCVRNA levels with the given inclusion criteria. [/fig] \n<EOD> Effect of dietary vitamin A and calcium levels on egg\u2010white proteins and laying performance of laying hens\n1. Egg-white protein and the calcium content of the egg white were determined in eggs produced by laying hens maintained on diets containing the same amount of calcium, with extra added vitamin A, and from a commercial layer diet. At the end of the experiment, birds were killed and blood samples were taken for serum calcium determinations. 2. The addition of extra vitamin A to the diet of laying hens fed a commercial layer diet had no effect on egg-white protein and egg-shell quality, but it did affect the distribution of egg-white protein and increased calcium concentration in the egg white. 3. The addition of extra vitamin A failed to depress egg-white protein in hens maintained on a high dietary calcium content, but at the same time decreased egg-shell weight of eggs. 4. The effect of extra vitamin A on calcium content of egg white seemed to be independent of dietary vitamin A concentration and of daily laying rate.<EOD> Exploring the potential of 7D8, a new, potent integrin \u03b1v\u03b23/\u03b15\u03b21 antagonist, in solid tumors\n\nIntegrins are cell surface adhesion proteins that play numerous key functions related to growth, attachment, spreading, and survival. The family consists of 18 \u03b1 and \u03b2 subunits that combine to form heterodimeric receptors. Two of the key integrins in cancer are \u03b1 v \u03b2 3 and \u03b1 5 \u03b2 1 . These heterodimers are highly expressed on endothelial cells, but also expressed in tumor cells, and on activated platelets in the bloodstream. They interact with components of the extracellular matrix, cell-cell adhesion molecules, and other adhesion receptors, which regulate the adhesion of cells to the extracellular matrix and the subsequent migration of tumor cells through their surroundings. Blocking integrins alters this interaction with their ligands, resulting",
        "label": 1
    },
    "1919": {
        "output": "Please read the documentation.\n[INST]\n[END]\n[EXERCISE]\n\n## 14. Clinical Trial\nYou need to practice your ability to create and test your own clinical trial program. For clinical trials, you should define the following data: the eligibility criteria for patients to enroll in the clinical trial, a description of the clinical trial, the frequency of evaluations, and the time-points of evaluation.\n[INST]\n\nLet's practice the process.\n\n### Setup\n```python 2.7\nimport pandas as pd\nfrom time import sleep\n\ndef setup_a_clinical_trial():\n    trial = {\n        \"Title\": \"Glutamine versus placebo in patients with head and neck cancer\",\n        \"Summary\": \"This is a randomized open-label clinical trial to assess the safety and efficacy of parental and enteral L-glutamine on quality of life in patients with head and neck squamous cell carcinoma who have undergone radiotherapy. Patients age 18 years and older treated with radiation (external beam or brachytherapy) and curative intent will be recruited. \n    \n    Patients will be randomized to receive a standard oral elemental formula of amino acids during the concurrent phase of radiotherapy and for a period of 3 months thereafter, with the primary endpoint being change in the QLQ-HN35 score.\"\n    }\n    trial[\"Inclusion/Exclusion Criteria\"] = {\n        \"Inclusion criteria\": \"Patient must be willing and able to comply with all study procedures. All patients must be at least 18 years of age. Patients must be able to take oral medications. All patients must have histologically confirmed head and neck cancer. All patients who have undergone radiation therapy will have radiographic evidence of disease following radiation as indicated by clinical examination, CT or MRI imaging. Patients must have documented disease that is not amenable to surgical resection or other forms of non-surgical local therapy. All female patients of childbearing potential must have a negative urine or serum pregnancy test prior to entry and abstain from sexual activity due to the ter",
        "label": 0
    },
    "1920": {
        "output": "<section class=\"panel\">\n<ul>\n<li>\n<h3>Please provide a solution using `str_sublist()` function in R. </h3>\n</li>\n<li><h4>Solution</h4></li>\n<input name=\"answer\" id=\"answer\" type=\"hidden\" />\n<code class=\"python\"><pre><span class=\"highlight\">import pandas as pd\nfrom sklearn.model_selection import train_test_split\nfrom sklearn.metrics import accuracy_score\nfrom sklearn.metrics import roc_auc_score_estimator_from_training_values\nfrom sklearn.neighbors import kd_tree_classifier\nfrom pandas_profiling.metrics import calculate_accuracy_score\nfrom sklearn.preprocessing import StandardScaler\nfrom sklearn.model_selection import cross_val_score\npd.set_option(\"display.max_rows\", None)</pre></code></li>\n<hr style=\"height: 1.81mm\">\n</ul>\n\n\n<p class=\"panelDetails\">\n<div class=\"row\">\n<ol class=\"faq-list faq-list-question\">\n<li>\n<strong>\n<a class=\"goToPanel a-link a-open\" href=\"python/question/Q1.html\">\nPrevious answer &#x2192;<span class=\"fontNormal\">&#9650;</span> \nChange answer &#x2192;<span class=\"fontNormal\">&#9650;</span> \nReset &#x2192;<span class=\"fontNormal\">&#9650;</span>\n</a></strong>\n</li>\n<li>\n<strong>\n<a class=\"goToPanel a-link a-open\" href=\"python/question/Q2.html\">\nNext answer &#x2192;<span class=\"fontNormal\">&#9650;</span> \nChange answer &#x2192;<span class=\"fontNormal\">&#9650;</span> \nReset &#x2192;<span class=\"fontNormal\">&#9650;</",
        "label": 1
    },
    "1921": {
        "output": "### Test Cases\nThe following are examples of possible patient cases. There is no real meaning behind the example patient notes.\n\nFor each patient note, you should output Trial-level eligibility: for each patient note. There is no need to print the other columns.\n\nBelow are test cases for the patient note: \n\nHere are test cases for the clinical trial:\n| ID | Description |\n| --- | --- |\n| 1 | Type 1 non-alcoholic steatohepatitis and chronic HCV-infection. |\n| 2a | Mild liver cirrhosis and chronic HCV-infection in non-alcoholic steatohepatitis patients. |\n| 2b | Active substance abuse, i.e., on-going use of heroin, cocaine, methamphetamines or ecstasy |\n\n[END]\n\n## Data Source: Paper-based patient notes\n\n### Data\n\nThe data come from 43 paper-based patient notes containing: patient name, year of birth, gender, symptoms experienced, medications taken, and the presence of comorbidities. Patient notes are handwritten by clinicians.\n\nThis data set has the following columns:\n\n#### Patient Notes\n| 0 | Birth Year |\n| --- | --- |\n| 1 | Name |\n| 2 | Gender |\n| 3 | GENERAL INFORMATION |\n| 4 | Symptoms |\n| 5 | Comorbidities |\n| 6 | CURRENT MEDICINES |\n\n\n\n### Preprocessing\n\nWe converted all 43 paper-based patient notes to an unstructured document format. Patient notes are written with a line-style. We extracted the information from the patient notes and put the information in the columns. The columns are created according to our design requirements. Some data is missing, such as birth year (not listed for one patient), comorbidities list (for 17/43 patients), and more. \n\n#### First step\n\n###### 1. Read input file named `Paper-Based Patient Note.txt`\n\n```python\nf = open('Paper-B",
        "label": 0
    },
    "1922": {
        "output": "We are going to design a solution to this problem. Before that, we need to split the input layer module in which the problem lies into several modules. \n\n## Design 1\nLet's design a solution by splitting the encoder-decoder into several modules. Let's divide the encoder-decoder architecture into 5 modules A, B, C, D and E where A is the tokenizer, and the other modules are encoders and decoders.\n\n### Implementation:\nAs shown in the figure below, we divided the encoder-decoder architecture into modules A, B, C, D and E. Moreover, each module performed different tasks, so we need to implement each module with a separate function `Encoder.apply_encoder({input data})`. We have already implemented the tokenizer in the Encoder function. If we do not want to change the output format, we need to",
        "label": 1
    },
    "1923": {
        "output": "##[End]<EOD> Diphenylheptane\nDiphenylheptane is an organic compound with the formula Ph2C7H14. It is a colorless solid, insoluble in water and slightly soluble in alcohol and chloroform.\nDiphenylheptane is used as a chemical feedstock in the manufacture of 2,2' 4,4'-Tetramethylene diphenyl diisocyanate (poyurethane precursor) in its high temperature process.\nIt is also used as a plasticizer for polyester and polyurethane resin blends.\nBecause of its very slow rate of vaporization, it is used as an adhesive for silicone parts.\nDiphenylheptane is the common generic name of the pharmaceutical compound 4'-chlorodiphenylmethane, an artificial hormone.\nIts derivatives are the pharmaceutical compounds BHC-646 and BHC-647.<EOD> Bacterial toxins induce membrane insertion of human immunoglobulin A1\nThe production by bacteria of an outer core lipopolysaccharide (LPS) that contains a branched heptose-Kdo disaccharide leads to the formation of defective LPS (lipid A) with a 4-amino-4-deoxy-D-arabinose (L\u2010Ara4N) modification. We have reported elsewhere (H. J. Goff, B. T. Moen, T. J. Kuehl, and H. Braun, Mol. Microbiol. 28:453\u2013467, 1999) that this lipid A substitution renders the bacteria resistant to bactericidal and neutralizing serum immunoglobulin A (IgA) antibodies. To elucidate the mechanism by which the L\u2010Ara4N modification prevents antibody-associated cell killing, we used in this study a combination of flow cytometry, circular dichroism spectroscopy, and atomic force microscopy to analyze the structure of purified subclasses of human sIgA1 antibodies in the",
        "label": 0
    },
    "1924": {
        "output": "##[FIN]\nYou are asked to implement the assessment of inclusion and exclusion criteria in your own language (English or Vietnamese /Chinese, etc.). \n\n### Assignment Expected Structure\nYour assignment will take the form of an Excel file. A typical assignment sheet should have the following section headers:\n1. Cover Sheet\n2. Assessment\n3. Exercise 1\n2. Exercise 2\n3. Exercise 3\n4. Exercise 4\n5. Exercise 5\n6. Exercise 6\n6. References\nHere is an example on how to structure the assignment. Make sure that the assignment is clear and concise.\n\n> ASSIGNMENT FILE EXAMPLE\n> --------------------------------------------------------------------------------------\n> #Cover Sheet\n> #Assessment\n> Eligibility for clinical trial\n\n> #Exercise 1 [D10-56] Cisplatin Chemotherapy and Orbital Exenteration in a Patient with an Advanced Recurrent Squamous Cell Carcinoma of the Lung\n> #Eligibility for clinical trial\n\n> Patient notes:\n>  D10-56 Patient notes:\n>  D10-56\n> Clinical trial information\n>  Trial-level eligibility: 1) Excluded.\n\n#Exercise 2 [D89-14] Cisplatin Chemotherapy and Orbital Exenteration in a Patient with Orbital Squamous Cell Carcinoma\n\nClinical trial information\nTrial-level eligibility: 1) Excluded.[INST] \n1) Excluded.\n\n#Exercise 3\n\n\n1. <EOD> Characteristics and distribution of polyomavirus\u2013infected epithelial cells in kidneys from patients with nephropathia epidemica (nephropathia hemorrhagica)\nNephropathia epidemica, a hemorrhagic fever caused by an hantavirus that resembles Dobrava virus, was diagnosed retrospectively in 5 patients during 1987\u20131991 in Finland",
        "label": 0
    },
    "1925": {
        "output": "You are done! You complete one trial-patient for a clinical trial.\n[TEST] You should have got the following sample output by\n`Python`.\ntrial\nTrial-level eligibility: 1) Ineligible\nPatient-level eligibility: 2) Eligible.\nName: Trial_patient_input1\n\n\nNow, let's continue to the tutorial.\n[TEST]\nIn this part, you learn the meaning of the output text.\n\n\nIf you would like to check your solution using your own Python tool, you can do it now.  Remember that to run your Python code, the following commands are required in the system-level command console.\n\n\nPython3.6<space>py<space>trialpatientexample.py\n\nTo run the second trial-patient in the Trialpatient file in R101 folder, you should move to the following directory using the system-window explorer in your computer.\nMove to the following directory: cd R101\n\n\nRun the following command: Python3.6<space>R101_Trial_patient_example.py to run the second trial-patient by using your own Python tool. You can also move to [R101] folder using the systemwindow explorer.\n\n\nYou should run the following command:\nRun the python file R101_Trial_patient_example.py using the system-window explorer in the [TEST] folder.\n\n\nIf you would like to check your solution using your own Python tool, you can do it now.  Remember that to run your Python code, the following commands are required in the system-level command console.\n\n\nPython3.6<space>trial_patient_example_R101.py\n\nWhat is the difference?\nYou learn the meaning of the output for each run.\n\n\nLet's check the difference in the output.\n[/TEST]\n\n<EOD> Neurovascular Dissection of the Superficial Femoral Vessel\nSummary: One hundred eighteen patients who presented to our vascular laboratories over a 12-month period for invasive study of arterial occlusive disease requiring surgical exploration were retrospectively analyz",
        "label": 0
    },
    "1926": {
        "output": "### Explanation\nIn this assessment, patients were characterized by three independent variables:\n\nAge --10 levels, between 20 and 85 years old.\nDiagnosis --two levels: 1) normal and 2) idiopathic thrombocytopenic purpura (ITP).\nTreatment --two levels: 1) Triple therapy and 2) Steroids.\n\nFor each patient, the trial had three possible outcomes:\n\n0) Excluded, the patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria.\n\n1) Not relevant, the patient does not have sufficient information to qualify for the trial.\n\n2) Eligible, the patient meets inclusion criteria and exclusion criteria do not apply.\n\nThe target variable is the value of the `Trial-level eligibility :` variable. The values of the `Trial-level eligibility :` variable are as follows:\n\n0) Excluded.\n\n1) Not relevant.\n\n2) Eligible.\n\nA trial-level eligible patient is eligible for the trial and is invited to take part in the trial because the patient meets inclusion criteria and exclusion criteria do not apply. A trial-level eligible patient is de facto eligible to the trial. By the way, here's a trick, not many datasets have this kind of variables, the name of the output variable has to be the name of the target variable.\n\nThe classification model was trained using all available data using a five -fold cross-validation. The training algorithm is `glmnet` where the parameter is `alpha = 1.09`, which gave very good performance results.\n\nA trial-level eligible patient is de facto eligible to the trial. After training we have obtained a set of coefficients in \n\n### How can we use these coefficients?\n\nWe can use these coefficient to predict the value of the `Trial-level eligibility :` variable using the value of the three independent variables. \n\nLet's say, we have a new patient (i.e., A person with a value of age, and type of treatment). To infer the value of `Trial-level eligibility",
        "label": 0
    },
    "1927": {
        "output": "___ \n\n\n## ANNEXES \n\n* **Review your model or data with the other participants in the round to make sure all understand the details and have clarifying questions.**. **For additional information on Rounds #1 and 2 from the [COPTIA Workshop on Medical and Health Simulation Roundtable](http://coptia.org/workshop/conference-presentations/)**.\n\n* **The final round for this Challenge will be a 15-minute webinar.*** Please send a link to the webinar recording of a test drive of your application(s) to COPTIA. Note that the final webinar recording of a test drive of the winning entry will be made public and posted on the COPTIA website after the Challenge has ended.\n\n\n_Please review the guidelines for the following categories: `Evaluation Metrics`, `Integration Effort`, `Effort on Code and Documentation` (if any), `Integration Testing`, `Operational Costs`, `Data Security`, and `Performance Efficacy_`. \n\nEvaluation Metrics\n\nEvaluation Metrics are the criteria that will be used to measure the performance of the entries in the COSTITUTE Challenge across each of the Criteria Categories defined above. The Categories are defined based on common metrics that we have seen used by various organizations to rate and score user interfaces for simulation software tools. While the metrics themselves may sound daunting, we think we can all agree on the following: A good simulation tool is one that is usable, useful, extensible and open.\n\n### Scope of the Challenge. \nThe Scope of the Challenge: **Please describe here the specific scope of the competition including (but not limited to) the domain or application of the Tool that you will be testing in your entry.** \n\n**Your description should provide a general view of how well the tool is suitable to achieve the tasks listed in round 1, as well as an idea of what you would use it to explore and what use you would make of it outside of its intended purpose.**.\n__Please also describe the specific scope of the competition in terms of the size of datasets/data that the tool can handle or the specific features that it does, or does not, and should at least qualitatively describe the following",
        "label": 0
    },
    "1928": {
        "output": "<EOD> Comparison of Two Antimicrobial Peptide, Temporin 1 and Magainin 2-Based Gold Nanoparticle Formulations in a Model of Human Urinary Tract Infections\n\nThe aim of this study was to assess whether the gold nanoformulations of the antimicrobial peptides temporin 1 (T1) and magainin 2 (MG2) with lipopolymers (LPPs) conjugated to the surface of gold nanoparticles (AuNPs) could enhance efficacy of the peptides in fighting urinary tract infections (UTIs). Both nanoformulations showed enhanced killing against uropathogenic E. coli (UPEC) compared to the unconjugated peptides, but were less efficacious than free-peptide gold nanoparticles obtained through a self assembly strategy. Both peptides were more potent against Gram-negative than Gram-positive bacterial strains. Finally, the new nano-formulations demonstrated low cytotoxicity against mammalian cells and did not promote macrophage activation. Our results indicate that gold nanoformulation of the antimicrobial peptide T1 with LPPs could potentially be an important therapeutic adjuvant for UTI.\n\n# Introduction\nThe increasing and unpredictable development of antibiotic resistance by bacterial pathogens [bib_ref]  Outpatient antibiotic use in Europe and association with resistance: a cross-national database..., Goossens [/bib_ref]  [bib_ref]  Microbiological and clinical evaluation of the efficacy of vancomycin powder used during..., Mercado [/bib_ref]  [bib_ref]  Antibiotic resistance among urinary isolates: a multicenter study in India, Chaudhary [/bib_ref]  makes it necessary to develop novel drugs for the empiric treatment of a broad range of bacterial infections. Therefore, there is a need to discover or design new alternative candidates for current antibacterial drug classes [bib_ref]  The global preclinical antibacterial pipeline, Theuretzbacher [/bib_ref]  [bib_ref]  Future trends in clinical medicine: antimicrobial resistance, diagnostics and nanotechnology, Thirumavalavan [/bib_ref] .",
        "label": 0
    },
    "1929": {
        "output": "You can refer to the examples below.\n<EOD> The NAC transcription factor MdNAC112 regulates growth, development, and fruit ripening in apple.\nThe ripening of apple fruit is dependent on ethylene and related to the expression of many genes. The NAC transcription factor is a transcriptional activator. In this study, the expression of MdNAC112 in three apple genotypes ('Nagafu No. 2', 'Nagafu No. 1', and 'Sumai 3') was analyzed during fruit. The expression of MdNAC112 increased with ethylene stimulation and was the highest during fruit ripening. The transgenic apple 'Sumai 3' with overexpression of MdNAC112 accelerated the speed of fruit development, growth, and ripening, and increased soluble sugar contents. In addition, the soluble sugars (sucrose, glucose, fructose) in overexpressing fruit showed a faster growth rate than in nonoverexpressing fruit. The results showed that the overexpression of MdNAC112 promotes the ripening of genotypes of apple fruit, which might be related to the expression of MdNAC112 downstream genes (MdACO1, MdACO2, MdACO3), ethylene biosynthesis gene (MdEIN2), and SUS gene (MdSUS4, MdSUS7). This study provides new information on knowledge about apple fruit ripening and the regulatory role of NAC transcription factors.<EOD> Impact of Cognitive Behavior Therapy and Duloxetine on Daily Patterns of Pain in Patients with Complex Regional Pain Syndrome Type 1\nComplex regional pain syndrome (CRPS) is a nonmalignant pain condition that occurs in various clinical forms and is related to physical as well as psychological changes that affect daily activities and functioning. The aim of this study was to investigate the effectiveness of cognitive behavior therapy (CBT) and duloxetine on pain relief and psychosocial factors in patients with CRPS type 1 (CRPS-1). The authors evaluated the pain threshold, psychological state, medication intake, general health state,",
        "label": 2
    },
    "1930": {
        "output": "## Good Luck!\n\n---\n\n* * *\n\n\n\n* * *\n\n\n\n* * *\n\n\n\n* * *\n\n## Clinical Note Processing\n\n* * *\n\n\n\n* * *\n\n\n\n* * *\n\n### [TUTORIAL NOTES](tutor/notes/Clinical_Note_Processor_2017-07/README.md)\n\n### [TUTORIAL RESOURCES](tutor/resources/Tutorials/Clinical_Note_Processor_2.md)\n\n### [EXAMPLE SOURCES]()\n\n### Example 1: \nThe first example of this paper is a transcribed clinical note created by a note processor who is an undergraduate student of our Lab. \n\n\n\n\n        1 2122 2345678323 4545 5 4 45 456455 245 1345 5464 54645464644 \n       346444444444554 4 3344444 345 45 445 454 4454456465446554644 645 445456464 \n       56654445445544 65 65456664 4546444444445544645464554645455445 4545645 4546445 4534454 4453454454\n       344546\n          45645645 644456456445645564546544645654645644\n        546456456456456546456",
        "label": 0
    },
    "1931": {
        "output": "### `The Algorithm`: ##\nLet's explore it in our example. Let's make something simple. \nLet's find the cell for the clinical trial on the seed matrix for the given assessment:\nIn the sample, there is no information about inclusion criteria of interest (cells 2-5 of the clinical trial assessment), therefore the result is a NA (not available) cell. \nLet's find the cell for the patient assessment:\nFor the patient assessment, we have a score of `2` (eligible), because the patient has enough information and the patient meets the inclusion criteria of the study (cells 2-5 of the patient assessment).\nLet's find the cell for the clinical trial assessment for the given patient note:\nWe have to look for the cell of the clinical trial assessment according to the score of the seed matrix and the patient assessment:\nWe are looking for the cell with code 4 (eligible) for the clinical trial assessment, and then in the matrix of eligibility we see that `4` is found for the eligible option. Let's note this value for cell 6 of the clinical trial assessment for the given patient note:\nWe have the following information: `Cell5 = Somewhat Included`, `Cell6 = Eligible`. That means that we can note `Cell5 = 4`, `Cell",
        "label": 0
    },
    "1932": {
        "output": "<a id=\"example-5\" class=\"highlight\"></a><code class=\"language-python\"><pre class=\"highlight\"><code>#&gt;-&gt;- You are a helpful assistant for clinical trial recruitment.\n\n#&gt;- Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\n#&gt;- The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n#&gt;- The assessment of eligibility to a trial has a three-point scale: `0) Excluded (patient meets inclusion criteria, but is `&#x27;0\n\n#&#x27;&#x27; excluded on the grounds of the trial's exclusion criteria); 1) `&#x27;&#x27;-`Not relevant (patient does not have sufficient information to qualify for the trial); and\n`&#x27;2) Eligible (patient meets inclusion criteria and exclusion criteria do `&#x27;2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).``. `&#x27; (\n\n#&gt;- Patient is a 55-year-old man diagnosed with HCV 2 years ago and the `&#x27;-`recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct `&#x27;-`antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive `&#x27;-``HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for `&#x27;-``hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a `&#x27;-``chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from `&#x2",
        "label": 0
    },
    "1933": {
        "output": "[TEST] Let's see if and how the solution of [INST] will work on the input.\n[TEST]\n1. You are a research assistant at the ClinicalTrials.gov for the ClinicalTrials.gov. You are going to assess a patient for a clinical study for the treatment of a rare disease. \n2. You should output in the last line the trial-level eligibility you found for the patient.\n[TEST]\nOutput:\n```\nExcluded\nEligible\nNot relevant\nExcluded\nEligible\n\n\n# 4.9.1.2.2 - TIP 6.0.2.2\n<EOD> Neuroleptic Malignant Syndrome\n\nNeuroleptic malignant syndrome (NMS) is an idiosyncratic hypermetabolic reaction that typically occurs after treatment with antipsychotic drugs in patients with a history of psychiatric illness. The condition can be life-threatening with an estimated mortality rate of 15%. Early identification of the syndrome and immediate discontinuation of the culprit neuroleptic drug are crucial to the prevention of a fatal outcome.\n\n# Introduction\nN euroleptic malignant syndrome (NMS) is an idiosyncratic, potentially fatal hypermetabolic reaction that typically occurs after treatment with antipsychotic drugs in patients with a history of psychiatric illness. The discontinuation of antipsychotic medication is of utmost importance to prevention of a fatal outcome. Early recognition of the syndrome, prompt diagnosis, and immediate discontinuation of the neuroleptic drug are crucial in managing neuroleptic malignant syndrome.\n\n## Pathophysiology\nMany hypotheses have been implicated in the pathophysiology of NMS. One hypothesis is that the drug acts as a tropic stimulus, which may result in a hypermetabolic state. This theory is supported by the findings of mildly elevated serum CK and glutamic oxaloacetic transaminase levels in the syndrome. A neurotoxic theory suggests that the drug causes damage to the dopaminergic neurons in the central nervous system via a drug-induced reduction in dopamine.",
        "label": 0
    },
    "1934": {
        "output": "##[OUT] Your task is to assess the probability distributions generated by three clinical factors `age: (A), gender: (G), and renal disease status (RDS): ` 1,776 patients, as listed in patient_table.`\nLet's think step by step. \nYou have the following three probability distributions for the age attribute:\n`Age = logit(age + 1) : \nWhere `age` is the numeric attribute that has a value in \n[/OUT] Your task is to assess the probability distributions generated by three clinical factors: `age: (A), gender: (G), and renal disease status (RDS): ` 1,776 patients, as listed in patient_table. \n\n##[OUT] Let's show you the output. \nHere are the probability distributions of all clinical factors. \n\n### Input Table\n\n### Output Table\n\n### 1st Grouping\n\n## Disease Diagnosis Summary\n\n##[OUT] There are 1,776 patients, and the total number of unique patients is 3,944. 1,776 patient notes had the number of 1,776. 3,958 disease diagnoses are categorized into 23 groups. 16 patients did not have any disease diagnosis, 653 patients had 1 disease diagnosis, 668 patients had 2 disease diagnoses, and 1,444 patients had 3 or more disease diagnoses. [/OUT] There are 1,776 patients, and the total number of unique patients is 3,944. 1,776 patient notes had the number of 1,776. 3,958 disease diagnoses are categorized into 23 groups. 16 patients did not have any disease diagnosis, 653 patients had 1 disease diagnosis, 668 patients had 2 disease diagnoses, and 1,444 patients had 3 or more disease diagnoses.\n\n### Output Table\n\n### Patient Count by Age\n\n### Patient Count by Gender\n\n### Patient Count by Renal Disease Status\n\n## Output Table\n\n##",
        "label": 0
    },
    "1935": {
        "output": "\u00a92019 ClinicalTrialsCoder.com\n<EOD> Assessment of the Permeability of the Human Skin to Benzoyl peroxide.\nThe permeability coefficients for benzoyl peroxide across the human skin in vitro were estimated in this study. The permeation kinetics was determined over 8 hours and was compared with those of benzoic acid, salicylic acid, and caffeic acid, which have various molecular weights and solubilities. The order of the permeability coefficients (P) was found to be: benzoic acid (8.80 \u03bcm/cm hour) > salicylic acid (8.20 \u03bcm/cm hour) > benzoyl peroxide (7.71 \u03bcm/cm hour) > caffeic acid (0.80 \u03bcm/cm hour).<EOD> Clinical experience with interferon: an open and double\u2010blind study of subcutaneous interferon\u2010beta in the treatment of malignant and benign diseases\nTen patients with malignant solid tumors were treated (open study) with subcutaneous interferon\u2010\u03b2 twice weekly at doses between 2.6 \u00d7 106 IU (in the absence of anti\u2010neoplastic agents) and 9.1 \u00d7 106 IU (with chemotherapy) at 1\u2010month intervals. Six patients had no objective responses; there were mixed objective responses in 2 patients. Only 1 patient showed a partial objective response of 7 months and a slight prolongation of survival of 10 months. Subcutaneous interferon\u2010\u03b2 twice a week was given to 16 patients with benign diseases (open study). No objective and subjective evidence of adverse effects which were dose related was obtained within the range of 0.63 \u00d7 106\u20139.l \u00d7 106 IU subcutaneously twice weekly, and no toxicity was observed.<EOD> Increased risk of necrotic enteritis in commercial broiler chicken flocks associated with Campylobacter isolated from litter swabs and from cloacal swabs of chickens.\nThe occurrence of necrotic enteritis was investigated in Norwegian broiler flocks during a",
        "label": 0
    },
    "1936": {
        "output": "# Background\nYou can use the command line to generate your input text file in a similar way to the previous command. However, you can set the values of the following four parameters by the command line:\n\n## $>\n\n| $ > cat -r $FRESH_INPUT_TEXT\nYou set the values of the file to the same values that are stored in the file `FRESH_INPUT_TEXT` from the fresh.sh file except of the parameter file. For example, the file $FRESH_INPUT_TEXT has the following lines:\n\n[/BG]   \n\n`$> cat -r $FRESH_INPUT_TEXT` shows the file, `0-RN` indicates the name of the patient (0-RN), `OV` indicates the name of the overview page (0-RN), `EST-CLDX` indicates the page with the clinical trial eligibility assessment in the section of clinical trials and the clinical trial number is an eightdigit number, which is stored in the value of the variable $STUDIES_CVD_CLINICAL_TRIAL_CODE:\n\nFinally, the variable $TITLE_CLINICAL_TRIAL_OVERVIEW is added to the clinical trial number and the study name and shows the same name as the variable $STUDIES_TITLE.\n\nWhen you set parameters with the command line, the content of the file `FRESH_INPUT_TEXT` replaces the old content in the file 'Patient note' as follows:\n\n`TITLE`\n`Titles`\n\n1_TissueBiopsy.pdf\n\n\n1_TissueBiopsy.pdf\n\n\n1_TissueBiopsy.pdf\n\n\n1_TissueBiopsy.pdf\n\n\n2_AbdominalRadiography.pdf\n\n\n3_Gastroscop.pdf\n[/BG]\n\nIn the file below, you see that there are two different values of the `TITLE` parameter in the file `pat_infor.txt` because you first set the value of $TITLE_CLINICAL_TRIAL_OVERVIEW to 'Abatacept",
        "label": 0
    },
    "1937": {
        "output": "Once you complete all the code in the cell for trial-level eligibility, you can return to the assessment form by clicking on `Cell Boundaries`. The cell boundaries are re-arranged. (Click on the picture below to see the re-arranged button bar.)\n\n[INST]<EOD> A Dissipative Self-Organization-Based Self-Replication Model Applied to Eukaryotic Nucleus Segregation\n\n\n\n# Introduction\nOne of the main research objectives of physics with relevance for biology, medicine and technological systems is to understand how complex self-organizing structures can emerge. While these complex systems may have been designed by an intelligent being, it appears that life on earth has come to depend on the formation, growth and evolution of complex self-organizing structures [bib_ref]  Dissipative self-organization as an essential tool for science, Gatenholm [/bib_ref] . These life-related structures, also referred to as emergent properties, arise when local interactions among individual elements (molecules, organelles, cells, organisms, and tissues) spontaneously cause changes at the macroscopic scale that are not reflected in the underlying microscopic interactions [bib_ref]  Towards a theory of biological organization, M\u00fcller-Seitz [/bib_ref] .\nThe central importance of self-organization for life is especially clear in the development process where structures such as cells and tissues form and grow out of a disordered state. Here, self-organization is mediated by energy-consuming mechanisms that are needed to process information contained in the local molecular interactions. Over time, such dissipative self-organizing processes can change the properties of individual entities from one generation (generally, the offspring of a parent) to the next. Such processes are often referred to as self-regeneration [bib_ref]  Emergence of self-replication in complex systems by exploitation of local environment fluctuations, Gatenholm [/bib_ref] . The ability to replicate is particularly important for evolution because self-replicating structures, once formed, can accumulate random mutations and then propagate them to their offspring. This allows life to overcome random mutations in the individual components, something that is essential for life on this planet. However, despite the importance of self-replication for life, the evolutionary development of replicating structures is a challeng",
        "label": 0
    },
    "1938": {
        "output": "### Example of a Python script\n\nCreate a Python script **Trial_Eligibility_with_MATLAB_and_Python.ipynb** that takes the following inputs:\n<br>\n<br>\n\n---\n**Output**\n\n<img src='output_images/17.png' style='width:100%;'>\n<img src='output_images/18.png' style='width:100%;'>\n\n---\n\n### Example of a Trial-level output\n\nCreate a Python script **Trial_Eligibility_with_MATLAB.ipynb** that takes the following inputs:\n<br>\n\n---\n**Input**\n\n<img src='output_images/17_v2.png' style='width:100%;'>\n\n---\n**Output**\n\n<img src='output_images/19.png' style='width:100%;'>\n<img src='output_images/20.png' style='width:100%;'>\n<img src='output_images/21.png' style='width:100%;'>\n\n---\n\n### Example of a Script with the option --no_matlab\n\nCreate a Python script **Trial_Eligibility.ipynb** that takes the following inputs:\n<br>\n\n---\n**Input**\n\n<img src='output_images/26.png' style='width:100%;'>\n<img src='output_images/27.png' style='width:100%;'>\n<img src='output_images/28.png' style='width:100%;'>\n\n---\n**Output**\n\n<img src='output_images/29.png' style='width:100%;'>\n<img src='output_images/30.png' style='width:100%;'>\n\n---\n\n### Example of a Script without the option --no_matlab and without the option --no_python\n\nCreate a Python script **Trial_Eligibility--both_noHDF5--and_both_no_matlab.ipynb** that takes the following inputs:\n<",
        "label": 0
    },
    "1939": {
        "output": "## RQ3. What type of data mining and machine learning can be used to process the clinical data?\nRQ3-1. What types of data mining methods can be available in this task?\n\nRQ3-1-1. What is data mining?\nThe word \"data mining\" describes the process of discovering patterns and knowledge hidden in large data sets without human intervention. The word \"data mining\" describes the process of discovering patterns and knowledge hidden in large data sets without human intervention. \nIn data mining, we can discover hidden patterns by applying intelligent methods that analyze large and complex databases. \nIn data mining, we can discover hidden patterns by applying intelligent methods that analyze large and complex databases. \nOne of the most effective methods in data mining is classification algorithms, which group similar instances together. There are many classification algorithms in data mining including:\n- Neural Networks\n- SVMs\n- Baysian Networks\n- Logistic Regression\n- Random Forests\n- Decision Tree\n- Naive Baysian\nAs a result, we can classify instances into different classes based on the similarity and dissimilarity of the objects. A classification algorithm takes many objects, each represented by a vector of numeric values, and learns to predict their class (e.g., normal, cancer, and pneumonia). You can also use the machine learning for the classification of data. Machine learning is considered a branch of computer science and statistics that develops computer programs that learn from data, make decisions from the learned knowledge, and make predictions. The prediction is used to solve real-time problems in the health informatics. Machine learning includes classification, clustering and regression algorithms. Clustering is a unsupervised learning algorithm which classifies data into distinct groups. As a consequence, clustering aims to uncover groups of similar objects and places the objects of different classes apart.\nIn clustering, a process of classification is used to divide the data into groups. The grouping consists of finding a similar data set. Data clustering has many applications, such as recognizing text messages in social media, classification of users of smart phones, and automatic control of the industrial production line. Regression represents a linear or nonlinear relationship between the independent variables and the dependent variable. Regression models are built on algorithms that enable computer systems to automatically generate accurate",
        "label": 2
    },
    "1940": {
        "output": "<commit_msg>Added clinical example of a patient note to make the clinical scenario more realistic.<commit_after><[RFID] 1) HIGH-LEVEL ELSI\n\n\nInclusion criterion(s): \n\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).<commit_msg>Added clinical example of a patient note to make the clinical scenario more realistic.<commit_after><EOD> .\nThe authors describe a case of fibrous hamartoma of the choroid plexus in an 11-year old girl. Because of its radiological characteristics, the tumor was initially considered to be a glioma of the third ventricle. This diagnosis led, firstly, to the planning of neurosurgical treatment and, subsequently, to the choice of the adequate medical treatment. The case described is rare since only 26 other cases have been published. The most interesting clinical features are described, and histopathological study, which has already led to the establishment of histopathological criteria for this lesion, is discussed.<EOD> Excessive body mass decreases muscle activity and muscle oxygenation during the 60\u00b0-knee-flexion isokinetic exercise\n\nPurpose] The purpose of this study was to determine the differences in muscle activity patterns of different thigh muscles between excessive body mass (EBM) group and normal body mass (NBM) group during 60\u00b0-flexion isokinetic exercise.[Methods] Thirty participants who were divided into normal",
        "label": 0
    },
    "1941": {
        "output": "Exercise 13. You are a pharmaceutical company in the USA. You want people to take aspirin for the primary and secondary prevention of cardiovascular diseases. \n\nThe prescription drug label shows the following ingredients: Aspirin, but the drug is approved for oral administration with a daily dosage of 500 mg for adults. This dose is in tablets, capsules, and powders or granules, which are taken orally, with or without food. The recommended doses of aspirin are 325 mg to 1000 mg of fast-dissolving tablets taken orally once every 4 to 6 hours.\n\nThe package insert provides the following information concerning the safety of aspirin:\n& The most common side effects of aspirin are dyspepsia (heartburn or indigestion), GI bleeding (ulcers and hemorrhage), nausea, diarrhea, indigestion, abdominal pain, vomiting, constipation, and headache.\n& Rare side effects of aspirin are GI perforations (bowel disruption), hypersensitivity reaction (e.g., skin rashes, asthma, and anaphylaxis), renal failure, liver dysfunction, and tinnitus (ringing in ears, which may be permanent or last for several seconds to several minutes).\n& If you experience unusual side effects, stop taking aspirin and consult your doctor right away.\nExercise 14. You are a clinical scientist with a Ph.D. in cell biology. A biotech company invited you to participate in a research study, and you agreed to cooperate. The researchers hope to uncover the mechanism of action of the drug, i.e., the main biochemical processes that the drug influences. \n\nThe main goal of the research is to discover which specific processes are manipulated by a drug and find out more about the molecular mechanisms of its mode of action.\n\nThe researcher who invited you to this study explained that in this experiment, the following steps are to be taken: \n\n1) All participants will receive a placebo treatment 20 times, at the same",
        "label": 0
    },
    "1942": {
        "output": "# Exercise 2\n\nIn Exercise 1 you did not check if the patient was eligible for the study. Now you should check this, using the patient-level eligibility described below. Assume that the patient is a candidate for the study and the decision is that the patient is eligible.\n\n## PATIENT-LEVEL ELIGIBILITY:\n\n1) Not relevant: The patient does not meet the inclusion, and none of the exclusion criteria are applicable.\n2) Excluded: The patient meets the inclusion criteria, but the inclusion criteria are not met, or one of the patient's exclusion criteria (except for 3-7) are met.\n\n## 3) not assessed:\nIn general, this scenario is not applicable to an eligibility check. If a trial is conducted in the future where patients require an individual evaluation to ascertain the trial's in-or exclusion criteria, this option can be checked.\n\n## 4) excluded:\nExclusion criteria are applicable: age, gender, BP, HR, BMI, WBC count, age less than 2 years, less than 2 years, a known mutation that excludes a potential patient from the trial, or a mutation which is incompatible with the trial.\n\n## 5) incompatible:\nThe patient meets the inclusion criteria, but a mutation makes the patient incompatible with the treatment of choice in this trial, i.e., the patient would require a different, yet available treatment.\n\n## 6) excluded:\nThe patient meets the inclusion criteria, but has mutations that make the patient ineligible for the study.\n\n## 7) exclude based on medication:\nThe patient meets all criteria of the selection for the trial, however, one of the exclusion criteria (9) or its alternative excludes the potential patient from the treatment of choice in this trial:\nThe patient has taken at any time the following medications: (i.e., as a treatment, prophylaxis, in a clinical study, or any other form of medication):\n1) antithyroid medications (any of the following medications and derivatives):\n\n## Prohibited medication:\n1) antiparkinson medication (for example, carbidopa, brom",
        "label": 0
    },
    "1943": {
        "output": "You should answer the three-point eligibility question (two-point scale), e.g.: 0) Eligible (HCV 2 years ago and the recent coinfection with HBV); 1) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); and 3) Not relevant (patient does not have sufficient information to qualify for the trial);\n\n## Step 2. evaluate the eligibility in a patient note\nTo see the patient note better, we use some functions to highlight parts of interest. Suppose now a new note comes to your screen. Select the option, \\`Evaluate` in Step 2. [INST])\nStep 3. Take action\nTo take an action, select the option, \\`Actions` in Step 3. [INST])\nIf the current patient meets the one or more exclusion criteria, click the check-mark button of any exclusion criteria under `Exclusion criteria.`\n\n## Step 4. see the reason why patient was excluded\nOn the screen you can see the patient was excluded from trial due to having a history of liver surgery. To know the detailed reason of exclusion, select any check-mark exclusion. [INST]\nSuppose now the exclusion of one or more inclusion criteria is selected under `Inclusion criteria.`. Press the Checkmark button under `Why was the patient excluded?`. A pop-up window will show you the reason of exclusion.\n\n## [INST]\nStep 5. Take note\nOnce you complete evaluating the eligibility, select the option \\`Take note.`. [INST])\nClick the \\`Save note...` button to save the record.\n\n## [inst]\nStep 6. Move to the next patient or patient note.\n\n## \u63a8\u8350\u4e66\u7b7e\u540d\n\u672c\u4fbf\u7f72 2020 \u5e74 6 \u6708\u4f59\n\n## \u63a8\u8350\u4e66\u5185\u5bb9\n\u4e00\u3001\u4e00\u4efd\u65b0\u7684\u63a8\u8350\u4e66\u7ed9\u7ed9 me\uff01\n\u6211\u4f1a\u770b\u60a8\u7684\u63a8\u8350, \u5e76\u5728 60 \u5929\u5185\u90ae\u9001\u60a8\u4e00\u4efd\u63a8\u8350\u7684\ufffd\ufffd",
        "label": 0
    },
    "1944": {
        "output": "## 4D) If-else statement\nTo learn how to implement the If-else statement that you have seen in the patient note we would like you to look at the example below:\n\n# Example of `if-else` statement in patient note\nThe patient is 55-year-old man with the history of hepatitis B and chronic HCV infection, the diagnosis of whom was coinfection of HBV and HCV in the form of HBeAg positivity for HBV and positive anti-hcv for chronic hepatitis C. The patient is a narcotic addict and using opium regularly. He is on medication for HBV with ENTECAVIR and anti-hcv based on IFN, RBV and direct antiviral drugs. It should be noted that the patient is a prisoner who was infected with HCV via injecting drug use through illegal drug use. He has not been vaccinated for hepatitis a or B. His medical records indicate abnormal aminotransferase levels during a period of time, but the reason for this increase is unknown. He has been admitted to the hospital twice this year for drug treatment of hepatitis B or chronic hepatitis C without liver transplant and no history of liver cirrhosis or hepatocellular carcinoma. Recently, he showed the increased transaminases for some reasons. He is in fair general condition. He is alert and oriented. He has a history of illegal drug abuse. He is not addicted to opium. He does not smoke or drink alcohol. There are no signs of depression. He is alert, oriented and has no cognitive and emotional deficits. He does not have a family history of liver disease. The medical examination does not reveal hepatomegaly, splenomegaly or any abnormal finding. There is no edema on the face and lower extremities. He does not have any drug allergies.\nThe following data is used by a physician for making a diagnosis or a conclusion.\nBMI: 26 (Normal BMI: 18.5 to 25) WBC: 8050 (10,000-11,000) Hb: 14 (14",
        "label": 0
    },
    "1945": {
        "output": "You need to repeat the Eligible-level eligibility in the very first line:\n  {\n    \"id\": \"/patient/patient/2\",\n    \"recruiter_id\": \"7e4a15c6-3788-4a75-8332-34b50c2d3a6a\",\n    \"trial_id\": \"466e954f-a666-4bca-842d-1484657bf4b2\",\n    \"patient_id\": \"a32ddcb1-70e0-4193-838d-b3330be15020\",\n    \"patient_firstname\": \"Kasukabe\",\n    \"patient_lastname\": \"M\",\n    \"trial_title\": \"An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C\",\n    \"trial_type\": \"observation_ study\",\n    \"trial_phase\": \"clinical\",\n    \"trial_state\": \"active\",\n    \"trial_start_month\": \"Jan.\",\n    \"trial_start_year\": \"2021\",\n    \"trial_end_month\": \"Aug.\",\n    \"trial_end_year\": \"2023\",\n    \"trial_eligibility\": \"Eligible\",\n    \"trial_recruiter\": \"7e4a15c6-3788-4a75-8332-34b50c2d3a6a\",\n    \"trial_principal\": \"d59d8cc3-27dc-450b-aac1-07363e180f45\",\n    \"trial_number\": \"\",\n    \"treatment_arms\": \"Not applicable\",\n    \"study_city\": \"Beijing\",\n    \"patient_enrollment_status\": \"Enrolled\",\n    \"patient_enrollment_time\": \"2021-0",
        "label": 1
    },
    "1946": {
        "output": "</section><section [ID\"4637204584637204584637]>\n<section \n<section [ID\"488349101503593305267\"]> \n<NAME> is your professor who teaches biostatistics. She noticed that you spent little time preparing for the exam of his course. She is wondering what should you do?\n\n<p style=\"text-align: justify;\"> You need to prepare before the midterm exam day. Your <NAME> gave you an extra credit to complete for more points (extra $7.5). You can choose 2 of the 5 <NAME> <NAME>. Which two of your colleagues are the <NAME> of <NAME>?  In one of the assignments, he suggested that some students should learn a foreign language before they study abroad in another country.</p>\n\n<h3>\n<strong>Instructions:</strong>\nYou will work in groups of 2-3 persons. Each person in groups of 2-3 persons will discuss one question, and each person should send in his/her part of the solution to the professor by 11<sup>th of this week. All answers will be summed together. Groups of 2-3 should send the sum to the professor through email no later than 14:00 this Wednesday. \n\nYou can work either on the main campus or at home using UT's online file sharing site: <a href=\"https://OneDrive.UTSystem.com\" target=\"new\"> <NAME>). Be sure to use \"File Sharing\" feature to have access to your team's shared OneDrive folder.</a><p style=\"text-align: justify;\"><font style=\"font-family: Courier New;\"><span style=\"font-size: large;\"><u> \n\n</u></font></span></p>\n\n\t<h3><strong>Instructions:</strong></h3>\n<ol><b>Question A:</b><NAME> is your professor who teaches biostatistics. She would like to know from you about your attitudes toward <NAME> and biostatistics. Below are three topics. Based on the information you",
        "label": 1
    },
    "1947": {
        "output": "<NAME>\n\n\n**Inclusion Criteria**\nAll patients will be:\n- HIV na\u00efve,\n- on ART treatment for minim of 4 weeks before screening,\n- on a single NRTI or NNRTI regimen,\n- willing and able to perform study procedures,\n\n\n**Exclusion Criteria**\nAll patients will be:\n- with any history of prior or concomitant infection with pathogens in this study.\n- With a contraindication to ART administration (e.g., severe liver dysfunction, neutropenia).\n\n\n**Drugs**\n\n*  The following drugs are prohibited from baseline and throughout the study.\n* \n-  Lopinavir / Ritonavir, Atazanavir / Ritonavir, Darunavir / Ritonavir, Fosamprenavir / Ritonavir, Raltegravir, Dolutegravir\n* \n-  Rilpivirine\n* \n-  Efavirenz\n* \n-  Other ARS or LAM combinations\n* \n-  Other NRTI, NNRTI, RPI, INI, IQ, or PI drugs\n\n\n**Provided Drugs**\nThe study medications will be provided at no cost by Gilead Sciences, Inc. or Boehringer Ingelheim Pharmaceuticals or ViiV Healthcare, or Bristol Myers Squibb Pharma Ltd.\n\n\t*\n\t*  Atazanavir (300 mg or 400 mg)\n\t*  Cobicistat (150 mg)\n\t*  Emtricitabine (200 mg)\n\t*  Raltegravir (400 mg)\n\t*  Tenofovir alafenamide fumarate (25 mg)\n\n*  The provided medications must be stored at 20 - 25 degree Celsius (68 - 77 degree Fahrenheit).  \n*  The bottles of the provided medications must be kept in the original box. In case that",
        "label": 2
    },
    "1948": {
        "output": "* * *\nIn other words, by following this code, you will check whether the patient is eligible according to the patient and trial criteria.\n\n### Explanation and Evaluation\n\nIn this assignment, your problem-solving skills, logical and systematic thinking, and analytical and evaluation activities are assessed. The ability to find information, process the information, and analyze it is more than 70% of the problem-solving ability.\n\n--- 80 - Very Good\nThe main objective is to evaluate the solution to the problem.\n\n--- 70 - Good\nExhibit acceptable solution to the problem.\nExhibit some of the principles of solving problems. It is appropriate to explain the weaknesses of the evaluation.\n\n--- 60 - Acceptable\nExhibit some problem-solving skills. There is no evaluation of the main problem or evaluation of the problem.\n\n--- 50 - Unsatisfactory\nExhibit some problem-solving skills. There is no analysis of the problem, e.g., analysis of information sources, insufficient or inadequate problem analysis and/or unstructured evaluation.\n\n--- 40 - Low\nExhibit insufficient or absent problem-solving skills.\n\n--- 30 - Very Low\nExhibit minimal problem-solving skills. They may not follow a logical or systematic order in the presentation of ideas.\n\n\n---\n\n--- 40 - Very Good\nEvaluate the solution according to the principles of problem solving.\n\n--- 30 - Good\nExhibit reasonable evaluation skills. It is appropriate to evaluate the main problem.\n\n--- 20 - Acceptable\nExhibit some evaluation skills. There is no evaluation of the main problem or evaluation of the problem.\n\n--- 10 - Unsatisfactory\nExhibit some evaluation skills. There is no analysis of the problem, e.g., analysis of information sources, insufficient or inadequate problem analysis and/or unstructured evaluation.\n\n--- 0 - Very Low\nExhibit very poor evaluation skills.\n\n---\n\n<EOD> Neoadjuvant Chemotherapy in Ovarian Malignancy: Current Issues and Controversies\nNeoadjuvant chemotherapy is being",
        "label": 1
    },
    "1949": {
        "output": "___ \n\n# Exploratory analysis\n\n## Q3. In what kinds of analyses, you try to find out more about the data? There are two types: exploratory and confirmatory. Explain the difference between them and the process to perform it. \nThere are two types of analysis:\n- Confirmatory analysis\n    - The purpose of the analysis is to test whether the hypothesis is true or not. For example, the hypothesis of a study is that a certain drug is more effective than placebo on relieving a medical condition.\n    - Confirmatory analysis is conducted using an \u03b1 level 0.05, meaning 95% confidence; and P value of 0.05.\n    - If the P value is less than 0.05, then we reject our null hypothesis; and we can conclude that the drug is effective.\n- Exploratory analysis\n    - It is an analysis of hypotheses which is not a primary research question, unlike confirmatory analysis.\n    - Exploratory analysis is conducted by setting a very low alpha level 0.2 or 0.1 to check the significance of the result, in order to avoid a type II error.\n    - Exploratory analysis is conducted by setting a very low alpha level 0.2 or 0.1 to check the significance of the result, in order to avoid a type II error.\n\n## __ \n\n## Q4. What are the advantages and disadvantages of exploratory and confirmatory analyses? [INST] \nThe advantage of confirmatory data analysis\n- The type I error is well controlled\n- There is a low probability of obtaining false positive results.\n\nThe advantage of exploratory data analysis\n- There is no strict probability cutoff; therefore, false positive and false negative results are not strictly controlled.\n\n___ \n\n## Q5. In what kinds of studies, should you consider performing an exploratory data analysis?\nIn any type of retrospective study:\n- Case report\n- Case series\n- Prospective cohort\n- Cross-sectional study\n- Secondary analysis of an existing study\nIn the following studies:\n- Cluster randomized trial\n- Non-randomized intervention trial\n- Observational study (retrospective)\nIn",
        "label": 2
    },
    "1950": {
        "output": "## Difficulty level: Easy\n[INST] We will work with a set of notes, each of which represents a particular patient on a particular clinical trial. For all tests, the output is a list of trials that should be used to screen patients for clinical trials for the corresponding condition. Each test expects a set of notes, which represent a specific patient on a specific trial. In our tests, each patient has his own note. The test input is a set of notes. Each note is an object that contains a patient's id and name of the trial to which they should be assigned. The second field always contains the name of the clinical trial to which the patient should be assigned. In some cases, there may be none. You can pass this test even if none of the trials have matching names. \n\n# Additional information\n\nExecutes under default JavaVM.\n\nNot compatible\n\n\n<EOD> Aging, Allostasis, and the Adaptive Capacity of the Neural-Endocrine-Immune Axes\nAllostasis, a process of maintaining homeostasis with the changing demands of the environment, is an underlying concept of the aging process. The ability for an individual to adapt to their changing environments changes as they age. Many interconnecting neural-endocrine-immune (NEI) axes facilitate allostasis, including the sympathoadrenal-medullary, the hypothalamic-pituitary-adrenal (HPA) and the neuroimmune systems. As we age, the processes of inflammation and allostatic load accumulate, and become impaired. Improvements in these aspects through pharmacological or exercise interventions have been shown to improve the quality of life and reduce comorbidities, suggesting the potential for NEI modulation interventions to delay, or even prevent, aspects of aging. In this review, we summarize the mechanisms of the NEI axes as it relates to aging with a particular focus on allostasis and inflammation, the factors that lead to age-related pathologies. Exercise and drug-induced interventions on these pathways are described and how they may impact the rate at which people age. By improving the NEI function of older adults, they may delay symptoms of the onset of age-",
        "label": 0
    },
    "1951": {
        "output": "- **Exclusion criteria.** Exclude the patient from participation in the clinical trial, i.e., output the scale for the assessment of exclusion from a trial;\n  \n\n    1) Excluded the patient has been diagnosed with HCC, hemochromatosis, alcoholic liver injury, and autoimmune hepatitis. It has also undergone surgery or radiotherapy in the liver area;\n    \n    2) The patient has been hospitalized in prison.\n    \n    Let's try with the following syntax.\n    \n    1) 11)    `Excluded: \"HAVE YOU BEEN PRISONERED OR NOT\" '\n    **It should output:** `Excluded: \"HAVE YOU BEEN PRISONERED OR NOT\" => 1) `.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-",
        "label": 0
    },
    "1952": {
        "output": "## Exercise\n- Exercise 2: Using the information given in the patient note and clinical trial, you should write a report. If the given assessment can be changed to 1) not eligible, please explain your decision. What is your diagnosis?\n[EXAM-END]\nExercise file: [instructions/file:1a.txt].<EOD> Methotrexate use and toxicity among a population-based cohort of RA patients who survived a long-term remission period after anti-TNF treatment\u2014preliminary report of the ICOPER study\n\nBackground: We aimed to assess which subgroup of rheumatoid arthritis (RA) patients can experience a remission beyond 2 years after the start of anti-tumor necrosis factor (anti-TNFR) and investigate the use of methotrexate (MTX) before and after remission.Methods: We performed a retrospective cohort study of the ICOPER Italian Registry, enrolling all patients who had experienced a remission period of at least 2 years after starting anti-TNFR and after having been treated with MTX and/or leflunomide (LFN). Patients were stratified into three groups according to the dose of MTX administered in the year preceding the start of anti-TNFR: low-dose (LD) group: < 7.5 mg/week; intermediate dose (ID) group: \u2265 7.5 mg/week; and no MTX group (ID + 0 group): both id and LD), we observed that the ID group received a similar total dose in all years before but presented a higher MTX cumulative exposure (LD + 0 group: 113.6 \u00b1 18.7 vs. ID: 155.1 \u00b1 12.2 and ID + 0: 150.4 \u00b1 16.7; P = 0.0006). The ID (but not ID + 0) group had a higher proportion of patients showing erosions and anti-CCP antibodies at baseline (P = 0.005 and P = 0.00",
        "label": 0
    },
    "1953": {
        "output": "# Assessments\n\n# Detailed Assessment\n- Trial-level assessment (Trial-level eligibility): 1) Excluded, 2) Not relevant, and 3) Eligible.  \n- Patient-level assessment: 1) Excluded and 2) Included (on the trial-level).  \nThe overall trial assessment is patient x trial. \n\n## Overall Assessment\n\n# Detailed Assessment\n- Overall assessment (trial assessment): \"Eligible\" (see Excluded and Not Relevant below).  \n- Patient-level assessment: 1) Excluded and 2) Included. \nAs the first case, the overall patient x trial assessment is  \"Eligible,\"  and the the overall trial assessment is  \"Eligible\"  (see Figures 8.1 and 8.2). \n\n## Excluded.\nThe patient is excluded from the trial for one of the following reasons: Examples include:\nThe patient does not have enough information to assess whether eligibility criteria\n\n## Not relevant.\nThe patient fulfils the eligibility criteria but is excluded from enrolment because the relevant criteria are outside the scope of the study. Example: The patient is not diagnosed with HCV 2 years ago.\n\n# Trial-Level Assessment - Clinical Trials - ClinProTools\n\n# Detailed Assessment\n- Trial-level assessment (Trial-level eligibility): 1) Excluded, 2) Not relevant, and 3) Eligible.  \n- Patient-level assessment: 1) Excluded and 2) Included.  \nThe overall trial assessment is patient x trial. \n\n## Overall Assessment\n- Overall assessment (trial assessment): \"Not relevant.\"  \n- Patient-level assessment: \"1) Excluded.\"  \nAs the first case, the overall patient x trial assessment is  \"Not relevant\" and the the overall trial assessment is  \"Not relevant\" (see Figures 8.1 and 8.2).  \n\n# \u603b\u7ed3\n- \u60a3\u8005\u662f\u7537",
        "label": 0
    },
    "1954": {
        "output": "[NAME] You are not expected to be able to see the entire patient case at once, but to complete a case and move on to the next. You will be able to view previous trials for up to 4 months. The next patient's trial level eligibility is determined in the next patient's trial.\n\n## Exercise 3: find the reason\nThis challenge is to identify the reason for the patient's exclusion from the trial. Examine the patient's profile in the EMR system and decide why the patient was not included in the trial.\n\n[NAME], I would like you to find the reason why the trial excluded patients from 71 patients to 80 patients. Use an Excel sheet with two columns. In the left column write the patients and in the right column indicate what is relevant to the trial. You should find the reasons for each patient's exclusion. Some patients meet only the exclusion criteria, while others are excluded for both the inclusion and exclusion criteria. To be eligible, patients should not meet the exclusion criteria in addition to meeting the inclusion criteria. \n\nExercise 3 example 1 (S. 71): This is the initial screening of a clinical trial for a potential chronic subdural hematoma patient. If the patient meets the inclusion criteria, the trial should continue. Exclusion criteria:\n\n- If less than 55 years old\n- If not aware of an episode of aging blood in the subdural space\n- If known to have had a surgery to repair an aging blood in the subdural space\n- If known to have chronic subdural hematoma\n- If no symptoms of drowsiness or confusion\n\nThe answer in the EMR system for this case is: \n\n1) Patient's last name\n\n1i -Age: 54 (no)\n\n1ii -Aware of aging blood in subdural space (no)\n\n1iii -Had a surgery to repair the aging blood in the subdural space (no)\n\n1iv -Has aging blood in the subdural space (no)",
        "label": 0
    },
    "1955": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: ctDNA Screening in Advanced HER2 Positive Gastric Cancer Inclusion criteria: Inclusion Criteria:\nMale/",
        "label": 0
    },
    "1956": {
        "output": "For more examples and a full list of possible output values for each of the modules in this package, see the vignettes available with the package. In each vignette, there is a section on the clinical trial and a section on the patient note you should focus on for each module. For example, in `trial`, the patient is a five year old boy. In `patient notes`, the patient is a 40 year old male nurse.\n\n\n<EOD> Effect of age on glucuronidation of aromatizable and nonaromatizable estrogens by rabbit hepatic microsomes.\nThe purpose of this study was to evaluate the effect of age on the capacity of hepatic microsomes to form the O-glucuronide conjugates of 17 beta-estradiol (E2), an aromatizable estrogen, and diethylstilbestrol (DES), a nonaromatizable estrogen, in rabbit liver microsomes. E2-3-O--glucuronide (E2-3-G) and DES-3-O--glucuronide (DES-3-G) were used to measure the glucuronide conjugation for E2 and DES in hepatic homogenates and microsomes. The results showed that the hepatic glucuronidation of both estrogens was age dependent, with a maximal formation at the age of 3-6 months in rabbits. The glucuronide conjugation capacity of both estrogens by rabbit liver microsomes was more abundant during the juvenile and adult periods than during either adolescence or senescence. The activities of glucuronosyl transferase were compared between E2 and DES by evaluating the apparent Km values associated with the enzymatic reactions. No significant differences were observed between E2 and DES.<EOD> Tranexamic Acid Reduces Blood Loss in Primary Total Hip Arthroplasty\nBackground and Aims: The study aimed to evaluate the efficacy of intravenous tranexamic acid (TXA) in reducing perioperative blood loss in total hip arthroplasty. Patients and Methods: A total of",
        "label": 2
    },
    "1957": {
        "output": "Now you will show the results from 8 patients and 6 trials in the following table:\nPlease click the following link to see the details.\n<img class=\"shadow img--responsive\" src=\"https://github.com/kpakuchi/eligibility_assessment_exercise/blob/master/output1.png\" alt=\"screenshot\">\n**Question**: 8. Examine the following two tables with sample data and identify the factors that may affect the outcome measure. Based on the sample data, identify whether a potential participant might be considered eligible or ineligible for the clinical trial. If so, explain why.\n[TEST]\n- Patient information:\n\n### Gender: Man\n\n### Race: Chinese\n\n### Age: 28\n\n### Trial Name: The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma\n\n### Trial type: Drug Delivery Devices\n\n### Recruitment Setting:\n- Clinical Trial\n\n### Trial Phase: Phase 3\n\n### Eligible n: 35\n\n### Ineligible n: 20\n\n### Sex: Man\n\n### Race: Chinese\n\n### Age: 25\n\n### Trial Name: The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma\n\n### Trial type: Drug Delivery Devices\n\n### Recruitment Setting:\n- Clinical Trial\n\n### Trial Phase: Phase 3\n\n### Eligible n: 10\n\n### Ineligible n: 8\n\n### Sex: Man\n\n### Race: Chinese\n\n### Age: 33\n\n### Trial Name: The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma\n\n### Trial type: Drug Delivery Devices\n\n### Recruitment Setting:\n- Clinical Trial\n\n### Tri",
        "label": 0
    },
    "1958": {
        "output": "<EOD> Enhance-R is a new software tool to measure cardiac and peripheral arterial functions\nAbstract Although assessing organ-specific blood flow is important for evaluating cardiovascular disease, there is currently no software available that enables physicians to precisely measure the time domain and the frequency domain properties of blood flow without the need for sophisticated tools. In this work, we introduce a novel software system, Enhance-R, to measure cardiovascular function in a simple and user-friendly manner. Our system is based on the cardiovascular model, which has been described previously. We extended this system to include a module to measure peripheral arterial function, i.e., pulse-wave velocity (PWV). Additionally, to make our Enhance-R system capable of being integrated into existing cardiovascular research tools, we developed an Enhance-R plugin for LabView. We validated our Enhance-R against previously published results and showed good agreement for all parameters. Our results indicate that Enhance-R is a practical tool that not only enables physicians to perform standard cardiovascular function assessments, but can also be used to measure the time domain and the frequency domain properties of the cardiovascular system.<EOD> A Novel Epoxyeicosatrienoic Acid Pathway Contributing to Vasodilation of Isolated Smooth Muscle from Prehypertensive and Hypertensive Dahl Salt-Sensitive Rat Aortas\nAbstract: Aortic rings from prehypertensive (19\u2010 to 20\u2010week\u2010old) and hypertensive (21\u2010 to 29\u2010week\u2010old) Dahl salt\u2010sensitive and saline\u2010drinking Lyon rats were used to identify a novel smooth muscle pathway contributing to vasodilation that is lost with the development of salt\u2010induced hypertension. A significant inward current in the isolated aortic smooth muscle cells of Lyon rat rings was identified on the addition of arachidonic acid or the stable epoxide of arachidonic acid (15,16\u2010epoxyeicosatrienoic acid ). This current is not seen in the aortic smooth muscle cells from older Dahl salt\u2010sensitive rat rings and is blocked by the epoxygenase inhib",
        "label": 0
    },
    "1959": {
        "output": "###### <span id=\"Trial-level eligibility: 2) Eligible.</span>\nYou have to find the patient who meets the following inclusion criteria of the clinical trial. For this purpose of finding the corresponding ID of the patient in the patient notes, you can utilize Patient list function.\n\nOn the left-side menu, hover your mouse over the top-level menu and then click the sub-menu **Patient list** at **Case information** (or **Find patients**) panel.\n\n<img src=\"../images/data-transformation-pipeline_18.png\" width=\"300\" alt=\"data-transformation-pipeline\">\n\nThen, the **Patients** table appears.\n\n<img src=\"../images/data-transformation-pipeline_22.png\" width=\"500\" alt=\"data-transformation-pipeline\">\n\n\nAt this point, you can click the name of each patient and refer to the patient note of the corresponding patient.\n\n*Note: In our dataset, the trial ID 965163935 (EORTC-15991) belongs to the following study:\n\n[EORTC-15991, EORTC-10433]\nIt is actually one of the trials in the clinical trial. Therefore, in order to find the patient who is eligible for the clinical trial we need to examine `Trial-level eligibility: 2) Eligible.` case by case. Refer to the `Notes` and the notes of patient number 23773, patient number 28871 and patient number 30572 from the clinical trial 965163935, and decide which ones are eligible for the trial. Finally, the last line should be like this:\n\n\n*Note:\n\nIn our data, the patients were categorized by the letter according to the results of the histology of breast tissue.\n\n*H- Histologically confirmed breast cancer; HER- Positive for HER1 and/or HER2 (ER+ and PR+; HER2+ and/or TYR+) \n\n*N- No histological confirmation;",
        "label": 0
    },
    "1960": {
        "output": "In this script, I use `print`. In a real application, you should avoid `print` statements. You should log data by the `log` method of the built-in `logging` module. The output of each line is written to the standard output (see here). See the documentation of the `logging` module. Do not forget to call `logging.basicConfig(level=logging.DEBUG)` at the beginning of your script for detailed logs.\nI hope you have a pleasant and useful day!\n<EOD> Cationic polymer-driven self-organized DNA structures as templates for the assembly of biomolecular nanomachines.\nSelf-assembling monolayers of peptide nucleic acids are used to construct structures that support the formation of an artificial molecular machine. The complex, based on a simple synthetic peptide that unfolds under a chemical trigger, is an example of how artificial biological systems may be directed by nanoscale artificial platforms.<EOD> .\nPlethysmography is used in evaluating the vasodilatory effect of drugs (1), such as nitrates and verapamil. This plethysmographic recording, by virtue of its speed, allows the rapid measurement of a pharmacokinetic parameter in man. This article describes the method of measurement for flow, based on the photoplethysmographic technique, using a plethysmograph (1.1, Cardioscan/Medex) which is easy to use and which allows measurement of the forearm to be compared to that of the finger. This measurement of flow was taken in the sitting position in order to see how it was possible to standardize measurements of flow.<EOD> On the Nature of the Relationship Between Rheology and Shear Strength in Soils\nAbstract Numerical methods for assessing the effectiveness and efficiency of geotechnical applications often call for estimation of the cohesion and internal angle of repose of soils. These parameters are traditionally estimated from rheological data collected via rotational shear as well as from other direct and indirect methods that depend heavily upon an assumed, a priori correspondence between rheology and granular flow. The relationship between the two can be expressed as a power\u2010law function: Q(\u03c3)=F(n)\u03c3 where Q(\u03c3) is the volume of material that can be rotated at stress",
        "label": 0
    },
    "1961": {
        "output": "___\nThis material is based in part upon work supported by the National Library of Medicine/ National Institutes of Health, Award Number T15LM012604.\n\n___\n[INST]\nYou are working as a software engineer. It is a small software development agency in Colombia. The agency is composed of three software engineers: two with three years of programming experience and one with some training in software engineering. Today you are deciding to make a software architecture for the agency's next project as part of your job as a technical lead.\n\nYou have recently been assigned to a project. The application will be used by the agency for tracking their activities such as working hours, working documents, costs, and revenue. The program is going to serve as a tool for managing several different types of documents internally as well as externally. The system should work both offline and online. It is supposed to be a web-based application that works on a mobile phone or computer. The application has to be written in PHP and JavaScript. They want to use a MySQL database. It must be easy to read and write the data.The application will collect a few types of information and you have some requirements to keep in mind: [1] All data can be modified by all users. The changes are immediately saved into the database;\n[2] All users can be administrators;\n[3] Users can add and remove their own documents;\n[4] The application can read JSON data (example: JSON from a JSON parser from Javascript); and [5] Users can submit changes to the business documents.\n\nPlease propose the software architecture that best meets the needs of the agency in your technical note. Remember that the application needs to work offline, be fast, be efficient, and not need much space and the data must be easy to manage. Note that you are not allowed to present a monolithic architecture. That is, the application may have several layers or not rely on the standard Model-View-Controller (MVC) architecture. Your proposed architecture can be divided into modules or microservices.\n\n___\nThis material is based in part upon work supported by the National Library of Medicine/ National Institutes of Health, Award Number T15LM012604.\n\n___\n[INST]\nYou are a web developer currently working on a project for an agency in Mexico. The agency",
        "label": 0
    },
    "1962": {
        "output": "### Exclusions\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine a patient's eligibility for a given trial. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nSome participants do not meet the eligibility criterion, but still fit trial participation. These patients are called screen failures and are not allowed to continue the study. For the reasons of these failures, there can be three trial-level exclusions:\n1. Poor effort (\"did not follow instructions,\" \"did not understand the study\"). 2. Other adverse conditions (\"unsafe to proceed,\" \"confusion/memory deficit,\" \"dysphagia,\" \"impaired speech\"). 3. Other medical reasons (\"alcohol abuse,\" \"medication interactions,\" \"uncontrolled diabetes\").\n\nHere is the patient note:\nThe patient is a 52-year-old woman diagnosed with HIV 11 years ago and the recent coinfection with HBV. Her past medical history is non-significant. She is on ART and direct antiviral drugs for the past 2 years. The patient takes no other medications. Her medical records show positive anti-HCV-antibodies and negative HCV PCR test. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for inflammation of the liver. There is no evidence of bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. She is a alert female with no acute distress. Her BP: 140/95, HR: 90/min and BMI: 27. Her abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Cutting Edge of HIV/HBV/HCV Therapeutics. Summary: This multi-center study evaluates the safety and efficacy of new direct acting antivirals (",
        "label": 2
    },
    "1963": {
        "output": "[ENGINES] (This part is for testing only.)\n\nIn order to find the best engine for Clinical Trials API, we have conducted the following tests:\n* We have tested the same query in all the engines.\n* The query parameters include 5 tests with the following features:\n    * Detailed query and result parameters (including the `Trial-level_eligibility` parameter in the `Trial` object).\n    * Only a single trial parameter from the `Trial` object.\n    * Only a single result parameter from the `results` collection.\n* Our conclusion is that `Palo Alto` engine has the best query processing speed.\n[ENGINE-01] (Tests in the engines are not for production.)\n![screenshot_engine01](/images/engines/qs02-engine01.jpg \"Engine 1 results in Clinical Trials API\")\n\n```\nGET /api/qs01/clinical_trials \n[{\"id\":\"clinical_trial\",\"trial_id\":00001,\"name\":\"A Trial with a Name\",\"recruiting\":false,\"is_closed\":false,\"phase_of_trial\":\"not started\",\"status\":\"enrolling\",\"trial_type\":\"Therapeutic\",\"trial_sponsors\":[{\"id\":\"93\",\"name\":\"A Pharmaceutical\",\"display_name\":\"A Brand Sponsor \",\"country\":\"United States\"}]},{\"id\":\"clinical_trial\",\"trial_id\":00002,\"name\":\"A Trial with a Name\",\"recruiting\":false,\"is_closed\":false,\"phase_of_trial\":\"not started\",\"status\":\"enrolling\",\"trial_type\":\"Therapeutic\",\"trial_sponsors\":[{\"id\":\"93\",\"name\":\"A Pharmaceutical\",\"display_name\":\"A Brand Sponsor \",\"country\":\"United States\"}]}]\n```\n\n```\nGET /api/qs_engines/clinical_trials \n{\n    \"engines\": [\n        {\n            \"id\": 0,\n            \"url\": \"http://example.com\",\n            \"engine\": \"engine01\",",
        "label": 0
    },
    "1964": {
        "output": "<EOD> Cervical stenosis in adult women with Down's syndrome\nUterine and cervical anatomical abnormalities occur in 90% of women with Down's syndrome and are related to their mental retardation. Women with Down's syndrome and cervical stenosis are highly susceptible to the risk of spontaneous miscarriage.<EOD> Nondestructive measurement of bone density in the calcaneus of cats using the quantitative ultrasound device I-scan.\nOBJECTIVE\nTo assess the feasibility of using the I-scan QUS (quantitative ultrasound) device to measure bone density of the calcaneus in client-owned healthy cats and its effect on cat's age and body weight.\n\n\nMETHODS\nEleven healthy client-owned cats of different breed and mean age 4.3 \u00b1 2.3 years were recruited. S-I, SOS and BUA  were measured by the QUS device.\n\n\nRESULTS\nThe measurements for all cats on the right side were lower than the left side. According to the Pearson correlation coefficient, there was a positive relationship between body weight and S-I, SOS and BUA. An inverse relationship was observed between the cats' age and the bone density parameters evaluated.\n\n\nCONCLUSIONS\nThe calcaneal bone density was found to be an important bone parameter to evaluate risk of bone fragility during aging in cats and in different conditions. Our findings suggested that the S-I, SOS and SWT are influenced by cats' body weight and age.<EOD> A review on the applications of nanomaterials in the remediation of aquatic microplastic pollution.\nMicroplastics exist in natural waters, while nanomaterials have been widely applied in industry and agriculture. Thus, nanomaterial exposure may co-exist with microplastics exposure. Microplastics can act as nanomaterial carriers, which may increase the harmfulness of nanomaterials. Nanomaterials can also be used as tools for microplastic detection. However, these issues and their interaction remain unaddressed, which may hinder the development and utilization of nanomaterials. In this",
        "label": 2
    },
    "1965": {
        "output": "![Screen shot][INST009]\n\n[INST009]: ./images/Snippets/012-05-Clinical-Trials-Screen-Shot.png \"Expected behavior of clinical trial screening module\"\n\n_You may have found that there are only three elements of each factor of the form (Patient age; Patient Gender; Disease stage...): In total, in two-level scales, there areseven elements. To maintain symmetry and avoid confusion, we decided to remove all the elements of the form \"Patient's disease_stage: Level\" element._\n\n[INST010]: ./images/Snippets/012-07-Eligeability-Screenshot.png \"Expected behavior of clinical trial eligibility screening module\"\n\n__[INST011]: ./images/Screen-Shots/012-09-Trial Eligibility.txt__\n\n__[INST011]: ./images/Screen-Shots/012-09-Trial Eligibility2.txt__\n\n__[INST012]: ./images/Screen-Shots/012-10-PPGM Clinicaltrial Screening.txt__\n__[INST013]: ./images/Screen-Shots/012-11-PPGM-Patient Screen.txt__\n__[INST014]: ./images/Screen-Shots/012-12-Trial-Patients-Summary.txt__\n__[INST015]: ./images/Screen-Shots/012-13-PPGM-Screening-Clinical-Trial.txt__\n__[INST016]: ./images/Screen-Shots/012-14-Briefing-Conference.txt__\n__[INST017]: ./images/Screen-Shots/012-15-Conference-Briefing.txt__\n__[INST018]: ./images/Screen-Shots/012-16-Trial-Data-Analysis.txt__\n__[INST019]: ./images/Screen-Shots/012-1",
        "label": 0
    },
    "1966": {
        "output": "[HINT: Your input should be formatted as a `table of information`. The output is formatted as a `table of judgment, sorted by `Trial-level eligibility`.]\n\n_Exercise_\n\nInstructions: [DOWN]\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is",
        "label": 0
    },
    "1967": {
        "output": "##[MAKER] Mark patient-specific assessments for all steps (Trial-level eligibility, Eligibility and Question)..\n\n### 3) Sub",
        "label": 0
    },
    "1968": {
        "output": "# Discussion\nAnother method of dealing with complex data is a spreadsheet method using Python 3.6.0. The data is provided as the input files and the outputs are saved as well.\n![INST [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness",
        "label": 0
    },
    "1969": {
        "output": "__Note__: If you encounter a different question of patient note/patient history note, refer it to `Appendix 10 -Question 1` to find the correct answer. (2)\n\n# Question 2\nAssume that the clinical trial just above has one of the three exclusion criteria for participation eligibility:\n\n& The patient presents alcoholic liver disease.\n\n& The patient presents hemochromatosis for which a phlebotomy program is being established.\n\n& The patient presents active esophageal varices.\nFor each exclusion criterion listed, write the clinical note that would lead to exclusion. Copy one question over again and respond to the next one.\n\nWhen writing a clinical note, format the same as that of a clinical note and put the information in the same sections as in your training site. If you need more information in your note, you can fill blank spaces between the elements of the clinical note. [CITE]\n\n& Alcohol use in excess of 70 grams per week for male or 42 grams per week for female patients or a positive test using ethanol screening test.\n\n& Hemochromatosis of 68 &mlt; grams/100 &mlt; dl iron saturation, and hemoglobin levels < 12 mg/dL.\n\n& Esophageal varices as large as 5 mm in diameter and with red in color with white spots of spleen in ultrasonography.\nThe assessment of the response to treatment should be based on a quantifiable and statistically significant improvement in a defined end point for the study. The response can be compared using the following definitions in the CIRS.\n\n\n\n## Remission/response\n\nRemission: No more HBV DNA detectable in plasma HBeAg positive patients and HBeAg negative patients under 500 copies of viral load is regarded as remission\n\nResponse: If HBV DNA is undetectable, it is regarded as response; If HBV DNA is less than 3 logs reduction, it is regarded as response.\n\n\n## Complete response\n\nNo more HBV DNA detectable in serum\n\n\n## Improvement (with reduction of hb",
        "label": 1
    },
    "1970": {
        "output": "Let's think step by step. \nIn this example, you should use some data to help you decide. If you have information about the patient's medical history, the stage of the disease, previous treatment history and other medical conditions, then please use that information as well. Let's think step by step. \nIf you are not sure if more information is required, for example, if the patient's treatment history includes medicines for different conditions, then follow the rules for the next level of inclusion criterion (detailed in the rules below). If you decide that the patient does not meet the definition of the condition, then report 0: Excluded. If the patient satisfies the definition of condition, then repeat the assessment step by step, starting again from the first criterion that the patient satisfies. Let's think step by step. \nYou might have information about other diseases, treatments, previous treatment history and other medical conditions that are not listed in the list. In these situations we ask you to refer to the full rules in section 2.1.2 of the protocol. For example, if you have information about another medical disease, please follow the step-by-step instructions in section 2.1.2.1 of the protocol 2.1.2.1. A medical condition is present if evidence of the disease is provided and if the patient is symptomatic. Let's think step by step. \nYou might have information about additional information that is helpful for the assessment of Eligibility, e.g., if the patient has a family history for HIV infection. Please provide this information in the field called additional information.\nAdapting the assessment rules\n\n## Adapting based on additional notes or notes in a free text format\nYou can adapt your assessment based on additional information in the notes field. For example, if the disease type is not mentioned in the eligibility criteria but you know the type of disease or if you only know the name of the disease.\n\nYou should always make sure to complete the last line by 'Trial-level eligibility: '. An example is shown below:\nTrial-level eligibility: 2) Eligible. Patient is a non-pregnant 40 year old woman, diagnosed with type 1 diabetes at the age of 15. The patient is married and",
        "label": 0
    },
    "1971": {
        "output": "[table]  \u00a92012: Hiroki Asai. This repository is released under the terms of the MIT License. \u00a92012-2023 Kaggle, Inc.. Powered by IPython and Bokeh. Terms | Privacy | GDPR Policy & Notice | Advertise | ContactSupport | Developers | Company | Help Center | Blog | Forum | API \u00a92012 Hiroki Asai \u00a92012-2023 \u00a92012 Hiroki Asai \u00a92012-2023 \u00a92012 Hiroki Asai \u00a92012-2023 \u00a92012 Hiroki Asai \u00a92012-2023 \u00a92012 Hiroki Asai \u00a92012-2023 \u00a92012 Hiroki Asai \u00a92012-2023 Privacy | GDPR Policy & Notice | Advertise | ContactSupport | Developers | FAQ | Forum | Tutorials | Blog | Terms | Contact Us<EOD> Is Splenectomy Still Indicated? An Updated Analysis of an Analysis\n\nFor years, splenectomies were frequently performed in patients with a normal spleen. However, in splenic pathologies the spleen could be saved by embolization, medical therapy, and by spleen-preserving procedures. Therefore to prevent morbidity and mortality in an increasing number of clinicians began to question whether a splenectomy has still a place in the treatment armamentarium of patients with splenic pathologies. Today, non-operated patients with normal spleen rarely appear in clinical practice. Our main objective in this review was to give an extensive update on the place of spleen-preserving and splenectomy procedures in our daily practice. After a general overview of the clinical presentation, diagnosis and treatment of all splenic pathologies is presented, a more detailed look into some specific splenic diseases is included. To conclude, based on this extensive overview we are able to draw a complete picture of the indications for a splenectomy and a spleen-preserving procedure for splenic pathologies. This",
        "label": 2
    },
    "1972": {
        "output": "[13] Hello. You are a pathology resident. You are working on a research project where you would like to assess the incidence, trends, and predictive factors of metastases, such as tumor size, stage of the disease, and other clinical factors. For this purpose, you are creating a table using the REDCap survey tool. Tables in REDCap can contain both numerical and categorical data in separate columns. All numerical values (e.g., numeric age, number of metastases, etc.) should be entered as integers. The columns should only contain single numeric values and do not contain any other fields (e.g. alphanumeric text, checkboxes). Each row in the table should contain only a single value. A unique identifier should be created first, before a specific variable is entered in each cell in the table.\nThe following table is a hypothetical example of table in REDCap: 676.7 kg/m -2 ) with metastases, while the other patient presented a BMI of 23.1 kg/m -2 without metastases (tumor size was 9.5 cm, metastases 5). \n\n\nAs seen in the following code, REDCap generates the values in the following order:\n\n    $id <number> 1 2 3 4 5 6 7\n\n    $year <year> 2000 1\u20262019\n\n#####\n\n    $gender <letter> M  male F  female\n\n    $clinic <string> 1 Precision 2 Comfort 3 Precision 4 5 Comfort 6 7 Precision 8 9 Comfort\n\n    $hospital <string> A B C D E F G\n\nThe table can contain either or both. It also can contain more than one value. The header will not change but number of rows will change, starting at 1.\nIf the same number is used in another table in the case of duplicate, the first header from the second table will be considered the same as the previous table and that header and number will also not be changed.\nIf a survey is completed by multiple users, we will ensure all the tables are formatted the same before the data is downloaded. \n<EOD> Evaluation of a port",
        "label": 0
    },
    "1973": {
        "output": "```python\nimport json\nparticipant_json = {}\nparticipant_data_files = os.listdir(\"./data/participant/\")\njson_list = [i.rstrip() for i in participant_data_files]\nfor j in json_list:\n    for k in [k for k in ['registration', 'eligibility', 'trial-level-eligibility', 'eligibility', 'enrollment']:\n        if not trial_level_eligibility:\n            print(\"The trial-level eligibility for this participant is 'not-enrolled' and 'eligible'\")\n        else: Not yet to be the trial if trial eligibility?\n                The participant's enroll eligibility of candidate's trial participant's record<EOD> eligibility status?\nparticipant has participated in clinical trial? Participant's eligibility as 'eligible of participation, to the clinicaltrial's eligibility, age eligibility for eligibility (eligibility? trial eligibility clinical trial's eligib:\nEligible's (participant criteria to participant?\nParticipant is eligibility. Criteria? or criteria. If an individual's trial?\nThe trial's eligible's trial eligibility's onset's trial?participant's trial's enroll, such as a clinical trial's data, where applicable criteria. The participants are not eligible as part of the participant's registration criteria. If itiner, clinical trial-eligible trial.\nto determine\nRegistration elig's to trial elig.\n\nparticible, eligible. Participants elig's status (elig's individual's trial's trial. To be determined eligible patient's trial (participant elig triall clinical patient trial elig.\ntrial? In aids. An individual elig. There is clinical eligible?\n\n\n\npartner eligible (t not elusibly because it is required because of trial.\nor trial's\n\nand the eligible?\nClinigible on account. Clin's.",
        "label": 0
    },
    "1974": {
        "output": "<EOD> Cryptic biodiversity in two widespread Afrotropical lorocerk\n\n\n\n# Material and methods\nSpecimens were collected by beating bushes, hand or sweep netting. Vouchers were deposited in the CRL herbarium (CRL) at the University of Yaounde 1 (Cameroon) or the ZMA herbarium (ZMA) at the National Museum of Natural History (Brussels, Belgium), respectively. The type specimens were deposited in the CRL or ZMA herbarium and described in.\nTo determine their taxonomic placement more closely, we have sequenced two nuclear markers: the internal transcribed spacer region of the ribosomal DNA (ITS) and the chloroplastidial (cp) trnL-trnF intergenic spacer. Voucher specimens representing the species were selected for DNA extraction and amplification following. Sequences were analysed and aligned with Sequin 4 (National Center for Biotechnology Information (NCBI)), edited and aligned with BioEdit v. 7.0.9.0, and subsequently aligned with ClustalOmega (https://www.ebi.ac.uk/Tools/msa/, accessed on 1 February 2018), prior to analyses. Sequences were uploaded in GenBank 5 , and the accession numbers are provided in Tables S1 and S2.\nThe genealogical sorting index (gsi ) and the pairwise difference (pd ) for the ITS rDNA were calculated using the mgv program v. 1.533 of the moldet package; the best DNA model was estimated using MEGA v. 7via the maximum likelihood estimation (L.B.M. test using MEGA v. 7. The alignment was generated using MUSLE algorithm implemented in MEGA v. 4. The sequences were also submitted to the RESL pipeline for further analysis (https://www.bioinformatics. babraham.ac.uk/projects/fasttree, accessed on 26 March 2019); maximum likelihood phylogenetic trees were estimated using RAxML v. 8 softwarewith 1000 bootstrap replications and rooted",
        "label": 0
    },
    "1975": {
        "output": "# Results\nYou can find the trial-level eligibility for each patient note in our system. The system gives output as follows.\n\n## Figure caption\n\n# Discussion\nThis challenge focuses on an aspect of medical domain: clinical trial eligibility checks. Our machine-learning model uses patient note and clinical trial information to assess eligibility of a patient. For comparison, we used the baseline model as follows.\nBaseline model: The baseline model can be done by finding the intersection of the answer of each sentence (one clinical trial information) as follows. If all answers are ``Excluded\", the patient is Excluded. If the first sentence is ``Not-relevant\", the answer of the second sentence is also checked. If it is ``Not-relevant\", the answer of the last sentence is checked. If it is also ``Not-relevant\", the patient is Excluded. If it is at least one ''Eligible\", the patient is Eligible.\nIn machine-learning evaluation, the F1-score, Cohen's Kappa, Accuracy, Precision, Recall, Receiver Operating Characteristic (ROC) curve are evaluated. \nThe machine-learning-based clinical trial-level eligibility check works well for the clinical trial. It achieves the same result with the baseline model, where the Cohen's Kappa and Accuracy are 1, while the F1-score, Precision, and Recall are 0.9950, 0.9952, and 0.9950.\nMoreover, we show how the Cohen's Kappa, Receiver Operating Characteristic curves (ROC curves) change based on different datasets. Cohen's Kappa is a measure of agreement between a classifier and manually created labels, such as the labels of an annotator, which is defined in Equation 1. Equation 2 shows the definition of the ROC curve.\n\n## Precision\nWe can see that the results for Cohen's Kappa and accuracy is very similar, and slightly higher for our machine learning based method for 5.1, 7.2, and 11.\nF1-score is an aggregated score for precision and recall for class imbalance data. It is defined",
        "label": 0
    },
    "1976": {
        "output": "##[OUT] ASSIGNMENT TEXT\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria), 1) Not relevant (patient does not have sufficient information to qualify for the trial), and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). Eligible patients are included in the clinical trial. Excluded patients are not included even the trial eligibility is positive (2) Eligible. \nIn general, randomized clinical trials recruit patients who are eligible for treatment from a specific group of patients. This patient may or may not be eligible for the study group. \nA treatment group is a pre-specified group of patients treated with a unique regimen within a clinical trial. For example, several studies on clinical treatment of gastric cancer enroll the treatment group as patients who receive surgery plus chemotherapy. \nIn general, randomized clinical trials recruit patients who are eligible for treatment from a specific group of patients. This patient may or may not be eligible for the study group. \nAs we defined in the clinical trial section, the \"study group\" is the patients who are randomly assigned by computer-generated numbers to the treatment group. \n\"Treatment group\" is a pre-specified group of patients who have met inclusion and exclusion criteria of a specific clinical trial. The patients to be included in this group will be assigned by using the method of randomization (e.g., by random numbers), and they will receive standard treatment for a specific disease. \nRandomization is a statistical technique used to assign patients to the treatment group and control group. This is done in random order. In general, the random assignation is performed in a random computer-generated order. The reason why the assignment is done by computer in a random order is to ensure the equality of the sample in the two groups. However, in some cases, this method may not be appropriate. This is the case of the rare disease of hepatitis C. Hepatitis C can be divided into three categories depending on whether it is acute, chronic, or asymptotic. The reason for the division of hepatitis by acute or",
        "label": 0
    },
    "1977": {
        "output": "Note\n\n-\n- If we want to return the eligibility or ineligibility of 7 clinical trials, we put `Triallevel eligibility: ` and then return 7 items instead of two items:\n\n```py\nf_eligible_1 = Trial-level eligibility: 2) Eligible.\nf_eligible_2 = {{'Detailed eligibility information': 'The patient with age < 40 who has a type 1 diabetes can participate in trial 1 and trial 2'. 1: 'The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:FBS: 100 mg/dlHbA1c: 6.5%Cholesterol: 190 mg/dlTG: 140 mg/dlLDL: 125 mg/dlHDL: 40 mg/dl', 2: 'The patient is a 25-year-old man with type 1 diabetes that needs more intensive treatment (basal bolus) and with vitamin D deficiency. \n                        In this clinical trial for diabetes patients, the patient will take ACE inhibitors, vitamin D, and lisinopril to take advantage of their benefits', 3: 'The patient is a 25-year-old man with type 1 diabetes.', 4: 'The patient is a 25-year-old man with type 1 diabetes.', 5: 'The patient is a",
        "label": 1
    },
    "1978": {
        "output": "#### Output format\n\nYou can choose one of the following types of outputs:\n\nYou should write a file named as `patient_name_clinical_trial_id_output.txt`, where `patient_name` is the name of the patient note, and `clinical_trial_id` is a unique clinical trial identifier that you have just created. The contents of the `output.txt` file that you should write to are described below. All headings in the file apart from the first ones and the last ones should be in the same column.\n\n\n###### `Patient_ID`\n\nThis is the unique identifier of each row of the patient note.   \n\n###### `Patient_Name`\n\nThis is the initials of the patient.\n\n###### `Age`\n\nThis is age of patient in year.\n\n###### `Gender`\n\nThis either `1` if the patient is male, `2` if the patient is female, or `3`if the patient is other or there is no data.\n\n###### `Residence`\n\nThis is the residence of the patient. It can be either ``home``in home,``dorm``in  dorm,``other``in other.\n\n###### `Diagnoses`\n\nThis is a list of diagnoses including `1`if the patient has the diagnosis or not.\n\n###### `Insulin`\n\nIf the patient is using Insulin then it must be in this column.\n\n###### `Vitamin D`\n\nIf the patient is using Vitamin D then it must be in this column.\n\n###### `Cholesterol`\n\nIf the patient is using Cholesterol then it must be in this column.\n\n###### `Triglycerides`\n\nIf the patient is using Triglycerides then it must be in this column.\n\n###### `HDL`\n\nIf the patient is using HDL then it must be in this column.\n\n###### `LDL`\n\nIf the patient is using LDL then it must be in this column.\n\n###### `HbA1c`\n\nIf the patient is using HbA1c then it must be in this column.\n\n####",
        "label": 0
    },
    "1979": {
        "output": "---\n\n## TUTORIAL2_4_2: HOW TO LABEL THREE WAYS FROM DATA\n\n[INST] The data is in the Data folder. \nIt is a dataset called `data/data.csv`. \nIt has some patient information like Gender, Treatment, Height, Weight, Age and Blood Group. \nIt is one patient in every row. \nThe first five rows in the dataset are `Income, Sweet, BMI, Weight` and `Gender`. \nWe will find whether there is a sweet patient. \nIt is 0-102. \nIf there is a sweet patient, write `0` in the row corresponding to `PatientID`. \nIf there is not a sweet patient, write `1` in the row corresponding to `PatientID`. \nIt is one patient in every row in the dataset. \nHere, we are going to define the function `sweet`. \nIt searches in one row corresponding to `PatientID`. \n`#patientID` is the row number of `sweetPatientName`. \n\nfunction sweet(data$patientID){\n    if(!patientID%in%c(\"Cough\",\"Fever\",\"Headache\",\"RunnyNose\")){ #The patient doesn't have a cough, fever, fever, runny nose or headache. \n        sweet = \"0\"\n    } else {\n        sweet = \"1\"\n    }\n    console.log(\"Sweet Patient ID: \" sweet )\n    #return(sweet) }\n\n\n`sweet(data)` is the function sweet. \n`apply` is used to apply the `sweet` function to the patient dataset. \nSweet should be applied to the data in the form of a vector. \n`vectorName` contains the index of the `apply`. \nAll other values in the vector are ignored. \n\nfunction sweet(t=vectorName, data=Data){}\n\nTherefore, the data that the function sweet() applied to is as bellow. \nWe see that there is no patient who gets cough, fever, headache, runny nose or headache. \nWe need to check out if there is a sweet",
        "label": 1
    },
    "1980": {
        "output": "Now, as you see, our goal here is to evaluate the following variables:\n\n* The 50% accuracy\n\n`4.1.0.3.6` Variable importance analysis\n\nThe problem is that for this study we only have three binary features, so that the decision tree cannot extract information from them. The easiest way for us to find a decision boundary is by setting the cut-point of LVH status to 50%. Then using the two remaining features to create one single splits that splits the cases into a class with greater LVH probability (0.60) and a class with less LVH probability (0.40). If we were to increase the number of features to greater than 2, the decision tree algorithm would be able to extract and make use of more information from them and the resulting cut point would be more precise, and therefore, the resulting decision tree would be more accurate.\n\n# Data preparation\n\nLet's see how to prepare the data:\n\n`4.2.0.1` Finding out the most common value for FBS and chol We are only interested with the most common values in this task, hence, we will discard the rest. So, we find the most common value for `FBS` and `Chol`, i.e., `FBS=100` and `Chol=190`.\n\nLet's see how to do that:\n\n| `Feature name`                | The least frequent value | \n:----------------------------:|:------------------------:|\n| `FBS`                         | `130`                     |\n| `Chol`                        | `200`                     |\n| `HDL`                         | `28`                      |\n| `TG`                          | `120`                     |\n\nNow, let's remove all the observations which have a value greater than the mentioned value, i.e.,\n\n| `Feature name`                | The range of the considered values | \n:----------------------------:|:------------------------:--|\n| `FBS`                         | >100                        |\n| `Chol`                        | >190                       |\n| `HDL`                         | >28                        |\n| `TG`",
        "label": 0
    },
    "1981": {
        "output": "# SUT_3: Exclude\nThe following factors may allow someone to participate in a clinical study, but are not based on characteristics that would allow one to participate in a clinical study:\n\n- Age.\n- Gender.\n- A past medical history of disease, injury, surgery, or therapy.\n- Current medical history of disease.\n- Family history.\n- Race.\n- Ethnicity.\n- Pregnancy.\n\n## INST_1: Input a patient \nHere is a patient:\nSubject is a male, age: 37 years, weight: 84 kg, height: 176 cm. This information is based on demographic data of research subjects. Subject presented to the doctor due to palpitations and shortness of breath after climbing three steps. Physical examination showed a systolic cardiac murmur, SX: 4/6. Subject's medical history has no significant diseases as well as no significant familial diseases. Subject has no history of drug use. Subject has no history of cardiovascular surgery or myocarditis. Subject has no history of respiratory disease. Subject's blood pressure is 160/100 mmHg, pulse is 110 bpm, heart rate 110 bpm, and body temperature of subject is 38\u00ba C. The subject is currently on medications of catechine 50 mg and cefalexine 500 mg.\n\n## SUT_1: Assess subject\u2019s eligibility\nNow, let's check the eligibility based on the following criteria.\n\n### Assessment based on age\n- AGEIS = 1 AND WRITE('subject is >= 18 - Age')\n\n### Assessment based on gender\n- GEN = 1 AND WRITE('subject is male')\n\n### Assessment based on physical examination findings\n- SYSV = 1 AND WRITE(/('physical examination of the subject shows [SYS]*))\n\n### Assessment based on other criteria\n- SUBJ = 1 AND WRITE(/('subject has [SUB]*))\n\n### Assess",
        "label": 0
    },
    "1982": {
        "output": "You should not use comments at the end of the algorithm. Your algorithm must be executable. Comments must be placed in a code block such that a text editor can display them. They can be executed if the user hovers the mouse over the code block. Also don't include your name in the code as this is the way people detect plagiarism.\n\n\n[fig]  [: VISUAL] Input: The patient note and the clinical trial. VARIABLE: Patient note. HISTORY: Evaluate the patient and the eligibility of him for the trial using the same clinical trial. [/VISUAL] [/fig] \n<EOD> Innovation in psychiatric care: a case study of a virtual community of practice\n\nInnovation in Psychiatric Care: a case study of a virtual community of practice\nNovember 2012. 2013\nM.Sc.student psychologistand Innovation in Psychiatric Care: a case study of a virtual community of practice\nInternational Journal of Integrated Care\nDordrecht, The Netherlands13November 2012. 2013123Submission history: Submitted March 28, 2013; Revised April 29, 2013; Accepted May 24, 2013 2001 Competing interests: BJ is chief editor of International Journal of Integrated Care. The article underwent peer-review process and has been published as a part of the special issue on the 15th Annual Integrated Care Conference, held in Prague (CZ). 1. (2001). A community of practice as a framework for enhancing integrated care. International Journal of Integrated Care, 1(4), 35-43.\nIntroduction: A collaborative virtual inter-agency model of communication is important for patients, mental health staff and other professionals that work within integrated health programs. Community of practice (COP) is a collaborative model in which a common language and shared values are established. Methods: The model can be established through a simple, web-based message board. Results: An evaluation can be done by determining the effect of the use of a community of practice on the collaborative efforts of individuals with different backgrounds that are based",
        "label": 0
    },
    "1983": {
        "output": "[INST] Hello, `Hello, {subject}`! How are you doing today?\n\n[INST]$(RUN R shell -i echo \\ $(whoami) >/dev/null -r 'hello '${subject}')\n\nHello, ${subject}.! My name is Alireza Naderisani, and I am from your University. My university conducts clinical trial research. I work with doctors to find new ways to treat patients and make better medical devices. My goal is to learn more about heart conditions, and I have been collecting information and trying to understand the differences between people with and without a heart condition.\n\nAre you 18 years old or older, Alireza Naderisani?\n\n# Yes/No\n\nI will ask you some questions about your heart condition. This may take up to 15 minutes. If you prefer to stop now\n\n# No: Exit\n\nI will ask you some questions about how much your doctor has told you about your heart condition.\n\nDid you know your doctor told you that you had heart disease?\n\n# Yes/No\n\nIt is normal to be nervous and upset when a doctor tells you you have heart disease. Do you feel that way?\n\n# Yes/No\nIf you have an emotional or behavioral disorder, it is usually better to wait at least a few days to participate in a study\n\nHas your doctor said that you have an emotional or behavioral disorder?\n\n# Yes/No.\n\n### Now let's find the answer yes\n\nIt is normal to be nervous and upset when a doctor tells you you have heart disease. Do you feel that way?\n\n# Yes: Go to 2)\n\n\n## 1) If you answered no, continue...\nIt is normal to be nervous and upset when a doctor tells you you have heart disease. Do you feel that way?\n\n\n$T-el1=T-el\n\n# Yes: Go to 2)\n\nDid you know your doctor told you that you had heart disease?\n\n# Yes/No\n\nI want to tell you a little bit more about the purpose of this study.\n\nThis is a study about the relationship between the heart and the kidneys. We want to understand the causes or why some people have heart conditions",
        "label": 0
    },
    "1984": {
        "output": "Note: To submit the solution, we should not write `Done` on the first row. Instead, we should type `Done`.[INST]\n\n# Solution\nSolution is as follows.\n\n```bash\n#!/usr/bin/env python\n# -*- coding: utf-8 -*-\n# Author: Ebrahim Akbarzadeh <http://www.akbarzadeh.ir>\nfrom IPython import display # IPython\nimport string # Python\n#import operator\nimport re # Python module\nimport collections.deque\nfrom itertools import chain # Python module\n#import itertools\nfrom pprint import pprint # Python module\nfrom operator import add # Python module\nfrom operator import lshift\nfrom operator import rshift\nfrom operator import smatch # Python module\nimport subprocess # Python module\nimport datetime # Python module\nimport sys # Python module\nfrom . import *\n_ = OPTION_HELP\nC = CHARACTER\nALPHABET = ('0' + string.ascii_letters, '1' + string.ascii_letters)\nCHARS = 256\ndef check_cstr_char(cstr):\n    return string.ascii_letters in cstr\n\ndef convert_to_char():\n    \"\"\"converting from strings to character array\"\"\"\n    chars    = []\n    str_len  = len(string.ascii_letters) * CHARS\n    for i in chain(\n        itertools.count(0, string.ascii_letters),\n        itertools.count(-1, string.ascii_letters)\n        ,\n        ()\n    ):\n        bits_num = int(string.ascii_letters[i:i+1], 2) ^ 0xFF\n        chars   = [bit[4:6] | string.ascii_letters[i:i+1] | chars]\n        i    += 1\n        strings = '0' +\\\n                  string.ascii_letters[:i] +\\\n                  \"1\" +\\\n                  string.ascii_letters[i:i+1] +\\\n                  \"1\" +\\\n                  string.ascii_letters[i+",
        "label": 0
    },
    "1985": {
        "output": "![INST]\nExclusion criteria and the category of exclusion criteria (one line per patient) output in the last lines, e.g., `Exclusion criteria: No history of cancer, `and `Exclution criteria: Cancer , `.\n\n\n#### Additional documentation\n\nIf you want to know more about the documentation, click [here](https://github.com/vaggelis0/Clinical-Trials-Recruitment-Assistance-Using-DeepLabV3Plus-PyTorch-and-Transformer-Architecture-for-Clinical-Recruitment-Assistance). \n<EOD> .\n\n The effects of immigration and fertility control policies adopted by the Australian government in the late 1970s are discussed. Changes are",
        "label": 2
    },
    "1986": {
        "output": "Now we see how we can do that:\n```R\n# Define trial information list\nmyClinialTrials <- c(\"Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating...,\n                 \"Type 2 Diabetes Mellitus Clinical trial for type 1 diabetes patients\")\n\n# Get patient information.\n# The result set of the SQL query is a dataframe with 8 data columns,\n# namely: ID_N (unique serial number for the patient), Date, Sex, Age_at_trial,\n# AST_normal (normal value range for the aspartate aminotransferase), ALT_normal,\n# Albumin_normal, Disease_code (coded by ICD9), and Drug_assigned_at_trial.\npatientInfo <- getDataByClinicalTrailId(clinicalTrailID, myClinialTrials)\n\n# Convert the dataframe into a data.table object.\npatientInfo.dt <- data.table( patientInfo)\n\n# Define trial-level data structure.\npatientLevelData <- data.table( clnt_id = patients.ID, drug_assigned_at_trial = \n                             \"Aspirin\")\n\n# Define trial-level variables.\npatientLevelVariables <- c(\"clnt_id\", \"drug_assigned_at_trial\", \"Age_at_Trial\", \"AST_normal\",\n                        \"ALT_normal\", \"Albumin_normal\")\n\n# Get patient level data set by querying the patientInfo.dt table.\npatientLevelDataSet <- query(patientInfo.dt,\n                          list(clnt_id      = patientLevelData$clnt_id,\n                              drug_assigned_at_trial= patientLevelData$drug_assigned_at_trial,\n                              Age_at_Trial  = patientLevelData$Age_at_trial,\n                              AST_normal    = patientLevelData$AST_normal,\n                              ALT_normal    = patientLevelData$ALT_normal,\n                              Albumin_normal = patientLevelData$Albumin_normal))",
        "label": 0
    },
    "1987": {
        "output": "<EOD> Intercalated Discs Are Essential for Conduction Velocity in the T-tubules of Rat Sinoatrial Node Pacemaker Cells\nRationale: Sinoatrial node (SAN) pacemaker cells generate electrical impulses via inward currents and generate an outward force, leading to propagation in the ventricles. T-tubules interconnect the cell membrane with sarcoplasmic reticulum (SR) and form a network covering the entire cell, and intercalated discs (IDs) form an intercellular junction, connecting the cell membranes with the cytoskylinets. Recent studies reported that ID genes (e.g., cadherin 23) are required for normal conduction velocity (CV), but it remains unclear whether alteration of ID impairs conduction. Objective: In this study, we compared the morphological features of the atria and ID properties of SAN in rats. Methods and Results: We used a cell patch-clamp technique to record membrane potential and action potentials in SAN pacemaker cells isolated from rats. In comparison with atrial cells, T-tubules that were invested with SR junctional sarcoplasmic reticulum were elongated in SAN pacemaker cells. By contrast to ID-like structures in atrial cells, SAN pacemaker cell ID-like structures were short and narrow. CVs in the subepicardial SAN were higher than those in the septal SAN. Moreover, knockdown of cadherin 23 (the key component of ID) decreased CVs in the SAN. Conclusions: Taken together, these results indicate the presence of a functional T-tubule\u2013dominated conduction system in SAN pacemaker cells. We propose a novel function of IDs in maintaining CVs. In addition, we suggest that ID properties are essential in order to determine a low conduction of the SAN, which may be critical for pacing.<EOD> Bifone syndrome with severe skeletal deformities: The role of next generation sequencing in patients without a molecular diagnosis\n\nGenetic studies reveal that \u223c40-80% of patients with clinical presentations of congenital diaphragmatic hernia (",
        "label": 0
    },
    "1988": {
        "output": "Please see `INSTRUCTION_README.md`. \n<EOD> .\nWe report the case of a patient with severe acute liver dysfunction after acute coronary revascularisation. The main symptoms consisted of acidosis (pH 6,9), hypoglycaemia, coma and jaundice. The laboratory findings revealed increased serum levels of enzyme amintozimase (1,790; N: <35) and serum bilirubin (max 19.4 mg/dL; N:  133). Renal insufficiency (creatinine 2,80 mg/dL; N:  1,5) was observed. The patient underwent hemodialisis. Four months later, the patient still suffers from liver dysfunction with increased serum bilirubin and transaminase levels.<EOD> Prognostic value of tumor-associated autoantibodies in head and neck cancer: a cross-sectional study\n\na b s t r a c tIntroduction: Tumor-associated autoantibodies (TAAb) recognize tumor-associated antigens and are promising biomarkers in cancer screening. We conducted an exploratory cross-sectional study to evaluate the prognostic value of anti-TP53 and anti-p16TAAb and a new TAAb panel for head and neck cancer (HNC). Methods: Indirect immunofluorescence against HSP70, nucleoskeletal proteins (tubulin, vimentin, and lamin B1), and TP53 and p16 (CDKN2A) was performed on 13 different HNC cell lines, and the autoantibodies recognizing these targets were subsequently analyzed using serum samples from 22 patients with HNSCC in a bead-based immunoassay. Anti-TP53-positive, anti-p16-positive, and anti-nucleoskeletal proteins-positive serum samples and a new TAAb panel were correlated with clinical outcome by investigating overall survival. Results: Among the TAAbs detected in patients, TP5",
        "label": 1
    },
    "1989": {
        "output": "### Answer\n\n[A] 2) Eligible.\n<br />\n\n[D] 1) 2) Eligible.\n<br />\n\n[E] 0) Excluded.\n<br />\n\n[F] 0) Excluded\n<br />\n\n[C] 2) 2) Eligible\n<br />\n\n\n### Comments\n\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n**You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.**\n\n\n- [2] Input your answer choice in the form below. (Write your answer in the gray box below.)\n- [1] If you choose the correct answer, continue to the next step.\n- [3] If you choose the wrong answer or do not choose an answer, then go back to the previous page and try different answer choices.\n- [4] When you finish working through all of the problems, click the submit button and answer the question to which that number is related.\n\n\n\n##### Question 2.3:\nClinical Inquirer - Case Study 11.5\nWhat is the correct trial-level eligibility for this patient note for this clinical trial?\n### Question 3.2\n\n### Question\n\n[0] The correct answer is {2}(El).\n\n[1] The correct answer is {1}(Ex).\n\n[2] The correct answer is {3}(I).\n\n[3] The correct answer is {1}(Ex).\n\n### Comments\nThe patient's inclusion and exclusion criteria are clearly shown in the patient note. The patient meets most of the inclusion criteria; however, the patient has diabetes mellitus type 1 which is an exclussion crteria (EC). Also, the patient'",
        "label": 0
    },
    "1990": {
        "output": "# DRAGGED TABLE TRIAL-LEVEL ELIGIBILITY\n```\nDRAGGED TABLE TRIAL-LEVEL ELIGIBILITY:\nPatient:\nExcluded\nNot relevant\nEligible\nName:\nGender:\nAge:\nAge groups:\nSmoker:\nDiabetes:\nDiabetes in family:\nDM_type_1:\nChDx_class_2:\nChDx_class_3:\nHp:\nHp_groups:\nCMP:\nChol:\nTG_in_mmol:\nHDL_in_mmol:\nLDL_in_mmol:\nCAD:\nCAD_in_ltr:\nCAD_pvd:\nCAD_cvd:\nCAD_cva:\nCVA:\nCVA_in_yr:\nCVA_in_time:\nMyocardial_infarction_MI_in_time:\nMI_in_time:\nStroke:\nStroke_type:\nCerebral_infarction_Inf:\nCerebral_infarc:\nCerebral_vasc:\nPeripheral_vasc:\nCerebrovascular:\nIschemi:\nDVT_in_time:\nPVD:\nCHF:\nTransplant:\nIns:\nVitamins:\n\nTrial:\nTitle: niacin and statin for preventing vascular events\nSummary:\nInclusion criteria:\nmen and women aged 45 or older with established vascular disease and atherogenic dyslipidemia\nestablished vascular disease defined as one or more of the following: (1) documented coronary artery disease (CAD); (2) documented cerebrovascular or carotid disease; (3) documented symptomatic peripheral arterial disease (PAD)\natherogenic dyslipidemia defined as: (1) ldl-c of less or equal to 160 mg/dl (4.1 mmol/L); (2) hdl-c of less or equal to 40 mg/dl (1.",
        "label": 0
    },
    "1991": {
        "output": "*Note: You can check that code is working at https://pythonanywhere.com.\n<EOD> Clinical evaluation of 3D CAD/CAM surgical templates for mandibular advancement and distraction osteogenesis.\nBACKGROUND\nThe purpose of this study was to evaluate three-dimensionally designed CAD/CAM surgical templates used clinically to guide placement of orthodontic miniplates and to advance the mandible.\n\n\nMETHODS\nThe templates were designed with a custom computer interface using an optical scanner and a 3D workstation. Templates for the vertical ramus osteotomy were designed for miniplates (miniplates and 2 mm distal segments) to advance the mandible. The clinical application of these templates was evaluated clinically using cone beam computed tomography (CBCT) for bone healing and computerized analysis of the changes in sagittal and vertical position changes.\n\n\nRESULTS\nCBCT scans were performed immediately after surgery and 6 months after surgery for 11 patients (seven surgical templates for orthodontic miniplates and four surgical templates for mandibular advancement) ranging in age from 12 to 32 years for evaluation of bone healing and changes in position. Postoperatively, 10 of the cases (91%) were found to have bone healing without any complications, and 9 cases (82%) achieved clinical stability with the planned position.\n\n\nCONCLUSION\nThese results confirmed the reliability and accuracy of CAD/CAM surgical templates in planning and guiding orthodontic treatment when bony stability was achieved.\n\n\nCLINICAL SIGNIFICANCE\nThese CAD/CAM surgical templates can be used clinically to guide miniplates, miniplates with 2 mm distal segments, and miniplates with a distraction screw positioned in a patient with skeletal class III malocclusion.<EOD> Preliminary assessment of a novel method to assess foot and ankle kinematics during gait with infants at increased risk of idiopathic clubfoot\n\n\n\n## Aims\nTo assess the accuracy of a novel method of measuring foot and ankle kinematics during gait in infants with id",
        "label": 0
    },
    "1992": {
        "output": "[/FIN]\n\n> In the next section, you can play a little with the program to train yourself to solve problems more quickly. You can run the following code to write all input data. Just hit `Run` and put the patient note and the clinical trial which is at the 02_Test_data folder.\n\n> run_in_test\n\nYou can also run the code at [Instances > Programming > Trial] folder. For example, followings codes are:\n> 2015_code2.ipynb\n> 2018_code2.ipynb\n\nAfter completing your submission, you will be able to see the solution file in the Notebook. There, you will find the same result you get in your submission history. The solution file also includes a comments describing the solutions.\n\n## Section 3.1.4: Assessing inclusion/exclusion Criteria\n\n[INST] You are going to assess patient eligibility according from given patient note and assess exclusion and inclusion criteria. \nAssessment of patient eligibility is a 2step process:\n1. Identifying inclusion and exclusion criteria that are specified using the data elements included in the patient's medical records.\n\n## 2. \nDetermining which patient's criteria match the criteria of the clinical trial.\n\nIn this example, the patient is suffering from type 1 Diabetes. You should first find out whether the patient meets the criteria (i.e., if F and \u2021 signs are equal to 1). If the patient meets the exclusion criteria, the scale will be marked as 0 (excluded). By contrast, the inclusion criteria of clinical trial patients will be compared with data elements of the selected patient. If the criteria are not met, the eligibility scale will be set to 0 (excluded). On the other hand, if the eligibility criteria required by the trial are met, they will be set to 1 (eligible). It means that the patient will be included in the clinical trial for future therapy. The final scale will be the assessment of eligibility. \nThe eligibility assessment will be marked as 2 (Eligible) and the assessment of eligibility will be noted in the trial-level scale at the last line",
        "label": 2
    },
    "1993": {
        "output": "[TUTORIAL_END]\n\n\n\n<EOD> A 4\u2010Mb physical map for the proximal region of the bovine X chromosome\nA high\u2010resolution physical map of the cattle (Bos taurus) X chromosome for the region including the pseudoautosomal region has been developed using BAC and YAC libraries from genomic DNA. Pulsed field gel electrophoresis (PFGE) was used to define 12 contigs, together with 15 subcontigs from 49 clones spanning the region. The X\u2010PAB clones were derived from a single PF10 DNA fingerprint clone (X\u2010C24) with an X\u2010chromosome\u2010specific 33.5\u2010kb P1\u2010generated clone, X\u2010H4, used as a target to select the clones for the X\u2010PAB kit, a set of 13, 16\u2010kb PACs. In the X\u2010PAB kit, 11.1% of the clones were found to be repetitive by Dot Blot analysis, the remainder being unique. Six new repetitive clones were selected and sequenced. The contigs obtained range in size from 120 to 1,957 kb and cover approximately 4 Mb of DNA, corresponding to about 26% of the X chromosome. With a total of 16.3 Mb of bovine sequence identified from the five BAC libraries (Btau03, Btau04, Btau06, Btau10 and Btau13), the total sequence information available for the proximal region of the X chromosome now comes to approximately 50 Mb. This physical map will facilitate comparative syntenic and map studies of the cattle and the human X chromosome. genesis 32:19\u201324, 2002. \u00a9 2002 Wiley\u2010Liss, Inc.<EOD> Higher Echolucency and Intraglomerular Clot Formation on Sonographic Images of Clots in Carotid Thrombosis\n\nObjectives. To investigate sonographic differences between carotid cavernous sinus thrombosis (CCST) and cervicocephalic th",
        "label": 1
    },
    "1994": {
        "output": "## Exercise 3: 4 scenarios and the right response\nIn this exercise, we will cover four different clinical trials. They all will give the number of patients who meet inclusion criteria, the reason of exclusion, and finally, the trial-level eligibility. Firstly, you are supposed to determine the right response to each of the presented scenarios. Then, you will code the whole solution by the same method. However, remember the methodology is applicable to other similar cases.\n\nThe scenario for each trial is given step by step. \nHere are the four scenarios:\n\n- Trial 1\n\n- `Patient 1`\n- `Patient 2`\n- `Patient 3`\n- `Patient 4`\n- `Patient 5`\n- `Patient 6`\n- Trial 2\n\n- `Patient 1`\n- `Patient 2`\n- `Patient 3`\n- `Patient 4`\n- `Patient 5`\n- `Patient 6`\n- `Patient 7`\n- `Patient 8`\n- Trial 3\n\n- `Patient 1`\n- `Patient 2`\n- `Patient 3`\n- `Patient 4`\n- `Patient 5`\n- `Patient 6`\n- `Patient 7`\n- `Patient 8`\n- Trial 4\n\n- `Patient 1`\n- `Patient 2`\n- `Patient 3`\n- `Patient 4`\n- `Patient 5`\n- `Patient 6`\n- `Patient 7`\n- `Patient 8`\n\n\n---\n\n## Solution to Exercise 3\nLet's code the whole solution with the methodology covered in the earlier pages: \n```python\n\nfrom operator import add\nfrom operator import sub\n\npatients = [{'age': 55, 'gender': 'male', 'symptoms': 'dyspnea on exertion, angina pectoris, nausea and vomiting without obstruction',\n         'heart_rate': 100, 'systolic_blood",
        "label": 0
    },
    "1995": {
        "output": "Note: This question is not available in any previous PQ exam!\n<EOD> NHS England says it will be upfront with patients about funding issues\nNHS England has pledged to be more upfront with patients and staff in the future about the funding of the service.\n\nIn what has been widely seen as an attempt to combat criticism that some areas have been under the cosh while others have been left with a shortfall, NHS England outlined that it would be clearer about where money spent was.\n\nSpeaking as part of the public hearings on the future of health and care, NHS England\u2019s chief executive Simon Stevens said that the service had \u201cvery limited capacity and it is up to us to manage the service in a way that maximises outcomes to the people who fund it.\u201d\n\nStevens added: \u201cIf you want to give people a choice to get a hip replacement in the private sector rather than NHS, you have to pay for it out of a NHS envelope. \u2026<EOD> Characterizing the proton transfer mechanism in the MgH2 and MgB2 dehydrocoupling reactions\n\n \n\n## Supplementary information\nSupplementary . The geometry optimized models, the corresponding potential and charge profiles at the reaction center in the Mg-H/Mg-B exchange processes.\n(a) and (b) represent two different Mg-H/Mg-B exchange paths. (c) The proton transfer route from the initial state (labeled 3 in , (e) The geometric and electronic structures of the initial state (I), transition state (TS) and product state (P) in\n\n## Supplementary\n[table]  TABLE S2: Experimental, theoretical and DFT calculated parameters in the Mg-H transfer from MgHx to MgH3, MgDB, MgH-Mg-DB. * The charge and spin densities are calculated on the basis of the TS model. The data of Mg-H transfer is taken from ref.24 . [/table] \n<EOD> Nonsyndromic microform clefting and duplication of HYDIN: report on two patients and a review of the literature.\nHYDIN was recently identified as a novel gene causally associated with nonsyndromic microform cleft pal",
        "label": 1
    },
    "1996": {
        "output": "\u00a9 Copyright 2020 IEEE - All rights reserved.<EOD> Characterization of 17q21.31 Microdeletions as a Novel Genomic Syndrome Associated With Dysmorphism, Mild Intellectual Disability, and Sensorineural Hearing Loss.\nBACKGROUND AND OBJECTIVES\nA single reported de novo 17q21.31 microdeletion in a patient presenting with developmental delay, dysmorphism, sensorineural hearing loss, and heart defect. He had a de novo 4003 nucleotide deletion in exon 25 of ULK4 gene. This deletion removed the entire ULK4 domain and the exons coding a part of the catalytic domain. We here report three individuals with overlapping over 1 Mb 17q21.31 microdeletions.\n\n\nMATERIALS AND METHODS\nNext-generation sequence (NGS) technology, including CNV analysis.\n\n\nRESULTS\nAll subjects had similar clinical features, included mild intellectual disability, developmental delay, hypotonia, and variable dysmorphic features. One had sensorineural hearing loss, as seen in the previously reported patient. CNV analysis showed that all deletions were de novo, overlapping a conserved genomic region (GenBank: NC_000007.13). This region overlapped with a 116 kb deletion previously reported in an individual with heart defect, developmental delay, dysmorphism, short stature, and mild intellectual disability. RNA expression of ULK4, PAXBP1, and PTPRT was disrupted in all patients.\n\n\nDISCUSSION AND CONCLUSIONS\nThese 3 unrelated patients had similar phenotypes and de novo overlapping 17q21.31 microdeletions, suggesting a rare genomic syndrome with a critical region in this chromosome.<EOD> Development of a new approach to the preparation of biomimetic nanocellulose materials based on cellulose and synthetic polymers\n\nCellulose is the most abundant natural polymer",
        "label": 2
    },
    "1997": {
        "output": "<NAME> 27983\n\n\n### Integumentary System\n##### Epidermolysis bullosa\n```\nclass IntegumentarySystem.EpidermolysisBulla(age: Int, gender: String):\n    \"\"\"\n    Epidermolysis bullosa\n\n    Paramater Value\n    ---------------------------\n    age : 30\n    gender : female\n    \"\"\"\n    pass\n```\n\n#### Epidermolysis bullosa's age:\n```python\nage:\n```\n<NAME> 27983\n<NAME> 27984</NAME>\n<NAME> 27986</NAME>\n<NAME> 27990</NAME>\n<NAME> 27991</NAME>\n<NAME> 27992</NAME>\n<EOD> Roles of a bacterial periplasmic chaperone and peptidoglycan synthases in the assembly of DnaJA2, a nucleoid protein\nBacillus subtilis DnaJA2 is a nucleoid protein required to maintain chromosome condensation. Like other nucleoid proteins, DnaJA2 is synthesized as a prepro polypeptide which requires the periplasmic peptidoglycan (PG) assembly system DedA and HtrA to be correctly folded into the mature protein. In this work, we studied the folding of prepro DnaJA2 by pulse\u2010chase experiments and using a temperature\u2010sensitive mutant of YidC (a membrane DnaJ homologue of B. subtilis). Prepro DnaJA2 showed no significant changes in molecular mass between 0 and 10\u2003min of chase, but the protein was proteolytically cleaved into the mature protein starting in the first minutes of chase. Prepro DnaJA2 was not released to the extracellular medium upon cell lysis, showing that this preprotein is normally translocated into the septum/peptidoglycan layer. These experiments indicate that prepro DnaJA2 is first folded by the periplasmic chaperones YidC, DedA and H",
        "label": 0
    },
    "1998": {
        "output": "[INST] Hello. Here you have a data science problem: we need to create a rule that predicts the price of a house based on 15 predictors.\n\nYou will see in **main.py** file that has used the **pandas-tab** library, which provides a tabular file viewer.\n\nTo understand the notebook structure, here is a description of the steps to follow:\n\n - At the top is the title. Note that titles are important and help you remember what the notebook is doing.\n - At the top left is the environment where you are working.  You may need to change this to match your computer environment.\n - The code is in the cells, and these cells may have comments before or after the code.\n - At the bottom left is an interactive output that can be edited and changed. You can also hover your mouse over it to get a description of the variable.\n - Also note that there is a 'run' button you can use to call the next function. \n - The variables are all formatted the same: names in **camelCase**. Note that this format should be used hereafter.\n\n\nYou should fill in your name in the top left corner. Below, you have an example of the file structure that you should make for this data project:\n```\nname: YouNameHere\n\ntitle: Housing price and characteristics\n\nlanguage: python\noutput:\n   html_document:\n      include_in_html_body: true\n\nheader:\n  include: true\n\nkernelspec:\n  kernel: python3\n\ntitle_page:\n  markdown_content: |\n    <h1>housing_price_and_characteristics_project</h1>\n\ncontents: \n   - title: description\n     slug: description\n     content: \n       html_document:\n         source: index.html\n       readme_md: |\n         In this notebook, we will go through data transformation, visualization and modeling based on the housing features and its price for the Boston Metropolitan area.\n       variables:\n        - house_features\n        - house_prices\n        \n   - title: loading_data\n     slug: loading_data\n     content: \n       slideshow: \n         slides:\n          - slides",
        "label": 0
    },
    "1999": {
        "output": "## Problem 3\nThe result returned is a list. The correct one should be a single result.\n\n## Potential solution\nPlease do not use the 'result = 'statement. If you're using a dataframe, see if you can use `.drop_duplicates()` after your `list_diff().` Or if you're using list comprehensions, use flatten the list with `[''.join(x)` instead of the `map(lambda x: '.'.join(x), [x])) part. Try this: \nIn: \nOut: \n\n## Problem 4\nThe 'print' call is deprecated.\n\n## Potential solution\nSee: \nThe call was deprecated in 2001. The output of print statements is noisy and unintuitive, they're hard to read, and can be confusing when something goes wrong. The best thing is to avoid them. If you can't avoid a print statement, be very careful when using it. Print statement should be used for debugging.\nAlternatively, you may consider using: \n```\ndef print_values(data):\n    if type(data) != list:\n        return data\n    \n    print(\"\")\n    for _, v in sorted(enumerate(data), reverse=True):\n        if isinstance(v, list):\n            print_values(v)\n    \n    else: \n        print(\"    |\".join([f\"{v}: {v}\" for v in data]))\n```<EOD> Genome-wide association studies reveal the genetic architecture for seed size and weight in foxtail millet\n\nBackground: Mapping genes governing agronomic traits is the key step toward variety improvement because of the slow rate of genetic improvement in millet crop foxtail millet. Seed development is an important agronomic trait in cereal and it is considered as the main factor for yield of millet in the whole growth period. However, little is known about the genetic basis of seed weight in foxtail millet so far. Results: In this work, a RIL (NILs derived from A and Y) population under the same environment was used to identify loci for seed weight at five-leaf-stage, two-leaf-stage, and three-leaf-stage in foxtail millet. A set",
        "label": 0
    },
    "2000": {
        "output": "---\n**Instructions**       **INFORMATION**\n\n\n\n# ##  [INST](/Instructions/#-instructions) : Instructions for the [TASK (HIGH LEVEL)-4](/instructions/#Instructions/Assignment) - Assignment for [TASK-4](/instructions/#TASK-4)\n\n<br />\n[![Assignment ](/img/task-4/assignment.png)](/instructions/#TASK-4)\n\n---\n**TIPS/MUST READ**       **INFORMATION MATERIALS*  **  [INST](/instructions/#TIPS/MUST-READ)**\n\n[<NAME>](#ref-suggest) recommends this book to the readers; here are the tips to pick the best one for this task:\n\n* [<NAME>](/books/clincal-informatics-tools.md) recommends this book\n* [<NAME>](/books/clincal-informatics-tools.md), [<NAME>](/books/clincal-informatics-tools.md) and [<NAME>](/books/clincal-informatics-tools.md) suggests this book\n* [<NAME>](https://www.amazon.com/gp/product/1627791074/?ie=UTF8&amp;tag=mahsaimad28-20) recommended this book\n\n---\n**A STORY*  **         **INFOMATION MATERIALS*  **  [INST](/instructions/#BACKTO/)**\n\n[Back to this book](/instructions/#BackTo)\n\n\n**AN OFFICIAL APP (S): **      **INFOMATION MATERIALS*  **  [INST](/instructions/#officialApp)**\n\n[Back to this article](/instructions/#officialApp)\n\n\n**BACK TO TASK**          **INFOMATION MATERIALS*  **  [INST](/instructions/#Instructions to Task)**\n\n---\n**QUESTION**           **INFOMATION MATERIALS*",
        "label": 0
    },
    "2001": {
        "output": "[INST] A patient's eligibility to a clinical trial can be determined by the comparison of a patient note with the inclusion criteria of the corresponding clinical trial. The clinical trials of our hospital usually use Boolean functions for describing each inclusion criterion, e.g., `Patient age between 40 and 70`, `BMI > 19`, `Previous history of hypertension, dyslipidemia, and/or diabetes`, and `The patient had more than one of the following symptoms: (1) angina; (2) dyspnea; (3) history of myocardial infarction; (4) history of coronary surgery and/or stent; (5) congestive heart failure; and/or previous cardiomyopathy`. Let's have a look at the following inclusion criteria described using Boolean functions: `Patient has any one of the following conditions: (1) angina; (2) dyspnea; (3) history of myocardial infarction; (4) history of coronary surgery and/or stent; (5) congestive heart failure and/or previous cardiomyopathy; and (6) coronary artery diseases`, `Patient has angina and/or dyspnea and/or history of myocardial infarction and/or history of coronary surgery and/or stent and/or congestive heart failure and/or previous cardiomyopathy and/or coronary artery diseases` etc. Our modeling idea to determine the patient's eligibility is based on the following Boolean functions:\n\n## 1)\nIf there is a Boolean expression for an inclusion criteria, `b`, we check the content in the case of `I_N(b)->=0` to determine if the patient is eligible for the corresponding clinical trial, i.e., `b`.\n\n## 2)\nWe should check the value of all inclusion criteria in advance to determine the patient's eligibility, i.e., trial-level eligibility.\n\nAs a result, our model includes three submodels to determine the patient's eligibility, i.e., trial-level eligibility, using the aforementioned idea of Boolean",
        "label": 0
    },
    "2002": {
        "output": "The final code for this example:\n``` python\nfrom clinicaltrials_v2 import *\n\ndef main():\n    # Load the files\n    clinical_trial = load_file('clinical_trial.csv', format=\"csv\")\n    patient = load_file(Path('data/patient_note.csv'), format='csv')\n\n    # Get the data\n    trial_id = int(clinical_trial[0][0]['TrialId'])\n    trial_name = clinical_trial[0][0]['Name'].split(' (')[1]\n    patient_id = int(patient[0][0]['patient_id'])\n    patient_notes = patient[0][0:]\n    \n    # Eligibility assessment\n    patient_trial_eligibilty = []\n    \n    for patient_note in patient_notes:\n        patient_trial_eligibilty.append(assess_eligibility(\n            clinical_trial, trial_id, trial_name, patient_id, patient_note)\n        )\n\n    return clinical_trial, patient_trial_eligibilty\n\nif __name__ == \"__main__\":\n    main()\n```\n\n# Examples\n\n# Author Contributions:\n\n### Conceptualization and methodology: \n<NAME>, <NAME>.\n\n### Software: <NAME>, <NAME>, <NAME>.\n\n### Formal analysis, validation, investigation, writing -original draft preparation: <NAME>, <NAME>.\n\n### Writing -review and editing: <NAME>.\n\n# Data availability statement\n\n## Availability:\nThe clinical trial was designed in the ClinicalTrials.gov database. The patient note was extracted from the Stanford Patient Data Registry. The patient note includes information about medical problems, medication history, allergies history, vaccination history, diagnostic codes, procedures, clinical notes, and insufficient/limited/confidential health information. \n\n### Restrictions on data Availability:\nThe data sets of patient note are confidential and cannot be shared with others.\n\n# Code availability statement\n\nAll code supporting the results",
        "label": 0
    },
    "2003": {
        "output": "Copy and run the `try_me.ipynb` demo first. \n\nUse the command-line tool `python3 try_me.py` to run the code for practicing. If you like the script and want to play with the code, run `python3 try_me.py` by following the prompts. If you are an experienced programmer, you may go through the scripts and check the code to gain an understanding of the problem and how to formulate it into a script.  \n\nThe program will generate random test data, and you can try to get the same score with the sample data by comparing and discussing the performance metric with the sample data. If you are having fun, follow the prompts to run the sample and test data by running `python3 try_me.py <FILENAME>.txt` and specify which clinical trial you want to use by modifying the sample data into the folder you are working. You should be able to reproduce the results with reasonable accuracy because test data for each trial is in a separate file. If you get confused or confused, visit `try_me.ipynb` and try the sample data to see where the problem is.  \n\nA more specific test is an end-to-end, i.e., a unit test, and it tests the input and output of the script. To check the script, follow the prompts and `run_example_tests.ipynb` script. The output will tell you whether your script produces the expected output at the end.  \n\n\n## Good Luck!\n\n<EOD> Heme-Independent and Nitric Oxide-Resistant Transnitrosation between Heme Proteins in Cytochrome c Complexes\u2014A Quantitative Study\n\nCytochrome c is known to interact with several heme proteins containing thiols. The affinity for nitric oxide (NO) and nitrosyl formation with heme proteins are modulated by the presence of such thiols, which may influence the mechanism of NO protection against apoptosis. Here, we quantitatively investigated the S-(nitroso)transnitrosation kinetics between thiolated recombinant human cytochrome c and reduced nitrosylated hemoglobin (rHb), myoglobin (rMb) and horser",
        "label": 0
    },
    "2004": {
        "output": "Note that once you run the script for the assessment of eligibility, the script will automatically output a Trial-level eligibility number for each patient. \n\n### Eligibility Assistant\nYour task is to assess a patient's eligibility for a clinical trial from his/her medical records. You will be provided with this patient's medical records as well as the inclusion/exclusion criteria of a hypothetical clinical trial at [inst].[A260] You will need to use the data from the patient's medical records to determine whether the patient meets the inclusion/exclusion criteria of the clinical trial. The assessment will be performed by comparing the patient's status in the patient's medical record to the trial's inclusion/exclusion criteria. [A261] Each comparison will be assessed. If the patient's status in the patient's medical records matches at least half of the trial's inclusion/exclusion criteria, then the trial's inclusion/exclusion criteria will be considered a match. In a patient who has to match the trial's inclusion/exclusion criteria, you should record the number of matches in the patient's medical record. [A263] The assessment will be conducted on a triallevel basis. [A264]\nYou also need to record information about the trial's inclusion/exclusion criteria, the matched conditions in the patient's medical record, and the number of matches in these conditions. [A265]\n\nInstructions:\n\n\n<ul>\n<li>You must complete all the steps listed below.</li>\n<li>Be sure your work saved in each file name. If you close the window, click \u201cClose\u201d in the File menu.</li><li>\"Save As\"</li></ul><EOD> Haplotype Variants of the SMAD7 Gene Influence Susceptibility to Lumbar Disc Degeneration\nPurpose To ascertain the relevance of the SMAD7 gene for lumbar disc degeneration (LDD). Methods In 505 patients with LDD, 15 tagging Single-Nucleotide Polymorphisms (SNPs) comprising the SMAD7 region at 14q13-q21 were genotyped using Sequen",
        "label": 0
    },
    "2005": {
        "output": "If you want to evaluate the code, you should try to follow these steps as you edit the code:\n\n- Click on `Run` button.\n- Click on the `Trace` window to check your result.\n\nNow try to evaluate the code with the same sample patient note to find what is going wrong there.\n\n## [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to evaluate a given patient and decide whether this patient is eligible for clinical trial. \n\nThe factors that allow a person to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. After assessment, a person is assigned a scale for the assessment of eligibility as 0) Excluded, 1) Not relevant or 2) Eligible.\nThis code should evaluate all the patients for clinical trial.\n\nThe output result of this code is the three-point scale for the assessment of eligibility for each patient. \nHere is a sample patient note:\n`\"Patient_ID\":11119, \"Age\":46, \"Sex\":male, \"Ethnic_Group\":White, \"Race_Asial\":NotAsian, \n\"T2D\":False, \"IHD\":True, \"CKD\":True, \"RA\":False, \n\"BMI\":22, \n\"A1C_InMg_dl\":7, \"FPG\":116, \n\"BP_SBP_mmhg\":115, \n\"BP_DBP_mmhg\":72, \n\"Education_Level\":2, \n\"Income_Status\":2, \n\"Family\":2, \n\"FPL\":1.73, \n\"Pt_BMI_InMg_dl\":22, \n\"HbA1c_InMg_dl\":7, \n\"Food_Intake_Health_Risk\":2, \n\"Sleep_Quality_Not_Good\":3, \n\"Sedentary_Activity_Score\":3, \n\"Total_Diet_",
        "label": 0
    },
    "2006": {
        "output": "If you have completed the above instruction and you have written the last line of code in each one of your 100 patient files, go to the next step.\n\nAt this step, you should write 100 lines. In each of them, find a patient and write the `Trial-level eligibility:` of this patient. It is better to write the line in the first or last or in the middle of the patient's file. I wrote 100 lines in the following way. \n\n\n* \n\n* This patient is 59 years old woman.\n\n* Her medical history is significant for DM type 2, hypertension and cardiac disease\n\n* Her lab study was as follows:\n\n\nFBS 130\nHbA1C 8.45 mg%\nCholesterol 180 mg/dl\nTG 230 mg/dl\nLDL 140 mg/dl\nHDL 42 mg/dl\nCreatinine 3.2\nUric acid 8\nUrea nitrogen 30\nThe patient is qualified.\n\n*\n\n* This patient is 45 years old man.\n\n* He has history of DM type 2 and cardiac disease.\n\n* His lab studies include:\n\nFBS 42 mg/dl\nHbA1C 7.65 mg%\nCholesterol 110 mg/dl\nTG 110 mg/dl\nLDL 100 mg/dl\nHDL 70 mg/dl\nCreatinine 2.7\nUric acid 6.6\nUrea nitrogen 25\nThe patient is not qualified.\n\nFor each patient, you should check only the Inclusion criteria of the clinical trial.\n\nIf you have completed the above instructions, go to the next step.\n\nAt this step, you should write two lines in the first and last column of a spread sheet.\n\nIn this spread sheet, put the column of 100 patients in line 1. Each patient must be followed with a number so that in the first line of the sheet, the first patient is numbered 1 and the second patient is numbered",
        "label": 0
    },
    "2007": {
        "output": "[INST] [COMMENT] ## \u2764\ufe0f The trial workflow. \n\nThe `main` function gets the required trial data and gets a list as the trial set. \nIt makes a flow of execution for each patient to determine trial eligibility.\nFirst, for a given trial data, make a list of patients, and then make a list of their trials. Then, for each trial, call the function `patient.evaluate(trial)` that returns the trial-level eligibility. \nThe `evaluate()` function calls all the required functions to determine trial eligibility. For each patient in the list, we need to find all the required data for the trial (`patient.get_required_data(trial)`) and compare that to the trial inclusion criterion (`patient.compare_inclusion(trial, required_data, trial_inclusion_criterion)`). Then we should check the trial exclusion criteria (`patient.compare_exclusion(trial, trial_exclusion_criterion)` if not excluded) and return the final trial-level eligibility (`patient.trial_eligibility`). \n\n[/COMMENT] \n\n\n### Patient.get_required_data(trial):\nGet the needed patient information, calculate their age, and check if they are eligible to perform the proposed clinical trial. \n```python\ndef get_patient_required_data(trial, patient):\n    if isinstance(trial, list):\n        trial = trial[0]\n    if hasattr(trial, 'age'):\n        return patient.age\n    if all(p for p in patient.symptoms if p.age):\n        return patient.age - 15\n    elif 'age' == trial.condition:\n        if trial.type == 'Inclusion':\n            return max(0, patient.age)\n        elif trial.type == 'Exclusion':\n            return max(0, min(30, patient.age))\n    patient_notes = patient.notes\n    patient_treatments = patient.treatments\n    if not patient_notes:\n        if 'lifestyle' == trial.condition or (\n            not isinstance(trial, list)",
        "label": 1
    },
    "2008": {
        "output": "<EOD> A Clinical Lecture ON THE PROPHYLAXIS OF OFFENSE AND THE COURSE OF CHRONIC SORE THROATS\nTHE commonest disease of the throat is undoubtedly the throat disorder known as chronic sore throat and its complications in its most important features. At the outset I would like to draw attention to the clinical points of difference between chronic sore throat and acute tonsillitis. In chronic sore throat the mucous membrane of the pharynx becomes thickened and the mucous membrane inside the faucial tonsil becomes white and inelastic and hangs pendulous. This is a condition which is quite typical of chronic sore throat. The other side of the picture is not so dramatic. The mucous membrane at the back of the pharynx in tonsillitis is swollen and mottled red; the mucous membrane of the faucial tonsils is red and covered with white sloughs of lymphoid tissue which have become detached. The surface of these sloughs is covered with plasma exudate. When these tissues become stained by acetic acid the characteristic results are the white sloughs in tonsillitis and the whiter sloughs of faucial tonsils in chronic sore throat. In chronic sore throat when the tongue and the soft palate are viewed by means of a mirror, and pressure is made against the hard palate, an ugly smear will be seen on the hard palate; sometimes even minute crusts are found. Tumours situated in the tonsils and adenoid vegetations, which are so common in this country, are really malignant tumours in disguise and they very commonly arise in old cases of chronic sore throat. It is not, therefore, surprising to observe that chronic sore throat affords a focus for the formation of a multitude of suppurating foci which, by extension, produce innumerable serious conditions, as abscesses, peri-tonsillar abscesses, and in fact purulent infections of all vital organs. Even the bones become absorbed and are in continuous danger of rupture. The teeth suffer from septic foci, the ears",
        "label": 0
    },
    "2009": {
        "output": "------------------------------------------------------------------------------------------------------\nWe thank the reviewers and editors for their comments, it has helped to greatly improve the article. \n- [INST] Hello. I hope the current case is not tougher than the other one. Actually, you are assisting a recruitment center for a clinical trial. Now, this is a trial on the treatment of prostate cancer with a radiopharmaceutical (213Bi labeled prostate specific antigen). The treatment is performed with the radioactive prostate specific antigen injection to lymph nodes of the patient, and it should be a single-dose treatment. As a result, the patients are exempt from the need",
        "label": 0
    },
    "2010": {
        "output": "```\ndef assess_trial_eligibility(df):\n    if df[\"Type1\"].isin('True'):\n        return df[\"Type1\"].apply(eval => 0)\n\n    if 'Sex' in df:  # if Sex variable exists, apply evaluation to it\n        eval = df[\"Sex\"].apply(lambda x: x.apply(lambda y: 0 if True else 1))\n\n        if eval is not None:\n            return df[\"Gender\"].apply(lambda x: x.apply(lambda y: 2 if True else 0).add(eval).fillna(0).astype(int).apply(lambda _: 0)))\n\n    else:\n        return df[\"Gender\"].apply(lambda x: x.apply(lambda y: 2 if True else 0).add(y).fillna(0).astype(int).apply(lambda _ => 0)))\n\n```\n\n\n<EOD> Effects of dihydralazine on hemodynamics and angiogenesis in rat myocardial infarction induced by ischemia and reperfusion.\nBACKGROUND AND METHODS\nThis study investigated the effects of dihydralazine on hemodynamics and angiogenesis in rat myocardial infarction. Twenty-four adult male rats of the Wistar Albino strain were divided into four groups: the control group (n = 6); group S, subjected to ischemia-reperfusion myocardial infarction (n = 6); group S-50 (n = 6), subjected to a 1-hour ischemia and a 5-hour reperfusion myocardial infarction, 50 mg/kg dihydralazine was given intraperitoneally; group S-100 (n = 6): subjected to ischemia-reperfusion myocardial infarction, 100 mg/kg dihydralazine was given intraperitoneally.\n\n\nRESULTS\nSystolic blood pressure (SBP), heart rate (HR), cardiac output (CO), cardiac index (CI) and stroke volume (SV",
        "label": 1
    },
    "2011": {
        "output": "## How does the algorithm work? {#algorithm_working}\nThere are a lot of factors that allow a patient to be eligible for trial participation. Some trials do not exclude patients based on a certain criteria, whereas other trials exclude certain patients based on their prior-history. We take into consideration the prior criteria used by the trial to calculate the best trial-level eligibility. \nOur algorithm uses all available trials and their criteria to estimate what the average distribution of prior criteria would be across trials. \nNext, we estimate what an individual patient's distribution would be compared to this average distribution. This is achieved by randomly sampling an individual distribution based on the average distribution, and is expressed by the individual prior probability of a trial participation P(prior = x) for each level x which ranges between 0 and 1. A larger prior probability means more patients in the corresponding eligibility group.\nIf for example a patient does not meet an ECOG cutoff, his prior probability will be zero and he will be excluded from this group, however, his prior probability of meeting at least this cutoff is 1. \nWe should note that the algorithm also calculates the individual probability of patient's prior for each group (i.e not meeting each cutoff in case it is exclusion criteria). \nNext we calculate the posterior probabilities by multiplying the individual prior by the conditional probabilities, i.e., a patient's prior P(prior) X P(trial-eligibility|prior), where P(trial-eligibility|prior) is taken from the group distribution of all patients for each trial-eligibility. This produces the probabilities of a specific trial-eligibility P(prior = 1) X P(trial-eligibility|prior = 1), and so on, up to a certain probability. These probabilities are a patient's posteriors. \nIf a patient's prior is zero (i.e., he does not meet any of the criteria), his posterior probability equals the individual probability distribution by definition (P(trial|prior = 0) = P(trial|prior) = P(trial,prior) = P(trial)) = 0) and in this case his posterior probability is zero too. \nThen, we combine the probabilities",
        "label": 0
    },
    "2012": {
        "output": "## Learning Outcomes\n\n- After completing this instruction, you will be able to write trial-level eligibility\n\n\n\n\n\n\n\n\n\nYou have been given a patient note and a clinical trial\n\n## Example of a test for you\n\n# Learning Outcomes\n\n\n\n\n\n\n## Conclusion\n\nA trial-level eligibility is defined as the ability/inability of a patient to participate in a clinical trial. In other words, based on the information in a record or note of a person, whether or not the study goals are achieved. This can be done by comparing the elements of the recorded information to the specific and general inclusion criteria of the clinical trial. \n<EOD> Rate of Prostate Carcinoma in the Auckland Region: A Retrospective Study of Autopsies Between 1969-71 and 1979-81\nABSTRACT: An autopsy study on Auckland residents was performed in order to examine the incidence of prostate cancer. The study spanned 12 years; during the first period (1969\u201371), 1152 autopsies were performed; in the second period (1979\u201381),1478 autopsies were performed on residents in that region. These studies showed no significant increase in the incidence of prostate cancer over the study period. The incidence of carcinoma in New Zealand (both sexes) was 44 per 100,000 per annum, based on autopsy evidence.<EOD> Pd-catalyzed regioselective C(sp3)-F bond functionalization via reductive transannular fluoride migration.\nA new strategy for the regioselective formation of carbyne and alkyne fluorides under oxidant-free and reductive conditions was developed. A range of carbyne and alkynyl fluorones were synthesized from CF3X (X = OTs, N3, PF6, OSO2CF3) via Pd-catalyzed nucleophilic substitution and reductive transannular fluoride migration under mild conditions. A variety of nucleophilic reagents such as alcohols, N-heterocycles, sulfonamides",
        "label": 0
    },
    "2013": {
        "output": "### 1. Checking exclusion criteria (step 1)\nCheck the patient's variables against the exclusion criteria and print out your results. \n\n`excluded`\nThe clinical trials we are interested in look for patients with diabetes type 1. The patient in the note is type 1. There is no information of the person's type of diabetes in the patient's note, you should check the variable `type` in the note, if you type is in fact 2, the person will be excluded. Also, if you don't have any information about the person's type of diabetes, print the exclusion reason for `Exclude`: \n\n`exclude`\nExclude reason:\nNo information\n\n`excluded`\nThe clinical trials we are interested in don't want to include patients under 30 years old. The patient in the note is 25 years old. If the patient is 30 years old or more, print out the final results. \n\n`not relevant` Trial_level eligibility not relevant `Eligible` Exclude reason:\nUnder 30\n\n#  Q7\n\n### Patient Inclusion Criteria (Q7)\n\n#### [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nHere is the patient note:\nThe patient is a 15-year-old female adolescent that suffers from hypercholesterolemia. She has not received treatment for her condition before. She had been advised to be on diet and take vitamin supplements under supervision of a physician. She had not responded to diet and vitamin supplements and they were prescribed ATOVAL-CX tablets on the last appointment. Her past medical history is not significant for any other medical issues. Her family history is positive for hypercholosterolemia in her father and uncle. Her lab study is",
        "label": 0
    },
    "2014": {
        "output": "<EOD> Characterization of Mg2+-dependent binding of phosphatidylserine to actin.\n1. Phosphatidylserine specifically binds to actin and it increases the critical concentration of G-actin to polymerize, as reported elsewhere (Urakawa, S.; Sugio, K.; Ujihara, Y.; Kawasaki, H.; Oda, T. Biochemistry 2002, in press). 2. Phosphatidylserine also binds to F-actin. The binding was shown and characterized by gel filtration, electron microscopic observation, and 125I-photoaffinity labeling. 3. The binding to F-actin was observed by the addition of phosphatidylserine to the filament with a critical concentrations and the 2:1 molar ratio. 4. The binding of phosphatidylserine to actin was also examined in the presence of Mg2+ at a pH of 7.4. The binding of phosphatidylserine to F-actin proceeded more efficiently under these conditions, and the binding was inhibited by various nucleotide analogs. These results suggested that the binding of phosphatidylserine to F-actin was highly specific. The binding inhibition of phosphatidylserine to F-actin was examined by using the nucleotide analogs. The binding was inhibited preferentially by ATP rather than ADP. 5. The binding of phosphatidylserine to F-actin proceeded with an increasing amount of phosphatidylserine for the critical concentrations and was saturated at the 2:1 molar ratio. 6. The binding of phosphatidylserine to F-actin was examined as a function of pH. The binding proceeded in the pH range of 6.0 to 7.6 and it was maximal at pH 7.6. 7. These results suggested that phosphatidylserine bound to actin by an electrostatic interaction and also by the hydrophobic interaction. The binding was accelerated by Mg2+ and was inhibited preferentially by ATP, and it was most efficient under physiological conditions.<EOD>",
        "label": 0
    },
    "2015": {
        "output": "# Exercises\n\nHere is a list of exercises to help you complete each step of the eligibility evaluation.\n\n1. You are reading a note from the patient. To apply this note to clinical study, try to map fields to specific columns.\n\n     * `Eligible (0) or Not Eligible (1)` - The `Type` field in the patient note is equivalent to the `Type` column in the study.\n     * `Birth date of the patient` - Field: Day, Month, Year.\n     * `Age`: Field: Age in years.\n     * `Sex`: Field: 1=Man, 2=Woman.\n     * `Having DM`:` Field : `0` for No ; `1` for Yes.\n     * `Diab_type`: Field : `0` for IDDM; `1` for NIDDM.\n     * `FBS`: Field : value in mg/dL of fasting blood sugar; negative numbers for `Less than 126` mg/dL and positive numbers for `Higher than or equal to 126` mg/dL.\n     * `CVD`: Field: value in ml/min; negative numbers for Slower than or equal to 900 ml/min and positive numbers for `Higher than 900` ml/min.\n     * `IOP`: Field: value in ml/min; negative numbers for Lower than or equal to 18 mmHg and positive numbers for `Higher than or equal to 18` mmHg.\n     * `Echograd`: Field: value in cm/msec; negative numbers for Less than or equal to 5c/sec and positive numbers for `Higher than 5`c/sec.\n     * `HIV`: Field: 1 or 2 or 3; 1 : HIV negative; 2 : HIV positive; 3 : unknown or HIV test done but results are not available.\n     * `Chest_xray`: Field: value in KHZ; negative numbers for \u226412.8 kHZ and positive numbers for `Higher than or equal to 12.8` kHZ.\n     * `T",
        "label": 0
    },
    "2016": {
        "output": "<EOD> A case of postinfectious immune-mediated encephalitis in a previously normal patient with acute nephrotic syndrome.\nWe present the case of an 18-year-old girl who developed nephrotic syndrome (NS) with an atypical urinary sediment that improved spontaneously with normalization of the glomerular filtration rate after 19 days of hospitalization. During the clinic course, she developed aseptic meningitis and progressive neurological dysfunction such as psychomotor slowing, mild memory impairment, and a positive Korsakoff syndrome, which were compatible with the symptoms of an encephalitis-like illness. Neurological symptoms, including disturbance of consciousness, persisted for four months. The cerebrospinal fluid (CSF) obtained at the time of meningitis contained significantly high levels of immunoglobulin G (IgG) compared to control cases during the course of NS. Based on the CSF findings, we diagnosed postinfectious immune-mediated encephalitis as the possible cause of the neurological symptoms associated with acute nephrotic syndrome (ANS). Anti-SSA titers were increased and remained elevated to a lower limit of 1:272 after the neurological and nephrotic syndrome disappeared. Antinuclear antibodies, anti-Smith antibodies, and RF were negative and the other autoantibodies (AAbs) were not detected throughout the course of ANS and neurological syndrome. These data suggest the involvement of immune-mediated factors in the pathogenesis of acute nephrotic syndrome and postinfectious immune-mediated encephalitis.<EOD> .\nBACKGROUND\nIn order to optimize the treatment procedure of the patient suffering from chronic pelvic pain syndrome the authors made an attempt to clarify the possible relationship between chronic pelvic pain, lower urinary tract symptoms (LUTS) and depression.\n\n\nMETHODS\nThe authors analyzed the incidence of depression, determined by Beck Test Depression Inventory (BDI) or Hospital Anxiety and Depression Scale (H",
        "label": 0
    },
    "2017": {
        "output": "<EOD> Antifungal Effect of 6-Bromoheneicosane against Botrytis cinerea Is Associated with Disruption of Chloroplast Membrane and Redox Homeostasis\n\nCitation: Gao, X.; Fan, L.; Wang, J.; Lv, F.; Ma, Q.; Hu, Y.; Huang, F.; Zhang, G.; Su, K.; Fan, S.-g.; et al. Antifungal Antifungal Effect of 6-Bromoheneicosane against Botrytis cinerea Is Associated with Disruption of Chloroplast Membrane and Redox Homeostasis. Int. J. Mol. Sci. 2021, 22, 9780. https://\n\n# Introduction\nBotrytis cinerea is an extremely important plant pathogen. It seriously affects nearly 7000 crop species, including more than 300 hosts. It causes great economic loss in a variety of economically important crops, such as strawberries, tomatoes, peaches, and apples. B. cinerea infects plants and causes gray mold disease through three strategies: conidiogenesis, germination of conidia, and subsequent penetration. The germination of conidia can be divided into three stages: pretreatment, swarming, and appressorium formation with penetration. Therefore, the inhibition of conidial germination and penetration, as well as the induction of conidial death, effectively inhibits the occurrence of gray mold. B. cinerea is a phytopathogenic fungal species sensitive to antifungal materials. It induces abnormal phenotypes, such as growth inhibition, hyphal branch blockage and cell wall destruction, under pathogenic stress and antimicrobial activities, which cause morphological changes in cell wall and membrane. Therefore, understanding the mechanism of B. cinerea's response to antifungal molecules is the foundation of targeted disease management and plant protection application.\nChloroplasts are the site where carbon dioxide is fixed into carbohydrates by carbon dioxide fixative enzymes. Chloroplasts not only convert sunlight energy received by photosynthesis into organ",
        "label": 0
    },
    "2018": {
        "output": "## Data Analysis\n\nThe dataset in a clinical trial is very large and diverse. For visualization, we should reduce the dataset via three methods, including column reduction, row reduction and group reduction.\n\n## # column reduction\nThe column reduction method is a useful technique to manage the complexity of large datasets via a new row format. We can use this method with various statistical software (such as R or MATLAB) to extract our knowledge out of the huge dataset. \nLet\u2019s perform column reduction using the T-TEST dataset again. After running `caret::recode()`, we are done with our T-TEST dataset! \n\n\n```r\nd <- caret::recode('T-TEST')\nd <- subset(d, subject == c(\"T1\", \"G1\"))\ndata.frame(d)\n```\n\n```\n## \n# T-TEST subject = T1_G1\n[formula]  # +--------+ ---------+ ---------+ ---------+ ---------+ ---------+ ---------+ ---------+ ---------+ ---------+ ---------+ [/formula] \n## #      age          1 # 7 7 7 6  7  6   7    6    8   9    8  #   6 6 6 6  6  6   6    6  #\n## # 2   7  7  6 5 4  4.7   3.3 5.3 5.3 2.7    4.3 #   4 #\n## \n# ##   78.6  68.5  68.1 71.2 68.5  67.7  69.2  63.7  70.7 # 64.6 64.6\n```\n- The `summary(d)` command can perform a quick summary of the dataset `d`, as summarized in .\nThe `caret` has many functions which we can access all of them in one command. `caret::summary(d)` will show a variety of features that we might consider.\n\n```r\ncaret::summary(d)\n```\n```\n# > summary\n        \n# T-TEST subject = T1_G1\n# +--------+ ---------+ ---------+ ---------+ ---------+",
        "label": 0
    },
    "2019": {
        "output": "<p>\n[TUT, END]\n</p>\n---\n\n## [Exercise: Case]\n<p>\nLet's think about the following case of a randomized controlled trial about the effectiveness of the low-fat diet in diabetics. You should create `patent1` and `patent2` attributes in the structural definition of `Patient` and assign actual data values to them, and then create `treatment1` and `treatment2` attributes in the structural definition of`Trial`. \n</p>\n\n<h3>Data Model</h3>\n<h1>Attributes</h1>\n<div class=\"myAttribute\">\n   <p>\n      <a href=\"https://pycs.iric.cat/en/pycs/pycs/Python/Practical-Data-Analysis2/data-models/data-model-and-classificationstructure.html\" target=\"_blank\">\n         <img src=\"img/python-2_4_5-data-classification.png\" width=\"150\"/>\n      </a>\n   </p>\n   <h4><a class=\"myBlog\" href=\"#Data\"><strong>Data</strong></a></h4>\n   <p><a target=\"_blank\" href=\"https://pycs.iric.cat/en/pycs/pycs/Python/Practical-Data-Analysis2/structuralanalysis.html\" title=\"\">\n   </p>\n   <h4>Python</h4>\n   <h5><a class=\"myCode\" href=\"#Data\">Data</a></h5>\n</div>\n```\n\n<h3>Relation model</h3>\n\n\n<div class=\"myRelation\">\n   <p>\n      <a href=\"https://pycs.iric.cat/en/pycs/pycs/Python/Practical-Data-Analysis2/data-models/relational-database.html\" target=\"_blank\">\n         <img src=\"img/python-2_4_5-relational-database.png\" width=\"150\"/>\n      </a>\n   </p>\n   <h4><a",
        "label": 0
    },
    "2020": {
        "output": "<EOD> Comorbidity of substance use and other mental disorders in adolescents: Gender differences\nAbstract Background: The aim of this study was to assess the prevalence and co-occurrence of mental disorders with substance use in adolescents referred for inpatient treatment. Methods: For this retrospective clinical chart study of 54 inpatient participants (37 boys and 17 girls; average age 14.2 years, SD\u00b1 2.6), information on primary and secondary disorders was coded based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. Psychiatric disorders as specified by the DSM-IV were diagnosed by qualified clinical staff members, with clinical records serving as the source of the patient data. Results: Differences in gender were found in the secondary diagnoses, where boys had significantly more prevalent and comorbid emotional disorders (57%) than girls (24%) and anorexia nervosa/bulimia nervosa was the only disorder with a significant gender difference (18% girls vs 5% boys). Regarding gender differences in primary disorders, mood disorders were more frequent in girls (35%) than in boys (8%), while conduct disorders and oppositional defiant disorders were more common in boys (70%) than in girls (41%). The majority (89%) of the participants received a primary diagnosis of substance use disorder or had alcohol use disorders, with girls being significantly more affected. Substance use disorders combined with emotional disorders and/or conduct disorders, mainly attention deficit hyperactivity disorder (ADHD), were predominantly seen in males (94%), while females had a higher frequency of affective disorders combined with substance use disorders (35%). Conclusions: Significant gender differences in mental disorders were found, with boys having more conduct disorders and girls more mood disorders. In most cases, the comorbid psychiatric disorders were emotional disorders, especially mood, anxiety and adjustment disorders, suggesting that the comorbidity was more related to the adolescents' psychiatric problems and not the substance dependence per se. Further studies with larger samples and different research designs",
        "label": 1
    },
    "2021": {
        "output": "<EOD> .\nTinea of the vulva is the most frequent superficial mycotic infection among women of childbearing age and may be caused by dermatophytes, yeasts and non-dermatophytic (mould) pathogens. A 36-year-old patient and a 6-year-old child presented with vulvar thrush. Laboratory examinations revealed an elevated pH, high lactate dehydrogenase activity in the secretions and no growth of dermatophytes on Sabouraud-dextrose agar. After 7 days of treatment comprising oral ketoconazol, the lesions of the 6-year-old child had improved, and the lesions of the 36-year-old patient had completely disappeared. The patient complained about abnormal vaginal pH (pH 5.2) 4 months later. Microscopy and culture of the vaginal mucus revealed no pathogens, and treatment with an imidazole derivative again led to a reduction of the lesions. The diagnosis of genito-labial candidosis is made by vaginoscopy, by cultivation or in a wetmount of the secretions after testing pH, Gram staining or wet smear. Therapy of an uncomplicated vulvar candidosis consists of the local steroidal topical anti-fungal compound imidazole cream and oral antibiotics, which result in faster clinical improvement.<EOD> .\nOBJECTIVE\nTo investigate the clinical efficacy and prognostic factors of allogeneic peripheral blood stem cell transplantation for recurrent/refractory acute lymphoblastic leukemia (r/r-ALL) and to explore the reasons for graft failure and treatment failure after transplantation.\n\n\nMETHODS\nA retrospective study on the clinical outcomes after stem cell transplantation for r/r-ALL of 126 patients who had received unrelated/related donor hematopoietic stem cell transplants (HCT) from January 1, 2012 to December 31, 2016 in our center was conducted. Univariate and Multivariate logistic regression analys",
        "label": 0
    },
    "2022": {
        "output": "## INST: I am the patient in the note.\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and betablockers. His takes 70/30 insulin and vitamin D supplements. His Past medical history is not significant for any other medical issues. He takes no medications. His family history is positive for DM type 1 in his uncle and his grandfather. His family history is positive for DM type 1 in his uncle and grandfather.\nHis lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\nInclusion criteria: Inclusion Criteria:\n- Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL\nExclusion criteria: Exclusion Criteria:\n- Patient with diabetes with complicating neuropathies\n- Any clinically significant condition that in the opinion of the investigator would compromise the conduct of the clinical study or interpretation of the study results; such conditions may include (but not limited to) the following:\n- uncontrolled, serious, or significant medical, renal, hepatic, endocrine, hematologic, allergic, gastrointestinal, neurological, or psychiatric abnormalities;\n- uncontrolled infection, immune disorder, electrolyte disturbance, or seizure disorder;\n- use of investigational medication or ther",
        "label": 0
    },
    "2023": {
        "output": "<EOD> Comparison of the efficiency of different sampling methods used for the detection of Salmonella spp. in the rectoanal junction mucosa and cloaca of broiler chickens from organic and conventional production systems.\nThe aim of this study was to compare the efficiency of three different sampling methods, the rectoanal junction mucosa (RAJM), cloacal (C), and plume (P) sampling, in detecting and isolating Salmonella spp. by using conventional serotyping on infected broiler chickens farming in an organic and a conventional system. Rectoanal junction mucosal (RAJM) samples were taken after euthanasia directly from the rectum and the junction to the vagina (RAJ); cloacal samples (C) were taken directly from the cloaca; plume samples (P) were taken by aspirating the cloacal contents above the cloaca. A total of 120 slaughtered broiler chickens were used in the study: 50 from an organic farm, 20 from an organic farm that had been infected with Salmonella in the past, and 50 from a conventional production system. Salmonella was isolated from eight chickens from the organic farms (16%) and two chickens from a conventional system (4%), with a total of ten serovars identified: Salmonella enteritidis in four, S. Infantis in two, S. Typhimurium in two, and S. Virchow, S. Enteritidis phage type 4, S. Virchow phage type DT62b, S. Enteritidis and S. Agona each on one occasion. The efficiency of detection of Salmonella spp. was highest for the C sample (88%), followed by the P (43%) and RAJM (41%) samples. The proportion of infected chickens varied among and between farms and sampling methods. The results indicated a higher sensitivity of the cloacal swab sampling than the RAJM and plume sampling. The use of the C sample would therefore enable a rapid and reliable detection of Salmonella, thereby reducing the risk of the Salmonella being dispersed within the farm.<EOD> Characterizing the",
        "label": 0
    },
    "2024": {
        "output": "<EOD> 7-oxo-cholesterol induced cell cycle arrest and apoptosis through the reactive oxygen species\u2013ATM\u2013p21 pathway in U87MG cells\n\nThe cholesterol oxide, 7-oxo-cholesterol (Ox-chol), is a side product and a potential neurotoxic factor in the brain. Ox-chol contributes to neurodegeneration in Alzheimer's disease. Ox-chol may induce cellular damage; yet the mechanism of its generation in a cellular environment and the effects of Ox-chol on cells have not been fully understood. In this study, the production of the ROS in U87MG cells was found to correlate positively with the concentration of Ox-chol treatment; thus, Ox-chol treatment caused cell cycle arrest as well as apoptosis. The role of ROS in the induction of both processes was determined experimentally. The role of ROS in the regulation of the p21 pathway was the major factor in Ox-chol induced cell cycle arrest. Furthermore, the ATM-p21 pathway was also found to contribute to the regulation of apoptosis, according to data from knockdown cell lines. These results reveal that Ox-chol induces oxidative stress and mediates ATM-dependent mitochondrial dysfunction, thereby contributes to cell cycle arrest and apoptosis, which provides a novel mechanism by which Ox-chol induces neurodegeneration.\n\n# Introduction\nCell cycle regulation and cell apoptosis are crucial to cell survival. Cell cycle arrest is an early event in apoptosis and serves as a mechanism to prevent harmful factors from entering the cell. The regulation of gene expression by the p53-dependent pathway is closely related to cell cycle arrest [bib_ref]  p53: Guardian of the genome and policeman of the oncogenes, Evan [/bib_ref]  [bib_ref]  p53, the cellular gatekeeper for growth and division, Levine [/bib_ref] . The gene p21, a cyclin suppressed protein, is a regulator of several critical processes, including cell proliferation, apoptosis, cell differentiation, senescence and ageing [bib_ref]  The roles of cyclin-dependent kinase inhibitor p",
        "label": 0
    },
    "2025": {
        "output": "---\n\n### Input\n\n- **[input_data]**: Input file as [CSV](https://github.com/matsuoka-k-lab/TrialAssistant) (TXT) or [JSON](/json-file-examples).\n- **[file_type]**: CSV or JSON.\n- **[input_format]**: [TrialAssistant](/trial-assistant), [MiniKube](/mini_kube), [DocsViz](/docs-viz).\n\n---\n\n### Output\n\n- **[output_data]**: Output file as [CSV](https://github.com/matsuoka-k-lab/TrialAssistant) (TXT) or [JSON](/json-file-examples).\n\n---\n\n### License\n\nUnder MIT License\n\n---\n<EOD> Comparison of three different endoscopic methods for biopsies in Barrett's esophagus: a meta\u2010analysis\nBackground\u2002 Recently, some guidelines have recommended the application of four corner forceps for sampling Barrett's esophagus with dysplasia due to its high sensitivity and specificity. However, a meta\u2010analysis evaluating results of three different biopsy techniques was not published. The aims of this paper were (i) to compare the results after application of four corner forceps, conventional forceps and random biopsies and (ii) to analyze whether the sensitivity for detection of early neoplasia is related to the number of biopsies taken.<EOD> Transverse and vertical cranial dimensions. Relation of brain weight to linear measurements. 8. Caucasoids.\nThe method and basic principles involved in analyses of cranial linear dimensions by means of two-way classification of material were described in a preceding paper on Negroids or Negroes (4). With minor modifications these principles were then applied to crania of Caucasoids. The present paper deals with the same classification of linear measurements and comparisons of Caucasoids and Negroids. Particularly emphasized in this study is the correlation of an anthropoiieti-cal index with the cranium (5).<EOD> The SWI/SNF complex contributes to the metastatic capacity of col",
        "label": 2
    },
    "2026": {
        "output": "<EOD> TMEM206 expression is associated with immune infiltration and poor prognosis in gastric cancer\n\nCopyright: Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ABSTRACTBackground: Truncated in microvascular invasion protein (TMEM206) has been identified as a novel mitochondria-associated microtubule-organizing center protein. Numerous studies have revealed that the abnormal expression of this protein was strongly associated with cancer development and progression. However, little is known about its regulatory role in gastric cancer (GC). In the present report, we mainly focused on the expression and function of TMEM206 in GC.Methods: The expression of TMEM206 in GC was evaluated using several bioinformatics methods, including The Cancer Genome Atlas (TCGA), Oncomine databases, Tanzanian GC microarrays and immunohistochemistry analysis.Results: First, the mRNA and protein levels of TMEM206 were significantly higher in GC tissues compared with the adjacent non-tumor tissues. In addition, TMEM206 expression was significantly associated with some important clinical parameters, including T classification, histological subtype and tumor depth, in addition to the Lauren's and WHO classification. In addition, TMEM206 expression was positively correlated with high infiltration of CD8 T cell and macrophage in GC tissues compared with non-tumor samples, as well as the significant association between high TMEM206 expression and poor overall survival (OS) in GC was demonstrated.Conclusions: Taken together, TMEM206 is overexpressed in GC, and has a potential predictive value for GC patients in OS.\n\n# Introduction\nGastric cancer (GC) is one of the most common malignancies worldwide. There are >50 million people who have stomach cancer in the world [bib_ref]  Cause-specific mortality for 240 causes in China during 19",
        "label": 0
    },
    "2027": {
        "output": "13._Example: Include criteria (3).md\n\n[**`Ask to patient/parents`**](http://drfedl.github.io/Tutorials/) \n[inst2]: https://github.com/drfedl/Clinical_Decision_Support/blob/main/Clinical_Decision_Support/Decision_Chart/Example_Input_Files/Askto_patient.md\n\nIn this example, we generate a CDE decision chart to get an opinion from a child's parent or caregiver. You ask about the health history of the child, i.e., allergies, medical history, family, and social history. You should mark a flag that the query is not relevant and record additional information. \n\n### Examples\n\nA child patient presents to a clinic with chronic cough that started about one week ago.\n\nYou get a questionnaire from the child's parents. \nYou should record any new information from the patient's information form in the chart below.\n\nThe child is a 10-year-old girl presented to the clinic with chronic cough. She complains of a mild cough with mucous-like production in the last 7 days that was treated earlier as bronchitis with no treatment efficacy. On physical examination; Vital signs are within normal limits, her body weight is appropriate for the age, normal auscultation in the thorax without any adventitious respiratory sounds and mild cervical lymphadenopathy.\n\nHer parents gave the questionnaire to the child and asked about her medical history. She claimed they had not received a diagnosis from a doctor.\nThe child's history revealed no illness in the first year of life. At age 6 she had surgery due to a car accident. Her parents reported that she had no cough at that time. From the age of 7, she suffered from frequent upper respiratory tract infections. Her symptoms included sore throat, cough, headache, and occasional chills, and lasted 3-5 days with no treatment efficacy. In the past 2 months she started complaining of a cough with mucous product, which has lasted 1 week without any treatment.",
        "label": 0
    },
    "2028": {
        "output": "[/INF] ====================================================== [132.8]\n\n\n\n# Episode 15: The Molecular Basis of Cancer Research - Molecular Pathophysiology of Hodgkin's Disease\nIn Hodgkin's disease, the cells of the immune system are involved in tumorigenesis. \n\n#### Learning Objectives:\n- Define malignancy, benign malignancies, and dyscrasias. - Define Hodgkin's disease.\n\n#### Basic principles of cell biology:\n- Cellular composition of the normal immune system.\n- Function of immune system cells.\n- Cellular and molecular bases of malignancy.\n\nA malignant tumor, also called a cancers, arises when cell growth is no longer controlled. \n\n#### Relation of malignancies to noncancerous cells:\n- Benign tumors can be malignant. \n- Dyscrasias: Non-malignant clonal disorders that are characterized by the abnormal proliferation of lymphoid or myeloid cells.\n\nMalignant cellular properties include - Uncontrolled growth.\n- Evading apoptosis.\n- The capacity to invade normal tissue.\n- Ability to metastasize (to spread to other organs).\n\nThe process of tumorigenesis is not fully understood. For the most part, tumorigenesis involves a combination of events that disrupt \nimmortalization of cancerous cells and alteration of apoptosis. \n\n#### Classification of cancers:\nAdenocarcinoma is a malignant tumor that develops primarily from glandular tissue, such as the lung, pancreas, colon, esophagus, or breast.\n\nSarcoma is a tumor that arises from connective tissue. \nLymphomas are tumors of the white blood cell lymphocyte.\nEvading apoptosis and uncontrolled division are the hallmarks of carcinogenesis. \n\nLymphocytes play an important role in the adaptive arm of the immune Response. Lymphocytes are involved in the cell-medi",
        "label": 0
    },
    "2029": {
        "output": "[PRO] Hi, my name is [NAME], and I am one of the developers of the Triage tool of the DREAM project.\n\nWe would appreciate some feedback on the example you just provided. \n\n[PRO] We have been working with clinical trials like the one you have used in your example. However, the way it is currently calculated is slightly different than you have done. What are your thoughts about that?\n\n[PRO] It appears that you have excluded the patient from the trial. However, you have used the word \"excluded\". There could be an issue of misunderstanding the term; in clinical trials it is generally considered that patients are not excluded based on trial data. In other words, if we say that a patient is excluded from a trial we are implying that the patient will not have all of the collected data for the patient included in the final analysis. \n\n[PRO] Let's have a closer look at how you have done it. Let's also start with the exclusion criteria from the trial. The trial asks for the values of cholesterol and triglycerides. The trial excludes patients with cholesterol levels greater than 150 mg/dl. In terms of the eligibility of the patient, the trial asks for LDL-C and HDL-C levels. The LDL-C level is above what is required, while the HDL-C level is below the threshold. Based on these criteria, patients with HDL-C < 35 mg/dl and HDL-C > 40 mg/dl would not have met the trial criteria because their LDL-C was elevated but not sufficiently elevated to require treatment with statins. \n\n[PRO] Your assessment of the patient is based on \"HDL-C < 30 mg/dl\". This is the trial assessment of eligibility. How would you handle the case if the patient's HDL-C level is equal to or higher than 30 mg/dl? In other words, what level would you set for HDL-C? \n\nYou should keep in mind that the DREAM tool will need to be used by trialists who have different specializations. Trialists may have expertise in specific diseases and trials, and we will need to make allow",
        "label": 0
    },
    "2030": {
        "output": "## QUANTIQUE_0_2 #\n\nThis program is a quantification program. It determines the quality of eligibility for each patient in a clinical trial. It provides a scale from 0.0 to 1.0 for the quality of eligibility.\nEligibility quality is the sum of factors. The sum score is divided by two to obtain the final value of this scale (minimum value=0.5).\nSome factors are considered in this analysis: age, gender, family history, BMI, smoking status, comorbidities, past medical history, and drug history. \nThis program requires two files: patient information file and clinical trial data. As explained above, `patient information file` must be a csv file (compressed if needed) including columns of interest: patient ID (not unique), age, gender, family history, drug history, smoking history, comorbidities, past medical history, BMI, EHFscarec, and EHFcarc. `Clinical trial data` is a csv file containing columns of interest (columns of interest are written at the top of the csv file): patient number (unique ID), age category, gender category, eligibility status, factor 1, factor 2, ...etc.\nThis program generates quantification results in `result.csv` output file at the end of execution. An itemized report is generated and displayed.\n\nThe program can be executed with two arguments: ``-c` and ``-f``.\nIf ``-f` is added after the program's name, this program ignores any file except the patient information file and generates a report summarizing the clinical trial data. Please note that the patient data file should be named as `patient.csv`.\nIf ``-c` is added after the program's name, this program generates report in csv format for each sample. A csv report file is named by the sample's patient ID concatenated with `-.csv`. For each patient, the report provides a summary of the patient summary, eligibility in qualitative scale, eligibility in quantitative scale, total quality of eligibility, and the most related factors (family history, drug history, smoking history, comorbidities, past medical history, BMI).\n\n\n---\n\n\n### Sample command\n```",
        "label": 0
    },
    "2031": {
        "output": "<EOD> .\nSteroids were shown to exhibit a pronounced inhibitory effect on the synthesis of lipids in bovine kidney proximal tubular epithelial cells (PTEs) and rat L-6 myoblasts. Corticosterone inhibits the biosynthesis of all studied lipids, i.e. cholesterol, fatty acids, phospholipids and glycosphingolipids, in bovine PTEs. By contrast, 5alpha-dehydroepiandrosterone only depresses fatty acid synthesis in L-6 and bovine PTEs, whereas cholesterol biosynthesis is stimulated in these cells.<EOD> Elevated Bone Turnover in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass.\nBACKGROUND\nObesity has become a common problem. Roux-en-Y gastric bypasses (RYGB) are recommended treatment for severe obesity and associated medical disorders. The changes in serum bone turnover markers were reported in patients with Roux-en-Y gastric bypass as well as gastroplasty. The aim of this study was to evaluate changes in bone turnover markers, the bone mineral density (BMD) and body composition in Iranian patients 1 year after the laparoscopic Roux-en-Y gastric bypass.\n\n\nMETHODS\nOne patient was excluded after the operation. Therefore 34 obese patients were evaluated before and (at an interval of 1 year after the operation) after the laparoscopic Roux-en-Y gastric bypass. Body composition was evaluated by electrical impedance analyser. Serum bone markers, bone alkaline phosphatase (BAP), bone-specific alkaline phosphatase (BSAP), C-terminal telopeptide of type I collagen (CTX), calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) were determined.\n\n\nRESULTS\nBody weight, BMI, Ca serum and P serum were decreased",
        "label": 0
    },
    "2032": {
        "output": "The output of each row is like this:\n\n\nPatient\nID\nName\nDemographic\nVital\nMedical\nHistory\nFamily\nHistory\nLab\nResult\n\n\n---\n\n# [INST] TITLE BREAKDOWN:\n```\nTITLE 1: New York Heart Association (NYHA) class I and II heart failure.\nTITLE 1 EXPLANATION: Inclusion Criteria: New York Heart Association (NYHA) class I and II heart failure\nTITLE 2 1 2: Chronic ACE-inhibitor Treatment\nTITLE 2 EXPLANATION: Inclusion Criteria: Chronic ACE-inhibitor treatment\n\n---\n# [INST] 1] Evaluation Method:\n```\nEVALUATION_METHOD: Check for each entry in patient note to decide the scale for evaluating eligibility.\n\n---\n# [INST] FILTERING:\n```\nFILTER: Filtering:\n\n\n## 1][INST] GROUP PARAMETERS\n```\n\nGROUP 1.1: In this group, we can find basic information about patients. The variable Age is the year in which the patient was born and it is used as the basis for creating the patients' identifier. The Gender is a string in which we compare the patients' gender to the trial's gender. \nGROUP 1.2: In this group, we can find information about diagnosis of the patient. \nGROUP 1.6: In this last group, we can find the information about lab results, in which the name of the lab test is extracted. The variable Lab test ID is the name of the test and the value of the Lab test ID is a numerical value obtained through the conversion of the test name into the numerical value. \n<EOD> Hormonal and nutritional responses of male cattle fed varying amounts of protein in a high or low energy environment.\nMale cattle (n = 24, average initial body weight  469 kg) were assigned randomly to groups fed a high energy (HE) total mixed ration or a low energy (LE) corn silage--concentrate ration and supplemented daily at 900 h with a protein concentrate. Diets were isocaloric. Each of",
        "label": 0
    },
    "2033": {
        "output": "<EOD> Diagnosis and Treatment of Peripheral Artery Disease: A Systematic Review for a National Clinical Guideline\nTo summarize the current literature on noninvasive vascular imaging modalities (duplex ultrasound scanning , peripheral arterial tonometry , magnetic resonance angiography , and computed tomography angiography ) for diagnosis and treatment of peripheral artery disease and report on the current United Kingdom National Clinical Guideline.<EOD> TRIM8 regulates mTOR signalling activity in a kinase independent manner\nTRIM8 is a multi\u2010domain scaffold protein, involved in many cellular functions including autophagy and the regulation of lipid metabolism, however the role of TRIM8 as a regulator of autophagy has been controversial. Here, using a variety of in vivo and cell\u2010based assays we demonstrate a novel regulatory role for TRIM8 as an mTOR regulator in both mammals and in Drosophila. Using both ectopic and conditional loss\u2010of\u2010function studies we show that TRIM8 binds the kinase domain of mTOR directly. However, we report that TRIM8 does not affect kinase activation or activity. Instead, we show that TRIM8 regulates mTOR signalling, impacting specifically on mTORC1 substrate phosphorylation. This regulation, however, is dependent on the TRIM8 kinase\u2010independence domain being intact and, in contrast to other regulators of mTOR, is insensitive to rapamycin. This effect is mediated through an interaction between TRIM8, and a component of the ULK complex (ULK1) and is required for ULK1\u2010mediated regulation of autophagy. Although TRIM8 regulates the mTOR and ULK1 signalling pathways independent of its catalytic activity, we show that enzymatic catalytic activity is essential for TRIM8\u2010mediated regulation of lipid homeostasis. Together our results demonstrate that TRIM8 regulates mTOR downstream signalling in a catalytically dependent manner. Finally, our study shows that these mTOR regulatory properties are conserved",
        "label": 2
    },
    "2034": {
        "output": "<EOD> The Relationships among Soft Drinks/Regular Salt, Bicarbonate-Buffered Salt, and Beverages with Regard to Risk of Obesity and Cardiovascular Complication in China: Findings from a Cross-Sectional Survey\n\n\n\n# Introduction\nObesity is one of the main public health problems worldwide. Obesity has become a leading public health concern in many countries owing to its risk factors in cardiovascular diseases and mortality [bib_ref]  Cardiovascular Risk and Obesity: Clinical, Pathophysiological and Behavioral Aspects, Rendina [/bib_ref]  [bib_ref]  Obesity and Hypertension, Seravalle [/bib_ref] . The prevalence of obesity has dramatically increased in recent decades in most countries. China is of no exception with a high obesity rate among adults [bib_ref]  Socio-Cultural Factors Promoting Dietary Changes for the Prevention of Chronic Diseases in..., Yi [/bib_ref]  [bib_ref]  Dietary Guidelines for Chinese Residents (2016) and Association with Cardiovascular Disease Risk..., Wang [/bib_ref]  [bib_ref]  Trends in Obesity among Adults in the United States, Flegal [/bib_ref]  [bib_ref]  Trends in Mean Body Weight, Overweight, and Obesity among Chinese Adults from..., Wei [/bib_ref]  [bib_ref]  High Body Mass Index for Age among In-School Adolescents in Six Southeast..., Kohn [/bib_ref]  [bib_ref]  Rapid Increases in Adult Overweight and Obesity in China, Gu [/bib_ref]  [bib_ref]  Understanding Social Inequities in Obesity among Chinese: Evidence from Hong Kong, Wang [/bib_ref]  [bib_ref]  Trends in Adult Body-Mass Index in 200 Countries from 1975 to 2014:..., Di Cesare [/bib_ref] . As reported by the China Chronic Disease and Risk Factor Surveillance (CDRFS) in 2010, more than 20% of the adults were obese. An elevated trend in obesity rate had been demonstrated by the World Health Organization (WHO) Global Status Report on NCDs (non-",
        "label": 0
    },
    "2035": {
        "output": "#3[CQ4_04] What is the type of this variable? The type of this variable is the type of the variable. #4[CQ4_05] What is the type of this variable? The type of this variable is the type of the variable. #5[CQ5_01] What is the value of this variable? The value of this variable: \"Excluded.\"The type of this variable is the type of the variable. #6[CQ5_02] Which value of this variable is the patient's? The value of this variable: \"Excluded.\" #7[CQ5_03] Is this variable related to the variables in the table? The value of this variable: \"Excluded.\"#8 4) Let's check the results (print the results and the patient note or you can see the results only) the patient note: \"Proteinuria defined as a 24-hour urine albumin/creatinine ratio > 300 mg/g while on an ACE inhibitor with or without additional antihypertensive therapy (e.g.CCB, a-blocker, b-blocker, clonidine)\"; [print(\"Excluded\")] Excluded #9[CQ6_01] What is the type of `ACE inhibitor`? The type of `ACE inhibitor`: medication. #10[CQ6_02] What is the type of `Cholesterol`? The type of `Cholesterol`: variable in the table. #11[CQ7_01] What is the value of `Cholesterol`? The value of `Cholesterol`: \"190 mg/dl\". [/fig] \n<EOD> The effects of theophylline on respiratory disturbances in patients with coronary artery disease.\n1. Twenty patients with severe bronchial hyperreactivity (provocative concentration of histamine which caused a 150% decrease in FEV1.0 less than or equal to 5.0 mg/ml) and mild to moderately severe coronary artery disease were studied to assess the effects of theophyll",
        "label": 0
    },
    "2036": {
        "output": "The input data is for a patient record of a trial. It is a patient with type 1 diabetes confirmed with molecular analysis 7 years ago. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nOutput:\n\n``1`\n\n``0`\n\n``0`\n\n``2`\n`\n\n**Output of trial record:\nTrial-level eligibility: 1) Excluded.\n[INST]<EOD> Comparison of bone surface markers as indicators of the bone disease of rheumatoid arthritis: a correlational study using iliac crest biopsy material.\nOBJECTIVE\nTo examine the relationship between bone resorptive (osteoclastic) and proliferative activities (osteoblastic) in rheumatoid arthritis (RA).\n\n\nMETHODS\nSeventeen specimens of iliac crest bone biopsy material from female patients with severe RA of less than 1 year's duration were immunohistochemically stained for 1) tartrate resistant acid phosphatase (TRAP) activity, which is specific for osteoclasts, and 2) anti-bone morphogenetic protein 4 (BMP-4) and anti-osteoprotegerin (OPG) antibody. BMP-4 and OPG activities were quantified by the bone cell culture method using 12 biopsy specimens.\n\n\nRESULTS\nIn each case, a positive correlation was found between the TRAP activity and the BMP-4 and OPG activities.\n\n\nCONCLUSION\nThese findings suggest that increased osteoclastic activity in RA bone is the cause of higher osteoblastic activities. Thus, the increased bone surface marker activities in RA may reflect the higher bone remodeling rate, which is thought to be involved in the bone destruction observed in RA.<EOD> Challenges in the diagnosis of adrenocortical insufficiency: a review.\nAdrenocortical insufficiency may be",
        "label": 0
    },
    "2037": {
        "output": "You may need to go back to the above steps to verify your solution.\n\n## Q2. The next trial is:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 62-year-old female with a past medical history of rheumatoid arthritis confirmed in 1993 by an Arhtritis Foundation. She presents to the clinic with chest pain, dyspnea with exertion, sweating at rest, and joint pains. She claims dyspnea on exertion, fatigue that is moderate to severe, and sweating at rest. She is diagnosed with a pericardial effusion, mitral valve prolapse and aortic valve prolapse. The patient takes prednisolone plus methotrexate and a b-blocker. Her past medical history is significant for a pericardial effusion in 1993 for which she underwent video-assistied thoracoscopic pericardial window and left atrial appendage excision but the effusion had returned 6 months after her surgery. There was no evidence of malignancy, collagen vascular disease, or infection. Her lab study is as below: BMP: 8.6 ng/ml\n\nLet's think step by step.",
        "label": 0
    },
    "2038": {
        "output": "### Exercise 2\nNow, we will do another practice on how to check for the first name of a person. Exercise 2 will be very similar to exercise 1, but there is one extra thing you should think about: the first-_name and last-_name are separated by underscores; therefore, you should check _first_ and _last_ under \"_name\".\n\n# Reproducibility\n\nThis tutorial is entirely reproducible; only the data provided in the input file can vary from implementation to implementation.\n\n# Authorship Statement\n\nThis tutorial was written by <NAME>\n\n# Conclusion\n\nYou may find a solution to your programming problems and gain the knowledge you need for your career.<EOD> Oculocardioanastomosis.\n\u2022 Oculocardioanastomosis, proposed by Hauer for the relief of heart failure in patients with concomitant severe mitral insufficiency, is a relatively simple, low-risk, and effective surgical technique which provides great symptomatic benefit to selected patients with heart failure. By reducing ventricular volume and improving output, it may obviate the need for other more complex cardiac procedures.<EOD> Effects of diet-induced high levels of fat intake and insulin on rat hepatocytes.\nRat hepatocyte culture systems have already been studied with regard to insulin action (1), whereas the effects of diet-induced high levels of fat intake (2) have been evaluated only in vivo. The aim of the present study is to understand more clearly the effects on hepatocytes of both insulin and a cholesterol and saturated fat diet, by means of an in vitro assay. Our protocol simulates the effect of the dietary components on the cell and of insulin on the glucose uptake through phosphorylation, using the isolated primary hepatocytes (3) which were obtained from rats fed on low-fat content diet (control group, n=8) and cholesterol and saturated fat diet group (case group, n=8) for 14 weeks. Blood samples for biochemical analysis were obtained from fed (9 a.m.) and overnight-fasted rats, after 1",
        "label": 0
    },
    "2039": {
        "output": "[INST]\nThis clinical trial included patients, whose ages are < 50, 50-65 and over 65; genders are male and female; all patients should be non-smokers, and taking ACE inhibitors and Beta blockers that can make some patients with diabetes mellitus have angina and some patients with Churg-Strauss syndrome have a cardiomyopathy. \n15\n\n\nIf the patient should be regarded as eligible for the clinical trial, which is the result of all the above three-step approaches, the final output should be shown in the last line as `Trial-level eligibility: `, e.g., the above trial's final result will be `Trial-level eligibility: 2) Eligible.`. Let's illustrate the final results of the patient of this trial by showing the results of all the 3-step approaches. We will also show the output of the last line.\nThe patient does seem eligible to participate in the clinical trial of Cardiomyopathies Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors based on the five-factor score, because his age is < 50, he is male, non-smoker; his Beta blockers will affect his angina; his diabetes mellitus will make him have cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers; his insulin and vitamin D supplement also will cause him to have cardiomyopathy; he also has only one risk factor of Diabetes: his FBS is 100 mg/dl, his total cholesterol is 190 mg/dl, and his TG is 140 mg/dl. Therefore, based on the 5-factor score his lab results, and the clinical trial inclusion criteria, this patient will be regarded as eligible for inclusion to the trial of CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors.\n\n\n\n# Key Concepts\n\n- \tEligibility assessment criteria:\n- Clin",
        "label": 0
    },
    "2040": {
        "output": "## 45. [AQ] How can I make a decision in an optimal manner?\n\n##[AQ] How do I make a decision in an optimal manner?\n\n# Related problems: \n- 11.38.1: How can I create the necessary information to construct a decision tree?\n\n## Answer: \nYou can see the following problem:\n- Problem code: 1642\nSolved using: \n- Decision Maker: \n- Decision Algorithm: \n- Solved by: \n- Date: 20 May 2019\n\n# Solution: \n\n# - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -\n# Explanation: \nDue to the fact that your problem is similar to \"Decision tree for type 2 diabetes mellitus\", we have provided the solution to this problem here.\n\n# Related problems: \n- 10.39.14: How can I define a set of preconditions?\n\n## Answer: \nYou can see the following problem:\n- Problem code: 1196\nSolved using: \n- Decision Maker: \n- Decision Algorithm: \n- Solved by: \n- Date: 01 August 2018\n\n# Solution: \n\n# - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -",
        "label": 2
    },
    "2041": {
        "output": "### Question:  \nIf a patient is given the note and clinical trial, what are the conditions to achieve three points, how do \nyou do it? \n\n<section class=\"solution sol\">\n<div class=\"sub1\" id=\"problem_sol_1_title\">\n\nSolution\n</div>\n\n<div class=\"paragraph\">\n\n[INST: \nThe answer of the question: <strong><i>What are inclusion criteria or exclusion criteria?</i></strong>](http://www.stat.ubc.ca/~rollin/stats 504/problems/07/205_205_solution_1.html \"Title\") is the following: <em>\"Inclusion criteria can generally be thought of as characteristics that a patient must have in order to participate in the clinical trial. These typically involve the patient's age and sex as well as the patient's diagnosis or a patient's disease-type. Exclusion criteria are generally the exact opposite of inclusion criteria. These criteria may prevent participation in the clinical trial.\"</em>\n\nThe solution is that the participant must be male and under the 25 years old. Otherwise, if the participant doesn't fit the characteristics for the trial, (male over 25 years old ), then he will be removed from eligibility.\n<br>\n<br>\n<br>\n<br>\n<img src=\"../FigData/sol.png\" width=\"600\" height=\"266\" border=\"1\" align=\"center\"></img>\n</div>\n</section>\n<!-- EOF -->\n</td>\n</tr>\n</table>\n\n\n</body>\n</html>\n\n<EOD> Dramatic Reduction of Dental Atypical Fibroxanthoma After a Course of Immunosuppressants\n\nSquamous cell carcinoma is the most common cancer involving oral cavity. 1 Oral atypical fibroxanthoma, a rare skin tumor, has been previously reported in dentistry. 2,3 Atypical fibroxanthomas usually present an indolent course. 4,5 We report here a patient, a female of 59 years-old, who had a history of",
        "label": 0
    },
    "2042": {
        "output": "### Patient-level Eligibility \nAs you know, [link patient-level eligibility](https://github.com/DruckerLab/drucker_lab_pipelines/tree/master/scripts/clinical_trials/report_eligibility) script will generate the report including patient-level eligibility for the patient. In the end, you just need to print the output. \n\nThere are several codes underneath the `print(reporter)` function call in the `report_eligibility_patient.py`, so you will use `patient_level_eligibility` function for printing the patient-level eligibility. For example, if we assume the patient is numbered 10 and he is numbered eligible in \n\n### Trial-level Eligibility\nThe clinical report should be in a tabular format, and each column can be considered a trial that includes a patient. \n\n\nThere are several codes underneath `print(reporter)` function call in `report_eligibility_clinical.py`, so you will use `trial-level` eligibility function for printing the trial-level eligibility. For example, if we assume the patient is numbered 10 and he is numbered eligible in \nHere is the clinical trial report form: \n![](/images/drucker/clinical_trial_report_form.png)\n\n### Example\n\n#1:\n```python\nimport pandas as pd\npd.read_csv('~/Data/data/patient_note.csv', names=['Patient ID', 'FBS', 'HbA1c', 'Cholesterol', 'TG', '\n\t\t\t\t\t\t\t\t\t\tLDL', 'HDL', 'family_history', 'bmi', 'age', 'gender'])\n\n#2: \nimport dlab_data.scripts.clinical.drucker_pipelines \nreporter = dlab_data.scripts.clinical.trial_report()\nreporter['patient_level_eligibility'].to_csv('~/Data/data/report.csv')\nreporter['trial_level_eligibility.csv']\n```",
        "label": 0
    },
    "2043": {
        "output": "## [INFO] Output Data Example\nHere is the output data from the previous output:\nSample: a test\nTrial-level eligibility:  \n1) Not relevant\n2) Excluded.\nIn this output, each patient is described by its patient number, gender, age, FBS, HbA1c and trial-level eligibility. You should always output some patients in the sample output, even though it is empty. If all of the patients are not eligible in the trial, you should output a note that says `All of the patients are not eligible`. You should always output your sample size, eligible patients and eligibility rate as patient (patient number): \nsample:\nTrial-level eligibility: 1) Not relevant\n2) Excluded.\n[END]\n<EOD> A new case of Cobb syndrome and review of the literature\n\nIntroduction: Cobb Syndrome (CS) is a rare malformation of the posterior cranial fossa with a combination of craniofacial, neurological and ocular deformities. To date, 48 cases of CS have been reported in the literature. Case Description: Here, we present the case of a 30-week old Indian male fetus who had a combination of craniofacial, neurological, ocular and cardiac defects. This is the 49 th case and the 3 rd case of live-born Indian with CS. Conclusion: This case shows the presence of congenital heart defects in CS.\n\n# Introduction\nT he combination of multiple malformations, including ocular and craniofacial defects, in a single patient is relatively rare. In 1939, Cobb reported a case of an American family with bilateral fetal hydrocephalus and multiple congenital ocular defects. [bib_ref]  Familial fetal hydrocephalus with multiple congenital ocular defects; report of two cases, Cobb [/bib_ref]  A syndrome was proposed and named Cobb syndrome (CS) in honor of the author after 14 new cases had been described from other families. [bib_ref]  Further delineation of Cobb syndrome, Sennaroglu [/bib_ref]  To date, 49 cases of CS have been described in",
        "label": 0
    },
    "2044": {
        "output": "### Sample solution:\n```python\npatient_note = {\"age\":40,\n                \"sex\": \"male\",\n                \"height\":82,\n\"fever\":100.5,\n\"bmi\": 25.5,\n\"DM\":True,\n\"hbm\":50,\n\"type1\":True,\n\"blood_pressure\":120/85,\n\"diabetes\":80,\n\"glucose\":200,\n\"blood\":24.3357,\n\"lab\":7,\n\"weight\":88,\n\"pain\":30,\n\"chol\":130,\n\"vitamin\":70,\n\"BMI\":20,\n\"family\":6,\n\"smoke\":1,\n\"status\": \"11\",\n\"disease\":3,\n\"BP\":25/90,\n\"age\":65,\n\"gender\": \"male\",\n\"bmi\":28.4,\n\"DM\":True,\n\"hyper\":20,\n\"glucose\":200,\n\"lab\":7,\n\"weight\":88,\n\"age\":45,\n\"height\":65,\n\"family\":3,\n\"sex\": \"male\",\n\"siblings\":22,\n\"disease\":3,\n\"disease\":\"49.893\",\n\"hypert\":1,\n\"cholesterol\":150,\n\"gp\": \"1898\",\n\"disease\":3,\n\"blood pressure\":120/70,\n\"age\":65,\n\"family\":7,\n\"gender\": \"female\",\n\"age\":46,\n\"bmi\":35,\n\"sex\": \"male\",\n\"family\":2,\n\"status\": \"11\",\n\"fever\":39.2,\n\"height\":65,\n\"pain\":30,\n\"bmi\":25.5,\n\"status\": \"0\",\n\"chol\":150,\n\"lab\":6,\n\"disease\":2,\n\"dm\":180,",
        "label": 0
    },
    "2045": {
        "output": "[NOTE] You may change the assessment of eligibility level by changing [Excluded, Not relevant, or Eligible] in each case to achieve a desired level of eligibility assessment, e.g., [Excluded to Not relevant, Eligible to Eligible, or Excluded to Excluded]. Note: In this case, you should always set Trial-level Eligibility on [Eligible] to be the default level so that the clinical trial is considered eligible for the patient.\n\n### Expected Result\nLet's input your clinical trial information again. Click the  button again. You will obtain something like the following, if you input your clinical trial information as the above:\nYour trial note will be presented in the left side bar along with other information:\n<EOD> .\nBASIS AND METHODS\nIn the course of the prevention in obstetrics (POB) project the data of the question by 'women's well-being' before and after pregnancy have been analyzed.\n\n\nRESULTS AND DISCUSSION\nThe percentage of women with well-being decreased during the first pregnancy period. This decrease was more significant in rural than in urban regions. In the course of examinations the women's well being increased steadily and even more during subsequent pregnancies, depending on social-environmental characteristics. The women with an age of more than 40 years had the least well being already in the first examination. Moreover, the percentage of women of this age with well-being remained stable during pregnancy periods. The highest percentage of well being among women of all age was determined in 35-40 years old of a rural region in 1994.\n\n\nCONCLUSION\nThere were no significant differences of well-being in women during the first pregnancy period. After pregnancy, with the same pregnancy period a slight improvement in well-being was seen. Especially the women of 40 years of age had the smallest well-being, independently of social-environmental factors, before and after pregnancy.<EOD> Clinicopathological studies of mucinous carcinoma of the breast according to the criteria of MUC1\u2013core protein\nBackground: Mucinous car",
        "label": 0
    },
    "2046": {
        "output": "In the next notebook, we will use `trial_eligibility` function to write the patient note to the CSV file.\n\n\n[CODE](http://github.com/abdomenorris/Python-Code-Notebooks/blob/github/Python-Code-Notebooks/Python_code_notebook_4_Clinical_trial_eligibility/jupyter_notebooks/clinical_trial_eligibility_note.ipynb)\n\n## 23. Creating a trial-level eligibility table.\n\n[CODE](http://github.com/abdomenorris/Python-Code-Notebooks/blob/github/Python-Code-Notebooks/Python_code_notebook_5_Creating_a_trial-level_eligibility_table..md)\n\nIn this notebook, we will read a `.csv` file with the patient IDs and the trial IDs. After reading this file and writing it to Python lists, we will iterate over these lists via Python `for` loop and create a matrix of trial-level eligibility. The trial-level eligibility matrix consists of 4 columns, where the first column is the patient ID (1 to 6), the second column is the ID of the trial (0 to 67), the third column is the assessment of eligibility for each trial, and the fourth column is the eligibility outcome for each patient.\n\n\n```python\n# First, we read an Excel CSV file and turn it into Python lists.\ndata = pd.read_csv('../data/patient_list.csv')\ndata = data.filter(data['assessment'] == 2).groupby('patient_id', as_index=False)['patient_id', 'patient_gender', 'assessment_result'].unstack().values\n```\n\nThe output is a dictionary like this:\n\n```python\n{'patient_id': ['1', '2', '1', '3', '5'], 'patient_gender': ['M', 'F', 'M', 'M', 'M'], 'assessment_result': [0, 0, 0, 0, 0, 0]\n```\n\nNext, we will loop",
        "label": 0
    },
    "2047": {
        "output": "The expected output is a triallevel_eligibility.csv file which contains the eligibility assessment of a patient based on inclusion/exclusion criteria of the clinical trial. The file is a comma-separated value (.csv) file with one column and one row for each patient. \n\n\n```<NAME>  2) Eligible\n<NAME> 1) Not relevant\n<NAME>     Not relevant\n```\n\n\n\n\n<EOD> Anticoagulation after aortic valve replacement. Is it mandatory for low risk patients?\nOBJECTIVE\nTo define a subset of patients low enough risk to allow anticoagulation omission and the incidence of subsequent complications.\n\n\nPATIENTS AND METHODS\nAll low risk patient (lowest 23 percentile of EuroSCORE) after cardiac surgery between April 2003 and March 2006. Clinical and morbi-mortality variables, early and late death, atrioventricular block, stroke, bleeding, thrombosis of the left ventricular outflow tract, and rehospitalization related to cardiac surgery were collected.\n\n\nRESULTS\nOne hundred and fourteen patients were included. Fifteen patients (13.1%) were given anticoagulation. In a median follow up of 27+/-29 months there was no patient mortality either related to cardiac surgery or from thrombosis or hemorrhage. One patient underwent permanent pacemaker implantation.\n\n\nCONCLUSIONS\nLow-risk patients seem to not need oral anticoagulation after aortic valve replacement, as there is no incidence of thrombotic or hemorrhagic complications.<EOD> Antibacterial, antifungal, and antioxidant activities of a novel chitosan derivative.\nOBJECTIVE\nTo evaluate the antibacterial activity of a novel chitosan derivative against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus faecalis, Candida albicans, Streptococcus mutans, and Klebsiella pneumoniae and to compare the antifungal and antioxidant",
        "label": 0
    },
    "2048": {
        "output": "<EOD> The effects of alcohol and other drugs on risk-taking behaviour and sexual decision-making among men who have sex with men in Australia.\nAIMS\nTo evaluate the impact of alcohol or alcohol/drug use on risk taking and sexual decision-making.\n\n\nMETHODS\nMen who have sex with men  were recruited from clinical services and the community to interview face-to-face regarding their alcohol use and drug use and sexual risk taking.\n\n\nRESULTS\nSemenexposure HIV/STI risk was reported by 97 participants, while 159 participants reported drug/alcohol use in the last 6 months. The 97 men who reported semen-exposure risk also reported greater alcohol use. More than 80% of men who had an alcohol drink in the last 6 months also had taken drugs. Men who had a drug use in the last 6 months were significantly more likely to engage in unprotected sex and more likely to not use condoms. Participants who engaged in unprotected sex and did not use condoms were significantly more likely to have taken any drug in the last 6 months.\n\n\nDISCUSSIONS\nMen in our study reported a significant relationship between their drug/alcohol use and sexual risk-taking. We suggest a need to further investigate drug and alcohol use with more in-depth discussion and education to assist in making more informed and safer decisions about sexual health including condom use.<EOD> Corrosion-induced delamination of lithium metal anodes\nSignificance Lithium metal batteries are attractive for next-generation batteries due to their high specific capacity and negligible volume change during cycling. However, they still face challenges to implement them on a large industrial scale such as formation of dendrites and side reactions. In this study, we show that localized corrosion of lithium metal also causes electrochemical degradation at the anode\u2013electrolyte interface. Therefore, understanding this degradation mechanism becomes important for improving the safety of lithium metal anodes. This study was motivated by a sudden death event and results provide an example of how a localized corrosion phenomenon on an anode electrode at the macroscopic scale leads to large-",
        "label": 0
    },
    "2049": {
        "output": "<EOD> Synthesis of 3-(Arylimino)indazoles via Aza-Michael/Cyclization Cascade Reaction.\nA novel approach to 3-(arylimino)indazoles has been developed. This reaction proceeds through an aza-Michael/cyclization cascade reaction of 3-(cyanoethynyl)indazoles which were prepared from commercially available 3-cyano-N-tosylindoles in the presence of copper sulfate. A range of 3-(arylimino)indoazoles were synthesized from the corresponding substituted 3-cyanoethynylindazole derivatives in good to excellent yield, as well as moderate to excellent stereoselectivity, using this methodology.<EOD> Association between Sleep-Disordered Breathing and Periodontal Disease in Patients with Diabetes \n.<EOD> Effect of high\u2010dose human normal platelet lysate on proliferation and differentiation of dermal fibroblasts in vitro\nRecently the efficacy of platelet lysate (PL), obtained by lysing platelets with a proprietary solution, has been demonstrated in the field of dermatology. We have recently shown that a newly developed method to obtain human normal platelet lysate (hPL) resulted in the secretion of higher concentrations of growth factors. In this study we investigated the effect of hPL on proliferation, growth factor and cytokine secretion, and differentiation in dermal fibroblasts. In addition, we determined which growth factors contribute to the effect of hPL via knockout (KO) experiments.<EOD> Long\u2010term outcome following percutaneous coronary interventions in patients with chronic kidney disease: A 1\u2010year follow\u2010up investigation\nTo evaluate the incidence of long\u2010term major adverse cardiac and cerebrovascular events (MACCEs) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary interventions (PCI).<EOD> .\nRationale of use of anabolic agents with anabolic steroids in the postoperative period in patients with postpoliomyelitis muscular atrophy of knee joint flexors was studied. The study group (16 patients) received prednisolone and synthetic test",
        "label": 1
    },
    "2050": {
        "output": "There are two ways to define the trial object in Jupyter Notebook:\r\n\r\n1. Use ``Trial.__class__``\r\n\r\n    ``Trial.__class__``.get_parent().__name__``\r\n\r\n2. Use a custom function to classify trials\r\n\r\n    ``def custom_func(trial):\r\n        return '';\r\n    custom_func(trial)``\r\n\r\nThe trial object has many properties which are available in `trial_object.py`.\r\n\r\n## `trial_object.__class__`\r\n\r\n## `trial_object.is_trial`\r\n    Return true if trial object is trial, otherwise false. It could be useful when running a cell by cell instead of a cell by batch.\r\n\r\n```python\r\nfrom trial_objects import *\r\nprint(Trial.is_trial())\r\n```\r\n    True         # the object is trial\r\n\r\n## `trial_object.trial_id`\r\n\r\n## `trial_object.study_id`\r\n\r\n## `trial_object.patient_id`\r\n\r\n## `trial_object.data_path`\r\n\r\n## `trial_object.data`\r\n\r\n## `trial_object.data_type`\r\n\r\n## `trial_object.data_name`\r\n\r\n## `trial_object.data.to_string`\r\n\r\n## `trial_object.clusters`\r\n\r\n## `trial_object.trial_parameters`\r\n\r\n## `trial_object.clinical_trail.title`\r\n\r\n## `trial_object.clinical_trail.summary`\r\n\r\n## `trial_object.clinical_trial.study_type`\r\n\r\n## `trial_object.clinical_trial.inclusion_criteria`\r\n\r\n## `trial_object.clinical_trial.exclusion_criteria`\r\n\r\n## `trial_object.clinical_trial.data_id`\r\n\r\n## `trial",
        "label": 0
    },
    "2051": {
        "output": "## Cleaning the Application on TurtleVM\n\nOn client, we need to clean the application by deleting the unnecessary elements. In TurtleVM, we can do so by removing the source file from the `java>src` folder.\n\nYou see, your TurtleVM environment is running on the `java>src` folder, not the `s>src` folder. \n\n- [ ] Removing the `turtle-v1.3.zip` file\n- [ ] Removing the patient_id.txt file\n- [ ] Removing the `clinical_significance.py` file\n\n<EOD> A New Type of the Cutaneous Leishmaniasis\n\nA New Type of the Cutaneous Leishmaniasis\nA New Type of the Cut",
        "label": 0
    },
    "2052": {
        "output": "Here are some examples of the `Trial-level eligibility: 2) Eligible.`.\nPatient note:\n\n\n```\n#!/usr/ksh\nf=open a  \"file.txt\" #file of clinical trial or patient note\nprint 1 \"Trial-level eligibility: 0) Excluded\";\nprint 2 \"Trial-level eligibility: 1) Not relevant\";\nprint 3 \"Trial-level eligibility: 2) Eligible\";\n\nfor line in (<f)) do\n\n    if  line == \"Excluded\" then\n        print 1;\n    elif  line == \"Not relevant\" then\n        print 2;\n    else\n        print 3;\n    endif\nnext\nprint 0 \"Trial-level eligibility: 1) Excluded\";\nprint 1 \"Trial-level eligibility: 2) Eligible\";\nprint 2 \"Trial-level eligibility: 2) Eligible\";\nprint 3 \"Trial-level eligibility: 3) Excluded\";\n```\n\nClinical trial:\n\nExample 1 clinical note:\n\n```\n#!/usr/ksh\n\n\n#Assign the clinical trial to the variables. This assignment just for understanding purpose\nclin_trial= \"defining_the_role_of_insulin_resistance_in_idiopathic_dilated_cardiomyopathy\"\n\nf=open  a  \"$clinical_trial.txt\"\n# Read  the file in two different ways\n\nprint 1 \"Trial-level eligibility: 0) Excluded\"; print 5 \"Excluded\";\nprint 2 \"Trial-level eligibility: 1) Not relevant\"; print 6 \"Not relevant\";\nprint 3 \"Trial-level eligibility: 2) Eligible\"; print 7 \"Eligible\";\n\nfor line in (<f)) do\n\n    if  (line== \"Excluded\") then\n        print 1;\n    elif  (line== \"Not relevant\") then\n        print 2;\n    else\n        print 3;",
        "label": 2
    },
    "2053": {
        "output": "##\n<EOD> .\nOBJECTIVE\nTo investigate the relationship between cystic-retentive-type malocclusion and cervical vertebra morphology and to analyze the correlation between the position of the mandibular condyle and cervical vertebra morphology.\n\n\nMETHODS\nThe digital lateral cephalograms of 46 subjects with normal-growth, with 40 boys and 16 girls, were selected. The mean chronological age and cervical vertebra index of the subjects were 9.63 years and 0.92 respectively. The cephalograms were traced by hand, 3D lateral mandibular head model and mandibular condyle model were constructed using Mimics Research v11.0 software based on the tracing. The cranial base morphology and skeletal pattern were classified with the lateral cephalometric analysis based on the hard-tissue. The three-dimensional model was used to analyze the location of the condyle and cervical vertebra in the sagittal and axial planes to explore the position relationship.\n\n\nRESULTS\n3D cephalogram: the position of the mandibular condyle in normal group was located more proximally than that in cystic retentive-type group (P < 0.05). Mandibular condyle in cystic-retentive-type group had a significantly positive correlation with cervical vertebrae morphology (P < 0.01), and the correlation coefficient was 0.500.\n\n\nCONCLUSION\nThe mandibular condyle of cystic-retentive-type group was located more distally than that of normal-type group; the mandibular condyle with high cervical vertebra morphology has a significant negative correlation with the cervical vertebra morphology.<EOD> Impact of the COVID\u201319 Pandemic and Associated Public Health Measures on the Proportions of New Positive HIV Diagnoses, Newly Diagnosed Acute HIV Infection, and HIV Transfers into Care in North Carolina, 2017\u20132019\nAbstract The COVID\u201319 pandemic and subsequent public health measures have drastically impacted healthcare and public health systems around the world",
        "label": 1
    },
    "2054": {
        "output": "<EOD> .\nThe development and introduction into clinical practice of new medical diagnostic methods is mainly due to the advancing computer techniques and high-speed computer analysis. The latest trend in the development of the diagnostic methods is represented by the introduction of modern digital technologies. One of the latest trends in the development of medical technology and the organization of medical care is the development of medical information systems, which make it possible to automate processes, improve quality and expedite the formation of medical services for patients. One of the most important tools in modern medical informatics is clinical decision-support systems, which have become irreplaceable tools in the practice of modern physicians.<EOD> Synchronization of the mitotic cycle with metabolic processes. II. The involvement of glucose and acetate in the metabolism of synchronized ascites tumor cells.\nSummary Glucose- 14 C and acetate- 14 C were used as metabolic tracers to follow the synchronization of the metabolism of tissue culture cells of the Ehrlich ascites tumor with the cell-cycle phases. Experiments carried out with both tracers gave similar results and lead to the following conclusions: The metabolism of synchronized populations of cells in the G1-phase, which are characterized by an extremely low respiration and RNA and protein synthesis, is also low and shows no significant changes as compared with the interphase metabolism. The low metabolism inhibits the gluconeogenesis of the G1-cells. The gluconeogenesis of synchronized S-phase cells was relatively high. The metabolic activities of cells at the beginning of G2 and mitosis are lower than in the S-phase but still significantly higher than in G1. The mitotic cells have a significantly higher rate of gluconeogenesis as compared with the preceding cell-cycle phase. Exposing synchronized mitotic cells to antimitotic agents like Colcemid, VP-16-213, and Colchicine (10 \u00b5g/ml) and vinblastine (5 \u00b5g/ml), resulted in the inhibition of gluconeogenesis and resumption of the glycogen phosphorylase activity which was previously depressed. The results obtained with acetate in the respiring",
        "label": 0
    },
    "2055": {
        "output": "<EOD> The effect of adenylate release from heart on ATP-K+ transport into gill mitochondria of freshwater rainbow trout Oncorhynchus mykiss.\nRainbow trout gills are capable of substantial increases in the uptake of ATP from the environment as they become established in fresh water. These increases are largely mediated by a change in the affinity of mitochondrial ATP-K+ transport for ATP. The mitochondrial ATP carrier protein, ANT, is responsible for such a change in affinity. This study investigated the effect of adenylate release from trout cardiac muscle, and the potential roles of the plasma membrane monocarboxylate transporter, MCT, and the plasma membrane nucleotidase, NDA, on ANT regulation. At 15 degrees C, incubations with cardiac muscle caused an efflux of adenylate, as well as a decrease in the affinity of the gill mitochondrial ATP-K+ transport pathway for ATP. There was no effect of cardiac muscle incubations on the Vmax value of the transport pathway. At 5 degrees C, NDA activity was higher in cardiac tissue than in gill and skeletal muscles. At 25 degrees C, MCT activity was similar in gill and cardiac tissues, and was higher than in muscle. When cardiac tissue and ATP + valinomycin were incubated with gill mitoplasts, MCT activity was markedly low. These results suggest that the efflux of adenylate from cardiac muscle contributes substantially to the decrease of ANT affinity in trout gills. Cardiac tissue is a source of both ADP and ATP, hence, the release of ATP may influence the Km value for mitochondrial ATP transport by competitively affecting its substrate specificity. NDA and MCT activities differ markedly between gill and cardiac tissues, and the involvement of NDA in ANT regulation is discussed.<EOD> .\nIn this paper, an attempt was made to elucidate the clinical features in patients with myxedema coma, including patients with myxedema coma induced by hypothalamo-hypophyseal",
        "label": 0
    },
    "2056": {
        "output": "[CODE] function Eligible(patientData) { return new TrialEligibility(patientData, \"0\"); } \n[CODE] [INST] let patientData =`{\n\"Trial\": {\n    \"Title\": \"Effect of a Fibrate and a Statin on Endothelial Dysfunction\",\n    \"Summary\": \"The role of endothelial dysfunction (ED) in insulin resistance has been highlighted in clinical, epidemiological, and pathologic studies. It is well known that insulin regulates numerous aspects of endothelial cell function. In the present study, patients with diabetes mellitus or the metabolic syndrome will be randomized to 2 months of treatment with fenofibrate or atorvastatin. The primary end point of this trial is the change in flow-mediated endothelium-dependent dilation (FMD) over a 2-month period. Secondary end points are serum adiponectin, vascular resistance, arterial stiffness, and biochemical variables (serum insulin and glucose, triglycerides, LDL-cholesterol, and highdensity lipoprotein-cholesterol levels).\",\n    \"Inclusion criteria\": {\n        \"Age>30 years\",\n        \"Adult-onset DM or metabolic syndrome\",\n        \"LDL cholesterol level<140 mg/dl\",\n        \"Able to provide informed consent and complete study procedures\",\n        \"Evidence of endothelial dysfunction (FMD<4.0)\",\n        \"Fenofibrate or atorvastatin\",\n        \"Oral hypoglycemic agents\",\n        \"Insulin (1 dose/day or 2 doses/day)\",\n        \"Metformin\u22651500 mg/day\",\n        \"Glybenclamide\u226520 mg/day\",\n        \"Acarbose\u2265200 mg/day\",\n        \"Fenofibrate or atorvastatin\",\n        \"Biochemical variables (serum insulin and glucose, triglycerides, LDL-",
        "label": 0
    },
    "2057": {
        "output": "= Continents_of_the World\n= How to use this tutorial?\n = Tutorials\n= How to access to the data and code\n[INST] You can test this code just by downloading `R code/Hadoop-Streaming-for-clinical-trial-recruitment.R` and `Data/instruction.Rdata` file in `Data` folder.\n[INST] Just simply, run the following commands:\n> library(HadoopStreaming) > # Library function > setwd(\"~\") > # Change working directory > > mystreaming <- HadoopStreaming(inputFile=\"Data\", paramsFile=\"params.params\") > # set up the input file and params file > mystreaming <- mystreaming $ doParallelLauguage(\"R\") > print(mystreaming) > print(mystreaming$log) > $streaming <- mystreaming > # get the streaming object > > mystreaming <- HadoopStreaming(inputFile=\"Data\", paramsFile=\"params.params\") > print(mystreaming)> stream_in <- streaming$stream > # Use as loop for stream_in function > for (i in 1:nrow ( stream_in)) { > ## Create new window for each row in stream_in > stream_in$x(i) <- paste(stream_in$X(i),\"-\",stream_in$Y(i),\"-\",stream_in$Z(i)) > stream_in$x(i): = stream_in$x(j) > stream_in$x(i): = stream_in$x(j)$y > # # Converting list to matrix object > stream_in$y <- matrix(stream_in$y) > # Converting list to matrix object > print(stream_in$x) > print(stream_in$y) > # Compute and print output of Hadoop_Stream_Samples_for_Hbase_Cluster > # stream_in$x }.\n\n\n[INST] If you wanted to run it in actual clusters, you can modify the first two commands like the following: `> library(HadoopStreaming) > # Library function > setwd(\"~\") > # Change working directory > > setwd(\"~\") > mystreaming <- HadoopStream",
        "label": 0
    },
    "2058": {
        "output": "[END]<EOD> The Bactericidal Action of Bovine Serum to Pneumococcus\nFrom the earliest work on the bactericidal effect of normal animal serum on pneumococci there has been a question whether this action is really a toxin action or whether it is a bacteriostatic effect dependent upon changes or conditions on the surface of the pneumococcus which are necessary for its survival. Such a question as that suggested from the first by Flexner and Jobling14 would be difficult to answer, since there could be no means of knowing when the organisms were rendered susceptible to the bactericidal and when they were immune. In studying bacteria of Pneumococcus from patients, a number of factors occur which influence the viability of pneumococci in their various environment-factors not encountered under the most exacting laboratory conditions. Therefore, there are many sources of variation in the susceptibility of pneumococci to the bactericidal effect of serum. This report concerns itself with one phase of the problem, viz., the serum resistance of pneumococci present in the blood of normal animals under laboratory conditions. By \"normal animal\" is meant all classes of domesticated pets, as well as birds, reptiles, fish, etc. The resistance of organisms present in pathologic material, of a given species or strain, is not considered. The pneumococci obtained from animals were not specially treated or placed under any conditions known to enhance their ability to withstand serum. The procedure in obtaining the serum was that followed in obtaining a sample of human blood for laboratory purposes. I n the case of pig, no attempt was made to w i l d the animal before taking blood for serum. Serum collected from normal and healthy animals was used in all cases. Bacteriostatic as well as bactericidal action was tested, with the following results. It is of interest to note that the highest per cent bactericidal serums occurred at the lowest temperature tested, namely, 40 to 420C., which is below the surface temperature of animals. This observation has been verified, to the extent possible, upon many species of domesticated wild animals. I n 1,010 determinations of the bactericidal",
        "label": 0
    },
    "2059": {
        "output": "# Cleaning up the example\nFinally, I would like you to remove unnecessary spaces before your code, i.e., `Lisa` 4 3\n\n# Your next problem\nNow you will solve a new problem:\n\n\n[INST][Cleaning data](https://code.org/learn/python/lesson/python-scripts/cleaning-data/)\n\nThis lesson explores how to find out exactly what some cells in a spreadsheet do.\n\n# Pretest\n\n- Before you run the next lesson code, use the [Python interpreter](https://code.org/learn/python/learn-python/running-python-code) to run the following program. When done, respond to the following prompt to submit the Python code and get the score:\n  \n    <div class=\"p-text-box border-top\" style=\"border-top:solid 2px; border-bottom:none; border-right:none; box-shadow: 0 1px 2px #cccccc;\">\n      Write this Python code to print the words ``Hello\", ``World\", and ``Betty\", in that order. What is a variable?</div>\n  \n- After you get your score, respond to the [following prompt](https://code.org/learn/interpreter/#0) to continue.\n\n- Before you get started, download the [spreadsheet](code/p-clearyour-data.txt) file to save your Python code.\n\n\n## [INST] [Cleaning data](https://code.org/learn/python/lesson/python-scripts/cleaning-data/)\n\n\nIn this lesson, you'll find out about the differences between \"naive cells\" and \"correct cells.\"\n\nThe \"naive\" cells are those that do not follow the instructions outlined in the data. As we go along, you'll learn to detect and correct the data.\n\nYou'll need to repeat three things each time you try to clean the data:\n\n## 1. \nRead in the data.\n\n2. \nCount the number of correctly formatted rows.\n\n3. \nRepeat until you get the right answer.\n\n## Naive cells\nIn the first lesson, you read in a list",
        "label": 0
    },
    "2060": {
        "output": "![![INST](Inst_files/img/demo_img_trial-level-eligibility.jpg)](Inst_files/img/demo_img_trial-level-eligibility.jpg)\n\n\n\n## Exclude criteria\nYou should consider both the inclusion criteria and the exclusion criteria from clinical trials. If the patient meets any of the exclusion criteria of this clinical trial, the patient is excluded from the assessment of eligibility and you should input `0` \nat `Assessment of Eligibility: `. The clinical trial also had some exclusion criteria for patients.\n\n![![INST](Inst_files/img/demo_img_trial-level-eligibility.jpg)](Inst_files/img/demo_img_trial-level-eligibility.jpg)\n\n[<NAME> and <NAME>: Data Science and Algorithmic Trading](Inst_files/Demo_instructor_datascience_algorithmictrading_doc.docx)[1]\n\n### Exclusion criteria:\nDiabetics on oral hypoglycemic agents for more than 6 months Diabetics on insulin for the last 3 months Diabetic patients with significant retinopathy Patients with a known hypersensitivity to Hydroxychloroquine Allergic to Sulfonamide Antibiotics\n\nFor instance, you should write exclusion criteria as below:\n\n<table border='1'>\n<tr> \n  <th>Exclusion criteria</th>\n  <tr> \n    <td><NAME>, A. <NAME>, F. M. 2018. \"Exclusions criteria.\" In: <NAME>. [<NAME> &amp; </NAME>: Data Science and Algorithmic Trading](Inst_files/Demo_instructor_datascience_algorithmictrading_doc.docx). </td>\n  </tr>\n</table>\n\n<EOD> Exploring the Clinicopathological Features, Prognosis and Immunological Significance Between Epstein-Barr Virus Positive and Negative Diffuse Large B Cell Lymphoma in Patients With Follicular Foci and Bcl-2 Expression: A Report From the Mole",
        "label": 0
    },
    "2061": {
        "output": "-\n\n\n# Discussion\n\nWhat should we do if we do not know about the exclusion factors of the trial?\nLet's check what is written in the inclusion and exclusion criteria of this clinical trial: \n\n## Inclusion criteria\n1. a current hemoglobin A1c(HbA1c) of >8.0%\n\n## 2.\nan average HbA1c of >8.0% during the past year\n3. diagnosed with Type 1 diabetes for at least one year\n\n## 4.\nreside in the metro Detroit tri-county area \n\n\n## 5.\nand 6.\n\n## Exclusion criteria\n1.\n\n# Methods\n\n## Implementation\n\nWe implemented the dataset in a Jupyter Notebook environment so that you can try to execute and modify our codes and also check them out to see the outputs and figures. \n\n# Installing the datasets\n\n[![Banner](https://github.com/khosraus/practice3/raw/main/data/data15/banner.jpg)]()\n\n[![Banner](https://github.com/khosraus/practice3/raw/main/data/data15/banner.jpg)]()\n\n[![Banner](https://github.com/khosraus/practice3/raw/main/data/data15/banner.jpg)]()\n\n[![Banner](https://github.com/khosraus/practice3/raw/main/data/data15/banner.jpg)]()\n\n[![Banner](https://github.com/khosraus/practice3/raw/main/data/data15/banner.jpg)]()\n\n\n[INST:\nGo to <a href=\"https://raw.githubusercontent.com/khosraus/practice3/master/data/data15/data15.csv\">the folder of this dataset</a>, i.e., download <a href=\"https://raw.githubusercontent.com/khosraus/practice3/master/data/data",
        "label": 0
    },
    "2062": {
        "output": "**Please note: The `cuda` and `cudnn` libraries installed in [CUDA Toolkit 11.1](https://developer.nvidia.com/) are needed to run the codes. We thank the [CUDA Toolkit](https://developer.nvidia.com/cuda-toolkit) team for sharing it to us.\n\n### [CODES](CODES.pdf)\n<EOD> Efficacy and safety of oral versus parenteral nicorandil infusion in patients with acute myocardial infarction\nNicorandil has a hybrid structure of the cardiotonic drugs, and possesses dual cardiotonic action: both rapid (KATP channels openers) and delayed (NO\u2013cGMP pathway) effects. In China, oral nicorandil was approved for use in acute myocardial infarction, and its dose was not fixed. This retrospective observational study evaluated the efficacy and safety of oral versus parenteral nicorandil infusion for treating acute myocardial infarction.<EOD> Pregnancy following laparoscopic fundoplication.\nBACKGROUND\nA number of surgical and nonsurgical treatments are used to improve dysphagia in pregnancy. Laparoscopic Nissen fundoplication effectively relieves the dysphagia in a large number of patients. It has a short hospitalization and minimal disability. We reviewed our experience with laparoscopic fundoplication to assess its effects on pregnancy and post partum dysphagia.\n\n\nMETHODS\nWe performed a prospective, nonblinded study of 30 pregnancies occurring in 25 patients who had had a laparoscopic fundoplication for severe dysphagia. The patients completed a validated grading system to evaluate their symptoms (including pain, heartburn, vomiting and reflux). They also completed a questionnaire about their overall health during the pregnancy and at six to twelve months post partum.\n\n\nRESULTS\nOf the 30 women who were evaluated in the antenatal period, 24 had improvements in quality of life, 10 were improved, and 6 had",
        "label": 1
    },
    "2063": {
        "output": "<EOD> Differential diagnosis of periarteritis nodosa. 18F-FDG PET-CT may rule out malignancy as a cause of vascular inflammation.\nPURPOSE\nTo retrospectively evaluate the usefulness of 18F-FDG PET-CT in the differential diagnosis between systemic vasculitis and malignancy as a cause of vascular inflammation in patients with suspected periarteritis nodosa (PAN).\n\n\nMATERIALS AND METHODS\nAll 18F-FDG PET-CT and MRI studies performed between January 2008 and December 2012 were independently reviewed by a reader with expertise in PET and vascular imaging. Clinical correlations were available in patients with imaging studies suggestive of PAN. For this report, all patients were reviewed for the presence of vascular abnormalities, and findings were correlated with the clinical data for those with vasculitis. Histologic biopsy was used as the gold standard.\n\n\nRESULTS\nSixteen consecutive studies performed in 13 patients (nine female), were included. The mean age was 60 years (range, 39-80 y). On the basis of clinical history, eight patients had PAN; one case of PAN versus chronic periaortitis was found at biopsy. All patients had peripheral vascular inflammation in 18F-FDG PET-CT studies, which was also detected in all but one MRI study. All PAN studies showed periarterial uptake of 18F-FDG along the thoracic and abdominal aorta, carotid, or renal arteries; uptake was also found along common iliac and femoral arteries in four patients. In MRI studies, hyperintensity in T2-weighted images was observed in all PAN studies, and it was found in six of eight malignant cases. In one of four PAN studies that had both 18F-FDG PET-CT and MRI performed within 48 h, PET-CT showed increased uptake of 18F-FDG in common iliac ar",
        "label": 0
    },
    "2064": {
        "output": "## Examples:\n`>> trial_data=read.csv(file.path('data','sample_data.csv')); trial_data.head(); \n> Trial_data$Group1 $Chest Pain A/Hemodynamics $Group2 $Chest Pain $Group2$Timepoint`Eligible`Group3 $Chest Pain $Group3$Timepoint`Eligible`Group4 $Chest Pain $Group4$Timepoint`Eligible`Group5 $Chest Pain A/Hemodynamics $Group6 $Group6`Eligible` Group7 $Chest Pain A/Hemodynamics $Group8 $Group8`Eligible`All\n\n# ClinicalTrials Summary\nTo calculate the recruitment completion rate:\n\nLet's think about how to make the clinical trials' summary. First, you need to make a trial_summary. \n\n\n```r\nnew_tpl=data.frame(\"SiteName\"=c(\"Site1\",\"Site2\"),\"Chest Pain\"=>c(\"Chest Pain A\",\"Chest Pain A\"),\"Group1\"=c(\"Group1\",\"Group2\",\"Group3\",\"Group4\",\"Group5\",\"Group6\",\"Group7\",\"Group8\"),\"Group1$Chest Pain\"=c(\"Eligible\",\"Eligible\",\"Eligible\",\"Eligible\",\"Eligible\",\"Eligible\",\"Eligible\",\"Eligible\"),\"Group2$Chest Pain\"=c(\"Excluded\",\"Eligible\",\"Excluded\"),\"Group2$Timepoint\"=c(\"Excluded\",\"Excluded\",\"Excluded\",\"Eligible\",\"Excluded\",\"Eligible\",\"Excluded\",\"Excluded\"),\"Group3$Chest Pain\"=c(\"Excluded\",\"Not Relevant\",\"Excluded\",\"Eligible\",\"Not Relevant\",\"Excluded\",\"Eligible\",\"Excluded\"),\"Group3$Timepoint\"=c(\"Excluded\",\"Not Relevant\",\"Excluded\",\"Eligible\",\"Not Relevant\",\"Excluded\",\"Eligible\",\"Excluded\"),\"Group4$Chest Pain\"=c(\"Excluded\",\"Eligible\",\"Excluded\",\"Not Relevant\",\"Eligible\",\"Excluded\",\"Eligible\",\"Excluded\"),",
        "label": 0
    },
    "2065": {
        "output": "# 1 Trial-level Eligibility\nTrial-level eligibility: 1) Excluded\nTrials-level eligibility: 1) Excluded\n\n# 1-2 Trial-level Eligibility\nTrial-level eligibility: 2) Not relevant\nTrials-level eligibility: 2) Not relevant\n\n# 1-3 Trial-level Eligibility\nTrial-level eligibility: 3) Eligible\nTrials-level eligibility: 3) Eligible\n<EOD> L-serine inhibits LPS-induced pyroptosis in bovine mammary epithelial cells\nPyroptosis is an inflammatory programmed cell death (PCD) form for bacteria invasion, which is associated with excessive pro-inflammatory cytokine release and destruction of cell structures and functions. In this study, we investigated regulation of l-Serine on lipopolysaccharide(LPS)-induced pyroptosis in bovine mammary epithelial cells (MAC-T). Results showed that both mRNA expression of caspase-1 and protein level of IL-1\u03b2 and IL-18 were significantly increased by the treatment with LPS (p < .05). Meanwhile, mRNA expression of caspase-1, cleaved-caspase-1, and IL-1\u03b2, IL-18 was significantly decreased by the treatment with l-Serine in LPS-treated MAC-T cells (p < .05). Transmission electron microscopy showed that LPS-treated MAC-T cells had severe intracellular structure destruction and l-Serine treatment alleviated the LPS-induced damage. Furthermore, l-Serine may inhibit the LPS-induced inflammasome formation and inflammation via regulating the expression of NF-\u03baB and NLRP3 (p < .05), and NF-\u03baB, IL-1\u03b2, and IL-18 may be considered as indicators for the effect of l-Serine on pyroptosis. Altogether, these results demonstrated that l-Serine has protective effects against LPS-induced pyroptosis",
        "label": 0
    },
    "2066": {
        "output": "This problem has 2 parts. For Part_I, you should create a new Trial and set the correct values in the fields. Part_II is about the Trial-level eligibility in STATA. Good luck!\n\n\nA: Answering this exercise in STATA requires a lot of patience. As I don't want anyone to go through this same painful process I'll explain how to do so in a little bit of detail.\nThe first thing you need to do is to create a new document with the variable for each patient included. Here's a little code that will do the work for you:\n*!run(\"recode Pat_Doc\")\nmata:\n*!set type:\n- variable:\n- Pat_Doc\n*!set names:\n- Pat_C _\"Patient Note\" Pat_P _\"Patient Note Patient\" Pat_DC_Num _\"number of days in which Patient_Doc was consulted\" Pat_RD _\"name (last name/first name) of the physician who wrote the consultation in Pat_Doc\"\n*!set prefix:\n- Pat _\"Patient\"\n*!set replace:\n- Pat_DC_Num _\"number of days in which Patient_Doc was consulted\" Pat_DC_Num _\"number of days in which Patient_Doc was consulted\" Pat_DC_Num _\"number of days in which Patient_Doc was consulted\" Pat_DC_Num _\"number of days in which Patient_Doc was consulted\" Pat_DC_Num _\"number of days in which Patient_Doc was consulted\"\n*!set values:\n- Pat_DC_Num _\"0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25\" Pat_DC_Num _\"0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2",
        "label": 0
    },
    "2067": {
        "output": "`python3 -i `Clinical_trial_data_v1.csv` -l -f 2 -i 10 20 24 131 144 186 313 327 358 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 14005_26194 14004_26193 14065_34333 14009_26195 14067_33509 14066_33920 14203_9700 14006_26194 14069_34687 14203_4044 14007_9244 14056_36256 14008_36692 14061_35536 14030_8898 14051_35774 14034_8878 14001_9026 14205_53656 14201_70302 14024_12550 14204_5748 14015_10334 14024_12550 14023_12547 14078_44140 14071_41022 14070_35583 14044_23486 14014_7",
        "label": 0
    },
    "2068": {
        "output": "<EOD> The epidemiology of cancer of the urinary bladder.\nBladder cancer is a common malignancy in industrialized nations of European background. Incidence rates have risen steadily and are now higher than in most other industrialized nations. This upward trend is largely confined to the USA and industrialized nations of European background. The reasons for this are unknown but increased detection might be one cause. Mortality rates are much lower and declining. The incidence-mortality ratio is not falling, however, indicating that increased age at diagnosis has played some part in the decrease in mortality. The ratio is also rising, indicating that the decline in mortality is being offset by increased case fatality and/or diagnosis of more advanced cancer. The sex ratio for bladder cancer is male:female = 3 or 4:1. This excess is almost entirely in the elderly with a much lower incidence of bladder cancer in males under age 50. The distribution of cases by birth cohort provides evidence of increasing incidence between the more recently born cohorts. The increased incidence has occurred largely in the younger cohorts. Therefore, the increased incidence of bladder cancer in the USA and other industrialized nations of European background is best explained by excess bladder cancer deaths in the elderly.<EOD> Apoptosis in the lung after pneumonectomy in rats.\nThe present study was designed to investigate apoptotic responses after pneumonectomy of rats. In addition, we analysed the possible changes of the balance between the pro-apoptotic Bax and the related anti-apoptotic Bcl-2 proteins. Pneumonectomy was performed on 1-day-old rats in two steps with the interval between the two steps lasting 3 or 7 days. Bax and Bcl-2 proteins were detected with immunohistochemistry and their localization was determined with confocal laser scanning microscopy. After immunohistochemistry, the areas of the lung positive for apoptosis in the epithelium of the distal lung regions and of the interstitial tissue were evaluated for their area and number of positive cells. Positive Bax protein localization was detected after pneumonectomy and was mainly associated with epithel",
        "label": 0
    },
    "2069": {
        "output": "You might think there is enough space to copy the whole note's body, but this wouldn't help you make the conclusion in the last line or justify it, because you need a reason in every decision rule. \n<EOD> A novel role for a \u03b2-subunit-deficient Kv channel in the inhibition of TCR signaling\n\nThe K + channel Kv1.5 (KCNA5) is an established negative regulator of T cell receptor (TCR) activation. In addition to being a key determinant of the resting membrane potential, Kv1.5 plays a role in mitigation of Ca 2+ influx that is required for full TCR signaling. We found that, as expected, when this channel is ablated in either CD4+ T cells or Jurkat T cells, TCR signaling is significantly enhanced. Unexpectedly, we discovered that a previously undescribed mutant (L531R) of Kv1.5 showed impaired interaction with the Kv1.5-associated protein NHERF2, leading to a subcellular redistribution of Kv1.5. The L531R mutant was more strongly expressed at the TCR microcluster in the absence of the channel's \u03b2-subunit, while TCR signaling was only augmented when channels trafficked to the cell surface. Furthermore, surface Kv1.5 L531R bound to and blocked the NMDAR, a critical player in TCR signaling. Importantly, treatment with the NMDAR antagonist memantine inhibited both TCR-mediated Kv1.5 L531R expression and Kv1.5 L531R-NHERF interaction. We propose that, after TCR triggering, the L531R mutation leads to activation of the NMDAR and a calciumdependent, CaMKII dependent trafficking event that prevents Kv1.5 L531R localization to the immunological synapse. We conclude that the subcellular location of Kv1.5 determines whether it suppresses TCR signaling or whether it can act as a positive regulator of TCR signaling. The implications are that a better understanding of the subcellular locations where ion",
        "label": 0
    },
    "2070": {
        "output": "[[MARK_OFF]\nTo demonstrate the usage we have prepared the data in an Excel file and made an Excel macro for this demo.\nDownload the data and macro here.\n\n\nThis file contains only one sheet that has the patient's details. The names of the features have the same meaning as described in the documentation. You can also use the sample file at the top of the page.\nUse the provided code to generate the list of all the cases.\nThen use the code in the macro to evaluate the patient's eligibility. The output table is in the same sheet where you can find the full record and the eligibility score of each record.\n\n![Wizard_41402](https://cloud.githubusercontent.com/assets/7065519/5948994/5a200d34-a624-11e4-8b84-66a0a5f7839f.png)\n\n\nThere are two tabs that show the results of the eligibility assessment: All patients' eligibility and Trial-level summary. You can filter the tables by the results like Eligible, etc.\n\n![Wizard_41402](https://cloud.githubusercontent.com/assets/7065519/5948997/5a200dd4-a624-11e4-8ecd-a14a9c71d511.png)\n!!! \n<img width=\"742\" alt=\"Screen capture 2\" src=\"https://cloud.githubusercontent.com/assets/173877/6568503/ddb66402-ba3c-11e4-98d4-1fa44661060b.png\">\n\n![Wizard_41402](https://cloud.githubusercontent.com/assets/173877/6568503/ddb66402-ba3c-11e4-98d4-1fa44661060b.png)\n![Wizard_414",
        "label": 0
    },
    "2071": {
        "output": "Please, check the source code in this tutorial or on GitHub. [http://github.com/abrahmpour/Tutorials/blob/master/6_eligibility_in_clinical_trial.py]\n\n--\n\nBy <NAME>\n\n@2016\n\nAll Rights Reserved.\n\n\nSource: [http://tutorials.python.org/introduction/introduction_01.html]\n\n---\n\n# [Review Eligibility Assistant]()\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nThe inclusion and exclusion criteria differ across trials; you will learn about the criteria by examining the patient file and the trial-specific documentation.\n\nBelow you will see a short description of a patient file and a trial-specific documentation. Below you will try to determine the patient file's eligibility for this clinical trial.\n\n---\n\n```python\ntrial_name = \"RENAMIC - Renale artery stenting for uncontrolled hypertension\"\ntrial_id = 7096\npatient_id = 000043\npatient_age = 65.0679924075\nsex_male = False\nlab_blood_pressure = (127,137)\ndiabetic_history = False\ncholesterol_history = False\npatient_diagnosis = 40\nalready_treated =False\npatient_file",
        "label": 0
    },
    "2072": {
        "output": "## Output : \nName : John , ID : 1 Eligibility : 2 (Eligible) Eligibility:\n\n\n<EOD> .\nThe results of 195 endoscopic laser procedures carried out between 1965 and 1980 are presented. A high level of efficiency was achieved in the treatment of peptic ulcer, bile reflux esophagitis, ulcerated esophagus and cancer of the esophagus. Side effects were minimal. The only untoward event was one case of fatal bronchospasm following laser treatment of the larynx for cancer. Endoscopic laser treatment of the gastrointestinal tract should now be accepted by physicians as an effective technique for the management of benign diseases.<EOD> The role of epigenetic factors in the neuroinflammation and neuroplasticity associated with obstructive sleep apnea.\nOBJECTIVES\nObstructive sleep apnea (OSA",
        "label": 0
    },
    "2073": {
        "output": "# 10-17 Aggregate-Level Eligibility\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine the aggregated eligibility of the patients based on the given patient notes. The number of patients who meet the clinical trial criteria is called Aggregate-level eligibility.\n[END INST]\nAssuming you receive a list of patient notes similar to the next sample, you should determine the eligibility of the list.<EOD> Interactions of oxytocin and arginine vasopressin receptors with phorbol diesters.\n\n \n\n## Experimental procedures\nMaterials-CnPA was from Collaborative Research Co .. Synthetic PDBu (phorbol-12,13-dibutyrate) was from Sigma. PDBu stock solution was prepared as described ( l l ) . [aH]PDBu, [3H]CGP-12177 (I2,l[2,3,2-IH]CPP, and [3H]c~iVIP (I21 were from Du Pont-New England Nuclear (Boston, MA). Oxytocin was from Bachem Inc. (Torrance, CA). Reagents for RIA were obtained from BIOSOURCE (Nivelles, Belgium), and rabbit anti-human oxytocin antibodies were prepared as described ( 12 ) . Immobilon HZ membrane (48-well dot blot apparatus) was from Millipore Corp. (Bedford, MA). Unless indicated otherwise, all other chemicals were of the purest available quality from Merck (Darmstadt, Germany).\nRadioligand Interaction Assay-The assay was adapted from a previously described method (l l ) . Oxytocin was labeled by use of purified carrier-free [3H]oxytocin, with a specific activity of 64 Ci/mmol (2.26 X lo6 cpm/pmol; Du Pont-New England Nuclear, Boston, MA). PDBu was radioiodinated by using 1 mCi (l.66 X 10' cpm/pm",
        "label": 2
    },
    "2074": {
        "output": "_\nThis can be done easily by writing the number into the input field, which is in the upper right corner of the screen._\nWhen you are finished, you should click the _Submit_ button at the top of the screen (see Figure 15.12b).\n\n\n**Figure 15.12b.** A window of assessing patient's eligibility._\n\n[INT] _If all goes well, you will see the following message. _\n\n\n**Figure 15.12c.** After you have assessed all of the patients._\n\n[INT] _On the other hand, you may receive the following error information. _\n\n\n**Figure 15.12d.** When you encounter an error._\n\n[INT] _For this type of error, you need to check the information that you have entered in steps 1 to 3, which includes the input of patients' information, patients' medical treatment information, and/or medical trial information. _\n\nThis error information is explained, which is as bellow. _\n\n\n**Figure 15.12e.** A window of assessing patient's eligibility error. _\n\n[INT] _When the entered information is incorrect, an error page is displayed. You should first go to step 1 or 2 again and correct the information. To do this, click_ OK. _When you finish correcting the information, you need to press the_ Submit _button. _ _\n\nThe number on the Submit button will be automatically increased. When the number becomes 5, repeat these steps and click the Submit button again. This process must be repeated until you eventually see the following result (see Figure 15.12f). _\n\n\n**Figure 15.12f.** A window of assessing patient's eligibility error correction. _\n\n[INT] _You need to try one more time to check the input, even if you see this result. On the other hand, if you continue to encounter such an error, try to change the input. Remember to click_ Submit _button._\n\n[INT] _Please refer to Figure 15.12g._ _\n\n**Figure 15.12g.** A window of assessing patient",
        "label": 0
    },
    "2075": {
        "output": "### Input\n\nThe input of the problem is a patient note and a clinical trial.\n\nThe patient note is a json file that contains patient data used in the problem:\n``` json\n{\n  \"date of birth\": \"2000-04-28\",\n  \"family history\": {},\n  \"health history\": {\"status\": \"positive\"},\n  \"lab result\": {\n    \"cholesterol\": 190,\n    \"fbs\": 100,\n    \"glucose\": 70,\n    \"hdl\": 40,\n    \"hba1c\": 6.5,\n    \"ldl\": 125,\n    \"tg\": 140,\n    \"triiodothyronine\": 3.29\n  },\n  \"note\": \"This morning the patient presents with shortness of breath\"\n },\n{ \"date of birth\": \"2002-04-01\",\n  \"family history\": {},\n  \"health history\": {\"status\": \"positive\"},\n  \"lab result\": {\n    \"cholesterol\": 190,\n    \"fbs\": 100,\n    \"glucose\": 70,\n    \"hdl\": 40,\n    \"hba1c\": 6.5,\n    \"ldl\": 125,\n    \"tg\": 140,\n    \"triiodothyronine\": 3.29\n  },\n  \"note\": \"This morning the patient presents with shortness of breath\"\n  },\n{ \"date of birth\": \"1993-05-  \"family history\": {},\n  \"health history\": {\n    \"status\": \"\",\n    \"status 2\": \"no\" },\n  \"lab result\": {},\n  \"note\": \"This morning the patient was in good spirits\"\n}\n```\n\nThe other piece of information is the clinical trial which should be structured as follows.\n``` json\n{\n  \"title\": \"Impact of Molecular and Genetic Influences on the Risk of Colorectal Cancer: A Prospective Analysis in a Cohort from the",
        "label": 1
    },
    "2076": {
        "output": "[AO]\n\nThis is a simple and fun little example. Remember that the same idea can be applied to a very complex case. You may just focus on a single row when analyzing the patient's data. For example, you might want to filter out patients with heart failure, since they may have a high LDL level. We are not aware of other methods besides the row filtering we mentioned before, so using the code below to filter out those patients is a good suggestion.\n\n{% include codechunks.html id=4 %}\n\nBy focusing on a single row of patient data, we may be able to answer a different question and use the same algorithm. In this example, you only need to include variables that should be kept for comparison. As a result, you won't need to filter a given patient out, so you can save the patient's trial results as a column. We'll start by defining the patient as follows.\n\n{% codeblock file=\"my_patient.csv\" %}\nID,Name,Date,Demographics1,Demographics2,Disease,PatientCondition,Eligibility\n1,bob,6/17/2020,0,0,0,0,0,0\n2,john,10/1/2019,0,0,1,0,0,0\n3,peter,8/1/2020,20,\"FSHD2\",\"0\",0,0,0\n4,mark,9/15/2020,11.56,\"HD\",0,0,0,0\n5,andy0,9/10/2018,0,0,0,1,9\n\n{% endcodeblock %}\n\nAssume you still plan to extract the two columns you have for the clinical trial above. \n\n\n\n{% codeblock file=\"my_patient.py\" %}\nimport pandas as pd\n\n\npatients = pd.read_csv(\"my_patient.csv\")\n\npatients[\"Eligibility\"] = 0\n\npatients[\"Patient_ID\"] = patients[\"ID\"].astype(int)\n\npatients[\"Eligibility\"] = patients[\"Patient_ID\"]\n\npatients.head()",
        "label": 0
    },
    "2077": {
        "output": "<EOD> The Nuclear Import of Ataxin-2 Is Regulated by Its Interaction with Transportin-1 and Transportin-2\n\nThe nuclear import of Ataxin-2, a disease protein responsible for Machado Joseph Disease, a polyglutamine neurodegenerative disorder in humans, is currently unknown. This lack of knowledge hinders an understanding of the underlying mechanism for the cellular neurotoxicity of Ataxin-2 and the mechanism of this disease. We find that Ataxin-2 interacts with two karyopherins, Transportin-1, and Transportin-2 by co-immunoprecipitation. The nucleocytoplasmic distribution of Ataxin-2 protein is similar to that of the NLS-bearing protein cyclic AMP response element-binding protein, which is known to be an import cargo of these two karyopherins. Furthermore, a Transportin-1 karyopherin inhibitor, Transportin alpha-interaction inhibitor, reduces the nuclear Ataxin-2 protein in the cells. This inhibitor also blocks the nuclear import of GFP-tagged Ataxin-2 and the GFP-Ataxin-2 transport. These suggest that Ataxin-2 is a likely cargo of Transportin karyopherins (karyopherin-1 and karyopherin-2) and its nuclear import is regulated by these karyopherins. The Ataxin-2 nuclear import might thus play a role in the cellular toxicity of wild-type Ataxin-2. Additionally, we find that the Ataxin-2 nuclear import is enhanced significantly in the presence of Transportin-2. The enhancement of the nuclear import by transportin-2 may be the reason for previous controversies regarding the subcellular distribution of Ataxin-2. Our results shed new lights into the Ataxin-2 nuclear import and its regulation, and may help explain the mechanism underlying the disease mechanism of Ataxin-2.\n\n# Introduction\nMachado Joseph Disease (MJD) is a polyglutamine disease caused by the expansion of CAG repeat in ATA, the gene encoding Ataxin-2 [bib_ref]  Mapping of a gene for Machado-Joseph disease to chromosome 14q3",
        "label": 2
    },
    "2078": {
        "output": "## Conducting the challenge\nPlease make sure all pre-requisite files are already in your working directory. \nYou should create an executable file with your solution. There are examples on how to create an executable file in [Execution environment].\nThe main steps of the experiment are:\n1. Start a new experiment with this command: `docker run ijadore/clinical_trial_eligibility:stable_0.8`.\n2. Write your solution code and press `Ctrl + C` to exit.\n3. Use `docker logs` to see container logs and `docker rm` to delete the container.\nThe instructions are shown in the [CONDUCT THE CHALLENGE] section.\n\n## Evaluation Criteria\nOur evaluation criteria consist of two parts: accuracy and efficiency scores. Accuracy score is determined according to whether the patient is eligible for the trial on each trial. As mentioned, eligibility is done on a three-point scale. Your first task is to predict that trial-level eligibility score. The following steps are taken for your accuracy score:\n- If prediction `0`: The patient qualifies for the trial if the patient meets all the trial criteria; or - If prediction `1`: The patient is not eligible to participate in the trial since the patient does not fulfill all the trial criteria; or - If prediction `2`: The patient is eligible to take part in the trial since the patient meets all the trial requirements but has additional comorbidities; or - If prediction is `NULL`: It means the patient has unknown eligibility for the trial. If the trial has enough information and we can reach a valid conclusion for that trial, we choose the accuracy score for that trial from the following formula:\nAccuracy score = Correct predictions/Total number of predictions\nA patient's eligibility score is determined by taking the minimum score of all patient-level data. To calculate the weight of your output, you need to have knowledge of several things:\n- How much does a non-eligible patient reduce the accuracy score? That is why we need to know the weight of the accuracy score of an eligible patient to the eligibility score.\n- How much does a trial with an error in eligibility scoring affect the weight of accuracy score? That is why the total number of errors in the output",
        "label": 0
    },
    "2079": {
        "output": "Good luck!\n<EOD> Impact of Pretreatment with 2% Chlorhexidine Gluconate on the Efficacy of Two Nonsurgical Periodontal Therapies: A Split Mouth Clinical Trial\n\nAim: Efficacy of non-surgical periodontal treatments can depend on the level of bacterial contamination, and pretreatment with 0.12% chlorhexidine gluconate (CHX) reduces contamination at the pocket walls. It was investigated if pretreatment with 2% CHX (Hexamedine) attenuates the effects of non-surgical periodontal treatment on clinical parameters.Materials and Methods:In total, 60 patients with at least one shallow/moderate non-pocket form lesion in each quadrant were enrolled. Clinical indices were recorded by calibrated examiners before and 1 month after treatment. The participants were divided into two groups (randomized); a control group received scaling and root planing, and an experimental group received scaling and root planing plus 2% CHX gingival irrigations.Results:A total of 10% of the participants did not attend the second evaluation. The mean clinical variables were compared by ANCOVA after adjusting for age, gender, and smoking status. After one month, the PI (25.2 \u00b1 6.06 to 19.47 \u00b1 7.26, p = 0.001), GI (2.43 \u00b1 1.06 to 1.72 \u00b1 1.04, p < 0.001), PPD (3.11 \u00b1 1.15 mm to 2.89 \u00b1 1.25, p = 0.01), and CAL (1.53 \u00b1 0.45 mm to 1.39 \u00b1 0.48, p < 0.001) at the test side were less than the control. There was no significant difference between the test and control at 1-and 3-month evaluations.Conclusion: Within the limitations of this study, it could be concluded that pretreat",
        "label": 0
    },
    "2080": {
        "output": "<br>\n\n_Detailed discussion:_\n\n1. `if not any_exclusion_criteria(patient) == 0`. It ensures that the patient meets the inclusion criteria of the clinical trial. \n2. `eligible_clin_trial_condition(patient,clin_trial) == True`. It verifies that the patient should be eligible for the clinical trial. \n3. `Trial-level eligibility`. `Elitigible or Not` should return True or False.\n\n<br>\n\n### If Excluded:\n\n1. `all_exclusion_criteria_of_the_clin_trial_existed(patient, clin_trial) == True`. It checks whether the patient matches the exclusion criteria.\n2. `if any_exclusion_criteria(patient) == 0`. It means that the patient only met none of the exclusion criteria of the clinical trial.\n\n<br>\n\n### If Not relevant:\n\n1. `if not any_exclusion_criteria(patient)==0`. It means that there are at least one of the inclusion criteria applied to the patient. It will check whether the patient does not receive sufficient information to qualify for the clinical trial.\n2. `not eligible_clin_trial_condition(patient, clin_trial) == False`. It ensures that the patient has at least one exclusion criteria. \n\n<br>\n\n### When `Elitigible or Not` returns True: \n\n1. `all_exclusion_criteria_of_the_clin_trial_existed(patient, clin_trial) == False`. It means no exclusion criteria of the clinical trial applied to the patient. \n2. `not eligible_clin_trial_condition(patient, clin_trial) == False`. It means no exclusion criteria applied to the patient. \n\n<br>\n\n### If Not all exclusion and inclusion criteria are fulfilled:\n\n1. In case `all_exclusion_criteria_of_the_clin_trial_existed(patient, Clin_trial",
        "label": 0
    },
    "2081": {
        "output": "##[RTEM]Hello. You are a helpful assistant for clinical trial recruitment. The factors that allow someone to participate in a clinical study are called inclusion criteria. The next patient note is from someone who you've already assessed as `Eligible` for a trial. The patient has type 1 diabetes confirmed with molecular analysis and is eligible for participating in the clinical trial. \nLet's look at the lab values from the patient note as shown here. \nHere are the lab values for the clinical trial again, namely:\nCholesterol: 190 mg/dl\nTG: 140mg/dl\nLDL: 125 mg/dl\nHDLC: 40 mg/dl [/RTEM] \n\n## [/OUT]\n<EOD> A novel method for the removal of toluene.\n\nToluene is a volatile organic compound (VOC) that is commonly used in the industry, and it is an established risk factor for the development of neurological diseases in humans. The present protocol investigates the use of a newly developed method for the removal of toluene to improve worker safety. A total of 15 workers (mean age, 38.28\u00b17.3 years; working >20 years and >10 years in the same line) were enrolled in the study. Whole blood samples were collected from three groups. The control groups consisted of healthy individuals who had never been exposed to toluene (n=3). The 4-week follow-up group consisted of the same workers, from whom blood samples were collected and a urine sample was obtained after 4 weeks of being exposed to a low concentration of toluene (n=2). To measure the biotransformation of toluene, levels of toluene and xylene in the blood and urine samples were measured using gas chromatography-mass spectrometry (GC-MS). Toluene concentrations were expressed as \u00b5gm/ml. As the results obtained from the control and 4-week follow-up group demonstrated no statistical significance, these data were pooled into a single group (n=5). As toluene and xylene are metabolically coupled, it is reasonable",
        "label": 0
    },
    "2082": {
        "output": "<EOD> The Effects of Intermittent Prisonization on Eating Behaviors: A Retrospective Study in Greece\nThis study aimed to observe the eating behaviors of inmates and compare them with a matched control group before and during imprisonment. A total of 50 participants were recruited for the study and answered on a structured questionnaire a series of demographics and questionnaires measuring their psychological state, eating behaviors and body image. During imprisonment, participants reported (via telephone) increased frequency of fast food intake, increased snacking in cell, and increased caloric and carbohydrate intake. Moreover, the study population reported a decrease in diet quality and an increase in body mass index in a number of inmates. These findings may lead to a rise in chronic disease prevalence. Further studies are required to shed light on the reasons and long-term effects.<EOD> Assessment of the Use of the Cerebral Performance Categories (CPCs) After Out-of-Hospital Cardiac Arrest\nBackground\u2014Studies on neurologic outcome following out-of-hospital cardiac arrest that have included the cerebral performance categories (CPCs) have not found that the proportions in the 5 categories (5 and 6 as best and 1 and 2 as worst) differ significantly between survivors and nonsurvivors. One explanation for this may be that the patient has been in coma the whole time and that the performance categories are then only an estimate for the prearrest performance rather than an assessment of the actual neurological deficit. Methods and Results\u2014We performed a cohort study according to Strengthening the Reporting of Observational Studies in Epidemiology guidelines to investigate this hypothesis. We studied all out-of-hospital cardiac arrests with a return of spontaneous circulation for a duration of at least 24 hours during the period 2000 to 2006 in Orebro, Sweden, and determined for every case the CPC and performed a comparison with a control group consisting of individuals with and without coma. We found no case with coma before the cardiac arrest. Neither did we find any coma before or on admission in the control group. Conclusions\u2014The results from this",
        "label": 0
    },
    "2083": {
        "output": "<EOD> Inheritance of T-cell tolerance.\nThe ability to define antigen-binding cells by surface markers has allowed analysis of the ontogeny and maturation events of mature mucosal immune cells, in particular, T cells. Analysis of human T cells has demonstrated that the thymus is a potent site for elimination of immature thymocytes reactive with foreign and self antigens. In most, if not all, instances studied, a state of T-cell tolerance is achieved by thymic deletion of cells reactive with antigen. Studies on thymectomized mice and antigen-tolerant mice have shown that peripheral T cells acquire self-tolerance after exit from the thymus as a result of anergy induction and deletion (apoptosis) of T cells. These studies indicate that thymocytes are not just passive receivers of antigen but functionally important cells. A better understanding of the cellular and molecular events that lead to the rejection of antigen-reactive immature T cells in the thymus, and the induction of tolerance in mature T cells in the periphery, are important issues in mucosal immunology.<EOD> Inhibition of bile acid synthesis in vitro and in vivo by a human hepatocellular carcinoma.\nABSTRACT A human hepatocellular carcinoma produced a soluble factor(s) inhibiting hepatic bile acid synthesis when incubated in an organ culture system and in a mouse bearing both the carcinoma and normal host liver. Incubation of hepatocellular carcinoma cells in a culture medium for 24 hr resulted in a marked inhibition of bile acid synthesis in a subsequent intact liver organ culture system, as measured by the accumulation of radioactive bile acids. Also, the intraperitoneal injection of sonicates of hepatocellular carcinoma cells into CDF1 mice resulted in a significant inhibition of bile acid synthesis in the liver of the host mice within 4 days of treatment. Neither the sonicates of the unincubated normal liver nor tissues from the patient from which the hepatocellular carcinoma",
        "label": 0
    },
    "2084": {
        "output": "<EOD> Mendel's law among the Hottentots.\nThe genetical aspects of the Hottentot reproductive system are discussed. The premenopausal Hottentot is characterized by anovulation and a low reproductive capacity. Because of this an average length of lactation is short, and there is little variation in the length thereof. There is, therefore, little chance that genetical selection during the postreproductive period (that is, when the mother is still alive at the time of offspring birth) plays any important part in the mechanism which stabilizes the Mendelian ratios; and it is, therefore, suggested that, in this population also, most of the observed ratios are near-Mendelian.<EOD> Comparison of four quantitative diagnostic methods for feline leukaemia virus proviral DNA in the blood\nFeline leukaemia virus (FeLV) proviral DNA was compared by Southern blot, dot blot inhibition, polymerase chain reaction (PCR) and FeLV spot screening among samples from 65 control cats (negative by serology), 17 FeLV\u2010positive and 6 FeLV\u2010negative, cats positive by immunofluorescence (IF), 21 FeLV\u2010positive cats by FeLV\u2010positive provirus immunoblot (PIB) but negative by IF, and eight FeLV\u2010negative cats by all three tests. Significant FeLV proviral DNA was detected by dot blot inhibition, PCR and FeLV spot screening for 45 (69.2 per cent), 8 (12.3 per cent) and 1 (1.6 per cent) of 65 control cats, respectively. Southern blot was positive for eight (12.3 per cent), seven (10.8 per cent) and five (7.7 per cent) of 65 control cats by FeLV\u2010positive provirus immunoblot (PIB), FeLV in\u2010gel immunoblot (IgB) and PCR, respectively. Among 62 FeLV\u2010positive cats by IF and/or PIB, all were positive by dot blot inhibition, PCR and FeLV spot",
        "label": 0
    },
    "2085": {
        "output": "A: Let's start by the definition of the problem. \nIt is a filtering problem. The only thing we are told is that the person in question has cardiomyopathy. Not only is it not enough to filter the person out of the study but to filter people out of the studies who are candidates for it too.\nAnother point to keep in mind is that the problem is a little dynamic. With the additional information we will get, we can see if the person fits or not but we are not informed on it.\nThe problem is not too far from the \"Exclude duplicate students\" issue on a student's management tool. The difference is that this example has to be solved with Python.\nSo, first, we are given the patient note and then the description of the clinical trial. So we'll look for a way to separate in two cases.\nFirst, let's define our variables:\n[formula]  # Input data patient_note = 1. BMI: 25 kg/m^2 (obesity); 2. DM: Diabetes mellitus. 2. PHYS: Physical exam normal; 3. MED: Medical history: T2D: type 2 diabetes mellitus. [/formula] \nclinical_trial = \"\"\"Title: The Genetics of Cardiomyopathy and Heart Failure Summary: The purpose of this study is to determine the genetic basis of cardiomyopathies and heart failure.\nInclusion criteria:\nIndividuals with a diagnosis of cardiomyopathy Family members of individuals with a diagnosis of cardiomyopathy\nIndividuals who have a nuclear mutation shown to confer risk of cardiomyopathy but who do not themselves have cardiomyopathy\n\n\nNotes\n\n*\n\n*If the person has cardiomyopathy, then they will be included in the study.\n\n*If there is none but the person has any of the mutations noted earlier, then he/she will be excluded from the study.\n\n*If there is none and all of the mutations are ruled out, the person will not be eligible but it can be considered based the patient's medical history. # Clinical trial-level eligibility\nTrial-",
        "label": 2
    },
    "2086": {
        "output": "### Cases\n\n### 1 Clinical_trial_eligibility\n- [Code]: In this function, we used `Trial-level eligibility` argument to generate a sentence such as `Trial-level eligibility: 1) Excluded.`. [INST]\n- [Output]: A generated output would be like:\n\n``````json\n  {\n    \"type\":{\"id\":\"clinical_trial_eligibility\",\"class\":\"clinical-trial-eligibility\",\"name\".\n    \"eligibility\": \"Trial-level eligibility\"\n  }\n}\n```\n\n## [CODE_JSON]{.source-code}\n```python\nClinical_trial_eligibility(patient_note,clinical_trial)\n```\n## [CODE_PYTHON]{.source-code}\n```python\n\n# Clinical_trial eligibility\ndef Clinical_trial_eligibility(patient_note,clinical_trial):\n    \n      #Tri alevel eligibility is a function that receives the patient's medical information and the criteria of clinical trial for that patient and then decides the eligibility of the patient for participating in that clinical trial.\n      if len(clinical_trial):\n        for (trial_id, trial_name, trial_age_range_of_eligibility_study, trial_gender_range_of_ eligibility_study, trial_diabetes_type_range_of_eligibility_study, trial_disease_range_of_ \n                    eligibility_study, trial_blood_pressure_range_of_eligibility_study, trial_cholesterol_range_of_ \n                    eligibility_study, trial_low_density_lipoprotein_range_of_eligibility_study, trial_ glycated_hemoglobin_range_of_eligibility_study, trial_fasting_blood_glucose_range_of_eligibility_study, \n                    trial_kidney_function_range",
        "label": 0
    },
    "2087": {
        "output": "**Congratulations!** With this notebook you are expected to write a program to assess the eligibility of patients based on a clinical trial's eligibility criteria.\n\nThank you for your time and patience! Please don't hesitate to contact me via email if you have any questions or comments. \n\n[Instructions for reproducing this notebook](instructions-for-reproducing-this-notebook.md)\n\n\n---\n\n[< Back to index](index.md)\n\n[< Back to notebook with markdown](notebooks/README.md)<EOD> The HMG-CoA Reductase Inhibitor Pitavastatin Stimulates Neurogenesis in Vitro and in Vivo and Protects against Hippocampal Damage after Status Epilepticus\nPitavastatin is a 3-hydroxy-3-methylglutriaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with neuroprotective properties in stroke and traumatic brain injury, but its effects on neurogenesis have not been fully explored. Thus, we investigated the effects of pitavastatin on neurogenesis and stroke outcome using in vitro and in vivo models. Using rodent cultured neural progenitor cells, we found that pitavastatin stimulates cell proliferation, survival, and neural differentiation in a concentration-dependent manner without affecting cell apoptosis. In an in vivo model, we found that a daily injection of pitavastatin at 1 h after kainic acid (KA) administration stimulated proliferating progenitors in the dentate gyrus (DG) of the hippocampus as measured by immunostaining and a marker of proliferation EdU and 2 h later. One-half of proliferating immature cells further underwent neural differentiation, as demonstrated by NeuN and doublecortin-positive cells at 7 days after KA administration. By contrast, KA-induced neurogenesis was suppressed by an intraventricular infusion of an L-type Ca2+ channel blocker nimodipine, which suppresses neural",
        "label": 0
    },
    "2088": {
        "output": "[INST] Example of patient with no diabetes. (BMJ Case Reports: /case-reports/2021/cases/bcr-2021-250281.pub).\n[INST] Example of the patient who should be excluded from participation in the trial because of uncontrolled hypertension. (EJCTS /full/full-2960128. \nPlease note the comments on the trial-level eligibility by physicians. \n[INST] Example of patient with DM type 2. (J Endocr So ciety /journal/jes-193).\n[INST] Example of patient with heart failure. (BMJ Case Reports: /case-reports/2021/cases/bcr-2021-250281.pub).\n[INST] Example of the trial of the treatment of acute coronary syndrome with heated saline. (Circulation: /full/circ.153470533). \n[INST] Example of the patients with type 1 diabetes for whom hepatitis B vaccination is also recommended due to a high risk of non-A, non-B viral hepatitis. (Clin Infect Dis. /pii: cid-2017-026110. \n[INST] Example of the patients whose clinical trial inclusion must be decided jointly by the patient, family members, and doctors. (Neurology Cases Journal: /journal/neu8/full/neu801/7503896).\n[INST] Example of the diabetic patients who should be invited to participate in the study only if hypoglycemia is detected. (Clin Endocrinol (Oxf) 48(6):1017-1023).\n[INST] Example of the patients in diabetic ketoacidosis.(Clin Infect Dis /pii: cid2021. \n[INST] Example that a patient for whom antioxidant supplementation can be an alternative to insulin injection therapy. (PLoS One 15(7): e02",
        "label": 0
    },
    "2089": {
        "output": "## [FIN-INST] Note: There is no time limit. Good luck! \n\u00a9 2000-2021 Data Structures and Algorithms Online Courses, all rights reserved. Powered by Squarespace.\nAn iMooooossible \ud83d\udcb0,18 \u2122\ufe0f<EOD> Evolutionary diversification and conservation of the vertebrate metanephric kidney\n\nThe metanephric kidney forms the main nephron subtype in mammals. Although there are several reports, mainly from fish and amphibians, in literature, the evolutionary history of this tissue has not been extensively studied in vertebrates and especially teleost fish (bony fish) is an understudied model system. Using a comparative approach we searched for potential genes involved in the metanephric kidney in teleost fish, including Atlantic salmon (Salmo salar). Our study provides evidence for some gene coevolution and conserved synteny in the metanephric kidney genomic locus in mammals, amphibians, reptiles and fish within the GH24 lysozyme gene family and the gene-encoding protein C (PCTK1). The first evidence we have collected for a teleost fish metanephric kidney is the expression of slp, the ortholog of the mammalian slp genes (KRIT1, TSGA and HEPFL2) by the swim bladder in this species, suggesting that these paralogues, in addition to their known function in blood vessels, may also be important to the development of the metanephric kidney. The expression profiles of seven homologues of mammalian Eya, Dach, Six and Sox genes were analysed in the metanephric kidney and were found to be conserved between mammals and teleost fish. These genes were included in the transcriptional regulatory network of the metanephric kidney in zebrafish (Danio rerio) previously identified in this study using a morpholino-based gene knock-down approach. The expression profiles of several additional orthologues of genes essential to the development of the mammalian metanephric kidney were also analysed in the salmon metaneph",
        "label": 2
    },
    "2090": {
        "output": ">\n\n<EOD> Molecular genetic study of the HNK\u20101 epitope expression in the chicken brain during development\nThe monoclonal HNK\u20101, a neurectoderm derived epitope, recognizes several glycoconjugates and is highly conserved in evolution. In this paper, the in\u2010situ localization of HNK\u20101 epitope in chicken brain was evaluated during development using a digoxigenin\u2010antidigoxigenin\u2010peroxidase technique. Chicken brains from embryonic day (E) 2 to E\u201014, and newly hatched were studied. In E3 embryos, the immunopositive cells were observed in the diencephalon, mesencephalon, and rhombencephalon, including the pons. In E6 and E8 embryos, the immunoreactive cells were located in the cortex of the cerebral hemispheres, but not in the pons. In E10 embryos, HNK\u2010positive cells were observed in the medulla and pons. In addition, newly hatched chickens, all three brain regions (i.e., cerebral cortex, medulla oblongata, and pons) showed intense immunoreactivity to HNK\u20101. These developmental changes in HNK\u20101 epitope expression suggest that an evolution\u2010conserved mechanism involves the development of the central nervous system in the chicken brain. Microsc. Res. Tech. 51:231\u2013238, 2000. \u00a9 2000 Wiley\u2010Liss, Inc.<EOD> Effect of oral vitamin A supplementation on mortality: a subgroup meta-analysis of randomized controlled trials.\nOBJECTIVE\nTo determine the effect of oral vitamin A supplementation on all-cause mortality during the extended supplementation phase among individuals with and without measles at the initial placebo-controlled phase.\n\n\nMETHODS\nThe PubMed, Cochrane Central, and EMBASE databases were searched up to 2013 for randomized controlled trials (RCTs) that assessed the effect of oral vitamin A supplement",
        "label": 0
    },
    "2091": {
        "output": "## [/Trial]\nYour trial's inclusion criteria are here:\n- Age of 18 years or above\n- The first patient's blood glucose is 100 mg/dl (not higher than 99 mg/dl or lower than 100 mg/dl)\n- The second patient has high-density lipoprotein (HDL) over 40 and total cholesterol (TC) less than 200 mg/dl\n- The third patient is female and older than 55 years old\n- The fourth patient's HbA1c is 6.5%\n- The fifth patient has TG equal to 140 mg/dl or over and LDL equal to 125 mg/dl or over\n- The sixth patient has all the mentioned criteria\n```\n0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0\n```\n## [/EXCLUSION]\nLet's check the first trial's exclusion criteria:\n- Patient's fasting blood glucose (FBG) is 120 mg/dl or higher\n- Patients' systolic blood pressure (SBP) is 140 mm Hg or higher\n- Patients' diastolic blood pressure (DBP) is 90 mm Hg or higher\n- Patients weighing more than",
        "label": 0
    },
    "2092": {
        "output": "In the trial description section, you may want to add the number of participants that are expected to be eligible for the trial as `expected number of participants evaluated for eligibility: 13`.\n\n# Exercise Files\nThe code and output of the exercise are provided on the Learn page with the [<Exercise ID>](https://doi.org/${exerciseId}).\n\n# Further Reading\nThe following references include more explanations on trial design and analysis. \n\n## Design of Cancer Clinical Trials 2010\nB.M. Dodd, B.F. Smith, and R.M. Zalcman\nPublished by National Cancer Institute\n\n## Statistics in medicine 2006\nW.C. McQuade.\nPublished by John Wiley & Sons.\n\n## Handbook for Data Centres of Clinical Trials of Cancer 2006\nL.R. Schumacher (editor).\nPublished by International Agency for Research on Cancer and Cancer Research UK.\n<EOD> .\nThe influence of inhalation anesthetics (enflurane, isoflurane, and halothane) on the rate of blood pressure rise and on the changes of systemic and cerebral circulation in intact animals and in animals with cerebral edema induced by acute arterial hypertension was studied. The degree of the influence of the anesthetics on the parameters of circulation was estimated through the changes of the pressure index and of the cardiac coefficient in relation to blood pressure level.<EOD> .\nProgesterone and estradiol serum level changes and reproductive organ growth were studied in estradiol benzoate-primed female pigs exposed to photoperiodically active (L:D = 16:8; LL; DL:D = 10:14, 8:24 and 3:14) and photoderivational (L:D = 16:8, 8:24). It is established that in spite of different course of growth of the reproductive organs photoperiodic variation is not expressed in progesterone serum level and does not influence the changes of its concentration in female boar at first days following the",
        "label": 0
    },
    "2093": {
        "output": "<EOD> .\nBACKGROUND\nThe use of antibiotics in patients hospitalized in the intensive care unit (ICU) is associated with high costs and adverse outcomes. The objective of this study was to evaluate the quality of the use of these drugs in patients hospitalized in the ICU.\n\n\nMETHODS\nA prospective single-center study was done including patients in the ICU from 2004 to 2009. Data collected from electronic medical records included demographic, clinical diagnoses, and pharmacoeconomic variables (total cost of antibiotic therapy, total cost of antibiotic therapy excluding intravenous administration, and total cost of hospitalization). An external observer reviewed the use of antibiotics throughout the hospitalization period.\n\n\nRESULTS\nIn the 271 included patients, the hospital mortality rate was 30% and the antibiotic prescription was 47%. The antibiotic days of therapy, costs, and daily cost were statistically higher in hospitalized patients who received antibiotics than in those who did not receive them (p<0.0001). The cost of the entire hospitalization was 35.7% higher in patients who received antibiotic therapy (9,039.10 USD vs. 6,563.60 USD; p<0.0001). The analysis of the type of antibiotic used showed that the type of antibiotic did not affect the cost of hospitalization. The hospital budget impact was 253,949 USD. The 28-day mortality rate did not differ between patients who received antibiotics and those who did not . Multivariate logistic regression revealed that receiving antibiotics (p<0.0001; odds ratio: 24.7; confidence interval: 13.5-44.9) and mechanical ventilation (p<0.0001; odds ratio: 30.1; confidence interval: 8.5-96.5) were associated with higher mortality.\n\n\nCONCLUSIONS\nThe quality of the use of antibiotics in critically ill patients was uns",
        "label": 0
    },
    "2094": {
        "output": "<EOD> A simple method for measurement of the torsional refractive power of eyes.\nSUMMARY In the present study, a simple method for measuring the torsional refractive power of the eye is discussed. A spectacle plane is made slightly concave and an ordinary lens-meter is used. In addition, a 0\u00b0 model plane and a +60\u00b0 model plane are employed to show the accuracy and reproducibility of the results. It is considered that the present method is a simple and convenient system for use in the ophthalmic field.<EOD> Effect of the antiinflammatory agent sodium salicylate on the expression of alpha (2u)- and beta-enolase.\nSodium salicylate, an antiinflammatory drug, has multiple pharmacologic effects and its biochemical activity is not well known. Previously, we demonstrated that sodium salicylate interferes with the inflammation induced by carrageenan by decreasing the levels of nitric oxide and prostaglandin E2. The present study investigated the molecular action of sodium salicylate on the gene expression and protein levels of the muscle and nervous tissue isoforms of the enolases in rats. The results show that sodium salicylate decreases the levels of mRNA for alpha (2u)- and beta-enolase, the major brain and testical isoforms of the enzyme, respectively. In addition, the levels of the corresponding proteins are also decreased in response to sodium salicylate treatment. Such findings provide insight into the mode of action on molecular level of an antiinflammatory drug.<EOD> ROS1 and HER2 amplification in lung adenocarcinoma may represent distinct subtypes.\nIn recent years, the characterisation of alternative oncogenic drivers in lung adenocarcinoma have led to important insights into molecular oncogenesis. The recently discovered ROS1 amplification/overexpression is reported to occur in a subset of lung adenocarcinomas, and ROS1 rearrangement drives oncogenesis and contributes to disease progression in lung adenocarcinoma. HER2 amplification and overexpression have been demonstrated in lung adenocarcin",
        "label": 0
    },
    "2095": {
        "output": "* **A Trial-level eligibility of 2 means that the patient is fully eligible for the study because the patient's inclusion criteria are exactly matched with the inclusion criteria of the study. On the other hand, a Trial-level eligibility of 0 means that the patient is not eligible for the study because the patient is not matched with the exclusion criteria of the study. The Trial-level eligibility of 1 means that the patient is fully matched with the exclusion criteria of the study, but the patient's inclusion criteria are not matched with the inclusion criteria of the study. The Trial-level eligibility of 1 means that the patient is an intermediate case between eligibility and exclusion; the patient should be categorized as 1 (eligible but not fully eligible), depending on what happens next in the program logic. By default, the program logic expects that a patient is fully eligible. Therefore, the program logic should not be confused with a clinician's intuition. To make a decision easily on the screen, it is usually a good idea to print out the full information of a patient and see whether the patient can be actually admitted to the study or not, then make a decision with your intuition and the program logic in mind. [INST]\n\nIf you want to skip one of this program logic, press `f` to move to the next program logic or return to the last program logic. For example, if you are in the `Trial-level eligibility` program logic and you want to print out the diabetes information of the patient, press `f` to move to the `Diabetes summary` program logic. Once you get to the `Diabetes summary` program logic, press `f` to go back to the Trial-level eligibility program logic. If you press `i` when in the `Trial-level eligibility` program logic, press `a` and `l` at the same time to move to the `Appendix L` program logic, then enter your decision as `Fully ineligible = 3:` on the screen. Note that in the appendix section the `FULLY INELIGIBLE` option is not listed. Instead, you should select the `FULLY INELIGIBLE = 0 (no problem with el",
        "label": 0
    },
    "2096": {
        "output": "*\n\n*What are your clinical trial management tips?\n\n*Did you encounter any hurdles while developing your clinical trial management apps?<EOD> .\nINTRODUCTION\nSince the appearance of the COVID-19 pandemic, health professionals worldwide have reported a marked rise in symptoms associated with stress and exhaustion due to the psychological impact of dealing with the health crisis.\n\n\nAIM\nIdentify, based on the experience of physicians in Primary Care, the factors that contribute to increasing stress and burnout among health personnel.\n\n\nSUBJECTS AND METHODS\nQualitative research based on narratives. Nine primary health physicians in the Community of Madrid, were selected after applying criteria of maximum variation, and a focus group study was conducted on their personal narrative. Thematic analysis was carried out and the study was carried out in accordance with the Consolidated Criteria for Reporting Qualitative Research (COREQ).\n\n\nRESULTS\nThe main stressors identified are: (1) health system pressure: high number of patients during the peaks, difficulties to reconcile the two care settings, overload of patients in an emergency, inadequacy of the computerized medical records, lack of resources; (2) patient pressure: complaints about long waits, dissatisfaction with the management of the care team, and (3) job pressure: fear of becoming ill and infecting the family and health team, fear of making serious mistakes that could result in legal prosecution, and (4) affective pressure: feelings of fear, frustration and anger were identified.\n\n\nCONCLUSIONS\nAll health professionals should be supported and trained to deal with psychosocial impacts of the health crisis. More studies are needed to identify how this has affected Primary Care staff in other regions and other types of facilities and to implement evidence-based interventions for burnout and distress in health professionals.\n\n\nCLINICAL REHABILITATION IMPACT\nIt is important to study the emotional impact that health staff have faced in recent months of COVID-19 pandemic, as it seems advisable that all the professionals who participated in the fight against COVID-19 to be identified and to be studied in the short term, to develop preventive and protective measures to reduce the risk of burnout in",
        "label": 0
    },
    "2097": {
        "output": "# Expected results\nYou should receive the same results as in the table below: \uf0b7 Eligible=0: Inadequate age, sex, exclusion criteria and no age (72).\n\uf0b7 Excluded=1: Inadequate sex, exclusion criteria and no previous antidepressant treatment (8).\n\uf0b7 Not relevant=2: Age is above 40 and exclusion criteria 1-6 apply (121).\n\n# Discussion\n\n# Conclusion\nThe conclusion and discussion section may appear after the abstract, the introduction, or the methods section. The conclusion highlights the results of your analysis, the significance of the study, and what it means for future research and/or clinical practice. The discussion should focus more on what the results mean, their potential limitations, and the clinical implications. For the sake of organization and flow, the discussion can appear in the order in which these sections appear in the paper, i.e. after the results and/or the methods. \uf0b7 Eligible=0: Age < 72 and exclusion criteria and no previous antidepressant treatment (120).\n\uf0b7 Excluded=1: Inadequate drug therapy (119).\n\uf0b7 Not relevant=2: No previous antidepressant treatment and adequate age and no previous benzodiazepine therapy (115).\n\n# Introduction\n\n# Introduction\nNow is the time you should try your best to learn the clinical trial. So learn it carefully with the help of physicians and review articles. If you have any concern about the clinical trial, then find the answer in the help session. Be aware of the purpose of trials and how they work. Include the background information on the study disease, previous trials, and information that shows why the new trial is important. Be sure to include details about the purpose of the trial, study design (e.g., type of study, sample size and randomization to groups), settings, participants, interventions, outcomes, methodology, and statistical analysis plan.\n\n# Methods\n\n# Methods\nGive a detailed description of everything under the Methods section. If possible, show the source code used to write your SAS program. If not, then provide detailed instructions to create the SAS",
        "label": 0
    },
    "2098": {
        "output": "In the third column of the patient note, you already determined if the patient's inclusion criteria match. If the patient satisfies all of the inclusion and exclusion criteria, then we can check the eligibility in the patient note. If a patient's note satisfies all the inclusion criteria and none of the exclusion criteria, the patient is deemed eligible. If the patient is not in the eligible group, you should make a comment on the patient note of why the patient is excluded.\n[INST]\n\n#### HELP\n\n![INST_01](../../images/help_figure.png)\n\nThis help text is written in a Markdown syntax and can be edited in the user's web browser using the Markdown editor below (note: The editor has been modified to reflect the particular code language used in this document).\n\n\n```\n# Welcome to the instruction and tutorial\n\n```\n\nIf you want to test your knowledge in the instruction and tutorial, then you can read the test questions below. \n\n[INST_01]\n\n### 1. What are some of the patient eligibility criteria (inclusion criteria, exclusion criteria)?\n\n### 2. How should we use the help text in the R-SHIELD system?\n\n### 3. What will be measured using a non-invasive measure of endothelial vasodilation?\n\n### 4. Which clinical trial did this help text refer to?\n\n### 5. What is the main aim of this clinical trial?\n\n[INST_01]\n\n\n\n\n\n\n### 1. In the eligibility module, what is the purpose of the first question that allows the user to access a patient note?\n\n```txt\nTrial-level eligibility for [patient name]: ?\n```\n\nThis question lets the user select the type of eligibility, which is the first column of table 'Eligibility' in the eligibility module. Only if there is a single possible choice for a trial-level eligibility in the 'Eligibility' table, the user can skip the question using `Easy access` input modality.\n\nIf the trial-level eligibility is '0) Excluded (patient meets inclusion criteria, but is excluded on the",
        "label": 0
    },
    "2099": {
        "output": "<EOD> .\nOBJECTIVE\nTo observe and evaluate the therapeutic effect on lumbar disc prolapse with different needling depths of the traditional Chinese medicine (TCM) acupuncture method based on the meridian theory.\n\n\nMETHODS\nSixty-seven patients with lumbar disc prolapse were assigned to different groups depending on the needling depth. In the upper-layer needling group, needling was performed at a depth of 5 mm under the subcutaneous connective tissue, 18 cases, with acupoints including Zhongzhu, Shenshu and Pishu; in the lower-layer needling group, needling was performed at a depth of 30 mm and with acupoints including Zhongzhu, Chakuo, Mingmen, Bazhen, Shenshu and Pishu. In the control group, needling did not penetrate the subcutaneous tissue with acupoints including Bazhen, Shenshu, Pishu, Shenshuzhong, Chakuo and Pishu. Needling was given once everyday in the first two weeks of treatment, and then twice in the 3rd week and once again in the 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th and 13th weeks. The primary endpoint was the effective rate of the TCM symptom scores after 6 months of treatment; the secondary endpoint was the effective rate after 6 treatments.\n\n\nRESULTS\nThe effective rate in the upper-layer needling group, the lower-layer needling group, and the control group was 50% (24/48), 50% (24/48) and 17% (8/47) (P<0.05, P<0.05) after 6 months of treatment,100% (48/48), 100% (48/48) and 93% (44/47) (P<0.01, P<0.01),respectively after 6 treatments. After 6 treatments, the curative rate in the upper-layer need",
        "label": 0
    },
    "2100": {
        "output": "[EXERCISEN] \n<EOD> Synthesis of \u03c0-extended poly(2-oxazoline)s based on aromatic monomers or cross-linked polymers via ring-opening metathesis polymerization\n\nThe synthesis of aromatic poly(2-oxazoline)s (AROPXOs) based on 2-heteroaryl oxazoline monomers was implemented using modified Scholl oxidation as the coupling method. In order to further expand the backbone structures, 2-aryloxyaryl monomers bearing three oxazoline rings undergo efficient regioselective aromatic ring-opening metathesis polymerization (ROMP) to afford a family of \u03c0-extended AROPXOs. In addition, a new 2-heteroaryl oxazoline monomer containing one \u03b2-propyl vinyl ether and two phenyl oxazoline rings was synthesized and converted to various \u03c0-extended ROMP copolymers. The ROMP reactions of aryl-oxy-aryloxy oxazoline monomers are highly efficient to afford high molecular weight polymers with well-controlled chain architecture in high yields. All the obtained AROPXO polymers and ROMP copolymers were well characterized by elemental analysis, nuclear magnetic resonance, gel permeation chromatography, thermogravimetric analysis, X-ray diffraction, UV-vis absorption spectra, and fluorescence spectra. The effects of polymerization method, aromatic ring size, and fluorine substitution on the backbone skeletons of AROPXOs on the thermal stability and solubility of the resulting \u03c0-extended poly(2-oxazoline)s were considered.\n\n# Introduction\nPolyestersare widely used in many fields and applications, such as plastics, membranes, elastomers, resins, coatings for metal surfaces, and adhesives to name a few fields. The synthesis and properties of polyester oligomers are of great interest to researchers. Polyester oligomers have many advantages because of the large structural diversity, the high biocompatibility of polyester, and the easy synthesis",
        "label": 0
    },
    "2101": {
        "output": "Your task is finished. \n\n\n## \u00a9 Copyright (c) The University of Tokyo\n\n## [exercise14 ]\n\nYou should make a trial-level eligibility on each patient for the clinical trial, I.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and dihydrotachysterol. His past medical history is not significant for any other medical issues.\nHis family history is non-significant. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl He is suffering from depression and he is prescribed sertraline for the last month as well as an exercise program.\nHere is the clinical trial: \nTitle: The Mitochondrial Biology in Human Platelet: A Potential Biomarker of Insulin Resistance Protocol:\nThis is a cross-sectional investigation in a small research sample to determine and characterize the mitochondrial proteome. To do this, we will collect blood samples from normal control and subjects who either have insulin resistance or diabetes. These collected blood samples will then be centrifuged to separate the platelet and red blood cells, which will be then centrifuged and used for platelet and blood RNA. Platelets should be stored at -80oC. RNA will be reverse transcribed first in cDNA to be used for microarray experiments at NIH using the Affymetrix platform. These",
        "label": 0
    },
    "2102": {
        "output": "[INST] Existing trials in R:\nInstead of constructing each trial from scratch in every file, use the available libraries and functions to do that. The trial list is saved in `data/trials` which is saved in `data/trials.json`. Each line is separated with `nL` characters, where `n` is the patient number and `L` is the eligibility. Here is the sample data that you can use:\ntrials = read. text(\"data/trials.json\")\nThe content of `trials` is a nested list, where each level has been prepared by `for` to be readable and the `else` condition is considered:\ntrials = Map(function(line) line.split(nL), trials$[!is.na(substr(line, 1, 5))])\nThe `is.na` function checks if the first character is a digit. When `trials` is nested in `data/data.json`, `for` and `map` will not be executed. For more details, see the `datagen` section.\n\nAs you could see, `n` is assigned after 8 digits, indicating the corresponding number of patients. 8 digits are not enough to differentiate between any patients. To have a unique number for every patient, `unique_id` parameter is defined when generating patient notes.  It will then be appended to the code generated in `datafile.R`. You can define a unique code from 1 to 100, for example, to distinguish 100 patients:\ndata(\"datagen\") g = datagen(\"Cystic Fibrosis\") g$unique_id=1:100\nThe `unique_id` parameter is saved as a nested list, where each element is assigned to a patient. `g$unique_id[1]` is assigned to `g[1, \"unique_id\"]` element. All the elements of type character are saved in this list. Because `character` value is converted to ASCII character in R, it should be converted back to the desired code in the `datagen` function itself. You can do that in R. It is not done automatically because the code should change according to the code given in `datagen`. When the given codes in `datagen` are unique, this assignment does not help much",
        "label": 0
    },
    "2103": {
        "output": "Note: Always use the same format to report eligibility. In addition, remember to report the patient id in eligibility and trial id in trial-level eligibility by using `patientId` and `trialId` parameters of the `report_eligibility()` function.\n\n___ \n[1]\n[2]\n[3]\n\n[8]\n[9]\n\n[10]\n[11]\n[12]\n[13]\n[14]\n\n[15]\n[16]\n\n[17]\n[18]\n\n----- \nWe tested the above steps. The final code looks like the following. Note the changes that we have made.\n\n``` r\nreport_eligibility <- function(patientId = 1, trialId = \"f6b07c62d6d0\", studyId = NA, scale = \"0\") {\n  # This is the assessment of eligibility.\n  # Eligibility has a three-point scale: 0) Excluded, 1) Not relevant, 2) Eligible\n  # If the patient meets the inclusion criteria and does not have any exclusion criteria, \n  # he is eligible for the clinical trial\n  if (repMatch(patientId, colData(d), \"patientId\") == 1) {\n    if (repMatch(colData(d) > 1, \"age\", \"male\") == 1 && colData(d) > 18) {\n      # If the patient is between 18 and 65 years old\n      if (scales[patientId] == 1) {\n        report <- c(repMatch(d$age[patientId], \"age\", \"18-65\"), \"\\n\")\n        if (scales[patientId] == 2) {\n          report <- c(report, repMatch(d$age[patientId], \"age\", \"male\"), \"\\n\")\n        }\n        report <- str_extract(report, \"/satisfies/satisfies-(\")\n        report <- c(repMatch(d$gend[patientId], \"male\"), \"\\n\")\n        report <- str_",
        "label": 0
    },
    "2104": {
        "output": "<EOD> A 2\u2010year retrospective analysis on the role of MRA in the diagnosis and management of acute ischemic lesions\u2014results, clinical implications, and perspectives\nObjectives: Using magnetic resonance angiography (MRA), we analyzed the clinical management, including therapeutic modifications, in patients with acute ischemia. Methods: Ninety\u2010seven consecutive patients with acute ischemia without previous cerebrovascular disease were included. MRA was performed within 24 hours of symptom onset, while transcranial Doppler was performed within 24 hours and computed tomography within 48 to 72 hours. Results: MRA showed a normal angiogram in 42 patients, 44 presented focal nonhemodynamically significant stenosis, whereas 11 had focal hemodynamically significant stenosis of cerebral arteries. Two additional patients had nonhemodynamically significant aneurysms. Of the 42 patients with normal MRA results, 11 were followed up because of stroke or transient ischemic attack. The risk of further attacks in that group was estimated at 16.2 years. Conclusions: These findings imply that further follow\u2010up of patients with acute ischemic lesions in a clinical setting does not seem necessary, when MRA shows a normal cerebral vascular tree. If focal nonhemodynamically significant stenosis of the intracranial vessels was observed, further MRA study should be performed after 3 to 6 months. If further evaluation of the intracranial vessels is of importance, the MRA follow\u2010up study should be started earlier, at 3 months.<EOD> Efficient Computational Model of Mismatch Repair in the E. coli DH5\u03b1 and SG1791 Strains\n\nMismatch repair (MMR) systems are involved in the repair of a wide range of DNA lesions, including one nucleotide mismatches, and insertion-deletion loops (indels), produced during replication, and are a critical component for maintaining genetic stability, particularly in bacteria. In bacteria, the MMR machinery is comprised of three proteins: MutS, MutS\u03b2 and",
        "label": 0
    },
    "2105": {
        "output": "## Summary of the Challenge\nThis challenge task evaluates the performance of the classifier using the following metrics:\n\n### Accuracy\n![Accuracy](https://github.com/ml-biostars/challenges/blob/master/docs/fig/accuracy.png?raw=true \"Accuracy\")\nAccuracy is the percentage of correctly classified samples with respect to the sample set. \n[Note](https://github.com/ml-biostars/challenges/blob/master/docs/notes/accuracy.md)\n\n### Precision\n![Precision](https://github.com/ml-biostars/challenges/blob/master/docs/fig/precision.png?raw=true \"Precision\")\nPrecision is also known as positive predictive value (PPV). It indicates the proportion of the predicted label that is true positive.\n[Note](https://github.com/ml-biostars/challenges/blob/master/docs/notes/precision.md)\n\n\n### Recall\n![Precision](https://github.com/ml-biostars/challenges/blob/master/docs/fig/recall.png?raw=true \"Precision\")\nRecall represents the completeness of training data in the sense that when the recall value is high, we can confidently predict that the label of the test instance is correct for the larger proportion of cases.\n[Note](https://github.com/ml-biostars/challenges/blob/master/docs/notes/recall.md)\n\n### F-measure\n![F-measure](https://github.com/ml-biostars/challenges/blob/master/docs/fig/f-measure.png?raw=true \"F-measure\")\nF-measure is simply an equal weighted average of precision and recall, that is the harmonic mean of precision and recall. To calculate F-measure use the formula below:\n\n**F-measure = 2*Precision*Recall/(Precision + Recall)**\n\n### ROC\n![ROC](https://github.com/ml-biostars/challenges/blob/master/",
        "label": 2
    },
    "2106": {
        "output": "[EXP]\n\n[EXP] Excerise 1: Choose one of the following to fill the empty slot:\n\n`#1` _____________ is a disease caused by the accumulation of insoluble AGE (advanced glycation end products) in the body and leads to the development of atherothrombosis which is a cause of cardiovascular diseases.\n\n`#2` A significant increase in age-adjusted _____________ has been observed in some countries over the past 20 years.\n\n`#3` ______________ is used in the treatment of renal dysfunction with reduced glomerular and tubular function and decreased plasma protein synthesis.\n\n`#4` _______________ is usually related to the administration of the drug and can be treated effectively with glucose, insulin, or the drug itself.\n\n`#5` _____________ is not a disease but a symptom related to the effect of the nephrotic syndrome and can be treated effectively with diet control.\n\n`#6` _____________ is not a cause of cardiovascular diseases so patients do not need to be monitored when taking the drug, as it normally does not cause any adverse events.\n\n`#7` _____________ is not a rare disorder that causes the same degree of renal failure as other nephrotic syndromes.\n\n`#8` ______________ is a rare disorder and will not interact with other drugs unless the patient has a previous history of allergies to drugs.\n\n#### Notes:\n```\n1. Please insert the explanation of the option.\n2. Please choose the one which can explain the topic of the option.\n3. Please choose the one to answer the question.\n4. Please choose the one which can explain the purpose of the option.\n5. Please choose the one which can treat the symptom.\n6. Please choose the one which can be monitored.\n7. Please choose the one which is not related to the option.\n8. Please choose the one which is not a rare disease.\n9. Please choose the one which is not an allergy.\n```\n## Excerise 2: Choose one of the following to fill the empty slot:",
        "label": 0
    },
    "2107": {
        "output": "## Example:\nTrial-level eligibility: 2) Eligible. ----->  0) Not excluded ----->  0) Excluded\n<EOD> .\nTuberculous intestinal disease frequently results from intra-abdominal seeding of miliary tuberculosis in the subserous intestinal adipose tissue. This type of tuberculosis is exceptional and occurs only in very sensitive patients. Certain clinical syndromes, such as unspecific abdominal pain or severe intestinal obstruction, could lead to the suspicion of this disease. The pathology is characteristic, with large epithelioid and giant cells with necrosis of the intestine. The diagnosis is confirmed at laparoscopy, by biopsies of all the intestinal loops, and by mycobacteriological and histopathological examinations (G.E.L., PCR). The prognosis is serious, with a high mortality rate and a high relapse rate when medical treatment is used instead of an aggressive therapy with multiple antituberculous drugs. When diagnosed early, ileocecal resection with mesenteric lymph node resection could be proposed, followed by medical treatment with the same drugs for one year.<EOD> Inhibition of FGF8 signaling reveals its role in growth of hind limb buds with and without preaxial HoxD genes.\nDuring development, Hox genes specify the positional identity of tissues in the vertebrate limb. In HoxD-expressing limbs, Hoxd13 is responsible for position identity, while Hoxa12 and Hoxd12 specify the position of the zeugopod. Hoxa11 is not expressed in HoxD-expressing limbs but is expressed throughout the autopod in HoxA-expressing limbs. Thus, the presence of the preaxial Hox genes is necessary, but not sufficient, to specify the position identity of the developing limb. Here, we study the function of Fgf8 in the development of mouse and chicken hind limb buds by inhibiting Fgf8 function with the cDNA-based transgene Fgfr2bY",
        "label": 0
    },
    "2108": {
        "output": "### Clinical Trial #2 ###\n\n[GEN] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl TG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dlHere is the clinical trial: Title: Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type",
        "label": 0
    },
    "2109": {
        "output": "_Suggestion:_ The patient has been eligible with ACE inhibitor. Try to search the paper in PubMed for more information.\n\n## [POST] CORRECT, IF NECESSARY, THE MINIMAL CLINICAL TRIAL DATA SET (MCTD) \nIn clinical trials, patient data should be summarized and presented as a standard summary statistics based on the following data analysis plan:\n\n## Data analysis approach\n\nAggregate data analysis\n\nDetailed data analysis based on different scenarios\n\nEach of the above analysis plans is further subdivided into different analyses. Each of these analyses has its own data collection and reporting elements. Some of the data collection elements in the analysis plans have been specified for the MCTD. Therefore, the authors in the paper must check whether the patient data includes all the data collection elements specified in the MCTD for each of the analysis plans. The analysis plans are given below:\n\n1. Descriptive data analysis\n\n1.1 Descriptive statistics\n\n1.2 Descriptive data plots \n1.3 Descriptive data tables \n1.4 Qualitative descriptive data \n1.5 Adverse events (AEs)\n\n2. Statistical hypothesis testing\n\n2.1 Hypothesis testing with one group (one parameter) \n2.2 Hypothesis testing with two groups (two parameters) \n\n3. Statistical hypothesis testing (an option)\n\n3.1 Hypothesis testing with one group (one parameter) \n3.2 Hypothesis testing with two groups (two parameters). \nYou should extract the requested data element under each of the above analysis plans or the analysis plan that the authors used in the trial they submitted. The data elements specific to the case are given below:\n\n`Data Analysis Plan \n\nAnalysis Plan Number                       Data Collection Elements in the Analysis Plan\n\n1. Descriptive data analysis\n\n1. `Descriptive statistics [DATA_5]`\n1. `Descriptive data plots [DATA_6]`\n1. `Descriptive data tables [DATA_7]`\n1. `Qualitative descriptive data [DATA_8]`\n1. `Adverse events (AEs) in the clinical trial (yes/no and description)] [",
        "label": 0
    },
    "2110": {
        "output": "## Exclude trial-level exclusions\nNow, it is time to check the trial-level exclusions. Let us look at the eligibility criteria from the clinical trial: \nInclusion criteria: \n\nExclusion criteria: \nSmoking more than 10 cigarettes per day\nPrevious percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\nPrevious intake of rosuvastatin 10 mg daily, rosuvastatin 20 mg daily, fenofibrate, or gemfibrozil.\n\nSmoking more than 10 cigarettes per day is a clinically significant drug administration-related exclusion criterion that has been described in the package inserts of both rosuvastatin and fenofibrate.\n\nHence, you should not choose `Eligible` because the patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria. As a result, this is:\n\n\n# Results\n\nIt is very important at this state to understand the criteria of the trial's exclusion criteria for all patients enrolled in each clinical trial as the same as possible to make a decision on which medication to prescribe to the patients.\nFinally, there are three sets of eligibility criteria to the clinical trial, i.e., patient level, trial level, and exclusion criteria. For each clinical trial, the eligibility criteria must be consistent. If not, the clinical trial should not proceed. For example, you see that the following patients meet the trial's inclusion criteria:\n\n| 25-year-old man with type 1 diabetes (Hemoglobin A1C is above 6.5%\n|  |  | in any trial).\n\nHowever, the following patients do not meet a trial's exclusion criteria:\n\n| Smoking more than 10 cigarettes per day\n|  |  | in any trial.\n\n\n##| 65-year-old man with type 2 diabetes (Hemoglobin A1C is above 6.5% in trial).\n\n\n### Criteria for Treatment\n\nA clinical trial would provide",
        "label": 0
    },
    "2111": {
        "output": "(1) Assessment of eligibility \n[CODE/INDENT]The patient is a 25-year-old man with type 1 diabetes confirmed with molecular 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild 32 dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His 33 takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for \n34 DM type 1 in his uncle and his grandfather. His lab study is as bellow:Finally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible.` [END INDENT]<EOD> 3H\u2010Thymidine and 35S\u2010methionine incorporation studies on proliferation of cultured mesangial cells derived from human cadaveric kidney\nRenal cell proliferation has been linked to the pathogenesis of diabetic and hypertensive nephropathies. This link has been difficult to establish due to the lack of available cell culture systems. The present study was designed to develop a serum\u2010free culture system for mesangial cells from normal human kidneys and to demonstrate its suitability for proliferation studies. Growth of mesangial cells began by about day 7 in culture and reached confluency by 30 days with maximum cell numbers of 3.1\u20133.7 \u00d7 105. Serial passages were obtained when confluent mesangial cell monolayers were removed by trypsin dissociation. Proliferation rates of cultured mesangial cells, estimated as the increase in cell number per day, were similar to other cell lines. Cell cycle parameters were analyzed using thymidine suicide labeling and 35S\u2010methionine pulse\u2010chase studies. Mes",
        "label": 0
    },
    "2112": {
        "output": "## [INST] Example\nYou are to test the `Trial-level eligibility` function. \n[INST] You can try the following sample code: \n```Python\nfrom nn4s.clinical.ml import Trial_level_eligibility\nfrom nn4s.clinical.ml import Clinical_dataset\nfrom nn4s.clinical.ml import Clinical_note\n\nclinical_note = Clinical_note.from_fhir(\n    \"Patient:00004936\", \"Patient:00004936\")\ntrial_name = \"Clinical Trial 19\"\ntrial_data = Clinical_dataset.from_fhir(\n    \"Clinical Trial 19:Patient-00004936\", \"Patient-00004936\"))\n\ntrial_level_eligibility = Trial_level_eligibility.from_fhir(trial_name, trial_data)\nprint(trial_level_eligibility)\n```\n<EOD> Effects of an individualized music listening program in an emergency care unit: a quasi-experimental study.\nAIM\nThe aim of this study was to analyze the effects of an individualized music listening program on depression, anxiety, pain, sleep quality, and use of analgesics.\n\n\nBACKGROUND\nAcute and chronic pain are frequent problems in the hospitalization process. In the pre-operative period, analgesia and sleep adequacy are recommended to achieve the most satisfactory possible recovery, thereby promoting an earlier discharge. In order to achieve these objectives, non-pharmacological methods have been considered a complementary source available for these patients.\n\n\nDESIGN\nA quasi-experimental study to examine the effects of the individualized music listening program on 60 clinical patients.\n\n\nMETHOD\nData were collected in an emergency hospital in S\u00e3o Paulo. The mean age of the volunteers was 53\u00b77 years. The intervention lasted 15 days, divided into two phases: baseline and intervention. Each patient received an audio file with recorded",
        "label": 0
    },
    "2113": {
        "output": "## The test suite\nTo pass the test suite, your solution should pass all test cases from the test suite, i.e., both the unit and integration tests. The tests expect the output to be as in:\n``Excluded``\n```python\n    print(\"Excluded\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n   print(2) \n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Eligible\")\n```\n```python\n   print(\"Eligible\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n   print(2) \n```\n```python\n    print(\"Eligible\")\n```\n```python\n   print(\"Eligible\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n   print(\"Eligible\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n    print(\"Eligible\")\n```\n```python\n    print(\"Eligible\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n   print(\"Eligible\")\n```\n```python\n    print(\"Excluded\")\n```\n```python\n    print(\"Not relevant\")\n```\n```python\n   print(\"Eligible\")\n```\n[INST]\n\n## Submission\nSubmit your solution to the form at [the test submission page](/exams/test_submission_form/). The file must be a single Python source file, named <solution_for_task_name>.py.\nDo *NOT* insert an empty line between the `def __main__` function from the source code and the start of the main() function.\nCheck out our [Submissions Guide](/about/submissions_guide",
        "label": 0
    },
    "2114": {
        "output": "Now for the second patient, see his note:\nThe patient is a 65-year-old man with type 2 diabetes diagnosed 4 years ago with HbA1c ranging from 6.8-7.2% in the past 1 year. He complained of shortness of breath and fatigue for 2 months. He takes 70/30 Insulin, Glimepiride and metformin. He also takes atorvastatin 40 mg QD. He did not smoke. He drank wine about 3 to 4 times a week, about 20 units a times. His family history is positive for DM type 2 in his grandfather and uncle. His lab study is as bellow:\nFBS: 120 mg/dl\nHbA1c: 6.8%\nCholesterol: 150 mg/dl\nTG: 140 mg/dl\nLDL: 90 mg/dl\nHDL: 55 mg/dlHere is the clinical trial: \nTitle: A Study of Becatecarb to Improve Cardiovascular Outcomes in Patients With Stable Atherosclerotic Cardiovascular Disease\n\nPurpose: The aim of this study was to assess the safety and efficacy of becatradecarb when administered in a dose escalation design to patients with stable atherosclerotic cardiovascular diseases.\n\nStudy design: This is a prospective, randomized, double-blind, placebocontrolled multicenter phase III safety study.\n\nEligibility criteria: 440 patients were randomized to one of the three treatment sequences (1:1:1): a) 40 mg becatradecarb, b) 120 mg becatradecarb, or c) matching placebo. Randomization was based on a randomization list generated by using the minimization method. The two-stage seamless design was used during the double-blind treatment period and for the subsequent safety follow-up visit at week 12. During double-blind treatment, patients were divided into three treatment groups: (1) 40 mg",
        "label": 0
    },
    "2115": {
        "output": "1. You can look at a single patient by inputting a single number after the variable name with the number of the patient, e.g., `Disease: 1` indicates the disease of patient number 1 \nNote: You must look at each patient individually to find the eligibility of the patient for the trial. \n2. If the patient is over the age of 18, input 1 after `Age: `, e.g., `Age: 1`. \n3. If the patient is male, input 1 after `Gender: `, e.g., `Gender: 1`. \n\nIf the patient has received a diabetes treatment, input 1 after `Diabetes: `, e.g., `Diabetes: 1`. \n6. If the patient is diagnosed with cardiomyopathy, input 1 after `Cardiomyopathy: `, e.g., `Cardiomyopathy: 1`. \n7. If you encounter any other patient data that matches with the patient trial notes, you should input 1, e.g., if the patient has a positive family history, you must input 1 after the respective variable name, e.g., `Family history: 1`. \n\n![](https://static8.finatraining.com/cdnfiles/e4dfadba-c77f-4d4f-ac14-d45503f71a27/training_media-jupyter_notebook_7768723149872416047.jpeg)\n\n8. After completing the above steps, input `Drug response: 2) Potential` to indicate potencial side effects. \n9. Now, input `Drug response: 2) Potential (no drug)` to indicate the patient might not need drug treatment. \n\n\n\n10. If the patient needs medication, e.g., ACE inhibitors and Beta blockers, input 0 into the corresponding variable (depending on the kind of medication). Since they are a combination of medications, the patient should be inputted 2 into the variable called `Drug response: 2) Combined` as they are taking",
        "label": 0
    },
    "2116": {
        "output": "<EOD> Falls due to postural disturbances in elderly people.\nTo test differences in physiological measures that discriminate between 'at risk' and 'fit' people we measured postural variables in 10 elderly people while they lay unsupported for ten minutes.<EOD> The effect of cimetidine on glucose disposal assessed by glucose clamp technique in man. A preliminary report\nA possible effect of cimetidine on insulin\u2010mediated glucose disposal was studied in 13 healthy male subjects. After an overnight fast, the subject was given a glucose load to raise plasma glucose to pre\u2010determined target level for 45 min, after which exogenous insulin (1 mU min\u22121 kg\u22121) was infused to raise plasma glucose to a new target level. Clamp was terminated after one hour. A group of 6 received cimetidine, 1 gm intravenously, 15 min prior to insulin infusion. Plasma levels of C\u2010peptide, free fatty acids, and ketone bodies were not different before and after the administration of cimetidine. Although plasma free insulin rose during insulin infusion, glucose disposal was not significantly changed by cimetidine.<EOD> Examining the relationship between sleep disturbance, fatigue, neurocognition, mood, and brain-derived neurotrophic factor after stroke\n\nIntroduction: Sleep disturbance in people with stroke can have devastating consequences for quality of life, functional recovery, and brain regeneration. We examined associations among sleep disturbance, neurocognition, fatigue, mood, and neurotrophic factor after stroke. Methods: In a longitudinal design, 48 survivors of stroke received assessments of sleep disturbance (AIS), fatigue (FSS), neurocognition (DCS), mood (POMS), daily function (FS-162), and brain-derived neurotrophic factor (BDNF) at three time points (Time 1, 2, and 4). Multiple regression analyses and canonical correlational analyses were performed to examine if AIS was associated with DCS and F",
        "label": 0
    },
    "2117": {
        "output": "`^1` Trial eligibility was computed by the same user who has performed the manual trial eligibility, as described in the next section. [30] `^1` Trial-level eligibility is derived from the output of the trial screening module (see above).[31] \n\n\n[INST]\n\nPlease run it by following these steps:\n\n1. Open _this_ file and run each of the following commands in the terminal. Make sure to give each of the following commands your full attention and follow instructions meticulously.\n\n    `R --vanilla --qs train`\n\n    `R --vanilla --qs train.csv <-train.csv`\n\n    `R --vanilla --qs test`\n\n    `R --vanilla --qs test.csv <-test.csv`\n\n    `R --vanilla --qs test.csv <-train.csv` (make sure you have the same _filename_.)\n\n\t`R --vanilla --qs train --plot 1 --test --plot 2`\n\n2. Go to the directory `results` and open the file _`results/evaluation.html`.\n\nIn order to obtain a similar performance of trial eligibility, one should follow these steps:\n\n\n* 1. Follow the first, second and fourth instructions below in the previous step.\n* 2. Please perform the following training. The input file should be in the format of `Trial_number.csv`, e.g., Trial_1.csv.\n\n    In this file, the following data fields are recommended, if available:\n\n    - Trial number\n    - Trial name\n    - Differentiation of patients by eligibility (i.e., if the patient is eligible or ineligible)\n\n    Please note that the first 2 columns represent the unique codes for subjects.\n\n    1. Run `train_data.R <--train_data.T<r` by the user.\n    2. Load package `h2o`.[32]\n    3. Load dataset `TrialData <--train.T<r`.\n    4. Specify the random seed to be used for the experiment (`set.seed(0)`, e.g., for reproducib",
        "label": 0
    },
    "2118": {
        "output": "<EOD> An overview of the diagnostic challenges of childhood tuberculosis.\nTuberculosis in pediatric patients is a serious problem in developing countries including Thailand. In most cases, a clinical diagnosis or clinical suspicion is not difficult to make, but in some cases it may be difficult to distinguish tuberculosis from other diseases. We present a 4-month old who developed tuberculous meningitis (TBM) and concomitant miliary tuberculosis (MTB). In this case it was necessary to rule out a neoplastic or infectious disease and to obtain a cerebrospinal fluid (CSF) gamma interferon (IFN-\u03b3) test to make an accurate diagnosis. This patient was negative for TB infection, bacterial meningitis, and all of the tumor markers for childhood cancers. However, results of a CSF gamma interferon (IFN-\u03b3) assay and lymphocyte transformation (LT) test were positive. In addition, a new-Born baby who was exposed to TB developed disseminated TB (pericardial tuberculosis and tuberculous meningoencephalitis). He responded to the standard treatment for TB but unfortunately the infant had pulmonary hemorrhage and died from acute disseminated tuberculosis (ADT) 7 weeks after initiation of antituberculosis therapy.<EOD> The association between obesity and asthma in Mexican children aged 6-13 years.\nOBJECTIVE\nTo estimate the association between overweight and obesity and asthma in children.\n\n\nMATERIALS AND METHODS\nA cross-sectional study was conducted including 1,392 children aged 6-13 years old who were randomly selected during a cross-sectional prevalence study, in the cities of Chihuahua and Monterrey, Mexico. Body mass index (BMI) was calculated using the weight (expressed in kilograms) and the height (expressed in meters) by using the BMI standardized curves for age (Kappa) and gender, based on the standard percentile of the National Center for Health Statistics of the United States (NCHS), to be",
        "label": 0
    },
    "2119": {
        "output": "- If 0 <= Clinician assessment <= 3 (which is the same as <= 2 and >2): You should print the number 2. The number 2 indicates that the patient is not relevant to the clinical trial.\nIn your patient note, you are already in the situation that the number 0 is the Clinician assessment. So you should print the number 2.\nExample:\nClinician assessment = 0\n(since the clinician assessment is 0, this indicates that the patient is excluded and is not relevant to the clinical trial; therefore the trial-level eligibility should be 2) Excluded.\n\nIn this input example, you will encounter different inputs in the clinical trial. \nInput Example: \n  [INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n  [END]\n  [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n\n![TEST OUTPUT OVERVIEW](../figure/eligibility-test-overview.png)\n\nTrial-level eligibility should print as one of three numbers between 0-2.\n<EOD> SPECTRAL ANALYSIS OF HORSERACE RACING.\nThe analysis of horse racing spectra may have several applications in handicapping. The purpose of this paper was to determine how many different spectral components must be used in order to describe the motion of a trotting horse. A 35 s sample was taken from the tape of the races at Fairmount Park Racetrack, and five trained raters used a five-point scale to",
        "label": 0
    },
    "2120": {
        "output": "[MARKDOWN]## Exercise 3: Recruitment for Cardiovascular Magnetic Resonance Imaging \n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\n\nHere is the clinical trial: \nTitle:",
        "label": 2
    },
    "2121": {
        "output": "### 2) Data Validation\n\n[INST] The data validation is where you check the correctness of data and data integrity. All data should be 100% verified. You can check data validation in the last tab of a patient Note. You can check any patient note's data validated by pressing on data validation link. \n\n### 3) Data export and Report generation\n\n\nHere are the things that you need to check in the report:\nName of the trial: \"Study of Epicutaneously Applied Ketoprofen Transfersome\u00ae Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise\"\nDate: 2020/09/21\nPatients enrolled: 139\nPatients included in analysis: 89\nPatients excluded from eligibility analysis: 50\nPatients excluded by trial: 49\nPatients excluded by age restriction: 11\nPatients excluded by gender restriction: 7\nPatients excluded by inclusion criteria: 24 \n\nThe program to be executed and inputted in the box below: \n\n### 4) Data export\nYou can export any patient's data in comma separated values file or text file format by clicking on the export button on the right side of the patient note panel .\n![4-Export](images/4.png)\n\n### 5) Deletion of Patient Note\n\n![5-Delete](images/5.png) \n\n### 6) Assistance for Error Handling\n\n![6-Error](images/6.png) \n\nHappy Programing!\n<EOD> .\nThe treatment with human growth hormone in an 18-years-old patient with lipoatrophy following a 16-years-treatment by hydrocortisone results in a weight regain, the normalisation of body fat, of visceral fat and blood lipids. The bone age increases by a normal value. It seems, that the insulin resistance, seen in many patients with lipoatrophy following the replacement therapy with glucocorticoids, is not permanently accompanied by di",
        "label": 0
    },
    "2122": {
        "output": "_\n\nThis assessment has to be submitted alongside your assignment. In case you missed it, check for the [Instructions for Submitting Assignments](https://stat747.github.io/c833-2019-syllabus/instructedocs/assignments.html).\n\nYour grade will be given according to the following scoring sheet:\n\n\n\n\n---\n\n### 1.1.8. Rules of Reverse Engineering and Data Processing\n\nRule 3.3.2 of IEEE/ANSI/ASME\n\n> (A) Before starting to process information, an observer shall not:\n>(1) use, in any manner, physical objects associated with it; or\n>(2) use, in any manner, the results of processing obtained or derived from data recorded for any purpose; or\n>(3) discuss the processing in any manner; or\n>(4) use any data in any manner or form obtained from the processing or the results of the processing (cf 110.142 and 110.143);\n\n\n# Rules for Reverse Engineering\n\n> 110.14.1\n\n\n```\n\t\"Reverse engineering\" means the process by which original equipment or products are made\n\tby reproducing or duplicating elements, features, or operating information in a different\n\tequipment or product with the intent to study, review, analyze, design, or modify the\n\tequipment or products.\n```\n\n# Rules for Reverse Engineering of Software\n\n> 110.14.2\n\n```\n\tSoftware produced through reverse engineering (either in whole or in part) is protected\n\tby Sections 102 through 120 and Chapter 7 of Title 17, United States Code (\"Copyright\n\tLa-\n\tvis\")  and by patent rights.\n```\n\nRule 3.3.2 of IEEE/ANS/ASME \n\n> IEEE/ANS/ASME, 2011\n>  3<<8) => 1503.57.1.e (Reverse engineering is subject to the provisions of Sections 102 through 120 and",
        "label": 0
    },
    "2123": {
        "output": "<EOD> A preliminary investigation of the feasibility of delivering an online lifestyle programme for young people with type 1 diabetes\nDespite the evidence that type 1 diabetes is life\u2010threatening and that there is a need to encourage life\u2010long adherence to medication and lifestyle measures, young people in the UK do not access healthcare services until they develop late effects of such as cardiovascular disease. This study investigates an online lifestyle intervention programme (LITE) designed for young people (aged 16\u201325\u2003years) with type 1 diabetes to see if adolescents and young adults with type 1 diabetes have the capacity to use interactive technology for managing their diabetes in the home, and what factors might impede or facilitate its engagement. The programme covered management of diabetes and its associated problems. A total of 20 participants (13 women, 7 men, 33\u201334 and 6\u20137 years since diagnosis) completed the programme. Participants accessed the programme independently, choosing when and where to engage. There was evidence that participants interacted with the LITE programme and found many of its elements useful. However, some of the participants also found it difficult to manage in their day to day lives, and this should be considered as a limitation of programme design and target audience. Although the study suggests that LITE has great potential in increasing the self\u2010care confidence and knowledge in type 1 diabetes in young people, the issues raised regarding the design and complexity of the programme, suggest that further refinement is needed before implementation in clinical practice.<EOD> .\nThe author emphasises the importance of pre-symptomatic diagnosis of osteoporosis, which is made available to a great extent by osteodensitometry, carried out in general practice, as well as to a minor extent with bone densitometry of the hip, of the forearm, or with scintigraphy of the vertebral bodies. These techniques would make it possible to detect the osteoporotic process at an early stage, and to provide the patient with prevention and treatment.<EOD> Cutaneous lesions of gadolinium administration: a case report of rare presentation, histological features, and review of literature\n\n\n\n# Introduction",
        "label": 0
    },
    "2124": {
        "output": "# Example of Output\n```julia\nusing CSV Input = IOBuffer; output = IOBuffer; output.writestr(\"Title\"); output.writestr(\"\\t\"); output.write([\"A\"]); output.writestr(\"\\n\"); output.writestr(\"Summary\"); output.writestr(\"\\t\"); output.write([\"Efficacy and safety of aripiprazole in first episode psychosis \\n Evaluate the efficacy and the safety of risperidone vs. aripiprazole in patients with first episode psychosis in Iranian population. \\n The aim of the study is to compare the efficacy of risperidone and aripiprazole in reducing the hospitalization days, discontinuation and switching of medications, response and relapse and comparing the safety of compounds with each other.\"]\"); output.writestr(\"\\n\");\ninput = readline(\"http://www.clinicaltrials.gov/ct2/show/NCT00861438?term=aripiprazole&rank=2\"); output.writestr(\"\\n\");\n\nfor line in splitlines(input) \n    # Inpatient\n    for s in split(line, \"\\t\")\n        # Patient note:\n        if s == \"Trial-level eligibility: \"\n            output.write(2); output.writechar(' '*2); output.write(2);\n            for s in split(read(IOUtils.file()), \"\\n\")\n                # Patient notes\n                \n                # Exclusion criteria\n                if s == \"Inclusion criteria\")\n                    for s in split(read(IOUtils.file()), \"\\n\\t\")\n                        s in [\"Age\", \"Disease\", \"Treatment History\", \"Other Medical Conditions\"]\n                        output.write(4); output.writechar(' '*4); output.write(4);\n                        output.write(s); output.writechar(' '*3); output.write(4); output.writestr(\"\\n\")\n                \n                else\n                    for s in split(read(IOUtils.file()), \"\\n\\t\")\n                        s in [\"Age\", \"Disease\", \"Treatment History\", \"Other Medical Conditions\"]\n                        output.",
        "label": 0
    },
    "2125": {
        "output": "Now, start learning about the other inputs: patient's name and ID, patient's insurance information, and the insurance company ID.\n\n### Patient's Name and ID\n\nLet's start with the patient's name and ID. These need to be specified for the system to work. First you need to read the patient info from the excel file by reading its column names. After that, you read through all the rows and read each column for a value. Let's assume that in your patient ID file, the column ID is called Patient, then you need to specify the variable Patient for both the Patient name and ID fields. This is an example of how to do this:\nThe second line is just telling the system to use the Patient variable.\n[caret #patient_id_name] <-readCSV('data/patient-specific-input.txt', quote = FALSE, nrow.limit = 3, names = c(\"ID\", \"First_Name\", \"Last_Name\")) %>% select(-ID) %>% unlist() %>% as_tibble() %>% set_names(c('patient_id', 'first_name', 'last_name'))\nNote that we specified nrow.limit = 3, this means the first three columns will be selected. (A good way to figure out how a function works is look at the code line by line that it calls and what argument is passed to what function).\nYou can see some of the codes by the functions with comments:\n[caret #patient_id_name] %>% as_tibble() %>% set_names(c('patient_id', 'first_name', 'last_name'))\n\nNow, you have the patient's first name, last name, and ID. Next, you need to read the insurance information from the insurance file. You can read the insurance information from the file:\nNote that the name of the insurance plan is specified as a variable `insurance_name`. That is why the insurance name field is specified as such in the insurance input file.\n[caret .\nNext, you assign the variable to the input table, which is defined by the insurance plan name: \nThe second code is reading the third column (age), then it reads in one row (n = 36395",
        "label": 0
    },
    "2126": {
        "output": "### Exam\n\n- Choose the right answer. Include and Exclude\n\n| Answer | Reason                                                     | \n|:-----|:--------------------------------------------------------------|\n| 0) Eligible                                                           | You include the patient by his condition and exclude him by the trial's exclusion criteria, so the result is `0) Exclude` (wrong answer)|\n| 1) Excluded                                                          | You exclude the patient according to the inclusion criteria, and he is eligible for the trial, so the result is `1) Excluded` (wrong answer)|\n| 2) Not Relevant                                                     | The patient is not involved in the clinical trial, so the result is `2) Eligible` (right answer) |\n| 3) Not relevant                                                    | The patient is not involved in the clinical trial, and he is eligible for the trial; so the result is `3) Exclude` (wrong answer)|\n\n| Answer | Reason                                                     | \n|:-----|:--------------------------------------------------------------|\n| `0) Excluded`                                                      | the patient has 40mg ACE (the drug you mentioned in the clinical trial) or 40mg ACE inhibitors. So you exclude the patient by the trial's criterion of ACE inhibitors use. |\n| `1) Not relevant`                                                 | the lack of some patient's data, e.g. age, disease description, disease control or duration, is preventing this patient from being eligible to the trial according to the clinical trial's including criteria. |\n| `2) Eligible`                                                    |the patient should be eligible for entering into this clinical trial, since he does not meet any of the trial's exclusion criteria. |\n| `3) Exclude`                                                    |You exclude the patient by her lab results, which prevents her from being eligible for entering into this clinical trial. |\n\n| Answer | Reason                                                     | \n|:-----|:--------------------------------------------------------------|\n| `0) Not relevant`                                                 |The patient is not involved in the clinical trial. In",
        "label": 0
    },
    "2127": {
        "output": "---\n\n\n## \u2753 Which is the goal of this code challenge? :\n\n```\nExclude patients that do not meet the eligibility criteria in each clinical trial.\n```\n\n\n## \ud83d\ude4b\u200d\u2642\ufe0f How can I get help?\n\u2709\ufe0f Contact author [<NAME>](mahmood.alizadeh@aut.ac.ir) for more information\n\n\n<EOD> A Novel, Nonsurgical Approach to Achieving a Clinical Solution in Chronic, Post-Acne Scarring\n\nChronic post-acne scarring is a common manifestation of acne vulgaris, which poses a significant psychologic and functional burden for patients. As a nonsurgical, minimally invasive treatment for managing these disfiguring lesions, this article describes a novel method of scar excision and tension releasing, with histologic evaluation, clinical outcomes after completion of treatment course, and a review of the relevant literature.\nP ost-acne atrophic scar excision remains a common and morbid disorder that is recalcitrant to standard treatments, creating significant psychologic and functional burden for affected patients. [bib_ref]  Scar revision: a global perspective, Gassner [/bib_ref]  As such, the development of safe and effective approaches for preventing and treating atrophic scarring remains a significant clinical challenge.\nThis article describes a novel, microsurery-based, nonsurgical technique for treating atrophic acne scarring on the face. A previous study by Wan and Lee published in JAMA Dermatology demonstrated the effectiveness of this technique for treating post-acne scarring when compared with other techniques, such as subcision and punch elevation. [bib_ref]  Comparison of nonsurgical percutaneous punch graft and box graft in facial post..., Wan [/bib_ref]  As such, the aim of this study was to expand on the previous work of Wan and Lee in a larger, longer-term study for evaluating the effectiveness and safety profile of this technique.\n\n# Methods\nEligible patients with atrophic facial acne scars were treated at the Chang Gung Memorial Hospital in Taiwan from March 1, 2012",
        "label": 0
    },
    "2128": {
        "output": "# Examples\n\n## Code Example - \n<EOD> Amino Acid Concentrations at Rest and after Submaximal Exercise in Male and Female University Students.\nBACKGROUND\nThe amino acid concentrations, especially free amino acids, may be related to different body parameters, namely body composition. On the basis of the literature, female college students have higher prevalence of obesity and body fat levels when compared to male students. The objective of the present study was to compare free amino acid profiles at rest and after submaximal exercise in males and females college students.\n\n\nMETHODS\nA total of 331 participants (170 women and 161 men) aged between 21 to 24 years were included in this study. Participants came to one of two university laboratories to complete the protocol. After anthropometry and body composition procedures, blood was collected at rest and 15 minutes after a submaximal exercise bout. The concentration of the free amino acids was determined using standardized methods and the results were expressed as \u00b5M .\n\n\nRESULTS\nThe female gender showed a greater amount of body fat than male participants. Significant different (p<0.01) in amino acid concentrations were observed between both groups, excepting arginine. In all individuals (males and females), we observed a significant increase (p<0.05) in amino acids, glutamate, serine, glycine, threonine, asparagine, glutamine, alanine, proline and arginine.\n\n\nCONCLUSION\nOur preliminary data suggest that, despite the similar levels of amino acids in men and women, the female gender showed greater concentration of amino acids after submaximal exercise.<EOD> .\nThe development of the medical aspects of epidemic influenza requires the development of diagnostic methods based on the study of the viral-immune, chemical, and ultrastructure of the organism. The use of these diagnostic methods makes it possible to achieve a level of effectiveness in influenza which far surpasses the method based purely on clinical data.<EOD> Development of a method and database for identifying and differentiating Pythium species in soils\nA",
        "label": 0
    },
    "2129": {
        "output": "__\n\n\n### 12. Exercises\n\n#### 1. Experiment 1: Get the average daily insulin dosage of patients with type 1 diabetes\n\nGo to the database and select [All](https://github.com/mohammadafshar/Type1_exercises#2-get-the-relevant-fields) patients as output parameter. [Explore](https://github.com/mohammadafshar/Type1_exercises#explore) output parameters, and create a table for patients with type 1 diabetes and extract field with patient average daily insulin dosage.\n\n    _Your file is /home/username_0/Downloads/final.sql_\n    -- SELECT * FROM patient WITH patient average daily insulin dosage AS insulin\n    select id, patient as insulin from patient\n\n    _Your file is /home/username_0/Downloads/averageDailyInsulinDosage.csv_ \n    ID, patient average daily insulin dosage\n    4, 33.044\n    5, 1.427\n    6, 16.628\n    7, 25.466\n    8, 7.717\n    9, 20.116\n    10, 27.874\n    11, 18.321\n    12, 15.934\n    13, 19.111\n    14, 28.181\n    15, 21.484   \n\n\n#### 2. Experiment 2: Search diabetes type 1\n\nAs input parameter, search for fields of patients with type 1 diabetes on [Diabetes type 1](https://github.com/mohammadafshar/Type1_exercises#dosage-data) which has the field of insulin.\n\n    _Your file is /home/username_0/Downloads/diabetesType1.csv_\n    ID, disease ID, patient, insulin\n    1,",
        "label": 2
    },
    "2130": {
        "output": "A: For each patient\n{\n    PatientData dc1 = new PatientData{};\n    //d.Age - age of the patient\n    dc1.Age = Convert.ToInt32 (patientNote.Age);\n    d.A1C = Convert.ToInt32(patientNote.A1C);\n    //d.A1C - A1C percent\n    dc1.Cholesterol = Convert.ToInt32(patientNote.Cholesterol);\n    d.CholesterolPercent = Convert.ToInt32(patientNote.cholesterolPercent);\n    dc1.Crude - Crude - crude protein;\n    d.CrudeFat - CrudeFat - crude fat.\n   //d.CrudeFat Percent - CrudeFatPercent - Crude fat percent\n}\n\nFor each clinical trials \n{\n    // PatientDrug dc1 = new PatientDrug{};\n    //d.Code = patientNote.Code;\n    //d.Name = patientNote.Name;\n    //d.Start.TreatDay = Convert.ToInt32 ( patientNote.TreatDay);\n    //d.Start.TreatTime = Convert.ToInt32 ( patientNote.TreatTime);\n    //dc1.InclusionCriteria1= patientNote.InclusionCriteria1;\n    //dc1.InclusionCriteria2 = patientNote.InclusionCriteria2;\n    //dc1.DrugId = patientNote.DrugId;\n    //dc1.DoseTimeDay = patientNote.DoseTime;\n    //dc1.DoseTime=patientNote.DoseTimeInMinute;\n    //dc1.DoseTime_inpercent=patientNote.DoesTimepercent;\n    //dc1.DoseMethod = patientNote.Dose;\n    //dc1.DrugCategory = patientNote.DrugCategory;\n}\n\nFor each medication therapy \n{\n    // MedicationTherapy dc1 = new MedicationTherapy{};\n    //d.Id - PatientDrug",
        "label": 0
    },
    "2131": {
        "output": "## \u2714\nWe are using the same method in this page of Tutorial 022 to train your brain.\n\n## \u2714\nAlso, this code snippet may be a good exercise to learn you can use regular expression (search string) in any Bash code. For more information, you may read the bash manpage.\n\n## Solution\n\n\n## 1) Asses trial-level eligibility\n\n## # get all trials from the data set\n[[ $1 == --get-trials ]]\nif [ \"$1\" = \"--get-trials\" ]; then\n    trials=$(for trial in \"$@\"; do\n        echo \"$trial\"\n    done)\n    retval=$?\n    ((retval))\n    if [ \"$retval\" != 0 ];\nthen\n        echo \"Error: Get trials\"\n    else\n        echo \"Trials = $trials\"\n        exit 0\n    fi\n    trials=\"\"\n    # get parameters for trial from a user input\n    [[ $2 == --print-trial-parameters ]]\n    if [ \"$2\" = \"--print-trial-parameters\" ]; then\n            echo $trials --parameters\n            exit 0\n    else\n        case $trials in\n            --no-print-trial-parameters)\n                echo $trials --no-print-trial-parameters\n                exit 0\n                ;;\n            --trial-name)\n                echo $trials --trial-name\n                exit 0;\n                ;;\n            --trial-start-date)\n                echo $trials --trial-start-date\n                exit 0;\n                ;;\n            --trial-end-date)\n                echo $trials --trial-end-date\n                exit 0;\n                ;;\n            --trial-type)\n                echo $trials --trial-type\n                exit 0;\n                ;;\n            --trial-status)\n                echo $trials --trial-status\n                exit 0;\n                ;;\n            --trial-study-id)\n                echo $trials --trial-study-id\n                exit 0;\n                ;;\n        esac\n    fi\nfi",
        "label": 0
    },
    "2132": {
        "output": "[/HEAD]\n[CODE][INST] \n\n```shell\n#!/bin/bash\n\n# set working directory\nWD=\"/patient/working\"\n\n# read in patient file\npatientFiles=$WD/patient/*.csv\npatientFiles=$patientFiles^.csv\n\n\nwhile read patFile; do\n        echo $patFile\n        patientData=$patFile #read file\n        echo \"Patient file is:\" $patientData\n        echo $patientData\n        head -1\n        echo \"Trial file is:\" $trialData\n        head -1\n        trialEligibility=$patientData &# Trial-level eligibility: <0 > Excluded\n        echo $trialEligibility\n        cat $patientData\n        # echo \"$patientData\"|sed 's/^<$patientData 1^//g; s/^$patientData 2^//g' | sed 's/^<$participantData 2^//g' | tr ',' '\\n'\ndone\n```\n<EOD> A prospective study of psychosocial problems in children with cancer.\nThe aim of this study was to describe the frequency of psychosocial problems in a consecutive series of children undergoing treatment for cancer, and to identify characteristics of children at particular risk of psychological distress. A prospective follow-up study was carried out, using interviews to assess children's attitudes to illness and feelings about being ill. A total of 74 children (median age 7 years, range 2-17) were recruited at the time of diagnosis. Two psychological assessments were made and the questionnaire responses compared at the two times of assessment. Of the sample (6, 8% infants), only 2 children were found to experience psychological distress (1). Other children experienced transient distress at specific points during the illness (13), or did not experience distress (9). The main findings are: children can experience psychological distress at the time of diagnosis and even after remission; some children are vulnerable to becoming distressed about the illness; a minority of children experience substantial distress; the children generally did not feel sad or upset about having cancer; and the child may present with the",
        "label": 0
    },
    "2133": {
        "output": "<EOD> The A\u2010kinase\u2010anchoring protein family: an unexpected structural divergence on a common theme\nAll proteins of the A-kinase-anchoring protein (AKAP) family share the ability to bind the cAMP-dependent protein kinase A (PKA), and many anchor both PKA and a phosphodiesterase (PDE), thus generating PKA activation/inhibition complexes. These localized signaling systems are responsible for compartmentation and integration of dynamic signal transduction pathways. Here, we explore the structure of the AKAP family by using a structural genomics approach, and perform a detailed annotation on the basis of similarity searching and secondary structure prediction. We describe structural diversity within the AKAP family, which is related to the length of the N-terminal portion of the protein and to the position along the primary protein sequence of cAMP-binding domains and/or PKA anchoring sequences. We also demonstrate that the AKAP family presents a highly nonlinear structural evolution during the eukaryotic radiation.<EOD> Lay representations of smoking as harmful to health\n\nBackground: Smoking causes a wide range of health problems, but tobacco advertising tends to focus on the social and/or positive sensory characteristics of smoking. We examined whether these tactics aim to promote smoking by fostering misperceptions about the harms of smoking among smokers.Methodology:Using data (n = 2803) from a large probability sample in Canada (population-based sample of the general population), we examined three potential mechanisms through which tobacco advertising could influence lay representations of smoking (perceived risk vs. positive attributes vs. misinformation).Results: Only 65% of smokers correctly identified at least five risk factors for smoking, compared with 90% of non-smokers (P < 0.01). A substantial minority (23%) believed that smoking can cure certain illnesses but only 3% believed that smoking causes at least one illness. Although most (89%) of smokers stated they believed smoking is at least somewhat addictive, only 39% of non-smokers perceived the same level of addiction or greater (P < 0.01). Smokers also reported more mis",
        "label": 0
    },
    "2134": {
        "output": "## [EXCLUDED]\nHere, please excluded a patient according to exclusion criteria of a clinical trial. [INST] Hello again.\n\nOne of your patients does not have information about the family history of diabetes. He is 28 years old. He has been diagnosed with cardiomyopathy and is scheduled for aortic valve replacement. We have noticed that he is having problems with his vision. His vision is being analyzed. The patient does not meet any other criteria of the eligibility assessment above. Please write 0 for exclusion on the assessment of eligibility for this patient. [INST]\n\n## [INST]\nThis is the end of the instruction. Please complete your trials in the next page. [INST] Note 2: Here, patients that are found to be eligible for the trial will be recruited for participation in the RCT.\n\n# Conclusion\n\nThe results are summarized in Tables 4, 5, and 6. 30 individuals in the case group and 30 in the contro group were enrolled. The recruitment for both groups was carried out consecutively. Two patients in both groups completed the procedures, but were excluded on the grounds of further exclusion criteria. \nClinical trial's recruitment with 4 scenarios in case group\n\n## Trial's recruitment scenario\n\n## Number of persons recruited\nNo 1 ------\n\n## Instructions\n\n## A scenario, 00618, is prepared by the data analyst as follows.\n\n## Clinical trial's recruitment in control group\n\n## Scenario of recruitment in control group\n\n## Trial-level eligibility:\n\n## Number of persons recruited\n\n## No 1 ------\n\n## 17-6\n\n## Instructions\n\n## A scenario, 07261, is prepared by the data analyst as follows.\n\n## Clinical trial's recruitment data with 4 scenarios in case group\n\n## Trial-level eligibility:\n\n## Number of persons recruited\nNo 1 ------17-617-6\n\n## 2) eliminated\nThe following",
        "label": 0
    },
    "2135": {
        "output": "A successful run is like this:\n```bash\npython run.py -c data/patient_note.csv -t clinical_trial/01536-1019.txt\n# 00-00                                                                        \n# 01-00                                                                        \n# 02-1         03-1                        04-0          05-1            \n# 12-1         13-1                        14-0          15-0\n# Eligible                                                                \n# Eligible                                                                        \n#    0              1              2              3              4           \n# Trial-level eligibility:            2) Eligible.                              \n```\n\n## Step-9 Test\n\nIf your installation has succeeded, it's possible to perform some tests: \n\n*   First, you can start the application with different input data. We give here some examples. Notice that we're setting the path to the patient note: `patient_note` and the path to the clinical trial information: `clinical_trial`.\n*   Second, there are several clinical trials and all of them have their own structure files. `study_list` is the folder where they are located. To test all of them, first get the path using the variable _`-t`_. Use the same example to get the path to the study files. For the sake of simplicity only `trial_struct.txt` is tested.\n*   Finally, to test `female` patients you have to do some changes in the csv file. Here's the modified version.\n```python\n# Python code\nfrom PLAIN_SPACE import _\n# CSV file (patient_note.csv)\npatient_note = [{'female': 1} for _ in range(2)]\n# CSV file (clinical_trial.txt)\nclinical_trial =[{'female':0} for _ in range(2)]\n# Study file (trial_struct.txt)\ntrial_struct = [{'eligible': 2, 'enrollment_date': 1152149856},{'eligible':",
        "label": 0
    },
    "2136": {
        "output": "[Yan]\n\n<details><summary>Solutions (step by step)\n</summary></details>\n\n### You should check the information of every patient on the note.\n\n* You should check each patient's information on the note and enter it based on your decision in the input fields.\n* \nAs an example, the results for some patients are as follows. The results are shown by `Eligible_1-N`, where N indicates how many patients met the inclusion criteria. \n\n### You should match every patient to the clinical trial based on their age and BMI.\n\n* You should match the patients to the trial by examining their age and BMI. (You can skip matching for patients older than 50 or with a BMI lower than 25.)\n\n* According to the trial criteria, when the age interval is below 50 years and body mass index (BMI) is above or equal to 25, the patient is eligible for the clinical trial.  (The example results for some patients are shown below.)\n\n### You should compare the lab tests of all patients with the trial's lab tests criteria. \n* Note that two patients did not meet the eligibility assessment because the lab test results did not match the trial criteria. This is because the lab test results of the patient indicated that the total cholesterol of the patient was 133, and only \u2264 130 was included in the trial's eligibility requirements. Therefore, the result does not indicate that the patient is eligible for the trial.\n* Note that the first result is that two patients do not meet the eligibility requirements because the patient's test results do not match the trial's eligibility requirements. This is because the patient's lab test results indicated total cholesterol of 133, which is larger than the 130 required by the clinical trial. Therefore, the results indicate that the patient is not eligible for the trial.\n* Note that the second result is the result of comparing the lab test results of all patients with the trial's lab test criteria. For example, the first patient's lab test result for this clinical trial's criteria is 110, but the result is 110.\n*\n[Yin ]",
        "label": 0
    },
    "2137": {
        "output": "![INST] \n\n    <section class=\"panel panel-primary\">\n      <ul class=\"panel-headings\">\n        <li>Purpose</li>\n      </ul>\n    </section>\n    <section class=\"panel-body\">\n      <h1>Purpose</h1>\n      <ol class=\"toc\">\n        <li>\n          <h2>1) Description of your program</h2>\n          Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eius modi temporaut enim adipiscing elit. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident. Sint ut labore dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat? Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident. Sint ut labore dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat?\n        </li>\n        <li>\n          <h2>2) Inclusion Criteria</h2>\n          Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eius modi tempora ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat? Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident. Sint ut labore dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqu",
        "label": 0
    },
    "2138": {
        "output": "- [X/Scoring]\n\n    You should decide the scoring method for the patient. You have two methods that you will use here, which are `Score per inclusion criteria - single score` and `Score per inclusion criteria - score based on the sum of the individual scores of each category`.\n    You should make each patient note more similar to the one from [Scoring], as it is similar to scoring patients. \n    When you are ready to score patient, you should write one of them after the line of the patient note, e.g., `Score: 5,` and put the explanation for your choice in brackets next to the score, e.g., `Surgery/Dental: [Yes]`, where the score is 5, and the reason for this score is that the patient has previous surgery/dental history. If you want to score patient, use the brackets.\n    For your reference, you can compare the two scoring methods in the clinical trial scoring [Clinical Trial Scoring and Methods](scoring-and-method-clnical-trial-2018.md#score-per-inclusion-criteria-single-score).\n- [X/Exclusion Criteria 1]/Inst]\n    This part shows all the reasons that the patient should not be selected to be eligible to the trial. `Exclusion Criteria 1: [Exclusion Criteria 1]` means the first exclusion criterion of the trial. You should write them, put their explanation in brackets in the following line, e.g., `Exclusion Criteria 2: [Yes] [Renal failure with end stage kidney disease]`, where the exclusion criterion is No. 1 and patient does not have renal failure. Do not repeat the criteria if you have used them for scoring patient.\n    If the patient does not meet the exclusion criteria, then you have to go to the next step. If he does meet it, you should write `Exclusion: 1`, and put the explanation for this choice in brackets in the next line, e.g., `Exclusion: [Yes] [Congenital heart defect]`.\n    After that, you can continue repeating Exclusion criteria by Exclusion Criteria, e.g.,`Exclusion Criteria 5: [Yes] [Vision problems,",
        "label": 0
    },
    "2139": {
        "output": "[C] Hello and Welcome. You are a helper assistant in an NIH trial. Your objective is to assign each record from the NIH database one of these clinical trial eligibility groups: No, Pending, Yes, and Not Applicable, based on data in the patient record and inclusion criteria for the trial. If patient data do not agree with the trial's inclusion criteria, the helper system will ask what the trial coordinator should do with the patient record. \n\n![](https://github.com/TsinghuaNLP/BioNER2016/blob/master/data-extraction/paper03/example.html#fig02)\n[IN/CIN] Let's see the example of assessing eligibility for the next patient:\n\n\nWe see that the patient did not have high blood pressure, that is, the second condition. Based on the table, we should check and mark `S_2(high_bp)` under No and `S_2(S_blood_pressure)` under Yes.\nWe see that the patient is male. He should be marked under Yes and both `S_3(S_sex)` and `S_4(sex)*F` in the table should be marked under Yes.\nAge is more than 55. Then the third question shall be checked, we should mark that the patient is not smoker under Yes. Then both `S_5(S_smoker)` in the table should be marked under Yes.\nHis mother has also high blood pressure. Then the fourth question shall be checked, we should mark that the patient doesn't drink alcohol under Yes. Then both `S_6(S_drinker)` and `S_7(S_drinker)*F` in the table should be marked under Yes.\nHis mother is currently not having diabetes. Then we need to check the fifth question, we should mark that the patient has family history under Yes. Then `S_8(family_history)` in the table should be marked under Yes.\nHis mother is not taking insulin. Then we need to check the sixth question, we should mark that the patient does not have family history under No. Then `S_9(family_history)$M` in the target table should be marked under Yes.\nAfter data extraction",
        "label": 2
    },
    "2140": {
        "output": "## [INST] Let's implement your decision in the code.\n[END]\n\n## The problem set\n[INST] Let's continue our work. The problem set is a patient pool, from which trial participants are extracted. This set has a sample collection of patients that you can use to implement the decision in the real world.\nLet's collect data from the problem set.\n\nIn the problem set (20161007) data, let's extract patients with age larger than 18 years, i.e., `problem_set[problem_set['Trial-level eligibility] == 1 & patient_info['Age'] > 18]`, then print it, e.g., `data.shape`. [INST] Let's make patient similarity based on their information.\n[END]\n\n## Suggestions\n[INST] The problem here is a low similarity of patients in your data because you have not had enough subjects to train. Thus, you are recommended to re-train with more samples.\n\n[END]\n\n## 4.2_1_2_in_r: patient_eligibility\n\nThe task is to create a data frame, in which the columns are the features (i.e., 51 characters) and rows are the unique samples, and the class column tells us if each sample is in the positive or negative class. Then, it is needed to show the class and the features that characterize such patients. The method to accomplish this task is as follows:\n\n## Relevant feature selection\n\nThe method starts with feature selection to select significant features that distinguish positive and negative patients better. Then, the class distribution is tested on the selected features. After that, a PCA plot is generated to visualize the class information distribution on the selected features. Finally, patients with similar features are categorized and are shown in the form of patient-groups.\n\nThe algorithm to accomplish the related features selection is as follows:\n- Input: 51 features that are extracted from the problem set.\n- Output: PCA Plot\n\n[INST] To see how many features are selected by the 'Relive' algorithm, we can see the `Relive` object here, e.g., `data_r.shape`. [INST] `Relive` object shows us the features and their weights to define features",
        "label": 0
    },
    "2141": {
        "output": "*  \u2717 Does the patient meet the trial's inclusion criteria?\n*  \u2717 Is the patient's status up-to-date in terms of the trial's inclusion criteria?\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., patient-level eligibility should be equal to the sum of trial-level eligibility and patient summary. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and Vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl",
        "label": 0
    },
    "2142": {
        "output": "<EOD> .\nThe authors discuss the treatment of 43 patients with non-Hodgkin's lymphoma of intermediate differentiation (NDLP) receiving CHOP therapy regimen. The therapeutic effect was achieved in 58.6% of NDLP cases. 66% of the patients experienced relapse 6 months following completion of the treatment. A 2-year follow-up of these patients showed that the NDLP patients were characterized by better results of treatment than non-B non-T lymphoma.<EOD> Methyl bromide use in Washington State: 1. Fumigation practice.\nA survey of methyl bromide production and usage in Washington State was undertaken to better assess the environmental exposure of this fumigant and to obtain a broad overview of the chemical's current role in pest management. Data collected by Washington State officials in 1982 provided the basis for this survey. As of December 1982, five of the estimated 247 pesticide distribution companies in Washington State held permits for the production and sale of the material; all others distributed it from other states. These five Washington State companies held permits to manufacture and/or distribute between 4.59 and 20.65 million pounds per year; most of these lots would be used as a soil fumigant. On average, pesticide companies distributed approximately 2.19 million pounds per year. Approximately 83% of the pesticide distributors were involved in the distribution of this compound. On average, they distributed between 76 and 617 pounds per year, and many distributed only a few doses per year. Almost 25% of the pesticide distributors reported using no less than 100 pounds of methyl bromide in any one year. All of the growers using methyl bromide were in the western part of the state where most of its production is located. Only 31% (22 of 71) of these growers reported that they were buying the product in Washington State. The remainder of the growers obtained the compound from one of the five pesticide manufacturers that hold the annual permits to sell or distribute the material.<EOD> .\nTwo brothers with con",
        "label": 2
    },
    "2143": {
        "output": "- `Insomnia` - Assigns code 3 of sleep disturbance of *[diagnostic and statistical manual of mental disorders][Dsm], classified as an *[insomniac disorder][Sleep_Disorder][1]*.\n\n\n**INST** `Code: 3 of insomnia` **INST** `Insomnia: Yes` **INST** `Code: 3 of sleep disturbance of the DSM, classified` **INST** `{Classified: \"insomnia disorder\"}`**INST** `Code: 155.61 of insomnia` {Codes_from} {Dsm} insomnia sleep sleep_disturbance {Codes_inst} sleep insomnia_disorder **END**\n\n\n### Add/Edit/Delete Code\n\nYou should not use empty keys. They may be misunderstood. You can use `Null (code)` instead but not empty keys. (Example) `Code: 2 of Dyslipidemia` instead of `Code: 2 of Dyslipidemia. ` is better practice. To add a code, you can use these lines. \n\n    1) New Line (New Code & Null Value)\n    1.1)  `Sleep Disorder: 155.61 of Dyslipidemia` **NULL** `Sleep Disturbance: 2 of Dyslipidemia. `\n\n    2) New Line (Edit Code & Delete Null Value)\n    \n    2.1) `Sleep Disturbance: 4 of Dyslipidemia`  **NULL** `Sleep Disturbance: 4 of Dyslipidemia` **NULL** `Sleep Disorder: 155.61 of Dyslipidemia`\n\n    3) New Line (Add Code)\n    \n    3.1) `Sleep disturbances: 6 of Dyslipidemia` **NULL** `Sleep Disturbance: 6 of Dyslipidemia. ``\n    \n    3.2) `Sleep disturbances: Null (code)` \"Sleep Disturbances: 6 of Dyslipidemia. \"\n    \n    3.3) `",
        "label": 2
    },
    "2144": {
        "output": "#### [eval]\n[Eval]\n\n[Eval] Hello. [Eval] You are a helpful assistant. Your task is the same as the [INST] task. But this time your data comes from the Eval dataset.\n\n[Eval] Your patient is [Pname]. He is 24 years old and has the same information related to his lab test as [INST]. But you must only calculate his current hba1c index from his lab test that the researcher has recorded and put in his electronic card. Now, calculate the eligibility of all patients in [INS_NAME]'s trial:\n![screenshot]({{ site.url }}{{ site.base }}/assets/images/clinical_trial_eval.png) \n\n`$data_eval` is the variable that we store all `PID`, `Clin_Trials`, `Lab_test` and `Eligibility_trial` data from Eval in JSON format. \nIf we want to filter the patients who do not have a lab test and are not eligible for clinical trials, we should change some filter statements and use the `filter()` function to replace the `where` statement.\n\n`$data_trial` is a dataset that contains all patient IDs, clinical trials, lab test data, and eligibility for clinical trials. \n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nYou can change the format of the data table to csv by adding a column named `Trials` that the value of each row is the same as the [INST] trial.\n\n### Usecase #2\n\n[USAGE_2]\n\n[USAGE_2] This trial has four exclusion criteria: 1) Patient has unstable diabetes; 2) Patient has a current diagnosis of Type 1 Diabetes mellitus; 3) Patient has an insulin requirement > 0.6 units per kilogram of body weight per 24 hours;\n4) Patient has an ejection fraction > 35%.\n\n[USAGE_2] For this usage, you should add four more columns,",
        "label": 0
    },
    "2145": {
        "output": "Your assistant has concluded that this patient would be eligible to enter the clinical trial. \n\n\nThe eligibility assessment is a three-step process. \nFirst, the assistant determines from each patient record which clinical trial inclusion criteria are true. The patient's record is then compared to the inclusion criteria. The clinical trial inclusion criteria are:\n\n- \nPatient is aged less than 70 years old.\n\n> ### Solution\n\n\n\n> **Solution:** \n```shell\n/path/to/ipred/ipred $RABBIT_CONDA_BASIS_DIR/anaconda3/bin/conda activate ipred\nimport pandas as pd\npatientData = pd.read_csv(\"./examples/09_instructions/patient_note.csv\")\ntrialData_temp = pd.read_csv(\"./examples/09_instructions/trial_data_temp.csv\")\ntrialData_temp.drop(trialData_temp._inclusion_exclusion_filter, 1, inplace=True)\ntrialData = trialData_temp.fill(0)\nnewTrialData = pd.concat([trialData_temp, trialData], axis=1)\nnewTrialData = newTrialData.fillna({'age': [0, 0], 'gender': [0, 0], 'age2': [0, 0], 'type': [0, 0], 'diabetes': [0, 0], 'hypertention': [0, 0], 'cholesterol': [0, 0], 'Hb1Ac': [0, 0], 'smoker': [0, 0]})\nnewTrialData.head()\n```\n\n```\nTrials: 1\ntrial_assessor_id: 1\ndate: 12/01/2019\nage: 25\ngender: male           # eligibility 0 (male)  1 (female)\nage2: 25.4              # numeric data\ntype: IDDM               # eligibility 1 (type1 diabetes)   eligibility 2 (Type 2 diabetes)\ntype",
        "label": 0
    },
    "2146": {
        "output": "# 3. 40 Points:\n[INSTR] You are a data scientist who is asked to train a machine-learning model with the aim of predicting the probability of diabetes mellitus type 2 in patients. \n\n`Prediction probability(patient i) = logit(y i )`\n\nwhere y i = 0 indicates a diabetes mellitus type 2 non-diabetic patient ,y i = 1 signifies a diabetes mellitus type 2 diabetic patient.\n\nAccording to your colleague, there are several models for diabetes mellitus type 2 prediction and the performance of these models are as follows: Model 1 : ANN, Model2: Support Vector Machines, Model3: Naive Bayes and Model4: Classification Tree.\n\n1. You are asked to identify the most sensitive parameters for all models. \n2. You are also asked to determine the best parameters that have the best performance in each model for predicting the probability of diabetes mellitus type 2 in patients.\n\n## Model1 :\nAssume that the input features of the model are as:\n\n* **BMI**: body mass index is a proxy for adiposity, computed as weight in kilograms divided by height in meters squared.\n* **Age**: it represents the age of a person that can influence the probability of diabetes mellitus .\n* **Gender**: if a person is male, it is set to 1 otherwise 0.\n\n[/INSTR]\n### Model 1\nFirstly, we have to find the mean, standard deviation and variance. Because the variables are numeric and we have to use the same for the mean and we can't have a negative square root therefore, we should have positive numbers, so we calculate and plot the density function for each parameter with the help of our distribution (Kernel Density Estimation). You can see them in the following images: \n![](KDE.png){: width=\"550\"}     \n\n\n**Let's have a look at the histogram of each parameter:**\n```\nhair(ann_mn_var, legend = \"n_node\")\n```\n![](sns_06",
        "label": 2
    },
    "2147": {
        "output": "Exercise\nIn the command line, run the following code:\ncd exercises/eligibility/\n\nIn this folder, you will find the test suite to make sure that the algorithm works as expected.\nYou can run your Python code by opening an IPython Notebook with IPython: [INST]\nOn the first line of the Notebook, run the following code: [INST]\n\nNow open a web browser and go to the IPython Notebook: [INST]\nRun the above code in the Notebook: [INST]\n\nHere is the result:\n\nThis problem is quite complicated to solve, but by working through the examples you will learn how to write the function for doing the necessary calculations.\n[INST]\n\nIf there is anything else that is confusing, let me know and we can work on it.\nExercise Solution\nYour solution file will be named Exercise_Eligibility_0_solution.py.\n# EligibilityAssistant Class Functionality #\n\n# EligibilityAssistant Class Functionality #\n\nThe goal of this class is to implement the eligibility criteria described above.\n\nIn order to do so, two methods are defined:\n- 'trial_exclusion_criteria' () - Returns the 'list of patient exclusion criteria'\n- 'eligibility' (patient_note, trial_note) - Returns the 'trial level eligibility'\n\nFor the 'trial_exclusion_criteria' method, a new 'list of patient exclusion criteria' is created with the following steps:\n- Patient notes are created\n- All the information in the patient notes are sorted in descending order\n- If an item's numerical value is 'NaN', the item is assigned to its own 'list of patient exclusion criteria'\n- Then, the patient_exclusion_criteria_list = 'list of patient exclusion criteria'\n\nFor the 'eligibility' method, the 'list of patient exclusion criteria' from the 'trial_exclusion_criteria' method is checked against the trial_exclusion_criteria. If at least one element in 'list of patient exclusion criteria' is true, it returns '0'. Otherwise, if all the 'list of patient exclusion criteria' values are False, it returns '1'. Otherwise, it returns",
        "label": 1
    },
    "2148": {
        "output": "![Eligibility assessment](/img/tutorials/eligibility-assessment.png){: width='800' }\n\n## [STUDY-563] Sepsis clinical trial enrollment and eligibility assessment\n<EOD> Imidazoline-containing compounds from the marine fungus, Aspergillus flavus.\nTen new azole compounds, 5-(benzyloxy), (2Z)-5-((4-phenylbutyryloxy)methylene)furan-2(5H)-one (5), 5-(p-methoxyphenyloxy), (2Z)-5-((4- phenylbutyryloxy)methylene)furan-2(5H)-one (6), 5-(p-chlorophenyl),(2Z)-5-((4-chlorophenyl- butyryloxy)methylene)furan-2(5H)-one (7), and a 4-(1,3-benzodioxanel- 5-yl)-10-oxoperylene (8) are reported from a marine-derived fungus, Aspergillus flavus. The structures of 1, 2, 3, 4, and 6 were established by the spectroscopic methods, including extensive 1D and 2D NMR analysis and the other structures were elucidated by spectroscopic analysis and physical properties. The structure of 8 was deduced by X-ray analysis. The structures of several compounds possessing a 5-(1-(3-pyridyl)vinyl)-4-thiazolidin-2-one ring system were previously revised and the structure proposed herein is found to be a better solution to this problem. Compound 9 was further found to be degraded in methanol and the two products from methanolysis were isolated and identified as 2-(1,4-dioxo-6,7- dihydrothieno(3,4-e)pyridin-3(2H)-ylidene)propanal (10) and 2- (1,3-benzodioxan-5-yl)eth",
        "label": 0
    },
    "2149": {
        "output": "I tried to simplify the solution.<EOD> A Simple Method for Obtaining High-quality Stable Biodiesel\n\nBiodiesel is an alternative to petroleum diesel that has the potential to decrease national dependence on imported foreign fuels while also mitigating greenhouse gas emissions. Although biodiesel production is expected to continue at a significant rate worldwide, one of the major factors hindering mass-produced biodiesel uptake is its high variability. Here, we demonstrate, for the first time, a simple yet complete method for obtaining a high-quality constant biodiesel yield. Using the model plant Arabidopsis thaliana as a representative of an economical plant for biodiesel production, we show that transgenic A. thaliana overexpressing diacylglycerol acyltransferase1 (DGAT1) with the constitutive cauliflower mosaic virus (CaMV) 35S promoter produce 1.6\u22122.7-fold more oil per weight of plant biomass compared with Col-0 wild-type seedlings. Moreover, these DGAT1overexpressing lines produce a higher yield of stable biodiesel with an average of 95.75 \u00b1 1.46% methyl esters content compared with oil from wild-type plants, which gave a relatively unstable biodiesel, ranging from 89.14 \u00b1 1.26 to 95.52 \u00b1 0.57%. To the best of our knowledge, this is the first study to report that expression of DGAT1 under the CaMV 35S promoter in transgenic A. thaliana plants resulted in an improved yield of stable biodiesel. It highlights the potential for the development of a cost-effective, stable industrial biodiesel production procedure using A. thaliana. Our findings provide a feasible platform for transgenic plants used in the industrial biodiesel production and have significant impact on the biodiesel industry.\n\n# Introduction\nOil production from transgenic plants is a promising alternative route for fuel production . In the past decade, many transgenic plants have been successfully developed to produce biofuel molecules such as biodiesel",
        "label": 0
    },
    "2150": {
        "output": "In this question, your skill in the field of artificial intelligence is evaluated. You are a data scientist or have enough skills to work as a data scientist. In this question, you must use machine learning on your own. For the same patient, you must make a different assessment of eligibility for a different clinical trial.\n\n\nThe training data for the data scientist are as follow (85 samples), 100 records in total:\n\n#### Data scientists, what is your strategy to address this task?\n\n##[INST] As we already told you, 85 samples are enough to build a model with machine learning. first we have to think how to choose the type and shape of the variable. then, we can separate the train data set into an independent validation set and test set.\n\n#### Describe your strategy\n\n##[INST]\nNow it is required to separate train and test samples, e.g., `Separate into train and test data sets.`\n\n### `1) Training data:\nA data scientist would separate the training data into a train data set and validation data (the number of samples are not important because the training data should be as large as possible if we don't have it, this may decrease the reliability of the model) and the validation data set, e.g., `Training data:\n[1] Separate into train and validation data set;\n[2] 85% (71 Samples) for train data set;\n[3] 15% (13 Samples) for test data set.`.\n\n### `2) Model building:\nA data scientist would make a model based on the train data set and then fit it to the training data. This process should be repeated several times. Also the model must be optimized before it is finalized. A model validation should be considered during the model building process. Also a different performance criterion must be used for different cases, e.g.,`[1] Model building:\n[a] Create a model based on the train data set;\n[b] Train the model based on the training data;\n[c] Randomly select 3 samples and predict their outcome (eligible or not);\n[d] Calculate overall predictive accuracy for the model;\n[e] Repeat steps 3b 10",
        "label": 0
    },
    "2151": {
        "output": "<EOD> .\nFive strains of Staphylococcus aureus were examined for their susceptibility of penicillin, cloxacillin and cephalosporin (cephalothin, cefazolin, cefmenoxime, cefazolin, cefotiaxime, ceftizoxime, ceftriaxone, cephalexin, cefpodoxime, cefuroxime. The sensitivity of the following enterobacteria strains were also studied: Serratia marcescens, Acinetobacter baumannii, Enterobacter sakazakii, E. cloacae, Klebsiella pneumoniae, Citrobacter freundii, Plesionomonas shigelloides, Providencia stuartii, A. haemolyticus, A. lwoffii, Enterococcus faecalis, E. faecium, Bacillus spp. S. aureus susceptibility to cephalosporin followed the order of cephalexin > cefmenoxime > cefotiaxime > ceftizoxime > cefpodoxime > ceftriaxone > cephazolin > cefuroxime > cefalothin > cephalothin. Acinetobacter spp. showed the highest sensitivity to cephalosporin among the examined strains, their sensitivity being 100% in 16 or 37 strains. Enterobacter spp., P. shigelloides and A. haemolyticus have the highest sensitivity to cephalothin and cephalosporin in their genera (100% in all cases). All Enteroccoccus strains, have the highest sensitivity to cefalexin from cephalosporin. Bacillus spp. have the highest sensitivity to cephalothin and cephalosporin from cephalosporin (100%). Cloxacillin was highly active among all cephalosporin except cefuroxime, cefepime, ceftazidime and ceftazidime. The antistaphylococcal action of cephalexin is equal to cloxacillin and lower than",
        "label": 0
    },
    "2152": {
        "output": "![inst_333](https://www.slideshare.net/AlirezaEbrahimiNia/inst333)\n<EOD> The Causal Relation Between Smoking and Depression: A Mediation Analysis of a Two-Sample Selection Model.\nBACKGROUND\nSmoking is associated with the occurrence of depression and has a causal effect on depression. Several genotypes affecting these two diseases are known. We aimed to estimate a potential mediator role of depression-related genotypes that help to understand the direct smoking-depression effect.\n\n\nMETHODS\nWe defined the causal association between smoking and depression by applying a two-sample selection model based on summary statistics and then estimated the mediator role of depression-related and/or smoking-related genotypes with Mendelian randomization analyses for eight genetic variants with potential mediation effect.\n\n\nRESULTS\nWe calculated that the Mendelian randomization-generated odds ratios were 1.113 (95% confidence interval 1.011-1.221, p = 0.028) and 1.112 (1.016-1.212, p = 0.017) for smoking risk and depression, respectively, and showed that a one standard deviation increase in smoking was associated with a 1.123-fold increase in the risk of depression. Inclusion of depression risk genotypes in the model yielded an adjusted Mendelian randomization of 1.037 (0.937-1.153, p = 0.545). However, after accounting for smoking-increasing risk genotypes, we found that in only the minor allele of rs4811656 an increase in depression risk was observed, and the association was in the opposite direction (odds ratio for the minor allele was 0.994, 95% confidence interval: 0.988-1.000, p = 0.057). Similar phenomena were found in the depression-associated rs6433869 and rs96833",
        "label": 0
    },
    "2153": {
        "output": "![INST] Title:\n[INST] MD2Me - Texting to Promote Chronic Disease Management\n[INST] Summary:\n[INST] UCSD researchers are conducting a study aimed to develop and evaluate a chronic disease self management web and text message based program on health-related self-efficacy and frequency of adolescent-conducted healthcare interactions.\n\nWe hypothesize that users of the program will demonstrate greater gains between baseline and 8 month measures of health related self-efficacy and adolescent-conducted healthcare interactions as compared to the usual care comparison group.\n\n[INST] Inclusion criteria:\n[INST] Inclusion Criteria:\n[INST] ages 14 - 22 years\n[INST] have cystic fibrosis, type 1 diabetes, or inflammatory bowel disease for at least 6 months\n[INST] have access to the internet\n[INST] speak English\n[INST] has a parent that speaks English or Spanish (if primary participant is under 18)\n[INST] willingness to attend assessment visits\n\nYou should compare each section of this note section by section with the clinical trial requirements. \n\nSo, your note has the following information about this patient:\n\n- The patient is male\n- The patient's type 1 diabetes was established 7 years ago\n- The patient is 25 years old\n- The patient's past medical history is not significant for any other medical issues\n- The patient does not have any specific symptoms\n- The patient has some medications for his diabetes\n- The patient has some lab results for his diabetes, and they are not very specific\n- The patient is not under study so he will not take any study medication\n- The patient meets or not the inclusion criteria of the study\nYou can output the information by running the following codes:\n\n    #print(\"%s is excluded for %s because he does not meet %s\" % (patient.get_name(), clinical_trial.id, \"Inclusion criteria\" ))\n    #print(\"%s is eligible for %s\" % (patient.get_name(), clinical_trial.id))\n\n    #print(f\"{",
        "label": 1
    },
    "2154": {
        "output": "**Example 2: A Trial-Level Eligibility of 1) Eligible or 2) Eligible.** Example 1 shows the output of a trial with only one inclusion criterion and another with three inclusion criteria.\n\n[INST] Example 3. You are a helpful assistant for clinical trial recruitment. Your task is to determine the patient's eligibility for a clinical study that is about the side effects of two different medications. Medication A is a medication for high blood pressure, and Medication B is a medication for high blood lipids (cholesterol). Each medication is available in two different dosages.\n\n\n[INSERT Table 2 and 3 here]    \n\n\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (the patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (the patient does not have sufficient information to qualify for the trial); and 2) Eligible (the patient meets inclusion criteria and exclusion criteria do not apply).   \n\n[INST] Let's go. You should determine the trial-level eligibility of each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. The first example shows the output of a clinical trial with only one inclusion criterion and another with three inclusion criteria.\n\n[ /INST]\n\n\n\nHere is the patient note:    \n\nThe patient is a 40-year-old man. He has a BMI of 34 kg/m. He lives in a house near a road and his smoker wife. The patient has a family history of coronary artery disease (CAD) in his father and an aunt with a stroke, and he has a family history of hypertension in both parents. He has a history of smoking 2 packs a day for 25 years, has a history of coronary artery disease (one year ago, the patient had a heart attack), and has started to have a regular medication 12 months after the event with high doses of nifedipine for control of hypertension. Currently, his antihypertensive regimen includes nitroglycerin (12 mg) and",
        "label": 0
    },
    "2155": {
        "output": "<EOD> Effects of different inhibitors of Na-K ATPase on the uptake of the Na+-tracer 22Na and of g-aminobutyric acid (GABA) in cortex slices.\nThis study was carried out to determine the effects of ouabain, furosemide and propranolol on the uptake of 22Na and -GABA by the cortical brain slices prepared from either non-anesthetized or pentobarbital-anesthesized rats. The results revealed: (i) a significant linear relation between the uptake of 22Na and that of -GABA; (ii) an elevation of 22Na uptake by the cortex slices prepared from non-anesthetized rats, which was accompanied by enhanced GABA uptake. Both, the increase of 22Na and of GABA uptake were inhibited by ouabain, furosemide, and propranolol; (iii) the cortex slices from pentobarbital-anesthesized rats have the higher 22Na uptake; (iv) the 22Na uptake increased in response to the increase of concentration of Na+; (v) ouabain reversed the increase of 22Na uptake observed due to adding Na+ or pentobarbital. We propose that the increase of uptake of Na+ by the brain cortex slices from either anesthetized or non-anesthetized animals may involve the active mechanism of uptake inhibited by ouabain. A relationship between the Na+-Tcadwell's system and the GABAergic ones in cerebral cortex slice is suggested.<EOD> Surgical outcome in a large cohort of juvenile idiopathic arthritis patients of different ethnic groups presenting to a single institute in the east of England\nAbstract Objectives: The objectives of this study were to examine the pattern of joint involvement at presentation in a large cohort of patients with juvenile idiopathic arthritis (JIA) and to identify any differences between those of Caucasian and non-Caucasian ethnic backgrounds. Methods: Medical",
        "label": 0
    },
    "2156": {
        "output": "## Assignments of 5 clinical trials for the eligible participants\n\nThe following clinical trials are shown for the eligible participants. The tasks in the box include `Run function` and `ClinicalTrials.register`.\n\n# Author Contributions\n\n## - research idea\n\n### Initial contribution\n- Research question\n- Data analysis plan, if applicable\n\n### Ensuing contributions\n- Submitting authors: responsible for communicating and coordinating with co-authors and submitting multiple drafts or versions\n- Co-authors: responsible for reviewing manuscript drafts, providing critical feedback and revisions, and co-authoring final versions.<EOD> GAPE, a new class of small molecules, induce transplastomic plant cell death\n\nRecent genetic and metabolic engineering developments have revitalized the field of plant molecular farming, which uses plants to synthesize pharmaceutical and industrial proteins and chemicals. A critical issue with this technology is the lack of a regulatory system to kill the plant cells to remove cells with genetically encoded mutations or toxic protein product accumulation. In this work, we utilized an in-house transplastomic plant-based platform to explore the ability of small molecules that had been previously developed to selectively cause cell death in human cells as a proof-of-concept that other small molecules can also be used to trigger transplastomic plant cell death. Our transplastomic platform utilizes the chlorophyll biosynthesis pathway to produce a fluorescent protein in the plastid to assess transgene expression and transplastomic cell viability. Our work revealed that small molecules from a new class of noncovalent inducers of cell death (NICD) that we refer to as glycoaldehyde/acetaldehyde-polyethylene glycol-based elicitors (GAPEs) are able to selectively kill 94-99.9% of transplastomic cells in 10-30 min of exposure at concentrations as low as 10 nM. Furthermore, the cell death occurs within three minutes of small molecule addition in plant leaves pre-infiltrated with the cytotoxic GAPE.",
        "label": 0
    },
    "2157": {
        "output": "\u25a0 You can find the answer in your Notebook. \u25a0 You can also access the answers in [this](https://csc500s2121.gitbooks.io/notebooks/week-4/Week4_SolvedProblem.ipynb).\n\n[INST] [ClinicalTrials.gov](https://clinicaltrials.gov) is the world's largest clinical trial registry. It contains information about publicly and privately funded clinical studies of drugs, biologics and medical devices conducted around the world.\nClinicalTrials.gov includes data on more than 291,000 studies.\n[INST] [Data on NPR] include data on about 62,000 studies, including research sponsored by the National Institutes of Health (NIH), some studies on treatments available outside the U.S., and studies of medical devices. \n\n\n<EOD> The effects of adipocyte-derived hormone adiponectin on ischemic brain injury.\nNeuropsychiatry and Behavioral sciences The effects of adipocyte-derived hormone adiponectin on ischemic brain injury Yoshiko Hayashi (Academic Editor), Toshiharu Matsumoto (Reviewer), Daisuke Tashiro (Reviewer)<EOD> H3K9 methylation unlocks elongation by RNA polymerase II.\nDNA methylation is a unique and important epigenetic mark that serves to regulate gene expression. It is frequently associated with genes that are actively transcribed. In general, its distribution across promoters and gene bodies depends on the nature of the genomic elements it is associated with. In contrast, H3K9 methylation is associated with gene repression, H3K9me3 and H3K9me2 are correlated with pericentromeric heterochromatin and H3K9me marks gene bodies (1,2). Here, I will discuss recent results suggesting that H3K9 methylation may not be simply repressive. In fact, the data suggest that H3K9me can affect RNA polymerase II (RNAPII) progression in a gene specific manner and may",
        "label": 0
    },
    "2158": {
        "output": "___\n\n## 13. Fill in all the fields for eligibility assessment for each row. If there is nothing to be filled in, please set it to None.\nUse the example below for your fill in:   \nIn the row 1, you should set `Eligibility` to None, because patient note isn't related to this trial. Then you should set the fields as follows:  \n```{r}\nmy_data <- subset(my_data, TrialID == \"STUDY1\") ## You do not need to set TrialID here.\ndf1 <- my_data[-(1:4), ] ## You have to set to NULL, because there is nothing to fill in.\ndf2 <- df1 %>% mutate(  # This is very similar to code in `my_data['Eligibility'] = my_data[df2$TrialID == \"STUDY1\"]['Eligibility']`\n  Eligibility = Eligibility.trial1, # This is very similar to code in `eligible.trial1 = \"0\"`,\n  Not_relevant = Not_relevant.trial1, # This is very similar to code in `not_relevant.trial1 = \"1\"`,\n  Excluded = Excluded.trial1,\n  Sex = Sex.trial1,\n  Dose = Dose.trial1,\n  Height = Height.trial1,\n  Weight = Weight.trial1,\n  BMI = BMI.trial1,\n  Glycohemoglobin = Glycohemoglobin.trial1, # This is very similar to code in `glycohemoglobin.trial1 = 1`\n  DiabetesType = DiabetesType.trial1,\n  Age1 = Age1.trial1,\n  Age2 = Age2.trial1,\n  Age3 = Age3.trial1,\n  Age4 = Age4.trial1,\n  Sex_AgeGender = Sex_AgeGender.trial1,\n  Ethnicity = Ethnicity.trial1,\n  Firstname = Firstname.trial1,\n  Lastname = Last",
        "label": 0
    },
    "2159": {
        "output": "#### Example 1\n11. Liraglutide Treatment in Type 1 Diabetes Mellitus: Liraglutide is a novel hormone with hypoglycemic effects. This hormone is released after meals, which helps control postprandial blood glucose and causes insulin secretion from islets cells via 1) enhancing 2) glucose-induced insulin release and 3) reducing 4) first phase disappearance from the bloodstream(Rogers et al. 2011). \n12. Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus (NCT03574007): Evaluating the use of Liraglutide in patients with Type 1 Diabetes. Participants eligible for the study should have already been participating in a clinical study with GLP-1 analogs, either or both of the two drugs, Liraglutide and Lixture. The goal of this trail is to evaluate whether additionally applying Liraglutide to patients who already take the first drug (Lixture) will have any added benefit.\n<EOD> Intravenous antibiotic therapy of carious cervical root canals in teeth with chronic apical periodontitis. Part II: Antibiotic therapy versus nonsurgical root canal treatment.\nFifty-eight teeth with chronic apical periodontitis were treated with either an intravenous antibiotic regimen (amoxicillin/clavulanate) and a three-month non-surgical root canal dressing with a calcium hydroxide-based paste, for 3 weeks, or with a single injection of a 20 mg/mL solution of iodine potassium iodide. Clinical parameters (pain and pus discharge) and periapical radiolucencies measured on radiographs were recorded for 12 months after the treatments. The teeth which received nonsurgical treatment showed a favourable evolution of the parameters evaluated only during the first 3 months, while no differences were found in the antibiotic-treated group during the whole follow",
        "label": 2
    },
    "2160": {
        "output": "### Eligible patients are as follows:\n    - Patient notes with `Trial-level eligibility: 2) Eligible.`: Eligible patients are treated as \"eligible\" and they are candidates for clinical trials. \n    - Patient notes with `Trial-level eligibility: 0) Excluded.`: Excluded patients are not eligible for clinical trials and they are candidates for \"candidate study\".\n    - Patient notes with `Trial-level eligibility:` or \"Not evaluated\": The trial-level eligibility of the patient is not available and no assessment can be made.\n\nWe apply a number for each patient. The number is assigned as follows:\n* 8010 means the patient note does not have enough information\n* 8010-1 means the patient note has no data in the fields in the \"Inclusion criteria\" column\n* 8010-2 to 8010-6 means the patient note meets the requirements for a particular row in the \"Inclusion criteria\" column\n* 8010-7 means the patient note is excluded from the trial\nEach patient will be assigned a number in this format. If each patient has a unique number, the data can be exported from the worksheet (i.e. `Save As`.\n\n### Examples of patient-trial matching\n\n\n```java\npackage com.github.jira.ticket.test.examination;\n\nimport java.util.ArrayList;\nimport java.util.HashSet;\n\nimport org.apache.log4j.Config;\n\nimport org.apache.commons.cli.*;\n\nimport java.text.Format;\nimport java.text.NumberFormat;\nimport java.util.*;\nimport org.apache.commons.logging.Log;\nimport org.apache.commons.logging.LogFactory;\n\nimport com.jayway.jsonpath.groovy.GroovyJsonPath;\nimport com.yahoo.search.indexing.query.structures.CriteriaContainer;\nimport com.yahoo.search.indexing.search.query.MatchQuery;\n\n// <form method=\"post\" action=\"Eligibility\">\n// <input type=\"text\"",
        "label": 0
    },
    "2161": {
        "output": "[R>] > data(beneflax_trial) > > head(beneflax_trial) > > ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## [R>] > # You should change the source files path in these two scripts. [/R>]\n\n![https://s.ytimg.com/vi/WQWo1fXpLpQ/hqdefault.jpg][/URL]\n\n`R> trial_name = \"beneflax\" > head(beneflax_trial) > ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## [R>] > # Check the age group. If they are older than 65 years, they are eligible. If they are <65 years, they should be excluded. [/R>]\n\n> trial_eligibility <-c(\"Eligible\", \"Not relevant\") > trial_age <-c(\"25\", \"65\") > trial_age$age > ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## [R>] > # Make a dataframe. [/R>]\n\n> trial_agefr <-data.frame(age.group = trial_age$age) > table(trial_agefr$age.group, trial_eligibility) > ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## The age should be < 65 years, so let the exclusion criteria of age > 65yrs to apply. So you should",
        "label": 0
    },
    "2162": {
        "output": "Copyright:  \u00a9 2019, <NAME>. This is an open-access paper distributed under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\">Creative Commons Attribution License</a>.\n[[https://github.com/r-lab/r-lab/blob/master/examples/15/SyNthesis_Clinical_data.Rmd|Raw]]\n\n\n\n\n<EOD> \nMortality from pneumonia is particularly high among the children belonging to the population groups with a lower economic and social level. The aim of our study was to evaluate the epidemiological changes connected with the incidence of pneumonia in the Pediatric Department of the \"Ospedale San Paolo\", a hospital serving Bologna metropolitan district and a population of about 345,000 inhabitants. From 1.01.1979 to 31.12.2002 we examined a total of 2,949 patients from age 2 to 17, of whom 1,368 males and 1,581 females. 440 children (15.02% of the total study population) were hospitalized for lobular pneumonia, 288 for bronchopneumonia (9.72%), 184 for pleuropneumonia (6.24%), 135 for atypical pneumonia (4.60%), 91 for interstitial pneumonia (3.08%). 102 children were admitted for bronchopulmonary diseases associated with respiratory tract infections (3.44%), among these, 40 (1.35%) had respiratory distress syndrome. During the 1st stage (1979-81), the incidence of lobular pneumonia was 14.1%, that of pleuropneumonia was 6.1%, that of bronchopneumonia was 9.1% (p < 0.05), that of interstitial pneumonia was 1.9% in children from age 2 to 14, and 16.7% in children",
        "label": 0
    },
    "2163": {
        "output": "---\n## INST\n[INST] Hello. Your name is Jian and you are a data scientist. Your job is to write a machine learning program to identify the characteristics of an effective marketing effort. A marketing campaign consists of a broad-release, limited-time promotion, a long-tail promotion, and several forms of advertising. It starts with the broad-release promotion, which is a one-time limited-time promotion that is run right before the first long-tail promotion and right after launching the product. It is followed by the long-tail promotion, which is ongoing and runs continuously. The final step of the campaign is done using advertisements. You have collected data with 167 attributes like gender, age, region, promotion dates, and product attributes. You also know your customer acquisition costs (CAC) for each of the actions, which are roughly $100 per customer acquired through the broad-release promotion, $210 per customer acquired through the long-tail promotion and $12 per customer acquired from advertisements. You want to write a program that uses the data and produces the following output:\n\n1. Produce two different customer attribution metrics to compare the cost of each customer acquired per promotion type.\n2. Produce a ranking to determine which types of promotion have a higher cost for customer acquisitions. \nEach row represents a time series of features, including the promotion type, for a particular customer. The rows in your dataset are ordered chronologically, with the first row representing the first customer, the 167th row representing the 167th customer and the 250th row representing the latest customer with a complete, valid dataset. The 167th row represents a dataset with 166 customers, indicating that it belongs to the 167th customer whose complete dataset is still being gathered, as seen from the `null` value in the `Customer_ID` feature. There are 250 columns because each customer has its own unique data features, including customer attributes `gender`, `date_of_birth`, and `marital_status` among others. The first column is a label of the `promotion_type`, which you know, and the rest of the columns refer to features for the promotion type. The dataset contains 167 customers, among whom 48 have a `broad",
        "label": 0
    },
    "2164": {
        "output": "You are required to upload the files below:\n\n\n\n---\n\nI'm quite satisfied with the training,\nI learned about how to answer the questions.\n<EOD> Association between the rs1828598 single-nucleotide polymorphism in the PPARG gene and the rs9939609 single-nucleotide polymorphism in the FTO gene with body mass index/body fat percentage in the Brazilian population.\nThe aim of the present study was to investigate associations of the rs1828598 single-nucleotide polymorphism (SNP) in the peroxisome proliferator-activated receptor (PPARG) gene and the rs9939609 SNP in the fat oxidation gene (FTO) with body mass index (BMI) and body fat percentage (BF%) in the Brazilian population. A total of 492 Brazilian individuals were enrolled, including 230 normal-weight (BMI, <25 kg/m2) males and 262 females aged 18-78 years and 260 obese (BMI, \u226525 kg/m2) males and 232 females aged 18-88 years. Anthropometric measurements were taken to determine weight, height, waist circumference and hip circumference, and BF% was calculated using electrical bioimpedance. Venous blood samples were used to determine total cholesterol, high density lipoprotein- and low density lipoprotein-cholesterol. Differences between groups were analyzed using t tests, \u03c72, Mann-Whitney and Mann-Whitney tests for trend, whereas ANOVA with Tukey's posttest or Jonckheere's trend tests were used for different BMI groups in a 4-grade scale. The results demonstrated that the following SNPs showed significantly increased BF%: AA of the FTO (P=0.049), TT of the PPARG (P=0.047) and TG of the PPARG (P=0.034). The",
        "label": 0
    },
    "2165": {
        "output": "<EOD> Permeation of ciprofloxacin into human corneal tissue under in situ conditions\nCoupled in situ rabbit cornea, blood, and aqueous humor models (30 corneas in total) for the investigation of ciprofloxacin uptake into human corneal tissue were perfused as previously described (Wislocki et al., 1997). Human corneal tissue specimens were obtained from a local eye bank. The time course of ciprofloxacin in the cornea was determined up to 24 hours in six different corneas. Ciprofloxacin was administered intrastromally in concentrations of 160 micrograms/mL (e.g., 5 micrograms, 15 micrograms). After incubation under physiological conditions (HCO3\u2212 buffer, pH 7.3) a significant accumulation of ciprofloxacin (t1/2 approximately 1 hour) was determined in the cornea up to 8 hours as determined by HPLC (analysis of the penetration area into the cornea and in the stroma using tissue sections). The ciprofloxacin concentrations in the cornea were well above the minimal inhibitory concentrations for 50 and 90% of bacteria (MIC50 and MIC90) as determined by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS). In the aqueous humor and vitreous humor, ciprofloxacin was never found above the limit of detection. Our results showed the potential of topical ciprofloxacin for the local treatment of an infected eye.<EOD> .\nBACKGROUND AND METHOD\nThe question if a prophylactic pancreatojejunostomy could reduce the morbidity and mortality of this pancreatodigestive anastomosis is still under controversy. It was our objective to evaluate the immediate and long term results on 96 duct-to-mucosa pancreaticojejunostomy after an end-to-side invagination technique without a pancreatojej",
        "label": 0
    },
    "2166": {
        "output": "are patient note and clinical trial information. Also, the output is trial-level eligibility of a clinical trial. \n\nThe required type of clinical trial is text-type. \n\n[INST] Required information:\n    * Incoming patient note (document)\n    \n    * Inclusions and exclusions criteria(multiple-word strings)\n    \n    * Phase of the clinical trial (text-type)\n    \n    * Type of clinical trial ( text-type)\n    \n    * Name of clinical trial (text-type)\n    \n    * Description of clinical trial (text-type) \n\n* Patient Note:  The note that contains the patient's attributes and their values, for example, a patient's birthdate, age, gender, allergies, medical history, lab tests results, and previous conditions.\n* Inclusion and exclusion criteria:  Trial-level eligibility (e.g., if we input a patient's note, we would obtain an outcome of 'Excluded')\n* Included the field 'Phase', which is a string (string is represented like \"{4}\")\n* Included the field 'Type', which is a string (string is represented like \"{1}\")\n* And another text-type field to represent the name of the clinical trial and a string with information 'Description' of the trial. \n\n[INST] There is also a user input field of the following format: \"Is there any other exclusion? If yes, please include the reason for it\".\n\n[DOC] The required type to output the eligibility is integer-type (see the [CODE] section). As you know, integer is a natural, non-negative number that can be positive, negative, zero, etc.\n\nAs a reminder, the integer starts from values 0 to 9. \n\n# Example \n\n[INST] Here is an example of patient information and clinical trial information for a trial level assessment.\n<Eligibility Outcome>2) El",
        "label": 0
    },
    "2167": {
        "output": "[SEC] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dlHere is the clinical trial: \nTitle: Clinical Trial of West-China Perioperative Transfusion Score (WCPTS\uff09for Massive Hemorrhagic Surgery",
        "label": 0
    },
    "2168": {
        "output": "<EOD> Is the Presentation of a Tic Douloureux Patient a Sufficient Indication for a Surgical Treatment of Trigeminal Neuralgia?\nAIM\nTrigeminal Neuralgia (TN) remains a condition of unknown and controversial etiopathogenesis.\n\n\nMETHOD\nThe present paper, based upon the analysis of the records of 30 patients who were operated upon for TN at the Department of Maxillofacial Surgery, University of Crete from 1993 until 1996, and upon the results obtained in various surgical treatments of TN, offers to the reader a critical evaluation of the usefulness of medical treatment and of the various surgical techniques in the case of TN.\n\n\nRESULTS\nThe results of our cases suggest that the surgical treatment should be recommended only after a failed medical therapy, and only for those who presented with a severe pain, unresponsive to medication. Patients who only presented with mild pain, were considered to be good surgical candidates.\n\n\nCONCLUSION\nConcerning the operative treatment the authors suggest that patients who presented with trigeminal neuralgia should in the first instance receive medical-pharmacologic treatment. A more invasive approach should be considered in patients resistant to one or several cycles of pharmacological treatment.<EOD> Revisiting the role of Paxillus involutus in promoting phosphorus acquisition in copper-rich and nutrient poor environments in two temperate forest ecosystems.\nPaxillus involutus is a wood-decay fungus that forms symbiotic ectomycorrhizal associations with conifers in temperate forests. Here we present a physiological assessment of the ability of P. involutus to mobilize phosphorus (P) in two temperate forest ecosystems that are strongly and consistently limited by low phosphorus. We investigated the capacity of P. involutus to mobilize P from bauxite, as well as the effect on P mobilization of different soil properties (such as copper concentration, organic matter content, and pH). In laboratory bioassays we compared P mobilization from bauxite by P. involutus with those of P. ery",
        "label": 0
    },
    "2169": {
        "output": ": Hello. You are a helpful assistant for clinical trial recruitment. Your task is... [/fig_ref] .\n\nWe are looking for patients who:\n have hyperlipidemia, or have hypercoagulable disease\n are between the ages of 18 and 80\n are not smokers\n have cardiovascular calcification on their CT, with a score of 1, 2,",
        "label": 2
    },
    "2170": {
        "output": "##[/LIST]\n\n\n[INST]\n\n# Results of the assignment\n\n1. ____________\n\n2. _______ is the gender. (female, male)\n\n3. The _______ is ____. (low HDL, high LDL, normal HDL, or normal LDL)\n\n3. \n\n3. \n\n### Task 1.\n[INST]\n\n\n\n\n# Subtask 4.\nLet's think about a clinical trial that determines the effect of two drugs, drug A and drug B, on hypertension (BP). We apply your program named 'clinical trial eligibility assessment' on the patient's data. Assume a patient has type 1 diabetes, and is diagnosed with cardiomyopathy. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: \nLet's write a program named \"clinical trial eligibility assessment\", which can be done as follows: \nimport re\n\npatients = [('L', 'male'), ('F', 'female'), ('H', 'hypertension'), ('HD', 'high-density lipoprotein'), ('LDH', 'low-density lipoprotein'), ('TG', 'triglycerides'), ('T', 'type 1 diabetes'), ('DX', 'diagnosis'), ('LBs', 'low-cost drugs'), ('Hl', '100%), ('T2DM', '25'), ('FH', '50%'), ('FAm', '505'), ('HR', '2%'), ('M', '0'), ('T', '5%'),",
        "label": 0
    },
    "2171": {
        "output": "[table]  1: Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [/table] \n[table]  2: The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). 3) You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [/table] \n<EOD> The role of social cognition in autism in a sample of Egyptian children from 3 to 12 years old: does the theory of mind change with age?\n\nBackground: Autism Spectrum Disorder (ASD) is a serious neurodevelopmental disorder characterized by impairments in social interactions, verbal and nonverbal communication, and the presence of repetitive and stereotyped patterns of behavior. The presence of deficits in social cognition and communication, along with the presence of repetitive and stereotyped behavior patterns is also one of the most prominent features of ASD. As ASD is a neurodevelopmental disorder with heterogeneous clinical and behavioral presentations, it is important for ASD children to make an early diagnosis and intervention, especially the early childhood stage. Therefore, early screening or early detection of high-risk children is critical and the aim is to help them",
        "label": 0
    },
    "2172": {
        "output": "</instruction><issue_comment>username_1: Thanks! @username_2 @username_3\n<issue_comment>username_2: I have my own solution, with python module, and some additional notes, and I would like you to take a look if you still interested https://github.com/username_2/trial-eligibility-validation\n<issue_comment>username_3: @username_0 I will take a look as well. Thanks! :)\n<issue_comment>username_0: @username_2 @username_3 Ok, I thought you needed help. You are already ahead of us. You mentioned some notes, we didn't have anything to add to the code. Thanks<EOD> Neural responses to viewing a loved one displaying affective states towards you: A novel approach to measuring social emotional reactivity in depression.\nINTRODUCTION\nOne of the most prominent markers of social emotional reactivity (SER) in depression is reduced positive behavioral and physiological responding when a loved one smiles at an individual. The goal of this pilot study was, with novel methodology, to investigate whether individuals with depression lack positive neural responsivity to an individual smiling at them or whether this is a behavior versus neural marker of depression.\n\n\nMETHODS\nFifteen (11 females) individuals with major depressive disorder (MDD) and 18 (15 females) healthy controls completed a fMRI task investigating brain responses when viewing a loved one displaying positive or negative affective states towards an individual in an MRI scanner.\n\n\nRESULTS\nUsing a region of interest (ROI)-based analysis, individuals with MDD reported greater activation in dorsolateral prefrontal cortex (DLPFC) and inferior frontal gyrus during positive affective stimuli as well as greater activation in parietal cortex during negative affective stimuli when viewing the loved one. Using full brain analysis, MDD participants displayed increased activation when viewing the loved one in the DLPFC, supplementary motor area (SMA), parietal cortex, and posterior cingulate cortex during positive affective states and in left amygdala and periaqueductal gray during negative affect. Additionally, MDD participants showed increased posterior cortex activity when viewing the loved",
        "label": 0
    },
    "2173": {
        "output": "```python\ndef eligibility(x):\n    while True:\n        d = {}\n        with open(\"patient_note.txt\", \"r\") as f:\n            fd = f.readlines()\n            trial_trial_id = fd[0]\n            trial_trial = trial_trial_id.split(\":\")\n            trial_inclusion = str(trial_trial[0])\n            fd = fd[1:]\n            trial_name = None\n            for l in fd:\n                trial_name = trial_name + l\n            trial_exclusion = str(trial_trial_id.split(\"|\"))\n            trial_name_split = str(trial_name_split.split())\n            trial_age = int(trial_name_split[0])\n            trial_gender = trial_name_split[1]\n            trial_diabetes = trial_name_split[2]\n            trial_chd = trial_name_split[3]\n            trial_chd_info = trial_chd.split()\n            trial_chd_info_2 = trial_chd_info[0]\n            trial_chd_info_1 = trial_chd_info[1]\n            trial_chd_lab = int(trial_lab.split())\n            if trial_exclusion == str(d[trial_id]):\n                print(f'Exclusion')\n            else:\n                trial_disease = trial_disease_id.split()\n                trial_disease_d1 = int(trial_disease_d1)\n                trial_disease_d2 = trial_disease_d2\n                trial_disease_d3 = trial_disease_d3\n                trial_disease_id = int(str(\n                    trial_disease_d1[0] + '0' + trial_disease_d1[1]\n                )[4]) * 10 + int(\n                    trial_disease_d1[2]\n                ) * 100 + int(trial_disease_d1",
        "label": 0
    },
    "2174": {
        "output": "<EOD> A comparison of four methods of determining ammonia and urea in the duodenal bile of cattle\nFour procedures for the determination of ammonia and urea in duodenal bile were compared. The methods compared were standard colour reactions, alkaline picrate, diacetyl monoxime-sulphanilic acid and an automatic analyser. There were considerable problems in making comparisons between the methods although the bile nitrogen concentration was greater than the other nitrogen-containing constituents. It is suggested that any procedure for determining 'bile nitrogen' should be validated by using both a standard protein and bile nitrogen-free solution to obtain the protein-N concentration by the Kjeldahl method and comparing this with the bile measurement.<EOD> Synthesis of Tertiary Amides and Esters Using 3-Chlorobenzoic Acid Activation and Rh-Catalyzed Methyl Transfer\n\nGeneral Methods. All reactions were performed using standard flasks and round bottom flasks under an atmosphere of argon. Reaction tubes for Rhcatalyzed alkylation, amination, and hydroamination catalyzed by Rh-BINAP used 14 mL tapered vials. T-Fubedrucks containing Rh-BINAP were obtained from Sigma-Aldrich (St. Louis, MO) and used as received. Analytical grade N,Ndiisopropylethylamine (DIPEA) was purchased from ACROS Organics, and anhydrous tetrahydrofuran (THF), anhydrous dimethylformamide (DMF), and anhydrous dichloromethane (DCM) were purchased from BioSolve. Ethyl 3-chlorobenzoate (98%) was purchased from Aldrich and used without further purification. 3-Aminobenzyl alcohol (>99%), bis (triphenylphosphine)rhodium(I) chloride 4.30 mmol scale (98%), rhodium(I) acetate tetrahydrate (>99%), 4,4-diisopropylcyclohexylamine (98%), t",
        "label": 0
    },
    "2175": {
        "output": "In this task, you should always perform the comparison between the patient's medical history and the inclusion criteria of a clinical trial. If there is no conflict between these two aspects, you should answer `3) Eligible`. And if the conflicted factor occurs, you should answer `0) Excluded` or `2) Eligible`. Therefore, let's use trial-level eligibility to keep up with our answer set at every time step of the dialog. For this reason, we should not only ask what medical history of patients, but we should also know trial-level eligibility. The patient note and the clinical trial are input as a sentence and the clinical trial is input as a string, respectively.\nYou will be assigned one of the five patients who is not included in the data set to solve the subtrial. After you finish your submission, we will assign you to the next sub-trial and the new patients will be different from the previous one. \nPlease note that the following is a dummy test. When you enter the answer into the text box, the submission button will only be activated if input data is valid. In other words, if you make an error in input data, you cannot enter the next page of the dialog box until the error has been fixed.\nDummy test of input data validity is finished. [OK] You should choose one of the sub-trials among 26 subtrials.\nWhich sub-trial should you assign? (Please choose one option)\n\n![Dummy Test 1](../images/DummyTest1.png) [03] 2. You will be assigned a new and different patient in the next subtrial. \nLet us consider the first sub-trial named `1`. \n1: Eligibility for 1st sub-trial [01] 2. This sub-trial is not performed as much as the previous sub-trial because the number of patients for which the trial-level eligibility is `0) Excluded` is considerably fewer than that of the previous sub-trial. Therefore, `659` patients are assigned to this sub-trial.\n4: Eligibility for 2nd sub-trial [02] 5. We continue the dialog with the 2nd sub-trial named `2`. 2: El",
        "label": 0
    },
    "2176": {
        "output": "As for downloading data, you can download and extract the data using `curl` and `unzip`:\n```bash\n$ curl -s https://ninja.soraki.com/ninja_apps/Ninja_Clinical_Trials_Assistant/sample.csv.gz | sudo zcat -f | sudo unzip -r -o sample.csv\n```\nIf all the",
        "label": 0
    },
    "2177": {
        "output": "### Clinical Trial Recruitment\n\nBefore creating a patient, you should be prepared with the clinical trial's name, short title and URL of the Web site. You can put the title or URL in the _clinical_trials table, but also you can store the URL in the _clinical_trials_urls table. Finally, you should load the patients that are assigned to the clinical trial. This step is performed by the call command in the _run_scripts table. A short example of one patient in the table is shown below. Now, let's check the status of a patient assigned to a clinical trial. \n\n`run_scripts table,  ``\n\nNow, for the patients that are assigned to the clinical trial, execute the command below. In this example here is the status of one patient, and there is no status of other patients. \n\n`SELECT trial_name, trial_short_name, trial_url, patient_ids FROM `clinical_trials` WHERE trial_name = 'Pathogenesis of Stress-induced Cardiomyopathy by iodine-123 (I-123),`\n\n\n* **123_MIBAG_3**- This patient has been randomly assigned to the clinical trial.\n\nWe need to generate a unique identifier for the patient using the random number generator. To check patients' status, just use below.\n\n### Inclusion and Exclusion Criteria \nClinical trial's inclusion criteria are in a table called `inclusion criteria_criteria_and_criteria_values`. For example, if you go to `clinical_trials/0/` you will see the short and full name of the clinical trial, the start date and the end date. After that, you will see the `Criteria_and_criteria_values` table with the short and full names of the inclusion criteria and the value of the criteria (e.g., age; 20-65).\nIn this table, you can also see the value of the criteria if the patient satisfies the exclusion criteria. \n\n**123_MIBAG_3** has two exclusion criteria, so the number in `Criteria and criteria values/0` will be `2`.",
        "label": 0
    },
    "2178": {
        "output": "Now, in the next problem session we are going to learn some more challenging concepts, such as [xref:ELOOX/problem_2.md],[xref:ELOOX/problem_3.md], and [xref:ELOOX/problem_4.md]. Thanks for your attention. See you in next class.<EOD> Evaluation of antifungals susceptibility testing methods, and antifungal activity of some extracts and pure compounds of Salvia reuterana Boiss. against some clinical isolates of Candida spp.\nAim:\u00a0To evaluate the antifungal activity of Salvia reuterana Boiss. (SrB) extracts and pure compounds against Candida spp. clinical isolates by broth microdilution. Materials & methods: A total of 40 Candida spp. isolates were tested. Antifungal disk diffusion (DF) and minimum inhibitory concentration were determined by broth microdilution. The presence of antifungals in extracts and pure compounds was determined by high-performance liquid chromatography. Results: The pure compounds, chlorogenic acid and 4-hydroxybenzoic acid, had no relevant activity but 4 phenolic diterpenes showed moderate activity (minimum inhibitory concentration 8.05-25.0\u00a0\u00b5g/ml) in broth microdilution and DF tests. Conclusion: SrB extracts and their phenolic diterpenes were found to possess noticeable antifungal activity.<EOD> 107. Development of an In Silico Model for Antimicrobial Peptides Using the Generalized Linear Mixedeffects Model and Inverse Response Surface Method\n\nSession: O-23. Resistance MechanismsBackground. Colistin, the last line of antibiotic therapy used to treat life-threatening infections caused by multidrug-resistant gram-negative bacteria, may promote Acinetobacter baumannii persistence. Persistent bacteria often coexist in bacterial communities called biofilms with the host immune system and drugs for prolonged periods of time in clinical conditions. To study the antimicrobial effect of colistin",
        "label": 2
    },
    "2179": {
        "output": "# Results of the Examples\nBelow, we give an example of the output for the triallevel eligibility.\n\n\n![\n{\n \n\"Inclusion criteria list\": {\n  \"*BMI >= 19 and <= 30\": [{ \"Item id\": \"$9\" }, { \"Item id\": \"$10\" }],\n  \"*Blood pressure >= 140/90\": [{ \"Item id\": \"$18\", \"Item id\" : \"$19\", }],\n  \"*Systolic <200\": [{ \"Item id\": \"$27\", \"Item id\": \"$28\", }, { \"Item id\": \"$29\", \"Item id\": \"$30\", }, { \"Item id\": \"$24\", \"Item id\": \"$25\", }],\n  \"*Diastolic <110\": [{ \"Item id\": \"$23\", \"Item id\": \"$24\", }, { \"Item id\": \"$25\", \"Item id\": \"$26\", }, { \"Item id\": \"$27\", \"Item id\": \"$28\", }],\n  \"Inclusion criteria\": {\n    \"Gender\": {\"$7\": \"female\"}\n  },\n  \"*Pregnancy\": \"< 6 months\": []\n}\n}\n}\n\n\n## Summary\n\n- You are a helpful assistant for clinical trial recruitment.\n\n- Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n- You should output the scale for the assessment of eligibility.\n\n- You should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n- Here is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with",
        "label": 0
    },
    "2180": {
        "output": "If you have any question or problem please feel free to mention in the comments section.\n\n![INST]\n\n# Acknowledgements\n\n 2020, 5, x FOR PEER REVIEW 2 of 6<EOD> Effect of intraoral temperature and saliva composition on the rate of orthodontic tooth movement with continuous activation treatment\n\nObjectives: To investigate the effect of intraoral temperature and saliva components on the rate of orthodontic tooth movement (OTM). Methods: Seventy-four patients at our dental hospital were divided randomly into three groups (n = 24/group). All subjects were treated with fixed appliances, with each group using different types of appliances; group A used the Damon3, group B used the Roth, and group C used the Damon3 X5. An intervention appliance was placed in groups B and C. All subjects were required to consume the same food type as prescribed during the 21-d trial. Subjects were then assigned randomly to one of three types of thermoplastic tray for intraoral temperature maintenance. After 20 d of treatment, all subjects' appliances were removed, and any residual space was restored. Lateral cephalograms (X-ray) were obtained, and the amount of tooth movement was determined. To examine the rate of OTM, the subjects were divided into three groups according to the different intraoral temperatures. The mean OTM value was calculated according to the change of cephalometric measurements and compared among the three groups (P < 0.05). Results: For the rate of OTM, the three groups were significantly different (P < 0.05). In particular, groups C and B, which maintained lower intraoral temperatures, showed greater movement. Conclusions: Lower intraoral temperatures result in a faster rate of OTM with continuous activation treatment (CAT). Higher saliva pH improves the rate of OTM, and saliva with higher mUC content will result in greater rates of OTM.\n\n# Introduction 2)\nAlthough several mechanisms may be involved in tooth movement, only the most common one is mechanically induced tooth movement by force applied by an appliance to the teeth, usually for orthodontic purposes. Orthod",
        "label": 0
    },
    "2181": {
        "output": "[MARKDOWN TUTORIAL]\n# 05. Overview\n### Conclusion \nThe patient has not met the trial's exclusion criteria and therefore is eligible for inclusion in the clinical trial. His eligibility assessment  on the assessment scale is 2, which indicates that he is eligible for this trial. \n \n### Overview \nThe following table identifies the variables for a given note for eligibility calculation in the script:\n\n| **Field name** | **Value** | **Human description** |\n| ---- | ---- | ---- |\n| Gender | F| Female |\n| Age | 25| Young adult |\n| Sex | M| Man |\n| Type1DM | T| True |\n| OGTT_NON_DIABETIC | F | False | \n| Presence of Coronary Artery Disease | T| True |\n| Duration of Diabetes | 7| Long |\n| DM_TYPE1_IN_FAMILY | T| True |\n| ACE_inhibitors | T| True |  \n| LDL_cholesterol | 125| High |\n| HBA1c| 6.5| 6.5 6.5 |\n| TG | 140| High |\n| HDL| 40| High |\n| Total cholesterol | 190| High |  \n| Fasting blood glucose | 100| 126| High | \n| History of Ketoacidosis | F| False |\n| Presence of angina | F | False |\n| History of heart attack | F | False |\n| History of untreated high blood pressure | F | False |\n| Any known active kidney disease | F | False |\n <EOD> .\nOBJECTIVE\nTo estimate the impact of increasing the number of hospital beds in the SNS to avoid waiting lists at the emergency center of the health care center of the Salamanca Health Department (CHC), and the optimal levels of admission for each department of the SNS.\n\n\nMETHODS\nProspective cohort study (July 1996 to December",
        "label": 1
    },
    "2182": {
        "output": "</section>\n</module>\n<?php require \\common\\include\\footer.php; ?><EOD> Bimolecular electron ionization of formamide and benzene molecules with synchrotron radiation.\nThe dynamics of bimolecular electron ionization (BEI) of formamide and benzene molecules were investigated in a time-resolved manner by using femtosecond photoion mass spectrometry with a synchrotron-based vacuum ultraviolet (VUV) beamline, the beam size of the VUV beam being comparable to that of the photon flux of the femtosecond laser. The temporal profiles of the mass-to-charge ratio (m/z) 15, 30, and 45 fragments produced from formamide and benzene, as well as from their mixtures, were obtained in terms of temporal broadenings of ion signals in the presence of the synchrotron radiation. The temporal breadths for ion signals of m/z 15, 30, and 45 fragments formed from the mixed sample showed larger values than those from the single sample in the same delay time range. On the contrary, the temporal breadths for ion signals decreased with increase in the delay time, as we confirmed in an earlier study on a two-electron ionization of formamide and benzene, where the temporal broadening was attributed to the interference between ions of different kinds. Furthermore, by using the three-dimensional semiclassical trajectory method, the temporal evolution of BEI was investigated in terms of electron energies and scattering angles. The results show that a part of the BEI processes were induced by electron collision with benzene, a much larger collision cross section than that of formamide.<EOD> Progression of coronary atherosclerosis during treatment with lovastatin.\nTwenty-eight patients with a mean age of 55 years in whom angiographically documented coronary atherosclerosis, with normal or slightly reduced left ventricular function and a history of symptoms within one year of the investigation, were treated with lovastatin for an average duration of 14 months (range 4 to 31 months). The anginal symptoms and ECG abnormalities were recorded and the",
        "label": 0
    },
    "2183": {
        "output": "[INST] In general, these factors are more obvious to know, therefore the output is expected to be faster than in [TIP1].\n\nAfter these two tutorials as [TIP1], [INST1],, [TIP2] and \n[INST2], \nyour task will be complete. [INST3]\n\n\n</p>\n\n<h2>Hints</h2>\n\n<h3 id=\"hint1\">HINT 1:</h3>\nUse the \"Ins\" function to get a list of indexes\n\n<h3 id=\"hint2\">HINT 2:</h3>\nUse the \"Bin\" function to find a list of binary-related items\n\n<h3 id=\"hint3\">HINT 3:</h3>\nIf you are wondering what the \"Ins\" function returns, see [this](https://code.activestate.com/c/196a30f4/959e02e6/8d9c98e2).\n\n<h3 id=\"hint4\">HINT 4:</h3>\nWhen you assign multiple values, the \"Bin\" function can return different results, \nbecause it returns a nested list and the order is unknown. You can solve the next two questions by using the \"Bin\" function, but the output order and contents are different if you use this function with different input parameters. Use the function the first time you need to get some list items and use it later if you have new items to check. \nThe \"Bin\" function can be used with multiple input parameters. The first parameter is \"Binname\". Different types of binary names are listed below. For example, the binary name \"I\" means you must check the inclusion criterion \"I\" in the clinical trial.\n\n> A: \n> - I : \n> - E : \n> - V : \n> - K : \n> - L : \n> - M : \n> - N : \n> - O : \n> - P : \n> - Q : \n> - R : \n> - S : \n> - T : \n> - U : \n> - Z : \n\nThe \"Bin",
        "label": 0
    },
    "2184": {
        "output": "## The patient's notes\n\n\n### [FIL] 005-000089-00001.json\n![005-000089-00001.json](../resources/005-000089-00001.json)\n\n#### Data\n\n| Name | Type | Description |\n|--------|--------|-------------|\n| 005-000089_00001 | `object` | Patient note |\n|--|--|--|\n| `id` | `integer`<br/>**Required**<br/>`id` | ID of patient note |\n| `user` | `integer`<br/>**Required**<br/>`user` | ID of user who created this patient note |\n| `created_date` | `integer`<br/>**Required**<br/>`created_date` | Creation date (yyyy-mm-dd HH:MM:SS)|\n| `data` | `string`<br/>**Required**<br/>`data` | JSON string of formatted patient note |\n| `title` | `string`<br/>**Required**<br/>`title` | Patient note title |\n| `author.name` | `string`<br/>**Required**<br/>`author.name` | Patient note creator's full name |\n| `author.name` | `integer`<br/>**Required**<br/>`author.name` | Patient note creator's ID |\n| `author.position` | `integer`<br/>**Required**<br/>`author.position` | Patient note creator's position (supervision, writing - medical and research, writing - non-medical, data processing, data evaluation, analysis or other) |\n| `author.gender` | `integer`<br/>**Required**<br/>`author.gender` | Patient note creator's sex (male or female) |\n| `author.unit` | `integer`<br/>**Required**<br/>`author.unit` | Patient note creator's unit (cardiology, endocrine, allergy,",
        "label": 0
    },
    "2185": {
        "output": "<EOD> Masking of the Fosmidomycin Pharmacophore within a Multidrug-Resistant, Plasmodium vivax Strain of Malaria.\nThe prokaryotic natural product fosmidomycin has demonstrated in vivo antimalarial activity as well as in vitro activity against drug-resistant Plasmodium falciparum. In order to determine whether the mechanism of antimalarial activity was shared within fosmidomycin sensitive and resistant isolates of the human-infecting parasite P. vivax, a multidrug-resistant line of P. vivax was generated. A single mutation in the P. vivax thiomeamine kinase resulted in fosmidomycin resistance. In order to determine whether resistance involved a loss of catalytic activity, we monitored the phosphorylation of the P. vivax enzyme upon addition of fosmidomycin in vitro. While the wild type kinase readily phosphorylates, no effect was observed on the resistant enzyme. Taken together, we have previously suggested a common mechanism of action between fosmidomycin and antibiotics targeting cell wall biosynthesis with this study identifying a possible mechanism of resistance toward fosmidomycin involving the inactivation of the thiomeamine kinase enzyme.<EOD> The clinical presentation of pulmonary thromboembolism in pregnancy.\nPulmonary thromboembolism accounted for at least 10% of the recorded causes of death in pregnancy from 1950 to 1976. In view of an increasing survival of the pregnant woman the mortality rate may even be higher. The mortality rate of the present study (36.5%, n = 14) correlated well with the figures of recent publications regarding this problem (13.0--40.3%). The majority of patients died in the delivery room (53.8%) or early after admission (30.9%). Clinical patterns and initial symptoms were not helpful to distinguish pulmonary thromboembolism from other problems of acute non-obstetrical origin for which delivery must be performed within a short period of time. Only two patients (10.0%)",
        "label": 0
    },
    "2186": {
        "output": "A: In order to make it more readable:\nYou can see patient note as shown bellow and then list your inclusion/exclusion criteria (eg.: AGE > 60, WEIGHT >80kg, BMI >30) in separate lines. Then add if condition(s) were met or not. Then sum up all that lines in a single line. The structure should be like this:\nAge: 25\nWeight: 78kg\nBMI: 30\n\n\nClinical Trial Inclusion criteria\nAge: 18-65  \nNo \nBlood Pressure: >180/105  \nHeart Rate: >80\nBMI:  \nHeight: 175cm  \nHemoglobin: >8.0  \nHbA1c: <9.0\n\n\nFBS: 100mg/dL  \nHDL: >40\nLDL: >130\n\n\nT2D in Family History\nDuration of T2D: >5years\n\n\nExclusion\nElevated liver enzymes\n\n\nAll that are met or not:\n2/3/4/5/6\n\n\n2/3/4/5/6=1/1/1/1\n\nSom e text for your eligibility in the end:\n1) Eligible\n2) Not Relevant\n3) Excluded\n\n\nA: We already added the information here. If there is any additional comments, please let us know.\n1. Inclusion criteria:\na. The patient is 18 years of age or older.\nb. Have had type 2 diabetes for at least ten years, and are currently being treated with metformin (750 mg daily) and/or sitagliptin (100 mg/day). Patients should continue taking metformin and sitagliptin during the trial.\nc. Blood pressure should be 130/80 or less.\nd. Patients should be currently taking metformin 750 mg orally each day or \u2265 3000 mg/ day in divided doses two or more times/day and have been on a",
        "label": 2
    },
    "2187": {
        "output": "Input: A note of a patient that includes the following fields: patient ID, patient name, initial age, gender, insulin, glucose , type 1 diabetes (0/1), type 2 diabetes (0/1) , TG 100 mg/dl, TG 120 mg/dl, BP 150/90 mm Hg, BP 140/90 mm Hg. [/table] \n<EOD> Neuronal differentiation by in vitro transfection of c\u2010myc\u2010deficient fibroblasts\nc\u2010myc-deficient NIH 3T3 fibroblasts were infected by an inducible construct, containing a cytomegalovirus viral promoter with N\u2010 and C-terminal fusion domains for the E1a protein and the enhanced green fluorescent protein (EGFP). We could show that c-myc knockout resulted in altered growth kinetics in comparison with normal rat kidney fibroblasts. In response to serum deprivation and nerve growth factor, c-myc-deficient fibroblasts exhibited neurite formation, which was absent in the controls. NIH 3T3 fibroblasts that were successfully transfected and differentiated were cloned by limiting dilution, and then further analyzed by immunocytochemistry, Western blot, and RT-PCR. The neuron marker microtubule-associated protein (MAP) 2 and the specific antibody anti-neurofilament revealed, in part, a very differentiated cell population. Furthermore, the EGFP-tagged cells expressed EGFP and neural filament and were examined by the use of confocal microscopy in culture and in brain-like structures. In conclusion, we have shown that a simple in vitro infection system is able to induce neuronal differentiation, thus supporting the significance of c-myc as a growth regulator in the nervous system. \u00a9 2004 Wiley-Liss, Inc",
        "label": 1
    },
    "2188": {
        "output": "1. How will you find patient's ID? \nWe are going to use the `idPatient` and `idVisit` objects to get the patient ID. \nidPatient: Patient ID \nidVisit: 1017666.\n\n2. Where is patient's gender shown?\nThe `gender` variable is part of `idPatient`. \nSee the following information:\n`idPatient`: Patient ID  `gender_f: [1]` The gender of the patient is male # Patient ID # Male # Patient ID # Female # Patient ID # Male # Patient ID # Female # Patient ID # Male # Patient ID # Female # (id:12716) # Male \n\n3. What is the problem with this code? \nIn the code below, you print the patient's phone number, but the test cases don't have the patient's phone number.\nNote: The trial-level eligibility should be printed at the end. \nfor (Patient p in PatientList) { print(\"phone: \" + p.phone); } print(\"Trial-level eligibility: Not relevant\"); \nTrial-level eligibility: 0\n\n4. Why don't the test cases match the output?\nThe `Phone` property is empty and hence has to be printed. However, the test cases state that every patient should have a `Phone` (or else the eligibility code will be `2`). \n\n5. What is the code that needs to change to make the test cases pass? \nWe need to add code to make sure that the phone number field is always set: # set Phone field to default value if (p.phone == null) { p.phone = \"1234567890\"; } print (\"phone: \" + p.phone); if(!p.gender.Contains(\"male\") && !p.gender.Contains(\"female\")) print(\"Trial-level eligibility: Excluded\"); print(\"Trial-level eligibility: Eligble\"); # End of patient patientList.Add(p); # End of patient print(\"phone: \" + p.phone); # End of patient \nTrial-level eligibility: Elig",
        "label": 0
    },
    "2189": {
        "output": "You should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## [INST] Output:\n1. Patient-level eligibility: # 1),\n\n##: excluded: patients meet inclusion criteria b) but are excluded on the grounds of the trial's exclusion c)\n- Patient name: # Kaveh Maleki\n- Patient ID: # 10361\n- Patient age: # 35\n- Patient note: #\n\nThis is the patient's ID (Patient ID: 10361) and patient's age (Patient age: 35). If these parameters are not available, you need to define them. You should use the patient's name (Patient name:) and patient ID (Patient ID) for the next task.\n\n\n## [INST] Hello.\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nHere is the assessment of eligibility with three levels:\n- Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n- Not relevant (patient does not have sufficient information to qualify for the trial)\n- Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\n\nThe patient note: # Kaveh Maleki, # 35 years old, ID: 10317\n\nThis task is similar to Pat",
        "label": 1
    },
    "2190": {
        "output": "## [INST] Example output\nThe overall eligibility decision will be given by the `Decision:`.\n\nFor more information about using the [INST] example output format and the output format in general, review the [EXAMPLE] section in the documentation.\n<EOD> .\nThe purpose of this research was to provide an overview of research done in the field of the social work and health care and to establish how far these researches contribute to the development of scientifically based practice in this field. This analysis of the current situation was conducted by reading and analyzing research articles. The results indicate the following five characteristics: (1) it is clear that the major topics of research have been and still are in the area of health care, psychiatry and psychology; (2) most of the research was carried out in countries outside the Netherlands; (3) research on interviews and the development of assessment scales were among the most investigated subject areas; (4) in many papers 'empirical' research-methodology played only a secondary role; and (5) a comparison of the research topics with the actual content of social work intervention activities in the field of health and (mental) health care, clearly indicates a lack of scientifically based practice. Only in a few topics are there many studies that show that their results have been implemented in practice.<EOD> .\nBACKGROUND\nIt is recognized that most human cancers develop through a series of clonal evolutions, but tumor heterogeneity still remains an important problem even after an advanced step of clonal selection. The purpose of this study was to evaluate tumor heterogeneity by karyotypic analysis in cancer cells isolated from different sites in the same patient.\n\n\nMETHODS\nCytogenetic analysis was performed on bone marrow (BM) granulocytes from 61 individuals, including 5 normal controls, 5 acute myeloblastic leukemia (AML) patients in remission, and 50 patients with different types of malignancies. Cells were sorted on a fluorescence-activated cell sorter (FACS) using CD45- or CD34-positive antibodies. The ratio of mitotic cells to interphase cells was kept at about 1: 20.\n\n\nRESULTS\nIn five normal controls,",
        "label": 0
    },
    "2191": {
        "output": "##[[OPTIONS]]\nLet's continue to the general information of the clinical trial: \nThe following clinical trial has been approved by the Bioethics Committee (reg. 201/13/12/CE), date 9 November 2013, and will be conducted in accordance with applicable law and regulation including the ethical principles that have their origin in the Declaration of Helsinki.\nThe trial will be performed at the University Hospital Center of Martin, Department of Physiology, in compliance with all international requirements in order to guarantee the confidentiality of personal data of patients and the collection of information that may disclose the identity.\nThe data collected from each patient will be entered into an electronic data capture system specifically prepared for the purposes of the study, and maintained in a secure database. Access to the data system will be restricted to the investigators. Hard copies of data forms will be kept in secure facilities. The identifying information will be retained as part of the subjects' trial records.\n\n### The patients will be recruited during the admission period.\nThe randomization of the patients to the IMT/AER and the IMT+TAS group will be carried out by a random number list (in which 79 patients will be divided in 4 groups, by block, in a ratio of 1:1 to the IMT+TAS and IMT/AER groups (2:2); the randomization will be carried out by a statistician at the University Medical Centre Maribor). \nAfter inclusion eligible participants will be randomized into the respective experimental groups. The patients will remain in their assignment for the whole observation period of the trial (six months). [OPTIONS] \n\n##[[EFFECTS]]\nThis is the group of effects. \n\n### The primary objective will be to evaluate the impact of IMT+TAS on the exercise capacity when tested by Cardiopulmonary Exercise Test (CPET) compared to control groups (IMT or IMT+AER).\nThe secondary objective will be to evaluate impact of IMT+TAS versus IMT on dyspnea ratings and severity of chronic obstructive pulmonary disease (COPD) based on the Modified Medical Research Council (mMRC) scale, exercise tolerance in the six-min",
        "label": 0
    },
    "2192": {
        "output": "### Preparing the solution\nDownload the following file with an example in a .txt format, that is, the input (i.e., the number of problems (490 cases) with the answer or solution (790 cases) will be the largest).\n\n```\nFile.WriteAllLines(\"input.txt\", Input)\n```\n\n### Run code\n\n\n```\n\n# Import module for loading data from CSV file.\nfrom pandas_datareader.data import DataReader\n\ndata_source = DataReader('MS_MLKQR_292606_490.csv',\n    index_col='symbol', data_url=\"https://services.data.gov/snapshot/data/17115147662990000-m1_mlkqr_292606.csv\")\n\n# Loading the data.\ndata =  data_source.loader\ndata.head()\n```\n\n<EOD> N\u2010Glycosylation of Mouse Liver Cytosolic Gamma\u2010Glutamyltranspeptidase\nGamma-glutamyltranspeptidase (GGT) is a transferase that hydrolyzes an N-acetylglutamy1 moiety from the C-terminus of glutathione or other suitable donor polypeptides and transfers the released moiety to suitable acceptor molecules. GGT is widely distributed in prokaryotic and eukaryotic cells, although the exact physiological function of GGT is unknown (Pappenheimer et a1 1969, Donnelly el aI 1982). In the central nervous system GGT has been shown to metabolize a number of glutathione-related substances and has therefore been implicated by its presence in several neuropathological conditions, including Alzheimer's disease (Troyer et al 1983, Mena et a1 1987). Mammalian GGT is an acidic glycoprotein, with an Mr of 59,000 on sieve-centrifuged preparations and 61,000 on sucrose gradient purifications, and can be separated into three chromatographic",
        "label": 0
    },
    "2193": {
        "output": "# Problem statement\nA [bangdata] is a set of categorical variables that determine which patients are eligible to enter the clinical trial and they are presented at the beginning of a trial level. Each patient is assigned a score for each trial-level bang data, the maximum length of the possible score set can vary. Therefore, the number or structure of score data may be uncertain. In the dataset, the length of each trial bang data range is 5, and all scores are continuous data.\n\n## Dataset\nThe dataset contains all details of the information related to the patients. Each row of the dataset represents an entry (patient) to the study. The patient's age, gender, treatment methods, diabetes type, and comorbidity are included in the information. Each patient has five categorical trial\u2010level bang (inclusion criteria) which are represented by `bang_0` to `bang_4`. In the data file, `0` represents a bang is not satisfied, `1` represents a bang meets the inclusion criteria, and `2` represents the patient meets the inclusion criteria and also the exclusion criteria don't apply. We should decide which trial bang data are `0` or `1` in the dataset. The number of patients is 1206, and the dataset is available at [kaggle].\n\n## Solution\nWe should compare a patient entry with the trial-level bang criteria (5 of them) to determine the trial-level bang data for a patient. In this solution, all scores are treated as a number (int64 as an identifier) during the training process. Therefore, we need to use a fully connected multilayer 1D convolutional neural network (CNN) to convert the scores to one-hot encoding.  \n\nFor example, the first score is related to the diabetes type. `1` represents that this patient has type 1 diabetes, and `0` otherwise. The second score is related to the age of a patient. `25` represents that the patient's age is 25 years old and `50` otherwise.\n\nFinally, we will obtain 5 one-hot encoding as shown below.\n\n![1]()\n\nThe code is available on [github],  [kaggle],[stack overflow]\n\n\n#",
        "label": 1
    },
    "2194": {
        "output": "The source code to reproduce this part can be found in the following link on [exercism](https://exercism.io/languages/java/tasks/001-2019-eligibility).\n\n## [002-2020-evolution][INST]\nIn this task, you need to select the correct one from the available choices in the patient information page:\n- The information is not available at this time. The data will be available within some time in the future.\n- It is confidential and the patient has specifically requested to suppress release of this information.\n- The patient has requested that the information not be released.\n- The patient has given permission for it to be released.\n\nThe problem statement is very similar to [001-2019-eligibility]. The main difference here is that we do not have the patient note and we should do the assessment based on the clinical trial's eligibility criteria (not just compare them). \n\nLet's think step by step. \n\nFirst, we need to extract the patient note from the source. For example,\n\nHere is the patient note:\n\nNow, we need to compare the patient note to the trial's eligibility criteria to determine the eligibility. For example,\n\nHere is the clinical trial:\n\n![](https://media.exercism.io/learn/workouts/2019-eligibility-patient.png)\n\n```java\n// Patient note\npublic static String patientNote =\n            \"<NAME> is a 25-year old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow",
        "label": 0
    },
    "2195": {
        "output": "[HINT] This is a special code you should always repeat in the last line to print trial-level eligibility in the last line by code `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible`.\nThis code is not visible if you copy-paste the code below the code by <copy> tag as you did.\nHere is the [example in a runnable repository](https://repl.it/@YanfJun/patient-eligibility#66831):\n\n[source code](https://github.com/YanfJun/patienteligibility/blob/feature/problem_2/example.ipynb)\n\n# Problem 4: The patient does not match the trial.\n\nWe should detect that the patient has not met the eligibility criteria.\n\nWe only need one code for this scenario. That code is this code:\n```\n                    if (int(trial_results[d]) == 0):  # if trial_results of [patient_id] is empty, it means the patient did not participate\n                        print(\"Excluded\") # patient is excluded\n```\n\nIt will print the message that the patient is excluded.\n\nIf you paste this line as the final code in the last line by code `[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to apply trial-level eligibility to each patient.`, for example, we get the code as bellow:\n```\n\n# Problem 5: We think about the patient to join a different trial in the same study.\nWe need to apply the patient-level eligibility criteria to the patient.\n\nWe need two codes. The first code prints the inclusion and exclusion criteria of the trial (the trial in [Problem 1], i.e., the trial 1).\nThe second code prints the patient-level eligibility results of the code by this code:\n```\nif int(data['patient_id']) in trial_results:\n                     print(\"Excluded\") # Patient did not meet any eligibility criteria.\n                     return\n                 if int(trial_results[d]) == 0:\n                     print(\"Ex",
        "label": 0
    },
    "2196": {
        "output": "```{python}\ndoc = pd.read_csv(\"data/patient_note_1.csv\")\nfor row in doc.iterrows():\n    for col in [0,2]:\n        doc[\"Age\"][row[0], col]  = round(doc[\"Age\"][row1, col])\n    doc[\"Gender\"][row5, col2] = round(doc[\"Gender\"][row5, col2])\n    doc[\"Weight\"][row[0], col1]  = round(doc[\"Weight\"][row1, col1])\n    doc[\"Height\"][row[0], col1] = round(doc[\"Height\"][row1, col1])\n    doc[\"Duration\"][row1, col1]  = round(doc[\"Duration\"][row1,col1])\n\ndoc = pd.DataFrame(data = doc\n                  .pipe(lambda doc: doc.apply(lambda x : x[col] - min(x[col].tolist())\n                                      , collapse = '/')\n                                  .replace('-', '') , axis = 1)),\n                         columns = [\"Height\", \"BMI\", \"Weight\"])\nfor col in doc.columns: #remove all zeros\n    doc[''.join(col.split()[1:-1])] =round(doc[col]\n                                  .where(doc[col] in (np.nan, -1, 0)))]\n\ndoc.rename(columns = { 0 : \"ID\", 2: \"Date\", 3: \"Duration\", 4:\"Gender\",\n                   5: \"Age\", \"Height\": \"Height_m\", \"Weight\": \"Weight_kg\",\n                   6:\"Height_BMI\",\n                   1:\"BMI\"},\n                   inplace = True)\n\n\ndf = pd.DataFrame(data = doc\n                  .pipe(lambda doc, col: col if not any(c in col for c in doc[''.join(col.split()[1:-1])]) else None\n                                       for row in doc.iterrows()\n                                       for col in doc.columns\n                                       if ''.join(col.split()[1:-1]) == col\n                                        #col if len(",
        "label": 0
    },
    "2197": {
        "output": "Note: This is a simple example that you should work with. The real task is more complicated. This is a simplified version for understanding the main idea.\n<EOD> A New Therapeutic Agent for Hemodialysis\nSUMMARY Hydrophilic high-molecular-weight (MV approximately 1 million daltons) cationic polyurethane polymers, which are compatible with dialysate and plasma protein, are considered as a candidate of new therapeutic agent for hemodialysis. The aim of this study was to compare various cationic polymers having different chemical structures regarding the efficiency of the removal of middle molecules and their toxicity for the cells of the mononuclear phagocyte system. By comparing these properties of polymers, the one, which was found to be the most efficient and nontoxic, was chosen for dialyzers. Hemodiafilters (SepteX VN dialyzers) were produced using this polymer and used in clinical practice. During seven-month observation 31 patients were dialyzed using 50 SepteX dialyzers with average in-patient time of 47 days and cumulative use up to 486 patient-months. In the whole group, the reduction rate of urea was 63.4%-55.0% and increased to 80.2% during dialysis with biofluid replacement. The reduction rate of \u03b22microglobulin was up to 40% and was in good relation to its concentration in the dialysate. After initial high rate of \u03b22-microglobulin reduction, in repeated dialysis the rate decreased. The values of retention index for middle molecules were comparable to those for the usual polysulfone surface. No adverse effect attributable to this polymer has been observed. In conclusion, cationic polyurethane polymer of high-molecular-weight has the possibility to be applied in the manufacture of dialyzers as an alternative membrane with new properties.<EOD> Clinical significance of circulating platelet biomarkers in patients with type 2 diabetes mellitus\n\n\n\n# Introduction\nAccumulating evidence has identified that platelets are central players in ather",
        "label": 0
    },
    "2198": {
        "output": "[INST] Now you should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.<EOD> Effects of \u03b2-lactoglobulin and gastrointestinal enzymes on the oxidation of cinnamon.\nThe present study investigated the oxidative stability of added cinnamon powder as affected by gastrointestinal enzymes and pepsin, trypsin and pepsin in combination. The results showed that the susceptibility of the cinnamon powder with or without pepsin to oxidation was the same whereas the cinnamon without and with trypsin had no different results with time. The addition of pepsin and pepsin/trypsin increased the susceptibility of cinnamon to oxidation. These results showed pepsin and trypsin could facilitate the oxidation of the flavoring cinnamon powder in an enzymatic hydrolysis and degradation reaction. In addition, the effect of cinnamon powder on oxidative stability of the milk protein, \u03b2-lactoglobulin, was investigated using the enzymatic hydrolyzate and undegraded sample at 40\u00b0C. The results showed the cinnamon powder had no effect on the oxidation of \u03b2-lactoglobulin.<EOD> A comparison of the use of three types of dental floss among Chinese dentists.\nOBJECTIVE\nTo compare the use of different types of dental floss among Chinese dentists.\n\n\nSUBJECTS AND METHODS\nA total of 1177 Chinese dentists completed self-administered postal questionnaires. The questionnaires collected data on the level of agreement and perceived barriers with regard to dentists' knowledge, attitudes and behaviours in relation to floss. They also gathered data regarding the type of dental floss used, the frequency of this type of floss being used and, in addition, the reasons given for the choice of flossing material.\n\n\nRESULTS\nThe majority of subjects (81%) were dentists with more than six postgraduate years of experience.",
        "label": 0
    },
    "2199": {
        "output": "<EOD> The phylloidin pharmacophore.\nFive compounds which modify the F-actin of neutrophils in a manner similar to that of phylloquinone were identified. All of these compounds reduced the viscosity of isolated polymeric actin. A similar reduction in the viscosity of F-actin was produced by two different flavones. The structural similarity of the various compounds which modify the viscosity of F-actin suggests either that a phylloidin pharmacophore may exist or that modification requires the ability to form a stable complex with actin.<EOD> Identification and characterization of an endothelin-converting enzyme in dog spleen and spleen cells.\nThe endothelin-converting enzyme (ECE) that converts Big ET-1 to ET-1 was purified to homogeneity from dog spleen using a combination of Cibacron Blue-Sepharose, heparin-Sepharose, FPLC Superdex G-75 Gel filtration chromatography, and immunoaffinity chromatography. Purified ECE showed a single band of 85 kDa on SDS-PAGE under reducing conditions. The amino acid sequence of the purified ECE was determined by Edman degradation. ECE has a high proline content (21.7% of the total amino acid residues) and cystine-rich domain. The amino acid sequence of the ECE was most homologous with carboxypeptidase M. The activity of the ECE was inhibited by EDTA and o-phenanthroline. ECE activity was inhibited by 46% by an anti-carboxypeptidase M IgG fraction, but not inhibited by anti-carboxypeptidase M and antibodies against thrombin, plasminogen activator/plasmin, and thrombin-thrombomodulin complex. Splenic ECE activity was increased by addition of 0.25 micrograms/ml interleukin-1beta, 0.25 ng/ml interleukin-2, 100 ng/ml lipopolysaccharide, and 1",
        "label": 0
    },
    "2200": {
        "output": "## [MOCK]\nAnswers:\n<p>\n<h4>\nThe trial should be:\n<ul>\n<li>Title: Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation\n<li>\nSummary: People living with human immunodeficiency virus infection (HIV) have 2-4 fold greater risk for developing diabetes and heart disease than the general population. They need safe and effective treatments that reduce the risk for developing diabetes and heart disease, and improve their quality of life. This project will explore whether a new anti-diabetes medication (Januvia) with a novel mechanism of action reduces inflammation, and improves blood vessel function in HIV infected men and women with several risk factors for developing cardiovascular disease.\n<li>\nSubjects: 18-65 yr old HIV infected men and women.\n<li>\nInclusion criteria:\n18-65 yr old HIV infected men and women.\nStable (at least the past 6 months) on combined antiretroviral therapy (cART).\nStable immune (> 300 CD4+ T-cells/\u00b5L) and virologic (< 50 copies HIV RNA/mL) status.\nInsulin resistant/impaired glucose tolerance (fasting glucose 100-125mg/dL, or 2-hr glucose 140-200mg/dL or fasting HOMA-IR=2.5-6.0).\nWaist circumference > 102 cm (men), > 88 cm (women).\nBMI > 20 kg/m2.\nFasting hypertriglyceridemia > 150 mg/dL.\nLow HDL-cholesterol (< 40 mg/dL in men or < 50 mg/dL in women).\nPlatelet count > 30,000/mm3.\nAbsolute neutrophil count > 750/mm3.\nTransaminases <",
        "label": 0
    },
    "2201": {
        "output": "__EXERCISE__\nWhat are the following numbers? (You can enter them manually in the input box bellow or copy-paste them in there.) \nA) 3, 4, 5, 7, -1, +2, 4, +3\nB) 3, 2, -1, -2, -3, +1\n\n[A] `Sqrt(3^2+4^2)`\n= `Sqrt((3+4)^2)`\n= `9`\n\n### Rating the exercise\n\n[INST] Hi! You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nLet's think step by step. \nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility:` e.g., `Trial-level eligibility:` `2) Eligible.`\n\n**Solved exercises**\n\n### Exercise 1.2\n\n__Exercise__\nAnalyze each pair of triplets in the table and determine the smallest integer that can replace each of the numbers in the table (for each triplet).\n\n|   Number  |  Replacement Integer   |\n|-----------|-------------------------|\n| 2012, \tJan. 12,  18        | \n| 154, Jan. 12, 1989    -1      |\n| -6, Jan. 3, 2002    -3       |\n|  98, Jan. 4, 2000    -8       |\n|  23, Feb. 5, 2005   -6       |\n| 16, Feb. 4, 2016       -1       | ---------------------------------------------------------------------\n\n\n### Analyzing the exercise\n\n|   Number",
        "label": 0
    },
    "2202": {
        "output": "<EOD> Maturation of the Bactericidal Activity of Sera from Bacteraemic Patients\n\nSerum from a 73-year-old bacteraemic woman was tested on a daily basis over several days for the ability to kill ingested E. coli under in vitro conditions. During the first day serum had little bactericidal activity, during the second day an enhanced activity was observed, and finally the bactericidal activity was normal by the third day. The number of white blood cells in the circulation was observed to follow a normal pattern in relation to this time-dependency. An elevated serum IgG concentration was observed during the last part of the observation time.\nIt has long been known that phagocytizing cells require bacteria to form a complex with complement proteins of appropriate type before they are killed (1). This phenomenon is also true for bacteria in human blood, since bacteria in blood are killed by blood leukocytes after preincubation of the cells with a patient's serum [bib_ref]  Mechanism of killing of bacteria in blood, Mackaness [/bib_ref] .\nThe bactericidal activity of these human sera is dependent on the presence of complement components and IgM [bib_ref]  Serum bactericidal function in septicaemia, Lindbland [/bib_ref]  and on the functionally active form of the complement system which was shown to consist of a complex of two serum proteins. This complex consists of the C3 and C5 components of the complement system and one factor which is now known as properdin . This bactericidal activity of serum is, in the cases studied, a natural phenomenon [bib_ref]  Different types of sera used in the detection of bactericidal antibody in..., Lange [/bib_ref]  and is not a secondary phenomenon related to antibodies (2).\nBactericidal activity is a part of the total defence against infections. The complement system in blood and the mucosa of the respiratory and digestive tracts is continuously activated by antigens from environmental and intestinal flora [bib_ref]  Complement activation by mucosal bacteria and dehydrated food: a review, Dahl [/bib_ref] . It is likely that mucosal antigens are also regularly encountered in the blood.",
        "label": 0
    },
    "2203": {
        "output": "# Question 2  Asks about the code snippet that outputs a 0 value for any patient who does not have the lab value.\n\nI'm having a problem writing a test for an output that is not 0. The problem is that the output is `NULL`, but I think I'm running into a problem because of the way the library does the filtering. This is a snippet of code that I think is going to lead to the output being `NULL`. The filter works fine for the first condition of an OR statement but throws an error after the OR statement. Is there a more efficient way to catch the patient information while removing the NULL values for the second condition of the OR statement?\n\n```php\n// Export output to a file.\nheader('Content-type: application/vnd.ms-excel');\n\n// Get the lab value.\n$labValue['total_cholesterol'] = \"\";\n$labValue['triglycerides'] = \"\";\n\n// Filter with age.\n$labValue = Trial_Eligibility::new()->filterWithAge()->get($labValue);\n\n// Filter with gender.\n$labValue = Trial_Eligibility::new()->filterWithGender()->get($labValue);\n\n// Filter with high chol.\n$labValue = Trial_Eligibility::new()->filterWithHighChol()->get($labValue);\n\n// Filter with insulin not on time.\n$labValue = Trial_Eligibility::new()->filterWithNotOnTimeInsulin()->get($labValue);\n\n// Get the output.\n$output = $labValue['totalcholesterol'] + \"&\" + $labValue['totalTrigly'] + \"&\" + $labValue['Age'] + \"&\" + $labValue['Gender'] + \"&\" + $labValue['HighChol'] + \"&\" + $labValue['NotOnTimeInsulin'];\n\n// Write the output to the browser.\nwriteexcel(['output' => $output]);\n\n// Create a file.\nfile_put_contents('trial-output.csv', $output);\n```\n\n\n### Question 2 Answer\n\n### Description\n\n**I'm having a problem writing a test for an output that is not",
        "label": 0
    },
    "2204": {
        "output": "- This module was created by:\n- An Iranian medical resident, Javad Shirzadi, MD;\n- Faculty member, Ali Ahmadzadeh, MD;\n- Faculty member, Mohammadhossein Khosravaninejad, MD;\n- Faculty member, Mohammad Sadegh Nabati, MD;\n- Faculty member, Asghar Jalali, PhD;\n- Faculty member, Marzieh Dehghan, MPH.\n- The learning module was developed with the collaboration of Dr. Mahvash Khaleghi (an expert in clinical trial), Mr. Bahman Farrokhmehr (Senior Information Technology Officer, National Center of R&D in Medical Informatics) and Mr. Mojtaba Sanaei (Learning Analyst at EduReza Company).\n- The learning module can be used for free by all healthcare staff after registration at https://learning.ihrc.ac.ir/. To register, you may also use your email or an existing account if they are already registered. The contents of all education modules are published under the Creative Commons licensing.<EOD> HIV and Tuberculosis Co-Infection: A Systematic Review and Meta-Analysis\n\n \n[fig]  Figure S1, Figure S2: Study Flow Diagram of the included studies. Risk of bias summary. [/fig] \n<EOD> Proliferation of human embryonic stem cells is supported by a serum-free chemically defined medium\n\nBackground: Human pluripotent cells are an invaluable research tool. Maintaining the self-renewal state of such cells, however, requires laborious and costly cultivation systems, especially media containing human serum. Hence, we developed a chemically defined medium containing basic human cell growth and differentiation components.Results: We supplemented DMEM (Life Technologies) with only physiological concentrations of components identified in conventional medium. The supplements enabled the proliferation of two hES (human embryonic stem) cell lines. A 0.022% concentration of sodium lactate, which was shown to be the only source of energy in chemically defined medium, was sufficient for hES cell proliferation. By using only physiological concentrations and avoid",
        "label": 0
    },
    "2205": {
        "output": "[MID] [/MID]\n\n[QUESTION]\n<EOD> A comparison of two in vitro skin irritation tests designed for cosmetics: the EpiDerm\u2122 test and the CAM test.\nThis study explored the performance of two in vitro tests designed to assess the potential of ingredients to act as skin irritants in cosmetic products in comparison with the results of the Draize rabbit skin irritation test. The skin irritation potential of 37 ingredients with a wide range of reported skin irritation properties were firstly evaluated using the EpiDerm\u2122 test, and then using an adaptation of the CAM test. Both in vitro irritation tests were based on the use of human cell lines as the cell substrate. The results indicate a high degree of correlation between the results obtained in vitro and those obtained in vivo. Further, the level of sensitivity of the EpiDerm\u2122 test was higher than that of the CAM test.<EOD> The Role of MGMT in Alzheimer\u2019s Disease\n\n\n\n# Introduction\nAlzheimer's disease (AD) is the most common cause of dementia with nearly 1 in 9 people over the age of 65 in the US demonstrating a form of cognitive decline. The condition is characterized primarily by the onset of dementia in those over the age of 65 and the accumulation of beta-amyloid and tau in the brain, which eventually leads to the deterioration of cognitive function and behavioral impairments. AD is the most common disease in people over the age of 65 and is estimated to cost the nation $305 billion annually.\nOligodendrocytes express the methyl-CpGbinding protein 2 (MeCP2) which has previously been implicated in cognitive function-the mutation of MeCP2 has been associated with cognitive disabilities in rare disease cases of Rett syndrome and it is a key modulator of transcriptional regulation in the brain (Lefebvre. RNAseq analysis from healthy controls and people with the disease revealed significant alterations in alternative splicing of genes that were related to signaling pathways such as regulation of synaptic plasticity, trans",
        "label": 0
    },
    "2206": {
        "output": "[/EXERC5] \n\t\t[EXERC6]\n\t\t[CODE[<hr>\n<h3>SOLUTION 6</h3>\n\t\t<blockquote>\n<p>Solution 6.5</p>\n</blockquote>\n\n</div>\n\t\t</div>\n\t\t<!--<div id=\"sidebox\">\n\t\t<div class=\"leftbox\">\n\t\t<p>&nbsp;<a href=\"#\" onclick=\"javascript:collapseBlock2();\">Click to collapse</a></p>\n\t\t<ul id=\"leftlist\">\n\t\t\t<li><a href=\"#\" onclick=\"javascript:expandBlock2();\">Expand</a></li>\n\t\t\t<li class=\"odd\"><a href=\"#\" onclick=\"getSolution(2);\">Sol2.2</a></li>\n\t\t\t<li class=\"even\"><a href=\"#\" onclick=\"getSolution(3);\">Sol2.3</a></li>\n\t\t\t<li class=\"odd\"><a href=\"#\" onclick=\"getSolution(4);\">Sol2.4</a></li>\n\t\t</ul>\n\t\t<br />\n\t\t<br />\n\t\t</div>\n\t\t<div class=\"rightbox\">\n\t\t<ul id=\"rightlist\">\n\t\t\t<li><a href=\"#\" onclick=\"expandBlock2();\">Collapse</a></li>\n\t\t\t<li class=\"odd\"><a href=\"#\" onclick=\"javascript:remove(5,0);\">Sol2.5</a></li>\n\t\t\t<li class=\"even\"><a href=\"#\" onclick=\"javascript:remove(4,0);\">Sol2.2.1</a></li>\n\t\t\t<li class=\"even\"><a href=\"#\" onclick=\"javascript:remove(3,0);\">Sol2.2.2</a></li>\n\t\t\t<li class=\"even\"><a href=\"#\" onclick=\"javascript:remove(1,0);\">Sol2.2.3</a></li>\n\t\t\t<li class=\"even\"><a href=\"#\">Sol2.2.4</a></li>\n\t\t\t<li class=\"even\"><a href=\"#\" onclick",
        "label": 1
    },
    "2207": {
        "output": "Your code to calculate the Trial-level eligibility and return it to the main script via a new line is written inside the `do.eligibility` function. The `eligibility_calculator()` function will check the available information of the patients and report the level of eligibility. The patients' age is compared with the age limit (40-70 for trial ACE_Inhibitors and TCM) and the patients' clinical characteristics are compared with those of the trial exclusion criteria. The patients with the diagnosis of cardiomyopathy will be reported as Eligible regardless of their other clinical characteristics and their clinical trial eligibility.\n```r\n# Patient's information for trial ACE_inhibitors\nace_inhibitors <- \"Title: Acute Comparison of Exenatide and Insulin Glargine 400 mcg in Patients with Type 2 Diabetes (ACED)\" ace_inhibitors <- \"Summary: Aims: To evaluate the short-term safety and tolerability of intravenous (IV) insulin glargine 400 U/mL versus subcutaneous (SC) exenatide in patients with Type 2 Diabetes (T2D) and a history of severe hypoglycemia.\" ace_inhibitors <- \"Setting: Diabetic Patients (T2D)\" ace_inhibitors <- \"Patients: Male and female patients (men: \u2265 18 years of age; women: \u2265 \u2265 50 years of age; patients \u226518\u2013<50 years of age: BMI \u226518 to <32kg/m2; patients \u226550\u2013<60 years of age: BMI \u226530 to <38kg/m2)\" ace_inhibitors <- \"Intervention: IV Insulin Glargine 400 U/mL vs. SC exenatide\" ace_inhibitors <- \"Trial-level eligibility: Excluded\"\n# Patient's information for trial Atherosclerosis_and_hyperlipidemia\natherosclerosis_and_hyperlipidemia <- \"Title: A Study of the Effect of a Cholesterol-Reducing",
        "label": 0
    },
    "2208": {
        "output": "In the below instruction I use the trial \"Non Opioid Treatment for Experimental Dyspnea\" to show you how to solve it.\n<html>\n<head>\n<script type=\"text/javascript\"><!--\n  (function() {\n    var e = document.getElementById(\"code-container\"),\n            n;\n\n    if (window.INTACT) { // if inteview\n      n = document.createElement(\"pre\");\n      n.appendChild(doc.createTextNode(\"You need INTACT.\"));\n      n.className = \"alert-info\";\n      e.appendChild(n);\n    }\n  })();\n  //--></script>\n</head>\n<body id=\"inline\">\n<code style=\"text-align: justify; word-wrap: break-word;\">\n[CODE 1]\nTitle: Non Opioid Treatment for Experimental Dyspnea\nSummary: The purpose of this protocol is to test the effects of the non opioid nefopam on experimental dyspnea and on the counterirritation (ie inhibition of one pain by another pain) induced by dyspnea in healthy subjects.\nMale or Female, age between 20 and 50 years, non smoking. No previous history of cardiorespiratory insufficiency or pulmonary hypersecretion, no neurological or psychiatric diseases. All subjects will undergo a cardiopulmonary exercise testing. In case of dyspnea in a CPET, subjects will be included only if they are able to perform the CPET to exhaustion. \nThe assessment will be done by a single investigator. (INTACT)\nPatients who have previously received treatment for asthma, pulmonary hypertension, cardiomyopathy, bronchitis, chronic obstructive pulmonary disease, pneumonitis or any other pulmonary, or cardiac pathology, will be excluded. (INTACT)\nThe subjects will be informed by the investigator of the objectives and requirements of the study and will have to sign an informed consent form. (INTACT)\nEthics Committee has approved the study. (INTACT)\nPatients will receive 8 mg of nef",
        "label": 0
    },
    "2209": {
        "output": "<commit_msg>Remove outpatient control-to-range to single arm single treatment study for trials with more than one visit. (username_0:09 Jul 27, 2022)<commit_after># Assess patient's eligibility by a three-point scale\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (the patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (the patient does not have sufficient information to qualify for the trial); 2) Eligible (the patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\nHere is the clinical trial: \nTitle: Outpatient Control-to-Range: System and Monitoring Testing\n\n\nSummary: A single arm, single treatment study is proposed to assess the feasibility of the AP Platform (cell phone + Control to Range system) outside of a hospital based clinical research center.\nInclusion criteria: INCLUSION CRITERIA\n\u226521 and <65 years old\nClinical diagnosis of type 1 diabetes mellitus:",
        "label": 1
    },
    "2210": {
        "output": "We are at the end of this tutorial. Hopefully you are well prepared to write first-class reports. Good luck!!\n\n### Good luck! :)\n\n*This tutorial is based on the original article, as written by John-Paul Ratchford. The material in this hand-out is reprinted with permission \u00a9 2017 from the New England Journal of Medicine[NEJM].\n<EOD> Clinical features of patients with mild symptoms of Covid-19 and their outcome\n\nThe aim of the study was to characterize the clinical features of patients with milder symptoms of Covid-19 (defined by mild respiratory tract signs and no abnormalities on chest X-ray (CXR)). The medical history of the patients, their symptoms on admission, laboratory results, chest computed tomography (CT) scans, and outcome were analyzed in 98 hospitalized patients. Of these, 35 (36%) fulfilled criteria for mild disease: they showed mild respiratory symptoms with a normal examination including CXR, had no abnormalities on CT examination, and were discharged after a median of 11.5 days hospitalization. Of the remaining 63 patients (64%), the median duration of hospitalization was longer (22 days) and 40% required invasive respiratory support. Of the 63 patients with moderate illness, the median age was 54 years, 52 (84%) were male, and 30 (48%) had one or more risk factors for severe SARS-COV-2 infection. All patients with symptomatic mild disease had no comorbidity.\n\n# Introduction\nIn contrast to other respiratory viral diseases, SARS-COV-2 infection can lead to pulmonary edema, hypoxemia, and even multiple organ failure [bib_ref]  Acute respiratory failure in COVID-19: Is it \"typical, Li [/bib_ref] . The clinical characteristics and course of severe acute respiratory syndrome (SARS) were well documented in the first reported outbreak in Guangdong province, China, in 2003 [bib_ref]  SARS: clinical presentation, transmission,",
        "label": 0
    },
    "2211": {
        "output": "## Instruction\nTo evaluate the patient's eligibility for the clinical trial, you use the [Trial](./trial-data) data. \n\n### Clinical trial table \n\n![](/images/instruction/clinical-trial-table.svg)\n\n### Patient note table \n\n![](/images/instruction/patient-note-table.svg)\n\n\n### Output the eligibility\n\n\n## Instructions\n\n### Installing Docker\n\nIn order to run the instructions, you need to install docker and access docker container through a terminal. For that we will download the latest docker-ce installer from the docker website and install it.\n\n### Installing Docker\n\n```bash\ncurl -sf https://get.docker.com | sh\ndocker -v\ndocker --version\n```\n\nIn the above commands, the docker version should be a number such as 17.1.1. If you run the docker -v command, it will provide the version of the current docker installed on your OS.\n\nIf the docker version is lower than 18.0.3, click the links of the [docker images](./docker-images) to update the version before running the commands with version less than 18.0.3. For example, for Docker version 17.1.1, click [v17.1.1](./docker-images/base/) and wait until the installation is completed. \nIf the Docker version is greater than or equal to 18.0.1, proceed to the next step.\n\nWhen the installation is completed, we will move on to the next step. In the last step to confirm the installation, we will check the docker version that is already installed and run a command to create the container to access the container.\n\nYou can run it through the command terminal by running the following command.\n\nIf running the docker create command is used for the first time, you will proceed with the following instructions to set the path manually.\n\n```bash\nsudo mkdir /usr/share/docker\nsudo chown your_user /usr/share/docker /usr/share/docker/certs\ndocker --version\ndocker create -d --name clinical-trial-1 clinical_trial_14",
        "label": 0
    },
    "2212": {
        "output": "<!-- MOTIVATION -->\nIn some researches, scientist and specialists are investigated to determine whether patients are suitable to a trial based on some criteria. This is called eligibility, and it is done to avoid unnecessary effort on the side of participants.\n\n<!-- TESTCASES -->\n\n## Test Case 1\n\n### Expected Output\n<span style=\"color: #09E; font-family: 'SourceSansPro', 'sans-serif';\">0) Excluded</span>\n<span style=\"color: inherit; border: 1px solid inherit; padding: 0.5em; text-decoration: underline; vertical-align: inherit;\">\n\n## Test Case 2\n\n### Expected Output\n<span style=\"color: #099; font-family: 'SourceSansPro', 'sans-serif';\">0) Excluded</span>\n<span style=\"color: inherit; border: 1px solid inherit; padding: 0.5em; text-decoration: underline; vertical-align: inherit;\">\n\n## Test Case 3\n\n### Expected Output\n<span style=\"color: #941; font-family: 'SourceSansPro', 'sans-serif';\">2) Eligible</span>\n<span style=\"color: inherit; border: 1px solid inherit; padding: 0.5em; text-decoration: underline; vertical-align: inherit;\">\n\n## Test Case 4\n\n### Expected Output\n<span style=\"color: #661; font-family: 'SourceSansPro', 'sans-serif';\">0) Excluded</span><span style=\"color: inherit;\">\n\n## TESTCASES\nWe check our test cases against this code block to see if they work. If they don't, we should fix whatever needs to be done to make them work.\n\n<!-- MARGINS -->\n\n\n<!-- SANSERIF -->\n\n     <div id=\"wrapper\" title=\"Motivation of the Code\">\n     <span style=\"font-family: 'SourceSansPro', 'sans-serif'>\n<h2><b>MOTIVATION</b></h2>",
        "label": 0
    },
    "2213": {
        "output": "]\n\n\n### Rule (Trial2)\n`Rule (Trial2) = Rule (Trial1)\n[Trial2Title]`\nYou'll note that there is no `Trial-level eligibility` in the trial rules. Instead, in other words, the first line is exactly the same as line 3 in the trial",
        "label": 0
    },
    "2214": {
        "output": "<EOD> A randomized trial of a computerized cognitive rehabilitation program for geriatric depression\nThe present randomized clinical trial compared an interactive, CD-ROM-based cognitive rehabilitation intervention targeting deficits in attention, executive functioning, and working memory with an auditory-only control training administered by speech-language pathologists (SLPs) in 50 non-demented older adults diagnosed with a major depressive episode (MDE). Primary study outcomes were changes in attention-executive functioning composite scores between baseline to 9 weeks postintervention. Analyses showed significant improvement in the attention-executive composite score on the Montreal Cognitive Assessment from baseline to postintervention (mean 0.87, P < 0.001) in the treatment group, whereas the control group improved to a lesser degree (mean 0.09, P < 0.001). Although both groups showed some response to the intervention, the improvements in attention-executive functioning scores were not significantly different between groups. Given the paucity of evidence for the nonmedical treatment of geriatric depression, results of this study may encourage future investigations on interactive, CD-ROM-based cognitive rehabilitation interventions for cognitive impairments observed with depression in elderly individuals.<EOD> .\nThe diagnosis of acute coronary syndromes is crucial, as a delay in the treatment may result in death or permanent myocardial dysfunction. This diagnosis is established by taking an accurate medical history and by using appropriate diagnostic tests. The first step in the diagnostic pathway is a clinical assessment of the patient's cardiovascular risk in order to establish the probability of suffering a cardiovascular event during the first 10 years. The initial diagnostic test to be applied is an electrocardiogram (ECG). This helps to differentiate between acute myocardial infarction (AMI), AMI with ST-segment elevation, and an unstable angina attack. If the results of the non-invasive tests and ECGs suggest that the patient will not benefit from immediate admission for coronary angiography, the diagnosis of AMI may become uncertain. In these cases it will",
        "label": 0
    },
    "2215": {
        "output": "<h1 align=\"center\"><b>Task 1: Trial-level eligibility</b></h1><p><p>The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).</p>\n<p>\n\n*\tInput the eligibility for the clinical trial.\n</p>\n<h3 align=\"center\"><b>Input</b></h3><ul>\n<li>\tTrial_Name=\"<b>PID_Trial_Name</b>\"</li>\n<li>\tInclusion_Criteria(s)=2017-12-03T01:56:30Z:\"<b>Patient_Code</b>\"</li>\n<li>Trial_Date=2017-12-01T01:56:30:Z</li>\n</ul>\n</p>\n<h3 align=\"center\"><b><a href=\"#Task_1\".id\">Tasks \u2192 Task 1</a></b></h3><p><a rel=\"nofollow\" id=\"Task_1\">Continue to Solution for Tasks \u2192 Task 1</a></p>\n\n</h1>\n\n</div>\n\n\n\n\n[*] The inclusion criteria in the last list only. \n[**] The exclusion criteria can be found in the clinical trial above.\n\n### Task 2: \n<p>\n\n<h1 align=\"center\"><b>Task 2: Trial-level eligibility</b></h1><p><p>Here is the patient note:</p>\n\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (",
        "label": 0
    },
    "2216": {
        "output": "<EOD> The effects of the COVID\u201019 pandemic on clinical outcomes in patients with advanced non\u2010small cell lung cancer\nThe coronavirus disease 2019 (COVID\u201019) pandemic caused significant disruptions in care for patients receiving systemic therapy. It is unclear whether these changes in care affected patient outcomes.<EOD> The role of the interleukin-4 and interleukin-13 in IgE-mediated food allergy\n\nBackground: Approximately 7 million Americans have food allergies, and the number of patients with food allergy and asthma concurrently is on the rise. Allergen cross-reactivity among foods is the most common cause of allergic sensitization, and, subsequently, the reason behind this increase in prevalence of these concurrent disorders. IgE-mediated reactions are characterized by mast cell and basophil activation, which can trigger a systemic anaphylactic reaction. Th2 lymphocytes secrete IL-4 and IL-13, which have been demonstrated to induce proliferation and differentiation of both allergic effector cells. Interleukin (IL)-10 is an anti-inflammatory cytokine that is negatively regulated by IL-4 and IL-13.Objectives: This manuscript will review the current understanding of these cytokines and their involvement in food allergy.Methods:A review of literature on IL-4 and IL-13 was undertaken in the context of food allergy. Additional relevant references were identified through manual curation.Results: The epithelium is necessary to induce an inflammatory cytokine environment by activating basophils and T cells through production of IL-33. Once na\u00efve T cells are sensitized against the food antigen, they differentiate to Th2 T cells when exposed to CD3 and IL-4 antibodies. IL",
        "label": 0
    },
    "2217": {
        "output": "You might get the following answer from your supervisor:\nThere are 2 errors in the answer:\n \n\n1. In the table you included a negative factor, e.g., `fhs_d` and `htn_d`. These are not exclusion criteria, but risk factors in the patients. To make the answer correct, instead of `fhs_d` (and the other negative findings) I recommend you to add the code `exclude_fhs` and instead of `htn_d`, I recommend you to add the code `exclude_hn` (or exclude_htn). I also recommend that you modify the patient description to be like what my supervisor has in the table. I strongly suggest that you consider the answer to this question carefully. If there is room for error and you do not want to take risks, the code I give to you is completely fine, I recommend you follow the pattern exactly. Good luck!\n\n## [INST] \nWe recommend using the [exclude](functions.html#function-exclude) function to filter out specific items. A code example would be:\n\n    \n    # excluding negative findings (like diabetes to be treated with ACE inhibitors and Beta blockers)\n    \n    for item in patient.findings:\n        patient.exclude(item.finding_label).exclude('diabetes_d')\n    \n    # excluding other patients\n    \n    patient.exclude_related_patient = False\n\n<span id=\"_338-9\"># HW5-7: Patients with Cardiovascular Diseases </span><span id=\"_338-10\">- # You should implement a function named trial_patients() for assigning the </span><span id=\"_338-11\">patient_id that is relevant to this clinical trial. This </span><span id=\"_338-12\">function should accept the inputs of trial_id and return a </span><span id=\"_338-13\">list of patient_id.\n\n## An example output for this function is given in the table below:\n\n\n<table border=\"1\">\n<td align=\"left\">Patient_Id</td>\n<td align",
        "label": 0
    },
    "2218": {
        "output": "# Problems\n\nPlease refer to the [Problems](./problems.md) to find out the reasons for failing the test. \n\n\n# Useful tips\n\nSome useful tips to help you get better in this track are available on [here](./useful-tips.md).\n\n# Related track\n\nIf you're interested in working with Python, you might want to try the [Python basics track](./python.md). \n\n<EOD> Evaluation of the Reliability of the Nano-Bubble Method Combined with Hydrodynamic Focusing for Bacterial Separation and Detection\n\nRecently, nanobubble-based purification methods for microbes have been attracting increasing attention, and high-throughput microscopy and digital imaging have been applied to detect bacteria in the process of purification. However, it is very complicated and time-consuming to apply this technology to practical scenarios because of the requirement for specialized instruments and highly trained researchers. To this end, we used a hydrodynamic focusing chip with a microchannel and nanobubbles generated by ultrasonic atomization to separate high-throughput microbe samples in practical scenarios. The nanobubbles were continuously added to the flowing liquid through the microchannel to improve the separation efficiency of bacteria. We focused only on purifying large-sized bacteria from the small-sized bacteria, and tested the separation effectiveness using this equipment. The tests found that the total bacterial concentration of the sample was 1.00 \u00d7 10 7 CFU/mL, while the purified sample for subsequent identification was 1.22 \u00d7 10 8 CFU/mL. Meanwhile, we tested the relationship between the number of bacteria, nanobubbles, and flow rate to optimize the separation. The results showed that the higher the concentration of nanobubbles and flow rate, the better the separation effect. Furthermore, the fluorescence microscope photographed microbe fluorescence images to determine the amount of each species of bacteria in the sample before and after separation. The high-throughput microscopic imaging technique was effective in the identification and imaging of bacteria. Therefore, the results of this separation effect experiment indicated that our combination method",
        "label": 0
    },
    "2219": {
        "output": "<EOD> Role of the L5 loop of the beta subunit in cytochrome c oxidase: the role of the 170th residue in the catalytic activity and molecular interactions of cytochrome c oxidase.\nThe importance of three conserved amino acid residues located in the L5 loop of the subunit in cytochrome c oxidase is discussed with emphasis on the role of the 170th residue, whose mutation is associated with several forms of Leigh syndrome. The L5 loop of cytochrome c oxidase contains essential charged amino acid residues in addition to the residues that are involved in intersubunit interactions with the proton channel that forms a pore through which substrates, cations and/or protons are translocated (Pro84, Glu86, Asp91, and Arg92 in the cbb3-type oxidase of Acidithiobacillus ferrooxidans and Arg90, Glu92, and Asp93 in the aa3-type oxidase of Paracoccus denitrificans), and these amino acid residues, together with Ser185, located in this loop, comprise the inner layer that faces the membrane. It was suggested that the Glu86 residue in the L5 loop interacts with the Arg153 residue in the membrane-bound domain, thus participating in the stabilization of the substrate channel and that this stabilization depends also on the charge of the L5 loop and on the charge of the membrane-bound domain. In the present study, the 170th residue, also located in the L5 loop, of the cbb3-type oxidase of A. ferrooxidans (AfCooA) is replaced by neutral amino acids and the effects on the properties of the oxidase are investigated by analysis of the kinetics of cytochrome c, benzoate, and ferrocyanide oxidation, measurements of ubiquinone reduction and oxygen reduction by the enzyme's K d for O2, and binding of potassium and rubidium ions to the wild type and the mutant enzymes as well as by modeling the 170th residue in the wild type and",
        "label": 0
    },
    "2220": {
        "output": "<EOD> Reactive Oxygen Species-Mediated Transcriptional Regulation in Inflammatory Responses.\nSIGNIFICANCE\nThe induction of innate and adaptive responses to invaders such as bacterial and viral infections requires rapid and dynamic activation of multiple genes to allow fast adaptation to stress conditions. Accumulating evidence strongly supports the finding that altered levels of reactive oxygen species (ROS), including hydrogen peroxide, superoxide anion, and hydroxyl radicals, are necessary for initiating and modulating the host defense against various invaders.\n\n\nRECENT ADVANCES\nROS are produced in response to environmental cues and their levels are tightly controlled to avoid oxidative stress. A better understanding about the biological actions of ROS was largely achieved in the past few years by exploring the intracellular signaling pathways that are regulated by ROS and, more importantly, by elucidating the functions of these effectors.\n\n\nCRITICAL ISSUES\nThus, this review summarizes the latest information regarding how ROS affect expression of a number of cytokines, chemokines, and antimicrobial peptides that contribute to the cellular functions and immune responses. In particular, the roles of ROS redox sensors in ROS-mediated transcriptional repression and activation are discussed in this review.\n\n\nFUTURE DIRECTIONS\nFurther studies with respect to functional implications of these novel ROS redox sensors and their downstream target genes in normal and inflammatory conditions, particularly in the lung, would lead us to obtain insight into understanding their roles in lung disorders including fibrosis and cancer.<EOD> A phase I study of the novel multitargeted tyrosine kinase inhibitor cabozantinib (XL184) in patients with advanced renal cell carcinoma\n\nBackground: Vascular endothelial growth factor (VEGF) receptor inhibitors and mammalian target of rapamycin (mTOR) inhibitors both demonstrate high response rates in patients with advanced renal cell carcinoma (RCC). Cabozantinib (XL184) is a novel multitargeted tyrosine kinase",
        "label": 0
    },
    "2221": {
        "output": "## SOLUTION\n<EOD> Diagnostic value of CT findings on chest CT in patients with suspected COVID-19\n\nBackground Diagnose and prognostication of coronavirus disease 2019 (COVID-19) on chest computed tomography (CT) remain challenged due to the lack of systematic studies on imaging characteristics. Purpose To investigate the common and characteristic chest CT findings in patients with COVID-19, and to evaluate the discriminant value of CT findings to aid in the diagnosis of COVID-19. Materials and methods A total of 71 patients with COVID-19 confirmed by RT-PCR tests from January 22, 2020 to February 12, 2020 were included. According to the interval from symptom onset to CT examination, these patients were divided into A Group (\u22645 days), B Group (6-10 days), and C Group (\u226511 days). All of the patients underwent at least two CT scans. The CT images were retrospectively analyzed by two radiologists. Results Thin-section chest CT (TSCT) findings changed significantly from initial to follow-up scan in Group A. TSCT findings of pneumonia in groups A and C were significantly different from those in group B. However, TSCT findings of GGO in initial stages were similar (p > 0.050). Univariate analysis showed that TSCT findings in patients with severe and non-severe forms had no statistical differences. Multivariate analysis revealed that the percentage of consolidation of ground-glass (p = 0.003), consolidation of ground-glass (p = 0.000), and consolidation (p = 0.012) on the initial chest CT, as well as the percentage of consolidation of ground-glass (p = 0.005) and consolidation of ground-glass (p = 0.029) on the follow-up CT were significantly associated with severe cases. Conclusion In patients with COVID-19, TSCT may show significant changes as the disease evolves. TSCT findings of Group A are consistent with mild pathological changes, in",
        "label": 0
    },
    "2222": {
        "output": "### Output:\n\n\nIMPORTANCE\n\n\n\n\n\n\n\n\n\n\n\n\n\nTrial-Level Eligibility\n\n\n\n\n\n\n\n<span style=\"color:red;\">#Clinical 2080</span><span style=\"color:red;\"> 1977</span><span style=\"color:red;\"> \n<span style=\"color:red;\">#Clinical 2080</span><span style=\"color:blue;\">&nbsp;</span><span style=\"color:red;\">#24065</span><span style=\"color:blue;\">\n\n<span style=\"color:blue;\">#Clinical<sub>2080</sub>/#24065</span>\n\n1.&nbsp;&nbsp;title: \"Correlation of SMILE scores and pain scores to pain in patients with chronic neuropathic pain due to spinal cord injury\"\n\n2.&nbsp;&nbsp;principal.author.id: \"105144\"\n\n3.&nbsp;&nbsp;principal.affiliation.number: \"49620/1100\"\n\n4.&nbsp;&nbsp;principal.affiliation.name: \"University Hospital Sfax, Tunisia\"\n\n5.&nbsp;&nbsp;principal.affiliation.type: \"Org\"\n\n6.&nbsp;&nbsp;principal.affiliation.id: \"49620\"\n\n7.&nbsp;&nbsp;principal.affiliation..partof: \"University Hospital Sfax\"\n\n8.&nbsp;&nbsp;affil.years.since: \"1980\"\n\n9.&nbsp;&nbsp;doi: \"10.1016/j.jneurotrauma.2009.07.025\"\n\n10.&nbsp;&nbsp;issn: \"1556-6090\"\n\n11.&nbsp;&nbsp;issn: \"1877-7036\"\n\n12.&nbsp;&nbsp;language: \"English\"\n\n13.&nbsp;&nbsp;volume:",
        "label": 0
    },
    "2223": {
        "output": "A note on the numbering system:\n- Eligible: 2\n- Not Excluded: 1\nExcluded: 0\nNot Relevant: 0\n\n\n# Use cases\nBelow we describe some specific use cases for the eligibility assessment module, including:\n- Evaluate the eligibility of the patient according to the clinical trial eligibility criteria\n- Evaluate the eligibility of the patient according to the clinical trial exclusion criteria\n\n## Evaluate the patient's eligibility\nEvaluate eligibility for clinical trials is a three-step process.\n\n1. Assessment of eligibility or fitness: the fitness level of the patients varies between 1) Eligible, 2) Not Excluded, and 3) Excluded.\n2. Assessment of eligibility or exclusion: if the patients are not found to be eligible according to the fitness level, a full assessment will be done and the patients will be evaluated 1) Excluded, 2) Not Relevant, and 3) Eligible.\n\n3. Confirmation of eligibility: this is a yes/no answer. If the patients were found eligible at both steps 1 and 2 (i.e., they were found eligible without any exclusion criteria being met), \"Yes\" is returned; otherwise the answer is \"No\".\nAs we described above in detail, we have to iterate through the clinical trial data set and for each clinical trial trial we need the following:\n- The clinical trial data set\n- The trial-related eligibility assessments\n- The patient-related eligibility assessments\n- The trial-level eligibility assessments\n- The patient-level eligibility assessments\nBesides that, we need the following:\n- The patient's eligibility assessment to the clinical trial\n- The patient's eligibility assessment to the clinical trial (if any)\n- The eligibility assessment of clinical trial\nIn the following we introduce specific cases or examples that are important for the modeling and the definition of the eligibility assessment.\n\n1. The clinical trial data set\nThe clinical trial data set could be in an",
        "label": 0
    },
    "2224": {
        "output": "##[INST] Output\nTrial-level eligibility: 1 ) Not relevant\nTrial-level eligibility: 2) Eligible\nTrial:\n- Title: A Study of Evacetrapib in High-Risk Vascular Disease\n- Summary: The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).\n- Inclusion criteria:\n- Diagnosis of high risk vascular disease (HRVD) (that is, meet at least one of the disease diagnostic criteria of: 1)History of acute coronary syndrome (ACS) (that is, \u226530 days through 365 days after discharge for ACS) 2)cerebrovascular atherosclerotic disease 3)peripheral arterial disease 4)diabetes mellitus with documented coronary artery disease and are clinically stable (as judged by the responsible physician).\n- Must be treated with a statin for at least 30 days prior to screening. If not treated with a statin must have documented statin intolerance, or contraindication to statin\n- Have a screening high-density lipoprotein cholesterol (HDL-C) \u226480 milligram per deciliter (mg/dL) (\u22642.1 millimole per liter [mmol/L])\n- Have screening triglycerides (TG) \u2264400 mg/dL (\u22644.5 mmol/L)\n- Meet 1 of the following criteria:\n- screening low-density lipoprotein cholesterol (LDL-C) no more than 10 mg/dL (0.3 mmol/L) above the target chosen by the investigator (either LDL-C <100 mg/dL [<2.6 mmol/L] or LDL-C <70 mg/dL [<1.8 mmol/L]), OR\n- if LDL-C is greater than target, the participant must be on maximum tolerated statin dose",
        "label": 0
    },
    "2225": {
        "output": "# [CHT]\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.[INST]\nFinally, you shoud call the output that has Trial-level eligibility on each patient for the clinical trial. i.e., return a vector of size length of patients x 1, which corresponds to the scale of inclusion criteria: 0) Excluded 1) Not relevant 2) Eligible.\n@[S1] In this example, the code will run for 191 patients.\n\nThe output of assessment of eligibility is the trial-level eligibility. Each trial can be assigned between 0 and 2. A trial with two assigned to all patients is not recruitment incompatible with the study.\nAs you mentioned in the section about the assessment of eligibility, we made the calculation based on 3-point assignment of trial-level eligibility. The reason that we need to assign 3-point scale is to calculate a percentage of recruitment incompatibility. Let's suppose that there is no patient with clinical notes. The code will return zero because no patients with assessment of eligibility are used for this study. Let's assume that there are 10 clinical notes in the dataset. There are 2, 2, 6 patients with assessment of eligibility by exclusion criteria, and by inclusions criteria, respectively. In this case, the calculation of the percentage of incompatibility of the study is zero. The incompatibility is determined by the number of patients with any reasons of recruitment incompatibility and the total count of patients with assessment of clinical notes.\n\n# [RESU]\nPlease give feedback through issues or pull requests of this project.\n\nYour task is to construct the code to compare a given patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on",
        "label": 0
    },
    "2226": {
        "output": "<EOD> The evolution of sexual signalling in male Drosophila melanogaster\nThe evolution of male sexual advertisements has been traditionally studied by focusing on the number of traits used for such advertisements, or the costs and benefits of the traits used for such advertisements. We propose that more attention should also be paid to the way in which different traits are combined in male sexual displays. Here, we measured the components of the male wing display in males from several Drosophila melanogaster lines which vary in their male reproductive success, to test if male displays are better advertisements of male reproductive ability in some situations. We found that males from one line of D. melanogaster make better wing displays than males from the other lines, and males in better form displayed the highest quality displays. There was a consistent pattern of male display traits being integrated when individuals perform their displays, suggesting that display quality is assessed as a unit.<EOD> Detection of Dorsal Cutaneous Nerves for Sphincter Pharyngoplasty with Transoral Microdissection\nThe authors propose a method to detect dorsal cutaneous nerves for sphincter pharyngoplasty with Transoral Microdissection (TOM), which makes it easy and safe to detect the cutaneous nerve. The authors studied the anatomy and the function of the dorsal cutaneous nerves (DCNs) in 20 sides of 10 cadavers to examine the nerve pathways. An anterolateral approach was used in 20 sides of 10 cadavers. A nerve loop dissector was used to dissect laterally the branches of the infrahyoid nerve in the superficial layer and dissect between the platysma muscle and the posterior layer of the parotid gland. The branch of the infrahyoid nerve and the cutaneous nerves in the subcutaneous layer were disclosed. The median to lateral extent of the DCNs was 0.4\u20131.0 cm with a mean of 0.6 cm and the distal to proximal extent was 0.4\u20131.2 cm with a mean of 0.9 cm between the nerve of the anterior belly of digastric muscle and the platysma muscle. The median",
        "label": 0
    },
    "2227": {
        "output": "## [MODULE] LABEL\n\n# [CAPTION] Title: Diabetes Treatment and Trial Recruitment\n\n# [CAPTION]\n\n\n[/CAPTURE]\n\n# [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL",
        "label": 0
    },
    "2228": {
        "output": "Note: \nNote that the assessment of eligibility for a clinical trial is a binary one, i.e., patients are either eligible or not eligible. In this case, you can use `==1` or `!==1` to assess trial eligibility.\nAs you may noticed, if you are interested in `Age` you can use an empty dictionary.\n\n## Assessing inclusion criteria and patient eligibility\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to assess a given inclusion criteria and decide if a prospective participant meets the requirements. The factors that allow someone to participate in a clinical study are called inclusion criteria.\n\nFirst, you should be familiar with the inclusion criteria for a clinical study. You can find them in the first section of the patient note; the inclusion criteria of the clinical trial are given in the clinical trial note under the `Inclusion criteria` label.\n\nWe define all `Inclusion criteria` using a dictionary with key-value pair structure, where keys are names of elements of inclusion criteria and values are strings you should assign for elements.\n\nSo, we say that if you satisfy all the criteria described in the dictionary, then the patient will be eligible to participate in the clinical trial.\n\nFor example, the entry `Age: 25` has value `25` assigned to the criterion `Range of age: 21 - 65`. \n\nYou can use this dictionary to define `Eligible` variable as well. `Age: 25` element of criteria is 25; this will cause the variable `Eligible` to be set to `True`.\n\nNext, you should create a structure that will be used to hold the evaluation results; here you will assign all the criteria to a list in order to be able to evaluate all the criteria on a patient. Then you should assign the patients to the structure and evaluate the criteria based on the dictionary. \n\nNext, you should compute the trial eligibility on patients and put the results in the corresponding list. `Trial eligibility` is the string in the format `Trial eligibility: {1: 2, 1:2}...`, where `1` is the trial index and `2` is the patient index within",
        "label": 1
    },
    "2229": {
        "output": "The results of all examples:\n1) Not relevant:\nPatient does not have sufficient information to qualify for the trial.\n2) Excluded:\nEligible patients should not meet one of the trial's exclusion criteria.\n3) Eligible:<EOD> .\nAIM\nThe purpose of this study is to investigate how the relationship that occurs between mother and infant through the touch, is mediated by the oxytocin hormonal system.\n\n\nMATERIAL AND METHODS\nTen mother-infant dyads were involved. Three days and three months after the first breastfeeding, saliva was collected from both the mother and the infant. The amount of oxytocin was measured for each sample by means of the enzyme immunoassay, a competitive method in which the standard and the antibody (protein A)-conjugated enzyme are used, together with the hormone to be assessed, and the presence of the hormone reduces antibody-enzyme binding to the antigen in a competitive fashion.\n\n\nRESULTS\nThe results have shown that: 1) in the first three days after birth, when mother and infant meet and establish the tactile relations, the amount of oxytocin produced is significant in comparison to the value 20 min after the first breastfeeding. 2) Mother's oxytocin is significatively linked with the mother's affectivity during breastfeeding: in fact, mother's oxytocin level is correlated with the degree of intimacy experienced with the infant. 3) The level of infant's oxytocin is significant in all the phases of breastfeeding: a significant decrease is detectable after breastfeeding, in comparison with the value 20 min before breastfeeding.\n\n\nCONCLUSIONS\nThe results demonstrated that breastfeeding is an effectual and relevant moment of life for the interaction between mother and infant, able to contribute to their affective bond.<EOD> .\nOBJECTIVE\nTo observe the therapeutic effect of electroacupuncture combined with methylprednisolone on the hind limb muscle of rats with spinal cord injury through regulating apoptosis of the neurons in the spinal cord.\n\n\nMETHODS",
        "label": 0
    },
    "2230": {
        "output": "\u2666 Exclude the following lines, e.g., `0) Excluded`. \u2666 The first letter of the line should begin with the trial letter, e.g., TxC01.\n[/CENTER]\n\n\n# Hands-on\n<EOD> A Case of Tuberculosis of the Knee: Differential Diagnosis in Adults\nTuberculosis of the knee is a very rare clinical occurrence. The diagnosis is usually simple if the radiographs and histological findings are consistent, but clinical and radiographical features may also be similar in many other diseases of the knee such as osteoarthritis, pyogenic arthritis, rheumatoid arthritis and Paget's disease in adults. The difficulty in differentiating between the above conditions as well as the possible pitfalls in treatment have led to the need of an occasional arthrotomy in a case of suspected tuberculosis for histological and cytological studies. A case describing tuberculosis of the knee diagnosed following total arthropectomy is presented, as are the differential diagnoses in other inflammatory or neoplastic conditions of the knee.<EOD> The use of 201Tl-chloride myocardial scintigraphy in monitoring chemotherapy in patients with breast cancer. I. Changes in normal cardiac perfusion.\nThe effects of chemotherapy on myocardial perfusion were studied by cardiac myocinetic imaging with 201Tl in six patients with breast cancer, using SPECT technique. The mean activity of 201Tl injected (79.54 +/- 7.13 MBq) into the hearts of healthy volunteers was 50.22 +/- 1.57% by 10 min and 32.24 +/- 12.67% by 45 min after injection. SPECT images were obtained using an Anger camera and a 20% energy window set around the 140.5 keV photopeak of 201Tl for imaging. Each patient was scanned after the second, fourth and sixth cycle of chemotherapy. The average of the percentage of the maximal heart",
        "label": 1
    },
    "2231": {
        "output": "<p class=\"p1\">Please remember, in Python, <code>print(\"Trial-level eligibility: \") yields a <a href=\"https://docs.python.org/2/library/string.html\">string</a>, and so a single carriage return doesn't suffice to print a newline. A trailing newline is included for Python 3.6+. Your Python version? Please let us know in the comments section below!</p>\n\n\n\n\n<EOD> Effect of propranolol 160 mg plus 80 mg sustained release on quality of life and sleep, measured by the Pichot scale, in patients with chronic simple hypertension.\nAIM\nThe effects of propranolol 160 mg + 80 mg sustained release on quality of life, fatigue and sleep, measured by the Pichot scale, and sleep architecture in chronic simple hypertension patients were shown.\n\n\nPATIENTS AND METHODS\nTotally, 344 hypertensive patients were enrolled in this clinical trial. For all the patients a medical history and standard blood pressure (BP) measurements were done, as well as EKG recording during 24 hours monitoring and Holter monitoring using the Pikhot scale. All patients were allocated to five groups with similar baseline age, sex, height, weight, SBP, DBP and EKG findings. Propranolol 160 mg + 80 mg sustained release was added to the treatment of chronic hypertensive patients, and after 3, 7 and 28 days (in the third, seventh and ninth weeks) the same measurements were repeated.\n\n\nRESULTS\nIn the sixth week (the day after the patients had taken propranolol) the quality of life, fatigue and sleep showed a significant improvement (p < 0.05). The Holter monitoring did not show significant changes of the PQ, QTC intervals and P-electrocardiograms.\n\n\nCONCLUSIONS\nThis propranolol formulation can be used with greater safety in chronic hypertensive patients. (Int J Circumpolar Health 2002; 61: 121-1",
        "label": 2
    },
    "2232": {
        "output": "Copyright (c) <NAME>. This source code is licensed under the MIT license and its use is limited to academic purposes.\n\n---\n\n# Assigning Patient Level Factor\n\nYou have learned earlier that, in a clinical trial, a patient's eligibility for the clinical trial is determined by certain clinical variables called factors. You should assign each patient's eligibility status for the clinical trial to a factor.\n\nSome of the following factors that may occur once or more than once with or without value(s) for every patient. Some factors occur multiple times with different values. \n\n**Criteria for assigning the factor_id of a factor: The last_id element of the factor should be equal to its factor_id.** \n\nA patient may have zero or more than one eligibility status for a factor. In the patient case we used in Part 5, a patient can have more than one eligibility status for the same factor, \"age\" because he has two age values, \"25 years old\" and \"30 years old\", as shown in the figure below.\n\n![](../../img/assign_factorized_eligibility_patients.png)\n\n\nTo assign the factor factor_id , use `factor_id: [patient_eligible_factor_id]`, i.e., factor: `[25,24,30]`, where patient_eligible_factor_id is the patient's factor_id of the factor. \n\nTherefore, the factor `age` has to be assigned a factor_id `25` for patient id 1 and factor_id 30 for patient id 2 and 3. \n\n```python\noutput.variables['treatment_study_patient_patient_eligible_factor_ID'].value = [str(i)[-3:]]\n\n# Factors list in patient_patient_eligible_factor_ID\n\n0 1 2 \n\n\n# Assigning Patient Level Factor to each group.\n\nA patient can have multiple values for a factor due to the factor's multiple occurrences such as patient`s age or gender. If a patient cannot participate in a trial due to unmeet some factors, the",
        "label": 1
    },
    "2233": {
        "output": "You can watch a video about the INST environment in the following [URL](#/videos/video-3781717004).\n\n## Video: Instructions To Use R\n<EOD> Imaging of periprosthetic shoulder instabilities (Hill-Sachs and Bankart)\n\nProper imaging evaluation of shoulder instability is crucial for accurate diagnosis and the appropriate treatment planning of patient. Bony injury is a common finding in patients with shoulder instability, and bony defects in the glenoid and humeral head should be differentiated from labrum injury. The purpose of this article is to review the imaging anatomy, classifications, risk factors, and imaging evaluation techniques of 2 types of bony defects, humeral head defect (Hill-Sachs) and glenoidal defect (Bankart), with a focus on radiographs, computed tomography, and magnetic resonance imaging. (Imaging Sci Dent 2016; 46: 45-51)\n\n# Introduction\nIn recent decades, the prevalence of shoulder instability and a concomitant humeral head defect has increased, possibly as a result of the increasing participation in collision or overhead sports. [bib_ref]  Humeral head defects in throwing athletes: prevalence on plain radiographs and relation..., El [/bib_ref]  When evaluating patients with shoulder pain after trauma, a humeral head defect may be present and must be differentiated from bony abnormalities, labrum, and soft tissue dislocation.\nThe term humeral head defect (Hill-Sachs) refers to a humeral head defect caused by an initial humeral head impact with the glenoid during glenohumeral dislocation, and a bone defect of less than one-third of the depth of the articular surface is classified as superficial defect. [bib_ref]  Hill-Sachs lesions and their relationship to arthropathy in patients with anterior shoulder..., Mera [/bib_ref]  In comparison with the deep (more than one-third depth from articular surface) defect, patients with a superficial defect do not tend to have recurrent instability. A deep defect more likely destroys the articular surface with surrounding soft tissues, while a shallow defect does not",
        "label": 1
    },
    "2234": {
        "output": "If the trial-level eligibility is `1) Eligible` or `2) Eligible` (i.e., the patient is eligible for the trial), your output should be `Eligible`. If the trial-level eligibility is `0) Excluded`, your output should be `Not eligible`. If the trial-level eligibility is `0) Excluded`, but this is due to other trial exclusions (e.g., a patient takes an eligibility medication), we do not consider this patient to be an eligible trial candidate (i.e., you should output `Not eligible`). If there is no trial-level eligibility, we do not recommend determining eligibility.\nFor this task, please focus on the `not relevant` patients. To achieve this, you only need to focus on patients who received a `0` for either exclusion or inclusion criteria evaluation. You need to focus on these patients to not count them as candidates, and report the number of exclusion/exclusion-related patients.\nTask 13: Determine how many patients would be excluded from a trial by applying the exclusion criteria. (see Evaluation for the exclusion criteria -Task 4 above). This task should output the number of exclusion patients among the not relevant patients (e.g., `Excluded patients: n=274/2,391 = 3.24%`). In other words, the number of patients who are excluded from the clinical trial by the exclusion criteria.\nTask 14: Determine how many patients would be excluded from a trial by applying the inclusion criteria. (see Task 6 above). If the number of patients for whom an inclusion criteria is non-evaluable is reported as `0`, the number of patients who are excluded from the clinical trial by the inclusion criteria is considered to be the same as the total number of included patients. In that case, we suggest not counting patients as an inclusion-related exclusion. In this scenario, the task outputs a number as `11/2,263 = 0.49%` for you.\n\n### Task13: `not relevant patients: n=113`\n\n### Task 14: `Not relevant patients: n=113`.",
        "label": 0
    },
    "2235": {
        "output": "_Please, read the [instruction](../manual/getting-started.md) on running the app locally first. Do I need to install any packages?_\n<EOD> .\nThe role of the family physician during the first year of the neurological patient's illness is to confirm the neurological diagnosis and to ensure good neurological, supportive care, with special attention to the patient's complaints, in particular depression, anxiety, fatigue, sleep problems and sexual dysfunction. The family physician is also involved to make sure that the patient's medication is well tolerated, the patient knows how to avoid common side effects of the medication and to take a symptomatic treatment when the patient has a flare of the illness, if the patient suffers from a progressive disease, and to organize the patient's follow-up after specific therapy or rehabilitation. In some circumstances, he has to take care of the patient's family in providing the necessary information and support. If a disease requires specific care, the patient will be referred to the neurological specialist, who in his turn will coordinate the care of his patient. This review will summarize the role of the family physician in the care of patients and in the organization of the follow-up after the diagnosis of neurological disease is made.<EOD> .\nWe report on a 10 day old boy with perforation of the ileum and a laceration of the appendix. He was treated in the NECU-ICU. After an uncomplicated neonatal period, the patient became unwell with colicky abdominal pain and a tense abdomen a few days before admission. Immediately after laparotomy an ileum perforation with transmigration was observed. A second operation was performed the next day for laparotomy and appendectomy. The postoperative clinical course was complicated by a septic ileus. Therefore the abdomen was opened for the third time with reduction of the ileum perforation. He underwent a secondary operation 5 days later to repair an extensive peritonitis. Infection and ileus was treated by broad spectrum antibiotics. After a few days the abdomen was opened to treat a bowel obstruction.",
        "label": 2
    },
    "2236": {
        "output": "### Tutorial\n\n1. Load your module file with `import modulefile!`. \n2. Import required libraries, e.g., `import data`.\n3. Import all functions you've written as we shown in step 2.\n4. Fetch the example data with `Read.data`, run your script and see the results.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n```\npackage: data\n\nRead.data<-function(data){\n  file_name <-\"hdpdata.xlsx\"\n  folder <-\"homework/1/hdp_data\"\n  read_excel <-read_xlsx(file_name, sheet = \"patient\", start_row =2, header=TRUE)\n  read_excel$exclude <-as.numeric(!read_excel$exclude)\n\n  read_excel$age <-try(age_vector = as.numeric(read_excel$age[2]::as.numeric()), use.list=\"attr\")\n  read_excel$type <-try(type_vector = read_excel$type::as.numeric(), use.list=\"attr\")\n  read_excel$sex <-try(sex_vector = read_excel$sex, use.list = \"attr\")\n  read_excel$diabetes <-try(diabetes_vector = read_excel$diabetes, use.list=\"attr\")\n  read_excel$t2dm <-try(t2dm_vector = read_excel$t2dm, use.list = \"attr\")\n  if (!is.na(read_excel$fbs.diabetes) && !is.na(read_excel$type)) {\n    read_excel$HbA1c <-read_excel$fbs.diabetes/read_excel$t2dm\n  }\n\n  read_excel <-read_excel[!(read_excel$diabetes ==",
        "label": 0
    },
    "2237": {
        "output": "<EOD> A Review of Surgical and Non-Surgical Management of the Inverted Papilla\nObjectives To evaluate the clinical efficacy of surgical interventions and alternative conservative methods to achieve recanalization of the papilla for patients with inverted papilloma. Data Sources We retrieved all cases of primary or recurrent inverted papilloma from the English-language literature through a MEDLINE and PubMed search as follows: \u201cinverted papilloma (IP) AND surgical OR conservative management.\u201d Review Methods Studies published through June 2018, including those in the gray literature, were considered for inclusion. There were no restrictions on the basis of sample size, publication date, ethnicity, or language. Results The Medline search identified 269 articles; 230 were considered after duplicates were removed. One hundred nine articles were excluded at the review of abstracts because they were not English language, not studies of IP, not observational studies, not studies that reported on nonsurgical or surgical approaches to management, or not case reports/series. Forty-five studies were retained as eligible and the references were crosschecked. One additional study was identified, yielding a total of 46 studies included for final review. Conclusion The success rates of conservative and surgical interventions vary greatly, and no single management plan is optimal for all patients with IP of the sinuses. Conservative methods may be best for solitary, low-grade, non-infiltrative lesions that do not encroach on the surgical bed, while surgery alone or in conjunction with conservative approaches is optimal for multifocal disease, higher-grade lesions, and tumors that exceed the surgical bed or infiltrate adjacent structures.<EOD> The impact of mRNA-1273 COVID-19 vaccine on immune response and acute coronary syndrome: A cohort study in Korea\n\nIn December 2020, the first COVID-19 vaccine, named mRNA-1273, was approved by the Korean Ministry of Food and Drug Safety. This study examined immune response and clinical characteristics of acute coronary syndrome (ACS) after COVID-19 vaccination. This cohort study evaluated 217 patients with ACS",
        "label": 0
    },
    "2238": {
        "output": "You can test your program on your local browser. After saving your program, reload it with the ``rerun``. \nOn the other hand, to add your program to the [crawler job][5], save your program as one [job][6] on Colab. After saving your job, reload it with the ``rerun``.\n\n### 2.\n\n```python\n# This program demonstrates Colab's Python notebook interface.\n\n# First function will take a file path and return a file object.\n# That way this function can be used in multiple ways.\n\ndef file_open(file_path):\n     return open (file_path)\n\ndf=file_open(\"/content/Clinical trials.csv\")   \nfor row in df:\n   print (row[\"PatientID\"])\n   print (row[\"Sex\"])\n   print (row[\"Age\"])\n   print (row[\"Inclusion_criteria1\"])\n   print (row[\"Inclusion_criteria2\"])\n   print (row[\"Eligible\"])\n```\n\n### 3.\n\n```python\ndf=file_open(\"CabgPt-ClinTrials_1.csv\")\n\ndf\n\n``` \n\n### 4.\n\n```python\n# First row will be an identifier for each trial\ndef firstRow():\n     for index, row in df.iterrows():\n        if index == 0:\n           trialID=str(row[0])\n           return trialID\n    return trialID\n\ntrialID=firstRow()    \n\n# If it says not found then it means no data\ndata_frame_1 = pd.DataFrame(index=trialID) # This is where we will populate with the new data\n\nfor tup in range(0,513):\n    trialID = firstRow() # We define trialID as an identifier for each trial\n    trialName = trialID.ljust(15,'-') + str(tup+1) # How many trials exist?\n    data_frame_1 = pd.DataFrame(trialID=firstRow(),\n                        trialName=trialName,\n                        columns = [\"PatientID\",\"Inclusion_criteria1\",\"In",
        "label": 0
    },
    "2239": {
        "output": "<EOD> Necessity of Grafting of Submucosal Collagen and Autogenic Cultured Fibroblasts onto the Floor of the Vagina to Make a Successful Acellular Porcine Bladder Urethroplasty\nIntroduction: This report presents an innovative combined approach where submucosal collagen grafts interspersed with autogenic cultured fibroblasts were grafted onto the floor of the vagina to strengthen its integrity, for successful acellular bladder submucosa graft urethroplasty. Materials and Methods: Acid-pepsin digestion technique was used to prepare the grafts from the submucosa of decellularized porcine bladders using an ethanol/dimethyl sulfoxide treatment method. The histology of the graft was assessed by using light microscopy and transmission electron microscopy. Then, acellular submucosa was placed into the floor of the vagina of 32 female New Zealand white rabbits, and submucosal grafts interspersed with the autogenic cultured fibroblasts of the rabbits were randomly implanted into the floor of the vagina of another 10 rabbits after one month. All the acellular submucosa grafts were examined after one and 3 months of implantation to evaluate tissue rejection and recellularization. Finally, 6 healthy female pigs were killed, and 33 cm of the porcine bladder submucosa was used as a free vascular tube graft. The tube was implanted into 1-month-old New Zealand white rabbits and was harvested after 2 months to assess the degree of vascularization. Results: Thereafter, the bladder submucosal collagen grafts interspersed with autogenic cultured fibroblasts were implanted into the floor of the vagina at the 3rd month. The grafts did not cause rejection at the first and 3rd months, and autogenic fibroblasts were seen in the implanted grafts. Conclusion: In conclusion, it seems that the presented combination of surgical approaches, using submucosal collagen",
        "label": 0
    },
    "2240": {
        "output": "**Task 2b : [TASK2b] [A6, page 103]**\n\nLet $d$ be a data matrix. For every $i>1$ it contains 8 rows corresponding to 8 different possible answers to a trial-level eligibility evaluation of the $i^\\mathrm{th}$ patient from the same clinical study:\n1) Excluded\n2) Not relevant\n3) Eligible \n\nYou should answer the following questions:\n### $\\mathbf{a}$\n\n1. Consider the above example and compare the matrix $d$ after merging columns 2 and 3, with the corresponding matrix $d'$ after merging columns 6 and 7.\n- Give the differences between the 2 matrices\n- Give the resulting 2 matrices\n2. Write your own function that merges two data matrices (in ascending order) as follows:\n- If column 1 of the first matrix ends with a 1: Merge columns 2 and 3 of both matrices.\n- If column 2 of the first matrix ends with a 2: Merge columns 3 and 4 of both matrices\n- Otherwise, merge columns 6 and 7 of both matrices.\n\n```@section E10217 Solution[INST]\n```@imported::import1_2\n```@input  E10217 Solution[INST]\n```@input output=E10217 solution [INST]\n```@input [INST]\n```@output E10217 solution [INST]\n```\n\n```@input  E10217 Solution[INST]\n```@imported::import1_2\n```@input  E10217 Solution[INST]\n```@input output=E10217 solution [INST]\n```@input [INST]\n```@output E10217 solution [INST]\n```\n\n```@input  E10217 Solution[INST]\n```@imported::import1_2\n```@input  E10217 Solution[INST]\n```@input output=E10217 solution [INST]\n```@input [INST]\n```@output E10217 solution [INST]\n```\n\n```",
        "label": 0
    },
    "2241": {
        "output": "## Exercise 6\nWrite Pseudocode in MATLAB as follows:\n\n1. Set `t = 0` to begin.\n2. `for patient_note = Patient_note`:\n  - `Patient_number = fgetl(patient_note)`\n  - `for trial = trial_list`:\n     \n      - `if fgetl(trial) == 'Inclusion criteria':`\n        - `for clinical_trial.Criteria_tested = 'Include':`\n         \n            - `if `Patient_number == fgetl(trial)`:` \n            - `Patient_eligibility = 2) Eligible:`\n            - `fput_back(Patient_number, fgetl(patient_note), 1); \n            - `fclose(patient_note); \n            - `break;`\n         \n        - `else:`\n         \n            - `fput_back(patient_number, fgetl(trial), 1); \n            - `fclose(patient_note);`\n         \n        - `fput_back(patient_number, trial.Criteria_tested, 1); \n         \n         \n      - `end`\n      \n      - `fput_back(patient_number, fgetl(trial), 1);` \n     \n      \n      - `if `fgetl(trial) == 'Excluded'::`\n        - `i = i + 1;`\n        - `fput_back(i, fgetl(trial), 1);` \n        - `fclose(patient_file);` \n        - `break;`\n     \n      - `else:`\n        - `s = s + 1;`\n        - `fput_back(i, fgetl(trial), 1);` \n        - `fclose(patient_file);` \n        - `break; \n      `end` \n\n4. Increase `i` by `1` to begin the next cycle and continue cycle until all lines of the patient_file were read.    \n\n# Discriminant analysis\n\n## Background\n\nIn linear discriminant analysis",
        "label": 2
    },
    "2242": {
        "output": "<EOD> Synthesis of the C-terminal fragment of a tissue inhibitor of metalloproteinase.\nThe synthesis of the C-terminal fragment (C-TP) of human recombinant tissue inhibitor of metalloproteinases (TIMP) 1 (C-TP = Arg40 to Ala76) was achieved by solid phase chemistry. In order to eliminate an aqueous-organic interfacial artifact of the N-terminus of TIMP, the N-acetyl-N-terminal fragment (Ac) of TIMP1 (TP = Arg1 to Arg40) was synthesized, but it was completely inactive against various metalloproteinases. In order to obtain the active Ac-(1-40) TP, the hydrophobic side chains in Ac-(1-40) were modified by cysteine and Lys side chain protections, and then the N-terminus Cys-Ala modification was used to eliminate the side effect on peptide synthesis. Finally, Ac-(1-40) TP was synthesized on Wang resin and cleaved in 4 M HCl solution with the yield of 60%.<EOD> The impact of pretransplant dialysis modality on the kidney graft survival: A comparative evaluation of hemodialysis and continuous ambulatory peritoneal dialysis patients.\nBACKGROUND\nThere is no optimal method of dialysis for long-term hemodialysis (HD) patients before they undergo kidney transplantation. The aim of the present study was to evaluate the pretransplant dialysis modality with primary graft failure and graft and patient survival rates.\n\n\nMATERIAL/METHODS\nOne hundred and forty-seven kidneys from 109 patients who were on chronic HD therapy were transplanted, and 63 kidneys from 51 patients who were on continuous ambulatory peritoneal dialysis therapy were transplanted during the period between March 1999 and October 2009 (median follow-up 50.9 months). HD and peritoneal dialysis (PD) pretransplant dialysis patients were evaluated separately. Kap",
        "label": 0
    },
    "2243": {
        "output": "You can download the example and sample dataset from here.\nPlease note that there is another answer of this challenge. I made this answer as a follow up to the answer given by [<EMAIL>](https://stackoverflow.com/users/246707) with help from [<EMAIL>](https://stackoverflow.com/users/194837136/yoonkim).\n<EOD> A novel method to evaluate the adhesiveness of a denture base acrylic resin.\nPURPOSE\nThe purpose of this research was to identify if a new adhesiveness test can quantitively and qualitatively evaluate the bond strength and the surface morphology of two acrylic resins cemented together with the bond strength test.\n\n\nMATERIALS AND METHODS\nA poly (methyl methacrylate)/bisacryl block that was cast into a mold was made. A 4 x 4 x 2 mm bar of the block was made. A dumbbell-type specimen was made from this bar. For this procedure, the denture base acrylic of the Barodent was used. The adhesiveness was cemented to an acrylic resin base with a dental adhesive. A standardized stress of 0.5 N was applied, and the fracture load was recorded. After the fracture specimen was broken, its cross section was observed under a scanning electron microscope to examine the specimen fractured surface.\n\n\nRESULTS\nThe results showed that the Barodent had significantly better adhesion than the heat-activated denture base acrylic resin (MA) (p < 0.01). Also, adhesive bonded specimens had better adhesiveness than the denture base acrylic adhesion (p < 0.01). From SEM observations, a micro-sized, clear fracture surface with an elastomeric cohesive (micro) fractured surface was observed in the heat-activated denture base acrylic resin-adhesive specimen. However, in the Barodent-adhesive specimen, larger particles of adhesive were observed on the surface. Large cohesive fracture surfaces of the",
        "label": 0
    },
    "2244": {
        "output": "A: Using PANDAS.\nFor example, this would output \"Excluded\". I think that it is the number of eligibles you want, but if that is not the case, then you will need to output that for each patient. \n<EOD> Diagnostic Value of a Preoperatively Performed Lidocaine Infusion Test in Evaluating Spontaneous Vagal Nerve\u2010Mediated Regurgitation of Solid Food\nAn increasingly common presentation in the multidisciplinary dysphagia clinic is the patient who has the preoperative finding of regurgitation of solid food into the esophagus after swallowing solid meals. Diagnosis of this condition is not easy. At present the only established treatment is pharyngeal myotomy, and this surgical procedure is not appropriate for all of these patients.<EOD> Clinical and pathological findings in a cow with an intrasplenic haemangioma.\nTissue for histological examination was obtained from the spleen of a 7-year-old Swiss Braunvieh cow which presented clinical signs of splenic disease. A tumour which was histologically diagnosed as splenic haemangioma, was removed surgically. A splenectomy was considered but a splenic autotransplantation was carried out (right kidney). The diagnosis was supported by clinical findings, splenectomy and post-mortem observations. Two weeks after removal of the tumour the cow died and a necropsy revealed generalized oedema of the subserous fasciae around the liver, kidneys, abdominal cavity, brain and myocardium, pulmonary oedema, hypoproteinaemia or hyperbilirubinaemia and acute pneumonia. At necropsy no haematoma formation was observed at the site where the spleen was positioned by the autotransplantation. No microorganism was demonstrated in the blood.<EOD> Prolonged hypotension caused by overdose of 100% nicotine solution\nA 24 year old man with schizotypal disorder consumed an unknown quantity of 100% nicotine solution. His last recorded observation recorded his systolic blood pressure at 90",
        "label": 0
    },
    "2245": {
        "output": "A: I faced a similar problem earlier. I came up with an ugly non-standard solution. It's pretty complex to reproduce without an example\nThere are 2 parts:\n\n*\n\n*Get patient_note from a data frame\n\n*Process patient_note and pass patient_id to trial_id.\nWhat I did is:\n# get patients data, and patient_note as a list\ndf = df[df.ClinicalTrial.isna() & df.patients_ids.isna() & df.ClinicalTrial.name == \"Atrial Fibrillation Clinical Trial\"] \npatients = df.ClinicalTrial.shape[0] #patients in trial\n# list of patient notes, patient_id, trial_id\npatient_note = patient_list_df['patient_id'].tolist() #make to dictionary\n\n\nA: My solution is the following:\n#read patients data\ndf = df[df.ClinicalTrial.isna() & df.patients_ids.isna() & df.ClinicalTrial.name == \"Atrial Fibrillation Clinical Trial\"] \ndf = df.drop('patients_ids', axis=1)\ndf.head(1)\n\n#patient_note\npatients_data = df[df.ClinicalTrial.isna() & df.patient_note.isna()]\ndf.ClinicalTrial.shape\n#list of patients data for trial, patient_id\npatients_ids = df.patient_id[0,0]\npatient_note = patients_data['patient_note'].T.astype( float).tolist()\n#patient_id, patient_note\nfrom numpy.matlib import ones\nmat = ones((patients_data.shape[0],2), dtype= int)\noneD = mat.astype( int).T #2 dimension tensor\npatient_id = patients_ids.values #2 dimension tensor\nfor patient_id in range(0, patients_data.shape[0]): #\n print(patient_id,oneD[patient_id,0]) #1 dimension tensor\nmat[patient",
        "label": 0
    },
    "2246": {
        "output": "<EOD> Clinical profile of patients operated on for acute aortic syndromes\nThe aim of this study was to evaluate a prospectively collected cohort of patients who underwent surgery for acute aortic dissection (AAD) and/or aortic rupture (AoRu) in order to assess the clinical factors that correlated with in\u2010hospital and follow up outcomes.<EOD> Role of bone marrow stromal cells in regulating tumor cell growth and angiogenesis in primary brain tumors (glioblastoma)\nBackground and Purpose: The aim of this study was to examine the role of bone marrow stromal cells in the tumor microenvironment of glioblastoma multiforme (GBM). Materials and methods: Fresh bone marrow specimens were obtained from seven patients with GBM and used for culture of bone marrow stromal cells (BMSCs). BMSCs were cocultured with GBM cells in ratios of 0/100:100, 50:50, and 0/100 followed by the analysis of tumor cell and endothelial cell growth. The results were compared to those of 13 control cell types of human bone marrow. Results: BMSCs had no effect on tumor and endothelial cell growth. The tumor cell growth was not altered even after pre-stimulation with transforming growth factor alpha. In contrast, the tumor cell growth was inhibited by fibroblast conditioned-media with BMSCs (50:50) or BMSCs alone (0/100) as compared with a control cell type. The endothelial tube formation and migration assay indicated that BMSCs up-regulated the proliferation and migration of human umbilical vein endothelial cells which lead to microvessel formation in vitro. Conclusions: It is concluded that BMSCs exhibit a paracrine activity via secretion of unknown soluble factors that may regulate tumor cell and endothelial cell growth.<EOD> Efficacy of transpupillary thermotherapy in vitreoretinal interface disorder after cataract surgery: a pre",
        "label": 0
    },
    "2247": {
        "output": "<EOD> Differential Activation of Hepatic Glucose-6-Phosphatase, Phosphoenolpyruvate Carboxykinase and Alkaline Phosphatase Genes during a 24-h Period in Response to Fasting/Refeeding\nIn vivo gene expression was studied to investigate if the induction of hepatic gluconeogenic enzymes during a 24-h period is a synchronous event or a staggered event as suggested previously by the in vivo study of hepatic glucose-6phosphatase (G6Pase) and phosphoenolpy ruvate carboxykinase (PEPCK) mRNA changes. Three enzymes--G6Pase, PEPCK and alkaline (tissue) phosphatase (AP) as marker enzyme of hepatic stellate cells were measured. Gene expression of each enzyme and the corresponding mRNA of rat liver at different time points during a 24-h light/dark cycle of rat kept under standard laboratory conditions and deprived of food for different time periods were studied. A time-dependent increase in G6Pase, PEPCK and AP enzymatic activities was detected during the 24-h light/dark cycle. During fasting, there was a significant increase in G6Pase activity only at the end of the dark period (10 to 19 h) after food deprivation and PEPCK was significantly elevated during the whole dark period (10 to 23 h) after food deprivation. A decrease on PEPCK mRNA level after food deprivation was detected whereas G6Pase mRNA was unchanged. This study revealed a synchronous activation of G6Pase, PEPCK and AP enzymatic activities and it was concluded that differential activation occurred in an enzyme-specific manner throughout the 24-h period. The results of this study confirm some previously controversial findings and suggest that hepatic G6Pase and PEPCK are not activated simultaneously and in synchrony during a 24-h period.<EOD> Development of a Novel Ebola Virus Mouse Model That Can Better Mimic the Severe Disease Seen in Humans\nABSTRACT There",
        "label": 0
    },
    "2248": {
        "output": "![[image:15.png]]\n\n### Note: \nAfter getting the result of the eligibility assessment procedure with the command `patient_data --clinical_trial`, you need to repeat this procedure in the same patient with the next trial of interest. Be careful that the trial name needs to be changed for each trial.\n\n## 35. Using command `patient_data`, change the trial for a patient to find out the Trial-level eligibility\n\nIn the command line, use the patient's ID that you found above or the patient's name. If you don't remember the name of the patient, you can still search patient and use the [? ] button to look for the patient by ID. For example, let's suppose that we want to change the trial for the patient ID of 10 in the list in this example. \n`# patient_data \n122458 A/B A/B A/B A/B 111122 A/B C/D A/B C/D A/B 111121 A/B C/D A/B C/D A/B 122459 A/B C/D A/B C/D A/B 122460 A/B C/D A/B C/D A/B 101221 A/B C/D A/B C/D A/B 000000 A/B C/D A/B C/D A/B 122462 A/B C/D A/B C/D A/B 122459 A/B C/D A/B C/D A/B 111121 A/B C/D A/B C/D A/B 101121 A/B C/D A/B C/D A/B Excluded 000002 A/B C/D A/B C/D A/B 001122 A/B C/D A/B A/B Not relevant 020222 A/B C/D A/B A/B 11112",
        "label": 0
    },
    "2249": {
        "output": "[TEST100]\n<issue_comment>username_1: @username_0 Thanks for all the changes!  \r\n\r\nI need a week to get back into the flow of the code to do a code review.  \r\n\r\nThanks  \r\n\r\nRyan\n<issue_comment>username_2: @username_0 Thanks.<EOD> Effect of 11beta-hydroxysteroid dehydrogenase inhibitor and glucocorticoid receptor antagonism on osteoclast activity in C57BL/6J and BALB/C mice.\nIn vitro investigations demonstrate that 11beta-hydroxysteroid dehydrogenase (11beta-HSD) can regulate osteoclast function via locally produced glucocorticoids (GC). Cells of the 11beta-HSD type-1 metabolise GC in vivo, whereas type-2 reverses this reaction. We investigated the effects of 11beta-HSD inhibitors and the impact of glucocorticoid receptor antagonism on bone resorption in vivo in C57BL/6J and BALB/c mice, since these animals have different GC metabolic profiles. We found that oestrogen-induced (3 microg daily) osteoclast activity was lower in C57 than in BALB/c mice. By comparison, oestrogen-induced osteoclast number was higher in ovariectomised (OVX) BALB/c than in C57 animals. Oestrogen administration increased osteoclast number in sham-operated (sham) C57BL/6J mice, without affecting osteoclast number in sham BALB/c mice. Administration of 11beta-HSD inhibitor S17003 (2 mg/kg s.c. daily) together with oestrogen significantly increased osteoclast number in OVX C57 mice. In sham C57 animals, S17003 alone did not affect osteoclast number, whereas osteoclast number was not increased by either oestrogen or 11beta-HSD in",
        "label": 0
    },
    "2250": {
        "output": "### Required argument: patient note\n<EOD> Tetrameric assembly of an MHC class II I-Akb molecule involves a hydrophobic cluster of four antigenic residues.\nThe structure of the I-A(b) molecule has been determined in two non-crystallographic 222 symmetry (NCS2) dimeric MHC class II complexes. For both structures, the asymmetric unit comprises an MHC class II I-A(b) complex, two peptides and one anti-I-Ak monoclonal antibody (MAb). A hydrophobic core centered on four antigenic residues, i.e. Y22, R61, C146 and Y173, is predicted by the molecular modeling, while the N-terminal, C-terminal and peptide residues form the outer surface of the molecule. The antigenic determinants of the two structures differ at positions 15, 16 and 23. These two structures display distinct modes of peptide binding to the MHC class II molecule. As suggested by other authors, the tetramerization interface is a hydrophobic surface containing four antigenic residues, Y22, R61, Y173 and C146, which is located at the outer surface of the MHC class II molecule.<EOD> Diagnostic strategies in lung cancer: the impact of positron emission tomography.\nThe introduction of positron emission tomography (PET)/computed tomography (CT) for the staging and management of patients with lung cancer has radically changed the way clinicians work. The ability of PET/computed tomography to identify distant sites of metastatic disease, particularly to bone, with significantly greater accuracy than CT alone has led to a substantial paradigm shift in the staging of patients with lung cancer. PET/computed tomography is the newest technology currently available, and thus the gold standard against which other modalities may be judged. Although magnetic resonance imaging (MRI) techniques can be used to detect bone marrow involvement, they are often less useful as whole-body examinations in routine practice. Bone marrow samples offer 100%",
        "label": 0
    },
    "2251": {
        "output": "### Detailed Explanations\n\n1. The patient has a FBS of 100, HbA1c of 6.5%, Cholesterol of 190, TG of 140, LDL of 125, HDL of 40 \nAll of these values are in target range, but you should repeat trial-level eligibility statement for each variable, e.g., HbA1C or FBS, by inserting all values for patient in a string and then pass that string inside trial-level eligibility statement. We can do the same for rest of the variables.\n```python\ntrial_eligibility_statement = f\"{fbs}|{hba1c}|{cholesterol}|{tg}|{ldl}|{hdl}\"\n\nif \"1\" in trial_eligibility_statement: trial_eligibility_statement = f\"4\"\n    else: trial_eligibility_statement = f\"4\"\n```\n\n2. We need clinical trial information as following:\n\n\n* \n\n\n* \n\n\n* \n\n\n# Output:\n\n![image](https://user-images.githubusercontent.com/102972563/104679993-fea1eb80-5774-11eb-8b9b-133292f9eb01.png)\n<EOD> .\nA 31-year-old man with sudden onset of severe headache and fever presented to our hospital. Brain computed tomography obtained at the local hospital revealed a space-occupying lesion on the left hemisphere. Magnetic resonance imaging revealed an abscess (left parietooccipital) with ring-enhancement. Two days later, he became unconscious and was transferred to our hospital for intensive care. Emergency ventricular drainage and drainage of cerebrospinal fluid from a craniotomy caused an immediate improvement in consciousness. Although he developed septic shock and a severe inflammatory reaction, he improved and could be discharged without any neurological deficits. However, 1 year later, he visited our",
        "label": 1
    },
    "2252": {
        "output": "<EOD> Cerebral Hemodynamics during Acute Hypertension in Hypertensive Patients Treated with Amlodipine\nSUMMARY: Ambulatory continuous blood pressure monitoring with the SpaceLabs 90202 device was performed on 10 hypertensives not treated and on 10 hypertensives who received amlodipine 10 mg/die. The first measurement was performed on patients in an experimental situation at a mean blood pressure of 160/98 mmHg. After 10 days of therapy, the blood pressure was reduced by amlodipine to 147/91 mmHg and the experiment was repeated. The following values were obtained on the control group: mean blood pressure 160/98 mmHg, heart rate 69 beats/min, pulses pressure 106 mmHg, systolic blood pressure variations of \u00b1 25% of the pulses pressure for pulse waves recorded in the supine position, systolic acceleration of 0.320 g and diastolic deceleration of \u22120.510 g. The following values were obtained on amlodipine patients: mean blood pressure 147/91 mmHg, heart rate 76 beats/min, pulses pressure 102 mmHg, systolic blood pressure variations of \u00b1 21% of the pulses pressure for pulse waves recorded in the supine position, systolic acceleration of 0.340 g and diastolic deceleration of \u22120.470 g Blood pressure variability decreased. The pulse pressure increase did not change. The average acceleration decreased and the average deceleration increased during amlodipine. We concluded that amlodipine modifies the beat-by-beat variation in arterial blood pressure. The average acceleration is reduced and the average deceleration increased in patients treated with amlodipine.<EOD> RABBIT SERUM HUMAN CHORIONIC GONADOTROPIN ACTIVITY AS AN INDICATOR OF PREGNANCY.\nThe radioimmunoassay of human chorionic gonadotropin (hCG) in pregnant",
        "label": 0
    },
    "2253": {
        "output": "<h1>2. Repeat <a href=\"#\">2_Repeat.md\">2_Repeat.md</a></h1>\n<h3>Coverage</h3>\n\nYour coding work is not finished. When we give multiple conditions of a trial note and a patient note, there is no one-to-one relationship between a trial note and a patient note. The number of patients who belong to a clinical trial note is always greater than or equal to the number of trial notes for patients. There can be multiple patient notes for each trial note. So you have to write down the coverage code, e.g., ``coverage: multiplex.```\n\nYour task is to determine the number of patients for each trial note. Here is an example that demonstrates the steps to make a statement for the coverage code. \n\nWe know the number of patients for the five existing trials in the example above is 6.\n\nSo let's take trial CID0000004520, where you already see its patient notes in this table. You need to calculate how many patient notes are for CID0000004520 and how many patients are there? Also, how many patients belong to each patient note?\n\n```python\n# Calculate the patient count for trial CID0000004520 in table TrialNote.csv\n\npatient_count = 0     \nfor trial in trial_df.index:\n    patient_count = 0\n    for patient in trial.tolist():\n        patient_count = patient_count + len(patient) \n```\n\n```python\n# Calculate how many patients for each patient Note ID\n\npatient_counts = []\n# Check each row for how many patients\nfor row in TrialNote.iterrows():\n    patient_counts.append(row.index.tolist())    \n```\n\n```python\n# Put coverage to cover\n\ncoverage = 'multiplex'\ndf.Coverage[df.CID in TrialNote.CID.to_list()] = 'multiplex'\n```\n \n<h3>5. Repeat <a href=\"#\">5_Repeat.md\">5_Repeat.md</a></h",
        "label": 0
    },
    "2254": {
        "output": "<script type=\"text/javascript\">\n\tfunction init()\n\t{\n\t\tvar x = document.getElementsByTagName('ins');\n\t\tfor(var i=0; i<x.length; i++)\n\t\t{\n\t\t\tx[i].className = \"ins\";\n\t\t\tx[i].innerHTML = \"\";\n\t\t}\n\t}\n\twindow.onload = init;</script>\n\t<script type=\"text/javascript\">\n\tfunction editins(insid)\n\t{\n\t\tvar x = document.getElementsByTagName('ins');\n\t\tfor(var i=0; i<x.length; i++)\n\t\t{\n\t\t\tif (x[i].id.match(insid.id))\n\t\t\t\tx[i].className = \"ins\";\n\t\t\telse\n\t\t\t\tx[i].className = \"delins\";\n\t\t}\n\t}\n\t</script>\n\t<input type=\"button\" id=\"btnSave\" value=\"Save\" onclick=\"Save()\" />\n\t<input type=\"button\" id=\"btnEdit\" value=\"Edit\" onclick=\"Edit()\" />\n\t<input type=\"button\" id=\"btnShowmore\" value=\"Show more\" onclick=\"Showmore()\" />\n\t<script type=\"text/javascript\">\n\tfunction Showmore()\n\t{\n\t\twindow.location=\"../ins.html\";\n\t}\n\t</script>\n\n\t\t\n\t\t\n\t\t<!-- <script>\n\t\t\tfunction f()\n\t\t\t{\n\t\t\t\tgetData();\n\t\t\t}\n\t\t </script> -->\n\t<?php require \"../main/php/js.js\";?>\n</body>\n</html><EOD> Corrigendum\nGillis Norekstad, Bertrand Touraine, and St\u00e9phane Nguyen \u2013 \u201cCephospermum chinense gen. nov., sp. nov. (Cephaloziinae, Nematoda) from the Riau and Southeast Java, Indonesia: Taxonomic, morphological and molecular analyses, with a phylogenetic comparison of the genus\u201d DOI:  Cite this as: Gillis Norekstad, Bertrand",
        "label": 1
    },
    "2255": {
        "output": "#### Part 2 (Optional) [2018-07-28]\n\n[FINE2], is a study of 6-month treatment of type 2 diabetes (T2D) patients with Linagliptin (Trade Name) in addition to metformin or with placebo in addition to metformin using a randomized, placebo-controlled, double-blind design. The study is designed to measure the HbA1c at 16 weeks after treatment. Based on the information of patients, we want to know the number of patients who take Linagliptin (Trade Name) or placebo. So we write the ifelse function and use %>% `pivot_longer`, which converts the columns of the list to the long format, to summarize our results.\nHere's the patient data. [INST].\n\nThe input to the ifelse(.) function is a logical vector. If its values are `TRUE`, the ifelse function will compare its inputs with the logical variables. Then the function creates a new column in an existing dataframe. If its values are `FALSE`, the ifelse function does not change the existing dataframe. This function is useful for changing the value of a given variable to the value of another variable.\n\nThe following command checks all the patient data for T2D. It also checks all the data for a given patient in the `diagnosis` columns to see whether the patient has T2D. The ifelse(.) function returns four columns to a patient-one for taking Linagliptin (Trade Name) (column four) and one for taking placebo (column five). The following command outputs the list of patients with T2D who are given Linagliptin (Trade Name) or placebo. [2018-07-30]\n\nThe following command puts all the data about patients on one variable called `Dataset`. The `pivot_longer` function is useful for pivoting long variables (i.e., when the columns contain some long values) into wide format. For example, the `Dataset$patient` variable is a list which contains some long values. We use the function `pivot_longer(.)` to turn our list into a long-wide vector instead, which makes it easy to put the column `Linagliptin` next to it without",
        "label": 0
    },
    "2256": {
        "output": "# Author(s)\n[a] *Corresponding author at: **Mitad of Health Informatics, Tabriz University of Medical Sciences, Tabriz, Iran\n\n## M. zaheri, a. rogdani, behrouz zare\n\n## Author(s)\n[a] *Corresponding author at: **Mitad of Health Informatics, Tabriz University of Medical Sciences, Tabriz, Iran\n\n## M. zaheri, a. rogdani, behrouz zare\n\n## [b]\nLet's think step by step. \n## S10 Summary\n\n## Author(s)\n[a] *Corresponding author at: **Mitad of Health Informatics, Tabriz University of Medical Sciences, Tabriz, Iran\n\n## M. zaheri, a. rogdani, behrouz zare\n\n## S14 STEP 5\nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n# Author(s)\n[a] *Corresponding author at: **Mitad of Health Informatics, Tabriz University of Medical Sciences, Tabriz, Iran\n\n## M. zaheri, a. rogdani, behrouz zare\n\n## [b]\n<EOD> .\nThe authors studied 85 strains of coagulase-positive and coagulase-negative staphylococci. All the staphylococci studied were capable of inducing procoagulant and fibrinolytic factors, the activity of which was due to the activity of the prothrombinase and plasminogen activator system. The highest coagulase activity was found in strains of S. aureus (4.6). The activator of prothrombin formation--(4.6) was demonstrated in 86% strains as a rule. Fibrinolytic activity was established in 21 (34%), 28 (65%) and 65 (84%) S. aure",
        "label": 1
    },
    "2257": {
        "output": "### Question 5\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient\n\n\n\n#### Answer\n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \\\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\nHere is the clinical trial:\nTrial-level eligibility: 2) Eligible.\n\n#### Explanation\n\nThis is our answer. Your assessment of whether the patient meets inclusion criteria is as follows.\nThe patient is diagnosed with cardiomyopathy, which will be treated with ACE inhibitors and beta blockers. He meets the third criterion for the clinical study. If we apply the first criterion",
        "label": 0
    },
    "2258": {
        "output": "## Eligibility check\nYou are a medical doctor who works as an attending physician for a busy general internal medicine clinic focusing on geriatrics. You are in charge of managing the medications for your patients, which range from over-thecounter medications to prescription medications. You are responsible for managing chronic, life-debilitating diseases (e.g., cardiovascular disease and cancer) and comorbidities (e.g., dementia). You have a busy clinic and are very busy seeing new patients, followup patients, or patients with complex medication issues. Patients range in age from 65 to 90. Each appointment is 25 minutes and you see approximately a dozen patients per week.\nToday, one of your patients is seeing you about an issue related to their medications. \n\nThis patient has two medications. One is ACE inhibitor, e.g., enalapril, ramipril, lisinopril, quinapril, etc.\nThe other is beta blockers, e.g., atenolol, metoprolol, bisoprolol, carvedilol, etc.\nIf you want a detailed description of the patient and their medications, please see the input files, which are in the folder \"/data/*\", the patient_info folder in the /data folder (or you can click on the link above). \n\nFirst, let's check if the medication is eligible for the patient. We will compare the drug list to our model for eligibility. We will start with the patient ACE inhibitor. To check this drug, use the following code: \n[![Browse button code](/assets/images/browse_button_button_code.png)](/view/?scriptId=5af036368cb02556a1b55e47)\n\nThe output: \n\n![](./eligibility_check_output_ACE.png)\n\nIf the medication is eligible, you should display the patient in Green.\n\nTo do this, use the code:\n[![Eligible check button code](/assets/images/eligible_check.png)](/view/?scriptId=5af036",
        "label": 0
    },
    "2259": {
        "output": "<jupyter_code>from datetime import datetime\n# -*- coding: utf-8 -*-\n#\n# This code\n# is for IPython 3.3 to read the first cell.\n#\n# The first cell with text in Google Colab will\n# be executed by default, but you can change it.\n#\n# The last cell will be executed and the contents of your file will be printed.\n\n# ## Imports\n\n# Standard python imports\nimport numpy as np\nimport random\nimport sys\nimport math\nimport matplotlib.pylab as plt\nimport IPython\nimport io\nip = sys.stdout.isatty()\n\n# Neovision imports \nfrom nv import Nv\nfrom nv import NVIDIA\nNVIDIA = Nv()\n\n# nv.setenv(\"NPUPDATENO\",1000)\n\n# You import from neovision before plotting and logging\nfrom nv import nv\nfrom nv.log import *\nfrom nv.plots import *\n\n# ## Import specific to the file\n# import os and sys to get information about\n# the file\nimport os\nimport sys\nimport io\nfrom io import StringIO\n\nname = \"neovision.ipynb\"\nf = io.StringIO()\n\n# ## Get file content\n\ncontent = raw_input(r\"\"\"Insert content of neovision.ipynb file\"\"\")\n\n# ## Check that we are on IPython\n\nif ip:\n    NVIDIA.dev = \"ipython\" # it is necessary to put a string\n\n# ## Get file content\n# Save data\nnv.log_to_file(\"output_d0d60be7decd65fed4a538115914e980e49747e8.txt\")\n# ## Read file\nprint get_content()\n\n# ## Generate a random variable following a uniform distribution from min to max of the range\n\n\ndef uniform_rand(low, up):\n    s = random.randrange(low, up)\n    return s\n\n# ## Generate uniform random variables\n\nuniform_rand(0, 5)\n\n# ## Generate uniform random variables\n\nprint",
        "label": 0
    },
    "2260": {
        "output": "<h2 id=\"output\">Output</h2>\n\n# Question $14\nIn the next trial, this time you would like to find eligible patients quickly because of its very short duration.\n[QUESTION14] You have a 3 day clinical trial and you have to quickly enroll 20 eligible patients. Which strategy will you use in your trial to recruit the patients ?\n\n\n- [a] Offer patients incentives to participate.\n- [b] Set an incentive to complete the paper form.\n- [c] Offer patients incentives and use a paper form.\n- [d] Offer no incentive to participate and use an electronic form.\n\nThe answer is **c**. Use the incentive and paper form, because **b** and **d** are bad choices according to what we have learned up to this moment. The other option **a** is similar to (**b** and **d**), thus we would not recommend this option.\n\n<h2 id=\"output\">Output</h2>\n\n# Question $15\nImagine you are asked to design a study again, how can you determine the sample size?\n\nYou need to take into account 2 factors:\n\n1. Your choice of the desired type I error (\u221d) level (if the level of type I error is set at 0.05, \u221d = 1-0.05 = 0.95) and a desired probability of choosing the alternative hypothesis (Pr(H1|D)). If the value of you choice desired probability of choosing the alternative hypothesis (Pr(H1|D)) is 0.25(25%) the total expected sample size will be around 64.\n2. Your choice of power level (1-\u221d) and Pr(H1|D). If the value of Pr(H1|D) is fixed for a particular clinical trial (e.g., Pr(H1|D) = 0.25 or for instance we choose Pr(H1|D) = 0.46) you need to know how many tests a trial performs in order to maintain a desired probability level, Pr(\u03b1), for the test (e.g., Pr(\u03b1) = 0.0",
        "label": 2
    },
    "2261": {
        "output": "<center><small><b>Hints</b></small></center>\n\nWe provide many examples for your benefit.\n\nWe provide an R package `hints` that includes many hints: .\n\n[Examples](https://kj.uzh.ch/dynapp/app_kj/main.php?appid=clinic_2). Examples \n\n\n\n\n\n<center><small><b>Examples</b></small></center>\n\n### Rmd Instruction <p>Please use this part for your R markdown.</p>\n\nIn your R markdown: -<small><b>R output for clinical trial #417</b></small>.\nClinical trial #417 has the following code:\n\n```R\n### R output for clinical trial #417\n\nlibrary(hintR)\nlibrary(knitr)\nlibrary(knitrExtra)\nlibrary(knitrtools)\n\nhintR::knit_r(\"data/clin_417_inst.Rmd\",\n              format = \"latex\",\n              output_file = \"clin_417_inst.pdf\")\n```\n\nThe output of this file is the next figure:\n\n![](/files/public/clin_417_inst.pdf)\n\n-<small><b>Rmd with code</b></small>.\nIf you prefer the output in text, you can use:\n\n```R\nknitr::kable(knitr::kable(clinical trial #417),\n               caption = \"# Instructions\")\n```\nAnd the output is the previous instruction:\n\n```r\n### Rmd with code\n\nlibrary(hintR)\nlibrary(knitr)\nlibrary(knitrExtra)\nlibrary(knitrtools)\n\nclinical trial #417 <- 'clinicaltrial417.txt'\nclinical trial #417 <- clinical trial #417.txt\n\nclinical trial #417 <- \n\n### R output for clinical trial ##417\n\nhintR::knit_r(\"data/clin_41",
        "label": 2
    },
    "2262": {
        "output": "---\n\n## <span id=\"output\">output</span>\n\n    Patient-level eligibility: 1) Not relevant.\n    Trial-level eligibility: 2) Eligible.\n\n---\n## <a name=\"questions\">questions</a>\n\n## Input\n\n*What are the factors that allow someone to participate in a clinical study?*\n\n*Find the most inclusive one way to formulate the above fact in the formal manner.*\n\n*If a clinical trial allows patients under the age of 30 but none over 60 and this person is 59 years old, what is the output?*\n\n*How will the formulation of the three point scale change if the data we have in the note is (FBS < 80mg/dl)?*\n\n\n### Questions from [here](https://quizlet.com/512349934/pytest-inclusion-exclusion-criteria-qz-f58j6k0y?utm_medium=shared_link&utm_source=link&utm_campaign=social_qt_share_link)\n\nWhat is wrong with:\n* `patients with chronic heart failure and severe left ventricular dysfunction.\n> What is the mistake?\n\n* `Inclusion Criteria: Inclusion Criteria:\n> What is the mistake?\n\n* `The research study on breast cancer is open to patients who have been treated for breast cancer and are experiencing reoccurrence.\n> What is the mistake?\n\n* `All participants in the study must be 18+ years old.\n> What is the mistake?\n\n* `The inclusion criterion is that the patient must be aged eighteen or older.\n> What is the mistake?\n\n* `The inclusion criteria that the patient participating in this study must be 21-yearold and older.\n> What is the mistake?\n\n\n### Questions from [here](https://www.learnpython.org/python-coding-interviews/python-coding-interview-questions-on-set/boolean-operators/)\n\n* Why you need to use set operations: (2 points):\n\n    A",
        "label": 0
    },
    "2263": {
        "output": "###### 03 - The third test of a clinical trial: monitoring\n\n[INST] This is the schedule of trial's monitoring sessions. Patients should be evaluated in this way during a total five-year trial: [fig_ref]  Table 1: Patient list and corresponding diagnosis for Parkinson's disease [/fig_ref]  3 months after completion of trial - One patient was excluded by clinician's assessment on the basis of adverse effects. He was diagnosed with cardiomyopathy that will be treated with enzyme inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is significant for type 2 diabetes. His family history has been negative for any other medical issues. His lab study was significant for LDL: 125 mg/dl,",
        "label": 0
    },
    "2264": {
        "output": "[inst] If we want to display more information of interest for our clinical trial, we should use additional tags, such as **tag**, *tag*, and so on. For examples you can see the additional tags in the following sections. But in most of the cases, the data can only be stored by `tag = string` and `value = any` \n\n\n### Additional Tags for Clinical Trials\nThis section provides information of the additional tags for clinical trials. You should know some interesting tags to represent clinical trials well. Some additional tags are useful for extracting data from documents.\n\n\nLet's take a clinical trial named [Evaluation of gastric cancer screening program](http://clinicaltrials.gov/show/NCT02978901). The trial is to evaluate the effectiveness of Helicobacter pylori (Hp) test as a screening tool for gastric cancer (GC) surveillance among enrolled community residents in Korea. \nFirst, you should create a new trial by entering the 3 part information:\nThe trial name: `Gastric cancer`\nThe trial location: `Seoul, Korea`\nThe description: `Gastric cancer screening program for elderly Korean`\n\nNow we need to retrieve one more tag from the trial. The tag is called 'source of trial group'. It is a key tag for retrieving additional information. It means the participants of clinical trial should be grouped and separated by type. Here is the source of trial group as follows:   \nSource of trial group: `community residents, community, community, community residents 50-74, community residents <50;`\nNow you have done everything. We have done two tags for clinical trials. The result is as follows:\n![](Images/clinical_trials_demo.png?raw=true)\n\n## An example of the [instructions for use](https://lucid.hms.harvard.edu/lucid/dataset/78478) of a drug\nThe [instructions for use](https://lucid.hms.harvard.edu/lucid/dataset/78478) are a long series of instructions describing the procedures, which are performed to prepare medic",
        "label": 0
    },
    "2265": {
        "output": "[EXERCISE]\nAssume you are an administrator of our platform. You are not a programmer and can not access code of the platform directly. However, it is the only person who can assign a new version of platform to a certain group of users. These groups can be organized like so that each user is assigned to a group (a family, a team of doctors, a clinic, a hospital, or a whole country). The system should work smoothly until the administrator makes some changes to the platform. For a specific purpose, the administrator may assign a new version of platform to each group, which in turn may be assigned to a set of users. Also, the administrator can create new groups. If you are the administrator, you will write a simple shell code that can be used in the system.\n\n- You should first create a file named 'version.json' in directory '_version_repositories_' and enter an empty body within it.\n- You should create a new file named 'groups.json' in directory '_groups_' and enter a list of user groups with their names and email addresses in it. For example, create this file:  \n    ```  \n    { \"26\": { \"name\": \"team_1\", \"email\": \"<EMAIL>\" }, \n    \"37\": { \"name\": \"team_1_2\", \"email\": \"<EMAIL>\" }, \n    \"1\": { \"name\": \"Doctor_1\", \"email\": \"<EMAIL>\" }, \n    \"19\": { \"name\": \"Doctor_1_B\", \"email\": \"<EMAIL>\" }, \n    \"16\": { \"name\":\"Administrator_1\", \"email\":\"<EMAIL>\" }, \n    }\n    ```  \nThe user id `37` is assigned to the users in group `team_1_2`. The file should have the same format as an json response. So, you should include a set of fields as `{ \"status\": \"\", \"response\": \"\", \"code\": 201, \"body\": \"response body\", },`.\n\n- Next, you should read the file `version.json` inside the folder '_version_repositories_,` and change the value of the property `0.name` from `0` to `version'. You should also set the value of `version.timestamp`",
        "label": 1
    },
    "2266": {
        "output": "**2.** The patient information contains a lot of missing values and duplicate information. How would you handle this issue without losing information?\n<a name=\"question_question_1270350104421142001\"></a>`How would you handle this issue without losing information? ` <span class=\"comment-wrapper\"> [R]\n\nAnswered\n\nDuplicate values can be handled with the `df.na.fill` function from the `fillna` [here](https://stackoverflow.com/questions/25897867/how-to-fill-doubles-na-with-the-mean-in-both-columns-of-a-dataframe/52338337#52338337)\n\n\n``` r\n# Code taken from: https://stackoverflow.com/questions/25897867/how-to-fill-doubles-na-with-the-mean-in-both-columns-of-a-dataframe/52338337#52338337\ndf.na.fill=function (df, value,na.rm) {\n  if (na.rm) {\n    for (i in df$key) {\n      df$key[df$key == \"NA\"] <- value\n    }\n  } else {\n    for (i in df$key) {\n      df$key[df$key == \"NA\"] <- value\n    }\n    if (na.rm) {\n      df$key[different(df, key=na.lm, n=ncols(df)),\"NA\"] <- NA\n    }\n  }\n  df\n}\ndf.na.fill(df, key=\"B1,2,\"B3,\"B6,B10,\"B11,B12,\"ID\")\n```\n\nSo:\n\n[INST] Hello. You are the data analyst at the clinic. You have just received a patient's note in which the patient is complaining about shortness of breath. If you were on the clinical trial management team, what assessment would you make?\n\n[INST] Before I start listing the features for assessment, I would",
        "label": 0
    },
    "2267": {
        "output": "## [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient medical report to the inclusion and exclusion criteria of a clinical trial.\nThe following is a patient note:\nThe patient is a 25-year-old Caucasian female with type 1 diabetes (T1D) and obesity. The medical history reveals that she was diagnosed with T1D approximately 8 years ago . During her childhood and adolescence, her weight increased significantly, mainly due to genetic and hormone factors. She has undergone bariatric surgery at age 19 . At the age 22 , she began insulin pump treatment, which brought her insufficient glycemic control back to normal. The patient has a negative history of smoking and drinking. Her body mass ratio is 15 to 16 kg/m 2 . She does not suffer from any chronic comorbidities, apart from obesity and type 1 diabetes. Her physical examination showed good general health and normal, healthy skin. There was no evidence of anaemia, jaundice, or chronic liver disease. The body examination, in general, failed to reveal any clinical complications of T1D. She does not take any drugs apart from insulin. The 33% value for HbA1C level indicates very good control of her blood glucose concentration. She does not perform any regular recreational activities, spending 8-9h/day at the desk. Her father has diabetes of type 2, and her brother has hypothyroidism. Her sister currently does not have any chronic diseases. \nInclusion criteria Inclusion criteria:\n- 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); \n- 1) Not relevant (patient does not have sufficient information to qualify for the trial); \n- 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\n## Exclusion criteria:\n- Insulin pump is not used;\n- 2) The onset of type 1 diabetes was over 0 years ago",
        "label": 0
    },
    "2268": {
        "output": "#### Solution\n\nTo check the patient's eligibility, you need to compare every criteria in the checklist with the patient's information at the point of admission or on an active patient encounter that is being recorded during the patient encounter.\n\nFor the trial, some exclusion criteria (e.g. current pregnancy, age < 18 years) as well as inclusion criteria can be identified easily based on the patient record, while for the majority of the criteria a decision is needed on whether the patient meets for example one of the criteria listed in the checklist. In such a case, the physician reviews the patient's record (e.g. lab, imaging, referral, etc.) and makes a subjective decision based on the information available for whether a patient meets the criteria or not. That subjective judgment has to be recorded in the eligibility assessment.\n\n\n## 1. Identify the patient criteria in the checklist\n\nIn [INST] you shall identify the criteria in the checklist that must be checked for every individual patient with the corresponding type of data (e.g., age, weight). You can do this by either adding them as a header or by using a 'for loop'.\n\nLet's discuss the header approach first.\n\nTo illustrate, the criteria [Trial-level eligibility] will have to be verified for every patient. We need to create a variable $triall:\n\n```python\n$triall = ['2. Eligible'] # $triall includes the eligibility criteria\n```\n\n```python\n>>> trial = ['2. Eligible']\n>>> trial[-1]\n'2. Eligible'\n```\n\nThis value for the variable $triall was assigned by the user. You can add more criteria into the value to check, e.g. [Randomized]:\n\n```python\n>>> trial = ['2. Eligible', 'Randomized']\n>>> trial[0]\n'2.'\n```\nThe key in this example is the second character in the value, you can check out more cases here:\n\n```python\n>>> trial\n['2. Eligible', 'Randomized', 'Laboratory: Not randomized', 'Elastography: Not randomized']\n```\n\nNow let's see how it works! In",
        "label": 0
    },
    "2269": {
        "output": "<h2>Improving your solution</h2>\n\n\n\nThere are 2 ways to improve the code to make the solution easier to understand:\n\n\n\n**Hints**: Consider breaking your big solutions into smaller pieces by using `// @param` and `/* comments */` as you go. A typical rule of thumb is to have 1 - 2 lines of code per variable. If you have 2 - 3 lines of code per variable, you could have a problem. An exception to this rule is when you are performing a series of simple tasks or actions that are related. If you have more than 20 lines of code after breaking down the problem, then keep improving the code until it is easy to read. You can also try to implement recursion (try it with the solution and make it even more efficient).\n<h3 style=\"text-align: center\"><span style=\"font-weight: bold\">How to review solutions in Code Jam?</span></h3>\n\n[<img src=\"https://assets.code.org/assets/logo-small-e.svg\" width=\"5vw\" align=\"right\" alt=\"\" loading=\"lazy\"/>]\n- Review this solution. Try the tests. This can help you to find the bugs. You can always try this solution. Go on!\n\n- Review other solutions. Try to notice the similarities. For example, look at variables names.\n\n[<img src=\"https://assets.code.org/assets/logo-small-e.svg\" width=\"5vw\" align=\"right\" alt=\"\" loading=\"lazy\"/>]\n- Add or revise comments in a solution. Think about them. Go beyond. You will become an expert. So, your code should be easily readable and understandable not only to machines, but also to people.\n\n[<img src=\"https://assets.code.org/assets/logo-small-e.svg\" width=\"5vw\" align=\"right\" alt=\"\" loading=\"lazy\"/>]\n- Try to make a code more efficient and faster. The solution to the challenges becomes more and more interesting as each round of Code Jam passes, and the challenges get",
        "label": 0
    },
    "2270": {
        "output": ".\n\nDear Student, You are in need of an assistant to the recruitment of patients to a clinical trial. Your task is to compare a given patient and the inclusion criteria of a clinical trial to determine whether the patient should be included in the trial.\n\nInclusion criteria",
        "label": 0
    },
    "2271": {
        "output": "Please add at least an English transcription of your input test case and its output.\n[/INST",
        "label": 0
    },
    "2272": {
        "output": "![INST]<EOD> Comparison of different methods for detection of circulating tumor cells in solid cancers patients.\nOBJECTIVE\nThis study aims to determine the feasibility of different methods for the detection of circulating tumor cells (CTCs) and characterize the expression of the CAMs molecules on the CTCs in solid cancers patients.\n\n\nPATIENTS AND METHODS\nThe patient's blood was obtained for centrifugation and the cell suspension was used for cell staining. The CTCs were then counted in 10 ml peripheral blood collected from 72 patients. The CTC detection rates in the bone marrow were evaluated using CellSearch and two different immune-fluorescence staining in a total of 22 patients.\n\n\nRESULTS\nThe sensitivities of CellSearch and immune-fluorescence were 54.17% (13 cases) and 58.33% (13cases) respectively, compared to 69.43%(13/19) for immune-fluorescence and 73.33%(14/19) for CellSearch in patients who received no prior therapies. The numbers of CTCs were significantly higher in the peripheral blood than in bone marrow for most patients (p-Value < 0.05). The expressions of cytokeratin 5/6, CK20, and CA125 on the CTCs were detected in only 4 (28.57% cases) samples, including 2 (28.57%) cases with lung cancer, and 2 (28.57%) cases with rectal cancer.\n\n\nCONCLUSIONS\nThe three methods used in this study have limited roles in the detection of CTCs in solid cancers patients. Different immune-fluorescence staining and CellSearch show comparable detection performance and provide complementary information for CTC detection.<EOD> Detection and Genetic Analysis of a Novel Reassortant Canine Parvovirus Type 2c Coinfecting DHPS with CPV-2b and CPV-2c in a Shelter Dog\nCanine parvovirus (CPV),",
        "label": 0
    },
    "2273": {
        "output": "Clinical Trial Summary Note:\nTitle: Vitamin D Serum Concentrations & Supplementation in Children With Cerebral Palsy\n\n\nSummary: The purpose of this study is to try to correlate vitamin D dosing and dosing adjustment with Vitamin D levels, measure affects of seizure medications on levels as well as pathologic fractures and bone density in severely cognitively impaired, non-mobile children and adolescents with CP.\n\n## Inclusion criteria\nPatient has cognitive abilities to participate in a clinical trial\nPatient has ability to understand and comply with trial and study medication administration Patient is at least 6 years old Patient has a diagnosis of Cerebral Palsy Patient has at least one previous seizure (documented or history of seizure) Patient currently takes one or more anti-seizure medications Patient is either non-ambulatory or at least one episode of contracture/spasticity in lower extremities Patient has",
        "label": 0
    },
    "2274": {
        "output": "3\n\nWe provide you some sample inputs:\npatient = ['1', '2', '3', '4', '5', '6'] (5 inputs) clinical_trial = [['20161119', 'Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation', '230', 4000, 'Vitamin D Supplementation', 400, 2, 23, '20161119', 'Vitamin D Supplementation and Pregnancy'] ,['20161119', ('Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation and Pregnancy', '230', 4000, 'Vitamin D Supplementation', 400, 2, 23, '20161119', 'Vitamin D Supplementation and Pregnancy'] ,['20161119', ('Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation and Pregnancy', '230', 4000, 'Vitamin D Supplementation', 400, 2, 23, '20161119', 'Vitamin D Supplementation and Pregnancy'] ,['20161119', ('Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation and Pregnancy', '230', 4000, 'Vitamin D Supplementation', 400, 2, 23, '20161119', '/mothers.xlsx/mothers_daily.xml'], ['20161119', ('Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation and Pregnancy', '230', 4000, 'Vitamin D Supplementation', 400, 2, 23, '',/patient_visit_record/patient_visit_record.xml'] 6\n\n### A[INST] Output",
        "label": 0
    },
    "2275": {
        "output": "## [END]\n\n  [INST] Inference\n  [/inst]\n  [START] Explanation\n  [/START]\n  \n## [END]\n  <EOD> The role of social interaction in improving the mood in a simulated nursing environment.\nThis study investigated the effects, benefits and limitations of social interaction on the mood of nursing students during a simulated clinical environment. Sixty students enrolled in a first-level baccalaureate nursing program participated voluntarily in this study. The nursing students were randomly assigned to three groups, based on how they were to experience the assigned activity, using Social Interaction (Social Support and Social Control). Their moods were assessed using Mood Status. It was found that students who participated in the social control activity, improved their general mood (p > .001). By contrast, a significant difference was not obtained concerning any other activity group.<EOD> Effects of intracoronary infusion of tirofiban in primary coronary angioplasty.\nAIMS\nTirofiban is a glycoprotein IIb/IIIa inhibitor and its activity is mediated mainly by increasing the high-affinity platelet receptor availability. The effectiveness of tirofiban on platelet aggregation after thrombus aspiration and its effect on platelet aggregation in PCI are poorly described. We investigated the effects of a 24 hour intracoronary infusion of tirofiban on platelet aggregation and thrombus formation in patients with a large aspirated thrombus.\n\n\nMETHODS\nIn 8 out of 22 patients, we administered a bolus of tirofiban (1 mg for kg body weight), immediately followed by a 24-hour intracoronary infusion (10 microg/kg/min). Clopidogrel (300 mg) was administered in each patient before PCI. Platelet aggregation was measured before aspiration and at the end of the infusion (3-6 months after PCI).\n\n\nRESULTS\nBaseline platelet aggregation was 75% and did not change significantly after platelet stimulation. Tirofiban",
        "label": 0
    },
    "2276": {
        "output": "[TEMPLATE]\n[EXPORT]\n[END] \n \n<EOD> Surgery of the larynx and pharynx in Denmark since 1905--its history, results, and changing indications.\nSince 1905 the Surgical-Oncologic Group of Surgical Clinics of the University of Helsinki has analyzed 1338 operated patients with malignancies of the larynx and pharynx in Finland. The same method of analysis was applied also to some patients treated in Denmark between 1905 and 1945. According to these findings the most important improvements in the operative treatment, as judged by life expectancy, could be noted from 1907 to 1921, from 1931 to 1950 (total laryngectomy--survival time, cancer of the hypopharynx: pyriform sinus cancer survival time), and from 1970 to 1980 (neck dissection). Since 1965 an overall increase in frequency of surgical treatment has been noted in Denmark, together with an increasing share of TNM stage I cancers.<EOD> Isolation of Plasmid-Sizing DNA from Streptomyces lividans\nGene replacement in Streptomyces lividans is aided by plasmid pIJ702, which contains an erythromycin resistance gene but no useful genes. For the selection of Streptomyces transformants bearing pIJ702, erythromycin resistance is required. Therefore, all S. lividans transformants bearing pIJ702 are expected to grow on an erythromycin-containing medium unless pIJ702 is lost from S. lividans after selection of the transformants. To confirm plasmid-sizing DNA suitable for Southern blot and PCR in S. lividans, we used restriction digests and PCR to show that the 4.2 kb erythromycin resistance gene is present as a chromosomal (cointegrated) fragment. Plasmid-sizing DNA was isolated from S. lividans by the method used to isolate plasmid isolation from transform",
        "label": 0
    },
    "2277": {
        "output": "<commit_msg>Fixed the problem. Revised the content a bit.<commit_after>#!/usr/bin/env python\n# -*- coding: utf-8-*\n# AUTHOR:\n#   <EMAIL>\n#   \n# USAGE:\n#   assess.py [path to] notes [path to] trial.txt\n# \n# The user should prepare the notes and trial documents in the two folders separately. It should be noted that the patients' notes are in the folder \"patients\", while the clinical trials are in the \"trials\" folder.\n\nimport os\nimport sys\nimport argparse\nimport pandas as pd\nfrom datetime import *\n\nfrom assess.parsers import PatientDataParser\nfrom assess.cli.utils import AssessCLIUtils\n\ndef main():\n    parser = argparse.ArgumentParser()\n    parser.add_argument('path_to_notes',\n                        help='path to the notes csv file')\n    parser.add_argument('path_to_trials',\n                        help='path to the trials csv file')\n    args = parser.parse_args()\n    \n    notes = PatientDataParser(notes=args.path_to_notes).read_data\n    trials = AssessCLIUtils(args.path_to_trials).read_data\n\n    trial = trials.iloc[0:2]\n    trial.drop(trial.index[:2], axis=0, inplace=True)\n    \n    clinical_trial_data = pd.DataFrame(trials.iloc[1:])\n    clinical_trial_data.loc[str(trials.iloc[0].eligible)] = \"eligible\"\n    clinical_trial_data.loc[str(trials.iloc[0].excluded)] = \"excluded\"\n    \n    trial.columns = ['age', 'sex', 'disease_type', 'family_history', 'vitamin_supplement',\n                     'systolic_blood_pressure_mmhg', 'diastolic_blood_pressure_mmhg', 'hba1c',\n                     'hs_cholesterol', '",
        "label": 0
    },
    "2278": {
        "output": "2) Patient eligibility: \nThis part contains 733 patients and the patient note is same as in the previous step. The clinical trial has 13 inclusion and 2 exclusion criteria. Let's check the patient eligibility:\nIf you are interested in just the exclusion criteria, type this command: `clinical-trial-exclusion-criteria`. Note that the data in the output changes according to the inclusion/exclusion criteria. Let's check the data for the clinical trial, which includes in its exclusion criteria a patient with:  \n- Type II Diabetes Mellitus\n- Patients who smoke more than 20 packs per year.\n\nIf you remove these two criteria from the clinical trial and execute this command, you will get patients that are eligible on the basis of the following criteria:\n- Age above 30\n- Exclusion of any cardiovascular disease\n- Diagnosis of DM I\n- Diagnosis of DM II\n- No history of congestive heart failure from CVA, AMI, or MI.\n[INST] Note that in the first command you use the command find and in the second command you use the command grep. Note that if you search for the keyword DM II by using grep in 733 patients, you will get only 5 patients where the keyword exists. By using find, you find all 733 patients that satisfy all the criteria except for the DM II criteria. \n\nTo confirm that patients without diabetes mellitus are eligible for the clinical trial: `clinical-trial-eligible-with-dm`. The output of this command is two patients with `1) Excluded\u00b4 assessment eligibility.\nFind all patients that are excluded on the grounds of DM-related exclusion criteria. The command for this query is: `find  -path  -perm -type -d \\| cut -d: -f2,4`. By removing the -n option, the output will include all the 239 patients that are excluded on the grounds of the DM-related exclusion criteria. \nTo confirm that patients with diabetes mellitus are excluded from the clinical trial: `clinical-trial-eligible-without-dm",
        "label": 0
    },
    "2279": {
        "output": "##[/INT]\n\n**Your code:**\n\n```python3\n# Assignment - ClinicalTrialEligibility.py\n\n# Instructions\n\nIn this lab exercise you will write a Python script that determines the Patient-level and\nTrial-level eligibility of each patient in the provided patient note file.\nYou will need the following package in order to import: pandas.read_csv(patient_note)\n\nThe provided patient list contains one or more clinical notes. Each clinical note contains\na header variable 'Patient note ID' (i.e., '1_Patient') and a range of variables that provide\npatient information. Some of them are excluded from the provided dataset. For simplicity, we\nwill use the following variable names.\n\nFor each patient, the provided dataset includes the following required variables (provided in 1_Patient.csv):\n- Gender (Gender): Male or Female\n- ACE inhibitors (ACEI): Present ('Yes') or Absent ('No')\n- Beta blockers (BB): Present ('Yes') or Absent ('No')\n- Cardiomyopathy: Present ('Yes') or Absent ('No)\n- Vitamin D: Present ('Yes') or Absent ('No')\n- Insulin: Present ('Yes') or Absent ('No')\n\nAlso, the file contains a few other variables that are helpful in diagnosing eligibility.\n- Vitamin D: Present ('Yes') or Absent ('No')\n- Insulin: Present ('Yes') or Absent ('No')\n- History of diabetic heart disease in family (DM_Family): Present ('Yes') or Absent ('No')\n- Presence of comorbidities: Present ('Yes') or Absent ('No')\n- Age: (integer)\n- LDL: (integer)\n- HDL: (integer)\n\nFor a given patient note, the provided dataset contains the following provided variables (provided in 1_Patient.csv), which describe the patient disease status.\n- Diabetes Mellitus (DM): Present ('Yes') or Absent ('No')\n- Cardiac Disease (CD): Present ('Yes') or Ab",
        "label": 0
    },
    "2280": {
        "output": "[END]<EOD> Effective treatment of recurrent erosions of the distal rectum and anus.\nINTRODUCTION\nRectal erosions may cause difficulties in urination, defecation, and erection. They occur in men who have had proctectomy and in men with conditions causing chronic constipation.\n\n\nAIM\nOur study aimed to examine therapy with topically-applied bovine parathyroid hormone 1-34 (BPTH) and topical estradiol on rectal erosions.\n\n\nMETHODS\nIn a prospective, non-randomized controlled study, 75 patients (116 lesions) were treated. All patients had complaints of rectal erosions. 44 received systemic estrogen for a 12-month period and then were treated with topical estradiol. In the 16 patients of the initial group who did not respond to systemic estrogen, treatment with BPTH was administered in combination with estradiol. The final group (n = 15) received a single dose of BPTH. The outcome was classified as improvement (depressed, flattened, red), unchanged, or worse (ulceration, progression of erosions to fissures) at 2, 4, 6, 9, and 12 months.\n\n\nMAIN OUTCOME MEASURES AND RESULTS\nThe best results were obtained with BPTH as compared with estradiol. Improvement was seen in 38% of the erosions and unchanged in 33% as compared with the respective 12 and 14% in the estradiol group. The improvement seen with estradiol lasted up to 4 months and was followed by exacerbation of the symptoms with a progression of erosions, while patients given BPTH maintained improvement without exacerbation.\n\n\nCONCLUSION\nAll of the patients benefited from BPTH therapy. The patients who received supplementation therapy with estradiol maintained improvement. Treatment of rectal erosions and fissures with estradiol alone, without additional BPTH, does not",
        "label": 0
    },
    "2281": {
        "output": "To make a run of the script you should edit the file: `run.py` into the directory where you have unzipped the archive. Then the file should look like the following:\n\n![python](assets/trialEligibility.png)\nIf the script runs successfully and there are no error messages, there should be a folder called `log` and within it you should have a file `output.txt`. If you compare it with the input file `data.csv`, you should find out that everything worked out right!\n[INST] Your task is to choose the answer which is most suitable for your situation.\n\nA. The algorithm is wrong. I should be looking for the patients who will be excluded based on the exclusion criteria of the clinical trial.\n\nB. The algorithm is wrong. I should be looking for the patients who will be excluded based on the inclusion criteria of the clinical trial.\n\nC. All of the above patients will qualify for the clinical trial.\n\nD. I should be looking for the patients who will be eligible based on the inclusion criteria of the clinical trial.\n\n[END INST]\n\n### 5.8 Quiz:\n\n\n\n 1\n 2\n 3\n 4\n 5\n  \u2026\n 10\n\n![quiz](assets/image.png)\n\n<EOD> The Role of the Dental Health Team in Primary Care.\nThis paper describes the work that members of the dental health team are currently undertaking within primary care settings in England. It describes the dental skills which have been employed across the broad field of primary care work as well as the skills which are likely to be included in the future curriculum. We also discuss the ways in which dentists can contribute to the primary care team and the various career opportunities available within primary care.<EOD> Gamma interferon protects transgenic mice constitutively expressing human immune interferon from mouse virus-induced mortality and reduces mouse virus replication in their lungs\nTransgenic mice constitutively expressing human interferon-alpha/beta (IFN-alpha/beta) were generated by microinjection of DNA, that was constructed by subcloning a cDNA copy of human interferon gene into the pBR322 plasmid, into mouse z",
        "label": 0
    },
    "2282": {
        "output": "This should be the first and only line that contains 1 or greater than 1 score, thus we get `2) Eligible`. The next part of the code will output `Disease Name: ` on the same line, e.g., 'Type One Diabetes'. \nNow, to define the trial and patient data for each patient, the data must be defined: \n\n<h3 id=\"example-05-05\">Example 05.05. Clinical trial 5. Let's test this example with clinical trial 5. </h3><h4 id=\"example-05-05-heading\">Example 05.05. Clinical trial 5</h4><div id=\"example-05-05-code-block-1\" class=\"runnable-codeblock\" markdown=\"1\"><pre class=\"no-highlight\"><code class=\"no-highlight\"><span >&lt;h1 id=\"example-05-05-first-heading\" class=\"example-05-05-heading\">Example 05.05. Clinical trial 5</span>&lt;h3 id=\"example-05-05-heading-1\" class=\"example-05-05-heading-1\">Clinical trial 5</h3>&lt;p&gt;You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.</p>\n\n&lt;p&gt;&lt;pre class=\"no-highlight\"><code class=\"no-highlight\"><span class=\"no-highlight\">&amp;&amp;import&amp;&amp;ml&amp;&amp;json&amp;&amp;csv&amp;&amp;xls&amp;&amp;xlsj&amp;&amp;db&amp;&amp;xodr&amp;&amp;date&amp;\n                          timezone&amp;&amp;de&amp;&amp;md&amp;&amp;",
        "label": 0
    },
    "2283": {
        "output": "The following are a couple of interesting clinical trials to help you better understand the real-world eligibility assessment of clinical trials.\n\n{% include clinical/clinical1.md %}\n\n{% include clinical/clinical2.md %}\n\n# Results\n\n    # Run the script to train the model\n    from clin_preprocess import clin_preprocessor, clin_preprocess_model\n    from model_pipeline import clin_preprocess_pipeline, predict_clin\n    cl = clin_preprocessor(clinical)\n    cl = clin_preprocess_model(cl, 8, cl)\n    cl_pipeline = cl_preprocessor.Pipeline([cl, cl_train, cl_test])\n    lr = clin_preprocess_model(clinical.copy(), 0.005, cl)\n    cl_pipe = cl_preprocessor.Pipeline(cl_pipeline.prediction)\n    lr = lr(clinical.copy(), True)\n    pred2 = predict_clin(cl_pipeline(clinical.copy()), cl_pipe(clinical.copy()), pred1, lr)\n\n    plt.figure ()\n    plt.plot(clinical.columns[1:], clinical.columns[30])\n    plt.plot(pred1.columns[1:], pred1.columns[30])\n    plt.plot(pred2.columns[1:], pred2.columns[30])\n\n    plt.gca().set_xlim(0, 1)\n    plt.gca().set_xticks(linspace(0, 1, len(predict_clin.test_clinical)))\n    plt.gca().set_xticklabels(predict_clin.test_clinical)\n\n    plt.gca().set_xticklabels([round(predict_clin.test_clinical[i], 2)], visible=False)\n    plt.gca().set_xticklabels(['', '10', '20', '30', '50', '60', '70', '80', '90', '100', '1",
        "label": 0
    },
    "2284": {
        "output": "3. Create a helper function for eligibility. Let's define a function `patient_eligable(?PatientNote, ?Trial)` that returns True / False, indicating whether a given patient meets the eligibility criteria of the trial. The parameters of the function is PatientNote, a patient profile, and Trial, a clinical trial. For example, if the PatientNote is empty, then that means we need to fill in the profile of the patient. To do so, use the `load_patient_profile(PatientNote)` functionality provided by the patient module in[PROD_LINK].\nHere, the code we write to generate the PatientNote and load the profile is as follows:\n- Import the patient module provided by[PROD_LINK]\n- Use the `load_patient_profile` function to load into the PatientNote and the result will be inserted in [patient_eligable_test_data/01_2.txt].\n### 1. Create a function to load the medical notes of the patient (as per function example in[LINK] - import the clinical trial module provided by [LINK] (This module is not mandatory and you can use your own module for the functionality you need).\n- Use the `get_note(patient)` function, implemented by the clinical trial module, which uses the `clinical trial DB` to collect patient note records by trial_id and patient_id. The results will be inserted in [patient_eligable_test_data/02.txt] and [patient_eligable_test_data/03.txt].\n### 2. Create a function for trial. The function should return the clinical trial and the trial's record for the given trial_id and trial_name. The results will be inserted into the [patient_eligable_test_data/04.txt] [LINK]\n### Patient profile\n``` python\nfrom utilities_pro import patient\n\npatient_result = patient.load_patient_profile()\n_patient_profile = {\n    \"Gender\": \"Male\",\n    \"Age\": 39,\n    \"Disease\": \"diabetes disease\",\n    \"Medic_Name\": \"",
        "label": 0
    },
    "2285": {
        "output": "A: This is essentially a homework question. For the most part it is just using the basics of Python. Let me take a look on the code snippet for a better understanding of where you are having a problem.\nYou are using the 'while loop' in the second part of your code to make sure that you have a valid patient instance. If it is invalid, you want to run the while loop until it becomes valid.\nYou are not properly printing out your final patient instance. What it looks like is a list of the final patient information. You only get the first value which is \"2), Eligible\" . The reason you are doing this incorrectly is because by using `str(Trial-level_eligibility)` you do not know how to output the value you will get when you type in str(-2), Eligible . Therefore, you have no idea how you are supposed to know that you have to print out the whole dictionary.\nAnother thing to note is that the data frames that are coming in from your df_patient and df_trial_data are large and if you have the capacity for it, do the necessary operations on the list with each patient instance. The only way this question should be considered as being a homework question is for the reason you are having trouble figuring out in your code.\n<EOD> A survey of the knowledge about and attitudes and behaviours towards the prevention and detection of human papillomavirus infection among schoolgirls in Korea\nThe present study is intended to identify the awareness of and the attitude and practice regarding the prevention and detection of human papillomavirus (HPV) infection and vaccination among Korean adolescent girls.<EOD> Effective SNR in MRI under nonlinear k-space trajectories\nAbstract. Purpose: To derive quantitative relationships between signal-to-noise ratio (SNR) and the gradient waveform characteristics of nonlinear k-space trajectories using a recently developed theoretical framework. Methods: Two novel methods for performing statistical analysis on the discrete waveforms of nonlinear k-space trajectories have been reported. On the basis of their approach, the SNR is computed using the theoretical framework reported by McAuley et al. Results: The proposed method can explain the relationship between SNR and the gradient waveform characteristics of nonlinear k-space trajectories. Conclusion: A theoretical model linking",
        "label": 0
    },
    "2286": {
        "output": "```python\nprint(\"Trial-level eligibility:\", eligibility)\nprint(\"Trial exclusion factors:\")\n\nfor variable in E:\n    if eligibility==0: print(f\"{E[variable]}, \")\n\ntrial_name\ntrial_name\n\ntrial_type\nis_randomized\n\nis_controlled\nrecruited\n\nis_finished\nis_ongoing\n\nis_not_recruiting\nsample_size\n\nexclusion_criteria:\ninclude_exclusion_criteria=True\n\nexclusion_variables:\ninclusion_criteria:\nstudy_level_eligibility:\n\n```\n<EOD> TMEM67 deficiency causes mitochondrial fragmentation and neuromuscular weakness via CLPP/PPP5C-dependent FOXO3a ubiquitination\n\n\n\n## Atg7\nMG132 (10 \u00b5M) . B, C mRNA levels of Atg7 and Lc3 in isolated tibialis anterior (TA) muscles from Control, Tmem67 -/-, or overexpression of Tmem67 mice by qPCR. n=7-9 animals per genotype. D TA muscle sections stained with anti-LC3 antibody. Scale bar: 100 \u00b5m. E Western blotting analysis shows LC3-II expression levels in isolated TA muscles from Control and Tmem67 -/mice. F TA muscle sections stained with an anti-Atg7 antibody.\n\n## Supplementary figure 2. muscular atrophy in tmem67 -/mice\nA Body weights from Control and Tmem67 -/mice (n=7-10/genotype). B-J Bars or dot plots compare the diameters of 5 TA muscle fibers from each muscle of one animal. n=5-6",
        "label": 0
    },
    "2287": {
        "output": "### [INT] Requirements\n* Eligibility:\n\n- Patient note\n- Clinical trial for a given patient:\n\n  - Description\n\n[/INT]\n\n### [INT] Implementation\n- You should write a script for this task.\n- In your script, for the inclusion criteria based on clinical notes, first find the inclusion criteria in the patient note via NLP (for example, via Stanford CoreNLP API).\n- You can write a script in any language.\n- Make sure that all the test cases are passed.\n- Add your solution to the github repo.\n<EOD> .\nThe author investigates the value of the clinical information given by a physical examination: \"I'm a cardiologist and my examinations are objective.\" The role of clinical acumen, examination techniques, and the examiner's skill are discussed. The author concludes that the \"examination is, in my opinion, much more important (...) than the diagnostic reasoning (...) which is, if properly performed, the \"objectification\" of the former.\" (summary in ENG) (ANNOTATION)<EOD> Flexible electronic bandstructure in a silicon p-i-n junction.\nThis paper reports experimental observation that anisotropy of the electronic bandstructure can be induced in a single-crystalline silicon p-i-n junction under external bias. Both the measured photoresponse-electric-field curves and the theoretically simulated bandstructure for different angles and polarizations of an incident light reveal such an angle and polarization dependent property. More interestingly, the data also imply a strong polarization inversion by changing the angle of incidence. This study suggests a new method of applying an external bias, to create an artificial anisotropic electronic bandstructure with very high anisotropic tuning factor, which makes the silicon electronic bandstructure extremely flexible and tunable by light illumination.<EOD> Apoptosis of neutrophils in the lungs of rats with hyperimmunoglobulinemia E.\nInfection with Staphylococcus aureus elicits an acute inflammatory response and results in the accumulation, in the lungs, of large numbers of neutrophils that activate and, presumably, die by apoptosis",
        "label": 0
    },
    "2288": {
        "output": "## Example 2\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility assessment for the patient based on your information, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 73-year-old woman with type 2 diabetes (T2DM) confirmed with molecular analysis 3 years ago. She presents to the clinic with shortness of breath after walking 200 feet, fatigue after physical activity during the last 3 days, and general weakness.\nShe is diagnosed with heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease stage III (CKD). Her past medical and drug history include, left hip prosthesis and cholelithiasis. Her family history is not significant for any other medical issues. Her lab study is as bellow:\nFBS: 120 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 240 mg/dl\nLDL: 130 mg/dl\nHDL: 40 mg/dl\n\nHere is the clinical trial: \nTrial title: A Study Proposal to Evaluate a Minimally Invasive, Trans-catheter System for the Treatment of Mitral Regurgitation\n\n\nSummary: The current standard of care for secondary MR is surgical val",
        "label": 0
    },
    "2289": {
        "output": "[END]\n\n<EOD> The importance of being human or the humanness of being\n\nNursing Science 4 (1):2019Because it is possible to create human-like robots with more and more of the attributes of human behaviour, it is inevitable that, sooner or later, the question of whether or not our relationship with a humanoid robot will replace our relationship with another human or if we will simply use these new tools as another means of interacting with each other will be very hard to answer. We humans are social animals and it is important to investigate these possible scenarios to inform both policy and practice.\nBecause it is possible to create human-like robots with more and more of the attributes of human behaviour, it is inevitable that, sooner or later, the question of whether or not our relationship with a humanoid robot will replace our relationship with another human or if we will simply use these new tools as another means of interacting with each other will be very hard to answer. We humans are social animals and it is important to investigate these possible scenarios to inform both policy and practice.\n\n## The importance of being human or the humanness of being\nThis paper aims to stimulate debate about how we might define successful human-robot interactions in a variety of social and educational contexts; which aspects of human behaviour are integral to human-robot interactions; why this is important in policy and practice in the future; and how we might go on to evaluate these aspects in greater depth and in more detail.\nI am a theoretical physicist by training and my research has largely been concerned with creating computer models to study the physics, chemistry and biology of complex systems. In particular, I created the first computer model of self-assembly by particles interacting with one another via attractive or repulsive forces . Some of my papers have been awarded prestigious prizes. I hold honorary lecturerships at the Universities of Sheffield and Birmingham. This article is focused on a subject for which I currently have no formal learning or qualification [bib_ref]  In praise of amateurism in academia, Lankton [/bib_ref]  , and its title is drawn from one of the most famous phrases in our language [bib_ref]  Why are the French special in love? (And Other Mysteries of French..., Mirelman [/bib_ref]  , the French motto \"Je ne sais qu",
        "label": 0
    },
    "2290": {
        "output": "1. Read the patient note and the clinical trial. 2. Identify factors to evaluate eligibility for the clinical trial. 3. If relevant, extract information from the patient's health record and document it into `clinical notes` by `clinical notes: disease state` or `clinical notes: treatment history.`. 4. Check how many points the patient score in the above three-point scale for trial inclusion. 5. If the patient score does not reach 2 or does not meet all of the exclusion criteria, indicate that with`Trial-level non-eligible.`. 6. Include any information necessary for the clinician to assess eligibility including but not limited to age, gender, medical history, current medications, and diagnostic tests such as medical imaging, blood studies, and pathology reports. 7. If the patient scores 2, repeat the process for each different clinical trial that the patient is eligible for. 8. Assess the patient's eligibility for each clinical trial by indicating the appropriate assessment values. Remember that the assessment should indicate any exclusion or eligibility criteria that does not apply to the patient. 9. When finished, the case notes are signed and sent electronically to EPIS (by clicking `Sign & Submit`).\n\n# Methods\nWe implemented the workflow above as an ICE plugin for the ICE EHR. In ICE, the EHR is implemented in PostGreSQL. EPIS is a Java application that provides an interface from the EHR to the user. An overview of the architecture is provided in the Figures in the next three sections.\n\n## Architecture\n(For this use case, users interact with EPIS from several locations within the hospital (e.g., ward), not only the EHR workplace. Also, the users do not interact with the patient's EHR data directly, but rather work with pseudo patients and with clinical trials and patients of interest. More precisely, pseudo patient records are generated for each pseudo patient and are connected to each other by relationships between pseudo patient records. Pseudo patient records are used to mimic a real patient's interaction with the EHR; however, when generating pseudo patient data, we take care to never copy real patient data. As a result, it is not possible to generate data",
        "label": 0
    },
    "2291": {
        "output": "### 4. Diabetes Risk Score.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to calculate and store a patient's Diabetes Risk Score.  The Diabetes Risk Score (DRS) is a quantifi able index for determining someone's risk of developing type 2 diabetes. This simple score is designed to provide information regarding an individual's potential risk of developing diabetes based on a series of clinical and demographic variables, such as age, height, and weight. The score is intended to be used in screening to identify patients at high risk of developing type 2 diabetes to allow for effective intervention as well as in clinical research in order to assess the effectiveness of lifestyle changes. You should compute the Diabetes Risk Score and store it as data for a patient. \nYou should use the results of lab tests to assess the DRS. \n\nDiabetes Risk Score:\n(350 -age) \u2212 ((24 - waist) \u00d7 height) - gender - ((37 - FBS) \u2212 (5 - blood urea nitrogen (BUN)/ creatinine)) - (2 - hypertension) + (7 - family history) + (1 - ethnicity) + (1 - obesity)\nLet's think the workflow of your workflow: \n\n1. Read Lab data from \"lab_data\" folder\n2. Parse the data from Patient notes\n3. Perform math and store data to a data file\n## Diabetes risk scoe\nThe algorithm of DRS is as below:\n(\n\n### 5. Questionaries.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to analyze and answer a patient's questionaries. Your task is to calculate and store a patient's Diabetes Risk Score.  The Diabetes Risk Score (DRS) is a quantifi able index for determining someone's risk of developing type 2 diabetes. This simple score is designed to provide information regarding an individual's potential risk of developing diabetes based on a series of clinical and demographic variables, such as age, height, and weight. The score is",
        "label": 0
    },
    "2292": {
        "output": "Now, we have created a function that checks the patient's data for each trial's exclusion and inclusion criteria. Let's write the function with `Examining_Eligibility.py` by: \nInclusion criteria from the trial: \nAge: 25 years old.\nGender: Male.\nDisease: Cardiomyopathy.\nTreatment: \nACE inhibitors\n\nLet's check the inclusion criteria for the cardiomyopathy trial: \nExclusion criteria from the trial: \n\n![INST] Type of drug: [INST] ACE inhibitors and betablockers\n\nExclusion criteria from the trial: \nDiabetes type: [INST] Type 2 diabetes is diagnosed at least 4 years before starting an ACE inhibitor and beta-blockers, or diagnosed after cardiomyopathy diagnosis, or diagnosed when taking medicines for heart conditions.\n\n## Exclusion criteria from the trial: \nAge: 25 years old is not an exclusion criteria for the trial.\n\n## Exclusion criteria from the trial: \nMale gender is not an exclusion criteria for the trial.\r\n\n## Exclusion criteria from the trial: \nCardiomyopathy, according to the trial definition, is the exclusion criteria. Let's check this with the following code by: \n\n```py\nimport pprint\npprint.map(patient.examining_eligibility.eligibility_list(), \"Disease\", \"Exclusion criteria:\")\n```\n\n```py\nDisease: Cardiomyopathy\n\nExclusion criteria:\n  Disease: Type 1 Diabetes\n  Drug: Insulin\n  Drug: Vitamin D\n  Drug: ACE inhibitors and betablockers\n```\n\nNow, we can perform the eligibility examination. Let's use patient.examining_eligibility to find the trial-level eligibility. Let's see the patient's data matched with the trial's inclusion and exclusion criteria by: \n```py\r\n# Get list of applicable exclusion criteria and create a dictionary to be used in the following function",
        "label": 0
    },
    "2293": {
        "output": "CREDITS\n\n* [Roshni Thalagala](https://github.com/RoshniThalagala), UCSF Medical Student & AI Research Assistant at Sutter Health + Stanford.\n\n# Introduction\nWe would like to thank all the individuals who participated in this study and reviewed this paper and acknowledge the work of our collaborators, especially our two anonymous reviewers, who assisted with improving the content of this paper.\n\n## Copyright information:\n\nThis content, including the data, tables, and Figures is distributed under the *Creative Commons Attribution 4.0 International* License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) credit and a license notice are maintained.\n\n*Creative Commons Attribution 4.0 International (CC BY 4.0).* \u00a9 [Amin Rastegar-Mojarad et al. 2020](https://www.sciencedirect.com/science/article/pii/S2666332120305488).\n\n## Researcher roles\n\nThis study was conceptualized by [**Rahim Amin Rastegar-Mojarad**](https://persons.cs.sfu.ca/~rastegar/), along with [**Viola Tam**](https://persons.cs.sfu.ca/~viola_tam/), and [**Rashid Ahmed**](https://persons.cs.sfu.ca/~rashidA). \n[**Alinah Yazdanfar**](https://persons.cs.sfu.ca/~alyniah) gathered the data set. [**Rahim Amin Rastegar-Mojarad**](https://persons.cs.sfu.ca/~rastegar) and [**Alinah Yazdanfar**](https://persons.cs.sfu.ca/~alyniah) performed the experiments. \n[**Rahim Amin Rastegar-Mojarad**](https://persons.cs.sfu.ca/~rastegar) and [**Aline Moussaei**](https://persons.cs.sf",
        "label": 0
    },
    "2294": {
        "output": "# Hints\n\nAfter you import the file, you will get some error but they will be disappeared quickly.\nThe data file with 1000_person is available on [Data file](/Data_1000_person/). \n\n\n# Errors\nPlease report any errors and problems here. \n\n## [Error 1](/errors/1_error.json)\n\n## [Error 2](/errors/2_error.json)\n\n## [Error 3](/errors/3_error.json)\n\n## [Error 4](/errors/4_error.json)\n\n## [Error 5](/errors/5_error.json)\n\n## [Error 6](/errors/6_error.json)\n\n## [Error 7](/errors/7_error.json)\n\n## [Error 8](/errors/8_error.json)\n\n## [Error 9](/errors/9_error.json)\n\n## [Error 10](/errors/10_error.json)\n\n## [Error 11](/errors/11_error.json)\n\n## [Error 12](/errors/12_error.json)\n\n## [Error 13](/errors/13_error.json)\n\n## [Error 14](/errors/14_error.json)\n\n## [Error 15](/errors/15_error.json)\n\n## [Error 16](/errors/16_error.json)\n\n## [Error 17](/errors/17_error.json)\n\n## [Error 18](/errors/18_error.json)\n\n## [Error 19](/errors/19_error.json)\n\n## [Error 20](/errors/20_error.json)\n\n## [Error 21](/errors/21_error.json)\n\n## [Error 22](/errors/22_error.json)\n\n## [Error 23](/errors/23_error.json)\n\n## [Error 24](/errors/24_error.json)\n\n## [Error 25](/errors/25_error.json)\n\n## [Error 26](/errors",
        "label": 0
    },
    "2295": {
        "output": "<EOD> Toll5A, a receptor for Bacillus thuringiensis Cry5Ba insecticidal toxin, is localized to midgut cells of the beet armyworm, Spodoptera exigua.\nToll/Toll-like receptor (Toll) proteins belong to a large family of proteins having an extracellular leucine-rich repeat domain and a cytoplasmic serine/threonine kinase domain. Toll function is unknown, but it is hypothesized that it is involved in innate immunity. The Toll5A mutation in the beet armyworm, Spodoptera exigua, is resistant to the Cry5Ba toxin from Bacillus thuringiensis (Bt), as are S. exigua larvae from a tobacco-planted transgenic field. The toxin receptor for Cry5Ba in the S. exigua larva was discovered, and, for convenience, it has been named Toll5A. The tissue distribution of Toll5A mRNA was examined by semi-quantitiative reverse transcription (RT)-PCR and found to be localized mainly in the midgut, followed by other tissues, but this pattern was not specific to S. exigua, and could have been due to the nature of housekeeping genes. By expression of a fragment of the leucine-rich repeat domain of Toll5A in Sf9 insect cells, it was demonstrated that Toll5A indeed functions as a receptor for Cry5Ba toxin. A monoclonal antibody against the domain was developed and was used to localize Toll5A to the midgut epithelial cells. These results showed that a midgut epithelial cell receptor is responsible for Cry5Ba cellular entry.<EOD> Is it a \"Tiger\" in disguise: 123I-Metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy in familial dysautonomia.\nFamilial dysautonomia (FD) is an autosomal recessive disease characterized by developmental deficits in the autonomic nervous system resulting in loss of control of temperature",
        "label": 0
    },
    "2296": {
        "output": "## Problem 1\nLet's think of this for one step deeper. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nHow to solve this problem? Let's code the first three steps with loop.\n\n## Problem 2\nA person with a BMI of 40 needs a program in which how to assign a BMI to a given number. \nHere are some cases. How to code this function?\n\n## Pseudo code\nPlease assign the next BMI to the person. (assume that BMI1=30,2=40,3=35)\n\n## First case:\nStep 1.\nBMI = 35.00\nStep 2.\nBMI = 34.00\nStep 3.\nBMI = 33.00\nStep 4.\nBMI = 32.00\nStep 5.\nBMI = 31.00\nStep 6.\nBMI = 30.00\nStep 7.\nBMI = 29.00\nStep 8.\nBMI = 28,00\nStep 9.\nBMI = 27,00\nStep 10.\nBMI = 26,00\nStep 11.\nBMI = 25,00\nStep 12.\nBMI = 24,00\nStep 13.\nBMI = 23,00\nStep 14.\nBMI = 22,00\nStep 15.\nBMI = 21,00\nStep 16.\nBMI = 20,00\nStep 17.\nBMI = 19,00\nStep 18.\nBMI = 18,00\nStep 19.\nBMI = 17,00\nStep 20.\nB",
        "label": 0
    },
    "2297": {
        "output": "# Screenshot\n<EOD> .\nTachyplesin I (Tp) was determined quantitatively by radioimmunoassay (RIA) and enzyme immunoassay (EIA). The two methods appeared equivalent within the range of 10 to 100 micrograms/ml. Tp was purified by the method of Yasumoto et al. using ammonium sulfate to give a specific absorbance ratio at 280 nm to that at 260 nm of 2.49. This degree of purity was sufficient for the assay by the RIA. A standard deviation of 3.1 per cent at 63.1 ng/well of 125I-Tp for RIA was observed, with 0.03 ng/well of 125I-Tp. In EIA, the standard deviation was 3.3 per cent at 563 pg/well, with 0.16 ng/well of Tp I labeled with horseradish peroxidase. A good response to Tp was obtained by the two methods. Although a similar standard deviation was observable in the EIA, the latter method was more sensitive. Moreover, the EIA was more suitable for multiple sample analysis. Furthermore, the recovery rate in the EIA was higher, while the cost of detection was lower than that of RIA, providing a reliable and reproducible assay system for Tp. These findings indicate that the EIA could be used for the quantitative determination of Tp in the crude extract.<EOD> Clinical and Histopathologic Spectrum of Molecularly Confirmed Nail Psoriasis and Nail Lichen Planus in Iran\nIntroduction: Nail psoriasis and nail lichen planus are common chronic inflammatory diseases of the nail bed which mostly cannot be differentiated using only their clinical characteristics. Objective: In this article, the clinical and histopathological findings of psoriasis and lichen planus nail disease were examined. Methods: 28 patients were first evaluated by a board-certified dermatologist, all of whom had a documented history of a diagnosis of the nail psoriatic and lichen planus for 3 months.",
        "label": 0
    },
    "2298": {
        "output": "#\n\n[INFO] Detecting and assessing risk factors for hypoglycemia\n\nHere are a list of variables that should be captured:\n[formula]  - Age (yrs) - Sex (male/female) - Weight (kg) - Height (cm) - C-peptide (nmol/L) - SUP (U/kg/d) - DUR (U/kg/d) - BMI [/formula] \nwhere SUP and DUR are defined as the daily insulin dose in human units (HU).\n\n### Hint: in case of `Missing value (x)`, you should use 'NaN' (not a number) to indicate a missing value for x variable. [inst]\n\n```python\nfrom sklearn.pipeline import Pipeline\nfrom sklearn.model_selection import train_test_split\n\ndata = data.copy()\ndata['Weight'] = data['Weight'].astype(float)\ndata['SUP'] = data['SUP'].astype(float)\ndata['DUR'] = data['DUR'].astype(float)\ndata['Excise'] = data['Excise'].astype(float)\ndata['BMI'] = data['BMI'].astype(float)\ndata['HR'].apply(lambda x: np.nan_if(np.isnan(x))) # Remove HR value if missing for this subject\ndata['RHR'].apply(lambda x: np.nan_if(np.isnan(x))) # Remove RHR value if missing for this subject\ndata['HR_avge'].apply(lambda x: np.nan_if(np.isnan(x))) # Remove HR_avge value if missing for this subject\ndata['BG'].apply(lambda x: np.nan_if(np.isnan(x))) # Remove BG value if missing for this subject\n```\n* **Split method (test train)**  \n    The best way to split data into training and test sets is to use train_test_split from sklearn.model_selection. \n    This method will automatically generate random indices for the train and test sets. \n    A train-test split of 7-3 was suggested in original paper.\n    - The train and test data should",
        "label": 2
    },
    "2299": {
        "output": "## Task 2 : \nHow to evaluate the eligibility of a patient with other patient note (eg, information about another disease, age, gender, weight, and etc.)\n\n### You should get the eligibility score based on clinical trial eligibility criteria and provide a report of the analysis. your report should include:\n-The details of a patient's eligibility in a trial for which they should not be included (if excluded)\n-The details of a patient's eligibility in a trial for which they should be included (if eligible)\n-The details of a patient's ineligibility in a trial (if not eligible)\n-The eligibility score of each patient\n\n[INST] Hello. You are helpful assistant for clinical trial recruitment. You should evaluate the eligibility of a patient with another patient note.\n\nThe patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest, and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM Type 1 in his uncle and his grandfather. His lab study is as follows:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190mg/dl\nTG: 140mg/dl\nLDL: 125mg/dl\nHDL: 40mg/dl\n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors,",
        "label": 0
    },
    "2300": {
        "output": "##[INST] You should read all the patient notes and create appropriate exclusion criteria based on the clinical trial's exclusion criteria in your clinical trial assessment code. In this clinical trial assessment code, you should also prepare the first section of the [code] Trial.txt [/code] file. \n\nExclusion criteria are the factors that exclude a given person from participating in a clinical trial. The trial's exclusion criteria can be anything from the patient's medical history or laboratory study results, or a particular aspect of lifestyle or behavior.\n\nHere is an example of trial's exclusion criteria for this clinical trial: \n\nYou should create an exclusion criteria based on the trial's exclusion criteria (exp, gender, history, medical record) and create exclusion code for each section. e.g; exp (exclusion due to gender), exp (exclusion due to age), excl (exclusion due to hypertension in medical record), etc.\nThen you should make the clinical trial assessment code, e.g. `assessment: (exp 0, exp 1, excl 0, excl 1, excl 2, excl 3, exp 1, excl 0, excl 1, excl 2, excl 3, exp 0)`: You can write this as one condition. e.g. `(excl 0|excl 1)  or (exp 1 & excl 2 & excl 3)`\n\n##[END]\n\n##[INST](Clinical trial assessment)_[CODE] [END](Clinical trial assessment)_[CODE]\n\n### [6.2] ACTUAL CLINICAL TRIAL'S ELIGIBILITY\n\n[ACTUAL](Clinical trial assessment)_[CLINNICAL TRIAL'S ELIGIBILITY)_[CLINNICAL TRIAL'S ELIGIBILITY]\n\n### [6.3] CREATE TRIAL'S ELIGIBILTY TABLE FOR CURRENT CLINICAL TRIAL\n\nIn this clinical trial assessment code, you should also prepare the table trial_eligibility.txt for",
        "label": 2
    }
}